PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Hollmen, M; Maatta, JA; Bald, L; Sliwkowski, MX; Elenius, K				Hollmen, M.; Maatta, J. A.; Bald, L.; Sliwkowski, M. X.; Elenius, K.			Suppression of breast cancer cell growth by a monoclonal antibody targeting cleavable ErbB4 isoforms	ONCOGENE			English	Article						ectodomain shedding; EGFR; HER4; neuregulins; therapeutic antibodies	RECEPTOR TYROSINE KINASES; NUCLEAR-LOCALIZATION; ECTODOMAIN CLEAVAGE; EXPRESSION; HER2; PHOSPHORYLATION; DEGRADATION; ACTIVATION; SURVIVAL; PROTEIN	ErbB4 isoforms mediate different cellular activities depending on their susceptibility to proteolytic cleavage. The biological significance of ErbB4 cleavage in tumorigenesis, however, remains poorly understood. Here, we describe characterization of a monoclonal antibody (mAb 1479) that selectively recognizes the ectodomain of cleavable ErbB4 JM-a isoforms both in vitro and in vivo. mAb 1479 was used to analyse ErbB4 JM-a expression and ectodomain shedding in a series of 17 matched breast cancer/histologically normal peripheral breast tissue pairs. ErbB4 ectodomain was observed in 75% of tumors expressing ErbB4 but only in 18% of normal breast tissue samples expressing ErbB4. Difference in the relative quantity of ErbB4 ectodomain between normal and tumor tissue pairs was statistically significant (P=0.015). Treatment with mAb 1479 suppressed ErbB4 function by inhibiting ErbB4 tyrosine phosphorylation and ectodomain shedding, and by stimulating ErbB4 downregulation and ubiquitination. mAb 1479 suppressed both anchorage-dependent and -independent growth of human breast cancer cell lines that naturally express cleavable ErbB4 JM-a. These findings indicate that ErbB4 ectodomain shedding is enhanced in breast cancer tissue in vivo, and that mAb 1479 represents a potential drug candidate that suppresses breast cancer cell growth by selectively binding cleavable ErbB4 isoforms.	[Hollmen, M.; Maatta, J. A.; Elenius, K.] Univ Turku, Dept Med Biochem & Genet, Med Res Labs, FIN-20520 Turku, Finland; [Hollmen, M.] Turku Grad Sch Biomed Sci, Turku, Finland; [Bald, L.; Sliwkowski, M. X.] Genentech Inc, San Francisco, CA 94080 USA; [Elenius, K.] Turku Univ Hosp, Dept Oncol, FIN-20520 Turku, Finland	University of Turku; University of Turku; Roche Holding; Genentech; University of Turku	Elenius, K (corresponding author), Univ Turku, Dept Med Biochem & Genet, Med Res Labs, Kiinamyllynkatu 10, FIN-20520 Turku, Finland.	klaus.elenius@utu.fi	Hollmén, Maija/B-5831-2017; Elenius, Klaus/AAI-7594-2021	Hollmén, Maija/0000-0002-3250-7653; Elenius, Klaus/0000-0001-5700-0827; Maatta, Jorma/0000-0001-8752-6862	Academy of Finland; Finnish Cancer Organizations; Finnish Cultural Foundation; Foundation for the Finnish Cancer Institute; Jenny and Antti Wihuri Foundation; Sigrid Juselius Foundation; Turku University Central Hospital; Research and Science Foundation of Farmos	Academy of Finland(Academy of Finland); Finnish Cancer Organizations; Finnish Cultural Foundation(Finnish Cultural FoundationFinnish IT center for science); Foundation for the Finnish Cancer Institute; Jenny and Antti Wihuri Foundation; Sigrid Juselius Foundation(Sigrid Juselius Foundation); Turku University Central Hospital; Research and Science Foundation of Farmos	We thank Tero Vahlberg and Tuire Palokangas for statistical analyses, and Maria Tuominen, Minna Santanen and Mika Savisalo for excellent technical assistance. This work has been supported by Academy of Finland, Finnish Cancer Organizations, Finnish Cultural Foundation, Foundation for the Finnish Cancer Institute, Jenny and Antti Wihuri Foundation, Sigrid Juselius Foundation, Turku University Central Hospital and Research and Science Foundation of Farmos.	Agus DB, 2002, CANCER CELL, V2, P127, DOI 10.1016/S1535-6108(02)00097-1; Bao JX, 2003, J CELL BIOL, V161, P1133, DOI 10.1083/jcb.200212085; Borrell-Pages M, 2003, EMBO J, V22, P1114, DOI 10.1093/emboj/cdg111; Carter P, 2001, NAT REV CANCER, V1, P118, DOI 10.1038/35101072; Cheng QC, 2003, J BIOL CHEM, V278, P38421, DOI 10.1074/jbc.M302111200; Cho HS, 2003, NATURE, V421, P756, DOI 10.1038/nature01392; Ding L, 2008, NATURE, V455, P1069, DOI 10.1038/nature07423; Elenius K, 1997, J BIOL CHEM, V272, P26761, DOI 10.1074/jbc.272.42.26761; Franklin MC, 2004, CANCER CELL, V5, P317, DOI 10.1016/S1535-6108(04)00083-2; Furger C, 1998, CANCER RES, V58, P1773; Gilbertson RJ, 1997, CANCER RES, V57, P3272; Gilbertson RJ, 2002, CLIN CANCER RES, V8, P3054; Gilmore JL, 2004, ONCOL RES, V14, P589, DOI 10.3727/0965040042707907; Gomes AQ, 2003, MOL BIOL CELL, V14, P1882, DOI 10.1091/mbc.E02-10-0639; Haugen DRF, 1996, CANCER RES, V56, P1184; Hynes NE, 2005, NAT REV CANCER, V5, P341, DOI 10.1038/nrc1609; Iivanainen E, 2007, EXP CELL RES, V313, P2896, DOI 10.1016/j.yexcr.2007.03.042; Junttila TT, 2005, CANCER RES, V65, P1384, DOI 10.1158/0008-5472.CAN-04-3150; Junttila TT, 2000, TRENDS CARDIOVAS MED, V10, P304, DOI 10.1016/S1050-1738(01)00065-2; Junttila TT, 2003, CLIN CANCER RES, V9, P5346; Kainulainen V, 2000, J BIOL CHEM, V275, P8641, DOI 10.1074/jbc.275.12.8641; Katz M, 2002, TRAFFIC, V3, P740, DOI 10.1034/j.1600-0854.2002.31006.x; Klapper LN, 2000, CANCER RES, V60, P3384; Komuro A, 2003, J BIOL CHEM, V278, P33334, DOI 10.1074/jbc.M305597200; Lee HJ, 2002, J BIOL CHEM, V277, P6318, DOI 10.1074/jbc.M110371200; Maatta JA, 2006, MOL BIOL CELL, V17, P67, DOI 10.1091/mbc.E05-05-0402; Mendelsohn J, 2000, ONCOGENE, V19, P6550, DOI 10.1038/sj.onc.1204082; Molina MA, 2001, CANCER RES, V61, P4744; Ni CY, 2001, SCIENCE, V294, P2179, DOI 10.1126/science.1065412; Omerovic J, 2007, FASEB J, V21, P2849, DOI 10.1096/fj.06-7925com; Paatero Ilkka, 2008, Recent Pat DNA Gene Seq, V2, P27; PABORSKY LR, 1990, PROTEIN ENG, V3, P547, DOI 10.1093/protein/3.6.547; PLOWMAN GD, 1993, P NATL ACAD SCI USA, V90, P1746, DOI 10.1073/pnas.90.5.1746; Prewett M, 1998, CLIN CANCER RES, V4, P2957; Rio C, 2000, J BIOL CHEM, V275, P10379, DOI 10.1074/jbc.275.14.10379; Schlessinger J, 2006, CELL, V127, P45, DOI 10.1016/j.cell.2006.09.013; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; Srinivasan R, 1999, CLIN CANCER RES, V5, P2877; Srinivasan R, 1998, J PATHOL, V185, P236, DOI 10.1002/(SICI)1096-9896(199807)185:3<236::AID-PATH118>3.0.CO;2-7; SUNADA H, 1986, P NATL ACAD SCI USA, V83, P3825, DOI 10.1073/pnas.83.11.3825; Sundvall M, 2007, ONCOGENE, V26, P6905, DOI 10.1038/sj.onc.1210501; Sundvall M, 2008, J MAMMARY GLAND BIOL, V13, P259, DOI 10.1007/s10911-008-9079-3; Sundvall M, 2008, P NATL ACAD SCI USA, V105, P4162, DOI 10.1073/pnas.0708333105; Vecchi M, 1996, J BIOL CHEM, V271, P18989, DOI 10.1074/jbc.271.31.18989; Witton CJ, 2003, J PATHOL, V200, P290, DOI 10.1002/path.1370; Zhang K, 1996, J BIOL CHEM, V271, P3884	46	42	48	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2009	28	10					1309	1319		10.1038/onc.2008.481	http://dx.doi.org/10.1038/onc.2008.481			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	417ZC	19151766				2022-12-28	WOS:000264116000003
J	Xu, K; Chang, CM; Gao, H; Shu, HK				Xu, K.; Chang, C-M; Gao, H.; Shu, H-KG			Epidermal growth factor-dependent cyclooxygenase-2 induction in gliomas requires protein kinase C-delta	ONCOGENE			English	Article						epidermal growth factor receptor; cyclooxygenase-2; protein kinase C-delta; Sp1 transcription factor; glioma	VASCULAR SMOOTH-MUSCLE; MAPK SIGNAL PATHWAYS; FACTOR RECEPTOR; MESSENGER-RNA; SP1 PHOSPHORYLATION; COX-2 INHIBITOR; CELL-LINES; IN-VITRO; GLIOBLASTOMA-MULTIFORME; MALIGNANT GLIOMAS	Earlier, we showed that epidermal growth factor receptor (EGFR) signaling in human glioma cells increased cyclooxygenase-2 (COX-2) expression through p38-mitogen-activated protein kinase (MAPK)-dependent activation of the Sp family of transcription factors. Further mechanistic details of EGFR-dependent induction of COX-2 expression in glioma cells remained elusive. Protein kinase Cs (PKCs) comprise a family of serine-threonine kinases that are major mediators of signaling from receptor tyrosine kinases. Here, we report that PKC-delta, a novel PKC isoform, plays a role in EGF-dependent COX-2 induction in human glioma cells. Pharmacological inhibition and genetic silencing (through siRNA or dominant-negative expression) of PKC-delta confirm a role for this PKC isoform in EGF-dependent COX-2 induction. Overexpression of a functional PKC-delta enhanced COX-2 expression indicating that PKC-delta is not only necessary but also sufficient to regulate COX-2 levels. Inhibition of p38-MAPK pharmacologically or with siRNA further shows that p38-MAPK is required for activation of PKC-delta by EGF while inhibition of PKC-delta had no discernible effects on p38-MAPK activation. Finally, EGF stimulation promotes physical interactions between PKC-delta and Sp1 resulting in phosphorylation and nuclear localization of this transcription factor. These data provide the first evidence that PKC-delta is a critical link between p38-MAPK and Sp1-dependent COX-2 expression in human glioma cells.	[Xu, K.; Chang, C-M; Gao, H.; Shu, H-KG] Emory Univ, Dept Radiat Oncol, Atlanta, GA 30332 USA	Emory University	Shu, HK (corresponding author), Emory Univ, Dept Radiat Oncol, 1365 Clifton Rd,NE,Bldg C,Room C-3082, Atlanta, GA 30332 USA.	hui-kuo@radonc.emory.org			Childhood Brain Tumor Foundation	Childhood Brain Tumor Foundation	This study was supported, in part, by a grant to H-K Shu from the Childhood Brain Tumor Foundation. We thank Dr Jiahuai Han for providing mammalian expression plasmids-containing MKK3 and MKK6 and Dr Jae-Won Soh for providing mammalian expression plasmids-containing PKC-delta variants.	Abbott KL, 2000, MOL PHARMACOL, V58, P946, DOI 10.1124/mol.58.5.946; Awasthi V, 2000, AM J PHYSIOL-LUNG C, V279, pL942, DOI 10.1152/ajplung.2000.279.5.L942; Baltuch GH, 1996, BRAIN RES, V710, P143, DOI 10.1016/0006-8993(95)01395-4; Bijnsdorp IV, 2007, J NEURO-ONCOL, V85, P25, DOI 10.1007/s11060-007-9385-4; Bornancin F, 1997, J BIOL CHEM, V272, P3544, DOI 10.1074/jbc.272.6.3544; Bredel M, 1997, ACTA NEUROCHIR, V139, P1000, DOI 10.1007/BF01411552; Buccoliero AM, 2006, CLIN NEUROPATHOL, V25, P59; Chupreta S, 2000, AM J PHYSIOL-CELL PH, V278, pC697, DOI 10.1152/ajpcell.2000.278.4.C697; COULDWELL WT, 1991, NEUROSURGERY, V29, P880, DOI 10.1227/00006123-199112000-00013; COULDWELL WT, 1990, J NEUROSURG, V73, P594, DOI 10.3171/jns.1990.73.4.0594; D'Addario M, 2002, J BIOL CHEM, V277, P47541, DOI 10.1074/jbc.M207681200; D'Addario M, 2006, GENE, V379, P51, DOI 10.1016/j.gene.2006.04.012; Doller A, 2007, MOL BIOL CELL, V18, P2137, DOI 10.1091/mbc.E06-09-0850; Guan ZH, 1998, J BIOL CHEM, V273, P28670, DOI 10.1074/jbc.273.44.28670; Hofmann J, 2004, CURR CANCER DRUG TAR, V4, P125, DOI 10.2174/1568009043481579; Hsieh HL, 2007, CELL SIGNAL, V19, P330, DOI 10.1016/j.cellsig.2006.07.006; HUMPHREY PA, 1991, BIOCHEM BIOPH RES CO, V178, P1413, DOI 10.1016/0006-291X(91)91051-D; Iwabu A, 2004, J BIOL CHEM, V279, P14551, DOI 10.1074/jbc.M311981200; Joki T, 2000, CANCER RES, V60, P4926; Kang KB, 2007, INT J RADIAT ONCOL, V67, P888, DOI 10.1016/j.ijrobp.2006.09.055; Karim A, 2005, ANTICANCER RES, V25, P675; Kuwahara J, 2000, Nucleic Acids Symp Ser, P265; Lee J, 2006, FASEB J, V20, P2375, DOI 10.1096/fj.06-5957fje; Lee MY, 2006, AM J PHYSIOL-GASTR L, V291, pG744, DOI 10.1152/ajpgi.00551.2005; Li B, 2004, ONCOGENE, V23, P4594, DOI 10.1038/sj.onc.1207602; LIBERMANN TA, 1985, NATURE, V313, P144, DOI 10.1038/313144a0; Machide M, 1998, J NEUROCHEM, V71, P592; Martelli AM, 2003, HISTOL HISTOPATHOL, V18, P1301, DOI 10.14670/HH-18.1301; Merchant JL, 1999, BIOCHEM BIOPH RES CO, V254, P454, DOI 10.1006/bbrc.1998.9964; Mimura Y, 2004, J INVEST DERMATOL, V122, P1390, DOI 10.1111/j.0022-202X.2004.22618.x; MORIYA M, 1994, NEUROREPORT, V5, P929, DOI 10.1097/00001756-199404000-00019; Murphy TJ, 2002, METHOD ENZYMOL, V345, P539; Musashi M, 2000, INT J HEMATOL, V72, P12; Newton AC, 1997, CURR OPIN CELL BIOL, V9, P161, DOI 10.1016/S0955-0674(97)80058-0; NISHIZUKA Y, 1995, FASEB J, V9, P484, DOI 10.1096/fasebj.9.7.7737456; Pal S, 1998, J BIOL CHEM, V273, P26277, DOI 10.1074/jbc.273.41.26277; Pang LH, 2002, FASEB J, V16, P1435, DOI 10.1096/fj.02-0169fje; Park YS, 2007, ARTERIOSCL THROM VAS, V27, P1319, DOI 10.1161/ATVBAHA.106.132837; POLLACK IF, 1990, J NEUROSURG, V73, P98, DOI 10.3171/jns.1990.73.1.0098; Prayson Richard A, 2002, Ann Diagn Pathol, V6, P148, DOI 10.1053/adpa.2002.33900; Rafty LA, 2001, NUCLEIC ACIDS RES, V29, P1027, DOI 10.1093/nar/29.5.1027; Reisinger K, 2003, J CELL SCI, V116, P225, DOI 10.1242/jcs.00237; Rojo AI, 2006, FREE RADICAL BIO MED, V41, P247, DOI 10.1016/j.freeradbiomed.2006.04.002; Rosell R, 2006, CLIN CANCER RES, V12, P7222, DOI 10.1158/1078-0432.CCR-06-0627; Shono T, 2001, CANCER RES, V61, P4375; Sminia P, 2005, J CANCER RES CLIN, V131, P653, DOI 10.1007/s00432-005-0020-5; Soh JW, 1999, MOL CELL BIOL, V19, P1313; Subbaramaiah K, 1998, J BIOL CHEM, V273, P32943, DOI 10.1074/jbc.273.49.32943; Wang HQ, 2001, MOL PHARMACOL, V59, P860, DOI 10.1124/mol.59.4.860; Xu KM, 2007, CANCER RES, V67, P6121, DOI 10.1158/0008-5472.CAN-07-0141; Xu KM, 2000, J BIOL CHEM, V275, P7604, DOI 10.1074/jbc.275.11.7604; Xu Q, 2000, J BIOL CHEM, V275, P24583, DOI 10.1074/jbc.M003894200; Yu WS, 2003, J BIOL CHEM, V278, P11167, DOI 10.1074/jbc.M211424200; Zheng XL, 2001, J BIOL CHEM, V276, P13822, DOI 10.1074/jbc.M011031200	54	21	22	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2009	28	11					1410	1420		10.1038/onc.2008.500	http://dx.doi.org/10.1038/onc.2008.500			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	421JE	19169273				2022-12-28	WOS:000264354400002
J	Fukuzawa, R; Anaka, MR; Weeks, RJ; Morison, IM; Reeve, AE				Fukuzawa, R.; Anaka, M. R.; Weeks, R. J.; Morison, I. M.; Reeve, A. E.			Canonical WNT signalling determines lineage specificity in Wilms tumour	ONCOGENE			English	Article						WTX; cancer stem cell; nephrogenic rest; mesenchymal stem cell; multiplex ligation-dependent probe amplification	GROWTH-FACTOR-II; BETA-CATENIN; STEM-CELLS; NEPHROGENIC RESTS; CTNNB1 MUTATIONS; TARGET GENES; WT1; CANCER; OVEREXPRESSION; PATHOGENESIS	Wilms tumours (WTs) have two distinct types of histology with or without ectopic mesenchymal elements, suggesting that WTs arise from either the mesenchymal or epithelial nephrogenic lineages. Regardless of the presence or absence of CTNNB1 mutations, nuclear accumulation of beta-catenin is often observed in WTs with ectopic mesenchymal elements. Here, we addressed the relationship between the WNT-signalling pathway and lineage in WTs by examining CTNNB1 and WT1 mutations, nuclear accumulation of beta-catenin, tumour histology and gene expression profiles. In addition, we screened for mutations in WTX, which has been proposed to be a negative regulator of the canonical WNT-signalling pathway. Unsupervised clustering analysis identified two classes of tumours: mesenchymal lineage WNT-dependent tumours, and epithelial lineage WNT-independent tumours. In contrast to the mesenchymal lineage specificity of CTNNB1 mutations, WTX mutations were surprisingly observed in both lineages. WTX-mutant WTs with ectopic mesenchymal elements had nuclear accumulation of beta-catenin, upregulation of WNT target genes and an association with CTNNB1 mutations in exon 7 or 8. However, epithelial lineage WTs with WTX mutations had no indications of active WNT signalling, suggesting that the involvement of WTX in the WNT-signalling pathway may be lineage dependent, and that WTX may have an alternative function to its role in the canonical WNT-signalling pathway.	[Fukuzawa, R.; Anaka, M. R.; Weeks, R. J.; Morison, I. M.; Reeve, A. E.] Univ Otago, Dept Biochem, Canc Genet Lab, Dunedin, New Zealand	University of Otago	Fukuzawa, R (corresponding author), Univ Otago, Dept Biochem, Canc Genet Lab, POB 56, Dunedin, New Zealand.	ryuji.fukuzawa@otago.ac.nz	Weeks, Robert J/A-6876-2012; Morison, Ian M/A-1236-2008	Weeks, Robert J/0000-0003-0474-9089; Morison, Ian M/0000-0003-3616-0025	Health Research Council of New Zealand	Health Research Council of New Zealand(Health Research Council of New Zealand)	This study was supported by the Health Research Council of New Zealand.	Barberi T, 2005, PLOS MED, V2, P554, DOI 10.1371/journal.pmed.0020161; Barker N, 2007, NATURE, V449, P1003, DOI 10.1038/nature06196; Beachy PA, 2004, NATURE, V432, P324, DOI 10.1038/nature03100; BECKWITH J B, 1990, Pediatric Pathology, V10, P1; Beckwith JB, 1998, AM J MED GENET, V79, P268, DOI 10.1002/(SICI)1096-8628(19981002)79:4<268::AID-AJMG7>3.0.CO;2-I; Boccaccio C, 2006, NAT REV CANCER, V6, P637, DOI 10.1038/nrc1912; Breslow NE, 2006, PEDIATR BLOOD CANCER, V47, P260, DOI 10.1002/pbc.20891; Bunting KD, 2002, STEM CELLS, V20, P11, DOI 10.1002/stem.200011; Clevers H, 2006, CELL, V127, P469, DOI 10.1016/j.cell.2006.10.018; Eberhart CG, 2001, PEDIATR DEVEL PATHOL, V4, P351, DOI 10.1007/s10024001-0037-y; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; Etheridge SL, 2004, STEM CELLS, V22, P849, DOI 10.1634/stemcells.22-5-849; Fodde R, 2003, NAT CELL BIOL, V5, P190, DOI 10.1038/ncb0303-190; Fukuzawa R, 2008, J PATHOL, V215, P377, DOI 10.1002/path.2366; Fukuzawa R, 2004, PEDIATR DEVEL PATHOL, V7, P125, DOI 10.1007/s10024-003-3023-8; Fukuzawa R, 2004, LANCET, V363, P446, DOI 10.1016/S0140-6736(04)15491-3; Fukuzawa R, 2007, J CLIN PATHOL, V60, P1013, DOI 10.1136/jcp.2006.043083; Grohmann A, 2007, J CELL SCI, V120, P3738, DOI 10.1242/jcs.011320; Irizarry RA, 2003, NUCLEIC ACIDS RES, V31, DOI 10.1093/nar/gng015; JENKINS ZA, NAT GENET IN PRESS; Koesters R, 1999, CANCER RES, V59, P3880; Koesters R, 2003, J PATHOL, V199, P68, DOI 10.1002/path.1248; Li CM, 2004, AM J PATHOL, V165, P1943, DOI 10.1016/S0002-9440(10)63246-4; Lindsley RC, 2006, DEVELOPMENT, V133, P3787, DOI 10.1242/dev.02551; Maiti S, 2000, CANCER RES, V60, P6288; Major MB, 2007, SCIENCE, V316, P1043, DOI 10.1126/science/1141515; Mishra L, 2005, SCIENCE, V310, P68, DOI 10.1126/science.1118389; Morison IM, 1996, NAT MED, V2, P311, DOI 10.1038/nm0396-311; OGAWA O, 1993, NATURE, V362, P749, DOI 10.1038/362749a0; Pardal R, 2003, NAT REV CANCER, V3, P895, DOI 10.1038/nrc1232; Perotti D, 2008, ONCOGENE, V27, P4625, DOI 10.1038/onc.2008.93; Ridgeway AG, 2001, J BIOL CHEM, V276, P19033, DOI 10.1074/jbc.M011491200; Rivera MN, 2007, SCIENCE, V315, P642, DOI 10.1126/science.1137509; Ruteshouser EC, 2008, GENE CHROMOSOME CANC, V47, P461, DOI 10.1002/gcc.20553; Schouten JP, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/gnf056; Smyth G.K., 2004, STAT APPL GENET MOL, V3, P3, DOI [10.2202/1544-6115.1027, DOI 10.2202/1544-6115.1027]; Wang YJ, 2005, J BONE MINER RES, V20, P1624, DOI 10.1359/JBMR.050516; Zavadil J, 2005, ONCOGENE, V24, P5764, DOI 10.1038/sj.onc.1208927; Zirn B, 2006, GENE CHROMOSOME CANC, V45, P565, DOI 10.1002/gcc.20319	39	45	47	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB	2009	28	8					1063	1075		10.1038/onc.2008.455	http://dx.doi.org/10.1038/onc.2008.455			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	412KE	19137020				2022-12-28	WOS:000263722900002
J	Feres, KJ; Ischenko, I; Hayman, MJ				Feres, K. J.; Ischenko, I.; Hayman, M. J.			The RON receptor tyrosine kinase promotes MSP-independent cell spreading and survival in breast epithelial cells	ONCOGENE			English	Article						RON; MSP; c-Src; breast cancer; cell spreading; survival	EPIDERMAL-GROWTH-FACTOR; MACROPHAGE-STIMULATING PROTEIN; C-SRC; CANCER CELLS; MESENCHYMAL TRANSITION; TUMOR-CELLS; MET FAMILY; ACTIVATION; PHOSPHORYLATION; OVEREXPRESSION	The recepteur d'origine nantais (RON) is a receptor tyrosine kinase (RTK) in the scatter factor family, which includes the c-Met receptor. RON exhibits increased expression in a significant number of human breast cancer tissues as well as in many established breast cancer cell lines. Recent studies have indicated that in addition to ligand-dependent signaling events, RON also promotes signals in the absence of its only known ligand, MSP, when expressed in epithelial cells. In this study, we found that when expressed in MCF-10A breast epithelial cells, RON exhibits both MSP-dependent and MSP-independent signaling, which lead to distinct biological outcomes. In the absence of MSP, RON signaling promotes cell survival, increased cell spreading and enhanced migration in response to other growth factors. However, both RON-mediated proliferation and migration require the addition of MSP in MCF-10A cells. Both MSP-dependent and MSP-independent signaling by RON are mediated in part by Src family kinases. These data suggest that RON has two alternative modes of signaling that can contribute to oncogenic behavior in normal breast epithelial cells.	[Feres, K. J.; Ischenko, I.; Hayman, M. J.] SUNY Stony Brook, Dept Mol Genet & Microbiol, Stony Brook, NY 11794 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Hayman, MJ (corresponding author), SUNY Stony Brook, Dept Mol Genet & Microbiol, Life Sci Bldg, Stony Brook, NY 11794 USA.	mhayman@ms.cc.sunysb.edu			NCI [CA28146]; Beauty Foundation; Long Island League to Abolish Cancer (LILAC); NIH [T32-CA009176]; NATIONAL CANCER INSTITUTE [T32CA009176, P01CA028146] Funding Source: NIH RePORTER	NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Beauty Foundation; Long Island League to Abolish Cancer (LILAC); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Roger Daly and Joan S. Brugge for providing the MCF-10A/ecoR cell line, James Keller for RT-PCR assistance, Dr W Todd Miller for the DN-Src construct, Kyeisha Hodge for generating the K114M mutant and Dr Edward Chan for various reagents used throughout this study. We also thank members of our laboratory plus Dr Mina Bissell for helpful discussions. The studies were funded by NCI grant CA28146, the Walk for Beauty Foundation and Long Island League to Abolish Cancer (LILAC) to MJH. KJF was supported by NIH T32-CA009176.	Bezerra JA, 1998, J CLIN INVEST, V101, P1175, DOI 10.1172/JCI1744; Biscardi JS, 2000, BREAST CANCER RES, V2, P203, DOI 10.1186/bcr55; Chen YQ, 2000, EXP CELL RES, V261, P229, DOI 10.1006/excr.2000.5012; Cote M, 2007, BIOCHEM BIOPH RES CO, V360, P219, DOI 10.1016/j.bbrc.2007.06.033; Danilkovitch A, 2000, MOL CELL BIOL, V20, P2218, DOI 10.1128/MCB.20.6.2218-2227.2000; Danilkovitch-Miagkova A, 2000, J BIOL CHEM, V275, P14783, DOI 10.1074/jbc.C000028200; Danilkovitch-Miagkova A, 2003, CURR CANCER DRUG TAR, V3, P31, DOI 10.2174/1568009033333745; Debnath J, 2003, METHODS, V30, P256, DOI 10.1016/S1046-2023(03)00032-X; Emaduddin M, 2008, P NATL ACAD SCI USA, V105, P2358, DOI 10.1073/pnas.0712176105; Hofmann C, 2007, GASTROENTEROLOGY, V132, P587, DOI 10.1053/j.gastro.2006.11.017; Hsu PY, 2006, J UROLOGY, V176, P2262, DOI 10.1016/j.juro.2006.07.048; Ishizawar R, 2004, CANCER CELL, V6, P209, DOI 10.1016/j.ccr.2004.09.001; Ishizawar RC, 2004, J BIOL CHEM, V279, P23773, DOI 10.1074/jbc.M312368200; Kang HG, 2007, CANCER RES, V67, P3094, DOI 10.1158/0008-5472.CAN-06-3259; Lee WY, 2005, CLIN CANCER RES, V11, P2222, DOI 10.1158/1078-0432.CCR-04-1761; Maggiora P, 1998, ONCOGENE, V16, P2927, DOI 10.1038/sj.onc.1201812; Mehlen P, 2006, NAT REV CANCER, V6, P449, DOI 10.1038/nrc1886; Montesano R, 1998, CELL GROWTH DIFFER, V9, P355; Moro L, 2002, J BIOL CHEM, V277, P9405, DOI 10.1074/jbc.M109101200; Muller EJ, 2008, J INVEST DERMATOL, V128, P501, DOI 10.1038/sj.jid.5701248; Muraoka RS, 1999, ENDOCRINOLOGY, V140, P187, DOI 10.1210/en.140.1.187; Muthuswamy SK, 2001, NAT CELL BIOL, V3, P785, DOI 10.1038/ncb0901-785; O'Toole JM, 2006, CANCER RES, V66, P9162, DOI 10.1158/0008-5472.CAN-06-0283; OTTENHOFFKALFF AE, 1992, CANCER RES, V52, P4773; Petrenko O, 1999, IMMUNITY, V10, P691, DOI 10.1016/S1074-7613(00)80068-0; Riggins RB, 2006, CANCER RES, V66, P7007, DOI 10.1158/0008-5472.CAN-05-3952; RONSIN C, 1993, ONCOGENE, V8, P1195; Santoro MM, 2003, DEV CELL, V5, P257, DOI 10.1016/S1534-5807(03)00201-6; Stahl S, 1997, J CELL SCI, V110, P55; Stommel JM, 2007, SCIENCE, V318, P287, DOI 10.1126/science.1142946; Tagliaferri P, 2005, CURR DRUG TARGETS, V6, P289, DOI 10.2174/1389450053765897; Thomas RM, 2007, CANCER RES, V67, P6075, DOI 10.1158/0008-5472.CAN-06-4128; Tice DA, 1999, P NATL ACAD SCI USA, V96, P1415, DOI 10.1073/pnas.96.4.1415; Van Slambrouck S, 2007, INT J ONCOL, V31, P1501; Wang D, 2004, ONCOGENE, V23, P1668, DOI 10.1038/sj.onc.1207282; Wang MH, 2003, CARCINOGENESIS, V24, P1291, DOI 10.1093/carcin/bgg089; Wang R, 1996, P NATL ACAD SCI USA, V93, P8425, DOI 10.1073/pnas.93.16.8425; Wang R, 2001, J CELL BIOL, V153, P1023, DOI 10.1083/jcb.153.5.1023; Wei X, 2005, J BIOL CHEM, V280, P35098, DOI 10.1074/jbc.M505737200; Weiss FU, 1997, CURR OPIN GENET DEV, V7, P80, DOI 10.1016/S0959-437X(97)80113-X; Welm AL, 2007, P NATL ACAD SCI USA, V104, P7570, DOI 10.1073/pnas.0702095104; WILSON LK, 1989, MOL CELL BIOL, V9, P1536, DOI 10.1128/MCB.9.4.1536; Wu WD, 2002, J BIOL CHEM, V277, P24252, DOI 10.1074/jbc.M200437200; Yamaguchi H, 2005, CURR OPIN CELL BIOL, V17, P559, DOI 10.1016/j.ceb.2005.08.002; Yamamoto N, 2006, J CELL SCI, V119, P4623, DOI 10.1242/jcs.03236; Yokoyama N, 2005, J BIOL CHEM, V280, P8893, DOI 10.1074/jbc.M412623200; Zalcenstein A, 2006, ONCOGENE, V25, P359, DOI 10.1038/sj.onc.1209061; Zinser GM, 2006, CANCER RES, V66, P11967, DOI 10.1158/0008-5472.CAN-06-2473	48	37	38	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2009	28	2					279	288		10.1038/onc.2008.383	http://dx.doi.org/10.1038/onc.2008.383			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	395CY	18836480	Green Accepted			2022-12-28	WOS:000262501100011
J	Hezel, AF; Bardeesy, N				Hezel, A. F.; Bardeesy, N.			LKB1; linking cell structure and tumor suppression	ONCOGENE			English	Review						polarity; mouse models; Peutz-Jeghers; cancer; hamartoma; STK11	PEUTZ-JEGHERS-SYNDROME; ACTIVATED PROTEIN-KINASE; SOMATIC MUTATIONS; GLUCOSE-HOMEOSTASIS; LKB1-AMPK PATHWAY; SPORADIC BREAST; DROSOPHILA LKB1; LUMEN POLARITY; C-ZETA; CANCER	Germ line mutations in the LKB1 tumor suppressor gene are associated with the Peutz-Jeghers polyposis and cancer syndrome. Somatic mutations in Lkb1 are observed in sporadic pulmonary, pancreatic and biliary cancers and melanomas. The LKB1 serine-threonine kinase functionally and biochemically links control of cellular structure and energy utilization through activation of the AMPK family of kinases. Lkb1 regulates cell polarity through downstream kinases including AMPKs, MARKs and BRSKs, and nutrient utilization and cellular metabolism through the AMPK-mTOR pathway. LKB1 has been shown to affect normal chromosomal segregation, TGF-beta signaling in the mesenchyme and WNT and p53 activity. Although each of the LKB1-dependent processes and downstream pathways have been individually delineated through work across a range of experimental systems, how they relate to Lkb1's role as a tumor suppressor remains to be fully explored and elucidated. The recent development of mouse cancer models harboring engineered mutations in Lkb1 have offered insights into how LKB1 may be functioning to restrain tumorigenesis and how its role as a master regulator of polarity and metabolism could contribute to its tumor suppressor function.	[Hezel, A. F.; Bardeesy, N.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Ctr Canc,Dept Med, Boston, MA 02114 USA	Harvard University; Harvard Medical School; Massachusetts General Hospital	Bardeesy, N (corresponding author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Ctr Canc,Dept Med, Boston, MA 02114 USA.	Bardeesy.Nabeel@MGH.Harvard.edu						Alessi DR, 2006, ANNU REV BIOCHEM, V75, P137, DOI 10.1146/annurev.biochem.75.103004.142702; Amin RMS, 2008, PATHOL INT, V58, P84, DOI 10.1111/j.1440-1827.2007.02194.x; Aretz S, 2005, HUM MUTAT, V26, P513, DOI 10.1002/humu.20253; Asada N, 2007, J NEUROSCI, V27, P11769, DOI 10.1523/JNEUROSCI.1938-07.2007; Avizienyte E, 1998, CANCER RES, V58, P2087; Avizienyte E, 1999, AM J PATHOL, V154, P677, DOI 10.1016/S0002-9440(10)65314-X; Baas AF, 2004, TRENDS CELL BIOL, V14, P312, DOI 10.1016/j.tcb.2004.04.001; Baas AF, 2004, CELL, V116, P457, DOI 10.1016/S0092-8674(04)00114-X; Baas AF, 2003, EMBO J, V22, P3062, DOI 10.1093/emboj/cdg292; Bardeesy N, 2002, NATURE, V419, P162, DOI 10.1038/nature01045; Barnes AP, 2007, CELL, V129, P549, DOI 10.1016/j.cell.2007.03.025; Bettencourt-Dias M, 2004, NATURE, V432, P980, DOI 10.1038/nature03160; Bhowmick NA, 2004, SCIENCE, V303, P848, DOI 10.1126/science.1090922; Bignell GR, 1998, CANCER RES, V58, P1384; Blumer JB, 2003, J BIOL CHEM, V278, P23217, DOI 10.1074/jbc.C200686200; Bonaccorsi S, 2007, DEVELOPMENT, V134, P2183, DOI 10.1242/dev.02848; Boudeau J, 2004, J CELL SCI, V117, P6365, DOI 10.1242/jcs.01571; Carling D, 2004, TRENDS BIOCHEM SCI, V29, P18, DOI 10.1016/j.tibs.2003.11.005; Carretero J, 2007, ONCOGENE, V26, P1616, DOI 10.1038/sj.onc.1209951; Cohen D, 2004, J CELL BIOL, V164, P717, DOI 10.1083/jcb.200308104; Cohen D, 2007, MOL BIOL CELL, V18, P2203, DOI 10.1091/mbc.E07-02-0095; Collins SP, 2000, BIOCHEM J, V345, P673, DOI 10.1042/0264-6021:3450673; Contreras CM, 2008, CANCER RES, V68, P759, DOI 10.1158/0008-5472.CAN-07-5014; Corradetti MN, 2004, GENE DEV, V18, P1533, DOI 10.1101/gad.1199104; de Leng WWJ, 2003, CLIN CANCER RES, V9, P3065; Drewes G, 1997, CELL, V89, P297, DOI 10.1016/S0092-8674(00)80208-1; Dunlop MG, 2002, GUT, V51, pV21, DOI 10.1136/gut.51.suppl_5.v21; Elbert M, 2006, MOL BIOL CELL, V17, P3345, DOI 10.1091/mbc.E06-03-0193; Entius MM, 2001, J CLIN PATHOL, V54, P126, DOI 10.1136/jcp.54.2.126; Esteller M, 2000, ONCOGENE, V19, P164, DOI 10.1038/sj.onc.1203227; Etienne-Manneville S, 2008, ONCOGENE, V27, P6970, DOI 10.1038/onc.2008.347; Evans JMM, 2005, BMJ-BRIT MED J, V330, P1304, DOI 10.1136/bmj.38415.708634.F7; Forcet C, 2005, HUM MOL GENET, V14, P1283, DOI 10.1093/hmg/ddi139; FORCET C, 2007, SCI STKE, pPE51; Forster LF, 2000, J CLIN PATHOL, V53, P791, DOI 10.1136/jcp.53.10.791; Giardiello FM, 2006, CLIN GASTROENTEROL H, V4, P408, DOI 10.1016/j.cgh.2005.11.005; Giardiello FM, 2000, GASTROENTEROLOGY, V119, P1447, DOI 10.1053/gast.2000.20228; GIARDIELLO FM, 1987, NEW ENGL J MED, V316, P1511, DOI 10.1056/NEJM198706113162404; Gruber SB, 1998, CANCER RES, V58, P5267; Guldberg P, 1999, ONCOGENE, V18, P1777, DOI 10.1038/sj.onc.1202486; Gurumurthy S, 2008, CANCER RES, V68, P55, DOI 10.1158/0008-5472.CAN-07-3225; Gwinn DM, 2008, MOL CELL, V30, P214, DOI 10.1016/j.molcel.2008.03.003; Hardie DG, 2007, NAT REV MOL CELL BIO, V8, P774, DOI 10.1038/nrm2249; Hatakeyama M, 2008, ONCOGENE, V27, P7047, DOI 10.1038/onc.2008.353; Hawley Simon A, 2003, J Biol, V2, P28, DOI 10.1186/1475-4924-2-28; Hearle N, 2006, CLIN CANCER RES, V12, P3209, DOI 10.1158/1078-0432.CCR-06-0083; Hemminki A, 1998, NATURE, V391, P184, DOI 10.1038/34432; Hemminki A, 1997, NAT GENET, V15, P87, DOI 10.1038/ng0197-87; Hezel AF, 2008, MOL CELL BIOL, V28, P2414, DOI 10.1128/MCB.01621-07; Horman S, 2008, J BIOL CHEM, V283, P18505, DOI 10.1074/jbc.M802053200; Huang X, 2008, BIOCHEM J, V412, P211, DOI 10.1042/BJ20080557; Hurov J, 2007, CELL CYCLE, V6, P1966, DOI 10.4161/cc.6.16.4576; Hurov JB, 2007, P NATL ACAD SCI USA, V104, P5680, DOI 10.1073/pnas.0701179104; Ikediobi ON, 2006, MOL CANCER THER, V5, P2606, DOI 10.1158/1535-7163.MCT-06-0433; Jansen M, 2006, GUT, V55, P1, DOI 10.1136/gut.2005.069062; JEGHERS H, 1949, NEW ENGL J MED, V241, P1031, DOI 10.1056/NEJM194912292412601; Ji HB, 2007, NATURE, V448, P807, DOI 10.1038/nature06030; Jimenez AI, 2003, CANCER RES, V63, P1382; Jishage K, 2002, P NATL ACAD SCI USA, V99, P8903, DOI 10.1073/pnas.122254599; Jones RG, 2005, MOL CELL, V18, P283, DOI 10.1016/j.molcel.2005.03.027; Katajisto P, 2008, NAT GENET, V40, P455, DOI 10.1038/ng.98; Katajisto P, 2007, BBA-REV CANCER, V1775, P63, DOI 10.1016/j.bbcan.2006.08.003; KEMPHUES KJ, 1988, CELL, V52, P311, DOI 10.1016/S0092-8674(88)80024-2; Kim BG, 2006, NATURE, V441, P1015, DOI 10.1038/nature04846; Koh HJ, 2006, MOL CELL BIOL, V26, P8217, DOI 10.1128/MCB.00979-06; Koivunen JP, 2008, BRIT J CANCER, V99, P245, DOI 10.1038/sj.bjc.6604469; Lee JH, 2007, NATURE, V447, P1017, DOI 10.1038/nature05828; Liang JY, 2007, NAT CELL BIOL, V9, P218, DOI 10.1038/ncb1537; Lim W, 2004, GASTROENTEROLOGY, V126, P1788, DOI 10.1053/j.gastro.2004.03.014; Lin-Marq N, 2005, MOL GENET GENOMICS, V273, P184, DOI 10.1007/s00438-005-1124-y; Lizcano JM, 2004, EMBO J, V23, P833, DOI 10.1038/sj.emboj.7600110; Martin SG, 2003, NATURE, V421, P379, DOI 10.1038/nature01296; Mehenni H, 2005, HUM MOL GENET, V14, P2209, DOI 10.1093/hmg/ddi225; Memmott RM, 2008, CANCER RES, V68, P580, DOI 10.1158/0008-5472.CAN-07-3091; Mirouse V, 2007, J CELL BIOL, V177, P387, DOI 10.1083/jcb.200702053; Miyaki M, 2000, CANCER RES, V60, P6311; Miyoshi H, 2002, CANCER RES, V62, P2261; Nakau M, 2002, CANCER RES, V62, P4549; Narbonne P, 2006, DEVELOPMENT, V133, P611, DOI 10.1242/dev.02232; Olschwang S, 2001, J MED GENET, V38, P356, DOI 10.1136/jmg.38.6.356; Ossipova O, 2003, NAT CELL BIOL, V5, P889, DOI 10.1038/ncb1048; Partanen JI, 2007, P NATL ACAD SCI USA, V104, P14694, DOI 10.1073/pnas.0704677104; Pearson HB, 2008, CANCER RES, V68, P2223, DOI 10.1158/0008-5472.CAN-07-5169; PEUTZ J, 1921, NED MAANDSCHR GENEES; PODCZASKI E, 1991, GYNECOL ONCOL, V42, P74, DOI 10.1016/0090-8258(91)90234-V; Rossi DJ, 2002, P NATL ACAD SCI USA, V99, P12327, DOI 10.1073/pnas.192301399; Rowan A, 1999, J INVEST DERMATOL, V112, P509, DOI 10.1046/j.1523-1747.1999.00551.x; Sahin F, 2003, MODERN PATHOL, V16, P686, DOI 10.1097/01.MP.0000075645.97329.86; Sakamoto K, 2005, EMBO J, V24, P1810, DOI 10.1038/sj.emboj.7600667; Sanchez-Cespedes M, 2002, CANCER RES, V62, P3659; Sapkota GP, 2002, BIOCHEM J, V368, P507, DOI 10.1042/BJ20021284; Sapkota GP, 2002, BIOCHEM J, V362, P481, DOI 10.1042/0264-6021:3620481; Sapkota GP, 2001, J BIOL CHEM, V276, P19469, DOI 10.1074/jbc.M009953200; Sato N, 2001, AM J PATHOL, V159, P2017, DOI 10.1016/S0002-9440(10)63053-2; Schneider MB, 2001, GASTROENTEROLOGY, V120, P1263, DOI 10.1053/gast.2001.23258; Screaton RA, 2004, CELL, V119, P61, DOI 10.1016/j.cell.2004.09.015; Shaw RJ, 2006, CURR OPIN CELL BIOL, V18, P598, DOI 10.1016/j.ceb.2006.10.005; Shaw RJ, 2005, SCIENCE, V310, P1642, DOI 10.1126/science.1120781; Shaw RJ, 2004, P NATL ACAD SCI USA, V101, P3329, DOI 10.1073/pnas.0308061100; Shaw RJ, 2004, CANCER CELL, V6, P91, DOI 10.1016/j.ccr.2004.06.007; Shelly M, 2007, CELL, V129, P565, DOI 10.1016/j.cell.2007.04.012; Song P, 2008, J BIOL CHEM, V283, P12446, DOI 10.1074/jbc.M708208200; Song P, 2007, CIRCULATION, V116, P1585, DOI 10.1161/CIRCULATIONAHA.107.716498; Spicer J, 2003, ONCOGENE, V22, P4752, DOI 10.1038/sj.onc.1206669; SPIGELMAN AD, 1989, GUT, V30, P1588, DOI 10.1136/gut.30.11.1588; Su GH, 1999, AM J PATHOL, V154, P1835, DOI 10.1016/S0002-9440(10)65440-5; Takeda H, 2006, ONCOGENE, V25, P1816, DOI 10.1038/sj.onc.1209207; Tiainen M, 1999, P NATL ACAD SCI USA, V96, P9248, DOI 10.1073/pnas.96.16.9248; Tiainen M, 2002, HUM MOL GENET, V11, P1497, DOI 10.1093/hmg/11.13.1497; Tomlinson IPM, 1997, J MED GENET, V34, P1007, DOI 10.1136/jmg.34.12.1007; Udd L, 2004, GASTROENTEROLOGY, V127, P1030, DOI 10.1053/j.gastro.2004.07.059; Volikos E, 2006, J MED GENET, V43, DOI 10.1136/jmg.2005.039875; Wang ZJ, 1999, J PATHOL, V188, P9, DOI 10.1002/(SICI)1096-9896(199905)188:1<9::AID-PATH326>3.0.CO;2-E; Wang ZJ, 1998, AM J PATHOL, V153, P363, DOI 10.1016/S0002-9440(10)65579-4; Watts JL, 2000, DEVELOPMENT, V127, P1467; Wei C, 2008, CLIN CANCER RES, V14, P1167, DOI 10.1158/1078-0432.CCR-07-4007; Wei CJ, 2005, CANCER RES, V65, P11297, DOI 10.1158/0008-5472.CAN-05-0716; Westerman AM, 1999, LANCET, V353, P1211, DOI 10.1016/S0140-6736(98)08018-0; Williams T, 2008, TRENDS CELL BIOL, V18, P193, DOI 10.1016/j.tcb.2008.01.008; Xie ZL, 2006, J BIOL CHEM, V281, P6366, DOI 10.1074/jbc.M511178200; Yee NS, 2003, CANCER BIOL THER, V2, P38; Ylikorkala A, 2001, SCIENCE, V293, P1323, DOI 10.1126/science.1062074; YOUNG S, 1995, AM J SURG PATHOL, V19, P50, DOI 10.1097/00000478-199501000-00007; Zakikhani M, 2006, CANCER RES, V66, P10269, DOI 10.1158/0008-5472.CAN-06-1500; Zhang L, 2006, P NATL ACAD SCI USA, V103, P17272, DOI 10.1073/pnas.0608531103; Zhang SM, 2008, CANCER RES, V68, P740, DOI 10.1158/0008-5472.CAN-07-2989; Zheng B, 2007, P NATL ACAD SCI USA, V104, P819, DOI 10.1073/pnas.0610157104	127	166	177	1	25	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 24	2008	27	55					6908	6919		10.1038/onc.2008.342	http://dx.doi.org/10.1038/onc.2008.342			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	375IU	19029933				2022-12-28	WOS:000261108200004
J	Liu, Y; Borchert, GL; Surazynski, A; Phang, JM				Liu, Y.; Borchert, G. L.; Surazynski, A.; Phang, J. M.			Proline oxidase, a p53-induced gene, targets COX-2/PGE(2) signaling to induce apoptosis and inhibit tumor growth in colorectal cancers	ONCOGENE			English	Article						proline oxidase; COX-2; signaling cross talk; colorectal cancer; tumor suppressor	FACTOR RECEPTOR; COLON-CANCER; POSTTRANSCRIPTIONAL CONTROL; CYCLOOXYGENASE-2; EXPRESSION; CARCINOGENESIS; PATHWAY; OXYGEN; CELLS; CHEMOPREVENTION	Proline oxidase (POX), a flavoenzyme localized at the inner mitochondrial membrane, catalyzes the first step of proline degradation by converting proline to pyrroline-5-carboxylate (P5C). POX is markedly elevated during p53-induced apoptosis and generates proline-dependent reactive oxygen species (ROS), specifically superoxide radicals, to induce apoptosis through both mitochondrial and death receptor pathways. These previous studies also showed suppression of the mitogen-activated protein kinase pathway leading us to broaden our exploration of proliferative signaling. In our current report, we used DLD-1 colorectal cancer cells stably transfected with the POX gene under the control of a tetracycline-inducible promoter and found that three pathways which cross talk with each other were downregulated by POX: the cyclooxygenase-2(COX-2) pathway, the epidermal growth factor receptor (EGFR) pathway and the Wnt/beta-catenin pathway. First, POX markedly reduced COX-2 expression, suppressed the production of prostaglandin E2 (PGE2) and importantly, the growth inhibition by POX was partially reversed by treatment with PGE2. Phosphorylation of EGFR was decreased with POX expression and the addition of EGF partially reversed the POX-dependent downregulation of COX-2. Wnt/beta-catenin signaling was decreased by POX in that phosphorylation of glycogen synthase kinase-3 beta (GSK-3 beta) was decreased on the one hand and phosphorylation of beta-catenin was increased on the other. There changes led to decreased accumulation of beta-catenin and decreased beta-catenin/TCF/LEF-mediated transcription. Our newly described POX-mediated suppression of proliferative signaling together with the previously reported induction of apoptosis suggested that POX could function as a tumor suppressor. Indeed, in human colorectal tissue samples, immunohistochemically-monitored POX was dramatically decreased in tumors compared with normal counterparts. Thus, POX metabolism of substrate proline affects multiple signaling pathways, modulating both apoptosis and tumor growth, and could be an attractive target to metabolically control the cancer phenotypes.	[Liu, Y.; Borchert, G. L.] NCI, Basic Res Program, SAIC Frederick Inc, Frederick, MD 21702 USA; [Surazynski, A.; Phang, J. M.] NCI, Ctr Canc Res, Comparat Carcinogenesis Lab, Frederick, MD 21702 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Liu, Y (corresponding author), NCI, Basic Res Program, SAIC Frederick Inc, Bldg 538,Room 144, Frederick, MD 21702 USA.	liuy@ncifcrf.gov	Surażynski, Arkadiusz/ABG-2795-2020	Surażynski, Arkadiusz/0000-0003-4475-873X	NIH [N01-CO-12400]; National Cancer Institute; Center for Cancer Research; NATIONAL CANCER INSTITUTE [ZIABC010743] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Center for Cancer Research(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This research is supported by the Intramural Research Program of the NIH, National Cancer Institute, Center for Cancer Research. This project also has been funded in part with Federal funds from the National Cancer Institute, National Institutes of Health under Contract No. N01-CO-12400. The content of this publication does not necessarily reflect the views or policies of the Department of Health and Human Services, nor does mention of trade names, commercial products, or organizations imply endorsement by the US Government.	Albini A, 2007, NAT REV CANCER, V7, P139, DOI 10.1038/nrc2067; Araki Y, 2003, CANCER RES, V63, P728; Bensaad K, 2007, TRENDS CELL BIOL, V17, P286, DOI 10.1016/j.tcb.2007.04.004; Buchanan FG, 2003, J BIOL CHEM, V278, P35451, DOI 10.1074/jbc.M302474200; Castellone MD, 2005, SCIENCE, V310, P1504, DOI 10.1126/science.1116221; Chen JJ, 2005, MOL BIOL CELL, V16, P5579, DOI 10.1091/mbc.E05-08-0778; Dannenberg AJ, 2005, J CLIN ONCOL, V23, P254, DOI 10.1200/JCO.2005.09.112; Dixon DA, 2000, J BIOL CHEM, V275, P11750, DOI 10.1074/jbc.275.16.11750; Dixon DA, 2004, CURR PHARM DESIGN, V10, P635, DOI 10.2174/1381612043453171; Donald SP, 2001, CANCER RES, V61, P1810; Gupta RA, 2001, NAT REV CANCER, V1, P11, DOI 10.1038/35094017; HAGEDORN CH, 1986, ARCH BIOCHEM BIOPHYS, V248, P166, DOI 10.1016/0003-9861(86)90413-3; Huang B, 2002, ACTA NEUROPATHOL, V103, P415, DOI 10.1007/s00401-001-0479-3; Jemal A, 2005, CA-CANCER J CLIN, V55, P10, DOI 10.3322/canjclin.55.1.10; Kawamori T, 1998, CANCER RES, V58, P409; Kim J, 2005, CANCER RES, V65, P8242, DOI 10.1158/0008-5472.CAN-05-0942; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; Korswagen HC, 2006, DEV CELL, V10, P687, DOI 10.1016/j.devcel.2006.05.007; Liu LZ, 2004, SER INF MANAGE SCI, V3, P279; Liu XL, 2006, ADV ANAT PATHOL, V13, P270, DOI 10.1097/01.pap.0000213046.61941.5c; Liu Y, 2006, ONCOGENE, V25, P5640, DOI 10.1038/sj.onc.1209564; Liu YM, 2005, CARCINOGENESIS, V26, P1335, DOI 10.1093/carcin/bgi083; Maxwell SA, 2003, J BIOL CHEM, V278, P9784, DOI 10.1074/jbc.M210012200; McDonald-McGinn DM, 2006, AM J MED GENET A, V140A, P906, DOI 10.1002/ajmg.a.31199; Merida Isabel, 2006, Clin Transl Oncol, V8, P711, DOI 10.1007/s12094-006-0117-6; Oshima M, 1996, CELL, V87, P803, DOI 10.1016/S0092-8674(00)81988-1; Pandhare J, 2006, J BIOL CHEM, V281, P2044, DOI 10.1074/jbc.M507867200; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; Prescott SM, 2000, BBA-REV CANCER, V1470, pM69, DOI 10.1016/S0304-419X(00)00006-8; Rivera A, 2005, J BIOL CHEM, V280, P29346, DOI 10.1074/jbc.M504852200; Sevenet N, 1999, HUM MOL GENET, V8, P2359, DOI 10.1093/hmg/8.13.2359; Shao JY, 2004, J BIOL CHEM, V279, P14287, DOI 10.1074/jbc.M313276200; Shao JY, 2005, J BIOL CHEM, V280, P26565, DOI 10.1074/jbc.M413056200; Surazynski A, 2008, INT J CANCER, V122, P1435, DOI 10.1002/ijc.23263; Williams CS, 1997, J CLIN INVEST, V100, P1325, DOI 10.1172/JCI119651; Wood LD, 2007, SCIENCE, V318, P1108, DOI 10.1126/science.1145720; Worthley DL, 2007, WORLD J GASTROENTERO, V13, P3784; YEH GC, 1988, J BIOL CHEM, V263, P13083	38	82	84	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 13	2008	27	53					6729	6737		10.1038/onc.2008.322	http://dx.doi.org/10.1038/onc.2008.322			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	371XO	18794809	Green Accepted			2022-12-28	WOS:000260866200003
J	Motrescu, ER; Blaise, S; Etique, N; Messaddeq, N; Chenard, MP; Stoll, I; Tomasetto, C; Rio, MC				Motrescu, E. R.; Blaise, S.; Etique, N.; Messaddeq, N.; Chenard, M-P; Stoll, I.; Tomasetto, C.; Rio, M-C			Matrix metalloproteinase-11/stromelysin-3 exhibits collagenolytic function against collagen VI under normal and malignant conditions	ONCOGENE			English	Article						matrix metalloproteinase-11/stromelysin-3; collagen VI; adipocyte; fat tissue; breast cancer	STROMAL CELL-INTERACTIONS; BREAST-CANCER; IN-VIVO; HUMAN STROMELYSIN-3; C5 DOMAIN; DIFFERENTIATION; IDENTIFICATION; METALLOPROTEINASES; PROGRESSION; ADIPOCYTES	The substrate of matrix metalloproteinase 11 (MMP11) remains unknown. We have recently shown that MMP11 is a negative regulator of adipogenesis, able to reduce and even to revert mature adipocyte differentiation. Here, we have used mouse 3T3L1 cells and human U87MG and SaOS cells to show that MMP11 cleaves the native alpha 3 chain of collagen VI, which is an adipocyte-related extracellular matrix component. It is known that extracellular proteolytic processing of this chain is required for correct collagen VI folding. Interestingly, MMP11-deficient fat tissue is less cohesive and exhibits collagen VI alteration, dramatic adipocyte plasma and basement membrane abnormalities and lipid leakage. MMP11 is thus required for correct collagen VI folding and therefore for fat tissue cohesion and adipocyte function. Both MMP11 and collagen VI favor tumor progression. Similar spatio-temporal overexpression at the adipocyte-cancer cell interface has been reported for the two proteins. MMP11-dependent collagen VI processing might therefore be expected to occur during malignancy. Accordingly, collagen VI no longer delineates adipocytes located at the invasive front of breast carcinomas. In conclusion, the native a3 chain of collagen VI constitutes a specific MMP11 substrate. This MMP11 collagenolytic activity is functional in fat tissue ontogenesis as well as during cancer invasive steps.	[Motrescu, E. R.; Blaise, S.; Etique, N.; Messaddeq, N.; Stoll, I.; Tomasetto, C.; Rio, M-C] Univ Strasbourg 1, INSERM, Dept Canc Biol, Inst Genet & Biol Mol & Cellulaire,UMR 7104,U596, F-67404 Illkirch Graffenstaden, France; [Chenard, M-P] Ctr Hosp Univ Hautepierre, Serv Anat Pathol Gen, Strasbourg, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; CHU Strasbourg	Rio, MC (corresponding author), Univ Strasbourg 1, INSERM, Dept Canc Biol, Inst Genet & Biol Mol & Cellulaire,UMR 7104,U596, BP 10142, F-67404 Illkirch Graffenstaden, France.	rio@igbmc.u-strasbg.fr	Tomasetto, Catherine Laure/J-2783-2014; etique, nicolas/J-4159-2017; BLAISE, Sebastien/AAS-1022-2020; Chenard, Marie-Pierre/O-2373-2016	Tomasetto, Catherine Laure/0000-0002-1811-5848; etique, nicolas/0000-0001-6613-9257; BLAISE, Sebastien/0000-0003-3012-1500; 	Institut National de la Sante et de la Recherche Medicale; Centre National de la Recherche Scientifique; Hopital Universitaire de Strasbourg; Association pour la Recherche sur le Cancer; Ligue Nationale Francaise contre le Cancer and the Comites du Haut-Rhin et du Bas-Rhin; European Commission [FP6 LSHC-CT-2003-503297]; Cancer Degradome Project; Institut National du Cancer; Fond National pour la Sante [ACI 2004]; Canceropole Grand-Est and the 'Ruban Rose' prize	Institut National de la Sante et de la Recherche Medicale(Institut National de la Sante et de la Recherche Medicale (Inserm)); Centre National de la Recherche Scientifique(Centre National de la Recherche Scientifique (CNRS)); Hopital Universitaire de Strasbourg; Association pour la Recherche sur le Cancer(Fondation ARC pour la Recherche sur le CancerAustralian Research Council); Ligue Nationale Francaise contre le Cancer and the Comites du Haut-Rhin et du Bas-Rhin; European Commission(European CommissionEuropean Commission Joint Research Centre); Cancer Degradome Project(European Commission); Institut National du Cancer(Institut National du Cancer (INCA) France); Fond National pour la Sante; Canceropole Grand-Est and the 'Ruban Rose' prize	We thank Takako Sasaki from the Max-Planck-Institute for Biochemistry, Munich, Germany for his help. This study was supported by funds from the Institut National de la Sante et de la Recherche Medicale, the Centre National de la Recherche Scientifique, the Hopital Universitaire de Strasbourg, the Association pour la Recherche sur le Cancer, the Ligue Nationale Francaise contre le Cancer and the Comites du Haut-Rhin et du Bas-Rhin (equipe labellisee), the European Commission (FP6 LSHC-CT-2003-503297; Cancer Degradome Project), the Institut National du Cancer, Fond National pour la Sante ACI 2004 Canceropole Grand-Est and the 'Ruban Rose' prize. EM was a recipient of an EU fellowship.	Aigner T, 2002, BIOCHEM BIOPH RES CO, V290, P743, DOI 10.1006/bbrc.2001.6227; Andarawewa KL, 2005, CANCER RES, V65, P10862, DOI 10.1158/0008-5472.CAN-05-1231; Basset P, 1997, MATRIX BIOL, V15, P535, DOI 10.1016/S0945-053X(97)90028-7; BASSET P, 1990, NATURE, V348, P699, DOI 10.1038/348699a0; BERNLOHR DA, 1984, P NATL ACAD SCI-BIOL, V81, P5468, DOI 10.1073/pnas.81.17.5468; Boulay A, 2001, CANCER RES, V61, P2189; Celis JE, 2005, MOL CELL PROTEOMICS, V4, P492, DOI 10.1074/mcp.M500030-MCP200; Dieudonne MN, 2006, BIOCHEM BIOPH RES CO, V345, P271, DOI 10.1016/j.bbrc.2006.04.076; Gregoire FM, 2001, EXP BIOL MED, V226, P997, DOI 10.1177/153537020122601106; HAN J, 1995, CONNECT TISSUE RES, V31, P161, DOI 10.3109/03008209509028404; Iyengar P, 2003, ONCOGENE, V22, P6408, DOI 10.1038/sj.onc.1206737; Iyengar P, 2005, J CLIN INVEST, V115, P1163, DOI 10.1172/JCI200523424; Kannan R, 1999, PROTEIN EXPRES PURIF, V16, P76, DOI 10.1006/prep.1999.1068; KIELTY CM, 1993, BIOCHEM BIOPH RES CO, V191, P1230, DOI 10.1006/bbrc.1993.1349; Kuo HJ, 1997, J BIOL CHEM, V272, P26522, DOI 10.1074/jbc.272.42.26522; Lamande SR, 2006, J BIOL CHEM, V281, P16607, DOI 10.1074/jbc.M510192200; Manabe Y, 2003, J PATHOL, V201, P221, DOI 10.1002/path.1430; Masson R, 1998, J CELL BIOL, V140, P1535, DOI 10.1083/jcb.140.6.1535; McCawley LJ, 2001, CURR OPIN CELL BIOL, V13, P534, DOI 10.1016/S0955-0674(00)00248-9; MOTRESCU ER, 2008, BIOL CHEM, V389; Myint E, 1996, CORNEA, V15, P490; Nakajima I, 2002, DIFFERENTIATION, V70, P84, DOI 10.1046/j.1432-0436.2002.700203.x; NOEL A, 1995, J BIOL CHEM, V270, P22866, DOI 10.1074/jbc.270.39.22866; Noel A, 2000, ONCOGENE, V19, P1605, DOI 10.1038/sj.onc.1203465; PEI DQ, 1995, NATURE, V375, P244, DOI 10.1038/375244a0; PEI DQ, 1994, J BIOL CHEM, V269, P25849; RIO MC, 2002, STROMELYSIN 3 PARTIC; Ruhl M, 1999, EXP CELL RES, V250, P548, DOI 10.1006/excr.1999.4540; Schaffler A, 2007, NAT CLIN PRACT ENDOC, V3, P345, DOI 10.1038/ncpendmet0456	29	85	87	0	20	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT	2008	27	49					6347	6355		10.1038/onc.2008.218	http://dx.doi.org/10.1038/onc.2008.218			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	363JK	18622425				2022-12-28	WOS:000260263400004
J	Iwanaga, R; Ozono, E; Fujisawa, J; Ikeda, MA; Okamura, N; Huang, Y; Ohtani, K				Iwanaga, R.; Ozono, E.; Fujisawa, J.; Ikeda, M. A.; Okamura, N.; Huang, Y.; Ohtani, K.			Activation of the cyclin D2 and cdk6 genes through NF-kappa B is critical for cell-cycle progression induced by HTLV-I Tax	ONCOGENE			English	Article						HTLV-I; Tax; cell cycle; E2F; cyclin D2; cdk6	VIRUS TYPE-I; ONCOGENE PRODUCT TAX; TYPE-1 TAX; PROTEIN; TRANSFORMATION; MECHANISMS	Human T-cell leukemia virus type I (HTLV-I) can infect a variety of cell types, so the cause of T-cell-specific oncogenesis remains to be elucidated. The trans-activator protein Tax of HTLV-I can promote cell-cycle progression in resting T cells along with induction of cyclin D2 and cyclin-dependent kinase (cdk6) gene expression. Here, we found that Tax cannot induce cell-cycle progression in resting fibroblasts and analysed the molecular basis of the cell-type specificity. Tax activated cyclin D2 and cdk6 promoters in T cells, but not in fibroblasts, depending on its ability to activate the transcription factor nuclear factor (NF)-kappa B. Expression of cyclin D2 and CDK6 activated the transcription factor E2F, which is essential for cell-cycle progression, in both T cells and fibroblasts. Short-hairpin RNA (shRNA)-mediated inhibition of cyclin D2 and CDK6 induction suppressed Tax-induced activation of E2F in T cells. Finally, shRNA-mediated downregulation of NF-kappa B p65 or p100 expression reduced Tax-induced activation of cyclin D2 and/or cdk6 promoters and cell-cycle progression in T cells. These results indicate that Tax-induced cell-cycle progression in T cells is mediated, at least in part, through cell-type-specific activation of the cyclin D2 and cdk6 genes through NF-kappa B and may be important for the cell-type-specific oncogenesis.	[Ohtani, K.] Tokyo Med & Dent Univ, Human Gene Sci Ctr, Bunkyo Ku, Tokyo 1138510, Japan; [Iwanaga, R.; Okamura, N.] Tokyo Med & Dent Univ, Grad Sch Hlth Sci, Lab Microbiol & Immunol, Tokyo 1138510, Japan; [Ozono, E.; Ikeda, M. A.] Tokyo Med & Dent Univ, Grad Sch, Sect Mol Embryol, Tokyo, Japan; [Fujisawa, J.] Kansai Med Univ, Dept Microbiol, Osaka, Japan; [Huang, Y.] E China Univ Sci & Technol, Sch Pharm, Dept Pharmaceut Sci, Shanghai 200237, Peoples R China	Tokyo Medical & Dental University (TMDU); Tokyo Medical & Dental University (TMDU); Tokyo Medical & Dental University (TMDU); Kansai Medical University; East China University of Science & Technology	Ohtani, K (corresponding author), Tokyo Med & Dent Univ, Human Gene Sci Ctr, Bunkyo Ku, 1-5-45 Yushima, Tokyo 1138510, Japan.	kiyo.gene@cmn.tmd.ac.jp		Ozono, Eiko/0000-0002-3919-205X				Huang YP, 2001, ONCOGENE, V20, P1094, DOI 10.1038/sj.onc.1204198; Inoue J, 2007, CANCER SCI, V98, P268, DOI 10.1111/j.1349-7006.2007.00389.x; Iwanaga R, 2001, ONCOGENE, V20, P2055, DOI 10.1038/sj.onc.1204304; LEE B, 1989, TOHOKU J EXP MED, V157, P1, DOI 10.1620/tjem.157.1; Manel N, 2003, CELL, V115, P449, DOI 10.1016/S0092-8674(03)00881-X; NAKAMURA M, 1989, J BIOL CHEM, V264, P20189; Neuveut C, 1998, MOL CELL BIOL, V18, P3620, DOI 10.1128/MCB.18.6.3620; Ohtani K, 2000, J BIOL CHEM, V275, P11154, DOI 10.1074/jbc.275.15.11154; OHTANI K, 1987, EMBO J, V6, P389, DOI 10.1002/j.1460-2075.1987.tb04767.x; Ohtani K, 1998, J BIOL CHEM, V273, P14119, DOI 10.1074/jbc.273.23.14119; Schmitt I, 1998, J VIROL, V72, P633, DOI 10.1128/JVI.72.1.633-640.1998; Sun SC, 2005, ONCOGENE, V24, P5952, DOI 10.1038/sj.onc.1208969; Yamaoka S, 1996, EMBO J, V15, P873, DOI 10.1002/j.1460-2075.1996.tb00422.x; Yoshida M, 2005, ONCOGENE, V24, P5931, DOI 10.1038/sj.onc.1208981	14	44	46	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 18	2008	27	42					5635	5642		10.1038/onc.2008.174	http://dx.doi.org/10.1038/onc.2008.174			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	349KX	18504428				2022-12-28	WOS:000259280800009
J	Cid, VJ; Rodriguez-Escudero, I; Andres-Pons, A; Roma-Mateo, C; Gil, A; den Hertog, J; Molina, M; Pulido, R				Cid, V. J.; Rodriguez-Escudero, I.; Andres-Pons, A.; Roma-Mateo, C.; Gil, A.; den Hertog, J.; Molina, M.; Pulido, R.			Assessment of PTEN tumor suppressor activity in nonmammalian models: the year of the yeast	ONCOGENE			English	Review						PTEN; PI3K; tumor suppression; oncogenesis; yeast	CAENORHABDITIS-ELEGANS; SCHIZOSACCHAROMYCES-POMBE; PROTEIN-KINASES; CELL-SIZE; TRASTUZUMAB RESISTANCE; FUNCTIONAL-EVALUATION; PHOSPHATASE-ACTIVITY; REGULATES LONGEVITY; SIGNALING PATHWAY; DAUER FORMATION	Model organisms have emerged as suitable and reliable biological tools to study the properties of proteins whose function is altered in human disease. In the case of the PI3K and PTEN human cancer-related proteins, several vertebrate and invertebrate models, including mouse, fly, worm and amoeba, have been exploited to obtain relevant functional information that has been conserved from these organisms to humans along evolution. The yeast Saccharomyces cerevisiae is an eukaryotic unicellular organism that lacks a canonical mammalian-like PI3K/PTEN pathway and PIP3 as a physiological second messenger, PIP2 being essential for its life. The mammalian PI3K/PTEN pathway can be reconstituted in S. cerevisiae, generating growth alteration phenotypes that can be easily monitored to perform in vivo functional analysis of the molecular constituents of this pathway. Here, we review the current nonmammalian model systems to study PTEN function, summarize our knowledge of PTEN orthologs in yeast species and propose the yeast S. cerevisiae as a sensitive biological sensor of PI3K oncogenicity and PTEN tumor suppressor activity.	[Andres-Pons, A.; Roma-Mateo, C.; Gil, A.; Pulido, R.] Ctr Invest Principe Felipe, Valencia, Spain; [Cid, V. J.; Molina, M.] Univ Complutense Madrid, Dept Microbiol 2, Madrid, Spain; [den Hertog, J.] Hubrecht Inst, Utrecht, Netherlands	Prince Felipe Research Center; Complutense University of Madrid; Royal Netherlands Academy of Arts & Sciences; Hubrecht Institute (KNAW)	Pulido, R (corresponding author), Ctr Invest Principe Felipe, Valencia, Spain.	rpulido@cipf.es	Romá-Mateo, Carlos/B-6640-2016; CID, VICTOR JIMENEZ/I-1240-2015; Rodríguez, Isabel/I-5955-2017; Molina, Maria/ABE-7186-2021; JIMENEZ CID, VICTOR/ABC-4858-2021	Romá-Mateo, Carlos/0000-0002-7981-7157; CID, VICTOR JIMENEZ/0000-0002-3933-2016; Rodríguez, Isabel/0000-0002-1792-1143; Molina, Maria/0000-0003-0074-3309; JIMENEZ CID, VICTOR/0000-0002-3933-2016; Pulido, Rafael/0000-0001-9100-248X; Andres-Pons, Amparo/0000-0001-5801-4024	Ministerio de Educacion y Ciencia [SAF2006-083139, S-SAL-0246-2006]; Instituto de Salud Carlos III [ISCIII-RETIC RD06/0020, CP04/00318]; Spain-FEDER; European Research Training Network [MRTN-CT2006-035830]; Comunidad Autonoma de Madrid, Spain; Ministerio de Educacion y Ciencia; Ayuntamiento de Valencia, Spain	Ministerio de Educacion y Ciencia(Spanish Government); Instituto de Salud Carlos III(Instituto de Salud Carlos IIIEuropean Commission); Spain-FEDER(European Commission); European Research Training Network; Comunidad Autonoma de Madrid, Spain(Comunidad de Madrid); Ministerio de Educacion y Ciencia(Spanish Government); Ayuntamiento de Valencia, Spain	We thank T Maehama (National Institute of Infectious Diseases, Tokyo, Japan) and E Hidalgo (Universitat Pompeu Fabra, Barcelona, Spain) for providing DNA samples. Work at the authors' labs is supported by Grants SAF2006-083139 from Ministerio de Educacion y Ciencia, and Grants ISCIII-RETIC RD06/0020 (to R Pulido) and CP04/00318 (to A Gil) from Instituto de Salud Carlos III, Spain-FEDER; European Research Training Network Grant MRTN-CT2006-035830 (to R Pulido and J den Hertog); and Grants BIO2004-02019 from Ministerio de Educacion y Ciencia, and S-SAL-0246-2006 from Comunidad Autonoma de Madrid, Spain (to M Molina). A Andres-Pons and C Roma-Mateo have been the recipients of predoctoral fellowships from Ministerio de Educacion y Ciencia and Ayuntamiento de Valencia, Spain.	Andres-Pons A, 2007, CANCER RES, V67, P9731, DOI 10.1158/0008-5472.CAN-07-1278; Beeton CA, 2000, BIOCHEM J, V350, P353, DOI 10.1042/0264-6021:3500353; Berns K, 2007, CANCER CELL, V12, P395, DOI 10.1016/j.ccr.2007.08.030; Bhaskar PT, 2007, DEV CELL, V12, P487, DOI 10.1016/j.devcel.2007.03.020; Casamayor A, 1999, CURR BIOL, V9, P186, DOI 10.1016/S0960-9822(99)80088-8; Chen LF, 2007, DEV CELL, V12, P603, DOI 10.1016/j.devcel.2007.03.005; Chow LML, 2006, CANCER LETT, V241, P184, DOI 10.1016/j.canlet.2005.11.042; Croushore JA, 2005, DEV DYNAM, V234, P911, DOI 10.1002/dvdy.20576; Fabrizio P, 2001, SCIENCE, V292, P288, DOI 10.1126/science.1059497; Faucherre A, 2008, ONCOGENE, V27, P1079, DOI 10.1038/sj.onc.1210730; Fox JA, 2002, J IMMUNOL, V169, P49, DOI 10.4049/jimmunol.169.1.49; Frattini M, 2007, BRIT J CANCER, V97, P1139, DOI 10.1038/sj.bjc.6604009; Friant S, 2001, EMBO J, V20, P6783, DOI 10.1093/emboj/20.23.6783; Fukuyama M, 2006, CURR BIOL, V16, P773, DOI 10.1016/j.cub.2006.02.073; Funaki M, 1999, J BIOL CHEM, V274, P22019, DOI 10.1074/jbc.274.31.22019; Funamoto S, 2002, CELL, V109, P611, DOI 10.1016/S0092-8674(02)00755-9; Gao P, 2005, BLOOD, V106, P2619, DOI 10.1182/blood-2004-08-3362; Gao XS, 2000, DEV BIOL, V221, P404, DOI 10.1006/dbio.2000.9680; Georgescu MM, 1999, P NATL ACAD SCI USA, V96, P10182, DOI 10.1073/pnas.96.18.10182; Georgescu MM, 2000, CANCER RES, V60, P7033; Gil EB, 1999, P NATL ACAD SCI USA, V96, P2925, DOI 10.1073/pnas.96.6.2925; Goberdhan DCI, 1999, GENE DEV, V13, P3244, DOI 10.1101/gad.13.24.3244; Grunwald V, 2002, CANCER RES, V62, P6141; Gupta R, 2002, PLANT CELL, V14, P2495, DOI 10.1105/tpc.005702; Han SY, 2000, CANCER RES, V60, P3147; Hanada M, 2004, BBA-PROTEINS PROTEOM, V1697, P3, DOI 10.1016/j.bbapap.2003.11.009; Hariharan IK, 2006, ANNU REV GENET, V40, P335, DOI 10.1146/annurev.genet.39.073003.100738; Heymont J, 2000, P NATL ACAD SCI USA, V97, P12672, DOI 10.1073/pnas.97.23.12672; Hoeller O, 2007, CURR BIOL, V17, P813, DOI 10.1016/j.cub.2007.04.004; Huang H, 1999, DEVELOPMENT, V126, P5365; Humphrey JS, 1997, P NATL ACAD SCI USA, V94, P5820, DOI 10.1073/pnas.94.11.5820; Iijima M, 2004, J BIOL CHEM, V279, P16606, DOI 10.1074/jbc.M312098200; Iijima M, 2002, CELL, V109, P599, DOI 10.1016/S0092-8674(02)00745-6; Inagaki M, 1999, MOL CELL BIOL, V19, P8344; Isakoff SJ, 1998, EMBO J, V17, P5374, DOI 10.1093/emboj/17.18.5374; ISHIOKA C, 1993, NAT GENET, V5, P124, DOI 10.1038/ng1093-124; Jiang ZB, 2007, CANCER RES, V67, P4467, DOI 10.1158/0008-5472.CAN-06-3398; Kaeberlein M, 2005, SCIENCE, V310, P1193, DOI 10.1126/science.1115535; Karakas B, 2006, BRIT J CANCER, V94, P455, DOI 10.1038/sj.bjc.6602970; Kato H, 2000, CLIN CANCER RES, V6, P3937; Kishimoto H, 2003, CELL STRUCT FUNCT, V28, P11; KUNZ J, 1993, CELL, V73, P585, DOI 10.1016/0092-8674(93)90144-F; Lacalle RA, 2004, J CELL SCI, V117, P6207, DOI 10.1242/jcs.01545; Lee JO, 1999, CELL, V99, P323, DOI 10.1016/S0092-8674(00)81663-3; Li LW, 1997, J BIOL CHEM, V272, P29403, DOI 10.1074/jbc.272.47.29403; Liu K, 2005, BIOCHEM SOC T, V33, P1170, DOI 10.1042/BST0331170; Liu K, 2005, J BIOL CHEM, V280, P22679, DOI 10.1074/jbc.M502972200; LoPiccolo J, 2008, DRUG RESIST UPDATE, V11, P32, DOI 10.1016/j.drup.2007.11.003; LORENZ MC, 1995, J BIOL CHEM, V270, P27531, DOI 10.1074/jbc.270.46.27531; Maehama T, 2004, FEBS LETT, V565, P43, DOI 10.1016/j.febslet.2004.03.074; Maehama T, 2001, ANNU REV BIOCHEM, V70, P247, DOI 10.1146/annurev.biochem.70.1.247; Mager WH, 2005, TRENDS PHARMACOL SCI, V26, P265, DOI 10.1016/j.tips.2005.03.004; Marone R, 2008, BBA-PROTEINS PROTEOM, V1784, P159, DOI 10.1016/j.bbapap.2007.10.003; Masse I, 2005, DEV BIOL, V286, P91, DOI 10.1016/j.ydbio.2005.07.010; Matsuo T, 2003, EMBO J, V22, P3073, DOI 10.1093/emboj/cdg298; Melese T, 2002, TRENDS PHARMACOL SCI, V23, P544, DOI 10.1016/S0165-6147(02)02097-7; Mihaylova VT, 1999, P NATL ACAD SCI USA, V96, P7427, DOI 10.1073/pnas.96.13.7427; Mitra P, 2004, J CELL BIOL, V166, P205, DOI 10.1083/jcb.200404150; Nagata Y, 2004, CANCER CELL, V6, P117, DOI 10.1016/j.ccr.2004.06.022; Niederberger C, 1999, MOL GEN GENET, V261, P177, DOI 10.1007/s004380050955; Nishio M, 2007, NAT CELL BIOL, V9, P36, DOI 10.1038/ncb1515; Ogg S, 1998, MOL CELL, V2, P887, DOI 10.1016/S1097-2765(00)80303-2; Palomero T, 2007, NAT MED, V13, P1203, DOI 10.1038/nm1636; Pascual-Ahuir A, 2007, CELL CYCLE, V6, P2445, DOI 10.4161/cc.6.20.4792; Pedruzzi I, 2003, MOL CELL, V12, P1607, DOI 10.1016/S1097-2765(03)00485-4; Pinal N, 2006, CURR BIOL, V16, P140, DOI 10.1016/j.cub.2005.11.068; Pulido R, 2008, FEBS J, V275, P848, DOI 10.1111/j.1742-4658.2008.06250.x; Rodriguez-Escudero I, 2005, BIOCHEM J, V390, P613, DOI 10.1042/BJ20050574; Roelants FM, 2002, MOL BIOL CELL, V13, P3005, DOI 10.1091/mbc.E02-04-0201; Roosen J, 2005, MOL MICROBIOL, V55, P862, DOI 10.1111/j.1365-2958.2004.04429.x; Rouault JP, 1999, CURR BIOL, V9, P329, DOI 10.1016/S0960-9822(99)80143-2; Roux AE, 2006, AGING CELL, V5, P345, DOI 10.1111/j.1474-9726.2006.00225.x; Scanga SE, 2000, ONCOGENE, V19, P3971, DOI 10.1038/sj.onc.1203739; Sharrard RM, 2000, BBA-GENE STRUCT EXPR, V1494, P282, DOI 10.1016/S0167-4781(00)00210-4; Shimodaira H, 1998, NAT GENET, V19, P384, DOI 10.1038/1277; Smith A, 1999, BBA-GENE STRUCT EXPR, V1447, P313, DOI 10.1016/S0167-4781(99)00172-4; Solari F, 2005, ONCOGENE, V24, P20, DOI 10.1038/sj.onc.1207978; Song ZH, 2007, EXP CELL RES, V313, P1161, DOI 10.1016/j.yexcr.2007.01.004; Steelman LS, 2008, ONCOGENE, V27, P4086, DOI 10.1038/onc.2008.49; Stocker H, 2002, SCIENCE, V295, P2088, DOI 10.1126/science. 1068094; Strahl T, 2007, BBA-MOL CELL BIOL L, V1771, P353, DOI 10.1016/j.bbalip.2007.01.015; Subramanian KK, 2007, BLOOD, V109, P4028, DOI 10.1182/blood-2006-10-055319; Sun YD, 2000, MOL CELL BIOL, V20, P4411, DOI 10.1128/MCB.20.12.4411-4419.2000; Suzuki A, 2008, CANCER SCI, V99, P209, DOI 10.1111/j.1349-7006.2007.00670.x; Suzuki T, 1998, GENE CHROMOSOME CANC, V21, P290, DOI 10.1002/(SICI)1098-2264(199804)21:4<290::AID-GCC2>3.0.CO;2-U; Tamguney T, 2007, J CELL SCI, V120, P4071, DOI 10.1242/jcs.015230; Tugendreich S, 2001, GENOME RES, V11, P1899, DOI 10.1101/gr.191601; Ueno S, 2006, DEV BIOL, V297, P274, DOI 10.1016/j.ydbio.2006.06.001; Urban J, 2007, MOL CELL, V26, P663, DOI 10.1016/j.molcel.2007.04.020; Valiente M, 2005, J BIOL CHEM, V280, P28936, DOI 10.1074/jbc.M504761200; Vogt PK, 2007, TRENDS BIOCHEM SCI, V32, P342, DOI 10.1016/j.tibs.2007.05.005; von Stein W, 2005, DEVELOPMENT, V132, P1675, DOI 10.1242/dev.01720; Walther TC, 2007, EMBO J, V26, P4946, DOI 10.1038/sj.emboj.7601933; Wan WZ, 2007, CELL SIGNAL, V19, P2227, DOI 10.1016/j.cellsig.2007.06.007; Wessels D, 2007, J CELL SCI, V120, P2517, DOI 10.1242/jcs.010876; Wu H, 2007, MOL CELL, V28, P886, DOI 10.1016/j.molcel.2007.10.028; Wu XY, 2000, P NATL ACAD SCI USA, V97, P4233, DOI 10.1073/pnas.97.8.4233; Wu Y, 2000, J BIOL CHEM, V275, P21477, DOI 10.1074/jbc.M909741199; Yu JW, 2004, MOL CELL, V13, P677, DOI 10.1016/S1097-2765(04)00083-8; Zhang XL, 1997, J BIOL CHEM, V272, P17756, DOI 10.1074/jbc.272.28.17756	100	24	25	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 15	2008	27	41					5431	5442		10.1038/onc.2008.240	http://dx.doi.org/10.1038/onc.2008.240			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	349KW	18794878				2022-12-28	WOS:000259280700005
J	Calvo, A; Catena, R; Noble, MS; Carbott, D; Gil-Bazo, I; Gonzalez-Moreno, O; Huh, JI; Sharp, R; Qiu, TH; Anver, MR; Merlino, G; Dickson, RB; Johnson, MD; Green, JE				Calvo, A.; Catena, R.; Noble, M. S.; Carbott, D.; Gil-Bazo, I.; Gonzalez-Moreno, O.; Huh, J-I; Sharp, R.; Qiu, T-H; Anver, M. R.; Merlino, G.; Dickson, R. B.; Johnson, M. D.; Green, J. E.			Identification of VEGF-regulated genes associated with increased lung metastatic potential: functional involvement of tenascin-C in tumor growth and lung metastasis	ONCOGENE			English	Article						metastasis; vascular endothelial growth factor; transgenic mice; mammary cancer; tenascin-C	BREAST-CANCER METASTASIS; TRANSGENIC MICE; MOUSE MAMMARY; MYC; ANGIOGENESIS; EXPRESSION; PROGNOSIS; LAMININ-5; MIGRATION; INVASION	Metastasis is the primary cause of death in patients with breast cancer. Overexpression of c-myc in humans correlates with metastases, but transgenic mice only show low rates of micrometastases. We have generated transgenic mice that overexpress both c-myc and vascular endothelial growth factor (VEGF) (Myc/VEGF) in the mammary gland, which develop high rates of pulmonary macrometastases. Gene expression pro. ling revealed a set of deregulated genes in Myc/VEGF tumors compared to Myc tumors associated with the increased metastatic phenotype. Cross-comparisons between this set of genes with a human breast cancer lung metastasis gene signature identified five common targets: tenascin-C (TNC), matrix metalloprotease-2, collagen-6-A1, mannosidase-alpha-1A and HLA-DPA1. Signaling blockade or knockdown of TNC in MDA-MB-435 cells resulted in a significant impairment of cell migration and anchorage-independent cell proliferation. Mice injected with clonal MDA-MB-435 cells with reduced expression of TNC demonstrated a signifiant decrease (P < 0.05) in (1) primary tumor growth; (2) tumor relapse after surgical removal of the primary tumor and (3) incidence of lung metastasis. Our results demonstrate that VEGF induces complex alterations in tissue architecture and gene expression. The TNC signaling pathway plays an important role in mammary tumor growth and metastases, suggesting that TNC may be a relevant target for therapy against metastatic breast cancer.	[Calvo, A.; Huh, J-I; Sharp, R.; Qiu, T-H; Merlino, G.; Green, J. E.] NCI, Lab Canc Biol & Genet, NIH, Bethesda, MD 20892 USA; [Calvo, A.; Catena, R.; Gil-Bazo, I.; Gonzalez-Moreno, O.] Univ Navarra, Ctr Appl Med Res CIMA, Div Oncol, E-31080 Pamplona, Spain; [Calvo, A.; Catena, R.; Gil-Bazo, I.; Gonzalez-Moreno, O.] Univ Navarra, Dept Histol & Pathol, E-31080 Pamplona, Spain; [Noble, M. S.; Carbott, D.; Dickson, R. B.; Johnson, M. D.] Georgetown Univ, Med Ctr, Lombardi Comprehens Canc Ctr, Dept Oncol, Washington, DC 20007 USA; [Gil-Bazo, I.] Univ Navarra Clin, Dept Oncol, Pamplona, Spain; [Anver, M. R.] Frederick Canc Res & Dev Ctr, Pathol & Histol Lab, SAIC, Frederick, MD USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University of Navarra; University of Navarra; Georgetown University; University of Navarra; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick	Johnson, MD (corresponding author), NCI, Dr Lab Canc Biol & Genet, NIH, Bldg 37 Room 4054 37 Convent Dr, Bethesda, MD 20892 USA.	Johnsom@georgetown.edu; jegreen@nih.gov	Calvo, Alfonso/V-7945-2017; Gil-Bazo, Ignacio/E-4581-2019	Calvo, Alfonso/0000-0003-4074-4242; Gil-Bazo, Ignacio/0000-0002-2626-5109; , Janet/0000-0001-9020-6982	Intramural Research Program of the NIH; National Cancer Institute; Center for Cancer Research; NIH [NO1-CO-12400, R01 CA72460, 2R01 CA104963, 2 R01 AG14963-06]; Susan G Komen Foundation; DOD Breast Cancer Program [DAMD17-01-1-0255]; ISCIII-RETIC [RD06/0020]; Fulbright-MEC fellowship; Spanish MEC fellowship; NATIONAL CANCER INSTITUTE [ZIABC005740, ZIABC011229, Z01BC010871] Funding Source: NIH RePORTER	Intramural Research Program of the NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Center for Cancer Research(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Susan G Komen Foundation(Susan G. Komen Breast Cancer Foundation); DOD Breast Cancer Program(United States Department of Defense); ISCIII-RETIC(Instituto de Salud Carlos III); Fulbright-MEC fellowship; Spanish MEC fellowship; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We would like to thank Ms Mercedes Calvo for manuscript preparation, Victor Segura and Elizabeth Guruceaga (CEIT and Tecnun, Pamplona, Spain) for their help in bioinformatic analysis, GlaxoSmithKline for the GW654652 compound, Dr Rene Bernards (The Netherlands Cancer Institute) for the pMSCV-Delta 3<SUP>1</SUP>LTR vector, Dr Linda Metheny-Barlow (at the LCCC) for helpful discussions, Edward C Rosfjord and Sandra L Deming and Gloria Chepko for contributions to the initial Myc/VEGF crossbreeding study. This research was supported in part by the Intramural Research Program of the NIH, National Cancer Institute, Center for Cancer Research, with funds from NIH(to GM) under Contract No. NO1-CO-12400, a grant from the Susan G Komen Foundation (to RBD), a grant from the DOD Breast Cancer Program DAMD17-01-1-0255 (to MDJ), NIH R01 CA72460 (to RBD), NIH 2R01 CA104963 (to RBD) ISCIII-RETIC (RD06/0020, to AC) and a Fulbright-MEC fellowship (AC); O G-M was supported by a Spanish MEC fellowship, and RBD by an NIH grant 2 R01 AG14963-06.	Adams J, 2000, CANCER RES, V60, P2898; AMUNDADOTTIR LT, 1995, CELL GROWTH DIFFER, V6, P737; Calvo A, 2002, CANCER RES, V62, P5325; Chiquet-Ehrismann R, 2003, J PATHOL, V200, P488, DOI 10.1002/path.1415; De Paola F, 2002, INT J CANCER, V98, P228, DOI 10.1002/ijc.10118; Deming SL, 2000, BRIT J CANCER, V83, P1688, DOI 10.1054/bjoc.2000.1522; Eckhardt BL, 2005, MOL CANCER RES, V3, P1; Ferrara N, 1999, KIDNEY INT, V56, P794, DOI 10.1046/j.1523-1755.1999.00610.x; Folkman J, 2002, SEMIN ONCOL, V29, P15, DOI 10.1053/sonc.2002.37263; Giannelli G, 2001, CLIN EXP METASTAS, V18, P439; Gupta GP, 2007, NATURE, V446, P765, DOI 10.1038/nature05760; Gupta GP, 2006, CELL, V127, P679, DOI 10.1016/j.cell.2006.11.001; Huh JI, 2005, ONCOGENE, V24, P790, DOI 10.1038/sj.onc.1208221; Hundley JE, 1997, CANCER RES, V57, P600; Jemal A, 2007, CA-CANCER J CLIN, V57, P43, DOI 10.3322/canjclin.57.1.43; JHAPPAN C, 1990, CELL, V61, P1137, DOI 10.1016/0092-8674(90)90076-Q; Kalembeyi I, 2003, INT J CANCER, V105, P53, DOI 10.1002/ijc.11037; Minn AJ, 2005, NATURE, V436, P518, DOI 10.1038/nature03799; Miralem T, 2001, ONCOGENE, V20, P5511, DOI 10.1038/sj.onc.1204753; Miyazaki K, 2006, CANCER SCI, V97, P91, DOI 10.1111/j.1349-7006.2006.00150.x; Noel A, 2004, J CLIN PATHOL, V57, P577, DOI 10.1136/jcp.2003.014472; Pei XF, 2004, IN VITRO CELL DEV-AN, V40, P14; PYKE C, 1994, AM J PATHOL, V145, P782; Qiu TH, 2004, CANCER RES, V64, P5973, DOI 10.1158/0008-5472.CAN-04-0242; Ramaswamy S, 2003, NAT GENET, V33, P49, DOI 10.1038/ng1060; Schmitz AAP, 2000, EXP CELL RES, V261, P1, DOI 10.1006/excr.2000.5049; Schoeffner DJ, 2005, LAB INVEST, V85, P608, DOI 10.1038/labinvest.3700258; Shih SC, 2002, AM J PATHOL, V161, P35, DOI 10.1016/S0002-9440(10)64154-5; Stamenkovic I, 2000, SEMIN CANCER BIOL, V10, P415, DOI 10.1006/scbi.2000.0379; Suyama E, 2003, P NATL ACAD SCI USA, V100, P5616, DOI 10.1073/pnas.1035850100; Talts JF, 1999, J CELL SCI, V112, P1855; Tsunoda T, 2003, AM J PATHOL, V162, P1857, DOI 10.1016/S0002-9440(10)64320-9; Yamamoto H, 2001, CLIN CANCER RES, V7, P896; Zagzag D, 2002, CANCER RES, V62, P2660; Zagzag D, 2002, HISTOL HISTOPATHOL, V17, P301, DOI 10.14670/HH-17.301	35	61	67	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 11	2008	27	40					5373	5384		10.1038/onc.2008.155	http://dx.doi.org/10.1038/onc.2008.155			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	346UW	18504437	Green Accepted, Green Published			2022-12-28	WOS:000259096100010
J	Hoskins, EE; Gunawardena, RW; Habash, KB; Wise-Draper, TM; Jansen, M; Knudsen, ES; Wells, SI				Hoskins, E. E.; Gunawardena, R. W.; Habash, K. B.; Wise-Draper, T. M.; Jansen, M.; Knudsen, E. S.; Wells, S. I.			Coordinate regulation of Fanconi anemia gene expression occurs through the Rb/E2F pathway	ONCOGENE			English	Article						Fanconi anemia; Rb protein family; E2F; transcription	CERVICAL-CARCINOMA CELLS; HUMAN-PAPILLOMAVIRUS E7; OVARIAN-CANCER; DNA-REPLICATION; POCKET PROTEINS; MESSENGER-RNA; FA PATHWAY; IN-VIVO; BRCA1; TUMOR	Fanconi anemia (FA) is a genome instability syndrome that is characterized by progressive bone marrow failure and a high risk of cancer. FA patients are particularly susceptible to leukemia as well as squamous cell carcinomas (SCCs) of the head and neck, anogenital region and skin. Thirteen complementation groups and the corresponding FA genes have been identified, and their protein products assemble into nuclear core complexes during DNA-damage responses. Much progress has been made in our understanding of post-translational FA protein modi. cations and physical interactions. By contrast, little is known about the control of protein availability at the level of transcription. We report here that multiple FA proteins were downregulated during the proliferative arrest of primary human keratinocytes and HeLa cells, and that the observed regulation was at a transcriptional level. Proliferative stimuli such as expression of HPV16 E7 as well as E2F1 overexpression in primary cells resulted in coordinate FA upregulation. To de. ne the underlying mechanism, we examined the endogenous FANCD2 promoter, and detected regulated binding of members of the E2F/Rb family in chromatin immunoprecipitation assays. Finally, a 1 kb promoter fragment was sufficient to confer E2F/Rb regulation in reporter assays. Taken together, our data demonstrate FA gene co-regulation in synchrony with the cell cycle and suggest that deregulated expression of individual FA genes-in addition to FA gene mutation-may promote FA-related human cancer.	[Hoskins, E. E.; Habash, K. B.; Wise-Draper, T. M.; Wells, S. I.] Cincinnati Childrens Hosp, Med Ctr, Div Hematol Oncol, Cincinnati, OH 45229 USA; [Gunawardena, R. W.; Knudsen, E. S.] Thomas Jefferson Univ, Kimmel Canc Ctr, Dept Canc Biol, Philadelphia, PA 19107 USA; [Jansen, M.] Cincinnati Childrens Hosp, Med Ctr, Dept Pediat, Div Expt Hematol, Cincinnati, OH 45229 USA	Cincinnati Children's Hospital Medical Center; Jefferson University; Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati	Wells, SI (corresponding author), Cincinnati Childrens Hosp, Med Ctr, Div Hematol Oncol, 3333 Burnet Ave,TCHRF Room S7-206, Cincinnati, OH 45229 USA.	Susanne.Wells@cchmc.org		Wise-Draper, Trisha/0000-0002-7279-4028	NATIONAL CANCER INSTITUTE [R01CA116316, R01CA104213, R01CA102357] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA116316-01A1, R01 CA102357-01A1, CA104213, R01 CA102357, R01 CA116316, CA102357] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alter BP, 2003, CANCER-AM CANCER SOC, V97, P425, DOI 10.1002/cncr.11046; Angus SP, 2004, MOL CELL BIOL, V24, P5404, DOI 10.1128/MCB.24.12.5404-5420.2004; Angus SP, 2002, EXP CELL RES, V276, P201, DOI 10.1006/excr.2002.5510; Bagby GC, 2006, SEMIN HEMATOL, V43, P147, DOI 10.1053/j.seminhematol.2006.04.005; Bindra RS, 2007, CANCER METAST REV, V26, P249, DOI 10.1007/s10555-007-9061-3; Bindra RS, 2006, CANCER BIOL THER, V5, P1400, DOI 10.4161/cbt.5.10.3454; Bridge AJ, 2003, NAT GENET, V34, P263, DOI 10.1038/ng1173; Chang YJE, 2002, J VIROL, V76, P8864, DOI 10.1128/JVI.76.17.8864-8874.2002; Chen CC, 2007, J MOL MED, V85, P497, DOI 10.1007/s00109-006-0153-2; Chen Q, 2005, BLOOD, V106, P698, DOI 10.1182/blood-2004-11-4286; Classon M, 2001, EXP CELL RES, V264, P135, DOI 10.1006/excr.2000.5135; Cobrinik D, 2005, ONCOGENE, V24, P2796, DOI 10.1038/sj.onc.1208619; Dhillon VS, 2004, MOL CANCER, V3, DOI 10.1186/1476-4598-3-33; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; Dotto GP, 1999, CRIT REV ORAL BIOL M, V10, P442; Dressman HK, 2007, J CLIN ONCOL, V25, P517, DOI 10.1200/JCO.2006.06.3743; Duensing S, 2004, INT J CANCER, V109, P157, DOI 10.1002/ijc.11691; Fehrmann Frauke, 2005, Methods Mol Biol, V292, P317; Garcia-Higuera I, 2001, MOL CELL, V7, P249, DOI 10.1016/S1097-2765(01)00173-3; Goodwin EC, 2000, P NATL ACAD SCI USA, V97, P12513, DOI 10.1073/pnas.97.23.12513; Goodwin EC, 2000, P NATL ACAD SCI USA, V97, P10978, DOI 10.1073/pnas.97.20.10978; Gunawardena RW, 2004, J BIOL CHEM, V279, P29278, DOI 10.1074/jbc.M400395200; Gurtan AM, 2006, DNA REPAIR, V5, P1119, DOI 10.1016/j.dnarep.2006.05.009; Joenje H, 2001, NAT REV GENET, V2, P446, DOI 10.1038/35076590; Johung K, 2007, J VIROL, V81, P2102, DOI 10.1128/JVI.02348-06; Kennedy RD, 2005, GENE DEV, V19, P2925, DOI 10.1101/gad.1370505; Kennedy RD, 2007, J CLIN INVEST, V117, P1440, DOI 10.1172/JCI31245; Kiyono T, 1997, P NATL ACAD SCI USA, V94, P11612, DOI 10.1073/pnas.94.21.11612; Kobayashi Teruaki, 1994, Journal of Dermatological Science, V8, P171, DOI 10.1016/0923-1811(94)90050-7; Kutler DI, 2003, BLOOD, V101, P1249, DOI 10.1182/blood-2002-07-2170; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Leveille F, 2006, DNA REPAIR, V5, P556, DOI 10.1016/j.dnarep.2006.01.005; Marsit CJ, 2004, ONCOGENE, V23, P1000, DOI 10.1038/sj.onc.1207256; Mathew CG, 2006, ONCOGENE, V25, P5875, DOI 10.1038/sj.onc.1209878; Meijer GA, 2007, CELL ONCOL, V29, P181; Mulloy JC, 2005, P NATL ACAD SCI USA, V102, P4016, DOI 10.1073/pnas.0404701102; Nakahara T, 2005, J VIROL, V79, P13150, DOI 10.1128/JVI.79.20.13150-13165.2005; Narayan G, 2004, CANCER RES, V64, P2994, DOI 10.1158/0008-5472.CAN-04-0245; Niedzwiedz W, 2004, MOL CELL, V15, P607, DOI 10.1016/j.molcel.2004.08.009; Oberley MJ, 2003, J BIOL CHEM, V278, P42466, DOI 10.1074/jbc.M307733200; Pace P, 2002, EMBO J, V21, P3414, DOI 10.1093/emboj/cdf355; Pagano G, 2003, BIOESSAYS, V25, P589, DOI 10.1002/bies.10283; Patel KJ, 2007, DNA REPAIR, V6, P885, DOI 10.1016/j.dnarep.2007.02.002; Pejovic T, 2006, CANCER RES, V66, P9017, DOI 10.1158/0008-5472.CAN-06-0222; Reid S, 2007, NAT GENET, V39, P162, DOI 10.1038/ng1947; Reimer D, 2007, CLIN CANCER RES, V13, P144, DOI 10.1158/1078-0432.CCR-06-0780; Russell PA, 2000, INT J CANCER, V87, P317, DOI 10.1002/1097-0215(20000801)87:3<317::AID-IJC2>3.0.CO;2-B; Siddiqui H, 2003, MOL CELL BIOL, V23, P7719, DOI 10.1128/MCB.23.21.7719-7731.2003; Spardy N, 2007, J VIROL, V81, P13265, DOI 10.1128/JVI.01121-07; Taniguchi T, 2002, BLOOD, V100, P2414, DOI 10.1182/blood-2002-01-0278; Tategu M, 2007, GENE REGUL SYST BIO, V1, P1; THOMPSON ME, 1995, NAT GENET, V9, P444, DOI 10.1038/ng0495-444; van der Heijden MS, 2005, CLIN CANCER RES, V11, P7508, DOI 10.1158/1078-0432.CCR-05-1048; Wang WD, 2007, NAT REV GENET, V8, P735, DOI 10.1038/nrg2159; Wells SI, 2000, EMBO J, V19, P5762, DOI 10.1093/emboj/19.21.5762; Wells SI, 2003, P NATL ACAD SCI USA, V100, P7093, DOI 10.1073/pnas.1232309100; Wise-Draper TM, 2005, J VIROL, V79, P14309, DOI 10.1128/JVI.79.22.14309-14317.2005; Wreesmann VB, 2007, ORL-J OTO-RHIN-LARYN, V69, P218, DOI 10.1159/000101542; Xia B, 2007, NAT GENET, V39, P159, DOI 10.1038/ng1942	59	47	48	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 14	2008	27	35					4798	4808		10.1038/onc.2008.121	http://dx.doi.org/10.1038/onc.2008.121			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	337OJ	18438432	Green Accepted			2022-12-28	WOS:000258445100005
J	Tseng, RC; Lin, RK; Wen, CK; Tseng, C; Hsu, HS; Hsu, WH; Wang, YC				Tseng, R-C; Lin, R-K; Wen, C-K; Tseng, C.; Hsu, H-S; Hsu, W-H; Wang, Y-C			Epigenetic silencing of AXIN2/betaTrCP and deregulation of p53-mediated control lead to wild-type beta-catenin nuclear accumulation in lung tumorigenesis	ONCOGENE			English	Article						beta-catenin; AXIN2; betaTrCP; p53; epigenetic alteration; NSCLC	DOWN-REGULATION; EXPRESSION; CANCER; AXIN2; P53; MUTATIONS; ACTIVATION; STABILITY; CARCINOMA; PATHWAY	beta-catenin accumulation is often found in lung tumors, but only a few patients have mutations in beta-catenin gene. In addition, activated p53 downregulates beta-catenin. Therefore, we postulated that alteration of the degradation complex AXIN2 ( axis inhibition protein 2) and betaTrCP (beta-transducin repeat-containing protein) and p53 regulation could result in beta-catenin protein accumulation in lung cancer. Using the immunohistochemical and sequencing analyses, we found that patients with beta-catenin accumulation without mutation were associated with patients with p53 overexpression and low AXIN2 expression (P=0.023 similar to 0.041). Alteration of AXIN2 was associated with poor survival in early stage patients (P=0.016). Low expression of AXIN2 and betaTrCP was significantly associated with promoter hypermethylation and histone deacetylation. Ectopic expression and knockdown of p53, AXIN2 and betaTrCP genes in A549 (p53wild-type) and H1299 (p53 null) lung cancer cell lines showed cooperation between p53 and AXIN2/betaTrCP in the reduction of beta-catenin expression. Our clinical and cell model findings provide new evidence that epigenetic silencing of AXIN2/betaTrCP in the degradation complex and deregulation of p53-mediated control lead to wild-type beta-catenin nuclear accumulation in non-small cell lung cancer tumorigenesis. In addition, a high level of p53 downregulates the beta-catenin expression, but this effect is attenuated by non-functional AXIN2 or betaTrCP in lung cancer.	[Tseng, R-C; Lin, R-K; Wen, C-K; Wang, Y-C] Natl Cheng Kung Univ, Coll Med, Dept Pharmacol, Tainan 70101, Taiwan; [Tseng, C.] Natl Tsing Hua Univ, Dept Life Sci, Hsinchu, Taiwan; [Hsu, H-S] Natl Yang Ming Univ, Inst Emergency & Crit Care Med, Taipei Vet Gen Hosp, Dept Surg,Div Thorac Surg, Taipei 112, Taiwan	National Cheng Kung University; National Tsing Hua University; National Yang Ming Chiao Tung University; Taipei Veterans General Hospital	Wang, YC (corresponding author), Natl Cheng Kung Univ, Coll Med, Dept Pharmacol, 1 Univ Rd, Tainan 70101, Taiwan.	ycw5798@mail.ncku.edu.tw	Wang, Yi-Ching/J-8702-2019	Wang, Yi-Ching/0000-0002-7694-2067				Chen RH, 2000, J BIOL CHEM, V275, P17894, DOI 10.1074/jbc.M905336199; Chu YW, 1997, AM J RESP CELL MOL, V17, P353, DOI 10.1165/ajrcmb.17.3.2837; Chung GG, 2004, CANCER, V100, P2084, DOI 10.1002/cncr.20232; Damalas A, 1999, EMBO J, V18, P3054, DOI 10.1093/emboj/18.11.3054; Derks S, 2004, CELL ONCOL, V26, P291; Gregorieff A, 2005, GENE DEV, V19, P877, DOI 10.1101/gad.1295405; Hughes TA, 2006, CANCER LETT, V233, P338, DOI 10.1016/j.canlet.2005.03.026; Hughes TA, 2005, EXP CELL RES, V303, P32, DOI 10.1016/j.yexcr.2004.09.014; Jones PA, 2007, CELL, V128, P683, DOI 10.1016/j.cell.2007.01.029; Kase S, 2000, CLIN CANCER RES, V6, P4789; KASE S, 2000, CLIN CANC RES; Kim CJ, 2007, APMIS, V115, P127, DOI 10.1111/j.1600-0463.2007.apm_562.x; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; Koch A, 2005, CLIN CANCER RES, V11, P4295, DOI 10.1158/1078-0432.CCR-04-1162; Koinuma K, 2006, ONCOGENE, V25, P139, DOI 10.1038/sj.onc.1209009; Lee MN, 2007, CLIN CANCER RES, V13, P832, DOI 10.1158/1078-0432.CCR-05-2694; Levina E, 2004, ONCOGENE, V23, P4444, DOI 10.1038/sj.onc.1207587; Liu J, 2001, MOL CELL, V7, P927, DOI 10.1016/S1097-2765(01)00241-6; Liu WG, 2000, NAT GENET, V26, P146, DOI 10.1038/79859; Lustig B, 2002, MOL CELL BIOL, V22, P1184, DOI 10.1128/MCB.22.4.1184-1193.2002; Mazieres J, 2005, CANCER LETT, V222, P1, DOI 10.1016/j.canlet.2004.08.040; Minna JD, 2002, CANCER CELL, V1, P49, DOI 10.1016/S1535-6108(02)00027-2; Moon RT, 2004, NAT REV GENET, V5, P689, DOI 10.1038/nrg1427; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; Polakis P, 2000, GENE DEV, V14, P1837; Sadot E, 2001, MOL CELL BIOL, V21, P6768, DOI 10.1128/MCB.21.20.6768-6781.2001; Shigemitsu K, 2001, ONCOGENE, V20, P4249, DOI 10.1038/sj.onc.1204557; Spiegelman VS, 2000, MOL CELL, V5, P877, DOI 10.1016/S1097-2765(00)80327-5; Taketo MM, 2004, NAT GENET, V36, P320, DOI 10.1038/ng0404-320; Tseng RC, 2005, INT J CANCER, V117, P241, DOI 10.1002/ijc.21178; Wang YC, 2005, J CLIN ONCOL, V23, P154, DOI 10.1200/JCO.2005.03.139; Wodarz A, 1998, ANNU REV CELL DEV BI, V14, P59, DOI 10.1146/annurev.cellbio.14.1.59	32	38	39	2	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 24	2008	27	32					4488	4496		10.1038/onc.2008.83	http://dx.doi.org/10.1038/onc.2008.83			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	329PU	18372914	Bronze			2022-12-28	WOS:000257881700011
J	Eelen, G; Bempt, IV; Verlinden, L; Drijkoningen, M; Smeets, A; Neven, P; Christiaens, MR; Marchal, K; Bouillon, R; Verstuyf, A				Eelen, G.; Bempt, I. Vanden; Verlinden, L.; Drijkoningen, M.; Smeets, A.; Neven, P.; Christiaens, M. R.; Marchal, K.; Bouillon, R.; Verstuyf, A.			Expression of the BRCA1-interacting protein Brip1/BACH1/FANCJ is driven by E2F and correlates with human breast cancer malignancy	ONCOGENE			English	Article						Brip1; breast cancer; E2F; vitamin D; high grade; HER-2	FANCONI-ANEMIA; MOLECULAR PORTRAITS; DNA-REPLICATION; HELICASE BRIP1; TARGET GENES; SUSCEPTIBILITY; BACH1; TRANSCRIPTION; CARCINOMAS; MUTATIONS	Mutations in the BRCA1-interacting DEAH helicase Brip1 confer an increased risk of breast cancer. In the present study we aimed to unravel the transcriptional control of Brip1 and to determine its expression levels in a set of 101 primary invasive breast carcinomas. Transcription of Brip1 was found to be cell growth-related and controlled by the E2F/retinoblastoma (Rb) pathway through a conserved E2F-responsive site. Repression of Brip1 expression by the cell growth-inhibiting compound 1 alpha,25-dihydroxyvitamin D(3) depended on this same E2F-responsive site. In spite of its role as a tumor suppressor, both quantitative reverse transcriptase-PCR analyses and immunohistochemical stainings showed significantly elevated Brip1 expression levels in grade 3 tumors as compared to grade 1 or 2 carcinomas. Furthermore, increased Brip1 transcript levels were found in tumors with an estrogen receptor-negative, progesterone receptor-negative or HER-2-positive status. In conclusion, these data show that Brip1 is a genuine target gene for the E2F/Rb pathway and that elevated expression levels of Brip1 are detected in primary invasive breast carcinomas with unfavorable characteristics.	[Eelen, G.; Verlinden, L.; Verstuyf, A.] Katholieke Univ Leuven, LEGENDO, B-3000 Leuven, Belgium; [Bempt, I. Vanden; Drijkoningen, M.] Katholieke Univ Leuven, Univ Hosp, Dept Pathol, B-3000 Leuven, Belgium; [Drijkoningen, M.; Smeets, A.; Neven, P.; Christiaens, M. R.] Katholieke Univ Leuven, Univ Hosp, Multidisciplinary Breast Ctr, B-3000 Leuven, Belgium; [Marchal, K.] Katholieke Univ Leuven, CMPG, ESAT, B-3000 Leuven, Belgium	KU Leuven; KU Leuven; KU Leuven; KU Leuven	Verstuyf, A (corresponding author), Katholieke Univ Leuven, LEGENDO, 9th Floor,Bus 902,Herestr 49, B-3000 Leuven, Belgium.	mieke.verstuyf@med.kuleuven.be	Vanden Bempt, Isabelle/AAH-2501-2022; Marchal, Kathleen/B-5001-2013; Vanden Bempt, Isabelle/AFM-0163-2022; Verlinden, Lieve/E-6517-2011; smeets, ann/AAP-9191-2020; Marchal, Kathleen/O-7936-2017	Vanden Bempt, Isabelle/0000-0002-3433-555X; Marchal, Kathleen/0000-0002-2169-4588; Vanden Bempt, Isabelle/0000-0002-3433-555X; Marchal, Kathleen/0000-0002-2169-4588; Verstuyf, Annemieke/0000-0003-3193-2698; Verlinden, Lieve/0000-0002-9621-3662				Bracken AP, 2004, TRENDS BIOCHEM SCI, V29, P409, DOI 10.1016/j.tibs.2004.06.006; Bridge WL, 2005, NAT GENET, V37, P953, DOI 10.1038/ng1627; Cantor S, 2004, P NATL ACAD SCI USA, V101, P2357, DOI 10.1073/pnas.0308717101; Cantor SB, 2001, CELL, V105, P149, DOI 10.1016/S0092-8674(01)00304-X; Chin K, 2006, CANCER CELL, V10, P529, DOI 10.1016/j.ccr.2006.10.009; D'Andrea AD, 2003, NAT REV CANCER, V3, P23, DOI 10.1038/nrc970; Eelen G, 2007, CURR MED CHEM, V14, P1893; Eelen G, 2004, J STEROID BIOCHEM, V89-90, P405, DOI 10.1016/j.jsbmb.2004.03.008; Eelen G, 2004, J BONE MINER RES, V19, P133, DOI 10.1359/JBMR.0301204; Fridlyand J, 2006, BMC CANCER, V6, DOI 10.1186/1471-2407-6-96; Giangrande PH, 2004, GENE DEV, V18, P2941, DOI 10.1101/gad.1239304; ISHIDA R, 1982, CANCER RES, V42, P4000; Levitus M, 2005, NAT GENET, V37, P934, DOI 10.1038/ng1625; Levran O, 2005, NAT GENET, V37, P931, DOI 10.1038/ng1624; Litman R, 2005, CANCER CELL, V8, P255, DOI 10.1016/j.ccr.2005.08.004; Paris PL, 2004, HUM MOL GENET, V13, P1303, DOI 10.1093/hmg/ddh155; Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093; Pharoah PDP, 2002, NAT GENET, V31, P33, DOI 10.1038/ng853; POLL EHA, 1982, HUM GENET, V61, P228, DOI 10.1007/BF00296447; Raemaekers T, 2003, J CELL BIOL, V162, P1017, DOI 10.1083/jcb.200302129; Saiz AD, 2002, J PATHOL, V198, P157, DOI 10.1002/path.1185; Seal S, 2006, NAT GENET, V38, P1239, DOI 10.1038/ng1902; Sinclair CS, 2003, BREAST CANCER RES TR, V78, P313, DOI 10.1023/A:1023081624133; Sorlie T, 2004, EUR J CANCER, V40, P2667, DOI 10.1016/j.ejca.2004.08.021; Verlinden L, 2005, J BIOL CHEM, V280, P37319, DOI 10.1074/jbc.M503587200; Verlinden L, 2007, CANCER RES, V67, P6574, DOI 10.1158/0008-5472.CAN-06-3545; Whitfield ML, 2006, NAT REV CANCER, V6, P99, DOI 10.1038/nrc1802; Yan Z, 1998, P NATL ACAD SCI USA, V95, P3603, DOI 10.1073/pnas.95.7.3603; Yang L, 2007, LEUKEMIA, V21, P868, DOI 10.1038/sj.leu.2404624; Yu XC, 2003, SCIENCE, V302, P639, DOI 10.1126/science.1088753; Zacharatos P, 2004, J PATHOL, V203, P744, DOI 10.1002/path.1582; Zhang SY, 2000, CANCER EPIDEM BIOMAR, V9, P395	32	31	32	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL	2008	27	30					4233	4241		10.1038/onc.2008.51	http://dx.doi.org/10.1038/onc.2008.51			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	324DB	18345034	Green Published			2022-12-28	WOS:000257496800010
J	Obsil, T; Obsilova, V				Obsil, T.; Obsilova, V.			Structure/function relationships underlying regulation of FOXO transcription factors	ONCOGENE			English	Review						FOXO; forkhead transcription factors; 14-3-3 protein; phosphorylation; acetylation; ubiquitination	PROTEIN-KINASE-B; WINGED HELIX PROTEINS; DNA-BINDING DOMAIN; INSULIN-RESPONSE SEQUENCE; FORKHEAD GENE FAMILY; EXTENDS LIFE-SPAN; FACTOR AFX FOXO4; CRYSTAL-STRUCTURE; CAENORHABDITIS-ELEGANS; NUCLEAR-LOCALIZATION	The FOXO subgroup of forkhead transcription factors plays a central role in cell-cycle control, differentiation, metabolism control, stress response and apoptosis. Therefore, the function of these important molecules is tightly controlled by a wide range of protein-protein interactions and posttranslational modifications including phosphorylation, acetylation and ubiquitination. The mechanisms by which these processes regulate FOXO activity are mostly elusive. This review focuses on recent advances in structural studies of forkhead transcription factors and the insights they provide into the mechanism of DNA recognition. On the basis of these data, we discuss structural aspects of protein-protein interactions and posttranslational modi. cations that target the forkhead domain and the nuclear localization signal of FOXO proteins.	[Obsil, T.] Charles Univ Prague, Fac Sci, Dept Phys & Macromol Chem, Prague 12843, Czech Republic; [Obsil, T.; Obsilova, V.] Acad Sci Czech Republ, Inst Physiol, Prague, Czech Republic	Charles University Prague; Czech Academy of Sciences; Institute of Physiology of the Czech Academy of Sciences	Obsil, T (corresponding author), Charles Univ Prague, Fac Sci, Dept Phys & Macromol Chem, Prague 12843, Czech Republic.	obsil@natur.cuni.cz	Obsilova, Veronika/B-7116-2012; Obsil, Tomas/B-7142-2012	Obsilova, Veronika/0000-0003-4887-0323; Obsil, Tomas/0000-0003-4602-1272				AITKEN A, 1995, J BIOL CHEM, V270, P5706, DOI 10.1074/jbc.270.11.5706; Aitken A, 2006, SEMIN CANCER BIOL, V16, P162, DOI 10.1016/j.semcancer.2006.03.005; Alessi DR, 1996, FEBS LETT, V399, P333, DOI 10.1016/S0014-5793(96)01370-1; Anderson MJ, 1998, GENOMICS, V47, P187, DOI 10.1006/geno.1997.5122; Asada S, 2007, CELL SIGNAL, V19, P519, DOI 10.1016/j.cellsig.2006.08.015; Berdichevsky A, 2006, CELL, V125, P1165, DOI 10.1016/j.cell.2006.04.036; Biggs WH, 2001, MAMM GENOME, V12, P416, DOI 10.1007/s003350020002; Biggs WH, 1999, P NATL ACAD SCI USA, V96, P7421, DOI 10.1073/pnas.96.13.7421; Bois PRJ, 2005, MOL CELL BIOL, V25, P7645, DOI 10.1128/MCB.25.17.7645-7656.2005; Borkhardt A, 1997, ONCOGENE, V14, P195, DOI 10.1038/sj.onc.1200814; Boura E, 2007, J BIOL CHEM, V282, P8265, DOI 10.1074/jbc.M605682200; BRASELMANN S, 1995, EMBO J, V14, P4839, DOI 10.1002/j.1460-2075.1995.tb00165.x; Brownawell AM, 2001, MOL CELL BIOL, V21, P3534, DOI 10.1128/MCB.21.10.3534-3546.2001; Brunet A, 2002, J CELL BIOL, V156, P817, DOI 10.1083/jcb.200112059; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Brunet A, 2004, SCIENCE, V303, P2011, DOI 10.1126/science.1094637; Cahill CM, 2001, J BIOL CHEM, V276, P13402, DOI 10.1074/jbc.M010042200; Carlsson P, 2002, DEV BIOL, V250, P1, DOI 10.1006/dbio.2002.0780; CLARK KL, 1993, NATURE, V364, P412, DOI 10.1038/364412a0; Daitoku H, 2004, P NATL ACAD SCI USA, V101, P10042, DOI 10.1073/pnas.0400593101; Dalal SN, 1999, MOL CELL BIOL, V19, P4465; DAVIS RJ, 1994, CANCER RES, V54, P2869; DINGWALL C, 1991, TRENDS BIOCHEM SCI, V16, P478, DOI 10.1016/0968-0004(91)90184-W; Essers MAG, 2004, EMBO J, V23, P4802, DOI 10.1038/sj.emboj.7600476; Frescas D, 2005, J BIOL CHEM, V280, P20589, DOI 10.1074/jbc.M412357200; Fu HA, 2000, ANNU REV PHARMACOL, V40, P617, DOI 10.1146/annurev.pharmtox.40.1.617; Fukuoka M, 2003, INT J MOL MED, V12, P503; Furuyama T, 2000, BIOCHEM J, V349, P629, DOI 10.1042/0264-6021:3490629; Gajiwala KS, 2000, CURR OPIN STRUC BIOL, V10, P110, DOI 10.1016/S0959-440X(99)00057-3; GALILI N, 1993, NAT GENET, V5, P230, DOI 10.1038/ng1193-230; Greer EL, 2005, ONCOGENE, V24, P7410, DOI 10.1038/sj.onc.1209086; Grozinger CM, 2000, P NATL ACAD SCI USA, V97, P7835, DOI 10.1073/pnas.140199597; Guo SD, 1999, J BIOL CHEM, V274, P17184, DOI 10.1074/jbc.274.24.17184; Hillion J, 1997, BLOOD, V90, P3714, DOI 10.1182/blood.V90.9.3714; Hu MCT, 2004, CELL, V117, P225, DOI 10.1016/S0092-8674(04)00302-2; Huang H, 2005, P NATL ACAD SCI USA, V102, P1649, DOI 10.1073/pnas.0406789102; Huang HJ, 2006, SCIENCE, V314, P294, DOI 10.1126/science.1130512; Jin CW, 1999, J MOL BIOL, V292, P641, DOI 10.1006/jmbi.1999.3106; Kaestner KH, 2000, GENE DEV, V14, P142; KAUFMANN E, 1995, J MOL BIOL, V248, P239, DOI 10.1006/jmbi.1995.0218; Kobayashi Y, 2005, INT J MOL MED, V16, P237; Kops GJPL, 1999, NATURE, V398, P630, DOI 10.1038/19328; LAI E, 1993, P NATL ACAD SCI USA, V90, P10421, DOI 10.1073/pnas.90.22.10421; Lehmann OJ, 2003, TRENDS GENET, V19, P339, DOI 10.1016/S0168-9525(03)00111-2; Lehtinen MK, 2006, CELL, V125, P987, DOI 10.1016/j.cell.2006.03.046; Lin K, 1997, SCIENCE, V278, P1319, DOI 10.1126/science.278.5341.1319; LIU D, 1995, NATURE, V376, P191, DOI 10.1038/376191a0; Liu PP, 2002, PROTEINS, V49, P543, DOI 10.1002/prot.10227; Marsden I, 1998, J MOL BIOL, V278, P293, DOI 10.1006/jmbi.1998.1703; Matsuzaki H, 2003, P NATL ACAD SCI USA, V100, P11285, DOI 10.1073/pnas.1934283100; Matsuzaki H, 2005, P NATL ACAD SCI USA, V102, P11278, DOI 10.1073/pnas.0502738102; Mazet F, 2003, GENE, V316, P79, DOI 10.1016/S0378-1119(03)00741-8; Motta MC, 2004, CELL, V116, P551, DOI 10.1016/S0092-8674(04)00126-6; Muslin AJ, 1996, CELL, V84, P889, DOI 10.1016/S0092-8674(00)81067-3; Muslin AJ, 2000, CELL SIGNAL, V12, P703, DOI 10.1016/S0898-6568(00)00131-5; Nakae J, 1999, J BIOL CHEM, V274, P15982, DOI 10.1074/jbc.274.23.15982; OBrien RM, 1996, PHYSIOL REV, V76, P1109, DOI 10.1152/physrev.1996.76.4.1109; Obsil T, 2003, BIOCHEMISTRY-US, V42, P15264, DOI 10.1021/bi0352724; Obsil T, 2001, CELL, V105, P257, DOI 10.1016/S0092-8674(01)00316-6; Obsilova V, 2005, BIOCHEMISTRY-US, V44, P11608, DOI 10.1021/bi050618r; Ogg S, 1997, NATURE, V389, P994, DOI 10.1038/40194; Oh SW, 2005, P NATL ACAD SCI USA, V102, P4494, DOI 10.1073/pnas.0500749102; OVERDIER DG, 1994, MOL CELL BIOL, V14, P2755, DOI 10.1128/MCB.14.4.2755; PARRY P, 1994, GENE CHROMOSOME CANC, V11, P79, DOI 10.1002/gcc.2870110203; PIERROU S, 1994, EMBO J, V13, P5002, DOI 10.1002/j.1460-2075.1994.tb06827.x; Plas DR, 2003, J BIOL CHEM, V278, P12361, DOI 10.1074/jbc.M213069200; Rena G, 1999, J BIOL CHEM, V274, P17179, DOI 10.1074/jbc.274.24.17179; Rena G, 2002, EMBO J, V21, P2263, DOI 10.1093/emboj/21.9.2263; Rena G, 2001, BIOCHEM J, V354, P605, DOI 10.1042/0264-6021:3540605; Rittinger K, 1999, MOL CELL, V4, P153, DOI 10.1016/S1097-2765(00)80363-9; Seimiya H, 2000, EMBO J, V19, P2652, DOI 10.1093/emboj/19.11.2652; Sheng WY, 2002, BIOCHEMISTRY-US, V41, P3286, DOI 10.1021/bi011908k; Shiyanova T, 1999, ARCH BIOCHEM BIOPHYS, V362, P356, DOI 10.1006/abbi.1998.1040; Streeper RS, 1997, J BIOL CHEM, V272, P11698, DOI 10.1074/jbc.272.18.11698; Stroud JC, 2006, STRUCTURE, V14, P159, DOI 10.1016/j.str.2005.10.005; Sunayama J, 2005, J CELL BIOL, V170, P295, DOI 10.1083/jcb.200409117; Sutton J, 1996, J BIOL CHEM, V271, P23126, DOI 10.1074/jbc.271.38.23126; Takaishi H, 1999, P NATL ACAD SCI USA, V96, P11836, DOI 10.1073/pnas.96.21.11836; Tang ED, 1999, J BIOL CHEM, V274, P16741, DOI 10.1074/jbc.274.24.16741; Tran Hien, 2003, Sci STKE, V2003, pRE5, DOI 10.1126/stke.2003.172.re5; Tsai KL, 2007, NUCLEIC ACIDS RES, V35, P6984, DOI 10.1093/nar/gkm703; Tsai KL, 2006, J BIOL CHEM, V281, P17400, DOI 10.1074/jbc.M600478200; Tsuruta F, 2004, EMBO J, V23, P1889, DOI 10.1038/sj.emboj.7600194; Tzivion G, 2001, ONCOGENE, V20, P6331, DOI 10.1038/sj.onc.1204777; Tzivion G, 1998, NATURE, V394, P88, DOI 10.1038/27938; Van der Heide LP, 2005, BIOCHEM J, V391, P623, DOI 10.1042/BJ20050525; van der Heide LP, 2004, BIOCHEM J, V380, P297, DOI 10.1042/BJ20040167; Van der Hoeven PCJ, 2000, BIOCHEM J, V345, P297, DOI 10.1042/0264-6021:3450297; van der Horst A, 2004, J BIOL CHEM, V279, P28873, DOI 10.1074/jbc.M401138200; van der Horst A, 2007, NAT REV MOL CELL BIO, V8, P440, DOI 10.1038/nrm2190; van der Horst A, 2006, NAT CELL BIOL, V8, P1064, DOI 10.1038/ncb1469; van Dongen MJP, 2000, J MOL BIOL, V296, P351, DOI 10.1006/jmbi.1999.3476; Vielhaber E, 2000, MOL CELL BIOL, V20, P4888, DOI 10.1128/MCB.20.13.4888-4899.2000; Vincenz C, 1996, J BIOL CHEM, V271, P20029, DOI 10.1074/jbc.271.33.20029; Vogt PK, 2005, CELL CYCLE, V4, P908, DOI 10.4161/cc.4.7.1796; Wang MC, 2005, CELL, V121, P115, DOI 10.1016/j.cell.2005.02.030; Wang Y, 2006, MECH AGEING DEV, V127, P741, DOI 10.1016/j.mad.2006.05.005; WEIGEL D, 1990, CELL, V63, P455, DOI 10.1016/0092-8674(90)90439-L; WEIGEL D, 1989, CELL, V57, P645, DOI 10.1016/0092-8674(89)90133-5; Weigelt J, 2001, BIOCHEMISTRY-US, V40, P5861, DOI 10.1021/bi001663w; Woods YL, 2001, BIOCHEM J, V355, P597, DOI 10.1042/bj3550597; Wu YQ, 2006, CELL, V126, P375, DOI 10.1016/j.cell.2006.05.042; Xiao Bing, 1995, Nature (London), V376, P188, DOI 10.1038/376188a0; Yaffe MB, 2002, FEBS LETT, V513, P53, DOI 10.1016/S0014-5793(01)03288-4; Yaffe MB, 1997, CELL, V91, P961, DOI 10.1016/S0092-8674(00)80487-0; Zhang SS, 1999, J BIOL CHEM, V274, P24865, DOI 10.1074/jbc.274.35.24865; Zhang XH, 2002, J BIOL CHEM, V277, P45276, DOI 10.1074/jbc.M208063200; Zhao XS, 2004, BIOCHEM J, V378, P839, DOI 10.1042/BJ20031450; Zhu JY, 1998, CELL, V93, P851, DOI 10.1016/S0092-8674(00)81445-2	109	164	175	2	25	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 7	2008	27	16					2263	2275		10.1038/onc.2008.20	http://dx.doi.org/10.1038/onc.2008.20			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	285NE	18391969				2022-12-28	WOS:000254782700002
J	Kim, MA; Kim, HJ; Jee, HJ; Kim, AJ; Bae, YS; Bae, SS; Yun, J				Kim, M-A; Kim, H-J; Jee, H. J.; Kim, A. J.; Bae, Y-S; Bae, S. S.; Yun, J.			Akt2, but not Akt1, is required for cell survival by inhibiting activation of JNK and p38 after UV irradiation	ONCOGENE			English	Article						Akt1; Akt2; isotype-specific function; UV; JNK; p38	PROTEIN-KINASE-B; ISOFORM-SPECIFIC REGULATION; INSULIN-RESISTANCE; PHOSPHORYLATION; PATHWAY; CANCER; APOPTOSIS; AKT/PKB; ALPHA; MICE	The serine/threonine protein kinase, Akt/PKB, has an essential function in cell survival during response to various stresses. Recent studies have demonstrated that Akt isoforms exhibit some distinct physiological functions, but the isotype-specific functions for Akt in the stress response have not been fully identified. In this study, we analysed the cellular response to genotoxic stress using isogenic wild-type, Akt1(-/-) and Akt2(-/-) mouse embryonic fibroblasts (MEFs). Marked hypersensitivity of Akt2(-/-) MEFs was observed to UV irradiation, whereas wild-type and Akt1(-/-) MEFs showed comparable levels of resistance. Akt2(-/-) mouse aortic endothelial cells also showed hypersensitivity to UV and the reconstitution of Akt2 expression in the Akt2(-/-) MEFs restored the UV resistance of the cells. Interestingly, upon UV irradiation, JNK and p38 were significantly upregulated in Akt2(-/-) MEFs, compared to wild-type and Akt1(-/-) MEFs. Additionally, inhibition of JNK and p38 activation reduced UV-induced cell death. Furthermore, both the hyperactivation of JNK and p38 and the UV-induced cell death in Akt2(-/-) MEFs were completely inhibited by restoring Akt2 expression. These results indicate that Akt2, but not Akt1, is essential for cell survival upon UV irradiation, and that Akt2 prevents UV-induced cell death by inhibiting activation of JNK and p38.	[Kim, M-A; Kim, H-J; Jee, H. J.; Kim, A. J.; Bae, Y-S; Yun, J.] Dong A Univ, Coll Med, Dept Biochem, Pusan 602714, South Korea; [Bae, S. S.] Pusan Natl Univ, Coll Med, Dept Pharmacol, Pusan, South Korea	Dong A University; Pusan National University	Yun, J (corresponding author), Dong A Univ, Coll Med, Dept Biochem, 3-1 Dongdaesin Dong, Pusan 602714, South Korea.	yunj@dau.ac.kr			National R&D Program for Cancer Control, Ministry of Health & Welfare, Republic of Korea [0620060-2]; KOSEF (Korea Science and Engineering Foundation) [M1075604000107N560400110]	National R&D Program for Cancer Control, Ministry of Health & Welfare, Republic of Korea(Ministry of Health & Welfare (MOHW), Republic of Korea); KOSEF (Korea Science and Engineering Foundation)(Korea Science and Engineering Foundation)	This work was supported by a grant of the National R&D Program for Cancer Control, Ministry of Health & Welfare, Republic of Korea (0620060-2) and Research Program of dual regulation mechanisms of aging and cancer from KOSEF (Korea Science and Engineering Foundation) (M1075604000107N560400110).	Alessi DR, 1998, CURR OPIN GENET DEV, V8, P55, DOI 10.1016/S0959-437X(98)80062-2; Bae SS, 2003, J BIOL CHEM, V278, P49530, DOI 10.1074/jbc.M306782200; Brazil DP, 2004, TRENDS BIOCHEM SCI, V29, P233, DOI 10.1016/j.tibs.2004.03.006; Chan TO, 1999, ANNU REV BIOCHEM, V68, P965, DOI 10.1146/annurev.biochem.68.1.965; Cheng JQ, 2005, ONCOGENE, V24, P7482, DOI 10.1038/sj.onc.1209088; Cho H, 2001, J BIOL CHEM, V276, P38349, DOI 10.1074/jbc.C100462200; Cho H, 2001, SCIENCE, V292, P1728, DOI 10.1126/science.292.5522.1728; Coffer PJ, 1998, BIOCHEM J, V335, P1; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; Easton RM, 2005, MOL CELL BIOL, V25, P1869, DOI 10.1128/MCB.25.5.1869-1878.2005; George S, 2004, SCIENCE, V304, P1325, DOI 10.1126/science.1096706; Heron-Milhavet L, 2006, MOL CELL BIOL, V26, P8267, DOI 10.1128/MCB.00201-06; Ichijo H, 1999, ONCOGENE, V18, P6087, DOI 10.1038/sj.onc.1203129; Kim AH, 2001, MOL CELL BIOL, V21, P893, DOI 10.1128/MCB.21.3.893-901.2001; Kim MA, 2007, EXP MOL MED, V39, P205, DOI 10.1038/emm.2007.23; Liao Y, 2003, MOL CELL BIOL, V23, P6836, DOI 10.1128/MCB.23.19.6836-6848.2003; Pekarsky Y, 2000, P NATL ACAD SCI USA, V97, P3028, DOI 10.1073/pnas.040557697; Rane MJ, 2001, J BIOL CHEM, V276, P3517, DOI 10.1074/jbc.M005953200; Ronai Z, 1999, ONCOGENE, V18, P6084, DOI 10.1038/sj.onc.1203175; Vivanco I, 2002, NAT REV CANCER, V2, P489, DOI 10.1038/nrc839; Yuan ZQ, 2003, J BIOL CHEM, V278, P23432, DOI 10.1074/jbc.M302674200; Yuan ZQ, 2002, J BIOL CHEM, V277, P29973, DOI 10.1074/jbc.M203636200; Yun JH, 2005, ONCOGENE, V24, P4009, DOI 10.1038/sj.onc.1208575; Yun SJ, 2008, BIOCHEM BIOPH RES CO, V371, P138, DOI 10.1016/j.bbrc.2008.04.029	24	19	19	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 5	2009	28	9					1241	1247		10.1038/onc.2008.487	http://dx.doi.org/10.1038/onc.2008.487			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	415AH	19151757				2022-12-28	WOS:000263906200008
J	Lahsnig, C; Mikula, M; Petz, M; Zulehner, G; Schneller, D; van Zijl, F; Huber, H; Csiszar, A; Beug, H; Mikulits, W				Lahsnig, C.; Mikula, M.; Petz, M.; Zulehner, G.; Schneller, D.; van Zijl, F.; Huber, H.; Csiszar, A.; Beug, H.; Mikulits, W.			ILEI requires oncogenic Ras for the epithelial to mesenchymal transition of hepatocytes and liver carcinoma progression	ONCOGENE			English	Article						hepatocyte; ILEI; epithelial to mesenchymal transition; HCC; tumor progression	HUMAN HEPATOCELLULAR-CARCINOMA; GROWTH-FACTOR-BETA; TGF-BETA; SIGNAL TRANSDUCERS; TUMOR-SUPPRESSOR; CANCER; CELLS; HEPATOCARCINOGENESIS; METASTASIS; ACTIVATION	In human hepatocellular carcinoma (HCC), epithelial to mesenchymal transition (EMT) correlates with aggressiveness of tumors and poor survival. We employed a model of EMT based on immortalized p19(ARF) null hepatocytes (MIM), which display tumor growth upon expression of oncogenic Ras and undergo EMT through the synergism of Ras and transforming growth factor (TGF)-beta. Here, we show that the interleukin-related protein interleukin-like EMT inducer (ILEI), a novel EMT-, tumor-and metastasis-inducing protein, cooperates with oncogenic Ras to cause TGF-beta-independent EMT. Ras-transformed MIM hepatocytes overexpressing ILEI showed cytoplasmic E-cadherin, loss of ZO-1 and induction of a-smooth muscle actin as well as platelet-derived growth factor (PDGF)/PDGF-R isoforms. As shown by dominant-negative PDGF-R expression in these cells, ILEI-induced PDGF signaling was required for enhanced cell migration, nuclear accumulation of beta-catenin, nuclear pY-Stat3 and accelerated growth of lung metastases. In MIM hepatocytes expressing the Ras mutant V12-C40, ILEI collaborated with PI3K signaling resulting in tumor formation without EMT. Clinically, human HCC samples showed granular or cytoplasmic localization of ILEI correlating with well and poorly differentiated tumors, respectively. In conclusion, these data indicate that ILEI requires cooperation with oncogenic Ras to govern hepatocellular EMT through mechanisms involving PDGF-R/beta-catenin and PDGF-R/Stat3 signaling.	[Lahsnig, C.; Zulehner, G.; Schneller, D.; van Zijl, F.; Huber, H.; Mikulits, W.] Med Univ Vienna, Dept Med 1, Div Inst Canc Res, A-1090 Vienna, Austria; [Mikula, M.; Petz, M.; Csiszar, A.; Beug, H.] Res Inst Mol Pathol, A-1030 Vienna, Austria	Medical University of Vienna; Vienna Biocenter (VBC); Research Institute of Molecular Pathology (IMP)	Mikulits, W (corresponding author), Med Univ Vienna, Dept Med 1, Div Inst Canc Res, Borschke Gasse 8A, A-1090 Vienna, Austria.	wolfgang.mikulits@meduniwien.ac.at	Csiszar, Agnes/I-2747-2019; Mikulits, Wolfgang/AAH-4043-2021	Csiszar, Agnes/0000-0001-7911-3427; Petz, Michaela/0000-0002-6854-9919; Mikula, Mario/0000-0001-5782-0681; Mikulits, Wolfgang/0000-0003-4612-7106	Austrian Science Fund, FWF [SFBF28, P19598-B13]	Austrian Science Fund, FWF(Austrian Science Fund (FWF))	We thank ORIDIS Biomed for providing HCC tissue arrays and immunohistochemical staining. This work was supported by grants from the Austrian Science Fund, FWF, Grant number SFBF28 and P19598-B13.	Breuhahn K, 2006, ONCOGENE, V25, P3787, DOI 10.1038/sj.onc.1209556; Bruix J, 2004, CANCER CELL, V5, P215, DOI 10.1016/S1535-6108(04)00058-3; Calvisi DF, 2006, GASTROENTEROLOGY, V130, P1117, DOI 10.1053/j.gastro.2006.01.006; Campbell JS, 2007, DIFFERENTIATION, V75, P843, DOI 10.1111/j.1432-0436.2007.00235.x; Campbell JS, 2005, P NATL ACAD SCI USA, V102, P3389, DOI 10.1073/pnas.0409722102; EDMONDSON HA, 1954, CANCER-AM CANCER SOC, V7, P462, DOI 10.1002/1097-0142(195405)7:3<462::AID-CNCR2820070308>3.0.CO;2-E; Eger A, 2005, ONCOGENE, V24, P2375, DOI 10.1038/sj.onc.1208429; El-Serag HB, 2007, GASTROENTEROLOGY, V132, P2557, DOI 10.1053/j.gastro.2007.04.061; Fischer ANM, 2007, ONCOGENE, V26, P3395, DOI 10.1038/sj.onc.1210121; Fischer ANM, 2005, CARCINOGENESIS, V26, P931, DOI 10.1093/carcin/bgi043; Garcia R, 2001, ONCOGENE, V20, P2499, DOI 10.1038/sj.onc.1204349; Giannelli G, 2005, GASTROENTEROLOGY, V129, P1375, DOI 10.1053/j.gastro.2005.09.055; Giebel B, 2006, CURR BIOL, V16, pR91, DOI 10.1016/j.cub.2006.01.022; Gotzmann J, 2006, ONCOGENE, V25, P3170, DOI 10.1038/sj.onc.1209083; Gotzmann J, 2002, J CELL SCI, V115, P1189; Grunert S, 2003, NAT REV MOL CELL BIO, V4, P657, DOI 10.1038/nrm1175; Herath NI, 2006, J GASTROEN HEPATOL, V21, P15, DOI 10.1111/j.1440-1746.2005.04043.x; Huber MA, 2005, CURR OPIN CELL BIOL, V17, P548, DOI 10.1016/j.ceb.2005.08.001; Hugo H, 2007, J CELL PHYSIOL, V213, P374, DOI 10.1002/jcp.21223; Jechlinger M, 2006, J CLIN INVEST, V116, P1561, DOI 10.1172/JCI24652; Kensler TW, 2003, NAT REV CANCER, V3, P321, DOI 10.1038/nrc1076; Kondoh N, 2001, INT J ONCOL, V18, P1271; Lacher MD, 2006, CANCER RES, V66, P1648, DOI 10.1158/0008-5472.CAN-05-2328; Lee HC, 2006, FRONT BIOSCI-LANDMRK, V11, P1901, DOI 10.2741/1933; Lee TK, 2006, CANCER RES, V66, P9948, DOI 10.1158/0008-5472.CAN-06-1092; Macheiner D, 2006, J HEPATOL, V45, P81, DOI 10.1016/j.jhep.2005.12.017; Mikula M, 2004, HEPATOLOGY, V39, P628, DOI 10.1002/hep.20084; Ogata H, 2006, ONCOGENE, V25, P2520, DOI 10.1038/sj.onc.1209281; Ogata H, 2006, GASTROENTEROLOGY, V131, P179, DOI 10.1053/j.gastro.2006.04.025; Pardali K, 2007, BBA-REV CANCER, V1775, P21, DOI 10.1016/j.bbcan.2006.06.004; Pietras K, 2003, CANCER CELL, V3, P439, DOI 10.1016/S1535-6108(03)00089-8; Rossmanith W, 2001, MICROSC RES TECHNIQ, V52, P430, DOI 10.1002/1097-0029(20010215)52:4<430::AID-JEMT1028>3.0.CO;2-3; Silva CM, 2004, ONCOGENE, V23, P8017, DOI 10.1038/sj.onc.1208159; Tannapfel A, 2001, ONCOGENE, V20, P7104, DOI 10.1038/sj.onc.1204902; Thiery JP, 2006, NAT REV MOL CELL BIO, V7, P131, DOI 10.1038/nrm1835; Thorgeirsson SS, 2002, NAT GENET, V31, P339, DOI 10.1038/ng0802-339; Waerner T, 2006, CANCER CELL, V10, P227, DOI 10.1016/j.ccr.2006.07.020; Yang J, 2004, CELL, V117, P927, DOI 10.1016/j.cell.2004.06.006; Yang SF, 2007, J CLIN PATHOL, V60, P642, DOI 10.1136/jcp.2006.036970; Yoshikawa H, 2001, NAT GENET, V28, P29, DOI 10.1038/88225; Zhou L, 2007, WORLD J SURG, V31, P1782, DOI 10.1007/s00268-007-9029-z	41	73	77	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 5	2009	28	5					638	650		10.1038/onc.2008.418	http://dx.doi.org/10.1038/onc.2008.418			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	403IN	19015638	Bronze, Green Accepted			2022-12-28	WOS:000263076400002
J	Mottet, D; Pirotte, S; Lamour, V; Hagedorn, M; Javerzat, S; Bikfalvi, A; Bellahcene, A; Verdin, E; Castronovo, V				Mottet, D.; Pirotte, S.; Lamour, V.; Hagedorn, M.; Javerzat, S.; Bikfalvi, A.; Bellahcene, A.; Verdin, E.; Castronovo, V.			HDAC4 represses p21(WAF1/Cip1) expression in human cancer cells through a Sp1-dependent, p53-independent mechanism	ONCOGENE			English	Article						histone deacetylase; p21(WAF1/Cip1); Sp1; siRNA; cancer	HISTONE DEACETYLASE INHIBITORS; TUMOR-SUPPRESSOR PROTEIN; WAF1/CIP1 GENE PROMOTER; IN-VIVO; DNA-BINDING; SP1 SITES; P53; TRANSCRIPTION; ACETYLATION; COLON	Cancer cells have complex, unique characteristics that distinguish them from normal cells, such as increased growth rates and evasion of anti-proliferative signals. Global inhibition of class I and II histone deacetylases (HDACs) stops cancer cell proliferation in vitro and has proven effective against cancer in clinical trials, at least in part, through transcriptionalreac tivation of the p21(WAF1/Cip1) gene. The HDACs that regulate p21(WAF1/Cip1) are not fully identified. Using small interfering RNAs, we found that HDAC4 participates in the repression of p21(WAF1/Cip1) through Sp1/Sp3-, but not p53-binding sites. HDAC4 interacts with Sp1, binds and reduces histone H3 acetylation at the Sp1/Sp3 binding site-rich p21(WAF1/Cip1) proximal promoter, suggesting a key role for Sp1 in HDAC4-mediated repression of p21(WAF1/Cip1). Induction of p21(WAF1/Cip1) mediated by silencing of HDAC4 arrested cancer cell growth in vitro and inhibited tumor growth in an in vivo human glioblastoma model. Thus, HDAC4 could be a useful target for new anti-cancer therapies based on selective inhibition of specific HDACs.	[Mottet, D.; Pirotte, S.; Lamour, V.; Bellahcene, A.; Castronovo, V.] Univ Liege, Metastasis Res Lab, GIGA Canc Ctr Expt Canc Res, B-4000 Liege, Belgium; [Mottet, D.; Verdin, E.] Univ Calif San Francisco, Gladstone Inst Virol & Immunol, San Francisco, CA 94158 USA; [Javerzat, S.; Bikfalvi, A.] Univ Bordeaux 1, INSERM, U920, European Lab Angiogenesis & Translat Res,Ex E0113, F-33405 Talence, France	University of Liege; University of California System; University of California San Francisco; The J David Gladstone Institutes; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite de Bordeaux	Castronovo, V (corresponding author), Univ Liege, Metastasis Res Lab, GIGA Canc Ctr Expt Canc Res, B23, B-4000 Liege, Belgium.	everdin@gladstone.ucsf.edu; vcastronovo@ulg.ac.be	Verdin, Eric/AAB-7999-2019	Hagedorn, Martin/0000-0002-0960-5116; Verdin, Eric/0000-0003-3703-3183	European FP6 (STROMA and METABRE); National Fund for Scientific Research (Belgium); Centre Anti-Cancereux pres de l'Universite de Liege; Fonds Leon Fredericq; TELEVIE and Interuniversity Attraction Pole Program-Belgian Science Policy [IAP 5/31]	European FP6 (STROMA and METABRE)(European Commission); National Fund for Scientific Research (Belgium)(Fonds de la Recherche Scientifique - FNRS); Centre Anti-Cancereux pres de l'Universite de Liege; Fonds Leon Fredericq; TELEVIE and Interuniversity Attraction Pole Program-Belgian Science Policy	This work was supported by grants from European FP6 (STROMA and METABRE), the National Fund for Scientific Research (Belgium), the Centre Anti-Cancereux pres de l'Universite de Liege, the Fonds Leon Fredericq, TELEVIE and Interuniversity Attraction Pole Program-Belgian Science Policy (IAP 5/31). DM and AB are Research Associates at the National Fund for Scientific Research (Belgium). VL and SP are NFSR National Fund for Scientific Research fellows.	Acharya MR, 2005, MOL PHARMACOL, V68, P917, DOI 10.1124/mol.105.014167; Archer SY, 1998, P NATL ACAD SCI USA, V95, P6791, DOI 10.1073/pnas.95.12.6791; Basile V, 2006, J BIOL CHEM, V281, P2347, DOI 10.1074/jbc.M507712200; Bolden JE, 2006, NAT REV DRUG DISCOV, V5, P769, DOI 10.1038/nrd2133; Davie JR, 2003, J NUTR, V133, p2485S, DOI 10.1093/jn/133.7.2485S; De Ruijter AJM, 2003, BIOCHEM J, V370, P737, DOI 10.1042/BJ20021321; Doetzlhofer A, 1999, MOL CELL BIOL, V19, P5504; Dokmanovic M, 2007, MOL CANCER RES, V5, P981, DOI 10.1158/1541-7786.MCR-07-0324; Duvic M, 2007, DRUG TODAY, V43, P585, DOI 10.1358/dot.2007.43.9.1112980; Duvic M, 2007, EXPERT OPIN INV DRUG, V16, P1111, DOI 10.1517/13543784.16.7.1111; Enya K, 2008, J LEUKOCYTE BIOL, V83, P190, DOI 10.1189/jlb.0106008; Fang JY, 2002, WORLD J GASTROENTERO, V8, P400, DOI 10.3748/wjg.v8.i3.400; Fischle W, 2002, MOL CELL, V9, P45, DOI 10.1016/S1097-2765(01)00429-4; FOGH J, 1977, J NATL CANCER I, V58, P209, DOI 10.1093/jnci/58.2.209; Geng L, 2006, CANCER RES, V66, P11298, DOI 10.1158/0008-5472.CAN-06-0049; Glenisson W, 2007, BBA-MOL CELL RES, V1773, P1572, DOI 10.1016/j.bbamcr.2007.05.016; Glozak MA, 2005, GENE, V363, P15, DOI 10.1016/j.gene.2005.09.010; Grozinger CM, 2000, P NATL ACAD SCI USA, V97, P7835, DOI 10.1073/pnas.140199597; Hagedorn M, 2005, P NATL ACAD SCI USA, V102, P1643, DOI 10.1073/pnas.0408622102; Halkidou K, 2004, EUR UROL, V45, P382, DOI 10.1016/j.eururo.2003.10.005; Han JW, 2001, J BIOL CHEM, V276, P42084, DOI 10.1074/jbc.M106688200; Han JW, 2000, CANCER RES, V60, P6068; He SH, 2005, MOL BIOL CELL, V16, P4073, DOI 10.1091/mbc.e05-05-0388; Hildmann C, 2007, APPL MICROBIOL BIOT, V75, P487, DOI 10.1007/s00253-007-0911-2; Huang BH, 2005, CELL DEATH DIFFER, V12, P395, DOI 10.1038/sj.cdd.4401567; Huang EY, 2000, GENE DEV, V14, P45; Huang LL, 2000, MOL MED, V6, P849, DOI 10.1007/BF03401823; Huang WF, 2006, BIOCHEM BIOPH RES CO, V339, P165, DOI 10.1016/j.bbrc.2005.11.010; Imbriano C, 2005, MOL CELL BIOL, V25, P3737, DOI 10.1128/MCB.25.9.3737-3751.2005; Kang JE, 2005, CELL PHYSIOL BIOCHEM, V16, P23, DOI 10.1159/000087728; Kao GD, 2003, J CELL BIOL, V160, P1017, DOI 10.1083/jcb.200209065; Kao HY, 2000, GENE DEV, V14, P55; Kelly WK, 2005, NAT CLIN PRACT ONCOL, V2, P150, DOI 10.1038/ncponc0106; Khochbin S, 2001, CURR OPIN GENET DEV, V11, P162, DOI 10.1016/S0959-437X(00)00174-X; Kim YB, 1999, ONCOGENE, V18, P2461, DOI 10.1038/sj.onc.1202564; LABARCA C, 1980, ANAL BIOCHEM, V102, P344, DOI 10.1016/0003-2697(80)90165-7; Lagger G, 2003, MOL CELL BIOL, V23, P2669, DOI 10.1128/MCB.23.8.2669-2679.2003; Lagger G, 2002, EMBO J, V21, P2672, DOI 10.1093/emboj/21.11.2672; Lavrrar JL, 2004, J BIOL CHEM, V279, P46343, DOI 10.1074/jbc.M402692200; Lemercier C, 2002, J BIOL CHEM, V277, P22045, DOI 10.1074/jbc.M201736200; Lleonart ME, 2006, ONCOL REP, V16, P603; Luo JY, 2004, P NATL ACAD SCI USA, V101, P2259, DOI 10.1073/pnas.0308762101; Marks Paul A, 2004, Novartis Found Symp, V259, P269; Martin-Caballero J, 2001, CANCER RES, V61, P6234; McLaughlin F, 2004, BIOCHEM PHARMACOL, V68, P1139, DOI 10.1016/j.bcp.2004.05.034; Minucci S, 2006, NAT REV CANCER, V6, P38, DOI 10.1038/nrc1779; Mottet D, 2007, CIRC RES, V101, P1237, DOI 10.1161/CIRCRESAHA.107.149377; Nakano K, 1997, J BIOL CHEM, V272, P22199, DOI 10.1074/jbc.272.35.22199; Philipp J, 1999, ONCOGENE, V18, P4689, DOI 10.1038/sj.onc.1202840; Poole AJ, 2004, ONCOGENE, V23, P8128, DOI 10.1038/sj.onc.1207994; Rasheed WK, 2007, EXPERT OPIN INV DRUG, V16, P659, DOI 10.1517/13543784.16.5.659; Richon VM, 2000, P NATL ACAD SCI USA, V97, P10014, DOI 10.1073/pnas.180316197; Rocchi P, 2005, ONCOL REP, V13, P1139; Roy S, 2005, CELL DEATH DIFFER, V12, P482, DOI 10.1038/sj.cdd.4401581; Saito A, 1999, P NATL ACAD SCI USA, V96, P4592, DOI 10.1073/pnas.96.8.4592; Sambucetti LC, 1999, J BIOL CHEM, V274, P34940, DOI 10.1074/jbc.274.49.34940; Sawa H, 2004, ACTA NEUROPATHOL, V107, P523, DOI 10.1007/s00401-004-0841-3; Senese S, 2007, MOL CELL BIOL, V27, P4784, DOI 10.1128/MCB.00494-07; Sowa Y, 1999, CANCER RES, V59, P4266; Sowa Y, 1997, BIOCHEM BIOPH RES CO, V241, P142, DOI 10.1006/bbrc.1997.7786; Spurling CC, 2008, MOL CARCINOGEN, V47, P137, DOI 10.1002/mc.20373; Sun JM, 2002, J BIOL CHEM, V277, P35783, DOI 10.1074/jbc.C200378200; Tang H, 1998, J BIOL CHEM, V273, P29156, DOI 10.1074/jbc.273.44.29156; Topley GI, 1999, P NATL ACAD SCI USA, V96, P9089, DOI 10.1073/pnas.96.16.9089; Urban G, 2003, J BIOL CHEM, V278, P9747, DOI 10.1074/jbc.M210993200; Waltregny D, 2005, FASEB J, V19, P966, DOI 10.1096/fj.04-2303fje; Wilson AJ, 2006, J BIOL CHEM, V281, P13548, DOI 10.1074/jbc.M510023200; WILSON AJ, 2008, MOL BIOL CELL; Wouters BG, 1997, CANCER RES, V57, P4703; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; Xu WS, 2007, ONCOGENE, V26, P5541, DOI 10.1038/sj.onc.1210620; Yang XJ, 2008, NAT REV MOL CELL BIO, V9, P206, DOI 10.1038/nrm2346; Zhao Y, 2006, MOL CELL BIOL, V26, P2782, DOI 10.1128/MCB.26.7.2782-2790.2006	73	119	127	0	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2009	28	2					243	256		10.1038/onc.2008.371	http://dx.doi.org/10.1038/onc.2008.371			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	395CY	18850004				2022-12-28	WOS:000262501100008
J	Kurisetty, VV; Johnston, PG; Johnston, N; Erwin, P; Crowe, P; Fernig, DG; Campbell, FC; Anderson, IP; Rudland, PS; El-Tanani, MK				Kurisetty, V. V.; Johnston, P. G.; Johnston, N.; Erwin, P.; Crowe, P.; Fernig, D. G.; Campbell, F. C.; Anderson, I. P.; Rudland, P. S.; El-Tanani, M. K.			RAN GTPase is an effector of the invasive/metastatic phenotype induced by osteopontin	ONCOGENE			English	Article						osteopontin; RAN; breast cancer invasion and metastasis	MAMMARY EPITHELIAL-CELLS; GROWTH-FACTOR RECEPTOR; BREAST-CANCER; BINDING-PROTEIN; PLASMA OSTEOPONTIN; NUCLEAR-PROTEIN; RAN/TC4 GTPASE; C-MET; EXPRESSION; METASTASIS	Osteopontin (OPN) is a phosphorylated glycoprotein that binds to alpha v-containing integrins and is important in malignant transformation and cancer. Previously, we have utilized suppressive subtractive hybridization between mRNAs isolated from the Rama 37 (R37) rat mammary cell line and a subclone rendered invasive and metastatic by stable transfection with an expression vector for OPN to identify RAN GTPase (RAN) as the most over-expressed gene, in addition to that of OPN. Here we show that transfection of noninvasive R37 cells with an expression vector for RAN resulted in increased anchorage-independent growth, cell attachment and invasion through Matrigel in vitro, and metastasis in syngeneic rats. This induction of a malignant phenotype was induced independently of the expression of OPN, and was reversed by specifically reducing the expression of RAN using small-interfering RNAs. By using a combination of mutant protein and inhibitors, it was found that RAN signal transduction occurred through the c-Met receptor and PI3 kinase. This study therefore identifies RAN as a novel effector of OPN-mediated malignant transformation and some of its downstream signaling events in a mammary epithelial model of cancer invasion/metastasis.	[Johnston, P. G.; Johnston, N.; Erwin, P.; Crowe, P.; Campbell, F. C.; El-Tanani, M. K.] Queens Univ Belfast, Ctr Canc Res & Cell Biol, Belfast BT9 7LB, Antrim, North Ireland; [Fernig, D. G.; Anderson, I. P.; Rudland, P. S.] Univ Liverpool, Canc & Polio Res Fund Labs, Sch Biol Sci, Liverpool L69 3BX, Merseyside, England	Queens University Belfast; University of Liverpool	El-Tanani, MK (corresponding author), Queens Univ Belfast, Ctr Canc Res & Cell Biol, 97 Lisburn Rd, Belfast BT9 7LB, Antrim, North Ireland.	m.el-tanani@qub.ac.uk	Johnston, Nick/C-3028-2008; Fernig, David G/A-3590-2008	Fernig, David G/0000-0003-4875-4293; Campbell, Frederick/0000-0002-0363-9964; El-Tanani, Mohamed/0000-0002-4735-5445	Research and Development Office, Queen's University Belfast, Northern Ireland, UK; Cancer and Polio Research Fund, Wirral, UK; Northwest Cancer Research Fund, Liverpool, UK	Research and Development Office, Queen's University Belfast, Northern Ireland, UK; Cancer and Polio Research Fund, Wirral, UK; Northwest Cancer Research Fund, Liverpool, UK	This work was supported by grants from Research and Development Office, Queen's University Belfast, Northern Ireland, UK and The Cancer and Polio Research Fund, Wirral, UK. DGF's post is funded by the Northwest Cancer Research Fund, Liverpool, UK.	Abe H, 2008, INT J CANCER, V122, P2391, DOI 10.1002/ijc.23400; Azuma K, 2004, CLIN CANCER RES, V10, P6695, DOI 10.1158/1078-0432.CCR-04-0818; Berns K, 2004, NATURE, V428, P431, DOI 10.1038/nature02371; Beviglia L, 1997, INT J CANCER, V74, P301, DOI 10.1002/(SICI)1097-0215(19970620)74:3<301::AID-IJC12>3.0.CO;2-E; BISCHOFF FR, 1994, P NATL ACAD SCI USA, V91, P2587, DOI 10.1073/pnas.91.7.2587; Bramwell VHC, 2006, CLIN CANCER RES, V12, P3337, DOI 10.1158/1078-0432.CCR-05-2354; Carey KL, 1996, J CELL BIOL, V133, P985, DOI 10.1083/jcb.133.5.985; Chen HJ, 1997, ONCOGENE, V14, P1581, DOI 10.1038/sj.onc.1200993; Darzynkiewicz Z, 2001, Curr Protoc Cell Biol, VChapter 8, DOI 10.1002/0471143030.cb0804s01; Das R, 2005, IUBMB LIFE, V57, P441, DOI 10.1080/15216540500159424; DAVIES BR, 1993, ONCOGENE, V8, P999; Denti S, 2004, J BIOL CHEM, V279, P13027, DOI 10.1074/jbc.M313515200; DUNNINGTON DJ, 1983, J NATL CANCER I, V71, P1227; El-Tanani M, 2001, CANCER RES, V61, P5619; El-Tanani M, 2004, J BIOL CHEM, V279, P20794, DOI 10.1074/jbc.M311131200; El-Tanani MK, 2006, J BIOL CHEM, V281, P26587, DOI 10.1074/jbc.M604403200; El-Tanani MK, 2006, CYTOKINE GROWTH F R, V17, P463, DOI 10.1016/j.cytogfr.2006.09.010; Emberley ED, 2002, BMC CANCER, V2, DOI 10.1186/1471-2407-2-28; Furger KA, 2003, MOL CANCER RES, V1, P810; Hafizi S, 2005, INT J BIOCHEM CELL B, V37, P2344, DOI 10.1016/j.biocel.2005.05.006; Hara S, 2008, BIOCHEM BIOPH RES CO, V370, P123, DOI 10.1016/j.bbrc.2008.03.042; Johnston NIF, 2008, FRONT BIOSCI-LANDMRK, V13, P4361, DOI 10.2741/3009; Kilty IC, 1999, J NEUROCHEM, V73, P1859; KURISETTY VV, 2008, BMC RES NOT IN PRESS; Lounsbury KM, 1996, J BIOL CHEM, V271, P32834, DOI 10.1074/jbc.271.51.32834; Margalit DN, 2004, P NATL ACAD SCI USA, V101, P11821, DOI 10.1073/pnas.0404439101; Maulik G, 2002, CYTOKINE GROWTH F R, V13, P41, DOI 10.1016/S1359-6101(01)00029-6; Morgan-Lappe SE, 2007, CANCER RES, V67, P4390, DOI 10.1158/0008-5472.CAN-06-4132; Moye VE, 2004, BRIT J CANCER, V90, P1796, DOI 10.1038/sj.bjc.6601683; Nishitani H, 2001, GENE, V272, P25, DOI 10.1016/S0378-1119(01)00553-4; Oates AJ, 1996, ONCOGENE, V13, P97; Ouellet V, 2006, INT J CANCER, V119, P599, DOI 10.1002/ijc.21902; Peruzzi B, 2006, CLIN CANCER RES, V12, P3657, DOI 10.1158/1078-0432.CCR-06-0818; Pisani P, 1999, INT J CANCER, V83, P18, DOI 10.1002/(SICI)1097-0215(19990924)83:1&lt;18::AID-IJC5&gt;3.0.CO;2-M; Rudland PS, 2002, CANCER RES, V62, P3417; Sakata H, 1997, J BIOL CHEM, V272, P9457; Sarbassov DD, 2005, SCIENCE, V307, P1098, DOI 10.1126/science.1106148; Sazer S, 2000, J CELL SCI, V113, P1111; Shinohara ML, 2008, P NATL ACAD SCI USA, V105, P7235, DOI 10.1073/pnas.0802301105; Shulkla S, 2007, INT J CANCER, V121, P1424, DOI 10.1002/ijc.22862; Singhal H, 1997, CLIN CANCER RES, V3, P605; SU LC, 1995, ONCOGENE, V10, P2163; Tuck AB, 2003, ONCOGENE, V22, P1198, DOI 10.1038/sj.onc.1206209; Tuck AB, 2000, J CELL BIOCHEM, V78, P465, DOI 10.1002/1097-4644(20000901)78:3<465::AID-JCB11>3.0.CO;2-C; Tuck AB, 1998, INT J CANCER, V79, P502, DOI 10.1002/(SICI)1097-0215(19981023)79:5<502::AID-IJC10>3.0.CO;2-3; Tuck AB, 2007, J CELL BIOCHEM, V102, P859, DOI 10.1002/jcb.21520; Ue T, 1998, INT J CANCER, V79, P127, DOI 10.1002/(SICI)1097-0215(19980417)79:2<127::AID-IJC5>3.0.CO;2-V; Wang DK, 2002, J BIOL CHEM, V277, P36216, DOI 10.1074/jbc.M205111200; Wang GZ, 2006, CANCER RES, V66, P1199, DOI 10.1158/0008-5472.CAN-05-2605; Wennerberg K, 2005, J CELL SCI, V118, P843, DOI 10.1242/jcs.01660; Yuan Y, 2006, NEUROSCI LETT, V407, P26, DOI 10.1016/j.neulet.2006.06.059	51	56	56	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC	2008	27	57					7139	7149		10.1038/onc.2008.325	http://dx.doi.org/10.1038/onc.2008.325			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	379GG	18794800				2022-12-28	WOS:000261384100001
J	Javier, RT				Javier, R. T.			Cell polarity proteins: common targets for tumorigenic human viruses	ONCOGENE			English	Review						virus; polarity; tumor suppressor; PDZ; migration	LARGE TUMOR-SUPPRESSOR; TIGHT JUNCTION PROTEIN; HUMAN-PAPILLOMAVIRUS E6; PDZ DOMAIN PROTEIN; ADENOVIRUS TYPE 9; LATE GENE-EXPRESSION; PROTEASOME-MEDIATED DEGRADATION; DISTINCT ACTIVITIES CONTRIBUTE; ADENOMATOUS POLYPOSIS-COLI; MAMMALIAN EPITHELIAL-CELLS	Loss of polarity and disruption of cell junctions are common features of epithelial-derived cancer cells, and mounting evidence indicates that such defects have a direct function in the pathology of cancer. Supporting this idea, results with several different human tumor viruses indicate that their oncogenic potential depends in part on a common ability to inactivate key cell polarity proteins. For example, adenovirus (Ad) type 9 is unique among human Ads by causing exclusively estrogen-dependent mammary tumors in experimental animals and in having E4 region-encoded open reading frame 1 (E4-ORF1) as its primary oncogenic determinant. The 125-residue E4-ORF1 protein consists of two separate protein-interaction elements, one of which defines a PDZ domain-binding motif (PBM) required for E4-ORF1 to induce both cellular transformation in vitro and tumorigenesis in vivo. Most notably, the E4-ORF1 PBM mediates interactions with a selected group of cellular PDZ proteins, three of which include the cell polarity proteins Dlg1, PATJ and ZO-2. Data further indicate that these interactions promote disruption of cell junctions and a loss of cell polarity. In addition, one or more of the E4-ORF1-interacting cell polarity proteins, as well as the cell polarity protein Scribble, are common targets for the high-risk human papillomavirus (HPV) E6 or human T-cell leukemia virus type 1 (HTLV-1) Tax oncoproteins. Underscoring the significance of these observations, in humans, high-risk HPV and HTLV-1 are causative agents for cervical cancer and adult T-cell leukemia, respectively. Consequently, human tumor viruses should serve as powerful tools for deciphering mechanisms whereby disruption of cell junctions and loss of cell polarity contribute to the development of many human cancers. This review article discusses evidence supporting this hypothesis, with an emphasis on the human Ad E4-ORF1 oncoprotein.	Baylor Coll Med, Dept Mol Virol & Microbiol, Houston, TX 77030 USA	Baylor College of Medicine	Javier, RT (corresponding author), Baylor Coll Med, Dept Mol Virol & Microbiol, Houston, TX 77030 USA.	rjavier@bcm.edu			NCI NIH HHS [R01 CA058541] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA058541] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abdelilah-Seyfried S, 2003, DEVELOPMENT, V130, P1927, DOI 10.1242/dev.00420; Adriance MC, 2005, BREAST CANCER RES, V7, P190, DOI 10.1186/bcr1286; ANKERST J, 1974, INT J CANCER, V13, P286, DOI 10.1002/ijc.2910130303; ANKERST J, 1989, J NATL CANCER I, V81, P294, DOI 10.1093/jnci/81.4.294; Aoki M, 2001, P NATL ACAD SCI USA, V98, P136, DOI 10.1073/pnas.011528498; Aranda V, 2006, NAT CELL BIOL, V8, P1235, DOI 10.1038/ncb1485; Arpin-Andre C, 2007, J BIOL CHEM, V282, P33132, DOI 10.1074/jbc.M702279200; Balasubramanian S, 2007, J BIOL CHEM, V282, P4162, DOI 10.1074/jbc.M607695200; Balda MS, 2003, J CELL BIOL, V160, P423, DOI 10.1083/jcb.200210020; Barnard AL, 2005, BLOOD, V106, P988, DOI 10.1182/blood-2004-07-2850; Barritt DS, 2000, J CELL BIOCHEM, V79, P213, DOI 10.1002/1097-4644(20001101)79:2<213::AID-JCB50>3.0.CO;2-G; Beatch M, 1996, J BIOL CHEM, V271, P25723, DOI 10.1074/jbc.271.42.25723; Becamel C, 2001, J BIOL CHEM, V276, P12974, DOI 10.1074/jbc.M008089200; Betanzos A, 2004, EXP CELL RES, V292, P51, DOI 10.1016/j.yexcr.2003.08.007; Bhaskar PT, 2007, DEV CELL, V12, P487, DOI 10.1016/j.devcel.2007.03.020; Bilder D, 2003, CURR BIOL, V13, pR661, DOI 10.1016/S0960-9822(03)00599-2; Bilder D, 2004, GENE DEV, V18, P1909, DOI 10.1101/gad.1211604; Bissell MJ, 2003, BREAST CANCER RES, V5, P117, DOI 10.1186/bcr579; Blume-Jensen P, 2001, NATURE, V411, P355, DOI 10.1038/35077225; BRIDGE E, 1990, VIROLOGY, V174, P345, DOI 10.1016/0042-6822(90)90088-9; BRIDGE E, 1989, J VIROL, V63, P631, DOI 10.1128/JVI.63.2.631-638.1989; Cai CL, 2006, J BIOL CHEM, V281, P4267, DOI 10.1074/jbc.M505886200; Caruana G, 2001, MOL CELL BIOL, V21, P1475, DOI 10.1128/MCB.21.5.1475-1483.2001; Chetkovich DM, 2002, J NEUROSCI, V22, P6415; Chlenski A, 1999, INT J CANCER, V82, P137, DOI 10.1002/(SICI)1097-0215(19990702)82:1<137::AID-IJC23>3.0.CO;2-F; Chlenski A, 1999, INT J CANCER, V83, P349, DOI 10.1002/(SICI)1097-0215(19991029)83:3<349::AID-IJC10>3.0.CO;2-C; Chlenski A, 2000, BBA-GENE STRUCT EXPR, V1493, P319, DOI 10.1016/S0167-4781(00)00185-8; Chung SH, 2008, ONCOGENE, V27, P1412, DOI 10.1038/sj.onc.1210784; Chung SH, 2007, J VIROL, V81, P4787, DOI 10.1128/JVI.02855-06; Cochand-Priollet B, 1998, ULTRASTRUCT PATHOL, V22, P413; Crawford J.M., 1994, ROBBINS PATHOLOGIC B, V5th, P910; Curto M, 2007, J CELL BIOL, V177, P893, DOI 10.1083/jcb.200703010; CUTT JR, 1987, J VIROL, V61, P543, DOI 10.1128/JVI.61.2.543-552.1987; Dobner T, 1996, SCIENCE, V272, P1470, DOI 10.1126/science.272.5267.1470; Dow LE, 2007, ONCOGENE, V26, P2272, DOI 10.1038/sj.onc.1210016; DYSON N, 1992, J VIROL, V66, P4606, DOI 10.1128/JVI.66.7.4606-4611.1992; Endo K, 2002, J VIROL, V76, P2648, DOI 10.1128/JVI.76.6.2648-2653.2002; Endter C, 2004, CURR TOP MICROBIOL, V273, P163; Engelman JA, 2006, NAT REV GENET, V7, P606, DOI 10.1038/nrg1879; Etienne-Manneville S, 2005, J CELL BIOL, V170, P895, DOI 10.1083/jcb.200412172; Etienne-Manneville S, 2003, CURR OPIN CELL BIOL, V15, P67, DOI 10.1016/S0955-0674(02)00005-4; Etienne-Manneville S, 2003, NATURE, V421, P753, DOI 10.1038/nature01423; Etienne-Manneville S, 2001, CELL, V106, P489, DOI 10.1016/S0092-8674(01)00471-8; Etienne-Manneville S, 2002, NATURE, V420, P629, DOI 10.1038/nature01148; Feng HC, 2008, SCIENCE, V319, P1096, DOI 10.1126/science.1152586; Fink C, 2006, NEOPLASIA, V8, P1019, DOI 10.1593/neo.06559; Flint SJ, 2003, CURR TOP MICROBIOL, V272, P287; FLINT SJ, 2000, PRINCIPLES VIROLOGY, P552; Frese KK, 2006, EMBO J, V25, P1406, DOI 10.1038/sj.emboj.7601030; Frese KK, 2003, ONCOGENE, V22, P710, DOI 10.1038/sj.onc.1206151; Gardiol D, 1999, ONCOGENE, V18, P5487, DOI 10.1038/sj.onc.1202920; Gardiol D, 2002, J GEN VIROL, V83, P283, DOI 10.1099/0022-1317-83-2-283; Gardiol D, 2006, INT J CANCER, V119, P1285, DOI 10.1002/ijc.21982; Gardner LA, 2007, J BIOL CHEM, V282, P5085, DOI 10.1074/jbc.M608871200; GAZZOLO L, 1987, NATURE, V326, P714, DOI 10.1038/326714a0; Glaunsinger BA, 2000, ONCOGENE, V19, P5270, DOI 10.1038/sj.onc.1203906; Glaunsinger BA, 2001, EMBO J, V20, P5578, DOI 10.1093/emboj/20.20.5578; Gomes ER, 2005, CELL, V121, P451, DOI 10.1016/j.cell.2005.02.022; Gonzalez-Mariscal L, 2000, SEMIN CELL DEV BIOL, V11, P315, DOI 10.1006/scdb.2000.0178; Goode S, 1997, GENE DEV, V11, P2532, DOI 10.1101/gad.11.19.2532; GRAHAM FL, 1984, ADENOVIRUSES, P339; GREEN M, 1979, VIROLOGY, V93, P481, DOI 10.1016/0042-6822(79)90251-4; Gudjonsson T, 2002, GENE DEV, V16, P693, DOI 10.1101/gad.952602; Gudjonsson T, 2002, J CELL SCI, V115, P39; Gudjonsson T, 2005, J MAMMARY GLAND BIOL, V10, P261, DOI 10.1007/s10911-005-9586-4; HALBERT DN, 1985, J VIROL, V56, P250, DOI 10.1128/JVI.56.1.250-257.1985; Hamazaki Y, 2002, J BIOL CHEM, V277, P455, DOI 10.1074/jbc.M109005200; Harris BZ, 2001, J CELL SCI, V114, P3219; Haskins J, 1998, J CELL BIOL, V141, P199, DOI 10.1083/jcb.141.1.199; HERISSE J, 1981, NUCLEIC ACIDS RES, V9, P4023, DOI 10.1093/nar/9.16.4023; Hernandez S, 2007, EXP CELL RES, V313, P1533, DOI 10.1016/j.yexcr.2007.01.026; Heydecke D, 2006, J ANDROL, V27, P390, DOI 10.2164/jandrol.05166; Higuchi M, 2001, CURR BIOL, V11, P1958, DOI 10.1016/S0960-9822(01)00599-1; Higuchi M, 2007, J VIROL, V81, P11900, DOI 10.1128/JVI.00532-07; Hirabayashi S, 2003, MOL CELL BIOL, V23, P4267, DOI 10.1128/MCB.23.12.4267-4282.2003; Hirata A, 2004, VIROLOGY, V318, P327, DOI 10.1016/j.virol.2003.10.006; HOGENKAMP T, 1990, NUCLEIC ACIDS RES, V18, P3065, DOI 10.1093/nar/18.10.3065; HORWITZ MS, 2001, FIELDS VIROLOGY, P2301; HOUWELING A, 1980, VIROLOGY, V105, P537, DOI 10.1016/0042-6822(80)90054-9; HUANG MM, 1989, GENE DEV, V3, P1699, DOI 10.1101/gad.3.11.1699; HUANG MM, 1989, J VIROL, V63, P2605, DOI 10.1128/JVI.63.6.2605-2615.1989; Humbert P, 2003, BIOESSAYS, V25, P542, DOI 10.1002/bies.10286; Humbert PO, 2006, TRENDS CELL BIOL, V16, P622, DOI 10.1016/j.tcb.2006.10.005; Iizuka-Kogo A, 2007, DEVELOPMENT, V134, P1799, DOI 10.1242/dev.02830; Inoue M, 2006, MOL BIOL CELL, V17, P2303, DOI 10.1091/mbc.E06-01-0030; Ishidate T, 2000, ONCOGENE, V19, P365, DOI 10.1038/sj.onc.1203309; Ishioka K, 2006, RETROVIROLOGY, V3, DOI 10.1186/1742-4690-3-71; James MA, 2006, J VIROL, V80, P5301, DOI 10.1128/JVI.01942-05; Javier R, 1996, BREAST CANCER RES TR, V39, P57, DOI 10.1007/BF01806078; JAVIER R, 1991, J VIROL, V65, P3192, DOI 10.1128/JVI.65.6.3192-3202.1991; JAVIER R, 1992, SCIENCE, V257, P1267, DOI 10.1126/science.1519063; JAVIER RT, 1994, J VIROL, V68, P3917, DOI 10.1128/JVI.68.6.3917-3924.1994; Jeansonne B, 2003, CELL MOL BIOL, V49, P13; JESAITIS LA, 1994, J CELL BIOL, V124, P949, DOI 10.1083/jcb.124.6.949; Joberty G, 2000, NAT CELL BIOL, V2, P531, DOI 10.1038/35019573; KIM E, 1995, NATURE, V378, P85, DOI 10.1038/378085a0; KIM SK, 1995, CURR OPIN CELL BIOL, V7, P641, DOI 10.1016/0955-0674(95)80105-7; Kimber WA, 2002, BIOCHEM J, V361, P525, DOI 10.1042/0264-6021:3610525; Kiyono T, 1997, P NATL ACAD SCI USA, V94, P11612, DOI 10.1073/pnas.94.21.11612; Kondo R, 2006, RETROVIROLOGY, V3, DOI 10.1186/1742-4690-3-88; KORNAU HC, 1995, SCIENCE, V269, P1737, DOI 10.1126/science.7569905; Kotelevets L, 2004, FASEB J, V18, P115, DOI 10.1096/fj.04-1942fje; Krummel MF, 2006, NAT IMMUNOL, V7, P1143, DOI 10.1038/ni1404; Kuballa P, 2007, J BIOL CHEM, V282, P65, DOI 10.1074/jbc.M605117200; Kuhne C, 2000, ONCOGENE, V19, P5884, DOI 10.1038/sj.onc.1203988; Lakhani S, 2005, J MAMMARY GLAND BIOL, V10, P197, DOI 10.1007/s10911-005-9580-x; Lallemand D, 2003, GENE DEV, V17, P1090, DOI 10.1101/gad.1054603; Laprise P, 2004, J BIOL CHEM, V279, P10157, DOI 10.1074/jbc.M309843200; Latorre IJ, 2005, J CELL SCI, V118, P4283, DOI 10.1242/jcs.02560; Laura RP, 2002, EXP CELL RES, V275, P155, DOI 10.1006/excr.2002.5475; Le SS, 1997, P NATL ACAD SCI USA, V94, P6670, DOI 10.1073/pnas.94.13.6670; Lee CH, 2004, J VIROL, V78, P12366, DOI 10.1128/JVI.78.22.12366-12377.2004; Lee OK, 2003, NAT CELL BIOL, V5, P987, DOI 10.1038/ncb1055; Lee SS, 2000, J VIROL, V74, P9680, DOI 10.1128/JVI.74.20.9680-9693.2000; Lemmers C, 2002, J BIOL CHEM, V277, P25408, DOI 10.1074/jbc.M202196200; Leonoudakis D, 2004, J BIOL CHEM, V279, P19051, DOI 10.1074/jbc.M400284200; Levin ER, 2002, STEROIDS, V67, P471, DOI 10.1016/S0039-128X(01)00179-9; LEVINE AJ, 1990, VIROLOGY, V177, P419, DOI 10.1016/0042-6822(90)90505-L; Luconi M, 2002, J STEROID BIOCHEM, V80, P369, DOI 10.1016/S0960-0760(02)00041-9; Ludford-Menting MJ, 2005, IMMUNITY, V22, P737, DOI 10.1016/j.immuni.2005.04.009; Mahieux Renaud, 2003, Rev Clin Exp Hematol, V7, P336; Mahoney ZX, 2006, P NATL ACAD SCI USA, V103, P19872, DOI 10.1073/pnas.0609326103; Mantovani F, 2001, ONCOGENE, V20, P7874, DOI 10.1038/sj.onc.1204869; Marcello E, 2007, J NEUROSCI, V27, P1682, DOI 10.1523/JNEUROSCI.3439-06.2007; Martin TA, 2004, EUR J CANCER, V40, P2717, DOI 10.1016/j.ejca.2004.08.008; Massimi P, 2006, ONCOGENE, V25, P4276, DOI 10.1038/sj.onc.1209457; Massimi P, 2004, ONCOGENE, V23, P8033, DOI 10.1038/sj.onc.1207977; Matsumine A, 1996, SCIENCE, V272, P1020, DOI 10.1126/science.272.5264.1020; Matsumoto Y, 2006, J MED VIROL, V78, P501, DOI 10.1002/jmv.20568; Matsuoka M, 2007, NAT REV CANCER, V7, P270, DOI 10.1038/nrc2111; Matter K, 2003, NAT REV MOL CELL BIO, V4, P225, DOI 10.1038/nrm1055; Mauceri D, 2007, J NEUROCHEM, V100, P1032, DOI 10.1111/j.1471-4159.2006.04267.x; McDonnell DP, 2002, SCIENCE, V296, P1642, DOI 10.1126/science.1071884; MECHTERSHEIMER G, 1990, PATHOL RES PRACT, V186, P427, DOI 10.1016/S0344-0338(11)80460-7; Medema RH, 2000, NATURE, V404, P782, DOI 10.1038/35008115; Michel D, 2005, J CELL SCI, V118, P4049, DOI 10.1242/jcs.02528; Mimori-Kiyosue Y, 2007, GENES CELLS, V12, P219, DOI 10.1111/j.1365-2443.2007.01045.x; Mol CD, 1996, STRUCTURE, V4, P1077, DOI 10.1016/S0969-2126(96)00114-1; Moore M, 1996, P NATL ACAD SCI USA, V93, P11295, DOI 10.1073/pnas.93.21.11295; MULLER BM, 1995, J NEUROSCI, V15, P2354, DOI 10.1523/JNEUROSCI.15-03-02354.1995; MULLER U, 1992, J VIROL, V66, P5867; Murata M, 2005, CELL TISSUE RES, V319, P341, DOI 10.1007/s00441-004-1017-0; Naim E, 2005, KIDNEY INT, V68, P955, DOI 10.1111/j.1523-1755.2005.00489.x; Nakagawa S, 2000, MOL CELL BIOL, V20, P8244, DOI 10.1128/MCB.20.21.8244-8253.2000; Nakagawa S, 2004, BRIT J CANCER, V90, P194, DOI 10.1038/sj.bjc.6601465; Navarro C, 2005, ONCOGENE, V24, P4330, DOI 10.1038/sj.onc.1208632; Nevels M, 1997, P NATL ACAD SCI USA, V94, P1206, DOI 10.1073/pnas.94.4.1206; Nevels M, 1999, ONCOGENE, V18, P9, DOI 10.1038/sj.onc.1202284; Nevels M, 1999, J VIROL, V73, P1591, DOI 10.1128/JVI.73.2.1591-1600.1999; Nevels M, 2001, J VIROL, V75, P3089, DOI 10.1128/JVI.75.7.3089-3094.2001; Nevels M, 2000, J VIROL, V74, P5168, DOI 10.1128/JVI.74.11.5168-5181.2000; Nguyen ML, 2003, J VIROL, V77, P6957, DOI 10.1128/JVI.77.12.6957-6964.2003; Nguyen MM, 2003, MOL CELL BIOL, V23, P8970, DOI 10.1128/MCB.23.24.8970-8981.2003; Nunbhakdi-Craig V, 2003, J VIROL, V77, P2807, DOI 10.1128/JVI.77.5.2807-2818.2003; Nunbhakdi-Craig V, 2002, J CELL BIOL, V158, P967, DOI 10.1083/jcb.200206114; O'Shea C, 2005, EMBO J, V24, P1211, DOI 10.1038/sj.emboj.7600597; O'Shea CC, 2005, CELL CYCLE, V4, P883, DOI 10.4161/cc.4.7.1791; Ohashi M, 2004, VIROLOGY, V320, P52, DOI 10.1016/j.virol.2003.11.014; Onishi K, 2007, GENES CELLS, V12, P535, DOI 10.1111/j.1365-2443.2007.01071.x; Osmani N, 2006, CURR BIOL, V16, P2395, DOI 10.1016/j.cub.2006.10.026; Pagliarini RA, 2003, SCIENCE, V302, P1227, DOI 10.1126/science.1088474; Patrie KM, 2002, J BIOL CHEM, V277, P30183, DOI 10.1074/jbc.M203072200; Pechoux C, 1999, DEV BIOL, V206, P88, DOI 10.1006/dbio.1998.9133; Philipp S, 1997, FEBS LETT, V413, P243, DOI 10.1016/S0014-5793(97)00877-6; Pim D, 2000, ONCOGENE, V19, P719, DOI 10.1038/sj.onc.1203374; Pim D, 2002, ONCOGENE, V21, P8140, DOI 10.1038/sj.onc.1206026; Polyak K, 2005, J MAMMARY GLAND BIOL, V10, P231, DOI 10.1007/s10911-005-9584-6; PRASAD R, 1993, CANCER RES, V53, P5624; Primo L, 2007, J CELL BIOL, V176, P1035, DOI 10.1083/jcb.200607053; Procko E, 2005, BIOESSAYS, V27, P153, DOI 10.1002/bies.20157; Qin Y, 2005, J CELL BIOL, V171, P1061, DOI 10.1083/jcb.200506094; Rebeaud F, 2007, TRENDS IMMUNOL, V28, P196, DOI 10.1016/j.it.2007.03.004; Reuver SM, 1998, J CELL SCI, V111, P1071; Rincon M, 2007, NAT IMMUNOL, V8, P126, DOI 10.1038/ni0207-126; Round JL, 2005, J EXP MED, V201, P419, DOI 10.1084/jem.20041428; Round JL, 2007, NAT IMMUNOL, V8, P154, DOI 10.1038/ni1422; Rousset R, 1998, ONCOGENE, V16, P643, DOI 10.1038/sj.onc.1201567; Sakurai A, 2006, MOL BIOL CELL, V17, P966, DOI 10.1091/mbc.E05-07-0647; Saras J, 1996, TRENDS BIOCHEM SCI, V21, P455, DOI 10.1016/S0968-0004(96)30044-3; Sato N, 2003, CANCER RES, V63, P3735; SATO T, 1995, SCIENCE, V268, P411, DOI 10.1126/science.7536343; Schaley J, 2000, J VIROL, V74, P2084, DOI 10.1128/JVI.74.5.2084-2093.2000; Shai A, 2007, CANCER RES, V67, P1626, DOI 10.1158/0008-5472.CAN-06-3344; Sheng M, 1996, CURR OPIN NEUROBIOL, V6, P602, DOI 10.1016/S0959-4388(96)80091-2; Sheng M, 1996, NEURON, V17, P575, DOI 10.1016/S0896-6273(00)80190-7; SHENK T, 1991, ADV CANCER RES, V57, P47; Shenk T, 2001, FIELDS VIROLOGY, V2, P2265; Shin K, 2005, J CELL BIOL, V168, P705, DOI 10.1083/jcb.200408064; Shin K, 2007, EMBO REP, V8, P158, DOI 10.1038/sj.embor.7400890; Shin K, 2006, ANNU REV CELL DEV BI, V22, P207, DOI 10.1146/annurev.cellbio.22.010305.104219; Siegrist SE, 2007, GENE DEV, V21, P483, DOI 10.1101/gad.1511207; Simonson SJS, 2005, CANCER RES, V65, P8266, DOI 10.1158/0008-5472.CAN-05-1651; Soler AP, 1999, CARCINOGENESIS, V20, P1425, DOI 10.1093/carcin/20.8.1425; Songyang Z, 1997, SCIENCE, V275, P73, DOI 10.1126/science.275.5296.73; STILLMAN B, 1986, CANCER SURV, V5, P389; Storrs CH, 2007, J VIROL, V81, P4080, DOI 10.1128/JVI.02545-06; Stracker TH, 2002, NATURE, V418, P348, DOI 10.1038/nature00863; Stucke VM, 2007, MOL BIOL CELL, V18, P1744, DOI 10.1091/mbc.E06-11-0980; Sugihara-Mizuno Y, 2007, GENES CELLS, V12, P473, DOI 10.1111/j.1365-2443.2007.01066.x; Suzuki A, 2006, J CELL SCI, V119, P979, DOI 10.1242/jcs.02898; Suzuki T, 1999, ONCOGENE, V18, P5967, DOI 10.1038/sj.onc.1203008; Thomas DL, 1999, J VIROL, V73, P3071, DOI 10.1128/JVI.73.4.3071-3079.1999; Thomas DL, 2001, J VIROL, V75, P557, DOI 10.1128/JVI.75.2.557-568.2001; Thomas M, 2001, ONCOGENE, V20, P5431, DOI 10.1038/sj.onc.1204719; Thomas M, 2008, ONCOGENE, V27, P7018, DOI 10.1038/onc.2008.351; Thomas U, 1997, MECH DEVELOP, V62, P161, DOI 10.1016/S0925-4773(97)00658-8; TRENTIN JJ, 1962, SCIENCE, V137, P835, DOI 10.1126/science.137.3533.835; Tsubata C, 2005, RETROVIROLOGY, V2, DOI 10.1186/1742-4690-2-46; Umeda K, 2006, CELL, V126, P741, DOI 10.1016/j.cell.2006.06.043; Valiente M, 2005, J BIOL CHEM, V280, P28936, DOI 10.1074/jbc.M504761200; VANDENELSEN P, 1983, VIROLOGY, V128, P377; Vermeer PD, 2003, NATURE, V422, P322, DOI 10.1038/nature01440; Wada H, 2005, DEVELOPMENT, V132, P2273, DOI 10.1242/dev.01810; Wang TG, 2000, AIDS RES HUM RETROV, V16, P1661, DOI 10.1089/08892220050193119; Watson RA, 2003, J CELL SCI, V116, P4925, DOI 10.1242/jcs.00809; Weiss RS, 1996, J VIROL, V70, P862, DOI 10.1128/JVI.70.2.862-872.1996; Weiss RS, 1997, J VIROL, V71, P7873, DOI 10.1128/JVI.71.10.7873-7880.1997; Weiss RS, 1997, J VIROL, V71, P1857, DOI 10.1128/JVI.71.3.1857-1870.1997; Weitzman MD, 2005, ONCOGENE, V24, P7686, DOI 10.1038/sj.onc.1209063; Weitzman MD, 2005, FRONT BIOSCI-LANDMRK, V10, P1106, DOI 10.2741/1604; WILLOTT E, 1993, P NATL ACAD SCI USA, V90, P7834, DOI 10.1073/pnas.90.16.7834; Wodarz A, 2006, CELL, V124, P1121, DOI 10.1016/j.cell.2006.03.004; Wodarz A, 2007, NAT CELL BIOL, V9, P1016, DOI 10.1038/ncb433; WOODS DF, 1989, DEV BIOL, V134, P222, DOI 10.1016/0012-1606(89)90092-4; Woods DF, 1996, J CELL BIOL, V134, P1469, DOI 10.1083/jcb.134.6.1469; WOODS DF, 1991, CELL, V66, P451, DOI 10.1016/0092-8674(81)90009-X; Wu HJ, 2002, J BIOL CHEM, V277, P30928, DOI 10.1074/jbc.M203735200; Wu HJ, 1998, J CELL SCI, V111, P2365; Xavier R, 2004, J CELL BIOL, V166, P173, DOI 10.1083/jcb.200309044; Xie L, 2006, BLOOD, V107, P1980, DOI 10.1182/blood-2005-03-1333; Yamada KM, 2001, J CELL SCI, V114, P2375; Yamano S, 1999, J VIROL, V73, P10095, DOI 10.1128/JVI.73.12.10095-10103.1999; Yu Y, 1999, J CELL PHYSIOL, V178, P235, DOI 10.1002/(SICI)1097-4652(199902)178:2<235::AID-JCP13>3.3.CO;2-J	233	85	90	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 24	2008	27	55					7031	7046		10.1038/onc.2008.352	http://dx.doi.org/10.1038/onc.2008.352			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	375IU	19029943	Green Accepted			2022-12-28	WOS:000261108200014
J	Danielian, PS; Friesenhahn, LB; Faust, AM; West, JC; Caron, AM; Bronson, RT; Lees, JA				Danielian, P. S.; Friesenhahn, L. B.; Faust, A. M.; West, J. C.; Caron, A. M.; Bronson, R. T.; Lees, J. A.			E2f3a and E2f3b make overlapping but different contributions to total E2f3 activity	ONCOGENE			English	Article						E2f3; Arf; cell cycle; E2f1	HUMAN BLADDER-CANCER; CELLULAR PROLIFERATION; TRANSCRIPTION FACTOR; OVEREXPRESSION; AMPLIFICATION; EXPRESSION; IDENTIFICATION; SPECIFICITY; REPRESSION; APOPTOSIS	The E2f transcription factors are key downstream targets of the retinoblastoma protein tumor suppressor that control cell proliferation. E2F3 has garnered particular attention because it is amplified in various human tumors. E2f3 mutant mice typically die around birth and E2f3-deficient cells have a proliferation defect that correlates with impaired E2f target gene activation and also induction of p19(Arf) and p53. The E2f3 locus encodes two isoforms, E2f3a and E2f3b, which differ in their N-termini. However, it is unclear how E2f3a versus E2f3b contributes to E2f3's requirement in either proliferation or development. To address this, we use E2f3a- and E2f3b-specific knockouts. We show that inactivation of E2f3a results in a low penetrance proliferation defect in vitro whereas loss of E2f3b has no effect. This proliferation defect appears insuficient to disrupt normal development as E2f3a and E2f3b mutant mice are both fully viable and have no detectable defects. However, when combined with E2f1 mutation, inactivation of E2f3a, but not E2f3b, causes significant proliferation defects in vitro, neonatal lethality and also a striking cartilage defect. Thus, we conclude that E2f3a and E2f3b have largely overlapping functions in vivo and that E2f3a can fully substitute for E2f1 and E2f3 in most murine tissues.	[Danielian, P. S.; Friesenhahn, L. B.; Faust, A. M.; West, J. C.; Caron, A. M.; Lees, J. A.] MIT, David H Koch Inst Integrat Canc Res, Cambridge, MA 02139 USA; [Bronson, R. T.] Tufts Cummings Sch Vet Med, North Grafton, MA USA	Massachusetts Institute of Technology (MIT)	Lees, JA (corresponding author), MIT, David H Koch Inst Integrat Canc Res, 77 Mass Ave,E17-517B, Cambridge, MA 02139 USA.	jalees@mit.edu		Danielian, Paul/0000-0003-2651-0386	NIH [CA118757]; NATIONAL CANCER INSTITUTE [R01CA118757] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Aurora Burds Connor and the MIT Fannie E Rippel transgenic facility; the KI Flow Cytometry facility for technical assistance; Donald Court, Neal Copeland, Nancy Jenkins and Lili Yamasaki for reagents and mouse strains and Keara Lane, Daniel Garcia, GuangJun Zhang and Lees laboratory members for helpful suggestions. This work was supported by an NIH grant to JAL (CA118757). JAL is a Ludwig Scholar.	Adams MR, 2000, MOL CELL BIOL, V20, P3633, DOI 10.1128/MCB.20.10.3633-3639.2000; Aslanian A, 2004, GENE DEV, V18, P1413, DOI 10.1101/gad.1196704; Attwooll C, 2004, EMBO J, V23, P4709, DOI 10.1038/sj.emboj.7600481; Berthet C, 2007, ONCOGENE, V26, P4469, DOI 10.1038/sj.onc.1210243; Blais A, 2007, CURR OPIN CELL BIOL, V19, P658, DOI 10.1016/j.ceb.2007.10.003; Cloud JE, 2002, MOL CELL BIOL, V22, P2663, DOI 10.1128/MCB.22.8.2663-2672.2002; Cooper CS, 2006, LUNG CANCER, V54, P155, DOI 10.1016/j.lungcan.2006.07.005; Courel M, 2008, DEV DYNAM, V237, P1232, DOI 10.1002/dvdy.21516; Danielian PS, 2007, DEV BIOL, V305, P564, DOI 10.1016/j.ydbio.2007.02.037; Dimova DK, 2005, ONCOGENE, V24, P2810, DOI 10.1038/sj.onc.1208612; Feber A, 2004, ONCOGENE, V23, P1627, DOI 10.1038/sj.onc.1207274; Field SJ, 1996, CELL, V85, P549, DOI 10.1016/S0092-8674(00)81255-6; Foster CS, 2004, ONCOGENE, V23, P5871, DOI 10.1038/sj.onc.1207800; He YW, 2000, ONCOGENE, V19, P3422, DOI 10.1038/sj.onc.1203682; Humbert PO, 2000, GENE DEV, V14, P690; Hurst CD, 2008, ONCOGENE, V27, P2716, DOI 10.1038/sj.onc.1210934; Janumyan YM, 2003, EMBO J, V22, P5459, DOI 10.1093/emboj/cdg533; Leone G, 2000, MOL CELL BIOL, V20, P3626, DOI 10.1128/MCB.20.10.3626-3632.2000; Oeggerli M, 2006, ONCOGENE, V25, P6538, DOI 10.1038/sj.onc.1209946; Oeggerli M, 2004, ONCOGENE, V23, P5616, DOI 10.1038/sj.onc.1207749; Orlic M, 2006, GENE CHROMOSOME CANC, V45, P72, DOI 10.1002/gcc.20263; Parisi T, 2007, MOL CELL BIOL, V27, P2283, DOI 10.1128/MCB.01854-06; Sharma N, 2006, J BIOL CHEM, V281, P36124, DOI 10.1074/jbc.M604152200; Timmers C, 2007, MOL CELL BIOL, V27, P65, DOI 10.1128/MCB.02147-06; Trimarchi JM, 2002, NAT REV MOL CELL BIO, V3, P11, DOI 10.1038/nrm714; Wu LZ, 2001, NATURE, V414, P457, DOI 10.1038/35106593; Ziebold U, 2003, MOL CELL BIOL, V23, P6542, DOI 10.1128/MCB.23.18.6542-6552.2003	27	43	43	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 30	2008	27	51					6561	6570		10.1038/onc.2008.253	http://dx.doi.org/10.1038/onc.2008.253			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	366RS	18663357	Green Submitted, Green Accepted			2022-12-28	WOS:000260501700003
J	Ndozangue-Touriguine, O; Sebbagh, M; Merino, D; Micheau, O; Bertoglio, J; Breard, J				Ndozangue-Touriguine, O.; Sebbagh, M.; Merino, D.; Micheau, O.; Bertoglio, J.; Breard, J.			A mitochondrial block and expression of XIAP lead to resistance to TRAIL-induced apoptosis during progression to metastasis of a colon carcinoma	ONCOGENE			English	Article						TRAIL; colon cancer; metastasis; resistance	CYTOCHROME-C RELEASE; PROTEASOME INHIBITOR BORTEZOMIB; BCL-2 FAMILY-MEMBERS; X-LINKED INHIBITOR; NF-KAPPA-B; CANCER CELLS; MEDIATED APOPTOSIS; TUMOR-METASTASIS; DEATH RECEPTORS; DECOY RECEPTORS	A pair of isogenic colon carcinoma cells, SW480 and 620, was used to investigate the mechanisms of acquired tumour necrosis factor-related apoptosis-inducing ligand (TRAIL)-resistance during tumour progression. Whereas primary tumour SW480 cells are sensitive to TRAIL-induced apoptosis, metastatic SW620 cells are resistant. The apoptotic signalling activated by TRAIL in SW480 cells is a type II pathway. We show that in SW620 cells, although caspase-8 is recruited and activated at the death-inducing-signalling complex and Bid is cleaved, this does not lead to caspase-9 activation. Comparison of Bcl-2, Bcl-xL and Mcl-1 levels in both cell lines showed no difference. In SW620 cells transfected with a tBid-GFP construct, tBid-GFP was correctly localized to the mitochondria. Thus, the resistance of SW620 cells is at the level of the mitochondria that can withstand large amounts of tBid. Although caspase-3 was directly cleaved by caspase-8 in SW620 cells to yield the p20 fragment, no further autocatalytic maturation into the p17 fragment was observed. We show that, in contrast to SW480 cells, the SW620 cell line expresses high amounts of X-linked inhibitor of apoptosis ( XIAP). Downregulation of XIAP with bortezomib or small-interfering RNA was sufficient to restore the sensitivity of SW620 cells to TRAIL-induced apoptosis in the absence of SMAC/Diablo or cytochrome c release from the mitochondria. Thus, SW620 cells have developed a dual resistance to TRAIL-induced apoptosis: a block at the level of the mitochondria and, after a conversion to a type I pathway, an increased expression of XIAP which inhibits this pathway.	[Ndozangue-Touriguine, O.; Bertoglio, J.; Breard, J.] Fac Pharm Chatenay Malabry, INSERM, U749, F-92290 Chatenay Malabry, Hauts Seine, France; [Sebbagh, M.] INSERM, UMR 891, Inst Paoli Calmettes, F-13258 Marseille, Bouches Rhone, France; [Merino, D.; Micheau, O.] INSERM, U866, Dijon, Cote Or, France; [Merino, D.; Micheau, O.] Univ Bourgogne, Dijon, Cote Or, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Saclay; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite; UNICANCER; Institut Paoli-Calmette (IPC); Institut Agro; AgroSup Dijon; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Bourgogne; Universite de Bourgogne	Breard, J (corresponding author), Fac Pharm Chatenay Malabry, INSERM, U749, 5 Rue JB Clement, F-92290 Chatenay Malabry, Hauts Seine, France.	jacqueline.breard@u-psud.fr	Merino, Delphine/L-9159-2017; micheau, olivier/C-3574-2011; Sebbagh, Michael/E-8502-2017	Merino, Delphine/0000-0002-8075-6275; micheau, olivier/0000-0001-8499-7984; Sebbagh, Michael/0000-0003-2468-7006	INSERM; Ligue Nationale contre le Cancer; Olivia Ndozangue-Touriguine; ARC	INSERM(Institut National de la Sante et de la Recherche Medicale (Inserm)European Commission); Ligue Nationale contre le Cancer(Ligue nationale contre le cancer); Olivia Ndozangue-Touriguine; ARC(Australian Research Council)	We thank Valerie Nicolas for her assistance in confocal microscopy and G Ortiz-Ferron for providing FLBid-GFP vector. This work was supported by INSERM and the Ligue Nationale contre le Cancer (equipe labellisee). Olivia Ndozangue-Touriguine was a recipient of a fellowship from the Ministry of Research and Education and is a recipient of an ARC fellowship for her fourth year of PhD.	Ashkenazi A, 2002, NAT REV CANCER, V2, P420, DOI 10.1038/nrc821; Cassidy-Stone A, 2008, DEV CELL, V14, P193, DOI 10.1016/j.devcel.2007.11.019; Ceballos-Cancino G, 2007, ONCOGENE, V26, P7569, DOI 10.1038/sj.onc.1210560; Certo M, 2006, CANCER CELL, V9, P351, DOI 10.1016/j.ccr.2006.03.027; Choi SY, 2007, CELL DEATH DIFFER, V14, P597, DOI 10.1038/sj.cdd.4402020; Cretney E, 2002, J IMMUNOL, V168, P1356, DOI 10.4049/jimmunol.168.3.1356; Deng J, 2007, CANCER CELL, V12, P171, DOI 10.1016/j.ccr.2007.07.001; Deveraux QL, 1999, GENE DEV, V13, P239, DOI 10.1101/gad.13.3.239; GAGOS S, 1995, ANTICANCER RES, V15, P369; Gonzalvez F, 2005, CELL DEATH DIFFER, V12, P659, DOI 10.1038/sj.cdd.4401585; Gonzalvez F, 2005, CELL DEATH DIFFER, V12, P614, DOI 10.1038/sj.cdd.4401571; Gross A, 1999, GENE DEV, V13, P1899, DOI 10.1101/gad.13.15.1899; Grosse-Wilde A, 2008, J CLIN INVEST, V118, P100, DOI 10.1172/JCI33061; Han J, 2006, J BIOL CHEM, V281, P10153, DOI 10.1074/jbc.M510349200; Henson ES, 2003, J CELL BIOCHEM, V89, P1177, DOI 10.1002/jcb.10597; Hewitt RE, 2000, J PATHOL, V192, P446; Huang SB, 2008, CANCER RES, V68, P2944, DOI 10.1158/0008-5472.CAN-07-2508; Huerta S, 2007, J SURG RES, V142, P184, DOI 10.1016/j.jss.2006.12.551; Johnson TR, 2003, ONCOGENE, V22, P4953, DOI 10.1038/sj.onc.1206656; Kashkar H, 2007, BLOOD, V109, P3982, DOI 10.1182/blood-2006-10-053959; Kim H, 2006, NAT CELL BIOL, V8, P1348, DOI 10.1038/ncb1499; Kim TH, 2004, MOL BIOL CELL, V15, P3061, DOI 10.1091/mbc.E03-12-0864; Kischkel FC, 2000, IMMUNITY, V12, P611, DOI 10.1016/S1074-7613(00)80212-5; Koschny R, 2007, CLIN CANCER RES, V13, P6541, DOI 10.1158/1078-0432.CCR-07-1759; Koschny R, 2007, J MOL MED, V85, P923, DOI 10.1007/s00109-007-0194-1; Krueger A, 2001, J BIOL CHEM, V276, P20633, DOI 10.1074/jbc.M101780200; Kyritsis AP, 2007, CLIN CANCER RES, V13, P6540, DOI 10.1158/1078-0432.CCR-07-1447; LEIBOVITZ A, 1976, CANCER RES, V36, P4562; Letai A, 2002, CANCER CELL, V2, P183, DOI 10.1016/S1535-6108(02)00127-7; Leverkus M, 2003, MOL CELL BIOL, V23, P777, DOI 10.1128/MCB.23.3.777-790.2003; Liu J, 2004, APOPTOSIS, V9, P533, DOI 10.1023/B:APPT.0000038034.16230.ea; Liu XG, 2007, CANCER RES, V67, P4981, DOI 10.1158/0008-5472.CAN-06-4274; Lucken-Ardjomande S, 2008, CELL DEATH DIFFER, V15, P484, DOI 10.1038/sj.cdd.4402280; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Lutter M, 2000, NAT CELL BIOL, V2, P754, DOI 10.1038/35036395; Menoret E, 2006, BLOOD, V108, P1346, DOI 10.1182/blood-2005-12-007971; Nagy K, 2006, PATHOL ONCOL RES, V12, P133, DOI 10.1007/BF02893359; Nikrad M, 2005, MOL CANCER THER, V4, P443; Oltersdorf T, 2005, NATURE, V435, P677, DOI 10.1038/nature03579; Ortiz-Ferron G, 2006, CELL DEATH DIFFER, V13, P1857, DOI 10.1038/sj.cdd.4401875; Pierce JW, 1997, J BIOL CHEM, V272, P21096, DOI 10.1074/jbc.272.34.21096; Ravi R, 2006, CANCER RES, V66, P1730, DOI 10.1158/0008-5472.CAN-05-3377; Roucou X, 2002, BIOCHEM J, V368, P915, DOI 10.1042/BJ20020972; Sayers TJ, 2003, BLOOD, V102, P303, DOI 10.1182/blood-2002-09-2975; Secchiero P, 2004, CELL MOL LIFE SCI, V61, P1965, DOI 10.1007/s00018-004-4197-6; Sheridan JP, 1997, SCIENCE, V277, P818, DOI 10.1126/science.277.5327.818; Smyth MJ, 2001, J EXP MED, V193, P661, DOI 10.1084/jem.193.6.661; Sohn D, 2005, J BIOL CHEM, V280, P5267, DOI 10.1074/jbc.M408585200; Sun XM, 2002, J BIOL CHEM, V277, P11345, DOI 10.1074/jbc.M109893200; Takeda K, 2001, NAT MED, V7, P94, DOI 10.1038/83416; Taniai M, 2004, CANCER RES, V64, P3517, DOI 10.1158/0008-5472.CAN-03-2770; Tyurin VA, 2007, CELL DEATH DIFFER, V14, P872, DOI 10.1038/sj.cdd.4402068; Villunger A, 2003, SCIENCE, V302, P1036, DOI 10.1126/science.1090072; Voelkel-Johnson C, 2005, MOL CANCER THER, V4, P1320, DOI 10.1158/1535-7163.MCT-05-0086; Voortman J, 2007, MOL CANCER THER, V6, P2103, DOI 10.1158/1535-7163.MCT-07-0167; Wei MC, 2001, SCIENCE, V292, P727, DOI 10.1126/science.1059108; Zhu HB, 2005, CANCER BIOL THER, V4, P781, DOI 10.4161/cbt.4.7.1897; Zou H, 2003, J BIOL CHEM, V278, P8091, DOI 10.1074/jbc.M204783200	58	75	75	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 9	2008	27	46					6012	6022		10.1038/onc.2008.197	http://dx.doi.org/10.1038/onc.2008.197			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	358BO	18560353				2022-12-28	WOS:000259891600004
J	Chaput, N; Conforti, R; Viaud, S; Spatz, A; Zitvogel, L				Chaput, N.; Conforti, R.; Viaud, S.; Spatz, A.; Zitvogel, L.			The Janus face of dendritic cells in cancer	ONCOGENE			English	Review						tumor immunity; dendritic cells; tolerance	COLONY-STIMULATING FACTOR; NATURAL-KILLER-CELLS; REGULATORY T-CELLS; PEPTIDE-BASED VACCINE; SENTINEL LYMPH-NODES; TUMOR-ANTIGEN MUC1; RESPONSES IN-VIVO; HLA-DR ANTIGEN; ANTITUMOR IMMUNITY; BREAST-CANCER	On the basis of experimental models and some human data, we can assume that tumor outgrowth results from the balance between immunosurveillance (the extrinsic tumor suppressor mechanisms) and immunosubversion dictated by transformed cells and/or the corrupted surrounding microenvironment. Cancer immunosurveillance relies mainly upon conventional lymphocytes exerting either lytic or secretory functions, whereas immunosubversion results from the activity of regulatory T or suppressor myeloid cells and soluble mediators. Although specific tools to target or ablate dendritic cells (DCs) became only recently available, accumulating evidence points to the critical role of the specialized DC system in dictating most of the conventional and regulatory functions of tumor-specific T lymphocytes. Although DC can be harnessed to silence tumor development, tumors in turn can exploit DC to evade immunity. Indeed, DCs harbor defects in their differentiation and stimulatory functions in cancer-bearing hosts and can actively promote T-cell tolerance to self-tumor antigens. In this review, we will focus on the dual role of DC during tumor progression and discuss pharmacoimmunological strategies to harness DC against cancer.	[Chaput, N.; Conforti, R.; Viaud, S.; Zitvogel, L.] Inst Gustave Roussy, INSERM, U805, F-94805 Villejuif, France; [Chaput, N.; Conforti, R.; Zitvogel, L.] Inst Gustave Roussy, CBT507, Ctr Clin Invest, F-94805 Villejuif, France; [Spatz, A.] Inst Gustave Roussy, Dept Biopathol, F-94805 Villejuif, France; [Zitvogel, L.] Univ Paris 11, Fac Paris Sud, Le Kremlin Bicetre, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Gustave Roussy; UNICANCER; Gustave Roussy; UNICANCER; Gustave Roussy; UDICE-French Research Universities; Universite Paris Saclay	Zitvogel, L (corresponding author), Inst Gustave Roussy, INSERM, U805, 39 Rue Camille Desmoulins, F-94805 Villejuif, France.	zitvogel@igr.fr	SPATZ, ALAN/B-8645-2009	SPATZ, ALAN/0000-0003-3020-1420; ZITVOGEL, laurence/0000-0003-1596-0998	EU; INCa; Ligue Nationale contre le Cancer	EU(European Commission); INCa(Institut National du Cancer (INCA) France); Ligue Nationale contre le Cancer(Ligue nationale contre le cancer)	This work has also been supported by EU grants (ALLOSTEM, DC THERA), INCa and Ligue Nationale contre le Cancer (equipes labelisees by LZ). RC receives a salary from Innate Pharma.	Albert ML, 1998, NAT MED, V4, P1321, DOI 10.1038/3315; Alli R, 2004, EUR J IMMUNOL, V34, P1119, DOI 10.1002/eji.200324793; Almand B, 2000, CLIN CANCER RES, V6, P1755; AMBE K, 1989, CANCER, V63, P496, DOI 10.1002/1097-0142(19890201)63:3<496::AID-CNCR2820630318>3.0.CO;2-K; Andre F, 2004, J IMMUNOL, V172, P2126, DOI 10.4049/jimmunol.172.4.2126; Apetoh L, 2007, NAT MED, V13, P1050, DOI 10.1038/nm1622; Aspord C, 2007, J EXP MED, V204, P1037, DOI 10.1084/jem.20061120; Asselin-Paturel C, 2003, J IMMUNOL, V171, P6466, DOI 10.4049/jimmunol.171.12.6466; Banchereau J, 2001, CANCER RES, V61, P6451; Bell D, 1999, J EXP MED, V190, P1417, DOI 10.1084/jem.190.10.1417; Bellone G, 2006, J IMMUNOL, V177, P3448, DOI 10.4049/jimmunol.177.5.3448; Bereta M, 2004, CANCER GENE THER, V11, P808, DOI 10.1038/sj.cgt.7700762; Blank C, 2007, CANCER IMMUNOL IMMUN, V56, P739, DOI 10.1007/s00262-006-0272-1; Bonifaz L, 2002, J EXP MED, V196, P1627, DOI 10.1084/jem.20021598; Borg C, 2004, J CLIN INVEST, V114, P379, DOI 10.1172/jci20041102; Bui JD, 2007, CURR OPIN IMMUNOL, V19, P203, DOI 10.1016/j.coi.2007.02.001; Cai XY, 2006, J CANCER RES CLIN, V132, P293, DOI 10.1007/s00432-006-0075-y; Cao W, 2006, J EXP MED, V203, P1399, DOI 10.1084/jem.20052454; Carlos CA, 2005, J IMMUNOL, V175, P1628, DOI 10.4049/jimmunol.175.3.1628; Casares N, 2005, J EXP MED, V202, P1691, DOI 10.1084/jem.20050915; Cella M, 1996, J EXP MED, V184, P747, DOI 10.1084/jem.184.2.747; Chan CW, 2006, NAT MED, V12, P207, DOI 10.1038/nm1352; Chaperot L, 2001, BLOOD, V97, P3210, DOI 10.1182/blood.V97.10.3210; Chaput N, 2004, J IMMUNOL, V172, P2137, DOI 10.4049/jimmunol.172.4.2137; Chen ML, 2005, P NATL ACAD SCI USA, V102, P419, DOI 10.1073/pnas.0408197102; Colonna M, 2007, IMMUNITY, V27, P419, DOI 10.1016/j.immuni.2007.08.006; Coventry BJ, 2003, BRIT J CANCER, V89, P533, DOI 10.1038/sj.bjc.6601114; Della Bella S, 2003, BRIT J CANCER, V89, P1463, DOI 10.1038/sj.bjc.6601243; Della Bella S, 2006, CLIN IMMUNOL, V119, P317, DOI 10.1016/j.clim.2006.01.011; Dong HD, 2002, NAT MED, V8, P793, DOI 10.1038/nm730; Drake CG, 2006, ADV IMMUNOL, V90, P51, DOI 10.1016/S0065-2776(06)90002-9; DRANOFF G, 1993, P NATL ACAD SCI USA, V90, P3539, DOI 10.1073/pnas.90.8.3539; Dubsky P, 2007, EUR J IMMUNOL, V37, P1678, DOI 10.1002/eji.200636329; Dudziak D, 2007, SCIENCE, V315, P107, DOI 10.1126/science.1136080; Dunn GP, 2006, NAT REV IMMUNOL, V6, P836, DOI 10.1038/nri1961; Dunn GP, 2002, NAT IMMUNOL, V3, P991, DOI 10.1038/ni1102-991; Eisenthal A, 2001, HUM PATHOL, V32, P803, DOI 10.1053/hupa.2001.26455; Elliott B, 2007, CLIN CANCER RES, V13, P3825, DOI 10.1158/1078-0432.CCR-07-0358; ENK AH, 1992, J IMMUNOL, V149, P92; Fanger NA, 1999, J EXP MED, V190, P1155, DOI 10.1084/jem.190.8.1155; Ferlazzo G, 2002, J EXP MED, V195, P343, DOI 10.1084/jem.20011149; Fernandez NC, 1999, NAT MED, V5, P405, DOI 10.1038/7403; Fujii SI, 2004, J EXP MED, V199, P1607, DOI 10.1084/jem.20040317; FURIHATA M, 1992, VIRCHOWS ARCH B, V61, P409, DOI 10.1007/BF02890444; FURUKAWA T, 1984, JPN J CLIN ONCOL, V14, P647; Furumoto K, 2004, J CLIN INVEST, V113, P774, DOI 10.1172/JCI200419762; Galon J, 2006, SCIENCE, V313, P1960, DOI 10.1126/science.1129139; Gerlini G, 2007, CLIN IMMUNOL, V125, P184, DOI 10.1016/j.clim.2007.07.018; Ghiringhelli F, 2005, J EXP MED, V202, P919, DOI 10.1084/jem.20050463; Gillessen S, 2003, P NATL ACAD SCI USA, V100, P8874, DOI 10.1073/pnas.1033098100; Gilliet M, 2002, J EXP MED, V195, P695, DOI 10.1084/jem.20011603; Gilliet M, 2002, HUM IMMUNOL, V63, P1149, DOI 10.1016/S0198-8859(02)00753-X; Goldman SA, 1998, ARCH OTOLARYNGOL, V124, P641, DOI 10.1001/archotol.124.6.641; Grohmann U, 2002, NAT IMMUNOL, V3, P1097, DOI 10.1038/ni846; Hartmann E, 2003, CANCER RES, V63, P6478; Hiltbold EM, 2000, J IMMUNOL, V165, P3730, DOI 10.4049/jimmunol.165.7.3730; Hirano F, 2005, CANCER RES, V65, P1089; Hoeffel G, 2007, IMMUNITY, V27, P481, DOI 10.1016/j.immuni.2007.07.021; Honig A, 2005, ANTICANCER RES, V25, P1747; Ikarashi Y, 2001, J EXP MED, V194, P1179, DOI 10.1084/jem.194.8.1179; Inoshima N, 2002, CLIN CANCER RES, V8, P3480; INOUE K, 1993, VIRCHOWS ARCH A, V422, P351, DOI 10.1007/BF01605452; Ishigami S, 2003, ONCOL REP, V10, P1237; Ishigami S, 1998, ONCOLOGY-BASEL, V55, P65, DOI 10.1159/000011837; Ito T, 2007, J EXP MED, V204, P105, DOI 10.1084/jem.20061660; Iwamoto M, 2003, INT J CANCER, V104, P92, DOI 10.1002/ijc.10915; Josien R, 1997, J EXP MED, V186, P467, DOI 10.1084/jem.186.3.467; Ju XS, 2004, GENE, V331, P159, DOI 10.1016/j.gene.2004.02.018; Jung S, 2002, IMMUNITY, V17, P211, DOI 10.1016/S1074-7613(02)00365-5; Kaplan DH, 2005, IMMUNITY, V23, P611, DOI 10.1016/j.immuni.2005.10.008; Kawamura K, 2006, BLOOD, V107, P1031, DOI 10.1182/blood-2005-04-1737; Kissenpfennig A, 2005, IMMUNITY, V22, P643, DOI 10.1016/j.immuni.2005.04.004; Kissenpfennig A, 2006, TRENDS IMMUNOL, V27, P132, DOI 10.1016/j.it.2006.01.003; Kissenpfennig A, 2005, MOL CELL BIOL, V25, P88, DOI 10.1128/MCB.25.1.88-99.2005; Kohrt HE, 2005, PLOS MED, V2, P904, DOI 10.1371/journal.pmed.0020284; Kukreja A, 2006, J EXP MED, V203, P1859, DOI 10.1084/jem.20052136; Kusmartsev S, 2003, CANCER RES, V63, P4441; Ladanyi A, 2004, CLIN CANCER RES, V10, P521, DOI 10.1158/1078-0432.CCR-1161-03; Ladanyi A, 2007, CANCER IMMUNOL IMMUN, V56, P1459, DOI 10.1007/s00262-007-0286-3; Lespagnard L, 1999, INT J CANCER, V84, P309; Liu JG, 2004, J IMMUNOL, V173, P1184, DOI 10.4049/jimmunol.173.2.1184; Liu YJ, 2005, ANNU REV IMMUNOL, V23, P275, DOI 10.1146/annurev.immunol.23.021704.115633; Long EO, 2007, IMMUNITY, V26, P385, DOI 10.1016/j.immuni.2007.04.001; Loser K, 2005, J IMMUNOL, V174, P5298, DOI 10.4049/jimmunol.174.9.5298; Lucas M, 2007, IMMUNITY, V26, P503, DOI 10.1016/j.immuni.2007.03.006; Mach N, 2000, CANCER RES, V60, P3239; MAYORDOMO JI, 1995, NAT MED, V1, P1297, DOI 10.1038/nm1295-1297; McLellan AD, 1996, EUR J IMMUNOL, V26, P1204, DOI 10.1002/eji.1830260603; Menetrier-Caux C, 1998, BLOOD, V92, P4778, DOI 10.1182/blood.V92.12.4778; Mirza N, 2006, CANCER RES, V66, P9299, DOI 10.1158/0008-5472.CAN-06-1690; Mohamadzadeh M, 2001, J EXP MED, V194, P1013, DOI 10.1084/jem.194.7.1013; Moretta A, 2002, NAT REV IMMUNOL, V2, P957, DOI 10.1038/nri956; Moseman EA, 2004, J IMMUNOL, V173, P4433, DOI 10.4049/jimmunol.173.7.4433; Munn DH, 2005, BLOOD, V105, P2618, DOI 10.1182/blood-2005-01-0122; Munn DH, 2004, J CLIN INVEST, V114, P280, DOI 10.1172/JCI200421583; Nakakubo Y, 2003, BRIT J CANCER, V89, P1736, DOI 10.1038/sj.bjc.6601331; Nefedova Y, 2004, J IMMUNOL, V172, P464, DOI 10.4049/jimmunol.172.1.464; O'Donnell RK, 2007, CANCER LETT, V255, P145, DOI 10.1016/j.canlet.2007.04.003; Obeid M, 2007, NAT MED, V13, P54, DOI 10.1038/nm1523; Pages F, 2005, NEW ENGL J MED, V353, P2654, DOI 10.1056/NEJMoa051424; Pashenkov M, 2006, J CLIN ONCOL, V24, P5716, DOI 10.1200/JCO.2006.07.9129; Pereira CF, 2007, J IMMUNOTHER, V30, P705, DOI 10.1097/CJI.0b013e31812e6256; Perrot I, 2007, J IMMUNOL, V178, P2763, DOI 10.4049/jimmunol.178.5.2763; Pulendran B, 2004, EUR J IMMUNOL, V34, P66, DOI 10.1002/eji.200324567; Reichert TE, 2001, CANCER, V91, P2136, DOI 10.1002/1097-0142(20010601)91:11<2136::AID-CNCR1242>3.0.CO;2-Q; Riemann H, 2005, J IMMUNOL, V175, P5866, DOI 10.4049/jimmunol.175.9.5866; Rissoan MC, 1999, SCIENCE, V283, P1183, DOI 10.1126/science.283.5405.1183; Rissoan MC, 2002, BLOOD, V100, P3295, DOI 10.1182/blood-2002-02-0638; SAHIN U, 1995, P NATL ACAD SCI USA, V92, P11810, DOI 10.1073/pnas.92.25.11810; Salaun B, 2007, CLIN CANCER RES, V13, P4565, DOI 10.1158/1078-0432.CCR-07-0274; Sandel MH, 2005, CLIN CANCER RES, V11, P2576, DOI 10.1158/1078-0432.CCR-04-1448; Schmitz V, 2006, HEPATOLOGY, V44, P430, DOI 10.1002/hep.21274; Schnurr M, 2003, BLOOD, V102, P613, DOI 10.1182/blood-2002-12-3745; Schnurr M, 2004, BLOOD, V103, P1391, DOI 10.1182/blood-2003-06-1959; Schnurr M, 2005, BLOOD, V105, P2465, DOI 10.1182/blood-2004-08-3105; Shimizu K, 2007, J EXP MED, V204, P2641, DOI 10.1084/jem.20070458; Simonetti O, 2007, INT J IMMUNOPATH PH, V20, P325, DOI 10.1177/039463200702000212; Smyth MJ, 2006, ADV IMMUNOL, V90, P1, DOI 10.1016/S0065-2776(06)90001-7; Soiffer R, 2003, J CLIN ONCOL, V21, P3343, DOI 10.1200/JCO.2003.07.005; Spisek R, 2007, BLOOD, V109, P4839, DOI 10.1182/blood-2006-10-054221; Srivastava RM, 2007, INT IMMUNOL, V19, P591, DOI 10.1093/intimm/dxm024; Stary G, 2007, J EXP MED, V204, P1441, DOI 10.1084/jem.20070021; Steinbrink K, 1997, J IMMUNOL, V159, P4772; Steinman RM, 2007, NAT MED, V13, P1155, DOI 10.1038/nm1643; Steinman RM, 2007, NATURE, V449, P419, DOI 10.1038/nature06175; Steinman RM, 2003, ANNU REV IMMUNOL, V21, P685, DOI 10.1146/annurev.immunol.21.120601.141040; Sumimoto H, 2006, J EXP MED, V203, P1651, DOI 10.1084/jem.20051848; Suzuki A, 2002, J PATHOL, V196, P37, DOI 10.1002/path.1018; Tacken PJ, 2005, BLOOD, V106, P1278, DOI 10.1182/blood-2005-01-0318; Taieb J, 2006, NAT MED, V12, P214, DOI 10.1038/nm1356; Taieb J, 2006, J IMMUNOL, V176, P2722, DOI 10.4049/jimmunol.176.5.2722; Tang QZ, 2006, NAT IMMUNOL, V7, P551, DOI 10.1038/ni0606-551; Tang TJ, 2006, HUM PATHOL, V37, P332, DOI 10.1016/j.humpath.2005.11.007; TEPPER RI, 1994, HUM GENE THER, V5, P153, DOI 10.1089/hum.1994.5.2-153; Treilleux I, 2004, CLIN CANCER RES, V10, P7466, DOI 10.1158/1078-0432.CCR-04-0684; Trinite B, 2000, J IMMUNOL, V165, P4202, DOI 10.4049/jimmunol.165.8.4202; Trinite B, 2005, J IMMUNOL, V175, P2408, DOI 10.4049/jimmunol.175.4.2408; TSUJITANI S, 1990, CANCER, V66, P2012, DOI 10.1002/1097-0142(19901101)66:9<2012::AID-CNCR2820660928>3.0.CO;2-N; Ueno H, 2007, IMMUNOL REV, V219, P118, DOI 10.1111/j.1600-065X.2007.00551.x; Valmori D, 2007, P NATL ACAD SCI USA, V104, P8947, DOI 10.1073/pnas.0703395104; Villadangos JA, 2007, NAT REV IMMUNOL, V7, P543, DOI 10.1038/nri2103; von Bergwelt-Baildon MS, 2006, BLOOD, V108, P228, DOI 10.1182/blood-2005-08-3507; Yanagimoto H, 2005, CLIN IMMUNOL, V114, P52, DOI 10.1016/j.clim.2004.09.007; Yilmaz A, 2006, J LEUKOCYTE BIOL, V79, P529, DOI 10.1189/jlb.0205064; Yin XY, 2003, HEPATO-GASTROENTEROL, V50, P1281; Yoneyama H, 2005, J EXP MED, V202, P425, DOI 10.1084/jem.20041961; Zhang JQ, 2006, BLOOD, V107, P3600, DOI 10.1182/blood-2005-09-3842; Zhang L, 2003, NEW ENGL J MED, V348, P203, DOI 10.1056/NEJMoa020177; Zhang Q, 2005, CANCER RES, V65, P1761, DOI 10.1158/0008-5472.CAN-04-3169; Zitvogel L, 2002, J EXP MED, V195, pf9, DOI 10.1084/jem.20012040; Zitvogel L, 1998, NAT MED, V4, P594, DOI 10.1038/nm0598-594; Zitvogel L, 2008, NAT REV IMMUNOL, V8, P59, DOI 10.1038/nri2216; Zou WP, 2001, NAT MED, V7, P1339, DOI 10.1038/nm1201-1339	153	68	71	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 6	2008	27	45					5920	5931		10.1038/onc.2008.270	http://dx.doi.org/10.1038/onc.2008.270			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	355QE	18836473				2022-12-28	WOS:000259722600007
J	Sun, B; Karin, M				Sun, B.; Karin, M.			NF-kappa B signaling, liver disease and hepatoprotective agents	ONCOGENE			English	Review						NF-kappa B; liver disease; hepatitis; hepatocellular carcinoma; apoptosis	HEPATITIS-C VIRUS; HELICOBACTER-PYLORI INFECTION; CYTOLETHAL DISTENDING TOXIN; CHRONIC ACTIVE HEPATITIS; STELLATE CELL APOPTOSIS; NITRIC-OXIDE; MICE LACKING; GROWTH-FACTOR; TNF-ALPHA; CYCLOOXYGENASE-2 EXPRESSION	The NF-kappa B signaling pathway has particular relevance to several liver diseases including hepatitis (liver infection by Helicobacter, viral hepatitis induced by HBV and HCV), liver fibrosis and cirrhosis and hepatocellular carcinoma. Furthermore, the NF-kappa B signaling pathway is a potential target for development of hepatoprotective agents. Several types of drugs including: selective estrogen receptor modulators (SERMs), antioxidants, proteasome inhibitors, IKK inhibitors and nucleic acid-based decoys have been shown to interfere with NF-kappa B activity at different levels and may be useful for the treatment of liver diseases. However, NF-kappa B also plays an important hepatoprotective function that needs to be taken into consideration during development of new therapeutic regimens.	[Karin, M.] Univ Calif San Diego, Sch Med, Lab Gene Regulat & Signal Transduct, Dept Pharmacol & Pathol,Canc Ctr, La Jolla, CA 92093 USA; [Sun, B.] Nanjing Med Univ, Ctr Canc, Nanjing, Jiangsu Prov, Peoples R China; [Sun, B.] Nanjing Med Univ, Affiliated Hosp 1, Liver Transplantat Ctr, Nanjing, Jiangsu Prov, Peoples R China	University of California System; University of California San Diego; Nanjing Medical University; Nanjing Medical University	Karin, M (corresponding author), Univ Calif San Diego, Sch Med, Lab Gene Regulat & Signal Transduct, Dept Pharmacol & Pathol,Canc Ctr, 9500 Gilman Dr, La Jolla, CA 92093 USA.	karinoffice@ucsd.edu		Sun, Beicheng/0000-0002-8657-7024	Jiangsu Province's Outstanding Medical Academic Leader program [RC2007057]; Natural Science Foundation of China [30672367]; Ministry of Health, China [Wkj2006-2-021]; Jiangsu Province 'six adults just' high peak [06-B-032]; National Institutes of Health (NIH); American Association for Cancer Research (AACR)	Jiangsu Province's Outstanding Medical Academic Leader program; Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Ministry of Health, China; Jiangsu Province 'six adults just' high peak; National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); American Association for Cancer Research (AACR)	Work in BS laboratory is supported by Jiangsu Province's Outstanding Medical Academic Leader program (RC2007057, BS), grants from Natural Science Foundation of China (30672367, BS) and Ministry of Health, China (Wkj2006-2-021, BS), and Jiangsu Province 'six adults just' high peak: (06-B-032). Work in MK laboratory is supported by grants from the National Institutes of Health (NIH) and American Association for Cancer Research (AACR). MK is an American Cancer Society Research Professor.	Alderton WK, 2001, BIOCHEM J, V357, P593, DOI 10.1042/0264-6021:3570593; Alm RA, 1999, NATURE, V397, P176, DOI 10.1038/16495; Anan A, 2006, HEPATOLOGY, V43, P335, DOI 10.1002/hep.21036; Andersen LP, 2001, DIGEST DIS, V19, P112, DOI 10.1159/000050664; Atabay HI, 1998, J APPL MICROBIOL, V84, P1017, DOI 10.1046/j.1365-2672.1998.00438.x; Bae MK, 2006, ONCOL REP, V15, P1557; Bataller R, 2005, J CLIN INVEST, V115, P209, DOI 10.1172/JCI200524282; Bautista AP, 2002, FRONT BIOSCI-LANDMRK, V7, pA117; BEG AA, 1995, NATURE, V376, P167, DOI 10.1038/376167a0; Benelli R, 2001, FASEB J, V15, P267, DOI 10.1096/fj.01-0651fje; Bernier M, 2006, J BIOL CHEM, V281, P2551, DOI 10.1074/jbc.M511878200; Bogdan C, 2001, NAT IMMUNOL, V2, P907, DOI 10.1038/ni1001-907; Bonizzi G, 2004, TRENDS IMMUNOL, V25, P280, DOI 10.1016/j.it.2004.03.008; Bonnard M, 2000, EMBO J, V19, P4976, DOI 10.1093/emboj/19.18.4976; Bose S, 2003, J INTERF CYTOK RES, V23, P401, DOI 10.1089/107999003322277810; Bose S, 2003, P NATL ACAD SCI USA, V100, P10890, DOI 10.1073/pnas.1832775100; Cervello M, 2004, INT J MOL MED, V13, P741; Chaisson ML, 2002, J CLIN INVEST, V110, P193, DOI 10.1172/JCI200215295; Chang CS, 2007, HEPATO-GASTROENTEROL, V54, P2061; Chang LF, 2006, CELL, V124, P601, DOI 10.1016/j.cell.2006.01.021; Chen CJ, 2007, NAT MED, V13, P851, DOI 10.1038/nm1603; Chen D, 2008, HISTOL HISTOPATHOL, V23, P487, DOI 10.14670/HH-23.487; Chen LW, 2003, NAT MED, V9, P575, DOI 10.1038/nm849; Chen Y, 2008, PHARM RES-DORDR, V25, P72, DOI 10.1007/s11095-007-9504-0; Cheng Y, 2007, CHINESE MED J-PEKING, V120, P794, DOI 10.1097/00029330-200705010-00011; Chong LW, 2006, J BIOMED SCI, V13, P403, DOI 10.1007/s11373-006-9079-5; Chuang SE, 2000, FOOD CHEM TOXICOL, V38, P991, DOI 10.1016/S0278-6915(00)00101-0; Claudio E, 2002, NAT IMMUNOL, V3, P958, DOI 10.1038/ni842; Cooper A, 2005, J IMMUNOL, V175, P3165, DOI 10.4049/jimmunol.175.5.3165; Coornaert B, 2008, NAT IMMUNOL, V9, P263, DOI 10.1038/ni1561; Crispe IN, 2003, NAT REV IMMUNOL, V3, P51, DOI 10.1038/nri981; Diao JY, 2001, CYTOKINE GROWTH F R, V12, P189, DOI 10.1016/S1359-6101(00)00034-4; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; Dubois RN, 1998, FASEB J, V12, P1063, DOI 10.1096/fasebj.12.12.1063; Eferl R, 2003, CELL, V112, P181, DOI 10.1016/S0092-8674(03)00042-4; Elsharkawy AM, 2007, HEPATOLOGY, V46, P590, DOI 10.1002/hep.21802; Elsharkawy AM, 2005, APOPTOSIS, V10, P927, DOI 10.1007/s10495-005-1055-4; Elsharkawy AM, 1999, HEPATOLOGY, V30, P761, DOI 10.1002/hep.510300327; Fan CG, 2004, J CLIN INVEST, V113, P746, DOI 10.1172/JCI200417337; Farinati F, 2007, J VIRAL HEPATITIS, V14, P821, DOI 10.1111/1365-2893.2007.00878.x; FOX JG, 1995, J CLIN MICROBIOL, V33, P445, DOI 10.1128/JCM.33.2.445-454.1995; FOX JG, 1994, J CLIN MICROBIOL, V32, P1238, DOI 10.1128/JCM.32.5.1238-1245.1994; Gao B, 2008, HEPATOLOGY, V47, P729, DOI 10.1002/hep.22034; Gasperini S, 1999, J IMMUNOL, V162, P4928; Gerondakis S, 2006, ONCOGENE, V25, P6781, DOI 10.1038/sj.onc.1209944; Ghosh S, 2002, CELL, V109, pS81, DOI 10.1016/S0092-8674(02)00703-1; Greten FR, 2007, CELL, V130, P918, DOI 10.1016/j.cell.2007.07.009; HACKER H, 2006, SCI STKE, DOI DOI 10.1126/STKE.3572006RE13; Hayden Matthew S, 2006, Cell, V127, P1286; Hegewisch-Becker S, 2004, J CLIN ONCOL, V22, P4089; HELMBERG A, 1995, EMBO J, V14, P452, DOI 10.1002/j.1460-2075.1995.tb07021.x; Hemming AW, 2001, ANN SURG, V233, P652, DOI 10.1097/00000658-200105000-00009; Hildt E, 1998, RECENT RES CANCER, V154, P315; Hiscott J, 2003, ANN NY ACAD SCI, V1010, P237, DOI 10.1196/annals.1299.042; Hoeflich KP, 2000, NATURE, V406, P86, DOI 10.1038/35017574; Hopkins RJ, 1996, GASTROENTEROLOGY, V110, P1244, DOI 10.1053/gast.1996.v110.pm8613015; Hoshino K, 1999, J IMMUNOL, V162, P3749; Hu KQ, 2008, AM J GASTROENTEROL, V103, P1824, DOI 10.1111/j.1572-0241.2008.01878.x; Hu YL, 1999, SCIENCE, V284, P316, DOI 10.1126/science.284.5412.316; Huang IC, 2006, J GEN VIROL, V87, P1715, DOI 10.1099/vir.0.81718-0; Hurgin V, 2007, P NATL ACAD SCI USA, V104, P5044, DOI 10.1073/pnas.0611608104; Hwang ES, 2006, EXP BIOL MED, V231, P322; Iredale JP, 1998, J CLIN INVEST, V102, P538, DOI 10.1172/JCI1018; Ishikawa T, 2008, DIGEST DIS SCI, V53, P1785, DOI 10.1007/s10620-007-0070-4; Ito K, 2008, DIGEST DIS SCI, V53, P2541, DOI 10.1007/s10620-007-0164-z; Jaiswal M, 2001, AM J PHYSIOL-GASTR L, V281, pG626, DOI 10.1152/ajpgi.2001.281.3.G626; Johnson CL, 2007, J BIOL CHEM, V282, P10792, DOI 10.1074/jbc.M610361200; Joo MS, 2005, J VIROL, V79, P7648, DOI 10.1128/JVI.79.12.7648-7657.2005; Joshi-Barve S, 2003, HEPATOLOGY, V38, P1178, DOI 10.1053/jhep.2003.50470; Kalaitzidis D, 2005, TRENDS ENDOCRIN MET, V16, P46, DOI 10.1016/j.tem.2005.01.004; Kamata H, 2005, CELL, V120, P649, DOI 10.1016/j.cell.2004.12.041; Karin M, 2004, NAT REV DRUG DISCOV, V3, P17, DOI 10.1038/nrd1279; Karin M, 2006, NATURE, V441, P431, DOI 10.1038/nature04870; Kawai T, 1999, IMMUNITY, V11, P115, DOI 10.1016/S1074-7613(00)80086-2; Kawai T, 2001, J IMMUNOL, V167, P5887, DOI 10.4049/jimmunol.167.10.5887; Kayano K, 2000, J GASTROENTEROL, V35, P250, DOI 10.1007/s005350050339; Khan N, 2008, ANTIOXID REDOX SIGN, V10, P475, DOI 10.1089/ars.2007.1740; Kiechl S, 2002, NEW ENGL J MED, V347, P185, DOI 10.1056/NEJMoa012673; Lang A, 2000, J HEPATOL, V33, P49, DOI 10.1016/S0168-8278(00)80159-2; Lawrence T, 2007, SCIENCE, V317, P51, DOI 10.1126/science.1146052; Lazarus DD, 1997, INT J IMMUNOPHARMACO, V19, P49, DOI 10.1016/S0192-0561(96)00052-5; Li QT, 1999, SCIENCE, V284, P321, DOI 10.1126/science.284.5412.321; Li ZW, 1999, J EXP MED, V189, P1839, DOI 10.1084/jem.189.11.1839; Liang MC, 2003, MOL PHARMACOL, V64, P123, DOI 10.1124/mol.64.1.123; Lin A, 2003, SEMIN CANCER BIOL, V13, P107, DOI 10.1016/S1044-579X(02)00128-1; Luedde T, 2005, J CLIN INVEST, V115, P849, DOI 10.1172/JCI200523493; Luedde T, 2007, CANCER CELL, V11, P119, DOI 10.1016/j.ccr.2006.12.016; Maaroos HI, 1999, SCAND J GASTROENTERO, V34, P864, DOI 10.1080/003655299750025318; Maeda S, 2005, CELL, V121, P977, DOI 10.1016/j.cell.2005.04.014; Maeda S, 2003, IMMUNITY, V19, P725, DOI 10.1016/S1074-7613(03)00301-7; Maher SG, 2007, CURR MED CHEM, V14, P1279, DOI 10.2174/092986707780597907; Makris C, 2000, MOL CELL, V5, P969, DOI 10.1016/S1097-2765(00)80262-2; Malmgaard L, 2004, J INTERF CYTOK RES, V24, P439, DOI 10.1089/1079990041689665; Mann EA, 2006, VIRUS RES, V121, P51, DOI 10.1016/j.virusres.2006.04.001; Mannick EE, 1996, CANCER RES, V56, P3238; Marino M, 2005, J ENDOCRINOL INVEST, V28, P280, DOI 10.1007/BF03345386; May MJ, 2000, SCIENCE, V289, P1550, DOI 10.1126/science.289.5484.1550; Micheau O, 2003, CELL, V114, P181, DOI 10.1016/S0092-8674(03)00521-X; Mukherjee S, 2008, GASTROENTEROLOGY, V134, P1777, DOI 10.1053/j.gastro.2008.02.035; Naugler WE, 2007, SCIENCE, V317, P121, DOI 10.1126/science.1140485; Oakley F, 2003, AM J PATHOL, V163, P1849, DOI 10.1016/S0002-9440(10)63544-4; Olivier S, 2006, MOL PHARMACOL, V69, P1615, DOI 10.1124/mol.105.020479; Osada S, 2004, J SURG ONCOL, V85, P48, DOI 10.1002/jso.20006; PARSONNET J, 1994, NEW ENGL J MED, V330, P1267, DOI 10.1056/NEJM199405053301803; PARSONNET J, 1991, NEW ENGL J MED, V325, P1127, DOI 10.1056/NEJM199110173251603; Peng ZH, 2005, INT J ONCOL, V26, P467; Pham CG, 2004, CELL, V119, P529, DOI 10.1016/j.cell.2004.10.017; Pikarsky E, 2004, NATURE, V431, P461, DOI 10.1038/nature02924; Prusty BK, 2007, MOL MED, V13, P518, DOI 10.2119/2007-00055.Prusty; Renshaw M, 2002, J IMMUNOL, V169, P4697, DOI 10.4049/jimmunol.169.9.4697; Ribeiro PS, 2004, AM J GASTROENTEROL, V99, P1708, DOI 10.1111/j.1572-0241.2004.40009.x; Ristimaki A, 1997, CANCER RES, V57, P1276; Rius J, 2008, NATURE, V453, P807, DOI 10.1038/nature06905; Rogers AB, 2007, CANCER RES, V67, P11536, DOI 10.1158/0008-5472.CAN-07-1479; Rothwarf D M, 1999, Sci STKE, V1999, pRE1, DOI 10.1126/stke.1999.5.re1; Rudolph D, 2000, GENE DEV, V14, P854; Saile B, 2001, EUR J CELL BIOL, V80, P554, DOI 10.1078/0171-9335-00182; Saile B, 2004, LAB INVEST, V84, P1037, DOI 10.1038/labinvest.3700116; Sakurai T, 2008, CANCER CELL, V14, P156, DOI 10.1016/j.ccr.2008.06.016; Sakurai T, 2006, P NATL ACAD SCI USA, V103, P10544, DOI 10.1073/pnas.0603499103; SALVEMINI D, 1993, P NATL ACAD SCI USA, V90, P7240, DOI 10.1073/pnas.90.15.7240; Sato Y, 2006, GUT, V55, P1801, DOI 10.1136/gut.2005.070417; Scheidereit C, 2006, ONCOGENE, V25, P6685, DOI 10.1038/sj.onc.1209934; Schwabe RF, 2003, HEPATOLOGY, V37, P824, DOI 10.1053/jhep.2003.50135; Schwabe RF, 2006, GASTROENTEROLOGY, V130, P1886, DOI 10.1053/j.gastro.2006.01.038; Seki E, 2007, NAT MED, V13, P1324, DOI 10.1038/nm1663; Senftleben U, 2001, SCIENCE, V293, P1495, DOI 10.1126/science.1062677; Smith WL, 1996, J BIOL CHEM, V271, P33157, DOI 10.1074/jbc.271.52.33157; Solnick JV, 2001, CLIN MICROBIOL REV, V14, P59, DOI 10.1128/CMR.14.1.59-97.2001; STANLEY J, 1994, MICROBIOL-UK, V140, P3441, DOI 10.1099/13500872-140-12-3441; Stein M, 2000, P NATL ACAD SCI USA, V97, P1263, DOI 10.1073/pnas.97.3.1263; Su F, 1996, J VIROL, V70, P4558, DOI 10.1128/JVI.70.7.4558-4566.1996; Suerbaum Sebastian, 2002, Trends in Microbiology, V10, P351, DOI 10.1016/S0966-842X(02)02398-3; Suetsugu H, 2005, GUT, V54, P835, DOI 10.1136/gut.2004.043034; SUN SC, 1993, SCIENCE, V259, P1912, DOI 10.1126/science.8096091; Sung JJY, 2000, AM J PATHOL, V157, P729, DOI 10.1016/S0002-9440(10)64586-5; Sunitha S, 2001, FITOTERAPIA, V72, P516, DOI 10.1016/S0367-326X(01)00259-3; Szabo G, 2002, FRONT BIOSCI-LANDMRK, V7, pA80, DOI 10.2741/szabo; Tai DI, 2000, HEPATOLOGY, V31, P656, DOI 10.1002/hep.510310316; Takada Y, 2004, ONCOGENE, V23, P9247, DOI 10.1038/sj.onc.1208169; Takeda K, 1999, SCIENCE, V284, P313, DOI 10.1126/science.284.5412.313; Tanaka K, 2006, INT J MOL MED, V17, P827; Tang WL, 2007, AM J PATHOL, V171, P1831, DOI 10.2353/ajpath.2007.070413; Thumann C, 2008, GASTROEN CLIN BIOL, V32, P59, DOI 10.1016/j.gcb.2007.12.006; TIEGS G, 1992, J CLIN INVEST, V90, P196, DOI 10.1172/JCI115836; Tissing WJE, 2003, LEUKEMIA, V17, P17, DOI 10.1038/sj.leu.2402733; Toledo LP, 2003, NUTR CANCER, V47, P62, DOI 10.1207/s15327914nc4701_8; Tomb JF, 1997, NATURE, V388, P539, DOI 10.1038/41483; Trejo-Avila L, 2007, ANN HEPATOL, V6, P174; Tsujii M, 1997, P NATL ACAD SCI USA, V94, P3336, DOI 10.1073/pnas.94.7.3336; Turini ME, 2002, ANNU REV MED, V53, P35, DOI 10.1146/annurev.med.53.082901.103952; Uchinami H, 2002, AM J PHYSIOL-GASTR L, V282, pG962, DOI 10.1152/ajpgi.00466.2001; Uemura N, 2001, NEW ENGL J MED, V345, P784, DOI 10.1056/NEJMoa001999; Um HR, 2007, VIRUS RES, V125, P1, DOI 10.1016/j.virusres.2006.11.007; Umemura T, 2003, CARCINOGENESIS, V24, P1105, DOI 10.1093/carcin/bgg053; Vergani D, 2004, Minerva Gastroenterol Dietol, V50, P113; Wahl C, 1998, J CLIN INVEST, V101, P1163, DOI 10.1172/JCI992; WARD JM, 1994, AM J PATHOL, V145, P959; WARD JM, 1994, JNCI-J NATL CANCER I, V86, P1222, DOI 10.1093/jnci/86.16.1222; Waris G, 2003, J BIOL CHEM, V278, P40778, DOI 10.1074/jbc.M303248200; Waris G, 2003, J BIOSCIENCES, V28, P311, DOI 10.1007/BF02970150; Waris G, 2002, BIOCHEM PHARMACOL, V64, P1425, DOI 10.1016/S0006-2952(02)01300-X; Weil R, 1999, MOL CELL BIOL, V19, P6345; Wiegand J, 2008, INTERNIST, V49, P817, DOI 10.1007/s00108-008-2146-4; Williams CS, 1997, J CLIN INVEST, V100, P1325, DOI 10.1172/JCI119651; Wong CM, 2008, LIVER INT, V28, P160, DOI 10.1111/j.1478-3231.2007.01637.x; Yamada Y, 1997, P NATL ACAD SCI USA, V94, P1441, DOI 10.1073/pnas.94.4.1441; Yan MS, 2007, STEROIDS, V72, P415, DOI 10.1016/j.steroids.2007.02.004; Yin M, 2001, J IMMUNOL, V166, P4737, DOI 10.4049/jimmunol.166.7.4737; Young VB, 2000, J INFECT DIS, V182, P620, DOI 10.1086/315705; Young VB, 2000, INFECT IMMUN, V68, P184, DOI 10.1128/IAI.68.1.184-191.2000; Yun C, 2002, CANCER LETT, V184, P97, DOI 10.1016/S0304-3835(02)00187-8; Zarrilli R, 1999, CELL MICROBIOL, V1, P93, DOI 10.1046/j.1462-5822.1999.00018.x; Zhao YH, 2005, CHINESE J CHEM ENG, V13, P96; Zimmermann M, 2008, J HEPATOL, V48, P51, DOI 10.1016/j.jhep.2007.08.008	175	230	245	2	25	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT	2008	27	48					6228	6244		10.1038/onc.2008.300	http://dx.doi.org/10.1038/onc.2008.300			17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	361YB	18931690				2022-12-28	WOS:000260162800005
J	Yang, J; Song, K; Krebs, TL; Jackson, MW; Danielpour, D				Yang, J.; Song, K.; Krebs, T. L.; Jackson, M. W.; Danielpour, D.			Rb/E2F4 and Smad2/3 link survivin to TGF-beta-induced apoptosis and tumor progression	ONCOGENE			English	Article						prostate cancer; promoter regulation; apoptosis; CDE; CHR; E2F	GROWTH-FACTOR-BETA; EPITHELIAL-CELL LINES; PROSTATE-CANCER CELLS; TRANSCRIPTIONAL REPRESSION; MALIGNANT-TRANSFORMATION; C-MYC; RECEPTOR; EXPRESSION; ACTIVATION; MECHANISMS	Survivin is a prosurvival protein overexpressed in many cancers through mechanisms that remain poorly explored, and is implicated in control of tumor progression and resistance to cancer chemotherapeutics. Here, we report a critical role for survivin in the induction of apoptosis by transforming growth factor-beta (TGF-beta). We show that TGF-beta rapidly downregulates survivin expression in prostate epithelial cells, through a unique mechanism of transcriptional suppression involving Smads 2 and 3, Rb/E2F4, and the cell-cycle repressor elements CDE and CHR. This TGF-beta response is triggered through a Smad2/3-dependent hypophosphorylation of Rb and the subsequent association of the Rb/E2F4 repressive complex to CDE/CHR elements in the proximal region of the survivin promoter. Viral-mediated gene delivery experiments, involving overexpressing or silencing survivin, reveal critical roles of survivin in apoptosis induced by TGF-b alone or in cooperation with cancer therapeutic agents. We propose a novel TGF-beta/Rb/survivin axis with a putative role in the functional switch of TGF-beta from tumor suppressor to tumor promoter.	[Yang, J.; Song, K.; Krebs, T. L.; Danielpour, D.] Case Western Reserve Univ, Div Gen Med Sci Oncol, Case Sch Med, Cleveland, OH 44106 USA; [Yang, J.] Case Western Reserve Univ, Case Sch Med, Dept Biochem, Cleveland, OH 44106 USA; [Jackson, M. W.] Case Western Reserve Univ, Case Sch Med, Dept Pathol, Cleveland, OH 44106 USA; [Danielpour, D.] Case Western Reserve Univ, Case Sch Med, Dept Pharmacol, Cleveland, OH 44106 USA	Case Western Reserve University; Case Western Reserve University; Case Western Reserve University; Case Western Reserve University	Danielpour, D (corresponding author), Case Western Reserve Univ, Div Gen Med Sci Oncol, Case Sch Med, Wolstein Res Bldg,2103 Cornell Rd,Room 3532, Cleveland, OH 44106 USA.	dxd49@case.edu			Gene Expression and Genotyping Facility; Case Comprehensive Cancer Center [P30 CA43703]; NCI [R01CA092102, R01CA102074]; NATIONAL CANCER INSTITUTE [P30CA043703, R01CA102074, R01CA092102] Funding Source: NIH RePORTER	Gene Expression and Genotyping Facility; Case Comprehensive Cancer Center; NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This research was supported by the Gene Expression and Genotyping Facility, the Flow Cytometry Core Facility of the Case Comprehensive Cancer Center (P30 CA43703). Grant support: NCI grants R01CA092102 and R01CA102074 (to D Danielpour).	Altieri DC, 2003, NAT REV CANCER, V3, P46, DOI 10.1038/nrc968; Altieri DC, 2003, ONCOGENE, V22, P8581, DOI 10.1038/sj.onc.1207113; Bello D, 1997, CARCINOGENESIS, V18, P1215, DOI 10.1093/carcin/18.6.1215; Chen CR, 2002, CELL, V110, P19, DOI 10.1016/S0092-8674(02)00801-2; Chipuk JE, 2001, J BIOL CHEM, V276, P26614, DOI 10.1074/jbc.M100913200; Chipuk JE, 2002, J BIOL CHEM, V277, P1240, DOI 10.1074/jbc.M108855200; DANIELPOUR D, 1994, CANCER RES, V54, P3413; Danielpour D, 2006, CYTOKINE GROWTH F R, V17, P59, DOI 10.1016/j.cytogfr.2005.09.007; Danielpour D, 2005, EUR J CANCER, V41, P846, DOI 10.1016/j.ejca.2004.12.027; Derynck R, 2003, NATURE, V425, P577, DOI 10.1038/nature02006; Frederick JP, 2004, MOL CELL BIOL, V24, P2546, DOI 10.1128/MCB.24.6.2546-2559.2004; Harbour JW, 2000, NAT CELL BIOL, V2, pE65, DOI 10.1038/35008695; Heinemeyer T, 1998, NUCLEIC ACIDS RES, V26, P362, DOI 10.1093/nar/26.1.362; Hilger-Eversheim K, 2000, GENE, V260, P1, DOI 10.1016/S0378-1119(00)00454-6; Hsing AY, 1996, CANCER RES, V56, P5146; Inman GJ, 2002, MOL PHARMACOL, V62, P65, DOI 10.1124/mol.62.1.65; Jackson MW, 2005, J CELL SCI, V118, P1821, DOI 10.1242/jcs.02307; Jarrard DF, 2002, CANCER LETT, V185, P191, DOI 10.1016/S0304-3835(02)00282-3; Jiang YY, 2004, J BIOL CHEM, V279, P40511, DOI 10.1074/jbc.M404496200; Kishi H, 2004, J UROLOGY, V171, P1855, DOI 10.1097/01.ju.0000120317.88372.03; Knudsen KE, 1999, ONCOGENE, V18, P5239, DOI 10.1038/sj.onc.1202910; Le Cam L, 1999, EMBO J, V18, P1878, DOI 10.1093/emboj/18.7.1878; Liston P, 2003, ONCOGENE, V22, P8568, DOI 10.1038/sj.onc.1207101; Liu NS, 1997, NUCLEIC ACIDS RES, V25, P4915, DOI 10.1093/nar/25.24.4915; Lucibello FC, 1997, NUCLEIC ACIDS RES, V25, P4921, DOI 10.1093/nar/25.24.4921; Massague J, 2000, EMBO J, V19, P1745, DOI 10.1093/emboj/19.8.1745; Massague J, 2005, GENE DEV, V19, P2783, DOI 10.1101/gad.1350705; Pennati M, 2004, ONCOGENE, V23, P386, DOI 10.1038/sj.onc.1207071; Roberts AB, 2003, P NATL ACAD SCI USA, V100, P8621, DOI 10.1073/pnas.1633291100; Salvesen GS, 2002, NAT REV MOL CELL BIO, V3, P401, DOI 10.1038/nrm830; Shariat SF, 2004, CANCER, V100, P751, DOI 10.1002/cncr.20039; Sharma A, 2007, CANCER RES, V67, P6192, DOI 10.1158/0008-5472.CAN-06-4424; Shi YG, 2003, CELL, V113, P685, DOI 10.1016/S0092-8674(03)00432-X; Song K, 2003, J BIOL CHEM, V278, P38342, DOI 10.1074/jbc.M304583200; Song K, 2003, CANCER RES, V63, P4358; Song KY, 2006, EMBO J, V25, P58, DOI 10.1038/sj.emboj.7600917; Tang BW, 1999, CANCER RES, V59, P4834; Taylor WR, 2001, J BIOL CHEM, V276, P1998, DOI 10.1074/jbc.M005101200; ten Dijke P, 2004, TRENDS BIOCHEM SCI, V29, P265, DOI 10.1016/j.tibs.2004.03.008; Wajapeyee N, 2006, J BIOL CHEM, V281, P16207, DOI 10.1074/jbc.M600539200; Wang H, 2005, J BIOL CHEM, V280, P5154, DOI 10.1074/jbc.M411575200; WRANA JL, 1992, CELL, V71, P1003, DOI 10.1016/0092-8674(92)90395-S; Zawel L, 1998, MOL CELL, V1, P611, DOI 10.1016/S1097-2765(00)80061-1; Zhang M, 2005, ONCOGENE, V24, P2474, DOI 10.1038/sj.onc.1208490	44	52	55	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 11	2008	27	40					5326	5338		10.1038/onc.2008.165	http://dx.doi.org/10.1038/onc.2008.165			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	346UW	18504435	Green Accepted			2022-12-28	WOS:000259096100005
J	Manenti, G; Trincucci, G; Pettinicchio, A; Amendola, E; Scarfo, M; Dragani, TA				Manenti, G.; Trincucci, G.; Pettinicchio, A.; Amendola, E.; Scarfo, M.; Dragani, T. A.			Cis-acting genomic elements of the Pas1 locus control Kras mutability in lung tumors	ONCOGENE			English	Article						mouse; heredity; genetic susceptibility; lung cancer	K-RAS GENE; TRANSGENIC MICE; H-RAS; N-RAS; MOUSE; SUSCEPTIBILITY; CANCER; TUMORIGENESIS; ACTIVATION; CARCINOGENESIS	The Pas1 locus is the major tumor modi. er of lung tumorigenesis in mouse inbred strains. Of six genes contained in a conserved haplotype, three (Casc1, Kras and Ifltd1) have been proposed as Pas1 candidates, but mechanistic evidence is sparse. Herein, we examined urethane-induced lung tumorigenesis in a new mouse model developed by replacing the Kras gene with an Hras gene in the susceptible A/J-type Pas1 locus and crossing these mice with either C57BL/6J or A/J mice. Heterozygous mice carrying the Hras-replacement gene were more susceptible than wild-type mice to lung carcinogenesis, indicating that Hras replacement not only compensates for Kras functions, but is more active. Indeed, most lung tumors carried a Gln61Leu mutation in the Hras-replacement gene, whereas no mutations were observed in the endogenous Hras gene. Thus, the context of the Kras locus determined mutability of ras genes. In mice carrying the Hras-replacement gene, the mutation frequency affecting the wild-type Kras gene was much higher when this gene was located in the A/J type than in the C57BL/6J-type Pas1 locus (12 versus 0%, -log P = 5.0). These findings identify cis-acting elements in the Pas1 locus as the functional components controlling genetic susceptibility to lung tumorigenesis by modulating mutability of the Kras gene.	[Manenti, G.; Trincucci, G.; Pettinicchio, A.; Dragani, T. A.] Ist Nazl Tumori, Fdn IRCCS, Dept Expt Oncol & Labs, I-20133 Milan, Italy; [Amendola, E.; Scarfo, M.] Staz Zoolog Anton Dohrn, Naples, Italy; [Amendola, E.; Scarfo, M.] Biogem SC Ar L, IRGS, Ariano Irpino, Italy	Fondazione IRCCS Istituto Nazionale Tumori Milan; Stazione Zoologica Anton Dohrn di Napoli	Dragani, TA (corresponding author), Ist Nazl Tumori, Fdn IRCCS, Dept Expt Oncol, Via G Venezian 1, I-20133 Milan, Italy.	tommaso.dragani@istitutotumori.mi.it	Dragani, Tommaso A./K-4493-2016; Manenti, Giacomo/J-3339-2017	Dragani, Tommaso A./0000-0001-5915-4598; Manenti, Giacomo/0000-0002-4887-4482	Associazione and Fondazione Italiana Ricerca Cancro (AIRC and FIRC)	Associazione and Fondazione Italiana Ricerca Cancro (AIRC and FIRC)(Fondazione AIRC per la ricerca sul cancro)	This work was funded in part by grants from Associazione and Fondazione Italiana Ricerca Cancro (AIRC and FIRC). The funders had no role in the design and conduct of the study, in the collection, analysis and interpretation of the data, and in the preparation, review or approval of the article.	CHEN B, 1994, CARCINOGENESIS, V15, P2031, DOI 10.1093/carcin/15.9.2031; De Gregorio L, 1998, INT J CANCER, V79, P269, DOI 10.1002/(SICI)1097-0215(19980619)79:3<269::AID-IJC10>3.3.CO;2-J; Dragani TA, 2000, CANCER RES, V60, P5017; Dragani TA, 1995, ADV CANCER RES, V67, P83, DOI 10.1016/S0065-230X(08)60711-3; Johnson L, 2001, NATURE, V410, P1111, DOI 10.1038/35074129; Johnson L, 1997, GENE DEV, V11, P2468, DOI 10.1101/gad.11.19.2468; Jones-Bolin SE, 1998, CARCINOGENESIS, V19, P1503, DOI 10.1093/carcin/19.8.1503; Koera K, 1997, ONCOGENE, V15, P1151, DOI 10.1038/sj.onc.1201284; MAHER J, 1995, ONCOGENE, V11, P1639; Manenti G, 2005, CARCINOGENESIS, V26, P875, DOI 10.1093/carcin/bgh299; Manenti G, 2004, ONCOGENE, V23, P4495, DOI 10.1038/sj.onc.1207584; MANENTI G, 1995, GENOMICS, V29, P438, DOI 10.1006/geno.1995.9984; Manenti G, 2006, CARCINOGENESIS, V27, P1386, DOI 10.1093/carcin/bgi332; MARONPOT RR, 1991, EXP LUNG RES, V17, P305, DOI 10.3109/01902149109064420; Mascaux C, 2005, BRIT J CANCER, V92, P131, DOI 10.1038/sj.bjc.6602258; Meuwissen R, 2001, ONCOGENE, V20, P6551, DOI 10.1038/sj.onc.1204837; Ogawa K, 1996, CARCINOGENESIS, V17, P341, DOI 10.1093/carcin/17.2.341; Potenza N, 2005, EMBO REP, V6, P432, DOI 10.1038/sj.embor.7400397; To MD, 2006, NAT GENET, V38, P926, DOI 10.1038/ng1836; Tomisawa M, 2003, TOXICOL LETT, V142, P111, DOI 10.1016/S0378-4274(03)00018-3; Umemura T, 1999, CANCER LETT, V145, P101, DOI 10.1016/S0304-3835(99)00237-2; Wang M, 2005, ONCOGENE, V24, P1958, DOI 10.1038/sj.onc.1208295; YOU M, 1992, P NATL ACAD SCI USA, V89, P5804, DOI 10.1073/pnas.89.13.5804; Zhang ZQ, 2003, P NATL ACAD SCI USA, V100, P12642, DOI 10.1073/pnas.2133947100	24	11	11	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP	2008	27	43					5753	5758		10.1038/onc.2008.194	http://dx.doi.org/10.1038/onc.2008.194			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	352HM	18560355				2022-12-28	WOS:000259487100010
J	Sankar, N; Baluchamy, S; Kadeppagari, RK; Singhal, G; Weitzman, S; Thimmapaya, B				Sankar, N.; Baluchamy, S.; Kadeppagari, R-K; Singhal, G.; Weitzman, S.; Thimmapaya, B.			p300 provides a corepressor function by cooperating with YY1 and HDAC3 to repress c-Myc	ONCOGENE			English	Article						c-Myc; p300; gene expression; cell cycle; YY1; HDAC3	TRANSCRIPTIONAL REPRESSION; BINDING PROTEIN; CELL-GROWTH; G(1) EXIT; PROMOTER; ACETYLATION; CBP; ASSOCIATION; ACTIVATION; DEPLETION	We showed earlier that p300/CBP plays an important role in G1 progression by negatively regulating c-Myc and thereby preventing premature G1 exit. Here, we have studied the mechanism by which p300 represses c-Myc and show that in quiescent cells p300 cooperates with histone deacetylase 3 (HDAC3) to repress transcription. p300 and HDAC3 are recruited to the upstream YY1-binding site of the c-Myc promoter resulting in chromatin deacetylation and repression of c-Myc transcription. Consistent with this, ablation of p300, YY1 or HDAC3 expression results in chromatin acetylation and induction of c-Myc. These three proteins exist as a complex in vivo and form a multiprotein complex with the YY1-binding site in vitro. The C-terminal region of p300 is both necessary and sufficient for the repression of c-Myc. These and other results suggest that in quiescent cells the C-terminal region of p300 provides corepressor function and facilitates the recruitment of p300 and HDAC3 to the YY1-binding site and represses the c-Myc promoter. This corepressor function of p300 prevents the inappropriate induction of c-Myc and S phase.	[Sankar, N.; Baluchamy, S.; Kadeppagari, R-K; Singhal, G.; Thimmapaya, B.] Northwestern Univ, Feinberg Sch Med, Dept Microbiol & Immunol, Chicago, IL 60611 USA; [Weitzman, S.] Northwestern Univ, Feinberg Sch Med, Dept Med, Chicago, IL 60611 USA	Northwestern University; Feinberg School of Medicine; Northwestern University; Feinberg School of Medicine	Thimmapaya, B (corresponding author), Northwestern Univ, Sch Med, Dept Microbiol & Immunol, 303 E Chicago Ave,Olson 8452, Chicago, IL 60611 USA.	b-thimmapaya@northwestern.edu	Natesan, Sankar/C-9866-2015; KADEPPAGARI, RAVI KUMAR/C-1682-2015	KADEPPAGARI, RAVI KUMAR/0000-0003-0576-9508	NIH [CA73303]; NATIONAL CANCER INSTITUTE [R43CA073303] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We are very grateful to Drs E Seto (Moffits Cancer Center), Dr Wu (University of Oregon), Yang Shi (Harvard University), N Perkins and R Hayward (University of Dundee, UK), and G Chinnadurai (St Louis University) for providing various plasmids and viruses. We also thank Dr Kathy Rundell for helpful discussion and editing this article. This work was supported by the NIH Grant CA73303.	Agalioti T, 2002, CELL, V111, P381, DOI 10.1016/S0092-8674(02)01077-2; Albert T, 2001, J BIOL CHEM, V276, P20482, DOI 10.1074/jbc.M100265200; Baluchamy S, 2007, ONCOGENE, V26, P781, DOI 10.1038/sj.onc.1209825; Baluchamy S, 2003, P NATL ACAD SCI USA, V100, P9524, DOI 10.1073/pnas.1633700100; Black JC, 2006, MOL CELL, V23, P809, DOI 10.1016/j.molcel.2006.07.018; Christova R, 2002, NAT CELL BIOL, V4, P79, DOI 10.1038/ncb733; Dang CV, 1999, MOL CELL BIOL, V19, P1; Filippova GN, 1996, MOL CELL BIOL, V16, P2802; Frisch SM, 2002, NAT REV MOL CELL BIO, V3, P441, DOI 10.1038/nrm827; Girdwood D, 2003, MOL CELL, V11, P1043, DOI 10.1016/S1097-2765(03)00141-2; Goodman RH, 2000, GENE DEV, V14, P1553; Guermah M, 2006, CELL, V125, P275, DOI 10.1016/j.cell.2006.01.055; Guidez F, 2005, MOL CELL BIOL, V25, P5552, DOI 10.1128/MCB.25.13.5552-5566.2005; Hassig CA, 1998, P NATL ACAD SCI USA, V95, P3519, DOI 10.1073/pnas.95.7.3519; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; Hong R, 2003, J BIOL CHEM, V278, P44505, DOI 10.1074/jbc.M303138200; Ishizuka T, 2003, MOL CELL BIOL, V23, P5122, DOI 10.1128/MCB.23.15.5122-5131.2003; Iyer NG, 2007, ONCOGENE, V26, P21, DOI 10.1038/sj.onc.1209771; Iyer NG, 2004, ONCOGENE, V23, P4225, DOI 10.1038/sj.onc.1207118; Izzo MW, 1999, J BIOL CHEM, V274, P19498, DOI 10.1074/jbc.274.27.19498; Jayaraman G, 1999, J BIOL CHEM, V274, P17342, DOI 10.1074/jbc.274.24.17342; Kolli S, 2001, P NATL ACAD SCI USA, V98, P4646, DOI 10.1073/pnas.081141998; Kung AL, 2000, GENE DEV, V14, P272; LEE JS, 1995, GENE DEV, V9, P1188, DOI 10.1101/gad.9.10.1188; Munshi N, 1998, MOL CELL, V2, P457, DOI 10.1016/S1097-2765(00)80145-8; Murphy DJ, 1999, MOL CELL BIOL, V19, P2724; Nakajima T, 1997, CELL, V90, P1107, DOI 10.1016/S0092-8674(00)80376-1; Poizat C, 2000, MOL CELL BIOL, V20, P8643, DOI 10.1128/MCB.20.23.8643-8654.2000; Rajabi HN, 2005, J BIOL CHEM, V280, P361, DOI 10.1074/jbc.M408633200; Santoso BY, 2006, NAT STRUCT MOL BIOL, V13, P131, DOI 10.1038/nsmb1048; Schwartz YB, 2007, NAT REV GENET, V8, P9, DOI 10.1038/nrg1981; SOULE HD, 1990, CANCER RES, V50, P6075; Sui GC, 2004, CELL, V117, P859, DOI 10.1016/j.cell.2004.06.004; Waltzer L, 1998, NATURE, V395, P521, DOI 10.1038/26785; YACIUK P, 1991, MOL CELL BIOL, V11, P5389, DOI 10.1128/MCB.11.11.5389; Yao TP, 1998, CELL, V93, P361, DOI 10.1016/S0092-8674(00)81165-4; Yao YL, 2001, MOL CELL BIOL, V21, P5979, DOI 10.1128/MCB.21.17.5979-5991.2001; Zhang Y, 1999, GENE DEV, V13, P1924, DOI 10.1101/gad.13.15.1924; Zou X, 1997, CURR TOP MICROBIOL, V224, P57	39	54	56	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP	2008	27	43					5717	5728		10.1038/onc.2008.181	http://dx.doi.org/10.1038/onc.2008.181			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	352HM	18542060				2022-12-28	WOS:000259487100007
J	Vincent, T; Kukalev, A; Andang, M; Pettersson, R; Percipalle, P				Vincent, T.; Kukalev, A.; Andang, M.; Pettersson, R.; Percipalle, P.			The glycogen synthase kinase (GSK) 3 beta represses RNA polymerase I transcription	ONCOGENE			English	Article						GSK3 beta; PTEN; rDNA; Pol I transcription; cell proliferation; tumour suppressors	TUMOR SUPPRESSION; PTEN; GLYCOGEN-SYNTHASE-KINASE-3-BETA; PHOSPHORYLATION; KINASE-3-BETA; INHIBITOR; PATHWAYS; HOMOLOG; COMPLEX; PROTEIN	Several oncogenic proteins and tumour suppressors target the RNA polymerase I and interfere with rRNA synthesis. Here, we show that the glycogen synthase kinase (GSK) 3 beta, which phosphorylates the tumour suppressor PTEN (phosphatase and tensin homologue deleted on chromosome 10), is selectively enriched in nucleoli of RAS-transformed cells. Immunoprecipitation and chromatin immunoprecipitation assays performed on epithelial and endothelial cells transformed with oncogenic RAS show that GSK3 beta and PTEN are part of the same complex and associate with promoter and coding region of the rDNA. An active GSK3 beta mutant abolished nucleolar BrUTP incorporation and associated with the member of the selectivity factor 1 complex TAF(I)110. Finally, GSK3 beta inhibition upregulated 45S, 18S and 28S rRNA synthesis in RAS-transformed epithelial cells as revealed by semiquantitative real-time PCR and promoted cellular proliferation. Our results underscore a repressive function for GSK3 beta in rRNA biogenesis supporting its role as a tumour supressor.	[Kukalev, A.; Percipalle, P.] Karolinska Inst, Dept Cell & Mol Biol, Med Nobel Inst, S-17177 Stockholm, Sweden; [Vincent, T.; Pettersson, R.] Karolinska Inst, Stockholm Branch, Ludwig Inst Canc Res, S-17177 Stockholm, Sweden; [Andang, M.] Karolinska Inst, Dept Med Biochem & Biophys, S-17177 Stockholm, Sweden	Karolinska Institutet; Karolinska Institutet; Ludwig Institute for Cancer Research; Karolinska Institutet	Percipalle, P (corresponding author), Karolinska Inst, Dept Cell & Mol Biol, Med Nobel Inst, Box 285,Nobels Vag 3, S-17177 Stockholm, Sweden.	piergiorgio.percipalle@ki.se	Andäng, Michael/GRE-9898-2022; VIncent, Theresa/HDN-9575-2022	Vincent, Theresa/0000-0002-7248-066X; Andang, Michael/0000-0002-2886-7891	Swedish Research Council (Vetenskapsra det); Cancerfonden; Lars Hiertas Minne Foundation; Jeansson Foundation	Swedish Research Council (Vetenskapsra det)(Swedish Research Council); Cancerfonden(Swedish Cancer Society); Lars Hiertas Minne Foundation; Jeansson Foundation	We thank J Arbiser (Emory University, USA) and H Beug ( Institute of Molecular Pathology, Vienna) for providing EpRAS and SVR cells. This work was supported by grants from the Swedish Research Council (Vetenskapsra det), Cancerfonden, the Lars Hiertas Minne Foundation and the Jeansson Foundation to PP.	Al-Khouri AM, 2005, J BIOL CHEM, V280, P35195, DOI 10.1074/jbc.M503045200; Arbiser JL, 1997, P NATL ACAD SCI USA, V94, P861, DOI 10.1073/pnas.94.3.861; Bachelder RE, 2005, J CELL BIOL, V168, P29, DOI 10.1083/jcb.200409067; Baker SJ, 2007, CELL, V128, P25, DOI 10.1016/j.cell.2006.12.023; Bijur GN, 2003, NEUROREPORT, V14, P2415, DOI 10.1097/00001756-200312190-00025; Chu EC, 2004, MED SCI MONITOR, V10, pRA235; Di Cristofano A, 1998, NAT GENET, V19, P348, DOI 10.1038/1235; DOMINGUEZ I, 1995, P NATL ACAD SCI USA, V92, P8498, DOI 10.1073/pnas.92.18.8498; Grummt I, 2003, GENE DEV, V17, P1691, DOI 10.1101/gad.1098503R; Janda E, 2002, J CELL BIOL, V156, P299, DOI 10.1083/jcb.200109037; Jope RS, 2004, TRENDS BIOCHEM SCI, V29, P95, DOI 10.1016/j.tibs.2003.12.004; Leslie NR, 2004, BIOCHEM J, V382, P1, DOI 10.1042/BJ20040825; Ma C, 2007, CANCER RES, V67, P7756, DOI 10.1158/0008-5472.CAN-06-4665; Mayer C, 2005, CELL CYCLE, V4, P1036, DOI 10.4161/cc.4.8.1925; Meijer L, 2003, CHEM BIOL, V10, P1255, DOI 10.1016/j.chembiol.2003.11.010; Morisco C, 2000, J BIOL CHEM, V275, P14466, DOI 10.1074/jbc.275.19.14466; Percipalle P, 2006, EMBO REP, V7, P525, DOI 10.1038/sj.embor.7400657; Salas TR, 2003, J BIOL CHEM, V278, P41338, DOI 10.1074/jbc.M302972200; Savino TM, 1999, J CELL SCI, V112, P1889; Seither P, 1996, GENOMICS, V37, P135, DOI 10.1006/geno.1996.0531; Torres J, 2001, J BIOL CHEM, V276, P993, DOI 10.1074/jbc.M009134200; Tseng AS, 2006, CHEM BIOL, V13, P957, DOI 10.1016/j.chembiol.2006.08.004; Wang YM, 2006, J INFRARED MILLIM W, V25, P50; White RJ, 2005, NAT REV MOL CELL BIO, V6, P69, DOI 10.1038/nrm1551; Zhang C, 2005, MOL CELL BIOL, V25, P6899, DOI 10.1128/MCB.25.16.6899-6911.2005	25	21	21	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP	2008	27	39					5254	5259		10.1038/onc.2008.152	http://dx.doi.org/10.1038/onc.2008.152			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	344GO	18490923				2022-12-28	WOS:000258915100009
J	Gentilella, A; Passiatore, G; Deshmane, S; Turco, MC; Khalili, K				Gentilella, A.; Passiatore, G.; Deshmane, S.; Turco, M. C.; Khalili, K.			Activation of BAG3 by Egr-1 in response to FGF-2 in neuroblastoma cells	ONCOGENE			English	Article						BAG3; Egr-1; neuron/neuronal	FIBROBLAST GROWTH FACTOR-2; TRANSCRIPTION FACTOR EGR-1; SMOOTH-MUSCLE-CELLS; BCL-2-BINDING PROTEIN; REACTIVE ASTROCYTES; APOPTOSIS; GENE; SURVIVAL; FAMILY; BRAIN	The co-chaperone protein, BAG3, which belongs to the BAG protein family, has an established antiapoptotic function in different tumor cell lines. Here we demonstrated that treatment of the human neuroblastoma cell line, SK-N-MC, with. broblast growth factor-2 (FGF-2) results in induction of BAG3 expression. Induction of BAG3 protein by FGF-2 occurs at the transcriptional level; it requires the extracellular regulated kinase1/2 pathway and is dependent on the activity of Egr-1 upon the BAG3 promoter. Targeted suppression of BAG3 by small-interfering RNA results in dysregulation of cell-cycle progression most notably at S and G(2) phases, which corroborates the decreased level of cyclin B1 expression. These observations suggest a new role for BAG3 in regulation of the cell cycle.	[Gentilella, A.; Passiatore, G.; Deshmane, S.; Khalili, K.] Temple Univ, Sch Med, Dept Neurosci, Ctr Neurovirol, Philadelphia, PA 19122 USA; [Turco, M. C.] Univ Salerno, Dept Pharmaceut Sci, I-84100 Salerno, Italy	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; University of Salerno	Khalili, K (corresponding author), Temple Univ, Sch Med, Dept Neurosci, Ctr Neurovirol, 1900 N 12th St,015-96,Room 203, Philadelphia, PA 19122 USA.	kamel.khalili@temple.edu	TURCO, Maria Caterina/AAC-5282-2022; Gentilella, Antonio/AAA-9864-2020	TURCO, Maria Caterina/0000-0002-7835-359X; 	NIH	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	We thank past and present members of the Department of Neuroscience and Center for Neurovirology for sharing of ideas and reagents, and their encouragement throughout this study. We also thank Dr Francesca Peruzzi, Dr Davide Eletto and Dr Thersa M Sweet for their advices, William Yen and Jessica Otte for their technical support, Dr Martyn White for his time and assistance in the preparation of the manuscript and C Schriver for editorial assistance. This study is dedicated to our friend and colleague, Dr Arturo Leone. This work was made possible by grants awarded by NIH to KK.	Alzheimer C, 2002, ADV EXP MED BIOL, V513, P335; ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; Baird Andrew, 1994, Current Opinion in Neurobiology, V4, P78, DOI 10.1016/0959-4388(94)90035-3; BASILICO C, 1992, ADV CANCER RES, V59, P115, DOI 10.1016/S0065-230X(08)60305-X; Bikfalvi A, 1997, ENDOCR REV, V18, P26, DOI 10.1210/er.18.1.26; Carreras I, 2001, AM J PHYSIOL-LUNG C, V281, pL766, DOI 10.1152/ajplung.2001.281.4.L766; Chiappetta G, 2007, J CLIN ENDOCR METAB, V92, P1159, DOI 10.1210/jc.2006-1712; Doong H, 2002, CANCER LETT, V188, P25, DOI 10.1016/S0304-3835(02)00456-1; Doong H, 2003, J BIOL CHEM, V278, P28490, DOI 10.1074/jbc.M209682200; Doong H, 2000, ONCOGENE, V19, P4385, DOI 10.1038/sj.onc.1203797; Gotz R, 2005, NAT NEUROSCI, V8, P1169, DOI 10.1038/nn1524; Gremo F, 2000, INT J DEV NEUROSCI, V18, P271, DOI 10.1016/S0736-5748(99)00095-7; Gritti A, 1996, J NEUROSCI, V16, P1091; Her S, 2004, MOL BRAIN RES, V126, P157, DOI 10.1016/j.molbrainres.2004.04.002; Homma S, 2006, AM J PATHOL, V169, P761, DOI 10.2353/ajpath.2006.060250; Issa Razao, 2005, Angiogenesis, V8, P53, DOI 10.1007/s10456-005-5613-8; Kim MS, 2004, J PATHOL, V202, P103, DOI 10.1002/path.1497; Kontaridis MI, 2002, MOL CELL BIOL, V22, P3875, DOI 10.1128/MCB.22.11.3875-3891.2002; Lee JH, 1999, ONCOGENE, V18, P6183, DOI 10.1038/sj.onc.1203043; Lee MY, 2002, EXP MOL MED, V34, P167, DOI 10.1038/emm.2002.24; Lee MY, 2002, EXP NEUROL, V175, P338, DOI 10.1006/exnr.2002.7903; Liao Q, 2001, FEBS LETT, V503, P151, DOI 10.1016/S0014-5793(01)02728-4; Liman J, 2005, MOL CELL BIOL, V25, P3715, DOI 10.1128/MCB.25.9.3715-3725.2005; Lowe B, 2003, ANAL BIOCHEM, V315, P95, DOI 10.1016/S0003-2697(02)00695-4; Midgley VC, 2004, J BIOL CHEM, V279, P40289, DOI 10.1074/jbc.M406063200; O'Donovan KJ, 1999, TRENDS NEUROSCI, V22, P167, DOI 10.1016/S0166-2236(98)01343-5; Pagliuca MG, 2003, FEBS LETT, V541, P11, DOI 10.1016/S0014-5793(03)00274-6; Romano MF, 2003, CANCER BIOL THER, V2, P508, DOI 10.4161/cbt.2.5.524; Romano MF, 2003, CELL DEATH DIFFER, V10, P383, DOI 10.1038/sj.cdd.4401167; Rosati A, 2007, INT J BIOCHEM CELL B, V39, P1337, DOI 10.1016/j.biocel.2007.03.007; Rosati A, 2007, J CELL PHYSIOL, V210, P676, DOI 10.1002/jcp.20865; Rossler OG, 2004, AM J PHYSIOL-CELL PH, V286, pC1118, DOI 10.1152/ajpcell.00301.2003; Russo VC, 2004, J CELL PHYSIOL, V199, P371, DOI 10.1002/jcp.10416; SCHWARTZ SM, 1993, J CARDIOVASC PHARM, V21, pS31, DOI 10.1097/00005344-199321001-00007; Smits VAJ, 2000, J BIOL CHEM, V275, P19375, DOI 10.1074/jbc.M001764200; Song JW, 2001, NAT CELL BIOL, V3, P276, DOI 10.1038/35060068; Takayama S, 1999, J BIOL CHEM, V274, P781, DOI 10.1074/jbc.274.2.781; TEMPLE S, 1995, NEURON, V15, P249, DOI 10.1016/0896-6273(95)90030-6; Thiel G, 2002, J CELL PHYSIOL, V193, P287, DOI 10.1002/jcp.10178; Vogel S, 2006, J CELL PHYSIOL, V206, P25, DOI 10.1002/jcp.20437; Zapata JM, 1998, J BIOL CHEM, V273, P6916, DOI 10.1074/jbc.273.12.6916	41	40	42	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 28	2008	27	37					5011	5018		10.1038/onc.2008.142	http://dx.doi.org/10.1038/onc.2008.142			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	344GL	18469860				2022-12-28	WOS:000258914800004
J	Zhu, Q; Youn, H; Tang, J; Tawfit, O; Dennis, K; Terranova, PF; Du, J; Raynal, P; Thrasher, JB; Li, B				Zhu, Q.; Youn, H.; Tang, J.; Tawfit, O.; Dennis, K.; Terranova, P. F.; Du, J.; Raynal, P.; Thrasher, J. B.; Li, B.			Phosphoinositide 3-OH kinase p85 alpha and p110 beta are essential for androgen receptor transactivation and tumor progression in prostate cancers	ONCOGENE			English	Article						prostate cancer; PI3K; androgen receptor; siRNA; tumor progression; mouse xenograft	PROTEIN-COUPLED RECEPTORS; GENE-EXPRESSION; PHOSPHATIDYLINOSITOL 3-KINASES; BETA-GAMMA; ACTIVATION; CELLS; TRANSCRIPTION; PATHWAY; P110-ALPHA; SUBUNITS	Phosphoinositide 3-OH kinases (PI3Ks) are a group of major intracellular signaling molecules. In our previous study, we found that inhibition of PI3K activity suppressed the androgen receptor (AR)-mediated gene expression in prostate cancer cells. The AR has been considered as a critical determinant for the development and progression of human prostate cancers. In this study, we sought to identify the PI3K isoforms involved in AR transactivation. Using a gene-specific small interference RNA (siRNA) approach, we determined that the regulatory isoform p85 alpha and the catalytic isoform p110 beta, but not p110 alpha, were required for androgen-stimulated AR transactivation and cell proliferation in prostate cancer cells. Consistently, overexpression of wild-type p110b but not p110 alpha gene led to androgen-independent AR transactivation. Silencing p110 beta gene in prostate cancer cells abolished tumor growth in nude mice. Of the dual (lipid and protein) kinase activities, p110 beta's lipid kinase activity was required for AR transactivation. Further analysis by a chromatin immunoprecipitation assay showed that p110 beta is indispensable for androgen-induced AR-DNA interaction. Finally, gene expression analysis of clinical specimens showed that both p85 alpha and p110 beta were highly expressed in malignant prostate tissues compared to the nonmalignant compartments, and their expression levels correlated significantly with disease progression. Taken together, our data demonstrated that p85 alpha and p110 beta are essential for androgen-stimulated AR transactivation, and their aberrant expression or activation might play an important role in prostate cancer progression.	[Zhu, Q.; Youn, H.; Tang, J.; Thrasher, J. B.; Li, B.] Univ Kansas, Med Ctr, Dept Urol, Kansas City, KS 66160 USA; [Zhu, Q.; Li, B.] Xian Jiaotong Univ, Affiliated Hosp 1, Dept Med Oncol, Xian 710049, Peoples R China; [Tawfit, O.; Dennis, K.; Li, B.] Univ Kansas, Med Ctr, Dept Pathol, Kansas City, KS 66160 USA; [Tawfit, O.; Dennis, K.; Li, B.] Univ Kansas, Med Ctr, Lab Med, Kansas City, KS 66160 USA; [Terranova, P. F.; Li, B.] Univ Kansas, Med Ctr, Deptt Mol & Integrated Physiol, Kansas City, KS 66160 USA; [Du, J.] Baylor Coll Med, Dept Med, Houston, TX 77030 USA; [Raynal, P.] Hop Purpan, INSERM, U563, Bat C, Toulouse, France	University of Kansas; University of Kansas Medical Center; Xi'an Jiaotong University; University of Kansas; University of Kansas Medical Center; University of Kansas; University of Kansas Medical Center; University of Kansas; University of Kansas Medical Center; Baylor College of Medicine; CHU de Toulouse; Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm)	Li, B (corresponding author), Univ Kansas, Med Ctr, Dept Urol, 3901 Rainbow Blvd,Lied 2045, Kansas City, KS 66160 USA.	bli@kumc.edu	Raynal, Patrick/O-1926-2018	Youn, Hyewon/0000-0003-1006-2689; Raynal, Patrick/0000-0002-6731-3007	NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR015563] Funding Source: NIH RePORTER; NCRR NIH HHS [P20 RR015563, P20 RR015563-096219, 1P20RR15563] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		Bader AG, 2005, NAT REV CANCER, V5, P921, DOI 10.1038/nrc1753; Chini B, 2004, J MOL ENDOCRINOL, V32, P325, DOI 10.1677/jme.0.0320325; Cinar B, 2007, J BIOL CHEM, V282, P29584, DOI 10.1074/jbc.M703310200; Czauderna F, 2003, NUCLEIC ACIDS RES, V31, DOI 10.1093/nar/gng127; Engelman JA, 2006, NAT REV GENET, V7, P606, DOI 10.1038/nrg1879; Hayakawa M, 2006, BIOORGAN MED CHEM, V14, P6847, DOI 10.1016/j.bmc.2006.06.046; Heinlein CA, 2004, ENDOCR REV, V25, P276, DOI 10.1210/er.2002-0032; Holzbeierlein J, 2004, AM J PATHOL, V164, P217, DOI 10.1016/S0002-9440(10)63112-4; Jackson SP, 2005, NAT MED, V11, P507, DOI 10.1038/nm1232; Kasbohm EA, 2005, J BIOL CHEM, V280, P11583, DOI 10.1074/jbc.M414423200; Latil A, 2001, CANCER RES, V61, P1919; Lee SO, 2003, ONCOGENE, V22, P7981, DOI 10.1038/sj.onc.1206735; Li BY, 2007, ASIAN J ANDROL, V9, P41, DOI 10.1111/J.1745-7262.2007.00226.x; Li BY, 2007, CARCINOGENESIS, V28, P572, DOI 10.1093/carcin/bgl193; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; Li PF, 2001, J BIOL CHEM, V276, P20444, DOI 10.1074/jbc.M010226200; Liao XB, 2004, ENDOCRINOLOGY, V145, P2941, DOI 10.1210/en.2003-1519; Liao XB, 2005, MOL CANCER THER, V4, P505, DOI 10.1158/1535-7163.MCT-04-0313; Lu ML, 2001, J BIOL CHEM, V276, P13442, DOI 10.1074/jbc.M006598200; Majumder PK, 2005, ONCOGENE, V24, P7465, DOI 10.1038/sj.onc.1209096; Mellinghoff IK, 2004, CANCER CELL, V6, P517, DOI 10.1016/j.ccr.2004.09.031; Murga C, 1998, J BIOL CHEM, V273, P19080, DOI 10.1074/jbc.273.30.19080; Murillo H, 2001, ENDOCRINOLOGY, V142, P4795, DOI 10.1210/en.142.11.4795; Scher HI, 2005, J CLIN ONCOL, V23, P8253, DOI 10.1200/JCO.2005.03.4777; Shang YF, 2002, MOL CELL, V9, P601, DOI 10.1016/S1097-2765(02)00471-9; Shanmugam I, 2007, CELL DEATH DIFFER, V14, P2085, DOI 10.1038/sj.cdd.4402227; Sharma M, 2002, J BIOL CHEM, V277, P30935, DOI 10.1074/jbc.M201919200; Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356; Sun AJ, 2007, PROSTATE, V67, P976, DOI 10.1002/pros.20586; Sun A, 2007, PROSTATE, V67, P203, DOI 10.1002/pros.20521; Sun M, 2003, J BIOL CHEM, V278, P42992, DOI 10.1074/jbc.M306295200; Yart A, 2002, J BIOL CHEM, V277, P21167, DOI 10.1074/jbc.M110411200; Zhao JJ, 2005, P NATL ACAD SCI USA, V102, P18443, DOI 10.1073/pnas.0508988102	33	68	73	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 31	2008	27	33					4569	4579		10.1038/onc.2008.91	http://dx.doi.org/10.1038/onc.2008.91			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	332IS	18372911	Green Accepted			2022-12-28	WOS:000258077300006
J	Lin, J; Arlinghaus, R				Lin, J.; Arlinghaus, R.			Activated c-Abl tyrosine kinase in malignant solid tumors	ONCOGENE			English	Review						c-Abl; FUS1; NSCLC; lung cancer; imatinib; breast cancer	EPIDERMAL-GROWTH-FACTOR; BREAST-CANCER CELLS; HOMOZYGOUS DELETION REGION; SRC-FAMILY KINASES; LUNG-CANCER; ONCOGENIC ACTIVATION; GENE-PRODUCT; FUS1 PROTEIN; IN-VITRO; EXPRESSION	Mutant forms of the c-ABL gene are well known to be involved in hematopoietic malignancies such as chronic myeloid leukemia (CML). CML patients possess a fused BCR-ABL gene that activates the Abl tyrosine kinase domain within Bcr-Abl. In general fusion proteins that cause oligomerization of Abl lead to activation of its tyrosine kinase activity. In this review, we highlight recent discoveries indicating that the activated c-Abl tyrosine kinase, not as a fusion protein, plays an important role in malignant solid tumors of lung and breast.	[Lin, J.; Arlinghaus, R.] Univ Texas Houston, MD Anderson Canc Ctr, Dept Mol Pathol, Houston, TX 77054 USA	University of Texas System; University of Texas Health Science Center Houston; UTMD Anderson Cancer Center	Arlinghaus, R (corresponding author), Univ Texas Houston, MD Anderson Canc Ctr, Dept Mol Pathol, 1515 Holcomb Blvd, Houston, TX 77054 USA.	rarlingh@mdanderson.org						Buchdunger E, 1996, CANCER RES, V56, P100; Bunn PA, 2002, SEMIN ONCOL, V29, P38, DOI 10.1053/sonc.2002.35646; Dowell JE, 2005, NEW ENGL J MED, V352, P830, DOI 10.1056/NEJMe058033; Girard L, 2000, CANCER RES, V60, P4894; Hantschel O, 2003, CELL, V112, P845, DOI 10.1016/S0092-8674(03)00191-0; Ito T, 2004, OPT REV, V11, P7, DOI 10.1007/s10043-004-0007-5; Ji L, 2002, CANCER RES, V62, P2715; Kondo M, 2001, ONCOGENE, V20, P6258, DOI 10.1038/sj.onc.1204832; LEROITH D, 1995, ENDOCR REV, V16, P143, DOI 10.1210/er.16.2.143; Lin J, 2007, ONCOGENE, V26, P6989, DOI 10.1038/sj.onc.1210500; LIN J, 2005, 96 ANN AM ASS CANC R; Ling XY, 2003, CANCER RES, V63, P298; Liu JX, 1996, CANCER RES, V56, P5120; Ma ZY, 2007, CELL MOL BIOL LETT, V12, P556, DOI 10.2478/s11658-007-0022-1; Miller CT, 2003, ONCOGENE, V22, P7950, DOI 10.1038/sj.onc.1206529; Negri T, 2007, BRIT J CANCER, V96, P180, DOI 10.1038/sj.bjc.6603542; OSHEROV N, 1994, EUR J BIOCHEM, V225, P1047, DOI 10.1111/j.1432-1033.1994.1047b.x; Pendergast AM, 2002, ADV CANCER RES, V85, P51, DOI 10.1016/S0065-230X(02)85003-5; Plattner R, 1999, GENE DEV, V13, P2400, DOI 10.1101/gad.13.18.2400; Plattner R, 2003, CELL CYCLE, V2, P273, DOI 10.4161/cc.2.4.409; Pluk H, 2002, CELL, V108, P247, DOI 10.1016/S0092-8674(02)00623-2; Prudkin L, 2008, CLIN CANCER RES, V14, P41, DOI 10.1158/1078-0432.CCR-07-1252; Ross JS, 1998, STEM CELLS, V16, P413, DOI 10.1002/stem.160413; Sirvent A, 2007, ONCOGENE, V26, P7313, DOI 10.1038/sj.onc.1210543; Srinivasan D, 2008, ONCOGENE, V27, P1095, DOI 10.1038/sj.onc.1210714; Srinivasan D, 2006, CANCER RES, V66, P5648, DOI 10.1158/0008-5472.CAN-06-0734; Taagepera S, 1998, P NATL ACAD SCI USA, V95, P7457, DOI 10.1073/pnas.95.13.7457; Tanos B, 2006, J BIOL CHEM, V281, P32714, DOI 10.1074/jbc.M603126200; Uno F, 2004, CANCER RES, V64, P2969, DOI 10.1158/0008-5472.CAN-03-3702; *US CANC STAT WORK, 2004, US CANC STAT 2001 IN; Vlahovic G, 2006, BRIT J CANCER, V95, P1013, DOI 10.1038/sj.bjc.6603366; Wang JYJ, 2000, ONCOGENE, V19, P5643, DOI 10.1038/sj.onc.1203878; Wen ST, 1997, GENE DEV, V11, P2456, DOI 10.1101/gad.11.19.2456; Woodring PJ, 2003, J CELL SCI, V116, P2613, DOI 10.1242/jcs.00622; Zabarovsky ER, 2002, ONCOGENE, V21, P6915, DOI 10.1038/sj.onc.1205835; Zhang Peilin, 2003, Mol Cancer, V2, P1	36	55	56	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 24	2008	27	32					4385	4391		10.1038/onc.2008.86	http://dx.doi.org/10.1038/onc.2008.86			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	329PU	18391983				2022-12-28	WOS:000257881700001
J	Dong, LF; Low, P; Dyason, JC; Wang, XF; Prochazka, L; Witting, PK; Freeman, R; Swettenham, E; Valis, K; Liu, J; Zobalova, R; Turanek, J; Spitz, DR; Domann, FE; Scheffler, IE; Ralph, SJ; Neuzil, J				Dong, L-F; Low, P.; Dyason, J. C.; Wang, X-F; Prochazka, L.; Witting, P. K.; Freeman, R.; Swettenham, E.; Valis, K.; Liu, J.; Zobalova, R.; Turanek, J.; Spitz, D. R.; Domann, F. E.; Scheffler, I. E.; Ralph, S. J.; Neuzil, J.			alpha-tocopheryl succinate induces apoptosis by targeting ubiquinone-binding sites in mitochondrial respiratory complex II	ONCOGENE			English	Article						alpha-tocopheryl succinate; complex II; ubiquinonebinding sites; reactive oxygen species; apoptosis; anti-cancer drug target	VITAMIN-E SUCCINATE; BREAST-CANCER CELLS; ELECTRON-TRANSPORT; E ANALOGS; 3-NITROPROPIONIC ACID; OXIDATIVE STRESS; LIVER-CANCER; OXYGEN; DEHYDROGENASE; ANTIOXIDANT	alpha-Tocopheryl succinate (alpha-TOS)is a selective inducer of apoptosis in cancer cells, which involves the accumulation of reactive oxygen species (ROS). The molecular target of alpha-TOS has not been identified. Here, we show that alpha-TOS inhibits succinate dehydrogenase (SDH) activity of complex II (CII) by interacting with the proximal and distal ubiquinone (UbQ)-binding site (Q(P) and Q(D), respectively). This is based on biochemical analyses and molecular modelling, revealing similar or stronger interaction energy of a- TOS compared to that of UbQ for the QP and QD sites, respectively. CybL-mutant cells with dysfunctional CII failed to accumulate ROS and underwent apoptosis in the presence of alpha-TOS. Similar resistance was observed when CybL was knocked down with siRNA. Reconstitution of functional CII rendered CybL-mutant cells susceptible to alpha-TOS. We propose that alpha-TOS displaces UbQ in CII causing electrons generated by SDH to recombine with molecular oxygen to yield ROS. Our data highlight CII, a known tumour suppressor, as a novel target for cancer therapy.	[Low, P.; Ralph, S. J.] Griffith Univ, Sch Med Sci, Genom Res Ctr, Southport, Qld 4215, Australia; [Dong, L-F; Wang, X-F; Freeman, R.; Swettenham, E.; Liu, J.; Zobalova, R.; Neuzil, J.] Griffith Univ, Sch Med Sci, Apoptosis Res Grp, Southport, Qld 4215, Australia; [Dyason, J. C.] Griffith Univ, Inst Glycom, Southport, Qld 4215, Australia; [Prochazka, L.; Turanek, J.] Vet Res Inst, Dept Immunol, CS-62132 Brno, Czech Republic; [Witting, P. K.] Concord Hosp, Med Res Inst, ANZAC, Sydney, NSW, Australia; [Valis, K.; Zobalova, R.; Neuzil, J.] Acad Sci Czech Republ, Inst Biotechnol, Mol Therapy Grp, Prague, Czech Republic; [Spitz, D. R.; Domann, F. E.] Univ Iowa, Dept Radiat Oncol, Free Rad & Radiat Biol Program, Iowa City, IA USA; [Scheffler, I. E.] Univ Calif San Diego, Div Biol, San Diego, CA 92103 USA	Griffith University; Griffith University; Griffith University; Czech Veterinary Research Institute; Concord Repatriation General Hospital; Czech Academy of Sciences; Institute of Biotechnology of the Czech Academy of Sciences; University of Iowa; University of California System; University of California San Diego	Ralph, SJ (corresponding author), Griffith Univ, Sch Med Sci, Genom Res Ctr, Southport, Qld 4215, Australia.	s.ralph@grif.th.edu.au; j.neuzil@grif.th.edu.au	Prochazka, Lubomir/J-5284-2014; Dyason, Jeffrey C/L-5534-2014; Witting, Paul/ABD-2053-2020; Witting, Paul/L-9786-2019; DONG, LANFENG/S-8805-2019; Ralph, Stephen J./AAE-4888-2019; Vališ, Karel/D-6463-2017; Neuzil, Jiri/H-7204-2014; Zobalova, Renata/H-7242-2014	Witting, Paul/0000-0003-2237-7004; Ralph, Stephen J./0000-0002-4335-092X; Vališ, Karel/0000-0002-3036-4345; Neuzil, Jiri/0000-0002-2478-2460; Domann, Frederick/0000-0002-0489-2179; Zobalova, Renata/0000-0002-9097-4700; Dong, Lanfeng/0000-0002-9857-6352; Spitz, Douglas/0000-0002-1254-8765	NCI NIH HHS [R01 CA073612, R01 CA073612-08, R01 CA100045-04, R01 CA100045-05, R01 CA100045-03, R01 CA073612-07, R01-CA73612, R01 CA100045, R01-CA100045] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA100045, R01CA073612] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		*ACC INC, 2001, INS, V2; Adam-Vizi V, 2006, TRENDS PHARMACOL SCI, V27, P639, DOI 10.1016/j.tips.2006.10.005; Albayrak T, 2003, MOL BIOL CELL, V14, P3082, DOI 10.1091/mbc.e02-10-0631; Allen FH, 2002, ACTA CRYSTALLOGR B, V58, P380, DOI 10.1107/S0108768102003890; Allen RG, 2003, EXP CELL RES, V289, P307, DOI 10.1016/S0014-4827(03)00279-9; Alleva R, 2001, FEBS LETT, V503, P46, DOI 10.1016/S0014-5793(01)02694-1; BERRIDGE MV, 1993, ARCH BIOCHEM BIOPHYS, V303, P474, DOI 10.1006/abbi.1993.1311; Bonnet S, 2007, CANCER CELL, V11, P37, DOI 10.1016/j.ccr.2006.10.020; BURNELL JN, 1975, BIOCHEM J, V150, P527, DOI 10.1042/bj1500527; Case D.A., 2002, AMBER, V7; Cheng VWT, 2006, J BIOL CHEM, V281, P27662, DOI 10.1074/jbc.M604900200; CHOUDHRY ZM, 1985, FEBS LETT, V182, P171, DOI 10.1016/0014-5793(85)81177-7; CHOUDHRY ZM, 1986, BIOCHIM BIOPHYS ACTA, V850, P131, DOI 10.1016/0005-2728(86)90017-4; CHURCH SL, 1993, P NATL ACAD SCI USA, V90, P3113, DOI 10.1073/pnas.90.7.3113; Degterev A, 2001, NAT CELL BIOL, V3, P173, DOI 10.1038/35055085; Dias N, 2005, BIOCHEM PHARMACOL, V70, P1, DOI 10.1016/j.bcp.2005.03.021; Don AS, 2004, TRENDS MOL MED, V10, P372, DOI 10.1016/j.molmed.2004.06.005; Dong LF, 2007, CANCER RES, V67, P11906, DOI 10.1158/0008-5472.CAN-07-3034; Fariss MW, 2001, FREE RADICAL BIO MED, V31, P530, DOI 10.1016/S0891-5849(01)00615-3; Geschwind JFH, 2002, CANCER RES, V62, P3909; Gottlieb E, 2005, NAT REV CANCER, V5, P857, DOI 10.1038/nrc1737; GUY CT, 1992, P NATL ACAD SCI USA, V89, P10578, DOI 10.1073/pnas.89.22.10578; Hail N, 2005, APOPTOSIS, V10, P687, DOI 10.1007/s10495-005-0792-8; Hartshorn MJ, 2002, J COMPUT AID MOL DES, V16, P871, DOI 10.1023/A:1023813504011; Huang LS, 2006, J BIOL CHEM, V281, P5965, DOI 10.1074/jbc.M511270200; Ishii N, 1998, NATURE, V394, P694, DOI 10.1038/29331; Ishii T, 2005, CANCER RES, V65, P203; James AM, 2005, J BIOL CHEM, V280, P21295, DOI 10.1074/jbc.M501527200; James AM, 2007, J BIOL CHEM, V282, P14708, DOI 10.1074/jbc.M611463200; Kang YH, 2004, INT J CANCER, V112, P385, DOI 10.1002/ijc.20424; Kelso GF, 2001, J BIOL CHEM, V276, P4588, DOI 10.1074/jbc.M009093200; Ko YH, 2004, BIOCHEM BIOPH RES CO, V324, P269, DOI 10.1016/j.bbrc.2004.09.047; Ko YH, 2001, CANCER LETT, V173, P83, DOI 10.1016/S0304-3835(01)00667-X; Kogure K, 2002, CANCER LETT, V186, P151, DOI 10.1016/S0304-3835(02)00344-0; Lahouel M, 2007, BIOCHEM BIOPH RES CO, V355, P252, DOI 10.1016/j.bbrc.2007.01.145; Le SB, 2007, J BIOL CHEM, V282, P8860, DOI 10.1074/jbc.M611777200; MAEHARA Y, 1988, ONCOLOGY-BASEL, V45, P434, DOI 10.1159/000226660; McLennan HR, 2000, J BIOENERG BIOMEMBR, V32, P153, DOI 10.1023/A:1005507913372; Milanesi E, 2006, J BIOL CHEM, V281, P10066, DOI 10.1074/jbc.M513708200; Morris GM, 1998, J COMPUT CHEM, V19, P1639, DOI 10.1002/(SICI)1096-987X(19981115)19:14<1639::AID-JCC10>3.0.CO;2-B; Neuzil J, 2005, BIOCHEM BIOPH RES CO, V327, P1024, DOI 10.1016/j.bbrc.2004.12.115; Neuzil J, 2001, FASEB J, V15, P403, DOI 10.1096/fj.00-0251com; Neuzil J, 2001, BRIT J CANCER, V84, P87, DOI 10.1054/bjoc.2000.1559; Neuzil J, 2007, J BIOENERG BIOMEMBR, V39, P65, DOI 10.1007/s10863-006-9060-z; Neuzil J, 2007, MOL PHARMACOL, V71, P1185, DOI 10.1124/mol.106.030122; Neuzil J, 2006, FEBS LETT, V580, P5125, DOI 10.1016/j.febslet.2006.05.072; Newmeyer DD, 2003, CELL, V112, P481, DOI 10.1016/S0092-8674(03)00116-8; Niemann S, 2000, NAT GENET, V26, P268, DOI 10.1038/81551; OOSTVEEN FG, 1995, J BIOL CHEM, V270, P26104, DOI 10.1074/jbc.270.44.26104; Rice J.E., 1997, SUBCELLULAR FRACTION, V1st, P107; Robinson BWS, 2005, LANCET, V366, P397, DOI 10.1016/S0140-6736(05)67025-0; SAFFORD SE, 1994, CANCER RES, V54, P4261; SANBORN BM, 1971, BIOCHIM BIOPHYS ACTA, V227, P219, DOI 10.1016/0005-2744(71)90055-6; Sanner MF, 1999, J MOL GRAPH MODEL, V17, P57; Scallet AC, 2003, ANN NY ACAD SCI, V993, P305, DOI 10.1111/j.1749-6632.2003.tb07538.x; Seo BB, 1998, P NATL ACAD SCI USA, V95, P9167, DOI 10.1073/pnas.95.16.9167; Sever N, 2004, J BIOL CHEM, V279, P43136, DOI 10.1074/jbc.M406406200; Shiau CW, 2006, J BIOL CHEM, V281, P11819, DOI 10.1074/jbc.M511015200; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; Slane BG, 2006, CANCER RES, V66, P7615, DOI 10.1158/0008-5472.CAN-06-0833; Soller M, 2007, MOL PHARMACOL, V71, P1535, DOI 10.1124/mol.107.034371; SPENCER TL, 1976, BIOCHEM J, V160, P121, DOI 10.1042/bj1600121; Stapelberg M, 2005, J BIOL CHEM, V280, P25369, DOI 10.1074/jbc.M414498200; Sun F, 2005, CELL, V121, P1043, DOI 10.1016/j.cell.2005.05.025; Swettenham E, 2005, J NEUROCHEM, V94, P1448, DOI 10.1111/j.1471-4159.2005.03298.x; Trachootham D, 2006, CANCER CELL, V10, P241, DOI 10.1016/j.ccr.2006.08.009; Tran QM, 2006, J BIOL CHEM, V281, P32310, DOI 10.1074/jbc.M607476200; Trounce I A, 1996, Methods Enzymol, V264, P484, DOI 10.1016/S0076-6879(96)64044-0; WALLACE AC, 1995, PROTEIN ENG, V8, P127, DOI 10.1093/protein/8.2.127; Wang XF, 2005, BIOCHEM BIOPH RES CO, V326, P282, DOI 10.1016/j.bbrc.2004.11.028; Wang XF, 2007, CANCER RES, V67, P3337, DOI 10.1158/0008-5472.CAN-06-2480; Weber T, 2003, BIOCHEMISTRY-US, V42, P4277, DOI 10.1021/bi020527j; Weber T, 2002, CLIN CANCER RES, V8, P863; Word JM, 1999, J MOL BIOL, V285, P1735, DOI 10.1006/jmbi.1998.2401; Xu RH, 2005, CANCER RES, V65, P613; Yankovskaya V, 2003, SCIENCE, V299, P700, DOI 10.1126/science.1079605; YU L, 1983, BIOCHIM BIOPHYS ACTA, V723, P139, DOI 10.1016/0005-2728(83)90113-5; Zhang JG, 2001, ARCH BIOCHEM BIOPHYS, V393, P87, DOI 10.1006/abbi.2001.2486; Zhao ZW, 2006, BIOCHEM CELL BIOL, V84, P1013, DOI 10.1139/O06-188	79	225	235	2	38	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 17	2008	27	31					4324	4335		10.1038/onc.2008.69	http://dx.doi.org/10.1038/onc.2008.69			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	326WY	18372923	Green Published, Green Accepted			2022-12-28	WOS:000257691100007
J	Samanta, M; Iwakiri, D; Takada, K				Samanta, M.; Iwakiri, D.; Takada, K.			Epstein-Barr virus-encoded small RNA induces IL-10 through RIG-I-mediated IRF-3 signaling	ONCOGENE			English	Article						EBV; Burkitt's lymphoma; EBER; RIG-I; IRF-3; IL-10	LYMPHOMA CELL-LINE; BURKITTS-LYMPHOMA; GROWTH TRANSFORMATION; (EBV)-ENCODED RNA; T-CELLS; EBV; PROTEIN; TRANSCRIPTION; EXPRESSION; INDUCTION	Epstein-Barr virus-encoded small RNA (EBER) is nonpolyadenylated, noncoding RNA, forms stem-loop structure by intermolecular base-pairing giving rise to double-stranded RNA (dsRNA)-like molecule and exists abundantly in EBV-infected cells. EBER induces IL-10 and thus supports the growth of Burkitt's lymphoma (BL) cells. In this study, the mechanism of IL-10 induction by EBER was analysed in the context of dsRNA signaling pathway. Knockdown of retinoic acid-inducible gene I (RIG-I) by small interfering RNA (siRNA), and expression of dominant-negative RIG-I downregulated IL-10 induction in EBER(+) EBV-infected and EBER plasmid-transfected BL cells. Transfection of EBER-expressing plasmid or in vitro synthesized EBER induced IL-10 in RIG-I-expressing cell clones, and activation of IL-10 promoter by EBER was blocked by dominant-negative RIG-I. Blocking of nuclear factor (NF)-kappa B by dominant-negative I kappa B-alpha plasmid did not block IL-10 expression, whereas knockdown of IRF-3 by siRNA resulted in downregulation of IL-10 in EBER(+) BL cells. NF-kappa B is reported to function downstream of RIG-I signaling pathway and is involved in the induction of proinflammatory cytokines. Our results indicate that EBER induces an anti-inflammatory cytokine IL-10 through RIG-I-mediated IRF-3 but not NF-kappa B signaling. These findings suggest a new mechanism of dsRNA signaling pathway that triggers the expression of IL-10, which acts as an autocrine growth factor in BL cells.	[Samanta, M.; Iwakiri, D.; Takada, K.] Hokkaido Univ, Dept Tumor Virol, Inst Med Genet, Kita Ku, Sapporo, Hokkaido 0600815, Japan	Hokkaido University	Takada, K (corresponding author), Hokkaido Univ, Dept Tumor Virol, Inst Med Genet, Kita Ku, Sapporo, Hokkaido 0600815, Japan.	kentaka@igm.hokudai.ac.jp	Takada, Kenzo/A-6666-2012					AB RICKINSON, 2001, FIELDS VIROLOGY, P2575; ARRAND JR, 1989, J VIROL, V63, P983, DOI 10.1128/JVI.63.2.983-986.1989; CLARKE PA, 1991, NUCLEIC ACIDS RES, V19, P243, DOI 10.1093/nar/19.2.243; GLICKMAN JN, 1988, J VIROL, V62, P902, DOI 10.1128/JVI.62.3.902-911.1988; GREGORY CD, 1990, J GEN VIROL, V71, P1481, DOI 10.1099/0022-1317-71-7-1481; HEITBROCK LZ, 2003, J IMMUNOL, V171, P285; Imaizumi T, 2004, LIFE SCI, V75, P1171, DOI 10.1016/j.lfs.2004.01.030; Iwakiri D, 2005, ONCOGENE, V24, P1767, DOI 10.1038/sj.onc.1208357; Iwakiri D, 2003, CANCER RES, V63, P7062; Kato H, 2005, IMMUNITY, V23, P19, DOI 10.1016/j.immuni.2005.04.010; KIEFF E, 2001, FIELDS VIROLOGY, P2511; Kitagawa N, 2000, EMBO J, V19, P6742, DOI 10.1093/emboj/19.24.6742; KLEIN E, 1968, CANCER RES, V28, P1300; Komano J, 1999, J VIROL, V73, P9827, DOI 10.1128/JVI.73.12.9827-9831.1999; LERNER MR, 1981, P NATL ACAD SCI-BIOL, V78, P805, DOI 10.1073/pnas.78.2.805; Lin RT, 1999, MOL CELL BIOL, V19, P959; MALEFYT RD, 1991, J EXP MED, V174, P915; MALEFYT RD, 1993, J IMMUNOL, V150, P4754; MITCHELL T, 1995, J VIROL, V69, P2968, DOI 10.1128/JVI.69.5.2968-2976.1995; NAKAGOMI H, 1994, INT J CANCER, V57, P240, DOI 10.1002/ijc.2910570218; Nanbo A, 2002, EMBO J, V21, P954, DOI 10.1093/emboj/21.5.954; ROSA MD, 1981, MOL CELL BIOL, V1, P785, DOI 10.1128/MCB.1.9.785; Ruf IK, 2000, J VIROL, V74, P10223, DOI 10.1128/JVI.74.21.10223-10228.2000; Samanta M, 2006, EMBO J, V25, P4207, DOI 10.1038/sj.emboj.7601314; SHARP TV, 1993, NUCLEIC ACIDS RES, V21, P4483, DOI 10.1093/nar/21.19.4483; SHIMIZU N, 1994, J VIROL, V68, P6069, DOI 10.1128/JVI.68.9.6069-6073.1994; TAKADA K, 1991, VIRUS GENES, V5, P147, DOI 10.1007/BF00571929; TOCZYSKI DP, 1994, P NATL ACAD SCI USA, V91, P3463, DOI 10.1073/pnas.91.8.3463; TOCZYSKI DPW, 1991, EMBO J, V10, P459, DOI 10.1002/j.1460-2075.1991.tb07968.x; Tone M, 2000, J IMMUNOL, V165, P286, DOI 10.4049/jimmunol.165.1.286; Wagoner J, 2007, J VIROL, V81, P309, DOI 10.1128/JVI.01411-06; Wu Y, 2007, J VIROL, V81, P11236, DOI 10.1128/JVI.00579-07; Yajima M, 2005, J VIROL, V79, P4298, DOI 10.1128/JVI.79.7.4298-4307.2005; Yamamoto N, 2000, FEBS LETT, V484, P153, DOI 10.1016/S0014-5793(00)02145-1; Yang LX, 2004, CANCER RES, V64, P5332, DOI 10.1158/0008-5472.CAN-04-0733; Yoneyama M, 2004, NAT IMMUNOL, V5, P730, DOI 10.1038/ni1087	36	117	125	1	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2008	27	30					4150	4160		10.1038/onc.2008.75	http://dx.doi.org/10.1038/onc.2008.75			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	324DB	18362887				2022-12-28	WOS:000257496800002
J	Ren, L; Hong, SH; Cassavaugh, J; Osborne, T; Chou, AJ; Kim, SY; Gorlick, R; Hewitt, SM; Khanna, C				Ren, L.; Hong, S. H.; Cassavaugh, J.; Osborne, T.; Chou, A. J.; Kim, S. Y.; Gorlick, R.; Hewitt, S. M.; Khanna, C.			The actin-cytoskeleton linker protein ezrin is regulated during osteosarcoma metastasis by PKC	ONCOGENE			English	Article						ezrin; ERM; PKC; tumor metastasis	EZRIN/RADIXIN/MOESIN ERM PROTEINS; KINASE-C; PLASMA-MEMBRANE; EPITHELIAL-CELLS; CARCINOMA-CELLS; T-LYMPHOCYTES; CRUCIAL ROLE; PHOSPHORYLATION; EXPRESSION; MOESIN	Ezrin is a member of the ERM (ezrin, radixin, moesin) protein family and links F-actin to the cell membrane following phosphorylation. Ezrin has been associated with tumor progression and metastasis in several cancers including the pediatric solid tumors, osteosarcoma and rhabdomyosarcoma. In this study, we were surprised to find that ezrin was not constitutively phosphorylated but rather was dynamically regulated during metastatic progression in osteosarcoma. Metastatic osteosarcoma cells expressed phosphorylated ERM early after their arrival in the lung, and then late in progression, only at the invasive front of larger metastatic lesions. To pursue mechanisms for this regulation, we found that inhibitors of PKC (protein kinase C) blocked phosphorylation of ezrin, and that ezrin coimmunoprecipitated in cells with PKC alpha, PKC iota and PKC gamma. Furthermore, phosphorylated forms of ezrin and PKC had identical expression patterns at the invasive front of pulmonary metastatic lesions in murine and human patient samples. Finally, we showed that the promigratory effects of PKC were linked to ezrin phosphorylation. These data are the first to suggest a dynamic regulation of ezrin phosphorylation during metastasis and to connect the PKC family members with this regulation.	[Khanna, C.] NCI, Tumor & Metastasis Biol Sect, Pediat Oncol Branch, Ctr Canc Res, Bethesda, MD 20892 USA; [Chou, A. J.] Mem Sloan Kettering Canc Ctr, Dept Pediat, New York, NY 10021 USA; [Gorlick, R.] Childrens Hosp Montefiore, Albert Einstein Coll Med, Dept Pediat, Bronx, NY USA; [Hewitt, S. M.] NCI, Tissue Array Res Program, Pathol Lab, Ctr Canc Res, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Memorial Sloan Kettering Cancer Center; Yeshiva University; Albert Einstein College of Medicine; Childrens Hospital at Montefiore; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Khanna, C (corresponding author), NCI, Tumor & Metastasis Biol Sect, Pediat Oncol Branch, Ctr Canc Res, 37 Convent Dr,Rm 2144, Bethesda, MD 20892 USA.	khannac@mail.nih.gov		Hewitt, Stephen/0000-0001-8283-1788; GORLICK, RICHARD/0000-0001-8995-2929; Chou, Alexander/0000-0002-7926-3326	Intramural NIH HHS [Z01 BC010566] Funding Source: Medline; NATIONAL CANCER INSTITUTE [ZIGBC010931, Z01BC010931, Z01BC010566, ZIABC011024, Z01BC011024, ZIABC010566] Funding Source: NIH RePORTER	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BERRYMAN M, 1993, J CELL SCI, V105, P1025; BLOBE GC, 1994, CANCER METAST REV, V13, P411, DOI 10.1007/BF00666107; Bornancin F, 1997, J BIOL CHEM, V272, P3544, DOI 10.1074/jbc.272.6.3544; Bretscher A, 2002, NAT REV MOL CELL BIO, V3, P586, DOI 10.1038/nrm882; Bretscher A, 2000, ANNU REV CELL DEV BI, V16, P113, DOI 10.1146/annurev.cellbio.16.1.113; Bretscher A, 1997, J CELL SCI, V110, P3011; Brown MJ, 2003, BLOOD, V102, P3890, DOI 10.1182/blood-2002-12-3807; Bruce B, 2007, CLIN EXP METASTAS, V24, P69, DOI 10.1007/s10585-006-9050-x; Cant SH, 2005, MOL BIOL CELL, V16, P3088, DOI 10.1091/mbc.E04-10-0877; Chuan YC, 2006, J BIOL CHEM, V281, P29938, DOI 10.1074/jbc.M602237200; Dard N, 2004, DEV BIOL, V271, P87, DOI 10.1016/j.ydbio.2004.03.024; Elliott BE, 2005, BREAST CANCER RES, V7, pR365, DOI 10.1186/bcr1006; Fievet BT, 2004, J CELL BIOL, V164, P653, DOI 10.1083/jcb.200307032; Forte E, 2008, BBA-MOL CELL RES, V1783, P334, DOI 10.1016/j.bbamcr.2007.11.004; Gautreau A, 2000, J CELL BIOL, V150, P193, DOI 10.1083/jcb.150.1.193; HERBERT JM, 1993, BIOCHEM PHARMACOL, V45, P527, DOI 10.1016/0006-2952(93)90123-E; Hishiya A, 1999, J BIOL CHEM, V274, P26705, DOI 10.1074/jbc.274.38.26705; Ilmonen S, 2005, MODERN PATHOL, V18, P503, DOI 10.1038/modpathol.3800300; Khanna C, 2000, CLIN EXP METASTAS, V18, P261, DOI 10.1023/A:1006767007547; Khanna C, 2004, NAT MED, V10, P182, DOI 10.1038/nm982; Khanna C, 2001, CANCER RES, V61, P3750; Kivela T, 2000, CELL TISSUE RES, V301, P217, DOI 10.1007/s004410000225; Kobel M, 2006, INT J GYNECOL PATHOL, V25, P121, DOI 10.1097/01.pgp.0000185410.39050.ac; Koivunen J, 2004, CANCER RES, V64, P5693, DOI 10.1158/0008-5472.CAN-03-3511; KRIEG J, 1992, J BIOL CHEM, V267, P19258; Krishnan K, 2006, CLIN EXP METASTAS, V23, P227, DOI 10.1007/s10585-006-9033-y; Makitie T, 2001, INVEST OPHTH VIS SCI, V42, P2442; Matsui T, 1999, CURR BIOL, V9, P1259, DOI 10.1016/S0960-9822(99)80508-9; Matsui T, 1998, J CELL BIOL, V140, P647, DOI 10.1083/jcb.140.3.647; Musashi M, 2000, INT J HEMATOL, V72, P12; Nakamura N, 2000, GENES CELLS, V5, P571, DOI 10.1046/j.1365-2443.2000.00348.x; Ng T, 2001, EMBO J, V20, P2723, DOI 10.1093/emboj/20.11.2723; Ohtani K, 1999, CANCER LETT, V147, P31, DOI 10.1016/S0304-3835(99)00272-4; Oshiro N, 1998, J BIOL CHEM, V273, P34663, DOI 10.1074/jbc.273.52.34663; Pang ST, 2004, UROLOGY, V63, P609, DOI 10.1016/j.urology.2003.09.068; Pearson MA, 2000, CELL, V101, P259, DOI 10.1016/S0092-8674(00)80836-3; Pietromonaco SF, 1998, J BIOL CHEM, V273, P7594, DOI 10.1074/jbc.273.13.7594; Polesello C, 2004, TRENDS CELL BIOL, V14, P294, DOI 10.1016/j.tcb.2004.04.003; Reczek D, 1997, J CELL BIOL, V139, P169, DOI 10.1083/jcb.139.1.169; Saotome I, 2004, DEV CELL, V6, P855, DOI 10.1016/j.devcel.2004.05.007; Serrador JM, 1999, TRENDS CELL BIOL, V9, P228, DOI 10.1016/S0962-8924(99)01553-6; Simons PC, 1998, BIOCHEM BIOPH RES CO, V253, P561, DOI 10.1006/bbrc.1998.9823; Srivastava J, 2005, MOL BIOL CELL, V16, P1481, DOI 10.1091/mbc.e04-08-0721; Sullivan RM, 2000, MOL PHARMACOL, V58, P729, DOI 10.1124/mol.58.4.729; TSUKITA S, 1994, J CELL BIOL, V126, P391, DOI 10.1083/jcb.126.2.391; Wald FA, 2008, J CELL SCI, V121, P644, DOI 10.1242/jcs.016246; Weng WH, 2005, CLIN CANCER RES, V11, P6198, DOI 10.1158/1078-0432.CCR-05-0548; Yonemura S, 1998, J CELL BIOL, V140, P885, DOI 10.1083/jcb.140.4.885; Yu YL, 2004, NAT MED, V10, P175, DOI 10.1038/nm966; Zh LX, 2007, AM J PHYSIOL-CELL PH, V293, pC874, DOI 10.1152/ajpcell.00111.2007	51	99	111	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2009	28	6					792	802		10.1038/onc.2008.437	http://dx.doi.org/10.1038/onc.2008.437			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	406UI	19060919	Green Accepted			2022-12-28	WOS:000263320000002
J	Brenet, F; Socci, ND; Sonenberg, N; Holland, EC				Brenet, F.; Socci, N. D.; Sonenberg, N.; Holland, E. C.			Akt phosphorylation of La regulates specific mRNA translation in glial progenitors	ONCOGENE			English	Article						Ras/Akt pathway; La autoantigen; translation; ribonomics; polysomes	GLIOBLASTOMA FORMATION; ENHANCES TRANSLATION; NEURAL PROGENITORS; POLIOVIRUS RNA; AUTOANTIGEN LA; SS-B; PROTEIN; BINDING; OVEREXPRESSION; LOCALIZATION	The Akt signaling pathway activity increases as normal tissue progresses to malignant transformation, and regulates the translation of specific messenger RNAs (mRNAs) through multiple mechanisms. We have identified one such mechanism of Akt-dependent translation control as involving the lupus autoantigen La. La is an RNA-associated protein that contains multiple trafficking elements to support the interaction with RNAs in different subcellular locations. We show here that the La protein is a direct target of the serine/threonine protein kinase Akt on threonine 301, and La nuclear export in mouse glial progenitors, as well as its association with polysomes is modulated by Akt activity. Using a functional approach to determine the network of genes affected by La in the cytoplasm by microarray analysis of polysome-bound mRNAs, we found that La binds 34% of the polysome bound mRNAs and regulates the expression of a specific pool of mRNAs under KRas/Akt activation. Therefore, La appears to be an important contributor to Akt-mediated translational regulation of these transcripts in murine glial cells.	[Brenet, F.; Holland, E. C.] Mem Sloan Kettering Canc Ctr, Dept Canc Biol & Genet, New York, NY 10021 USA; [Socci, N. D.] Mem Sloan Kettering Canc Ctr, Computat Biol Ctr, New York, NY 10021 USA; [Sonenberg, N.] McGill Univ, Dept Biochem, Montreal, PQ, Canada; [Holland, E. C.] Mem Sloan Kettering Canc Ctr, Dept Surg, New York, NY 10021 USA; [Holland, E. C.] Mem Sloan Kettering Canc Ctr, Dept Neurosurg, New York, NY 10021 USA; [Holland, E. C.] Mem Sloan Kettering Canc Ctr, Dept Neurol, New York, NY 10021 USA; [Holland, E. C.] Mem Sloan Kettering Canc Ctr, Brain Tumor Ctr, New York, NY 10021 USA	Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; McGill University; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center	Brenet, F (corresponding author), Cornell Univ, Dept Med, Weill Med Coll, 1300 York Ave,Room A635, New York, NY 10021 USA.	fab2008@med.cornell.edu	Brenet, Fabienne/R-1881-2016	Brenet, Fabienne/0000-0003-4098-1096	National Institutes of Health [UO1CA04002]	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	We thank Dr Agnes Viale and the members of the Genomic Core Facility (MSKCC) for generation of Affymetrix data, Yelena Lyustikman for reading of the manuscript and Gloria Curto- Gonzalez, Elena Fomchenko and Hiro Momota for discussion and technical suggestions. We also thank Keryx Biopharmaceuticals for generously providing us with perifosine. This work was supported by a National Institutes of Health Grant (UO1CA04002).	Alfano C, 2004, NAT STRUCT MOL BIOL, V11, P323, DOI 10.1038/nsmb747; BABOONIAN C, 1989, CLIN EXP IMMUNOL, V78, P454; BACHMANN M, 1990, EXP CELL RES, V191, P171, DOI 10.1016/0014-4827(90)90002-R; Bayfield MA, 2007, MOL CELL BIOL, V27, P3303, DOI 10.1128/MCB.00026-07; Benjamin D, 2006, MOL CELL BIOL, V26, P9497, DOI 10.1128/MCB.01099-06; Brenet F, 2005, MOL CELL BIOL, V25, P7505, DOI 10.1128/MCB.25.17.7505-7521.2005; Broekhuis CHD, 2000, BIOCHEMISTRY-US, V39, P3023, DOI 10.1021/bi992308c; Cardinali B, 2003, J BIOL CHEM, V278, P35145, DOI 10.1074/jbc.M300722200; CHANG YN, 1994, J VIROL, V68, P7008, DOI 10.1128/JVI.68.11.7008-7020.1994; Crosio C, 2000, NUCLEIC ACIDS RES, V28, P2927, DOI 10.1093/nar/28.15.2927; Crul M, 2002, EUR J CANCER, V38, P1615, DOI 10.1016/S0959-8049(02)00127-2; Dai C, 2001, GENE DEV, V15, P1913, DOI 10.1101/gad.903001; de Silanes IL, 2003, ONCOGENE, V22, P7146, DOI 10.1038/sj.onc.1206862; Dong G, 2004, EMBO J, V23, P1000, DOI 10.1038/sj.emboj.7600115; Evdokimova V, 2006, MOL CELL BIOL, V26, P277, DOI 10.1128/MCB.26.1.277-292.2006; Fan H, 1998, MOL CELL BIOL, V18, P3201, DOI 10.1128/MCB.18.6.3201; Gherzi R, 2007, PLOS BIOL, V5, P82, DOI 10.1371/journal.pbio.0050005; Gingras AC, 1999, GENE DEV, V13, P1422, DOI 10.1101/gad.13.11.1422; Gingras AC, 1998, GENE DEV, V12, P502, DOI 10.1101/gad.12.4.502; Gouble A, 2002, CANCER RES, V62, P1489; Graff JR, 2003, CLIN EXP METASTAS, V20, P265, DOI 10.1023/A:1022943419011; He X, 2007, ONCOGENE, V26, P4961, DOI 10.1038/sj.onc.1210307; Holcik M, 2003, MOL CELL BIOL, V23, P280, DOI 10.1128/MCB.23.1.280-288.2003; Holland EC, 2000, NAT GENET, V25, P55, DOI 10.1038/75596; Holland EC, 1998, GENE DEV, V12, P3644, DOI 10.1101/gad.12.23.3644; Intine RV, 2003, MOL CELL, V12, P1301, DOI 10.1016/S1097-2765(03)00429-5; Kim YK, 2001, NUCLEIC ACIDS RES, V29, P5009, DOI 10.1093/nar/29.24.5009; LAZARISKARATZAS A, 1990, NATURE, V345, P544, DOI 10.1038/345544a0; Li XQ, 2006, J BIOL CHEM, V281, P13837, DOI 10.1074/jbc.M602060200; MANNING BD, 2002, SCI STKE, V162, pPE49; MEEROVITCH K, 1993, J VIROL, V67, P3798, DOI 10.1128/JVI.67.7.3798-3807.1993; MEEROVITCH K, 1989, GENE DEV, V3, P1026, DOI 10.1101/gad.3.7.1026; Meyuhas O, 2000, EUR J BIOCHEM, V267, P6321, DOI 10.1046/j.1432-1327.2000.01719.x; Momota H, 2005, CANCER RES, V65, P7429, DOI 10.1158/0008-5472.CAN-05-1042; Palamarchuk A, 2005, CANCER RES, V65, P11282, DOI 10.1158/0008-5472.CAN-05-3469; Rajasekhar VK, 2003, MOL CELL, V12, P889, DOI 10.1016/S1097-2765(03)00395-2; Rajasekhar VK, 2004, ONCOGENE, V23, P3248, DOI 10.1038/sj.onc.1207546; Ruggero D, 2004, NAT MED, V10, P484, DOI 10.1038/nm1042; Tenenbaum SA, 2000, P NATL ACAD SCI USA, V97, P14085, DOI 10.1073/pnas.97.26.14085; Tessier CR, 2004, CANCER RES, V64, P209, DOI 10.1158/0008-5472.CAN-03-2927; Trotta R, 2003, CANCER CELL, V3, P145, DOI 10.1016/S1535-6108(03)00020-5; Wendel HG, 2004, NATURE, V428, P332, DOI 10.1038/nature02369; Yoo CJ, 1997, CELL, V89, P393, DOI 10.1016/S0092-8674(00)80220-2	43	40	43	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 8	2009	28	1					128	139		10.1038/onc.2008.376	http://dx.doi.org/10.1038/onc.2008.376			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	392HP	18836485				2022-12-28	WOS:000262294100013
J	Fridman, AL; Tainsky, MA				Fridman, A. L.; Tainsky, M. A.			Critical pathways in cellular senescence and immortalization revealed by gene expression profiling	ONCOGENE			English	Review						immortalization; senescence; cell cycle; interferon; cytoskeletal; IGF-related genes	MAMMARY EPITHELIAL-CELLS; PLASMINOGEN-ACTIVATOR INHIBITOR-1; FACTOR-BINDING PROTEIN-5; ONE COMPLEMENTATION GROUP; REPLICATIVE LIFE-SPAN; HUMAN FIBROBLASTS; IN-VITRO; DNA METHYLATION; GROWTH ARREST; TRANSCRIPTION FACTOR	Bypassing cellular senescence and becoming immortal is a prerequisite step in the tumorigenic transformation of a cell. It has long been known that loss of a key tumor suppressor gene, such as p53, is necessary, but not sufficient, for spontaneous cellular immortalization. Therefore, there must be additional mutations and/or epigenetic alterations required for immortalization to occur. Early work on these processes included somatic cell genetic studies to estimate the number of senescence genes, and microcell-mediated transfer of chromosomes into immortalized cells to identify putative senescence-inducing genetic loci. These principal studies laid the foundation for the field of senescence/immortalization, but were labor intensive and the results were somewhat limited. The advent of gene expression pro. ling and bioinformatics analysis greatly facilitated the identification of genes and pathways that regulate cellular senescence/ immortalization. In this review, we present the findings of several gene expression pro. ling studies and supporting functional data, where available. We identified universal genes regulating senescence/ immortalization and found that the key regulator genes represented six pathways: the cell cycle pRB/p53, cytoskeletal, interferon-related, insulin growth factor-related, MAP kinase and oxidative stress pathway. The identification of the genes and pathways regulating senescence/ immortalization could provide novel molecular targets for the treatment and/or prevention of cancer.	[Tainsky, M. A.] Wayne State Univ, Sch Med, Program Mol Biol & Genet, Barbara Ann Karmanos Canc Inst, Detroit, MI 48201 USA; Wayne State Univ, Sch Med, Dept Pathol, Ctr Mol Med & Genet, Detroit, MI 48201 USA	Barbara Ann Karmanos Cancer Institute; Wayne State University; Wayne State University	Tainsky, MA (corresponding author), Wayne State Univ, Sch Med, Program Mol Biol & Genet, Barbara Ann Karmanos Canc Inst, 110 E Warren Ave, Detroit, MI 48201 USA.	tainskym@karmanos.org		Tainsky, Michael/0000-0002-0261-831X	Barbara Ann Karmanos Cancer Institute; State of Michigan Life Sciences Corridor; Wayne State University; Michigan Center for Genomic Technologies Applied Genomics Technology Center [MEDC 085P10009816]; Genomics and Biostatistics Cores of the Barbara Ann Karmanos Cancer Institute [P30CA022453]; NATIONAL CANCER INSTITUTE [P30CA022453] Funding Source: NIH RePORTER	Barbara Ann Karmanos Cancer Institute; State of Michigan Life Sciences Corridor; Wayne State University; Michigan Center for Genomic Technologies Applied Genomics Technology Center; Genomics and Biostatistics Cores of the Barbara Ann Karmanos Cancer Institute; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This study was supported by the Barbara and Fred Erb Endowed Chair in Cancer Genetics (to MAT), and by funds from the Barbara Ann Karmanos Cancer Institute, the State of Michigan Life Sciences Corridor, Wayne State University and Michigan Center for Genomic Technologies Applied Genomics Technology Center (MEDC 085P10009816), and the Genomics and Biostatistics Cores of the Barbara Ann Karmanos Cancer Institute (P30CA022453). We thank the numerous members of the Tainsky lab who over the past 20 years have contributed to the studies of the immortalization of Li-Fraumeni cells, including Sun Yim, Farideh Bischoff, Tian-Ai Wu, Eliayhu Kraus, Sylvia Dryden, Olga Kulaeva, Lin Tang, Rita Rosati, Janice Kraniak and Qunfang Li. We acknowledge Louise C Strong whose insight into human cancer genetics led to the establishment of cell lines from Li-Fraumeni patients. We thank Dr Janice Kraniak for critical reading of the manuscript.	Bachinski LL, 2005, CANCER RES, V65, P427; Baylin SB, 2001, HUM MOL GENET, V10, P687, DOI 10.1093/hmg/10.7.687; Baylin SB, 2000, TRENDS GENET, V16, P168, DOI 10.1016/S0168-9525(99)01971-X; Benvenuti S, 2002, ONCOGENE, V21, P4403, DOI 10.1038/sj.onc.1205525; Benvenuti S, 2002, MOL CELL PROTEOMICS, V1, P280, DOI 10.1074/mcp.M100028-MCP200; BERRY IJ, 1994, MOL CARCINOGEN, V9, P134, DOI 10.1002/mc.2940090305; Bertram MJ, 1999, MOL CELL BIOL, V19, P1479; Berube NG, 1998, AM J HUM GENET, V62, P1015, DOI 10.1086/301848; BISCHOFF FZ, 1990, CANCER RES, V50, P7979; BISCHOFF FZ, 1991, ONCOGENE, V6, P183; Bodnar AG, 1998, SCIENCE, V279, P349, DOI 10.1126/science.279.5349.349; Boulet G, 2007, INT J BIOCHEM CELL B, V39, P2006, DOI 10.1016/j.biocel.2007.07.004; Bringold F, 2000, EXP GERONTOL, V35, P317, DOI 10.1016/S0531-5565(00)00083-8; Campisi J, 2001, TRENDS CELL BIOL, V11, pS27, DOI 10.1016/S0962-8924(01)02151-1; Campisi J, 2001, EXP GERONTOL, V36, P1619, DOI 10.1016/S0531-5565(01)00160-7; Chang BD, 2002, P NATL ACAD SCI USA, V99, P389, DOI 10.1073/pnas.012602599; CHEN Q, 1995, P NATL ACAD SCI USA, V92, P4337, DOI 10.1073/pnas.92.10.4337; CHEN Q, 1994, P NATL ACAD SCI USA, V91, P4130, DOI 10.1073/pnas.91.10.4130; Chen QM, 1998, BIOCHEM J, V332, P43, DOI 10.1042/bj3320043; Chuaqui RF, 2002, NAT GENET, V32, P509, DOI 10.1038/ng1034; Coates PJ, 2002, J PATHOL, V196, P371, DOI 10.1002/path.1073; Cong YS, 2002, MICROBIOL MOL BIOL R, V66, P407, DOI 10.1128/MMBR.66.3.407-425.2002; CRISTOFALO VJ, 1993, PHYSIOL REV, V73, P617, DOI 10.1152/physrev.1993.73.3.617; DADDA DF, 2003, NATURE, V426, P194, DOI DOI 10.1038/NATURE02118; Dairkee SH, 2007, ONCOGENE, V26, P6269, DOI 10.1038/sj.onc.1210452; Di Bacco A, 2003, ONCOGENE, V22, P5436, DOI 10.1038/sj.onc.1206670; Dimri GP, 2000, MOL CELL BIOL, V20, P273, DOI 10.1128/MCB.20.1.273-285.2000; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; Drayton S, 2002, CURR OPIN GENET DEV, V12, P98, DOI 10.1016/S0959-437X(01)00271-4; DUNCAN EL, 1993, EXP CELL RES, V205, P337, DOI 10.1006/excr.1993.1095; Esteller M, 2001, CANCER RES, V61, P3225; Feinberg AP, 2002, SEMIN CANCER BIOL, V12, P389, DOI 10.1016/S1044-579X(02)00059-7; Forsyth NR, 2004, NEOPLASIA, V6, P258, DOI 10.1593/neo.04103; Fridman AL, 2007, BIOCHEM BIOPH RES CO, V357, P785, DOI 10.1016/j.bbrc.2007.04.019; Fridman AL, 2006, J GERONTOL A-BIOL, V61, P879, DOI 10.1093/gerona/61.9.879; Garbe J, 1999, ONCOGENE, V18, P2169, DOI 10.1038/sj.onc.1202523; Garkavtsev I, 1997, MOL CELL BIOL, V17, P2014, DOI 10.1128/MCB.17.4.2014; Garkavtsev I, 1998, NATURE, V391, P295, DOI 10.1038/34675; Goeman F, 2005, MOL CELL BIOL, V25, P422, DOI 10.1128/MCB.25.1.422-431.2005; GOLDSTEIN S, 1991, P NATL ACAD SCI USA, V88, P9680, DOI 10.1073/pnas.88.21.9680; Gollahon LS, 1998, ONCOGENE, V17, P709, DOI 10.1038/sj.onc.1201987; Gonzalez L, 2006, ONCOGENE, V25, P5173, DOI 10.1038/sj.onc.1209526; HAAF T, 1995, PHARMACOL THERAPEUT, V65, P19, DOI 10.1016/0163-7258(94)00053-6; Hagen TM, 1997, P NATL ACAD SCI USA, V94, P3064, DOI 10.1073/pnas.94.7.3064; Haq R, 2002, CANCER RES, V62, P5076; Harley CB, 2002, ONCOGENE, V21, P494, DOI 10.1038/sj.onc.1205076; HARVEY M, 1993, ONCOGENE, V8, P2457; HAYFLICK L, 1965, EXP CELL RES, V37, P614, DOI 10.1016/0014-4827(65)90211-9; Hayflick L, 1985, Clin Geriatr Med, V1, P15; Itahana K, 2004, BIOGERONTOLOGY, V5, P1, DOI 10.1023/B:BGEN.0000017682.96395.10; Itahana K, 2003, MOL CELL BIOL, V23, P389, DOI 10.1128/MCB.23.1.389-401.2003; Jha KK, 1998, EXP CELL RES, V245, P1, DOI 10.1006/excr.1998.4272; Kanai Y, 2001, J CANCER RES CLIN, V127, P697; Kanehisa M, 2000, NUCLEIC ACIDS RES, V28, P27, DOI 10.1093/nar/28.1.27; KANEKO S, 1995, CELL STRUCT FUNCT, V20, P107, DOI 10.1247/csf.20.107; Kang MK, 2003, EXP CELL RES, V287, P272, DOI 10.1016/S0014-4827(03)00061-2; Karpf AR, 2002, ONCOGENE, V21, P5496, DOI 10.1038/sj.onc.1205602; Kim KS, 2007, MOL BIOL CELL, V18, P4543, DOI 10.1091/mbc.E07-03-0280; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; Kortlever RM, 2006, CELL CYCLE, V5, P2697, DOI 10.4161/cc.5.23.3510; Kortlever RM, 2006, NAT CELL BIOL, V8, P877, DOI 10.1038/ncb1448; Kraniak JM, 2006, MOL CARCINOGEN, V45, P141, DOI 10.1002/mc.20145; Krtolica A, 2001, P NATL ACAD SCI USA, V98, P12072, DOI 10.1073/pnas.211053698; Kulaeva OI, 2003, ONCOGENE, V22, P4118, DOI 10.1038/sj.onc.1206594; LeckaCzernik B, 1996, EXP GERONTOL, V31, P159, DOI 10.1016/0531-5565(95)02014-4; Lee AC, 1999, J BIOL CHEM, V274, P7936, DOI 10.1074/jbc.274.12.7936; Lee CC, 2002, BIOCHEM BIOPH RES CO, V291, P185, DOI 10.1006/bbrc.2002.6415; Leung KM, 2002, CANCER RES, V62, P4890; Li QF, 2008, MOL CANCER RES, V6, P770, DOI 10.1158/1541-7786.MCR-07-0114; Li YZ, 2007, MOL CANCER, V6, DOI 10.1186/1476-4598-6-7; Liang G, 2002, CANCER RES, V62, P961; LINSKENS MHK, 1995, NUCLEIC ACIDS RES, V23, P3244, DOI 10.1093/nar/23.16.3244; Lopatina N, 2002, J CELL BIOCHEM, V84, P324, DOI 10.1002/jcb.10015; Lopez-Bermejo A, 2000, ENDOCRINOLOGY, V141, P4072, DOI 10.1210/en.141.11.4072; Lundberg AS, 2000, CURR OPIN CELL BIOL, V12, P705, DOI 10.1016/S0955-0674(00)00155-1; Macip S, 2002, EMBO J, V21, P2180, DOI 10.1093/emboj/21.9.2180; Morelli C, 2000, GENE, V252, P217, DOI 10.1016/S0378-1119(00)00231-6; Morelli C, 2002, ONCOGENE, V21, P7266, DOI 10.1038/sj.onc.1205573; MURANO S, 1991, MOL CELL BIOL, V11, P3905, DOI 10.1128/MCB.11.8.3905; Nam TJ, 1997, ENDOCRINOLOGY, V138, P2972, DOI 10.1210/en.138.7.2972; Neumeister P, 2002, INT J BIOCHEM CELL B, V34, P1475, DOI 10.1016/S1357-2725(02)00079-1; Ozawa S, 2006, BIOCHEM BIOPH RES CO, V348, P406, DOI 10.1016/j.bbrc.2006.07.070; Paz MF, 2003, CANCER RES, V63, P1114; PEREIRASMITH OM, 1988, P NATL ACAD SCI USA, V85, P6042, DOI 10.1073/pnas.85.16.6042; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; Quackenbush J, 2003, SCIENCE, V302, P240, DOI 10.1126/science.1090887; ROGAN EM, 1995, MOL CELL BIOL, V15, P4745; ROHME D, 1981, P NATL ACAD SCI-BIOL, V78, P5009, DOI 10.1073/pnas.78.8.5009; Romanov SR, 2001, NATURE, V409, P633, DOI 10.1038/35054579; Roninson IB, 2003, CANCER RES, V63, P2705; Rubin H, 2002, NAT BIOTECHNOL, V20, P675, DOI 10.1038/nbt0702-675; RUSSO T, 1995, J BIOL CHEM, V270, P29386, DOI 10.1074/jbc.270.49.29386; Salomonis N, 2007, BMC BIOINFORMATICS, V8, DOI 10.1186/1471-2105-8-217; SANDHU AK, 1994, P NATL ACAD SCI USA, V91, P5498, DOI 10.1073/pnas.91.12.5498; SASAKI M, 1994, CANCER RES, V54, P6090; SATOH Y, 1994, MUTAT RES, V316, P25, DOI 10.1016/0921-8734(94)90005-1; Schroder K, 2004, J LEUKOCYTE BIOL, V75, P163, DOI 10.1189/jlb.0603252; Schwarze SR, 2002, J BIOL CHEM, V277, P14877, DOI 10.1074/jbc.M200373200; Sekaric P, 2007, ONCOGENE, V26, P6261, DOI 10.1038/sj.onc.1210462; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; SHAY JW, 1995, MOL CELL BIOL, V15, P425, DOI 10.1128/MCB.15.1.425; Shelton DN, 1999, CURR BIOL, V9, P939, DOI 10.1016/S0960-9822(99)80420-5; Shibanuma M, 1997, MOL CELL BIOL, V17, P1224, DOI 10.1128/MCB.17.3.1224; Shou JY, 2002, P NATL ACAD SCI USA, V99, P2830, DOI 10.1073/pnas.052705299; Smith JR, 1996, SCIENCE, V273, P63, DOI 10.1126/science.273.5271.63; Sommer M, 2006, CELL CYCLE, V5, P2005, DOI 10.4161/cc.5.17.3194; Sorrell AM, 2006, J BIOL CHEM, V281, P10883, DOI 10.1074/jbc.M508505200; Stampfer MR, 2003, CANCER LETT, V194, P199, DOI 10.1016/S0304-3835(02)00707-3; Stratford FLL, 2006, FEBS LETT, V580, P3989, DOI 10.1016/j.febslet.2006.06.029; Suzuki T, 2001, EXP GERONTOL, V36, P465, DOI 10.1016/S0531-5565(00)00223-0; SWISSHELM K, 1995, P NATL ACAD SCI USA, V92, P4472, DOI 10.1073/pnas.92.10.4472; Takaoka A, 2006, CELL MICROBIOL, V8, P907, DOI 10.1111/j.1462-5822.2006.00716.x; Takebayashi S, 2001, BIOCHEM BIOPH RES CO, V288, P921, DOI 10.1006/bbrc.2001.5863; Tandle AT, 2005, CYTOKINE, V30, P347, DOI 10.1016/j.cyto.2005.01.020; Tominaga K, 2002, MECH AGEING DEV, V123, P927, DOI 10.1016/S0047-6374(02)00030-1; TSUTSUI T, 1995, CARCINOGENESIS, V16, P25, DOI 10.1093/carcin/16.1.25; Tsutsui T, 1997, MOL CARCINOGEN, V18, P7, DOI 10.1002/(SICI)1098-2744(199701)18:1<7::AID-MC2>3.0.CO;2-F; Untergasser G, 2002, CANCER RES, V62, P6255; Varley JM, 1997, CANCER RES, V57, P3245; Vogt M, 1998, CELL GROWTH DIFFER, V9, P139; Vojta PJ, 1996, GENE CHROMOSOME CANC, V16, P55; VONZGLINICKI T, 1995, EXP CELL RES, V220, P186, DOI 10.1006/excr.1995.1305; Wang WP, 2002, MOL CELL BIOL, V22, P3389, DOI 10.1128/MCB.22.10.3389-3403.2002; Wilson HMP, 2002, CELL GROWTH DIFFER, V13, P205; Yaswen P, 2002, INT J BIOCHEM CELL B, V34, P1382, DOI 10.1016/S1357-2725(02)00047-X; Yoon IK, 2004, EXP GERONTOL, V39, P1369, DOI 10.1016/j.exger.2004.07.002; Zhang H, 2004, GENE DEV, V18, P3028, DOI 10.1101/gad.1253004; Zhang H, 2004, ONCOGENE, V23, P6193, DOI 10.1038/sj.onc.1207834; Zhang H, 2003, P NATL ACAD SCI USA, V100, P3251, DOI 10.1073/pnas.2627983100	129	164	171	0	15	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 9	2008	27	46					5975	5987		10.1038/onc.2008.213	http://dx.doi.org/10.1038/onc.2008.213			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	358BO	18711403	Green Accepted			2022-12-28	WOS:000259891600001
J	Hirose, K; Abramovich, C; Argiropoulos, B; Humphries, RK				Hirose, K.; Abramovich, C.; Argiropoulos, B.; Humphries, R. K.			Leukemogenic properties of NUP98-PMX1 are linked to NUP98 and homeodomain sequence functions but not to binding properties of PMX1 to serum response factor	ONCOGENE			English	Article						homeodomain; nucleoporin; hematopoiesis	ACUTE MYELOID-LEUKEMIA; NUCLEAR-PORE COMPLEX; FUSION GENE; HOX GENES; HOMEOBOX GENE; FG REPEATS; PROTEIN; NUCLEOPORIN; TRANSCRIPTION; MEIS1	PMX1 is a member of a non-clustered homeobox gene family, not normally expressed in hematopoietic cells, and first identified for its role in enhancing the binding of the serum response factor (SRF) to the serum responsive element (SRE). PMX1 has never been linked to leukemia on its own, raising the possibility of unique mechanisms underlying the oncogenicity of NUP98-PMX1. To elucidate the leukemogenic potential of NUP98-PMX1, we compared the effects of PMX1 and NUP98-PMX1 and, through strategic mutations, the involvement of the SRE in NUP98-PMX1-mediated leukemia. NUP98-PMX1, but not PMX1, had potent ability to impair differentiation, promote proliferation of myeloid progenitors, induce lethal myeloproliferative disease and to activate a number of genes previously linked to leukemic stem cells. Similar to NUP98-HOX fusions, the transforming potential of NUP98-PMX1 required the NUP98 portion and DNA-binding capability of the PMX1 homeodomain and collaborated with Meis1 to induce more rapid onset myeloproliferative-like myeloid leukemia. The transforming activity of NUP98-PMX1 was independent of its ability to interact with SRF. These findings provide novel evidence of the contributory role of the NUP98 sequence in conferring leukemogenic properties on a partner gene and point to common leukemogenic pathways for NUP98-PMX1 and NUP98-clustered HOX fusions.	[Hirose, K.; Abramovich, C.; Argiropoulos, B.; Humphries, R. K.] British Columbia Canc Res Ctr, Terry Fox Lab, Vancouver, BC V5Z 1L3, Canada; [Humphries, R. K.] Univ British Columbia, Dept Med, Vancouver, BC, Canada	British Columbia Cancer Agency; University of British Columbia	Humphries, RK (corresponding author), British Columbia Canc Res Ctr, Terry Fox Lab, 675 W 10th Ave, Vancouver, BC V5Z 1L3, Canada.	khumphri@bccrc.ca	Hirose, Koichi/I-1506-2017	Hirose, Koichi/0000-0001-7498-9630; Humphries, Richard/0000-0003-0540-7005	Terry Fox Foundation of Canada; Canadian Institutes of Health for Research; Leukemia and Lymphoma Society of Canada	Terry Fox Foundation of Canada; Canadian Institutes of Health for Research(Canadian Institutes of Health Research (CIHR)); Leukemia and Lymphoma Society of Canada	This work was supported by the Terry Fox Foundation of Canada and by the Canadian Institutes of Health for Research. KH and BA were recipients of fellowships from the Leukemia and Lymphoma Society of Canada. We thank Drs Florian Kuchenbauer and Eric Yung for technical assistance.	ALEXANDRE C, 1991, ONCOGENE, V6, P543; Argiropoulos B, 2007, ONCOGENE, V26, P6766, DOI 10.1038/sj.onc.1210760; Bai XT, 2006, CANCER RES, V66, P4584, DOI 10.1158/0008-5472.CAN-05-3101; CSERJESI P, 1992, DEVELOPMENT, V115, P1087; Eklund EA, 2007, CURR OPIN HEMATOL, V14, P85, DOI 10.1097/MOH.0b013e32801684b6; Eklund EA, 2006, CURR OPIN HEMATOL, V13, P67, DOI 10.1097/01.moh.0000208467.63861.d6; Ghannam G, 2004, J BIOL CHEM, V279, P866, DOI 10.1074/jbc.M307280200; Griffis ER, 2003, MOL BIOL CELL, V14, P600, DOI 10.1091/mbc.E02-09-0582; Griffis ER, 2002, MOL BIOL CELL, V13, P1282, DOI 10.1091/mbc.01-11-0538; GRUENEBERG DA, 1992, SCIENCE, V257, P1089, DOI 10.1126/science.257.5073.1089; Gurevich RM, 2004, BLOOD, V104, P1127, DOI 10.1182/blood-2003-10-3550; Jankovic D, 2008, BLOOD, V111, P5672, DOI 10.1182/blood-2007-09-108175; Jeganathan KB, 2005, NATURE, V438, P1036, DOI 10.1038/nature04221; Kasper LH, 1999, MOL CELL BIOL, V19, P764; Kato N, 2000, HEPATOLOGY, V32, P405, DOI 10.1053/jhep.2000.9198; KERN MJ, 1994, GENOMICS, V19, P334, DOI 10.1006/geno.1994.1066; Kogan SC, 2002, BLOOD, V100, P238, DOI 10.1182/blood.V100.1.238; Kroon E, 2001, EMBO J, V20, P350, DOI 10.1093/emboj/20.3.350; MARTIN JF, 1995, GENE DEV, V9, P1237, DOI 10.1101/gad.9.10.1237; Martin KA, 1997, DNA CELL BIOL, V16, P653, DOI 10.1089/dna.1997.16.653; McKean DM, 2003, J CELL BIOL, V161, P393, DOI 10.1083/jcb.jcb.200302126; Nakamura T, 2005, INT J HEMATOL, V82, P21, DOI 10.1532/IJH97.04160; Nakamura T, 1999, BLOOD, V94, P741, DOI 10.1182/blood.V94.2.741.414k04_741_747; Palmqvist L, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000768; Pineault N, 2004, MOL CELL BIOL, V24, P1907, DOI 10.1128/MCB.24.5.1907-1917.2004; Pineault N, 2003, BLOOD, V101, P4529, DOI 10.1182/blood-2002-08-2484; RADU A, 1995, CELL, V81, P215, DOI 10.1016/0092-8674(95)90331-3; Romana SP, 2006, LEUKEMIA, V20, P696, DOI 10.1038/sj.leu.2404130; Saito S, 2004, INT J CANCER, V111, P501, DOI 10.1002/ijc.20296; Simon KJ, 1997, MOL CELL BIOL, V17, P6653, DOI 10.1128/MCB.17.11.6653; Slape C, 2004, LEUKEMIA LYMPHOMA, V45, P1341, DOI 10.1080/10428190310001659325; ten Berge D, 1998, DEVELOPMENT, V125, P3831; ten Berge D, 2001, DEVELOPMENT, V128, P2929; Thorsteinsdottir U, 2001, MOL CELL BIOL, V21, P224, DOI 10.1128/MCB.21.1.224-234.2001; VERSHON AK, 1995, GENE DEV, V9, P182, DOI 10.1101/gad.9.2.182; VONLINDERN M, 1992, BAILLIERE CLIN HAEM, V5, P857, DOI 10.1016/S0950-3536(11)80049-1; Wang GG, 2007, NAT CELL BIOL, V9, P804, DOI 10.1038/ncb1608; Wang GG, 2006, MOL CELL BIOL, V26, P3902, DOI 10.1128/MCB.26.10.3902-3916.2006; Wu XS, 2001, P NATL ACAD SCI USA, V98, P3191, DOI 10.1073/pnas.051631598; Zhang L, 2007, CANCER GENET CYTOGEN, V178, P42, DOI 10.1016/j.cancergencyto.2007.06.012	40	18	18	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 9	2008	27	46					6056	6067		10.1038/onc.2008.210	http://dx.doi.org/10.1038/onc.2008.210			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	358BO	18604245				2022-12-28	WOS:000259891600008
J	Faux, MC; Coates, JL; Catimel, B; Cody, S; Clayton, AHA; Layton, MJ; Burgess, AW				Faux, M. C.; Coates, J. L.; Catimel, B.; Cody, S.; Clayton, A. H. A.; Layton, M. J.; Burgess, A. W.			Recruitment of adenomatous polyposis coli and beta-catenin to axin-puncta	ONCOGENE			English	Article						APC; axin; beta-catenin	WNT-SIGNALING PATHWAY; TUMOR-SUPPRESSOR PROTEIN; F-BOX PROTEIN; SINGLE-PARTICLE TRACKING; PLASMA-MEMBRANE; NEGATIVE REGULATOR; CELL-MIGRATION; APC PROTEIN; IN-VITRO; MICROTUBULES	The adenomatous polyposis coli (APC) tumour suppressor is a multifunctional protein involved in the regulation of Wnt signalling and cytoskeletal dynamics. Little is known about how APC controls these disparate functions. In this study, we have used APC- and axin-fluorescent fusion proteins to examine the interactions between these proteins and show that the functionally distinct populations of APC are also spatially separate. Axin-RFP forms cytoplasmic punctate structures, similar to endogenous axin puncta. Axin-RFP recruits beta-catenin destruction complex proteins, including APC, b-catenin, glycogen synthase kinase-3-beta (GSK3-beta) and casein kinase-1-alpha (CK1-alpha). Recruitment into axin-RFP puncta sequesters APC from clusters at cell extensions and this prevents its microtubule-associated functions. The interaction between APC-GFP and axin-RFP within the cytoplasmic puncta is direct and dramatically alters the dynamic properties of APC-GFP. However, recruitment of APC to axin puncta is not absolutely required for beta-catenin degradation. Instead, formation of axin puncta, mediated by the DIX domain, is required for beta-catenin degradation. An axin Delta DIX mutant did not form puncta, but still mediated recruitment of destruction complex proteins and phosphorylation of beta-catenin. We conclude that there are distinct pools of APC and that the formation of axin puncta, rather than the axin/APC complex, is essential for beta-catenin destruction.	[Faux, M. C.; Coates, J. L.; Catimel, B.; Cody, S.; Clayton, A. H. A.; Layton, M. J.; Burgess, A. W.] Royal Melbourne Hosp, Ludwig Inst Canc Res, Epithelial Biol Lab, Melbourne Tumour Biol Branch, Parkville, Vic 3050, Australia	Ludwig Institute for Cancer Research; Royal Melbourne Hospital	Faux, MC (corresponding author), Royal Melbourne Hosp, Ludwig Inst Canc Res, Epithelial Biol Lab, Melbourne Tumour Biol Branch, POB 2008, Parkville, Vic 3050, Australia.	maree.faux@ludwig.edu.au		CATIMEL, Bruno/0000-0002-4350-6875	NHMRC program [234703]; NH&MRC RD Wright Research	NHMRC program(National Health and Medical Research Council (NHMRC) of Australia); NH&MRC RD Wright Research(National Health and Medical Research Council (NHMRC) of Australia)	We thank Dr M Prescott, Dr F Costantini and Dr D Capelluto for cDNA constructs. MCF, MJL and AWB are supported by NH&MRC program grant 234703; AHAC is an NH&MRC RD Wright Research Fellow.	Aberle H, 1997, EMBO J, V16, P3797, DOI 10.1093/emboj/16.13.3797; Barth AIM, 2002, J CELL SCI, V115, P1583; Behrens J, 1998, SCIENCE, V280, P596, DOI 10.1126/science.280.5363.596; Bilic J, 2007, SCIENCE, V316, P1619, DOI 10.1126/science.1137065; Campbell RE, 2002, P NATL ACAD SCI USA, V99, P7877, DOI 10.1073/pnas.082243699; Catimel B, 2006, BIOMED CHROMATOGR, V20, P569, DOI 10.1002/bmc.648; Ciani L, 2004, J CELL BIOL, V164, P243, DOI 10.1083/jcb.200309096; Clayton AHA, 2005, J BIOL CHEM, V280, P30392, DOI 10.1074/jbc.M504770200; Clevers H, 2006, CELL, V127, P469, DOI 10.1016/j.cell.2006.10.018; Cliffe A, 2003, CURR BIOL, V13, P960, DOI 10.1016/S0960-9822(03)00370-1; Cong F, 2004, DEVELOPMENT, V131, P5103, DOI 10.1242/dev.01318; Dayanandan R, 2003, CELL MOTIL CYTOSKEL, V54, P237, DOI 10.1002/cm.10096; Fagotto F, 1999, J CELL BIOL, V145, P741, DOI 10.1083/jcb.145.4.741; Faux MC, 2004, J CELL SCI, V117, P427, DOI 10.1242/jcs.00862; Fodde R, 2003, NAT CELL BIOL, V5, P190, DOI 10.1038/ncb0303-190; Hanley QS, 2005, J MICROSC-OXFORD, V218, P62, DOI 10.1111/j.1365-2818.2005.01463.x; Hart M, 1999, CURR BIOL, V9, P207, DOI 10.1016/S0960-9822(99)80091-8; Harte D, 1998, J NONLINEAR SCI, V8, P581, DOI 10.1007/s003329900060; Hsu W, 1999, J BIOL CHEM, V274, P3439, DOI 10.1074/jbc.274.6.3439; Kawasaki Y, 2000, SCIENCE, V289, P1194, DOI 10.1126/science.289.5482.1194; Kishida S, 1999, MOL CELL BIOL, V19, P4414; Kishida S, 1998, J BIOL CHEM, V273, P10823, DOI 10.1074/jbc.273.18.10823; Kita K, 2006, MOL BIOL CELL, V17, P2331, DOI 10.1091/mbc.E05-06-0498; Kitagawa M, 1999, EMBO J, V18, P2401, DOI 10.1093/emboj/18.9.2401; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; Kroboth K, 2007, MOL BIOL CELL, V18, P910, DOI 10.1091/mbc.E06-03-0179; Langford KJ, 2006, BMC CELL BIOL, V7, DOI 10.1186/1471-2121-7-3; Latres E, 1999, ONCOGENE, V18, P849, DOI 10.1038/sj.onc.1202653; Lee E, 2003, PLOS BIOL, V1, P116, DOI 10.1371/journal.pbio.0000010; LEIBOVITZ A, 1976, CANCER RES, V36, P4562; Levina E, 2004, ONCOGENE, V23, P4444, DOI 10.1038/sj.onc.1207587; Logan CY, 2004, ANNU REV CELL DEV BI, V20, P781, DOI 10.1146/annurev.cellbio.20.010403.113126; Magde D, 1999, PHOTOCHEM PHOTOBIOL, V70, P737, DOI 10.1111/j.1751-1097.1999.tb08277.x; Mimori-Kiyosue Y, 2000, J CELL BIOL, V148, P505, DOI 10.1083/jcb.148.3.505; MUNEMITSU S, 1994, CANCER RES, V54, P3676; MUNEMITSU S, 1995, P NATL ACAD SCI USA, V92, P3046, DOI 10.1073/pnas.92.7.3046; Nakamura M, 2001, CURR BIOL, V11, P1062, DOI 10.1016/S0960-9822(01)00297-4; Nakamura T, 1998, GENES CELLS, V3, P395, DOI 10.1046/j.1365-2443.1998.00198.x; Nathke IS, 1996, J CELL BIOL, V134, P165, DOI 10.1083/jcb.134.1.165; Nathke IS, 2004, ANNU REV CELL DEV BI, V20, P337, DOI 10.1146/annurev.cellbio.20.012103.094541; Orford K, 1997, J BIOL CHEM, V272, P24735, DOI 10.1074/jbc.272.40.24735; Park TJ, 2005, CURR BIOL, V15, P1039, DOI 10.1016/j.cub.2005.04.062; Penman GA, 2005, J CELL SCI, V118, P4741, DOI 10.1242/jcs.02589; Polakis P, 2000, GENE DEV, V14, P1837; Polakis P, 1997, BBA-REV CANCER, V1332, pF127, DOI 10.1016/S0304-419X(97)00008-5; Sage D, 2005, IEEE T IMAGE PROCESS, V14, P1372, DOI 10.1109/TIP.2005.852787; Sakanaka C, 1999, J BIOL CHEM, V274, P14090, DOI 10.1074/jbc.274.20.14090; Saxton MJ, 1997, ANNU REV BIOPH BIOM, V26, P373, DOI 10.1146/annurev.biophys.26.1.373; Schneikert J, 2007, GUT, V56, P417, DOI 10.1136/gut.2006.093310; Schwarz-Romond T, 2005, J CELL SCI, V118, P5269, DOI 10.1242/jcs.02646; Schwarz-Romond T, 2007, J CELL SCI, V120, P2402, DOI 10.1242/jcs.002956; Schwarz-Romond T, 2007, NAT STRUCT MOL BIOL, V14, P484, DOI 10.1038/nsmb1247; Sharma M, 2006, J BIOL CHEM, V281, P17140, DOI 10.1074/jbc.M513027200; Smalley MJ, 1999, EMBO J, V18, P2823, DOI 10.1093/emboj/18.10.2823; SU LK, 1995, CANCER RES, V55, P2972; van Munster EB, 2004, CYTOM PART A, V58A, P185, DOI 10.1002/cyto.a.20013; Watanabe T, 2004, DEV CELL, V7, P871, DOI 10.1016/j.devcel.2004.10.017; Wen Y, 2004, NAT CELL BIOL, V6, P820, DOI 10.1038/ncb1160; Wiechens N, 2004, J BIOL CHEM, V279, P5263, DOI 10.1074/jbc.M307253200; Wilson KM, 1996, J CELL SCI, V109, P2101; Winston JT, 1999, GENE DEV, V13, P270, DOI 10.1101/gad.13.3.270; Zeng L, 1997, CELL, V90, P181, DOI 10.1016/S0092-8674(00)80324-4	62	49	49	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 2	2008	27	44					5808	5820		10.1038/onc.2008.205	http://dx.doi.org/10.1038/onc.2008.205			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	355QC	18591934				2022-12-28	WOS:000259722400005
J	Horn, HF; Vousden, KH				Horn, H. F.; Vousden, K. H.			Cooperation between the ribosomal proteins L5 and L11 in the p53 pathway	ONCOGENE			English	Article						p53; MDM2; L5; L11	POLYMERASE-III TRANSCRIPTION; UBIQUITIN LIGASE ACTIVITY; TUMOR-SUPPRESSOR P53; RING FINGER DOMAIN; 5S RNA; ONCOPROTEIN MDM2; MOLECULAR-BASIS; NUCLEAR EXPORT; CELL-CYCLE; IN-VITRO	MDM2 is a ubiquitin ligase that plays a key role in regulating the stability of the p53 tumor suppressor protein. Several proteins have been shown to activate the p53 pathway by interacting with and inhibiting the E3 function of MDM2, thereby leading to an accumulation of p53. These include the alternate reading frame (ARF) proteins and the ribosomal proteins L5 and L11. We found that when overexpressed alone, L11 is much less potent in inhibiting MDM2 than p14(ARF). However, L11 cooperates with L5, resulting in a robust inhibition of the E3 activity of MDM2, and a stabilization and activation of p53 approaching that achieved by p14(ARF). We further showed that the ability of L11 to bind the 5S rRNA is important for the cooperation with L5, and a mutant L11, which cannot bind the 5S rRNA, cannot cooperate with L5 in inhibiting MDM2.	[Horn, H. F.; Vousden, K. H.] Beatson Inst Canc Res, Glasgow G61 1BD, Lanark, Scotland	Beatson Institute	Vousden, KH (corresponding author), Beatson Inst Canc Res, Garscube Estate,Switchback Rd, Glasgow G61 1BD, Lanark, Scotland.	k.vousden@beatson.gla.ac.uk		Horn, Henning/0000-0002-5885-8996	Cancer Research, UK	Cancer Research, UK(Cancer Research UK)	We are grateful to Professor Dr Joachim Hauber for sending us a human L5 expression plasmid (p3L5) and anti-human L5 antibody. This work was funded by Cancer Research, UK.	Bernardi R, 2004, NAT CELL BIOL, V6, P665, DOI 10.1038/ncb1147; Bhat KP, 2004, EMBO J, V23, P2402, DOI 10.1038/sj.emboj.7600247; BLOBEL G, 1971, P NATL ACAD SCI USA, V68, P1881, DOI 10.1073/pnas.68.8.1881; Bothner B, 2001, J MOL BIOL, V314, P263, DOI 10.1006/jmbi.2001.5110; Brooks CL, 2003, CURR OPIN CELL BIOL, V15, P164, DOI 10.1016/S0955-0674(03)00003-6; Cairns CA, 1998, EMBO J, V17, P3112, DOI 10.1093/emboj/17.11.3112; Carter S, 2007, NAT CELL BIOL, V9, P428, DOI 10.1038/ncb1562; CHEN JD, 1995, MOL MED, V1, P142, DOI 10.1007/BF03401562; Chesnokov I, 1996, MOL CELL BIOL, V16, P7084; Christophorou MA, 2006, NATURE, V443, P214, DOI 10.1038/nature05077; Crighton D, 2003, EMBO J, V22, P2810, DOI 10.1093/emboj/cdg265; Dai MS, 2004, J BIOL CHEM, V279, P44475, DOI 10.1074/jbc.M403722200; Dai MS, 2004, MOL CELL BIOL, V24, P7654, DOI 10.1128/MCB.24.17.7654-7668.2004; Dai MS, 2006, J BIOL CHEM, V281, P24304, DOI 10.1074/jbc.M602596200; Efeyan A, 2007, CELL CYCLE, V6, P1006, DOI 10.4161/cc.6.9.4211; Efeyan A, 2006, NATURE, V443, P159, DOI 10.1038/443159a; Elenbaas B, 1996, MOL MED, V2, P439, DOI 10.1007/BF03401903; GRAY PN, 1972, EUR J BIOCHEM, V28, P412, DOI 10.1111/j.1432-1033.1972.tb01927.x; Harms J, 2001, CELL, V107, P679, DOI 10.1016/S0092-8674(01)00546-3; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Honda R, 1997, FEBS LETT, V420, P25, DOI 10.1016/S0014-5793(97)01480-4; Honda R, 2000, ONCOGENE, V19, P1473, DOI 10.1038/sj.onc.1203464; Honda R, 1999, EMBO J, V18, P22, DOI 10.1093/emboj/18.1.22; Ishizuka A, 2002, GENE DEV, V16, P2497, DOI 10.1101/gad.1022002; Itahana K, 2007, CANCER CELL, V12, P355, DOI 10.1016/j.ccr.2007.09.007; Iwasaki K, 2002, BIOSCI BIOTECH BIOCH, V66, P103, DOI 10.1271/bbb.66.103; Jin A, 2004, MOL CELL BIOL, V24, P7669, DOI 10.1128/MCB.24.17.7669-7680.2004; Kamijo T, 1998, P NATL ACAD SCI USA, V95, P8292, DOI 10.1073/pnas.95.14.8292; KNIGHT E, 1967, J MOL BIOL, V28, P491, DOI 10.1016/S0022-2836(67)80099-8; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Lindstrom MS, 2007, MOL CELL BIOL, V27, P1056, DOI 10.1128/MCB.01307-06; Lohrum MAE, 2003, CANCER CELL, V3, P577, DOI 10.1016/S1535-6108(03)00134-X; Lowe SW, 1999, ENDOCR-RELAT CANCER, V6, P45, DOI 10.1677/erc.0.0060045; Lukashchuk N, 2007, MOL CELL BIOL, V27, P8284, DOI 10.1128/MCB.00050-07; MARECHAL V, 1994, MOL CELL BIOL, V14, P7414, DOI 10.1128/MCB.14.11.7414; MARION MJ, 1981, BIOCHIM BIOPHYS ACTA, V652, P193, DOI 10.1016/0005-2787(81)90222-7; MARSTON NJ, 1994, ONCOGENE, V9, P2707; Midgley CA, 2000, ONCOGENE, V19, P2312, DOI 10.1038/sj.onc.1203593; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; Nakashima T, 2001, RNA, V7, P692, DOI 10.1017/S1355838201002345; Perederina A, 2002, RNA, V8, P1548, DOI 10.1017/S1355838202029953; PERRY RP, 1970, J CELL PHYSIOL, V76, P127, DOI 10.1002/jcp.1040760202; Pestov DG, 2001, MOL CELL BIOL, V21, P4246, DOI 10.1128/MCB.21.13.4246-4255.2001; Pomerantz J, 1998, CELL, V92, P713, DOI 10.1016/S0092-8674(00)81400-2; Schatz O, 1998, P NATL ACAD SCI USA, V95, P1607, DOI 10.1073/pnas.95.4.1607; Sherr CJ, 2000, CURR OPIN GENET DEV, V10, P94, DOI 10.1016/S0959-437X(99)00038-6; Sherr CJ, 1998, GENE DEV, V12, P2984, DOI 10.1101/gad.12.19.2984; Spahn CMT, 2001, CELL, V107, P373, DOI 10.1016/S0092-8674(01)00539-6; SPIERER P, 1978, BIOCHEMISTRY-US, V17, P2474, DOI 10.1021/bi00606a002; STEITZ JA, 1988, J CELL BIOL, V106, P545, DOI 10.1083/jcb.106.3.545; Stott FJ, 1998, EMBO J, V17, P5001, DOI 10.1093/emboj/17.17.5001; Sun XX, 2008, J BIOL CHEM, V283, P12387, DOI 10.1074/jbc.M801387200; Szymanski M, 2003, BIOCHEM J, V371, P641, DOI 10.1042/BJ20020872; Thut CJ, 1997, GENE DEV, V11, P1974, DOI 10.1101/gad.11.15.1974; Toledo F, 2006, CANCER CELL, V9, P273, DOI 10.1016/j.ccr.2006.03.014; Toledo F, 2006, NAT REV CANCER, V6, P909, DOI 10.1038/nrc2012; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; White RJ, 2004, ONCOGENE, V23, P3208, DOI 10.1038/sj.onc.1207547; Xirodimas DP, 2004, CELL, V118, P83, DOI 10.1016/j.cell.2004.06.016; Yuan XJ, 2005, MOL CELL, V19, P77, DOI 10.1016/j.molcel.2005.05.023; Zhang JY, 2007, GENE DEV, V21, P2580, DOI 10.1101/gad.1569307; Zhang YP, 2001, CELL GROWTH DIFFER, V12, P175; Zhang YP, 1998, CELL, V92, P725, DOI 10.1016/S0092-8674(00)81401-4; Zhang YP, 2003, MOL CELL BIOL, V23, P8902, DOI 10.1128/MCB.23.23.8902-8912.2003	64	100	104	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 2	2008	27	44					5774	5784		10.1038/onc.2008.189	http://dx.doi.org/10.1038/onc.2008.189			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	355QC	18560357				2022-12-28	WOS:000259722400002
J	Song, LL; Peng, Y; Yun, J; Rizzo, P; Chaturvedi, V; Weijzen, S; Kast, WM; Stone, PJB; Santos, L; Loredo, A; Lendahl, U; Sonenshein, G; Osborne, B; Qin, JZ; Pannuti, A; Nickoloff, BJ; Miele, L				Song, L. L.; Peng, Y.; Yun, J.; Rizzo, P.; Chaturvedi, V.; Weijzen, S.; Kast, W. M.; Stone, P. J. B.; Santos, L.; Loredo, A.; Lendahl, U.; Sonenshein, G.; Osborne, B.; Qin, J. -Z; Pannuti, A.; Nickoloff, B. J.; Miele, L.			Notch-1 associates with IKK alpha and regulates IKK activity in cervical cancer cells	ONCOGENE			English	Article						Notch; NF-kappa B; apoptosis; IKK alpha	NF-KAPPA-B; KINASE-ALPHA; SIGNALING PATHWAY; EXPRESSION; ACTIVATION; APOPTOSIS; TRANSFORMATION; TRANSCRIPTION; DEREPRESSION; PROTEINS	Notch-1 inhibits apoptosis in some transformed cells through incompletely understood mechanisms. Notch-1 can increase nuclear factor-kappa B (NF-kappa B) activity through a variety of mechanisms. Overexpression of cleaved Notch-1 in T-cell acute lymphoblastic leukemia cells activates NF-kappa B via interaction with the I kappa B kinase (IKK) signalosome. Concomitant activation of the Notch and NF-kappa B pathways has been described in a large series of cervical cancer specimens. Here, we show that wild-type, spontaneously expressed Notch-1 stimulates NF-kappa B activity in CaSki cervical cancer cells by associating with the IKK signalosome through IKK alpha. A significant fraction of tumor necrosis factor (TNF)-alpha-stimulated I kappa B kinase activity in CaSki cells is Notch-1-dependent. In addition, Notch-1 is found in the nucleus in association with IKK alpha at IKK alpha-stimulated promoters and is required for association of IKK alpha with these promoters under basal and TNF-alpha-stimulated conditions. Notch-1-IKK alpha complexes are found in normal human keratinocytes as well, suggesting that IKK regulation is a physiological function of Notch-1. Both Notch-1 and IKK alpha knockdown sensitize CaSki cells to cisplatin-induced apoptosis to equivalent extents. Our data indicate that Notch-1 regulates NF-kappa B in cervical cancer cells at least in part via cytoplasmic and nuclear IKK-mediated pathways.	[Song, L. L.; Peng, Y.; Yun, J.; Rizzo, P.; Pannuti, A.; Miele, L.] Loyola Univ Chicago, Cardinal Bernardin Canc Ctr, Breast Canc Program, Maywood, IL USA; [Chaturvedi, V.; Qin, J. -Z; Nickoloff, B. J.] Loyola Univ Chicago, Cardinal Bernardin Canc Ctr, Dept Pathol, Maywood, IL USA; [Chaturvedi, V.; Qin, J. -Z; Nickoloff, B. J.] Loyola Univ Chicago, Cardinal Bernardin Canc Ctr, Skin Can Program, Maywood, IL USA; [Weijzen, S.] Loyola Univ Chicago, Cardinal Bernardin Canc Ctr, Canc Immunol Program, Maywood, IL USA; [Kast, W. M.; Stone, P. J. B.] Univ So Calif, Kenneth Norris Jr Comprehens Canc Ctr, Los Angeles, CA 90033 USA; [Santos, L.] Inst Sci & Technol Res San Luis Potosi, Dept Mol Biol, San Luis Potosi, Mexico; [Santos, L.] Mexican Inst Social Secur, Dept Pathol, Mexico City, DF, Mexico; [Lendahl, U.] Karolinska Inst, Dept Cell & Mol Biol, Stockholm, Sweden; [Sonenshein, G.] Boston Univ, Sch Med, Dept Biochem, Boston, MA 02118 USA; [Osborne, B.] Univ Massachusetts, Dept Vet & Anim Sci, Amherst, MA 01003 USA	Loyola University Chicago; Loyola University Chicago; Loyola University Chicago; Loyola University Chicago; University of Southern California; Instituto Potosino Investigacion Cientifica y Tecnologica; Instituto Mexicano del Seguro Social; Karolinska Institutet; Boston University; University of Massachusetts System; University of Massachusetts Amherst	Miele, L (corresponding author), Loyola Univ, Med Ctr, Cardinal Bernardin Canc Ctr, 2160 S 1st Ave,Bldg 112,Room 236, Maywood, IL 60153 USA.	lmiele@lumc.edu		Kast, W Martin/0000-0003-2321-3159; Miele, Lucio/0000-0002-5853-7287; rizzo, paola/0000-0001-7174-9674; Lendahl, Urban/0000-0001-9543-8141	NIH [RO1 CA084065, 1 PO1 AG025531]; V + Whittier Foundation; NATIONAL CANCER INSTITUTE [R01CA084065] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P01AG025531] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); V + Whittier Foundation; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	This work was supported by NIH grants RO1 CA084065 and 1 PO1 AG025531, and the V + Whittier Foundation (WMK). WMK holds the Walter A Richter Cancer Research Chair. We are grateful to Anna Bigas for critical reading of this manuscript and to Raphael Kopan for helpful discussion of our data and for the gift of the Notch-1/Renilla construct used for quantitative immunoprecipitation.	Aguilera C, 2004, P NATL ACAD SCI USA, V101, P16537, DOI 10.1073/pnas.0404429101; Anest V, 2003, NATURE, V423, P659, DOI 10.1038/nature01648; Bash J, 1999, EMBO J, V18, P2803, DOI 10.1093/emboj/18.10.2803; Daniel B, 1997, J GEN VIROL, V78, P1095, DOI 10.1099/0022-1317-78-5-1095; Fernandez-Majada V, 2007, P NATL ACAD SCI USA, V104, P276, DOI 10.1073/pnas.0606476104; Gray GE, 1999, AM J PATHOL, V154, P785, DOI 10.1016/S0002-9440(10)65325-4; Guan E, 1996, J EXP MED, V183, P2025, DOI 10.1084/jem.183.5.2025; Hoberg JE, 2006, MOL CELL BIOL, V26, P457, DOI 10.1128/MCB.26.2.457-471.2006; Hoberg JE, 2004, MOL CELL, V16, P245, DOI 10.1016/j.molcel.2004.10.010; Karin M, 2004, NAT REV DRUG DISCOV, V3, P17, DOI 10.1038/nrd1279; Kim SH, 2004, J CANCER RES CLIN, V130, P551, DOI 10.1007/s00432-004-0567-6; Lathion S, 2003, CANCER RES, V63, P8687; Lin A, 2003, SEMIN CANCER BIOL, V13, P107, DOI 10.1016/S1044-579X(02)00128-1; Manna SK, 2000, J IMMUNOL, V165, P4927, DOI 10.4049/jimmunol.165.9.4927; Miele L, 2006, CLIN CANCER RES, V12, P1074, DOI 10.1158/1078-0432.CCR-05-2570; Miele L, 2006, CURR MOL MED, V6, P905, DOI 10.2174/156652406779010830; Nair A, 2003, ONCOGENE, V22, P50, DOI 10.1038/sj.onc.1206043; Nickoloff BJ, 2003, ONCOGENE, V22, P6598, DOI 10.1038/sj.onc.1206758; Nickoloff BJ, 2002, CELL DEATH DIFFER, V9, P842, DOI 10.1038/sj.cdd.4401036; Osipo C, 2008, LAB INVEST, V88, P11, DOI 10.1038/labinvest.3700700; Perkins ND, 2007, NAT REV MOL CELL BIO, V8, P49, DOI 10.1038/nrm2083; PROCHASKA HJ, 1988, ANAL BIOCHEM, V169, P328, DOI 10.1016/0003-2697(88)90292-8; Prusty BK, 2005, FRONT BIOSCI-LANDMRK, V10, P1510, DOI 10.2741/1635; Ramdass B, 2007, GYNECOL ONCOL, V104, P352, DOI 10.1016/j.ygyno.2006.08.054; Rangarajan A, 2001, VIROLOGY, V286, P23, DOI 10.1006/viro.2001.0867; Shin HM, 2006, EMBO J, V25, P129, DOI 10.1038/sj.emboj.7600902; SKEHAN P, 1990, J NATL CANCER I, V82, P1107, DOI 10.1093/jnci/82.13.1107; Talora C, 2002, GENE DEV, V16, P2252, DOI 10.1101/gad.988902; Vacca A, 2006, EMBO J, V25, P1000, DOI 10.1038/sj.emboj.7600996; Venkatraman M, 2005, MOL CARCINOGEN, V44, P51, DOI 10.1002/mc.20116; Vilimas T, 2007, NAT MED, V13, P70, DOI 10.1038/nm1524; Vooijs M, 2004, J BIOL CHEM, V279, P50864, DOI 10.1074/jbc.M409430200; Wang JH, 2001, J IMMUNOL, V167, P289, DOI 10.4049/jimmunol.167.1.289; Wei LH, 2005, ONCOGENE, V24, P390, DOI 10.1038/sj.onc.1208192; Weijzen S, 2003, J CELL PHYSIOL, V194, P356, DOI 10.1002/jcp.10217; Weijzen S, 2002, NAT MED, V8, P979, DOI 10.1038/nm754; Woo SH, 2004, INT J CANCER, V112, P596, DOI 10.1002/ijc.20433; Yamamoto Y, 2003, NATURE, V423, P655, DOI 10.1038/nature01576; Yamamoto Y, 2001, J CLIN INVEST, V107, P135, DOI 10.1172/JCI11914; ZAGOURAS P, 1995, P NATL ACAD SCI USA, V92, P6414, DOI 10.1073/pnas.92.14.6414	40	103	114	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 2	2008	27	44					5833	5844		10.1038/onc.2008.190	http://dx.doi.org/10.1038/onc.2008.190			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	355QC	18560356				2022-12-28	WOS:000259722400007
J	Katsuno, Y; Hanyu, A; Kanda, H; Ishikawa, Y; Akiyama, F; Iwase, T; Ogata, E; Ehata, S; Miyazono, K; Imamura, T				Katsuno, Y.; Hanyu, A.; Kanda, H.; Ishikawa, Y.; Akiyama, F.; Iwase, T.; Ogata, E.; Ehata, S.; Miyazono, K.; Imamura, T.			Bone morphogenetic protein signaling enhances invasion and bone metastasis of breast cancer cells through Smad pathway	ONCOGENE			English	Article						TGF-beta; BMP; breast cancer; metastasis; invasion	TUMOR-SUPPRESSOR; BETA; GROWTH; EXPRESSION; OVEREXPRESSION; PROGRESSION; TRANSITION; MEMBRANE; MELANOMA; SKI	Transforming growth factor (TGF)-beta is known to promote tumor invasion and metastasis. Although bone morphogenetic proteins ( BMPs), members of the TGF-beta family, are expressed in a variety of human carcinoma cell lines, their roles in tumor progression have not been fully clarified. In this study, we sought to determine the roles of BMPs in the progression of breast cancer bone metastasis using human breast cancer samples and a mouse xenograft model. Immunohistochemical analysis of samples from breast cancer patients as well as a mouse xenograft model of MDA-231-D, highly metastatic human breast cancer cells, revealed phospho-Smad2 and phospho-Smad1/5/8 staining in the nuclei of cancer cells in primary tumor and/or bone metastasis. Using a functional in vivo bioluminescence imaging system, we showed that TGF-beta- and BMP-induced transcriptional pathways are active in bone metastatic lesions in vivo. In addition, both TGF-beta 3 and BMP-2 promoted the motility and invasiveness of the MDA-231-D cells in vitro. Moreover, expression of dominant-negative receptors for TGF-beta and/or BMPs in the MDA-231-D cells inhibited invasiveness in vitro and bone metastasis in the xenograft model. These results suggest that BMPs as well as TGF-beta promote invasion and bone metastasis of breast cancer.	[Katsuno, Y.; Hanyu, A.; Miyazono, K.; Imamura, T.] Japanese Fdn Canc Res, Inst Canc, Dept Biochem, Koto Ku, Tokyo 1358550, Japan; [Katsuno, Y.; Ehata, S.; Miyazono, K.] Univ Tokyo, Grad Sch Med, Dept Mol Pathol, Bunkyo Ku, Tokyo, Japan; [Kanda, H.; Ishikawa, Y.; Akiyama, F.] Japanese Fdn Canc Res, Inst Canc, Dept Pathol, Koto Ku, Tokyo 1358550, Japan; [Iwase, T.] Canc Inst Hosp, Dept Breast Oncol, Koto Ku, Tokyo, Japan; [Ogata, E.] Japanese Fdn Canc Res, Canc Inst Hosp, Koto Ku, Tokyo 1358550, Japan	Japanese Foundation for Cancer Research; University of Tokyo; Japanese Foundation for Cancer Research; Japanese Foundation for Cancer Research	Imamura, T (corresponding author), Japanese Fdn Canc Res, Inst Canc, Dept Biochem, Koto Ku, 3-10-6 Ariake, Tokyo 1358550, Japan.	timamura-ind@umin.ac.jp		Ehata, Shogo/0000-0002-6740-9391	Ministry of Education, Culture, Sports, Science and Technology of Japan; KAKENHI	Ministry of Education, Culture, Sports, Science and Technology of Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); KAKENHI(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	We thank Dr H Miyoshi (RIKEN, Tsukuba) for the lentivirus system, and K Nomura, E Kobayashi, N Kaneniwa and Y Yuuki (The Cancer Institute) for technical assistance. This research was supported by KAKENHI (Grants-in-Aid for Scientific Research) from the Ministry of Education, Culture, Sports, Science and Technology of Japan. TI was supported by the Naito Foundation.	Arwert E, 2007, CANCER RES, V67, P7335, DOI 10.1158/0008-5472.CAN-07-0077; Azuma H, 2005, JNCI-J NATL CANCER I, V97, P1734, DOI 10.1093/jnci/dji399; Bailey JM, 2007, J CELL BIOCHEM, V102, P829, DOI 10.1002/jcb.21509; Bleuming SA, 2007, CANCER RES, V67, P8149, DOI 10.1158/0008-5472.CAN-06-4659; Buijs JT, 2007, CANCER RES, V67, P8742, DOI 10.1158/0008-5472.CAN-06-2490; Deckers M, 2006, CANCER RES, V66, P2202, DOI 10.1158/0008-5472.CAN-05-3560; Derynck R, 2001, NAT GENET, V29, P117, DOI 10.1038/ng1001-117; Ehata S, 2007, CANCER SCI, V98, P127, DOI 10.1111/j.1349-7006.2006.00357.x; Feeley BT, 2006, J BONE MINER RES, V21, P1571, DOI 10.1359/JBMR.060706; Feeley BT, 2006, BONE, V38, P154, DOI 10.1016/j.bone.2005.07.015; Feng XH, 2005, ANNU REV CELL DEV BI, V21, P659, DOI 10.1146/annurev.cellbio.21.022404.142018; Fukuchi M, 2004, INT J CANCER, V108, P818, DOI 10.1002/ijc.11651; Grijelmo C, 2007, CELL SIGNAL, V19, P1722, DOI 10.1016/j.cellsig.2007.03.008; Haramis APG, 2004, SCIENCE, V303, P1684, DOI 10.1126/science.1093587; HATAKEYAMA S, 1993, BIOCHEM BIOPH RES CO, V190, P695, DOI 10.1006/bbrc.1993.1105; He J, 2003, J BIOL CHEM, V278, P30540, DOI 10.1074/jbc.M304016200; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; Helms MW, 2005, J PATHOL, V206, P366, DOI 10.1002/path.1785; Hogan BLM, 1996, CURR OPIN GENET DEV, V6, P432, DOI 10.1016/S0959-437X(96)80064-5; Howe JR, 2001, NAT GENET, V28, P184, DOI 10.1038/88919; Javelaud D, 2007, CANCER RES, V67, P2317, DOI 10.1158/0008-5472.CAN-06-3950; Kakonen SM, 2002, J BIOL CHEM, V277, P24571, DOI 10.1074/jbc.M202561200; Kang YB, 2005, P NATL ACAD SCI USA, V102, P13909, DOI 10.1073/pnas.0506517102; Kang YB, 2003, CANCER CELL, V3, P537, DOI 10.1016/S1535-6108(03)00132-6; Katagiri Takenobu, 2008, P121; Kim IY, 2000, CANCER RES, V60, P2840; Langenfeld EM, 2003, CARCINOGENESIS, V24, P1445, DOI 10.1093/carcin/bgg100; Miyazawa K, 2002, GENES CELLS, V7, P1191, DOI 10.1046/j.1365-2443.2002.00599.x; Miyazono K, 2005, CYTOKINE GROWTH F R, V16, P251, DOI 10.1016/j.cytogfr.2005.01.009; Piccirillo SGM, 2006, NATURE, V444, P761, DOI 10.1038/nature05349; Reddi AH, 1998, NAT BIOTECHNOL, V16, P247, DOI 10.1038/nbt0398-247; Rothhammer T, 2005, CANCER RES, V65, P448; Shi YG, 2003, CELL, V113, P685, DOI 10.1016/S0092-8674(03)00432-X; Sneddon JB, 2006, P NATL ACAD SCI USA, V103, P14842, DOI 10.1073/pnas.0606857103; Tang BW, 2003, J CLIN INVEST, V112, P1116, DOI 10.1172/JCI200318899; ten Dijke P, 2003, MOL CELL ENDOCRINOL, V211, P105, DOI 10.1016/j.mce.2003.09.016; Waite KA, 2003, NAT REV GENET, V4, P763, DOI 10.1038/nrg1178; Wakefield LM, 2002, CURR OPIN GENET DEV, V12, P22, DOI 10.1016/S0959-437X(01)00259-3; Wozney JM, 1998, CLIN ORTHOP RELAT R, P26; Yang SX, 2005, CANCER RES, V65, P5769, DOI 10.1158/0008-5472.CAN-05-0289; Yin JJ, 1999, J CLIN INVEST, V103, P197, DOI 10.1172/JCI3523; Yui PB, 2008, NAT CHEM BIOL, V4, P33, DOI 10.1038/nchembio.2007.54	42	181	193	1	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT	2008	27	49					6322	6333		10.1038/onc.2008.232	http://dx.doi.org/10.1038/onc.2008.232			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	363JK	18663362				2022-12-28	WOS:000260263400002
J	Kitagawa, M; Aonuma, M; Lee, SH; Fukutake, S; McCormick, F				Kitagawa, M.; Aonuma, M.; Lee, S. H.; Fukutake, S.; McCormick, F.			E2F-1 transcriptional activity is a critical determinant of Mdm2 antagonist-induced apoptosis in human tumor cell lines	ONCOGENE			English	Article						E2F-1; p53; Mdm2 antagonist; apoptosis; Nutlin-3	S-PHASE ENTRY; P53 PATHWAY; P53-DEPENDENT APOPTOSIS; P73; ACTIVATION; EXPRESSION; INDUCTION; P14(ARF); NUTLIN-3; LEADS	Nutlin-3 is a selective inhibitor of the p53-Mdm2 interaction, and inhibits growth in most tumor cells with wild-type p53. However, it only induces apoptosis in subsets of tumor cells. We report that the apoptotic response induced by Nutlin-3 correlates with its antitumor effects in xenograft models in athymic mice. We have investigated signals that sensitize cells to undergo apoptosis induced by Nutlin-3. We demonstrate that adenovirus E1A increases Nutlin-3-induced apoptosis through pRb inhibition in mouse embryonic fibroblast cells in a p53-dependent manner. Consistent with this, pRb depletion by siRNA transfection with Nutlin-3 synergistically increases apoptosis in HCT116 human colon cancer cells, which are insensitive to induction of apoptosis by Nutlin-3 alone. As pRb is a key negative regulator of E2F, we asked whether E2F transcriptional activity determines the apoptotic response of cancer cells to Nutlin-3. We demonstrate that transcriptional activity of E2F correlates with the apoptotic response to Nutlin-3 in various tumor cells and depletion of E2F-1 suppresses Nutlin-3-induced apoptosis in cells possessing high transcriptional activity of E2F, including retinoblastoma cells harboring mutated Rb with wild-type p53. Furthermore, we report that expression of the p53 homologue p73, a target of E2F-1, is markedly increased by Nutlin-3 in Rb-mutated tumor cells harboring wild-type p53. Depletion of p73 by siRNA transfection suppresses Nutlin-3-induced apoptosis in these cells. Taken together, our results demonstrate that E2F-1 transcriptional activity is a critical determinant of Mdm2 antagonist-induced apoptosis and p73 is important for E2F-1-mediated apoptosis induced by Nutlin-3, especially in tumor cells with mutated Rb. Furthermore, our results suggest that tumor cells, including Rb mutated cells, which harbor wildtype p53 and high E2F transcriptional activity, could be a good target for Mdm2 antagonist therapy.	[Kitagawa, M.; Lee, S. H.; McCormick, F.] Univ Calif San Francisco, Helen Diller Family Comprehens Canc Ctr, San Francisco, CA 94115 USA; [Kitagawa, M.; Lee, S. H.; McCormick, F.] Univ Calif San Francisco, Canc Res Inst, San Francisco, CA 94115 USA; [Kitagawa, M.; Aonuma, M.; Fukutake, S.] Daiichi Sankyo Co Ltd, Kasai R&D Ctr, Tokyo, Japan	University of California System; University of California San Francisco; UCSF Medical Center; UCSF Helen Diller Family Comprehensive Cancer Center; University of California System; University of California San Francisco; Daiichi Sankyo Company Limited	McCormick, F (corresponding author), Univ Calif San Francisco, Helen Diller Family Comprehens Canc Ctr, 2340 Sutter St N315,UCSF Box 0128, San Francisco, CA 94115 USA.	mccormick@cc.ucsf.edu						Ambrosini G, 2007, ONCOGENE, V26, P3473, DOI 10.1038/sj.onc.1210136; Bates S, 1998, NATURE, V395, P124, DOI 10.1038/25867; BROCKMANN D, 1995, CURR TOP MICROBIOL, V199, P81; Chen LH, 1999, MOL MED, V5, P21, DOI 10.1007/BF03402136; Coll-Mulet L, 2006, BLOOD, V107, P4109, DOI 10.1182/blood-2005-08-3273; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; Holmberg C, 1998, ONCOGENE, V17, P143, DOI 10.1038/sj.onc.1201915; Irwin M, 2000, NATURE, V407, P645, DOI 10.1038/35036614; Kojima K, 2005, BLOOD, V106, P3150, DOI 10.1182/blood-2005-02-0553; Lau LMS, 2008, ONCOGENE, V27, P997, DOI 10.1038/sj.onc.1210707; Laurie NA, 2006, NATURE, V444, P61, DOI 10.1038/nature05194; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; Nicholson SA, 2001, CANCER RES, V61, P5636; Patton JT, 2006, CANCER RES, V66, P3169, DOI 10.1158/0008-5472.CAN-05-3832; Putzer BM, 2000, CELL DEATH DIFFER, V7, P177, DOI 10.1038/sj.cdd.4400618; QIN XQ, 1994, P NATL ACAD SCI USA, V91, P10918, DOI 10.1073/pnas.91.23.10918; Samuelson AV, 1997, P NATL ACAD SCI USA, V94, P12094, DOI 10.1073/pnas.94.22.12094; Secchiero P, 2006, BLOOD, V107, P4122, DOI 10.1182/blood-2005-11-4465; Semizarov D, 2004, NUCLEIC ACIDS RES, V32, P3836, DOI 10.1093/nar/gkh714; SHAN B, 1994, MOL CELL BIOL, V14, P8166, DOI 10.1128/MCB.14.12.8166; Stanelle J, 2006, TRENDS MOL MED, V12, P177, DOI 10.1016/j.molmed.2006.02.002; Stiewe T, 2000, NAT GENET, V26, P464, DOI 10.1038/82617; Stuhmer T, 2005, BLOOD, V106, P3609, DOI 10.1182/blood-2005-04-1489; Tovar C, 2006, P NATL ACAD SCI USA, V103, P1888, DOI 10.1073/pnas.0507493103; Van Maerken T, 2006, CANCER RES, V66, P9646, DOI 10.1158/0008-5472.CAN-06-0792; Vassilev LT, 2004, SCIENCE, V303, P844, DOI 10.1126/science.1092472; Vousden KH, 2000, CELL, V103, P691, DOI 10.1016/S0092-8674(00)00171-9; Vousden KH, 2002, NAT REV CANCER, V2, P594, DOI 10.1038/nrc864; Wade M, 2006, J BIOL CHEM, V281, P33036, DOI 10.1074/jbc.M605405200; Zindy F, 1998, GENE DEV, V12, P2424, DOI 10.1101/gad.12.15.2424	31	73	74	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 11	2008	27	40					5303	5314		10.1038/onc.2008.164	http://dx.doi.org/10.1038/onc.2008.164			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	346UW	18521084				2022-12-28	WOS:000259096100003
J	Frechet, M; Warrick, E; Vioux, C; Chevallier, O; Spatz, A; Benhamou, S; Sarasin, A; Bernerd, F; Magnaldo, T				Frechet, M.; Warrick, E.; Vioux, C.; Chevallier, O.; Spatz, A.; Benhamou, S.; Sarasin, A.; Bernerd, F.; Magnaldo, T.			Overexpression of matrix metalloproteinase 1 in dermal fibroblasts from DNA repair-deficient/cancer-prone xeroderma pigmentosum group C patients	ONCOGENE			English	Article						xeroderma pigmentosum; skin; cancer; MMP1; AP-1; ROS	SQUAMOUS-CELL CARCINOMA; MATRIX METALLOPROTEINASES; GENE-EXPRESSION; SUPEROXIDE-DISMUTASE; HYDROGEN-PEROXIDE; COLLAGENASE GENE; MOLECULAR-BASIS; SKIN; CANCER; INDUCTION	Xeroderma pigmentosum (XP) is a rare, recessively inherited genetic disease characterized by skin cancer proneness and premature aging in photoexposed area. The disease results from defective nucleotide excision repair of ultraviolet (UV)-induced DNA lesions. Reconstruction of group C (XP-C) skin in vitro previously suggested that patients' dermal fibroblasts might be involved in promoting skin cancer development, as they elicited microinvasions of both control and XP-C keratinocytes within dermal equivalents. Here we show that in the absence of UV exposure XP-C fibroblasts exhibit aged-like features such as an elongated and dendritic shape. We analysed the repertoire of expression of matrix metalloproteinases ( MMPs) involved in skin aging and cancer. All XP-C fibroblasts tested in this study overexpressed specifically and significantly MMP1. MMP1 expression was also found increased in the dermis of XP-C skin sections suggesting the active contribution of XP-C mesenchymal cells to skin aging and exacerbated carcinogenesis. Increased MMP1 expression in cultured XP-C fibroblasts resulted from MMP1 mRNA accumulation and enhanced transcriptional activity of the MMP1 gene promoter. Deletion analysis revealed the essential role of AP-1 activation in constitutive MMP1 overexpression in XP-C primary fibroblasts. In parallel, levels of reactive oxygen species and FOSB DNA-binding activity were found increased in XP-C fibroblasts. Altogether, these observations suggest that beyond its role in nucleotide excision repair the XPC protein may be important in cell metabolism and fate in the absence of UV.	[Frechet, M.; Warrick, E.; Chevallier, O.; Spatz, A.; Benhamou, S.; Sarasin, A.; Magnaldo, T.] Inst Gustave Roussy, CNRS, FRE 2939, F-94805 Villejuif, France; [Warrick, E.; Vioux, C.; Bernerd, F.] LOreal, Life Sci Adv Res, Ctr C Zviak, F-92583 Clichy, France	Centre National de la Recherche Scientifique (CNRS); UNICANCER; Gustave Roussy; L'Oreal Group	Magnaldo, T (corresponding author), Inst Gustave Roussy, CNRS, FRE 2939, Rue Camille Desmoulins, F-94805 Villejuif, France.	magnaldo@igr.fr	Benhamou, Simone/K-6554-2015; Benhamou, Simone/ABD-2590-2020; SPATZ, ALAN/B-8645-2009	SPATZ, ALAN/0000-0003-3020-1420; BENHAMOU, Simone/0000-0001-5853-8047	Association pour la Recherche sur le Cancer [3590]; Fondation de l'Avenir, the Societe Francaise de Dermatologie, the Association Francaise contre les Myopathies; Les enfants de la Lune	Association pour la Recherche sur le Cancer(Fondation ARC pour la Recherche sur le CancerAustralian Research Council); Fondation de l'Avenir, the Societe Francaise de Dermatologie, the Association Francaise contre les Myopathies(Association Francaise contre les Myopathies); Les enfants de la Lune	Dr Asselineau and Dr J Leclaire are gratefully acknowledged for continuous support and encouragements. We are indebted to V Marty, C Pierrard and Dr C Marionnet for their expert help. We are also grateful to Dr A Jalil for confocal microscopy. We thank Professor P Herrlich and Professor CE Brinckerhoff for DNA reporter constructs. Many thanks to F Duvigneau for editing English usage in the article. TM gratefully acknowledges fundings from the Association pour la Recherche sur le Cancer (no. 3590), the Fondation de l'Avenir, the Societe Francaise de Dermatologie, the Association Francaise contre les Myopathies. AS thanks the association 'Les enfants de la Lune' for its support.	Airola K, 2001, J INVEST DERMATOL, V116, P85, DOI 10.1046/j.1523-1747.2001.00223.x; ANGEL P, 1987, MOL CELL BIOL, V7, P2256, DOI 10.1128/MCB.7.6.2256; Arnaudeau-Begard C, 2003, HUM GENE THER, V14, P983, DOI 10.1089/104303403766682241; ASSELINEAU D, 1985, EXP CELL RES, V159, P536, DOI 10.1016/S0014-4827(85)80027-6; Benbow U, 1999, J BIOL CHEM, V274, P25371, DOI 10.1074/jbc.274.36.25371; Bernerd F, 2005, PHOTOCHEM PHOTOBIOL, V81, P19, DOI 10.1562/2004-07-29-IR-250.1; Bernerd F, 1997, DEV BIOL, V183, P123, DOI 10.1006/dbio.1996.8465; Bernerd F, 2001, P NATL ACAD SCI USA, V98, P7817, DOI 10.1073/pnas.141221998; BOOTSMA D, 1995, PHILOS T ROY SOC B, V347, P75, DOI 10.1098/rstb.1995.0012; Brenneisen P, 1997, FREE RADICAL BIO MED, V22, P515, DOI 10.1016/S0891-5849(96)00404-2; Brinckerhoff CE, 2000, CLIN CANCER RES, V6, P4823; Cat B, 2006, J CELL SCI, V119, P2727, DOI 10.1242/jcs.03011; Chung JH, 2001, J INVEST DERMATOL, V117, P1218, DOI 10.1046/j.0022-202x.2001.01544.x; Chung JH, 2000, J INVEST DERMATOL, V115, P177, DOI 10.1046/j.1523-1747.2000.00009.x; COLLIER IE, 1988, J BIOL CHEM, V263, P10711; Comoglio PM, 2005, NAT MED, V11, P1156, DOI 10.1038/nm1105-1156; D'Errico M, 2006, EMBO J, V25, P4305, DOI 10.1038/sj.emboj.7601277; Del Rio M, 2002, HUM GENE THER, V13, P959, DOI 10.1089/10430340252939069; DePinho RA, 2000, NATURE, V408, P248, DOI 10.1038/35041694; Egeblad M, 2002, NAT REV CANCER, V2, P161, DOI 10.1038/nrc745; Fisher GJ, 1996, NATURE, V379, P335, DOI 10.1038/379335a0; Fligiel SEG, 2003, J INVEST DERMATOL, V120, P842, DOI 10.1046/j.1523-1747.2003.12148.x; Fratelli M, 2005, P NATL ACAD SCI USA, V102, P13998, DOI 10.1073/pnas.0504398102; Frechet Mathilde, 2006, Methods Mol Biol, V314, P9; FRISCH SM, 1990, ONCOGENE, V5, P75; GRAY ST, 1992, AM J PATHOL, V141, P301; Inoue D, 2004, J BIOL CHEM, V279, P49795, DOI 10.1074/jbc.M404096200; Jorissen HJMM, 2007, BIOCHEMISTRY-US, V46, P8360, DOI 10.1021/bi700494v; Karin M, 1997, CURR OPIN CELL BIOL, V9, P240, DOI 10.1016/S0955-0674(97)80068-3; Kerkela E, 2003, EXP DERMATOL, V12, P109, DOI 10.1034/j.1600-0625.2003.120201.x; Kerkela E, 2002, J PATHOL, V198, P258, DOI 10.1002/path.1198; Khorramizadeh MR, 1999, MOL CELL BIOCHEM, V194, P99, DOI 10.1023/A:1006909021352; Kraemer KH, 1997, P NATL ACAD SCI USA, V94, P11, DOI 10.1073/pnas.94.1.11; Milde-Langosch K, 2004, BREAST CANCER RES TR, V86, P139, DOI 10.1023/B:BREA.0000032982.49024.71; Monhian N, 2005, ARCH FACIAL PLAST S, V7, P238, DOI 10.1001/archfaci.7.4.238; Mueller MM, 2004, NAT REV CANCER, V4, P839, DOI 10.1038/nrc1477; NISHIGORI C, 1989, J INVEST DERMATOL, V93, P506, DOI 10.1111/1523-1747.ep12284060; Otto AI, 1999, CANCER RES, V59, P1212; Radisky DC, 2005, NATURE, V436, P123, DOI 10.1038/nature03688; Rhie GE, 2001, J INVEST DERMATOL, V117, P1212, DOI 10.1046/j.0022-202x.2001.01469.x; Rosenfeldt H, 1998, MOL CELL BIOL, V18, P2659, DOI 10.1128/MCB.18.5.2659; Rutter JL, 1997, J CELL BIOCHEM, V66, P322, DOI 10.1002/(SICI)1097-4644(19970901)66:3<322::AID-JCB5>3.3.CO;2-D; Shimizu Y, 2003, EMBO J, V22, P164, DOI 10.1093/emboj/cdg016; Shimokawa N, 2005, J CELL PHYSIOL, V205, P77, DOI 10.1002/jcp.20369; Shin MH, 2005, J INVEST DERMATOL, V125, P221, DOI 10.1111/j.0022-202X.2005.23823.x; Stamenkovic I, 2003, J PATHOL, V200, P448, DOI 10.1002/path.1400; STEIN B, 1989, MOL CELL BIOL, V9, P5169, DOI 10.1128/MCB.9.11.5169; Sternlicht MD, 2001, ANNU REV CELL DEV BI, V17, P463, DOI 10.1146/annurev.cellbio.17.1.463; Tsukifuji R, 1999, BRIT J CANCER, V80, P1087, DOI 10.1038/sj.bjc.6690468; Vandesompele J, 2002, GENOME BIOL, V3, DOI 10.1186/gb-2002-3-7-research0034; Varani J, 2004, J INVEST DERMATOL, V122, P1471, DOI 10.1111/j.0022-202X.2004.22614.x; Vu TH, 2000, GENE DEV, V14, P2123, DOI 10.1101/gad.815400; VUILLAUME M, 1992, CARCINOGENESIS, V13, P321, DOI 10.1093/carcin/13.3.321; Wenk J, 1999, J BIOL CHEM, V274, P25869, DOI 10.1074/jbc.274.36.25869; White LA, 1995, MATRIX BIOL, V14, P715, DOI 10.1016/S0945-053X(05)80014-9	55	15	15	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP	2008	27	39					5223	5232		10.1038/onc.2008.153	http://dx.doi.org/10.1038/onc.2008.153			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	344GO	18469853				2022-12-28	WOS:000258915100006
J	Wei, JS; Song, YK; Durinck, S; Chen, QR; Cheuk, ATC; Tsang, P; Zhang, Q; Thiele, CJ; Slack, A; Shohet, J; Khan, J				Wei, J. S.; Song, Y. K.; Durinck, S.; Chen, Q-R; Cheuk, A. T. C.; Tsang, P.; Zhang, Q.; Thiele, C. J.; Slack, A.; Shohet, J.; Khan, J.			The MYCN oncogene is a direct target of miR-34a	ONCOGENE			English	Article						microRNA; miR-34a; MYCN; 1p36 LOH; neuroblastoma; translation regulation	TUMOR-SUPPRESSOR GENE; HUMAN NEUROBLASTOMA-CELLS; N-MYC; EXPRESSION PROFILES; FREQUENT DELETIONS; CONSENSUS REGION; TRANSGENIC MICE; NERVOUS-SYSTEM; CHROMOSOME 1P; APOPTOSIS	Loss of 1p36 heterozygosity commonly occurs with MYCN amplification in neuroblastoma tumors, and both are associated with an aggressive phenotype. Database searches identified five microRNAs that map to the commonly deleted region of 1p36 and we hypothesized that the loss of one or more of these microRNAs contributes to the malignant phenotype of MYCN-amplified tumors. By bioinformatic analysis, we identified that three out of the five microRNAs target MYCN and of these miR-34a caused the most significant suppression of cell growth through increased apoptosis and decreased DNA synthesis in neuroblastoma cell lines with MYCN amplification. Quantitative RT-PCR showed that neuroblastoma tumors with 1p36 loss expressed lower level of miR-34a than those with normal copies of 1p36. Furthermore, we demonstrated that MYCN is a direct target of miR-34a. Finally, using a series of mRNA expression pro. ling experiments, we identified other potential direct targets of miR-34a, and pathway analysis demonstrated that miR- 34a suppresses cell-cycle genes and induces several neural-related genes. This study demonstrates one important regulatory role of miR-34a in cell growth and MYCN suppression in neuroblastoma.	[Wei, J. S.; Song, Y. K.; Durinck, S.; Chen, Q-R; Cheuk, A. T. C.; Tsang, P.; Zhang, Q.; Khan, J.] Natl Canc Inst, Oncogenom Sect, Pediat Oncol Branch, Adv Technol Ctr, Gaithersburg, MD 20892 USA; [Chen, Q-R] NCI, Adv Biomed Comp Ctr, SAIC Frederick Inc, Frederick, MD 21701 USA; [Thiele, C. J.] Natl Canc Inst, Cell & Mol Biol Sect, Pediat Oncol Branch, Bethesda, MD USA; [Slack, A.; Shohet, J.] Baylor Coll Med, Dept Pediat, Hematol Oncol Sect, Houston, TX 77030 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Baylor College of Medicine	Khan, J (corresponding author), Natl Canc Inst, Oncogenom Sect, Pediat Oncol Branch, Adv Technol Ctr, Room 134E,8717 Grovemont Circle, Gaithersburg, MD 20892 USA.	khanjav@mail.nih.gov	Khan, Javed/P-9157-2014		Intramural Research Program of the National Institutes of Health, National Cancer Institute, Center for Cancer Research; NATIONAL CANCER INSTITUTE [Z01BC010788, ZIASC010366, ZIABC011001, ZIABC011002] Funding Source: NIH RePORTER	Intramural Research Program of the National Institutes of Health, National Cancer Institute, Center for Cancer Research(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Dr Joon-Yong Chung and Xinyu Wen, MS for their excellent technical support. We also thank Dr John Maris, Dr Wendy London (Children's Oncology Group, Philadelphia, PA, USA) and Dr Steven Qualman (Cooperative Human Tissue Network, Columbus, OH, USA) for the NB tumor samples, and for invaluable discussion of this study with Dr John Maris and his group. This study is supported by the Intramural Research Program of the National Institutes of Health, National Cancer Institute, Center for Cancer Research. The content of this publication does not necessarily reflect the views or policies of the Department of Health and Human Services, nor does mention of trade names, commercial products or organizations imply endorsement by the US government.	Abel F, 2004, INT J ONCOL, V25, P1297; Ambros V, 2004, NATURE, V431, P350, DOI 10.1038/nature02871; Attiyeh EF, 2005, NEW ENGL J MED, V353, P2243, DOI 10.1056/NEJMoa052399; BADER SA, 1991, CELL GROWTH DIFFER, V2, P245; Bagchi A, 2007, CELL, V128, P459, DOI 10.1016/j.cell.2006.11.052; Barbashina V, 2005, CLIN CANCER RES, V11, P1119; Bartel B, 2003, PLANT PHYSIOL, V132, P709, DOI 10.1104/pp.103.023630; Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5; Bieche I, 1998, ONCOL REP, V5, P267; BLACKWELL TK, 1993, MOL CELL BIOL, V13, P5216, DOI 10.1128/MCB.13.9.5216; BRODEUR GM, 1977, CANCER-AM CANCER SOC, V40, P2256, DOI 10.1002/1097-0142(197711)40:5<2256::AID-CNCR2820400536>3.0.CO;2-1; Brodeur GM, 2003, NAT REV CANCER, V3, P203, DOI 10.1038/nrc1014; Calin GA, 2002, P NATL ACAD SCI USA, V99, P15524, DOI 10.1073/pnas.242606799; Chang TC, 2007, MOL CELL, V26, P745, DOI 10.1016/j.molcel.2007.05.010; Chen QR, 2004, BMC GENOMICS, V5, DOI 10.1186/1471-2164-5-70; Cheung TH, 2005, GYNECOL ONCOL, V96, P510, DOI 10.1016/j.ygyno.2004.10.035; Cimmino A, 2005, P NATL ACAD SCI USA, V102, P13944, DOI 10.1073/pnas.0506654102; Costinean S, 2006, P NATL ACAD SCI USA, V103, P7024, DOI 10.1073/pnas.0602266103; Dennis G, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-9-r60; Durinck S, 2005, BIOINFORMATICS, V21, P3439, DOI 10.1093/bioinformatics/bti525; Eggert A, 2002, EUR J CANCER, V38, P92, DOI 10.1016/S0959-8049(01)00347-1; Ejeskar K, 2005, BMC CANCER, V5, DOI 10.1186/1471-2407-5-161; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; FONG CT, 1989, P NATL ACAD SCI USA, V86, P3753, DOI 10.1073/pnas.86.10.3753; Guo C, 1999, ONCOGENE, V18, P4948, DOI 10.1038/sj.onc.1202887; HASHIMOTO N, 1995, GENE CHROMOSOME CANC, V14, P295, DOI 10.1002/gcc.2870140408; He HL, 2005, P NATL ACAD SCI USA, V102, P19075, DOI 10.1073/pnas.0509603102; He L, 2007, NATURE, V447, P1130, DOI 10.1038/nature05939; Henrich KO, 2006, CLIN CANCER RES, V12, P131, DOI 10.1158/1078-0432.CCR-05-1431; Hogarty MD, 2000, MED PEDIATR ONCOL, V35, P512, DOI 10.1002/1096-911X(20001201)35:6<512::AID-MPO2>3.0.CO;2-D; HOSOI G, 1994, CANCER, V73, P3087, DOI 10.1002/1097-0142(19940615)73:12<3087::AID-CNCR2820731230>3.0.CO;2-9; Iorio MV, 2005, CANCER RES, V65, P7065, DOI 10.1158/0008-5472.CAN-05-1783; Kang JH, 2006, BIOCHEM BIOPH RES CO, V351, P192, DOI 10.1016/j.bbrc.2006.10.020; KOHL NE, 1984, SCIENCE, V226, P1335, DOI 10.1126/science.6505694; Kong Xiao-Tang, 1999, Neoplasia (New York), V1, P80, DOI 10.1038/sj.neo.7900010; LAHTI JM, 1994, NAT GENET, V7, P370, DOI 10.1038/ng0794-370; Li C, 2001, P NATL ACAD SCI USA, V98, P31, DOI 10.1073/pnas.011404098; Lim LP, 2005, NATURE, V433, P769, DOI 10.1038/nature03315; Lu J, 2005, NATURE, V435, P834, DOI 10.1038/nature03702; Maris JM, 1997, EUR J CANCER, V33, P1991, DOI 10.1016/S0959-8049(97)00279-7; Maris JM, 2000, J CLIN ONCOL, V18, P1888, DOI 10.1200/JCO.2000.18.9.1888; Maris JM, 2001, MED PEDIATR ONCOL, V36, P32, DOI 10.1002/1096-911X(20010101)36:1<32::AID-MPO1009>3.0.CO;2-0; Mathysen D, 2004, EUR J CANCER, V40, P1255, DOI 10.1016/j.ejca.2004.01.013; Mori N, 1998, BLOOD, V92, P3405, DOI 10.1182/blood.V92.9.3405.421k44_3405_3409; Mosse YP, 2005, GENE CHROMOSOME CANC, V43, P390, DOI 10.1002/gcc.20198; Nara K, 2007, INT J ONCOL, V30, P1189; Nesbit CE, 1999, ONCOGENE, V18, P3004, DOI 10.1038/sj.onc.1202746; Ozaki T, 2005, CANCER LETT, V228, P29, DOI 10.1016/j.canlet.2004.12.050; Poetsch M, 1998, CANCER GENET CYTOGEN, V104, P146, DOI 10.1016/S0165-4608(97)00471-8; Raver-Shapira N, 2007, MOL CELL, V26, P731, DOI 10.1016/j.molcel.2007.05.017; SCHWAB M, 1988, P NATL ACAD SCI USA, V85, P9585, DOI 10.1073/pnas.85.24.9585; Slack A, 2005, P NATL ACAD SCI USA, V102, P731, DOI 10.1073/pnas.0405495102; Strieder V, 2003, J BIOL CHEM, V278, P2983, DOI 10.1074/jbc.M207596200; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Thompson PM, 2003, ONCOGENE, V22, P1002, DOI 10.1038/sj.onc.1206211; Valentijn LJ, 2005, CANCER RES, V65, P3136, DOI 10.1158/0008-5472.CAN-04-2469; VOGAN K, 1993, CANCER RES, V53, P5269; Wei J.S., 2002, DNA MICROARRAYS MOL, P110; Wei JS, 2005, ONCOGENE, V24, P7976, DOI 10.1038/sj.onc.1208947; Weiss WA, 1997, EMBO J, V16, P2985, DOI 10.1093/emboj/16.11.2985; Welch C, 2007, ONCOGENE, V26, P5017, DOI 10.1038/sj.onc.1210293; White PS, 2005, ONCOGENE, V24, P2684, DOI 10.1038/sj.onc.1208306; WHITE PS, 1995, P NATL ACAD SCI USA, V92, P5520, DOI 10.1073/pnas.92.12.5520; WOO CM, 2007, PEDIAT BLOOD CANC, V50, P208; ZIMMERMAN KA, 1986, NATURE, V319, P780, DOI 10.1038/319780a0; Zindy F, 2006, P NATL ACAD SCI USA, V103, P11579, DOI 10.1073/pnas.0604727103	66	222	231	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP	2008	27	39					5204	5213		10.1038/onc.2008.154	http://dx.doi.org/10.1038/onc.2008.154			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	344GO	18504438	Green Accepted			2022-12-28	WOS:000258915100004
J	Liu, P; Kao, TP; Huang, H				Liu, P.; Kao, T. P.; Huang, H.			CDK1 promotes cell proliferation and survival via phosphorylation and inhibition of FOXO1 transcription factor	ONCOGENE			English	Article						FOXO1; CDK1; phosphorylation; cell cycle; apoptosis; prostate cancer	PROSTATE-CANCER CELLS; PROTEIN-KINASE-B; CYCLIN-DEPENDENT KINASES; FACTOR FKHR; TUMOR SUPPRESSION; PROTEASOMAL DEGRADATION; INCREASED EXPRESSION; NUCLEAR EXCLUSION; BCL-2 EXPRESSION; DOWN-REGULATION	The forkhead box O (FOXO) transcription factor FOXO1 functions as a tumor suppressor by regulating expression of genes involved in apoptosis, cell cycle arrest and oxidative detoxification. Here, we demonstrate that cyclin-dependent kinase 1 (CDK1) specifically phosphorylates FOXO1 at serine 249 (S249) in vitro and in vivo. Coimmunoprecipitation assays demonstrate that both endogenous CDK1 and ectopically expressed CDK1 form a protein complex with FOXO1 in prostate cancer (PCa) cells. In vitro protein binding assays reveal that CDK1 interacts directly with FOXO1. Accordingly, overexpression of CDK1 inhibits the transcriptional activity of FOXO1 in PCa cells through S249 phosphorylation on FOXO1. Consistent with the roles of FOXO3a and FOXO4 (two other members of the FOXO family) in cell cycle regulation, forced expression of FOXO1 causes a delay in the transition from G2 to M phase. This effect is blocked completely by overexpression of CDK1 and cyclin B1. Ectopic expression of constitutively active CDK1 also inhibits FOXO1-induced apoptosis in PCa cells. Moreover, we demonstrate that the inhibitory effect of FOXO1 on Ras oncogene-induced colony formation in fibroblasts is diminished by overexpression of CDK1. Given that CDK1 and cyclin B1 are often overexpressed in human cancers including PCa, our findings suggest that aberrant activation of CDK1 may contribute to tumorigenesis by promoting cell proliferation and survival via phosphorylation and inhibition of FOXO1.	[Liu, P.; Kao, T. P.; Huang, H.] Univ Minnesota, Ctr Canc, Minneapolis, MN 55455 USA; [Liu, P.; Kao, T. P.; Huang, H.] Univ Minnesota, Dept Lab Med & Pathol, Minneapolis, MN 55455 USA	University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities	Huang, H (corresponding author), Univ Minnesota, Ctr Canc, MMC 806,420 Delaware St SE, Minneapolis, MN 55455 USA.	huang253@umn.edu						Aoki M, 2004, P NATL ACAD SCI USA, V101, P13613, DOI 10.1073/pnas.0405454101; Biggs WH, 1999, P NATL ACAD SCI USA, V96, P7421, DOI 10.1073/pnas.96.13.7421; Borkhardt A, 1997, ONCOGENE, V14, P195, DOI 10.1038/sj.onc.1200814; Brunet A, 2001, MOL CELL BIOL, V21, P952, DOI 10.1128/MCB.21.3.952-965.2001; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Chen SY, 2006, P NATL ACAD SCI USA, V103, P15969, DOI 10.1073/pnas.0604193103; Dijkers PF, 2000, CURR BIOL, V10, P1201, DOI 10.1016/S0960-9822(00)00728-4; Dong XY, 2003, AM J HUM GENET, V72, P270, DOI 10.1086/346094; Fernandez-Zapico ME, 2003, EMBO J, V22, P4748, DOI 10.1093/emboj/cdg470; Furukawa-Hibi Y, 2002, J BIOL CHEM, V277, P26729, DOI 10.1074/jbc.C200256200; GALILI N, 1993, NAT GENET, V5, P230, DOI 10.1038/ng1193-230; Gilley J, 2003, J CELL BIOL, V162, P613, DOI 10.1083/jcb.200303026; Goga A, 2007, NAT MED, V13, P820, DOI 10.1038/nm1606; Gray NS, 1998, SCIENCE, V281, P533, DOI 10.1126/science.281.5376.533; Green DR, 2002, CANCER CELL, V1, P19, DOI 10.1016/S1535-6108(02)00024-7; Greer EL, 2005, ONCOGENE, V24, P7410, DOI 10.1038/sj.onc.1209086; Hillion J, 1997, BLOOD, V90, P3714, DOI 10.1182/blood.V90.9.3714; Hu MCT, 2004, CELL, V117, P225, DOI 10.1016/S0092-8674(04)00302-2; Huang H, 2005, P NATL ACAD SCI USA, V102, P1649, DOI 10.1073/pnas.0406789102; Huang H, 2001, J BIOL CHEM, V276, P38830, DOI 10.1074/jbc.M103632200; Huang HJ, 2007, J CELL SCI, V120, P2479, DOI 10.1242/jcs.001222; Huang HJ, 2006, SCIENCE, V314, P294, DOI 10.1126/science.1130512; Huang HJ, 2004, ONCOGENE, V23, P2161, DOI 10.1038/sj.onc.1207326; Huang HJ, 2004, J BIOL CHEM, V279, P13866, DOI 10.1074/jbc.M314143200; Kallakury BV, 1998, J CLIN ONCOL, V16, P1302, DOI 10.1200/JCO.1998.16.4.1302; Kallakury BVS, 1997, CANCER-AM CANCER SOC, V80, P753, DOI 10.1002/(SICI)1097-0142(19970815)80:4<753::AID-CNCR15>3.0.CO;2-S; Knockaert M, 2002, TRENDS PHARMACOL SCI, V23, P417, DOI 10.1016/S0165-6147(02)02071-0; Kops GJPL, 1999, NATURE, V398, P630, DOI 10.1038/19328; Kops GJPL, 2002, MOL CELL BIOL, V22, P2025, DOI 10.1128/MCB.22.7.2025-2036.2002; Maddison LA, 2004, PROSTATE, V58, P335, DOI 10.1002/pros.10341; Mashal RD, 1996, CANCER RES, V56, P4159; Matsuoka S, 2007, SCIENCE, V316, P1160, DOI 10.1126/science.1140321; Matsuzaki H, 2003, P NATL ACAD SCI USA, V100, P11285, DOI 10.1073/pnas.1934283100; Medema RH, 2000, NATURE, V404, P782, DOI 10.1038/35008115; Modur V, 2002, J BIOL CHEM, V277, P47928, DOI 10.1074/jbc.M207509200; Nakamura N, 2000, MOL CELL BIOL, V20, P8969, DOI 10.1128/MCB.20.23.8969-8982.2000; Ozen M, 2005, CLIN CANCER RES, V11, P4701, DOI 10.1158/1078-0432.CCR-04-2551; Paik JH, 2007, CELL, V128, P309, DOI 10.1016/j.cell.2006.12.029; PARKER LL, 1992, SCIENCE, V257, P1955, DOI 10.1126/science.1384126; Pinkston JM, 2006, SCIENCE, V313, P971, DOI 10.1126/science.1121908; Pinkston-Gosse J, 2007, NAT GENET, V39, P1403, DOI 10.1038/ng.2007.1; Plas DR, 2003, J BIOL CHEM, V278, P12361, DOI 10.1074/jbc.M213069200; Ramaswamy S, 2002, CANCER CELL, V2, P81, DOI 10.1016/S1535-6108(02)00086-7; Rena G, 1999, J BIOL CHEM, V274, P17179, DOI 10.1074/jbc.274.24.17179; Rena G, 2002, EMBO J, V21, P2263, DOI 10.1093/emboj/21.9.2263; Santamaria D, 2007, NATURE, V448, P811, DOI 10.1038/nature06046; Schmidt M, 2002, MOL CELL BIOL, V22, P7842, DOI 10.1128/MCB.22.22.7842-7852.2002; Seoane J, 2004, CELL, V117, P211, DOI 10.1016/S0092-8674(04)00298-3; Sherr CJ, 2004, GENE DEV, V18, P2699, DOI 10.1101/gad.1256504; Soria JC, 2000, CANCER RES, V60, P4000; Stahl M, 2002, J IMMUNOL, V168, P5024, DOI 10.4049/jimmunol.168.10.5024; Stanbrough M, 2006, CANCER RES, V66, P2815, DOI 10.1158/0008-5472.CAN-05-4000; Tang ED, 1999, J BIOL CHEM, V274, P16741, DOI 10.1074/jbc.274.24.16741; Tran H, 2002, SCIENCE, V296, P530, DOI 10.1126/science.1068712; Woods YL, 2001, BIOCHEM J, V355, P597, DOI 10.1042/bj3550597; Wu XL, 2006, HUM MUTAT, V27, P742, DOI 10.1002/humu.20321; Wu XY, 1998, P NATL ACAD SCI USA, V95, P15587, DOI 10.1073/pnas.95.26.15587	57	114	120	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG	2008	27	34					4733	4744		10.1038/onc.2008.104	http://dx.doi.org/10.1038/onc.2008.104			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	334QM	18408765	Bronze			2022-12-28	WOS:000258236300011
J	Qiu, W; Wu, J; Walsh, EM; Zhang, Y; Chen, CY; Fujita, J; Xiao, ZXJ				Qiu, W.; Wu, J.; Walsh, E. M.; Zhang, Y.; Chen, C-Y; Fujita, J.; Xiao, Z-X J.			Retinoblastoma protein modulates gankyrin-MDM2 in regulation of p53 stability and chemosensitivity in cancer cells	ONCOGENE			English	Article						chemotherapy; gankyrin; MDM2; p53; retinoblastoma protein	TUMOR-SUPPRESSOR; ACIDIC DOMAIN; ONCOPROTEIN MDM2; RB FUNCTION; DEGRADATION; PHOSPHORYLATION; PRB; PATHWAYS; PROMOTES; BINDING	MDM2 is a key ubiquitin E3 ligase for p53 and its activity is critically regulated by a set of modulators, including ARF, p300, YY1 and recently by gankyrin, an oncoprotein frequently overexpressed in human heptocellular carcinomas. We have previously shown that MDM2 binds to and promotes retinoblastoma protein ( Rb) degradation. Here we show that Rb inhibits MDM2 E3 ligase activity resulting in stabilization of p53. In addition, we demonstrated that Rb inhibits MDM2-mediated p53 ubiquitination in a gankyrin-dependent manner and the Rb-gankyrin interaction is critical for Rb-induced p53 stabilization. Furthermore, acute ablation of Rb facilitates gankyrin-mediated p53 destabilization, and desensitizes cancer cells for chemotherapy-induced apoptosis. These results indicate that Rb antagonizes gankyrin to inhibit MDM2-mediate p53 ubiquitination in cancer cells and suggest that the status of both p53 and Rb is important for efficacy of cancer chemotherapy.	[Qiu, W.; Wu, J.; Walsh, E. M.; Xiao, Z-X J.] Boston Univ, Sch Med, Dept Biochem, Boston, MA 02118 USA; [Qiu, W.; Xiao, Z-X J.] Boston Univ, Sch Med, Dept Med, Grad Program Mol Med, Boston, MA 02118 USA; [Zhang, Y.] Boston Univ, Sch Med, Dept Med, Ctr Pulm, Boston, MA 02118 USA; [Chen, C-Y] Boston Univ, Sch Med, Dept Pathol, Boston, MA 02118 USA; [Fujita, J.] Kyoto Univ, Grad Sch Med, Dept Clin Mol Biol, Sakyo Ku, Kyoto, Japan	Boston University; Boston University; Boston University; Boston University; Kyoto University	Xiao, ZXJ (corresponding author), Boston Univ, Sch Med, Dept Biochem, 715 Albany St, Boston, MA 02118 USA.	jxiao@bu.edu			NATIONAL CANCER INSTITUTE [R01CA079804] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM070017] Funding Source: NIH RePORTER; NCI NIH HHS [CA79804] Funding Source: Medline; NIGMS NIH HHS [GM70017] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Argentini M, 2001, ONCOGENE, V20, P1267, DOI 10.1038/sj.onc.1204241; Beroud C, 1998, NUCLEIC ACIDS RES, V26, P200, DOI 10.1093/nar/26.1.200; Bond GL, 2005, CURR CANCER DRUG TAR, V5, P3, DOI 10.2174/1568009053332627; Classon M, 2002, NAT REV CANCER, V2, P910, DOI 10.1038/nrc950; CordonCardo C, 1997, CANCER RES, V57, P1217; Dawson S, 2006, TRENDS CELL BIOL, V16, P229, DOI 10.1016/j.tcb.2006.03.001; de Bruin A, 2003, P NATL ACAD SCI USA, V100, P6546, DOI 10.1073/pnas.1031853100; Dick FA, 2003, MOL CELL, V12, P639, DOI 10.1016/S1097-2765(03)00344-7; Gotz C, 1999, EUR J BIOCHEM, V266, P493, DOI 10.1046/j.1432-1327.1999.00882.x; Grossman SR, 1998, MOL CELL, V2, P405, DOI 10.1016/S1097-2765(00)80140-9; Grossman SR, 2003, SCIENCE, V300, P342, DOI 10.1126/science.1080386; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Higashitsuji H, 2005, CANCER CELL, V8, P75, DOI 10.1016/j.ccr.2005.06.006; Higashitsuji H, 2000, NAT MED, V6, P96, DOI 10.1038/71600; Hjerrild M, 2001, BIOCHEM J, V355, P347, DOI 10.1042/0264-6021:3550347; Hsieh JK, 1999, MOL CELL, V3, P181, DOI 10.1016/S1097-2765(00)80309-3; Kawai H, 2003, MOL CELL BIOL, V23, P4939, DOI 10.1128/MCB.23.14.4939-4947.2003; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Kulikov R, 2005, MOL CELL BIOL, V25, P7170, DOI 10.1128/MCB.25.16.7170-7180.2005; Kulikov R, 2006, J BIOL CHEM, V281, P28575, DOI 10.1074/jbc.M513311200; Lipinski MM, 2001, EMBO J, V20, P3402, DOI 10.1093/emboj/20.13.3402; Ma JH, 2006, BIOCHEMISTRY-US, V45, P9238, DOI 10.1021/bi060661u; Meulmeester E, 2003, MOL CELL BIOL, V23, P4929, DOI 10.1128/MCB.23.14.4929-4938.2003; Oren M, 2003, CELL DEATH DIFFER, V10, P431, DOI 10.1038/sj.cdd.4401183; Pomerantz J, 1998, CELL, V92, P713, DOI 10.1016/S0092-8674(00)81400-2; Sdek P, 2005, MOL CELL, V20, P699, DOI 10.1016/j.molcel.2005.10.017; Sdek P, 2004, J BIOL CHEM, V279, P53317, DOI 10.1074/jbc.M406062200; Sherr CJ, 2004, CELL, V116, P235, DOI 10.1016/S0092-8674(03)01075-4; Sherr CJ, 2002, CANCER CELL, V2, P103, DOI 10.1016/S1535-6108(02)00102-2; Stevaux O, 2002, CURR OPIN CELL BIOL, V14, P684, DOI 10.1016/S0955-0674(02)00388-5; Sui GC, 2004, CELL, V117, P859, DOI 10.1016/j.cell.2004.06.004; Uchida CH, 2005, EMBO J, V24, P160, DOI 10.1038/sj.emboj.7600486; Vogelstein B, 2004, NAT MED, V10, P789, DOI 10.1038/nm1087; Wang CG, 2005, EMBO J, V24, P3279, DOI 10.1038/sj.emboj.7600791; Weber JD, 1999, NAT CELL BIOL, V1, P20, DOI 10.1038/8991; Wu LZ, 2003, NATURE, V421, P942, DOI 10.1038/nature01417; XIAO ZX, 1995, NATURE, V375, P694, DOI 10.1038/375694a0; Xu HJ, 1996, CLIN CANCER RES, V2, P1169; Zhang YP, 1998, CELL, V92, P725, DOI 10.1016/S0092-8674(00)81401-4; Zhang YP, 2003, MOL CELL BIOL, V23, P8902, DOI 10.1128/MCB.23.23.8902-8912.2003	40	26	29	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 3	2008	27	29					4034	4043		10.1038/onc.2008.43	http://dx.doi.org/10.1038/onc.2008.43			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	321RV	18332869				2022-12-28	WOS:000257325100003
J	van der Vos, KE; Coffer, PJ				van der Vos, K. E.; Coffer, P. J.			FOXO-binding partners: it takes two to tango	ONCOGENE			English	Review						FOXO; transcription; co-factor; DNA-binding; PKB; PI3K	FORKHEAD TRANSCRIPTION FACTOR; PROSTATE-CANCER CELLS; ACTIVATED RECEPTOR-GAMMA; SMOOTH-MUSCLE-CELLS; ANDROGEN RECEPTOR; CAENORHABDITIS-ELEGANS; GENE-EXPRESSION; SKELETAL-MUSCLE; INSULIN ACTION; FACTOR FKHR	Modulation FOXO transcription factor activities can lead to a variety of cellular outputs resulting in changes in proliferation, apoptosis, differentiation and metabolic responses. Although FOXO proteins all contain an identical DNA-binding domain their cellular functions appear to be distinct, as exemplified by differences in the phenotype of Foxo1, Foxo3 and Foxo4 null mutant mice. While some of these differences may be attributable to the differential expression patterns of these transcription factors, many cells and tissues express several FOXO isoforms. Recently it has become clear that FOXO proteins can regulate transcriptional responses independently of direct DNA-binding. It has been demonstrated that FOXOs can associate with a variety of unrelated transcription factors, regulating activation or repression of diverse target genes. The complement of transcription factors expressed in a particular cell type is thus critical in determining the functional end point of FOXO activity. These interactions greatly expand the possibilities for FOXO-mediated regulation of transcriptional programmes. This review details currently described FOXO-binding partners and examines the role of these interactions in regulating cell fate decisions.	[van der Vos, K. E.; Coffer, P. J.] Univ Med Ctr, Wilhelmina Childrens Hosp, Dept Immunol, Mol Immunol Lab, NL-3584 EA Utrecht, Netherlands; [Coffer, P. J.] Univ Med Ctr, Wilhelmina Childrens Hosp, Dept Pediat Immunol, NL-3584 EA Utrecht, Netherlands	Utrecht University; Utrecht University Medical Center; Wilhelmina Kinderziekenhuis; Utrecht University; Utrecht University Medical Center; Wilhelmina Kinderziekenhuis	Coffer, PJ (corresponding author), Univ Med Ctr, Wilhelmina Childrens Hosp, Dept Immunol, Mol Immunol Lab, Lundlaan 6, NL-3584 EA Utrecht, Netherlands.	p.j.coffer@umcutrecht.nl	Coffer, Paul/AAF-7970-2020; Coffer, Paul J/A-5769-2009					Almeida M, 2007, J BIOL CHEM, V282, P27298, DOI 10.1074/jbc.M702811200; Arce L, 2006, ONCOGENE, V25, P7492, DOI 10.1038/sj.onc.1210056; Armoni M, 2003, J BIOL CHEM, V278, P30614, DOI 10.1074/jbc.M304654200; Armoni M, 2007, TRENDS ENDOCRIN MET, V18, P100, DOI 10.1016/j.tem.2007.02.001; Armoni M, 2006, J BIOL CHEM, V281, P19881, DOI 10.1074/jbc.M600320200; Barr FG, 2001, ONCOGENE, V20, P5736, DOI 10.1038/sj.onc.1204599; Barthel A, 2005, TRENDS ENDOCRIN MET, V16, P183, DOI 10.1016/j.tem.2005.03.010; Benson GV, 1996, DEVELOPMENT, V122, P2687; Berg AH, 2001, NAT MED, V7, P947, DOI 10.1038/90992; Biggins JB, 2007, CURR OPIN CHEM BIOL, V11, P99, DOI 10.1016/j.cbpa.2006.10.042; Birkenkamp KU, 2003, J IMMUNOL, V171, P1623, DOI 10.4049/jimmunol.171.4.1623; Bocchinfuso WP, 1997, J MAMMARY GLAND BIOL, V2, P323, DOI 10.1023/A:1026339111278; Brar AK, 1997, ENDOCRINE, V6, P301, DOI 10.1007/BF02820507; Brunet A, 2004, SCIENCE, V303, P2011, DOI 10.1126/science.1094637; Buzzio OL, 2006, ENDOCRINOLOGY, V147, P3870, DOI 10.1210/en.2006-0167; Christian M, 2002, J BIOL CHEM, V277, P20825, DOI 10.1074/jbc.M201018200; Deroo BJ, 2006, J CLIN INVEST, V116, P561, DOI 10.1172/JCI27987; Dong XY, 2006, CANCER RES, V66, P6998, DOI 10.1158/0008-5472.CAN-06-0411; Dowell P, 2003, J BIOL CHEM, V278, P45485, DOI 10.1074/jbc.M309069200; Essers MAG, 2004, EMBO J, V23, P4802, DOI 10.1038/sj.emboj.7600476; Essers MAG, 2005, SCIENCE, V308, P1181, DOI 10.1126/science.1109083; Fan WQ, 2007, J BIOL CHEM, V282, P7329, DOI 10.1074/jbc.M610447200; Fievet C, 2006, CURR OPIN PHARMACOL, V6, P606, DOI 10.1016/j.coph.2006.06.009; Finck BN, 2006, J CLIN INVEST, V116, P615, DOI 10.1172/JCI27794; Foucher I, 2002, DEVELOPMENT, V129, P4065; Gao WQ, 2005, CHEM REV, V105, P3352, DOI 10.1021/cr020456u; GIUDICE LC, 1993, J CLIN ENDOCR METAB, V76, P1115, DOI 10.1210/jc.76.5.1115; Glass DA, 2007, ENDOCRINOLOGY, V148, P2630, DOI 10.1210/en.2006-1372; Gomis RR, 2006, CANCER CELL, V10, P203, DOI 10.1016/j.ccr.2006.07.019; Gomis RR, 2006, P NATL ACAD SCI USA, V103, P12747, DOI 10.1073/pnas.0605333103; GOTTLIEB S, 1994, GENETICS, V137, P107; Grinius L, 2006, J ENDOCRINOL, V189, P179, DOI 10.1677/joe.1.06451; Hanashima C, 2004, SCIENCE, V303, P56, DOI 10.1126/science.1090674; Hayashi K, 1999, J CELL BIOL, V145, P727, DOI 10.1083/jcb.145.4.727; Hirota K, 2003, J BIOL CHEM, V278, P13056, DOI 10.1074/jbc.C200553200; Hosaka T, 2004, P NATL ACAD SCI USA, V101, P2975, DOI 10.1073/pnas.0400093101; Huang HJ, 2004, J BIOL CHEM, V279, P13866, DOI 10.1074/jbc.M314143200; Kamei Y, 2003, FEBS LETT, V536, P232, DOI 10.1016/S0014-5793(03)00062-0; Kim JJ, 2005, BIOL REPROD, V73, P833, DOI 10.1095/biolreprod.105.043182; Kim JJ, 2003, BIOL REPROD, V68, P24, DOI 10.1095/biolreprod.102.009316; Kitamura T, 2007, J CLIN INVEST, V117, P2477, DOI 10.1172/JCI32054; Kodama S, 2004, MOL CELL BIOL, V24, P7931, DOI 10.1128/MCB.24.18.7931-7940.2004; Kortylewski M, 2003, J BIOL CHEM, V278, P5242, DOI 10.1074/jbc.M205403200; Krebs LT, 2000, GENE DEV, V14, P1343; LARSEN PL, 1995, GENETICS, V139, P1567; Li PF, 2003, MOL CELL BIOL, V23, P104, DOI 10.1128/MCB.23.1.104-118.2003; Li PF, 2001, J BIOL CHEM, V276, P20444, DOI 10.1074/jbc.M010226200; Li YW, 2007, J BIOL CHEM, V282, P21542, DOI 10.1074/jbc.M701978200; Liu ZP, 2005, DEV CELL, V9, P261, DOI 10.1016/j.devcel.2005.05.017; Luo D, 2005, SEMIN CELL DEV BIOL, V16, P612, DOI 10.1016/j.semcdb.2005.07.002; Medema RH, 2000, NATURE, V404, P782, DOI 10.1038/35008115; Nakae J, 2001, J CLIN INVEST, V108, P1359, DOI 10.1172/JCI200112876; Nakae J, 2003, DEV CELL, V4, P119, DOI 10.1016/S1534-5807(02)00401-X; Nakai J, 2002, NAT GENET, V32, P245, DOI 10.1038/ng890; Nechamen CA, 2007, MOL CELL ENDOCRINOL, V260, P93, DOI 10.1016/j.mce.2006.08.014; Nerlov C, 2007, TRENDS CELL BIOL, V17, P318, DOI 10.1016/j.tcb.2007.07.004; Ogg S, 1997, NATURE, V389, P994, DOI 10.1038/40194; Owens GK, 2004, PHYSIOL REV, V84, P767, DOI 10.1152/physrev.00041.2003; Paik JH, 2007, CELL, V128, P309, DOI 10.1016/j.cell.2006.12.029; Pardee Keith, 2004, Sci Aging Knowledge Environ, V2004, pre8, DOI 10.1126/sageke.2004.47.re8; Park KW, 2005, ARTERIOSCL THROM VAS, V25, P742, DOI 10.1161/01.ATV.0000156288.70849.26; Patterson GI, 1997, GENE DEV, V11, P2679, DOI 10.1101/gad.11.20.2679; Picard F, 2004, NATURE, V429, P771, DOI 10.1038/nature02583; Pilch PF, 2006, MOL PHARMACOL, V70, P779, DOI 10.1124/mol.106.026104; Plevin MJ, 2005, TRENDS BIOCHEM SCI, V30, P66, DOI 10.1016/j.tibs.2004.12.001; Pohnke Y, 1999, J BIOL CHEM, V274, P24808, DOI 10.1074/jbc.274.35.24808; Puigserver P, 2003, NATURE, V423, P550, DOI 10.1038/nature01667; Qiao LP, 2006, J BIOL CHEM, V281, P39915, DOI 10.1074/jbc.M607215200; Qu S, 2007, AM J PHYSIOL-ENDOC M, V292, pE421, DOI 10.1152/ajpendo.00157.2006; Ramaswamy S, 2002, CANCER CELL, V2, P81, DOI 10.1016/S1535-6108(02)00086-7; Ren PF, 1996, SCIENCE, V274, P1389, DOI 10.1126/science.274.5291.1389; Rudd MD, 2007, J MOL ENDOCRINOL, V38, P673, DOI 10.1677/JME-07-0017; Samuel VT, 2006, DIABETES, V55, P2042, DOI 10.2337/db05-0705; Sandri M, 2004, CELL, V117, P399, DOI 10.1016/S0092-8674(04)00400-3; Sandri M, 2006, P NATL ACAD SCI USA, V103, P16260, DOI 10.1073/pnas.0607795103; Schilling MM, 2006, NATURE, V443, pE10, DOI 10.1038/nature05288; Schuur ER, 2001, J BIOL CHEM, V276, P33554, DOI 10.1074/jbc.M105555200; Sekine K, 2007, EMBO J, V26, P3607, DOI 10.1038/sj.emboj.7601784; Seoane J, 2004, CELL, V117, P211, DOI 10.1016/S0092-8674(04)00298-3; Shi YG, 2003, CELL, V113, P685, DOI 10.1016/S0092-8674(03)00432-X; So CW, 2003, BLOOD, V101, P633, DOI 10.1182/blood-2002-06-1785; van der Horst A, 2007, NAT REV MOL CELL BIO, V8, P440, DOI 10.1038/nrm2190; WANG ND, 1995, SCIENCE, V269, P1108, DOI 10.1126/science.7652557; Wang ZG, 2004, NATURE, V428, P185, DOI 10.1038/nature02382; Yamamura Y, 2006, J BIOL CHEM, V281, P5267, DOI 10.1074/jbc.M512151200; Zhao HH, 2001, J BIOL CHEM, V276, P27907, DOI 10.1074/jbc.M104278200	86	163	165	1	27	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 7	2008	27	16					2289	2299		10.1038/onc.2008.22	http://dx.doi.org/10.1038/onc.2008.22			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	285NE	18391971	Green Published			2022-12-28	WOS:000254782700004
J	Yang, XY; Guan, M; Vigil, D; Der, CJ; Lowy, DR; Popescu, NC				Yang, X-Y; Guan, M.; Vigil, D.; Der, C. J.; Lowy, D. R.; Popescu, N. C.			p120Ras-GAP binds the DLC1 Rho-GAP tumor suppressor protein and inhibits its RhoA GTPase and growth-suppressing activities	ONCOGENE			English	Article						deleted in liver cancer; Ras-GAP; protein interaction; modulation of tumor cell proliferation; Rho-GAP; SH3	ACTIVATING PROTEIN; CELL-PROLIFERATION; GENE-EXPRESSION; RAS; CANCER; SH3; DOMAIN; CLONING; TUMORIGENICITY; TRANSFORMATION	DLC1 (deleted in liver cancer 1), which encodes a Rho GTPase-activating protein (Rho-GAP), is a potent tumor suppressor gene that is frequently inactivated in several human cancers. DLC1 is a multidomain protein that has been shown previously to bind members of the tensin gene family. Here we show that p120Ras-GAP (Ras-GAP; also known as RASA1) interacts and extensively colocalizes with DLC1 in focal adhesions. The binding was mapped to the SH3 domain located in the N terminus of Ras-GAP and to the Rho-GAP catalytic domain located in the C terminus of the DLC1. In vitro analyses with purified proteins determined that the isolated Ras-GAP SH3 domain inhibits DLC1 Rho-GAP activity, suggesting that Ras-GAP is a negative regulator of DLC1 Rho-GAP activity. Consistent with this possibility, we found that ectopic overexpression of Ras-GAP in a Ras-GAP-insensitive tumor line impaired the growth-suppressing activity of DLC1 and increased RhoA activity in vivo. Our observations expand the complexity of proteins that regulate DLC1 function and define a novel mechanism of the cross talk between Ras and Rho GTPases.	[Yang, X-Y; Guan, M.; Popescu, N. C.] NCI, Expt Carcinogenesis Lab, Ctr Canc Res, Bethesda, MD 20892 USA; [Vigil, D.; Der, C. J.] Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA; [Lowy, D. R.] NCI, Cellular Oncol Lab, Ctr Canc Res, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University of North Carolina; University of North Carolina Chapel Hill; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Popescu, NC (corresponding author), NCI, Expt Carcinogenesis Lab, Ctr Canc Res, Bldg 37,Room 4128,37 Convent Dr,MSC4262, Bethesda, MD 20892 USA.	popescun@mail.nih.gov	yang, xuyu/D-1414-2012	Der, Channing/0000-0002-7751-2747	NIH [1R01CA129610]; American Cancer Society; NATIONAL CANCER INSTITUTE [ZIABC010038, ZIABC008905, R01CA129610] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); American Cancer Society(American Cancer Society); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	The Intramural Research Program of the National Cancer Institute, Center for Cancer Research, NIH supported this work. CJD is also supported by an NIH grant (1R01CA129610), and DV was supported by a fellowship from the American Cancer Society.	Abdellatif M, 1998, MOL CELL BIOL, V18, P6729, DOI 10.1128/MCB.18.11.6729; Baselga J, 2008, J CLIN ONCOL, V26, P1582, DOI 10.1200/JCO.2007.15.3700; Bradley WD, 2006, MOL BIOL CELL, V17, P4827, DOI 10.1091/mbc.E06-02-0132; Bradshaw JM, 2003, ADV PROTEIN CHEM, V61, P161; Brouns MR, 2000, DEVELOPMENT, V127, P4891; BRYANT SS, 1995, J BIOL CHEM, V270, P17947, DOI 10.1074/jbc.270.30.17947; Clark GJ, 1997, J BIOL CHEM, V272, P1677, DOI 10.1074/jbc.272.3.1677; Durkin ME, 2007, ONCOGENE, V26, P4580, DOI 10.1038/sj.onc.1210244; Durkin ME, 2007, J CELL MOL MED, V11, P1185, DOI 10.1111/j.1582-4934.2007.00098.x; Durkin ME, 2005, FEBS LETT, V579, P1191, DOI 10.1016/j.febslet.2004.12.090; Ferraro E, 2007, NUCLEIC ACIDS RES, V35, pW451, DOI 10.1093/nar/gkm296; Forbes S, 2006, BRIT J CANCER, V94, P318, DOI 10.1038/sj.bjc.6602928; Gigoux V, 2002, J BIOL CHEM, V277, P23742, DOI 10.1074/jbc.C200121200; Guan M, 2008, CANCER GENE THER, V15, P371, DOI 10.1038/cgt.2008.13; Healy KD, 2008, MOL CARCINOGEN, V47, P326, DOI 10.1002/mc.20389; Hu KQ, 1997, EMBO J, V16, P473, DOI 10.1093/emboj/16.3.473; Jin YL, 2008, ONCOL REP, V19, P669; Jones S, 2008, SCIENCE, V321, P1801, DOI 10.1126/science.1164368; Kawai K, 2007, BIOCHEM BIOPH RES CO, V364, P783, DOI 10.1016/j.bbrc.2007.10.052; Kennedy D, 2002, J CELL BIOCHEM, V84, P173, DOI 10.1002/jcb.1277; Kim TY, 2008, J BIOL CHEM, V283, P32762, DOI 10.1074/jbc.M800617200; Kim TY, 2007, BIOCHEM BIOPH RES CO, V355, P72, DOI 10.1016/j.bbrc.2007.01.121; Leblanc V, 1999, ONCOGENE, V18, P4884, DOI 10.1038/sj.onc.1202855; Leblanc V, 1998, MOL CELL BIOL, V18, P5567, DOI 10.1128/MCB.18.9.5567; Leung THY, 2005, P NATL ACAD SCI USA, V102, P15207, DOI 10.1073/pnas.0504501102; Li SSC, 2005, BIOCHEM J, V390, P641, DOI 10.1042/BJ20050411; Liao YC, 2008, CANCER RES, V68, P7718, DOI 10.1158/0008-5472.CAN-08-2042; Liao YC, 2007, J CELL BIOL, V176, P43, DOI 10.1083/jcb.200608015; MAYER BJ, 1995, CURR BIOL, V5, P364, DOI 10.1016/S0960-9822(95)00073-X; Musacchio A, 2003, ADV PROTEIN CHEM, V61, P211; Pamonsinlapatham P, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002902; Qian XL, 2007, P NATL ACAD SCI USA, V104, P9012, DOI 10.1073/pnas.0703033104; Ross B, 2007, BIOCHEM BIOPH RES CO, V353, P463, DOI 10.1016/j.bbrc.2006.12.044; Shang X, 2007, J BIOL CHEM, V282, P8801, DOI 10.1074/jbc.M609375200; Shankavaram UT, 2007, MOL CANCER THER, V6, P820, DOI 10.1158/1535-7163.MCT-06-0650; Shutes A, 2005, METHODS, V37, P183, DOI 10.1016/j.ymeth.2005.05.019; Tocque B, 1997, CELL SIGNAL, V9, P153, DOI 10.1016/S0898-6568(96)00135-0; TRAHEY M, 1988, SCIENCE, V242, P1697, DOI 10.1126/science.3201259; Ullmannova V, 2006, INT J ONCOL, V29, P1127; VOGEL US, 1988, NATURE, V335, P90, DOI 10.1038/335090a0; Wong CM, 2005, CANCER RES, V65, P8861, DOI 10.1158/0008-5472.CAN-05-1318; Xue W, 2008, GENE DEV, V22, P1439, DOI 10.1101/gad.1672608; Yam JWP, 2006, CANCER RES, V66, P8367, DOI 10.1158/0008-5472.CAN-05-2850; Yuan BZ, 1998, CANCER RES, V58, P2196; Yue YZ, 2004, J BIOL CHEM, V279, P12883, DOI 10.1074/jbc.M312308200; Zhou X, 2008, INT J ONCOL, V32, P1285; Zhou XL, 2004, ONCOGENE, V23, P1308, DOI 10.1038/sj.onc.1207246	48	44	47	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2009	28	11					1401	1409		10.1038/onc.2008.498	http://dx.doi.org/10.1038/onc.2008.498			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	421JE	19151751	Green Submitted, Green Accepted			2022-12-28	WOS:000264354400001
J	Lin, L; Amin, R; Gallicano, GI; Glasgow, E; Jogunoori, W; Jessup, JM; Zasloff, M; Marshall, JL; Shetty, K; Johnson, L; Mishra, L; He, AR				Lin, L.; Amin, R.; Gallicano, G. I.; Glasgow, E.; Jogunoori, W.; Jessup, J. M.; Zasloff, M.; Marshall, J. L.; Shetty, K.; Johnson, L.; Mishra, L.; He, A. R.			The STAT3 inhibitor NSC 74859 is effective in hepatocellular cancers with disrupted TGF-beta signaling	ONCOGENE			English	Article						IL6; stem cell; TGF-beta; STAT3; beta 2SP; hepatocellular carcinoma	LIVER STEM-CELLS; SERINE PHOSPHORYLATION; STEM/PROGENITOR CELLS; GENE-EXPRESSION; CARCINOMA CELLS; MICE; ACTIVATION; PATHWAY; CHEMORESISTANCE; CD133(+)	Hepatocellular carcinoma (HCC) is the third leading cause of cancer deaths worldwide, with few effective therapeutic options for advanced disease. At least 40% of HCCs are clonal, potentially arising from STAT3+, NANOG+ and OCT3/4+ liver progenitor/stem cell transformation, along with inactivation of transforming growth factor-beta (TGF-beta) signaling. Here we report significantly greater signal transducer and activator of transcription 3 (STAT3) and tyrosine phosphorylated STAT3 in human HCC tissues (P<0.0030 and P<0.0455, respectively) than in human normal liver. Further, in HCC cells with loss of response to TGF-b, NSC 74859, a STAT3-specific inhibitor, markedly suppresses growth. In contrast, CD133(+) status did not affect the response to STAT3 inhibition: both CD133(+) Huh-7 cells and CD133(-) Huh-7 cells are equally sensitive to NSC 74859 treatment and STAT3 inhibition, with an IC50 of 100 mu M. Thus, the TGF-beta/beta2 spectrin (beta 2SP) pathway may reflect a more functional 'stem/progenitor' state than CD133. Furthermore, NSC 74859 treatment of Huh-7 xenografts in nude mice significantly retarded tumor growth, with an effective dose of only 5 mg/kg. Moreover, NSC 74859 inhibited tyrosine phosphorylation of STAT3 in HCC cells in vivo. We conclude that inhibiting interleukin 6 (IL6)/STAT3 in HCCs with inactivation of the TGF-beta/beta 2SP pathway is an effective approach in management of HCCs. Thus, IL6/STAT3, a major signaling pathway in HCC stem cell renewal and proliferation, can provide a novel approach to the treatment of specific HCCs.	[Lin, L.; Glasgow, E.; Marshall, J. L.; He, A. R.] Georgetown Univ, Lombardi Comprehens Canc Ctr, Dept Med & Oncol, Washington, DC 20007 USA; [Lin, L.; Amin, R.; Glasgow, E.; Jogunoori, W.; Zasloff, M.; Shetty, K.; Johnson, L.; Mishra, L.; He, A. R.] Georgetown Univ, Dept Surg, Washington, DC 20007 USA; [Gallicano, G. I.] Georgetown Univ, Med Ctr, Dept Biochem & Mol & Cellular Biol, Washington, DC 20007 USA; [Jessup, J. M.] NCI, Canc Diag Program, Rockville, MD USA; [Shetty, K.; Johnson, L.] Georgetown Univ, Inst Transplant Surg, Dept Surg, Washington, DC USA; [Mishra, L.] Dept Vet Affairs Med Ctr, Washington, DC USA	Georgetown University; Georgetown University; Georgetown University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Georgetown University	He, AR (corresponding author), Georgetown Univ, Lombardi Comprehens Canc Ctr, Dept Med & Oncol, 3800 Reservoir Rd NW, Washington, DC 20007 USA.	lm229@georgetown.edu; aiwu.r.he@gunet.georgetown.edu		Mishra, Lopa/0000-0002-6850-0808; Glasgow, Eric/0000-0001-7729-3954	NCI NIH HHS [P01 CA130821, R01 CA042857, R01 CA106614A, R01 CA4285718A, P30 CA51008-13, P30 CA051008, R01 CA106614-01A2, R01 CA106614, R01 CA042857-18A1] Funding Source: Medline; NIDDK NIH HHS [R01 DK056111-01, R01 DK56111, R01 DK056111] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA051008, ZIABC011199, R01CA042857, R01CA106614, P01CA130821] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK056111] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Aaronson DS, 2002, SCIENCE, V296, P1653, DOI 10.1126/science.1071545; Alison MR, 2005, STEM CELL REV, V1, P253, DOI 10.1385/SCR:1:3:253; Bao SD, 2006, NATURE, V444, P756, DOI 10.1038/nature05236; Bromberg JF, 1999, CELL, V98, P295, DOI 10.1016/S0092-8674(00)81959-5; Cabibbo A, 1998, ONCOGENE, V16, P2935, DOI 10.1038/sj.onc.1201825; Chung JK, 1997, MOL CELL BIOL, V17, P6508, DOI 10.1128/MCB.17.11.6508; Dando JS, 2005, STEM CELLS, V23, P550, DOI 10.1634/stemcells.2004-0205; Frank NY, 2005, CANCER RES, V65, P4320, DOI 10.1158/0008-5472.CAN-04-3327; Hambardzumyan D, 2006, CANCER CELL, V10, P454, DOI 10.1016/j.ccr.2006.11.008; Im YH, 2001, CANCER RES, V61, P6665; Kanzler S, 2001, ONCOGENE, V20, P5015, DOI 10.1038/sj.onc.1204544; KEW MC, 1971, BMJ-BRIT MED J, V4, P408, DOI 10.1136/bmj.4.5784.408; Kitisin K, 2007, ONCOGENE, V26, P7103, DOI 10.1038/sj.onc.1210513; Kojima H, 2005, P NATL ACAD SCI USA, V102, P4524, DOI 10.1073/pnas.0500679102; KOPF M, 1994, NATURE, V368, P339, DOI 10.1038/368339a0; LaBarge MA, 2008, J CLIN INVEST, V118, P2021, DOI 10.1172/JCI36046; Lim CP, 1999, J BIOL CHEM, V274, P31055, DOI 10.1074/jbc.274.43.31055; Lim CP, 2001, J BIOL CHEM, V276, P21004, DOI 10.1074/jbc.M007592200; Liu GT, 2006, MOL CANCER, V5, DOI 10.1186/1476-4598-5-67; Ma S, 2008, ONCOGENE, V27, P1749, DOI 10.1038/sj.onc.1210811; Ma S, 2007, GASTROENTEROLOGY, V132, P2542, DOI 10.1053/j.gastro.2007.04.025; Manghisi G, 1998, HEPATOLOGY, V28, P751; Massague J, 2000, CELL, V103, P295, DOI 10.1016/S0092-8674(00)00121-5; Nguyen LN, 2007, HEPATOLOGY, V45, P31, DOI 10.1002/hep.21466; Ohkawara B, 2004, GENE DEV, V18, P381, DOI 10.1101/gad.1166904; Roskams T, 2006, ONCOGENE, V25, P3818, DOI 10.1038/sj.onc.1209558; Shmelkov SV, 2008, J CLIN INVEST, V118, P2111, DOI 10.1172/JCI34401; Sicklick JK, 2006, AM J PHYSIOL-GASTR L, V290, pG859, DOI 10.1152/ajpgi.00456.2005; Sicklick JK, 2006, CARCINOGENESIS, V27, P748, DOI 10.1093/carcin/bgi292; Siddiquee K, 2007, P NATL ACAD SCI USA, V104, P7391, DOI 10.1073/pnas.0609757104; Suetsugi A, 2006, BIOCHEM BIOPH RES CO, V351, P820, DOI 10.1016/j.bbrc.2006.10.128; Tang BW, 1998, NAT MED, V4, P802, DOI 10.1038/nm0798-802; Tang Y, 2003, SCIENCE, V299, P574, DOI 10.1126/science.1075994; Tang Y, 2008, P NATL ACAD SCI USA, V105, P2445, DOI 10.1073/pnas.0705395105; Turkson J, 2001, J BIOL CHEM, V276, P45443, DOI 10.1074/jbc.M107527200; VISTICA DT, 1991, CANCER RES, V51, P2515; Wallner L, 2006, CANCER RES, V66, P3087, DOI 10.1158/0008-5472.CAN-05-3447; Weinstein M, 2000, CYTOKINE GROWTH F R, V11, P49, DOI 10.1016/S1359-6101(99)00028-3; WEN ZL, 1995, CELL, V82, P241, DOI 10.1016/0092-8674(95)90311-9; Wurmbach E, 2007, HEPATOLOGY, V45, P938, DOI 10.1002/hep.21622; Yang SF, 2007, J CLIN PATHOL, V60, P642, DOI 10.1136/jcp.2006.036970; Yeoh GCT, 2007, HEPATOLOGY, V45, P486, DOI 10.1002/hep.21535; Yin SY, 2007, INT J CANCER, V120, P1444, DOI 10.1002/ijc.22476; Zender L, 2006, CELL, V125, P1253, DOI 10.1016/j.cell.2006.05.030; Zhou JB, 2007, P NATL ACAD SCI USA, V104, P16158, DOI 10.1073/pnas.0702596104	45	174	195	0	19	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 19	2009	28	7					961	972		10.1038/onc.2008.448	http://dx.doi.org/10.1038/onc.2008.448			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	408TH	19137011	Green Accepted			2022-12-28	WOS:000263457400003
J	Gresko, E; Ritterhoff, S; Sevilla-Perez, J; Roscic, A; Frobius, K; Kotevic, I; Vichalkovski, A; Hess, D; Hemmings, BA; Schmitz, ML				Gresko, E.; Ritterhoff, S.; Sevilla-Perez, J.; Roscic, A.; Froebius, K.; Kotevic, I.; Vichalkovski, A.; Hess, D.; Hemmings, B. A.; Schmitz, M. L.			PML tumor suppressor is regulated by HIPK2-mediated phosphorylation in response to DNA damage	ONCOGENE			English	Article						HIPK2; PML; phosphorylation; cell death	ACUTE PROMYELOCYTIC LEUKEMIA; HOMEODOMAIN-INTERACTING PROTEIN-KINASE-2; NUCLEAR-BODIES; RAR-ALPHA; PROTEIN KINASE-2; P53 ACTIVITY; CELL-DEATH; HIPK2; TRANSCRIPTION; APOPTOSIS	The promyelocytic leukemia (PML) tumor suppressor protein, a central regulator of cell proliferation and apoptosis, is frequently fused to the retinoic acid receptor-alpha (RAR alpha) in acute PML. Here we show the interaction of PML with another tumor suppressor protein, the serine/threonine kinase homeodomain-interacting protein kinase (HIPK2). In response to DNA damage, HIPK2 phosphorylates PML at serines 8 and 38. Although HIPK2-mediated phosphorylation of PML occurs early during the DNA damage response, the oncogenic PML-RAR alpha fusion protein is phosphorylated with significantly delayed kinetics. DNA damage or HIPK2 expression leads to the stabilization of PML and PML-RARa proteins. The N-terminal phosphorylation sites contribute to the DNA damage-induced PML SUMOylation and are required for the ability of PML to cooperate with HIPK2 for the induction of cell death.	[Ritterhoff, S.; Sevilla-Perez, J.; Roscic, A.; Froebius, K.; Schmitz, M. L.] Univ Giessen, Inst Biochem, D-35392 Giessen, Germany; [Gresko, E.] Univ Bern, Dept Chem & Biochem, Bern, Switzerland; [Gresko, E.; Vichalkovski, A.; Hess, D.; Hemmings, B. A.] Friedrich Miescher Inst Biomed Res, Basel, Switzerland; [Roscic, A.] Novartis Pharma AG, Basel, Switzerland; [Kotevic, I.] Univ Zurich, Inst Biomed Engn, Zurich, Switzerland; [Kotevic, I.] ETH, Zurich, Switzerland	Justus Liebig University Giessen; University of Bern; Friedrich Miescher Institute for Biomedical Research; Novartis; University of Zurich; Swiss Federal Institutes of Technology Domain; ETH Zurich	Schmitz, ML (corresponding author), Univ Giessen, Inst Biochem, Friedrichstr 24, D-35392 Giessen, Germany.	lienhard.schmitz@biochemie.med.uni-giessen.de	Schmitz, M. Lienhard/D-9328-2017	Schmitz, M. Lienhard/0000-0002-6984-7192	Deutsche Forschungsgemeinschaft [SCHM 1417/4-1, SCHM 1417/5-1, SFB 547]; ECCPS-Excellence Cluster Cardio-Pulmonary System; Swiss Cancer League [OCS 01667-02-2005]	Deutsche Forschungsgemeinschaft(German Research Foundation (DFG)); ECCPS-Excellence Cluster Cardio-Pulmonary System(German Research Foundation (DFG)); Swiss Cancer League	We are grateful to Drs Giannino Del Sal (Trieste, Italy) and Myung K Kim (NIH, USA) for generously providing expression vectors. The study from our laboratory was supported by grants from the Deutsche Forschungsgemeinschaft projects SCHM 1417/4-1, SCHM 1417/5-1, SFB 547 and the ECCPS-Excellence Cluster Cardio-Pulmonary System. FMI is a part of Novartis Research Foundation and EG was supported by the Swiss Cancer League Grant OCS 01667-02-2005.	Bernardi R, 2004, NAT CELL BIOL, V6, P665, DOI 10.1038/ncb1147; Bernardi R, 2007, NAT REV MOL CELL BIO, V8, P1006, DOI 10.1038/nrm2277; Bischof O, 2002, EMBO J, V21, P3358, DOI 10.1093/emboj/cdf341; Boisvert FM, 2000, J CELL BIOL, V148, P283, DOI 10.1083/jcb.148.2.283; Borden KLB, 2008, BBA-MOL CELL RES, V1783, P2145, DOI 10.1016/j.bbamcr.2008.06.005; Calzado MA, 2007, CELL CYCLE, V6, P139, DOI 10.4161/cc.6.2.3788; D'Orazi G, 2002, NAT CELL BIOL, V4, P11, DOI 10.1038/ncb714; Dauth I, 2007, CANCER RES, V67, P2274, DOI 10.1158/0008-5472.CAN-06-2884; de Stanchina E, 2004, MOL CELL, V13, P523, DOI 10.1016/S1097-2765(04)00062-0; Dellaire G, 2004, BIOESSAYS, V26, P963, DOI 10.1002/bies.20089; Dellaire G, 2006, J CELL BIOL, V175, P55, DOI 10.1083/jcb.200604009; DETHE H, 1991, CELL, V66, P675, DOI 10.1016/0092-8674(91)90113-D; Di Stefano V, 2004, ONCOGENE, V23, P5185, DOI 10.1038/sj.onc.1207656; Fogal V, 2000, EMBO J, V19, P6185, DOI 10.1093/emboj/19.22.6185; Gresko E, 2006, EMBO J, V25, P1883, DOI 10.1038/sj.emboj.7601077; Hayakawa F, 2004, CANCER CELL, V5, P389, DOI 10.1016/S1535-6108(04)00082-0; Hess D, 2008, J BIOL CHEM, V283, P7354, DOI 10.1074/jbc.M710251200; Hofmann TG, 2002, NAT CELL BIOL, V4, P1, DOI 10.1038/ncb715; Ito K, 2008, NATURE, V453, P1072, DOI 10.1038/nature07016; Kamitani T, 1998, J BIOL CHEM, V273, P3117, DOI 10.1074/jbc.273.6.3117; Kramer OH, 2008, FASEB J, V22, P1369, DOI 10.1096/fj.06-8050com; Lallemand-Breitenbach V, 2008, NAT CELL BIOL, V10, P547, DOI 10.1038/ncb1717; Li XL, 2007, ONCOGENE, V26, P7231, DOI 10.1038/sj.onc.1210523; Link N, 2007, J CELL BIOL, V178, P567, DOI 10.1083/jcb.200702125; Maul GG, 2000, J STRUCT BIOL, V129, P278, DOI 10.1006/jsbi.2000.4239; Moller A, 2003, CANCER RES, V63, P4310; Perkins DN, 1999, ELECTROPHORESIS, V20, P3551, DOI 10.1002/(SICI)1522-2683(19991201)20:18<3551::AID-ELPS3551>3.0.CO;2-2; Reineke EL, 2008, MOL CELL BIOL, V28, P997, DOI 10.1128/MCB.01848-07; Rinaldo C, 2007, BIOCHEM CELL BIOL, V85, P411, DOI 10.1139/O07-071; Roscic A, 2006, MOL CELL, V24, P77, DOI 10.1016/j.molcel.2006.08.004; Scaglioni PP, 2006, CELL, V126, P269, DOI 10.1016/j.cell.2006.05.041; Shen TH, 2006, MOL CELL, V24, P331, DOI 10.1016/j.molcel.2006.09.013; Tagata Y, 2008, LEUKEMIA, V22, P273, DOI 10.1038/sj.leu.2405024; Takahashi Y, 2004, ONCOGENE, V23, P2819, DOI 10.1038/sj.onc.1207533; Tatham MH, 2008, NAT CELL BIOL, V10, P538, DOI 10.1038/ncb1716; Villa R, 2007, CANCER CELL, V11, P513, DOI 10.1016/j.ccr.2007.04.009; Wang ZY, 2008, BLOOD, V111, P2505, DOI 10.1182/blood-2007-07-102798; Wei GW, 2007, P NATL ACAD SCI USA, V104, P13040, DOI 10.1073/pnas.0703213104; Yang ST, 2002, NAT CELL BIOL, V4, P865, DOI 10.1038/ncb869	39	33	37	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 5	2009	28	5					698	708		10.1038/onc.2008.420	http://dx.doi.org/10.1038/onc.2008.420			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	403IN	19015637	Bronze			2022-12-28	WOS:000263076400007
J	Li, DD; Wang, L; Deng, R; Tang, J; Shen, Y; Guo, JF; Wang, Y; Xia, LP; Feng, GK; Liu, QQ; Huang, WL; Zeng, YX; Zhu, XF				Li, D-D; Wang, L-L; Deng, R.; Tang, J.; Shen, Y.; Guo, J-F; Wang, Y.; Xia, L-P; Feng, G-K; Liu, Q. Q.; Huang, W-L; Zeng, Y-X; Zhu, X-F			The pivotal role of c-Jun NH2-terminal kinase-mediated Beclin 1 expression during anticancer agents-induced autophagy in cancer cells	ONCOGENE			English	Article						c-Jun NH2-terminal kinase (JNK); autophagy; ceramide; Beclin 1	PROTEIN-KINASE; CERAMIDE; DEATH; MACROAUTOPHAGY; PATHWAY; INHIBITION; SURVIVAL; DEGRADATION; MECHANISMS; INDUCTION	The c-Jun NH2-terminal kinase (JNK) pathway represents one subgroup of MAP kinases that are activated primarily by cytokines and exposure to environmental stress. Autophagy is a protein-degradation system characterized by the formation of double-membrane vacuoles termed autophagosomes. Autophagy-related gene beclin 1 plays a key role in autophagosome formation. However, the relationships between activation of JNK pathway, autophagy induction and Beclin 1 expression remain elusive. In this study, we used human cancer cell lines CNE2 and Hep3B to investigate the role of JNK-mediated Beclin 1 expression in ceramide-induced autophagic cell death. Ceramide-treated cells exhibited the characteristics of autophagy (that is, acidic vesicular organelle formation and the LC3-II generation). JNK was activated in these two cell lines exposed to ceramide and the phosphorylation of c-Jun also increased. In the meantime, we found that ceramide upregulated Beclin 1 expression in cancer cells. The upregulation of Beclin 1 expression could be blocked by SP600125 (a specific inhibitor of JNK) or a small interfering RNA (siRNA) directed against JNK1/2 or c-Jun. Chromatin immunoprecipitation and luciferase reporter analysis revealed that c-Jun was involved in the regulation of beclin 1 transcription in response to ceramide treatment. In addition, inhibition of JNK activity by SP600125 could inhibit autophagy induction by ceramide. Furthermore, Beclin 1 knockdown by siRNA also inhibited ceramide-mediated autophagic cell death. JNK-mediated Beclin 1 expression was also observed in topotecan-induced autophagy. These data suggest that activation of JNK pathway can mediate Beclin 1 expression, which plays a key role in autophagic cell death in cancer cells.	[Li, D-D; Wang, L-L; Deng, R.; Tang, J.; Shen, Y.; Guo, J-F; Wang, Y.; Xia, L-P; Feng, G-K; Liu, Q. Q.; Huang, W-L; Zeng, Y-X; Zhu, X-F] Sun Yat Sen Univ, State Key Lab Oncol S China, Ctr Canc, Guangzhou 510060, Guangdong, Peoples R China	Sun Yat Sen University	Zhu, XF (corresponding author), Sun Yat Sen Univ, State Key Lab Oncol S China, Ctr Canc, 651 Dongfeng Rd E, Guangzhou 510060, Guangdong, Peoples R China.	zhuxfeng@mail.sysu.edu.cn	huang, wen/GXW-0661-2022		National Nature Science Foundation of China [30572363, 30873085]; 863 programme [2006AA02A404]	National Nature Science Foundation of China(National Natural Science Foundation of China (NSFC)); 863 programme(National High Technology Research and Development Program of China)	This study was supported by grants from the National Nature Science Foundation of China (30572363, 30873085) and 863 programme (2006AA02A404).	Abeliovich H, 2000, J CELL BIOL, V151, P1025, DOI 10.1083/jcb.151.5.1025; Arico S, 2001, J BIOL CHEM, V276, P35243, DOI 10.1074/jbc.C100319200; Baehrecke EH, 2003, CELL DEATH DIFFER, V10, P940, DOI 10.1038/sj.cdd.4401280; Bergamini E, 2003, BIOMED PHARMACOTHER, V57, P203, DOI 10.1016/S0753-3322(03)00048-9; BLOMMAART EFC, 1995, J BIOL CHEM, V270, P2320, DOI 10.1074/jbc.270.5.2320; Bursch W, 2001, CELL DEATH DIFFER, V8, P569, DOI 10.1038/sj.cdd.4400852; Cao Q, 2008, INT J BIOCHEM CELL B, V40, P272, DOI 10.1016/j.biocel.2007.07.020; Chu CT, 2007, AUTOPHAGY, V3, P663, DOI 10.4161/auto.4625; CIFONE MG, 1994, J EXP MED, V180, P1547, DOI 10.1084/jem.180.4.1547; Cuervo AM, 2004, TRENDS CELL BIOL, V14, P70, DOI 10.1016/j.tcb.2003.12.002; Daido S, 2004, CANCER RES, V64, P4286, DOI 10.1158/0008-5472.CAN-03-3084; Degenhardt K, 2006, CANCER CELL, V10, P51, DOI 10.1016/j.ccr.2006.06.001; Deng R, 2006, ONCOGENE, V25, P7070, DOI 10.1038/sj.onc.1209686; Ertmer A, 2007, LEUKEMIA, V21, P936, DOI 10.1038/sj.leu.2404606; Furuya N, 2005, AUTOPHAGY, V1, P46, DOI 10.4161/auto.1.1.1542; Gewies A, 2000, LAB INVEST, V80, P671, DOI 10.1038/labinvest.3780070; Goggel R, 2004, NAT MED, V10, P155, DOI 10.1038/nm977; Gururajan M, 2005, BLOOD, V106, P1382, DOI 10.1182/blood-2004-10-3819; HAIMOVITZFRIEDMAN A, 1994, J EXP MED, V180, P525, DOI 10.1084/jem.180.2.525; Hamdi M, 2005, ONCOGENE, V24, P7135, DOI 10.1038/sj.onc.1208875; Huwiler A, 2004, BBA-MOL CELL BIOL L, V1636, P159, DOI 10.1016/j.bbalip.2003.08.010; Kabeya Y, 2000, EMBO J, V19, P5720, DOI 10.1093/emboj/19.21.5720; Kanzawa T, 2004, CELL DEATH DIFFER, V11, P448, DOI 10.1038/sj.cdd.4401359; Kihara A, 2001, EMBO REP, V2, P330, DOI 10.1093/embo-reports/kve061; KIM MY, 1991, J BIOL CHEM, V266, P484; Kim WH, 2005, NEUROCHEM RES, V30, P969, DOI 10.1007/s11064-005-6223-y; Kondo Y, 2005, NAT REV CANCER, V5, P726, DOI 10.1038/nrc1692; Kops GJPL, 2002, NATURE, V419, P316, DOI 10.1038/nature01036; Larsen KE, 2002, HISTOL HISTOPATHOL, V17, P897, DOI 10.14670/HH-17.897; Levine B, 2004, DEV CELL, V6, P463, DOI 10.1016/S1534-5807(04)00099-1; Levine B, 2007, NATURE, V446, P745, DOI 10.1038/446745a; Liang XH, 1999, NATURE, V402, P672, DOI 10.1038/45257; Liang XH, 2001, CANCER RES, V61, P3443; Liu JN, 2007, LEUKEMIA, V21, P1300, DOI 10.1038/sj.leu.2404652; Melendez A, 2003, SCIENCE, V301, P1387, DOI 10.1126/science.1087782; Mengubas K, 1999, ONCOGENE, V18, P2499, DOI 10.1038/sj.onc.1202622; Mizushima N, 2004, INT J BIOCHEM CELL B, V36, P2491, DOI 10.1016/j.biocel.2004.02.005; Mochizuki T, 2002, J BIOL CHEM, V277, P2790, DOI 10.1074/jbc.M106361200; Nishino Ichizo, 2003, Curr Neurol Neurosci Rep, V3, P64, DOI 10.1007/s11910-003-0040-y; Noda T, 1998, J BIOL CHEM, V273, P3963, DOI 10.1074/jbc.273.7.3963; OBEID LM, 1993, SCIENCE, V259, P1769, DOI 10.1126/science.8456305; Ogata M, 2006, MOL CELL BIOL, V26, P9220, DOI 10.1128/MCB.01453-06; Ogier-Denis E, 2003, BBA-REV CANCER, V1603, P113, DOI 10.1016/S0304-419X(03)00004-0; Otto GP, 2003, J BIOL CHEM, V278, P17636, DOI 10.1074/jbc.M212467200; Petiot A, 2000, J BIOL CHEM, V275, P992, DOI 10.1074/jbc.275.2.992; Saftig P, 2001, TRENDS MOL MED, V7, P37, DOI 10.1016/S1471-4914(00)01868-2; Scarlatti F, 2004, J BIOL CHEM, V279, P18384, DOI 10.1074/jbc.M313561200; SEGLEN PO, 1992, EXPERIENTIA, V48, P158, DOI 10.1007/BF01923509; Verheij M, 1996, NATURE, V380, P75, DOI 10.1038/380075a0; Wang ZH, 2007, GYNECOL ONCOL, V107, P107, DOI 10.1016/j.ygyno.2007.05.034; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Yu L, 2004, SCIENCE, V304, P1500, DOI 10.1126/science.1096645; Yuan J, 2003, NEURON, V40, P401, DOI 10.1016/S0896-6273(03)00601-9; Yue ZY, 2003, P NATL ACAD SCI USA, V100, P15077, DOI 10.1073/pnas.2436255100; Zhang PS, 1996, J NEUROSCI RES, V46, P114, DOI 10.1002/(SICI)1097-4547(19961001)46:1<114::AID-JNR14>3.0.CO;2-5; Zheng W, 2006, BBA-BIOMEMBRANES, V1758, P1864, DOI 10.1016/j.bbamem.2006.08.009; Zhou JM, 2006, ONCOGENE, V25, P503, DOI 10.1038/sj.onc.1209067; Zhu XF, 2005, MOL PHARMACOL, V67, P1444, DOI 10.1124/mol.104.009894	58	210	220	1	29	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2009	28	6					886	898		10.1038/onc.2008.441	http://dx.doi.org/10.1038/onc.2008.441			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	406UI	19060920				2022-12-28	WOS:000263320000011
J	Kang, X; Chen, W; Kim, RH; Kang, MK; Park, NH				Kang, X.; Chen, W.; Kim, R. H.; Kang, M. K.; Park, N-H			Regulation of the hTERT promoter activity by MSH2, the hnRNPs K and D, and GRHL2 in human oral squamous cell carcinoma cells	ONCOGENE			English	Article						hTERT; telomerase; GRHL2; hnRNPs; MSH2; oral cancer	TELOMERASE-REVERSE-TRANSCRIPTASE; CATALYTIC SUBUNIT; GENE; EXPRESSION; BINDING; PROTEIN; CANCER; KERATINOCYTES; SP1; CARCINOGENESIS	Higher expression of human telomerase reverse transcriptase (hTERT) and subsequent activation of telomerase occur during cellular immortalization and are maintained in cancer cells. To understand the mode of hTERT expression in cancer cells, we identified cancer-specific trans-regulatory proteins that interact with the hTERT promoter, using the promoter magnetic precipitation assay coupled with mass spectrometry. The identified proteins include MutS homolog 2(MSH2), heterogeneous nuclear ribonucleoprotein (hnRNP) D, hnRNP K and grainyhead-like 2(GRHL2). We noticed a higher expression of these proteins in human oral squamous cell carcinoma (OSCC) cells than in normal cells, which do not exhibit telomerase activity. Knockdown of MSH2, hnRNP D and GRHL2 resulted in a notable reduction of the hTERT promoter activity in tested cancer cells. Silencing of the above genes resulted in a significant reduction of the telomerase activity in OSCC cells. Interestingly, among the four identified genes, silencing of GRHL2 was essential in reducing telomerase activity and viability of tested cancer cells. These results suggest a possible role of GRHL2 in telomerase activation during cellular immortalization.	[Kang, X.; Chen, W.; Kim, R. H.; Kang, M. K.; Park, N-H] Univ Calif Los Angeles, Sch Dent, Ctr Hlth Sci, Los Angeles, CA 90095 USA; [Kim, R. H.; Kang, M. K.; Park, N-H] Univ Calif Los Angeles, Dent Res Inst, Los Angeles, CA 90095 USA; [Kim, R. H.; Kang, M. K.; Park, N-H] Univ Calif Los Angeles, Jonsson Comprehens Canc Ctr, Los Angeles, CA 90095 USA; [Park, N-H] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; UCLA Jonsson Comprehensive Cancer Center; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Kang, MK (corresponding author), Univ Calif Los Angeles, Sch Dent, Ctr Hlth Sci, Room 43-009,10833 Le Conte Ave, Los Angeles, CA 90095 USA.	mkang@dentistry.ucla.edu; nhpark@dentistry.ucla.edu			NIDCR [K22DE15316, R01DE18295, K02DE18959]; NIH; NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [K02DE018959] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE018295, K22DE015316, R01DE014147] Funding Source: NIH RePORTER	NIDCR(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))	We thank Dr JC Barrett (NIEHS/NIH) for providing the pGL3B-TRTP vector. This study was supported in part by the Grants (K22DE15316, R01DE18295, and K02DE18959 to MKK and R01DE14147 to N-HP) from NIDCR/NIH.	Cairney CJ, 2008, BIOCHIMIE, V90, P13, DOI 10.1016/j.biochi.2007.07.025; Campbell MR, 2006, ONCOGENE, V25, P2531, DOI 10.1038/sj.onc.1209277; Cong YS, 1999, HUM MOL GENET, V8, P137, DOI 10.1093/hmg/8.1.137; Deng WG, 2007, J BIOL CHEM, V282, DOI 10.1074/jbc.M610579200; EMILI A, 1994, MOL CELL BIOL, V14, P1582, DOI 10.1128/MCB.14.3.1582; Fujiki T, 2007, ONCOGENE, V26, P5258, DOI 10.1038/sj.onc.1210331; He C, 2006, EMBO J, V25, P3823, DOI 10.1038/sj.emboj.7601264; Isenmann S, 2007, J BONE MINER RES, V22, P897, DOI 10.1359/JBMR.070308; Kang MK, 2007, BRIT J CANCER, V96, P126, DOI 10.1038/sj.bjc.6603529; Kang MK, 2004, J CELL PHYSIOL, V199, P364, DOI 10.1002/jcp.10410; Kang MK, 1998, CELL GROWTH DIFFER, V9, P85; Kiledjian M, 1997, MOL CELL BIOL, V17, P4870, DOI 10.1128/MCB.17.8.4870; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; Kim RH, 2007, EXP CELL RES, V313, P462, DOI 10.1016/j.yexcr.2006.10.025; Kyo S, 2000, NUCLEIC ACIDS RES, V28, P669, DOI 10.1093/nar/28.3.669; Lebel R, 2007, BIOCHEMISTRY-US, V46, P10279, DOI 10.1021/bi700076m; Lou F, 2007, MOL CANCER RES, V5, P793, DOI 10.1158/1541-7786.MCR-07-0065; Lynch M, 2005, MOL CELL BIOL, V25, P6436, DOI 10.1128/MCB.25.15.6436-6453.2005; Moumen A, 2005, CELL, V123, P1065, DOI 10.1016/j.cell.2005.09.032; Ostareck-Lederer A, 2004, BIOL CELL, V96, P407, DOI 10.1016/j.biolcel.2004.03.010; Ostrowski J, 2004, J BIOL CHEM, V279, P54599, DOI 10.1074/jbc.M406753200; PARK NH, 1991, CARCINOGENESIS, V12, P1627, DOI 10.1093/carcin/12.9.1627; Poole JC, 2001, GENE, V269, P1, DOI 10.1016/S0378-1119(01)00440-1; Rizki A, 2001, NATURE, V411, P713, DOI 10.1038/35079641; Roychoudhury P, 2007, BRIT J CANCER, V97, P574, DOI 10.1038/sj.bjc.6603911; Shay JW, 2008, BRIT J CANCER, V98, P677, DOI 10.1038/sj.bjc.6604209; Stramer B, 2005, CURR BIOL, V15, pR425, DOI 10.1016/j.cub.2005.05.034; Suzuki T, 2003, J BIOL CHEM, V278, P28758, DOI 10.1074/jbc.M302228200; Wagner BJ, 1998, GENOMICS, V48, P195, DOI 10.1006/geno.1997.5142; Wilanowski T, 2002, MECH DEVELOP, V114, P37, DOI 10.1016/S0925-4773(02)00046-1; Won J, 2002, J BIOL CHEM, V277, P38230, DOI 10.1074/jbc.M206064200; Yan P, 2001, J PATHOL, V193, P21, DOI 10.1002/1096-9896(2000)9999:9999<::AID-PATH728>3.0.CO;2-G; Zhu QJ, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001446	33	75	86	1	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 29	2009	28	4					565	574		10.1038/onc.2008.404	http://dx.doi.org/10.1038/onc.2008.404			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	400KM	19015635	Green Accepted			2022-12-28	WOS:000262866500010
J	Segditsas, S; Rowan, AJ; Howarth, K; Jones, A; Leedham, S; Wright, NA; Gorman, P; Chambers, W; Domingo, E; Roylance, RR; Sawyer, EJ; Sieber, OM; Tomlinson, IPM				Segditsas, S.; Rowan, A. J.; Howarth, K.; Jones, A.; Leedham, S.; Wright, N. A.; Gorman, P.; Chambers, W.; Domingo, E.; Roylance, R. R.; Sawyer, E. J.; Sieber, O. M.; Tomlinson, I. P. M.			APC and the three-hit hypothesis	ONCOGENE			English	Article						two hits; tumour suppressor; APC; Wnt; copy number change; 'just right'	FAMILIAL ADENOMATOUS POLYPOSIS; COMPARATIVE GENOMIC HYBRIDIZATION; CHROMOSOMAL INSTABILITY; COLORECTAL ADENOMAS; SOMATIC MUTATIONS; GERMLINE MUTATION; BETA-CATENIN; CANCERS; ALLELES; MODEL	The seminal 'two-hit hypothesis' implicitly assumes that bi-allelic tumour suppressor gene (TSG) mutations cause loss of protein function. All subsequent events in that tumour therefore take place on an essentially null background for that TSG protein. We have shown that the two-hit model requires modi. cation for the APC TSG, because mutant APC proteins probably retain some function and the two hits are co-selected to produce an optimal level of Wnt activation. We wondered whether the optimal Wnt level might change during tumour progression, leading to selection for more than two hits at the APC locus. Comprehensive screening of a panel of colorectal cancer (CRC) cell lines and primary CRCs showed that some had indeed acquired third hits at APC. These third hits were mostly copy number gains or deletions, but could be protein-truncating mutations. Third hits were significantly less common when the second hit at APC had arisen by copy-neutral loss of heterozygosity. Both polyploid and near-diploid CRCs had third hits, and the third hits did not simply arise as a result of acquiring a polyploid karyotype. The third hits affected mRNA and protein levels, with potential functional consequences for Wnt signalling and tumour growth. Although some third hits were probably secondary to genomic instability, others did appear specifically to target APC. Whilst it is generally believed that tumours develop and progress through stepwise accumulation of mutations in different functional pathways, it also seems that repeated targeting of the same pathway and/or gene is selected in some cancers.	[Segditsas, S.; Rowan, A. J.; Howarth, K.; Jones, A.; Gorman, P.; Chambers, W.; Domingo, E.; Roylance, R. R.; Sawyer, E. J.; Sieber, O. M.; Tomlinson, I. P. M.] Canc Res UK, London Res Inst, Mol & Populat Genet Lab, London, England; [Leedham, S.; Wright, N. A.] Canc Res UK, London Res Inst, Histopathol Lab, London, England; [Chambers, W.] Oxford Radcliffe Hosp, Dept Colorectal Surg & Genet Knowledge Pk, Oxford, England	Cancer Research UK; Cancer Research UK; University of Oxford	Tomlinson, IPM (corresponding author), Univ Oxford, Wellcome Trust Ctr Human Genet, Roosevelt Dr, Oxford OX3 7BN, England.	iant@well.ox.ac.uk	Domingo, Enric/A-9099-2018; Sieber, Oliver/ABA-9211-2021; Wright, Nicholas/HHY-7227-2022; Sieber, Oliver/M-9473-2015	Domingo, Enric/0000-0003-4390-8767; Sieber, Oliver/0000-0001-9480-0786; Sieber, Oliver/0000-0001-9480-0786; Wright, Nicholas/0000-0002-5525-3457	MRC [G84/6549] Funding Source: UKRI; National Institute for Health Research [03/DHCS/03/G121/51] Funding Source: researchfish; Medical Research Council [G84/6549] Funding Source: Medline	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); National Institute for Health Research(National Institute for Health Research (NIHR)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Albuquerque C, 2002, HUM MOL GENET, V11, P1549, DOI 10.1093/hmg/11.13.1549; Fiegler H, 2003, GENE CHROMOSOME CANC, V36, P361, DOI 10.1002/gcc.10155; Fodde R, 2001, TRENDS MOL MED, V7, P369, DOI 10.1016/S1471-4914(01)02050-0; Gaasenbeek M, 2006, CANCER RES, V66, P3471, DOI 10.1158/0008-5472.CAN-05-3285; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Jones AM, 2007, J PATHOL, V213, P249, DOI 10.1002/path.2234; Knudson AG, 2001, NAT REV CANCER, V1, P157, DOI 10.1038/35101031; Lamlum H, 1999, NAT MED, V5, P1071, DOI 10.1038/12511; Leslie A, 2006, GENE CHROMOSOME CANC, V45, P126, DOI 10.1002/gcc.20271; Michor F, 2005, SEMIN CANCER BIOL, V15, P43, DOI 10.1016/j.semcancer.2004.09.007; Schneikert J, 2007, HUM MOL GENET, V16, P199, DOI 10.1093/hmg/ddl464; Sieber OM, 2006, GUT, V55, P1440, DOI 10.1136/gut.2005.087106; Sieber OM, 2005, NAT REV CANCER, V5, P649, DOI 10.1038/nrc1674; Sieber OM, 2002, P NATL ACAD SCI USA, V99, P16910, DOI 10.1073/pnas.012679099; Spirio LN, 1998, NAT GENET, V20, P385, DOI 10.1038/3865; Su LK, 2000, AM J HUM GENET, V67, P582, DOI 10.1086/303058; Wood LD, 2007, SCIENCE, V318, P1108, DOI 10.1126/science.1145720	17	45	45	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 8	2009	28	1					146	155		10.1038/onc.2008.361	http://dx.doi.org/10.1038/onc.2008.361			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	392HP	18836487				2022-12-28	WOS:000262294100015
J	Schaeffer, EM; Marchionni, L; Huang, Z; Simons, B; Blackman, A; Yu, W; Parmigiani, G; Berman, DM				Schaeffer, E. M.; Marchionni, L.; Huang, Z.; Simons, B.; Blackman, A.; Yu, W.; Parmigiani, G.; Berman, D. M.			Androgen-induced programs for prostate epithelial growth and invasion arise in embryogenesis and are reactivated in cancer	ONCOGENE			English	Article						prostate organogenesis; androgen signaling; prostate cancer; microarray	INTRAEPITHELIAL NEOPLASIA; GENE-EXPRESSION; MURINE PROSTATE; MOUSE PROSTATE; BETA-CATENIN; STEM-CELLS; RECEPTOR; ADENOCARCINOMA; TUMORIGENESIS; GENOME	Cancer cells differentiate along specific lineages that largely determine their clinical and biologic behavior. Distinct cancer phenotypes from different cells and organs likely result from unique gene expression repertoires established in the embryo and maintained after malignant transformation. We used comprehensive gene expression analysis to examine this concept in the prostate, an organ with a tractable developmental program and a high propensity for cancer. We focused on gene expression in the murine prostate rudiment at three time points during the first 48 h of exposure to androgen, which initiates proliferation and invasion of prostate epithelial buds into surrounding urogenital sinus mesenchyme. Here, we show that androgen exposure regulates genes previously implicated in prostate carcinogenesis comprising pathways for the phosphatase and tensin homolog (PTEN), fibroblast growth factor (FGF)/mitogen-activated protein kinase (MAPK), and Wnt signaling along with cellular programs regulating such 'hallmarks' of cancer as angiogenesis, apoptosis, migration and proliferation. We found statistically significant evidence for novel androgen-induced gene regulation events that establish and/or maintain prostate cell fate. These include modulation of gene expression through microRNAs, expression of specific transcription factors, and regulation of their predicted targets. By querying public gene expression databases from other tissues, we found that rather than generally characterizing androgen exposure or epithelial budding, the early prostate development program more closely resembles the program for human prostate cancer. Most importantly, early androgen-regulated genes and functional themes associated with prostate development were highly enriched in contrasts between increasingly lethal forms of prostate cancer, confirming a 'reactivation' of embryonic pathways for proliferation and invasion in prostate cancer progression. Among the genes with the most significant links to the development and cancer, we highlight coordinate induction of the transcription factor Sox9 and suppression of the proapoptotic phospholipid-binding protein Annexin A1 that link early prostate development to early prostate carcinogenesis. These results credential early prostate development as a reliable and valid model system for the investigation of genes and pathways that drive prostate cancer.	[Schaeffer, E. M.; Huang, Z.; Simons, B.; Parmigiani, G.; Berman, D. M.] Johns Hopkins Univ, Sch Med, Dept Pathol, Baltimore, MD 21231 USA; [Schaeffer, E. M.; Huang, Z.; Berman, D. M.] Johns Hopkins Univ, Sch Med, Dept Urol, Baltimore, MD 21231 USA; [Schaeffer, E. M.; Marchionni, L.; Blackman, A.; Yu, W.; Parmigiani, G.; Berman, D. M.] Johns Hopkins Univ, Sch Med, Dept Oncol, Baltimore, MD 21231 USA; [Parmigiani, G.] Johns Hopkins Univ, Sch Med, Dept Biostat, Baltimore, MD 21231 USA	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University	Berman, DM (corresponding author), Johns Hopkins Univ, Sch Med, Dept Pathol, CRB2 Room 545,1550 Orleans St, Baltimore, MD 21231 USA.	berman@jhmi.edu	Simons, Brian W./G-7352-2015; Marchionni, Luigi/S-6774-2017; berman, david/HIR-4177-2022; Thomson, Axel/A-7893-2013	Simons, Brian W./0000-0003-0644-211X; Marchionni, Luigi/0000-0002-7336-8071; berman, david/0000-0001-5985-3698	Evensen Family; Evensen Family, Passano and Patrick C Walsh Prostate Cancer Foundations;  [NIH5K08DK059375];  [NIHK08 DK081019];  [NIH5P30CA06973-39];  [NSF034211]; NATIONAL CANCER INSTITUTE [P30CA006973] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K08DK059375, K08DK081019] Funding Source: NIH RePORTER	Evensen Family; Evensen Family, Passano and Patrick C Walsh Prostate Cancer Foundations; ; ; ; ; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	We thank W Matsui and N Watkins for comments on the manuscript, A DeMarzo and J Epstein for TMAs and YQ Chen for prostate regeneration data. These studies were funded by the Evensen Family, Passano and Patrick C Walsh Prostate Cancer Foundations, and NIH5K08DK059375 (DB) NIHK08 DK081019 (EMS), NIH5P30CA06973-39 (GP) and NSF034211 (GPand LM).	Acevedo VD, 2007, CANCER CELL, V12, P559, DOI 10.1016/j.ccr.2007.11.004; Ashburner M, 2003, COLD SPRING HARB SYM, V68, P227, DOI 10.1101/sqb.2003.68.227; Bailey P, 1925, ARCH NEURO PSYCHIATR, V14, P192, DOI 10.1001/archneurpsyc.1925.02200140055002; Benjamini Y, 2001, BEHAV BRAIN RES, V125, P279, DOI 10.1016/S0166-4328(01)00297-2; Berman DM, 2004, DEV BIOL, V267, P387, DOI 10.1016/j.ydbio.2003.11.018; Bernards R, 2002, NATURE, V418, P823, DOI 10.1038/418823a; Bhatia-Gaur R, 1999, GENE DEV, V13, P966, DOI 10.1101/gad.13.8.966; Bivalacqua TJ, 2007, AM J PHYSIOL-HEART C, V292, pH1278, DOI 10.1152/ajpheart.00685.2006; Bostwick DG, 2004, MODERN PATHOL, V17, P360, DOI 10.1038/modpathol.3800053; Crawford HC, 1999, ONCOGENE, V18, P2883, DOI 10.1038/sj.onc.1202627; Cunha GR, 2004, ARCH HISTOL CYTOL, V67, P417, DOI 10.1679/aohc.67.417; Donjacour AA, 2003, DEV BIOL, V261, P39, DOI 10.1016/S0012-1606(03)00250-1; Drews U, 2001, HISTOCHEM CELL BIOL, V116, P427, DOI 10.1007/s00418-001-0335-5; ENGLISH HF, 1987, PROSTATE, V11, P229, DOI 10.1002/pros.2990110304; FRIEND SH, 1986, NATURE, V323, P643, DOI 10.1038/323643a0; Garraway LA, 2006, NAT REV CANCER, V6, P593, DOI 10.1038/nrc1947; Gentleman RC, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-10-r80; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; IHAKA R, 1996, J COMPUTATIONAL GRAP, V5, P299, DOI DOI 10.2307/1390807; Ii M, 2006, EXP BIOL MED, V231, P20; Irizarry RA, 2005, NAT METHODS, V2, P345, DOI 10.1038/nmeth756; Joesting MS, 2005, CANCER RES, V65, P10423, DOI 10.1158/0008-5472.CAN-05-0824; JOST A, 1968, PERSPECT BIOL MED, V11, P371; Kanehisa M, 2004, NUCLEIC ACIDS RES, V32, pD277, DOI 10.1093/nar/gkh063; Kang JS, 2002, CLIN CANCER RES, V8, P117; Kang YB, 2003, CANCER CELL, V3, P537, DOI 10.1016/S1535-6108(03)00132-6; Kho AT, 2004, GENE DEV, V18, P629, DOI 10.1101/gad.1182504; Kousteni S, 2001, CELL, V104, P719, DOI 10.1016/S0092-8674(01)00268-9; Lapointe J, 2004, P NATL ACAD SCI USA, V101, P811, DOI 10.1073/pnas.0304146101; Lawson DA, 2007, P NATL ACAD SCI USA, V104, P181, DOI 10.1073/pnas.0609684104; Long X, 2005, CURR BIOL, V15, P702, DOI 10.1016/j.cub.2005.02.053; Lu J, 2004, DEV BIOL, V273, P418, DOI 10.1016/j.ydbio.2004.05.035; Manolagas SC, 2002, RECENT PROG HORM RES, V57, P385, DOI 10.1210/rp.57.1.385; McMenamin ME, 1999, CANCER RES, V59, P4291; Memarzadeh S, 2007, CANCER CELL, V12, P572, DOI 10.1016/j.ccr.2007.11.002; Mohammadi M, 2005, CYTOKINE GROWTH F R, V16, P107, DOI 10.1016/j.cytogfr.2005.01.008; Nam JS, 2007, DEV BIOL, V311, P124, DOI 10.1016/j.ydbio.2007.08.023; Nusse R, 2005, CELL RES, V15, P28, DOI 10.1038/sj.cr.7290260; Olsen SK, 2003, J BIOL CHEM, V278, P34226, DOI 10.1074/jbc.M303183200; Ornstein DK, 2006, UROL ONCOL-SEMIN ORI, V24, P231, DOI 10.1016/j.urolonc.2005.11.035; Ramaswamy S, 2001, P NATL ACAD SCI USA, V98, P15149, DOI 10.1073/pnas.211566398; Scher HI, 2005, J CLIN ONCOL, V23, P8253, DOI 10.1200/JCO.2005.03.4777; Shen MM, 2007, CANCER RES, V67, P6535, DOI 10.1158/0008-5472.CAN-07-1271; Smyth G.K., 2004, STAT APPL GENET MOL, V3, P3, DOI [10.2202/1544-6115.1027, DOI 10.2202/1544-6115.1027]; Stefani G, 2008, NAT REV MOL CELL BIO, V9, P219, DOI 10.1038/nrm2347; STEHELIN D, 1976, NATURE, V260, P170, DOI 10.1038/260170a0; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Thomson AA, 2001, REPRODUCTION, V121, P187, DOI 10.1530/rep.0.1210187; Tomlins SA, 2007, NAT GENET, V39, P41, DOI 10.1038/ng1935; Treister NS, 2005, J DENT RES, V84, P160, DOI 10.1177/154405910508400210; Verras M, 2006, CANCER LETT, V237, P22, DOI 10.1016/j.canlet.2005.06.004; Wang HY, 2007, CANCER RES, V67, P528, DOI 10.1158/0008-5472.CAN-06-1672; Wang SY, 2003, CANCER CELL, V4, P209, DOI 10.1016/S1535-6108(03)00215-0; Wang XD, 2007, DIFFERENTIATION, V75, P219, DOI 10.1111/j.1432-0436.2006.00135.x; Weir BA, 2007, NATURE, V450, P893, DOI 10.1038/nature06358; WILSON JD, 1980, BIOL REPROD, V22, P9, DOI 10.1095/biolreprod22.1.9; Xin L, 2005, P NATL ACAD SCI USA, V102, P6942, DOI 10.1073/pnas.0502320102; Xin L, 2003, P NATL ACAD SCI USA, V100, P11896, DOI 10.1073/pnas.1734139100; Xu JF, 2005, CANCER EPIDEM BIOMAR, V14, P2563, DOI 10.1158/1055-9965.EPI-05-0356; Yeager N, 2008, CANCER RES, V68, P444, DOI 10.1158/0008-5472.CAN-07-3030; Zeng L, 2005, PROSTATE CANCER P D, V8, P7, DOI 10.1038/sj.pcan.4500757; Zhang TJ, 2006, GENE EXPR PATTERNS, V6, P310, DOI 10.1016/j.modgep.2005.07.005; Zwick E, 2002, TRENDS MOL MED, V8, P17, DOI 10.1016/S1471-4914(01)02217-1	63	128	137	2	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC	2008	27	57					7180	7191		10.1038/onc.2008.327	http://dx.doi.org/10.1038/onc.2008.327			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	379GG	18794802	Green Accepted			2022-12-28	WOS:000261384100005
J	McKinnon, CM; Lygoe, KA; Skelton, L; Mitter, R; Mellor, H				McKinnon, C. M.; Lygoe, K. A.; Skelton, L.; Mitter, R.; Mellor, H.			The atypical Rho GTPase RhoBTB2 is required for expression of the chemokine CXCL14 in normal and cancerous epithelial cells	ONCOGENE			English	Article						Rho GTPase; BTB domain; microarray; cancer; tumor microenvironment; chemokine	MUTATION ANALYSIS; DENDRITIC CELLS; BREAST-CANCER; PROBE LEVEL; IN-VIVO; DBC2; GENE; BRAK; CANDIDATE; TISSUE	The Rho family of small GTPases control cell migration, cell invasion and cell cycle. Many of these processes are perturbed in cancer and several family members show altered expression in a number of tumor types. RhoBTB2/DBC2 is an atypical member of this family of signaling proteins, containing two BTB domains in addition to its conserved Rho GTPase domain. RhoBTB2 is mutated, deleted or silenced in a large percentage of breast and lung cancers; however, the functional consequences of this loss are unclear. Here we use RNA interference in primary human epithelial cells to mimic the loss of RhoBTB2 seen in cancer cells. Through microarray analysis of global gene expression, we show that loss of RhoBTB2 results in downregulation of CXCL14 - a chemokine that controls leukocyte migration and angiogenesis, and whose expression is lost through unknown mechanisms in a wide range of epithelial cancers. Loss of RhoBTB2 expression correlates with loss of CXCL14 secretion by head and neck squamous cell carcinoma cell lines, whereas reintroduction of RhoBTB2 restores CXCL14 secretion. Our studies identify CXCL14 as a gene target of RhoBTB2 and support downregulation of CXCL14 as a functional outcome of RhoBTB2 loss in cancer. Oncogene (2008) 27, 6856 - 6865; doi: 10.1038/onc.2008.317;published online 1 September 2008	[McKinnon, C. M.; Lygoe, K. A.; Skelton, L.; Mellor, H.] Univ Bristol, Dept Biochem, Sch Med Sci, Bristol BS8 1TD, Avon, England; [Mitter, R.] Canc Res UK, London, England	University of Bristol; Cancer Research UK	Mellor, H (corresponding author), Univ Bristol, Dept Biochem, Sch Med Sci, Bristol BS8 1TD, Avon, England.	h.mellor@bris.ac.uk		Mitter, Richard/0000-0002-1279-3760; Mellor, Harry/0000-0003-3894-0623	Cancer Research UK	Cancer Research UK(Cancer Research UK)	We thank Ian Paterson for providing the HNSCC cell lines and Adrian Thrasher for the provision of lentiviral reagents. We particularly thank James Doherty, who provided initial analysis of the microarray data. This work was supported by a grant awarded to HM by Cancer Research UK.	Aspenstrom P, 2004, BIOCHEM J, V377, P327, DOI 10.1042/BJ20031041; BARDWELL VJ, 1994, GENE DEV, V8, P1664, DOI 10.1101/gad.8.14.1664; Beder LB, 2006, J CANCER RES CLIN, V132, P19, DOI 10.1007/s00432-005-0033-0; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Chang FK, 2006, J MOL BIOL, V364, P302, DOI 10.1016/j.jmb.2006.09.026; Clark EA, 2000, NATURE, V406, P532, DOI 10.1038/35020106; Demaison C, 2002, HUM GENE THER, V13, P803, DOI 10.1089/10430340252898984; Frederick MJ, 2000, AM J PATHOL, V156, P1937, DOI 10.1016/S0002-9440(10)65067-5; Gautier L, 2004, BIOINFORMATICS, V20, P307, DOI 10.1093/bioinformatics/btg405; Gentleman RC, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-10-r80; Hamaguchi M, 2002, P NATL ACAD SCI USA, V99, P13647, DOI 10.1073/pnas.212516099; Hromas R, 1999, BIOCHEM BIOPH RES CO, V255, P703, DOI 10.1006/bbrc.1999.0257; Irizarry RA, 2003, BIOSTATISTICS, V4, P249, DOI 10.1093/biostatistics/4.2.249; Kelly KF, 2006, TRENDS CELL BIOL, V16, P578, DOI 10.1016/j.tcb.2006.09.003; Knowles MA, 2005, CANCER LETT, V225, P121, DOI 10.1016/j.canlet.2004.10.047; Kobayashi A, 2004, MOL CELL BIOL, V24, P7130, DOI 10.1128/MCB.24.16.7130-7139.2004; Kurth I, 2001, J EXP MED, V194, P855, DOI 10.1084/jem.194.6.855; Ohadi M, 2007, ACTA ONCOL, V46, P770, DOI 10.1080/02841860601047752; Pasqualucci L, 2003, LEUKEMIA LYMPHOMA, V44, pS5, DOI 10.1080/10428190310001621588; Perez-Torrado R, 2006, BIOESSAYS, V28, P1194, DOI 10.1002/bies.20500; Prime S, 2004, J PATHOL, V203, P927, DOI 10.1002/path.1603; Ramos S, 2002, GENE, V298, P147, DOI 10.1016/S0378-1119(02)00980-0; Redner RL, 2002, LEUKEMIA, V16, P1927, DOI 10.1038/sj.leu.2402720; Ridley AJ, 2004, BREAST CANCER RES TR, V84, P13, DOI 10.1023/B:BREA.0000018423.47497.c6; Ridley AJ, 2006, TRENDS CELL BIOL, V16, P522, DOI 10.1016/j.tcb.2006.08.006; Rivero F, 2001, NUCLEIC ACIDS RES, V29, P1068, DOI 10.1093/nar/29.5.1068; Sahai E, 2002, NAT REV CANCER, V2, P133, DOI 10.1038/nrc725; Schaerli P, 2005, IMMUNITY, V23, P331, DOI 10.1016/j.immuni.2005.08.012; Schwarze SR, 2002, J BIOL CHEM, V277, P14877, DOI 10.1074/jbc.M200373200; Shellenberger TD, 2004, CANCER RES, V64, P8262, DOI 10.1158/0008-5472.CAN-04-2056; Shurin GV, 2005, J IMMUNOL, V174, P5490, DOI 10.4049/jimmunol.174.9.5490; Siripurapu V, 2005, J MOL BIOL, V346, P83, DOI 10.1016/j.jmb.2004.11.043; Smyth GK, 2005, STAT BIOL HEALTH, P397, DOI 10.1007/0-387-29362-0_23; Starnes T, 2006, EXP HEMATOL, V34, P1101, DOI 10.1016/j.exphem.2006.05.015; Wilkins A, 2004, GENE DEV, V18, P856, DOI 10.1101/gad.1177904; Yang L, 2004, ADV CANCER RES, V92, P13, DOI 10.1016/S0065-230X(04)92002-7	36	31	31	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 20	2008	27	54					6856	6865		10.1038/onc.2008.317	http://dx.doi.org/10.1038/onc.2008.317			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	375IS	18762809				2022-12-28	WOS:000261108000006
J	Heath-Engel, HM; Chang, NC; Shore, GC				Heath-Engel, H. M.; Chang, N. C.; Shore, G. C.			The endoplasmic reticulum in apoptosis and autophagy: role of the BCL-2 protein family	ONCOGENE			English	Review						BH3; ER stress; calcium; mitochondria; Beclin-1	STRESS-INDUCED APOPTOSIS; CYTOCHROME-C RELEASE; GLYCOGEN-SYNTHASE KINASE-3-BETA; CELL-DEATH PROGRAM; OUTER-MEMBRANE PERMEABILIZATION; THAPSIGARGIN-INDUCED APOPTOSIS; INOSITOL TRISPHOSPHATE RECEPTOR; DEPLETION-INDUCED APOPTOSIS; ER STRESS; PHOSPHATASE 2A	Apoptosis is essential for normal development and maintenance of homeostasis, and disruption of apoptotic pathways is associated with multiple disease states, including cancer. Although initially identified as central regulators of apoptosis at the level of mitochondria, an important role for BCL-2 proteins at the endoplasmic reticulum is now well established. Signaling pathways emanating from the endoplasmic reticulum ( ER) are involved in apoptosis initiated by stimuli as diverse as ER stress, oncogene expression, death receptor (DR) ligation and oxidative stress, and the BCL-2 family is almost invariably implicated in the regulation of these pathways. This also includes Ca2(+)-mediated cross talk between ER and mitochondria during apoptosis, which contributes to the mitochondrial dynamics that support the core mitochondrial apoptosis pathway. In addition to the regulation of apoptosis, BCL-2 proteins at the ER also regulate autophagy, a survival pathway that limits metabolic stress, genomic instability and tumorigenesis. In cases where apoptosis is inhibited, however, prolonged autophagy can lead to cell death. This review provides an overview of ER-associated apoptotic and autophagic signaling pathways, with particular emphasis on the BCL-2 family proteins.	[Heath-Engel, H. M.; Chang, N. C.; Shore, G. C.] McGill Univ, Dept Biochem, Montreal, PQ H3G 1Y6, Canada	McGill University	Shore, GC (corresponding author), McGill Univ, Dept Biochem, McIntyre Med Sci Bldg,Room 906B,3655 Promenade Si, Montreal, PQ H3G 1Y6, Canada.	gordon.shore@mcgill.ca		Chang, Natasha C./0000-0003-0589-9660	Canadian Institutes of Health Research Canada Graduate Scholarships Doctoral award	Canadian Institutes of Health Research Canada Graduate Scholarships Doctoral award(Canadian Institutes of Health Research (CIHR))	NCC is a recipient of the Canadian Institutes of Health Research Canada Graduate Scholarships Doctoral award.	Adams JM, 2007, ONCOGENE, V26, P1324, DOI 10.1038/sj.onc.1210220; Adams JM, 2007, CURR OPIN IMMUNOL, V19, P488, DOI 10.1016/j.coi.2007.05.004; Annis MG, 2001, ONCOGENE, V20, P1939, DOI 10.1038/sj.onc.1204288; Armstrong JL, 2007, APOPTOSIS, V12, P613, DOI 10.1007/s10495-006-0020-1; Baliga BC, 2004, CELL DEATH DIFFER, V11, P1234, DOI 10.1038/sj.cdd.4401492; Baltzis D, 2007, J BIOL CHEM, V282, P31675, DOI 10.1074/jbc.M704491200; Bassik MC, 2004, EMBO J, V23, P1207, DOI 10.1038/sj.emboj.7600104; Bayir H, 2006, BBA-BIOENERGETICS, V1757, P648, DOI 10.1016/j.bbabio.2006.03.002; Bhatt K, 2008, AM J PHYSIOL-RENAL, V294, pF499, DOI 10.1152/ajprenal.00415.2007; Boya P, 2002, CELL DEATH DIFFER, V9, P465, DOI 10.1038/sj.cdd.4401006; Breckenridge DG, 2003, J CELL BIOL, V160, P1115, DOI 10.1083/jcb.200212059; Breckenridge DG, 2003, ONCOGENE, V22, P8608, DOI 10.1038/sj.onc.1207108; Brewster JL, 2006, MOL CELL NEUROSCI, V32, P242, DOI 10.1016/j.mcn.2006.04.006; Buytaert E, 2006, FASEB J, V20, P756, DOI 10.1096/fj.05-4305fje; Chae HJ, 2004, MOL CELL, V15, P355, DOI 10.1016/j.molcel.2004.06.038; Chami M, 2004, J BIOL CHEM, V279, P54581, DOI 10.1074/jbc.M409663200; Chen G, 2004, FASEB J, V18, P1162, DOI 10.1096/fj.04-1551fje; Chen R, 2004, J CELL BIOL, V166, P193, DOI 10.1083/jcb.200309146; Cheung HH, 2006, EXP CELL RES, V312, P2347, DOI 10.1016/j.yexcr.2006.03.027; Chiang CW, 2003, MOL CELL BIOL, V23, P6350, DOI 10.1128/MCB.23.18.6350-6362.2003; Chiang CW, 2001, BLOOD, V97, P1289, DOI 10.1182/blood.V97.5.1289; Chipuk JE, 2008, TRENDS CELL BIOL, V18, P157, DOI 10.1016/j.tcb.2008.01.007; Christen V, 2007, HEPATOLOGY, V46, P558, DOI 10.1002/hep.21611; Cipolat S, 2006, CELL, V126, P163, DOI 10.1016/j.cell.2006.06.021; Cribbs JT, 2007, EMBO REP, V8, P939, DOI 10.1038/sj.embor.7401062; Dahmer MK, 2005, J NEUROSCI RES, V80, P576, DOI 10.1002/jnr.20471; Danial NN, 2004, CELL, V116, P205, DOI 10.1016/S0092-8674(04)00046-7; Danial NN, 2003, NATURE, V424, P952, DOI 10.1038/nature01825; Demaurex N, 2003, SCIENCE, V300, P65, DOI 10.1126/science.1083628; Deniaud A, 2008, ONCOGENE, V27, P285, DOI 10.1038/sj.onc.1210638; Di Sano F, 2006, J BIOL CHEM, V281, P2693, DOI 10.1074/jbc.M509110200; Dimmeler S, 1999, J EXP MED, V189, P1815, DOI 10.1084/jem.189.11.1815; Ding QQ, 2007, MOL CELL BIOL, V27, P4006, DOI 10.1128/MCB.00620-06; Distelhorst CW, 2004, ONCOGENE, V23, P2875, DOI 10.1038/sj.onc.1207519; Dong Z, 2006, ANNU REV PATHOL-MECH, V1, P405, DOI 10.1146/annurev.pathol.1.110304.100218; Dremina ES, 2006, BIOCHEMISTRY-US, V45, P175, DOI 10.1021/bi050800s; Dremina ES, 2004, BIOCHEM J, V383, P361, DOI 10.1042/BJ20040187; Elyaman W, 2002, MOL BRAIN RES, V109, P233, DOI 10.1016/S0169-328X(02)00582-X; Fischer H, 2002, BIOCHEM BIOPH RES CO, V293, P722, DOI 10.1016/S0006-291X(02)00289-9; Foskett JK, 2007, PHYSIOL REV, V87, P593, DOI 10.1152/physrev.00035.2006; Foyouzi-Youssefi R, 2000, P NATL ACAD SCI USA, V97, P5723, DOI 10.1073/pnas.97.11.5723; Frezza C, 2006, CELL, V126, P177, DOI 10.1016/j.cell.2006.06.025; Fujita E, 2002, CELL DEATH DIFFER, V9, P1108, DOI 10.1038/sj.cdd.4401080; Gao G, 2000, J CELL BIOCHEM, V80, P53; Gao ZH, 2005, J BIOL CHEM, V280, P38271, DOI 10.1074/jbc.M506488200; Garrido C, 2006, CELL DEATH DIFFER, V13, P1423, DOI 10.1038/sj.cdd.4401950; Germain M, 2005, EMBO J, V24, P1546, DOI 10.1038/sj.emboj.7600592; Gil-Parrado S, 2002, J BIOL CHEM, V277, P27217, DOI 10.1074/jbc.M202945200; Gonzalvez F, 2007, APOPTOSIS, V12, P877, DOI 10.1007/s10495-007-0718-8; Groenendyk J, 2004, MOL CELLS, V17, P383; Hacki J, 2000, ONCOGENE, V19, P2286, DOI 10.1038/sj.onc.1203592; Hajnoczky G, 2003, BIOCHEM BIOPH RES CO, V304, P445, DOI 10.1016/S0006-291X(03)00616-8; HANSON CJ, 2008, CELL CALCIUM; Hassan M, 2008, ONCOGENE, V27, P4557, DOI 10.1038/onc.2008.90; He Q, 2002, ONCOGENE, V21, P2623, DOI 10.1038/sj.onc.1205345; Heath-Engel HM, 2006, BBA-MOL CELL RES, V1763, P549, DOI 10.1016/j.bbamcr.2006.02.006; Hetz C, 2007, CELL DEATH DIFFER, V14, P1386, DOI 10.1038/sj.cdd.4402166; Hetz C, 2006, SCIENCE, V312, P572, DOI 10.1126/science.1123480; Hetz C, 2008, TRENDS CELL BIOL, V18, P38, DOI 10.1016/j.tcb.2007.10.003; Hetz CA, 2007, ANTIOXID REDOX SIGN, V9, P2345, DOI 10.1089/ars.2007.1793; Hidvegi T, 2005, J BIOL CHEM, V280, P39002, DOI 10.1074/jbc.M508652200; Hitomi J, 2004, J CELL BIOL, V165, P347, DOI 10.1083/jcb.200310015; Hitomi J, 2004, NEUROSCI LETT, V357, P127, DOI 10.1016/j.neulet.2003.12.080; Hoyer-Hansen M, 2007, MOL CELL, V25, P193, DOI 10.1016/j.molcel.2006.12.009; Iizaka Toru, 2007, Toxicology, V241, P146, DOI 10.1016/j.tox.2007.08.095; Imai T, 2007, NEUROSCIENCE, V147, P639, DOI 10.1016/j.neuroscience.2007.04.057; Jiang CC, 2007, CANCER RES, V67, P9750, DOI 10.1158/0008-5472.CAN-07-2047; Jimbo A, 2003, EXP CELL RES, V283, P156, DOI 10.1016/S0014-4827(02)00033-2; Jin SK, 2008, AUTOPHAGY, V4, P563, DOI 10.4161/auto.5830; Kalai M, 2003, J CELL BIOL, V162, P457, DOI 10.1083/jcb.200303157; Kamada S, 1997, ONCOGENE, V15, P285, DOI 10.1038/sj.onc.1201192; Karantza-Wadsworth V, 2007, GENE DEV, V21, P1621, DOI 10.1101/gad.1565707; Karki P, 2007, BIOCHEM BIOPH RES CO, V356, P1056, DOI 10.1016/j.bbrc.2007.03.102; Kieran D, 2007, P NATL ACAD SCI USA, V104, P20606, DOI 10.1073/pnas.0707906105; Kihara A, 2001, EMBO REP, V2, P330, DOI 10.1093/embo-reports/kve061; Kim BJ, 2006, J BIOL CHEM, V281, P21256, DOI 10.1074/jbc.M510644200; Kim KW, 2006, J BIOL CHEM, V281, P36883, DOI 10.1074/jbc.M607094200; Kinnally KW, 2007, APOPTOSIS, V12, P857, DOI 10.1007/s10495-007-0722-z; Kitamura Y, 2003, J PHARMACOL SCI, V92, P228; Kouroku Y, 2002, HUM MOL GENET, V11, P1505, DOI 10.1093/hmg/11.13.1505; Kuo TH, 1998, ONCOGENE, V17, P1903, DOI 10.1038/sj.onc.1202110; Leber B, 2007, APOPTOSIS, V12, P897, DOI 10.1007/s10495-007-0746-4; Lei K, 2003, P NATL ACAD SCI USA, V100, P2432, DOI 10.1073/pnas.0438011100; Letai AG, 2008, NAT REV CANCER, V8, P121, DOI 10.1038/nrc2297; Levine B, 2004, DEV CELL, V6, P463, DOI 10.1016/S1534-5807(04)00099-1; Levine B, 2008, CELL, V132, P27, DOI 10.1016/j.cell.2007.12.018; Li C, 2002, P NATL ACAD SCI USA, V99, P9830, DOI 10.1073/pnas.152571899; Li C, 2007, P NATL ACAD SCI USA, V104, P12565, DOI 10.1073/pnas.0702489104; Li JZ, 2006, J BIOL CHEM, V281, P7260, DOI 10.1074/jbc.M509868200; Li XD, 2005, VIROLOGY, V333, P180, DOI 10.1016/j.virol.2005.01.002; Liang XH, 1998, J VIROL, V72, P8586, DOI 10.1128/JVI.72.11.8586-8596.1998; Liao PC, 2008, J CELL BIOCHEM, V104, P1509, DOI 10.1002/jcb.21730; Lin CF, 2007, J CELL SCI, V120, P2935, DOI 10.1242/jcs.03473; Lin SS, 2006, J BIOL CHEM, V281, P23003, DOI 10.1074/jbc.M602648200; Linseman DA, 2004, J NEUROSCI, V24, P9993, DOI 10.1523/JNEUROSCI.2057-04.2004; Liu N, 2006, VIROLOGY, V348, P398, DOI 10.1016/j.virol.2006.01.002; Lopez-Anton N, 2006, J BIOL CHEM, V281, P33078, DOI 10.1074/jbc.M607904200; Luo X, 2005, CELL DEATH DIFFER, V12, P1310, DOI 10.1038/sj.cdd.4401659; Ma YJ, 2002, J MOL BIOL, V318, P1351, DOI 10.1016/S0022-2836(02)00234-6; Maiuri MC, 2007, EMBO J, V26, P2527, DOI 10.1038/sj.emboj.7601689; Malhotra JD, 2007, SEMIN CELL DEV BIOL, V18, P716, DOI 10.1016/j.semcdb.2007.09.003; Marciniak SJ, 2004, GENE DEV, V18, P3066, DOI 10.1101/gad.1250704; Masud A, 2007, J BIOL CHEM, V282, P14132, DOI 10.1074/jbc.M700077200; Mathai JP, 2005, J BIOL CHEM, V280, P23829, DOI 10.1074/jbc.M500800200; Mathai JP, 2002, ONCOGENE, V21, P2534, DOI 10.1038/sj.onc.1205340; Mathew R, 2007, NAT REV CANCER, V7, P961, DOI 10.1038/nrc2254; Mathew R, 2007, GENE DEV, V21, P1367, DOI 10.1101/gad.1545107; Maurer U, 2006, MOL CELL, V21, P749, DOI 10.1016/j.molcel.2006.02.009; McCullough KD, 2001, MOL CELL BIOL, V21, P1249, DOI 10.1128/MCB.21.4.1249-1259.2001; Morishima N, 2004, J BIOL CHEM, V279, P50375, DOI 10.1074/jbc.M408493200; Morishima N, 2002, J BIOL CHEM, V277, P34287, DOI 10.1074/jbc.M204973200; Murakami Y, 2007, J BIOCHEM, V141, P401, DOI 10.1093/jb/mvm044; Muscarella DE, 2008, TOXICOL APPL PHARM, V228, P93, DOI 10.1016/j.taap.2007.11.032; Nakagawa T, 2000, NATURE, V403, P98, DOI 10.1038/47513; Nakagawa T, 2000, J CELL BIOL, V150, P887, DOI 10.1083/jcb.150.4.887; Nawrocki ST, 2005, CANCER RES, V65, P11510, DOI 10.1158/0008-5472.CAN-05-2394; Ng FWH, 1997, J CELL BIOL, V139, P327, DOI 10.1083/jcb.139.2.327; Nguyen M, 2000, MOL CELL BIOL, V20, P6731, DOI 10.1128/MCB.20.18.6731-6740.2000; Nickson P, 2007, CARDIOVASC RES, V73, P48, DOI 10.1016/j.cardiores.2006.10.001; Nieto-Miguel T, 2007, CANCER RES, V67, P10368, DOI 10.1158/0008-5472.CAN-07-0278; Novoa I, 2001, J CELL BIOL, V153, P1011, DOI 10.1083/jcb.153.5.1011; Nutt LK, 2002, J BIOL CHEM, V277, P20301, DOI 10.1074/jbc.M201604200; Nutt LK, 2002, J BIOL CHEM, V277, P9219, DOI 10.1074/jbc.M106817200; Oakes SA, 2006, CURR MOL MED, V6, P99, DOI 10.2174/156652406775574587; Oakes SA, 2005, P NATL ACAD SCI USA, V102, P105, DOI 10.1073/pnas.0408352102; Obeng EA, 2005, J BIOL CHEM, V280, P29578, DOI 10.1074/jbc.M502685200; Oberstein A, 2007, J BIOL CHEM, V282, P13123, DOI 10.1074/jbc.M700492200; Oda T, 2008, NEUROSCI RES, V60, P29, DOI 10.1016/j.neures.2007.09.005; Oh SH, 2004, BIOCHEM PHARMACOL, V68, P1845, DOI 10.1016/j.bcp.2004.06.021; Oltersdorf T, 2005, NATURE, V435, P677, DOI 10.1038/nature03579; Orrenius S, 2007, DRUG METAB REV, V39, P443, DOI 10.1080/03602530701468516; Ott M, 2007, CELL DEATH DIFFER, V14, P1243, DOI 10.1038/sj.cdd.4402135; Ott M, 2002, P NATL ACAD SCI USA, V99, P1259, DOI 10.1073/pnas.241655498; Palmer AE, 2004, P NATL ACAD SCI USA, V101, P17404, DOI 10.1073/pnas.0408030101; Pattingre S, 2005, CELL, V122, P927, DOI 10.1016/j.cell.2005.07.002; Pellegrini L, 2007, CELL DEATH DIFFER, V14, P1275, DOI 10.1038/sj.cdd.4402145; Petrosillo G, 2004, J BIOL CHEM, V279, P53103, DOI 10.1074/jbc.M407500200; Pinton P, 2006, CELL DEATH DIFFER, V13, P1409, DOI 10.1038/sj.cdd.4401960; Pinton P, 2001, EMBO J, V20, P2690, DOI 10.1093/emboj/20.11.2690; Pinton P, 2000, J CELL BIOL, V148, P857, DOI 10.1083/jcb.148.5.857; Pizzo P, 2007, TRENDS CELL BIOL, V17, P511, DOI 10.1016/j.tcb.2007.07.011; Puthalakath H, 2007, CELL, V129, P1337, DOI 10.1016/j.cell.2007.04.027; Qu LK, 2004, GENE DEV, V18, P261, DOI 10.1101/gad.1165804; Rahmani M, 2007, MOL CELL BIOL, V27, P5499, DOI 10.1128/MCB.01080-06; Rao RV, 2006, CELL DEATH DIFFER, V13, P415, DOI 10.1038/sj.cdd.4401761; Rao RV, 2002, FEBS LETT, V514, P122, DOI 10.1016/S0014-5793(02)02289-5; Rao RV, 2002, J BIOL CHEM, V277, P21836, DOI 10.1074/jbc.M202726200; Rao RV, 2001, J BIOL CHEM, V276, P33869, DOI 10.1074/jbc.M102225200; Reddy RK, 2003, J BIOL CHEM, V278, P20915, DOI 10.1074/jbc.M212328200; Reed JC, 2006, CELL DEATH DIFFER, V13, P1378, DOI 10.1038/sj.cdd.4401975; Reimertz C, 2003, J CELL BIOL, V162, P587, DOI 10.1083/jcb.200305149; Roderick HL, 2008, NAT REV CANCER, V8, P361, DOI 10.1038/nrc2374; Rong Y, 2008, ANNU REV PHYSIOL, V70, P73, DOI 10.1146/annurev.physiol.70.021507.105852; Roy S, 2008, P NATL ACAD SCI USA, V105, P4133, DOI 10.1073/pnas.0706658105; Rudner J, 2001, J CELL SCI, V114, P4161; Ruiz-Vela A, 2005, EMBO REP, V6, P379, DOI 10.1038/sj.embor.7400375; Ruvolo PP, 1999, J BIOL CHEM, V274, P20296, DOI 10.1074/jbc.274.29.20296; Ruvolo PP, 2002, J BIOL CHEM, V277, P22847, DOI 10.1074/jbc.M201830200; Saleh M, 2004, NATURE, V429, P75, DOI 10.1038/nature02451; Sanges D, 2006, APOPTOSIS, V11, P1629, DOI 10.1007/s10495-006-9006-2; Schroder M, 2005, MUTAT RES-FUND MOL M, V569, P29, DOI 10.1016/j.mrfmmm.2004.06.056; Schroder M, 2005, ANNU REV BIOCHEM, V74, P739, DOI 10.1146/annurev.biochem.73.011303.074134; Scorrano L, 2003, SCIENCE, V300, P135, DOI 10.1126/science.1081208; Scorrano L, 2002, DEV CELL, V2, P55, DOI 10.1016/S1534-5807(01)00116-2; Shi J, 2005, CELL DEATH DIFFER, V12, P1601, DOI 10.1038/sj.cdd.4401676; Shibue T, 2006, EMBO J, V25, P4952, DOI 10.1038/sj.emboj.7601359; Shimizu S, 2004, NAT CELL BIOL, V6, P1221, DOI 10.1038/ncb1192; Shiraishi H, 2006, J CELL SCI, V119, P3958, DOI 10.1242/jcs.03160; Simizu S, 2004, CANCER SCI, V95, P266, DOI 10.1111/j.1349-7006.2004.tb02214.x; Smith MI, 2007, CELL DEATH DIFFER, V14, P1011, DOI 10.1038/sj.cdd.4402089; Song L, 2002, J BIOL CHEM, V277, P44701, DOI 10.1074/jbc.M206047200; Srinivasan S, 2005, DIABETES, V54, P968, DOI 10.2337/diabetes.54.4.968; Srivastava RK, 1999, MOL CELL BIOL, V19, P5659; SZEGEZDI EHK, 2008, J CELL MOL MED; Takadera T, 2007, NEUROCHEM RES, V32, P1336, DOI 10.1007/s11064-007-9310-4; Tamura Y, 2004, FEBS LETT, V569, P249, DOI 10.1016/j.febslet.2004.06.003; Tan YF, 2006, J BIOL CHEM, V281, P16016, DOI 10.1074/jbc.M601299200; Tsuruta F, 2004, EMBO J, V23, P1889, DOI 10.1038/sj.emboj.7600194; Upton JP, 2008, MOL CELL BIOL, V28, P3943, DOI 10.1128/MCB.00013-08; Urano F, 2000, SCIENCE, V287, P664, DOI 10.1126/science.287.5453.664; Vanden Abeele F, 2002, CANCER CELL, V1, P169; Walter L, 2005, J BIOENERG BIOMEMBR, V37, P191, DOI 10.1007/s10863-005-6600-x; Wang B, 2008, CELL, V133, P1080, DOI 10.1016/j.cell.2008.04.042; Wang HG, 1999, SCIENCE, V284, P339, DOI 10.1126/science.284.5412.339; Wasiak S, 2007, J CELL BIOL, V177, P439, DOI 10.1083/jcb.200610042; White C, 2005, NAT CELL BIOL, V7, P1021, DOI 10.1038/ncb1302; Wlodkowic D, 2007, LEUKEMIA RES, V31, P1687, DOI 10.1016/j.leukres.2007.03.008; Wood DE, 1998, ONCOGENE, V17, P1069, DOI 10.1038/sj.onc.1202034; Wuytack F, 2002, CELL CALCIUM, V32, P279, DOI 10.1016/S0143416002001847; Xin MG, 2006, J BIOL CHEM, V281, P18859, DOI 10.1074/jbc.M512543200; Xu CY, 2008, J BIOL CHEM, V283, P11477, DOI 10.1074/jbc.M708385200; Xu LP, 2007, MOL CELL BIOCHEM, V295, P153, DOI 10.1007/s11010-006-9285-5; Yamaguchi H, 2004, J BIOL CHEM, V279, P45495, DOI 10.1074/jbc.M406933200; Yamaguchi H, 2003, CANCER RES, V63, P1483; Yamamoto K, 1999, MOL CELL BIOL, V19, P8469; Yoneda T, 2001, J BIOL CHEM, V276, P13935, DOI 10.1074/jbc.M010677200; Yorimitsu T, 2005, CELL DEATH DIFFER, V12, P1542, DOI 10.1038/sj.cdd.4401765; Youle RJ, 2008, NAT REV MOL CELL BIO, V9, P47, DOI 10.1038/nrm2308; Yue ZY, 2003, P NATL ACAD SCI USA, V100, P15077, DOI 10.1073/pnas.2436255100; Yukioka F, 2008, NEUROCHEM INT, V52, P683, DOI 10.1016/j.neuint.2007.08.017; Zalk R, 2007, ANNU REV BIOCHEM, V76, P367, DOI 10.1146/annurev.biochem.76.053105.094237; Zhang D, 2007, CELL DEATH DIFFER, V14, P703, DOI 10.1038/sj.cdd.4402072; Zhang DW, 2008, J BIOL CHEM, V283, P3476, DOI 10.1074/jbc.M707528200; Zhao Y, 2007, MOL CELL BIOL, V27, P4328, DOI 10.1128/MCB.00153-07; Zhong F, 2006, J CELL BIOL, V172, P127, DOI 10.1083/jcb.200506189; Zong WX, 2003, J CELL BIOL, V162, P59, DOI 10.1083/jcb.200302084	206	218	229	0	36	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 27	2008	27	50					6419	6433		10.1038/onc.2008.309	http://dx.doi.org/10.1038/onc.2008.309			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	366RR	18955970				2022-12-28	WOS:000260501600003
J	Yip, KW; Reed, JC				Yip, K. W.; Reed, J. C.			Bcl-2 family proteins and cancer	ONCOGENE			English	Review						Bcl-2; cancer; apoptosis; autophagy; necrosis; therapeutics	NON-HODGKINS-LYMPHOMA; CHRONIC LYMPHOCYTIC-LEUKEMIA; MITOCHONDRIAL-MEMBRANE PERMEABILIZATION; ENDOPLASMIC-RETICULUM STRESS; APOPTOSIS-BASED THERAPIES; SMALL-MOLECULE INHIBITORS; DRUG-INDUCED APOPTOSIS; PROGRAMMED CELL-DEATH; TUMOR-SUPPRESSOR P53; PROGNOSTIC-SIGNIFICANCE	BCL-2 was the first anti-death gene discovered, a milestone with far reaching implications for tumor biology. Multiple members of the human Bcl-2 family of apoptosis-regulating proteins have been identified, including six antiapoptotic, three structurally similar proapoptotic proteins and several structurally diverse proapoptotic interacting proteins that operate as upstream agonists or antagonists. The se proteins, in turn, are regulated through myriad post-translational modi. cations and interactions with other proteins. Bcl-2-family proteins regulate all major types of cell death, including apoptosis, necrosis and autophagy, thus operating as nodal points at the convergence of multiple pathways with broad relevance to oncology. Experimental therapies targeting Bcl-2 family mRNAs or proteins are currently in clinical testing, raising hopes that a new class of anticancer drugs may soon be available.	[Yip, K. W.; Reed, J. C.] Burnham Inst Med Res, La Jolla, CA 92037 USA	Sanford Burnham Prebys Medical Discovery Institute	Reed, JC (corresponding author), Burnham Inst Med Res, La Jolla, CA 92037 USA.	reedoffice@burnham.org			NIH	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	We thank M Hanaii and T Siegfried for manuscript preparation, and the NIH for generous support.	Aita VM, 1999, GENOMICS, V59, P59, DOI 10.1006/geno.1999.5851; Baehrecke EH, 2005, NAT REV MOL CELL BIO, V6, P505, DOI 10.1038/nrm1666; Becattini B, 2004, CHEM BIOL, V11, P389, DOI 10.1016/j.chembiol.2004.02.020; Bedikian AY, 2006, J CLIN ONCOL, V24, P4738, DOI 10.1200/JCO.2006.06.0483; Bernardi P, 2006, FEBS J, V273, P2077, DOI 10.1111/j.1742-4658.2006.05213.x; Bialik S, 2004, SEMIN CANCER BIOL, V14, P283, DOI 10.1016/j.semcancer.2004.04.008; Bivona TG, 2006, MOL CELL, V21, P481, DOI 10.1016/j.molcel.2006.01.012; Blais JD, 2004, MOL CELL BIOL, V24, P7469, DOI 10.1128/MCB.24.17.7469-7482.2004; Breckenridge DG, 2003, ONCOGENE, V22, P8608, DOI 10.1038/sj.onc.1207108; Brousset P, 1996, BLOOD, V87, P2470, DOI 10.1182/blood.V87.6.2470.bloodjournal8762470; Bruey JM, 2007, CELL, V129, P45, DOI 10.1016/j.cell.2007.01.045; Calin GA, 2005, NEW ENGL J MED, V353, P1793, DOI 10.1056/NEJMoa050995; Chen M, 2001, J BIOL CHEM, V276, P30724, DOI 10.1074/jbc.M103701200; Cheng EHY, 1997, SCIENCE, V278, P1966, DOI 10.1126/science.278.5345.1966; Chipuk JE, 2004, SCIENCE, V303, P1010, DOI 10.1126/science.1092734; Chipuk JE, 2008, TRENDS CELL BIOL, V18, P157, DOI 10.1016/j.tcb.2008.01.007; CHITTENDEN T, 1995, EMBO J, V14, P5589, DOI 10.1002/j.1460-2075.1995.tb00246.x; Cimmino A, 2005, P NATL ACAD SCI USA, V102, P13944, DOI 10.1073/pnas.0506654102; Cory S, 2003, ONCOGENE, V22, P8590, DOI 10.1038/sj.onc.1207102; Cummins JM, 2006, P NATL ACAD SCI USA, V103, P3687, DOI 10.1073/pnas.0511155103; Daneshmand S, 2007, HUM PATHOL, V38, P1547, DOI 10.1016/j.humpath.2007.03.014; Danial NN, 2008, NAT MED, V14, P144, DOI 10.1038/nm1717; Debatin KM, 2002, ONCOGENE, V21, P8786, DOI 10.1038/sj.onc.1206039; Degterev A, 2001, NAT CELL BIOL, V3, P173, DOI 10.1038/35055085; Deng XM, 2006, MOL CELL BIOL, V26, P4421, DOI 10.1128/MCB.01647-05; Dong DZ, 2008, CANCER RES, V68, P498, DOI 10.1158/0008-5472.CAN-07-2950; Edinger AL, 2004, CURR OPIN CELL BIOL, V16, P663, DOI 10.1016/j.ceb.2004.09.011; Edlich F, 2005, EMBO J, V24, P2688, DOI 10.1038/sj.emboj.7600739; Enyedy IJ, 2001, J MED CHEM, V44, P4313, DOI 10.1021/jm010016f; Eskes R, 2000, MOL CELL BIOL, V20, P929, DOI 10.1128/MCB.20.3.929-935.2000; Ferri KF, 2001, NAT CELL BIOL, V3, pE255, DOI 10.1038/ncb1101-e255; Forrester MT, 2006, ACS CHEM BIOL, V1, P355, DOI 10.1021/cb600244c; Gascoyne RD, 1997, BLOOD, V90, P244; Green DR, 2004, SCIENCE, V305, P626, DOI 10.1126/science.1099320; Han YH, 2006, ONCOGENE, V25, P2974, DOI 10.1038/sj.onc.1209358; HANADA M, 1993, BLOOD, V82, P1820; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; He HL, 1997, J CELL BIOL, V138, P1219, DOI 10.1083/jcb.138.6.1219; Hermine O, 1996, BLOOD, V87, P265, DOI 10.1182/blood.V87.1.265.bloodjournal871265; Hetz C, 2006, SCIENCE, V312, P572, DOI 10.1126/science.1123480; Hoyer-Hansen M, 2007, MOL CELL, V25, P193, DOI 10.1016/j.molcel.2006.12.009; IKEGAKI N, 1994, CANCER RES, V54, P6; Jaattela M, 2004, CELL DEATH DIFFER, V11, P135, DOI 10.1038/sj.cdd.4401333; KHANNA A, 1996, KIDNEY INT S, V53, P2; Kim R, 2006, APOPTOSIS, V11, P5, DOI 10.1007/s10495-005-3088-0; Kitada S, 2008, BLOOD, V111, P3211, DOI 10.1182/blood-2007-09-113647; Klasa RJ, 2002, ANTISENSE NUCLEIC A, V12, P193, DOI 10.1089/108729002760220798; Korsmeyer SJ, 2000, CELL DEATH DIFFER, V7, P1166, DOI 10.1038/sj.cdd.4400783; Krajewska M, 1996, CANCER RES, V56, P2422; Krajewska M, 1996, AM J PATHOL, V148, P1567; Krajewska M, 2008, CLIN CANCER RES, V14, P3011, DOI 10.1158/1078-0432.CCR-07-1955; KRAJEWSKI S, 1995, LAB INVEST, V72, P42; KRAJEWSKI S, 1995, CANCER RES, V55, P4471; Kroemer G, 2007, PHYSIOL REV, V87, P99, DOI 10.1152/physrev.00013.2006; Kuo TH, 1998, ONCOGENE, V17, P1903, DOI 10.1038/sj.onc.1202110; Kutzki O, 2002, J AM CHEM SOC, V124, P11838, DOI 10.1021/ja026861k; Kuwana T, 2002, CELL, V111, P331, DOI 10.1016/S0092-8674(02)01036-X; Leone M, 2003, CANCER RES, V63, P8118; Letai A, 2002, CANCER CELL, V2, P183, DOI 10.1016/S1535-6108(02)00127-7; Levine B, 2008, CELL, V132, P27, DOI 10.1016/j.cell.2007.12.018; Li C, 2002, P NATL ACAD SCI USA, V99, P9830, DOI 10.1073/pnas.152571899; Liang XH, 1998, J VIROL, V72, P8586, DOI 10.1128/JVI.72.11.8586-8596.1998; Liang XH, 1999, NATURE, V402, P672, DOI 10.1038/45257; Lin BZ, 2004, CELL, V116, P527, DOI 10.1016/S0092-8674(04)00162-X; Liu H, 2005, MOL CELL BIOL, V25, P3117, DOI 10.1128/MCB.25.8.3117-3126.2005; Luciano F, 2007, BLOOD, V109, P3849, DOI 10.1182/blood-2006-11-056879; Lum JJ, 2005, NAT REV MOL CELL BIO, V6, P439, DOI 10.1038/nrm1660; Lutter M, 2000, NAT CELL BIOL, V2, P754, DOI 10.1038/35036395; Manion MK, 2004, J BIOL CHEM, V279, P2159, DOI 10.1074/jbc.M306021200; McCullough KD, 2001, MOL CELL BIOL, V21, P1249, DOI 10.1128/MCB.21.4.1249-1259.2001; McMillin JB, 2002, BBA-MOL CELL BIOL L, V1585, P97, DOI 10.1016/S1388-1981(02)00329-3; Meier P, 2007, MOL CELL, V28, P746, DOI 10.1016/j.molcel.2007.11.016; Meijerink JPP, 1998, BLOOD, V91, P2991, DOI 10.1182/blood.V91.8.2991.2991_2991_2997; MIYASHITA T, 1995, CELL, V80, P293; MIYASHITA T, 1994, ONCOGENE, V9, P1799; Mohan KVPC, 2007, CELL BIOL INT, V31, P599, DOI 10.1016/j.cellbi.2006.11.034; Monni O, 1997, BLOOD, V90, P1168, DOI 10.1182/blood.V90.3.1168.1168_1168_1174; Mott JL, 2007, ONCOGENE, V26, P6133, DOI 10.1038/sj.onc.1210436; Muchmore SW, 1996, NATURE, V381, P335, DOI 10.1038/381335a0; Nguyen M, 2007, P NATL ACAD SCI USA, V104, P19512, DOI 10.1073/pnas.0709443104; O'Brien S, 2007, J CLIN ONCOL, V25, P1114, DOI 10.1200/JCO.2006.07.1191; Oda E, 2000, SCIENCE, V288, P1053, DOI 10.1126/science.288.5468.1053; Oltersdorf T, 2005, NATURE, V435, P677, DOI 10.1038/nature03579; Orrenius S, 2003, NAT REV MOL CELL BIO, V4, P552, DOI 10.1038/nrm1150; Pattingre S, 2005, CELL, V122, P927, DOI 10.1016/j.cell.2005.07.002; Pedersen IM, 2002, BLOOD, V100, P1795, DOI 10.1182/blood.V100.5.1795.h81702001795_1795_1801; Pellecchia M, 2004, CURR PHARM DESIGN, V10, P1387, DOI 10.2174/1381612043384880; Penninger JM, 2003, NAT CELL BIOL, V5, P97, DOI 10.1038/ncb0203-97; Pinton P, 2000, J CELL BIOL, V148, P857, DOI 10.1083/jcb.148.5.857; Puthalakath H, 1999, MOL CELL, V3, P287, DOI 10.1016/S1097-2765(00)80456-6; Puthalakath H, 2007, CELL, V129, P1337, DOI 10.1016/j.cell.2007.04.027; Rampino N, 1997, SCIENCE, V275, P967, DOI 10.1126/science.275.5302.967; Reed JC, 2006, CELL DEATH DIFFER, V13, P1378, DOI 10.1038/sj.cdd.4401975; Reed JC, 2002, NAT REV DRUG DISCOV, V1, P111, DOI 10.1038/nrd726; Reed JC, 2005, BLOOD, V106, P408, DOI 10.1182/blood-2004-07-2761; REED JC, 1990, CANCER RES, V50, P6565; Reed JC, 2008, BLOOD, V111, P3322, DOI 10.1182/blood-2007-09-078162; Ron D, 2007, NAT REV MOL CELL BIO, V8, P519, DOI 10.1038/nrm2199; Sakaki K, 2008, J BIOL CHEM, V283, P15370, DOI 10.1074/jbc.M710209200; Sattler M, 1997, SCIENCE, V275, P983, DOI 10.1126/science.275.5302.983; Sax JK, 2002, NAT CELL BIOL, V4, P842, DOI 10.1038/ncb866; Schendel SL, 1998, CELL DEATH DIFFER, V5, P372, DOI 10.1038/sj.cdd.4400365; Schwartz PS, 2007, MOL CANCER THER, V6, P2073, DOI 10.1158/1535-7163.MCT-06-0767; Scorrano L, 2003, SCIENCE, V300, P135, DOI 10.1126/science.1081208; Shimizu S, 2004, NAT CELL BIOL, V6, P1221, DOI 10.1038/ncb1192; Shohat G, 2002, BBA-PROTEINS PROTEOM, V1600, P45, DOI 10.1016/S1570-9639(02)00443-0; SILVESTRINI R, 1994, J NATL CANCER I, V86, P499, DOI 10.1093/jnci/86.7.499; Strasser A, 2005, NAT REV IMMUNOL, V5, P189, DOI 10.1038/nri1568; Szabadkai G, 2004, MOL CELL, V16, P59, DOI 10.1016/j.molcel.2004.09.026; TANAKA S, 1992, BLOOD, V79, P229; TANG SC, 1994, J CLIN ONCOL, V12, P149, DOI 10.1200/JCO.1994.12.1.149; Thomenius MJ, 2003, J CELL SCI, V116, P4493, DOI 10.1242/jcs.00829; TRON VA, 1995, AM J PATHOL, V146, P643; TSUJIMOTO Y, 1985, SCIENCE, V228, P1440, DOI 10.1126/science.3874430; Tzung SP, 2001, NAT CELL BIOL, V3, P183, DOI 10.1038/35055095; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; Walensky LD, 2004, SCIENCE, V305, P1466, DOI 10.1126/science.1099191; Wang HG, 1999, SCIENCE, V284, P339, DOI 10.1126/science.284.5412.339; Wang JL, 2000, P NATL ACAD SCI USA, V97, P7124, DOI 10.1073/pnas.97.13.7124; Wang JL, 2000, CANCER RES, V60, P1498; Wei MC, 2001, SCIENCE, V292, P727, DOI 10.1126/science.1059108; Wei MC, 2000, GENE DEV, V14, P2060; Wood DE, 1999, J BIOL CHEM, V274, P8309, DOI 10.1074/jbc.274.12.8309; Wood DE, 1998, ONCOGENE, V17, P1069, DOI 10.1038/sj.onc.1202034; Xu CY, 2008, J BIOL CHEM, V283, P11477, DOI 10.1074/jbc.M708385200; Xu CY, 2005, J CLIN INVEST, V115, P2656, DOI 10.1172/JCI26373; Xu QL, 1998, MOL CELL, V1, P337, DOI 10.1016/S1097-2765(00)80034-9; Yip KW, 2006, CLIN CANCER RES, V12, P5726, DOI 10.1158/1078-0432.CCR-06-0571; Yip KW, 2008, J BIOMOL SCREEN; Youn HD, 1999, SCIENCE, V286, P790, DOI 10.1126/science.286.5440.790; Yousefi S, 2006, NAT CELL BIOL, V8, P1124, DOI 10.1038/ncb1482; Yu J, 2003, P NATL ACAD SCI USA, V100, P1931, DOI 10.1073/pnas.2627984100; YUNIS JJ, 1989, NEW ENGL J MED, V320, P1047, DOI 10.1056/NEJM198904203201605; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3; Zheng HC, 2008, HUM PATHOL, V39, P1042, DOI 10.1016/j.humpath.2007.11.009	136	647	689	0	57	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 27	2008	27	50					6398	6406		10.1038/onc.2008.307	http://dx.doi.org/10.1038/onc.2008.307			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	366RR	18955968				2022-12-28	WOS:000260501600001
J	Waldhauer, I; Steinle, A				Waldhauer, I.; Steinle, A.			NK cells and cancer immunosurveillance	ONCOGENE			English	Review						NK cells; NKG2D; innate immunity; cancer immunosurveillance	NATURAL-KILLER-CELLS; MHC CLASS-I; ACTIVATING IMMUNORECEPTOR NKG2D; VIRUS-INFECTED CELLS; DELTA-T-CELLS; LINKED LYMPHOPROLIFERATIVE DISEASE; H-2-DEFICIENT LYMPHOMA VARIANTS; MOLONEY LEUKEMIA-CELLS; CUTTING EDGE; DENDRITIC CELLS	Natural killer (NK) cells are lymphocytes of the innate immune system that monitor cell surfaces of autologous cells for an aberrant expression of MHC class I molecules and cell stress markers. Since their first description more than 30 years ago, NK cells have been implicated in the immune defence against tumours. Here, we review the broadly accumulating evidence for a crucial contribution of NK cells to the immunosurveillance of tumours and the molecular mechanisms that allow NK cells to distinguish malignant from healthy cells. Particular emphasis is placed on the activating NK receptor NKG2D, which recognizes a variety of MHC class I-related molecules believed to act as 'immuno-alerters' on malignant cells, and on tumour-mediated counterstrategies promoting escape from NKG2D-mediated recognition.	[Waldhauer, I.; Steinle, A.] Univ Tubingen, Interfac Inst Cell Biol, Dept Immunol, Tubingen, Germany	Eberhard Karls University of Tubingen	Steinle, A (corresponding author), Interfak Inst Zellbiol, Immunol Abt, Morgenstelle 15, D-72076 Tubingen, Germany.	alexander.steinle@uni-tuebingen.de	Steinle, Alexander/E-6131-2012	Steinle, Alexander/0000-0001-5081-8503	Wilhelm Sander-Stiftung; Deutsche Krebshilfe.	Wilhelm Sander-Stiftung; Deutsche Krebshilfe.(Deutsche Krebshilfe)	We apologise to all investigators whose studies were not cited in this article due to space constraints. IW is supported by the Wilhelm Sander-Stiftung and Deutsche Krebshilfe.	Adam C, 2005, BLOOD, V106, P338, DOI 10.1182/blood-2004-09-3775; Albertsson PA, 2003, TRENDS IMMUNOL, V24, P603, DOI 10.1016/j.it.2003.09.007; Aldemir H, 2005, J IMMUNOL, V175, P7791, DOI 10.4049/jimmunol.175.12.7791; Algarra I, 2000, HUM IMMUNOL, V61, P65, DOI 10.1016/S0198-8859(99)00156-1; Anfossi N, 2006, IMMUNITY, V25, P331, DOI 10.1016/j.immuni.2006.06.013; Arnon TI, 2006, SEMIN CANCER BIOL, V16, P348, DOI 10.1016/j.semcancer.2006.07.005; Arnon TI, 2005, NAT IMMUNOL, V6, P515, DOI 10.1038/ni1190; Bahram S, 2005, CURR OPIN IMMUNOL, V17, P505, DOI 10.1016/j.coi.2005.07.016; BAHRAM S, 1994, P NATL ACAD SCI USA, V91, P6259, DOI 10.1073/pnas.91.14.6259; Bauer S, 1999, SCIENCE, V285, P727, DOI 10.1126/science.285.5428.727; Biron CA, 1999, ANNU REV IMMUNOL, V17, P189, DOI 10.1146/annurev.immunol.17.1.189; Bloushtain N, 2004, J IMMUNOL, V173, P2392, DOI 10.4049/jimmunol.173.4.2392; Bottino C, 2003, J EXP MED, V198, P557, DOI 10.1084/jem.20030788; Braud VM, 1998, NATURE, V391, P795, DOI 10.1038/35869; Brown MH, 1998, J EXP MED, V188, P2083, DOI 10.1084/jem.188.11.2083; Burgess SJ, 2006, J IMMUNOL, V176, P1490, DOI 10.4049/jimmunol.176.3.1490; Carayannopoulos LN, 2002, EUR J IMMUNOL, V32, P597, DOI 10.1002/1521-4141(200203)32:3<597::AID-IMMU597>3.3.CO;2-5; Carayannopoulos LN, 2002, J IMMUNOL, V169, P4079, DOI 10.4049/jimmunol.169.8.4079; Carlsten M, 2007, CANCER RES, V67, P1317, DOI 10.1158/0008-5472.CAN-06-2264; Carlyle JR, 2004, P NATL ACAD SCI USA, V101, P3527, DOI 10.1073/pnas.0308304101; Castriconi R, 2003, P NATL ACAD SCI USA, V100, P4120, DOI 10.1073/pnas.0730640100; Cerwenka A, 2000, IMMUNITY, V12, P721, DOI 10.1016/S1074-7613(00)80222-8; Cerwenka A, 2001, P NATL ACAD SCI USA, V98, P11521, DOI 10.1073/pnas.201238598; Chan A, 2007, J IMMUNOL, V179, P89, DOI 10.4049/jimmunol.179.1.89; Classen CF, 2003, HAEMATOLOGICA, V88, P509; Coca S, 1997, CANCER-AM CANCER SOC, V79, P2320, DOI 10.1002/(SICI)1097-0142(19970615)79:12<2320::AID-CNCR5>3.0.CO;2-P; Cosman D, 2001, IMMUNITY, V14, P123, DOI 10.1016/S1074-7613(01)00095-4; Costello RT, 2004, TRENDS IMMUNOL, V25, P328, DOI 10.1016/j.it.2004.04.005; Costello RT, 2002, BLOOD, V99, P3661, DOI 10.1182/blood.V99.10.3661; Das H, 2001, IMMUNITY, V15, P83, DOI 10.1016/S1074-7613(01)00168-6; Della Chiesa M, 2006, BLOOD, V108, P4118, DOI 10.1182/blood-2006-06-006700; Diefenbach A, 2000, NAT IMMUNOL, V1, P119, DOI 10.1038/77793; Diefenbach A, 2003, EUR J IMMUNOL, V33, P381, DOI 10.1002/immu.200310012; Diefenbach A, 2002, NAT IMMUNOL, V3, P1142, DOI 10.1038/ni858; Diefenbach A, 2001, IMMUNOL REV, V181, P170, DOI 10.1034/j.1600-065X.2001.1810114.x; Diefenbach A, 2001, NATURE, V413, P165, DOI 10.1038/35093109; Dorner BG, 2004, J IMMUNOL, V172, P3119, DOI 10.4049/jimmunol.172.5.3119; Dunn GP, 2004, ANNU REV IMMUNOL, V22, P329, DOI 10.1146/annurev.immunol.22.012703.104803; Eagle RA, 2007, NAT REV IMMUNOL, V7, P737, DOI 10.1038/nri2144; Eisele G, 2006, BRAIN, V129, P2416, DOI 10.1093/brain/awl205; El-Sherbiny YM, 2007, CANCER RES, V67, P8444, DOI 10.1158/0008-5472.CAN-06-4230; Esendagli G, 2008, LUNG CANCER, V59, P32, DOI 10.1016/j.lungcan.2007.07.022; Ferlazzo G, 2004, J IMMUNOL, V172, P1333, DOI 10.4049/jimmunol.172.3.1333; French AR, 2003, CURR OPIN IMMUNOL, V15, P45, DOI 10.1016/S095279150200002X; Freud AG, 2006, IMMUNOL REV, V214, P56, DOI 10.1111/j.1600-065X.2006.00451.x; Friese MA, 2004, CANCER RES, V64, P7596, DOI 10.1158/0008-5472.CAN-04-1627; Garrity D, 2005, P NATL ACAD SCI USA, V102, P7641, DOI 10.1073/pnas.0502439102; Gasser S, 2005, NATURE, V436, P1186, DOI 10.1038/nature03884; Gilfillan S, 2002, NAT IMMUNOL, V3, P1150, DOI 10.1038/ni857; Girardi M, 2001, SCIENCE, V294, P605, DOI 10.1126/science.1063916; Groh V, 2003, P NATL ACAD SCI USA, V100, P9452, DOI 10.1073/pnas.1632807100; Groh V, 1999, P NATL ACAD SCI USA, V96, P6879, DOI 10.1073/pnas.96.12.6879; Groh V, 2002, NATURE, V419, P734, DOI 10.1038/nature01112; Groh V, 1996, P NATL ACAD SCI USA, V93, P12445, DOI 10.1073/pnas.93.22.12445; Groh V, 2001, NAT IMMUNOL, V2, P255, DOI 10.1038/85321; Groh V, 2006, NAT IMMUNOL, V7, P755, DOI 10.1038/ni1350; Grundemann C, 2006, J IMMUNOL, V176, P1311, DOI 10.4049/jimmunol.176.3.1311; Hamerman JA, 2004, J IMMUNOL, V172, P2001, DOI 10.4049/jimmunol.172.4.2001; Hayakawa Y, 2006, J IMMUNOL, V176, P1517, DOI 10.4049/jimmunol.176.3.1517; Hayakawa Y, 2006, IMMUNOL REV, V214, P47, DOI 10.1111/j.1600-065X.2006.00454.x; Hayakawa Y, 2006, ADV CANCER RES, V95, P293, DOI 10.1016/S0065-230X(06)95008-8; HERBERMAN RB, 1975, INT J CANCER, V16, P216, DOI 10.1002/ijc.2910160204; HERBERMAN RB, 1975, INT J CANCER, V16, P230, DOI 10.1002/ijc.2910160205; Ho EL, 2002, J IMMUNOL, V169, P3667, DOI 10.4049/jimmunol.169.7.3667; Hokland M, 1999, IN VIVO, V13, P199; Holdenrieder S, 2006, INT J CANCER, V118, P684, DOI 10.1002/ijc.21382; Holdenrieder S, 2006, CANCER IMMUNOL IMMUN, V55, P1584, DOI 10.1007/s00262-006-0167-1; HOUCHINS JP, 1991, J EXP MED, V173, P1017, DOI 10.1084/jem.173.4.1017; Hsu KC, 2005, BLOOD, V105, P4878, DOI 10.1182/blood-2004-12-4825; Iizuka K, 2003, NAT IMMUNOL, V4, P801, DOI 10.1038/ni954; Imai K, 2000, LANCET, V356, P1795, DOI 10.1016/S0140-6736(00)03231-1; Ishigami S, 2000, CANCER, V88, P577, DOI 10.1002/(SICI)1097-0142(20000201)88:3<577::AID-CNCR13>3.3.CO;2-M; Ito M, 2006, J EXP MED, V203, P289, DOI 10.1084/jem.20051986; Jamieson AM, 2002, IMMUNITY, V17, P19, DOI 10.1016/S1074-7613(02)00333-3; Jinushi M, 2003, INT J CANCER, V104, P354, DOI 10.1002/ijc.10966; Kaiser BK, 2007, NATURE, V447, P482, DOI 10.1038/nature05768; Kaplan DH, 1998, P NATL ACAD SCI USA, V95, P7556, DOI 10.1073/pnas.95.13.7556; KARLHOFER FM, 1992, NATURE, V358, P66, DOI 10.1038/358066a0; KARRE K, 1986, NATURE, V319, P675, DOI 10.1038/319675a0; Kelley J, 2005, PLOS GENET, V1, P129, DOI 10.1371/journal.pgen.0010027; KIESSLING R, 1975, EUR J IMMUNOL, V5, P117, DOI 10.1002/eji.1830050209; KIESSLING R, 1975, EUR J IMMUNOL, V5, P112, DOI 10.1002/eji.1830050208; Kim S, 2005, NATURE, V436, P709, DOI 10.1038/nature03847; Kim S, 2000, P NATL ACAD SCI USA, V97, P2731, DOI 10.1073/pnas.050588297; Koebel CM, 2007, NATURE, V450, P903, DOI 10.1038/nature06309; Kubin M, 2001, EUR J IMMUNOL, V31, P1428, DOI 10.1002/1521-4141(200105)31:5<1428::AID-IMMU1428>3.0.CO;2-4; Lanier LL, 2005, ANNU REV IMMUNOL, V23, P225, DOI 10.1146/annurev.immunol.23.021704.115526; LANIER LL, 1983, J IMMUNOL, V131, P1789; Lanier LL, 2001, NAT MED, V7, P1178, DOI 10.1038/nm1101-1178; Lanier LL, 1998, ANNU REV IMMUNOL, V16, P359, DOI 10.1146/annurev.immunol.16.1.359; Lee JC, 2004, J IMMUNOL, V172, P7335, DOI 10.4049/jimmunol.172.12.7335; Lee N, 1998, P NATL ACAD SCI USA, V95, P5199, DOI 10.1073/pnas.95.9.5199; Li PW, 2001, NAT IMMUNOL, V2, P443, DOI 10.1038/87757; Li PW, 2002, IMMUNITY, V16, P77, DOI 10.1016/S1074-7613(02)00258-3; Lieberman J, 2003, NAT REV IMMUNOL, V3, P361, DOI 10.1038/nri1083; LJUNGGREN HG, 1985, J EXP MED, V162, P1745, DOI 10.1084/jem.162.6.1745; LJUNGGREN HG, 1990, IMMUNOL TODAY, V11, P237, DOI 10.1016/0167-5699(90)90097-S; Long EO, 1997, IMMUNOL REV, V155, P135, DOI 10.1111/j.1600-065X.1997.tb00946.x; Ma CS, 2007, ANNU REV IMMUNOL, V25, P337, DOI 10.1146/annurev.immunol.25.022106.141651; Mandelboim O, 2001, NATURE, V409, P1055, DOI 10.1038/35059110; Martin-Fontecha A, 2004, NAT IMMUNOL, V5, P1260, DOI 10.1038/ni1138; McMahon CW, 2001, CURR OPIN IMMUNOL, V13, P465, DOI 10.1016/S0952-7915(00)00242-9; Mocikat R, 2003, IMMUNITY, V19, P561, DOI 10.1016/S1074-7613(03)00264-4; Molinero LL, 2002, J LEUKOCYTE BIOL, V71, P791; Moretta A, 2001, ANNU REV IMMUNOL, V19, P197, DOI 10.1146/annurev.immunol.19.1.197; Moretta A, 1996, ANNU REV IMMUNOL, V14, P619, DOI 10.1146/annurev.immunol.14.1.619; Nakajima H, 2000, EUR J IMMUNOL, V30, P3309, DOI 10.1002/1521-4141(200011)30:11<3309::AID-IMMU3309>3.0.CO;2-3; Nedvetzki S, 2007, BLOOD, V109, P3776, DOI 10.1182/blood-2006-10-052977; Nomura M, 1996, J BIOCHEM-TOKYO, V120, P987; Nowbakht P, 2005, BLOOD, V105, P3615, DOI 10.1182/blood-2004-07-2585; Nutt SL, 2004, CRIT REV IMMUNOL, V24, P239, DOI 10.1615/CritRevImmunol.v24.i4.20; O'Callaghan CA, 2001, IMMUNITY, V15, P201, DOI 10.1016/S1074-7613(01)00187-X; Oppenheim DE, 2005, NAT IMMUNOL, V6, P928, DOI 10.1038/ni1239; Pardoll DM, 2001, SCIENCE, V294, P534, DOI 10.1126/science.1066284; Parham P, 2005, NAT REV IMMUNOL, V5, P201, DOI 10.1038/nri1570; Parolini S, 2000, J EXP MED, V192, P337, DOI 10.1084/jem.192.3.337; Pende D, 2005, MOL IMMUNOL, V42, P463, DOI 10.1016/j.molimm.2004.07.028; Pende D, 2006, BLOOD, V107, P2030, DOI 10.1182/blood-2005-07-2696; Pende D, 2001, EUR J IMMUNOL, V31, P1076, DOI 10.1002/1521-4141(200104)31:4<1076::AID-IMMU1076>3.0.CO;2-Y; Pierson BA, 1996, BLOOD, V88, P2279, DOI 10.1182/blood.V88.6.2279.bloodjournal8862279; Radaev S, 2001, IMMUNITY, V15, P1039, DOI 10.1016/S1074-7613(01)00241-2; Radosavljevic M, 2002, GENOMICS, V79, P114, DOI 10.1006/geno.2001.6673; Raulet DH, 2006, NAT REV IMMUNOL, V6, P520, DOI 10.1038/nri1863; Raulet DH, 2004, NAT IMMUNOL, V5, P996, DOI 10.1038/ni1114; Raulet DH, 2003, NAT REV IMMUNOL, V3, P781, DOI 10.1038/nri1199; Roberts AI, 2001, J IMMUNOL, V167, P5527, DOI 10.4049/jimmunol.167.10.5527; Rosen DB, 2004, J IMMUNOL, V173, P2470, DOI 10.4049/jimmunol.173.4.2470; Rosen DB, 2005, J IMMUNOL, V175, P7796, DOI 10.4049/jimmunol.175.12.7796; Rouas-Freiss N, 2005, CANCER RES, V65, P10139, DOI 10.1158/0008-5472.CAN-05-0097; Ruggeri L, 2007, CURR OPIN ONCOL, V19, P142, DOI 10.1097/CCO.0b013e3280148a1a; Salih HR, 2003, BLOOD, V102, P1389, DOI 10.1182/blood-2003-01-0019; Salih HR, 2002, J IMMUNOL, V169, P4098, DOI 10.4049/jimmunol.169.8.4098; Shankaran V, 2001, NATURE, V410, P1107, DOI 10.1038/35074122; Smyth MJ, 2004, J EXP MED, V200, P1325, DOI 10.1084/jem.20041522; Smyth MJ, 2002, NAT REV CANCER, V2, P850, DOI 10.1038/nrc928; Smyth MJ, 2005, J EXP MED, V202, P583, DOI 10.1084/jem.20050994; Steinle A, 2001, IMMUNOGENETICS, V53, P279, DOI 10.1007/s002510100325; Street SEA, 2004, J EXP MED, V199, P879, DOI 10.1084/jem.20031981; Sutherland CL, 2002, J IMMUNOL, V168, P671, DOI 10.4049/jimmunol.168.2.671; Swann JB, 2007, J CLIN INVEST, V117, P1137, DOI 10.1172/JCI31405; Tahara-Hanaoka S, 2006, BLOOD, V107, P1491, DOI 10.1182/blood-2005-04-1684; Takaki R, 2006, IMMUNOL REV, V214, P118, DOI 10.1111/j.1600-065X.2006.00466.x; Upshaw JL, 2006, NAT IMMUNOL, V7, P524, DOI 10.1038/ni1325; Urosevic M, 2008, CANCER RES, V68, P627, DOI 10.1158/0008-5472.CAN-07-2704; Vetter CS, 2002, J INVEST DERMATOL, V118, P600, DOI 10.1046/j.1523-1747.2002.01700.x; Villegas FR, 2002, LUNG CANCER-J IASLC, V35, P23, DOI 10.1016/S0169-5002(01)00292-6; Vitale M, 1998, J EXP MED, V187, P2065, DOI 10.1084/jem.187.12.2065; Vivier E, 2004, NAT REV IMMUNOL, V4, P190, DOI 10.1038/nri1306; von Strandmann EP, 2007, IMMUNITY, V27, P965, DOI 10.1016/j.immuni.2007.10.010; Voskoboinik I, 2006, NAT REV IMMUNOL, V6, P940, DOI 10.1038/nri1983; Waldhauer I, 2006, CANCER RES, V66, P2520, DOI 10.1158/0008-5472.CAN-05-2520; Walzer T, 2007, CURR OPIN IMMUNOL, V19, P365, DOI 10.1016/j.coi.2007.04.004; Welte S, 2006, NAT IMMUNOL, V7, P1334, DOI 10.1038/ni1402; Wiemann K, 2005, J IMMUNOL, V175, P720, DOI 10.4049/jimmunol.175.2.720; Wu J, 2003, ADV CANCER RES, V90, P127, DOI 10.1016/S0065-230X(03)90004-2; Wu J, 1999, SCIENCE, V285, P730, DOI 10.1126/science.285.5428.730; Wu JD, 2004, J CLIN INVEST, V114, P560, DOI 10.1172/JCI200422206; Yokoyama WM, 2006, IMMUNITY, V24, P249, DOI 10.1016/j.immuni.2006.03.006; Yokoyama WM, 2003, NAT REV IMMUNOL, V3, P304, DOI 10.1038/nri1055; YOKOYAMA WM, 1993, ANNU REV IMMUNOL, V11, P613, DOI 10.1146/annurev.iy.11.040193.003145; YOKOYAMA WM, 1993, CURR OPIN IMMUNOL, V5, P67, DOI 10.1016/0952-7915(93)90083-5; Zamai L, 1998, J EXP MED, V188, P2375, DOI 10.1084/jem.188.12.2375; Zamai L, 2007, J IMMUNOL, V178, P4011, DOI 10.4049/jimmunol.178.7.4011; Zitvogel L, 2006, NAT REV IMMUNOL, V6, P715, DOI 10.1038/nri1936	164	464	487	0	55	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 6	2008	27	45					5932	5943		10.1038/onc.2008.267	http://dx.doi.org/10.1038/onc.2008.267			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	355QE	18836474				2022-12-28	WOS:000259722600008
J	Liu, L; Guo, C; Dammann, R; Tommasi, S; Pfeifer, GP				Liu, L.; Guo, C.; Dammann, R.; Tommasi, S.; Pfeifer, G. P.			RASSF1A interacts with and activates the mitotic kinase Aurora-A	ONCOGENE			English	Article						RASSF1A; Aurora-A; centrosome; mitosis	TUMOR-SUPPRESSOR RASSF1A; ANAPHASE-PROMOTING COMPLEX; CELL-CYCLE PROGRESSION; DEATH INDUCER C19ORF5; CENTROSOME SEPARATION; BINDING-PROTEIN; CHROMOSOME SEGREGATION; CANCER SUSCEPTIBILITY; MICROTUBULE STABILITY; SPINDLE FORMATION	The RAS association domain family 1A (RASSF1A) gene is located at chromosome 3p21.3 within a specific area of common heterozygous and homozygous deletions. RASSF1A frequently undergoes promoter methylation-associated inactivation in human cancers. Rassf1a(-/-) mice are prone to both spontaneous and carcinogen-induced tumorigenesis, supporting the notion that RASSF1A is a tumor suppressor. However, it is not fully understood how RASSF1A is involved in tumor suppression pathways. Here we show that overexpression of RASSF1A inhibits centrosome separation. RASSF1A interacts with Aurora-A, a mitotic kinase. Surprisingly, knockdown of RASSF1A by siRNA led to reduced activation of Aurora-A, whereas overexpression of RASSF1A resulted in increased activation of Aurora-A, suggesting that RASSF1A is involved in Aurora-A activation. Like other Aurora-A activators, RASSF1A was also a substrate of Aurora-A in vitro. The failure of recombinant RASSF1A to activate recombinant Aurora-A indicates that RASSF1A may not activate Aurora-A directly and suggests that RASSF1A may function as a scaffold to bring together Aurora-A and its activator(s). Inhibition of centrosome separation by RASSF1A overexpression is most likely a consequence of hyperstabilization of microtubules by this protein.	[Liu, L.; Guo, C.; Tommasi, S.; Pfeifer, G. P.] City Hope Canc Ctr, Beckman Res Inst, Div Biol, Duarte, CA 91010 USA; [Dammann, R.] Univ Giessen, Inst Genet, Giessen, Germany	City of Hope; Beckman Research Institute of City of Hope; Justus Liebig University Giessen	Pfeifer, GP (corresponding author), City Hope Canc Ctr, Beckman Res Inst, Div Biol, 1500 E Duarte Rd, Duarte, CA 91010 USA.	gpfeifer@coh.org	Guo, Cai/E-8884-2010					ABBONDANZO SJ, 1993, METHOD ENZYMOL, V225, P803; Agathanggelou A, 2005, CANCER RES, V65, P3497, DOI 10.1158/0008-5472.CAN-04-4088; Anand S, 2003, CANCER CELL, V3, P51, DOI 10.1016/S1535-6108(02)00235-0; Andrews PD, 2003, CURR OPIN CELL BIOL, V15, P672, DOI 10.1016/j.ceb.2003.10.013; Bischoff JR, 1998, EMBO J, V17, P3052, DOI 10.1093/emboj/17.11.3052; Blangy A, 1995, CELL, V83, P1159, DOI 10.1016/0092-8674(95)90142-6; Boveri T, 1888, JENA Z NATURWISS, V22, P685; Carmena M, 2003, NAT REV MOL CELL BIO, V4, P842, DOI 10.1038/nrm1245; Castro A, 2002, EMBO REP, V3, P457, DOI 10.1093/embo-reports/kvf095; Crane R, 2004, BIOL CELL, V96, P215, DOI 10.1016/j.biolcel.2003.09.008; Dallol A, 2004, CANCER RES, V64, P4112, DOI 10.1158/0008-5472.CAN-04-0267; Dammann R, 2000, NAT GENET, V25, P315, DOI 10.1038/77083; Dammann R, 2005, HISTOL HISTOPATHOL, V20, P645, DOI 10.14670/HH-20.645; Doxsey S, 2005, TRENDS CELL BIOL, V15, P303, DOI 10.1016/j.tcb.2005.04.008; Doxsey S, 2001, NAT REV MOL CELL BIO, V2, P688, DOI 10.1038/35089575; Doxsey SJ, 2001, NAT CELL BIOL, V3, pE105, DOI 10.1038/35074618; Ewart-Toland A, 2005, CARCINOGENESIS, V26, P1368, DOI 10.1093/carcin/bgi085; Ewart-Toland A, 2003, NAT GENET, V34, P403, DOI 10.1038/ng1220; Gaglio T, 1996, J CELL BIOL, V135, P399, DOI 10.1083/jcb.135.2.399; Giet R, 2005, TRENDS CELL BIOL, V15, P241, DOI 10.1016/j.tcb.2005.03.004; Giet R, 2001, J CELL BIOL, V152, P669, DOI 10.1083/jcb.152.4.669; GLOVER DM, 1995, CELL, V81, P95, DOI 10.1016/0092-8674(95)90374-7; Guo C, 2007, CURR BIOL, V17, P700, DOI 10.1016/j.cub.2007.02.055; Guse A, 2005, CURR BIOL, V15, P778, DOI 10.1016/j.cub.2005.03.041; Hachet V, 2007, DEV CELL, V12, P531, DOI 10.1016/j.devcel.2007.02.015; Hinchcliffe EH, 2001, SCIENCE, V291, P1547, DOI 10.1126/science.1056866; Hirota T, 2003, CELL, V114, P585, DOI 10.1016/S0092-8674(03)00642-1; Honda K, 2000, ONCOGENE, V19, P2812, DOI 10.1038/sj.onc.1203609; Hutterer A, 2006, DEV CELL, V11, P147, DOI 10.1016/j.devcel.2006.06.002; Keen N, 2004, NAT REV CANCER, V4, P927, DOI 10.1038/nrc1502; Khokhlatchev A, 2002, CURR BIOL, V12, P253, DOI 10.1016/S0960-9822(02)00683-8; Kufer TA, 2002, J CELL BIOL, V158, P617, DOI 10.1083/jcb.200204155; Lerman MI, 2000, CANCER RES, V60, P6116; Littlepage LE, 2002, P NATL ACAD SCI USA, V99, P15440, DOI 10.1073/pnas.202606599; Liu L, 2007, CELL CYCLE, V6, P1663, DOI 10.4161/cc.6.13.4435; Liu LM, 2003, ONCOGENE, V22, P8125, DOI 10.1038/sj.onc.1206984; Liu LY, 2005, BIOCHEM BIOPH RES CO, V332, P670, DOI 10.1016/j.bbrc.2005.05.006; Liu LY, 2005, CANCER RES, V65, P4191, DOI 10.1158/0008-5472.CAN-04-3865; Liu LY, 2005, CANCER RES, V65, P1830, DOI 10.1158/0008-5472.CAN-04-3896; Marumoto T, 2005, NAT REV CANCER, V5, P42, DOI 10.1038/nrc1526; Marumoto T, 2002, GENES CELLS, V7, P1173, DOI 10.1046/j.1365-2443.2002.00592.x; Marumoto T, 2003, J BIOL CHEM, V278, P51786, DOI 10.1074/jbc.M306275200; Meraldi P, 2004, CURR OPIN GENET DEV, V14, P29, DOI 10.1016/j.gde.2003.11.006; Meraldi P, 2002, EMBO J, V21, P483, DOI 10.1093/emboj/21.4.483; Mortlock A, 2005, CURR TOP MED CHEM, V5, P199, DOI 10.2174/1568026053507651; Naruganahalli KS, 2006, CURR OPIN INVEST DR, V7, P1044; Ortiz-Vega S, 2002, ONCOGENE, V21, P1381, DOI 10.1038/sj.onc.1205192; Piel M, 2001, SCIENCE, V291, P1550, DOI 10.1126/science.1057330; Portier N, 2007, DEV CELL, V12, P515, DOI 10.1016/j.devcel.2007.01.019; Pugacheva EN, 2007, CELL, V129, P1351, DOI 10.1016/j.cell.2007.04.035; Pugacheva EN, 2005, NAT CELL BIOL, V7, P937, DOI 10.1038/ncb1309; Rieder CL, 2001, TRENDS CELL BIOL, V11, P413, DOI 10.1016/S0962-8924(01)02085-2; Rong R, 2007, ONCOGENE, V26, P7700, DOI 10.1038/sj.onc.1210575; Rong R, 2004, ONCOGENE, V23, P8216, DOI 10.1038/sj.onc.1207901; Satinover DL, 2004, P NATL ACAD SCI USA, V101, P8625, DOI 10.1073/pnas.0402966101; Shivakumar L, 2002, MOL CELL BIOL, V22, P4309, DOI 10.1128/MCB.22.12.4309-4318.2002; Song MS, 2004, NAT CELL BIOL, V6, P129, DOI 10.1038/ncb1091; Taguchi S, 2002, FEBS LETT, V519, P59, DOI 10.1016/S0014-5793(02)02711-4; Toji S, 2004, GENES CELLS, V9, P383, DOI 10.1111/j.1356-9597.2004.00732.x; Tommasi S, 2005, CANCER RES, V65, P92; Trieselmann N, 2003, J CELL SCI, V116, P4791, DOI 10.1242/jcs.00798; Tsai MY, 2003, NAT CELL BIOL, V5, P242, DOI 10.1038/ncb936; Uzbekov R, 2002, BIOL CELL, V94, P275, DOI 10.1016/S0248-4900(02)01202-9; van der Weyden L, 2005, MOL CELL BIOL, V25, P8356, DOI 10.1128/MCB.25.18.8356-8367.2005; Vos MD, 2004, CANCER RES, V64, P4244, DOI 10.1158/0008-5472.CAN-04-0339; Walter AO, 2000, ONCOGENE, V19, P4906, DOI 10.1038/sj.onc.1203847; Wang X, 2006, ONCOGENE, V25, P7148, DOI 10.1038/sj.onc.1209707; WATERS JC, 1993, J CELL BIOL, V122, P361, DOI 10.1083/jcb.122.2.361; Weaver BAA, 2006, CURR OPIN CELL BIOL, V18, P658, DOI 10.1016/j.ceb.2006.10.002; Zhang DW, 2004, ONCOGENE, V23, P8720, DOI 10.1038/sj.onc.1208153; Zhao ZS, 2005, MOL CELL, V20, P237, DOI 10.1016/j.molcel.2005.08.035; Zhou HY, 1998, NAT GENET, V20, P189, DOI 10.1038/2496	72	28	28	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT	2008	27	47					6175	6186		10.1038/onc.2008.220	http://dx.doi.org/10.1038/onc.2008.220			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	360UJ	18641684				2022-12-28	WOS:000260083100010
J	Bellavia, D; Checquolo, S; Campese, AF; Felli, MP; Gulino, A; Screpanti, I				Bellavia, D.; Checquolo, S.; Campese, A. F.; Felli, M. P.; Gulino, A.; Screpanti, I.			Notch3: from subtle structural differences to functional diversity	ONCOGENE			English	Review						Notch receptor structure; Notch3; Jagged1; oncogenic pathways; T-cell leukemia	NF-KAPPA-B; T-CELL DEVELOPMENT; EMBRYONIC LETHALITY; TRANSGENIC MICE; CONSTITUTIVE ACTIVATION; CAENORHABDITIS-ELEGANS; ANKYRIN REPEATS; MAMMARY-GLAND; RECEPTOR; LIGAND	The Notch3 gene was identified, at the beginning of 90s, as the third mammalian Notch and was initially reported as being expressed in proliferating neuroepithelium. Since then, increasing evidence has demonstrated a number of structural and functional differences between Notch3 and both Notch1 and Notch2, which exhibit the highest structural similarity among the four mammalian Notch receptors. Possibly due to its more restricted tissue distribution, targeted deletion of murine Notch3 does not lead to embryonic lethality as is observed with targeted deletion of Notch1 and Notch2. However, genetic mutation, amplification and deregulated expression of Notch3 have been correlated with the disruption of cell differentiation in transgenic mice and to development of diseases in mice and humans. This review discusses the possible relationships between the structural differences and the nonredundant roles that Notch3 plays in the pathogenesis of the human disease cerebral autosomal-dominant arteriopathy with subcortical infarcts and leukoencephalopathy and in the regulation of murine T-cell differentiation and leukemogenesis.	[Bellavia, D.; Checquolo, S.; Campese, A. F.; Felli, M. P.; Gulino, A.; Screpanti, I.] Univ Roma La Sapienza, Dept Expt Med, Lab Mol Pathol, I-00161 Rome, Italy	Sapienza University Rome	Screpanti, I (corresponding author), Univ Roma La Sapienza, Dipartimento Med Sperimentale, Lab Mol Pahtol, Vialae Regina Elena,324, I-00161 Rome, Italy.	isabella.screpanti@uniroma1.it	Campese, Antonio/A-9783-2015; Bellavia, Diana/AAO-6348-2021	FELLI, MARIA PIA/0000-0002-5765-2611; CAMPESE, Antonio Francesco/0000-0002-8535-6609; CHECQUOLO, Saula/0000-0001-5109-8392	Associazione Italiana per la Ricerca sul Cancro (AIRC); Ministero dell'Istruzione, dell'Universita e della Ricerca (MIUR)	Associazione Italiana per la Ricerca sul Cancro (AIRC)(Fondazione AIRC per la ricerca sul cancro); Ministero dell'Istruzione, dell'Universita e della Ricerca (MIUR)(Ministry of Education, Universities and Research (MIUR))	We thank members of Screpanti's laboratory, whose comments and work have contributed to the realization of this review. Work in the authors' laboratory is supported by Grants from the Associazione Italiana per la Ricerca sul Cancro (AIRC) and the Ministero dell'Istruzione, dell'Universita e della Ricerca (MIUR).	Anastasi E, 2003, J IMMUNOL, V171, P4504, DOI 10.4049/jimmunol.171.9.4504; Artavanis-Tsakonas S, 1999, SCIENCE, V284, P770, DOI 10.1126/science.284.5415.770; Ascano JM, 2003, J BIOL CHEM, V278, P8771, DOI 10.1074/jbc.M211427200; AUSTIN J, 1989, CELL, V58, P565, DOI 10.1016/0092-8674(89)90437-6; Barrick D, 2006, CELL, V124, P883, DOI 10.1016/j.cell.2006.02.028; Beatus P, 2001, MECH DEVELOP, V104, P3, DOI 10.1016/S0925-4773(01)00373-2; Bellavia D, 2000, EMBO J, V19, P3337, DOI 10.1093/emboj/19.13.3337; Bellavia D, 2002, P NATL ACAD SCI USA, V99, P3788, DOI 10.1073/pnas.062050599; Bellavia D, 2007, EMBO J, V26, P1670, DOI 10.1038/sj.emboj.7601626; Beverly LJ, 2003, CANCER CELL, V3, P551, DOI 10.1016/S1535-6108(03)00137-5; Bray SJ, 2006, NAT REV MOL CELL BIO, V7, P678, DOI 10.1038/nrm2009; Brou C, 2000, MOL CELL, V5, P207, DOI 10.1016/S1097-2765(00)80417-7; Cemerski S, 2006, CURR OPIN IMMUNOL, V18, P298, DOI 10.1016/j.coi.2006.03.011; Christensen S, 1996, DEVELOPMENT, V122, P1373; Dang TP, 2003, ONCOGENE, V22, P1988, DOI 10.1038/sj.onc.1206230; De Strooper B, 1999, NATURE, V398, P518, DOI 10.1038/19083; deAngelis MH, 1997, NATURE, V386, P717, DOI 10.1038/386717a0; Domenga V, 2004, GENE DEV, V18, P2730, DOI 10.1101/gad.308904; Felli MP, 2005, ONCOGENE, V24, P992, DOI 10.1038/sj.onc.1208302; Felli MP, 1999, INT IMMUNOL, V11, P1017, DOI 10.1093/intimm/11.7.1017; FITZGERALD K, 1993, DEVELOPMENT, V119, P1019; FORTINI ME, 1994, CELL, V79, P273, DOI 10.1016/0092-8674(94)90196-1; Gale NW, 2004, P NATL ACAD SCI USA, V101, P15949, DOI 10.1073/pnas.0407290101; Hamada Y, 1999, DEVELOPMENT, V126, P3415; Ikeuchi T, 2003, J BIOL CHEM, V278, P7751, DOI 10.1074/jbc.C200711200; Joutel A, 2000, J CLIN INVEST, V105, P597, DOI 10.1172/JCI8047; Joutel A, 1996, NATURE, V383, P707, DOI 10.1038/383707a0; Konishi J, 2007, CANCER RES, V67, P8051, DOI 10.1158/0008-5472.CAN-07-1022; KOPAN R, 1993, J CELL BIOL, V121, P631, DOI 10.1083/jcb.121.3.631; Kovall RA, 2007, CURR OPIN STRUC BIOL, V17, P117, DOI 10.1016/j.sbi.2006.11.004; Kurooka H, 1998, NUCLEIC ACIDS RES, V26, P5448, DOI 10.1093/nar/26.23.5448; Lacombe P, 2005, STROKE, V36, P1053, DOI 10.1161/01.STR.0000163080.82766.eb; LARDELLI M, 1994, MECH DEVELOP, V46, P123, DOI 10.1016/0925-4773(94)90081-7; LaVoie MJ, 2003, J BIOL CHEM, V278, P34427, DOI 10.1074/jbc.M302659200; Li K, 2008, J BIOL CHEM, V283, P8046, DOI 10.1074/jbc.M800170200; Li Yanxia, 2004, BMC Dev Biol, V4, P5, DOI 10.1186/1471-213X-4-5; Lubman OY, 2007, J MOL BIOL, V365, P577, DOI 10.1016/j.jmb.2006.09.071; Monet M, 2007, HUM MOL GENET, V16, P982, DOI 10.1093/hmg/ddm042; Nam Y, 2006, CELL, V124, P973, DOI 10.1016/j.cell.2005.12.037; Nehring LC, 2005, J BIOL CHEM, V280, P20349, DOI 10.1074/jbc.M500273200; Ong CT, 2006, J BIOL CHEM, V281, P5106, DOI 10.1074/jbc.M506108200; Park JT, 2006, CANCER RES, V66, P6312, DOI 10.1158/0008-5472.CAN-05-3610; Petcherski AG, 2000, CURR BIOL, V10, pR471, DOI 10.1016/S0960-9822(00)00577-7; Qi HL, 1999, SCIENCE, V283, P91, DOI 10.1126/science.283.5398.91; Rothenberg EV, 2001, NAT IMMUNOL, V2, P189, DOI 10.1038/85231; Sakamoto K, 2002, DEV BIOL, V241, P313, DOI 10.1006/dbio.2001.0517; Sansone P, 2007, J CLIN INVEST, V117, P3988, DOI 10.1172/JCI32533; Sansone P, 2007, STEM CELLS, V25, P807, DOI 10.1634/stemcells.2006-0442; Shah S, 2005, CELL, V122, P435, DOI 10.1016/j.cell.2005.05.022; Shimizu K, 1999, J BIOL CHEM, V274, P32961, DOI 10.1074/jbc.274.46.32961; SWIATEK PJ, 1994, GENE DEV, V8, P707, DOI 10.1101/gad.8.6.707; Talora C, 2003, EMBO REP, V4, P1067, DOI 10.1038/sj.embor.7400013; Tamura K, 1995, CURR BIOL, V5, P1416, DOI 10.1016/S0960-9822(95)00279-X; Vacca A, 2006, EMBO J, V25, P1000, DOI 10.1038/sj.emboj.7600996; Varnum-Finney B, 1998, BLOOD, V91, P4084, DOI 10.1182/blood.V91.11.4084.411k05_4084_4091; Voll RE, 2000, IMMUNITY, V13, P677, DOI 10.1016/S1074-7613(00)00067-4; von Boehmer H, 1998, IMMUNOL REV, V165, P111; Vooijs M, 2004, J BIOL CHEM, V279, P50864, DOI 10.1074/jbc.M409430200; WEINMASTER G, 1991, DEVELOPMENT, V113, P199; WEINMASTER G, 1992, DEVELOPMENT, V116, P931; WHARTON KA, 1985, CELL, V43, P567, DOI 10.1016/0092-8674(85)90229-6; Wilson JJ, 2006, CELL, V124, P985, DOI 10.1016/j.cell.2006.01.035; WINANDY S, 1995, CELL, V83, P289, DOI 10.1016/0092-8674(95)90170-1; Wu J, 2007, TRENDS BIOCHEM SCI, V32, P477, DOI 10.1016/j.tibs.2007.09.002; Xue YZ, 1999, HUM MOL GENET, V8, P723, DOI 10.1093/hmg/8.5.723; Zhang YM, 2007, BIOCHEM BIOPH RES CO, V355, P245, DOI 10.1016/j.bbrc.2007.01.151	66	57	74	1	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP	2008	27	38					5092	5098		10.1038/onc.2008.230	http://dx.doi.org/10.1038/onc.2008.230			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	344GM	18758477				2022-12-28	WOS:000258914900002
J	Maliekal, TT; Bajaj, J; Giri, V; Subramayam, D; Krishna, S				Maliekal, T. T.; Bajaj, J.; Giri, V.; Subramayam, D.; Krishna, S.			The role of Notch signaling in human cervical cancer: implications for solid tumors	ONCOGENE			English	Review						Notch; cervical cancer; HPV	HUMAN-PAPILLOMAVIRUS TYPE-16; SUPPRESSOR PATHWAYS; NEOPLASTIC LESIONS; EPITHELIAL-CELLS; CARCINOMA CELLS; GROWTH ARREST; TRANSFORMATION; EXPRESSION; ONCOGENES; E6	The detection of intracellular forms of Notch1 in human cervical cancers more than a decade ago prompted an investigation into the possible role of this pathway in driving these cancers. These tumors are consistently characterized by features of deregulated ligand-dependent signaling. Although Notch signaling complements the function of papillomavirus oncogenes in transformation assays of human keratinocytes, there are dose-dependent effects, which inhibit growth of established cervical cancer cell lines. Two pro-oncogenic effector mechanisms that have been suggested to operate in this context by Notch signaling are the activation of PI3K/Akt pathway and the upregulation of c-Myc. Collectively, there is a complex interplay between Notch signaling and papillomaviruses in the context of cervical carcinogenesis. Better animal model systems and identification of human cervical cancer stem cells should help clarify the possible stage specific and pleiotropic effects and regulation of Notch signaling.	[Maliekal, T. T.; Bajaj, J.; Subramayam, D.; Krishna, S.] Tata Inst Fundamental Res, Natl Ctr Biol Sci, Bangalore 560065, Karnataka, India; [Giri, V.] KIDWAI Mem Inst Oncol, Dept Radiotherapy, Bangalore, Karnataka, India	Tata Institute of Fundamental Research (TIFR); National Centre for Biological Sciences (NCBS); Kidwai Memorial Institute of Oncology	Krishna, S (corresponding author), Tata Inst Fundamental Res, Natl Ctr Biol Sci, GKVK Campus, Bangalore 560065, Karnataka, India.	skrishna@ncbs.res.in		Subramanyam, Deepa/0000-0002-1650-5690; Maliekal, Tessy/0000-0002-7311-7950	Department of Science and Technology and Council for Scientific and Industrial Research; Department of Biotechnology; TIFR	Department of Science and Technology and Council for Scientific and Industrial Research; Department of Biotechnology; TIFR	Maliekal TT and Bajaj J acknowledge Department of Science and Technology and Council for Scientific and Industrial Research, respectively, for financial support. Our research was supported by Department of Biotechnology and by core grants of TIFR.	Brake T, 2005, P NATL ACAD SCI USA, V102, P2490, DOI 10.1073/pnas.0409883102; Capobianco AJ, 1997, MOL CELL BIOL, V17, P6265, DOI 10.1128/MCB.17.11.6265; Chakrabarti O, 2004, J VIROL, V78, P5934, DOI 10.1128/JVI.78.11.5934-5945.2004; Daniel B, 1997, J GEN VIROL, V78, P1095, DOI 10.1099/0022-1317-78-5-1095; Fan X, 2006, CANCER RES, V66, P7445, DOI 10.1158/0008-5472.CAN-06-0858; Goodwin EC, 2000, P NATL ACAD SCI USA, V97, P12513, DOI 10.1073/pnas.97.23.12513; Jones EE, 2006, CURR MOL MED, V6, P795; Lathion S, 2003, CANCER RES, V63, P8687; Nair P, 2003, J VIROL, V77, P7106, DOI 10.1128/JVI.77.12.7106-7112.2003; Pett MR, 2004, CANCER RES, V64, P1359, DOI 10.1158/0008-5472.CAN-03-3214; Ramdass B, 2007, GYNECOL ONCOL, V104, P352, DOI 10.1016/j.ygyno.2006.08.054; Rangarajan A, 2001, VIROLOGY, V286, P23, DOI 10.1006/viro.2001.0867; REID R, 1983, GYNECOL ONCOL, V15, P239, DOI 10.1016/0090-8258(83)90080-X; ROBBINS J, 1992, J VIROL, V66, P2594, DOI 10.1128/JVI.66.4.2594-2599.1992; Ronchini C, 2001, MOL CELL BIOL, V21, P5925, DOI 10.1128/MCB.21.17.5925-5934.2001; Sade H, 2004, J BIOL CHEM, V279, P2937, DOI 10.1074/jbc.M309924200; Subramanyam D, 2006, VIROLOGY, V347, P191, DOI 10.1016/j.virol.2005.11.028; Talora C, 2005, EXP CELL RES, V305, P343, DOI 10.1016/j.yexcr.2005.01.015; Talora C, 2002, GENE DEV, V16, P2252, DOI 10.1101/gad.988902; Veeraraghavalu K, 2005, J VIROL, V79, P7889, DOI 10.1128/JVI.79.12.7889-7898.2005; Veeraraghavalu K, 2004, J VIROL, V78, P8687, DOI 10.1128/JVI.78.16.8687-8700.2004; Wang L, 2007, INT J GYNECOL CANCER, V17, P1283, DOI 10.1111/j.1525-1438.2007.00927.x; Weijzen S, 2003, J CELL PHYSIOL, V194, P356, DOI 10.1002/jcp.10217; Weng AP, 2004, SCIENCE, V306, P269, DOI 10.1126/science.1102160; Yugawa T, 2007, MOL CELL BIOL, V27, P3732, DOI 10.1128/MCB.02119-06; ZAGOURAS P, 1995, P NATL ACAD SCI USA, V92, P6414, DOI 10.1073/pnas.92.14.6414; zur Hausen H, 2002, NAT REV CANCER, V2, P342, DOI 10.1038/nrc798; zur Hausen H, 2000, JNCI-J NATL CANCER I, V92, P690, DOI 10.1093/jnci/92.9.690	28	77	88	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP	2008	27	38					5110	5114		10.1038/onc.2008.224	http://dx.doi.org/10.1038/onc.2008.224			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	344GM	18758479				2022-12-28	WOS:000258914900004
J	Rizzo, P; Osipo, C; Foreman, K; Golde, T; Osborne, B; Miele, L				Rizzo, P.; Osipo, C.; Foreman, K.; Golde, T.; Osborne, B.; Miele, L.			Rational targeting of Notch signaling in cancer	ONCOGENE			English	Review						Notch; cancer; targeted therapy	T-CELL LEUKEMIA; NF-KAPPA-B; GAMMA-SECRETASE INHIBITORS; ENDOTHELIAL GROWTH-FACTOR; CARCINOMA-IN-SITU; BREAST-CANCER; TUMOR-SUPPRESSOR; STRUCTURAL BASIS; DOWN-REGULATION; SELF-RENEWAL	Accumulating preclinical and clinical evidence supports a pro-oncogenic function for Notch signaling in several solid tumors, particularly but not exclusively in breast cancer. Notch inhibitory agents, such as gamma-secretase inhibitors, are being investigated as candidate cancer therapeutic agents. Interest in therapeutic modulation of the Notch pathway has been increased by recent reports, indicating that its role is important in controlling the fate of putative 'breast cancer stem cells'. However, as is the case for most targeted therapies, successful targeting of Notch signaling in cancer will require a considerable refinement of our understanding of the regulation of this pathway and its effects in both normal and cancer cells. Notch signaling has bidirectional 'cross talk' interaction with multiple other pathways that include candidate therapeutic targets. Understanding these interactions will greatly increase our ability to design rational combination regimens. To determine which patients are most likely to benefit from treatment with Notch inhibitors, it will be necessary to develop molecular tests to accurately measure pathway activity in specific tumors. Finally, mechanism-based toxicities will have to be addressed by a careful choice of therapeutic agents, combinations and regimens. This article summarizes the current state of the field, and briefly describes opportunities and challenges for Notch-targeted therapies in oncology.	[Rizzo, P.; Osipo, C.; Foreman, K.; Miele, L.] Loyola Univ, Cardinal Bernardin Canc Ctr, Breast Canc Program, Chicago, IL 60163 USA; [Golde, T.] Mayo Clin, Dept Neurol, Jacksonville, FL USA; [Osborne, B.] Univ Massachusetts, Dept Vet & Anim Sci, Amherst, MA 01003 USA	Loyola University Chicago; Mayo Clinic; University of Massachusetts System; University of Massachusetts Amherst	Miele, L (corresponding author), Loyola Univ, Cardinal Bernardin Canc Ctr, Breast Canc Program, 2160 S 1st Ave,Room 236, Chicago, IL 60163 USA.	lmiele@lumc.edu		rizzo, paola/0000-0001-7174-9674; Miele, Lucio/0000-0002-5853-7287	NIH [P01 AG2553101]; DOD IDEA [W81XWH-04-1-0478]; NATIONAL INSTITUTE ON AGING [P01AG025531] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); DOD IDEA; NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	This work was supported by NIH grant P01 AG2553101 and DOD IDEA grant . We are grateful to Antonio Pannuti for helpful discussions.W81XWH-04-1-0478	Allenspach EJ, 2002, CANCER BIOL THER, V1, P466, DOI 10.4161/cbt.1.5.159; Bash J, 1999, EMBO J, V18, P2803, DOI 10.1093/emboj/18.10.2803; Bellavia D, 2007, CELL CYCLE, V6, P2730, DOI 10.4161/cc.6.22.4894; Berman JN, 2007, CURR DRUG TARGETS, V8, P727, DOI 10.2174/138945007780830818; Beverly LJ, 2003, CANCER CELL, V3, P551, DOI 10.1016/S1535-6108(03)00137-5; Brou C, 2000, MOL CELL, V5, P207, DOI 10.1016/S1097-2765(00)80417-7; Chen YB, 2007, CANCER RES, V67, P7954, DOI 10.1158/0008-5472.CAN-07-1229; Dallman MJ, 2005, CURR OPIN IMMUNOL, V17, P259, DOI 10.1016/j.coi.2005.04.002; Deftos ML, 1998, IMMUNITY, V9, P777, DOI 10.1016/S1074-7613(00)80643-3; Dickson BC, 2007, MODERN PATHOL, V20, P685, DOI 10.1038/modpathol.3800785; Fan X, 2004, CANCER RES, V64, P7787, DOI 10.1158/0008-5472.CAN-04-1446; Farnie G, 2005, BREAST CANCER RES TR, V94, pS14; Farnie G, 2007, STEM CELL REV, V3, P169, DOI 10.1007/s12015-007-0023-5; Farnie G, 2007, JNCI-J NATL CANCER I, V99, P616, DOI 10.1093/jnci/djk133; Gordon WR, 2007, NAT STRUCT MOL BIOL, V14, P295, DOI 10.1038/nsmb1227; Gupta-Rossi N, 2004, J CELL BIOL, V166, P73, DOI 10.1083/jcb.200310098; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Houde C, 2004, BLOOD, V104, P3697, DOI 10.1182/blood-2003-12-4114; Jundt F, 2004, BLOOD, V103, P3511, DOI 10.1182/blood-2003-07-2254; Jundt F, 2002, BLOOD, V99, P3398, DOI 10.1182/blood.V99.9.3398; Kathrein KL, 2008, J BIOL CHEM, V283, P10476, DOI 10.1074/jbc.M709643200; Koch U, 2007, CELL MOL LIFE SCI, V64, P2746, DOI 10.1007/s00018-007-7164-1; Kopan R, 2004, NAT REV MOL CELL BIO, V5, P499, DOI 10.1038/nrm1406; Kukar T, 2008, CURR TOP MED CHEM, V8, P47, DOI 10.2174/156802608783334042; Kwon C, 2005, P NATL ACAD SCI USA, V102, P18986, DOI 10.1073/pnas.0509535102; Lai EC, 2005, GENE DEV, V19, P1067, DOI 10.1101/gad.1291905; Li K, 2008, J BIOL CHEM, V283, P8046, DOI 10.1074/jbc.M800170200; Liu ZJ, 2003, MOL CELL BIOL, V23, P14, DOI 10.1128/MCB.23.1.14-25.2003; Malyukova A, 2007, CANCER RES, V67, P5611, DOI 10.1158/0008-5472.CAN-06-4381; McKenzie GJ, 2005, EXPERT OPIN THER TAR, V9, P395, DOI 10.1517/14728222.9.2.395; Miele L, 2006, CLIN CANCER RES, V12, P1074, DOI 10.1158/1078-0432.CCR-05-2570; Miele L, 2006, CURR MOL MED, V6, P905, DOI 10.2174/156652406779010830; Minato Y, 2005, INT J HEMATOL, V82, P302, DOI 10.1532/IJH97.05095; Minter LM, 2005, NAT IMMUNOL, V6, P680, DOI 10.1038/ni1209x; Mukherjee A, 2005, NAT CELL BIOL, V7, P1191, DOI 10.1038/ncb1327; Nam Y, 2006, CELL, V124, P973, DOI 10.1016/j.cell.2005.12.037; Nam YS, 2007, P NATL ACAD SCI USA, V104, P2103, DOI 10.1073/pnas.0611092104; Nickoloff BJ, 2005, J INVEST DERM SYMP P, V10, P95, DOI 10.1111/j.1087-0024.2005.200404.x; Nickoloff BJ, 2002, CELL DEATH DIFFER, V9, P842, DOI 10.1038/sj.cdd.4401036; Nicolas M, 2003, NAT GENET, V33, P416, DOI 10.1038/ng1099; Noguera-Troise Irene, 2007, Novartis Found Symp, V283, P106; O'Neil J, 2007, J EXP MED, V204, P1813, DOI 10.1084/jem.20070876; O'Neill CF, 2007, AM J PATHOL, V171, P1023, DOI 10.2353/ajpath.2007.061029; Okajima T, 2002, CELL, V111, P893, DOI 10.1016/S0092-8674(02)01114-5; Osipo C, 2008, LAB INVEST, V88, P11, DOI 10.1038/labinvest.3700700; Oswald F, 2005, MOL CELL BIOL, V25, P10379, DOI 10.1128/MCB.25.23.10379-10390.2005; Oswald F, 2002, EMBO J, V21, P5417, DOI 10.1093/emboj/cdf549; Palomero T, 2007, NAT MED, V13, P1203, DOI 10.1038/nm1636; Parry M, 2004, GLOBAL ENVIRON CHANG, V14, P1, DOI 10.1016/j.gloenvcha.2003.10.003; Pece S, 2004, J CELL BIOL, V167, P215, DOI 10.1083/jcb.200406140; Pinnix CC, 2007, PIGM CELL RES, V20, P458, DOI 10.1111/j.1600-0749.2007.00410.x; Pitsouli C, 2005, DEVELOPMENT, V132, P4041, DOI 10.1242/dev.01979; Reedijk M, 2005, CANCER RES, V65, P8530, DOI 10.1158/0008-5472.CAN-05-1069; Ridgway J, 2006, NATURE, V444, P1083, DOI 10.1038/nature05313; Roy M, 2007, CURR OPIN GENET DEV, V17, P52, DOI 10.1016/j.gde.2006.12.001; Sansone P, 2007, STEM CELLS, V25, P807, DOI 10.1634/stemcells.2006-0442; Santolini E, 2000, J CELL BIOL, V151, P1345, DOI 10.1083/jcb.151.6.1345; Shih IM, 2007, CANCER RES, V67, P1879, DOI 10.1158/0008-5472.CAN-06-3958; Song LL, 2007, EXPERT OPIN BIOL TH, V7, P431, DOI 10.1517/14712598.7.4.431; Thompson BJ, 2007, J EXP MED, V204, P1825, DOI 10.1084/jem.20070872; Thurston G, 2007, NAT REV CANCER, V7, P327, DOI 10.1038/nrc2130; Tu LL, 2005, J EXP MED, V202, P1037, DOI 10.1084/jem.20050923; Vilimas T, 2007, NAT MED, V13, P70, DOI 10.1038/nm1524; Wang Y, 2004, P NATL ACAD SCI USA, V101, P9458, DOI 10.1073/pnas.0308126101; Wang ZW, 2006, CANCER RES, V66, P2778, DOI 10.1158/0008-5472.CAN-05-4281; Wang ZW, 2006, INT J CANCER, V118, P1930, DOI 10.1002/ijc.21589; Weijzen S, 2002, NAT MED, V8, P979, DOI 10.1038/nm754; Wong GT, 2004, J BIOL CHEM, V279, P12876, DOI 10.1074/jbc.M311652200; Wu J, 2005, MOL CELL BIOL, V25, P1458, DOI 10.1128/MCB.25.4.1458-1474.2005; Wu J, 2007, MOL CELL BIOL, V27, P2411, DOI 10.1128/MCB.02152-06; Yan MH, 2007, CLIN CANCER RES, V13, P7243, DOI 10.1158/1078-0432.CCR-07-1393; Yoo AS, 2005, SCIENCE, V310, P1330, DOI 10.1126/science.1119481; Zeng QH, 2005, CANCER CELL, V8, P13, DOI 10.1016/j.ccr.2005.06.004	73	314	325	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP	2008	27	38					5124	5131		10.1038/onc.2008.226	http://dx.doi.org/10.1038/onc.2008.226			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	344GM	18758481				2022-12-28	WOS:000258914900006
J	Hassan, M; Alaoui, A; Feyen, O; Mirmohammadsadegh, A; Essmann, F; Tannapfel, A; Gulbins, E; Schulze-Osthoff, K; Hengge, UR				Hassan, M.; Alaoui, A.; Feyen, O.; Mirmohammadsadegh, A.; Essmann, F.; Tannapfel, A.; Gulbins, E.; Schulze-Osthoff, K.; Hengge, U. R.			The BH3-only member Noxa causes apoptosis in melanoma cells by multiple pathways	ONCOGENE			English	Article						apoptosis; melanoma; Noxa; BH3-only proteins	ENDOPLASMIC-RETICULUM; BCL-2 FAMILY; TRIGGERS APOPTOSIS; SIGNALING PATHWAY; GENE-EXPRESSION; UP-REGULATION; C-JUN; DEATH; ACTIVATION; INDUCTION	The molecular causes for resistance of melanoma to apoptosis are currently only partly understood. In the present study, we examined gene transfer and expression of the proapoptotic BH3-only protein Noxa as an alternative approach to chemotherapy and investigated the molecular mechanisms regulating Noxa-induced apoptosis. Noxa gene transfer caused dysregulation of both mitochondria and, as shown for the first time, also the endoplasmic reticulum, resulting in the accumulation of reactive oxygen species. Interestingly, expression of Noxa not only triggered the classical mitochondrial caspase cascade, but also resulted in the activation of apoptosis signal-regulating kinase1 and its downstream effectors c-Jun N-terminal kinase and p38. The activation of these kinases was abolished by antioxidants. Moreover, inhibition of the kinases by RNA interference or pharmacological inhibitors significantly attenuated Noxa-induced apoptosis. Thus, our data provide evidence for the involvement of multiple pathways in Noxa-induced apoptosis that are triggered at mitochondria and the endoplasmic reticulum, and suggest Noxa gene transfer as a complementary approach to chemotherapy.	[Hassan, M.; Alaoui, A.; Mirmohammadsadegh, A.; Hengge, U. R.] Univ Dusseldorf, Dept Dermatol, D-40225 Dusseldorf, Germany; [Feyen, O.] Univ Dusseldorf, Dept Pediat Immunol & Oncol, D-40225 Dusseldorf, Germany; [Essmann, F.; Schulze-Osthoff, K.] Univ Dusseldorf, Inst Mol Med, D-40225 Dusseldorf, Germany; [Tannapfel, A.] Ruhr Univ Bochum, Dept Pathol, Bochum, Germany; [Gulbins, E.] Univ Duisburg Essen, Dept Mol Biol, Essen, Germany	Heinrich Heine University Dusseldorf; Heinrich Heine University Dusseldorf; Heinrich Heine University Dusseldorf; Ruhr University Bochum; University of Duisburg Essen	Hengge, UR (corresponding author), Univ Dusseldorf, Dept Dermatol, Moorenstr 5, D-40225 Dusseldorf, Germany.	ulrich.hengge@uni-duesseldorf.de	Essmann, Frank/ABG-7409-2020; Hassan, Mohamed/AHE-7565-2022; Schulze-Osthoff, Klaus/N-9025-2013	Essmann, Frank/0000-0003-4369-8456; Schulze-Osthoff, Klaus/0000-0003-1443-2720				Adler V, 1999, ONCOGENE, V18, P6104, DOI 10.1038/sj.onc.1203128; AKAO Y, 1994, CANCER RES, V54, P2468; Cai JY, 1998, BBA-BIOENERGETICS, V1366, P139, DOI 10.1016/S0005-2728(98)00109-1; Chen L, 2005, MOL CELL, V17, P393, DOI 10.1016/j.molcel.2004.12.030; Chun ACS, 2003, J BIOL CHEM, V278, P37439, DOI 10.1074/jbc.M307185200; Daniel PT, 2003, ESSAYS BIOCHEM, V39, P73, DOI 10.1042/bse0390073; DENIAUD A, 2007, ONCOGENE, V27, P274; Duan WR, 2003, J PATHOL, V199, P221, DOI 10.1002/path.1289; Eferl R, 2003, NAT REV CANCER, V3, P859, DOI 10.1038/nrc1209; Essmann F, 2005, J BIOL CHEM, V280, P37169, DOI 10.1074/jbc.M502052200; Essmann F, 2003, CELL DEATH DIFFER, V10, P1260, DOI 10.1038/sj.cdd.4401301; ESTUS S, 1994, J CELL BIOL, V127, P1717, DOI 10.1083/jcb.127.6.1717; Fernandez Y, 2005, CANCER RES, V65, P6294, DOI 10.1158/0008-5472.CAN-05-0686; Gillissen B, 2003, EMBO J, V22, P3580, DOI 10.1093/emboj/cdg343; Gomez-Bougie P, 2007, CANCER RES, V67, P5418, DOI 10.1158/0008-5472.CAN-06-4322; Hassan M, 2005, CELL MOL LIFE SCI, V62, P2015, DOI 10.1007/s00018-005-5172-6; Hassan M, 2005, VIROLOGY, V333, P324, DOI 10.1016/j.virol.2005.01.008; Hassan M, 2004, CELL SIGNAL, V16, P1375, DOI 10.1016/j.cellsig.2004.04.005; Hassan M, 2007, CELL SIGNAL, V19, P301, DOI 10.1016/j.cellsig.2006.07.002; Hershko T, 2004, J BIOL CHEM, V279, P8627, DOI 10.1074/jbc.M312866200; Horiuchi D, 2003, NEUROSCI RES, V47, P209, DOI 10.1016/S0168-0102(03)00216-5; Hossini AM, 2006, ONCOGENE, V25, P2160, DOI 10.1038/sj.onc.1209253; Hossini AM, 2003, FEBS LETT, V553, P250, DOI 10.1016/S0014-5793(03)01017-2; Ichijo H, 1997, SCIENCE, V275, P90, DOI 10.1126/science.275.5296.90; Kim JY, 2004, J EXP MED, V199, P113, DOI 10.1084/jem.20030613; Labi V, 2006, CELL DEATH DIFFER, V13, P1325, DOI 10.1038/sj.cdd.4401940; Lee AS, 2001, TRENDS BIOCHEM SCI, V26, P504, DOI 10.1016/S0968-0004(01)01908-9; Lindsten T, 2000, MOL CELL, V6, P1389, DOI 10.1016/S1097-2765(00)00136-2; LOS M, 1995, EMBO J, V14, P3731, DOI 10.1002/j.1460-2075.1995.tb00043.x; Oda E, 2000, SCIENCE, V288, P1053, DOI 10.1126/science.288.5468.1053; Oppermann M, 2005, ONCOGENE, V24, P7369, DOI 10.1038/sj.onc.1208890; Pardo J, 2006, J CELL BIOL, V174, P509, DOI 10.1083/jcb.200604044; Perez-Galan P, 2007, BLOOD, V109, P4441, DOI 10.1182/blood-2006-07-034173; Qin JZ, 2006, CANCER RES, V66, P9636, DOI 10.1158/0008-5472.CAN-06-0747; Qin JZ, 2004, MOL CANCER THER, V3, P895; Reed JC, 2006, CELL DEATH DIFFER, V13, P1378, DOI 10.1038/sj.cdd.4401975; Samraj AK, 2007, MOL BIOL CELL, V18, P84, DOI 10.1091/mbc.E06-04-0263; Scorrano L, 2003, SCIENCE, V300, P135, DOI 10.1126/science.1081208; Shibue T, 2003, GENE DEV, V17, P2233, DOI 10.1101/gad.1103603; Soengas MS, 2003, ONCOGENE, V22, P3138, DOI 10.1038/sj.onc.1206454; Soengas MS, 2001, NATURE, V409, P207, DOI 10.1038/35051606; Tobiume K, 2001, EMBO REP, V2, P222, DOI 10.1093/embo-reports/kve046; Villunger A, 2003, SCIENCE, V302, P1036, DOI 10.1126/science.1090072; Wei MC, 2001, SCIENCE, V292, P727, DOI 10.1126/science.1059108; Willis SN, 2007, SCIENCE, V315, P856, DOI 10.1126/science.1133289; Zanke BW, 1996, CURR BIOL, V6, P606, DOI 10.1016/S0960-9822(02)00547-X; Zong WX, 2003, J CELL BIOL, V162, P59, DOI 10.1083/jcb.200302084	47	49	51	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 31	2008	27	33					4557	4568		10.1038/onc.2008.90	http://dx.doi.org/10.1038/onc.2008.90			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	332IS	18408751				2022-12-28	WOS:000258077300005
J	Logunov, DY; Scheblyakov, DV; Zubkova, OV; Shmarov, MM; Rakovskaya, IV; Gurova, KV; Tararova, ND; Burdelya, LG; Naroditsky, BS; Ginzburg, AL; Gudkov, AV				Logunov, D. Y.; Scheblyakov, D. V.; Zubkova, O. V.; Shmarov, M. M.; Rakovskaya, I. V.; Gurova, K. V.; Tararova, N. D.; Burdelya, L. G.; Naroditsky, B. S.; Ginzburg, A. L.; Gudkov, A. V.			Mycoplasma infection suppresses p53, activates NF-kappa B and cooperates with oncogenic Ras in rodent fibroblast transformation	ONCOGENE			English	Article						oncogene; tumor suppressor; p21; senescence; transactivation	INSTABILITY; CHECKPOINT; PATHWAY; MICE	Prokaryotes of the genus Mycoplasma are the smallest cellular organisms that persist as obligate extracellular parasites. Although mycoplasma infection is known to be associated with chromosomal instability and can promote malignant transformation, the mechanisms underlying these phenomena remain unknown. Since persistence of many cellular parasites requires suppression of apoptosis in host cells, we tested the effect of mycoplasma infection on the activity of the p53 and nuclear factor (NF)-kappa B pathways, major mechanisms controlling programmed cell death. To monitor the activity of p53 and NF-kappa B in mycoplasma-infected cells, we used a panel of reporter cell lines expressing the bacterial beta-galactosidase gene under the control of p53- or NF-kappa B-responsive promoters. Cells incubated with media conditioned with different species of mycoplasma showed constitutive activation of NF-kappa B and reduced activation of p53, common characteristics of the majority of human tumor cells, with M. arginini having the strongest effect among the species tested. Moreover, mycoplasma infection reduced the expression level and inducibility of an endogenous p53- responsive gene, p21(waf1), and inhibited apoptosis induced by genotoxic stress. Infection with M. arginini made rat and mouse embryo fibroblasts susceptible to transformation with oncogenic H-Ras, whereas mycoplasma-free cells underwent irreversible p53- dependent growth arrest. Mycoplasma infection was as effective as shRNA-mediated knockdown of p53 expression in making rodent fibroblasts permissive to Ras-induced transformation. These observations indicate that mycoplasma infection plays the role of a p53- suppressing oncogene that cooperates with Ras in cell transformation and suggest that the carcinogenic and mutagenic effects of mycoplasma might be due to inhibition of p53 tumor suppressor function by this common human parasite.	[Burdelya, L. G.; Gudkov, A. V.] Roswell Pk Canc Inst, Dept Cell Stress Biol, Buffalo, NY 14263 USA; [Logunov, D. Y.; Scheblyakov, D. V.; Zubkova, O. V.; Shmarov, M. M.; Rakovskaya, I. V.; Naroditsky, B. S.; Ginzburg, A. L.] NF Gamalei Inst Epidemiol & Microbiol, Moscow, Russia; [Gurova, K. V.; Tararova, N. D.; Burdelya, L. G.; Gudkov, A. V.] Cleveland BioLabs Inc, Buffalo, NY USA	Roswell Park Cancer Institute; Russian Academy of Medical Sciences; Gamaleya National Research Center for Epidemiology & Microbiology, RAMS	Gudkov, AV (corresponding author), Roswell Pk Canc Inst, Dept Cell Stress Biol, MRC N 212,Elm & Carlton St, Buffalo, NY 14263 USA.	bsnar1941@yahoo.com; andrei.gudkov@roswellpark.org	Naroditsky, Boris S/F-9135-2012; Shmarov, Maxim M/D-8662-2014; Zubkova, Olga/E-4168-2014	Zubkova, Olga/0000-0001-7893-8419; Gintsburg, Alexander/0000-0003-1769-5059; Shmarov, Maxim/0000-0002-5268-1296; Gudkov, Andrei/0000-0003-2548-0154; Naroditsky, Boris/0000-0001-5522-8238	NCI NIH HHS [CA75179, R01 CA075179, CA098374, CA60730, R01 CA060730, R01 CA098374] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA098374, R01CA075179, R01CA060730] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Baek KH, 2003, J LEUKOCYTE BIOL, V73, P850, DOI 10.1189/jlb.1202607; Boiko AD, 2006, GENE DEV, V20, P236, DOI 10.1101/gad.1372606; Bubici C, 2006, HISTOL HISTOPATHOL, V21, P69, DOI 10.14670/HH-21.69; Burgert HG, 2002, CURR TOP MICROBIOL, V269, P273; Chu HW, 2005, J IMMUNOL, V174, P5713, DOI 10.4049/jimmunol.174.9.5713; Cimolai N, 2001, CAN J MICROBIOL, V47, P691, DOI 10.1139/cjm-47-8-691; Correa P, 2007, GASTROENTEROLOGY, V133, P659, DOI 10.1053/j.gastro.2007.06.026; De Marzo AM, 2007, NAT REV CANCER, V7, P256, DOI 10.1038/nrc2090; Donehower LA, 1996, PROG CLIN BIOL RES, V395, P1; Efeyan A, 2007, CELL CYCLE, V6, P1006, DOI 10.4161/cc.6.9.4211; Feng SH, 1999, MOL CELL BIOL, V19, P7995; Ferbeyre G, 2002, MOL CELL BIOL, V22, P3497, DOI 10.1128/MCB.22.10.3497-3508.2002; Gartel AL, 1999, EXP CELL RES, V246, P280, DOI 10.1006/excr.1998.4319; Gurova KV, 2004, CANCER RES, V64, P1951, DOI 10.1158/0008-5472.CAN-03-1541; Gurova KV, 2005, P NATL ACAD SCI USA, V102, P17448, DOI 10.1073/pnas.0508888102; JIANG S, 2007, J CELL BIOCH; Karin M, 2006, CELL, V124, P823, DOI 10.1016/j.cell.2006.02.016; Karin M, 2006, NATURE, V441, P431, DOI 10.1038/nature04870; Komarova EA, 1997, EMBO J, V16, P1391, DOI 10.1093/emboj/16.6.1391; Lee CH, 2007, BIOFACTORS, V29, P19, DOI 10.1002/biof.5520290103; Lisowska K, 2003, ARCH IMMUNOL THER EX, V51, P367; Lu T, 2004, ONCOGENE, V23, P2138, DOI 10.1038/sj.onc.1207332; Lu T, 2004, P NATL ACAD SCI USA, V101, P7112, DOI 10.1073/pnas.0402048101; Mantovani F, 2001, ONCOGENE, V20, P7874, DOI 10.1038/sj.onc.1204869; McCormick F, 2000, SEMIN CANCER BIOL, V10, P453, DOI 10.1006/scbi.2000.0336; Nelyudova AM, 2004, CELL CYCLE, V3, P1427, DOI 10.4161/cc.3.11.1204; ORIEL JD, 1983, SEX TRANSM DIS, V10, P263; Poyurovsky MV, 2006, GENE DEV, V20, P125, DOI 10.1101/gad.1397506; PROZOROVSKIY SV, 1995, MED MYCOPLASMOLOGY, P187; Razin S, 1998, MICROBIOL MOL BIOL R, V62, P1094, DOI 10.1128/MMBR.62.4.1094-1156.1998; Rottem S, 2003, PHYSIOL REV, V83, P417, DOI 10.1152/physrev.00030.2002; Sablina AA, 1999, CELL BIOL INT, V23, P323, DOI 10.1006/cbir.1999.0362; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Takeda K, 2002, J ENDOTOXIN RES, V8, P459, DOI 10.1179/096805102125001073; TSAI S, 1995, P NATL ACAD SCI USA, V92, P10197, DOI 10.1073/pnas.92.22.10197; Yaswen P, 2007, CELL, V128, P233, DOI 10.1016/j.cell.2007.01.005; Zhang BX, 1997, P SOC EXP BIOL MED, V214, P359	37	54	62	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 31	2008	27	33					4521	4531		10.1038/onc.2008.103	http://dx.doi.org/10.1038/onc.2008.103			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	332IS	18408766	Green Accepted			2022-12-28	WOS:000258077300002
J	Finkin, S; Aylon, Y; Anzi, S; Oren, M; Shaulian, E				Finkin, S.; Aylon, Y.; Anzi, S.; Oren, M.; Shaulian, E.			Fbw7 regulates the activity of endoreduplication mediators and the p53 pathway to prevent drug-induced polyploidy	ONCOGENE			English	Article						polyploidy; Fbw7; p53; spindle inhibitors	F-BOX PROTEIN; PHOSPHORYLATION-DEPENDENT DEGRADATION; CYCLIN-E; AURORA-A; UBIQUITIN LIGASE; CHROMOSOMAL INSTABILITY; ENDOMETRIAL CANCER; TUMOR SUPPRESSION; OVARIAN-CANCER; C-MYC	Fbw7 is a tumor suppressor that is mutated in numerous cancers. It encodes an E3 ubiquitin ligase, whose ability to decrease the levels of pivotal regulators of cell growth and proliferation underlies its tumor suppressor function. Here, we explore the consequences of Fbw7 inactivation on the outcome of chemotherapeutic treatments. When exposed to spindle toxins such as vinblastine and taxol, Fbw7-deficient cells undergo extensive mitotic slippage and endoreduplication, rendering them polyploid. A combined deregulation of several Fbw7 target proteins is required for this phenotype. Specifically, elevated expression of cyclin E and Aurora A in Fbw7-deficient cells is required for drug-induced polyploidy. However, overexpression of either cyclin E or Aurora A alone is not sufficient for drug-induced polyploidy. In addition, we demonstrate that Fbw7 deficiency limits the ability of p53 to respond to mitotic toxins but not to DNA damage. Furthermore, Fbw7 expression regulates the p53-dependent induction of genes such as Lats2 and p21 in response to vinblastine. Hence, we suggest that Fbw7 serves as a master regulator of the mitotic and tetraploidy checkpoints.	[Finkin, S.; Anzi, S.; Shaulian, E.] Hebrew Univ Jerusalem, Sch Med, Dept Expt Med & Canc Res, Jerusalem, Israel; [Aylon, Y.; Oren, M.] Weizmann Inst Sci, Dept Mol Cell Biol, IL-76100 Rehovot, Israel	Hebrew University of Jerusalem; Weizmann Institute of Science	Shaulian, E (corresponding author), Hebrew Univ Jerusalem, Sch Med, Dept Expt Med & Canc Res, Jerusalem, Israel.	eshaulian@md.huji.ac.il		Oren, Moshe/0000-0003-4311-7172; Shaulian, Eitan/0000-0001-6242-6849	NATIONAL CANCER INSTITUTE [R37CA040099] Funding Source: NIH RePORTER; NCI NIH HHS [R37 CA40099] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Anand S, 2003, CANCER CELL, V3, P51, DOI 10.1016/S1535-6108(02)00235-0; Aylon Y, 2006, GENE DEV, V20, P2687, DOI 10.1101/gad.1447006; Bartkova J, 2005, NATURE, V434, P864, DOI 10.1038/nature03482; Brito DA, 2006, CURR BIOL, V16, P1194, DOI 10.1016/j.cub.2006.04.043; Cassia R, 2003, J PATHOL, V201, P589, DOI 10.1002/path.1474; Chen SS, 2002, EMBO J, V21, P4491, DOI 10.1093/emboj/cdf409; DEFFIE A, 1995, MOL CELL BIOL, V15, P3926; Di Leonardo A, 1997, CANCER RES, V57, P1013; Doxsey S, 2005, TRENDS CELL BIOL, V15, P303, DOI 10.1016/j.tcb.2005.04.008; Fujii Y, 2006, CANCER SCI, V97, P729, DOI 10.1111/j.1349-7006.2006.00239.x; Gritsko TM, 2003, CLIN CANCER RES, V9, P1420; Gupta-Rossi N, 2001, J BIOL CHEM, V276, P34371, DOI 10.1074/jbc.M101343200; Hubalek MM, 2004, ONCOGENE, V23, P4187, DOI 10.1038/sj.onc.1207560; Katayama H, 2004, NAT GENET, V36, P55, DOI 10.1038/ng1279; Kimura T, 2003, CANCER SCI, V94, P431, DOI 10.1111/j.1349-7006.2003.tb01460.x; Koepp DM, 2001, SCIENCE, V294, P173, DOI 10.1126/science.1065203; Kwak EL, 2005, GYNECOL ONCOL, V98, P124, DOI 10.1016/j.ygyno.2005.04.007; Libertini SJ, 2005, CANCER RES, V65, P10700, DOI 10.1158/0008-5472.CAN-05-1666; Liu Q, 2004, J BIOL CHEM, V279, P18210, DOI 10.1074/jbc.M400678200; Mao JH, 2004, NATURE, V432, P775, DOI 10.1038/nature03155; Marumoto T, 2005, NAT REV CANCER, V5, P42, DOI 10.1038/nrc1526; Meraldi P, 2002, EMBO J, V21, P483, DOI 10.1093/emboj/21.4.483; Minella AC, 2007, ONCOGENE, V26, P6948, DOI 10.1038/sj.onc.1210518; Minella AC, 2005, CELL CYCLE, V4, P1356, DOI 10.4161/cc.4.10.2058; Minella AC, 2005, P NATL ACAD SCI USA, V102, P9649, DOI 10.1073/pnas.0503677102; Minella AC, 2002, CURR BIOL, V12, P1817, DOI 10.1016/S0960-9822(02)01225-3; Moberg KH, 2004, CURR BIOL, V14, P965, DOI 10.1016/j.cub.2004.04.040; Moberg KH, 2001, NATURE, V413, P311, DOI 10.1038/35095068; Montagnoli A, 1999, GENE DEV, V13, P1181, DOI 10.1101/gad.13.9.1181; Nakayama K, 2004, DEV CELL, V6, P661, DOI 10.1016/S1534-5807(04)00131-5; Nateri AS, 2004, SCIENCE, V303, P1374, DOI 10.1126/science.1092880; Oberg C, 2001, J BIOL CHEM, V276, P35847, DOI 10.1074/jbc.M103992200; Parisi T, 2003, EMBO J, V22, P4794, DOI 10.1093/emboj/cdg482; Rajagopalan H, 2004, NATURE, V428, P77, DOI 10.1038/nature02313; Reed SE, 2004, CANCER RES, V64, P795, DOI 10.1158/0008-5472.CAN-03-3417; Sheaff RJ, 1997, GENE DEV, V11, P1464, DOI 10.1101/gad.11.11.1464; Spruck CH, 2002, CANCER RES, V62, P4535; Spruck CH, 1999, NATURE, V401, P297, DOI 10.1038/45836; Stewart ZA, 1999, MOL CELL BIOL, V19, P205; Strohmaier H, 2001, NATURE, V413, P316, DOI 10.1038/35095076; Takahashi T, 2000, JPN J CANCER RES, V91, P1007, DOI 10.1111/j.1349-7006.2000.tb00878.x; Tanaka T, 1999, CANCER RES, V59, P2041; Toji S, 2004, GENES CELLS, V9, P383, DOI 10.1111/j.1356-9597.2004.00732.x; Vlach J, 1997, EMBO J, V16, P5334, DOI 10.1093/emboj/16.17.5334; Waldman T, 1996, NATURE, V381, P713, DOI 10.1038/381713a0; Wei WY, 2005, CANCER CELL, V8, P25, DOI 10.1016/j.ccr.2005.06.005; Welcker M, 2005, J BIOL CHEM, V280, P7654, DOI 10.1074/jbc.M413377200; Welcker M, 2004, P NATL ACAD SCI USA, V101, P9085, DOI 10.1073/pnas.0402770101; Wu GY, 2001, MOL CELL BIOL, V21, P7403, DOI 10.1128/MCB.21.21.7403-7415.2001; Yada M, 2004, EMBO J, V23, P2116, DOI 10.1038/sj.emboj.7600217	50	38	40	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 24	2008	27	32					4411	4421		10.1038/onc.2008.77	http://dx.doi.org/10.1038/onc.2008.77			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	329PU	18391985				2022-12-28	WOS:000257881700004
J	Bhattacharyya, S; Ishida, W; Wu, M; Wilkes, M; Mori, Y; Hinchcliff, M; Leof, E; Varga, J				Bhattacharyya, S.; Ishida, W.; Wu, M.; Wilkes, M.; Mori, Y.; Hinchcliff, M.; Leof, E.; Varga, J.			A non-Smad mechanism of fibroblast activation by transforming growth factor-beta via c-Abl and Egr-1: selective modulation by imatinib mesylate	ONCOGENE			English	Article						c-Abl; imatinib mesylate; TGF-beta; Egr-1; fibrosis; fibroblast	CHRONIC MYELOGENOUS LEUKEMIA; TYROSINE KINASE-ACTIVITY; TGF-BETA; SYSTEMIC-SCLEROSIS; TRANSCRIPTION FACTORS; SKIN FIBROBLASTS; CELLULAR-RESPONSE; POSITIVE CELLS; COLLAGEN GENE; DNA-DAMAGE	The nonreceptor protein tyrosine kinase c-Abl regulates cell proliferation and survival. Recent studies provide evidence that implicate c-Abl as a mediator for. brotic responses induced by transforming growth factor-beta (TGF-beta), but the precise mechanisms underlying this novel oncogene function are unknown. Here, we report that when expressed in normal fibroblasts, a constitutively active mutant of Abl that causes chronic myelogenous leukemia (CML) stimulated the expression and transcriptional activity of the early growth response factor 1 (Egr1). Mouse embryonic fibroblasts (MEFs), lacking c-Abl, were resistant to TGF-beta stimulation. Responsiveness of these MEFs to TGF-beta could be rescued by wild-type c-Abl, but not by a kinase-deficient mutant form of c-Abl. Furthermore, Abl kinase activity was necessary for the induction of Egr-1 by TGF-beta in normal fibroblasts, and Egr-1 was required for stimulation of collagen by Bcr-Abl. Lesional skin fibroblasts in mice with bleomycin-induced fibrosis of skin displayed evidence of c-Abl activation in situ, and elevated phospho-c-Abl correlated with increased local expression of Egr-1. Collectively, these results position Egr-1 downstream of c-Abl in the. brotic response, delineate a novel Egr-1-dependent intracellular signaling mechanism that underlies the involvement of c-Abl in certain TGF-beta responses, and identify Egr-1 as a target of inhibition by imatinib. Furthermore, the findings show in situ activation of c-Abl paralleling the upregulated tissue expression of Egr-1 that accompanies fibrosis. Pharmacological targeting of c-Abl and its downstream effector pathways may, therefore, represent a novel therapeutic approach to blocking TGF-beta-dependent fibrotic processes.	[Bhattacharyya, S.; Ishida, W.; Wu, M.; Mori, Y.; Hinchcliff, M.; Varga, J.] Northwestern Univ, Feinberg Sch Med, Div Rheumatol, Chicago, IL 60611 USA; [Wilkes, M.; Leof, E.] Mayo Clin, Div Pulm Med, Rochester, MN USA	Northwestern University; Feinberg School of Medicine; Mayo Clinic	Varga, J (corresponding author), Northwestern Univ, Feinberg Sch Med, Div Rheumatol, 240 E Huron St, Chicago, IL 60611 USA.	j-varga@northwestern.edu	Varga, John/AAK-6472-2021; Bhattacharyya, Swati/W-8145-2019	Wilkes, Mark/0000-0002-9600-6831; Hinchcliff, Monique/0000-0002-8652-9890	National Institutes of Health [AR-42309]; Department of Defence [W81-XWH-06-01-0278]; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR042309] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM055816] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Department of Defence; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We are grateful to Anthony Koleske (Yale University, New Haven, CT, USA) and Pamela Woodring (The Salk Institute, La Jolla, CA) for Abl- null/Arg-null and Abl reconstituted mouse embryonic. broblasts, and Leonidas Platanias (North-western University Feinberg School of Medicine) for Bcr-Abl plasmids and helpful discussions. This study was supported by grants from the National Institutes of Health (AR-42309) and the Department of Defence (W81-XWH-06-01-0278).	Bhattacharyya S, 2008, AM J PATHOL, V173, P1085, DOI 10.2353/ajpath.2008.080382; Bonn D, 2004, LANCET INFECT DIS, V4, P255, DOI 10.1016/S1473-3099(04)01014-X; Buchwalter G, 2004, GENE, V324, P1, DOI 10.1016/j.gene.2003.09.028; Ceni E, 2006, GASTROENTEROLOGY, V131, P1235, DOI 10.1053/j.gastro.2006.08.009; Che W, 2001, CIRCULATION, V104, P1399, DOI 10.1161/hc3701.095581; Chen SJ, 2006, J BIOL CHEM, V281, P21183, DOI 10.1074/jbc.M603270200; Chen SJ, 1999, J INVEST DERMATOL, V112, P49, DOI 10.1046/j.1523-1747.1999.00477.x; Danial NN, 2000, ONCOGENE, V19, P2523, DOI 10.1038/sj.onc.1203484; Daniels CE, 2004, J CLIN INVEST, V114, P1308, DOI 10.1175/JCI200419603; Deininger MWN, 1997, BLOOD, V90, P3691, DOI 10.1182/blood.V90.9.3691; Distler JHW, 2007, ARTHRITIS RHEUM-US, V56, P311, DOI 10.1002/art.22314; Druker BJ, 1996, NAT MED, V2, P561, DOI 10.1038/nm0596-561; GASHLER A, 1995, PROG NUCLEIC ACID RE, V50, P191, DOI 10.1016/S0079-6603(08)60815-6; Goldman JM, 2003, NEW ENGL J MED, V349, P1451, DOI 10.1056/NEJMra020777; Goumans MJ, 2002, EMBO J, V21, P1743, DOI 10.1093/emboj/21.7.1743; GROFFEN J, 1984, CELL, V36, P93, DOI 10.1016/0092-8674(84)90077-1; He X, 2006, CELL, V127, P40, DOI 10.1016/j.cell.2006.09.016; Hernandez SE, 2004, TRENDS CELL BIOL, V14, P36, DOI 10.1016/j.tcb.2003.11.003; Ihn H, 1997, J BIOL CHEM, V272, P24666, DOI 10.1074/jbc.272.39.24666; Ishida W, 2006, ARTHRITIS RHEUM, V54, pS776; Javelaud D, 2005, ONCOGENE, V24, P5742, DOI 10.1038/sj.onc.1208928; Jimenez SA, 2004, ANN INTERN MED, V140, P37, DOI 10.7326/0003-4819-140-1-200401060-00010; Khachigian LM, 2006, CIRC RES, V98, P186, DOI 10.1161/01.RES.0000200177.53882.c3; Kharas NG, 2005, CANCER RES, V65, P2047, DOI 10.1158/0008-5472.CAN-04-3888; Kharbanda S, 1997, NATURE, V386, P732, DOI 10.1038/386732a0; KHARBANDA S, 1995, NATURE, V376, P785, DOI 10.1038/376785a0; Kharbanda S, 1995, J BIOL CHEM, V270, P30278, DOI 10.1074/jbc.270.51.30278; La Rosee P, 2002, EXP HEMATOL, V30, P729, DOI 10.1016/S0301-472X(02)00836-6; Lakos G, 2004, AM J PATHOL, V165, P203, DOI 10.1016/S0002-9440(10)63289-0; Leask A, 2008, CELL SIGNAL, V20, P1409, DOI 10.1016/j.cellsig.2008.01.006; Lewis JM, 1998, J BIOL CHEM, V273, P14225, DOI 10.1074/jbc.273.23.14225; Lewis JM, 1996, P NATL ACAD SCI USA, V93, P15174, DOI 10.1073/pnas.93.26.15174; Lobo VJSA, 2005, BIOCHEM J, V387, P231, DOI 10.1042/BJ20040927; LUGO TG, 1990, SCIENCE, V247, P1079, DOI 10.1126/science.2408149; Massague J, 2005, GENE DEV, V19, P2783, DOI 10.1101/gad.1350705; Mori Y, 2004, ARTHRITIS RHEUM-US, V50, P4008, DOI 10.1002/art.20658; Mori Y, 2000, EXP CELL RES, V258, P374, DOI 10.1006/excr.2000.4930; MOUSTAKAS A, 2005, ONCOGENE, V24, P5742; Pannu J, 2004, CURR OPIN RHEUMATOL, V16, P739, DOI 10.1097/01.bor.0000137894.63091.1a; Pannu J, 2008, ARTHRITIS RHEUM-US, V58, P2528, DOI 10.1002/art.23698; Pannu J, 2007, J BIOL CHEM, V282, P10405, DOI 10.1074/jbc.M611742200; RAITANO AB, 1995, P NATL ACAD SCI USA, V92, P11746, DOI 10.1073/pnas.92.25.11746; Rajkumar VS, 2006, AM J PATHOL, V169, P2254, DOI 10.2353/ajpath.2006.060196; Renshaw MW, 2000, ONCOGENE, V19, P3216, DOI 10.1038/sj.onc.1203667; Rosenbloom J, 2008, ARTHRITIS RHEUM, V58, P2219, DOI 10.1002/art.23634; ROWLEY JD, 1973, NATURE, V243, P290, DOI 10.1038/243290a0; Schubert C, 2007, J BIOL CHEM, V282, P4094, DOI 10.1074/jbc.M608183200; Skorski T, 1997, EMBO J, V16, P6151, DOI 10.1093/emboj/16.20.6151; Stuart JR, 2005, ONCOGENE, V24, P8085, DOI 10.1038/sj.onc.1208953; SUKHATME VP, 1988, CELL, V53, P37, DOI 10.1016/0092-8674(88)90485-0; Svaren J, 2000, J BIOL CHEM, V275, P38524, DOI 10.1074/jbc.M005220200; Takagawa S, 2003, J INVEST DERMATOL, V121, P41, DOI 10.1046/j.1523-1747.2003.12308.x; Takahashi T, 2005, J BIOL CHEM, V280, P7100, DOI 10.1074/jbc.M411064200; Teckchandani AM, 2001, ONCOGENE, V20, P1739, DOI 10.1038/sj.onc.1204246; Van Etten RA, 1999, TRENDS CELL BIOL, V9, P179, DOI 10.1016/S0962-8924(99)01549-4; Varga J, 2007, J CLIN INVEST, V117, P557, DOI 10.1172/JCI31139; Varga JA, 2008, RHEUM DIS CLIN N AM, V34, P115, DOI 10.1016/j.rdc.2007.11.002; Virolle T, 2001, NAT CELL BIOL, V3, P1124, DOI 10.1038/ncb1201-1124; Wang SN, 2005, FASEB J, V19, P1, DOI 10.1096/fj.04-2370com; Wenner CE, 2003, J CELL PHYSIOL, V196, P42, DOI 10.1002/jcp.10243; Wilkes MC, 2006, J BIOL CHEM, V281, P27846, DOI 10.1074/jbc.M603721200; Woodring PJ, 2002, J CELL BIOL, V156, P879, DOI 10.1083/jcb.200110014; Yoshida K, 2000, MOL CELL BIOL, V20, P5370, DOI 10.1128/MCB.20.15.5370-5380.2000	63	61	62	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2009	28	10					1285	1297		10.1038/onc.2008.479	http://dx.doi.org/10.1038/onc.2008.479			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	417ZC	19151753	Green Accepted			2022-12-28	WOS:000264116000001
J	Connors, SK; Balusu, R; Kundu, CN; Jaiswal, AS; Gairola, CG; Narayan, S				Connors, S. K.; Balusu, R.; Kundu, C. N.; Jaiswal, A. S.; Gairola, C. G.; Narayan, S.			C/EBP beta-mediated transcriptional regulation of bcl-xl gene expression in human breast epithelial cells in response to cigarette smoke condensate	ONCOGENE			English	Article						cigarette smoke condensate; bcl-xl; C/EBP beta; gene regulation; breast carcinogenesis	MOUSE MAMMARY-GLAND; CANCER-CELLS; TOBACCO-SMOKE; NULL ASSOCIATION; ACTIVE SMOKING; PROTEIN; APOPTOSIS; BCL-X(L); RISK; OVEREXPRESSION	In earlier studies, we have shown that cigarette smoke condensate (CSC), a surrogate for cigarette smoke, is capable of transforming the spontaneously immortalized human breast epithelial cell line, MCF10A. These transformed cells displayed upregulation of the antiapoptotic gene, bcl-xl. Upregulation of this gene may impede the apoptotic pathway and allow the accumulation of DNA damage that can lead to cell transformation and carcinogenesis. In the present study, we have determined the mechanism of CSC-mediated transcriptional upregulation of bcl-xl gene expression in MCF10A cells. We cloned the human bcl-xl promoter (pBcl-xLP) and identified putative transcription factor binding sites. Sequential deletion constructs that removed the putative cis-elements were constructed and transfected into MCF10A cells to determine the CSC-responsive cis-element(s) on the pBcl-xLP. Gel-shift, super-shift and chromatin immunoprecipitation analysis confirmed that CCAAT/enhancer-binding protein (C/EBP beta) specifically bound to a C/EBP-binding site on the pBcl-xLP in vitro and in vivo. Additionally, overexpression of C/EBP beta-LAP2 stimulated pBcl-xLP activity and Bcl-xL protein levels, which mimicked the conditions of CSC treatment. Our results indicate that C/EBP beta regulates bcl-xl gene expression in MCF10A cells in response to CSC treatment; therefore, making it a potential target for chemotherapeutic intervention of cigarette smoke-induced breast carcinogenesis.	[Connors, S. K.; Balusu, R.; Kundu, C. N.; Jaiswal, A. S.; Narayan, S.] Univ Florida, UF Shands Canc Ctr, Gainesville, FL 32610 USA; [Connors, S. K.; Balusu, R.; Kundu, C. N.; Jaiswal, A. S.; Narayan, S.] Univ Florida, Dept Anat & Cell Biol, Gainesville, FL 32610 USA; [Gairola, C. G.] Univ Kentucky, Grad Ctr Toxicol, Lexington, KY USA	State University System of Florida; University of Florida; State University System of Florida; University of Florida; University of Kentucky	Narayan, S (corresponding author), Univ Florida, UF Shands Canc Ctr, Canc & Genet Res Complex,Room 255,POB 103633,1376, Gainesville, FL 32610 USA.	snarayan@ufl.edu		Kundu, Chanakya/0000-0003-0297-1030	NCI-NIH [CA-100247]; Flight Attendant Medical Research Institute; University Florida Shands Cancer Center; NATIONAL CANCER INSTITUTE [R01CA100247] Funding Source: NIH RePORTER	NCI-NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Flight Attendant Medical Research Institute; University Florida Shands Cancer Center; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Dr Michael Kilberg from the University of Florida for the gift of the C/EBP beta overexpression constructs. The financial support for these studies was provided by the Grants from NCI-NIH (CA-100247) and Flight Attendant Medical Research Institute to Satya Narayan, and T32-Training Grant in Cancer Biology from University Florida Shands Cancer Center to Shahnjayla K Connors.	Bennett WP, 1999, JNCI-J NATL CANCER I, V91, P2009, DOI 10.1093/jnci/91.23.2009; BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; Bundy L, 2005, MOL CANCER, V4, DOI 10.1186/1476-4598-4-43; Bundy LM, 2003, ONCOGENE, V22, P869, DOI 10.1038/sj.onc.1206216; CherbonnelLasserre C, 1996, ONCOGENE, V13, P1489; DATTA R, 1995, CELL GROWTH DIFFER, V6, P363; DeMarini DM, 2004, MUTAT RES-REV MUTAT, V567, P447, DOI 10.1016/j.mrrev.2004.02.001; DESCOMBES P, 1991, CELL, V67, P569, DOI 10.1016/0092-8674(91)90531-3; Eaton EM, 2001, J CELL PHYSIOL, V189, P91, DOI 10.1002/jcp.1139; ELBAYOUMY K, 1995, CARCINOGENESIS, V16, P431, DOI 10.1093/carcin/16.2.431; Espana L, 2004, BREAST CANCER RES TR, V87, P33, DOI 10.1023/B:BREA.0000041579.51902.89; Feng G, 2001, CANCER RES, V61, P7999; Fernandez Y, 2002, INT J CANCER, V101, P317, DOI 10.1002/ijc.10628; Fink AK, 2003, CANCER CAUSE CONTROL, V14, P497, DOI 10.1023/A:1024922824237; Gigliotti AP, 2003, EXP BIOL MED, V228, P278, DOI 10.1177/153537020322800306; Grillot DAM, 1997, J IMMUNOL, V158, P4750; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hecht SS, 2002, ENVIRON MOL MUTAGEN, V39, P119, DOI 10.1002/em.10071; Hoffmann D, 2001, CHEM RES TOXICOL, V14, P767, DOI 10.1021/tx000260u; HSU TC, 1991, MUTAT RES, V259, P67, DOI 10.1016/0165-1218(91)90110-8; Jaiswal AS, 2006, CARCINOGENESIS, V27, P252, DOI 10.1093/carcin/bgi225; Johnson KC, 2005, INT J CANCER, V117, P619, DOI 10.1002/ijc.21150; KUMAR R, 1990, ONCOGENE, V5, P1271; Kundu CN, 2007, ONCOGENE, V26, P1428, DOI 10.1038/sj.onc.1209925; Lash TL, 2002, BREAST CANCER RES TR, V75, P181, DOI 10.1023/A:1019625102365; Mendez O, 2005, CLIN EXP METASTAS, V22, P297, DOI 10.1007/s10585-005-8751-x; Mendez O, 2001, BREAST CANCER RES TR, V65, P171, DOI 10.1023/A:1006490622103; Mendez O, 2006, CARCINOGENESIS, V27, P1169, DOI 10.1093/carcin/bgi363; Milde-Langosch K, 2003, BREAST CANCER RES TR, V79, P175, DOI 10.1023/A:1023929504884; Nagata C, 2006, JPN J CLIN ONCOL, V36, P387, DOI 10.1093/jjco/hyl031; Narayan S, 1997, J BIOL CHEM, V272, P30619, DOI 10.1074/jbc.272.49.30619; Narayan S, 2004, ONCOGENE, V23, P5880, DOI 10.1038/sj.onc.1207792; Olopade OI, 1997, CANCER J SCI AM, V3, P230; PERERA FP, 1995, CANCER EPIDEM BIOMAR, V4, P233; PETRAKIS NL, 1978, SCIENCE, V199, P303, DOI 10.1126/science.619458; Reynolds P, 2004, JNCI-J NATL CANCER I, V96, P29, DOI 10.1093/jnci/djh002; Robinson GW, 1998, GENE DEV, V12, P1907, DOI 10.1101/gad.12.12.1907; Rubio N, 2001, LAB INVEST, V81, P725, DOI 10.1038/labinvest.3780281; Sabatakos G, 1998, BIOCHEM J, V334, P205, DOI 10.1042/bj3340205; SCHOTT AF, 1995, ONCOGENE, V11, P1389; Seagroves TN, 1998, GENE DEV, V12, P1917, DOI 10.1101/gad.12.12.1917; Sevilla L, 1999, MOL CELL BIOL, V19, P2624; SHAPIRO DJ, 1988, DNA-J MOLEC CELL BIO, V7, P47, DOI 10.1089/dna.1988.7.47; Simonian PL, 1997, BLOOD, V90, P1208, DOI 10.1182/blood.V90.3.1208.1208_1208_1216; SOULE HD, 1990, CANCER RES, V50, P6075; Stabbert R, 2003, J APPL TOXICOL, V23, P329, DOI 10.1002/jat.924; TAIT L, 1990, CANCER RES, V50, P6087; WELLS AJ, 2000, J WOMENS CANC, V2, P55; Zahnow CA, 2002, BREAST CANCER RES, V4, P109, DOI 10.1186/bcr428; [No title captured]; [No title captured]	51	13	13	1	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2009	28	6					921	932		10.1038/onc.2008.429	http://dx.doi.org/10.1038/onc.2008.429			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	406UI	19043455	Green Accepted			2022-12-28	WOS:000263320000014
J	Hoyos, JM; Ferraro, A; Sacchetti, S; Keller, S; De Martino, I; Borbone, E; Pallante, P; Fedele, M; Montanaro, D; Esposito, F; Cserjesi, P; Chiariotti, L; Troncone, G; Fusco, A				Hoyos, J. Martinez; Ferraro, A.; Sacchetti, S.; Keller, S.; De Martino, I.; Borbone, E.; Pallante, P.; Fedele, M.; Montanaro, D.; Esposito, F.; Cserjesi, P.; Chiariotti, L.; Troncone, G.; Fusco, A.			HAND1 gene expression is negatively regulated by the High Mobility Group A1 proteins and is drastically reduced in human thyroid carcinomas	ONCOGENE			English	Article						HMGA1; HAND1; knockout mice; ES cells; thyroid carcinomas	TRANSCRIPTION FACTOR; HMGA1 PROTEINS; IDENTIFICATION; CANCERS; REQUIRES; MICE	HMGA1 proteins exert their major physiological function during embryonic development and play a critical role in neoplastic transformation. Here, we show that Hand1 gene, which codes for a transcription factor crucial for differentiation of trophoblast giant cells and heart development, is upregulated in hmga1 minus embryonic stem cells. We demonstrate that HMGA1 proteins bind directly to Hand1 promoter both in vitro and in vivo and inhibit Hand1 promoter activity. We have also investigated HAND1 expression in human thyroid carcinoma cell lines and tissues, in which HMGA proteins are overexpressed, with respect to normal thyroid; an inverse correlation between HMGA1 and HAND1 expression was found in all thyroid tumor histotypes. A correlation between HAND1 gene repression and promoter hypermethylation was found in anaplastic carcinomas but not in other thyroid tumor histotypes. Therefore, we can hypothesize that HMGA1 overexpression plays a key role on HAND1 silencing in differentiated thyroid carcinomas and that promoter hypermethylation occurs in later stages of thyroid tumor progression. Finally, the restoration of the HAND1 gene expression reduces the clonogenic ability of two human thyroid carcinoma-derived cell lines, suggesting that HAND1 downregulation may have a role in the process of thyroid carcinogenesis.	[Hoyos, J. Martinez; Keller, S.; De Martino, I.; Fedele, M.; Esposito, F.; Chiariotti, L.; Fusco, A.] Univ Naples Federico II, Dipartimento Biol & Patol Cellulare & Mol, Ist Endocrinol & Oncol Sperimentale, CNR,Fac Med & Chirurg Napoli, I-80131 Naples, Italy; [Hoyos, J. Martinez; Ferraro, A.; Sacchetti, S.; Keller, S.; De Martino, I.; Borbone, E.; Pallante, P.; Montanaro, D.; Chiariotti, L.; Fusco, A.] CEINGE Biotecn Avanzate, NOGEC, Naples, Italy; [Cserjesi, P.] Tulane Univ, Dept Cell & Mol Biol, New Orleans, LA 70118 USA; [Troncone, G.] Univ Naples Federico II, Dipartimento Anat Patol & Citopatol, Fac Med & Chirurg, I-80131 Naples, Italy	Consiglio Nazionale delle Ricerche (CNR); Istituto per Endocrinologia e Oncologia "Gaetano Salvatore" (IEOS-CNR); University of Naples Federico II; CEINGE Biotecnologie Avanzate; Tulane University; University of Naples Federico II	Fusco, A (corresponding author), Univ Naples Federico II, Dipartimento Biol & Patol Cellulare & Mol, Ist Endocrinol & Oncol Sperimentale, CNR,Fac Med & Chirurg Napoli, Via Pansini 5, I-80131 Naples, Italy.	afusco@napoli.com	Chiariotti, Lorenzo/AAC-5262-2022; Ferraro, Angelo/H-3193-2019; Ferraro, Angelo/A-4172-2014; ESPOSITO, FRANCESCO/AAX-2044-2020; Esposito, Francesco/J-9136-2016; Fedele, Monica/C-1417-2015; Pallante, Pierlorenzo/AAX-8758-2020	Ferraro, Angelo/0000-0002-2044-7569; Ferraro, Angelo/0000-0002-2044-7569; Esposito, Francesco/0000-0002-7709-5736; Fedele, Monica/0000-0002-9171-1312; CHIARIOTTI, Lorenzo/0000-0001-6097-4171; Martinez Hoyos, Josefina/0000-0002-6909-8259; Fusco, Alfredo/0000-0003-3332-5197	Associazione Italiana Ricerca sul Cancro (AIRC); Ministero dell'Universita e della Ricerca Scientifica e Tecnologica (MIUR); NOGEC-Naples Oncogenomic Center; Associazione Partenopea per le Ricerche Oncologiche (APRO)	Associazione Italiana Ricerca sul Cancro (AIRC)(Fondazione AIRC per la ricerca sul cancro); Ministero dell'Universita e della Ricerca Scientifica e Tecnologica (MIUR)(Ministry of Education, Universities and Research (MIUR)); NOGEC-Naples Oncogenomic Center; Associazione Partenopea per le Ricerche Oncologiche (APRO)	This work was supported by grants from the Associazione Italiana Ricerca sul Cancro (AIRC), and the Ministero dell'Universita e della Ricerca Scientifica e Tecnologica (MIUR). This work was supported from NOGEC-Naples Oncogenomic Center. We thank the Associazione Partenopea per le Ricerche Oncologiche (APRO) for its support. We thank Gabriella Sole, INN-CNR of Cagliari, for statistical analysis.	Baldassarre G, 2001, P NATL ACAD SCI USA, V98, P7970, DOI 10.1073/pnas.141224998; Battista S, 2003, FASEB J, V17, P1496, DOI 10.1096/fj.02-0977fje; Berlingieri MT, 2002, ONCOGENE, V21, P2971, DOI 10.1038/sj.onc.1205368; Chiappetta G, 1996, ONCOGENE, V13, P2439; CROSS JC, 1995, DEVELOPMENT, V121, P2513; CSERJESI P, 1995, DEV BIOL, V170, P664, DOI 10.1006/dbio.1995.1245; Donato G, 2004, ONCOL REP, V11, P1209; Fedele M, 2006, CANCER RES, V66, P2536, DOI 10.1158/0008-5472.CAN-05-1889; Fedele M, 2001, CARCINOGENESIS, V22, P1583, DOI 10.1093/carcin/22.10.1583; Fusco A, 2007, NAT REV CANCER, V7, P899, DOI 10.1038/nrc2271; Hagihara A, 2004, ONCOGENE, V23, P8705, DOI 10.1038/sj.onc.1207783; Hoyos JM, 2004, CANCER RES, V64, P5728, DOI 10.1158/0008-5472.CAN-04-1410; Kaneda A, 2002, CANCER RES, V62, P6645; Knofler M, 2002, BIOCHEM J, V361, P641, DOI 10.1042/0264-6021:3610641; Kondo T, 2006, NAT REV CANCER, V6, P292, DOI 10.1038/nrc1836; Pallante P, 2005, BRIT J CANCER, V93, P464, DOI 10.1038/sj.bjc.6602721; Reeves R, 2001, GENE, V277, P63, DOI 10.1016/S0378-1119(01)00689-8; Riley P, 1998, NAT GENET, V18, P271, DOI 10.1038/ng0398-271; Ritter O, 1999, J CELL BIOCHEM, V74, P551, DOI 10.1002/(SICI)1097-4644(19990915)74:4<551::AID-JCB5>3.3.CO;2-0; Takada T, 2004, CANCER SCI, V95, P741, DOI 10.1111/j.1349-7006.2004.tb03255.x; Thanos D, 1995, CELL, V83, P1091, DOI 10.1016/0092-8674(95)90136-1	21	17	17	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2009	28	6					876	885		10.1038/onc.2008.438	http://dx.doi.org/10.1038/onc.2008.438			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	406UI	19060921				2022-12-28	WOS:000263320000010
J	Crane, CA; Panner, A; Murray, JC; Wilson, SP; Xu, H; Chen, L; Simko, JP; Waldman, FM; Pieper, RO; Parsa, AT				Crane, C. A.; Panner, A.; Murray, J. C.; Wilson, S. P.; Xu, H.; Chen, L.; Simko, J. P.; Waldman, F. M.; Pieper, R. O.; Parsa, A. T.			PI(3) kinase is associated with a mechanism of immunoresistance in breast and prostate cancer	ONCOGENE			English	Article						PI(3) kinase; B7-H1; immunoresistance; breast cancer; prostate cancer; T cell	CELL CARCINOMA PATIENTS; MHC CLASS-II; B7-H1 EXPRESSION; POTENTIAL MECHANISM; MOLECULE B7-H1; TUMOR; MELANOMA; TRANSLATION; PHOSPHATASE; PROGNOSIS	Immune escape describes a critical event whereby tumor cells adopt an immunoresistant phenotype to escape adaptive surveillance. We show that expression of a pivotal negative regulator of T-cell function, B7-H1, correlates with PI(3) kinase activation in breast and prostate cancer patients. B7-H1-mediated immunoresistance can be attenuated by inhibitors of the PI(3) kinase pathway, and is dependent on S6K1-mediated translational regulation of B7-H1 protein. Breast and prostate carcinoma cells with activated PI(3) kinase lose the immunoresistant phenotype after treatment with B7-H1 siRNA. Conversely, breast and prostate carcinoma cells with minimal PI(3) kinase activation adopt an immunoresistant phenotype when engineered to overexpress B7-H1 protein. These observations describe a mechanism for immune escape from tumor dormancy in humans that relates to oncogenesis.	[Crane, C. A.; Panner, A.; Murray, J. C.; Wilson, S. P.; Pieper, R. O.; Parsa, A. T.] Univ Calif San Francisco, Dept Neurol Surg, San Francisco, CA 94143 USA; [Xu, H.; Chen, L.] Johns Hopkins Univ, Sch Med, Dept Dermatol & Oncol, Baltimore, MD USA; [Simko, J. P.] Univ Calif San Francisco, Dept Pathol & Urol, San Francisco, CA 94143 USA; [Waldman, F. M.] Univ Calif San Francisco, Dept Lab Med, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; Johns Hopkins University; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Parsa, AT (corresponding author), Univ Calif San Francisco, Dept Neurol Surg, 505 Parnassus Ave,M-779, San Francisco, CA 94143 USA.	parsaa@neurosurg.ucsf.edu	Murray, Joseph C/J-8916-2014	Murray, Joseph C/0000-0001-6159-7814; Wilson, Sean/0000-0001-8667-6236	National Institute of Neurological Disorder and Stroke; National Cancer Institute; Seibrandt Vaccine Fund; Khatib Foundation; NATIONAL CANCER INSTITUTE [P50CA097257] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [K08NS046671] Funding Source: NIH RePORTER	National Institute of Neurological Disorder and Stroke(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Seibrandt Vaccine Fund; Khatib Foundation; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	We thank Pramod Srivastava and C David James for critical review of the manuscript, as well as the UCSF cancer center for providing tissue with known PI3K activation status. ATP was supported in part by a K08 grant from the National Institute of Neurological Disorder and Stroke, a career development award from Brain Specialized Programs of Research Excellence (SPORE) of the National Cancer Institute, the Seibrandt Vaccine Fund and the Khatib Foundation.	Baleeiro RB, 2008, MOL IMMUNOL, V45, P3502, DOI 10.1016/j.molimm.2008.04.005; Bui JD, 2007, CURR OPIN IMMUNOL, V19, P203, DOI 10.1016/j.coi.2007.02.001; Chang YC, 2008, BLOOD, V111, P5054, DOI 10.1182/blood-2007-12-130609; Dey N, 2008, CANCER RES, V68, P1862, DOI 10.1158/0008-5472.CAN-07-1182; Dong HD, 2002, NAT MED, V8, P793, DOI 10.1038/nm730; Geng L, 2008, J CANCER RES CLIN, V134, P1021, DOI 10.1007/s00432-008-0364-8; Gingras AC, 1998, GENE DEV, V12, P502, DOI 10.1101/gad.12.4.502; Inman BA, 2007, CANCER-AM CANCER SOC, V109, P1499, DOI 10.1002/cncr.22588; Johnson LE, 2007, CANCER IMMUNOL IMMUN, V56, P885, DOI 10.1007/s00262-006-0241-8; Koebel CM, 2007, NATURE, V450, P903, DOI 10.1038/nature06309; Kozikowski AP, 2003, J AM CHEM SOC, V125, P1144, DOI 10.1021/ja0285159; Krambeck AE, 2007, CLIN CANCER RES, V13, P1749, DOI 10.1158/1078-0432.CCR-06-2129; Liu VC, 2007, J IMMUNOL, V178, P2883, DOI 10.4049/jimmunol.178.5.2883; Loos M, 2008, CANCER LETT, V268, P98, DOI 10.1016/j.canlet.2008.03.056; Martin KA, 2002, ADV CANCER RES, V86, P1, DOI 10.1016/S0065-230X(02)86001-8; Mazanet MM, 2002, J IMMUNOL, V169, P3581, DOI 10.4049/jimmunol.169.7.3581; Meyer RG, 2007, LUNG CANCER, V58, P88, DOI 10.1016/j.lungcan.2007.05.003; Miled N, 2007, SCIENCE, V317, P239, DOI 10.1126/science.1135394; Mittenclorf EA, 2007, CANCER-AM CANCER SOC, V110, P1677, DOI 10.1002/cncr.22978; Parsa AT, 2007, NAT MED, V13, P84, DOI 10.1038/nm1517; Penn I, 1996, TRANSPLANTATION, V61, P274, DOI 10.1097/00007890-199601270-00019; Powell DJ, 2006, J IMMUNOL, V177, P6527, DOI 10.4049/jimmunol.177.9.6527; Roth TJ, 2007, CANCER RES, V67, P7893, DOI 10.1158/0008-5472.CAN-07-1068; Routh JC, 2008, J UROLOGY, V179, P1954, DOI 10.1016/j.juro.2008.01.056; Schartner JM, 2005, GLIA, V51, P279, DOI 10.1002/glia.20201; Shankaran V, 2001, NATURE, V410, P1107, DOI 10.1038/35074122; Siva A, 2008, CANCER IMMUNOL IMMUN, V57, P987, DOI 10.1007/s00262-007-0429-6; Slingluff CL, 2007, CLIN CANCER RES, V13, P6386, DOI 10.1158/1078-0432.CCR-07-0486; Slovin SF, 2008, CANCER J, V14, P26, DOI 10.1097/PPO.0b013e318161bffa; Small EJ, 2007, CLIN CANCER RES, V13, P1810, DOI 10.1158/1078-0432.CCR-06-2318; Tamura M, 1998, SCIENCE, V280, P1614, DOI 10.1126/science.280.5369.1614; Thompson RH, 2007, CLIN CANCER RES, V13, p709S, DOI 10.1158/1078-0432.CCR-06-1868; Thompson RH, 2006, CANCER RES, V66, P3381, DOI 10.1158/0008-5472.CAN-05-4303; Thompson RH, 2004, P NATL ACAD SCI USA, V101, P17174, DOI 10.1073/pnas.0406351101; Wang L, 2008, P NATL ACAD SCI USA, V105, P9331, DOI 10.1073/pnas.0710441105; Wintterle S, 2003, CANCER RES, V63, P7462; Zang X, 2007, P NATL ACAD SCI USA, V104, P19458, DOI 10.1073/pnas.0709802104	37	134	146	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2009	28	2					306	312		10.1038/onc.2008.384	http://dx.doi.org/10.1038/onc.2008.384			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	395CY	18850006	Green Accepted			2022-12-28	WOS:000262501100014
J	Ahmed, KM; Fan, M; Nantajit, D; Cao, N; Li, JJ				Ahmed, K. M.; Fan, M.; Nantajit, D.; Cao, N.; Li, J. J.			Cyclin D1 in low-dose radiation-induced adaptive resistance	ONCOGENE			English	Article						radiation resistance; cyclin D1; 14-3-3; Bax; human keratinocytes; adaptive response	FACTOR-KAPPA-B; IONIZING-RADIATION; GENOMIC INSTABILITY; APOPTOTIC RESPONSE; HUMAN-LYMPHOCYTES; GENE-EXPRESSION; CANCER CELLS; X-RAYS; PROTEIN; BAX	Cyclin D1 is involved in cell-cycle arrest in DNA-damage response. This study tested the hypothesis that cyclin D1 regulates mitochondrial apoptosis. Cycl in D1 was induced by low-dose ionizing radiation (LDIR; 10-cGy X-ray) in human keratinocytes with an adaptive radioresistance that can be inhibited by short interfering RNA (siRNA)mediated cyclin D1 inhibition. Cyclin D1 was found to form complex with chaperon 14-3-3 zeta in unstressed cells and mutation of 14-3-3 zeta Ser-58 to Asp (S58D) significantly impaired 14-3-3 zeta binding to cyclin D1. The formation of cyclin D1/14-3-3 zeta complex was differently regulated by exposure to low (10-cGy X-ray) versus high (5-Gy gamma-ray) doses of radiation. Unlike exposure to 5-Gy that predominantly enhanced cyclin D1 nuclear accumulation, LDIR induced the dissociation of the cyclin D1/14-3-3 zeta complex without nuclear translocation, indicating that cytosolic accumulation of cyclin D1 was required for LDIR-induced adaptive response. Further studies revealed a direct interaction of cyclin D1 with proapoptotic Bax and an improved mitochondrial membrane potential (Delta psi(m)) in LDIR-treated cells. Consistently, blocking cyclin D1/Bax formation by cyclin D1 siRNA reversed Delta psi(m) and inhibited the LDIR-associated antiapoptotic response. These results demonstrate the evidence that cytosolic cyclin D1 is able to regulate apoptosis by interaction with Bax in LDIR-induced adaptive resistance.	[Ahmed, K. M.; Fan, M.; Nantajit, D.; Cao, N.; Li, J. J.] Purdue Univ, Sch Hlth Sci, Div Mol Radiobiol, W Lafayette, IN 47907 USA; [Ahmed, K. M.; Fan, M.; Nantajit, D.; Cao, N.; Li, J. J.] Purdue Univ, Sch Hlth Sci, Grad Program Radiat & Canc Biol, W Lafayette, IN 47907 USA; [Li, J. J.] Purdue Canc Ctr, W Lafayette, IN USA	Purdue University System; Purdue University; Purdue University West Lafayette Campus; Purdue University System; Purdue University; Purdue University West Lafayette Campus	Li, JJ (corresponding author), Purdue Univ, Sch Hlth Sci, Div Mol Radiobiol, 550 Stadium Mall Dr, W Lafayette, IN 47907 USA.	jjli@purdue.edu	Cao, Ning/F-9480-2013; Nantajit, Danupon/CAF-7353-2022; Cao, Ning/I-3094-2013	Cao, Ning/0000-0002-3929-8604	NIH NCI [RO1 101990]; Department of Energy [DE-FG02-03ER63634]	NIH NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Department of Energy(United States Department of Energy (DOE))	We thank Dr N Colburn (National Cancer Institute, NIH) for providing human keratinocytes HK18 cells, Dr S Liu (Purdue University School of Health Sciences) for invaluable help with animal experiments. This work was supported by NIH NCI grant RO1 101990 and the Department of Energy grant DE-FG02-03ER63634 to JJL.	Ahmed KM, 2006, MOL CANCER RES, V4, P945, DOI 10.1158/1541-7786.MCR-06-0291; Biliran H, 2005, CLIN CANCER RES, V11, P6075, DOI 10.1158/1078-0432.CCR-04-2419; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Chen XF, 2002, CANCER RES, V62, P1213; Costantini P, 2000, J NATL CANCER I, V92, P1042, DOI 10.1093/jnci/92.13.1042; Daosukho C, 2002, ONCOGENE, V21, P3603, DOI 10.1038/sj.onc.1205448; Fan M, 2007, CANCER RES, V67, P3220, DOI 10.1158/0008-5472.CAN-06-2728; Feinendegen LE, 1996, MUTAT RES-FUND MOL M, V358, P199, DOI 10.1016/S0027-5107(96)00121-2; Guo GZ, 2003, MOL CELL BIOL, V23, P2362, DOI 10.1128/MCB.23.7.2362-2378.2003; Hermeking H, 1997, MOL CELL, V1, P3, DOI 10.1016/S1097-2765(00)80002-7; Hu CD, 2002, MOL CELL, V9, P789, DOI 10.1016/S1097-2765(02)00496-3; Karbowski M, 2006, NATURE, V443, P658, DOI 10.1038/nature05111; KELSEY KT, 1991, MUTAT RES, V263, P197, DOI 10.1016/0165-7992(91)90001-K; Klokov D, 2004, MUTAT RES-FUND MOL M, V568, P97, DOI 10.1016/j.mrfmmm.2004.06.049; Limoli CL, 2001, FREE RADICAL BIO MED, V31, P10, DOI 10.1016/S0891-5849(01)00542-1; Nomura M, 2003, J BIOL CHEM, V278, P2058, DOI 10.1074/jbc.M207880200; Oyama T, 1998, CANCER RES, V58, P2876; Pandey BN, 2006, ANTIOXID REDOX SIGN, V8, P1253, DOI 10.1089/ars.2006.8.1253; Paulovich AG, 1997, CELL, V88, P315, DOI 10.1016/S0092-8674(00)81870-X; Powell DW, 2003, MOL CELL BIOL, V23, P5376, DOI 10.1128/MCB.23.15.5376-5387.2003; Qi WQ, 2003, RADIAT RES, V160, P217, DOI 10.1667/RR3038; Rothkamm K, 2003, P NATL ACAD SCI USA, V100, P5057, DOI 10.1073/pnas.0830918100; Sakamaki T, 2006, MOL CELL BIOL, V26, P5449, DOI 10.1128/MCB.02074-05; SHADLEY JD, 1987, RADIAT RES, V111, P511, DOI 10.2307/3576936; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; Sumrejkanchanakij P, 2003, ONCOGENE, V22, P8723, DOI 10.1038/sj.onc.1206870; Ulsh BA, 2004, J ENVIRON RADIOACTIV, V74, P73, DOI 10.1016/j.jenvrad.2004.01.005; Wang T, 2005, J BIOL CHEM, V280, P12593, DOI 10.1074/jbc.M410982200; Xiao Bing, 1995, Nature (London), V376, P188, DOI 10.1038/376188a0; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; Yoshida K, 2005, NAT CELL BIOL, V7, P278, DOI 10.1038/ncb1228; Zhang L, 2000, SCIENCE, V290, P989, DOI 10.1126/science.290.5493.989	32	41	45	1	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 13	2008	27	53					6738	6748		10.1038/onc.2008.265	http://dx.doi.org/10.1038/onc.2008.265			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	371XO	18695676	Green Accepted			2022-12-28	WOS:000260866200004
J	Fukuyama, R; Niculaita, R; Ng, KP; Obusez, E; Sanchez, J; Kalady, M; Aung, PP; Casey, G; Sizemore, N				Fukuyama, R.; Niculaita, R.; Ng, K. P.; Obusez, E.; Sanchez, J.; Kalady, M.; Aung, P. P.; Casey, G.; Sizemore, N.			Mutated in colorectal cancer, a putative tumor suppressor for serrated colorectal cancer, selectively represses beta-catenin-dependent transcription	ONCOGENE			English	Article						colorectal cancer; MCC; Wnt; beta-catenin; serrated	NF-KAPPA-B; NUCLEAR EXPORT; E-CADHERIN; TNF-ALPHA; GENE; MCC; IDENTIFICATION; LOCALIZATION; EXPRESSION; PROTEIN	Mutated in colorectal cancer (MCC) was originally identified as a candidate gene for familial adenomatous polyposis (FAP) but further study identified adenomatous polyposis coli (APC) as responsible for FAP and the physiologic/pathologic roles of MCC remained poorly understood. Recently, MCC promoter methylation was discovered as a frequent early event in a distinct subset of precursor lesions and colorectal cancer (CRC) associated with the serrated CRC pathway. Here we provide the first evidence of the biological significance of MCC loss in CRC and the molecular pathways involved. We show MCC expression is dramatically decreased in many CRC cell lines and the distinct subset of sporadic CRC characterized by the CpG island methylator phenotype and BRAFV600E mutation due to promoter methylation as reported previously. Importantly, we find MCC interacts with beta-catenin and that reexpression of MCC in CRC cells specifically inhibits Wnt signaling, beta-catenin/T-cell factor/lymphoid-enhancer factor-dependent transcription and cellular proliferation even in the presence of oncogenic mutant APC. We also show that MCC is localized in the nucleus and identify two functional nuclear localization signals. Taken together, MCC is a nuclear, beta-cateninin-interacting protein that can act as a potential tumor suppressor in the serrated CRC	[Fukuyama, R.; Niculaita, R.; Ng, K. P.; Aung, P. P.; Casey, G.; Sizemore, N.] Cleveland Clin, Dept Canc Biol, Cleveland, OH 44195 USA; [Niculaita, R.; Sizemore, N.] Kent State Univ, Sch Biomed Sci, Kent, OH 44242 USA; [Obusez, E.; Casey, G.; Sizemore, N.] Case Western Reserve Univ, Lerner Coll Med, Cleveland Clin, Cleveland, OH 44106 USA; [Sanchez, J.; Kalady, M.; Casey, G.; Sizemore, N.] Cleveland Clin, Dept Colorectal Surg, Cleveland, OH 44195 USA	Cleveland Clinic Foundation; University System of Ohio; Kent State University; Kent State University Kent; Kent State University Salem; Case Western Reserve University; Cleveland Clinic Foundation; Cleveland Clinic Foundation	Sizemore, N (corresponding author), Cleveland Clin, Dept Canc Biol ND50, 9500 Euclid Ave, Cleveland, OH 44195 USA.	sizemon@ccf.org		Aung, Phyu/0000-0002-3398-0573	National Cancer Institute [CA 100748]; NATIONAL CANCER INSTITUTE [R01CA100748] Funding Source: NIH RePORTER	National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Dr Kenneth W Kinzler, Dr Kazuo Maruyama, Dr Inder Verma, Dr Bert Vogelstein and Dr Bryan Williams for the various reagents used for this work as well as Lisa Krumroy and Alona Merkulova for technical assistance. This work was supported by grants to NS from the Cleveland Clinic Taussig Cancer Center/Scott Hamilton CARES Initiative and the National Cancer Institute Grant CA 100748.	Agarwal A, 2005, ONCOGENE, V24, P1021, DOI 10.1038/sj.onc.1208296; ASHTONRICKARDT PG, 1991, ONCOGENE, V6, P1881; Bouwmeester T, 2004, NAT CELL BIOL, V6, P97, DOI 10.1038/ncb1086; Conacci-Sorrell M, 2003, J CELL BIOL, V163, P847, DOI 10.1083/jcb.200308162; Eleftheriou A, 2001, J BIOL CHEM, V276, P25883, DOI 10.1074/jbc.M102656200; Fukuyama R, 2007, MOL CARCINOGEN, V46, P402, DOI 10.1002/mc.20288; Gregorieff A, 2005, GENE DEV, V19, P877, DOI 10.1101/gad.1295405; Greten FR, 2004, CELL, V118, P285, DOI 10.1016/j.cell.2004.07.013; GRODEN J, 1991, CELL, V66, P589, DOI 10.1016/0092-8674(81)90021-0; Henderson BR, 2000, NAT CELL BIOL, V2, P653, DOI 10.1038/35023605; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; Heyer J, 1999, ONCOGENE, V18, P5325, DOI 10.1038/sj.onc.1203036; Ishikawa S, 2001, GENE, V267, P101, DOI 10.1016/S0378-1119(01)00378-X; Ishitani T, 2003, MOL CELL BIOL, V23, P1379, DOI 10.1128/MCB.23.4.1379-1389.2003; Ishitani T, 1999, NATURE, V399, P798, DOI 10.1038/21674; Jass JR, 2007, HISTOPATHOLOGY, V50, P113, DOI 10.1111/j.1365-2559.2006.02549.x; Jass JR, 2003, J CLIN PATHOL, V56, P69, DOI 10.1136/jcp.56.1.69; Jass JR, 2005, NAT CLIN PRACT ONCOL, V2, P398, DOI 10.1038/ncponc0248; Jass JR, 2002, GASTROENTEROLOGY, V123, P862, DOI 10.1053/gast.2002.35392; KINZLER KW, 1991, SCIENCE, V251, P1366, DOI 10.1126/science.1848370; KINZLER KW, 1991, SCIENCE, V253, P661, DOI 10.1126/science.1651562; Kohonen-Corish MRJ, 2007, ONCOGENE, V26, P4435, DOI 10.1038/sj.onc.1210210; Lindor Noralane M., 2006, Cancer Biomarkers, V2, P5; Luo JL, 2004, CANCER CELL, V6, P297, DOI 10.1016/j.ccr.2004.08.012; Matsumine A, 1996, J BIOL CHEM, V271, P10341, DOI 10.1074/jbc.271.17.10341; NISHISHO I, 1991, SCIENCE, V253, P665, DOI 10.1126/science.1651563; NOURRY C, 2003, SCI STKE; Ogino S, 2006, J MOL DIAGN, V8, P582, DOI 10.2353/jmoldx.2006.060082; Prall F, 2007, HUM PATHOL, V38, P1696, DOI 10.1016/j.humpath.2007.04.002; Rosin-Arbesfeld R, 2000, NATURE, V406, P1009, DOI 10.1038/35023016; Senda T, 1999, J HISTOCHEM CYTOCHEM, V47, P1149, DOI 10.1177/002215549904700907; Shinto E, 2005, LAB INVEST, V85, P257, DOI 10.1038/labinvest.3700199; Sizemore N, 2002, J BIOL CHEM, V277, P3863, DOI 10.1074/jbc.M110572200; Weisenberger DJ, 2006, NAT GENET, V38, P787, DOI 10.1038/ng1834; Zhang F, 2000, P NATL ACAD SCI USA, V97, P12577, DOI 10.1073/pnas.230435597; Zlobec I, 2007, J PATHOL, V212, P260, DOI 10.1002/path.2164	36	63	67	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 9	2008	27	46					6044	6055		10.1038/onc.2008.204	http://dx.doi.org/10.1038/onc.2008.204			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	358BO	18591935	Green Accepted			2022-12-28	WOS:000259891600007
J	Mazan-Mamczarz, K; Hagner, PR; Corl, S; Srikantan, S; Wood, WH; Becker, KG; Gorospe, M; Keene, JD; Levenson, AS; Gartenhaus, RB				Mazan-Mamczarz, K.; Hagner, P. R.; Corl, S.; Srikantan, S.; Wood, W. H.; Becker, K. G.; Gorospe, M.; Keene, J. D.; Levenson, A. S.; Gartenhaus, R. B.			Post-transcriptional gene regulation by HuR promotes a more tumorigenic phenotype	ONCOGENE			English	Article						post-transcriptional operon; MCT-1 oncogene; TSP1; HuR; RNA-binding protein; tumor angiogenesis	BINDING PROTEIN HUR; RNA-STABILITY FACTOR; MESSENGER-RNA; RIBONUCLEOPROTEIN COMPLEXES; TRANSLATIONAL REPRESSION; EXPRESSION; RICH; REGION; STABILIZATION; TRANSLOCATION	In a breast tumor xenograft model, the MCT-1 oncogene increases the in vivo tumorgenicity of MCF7 cells by promoting angiogenesis and inhibiting apoptosis. Increases in the tumor microvascular density are accompanied by a strong reduction in the levels of the angiogenesis inhibitor thrombospondin-1 (TSP1), but the mechanisms underlying this process are unknown. We show that TSP1 expression is controlled, at least in part, by post-transcriptional events. Using RNA interference to knock down the expression of the RNA-binding protein HuR in MCF7 cells as well as HuR overexpression, we demonstrate that HuR plays an important role in translation of the TSP1 mRNA. Furthermore, employing the RIP-Chip assay yielded 595 transcripts with significantly altered binding to HuR in the more tumorigenic breast cancer clones compared with the weakly tumorigenic clones. These mRNAs clustered in several pathways implicated in the transformed phenotype, such as the RAS pathway (involved in mitogenesis), the PI3K pathway (evasion of apoptosis) and pathways mediating angiogenesis and the cellular response to hypoxia. These findings demonstrate for the first time that global changes in HuR-bound mRNAs are implicated in the evolution to a more tumorigenic phenotype in an in vivo tumor model and underscore the role of global mRNA-protein interactions toward tumor progression.	[Mazan-Mamczarz, K.; Hagner, P. R.; Corl, S.; Gartenhaus, R. B.] Univ Maryland, Marlene & Stewart Greenebaum Canc Ctr, Baltimore, MD 21201 USA; [Srikantan, S.; Gorospe, M.] NIA, Cellular & Mol Biol Lab, NIH, Baltimore, MD 21224 USA; [Wood, W. H.; Becker, K. G.] NIA, Gene Express & Genom Unit, NIH, Baltimore, MD 21224 USA; [Keene, J. D.] Duke Univ, Med Ctr, Dept Mol Genet & Microbiol, Durham, NC USA; [Levenson, A. S.] Northwestern Univ, Dept Urol, Feinberg Sch Med, Chicago, IL 60611 USA; [Levenson, A. S.] Robert H Lurie Comprehens Canc Ctr, Chicago, IL USA	University System of Maryland; University of Maryland Baltimore; National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); Duke University; Northwestern University; Feinberg School of Medicine; Ann & Robert H. Lurie Children's Hospital of Chicago; Robert H. Lurie Comprehensive Cancer Center	Gartenhaus, RB (corresponding author), Univ Maryland, Marlene & Stewart Greenebaum Canc Ctr, 9-011 BRB,655 W Baltimore St,22 S Greene St, Baltimore, MD 21201 USA.	rgartenhaus@som.umaryland.edu	, Jack/L-6806-2019	srikantan, subramanya/0000-0003-1810-6519; Becker, Kevin/0000-0002-6794-6656	National Institute on Aging Intramural Research Program; NIH; NATIONAL INSTITUTE ON AGING [Z01AG000392, ZICAG000616, Z01AG000511, ZIAAG000511, Z01AG000616, ZIAAG000392] Funding Source: NIH RePORTER	National Institute on Aging Intramural Research Program(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	We thank Dr Y Zhang for assistance with the statistical analysis of the RIP-Chip array data and Dr J Hasday for technical support. A Merit Review Award from the Department of Veterans Affairs to RBG supported this work. MG and SS were supported by the National Institute on Aging Intramural Research Program, NIH.	Abdelmohsen K, 2007, MOL CELL, V25, P543, DOI 10.1016/j.molcel.2007.01.011; AGHIB DF, 1990, ONCOGENE, V5, P707; Akool ES, 2003, MOL CELL BIOL, V23, P4901, DOI 10.1128/MCB.23.14.4901-4916.2003; Bevilacqua A, 2003, J CELL PHYSIOL, V195, P356, DOI 10.1002/jcp.10272; Bhattacharyya SN, 2006, CELL, V125, P1111, DOI 10.1016/j.cell.2006.04.031; Brennan CM, 2001, CELL MOL LIFE SCI, V58, P266, DOI 10.1007/PL00000854; Calvano SE, 2005, NATURE, V437, P1032, DOI 10.1038/nature03985; Cheadle C, 2003, J MOL DIAGN, V5, P73, DOI 10.1016/S1525-1578(10)60455-2; De Silanes IL, 2004, GENE EXPRESSION, V12, P49, DOI 10.3727/000000004783992215; Galban S, 2003, MOL CELL BIOL, V23, P7083, DOI 10.1128/MCB.23.20.7083-7095.2003; Galban S, 2008, MOL CELL BIOL, V28, P93, DOI 10.1128/MCB.00973-07; Gorospe M, 2003, CELL CYCLE, V2, P412, DOI 10.4161/cc.2.5.491; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; HOLLIS GF, 1988, MOL CELL BIOL, V8, P124, DOI 10.1128/MCB.8.1.124; Katsanou V, 2005, MOL CELL, V19, P777, DOI 10.1016/j.molcel.2005.08.007; Kawai T, 2006, MOL CELL BIOL, V26, P3295, DOI 10.1128/MCB.26.8.3295-3307.2006; Keene JD, 2007, NAT REV GENET, V8, P533, DOI 10.1038/nrg2111; Keene JD, 2006, NAT PROTOC, V1, P302, DOI 10.1038/nprot.2006.47; Keene JD, 2002, MOL CELL, V9, P1161, DOI 10.1016/S1097-2765(02)00559-2; Keene JD, 2001, P NATL ACAD SCI USA, V98, P7018, DOI 10.1073/pnas.111145598; Kim HS, 2007, MOL CELL BIOL, V27, P6806, DOI 10.1128/MCB.01036-07; Kullmann M, 2002, GENE DEV, V16, P3087, DOI 10.1101/gad.248902; Lal A, 2005, EMBO J, V24, P1852, DOI 10.1038/sj.emboj.7600661; Lal A, 2006, MOL CELL, V22, P117, DOI 10.1016/j.molcel.2006.03.016; Lal A, 2004, EMBO J, V23, P3092, DOI 10.1038/sj.emboj.7600305; Leandersson K, 2006, NUCLEIC ACIDS RES, V34, P3988, DOI 10.1093/nar/gkl571; Levenson AS, 2005, CANCER RES, V65, P10651, DOI 10.1158/0008-5472.CAN-05-0845; Levy NS, 1998, J BIOL CHEM, V273, P6417, DOI 10.1074/jbc.273.11.6417; Liao BS, 2007, NAT STRUCT MOL BIOL, V14, P511, DOI 10.1038/nsmb1249; Lopez de Silanes I., 2005, RNA BIOL, V2, P11, DOI DOI 10.4161/RNA.2.1.1552; Mazan-Mamczarz K, 2006, MOL CELL BIOL, V26, P2716, DOI 10.1128/MCB.26.7.2716-2727.2006; Mazan-Mamczarz K, 2003, P NATL ACAD SCI USA, V100, P8354, DOI 10.1073/pnas.1432104100; MEIJLINK F, 1985, P NATL ACAD SCI USA, V82, P4987, DOI 10.1073/pnas.82.15.4987; Meng Z, 2005, NUCLEIC ACIDS RES, V33, P2962, DOI 10.1093/nar/gki603; Millard SS, 2000, MOL CELL BIOL, V20, P5947, DOI 10.1128/MCB.20.16.5947-5959.2000; Nabors LB, 2001, CANCER RES, V61, P2154; Orphanides G, 2002, CELL, V108, P439, DOI 10.1016/S0092-8674(02)00655-4; Piecyk M, 2000, EMBO J, V19, P4154, DOI 10.1093/emboj/19.15.4154; Prosniak M, 1998, CANCER RES, V58, P4233; Pullmann R, 2007, MOL CELL BIOL, V27, P6265, DOI 10.1128/MCB.00500-07; Ren B, 2006, BBA-REV CANCER, V1765, P178, DOI 10.1016/j.bbcan.2005.11.002; Sheflin LG, 2004, BIOCHEM BIOPH RES CO, V322, P644, DOI 10.1016/j.bbrc.2004.07.173; Tenenbaum SA, 2000, P NATL ACAD SCI USA, V97, P14085, DOI 10.1073/pnas.97.26.14085; WANG RK, 2000, P SOC PHOTO-OPT INS, V1, P12; Wang WG, 2000, MOL CELL BIOL, V20, P760, DOI 10.1128/MCB.20.3.760-769.2000; Watnick RS, 2003, CANCER CELL, V3, P219, DOI 10.1016/S1535-6108(03)00030-8; Weidner N, 1998, J PATHOL, V184, P119, DOI 10.1002/(SICI)1096-9896(199802)184:2<119::AID-PATH17>3.0.CO;2-D; Wilusz CJ, 2004, TRENDS GENET, V20, P491, DOI 10.1016/j.tig.2004.07.011; ZABRENETZKY V, 1994, INT J CANCER, V59, P191, DOI 10.1002/ijc.2910590209	49	98	102	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT	2008	27	47					6151	6163		10.1038/onc.2008.215	http://dx.doi.org/10.1038/onc.2008.215			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	360UJ	18641687	Green Accepted			2022-12-28	WOS:000260083100008
J	Reed, JC				Reed, J. C.			Foreword	ONCOGENE			English	Editorial Material									Burnham Inst Med Res, La Jolla, CA USA	Sanford Burnham Prebys Medical Discovery Institute	Reed, JC (corresponding author), Burnham Inst Med Res, La Jolla, CA USA.								0	2	2	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT	2008	27	48					6192	+		10.1038/onc.2008.296	http://dx.doi.org/10.1038/onc.2008.296			3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	361YB	18931686				2022-12-28	WOS:000260162800001
J	Endersby, R; Baker, SJ				Endersby, R.; Baker, S. J.			PTEN signaling in brain: neuropathology and tumorigenesis	ONCOGENE			English	Review						PTEN; PI3 kinase; tumor suppressor; brain; glioblastoma	LHERMITTE-DUCLOS-DISEASE; TUMOR-SUPPRESSOR GENE; PROTEIN-KINASE-B; GROWTH-FACTOR RECEPTOR; FORKHEAD TRANSCRIPTION FACTORS; RILEY-RUVALCABA-SYNDROME; HUMAN-MALIGNANT GLIOMAS; LOW-GRADE GLIOMAS; IN-VIVO; GLIOBLASTOMA-MULTIFORME	Phosphatase and tensin homolog deleted on chromosome 10 (PTEN) is a tumor suppressor that antagonizes the phosphatidylinositol-3-kinase (PI3K)/Akt/mTOR pathway by functioning as a lipid phosphatase. This ubiquitous and evolutionarily conserved signaling cascade influences numerous functions including cell growth, survival, proliferation, migration and metabolism. Inherited mutations in PTEN cause pleiotropic effects including cancer predisposition as well as a range of neurological abnormalities revealing specialized roles for PTEN in nervous system development and maintenance. Somatic mutations in PTEN occur frequently as late events in sporadic brain tumors. Mouse models based on Pten deletion in the brain have provided insights into the normal functions of Pten in the nervous system as well as the initiation and progression of gliomas. Compromised PTEN function may contribute to gliomagenesis through disrupted regulation of proliferation, migration, invasion, angiogenesis, stem cell self-renewal and regulation of other tumor suppressor pathways such as p53. Clinical findings in high-grade glioma suggest that PTEN gene alterations are associated with poor prognosis and may influence response to specific therapies. Emerging research using specific pharmacological inhibitors of the PI3K pathway may provide novel therapeutic options for the treatment of PTEN-deficient tumors.	[Endersby, R.; Baker, S. J.] St Jude Childrens Hosp, Dept Dev Neurobiol, Memphis, TN 38105 USA	St Jude Children's Research Hospital	Baker, SJ (corresponding author), St Jude Childrens Hosp, Dept Dev Neurobiol, 332 N Lauderdale St, Memphis, TN 38105 USA.	suzanne.baker@stjude.org	Endersby, Raelene/A-2969-2013; Baker, Suzanne J/N-8167-2018	Endersby, Raelene/0000-0003-3554-2769; 	National Institutes of Health; American Lebanese; Syrian Associated Charities of St Jude Children's Research Hospital; NATIONAL CANCER INSTITUTE [R01CA135554] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); American Lebanese; Syrian Associated Charities of St Jude Children's Research Hospital; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank members of the Baker laboratory for helpful comments and discussions. SJB is supported by grants from the National Institutes of Health and by the American Lebanese and Syrian Associated Charities of St Jude Children's Research Hospital.	Abel TW, 2005, J NEUROPATH EXP NEUR, V64, P341, DOI 10.1093/jnen/64.4.341; Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9; Backman SA, 2001, NAT GENET, V29, P396, DOI 10.1038/ng782; Baeza N, 2003, ACTA NEUROPATHOL, V106, P479, DOI 10.1007/s00401-003-0748-4; Balendran A, 1999, J BIOL CHEM, V274, P37400, DOI 10.1074/jbc.274.52.37400; Bao SD, 2006, NATURE, V444, P756, DOI 10.1038/nature05236; BELLACOSA A, 1995, INT J CANCER, V64, P280, DOI 10.1002/ijc.2910640412; Bianco R, 2003, ONCOGENE, V22, P2812, DOI 10.1038/sj.onc.1206388; Bigner SH, 1990, BRAIN PATHOL, V1, P12, DOI 10.1111/j.1750-3639.1990.tb00633.x; Bjornsti MA, 2004, NAT REV CANCER, V4, P335, DOI 10.1038/nrc1362; Boland E, 2007, AM J HUM GENET, V81, P292, DOI 10.1086/519999; Broderick DK, 2004, CANCER RES, V64, P5048, DOI 10.1158/0008-5472.CAN-04-1170; Brognard J, 2007, MOL CELL, V25, P917, DOI 10.1016/j.molcel.2007.02.017; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Butler MG, 2005, J MED GENET, V42, P318, DOI 10.1136/jmg.2004.024646; Chakravarti A, 2001, CLIN CANCER RES, V7, P2387; Chang CJ, 2004, J BIOL CHEM, V279, P29841, DOI 10.1074/jbc.M401488200; Chen ML, 2006, GENE DEV, V20, P1569, DOI 10.1101/gad.1395006; Chen WS, 2001, GENE DEV, V15, P2203, DOI 10.1101/gad.913901; Chen ZB, 2005, NATURE, V436, P725, DOI 10.1038/nature03918; Cheng JQ, 1996, P NATL ACAD SCI USA, V93, P3636, DOI 10.1073/pnas.93.8.3636; Cho H, 2001, J BIOL CHEM, V276, P38349, DOI 10.1074/jbc.C100462200; Cho H, 2001, SCIENCE, V292, P1728, DOI 10.1126/science.292.5522.1728; Chow LML, 2006, CANCER LETT, V241, P184, DOI 10.1016/j.canlet.2005.11.042; Cloughesy TF, 2008, PLOS MED, V5, P139, DOI 10.1371/journal.pmed.0050008; Dey N, 2008, CANCER RES, V68, P1862, DOI 10.1158/0008-5472.CAN-07-1182; Di Cristofano A, 2001, NAT GENET, V27, P222, DOI 10.1038/84879; Dijkers PF, 2002, J CELL BIOL, V156, P531, DOI 10.1083/jcb.200108084; Ding H, 2001, CANCER RES, V61, P3826; Easton RM, 2005, MOL CELL BIOL, V25, P1869, DOI 10.1128/MCB.25.5.1869-1878.2005; Eng C, 2003, HUM MUTAT, V22, P183, DOI 10.1002/humu.10257; Engelman JA, 2006, NAT REV GENET, V7, P606, DOI 10.1038/nrg1879; Ermoian RP, 2002, CLIN CANCER RES, V8, P1100; Fan QW, 2007, CANCER RES, V67, P7960, DOI 10.1158/0008-5472.CAN-07-2154; Fan QW, 2006, CANCER CELL, V9, P341, DOI 10.1016/j.ccr.2006.03.029; Folkman J, 2006, ANNU REV MED, V57, P1, DOI 10.1146/annurev.med.57.121304.131306; Fraser MM, 2008, NEUROSCIENCE, V151, P476, DOI 10.1016/j.neuroscience.2007.10.048; Fraser MM, 2004, CANCER RES, V64, P7773, DOI 10.1158/0008-5472.CAN-04-2487; Freeman DJ, 2003, CANCER CELL, V3, P117, DOI 10.1016/S1535-6108(03)00021-7; Furnari FB, 1998, CANCER RES, V58, P5002; Goffin A, 2001, AM J MED GENET, V105, P521, DOI 10.1002/ajmg.1477; Gottschalk AR, 2001, CANCER RES, V61, P2105; Goudar RK, 2005, MOL CANCER THER, V4, P101; Groszer M, 2006, P NATL ACAD SCI USA, V103, P111, DOI 10.1073/pnas.0509939103; Groszer M, 2001, SCIENCE, V294, P2186, DOI 10.1126/science.1065518; Gustafson S, 2007, SEMIN ONCOL, V34, P428, DOI 10.1053/j.seminoncol.2007.07.009; Hambardzumyan D, 2008, GENE DEV, V22, P436, DOI 10.1101/gad.1627008; Hartmann C, 2005, ACTA NEUROPATHOL, V109, P639, DOI 10.1007/s00401-005-1000-1; Hartmann W, 2005, AM J PATHOL, V166, P1153, DOI 10.1016/S0002-9440(10)62335-8; Hartmann W, 2006, CLIN CANCER RES, V12, P3019, DOI 10.1158/1078-0432.CCR-05-2187; Hayes MP, 2006, CLIN CANCER RES, V12, P5932, DOI 10.1158/1078-0432.CCR-06-1375; Hemminki A, 1998, NATURE, V391, P184, DOI 10.1038/34432; Hoekman MFM, 2006, GENE EXPR PATTERNS, V6, P134, DOI 10.1016/j.modgep.2005.07.003; Holland EC, 2000, NAT GENET, V25, P55, DOI 10.1038/75596; Homma T, 2006, J NEUROPATH EXP NEUR, V65, P846, DOI 10.1097/01.jnen.0000235118.75182.94; Horie Y, 2004, J CLIN INVEST, V113, P1774, DOI 10.1172/JCI200420513; Hu XY, 2005, NEOPLASIA, V7, P356, DOI 10.1593/neo.04595; Hunter C, 2006, CANCER RES, V66, P3987, DOI 10.1158/0008-5472.CAN-06-0127; Iida S, 1998, INT J MOL MED, V1, P925; Inoki K, 2002, NAT CELL BIOL, V4, P648, DOI 10.1038/ncb839; Jones G, 2001, CANCER RES, V61, P5688; Katajisto P, 2007, BBA-REV CANCER, V1775, P63, DOI 10.1016/j.bbcan.2006.08.003; Knobbe CB, 2003, BRAIN PATHOL, V13, P507; Kops GJPL, 2002, MOL CELL BIOL, V22, P2025, DOI 10.1128/MCB.22.7.2025-2036.2002; Koul D, 2001, ONCOGENE, V20, P6669, DOI 10.1038/sj.onc.1204799; Kraus JA, 2000, J NEURO-ONCOL, V48, P89, DOI 10.1023/A:1006402614838; Kubiatowski T, 2001, J NEUROSURG, V95, P480, DOI 10.3171/jns.2001.95.3.0480; Kwon CH, 2001, NAT GENET, V29, P404, DOI 10.1038/ng781; Kwon CH, 2006, NEURON, V50, P377, DOI 10.1016/j.neuron.2006.03.023; Lachlan KL, 2007, J MED GENET, V44, DOI 10.1136/jmg.2007.049981; Lee J, 2006, CANCER CELL, V9, P391, DOI 10.1016/j.ccr.2006.03.030; Lein ES, 2007, NATURE, V445, P168, DOI 10.1038/nature05453; Leslie NR, 2007, CURR BIOL, V17, P115, DOI 10.1016/j.cub.2006.12.026; Li DM, 1997, CANCER RES, V57, P2124; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; Li L, 2002, MOL CELL NEUROSCI, V20, P21, DOI 10.1006/mcne.2002.1115; Liang J, 2002, NAT MED, V8, P1153, DOI 10.1038/nm761; Liliental J, 2000, CURR BIOL, V10, P401, DOI 10.1016/S0960-9822(00)00417-6; Lin H, 1998, CLIN CANCER RES, V4, P2447; Maehama T, 1998, J BIOL CHEM, V273, P13375, DOI 10.1074/jbc.273.22.13375; Maier D, 1999, CANCER RES, V59, P5479; Maity A, 2000, CANCER RES, V60, P5879; Marino S, 2002, DEVELOPMENT, V129, P3513; Maroulakou IG, 2007, CANCER RES, V67, P167, DOI 10.1158/0008-5472.CAN-06-3782; Mayo LD, 2002, J BIOL CHEM, V277, P5484, DOI 10.1074/jbc.M108302200; Medema RH, 2000, NATURE, V404, P782, DOI 10.1038/35008115; Mellinghoff IK, 2005, NEW ENGL J MED, V353, P2012, DOI 10.1056/NEJMoa051918; Modur V, 2002, J BIOL CHEM, V277, P47928, DOI 10.1074/jbc.M207509200; Myers MP, 1997, P NATL ACAD SCI USA, V94, P9052, DOI 10.1073/pnas.94.17.9052; Myers MP, 1998, P NATL ACAD SCI USA, V95, P13513, DOI 10.1073/pnas.95.23.13513; Nagata Y, 2004, CANCER CELL, V6, P117, DOI 10.1016/j.ccr.2004.06.022; Nakayama K, 2006, CANCER BIOL THER, V5, P779, DOI 10.4161/cbt.5.7.2751; O'Reilly KE, 2006, CANCER RES, V66, P1500, DOI 10.1158/0008-5472.CAN-05-2925; Oda K, 2005, CANCER RES, V65, P10669, DOI 10.1158/0008-5472.CAN-05-2620; Ohgaki H, 2004, CANCER RES, V64, P6892, DOI 10.1158/0008-5472.CAN-04-1337; Pedrero JMG, 2005, INT J CANCER, V114, P242, DOI 10.1002/ijc.20711; Phillips HS, 2006, CANCER CELL, V9, P157, DOI 10.1016/j.ccr.2006.02.019; Pore N, 2006, MOL CANCER RES, V4, P471, DOI 10.1158/1541-7786.MCR-05-0234; Prados MD, 2006, NEURO-ONCOLOGY, V8, P67, DOI 10.1215/S1522851705000451; Pu PY, 2006, J NEURO-ONCOL, V76, P1, DOI 10.1007/s11060-005-3029-3; Raffel C, 1999, CLIN CANCER RES, V5, P4085; Raftopoulou M, 2004, SCIENCE, V303, P1179, DOI 10.1126/science.1092089; Rao G, 2004, ONCOGENE, V23, P6156, DOI 10.1038/sj.onc.1207818; Rasheed BKA, 1997, CANCER RES, V57, P4187; Raynaud FI, 2007, CANCER RES, V67, P5840, DOI 10.1158/0008-5472.CAN-06-4615; Rich JN, 2005, CANCER RES, V65, P4051, DOI 10.1158/0008-5472.CAN-04-3936; Rich JN, 2004, J CLIN ONCOL, V22, P133, DOI 10.1200/JCO.2004.08.110; Rickert CH, 2004, J NEUROPATH EXP NEUR, V63, P399, DOI 10.1093/jnen/63.5.399; Samuels Y, 2004, SCIENCE, V304, P554, DOI 10.1126/science.1096502; Sano T, 1999, CANCER RES, V59, P1820; Sarbassov DD, 2005, SCIENCE, V307, P1098, DOI 10.1126/science.1106148; Schlegel J, 2002, ANTICANCER RES, V22, P2837; Shannon P, 2005, AM J PATHOL, V167, P859, DOI 10.1016/S0002-9440(10)62057-3; Shaw RJ, 2006, NATURE, V441, P424, DOI 10.1038/nature04869; Shaw RJ, 2004, CANCER CELL, V6, P91, DOI 10.1016/j.ccr.2004.06.007; She QB, 2005, CANCER CELL, V8, P287, DOI 10.1016/j.ccr.2005.09.006; Shin I, 2002, NAT MED, V8, P1145, DOI 10.1038/nm759; Simpson L, 2001, EXP CELL RES, V264, P29, DOI 10.1006/excr.2000.5130; Singh SK, 2004, NATURE, V432, P396, DOI 10.1038/nature03128; Smith JS, 2001, JNCI-J NATL CANCER I, V93, P1246, DOI 10.1093/jnci/93.16.1246; Stahl M, 2002, J IMMUNOL, V168, P5024, DOI 10.4049/jimmunol.168.10.5024; Stambolic V, 2001, MOL CELL, V8, P317, DOI 10.1016/S1097-2765(01)00323-9; Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356; Suzuki A, 2003, J EXP MED, V197, P657, DOI 10.1084/jem.20021101; Suzuki A, 2003, CANCER RES, V63, P674; Suzuki A, 2001, IMMUNITY, V14, P523, DOI 10.1016/S1074-7613(01)00134-0; Tada K, 2001, J NEUROSURG, V95, P651, DOI 10.3171/jns.2001.95.4.0651; Tamura M, 1998, SCIENCE, V280, P1614, DOI 10.1126/science.280.5369.1614; The WHO, 2020, CLASSIFICATION TUMOU; Tohma Y, 1998, J NEUROPATH EXP NEUR, V57, P684, DOI 10.1097/00005072-199807000-00005; Tschopp O, 2005, DEVELOPMENT, V132, P2943, DOI 10.1242/dev.01864; Uhlmann EJ, 2004, GLIA, V47, P180, DOI 10.1002/glia.20036; Um SH, 2004, NATURE, V431, P200, DOI 10.1038/nature02866; Van Diepen MT, 2008, DEV NEUROSCI-BASEL, V30, P59, DOI 10.1159/000109852; Viglietto G, 2002, NAT MED, V8, P1136, DOI 10.1038/nm762; Wang MY, 2006, CANCER RES, V66, P7864, DOI 10.1158/0008-5472.CAN-04-4392; Wei QX, 2006, CANCER RES, V66, P7429, DOI 10.1158/0008-5472.CAN-06-0712; Wen SH, 2001, P NATL ACAD SCI USA, V98, P4622, DOI 10.1073/pnas.081063798; Wiencke JK, 2007, NEURO-ONCOLOGY, V9, P271, DOI 10.1215/15228517-2007-003; Xiao A, 2005, CANCER RES, V65, P5172, DOI 10.1158/0008-5472.CAN-04-3902; Xiao A, 2002, CANCER CELL, V1, P157, DOI 10.1016/S1535-6108(02)00029-6; Yang ZZ, 2005, MOL CELL BIOL, V25, P10407, DOI 10.1128/MCB.25.23.10407-10418.2005; Yilmaz OH, 2006, NATURE, V441, P475, DOI 10.1038/nature04703; Young J, 1998, MOL MED TODAY, V4, P313, DOI 10.1016/S1357-4310(98)01245-3; Yue Q, 2005, DEVELOPMENT, V132, P3281, DOI 10.1242/dev.01891; Zeng LH, 2007, NEUROBIOL DIS, V28, P184, DOI 10.1016/j.nbd.2007.07.015; Zhou JB, 2007, P NATL ACAD SCI USA, V104, P16158, DOI 10.1073/pnas.0702596104; Zhou XP, 2003, AM J HUM GENET, V73, P1191, DOI 10.1086/379382; Zhu YA, 2002, NAT REV CANCER, V2, P616, DOI 10.1038/nrc866; Zori RT, 1998, AM J MED GENET, V80, P399, DOI 10.1002/(SICI)1096-8628(19981204)80:4<399::AID-AJMG18>3.0.CO;2-O; Zundel W, 2000, GENE DEV, V14, P391	151	182	199	0	25	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 15	2008	27	41					5416	5430		10.1038/onc.2008.239	http://dx.doi.org/10.1038/onc.2008.239			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	349KW	18794877				2022-12-28	WOS:000259280700004
J	Jiang, H; Vogt, PK				Jiang, H.; Vogt, P. K.			Constitutively active Rheb induces oncogenic transformation	ONCOGENE			English	Article						Rheb; PI 3-kinase; Akt; TOR; S6-kinase; 4E-binding protein	PROTEIN-KINASE B; CELL-CYCLE PROGRESSION; SMALL GTPASE-RHEB; MAMMALIAN TARGET; FKBP12-RAPAMYCIN-ASSOCIATED PROTEIN; PROTEASOMAL DEGRADATION; NUCLEAR-LOCALIZATION; RAPAMYCIN MTOR; RAF KINASE; ACTIVATION	Rheb (Ras-homolog enriched in brain) is a component of the phosphatidylinositol 3-kinase (PI3K) target of rapamycin (TOR) signa ling pathway, functioning as a positive regulator of TOR. Constitutively active mutants of Rheb induce oncogenic transformation in cell culture. The transformed cells are larger and contain more protein than their normal counterparts. They show constitutive phosphorylation of the ribosomal protein S6 kinase and the eukaryotic initiation factor 4E-binding protein 1, two downstream targets of TOR. The TOR-specific inhibitor rapamycin strongly interferes with transformation induced by constitutively active Rheb, suggesting that TOR activity is essential for the oncogenic effects of mutant Rheb. Rheb-induced transformation is also dependent on a C-terminal farnesylation signal that mediates localization to a cellular membrane. An engineered N-terminal myristylation signal can substitute for the farnesylation. Immunofluorescence localizes wild-type and mutant Rheb to vesicular structures in the cytoplasm, overlapping with the endoplasmic reticulum.	[Jiang, H.; Vogt, P. K.] Scripps Res Inst, Dept Mol & Expt Med, La Jolla, CA 92037 USA	Scripps Research Institute	Jiang, H (corresponding author), Scripps Res Inst, Dept Mol & Expt Med, 10550 N Torrey Pines Rd,BCC 239, La Jolla, CA 92037 USA.	hjiang@scripps.edu	Vogt, Peter K./R-7547-2019	Vogt, Peter K./0000-0002-4519-7500	National Cancer Institute; NATIONAL CANCER INSTITUTE [P01CA078045, R01CA107094, R01CA078230] Funding Source: NIH RePORTER	National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Lynn Ueno, Dr Marco Gymnopoulos, Dr Peiging Sun and Dr William B Kiosses (Core Microscopy, The Scripps Research Institute) for expert technical assistance. This study was supported by grants from the National Cancer Institute. This article is numbered 19286 in the Scripps Research Institute.	Ahmed NN, 1997, P NATL ACAD SCI USA, V94, P3627, DOI 10.1073/pnas.94.8.3627; Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9; Alessi DR, 1998, CURR OPIN GENET DEV, V8, P55, DOI 10.1016/S0959-437X(98)80062-2; Alessi DR, 1997, CURR BIOL, V7, P776, DOI 10.1016/S0960-9822(06)00336-8; Aoki M, 1998, P NATL ACAD SCI USA, V95, P14950, DOI 10.1073/pnas.95.25.14950; Aoki M, 2004, P NATL ACAD SCI USA, V101, P13613, DOI 10.1073/pnas.0405454101; Aoki M, 2004, Curr Top Microbiol Immunol, V279, P321; Bader AG, 2008, ONCOGENE, V27, P1179, DOI 10.1038/sj.onc.1210719; Bader AG, 2003, P NATL ACAD SCI USA, V100, P12384, DOI 10.1073/pnas.2135336100; Bader AG, 2005, MOL CELL BIOL, V25, P2095, DOI 10.1128/MCB.25.6.2095-2106.2005; Bai XC, 2007, SCIENCE, V318, P977, DOI 10.1126/science.1147379; Basso AD, 2005, J BIOL CHEM, V280, P31101, DOI 10.1074/jbc.M503763200; Biggs WH, 1999, P NATL ACAD SCI USA, V96, P7421, DOI 10.1073/pnas.96.13.7421; BISTER K, 1977, VIROLOGY, V82, P431, DOI 10.1016/0042-6822(77)90017-4; BOS TJ, 1990, GENE DEV, V4, P1677, DOI 10.1101/gad.4.10.1677; Briaud I, 2005, J BIOL CHEM, V280, P2282, DOI 10.1074/jbc.M412179200; BROWN EJ, 1994, NATURE, V369, P756, DOI 10.1038/369756a0; Buerger C, 2006, BIOCHEM BIOPH RES CO, V344, P869, DOI 10.1016/j.bbrc.2006.03.220; Cahill CM, 2001, J BIOL CHEM, V276, P13402, DOI 10.1074/jbc.M010042200; Castro AF, 2003, J BIOL CHEM, V278, P32493, DOI 10.1074/jbc.C300226200; Chan TO, 1999, ANNU REV BIOCHEM, V68, P965, DOI 10.1146/annurev.biochem.68.1.965; Chang HW, 1997, SCIENCE, V276, P1848, DOI 10.1126/science.276.5320.1848; Clark GJ, 1997, J BIOL CHEM, V272, P10608; Cohen SB, 2001, ONCOGENE, V20, P141, DOI 10.1038/sj.onc.1204077; Cunningham MA, 2004, MOL ENDOCRINOL, V18, P1756, DOI 10.1210/me.2004-0071; Dan HC, 2002, J BIOL CHEM, V277, P35364, DOI 10.1074/jbc.M205838200; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; Davletov B, 1998, J BIOL CHEM, V273, P19093, DOI 10.1074/jbc.273.30.19093; Downward J, 1998, CURR OPIN CELL BIOL, V10, P262, DOI 10.1016/S0955-0674(98)80149-X; Drenan RM, 2004, J BIOL CHEM, V279, P772, DOI 10.1074/jbc.M305912200; DUFF RG, 1969, VIROLOGY, V39, P18, DOI 10.1016/0042-6822(69)90344-4; Furukawa-Hibi Y, 2002, J BIOL CHEM, V277, P26729, DOI 10.1074/jbc.C200256200; Garami A, 2003, MOL CELL, V11, P1457, DOI 10.1016/S1097-2765(03)00220-X; Gromov PS, 1995, FEBS LETT, V377, P221, DOI 10.1016/0014-5793(95)01349-0; Heo WD, 2006, SCIENCE, V314, P1458, DOI 10.1126/science.1134389; Hers I, 2005, BIOCHEM J, V388, P713, DOI 10.1042/BJ20041531; Himly M, 1998, VIROLOGY, V248, P295, DOI 10.1006/viro.1998.9290; Hsu YC, 2007, NATURE, V445, P785, DOI 10.1038/nature05528; HUGHES SH, 1987, J VIROL, V61, P3004, DOI 10.1128/JVI.61.10.3004-3012.1987; Im E, 2002, ONCOGENE, V21, P6356, DOI 10.1038/sj.onc.1205792; Inoki K, 2002, NAT CELL BIOL, V4, P648, DOI 10.1038/ncb839; Inoki K, 2003, GENE DEV, V17, P1829, DOI 10.1101/gad.1110003; Karbowniczek M, 2004, J BIOL CHEM, V279, P29930, DOI 10.1074/jbc.M402591200; Karbowniczek M, 2006, J BIOL CHEM, V281, P25447, DOI 10.1074/jbc.M605273200; Kim JE, 2000, P NATL ACAD SCI USA, V97, P14340, DOI 10.1073/pnas.011511898; Lawlor MA, 2001, J CELL SCI, V114, P2903; Li Y, 2004, MOL CELL BIOL, V24, P7965, DOI 10.1128/MCB.24.18.7965-7975.2004; Long X, 2005, CURR BIOL, V15, P702, DOI 10.1016/j.cub.2005.02.053; Long XM, 2005, J BIOL CHEM, V280, P23433, DOI 10.1074/jbc.C500169200; Mach KE, 2000, GENETICS, V155, P611; Manning BD, 2002, MOL CELL, V10, P151, DOI 10.1016/S1097-2765(02)00568-3; Medema RH, 2000, NATURE, V404, P782, DOI 10.1038/35008115; Patel PH, 2003, J CELL SCI, V116, P3601, DOI 10.1242/jcs.00661; SABATINI DM, 1994, CELL, V78, P35, DOI 10.1016/0092-8674(94)90570-3; Sabatini DM, 1999, SCIENCE, V284, P1161, DOI 10.1126/science.284.5417.1161; SABERS CJ, 1995, J BIOL CHEM, V270, P815, DOI 10.1074/jbc.270.2.815; Saito K, 2005, J BIOCHEM, V137, P423, DOI 10.1093/jb/mvi046; Sarbassov DD, 2005, SCIENCE, V307, P1098, DOI 10.1126/science.1106148; Sarbassov DD, 2004, CURR BIOL, V14, P1296, DOI 10.1016/j.cub.2004.06.054; Saucedo LJ, 2003, NAT CELL BIOL, V5, P566, DOI 10.1038/ncb996; Shah OJ, 2006, MOL CELL BIOL, V26, P6425, DOI 10.1128/MCB.01254-05; Shah OJ, 2004, CURR BIOL, V14, P1650, DOI 10.1016/j.cub.2004.08.026; Sonderegger CK, 2003, ONCOGENE, V22, P1749, DOI 10.1038/sj.onc.1206308; Stahl M, 2002, J IMMUNOL, V168, P5024, DOI 10.4049/jimmunol.168.10.5024; Stephens L, 1998, SCIENCE, V279, P710, DOI 10.1126/science.279.5351.710; Stocker H, 2003, NAT CELL BIOL, V5, P559, DOI 10.1038/ncb995; Stokoe D, 1997, SCIENCE, V277, P567, DOI 10.1126/science.277.5325.567; Takahashi K, 2005, J BIOL CHEM, V280, P32768, DOI 10.1074/jbc.M506280200; Tee AR, 2003, CURR BIOL, V13, P1259, DOI 10.1016/S0960-9822(03)00506-2; Urano J, 2005, MOL MICROBIOL, V58, P1074, DOI 10.1111/j.1365-2958.2005.04877.x; Urano J, 2001, METHOD ENZYMOL, V333, P217; Urano J, 2000, J BIOL CHEM, V275, P11198, DOI 10.1074/jbc.275.15.11198; van Slegtenhorst M, 2004, J BIOL CHEM, V279, P12706, DOI 10.1074/jbc.M313874200; Wan X, 2007, ONCOGENE, V26, P1932, DOI 10.1038/sj.onc.1209990; YAMAGATA K, 1994, J BIOL CHEM, V269, P16333; Yan LJ, 2006, J BIOL CHEM, V281, P19793, DOI 10.1074/jbc.C600028200; Yang WL, 2001, MOL MICROBIOL, V41, P1339, DOI 10.1046/j.1365-2958.2001.02599.x; Yee WM, 1997, MOL CELL BIOL, V17, P921, DOI 10.1128/MCB.17.2.921; Zhang XW, 2002, J BIOL CHEM, V277, P28127, DOI 10.1074/jbc.M202625200; Zhang Y, 2003, NAT CELL BIOL, V5, P578, DOI 10.1038/ncb999	80	51	52	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP	2008	27	43					5729	5740		10.1038/onc.2008.180	http://dx.doi.org/10.1038/onc.2008.180			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	352HM	18521078	Green Accepted			2022-12-28	WOS:000259487100008
J	Demidenko, ZN; Kalurupalle, S; Hanko, C; Lim, CU; Broude, E; Blagosklonny, MV				Demidenko, Z. N.; Kalurupalle, S.; Hanko, C.; Lim, C-u; Broude, E.; Blagosklonny, M. V.			Mechanism of G1-like arrest by low concentrations of paclitaxel: next cell cycle p53-dependent arrest with sub G1 DNA content mediated by prolonged mitosis	ONCOGENE			English	Article						cell cycle; cancer; G1 arrest; paclitaxel; mitosis	MAMMALIAN-CELLS; MITOTIC ARREST; G(1) ARREST; P53; CHECKPOINT; TRANSCRIPTION; INHIBITORS; TAXOL; P21; REREPLICATION	Paclitaxel (PTX) and other microtubule inhibitors cause mitotic arrest. However, low concentrations of PTX (low PTX) paradoxically cause G1 arrest ( without mitotic arrest). Here, we demonstrated that unexpectedly, low PTX did not cause G1 arrest in the first cell cycle and did not prevent cells from passing through S phase and entering mitosis. Mitosis was prolonged but cells still divided, producing either two or three cells (tripolar mitosis), thus explaining a sub G1 peak caused by low PTX. Importantly, sub G1 cells were viable and non-apoptotic. Some cells fused back and then progressed to mitosis, frequently producing three cells again before becoming arrested in the next cell-cycle interphase. Thus, low PTX caused postmitotic arrest in second and even the third cell cycles. By increasing concentration of PTX, tripolar mitosis was transformed to mitotic slippage, thus eliminating a sub G1 peak. Time-lapse microscopy revealed that prolonged mitosis ensured a p53-dependent postmitotic arrest. We conclude that PTX directly affects cells only in mitosis and the duration of mitosis determines cell fate, including p53-dependent G1-like arrest.	[Kalurupalle, S.; Hanko, C.; Lim, C-u; Broude, E.; Blagosklonny, M. V.] Ctr Canc, Ordway Res Inst, Albany, NY 12208 USA; [Demidenko, Z. N.; Blagosklonny, M. V.] Oncotarget, Ordway Res Inst, Albany, NY USA	Ordway Research Institute; Ordway Research Institute	Blagosklonny, MV (corresponding author), Ctr Canc, Ordway Res Inst, 150 New Scotland Ave, Albany, NY 12208 USA.	blagosklonny@oncotarget.com						Abal M, 2003, CURR CANCER DRUG TAR, V3, P193, DOI 10.2174/1568009033481967; An WG, 1998, EXP CELL RES, V244, P54, DOI 10.1006/excr.1998.4193; Andreassen PR, 2001, MOL BIOL CELL, V12, P1315, DOI 10.1091/mbc.12.5.1315; Blagosklonny MV, 2007, CELL CYCLE, V6, P70, DOI 10.4161/cc.6.1.3682; Blagosklonny MV, 2002, CELL CYCLE, V1, P67, DOI 10.4161/cc.1.1.102; Blagosklonny MV, 2004, CELL CYCLE, V3, P1050; Blagosklonny MV, 2006, CELL CYCLE, V5, P971, DOI 10.4161/cc.5.9.2711; Blagosklonny MV, 1999, INT J CANCER, V83, P151, DOI 10.1002/(SICI)1097-0215(19991008)83:2<151::AID-IJC1>3.0.CO;2-5; Broude EV, 2007, CELL CYCLE, V6, P1468; CROSS SM, 1995, SCIENCE, V267, P1353, DOI 10.1126/science.7871434; Demidenko ZN, 2004, CANCER RES, V64, P3653, DOI 10.1158/0008-5472.CAN-04-0204; Di Leonardo A, 1997, CANCER RES, V57, P1013; Fukasawa K, 1997, MOL CELL BIOL, V17, P506, DOI 10.1128/MCB.17.1.506; Giannakakou P, 2000, NAT CELL BIOL, V2, P709, DOI 10.1038/35036335; Giannakakou P, 2002, P NATL ACAD SCI USA, V99, P10855, DOI 10.1073/pnas.132275599; Giannakakou P, 2001, ONCOGENE, V20, P3806, DOI 10.1038/sj.onc.1204487; Gottesfeld JM, 1997, TRENDS BIOCHEM SCI, V22, P197, DOI 10.1016/S0968-0004(97)01045-1; HORWITZ SB, 1992, TRENDS PHARMACOL SCI, V13, P134; Jordan MA, 1996, CANCER RES, V56, P816; Jordan MA, 2004, NAT REV CANCER, V4, P253, DOI 10.1038/nrc1317; KESSOUS A, 1980, CANCER RES, V40, P1354; Khan SH, 1998, CANCER RES, V58, P396; Lanni JS, 1998, MOL CELL BIOL, V18, P1055, DOI 10.1128/MCB.18.2.1055; Mantel C, 2008, CELL CYCLE, V7, P484, DOI 10.4161/cc.7.4.5316; MARTINEZBALBAS MA, 1995, CELL, V83, P29, DOI 10.1016/0092-8674(95)90231-7; PRESCOTT DM, 1964, PROG NUCLEIC ACID RE, V3, P33, DOI 10.1016/S0079-6603(08)60738-2; Rieder CL, 2004, DEV CELL, V7, P637, DOI 10.1016/j.devcel.2004.09.002; ROWINSKY EK, 1995, NEW ENGL J MED, V332, P1004, DOI 10.1056/NEJM199504133321507; Shtutman M, 2006, CANCER RES, V66, P11370, DOI 10.1158/0008-5472.CAN-06-2106; Stark B, 2001, CANCER GENET CYTOGEN, V128, P108, DOI 10.1016/S0165-4608(01)00411-3; Uetake Y, 2004, J CELL BIOL, V165, P609, DOI 10.1083/jcb.200403014; Uetake Y, 2007, CURR BIOL, V17, P2081, DOI 10.1016/j.cub.2007.10.065; Wong C, 2005, BMC CELL BIOL, V6, DOI 10.1186/1471-2121-6-6	33	82	84	1	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 24	2008	27	32					4402	4410		10.1038/onc.2008.82	http://dx.doi.org/10.1038/onc.2008.82			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	329PU	18469851				2022-12-28	WOS:000257881700003
J	Green, M; Panesar, NK; Loewenstein, PM				Green, M.; Panesar, N. K.; Loewenstein, P. M.			The transcription-repression domain of the adenovirus E1A oncoprotein targets p300 at the promoter	ONCOGENE			English	Article						adenovirus; Ad E1A; transcription repression; p300; promoter interaction	TATA-BINDING PROTEIN; MAJOR LATE PROMOTER; ACTIVATES TRANSCRIPTION; MAMMALIAN-CELLS; IN-VITRO; COACTIVATOR; DIFFERENTIATION; RECRUITMENT; CHROMATIN; CBP/P300	Extensive mutational/functional analysis of the transcription-repression domain encoded in the N-terminal 80 amino acids of the adenovirus E1A 243R oncoprotein suggests a model for the molecular mechanism of E1A repression: E1A accesses transcriptional co-activators such as p300 on specific promoters and then interacts with TBP to disrupt the TBP - TATA complex. In support of this model, as reported here, a basal core promoter activated by tethering p300 is repressible by E1A at the promoter level as shown by chromatin immunoprecipitation (ChIP) analysis. Sequestration of p300 by E1A does not play a significant role, as indicated by dose-response measurements. Furthermore, when the core promoter is transcriptionally activated by tethering activation domains of several transcription factors that can recruit p300 (p65, MyoD, cMyb and TFE3), transcription is repressible by E1A. However, when the core promoter is activated by factors not known to recruit p300 (USF1 and USF2), transcription is resistant to E1A repression. Finally, tethering p300 to the non-repressible adenovirus major late promoter (MLP) renders it repressible by E1A. ChIP analysis shows that E1A occupies the repressed MLP. These findings provide support for the hypothesis that p300 can serve as a scaffold for the E1A repression domain to access specific cellular gene promoters involved in growth regulation.	[Green, M.; Panesar, N. K.; Loewenstein, P. M.] St Louis Univ, Sch Med, Inst Mol Virol, EA Doisy Res Ctr, St Louis, MO 63104 USA	Saint Louis University	Green, M (corresponding author), St Louis Univ, Sch Med, Inst Mol Virol, EA Doisy Res Ctr, 1100 S Grand Blvd, St Louis, MO 63104 USA.	green@slu.edu			NCI NIH HHS [CA29561] Funding Source: Medline; NIAID NIH HHS [AI-04739] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA029561] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Berk AJ, 2005, ONCOGENE, V24, P7673, DOI 10.1038/sj.onc.1209040; Boyd JM, 2002, J VIROL, V76, P1461, DOI 10.1128/JVI.76.3.1461-1474.2002; Burgers WA, 2007, ONCOGENE, V26, P1650, DOI 10.1038/sj.onc.1209950; CARTHEW RW, 1985, CELL, V43, P439, DOI 10.1016/0092-8674(85)90174-6; Chan HM, 2001, J CELL SCI, V114, P2363; CHINNADURAI G, 2006, NUCLEUS; Chinnadurai G., 2006, CTBP FAMILY PROTEINS, P1; Dorris DR, 2000, MOL CELL BIOL, V20, P4350, DOI 10.1128/MCB.20.12.4350-4358.2000; ECKNER R, 1994, GENE DEV, V8, P869, DOI 10.1101/gad.8.8.869; Frisch SM, 2002, NAT REV MOL CELL BIO, V3, P441, DOI 10.1038/nrm827; Gallimore PH, 2001, ONCOGENE, V20, P7824, DOI 10.1038/sj.onc.1204913; Goodman RH, 2000, GENE DEV, V14, P1553; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GREEN M, 1988, CELL, V53, P921, DOI 10.1016/S0092-8674(88)90429-1; Green M, 2008, VIROLOGY, V371, P1, DOI 10.1016/j.virol.2007.10.021; Lavrrar JL, 2004, J BIOL CHEM, V279, P46343, DOI 10.1074/jbc.M402692200; LILLIE JW, 1987, CELL, V50, P1091, DOI 10.1016/0092-8674(87)90175-9; Loewenstein PM, 2006, VIROLOGY, V351, P312, DOI 10.1016/j.virol.2006.03.041; Luo X, 1996, P NATL ACAD SCI USA, V93, P1308, DOI 10.1073/pnas.93.3.1308; MORAN E, 1993, CURR OPIN GENET DEV, V3, P63, DOI 10.1016/S0959-437X(05)80342-9; Parker SF, 1997, J VIROL, V71, P2004, DOI 10.1128/JVI.71.3.2004-2012.1997; Perkins ND, 1997, SCIENCE, V275, P523, DOI 10.1126/science.275.5299.523; Postigo AA, 1999, MOL CELL BIOL, V19, P7961; Postigo AA, 1999, P NATL ACAD SCI USA, V96, P6683, DOI 10.1073/pnas.96.12.6683; Qyang YB, 1999, MOL CELL BIOL, V19, P1508; Rasti M, 2005, J VIROL, V79, P5594, DOI 10.1128/JVI.79.9.5594-5605.2005; SAWADOGO M, 1985, CELL, V43, P165, DOI 10.1016/0092-8674(85)90021-2; SHENK T, 2001, FUNDAMENTAL VIROLOGY; SONG CZ, 1995, P NATL ACAD SCI USA, V92, P10330, DOI 10.1073/pnas.92.22.10330; SONG CZ, 1995, J VIROL, V69, P2907, DOI 10.1128/JVI.69.5.2907-2911.1995; Song CZ, 1997, MOL CELL BIOL, V17, P2186, DOI 10.1128/MCB.17.4.2186; SONG CZ, 1995, J BIOL CHEM, V40, P23263; Taatjes DJ, 2004, NAT REV MOL CELL BIO, V5, P403, DOI 10.1038/nrm1369; Takahashi Y, 2000, GENE DEV, V14, P804; WEBSTER KA, 1988, NATURE, V332, P553, DOI 10.1038/332553a0; Weilbaecher KN, 2001, MOL CELL, V8, P749, DOI 10.1016/S1097-2765(01)00360-4; WEINTRAUB SJ, 1995, NATURE, V375, P812, DOI 10.1038/375812a0; Yuan WC, 1996, J BIOL CHEM, V271, P9009, DOI 10.1074/jbc.271.15.9009	38	9	10	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 24	2008	27	32					4446	4455		10.1038/onc.2008.85	http://dx.doi.org/10.1038/onc.2008.85			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	329PU	18408753				2022-12-28	WOS:000257881700007
J	Steelman, LS; Navolanic, PM; Sokolosky, ML; Taylor, JR; Lehmann, BD; Chappell, WH; Abrams, SL; Wong, EWT; Stadelman, KM; Terrian, DM; Leslie, NR; Martelli, AM; Stivala, F; Libra, M; Franklin, RA; McCubrey, JA				Steelman, L. S.; Navolanic, P. M.; Sokolosky, M. L.; Taylor, J. R.; Lehmann, B. D.; Chappell, W. H.; Abrams, S. L.; Wong, E. W. T.; Stadelman, K. M.; Terrian, D. M.; Leslie, N. R.; Martelli, A. M.; Stivala, F.; Libra, M.; Franklin, R. A.; McCubrey, J. A.			Suppression of PTEN function increases breast cancer chemotherapeutic drug resistance while conferring sensitivity to mTOR inhibitors	ONCOGENE			English	Article						PTEN; Akt; mTOR; rapamycin; chemotherapeutic drugs	PROTEIN-KINASE-B; INVASIVE DUCTAL CARCINOMA; COWDEN-DISEASE; REDUCED EXPRESSION; MAMMALIAN TARGET; ACTIVATION; GENE; ANGIOGENESIS; TRASTUZUMAB; MUTATIONS	Ectopic expression of mutant forms of phosphatase and tensin homologue deleted on chromosome 10 ( PTEN) lacking lipid ( G129E) or lipid and protein ( C124S) phosphatase activity decreased sensitivity of MCF-7 breast cancer cells, which have wild-type PTEN, to doxorubicin and increased sensitivity to the mammalian target of rapamycin ( mTOR) inhibitor rapamycin. Cells transfected with a mutant PTEN gene lacking both lipid and protein phosphatase activities were more resistant to doxorubicin than cells transfected with the PTEN mutant lacking lipid phosphatase activity indicating that the protein phosphatase activity of PTEN was also important in controlling the sensitivity to doxorubicin, while no difference was observed between the lipid ( G129E) and lipid and protein ( C124S) phosphatase PTEN mutants in terms of sensitivity to rapamycin. A synergistic inhibitory interaction was observed when doxorubicin was combined with rapamycin in the phosphatase-deficient PTEN-transfected cells. Interference with the lipid phosphatase activity of PTEN was sufficient to activate Akt/mTOR/p70S6K signaling. These studies indicate that disruption of the normal activity of the PTEN phosphatase can have dramatic effects on the therapeutic sensitivity of breast cancer cells. Mutations in the key residues which control PTEN lipid and protein phosphatase may act as dominant-negative mutants to suppress endogenous PTEN and alter the sensitivity of breast cancer patients to chemo- and targeted therapies.	[Steelman, L. S.; Navolanic, P. M.; Sokolosky, M. L.; Taylor, J. R.; Chappell, W. H.; Abrams, S. L.; Wong, E. W. T.; Stadelman, K. M.; Franklin, R. A.; McCubrey, J. A.] E Carolina Univ, Brody Sch Med, Dept Microbiol & Immunol, Greenville, NC 27858 USA; [Lehmann, B. D.; Terrian, D. M.] E Carolina Univ, Brody Sch Med, Dept Anat & Cell Biol, Greenville, NC 27858 USA; [Terrian, D. M.; Franklin, R. A.; McCubrey, J. A.] E Carolina Univ, Brody Sch Med, Leo Jenkins Canc Ctr, Greenville, NC 27858 USA; [Stivala, F.; Libra, M.] Univ Catania, Dept Biomed Sci, Catania, Italy; [Leslie, N. R.] Univ Dundee, Sch Life Sci, Div Cell Signaling, Dundee, Scotland; [Martelli, A. M.] Univ Bologna, Dept Human Anat Sci, Bologna, Italy; [Martelli, A. M.] IOR, CNR, IGM, Bologna, Italy	University of North Carolina; East Carolina University; University of North Carolina; East Carolina University; University of North Carolina; East Carolina University; University of Catania; University of Dundee; University of Bologna; Consiglio Nazionale delle Ricerche (CNR)	McCubrey, JA (corresponding author), E Carolina Univ, Brody Sch Med, Dept Microbiol & Immunol, Greenville, NC 27858 USA.	mccubreyj@ecu.edu	Libra, Massimo/L-8241-2018; Libra, Massimo/ABF-6654-2020; Lehmann, Brian D./H-8464-2019; Leslie, Nicholas/D-2699-2009	Libra, Massimo/0000-0002-7232-7737; Libra, Massimo/0000-0002-7232-7737; Lehmann, Brian D./0000-0003-0407-5248; Franklin, Richard A./0000-0003-0299-9578; LESLIE, Nicholas/0000-0001-5131-0541; McCubrey, James/0000-0001-6027-3156	MRC [G9403619] Funding Source: UKRI; NATIONAL CANCER INSTITUTE [R01CA098195] Funding Source: NIH RePORTER; Medical Research Council [G9403619] Funding Source: Medline; NCI NIH HHS [R01 CA098195, R01CA098195] Funding Source: Medline	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abdel-Rahman MH, 2006, J CLIN ONCOL, V24, P288, DOI 10.1200/JCO.2005.02.2418; Agrawal S, 2006, HUM MOL GENET, V15, P777, DOI 10.1093/hmg/ddi492; Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9; Bose S, 2002, HUM PATHOL, V33, P405, DOI 10.1053/hupa.2002.124721; Chiang GG, 2005, J BIOL CHEM, V280, P25485, DOI 10.1074/jbc.M501707200; Clark AS, 2002, MOL CANCER THER, V1, P707; Davis JM, 2003, CLIN CANCER RES, V9, P1161; DeGraffenried LA, 2004, CLIN CANCER RES, V10, P8059, DOI 10.1158/1078-0432.CCR-04-0035; Eng C, 2003, HUM MUTAT, V22, P183, DOI 10.1002/humu.10257; Franke TF, 1997, SCIENCE, V275, P665, DOI 10.1126/science.275.5300.665; Frech M, 1997, J BIOL CHEM, V272, P8474, DOI 10.1074/jbc.272.13.8474; Garcia JM, 2004, GENE CHROMOSOME CANC, V41, P117, DOI 10.1002/gcc.20062; Inoki K, 2005, NAT GENET, V37, P19, DOI 10.1038/ng1494; Jin J, 2005, ONCOGENE, V24, P5459, DOI 10.1038/sj.onc.1208704; Klos KS, 2006, CANCER RES, V66, P2028, DOI 10.1158/0008-5472.CAN-04-4559; Lee JS, 2004, APPL IMMUNOHISTO M M, V12, P205, DOI 10.1097/00129039-200409000-00004; Lehmann BD, 2007, CELL CYCLE, V6, P595, DOI 10.4161/cc.6.5.3901; Leslie NR, 2000, BIOCHEM J, V346, P827, DOI 10.1042/0264-6021:3460827; Lin HJ, 2005, BRIT J CANCER, V93, P1372, DOI 10.1038/sj.bjc.6602862; Luo J, 2005, CELL CYCLE, V4, P1309, DOI 10.4161/cc.4.10.2062; Lynch ED, 1997, AM J HUM GENET, V61, P1254, DOI 10.1086/301639; Maehama T, 1998, J BIOL CHEM, V273, P13375, DOI 10.1074/jbc.273.22.13375; Marsh DJ, 1998, HUM MOL GENET, V7, P507, DOI 10.1093/hmg/7.3.507; Martelli AM, 2006, LEUKEMIA, V20, P911, DOI 10.1038/sj.leu.2404245; Martelli AM, 2007, CURR MED CHEM, V14, P2009; Nagata Y, 2004, CANCER CELL, V6, P117, DOI 10.1016/j.ccr.2004.06.022; Shelton JG, 2005, EXPERT OPIN THER TAR, V9, P1009, DOI 10.1517/14728222.9.5.1009; Shelton JG, 2005, CELL CYCLE, V4, P822, DOI 10.4161/cc.4.6.1724; Singh B, 1998, GENE CHROMOSOME CANC, V21, P166, DOI 10.1002/(SICI)1098-2264(199802)21:2<166::AID-GCC13>3.3.CO;2-V; Steelman LS, 2004, EXPERT OPIN THER TAR, V8, P537, DOI 10.1517/14728222.8.6.537; Stokoe D, 1997, SCIENCE, V277, P567, DOI 10.1126/science.277.5325.567; Tokunaga Eriko, 2006, Breast Cancer, V13, P137, DOI 10.2325/jbcs.13.137; Tsutsui S, 2005, CANCER-AM CANCER SOC, V104, P2048, DOI 10.1002/cncr.21471; Tsutsui S, 2005, ONCOLOGY-BASEL, V68, P398, DOI 10.1159/000086981; van Nimwegen MJ, 2006, MOL PHARMACOL, V70, P1330, DOI 10.1124/mol.106.026195; Weinstein-Oppenheimer CR, 2001, CLIN CANCER RES, V7, P2898	36	117	131	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 3	2008	27	29					4086	4095		10.1038/onc.2008.49	http://dx.doi.org/10.1038/onc.2008.49			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	321RV	18332865	Green Accepted			2022-12-28	WOS:000257325100008
J	Langenau, DM; Keefe, MD; Storer, NY; Jette, CA; Smith, ACH; Ceol, CJ; Bourque, C; Look, AT; Zon, LI				Langenau, D. M.; Keefe, M. D.; Storer, N. Y.; Jette, C. A.; Smith, A. C. H.; Ceol, C. J.; Bourque, C.; Look, A. T.; Zon, L. I.			Co-injection strategies to modify radiation sensitivity and tumor initiation in transgenic Zebrafish	ONCOGENE			English	Article						Myc; ras; heat-shock; T-cell acute lymphoblastic leukemia; rhabdomyosarcoma	ACUTE LYMPHOBLASTIC-LEUKEMIA; CELLS; TRANSPLANTATION; EXPRESSION; APOPTOSIS; GENESIS; MODEL	The zebrafish has emerged as a powerful genetic model of cancer, but has been limited by the use of stable transgenic approaches to induce disease. Here, a co-injection strategy is described that capitalizes on both the numbers of embryos that can be microinjected and the ability of transgenes to segregate together and exert synergistic effects in forming tumors. Using this mosaic transgenic approach, gene pathways involved in tumor initiation and radiation sensitivity have been identified.	[Langenau, D. M.; Keefe, M. D.; Storer, N. Y.; Smith, A. C. H.; Ceol, C. J.; Bourque, C.; Zon, L. I.] Childrens Hosp, Stem Cell Program, Boston, MA 02115 USA; [Langenau, D. M.; Keefe, M. D.; Storer, N. Y.; Smith, A. C. H.; Ceol, C. J.; Bourque, C.; Zon, L. I.] Childrens Hosp, Div Hematol Oncol, Boston, MA 02115 USA; [Langenau, D. M.; Keefe, M. D.; Storer, N. Y.; Smith, A. C. H.; Ceol, C. J.; Bourque, C.; Zon, L. I.] Dana Farber Canc Inst, Boston, MA 02115 USA	Harvard University; Boston Children's Hospital; Harvard University; Boston Children's Hospital; Harvard University; Dana-Farber Cancer Institute	Langenau, DM (corresponding author), Childrens Hosp, Stem Cell Program, 1 Blackfan Circle,Karp 7, Boston, MA 02115 USA.	dlangenau@enders.tch.harvard.edu	Langenau, David/GXI-0197-2022	Langenau, David/0000-0001-6664-8318	NATIONAL CANCER INSTITUTE [R01CA104605, R01CA103846, R01CA119066, R01CA093152, P01CA068484] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL088664] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K01DK074555] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007753] Funding Source: NIH RePORTER; Howard Hughes Medical Institute Funding Source: Medline; NCI NIH HHS [CA68484-11, CA104605-03, 5R01 CA103846-02, R01 CA104605, R01 CA093152, 1R01 CA119066-01, R01 CA119066, P01 CA068484, R01 CA103846, CA93152-05] Funding Source: Medline; NHLBI NIH HHS [HL-088664, R01 HL088664] Funding Source: Medline; NIDDK NIH HHS [1KO1 DK074555-01, K01 DK074555] Funding Source: Medline; NIGMS NIH HHS [T32 GM007753] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); Howard Hughes Medical Institute(Howard Hughes Medical Institute); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Berghmans S, 2005, P NATL ACAD SCI USA, V102, P407, DOI 10.1073/pnas.0406252102; Burns CE, 2005, GENE DEV, V19, P2331, DOI 10.1101/gad.1337005; Halloran MC, 2000, DEVELOPMENT, V127, P1953; Haramis APG, 2006, EMBO REP, V7, P444, DOI 10.1038/sj.embor.7400638; Hong WY, 2004, CANCER RES, V64, P7256, DOI 10.1158/0008-5472.CAN-04-0931; Jessen JR, 2001, GENESIS, V29, P156, DOI 10.1002/gene.1019; Kratz E, 2006, CELL DEATH DIFFER, V13, P1631, DOI 10.1038/sj.cdd.4402016; Langenau DM, 2007, GENE DEV, V21, P1382, DOI 10.1101/gad.1545007; Langenau DM, 2005, BLOOD, V105, P3278, DOI 10.1182/blood-2004-08-3073; Langenau DM, 2005, P NATL ACAD SCI USA, V102, P6068, DOI 10.1073/pnas.0408708102; Langenau DM, 2003, SCIENCE, V299, P887, DOI 10.1126/science.1080280; Le XN, 2007, P NATL ACAD SCI USA, V104, P9410, DOI 10.1073/pnas.0611302104; Oda E, 2000, SCIENCE, V288, P1053, DOI 10.1126/science.288.5468.1053; Patton EE, 2005, CURR BIOL, V15, P249, DOI 10.1016/j.cub.2005.01.031; Pyati UJ, 2005, DEVELOPMENT, V132, P2333, DOI 10.1242/dev.01806; Sabaawy HE, 2006, P NATL ACAD SCI USA, V103, P15166, DOI 10.1073/pnas.0603349103; Traver D, 2004, BLOOD, V104, P1298, DOI 10.1182/blood-2004-01-0100; Traver D, 2003, NAT IMMUNOL, V4, P1238, DOI 10.1038/ni1007; Tropepe V, 2000, SCIENCE, V287, P2032, DOI 10.1126/science.287.5460.2032; Xiao T, 2003, J NEUROSCI, V23, P4190	20	55	57	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2008	27	30					4242	4248		10.1038/onc.2008.56	http://dx.doi.org/10.1038/onc.2008.56			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	324DB	18345029	Green Accepted			2022-12-28	WOS:000257496800011
J	Garcia-Maceira, P; Mateo, J				Garcia-Maceira, P.; Mateo, J.			Silibinin inhibits hypoxia-inducible factor-1 alpha and mTOR/p70S6K/4E-BP1 signalling pathway in human cervical and hepatoma cancer cells: implications for anticancer therapy	ONCOGENE			English	Article						hypoxia-inducible factor-1 alpha; silibinin; cancer; mTOR; angiogenesis	ENDOTHELIAL GROWTH-FACTOR; MAMMALIAN TARGET; FACTOR 1-ALPHA; VEGF EXPRESSION; GENE-EXPRESSION; NITRIC-OXIDE; O-2 TENSION; FACTOR-I; MTOR; RAPAMYCIN	The hypoxia-inducible factor 1 (HIF-1) plays a critical role for tumour adaptation to microenvironmental hypoxia, and represents an appealing chemotherapeutic target. Silibinin is a nontoxic flavonoid reported to exhibit anticancer properties. However, the mechanisms by which silibinin inhibits tumour growth are not fully understood. In this study, silibinin was found to inhibit hypoxiainduced HIF-1 alpha accumulation and HIF-1 transcriptional activity in human cervical (HeLa) and hepatoma (Hep3B) cells. Neither HIEF-1 alpha protein degradation rate nor HIEF-1 alpha steady-state mRNA level was affected by silibinin. Rather, we found that suppression of HIF-1 alpha accumulation by silibinin correlated with strong dephosphorylation of mammalian target of rapamycin (mTOR) and its effectors ribosomal protein S6 kinase (p70S6K) and eukaryotic initiation factor 4E-binding protein-1 (4E-BP1), a pathway known to regulate HIEF-1 alpha expression at the translational level. Silibinin also activated Akt, a mechanistic feature exhibited by established mTOR inhibitors in many tumour cells. Moreover, silibinin reduced hypoxia-induced vascular endothelial growth factor (VEGF) release by HeLa and Hep3B cells, and this effect was potentiated by the PI3K/Akt inhibitor LY294002. Finally, silibinin was found to be a potent inhibitor of cell proliferation. These results show that silibinin is an effective inhibitor of HIF-1 and provide new perspectives into the mechanism of its anticancer activity.	[Garcia-Maceira, P.; Mateo, J.] CNIC, Dept Regenerat Cardiol, E-28029 Madrid, Spain	Centro Nacional de Investigaciones Cardiovasculares (CNIC)	Mateo, J (corresponding author), CNIC, Dept Regenerat Cardiol, Melchor Fernandez Almagro 3, E-28029 Madrid, Spain.	jmateo@cnic.es	de Castro, Jesus Mateo/N-4434-2014	de Castro, Jesus Mateo/0000-0003-4459-7083	ISCIII [FIS03-0924, FIS07-1168]; Centro Nacional de Investigaciones Cardiovasculares (CNIC); Spanish Ministry of Health and Consumer Affairs; Pro-CNIC Foundation	ISCIII(Instituto de Salud Carlos III); Centro Nacional de Investigaciones Cardiovasculares (CNIC); Spanish Ministry of Health and Consumer Affairs(Spanish Government); Pro-CNIC Foundation	This work was supported by grants from ISCIII (FIS03-0924 and FIS07-1168 to JM). PG-M holds a fellowship from the Centro Nacional de Investigaciones Cardiovasculares (CNIC)-Bancaja predoctoral program. CNIC is supported by the Spanish Ministry of Health and Consumer Affairs and the Pro-CNIC Foundation.	Alvarez-Tejado M, 2002, J BIOL CHEM, V277, P13508, DOI 10.1074/jbc.M200017200; Bhatia N, 1999, CANCER LETT, V147, P77, DOI 10.1016/S0304-3835(99)00276-1; Bjornsti MA, 2004, NAT REV CANCER, V4, P335, DOI 10.1038/nrc1362; Brown JM, 1998, CANCER RES, V58, P1408; Brugarolas J, 2004, GENE DEV, V18, P2893, DOI 10.1101/gad.1256804; Castedo M, 2002, CELL DEATH DIFFER, V9, P99, DOI 10.1038/sj/cdd/4400978; Chen PN, 2005, CHEM-BIOL INTERACT, V156, P141, DOI 10.1016/j.cbi.2005.08.005; Deep G, 2008, ONCOGENE, V27, P3986, DOI 10.1038/onc.2008.45; Fan QW, 2006, CANCER CELL, V9, P341, DOI 10.1016/j.ccr.2006.03.029; Ferrara N, 2004, ENDOCR REV, V25, P581, DOI 10.1210/er.2003-0027; Fingar DC, 2004, ONCOGENE, V23, P3151, DOI 10.1038/sj.onc.1207542; Giaccia A, 2003, NAT REV DRUG DISCOV, V2, P803, DOI 10.1038/nrd1199; Gu M, 2007, CANCER RES, V67, P3483, DOI 10.1158/0008-5472.CAN-06-3955; Guertin DA, 2007, CANCER CELL, V12, P9, DOI 10.1016/j.ccr.2007.05.008; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; Hockel M, 2001, JNCI-J NATL CANCER I, V93, P266, DOI 10.1093/jnci/93.4.266; Huang JX, 2008, MOL CELL BIOL, V28, P4104, DOI 10.1128/MCB.00289-08; Hudson CC, 2002, MOL CELL BIOL, V22, P7004, DOI 10.1128/MCB.22.20.7004-7014.2002; Jiang BH, 1996, AM J PHYSIOL-CELL PH, V271, pC1172, DOI 10.1152/ajpcell.1996.271.4.C1172; Lah JJ, 2007, WORLD J GASTROENTERO, V13, P5299, DOI 10.3748/wjg.v13.i40.5299; Laughner E, 2001, MOL CELL BIOL, V21, P3995, DOI 10.1128/MCB.21.12.3995-4004.2001; Manning BD, 2004, J CELL BIOL, V167, P399, DOI 10.1083/jcb.200408161; Masson N, 2001, EMBO J, V20, P5197, DOI 10.1093/emboj/20.18.5197; Mateo J, 2003, BIOCHEM J, V376, P537, DOI 10.1042/BJ20031155; O'Reilly KE, 2006, CANCER RES, V66, P1500, DOI 10.1158/0008-5472.CAN-05-2925; Pore N, 2004, MOL BIOL CELL, V15, P4841, DOI 10.1091/mbc.E04-05-0374; Sabatini DM, 2006, NAT REV CANCER, V6, P729, DOI 10.1038/nrc1974; Saller R, 2001, DRUGS, V61, P2035, DOI 10.2165/00003495-200161140-00003; Sarbassov DD, 2006, MOL CELL, V22, P159, DOI 10.1016/j.molcel.2006.03.029; Sarbassov DD, 2005, SCIENCE, V307, P1098, DOI 10.1126/science.1106148; Schofield CJ, 2004, NAT REV MOL CELL BIO, V5, P343, DOI 10.1038/nrm1366; Semenza GL, 2002, TRENDS MOL MED, V8, pS62, DOI 10.1016/S1471-4914(02)02317-1; Semenza GL, 2003, NAT REV CANCER, V3, P721, DOI 10.1038/nrc1187; Singh RP, 2008, CANCER RES, V68, P2043, DOI 10.1158/0008-5472.CAN-07-6247; Singh RP, 2005, ONCOGENE, V24, P1188, DOI 10.1038/sj.onc.1208276; Sun SY, 2005, CANCER RES, V65, P7052, DOI 10.1158/0008-5472.CAN-05-0917; Thomas GV, 2006, NAT MED, V12, P122, DOI 10.1038/nm1337; van den Beucken T, 2006, CANCER BIOL THER, V5, P749, DOI 10.4161/cbt.5.7.2972; Varghese L, 2005, CLIN CANCER RES, V11, P8441, DOI 10.1158/1078-0432.CCR-05-1646; WANG GL, 1995, J BIOL CHEM, V270, P1230, DOI 10.1074/jbc.270.3.1230; WANG GL, 1995, P NATL ACAD SCI USA, V92, P5510, DOI 10.1073/pnas.92.12.5510; Wellington K, 2001, BIODRUGS, V15, P465, DOI 10.2165/00063030-200115070-00005; Wood SM, 1998, J BIOL CHEM, V273, P8360, DOI 10.1074/jbc.273.14.8360; Wright G, 2003, J BIOL CHEM, V278, P20235, DOI 10.1074/jbc.M301391200; Xu Q, 2005, ONCOGENE, V24, P5552, DOI 10.1038/sj.onc.1208719; Zhong H, 1999, CANCER RES, V59, P5830; Zhong H, 2000, CANCER RES, V60, P1541; Zi XL, 1998, CLIN CANCER RES, V4, P1055; Zi ZL, 1999, P NATL ACAD SCI USA, V96, P7490, DOI 10.1073/pnas.96.13.7490	49	131	135	1	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 22	2009	28	3					313	324		10.1038/onc.2008.398	http://dx.doi.org/10.1038/onc.2008.398			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	395UZ	18978810				2022-12-28	WOS:000262550300001
J	Kim, HJ; Kim, YM; Lim, S; Nam, YK; Jeong, J; Kim, HJ; Lee, KJ				Kim, H. J.; Kim, Y. M.; Lim, S.; Nam, Y. K.; Jeong, J.; Kim, H-J; Lee, K-J			Ubiquitin C-terminal hydrolase-L1 is a key regulator of tumor cell invasion and metastasis	ONCOGENE			English	Article						UCH-L1; deubiquitinating enzyme; metastasis; tumor invasion; lung cancer; Akt activation; proteomics	LUNG-CANCER; ENDOTHELIAL-CELLS; PGP9.5; PROTEIN; PATHWAY; KINASE; GENE; INHIBITOR; P27(KIP1); MOTILITY	Ubiquitin C-terminal hydrolase-L1 (UCH-L1) catalyses the hydrolysis of ubiquitin ester and amide mainly in neuronal cells. Recently it was proposed as a marker with a potential role in carcinogenesis. However, the molecular mechanism underlying the biological function of UCH-L1 in tumor cells is poorly understood. We found that UCH-L1 is highly expressed in non-small lung cancer cell line H157, having high invasive potential, and that the expression of UCH-L1 in tumor cells enhances their invasive potential in vitro and in vivo. UCH-L1 changes cell morphology by regulating cell adhesion through Akt-mediated pathway. Suppressing UCH-L1 expression by RNAi significantly suppressed the invasion in vitro and in vivo, and the activation of Akt and downstream mitogen activated protein kinases c-Jun N-terminal kinases and p38, but not ERK. In Akt-negative mutants, overexpression of UCH-L1 does not affect the invasion and migration capability of H157 cells. These results suggest that UCH-L1 is a key molecule to regulate tumor-cell invasion by upstream activation of Akt.	[Lee, K-J] Ewha Womans Univ, Ctr Cell Signaling & Drug Discovery Res, Coll Pharm, Seoul 120750, South Korea; Ewha Womans Univ, Div Life & Pharmaceut Sci, Seoul 120750, South Korea	Ewha Womans University; Ewha Womans University	Lee, KJ (corresponding author), Ewha Womans Univ, Ctr Cell Signaling & Drug Discovery Res, Coll Pharm, Seoul 120750, South Korea.	kjl@ewha.ac.kr			KOSEF [R15-2006-002, FPR05A2-480]	KOSEF(Korea Science and Engineering Foundation)	This study was supported by SK Corp. Korea, KOSEF through the Center for Cell Signaling & Drug Discovery Research (CCS & DDR, R15-2006-002) at Ewha Womans University, by KOSEF Grant FPR05A2-480. Kim HJ, Nam YK, Kim YM, Kim HJ and Lim S were supported by the Brain Korea 21 project.	Brichory F, 2001, CANCER RES, V61, P7908; Caballero OL, 2002, ONCOGENE, V21, P3003, DOI 10.1038/sj.onc.1205390; Diebold BA, 2004, J BIOL CHEM, V279, P28136, DOI 10.1074/jbc.M313891200; Gong B, 2006, CELL, V126, P775, DOI 10.1016/j.cell.2006.06.046; Hibi K, 1999, AM J PATHOL, V155, P711, DOI 10.1016/S0002-9440(10)65169-3; Honda K, 1998, J CELL BIOL, V140, P1383, DOI 10.1083/jcb.140.6.1383; Huang C, 2004, CELL CYCLE, V3, P4, DOI 10.4161/cc.3.1.601; Kim YM, 2007, J PROTEOME RES, V6, P3278, DOI 10.1021/pr070168k; Kurisu S, 2005, ONCOGENE, V24, P1309, DOI 10.1038/sj.onc.1208177; Liu YC, 2003, CHEM BIOL, V10, P837, DOI 10.1016/j.chembiol.2003.08.010; Liu YC, 2002, CELL, V111, P209, DOI 10.1016/S0092-8674(02)01012-7; LOWE J, 1990, J PATHOL, V161, P153, DOI 10.1002/path.1711610210; Osaka H, 2003, HUM MOL GENET, V12, P1945, DOI 10.1093/hmg/ddg211; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; Reddy KB, 2003, CANCER METAST REV, V22, P395, DOI 10.1023/A:1023781114568; Rosas SLB, 2001, CANCER LETT, V170, P73, DOI 10.1016/S0304-3835(01)00449-9; Saigoh K, 1999, NAT GENET, V23, P47, DOI 10.1038/12647; Song EJ, 2005, MOL CELL BIOL, V25, P2511, DOI 10.1128/MCB.25.6.2511-2524.2005; Tezel E, 2000, CLIN CANCER RES, V6, P4764; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; Wojciak-Stothard B, 2005, AM J PHYSIOL-LUNG C, V288, pL749, DOI 10.1152/ajplung.00361.2004; Yamana N, 2006, MOL CELL BIOL, V26, P6844, DOI 10.1128/MCB.00283-06; Yamazaki T, 2002, CLIN CANCER RES, V8, P192; Yoeli-Lerner M, 2006, CELL CYCLE, V5, P603, DOI 10.4161/cc.5.6.2561	24	119	125	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 8	2009	28	1					117	127		10.1038/onc.2008.364	http://dx.doi.org/10.1038/onc.2008.364			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	392HP	18820707				2022-12-28	WOS:000262294100012
J	Moller, A; House, CM; Wong, CSF; Scanlon, DB; Liu, MCP; Ronai, Z; Bowtell, DDL				Moller, A.; House, C. M.; Wong, C. S. F.; Scanlon, D. B.; Liu, M. C. P.; Ronai, Z.; Bowtell, D. D. L.			Inhibition of Siah ubiquitin ligase function	ONCOGENE			English	Article						ubiquitin; degradation; hypoxia	HYPOXIA-INDUCIBLE FACTOR; FACTOR 1-ALPHA; TRANSCRIPTIONAL REPRESSOR; PROTEASOME PATHWAY; O-2 HOMEOSTASIS; DEGRADATION; HOMOLOGS; PROTEIN; SINA; HIF	Tumor hypoxia induces the upregulation of hypoxiainducible factor 1 alpha (Hif-1 alpha), which in turn induces the expression of genes including VEGF to recruit new blood vessel outgrowth, enabling tumor growth and metastasis. Interference with the Hif-1 pathway and neoangiogenesis is an attractive antitumor target. The hydroxylation of Hif-1 alpha by prolyl-hydroxylase (PHD) proteins during normoxia serves as a recognition motif for its proteasomal degradation. However, under hypoxic conditions, hydroxylation is inhibited and furthermore, PHD proteins are themselves polyubiquitylated and degraded by Siah ubiquitin ligases. Our data demonstrate for the first time that inhibition of the interaction between Siah and PHD proteins using a fragment derived from a Drosophila protein ( phyllopod) interferes with the PHD degradation. Furthermore, cells stably expressing the phyllopod fragment display reduced upregulation of Hif-1 alpha protein levels and Hif-1-mediated gene expression under hypoxia. In a syngeneic mouse model of breast cancer, the phyllopod fragment reduced tumor growth and neoangiogenesis and prolonged survival of the mice. In addition, levels of Hif-1 alpha and its target Glut-1 are reduced in tumors expressing the phyllopod fragment. These data show, in a proof-of-principle study, that Siah protein, the most upstream component of the hypoxia pathway yet identified, is a viable drug target for antitumor therapies.	[Moller, A.; House, C. M.; Wong, C. S. F.; Liu, M. C. P.; Bowtell, D. D. L.] Peter MacCallum Canc Ctr, Canc Genom & Biochem Lab, Melbourne, Vic 3002, Australia; [Moller, A.; Scanlon, D. B.; Bowtell, D. D. L.] Univ Melbourne, Dept Biochem & Mol Biol, Parkville, Vic 3052, Australia; [Ronai, Z.] Burnham Inst Med Res, Signal Transduct Program, La Jolla, CA USA	Peter Maccallum Cancer Center; University of Melbourne; Sanford Burnham Prebys Medical Discovery Institute	Bowtell, DDL (corresponding author), Peter MacCallum Canc Ctr, Canc Genom & Biochem Lab, St Andrews Pl, Melbourne, Vic 3002, Australia.	d.bowtell@petermac.org	Bowtell, David/H-1007-2016; Wong, Christina SF/G-9972-2017; Möller, Andreas/O-1063-2015	Bowtell, David/0000-0001-9089-7525; Möller, Andreas/0000-0002-8618-6998; RONAI, ZEEV/0000-0002-3859-0400	Australian National Health and Medical Research Council (NHMRC) [400321, 509331]; NATIONAL CANCER INSTITUTE [R01CA111515] Funding Source: NIH RePORTER	Australian National Health and Medical Research Council (NHMRC)(National Health and Medical Research Council (NHMRC) of Australia); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	The EO771 cells were a kind gift from Dr Robin Anderson, Peter MacCallum Cancer Centre. The expression plasmid for FLAG-TIEG-1 was provided by Steven Johnsen and Thomas Spelsburg ( Mayo Clinic and Foundation, Rochester, NY, USA). The expression plasmid for Myc-FIH-1 was a kind gift from Daniel Peet ( School of Molecular and Biomedical Science, University of Adelaide, Adelaide, Australia). This study was funded by grants of the Australian National Health and Medical Research Council (NHMRC) to AM, CH and DB ( no. 400321 and no. 509331).	Bottger A, 1997, J MOL BIOL, V269, P744, DOI 10.1006/jmbi.1997.1078; Boulton SJ, 2000, EMBO J, V19, P5376, DOI 10.1093/emboj/19.20.5376; CASEY AE, 1951, P SOC EXP BIOL MED, V77, P358; Chene P, 2000, J MOL BIOL, V299, P245, DOI 10.1006/jmbi.2000.3738; DELLA NG, 1993, DEVELOPMENT, V117, P1333; Depaux A, 2006, BIOCHEM BIOPH RES CO, V348, P857, DOI 10.1016/j.bbrc.2006.07.092; Dickins RA, 2002, MOL CELL BIOL, V22, P2294, DOI 10.1128/MCB.22.7.2294-2303.2002; Epstein ACR, 2001, CELL, V107, P43, DOI 10.1016/S0092-8674(01)00507-4; Freedman SJ, 2003, NAT STRUCT BIOL, V10, P504, DOI 10.1038/nsb936; Frew IJ, 2003, MOL CELL BIOL, V23, P9150, DOI 10.1128/MCB.23.24.9150-9161.2003; Fukuba H, 2007, BIOCHEM BIOPH RES CO, V353, P324, DOI 10.1016/j.bbrc.2006.12.051; Germani A, 2003, ONCOGENE, V22, P8845, DOI 10.1038/sj.onc.1206994; Glickman MH, 2002, PHYSIOL REV, V82, P373, DOI 10.1152/physrev.00027.2001; Hochstrasser M, 2000, NAT CELL BIOL, V2, pE153, DOI 10.1038/35019643; Holinger EP, 1999, J BIOL CHEM, V274, P13298, DOI 10.1074/jbc.274.19.13298; House CM, 2006, STRUCTURE, V14, P695, DOI 10.1016/j.str.2005.12.013; House CM, 2003, P NATL ACAD SCI USA, V100, P3101, DOI 10.1073/pnas.0534783100; Hu G, 1997, GENOMICS, V46, P103, DOI 10.1006/geno.1997.4997; Huang LE, 1998, P NATL ACAD SCI USA, V95, P7987, DOI 10.1073/pnas.95.14.7987; Iyer NV, 1998, GENE DEV, V12, P149, DOI 10.1101/gad.12.2.149; Jaakkola P, 2001, SCIENCE, V292, P468, DOI 10.1126/science.1059796; Johnsen SA, 2002, J BIOL CHEM, V277, P30754, DOI 10.1074/jbc.M204812200; Kane RC, 2003, ONCOLOGIST, V8, P508, DOI 10.1634/theoncologist.8-6-508; Khurana A, 2006, J BIOL CHEM, V281, P35316, DOI 10.1074/jbc.M606568200; Lando D, 2002, GENE DEV, V16, P1466, DOI 10.1101/gad.991402; Laney JD, 1999, CELL, V97, P427, DOI 10.1016/S0092-8674(00)80752-7; Li SH, 1997, CELL, V90, P469, DOI 10.1016/S0092-8674(00)80507-3; Maxwell PH, 1999, NATURE, V399, P271, DOI 10.1038/20459; Nakayama K, 2004, CELL, V117, P941, DOI 10.1016/j.cell.2004.06.001; Nakayama K, 2007, BIOCHEM J, V401, P217, DOI 10.1042/BJ20061135; Polekhina G, 2002, NAT STRUCT BIOL, V9, P68, DOI 10.1038/nsb743; Salceda S, 1997, J BIOL CHEM, V272, P22642, DOI 10.1074/jbc.272.36.22642; Schofield CJ, 2004, NAT REV MOL CELL BIO, V5, P343, DOI 10.1038/nrm1366; Semenza GL, 2000, BIOCHEM PHARMACOL, V59, P47, DOI 10.1016/S0006-2952(99)00292-0; Semenza GL, 1999, ANNU REV CELL DEV BI, V15, P551, DOI 10.1146/annurev.cellbio.15.1.551; Tang AH, 1997, CELL, V90, P459, DOI 10.1016/S0092-8674(00)80506-1; Wang JL, 2000, CANCER RES, V60, P1498; Wasylyk C, 1999, ONCOGENE, V18, P1921, DOI 10.1038/sj.onc.1202528; Zhang JS, 1998, GENE DEV, V12, P1775, DOI 10.1101/gad.12.12.1775	39	66	73	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2009	28	2					289	296		10.1038/onc.2008.382	http://dx.doi.org/10.1038/onc.2008.382			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	395CY	18850011	Green Accepted			2022-12-28	WOS:000262501100012
J	Chien, J; Narita, K; Rattan, R; Giri, S; Shridhar, R; Staub, J; Beleford, D; Lai, J; Roberts, LR; Molina, J; Kaufmann, SH; Prendergast, GC; Shridhar, V				Chien, J.; Narita, K.; Rattan, R.; Giri, S.; Shridhar, R.; Staub, J.; Beleford, D.; Lai, J.; Roberts, L. R.; Molina, J.; Kaufmann, S. H.; Prendergast, G. C.; Shridhar, V.			A role for candidate tumor-suppressor gene TCEAL7 in the regulation of c-Myc activity, cyclin D1 levels and cellular transformation	ONCOGENE			English	Article						TCEAL7; Myc; cyclin D1; tumor suppressor; transformation	OVARIAN-CARCINOMA CELLS; RNA-POLYMERASE-II; BURKITT-LYMPHOMA; CANCER CELLS; EARLY-STAGE; NETWORK; PROTEIN; FIDELITY; SCREEN; HTRA1	The pathophysiological mechanisms that drive the development and progression of epithelial ovarian cancer remain obscure. Recently, we identified TCEAL7 as a transcriptional regulatory protein often downregulated in epithelial ovarian cancer. However, the biological significance of such downregulation in cancer is not currently known. Here, we show that TCEAL7 is downregulated frequently in many human cancers and that in immortalized human ovarian epithelial cells this event promotes anchorage-independent cell growth. Mechanistic investigations revealed that TCEAL7 associates with cyclin D1 promoter containing Myc E-box sequence and transcriptionally represses cyclin D1 expression. Moreover, downregulation of TCEAL7 promotes DNA-binding activity of Myc-Max, and upregulates the promoter activity of c-Myc-target gene, ornithine decarboxylase (ODC), whereas enhanced expression of TCEAL7 inhibits Myc-induced promoter activity of ODC. Our findings suggest that TCEAL7 may restrict ovarian epithelial cell transformation by limiting Myc activity. These results also suggest a potential, alternative mechanism by which c-Myc activity may be deregulated in cancer by the downregulation of TCEAL7.	[Chien, J.; Rattan, R.; Staub, J.; Beleford, D.; Shridhar, V.] Mayo Clin, Coll Med, Div Expt Pathol, Rochester, MN USA; [Narita, K.] Univ Yamanashi, Fac Med, Dept Anat & Cell Biol, Chuo Yamanashi, Japan; [Giri, S.] Med Univ S Carolina, Children Res Inst, Dept Pediat, Charleston, SC 29425 USA; [Shridhar, R.] Wayne State Univ, Dept Radiat Oncol, Sch Med, Detroit, MI 48202 USA; [Lai, J.; Roberts, L. R.] Mayo Clin, Coll Med, Dept Gastroenterol & Hepatol, Rochester, MN USA; [Molina, J.] Mayo Clin, Coll Med, Dept Med Oncol, Rochester, MN USA; [Kaufmann, S. H.] Mayo Clin, Coll Med, Dept Oncol Res, Rochester, MN USA; [Prendergast, G. C.] Lankenau Inst Med Res, Wynnewood, PA USA	Mayo Clinic; University of Yamanashi; Medical University of South Carolina; Wayne State University; Mayo Clinic; Mayo Clinic; Mayo Clinic; Lankenau Medical Center; Lankenau Institute for Medical Research	Shridhar, V (corresponding author), Mayo Coll Med, Div Expt Pathol, 200 1st St SW,2-46 Stabile, Rochester, MN 55905 USA.	shridhar.vijayalakshmi@mayo.edu	Seal, Sudipta/A-7698-2012; Lai, Jinping/AAZ-6861-2021; Narita, Keishi/E-3539-2010; Chien, Jeremy/AID-8939-2022	Narita, Keishi/0000-0002-7602-8523; Kaufmann, Scott/0000-0002-4900-7145; Roberts, Lewis/0000-0001-7885-8574; Chien, Jeremy/0000-0003-4744-8374	Department of Defense OCRP [W81XWH-04-1-0085]; NATIONAL CANCER INSTITUTE [K12CA090628] Funding Source: NIH RePORTER	Department of Defense OCRP(United States Department of Defense); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This study was funded by Fraternal Order of Eagle to VS, by Department of Defense OCRP W81XWH-04-1-0085 to VS, and by Edith and Bernie Waterman Foundation and the Mayo Foundation to VS.	Baudino TA, 2001, MOL CELL BIOL, V21, P691, DOI 10.1128/MCB.21.3.691-702.2001; Bell DA, 2005, MODERN PATHOL, V18, pS19, DOI 10.1038/modpathol.3800306; Berns K, 2004, NATURE, V428, P431, DOI 10.1038/nature02371; Budhram-Mahadeo VS, 2006, EXPERT OPIN THER TAR, V10, P15, DOI 10.1517/14728222.10.1.15; Chien J, 1999, ONCOGENE, V18, P3376, DOI 10.1038/sj.onc.1202690; Chien J, 2005, ONCOGENE, V24, P5089, DOI 10.1038/sj.onc.1208700; Chien J, 2004, ONCOGENE, V23, P1636, DOI 10.1038/sj.onc.1207271; Chien J, 2006, J CLIN INVEST, V116, P1994, DOI 10.1172/JCI27698; Conover CA, 1998, EXP CELL RES, V238, P439, DOI 10.1006/excr.1997.3861; DALLAFAVERA R, 1982, P NATL ACAD SCI-BIOL, V79, P7824, DOI 10.1073/pnas.79.24.7824; Elliott K, 1999, ONCOGENE, V18, P3564, DOI 10.1038/sj.onc.1202670; Fernandez PC, 2003, GENE DEV, V17, P1115, DOI 10.1101/gad.1067003; Fukumoto M, 2006, PATHOL INT, V56, P233, DOI 10.1111/J.1440-1827.2006.01960.x; GILLETT C, 1994, CANCER RES, V54, P1812; Gomis RR, 2006, CANCER CELL, V10, P203, DOI 10.1016/j.ccr.2006.07.019; Grandori C, 2000, ANNU REV CELL DEV BI, V16, P653, DOI 10.1146/annurev.cellbio.16.1.653; Hall M, 1996, ADV CANCER RES, V68, P67, DOI 10.1016/S0065-230X(08)60352-8; Jeon C, 1996, P NATL ACAD SCI USA, V93, P13677, DOI 10.1073/pnas.93.24.13677; Kalli KR, 2002, ENDOCRINOLOGY, V143, P3259, DOI 10.1210/en.2001-211408; Lamb J, 2003, CELL, V114, P323, DOI 10.1016/S0092-8674(03)00570-1; Massague J, 2005, GENE DEV, V19, P2783, DOI 10.1101/gad.1350705; Nesbit CE, 1999, ONCOGENE, V18, P3004, DOI 10.1038/sj.onc.1202746; Nilsson JA, 2005, CANCER CELL, V7, P433, DOI 10.1016/j.ccr.2005.03.036; Orian A, 2003, GENE DEV, V17, P1101, DOI 10.1101/gad.1066903; Oster SK, 2002, ADV CANCER RES, V84, P81, DOI 10.1016/S0065-230X(02)84004-0; Shridhar V, 2002, CANCER RES, V62, P262; Shridhar V, 2001, CANCER RES, V61, P5895; Staub J, 2007, ONCOGENE, V26, P4969, DOI 10.1038/sj.onc.1210300; TAUB R, 1982, P NATL ACAD SCI-BIOL, V79, P7837, DOI 10.1073/pnas.79.24.7837; Thomas MJ, 1998, CELL, V93, P627, DOI 10.1016/S0092-8674(00)81191-5; Westbrook TF, 2005, CELL, V121, P837, DOI 10.1016/j.cell.2005.03.033; YEH CH, 1995, J BIOL CHEM, V270, P15815, DOI 10.1074/jbc.270.26.15815	32	32	34	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC	2008	27	58					7223	7234		10.1038/onc.2008.360	http://dx.doi.org/10.1038/onc.2008.360			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	382FI	18806825	Green Accepted			2022-12-28	WOS:000261590300001
J	Meyerkord, CL; Takahashi, Y; Araya, R; Takada, N; Weiss, RS; Wang, HG				Meyerkord, C. L.; Takahashi, Y.; Araya, R.; Takada, N.; Weiss, R. S.; Wang, H-G			Loss of Hus1 sensitizes cells to etoposide-induced apoptosis by regulating BH3-only proteins	ONCOGENE			English	Article						Hus1; Rad9; Bim; Puma; DNA damage; apoptosis	DNA-DAMAGE CHECKPOINT; HUMAN RAD9; GENOMIC INSTABILITY; IONIZING-RADIATION; CYCLE CHECKPOINT; BCL-2 FAMILY; MOUSE HUS1; COMPLEX; INTERACTS; RESPONSES	The Rad9-Rad1-Hus1 (9-1-1) cell cycle checkpoint complex plays a key role in the DNA damage response. Cells with a defective 9-1-1 complex have been shown to be sensitive to apoptosis induced by certain types of genotoxic stress. However, the mechanism linking the loss of a functional 9-1-1 complex to the cell death machinery has yet to be determined. Here, we report that etoposide treatment dramatically upregulates the BH3-only proteins, Bim and Puma, in Hus1-deficient cells. Inhibition of either Bim or Puma expression in Hus1-knockout cells confers significant resistance to etoposide-induced apoptosis, whereas knockdown of both proteins results in further resistance, suggesting that Bim and Puma cooperate in sensitizing Hus1-deficient cells to etoposide treatment. Moreover, we found that Rad9 collaborates with Bim and Puma to sensitize Hus1-deficient cells to etoposide-induced apoptosis. In response to DNA damage, Rad9 localizes to chromatin in Hus1-wild-type cells, whereas in Hus1-deficient cells, it is predominantly located in the cytoplasm where it binds to Bcl-2. Taken together, these results suggest that loss of Hus1 sensitizes cells to etoposide-induced apoptosis not only by inducing Bim and Puma expressions but also by releasing Rad9 into the cytosol to augment mitochondrial apoptosis.	[Meyerkord, C. L.; Takahashi, Y.; Araya, R.; Takada, N.; Wang, H-G] Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Drug Discovery Program, Tampa, FL 33612 USA; [Meyerkord, C. L.; Wang, H-G] Univ S Florida, H Lee Moffit Canc Ctr & Res Inst, Canc Biol PhD Program, Tampa, FL 33612 USA; [Weiss, R. S.] Cornell Univ, Dept Biomed Sci, Ithaca, NY USA	H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida; State University System of Florida; University of South Florida; Cornell University	Wang, HG (corresponding author), Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Drug Discovery Program, SRB-2,12902 Magnolia Dr, Tampa, FL 33612 USA.	Hong-Gang.Wang@Moffitt.org	Wang, Hong-Gang/A-3018-2015	Wang, Hong-Gang/0000-0003-0551-0571; Takahashi, Yoshinori/0000-0002-8004-4817	National Institutes of Health [CA90315, CA108773]; Department of Defense Breast Cancer [BC050563]; NATIONAL CANCER INSTITUTE [R01CA090315, R01CA108773] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Department of Defense Breast Cancer(United States Department of Defense); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank the Analytical Microscopy Core facility at the H Lee Moffitt Cancer Center and Research Institute for their technical assistance. This work was supported by grants from the National Institutes of Health (CA90315 to H-GW and CA108773 to RSW) and the Department of Defense Breast Cancer Research Program (BC050563 to CLM).	Abraham RT, 2001, GENE DEV, V15, P2177, DOI 10.1101/gad.914401; Adams JM, 2007, ONCOGENE, V26, P1324, DOI 10.1038/sj.onc.1210220; Bakkenist CJ, 2004, CELL, V118, P9, DOI 10.1016/j.cell.2004.06.023; Bao SL, 2004, ONCOGENE, V23, P5586, DOI 10.1038/sj.onc.1207753; Bermudez VP, 2003, P NATL ACAD SCI USA, V100, P1633, DOI 10.1073/pnas.0437927100; Brandt PD, 2006, BIOCHEM BIOPH RES CO, V347, P232, DOI 10.1016/j.bbrc.2006.06.064; Burtelow MA, 2000, J BIOL CHEM, V275, P26343, DOI 10.1074/jbc.M001244200; Burtelow MA, 2001, J BIOL CHEM, V276, P25903, DOI 10.1074/jbc.M102946200; Chen MJ, 2001, J BIOL CHEM, V276, P16580, DOI 10.1074/jbc.M008871200; Cory S, 2003, ONCOGENE, V22, P8590, DOI 10.1038/sj.onc.1207102; Dang TY, 2005, GENES CELLS, V10, P287, DOI 10.1111/j.1365-2443.2005.00840.x; Dijkers PF, 2000, CURR BIOL, V10, P1201, DOI 10.1016/S0960-9822(00)00728-4; Galonek HL, 2006, NAT CELL BIOL, V8, P1317, DOI 10.1038/ncb1206-1317; Hershko T, 2004, J BIOL CHEM, V279, P8627, DOI 10.1074/jbc.M312866200; Hirai I, 2002, J BIOL CHEM, V277, P25722, DOI 10.1074/jbc.M203079200; Hopkins KM, 2004, MOL CELL BIOL, V24, P7235, DOI 10.1128/MCB.24.16.7235-7248.2004; Huang DCS, 2000, CELL, V103, P839, DOI 10.1016/S0092-8674(00)00187-2; Ishii H, 2005, P NATL ACAD SCI USA, V102, P9655, DOI 10.1073/pnas.0504222102; Kinzel B, 2002, CANCER, V94, P1808, DOI 10.1002/cncr.10383; Komatsu K, 2000, FEBS LETT, V481, P122, DOI 10.1016/S0014-5793(00)01975-X; Komatsu K, 2000, NAT CELL BIOL, V2, P1, DOI 10.1038/71316; Lee MW, 2003, ONCOGENE, V22, P6340, DOI 10.1038/sj.onc.1206729; Lieberman HB, 2006, J CELL BIOCHEM, V97, P690, DOI 10.1002/jcb.20759; Lindsey-Boltz LA, 2001, P NATL ACAD SCI USA, V98, P11236, DOI 10.1073/pnas.201373498; Loegering D, 2004, J BIOL CHEM, V279, P18641, DOI 10.1074/jbc.M313536200; Melo J, 2002, CURR OPIN CELL BIOL, V14, P237, DOI 10.1016/S0955-0674(02)00312-5; Mendez J, 2000, MOL CELL BIOL, V20, P8602, DOI 10.1128/MCB.20.22.8602-8612.2000; Montecucco A, 2007, CANCER LETT, V252, P9, DOI 10.1016/j.canlet.2006.11.005; Nakano K, 2001, MOL CELL, V7, P683, DOI 10.1016/S1097-2765(01)00214-3; Niida H, 2006, MUTAGENESIS, V21, P3, DOI 10.1093/mutage/gei063; OLTVAI ZN, 1994, CELL, V79, P189, DOI 10.1016/0092-8674(94)90188-0; Parrilla-Castellar ER, 2004, DNA REPAIR, V3, P1009, DOI 10.1016/j.dnarep.2004.03.032; Puthalakath H, 2002, CELL DEATH DIFFER, V9, P505, DOI 10.1038/sj.cdd.4400998; Rauen M, 2000, J BIOL CHEM, V275, P29767, DOI 10.1074/jbc.M005782200; Shiloh Y, 2003, NAT REV CANCER, V3, P155, DOI 10.1038/nrc1011; Strasser A, 2005, NAT REV IMMUNOL, V5, P189, DOI 10.1038/nri1568; Sunters A, 2003, J BIOL CHEM, V278, P49795, DOI 10.1074/jbc.M309523200; Volkmer E, 1999, J BIOL CHEM, V274, P567, DOI 10.1074/jbc.274.2.567; Wang HG, 1996, CELL, V87, P629, DOI 10.1016/S0092-8674(00)81383-5; Wang X, 2003, GENE DEV, V17, P965, DOI 10.1101/gad.1065103; Weiss RS, 2000, GENE DEV, V14, P1886; Weiss RS, 2003, MOL CELL BIOL, V23, P791, DOI 10.1128/MCB.23.3.791-803.2003; Weiss RS, 2002, CURR BIOL, V12, P73, DOI 10.1016/S0960-9822(01)00626-1; Willis SN, 2005, CURR OPIN CELL BIOL, V17, P617, DOI 10.1016/j.ceb.2005.10.001; Wong HK, 2005, MOL CELL BIOL, V25, P8732, DOI 10.1128/MCB.25.19.8732-8747.2005; Yang JY, 2006, INT J ONCOL, V29, P643; Yoshida K, 2003, EMBO J, V22, P1431, DOI 10.1093/emboj/cdg134; Yoshida K, 2002, MOL CELL BIOL, V22, P3292, DOI 10.1128/MCB.22.10.3292-3300.2002; Zhou BBS, 2000, NATURE, V408, P433, DOI 10.1038/35044005; Zou L, 2002, GENE DEV, V16, P198, DOI 10.1101/gad.950302	50	9	11	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC	2008	27	58					7248	7259		10.1038/onc.2008.336	http://dx.doi.org/10.1038/onc.2008.336			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	382FI	18794804	Green Accepted			2022-12-28	WOS:000261590300003
J	Moreno-Bueno, G; Portillo, F; Cano, A				Moreno-Bueno, G.; Portillo, F.; Cano, A.			Transcriptional regulation of cell polarity in EMT and cancer	ONCOGENE			English	Review						cell polarity; EMT; Snail; ZEB; tumour markers; interacting networks	EPITHELIAL-MESENCHYMAL TRANSITION; TUMOR-SUPPRESSOR; E-CADHERIN; GENE-EXPRESSION; MIR-200 FAMILY; TGF-BETA; TIGHT JUNCTIONS; DOWN-REGULATION; BREAST-CANCER; STEM-CELLS	The epithelial-to-mesenchymal transition ( EMT) is a crucial process in tumour progression providing tumour cells with the ability to escape from the primary tumour, to migrate to distant regions and to invade tissues. EMT requires a loss of cell-cell adhesion and apical-basal polarity, as well as the acquisition of a fibroblastoid motile phenotype. Several transcription factors have emerged in recent years that induce EMT, with important implications for tumour progression. However, their effects on cell polarity remain unclear. Here, we have re-examined the data available related to the effect of EMT related transcription factors on epithelial cell plasticity, focusing on their impact on cell polarity. Transcriptional and post-transcriptional regulatory mechanisms mediated by several inducers of EMT, in particular the ZEB and Snail factors, downregulate the expression and/or functional organization of core polarity complexes. We also summarize data on the expression of cell polarity genes in human tumours and analyse genetic interactions that highlight the existence of complex regulatory networks converging on the regulation of cell polarity by EMT inducers in human breast carcinomas. These recent observations provide new insights into the relationship between alterations in cell polarity components and EMT in cancer, opening new avenues for their potential use as therapeutic targets to prevent tumour progression.	[Moreno-Bueno, G.; Portillo, F.; Cano, A.] Univ Autonoma Madrid, Inst Invest Biomed Alberto Sols, CSIC, Dept Bioquim, Madrid 28029, Spain	Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Investigaciones Biomedicas Alberto Sols (IIBM)	Cano, A (corresponding author), Univ Autonoma Madrid, Inst Invest Biomed Alberto Sols, CSIC, Dept Bioquim, Arturo Duperier 4, Madrid 28029, Spain.	acano@iib.uam.es	Moreno-Bueno, Gema/K-9354-2016	Moreno-Bueno, Gema/0000-0002-5030-6687; Portillo Perez, Francisco/0000-0003-4922-346X	Spanish Ministry of Education and Science [SAF2007-63051, NAN2004-09230C04, CSD2007-00017, SAF2007-63075]; EU [MRTN-CT-2004005428]; Fundacion Mutua Madrilena	Spanish Ministry of Education and Science(Spanish Government); EU(European Commission); Fundacion Mutua Madrilena(Instituto de Salud Carlos III)	We thank members of A Cano's laboratory for their excellent work and encouraging discussions, and Gonzalo Gomez (CNIO, Spain) for helping with the protein network analysis. Our work is supported by grants from the Spanish Ministry of Education and Science (SAF2007-63051, NAN2004-09230C04 and CONSOLIDER-INGENIO 2010 CSD2007-00017 to AC, and SAF2007-63075 to GMB), the EU (MRTN-CT-2004005428) to AC and from the Fundacion Mutua Madrilena (2006) to GMB. GMB is a junior researcher contracted on the Ramon y Cajal program, 2004.	Aigner K, 2007, ONCOGENE, V26, P6979, DOI 10.1038/sj.onc.1210508; Anderson JM, 2004, CURR OPIN CELL BIOL, V16, P140, DOI 10.1016/j.ceb.2004.01.005; Aranda V, 2008, ONCOGENE, V27, P6878, DOI 10.1038/onc.2008.340; Aranda V, 2006, NAT CELL BIOL, V8, P1235, DOI 10.1038/ncb1485; Assemat E, 2008, BBA-BIOMEMBRANES, V1778, P614, DOI 10.1016/j.bbamem.2007.08.029; Baas AF, 2004, TRENDS CELL BIOL, V14, P312, DOI 10.1016/j.tcb.2004.04.001; Barrallo-Gimeno A, 2005, DEVELOPMENT, V132, P3151, DOI 10.1242/dev.01907; Beltran M, 2008, GENE DEV, V22, P756, DOI 10.1101/gad.455708; Bermejo-Rodriguez C, 2006, GENOMICS, V87, P113, DOI 10.1016/j.ygeno.2005.09.014; Bjerkvig R, 2005, NAT REV CANCER, V5, P899, DOI 10.1038/nrc1740; Boussioutas A, 2003, CANCER RES, V63, P2569; Brabletz T, 2005, NAT REV CANCER, V5, P744, DOI 10.1038/nrc1694; Burk U, 2008, EMBO REP, V9, P582, DOI 10.1038/embor.2008.74; Christiansen JJ, 2006, CANCER RES, V66, P8319, DOI 10.1158/0008-5472.CAN-06-0410; Christoffersen NR, 2007, RNA, V13, P1172, DOI 10.1261/rna.586807; Cobaleda C, 2007, ANNU REV GENET, V41, P41, DOI 10.1146/annurev.genet.41.110306.130146; Contreras CM, 2008, CANCER RES, V68, P759, DOI 10.1158/0008-5472.CAN-07-5014; De Craene B, 2005, CANCER RES, V65, P6237, DOI 10.1158/0008-5472.CAN-04-3545; De Craene B, 2005, CELL SIGNAL, V17, P535, DOI 10.1016/j.cellsig.2004.10.011; Dow LE, 2007, INT REV CYTOL, V262, P253, DOI 10.1016/S0074-7696(07)62006-3; Ebnet K, 2008, HISTOCHEM CELL BIOL, V130, P1, DOI 10.1007/s00418-008-0418-7; Escriva M, 2008, MOL CELL BIOL, V28, P1528, DOI 10.1128/MCB.02061-07; Etienne-Manneville S, 2008, ONCOGENE, V27, P6970, DOI 10.1038/onc.2008.347; Filipowicz W, 2008, NAT REV GENET, V9, P102, DOI 10.1038/nrg2290; Gardiol D, 2006, INT J CANCER, V119, P1285, DOI 10.1002/ijc.21982; Goldstein B, 2007, DEV CELL, V13, P609, DOI 10.1016/j.devcel.2007.10.007; Gosens I, 2008, EXP EYE RES, V86, P713, DOI 10.1016/j.exer.2008.02.005; Gregory PA, 2008, NAT CELL BIOL, V10, P593, DOI 10.1038/ncb1722; Grotegut S, 2006, EMBO J, V25, P3534, DOI 10.1038/sj.emboj.7601213; Grunert S, 2003, NAT REV MOL CELL BIO, V4, P657, DOI 10.1038/nrm1175; Guaita S, 2002, J BIOL CHEM, V277, P39209, DOI 10.1074/jbc.M206400200; Gupta GP, 2006, CELL, V127, P679, DOI 10.1016/j.cell.2006.11.001; Hanada N, 2000, INT J CANCER, V86, P480, DOI 10.1002/(SICI)1097-0215(20000515)86:4<480::AID-IJC6>3.0.CO;2-6; Hartsock A, 2008, BBA-BIOMEMBRANES, V1778, P660, DOI 10.1016/j.bbamem.2007.07.012; He L, 2004, NAT REV GENET, V5, P522, DOI 10.1038/nrg1379; Hirohashi S, 2003, CANCER SCI, V94, P575, DOI 10.1111/j.1349-7006.2003.tb01485.x; Huber MA, 2005, CURR OPIN CELL BIOL, V17, P548, DOI 10.1016/j.ceb.2005.08.001; Humbert PO, 2008, ONCOGENE, V27, P6888, DOI 10.1038/onc.2008.341; Hurteau GJ, 2007, CANCER RES, V67, P7972, DOI 10.1158/0008-5472.CAN-07-1058; Ikenouchi J, 2003, J CELL SCI, V116, P1959, DOI 10.1242/jcs.00389; Jeanes A, 2008, ONCOGENE, V27, P6920, DOI 10.1038/onc.2008.343; Jorda M, 2005, J CELL SCI, V118, P3371, DOI 10.1242/jcs.02465; KEMPHUES KJ, 1988, CELL, V52, P311, DOI 10.1016/S0092-8674(88)80024-2; Knust E, 2002, SCIENCE, V298, P1955, DOI 10.1126/science.1072161; Kondo M, 2004, CELL DEATH DIFFER, V11, P1092, DOI 10.1038/sj.cdd.4401467; Korpal M, 2008, J BIOL CHEM, V283, P14910, DOI 10.1074/jbc.C800074200; Kuphal S, 2006, ONCOGENE, V25, P103, DOI 10.1038/sj.onc.1209008; Lee MH, 2008, J CELL SCI, V121, P1141, DOI 10.1242/jcs.016634; Liu LX, 2002, WORLD J GASTROENTERO, V8, P580, DOI 10.3748/wjg.v8.i4.580; Ma L, 2007, NATURE, V449, P682, DOI 10.1038/nature06174; Ma XJ, 2004, CANCER CELL, V5, P607, DOI 10.1016/j.ccr.2004.05.015; Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027; Mani SA, 2007, P NATL ACAD SCI USA, V104, P10069, DOI 10.1073/pnas.0703900104; Martin-Belmonte F, 2007, CELL, V128, P383, DOI 10.1016/j.cell.2006.11.051; Martinez-Estrada OM, 2006, BIOCHEM J, V394, P449, DOI 10.1042/BJ20050591; Moreno-Bueno G, 2006, CANCER RES, V66, P9543, DOI 10.1158/0008-5472.CAN-06-0479; Moustakas A, 2007, CANCER SCI, V98, P1512, DOI 10.1111/j.1349-7006.2007.00550.x; Muthuswamy SK, 2001, NAT CELL BIOL, V3, P785, DOI 10.1038/ncb0901-785; Niessen CM, 2007, J INVEST DERMATOL, V127, P2525, DOI 10.1038/sj.jid.5700865; Nollet F, 2000, J MOL BIOL, V299, P551, DOI 10.1006/jmbi.2000.3777; Ohkubo T, 2004, J CELL SCI, V117, P1675, DOI 10.1242/jcs.01004; Ozdamar B, 2005, SCIENCE, V307, P1603, DOI 10.1126/science.1105718; Park SM, 2008, GENE DEV, V22, P894, DOI 10.1101/gad.1640608; Peinado H, 2003, J BIOL CHEM, V278, P21113, DOI 10.1074/jbc.M211304200; Peinado HC, 2004, INT J DEV BIOL, V48, P365, DOI 10.1387/ijdb.041794hp; Peinado H, 2008, CANCER RES, V68, P4541, DOI 10.1158/0008-5472.CAN-07-6345; Peinado H, 2007, NAT REV CANCER, V7, P415, DOI 10.1038/nrc2131; Perez-Moreno M, 2003, CELL, V112, P535, DOI 10.1016/S0092-8674(03)00108-9; Perez-Moreno M, 2006, DEV CELL, V11, P601, DOI 10.1016/j.devcel.2006.10.010; Reya T, 2001, NATURE, V414, P105, DOI 10.1038/35102167; Richard M, 2006, HUM MOL GENET, V15, pR235, DOI 10.1093/hmg/ddl195; Scheel C, 2007, CANCER RES, V67, P11476, DOI 10.1158/0008-5472.CAN-07-1653; Schimanski CC, 2005, ONCOGENE, V24, P3100, DOI 10.1038/sj.onc.1208520; Spaderna S, 2008, CANCER RES, V68, P537, DOI 10.1158/0008-5472.CAN-07-5682; Spaderna S, 2006, GASTROENTEROLOGY, V131, P830, DOI 10.1053/j.gastro.2006.06.016; Suzuki A, 2006, J CELL SCI, V119, P979, DOI 10.1242/jcs.02898; Talmadge JE, 2007, CANCER RES, V67, P11471, DOI 10.1158/0008-5472.CAN-07-2496; Tarin D, 2005, CANCER RES, V65, P5996, DOI 10.1158/0008-5472.CAN-05-0699; Thiery JP, 2003, CURR OPIN CELL BIOL, V15, P740, DOI 10.1016/j.ceb.2003.10.006; Thiery JP, 2006, NAT REV MOL CELL BIO, V7, P131, DOI 10.1038/nrm1835; Thompson EW, 2005, CANCER RES, V65, P5991, DOI 10.1158/0008-5472.CAN-05-0616; Thuault S, 2006, J CELL BIOL, V174, P175, DOI 10.1083/jcb.200512110; Tsukita S, 1997, SOC GEN PHY, V52, P69; Tsuruga T, 2007, ONCOL RES, V16, P431, DOI 10.3727/000000007783980855; van't Veer LJ, 2002, NATURE, V415, P530, DOI 10.1038/415530a; Vandewalle C, 2005, NUCLEIC ACIDS RES, V33, P6566, DOI 10.1093/nar/gki965; Vasioukhin V, 2006, DEV NEUROSCI-BASEL, V28, P13, DOI 10.1159/000090749; Vega S, 2004, GENE DEV, V18, P1131, DOI 10.1101/gad.294104; Wang XY, 2008, BBA-MOL BASIS DIS, V1782, P51, DOI 10.1016/j.bbadis.2007.11.002; Whiteman EL, 2008, ONCOGENE, V27, P3875, DOI 10.1038/onc.2008.9; Wodarz A, 2007, NAT CELL BIOL, V9, P1016, DOI 10.1038/ncb433; Zallen JA, 2007, CELL, V129, P1051, DOI 10.1016/j.cell.2007.05.050; Zavadil J, 2005, ONCOGENE, V24, P5764, DOI 10.1038/sj.onc.1208927; Zhang SM, 2008, CANCER RES, V68, P740, DOI 10.1158/0008-5472.CAN-07-2989	94	459	483	1	58	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 24	2008	27	55					6958	6969		10.1038/onc.2008.346	http://dx.doi.org/10.1038/onc.2008.346			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	375IU	19029937				2022-12-28	WOS:000261108200008
J	Li, X; Placencio, V; Iturregui, JM; Uwamariya, C; Sharif-Afshar, AR; Koyama, T; Hayward, SW; Bhowmick, NA				Li, X.; Placencio, V.; Iturregui, J. M.; Uwamariya, C.; Sharif-Afshar, A-R; Koyama, T.; Hayward, S. W.; Bhowmick, N. A.			Prostate tumor progression is mediated by a paracrine TGF-beta/Wnt3a signaling axis	ONCOGENE			English	Article						prostate cancer; T beta RII; prostate stroma; Tgfbr2(fspKO); Wnt3a; Stat3	GROWTH-FACTOR-BETA; TGF-BETA; INTRAEPITHELIAL NEOPLASIA; HGF TRANSCRIPTION; EPITHELIAL-CELLS; CANCER PATIENTS; UP-REGULATION; II RECEPTOR; EXPRESSION; CATENIN	Transforming growth factor (TGF)-beta is an important paracrine factor in tumorigenesis. Ligand binding of the type I and II TGF-beta receptors initiate downstream signaling. The role of stromal TGF-beta signaling in prostate cancer progression is unknown. In mice, the conditional stromal knockout of the TGF-beta type II receptor expression (Tgfbr2(fspKO)) resulted in the development of prostatic intraepithelial neoplasia and progression to adenocarcinoma within 7 months. Clinically, we observed a loss of TGF-beta receptor type II expression in 69% of human prostate cancer-associated stroma, compared to 15% of stroma associated with benign tissues (n = 140, P-value <0.0001). To investigate the mechanism of paracrine TGF-beta signaling in prostate cancer progression, we compared the effect of the prostatic stromal cells from Tgfbr2(fspKO) and floxed TGF-beta type II receptor Tgfbr2(floxE2/floxE2) mice on LNCaP human prostate cancer cells in vitro and tissue recombination xenografts. Induction of LNCaP cell proliferation and tumorigenesis was observed by Tgfbr2(fspKO) prostate stroma as a result of elevated Wnt3a expression. Neutralizing antibodies to Wnt3a reversed LNCaP tumorigenesis. The TGF-beta inhibition of Wnt3a expression was in part through the suppression of Stat3 activity on the Wnt3a promoter. In conclusion, the frequent loss of stromal TGF-beta type II receptor expression in human prostate cancer can relieve the paracrine suppression of Wnt3a expression.	[Li, X.; Uwamariya, C.; Sharif-Afshar, A-R; Hayward, S. W.; Bhowmick, N. A.] Vanderbilt Univ, Vanderbilt Ingram Canc Ctr, Sch Med, Dept Urol Surg, Nashville, TN 37232 USA; [Placencio, V.] Vanderbilt Univ, Sch Med, Dept Pathol, Nashville, TN 37232 USA; [Placencio, V.] Dept Vet Affairs Med Ctr, Nashville, TN 37212 USA; [Koyama, T.] Vanderbilt Univ, Sch Med, Dept Biostat, Nashville, TN 37232 USA	Vanderbilt University; Vanderbilt University; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Tennessee Valley Healthcare System; Vanderbilt University	Bhowmick, NA (corresponding author), Vanderbilt Univ, Med Ctr, Dept Urol Surg, 1161 21st Ave S,A-1302 Med Ctr, Nashville, TN 37232 USA.	neil.bhowmick@vanderbilt.edu	Bhowmick, Neil/AAA-7302-2019; Hayward, Simon/A-1688-2011	Bhowmick, Neil/0000-0001-8747-5989; Hayward, Simon/0000-0002-6059-6550; , Xiaohong/0000-0001-5074-193X; Sharif Afshar, Ali Reza/0000-0003-0949-2630	DOD; DAMD [W81XWH-04-1-0046 to NAB]; NIH [CA108646, CA126505, FGM079879A]; NATIONAL CANCER INSTITUTE [T32CA009592, U54CA126505, R01CA108646] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F31GM079879] Funding Source: NIH RePORTER	DOD(United States Department of Defense); DAMD; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	Dr Xiuping Yu (Vanderbilt University) generously provided primers for the Wnt isoforms. This study was supported by the DOD through DAMD (W81XWH-04-1-0046 to NAB) as well as through NIH Grants (CA108646, CA126505 to NAB and FGM079879A to VRP).	Bhowmick NA, 2004, NATURE, V432, P332, DOI 10.1038/nature03096; Bhowmick NA, 2005, CURR OPIN GENET DEV, V15, P97, DOI 10.1016/j.gde.2004.12.003; Bhowmick NA, 2004, SCIENCE, V303, P848, DOI 10.1126/science.1090922; Bierie B, 2006, CYTOKINE GROWTH F R, V17, P29, DOI 10.1016/j.cytogfr.2005.09.006; Biswas S, 2007, J CLIN INVEST, V117, P1305, DOI 10.1172/JCI30740; Bright JJ, 1998, J IMMUNOL, V161, P1772; Buck MB, 2004, CLIN CANCER RES, V10, P491, DOI 10.1158/1078-0432.CCR-0320-03; Calin GA, 2000, INT J CANCER, V89, P230, DOI 10.1002/1097-0215(20000520)89:3<230::AID-IJC4>3.3.CO;2-A; Cardillo MR, 2000, ANAL QUANT CYTOL, V22, P1; Chen GP, 2004, CANCER-AM CANCER SOC, V101, P1345, DOI 10.1002/cncr.20518; Chesire DR, 2002, ONCOGENE, V21, P2679, DOI 10.1038/sj.onc.1205352; Clevers H, 2006, CELL, V127, P469, DOI 10.1016/j.cell.2006.10.018; CUNHA GR, 1994, CANCER, V74, P1030, DOI 10.1002/1097-0142(19940801)74:3+<1030::AID-CNCR2820741510>3.0.CO;2-Q; DAVIDSON D, 1995, J UROLOGY, V154, P1295, DOI 10.1016/S0022-5347(01)66840-X; DONJACOUR AA, 1990, ENDOCRINOLOGY, V126, P1343, DOI 10.1210/endo-126-3-1343; Elliott RL, 2005, J CLIN ONCOL, V23, P2078, DOI 10.1200/JCO.2005.02.047; Ellwood-Yen K, 2003, CANCER CELL, V4, P223, DOI 10.1016/S1535-6108(03)00197-1; FUJII H, 1982, J UROLOGY, V128, P858, DOI 10.1016/S0022-5347(17)53221-8; Gerdes MJ, 1998, J HISTOCHEM CYTOCHEM, V46, P379, DOI 10.1177/002215549804600312; Goggins M, 1998, CANCER RES, V58, P5329; Grady WM, 1999, CANCER RES, V59, P320; Guo YP, 1999, CANCER RES, V59, P1366; Hayward SW, 2001, CANCER RES, V61, P8135; HAYWARD SW, 1992, J CELL SCI, V102, P361; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; Hotz B, 2007, CLIN CANCER RES, V13, P4769, DOI 10.1158/1078-0432.CCR-06-2926; Johnson ML, 2006, REV ENDOCR METAB DIS, V7, P41, DOI 10.1007/s1154-006-9003-3; Kim IY, 1996, CLIN CANCER RES, V2, P1255; Kim IY, 1998, CLIN CANCER RES, V4, P1625; Kurita T, 2004, DEVELOPMENT, V131, P4955, DOI 10.1242/dev.01384; Kwok WK, 2007, CARCINOGENESIS, V28, P2467, DOI 10.1093/carcin/bgm185; Kwok WK, 2005, CANCER RES, V65, P5153, DOI 10.1158/0008-5472.CAN-04-3785; Labbe E, 2007, CANCER RES, V67, P75, DOI 10.1158/0008-5472.CAN-06-2559; Morin PJ, 1999, BIOESSAYS, V21, P1021, DOI 10.1002/(SICI)1521-1878(199912)22:1<1021::AID-BIES6>3.0.CO;2-P; Nishita M, 2000, NATURE, V403, P781, DOI 10.1038/35001602; Nissen RM, 2000, GENE DEV, V14, P2314, DOI 10.1101/gad.827900; NUSSE R, 1984, NATURE, V307, P131, DOI 10.1038/307131a0; NUSSE R, 1991, CELL, V64, P231, DOI 10.1016/0092-8674(91)90633-A; NUSSE R, 1982, CELL, V31, P99, DOI 10.1016/0092-8674(82)90409-3; Pasche B, 2001, J CELL PHYSIOL, V186, P153, DOI 10.1002/1097-4652(200002)186:2<153::AID-JCP1016>3.0.CO;2-J; QIAN JQ, 1995, CANCER RES, V55, P5408; Qiao H, 2002, J CELL BIOCHEM, V86, P665, DOI 10.1002/jcb.10239; Roberts AB, 2003, P NATL ACAD SCI USA, V100, P8621, DOI 10.1073/pnas.1633291100; Royuela M, 1998, GROWTH FACTORS, V16, P101, DOI 10.3109/08977199809002121; Sam MR, 2007, MOL CANCER, V6, DOI 10.1186/1476-4598-6-69; SCHMID P, 1995, CARCINOGENESIS, V16, P1499, DOI 10.1093/carcin/16.7.1499; Shi YG, 2003, CELL, V113, P685, DOI 10.1016/S0092-8674(03)00432-X; Shibamoto S, 1998, GENES CELLS, V3, P659; TURNER T, 1990, IN VITRO CELL DEV B, V26, P722; Verras M, 2006, CANCER LETT, V237, P22, DOI 10.1016/j.canlet.2005.06.004; Voeller HJ, 1998, CANCER RES, V58, P2520; Wang YH, 2000, CANCER RES, V60, P6008; Wojcik EJ, 2006, ONCOGENE, V25, P2773, DOI 10.1038/sj.onc.1209306; WONG YC, 1992, ACTA ANAT, V143, P139; Yardy GW, 2005, PROSTATE CANCER P D, V8, P119, DOI 10.1038/sj.pcan.4500794; Zhang Z, 2007, HUM PATHOL, V38, P598, DOI 10.1016/j.humpath.2006.10.004	56	119	120	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV	2008	27	56					7118	7130		10.1038/onc.2008.293	http://dx.doi.org/10.1038/onc.2008.293			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	376PQ	18724388	Green Accepted			2022-12-28	WOS:000261195900006
J	Lee, KY; Geng, H; Ng, KM; Yu, J; van Hasselt, A; Cao, Y; Zeng, YX; Wong, AHY; Wang, X; Ying, J; Srivastava, G; Lung, ML; Wang, LD; Kwok, TT; Levi, BZ; Chan, ATC; Sung, JJY; Tao, Q				Lee, K. Y.; Geng, H.; Ng, K. M.; Yu, J.; van Hasselt, A.; Cao, Y.; Zeng, Y-X; Wong, A. H. Y.; Wang, X.; Ying, J.; Srivastava, G.; Lung, M. L.; Wang, L-D; Kwok, T. T.; Levi, B-Z; Chan, A. T. C.; Sung, J. J. Y.; Tao, Q.			Epigenetic disruption of interferon-gamma response through silencing the tumor suppressor interferon regulatory factor 8 in nasopharyngeal, esophageal and multiple other carcinomas	ONCOGENE			English	Article						IRF8; methylation; CpG island; tumor suppressor gene; carcinoma	BINDING-PROTEIN ICSBP; PROMOTER HYPERMETHYLATION; ABERRANT METHYLATION; CELL CARCINOMA; MYELOID CELLS; GENE; CANCER; APOPTOSIS; EXPRESSION; ICSBP/IRF-8	16q24 is frequently deleted in multiple tumors including cancers of nasopharynx, esophagus, breast, prostate and liver. By array comparative genomic hybridization (aCGH), we refined a 16q24 hemizygous deletion in nasopharyngeal carcinoma (NPC) cell lines. Semi-quantitative RT-PCR analysis revealed interferon regulatory factor 8 (IRF8) as the only downregulated gene within this deletion. IRF8 belongs to a family of interferon (IFN) regulatory factors that modulate various important physiologic processes including host defense, cell growth and differentiation and immune regulation. In contrast to the broad expression of IRF8 in normal adult and fetal tissues, transcriptional silencing and promoter methylation of IRF8 were frequently detected in multiple carcinoma (except for hepatocellular) cell lines (100% in NPC, 88% in esophageal and 18-78% in other carcinoma cell lines) and in a large collection of primary carcinomas (78% in NPC, 36-71% in other carcinomas). Methylation of the IRF8 promoter led to the disruption of its response to IFN-gamma stimulation. Pharmacological and genetic demethylation could restore IRF8 expression, indicating a direct epigenetic mechanism. Ectopic expression of IRF8 in tumor cells lacking its expression strongly inhibited their clonogenicity, confirming its tumor suppressor function. Thus, IRF8 was identified as a functional tumor suppressor, which is frequently silenced by epigenetic mechanism in multiple carcinomas.	[Lee, K. Y.; Geng, H.; Ng, K. M.; Wong, A. H. Y.; Wang, X.; Ying, J.; Chan, A. T. C.; Tao, Q.] Chinese Univ Hong Kong, Prince Wales Hosp,Li Ka Shing Inst Hlth Sci, Dept Clin Oncol,State Key Lab Oncol S China, Canc Epigenet Lab,Sir YK Pao Ctr Canc,, Hong Kong, Hong Kong, Peoples R China; [Yu, J.; Sung, J. J. Y.] Chinese Univ Hong Kong, Inst Digest Dis, Dept Med & Therapeut, Hong Kong, Hong Kong, Peoples R China; [van Hasselt, A.] Chinese Univ Hong Kong, Dept Surg, Hong Kong, Hong Kong, Peoples R China; [Cao, Y.] Cent S Univ, Hunan Yale Xiang Ya Sch Med, Changsha 410083, Peoples R China; [Zeng, Y-X] Sun Yat Sen Univ, Ctr Canc, State Key Lab Oncol S China, Guangzhou 510275, Guangdong, Peoples R China; [Srivastava, G.] Univ Hong Kong, Dept Pathol, Hong Kong, Hong Kong, Peoples R China; [Lung, M. L.] Hong Kong Univ Sci & Technol, Dept Biol, Hong Kong, Hong Kong, Peoples R China; [Wang, L-D] Zhengzhou Univ, Coll Med, Henan Key Lab Esophageal Canc, Zhengzhou, Henan, Peoples R China; [Kwok, T. T.] Chinese Univ Hong Kong, Dept Biochem, Hong Kong, Hong Kong, Peoples R China; [Levi, B-Z] Technion Israel Inst Technol, Dept Food Engn & Biotechnol, IL-32000 Haifa, Israel	Chinese University of Hong Kong; Prince of Wales Hospital; Chinese University of Hong Kong; Chinese University of Hong Kong; Central South University; Sun Yat Sen University; University of Hong Kong; Hong Kong University of Science & Technology; Zhengzhou University; Chinese University of Hong Kong; Technion Israel Institute of Technology	Tao, Q (corresponding author), Chinese Univ Hong Kong, Prince Wales Hosp,Li Ka Shing Inst Hlth Sci, Dept Clin Oncol,State Key Lab Oncol S China, Canc Epigenet Lab,Sir YK Pao Ctr Canc,, Hong Kong, Hong Kong, Peoples R China.	qtao@clo.cuhk.edu.hk	Chan, Anthony Tak Cheung/R-3940-2018; Sung, Joseph J. Y./R-3203-2018; Tao, Qian/T-4743-2018; Yu, Jun/D-8569-2015; Kwok, Timothy/C-3725-2008; Lung, Maria Li/C-4495-2009	Chan, Anthony Tak Cheung/0000-0002-6912-8091; Sung, Joseph J. Y./0000-0003-3125-5199; Tao, Qian/0000-0001-5383-4808; Yu, Jun/0000-0001-5008-2153; Kwok, Timothy/0000-0001-9253-3549; Wang, Xian/0000-0003-0041-7589; Lung, Maria Li/0000-0003-2559-3626	Michael and Betty Kadoorie Cancer Genetics Research Program (MBKCGRP); Hong Kong RGC Central Allocation Grant [CA06/07.SC03]	Michael and Betty Kadoorie Cancer Genetics Research Program (MBKCGRP); Hong Kong RGC Central Allocation Grant(Hong Kong Research Grants Council)	This project was supported by a Michael and Betty Kadoorie Cancer Genetics Research Program (MBKCGRP) Grant to QT and a Hong Kong RGC Central Allocation Grant (CA06/07.SC03, QT). We thank Drs Bert Vogelstein, George Tsao (Dolly Huang), Sun Young Rha and Kaitai Yao for some cell lines, DSMZ (German Collection of Microorganisms and Cell Cultures) for the KYSE cell lines [Shimada et al., Cancer 69: 277-284 (1992)], Dr C Langford at the Wellcome Trust Sanger Institute, Cambridge, UK for aCGH slides, and Tzer- Jing Seng (Johns Hopkins Singapore) for her valuable help in aCGH analysis.	Baylin SB, 2006, NAT REV CANCER, V6, P107, DOI 10.1038/nrc1799; Bouker KB, 2005, CARCINOGENESIS, V26, P1527, DOI 10.1093/carcin/bgi113; Burchert A, 2004, BLOOD, V103, P3480, DOI 10.1182/blood-2003-08-2970; BUSSON P, 1988, INT J CANCER, V42, P599, DOI 10.1002/ijc.2910420422; Chang HW, 2003, INT J CANCER, V105, P851, DOI 10.1002/ijc.11162; Chen YJ, 1999, GENE CHROMOSOME CANC, V25, P169, DOI 10.1002/(SICI)1098-2264(199906)25:2<169::AID-GCC13>3.3.CO;2-9; Egwuagu CE, 2006, ONCOGENE, V25, P3670, DOI 10.1038/sj.onc.1209402; Hashmueli S, 2003, INT IMMUNOL, V15, P807, DOI 10.1093/intimm/dxg077; Holtschke T, 1996, CELL, V87, P307, DOI 10.1016/S0092-8674(00)81348-3; Hu GD, 2005, CANCER RES, V65, P7403, DOI 10.1158/0008-5472.CAN-05-0583; Jin H, 2007, ONCOGENE, V26, P7490, DOI 10.1038/sj.onc.1210559; Jin HC, 2007, P NATL ACAD SCI USA, V104, P12353, DOI 10.1073/pnas.0700153104; Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816; Kanno Y, 2005, J INTERF CYTOK RES, V25, P770, DOI 10.1089/jir.2005.25.770; Knudson AG, 2001, NAT REV CANCER, V1, P157, DOI 10.1038/35101031; Lo KW, 2000, CANCER RES, V60, P3348; Lo KW, 2004, CANCER CELL, V5, P423, DOI 10.1016/S1535-6108(04)00119-9; Lo KW, 2001, CANCER RES, V61, P3877; Lung HL, 2005, ONCOGENE, V24, P6525, DOI 10.1038/sj.onc.1208812; Lung HL, 2006, CANCER RES, V66, P9385, DOI 10.1158/0008-5472.CAN-06-0590; Nguyen Hannah, 1997, Cytokine and Growth Factor Reviews, V8, P293, DOI 10.1016/S1359-6101(97)00019-1; Paige AJW, 2000, CANCER RES, V60, P1690; Qiu GH, 2004, ONCOGENE, V23, P4793, DOI 10.1038/sj.onc.1207632; Rhee I, 2002, NATURE, V416, P552, DOI 10.1038/416552a; Schmidt M, 2004, BLOOD, V103, P4142, DOI 10.1182/blood-2003-01-0285; Schmidt M, 1998, BLOOD, V91, P22, DOI 10.1182/blood.V91.1.22.22_22_29; Srivastava G, 2000, BLOOD, V95, P2443, DOI 10.1182/blood.V95.7.2443.007k18_2443_2445; Steenbergen RDM, 2004, JNCI-J NATL CANCER I, V96, P294, DOI 10.1093/jnci/djh031; Sun D, 2007, ORAL ONCOL, V43, P82, DOI 10.1016/j.oraloncology.2006.01.007; Tamura T, 2005, BLOOD, V106, P1938, DOI 10.1182/blood-2005-01-0080; Tamura T, 2003, BLOOD, V102, P4547, DOI 10.1182/blood-2003-01-0291; Tamura T, 2002, J INTERF CYTOK RES, V22, P145, DOI 10.1089/107999002753452755; Tao Q, 2002, HUM MOL GENET, V11, P2091, DOI 10.1093/hmg/11.18.2091; Tao Qian, 2007, Expert Reviews in Molecular Medicine, V9, P1, DOI 10.1017/S1462399407000312; Toyooka KO, 2001, CANCER RES, V61, P4556; Tsao SW, 2002, BBA-MOL CELL RES, V1590, P150, DOI 10.1016/S0167-4889(02)00208-2; Watson GA, 2006, NEOPLASIA, V8, P31, DOI 10.1593/neo.05559; Wong ML, 2006, INT J ONCOL, V28, P767; Yang DF, 2007, J IMMUNOL, V179, P4775, DOI 10.4049/jimmunol.179.7.4775; Yang DF, 2007, CANCER RES, V67, P3301, DOI 10.1158/0008-5472.CAN-06-4068; Ying J, 2006, ONCOGENE, V25, P1070, DOI 10.1038/sj.onc.1209154; Ying JM, 2008, CLIN CANCER RES, V14, P55, DOI 10.1158/1078-0432.CCR-07-1644; Zhu CL, 2004, J BIOL CHEM, V279, P50874, DOI 10.1074/jbc.M405736200	43	61	63	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP	2008	27	39					5267	5276		10.1038/onc.2008.147	http://dx.doi.org/10.1038/onc.2008.147			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	344GO	18469857				2022-12-28	WOS:000258915100011
J	Talukder, AH; Li, DQ; Manavathi, B; Kumar, R				Talukder, A. H.; Li, D-Q; Manavathi, B.; Kumar, R.			Serine 28 phosphorylation of NRIF3 confers its co-activator function for estrogen receptor-alpha transactivation	ONCOGENE			English	Article						NRIF3; Pak1; ER alpha; phosphorylation	ACTIVATED PROTEIN-KINASE; BREAST-CANCER CELLS; TRANSCRIPTIONAL ACTIVATION; IN-VITRO; INDEPENDENT GROWTH; NUCLEAR RECEPTORS; TYROSINE KINASE; DNA-BINDING; ESTRADIOL; INSULIN	NRIF3 is an estrogen-inducible nuclear receptor coregulator that stimulates estrogen receptor-alpha (ER alpha) transactivation functions and associates with the endogenous ER and its target gene promoter. p21-activated protein kinase 1 (Pak1) phosphorylates ER alpha at Ser305 and this modification is important in ER alpha transactivation function. Although ERa transactivation functions are regulated by co-activator activity of NRIF3, it remains unclear whether Pak1 could impact ER functions via a posttranslational modi. cation of NRIF3. Here, we report that Pak1 phosphorylates NRIF3 at Serine28 and that NRIF3 binds to Pak1 in vitro and in vivo. We found that NRIF3 phosphorylation, co-activator activity and association with ER alpha increased following Pak1 phosphorylation of NRIF3's Ser28 and that activated ER alpha-Ser305 and NRIF3-Ser28 cooperatively support transactivation of ER alpha. NRIF3 expression increased significantly in cells with inducible Pak1 expression. We found that NRIF3 and ER alpha interaction, subcellular localization and ER alpha transactivation activity all increased in cells expressing the Pak1 phosphorylation-mimicking mutant NRIF3-Ser28Glu. Consistently, the NRIF3-Ser28Glu mutant exhibited an enhanced recruitment to the endogenous ER target genes and increased expression following estrogen stimulation. Finally, breast cancer cells with stable overexpression of NRIF3 showed increased proliferation and enhanced anchorage-independent growth. These findings suggest that NRIF3-Ser28 is a physiologic target of Pak1 signaling and contributes to the enhanced NRIF3 co-activator activity, leading to coordinated potentiation of ER alpha transactivation, its target gene expression and estrogen responsiveness of breast cancer cells.	[Talukder, A. H.; Li, D-Q; Manavathi, B.; Kumar, R.] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA; [Kumar, R.] Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; Baylor College of Medicine	Kumar, R (corresponding author), Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA.	rkumar@mdanderson.org		Manavathi, Bramanandam/0000-0002-1797-398X	NIH [CA90970, CA098823]; NATIONAL CANCER INSTITUTE [R01CA090970, R01CA098823] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Christopher J Barnes and Suresh Rayala for the confocal microscopy and western blotting, respectively. This study was supported by the NIH grants CA90970 and CA098823 to RK.	ALI S, 1993, EMBO J, V12, P1153, DOI 10.1002/j.1460-2075.1993.tb05756.x; ARNOLD SF, 1995, J STEROID BIOCHEM, V55, P163, DOI 10.1016/0960-0760(95)00177-2; ARNOLD SF, 1995, J STEROID BIOCHEM, V52, P159, DOI 10.1016/0960-0760(94)00166-J; ARNOLD SF, 1994, MOL ENDOCRINOL, V8, P1208, DOI 10.1210/me.8.9.1208; ARNOLD SF, 1995, MOL ENDOCRINOL, V9, P24, DOI 10.1210/me.9.1.24; ARONICA SM, 1993, MOL ENDOCRINOL, V7, P743, DOI 10.1210/me.7.6.743; Balasenthil S, 2004, J BIOL CHEM, V279, P1422, DOI 10.1074/jbc.M309937200; Bunone G, 1996, EMBO J, V15, P2174, DOI 10.1002/j.1460-2075.1996.tb00571.x; CASTORIA G, 1993, BIOCHEMISTRY-US, V32, P1740, DOI 10.1021/bi00058a007; de Mora JF, 2000, MOL CELL BIOL, V20, P5041, DOI 10.1128/MCB.20.14.5041-5047.2000; Freedman LP, 1999, CELL, V97, P5, DOI 10.1016/S0092-8674(00)80708-4; Glass CK, 2000, GENE DEV, V14, P121; Hermanson O, 2002, TRENDS ENDOCRIN MET, V13, P55, DOI 10.1016/S1043-2760(01)00527-6; IGNARTROWBRIDGE DM, 1993, MOL ENDOCRINOL, V7, P992, DOI 10.1210/me.7.8.992; JOEL PB, 1995, MOL ENDOCRINOL, V9, P1041, DOI 10.1210/me.9.8.1041; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; KATO S, 1995, SCIENCE, V270, P1491, DOI 10.1126/science.270.5241.1491; Kumar R, 2002, J CELL PHYSIOL, V193, P133, DOI 10.1002/jcp.10167; Lazaro JB, 2002, GENE DEV, V16, P1792, DOI 10.1101/gad.U-9988R; LEGOFF P, 1994, J BIOL CHEM, V269, P4458; Li DS, 1999, MOL CELL BIOL, V19, P7191; Li DS, 2001, MOL CELL BIOL, V21, P8371, DOI 10.1128/MCB.21.24.8371-8384.2001; MA ZQ, 1994, MOL ENDOCRINOL, V8, P910, DOI 10.1210/me.8.7.910; METZGER D, 1995, MOL ENDOCRINOL, V9, P579, DOI 10.1210/me.9.5.579; ONATE SA, 1995, SCIENCE, V270, P1354; Patrone C, 1996, MOL ENDOCRINOL, V10, P499, DOI 10.1210/me.10.5.499; Pierce KL, 2001, ONCOGENE, V20, P1532, DOI 10.1038/sj.onc.1204184; PIETRAS RJ, 1995, ONCOGENE, V10, P2435; Rowan BG, 2000, MOL CELL BIOL, V20, P8720, DOI 10.1128/MCB.20.23.8720-8730.2000; Spiegelman BM, 2004, CELL, V119, P157, DOI 10.1016/j.cell.2004.09.037; Talukder AH, 2004, MOL CELL BIOL, V24, P6581, DOI 10.1128/mcb.24.15.6581-6591.2004; Vadlamudi RK, 2000, J BIOL CHEM, V275, P36238, DOI 10.1074/jbc.M002138200; Wang RA, 2002, EMBO J, V21, P5437, DOI 10.1093/emboj/cdf543; Wang ZY, 2000, P NATL ACAD SCI USA, V97, P13549, DOI 10.1073/pnas.260463097; Wu RC, 2005, ENDOCR REV, V26, P393, DOI 10.1210/er.2004-0018; Wu RC, 2002, MOL CELL BIOL, V22, P3549, DOI 10.1128/MCB.22.10.3549-3561.2002; Wu RC, 2004, MOL CELL, V15, P937, DOI 10.1016/j.molcel.2004.08.019	37	8	9	1	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP	2008	27	39					5233	5242		10.1038/onc.2008.151	http://dx.doi.org/10.1038/onc.2008.151			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	344GO	18521086	Green Accepted			2022-12-28	WOS:000258915100007
J	Koch, A; Scherr, M; Breyer, B; Mancini, A; Kardinal, C; Battmer, K; Eder, M; Tamura, T				Koch, A.; Scherr, M.; Breyer, B.; Mancini, A.; Kardinal, C.; Battmer, K.; Eder, M.; Tamura, T.			Inhibition of Abl tyrosine kinase enhances nerve growth factor-mediated signaling in Bcr-Abl transformed cells via the alteration of signaling complex and the receptor turnover	ONCOGENE			English	Article						TrkA and Bcr-Abl; CML; imatinib; receptor internalization; CD34+cells	CHRONIC MYELOID-LEUKEMIA; TRK NEUROTROPHIN RECEPTORS; HEMATOPOIETIC-CELLS; C-KIT; PHILADELPHIA-CHROMOSOME; 5-PHOSPHATASE SHIP2; IN-VITRO; STI 571; EXPRESSION; NGF	Receptor tyrosine kinase-mediated signaling is tightly regulated by a number of cytoplasmic signaling molecules. In this report, we show that Bcr-Abl transformed chronic myelogenous leukemia (CML) cell lines, K562 and Meg-01, express the receptor for nerve growth factor (NGF), TrkA, on the cell surface; however, the NGF-mediated signal is not particularly strong. Treatment with imatinib, a potent inhibitor of Bcr-Abl tyrosine kinase, downmodulates phosphorylation of downstream molecules. Upon stimulation with NGF, Erk and Akt are phosphorylated to a much greater degree in imatinib-treated cells than in untreated cells. Knockdown of expression of Bcr-Abl using small interfering RNA technique also enhanced NGF-mediated Akt phosphorylation, indicating that Bcr-Abl kinase modifies NGF signaling directly. Imatinib treatment also enhanced NGF signaling in rat adrenal pheochromocytoma cell line PC12 that expresses TrkA and c-Abl, suggesting that it is not only restoration of responsiveness to NGF after blocking oncoprotein activity, but also c-Abl tyrosine kinase per se may be a negative regulator of growth factor signaling. Furthermore, inhibition of Abl tyrosine kinase enhanced clearance of surface TrkA after NGF treatment and simultaneously enhanced NGF-mediated signaling, suggesting that as in neuronal cells 'signaling endosomes' are formed in hematopoietic cells. To examine the role of TrkA in CML cells, we studied cell growth or colony formation in the presence or absence of imatinib with or without NGF. We found that NGF treatment induces cell survival in imatinib-treated CML cell lines, as well as colony formation of primary CD34+ CML cells, strongly suggesting that NGF/TrkA signaling contributes to aberrant signaling in CML.	[Koch, A.; Breyer, B.; Mancini, A.; Tamura, T.] Hannover Med Sch, Inst Biochem, OE 4310, D-30623 Hannover, Germany; [Scherr, M.; Battmer, K.; Eder, M.] Hannover Med Sch, OE 6860, D-30623 Hannover, Germany; [Kardinal, C.] Hannover Med Sch, OE 6780, D-30623 Hannover, Germany	Hannover Medical School; Hannover Medical School; Hannover Medical School	Tamura, T (corresponding author), Hannover Med Sch, Inst Biochem, OE 4310, Carl Neuberg Str 1, D-30623 Hannover, Germany.	tamura.teruko@MH-Hannover.de						Blero D, 2001, BIOCHEM BIOPH RES CO, V282, P839, DOI 10.1006/bbrc.2001.4639; Bonati A, 2000, CANCER RES, V60, P728; Bracci-Laudiero L, 2003, J NEUROIMMUNOL, V136, P130, DOI 10.1016/S0165-5728(03)00007-9; Buchdunger E, 1996, CANCER RES, V56, P100; Buchdunger E, 2000, J PHARMACOL EXP THER, V295, P139; Burton EA, 2003, EMBO J, V22, P5471, DOI 10.1093/emboj/cdg512; BUTTERFIELD JH, 1988, LEUKEMIA RES, V12, P345, DOI 10.1016/0145-2126(88)90050-1; Chen ZY, 2005, MOL BIOL CELL, V16, P5761, DOI 10.1091/mbc.E05-07-0651; CHEVALIER S, 1994, BLOOD, V83, P1479; Deininger M, 2005, BLOOD, V105, P2640, DOI 10.1182/blood-2004-08-3097; Druker BJ, 2001, NEW ENGL J MED, V344, P1038, DOI 10.1056/NEJM200104053441402; Druker BJ, 1996, NAT MED, V2, P561, DOI 10.1038/nm0596-561; Druker BJ, 2006, NEW ENGL J MED, V355, P2408, DOI 10.1056/NEJMoa062867; Feller SM, 2001, ONCOGENE, V20, P6348, DOI 10.1038/sj.onc.1204779; Giuriato S, 2002, BIOCHEM BIOPH RES CO, V296, P106, DOI 10.1016/S0006-291X(02)00787-8; Heinrich MC, 2000, BLOOD, V96, P925, DOI 10.1182/blood.V96.3.925.015k50_925_932; Howe CL, 2001, NEURON, V32, P801, DOI 10.1016/S0896-6273(01)00526-8; Huang EJ, 2003, ANNU REV BIOCHEM, V72, P609, DOI 10.1146/annurev.biochem.72.121801.161629; Kaebisch A, 1996, BRIT J HAEMATOL, V95, P102, DOI 10.1046/j.1365-2141.1996.d01-1874.x; Koch A, 2005, ONCOGENE, V24, P3436, DOI 10.1038/sj.onc.1208558; Koch A, 2000, FEBS LETT, V469, P72, DOI 10.1016/S0014-5793(00)01242-4; Mancini A, 2002, J BIOL CHEM, V277, P14635, DOI 10.1074/jbc.M109214200; MATSUDA H, 1988, P NATL ACAD SCI USA, V85, P6508, DOI 10.1073/pnas.85.17.6508; Mulloy JC, 2005, P NATL ACAD SCI USA, V102, P4016, DOI 10.1073/pnas.0404701102; Muraille E, 1999, BIOCHEM J, V342, P697, DOI 10.1042/0264-6021:3420697; O'Brien SG, 2003, NEW ENGL J MED, V348, P994, DOI 10.1056/NEJMoa022457; OBERMEIER A, 1993, J BIOL CHEM, V268, P22963; Rajagopal R, 2004, J NEUROSCI, V24, P6650, DOI 10.1523/JNEUROSCI.0010-04.2004; Riccio A, 1997, SCIENCE, V277, P1097, DOI 10.1126/science.277.5329.1097; Sattler M, 2002, CANCER CELL, V1, P479, DOI 10.1016/S1535-6108(02)00074-0; Saxena S, 2005, MOL CELL NEUROSCI, V28, P571, DOI 10.1016/j.mcn.2004.11.011; Scheijen B, 2002, ONCOGENE, V21, P3314, DOI 10.1038/sj.onc.1205317; Scherr M, 2005, GENE THER, V12, P12, DOI 10.1038/sj.gt.3302328; Scherr M, 2003, BLOOD, V101, P1566, DOI 10.1182/blood-2002-06-1685; Scherr M, 2002, BLOOD, V99, P709, DOI 10.1182/blood.V99.2.709; Simone MD, 1999, HEMATOL ONCOL, V17, P1; SNIDER WD, 1994, CELL, V77, P627, DOI 10.1016/0092-8674(94)90048-5; STEPHENS RM, 1994, NEURON, V12, P691, DOI 10.1016/0896-6273(94)90223-2; Tam SY, 1997, BLOOD, V90, P1807, DOI 10.1182/blood.V90.5.1807; Tanos B, 2006, J BIOL CHEM, V281, P32714, DOI 10.1074/jbc.M603126200; Tuveson DA, 2001, ONCOGENE, V20, P5054, DOI 10.1038/sj.onc.1204704; von Bubnoff N, 2003, LEUKEMIA, V17, P829, DOI 10.1038/sj.leu.2402889; Wang WL, 2000, ONCOGENE, V19, P3521, DOI 10.1038/sj.onc.1203698; Wisniewski D, 1999, BLOOD, V93, P2707, DOI 10.1182/blood.V93.8.2707.408k17_2707_2720; Yano H, 2000, J NEUROSCI RES, V59, P356, DOI 10.1002/(SICI)1097-4547(20000201)59:3<356::AID-JNR9>3.0.CO;2-G; Zhang YZ, 2000, J NEUROSCI, V20, P5671, DOI 10.1523/JNEUROSCI.20-15-05671.2000	46	23	23	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG	2008	27	34					4678	4689		10.1038/onc.2008.107	http://dx.doi.org/10.1038/onc.2008.107			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	334QM	18427551				2022-12-28	WOS:000258236300006
J	Huang, J; Chen, J				Huang, J.; Chen, J.			VprBP targets Merlin to the Roc1-Cul4A-DDB1 E3 ligase complex for degradation	ONCOGENE			English	Article						VprBP; Merlin; E3 ligase; degradation	CUL4-DDB1 UBIQUITIN LIGASE; NF2 TUMOR-SUPPRESSOR; CELL-CYCLE; NEUROFIBROMATOSIS TYPE-2; PLASMA-MEMBRANE; PROTEIN VPR; ARREST; GROWTH; DDB1; RAC	Inactivation of the neurofibromatosis type 2 ( NF2) tumor suppressor gene function has been observed not only in familial schwannomas and other central nervous system tumors, but also in malignant tumors unrelated to the NF2 syndrome, indicating a broader role of NF2 in human tumorigenesis. The NF2-encoded protein Merlin is closely related to the Ezrin-Radixin-Moesin family of membrane/cytoskeleton linker proteins, and has been demonstrated to suppress tumor growth by inhibiting extracellular signal-regulated kinase ( ERK) and Rac1 activation. Interestingly, serum deprivation has been shown to regulate Merlin at the protein level, however, exactly how such condition affects Merlin remains elusive. In this study, we provide evidence to show that Merlin is regulated in a Roc1-Cullin4A-DDB1-dependent manner. Following serum stimulation, Merlin is recruited to the E3 ligase complex through a direct interaction with the WD40-containing adaptor protein VprBP. Loading of Merlin to the E3 ubiquitin ligase complex resulted in its polyubiquitination, and consequently its proteasome-mediated degradation. Consistently, VprBP depletion abolished the in vivo interaction of Merlin and Roc1-Cullin4A-DDB1, which resulted in Merlin stabilization and inhibited ERK and Rac activation. Together, our data revealed a novel regulatory mechanism for the tumor suppressor function of Merlin.	[Huang, J.; Chen, J.] Yale Univ, Sch Med, Dept Therapeut Radiol, New Haven, CT 06520 USA	Yale University	Chen, J (corresponding author), Yale Univ, Sch Med, Dept Therapeut Radiol, Hunter Bldg 213C,333 Cedar St,POB 208040, New Haven, CT 06520 USA.	Junjie.chen@yale.edu	CHEN, JUNJIE/HHM-8428-2022					Alfthan K, 2004, J BIOL CHEM, V279, P18559, DOI 10.1074/jbc.M313916200; Angers S, 2006, NATURE, V443, P590, DOI 10.1038/nature05175; Belzile JP, 2007, PLOS PATHOG, V3, P882, DOI 10.1371/journal.ppat.0030085; Bretscher A, 2000, ANNU REV CELL DEV BI, V16, P113, DOI 10.1146/annurev.cellbio.16.1.113; den Bakker MA, 2000, J NEUROSCI RES, V62, P764, DOI 10.1002/1097-4547(20001215)62:6<764::AID-JNR2>3.0.CO;2-V; Gonzalez-Agosti C, 1999, J BIOL CHEM, V274, P34438, DOI 10.1074/jbc.274.48.34438; Gutmann DH, 1997, NEUROBIOL DIS, V3, P247, DOI 10.1006/nbdi.1997.0128; He YZJ, 2006, GENE DEV, V20, P2949, DOI 10.1101/gad.1483206; Higa LA, 2007, CELL DIV, V2, DOI 10.1186/1747-1028-2-5; Higa LA, 2006, NAT CELL BIOL, V8, P1277, DOI 10.1038/ncb1490; HOFER B, 1994, GENE, V144, P9, DOI 10.1016/0378-1119(94)90196-1; Hrecka K, 2007, P NATL ACAD SCI USA, V104, P11778, DOI 10.1073/pnas.0702102104; Jin HC, 2006, NATURE, V442, P576, DOI 10.1038/nature04856; Jin JP, 2006, MOL CELL, V23, P709, DOI 10.1016/j.molcel.2006.08.010; Kissil JL, 2003, MOL CELL, V12, P841, DOI 10.1016/S1097-2765(03)00382-4; Le Rouzic E, 2007, CELL CYCLE, V6, P182, DOI 10.4161/cc.6.2.3732; Lee J, 2007, MOL CELL, V26, P775, DOI 10.1016/j.molcel.2007.06.001; Lee JY, 2006, ONCOGENE, V25, P1143, DOI 10.1038/sj.onc.1209150; McClatchey AI, 1998, GENE DEV, V12, P1121, DOI 10.1101/gad.12.8.1121; Morrison H, 2007, CANCER RES, V67, P520, DOI 10.1158/0008-5472.CAN-06-1608; Okada T, 2005, J CELL BIOL, V171, P361, DOI 10.1083/jcb.200503165; ROULEAU GA, 1993, NATURE, V363, P515, DOI 10.1038/363515a0; Shaw RJ, 1998, J BIOL CHEM, V273, P7757, DOI 10.1074/jbc.273.13.7757; Shaw RJ, 2001, DEV CELL, V1, P63, DOI 10.1016/S1534-5807(01)00009-0; Tan L, 2007, J VIROL, V81, P10822, DOI 10.1128/JVI.01380-07; Trofatter J A, 1993, Cell, V75, P826; Wen XY, 2007, J BIOL CHEM, V282, P27046, DOI 10.1074/jbc.M703955200; Xu HM, 1998, J NEUROSCI RES, V51, P403, DOI 10.1002/(SICI)1097-4547(19980201)51:3<403::AID-JNR13>3.0.CO;2-7; Zhang SG, 2001, GENE, V263, P131, DOI 10.1016/S0378-1119(00)00583-7	29	52	55	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 3	2008	27	29					4056	4064		10.1038/onc.2008.44	http://dx.doi.org/10.1038/onc.2008.44			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	321RV	18332868				2022-12-28	WOS:000257325100005
J	Sasai, K; Parant, JM; Brandt, ME; Carter, J; Adams, HP; Stass, SA; Killary, AM; Katayama, H; Sen, S				Sasai, K.; Parant, J. M.; Brandt, M. E.; Carter, J.; Adams, H. P.; Stass, S. A.; Killary, A. M.; Katayama, H.; Sen, S.			Targeted disruption of Aurora A causes abnormal mitotic spindle assembly, chromosome misalignment and embryonic lethality	ONCOGENE			English	Article						mouse Aurora kinase A (Aurka) gene; mitotic spindle; chromosome segregation; Cre-LoxP recombination; morula/blastocyst	MAMMALIAN-CELLS; MESSENGER-RNA; PROTEIN; CHECKPOINT; KINASE; MICE; PHOSPHORYLATION; ENTRY; HURP; LOCALIZATION	Aurora A ( also known as STK15/BTAK in humans), a putative oncoprotein naturally overexpressed in many human cancers, is a member of the conserved Aurora protein serine/threonine kinase family that is implicated in the regulation of G(2)-M phases of the cell cycle. In vitro studies utilizing antibody microinjection, siRNA silencing and small molecule inhibitors have indicated that Aurora A functions in early as well as late stages of mitosis. However, due to limitations in specificity of the techniques, exact functional roles of the kinase remain to be clearly elucidated. In order to identify the physiological functions in vivo, we have generated Aurora A null mouse embryos, which show severe defects at 3.5 d.p.c. ( days post-coitus) morula/blastocyst stage and lethality before 8.5 d.p.c. Null embryos at 3.5 d.p.c. reveal growth retardation with cells in mitotic disarray manifesting disorganized spindle, misaligned and lagging chromosomes as well as micronucleated cells. These findings provide the first unequivocal genetic evidence for an essential physiological role of Aurora A in normal mitotic spindle assembly, chromosome alignment segregation and maintenance of viability in mammalian embryos.	[Sasai, K.; Brandt, M. E.; Carter, J.; Katayama, H.; Sen, S.] Univ Texas MD Anderson Canc Ctr, Dept Mol Pathol, Houston, TX 77054 USA; [Parant, J. M.; Adams, H. P.; Killary, A. M.] Univ Texas MD Anderson Canc Ctr, Dept Mol Genet, Houston, TX 77054 USA; [Stass, S. A.] Univ Maryland, Sch Med, Dept Pathol, Baltimore, MD 21201 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University System of Maryland; University of Maryland Baltimore	Sen, S (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Mol Pathol, 7435 Fannin, Houston, TX 77054 USA.	ssen@mdanderson.org			NATIONAL CANCER INSTITUTE [R01CA089716, P30CA016672] Funding Source: NIH RePORTER; NCI NIH HHS [CA16672, R01 CA89716] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Anand S, 2003, CANCER CELL, V3, P51, DOI 10.1016/S1535-6108(02)00235-0; Berdnik D, 2002, CURR BIOL, V12, P640, DOI 10.1016/S0960-9822(02)00766-2; Carmena M, 2003, NAT REV MOL CELL BIO, V4, P842, DOI 10.1038/nrm1245; Conte N, 2003, ONCOGENE, V22, P8102, DOI 10.1038/sj.onc.1206972; Cutts SM, 1999, HUM MOL GENET, V8, P1145, DOI 10.1093/hmg/8.7.1145; Dobles M, 2000, CELL, V101, P635, DOI 10.1016/S0092-8674(00)80875-2; Du J, 2004, P NATL ACAD SCI USA, V101, P8975, DOI 10.1073/pnas.0308484101; Dutertre S, 2004, J CELL SCI, V117, P2523, DOI 10.1242/jcs.01108; Giet R, 2002, J CELL BIOL, V156, P437, DOI 10.1083/jcb.200108135; Girdler F, 2006, J CELL SCI, V119, P3664, DOI 10.1242/jcs.03145; Gruss OJ, 2001, CELL, V104, P83, DOI 10.1016/S0092-8674(01)00193-3; Hirota T, 2003, CELL, V114, P585, DOI 10.1016/S0092-8674(03)00642-1; Hoar K, 2007, MOL CELL BIOL, V27, P4513, DOI 10.1128/MCB.02364-06; Howman EV, 2000, P NATL ACAD SCI USA, V97, P1148, DOI 10.1073/pnas.97.3.1148; Iwanaga Y, 2007, CANCER RES, V67, P160, DOI 10.1158/0008-5472.CAN-06-3326; Kalitsis P, 1998, P NATL ACAD SCI USA, V95, P1136, DOI 10.1073/pnas.95.3.1136; Katayama Hiroshi, 2003, Cancer and Metastasis Reviews, V22, P451, DOI 10.1023/A:1023789416385; Koffa MD, 2006, CURR BIOL, V16, P743, DOI 10.1016/j.cub.2006.03.056; Liu Q, 2006, P NATL ACAD SCI USA, V103, P5811, DOI 10.1073/pnas.0601425103; Luders J, 2007, NAT REV MOL CELL BIO, V8, P161, DOI 10.1038/nrm2100; Ma CQ, 2003, MOL CELL BIOL, V23, P1703, DOI 10.1128/MCB.23.5.1703-1716.2003; Marumoto T, 2002, GENES CELLS, V7, P1173, DOI 10.1046/j.1365-2443.2002.00592.x; Mendez R, 2000, NATURE, V404, P302, DOI 10.1038/35005126; Perera D, 2007, DEV CELL, V13, P566, DOI 10.1016/j.devcel.2007.08.008; Rieder CL, 2005, CHROMOSOMA, V114, P310, DOI 10.1007/s00412-005-0028-2; Satinover DL, 2006, CELL CYCLE, V5, P2268, DOI 10.4161/cc.5.19.3316; Sillje HHW, 2006, CURR BIOL, V16, P731, DOI 10.1016/j.cub.2006.02.070; Tay J, 2000, DEV BIOL, V221, P1, DOI 10.1006/dbio.2000.9669; Tulu US, 2006, CURR BIOL, V16, P536, DOI 10.1016/j.cub.2006.01.060; Uren AG, 2000, CURR BIOL, V10, P1319, DOI 10.1016/S0960-9822(00)00769-7; Wang Q, 2004, BLOOD, V103, P1278, DOI 10.1182/blood-2003-06-2158; Yu CTR, 2005, MOL CELL BIOL, V25, P5789, DOI 10.1128/MCB.25.14.5789-5800.2005	32	58	58	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 3	2008	27	29					4122	4127		10.1038/onc.2008.47	http://dx.doi.org/10.1038/onc.2008.47			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	321RV	18345035				2022-12-28	WOS:000257325100012
J	Tai, KY; Shieh, YS; Lee, CS; Shiah, SG; Wu, CW				Tai, K-Y; Shieh, Y-S; Lee, C-S; Shiah, S-G; Wu, C-W			Axl promotes cell invasion by inducing MMP-9 activity through activation of NF-kappa B and Brg-1	ONCOGENE			English	Article						Axl; Brg-1; ERK; MMP-9; NF-kappa B	RECEPTOR TYROSINE KINASE; TRANSCRIPTIONAL ACTIVATION; DIFFERENTIAL ACTIVATION; ENDOTHELIAL-CELLS; DNA METHYLATION; BREAST-CANCER; EXPRESSION; CARCINOMA; CHROMATIN; PATHWAYS	Activity of the Axl receptor tyrosine kinase is positively correlated with tumor metastasis; however, its detailed role in the mechanism of tumor invasion is still not completely understood. Here, we show that Axl enhances the expression of matrix metalloproteinase 9 ( MMP-9), required for Axl-mediated invasion both in vitro and in vivo. We found that the highly selective MEK1/2 inhibitors U0126 and PD98059, and the expressed dominant-negative form of extracellular signal-regulated kinase ( ERK), completely block Axl-mediated MMP-9 activation. In contrast, the phosphatidylinositol 3-kinase inhibitor LY294002 and wortmannin had little effect on activation. Interestingly, however, the Axl ligand Gas6 is not involved in Axl-mediated MMP-9 activation. Mutation of Glu59(Axl) and Thr77(Axl) dramatically reduced Gas6-Axl binding but continued to induce MMP-9 activation. In addition, overexpression of Axl-activated ERK and enhanced nuclear factor-kappa B (NF-kappa B) transactivation and brahma-related gene-1 ( Brg-1) translocation. Exposure to the NF-kappa B inhibitor silibinin, which inhibits I kappa B alpha kinase activity, or overexpression of the dominant-negative mutant I kappa B and Brg-1 strikingly inhibited Axl-mediated MMP-9 activation. These data indicate that coordination of ERK signaling and NF-kappa B and Brg-1 activation are indispensable to regulation of Axl-dependent MMP-9 gene transcription. Together with previous data, our results provide a plausible mechanism for Axl-mediated tumor invasion and establish a functional link between the Axl and MMP-9 signaling pathways.	[Tai, K-Y; Lee, C-S; Shiah, S-G; Wu, C-W] Natl Hlth Res Inst, Inst Canc Res, Miaoli 350, Miaoli County, Taiwan; [Shieh, Y-S] Natl Defense Med Ctr, Sch Dent, Taipei, Taiwan	National Health Research Institutes - Taiwan; National Defense Medical Center	Shiah, SG (corresponding author), Natl Hlth Res Inst, Inst Canc Res, 35 Keyan Rd,Zhunan Town, Miaoli 350, Miaoli County, Taiwan.	920114@nhri.org.tw; ken@nhri.org.tw	Shiah, Shine-Gwo/D-2087-2010	Tai, Kang-Yu/0000-0001-6867-3365; Shiah, Shine-Gwo/0000-0002-1003-973X				Banine F, 2005, CANCER RES, V65, P3542, DOI 10.1158/0008-5472.CAN-04-3554; Bittner M, 2000, NATURE, V406, P536, DOI 10.1038/35020115; Budagian V, 2005, EMBO J, V24, P4260, DOI 10.1038/sj.emboj.7600874; Chung BI, 2003, DNA CELL BIOL, V22, P533, DOI 10.1089/10445490360708946; CRAVEN RJ, 1995, INT J CANCER, V60, P791, DOI 10.1002/ijc.2910600611; Demarchi F, 2001, J BIOL CHEM, V276, P31738, DOI 10.1074/jbc.M104457200; Dhanalakshmi S, 2002, ONCOGENE, V21, P1759, DOI 10.1038/sj.onc.1205240; DiRenzo J, 2000, MOL CELL BIOL, V20, P7541, DOI 10.1128/MCB.20.20.7541-7549.2000; Fingleton B, 2006, FRONT BIOSCI-LANDMRK, V11, P479, DOI 10.2741/1811; Fridell YWC, 1996, MOL CELL BIOL, V16, P135; Genersch E, 2000, J CELL SCI, V113, P4319; Hafizi S, 2006, CYTOKINE GROWTH F R, V17, P295, DOI 10.1016/j.cytogfr.2006.04.004; Hasanbasic I, 2004, AM J PHYSIOL-HEART C, V287, pH1207, DOI 10.1152/ajpheart.00020.2004; Holland SJ, 2005, CANCER RES, V65, P9294, DOI 10.1158/0008-5472.CAN-05-0993; Ito T, 1999, THYROID, V9, P563, DOI 10.1089/thy.1999.9.563; Jacob ANK, 1999, CANCER DETECT PREV, V23, P325; Jin S, 2005, J BIOCHEM BIOPH METH, V65, P20, DOI 10.1016/j.jbbm.2005.08.006; Lakka SS, 2002, ONCOGENE, V21, P5601, DOI 10.1038/sj.onc.1205646; Lay JD, 2007, CANCER RES, V67, P3878, DOI 10.1158/0008-5472.CAN-06-3191; Liu Y, 2006, J BIOL CHEM, V281, P31359, DOI 10.1074/jbc.M604478200; Ma ZD, 2004, MOL CELL BIOL, V24, P5496, DOI 10.1128/MCB.24.12.5496-5509.2004; Melaragno MG, 1999, TRENDS CARDIOVAS MED, V9, P250, DOI 10.1016/S1050-1738(00)00027-X; Meric F, 2002, CLIN CANCER RES, V8, P361; Nakano T, 2003, CLIN EXP METASTAS, V20, P665, DOI 10.1023/A:1027355610603; Nemoto T, 1997, PATHOBIOLOGY, V65, P195, DOI 10.1159/000164123; NEUBAUER A, 1993, SEMIN HEMATOL, V30, P34; Roberts CWM, 2004, NAT REV CANCER, V4, P133, DOI 10.1038/nrc1273; Sasaki T, 2006, EMBO J, V25, P80, DOI 10.1038/sj.emboj.7600912; Shieh YS, 2005, NEOPLASIA, V7, P1058, DOI 10.1593/neo.05640; Singh RAK, 2004, J IMMUNOL, V173, P7299, DOI 10.4049/jimmunol.173.12.7299; Sun WS, 2004, ONCOLOGY-BASEL, V66, P450, DOI 10.1159/000079499; Tai KY, 2007, ONCOGENE, V26, P3989, DOI 10.1038/sj.onc.1210176; Vajkoczy P, 2006, P NATL ACAD SCI USA, V103, P5799, DOI 10.1073/pnas.0510923103; van Ginkel PR, 2004, CANCER RES, V64, P128, DOI 10.1158/0008-5472.CAN-03-0245; Wang W, 2003, CURR TOP MICROBIOL, V274, P143; Wu CW, 2002, ANTICANCER RES, V22, P1071; Yao J, 2001, ONCOGENE, V20, P8066, DOI 10.1038/sj.onc.1204944; Zeigler ME, 1999, J CELL PHYSIOL, V180, P271	38	125	150	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 3	2008	27	29					4044	4055		10.1038/onc.2008.57	http://dx.doi.org/10.1038/onc.2008.57			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	321RV	18345028				2022-12-28	WOS:000257325100004
J	Ho, VM; Schaffer, BE; Karnezis, AN; Park, KS; Sage, J				Ho, V. M.; Schaffer, B. E.; Karnezis, A. N.; Park, K. S.; Sage, J.			The retinoblastoma gene Rb and its family member p130 suppress lung adenocarcinoma induced by oncogenic K-Ras	ONCOGENE			English	Article						K-Ras; Rb; p130; p107; lung adenocarcinoma; mouse model	TUMOR-SUPPRESSOR; N-RAS; CANCER; PRB; PROTEIN; P107; DIFFERENTIATION; MOUSE; TUMORIGENESIS; PROGRESSION	Mutations of the retinoblastoma tumor suppressor gene RB are frequently observed in human cancers, but rarely in non-small cell lung carcinomas (NSCLCs). Emerging evidence also suggests that the RB-related gene p130 is inactivated in a subset of human NSCLCs. To directly test the specific tumor suppressor roles of RB and p130 in NSCLC, we crossed Rb and p130 conditional mutant mice to mice carrying a conditional oncogenic K-Ras allele. In this model, controlled oncogenic K-Ras activation leads to the development of adenocarcinoma, a major subtype of NSCLC. We found that loss of p130 accelerated the death of mice, providing direct evidence in vivo that p130 is a tumor suppressor gene, albeit a weak one in this context. Loss of Rb increased the efficiency of lung cancer initiation and resulted in the development of high-grade adenocarcinomas and rapid death. Thus, despite the low frequency of RB mutations in human NSCLCs and reports that K-Ras activation and loss of RB function are rarely found in the same human tumors, loss of Rb clearly cooperates with activation of oncogenic K-Ras in lung adenocarcinoma development in mice.	[Ho, V. M.; Schaffer, B. E.; Park, K. S.; Sage, J.] Stanford Med Sch, Dept Pediat & Genet, Stanford, CA 94305 USA; [Karnezis, A. N.] Univ Calif San Francisco, Canc Res Inst, Dept Pathol, Helen Diller Family Comprehens Canc Ctr, San Francisco, CA 94143 USA	Stanford University; University of California System; University of California San Francisco; UCSF Medical Center; UCSF Helen Diller Family Comprehensive Cancer Center	Sage, J (corresponding author), Stanford Med Sch, Dept Pediat & Genet, 269 Campus Dr,CCSR1215A, Stanford, CA 94305 USA.	julien.sage@stanford.edu			NATIONAL CANCER INSTITUTE [R01CA114102] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA114102-02, R01 CA114102] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Caterina C, 2005, ONCOGENE, V24, P5821, DOI 10.1038/sj.onc.1208880; Classon M, 2002, NAT REV CANCER, V2, P910, DOI 10.1038/nrc950; Classon M, 2000, P NATL ACAD SCI USA, V97, P10820, DOI 10.1073/pnas.190343497; Claudio PP, 2000, CLIN CANCER RES, V6, P754; Cobrinik D, 1996, GENE DEV, V10, P1633, DOI 10.1101/gad.10.13.1633; Dannenberg Jan-Hermen, 2006, V42, P183, DOI 10.1007/002; Dannenberg JH, 2004, GENE DEV, V18, P2952, DOI 10.1101/gad.322004; DeGregori J, 2006, MOL CELL BIOL, V26, P1165, DOI 10.1128/MCB.26.4.1165-1169.2006; Geng Y, 1996, ONCOGENE, V12, P1173; Grasemann C, 2005, ONCOGENE, V24, P6441, DOI 10.1038/sj.onc.1208792; Greenlee RT, 2001, CA-CANCER J CLIN, V51, P15, DOI 10.3322/canjclin.51.1.15; Jackson EL, 2005, CANCER RES, V65, P10280, DOI 10.1158/0008-5472.CAN-05-2193; Jackson EL, 2001, GENE DEV, V15, P3243, DOI 10.1101/gad.943001; JOHNSON DG, 1994, GENE DEV, V8, P1514, DOI 10.1101/gad.8.13.1514; Kaye FJ, 2002, ONCOGENE, V21, P6908, DOI 10.1038/sj.onc.1205834; Lara MF, 2008, MOL CARCINOGEN, V47, P105, DOI 10.1002/mc.20367; Lee KY, 1999, MOL CELL BIOL, V19, P7724; Meuwissen R, 2003, CANCER CELL, V4, P181, DOI 10.1016/S1535-6108(03)00220-4; Mulligan GJ, 1998, MOL CELL BIOL, V18, P206, DOI 10.1128/MCB.18.1.206; Olsson AY, 2007, ONCOGENE, V26, P1028, DOI 10.1038/sj.onc.1209854; RODENHUIS S, 1990, AM REV RESPIR DIS, V142, pS27, DOI 10.1164/ajrccm/142.6_Pt_2.S27; Ruiz S, 2005, CANCER RES, V65, P9678, DOI 10.1158/0008-5472.CAN-05-1853; Sage J, 2003, NATURE, V424, P223, DOI 10.1038/nature01764; Sage J, 2000, GENE DEV, V14, P3037, DOI 10.1101/gad.843200; Sherr CJ, 2002, CANCER CELL, V2, P103, DOI 10.1016/S1535-6108(02)00102-2; Suzuki T, 2006, EMBO J, V25, P3422, DOI 10.1038/sj.emboj.7601215; Takahashi C, 2006, NAT GENET, V38, P118, DOI 10.1038/ng1703; Takahashi C, 2004, MOL CELL BIOL, V24, P10406, DOI 10.1128/MCB.24.23.10406-10415.2004; Takahashi C, 2003, MOL CELL BIOL, V23, P5256, DOI 10.1128/MCB.23.15.5256-5268.2003; Takahashi C, 2006, CANCER RES, V66, P9345, DOI 10.1158/0008-5472.CAN-06-1250; Tedesco D, 2002, GENE DEV, V16, P2946, DOI 10.1101/gad.1011202; TRAVIS WD, 1995, CANCER-AM CANCER SOC, V75, P191, DOI 10.1002/1097-0142(19950101)75:1+<191::AID-CNCR2820751307>3.0.CO;2-Y; Tuveson DA, 2004, CANCER CELL, V5, P375, DOI 10.1016/S1535-6108(04)00085-6; Wikenheiser-Brokamp KA, 2006, CELL MOL LIFE SCI, V63, P767, DOI 10.1007/s00018-005-5487-3; Wikenheiser-Brokamp KA, 2004, DEVELOPMENT, V131, P4299, DOI 10.1242/dev.01232; Williams JP, 2006, MOL CELL BIOL, V26, P1170, DOI 10.1128/MCB.26.4.1170-1182.2006; Wistuba II, 2001, SEMIN ONCOL, V28, P3, DOI 10.1053/sonc.2001.25738	37	39	41	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2009	28	10					1393	1399		10.1038/onc.2008.491	http://dx.doi.org/10.1038/onc.2008.491			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	417ZC	19151761	Green Accepted			2022-12-28	WOS:000264116000012
J	Thorner, AR; Hoadley, KA; Parker, JS; Winkel, S; Millikan, RC; Perou, CM				Thorner, A. R.; Hoadley, K. A.; Parker, J. S.; Winkel, S.; Millikan, R. C.; Perou, C. M.			In vitro and in vivo analysis of B-Myb in basal-like breast cancer	ONCOGENE			English	Article						B-Myb; MYBL2; breast cancer; basal-like	RETINOBLASTOMA TUMOR-SUPPRESSOR; CENTRAL-NERVOUS-SYSTEM; C-MYB; CELL-CYCLE; A-MYB; EXPRESSION SIGNATURE; MOLECULAR PORTRAITS; GENE; TRANSCRIPTION; SUBTYPES	A defining feature of basal-like breast cancer, a breast cancer subtype with poor clinical prognosis, is the high expression of 'proliferation signature' genes. We identified B-Myb, a MYB family transcription factor that is often amplified and overexpressed in many tumor types, as being highly expressed in the proliferation signature. However, the roles of B-Myb in disease progression, and its mammary-specific transcriptional targets, are poorly understood. Here, we showed that B-Myb expression is a significant predictor of survival and pathological complete response to neoadjuvant chemotherapy in breast cancer patients. We also identified a significant association between the G/G genotype of a nonsynonymous B-Myb germline variant (rs2070235, S427G) and an increased risk of basal-like breast cancer [OR 2.0, 95% CI (1.1-3.8)]. In immortalized, human mammary epithelial cell lines, but not in basal-like tumor lines, cells ectopically expressing wild-type B-Myb or the S427G variant showed increased sensitivity to two DNA topoisomerase II alpha inhibitors, but not to other chemotherapeutics. In addition, microarray analyses identified many G2/M genes as being induced in B-Myb overexpressing cells. These results confirm that B-Myb is involved in cell cycle control, and that its dysregulation may contribute to increased sensitivity to a specific class of chemotherapeutic agents. These data provide insight into the influence of B-Myb in human breast cancer, which is of potential clinical importance for determining disease risk and for guiding treatment.	[Perou, C. M.] Univ N Carolina, Lineberger Comprehens Canc Ctr, Dept Genet, Chapel Hill, NC 27599 USA; [Thorner, A. R.] Univ N Carolina, Curriculum Genet & Mol Biol, Chapel Hill, NC 27599 USA; [Winkel, S.; Millikan, R. C.] Univ N Carolina, Dept Epidemiol, Chapel Hill, NC 27599 USA; [Perou, C. M.] Univ N Carolina, Dept Pathol & Lab Med, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill	Perou, CM (corresponding author), Univ N Carolina, Lineberger Comprehens Canc Ctr, Dept Genet, 450 West Dr, Chapel Hill, NC 27599 USA.	cperou@med.unc.edu	Perou, Charles M/H-9934-2014; Parker, Joel/AAG-1108-2019	Perou, Charles M/0000-0001-9827-2247; Hoadley, Katherine/0000-0002-1216-477X	NCI Breast SPORE [P50-CA5822309A1, RO1-CA-101227-01]; Breast Cancer Research Foundation; V Foundation for Cancer Research; NATIONAL CANCER INSTITUTE [R01CA101227, P50CA058223] Funding Source: NIH RePORTER	NCI Breast SPORE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Breast Cancer Research Foundation; V Foundation for Cancer Research; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Drs Melissa A Troester and William K Kaufmann for comments and discussion. This work was supported by funds from the NCI Breast SPORE program (P50-CA5822309A1), by RO1-CA-101227-01, by the Breast Cancer Research Foundation and the V Foundation for Cancer Research.	Bergamaschi A, 2006, GENE CHROMOSOME CANC, V45, P1033, DOI 10.1002/gcc.20366; Carey LA, 2007, CLIN CANCER RES, V13, P2329, DOI 10.1158/1078-0432.CCR-06-1109; Carey LA, 2006, JAMA-J AM MED ASSOC, V295, P2492, DOI 10.1001/jama.295.21.2492; Chin K, 2006, CANCER CELL, V10, P529, DOI 10.1016/j.ccr.2006.10.009; Davidson CJ, 2005, GENETICS, V169, P215, DOI 10.1534/genetics.104.034132; Derenzini M, 2008, CLIN CANCER RES, V14, P2199, DOI 10.1158/1078-0432.CCR-07-2065; Herschkowitz JI, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr2142; Hess KR, 2006, J CLIN ONCOL, V24, P4236, DOI 10.1200/JCO.2006.05.6861; Hoadley KA, 2007, BMC GENOMICS, V8, DOI 10.1186/1471-2164-8-258; Hosack DA, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-10-r70; Hu ZY, 2006, BMC GENOMICS, V7, DOI 10.1186/1471-2164-7-96; Hu ZY, 2005, BIOTECHNIQUES, V38, P121, DOI 10.2144/05381MT02; Ito M, 2001, PLANT CELL, V13, P1891, DOI 10.1105/tpc.13.8.1891; KLEMPNAUER KH, 1982, CELL, V31, P453, DOI 10.1016/0092-8674(82)90138-6; LEPRINCE D, 1983, NATURE, V306, P395, DOI 10.1038/306395a0; Malaterre J, 2007, P NATL ACAD SCI USA, V104, P3829, DOI 10.1073/pnas.0610055104; Miller LD, 2005, P NATL ACAD SCI USA, V102, P13550, DOI 10.1073/pnas.0506230102; Millikan R, 2003, BREAST CANCER RES TR, V79, P355, DOI 10.1023/A:1024068525763; Millikan RC, 2008, BREAST CANCER RES TR, V109, P123, DOI 10.1007/s10549-007-9632-6; MUCENSKI ML, 1991, CELL, V65, P677, DOI 10.1016/0092-8674(91)90099-K; Ness SA, 2003, BLOOD CELL MOL DIS, V31, P192, DOI 10.1016/S1079-9796(03)00151-7; NEWMAN B, 1995, BREAST CANCER RES TR, V35, P51, DOI 10.1007/BF00694745; NOMURA N, 1988, NUCLEIC ACIDS RES, V16, P11075, DOI 10.1093/nar/16.23.11075; Osterloh L, 2007, EMBO J, V26, P144, DOI 10.1038/sj.emboj.7601478; Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093; Pomeroy SL, 2002, NATURE, V415, P436, DOI 10.1038/415436a; Rosinski JA, 1998, J MOL EVOL, V46, P74, DOI 10.1007/PL00006285; Rouzier R, 2005, CLIN CANCER RES, V11, P5678, DOI 10.1158/1078-0432.CCR-04-2421; Sala A, 2005, EUR J CANCER, V41, P2479, DOI 10.1016/j.ejca.2005.08.004; Schwab R, 2008, ONCOGENE, V27, P2929, DOI 10.1038/sj.onc.1210947; SMITH PJ, 1994, BRIT J CANCER, V70, P914, DOI 10.1038/bjc.1994.420; Sorlie T, 2003, P NATL ACAD SCI USA, V100, P8418, DOI 10.1073/pnas.0932692100; Sorlie T, 2001, P NATL ACAD SCI USA, V98, P10869, DOI 10.1073/pnas.191367098; Tanaka Y, 1999, J BIOL CHEM, V274, P28067, DOI 10.1074/jbc.274.40.28067; Toscani A, 1997, NATURE, V386, P713, DOI 10.1038/386713a0; TRAUTH K, 1994, EMBO J, V13, P5994, DOI 10.1002/j.1460-2075.1994.tb06945.x; Troester MA, 2004, CANCER RES, V64, P4218, DOI 10.1158/0008-5472.CAN-04-0107; Tusher VG, 2001, P NATL ACAD SCI USA, V98, P5116, DOI 10.1073/pnas.091062498; van de Vijver MJ, 2002, NEW ENGL J MED, V347, P1999, DOI 10.1056/NEJMoa021967; VANEWIJK PH, 1993, ECOTOX ENVIRON SAFE, V25, P25, DOI 10.1006/eesa.1993.1003; Wang YX, 2005, LANCET, V365, P671, DOI 10.1016/S0140-6736(05)17947-1; Whitfield ML, 2006, NAT REV CANCER, V6, P99, DOI 10.1038/nrc1802; Whitfield ML, 2002, MOL BIOL CELL, V13, P1977, DOI 10.1091/mbc.02-02-0030; Zhu WC, 2004, EMBO J, V23, P4615, DOI 10.1038/sj.emboj.7600459	44	73	74	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 5	2009	28	5					742	751		10.1038/onc.2008.430	http://dx.doi.org/10.1038/onc.2008.430			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	403IN	19043454	Green Submitted, Green Accepted			2022-12-28	WOS:000263076400011
J	Min, SH; Kim, DM; Heo, YS; Kim, YI; Kim, HM; Kim, J; Han, YM; Kim, IC; Yoo, OJ				Min, S-H; Kim, D. M.; Heo, Y-S; Kim, Y-I; Kim, H. M.; Kim, J.; Han, Y-M; Kim, I-C; Yoo, O-J			New p53 target, phosphatase of regenerating liver 1 (PRL-1) downregulates p53	ONCOGENE			English	Article						p53 target; phosphatase of regenerating liver 1; PRL-1; EGR; PI3K	TUMOR-SUPPRESSOR PROTEIN; GENE-EXPRESSION; TYROSINE PHOSPHATASES; CANCER-CELLS; GROWTH; ACTIVATION; METASTASIS; INVASION; PHOSPHORYLATION; MDM2	Most of the p53 target genes, all except MDM2, COP1 and PIRH2, perform functions in apoptosis, differentiation and cell cycle arrest. The aforementioned oncogenes downregulate p53 through a negative feedback mechanism, and thus contribute to tumor development. In this study, we report a new p53 target, PRL-1, which is believed to be a significant regulator in the development and metastasis of a variety of cancer types. Phosphatase of regenerating liver 1 (PRL-1) overexpression reduced the levels of endogenous and exogenous p53 proteins, and inhibited p53-mediated apoptosis. On the other hand, the ablation of PRL-1 by small interfering RNA (siRNA) increased p53 protein levels. The p53 downregulation was mediated by p53 ubiquitination and subsequent proteasomal degradation. Furthermore, p53 ubiquitination by PRL-1 was achieved through two independent pathways, by inducing PIRH2 transcription and by inducing MDM2 phosphorylation through Akt signaling. In addition, we showed that the PRL-1 gene harbors a p53 response element in the first intron, and its transcription is regulated by the p53 protein. These findings imply that the new oncogenic p53 target, PRL-1, may contribute to tumor development by the downregulation of p53 by a negative feedback mechanism.	[Yoo, O-J] Korea Adv Inst Sci & Technol, Grad Sch Med Sci & Engn, Biomed Res Ctr, Dept Biol Sci, Taejon 305701, South Korea; [Kim, D. M.] Chonnam Natl Univ, Higher Educ Ctr Bioregulator Res BK21, Kwangju, South Korea; [Kim, I-C] Chonnam Natl Univ, Dept Biol, Kwangju, South Korea; [Yoo, O-J] Korea Adv Inst Sci & Technol, Grad Sch Med Sci & Engn, Biomed Res Ctr, Taejon 305701, South Korea	Korea Advanced Institute of Science & Technology (KAIST); Chonnam National University; Chonnam National University; Korea Advanced Institute of Science & Technology (KAIST)	Yoo, OJ (corresponding author), Korea Adv Inst Sci & Technol, Grad Sch Med Sci & Engn, Biomed Res Ctr, Dept Biol Sci, Taejon 305701, South Korea.	ojyoo@kaist.ac.kr	Kim, Ho Min/G-2712-2011; Yoo, Ook Joon/C-1860-2011		Ministry of Science and Technology of Korea [M1040101001-06N0101-00110]	Ministry of Science and Technology of Korea(Ministry of Science & Technology (MOST), Republic of Korea)	We thank Dr Sung Hyun Kang and Dr Kwang Hee Bae (KRIBB) for providing the FLAG-PRL-1. This work was supported by funding from the Ministry of Science and Technology of Korea (M1040101001-06N0101-00110).	Achiwa H, 2007, CANCER RES, V67, P643, DOI 10.1158/0008-5472.CAN-06-2436; Balint E, 2001, BRIT J CANCER, V85, P1813, DOI 10.1054/bjoc.2001.2128; Bunz F, 1999, J CLIN INVEST, V104, P263, DOI 10.1172/JCI6863; Daoud SS, 2003, CANCER RES, V63, P2782; DIAMOND RH, 1994, MOL CELL BIOL, V14, P3752, DOI 10.1128/MCB.14.6.3752; Dornan D, 2004, NATURE, V429, P86, DOI 10.1038/nature02514; Feng JH, 2004, J BIOL CHEM, V279, P35510, DOI 10.1074/jbc.M404936200; Fiordalisi JJ, 2006, CANCER RES, V66, P3153, DOI 10.1158/0008-5472.CAN-05-3116; GASHLER A, 1995, PROG NUCLEIC ACID RE, V50, P191, DOI 10.1016/S0079-6603(08)60815-6; GIUS D, 1990, MOL CELL BIOL, V10, P4243, DOI 10.1128/MCB.10.8.4243; Huang JH, 1998, ONCOGENE, V17, P401, DOI 10.1038/sj.onc.1201951; Jeong SJ, 2005, ONCOGENE, V24, P6719, DOI 10.1038/sj.onc.1208825; Jung HY, 2007, J BIOL CHEM, V282, P35293, DOI 10.1074/jbc.M705181200; Kim SB, 2007, CELL DEATH DIFFER, V14, P982, DOI 10.1038/sj.cdd.4402083; Kobayashi D, 2002, ANTICANCER RES, V22, P3963; Leng RP, 2003, CELL, V112, P779, DOI 10.1016/S0092-8674(03)00193-4; Li MY, 2003, SCIENCE, V302, P1972, DOI 10.1126/science.1091362; Liang FB, 2007, J BIOL CHEM, V282, P5413, DOI 10.1074/jbc.M608940200; McMahon SB, 1996, J LEUKOCYTE BIOL, V60, P159, DOI 10.1002/jlb.60.2.159; Milne D, 2004, FEBS LETT, V577, P270, DOI 10.1016/j.febslet.2004.09.081; Miskad UA, 2004, PATHOBIOLOGY, V71, P176, DOI 10.1159/000078671; Nair P, 1997, J BIOL CHEM, V272, P20131, DOI 10.1074/jbc.272.32.20131; Parker BS, 2004, CANCER RES, V64, P7857, DOI 10.1158/0008-5472.CAN-04-1976; QURESHI SA, 1991, J BIOL CHEM, V266, P20594; Resnick-Silverman L, 1998, GENE DEV, V12, P2102, DOI 10.1101/gad.12.14.2102; Saha S, 2001, SCIENCE, V294, P1343, DOI 10.1126/science.1065817; Seong HA, 2007, J BIOL CHEM, V282, P12075, DOI 10.1074/jbc.M609832200; Song MS, 2004, NAT CELL BIOL, V6, P129, DOI 10.1038/ncb1091; Stephens BJ, 2005, MOL CANCER THER, V4, P1653, DOI 10.1158/1535-7163.MCT-05-0248; Wang HH, 2007, CANCER RES, V67, P2922, DOI 10.1158/0008-5472.CAN-06-3598; Wang Q, 2002, CANCER LETT, V175, P63, DOI 10.1016/S0304-3835(01)00703-0; Weizer-Stern O, 2007, BRIT J HAEMATOL, V138, P253, DOI 10.1111/j.1365-2141.2007.06638.x; Werner SR, 2003, CANCER LETT, V202, P201, DOI 10.1016/S0304-3835(03)00517-2; Westfall MD, 2003, MOL CELL BIOL, V23, P2264, DOI 10.1128/MCB.23.7.2264-2276.2003; Wu XP, 2004, AM J PATHOL, V164, P2039, DOI 10.1016/S0002-9440(10)63763-7; Yoo YG, 2004, J BIOL CHEM, V279, P36242, DOI 10.1074/jbc.M401290200	36	34	38	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 29	2009	28	4					545	554		10.1038/onc.2008.409	http://dx.doi.org/10.1038/onc.2008.409			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	400KM	18997816				2022-12-28	WOS:000262866500008
J	Jeanes, A; Gottardi, CJ; Yap, AS				Jeanes, A.; Gottardi, C. J.; Yap, A. S.			Cadherins and cancer: how does cadherin dysfunction promote tumor progression?	ONCOGENE			English	Review						E-cadherin; beta-catenin; Wnt; growth factor receptor; cell polarity; metastasis	EPITHELIAL-CELL POLARITY; ADHESION MOLECULE UVOMORULIN; LOBULAR BREAST CANCERS; GROWTH-FACTOR RECEPTOR; BETA-CATENIN; ALPHA-CATENIN; MESENCHYMAL TRANSITION; DROSOPHILA HOMOLOG; JUNCTIONAL COMPLEX; CYTOPLASMIC DOMAIN	It has long been recognized that the cell-cell adhesion receptor, E-cadherin, is an important determinant of tumor progression, serving as a suppressor of invasion and metastasis in many contexts. Yet how the loss of E-cadherin function promotes tumor progression is poorly understood. In this review, we focus on three potential underlying mechanisms: the capacity of E-cadherin to regulate beta-catenin signaling in the canonical Wnt pathway; its potential to inhibit mitogenic signaling through growth factor receptors and the possible links between cadherins and the molecular determinants of epithelial polarity. Each of these potential mechanisms provides insights into the complexity that is likely responsible for the tumor-suppressive action of E-cadherin.	[Jeanes, A.; Yap, A. S.] Univ Queensland, Inst Mol Biosci, Mol Cell Biol Div, Brisbane, Qld, Australia; [Gottardi, C. J.] Northwestern Univ, Dept Med, Feinberg Sch Med, Chicago, IL 60611 USA	University of Queensland; Northwestern University; Feinberg School of Medicine	Yap, AS (corresponding author), Univ Queensland, Inst Mol Biosci, Mol Cell Biol Div, Brisbane, Qld, Australia.	a.yap@imb.uq.edu.au	Yap, Alpha S./J-1554-2014; Jeanes, Angela/D-9770-2011; Gottardi, Cara J./AAU-4691-2021	Yap, Alpha S./0000-0002-1038-8956; Jeanes, Angela/0000-0003-0717-6298; Gottardi, Cara J./0000-0003-0912-7617	National Health and Medical Research Council of Australia; NIH [GM076561]; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM076561] Funding Source: NIH RePORTER	National Health and Medical Research Council of Australia(National Health and Medical Research Council (NHMRC) of Australia); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We thank our colleagues in our labs for their thoughtful comments and support. AJ and ASY were funded by the National Health and Medical Research Council of Australia, whereas CJG is funded by the NIH (GM076561).	Abe K, 2008, P NATL ACAD SCI USA, V105, P13, DOI 10.1073/pnas.0710504105; Afonso C, 2006, J CELL SCI, V119, P4293, DOI 10.1242/jcs.03170; Anastasiadis PZ, 2000, J CELL SCI, V113, P1319; Bamji SX, 2006, J CELL BIOL, V174, P289, DOI 10.1083/jcb.200601087; Benton R, 2003, CELL, V115, P691, DOI 10.1016/S0092-8674(03)00938-3; Berx G, 1998, HUM MUTAT, V12, P226, DOI 10.1002/(SICI)1098-1004(1998)12:4<226::AID-HUMU2>3.0.CO;2-D; Berx G, 1996, ONCOGENE, V13, P1919; Berx G, 1995, EMBO J, V14, P6107, DOI 10.1002/j.1460-2075.1995.tb00301.x; Bhat MA, 1999, CELL, V96, P833, DOI 10.1016/S0092-8674(00)80593-0; Bilder D, 2004, GENE DEV, V18, P1909, DOI 10.1101/gad.1211604; Bilder D, 2003, NAT CELL BIOL, V5, P53, DOI 10.1038/ncb897; Bilder D, 2000, NATURE, V403, P676, DOI 10.1038/35001108; Bilder D, 2000, SCIENCE, V289, P113, DOI 10.1126/science.289.5476.113; BIRCHMEIER W, 1994, BBA-REV CANCER, V1198, P11, DOI 10.1016/0304-419X(94)90003-5; BROWN AMC, 1986, CELL, V46, P1001, DOI 10.1016/0092-8674(86)90699-9; BRUGMANS M, 1978, J CELL SCI, V33, P121; Bryant DM, 2004, TRENDS CELL BIOL, V14, P427, DOI 10.1016/j.tcb.2004.07.007; Bublil EM, 2007, CURR OPIN CELL BIOL, V19, P124, DOI 10.1016/j.ceb.2007.02.008; Caca K, 1999, CELL GROWTH DIFFER, V10, P369; Cadigan KM, 1997, GENE DEV, V11, P3286, DOI 10.1101/gad.11.24.3286; Capaldo CT, 2007, MOL BIOL CELL, V18, P189, DOI 10.1091/mbc.E06-05-0471; Chen YT, 1999, J CELL BIOL, V144, P687, DOI 10.1083/jcb.144.4.687; Choi HJ, 2006, J BIOL CHEM, V281, P1027, DOI 10.1074/jbc.M511338200; Ciruna B, 2001, DEV CELL, V1, P37, DOI 10.1016/S1534-5807(01)00017-X; Coman DR, 1944, CANCER RES, V4, P625; Cox RT, 1999, GENETICS, V153, P319; Daugherty RL, 2007, PHYSIOLOGY, V22, P303, DOI 10.1152/physiol.00020.2007; Derksen PWB, 2006, CANCER CELL, V10, P437, DOI 10.1016/j.ccr.2006.09.013; Drees F, 2005, CELL, V123, P903, DOI 10.1016/j.cell.2005.09.021; Eger A, 2000, J CELL BIOL, V148, P173, DOI 10.1083/jcb.148.1.173; Fagotto F, 1996, J CELL BIOL, V132, P1105, DOI 10.1083/jcb.132.6.1105; Fedor-Chaiken M, 2003, CELL COMMUN ADHES, V10, P105, DOI 10.1080/714040416; Fodde R, 2007, CURR OPIN CELL BIOL, V19, P150, DOI 10.1016/j.ceb.2007.02.007; FUNG YKT, 1985, MOL CELL BIOL, V5, P3337, DOI 10.1128/MCB.5.12.3337; Goodwin M, 2004, J MOL HISTOL, V35, P839, DOI 10.1007/s10735-004-1833-2; Gottardi CJ, 2001, CURR BIOL, V11, pR792, DOI 10.1016/S0960-9822(01)00473-0; Gottardi CJ, 2001, J CELL BIOL, V153, P1049, DOI 10.1083/jcb.153.5.1049; Greaves S, 1999, GENETICS, V153, P1753; Gregory PA, 2008, NAT CELL BIOL, V10, P593, DOI 10.1038/ncb1722; Guilford P, 1998, NATURE, V392, P402, DOI 10.1038/32918; GUMBINER B, 1988, J CELL BIOL, V107, P1575, DOI 10.1083/jcb.107.4.1575; Gumbiner BM, 2005, NAT REV MOL CELL BIO, V6, P622, DOI 10.1038/nrm1699; Ha NC, 2004, MOL CELL, V15, P511, DOI 10.1016/j.molcel.2004.08.010; Hamada F, 2002, NAT CELL BIOL, V4, P208, DOI 10.1038/ncb755; Harris TJC, 2004, J CELL BIOL, V167, P135, DOI 10.1083/jcb.200406024; HEASMAN J, 1994, CELL, V79, P791, DOI 10.1016/0092-8674(94)90069-8; Herzig M, 2007, ONCOGENE, V26, P2290, DOI 10.1038/sj.onc.1210029; HOSCHUETZKY H, 1994, J CELL BIOL, V127, P1375, DOI 10.1083/jcb.127.5.1375; Iden S, 2006, EMBO REP, V7, P1239, DOI 10.1038/sj.embor.7400819; KEMPHUES KJ, 1988, CELL, V52, P311, DOI 10.1016/S0092-8674(88)80024-2; Kuphal F, 2006, EXP CELL RES, V312, P457, DOI 10.1016/j.yexcr.2005.11.007; Lampugnani MG, 2006, J CELL BIOL, V174, P593, DOI 10.1083/jcb.200602080; Laprise P, 2004, J BIOL CHEM, V279, P10157, DOI 10.1074/jbc.M309843200; Lechler T, 2005, NATURE, V437, P275, DOI 10.1038/nature03922; Leckband D, 2006, ANNU REV BIOMED ENG, V8, P259, DOI 10.1146/annurev.bioeng.8.061505.095753; Lee MH, 2008, J CELL SCI, V121, P1141, DOI 10.1242/jcs.016634; Luo W, 2004, NEUROSIGNALS, V13, P99, DOI 10.1159/000076563; Maddugoda MP, 2007, J CELL BIOL, V178, P529, DOI 10.1083/jcb.200612042; McCartney BM, 2006, DEVELOPMENT, V133, P2407, DOI 10.1242/dev.02398; McLachlan RW, 2007, J MOL MED-JMM, V85, P545, DOI 10.1007/s00109-007-0198-x; Mege RM, 2006, CURR OPIN CELL BIOL, V18, P541, DOI 10.1016/j.ceb.2006.08.004; MOLITORIS BA, 1990, J CLIN INVEST, V85, P3, DOI 10.1172/JCI114427; Moreno-Bueno G, 2008, ONCOGENE, V27, P6958, DOI 10.1038/onc.2008.346; NAGAFUCHI A, 1989, CELL REGUL, V1, P37, DOI 10.1091/mbc.1.1.37; Navarro C, 2005, ONCOGENE, V24, P4330, DOI 10.1038/sj.onc.1208632; Nejsum LN, 2007, J CELL BIOL, V178, P323, DOI 10.1083/jcb.200705094; Nelson WJ, 2004, SCIENCE, V303, P1483, DOI 10.1126/science.1094291; OCHIAI A, 1994, BIOCHEM BIOPH RES CO, V205, P73, DOI 10.1006/bbrc.1994.2631; Oguma K, 2008, EMBO J, V27, P1671, DOI 10.1038/emboj.2008.105; Onder TT, 2008, CANCER RES, V68, P3645, DOI 10.1158/0008-5472.CAN-07-2938; Orsulic S, 1999, J CELL SCI, V112, P1237; OZAWA M, 1989, EMBO J, V8, P1711, DOI 10.1002/j.1460-2075.1989.tb03563.x; PEIFER M, 1990, CELL, V63, P1167, DOI 10.1016/0092-8674(90)90413-9; PEIFER M, 1991, DEVELOPMENT, V111, P1029; Perez-Moreno M, 2003, CELL, V112, P535, DOI 10.1016/S0092-8674(03)00108-9; Perl AK, 1998, NATURE, V392, P190, DOI 10.1038/32433; Perrais M, 2007, MOL BIOL CELL, V18, P2013, DOI 10.1091/mbc.E06-04-0348; Petronczki M, 2001, NAT CELL BIOL, V3, P43, DOI 10.1038/35050550; Piedra J, 2003, MOL CELL BIOL, V23, P2287, DOI 10.1128/MCB.23.7.2287-2297.2003; Qian XL, 2004, EMBO J, V23, P1739, DOI 10.1038/sj.emboj.7600136; Qin Y, 2005, J CELL BIOL, V171, P1061, DOI 10.1083/jcb.200506094; Reuver SM, 1998, J CELL SCI, V111, P1071; RODRIGUEZBOULAN E, 1989, SCIENCE, V245, P718, DOI 10.1126/science.2672330; Roura S, 1999, J BIOL CHEM, V274, P36734, DOI 10.1074/jbc.274.51.36734; Sadot E, 1998, P NATL ACAD SCI USA, V95, P15339, DOI 10.1073/pnas.95.26.15339; Sanson B, 1996, NATURE, V383, P627, DOI 10.1038/383627a0; Scott JA, 2006, J CELL SCI, V119, P4599, DOI 10.1242/jcs.03267; Stockinger A, 2001, J CELL BIOL, V154, P1185, DOI 10.1083/jcb.200104036; Suzuki A, 2002, J CELL SCI, V115, P3565, DOI 10.1242/jcs.00032; Tabuse Y, 1998, DEVELOPMENT, V125, P3607; TAKEICHI M, 1991, SCIENCE, V251, P1451, DOI 10.1126/science.2006419; Tanentzapf G, 2003, NAT CELL BIOL, V5, P46, DOI 10.1038/ncb896; TEPASS U, 1993, DEV BIOL, V159, P311, DOI 10.1006/dbio.1993.1243; TEPASS U, 1990, CELL, V61, P787, DOI 10.1016/0092-8674(90)90189-L; Tepass U, 1996, GENE DEV, V10, P672, DOI 10.1101/gad.10.6.672; Thiery JP, 2002, NAT REV CANCER, V2, P442, DOI 10.1038/nrc822; Tinkle CL, 2004, P NATL ACAD SCI USA, V101, P552, DOI 10.1073/pnas.0307437100; Tunggal JA, 2005, EMBO J, V24, P1146, DOI 10.1038/sj.emboj.7600605; van de Wetering M, 2001, CANCER RES, V61, P278; Vasioukhin V, 2001, CELL, V104, P605, DOI 10.1016/S0092-8674(01)00246-X; VEGASALAS DE, 1987, J CELL BIOL, V104, P905, DOI 10.1083/jcb.104.4.905; VLEMINCKX K, 1991, CELL, V66, P107, DOI 10.1016/0092-8674(91)90143-M; WATABE M, 1994, J CELL BIOL, V127, P247, DOI 10.1083/jcb.127.1.247; Wheelock MJ, 2008, J CELL SCI, V121, P727, DOI 10.1242/jcs.000455; WHEELOCK MJ, 1992, J CELL BIOL, V117, P415, DOI 10.1083/jcb.117.2.415; Yamanaka T, 2003, CURR BIOL, V13, P734, DOI 10.1016/S0960-9822(03)00244-6; Yanagisawa M, 2008, J BIOL CHEM, V283, P18344, DOI 10.1074/jbc.M801192200; Yang J, 2004, CELL, V117, P927, DOI 10.1016/j.cell.2004.06.006; Yang J, 2008, DEV CELL, V14, P818, DOI 10.1016/j.devcel.2008.05.009; Yap AS, 1998, CANCER INVEST, V16, P252, DOI 10.3109/07357909809039774; Yap AS, 2003, J CELL BIOL, V160, P11, DOI 10.1083/jcb.200208156	111	594	616	0	37	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 24	2008	27	55					6920	6929		10.1038/onc.2008.343	http://dx.doi.org/10.1038/onc.2008.343			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	375IU	19029934	Green Accepted			2022-12-28	WOS:000261108200005
J	Hemmati, PG; Normand, G; Gillissen, B; Wendt, J; Doerken, B; Daniel, PT				Hemmati, P. G.; Normand, G.; Gillissen, B.; Wendt, J.; Doerken, B.; Daniel, P. T.			Cooperative effect of p21(Cip1/WAF-1) and 14-3-3 sigma on cell cycle arrest and apoptosis induction by p14(ARF)	ONCOGENE			English	Article						p14(ARF); 14-3-3 sigma; p21; cell cycle; apoptosis; mitotic catastrophe	ARF TUMOR-SUPPRESSOR; NF-KAPPA-B; HUMAN CARCINOMA-CELLS; HUMAN CANCER-CELLS; DNA-DAMAGE; G(2) ARREST; P53-DEPENDENT APOPTOSIS; PROTEIN-BINDING; G2 ARREST; P21	P14(ARF) (p19(ARF) in the mouse) plays a central role in the regulation of cellular proliferation. Although the capacity of p14(ARF) to induce a cell cycle arrest in G1 phase depends on a functional p53/p21-signaling axis, the G2 arrest triggered by p14(ARF) is p53/p21-independent. Using isogeneic HCT116 cells either wild-type or homozygously deleted for p21, 14-3-3 sigma or both, we further investigated the cooperative effect of p21 and 14-3-3 sigma on cell cycle regulation and apoptosis induction by p14(ARF). In contrast to DNA damage, which induces mitotic catastrophe in 14-3-3 sigma-deficient cells, we show here that the expression of p14(ARF) triggers apoptotic cell death, as evidenced by nuclear DNA fragmentation and induction of pan-caspase activities, irrespective of the presence or absence of 14-3-3 sigma. The activation of the intrinsic mitochondrial apoptosis pathway by p14(ARF) was confirmed by cytochrome c release from mitochondria and induction of caspase-9- (LEHDase) and caspase-3/7-like (DEVDase) activities. Moreover, 14-3-3 sigma/p21 double-deficient cells were exceedingly sensitive to apoptosis induction by p14(ARF) as compared to wild-type cells or cells lacking either gene alone. Notably, p14(ARF)-induced apoptosis was preceded by an arrest in the G2 phase of cell cycle, which coincided with downregulation of cdc2 (cdk1) protein expression and lack of its nuclear localization. This indicates that p14(ARF) impairs mitotic entry by targeting the distal DNA damage-signaling pathway and induces apoptotic cell death, rather than mitotic catastrophe, out of a transient G2 arrest. Furthermore, our data delineate that the disruption of G2/M cell cycle checkpoint control critically determines the sensitivity of the cell toward p14(ARF)-induced mitochondrial apoptosis.	[Hemmati, P. G.; Gillissen, B.; Doerken, B.; Daniel, P. T.] Max Delbruck Ctr Mol Med, D-13125 Berlin, Germany; [Hemmati, P. G.; Normand, G.; Gillissen, B.; Wendt, J.; Doerken, B.; Daniel, P. T.] Univ Med Ctr Charite, Dept Hematol Oncol & Tumor Immunol, Berlin, Germany	Helmholtz Association; Max Delbruck Center for Molecular Medicine; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Daniel, PT (corresponding author), Max Delbruck Ctr Mol Med, Campus Berlin Buch,Lindenberger Weg 80, D-13125 Berlin, Germany.	pdaniel@mdc-berlin.de	Normand, Guillaume/A-1975-2010	Gillissen, Bernhard/0000-0002-1815-2091; Normand, Guillaume/0000-0003-1228-3813	Deutsche Krebshilfe [10-2088-Da3]	Deutsche Krebshilfe(Deutsche Krebshilfe)	This work was supported by the Deutsche Krebshilfe Grant 10-2088-Da3 to PTD and PGH. We would like to thank Ms Antje and Anja Richter for expert technical assistance.	Bhonde MR, 2006, J BIOL CHEM, V281, P8675, DOI 10.1074/jbc.M511333200; Bhonde MR, 2006, ONCOGENE, V25, P165, DOI 10.1038/sj.onc.1209017; Blagosklonny MV, 2002, CELL CYCLE, V1, P67, DOI 10.4161/cc.1.1.102; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; Chan TA, 1999, NATURE, V401, P616, DOI 10.1038/44188; Chan TA, 2000, GENE DEV, V14, P1584; Daniel PT, 1999, ANAL BIOCHEM, V266, P110, DOI 10.1006/abio.1998.2929; Datta SR, 2000, MOL CELL, V6, P41, DOI 10.1016/S1097-2765(00)00006-X; de Stanchina E, 1998, GENE DEV, V12, P2434, DOI 10.1101/gad.12.15.2434; DURO D, 1995, ONCOGENE, V11, P21; Eymin B, 2006, CELL CYCLE, V5, P759, DOI 10.4161/cc.5.7.2625; Eymin B, 2001, ONCOGENE, V20, P1033, DOI 10.1038/sj.onc.1204220; Eymin B, 2003, ONCOGENE, V22, P1822, DOI 10.1038/sj.onc.1206303; Eymin B, 2006, MOL CELL BIOL, V26, P4339, DOI 10.1128/MCB.02240-05; Giannakakou P, 2001, ONCOGENE, V20, P3806, DOI 10.1038/sj.onc.1204487; Gorospe M, 1996, MOL CELL BIOL, V16, P6654; Graves PR, 2001, ONCOGENE, V20, P1839, DOI 10.1038/sj.onc.1204259; Hemmati PG, 2006, ONCOGENE, V25, P6582, DOI 10.1038/sj.onc.1209668; Hemmati PG, 2005, ONCOGENE, V24, P4114, DOI 10.1038/sj.onc.1208579; Hemmati PG, 2002, ONCOGENE, V21, P3149, DOI 10.1038/sj.onc.1205458; Hermeking H, 2003, NAT REV CANCER, V3, P931, DOI 10.1038/nrc1230; Hermeking H, 1997, MOL CELL, V1, P3, DOI 10.1016/S1097-2765(00)80002-7; Janicke RU, 2007, CELL CYCLE, V6, P407; Jin P, 1996, J CELL BIOL, V134, P963, DOI 10.1083/jcb.134.4.963; Jin P, 1998, J CELL BIOL, V141, P875, DOI 10.1083/jcb.141.4.875; Li YX, 2004, ONCOGENE, V23, P7355, DOI 10.1038/sj.onc.1207957; MAO L, 1995, CANCER RES, V55, P2995; Martelli F, 2001, P NATL ACAD SCI USA, V98, P4455, DOI 10.1073/pnas.081061398; Martinez LA, 2002, CARCINOGENESIS, V23, P1289, DOI 10.1093/carcin/23.8.1289; Morgan DO, 1998, CANCER J SCI AM, V4, pS77; Nomura M, 2003, J BIOL CHEM, V278, P2058, DOI 10.1074/jbc.M207880200; Normand G, 2005, J BIOL CHEM, V280, P7118, DOI 10.1074/jbc.M412330200; Peng CY, 1997, SCIENCE, V277, P1501, DOI 10.1126/science.277.5331.1501; QUELLE DE, 1995, CELL, V83, P993; Radfar A, 1998, P NATL ACAD SCI USA, V95, P13194, DOI 10.1073/pnas.95.22.13194; Rocha S, 2005, CELL CYCLE, V4, P756, DOI 10.4161/cc.4.6.1739; Rocha S, 2003, MOL CELL, V12, P15, DOI 10.1016/S1097-2765(03)00223-5; Rocha S, 2005, EMBO J, V24, P1157, DOI 10.1038/sj.emboj.7600608; Samuel T, 2001, J BIOL CHEM, V276, P45201, DOI 10.1074/jbc.M106427200; Sanchez Y, 1997, SCIENCE, V277, P1497, DOI 10.1126/science.277.5331.1497; Sohn D, 2006, CANCER RES, V66, P11254, DOI 10.1158/0008-5472.CAN-06-1569; TAAGEPERA S, 1993, P NATL ACAD SCI USA, V90, P8407, DOI 10.1073/pnas.90.18.8407; Takizawa CG, 2000, CURR OPIN CELL BIOL, V12, P658, DOI 10.1016/S0955-0674(00)00149-6; von Haefen C, 2003, ONCOGENE, V22, P2236, DOI 10.1038/sj.onc.1206280; WALDMAN T, 1995, CANCER RES, V55, P5187; Waldman T, 1996, NATURE, V381, P713, DOI 10.1038/381713a0; Wendt J, 2006, ONCOGENE, V25, P972, DOI 10.1038/sj.onc.1209031; Zeng Y, 1999, MOL CELL BIOL, V19, P7410; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3; Zindy F, 1998, GENE DEV, V12, P2424, DOI 10.1101/gad.12.15.2424	50	19	19	2	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 13	2008	27	53					6707	6719		10.1038/onc.2008.193	http://dx.doi.org/10.1038/onc.2008.193			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	371XO	18806827				2022-12-28	WOS:000260866200001
J	Bijl, J; Krosl, J; Lebert-Ghali, CE; Vacher, J; Mayotte, N; Sauvageau, G				Bijl, J.; Krosl, J.; Lebert-Ghali, C-E; Vacher, J.; Mayotte, N.; Sauvageau, G.			Evidence for Hox and E2A-PBX1 collaboration in mouse T-cell leukemia	ONCOGENE			English	Article						Hoxb4; E2A-PBX1; collaborator oncogenes; T-ALL	ACUTE LYMPHOBLASTIC-LEUKEMIA; HEMATOPOIETIC STEM-CELLS; BONE-MARROW-CELLS; ACUTE MYELOID-LEUKEMIA; GENE-EXPRESSION; TRANSGENIC MICE; PRE-B; TRANSCRIPTIONAL ACTIVATOR; TRANSLOCATION PROTEIN; HOMEODOMAIN PROTEIN	Using murine Moloney leukemia virus (MMLV)-based proviral insertional mutagenesis, we previously showed a preferential targeting of a small region in the Hoxa gene locus in E2A-PBX1-induced lymphoid leukemia resulting in the overexpression of several Hoxa genes including Hoxa10, Hoxa9 and Hoxa7. This observation suggested a functional interaction between Hox gene overexpression and E2A-PBX1-induced lymphoid tumors. To further explore this possibility, we generated a series of compound E2A-PBX1 x Hox transgenic mice and tested the genetic interaction between these genes in the generation of lymphoid leukemia in vivo. Results presented in this report show that the onset of T-cell leukemia is significantly ccelerated in E2A-PBX1 x Hoxb4 compound transgenic animals when compared with control E2A-PBX1 or Hoxb4 littermates. Hoxa9 appears less potent than Hoxb4 to accelerate E2A-PBX1-induced T-cell leukemia in mice. E2A-PBX1-induced T-cell leukemias express much higher levels of Hoxa genes than MMLV-induced counterparts, possibly suggesting a contribution of these genes to T-cell transformation by E2A-PBX1. Collectively, these data provide the first genetic evidence showing oncogenic collaboration between E2A-PBX1 and a Hox gene in lymphoid malignancies in vivo and document the specific deregulation of a subgroup of Hoxa genes in these leukemias.	[Bijl, J.; Krosl, J.; Sauvageau, G.] Univ Montreal, Inst Res Immunol & Canc IRIC, Lab Mol Genet Hematopoiet Stem Cells, Montreal, PQ, Canada; [Bijl, J.; Lebert-Ghali, C-E; Sauvageau, G.] Hop Maison Neuve Rosemont, Res Ctr, Div Hematol, Montreal, PQ H1T 2M4, Canada; [Bijl, J.; Sauvageau, G.] Univ Montreal, Dept Med, Montreal, PQ H3C 3J7, Canada; [Vacher, J.] Clin Res Inst Montreal, Sect Cellular Interact & Dev, Montreal, PQ H2W 1R7, Canada; [Sauvageau, G.] Hop Maison Neuve Rosemont, Leukemia Cell Bank Quebec, Montreal, PQ H1T 2M4, Canada	Universite de Montreal; Universite de Montreal; Universite de Montreal; Institut de Recherche Clinique de Montreal (IRCM); Universite de Montreal; Universite de Montreal	Bijl, J (corresponding author), Hop Maison Neuve Rosemont, Ctr Rech Hop, 5415 Boul Lassompt, Montreal, PQ H1T 2M4, Canada.	jbijl.hmr@ssss.gouv.qc.ca		Sauvageau, Guy/0000-0002-4333-7266	Institute for Clinical Research of Montreal (IRCM); Canadian Cancer Society [018478]; Canada Research Chair	Institute for Clinical Research of Montreal (IRCM); Canadian Cancer Society(Canadian Cancer Society (CCS)); Canada Research Chair(Natural Resources CanadaCanadian Forest ServiceCanada Research Chairs)	We thank Melanie Frechette for assistance with the animal care and transplantation experiments, and to the personnel from the transgenic animal facility at the Institute for Clinical Research of Montreal (IRCM) for the generation of Hoxb4 and Hoxa9 transgenic lines. We also thank Eric Massicotte and Martine Dupuis from the flow cytometry service of IRCM, and Danielle Gagne from the. ow cytometry service of IRIC for assistance in FACS analysis. Dr Alex Thompson (Queen's University, Belfast, UK) is thanked for critically reading the manuscript. This work was supported by funds from the Canadian Cancer Society through a NCIC grant to GS(no. 018478) and the Canada Research Chair program also to GS.	Armstrong SA, 2005, J CLIN ONCOL, V23, P6306, DOI 10.1200/JCO.2005.05.047; Azpiazu N, 1998, GENE DEV, V12, P261, DOI 10.1101/gad.12.2.261; Bain G, 1997, MOL CELL BIOL, V17, P4782, DOI 10.1128/MCB.17.8.4782; BAIN G, 1994, CELL, V79, P885, DOI 10.1016/0092-8674(94)90077-9; Bergeron J, 2006, LEUKEMIA, V20, P1184, DOI 10.1038/sj.leu.2404187; Bijl J, 2005, GENE DEV, V19, P224, DOI 10.1101/gad.1268505; Caudell D, 2007, CANCER RES, V67, P8022, DOI 10.1158/0008-5472.CAN-06-3749; Cauwelier B, 2007, LEUKEMIA, V21, P121, DOI 10.1038/sj.leu.2404410; Cellot S, 2007, EXP HEMATOL, V35, P802, DOI 10.1016/j.exphem.2007.02.013; Chang CP, 1997, MOL CELL BIOL, V17, P81, DOI 10.1128/MCB.17.1.81; DEDERA DA, 1993, CELL, V74, P833, DOI 10.1016/0092-8674(93)90463-Z; Dik WA, 2005, LEUKEMIA, V19, P1948, DOI 10.1038/sj.leu.2403891; Ferrando AA, 2003, BLOOD, V102, P262, DOI 10.1182/blood-2002-10-3221; HOGAN B, 1983, NATURE, V306, P313, DOI 10.1038/306313a0; HOUGH MR, 1994, J EXP MED, V179, P177, DOI 10.1084/jem.179.1.177; KAMPS MP, 1993, MOL CELL BIOL, V13, P351, DOI 10.1128/MCB.13.1.351; KAMPS MP, 1990, CELL, V60, P547, DOI 10.1016/0092-8674(90)90658-2; Kroon E, 2001, EMBO J, V20, P350, DOI 10.1093/emboj/20.3.350; Kroon E, 1998, EMBO J, V17, P3714, DOI 10.1093/emboj/17.13.3714; Krosl J, 2000, ONCOGENE, V19, P5134, DOI 10.1038/sj.onc.1203897; Krosl J, 2003, NAT MED, V9, P1428, DOI 10.1038/nm951; LEBRUN DP, 1994, ONCOGENE, V9, P1641; Look AT, 1997, SCIENCE, V278, P1059, DOI 10.1126/science.278.5340.1059; LU Q, 1994, MOL CELL BIOL, V14, P3938, DOI 10.1128/MCB.14.6.3938; MANN RS, 1995, BIOESSAYS, V17, P855, DOI 10.1002/bies.950171007; Medina-Martinez O, 2003, DEV BIOL, V264, P77, DOI 10.1016/j.ydbio.2003.07.020; NOURSE J, 1990, CELL, V60, P535, DOI 10.1016/0092-8674(90)90657-Z; Pineault N, 2004, MOL CELL BIOL, V24, P1907, DOI 10.1128/MCB.24.5.1907-1917.2004; Sanyal M, 2007, BLOOD, V109, P4191, DOI 10.1182/blood-2006-10-054213; Sauvageau G, 1997, IMMUNITY, V6, P13, DOI 10.1016/S1074-7613(00)80238-1; Sauvageau G, 2001, BLOOD, V98, p836A; Soulier J, 2005, BLOOD, V106, P274, DOI 10.1182/blood-2004-10-3900; Speleman F, 2005, LEUKEMIA, V19, P358, DOI 10.1038/sj.leu.2403657; Su X, 2006, GENE CHROMOSOME CANC, V45, P846, DOI 10.1002/gcc.20348; Taghon T, 2002, BLOOD, V99, P1197, DOI 10.1182/blood.V99.4.1197; Taghon T, 2003, LEUKEMIA, V17, P1157, DOI 10.1038/sj.leu.2402947; Thompson A, 2003, BLOOD, V101, P1558, DOI 10.1182/blood.V101.4.1558; Thorsteinsdottir U, 1999, MOL CELL BIOL, V19, P6355; Thorsteinsdottir U, 1997, MOL CELL BIOL, V17, P495, DOI 10.1128/MCB.17.1.495; Thorsteinsdottir U, 2002, BLOOD, V99, P121, DOI 10.1182/blood.V99.1.121; TROUSSARD X, 1995, BRIT J HAEMATOL, V89, P516, DOI 10.1111/j.1365-2141.1995.tb08357.x; Van Vlierberghe P, 2008, BLOOD, V111, P4668, DOI 10.1182/blood-2007-09-111872; VANDIJK MA, 1993, P NATL ACAD SCI USA, V90, P6061, DOI 10.1073/pnas.90.13.6061; VANDIJK MA, 1995, MECH DEVELOP, V52, P99, DOI 10.1016/0925-4773(95)00394-G; Zhang XB, 2008, J CLIN INVEST, V118, P1502, DOI 10.1172/JCI34371	45	15	16	1	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT	2008	27	49					6356	6364		10.1038/onc.2008.233	http://dx.doi.org/10.1038/onc.2008.233			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	363JK	18679416				2022-12-28	WOS:000260263400005
J	Garcia-Echeverria, C; Sellers, WR				Garcia-Echeverria, C.; Sellers, W. R.			Drug discovery approaches targeting the PI3K/Akt pathway in cancer	ONCOGENE			English	Review						phosphoinositide-3 kinase; Akt; PDK1; HSP90; drug design; cancer therapy	PROTEIN-KINASE-B; 2,3,5-TRISUBSTITUTED PYRIDINE-DERIVATIVES; CYCLOOXYGENASE-2 INHIBITOR CELECOXIB; SURVIVAL-SIGNALING PATHWAY; SMALL-MOLECULE INHIBITORS; POTENT ANTITUMOR-ACTIVITY; GROWTH-FACTOR RECEPTOR; PHOSPHOINOSITIDE 3-KINASE; SELECTIVE INHIBITORS; DEPENDENT KINASE-1	The abnormal activation of the phosphatidylinositol 3-kinase (PI3K)/Akt pathway has been validated by epidemiological and experimental studies as an essential step toward the initiation and maintenance of human tumors. Notable in this regard are the prevalent somatic genetic alterations leading to the inactivation of the tumor suppressor gene PTEN and gain-of-function mutations targeting PIK3CA - the gene encoding the catalytic phosphosinositide-3 kinase subunit p110 alpha. A number of the intracellular components of this pathway have been targeted as anticancer drug discovery activities leading to the current panoply of clinical trials of inhibitors of PI3K, Akt and HSP90 in man. This review summarizes current preclinical knowledge of modulators of the PI3K/Akt pathway in which drug discovery and development activities have been advanced focusing on both the relevant clinical stage inhibitors and other disclosed tool compounds targeting PI3K, PDK1, Akt and HSP90.	[Garcia-Echeverria, C.] Novartis Inst Biomed Res, CH-4002 Basel, Switzerland; [Sellers, W. R.] Novartis Inst Biomed Res, Cambridge, MA USA	Novartis; Novartis	Garcia-Echeverria, C (corresponding author), Novartis Inst Biomed Res, WKL-125-13-16, CH-4002 Basel, Switzerland.	carlos.garcia-echeverria@novartis.com						Abraham RT, 2004, DNA REPAIR, V3, P883, DOI 10.1016/j.dnarep.2004.04.002; Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9; Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; Arico S, 2002, J BIOL CHEM, V277, P27613, DOI 10.1074/jbc.M201119200; BARNETT SF, 1985, BIOCHEM J, V385, P399; Basso AD, 2002, J BIOL CHEM, V277, P39858, DOI 10.1074/jbc.M206322200; Bellacosa A, 1998, ONCOGENE, V17, P313, DOI 10.1038/sj.onc.1201947; Biondi RM, 2000, EMBO J, V19, P979, DOI 10.1093/emboj/19.5.979; Bishop SC, 2007, CURR CANCER DRUG TAR, V7, P369, DOI 10.2174/156800907780809778; Bozulic L, 2008, MOL CELL, V30, P203, DOI 10.1016/j.molcel.2008.02.024; Breitenlechner CB, 2005, J MED CHEM, V48, P163, DOI 10.1021/jm049701n; Breitenlechner CB, 2004, J MED CHEM, V47, P1375, DOI 10.1021/jm0310479; BRIAN P. W., 1957, TRANS BRIT MYCOL SOC, V40, P365; Brough PA, 2008, J MED CHEM, V51, P196, DOI 10.1021/jm701018h; Carnero A, 2008, CURR CANCER DRUG TAR, V8, P187, DOI 10.2174/156800908784293659; Carpten JD, 2007, NATURE, V448, P439, DOI 10.1038/nature05933; Casamayor A, 1999, BIOCHEM J, V342, P287, DOI 10.1042/0264-6021:3420287; Chandarlapaty S, 2008, CLIN CANCER RES, V14, P240, DOI 10.1158/1078-0432.CCR-07-1667; Chen JS, 2008, MOL CANCER THER, V7, P841, DOI 10.1158/1535-7163.MCT-07-0393; Chiosis G, 2004, DRUG DISCOV TODAY, V9, P881, DOI 10.1016/S1359-6446(04)03245-3; Dasmahapatra GP, 2004, CLIN CANCER RES, V10, P5242, DOI 10.1158/1078-0432.CCR-03-0534; Davies SP, 2000, BIOCHEM J, V351, P95, DOI 10.1042/0264-6021:3510095; Davies TG, 2007, J MOL BIOL, V367, P882, DOI 10.1016/j.jmb.2007.01.004; DAVIS PD, 1992, J MED CHEM, V35, P994, DOI 10.1021/jm00084a004; Downward J, 2004, SEMIN CELL DEV BIOL, V15, P177, DOI 10.1016/j.semcdb.2004.01.002; Dymock BW, 2004, EXPERT OPIN THER PAT, V14, P837, DOI 10.1517/13543776.14.6.837; Eccles SA, 2008, CANCER RES, V68, P2850, DOI 10.1158/0008-5472.CAN-07-5256; Engel J, 2000, DRUG FUTURE, V25, P1257, DOI 10.1358/dof.2000.025.12.604732; ENGELMAN JA, 2008, DIFFERENTIAL E UNPUB; Ernst DS, 2005, INVEST NEW DRUG, V23, P569, DOI 10.1007/s10637-005-1157-4; Fan QW, 2007, CANCER RES, V67, P7960, DOI 10.1158/0008-5472.CAN-07-2154; Feldman RI, 2005, J BIOL CHEM, V280, P19867, DOI 10.1074/jbc.M501367200; Feng JH, 2004, J BIOL CHEM, V279, P41189, DOI 10.1074/jbc.M406731200; Foster P., 2007, 19 AACR NCI EORTC M; Fujita N, 2003, CANCER CHEMOTH PHARM, V52, pS24, DOI 10.1007/s00280-003-0591-2; Fujita N, 2002, J BIOL CHEM, V277, P10346, DOI 10.1074/jbc.M106736200; Garlich JR, 2008, CANCER RES, V68, P206, DOI 10.1158/0008-5472.CAN-07-0669; Gassel M, 2003, J MOL BIOL, V329, P1021, DOI 10.1016/S0022-2836(03)00518-7; Ge J, 2006, J MED CHEM, V49, P4606, DOI 10.1021/jm0603116; Han EKH, 2007, ONCOGENE, V26, P5655, DOI 10.1038/sj.onc.1210343; Hartnett JC, 2008, BIOORG MED CHEM LETT, V18, P2194, DOI 10.1016/j.bmcl.2007.12.040; Hennessy BT, 2007, CLIN CANCER RES, V13, P7421, DOI 10.1158/1078-0432.CCR-07-0760; Hill MM, 2002, PHARMACOL THERAPEUT, V93, P243, DOI 10.1016/S0163-7258(02)00193-6; Hill MM, 2001, J BIOL CHEM, V276, P25643, DOI 10.1074/jbc.C100174200; Hollingshead M, 2005, CANCER CHEMOTH PHARM, V56, P115, DOI 10.1007/s00280-004-0939-2; Howes AL, 2007, MOL CANCER THER, V6, P2505, DOI 10.1158/1535-7163.MCT-06-0698; Hsu AL, 2000, J BIOL CHEM, V275, P11397, DOI 10.1074/jbc.275.15.11397; Huang CH, 2007, SCIENCE, V318, P1744, DOI 10.1126/science.1150799; Huston A, 2008, CLIN CANCER RES, V14, P865, DOI 10.1158/1078-0432.CCR-07-1299; Ihle NT, 2005, MOL CANCER THER, V4, P1349, DOI 10.1158/1535-7163.MCT-05-0149; Islam I, 2007, BIOORG MED CHEM LETT, V17, P3814, DOI 10.1016/j.bmcl.2007.04.071; Islam I, 2007, BIOORG MED CHEM LETT, V17, P3819, DOI 10.1016/j.bmcl.2007.05.060; Janin YL, 2005, J MED CHEM, V48, P7503, DOI 10.1021/jm050759r; Jensen MR, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr1996; Jia WT, 2003, BLOOD, V102, P1824, DOI 10.1182/blood-2002-12-3785; JONES PF, 1991, CELL REGUL, V2, P1001, DOI 10.1091/mbc.2.12.1001; JONES PF, 1991, P NATL ACAD SCI USA, V88, P4171, DOI 10.1073/pnas.88.10.4171; Knight ZA, 2004, BIOORGAN MED CHEM, V12, P4749, DOI 10.1016/j.bmc.2004.06.022; Knight ZA, 2006, CELL, V125, P733, DOI 10.1016/j.cell.2006.03.035; Komander D, 2004, EMBO J, V23, P3918, DOI 10.1038/sj.emboj.7600379; KOMANDER D, 2001, BIOCHEM J, V375, P255; Kondapaka SB, 2004, CLIN CANCER RES, V10, P7192, DOI 10.1158/1078-0432.CCR-04-0772; Kondapaka SB, 2003, MOL CANCER THER, V2, P1093; Kumar CC, 2001, BBA-GEN SUBJECTS, V1526, P257, DOI 10.1016/S0304-4165(01)00143-X; LAIRD D, 2007, 19 AACR NCI EORTC M; Lawlor MA, 2002, EMBO J, V21, P3728, DOI 10.1093/emboj/cdf387; Li Qun, 2002, Current Topics in Medicinal Chemistry, V2, P939, DOI 10.2174/1568026023393318; Li X, 2006, ONCOGENE, V25, P525, DOI 10.1038/sj.onc.1209075; Lindsley CW, 2005, BIOORG MED CHEM LETT, V15, P761, DOI 10.1016/j.bmcl.2004.11.011; LUNDGREN K, 2007, 19 AACR NCI EORTC M; Luo Y, 2005, MOL CANCER THER, V4, P977, DOI 10.1158/1535-7163.MCT-05-0005; Maira SM, 2008, EXPERT OPIN THER TAR, V12, P223, DOI 10.1517/14728222.12.2.223 ; MAIRA SM, 2008, MOL CANC TH IN PRESS; MARRER E, 2008, P AM ASS CANC RES AA; Mitsiades CS, 2004, CURR CANCER DRUG TAR, V4, P235, DOI 10.2174/1568009043333032; Modi S, 2007, J CLIN ONCOL, V25, P5410, DOI 10.1200/JCO.2007.11.7960; Mora A, 2004, SEMIN CELL DEV BIOL, V15, P161, DOI 10.1016/j.semcdb.2003.12.022; Neckers Len, 2002, Expert Opin Emerg Drugs, V7, P277, DOI 10.1517/14728214.7.2.277; PATNAIK A, 2007, EORTC M; Posadas EM, 2005, CANCER BIOL THER, V4, P1133, DOI 10.4161/cbt.4.10.2064; Ramanathan RK, 2007, CLIN CANCER RES, V13, P1769, DOI 10.1158/1078-0432.CCR-06-2233; Raynaud FI, 2007, CANCER RES, V67, P5840, DOI 10.1158/0008-5472.CAN-06-4615; Redaelli Alberto, 2003, Expert Rev Anticancer Ther, V3, P695; Rhodes N, 2008, CANCER RES, V68, P2366, DOI 10.1158/0008-5472.CAN-07-5783; Roe SM, 1999, J MED CHEM, V42, P260, DOI 10.1021/jm980403y; Ruiter GA, 2003, ANTI-CANCER DRUG, V14, P167, DOI 10.1097/00001813-200302000-00011; Safa O, 1998, DRUG TODAY, V34, P15; Sarbassov DD, 2005, SCIENCE, V307, P1098, DOI 10.1126/science.1106148; Sato S, 2002, ONCOGENE, V21, P1727, DOI 10.1038/sj.onc.1205225; Sayle KL, 2003, BIOORG MED CHEM LETT, V13, P3079, DOI 10.1016/S0960-894X(03)00651-6; SCHNELL C, 2008, CANC RES; SERRA V, 2008, CANC RES; Shapiro G., 2007, 19 AACR NCI EORTC M; Shi Y, 2005, NEOPLASIA, V7, P992, DOI 10.1593/neo.05355; Solit DB, 2003, CANCER RES, V63, P2139; Stebbins CE, 1997, CELL, V89, P239, DOI 10.1016/S0092-8674(00)80203-2; Stephens L, 1998, SCIENCE, V279, P710, DOI 10.1126/science.279.5351.710; Stokoe D, 1997, SCIENCE, V277, P567, DOI 10.1126/science.277.5325.567; Stuhmer T, 2008, LEUKEMIA, V22, P1604, DOI 10.1038/leu.2008.111; Sydor JR, 2006, P NATL ACAD SCI USA, V103, P17408, DOI 10.1073/pnas.0608372103; Tian ZQ, 2004, BIOORGAN MED CHEM, V12, P5317, DOI 10.1016/j.bmc.2004.07.053; Tokunaga E, 2008, CURR CANCER DRUG TAR, V8, P27, DOI 10.2174/156800908783497140; Toral-Barza L, 2007, MOL CANCER THER, V6, P3028, DOI 10.1158/1535-7163.MCT-07-0211; Traiser M, 1998, DRUGS TODAY, V34, P67; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241; Walker EH, 2000, MOL CELL, V6, P909, DOI 10.1016/S1097-2765(05)00089-4; Walker G.J.A., 2000, COCHRANE DB SYST REV, V3; Welch S, 2007, GYNECOL ONCOL, V106, P305, DOI 10.1016/j.ygyno.2007.02.018; Weterings E, 2007, J CELL BIOL, V179, P183, DOI 10.1083/jcb.200705106; Whitesell L, 2005, NAT REV CANCER, V5, P761, DOI 10.1038/nrc1716; Wymann MP, 1996, MOL CELL BIOL, V16, P1722; Yan Y, 2007, BIOCHEM SOC T, V35, P239, DOI 10.1042/BST0350239; Yang J, 2002, NAT STRUCT BIOL, V9, P940, DOI 10.1038/nsb870; Yang J, 2002, MOL CELL, V9, P1227, DOI 10.1016/S1097-2765(02)00550-6; Yu K, 2005, CANCER BIOL THER, V4, P538, DOI 10.4161/cbt.4.5.1660; YUAN TL, 2008, P NATL ACAD SCI US; Zahler S, 2007, CHEM BIOL, V14, P1207, DOI 10.1016/j.chembiol.2007.10.010; Zhao ZJ, 2008, BIOORG MED CHEM LETT, V18, P49, DOI 10.1016/j.bmcl.2007.11.015; Zhao ZJ, 2005, BIOORG MED CHEM LETT, V15, P905, DOI 10.1016/j.bmcl.2004.12.062; Zhu JX, 2004, CANCER RES, V64, P4309, DOI 10.1158/0008-5472.CAN-03-4063	120	394	433	0	41	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 15	2008	27	41					5511	5526		10.1038/onc.2008.246	http://dx.doi.org/10.1038/onc.2008.246			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	349KW	18794885				2022-12-28	WOS:000259280700012
J	Bertucci, F; Orsetti, B; Negre, V; Finetti, P; Rouge, C; Ahomadegbe, JC; Bibeau, F; Mathieu, MC; Treilleux, I; Jacquemier, J; Ursule, L; Martinec, A; Wang, Q; Benard, J; Puisieux, A; Birnbaum, D; Theillet, C				Bertucci, F.; Orsetti, B.; Negre, V.; Finetti, P.; Rouge, C.; Ahomadegbe, J-C; Bibeau, F.; Mathieu, M-C; Treilleux, I.; Jacquemier, J.; Ursule, L.; Martinec, A.; Wang, Q.; Benard, J.; Puisieux, A.; Birnbaum, D.; Theillet, C.			Lobular and ductal carcinomas of the breast have distinct genomic and expression profiles	ONCOGENE			English	Article						breast cancer; DNA microarray; genetic profiles; array-CGH	MICROARRAY ANALYSIS; CANCER; PATTERNS; HYBRIDIZATION; DIFFERENTIATION; IDENTIFICATION; ASSOCIATION; SUBCLASSES; SURVIVAL; SUBTYPES	Invasive ductal carcinomas (IDCs) and invasive lobular carcinomas (ILCs) are the two major pathological types of breast cancer. Epidemiological and histoclinical data suggest biological differences, but little is known about the molecular alterations involved in ILCs. We undertook a comparative large-scale study by both array-compared genomic hybridization and cDNA microarray of a set of 50 breast tumors (21 classic ILCs and 29 IDCs) selected on homogeneous histoclinical criteria. Results were validated on independent tumor sets, as well as by quantitative RT-PCR. ILCs and IDCs presented differences at both the genomic and expression levels with ILCs being less rearranged and heterogeneous than IDCs. Supervised analysis defined a 75-BACs signature discriminating accurately ILCs from IDCs. Expression profiles identified two subgroups of ILCs: typical ILCs (similar to 50%), which were homogeneous and displayed a normal-like molecular pattern, and atypical ILCs, more heterogeneous with features intermediate between ILCs and IDCs. Supervised analysis identified a 75-gene expression signature that discriminated ILCs from IDCs, with many genes involved in cell adhesion, motility, apoptosis, protein folding, extracellular matrix and protein phosphorylation. Although ILCs and IDCs share common alterations, our data show that ILCs and IDCs could be distinguished on the basis of their genomic and expression profiles suggesting that they evolve along distinct genetic pathways.	[Bertucci, F.; Finetti, P.; Jacquemier, J.; Birnbaum, D.] Inst J Paoli I Calmettes, Ctr Cancerol Marseille, INSERM, UMR891, F-13009 Marseille, France; [Orsetti, B.; Negre, V.; Rouge, C.; Bibeau, F.; Ursule, L.; Theillet, C.] INSERM, CRLC Val Aurelle Paul Lamarque, IRCM, U896, F-34298 Montpellier 5, France; [Ahomadegbe, J-C] Univ Paris 11, UPRES 3535, Inst Gustave Roussy, Villejuif, France; [Bibeau, F.] CRLC Val Aurelle Paul Larmarque, Lab Anatomopathol, Montpellier, France; [Mathieu, M-C] Inst Gustave Roussy, Dept Biopathol, Villejuif, France; [Treilleux, I.] Ctr Leon Berard, Lab Anatomopathol, F-69373 Lyon, France; [Martinec, A.] Ipsogen SA, Marseille Luminy, France; [Wang, Q.; Puisieux, A.] Ctr Leon Berard, Oncol Mol Lab, F-69373 Lyon, France; [Benard, J.] CNRS, Inst Gustave Roussy, UMR 8126, Villejuif, France; [Puisieux, A.] Ctr Leon Berard, INSERM, U590, F-69373 Lyon, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Institut Paoli-Calmette (IPC); Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier; UNICANCER; Institut Regional du Cancer Montpellier / Val d'Aurelle (ICM); UDICE-French Research Universities; Universite Paris Saclay; UNICANCER; Gustave Roussy; UNICANCER; Universite de Montpellier; Institut Regional du Cancer Montpellier / Val d'Aurelle (ICM); UNICANCER; Gustave Roussy; UNICANCER; Centre Leon Berard; UNICANCER; Centre Leon Berard; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Universite Paris Saclay; UNICANCER; Gustave Roussy; Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Centre Leon Berard	Theillet, C (corresponding author), INSERM, CRLC Val Aurelle Paul Lamarque, IRCM, U896, Rue Croix Verte, F-34298 Montpellier 5, France.	theillet@valdorel.fnclcc.fr	Theillet, Charles/O-7634-2018; Finetti, Pascal/O-8669-2017	Finetti, Pascal/0000-0002-2674-3123; Birnbaum, Daniel/0000-0001-7920-9883; Theillet, Charles/0000-0001-5555-2759; PUISIEUX, Alain/0000-0002-9938-3798; Bertucci, Francois/0000-0002-0157-0959	INSERM; Association de Recherche sur le Cancer (ARC) [5102]; Institut National du Cancer; Canceropoles PACA; Grand Sud Ouest	INSERM(Institut National de la Sante et de la Recherche Medicale (Inserm)European Commission); Association de Recherche sur le Cancer (ARC)(Fondation ARC pour la Recherche sur le Cancer); Institut National du Cancer(Institut National du Cancer (INCA) France); Canceropoles PACA; Grand Sud Ouest	This study was developed as part of a joint program Developpement d'outils de diagnostic moleculaire en Cancerologie: Applications aux cancers du sein' Ministere de l'Enseignement Superieur, de la Recherche et de la Technologie and Federation Nationale des Centres de Lutte Contre le Cancer and was supported by funds from INSERM, the Association de Recherche sur le Cancer (ARC), grant 5102, Institut National du Cancer, Canceropoles PACA and Grand Sud Ouest. The help of the Genopole Montpellier Languedoc-Roussillon is gratefully acknowledged. We thank Pr Dominique Maraninchi and Dr Claude Mawas for setting up this work and Mrs Sophie Tourpin for technical help.	Bertucci F, 2004, ONCOGENE, V23, P2564, DOI 10.1038/sj.onc.1207361; Bertucci F, 2006, OMICS, V10, P429, DOI 10.1089/omi.2006.10.429; Berx G, 1995, EMBO J, V14, P6107, DOI 10.1002/j.1460-2075.1995.tb00301.x; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; Flagiello D, 1998, GENE CHROMOSOME CANC, V23, P300, DOI 10.1002/(SICI)1098-2264(199812)23:4<300::AID-GCC4>3.0.CO;2-N; Fridlyand J, 2006, BMC CANCER, V6, DOI 10.1186/1471-2407-6-96; Gunther K, 2001, J PATHOL, V193, P40, DOI 10.1002/1096-9896(2000)9999:9999<::AID-PATH745>3.0.CO;2-N; Hicks J, 2006, GENOME RES, V16, P1465, DOI 10.1101/gr.5460106; Jacquemier J, 2005, CANCER RES, V65, P767; Katz A, 2007, LANCET ONCOL, V8, P55, DOI 10.1016/S1470-2045(06)71011-7; Korkola JE, 2003, CANCER RES, V63, P7167; LAMOVEC J, 1991, J SURG ONCOL, V48, P28, DOI 10.1002/jso.2930480106; Li CI, 2003, JAMA-J AM MED ASSOC, V289, P1421, DOI 10.1001/jama.289.11.1421; Loo LWM, 2004, CANCER RES, V64, P8541, DOI 10.1158/0008-5472.CAN-04-1992; Loveday RL, 2000, INT J CANCER, V86, P494, DOI 10.1002/(SICI)1097-0215(20000515)86:4<494::AID-IJC8>3.3.CO;2-F; Orsetti B, 2006, BRIT J CANCER, V95, P1439, DOI 10.1038/sj.bjc.6603433; Pollack JR, 2002, P NATL ACAD SCI USA, V99, P12963, DOI 10.1073/pnas.162471999; SastreGarau X, 1996, CANCER, V77, P113, DOI 10.1002/(SICI)1097-0142(19960101)77:1<113::AID-CNCR19>3.0.CO;2-8; Sorlie T, 2003, P NATL ACAD SCI USA, V100, P8418, DOI 10.1073/pnas.0932692100; Sorlie T, 2001, P NATL ACAD SCI USA, V98, P10869, DOI 10.1073/pnas.191367098; Stange DE, 2006, CLIN CANCER RES, V12, P345, DOI 10.1158/1078-0432.CCR-05-1633; Toikkanen S, 1997, BRIT J CANCER, V76, P1234, DOI 10.1038/bjc.1997.540; Turashvili G, 2007, BMC CANCER, V7, DOI 10.1186/1471-2407-7-55; Zhao HJ, 2004, MOL BIOL CELL, V15, P2523, DOI 10.1091/mbc.E03-11-0786	24	85	87	1	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 11	2008	27	40					5359	5372		10.1038/onc.2008.158	http://dx.doi.org/10.1038/onc.2008.158			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	346UW	18490921	Green Submitted, Green Accepted			2022-12-28	WOS:000259096100009
J	Dufraine, J; Funahashi, Y; Kitajewski, J				Dufraine, J.; Funahashi, Y.; Kitajewski, J.			Notch signaling regulates tumor angiogenesis by diverse mechanisms	ONCOGENE			English	Review						angiogenesis; Notch; Jagged1; Dll4; sprout; VEGFR-2	HUMAN BREAST-CANCER; ENDOTHELIAL-CELLS; ARTERIOVENOUS-MALFORMATIONS; DELTA-LIKE-4 EXPRESSION; VASCULAR MORPHOGENESIS; EMBRYONIC LETHALITY; LIGAND JAGGED1; UP-REGULATION; ARTERIES; GROWTH	The Notch signaling pathway is fundamental to proper cardiovascular development and is now recognized as an important player in tumor angiogenesis. Two key Notch ligands have been implicated in tumor angiogenesis, Delta-like 4 and Jagged1. We introduce the proteins and how they work in normal developing vasculature and then discuss differing models describing the action of these Notch ligands in tumor angiogenesis. Endothelial Dll4 expression activates Notch resulting in restriction of new sprout development; for instance, in growing retinal vessels. In agreement with this activity, inhibit ion of Dll4-mediated Notch signaling in tumors results in hypersprouting of nonfunctional vasculature. This Dll4 inhibition may paradoxically lead to increased angiogenesis but poor tumor growth because the newly growing vessels are not functional. In contrast, Jagged1 has been described as a Notch ligand expressed in tumor cells that can have a positive influence on tumor angiogenesis, possibly by activating Notch on tumor endothelium. A novel Notch inhibitor, the Notch1 decoy, which blocks both Dll4 and Jagged1 has been recently shown to restrict tumor vessel growth. We discuss these models and speculate on therapeutic approaches.	[Kitajewski, J.] Columbia Univ, Med Ctr, Herbert Irving Comprehens Canc Ctr, New York, NY 10032 USA; [Funahashi, Y.] Eisai & Co Ltd, Tsukuba Res Labs, Ibaraki, Japan; [Dufraine, J.; Kitajewski, J.] Columbia Univ, Med Ctr, Dept Obstet & Gynecol, New York, NY 10032 USA; [Dufraine, J.; Kitajewski, J.] Columbia Univ, Med Ctr, Dept Pathol, New York, NY 10032 USA	Columbia University; Eisai Co Ltd; Columbia University; Columbia University	Kitajewski, J (corresponding author), Columbia Univ, Med Ctr, Herbert Irving Comprehens Canc Ctr, 1130 St Nicholas Ave, New York, NY 10032 USA.	jkk9@columbia.edu			NHLBI NIH HHS [R01 HL062454] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL062454] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Alva JA, 2004, CURR OPIN HEMATOL, V11, P278, DOI 10.1097/01.moh.0000130309.44976.ad; Artavanis-Tsakonas S, 1999, SCIENCE, V284, P770, DOI 10.1126/science.284.5415.770; Carlson TR, 2005, P NATL ACAD SCI USA, V102, P9884, DOI 10.1073/pnas.0504391102; Claxton S, 2004, GENE EXPR PATTERNS, V5, P123, DOI 10.1016/j.modgep.2004.05.004; Funahashi Y, 2008, CANCER RES, V68, P4727, DOI 10.1158/0008-5472.CAN-07-6499; Gale NW, 2004, P NATL ACAD SCI USA, V101, P15949, DOI 10.1073/pnas.0407290101; Gerhardt H, 2003, J CELL BIOL, V161, P1163, DOI 10.1083/jcb.200302047; Greenwald I, 1998, GENE DEV, V12, P1751, DOI 10.1101/gad.12.12.1751; Hellstrom M, 2007, NATURE, V445, P776, DOI 10.1038/nature05571; High FA, 2008, P NATL ACAD SCI USA, V105, P1955, DOI 10.1073/pnas.0709663105; High FA, 2008, NAT REV GENET, V9, P49, DOI 10.1038/nrg2279; Iso T, 2006, BIOCHEM BIOPH RES CO, V341, P708, DOI 10.1016/j.bbrc.2006.01.020; Jain RK, 2006, NAT CLIN PRACT ONCOL, V3, P24, DOI 10.1038/ncponc0403; Krebs LT, 2000, GENE DEV, V14, P1343; Krebs LT, 2004, GENE DEV, V18, P2469, DOI 10.1101/gad.1239204; Lawson ND, 2001, DEVELOPMENT, V128, P3675; Lawson ND, 2002, NAT REV GENET, V3, P674, DOI 10.1038/nrg888; Limbourg FP, 2005, CIRCULATION, V111, P1826, DOI 10.1161/01.CIR.0000160870.93058.DD; Lobov IB, 2007, P NATL ACAD SCI USA, V104, P3219, DOI 10.1073/pnas.0611206104; Mailhos C, 2001, DIFFERENTIATION, V69, P135, DOI 10.1046/j.1432-0436.2001.690207.x; Noguera-Troise I, 2006, NATURE, V444, P1032, DOI 10.1038/nature05355; Patel NS, 2006, CLIN CANCER RES, V12, P4836, DOI 10.1158/1078-0432.CCR-06-0285; Patel NS, 2005, CANCER RES, V65, P8690, DOI 10.1158/0008-5472.CAN-05-1208; Pece S, 2004, J CELL BIOL, V167, P215, DOI 10.1083/jcb.200406140; Reedijk M, 2005, CANCER RES, V65, P8530, DOI 10.1158/0008-5472.CAN-05-1069; REEDIJK M, 2007, BREAST CANC RES TREA; Ridgway J, 2006, NATURE, V444, P1083, DOI 10.1038/nature05313; Scehnet JS, 2007, BLOOD, V109, P4753, DOI 10.1182/blood-2006-12-063933; Shawber CJ, 2003, ANN NY ACAD SCI, V995, P162, DOI 10.1111/j.1749-6632.2003.tb03219.x; Siekmann AF, 2007, NATURE, V445, P781, DOI 10.1038/nature05577; Stylianou S, 2006, CANCER RES, V66, P1517, DOI 10.1158/0008-5472.CAN-05-3054; Suchting S, 2007, P NATL ACAD SCI USA, V104, P3225, DOI 10.1073/pnas.0611177104; Takeshita K, 2007, CIRC RES, V100, P70, DOI 10.1161/01.RES.0000254788.47304.6e; Thurston G, 2007, NAT REV CANCER, V7, P327, DOI 10.1038/nrc2130; Uyttendaele H, 2001, P NATL ACAD SCI USA, V98, P5643, DOI 10.1073/pnas.091584598; Villa N, 2001, MECH DEVELOP, V108, P161, DOI 10.1016/S0925-4773(01)00469-5; Wang HU, 1998, CELL, V93, P741, DOI 10.1016/S0092-8674(00)81436-1; Xue YZ, 1999, HUM MOL GENET, V8, P723, DOI 10.1093/hmg/8.5.723; Zeng QH, 2005, CANCER CELL, V8, P13, DOI 10.1016/j.ccr.2005.06.004; Zhong TP, 2000, SCIENCE, V287, P1820, DOI 10.1126/science.287.5459.1820; Zhong TP, 2001, NATURE, V414, P216, DOI 10.1038/35102599	41	213	230	1	28	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP	2008	27	38					5132	5137		10.1038/onc.2008.227	http://dx.doi.org/10.1038/onc.2008.227			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	344GM	18758482	Green Accepted			2022-12-28	WOS:000258914900007
J	Komatsu, D; Kato, M; Nakayama, J; Miyagawa, S; Kamata, T				Komatsu, D.; Kato, M.; Nakayama, J.; Miyagawa, S.; Kamata, T.			NADPH oxidase 1 plays a critical mediating role in oncogenic Ras-induced vascular endothelial growth factor expression	ONCOGENE			English	Article						Nox1; Ras; VEGF; ER K; Sp1	PROTEIN-TYROSINE-PHOSPHATASE; MAP KINASE PHOSPHATASES; REACTIVE OXYGEN; FACTOR GENE; ACTIVATION; CELLS; SUPEROXIDE; CANCER; NOX1; ADENOCARCINOMA	Reactive oxygen species (ROS)-generating enzyme Nox1 is important in the induction of oncogenic Ras transformation phenotypes, but it is not defined whether Nox1 is involved in Ras-induced upregulation of vascular endothelial growth factor (VEGF), a potent stimulator of tumor angiogenesis. Here we describe that ablation of the Nox1 activity by Nox1 small-interference RNAs (siRNAs) or diphenylene iodonium (DPI) inhibited synthesis of both VEGF proteins and VEGF mRNAs in K-Ras transformed normal rat kidney (KNRK) cells. Nox1siRNAs and DPI suppressed extracellular signal-regulated kinase (ERK)dependent phosphorylation of a transcription factor Sp1 and Sp1 binding to a VEGF promoter. Furthermore, tumors derived from Nox1siRNA-transfected KNRK cells markedly decreased neovascularization. The Nox1 activity was required for VEGF production in human colon cancer CaCO-2 cells, as in the case of KNRK cells. However, since overexpression of Nox1 in normal rat kidney cells failed to induce VEGF, the Nox1 activity alone was not sufficient to upregulate VEGF expression, which suggests that unlike the previously proposed model, Nox1 may act in concert with other effectors integrated into the Ras network. We propose that Nox1 mediates oncogenic Ras-induced upregulation of VEGF and angiogenesis by activating Sp1 through Ras-ERK-dependent phosphorylation of Sp1.	[Komatsu, D.; Kato, M.; Kamata, T.] Shinshu Univ, Grad Sch Med, Dept Mol Biol & Biochem, Nagano 3908621, Japan; [Komatsu, D.; Miyagawa, S.] Shinshu Univ, Grad Sch Med, Dept Surg, Nagano 3908621, Japan; [Nakayama, J.] Shinshu Univ, Grad Sch Med, Inst Organ Transplantat Reconstruct Med & Tissue, Nagano 3908621, Japan	Shinshu University; Shinshu University; Shinshu University	Kamata, T (corresponding author), Shinshu Univ, Sch Med, Dept Mol Biol & Biochem, 3-1-1 Asahi, Nagano 3908621, Japan.	kamatat@sch.md.shinshu-u.ac.jp						Arbiser JL, 2002, P NATL ACAD SCI USA, V99, P715, DOI 10.1073/pnas.022630199; Carnesecchi S, 2006, EXP CELL RES, V312, P3413, DOI 10.1016/j.yexcr.2006.07.003; Cheng GJ, 2004, J BIOL CHEM, V279, P34250, DOI 10.1074/jbc.M400660200; Chiarugi P, 2001, J BIOL CHEM, V276, P33478, DOI 10.1074/jbc.M102302200; Chupreta S, 2000, AM J PHYSIOL-CELL PH, V278, pC697, DOI 10.1152/ajpcell.2000.278.4.C697; FIALKOW L, 1994, J BIOL CHEM, V269, P31234; Forsythe JA, 1996, MOL CELL BIOL, V16, P4604; Fu XY, 2006, J BIOL CHEM, V281, P20368, DOI 10.1074/jbc.M603353200; Geiszt M, 2003, J IMMUNOL, V171, P299, DOI 10.4049/jimmunol.171.1.299; Gioeli D, 1999, CANCER RES, V59, P279; Kamata H, 2005, CELL, V120, P649, DOI 10.1016/j.cell.2004.12.041; Kondoh K, 2007, BBA-MOL CELL RES, V1773, P1227, DOI 10.1016/j.bbamcr.2006.12.002; Kranenburg O, 2004, BBA-REV CANCER, V1654, P23, DOI 10.1016/j.bbcan.2003.09.004; Lambeth JD, 2004, NAT REV IMMUNOL, V4, P181, DOI 10.1038/nri1312; Lee SR, 1998, J BIOL CHEM, V273, P15366, DOI 10.1074/jbc.273.25.15366; Meng TC, 2002, MOL CELL, V9, P387, DOI 10.1016/S1097-2765(02)00445-8; Merchant JL, 1999, BIOCHEM BIOPH RES CO, V254, P454, DOI 10.1006/bbrc.1998.9964; Milanini J, 1998, J BIOL CHEM, V273, P18165, DOI 10.1074/jbc.273.29.18165; Mitsushita J, 2004, CANCER RES, V64, P3580, DOI 10.1158/0008-5472.CAN-03-3909; Mochizuki T, 2006, ONCOGENE, V25, P3699, DOI 10.1038/sj.onc.1209406; Omachi T, 2007, CANCER LETT, V246, P167, DOI 10.1016/j.canlet.2006.02.013; Rhee SG, 2003, J AM SOC NEPHROL, V14, pS211, DOI 10.1097/01.ASN.0000077404.45564.7E; Sambrook J., 2001, MOL CLONING; Sen CK, 2002, J BIOL CHEM, V277, P33284, DOI 10.1074/jbc.M203391200; Shinohara M, 2007, J BIOL CHEM, V282, P17640, DOI 10.1074/jbc.M609450200; Shukla S, 2004, NEOPLASIA, V6, P390, DOI 10.1593/neo.04112; Szanto I, 2005, J PATHOL, V207, P164, DOI 10.1002/path.1824; Vaquero EC, 2004, J BIOL CHEM, V279, P34643, DOI 10.1074/jbc.M400078200; Wang FS, 2004, J BIOL CHEM, V279, P10331, DOI 10.1074/jbc.M308013200; Zachary I, 2001, CARDIOVASC RES, V49, P568, DOI 10.1016/S0008-6363(00)00268-6	30	84	86	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG	2008	27	34					4724	4732		10.1038/onc.2008.102	http://dx.doi.org/10.1038/onc.2008.102			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	334QM	18454179				2022-12-28	WOS:000258236300010
J	Ristriani, T; Fournane, S; Orfanoudakis, G; Trave, G; Masson, M				Ristriani, T.; Fournane, S.; Orfanoudakis, G.; Trave, G.; Masson, M.			A single-codon mutation converts HPV16 E6 oncoprotein into a potential tumor suppressor, which induces p53-dependent senescence of HPV-positive HeLa cervical cancer cells	ONCOGENE			English	Article						human papillomavirus; cervical cancer; E6 oncoprotein; senescence; p53 protein	HUMAN-PAPILLOMAVIRUS TYPE-16; CARCINOMA-CELLS; BIOPHYSICAL CHARACTERIZATION; GENE-EXPRESSION; PROTEIN; DEGRADATION; APOPTOSIS; DOMAIN; P53; DNA	High-risk mucosal human papillomaviruses (HPV), mainly HPV16 and HPV18, are implicated in cervical carcinogenesis. HPV16 E6 oncoprotein binds and often targets for degradation numerous cell proteins, including the tumor suppressor p53 and several PDZ domain proteins. Here, we show that a single-point mutation, F47R, is sufficient to convert the HPV16 E6 oncoprotein into a suppressor of HPV-positive HeLa cervical cancer cells proliferation. The E6 F47R mutant is defective for polyubiquitination and subsequent degradation of p53. When expressed in HPV-positive cervical cancer cells, E6 F47R acts as a dominant negative mutant by counteracting the p53 degradation activity of endogenous E6 and restoring high p53 protein levels. Moreover, the prolonged expression of E6 F47R leads to suppression of HeLa cells proliferation through the induction of premature senescence. This phenotype is independent on the PDZ-binding activity of E6. F47R-senescent HeLa cells exhibit a sustained expression of p53, hMDM2 and p21CIP proteins and a reduced expression of endogenous HPV18 E6 protein. Finally, small interfering RNAs directed against p53 counteract the effect of E6 F47R expression, indicating that E6 F47R-induced cellular senescence is strongly dependent on p53 signaling pathway.	[Ristriani, T.; Fournane, S.; Orfanoudakis, G.; Trave, G.; Masson, M.] CNRS, ESBS, Equipe Oncoprot, UMR 7175, F-67412 Illkirch Graffenstaden, Bas Rhin, France	Centre National de la Recherche Scientifique (CNRS)	Masson, M (corresponding author), CNRS, ESBS, Equipe Oncoprot, UMR 7175, Blvd Sebastien Brant,BP10413, F-67412 Illkirch Graffenstaden, Bas Rhin, France.	gtrave@titus.u-strasbg.fr; masson@esbs.u-strasbg.fr	TRAVE, Gilles/P-8577-2016	Orfanoudakis, Georges/0000-0002-0064-1305	University of Strasbourg; CNRS; Association de Recherche contre le Cancer (ARC); Ligue Nationale Contre le Cancer; Canceropole Grand-EST (INCA)	University of Strasbourg; CNRS(Centre National de la Recherche Scientifique (CNRS)); Association de Recherche contre le Cancer (ARC)(Fondation ARC pour la Recherche sur le Cancer); Ligue Nationale Contre le Cancer(Ligue nationale contre le cancer); Canceropole Grand-EST (INCA)(Institut National du Cancer (INCA) France)	We thank F Hoppe-Seyler for providing HeLa cells, H Zentgraf for the antibody 18E7C, G de Murcia for the PARP antibody and Arbor Vita Corp. (USA) for the HPV18 E6 antibody. We thank E Weiss, A-P Sibler, A-S Rinaldi and B Chatton for helpful discussions. This study was supported by the University of Strasbourg, CNRS, Association de Recherche contre le Cancer (ARC), Ligue Nationale Contre le Cancer. TR and SF were supported by the Canceropole Grand-EST (INCA).	Bernard B, 2003, BIOL CELL, V95, P17, DOI 10.1016/S0248-4900(02)01220-0; Butz K, 2003, ONCOGENE, V22, P5938, DOI 10.1038/sj.onc.1206894; Courtete J, 2007, MOL CANCER THER, V6, P1728, DOI 10.1158/1535-7163.MCT-06-0808; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; Griffin H, 2006, J MOL BIOL, V355, P360, DOI 10.1016/j.jmb.2005.10.077; Hall AHS, 2003, J VIROL, V77, P6066, DOI 10.1128/JVI.77.10.6066-6069.2003; Horner SM, 2004, J VIROL, V78, P4063, DOI 10.1128/JVI.78.8.4063-4073.2004; HUIBREGTSE JM, 1991, EMBO J, V10, P4129, DOI 10.1002/j.1460-2075.1991.tb04990.x; Johung K, 2007, J VIROL, V81, P2102, DOI 10.1128/JVI.02348-06; Lagrange M, 2007, BIOCHEM BIOPH RES CO, V361, P487, DOI 10.1016/j.bbrc.2007.07.040; Lee CJ, 2002, EXP CELL RES, V277, P173, DOI 10.1006/excr.2002.5554; Lipari F, 2001, BIOCHEMISTRY-US, V40, P1196, DOI 10.1021/bi001837+; Liu Y, 1999, J VIROL, V73, P7297, DOI 10.1128/JVI.73.9.7297-7307.1999; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Massimi P, 2004, ONCOGENE, V23, P8033, DOI 10.1038/sj.onc.1207977; Masson M, 2003, J GEN VIROL, V84, P2099, DOI 10.1099/vir.0.18961-0; Nomine Y, 2006, MOL CELL, V21, P665, DOI 10.1016/j.molcel.2006.01.024; Nomine Y, 2003, BIOCHEMISTRY-US, V42, P4909, DOI 10.1021/bi026980c; Nomine Y, 2001, PROTEIN EXPRES PURIF, V23, P22, DOI 10.1006/prep.2001.1451; Nomine Y, 2001, PROTEIN ENG, V14, P297, DOI 10.1093/protein/14.4.297; Ristriani T, 2000, J MOL BIOL, V296, P1189, DOI 10.1006/jmbi.2000.3527; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; Stewart D, 2004, J GEN VIROL, V85, P1419, DOI 10.1099/vir.0.19679-0; Talis AL, 1998, J BIOL CHEM, V273, P6439, DOI 10.1074/jbc.273.11.6439; Tang S, 2006, J VIROL, V80, P4249, DOI 10.1128/JVI.80.9.4249-4263.2006; Topffer S, 2007, J GEN VIROL, V88, P2956, DOI 10.1099/vir.0.83123-0; Veldman T, 2001, J VIROL, V75, P4467, DOI 10.1128/JVI.75.9.4467-4472.2001; VOUSDEN K, 1993, FASEB J, V7, P872, DOI 10.1096/fasebj.7.10.8393818; Wells SI, 2000, EMBO J, V19, P5762, DOI 10.1093/emboj/19.21.5762; Zanier K, 2007, PROTEIN EXPRES PURIF, V51, P59, DOI 10.1016/j.pep.2006.07.029; zurHausen H, 1996, BBA-REV CANCER, V1288, pF55	31	31	35	1	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 5	2009	28	5					762	772		10.1038/onc.2008.422	http://dx.doi.org/10.1038/onc.2008.422			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	403IN	19015633				2022-12-28	WOS:000263076400013
J	Ayada, T; Taniguchi, K; Okamoto, F; Kato, R; Komune, S; Takaesu, G; Yoshimura, A				Ayada, T.; Taniguchi, K.; Okamoto, F.; Kato, R.; Komune, S.; Takaesu, G.; Yoshimura, A.			Sprouty4 negatively regulates protein kinase C activation by inhibiting phosphatidylinositol 4,5-biphosphate hydrolysis	ONCOGENE			English	Article						VEGF; phospholipase C; phosphatidylinositol; ERK; Ras	ENDOTHELIAL GROWTH-FACTOR; SUBSTRATE MARCKS PROTEIN; INDUCED ERK ACTIVATION; TYROSINE PHOSPHORYLATION; GENE-EXPRESSION; CELLS; RECEPTOR; FGF; TRANSLOCATION; ANGIOGENESIS	Sproutys have been shown to negatively regulate growth factor-induced extracellular signal-regulated kinase (ERK) activation, and suggested to be an anti-oncogene. However, molecular mechanism of the suppression has not yet been clarified completely. Sprouty4 inhibits vascular endothelial growth factor (VEGF)-A-induced ERK activation, but not VEGF-C-induced ERK activation. It has been shown that VEGF-A-mediated ERK activation is strongly dependent on protein kinase C (PKC), whereas that by VEGF-C is dependent on Ras. This suggests that Sprouty4 inhibits the PKC pathway more specifically than the Ras pathway. In this study, we confirmed that Sprouty4 suppressed various signals downstream of PKC, such as phosphorylation of MARCKS and protein kinase D (PKD), as well as PKC-dependent nuclear factor (NF)-kappa B activation. Furthermore, Sprouty4 suppressed upstream signals of PKC, such as Ca2+ mobilization, phosphatidylinositol 4,5-biphosphate (PIP2) breakdown and inositol 1,4,5-triphosphate (IP3) production in response to VEGF-A. Those effects were dependent on the C-terminal cysteine-rich region, but not on the N-terminal region of Sprouty4, which is critical for the suppression of fibroblast growth factor (FGF)-mediated ERK activation. Sprouty4 overexpression or deletion of the Sprouty4 gene did not affect phospholipase C (PLC) gamma-1 activation, which is an enzyme that catalyzes PIP2 hydrolysis. Moreover, Sprouty4 inhibited not only VEGF-A-mediated PIP2 hydrolysis but also inhibited the lysophosphatidic acid (LPA)-induced PIP2 breakdown that is catalyzed by PLC beta/epsilon activated by G-protein coupled receptor (GPCR). Taken together, Sprouty4 has broader suppression activity for various stimuli than previously thought; it may function as an inhibitor for various types of PLC-dependent signaling as well as for ERK activation.	[Yoshimura, A.] Keio Univ, Sch Med, Dept Microbiol & Immunol, Shinjuku Ku, Tokyo 1608582, Japan; [Ayada, T.; Taniguchi, K.; Okamoto, F.; Kato, R.; Takaesu, G.; Yoshimura, A.] Kyushu Univ, Med Inst Bioregulat, Div Mol & Cellular Immunol, Fukuoka 812, Japan; [Ayada, T.; Komune, S.] Kyushu Univ, Grad Sch Med Sci, Dept Otorhinolaryngol, Fukuoka 812, Japan	Keio University; Kyushu University; Kyushu University	Yoshimura, A (corresponding author), Keio Univ, Sch Med, Dept Microbiol & Immunol, Shinjuku Ku, 35 Shinanomachi, Tokyo 1608582, Japan.	yoshimura@a6.keio.jp	Yoshimura, Akihiko/K-5515-2013	Takaesu, Giichi/0000-0002-1581-1055	Ministry of Education, Culture, Sports, Science and Technology of Japan; Program for Promotion of Fundamental Studies in Health Sciences of the National Institute of Biomedical Innovation (NIBIO); Takeda Science Foundation; Kato Memorial Trust for Nambyo Research; Mitsubishi Pharma Research Foundation; Nakatomi Foundation; Naito Foundation; Astellas Foundation for Research on Metabolic Disorders; Yakult Bioscience Research Foundation; Princess Takamatsu Cancer Research Fund	Ministry of Education, Culture, Sports, Science and Technology of Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Program for Promotion of Fundamental Studies in Health Sciences of the National Institute of Biomedical Innovation (NIBIO)(National Institute of Biomedical Innovation); Takeda Science Foundation(Takeda Science Foundation (TSF)); Kato Memorial Trust for Nambyo Research(Kato Memorial Trust for Nambyo Research); Mitsubishi Pharma Research Foundation; Nakatomi Foundation; Naito Foundation(Naito Memorial Foundation); Astellas Foundation for Research on Metabolic Disorders; Yakult Bioscience Research Foundation; Princess Takamatsu Cancer Research Fund	We thank T Yoshioka and M Ohtsu for technical assistance, Dr Sasaki (Akita University), Dr Kawahara, Dr Okuno and Dr Yokomizo (Kyushu University) for reagents and discussions and Y Nishi for manuscript preparation. This study was supported by special Grants-in-Aid from the Ministry of Education, Culture, Sports, Science and Technology of Japan, the Program for Promotion of Fundamental Studies in Health Sciences of the National Institute of Biomedical Innovation (NIBIO), the Takeda Science Foundation, the Kato Memorial Trust for Nambyo Research, the Mitsubishi Pharma Research Foundation, the Nakatomi Foundation, the Naito Foundation, Astellas Foundation for Research on Metabolic Disorders, the Yakult Bioscience Research Foundation and the Princess Takamatsu Cancer Research Fund.	Abe M, 2004, BIOCHEM BIOPH RES CO, V323, P1040, DOI 10.1016/j.bbrc.2004.08.198; Angrist M, 1996, NAT GENET, V14, P341, DOI 10.1038/ng1196-341; Armesilla AL, 1999, MOL CELL BIOL, V19, P2032; Basson MA, 2006, DEV BIOL, V299, P466, DOI 10.1016/j.ydbio.2006.08.051; Basson MA, 2005, DEV CELL, V8, P229, DOI 10.1016/j.devcel.2004.12.004; Brems H, 2007, NAT GENET, V39, P1120, DOI 10.1038/ng2113; BYERS DM, 1993, J NEUROCHEM, V60, P1414, DOI 10.1111/j.1471-4159.1993.tb03303.x; Casci T, 1999, CELL, V96, P655, DOI 10.1016/S0092-8674(00)80576-0; Fong CW, 2006, CANCER RES, V66, P2048, DOI 10.1158/0008-5472.CAN-05-1072; FUJITA T, 1993, GENE DEV, V7, P1354, DOI 10.1101/gad.7.7b.1354; Fukunaga K, 2001, J BIOL CHEM, V276, P43025, DOI 10.1074/jbc.M108288200; Gaudreau R, 1998, BIOCHEM J, V335, P15, DOI 10.1042/bj3350015; Gross I, 2001, J BIOL CHEM, V276, P46460, DOI 10.1074/jbc.M108234200; Guy GR, 2003, J CELL SCI, V116, P3061, DOI 10.1242/jcs.00652; Hacohen N, 1998, CELL, V92, P253, DOI 10.1016/S0092-8674(00)80919-8; Hanafusa H, 2002, NAT CELL BIOL, V4, P850, DOI 10.1038/ncb867; Hempstead BL, 2004, J CLIN INVEST, V113, P811, DOI 10.1172/JCI200421309; Impagnatiello MA, 2001, J CELL BIOL, V152, P1087, DOI 10.1083/jcb.152.5.1087; Kato R, 2003, BIOCHEM BIOPH RES CO, V302, P767, DOI 10.1016/S0006-291X(03)00259-6; Kelley GG, 2006, J BIOL CHEM, V281, P2639, DOI 10.1074/jbc.M507681200; Kramer S, 1999, DEVELOPMENT, V126, P2515; Kuriyama M, 2004, BIOCHEM BIOPH RES CO, V325, P843, DOI 10.1016/j.bbrc.2004.10.102; Lee SH, 2001, J BIOL CHEM, V276, P4128, DOI 10.1074/jbc.M006922200; LEMMON MA, 1995, P NATL ACAD SCI USA, V92, P10472, DOI 10.1073/pnas.92.23.10472; Lim J, 2002, MOL CELL BIOL, V22, P7953, DOI 10.1128/MCB.22.22.7953-7966.2002; Lo TL, 2006, CANCER LETT, V242, P141, DOI 10.1016/j.canlet.2005.12.032; Maeng YS, 2006, CELL SIGNAL, V18, P994, DOI 10.1016/j.cellsig.2005.08.007; Minowada G, 1999, DEVELOPMENT, V126, P4465; Ohmori S, 2000, J BIOL CHEM, V275, P26449, DOI 10.1074/jbc.M003588200; Ozdener F, 2002, MOL PHARMACOL, V62, P672, DOI 10.1124/mol.62.3.672; Qin LL, 2006, J BIOL CHEM, V281, P32550, DOI 10.1074/jbc.M604853200; Reich A, 1999, DEVELOPMENT, V126, P4139; Sasaki A, 2003, NAT CELL BIOL, V5, P427, DOI 10.1038/ncb978; Sasaki A, 2001, J BIOL CHEM, V276, P36804, DOI 10.1074/jbc.C100386200; Sivak JM, 2005, DEV CELL, V8, P689, DOI 10.1016/j.devcel.2005.02.011; Stauffer TP, 1998, CURR BIOL, V8, P343, DOI 10.1016/S0960-9822(98)70135-6; SWIERCZYNSKI SL, 1995, J BIOL CHEM, V270, P13436, DOI 10.1074/jbc.270.22.13436; Taketomi T, 2005, NAT NEUROSCI, V8, P855, DOI 10.1038/nn1485; Taniguchi K, 2007, MOL CELL BIOL, V27, P4541, DOI 10.1128/MCB.01600-06; Tefft JD, 1999, CURR BIOL, V9, P219, DOI 10.1016/S0960-9822(99)80094-3; Wang Y, 2008, GENE DEV, V22, P878, DOI 10.1101/gad.452908; Wong C, 2005, J BIOL CHEM, V280, P33262, DOI 10.1074/jbc.M503198200; Yao YG, 2004, BIOCHEM BIOPH RES CO, V321, P648, DOI 10.1016/j.bbrc.2004.06.176; Yigzaw Y, 2001, J BIOL CHEM, V276, P22742, DOI 10.1074/jbc.M100123200; Yusoff P, 2002, J BIOL CHEM, V277, P3195, DOI 10.1074/jbc.M108368200	45	28	29	1	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2009	28	8					1076	1088		10.1038/onc.2008.464	http://dx.doi.org/10.1038/onc.2008.464			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	412KE	19137008				2022-12-28	WOS:000263722900003
J	Cao, Y; Liu, X; Zhang, W; Deng, X; Zhang, H; Liu, Y; Chen, L; Thompson, EA; Townsend, CM; Ko, TC				Cao, Y.; Liu, X.; Zhang, W.; Deng, X.; Zhang, H.; Liu, Y.; Chen, L.; Thompson, E. A.; Townsend, C. M., Jr.; Ko, T. C.			TGF-beta repression of Id2 induces apoptosis in gut epithelial cells	ONCOGENE			English	Article						apoptosis; affymetrix oligonucleotide microarrays; inhibitor of differentiation; TranSignal Protein/DNA arrays; hypoxia-inducing factor	GROWTH-FACTOR-BETA; LOOP-HELIX PROTEINS; INDUCIBLE TRANSCRIPTION; FACTOR GENE; HYPOXIA; DIFFERENTIATION; EXPRESSION; PROLIFERATION; ID-1; COOPERATION	Transforming growth factor-beta (TGF-beta) regulates epithelial tissue homeostasis by activating processes that control cell cycle arrest, differentiation and apoptosis. Disruption of the TGF-beta signaling pathway often occurs in colorectal cancers. Earlier, we have shown that TGF-beta induces apoptosis through the transcription factor Smad3. Affymetrix oligonucleotide microarrays were used to identify TGF-beta/Smad3 target genes that regulate apoptosis in rat intestinal epithelial cells (RIE-1). We found that TGF-beta repressed the expression of the inhibitor of differentiation (Id) gene family. Knockdown of Id1 and Id2 gene expression induced apoptosis in RIE-1 cells, whereas overexpression of Id2 attenuated TGF-beta-induced apoptosis. TranSignal Protein/ DNA arrays were used to identify the hypoxia-inducing factor-1 (HIF-1) as a downstream target of TGF-beta. HIF-1 is a basic helix-loop-helix protein, and overexpression of Id2 blocked HIF-1 activation by TGF-beta. Furthermore, knockdown of HIF-1 blocked TGF-beta-induced apoptosis. Thus, we have identified HIF-1 as a novel mediator downstream of Id2 in the pathway of TGF-beta-induced apoptosis.	[Cao, Y.; Liu, X.; Zhang, W.; Deng, X.; Zhang, H.; Ko, T. C.] Univ Texas Hlth Sci Ctr Houston, Dept Surg, Houston, TX 77030 USA; [Liu, Y.; Chen, L.; Thompson, E. A.] Mayo Clin, Ctr Comprehens Canc, Jacksonville, FL 32224 USA; [Townsend, C. M., Jr.] Univ Texas Galveston, Med Branch, Dept Surg, Galveston, TX 77550 USA	University of Texas System; University of Texas Health Science Center Houston; Mayo Clinic; University of Texas System; University of Texas Medical Branch Galveston	Cao, Y (corresponding author), Univ Texas Hlth Sci Ctr Houston, Dept Surg, MSB4-608,6431 Fannin St, Houston, TX 77030 USA.	Yanna.Cao@uth.tmc.edu; Tien.C.Ko@uth.tmc.edu			Gastrointestinal Research Interdisciplinary Program at the University of Texas Medical Branch (YC); Public Health Service [R01 DK060105, P01 DK035608, P50GM038529]; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK060105, P01DK035608] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P50GM038529] Funding Source: NIH RePORTER	Gastrointestinal Research Interdisciplinary Program at the University of Texas Medical Branch (YC); Public Health Service(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We thank D Deng, Dr D Song and Z Chen for technical support; Dr H Guo for real-time quantitative PCR assay at the Real-Time PCR Core Facility, Sealy Center for Cancer Cell Biology, UTMB; Dr C Cox Jr and F Jimenez in the Department of Pediatric Surgery, UTHSC-Houston, and M Grif. n in the Flow Cytometry and Cell Sorting Core Facility, UTMB, for flow cytometric analysis. E Figueroa and S Schuenke in the Department of Surgery, UTMB, for manuscript preparation. This study was supported by a grant from the Gastrointestinal Research Interdisciplinary Program at the University of Texas Medical Branch (YC), and Public Health Service Grants R01 DK060105 (TCK), P01 DK035608 (CMT and TCK) and P50GM038529 (TCK).	Alliston T, 2005, J BIOL CHEM, V280, P24227, DOI 10.1074/jbc.M414305200; AndresBarquin PJ, 1997, CANCER RES, V57, P215; Babyatsky M. W., 1991, TXB GASTROENTEROLOGY, P475; Cao YN, 2007, AM J PHYSIOL-GASTR L, V292, pG28, DOI 10.1152/ajpgi.00437.2005; Cao YN, 2006, SURGERY, V140, P322, DOI 10.1016/j.surg.2006.05.006; Choy L, 2000, J CELL BIOL, V149, P667, DOI 10.1083/jcb.149.3.667; Conery AR, 2004, NAT CELL BIOL, V6, P366, DOI 10.1038/ncb1117; Florio M, 1998, MOL CELL BIOL, V18, P5435, DOI 10.1128/MCB.18.9.5435; Gold LI, 1999, CRIT REV ONCOGENESIS, V10, P303; Gordan JD, 2007, CANCER CELL, V11, P335, DOI 10.1016/j.ccr.2007.02.006; Hasskarl J, 2002, CANCER BIOL THER, V1, P91, DOI 10.4161/cbt.50; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; Kang YB, 2003, MOL CELL, V11, P915, DOI 10.1016/S1097-2765(03)00109-6; Kim D, 1999, MOL CELL BIOL, V19, P8240; Kim HJ, 2007, MOL CANCER RES, V5, P321, DOI 10.1158/1541-7786.MCR-06-0218; Ko T C, 1997, Prog Cell Cycle Res, V3, P43; Kondo M, 2004, CELL DEATH DIFFER, V11, P1092, DOI 10.1038/sj.cdd.4401467; Kowanetz M, 2004, MOL CELL BIOL, V24, P4241, DOI 10.1128/MCB.24.10.4241-4254.2004; Lasorella A, 2000, NATURE, V407, P592, DOI 10.1038/35036504; LEVY AP, 1995, J BIOL CHEM, V270, P13333, DOI 10.1074/jbc.270.22.13333; Ling MT, 2002, BBA-GEN SUBJECTS, V1570, P145, DOI 10.1016/S0304-4165(02)00189-7; Lofstedt T, 2004, J BIOL CHEM, V279, P39223, DOI 10.1074/jbc.M402904200; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; Massague J, 2000, CELL, V103, P295, DOI 10.1016/S0092-8674(00)00121-5; Nakajima T, 1998, P NATL ACAD SCI USA, V95, P10590, DOI 10.1073/pnas.95.18.10590; Nemetski SM, 2007, J BIOL CHEM, V282, P240, DOI 10.1074/jbc.M607275200; Nguyen KA, 2006, ANN SURG, V243, P619, DOI 10.1097/01.sla.0000216783.85214.c1; Norton JD, 2000, J CELL SCI, V113, P3897; Norton JD, 1998, MOL CELL BIOL, V18, P2371, DOI 10.1128/MCB.18.4.2371; Parrinello S, 2001, J BIOL CHEM, V276, P39213, DOI 10.1074/jbc.M104473200; Sanchez-Elsner T, 2004, J MOL BIOL, V336, P9, DOI 10.1016/j.jmb.2003.12.023; Sanchez-Elsner T, 2002, J BIOL CHEM, V277, P43799, DOI 10.1074/jbc.M207160200; Sanchez-Elsner T, 2001, J BIOL CHEM, V276, P38527, DOI 10.1074/jbc.M104536200; Semenza GL, 1999, ANNU REV CELL DEV BI, V15, P551, DOI 10.1146/annurev.cellbio.15.1.551; SEMENZA GL, 1991, P NATL ACAD SCI USA, V88, P5680, DOI 10.1073/pnas.88.13.5680; Shih SC, 2001, GROWTH FACTORS, V19, P19, DOI 10.3109/08977190109001073; Siegel PM, 2003, J BIOL CHEM, V278, P35444, DOI 10.1074/jbc.M301413200; Sikder HA, 2003, CANCER CELL, V3, P525, DOI 10.1016/S1535-6108(03)00141-7; Tanaka K, 1998, J BIOL CHEM, V273, P25922, DOI 10.1074/jbc.273.40.25922; WANG GL, 1995, J BIOL CHEM, V270, P1230, DOI 10.1074/jbc.270.3.1230; Wenger RH, 2002, FASEB J, V16, DOI 10.1096/fj.01-0944rev; Wenger Roland H, 2005, Sci STKE, V2005, pre12, DOI 10.1126/stke.3062005re12; Yokota Y, 2002, J CELL PHYSIOL, V190, P21, DOI 10.1002/jcp.10042; Zebedee Z, 2001, ONCOGENE, V20, P8317, DOI 10.1038/sj.onc.1205092	44	33	35	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2009	28	8					1089	1098		10.1038/onc.2008.456	http://dx.doi.org/10.1038/onc.2008.456			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	412KE	19137015	Green Accepted			2022-12-28	WOS:000263722900004
J	Fukukawa, C; Nagayama, S; Tsunoda, T; Toguchida, J; Nakamura, Y; Katagiri, T				Fukukawa, C.; Nagayama, S.; Tsunoda, T.; Toguchida, J.; Nakamura, Y.; Katagiri, T.			Activation of the non-canonical Dvl-Rac1-JNK pathway by Frizzled homologue 10 in human synovial sarcoma	ONCOGENE			English	Article						Frizzled; synovial sarcoma; JNK; cytoskeleton; anchorage-independent growth; Rac	BETA-CATENIN; DISHEVELLED PHOSPHORYLATION; SIGNALING CASCADE; GENE-EXPRESSION; PROTEIN; KINASE; RAC; RHO; TRANSLOCATION; BINDING	We previously reported that Frizzled homologue 10 (FZD10), a member of the Wnt signal receptor family, was highly and specifically upregulated in synovial sarcoma and played critical roles in its cell survival and growth. We here report a possible molecular mechanism of the FZD10 signaling in synovial sarcoma cells. We found a significant enhancement of phosphorylation of the Dishevelled (Dvl)2/Dvl3 complex as well as activation of the Rac1-JNK cascade in synovial sarcoma cells in which FZD10 was overexpressed. Activation of the FZD10-Dvls -Rac1 pathway induced lamellipodia formation and enhanced anchorage-independent cell growth cells. FZD10 overexpression also caused the destruction of the actin cytoskeleton structure, probably through the down-regulation of the RhoA activity. Our results have strongly implied that FZD10 transactivation causes the activation of the non-canonical Dvl-Rac1-JNK pathway and plays critical roles in the development/progression of synovial sarcomas.	[Katagiri, T.] Univ Tokyo, Inst Med Sci, Ctr Human Genome, Mol Med Lab,Minato Ku, Tokyo 1088639, Japan; [Tsunoda, T.] Inst Phys & Chem Res, RIKEN, SNP Res Ctr, Lab Med Informat, Yokohama, Kanagawa, Japan; [Toguchida, J.] Kyoto Univ, Inst Frontier Med Sci, Kyoto, Japan	University of Tokyo; RIKEN; Kyoto University	Katagiri, T (corresponding author), Univ Tokyo, Inst Med Sci, Ctr Human Genome, Mol Med Lab,Minato Ku, 4-6-1 Shirokanedai, Tokyo 1088639, Japan.	tkatagi@ims.u-tokyo.ac.jp	Katagiri, Toyomasa/I-7344-2012; Tsunoda, Tatsuhiko/K-2061-2014	Tsunoda, Tatsuhiko/0000-0002-5439-7918				Aepfelbacher M, 1996, J IMMUNOL, V157, P5070; Angers S, 2006, NAT CELL BIOL, V8, P348, DOI 10.1038/ncb1381; Bain J, 2007, BIOCHEM J, V408, P297, DOI 10.1042/BJ20070797; Brett D, 1997, HUM MOL GENET, V6, P1559, DOI 10.1093/hmg/6.9.1559; Bryja V, 2007, J CELL SCI, V120, P586, DOI 10.1242/jcs.03368; Bryja V, 2007, CELL SIGNAL, V19, P610, DOI 10.1016/j.cellsig.2006.08.011; Capelluto DGS, 2002, NATURE, V419, P726, DOI 10.1038/nature01056; Cheng TL, 2004, EXP CELL RES, V295, P497, DOI 10.1016/j.yexcr.2004.02.002; CLARK J, 1994, NAT GENET, V7, P502, DOI 10.1038/ng0894-502; Coindre JM, 2003, CANCER-AM CANCER SOC, V98, P2700, DOI 10.1002/cncr.11840; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; Endo Y, 2005, J BIOL CHEM, V280, P777, DOI 10.1074/jbc.M406391200; Frisch SM, 2001, CURR OPIN CELL BIOL, V13, P555, DOI 10.1016/S0955-0674(00)00251-9; Fukukawa C, 2008, CANCER SCI, V99, P432, DOI 10.1111/j.1349-7006.2007.00701.x; Gonzalez-Sancho JM, 2004, MOL CELL BIOL, V24, P4757, DOI 10.1128/MCB.24.11.4757-4768.2004; Habas R, 2003, GENE DEV, V17, P295, DOI 10.1101/gad.1022203; Habu S, 1998, SURG TODAY, V28, P401, DOI 10.1007/s005950050149; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Hamel M, 2006, ENDOTHELIUM-J ENDOTH, V13, P157, DOI 10.1080/10623320600760191; Hino S, 2003, J BIOL CHEM, V278, P14066, DOI 10.1074/jbc.M213265200; Hiraga H, 1999, J BONE JOINT SURG AM, V81A, P558, DOI 10.2106/00004623-199904000-00014; Hosono T, 2005, JPN J CLIN ONCOL, V35, P274, DOI 10.1093/jjco/hyi073; Kinoshita N, 2003, GENE DEV, V17, P1663, DOI 10.1101/gad.1101303; Kishida S, 2004, MOL CELL BIOL, V24, P4487, DOI 10.1128/MCB.24.10.4487-4501.2004; Koike J, 1999, BIOCHEM BIOPH RES CO, V262, P39, DOI 10.1006/bbrc.1999.1161; Lim FL, 1998, ONCOGENE, V17, P2013, DOI 10.1038/sj.onc.1202122; McGilbray TT, 2003, LANCET ONCOL, V4, P283, DOI 10.1016/S1470-2045(03)01075-1; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; Nagayama S, 2005, ONCOGENE, V24, P6201, DOI 10.1038/sj.onc.1208780; Nagayama S, 2002, CANCER RES, V62, P5859; Nielsen TO, 2002, LANCET, V359, P1301, DOI 10.1016/S0140-6736(02)08270-3; Nunnally AP, 2004, DEV GENES EVOL, V214, P144, DOI 10.1007/s00427-004-0386-4; Ochi N, 2004, ORL-J OTO-RHIN-LARYN, V66, P42, DOI 10.1159/000077233; Otto IM, 2000, CURR BIOL, V10, P345, DOI 10.1016/S0960-9822(00)00388-2; PATERSON HF, 1990, J CELL BIOL, V111, P1001, DOI 10.1083/jcb.111.3.1001; Rena G, 2004, EMBO REP, V5, P60, DOI 10.1038/sj.embor.7400048; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; Rosso SB, 2005, NAT NEUROSCI, V8, P34, DOI 10.1038/nn1374; Rothbacher U, 2000, EMBO J, V19, P1010, DOI 10.1093/emboj/19.5.1010; Segal NH, 2003, AM J PATHOL, V163, P691, DOI 10.1016/S0002-9440(10)63696-6; Shannon BA, 2005, ARCH PATHOL LAB MED, V129, P238; Soulez M, 1999, ONCOGENE, V18, P2739, DOI 10.1038/sj.onc.1202613; Szuhai K, 2004, CANCER GENET CYTOGEN, V153, P48, DOI 10.1016/j.cancergencyto.2003.12.012; TURCCAREL C, 1986, CANCER GENET CYTOGEN, V23, P93, DOI 10.1016/0165-4608(86)90153-6; Wang ZS, 2005, MOL CELL BIOL, V25, P5022, DOI 10.1128/MCB.25.12.5022-5030.2005; Wechezak AR, 2005, J CELL PHYSIOL, V202, P867, DOI 10.1002/jcp.20176; WEISS SW, 2001, ENZINGER WEISSS SOFT; Wharton KA, 2003, DEV BIOL, V253, P1, DOI 10.1006/dbio.2002.0869; Wiggan O, 2002, J CELL SCI, V115, P531; Williams DH, 2004, J UROLOGY, V171, P2376, DOI 10.1097/01.ju.0000125319.92634.9b	50	51	53	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2009	28	8					1110	1120		10.1038/onc.2008.467	http://dx.doi.org/10.1038/onc.2008.467			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	412KE	19137009				2022-12-28	WOS:000263722900006
J	Smalley, KSM; Xiao, M; Villanueva, J; Nguyen, TK; Flaherty, KT; Letrero, R; Van Belle, P; Elder, DE; Wang, Y; Nathanson, KL; Herlyn, M				Smalley, K. S. M.; Xiao, M.; Villanueva, J.; Nguyen, T. K.; Flaherty, K. T.; Letrero, R.; Van Belle, P.; Elder, D. E.; Wang, Y.; Nathanson, K. L.; Herlyn, M.			CRAF inhibition induces apoptosis in melanoma cells with non-V600E BRAF mutations	ONCOGENE			English	Article						melanoma; BRAF; CRAF; targeted therapy; sorafenib	MALIGNANT-MELANOMA; KINASE-KINASE; B-RAF; ERK; SURVIVAL; PROTEIN; PHOSPHORYLATION; SUPPRESSION; EXPRESSION; SORAFENIB	Here, we identify a panel of melanoma lines with non-V600E mutations in BRAF. These G469E- and D594G-mutated melanomas were found to exhibit constitutive levels of phospho-extracellular signal-regulated kinase (pERK) and low levels of phospho-mitogen-activated protein kinase/ERKkinase (pMEK) and were resistant to MEK inhibition. Upon treatment with the CRAF inhibitor sorafenib, these lines underwent apoptosis and associated with mitochondrial depolarization and relocalization of apoptosis-inducing factor, whereas the BRAF-V600-Emutated melanomas did not. Studies have shown low-activity mutants of BRAF (G469E/D594G) instead signal through CRAF. Unlike BRAF, CRAF directly regulates apoptosis through mitochondrial localization where it binds to Bcl-2 and phosphorylates BAD. The CRAF inhibitor sorafenib was found to induce a time-dependent reduction in both BAD phosphorylation and Bcl-2 expression in the D594G/G469E lines only. Knockdown of CRAF using a lentiviral shRNA suppressed both Bcl-2 expression and induced apoptosis in the D594G melanoma line but not in a V600E-mutated line. Finally, we showed in a series of xenograft studies that sorafenib was more potent at reducing the growth of tumors with the D594G mutation than those with the V600E mutation. In summary, we have identified a group of melanomas with low-activity BRAF mutations that are reliant upon CRAF-mediated survival activity.	[Smalley, K. S. M.; Xiao, M.; Villanueva, J.; Nguyen, T. K.; Herlyn, M.] Wistar Inst Anat & Biol, Philadelphia, PA 19104 USA; [Flaherty, K. T.] Univ Penn, Sch Med, Div Hematol Oncol, Philadelphia, PA 19104 USA; [Letrero, R.; Nathanson, K. L.] Univ Penn, Sch Med, Div Med Genet, Philadelphia, PA 19104 USA; [Van Belle, P.; Elder, D. E.] Univ Penn, Sch Med, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA; [Wang, Y.] Univ Penn, Sch Med, Dept Otorhinolaryngol, Philadelphia, PA 19104 USA; [Flaherty, K. T.; Nathanson, K. L.] Univ Penn, Sch Med, Abramson Canc Ctr, Philadelphia, PA 19104 USA	The Wistar Institute; University of Pennsylvania; University of Pennsylvania; University of Pennsylvania; University of Pennsylvania; University of Pennsylvania; Pennsylvania Medicine	Smalley, KSM (corresponding author), H Lee Moffitt Canc Ctr & Res Inst, Dept Mol Oncol, 12902 Magnolia Dr, Tampa, FL 33612 USA.	k.smalley@mac.com; herlynm@wistar.org	Smalley, Keiran S/A-1320-2007	Smalley, Keiran S/0000-0002-4121-8335; Nathanson, Katherine/0000-0002-6740-0901; Smalley, Keiran/0000-0003-1089-9307	Bayer Corporation [BAY 43-9006]; NATIONAL CANCER INSTITUTE [R01CA047159, P50CA093372, R01CA080999, P01CA114046, R01CA076674, P01CA025874] Funding Source: NIH RePORTER	Bayer Corporation(Bayer AG); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank the Bayer Corporation for providing the BAY 43-9006 (sorafenib).	Chen J, 2001, P NATL ACAD SCI USA, V98, P7783, DOI 10.1073/pnas.141224398; Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766; Dhomen N, 2007, CURR OPIN GENET DEV, V17, P31, DOI 10.1016/j.gde.2006.12.005; Dumaz N, 2006, CANCER RES, V66, P9483, DOI 10.1158/0008-5472.CAN-05-4227; Eisen T, 2006, BRIT J CANCER, V95, P581, DOI 10.1038/sj.bjc.6603291; Garnett MJ, 2005, MOL CELL, V20, P963, DOI 10.1016/j.molcel.2005.10.022; Gray-Schopfer V, 2007, NATURE, V445, P851, DOI 10.1038/nature05661; Haass NK, 2008, CLIN CANCER RES, V14, P230, DOI 10.1158/1078-0432.CCR-07-1440; Houben R, 2008, J INVEST DERMATOL, V128, P2003, DOI 10.1038/jid.2008.30; Jin SH, 2005, J BIOL CHEM, V280, P24698, DOI 10.1074/jbc.M413374200; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; O'Neill E, 2004, SCIENCE, V306, P2267, DOI 10.1126/science.1103233; Panka DJ, 2006, CANCER RES, V66, P1611, DOI 10.1158/0008-5472.CAN-05-0808; Rapp UR, 2004, BBA-MOL CELL RES, V1644, P149, DOI 10.1016/j.bbamcr.2003.10.015; Smalley KM, 2007, BRIT J CANCER, V96, P445, DOI 10.1038/sj.bjc.6603596; Smalley KSM, 2007, CANCER RES, V67, P209, DOI 10.1158/0008-5472.CAN-06-1538; Smalley KSM, 2003, INT J CANCER, V104, P527, DOI 10.1002/ijc.10978; Smalley KSM, 2006, MOL CANCER THER, V5, P1136, DOI 10.1158/1535-7163.MCT-06-0084; Smalley KSM, 2005, AM J PATHOL, V166, P1541, DOI 10.1016/S0002-9440(10)62370-X; Solit DB, 2006, NATURE, V439, P358, DOI 10.1038/nature04304; Spittle C, 2007, J MOL DIAGN, V9, P464, DOI 10.2353/jmoldx.2007.060191; von Gise A, 2001, MOL CELL BIOL, V21, P2324, DOI 10.1128/MCB.21.7.2324-2336.2001; Wan PTC, 2004, CELL, V116, P855, DOI 10.1016/S0092-8674(04)00215-6; Wang HG, 1996, P NATL ACAD SCI USA, V93, P7063, DOI 10.1073/pnas.93.14.7063; Wang HG, 1996, CELL, V87, P629, DOI 10.1016/S0092-8674(00)81383-5; Wilhelm SM, 2004, CANCER RES, V64, P7099, DOI 10.1158/0008-5472.CAN-04-1443; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3	27	164	173	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 8	2009	28	1					85	94		10.1038/onc.2008.362	http://dx.doi.org/10.1038/onc.2008.362			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	392HP	18794803	Green Accepted			2022-12-28	WOS:000262294100009
J	Talotta, F; Cimmino, A; Matarazzo, MR; Casalino, L; De Vita, G; D'Esposito, M; Di Lauro, R; Verde, P				Talotta, F.; Cimmino, A.; Matarazzo, M. R.; Casalino, L.; De Vita, G.; D'Esposito, M.; Di Lauro, R.; Verde, P.			An autoregulatory loop mediated by miR-21 and PDCD4 controls the AP-1 activity in RAS transformation	ONCOGENE			English	Article						miR-21; AP-1; PDCD4; PTEN; RAS; thyroid tumorigenesis	TUMOR-SUPPRESSOR PDCD4; GENE-EXPRESSION; C-JUN; MICRORNA-21 TARGETS; CELLS; TRANSLATION; INVASION; SURVIVAL; PROTEIN; PHOSPHORYLATION	The transcription factor AP-1 plays key roles in tumorigenesis, by regulating a variety of protein-coding genes, implicated in multiple hallmarks of cancer. Among non-coding genes, no AP-1 target has been described yet in tumorigenesis. MicroRNAs (miRNAs) are negative post-transcriptional regulators of protein-coding genes. miRNA expression signatures are highly relevant in cancer and several tumor-associated miRNAs (oncomirs) play critical roles in oncogenesis. Here, we show that the miRNA miR-21, which represents the most frequently upregulated oncomir in solid tumors, is induced by AP-1 in response to RAS. By analyzing validated miR-21 targets, we have found that the tumor suppressors PTEN and PDCD4 are downregulated by RAS in an AP-1- and miR-21-dependent fashion. We further show that, given the role of PDCD4 as negative regulator of AP-1, the miR-21-mediated downregulation of PDCD4 is essential for the maximal induction of AP-1 activity in response to RAS. Our data reveal a novel mechanism of positive autoregulation of the AP-1 complex in RAS transformation and disclose the function of oncomirs as critical targets and regulators of AP-1 in tumorigenesis.	[Verde, P.] CNR, Inst Genet & Biophys A Buzzati Traverso, Inst Genet & Biophys, I-80131 Naples, Italy; [Cimmino, A.] Univ Naples 2, Dept Biochem & Biophys, Sch Med, Naples, Italy; [De Vita, G.; Di Lauro, R.] Univ Naples Federico II, Dept Mol & Cellular Biol & Pathol, Sch Med, Naples, Italy	Consiglio Nazionale delle Ricerche (CNR); Istituto di Genetica e Biofisica "Adriano Buzzati-Traverso" (IGB-CNR); Universita della Campania Vanvitelli; University of Naples Federico II	Verde, P (corresponding author), CNR, Inst Genet & Biophys A Buzzati Traverso, Inst Genet & Biophys, Via P Castellino 111, I-80131 Naples, Italy.	verde@igb.cnr.it	D'Esposito, Maurizio/J-9205-2016; De Vita, Gabriella/H-4422-2011; Casalino, Laura/C-1506-2015; D'Esposito, Maurizio/AAY-6376-2020; Di Lauro, Roberto/A-2746-2012	De Vita, Gabriella/0000-0002-7302-1174; Casalino, Laura/0000-0002-2557-0443; Di Lauro, Roberto/0000-0001-9493-3036; Cimmino, Amelia/0000-0002-0004-9299	AIRC (Associazione Italiana per la Ricerca sul Cancro); AICR (Association for International Cancer Research, UK); AIRC and EU-Project-SIROCCO [LSHG-CT2006037900]	AIRC (Associazione Italiana per la Ricerca sul Cancro)(Fondazione AIRC per la ricerca sul cancro); AICR (Association for International Cancer Research, UK); AIRC and EU-Project-SIROCCO(Fondazione AIRC per la ricerca sul cancro)	We thank Robert Hennigan (University of Cincinnati, USA), Nancy Colburn (NCI, NIH, USA), Anders Lund (University of Copenhagen, Denmark) and Hideo Iba (University of Tokyo, Japan) for expression and reporter constructs. We also thank Floriana Della Ragione and Ingram Iaccarino (IGB) for technical help and critical reading of the paper. This work was supported by grants from AIRC (Associazione Italiana per la Ricerca sul Cancro) and AICR (Association for International Cancer Research, UK) to PV and AIRC and EU-Project-SIROCCO (Grant LSHG-CT2006037900) to RDL.	Ancrile B, 2007, GENE DEV, V21, P1714, DOI 10.1101/gad.1549407; Asangani IA, 2008, ONCOGENE, V27, P2128, DOI 10.1038/sj.onc.1210856; Bahassi EM, 2004, CLIN EXP METASTAS, V21, P293, DOI 10.1023/B:CLIN.0000046132.46946.dd; Bakiri L, 2000, EMBO J, V19, P2056, DOI 10.1093/emboj/19.9.2056; Bakiri L, 2002, MOL CELL BIOL, V22, P4952, DOI 10.1128/MCB.22.13.4952-4964.2002; Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5; Bitomsky N, 2004, ONCOGENE, V23, P7484, DOI 10.1038/sj.onc.1208064; Cai XZ, 2004, RNA, V10, P1957, DOI 10.1261/rna.7135204; Calin GA, 2006, NAT REV CANCER, V6, P857, DOI 10.1038/nrc1997; Casalino L, 2003, MOL CELL BIOL, V23, P4401, DOI 10.1128/MCB.23.12.4401-4415.2003; Chan JA, 2005, CANCER RES, V65, P6029, DOI 10.1158/0008-5472.CAN-05-0137; Cimmino A, 2005, P NATL ACAD SCI USA, V102, P13944, DOI 10.1073/pnas.0506654102; Corsten MF, 2007, CANCER RES, V67, P8994, DOI 10.1158/0008-5472.CAN-07-1045; Davis BN, 2008, NATURE, V454, P56, DOI 10.1038/nature07086; De Vita G, 2005, MOL ENDOCRINOL, V19, P76, DOI 10.1210/me.2004-0172; Dorrello NV, 2006, SCIENCE, V314, P467, DOI 10.1126/science.1130276; Eferl R, 2003, NAT REV CANCER, V3, P859, DOI 10.1038/nrc1209; Elmen J, 2008, NATURE, V452, P896, DOI 10.1038/nature06783; Esquela-Kerscher A, 2006, NAT REV CANCER, V6, P259, DOI 10.1038/nrc1840; Frankel LB, 2008, J BIOL CHEM, V283, P1026, DOI 10.1074/jbc.M707224200; Fujita S, 2008, J MOL BIOL, V378, P492, DOI 10.1016/j.jmb.2008.03.015; Fujita S, 2008, BIOINFORMATICS, V24, P303, DOI 10.1093/bioinformatics/btm589; Fulci V, 2007, BLOOD, V109, P4944, DOI 10.1182/blood-2006-12-062398; He HL, 2005, P NATL ACAD SCI USA, V102, P19075, DOI 10.1073/pnas.0509603102; He XY, 2007, CANCER RES, V67, P11099, DOI 10.1158/0008-5472.CAN-07-2672; Hettinger K, 2007, CELL DEATH DIFFER, V14, P218, DOI 10.1038/sj.cdd.4401946; Iorio MV, 2005, CANCER RES, V65, P7065, DOI 10.1158/0008-5472.CAN-05-1783; Jansen AP, 2005, CANCER RES, V65, P6034, DOI 10.1158/0008-5472.CAN-04-2119; Landgraf P, 2007, CELL, V129, P1401, DOI 10.1016/j.cell.2007.04.040; Leupold JH, 2007, ONCOGENE, V26, P4550, DOI 10.1038/sj.onc.1210234; Lim LP, 2005, NATURE, V433, P769, DOI 10.1038/nature03315; Loffler D, 2007, BLOOD, V110, P1330, DOI 10.1182/blood-2007-03-081133; Lu Z, 2008, ONCOGENE, V27, P4373, DOI 10.1038/onc.2008.72; Mechta F, 1997, ONCOGENE, V14, P837, DOI 10.1038/sj.onc.1200900; Meng FY, 2007, GASTROENTEROLOGY, V133, P647, DOI 10.1053/j.gastro.2007.05.022; Meng FY, 2006, GASTROENTEROLOGY, V130, P2113, DOI 10.1053/j.gastro.2006.02.057; O'Donnell KA, 2005, NATURE, V435, P839, DOI 10.1038/nature03677; Olive M, 1997, J BIOL CHEM, V272, P18586, DOI 10.1074/jbc.272.30.18586; Ozanne BW, 2007, ONCOGENE, V26, P1, DOI 10.1038/sj.onc.1209759; Pallante P, 2006, ENDOCR-RELAT CANCER, V13, P497, DOI 10.1677/erc.1.01209; Shaulian E, 2002, NAT CELL BIOL, V4, pE131, DOI 10.1038/ncb0502-e131; Si ML, 2007, ONCOGENE, V26, P2799, DOI 10.1038/sj.onc.1210083; Vallone D, 1997, EMBO J, V16, P5310, DOI 10.1093/emboj/16.17.5310; Vasudevan KM, 2007, CANCER RES, V67, P10343, DOI 10.1158/0008-5472.CAN-07-1827; Volinia S, 2006, P NATL ACAD SCI USA, V103, P2257, DOI 10.1073/pnas.0510565103; Wang Q, 2008, ONCOGENE, V27, P1527, DOI 10.1038/sj.onc.1210793; Yang HS, 2003, MOL CELL BIOL, V23, P26, DOI 10.1128/MCB.23.1.26-37.2003; Yang HS, 2006, MOL CELL BIOL, V26, P1297, DOI 10.1128/MCB.26.4.1297-1306.2006; Yang HS, 2003, ONCOGENE, V22, P3712, DOI 10.1038/sj.onc.1206433; Young MR, 1999, P NATL ACAD SCI USA, V96, P9827, DOI 10.1073/pnas.96.17.9827; Yu SL, 2008, CANCER CELL, V13, P48, DOI 10.1016/j.ccr.2007.12.008; Zhu SM, 2008, CELL RES, V18, P350, DOI 10.1038/cr.2008.24; Zhu SM, 2007, J BIOL CHEM, V282, P14328, DOI 10.1074/jbc.M611393200	53	200	215	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 8	2009	28	1					73	84		10.1038/onc.2008.370	http://dx.doi.org/10.1038/onc.2008.370			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	392HP	18850008				2022-12-28	WOS:000262294100008
J	Bernardi, R; Papa, A; Pandolfi, PP				Bernardi, R.; Papa, A.; Pandolfi, P. P.			Regulation of apoptosis by PML and the PML-NBs	ONCOGENE			English	Review						apoptosis; PML nuclear bodies; tumor suppression; cancer; APL	PROMYELOCYTIC LEUKEMIA PROTEIN; FAS-INDUCED APOPTOSIS; TUMOR-SUPPRESSOR PML; CELL-CYCLE ARREST; NUCLEAR-BODIES; DNA-DAMAGE; INTERACTING PROTEIN; RAR-ALPHA; CYTOPLASMIC PML; BINDING PROTEIN	The promyelocytic leukemia protein (PML) is a tumor suppressor identified in acute PML and implicated in the pathogenesis of a variety of tumors. PML is essential for the proper assembly of a nuclear macromolecular structure called the PML nuclear body (PML-NB). PML and PML-NBs are functionally promiscuous and have been associated with the regulation of several cellular functions. Above all these is the control of apoptosis, a function of PML whose physiological relevance is emphasized by in vivo studies that demonstrate that mice and cells lacking Pml are resistant to a vast variety of apoptotic stimuli. The function of PML in regulating apoptosis is not confined to a linear pathway; rather, PML works within a regulatory network that finely tunes various apoptotic pathways, depending on the cellular context and the apoptotic stimulus. Here, we will summarize earlier and recent advances on the molecular mechanisms by which PML regulates apoptosis and the implication of these findings for cancer pathogenesis.	[Bernardi, R.; Papa, A.; Pandolfi, P. P.] Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Dept Pathol & Med, Boston, MA 02115 USA; [Bernardi, R.; Papa, A.; Pandolfi, P. P.] Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Canc Genet Program, Boston, MA 02115 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School	Pandolfi, PP (corresponding author), Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Dept Pathol & Med, New Res Bldg,330 Brookline Ave, Boston, MA 02115 USA.	ppandolf@bidmc.harvard.edu	bernardi, rosa/B-1650-2013	bernardi, rosa/0000-0002-3607-6336; Papa, Antonella/0000-0001-8653-7121	NCI	NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank all past and present members of the Pandolfi lab at Memorial Sloan-Kettering Cancer Center and at Beth Israel Deaconess Medical Center for useful discussion and support. This work is supported by the NCI, through grants to PPP and RB.	Alsheich-Bartok O, 2008, ONCOGENE, V27, P3653, DOI 10.1038/sj.onc.1211036; Bellodi C, 2006, CELL CYCLE, V5, P2688, DOI 10.4161/cc.5.22.3504; Bernardi R, 2004, NAT CELL BIOL, V6, P665, DOI 10.1038/ncb1147; Bernardi R, 2003, ONCOGENE, V22, P9048, DOI 10.1038/sj.onc.1207106; Bernardi R, 2007, NAT REV MOL CELL BIO, V8, P1006, DOI 10.1038/nrm2277; Best JL, 2002, MOL CELL, V10, P843, DOI 10.1016/S1097-2765(02)00699-8; Bischof O, 2002, EMBO J, V21, P3358, DOI 10.1093/emboj/cdf341; Bissonnette N, 1998, ONCOGENE, V16, P3461, DOI 10.1038/sj.onc.1201899; Boisvert FM, 2000, J CELL BIOL, V148, P283, DOI 10.1083/jcb.148.2.283; Borden KLB, 2002, MOL CELL BIOL, V22, P5259, DOI 10.1128/MCB.22.15.5259-5269.2002; Buschbeck M, 2007, ONCOGENE, V26, P3415, DOI 10.1038/sj.onc.1210128; Cao XF, 2008, MOL CANCER THER, V7, P923, DOI 10.1158/1535-7163.MCT-07-0540; Carbone R, 2002, ONCOGENE, V21, P1633, DOI 10.1038/sj.onc.1205227; Chang HJ, 2007, PATHOL ONCOL RES, V13, P326, DOI 10.1007/BF02940312; Chang HY, 1998, SCIENCE, V281, P1860, DOI 10.1126/science.281.5384.1860; CHANG KS, 1995, BLOOD, V85, P3646, DOI 10.1182/blood.V85.12.3646.bloodjournal85123646; Cho YM, 1998, INT J MOL MED, V1, P717; Condemine W, 2006, CANCER RES, V66, P6192, DOI 10.1158/0008-5472.CAN-05-3792; Croxton R, 2006, CANCER RES, V66, P9026, DOI 10.1158/0008-5472.CAN-06-1047; D'Orazi G, 2002, NAT CELL BIOL, V4, P11, DOI 10.1038/ncb714; DANIEL MT, 1993, BLOOD, V82, P1858; de Stanchina E, 2004, MOL CELL, V13, P523, DOI 10.1016/S1097-2765(04)00062-0; Dellaire G, 2004, BIOESSAYS, V26, P963, DOI 10.1002/bies.20089; Dellaire G, 2006, J CELL BIOL, V175, P55, DOI 10.1083/jcb.200604009; DETHE H, 1991, CELL, V66, P675, DOI 10.1016/0092-8674(91)90113-D; Emelyanov AV, 2002, J BIOL CHEM, V277, P11156, DOI 10.1074/jbc.M111763200; Everett RD, 1997, EMBO J, V16, P1519, DOI 10.1093/emboj/16.7.1519; Ferbeyre G, 2000, GENE DEV, V14, P2015; Fogal V, 2000, EMBO J, V19, P6185, DOI 10.1093/emboj/19.22.6185; Fu CH, 2005, ONCOGENE, V24, P5401, DOI 10.1038/sj.onc.1208714; Guo A, 2000, NAT CELL BIOL, V2, P730, DOI 10.1038/35036365; Guo Y, 2002, J BIOL CHEM, V277, P13430, DOI 10.1074/jbc.M108029200; Gurrieri C, 2004, BLOOD, V103, P2358, DOI 10.1182/blood-2003-07-2200; Gurrieri C, 2004, JNCI-J NATL CANCER I, V96, P269, DOI 10.1093/jnci/djh043; Halazonetis TD, 2008, SCIENCE, V319, P1352, DOI 10.1126/science.1140735; Hayakawa F, 2004, CANCER CELL, V5, P389, DOI 10.1016/S1535-6108(04)00082-0; Hayashi N, 2006, NEUROSCI LETT, V397, P5, DOI 10.1016/j.neulet.2005.11.057; Hofmann TG, 2003, CELL DEATH DIFFER, V10, P1290, DOI 10.1038/sj.cdd.4401313; Hofmann TG, 2002, NAT CELL BIOL, V4, P1, DOI 10.1038/ncb715; Imai Y, 1999, NATURE, V398, P777, DOI 10.1038/19709; Ishov AM, 1999, J CELL BIOL, V147, P221, DOI 10.1083/jcb.147.2.221; Ito K, 2008, NATURE, V453, P1072, DOI 10.1038/nature07016; Jensen K, 2001, ONCOGENE, V20, P7223, DOI 10.1038/sj.onc.1204765; KAKIZUKA A, 1991, CELL, V66, P663, DOI 10.1016/0092-8674(91)90112-C; Kischkel FC, 2000, IMMUNITY, V12, P611, DOI 10.1016/S1074-7613(00)80212-5; Komura N, 2007, EXP CELL RES, V313, P2753, DOI 10.1016/j.yexcr.2007.03.032; Krieghoff E, 2007, CELL CYCLE, V6, P771, DOI 10.4161/cc.6.7.4046; Kurki S, 2003, J CELL SCI, V116, P3917, DOI 10.1242/jcs.00714; Lackinger D, 2000, MUTAT RES-FUND MOL M, V457, P113, DOI 10.1016/S0027-5107(00)00133-0; Lallemand-Breitenbach V, 2008, NAT CELL BIOL, V10, P547, DOI 10.1038/ncb1717; Lassus P, 2002, SCIENCE, V297, P1352, DOI 10.1126/science.1074721; Le XF, 1998, ONCOGENE, V16, P1839, DOI 10.1038/sj.onc.1201705; Lehembre F, 2001, ONCOGENE, V20, P1, DOI 10.1038/sj.onc.1204063; Li H, 2000, MOL CELL BIOL, V20, P1784, DOI 10.1128/MCB.20.5.1784-1796.2000; Li MY, 2002, NATURE, V416, P648, DOI 10.1038/nature737; Lin HK, 2004, NATURE, V431, P205, DOI 10.1038/nature02783; LIU JH, 1995, J EXP MED, V181, P1965, DOI 10.1084/jem.181.6.1965; Louria-Hayon I, 2003, J BIOL CHEM, V278, P33134, DOI 10.1074/jbc.M301264200; McNally BA, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002277; Meinecke I, 2007, P NATL ACAD SCI USA, V104, P5073, DOI 10.1073/pnas.0608773104; Melnick A, 1999, BLOOD, V93, P3167, DOI 10.1182/blood.V93.10.3167.410k44_3167_3215; Michaelson JS, 2003, J CELL SCI, V116, P345, DOI 10.1242/jcs.00234; Michaelson JS, 1999, GENE DEV, V13, P1918, DOI 10.1101/gad.13.15.1918; Milovic-Holm K, 2007, EMBO J, V26, P391, DOI 10.1038/sj.emboj.7601504; Moller A, 2003, CANCER RES, V63, P4310; Morgan M, 2002, J CELL BIOL, V157, P975, DOI 10.1083/jcb.200204039; Mu ZM, 1997, CARCINOGENESIS, V18, P2063, DOI 10.1093/carcin/18.11.2063; Mukhopadhyay D, 2006, J CELL BIOL, V174, P939, DOI 10.1083/jcb.200510103; Nadanaka S, 2007, MOL CELL BIOL, V27, P1027, DOI 10.1128/MCB.00408-06; Nguyen LA, 2005, BLOOD, V105, P292, DOI 10.1182/blood-2004-03-1185; PANDOLFI PP, 1991, ONCOGENE, V6, P1285; Paroni G, 2002, J BIOL CHEM, V277, P15147, DOI 10.1074/jbc.M112338200; Pearson M, 2000, NATURE, V406, P207, DOI 10.1038/35018127; Petrie K, 2008, NAT CELL BIOL, V10, P507, DOI 10.1038/ncb0508-507; Piazza F, 2001, ONCOGENE, V20, P7216, DOI 10.1038/sj.onc.1204855; Quignon F, 1998, NAT GENET, V20, P259, DOI 10.1038/3068; Reineke EL, 2008, MOL CELL BIOL, V28, P997, DOI 10.1128/MCB.01848-07; Salomoni P, 2005, BLOOD, V105, P3686, DOI 10.1182/blood-2004-09-3782; Sanchez-Pulido L, 2007, TRENDS BIOCHEM SCI, V32, P400, DOI 10.1016/j.tibs.2007.08.001; Scaglioni PP, 2006, CELL, V126, P269, DOI 10.1016/j.cell.2006.05.041; Seeler JS, 2003, NAT REV MOL CELL BIO, V4, P690, DOI 10.1038/nrm1200; Seker H, 2003, ONCOGENE, V22, P1620, DOI 10.1038/sj.onc.1206140; Shen TH, 2006, MOL CELL, V24, P331, DOI 10.1016/j.molcel.2006.09.013; Smith ML, 1997, P NATL ACAD SCI USA, V94, P12255, DOI 10.1073/pnas.94.23.12255; Stadler M, 1995, ONCOGENE, V11, P2565; Tagata Y, 2008, LEUKEMIA, V22, P273, DOI 10.1038/sj.leu.2405024; Takahashi Y, 2004, ONCOGENE, V23, P2819, DOI 10.1038/sj.onc.1207533; Tan JAT, 2008, J BIOL CHEM, V283, P18124, DOI 10.1074/jbc.M800512200; Tang J, 2005, CANCER BIOL THER, V4, P645, DOI 10.4161/cbt.4.6.1729; Tatham MH, 2008, NAT CELL BIOL, V10, P538, DOI 10.1038/ncb1716; Torii S, 1999, EMBO J, V18, P6037, DOI 10.1093/emboj/18.21.6037; Tournier C, 2000, SCIENCE, V288, P870, DOI 10.1126/science.288.5467.870; Trotman LC, 2006, NATURE, V441, P523, DOI 10.1038/nature04809; Waldman T, 1996, NATURE, V381, P713, DOI 10.1038/381713a0; Wang ZG, 1998, NAT GENET, V20, P266, DOI 10.1038/3073; Wei XL, 2003, J BIOL CHEM, V278, P29288, DOI 10.1074/jbc.M212215200; Wu WS, 2003, J BIOL CHEM, V278, P12294, DOI 10.1074/jbc.M211849200; Yang ST, 2006, J BIOL CHEM, V281, P26645, DOI 10.1074/jbc.M604391200; Yang ST, 2002, NAT CELL BIOL, V4, P865, DOI 10.1038/ncb869; Yang XL, 1997, CELL, V89, P1067, DOI 10.1016/S0092-8674(00)80294-9; Zhong S, 2000, NAT CELL BIOL, V2, pE85, DOI 10.1038/35010583; Zhong S, 2000, J EXP MED, V191, P631, DOI 10.1084/jem.191.4.631; Zhong S, 2000, BLOOD, V95, P2748, DOI 10.1182/blood.V95.9.2748.009k31a_2748_2752; Zhu HY, 2003, J BIOL CHEM, V278, P49286, DOI 10.1074/jbc.M308302200	104	109	119	2	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT	2008	27	48					6299	6312		10.1038/onc.2008.305	http://dx.doi.org/10.1038/onc.2008.305			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	361YB	18931695				2022-12-28	WOS:000260162800010
J	Roue, G; Pichereau, V; Lincet, H; Colomer, D; Sola, B				Roue, G.; Pichereau, V.; Lincet, H.; Colomer, D.; Sola, B.			Cyclin D1 mediates resistance to apoptosis through upregulation of molecular chaperones and consequent redistribution of cell death regulators	ONCOGENE			English	Article						cyclin D1; heat shock protein; apoptotic factor; B-cell lymphoma; multiple myeloma	HEAT-SHOCK PROTEINS; BREAST-CANCER CELLS; NF-KAPPA-B; ECTOPIC EXPRESSION; D1 OVEREXPRESSION; MULTIPLE-MYELOMA; LINE; CARCINOMA; HSP70; P53	Cyclin D1 is a key regulator of cell proliferation. It also controls other aspects of the cell fate, such as cellular senescence, apoptosis and tumourigenesis. We used B-lymphoid cell lines producing cyclin D1 to investigate the role of this protein in B-cell lymphomas and leukaemias. Constitutive low levels of cyclin D1 had no effect per se on cell proliferation, but conferred resistance to various apoptotic stimuli in B cells. Activation of the proapoptotic protein, Bax, was reduced and mitochondrial permeabilization and phosphatidylserine exposure following cytokine withdrawal were delayed in cyclin D1-producing cells. Proteomic analysis showed that the presence of cyclin D1 led to intracellular accumulation of various molecular chaperones. The chaperone, heat shock protein ( Hsp) 70, bound to both Bax and the mitochondrial apoptosis inducing factor following cytokine withdrawal, and impeded inhibitors of kappa B (I kappa B)mediated inhibition of nuclear factor-kappa B anti-apoptotic signalling. Impairment of Hsp70 activity-using a pharmacological Hsp inhibitor or transfecting cells with an Hsp70-blocking antibody-restored the cellular response to mitochondrial apoptosis triggering. Thus, constitutive de-novo cyclin D1 production in B cells delays commitment to apoptosis by inducing Hsp70 chaperoning activity on pre- and post-mitochondrial pro-apoptotic factors.	[Roue, G.; Colomer, D.] Inst Invest Biomed August Pi & Sunyer, Hosp Clin, Unitat Hematopathol, Barcelona 08036, Spain; [Roue, G.; Sola, B.] Univ Caen, IFR 146, EA 3919, F-14032 Caen, France; [Pichereau, V.] Univ Caen, IFR 146, EA 956, USC INRA 2017,Lab Microbiol Environm, F-14032 Caen, France; [Lincet, H.] Ctr Lutte Canc Francois Baclesse, IFR 146, EA1773, GRECAN, Caen, France	University of Barcelona; Hospital Clinic de Barcelona; IDIBAPS; Universite de Caen Normandie; INRAE; Universite de Caen Normandie; UNICANCER; Centre Francois Baclesse	Roue, G (corresponding author), Inst Invest Biomed August Pi & Sunyer, Hosp Clin, Unitat Hematopathol, Villarroel 170, Barcelona 08036, Spain.	groue@clinic.ub.es	PICHEREAU, Vianney/B-2168-2008; ROUÉ, GAËL/D-4759-2014; PICHEREAU, Vianney/Q-7236-2019; COLOMER, DOLORS/ABG-6894-2020	PICHEREAU, Vianney/0000-0003-1078-9407; ROUÉ, GAËL/0000-0003-0245-2257; PICHEREAU, Vianney/0000-0003-1078-9407; COLOMER, DOLORS/0000-0001-7486-8484; Sola, Brigitte/0000-0001-7278-9651	Cancer-Comite du Calvados; Association pour la Recherche contre le Cancer [7791, 3426]; Spanish Ministry of Education and Science [SAF06/8850]; Ligue Nationale contre le Cancer-Comite du Calvados; C-RED programme	Cancer-Comite du Calvados; Association pour la Recherche contre le Cancer(Fondation ARC pour la Recherche sur le Cancer); Spanish Ministry of Education and Science(Spanish Government); Ligue Nationale contre le Cancer-Comite du Calvados; C-RED programme	We thank A Barbaras and S Cabezas for expert technical assistance and JM Renoir (CNRS UMR 8612, Universite de Paris Sud, France) for the gift of anti-Hsp70/90 antibody. The work was financially supported by the Ligue contre le Cancer-Comite du Calvados, Cent pour sang la vie and the Association pour la Recherche contre le Cancer ( grant nos. 7791 and 3426) to BS, and by the Spanish Ministry of Education and Science (grant SAF06/8850) to DC. GR received a scholarship from the Ligue Nationale contre le Cancer-Comite du Calvados and has a postdoctoral position with the C-RED programme (Generalitat de Catalunya, Spain).	Adams JM, 2007, ONCOGENE, V26, P1324, DOI 10.1038/sj.onc.1210220; Agami R, 2000, CELL, V102, P55, DOI 10.1016/S0092-8674(00)00010-6; Alao JP, 2007, MOL CANCER, V6, DOI 10.1186/1476-4598-6-24; Andoh T, 2002, J BIOL CHEM, V277, P9655, DOI 10.1074/jbc.M110701200; Beere H M, 2001, Sci STKE, V2001, pre1, DOI 10.1126/stke.2001.93.re1; Bertoni F, 2004, CURR OPIN HEMATOL, V11, P411, DOI 10.1097/01.moh.0000138682.13354.da; Bible KC, 2000, CLIN CANCER RES, V6, P661; Burstein E, 2003, CURR OPIN CELL BIOL, V15, P732, DOI 10.1016/j.ceb.2003.10.005; Calderwood SK, 2006, TRENDS BIOCHEM SCI, V31, P164, DOI 10.1016/j.tibs.2006.01.006; CANMAN CE, 1995, GENE DEV, V9, P600, DOI 10.1101/gad.9.5.600; Casanovas O, 2000, J BIOL CHEM, V275, P35091, DOI 10.1074/jbc.M006324200; Ciocca DR, 2005, CELL STRESS CHAPERON, V10, P86, DOI 10.1379/CSC-99r.1; Danial NN, 2003, NATURE, V424, P952, DOI 10.1038/nature01825; Diehl JA, 2002, CANCER BIOL THER, V1, P226, DOI 10.4161/cbt.72; Duquesne F, 2001, CELL DEATH DIFFER, V8, P51, DOI 10.1038/sj.cdd.4400768; Ewen ME, 2004, TRENDS MOL MED, V10, P158, DOI 10.1016/j.molmed.2004.02.005; Fu MF, 2004, ENDOCRINOLOGY, V145, P5439, DOI 10.1210/en.2004-0959; Garrido C, 2001, BIOCHEM BIOPH RES CO, V286, P433, DOI 10.1006/bbrc.2001.5427; Garrido C, 2006, CELL CYCLE, V5, P2592, DOI 10.4161/cc.5.22.3448; Ghosh S, 2002, CELL, V109, pS81, DOI 10.1016/S0092-8674(02)00703-1; Gotoh T, 2004, CELL DEATH DIFFER, V11, P390, DOI 10.1038/sj.cdd.4401369; Han EKH, 1996, CELL GROWTH DIFFER, V7, P699; Hengartner MO, 2000, NATURE, V407, P770, DOI 10.1038/35037710; Hochhauser D, 1996, J NATL CANCER I, V88, P1269, DOI 10.1093/jnci/88.18.1269; Kamano H, 1997, ONCOGENE, V14, P1223, DOI 10.1038/sj.onc.1200945; Kehn K, 2007, ONCOGENE, V26, P5060, DOI 10.1038/sj.onc.1210319; Kornmann M, 1999, CANCER RES, V59, P3505; Krieger S, 2005, EXP HEMATOL, V33, P652, DOI 10.1016/j.exphem.2005.03.011; Kuhn DJ, 2003, J CELL BIOCHEM, V89, P824, DOI 10.1002/jcb.10557; Lamb J, 2003, CELL, V114, P323, DOI 10.1016/S0092-8674(03)00570-1; Lamb J, 2003, CELL CYCLE, V2, P525, DOI 10.4161/cc.2.6.584; Le Moguen K, 2006, PROTEOMICS, V6, P5183, DOI 10.1002/pmic.200500925; Lee KH, 2005, EXP CELL RES, V307, P276, DOI 10.1016/j.yexcr.2005.03.014; Liu M, 2006, J BIOL CHEM, V281, P18090, DOI 10.1074/jbc.M601324200; Macario AJL, 2007, FEBS LETT, V581, P3681, DOI 10.1016/j.febslet.2007.04.030; Martin JMC, 1999, CANCER RES, V59, P1134; Mesaeli N, 2004, MOL BIOL CELL, V15, P1862, DOI 10.1091/mbc.E03-04-0251; Niu MY, 2001, ONCOGENE, V20, P3506, DOI 10.1038/sj.onc.1204453; Orr MS, 1998, J BIOL CHEM, V273, P3803, DOI 10.1074/jbc.273.7.3803; Ortega S, 2002, BBA-REV CANCER, V1602, P73, DOI 10.1016/S0304-419X(02)00037-9; Palacios C, 2000, ONCOGENE, V19, P3556, DOI 10.1038/sj.onc.1203683; PALACIOS R, 1985, CELL, V41, P727, DOI 10.1016/S0092-8674(85)80053-2; Perez-Galan P, 2006, BLOOD, V107, P257, DOI 10.1182/blood-2005-05-2091; Ruchalski K, 2006, J BIOL CHEM, V281, P7873, DOI 10.1074/jbc.M513728200; Saleh A, 2000, NAT CELL BIOL, V2, P476, DOI 10.1038/35019510; Sauvageot N, 2002, EUR J BIOCHEM, V269, P5731, DOI 10.1046/j.1432-1033.2002.03288.x; Seidl S, 2003, LANCET ONCOL, V4, P557, DOI 10.1016/S1470-2045(03)01195-1; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Silva A, 1997, BLOOD, V89, P2717, DOI 10.1182/blood.V89.8.2717; Steel R, 2004, J BIOL CHEM, V279, P51490, DOI 10.1074/jbc.M401314200; Stuart JK, 1998, J BIOL CHEM, V273, P22506, DOI 10.1074/jbc.273.35.22506; Takayama S, 1997, EMBO J, V16, P4887, DOI 10.1093/emboj/16.16.4887; Wang Chenguang, 2004, Cancer Treat Res, V119, P217; Yokota S, 2000, CANCER RES, V60, P2942; Zahnow CA, 2002, BREAST CANCER RES, V4, P109, DOI 10.1186/bcr428	55	43	45	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 21	2008	27	36					4909	4920		10.1038/onc.2008.126	http://dx.doi.org/10.1038/onc.2008.126			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	339SF	18438428				2022-12-28	WOS:000258596900005
J	Rahman-Roblick, R; Hellman, U; Becker, S; Bader, FG; Auer, G; Wiman, KG; Roblick, UJ				Rahman-Roblick, R.; Hellman, U.; Becker, S.; Bader, F. G.; Auer, G.; Wiman, K. G.; Roblick, U. J.			Proteomic identification of p53-dependent protein phosphorylation	ONCOGENE			English	Article						p53; proteomics; phosphorylation	CELL-DEATH; P53; DJ-1; ACTIVATION; APOPTOSIS; GENE; METASTASIS; REGULATOR; NM23	The p53 tumor suppressor regulates transcription of target genes. We have previously analysed the p53-dependent proteome and identified novel protein targets. Here we have examined p53-dependent phosphorylation using two-dimensional gel electrophoresis and staining with the fluorescent phosphoprotein dye Pro-Q Diamond. We report that p53 induces phosphorylation of a subset of proteins including Nm23, DJ-1, ANXA1 and PrxII. Our identification of p53-dependent phosphorylation of specific target proteins reveals new aspects of the p53-dependent cellular response and suggests that such posttranslational modi. cations may contribute to p53-mediated tumor suppression.	[Wiman, K. G.] Karolinska Inst, Karolinska Univ Hosp R8 04, Canc Ctr Karolinska, Dept Oncol Pathol, SE-17176 Stockholm, Sweden; [Hellman, U.] Uppsala Univ, Ludwig Inst Canc Res, Uppsala, Sweden; [Becker, S.; Bader, F. G.; Auer, G.] Karolinska Inst, Karolinska Biom Ctr, Dept Oncol Pathol, SE-17176 Stockholm, Sweden; [Bader, F. G.; Roblick, U. J.] Univ Schleswig Holstein, Dept Surg, D-23538 Lubeck, Germany	Karolinska Institutet; Karolinska University Hospital; Ludwig Institute for Cancer Research; Uppsala University; Karolinska Institutet; University of Kiel; Schleswig Holstein University Hospital	Wiman, KG (corresponding author), Karolinska Inst, Karolinska Univ Hosp R8 04, Canc Ctr Karolinska, Dept Oncol Pathol, SE-17176 Stockholm, Sweden.	klas.wiman@ki.se	Wiman, Klas/AAB-8399-2021; Roblick, Uwe J/F-5906-2011	Wiman, Klas/0000-0002-7113-524X; Auer, Gert/0000-0003-3911-0285				Arur S, 2003, DEV CELL, V4, P587, DOI 10.1016/S1534-5807(03)00090-X; Bonifati V, 2003, SCIENCE, V299, P256, DOI 10.1126/science.1077209; Bretaud S, 2007, J NEUROCHEM, V100, P1626, DOI 10.1111/j.1471-4159.2006.04291.x; Chen SL, 2003, MOL CARCINOGEN, V36, P204, DOI 10.1002/mc.10110; Kim RH, 2005, CANCER CELL, V7, P263, DOI 10.1016/j.ccr.2005.02.010; Lavin MF, 2006, CELL DEATH DIFFER, V13, P941, DOI 10.1038/sj.cdd.4401925; Liu J, 2004, MOL CELL BIOL, V24, P10844, DOI 10.1128/MCB.24.24.10844-10856.2004; MACDONALD NJ, 1993, J BIOL CHEM, V268, P25780; Mihara M, 2003, MOL CELL, V11, P577, DOI 10.1016/S1097-2765(03)00050-9; Nagakubo D, 1997, BIOCHEM BIOPH RES CO, V231, P509, DOI 10.1006/bbrc.1997.6132; Rahman R, 2005, ONCOGENE, V24, P1320, DOI 10.1038/sj.onc.1208232; Rahman-Roblick R, 2007, P NATL ACAD SCI USA, V104, P5401, DOI 10.1073/pnas.0700794104; Ryan KM, 2001, CURR OPIN CELL BIOL, V13, P332, DOI 10.1016/S0955-0674(00)00216-7; Solito E, 2006, FASEB J, V20, P1498, DOI 10.1096/fj.05-5319fje; Solito E, 2001, BRIT J PHARMACOL, V133, P217, DOI 10.1038/sj.bjp.0704054; Taira T, 2004, EMBO REP, V5, P213, DOI 10.1038/sj.embor.7400074; Vousden KH, 2002, NAT REV CANCER, V2, P594, DOI 10.1038/nrc864; WANG LM, 1993, CANCER RES, V53, P717	18	27	30	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 14	2008	27	35					4854	4859		10.1038/onc.2008.124	http://dx.doi.org/10.1038/onc.2008.124			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	337OJ	18438429				2022-12-28	WOS:000258445100010
J	Frohlich, DA; McCabe, MT; Arnold, RS; Day, ML				Frohlich, D. A.; McCabe, M. T.; Arnold, R. S.; Day, M. L.			The role of Nrf2 in increased reactive oxygen species and DNA damage in prostate tumorigenesis	ONCOGENE			English	Article						tumorigenesis; Nrf2; oxidative stress; prostate cancer; DNA damage	GLUTATHIONE-S-TRANSFERASE; GENE-EXPRESSION; INTRAEPITHELIAL NEOPLASIA; OXIDATIVE STRESS; RESPONSE ELEMENT; ENZYME INDUCERS; CANCER; CARCINOGENESIS; MICE; REVEALS	The impact of oxidative stress in human cancer has been extensively studied. It is accepted that elevated reactive oxygen species (ROS) promote mutagenic DNA damage. Even with an extensive armament of cellular antioxidants and detoxification enzymes, alterations to DNA occur that initiate cellular transformation. Erythroid 2p45 (NFE2)-related factor 2 (Nrf2) is a basic-region leucine zipper transcription factor that mediates the expression of key protective enzymes through the antioxidant-response element (ARE). By analysing 10 human prostate cancer microarray data sets, we have determined that Nrf2 and members of the glutathione-S-transferase (GST) mu family are extensively decreased in human prostate cancer. Using the TRAMP transgene and Rb and Nrf2 knockout murine models, we demonstrated that the loss of Nrf2 initiates a detrimental cascade of reduced GST expression, elevated ROS levels and ultimately DNA damage associated with tumorigenesis. Based on overwhelming data from clinical samples and the current functional analysis, we propose that the disruption of the Nrf2-antioxidant axis leads to increased oxidative stress and DNA damage in the initiation of cellular transformation in the prostate gland.	[Frohlich, D. A.; Day, M. L.] Univ Michigan, UMCC, Dept Urol, Ann Arbor, MI 48109 USA; [McCabe, M. T.] Emory Univ, Sch Med, Dept Radiat Oncol, Atlanta, GA USA; [Arnold, R. S.] Emory Univ, Sch Med, Dept Pathol & Lab Med, Atlanta, GA 30322 USA	University of Michigan System; University of Michigan; Emory University; Emory University	Day, ML (corresponding author), Univ Michigan, UMCC, Dept Urol, 6219 CCGC,1500 E Med Ctr Dr, Ann Arbor, MI 48109 USA.	mday@umich.edu			NCI NIH HHS [5T32 CA009674] Funding Source: Medline; NIDDK NIH HHS [DK061488, 5T32 DK07758-05] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007758, R01DK061488] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Arnold RS, 2001, P NATL ACAD SCI USA, V98, P5550, DOI 10.1073/pnas.101505898; Baker AM, 1997, PROSTATE, V32, P229, DOI 10.1002/(SICI)1097-0045(19970901)32:4<229::AID-PROS1>3.0.CO;2-E; Bostwick DG, 2007, HUM PATHOL, V38, P1394, DOI 10.1016/j.humpath.2007.02.008; Bostwick DG, 2000, CANCER, V89, P123, DOI 10.1002/1097-0142(20000701)89:1<123::AID-CNCR17>3.0.CO;2-9; Brooks JD, 2001, CANCER EPIDEM BIOMAR, V10, P949; Chan KM, 1996, P NATL ACAD SCI USA, V93, P13943, DOI 10.1073/pnas.93.24.13943; Chanas SA, 2002, BIOCHEM J, V365, P405, DOI 10.1042/BJ20020320; Day KC, 2002, J BIOL CHEM, V277, P44475, DOI 10.1074/jbc.M205361200; De Marzo AM, 2007, NAT REV CANCER, V7, P256, DOI 10.1038/nrc2090; Dhakshinamoorthy S, 2000, CURR TOP CELL REGUL, V36, P201; Dhanasekaran SM, 2001, NATURE, V412, P822, DOI 10.1038/35090585; Glinsky GV, 2004, J CLIN INVEST, V113, P913, DOI 10.1172/JCI200420032; GREENBERG NM, 1995, P NATL ACAD SCI USA, V92, P3439, DOI 10.1073/pnas.92.8.3439; GUYTON KZ, 1993, BRIT MED BULL, V49, P523, DOI 10.1093/oxfordjournals.bmb.a072628; Hayes JD, 2005, ANNU REV PHARMACOL, V45, P51, DOI 10.1146/annurev.pharmtox.45.120403.095857; Hayes JD, 1995, CRIT REV BIOCHEM MOL, V30, P445, DOI 10.3109/10409239509083491; Ho SM, 2006, ANN NY ACAD SCI, V1089, P177, DOI 10.1196/annals.1386.005; Iida K, 2004, CANCER RES, V64, P6424, DOI 10.1158/0008-5472.CAN-04-1906; Itoh K, 1999, GENE DEV, V13, P76, DOI 10.1101/gad.13.1.76; Itoh K, 1997, BIOCHEM BIOPH RES CO, V236, P313, DOI 10.1006/bbrc.1997.6943; Jaiswal AK, 2000, FREE RADICAL BIO MED, V29, P254, DOI 10.1016/S0891-5849(00)00306-3; Klaunig JE, 2004, ANNU REV PHARMACOL, V44, P239, DOI 10.1146/annurev.pharmtox.44.101802.121851; Kwak MK, 2004, MUTAT RES-FUND MOL M, V555, P133, DOI 10.1016/j.mrfmmm.2004.06.041; Kwak MK, 2003, J BIOL CHEM, V278, P8135, DOI 10.1074/jbc.M211898200; Lapointe J, 2004, P NATL ACAD SCI USA, V101, P811, DOI 10.1073/pnas.0304146101; LaTulippe E, 2002, CANCER RES, V62, P4499; Lee JM, 2003, J BIOL CHEM, V278, P12029, DOI 10.1074/jbc.M211558200; Lee JM, 2003, BBA-GENE STRUCT EXPR, V1629, P92, DOI 10.1016/j.bbaexp.2003.08.006; Luo J, 2001, CANCER RES, V61, P4683; Ma Q, 2006, AM J PATHOL, V168, P1960, DOI 10.2353/ajpath.2006.051113; Magee JA, 2001, CANCER RES, V61, P5692; McCabe MT, 2005, NEOPLASIA, V7, P141, DOI 10.1593/neo.04394; McCabe MT, 2005, CANCER RES, V65, P3624, DOI 10.1158/0008-5472.CAN-04-2158; McCabe MT, 2006, CANCER RES, V66, P385, DOI 10.1158/0008-5472.CAN-05-2020; Myhre O, 2003, BIOCHEM PHARMACOL, V65, P1575, DOI 10.1016/S0006-2952(03)00083-2; Osburn WO, 2007, INT J CANCER, V121, P1883, DOI 10.1002/ijc.22943; Ouyang X, 2005, CANCER RES, V65, P6773, DOI 10.1158/0008-5472.CAN-05-1948; Ramos-Gomez M, 2001, P NATL ACAD SCI USA, V98, P3410, DOI 10.1073/pnas.051618798; Rangasamy T, 2005, J EXP MED, V202, P47, DOI 10.1084/jem.20050538; Rhodes DR, 2004, NEOPLASIA, V6, P1, DOI 10.1016/S1476-5586(04)80047-2; Tam NNC, 2006, PROSTATE, V66, P57, DOI 10.1002/pros.20313; Thimmulappa RK, 2006, BIOCHEM BIOPH RES CO, V351, P883, DOI 10.1016/j.bbrc.2006.10.102; Vanaja DK, 2006, CLIN CANCER RES, V12, P1128, DOI 10.1158/1078-0432.CCR-05-2072; Varambally S, 2005, CANCER CELL, V8, P393, DOI 10.1016/j.ccr.2005.10.001; Venugopal R, 1996, P NATL ACAD SCI USA, V93, P14960, DOI 10.1073/pnas.93.25.14960; Wang YH, 2000, CANCER RES, V60, P6008; Welsh JB, 2001, CANCER RES, V61, P5974; Yates MS, 2006, CANCER RES, V66, P2488, DOI 10.1158/0008-5472.CAN-05-3823; Yu X, 2005, MUTAT RES-FUND MOL M, V591, P93, DOI 10.1016/j.mrfmmm.2005.04.017; Yu YP, 2004, J CLIN ONCOL, V22, P2790, DOI 10.1200/JCO.2004.05.158; Zhu M, 2001, BIOCHEM BIOPH RES CO, V289, P212, DOI 10.1006/bbrc.2001.5944	51	142	151	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 17	2008	27	31					4353	4362		10.1038/onc.2008.79	http://dx.doi.org/10.1038/onc.2008.79			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	326WY	18372916	Bronze			2022-12-28	WOS:000257691100010
J	Sayan, AE; Sayan, BS; Gogvadze, V; Dinsdale, D; Nyman, U; Hansen, TM; Zhivotovsky, B; Cohen, GM; Knight, RA; Melino, G				Sayan, A. E.; Sayan, B. S.; Gogvadze, V.; Dinsdale, D.; Nyman, U.; Hansen, T. M.; Zhivotovsky, B.; Cohen, G. M.; Knight, R. A.; Melino, G.			p73 and caspase-cleaved p73 fragments localize to mitochondria and augment TRAIL-induced apoptosis	ONCOGENE			English	Article						p73; mitochondria; p53; transcription independent; apoptosis; TRAIL	C-ABL; PROTEIN STABILITY; TUMOR-SUPPRESSOR; REGULATES P73; P53; TRANSACTIVATION; ACTIVATION; DEGRADATION; CARCINOMA; ABSENCE	The p73 protein, a member of the p53 family, has both developmental and tumorigenic functions. Here we show that p73 is cleaved by caspase-3 and -8 both in vitro and in vivo during apoptosis elicited by DNA-damaging drugs and tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) receptor ligation. TAp73 and some of its cleavage products are localized to mitochondria. siRNA-mediated downregulation of p73 expression induced a small but significant change in the susceptibility of HCT116 cells to TRAIL-induced apoptosis. A transcription-deficient mutant of TAp73 enhanced TRAIL-induced apoptosis suggesting that p73 protein has transcriptionin-dependent functions during death receptor-mediated apoptosis. Additionally, recombinant p73 protein induced cytochrome c release from isolated mitochondria providing evidence that nonnuclear p73 may have additional functions in the progression of apoptosis.	[Sayan, A. E.; Sayan, B. S.; Dinsdale, D.; Hansen, T. M.; Cohen, G. M.; Knight, R. A.; Melino, G.] Univ Leicester, MRC, Toxicol Unit, Leicester LE1 9HN, Leics, England; [Gogvadze, V.; Nyman, U.; Zhivotovsky, B.] Karolinska Inst, Inst Environm Med, Div Toxicol, S-10401 Stockholm, Sweden	University of Leicester; Karolinska Institutet	Melino, G (corresponding author), Univ Leicester, MRC, Toxicol Unit, Hodgkin Bldg,Lancaster Rd,POB 138, Leicester LE1 9HN, Leics, England.	gm89@leicester.ac.uk	Gogvadze, Vladimir/A-4392-2014; Zhivotovsky, Boris/A-4346-2014; Nyman, Ulrika/D-3708-2013; SAYAN, A. EMRE/H-7330-2012	Zhivotovsky, Boris/0000-0002-2238-3482; SAYAN, A. EMRE/0000-0002-5291-1485	MRC [MC_U132670600] Funding Source: UKRI; Medical Research Council [MC_U132670600] Funding Source: Medline	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Agami R, 1999, NATURE, V399, P809; Aqeilan RI, 2004, P NATL ACAD SCI USA, V101, P4401, DOI 10.1073/pnas.0400805101; Asher G, 2005, GENE DEV, V19, P316, DOI 10.1101/gad.319905; Bernassola F, 2004, J EXP MED, V199, P1545, DOI 10.1084/jem.20031943; Chipuk JE, 2006, CELL DEATH DIFFER, V13, P994, DOI 10.1038/sj.cdd.4401908; Chipuk JE, 2005, SCIENCE, V309, P1732, DOI 10.1126/science.1114297; Chipuk JE, 2003, CANCER CELL, V4, P371, DOI 10.1016/S1535-6108(03)00272-1; Costanzo A, 2002, MOL CELL, V9, P175, DOI 10.1016/S1097-2765(02)00431-8; De Laurenzi V, 1998, J EXP MED, V188, P1763, DOI 10.1084/jem.188.9.1763; Essmann F, 2005, J BIOL CHEM, V280, P37169, DOI 10.1074/jbc.M502052200; Gong JG, 1999, NATURE, V399, P806; Grob TJ, 2001, CELL DEATH DIFFER, V8, P1213, DOI 10.1038/sj.cdd.4400962; Lamkanfi M, 2007, CELL DEATH DIFFER, V14, P44, DOI 10.1038/sj.cdd.4402047; Leu JIJ, 2004, NAT CELL BIOL, V6, P443, DOI 10.1038/ncb1123; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Luthi AU, 2007, CELL DEATH DIFFER, V14, P641, DOI 10.1038/sj.cdd.4402103; MacLachan TK, 2002, P NATL ACAD SCI USA, V99, P9492, DOI 10.1073/pnas.132241599; Mahyar-Roemer M, 2004, ONCOGENE, V23, P6226, DOI 10.1038/sj.onc.1207637; Mantovani F, 2004, MOL CELL, V14, P625, DOI 10.1016/j.molcel.2004.05.007; Marchenko ND, 2000, J BIOL CHEM, V275, P16202, DOI 10.1074/jbc.275.21.16202; Melino G, 2002, NAT REV CANCER, V2, P605, DOI 10.1038/nrc861; Melino G, 2004, J BIOL CHEM, V279, P8076, DOI 10.1074/jbc.M307469200; Melino G, 2003, TRENDS BIOCHEM SCI, V28, P663, DOI 10.1016/j.tibs.2003.10.004; Mihara M, 2003, MOL CELL, V11, P577, DOI 10.1016/S1097-2765(03)00050-9; Muller M, 2005, CELL DEATH DIFFER, V12, P1564, DOI 10.1038/sj.cdd.4401774; Munarriz E, 2005, BIOCHEM BIOPH RES CO, V333, P954, DOI 10.1016/j.bbrc.2005.05.188; Oberst A, 2005, BIOCHEM BIOPH RES CO, V331, P707, DOI 10.1016/j.bbrc.2005.03.158; Ozoren N, 2002, NEOPLASIA, V4, P551, DOI 10.1038/sj.neo.7900270; Rossi M, 2005, EMBO J, V24, P836, DOI 10.1038/sj.emboj.7600444; Sayan AE, 2001, ONCOGENE, V20, P5111, DOI 10.1038/sj.onc.1204669; Sayan AE, 2005, BIOCHEM BIOPH RES CO, V330, P186, DOI 10.1016/j.bbrc.2005.02.145; Sayan BS, 2007, P NATL ACAD SCI USA, V104, P10871, DOI 10.1073/pnas.0700761104; Sayan BS, 2006, J BIOL CHEM, V281, P13566, DOI 10.1074/jbc.M512467200; Schembri L, 2007, NAT METHODS, V4, P107, DOI 10.1038/nmeth0207-107; Sigal A, 2000, CANCER RES, V60, P6788; Stiewe T, 2002, CANCER RES, V62, P3598; Stiewe T, 2000, NAT GENET, V26, P464, DOI 10.1038/82617; Sun XM, 1999, J BIOL CHEM, V274, P5053, DOI 10.1074/jbc.274.8.5053; Takimoto R, 2000, ONCOGENE, V19, P1735, DOI 10.1038/sj.onc.1203489; Toledo F, 2006, NAT REV CANCER, V6, P909, DOI 10.1038/nrc2012; Tomita Y, 2006, J BIOL CHEM, V281, P8600, DOI 10.1074/jbc.M507611200; Yang A, 2000, NATURE, V404, P99, DOI 10.1038/35003607; Zaika AI, 1999, CANCER RES, V59, P3257	43	48	50	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 17	2008	27	31					4363	4372		10.1038/onc.2008.64	http://dx.doi.org/10.1038/onc.2008.64			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	326WY	18362891				2022-12-28	WOS:000257691100011
J	Lee, SJ; Yang, JW; Cho, IJ; Kim, WD; Cho, MK; Lee, CH; Kim, SG				Lee, S. J.; Yang, J. W.; Cho, I. J.; Kim, W. D.; Cho, M. K.; Lee, C. H.; Kim, S. G.			The gep oncogenes, G alpha(12) and G alpha(13), upregulate the transforming growth factor-beta 1 gene	ONCOGENE			English	Article						G alpha(12) members; transforming growth factor-beta 1; hepatic stellate cell; activating protein 1	HEPATIC STELLATE CELLS; KAPPA-B-ALPHA; LIVER FIBROSIS; G-PROTEINS; HEPATOCELLULAR-CARCINOMA; TRANSCRIPTION FACTOR; SIGNALING PATHWAYS; PROMOTER REGION; CIRRHOTIC LIVER; CANCER CELLS	Transforming growth factor-beta 1 (TGF beta 1) plays a role in neoplastic transformation and transdifferentiation. G alpha(12) and G alpha(13), referred to as the gep oncogenes, stimulate mitogenic pathways. Nonetheless, no information is available regarding their roles in the regulation of the TGF beta 1 gene and the molecules linking them to gene transcription. Knockdown or knockout experiments using murine embryonic fibroblasts and hepatic stellate cells indicated that a G alpha(12) and G alpha(13) deficiency reduced constitutive, auto-stimulatory or thrombin-inducible TGF beta 1 gene expression. In contrast, transfection of activated mutants of G alpha(12) and G alpha(13) enabled the knockout cells to promote TGF beta 1 induction. A promoter deletion analysis suggested that activating protein 1 (AP-1) plays a role in TGF beta 1 gene transactivation, which was corroborated by the observation that a deficiency of the G-proteins decreased the AP-1 activity, whereas their activation enhanced it. Moreover, mutation of the AP-1-binding site abrogated the ability of G alpha(12) and G alpha(13) to induce the TGF beta 1 gene. Transfection of a dominant-negative mutant of Rho or Rac, but not Cdc42, prevented gene transactivation and decreased AP-1 activity downstream of G alpha 12 and G alpha 13. In summary, G alpha 12 and G alpha 13 regulate the expression of the TGF beta 1 gene through an increase in Rho/Rac-dependent AP-1 activity, implying that the G-protein-coupled receptor (GPCR)-G alpha(12) pathway is involved in the TGF beta 1-mediated transdifferentiation process.	[Kim, S. G.] Seoul Natl Univ, Coll Pharm, Pharmaceut Sci Res Inst, Seoul 151742, South Korea; [Lee, S. J.; Yang, J. W.; Cho, I. J.; Kim, W. D.; Cho, M. K.; Kim, S. G.] Seoul Natl Univ, Coll Pharm, Innovat Drug Res Ctr Metab & Inflammatory Dis, Seoul 151742, South Korea; [Cho, M. K.] Dongguk Univ, Coll Oriental Med, Kyungju, South Korea; [Lee, C. H.] Hanyang Univ, Coll Med, Inst Biomed Sci, Seoul 133791, South Korea; [Lee, C. H.] Hanyang Univ, Coll Med, Dept Pharmacol, Seoul 133791, South Korea	Seoul National University (SNU); Seoul National University (SNU); Dongguk University; Hanyang University; Hanyang University	Kim, SG (corresponding author), Seoul Natl Univ, Coll Pharm, Pharmaceut Sci Res Inst, Seoul 151742, South Korea.	sgk@snu.ac.kr		Kim, Wondong/0000-0001-9030-9164	Korea government (MEST), Korea [R11-2007-10701001-0]	Korea government (MEST), Korea(Ministry of Education, Science & Technology (MEST), Republic of KoreaKorean Government)	We thank Dr SC Brooks III for helpful discussion and English editing. This work was supported by the Korea Science and Engineering Foundation (KOSEF) grant funded by the Korea government ( MEST) ( No. R11-2007-10701001-0), Korea.	Ankoma-Sey V, 2000, HEPATOLOGY, V31, P141, DOI 10.1002/hep.510310122; Bahr MJ, 1999, HEPATOLOGY, V29, P839, DOI 10.1002/hep.510290333; Bataller R, 2005, J CLIN INVEST, V115, P209, DOI 10.1172/JCI200524282; Bataller R, 2000, GASTROENTEROLOGY, V118, P1149, DOI 10.1016/S0016-5085(00)70368-4; Brown JH, 2006, CIRC RES, V98, P730, DOI 10.1161/01.RES.0000216039.75913.9e; Byun HJ, 2006, J BIOL CHEM, V281, P34833, DOI 10.1074/jbc.M605483200; CHAN AML, 1993, MOL CELL BIOL, V13, P762, DOI 10.1128/MCB.13.2.762; Coulouarn C, 2008, HEPATOLOGY, V47, P2059, DOI 10.1002/hep.22283; Dhanasekaran N, 1996, CELL SIGNAL, V8, P235, DOI 10.1016/0898-6568(96)00048-4; DOKTER WHA, 1995, LEUKEMIA, V9, P425; Fiorucci S, 2004, HEPATOLOGY, V39, P365, DOI 10.1002/hep.20054; Fransvea E, 2008, HEPATOLOGY, V47, P1557, DOI 10.1002/hep.22201; FRIEDMAN SL, 1993, NEW ENGL J MED, V328, P1828; Fujii T, 2005, J BIOL CHEM, V280, P23041, DOI 10.1074/jbc.M409397200; Gaca MDA, 2002, J HEPATOL, V36, P362, DOI 10.1016/S0168-8278(01)00285-9; George J, 2001, TOXICOLOGY, V156, P129, DOI 10.1016/S0300-483X(00)00352-8; George J, 1996, BBA-PROTEIN STRUCT M, V1292, P215, DOI 10.1016/0167-4838(95)00202-2; Giannelli G, 2005, GASTROENTEROLOGY, V129, P1375, DOI 10.1053/j.gastro.2005.09.055; Goldsmith ZG, 2007, ONCOGENE, V26, P3122, DOI 10.1038/sj.onc.1210407; Graupera M, 2003, HEPATOLOGY, V37, P172, DOI 10.1053/jhep.2003.50004; Gu JL, 2002, P NATL ACAD SCI USA, V99, P9352, DOI 10.1073/pnas.102291599; JENKINS SA, 1985, J HEPATOL, V1, P489, DOI 10.1016/S0168-8278(85)80747-9; Kang KW, 2003, J BIOL CHEM, V278, P17368, DOI 10.1074/jbc.M300471200; Kang KW, 2002, FASEB J, V16, P1988, DOI 10.1096/fj.02-0406fje; Kang KW, 2002, CHEM-BIOL INTERACT, V139, P61, DOI 10.1016/S0009-2797(01)00286-1; Kaufmann R, 2007, J CELL PHYSIOL, V211, P699, DOI 10.1002/jcp.21027; Kawanabe Y, 2002, MOL PHARMACOL, V61, P277, DOI 10.1124/mol.61.2.277; Kelly P, 2007, BIOCHEMISTRY-US, V46, P6677, DOI 10.1021/bi700235f; Ki SH, 2007, J BIOL CHEM, V282, P1938, DOI 10.1074/jbc.M606080200; KIM SJ, 1989, J BIOL CHEM, V264, P402; Kumar RN, 2006, ONCOGENE, V25, P899, DOI 10.1038/sj.onc.1209132; Kuner R, 2002, EUR J NEUROSCI, V16, P2333, DOI 10.1046/j.1460-9568.2002.02402.x; Kurose H, 2003, LIFE SCI, V74, P155, DOI 10.1016/j.lfs.2003.09.003; Lee JS, 2007, HEPATOLOGY, V45, P817, DOI 10.1002/hep.21564; Mikula M, 2006, J CELL PHYSIOL, V209, P560, DOI 10.1002/jcp.20772; Molteni Agostino, 2006, Anti-Cancer Agents in Medicinal Chemistry, V6, P451, DOI 10.2174/187152006778226521; Oklu R, 2000, BIOCHEM J, V352, P601, DOI 10.1042/0264-6021:3520601; Olaso E, 1997, HEPATOLOGY, V26, P634, DOI 10.1053/jhep.1997.v26.pm0009303493; Pinzani M, 1996, GASTROENTEROLOGY, V110, P534, DOI 10.1053/gast.1996.v110.pm8566602; Qi Z, 1999, P NATL ACAD SCI USA, V96, P2345, DOI 10.1073/pnas.96.5.2345; Radhika V, 2005, ONCOGENE, V24, P4597, DOI 10.1038/sj.onc.1208665; RHOADES KL, 1992, J BIOL CHEM, V267, P22102; SCHOOK LB, 1992, TOXICOL APPL PHARM, V116, P110, DOI 10.1016/0041-008X(92)90151-H; Smart DE, 2006, HEPATOLOGY, V44, P1432, DOI 10.1002/hep.21436; Solis-Herruzo JA, 1998, CELL SIGNAL, V10, P173, DOI 10.1016/S0898-6568(97)00036-3; Vogt S, 2003, J BIOL CHEM, V278, P28743, DOI 10.1074/jbc.M304570200; Weigert C, 2000, J AM SOC NEPHROL, V11, P2007, DOI 10.1681/ASN.V11112007; Xu J, 1997, NATURE, V389, P505, DOI 10.1038/39068; XU NZ, 1993, P NATL ACAD SCI USA, V90, P6741, DOI 10.1073/pnas.90.14.6741; XU NZ, 1994, BIOCHEM BIOPH RES CO, V201, P603, DOI 10.1006/bbrc.1994.1744; Yamaguchi Y, 2003, J BIOL CHEM, V278, P14936, DOI 10.1074/jbc.M301409200; Yoshiji H, 2007, CURR MED CHEM, V14, P2749, DOI 10.2174/092986707782360169; Yue JB, 2000, J BIOL CHEM, V275, P30765, DOI 10.1074/jbc.M000039200; Zhao SJ, 2008, CANCER RES, V68, P4221, DOI 10.1158/0008-5472.CAN-07-5123	54	20	21	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 5	2009	28	9					1230	1240		10.1038/onc.2008.488	http://dx.doi.org/10.1038/onc.2008.488			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	415AH	19151758				2022-12-28	WOS:000263906200007
J	Yeh, YH; Huang, YF; Lin, TY; Shieh, SY				Yeh, Y-H; Huang, Y-F; Lin, T-Y; Shieh, S-Y			The cell cycle checkpoint kinase CHK2 mediates DNA damage-induced stabilization of TTK/hMps1	ONCOGENE			English	Article						checkpoint; CHK2; TTK/hMps1	POLE BODY DUPLICATION; SPINDLE-CHECKPOINT; PROTEIN-KINASE; KINETOCHORE LOCALIZATION; CENTROSOME DUPLICATION; MITOTIC CHECKPOINT; HUMAN MPS1; CANCER-THERAPY; GENE MPS1; PHOSPHORYLATION	Cell cycle progression is monitored constantly to ensure faithful passage of genetic codes and genome stability. We have demonstrated previously that, upon DNA damage, TTK/hMps1 activates the checkpoint kinase CHK2 by phosphorylating CHK2 at Thr68. However, it remains to be determined whether and how TTK/hMps1 responds to DNA damage. In this report, we present evidence that TTK/hMps1 can be induced by DNA damage in normal human. broblasts. Interestingly, the induction depends on CHK2 because CHK2-targeting small interfering RNA or a CHK2 inhibitor abolishes the increase. Such induction is mediated through phosphorylation of TTK/hMps1 at Thr288 by CHK2 and requires the CHK2 SQ/TQ cluster domain/forkhead-associated domain. In cells, TTK/hMps1 phosphorylation at Thr288 is induced by DNA damage and forms nuclear foci, which colocalize partially with c-H2AX. Reexpression of TTK/hMps1 T288A mutant in TTK/hMps1-knockdown cells causes a defect in G2/M arrest, suggesting that phosphorylation at this site participates in the proper checkpoint execution. Our study uncovered a regulatory loop between TTK/hMps1 and CHK2 whereby DNA damage-activated CHK2 may facilitate the stabilization of TTK/hMps1, therefore maintaining the checkpoint control.	[Yeh, Y-H; Huang, Y-F; Lin, T-Y; Shieh, S-Y] Acad Sinica, Inst Biomed Sci, Taipei 115, Taiwan; [Huang, Y-F] Natl Tsing Hua Univ, Inst Mol & Cellular Biol, Hsinchu, Taiwan	Academia Sinica - Taiwan; National Tsing Hua University	Shieh, SY (corresponding author), Acad Sinica, Inst Biomed Sci, 128 Sect 2,Acad Rd, Taipei 115, Taiwan.	sy88@ibms.sinica.edu.tw	Shieh, Sheau-Yann/N-9512-2018	Shieh, Sheau-Yann/0000-0002-5351-4430	Academia Sinica; National Science Council of Taiwan	Academia Sinica(Academia Sinica - Taiwan); National Science Council of Taiwan(Ministry of Science and Technology, Taiwan)	This work was supported by grants from Academia Sinica and National Science Council of Taiwan to S-Y Shieh.	Abrieu A, 2001, CELL, V106, P83, DOI 10.1016/S0092-8674(01)00410-X; ALLEN JB, 1994, GENE DEV, V8, P2401, DOI 10.1101/gad.8.20.2401; Antoni L, 2007, NAT REV CANCER, V7, P925, DOI 10.1038/nrc2251; Bartek J, 2007, CURR OPIN CELL BIOL, V19, P238, DOI 10.1016/j.ceb.2007.02.009; Branzei D, 2005, CURR OPIN CELL BIOL, V17, P568, DOI 10.1016/j.ceb.2005.09.003; Cui Y, 2008, ONCOGENE, V27, P3122, DOI 10.1038/sj.onc.1210972; de Carcer G, 2007, CURR MED CHEM, V14, P969, DOI 10.2174/092986707780362925; Dimitrova DS, 2000, EXP CELL RES, V254, P321, DOI 10.1006/excr.1999.4770; DOUVILLE EMJ, 1992, MOL CELL BIOL, V12, P2681, DOI 10.1128/MCB.12.6.2681; Enders GH, 2006, GENE, V371, P1, DOI 10.1016/j.gene.2005.11.017; Fischer MG, 2004, CURR BIOL, V14, P2019, DOI 10.1016/j.cub.2004.11.008; Fisk HA, 2004, CELL CYCLE, V3, P439; Fisk HA, 2003, P NATL ACAD SCI USA, V100, P14875, DOI 10.1073/pnas.2434156100; Fisk HA, 2001, CELL, V106, P95, DOI 10.1016/S0092-8674(01)00411-1; He XW, 1998, J CELL SCI, V111, P1635; HOGG D, 1994, ONCOGENE, V9, P89; Hurley PJ, 2007, CELL CYCLE, V6, P414, DOI 10.4161/cc.6.4.3886; Iliakis G, 2003, ONCOGENE, V22, P5834, DOI 10.1038/sj.onc.1206682; Jaspersen SL, 2004, DEV CELL, V7, P263, DOI 10.1016/j.devcel.2004.07.006; Jelluma N, 2008, CELL, V132, P233, DOI 10.1016/j.cell.2007.11.046; Kang JS, 2007, P NATL ACAD SCI USA, V104, P20232, DOI 10.1073/pnas.0710519105; Kasbek C, 2007, MOL BIOL CELL, V18, P4457, DOI 10.1091/mbc.E07-03-0283; Lee JS, 2000, NATURE, V404, P201, DOI 10.1038/35004614; LINDBERG RA, 1993, ONCOGENE, V8, P351; Mattison CP, 2007, J BIOL CHEM, V282, P30553, DOI 10.1074/jbc.M707063200; MILLS GB, 1992, J BIOL CHEM, V267, P16000; MURAKAMI H, 1995, NATURE, V374, P817, DOI 10.1038/374817a0; Niida H, 2006, MUTAGENESIS, V21, P3, DOI 10.1093/mutage/gei063; Poss KD, 2004, GENE DEV, V18, P1527, DOI 10.1101/gad.1182604; Poss KD, 2002, DEVELOPMENT, V129, P5141; Shieh SY, 2000, GENE DEV, V14, P289; Straight PD, 2000, MOL BIOL CELL, V11, P3525, DOI 10.1091/mbc.11.10.3525; Stucke VM, 2004, CHROMOSOMA, V113, P1, DOI 10.1007/s00412-004-0288-2; Stucke VM, 2002, EMBO J, V21, P1723, DOI 10.1093/emboj/21.7.1723; Vigneron S, 2004, MOL BIOL CELL, V15, P4584, DOI 10.1091/mbc.E04-01-0051; Wang HC, 2006, CANCER RES, V66, P1391, DOI 10.1158/0008-5472.CAN-05-3270; Ward IM, 2001, J BIOL CHEM, V276, P47755, DOI 10.1074/jbc.C100587200; Wei JH, 2005, J BIOL CHEM, V280, P7748, DOI 10.1074/jbc.M410152200; Weiss E, 1996, J CELL BIOL, V132, P111, DOI 10.1083/jcb.132.1.111; WINEY M, 1991, J CELL BIOL, V114, P745, DOI 10.1083/jcb.114.4.745; Winey M, 2002, ONCOGENE, V21, P6161, DOI 10.1038/sj.onc.1205712; Xu XZ, 2002, MOL CELL BIOL, V22, P4419, DOI 10.1128/MCB.22.12.4419-4432.2002; Zhao Y, 2006, CURR BIOL, V16, P1764, DOI 10.1016/j.cub.2006.07.058	43	35	35	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2009	28	10					1366	1378		10.1038/onc.2008.477	http://dx.doi.org/10.1038/onc.2008.477			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	417ZC	19151762				2022-12-28	WOS:000264116000009
J	Goicoechea, SM; Bednarski, B; Garcia-Mata, R; Prentice-Dunn, H; Kim, HJ; Otey, CA				Goicoechea, S. M.; Bednarski, B.; Garcia-Mata, R.; Prentice-Dunn, H.; Kim, H. J.; Otey, C. A.			Palladin contributes to invasive motility in human breast cancer cells	ONCOGENE			English	Article						podosomes; migration; actin; metastasis	SMOOTH-MUSCLE-CELLS; EXTRACELLULAR-MATRIX DEGRADATION; INFLUENCES ZYXIN LOCALIZATION; PROTEIN PALLADIN; BINDING PARTNER; ACTIN CYTOSKELETON; DORSAL RUFFLES; ALPHA-ACTININ; PODOSOMES; INVADOPODIA	Cancer metastasis involves multiple steps including detachment of the metastatic cells from neighboring cells, the acquisition of motility and invasion to other tissue. All of these steps require the reorganization of the actin cytoskeleton. In this study, we found that the protein palladin, a molecular scaffold with an important function in actin organization, is expressed at higher overall levels in tumors compared with benign breast tissue, and also expressed significantly higher in four invasive breast cancer cell lines when compared with four non-invasive cell lines. In addition, we found that palladin plays a key role in the formation of podosomes. Podosomes are actin-rich structures that function in adhesion and matrix degradation, and have been found in many invasive cell types. Our results show that phorbol ester treatment stimulated the formation of palladin-containing podosomes in invasive, but not in non-invasive cell lines. More importantly, palladin knockdown resulted in decreased podosome formation and a significant reduction in transwell migration and invasive motility. Palladin overexpression induced podosome formation in the non-invasive MCF7 cells, which are otherwise unable to form podosomes, suggesting that palladin plays a critical role in the assembly of podosomes. Overall, these results indicate that palladin overexpression contributes to the invasive behavior of metastatic cells.	[Goicoechea, S. M.; Prentice-Dunn, H.; Otey, C. A.] Univ N Carolina, Dept Cell & Mol Physiol, Chapel Hill, NC 27599 USA; [Bednarski, B.; Kim, H. J.] Univ N Carolina, Sch Med, Dept Med, Chapel Hill, NC 27599 USA; [Garcia-Mata, R.] Univ N Carolina, Dept Cell & Dev Biol, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of North Carolina; University of North Carolina Chapel Hill	Goicoechea, SM (corresponding author), Univ N Carolina, Dept Cell & Mol Physiol, 103 Mason Farm Rd,5320 MBRB, Chapel Hill, NC 27599 USA.	sgoico@med.unc.edu		Goicoechea, Silvia/0000-0003-1107-389X; Garcia-Mata, Rafael/0000-0002-7116-4411	NIH [GM61743, CA09688]; NIH K08 [CA098240]; NATIONAL CANCER INSTITUTE [K08CA098240, T32CA009688] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM061743] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIH K08(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We are grateful to the following former lab members for their assistance in the early stages of this project: Dr Mana Parast, Amir Aghajanian and Xinshuo Wang. We thank Xiaoya Ding and Dave Cowan for help with immunohistochemistry. We also thank Dr Cercina Onesto for kindly sharing the breast cancer cell lines. This work was supported by NIH Grant GM61743 (to CO). HJK was supported by NIH K08 Grant CA098240 and BB was supported by NIH training Grant CA09688.	Boukhelifa M, 2006, FEBS J, V273, P26, DOI 10.1111/j.1742-4658.2005.05036.x; Boukhelifa M, 2004, CELL MOTIL CYTOSKEL, V58, P17, DOI 10.1002/cm.10173; Boukhelifa M, 2003, MOL CELL NEUROSCI, V23, P661, DOI 10.1016/S1044-7431(03)00127-1; Boukhelifa M, 2001, MOL BIOL CELL, V12, P2721, DOI 10.1091/mbc.12.9.2721; Bowden ET, 1999, ONCOGENE, V18, P4440, DOI 10.1038/sj.onc.1202827; Buccione R, 2004, NAT REV MOL CELL BIO, V5, P647, DOI 10.1038/nrm1436; Calle Y, 2006, EUR J CELL BIOL, V85, P151, DOI 10.1016/j.ejcb.2005.09.003; Carman CV, 2007, IMMUNITY, V26, P784, DOI 10.1016/j.immuni.2007.04.015; Di Modugno F, 2007, CANCER RES, V67, P2657, DOI 10.1158/0008-5472.CAN-06-1997; Dixon RDS, 2008, J BIOL CHEM, V283, P6222, DOI 10.1074/jbc.M707694200; Dumitrescu RG, 2005, J CELL MOL MED, V9, P208, DOI 10.1111/j.1582-4934.2005.tb00350.x; Flanagan L, 1999, BREAST CANCER RES TR, V58, P193, DOI 10.1023/A:1006331716981; Gimona M, 2003, MOL BIOL CELL, V14, P2482, DOI 10.1091/mbc.E02-11-0743; Gimona M, 2006, INT J BIOCHEM CELL B, V38, P1875, DOI 10.1016/j.biocel.2006.05.003; Goicoechea S, 2006, J CELL SCI, V119, P3316, DOI 10.1242/jcs.03076; Gringel A, 2006, J CELL PHYSIOL, V209, P568, DOI 10.1002/jcp.20777; Grunewald TGP, 2007, BRIT J CANCER, V96, P296, DOI 10.1038/sj.bjc.6603545; Grunewald TGP, 2006, EXP CELL RES, V312, P974, DOI 10.1016/j.yexcr.2005.12.016; Grunewald TGP, 2007, BMC CANCER, V7, P1, DOI 10.1186/1471-2407-7-198; Hai CM, 2002, EXP CELL RES, V280, P64, DOI 10.1006/excr.2002.5592; Hatakeyama H, 2006, PROTEOMICS, V6, P6300, DOI 10.1002/pmic.200600488; Honda K, 1998, J CELL BIOL, V140, P1383, DOI 10.1083/jcb.140.6.1383; Jin L, 2007, CIRC RES, V100, P817, DOI 10.1161/01.RES.0000261351.54147.de; Kelly T, 1998, CLIN EXP METASTAS, V16, P501, DOI 10.1023/A:1006538200886; Kuperwasser C, 2005, CANCER RES, V65, P6130, DOI 10.1158/0008-5472.CAN-04-1408; Lin YH, 2004, J CELL BIOL, V165, P421, DOI 10.1083/jcb.200311045; Linder S, 2003, TRENDS CELL BIOL, V13, P376, DOI 10.1016/S0962-8924(03)00128-4; Linder S, 2007, TRENDS CELL BIOL, V17, P107, DOI 10.1016/j.tcb.2007.01.002; Luo HJ, 2005, MOL CELL NEUROSCI, V29, P507, DOI 10.1016/j.mcn.2004.12.002; MONSKY WL, 1994, CANCER RES, V54, P5702; Mykkanen OM, 2001, MOL BIOL CELL, V12, P3060, DOI 10.1091/mbc.12.10.3060; Parast MM, 2000, J CELL BIOL, V150, P643, DOI 10.1083/jcb.150.3.643; Pogue-Geile KL, 2006, PLOS MED, V3, P2216, DOI 10.1371/journal.pmed.0030516; Rachlin AS, 2006, J CELL SCI, V119, P995, DOI 10.1242/jcs.02825; Ronty M, 2005, EXP CELL RES, V310, P88, DOI 10.1016/j.yexcr.2005.06.026; Ronty M, 2004, FEBS LETT, V566, P30, DOI 10.1061/j.febslet.2004.04.006; Ronty M, 2007, EXP CELL RES, V313, P2575, DOI 10.1016/j.yexcr.2007.04.030; Ronty MJ, 2006, J INVEST DERMATOL, V126, P2387, DOI 10.1038/sj.jid.5700427; Roy P, 2004, CELL MOTIL CYTOSKEL, V57, P84, DOI 10.1002/cm.10160; Ryu B, 2001, CANCER RES, V61, P1833; Seals DF, 2005, CANCER CELL, V7, P155, DOI 10.1016/j.ccr.2005.01.006; Suehara Y, 2006, PROTEOMICS, V6, P4402, DOI 10.1002/pmic.200600196; Wang WG, 2005, TRENDS CELL BIOL, V15, P138, DOI 10.1016/j.tcb.2005.01.003; Wang WG, 2004, CANCER RES, V64, P8585, DOI 10.1158/0008-5472.CAN-04-1136; Welsch T, 2007, CANCER LETT, V255, P205, DOI 10.1016/j.canlet.2007.04.008; Wittenmayer N, 2004, MOL BIOL CELL, V15, P1600, DOI 10.1091/mbc.E03-12-0873; Yamaguchi H, 2006, EUR J CELL BIOL, V85, P213, DOI 10.1016/j.ejcb.2005.10.004; Yamaguchi H, 2007, BBA-MOL CELL RES, V1773, P642, DOI 10.1016/j.bbamcr.2006.07.001; Zajchowski DA, 2001, CANCER RES, V61, P5168; Zhang J, 2007, J CLIN INVEST, V117, P2962, DOI 10.1172/JCI30710	50	61	62	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 29	2009	28	4					587	598		10.1038/onc.2008.408	http://dx.doi.org/10.1038/onc.2008.408			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	400KM	18978809	Green Accepted, Green Submitted			2022-12-28	WOS:000262866500012
J	Tomaic, V; Gardiol, D; Massimi, P; Ozbun, M; Myers, M; Banks, L				Tomaic, V.; Gardiol, D.; Massimi, P.; Ozbun, M.; Myers, M.; Banks, L.			Human and primate tumour viruses use PDZ binding as an evolutionarily conserved mechanism of targeting cell polarity regulators	ONCOGENE			English	Article						papillomavirus; oncoproteins; PDZ domains; Par3	PAPILLOMAVIRUS E6 PROTEINS; MEDIATED DEGRADATION; ACTIVATED RAS; ONCOPROTEIN; SCRIBBLE; SUPPRESSOR; SEQUENCE; RHPV-1; DOMAIN; MOTIF	A unique feature of the cancer-causing mucosotropic human papillomaviruses (HPVs) is the ability of their E6 proteins to interact with a number of PDZ domain-containing cellular substrates, including the cell polarity regulators hDlg and hScrib. These interactions are essential for the ability of these viruses to induce malignant progression. Rhesus papillomaviruses (RhPV) are similar to their human counterparts in that they also cause anogenital malignancy in their host, the Rhesus Macaque. However, unlike HPV E6, the RhPV E6 has no PDZ-binding motif. We now show that such a motif is present on the RhPV E7 oncoprotein. This motif specifically confers PDZ-binding activity and directs the interaction of RhPV E7 with the cell polarity regulator Par3, which it targets for proteasome-mediated degradation. These results demonstrate an amazing evolutionary conservation of function between the RhPV and the HPV oncoproteins, where both target proteins of the same cell polarity control network, although through different components and pathways.	[Tomaic, V.; Gardiol, D.; Massimi, P.; Myers, M.; Banks, L.] Int Ctr Genet Engn & Biotechnol, I-34012 Trieste, TS, Italy; [Ozbun, M.] Univ New Mexico, Sch Med, Dept Mol Genet & Microbiol, Albuquerque, NM 87131 USA	International Center for Genetic Engineering & Biotechnology (ICGEB); University of New Mexico	Banks, L (corresponding author), Int Ctr Genet Engn & Biotechnol, Padriciano 99, I-34012 Trieste, TS, Italy.	banks@icgeb.org	Ozbun, Michelle/AAN-2922-2021; Ozbun, Michelle Adair/Q-4158-2017	Ozbun, Michelle/0000-0001-8551-4606; Ozbun, Michelle Adair/0000-0001-8551-4606	NIH [CA103645]; NATIONAL CANCER INSTITUTE [R21CA103645] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [P51RR000164] Funding Source: NIH RePORTER; Associazione Italiana per la Ricerca sul Cancro Funding Source: Custom	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); Associazione Italiana per la Ricerca sul Cancro(Fondazione AIRC per la ricerca sul cancro)	This work was supported in part by a research grant from the Associazione Italiana per la Ricerca sul Cancro to LB and from a Public Health Service Grant from the NIH CA103645 (MAO) to MO.	Gardiol D, 1999, ONCOGENE, V18, P5487, DOI 10.1038/sj.onc.1202920; Humbert P, 2003, BIOESSAYS, V25, P542, DOI 10.1002/bies.10286; Humbert PO, 2006, TRENDS CELL BIOL, V16, P622, DOI 10.1016/j.tcb.2006.10.005; Joberty G, 2000, NAT CELL BIOL, V2, P531, DOI 10.1038/35019573; Kiyono T, 1997, P NATL ACAD SCI USA, V94, P11612, DOI 10.1073/pnas.94.21.11612; Le SS, 1997, P NATL ACAD SCI USA, V94, P6670, DOI 10.1073/pnas.94.13.6670; Lee CH, 2004, J VIROL, V78, P12366, DOI 10.1128/JVI.78.22.12366-12377.2004; Mantovani F, 2001, ONCOGENE, V20, P7874, DOI 10.1038/sj.onc.1204869; MATLASHEWSKI G, 1987, EMBO J, V6, P1741, DOI 10.1002/j.1460-2075.1987.tb02426.x; Munger K, 2001, ONCOGENE, V20, P7888, DOI 10.1038/sj.onc.1204860; Nakagawa S, 2000, MOL CELL BIOL, V20, P8244, DOI 10.1128/MCB.20.21.8244-8253.2000; Nguyen ML, 2003, J VIROL, V77, P6957, DOI 10.1128/JVI.77.12.6957-6964.2003; Nguyen MM, 2003, MOL CELL BIOL, V23, P8970, DOI 10.1128/MCB.23.24.8970-8981.2003; OSTROW RS, 1991, VIROLOGY, V181, P424; OSTROW RS, 1993, VIROLOGY, V196, P861, DOI 10.1006/viro.1993.1547; Reinstein E, 2000, ONCOGENE, V19, P5944, DOI 10.1038/sj.onc.1203989; Song S, 2000, VIROLOGY, V267, P141, DOI 10.1006/viro.1999.0106; Thomas M, 2002, ONCOGENE, V21, P5088, DOI 10.1038/sj.onc.1205668; Thomas M, 1996, ONCOGENE, V13, P471; Watson RA, 2003, J CELL SCI, V116, P4925, DOI 10.1242/jcs.00809; Wood CE, 2007, J VIROL, V81, P6339, DOI 10.1128/JVI.00233-07; Zhang Y, 2007, J VIROL, V81, P3618, DOI 10.1128/JVI.02044-06; zurHausen H, 1996, BBA-REV CANCER, V1288, pF55	23	53	53	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 8	2009	28	1					1	8		10.1038/onc.2008.365	http://dx.doi.org/10.1038/onc.2008.365			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	392HP	18820705	Green Accepted			2022-12-28	WOS:000262294100001
J	Kojima, T; Shimazui, T; Hinotsu, S; Joraku, A; Oikawa, T; Kawai, K; Horie, R; Suzuki, H; Nagashima, R; Yoshikawa, K; Michiue, T; Asashima, M; Akaza, H; Uchida, K				Kojima, T.; Shimazui, T.; Hinotsu, S.; Joraku, A.; Oikawa, T.; Kawai, K.; Horie, R.; Suzuki, H.; Nagashima, R.; Yoshikawa, K.; Michiue, T.; Asashima, M.; Akaza, H.; Uchida, K.			Decreased expression of CXXC4 promotes a malignant phenotype in renal cell carcinoma by activating Wnt signaling	ONCOGENE			English	Article						CXXC4; Idax; RCC; SNP array	COMPARATIVE GENOMIC HYBRIDIZATION; HIGH-RESOLUTION ANALYSIS; BETA-CATENIN; GENE-EXPRESSION; CANCER; LIVIN; INHIBITOR; PATHWAY; TARGET; IDENTIFICATION	The Wnt signaling pathway is involved in normal embryonic development and controls the homeostatic self-renewal of stem cells in adult tissues. Constitutive activation of Wnt signaling contributes to cancer development and progression. We identified a CXXC4 homozygous deletion at 4q24 in an aggressive renal cell carcinoma (RCC) using single-nucleotide polymorphism (SNP) arrays. CXXC4 encodes Idax, which negatively regulates Wnt signaling by binding to the PDZ domain of Dishevelled. CXXC4 mRNA levels in tumor samples were significantly lower in patients with metastases compared with those without (P = 0.0016). Patients whose tumors had lower CXXC4 expression than normal kidney showed a poorer cause-specific survival outcome than those with higher expression (P = 0.0095). Decreased expression of CXXC4 also correlated with cytoplasmic staining of beta-catenin. Knockdown of CXXC4 induced the nuclear translocation of beta-catenin and altered expression of a set of genes involved in cell proliferation, invasion and survival. Furthermore, reduced expression of CXXC4 by small interfering RNAs promoted cell proliferation and inhibited apoptosis after 5-FU and doxorubicin treatment in RCC cells. These data suggest that CXXC4 plays a critical role in tumor progression of RCC through Wnt signaling. Wnt signaling could thus be a potential molecular target in RCC indicating decreased CXXC4 expression.	[Kojima, T.; Shimazui, T.; Hinotsu, S.; Joraku, A.; Oikawa, T.; Kawai, K.; Akaza, H.] Univ Tsukuba, Grad Sch Comprehens Human Sci, Dept Mol Biol Oncol, Tsukuba, Ibaraki 3058575, Japan; [Kojima, T.; Horie, R.; Uchida, K.] Univ Tsukuba, Grad Sch Comprehens Human Sci, Dept Mol Biol Oncol, Tsukuba, Ibaraki, Japan; [Suzuki, H.] MCBI, Div Res, Tsukuba, Ibaraki, Japan; [Yoshikawa, K.] Aichi Med Univ, Sch Med, Dept Pathol, Aichi, Japan; [Michiue, T.; Asashima, M.] Natl Inst Adv Ind Sci & Technol, Organ Dev Res Lab, Tsukuba, Ibaraki, Japan	University of Tsukuba; University of Tsukuba; Aichi Medical University; National Institute of Advanced Industrial Science & Technology (AIST)	Uchida, K (corresponding author), Univ Tsukuba, Grad Sch Comprehens Human Sci, Dept Mol Biol Oncol, 1-1-1 Tennoudai, Tsukuba, Ibaraki 3058575, Japan.	kazuhiko.uchida@cbiri.org	Asashima, Makoto/O-8389-2018	Asashima, Makoto/0000-0002-0012-026X	Japan Society for the Promotion of Science (JSPS), Japan	Japan Society for the Promotion of Science (JSPS), Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science)	We thank Taeko Asano and Miyuki Katto for immunohistochemistry and microarray, respectively. We also thank Noriko Kunita for technical support. This study was performed in part as a collaborative research effort with the Clinical Informatics Research Initiative at the Organ Development Research Laboratory of the National Institute of Advanced Industrial Science and Technology (AIST), Japan. This study was supported by a grant from Scientific Research from the Japan Society for the Promotion of Science (JSPS), Japan.	Barker N, 2006, NAT REV DRUG DISCOV, V5, P997, DOI 10.1038/nrd2154; Bignell GR, 2004, GENOME RES, V14, P287, DOI 10.1101/gr.2012304; Bilim V, 2000, CLIN CANCER RES, V6, P460; Cohen HT, 2005, NEW ENGL J MED, V353, P2477, DOI 10.1056/NEJMra043172; Crnkovic-Mertens I, 2007, CELL MOL LIFE SCI, V64, P1137, DOI 10.1007/s00018-007-6510-7; Dahl E, 2007, ONCOGENE, V26, P5680, DOI 10.1038/sj.onc.1210345; Escudier B, 2007, NEW ENGL J MED, V356, P125, DOI 10.1056/NEJMoa060655; Gavert N, 2005, J CELL BIOL, V168, P633, DOI 10.1083/jcb.200408051; Guinan P, 1997, CANCER, V80, P992, DOI 10.1002/(SICI)1097-0142(19970901)80:5<992::AID-CNCR26>3.0.CO;2-Q; Gumz ML, 2007, CLIN CANCER RES, V13, P4740, DOI 10.1158/1078-0432.CCR-07-0143; Hino SI, 2001, MOL CELL BIOL, V21, P330, DOI 10.1128/MCB.21.1.330-342.2001; Jiang F, 2000, CANCER RES, V60, P6503; Jiang F, 1998, J PATHOL, V185, P382; Kasof GM, 2001, J BIOL CHEM, V276, P3238, DOI 10.1074/jbc.M003670200; Kempkensteffen C, 2007, CANCER LETT, V254, P227, DOI 10.1016/j.canlet.2007.03.006; Krig SR, 2007, J BIOL CHEM, V282, P9703, DOI 10.1074/jbc.M611752200; Kurose K, 2004, J UROLOGY, V171, P1314, DOI 10.1097/01.ju.0000101047.64379.d4; Lee MG, 2006, ONCOGENE, V25, P5807, DOI 10.1038/sj.onc.1209867; Levy DA, 1998, J UROLOGY, V159, P1163, DOI 10.1016/S0022-5347(01)63541-9; Liston P, 2001, NAT CELL BIOL, V3, P128, DOI 10.1038/35055027; Mann B, 1999, P NATL ACAD SCI USA, V96, P1603, DOI 10.1073/pnas.96.4.1603; Matsuzaki H, 2004, NAT METHODS, V1, P109, DOI 10.1038/nmeth718; Michiue T, 2004, DEV DYNAM, V230, P79, DOI 10.1002/dvdy.20037; MITRA AB, 1994, CANCER RES, V54, P4481; Moch H, 1996, CANCER RES, V56, P27; Motzer RJ, 2007, NEW ENGL J MED, V356, P115, DOI 10.1056/NEJMoa065044; Nannya Y, 2005, CANCER RES, V65, P6071, DOI 10.1158/0008-5472.CAN-05-0465; Ohba K, 2005, J UROLOGY, V174, P461, DOI 10.1097/01.ju.0000165150.46006.92; Qiao QL, 2001, INT J CANCER, V95, P194, DOI 10.1002/1097-0215(20010520)95:3<194::AID-IJC1033>3.3.CO;2-D; Ried T, 1996, GENE CHROMOSOME CANC, V15, P234, DOI 10.1002/(SICI)1098-2264(199604)15:4<234::AID-GCC5>3.0.CO;2-2; Shimokawa T, 2003, CANCER RES, V63, P6116; Storkel S, 1997, CANCER, V80, P987, DOI 10.1002/(SICI)1097-0142(19970901)80:5<987::AID-CNCR24>3.0.CO;2-R; Suzuki H, 1997, ONCOLOGY-BASEL, V54, P252; Swiercz R, 1998, CLIN CANCER RES, V4, P869; Ueta T, 2002, ONCOL REP, V9, P1197; Wagener N, 2007, BRIT J CANCER, V97, P1271, DOI 10.1038/sj.bjc.6604028; Wang TL, 2002, P NATL ACAD SCI USA, V99, P16156, DOI 10.1073/pnas.202610899; Yeh SH, 1996, GASTROENTEROLOGY, V110, P184, DOI 10.1053/gast.1996.v110.pm8536855; Yoshimoto T, 2007, J PATHOL, V213, P392, DOI 10.1002/path.2239; Yuan D, 2007, MOL CELL BIOCHEM, V306, P171, DOI 10.1007/s11010-007-9567-6; Yuan E, 2005, MOL CANCER RES, V3, P493, DOI 10.1158/1541-7786.MCR-05-0082	41	67	70	2	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2009	28	2					297	305		10.1038/onc.2008.391	http://dx.doi.org/10.1038/onc.2008.391			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	395CY	18931698				2022-12-28	WOS:000262501100013
J	Januschke, J; Gonzalez, C				Januschke, J.; Gonzalez, C.			Drosophila asymmetric division, polarity and cancer	ONCOGENE			English	Review						stem cells; asymmetric division; centrosomes; cell-of-origin; neuroblasts; cancer	NEURAL STEM-CELLS; CENTRAL-NERVOUS-SYSTEM; NEUROBLAST SELF-RENEWAL; REGULATES SPINDLE ORIENTATION; TUMOR-SUPPRESSOR GENES; BRAIN-TUMOR; POSTEMBRYONIC NEUROBLASTS; TRANSCRIPTION FACTORS; PROTEIN LOCALIZATION; EPITHELIAL POLARITY	A limited number of adult stem cells (SCs) maintain the homoestasis of different tissues through the lifetime of the individual by generating differentiating daughters and renewing themselves. Errors in the SC division rate or in the. ne balance between self-renewal and differentiation might result in tissue overgrowth or depletion, two potentially lethal conditions. A few types of SCs have been identified in Drosophila. These include the SCs of the adult intestine and malpighian tubes, (Micchelli and Perrimon, 2006; Ohlstein and Spradling, 2006; Singh et al., 2007), the prohematocytes that maintain the population of cells involved in the immunoresponse (Lanot et al., 2001; Lemaitre and Hoffmann, 2007), the SC of the follicle epithelia in the ovary (Nystul and Spradling, 2007), germ line SCs (GSCs) of both sexes (Fuller and Spradling, 2007) and neuroblasts (NBs), the fly neural SCs (Yu et al., 2006; Chia et al., 2008; Knoblich, 2008). Drosophila SCs have proved a fruitful model system to unveil some aspects of the molecular logic that sustains SC function. This review focuses on results obtained in the last few years from the study of NBs, particularly from the standpoint of the possible functional connection between asymmetric SC division and cancer.	[Januschke, J.; Gonzalez, C.] IRB Barcelona, Cell Div Grp, PCB, Barcelona 08028, Spain; [Gonzalez, C.] Inst Catalana Recerca & Estudis Avancats, Barcelona, Spain	Barcelona Institute of Science & Technology; Institute for Research in Biomedicine - IRB Barcelona; University of Barcelona; ICREA	Gonzalez, C (corresponding author), IRB Barcelona, Cell Div Grp, PCB, C Baldiri Reixac 10-12, Barcelona 08028, Spain.	gonzalez@irbbarcelona.org	Gonzalez, Cayetano/K-3055-2019; Gonzalez, Cayetano/K-3933-2019	Gonzalez, Cayetano/0000-0002-5259-3608; Januschke, Jens/0000-0001-8985-2717	EU and Spanish [ONCASYM-037398 FP6, BFU2006-05813]; ICREA Funding Source: Custom	EU and Spanish; ICREA(ICREA)	This study was supported by EU and Spanish Grants: ONCASYM-037398 FP6, BFU2006-05813, SGR2005 Generalitatde Catalunya and Consolider-Ingenio2010 CENTRO-SOME_3DCSD2006-23.	Albertson R, 2003, NAT CELL BIOL, V5, P166, DOI 10.1038/ncb922; Almeida MS, 2005, MECH DEVELOP, V122, P1282, DOI 10.1016/j.mod.2005.08.004; Atwood SX, 2007, J CELL SCI, V120, P3200, DOI 10.1242/jcs.014902; Basto R, 2008, CELL, V133, P1032, DOI 10.1016/j.cell.2008.05.039; Basto R, 2006, CELL, V125, P1375, DOI 10.1016/j.cell.2006.05.025; Beachy PA, 2004, NATURE, V432, P324, DOI 10.1038/nature03100; Bello B, 2006, DEVELOPMENT, V133, P2639, DOI 10.1242/dev.02429; Bello BC, 2008, NEURAL DEV, V3, DOI 10.1186/1749-8104-3-5; Betschinger J, 2006, CELL, V124, P1241, DOI 10.1016/j.cell.2006.01.038; Betschinger J, 2003, NATURE, V422, P326, DOI 10.1038/nature01486; Bilder D, 2004, GENE DEV, V18, P1909, DOI 10.1101/gad.1211604; Boone JQ, 2008, DEV NEUROBIOL, V68, P1185, DOI 10.1002/dneu.20648; Bowman SK, 2008, DEV CELL, V14, P535, DOI 10.1016/j.devcel.2008.03.004; Bowman SK, 2006, DEV CELL, V10, P731, DOI 10.1016/j.devcel.2006.05.005; Brawley C, 2004, SCIENCE, V304, P1331, DOI 10.1126/science.1097676; Broadus J, 1997, CURR BIOL, V7, P827, DOI 10.1016/S0960-9822(06)00370-8; Broadus J, 1998, NATURE, V391, P792, DOI 10.1038/35861; Castellanos E, 2008, CURR BIOL, V18, P1209, DOI 10.1016/j.cub.2008.07.029; Caussinus E, 2005, NAT GENET, V37, P1125, DOI 10.1038/ng1632; Caussinus Emmanuel, 2007, Prog Mol Subcell Biol, V45, P205; Ceron J, 2006, EUR J CELL BIOL, V85, P567, DOI 10.1016/j.ejcb.2006.02.006; Chabu C, 2008, DEVELOPMENT, V135, P2739, DOI 10.1242/dev.024059; Chia W, 2008, J CELL BIOL, V180, P267, DOI 10.1083/jcb.200708159; Choksi SP, 2006, DEV CELL, V11, P775, DOI 10.1016/j.devcel.2006.09.015; Doe CQ, 2008, DEVELOPMENT, V135, P1575, DOI 10.1242/dev.014977; DOE CQ, 1991, CELL, V65, P451, DOI 10.1016/0092-8674(91)90463-9; Duensing S, 2005, CELL BIOL INT, V29, P352, DOI 10.1016/j.cellbi.2005.03.005; Dumstrei K, 2003, J NEUROSCI, V23, P3325; EBENS AJ, 1993, CELL, V74, P15, DOI 10.1016/0092-8674(93)90291-W; Feiguin F, 1998, CURR TOP DEV BIOL, V36, P279; Frank DJ, 2002, DEVELOPMENT, V129, P399; Fuller MT, 2007, SCIENCE, V316, P402, DOI 10.1126/science.1140861; GATEFF E, 1978, SCIENCE, V200, P1448, DOI 10.1126/science.96525; GATEFF E, 1967, AM ZOOL, V7, P760; Gonczy P, 2008, NAT REV MOL CELL BIO, V9, P355, DOI 10.1038/nrm2388; Golubovsky MD, 2006, EXP GERONTOL, V41, P819, DOI 10.1016/j.exger.2006.06.035; Gonzalez C, 2007, NAT REV GENET, V8, P462, DOI 10.1038/nrg2103; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Harris H, 2005, BIOESSAYS, V27, P833, DOI 10.1002/bies.20263; Harris H, 2008, J CELL SCI, V121, P3, DOI 10.1242/jcs.025742; HARSHBAR.JC, 1968, ANNU REV ENTOMOL, V13, P159, DOI 10.1146/annurev.en.13.010168.001111; Humbert P, 2003, BIOESSAYS, V25, P542, DOI 10.1002/bies.10286; Huntly BJP, 2005, NAT REV CANCER, V5, P311, DOI 10.1038/nrc1592; IkeshimaKataoka H, 1997, NATURE, V390, P625, DOI 10.1038/37641; Isshiki T, 2001, CELL, V106, P511, DOI 10.1016/S0092-8674(01)00465-2; ITO K, 1992, DEV BIOL, V149, P134, DOI 10.1016/0012-1606(92)90270-Q; Izumi Y, 2004, J CELL BIOL, V164, P729, DOI 10.1083/jcb.200309162; Izumi Y, 2006, NAT CELL BIOL, V8, P586, DOI 10.1038/ncb1409; Kai T, 2004, NATURE, V428, P564, DOI 10.1038/nature02436; Kaltschmidt JA, 2000, NAT CELL BIOL, V2, P7, DOI 10.1038/71323; Kelly PN, 2007, SCIENCE, V317, P337, DOI 10.1126/science.1142596; KNOBLICH JA, 1995, NATURE, V377, P624, DOI 10.1038/377624a0; Kraut R, 1996, NATURE, V383, P50, DOI 10.1038/383050a0; Lanot R, 2001, DEV BIOL, V230, P243, DOI 10.1006/dbio.2000.0123; Le Borgne R, 2005, DEVELOPMENT, V132, P1751, DOI 10.1242/dev.01789; Lee CY, 2006, GENE DEV, V20, P3464, DOI 10.1101/gad.1489406; Lee CY, 2006, DEV CELL, V10, P441, DOI 10.1016/j.devcel.2006.01.017; Lee CY, 2006, NATURE, V439, P594, DOI 10.1038/nature04299; Lemaitre B, 2007, ANNU REV IMMUNOL, V25, P697, DOI 10.1146/annurev.immunol.25.022106.141615; Lengauer C, 1998, NATURE, V396, P643, DOI 10.1038/25292; Li L, 2000, GENE DEV, V14, P147; Li P, 1997, CELL, V90, P437, DOI 10.1016/S0092-8674(00)80504-8; Loop T, 2004, BMC GENOMICS, V5, DOI 10.1186/1471-2164-5-24; Lu BW, 1998, CELL, V95, P225, DOI 10.1016/S0092-8674(00)81753-5; Lucas EP, 2007, J CELL BIOL, V178, P725, DOI 10.1083/jcb.200704081; Maurange C, 2008, CELL, V133, P891, DOI 10.1016/j.cell.2008.03.034; MECHLER BM, 1991, ENVIRON HEALTH PERSP, V93, P63, DOI 10.2307/3431171; Micchelli CA, 2006, NATURE, V439, P475, DOI 10.1038/nature04371; Nigg EA, 2006, INT J CANCER, V119, P2717, DOI 10.1002/ijc.22245; Nystul T, 2007, CELL STEM CELL, V1, P277, DOI 10.1016/j.stem.2007.07.009; Ohlstein B, 2006, NATURE, V439, P470, DOI 10.1038/nature04333; Ohshiro T, 2000, NATURE, V408, P593, DOI 10.1038/35046087; Park Y, 2003, DEV BIOL, V253, P247, DOI 10.1016/S0012-1606(02)00019-2; Parmentier ML, 2000, J NEUROSCI, V20, part. no., DOI 10.1523/JNEUROSCI.20-14-j0003.2000; Pearson BJ, 2003, NATURE, V425, P624, DOI 10.1038/nature01910; Peng CY, 2000, NATURE, V408, P596, DOI 10.1038/35046094; Petronczki M, 2001, NAT CELL BIOL, V3, P43, DOI 10.1038/35050550; Potter CJ, 2000, TRENDS GENET, V16, P33, DOI 10.1016/S0168-9525(99)01878-8; Rebollo E, 2007, DEV CELL, V12, P467, DOI 10.1016/j.devcel.2007.01.021; REMENSBERGER P, 1968, CHROMOSOMA, V23, P386, DOI 10.1007/BF00625286; Reya T, 2001, NATURE, V414, P105, DOI 10.1038/35102167; Rolls MM, 2003, J CELL BIOL, V163, P1089, DOI 10.1083/jcb.200306079; Rolls MM, 2004, NAT NEUROSCI, V7, P1293, DOI 10.1038/nn1346; Rusan NM, 2007, J CELL BIOL, V177, P13, DOI 10.1083/jcb.200612140; Scadden DT, 2006, NATURE, V441, P1075, DOI 10.1038/nature04957; Schaefer M, 2000, CURR BIOL, V10, P353, DOI 10.1016/S0960-9822(00)00401-2; Schober M, 1999, NATURE, V402, P548, DOI 10.1038/990135; Schweisguth F, 2004, CURR BIOL, V14, pR129, DOI 10.1016/j.cub.2004.01.023; Shen CP, 1997, CELL, V90, P449, DOI 10.1016/S0092-8674(00)80505-X; Siegrist SE, 2005, CELL, V123, P1323, DOI 10.1016/j.cell.2005.09.043; Siller KH, 2006, NAT CELL BIOL, V8, P594, DOI 10.1038/ncb1412; Singh SR, 2007, CELL STEM CELL, V1, P191, DOI 10.1016/j.stem.2007.07.003; Smith CA, 2007, EMBO J, V26, P468, DOI 10.1038/sj.emboj.7601495; Sonoda J, 2001, GENE DEV, V15, P762, DOI 10.1101/gad.870801; Speicher S, 2008, CURR BIOL, V18, P831, DOI 10.1016/j.cub.2008.04.072; Tio M, 2001, NATURE, V409, P1063, DOI 10.1038/35059124; TRUMAN JW, 1988, DEV BIOL, V125, P145, DOI 10.1016/0012-1606(88)90067-X; Wang H, 2006, GENE DEV, V20, P3453, DOI 10.1101/gad.1487506; Wang HY, 2007, NATURE, V449, P96, DOI 10.1038/nature06056; WATSON KL, 1994, J CELL SCI, P19; Wodarz A, 1999, NATURE, V402, P544, DOI 10.1038/990128; Wodarz A, 2005, CURR OPIN CELL BIOL, V17, P475, DOI 10.1016/j.ceb.2005.08.005; Woodhouse E, 1998, DEV GENES EVOL, V207, P542, DOI 10.1007/s004270050145; WU CF, 1983, J NEUROSCI, V3, P1888; Yu FW, 2006, NEURON, V51, P13, DOI 10.1016/j.neuron.2006.06.016; Yu FW, 2003, J CELL BIOL, V162, P623, DOI 10.1083/jcb.200303174; Zhu CC, 2008, DEVELOPMENT, V135, P513, DOI 10.1242/dev.010876	107	65	66	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 24	2008	27	55					6994	7002		10.1038/onc.2008.349	http://dx.doi.org/10.1038/onc.2008.349			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	375IU	19029940				2022-12-28	WOS:000261108200011
J	Wang, H; Song, K; Krebs, TL; Yang, J; Danielpour, D				Wang, H.; Song, K.; Krebs, T. L.; Yang, J.; Danielpour, D.			Smad7 is inactivated through a direct physical interaction with the LIM protein Hic-5/ARA55	ONCOGENE			English	Article						Smad; TGF-beta; prostate; Smad2; Smad7; Hic-5	GROWTH-FACTOR-BETA; PLASMINOGEN-ACTIVATOR INHIBITOR-1; FACTOR-KAPPA-B; TGF-BETA; MALIGNANT-TRANSFORMATION; RECEPTOR COACTIVATOR; HIC-5; SUPPRESSION; EXPRESSION; APOPTOSIS	We recently reported that hydrogen peroxide-inducible clone-5 (Hic-5, also named androgen receptor-associated protein 55) can bind to the transforming growth factor-beta (TGF-beta)-signaling regulator Smad3, thereby inhibiting certain Smad3-dependent TGF-beta responses. We now show that Hic-5 can also control TGF-beta responses through an alternative mechanism involving Smad7, a key negative regulator of TGF-beta signaling. Hic-5 binds directly to Smad7. This interaction requires the LIM3 domain of Hic-5, and enhances TGF-beta signaling through causing loss of Smad7 protein but not mRNA. Enforced expression of Hic-5 reverses the ability of Smad7 to suppress TGF-beta-induced phosphorylation of Smads 2 and 3 and activation of the plasminogen activator inhibitor-1 promoter (in NRP-154 and PC3 prostate carcinoma and WPMY-1 prostate myofibroblast cell lines). Lentiviral-mediated small-hairpin RNA silencing of endogenous Hic-5 reduced TGF-beta responses in PC3 and WPMY-1 cells. Further work suggests that the level of Smad7 is modulated by its physical interaction with Hic-5 and targeted to a degradation pathway not likely to be proteasomal. Our findings support that Hic-5 functions as a cell-type-specific activator of TGF-beta signaling through its ability to physically interact with and neutralize Smad7. Oncogene (2008) 27, 6791-6805; doi:10.1038/onc.2008.291;published online 1 September 2008	[Wang, H.; Song, K.; Krebs, T. L.; Danielpour, D.] Case Western Reserve Univ, Case Comprehens Canc Ctr, Div Gen Med Sci Oncol, Dept Pharmacol,Sch Med, Cleveland, OH 44106 USA; [Yang, J.] Case Western Reserve Univ, Dept Biochem, Cleveland, OH 44106 USA	Case Western Reserve University; Case Western Reserve University	Danielpour, D (corresponding author), Case Western Reserve Univ, Case Comprehens Canc Ctr, Div Gen Med Sci Oncol, Dept Pharmacol,Sch Med, Wolstein Res Bldg,Room 3532,2103 Cornell Rd, Cleveland, OH 44106 USA.	david.danielpour@case.edu			NCI [1R01CA102074, 1R01CA092102]; NATIONAL CANCER INSTITUTE [R01CA092102, R01CA102074] Funding Source: NIH RePORTER	NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Dr Joan Massague for 3TP-lux plasmid, Dr Bert Vogelstein for SBE4<INF>BV</INF>-luciferase plasmid, Dr Kohei Miyazono for full-length mouse Flag-Smad7-pcDNA3 plasmid, Dr Bing-Cheng Wang for the pcDNA3-Myc plasmid, Dr Ryosuke Takahashi and Dr Yu-Chung Yang for HA-ubiquitin plasmid, Dr Malcolm Whitman for ARE-lux and Myc-FAST-1. This work was supported by NCI grants 1R01CA102074 and 1R01CA092102.	Chen X, 1997, NATURE, V389, P85, DOI 10.1038/38008; Chipuk JE, 2002, J BIOL CHEM, V277, P26412, DOI 10.1074/jbc.M201244200; Chipuk JE, 2002, J BIOL CHEM, V277, P1240, DOI 10.1074/jbc.M108855200; DABIRI G, 2008, J INVEST DE IN PRESS; DANIELPOUR D, 1994, CANCER RES, V54, P3413; Danielpour D, 2005, EUR J CANCER, V41, P846, DOI 10.1016/j.ejca.2004.12.027; Dong CM, 2002, P NATL ACAD SCI USA, V99, P3908, DOI 10.1073/pnas.062010399; Durand MK, 2004, THROMB HAEMOSTASIS, V91, P438, DOI 10.1160/TH03-12-0784; Ebisawa T, 2001, J BIOL CHEM, V276, P12477, DOI 10.1074/jbc.C100008200; Edlund S, 2003, MOL BIOL CELL, V14, P529, DOI 10.1091/mbc.02-03-0037; Fujimoto N, 1999, J BIOL CHEM, V274, P8316, DOI 10.1074/jbc.274.12.8316; Fujita H, 1998, J BIOL CHEM, V273, P26516, DOI 10.1074/jbc.273.41.26516; Gronroos E, 2002, MOL CELL, V10, P483, DOI 10.1016/S1097-2765(02)00639-1; Hayashi H, 1997, CELL, V89, P1165, DOI 10.1016/S0092-8674(00)80303-7; Heitzer MD, 2006, CANCER RES, V66, P7326, DOI 10.1158/0008-5472.CAN-05-2379; Heitzer MD, 2006, MOL ENDOCRINOL, V20, P56, DOI 10.1210/me.2005-0065; Hong S, 2007, CANCER RES, V67, P9577, DOI 10.1158/0008-5472.CAN-07-1179; Horrevoets AJG, 2004, BRIT J HAEMATOL, V125, P12, DOI 10.1111/j.1365-2141.2004.04844.x; Kavsak P, 2000, MOL CELL, V6, P1365, DOI 10.1016/S1097-2765(00)00134-9; Kim SG, 2005, MOL BIOL CELL, V16, P4672, DOI 10.1091/mbc.E05-01-0054; Koinuma D, 2003, EMBO J, V22, P6458, DOI 10.1093/emboj/cdg632; Komuro A, 2004, ONCOGENE, V23, P6914, DOI 10.1038/sj.onc.1207885; Lallemand F, 2005, J BIOL CHEM, V280, P27645, DOI 10.1074/jbc.M500188200; Lallemand F, 2001, ONCOGENE, V20, P879, DOI 10.1038/sj.onc.1204167; Landstrom M, 2000, CURR BIOL, V10, P535, DOI 10.1016/S0960-9822(00)00470-X; MASSAGUE J, 1992, MOL REPROD DEV, V32, P99, DOI 10.1002/mrd.1080320204; Massague J, 2000, CELL, V103, P295, DOI 10.1016/S0092-8674(00)00121-5; Mazars A, 2001, J BIOL CHEM, V276, P36797, DOI 10.1074/jbc.M101672200; Mori K, 2006, J BIOL CHEM, V281, P22048, DOI 10.1074/jbc.M513111200; Moustakas A, 2005, J CELL SCI, V118, P3573, DOI 10.1242/jcs.02554; Nakao A, 1997, NATURE, V389, P631, DOI 10.1038/39369; Nishiya N, 2001, MOL CELL BIOL, V21, P5332, DOI 10.1128/MCB.21.16.5332-5345.2001; Qin XF, 2003, P NATL ACAD SCI USA, V100, P183, DOI 10.1073/pnas.232688199; Rahimi RA, 2007, J CELL BIOCHEM, V102, P593, DOI 10.1002/jcb.21501; Rahman MM, 2003, P NATL ACAD SCI USA, V100, P5124, DOI 10.1073/pnas.0530097100; Shibanuma M, 2003, MOL BIOL CELL, V14, P1158, DOI 10.1091/mbc.02-06-0099; Shibanuma M, 1997, MOL CELL BIOL, V17, P1224, DOI 10.1128/MCB.17.3.1224; SHIBANUMA M, 1994, J BIOL CHEM, V269, P26767; Simonsson M, 2005, J BIOL CHEM, V280, P21797, DOI 10.1074/jbc.M503134200; Song K, 2006, J BIOL CHEM, V281, P7765, DOI 10.1074/jbc.M511781200; Song K, 2003, J BIOL CHEM, V278, P38342, DOI 10.1074/jbc.M304583200; Song K, 2003, CANCER RES, V63, P4358; Song KY, 2006, EMBO J, V25, P58, DOI 10.1038/sj.emboj.7600917; Tang BW, 1999, CANCER RES, V59, P4834; Thomas SM, 1999, J CELL SCI, V112, P181; Tumbarello DA, 2007, J CELL PHYSIOL, V211, P736, DOI 10.1002/jcp.20991; von Gersdorff G, 2000, J BIOL CHEM, V275, P11320, DOI 10.1074/jbc.275.15.11320; Wakefield LM, 2002, CURR OPIN GENET DEV, V12, P22, DOI 10.1016/S0959-437X(01)00259-3; Wang H, 2005, J BIOL CHEM, V280, P5154, DOI 10.1074/jbc.M411575200; Wang X, 2002, J BIOL CHEM, V277, P15426, DOI 10.1074/jbc.M111218200; Wicks SJ, 2005, ONCOGENE, V24, P8080, DOI 10.1038/sj.onc.1208944; Wilkes MC, 2006, J BIOL CHEM, V281, P27846, DOI 10.1074/jbc.M603721200; Wiznerowicz M, 2003, J VIROL, V77, P8957, DOI 10.1128/JVI.77.16.8957-8951.2003; WRANA JL, 1992, COLD SPRING HARB SYM, V57, P81, DOI 10.1101/SQB.1992.057.01.011; Wrana JL, 1996, TRENDS GENET, V12, P493, DOI 10.1016/S0168-9525(96)30109-1; YANG J, 2008, ONCOGENE IN PRESS; Yue JB, 1999, ONCOGENE, V18, P2033, DOI 10.1038/sj.onc.1202521; Zhang SP, 2007, MOL CELL BIOL, V27, P4488, DOI 10.1128/MCB.01636-06; Zhang Y, 1996, NATURE, V383, P168, DOI 10.1038/383168a0	59	47	49	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 20	2008	27	54					6791	6805		10.1038/onc.2008.291	http://dx.doi.org/10.1038/onc.2008.291			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	375IS	18762808	Green Accepted			2022-12-28	WOS:000261108000001
J	Leeman, JR; Weniger, MA; Barth, TF; Gilmore, TD				Leeman, J. R.; Weniger, M. A.; Barth, T. F.; Gilmore, T. D.			Deletion analysis and alternative splicing define a transactivation inhibitory domain in human oncoprotein REL	ONCOGENE			English	Article						c-Rel; NF-kappa B; alternative splicing; lymphoma; transactivation; inhibition	TRANSCRIPTION FACTOR REL; C-REL; V-REL; PHOSPHORYLATION; INDUCTION; CELLS; PROLIFERATION; STIMULATION; RESIDUES; DEFECTS	Misregulation of REL, a nuclear factor-kappa B family transcription factor, has been implicated in several human lymphoid malignancies. REL has a conserved N-terminal DNA-binding/dimerization domain called the Rel homology domain (RHD) and a C-terminal transactivation domain (TAD). Here, we define the sequences (amino acids (aa) 323-422) between the RHD and TAD as a REL inhibitory domain (RID) because deletion of these sequences increases both REL transactivation and DNA binding. Furthermore, we have characterized two REL mRNA splice variants that encode proteins with alterations near RID: one lacking exon 9 sequences (aa 308-330; RELD9) and one with an exonized Alu fragment insertion of 32 aa after aa 307 (REL + Alu). Deletion of RID or exon 9-encoded sequences increases transactivation by GAL4-REL by approximately threefold. Moreover, deletion of RID or exon 9 sequences increases transactivation by full-length REL from certain kappa B site-containing promoters and increases DNA binding by REL. Deletion of RID does not affect REL's ability to transform chicken spleen cells. Reverse transcriptase-polymerase chain reaction analysis of mRNA from both primary lymphoma samples and several transformed tissue culture cell lines indicates that the RELD9 splice variant is preferentially expressed in lymphoma, suggesting that the REL transcript lacking exon 9 could serve as a marker for certain types of lymphoid tumors.	[Leeman, J. R.; Gilmore, T. D.] Boston Univ, Dept Biol, Boston, MA 02215 USA; [Weniger, M. A.; Barth, T. F.] Univ Ulm, Dept Pathol, Ulm, Germany	Boston University; Ulm University	Gilmore, TD (corresponding author), Boston Univ, Dept Biol, 5 Cummington St, Boston, MA 02215 USA.	gilmore@bu.edu			NIH [CA47763]; Deutsche Krebshilfe [108060]; NATIONAL CANCER INSTITUTE [R01CA047763, R29CA047763] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Deutsche Krebshilfe(Deutsche Krebshilfe); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Mike Garbati, Melanie Herscovitch, Daniel Starczynowski and Francis Wolenski for helpful discussions, and Michaela Buck, Karola Dorsch, Iwona Nerbas and Ingo Melzner for technical assistance. This work was supported by NIH Grant CA47763 (TDG) and a grant from Deutsche Krebshilfe (108060; TFB).	Abid MR, 2004, J BIOL CHEM, V279, P44030, DOI 10.1074/jbc.M408285200; Bourdon JC, 2005, GENE DEV, V19, P2122, DOI 10.1101/gad.1339905; Brown PJ, 2008, BLOOD, V111, P2816, DOI 10.1182/blood-2007-09-115113; BROWNELL E, 1989, ONCOGENE, V4, P935; Bundesarztekammer ZEbd, 2003, DTSCH ARZTEBL, V100, pA1632; Epinat JC, 2000, ONCOGENE, V19, P599, DOI 10.1038/sj.onc.1203376; Gilmore TD, 2004, ONCOGENE, V23, P2275, DOI 10.1038/sj.onc.1207410; Gilmore TD, 2001, ONCOGENE, V20, P7098, DOI 10.1038/sj.onc.1204898; Grumont RJ, 1999, GENE DEV, V13, P400, DOI 10.1101/gad.13.4.400; GRUMONT RJ, 1994, CELL GROWTH DIFFER, V5, P1321; Hayden MS, 2008, CELL, V132, P344, DOI 10.1016/j.cell.2008.01.020; Huang DB, 2001, STRUCTURE, V9, P669, DOI 10.1016/S0969-2126(01)00635-9; Kalaitzidis D, 2002, ONCOGENE, V21, P8759, DOI 10.1038/sj.onc.1206033; Kalaitzidis D, 2002, GENE CHROMOSOME CANC, V34, P129, DOI 10.1002/gcc.10051; KONTGEN F, 1995, GENE DEV, V9, P1965, DOI 10.1101/gad.9.16.1965; LEEMAN JR, 2008, GENE IN PRESS; LIOU HC, 1994, MOL CELL BIOL, V14, P5349, DOI 10.1128/MCB.14.8.5349; Martin AG, 2001, J BIOL CHEM, V276, P15840, DOI 10.1074/jbc.M011313200; MITCHELL T, 1995, J VIROL, V69, P2968, DOI 10.1128/JVI.69.5.2968-2976.1995; O'Rourke JP, 2008, MOL CELL BIOL, V28, P2091, DOI 10.1128/MCB.01870-07; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Sanchez-Aguilera A, 2006, ONCOGENE, V25, P2565, DOI 10.1038/sj.onc.1209282; SCHATZLE JD, 1995, J VIROL, V69, P5383, DOI 10.1128/JVI.69.9.5383-5390.1995; Stamm S, 2005, GENE, V344, P1, DOI 10.1016/j.gene.2004.10.022; Starczynowski DT, 2007, ONCOGENE, V26, P2685, DOI 10.1038/sj.onc.1210089; Starczynowski DT, 2005, ONCOGENE, V24, P7355, DOI 10.1038/sj.onc.1208902; Starczynowski DT, 2003, ONCOGENE, V22, P6928, DOI 10.1038/sj.onc.1206801; Stoilov P, 2002, DNA CELL BIOL, V21, P803, DOI 10.1089/104454902320908450; Yu SH, 2004, J MOL MED, V82, P621, DOI 10.1007/s00109-004-0559-7; Zhong HH, 1998, MOL CELL, V1, P661, DOI 10.1016/S1097-2765(00)80066-0; Zhong HH, 2002, MOL CELL, V9, P625, DOI 10.1016/S1097-2765(02)00477-X	31	18	18	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 13	2008	27	53					6770	6781		10.1038/onc.2008.284	http://dx.doi.org/10.1038/onc.2008.284			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	371XO	18695674	Green Accepted			2022-12-28	WOS:000260866200007
J	Tagscherer, KE; Fassl, A; Campos, B; Farhadi, M; Kraemer, A; Bock, BC; Macher-Goeppinger, S; Radlwimmer, B; Wiestler, OD; Herold-Mende, C; Roth, W				Tagscherer, K. E.; Fassl, A.; Campos, B.; Farhadi, M.; Kraemer, A.; Boeck, B. C.; Macher-Goeppinger, S.; Radlwimmer, B.; Wiestler, O. D.; Herold-Mende, C.; Roth, W.			Apoptosis-based treatment of glioblastomas with ABT-737, a novel small molecule inhibitor of Bcl-2 family proteins	ONCOGENE			English	Article						apoptosis; brain tumors; glioma; ABT-737; Bcl-2 inhibitor	HUMAN-MALIGNANT GLIOMA; BH3 MIMETIC ABT-737; ACUTE LYMPHOBLASTIC-LEUKEMIA; GROWTH-FACTOR-RECEPTOR; CELL LUNG-CANCER; IN-VIVO; STEM-CELLS; IMMUNOHISTOCHEMICAL ANALYSIS; CHEMOTHERAPEUTIC-AGENTS; DOWN-REGULATION	Defects in the apoptotic signaling cascades contribute to the poor therapeutic response of malignant gliomas. As glioblastomas are characterized by high expression levels of anti-apoptotic Bcl-2 family proteins, we studied the effects of the novel Bcl-2 inhibitor, ABT-737, on malignant glioma cells. ABT-737 treatment released the pro-apoptotic Bax protein from its binding partner Bcl-2 and potently induced apoptotic cell death in glioblastoma cells in vitro and in vivo. The local administration of ABT-737 prolonged the survival in an intracranial glioma xenograft model. Downregulation of Mcl-1 and overexpression of Bcl-2 sensitized the cells to ABT-737mediated apoptosis. Moreover, ABT-737 potentiated the cytotoxicity of the chemotherapeutic drugs vincristine and etoposide, and of the death ligand TRAIL. As glioma stem cells may play a crucial role for the tumor progression and the resistance to treatment in glioblastomas, we investigated the effects of ABT-737 on the subpopulation of glioma cells exhibiting stem cell characteristics. Inhibition of proliferation and induction of apoptosis by ABT-737 were less efficient in glioma stem cells than in non-stem cell-like glioma cells. As the resistance of glioma stem cells was associated with high Mcl-1 expression levels, ABT-737 treatment combined with downregulation of Mcl-1 could represent a promising novel approach in glioblastoma treatment.	[Roth, W.] German Canc Res Ctr, DKFZ, D-69120 Heidelberg, Germany; [Campos, B.; Farhadi, M.; Herold-Mende, C.] Heidelberg Univ, Dept Neurosurg, Div Neurosurg Res, Heidelberg, Germany; [Macher-Goeppinger, S.; Roth, W.] Heidelberg Univ, Inst Pathol, Heidelberg, Germany; [Radlwimmer, B.] German Canc Res Ctr, Div Mol Genet, D-69120 Heidelberg, Germany	Helmholtz Association; German Cancer Research Center (DKFZ); Ruprecht Karls University Heidelberg; Ruprecht Karls University Heidelberg; Helmholtz Association; German Cancer Research Center (DKFZ)	Roth, W (corresponding author), German Canc Res Ctr, DKFZ, Neuenheimer Feld 280, D-69120 Heidelberg, Germany.	W.Roth@dkfz.de	Radlwimmer, Bernhard F/I-3229-2013; Fassl, Anne/AAA-5249-2022; Tagscherer, Katrin/AAS-3809-2021	Radlwimmer, Bernhard F/0000-0002-4553-7800; Tagscherer, Katrin/0000-0002-0657-6399	Deutsche Krebshilfe	Deutsche Krebshilfe(Deutsche Krebshilfe)	This work was supported by a grant from the Deutsche Krebshilfe to WR (German Cancer Aid, Max Eder Program). We thank Ilona Demir, Monika Frank-Stohr and Sarah MeBnard for expert technical assistance. We thank Manfred Jugold (Molecular Imaging, German Cancer Research Center) for performing magnetic resonance imaging of animals.	Adams JM, 2005, COLD SH Q B, V70, P469, DOI 10.1101/sqb.2005.70.009; Ahmadi R, 2006, FREE RADICAL BIO MED, V40, P763, DOI 10.1016/j.freeradbiomed.2005.09.031; Bao SD, 2006, NATURE, V444, P756, DOI 10.1038/nature05236; CAMPOS B, 2008, DIFFERENTIATIO UNPUB; Certo M, 2006, CANCER CELL, V9, P351, DOI 10.1016/j.ccr.2006.03.027; Chauhan D, 2007, ONCOGENE, V26, P2374, DOI 10.1038/sj.onc.1210028; Chawla-Sarkar M, 2004, CELL DEATH DIFFER, V11, P915, DOI 10.1038/sj.cdd.4401416; Chen S, 2007, CANCER RES, V67, P782, DOI 10.1158/0008-5472.CAN-06-3964; Cragg MS, 2007, PLOS MED, V4, P1681, DOI 10.1371/journal.pmed.0040316; Del Bufalo D, 2001, J CELL BIOCHEM, V83, P473, DOI 10.1002/jcb.1245; Deng J, 2007, CANCER RES, V67, P11867, DOI 10.1158/0008-5472.CAN-07-1961; Deng J, 2007, CANCER CELL, V12, P171, DOI 10.1016/j.ccr.2007.07.001; Dictus C, 2007, J NEUROSCI METH, V161, P250, DOI 10.1016/j.jneumeth.2006.11.012; Eramo A, 2006, CELL DEATH DIFFER, V13, P1238, DOI 10.1038/sj.cdd.4401872; Fulda S, 2002, ONCOGENE, V21, P2283, DOI 10.1038/sj.onc.1205258; Fulda S, 2002, NAT MED, V8, P808, DOI 10.1038/nm735; GILLIES RJ, 1986, ANAL BIOCHEM, V159, P109, DOI 10.1016/0003-2697(86)90314-3; Glaser T, 1999, ONCOGENE, V18, P5044, DOI 10.1038/sj.onc.1202882; Gong YX, 2007, PLOS MED, V4, P1655, DOI 10.1371/journal.pmed.0040294; Green DR, 2006, CANCER CELL, V9, P328, DOI 10.1016/j.ccr.2006.05.004; Hann CL, 2008, CANCER RES, V68, P2321, DOI 10.1158/0008-5472.CAN-07-5031; Huang SB, 2008, CANCER RES, V68, P2944, DOI 10.1158/0008-5472.CAN-07-2508; Kajiwara Y, 2003, CANCER-AM CANCER SOC, V97, P1077, DOI 10.1002/cncr.11122; Kang MH, 2008, JNCI-J NATL CANCER I, V100, P580, DOI 10.1093/jnci/djn076; Kang MH, 2007, BLOOD, V110, P2057, DOI 10.1182/blood-2007-03-080325; Karcher S, 2006, INT J CANCER, V118, P2182, DOI 10.1002/ijc.21648; Konopleva M, 2006, CANCER CELL, V10, P375, DOI 10.1016/j.ccr.2006.10.006; Krajewski S, 1997, AM J PATHOL, V150, P805; KRAJEWSKI S, 1995, AM J PATHOL, V146, P1309; Kraus JA, 2001, J NEURO-ONCOL, V52, P263, DOI 10.1023/A:1010684203704; Letai A, 2006, CANCER CELL, V10, P343, DOI 10.1016/j.ccr.2006.10.014; Lin X, 2007, ONCOGENE, V26, P3972, DOI 10.1038/sj.onc.1210166; Moore VD, 2008, BLOOD, V111, P2300, DOI 10.1182/blood-2007-06-098012; Moore VD, 2007, J CLIN INVEST, V117, P112, DOI 10.1172/JCI28281; Nagane M, 2000, CANCER RES, V60, P847; Nagane M, 1998, P NATL ACAD SCI USA, V95, P5724, DOI 10.1073/pnas.95.10.5724; Olejniczak ET, 2007, MOL CANCER RES, V5, P331, DOI 10.1158/1541-7786.MCR-06-0367; Oltersdorf T, 2005, NATURE, V435, P677, DOI 10.1038/nature03579; Pollack IF, 2001, CLIN CANCER RES, V7, P1362; Reed JC, 2006, NAT CLIN PRACT ONCOL, V3, P388, DOI 10.1038/ncponc0538; Rieger J, 1998, FEBS LETT, V427, P124, DOI 10.1016/S0014-5793(98)00409-8; Riemenschneider MJ, 2006, CANCER RES, V66, P5618, DOI 10.1158/0008-5472.CAN-06-0364; Roth W, 1999, BIOCHEM BIOPH RES CO, V265, P479, DOI 10.1006/bbrc.1999.1693; Sanai N, 2005, NEW ENGL J MED, V353, P811, DOI 10.1056/NEJMra043666; Sinicrope FA, 2004, CLIN CANCER RES, V10, P8284, DOI 10.1158/1078-0432.CCR-04-1289; Stupp R, 2007, NAT BIOTECHNOL, V25, P193, DOI 10.1038/nbt0207-193; Tahir SK, 2007, CANCER RES, V67, P1176, DOI 10.1158/0008-5472.CAN-06-2203; Trudel S, 2007, CLIN CANCER RES, V13, P621, DOI 10.1158/1078-0432.CCR-06-1526; Tse C, 2008, CANCER RES, V68, P3421, DOI 10.1158/0008-5472.CAN-07-5836; van Delft MF, 2006, CANCER CELL, V10, P389, DOI 10.1016/j.ccr.2006.08.027; Wagenknecht B, 1999, CELL DEATH DIFFER, V6, P370, DOI 10.1038/sj.cdd.4400503; Webb JL, 1963, ENZYMES METABOL INH, V1, P487; Weiler M, 2006, CELL DEATH DIFFER, V13, P1156, DOI 10.1038/sj.cdd.4401786; WELLER M, 1995, J CLIN INVEST, V95, P2633, DOI 10.1172/JCI117965; Zangemeister-Wittke U, 2003, ANN NY ACAD SCI, V1002, P90, DOI 10.1196/annals.1281.019	55	169	171	1	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV	2008	27	52					6646	6656		10.1038/onc.2008.259	http://dx.doi.org/10.1038/onc.2008.259			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	368QY	18663354				2022-12-28	WOS:000260638800003
J	Rebillard, A; Rioux-Leclercq, N; Muller, C; Bellaud, P; Jouan, F; Meurette, O; Jouan, E; Vernhet, L; Le Quement, C; Carpinteiro, A; Schenck, M; Lagadic-Gossmann, D; Gulbins, E; Dimanche-Boitrel, MT				Rebillard, A.; Rioux-Leclercq, N.; Muller, C.; Bellaud, P.; Jouan, F.; Meurette, O.; Jouan, E.; Vernhet, L.; Le Quement, C.; Carpinteiro, A.; Schenck, M.; Lagadic-Gossmann, D.; Gulbins, E.; Dimanche-Boitrel, M. T.			Acid sphingomyelinase deficiency protects from cisplatin-induced gastrointestinal damage	ONCOGENE			English	Article						acid sphingomyelinase; cisplatin; small intestine; endothelial cells; p53	RADIATION-INDUCED APOPTOSIS; COLON-CANCER CELLS; MICE; ACTIVATION; TOXICITY; CERAMIDE; ANALOGS; DRUGS	Cisplatin is one of the most effectively used chemotherapeutic agents for cancer treatment. However, in humans, important cytotoxic side effects are observed including dose-limiting renal damage and profound gastrointestinal symptomatology. The toxic responses to cisplatin in mice are similar to those in human patients. Here, we evaluated whether the acid sphingomyelinase (Asm) mediates at least some of the toxic in vivo effects of cisplatin. To this end, we determined the toxic effects of a single intraperitoneal dose of cisplatin (27 mg/kg) in wild type (Asm(+/+)) and Asm-deficient mice (Asm(-/-)). Tissue injury and apoptosis were determined histologically on hematox-ylin-eosin and TUNEL ( terminal deoxynucleotidyl transferase (TdT)-mediated nick end labeling) stainings 3, 12, 36 and 72 h after treatment. Our results revealed severe toxicity of cisplatin in Asm(+/+) mice with increased numbers of apoptotic cells in the thymus and small intestine. In marked contrast, Asm(-/-) mice were resistant to cisplatin and no apoptosis was observed in these organs after treatment. Moreover, cisplatin treatment primarily triggered apoptosis of endothelial cells in microvessels of intestine and thymus, an effect that was absent in mice lacking Asm. The data thus suggest that at least some toxic effects of cisplatin are mediated by the Asm in vivo resulting in early death of endothelial cells and consecutive organ damage.	[Rebillard, A.; Muller, C.; Meurette, O.; Jouan, E.; Vernhet, L.; Le Quement, C.; Lagadic-Gossmann, D.; Dimanche-Boitrel, M. T.] INSERM, UMR620, IFR GFAS 140, Rennes, France; [Rebillard, A.; Meurette, O.; Jouan, E.; Vernhet, L.; Le Quement, C.; Lagadic-Gossmann, D.; Dimanche-Boitrel, M. T.] Univ Rennes, UPRES EA SeRAIC, Rennes, France; [Rioux-Leclercq, N.; Bellaud, P.] Rennes Univ, Dept Pathol, Rennes, France; [Rioux-Leclercq, N.; Jouan, F.] Rennes Univ, CNRS, UMR6061, Rennes, France; [Carpinteiro, A.; Schenck, M.; Gulbins, E.] Univ Duisburg Essen, Dept Mol Biol, Essen, Germany	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Rennes; Universite de Rennes; Centre National de la Recherche Scientifique (CNRS); Universite de Rennes; University of Duisburg Essen	Dimanche-Boitrel, MT (corresponding author), Univ Rennes 1, INSERM, UMR620, Fac Pharm, 2 Av Pr Leon Bernard, F-35043 Rennes, France.	marie-therese.boitrel@rennes.inserm.fr	LAGADIC-GOSSMANN, Dominique/I-5079-2015; VERNHET, Laurent/K-3364-2015; Dimanche-Boitrel, Marie-Therese M/I-4642-2015; Gulbins, Erich/L-6989-2014	LAGADIC-GOSSMANN, Dominique/0000-0002-4888-236X; Gulbins, Erich/0000-0002-3117-1342; Dimanche-Boitrel, Marie-Therese/0000-0002-8038-7780; Vernhet, Laurent/0000-0001-6476-7583	Ligue Nationale Contre le Cancer; Region Bretagne [DFG-10-2238-Gu2]	Ligue Nationale Contre le Cancer(Ligue nationale contre le cancer); Region Bretagne(Region Bretagne)	We thank F Paris, M Le Vee and I Guenon. This study was supported by grants from the Ligue Nationale Contre le Cancer ( the Cote d'Armor, Ille et Vilaine and Loire-Atlantique Committees), Rennes Metropole, the Region Bretagne and DFG-10-2238-Gu2.	ALLAN SG, 1986, BRIT J CANCER, V53, P355, DOI 10.1038/bjc.1986.59; Bezombes C, 2004, BLOOD, V104, P1166, DOI 10.1182/blood-2004-01-0277; GRUNICKE H, 1992, PHARMACOL THERAPEUT, V55, P1, DOI 10.1016/0163-7258(92)90027-W; Gulbins E, 2003, ONCOGENE, V22, P7070, DOI 10.1038/sj.onc.1207146; Gulbins E, 2002, BBA-MOL CELL BIOL L, V1585, P139, DOI 10.1016/S1388-1981(02)00334-7; Harrison S D Jr, 1981, Fundam Appl Toxicol, V1, P382, DOI 10.1093/toxsci/1.5.382; HORINOUCHI K, 1995, NAT GENET, V10, P288, DOI 10.1038/ng0795-288; Huang CS, 1997, J BIOL CHEM, V272, P27753, DOI 10.1074/jbc.272.44.27753; Lacour S, 2004, CANCER RES, V64, P3593, DOI 10.1158/0008-5472.CAN-03-2787; LOEHRER PJ, 1984, ANN INTERN MED, V100, P704, DOI 10.7326/0003-4819-100-5-704; Morita Y, 2000, NAT MED, V6, P1109, DOI 10.1038/80442; Paris F, 2001, SCIENCE, V293, P293, DOI 10.1126/science.1060191; Pena LA, 2000, CANCER RES, V60, P321; PRESTAYKO AW, 1979, CANCER TREAT REP, V63, P1503; Rebillard A, 2007, CANCER RES, V67, P7865, DOI 10.1158/0008-5472.CAN-07-0353; Sansom OJ, 2002, ONCOGENE, V21, P5934, DOI 10.1038/sj.onc.1205760; Santana P, 1996, CELL, V86, P189, DOI 10.1016/S0092-8674(00)80091-4; Tamaki T, 2003, J INT MED RES, V31, P6, DOI 10.1177/147323000303100102; Vasey PA, 1996, MOL PHARMACOL, V50, P1536	19	30	32	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 30	2008	27	51					6590	6595		10.1038/onc.2008.257	http://dx.doi.org/10.1038/onc.2008.257			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	366RS	18679423				2022-12-28	WOS:000260501700006
J	Campoli, M; Ferrone, S				Campoli, M.; Ferrone, S.			HLA antigen changes in malignant cells: epigenetic mechanisms and biologic significance	ONCOGENE			English	Review						antigen processing machinery; cancer; HLA antigen; epigenetic; immune escape; NK cell-activating ligand	MHC-CLASS-II; HISTONE DEACETYLASE INHIBITORS; NATURAL-KILLER-CELLS; LOW-DOSE 5-AZA-2'-DEOXYCYTIDINE; INVARIANT CHAIN EXPRESSION; REGULATORY T-CELLS; DNA METHYLATION; GENE-EXPRESSION; B-CELL; TUMOR-CELLS	Changes in classical and nonclassical HLA class I as well as HLA class II antigens have been identified in malignant lesions. These changes, which are described in this review are believed to play a major role in the clinical course of the disease since both HLA class I and class II antigens are critical to the interaction between tumor cells and components of both innate and adaptive immune system. Abnormalities in HLA antigen expression in malignant cells, which range in frequency from 0-90%, are caused by distinct mechanisms. They include defects in beta(2)-microglobulin (beta(2)m) synthesis, loss of the gene(s) encoding HLA antigen heavy chain(s), mutations, which inhibit HLA antigen heavy chain transcription or translation, defects in the regulatory mechanisms, which control HLA antigen expression and/or abnormalities in one or more of the antigen processing, machinery (APM) components. More recently, epigenetic events associated with tumor development and progression have been found to underlie changes in HLA antigen, APM component, costimulatory molecule and tumor antigen (TA) expression in malignant cells. The types of epigenetic modi. cations that may occur in normal and malignant cells as well as their role in changes in HLA antigen expression by malignant cells have been reviewed. The epigenetic events associated with alterations in HLA antigen expression may be clinically relevant as, in some cases, they have been shown to impair the recognition of tumor cells by components of the adaptive immune system. The functional relevance and potential clinical significance of these epigenetic alterations have been addressed. Finally, unlike genetic alterations, epigenetic modi. cations can, in some cases, be reversed with pharmacologic agents that induce DNA hypomethylation or inhibit histone deacetylation. Therefore, strategies to overcome epigenetic modi. cations underlying changes in HLA antigen expression in malignant cells have been discussed.	[Ferrone, S.] Univ Pittsburgh, Inst Canc, Dept Surg, Pittsburgh, PA 15213 USA; [Ferrone, S.] Univ Pittsburgh, Inst Canc, Dept Pathol & Immunol, Pittsburgh, PA 15213 USA; [Campoli, M.] Univ Colorado, Hlth Sci Ctr, Dept Dermatol, Denver, CO 80202 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Ferrone, S (corresponding author), Univ Pittsburgh, Inst Canc, Dept Surg, Pittsburgh, PA 15213 USA.	soldano.ferrone@roswellpark.org			NATIONAL CANCER INSTITUTE [R01CA110249] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA110249, R01 CA110249-03] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Acharya MR, 2005, MOL PHARMACOL, V68, P917, DOI 10.1124/mol.105.014167; Altomonte M, 2003, ONCOGENE, V22, P6564, DOI 10.1038/sj.onc.1206960; Backstrom E, 2004, SCAND J IMMUNOL, V60, P14, DOI 10.1111/j.0300-9475.2004.01475.x; Bedford MT, 2005, MOL CELL, V18, P263, DOI 10.1016/j.molcel.2005.04.003; Berezikov E, 2005, CELL, V120, P21, DOI 10.1016/j.cell.2004.12.031; Bernsen MR, 2003, BRIT J CANCER, V88, P424, DOI 10.1038/sj.bjc.6600703; Bhalla KN, 2005, J CLIN ONCOL, V23, P3971, DOI 10.1200/JCO.2005.16.600; Bluestone JA, 2005, CURR OPIN IMMUNOL, V17, P638, DOI 10.1016/j.coi.2005.09.002; Bovenzi V, 1999, ANTI-CANCER DRUG, V10, P471, DOI 10.1097/00001813-199906000-00007; CABRERA T, 1995, SCAND J IMMUNOL, V41, P398, DOI 10.1111/j.1365-3083.1995.tb03584.x; Calin GA, 2004, P NATL ACAD SCI USA, V101, P11755, DOI 10.1073/pnas.0404432101; Campoli M, 2005, CANC TREAT, V123, P61; CAMPOLI M, 2006, EXPERT REV DERMATOL, V1, P737; Campoli Michael, 2004, Breast Dis, V20, P105; Chamuleau MED, 2006, IMMUNOBIOLOGY, V211, P619, DOI 10.1016/j.imbio.2006.05.005; Chan JA, 2005, CANCER RES, V65, P6029, DOI 10.1158/0008-5472.CAN-05-0137; Chang CC, 2005, ADV CANCER RES, V93, P189, DOI 10.1016/S0065-230X(05)93006-6; Chang CC, 2003, HUM IMMUNOL, V64, P1057, DOI 10.1016/j.humimm.2003.08.357; Chang CC, 2003, SEMIN CANCER BIOL, V13, P361, DOI 10.1016/S1044-579X(03)00027-0; Chang CC, 2007, CANCER IMMUNOL IMMUN, V56, P227, DOI 10.1007/s00262-006-0183-1; Chang CC, 2006, SEMIN CANCER BIOL, V16, P383, DOI 10.1016/j.semcancer.2006.07.001; Chattopadhyay S, 2005, CANCER IMMUNOL IMMUN, V54, P1153, DOI 10.1007/s00262-005-0699-9; Chil A, 2003, ACTA OBSTET GYN SCAN, V82, P1146, DOI 10.1046/j.1600-0412.2003.00252.x; Chiorean EG, 2003, BLOOD, V101, P3527, DOI 10.1182/blood-2002-04-1172; Chou SD, 2005, INT IMMUNOL, V17, P1483, DOI 10.1093/intimm/dxh326; Chuang JC, 2005, MOL CANCER THER, V4, P1515, DOI 10.1158/1535-7163.MCT-05-0172; CHUANG WL, 1990, CANCER, V65, P926, DOI 10.1002/1097-0142(19900215)65:4<926::AID-CNCR2820650418>3.0.CO;2-U; Chuikov S, 2004, NATURE, V432, P353, DOI 10.1038/nature03117; Coral S, 2006, J CELL PHYSIOL, V207, P58, DOI 10.1002/jcp.20540; CORAL S, 2007, CANCER RES, V66, P1105; Cresswell P, 2005, IMMUNOL REV, V207, P5, DOI 10.1111/j.0105-2896.2005.00320.x; De Ruijter AJM, 2003, BIOCHEM J, V370, P737, DOI 10.1042/BJ20021321; Demanet C, 2004, BLOOD, V103, P3122, DOI 10.1182/blood-2003-07-2500; Di Croce L, 2002, SCIENCE, V295, P1079, DOI 10.1126/science.1065173; DREXLER HG, 1988, CLIN EXP IMMUNOL, V71, P217; Dunker K, 2008, TISSUE ANTIGENS, V72, P137, DOI 10.1111/j.1399-0039.2008.01090.x; Dunn GP, 2002, NAT IMMUNOL, V3, P991, DOI 10.1038/ni1102-991; Egger G, 2004, NATURE, V429, P457, DOI 10.1038/nature02625; Eramo A, 2005, CANCER RES, V65, P11469, DOI 10.1158/0008-5472.CAN-05-1724; Esteller M, 2006, BRIT J CANCER, V94, P179, DOI 10.1038/sj.bjc.6602918; Esteller M, 2003, LANCET ONCOL, V4, P351, DOI 10.1016/S1470-2045(03)01115-X; Fang JY, 2003, WORLD J GASTROENTERO, V9, P1976, DOI 10.3748/wjg.v9.i9.1976; Feinberg AP, 2004, NAT REV CANCER, V4, P143, DOI 10.1038/nrc1279; Florenes VA, 2004, MELANOMA RES, V14, P173, DOI 10.1097/01.cmr.0000129579.49313.26; Fonsatti E, 2003, INT J CANCER, V105, P430, DOI 10.1002/ijc.11077; Fonsatti E, 2007, CLIN CANCER RES, V13, P3333, DOI 10.1158/1078-0432.CCR-06-3091; Fraga MF, 2005, CELL CYCLE, V4, P1377, DOI 10.4161/cc.4.10.2113; French LE, 2002, SEMIN CANCER BIOL, V12, P51, DOI 10.1006/scbi.2001.0405; Friese MA, 2004, CANCER RES, V64, P7596, DOI 10.1158/0008-5472.CAN-04-1627; Fuks F, 2001, EMBO J, V20, P2536, DOI 10.1093/emboj/20.10.2536; Germenis AE, 2007, IMMUNOL CELL BIOL, V85, P55, DOI 10.1038/sj.icb.7100006; Ghosh N, 2001, J BIOL CHEM, V276, P15264, DOI 10.1074/jbc.M100862200; Gollob JA, 2006, CLIN CANCER RES, V12, P4619, DOI 10.1158/1078-0432.CCR-06-0883; Grewal SIS, 2003, SCIENCE, V301, P798, DOI 10.1126/science.1086887; Guo ZS, 2006, CANCER RES, V66, P1105, DOI 10.1158/0008-5472.CAN-05-3020; Herman JG, 2003, NEW ENGL J MED, V349, P2042, DOI 10.1056/NEJMra023075; Hunt JS, 2006, REPROD BIOL ENDOCRIN, V4, DOI 10.1186/1477-7827-4-S1-S10; Insinga A, 2005, NAT MED, V11, P71, DOI 10.1038/nm1160; Issa JPJ, 2004, BLOOD, V103, P1635, DOI 10.1182/blood-2003-03-0687; Jiang Z, 1999, VIRCHOWS ARCH, V435, P32, DOI 10.1007/s004280050391; Jinushi M, 2003, INT J CANCER, V104, P354, DOI 10.1002/ijc.10966; Johnsen AK, 1999, J IMMUNOL, V163, P4224; Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816; Kanaseki T, 2003, J IMMUNOL, V170, P4980, DOI 10.4049/jimmunol.170.10.4980; Kawasaki H, 2004, NATURE, V431, P211, DOI 10.1038/nature02889; Khan ANH, 2008, CANCER IMMUNOL IMMUN, V57, P647, DOI 10.1007/s00262-007-0402-4; Khan ANH, 2004, CANCER IMMUNOL IMMUN, V53, P748, DOI 10.1007/s00262-004-0513-0; Kim R, 2007, IMMUNOLOGY, V121, P1, DOI 10.1111/j.1365-2567.2007.02587.x; Knutson KL, 2005, CANCER IMMUNOL IMMUN, V54, P721, DOI 10.1007/s00262-004-0653-2; Lachner M, 2003, J CELL SCI, V116, P2117, DOI 10.1242/jcs.00493; LECCHI M, 1989, LEUKEMIA RES, V13, P221, DOI 10.1016/0145-2126(89)90015-5; Lee N, 2003, J IMMUNOL, V171, P5264, DOI 10.4049/jimmunol.171.10.5264; Lettini AA, 2007, HISTOL HISTOPATHOL, V22, P1413, DOI 10.14670/HH-22.1413; Li H, 2004, BIOCHEM BIOPH RES CO, V324, P860, DOI 10.1016/j.bbrc.2004.09.130; Lin A, 2007, ANN ONCOL, V18, P1804, DOI 10.1093/annonc/mdm356; Lozupone F, 2003, EUR J IMMUNOL, V33, P556, DOI 10.1002/immu.200310032; Lucas DM, 2004, LEUKEMIA, V18, P1207, DOI 10.1038/sj.leu.2403388; Magner WJ, 2000, J IMMUNOL, V165, P7017, DOI 10.4049/jimmunol.165.12.7017; Maio M, 2003, ONCOGENE, V22, P6484, DOI 10.1038/sj.onc.1206956; Malmberg KJ, 2002, J CLIN INVEST, V110, P1515, DOI 10.1172/JC1200215564; Mann BS, 2007, ONCOLOGIST, V12, P1247, DOI 10.1634/theoncologist.12-10-1247; Marsman M, 2005, ADV CANCER RES, V93, P129, DOI 10.1016/S0065-230X(05)93004-2; Moore PS, 2004, BBA-MOL CELL RES, V1693, P167, DOI 10.1016/j.bbamcr.2004.07.001; Morandi F, 2007, CANCER RES, V67, P6433, DOI 10.1158/0008-5472.CAN-06-4588; Moretta L, 2005, IMMUNOL LETT, V100, P7, DOI 10.1016/j.imlet.2005.07.004; Morimoto Y, 2004, BRIT J CANCER, V90, P844, DOI 10.1038/sj.bjc.6601602; Natoni F, 2005, BBA-MOL CELL RES, V1745, P318, DOI 10.1016/j.bbamcr.2005.07.003; Neumeister P, 2002, INT J BIOCHEM CELL B, V34, P1475, DOI 10.1016/S1357-2725(02)00079-1; Nie Y, 2001, CARCINOGENESIS, V22, P1615, DOI 10.1093/carcin/22.10.1615; Ogretmen B, 1998, BIOCHEMISTRY-US, V37, P11679, DOI 10.1021/bi980573c; Ono K, 1996, J CLIN IMMUNOL, V16, P41, DOI 10.1007/BF01540971; Ostrand-Rosenberg S, 2004, CURR OPIN IMMUNOL, V16, P143, DOI 10.1016/j.coi.2004.01.003; Pierson BA, 1996, BLOOD, V88, P2279, DOI 10.1182/blood.V88.6.2279.bloodjournal8862279; Pistoia V, 2007, SEMIN CANCER BIOL, V17, P469, DOI 10.1016/j.semcancer.2007.07.004; Reith W, 2005, NAT REV IMMUNOL, V5, P793, DOI 10.1038/nri1708; Rodriguez T, 2007, BMC CANCER, V7, DOI 10.1186/1471-2407-7-34; Rouas-Freiss N, 2007, SEMIN CANCER BIOL, V17, P413, DOI 10.1016/j.semcancer.2007.07.003; Ruiter D J, 1991, Semin Cancer Biol, V2, P35; Satoh A, 2004, ONCOGENE, V23, P8876, DOI 10.1038/sj.onc.1208144; Scanlan MJ, 2002, IMMUNOL REV, V188, P22, DOI 10.1034/j.1600-065X.2002.18803.x; Schrump DS, 2006, CLIN CANCER RES, V12, P5777, DOI 10.1158/1078-0432.CCR-06-0669; Sebti Y, 2007, BRIT J HAEMATOL, V138, P202, DOI 10.1111/j.1365-2141.2007.06647.x; Seliger B, 2000, IMMUNOL TODAY, V21, P455, DOI 10.1016/S0167-5699(00)01692-3; SELIGER B, 2008, CANC IMMUNOL IMMUNOT; Serrano A, 2001, INT J CANCER, V94, P243, DOI 10.1002/ijc.1452; Setiadi AF, 2007, MOL CELL BIOL, V27, P7886, DOI 10.1128/MCB.01547-07; Sheu JJC, 2007, SEMIN CANCER BIOL, V17, P436, DOI 10.1016/j.semcancer.2007.06.012; Shogren-Knaak M, 2006, SCIENCE, V311, P844, DOI 10.1126/science.1124000; Sigalotti L, 2004, CANCER RES, V64, P9167, DOI 10.1158/0008-5472.CAN-04-1442; Sigalotti L, 2003, BLOOD, V101, P4644, DOI 10.1182/blood-2002-11-3458; SIGALOTTI L, 2002, BLOOD, V100, P2957; Sims RJ, 2003, TRENDS GENET, V19, P629, DOI 10.1016/j.tig.2003.09.007; Singh NP, 2003, CANCER RES, V63, P4067; Sontheimer EJ, 2005, CELL, V122, P9, DOI 10.1016/j.cell.2005.06.030; Szyf M, 2005, BIOCHEMISTRY-MOSCOW+, V70, P533, DOI 10.1007/s10541-005-0147-7; Takamura Y, 2004, GLIA, V45, P392, DOI 10.1002/glia.10343; Tamori Y, 2005, ONCOL REP, V14, P873; Tomasi TB, 2006, CANCER IMMUNOL IMMUN, V55, P1159, DOI 10.1007/s00262-006-0164-4; van den Elsen PJ, 2000, HUM IMMUNOL, V61, P850, DOI 10.1016/S0198-8859(00)00159-2; van der Stoep N, 2002, INT J CANCER, V97, P501, DOI 10.1002/ijc.1623; VERFAILLIE C, 1990, BLOOD, V76, P401; Villar-Garea A, 2004, INT J CANCER, V112, P171, DOI 10.1002/ijc.20372; Wang E, 2005, SPRINGER SEMIN IMMUN, V27, P105, DOI 10.1007/s00281-004-0198-7; Wassenegger M, 2005, CELL, V122, P13, DOI 10.1016/j.cell.2005.06.034; Whiteside TL, 2005, ANALYZING T CELL RESPONSES: HOW TO ANALYZE CELLULAR IMMUNE RESPONSES AGAINST TUMOR ASSOCIATED ANTIGENS, P43, DOI 10.1007/1-4020-3623-X_3; Wijermans P, 2000, J CLIN ONCOL, V18, P956, DOI 10.1200/JCO.2000.18.5.956; Wischhusell J, 2007, SEMIN CANCER BIOL, V17, P459, DOI 10.1016/j.semcancer.2007.07.005; Wright KL, 2006, TRENDS IMMUNOL, V27, P405, DOI 10.1016/j.it.2006.07.007; Ye SR, 2007, MODERN PATHOL, V20, P375, DOI 10.1038/modpathol.3800751; Yie SM, 2007, LUNG CANCER, V58, P267, DOI 10.1016/j.lungcan.2007.06.011; Yie SM, 2007, ANN SURG ONCOL, V14, P2721, DOI 10.1245/s10434-007-9464-y; Yu J, 2000, MOL CELL BIOL, V20, P2592, DOI 10.1128/MCB.20.7.2592-2603.2000	132	280	289	3	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 6	2008	27	45					5869	5885		10.1038/onc.2008.273	http://dx.doi.org/10.1038/onc.2008.273			17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	355QE	18836468	Green Accepted			2022-12-28	WOS:000259722600002
J	Whiteside, TL				Whiteside, T. L.			The tumor microenvironment and its role in promoting tumor growth	ONCOGENE			English	Review						chronic inflammation; human tumors; immune suppression; tumor escape	REGULATORY T-CELLS; MYELOID SUPPRESSOR-CELLS; INFILTRATING LYMPHOCYTES; PERIPHERAL-BLOOD; KAPPA-B; CLINICAL-SIGNIFICANCE; IMMUNE SUPPRESSION; PROGNOSTIC-FACTOR; DENDRITIC CELLS; NECROSIS-FACTOR	The tumor microenvironment is created by the tumor and dominated by tumor-induced interactions. Although various immune effector cells are recruited to the tumor site, their anti-tumor functions are downregulated, largely in response to tumor-derived signals. Infiltrates of inflammatory cells present in human tumors are chronic in nature and are enriched in regulatory T cells (T-reg) as well as myeloid suppressor cells (MSC). Immune cells in the tumor microenvironment not only fail to exercise anti-tumor effector functions, but they are co-opted to promote tumor growth. Sustained activation of the NF-kappa B pathway in the tumor milieu represents one mechanism that appears to favor tumor survival and drive abortive activation of immune cells. The result is tumor escape from the host immune system. Tumor escape is accomplished through the activation of one or several molecular mechanisms that lead to inhibition of immune cell functions or to apoptosis of anti-tumor effector cells. The ability to block tumor escape depends on a better understanding of cellular and molecular pathways operating in the tumor microenvironment. Novel therapeutic strategies that emerge are designed to change the protumor microenvironment to one favoring acute responses and potent anti-tumor activity.	[Whiteside, T. L.] Hillman Canc Ctr, Pittsburgh, PA 15213 USA; [Whiteside, T. L.] Univ Pittsburgh, Sch Med, Pittsburgh, PA USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Whiteside, TL (corresponding author), Hillman Canc Ctr, Suite L1-27,5117 Ctr Ave, Pittsburgh, PA 15213 USA.	whitesidetl@upmc.edu	木子, 瑞/N-8882-2015		NIH [PO-1 CA 109688]; NATIONAL CANCER INSTITUTE [P01CA109688] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This article was supported in part by the NIH Grant PO-1 CA109688.	ALBERS AE, 2002, CANCER IMMUNOL IMMUN, V62, P670; Aller MA, 2004, EXP BIOL MED, V229, P170, DOI 10.1177/153537020422900206; Almand B, 2000, CLIN CANCER RES, V6, P1755; Almand B, 2001, J IMMUNOL, V166, P678, DOI 10.4049/jimmunol.166.1.678; Bacchetta R, 2007, J ALLERGY CLIN IMMUN, V120, P227, DOI 10.1016/j.jaci.2007.06.023; Balkwill F, 2001, LANCET, V357, P539, DOI 10.1016/S0140-6736(00)04046-0; Balkwill F, 2004, NATURE, V431, P405, DOI 10.1038/431405a; Banerjee DK, 2006, BLOOD, V108, P2655, DOI 10.1182/blood-2006-03-011353; BAXEVANIS CN, 1994, CANCER, V74, P1275, DOI 10.1002/1097-0142(19940815)74:4<1275::AID-CNCR2820740416>3.0.CO;2-Q; Bergmann C, 2007, CANCER RES, V67, P8865, DOI 10.1158/0008-5472.CAN-07-0767; Bronte V, 2003, TRENDS IMMUNOL, V24, P302, DOI 10.1016/S1471-4906(03)00132-7; Chang CC, 2005, ADV CANCER RES, V93, P189, DOI 10.1016/S0065-230X(05)93006-6; Chen AS, 2007, CANCER RES, V67, P1291, DOI 10.1158/0008-5472.CAN-06-2622; Coronella JA, 2002, J IMMUNOL, V169, P1829, DOI 10.4049/jimmunol.169.4.1829; Curiel TJ, 2004, NAT MED, V10, P942, DOI 10.1038/nm1093; Denko NC, 2003, ONCOGENE, V22, P5907, DOI 10.1038/sj.onc.1206703; DRANOFF G, 1993, P NATL ACAD SCI USA, V90, P3539, DOI 10.1073/pnas.90.8.3539; DVORAK HF, 1986, NEW ENGL J MED, V315, P1650; Ferrone S, 2007, SURG ONCOL CLIN N AM, V16, P755, DOI 10.1016/j.soc.2007.08.004; Filipazzi P, 2007, J CLIN ONCOL, V25, P2546, DOI 10.1200/JCO.2006.08.5829; Fricke I, 2006, IMMUNOL INVEST, V35, P459, DOI 10.1080/08820130600803429; Gabrilovich DI, 1999, CLIN CANCER RES, V5, P2963; Gallina G, 2006, J CLIN INVEST, V116, P2777, DOI 10.1172/JCI28828; Gallucci S, 2001, CURR OPIN IMMUNOL, V13, P114, DOI 10.1016/S0952-7915(00)00191-6; Galon J, 2006, SCIENCE, V313, P1960, DOI 10.1126/science.1129139; Galon J, 2007, CANCER RES, V67, P1883, DOI 10.1158/0008-5472.CAN-06-4806; Gondek DC, 2005, J IMMUNOL, V174, P1783, DOI 10.4049/jimmunol.174.4.1783; Greten FR, 2004, CELL, V118, P285, DOI 10.1016/j.cell.2004.07.013; Harrison ML, 2007, J CLIN ONCOL, V25, P4542, DOI 10.1200/JCO.2007.11.2136; Janssens W, 2003, J IMMUNOL, V171, P4604, DOI 10.4049/jimmunol.171.9.4604; Johnson BD, 2007, J IMMUNOTHER, V30, P203, DOI 10.1097/01.cji.0000211336.91513.dd; KARIN M, 2004, NATURE, V431, P461; Kiessling R, 1996, SPRINGER SEMIN IMMUN, V18, P227, DOI 10.1007/BF00820668; KORNSTEIN MJ, 1983, CANCER RES, V43, P2749; Kuss I, 1999, CLIN CANCER RES, V5, P329; Lanier LL, 2003, CURR OPIN IMMUNOL, V15, P308, DOI 10.1016/S0952-7915(03)00039-6; Lee JC, 2004, J IMMUNOL, V172, P7335, DOI 10.4049/jimmunol.172.12.7335; Liyanage UK, 2002, J IMMUNOL, V169, P2756, DOI 10.4049/jimmunol.169.5.2756; Lluis JM, 2007, CANCER RES, V67, P7368, DOI 10.1158/0008-5472.CAN-07-0515; Loukinova E, 2000, ONCOGENE, V19, P3477, DOI 10.1038/sj.onc.1203687; Mahnke K, 2007, INT J CANCER, V120, P2723, DOI 10.1002/ijc.22617; MALIK STA, 1989, INT J CANCER, V44, P918, DOI 10.1002/ijc.2910440529; Mantovani A, 2003, TRENDS IMMUNOL, V24, P234, DOI 10.1016/S1471-4906(03)00074-7; Martinez FO, 2008, FRONT BIOSCI-LANDMRK, V13, P453, DOI 10.2741/2692; MIESCHER S, 1987, J IMMUNOL, V138, P4004; Mihm MC, 1996, LAB INVEST, V74, P43; Munn DH, 2007, J CLIN INVEST, V117, P1147, DOI 10.1172/JCI31178; Nair S, 2007, CANCER RES, V67, P371, DOI 10.1158/0008-5472.CAN-06-2903; Naito Y, 1998, CANCER RES, V58, P3491; Nakano O, 2001, CANCER RES, V61, P5132; O'Day SJ, 2007, CANCER-AM CANCER SOC, V110, P2614, DOI 10.1002/cncr.23086; Ochoa AC, 2007, CLIN CANCER RES, V13, p721S, DOI 10.1158/1078-0432.CCR-06-2197; Ostrand-Rosenberg S, 2004, CURR OPIN IMMUNOL, V16, P143, DOI 10.1016/j.coi.2004.01.003; Pages F, 2005, NEW ENGL J MED, V353, P2654, DOI 10.1056/NEJMoa051424; PAK AS, 1995, CLIN CANCER RES, V1, P95; Pikarsky E, 2004, NATURE, V431, P461, DOI 10.1038/nature02924; Reichert TE, 1998, CANCER RES, V58, P5344; Reichert TE, 1998, J IMMUNOTHER, V21, P295, DOI 10.1097/00002371-199807000-00007; Reichert TE, 2002, CLIN CANCER RES, V8, P3137; Romero P, 2006, ADV IMMUNOL, V92, P187, DOI 10.1016/S0065-2776(06)92005-7; Roncarolo MG, 2006, IMMUNOL REV, V212, P28; Salem ML, 2007, J IMMUNOTHER, V30, P40, DOI 10.1097/01.cji.0000211311.28739.e3; Serafini P, 2006, SEMIN CANCER BIOL, V16, P53, DOI 10.1016/j.semcancer.2005.07.005; Sheu BC, 1999, CANCER-AM CANCER SOC, V86, P1537, DOI 10.1002/(SICI)1097-0142(19991015)86:8<1537::AID-CNCR21>3.0.CO;2-D; Shevach EM, 2000, ANNU REV IMMUNOL, V18, P423, DOI 10.1146/annurev.immunol.18.1.423; Shevach EM, 2004, NAT MED, V10, P900, DOI 10.1038/nm0904-900; STEWART THM, 1993, CLIN EXP METASTAS, V11, P295, DOI 10.1007/BF00058049; Strauss L, 2007, CLIN CANCER RES, V13, P6301, DOI 10.1158/1078-0432.CCR-07-1403; Strauss L, 2007, CLIN CANCER RES, V13, P4345, DOI 10.1158/1078-0432.CCR-07-0472; Strauss L, 2007, J IMMUNOL, V178, P320, DOI 10.4049/jimmunol.178.1.320; Tsai CS, 2007, INT J RADIAT ONCOL, V68, P499, DOI 10.1016/j.ijrobp.2007.01.041; Uzzo RG, 1999, J NATL CANCER I, V91, P718, DOI 10.1093/jnci/91.8.718; Whiteside T. L., 1993, TUMOR INFILTRATING L; Whiteside Theresa L., 2007, P145, DOI 10.1007/978-1-4020-6087-8_7; Whiteside TL, 1998, CURR TOP MICROBIOL, V230, P221; Whiteside TL, 2006, SEMIN CANCER BIOL, V16, P3, DOI 10.1016/j.semcancer.2005.07.008; Woo EY, 2001, CANCER RES, V61, P4766; Zhou G, 2006, BLOOD, V107, P628, DOI 10.1182/blood-2005-07-2737; Zhou JH, 2004, J IMMUNOL, V173, P7622, DOI 10.4049/jimmunol.173.12.7622; Zitvogel L, 2006, NAT REV IMMUNOL, V6, P715, DOI 10.1038/nri1936	80	1381	1433	26	264	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 6	2008	27	45					5904	5912		10.1038/onc.2008.271	http://dx.doi.org/10.1038/onc.2008.271			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	355QE	18836471	Green Accepted			2022-12-28	WOS:000259722600005
J	Li, Y; Lau, YFC				Li, Y.; Lau, Y-F Chris			TSPY and its X-encoded homologue interact with cyclin B but exert contrasting functions on cyclin-dependent kinase 1 activities	ONCOGENE			English	Article						TSPY; TSPX; sex chromosomes; cyclin B-CDK1; kinase activities; protein-protein interaction	TGF-BETA-1 TARGET DENTT; TESTIS-SPECIFIC PROTEIN; GERM-CELL TUMORS; HUMAN Y-CHROMOSOME; CARCINOMA IN-SITU; GONADOBLASTOMA LOCUS; CANDIDATE GENE; EXPRESSION; SET; IDENTIFICATION	Testis-specific protein Y-encoded ( TSPY) is the putative gene for the gonadoblastoma locus on the Y chromosome (GBY). TSPY and an X-homologue, TSPX, harbor a conserved domain, designated as SET/NAP domain, but differ at their C termini. Ectopic expression of TSPY accelerates cell proliferation by abbreviating the G(2)/M stage, whereas overexpression of TSPX retards cells at the same stage of the cell cycle. Previous studies demonstrated that the SET oncoprotein is capable of binding to cyclin B. Using various protein interaction techniques, we demonstrated that TSPY and TSPX indeed bind competitively to cyclin B at their SET/NAP domains in vitro and in vivo. TSPY colocalizes with cyclin B1 during the cell cycle, particularly on the mitotic spindles at metaphase. TSPY enhances while TSPX represses the cyclin B1-CDK1 phosphorylation activity. The inhibitory effect of TSPX on the cyclin B1-CDK1 complex has been mapped to its carboxyl acidic domain that is absent in TSPY, suggesting that TSPX could serve a normal function in modulating cell-cycle progression at the G(2)/M stage, whereas TSPY has acquired a specialized function in germ cell renewal and differentiation. Epigenetic dysregulation of TSPY in incompatible germ or somatic cells could promote cell proliferation and predispose susceptible cells to tumorigenesis.	[Li, Y.; Lau, Y-F Chris] Univ Calif San Francisco, Dept Med, VA Med Ctr, San Francisco, CA 94121 USA	University of California System; University of California San Francisco	Lau, YFC (corresponding author), Univ Calif San Francisco, Dept Med, VA Med Ctr, 111C5,4150 Clement St, San Francisco, CA 94121 USA.	chris.lau@ucsf.edu	Lau, Yun-Fai C/E-4465-2014	Lau, Yun-Fai C/0000-0002-9119-7050	Merit Review; Prostate Cancer REAP from the Department of Veterans Affairs; Department of Defense to Y-FCL	Merit Review(US Department of Veterans Affairs); Prostate Cancer REAP from the Department of Veterans Affairs(US Department of Veterans Affairs); Department of Defense to Y-FCL(United States Department of Defense)	We thank Dr Tatsuo Kido for assistance in immuno fluorescence of transfected cells presented in Figures 4f-h. This work was partially supported by a Merit Review grant and a Prostate Cancer REAP from the Department of Veterans Affairs and an Idea Grant from the Department of Defense to Y-FCL. Y-FC Lau is a research career scientist of the Department of Veterans Affairs.	ADACHI Y, 1994, J BIOL CHEM, V269, P2258; Bowles J, 2007, DEVELOPMENT, V134, P3401, DOI 10.1242/dev.001107; Canela N, 2003, J BIOL CHEM, V278, P1158, DOI 10.1074/jbc.M207497200; Chai ZL, 2001, J BIOL CHEM, V276, P33665, DOI 10.1074/jbc.M007681200; Compagnone NA, 2000, MOL ENDOCRINOL, V14, P875, DOI 10.1210/me.14.6.875; Decordier I, 2008, MUTAT RES-GEN TOX EN, V651, P3, DOI 10.1016/j.mrgentox.2007.10.020; Delbridge ML, 2004, CHROMOSOME RES, V12, P345, DOI 10.1023/B:CHRO.0000034134.91243.1c; Estanyol JM, 1999, J BIOL CHEM, V274, P33161, DOI 10.1074/jbc.274.46.33161; Fukasawa K, 2007, NAT REV CANCER, V7, P911, DOI 10.1038/nrc2249; Gallagher WM, 2005, CARCINOGENESIS, V26, P1856, DOI 10.1093/carcin/bgi152; Gamble MJ, 2005, MOL CELL BIOL, V25, P797, DOI 10.1128/MCB.25.2.797-807.2005; Graves JAM, 1995, PHILOS T R SOC B, V350, P305, DOI 10.1098/rstb.1995.0166; Hoei-Hansen CE, 2006, J PATHOL, V209, P25, DOI 10.1002/path.1948; Honecker F, 2004, J PATHOL, V203, P849, DOI 10.1002/path.1587; Kandilci A, 2005, LEUKEMIA, V19, P1439, DOI 10.1038/sj.leu.2403826; KELLOGG DR, 1995, J CELL BIOL, V130, P661, DOI 10.1083/jcb.130.3.661; Kersemaekers AMF, 2005, HUM PATHOL, V36, P512, DOI 10.1016/j.humpath.2005.02.016; Kido T, 2005, GENESIS, V42, P263, DOI 10.1002/gene.20147; Kido T, 2006, BIOCHEM BIOPH RES CO, V350, P56, DOI 10.1016/j.bbrc.2006.08.191; Krick R, 2003, GENE, V302, P11, DOI 10.1016/S0378-1119(02)01104-6; Lau YFC, 2003, CYTOGENET GENOME RES, V101, P250, DOI 10.1159/000074345; Lau YFC, 2000, CYTOGENET CELL GENET, V91, P160, DOI 10.1159/000056838; Lau YFC, 2000, MOL CARCINOGEN, V27, P308, DOI 10.1002/(SICI)1098-2744(200004)27:4<308::AID-MC9>3.0.CO;2-R; Lau YFC, 1999, AM J HUM GENET, V64, P921, DOI 10.1086/302353; LAU YFC, 2007, CHROM MAL GERM CELL, P73; LI Y, 2006, MOL CELL ENDOCRINOL, V256, P69; Li YM, 2007, HUM PATHOL, V38, P1470, DOI 10.1016/j.humpath.2007.03.011; Li YM, 2007, UROL ONCOL-SEMIN ORI, V25, P141, DOI 10.1016/j.urolonc.2006.08.002; Lobrich M, 2007, NAT REV CANCER, V7, P861, DOI 10.1038/nrc2248; Looijenga LHJ, 2002, ANAL QUANT CYTOL, V24, P263; Masai H, 2000, J BIOL CHEM, V275, P29042, DOI 10.1074/jbc.M002713200; Oh H, 2005, BIOL REPROD, V72, P407, DOI 10.1095/biolreprod.104.034447; Oosterhuis JW, 2005, NAT REV CANCER, V5, P210, DOI 10.1038/nrc1568; Oram SW, 2006, BMC CANCER, V6, P1, DOI 10.1186/1471-2407-6-154; Ozbun LL, 2005, BBA-GENE STRUCT EXPR, V1728, P163, DOI 10.1016/j.bbaexp.2005.02.010; Ozbun LL, 2003, DEV DYNAM, V226, P491, DOI 10.1002/dvdy.10257; Ozbun LL, 2001, GENOMICS, V73, P179, DOI 10.1006/geno.2001.6505; PAGE DC, 1987, DEVELOPMENT, V101, P151; PINES J, 1992, CIBA F SYMP, V170, P187; PINES J, 1992, CIBA F SYMP, V170, P196; Porter Lisa A, 2003, Prog Cell Cycle Res, V5, P335; Puffenberger EG, 2004, P NATL ACAD SCI USA, V101, P11689, DOI 10.1073/pnas.0401194101; Rajesh Changanarnkandath, 2006, V42, P343, DOI 10.1007/003; Rajpert-De Meyts E, 2006, HUM REPROD UPDATE, V12, P303, DOI 10.1093/humupd/dmk006; Repping S, 2006, NAT GENET, V38, P463, DOI 10.1038/ng1754; Richter JD, 2001, P NATL ACAD SCI USA, V98, P7069, DOI 10.1073/pnas.111146498; SALO P, 1995, GENE CHROMOSOME CANC, V14, P210, DOI 10.1002/gcc.2870140309; Schmit TL, 2007, MOL CANCER THER, V6, P1920, DOI 10.1158/1535-7163.MCT-06-0781; Schnieders F, 1996, HUM MOL GENET, V5, P1801, DOI 10.1093/hmg/5.11.1801; Seo SB, 2001, CELL, V104, P119, DOI 10.1016/S0092-8674(01)00196-9; Skaletsky H, 2003, NATURE, V423, P825, DOI 10.1038/nature01722; Smits VAJ, 2001, BBA-GENE STRUCT EXPR, V1519, P1, DOI 10.1016/S0167-4781(01)00204-4; Tschop K, 2006, FEBS J, V273, P1681, DOI 10.1111/j.1742-4658.2006.05184.x; TSUCHIYA K, 1995, AM J HUM GENET, V57, P1400; Vera J, 2006, ONCOGENE, V25, P260, DOI 10.1038/sj.onc.1209050; Vijayakumar S, 2006, CANCER RES, V66, P4055, DOI 10.1158/0008-5472.CAN-05-3822; Vogel T, 1998, CYTOGENET CELL GENET, V81, P265, DOI 10.1159/000015042; Wang GS, 2004, NEURON, V42, P113, DOI 10.1016/S0896-6273(04)00139-4; Wang Q, 2004, DNA CELL BIOL, V23, P475, DOI 10.1089/1044549041562276; Whittaker SR, 2007, CELL CYCLE, V6, P3114, DOI 10.4161/cc.6.24.5142; Yin YH, 2005, BRIT J CANCER, V93, P458, DOI 10.1038/sj.bjc.6602716; Zhang Julie S., 1992, Human Molecular Genetics, V1, P717, DOI 10.1093/hmg/1.9.717	62	42	43	0	2	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT	2008	27	47					6141	6150		10.1038/onc.2008.206	http://dx.doi.org/10.1038/onc.2008.206			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	360UJ	18591933				2022-12-28	WOS:000260083100007
J	Li, D; Ambrogio, L; Shimamura, T; Kubo, S; Takahashi, M; Chirieac, LR; Padera, RF; Shapiro, GI; Baum, A; Himmelsbach, F; Rettig, WJ; Meyerson, M; Solca, F; Greulich, H; Wong, KK				Li, D.; Ambrogio, L.; Shimamura, T.; Kubo, S.; Takahashi, M.; Chirieac, L. R.; Padera, R. F.; Shapiro, G. I.; Baum, A.; Himmelsbach, F.; Rettig, W. J.; Meyerson, M.; Solca, F.; Greulich, H.; Wong, K-K			BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models	ONCOGENE			English	Article						EGFR; HER2; lung cancer; BIBW2992; therapeutics	GROWTH-FACTOR RECEPTOR; HER2 KINASE DOMAIN; TYROSINE KINASE; EGF RECEPTOR; ACQUIRED-RESISTANCE; MUTATIONS; GEFITINIB; SENSITIVITY; ADENOCARCINOMAS; TRANSFORMATION	Genetic alterations in the kinase domain of the epidermal growth factor receptor (EGFR) in non-small cell lung cancer (NSCLC) patients are associated with sensitivity to treatment with small molecule tyrosine kinase inhibitors. Although first-generation reversible, ATP-competitive inhibitors showed encouraging clinical responses in lung adenocarcinoma tumors harboring such EGFR mutations, almost all patients developed resistance to these inhibitors over time. Such resistance to first generation EGFR inhibitors was frequently linked to an acquired T790M point mutation in the kinase domain of EGFR, or upregulation of signaling pathways downstream of HER3. Overcoming these mechanisms of resistance, as well as primary resistance to reversible EGFR inhibitors driven by a subset of EGFR mutations, will be necessary for development of an effective targeted therapy regimen. Here, we show that BIBW2992, an anilino-quinazoline designed to irreversibly bind EGFR and HER2, potently suppresses the kinase activity of wild-type and activated EGFR and HER2 mutants, including erlotinib-resistant isoforms. Consistent with this activity, BIBW2992 suppresses transformation in isogenic cell-based assays, inhibits survival of cancer cell lines and induces tumor regression in xenograft and transgenic lung cancer models, with superior activity over erlotinib. These findings encourage further testing of BIBW2992 in lung cancer patients harboring EGFR or HER2 oncogenes.	[Solca, F.] Boehringer Ingelheim Austria, Dept Pharmacol, Vienna, Austria; [Li, D.; Ambrogio, L.; Shimamura, T.; Shapiro, G. I.; Meyerson, M.; Greulich, H.; Wong, K-K] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA; [Li, D.] Harvard Univ, Ctr Canc, Ludwig Ctr, Boston, MA 02115 USA; [Ambrogio, L.; Meyerson, M.; Greulich, H.] Broad Inst Harvard, Cambridge, MA USA; [Ambrogio, L.; Meyerson, M.; Greulich, H.] MIT, Cambridge, MA 02139 USA; [Shimamura, T.; Shapiro, G. I.; Meyerson, M.; Greulich, H.; Wong, K-K] Brigham & Womens Hosp, Dept Med, Boston, MA 02115 USA; [Shimamura, T.; Shapiro, G. I.; Meyerson, M.; Greulich, H.; Wong, K-K] Harvard Univ, Sch Med, Boston, MA USA; [Kubo, S.; Takahashi, M.] Beth Israel Deaconess Med Ctr, Dept Radiol, Boston, MA 02215 USA; [Chirieac, L. R.; Padera, R. F.] Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA; [Himmelsbach, F.] Boehringer Ingelheim Pharma GmbH & Co KG, Biberach, Germany	Boehringer Ingelheim; Harvard University; Dana-Farber Cancer Institute; Harvard University; Harvard University; Massachusetts Institute of Technology (MIT); Broad Institute; Massachusetts Institute of Technology (MIT); Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Brigham & Women's Hospital; Boehringer Ingelheim	Solca, F (corresponding author), Boehringer Ingelheim Austria, Dept Pharmacol, Dr Boehringer Gasse 5-11, Vienna, Austria.	flavio.solca@vie.boehringer-ingelheim.com	Chirieac, Lucian R./AAD-2030-2019; Meyerson, Matthew L/E-7123-2012		NATIONAL CANCER INSTITUTE [P20CA090578, R01CA122794, R01CA090687, P50CA090578] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [K08AG024004, R01AG027757] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA122794, P20 CA90578, R01 CA90687, R01 CA122794-04, P50 CA090578, R01 CA090687, P50 CA090578-06, P20 CA090578] Funding Source: Medline; NIA NIH HHS [R01 AG027757-03, R01 AG2400401, K08 AG024004, R01 AG027757] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Bedano PM, 2006, J THORAC ONCOL, V1, P582, DOI 10.1097/01243894-200607000-00015; COUSSENS L, 1985, SCIENCE, V230, P1132, DOI 10.1126/science.2999974; Engelman JA, 2005, P NATL ACAD SCI USA, V102, P3788, DOI 10.1073/pnas.0409773102; Engelman JA, 2007, SCIENCE, V316, P1039, DOI 10.1126/science.1141478; Eskens F, 2008, BRIT J CANCER, V98, P80, DOI 10.1038/sj.bjc.6604108; FAN Z, 1993, CANCER RES, V53, P4637; Greulich H, 2005, PLOS MED, V2, P1167, DOI 10.1371/journal.pmed.0020313; Hurwitz E, 2000, CANCER IMMUNOL IMMUN, V49, P226, DOI 10.1007/s002620000112; Hynes NE, 2005, NAT REV CANCER, V5, P341, DOI 10.1038/nrc1609; Janne PA, 2005, J CLIN ONCOL, V23, P3227, DOI 10.1200/JCO.2005.09.985; Jemal A, 2006, CA-CANCER J CLIN, V56, P106, DOI 10.3322/canjclin.56.2.106; Ji HB, 2006, P NATL ACAD SCI USA, V103, P7817, DOI 10.1073/pnas.0510284103; Ji HB, 2006, CANCER CELL, V9, P485, DOI 10.1016/j.ccr.2006.04.022; Jiang JR, 2005, CANCER RES, V65, P8968, DOI 10.1158/0008-5472.CAN-05-1829; Kobayashi S, 2005, CANCER RES, V65, P7096, DOI 10.1158/0008-5472.CAN-05-1346; Kobayashi S, 2005, NEW ENGL J MED, V352, P786, DOI 10.1056/NEJMoa044238; Krypuy M, 2006, BMC CANCER, V6, DOI 10.1186/1471-2407-6-295; Kwak EL, 2005, P NATL ACAD SCI USA, V102, P7665, DOI 10.1073/pnas.0502860102; Lee JC, 2006, PLOS MED, V3, P2264, DOI 10.1371/journal.pmed.0030485; Li DN, 2007, CANCER CELL, V12, P81, DOI 10.1016/j.ccr.2007.06.005; Li DN, 2007, J CLIN INVEST, V117, P346, DOI 10.1172/JCI30446; Lynch TJ, 2004, NEW ENGL J MED, V350, P2129, DOI 10.1056/NEJMoa040938; Mulloy R, 2007, CANCER RES, V67, P2325, DOI 10.1158/0008-5472.CAN-06-4293; Paez JG, 2004, SCIENCE, V304, P1497, DOI 10.1126/science.1099314; Pao W, 2005, PLOS MED, V2, P57, DOI 10.1371/journal.pmed.0020017; Pao W, 2005, PLOS MED, V2, P225, DOI 10.1371/journal.pmed.0020073; Pao W, 2004, P NATL ACAD SCI USA, V101, P13306, DOI 10.1073/pnas.0405220101; Rabindran SK, 2004, CANCER RES, V64, P3958, DOI 10.1158/0008-5472.CAN-03-2868; Riely GJ, 2006, CLIN CANCER RES, V12, P839, DOI 10.1158/1078-0432.CCR-05-1846; Schiffer HH, 2007, MOL PHARMACOL, V71, P508, DOI 10.1124/mol.106.027656; Shigematsu H, 2005, CANCER RES, V65, P1642, DOI 10.1158/0008-5472.CAN-04-4235; Shimamura T, 2006, CANCER RES, V66, P6487, DOI 10.1158/0008-5472.CAN-06-0971; Stephens P, 2004, NATURE, V431, P525, DOI 10.1038/431525b; ULLRICH A, 1984, NATURE, V309, P418, DOI 10.1038/309418a0; Vikis H, 2007, CANCER RES, V67, P4665, DOI 10.1158/0008-5472.CAN-07-0217; Wang SZE, 2006, CANCER CELL, V10, P25, DOI 10.1016/j.ccr.2006.05.023; Yuza Y, 2007, CANCER BIOL THER, V6, P661, DOI 10.4161/cbt.6.5.4003	37	1086	1170	6	122	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG	2008	27	34					4702	4711		10.1038/onc.2008.109	http://dx.doi.org/10.1038/onc.2008.109			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	334QM	18408761	Green Accepted			2022-12-28	WOS:000258236300008
J	Rzymski, T; Paantjens, A; Bod, J; Harris, AL				Rzymski, T.; Paantjens, A.; Bod, J.; Harris, A. L.			Multiple pathways are involved in the anoxia response of SKIP3 including HuR-regulated RNA stability, NF-kappa B and ATF4	ONCOGENE			English	Article						ATF4; SKIP3; anoxia; RNA stability; NF-kappa B	MESSENGER-RNA; CYCLOOXYGENASE-2 EXPRESSION; GENE-EXPRESSION; HYPOXIA; ACTIVATION; BINDING; CELL; TRB3; PHOSPHORYLATION; STABILIZATION	Under anoxia a coordinated, cytoprotective program is induced, called the unfolded protein response (UPR). Activating transcription factor 4 (ATF4) is a mediator of the UPR and activates a gene expression program, promoting tumour growth and survival under anoxia. A key gene induced by ATF4 under normoxic conditions is SKIP3. We characterized the induction of SKIP3 during anoxic exposure to determine whether UPR alone was sufficient or there was a more complex regulatory response to anoxia. There was temporal separation of acute hypoxia-inducible factor (HIF)-1 alpha- and chronic ATF4-dependent gene expression programs. SKIP3 was regulated by chronic (48 h) rather than acute anoxia (< 24h) by a complex set of pathways and mechanisms, besides ATF4 induced by the classical UPR, there was transcriptional regulation by nuclear factor-kappa B (NF-kappa B)and RNA stabilization by HuR. Temporal activation of the NF-kappa B pathway under anoxia protected cells from negative consequences of the oxygen stress and involved the canonical signalling pathways that promote I kappa BA phosphorylation and degradation, and reduced mRNA level of the inhibitory protein I kappa BA followed by the translational repression of I kappa BA. We also show that SKIP3 acts as an inhibitor of NF-kappa B and ATF4-dependent transcription under anoxia and provides a regulatory feedback loop. Repression of the survival pathway NF-kappa B by SKIP3 sensitized cells to metabolic consequences of the anoxic stress. Thus, the response to anoxia is mediated by three pathways independently of HIF, suggesting that combined therapeutic approaches would be needed to maximize effects against this pathway.	[Rzymski, T.; Paantjens, A.; Bod, J.; Harris, A. L.] Univ Oxford, John Radcliffe Hosp, Mol Oncol Labs, Weatherall Inst Mol Med,Canc Res UK, Oxford OX3 9DS, England	Cancer Research UK; University of Oxford	Harris, AL (corresponding author), Univ Oxford, John Radcliffe Hosp, Mol Oncol Labs, Weatherall Inst Mol Med,Canc Res UK, Oxford OX3 9DS, England.	aharris.lab@cancer.org.uk	Harris, Adrian L/ABA-3343-2020	Harris, Adrian L/0000-0003-1376-8409	Cancer Research UK Funding Source: Medline	Cancer Research UK(Cancer Research UK)		Ameri K, 2004, BLOOD, V103, P1876, DOI 10.1182/blood-2003-06-1859; Atasoy U, 1998, J CELL SCI, V111, P3145; Blais JD, 2004, MOL CELL BIOL, V24, P7469, DOI 10.1128/MCB.24.17.7469-7482.2004; Bowers AJ, 2003, ONCOGENE, V22, P2823, DOI 10.1038/sj.onc.1206367; Brown JM, 2004, NAT REV CANCER, V4, P437, DOI 10.1038/nrc1367; Chen CY, 2001, CELL, V107, P451, DOI 10.1016/S0092-8674(01)00578-5; Cummins EP, 2006, P NATL ACAD SCI USA, V103, P18154, DOI 10.1073/pnas.0602235103; de Silanes IL, 2004, P NATL ACAD SCI USA, V101, P2987, DOI 10.1073/pnas.0306453101; Deng J, 2004, MOL CELL BIOL, V24, P10161, DOI 10.1128/MCB.24.23.10161-10168.2004; Erkinheimo TL, 2005, GYNECOL ONCOL, V99, P14, DOI 10.1016/j.ygyno.2005.04.047; Erkinheimo TL, 2003, CANCER RES, V63, P7591; Evans SM, 2003, CANCER LETT, V195, P1, DOI 10.1016/S0304-3835(03)00012-0; Grosshans J, 2000, CELL, V101, P523, DOI 10.1016/S0092-8674(00)80862-4; Harding HP, 2000, MOL CELL, V6, P1099, DOI 10.1016/S1097-2765(00)00108-8; Harding HP, 2003, MOL CELL, V11, P619, DOI 10.1016/S1097-2765(03)00105-9; Imbert V, 1996, CELL, V86, P787, DOI 10.1016/S0092-8674(00)80153-1; Jousse C, 2007, J BIOL CHEM, V282, P15851, DOI 10.1074/jbc.M611723200; Kiss-Toth E, 2004, J BIOL CHEM, V279, P42703, DOI 10.1074/jbc.M407732200; KOONG AC, 1994, CANCER RES, V54, P5273; Koritzinsky M, 2006, EMBO J, V25, P1114, DOI 10.1038/sj.emboj.7600998; Koritzinsky M, 2005, RADIOTHER ONCOL, V76, P177, DOI 10.1016/j.radonc.2005.06.036; Koumenis C, 2002, MOL CELL BIOL, V22, P7405, DOI 10.1128/MCB.22.21.7405-7416.2002; Levy NS, 1998, J BIOL CHEM, V273, P6417, DOI 10.1074/jbc.273.11.6417; Liang GS, 1997, J BIOL CHEM, V272, P24088, DOI 10.1074/jbc.272.38.24088; Mouritzen P, 2003, EXPERT REV MOL DIAGN, V3, P27, DOI 10.1586/14737159.3.1.27; Nabors LB, 2001, CANCER RES, V61, P2154; Ohoka N, 2005, EMBO J, V24, P1243, DOI 10.1038/sj.emboj.7600596; Ord D, 2005, BIOCHEM BIOPH RES CO, V330, P210, DOI 10.1016/j.bbrc.2005.02.149; Ord D, 2003, EXP CELL RES, V286, P308, DOI 10.1016/S0014-4827(03)00070-3; Pan YX, 2005, J BIOL CHEM, V280, P34609, DOI 10.1074/jbc.M507802200; Patel NS, 2005, CANCER RES, V65, P8690, DOI 10.1158/0008-5472.CAN-05-1208; Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45; Royds JA, 1998, J CLIN PATHOL-MOL PA, V51, P55; Scheuner D, 2001, MOL CELL, V7, P1165, DOI 10.1016/S1097-2765(01)00265-9; Semenza GL, 2001, CELL, V107, P1, DOI 10.1016/S0092-8674(01)00518-9; Sheflin LG, 2004, BIOCHEM BIOPH RES CO, V322, P644, DOI 10.1016/j.bbrc.2004.07.173; TEICHER BA, 1994, CANCER METAST REV, V13, P139, DOI 10.1007/BF00689633; Wu M, 2003, J BIOL CHEM, V278, P27072, DOI 10.1074/jbc.M209814200	38	44	45	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 31	2008	27	33					4532	4543		10.1038/onc.2008.100	http://dx.doi.org/10.1038/onc.2008.100			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	332IS	18408768				2022-12-28	WOS:000258077300003
J	Cornforth, AN; Davis, JS; Khanifar, E; Nastiuk, KL; Krolewski, JJ				Cornforth, A. N.; Davis, J. S.; Khanifar, E.; Nastiuk, K. L.; Krolewski, J. J.			FOXO3a mediates the androgen-dependent regulation of FLIP and contributes to TRAIL-induced apoptosis of LNCaP cells	ONCOGENE			English	Article						FLIP; androgen; Forkhead; TRAIL; prostate cancer; apoptosis	PROSTATE-CANCER CELLS; FORKHEAD TRANSCRIPTION FACTOR; INHIBITORY PROTEIN GENE; RAT VENTRAL PROSTATE; FACTOR FKHR; DEATH; RECEPTOR; AKT; EXPRESSION; PTEN	Androgen-withdrawal-induced apoptosis (AWIA) is deregulated in androgen refractory prostate cancer. Androgens have been shown to positively regulate expression of the antiapoptotic FADD-like interleukin-1 beta-converting enzyme (FLICE)-like inhibitory protein (FLIP), and reduced FLIP expression precedes apoptosis after androgen withdrawal. Here, we show that FLIP protein expression is downregulated in castrated rats, while in LNCaP cells, androgens regulate FLIP in a manner that is dependent on phosphoinositol-3-kinase (PI3K) and Akt signaling. Specifically, treatment of LNCaP cells with LY294002, or expression of either PTEN or a non-phosphorylatable form of FOXO3a (FOXO3aTM), downregulates FLIP protein and mRNA. Conversely, treatment with androgens in the absence of PI3/Akt signaling, or following expression of FOXO3aTM, leads to increased FLIP expression. A FOXO3a binding site was identified in the FLIP promoter and shown necessary for the combined effects of androgens and FOXO3a on FLIP transcription. FOXO3a binds the androgen receptor, suggesting that the transcriptional synergy depends on an interaction between these proteins. Finally, LNCaP cells are sensitized to TRAIL-induced apoptosis by PTEN or LY294002, and rescued by androgens. FOX-O3aTMalso sensitizes cells to androgen-inhibited TRAIL apoptosis. Androgen rescue was diminished when either FOXO3a or FLIP was reduced by siRNA. These data support a role for FOXO3a in AWIA.	[Cornforth, A. N.; Davis, J. S.; Khanifar, E.; Nastiuk, K. L.; Krolewski, J. J.] Univ Calif Irvine, Dept Pathol & Lab Med, Sch Med, Irvine, CA 92697 USA; [Krolewski, J. J.] Univ Calif Irvine, Chao Family Comprehens Canc Ctr, Sch Med, Irvine, CA 92697 USA	University of California System; University of California Irvine; University of California System; University of California Irvine	Krolewski, JJ (corresponding author), Univ Calif Irvine, Dept Pathol & Lab Med, Sch Med, Med Sci 1 D450, Irvine, CA 92697 USA.	jkrolews@uci.edu		Davis, Jennifer/0000-0001-9456-1682	NATIONAL CANCER INSTITUTE [T32CA009054] Funding Source: NIH RePORTER; NCI NIH HHS [5T32CA009054] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ayala G, 2004, CLIN CANCER RES, V10, P6572, DOI 10.1158/1078-0432.CCR-04-0477; Bertram J, 2006, PROSTATE, V66, P895, DOI 10.1002/pros.20411; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Cully M, 2006, NAT REV CANCER, V6, P184, DOI 10.1038/nrc1819; Daskivich TJ, 2006, CURR OPIN UROL, V16, P173, DOI 10.1097/01.mou.0000193392.77469.e2; de la Taille A, 1999, PROSTATE, V40, P89, DOI 10.1002/(SICI)1097-0045(19990701)40:2<89::AID-PROS4>3.0.CO;2-E; Furutani T, 2002, BIOCHEM BIOPH RES CO, V294, P779, DOI 10.1016/S0006-291X(02)00564-8; Gao S, 2005, MOL ENDOCRINOL, V19, P1792, DOI 10.1210/me.2004-0445; Gao S, 2006, J MOL ENDOCRINOL, V36, P463, DOI 10.1677/jme.1.01991; Hermans KG, 2004, GENE CHROMOSOME CANC, V39, P171, DOI 10.1002/gcc.10311; Huang HJ, 2004, J BIOL CHEM, V279, P13866, DOI 10.1074/jbc.M314143200; Jemal A, 2006, CA-CANCER J CLIN, V56, P106, DOI 10.3322/canjclin.56.2.106; Kimura K, 2001, CANCER RES, V61, P5611; Krueger A, 2001, J BIOL CHEM, V276, P20633, DOI 10.1074/jbc.M101780200; KYPRIANOU N, 1988, ENDOCRINOLOGY, V122, P552, DOI 10.1210/endo-122-2-552; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; Li PF, 2003, MOL CELL BIOL, V23, P104, DOI 10.1128/MCB.23.1.104-118.2003; Li PF, 2001, J BIOL CHEM, V276, P20444, DOI 10.1074/jbc.M010226200; Liao YD, 2003, INT J CANCER, V107, P676, DOI 10.1002/ijc.11471; Longley DB, 2006, ONCOGENE, V25, P838, DOI 10.1038/sj.onc.1209122; Lynch RL, 2005, MOL CANCER RES, V3, P163, DOI 10.1158/1541-7786.MCR-04-0163; Majumder PK, 2005, ONCOGENE, V24, P7465, DOI 10.1038/sj.onc.1209096; Marti A, 1999, CELL DEATH DIFFER, V6, P1190, DOI 10.1038/sj.cdd.4400610; MARTIKAINEN P, 1990, ENDOCRINOLOGY, V127, P2963, DOI 10.1210/endo-127-6-2963; Matys V, 2003, NUCLEIC ACIDS RES, V31, P374, DOI 10.1093/nar/gkg108; Nastiuk KL, 2003, J CELL PHYSIOL, V196, P386, DOI 10.1002/jcp.10283; Nesterov A, 2001, J BIOL CHEM, V276, P10767, DOI 10.1074/jbc.M005196200; Nesterov A, 2002, ONCOGENE, V21, P1135, DOI 10.1038/sj.onc.1205151; Panka DJ, 2001, J BIOL CHEM, V276, P6893, DOI 10.1074/jbc.C000569200; Roth W, 2004, VITAM HORM, V67, P189; Shaw G, 2002, FASEB J, V16, P869, DOI 10.1096/fj.01-0995fje; Skurk C, 2004, J BIOL CHEM, V279, P1513, DOI 10.1074/jbc.M304736200; Srikanth S, 1998, CANCER RES, V58, P834; Sugihara A, 2001, IN VIVO, V15, P385; Suzuki A, 1996, ONCOGENE, V13, P31; Tang ED, 1999, J BIOL CHEM, V274, P16741, DOI 10.1074/jbc.274.24.16741; Yuan XJ, 2002, ONCOGENE, V21, P319, DOI 10.1038/sj/onc/1205054; Zhang XP, 2004, CANCER RES, V64, P7086, DOI 10.1158/0008-5472.CAN-04-1498	38	52	54	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 24	2008	27	32					4422	4433		10.1038/onc.2008.80	http://dx.doi.org/10.1038/onc.2008.80			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	329PU	18391984				2022-12-28	WOS:000257881700005
J	Liu, BH; Goh, CHK; Ooi, LLPJ; Hui, KM				Liu, B. H.; Goh, C. H. K.; Ooi, L. L. P. J.; Hui, K. M.			Identification of unique and common low abundance tumour-specific transcripts by suppression subtractive hybridization and oligonucleotide probe array analysis	ONCOGENE			English	Article						affymetrix GeneChip arrays; breast cancer; hepatocellular carcinoma; low abundance transcripts; nasopharyngeal carcinoma; suppression subtractive hybridization	GENE-EXPRESSION SIGNATURE; EPSTEIN-BARR-VIRUS; HEPATOCELLULAR-CARCINOMA; BREAST-CANCER; DNA; SURVIVAL	Most human cancers are characterized by genetic aberrations accompanied by altered expression and function of numerous genes. Applying genome-wide, microarray gene expression analysis to identify deregulated genes in different tumour types can provide potential gene candidates as diagnostic and prognostic tools and promising targets for drug development. However, the detection of deregulated genes with low levels of expression remains a major challenge. In this study, we have designed a strategy, termed modified suppression subtractive hybridization ( mSSH), to identify genes encoding rare transcripts. The strategy entails incorporating the T-7-promoter sequence at the 5 ' end of the noncoding cDNA strand during first strand cDNA synthesis to generate unidirectional antisense RNA from the resultant cDNA following conventional SSH. These transcripts are subsequently analysed by Affymetrix oligonucleotide gene arrays. Here, we have used five hepatocellular carcinoma ( HCC), five breast carcinoma and four nasopharyngeal carcinoma ( NPC) biopsies separately as testers and their corresponding normal biopsies as drivers to enrich for low abundance tumour type-specific transcripts. The total detectable number of probe sets following mSSH was reduced almost 10-fold in comparison to those detected for the same resected tumour tissues without undergoing subtraction, thus yielding a subtraction efficacy of over 90%. Using this experimental approach, we have identified 48 HCC-specific, 45 breast carcinoma-specific, and 83 NPC-specific genes. In addition, 115 genes were upregulated in all the three cancer types. When compared to gene-profiling data obtained without mSSH, the majority of these identified transcripts were of low abundance in the original cancer tissues. mSSH can therefore serve as a comprehensive molecular strategy for pursuing functional genomic studies of human cancers.	[Liu, B. H.; Hui, K. M.] Natl Canc Ctr, Humphrey Oei Inst Canc Res, Div Cellular & Mol Res, Bek Chai Heah Lab Canc Genom, Singapore 169610, Singapore; [Goh, C. H. K.] Singapore Gen Hosp, Dept Otolaryngol, Singapore 0316, Singapore; [Ooi, L. L. P. J.] Natl Canc Ctr, Div Surg Oncol, Singapore, Singapore	National Cancer Centre Singapore (NCCS); Singapore General Hospital; National Cancer Centre Singapore (NCCS)	Hui, KM (corresponding author), Natl Canc Ctr, Humphrey Oei Inst Canc Res, Div Cellular & Mol Res, Bek Chai Heah Lab Canc Genom, 11 Hosp Dr, Singapore 169610, Singapore.	cmrhkm@nccs.com.sg	Ooi, London Lucien/AGK-1395-2022; Hui, Kam/C-6186-2011	Hui, Kam/0000-0003-1820-1399				Alizadeh AA, 2000, NATURE, V403, P503, DOI 10.1038/35000501; Amatschek S, 2004, CANCER RES, V64, P844, DOI 10.1158/0008-5472.CAN-03-2361; Beer DG, 2002, NAT MED, V8, P816, DOI 10.1038/nm733; Bonavida B, 2007, ONCOGENE, V26, P3629, DOI 10.1038/sj.onc.1210365; Brentani H, 2003, P NATL ACAD SCI USA, V100, P13418, DOI 10.1073/pnas.1233632100; Chen HY, 2007, NEW ENGL J MED, V356, P11, DOI 10.1056/NEJMoa060096; Comijn J, 2001, MOL CELL, V7, P1267, DOI 10.1016/S1097-2765(01)00260-X; Del Rio M, 2007, J CLIN ONCOL, V25, P773, DOI 10.1200/JCO.2006.07.4187; Diatchenko L, 1996, P NATL ACAD SCI USA, V93, P6025, DOI 10.1073/pnas.93.12.6025; Draghici S, 2006, TRENDS GENET, V22, P101, DOI 10.1016/j.tig.2005.12.005; Kirk GD, 2005, ONCOGENE, V24, P5858, DOI 10.1038/sj.onc.1208732; Lah TT, 2000, CLIN CANCER RES, V6, P578; Lau WM, 2007, ONCOGENE, V26, P6050, DOI 10.1038/sj.onc.1210405; LEE SW, 1991, P NATL ACAD SCI USA, V88, P2825, DOI 10.1073/pnas.88.7.2825; Lipshutz RJ, 1999, NAT GENET, V21, P20, DOI 10.1038/4447; Odom DT, 2004, SCIENCE, V303, P1378, DOI 10.1126/science.1089769; Qin LX, 2006, BMC BIOINFORMATICS, V7, DOI 10.1186/1471-2105-7-23; Russo G, 2003, ONCOGENE, V22, P6497, DOI 10.1038/sj.onc.1206865; Sander C, 2000, SCIENCE, V287, P1977, DOI 10.1126/science.287.5460.1977; Shiota G, 1997, J HEPATOL, V27, P661, DOI 10.1016/S0168-8278(97)80083-9; Thornburg NJ, 2006, ONCOGENE, V25, P288, DOI 10.1038/sj.onc.1209023; Thuerigen O, 2006, J CLIN ONCOL, V24, P1839, DOI 10.1200/JCO.2005.04.7019; Tsopanomichalou M, 1999, LIVER, V19, P305, DOI 10.1111/j.1478-3231.1999.tb00054.x; Wang SM, 2007, CLIN CANCER RES, V13, P6275, DOI 10.1158/1078-0432.CCR-06-2236; Young LS, 2004, NAT REV CANCER, V4, P757, DOI 10.1038/nrc1452; Young LS, 2003, ONCOGENE, V22, P5108, DOI 10.1038/sj.onc.1206556; Yu K, 2006, CLIN CANCER RES, V12, P3288, DOI 10.1158/1078-0432.CCR-05-1530	27	10	11	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 3	2008	27	29					4128	4136		10.1038/onc.2008.50	http://dx.doi.org/10.1038/onc.2008.50			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	321RV	18332864				2022-12-28	WOS:000257325100013
J	Bachmaier, R; Aryee, DNT; Jug, G; Kauer, M; Kreppel, M; Lee, KA; Kovar, H				Bachmaier, R.; Aryee, D. N. T.; Jug, G.; Kauer, M.; Kreppel, M.; Lee, K. A.; Kovar, H.			O-GlcNAcylation is involved in the transcriptional activity of EWS-FLI1 in Ewing's sarcoma	ONCOGENE			English	Article						EWS-FLI1; Ewing's sarcoma; post-translational modification; O-GlcNAc; phosphorylation; transcription	RNA-POLYMERASE-II; DON 6-DIAZO-5-OXO-L-NORLEUCINE; N-ACETYLGLUCOSAMINE; TYROSINE KINASE; FUSION PROTEIN; PHASE-I; EWS; DOMAIN; PHOSPHORYLATION; GLYCOPROTEIN	The oncogene EWS-FLI1 encodes a chimeric transcription factor expressed in Ewing's sarcoma family tumors (ESFTs). EWS-FLI1 target gene expression is thought to drive ESFT pathogenesis and, therefore, inhibition of EWS-FLI1 activity holds high therapeutic promise. As the activity of many transcription factors is regulated by post-translational modi. cations, we studied the presence of modi. cations on EWS-FLI1. The immuno-purified fusion-protein was recognized by an antibody specific for O-linked beta-N-acetylglucosaminylation, and bound readily to a phosphoprotein-specific dye. Inhibition of Ser/Thr-specific phophatases increased EWS-FLI1 molecular weight and reduced its O-GlcNAc content, suggesting that phosphorylation and O-GlcNAcylation of EWS-FLI1 interact dynamically. By mutation analysis, O-GlcNAcylation was delineated to Ser/Thr residues of the amino-terminal EWS transcriptional-activation domain. Metabolic inhibition of the hexosamine biosynthetic pathway abrogated O-GlcNAcylation of EWS-FLI1 and interfered specifically with transcriptional activation of the EWS-FLI1 target Id2. These results suggest that drugs modulating glycosylation of EWS-FLI1 interfere functionally with its activity and might, therefore, constitute promising additions to the current ESFT chemotherapy.	[Bachmaier, R.; Aryee, D. N. T.; Jug, G.; Kauer, M.; Kreppel, M.; Kovar, H.] St Anna Kinder Krebsforsch, Childrens Canc Res Inst, A-1090 Vienna, Austria; [Lee, K. A.] Hong Kong Univ Sci & Technol, Dept Biol, Kowloon, Hong Kong, Peoples R China	Saint Anna Children's Hospital; Hong Kong University of Science & Technology	Kovar, H (corresponding author), St Anna Kinder Krebsforsch, Childrens Canc Res Inst, Kinderspitalgasse 6, A-1090 Vienna, Austria.	heinrich.kovar@ccri.at		Kovar, Heinrich/0000-0001-6873-9109	Austrian Science Fund (FWF) [P18046-B12]	Austrian Science Fund (FWF)(Austrian Science Fund (FWF))	This study was supported in part by Grant P18046-B12 of the Austrian Science Fund ( FWF).	Araya N, 2005, BIOCHEM BIOPH RES CO, V329, P653, DOI 10.1016/j.bbrc.2005.02.018; Aryee DNT, 2006, CANCER RES, V66, P9862, DOI 10.1158/0008-5472.CAN-05-4042; DELATTRE O, 1992, NATURE, V359, P162, DOI 10.1038/359162a0; Deloulme JC, 1997, J BIOL CHEM, V272, P27369, DOI 10.1074/jbc.272.43.27369; Guinamard R, 1997, SCAND J IMMUNOL, V45, P587, DOI 10.1046/j.1365-3083.1997.d01-447.x; Gupta Ramneek, 2002, Pac Symp Biocomput, P310; Hart GW, 2007, NATURE, V446, P1017, DOI 10.1038/nature05815; KELLY WG, 1993, J BIOL CHEM, V268, P10416; Kim J, 1999, P NATL ACAD SCI USA, V96, P14300, DOI 10.1073/pnas.96.25.14300; Kim J, 2000, FEBS LETT, V474, P121, DOI 10.1016/S0014-5793(00)01590-8; Kovar H, 2005, SEMIN CANCER BIOL, V15, P189, DOI 10.1016/j.semcancer.2005.01.004; LYNCH G, 1982, AM J CLIN ONCOL-CANC, V5, P541; Martin K, 2003, PROTEOMICS, V3, P1244, DOI 10.1002/pmic.200300445; Matsuoka Y, 2002, HYBRIDOMA HYBRIDOM, V21, P233, DOI 10.1089/153685902760213831; Ng KP, 2007, P NATL ACAD SCI USA, V104, P479, DOI 10.1073/pnas.0607007104; Ohlson J, 2005, NUCLEIC ACIDS RES, V33, DOI 10.1093/nar/gni169; Petermann R, 1998, ONCOGENE, V17, P603, DOI 10.1038/sj.onc.1201964; RAHMAN A, 1985, INVEST NEW DRUG, V3, P369; SNOW CM, 1987, J CELL BIOL, V104, P1143, DOI 10.1083/jcb.104.5.1143; Spahn L, 2003, ONCOGENE, V22, P6819, DOI 10.1038/sj.onc.1206810; SULLIVAN MP, 1988, CANCER CHEMOTH PHARM, V21, P78, DOI 10.1007/BF00262746; Wang M, 1999, EXP CELL RES, V246, P38, DOI 10.1006/excr.1998.4280; Wells L, 2002, MOL CELL PROTEOMICS, V1, P791, DOI 10.1074/mcp.M200048-MCP200; Zhang XK, 2005, J BIOCHEM, V137, P297, DOI 10.1093/jb/mvi032	24	39	40	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 5	2009	28	9					1280	1284		10.1038/onc.2008.484	http://dx.doi.org/10.1038/onc.2008.484			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	415AH	19151750	Green Accepted			2022-12-28	WOS:000263906200012
J	Khandrika, L; Lieberman, R; Koul, S; Kumar, B; Maroni, P; Chandhoke, R; Meacham, RB; Koul, HK				Khandrika, L.; Lieberman, R.; Koul, S.; Kumar, B.; Maroni, P.; Chandhoke, R.; Meacham, R. B.; Koul, H. K.			Hypoxia-associated p38 mitogen-activated protein kinase-mediated androgen receptor activation and increased HIF-1 alpha levels contribute to emergence of an aggressive phenotype in prostate cancer	ONCOGENE			English	Article						p38 MAPK; HIF-1 alpha; androgen independence; prostate cancer	ENDOTHELIAL GROWTH-FACTOR; INDUCIBLE FACTOR-1-ALPHA; MAP-KINASE; OXIDATIVE STRESS; VEGF EXPRESSION; CELL INVASION; LNCAP CELLS; IN-VITRO; ANGIOGENESIS; PATHWAY	Androgen receptor (AR) signaling is involved in the development and progression of prostate cancer. Tumor microvasculature contributes to continual exposure of prostate cancer cells to hypoxia-reoxygenation, however, the role of hypoxia-reoxygenation in prostate cancer progression and modulation of AR signaling is not understood. In this study, we evaluated the effects of hypoxia-reoxygenation in LNCaP cells, a line of hormone responsive human prostate cancer cells. Our results demonstrate that hypoxia-reoxygenation resulted in increased survival, higher clonogenicity and enhanced invasiveness of these cells. Moreover, hypoxia-reoxygenation was associated with an increased AR activity independent of androgens as well as increased hypoxia inducible factor (HIF-1 alpha) levels and activity. We also observed that the activation of p38 mitogen-activated protein (MAP) kinase pathway was an early response to hypoxia, and inhibition of p38 MAP kinase pathway by variety of approaches abolished hypoxia-reoxygenation induced increased AR activity as well as increased survival, clonogenicity and invasiveness. These results demonstrate a critical role for hypoxia-induced p38 MAP kinase pathway in androgen-independent AR activation in prostate cancer cells, and suggest that hypoxia-reoxygenation may select for aggressive androgen-independent prostate cancer phenotype.	[Khandrika, L.; Lieberman, R.; Koul, S.; Kumar, B.; Maroni, P.; Chandhoke, R.; Meacham, R. B.; Koul, H. K.] Univ Colorado, Denver & Hlth Sci Ctr, Sch Med,Program Urosci, Signal Transduct & Mol Urol Lab,Dep Surg,Div Urol, Aurora, CO 80045 USA; [Maroni, P.; Meacham, R. B.; Koul, H. K.] Univ Colorado, Denver & Hlth Sci Ctr, Ctr Comprehens Canc, Aurora, CO 80045 USA; [Koul, H. K.] Univ Colorado, Denver & Hlth Sci Ctr, Denver Vet Adm Med Ctr, Aurora, CO 80045 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado System; University of Colorado Anschutz Medical Campus	Koul, HK (corresponding author), Univ Colorado, Denver & Hlth Sci Ctr, Sch Med,Program Urosci, Signal Transduct & Mol Urol Lab,Dep Surg,Div Urol, Bldg P15 RC2,12700 E 19th Ave,Room 6001, Aurora, CO 80045 USA.	hari.koul@uchsc.edu	Kumar, Binod/K-3679-2013	Khandrika, Lakshmipathi/0000-0003-4438-9073	NIH/NCI-P20 [CA103680]; Student Cancer Research Fellowship Program; University of Colorado Cancer Center; Department of Surgery School of Medicine Academic Enrichment Funds; NATIONAL CANCER INSTITUTE [P20CA103680] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK054084] Funding Source: NIH RePORTER	NIH/NCI-P20(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Student Cancer Research Fellowship Program; University of Colorado Cancer Center; Department of Surgery School of Medicine Academic Enrichment Funds; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	Supported in part by NIH/NCI-P20 CA103680-Schwartz/Byers Program PI's ( H Koul, Pilot-Project PI), Student Cancer Research Fellowship Program ( H Koul, Preceptor), University of Colorado Cancer Center and Department of Surgery School of Medicine Academic Enrichment Funds ( H Koul). We thankfully acknowledge service provided by University of Colorado Cancer Center Flow Cytometry Core. We thank Dr Andrew Kung ( Dana-Faber Cancer Institute, Boston, MA, USA) for 3 x HRE luciferase plasmid, Dr Magnus Essand ( Uppsala University, Sweden) for AR responsive Luciferase Vector PSAe/TARPp and Professor Matthias Gaestel ( Institute of Biochemistry, Medical School, Hannover, Germany) for MK2 expression plasmids.	Akakura N, 2001, CANCER RES, V61, P6548; Asirvatham AJ, 2006, ENDOCRINOLOGY, V147, P257, DOI 10.1210/en.2005-0942; Baek SH, 2001, J CELL PHYSIOL, V188, P223, DOI 10.1002/jcp.1117; Berra E, 2000, CANCER METAST REV, V19, P139, DOI 10.1023/A:1026506011458; Bhattacharya S, 1999, GENE DEV, V13, P64, DOI 10.1101/gad.13.1.64; Boddy JL, 2005, CLIN CANCER RES, V11, P7658, DOI 10.1158/1078-0432.CCR-05-0460; Butterworth KT, 2008, INT J CANCER, V123, P760, DOI 10.1002/ijc.23418; Calvani M, 2008, CANCER RES, V68, P285, DOI 10.1158/0008-5472.CAN-07-5564; Carmeliet P, 2000, NATURE, V407, P249, DOI 10.1038/35025220; Cheng WS, 2003, ENDOCRINOLOGY, V144, P3433, DOI 10.1210/en.2003-0121; Culig Z, 2006, J CELL BIOCHEM, V99, P373, DOI 10.1002/jcb.20898; Horii K, 2007, MOL CANCER RES, V5, P383, DOI 10.1158/1541-7786.MCR-06-0226; HOROSZEWICZ JS, 1983, CANCER RES, V43, P1809; Huggins C, 1941, CANCER RES, V1, P293; Kimbro KS, 2006, ENDOCR-RELAT CANCER, V13, P739, DOI 10.1677/erc.1.00728; Kokontis JM, 1998, MOL ENDOCRINOL, V12, P941, DOI 10.1210/me.12.7.941; Kumar B, 2008, CANCER RES, V68, P1777, DOI 10.1158/0008-5472.CAN-07-5259; Kwon SJ, 2005, CLIN CANCER RES, V11, P7607, DOI 10.1158/1078-0432.CCR-05-0981; Luo Y, 2006, BJU INT, V98, P1315, DOI 10.1111/j.1464-410X.2006.06480.x; Maroni PD, 2005, J UROLOGY, V174, P757, DOI 10.1097/01.ju.0000164724.86631.6e; McDonald DM, 2003, NAT MED, V9, P713, DOI 10.1038/nm0603-713; Milosevic M, 2007, CANCER RES, V67, P6022, DOI 10.1158/0008-5472.CAN-07-0561; Miyazaki Y, 2008, INT J ONCOL, V32, P145; Mortimer HJ, 2007, PULM PHARMACOL THER, V20, P718, DOI 10.1016/j.pupt.2006.08.007; Murata M, 2006, J ORTHOP RES, V24, P1544, DOI 10.1002/jor.20168; Pages G, 2000, J BIOL CHEM, V275, P26484, DOI 10.1074/jbc.M002104200; Park SY, 2006, CANCER RES, V66, P5121, DOI 10.1158/0008-5472.CAN-05-1341; Pouyssegur J, 2006, NATURE, V441, P437, DOI 10.1038/nature04871; Powell CS, 2004, AM J PHYSIOL-LUNG C, V286, pL826, DOI 10.1152/ajplung.00119.2003; REPESH LA, 1989, INVAS METAST, V9, P192; RIZZINO A, 1987, METHOD ENZYMOL, V146, P341; Shida Y, 2007, BIOCHEM BIOPH RES CO, V353, P744, DOI 10.1016/j.bbrc.2006.12.077; Sumbayev VV, 2005, ARCH BIOCHEM BIOPHYS, V436, P406, DOI 10.1016/j.abb.2005.02.021; Sung SY, 2006, CANCER RES, V66, P9519, DOI 10.1158/0008-5472.CAN-05-4375; Vleugel MM, 2005, J CLIN PATHOL, V58, P172, DOI 10.1136/jcp.2004.019885; Winzen R, 1999, EMBO J, V18, P4969, DOI 10.1093/emboj/18.18.4969; Xu L, 2006, ONCOGENE, V25, P2987, DOI 10.1038/sj.onc.1209337; Yoshino Y, 2006, INT J ONCOL, V29, P981; Zetter BR, 1998, ANNU REV MED, V49, P407, DOI 10.1146/annurev.med.49.1.407; Zhong H, 1998, CANCER RES, V58, P5280; Zhong H, 2000, CANCER RES, V60, P1541; Zoubeidi A, 2007, CANCER RES, V67, P10455, DOI 10.1158/0008-5472.CAN-07-2057	42	66	69	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 5	2009	28	9					1248	1260		10.1038/onc.2008.476	http://dx.doi.org/10.1038/onc.2008.476			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	415AH	19151763	Green Accepted			2022-12-28	WOS:000263906200009
J	Finkbeiner, MR; Astanehe, A; To, K; Fotovati, A; Davies, AH; Zhao, Y; Jiang, H; Stratford, AL; Shadeo, A; Boccaccio, C; Comoglio, P; Mertens, PR; Eirew, P; Raouf, A; Eaves, CJ; Dunn, SE				Finkbeiner, M. R.; Astanehe, A.; To, K.; Fotovati, A.; Davies, A. H.; Zhao, Y.; Jiang, H.; Stratford, A. L.; Shadeo, A.; Boccaccio, C.; Comoglio, P.; Mertens, P. R.; Eirew, P.; Raouf, A.; Eaves, C. J.; Dunn, S. E.			Profiling YB-1 target genes uncovers a new mechanism for MET receptor regulation in normal and malignant human mammary cells	ONCOGENE			English	Article						YB-1; MET receptor; ChIP-on-chip; basal-like breast cancer; mammary progenitors	GROWTH-FACTOR RECEPTOR; BOX BINDING PROTEIN-1; BREAST-CANCER CELLS; EPITHELIAL STEM-CELLS; INVASIVE GROWTH; IN-VIVO; C-MET; EXPRESSION; HER-2; BINDING-PROTEIN-1	Basal-like breast cancers (BLBCs) are aggressive tumors with high relapse rates and poor survival. We recently reported that > 70% of primary BLBCs express the oncogenic transcription/translation factor Y-box binding protein-1 (YB-1) and silencing it with small interfering RNAs (siRNAs) attenuates the growth of BLBC cell lines. To understand the basis of these earlier findings, we profiled YB-1: DNA complexes by chromatin immunoprecipitation (ChIP)-on-chip. Several tumor growth-promoting genes such as MET, CD44, CD49f, WNT and NOTCH family members were identified. In addition, YB-1 and MET are coordinately expressed in BLBC cell lines, as well as in normal human mammary progenitor cells. MET was confirmed to be a YB-1 target through traditional ChIP and gel-shift assays. More specifically, YB-1 binds to -1018 bp on the MET promoter. Silencing YB-1 with siRNA decreased MET promoter activity, transcripts, as well as protein levels and signaling. Conversely, expressing wild-type YB-1 or a constitutively active mutant YB-1 (D102) increased MET expression. Finally, silencing YB-1 or MET attenuated anchorage-independent growth of BLBC cell lines. Together, these findings implicate MET as a target of YB-1 that work in concert to promote BLBC growth.	[Finkbeiner, M. R.; Astanehe, A.; To, K.; Fotovati, A.; Davies, A. H.; Zhao, Y.; Jiang, H.; Stratford, A. L.; Dunn, S. E.] Univ British Columbia, Dept Pediat, Lab Oncogen Res, Vancouver, BC V5Z 4H4, Canada; [Finkbeiner, M. R.; Astanehe, A.; To, K.; Fotovati, A.; Davies, A. H.; Zhao, Y.; Jiang, H.; Stratford, A. L.; Dunn, S. E.] Univ British Columbia, Dept Expt Med, Child & Family Res Inst, Vancouver, BC V5Z 4H4, Canada; [Shadeo, A.] British Columbia Canc Agcy, Canc Genet & Dev Biol, Vancouver, BC V5Z 4E6, Canada; [Boccaccio, C.; Comoglio, P.] Univ Turin, Sch Med, Inst Canc Res & Treatment IRCC, Candiolo, Italy; [Mertens, P. R.] Univ Hosp Aachen, Div Nephrol & Clin Immunol, Aachen, Germany; [Eirew, P.; Raouf, A.; Eaves, C. J.] British Columbia Canc Agcy, Terry Fox Lab, Vancouver, BC V5Z 1L3, Canada	University of British Columbia; Child & Family Research Institute; University of British Columbia; British Columbia Cancer Agency; IRCCS Fondazione del Piemonte per l'Oncologia; University of Turin; RWTH Aachen University; RWTH Aachen University Hospital; British Columbia Cancer Agency	Dunn, SE (corresponding author), Univ British Columbia, Dept Pediat, Lab Oncogen Res, 950 W 28th Ave, Vancouver, BC V5Z 4H4, Canada.	sedunn@interchange.ubc.ca	Boccaccio, Carla/AHE-7875-2022; Mertens, Peter/AAI-7310-2020	Boccaccio, Carla/0000-0003-2620-9083; Eaves, Connie/0000-0002-3452-1926; Shadeo, Ashleen/0000-0002-0866-0519; Comoglio, Paolo/0000-0002-7056-5328	Canadian Breast Cancer Research Alliance; National Institute of Health; Michael Smith Foundation; Canadian Institute for Health; Canadian Breast Cancer Foundation; US Department of Defense Breast Cancer Research; Terry Fox Foundation; National Cancer Institute of Canada; Canadian Imperial Bank of Commerce; Canadian Stem Cell Network Studentship	Canadian Breast Cancer Research Alliance; National Institute of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Michael Smith Foundation(Michael Smith Foundation for Health Research); Canadian Institute for Health(Canadian Institutes of Health Research (CIHR)); Canadian Breast Cancer Foundation(Canadian Cancer Society (CCS)); US Department of Defense Breast Cancer Research(United States Department of Defense); Terry Fox Foundation; National Cancer Institute of Canada(Canadian Cancer Society (CCS)); Canadian Imperial Bank of Commerce; Canadian Stem Cell Network Studentship	This project was funded by the Canadian Breast Cancer Research Alliance (awarded to SED) and the National Institute of Health (RO1 awarded to SED). A Astanehe, K To and A Davies are recipients of Michael Smith Foundation for Health Research Graduate Studentships. A Astanehe and K To are recipients of Canadian Institute for Health Graduate Studentships. A Stratford holds a Canadian Breast Cancer Foundation Postdoctoral Fellowship. P Eirew is the recipient of the US Department of Defense Breast Cancer Research Program Studentship, the Terry Fox Foundation Research Studentship from the National Cancer Institute of Canada, the Canadian Imperial Bank of Commerce Interdisciplinary Award and the Canadian Stem Cell Network Studentship.	Al-Hajj M, 2003, P NATL ACAD SCI USA, V100, P3983, DOI 10.1073/pnas.0530291100; Birchmeier C, 2003, NAT REV MOL CELL BIO, V4, P915, DOI 10.1038/nrm1261; Boccaccio C, 2006, NAT REV CANCER, V6, P637, DOI 10.1038/nrc1912; Boon EMJ, 2002, CANCER RES, V62, P5126; Charafe-Jauffret E, 2006, ONCOGENE, V25, P2273, DOI 10.1038/sj.onc.1209254; Colozza M, 2007, ONCOLOGIST, V12, P253, DOI 10.1634/theoncologist.12-3-253; Comoglio PM, 2008, NAT REV DRUG DISCOV, V7, P504, DOI 10.1038/nrd2530; Dontu G, 2004, BREAST CANCER RES, V6, pR605, DOI 10.1186/bcr920; Dunn BK, 2007, EUR J CANCER PREV, V16, P232, DOI 10.1097/CEJ.0b013e328011ed2d; Eirew P, 2008, NAT MED, V14, P1384, DOI 10.1038/nm.1791; Farnie G, 2007, JNCI-J NATL CANCER I, V99, P616, DOI 10.1093/jnci/djk133; Gambarotta G, 1996, ONCOGENE, V13, P1911; Habibi G, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr2156; Kuwano M, 2004, MOL CANCER THER, V3, P1485; Lee C, 2008, CANCER RES, V68, P8661, DOI 10.1158/0008-5472.CAN-08-1082; Leo C, 2007, GYNECOL ONCOL, V104, P181, DOI 10.1016/j.ygyno.2006.07.040; Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027; Okamoto T, 2000, ONCOGENE, V19, P6194, DOI 10.1038/sj.onc.1204029; Orian-Rousseau V, 2002, GENE DEV, V16, P3074, DOI 10.1101/gad.242602; Pennacchietti S, 2003, CANCER CELL, V3, P347, DOI 10.1016/S1535-6108(03)00085-0; Raouf A, 2008, CELL STEM CELL, V3, P109, DOI 10.1016/j.stem.2008.05.018; Sachs M, 2000, J CELL BIOL, V150, P1375, DOI 10.1083/jcb.150.6.1375; Shadeo A, 2006, BREAST CANCER RES, V8, DOI 10.1186/bcr1370; Shipitsin M, 2007, CANCER CELL, V11, P259, DOI 10.1016/j.ccr.2007.01.013; Sorlie T, 2001, P NATL ACAD SCI USA, V98, P10869, DOI 10.1073/pnas.191367098; Stingl J, 2006, NATURE, V439, P993, DOI 10.1038/nature04496; Stratford AL, 2007, BREAST CANCER RES, V9, DOI 10.1186/bcr1767; Stratford AL, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr2202; Sutherland BW, 2005, ONCOGENE, V24, P4281, DOI 10.1038/sj.onc.1208590; To K, 2007, MOL PHARMACOL, V72, P641, DOI 10.1124/mol.107.036111; Trusolino L, 2002, NAT REV CANCER, V2, P289, DOI 10.1038/nrc779; Trusolino L, 2001, CELL, V107, P643, DOI 10.1016/S0092-8674(01)00567-0; van Roeyen CRC, 2005, J AM SOC NEPHROL, V16, P2985, DOI 10.1681/ASN.2004111009; Welm AL, 2005, P NATL ACAD SCI USA, V102, P4324, DOI 10.1073/pnas.0500470102; Wu J, 2006, CANCER RES, V66, P4872, DOI 10.1158/0008-5472.CAN-05-3561; Yoshida S, 2004, J CLIN ENDOCR METAB, V89, P823, DOI 10.1210/jc.2003-030874; Zhao Y, 2007, STEM CELLS, V25, P1681, DOI 10.1634/stemcells.2006-0794	37	70	70	1	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2009	28	11					1421	1431		10.1038/onc.2008.485	http://dx.doi.org/10.1038/onc.2008.485			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	421JE	19151767				2022-12-28	WOS:000264354400003
J	Saharia, A; Stewart, SA				Saharia, A.; Stewart, S. A.			FEN1 contributes to telomere stability in ALT-positive tumor cells	ONCOGENE			English	Article						telomere; FEN1; genomic stability; ALT	REPLICATION FORK; DNA-REPLICATION; WRN HELICASE; COMPLEX; LENGTH; STRAND; MECHANISM; ENDS; STIMULATION; INHIBITION	Abrogation of telomere stability through loss-of-function mutations in telomere binding proteins contributes to genomic instability and cancer progression. Recently, Flap endonuclease 1 (FEN1) was shown to contribute to telomere stability in human cells that had not yet activated a telomere maintenance mechanism, suggesting that abrogation of FEN1 function influences the transformation process by compromising telomere stability and driving genomic instability. Here, we analyse the telomeres in human cancer cells following FEN1 depletion. We show that FEN1 is required for telomere stability in cells that rely on the alternative lengthening of telomere (ALT) mechanism. Indeed, FEN1 depletion resulted in telomere dysfunction, characterized by formation of telomere dysfunction-induced foci (TIFs) and end-to-end fusions in ALT-positive cells. In contrast, no telomere phenotype was observed in telomerase-positive cells on FEN1 depletion, suggesting that ongoing telomerase activity protected telomeres. In consonance with this, we found that expression of the catalytic component of telomerase (hTERT) but not an inactive allele rescued telomere dysfunction on FEN1 depletion in ALT cells. Our data suggest that mutations that arise in FEN1 affect telomere stability and genome fidelity by promoting telomere fusions and anaphase-bridge-breakage cycles, which further drive genome instability and thereby contribute to the transformation process.	[Stewart, S. A.] Washington Univ, Sch Med, Dept Med, St Louis, MO 63110 USA; [Saharia, A.; Stewart, S. A.] Washington Univ, Sch Med, Dept Cell Biol & Physiol, St Louis, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL)	Stewart, SA (corresponding author), Washington Univ, Sch Med, Dept Cell Biol & Physiol & Med, Campus Box 8228,660 S Euclid Ave, St Louis, MO 63110 USA.	sheila.stewart@cellbiology.wustl.edu	Stewart, Sheila A/C-5213-2012		Sidney Kimmel Foundation for Cancer Research; Edward Mallinckrodt, Jr Foundation; Lucille P Markey Program	Sidney Kimmel Foundation for Cancer Research; Edward Mallinckrodt, Jr Foundation; Lucille P Markey Program	This work was supported by the Sidney Kimmel Foundation for Cancer Research and the Edward Mallinckrodt, Jr Foundation. AS was supported by the Lucille P Markey Program. SAS is a Sidney Kimmel Scholar. We are grateful to Yu Tao for helpwith statistical analyses and members of the Stewart Laboratory for valuable discussions.	Artandi SE, 2000, CURR OPIN GENET DEV, V10, P39, DOI 10.1016/S0959-437X(99)00047-7; Blasco MA, 2005, NAT REV GENET, V6, P611, DOI 10.1038/nrg1656; Branzei D, 2005, CURR OPIN CELL BIOL, V17, P568, DOI 10.1016/j.ceb.2005.09.003; Bryan TM, 1997, NAT MED, V3, P1271, DOI 10.1038/nm1197-1271; Crabbe L, 2004, SCIENCE, V306, P1951, DOI 10.1126/science.1103619; DADDA DF, 2003, NATURE, V426, P194, DOI DOI 10.1038/NATURE02118; de Lange T, 2005, GENE DEV, V19, P2100, DOI 10.1101/gad.1346005; Forstemann K, 2000, NUCLEIC ACIDS RES, V28, P2690, DOI 10.1093/nar/28.14.2690; Fouche N, 2006, NUCLEIC ACIDS RES, V34, P6044, DOI 10.1093/nar/gkl757; Gilson E, 2007, NAT REV MOL CELL BIO, V8, P825, DOI 10.1038/nrm2259; Grobelny JV, 2001, HUM MOL GENET, V10, P1953, DOI 10.1093/hmg/10.18.1953; Hahn WC, 1999, NAT MED, V5, P1164, DOI 10.1038/13495; Hemann MT, 2001, CELL, V107, P67, DOI 10.1016/S0092-8674(01)00504-9; Kikuchi K, 2005, MOL CELL BIOL, V25, P6948, DOI 10.1128/MCB.25.16.6948-6955.2005; Kucherlapati M, 2007, ONCOGENE, V26, P6297, DOI 10.1038/sj.onc.1210453; LI XY, 1995, J BIOL CHEM, V270, P22109, DOI 10.1074/jbc.270.38.22109; Liu D, 2004, J BIOL CHEM, V279, P51338, DOI 10.1074/jbc.M409293200; Londono-Vallejo JA, 2004, CANCER RES, V64, P2324, DOI 10.1158/0008-5472.CAN-03-4035; Marcand S, 1999, EMBO J, V18, P3509, DOI 10.1093/emboj/18.12.3509; Nabetani A, 2004, J BIOL CHEM, V279, P25849, DOI 10.1074/jbc.M312652200; Ohki R, 2004, NUCLEIC ACIDS RES, V32, P1627, DOI 10.1093/nar/gkh309; Ouellette MM, 2000, J BIOL CHEM, V275, P10072, DOI 10.1074/jbc.275.14.10072; Parenteau J, 2002, GENETICS, V162, P1583; Parenteau J, 1999, MOL CELL BIOL, V19, P4143; Perrem K, 2001, MOL CELL BIOL, V21, P3862, DOI 10.1128/MCB.21.12.3862-3875.2001; Prasad R, 2000, J BIOL CHEM, V275, P4460, DOI 10.1074/jbc.275.6.4460; Saharia A, 2008, CURR BIOL, V18, P496, DOI 10.1016/j.cub.2008.02.071; Sharma S, 2004, MOL BIOL CELL, V15, P734, DOI 10.1091/mbc.E03-08-0567; Stewart SA, 2003, NAT GENET, V33, P492, DOI 10.1038/ng1127; Stewart SA, 2002, P NATL ACAD SCI USA, V99, P12606, DOI 10.1073/pnas.182407599; Takai H, 2003, CURR BIOL, V13, P1549, DOI 10.1016/S0960-9822(03)00542-6; Teixeira MT, 2004, CELL, V117, P323, DOI 10.1016/S0092-8674(04)00334-4; Tishkoff DX, 1997, CELL, V88, P253, DOI 10.1016/S0092-8674(00)81846-2; Zheng L, 2005, EMBO REP, V6, P83, DOI 10.1038/sj.embor.7400313; Zheng L, 2007, NAT MED, V13, P812, DOI 10.1038/nm1599	35	32	34	1	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2009	28	8					1162	1167		10.1038/onc.2008.458	http://dx.doi.org/10.1038/onc.2008.458			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	412KE	19137021				2022-12-28	WOS:000263722900011
J	Tamura, Y; Simizu, S; Muroi, M; Takagi, S; Kawatani, M; Watanabe, N; Osada, H				Tamura, Y.; Simizu, S.; Muroi, M.; Takagi, S.; Kawatani, M.; Watanabe, N.; Osada, H.			Polo-like kinase 1 phosphorylates and regulates Bcl-x(L) during pironetin-induced apoptosis	ONCOGENE			English	Article						apoptosis; Bcl-x(L); phosphorylation; Plk1; pironetin	BCL-2 FAMILY; SOMATIC WEE1; PROTEIN; IDENTIFICATION; INHIBITOR; DOMAIN; DEATH; GENE; ALPHA; PLK1	Bcl-x(L), an anti-apoptotic Bcl-2 family member protein, contributes to the resistance against chemotherapies such as tubulin-binder treatment in many human tumors. Although Bcl-x(L) is phosphorylated after tubulin-binder treatment, the role of the phosphorylation and its responsible kinase(s) are poorly understood. Here, we identified Plk1 (polo-like kinase 1) as a Bcl-x(L) kinase. Same location of Bcl-x(L) and Plk1 was revealed by immunocytochemical analyses at M-phase in situ. Plk1 phosphorylates Bcl-x(L) in vitro, and we identified Plk1 phosphorylation sites in Bcl-x(L). When all of these phosphorylation sites were substituted to alanines, the anti-apoptotic activity of the Bcl-x(L) mutant against the apoptosis induced by pironetin, but not against ultraviolet-induced apoptosis, was increased. These observations suggest that Plk1 is a regulator of Bcl-x(L) phosphorylation and controls the anti-apoptotic activity of Bcl-x(L) during pironetin-induced apoptosis.	[Tamura, Y.; Simizu, S.; Muroi, M.; Takagi, S.; Kawatani, M.; Watanabe, N.; Osada, H.] RIKEN, Antibiot Lab, Wako, Saitama 3510198, Japan; [Tamura, Y.; Simizu, S.; Muroi, M.; Takagi, S.; Kawatani, M.; Watanabe, N.; Osada, H.] RIKEN, Dept Biol Chem, Adv Sci Inst, Wako, Saitama 3510198, Japan; [Tamura, Y.; Takagi, S.; Osada, H.] Saitama Univ, Grad Sch Sci & Engn, Saitama 3388570, Japan	RIKEN; RIKEN; Saitama University	Osada, H (corresponding author), RIKEN, Antibiot Lab, 2-1 Hirosawa, Wako, Saitama 3510198, Japan.	hisyo@riken.jp	Watanabe, Nobumoto/N-6959-2015; Muroi, Makoto/C-7430-2017; Osada, Hiroyuki/N-4305-2014; Osada, Hiroyuki/AAY-6254-2020	Watanabe, Nobumoto/0000-0002-2130-1334; Simizu, Siro/0000-0003-2949-2427; Kawatani, Makoto/0000-0002-9571-4916; MUROI, Makoto/0000-0002-4323-9527				Barr FA, 2004, NAT REV MOL CELL BIO, V5, P429, DOI 10.1038/nrm1401; Basu A, 2003, FEBS LETT, V538, P41, DOI 10.1016/S0014-5793(03)00131-5; BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; Chang BS, 1997, EMBO J, V16, P968, DOI 10.1093/emboj/16.5.968; Chao DT, 1998, ANNU REV IMMUNOL, V16, P395, DOI 10.1146/annurev.immunol.16.1.395; Chen J, 2006, FEBS LETT, V580, P3624, DOI 10.1016/j.febslet.2006.05.047; Cheng EHY, 1996, NATURE, V379, P554, DOI 10.1038/379554a0; Cittelly DM, 2007, J NEUROSCI RES, V85, P1894, DOI 10.1002/jnr.21313; Cory S, 2002, NAT REV CANCER, V2, P647, DOI 10.1038/nrc883; Deverman BE, 2002, CELL, V111, P51, DOI 10.1016/S0092-8674(02)00972-8; Du LH, 2005, ONCOGENE, V24, P107, DOI 10.1038/sj.onc.1208189; Elia AEH, 2003, CELL, V115, P83, DOI 10.1016/S0092-8674(03)00725-6; Feng Y, 1999, BIOCHEM J, V339, P435, DOI 10.1042/0264-6021:3390435; Gumireddy K, 2005, CANCER CELL, V7, P275, DOI 10.1016/j.ccr.2005.02.009; Jeong SY, 2004, EMBO J, V23, P2146, DOI 10.1038/sj.emboj.7600225; Kaufmann T, 2003, J CELL BIOL, V160, P53, DOI 10.1083/jcb.200210084; Kawatani M, 2003, J BIOL CHEM, V278, P19732, DOI 10.1074/jbc.M213038200; Kondoh M, 1999, BIOCHEM J, V340, P411, DOI 10.1042/0264-6021:3400411; Liu XQ, 2003, P NATL ACAD SCI USA, V100, P5789, DOI 10.1073/pnas.1031523100; Muchmore SW, 1996, NATURE, V381, P335, DOI 10.1038/381335a0; Nakajima H, 2003, J BIOL CHEM, V278, P25277, DOI 10.1074/jbc.C300126200; Oltersdorf T, 2005, NATURE, V435, P677, DOI 10.1038/nature03579; Petros AM, 2004, BBA-MOL CELL RES, V1644, P83, DOI 10.1016/j.bbamcr.2003.08.012; Poruchynsky MS, 1998, CANCER RES, V58, P3331; Ree AH, 2003, ONCOGENE, V22, P8952, DOI 10.1038/sj.onc.1207000; Reed JC, 2002, NAT REV DRUG DISCOV, V1, P111, DOI 10.1038/nrd726; Schinzel A, 2004, BBA-MOL CELL RES, V1644, P95, DOI 10.1016/j.bbamcr.2003.09.006; Simizu S, 2000, NAT CELL BIOL, V2, P852, DOI 10.1038/35041102; Simizu S, 2005, CANCER RES, V65, P7455, DOI 10.1158/0008-5472.CAN-04-4446; Simizu S, 2004, CANCER SCI, V95, P266, DOI 10.1111/j.1349-7006.2004.tb02214.x; Tamura Y, 2004, FEBS LETT, V569, P249, DOI 10.1016/j.febslet.2004.06.003; Tsujimoto Y, 2000, FEBS LETT, V466, P6, DOI 10.1016/S0014-5793(99)01761-5; Usui T, 2004, CHEM BIOL, V11, P799, DOI 10.1016/j.chembiol.2004.03.028; Watanabe N, 2004, P NATL ACAD SCI USA, V101, P4419, DOI 10.1073/pnas.0307700101; Watanabe N, 2005, P NATL ACAD SCI USA, V102, P11663, DOI 10.1073/pnas.0500410102; Wyllie A H, 1980, Int Rev Cytol, V68, P251; Zheng JY, 2008, BIOPHYS J, V94, P286, DOI 10.1529/biophysj.107.104323	37	34	34	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 8	2009	28	1					107	116		10.1038/onc.2008.368	http://dx.doi.org/10.1038/onc.2008.368			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	392HP	18820703				2022-12-28	WOS:000262294100011
J	Ischenko, I; Camaj, P; Seeliger, H; Kleespies, A; Guba, M; De Toni, EN; Schwarz, B; Graeb, C; Eichhorn, ME; Jauch, KW; Bruns, CJ				Ischenko, I.; Camaj, P.; Seeliger, H.; Kleespies, A.; Guba, M.; De Toni, E. N.; Schwarz, B.; Graeb, C.; Eichhorn, M. E.; Jauch, K-W; Bruns, C. J.			Inhibition of Src tyrosine kinase reverts chemoresistance toward 5-fluorouracil in human pancreatic carcinoma cells: an involvement of epidermal growth factor receptor signaling	ONCOGENE			English	Article						5-fluorouracil; acquired resistance; thymidylate synthase; Src kinase inhibition; mouse xenograft pancreatic tumor model; epidermal growth factor receptor	THYMIDYLATE SYNTHASE INHIBITORS; COLORECTAL-CANCER CELLS; DIHYDROPYRIMIDINE DEHYDROGENASE; FAMILY KINASES; TUMOR-CELLS; STEM-CELLS; EXPRESSION; RESISTANCE; PROTEIN; DNA	Resistance to chemotherapy is believed to be a major cause of treatment failure in pancreatic cancer. Thus, it is necessary to explore alternative therapeutic modalities to overcome drug resistance in pancreatic cancer treatment. We tested the hypothesis that Src tyrosine kinase inhibition could augment the chemosensitivity of 5-fluorouracil (5-FU)-resistant human pancreatic cancer cells to 5-FU. As detected by MTT proliferation assay, propidium iodide and annexin V staining, a combination of 5-FU_Src kinase inhibitor PP2 (4-amino-5-(4-chlorophenyl)-7-(t-butyl) pyrazolo[3,4-d] pyrimidine) reflected the chemotherapeutic sensitivity and restored the 5-FU-induced apoptosis in 5-FU-resistant cells. Furthermore, when small-interfering RNA approach to silence Src gene expression was applied, the degree of 5-FU-induced apoptosis was increased in all cell lines independently of the chemoresistance status. Western blotting and RT-PCR analysis revealed that the expression of thymidylate synthase (TS) was higher in 5-FU-resistant cells, however, decreased significantly after pretreatment with PP2. Furthermore, the combination of 5-FU_PP2 decreased the 5-FU-induced activation of epidermal growth factor receptor (EGFR)-AKT pathway. Finally, PP2 in combination with 5-FU substantially decreased the in vivo tumor growth and inhibited distant metastases. Taken together, 5-FU chemoresistance can be reversed through indirect TS regulation by inhibiting Src tyrosine kinase. A potential mechanism of action of Src kinase inhibitors on 5-FU chemosensitivity might be linked to the inhibition of 5-FU-induced EGFR-AKT activation.	[Ischenko, I.; Camaj, P.; Seeliger, H.; Kleespies, A.; Guba, M.; Schwarz, B.; Graeb, C.; Eichhorn, M. E.; Jauch, K-W; Bruns, C. J.] Univ Munich, Dept Surg, D-81377 Munich, Germany; [De Toni, E. N.] Univ Munich, Dept Gastroenterol, D-81377 Munich, Germany	University of Munich; University of Munich	Ischenko, I (corresponding author), Univ Munich, Dept Surg, Grosshadern Campus,Marchioninistr 15, D-81377 Munich, Germany.	Ivan.Ischenko@med.uni-muenchen.de	Eichhorn, Martin/AAU-7204-2020; Guba, Markus/M-4309-2019; Ischenko, Ivan/A-4591-2011; Eichhorn, Martin/GRE-9126-2022; De Toni, Enrico N/C-6496-2008	Eichhorn, Martin/0000-0002-0362-0374; 	Deutsche Forschungsgemeinschaft (DFG) [KFO 128/1-3]; Deutsche Forschungsgemeinschaft (DFG) of the Schwerpunktprogramm [GU 489/3-1]	Deutsche Forschungsgemeinschaft (DFG)(German Research Foundation (DFG)); Deutsche Forschungsgemeinschaft (DFG) of the Schwerpunktprogramm(German Research Foundation (DFG))	We thank AstraZeneca for providing with AZM475271. This research was supported by the grant of the clinical research group KFO 128/1-3 of the Deutsche Forschungsgemeinschaft (DFG) and the research grant GU 489/3-1 of the Deutsche Forschungsgemeinschaft (DFG) of the Schwerpunktprogramm 'The tumor-vessel interface'. This report includes data that were generated during the doctoral thesis of Bettina Schwarz at the Medical School of the Ludwig-Maximilians-University, Munich.	BECK A, 1994, EUR J CANCER, V30A, P1517, DOI 10.1016/0959-8049(94)00216-R; Blaszkowsky Lawrence, 1998, Frontiers in Bioscience, V3, pE214; Bruns Christiane J., 1999, Neoplasia (New York), V1, P50, DOI 10.1038/sj.neo.7900005; Chu E, 1996, BIOESSAYS, V18, P191, DOI 10.1002/bies.950180306; Chu E, 2003, CANCER CHEMOTH PHARM, V52, pS80, DOI 10.1007/s00280-003-0625-9; CHU E, 1993, P NATL ACAD SCI USA, V90, P517, DOI 10.1073/pnas.90.2.517; Collins AT, 2005, CANCER RES, V65, P10946, DOI 10.1158/0008-5472.CAN-05-2018; Crnogorac-Jurcevic T, 2001, ONCOGENE, V20, P7437, DOI 10.1038/sj.onc.1204935; DECAPRIO JA, 1991, J CLIN ONCOL, V9, P2128, DOI 10.1200/JCO.1991.9.12.2128; Duxbury MS, 2004, CLIN CANCER RES, V10, P2307, DOI 10.1158/1078-0432.CCR-1183-3; Frame MC, 2002, BBA-REV CANCER, V1602, P114, DOI 10.1016/S0304-419X(02)00040-9; Ghoshal K, 1997, BIOCHEM PHARMACOL, V53, P1569, DOI 10.1016/S0006-2952(97)00040-3; Gibson S, 1999, J BIOL CHEM, V274, P17612, DOI 10.1074/jbc.274.25.17612; Hamaji Masayasu, 2002, Gan To Kagaku Ryoho, V29, P889; Hermann PC, 2007, CELL STEM CELL, V1, P313, DOI 10.1016/j.stem.2007.06.002; Igney FH, 2002, NAT REV CANCER, V2, P277, DOI 10.1038/nrc776; JOHNSTON PG, 1995, CANCER RES, V55, P1407; Karni R, 1999, ONCOGENE, V18, P4654, DOI 10.1038/sj.onc.1202835; Kleespies A, 2006, DRUG RESIST UPDATE, V9, P1, DOI 10.1016/j.drup.2006.02.002; Koizumi F, 2004, INT J CANCER, V108, P464, DOI 10.1002/ijc.11539; KOLLMANNSBERGER C, 1996, CANCER, V78, P654; LONN U, 1984, CANCER RES, V44, P3414; Lutz MP, 1998, BIOCHEM BIOPH RES CO, V243, P503, DOI 10.1006/bbrc.1997.8043; MAJOR PP, 1982, CANCER RES, V42, P3005; Masumoto N, 1997, Gan To Kagaku Ryoho, V24, P424; Miyazaki Y, 2001, GASTROENTEROLOGY, V120, P108, DOI 10.1053/gast.2001.20950; Moore PS, 2001, VIRCHOWS ARCH, V439, P798, DOI 10.1007/s004280100474; Nam JS, 2002, CLIN CANCER RES, V8, P2430; O'Brien CA, 2007, NATURE, V445, P106, DOI 10.1038/nature05372; Paul Manash K, 2004, Int J Med Sci, V1, P101; Peters GJ, 2002, BBA-MOL BASIS DIS, V1587, P194, DOI 10.1016/S0925-4439(02)00082-0; PINEDO HM, 1988, J CLIN ONCOL, V6, P1653, DOI 10.1200/JCO.1988.6.10.1653; Popat S, 2004, J CLIN ONCOL, V22, P529, DOI 10.1200/JCO.2004.05.064; Salonga D, 2000, CLIN CANCER RES, V6, P1322; Shi X, 2002, ONCOLOGY-BASEL, V62, P354, DOI 10.1159/000065068; Summy JM, 2005, PANCREAS, V31, P263, DOI 10.1097/01.mpa.0000178280.50534.0c; Summy JM, 2003, CANCER METAST REV, V22, P337, DOI 10.1023/A:1023772912750; Szotek PP, 2006, P NATL ACAD SCI USA, V103, P11154, DOI 10.1073/pnas.0603672103; Thomas SM, 1997, ANNU REV CELL DEV BI, V13, P513, DOI 10.1146/annurev.cellbio.13.1.513; Van Schaeybroeck S, 2005, CLIN CANCER RES, V11, P7480, DOI 10.1158/1078-0432.CCR-05-0328; Voboril R, 2004, J SURG RES, V120, P178, DOI 10.1016/j.jss.2003.11.023; Wang W, 2003, BRIT J CANCER, V88, P624, DOI 10.1038/sj.bjc.6600753; Wang WG, 2003, INT J CANCER, V104, P504, DOI 10.1002/ijc.10972; Wang WG, 2001, CANCER RES, V61, P5505; Wu YP, 1998, INT J ONCOL, V13, P1241; Yezhelyev MV, 2004, CLIN CANCER RES, V10, P8028, DOI 10.1158/1078-0432.CCR-04-0621; Zhao YP, 2006, J SURG RES, V136, P325, DOI 10.1016/j.jss.2006.06.031	47	59	62	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC	2008	27	57					7212	7222		10.1038/onc.2008.326	http://dx.doi.org/10.1038/onc.2008.326			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	379GG	18794807				2022-12-28	WOS:000261384100008
J	Banks, L; Humbert, PO				Banks, L.; Humbert, P. O.			On the guardians of polarity and the disorientation of cancer INTRODUCTION	ONCOGENE			English	Editorial Material									[Banks, L.] Int Ctr Genet Engn & Biotechnol, I-34012 Trieste, Italy; [Humbert, P. O.] Peter MacCallum Canc Inst, Div Res, Cell Cycle & Canc Genet Lab, Melbourne, Vic 8006, Australia	International Center for Genetic Engineering & Biotechnology (ICGEB); Peter Maccallum Cancer Center	Banks, L (corresponding author), Int Ctr Genet Engn & Biotechnol, Padriciano 99, I-34012 Trieste, Italy.	banks@icgeb.org; patrick.humbert@petermac.org	Humbert, Patrick O/L-4264-2016	Humbert, Patrick O/0000-0002-1366-6691					0	7	7	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 24	2008	27	55					6876	6877		10.1038/onc.2008.339	http://dx.doi.org/10.1038/onc.2008.339			2	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	375IU	19029930				2022-12-28	WOS:000261108200001
J	Humbert, PO; Grzeschik, NA; Brumby, AM; Galea, R; Elsum, I; Richardson, HE				Humbert, P. O.; Grzeschik, N. A.; Brumby, A. M.; Galea, R.; Elsum, I.; Richardson, H. E.			Control of tumourigenesis by the Scribble/Dlg/Lgl polarity module	ONCOGENE			English	Review						Scribble; Dlg; Lgl; cell polarity; tumour suppressors	LETHAL-GIANT-LARVAE; TUMOR-SUPPRESSOR PROTEIN; EPITHELIAL-CELL POLARITY; COMPARATIVE GENOMIC HYBRIDIZATION; UBIQUITIN-MEDIATED DEGRADATION; PDZ-CONTAINING PROTEINS; REGULATES SELF-RENEWAL; DOMAIN-BINDING MOTIF; NEURAL-TUBE DEFECTS; HUMAN HOMOLOG	The neoplastic tumour suppressors, Scribble, Dlg and Lgl, originally discovered in the vinegar fly Drosophila melanogaster, are currently being actively studied for their potential role in mammalian tumourigenesis. In Drosophila, these tumour suppressors function in a common genetic pathway to regulate apicobasal cell polarity and also play important roles in the control of cell proliferation, survival, differentiation and in cell migration/invasion. The precise mechanism by which Scribble, Dlg and Lgl function is not clear; however, they have been implicated in the regulation of signalling pathways, vesicle trafficking and in the Myosin II-actin cytoskeleton. We review the evidence for the involvement of Scribble, Dlg, and Lgl in cancer, and how the various functions ascribed to these tumour suppressors in Drosophila and mammalian systems may impact on the process of tumourigenesis.	[Humbert, P. O.; Galea, R.; Elsum, I.] Peter MacCallum Canc Inst, Div Res, Cell Cycle & Canc Genet Lab, Melbourne, Vic 8006, Australia; [Grzeschik, N. A.; Brumby, A. M.; Richardson, H. E.] Peter MacCallum Canc Inst, Div Res, Cell Cycle & Dev Lab, Melbourne, Vic 8006, Australia	Peter Maccallum Cancer Center; Peter Maccallum Cancer Center	Humbert, PO (corresponding author), Peter MacCallum Canc Inst, Div Res, Cell Cycle & Canc Genet Lab, Locked Bag 1,Abeckett St, Melbourne, Vic 8006, Australia.	patrick.humbert@petermac.org	Richardson, Helena E/A-8080-2013; Humbert, Patrick O/L-4264-2016	Richardson, Helena E/0000-0003-3852-4953; Humbert, Patrick O/0000-0002-1366-6691; Elsum, Imogen/0000-0003-4525-0727	Career Development Award; Australian NHMRC; Cancer Council Victoria; Association for International Cancer Research UK; Australian Cancer Council Victoria	Career Development Award; Australian NHMRC(National Health and Medical Research Council (NHMRC) of Australia); Cancer Council Victoria(Canadian Institutes of Health Research (CIHR)Cancer Council Victoria); Association for International Cancer Research UK; Australian Cancer Council Victoria(Canadian Institutes of Health Research (CIHR)Cancer Council Victoria)	We thank Linda Parsons and Sarah Russell for critical reading of the manuscript and numerous discussions. We also thank Shernaz Bamji, Lawrence Banks, Chris Doe, Scott Goode, Daniela Grifoni, Juergen Knoblich and Senthil Muthuswamy for communicating results before publication. We apologize to those authors whose work was not cited directly owing to space limitations. POH was supported by a Career Development Award, HER by a Senior Research Fellowship from the Australian NHMRC and IE by a Postgraduate Cancer Research Scholarship from the Cancer Council Victoria. This work was supported by grants from the Australian NHMRC (POH, AMB, NAG and HER), Association for International Cancer Research UK (POH) and Australian Cancer Council Victoria (POH and HER).	Adachi-Yamada T, 2004, J BIOCHEM, V136, P13, DOI 10.1093/jb/mvh099; Adey NB, 2000, CANCER RES, V60, P35; Aigner K, 2007, ONCOGENE, V26, P6979, DOI 10.1038/sj.onc.1210508; Albertson R, 2004, J CELL SCI, V117, P6061, DOI 10.1242/jcs.01525; Albertson R, 2003, NAT CELL BIOL, V5, P166, DOI 10.1038/ncb922; Anderson JM, 1996, CURR BIOL, V6, P382, DOI 10.1016/S0960-9822(02)00501-8; Aranda V, 2008, ONCOGENE, V27, P6878, DOI 10.1038/onc.2008.340; Arpin-Andre C, 2007, J BIOL CHEM, V282, P33132, DOI 10.1074/jbc.M702279200; Arquier N, 2001, DEVELOPMENT, V128, P2209; Assemat E, 2008, BBA-BIOMEMBRANES, V1778, P614, DOI 10.1016/j.bbamem.2007.08.029; Audebert S, 2004, CURR BIOL, V14, P987, DOI 10.1016/j.cub.2004.05.051; Barros CS, 2003, DEV CELL, V5, P829, DOI 10.1016/S1534-5807(03)00359-9; Beaucher M, 2007, DEV BIOL, V303, P625, DOI 10.1016/j.ydbio.2006.12.001; Beaucher M, 2007, DEV BIOL, V301, P287, DOI 10.1016/j.ydbio.2006.09.019; Betschinger J, 2005, CURR BIOL, V15, P276, DOI 10.1016/j.cub.2005.01.012; Betschinger J, 2006, CELL, V124, P1241, DOI 10.1016/j.cell.2006.01.038; Betschinger J, 2003, NATURE, V422, P326, DOI 10.1038/nature01486; Bialucha CU, 2007, J CELL BIOL, V178, P575, DOI 10.1083/jcb.200612022; Bilder D, 2004, GENE DEV, V18, P1909, DOI 10.1101/gad.1211604; Bilder D, 2003, NAT CELL BIOL, V5, P53, DOI 10.1038/ncb897; Bilder D, 2000, NATURE, V403, P676, DOI 10.1038/35001108; Bilder D, 2000, SCIENCE, V289, P113, DOI 10.1126/science.289.5476.113; Blankenship JT, 2007, J CELL SCI, V120, P3099, DOI 10.1242/jcs.004770; Boone JQ, 2008, DEV NEUROBIOL, V68, P1185, DOI 10.1002/dneu.20648; Bossinger O, 2001, DEV BIOL, V230, P29, DOI 10.1006/dbio.2000.0113; Boussioutas A, 2003, CANCER RES, V63, P2569; Bowman SK, 2008, DEV CELL, V14, P535, DOI 10.1016/j.devcel.2008.03.004; Brumby A, 2004, GENETICS, V168, P227, DOI 10.1534/genetics.104.026617; Brumby AM, 2005, NAT REV CANCER, V5, P626, DOI 10.1038/nrc1671; Brumby AM, 2003, EMBO J, V22, P5769, DOI 10.1093/emboj/cdg548; Bryant PJ, 2000, NAT CELL BIOL, V2, pE141, DOI 10.1038/35019616; Cao TT, 1999, NATURE, V401, P286, DOI 10.1038/45816; Caruana G, 2001, MOL CELL BIOL, V21, P1475, DOI 10.1128/MCB.21.5.1475-1483.2001; Caussinus E, 2005, NAT GENET, V37, P1125, DOI 10.1038/ng1632; Cavatorta AL, 2004, INT J CANCER, V111, P373, DOI 10.1002/ijc.20275; Chabu C, 2008, DEVELOPMENT, V135, P2739, DOI 10.1242/dev.024059; Clark PA, 2007, DEV DYNAM, V236, P3297, DOI 10.1002/dvdy.21381; Clevers H, 2006, CELL, V127, P469, DOI 10.1016/j.cell.2006.10.018; de la Cova C, 2004, CELL, V117, P107, DOI 10.1016/S0092-8674(04)00214-4; Dollar GL, 2005, NATURE, V437, P1376, DOI 10.1038/nature04116; Dow LE, 2007, ONCOGENE, V26, P2272, DOI 10.1038/sj.onc.1210016; Dow LE, 2003, ONCOGENE, V22, P9225, DOI 10.1038/sj.onc.1207154; DOW LE, 2008, ONCOGENE        0721, DOI DOI 10.1038/ONC.2008.219; Dow LE, 2007, INT REV CYTOL, V262, P253, DOI 10.1016/S0074-7696(07)62006-3; Eder AM, 2005, P NATL ACAD SCI USA, V102, P12519, DOI 10.1073/pnas.0505641102; Etienne-Manneville S, 2005, J CELL BIOL, V170, P895, DOI 10.1083/jcb.200412172; Etienne-Manneville S, 2008, ONCOGENE, V27, P6970, DOI 10.1038/onc.2008.347; Even-Faitelson L, 2006, MOL BIOL CELL, V17, P2869, DOI 10.1091/mbc.e05-11-1001; Fan Y, 2008, DEV CELL, V14, P399, DOI 10.1016/j.devcel.2008.01.003; Farkas R, 2000, CELL DEATH DIFFER, V7, P89, DOI 10.1038/sj.cdd.4400621; Farnie G, 2007, STEM CELL REV, V3, P169, DOI 10.1007/s12015-007-0023-5; Franklin JL, 2005, EXP CELL RES, V303, P457, DOI 10.1016/j.yexcr.2004.10.007; Frese KK, 2006, EMBO J, V25, P1406, DOI 10.1038/sj.emboj.7601030; Frese KK, 2003, ONCOGENE, V22, P710, DOI 10.1038/sj.onc.1206151; Fuja TJ, 2004, CANCER RES, V64, P942, DOI 10.1158/0008-5472.CAN-03-2100; Funke L, 2005, ANNU REV BIOCHEM, V74, P219, DOI 10.1146/annurev.biochem.74.082803.133339; Gallant P, 2005, CANCER RES, V65, P6485, DOI 10.1158/0008-5472.CAN-05-1101; Gangar A, 2005, CURR BIOL, V15, P1136, DOI 10.1016/j.cub.2005.05.046; Garcia-Mata R, 2007, MOL CELL BIOL, V27, P8683, DOI 10.1128/MCB.00157-07; Gardiol D, 2006, INT J CANCER, V119, P1285, DOI 10.1002/ijc.21982; GATEFF E, 1974, ROUX ARCH DEV BIOL, V176, P23, DOI 10.1007/BF00577830; GATEFF E, 1978, SCIENCE, V200, P1448, DOI 10.1126/science.96525; Giebel B, 2006, CURR BIOL, V16, pR91, DOI 10.1016/j.cub.2006.01.022; Gonzalez C, 2007, NAT REV GENET, V8, P462, DOI 10.1038/nrg2103; Goode S, 2005, DEV DYNAM, V232, P855, DOI 10.1002/dvdy.20336; Goulev Y, 2008, CURR BIOL, V18, P435, DOI 10.1016/j.cub.2008.02.034; Grifoni D, 2007, ONCOGENE, V26, P5960, DOI 10.1038/sj.onc.1210389; Grifoni D, 2004, ONCOGENE, V23, P8688, DOI 10.1038/sj.onc.1208023; Grzeschik NA, 2007, DEV BIOL, V311, P106, DOI 10.1016/j.ydbio.2007.08.025; Hanada N, 2000, INT J CANCER, V86, P480, DOI 10.1002/(SICI)1097-0215(20000515)86:4<480::AID-IJC6>3.0.CO;2-6; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Harris TJC, 2004, J CELL BIOL, V167, P135, DOI 10.1083/jcb.200406024; Harvey K, 2007, NAT REV CANCER, V7, P182, DOI 10.1038/nrc2070; Hawkins ED, 2008, ONCOGENE, V27, P7003, DOI 10.1038/onc.2008.350; Hering H, 2002, FEBS LETT, V521, P185, DOI 10.1016/S0014-5793(02)02831-4; Hirata A, 2004, VIROLOGY, V318, P327, DOI 10.1016/j.virol.2003.10.006; Hough CD, 1997, GENE DEV, V11, P3242, DOI 10.1101/gad.11.23.3242; Huh JR, 2004, CURR BIOL, V14, P1262, DOI 10.1016/j.cub.2004.06.015; Humbert PO, 2006, TRENDS CELL BIOL, V16, P622, DOI 10.1016/j.tcb.2006.10.005; Hutterer A, 2004, DEV CELL, V6, P845, DOI 10.1016/j.devcel.2004.05.003; Igaki T, 2006, CURR BIOL, V16, P1139, DOI 10.1016/j.cub.2006.04.042; Iizuka-Kogo A, 2007, DEVELOPMENT, V134, P1799, DOI 10.1242/dev.02830; Ishidate T, 2000, ONCOGENE, V19, P365, DOI 10.1038/sj.onc.1203309; Jang ACC, 2007, J MAMMARY GLAND BIOL, V12, P103, DOI 10.1007/s10911-007-9042-8; Januschke J, 2008, ONCOGENE, V27, P6994, DOI 10.1038/onc.2008.349; Javier RT, 2008, ONCOGENE, V27, P7031, DOI 10.1038/onc.2008.352; Kallay LM, 2006, J CELL BIOCHEM, V99, P647, DOI 10.1002/jcb.20992; Kamei Y, 2007, HUM PATHOL, V38, P1273, DOI 10.1016/j.humpath.2007.01.026; Karp CM, 2008, CANCER RES, V68, P4105, DOI 10.1158/0008-5472.CAN-07-6814; Kim SW, 2007, GENE CHROMOSOME CANC, V46, P1, DOI 10.1002/gcc.20384; Kiyono T, 1997, P NATL ACAD SCI USA, V94, P11612, DOI 10.1073/pnas.94.21.11612; Klein TJ, 2005, ANNU REV CELL DEV BI, V21, P155, DOI 10.1146/annurev.cellbio.21.012704.132806; Klezovitch O, 2004, GENE DEV, V18, P559, DOI 10.1101/gad.1178004; Kojima Y, 2008, HUM PATHOL, V39, P824, DOI 10.1016/j.humpath.2007.11.001; Koppen M, 2001, NAT CELL BIOL, V3, P983, DOI 10.1038/ncb1101-983; Korshunov A, 2006, ACTA NEUROPATHOL, V111, P465, DOI 10.1007/s00401-006-0057-9; Kuphal S, 2006, ONCOGENE, V25, P103, DOI 10.1038/sj.onc.1209008; Lahuna O, 2005, EMBO J, V24, P1364, DOI 10.1038/sj.emboj.7600616; Langevin J, 2005, CURR BIOL, V15, P955, DOI 10.1016/j.cub.2005.04.054; Laprise P, 2004, J BIOL CHEM, V279, P10157, DOI 10.1074/jbc.M309843200; Lassmann S, 2007, J MOL MED-JMM, V85, P289, DOI 10.1007/s00109-006-0126-5; Le SS, 1997, P NATL ACAD SCI USA, V94, P6670, DOI 10.1073/pnas.94.13.6670; Lee CY, 2006, NATURE, V439, P594, DOI 10.1038/nature04299; Legouis R, 2000, NAT CELL BIOL, V2, P415, DOI 10.1038/35017046; Legouis R, 2003, EMBO REP, V4, P1096, DOI 10.1038/sj.embor.7400006; Lin HT, 2004, GYNECOL ONCOL, V93, P422, DOI 10.1016/j.ygyno.2004.01.025; Lu H, 2005, NAT CELL BIOL, V7, P1232, DOI 10.1038/ncb1324; Ludford-Menting MJ, 2005, IMMUNITY, V22, P737, DOI 10.1016/j.immuni.2005.04.009; Mahoney ZX, 2006, P NATL ACAD SCI USA, V103, P19872, DOI 10.1073/pnas.0609326103; Mantovani F, 2001, J CELL SCI, V114, P4285; Mantovani F, 2001, ONCOGENE, V20, P7874, DOI 10.1038/sj.onc.1204869; Massimi P, 2006, ONCOGENE, V25, P4276, DOI 10.1038/sj.onc.1209457; Mathew D, 2002, CURR BIOL, V12, P531, DOI 10.1016/S0960-9822(02)00758-3; Matsumine A, 1996, SCIENCE, V272, P1020, DOI 10.1126/science.272.5264.1020; McMahon L, 2001, J CELL SCI, V114, P2265; MECHLER BM, 1985, EMBO J, V4, P1551, DOI 10.1002/j.1460-2075.1985.tb03816.x; Menut L, 2007, GENETICS, V177, P1667, DOI 10.1534/genetics.107.078360; Montcouquiol M, 2003, NATURE, V423, P173, DOI 10.1038/nature01618; Montcouquiol M, 2006, J NEUROSCI, V26, P5265, DOI 10.1523/JNEUROSCI.4680-05.2006; Moreno E, 2004, CELL, V117, P117, DOI 10.1016/S0092-8674(04)00262-4; Moreno-Bueno G, 2008, ONCOGENE, V27, P6958, DOI 10.1038/onc.2008.346; Munger K, 2001, ONCOGENE, V20, P7888, DOI 10.1038/sj.onc.1204860; Murdoch JN, 2003, HUM MOL GENET, V12, P87, DOI 10.1093/hmg/ddg014; Murdoch JN, 2001, GENOMICS, V78, P55, DOI 10.1006/geno.2001.6638; Musch A, 2002, MOL BIOL CELL, V13, P158, DOI 10.1091/mbc.01-10-0496; Nagasaka K, 2006, CANCER SCI, V97, P1217, DOI 10.1111/j.1349-7006.2006.00315.x; Nakagawa S, 2000, MOL CELL BIOL, V20, P8244, DOI 10.1128/MCB.20.21.8244-8253.2000; Navarro C, 2005, ONCOGENE, V24, P4330, DOI 10.1038/sj.onc.1208632; Naylor TL, 2005, BREAST CANCER RES, V7, pR1186, DOI 10.1186/bcr1356; Nechiporuk T, 2007, DEV CELL, V13, P338, DOI 10.1016/j.devcel.2007.07.017; Nguyen ML, 2003, J VIROL, V77, P6957, DOI 10.1128/JVI.77.12.6957-6964.2003; Nguyen MM, 2003, MOL CELL BIOL, V23, P8970, DOI 10.1128/MCB.23.24.8970-8981.2003; Ninomiya H, 2008, NAT CELL BIOL, V10, P61, DOI 10.1038/ncb1669; Ohshiro T, 2000, NATURE, V408, P593, DOI 10.1038/35046087; Osmani N, 2006, CURR BIOL, V16, P2395, DOI 10.1016/j.cub.2006.10.026; Overholtzer M, 2006, P NATL ACAD SCI USA, V103, P12405, DOI 10.1073/pnas.0605579103; Pagliarini RA, 2003, SCIENCE, V302, P1227, DOI 10.1126/science.1088474; Peng CY, 2000, NATURE, V408, P596, DOI 10.1038/35046094; Perez-Garijo A, 2004, DEVELOPMENT, V131, P5591, DOI 10.1242/dev.01432; Plant PJ, 2003, NAT CELL BIOL, V5, P301, DOI 10.1038/ncb948; Qin Y, 2005, J CELL BIOL, V171, P1061, DOI 10.1083/jcb.200506094; Radisky D, 2001, SEMIN CANCER BIOL, V11, P87, DOI 10.1006/scbi.2000.0360; Regala RP, 2005, CANCER RES, V65, P8905, DOI 10.1158/0008-5472.CAN-05-2372; Roegiers F, 2005, MOL BIOL CELL, V16, P3480, DOI 10.1091/mbc.E05-03-0177; Roh MH, 2003, J CELL SCI, V116, P2895, DOI 10.1242/jcs.00500; Rolls MM, 2003, J CELL BIOL, V163, P1089, DOI 10.1083/jcb.200306079; Rosenberg M, 2006, MOL BIOL CELL, V17, P1364, DOI 10.1091/mbc.e05-07-0597; Roy M, 2007, CURR OPIN GENET DEV, V17, P52, DOI 10.1016/j.gde.2006.12.001; Ryoo HD, 2004, DEV CELL, V7, P491, DOI 10.1016/j.devcel.2004.08.019; Sans N, 2005, NAT CELL BIOL, V7, P1179, DOI 10.1038/ncb1325; Santoni MJ, 2002, TRENDS GENET, V18, P494, DOI 10.1016/S0168-9525(02)02738-5; Schimanski CC, 2005, ONCOGENE, V24, P3100, DOI 10.1038/sj.onc.1208520; Sonawane M, 2005, DEVELOPMENT, V132, P3255, DOI 10.1242/dev.01904; Sotillos S, 2004, J CELL BIOL, V166, P549, DOI 10.1083/jcb.200311031; Spaderna S, 2008, CANCER RES, V68, P537, DOI 10.1158/0008-5472.CAN-07-5682; Stephenson LM, 2007, MOL CELL BIOL, V27, P7574, DOI 10.1128/MCB.00439-07; STRAND D, 1994, J CELL BIOL, V127, P1361, DOI 10.1083/jcb.127.5.1361; STRAND D, 1995, ONCOGENE, V11, P291; Su ZW, 2001, BIOCHEMISTRY-US, V40, P3606, DOI 10.1021/bi010082j; SUN Y, SCRIBBLE INTER UNPUB; Suzuki T, 1999, ONCOGENE, V18, P5967, DOI 10.1038/sj.onc.1203008; Szafranski P, 2007, DEV DYNAM, V236, P364, DOI 10.1002/dvdy.21020; Takizawa S, 2006, GENES CELLS, V11, P453, DOI 10.1111/j.1365-2443.2006.00954.x; Tanentzapf G, 2003, NAT CELL BIOL, V5, P46, DOI 10.1038/ncb896; Tapper J, 2001, CANCER GENET CYTOGEN, V128, P1, DOI 10.1016/S0165-4608(01)00386-7; Tepass U, 2001, ANNU REV GENET, V35, P747, DOI 10.1146/annurev.genet.35.102401.091415; Thiery JP, 2002, NAT REV CANCER, V2, P442, DOI 10.1038/nrc822; Thomas M, 2005, ONCOGENE, V24, P6222, DOI 10.1038/sj.onc.1208757; Thomas M, 2008, ONCOGENE, V27, P7018, DOI 10.1038/onc.2008.351; Uhlirova M, 2005, P NATL ACAD SCI USA, V102, P13123, DOI 10.1073/pnas.0504170102; Uhlirova M, 2006, EMBO J, V25, P5294, DOI 10.1038/sj.emboj.7601401; Vaccari T, 2008, J CELL BIOL, V180, P755, DOI 10.1083/jcb.200708127; Valiente M, 2005, J BIOL CHEM, V280, P28936, DOI 10.1074/jbc.M504761200; Velthuis AJWT, 2007, BMC EVOL BIOL, V7, DOI 10.1186/1471-2148-7-129; Vermeer PD, 2003, NATURE, V422, P322, DOI 10.1038/nature01440; Vervenne HBVK, 2008, DEV BIOL, V320, P267, DOI 10.1016/j.ydbio.2008.05.529; Vidal M, 2006, CURR OPIN GENET DEV, V16, P10, DOI 10.1016/j.gde.2005.12.004; Wada H, 2005, DEVELOPMENT, V132, P2273, DOI 10.1242/dev.01810; Wang H, 2006, GENE DEV, V20, P3453, DOI 10.1101/gad.1487506; Wasenius VM, 2003, CLIN CANCER RES, V9, P68; Watson RA, 2002, CARCINOGENESIS, V23, P1791, DOI 10.1093/carcin/23.11.1791; Wenthold RJ, 2003, ANNU REV PHARMACOL, V43, P335, DOI 10.1146/annurev.pharmtox.43.100901.135803; Whiteman EL, 2008, ONCOGENE, V27, P3875, DOI 10.1038/onc.2008.9; Wirtz-Peitz F, 2006, TRENDS CELL BIOL, V16, P234, DOI 10.1016/j.tcb.2006.03.006; WIRTZPEITZ F, 2008, CELL IN PRESS; Wodarz A, 2000, CURR BIOL, V10, pR624, DOI 10.1016/S0960-9822(00)00658-8; Wodarz A, 2007, NAT CELL BIOL, V9, P1016, DOI 10.1038/ncb433; WOLF AM, 2008, J NEUROSCI, V3456, P3; WOODHOUSE E, 1994, CELL GROWTH DIFFER, V5, P151; Woodhouse E, 1998, DEV GENES EVOL, V207, P542, DOI 10.1007/s004270050145; WOODS DF, 1989, DEV BIOL, V134, P222, DOI 10.1016/0012-1606(89)90092-4; Woods DF, 1996, J CELL BIOL, V134, P1469, DOI 10.1083/jcb.134.6.1469; Xia J, 2000, NEURON, V28, P499, DOI 10.1016/S0896-6273(00)00128-8; Yamamoto Y, 2004, ONCOGENE, V23, P3889, DOI 10.1038/sj.onc.1207495; Yamanaka T, 2003, CURR BIOL, V13, P734, DOI 10.1016/S0960-9822(03)00244-6; Yamanaka T, 2008, FRONT BIOSCI-LANDMRK, V13, P6693, DOI 10.2741/3182; Yamanaka T, 2006, J CELL SCI, V119, P2107, DOI 10.1242/jcs.02938; Yang J, 2008, DEV CELL, V14, P818, DOI 10.1016/j.devcel.2008.05.009; Yasumi M, 2005, J BIOL CHEM, V280, P6761, DOI 10.1074/jbc.C400440200; Yeaman C, 1999, CURR BIOL, V9, pR515, DOI 10.1016/S0960-9822(99)80324-8; Zarbalis K, 2004, PLOS BIOL, V2, P1177, DOI 10.1371/journal.pbio.0020219; Zeitler J, 2004, J CELL BIOL, V167, P1137, DOI 10.1083/jcb.200407158; Zeng Q, 2008, CANCER CELL, V13, P188, DOI 10.1016/j.ccr.2008.02.011; Zhang X, 2007, NAT CELL BIOL, V9, P743, DOI 10.1038/ncb1603; Zhang XY, 2005, J CELL BIOL, V170, P273, DOI 10.1083/jcb.200502055; Zhao M, 2008, GENETICS, V178, P1947, DOI 10.1534/genetics.108.086983	206	235	243	0	25	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 24	2008	27	55					6888	6907		10.1038/onc.2008.341	http://dx.doi.org/10.1038/onc.2008.341			20	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	375IU	19029932				2022-12-28	WOS:000261108200003
J	Pen, A; Moreno, MJ; Durocher, Y; Deb-Rinker, P; Stanimirovic, DB				Pen, A.; Moreno, M. J.; Durocher, Y.; Deb-Rinker, P.; Stanimirovic, D. B.			Glioblastoma-secreted factors induce IGFBP7 and angiogenesis by modulating Smad-2-dependent TGF-beta signaling	ONCOGENE			English	Article						glioblastoma; angiogenesis; IGFBP7; TGF-beta; Smad	GROWTH-FACTOR-BETA; BLOOD-BRAIN-BARRIER; PROSTACYCLIN-STIMULATING FACTOR; PROTEIN-RELATED PROTEIN-1; TUMOR-SUPPRESSIVE ACTIVITY; TRANSFORMING GROWTH-FACTOR-BETA-1; ENDOTHELIAL-CELLS; GENE-EXPRESSION; COLON-CANCER; PROSTATE-CANCER	Insulin-like growth factor-binding protein 7 (IGFBP7) is a selective biomarker of glioblastoma (GBM) vessels, stronglyexpressed in tumor endothelial cells and vascular basement membrane. IGFBP7 gene regulation and its potential role in tumor angiogenesis remain unclear. Mechanisms of IGFBP7 induction and its angiogenic capacity were examined in human brain endothelial cells (HBECs) exposed to tumor-like conditions. HBEC treated with GBM cell (U87MG)-conditioned media (-CM) exhibited fourfold upregulation of IGFBP7 mRNA and protein compared to control cells. IGFBP7 gene regulation in HBEC was methylation independent. U87MG-CM analysed by enzyme-linked immunosorbent assay contained similar to 5 pM transforming growth factor (TGF)-beta 1, a concentration sufficient to stimulate IGFBP7 in HBEC to similar levels as U87MG-CM. Both pan-TGF-beta-neutralizing antibody(1D11) and the TGF-beta 1 receptor (activin receptor-like kinase 5, ALK5) antagonist, SB431542, blocked U87MG-CM-induced IGFBP7 expression in HBEC, indicating that TGF-beta 1 is an important tumor-secreted effector capable of IGFBP7 induction in endothelial cells. HBEC exposed to either U87MG-CM or IGFBP7 protein exhibited increased capillary-like tube (CLT) formation in Matrigel. Both TGF-beta 1- and U87MG-CM-induced Smad-2 phosphorylation and U87MG-CM-induced CLT formation in HBEC were inhibited by the ALK5 antagonist, SB431542. These data suggest that proangiogenic IGFBP7 maybe induced in brain endothelial cells by TGF-beta s secreted by GBM, most likely through TGF-beta 1/ALK5/Smad-2 pathway. Oncogene (2008) 27, 6834-6844; doi: 10.1038/onc.2008.287; published online 18 August 2008	[Pen, A.; Moreno, M. J.; Stanimirovic, D. B.] Natl Res Council Canada, Inst Biol Sci, Cerebrovasc Res Grp, Neurobiol Program, Ottawa, ON K1A 0R6, Canada; [Pen, A.; Stanimirovic, D. B.] Univ Ottawa, Fac Med, Dept Cellular & Mol Med, Ottawa, ON, Canada; [Durocher, Y.] Natl Res Council Canada, Biotechnol Res Inst, Anim Cell Technol Grp, Montreal, PQ H4P 2R2, Canada; [Deb-Rinker, P.] Natl Res Council Canada, Inst Biol Sci, Neurogenesis & Brain Repair Grp, Montreal, PQ, Canada	National Research Council Canada; University of Ottawa; National Research Council Canada; National Research Council Canada	Stanimirovic, DB (corresponding author), Natl Res Council Canada, Inst Biol Sci, Cerebrovasc Res Grp, Neurobiol Program, 1200 Montreal Rd,Bldg M-54, Ottawa, ON K1A 0R6, Canada.	danica.stanimirovic@nrc-cnrc.gc.ca	Durocher, Yves/K-8709-2019					Ahmed AA, 2006, NAT PROD COMMUN, V1, P273; AKAOGI K, 1994, BIOCHEM BIOPH RES CO, V198, P1046, DOI 10.1006/bbrc.1994.1149; Akaogi K, 1996, P NATL ACAD SCI USA, V93, P8384, DOI 10.1073/pnas.93.16.8384; Beaty RM, 2007, J NEURO-ONCOL, V81, P241, DOI 10.1007/s11060-006-9227-9; Blanchette F, 2001, J BIOL CHEM, V276, P33986, DOI 10.1074/jbc.M100093200; Burger AM, 1998, ONCOGENE, V16, P2459, DOI 10.1038/sj.onc.1201772; Chen Y, 2007, J PATHOL, V211, P431, DOI 10.1002/path.2132; Chen YG, 1999, J BIOL CHEM, V274, P3672, DOI 10.1074/jbc.274.6.3672; CONSTAM DB, 1992, J IMMUNOL, V148, P1404; Dai CK, 2001, BBA-REV CANCER, V1551, pM19, DOI 10.1016/S0304-419X(01)00027-0; Davies DC, 2002, J ANAT, V200, P639, DOI 10.1046/j.1469-7580.2002.00065.x; de Caestecker M, 2004, CYTOKINE GROWTH F R, V15, P1, DOI 10.1016/j.cytogfr.2003.10.004; Deb-Rinker P, 2005, J BIOL CHEM, V280, P6257, DOI 10.1074/jbc.C400479200; Derynck R, 1998, CELL, V95, P737, DOI 10.1016/S0092-8674(00)81696-7; DINDA AK, 1993, J NEURO-ONCOL, V16, P149, DOI 10.1007/BF01324702; Durocher Y, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/30.2.e9; Engel ME, 1999, J BIOL CHEM, V274, P37413, DOI 10.1074/jbc.274.52.37413; Goumans MJ, 2002, EMBO J, V21, P1743, DOI 10.1093/emboj/21.7.1743; Goumans MJ, 2003, TRENDS CARDIOVAS MED, V13, P301, DOI 10.1016/S1050-1738(03)00142-7; Hata Y, 2000, J CLIN INVEST, V106, P541, DOI 10.1172/JCI8338; HIRANO A, 1975, HUM PATHOL, V6, P611, DOI 10.1016/S0046-8177(75)80045-1; Hwa V, 1999, ENDOCR REV, V20, P761, DOI 10.1210/er.20.6.761; Inman GJ, 2002, MOL PHARMACOL, V62, P65, DOI 10.1124/mol.62.1.65; KEETON MR, 1991, J BIOL CHEM, V266, P23048; Kishibe J, 2000, J BIOL CHEM, V275, P15321, DOI 10.1074/jbc.275.20.15321; KLEIHUES P, 1995, GLIA, V15, P211, DOI 10.1002/glia.440150303; Kniesel U, 2000, CELL MOL NEUROBIOL, V20, P57, DOI 10.1023/A:1006995910836; Komatsu S, 2000, BIOCHEM BIOPH RES CO, V267, P109, DOI 10.1006/bbrc.1999.1937; Kwak HJ, 2006, MOL CANCER RES, V4, P209, DOI 10.1158/1541-7786.MCR-05-0140; Lebrin F, 2005, CARDIOVASC RES, V65, P599, DOI 10.1016/j.cardiores.2004.10.036; Lin J, 2007, J PATHOL, V212, P83, DOI 10.1002/path.2144; LONG DM, 1970, J NEUROSURG, V32, P127, DOI 10.3171/jns.1970.32.2.0127; Louis DN, 2006, ANNU REV PATHOL-MECH, V1, P97, DOI 10.1146/annurev.pathol.1.110304.100043; Madden SL, 2004, AM J PATHOL, V165, P601, DOI 10.1016/S0002-9440(10)63324-X; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; MILLER SA, 1988, NUCLEIC ACIDS RES, V16, P1215, DOI 10.1093/nar/16.3.1215; Moreno MJ, 2006, GLIA, V53, P845, DOI 10.1002/glia.20345; MURPHY M, 1993, CELL GROWTH DIFFER, V4, P715; Mutaguchi K, 2003, CANCER RES, V63, P7717; Nagakubo D, 2003, J IMMUNOL, V171, P553, DOI 10.4049/jimmunol.171.2.553; Oh YM, 1996, J BIOL CHEM, V271, P30322, DOI 10.1074/jbc.271.48.30322; OLDENDORF WH, 1977, ANN NEUROL, V1, P409, DOI 10.1002/ana.410010502; OLOFSSON A, 1992, J BIOL CHEM, V267, P19482; Pen A, 2007, GLIA, V55, P559, DOI 10.1002/glia.20481; Pepper Michael S., 1997, Cytokine and Growth Factor Reviews, V8, P21, DOI 10.1016/S1359-6101(96)00048-2; Poncelet AC, 1998, AM J PHYSIOL-RENAL, V275, pF458; Ramsauer M, 2007, J CELL SCI, V120, P1810, DOI 10.1242/jcs.003533; REED MJ, 1994, J CELL PHYSIOL, V158, P169, DOI 10.1002/jcp.1041580121; Ruan WJ, 2007, CANCER BIOL THER, V6, P354, DOI 10.4161/cbt.6.3.3702; Sato J, 1999, J CELL BIOCHEM, V75, P187, DOI 10.1002/(SICI)1097-4644(19991101)75:2<187::AID-JCB1>3.0.CO;2-R; Sprenger CC, 1999, CANCER RES, V59, P2370; St Croix B, 2000, SCIENCE, V289, P1197; Stanimirovic D, 1996, J CELL PHYSIOL, V169, P455; TENDIJKE P, 1988, P NATL ACAD SCI USA, V85, P4715; Umeda F, 1998, J GASTROENTEROL, V33, P213, DOI 10.1007/s005350050072; Vajkoczy P, 2000, J NEURO-ONCOL, V50, P99, DOI 10.1023/A:1006474832189; Vajkoczy P, 1999, INT J DEV NEUROSCI, V17, P557, DOI 10.1016/S0736-5748(99)00021-0; van Beijnum JR, 2006, BLOOD, V108, P2339, DOI 10.1182/blood-2006-02-004291; Vaupel P, 1998, STRAHLENTHER ONKOL, V174, P6; Wajapeyee N, 2008, CELL, V132, P363, DOI 10.1016/j.cell.2007.12.032; Watabe T, 2003, J CELL BIOL, V163, P1303, DOI 10.1083/jcb.200305147; WELLER M, 1995, EXP CELL RES, V221, P395, DOI 10.1006/excr.1995.1390; Wick W, 2001, J NEURO-ONCOL, V53, P177, DOI 10.1023/A:1012209518843; Wilson HMP, 2002, CELL GROWTH DIFFER, V13, P205; Yakmovych I, 2001, FASEB J, V15, P553; YAMADA N, 1995, INT J CANCER, V62, P386, DOI 10.1002/ijc.2910620405; YAMAUCHI T, 1994, BIOCHEM J, V303, P591, DOI 10.1042/bj3030591	67	87	97	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 20	2008	27	54					6834	6844		10.1038/onc.2008.287	http://dx.doi.org/10.1038/onc.2008.287			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	375IS	18711401				2022-12-28	WOS:000261108000004
J	Yeung, BHY; Kwan, BWY; He, QY; Lee, AS; Liu, J; Wong, AST				Yeung, B. H. Y.; Kwan, B. W. Y.; He, Q. Y.; Lee, A. S.; Liu, J.; Wong, A. S. T.			Glucose-regulated protein 78 as a novel effector of BRCA1 for inhibiting stress-induced apoptosis	ONCOGENE			English	Article						GRP78; unfolded protein response; BRCA1; ovarian cancer; breast cancer; apoptosis	CANCER; BREAST; CHAPERONE; CELLS; GRP78	The tumor suppressor BRCA1 is mutated in a high percentage of familial breast and ovarian cancer, but our understanding of its mechanisms of action remains incomplete. We report here that glucose-regulated protein (GRP)-78, a critical regulator of the unfolded protein response (UPR), is a novel downstream target of BRCA1. We showed that overexpression of wild-type BRCA1 suppressed the expression of GRP78, whereas expression of mutant BRCA1 gene or targeted inhibition of endogenous BRCA1 using small-interfering RNA (siRNA) enhanced GRP78 expression. Knockdown of BRCA1 also led to induction of other components of UPR, such as GRP94 and CHOP. Consistent with a role of BRCA1 knockdown in mediating cell survival, forced expression of GRP78 stimulated cell proliferation and prevented apoptosis, including that induced by endoplasmic reticulum stress and chemotherapy, in ovarian OVCAR-3 and breast MCF-7 cancer cells. Overexpression of wild-type BRCA1 could increase the apoptosis of GRP78-over-expressing cells. Conversely, knockdown GRP78 by siRNA sensitized ovarian and breast cancer cells to apoptosis. This effect was reduced when the expression of BRCA1 was simultaneously knockdown by siRNA, indicating that BRCA1 also negatively regulates GRP78mediated cell survival and resistance to apoptosis.	[Yeung, B. H. Y.; Kwan, B. W. Y.; Wong, A. S. T.] Univ Hong Kong, Sch Biol Sci, Hong Kong, Peoples R China; [He, Q. Y.] Jinan Univ, Inst Life & Hlth Engn, Guangzhou, Peoples R China; [Lee, A. S.] Univ So Calif, Kenneth Norris Jr Comprehens Canc Ctr, Dept Biochem & Mol Biol, Los Angeles, CA 90033 USA; [Liu, J.] Univ Texas Houston, MD Anderson Canc Ctr, Dept Mol Pathol, Houston, TX 77030 USA	University of Hong Kong; Jinan University; University of Southern California; University of Texas System; University of Texas Health Science Center Houston; UTMD Anderson Cancer Center	Wong, AST (corresponding author), Univ Hong Kong, Sch Biol Sci, 4S-14 Kadoorie Biol Sci Bldg,Pokfulam Rd, Hong Kong, Peoples R China.	awong1@hku.hk	He, Qing-Yu/H-7078-2014; Wong, Alice/AFJ-4595-2022	He, Qing-Yu/0000-0003-0503-9492; Wong, Alice/0000-0002-0676-6475; Lee, Amy/0000-0002-0378-5443	Hong Kong Research Grants Council [7484/04M]	Hong Kong Research Grants Council(Hong Kong Research Grants Council)	The present work was supported by Hong Kong Research Grants Council Grant (7484/04M) (AST Wong).	Fernandez PM, 2000, BREAST CANCER RES TR, V59, P15, DOI 10.1023/A:1006332011207; Gowen LC, 1998, SCIENCE, V281, P1009, DOI 10.1126/science.281.5379.1009; He QY, 2005, GYNECOL ONCOL, V98, P68, DOI 10.1016/j.ygyno.2005.04.002; Jensen DE, 1998, ONCOGENE, V16, P1097, DOI 10.1038/sj.onc.1201861; Lee AS, 2007, CANCER RES, V67, P3496, DOI 10.1158/0008-5472.CAN-07-0325; Lee AS, 2005, METHODS, V35, P373, DOI 10.1016/j.ymeth.2004.10.010; Lee K, 2003, J BIOL CHEM, V278, P11818, DOI 10.1074/jbc.M210475200; Lou ZK, 2005, NAT STRUCT MOL BIOL, V12, P589, DOI 10.1038/nsmb953; Ma YX, 2003, ONCOGENE, V22, P10, DOI 10.1038/sj.onc.1206061; Mallery DL, 2002, EMBO J, V21, P6755, DOI 10.1093/emboj/cdf691; Moynahan ME, 1999, MOL CELL, V4, P511, DOI 10.1016/S1097-2765(00)80202-6; Reddy RK, 2003, J BIOL CHEM, V278, P20915, DOI 10.1074/jbc.M212328200; Shin BK, 2003, J BIOL CHEM, V278, P7607, DOI 10.1074/jbc.M210455200; Thangaraju M, 2000, J BIOL CHEM, V275, P33487, DOI 10.1074/jbc.M005824200; Welcsh PL, 2001, HUM MOL GENET, V10, P705, DOI 10.1093/hmg/10.7.705; Wilson CA, 1999, NAT GENET, V21, P236, DOI 10.1038/6029; Xu XL, 2001, NAT GENET, V28, P266, DOI 10.1038/90108; Zeng LF, 2004, EMBO J, V23, P950, DOI 10.1038/sj.emboj.7600106; Zheng WX, 2000, GYNECOL ONCOL, V76, P294, DOI 10.1006/gyno.1999.5664; Zhou CY, 2003, ONCOGENE, V22, P2396, DOI 10.1038/sj.onc.1206319	20	39	43	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 13	2008	27	53					6782	6789		10.1038/onc.2008.290	http://dx.doi.org/10.1038/onc.2008.290			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	371XO	18776923				2022-12-28	WOS:000260866200008
J	Reddy, NM; Kleeberger, SR; Bream, JH; Fallon, PG; Kensler, TW; Yamamoto, M; Reddy, SP				Reddy, N. M.; Kleeberger, S. R.; Bream, J. H.; Fallon, P. G.; Kensler, T. W.; Yamamoto, M.; Reddy, S. P.			Genetic disruption of the Nrf2 compromises cell-cycle progression by impairing GSH-induced redox signaling	ONCOGENE			English	Article						oxidative stress; Nrf2; cell cycle; G(2)/M-checkpoint; Akt	ALVEOLAR EPITHELIAL-CELLS; DNA-DAMAGE; S-GLUTATHIONYLATION; DEPENDENT PHOSPHORYLATION; OXIDATIVE STRESS; MICE LACKING; KINASE-B; LUNG; MECHANISMS; EXPRESSION	Genetic disruption of Nrf2 greatly enhances susceptibility to prooxidant- and carcinogen-induced experimental models of various human disorders; but the mechanisms by which this transcription factor confers protection are unclear. Using Nrf2-proficient (Nrf2(+/+)) and Nrf2-deficient (Nrf2(-/-)) primary epithelial cultures as a model, we now show that Nrf2 deficiency leads to oxidative stress and DNA lesions, accompanied by impairment of cell-cycle progression, mainly G(2)/M-phase arrest. Both N-acetylcysteine and glutathione (GSH) supplementation ablated the DNA lesions and DNA damage-response pathways in Nrf2(-/-) cells; however only GSH could rescue the impaired colocalization of mitosis-promoting factors and the growth arrest. Akt activation was deregulated in Nrf2(-/-) cells, but GSH supplementation restored it. Inhibition of Akt signaling greatly diminished the GSH-induced Nrf2(-/-) cell proliferation and wild-type cell proliferation. GSH depletion impaired Akt signaling and mitosis-promoting factor colocalization in Nrf2(+/+) cells. Collectively, our findings uncover novel functions for Nrf2 in regulating oxidative stress-induced cell-cycle arrest, especially G(2)/M-checkpoint arrest, and proliferation, and GSH-regulated redox signaling and Akt are required for this process.	[Reddy, N. M.; Kensler, T. W.; Reddy, S. P.] Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Dept Environm Hlth Sci, Baltimore, MD 21205 USA; [Kleeberger, S. R.] Natl Inst Environm Hlth Sci, NIH, Res Triangle Pk, NC USA; [Bream, J. H.; Fallon, P. G.] Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Dept Mol Microbiol & Immunol, Baltimore, MD 21205 USA; [Yamamoto, M.] Tohoku Univ, Grad Sch Med, Dept Med Biochem, Sendai, Miyagi 980, Japan	Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; Tohoku University	Reddy, SP (corresponding author), Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Dept Environm Hlth Sci, Room E7610,615 N Wolfe St, Baltimore, MD 21205 USA.	sreddy@jhsph.edu	Yamamoto, Masayuki/A-4873-2010; Reddy, Narsa/AHE-5604-2022; Kensler, Thomas W/D-8686-2014; Kleeberger, Steven R/F-1807-2019	Yamamoto, Masayuki/0000-0002-9073-9436; Kensler, Thomas W/0000-0002-6676-261X; Kleeberger, Steven R/0000-0003-2948-8452; Bream, Jay/0000-0002-9149-7643	NIH [HL66109, ES11863]; SCCOR [P50 HL073994]; NIEHS [P30 ES 038819]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL073994] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [ZIAES100513, R01ES011863] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); SCCOR(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIEHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))	This work was supported by NIH grants HL66109, ES11863 and SCCOR P50 HL073994 (to SPR), and NIEHS center grant P30 ES 038819. We acknowledge the help provided for FACS analysis by Becton Dickinson Immune Function Laboratory, Johns Hopkins Bloomberg School of Public Health.	Aoki Y, 2001, TOXICOL APPL PHARM, V173, P154, DOI 10.1006/taap.2001.9176; Bakkenist CJ, 2003, NATURE, V421, P499, DOI 10.1038/nature01368; Bracken AP, 2004, TRENDS BIOCHEM SCI, V29, P409, DOI 10.1016/j.tibs.2004.06.006; Buchold GM, 2007, MOL REPROD DEV, V74, P997, DOI 10.1002/mrd.20716; Chan KM, 1999, P NATL ACAD SCI USA, V96, P12731, DOI 10.1073/pnas.96.22.12731; Chen XL, 2003, J BIOL CHEM, V278, P703, DOI 10.1074/jbc.M203161200; Cho HY, 2006, ANTIOXID REDOX SIGN, V8, P76, DOI 10.1089/ars.2006.8.76; Cho HY, 2002, AM J RESP CELL MOL, V26, P175, DOI 10.1165/ajrcmb.26.2.4501; Clavreul N, 2006, ARTERIOSCL THROM VAS, V26, P2454, DOI 10.1161/01.ATV.0000242791.28953.4c; Conour JE, 2004, PHYSIOL GENOMICS, V18, P196, DOI 10.1152/physiolgenomics.00058.2004; Cross JV, 2004, BIOCHEM J, V381, P675, DOI 10.1042/BJ20040591; Dalle-Donne I, 2007, FREE RADICAL BIO MED, V43, P883, DOI 10.1016/j.freeradbiomed.2007.06.014; Dalle-Donne I, 2007, FREE RADICAL BIO MED, V42, P583, DOI 10.1016/j.freeradbiomed.2006.11.026; Dolado I, 2007, CANCER CELL, V11, P191, DOI 10.1016/j.ccr.2006.12.013; Fratelli M, 2005, P NATL ACAD SCI USA, V102, P13998, DOI 10.1073/pnas.0504398102; Fratelli M, 2004, EXPERT REV PROTEOMIC, V1, P365, DOI 10.1586/14789450.1.3.365; Gallogly MM, 2007, CURR OPIN PHARMACOL, V7, P381, DOI 10.1016/j.coph.2007.06.003; Gartel AL, 2003, EXP CELL RES, V283, P17, DOI 10.1016/S0014-4827(02)00020-4; Ghezzi P, 2005, ANTIOXID REDOX SIGN, V7, P964, DOI 10.1089/ars.2005.7.964; Golubnitschaja O, 2007, AMINO ACIDS, V32, P359, DOI 10.1007/s00726-006-0473-0; Helt CE, 2005, J BIOL CHEM, V280, P1186, DOI 10.1074/jbc.M410873200; Itoh K, 1997, BIOCHEM BIOPH RES CO, V236, P313, DOI 10.1006/bbrc.1997.6943; Kastan MB, 2000, NAT REV MOL CELL BIO, V1, P179, DOI 10.1038/35043058; Katayama K, 2005, MOL CELL BIOL, V25, P5725, DOI 10.1128/MCB.25.13.5725-5737.2005; Kensler TW, 2007, ANNU REV PHARMACOL, V47, P89, DOI 10.1146/annurev.pharmtox.46.120604.141046; Kim SS, 2006, MOL CELL BIOL, V26, P6983, DOI 10.1128/MCB.00796-06; King FW, 2004, CELL CYCLE, V3, P634; Kissel H, 2005, DEV CELL, V8, P353, DOI 10.1016/j.devcel.2005.01.021; Klatt P, 2002, METHOD ENZYMOL, V348, P157, DOI 10.1016/S0076-6879(02)48635-1; Laine H, 2007, J NEUROSCI, V27, P1434, DOI 10.1523/JNEUROSCI.4956-06.2007; Li N, 2004, J IMMUNOL, V173, P3467, DOI 10.4049/jimmunol.173.5.3467; Liang J, 2002, NAT MED, V8, P1153, DOI 10.1038/nm761; Lopez-Girona A, 1999, NATURE, V397, P172, DOI 10.1038/16488; Louria-Hayon I, 2003, J BIOL CHEM, V278, P33134, DOI 10.1074/jbc.M301264200; Marshall RP, 2002, CHEST, V121, p68S, DOI 10.1378/chest.121.3_suppl.68S; McAllister KA, 2002, BREAST CANCER RES, V4, P54, DOI 10.1186/bcr422; Meloche S, 2007, ONCOGENE, V26, P3227, DOI 10.1038/sj.onc.1210414; Meulmeester E, 2005, CELL CYCLE, V4, P1166, DOI 10.4161/cc.4.9.1981; Nguyen T, 2003, ANNU REV PHARMACOL, V43, P233, DOI 10.1146/annurev.pharmtox.43.100901.140229; Nigg EA, 2001, NAT REV MOL CELL BIO, V2, P21, DOI 10.1038/35048096; Niida H, 2006, MUTAGENESIS, V21, P3, DOI 10.1093/mutage/gei063; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; Ohta T, 2008, CANCER RES, V68, P1303, DOI 10.1158/0008-5472.CAN-07-5003; Okumura E, 2002, NAT CELL BIOL, V4, P111, DOI 10.1038/ncb741; Padmanabhan B, 2006, MOL CELL, V21, P689, DOI 10.1016/j.molcel.2006.01.013; Parra MT, 2002, CHROMOSOMA, V111, P53, DOI 10.1007/s00412-002-0185-5; Peng CY, 1997, SCIENCE, V277, P1501, DOI 10.1126/science.277.5331.1501; Putkey FR, 2002, DEV CELL, V3, P351, DOI 10.1016/S1534-5807(02)00255-1; Qian XS, 2006, EUR J IMMUNOL, V36, P906, DOI 10.1002/eji.200535253; Rangasamy T, 2004, J CLIN INVEST, V114, P1248, DOI 10.1172/JCI200421146; Reddy NM, 2007, PHYSIOL GENOMICS, V32, P74, DOI 10.1152/physiolgenomics.00126.2007; Reddy NM, 2007, AM J RESP CELL MOL, V37, P3, DOI 10.1165/rcmb.2007-0004RC; Reynaert NL, 2006, P NATL ACAD SCI USA, V103, P13086, DOI 10.1073/pnas.0603290103; Sears R, 2000, GENE DEV, V14, P2501, DOI 10.1101/gad.836800; Serrano-Mollar A, 2007, AM J RESP CRIT CARE, V176, P1261, DOI 10.1164/rccm.200610-1491OC; Shelton MD, 2005, ANTIOXID REDOX SIGN, V7, P348, DOI 10.1089/ars.2005.7.348; Shtivelman E, 2003, MOL CANCER RES, V1, P959; Singh A, 2006, PLOS MED, V3, P1865, DOI 10.1371/journal.pmed.0030420; Su TT, 2006, ANNU REV GENET, V40, P187, DOI 10.1146/annurev.genet.40.110405.090428; Sugahara K, 2006, RESPIROLOGY, V11, pS28, DOI 10.1111/j.1440-1843.2006.00804.x; Taylor WR, 2001, ONCOGENE, V20, P1803, DOI 10.1038/sj.onc.1204252; Thimmulappa RK, 2006, BIOCHEM BIOPH RES CO, V351, P883, DOI 10.1016/j.bbrc.2006.10.102; Timmers C, 2007, MOL CELL BIOL, V27, P65, DOI 10.1128/MCB.02147-06; Townsend DM, 2006, MOL PHARMACOL, V69, P501, DOI 10.1124/mol.105.018523; Trachootham D, 2006, CANCER CELL, V10, P241, DOI 10.1016/j.ccr.2006.08.009; Trotman LC, 2006, NATURE, V441, P523, DOI 10.1038/nature04809; Valko M, 2007, INT J BIOCHEM CELL B, V39, P44, DOI 10.1016/j.biocel.2006.07.001; Velu CS, 2007, BIOCHEMISTRY-US, V46, P7765, DOI 10.1021/bi700425y; Wakabayashi N, 2003, NAT GENET, V35, P238, DOI 10.1038/ng1248; Ward NE, 2000, BIOCHEMISTRY-US, V39, P10319, DOI 10.1021/bi000781g; Yoshida Y, 2003, GENE DEV, V17, P1201, DOI 10.1101/gad.1088003	71	107	110	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 2	2008	27	44					5821	5832		10.1038/onc.2008.188	http://dx.doi.org/10.1038/onc.2008.188			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	355QC	18542053	Green Accepted			2022-12-28	WOS:000259722400006
J	Zhao, L; Vogt, PK				Zhao, L.; Vogt, P. K.			Class IPI3K in oncogenic cellular transformation	ONCOGENE			English	Review						PI3K; PTEN; Akt; Ras; p85	FORKHEAD TRANSCRIPTION FACTOR; GLYCOGEN-SYNTHASE KINASE-3; CANCER-SPECIFIC MUTATIONS; P85 REGULATORY SUBUNIT; PHOSPHOINOSITIDE 3-KINASE P110-DELTA; LIPID PHOSPHATASE-ACTIVITY; MAMMARY EPITHELIAL-CELLS; PHOSPHATIDYLINOSITOL 3-KINASE; TUMOR-SUPPRESSOR; PROTEIN-KINASE	Class I phosphoinositide 3-kinase (PI3K) is a dimeric enzyme, consisting of a catalytic and a regulatory subunit. The catalytic subunit occurs in four isoforms designated as p110 alpha, p110 beta, p110 gamma and p110 delta. These isoforms combine with several regulatory subunits; for p110 alpha, beta and delta, the standard regulatory subunit is p85, for p110 gamma, it is p101. PI3Ks play important roles in human cancer. PIK3CA, the gene encoding p110 alpha, is mutated frequently in common cancers, including carcinoma of the breast, prostate, colon and endometrium. Eighty percent of these mutations are represented by one of the three amino-acid substitutions in the helical or kinase domains of the enzyme. The mutant p110 alpha shows a gain of function in enzymatic and signaling activity and is oncogenic in cell culture and in animal model systems. Structural and genetic data suggest that the mutations affect regulatory inter- and intramolecular interactions and support the conclusion that there are at least two molecular mechanisms for the gain of function in p110 alpha. One of these mechanisms operates largely independently of binding to p85, the other abolishes the requirement for an interaction with Ras. The non-alpha isoforms of p110 do not show cancer-specific mutations. However, they are often differentially expressed in cancer and, in contrast to p110 alpha, wild-type non-alpha isoforms of p110 are oncogenic when overexpressed in cell culture. The isoforms of p110 have become promising drug targets. Isoform-selective inhibitors have been identified. Inhibitors that target exclusively the cancer-specific mutants of p110 alpha constitute an important goal and challenge for current drug development.	[Zhao, L.; Vogt, P. K.] Scripps Res Inst, Div Oncovirol, Dept Mol & Expt Med, La Jolla, CA 92037 USA	Scripps Research Institute	Zhao, L (corresponding author), Scripps Res Inst, Div Oncovirol, Dept Mol & Expt Med, 10550 N Torrey Rd,BCC-239, La Jolla, CA 92037 USA.	leyna@scripps.edu	Vogt, Peter K./R-7547-2019	Vogt, Peter K./0000-0002-4519-7500	National Cancer Institute; Stein Foundation; National Cancer Institute [F32CA130304]; NATIONAL CANCER INSTITUTE [R01CA115521, F32CA130304, P01CA078045, R01CA078230] Funding Source: NIH RePORTER	National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Stein Foundation; National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by grants from the National Cancer Institute and by The Stein Foundation. Dr Li Zhao is the recipient of a postdoctoral fellowship from the National Cancer Institute (F32CA130304). This is manuscript no. 19561-MEM from The Scripps Research Institute. We thank Dr Jonathan Hart and Dr Marco Gymnopoulos for thoughtful discussions and critical information.	Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9; Ali IU, 1999, JNCI-J NATL CANCER I, V91, P1922, DOI 10.1093/jnci/91.22.1922; Ali K, 2004, NATURE, V431, P1007, DOI 10.1038/nature02991; Ali K, 2008, J IMMUNOL, V180, P2538, DOI 10.4049/jimmunol.180.4.2538; Arden KC, 2004, MOL CELL, V14, P416, DOI 10.1016/S1097-2765(04)00213-8; Bachman KE, 2004, CANCER BIOL THER, V3, P772, DOI 10.4161/cbt.3.8.994; Bader AG, 2006, P NATL ACAD SCI USA, V103, P1475, DOI 10.1073/pnas.0510857103; Bader AG, 2004, ONCOGENE, V23, P3145, DOI 10.1038/sj.onc.1207550; Bader AG, 2005, NAT REV CANCER, V5, P921, DOI 10.1038/nrc1753; Benistant C, 2000, ONCOGENE, V19, P5083, DOI 10.1038/sj.onc.1203871; Bi L, 1999, J BIOL CHEM, V274, P10963, DOI 10.1074/jbc.274.16.10963; Bi L, 2002, MAMM GENOME, V13, P169, DOI 10.1007/s00335-001-2123-x; Biggs WH, 1999, P NATL ACAD SCI USA, V96, P7421, DOI 10.1073/pnas.96.13.7421; Blanco-Aparicio C, 2007, CARCINOGENESIS, V28, P1379, DOI 10.1093/carcin/bgm052; Bony C, 2001, J CELL BIOL, V152, P717, DOI 10.1083/jcb.152.4.717; Broderick DK, 2004, CANCER RES, V64, P5048, DOI 10.1158/0008-5472.CAN-04-1170; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Campbell IG, 2004, CANCER RES, V64, P7678, DOI 10.1158/0008-5472.CAN-04-2933; Cantley LC, 2002, SCIENCE, V296, P1655, DOI 10.1126/science.296.5573.1655; Carson JD, 2008, BIOCHEM J, V409, P519, DOI 10.1042/BJ20070681; Chan TO, 2002, CANCER CELL, V1, P181, DOI 10.1016/S1535-6108(02)00033-8; Clayton E, 2002, J EXP MED, V196, P753, DOI 10.1084/jem.20020805; Corvera S, 1998, TRENDS CELL BIOL, V8, P442, DOI 10.1016/S0962-8924(98)01366-X; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; Cully M, 2006, NAT REV CANCER, V6, P184, DOI 10.1038/nrc1819; Deane JA, 2004, ANNU REV IMMUNOL, V22, P563, DOI 10.1146/annurev.immunol.22.012703.104721; DEGROOT RP, 1993, ONCOGENE, V8, P841; Denley A, 2008, ONCOGENE, V27, P2561, DOI 10.1038/sj.onc.1210918; DHAND R, 1994, EMBO J, V13, P522, DOI 10.1002/j.1460-2075.1994.tb06290.x; Eng C, 2003, HUM MUTAT, V22, P183, DOI 10.1002/humu.10257; Engelman JA, 2006, NAT REV GENET, V7, P606, DOI 10.1038/nrg1879; Foukas LC, 2006, NATURE, V441, P366, DOI 10.1038/nature04694; Foukas LC, 2004, BIOCHEM SOC T, V32, P330, DOI 10.1042/BST0320330; Foukas LC, 2004, MOL CELL BIOL, V24, P966, DOI 10.1128/MCB.24.3.966-975.2004; Fruman DA, 2004, BIOCHEM SOC T, V32, P315, DOI 10.1042/BST0320315; Garami A, 2003, MOL CELL, V11, P1457, DOI 10.1016/S1097-2765(03)00220-X; Gilley J, 2003, J CELL BIOL, V162, P613, DOI 10.1083/jcb.200303026; Graupera M, 2008, NATURE, V453, P662, DOI 10.1038/nature06892; Gregory MA, 2003, J BIOL CHEM, V278, P51606, DOI 10.1074/jbc.M310722200; Gymnopoulos M, 2007, P NATL ACAD SCI USA, V104, P5569, DOI 10.1073/pnas.0701005104; Harrington LS, 2004, J CELL BIOL, V166, P213, DOI 10.1083/jcb.200403069; Hartmann C, 2005, ACTA NEUROPATHOL, V109, P639, DOI 10.1007/s00401-005-1000-1; Hawkins PT, 2006, BIOCHEM SOC T, V34, P647, DOI 10.1042/BST0340647; Heo WD, 2006, SCIENCE, V314, P1458, DOI 10.1126/science.1134389; Hickey FB, 2006, J BIOL CHEM, V281, P2441, DOI 10.1074/jbc.M511173200; Hirsch E, 2000, SCIENCE, V287, P1049, DOI 10.1126/science.287.5455.1049; Hooshmand-Rad R, 2000, J CELL SCI, V113, P207; Huang CH, 2008, CELL CYCLE, V7, P1151, DOI 10.4161/cc.7.9.5817; Huang CH, 2007, SCIENCE, V318, P1744, DOI 10.1126/science.1150799; Ikenoue T, 2005, CANCER RES, V65, P4562, DOI 10.1158/0008-5472.CAN-04-4114; Inoki K, 2002, NAT CELL BIOL, V4, P648, DOI 10.1038/ncb839; Inoki K, 2003, GENE DEV, V17, P1829, DOI 10.1101/gad.1110003; Isakoff SJ, 2005, CANCER RES, V65, P10992, DOI 10.1158/0008-5472.CAN-05-2612; Ji H, 2007, BLOOD, V110, P2940, DOI 10.1182/blood-2007-04-086751; Jou ST, 2002, MOL CELL BIOL, V22, P8580, DOI 10.1128/MCB.22.24.8580-8591.2002; Kang S, 2006, P NATL ACAD SCI USA, V103, P1289, DOI 10.1073/pnas.0510772103; Kang S, 2005, CELL CYCLE, V4, P578, DOI 10.4161/cc.4.4.1593; Kang SY, 2005, P NATL ACAD SCI USA, V102, P802, DOI 10.1073/pnas.0408864102; Katso R, 2001, ANNU REV CELL DEV BI, V17, P615, DOI 10.1146/annurev.cellbio.17.1.615; KLIPPEL A, 1994, MOL CELL BIOL, V14, P2675, DOI 10.1128/MCB.14.4.2675; Knight ZA, 2007, BIOCHEM SOC T, V35, P245, DOI 10.1042/BST0350245; Knight ZA, 2006, CELL, V125, P733, DOI 10.1016/j.cell.2006.03.035; Knobbe CB, 2005, NEUROPATH APPL NEURO, V31, P486, DOI 10.1111/j.1365-2990.2005.00660.x; Kops GJPL, 1999, NATURE, V398, P630, DOI 10.1038/19328; Laffargue M, 2002, IMMUNITY, V16, P441, DOI 10.1016/S1074-7613(02)00282-0; Lee JW, 2005, ONCOGENE, V24, P1477, DOI 10.1038/sj.onc.1208304; Leslie NR, 2004, BIOCHEM J, V382, P1, DOI 10.1042/BJ20040825; Leverrier Y, 2003, J BIOL CHEM, V278, P38437, DOI 10.1074/jbc.M306649200; Levine DA, 2005, CLIN CANCER RES, V11, P2875, DOI 10.1158/1078-0432.CCR-04-2142; Li VSW, 2005, BMC CANCER, V5, DOI 10.1186/1471-2407-5-29; Li Z, 2000, SCIENCE, V287, P1046, DOI 10.1126/science.287.5455.1046; Liu ZN, 2006, CELL CYCLE, V5, P675, DOI 10.4161/cc.5.7.2605; Luo J, 2005, J CELL BIOL, V170, P455, DOI 10.1083/jcb.200503088; Maehama T, 1998, J BIOL CHEM, V273, P13375, DOI 10.1074/jbc.273.22.13375; Maehama T, 2001, ANNU REV BIOCHEM, V70, P247, DOI 10.1146/annurev.biochem.70.1.247; Medema RH, 2000, NATURE, V404, P782, DOI 10.1038/35008115; Miled N, 2007, SCIENCE, V317, P239, DOI 10.1126/science.1135394; Mizoguchi M, 2004, BRAIN PATHOL, V14, P372, DOI 10.1111/j.1750-3639.2004.tb00080.x; Myers MP, 1998, P NATL ACAD SCI USA, V95, P13513, DOI 10.1073/pnas.95.23.13513; Nalefski EA, 1996, PROTEIN SCI, V5, P2375, DOI 10.1002/pro.5560051201; Newton AC, 1998, BBA-REV BIOMEMBRANES, V1376, P155, DOI 10.1016/S0304-4157(98)00003-3; NIKOLAKAKI E, 1993, ONCOGENE, V8, P833; Okkenhaug K, 2003, NAT REV IMMUNOL, V3, P317, DOI 10.1038/nri1056; Okkenhaug K, 2002, SCIENCE, V297, P1031; ONO A, 2007, J THROMB HAEMOST, V5, pW238; Pacold ME, 2000, CELL, V103, P931, DOI 10.1016/S0092-8674(00)00196-3; Raynaud FI, 2007, CANCER RES, V67, P5840, DOI 10.1158/0008-5472.CAN-06-4615; Rizo J, 1998, J BIOL CHEM, V273, P15879, DOI 10.1074/jbc.273.26.15879; Rodriguez-Borlado L, 2003, J IMMUNOL, V170, P4475, DOI 10.4049/jimmunol.170.9.4475; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; RodriguezViciana P, 1996, EMBO J, V15, P2442, DOI 10.1002/j.1460-2075.1996.tb00602.x; Saal LH, 2005, CANCER RES, V65, P2554, DOI 10.1158/0008-5472-CAN-04-3913; Sadhu C, 2003, BIOCHEM BIOPH RES CO, V308, P764, DOI 10.1016/S0006-291X(03)01480-3; Salmena L, 2008, CELL, V133, P403, DOI 10.1016/j.cell.2008.04.013; Samuels Y, 2004, SCIENCE, V304, P554, DOI 10.1126/science.1096502; Samuels Y, 2006, CURR OPIN ONCOL, V18, P77, DOI 10.1097/01.cco.0000198021.99347.b9; Sarbassov DD, 2005, SCIENCE, V307, P1098, DOI 10.1126/science.1106148; Sasaki T, 2000, SCIENCE, V287, P1040, DOI 10.1126/science.287.5455.1040; Sawyer C, 2003, CANCER RES, V63, P1667; Sears R, 2000, GENE DEV, V14, P2501, DOI 10.1101/gad.836800; Seoane J, 2004, CELL, V117, P211, DOI 10.1016/S0092-8674(04)00298-3; Shekar SC, 2005, J BIOL CHEM, V280, P27850, DOI 10.1074/jbc.M506005200; Simpson L, 2001, EXP CELL RES, V264, P29, DOI 10.1006/excr.2000.5130; SKOLNIK EY, 1991, CELL, V65, P83, DOI 10.1016/0092-8674(91)90410-Z; Skorski T, 1997, EMBO J, V16, P6151, DOI 10.1093/emboj/16.20.6151; Stahl M, 2002, J IMMUNOL, V168, P5024, DOI 10.4049/jimmunol.168.10.5024; Stambolic V, 1998, CELL, V95, P29, DOI 10.1016/S0092-8674(00)81780-8; STEPHENS L, 1994, CELL, V77, P83, DOI 10.1016/0092-8674(94)90237-2; Suire S, 2006, NAT CELL BIOL, V8, P1303, DOI 10.1038/ncb1494; Sujobert P, 2005, BLOOD, V106, P1063, DOI 10.1182/blood-2004-08-3225; Takaishi H, 1999, P NATL ACAD SCI USA, V96, P11836, DOI 10.1073/pnas.96.21.11836; Tang ED, 1999, J BIOL CHEM, V274, P16741, DOI 10.1074/jbc.274.24.16741; Tee AR, 2003, CURR BIOL, V13, P1259, DOI 10.1016/S0960-9822(03)00506-2; van der Meijden PEJ, 2008, FEBS J, V275, P371, DOI 10.1111/j.1742-4658.2007.06207.x; Vanhaesebroeck B, 1999, EXP CELL RES, V253, P239, DOI 10.1006/excr.1999.4701; Vanhaesebroeck B, 2001, ANNU REV BIOCHEM, V70, P535, DOI 10.1146/annurev.biochem.70.1.535; Vanhaesebroeck B, 2005, TRENDS BIOCHEM SCI, V30, P194, DOI 10.1016/j.tibs.2005.02.008; Vanhaesebroeck B, 1999, NAT CELL BIOL, V1, P69, DOI 10.1038/9045; Vanhaesebroeck B, 1997, P NATL ACAD SCI USA, V94, P4330, DOI 10.1073/pnas.94.9.4330; Vanhaesebroeck B, 1997, TRENDS BIOCHEM SCI, V22, P267, DOI 10.1016/S0968-0004(97)01061-X; Vivanco I, 2002, NAT REV CANCER, V2, P489, DOI 10.1038/nrc839; Vogt PK, 2007, TRENDS BIOCHEM SCI, V32, P342, DOI 10.1016/j.tibs.2007.05.005; Walker EH, 1999, NATURE, V402, P313, DOI 10.1038/46319; Wang Y, 2005, HUM MUTAT, V25, DOI 10.1002/humu.9316; Wei WY, 2005, CANCER CELL, V8, P25, DOI 10.1016/j.ccr.2005.06.005; Wishart MJ, 2002, TRENDS CELL BIOL, V12, P579, DOI 10.1016/S0962-8924(02)02412-1; Wu H, 2007, BIOCHEM SOC T, V35, P242, DOI 10.1042/BST0350242; Yaguchi SI, 2006, JNCI-J NATL CANCER I, V98, P545, DOI 10.1093/jnci/djj133; Yip SC, 2004, CELL MOTIL CYTOSKEL, V59, P180, DOI 10.1002/cm.20032; Yu JH, 1998, MOL CELL BIOL, V18, P1379, DOI 10.1128/MCB.18.3.1379; Zhang Y, 2003, NAT CELL BIOL, V5, P578, DOI 10.1038/ncb999; Zhao JJ, 2005, P NATL ACAD SCI USA, V102, P18443, DOI 10.1073/pnas.0508988102; Zhao L, 2008, P NATL ACAD SCI USA, V105, P2652, DOI 10.1073/pnas.0712169105	133	441	512	1	28	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 15	2008	27	41					5486	5496		10.1038/onc.2008.244	http://dx.doi.org/10.1038/onc.2008.244			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	349KW	18794883	Green Accepted			2022-12-28	WOS:000259280700010
J	Deshmukh, H; Yeh, TH; Yu, J; Sharma, MK; Perry, A; Leonard, JR; Watson, MA; Gutmann, DH; Nagarajan, R				Deshmukh, H.; Yeh, T. H.; Yu, J.; Sharma, M. K.; Perry, A.; Leonard, J. R.; Watson, M. A.; Gutmann, D. H.; Nagarajan, R.			High-resolution, dual-platform aCGH analysis reveals frequent HIPK2 amplification and increased expression in pilocytic astrocytomas	ONCOGENE			English	Article						pilocytic astrocytomas; aCGH; HIPK2; amplification	HOMEODOMAIN-INTERACTING PROTEIN-KINASE-2; COMPARATIVE GENOMIC HYBRIDIZATION; GENE AMPLIFICATION; HUMAN GLIOMAS; TUMORS; TRANSCRIPTION; HETEROZYGOSITY; GLIOBLASTOMA; POLYMORPHISM; MUTATIONS	Pilocytic astrocytomas (PAs, WHO grade I) are the most common brain tumors in the pediatric and adolescent population, accounting for approximately one-fifth of central nervous system tumors. Because few consistent molecular alterations have been identified in PAs compared to higher grade gliomas, we performed array comparative genomic hybridization using two independent commercial array platforms. Although whole chromosomal gains and losses were not observed, a 1-Mb amplified region of 7q34 was detected in multiple patient samples using both array platforms. Copy-number gain was confirmed in an independent tumor sample set by quantitative PCR, and this amplification was correlated to both increased mRNA and protein expression of HIPK2, a homeobox-interacting protein kinase associated with malignancy, contained within this locus. Furthermore, overexpression of wild-type HIPK2, but not a kinase-inactive mutant, in a glioma cell line conferred a growth advantage in vitro. Collectively, these results illustrate the power and necessity of implementing high-resolution, multiple-platform genomic analyses to discover small and subtle, but functionally significant, genomic alterations associated with low-grade tumor formation and growth.	[Yeh, T. H.; Gutmann, D. H.] Washington Univ, Dept Neurol, Sch Med, St Louis, MO 63110 USA; [Deshmukh, H.; Yu, J.; Sharma, M. K.; Perry, A.; Watson, M. A.; Nagarajan, R.] Washington Univ, Dept Pathol & Immunol, Sch Med, St Louis, MO 63110 USA; [Leonard, J. R.] Washington Univ, Dept Neurosurg, Sch Med, St Louis, MO 63110 USA; [Yeh, T. H.] Chang Gung Mem Hosp & Univ, Dept Neurol, Taipei, Taiwan	Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL); Chang Gung Memorial Hospital	Gutmann, DH (corresponding author), Washington Univ, Dept Neurol, Sch Med, 660 S Euclid Ave,306 Biotechnol Bldg,Campus Box 8, St Louis, MO 63110 USA.	gutmannd@neuro.wustl.edu; rakesh@wustl.edu		Perry, Arie/0000-0002-8300-7261; Gutmann, David/0000-0002-3127-5045				AGAMANOLIS DP, 1995, CANCER GENET CYTOGEN, V81, P125, DOI 10.1016/0165-4608(94)00123-S; Albertson DG, 2006, TRENDS GENET, V22, P447, DOI 10.1016/j.tig.2006.06.007; Arjona D, 2006, CURR MOL MED, V6, P645, DOI 10.2174/156652406778195017; Calzado MA, 2007, CELL CYCLE, V6, P139, DOI 10.4161/cc.6.2.3788; Cheng Y, 2000, HISTOPATHOLOGY, V37, P437, DOI 10.1046/j.1365-2559.2000.01005.x; D'Orazi G, 2002, NAT CELL BIOL, V4, P11, DOI 10.1038/ncb714; Harada J, 2003, J BIOL CHEM, V278, P38998, DOI 10.1074/jbc.M307112200; Hayes VM, 1999, BRAIN PATHOL, V9, P463, DOI 10.1111/j.1750-3639.1999.tb00535.x; Ishii N, 1998, INT J CANCER, V76, P797, DOI 10.1002/(SICI)1097-0215(19980610)76:6<797::AID-IJC5>3.3.CO;2-1; JENKINS RB, 1989, CANCER GENET CYTOGEN, V39, P253, DOI 10.1016/0165-4608(89)90192-1; Jones DTW, 2006, J NEUROPATH EXP NEUR, V65, P1049, DOI 10.1097/01.jnen.0000240465.33628.87; Kim YH, 1998, J BIOL CHEM, V273, P25875, DOI 10.1074/jbc.273.40.25875; Konigshoff M, 2003, CLIN CHEM, V49, P219, DOI 10.1373/49.2.219; Koschny R, 2002, CANCER GENET CYTOGEN, V135, P147, DOI 10.1016/S0165-4608(01)00650-1; Lin M, 2004, BIOINFORMATICS, V20, P1233, DOI 10.1093/bioinformatics/bth069; Nannya Y, 2005, CANCER RES, V65, P6071, DOI 10.1158/0008-5472.CAN-05-0465; Ohgaki H, 2005, NEUROPATHOLOGY, V25, P1, DOI 10.1111/j.1440-1789.2004.00600.x; Ohgaki H, 2004, CANCER RES, V64, P6892, DOI 10.1158/0008-5472.CAN-04-1337; Pierantoni GM, 2002, BIOCHEM BIOPH RES CO, V290, P942, DOI 10.1006/bbrc.2001.6310; Sanoudou D, 2000, BRIT J CANCER, V82, P1218; Schmidt MC, 2002, J NEUROPATH EXP NEUR, V61, P321, DOI 10.1093/jnen/61.4.321; Sebat J, 2004, SCIENCE, V305, P525, DOI 10.1126/science.1098918; Sharma MK, 2006, NEUROLOGY, V66, P127, DOI 10.1212/01.wnl.0000188667.66646.1c; Tada K, 2003, NEURO-ONCOLOGY, V5, P228, DOI 10.1215/S115285170300005X; THIEL G, 1992, CANCER GENET CYTOGEN, V58, P109, DOI 10.1016/0165-4608(92)90095-P; Venkatraman ES, 2007, BIOINFORMATICS, V23, P657, DOI 10.1093/bioinformatics/btl646; von Deimling A, 2000, J NEUROPATH EXP NEUR, V59, P544, DOI 10.1093/jnen/59.6.544; Wei GW, 2007, P NATL ACAD SCI USA, V104, P13040, DOI 10.1073/pnas.0703213104; Wemmert S, 2006, INT J ONCOL, V28, P353; WHITE FV, 1995, HUM PATHOL, V26, P979, DOI 10.1016/0046-8177(95)90087-X; Wiggins AK, 2004, J CELL BIOL, V167, P257, DOI 10.1083/jcb.200406131; Zattara-Cannoni H, 1998, CANCER GENET CYTOGEN, V104, P157, DOI 10.1016/S0165-4608(97)00455-X; Zhang JS, 2007, NAT NEUROSCI, V10, P77, DOI 10.1038/nn1816	33	75	75	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG	2008	27	34					4745	4751		10.1038/onc.2008.110	http://dx.doi.org/10.1038/onc.2008.110			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	334QM	18408760				2022-12-28	WOS:000258236300012
J	Peng, SL				Peng, S. L.			Foxo in the immune system	ONCOGENE			English	Review						transcription factors; autoimmunity; T cells; B cells; arthritis; lupus	FORKHEAD TRANSCRIPTION FACTOR; OXIDATIVE-STRESS; NUCLEAR EXCLUSION; INFLAMMATORY ARTHRITIS; NEUTROPHIL APOPTOSIS; CELL PROLIFERATION; SIGNALING PATHWAY; TUMOR SUPPRESSION; FACTOR FKHR; DNA-DAMAGE	In addition to their key roles in cellular survival, death, proliferation and metabolism, the Foxo subfamily of forkhead (Fox) transcription factors play critical roles in the homeostasis of immune-relevant cells, including T cells, B cells, neutrophils and other non-lymphoid lineages that modulate inflammation in disease states such as inflammatory arthritis and systemic lupus erythematosus. This review summarizes such current and expanding knowledge of the Foxo family members in immunity, and their potential as therapeutic targets in inflammatory disease.	Clin Res & Exploratory Dev, Palo Alto, CA 94304 USA		Peng, SL (corresponding author), Clin Res & Exploratory Dev, LLC 3431 Hillview Ave,M-S A2-259, Palo Alto, CA 94304 USA.	stanford.peng@roche.com	Peng, Stanford/S-6723-2019					Asada S, 2007, CELL SIGNAL, V19, P519, DOI 10.1016/j.cellsig.2006.08.015; Asselin-Labat ML, 2004, BLOOD, V104, P215, DOI 10.1182/blood-2003-12-4295; Aud D, 2006, NAT CLIN PRACT RHEUM, V2, P434, DOI 10.1038/ncprheum0222; Behzad H, 2007, CYTOKINE, V38, P74, DOI 10.1016/j.cyto.2007.05.004; Birkenkamp KU, 2007, J BIOL CHEM, V282, P2211, DOI 10.1074/jbc.M606669200; Bosque A, 2007, BLOOD, V109, P1627, DOI 10.1182/blood-2006-05-022319; Brunet A, 2001, MOL CELL BIOL, V21, P952, DOI 10.1128/MCB.21.3.952-965.2001; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Brunet A, 2004, SCIENCE, V303, P2011, DOI 10.1126/science.1094637; Charvet C, 2006, J IMMUNOL, V177, P5024, DOI 10.4049/jimmunol.177.8.5024; Chen J, 2006, J IMMUNOL, V176, P2711, DOI 10.4049/jimmunol.176.5.2711; Coffer PJ, 2004, NAT REV IMMUNOL, V4, P889, DOI 10.1038/nri1488; Crellin NK, 2007, BLOOD, V109, P2014, DOI 10.1182/blood-2006-07-035279; Crossley LJ, 2003, J LEUKOCYTE BIOL, V74, P583, DOI 10.1189/jlb.0103020; Daitoku H, 2004, P NATL ACAD SCI USA, V101, P10042, DOI 10.1073/pnas.0400593101; De Ruiter ND, 2001, MOL CELL BIOL, V21, P8225, DOI 10.1128/MCB.21.23.8225-8235.2001; Dijkers PF, 2002, J CELL BIOL, V156, P531, DOI 10.1083/jcb.200108084; Essers MAG, 2004, EMBO J, V23, P4802, DOI 10.1038/sj.emboj.7600476; Fabre S, 2005, J IMMUNOL, V174, P4161, DOI 10.4049/jimmunol.174.7.4161; FABRE S, 2006, FOXOS B CANC, V93, pE36; Fallarino F, 2004, J EXP MED, V200, P1051, DOI 10.1084/jem.20040942; Fosbrink M, 2006, J BIOL CHEM, V281, P19009, DOI 10.1074/jbc.M602055200; Georgiades SN, 2005, ORG LETT, V7, P4091, DOI 10.1021/ol0513286; Hinman RM, 2007, J IMMUNOL, V178, P740, DOI 10.4049/jimmunol.178.2.740; Hu MCT, 2004, CELL, V117, P225, DOI 10.1016/S0092-8674(04)00302-2; Huang H, 2005, P NATL ACAD SCI USA, V102, P1649, DOI 10.1073/pnas.0406789102; Huang HJ, 2006, SCIENCE, V314, P294, DOI 10.1126/science.1130512; HUGHES LB, 2006, ANN M AM COLL RHE WA; Jacobsen EA, 2006, J IMMUNOL, V176, P6831, DOI 10.4049/jimmunol.176.11.6831; Jonsson H, 2005, NAT MED, V11, P666, DOI 10.1038/nm1248; Jonsson H, 2005, CELL MOL LIFE SCI, V62, P397, DOI 10.1007/s00018-004-4365-8; Kau TR, 2003, CANCER CELL, V4, P463, DOI 10.1016/S1535-6108(03)00303-9; Kops GJPL, 2002, NATURE, V419, P316, DOI 10.1038/nature01036; Lam EWF, 2006, BIOCHEM SOC T, V34, P722, DOI 10.1042/BST0340722; Lehtinen MK, 2006, CELL, V125, P987, DOI 10.1016/j.cell.2006.03.046; Lin L, 2004, IMMUNITY, V21, P203, DOI 10.1016/j.immuni.2004.06.016; Ludikhuize J, 2007, ARTHRITIS RHEUM-US, V56, P2180, DOI 10.1002/art.22653; Matsuzaki H, 2003, P NATL ACAD SCI USA, V100, P11285, DOI 10.1073/pnas.1934283100; Matsuzaki H, 2005, P NATL ACAD SCI USA, V102, P11278, DOI 10.1073/pnas.0502738102; Medema RH, 2000, NATURE, V404, P782, DOI 10.1038/35008115; Motta MC, 2004, CELL, V116, P551, DOI 10.1016/S0092-8674(04)00126-6; Nakae J, 2006, J CLIN INVEST, V116, P2473, DOI 10.1172/JCI25518; Nemoto S, 2002, SCIENCE, V295, P2450, DOI 10.1126/science.1069004; Pandiyan P, 2004, J EXP MED, V199, P831, DOI 10.1084/jem.20031058; Peng SL, 2007, AUTOIMMUNITY, V40, P462, DOI 10.1080/08916930701464913; Plas DR, 2003, J BIOL CHEM, V278, P12361, DOI 10.1074/jbc.M213069200; Ramaswamy S, 2002, CANCER CELL, V2, P81, DOI 10.1016/S1535-6108(02)00086-7; Reedquist KA, 2006, BIOCHEM SOC T, V34, P727, DOI 10.1042/BST0340727; Rena G, 2004, EMBO REP, V5, P60, DOI 10.1038/sj.embor.7400048; Rena G, 2002, EMBO J, V21, P2263, DOI 10.1093/emboj/21.9.2263; Riou C, 2007, J EXP MED, V204, P79, DOI 10.1084/jem.20061681; Schroeder FC, 2005, J NAT PROD, V68, P574, DOI 10.1021/np049624z; Sela U, 2006, EUR J IMMUNOL, V36, P2971, DOI 10.1002/eji.200636137; So CW, 2003, BLOOD, V101, P633, DOI 10.1182/blood-2002-06-1785; Stahl M, 2002, J IMMUNOL, V168, P5024, DOI 10.4049/jimmunol.168.10.5024; Tothova Z, 2007, CELL, V128, P325, DOI 10.1016/j.cell.2007.01.003; Tsuchida K, 2006, J MED CHEM, V49, P80, DOI 10.1021/jm050550d; van der Heide LP, 2005, TRENDS BIOCHEM SCI, V30, P81, DOI 10.1016/j.tibs.2004.12.002; van der Horst A, 2004, J BIOL CHEM, V279, P28873, DOI 10.1074/jbc.M401138200; van der Horst A, 2006, NAT CELL BIOL, V8, P1064, DOI 10.1038/ncb1469; Wijchers PJEC, 2006, BIOCHEM J, V397, P233, DOI 10.1042/BJ20060387; Woods YL, 2001, BIOCHEM J, V355, P597, DOI 10.1042/bj3550597; Yamamura Y, 2006, J BIOL CHEM, V281, P5267, DOI 10.1074/jbc.M512151200; Yang KY, 2003, CELL SIGNAL, V15, P225, DOI 10.1016/S0898-6568(02)00063-3; Yau CYF, 2005, CANCER RES, V65, P1497, DOI 10.1158/0008-5472.CAN-04-2940; You H, 2004, P NATL ACAD SCI USA, V101, P14057, DOI 10.1073/pnas.0406286101; You H, 2006, J EXP MED, V203, P1657, DOI 10.1084/jem.20060353; You H, 2006, P NATL ACAD SCI USA, V103, P9051, DOI 10.1073/pnas.0600889103; Yusuf I, 2004, BLOOD, V104, P784, DOI 10.1182/blood-2003-09-3071; Zhuang YL, 2006, NEUROENDOCRINOL LETT, V27, P53	70	84	86	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 7	2008	27	16					2337	2344		10.1038/onc.2008.26	http://dx.doi.org/10.1038/onc.2008.26			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	285NE	18391975				2022-12-28	WOS:000254782700008
J	Chaturvedi, D; Gao, X; Cohen, MS; Taunton, J; Patel, TB				Chaturvedi, D.; Gao, X.; Cohen, M. S.; Taunton, J.; Patel, T. B.			Rapamycin induces transactivation of the EGFR and increases cell survival	ONCOGENE			English	Article						mTOR; rapamycin; transactivation; EGFR; c-Src; apoptosis	GROWTH-FACTOR RECEPTOR; RIBOSOMAL S6 KINASE; MAMMALIAN TARGET; CANCER-CELLS; CARDIAC-HYPERTROPHY; PROTEIN-KINASE; SIGNAL-TRANSDUCTION; MTOR; PATHWAY; AKT	The mammalian target of rapamycin (mTOR) signa ling network regulates cell growth, proliferation and cell survival. Deregulated activation of this pathway is a common event in diverse human diseases such as cancers, cardiac hypertrophy, vascular restenosis and nephrotic hypertrophy. Although mTOR inhibitor, rapamycin, has been widely used to inhibit the aberrant signaling due to mTOR activation that plays a major role in hyperproliferative diseases, in some cases rapamycin does not attenuate the cell proliferation and survival. Thus, we studied the mechanism(s) by which cells may confer resistance to rapamycin. Our data show that in a variety of cell types the mTOR inhibitor rapamycin activates extracellularly regulated kinases (Erk1/2) signa ling. Rapamycin-mediated activation of the Erk1/2 signaling requires (a) the epidermal growth factor receptor (EGFR), (b) its tyrosine kinase activity and (c) intact autophosphorylation sites on the receptor. Rapamycin treatment increases tyrosine phosphorylation of EGFR without the addition of growth factor and this transactivation of receptor involves activation of c-Src. We also show that rapamycin treatment triggers activation of cell survival signaling pathway by activating the prosurvival kinases Erk1/2 and p90RSK. These studies provide a novel paradigm by which cells escape the apoptotic actions of rapamycin and its derivatives that inhibit the mTOR pathway.	[Chaturvedi, D.; Gao, X.; Patel, T. B.] Loyola Univ, Med Ctr, Stritch Sch Med, Dept Pharmacol & Expt Therapeut, Maywood, IL 60153 USA; [Cohen, M. S.; Taunton, J.] Univ Calif San Francisco, Dept Cellular & Mol Pharmacol, San Francisco, CA 94143 USA	Loyola University Chicago; University of California System; University of California San Francisco	Chaturvedi, D (corresponding author), Loyola Univ, Med Ctr, Stritch Sch Med, Dept Pharmacol & Expt Therapeut, 2160 S 1st Ave,Bldg 101,Rm 2716, Maywood, IL 60153 USA.	dchaturvedi@lumc.edu			American Heart Association-SDG [AHA-ID-0830411Z]; NIH [GM071434, GM 079226, GM73181]; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM079226, R01GM073181, R01GM071434] Funding Source: NIH RePORTER	American Heart Association-SDG(American Heart Association); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We are indebted to Dr PJ Bertics for providing us with the B82L cells, the EGFR cDNA and EGFR antibodies and to Ms Kuldeep Patel for the immunocytochemical analyses. This study was supported by American Heart Association-SDG AHA-ID-0830411Z ( to DC) and NIH Grants GM071434 ( to JT), GM 079226 and GM73181 ( to TBP).	Abraham RT, 1998, CURR OPIN IMMUNOL, V10, P330, DOI 10.1016/S0952-7915(98)80172-6; Arteaga CL, 1997, J BIOL CHEM, V272, P23247, DOI 10.1074/jbc.272.37.23247; Asakura M, 2002, NAT MED, V8, P35, DOI 10.1038/nm0102-35; Azzariti A, 2008, BIOCHEM PHARMACOL, V75, P1035, DOI 10.1016/j.bcp.2007.11.018; Banko JL, 2006, J NEUROSCI, V26, P2167, DOI 10.1523/JNEUROSCI.5196-05.2006; Bjornsti MA, 2004, NAT REV CANCER, V4, P335, DOI 10.1038/nrc1362; Boluyt MO, 2004, CARDIOVASC DRUG THER, V18, P257, DOI 10.1023/B:CARD.0000041245.61136.56; Chaturvedi D, 2006, MOL CELL BIOL, V26, P4586, DOI 10.1128/MCB.01422-05; CHEN RH, 1992, MOL CELL BIOL, V12, P915, DOI 10.1128/MCB.12.3.915; Cohen MS, 2005, SCIENCE, V308, P1318, DOI 10.1126/science1108367; Costa LJ, 2007, UROLOGY, V69, P596, DOI 10.1016/j.urology.2007.01.053; Daub H, 1997, EMBO J, V16, P7032, DOI 10.1093/emboj/16.23.7032; Dormond O, 2007, J BIOL CHEM, V282, P23679, DOI 10.1074/jbc.M700563200; Dummler BA, 2005, J BIOL CHEM, V280, P13304, DOI 10.1074/jbc.M408194200; Fischer OM, 2003, BIOCHEM SOC T, V31, P1203; Frias MA, 2006, CURR BIOL, V16, P1865, DOI 10.1016/j.cub.2006.08.001; Frodin M, 1999, MOL CELL ENDOCRINOL, V151, P65, DOI 10.1016/S0303-7207(99)00061-1; Fumarola C, 2005, CELL DEATH DIFFER, V12, P1344, DOI 10.1038/sj.cdd.4401660; Galanis E, 2005, J CLIN ONCOL, V23, P5294, DOI 10.1200/JCO.2005.23.622; Goudar RK, 2005, MOL CANCER THER, V4, P101; Gschwind A, 2003, EMBO J, V22, P2411, DOI 10.1093/emboj/cdg231; Guertin DA, 2005, TRENDS MOL MED, V11, P353, DOI 10.1016/j.molmed.2005.06.007; Hardie DG, 2006, J PHYSIOL-LONDON, V574, P7, DOI 10.1113/jphysiol.2006.108944; Harrington LS, 2004, J CELL BIOL, V166, P213, DOI 10.1083/jcb.200403069; Huang S, 2003, CURR OPIN PHARMACOL, V3, P371, DOI 10.1016/S1471-4892(03)00071-7; Inoki K, 2006, CELL, V126, P955, DOI 10.1016/j.cell.2006.06.055; Jacinto E, 2004, NAT CELL BIOL, V6, P1122, DOI 10.1038/ncb1183; Jacinto E, 2006, CELL, V127, P125, DOI 10.1016/j.cell.2006.08.033; Jin W, 2007, CANCER RES, V67, P3192, DOI 10.1158/0008-5472.CAN-06-3526; Kiley SC, 2007, AM J PHYSIOL-RENAL, V293, pF895, DOI 10.1152/ajprenal.00227.2007; Kris MG, 2007, J CLIN ONCOL, V25, p18s; Kudo N, 1996, BBA-LIPID LIPID MET, V1301, P67, DOI 10.1016/0005-2760(96)00013-6; Li J, 1999, J BIOL CHEM, V274, P11209, DOI 10.1074/jbc.274.16.11209; LORENZ MC, 1995, J BIOL CHEM, V270, P27531, DOI 10.1074/jbc.270.46.27531; Manning BD, 2004, J CELL BIOL, V167, P399, DOI 10.1083/jcb.200408161; McMullen JR, 2004, CIRCULATION, V109, P3050, DOI 10.1161/01.CIR.0000130641.08705.45; Metro G, 2006, REV RECENT CLIN TRIA, V1, P1, DOI 10.2174/157488706775246157; Milton DT, 2007, CANCER-AM CANCER SOC, V110, P599, DOI 10.1002/cncr.22816; Myers AP, 2004, MOL CELL BIOL, V24, P4255, DOI 10.1128/MCB.24.10.4255-4266.2004; O'Reilly KE, 2006, CANCER RES, V66, P1500, DOI 10.1158/0008-5472.CAN-05-2925; Parry TJ, 2005, EUR J PHARMACOL, V524, P19, DOI 10.1016/j.ejphar.2005.09.042; Prenzel N, 1999, NATURE, V402, P884, DOI 10.1038/47260; Roux PP, 2007, J BIOL CHEM, V282, P14056, DOI 10.1074/jbc.M700906200; Roux PP, 2003, MOL CELL BIOL, V23, P4796, DOI 10.1128/MCB.23.14.4796-4804.2003; Sabatini DM, 2006, NAT REV CANCER, V6, P729, DOI 10.1038/nrc1974; Saito Y, 2001, MOL CELL BIOL, V21, P6387, DOI 10.1128/MCB.21.19.6387-6394.2001; Sarbassov DD, 2005, CURR OPIN CELL BIOL, V17, P596, DOI 10.1016/j.ceb.2005.09.009; Sarbassov DD, 2006, MOL CELL, V22, P159, DOI 10.1016/j.molcel.2006.03.029; Sarbassov DD, 2004, CURR BIOL, V14, P1296, DOI 10.1016/j.cub.2004.06.054; Sharma S, 2006, CARDIOLOGY, V105, P128, DOI 10.1159/000090550; Shimamura A, 2000, CURR BIOL, V10, P127, DOI 10.1016/S0960-9822(00)00310-9; Sun SY, 2005, CANCER RES, V65, P7052, DOI 10.1158/0008-5472.CAN-05-0917; Tice DA, 1999, P NATL ACAD SCI USA, V96, P1415, DOI 10.1073/pnas.96.4.1415; Tzatsos A, 2006, MOL CELL BIOL, V26, P63, DOI 10.1128/MCB.26.1.63-76.2006; Um SH, 2004, NATURE, V431, P200, DOI 10.1038/nature02866; VanderWeele DJ, 2004, MOL CANCER THER, V3, P1605; Vega F, 2006, CANCER RES, V66, P6589, DOI 10.1158/0008-5472.CAN-05-3018; Vivanco I, 2002, NAT REV CANCER, V2, P489, DOI 10.1038/nrc839; Wan X, 2007, ONCOGENE, V26, P1932, DOI 10.1038/sj.onc.1209990; Wendel HG, 2004, NATURE, V428, P332, DOI 10.1038/nature02369; Wullschleger S, 2006, CELL, V124, P471, DOI 10.1016/j.cell.2006.01.016	61	41	44	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 5	2009	28	9					1187	1196		10.1038/onc.2008.490	http://dx.doi.org/10.1038/onc.2008.490			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	415AH	19151764	Green Accepted, Green Submitted			2022-12-28	WOS:000263906200003
J	Raimundo, N; Vanharanta, S; Aaltonen, LA; Hovatta, I; Suomalainen, A				Raimundo, N.; Vanharanta, S.; Aaltonen, L. A.; Hovatta, I.; Suomalainen, A.			Downregulation of SRF-FOS-JUNB pathway in fumarate hydratase deficiency and in uterine leiomyomas	ONCOGENE			English	Article						leiomyoma; mitochondria; fumarate hydratase; expression microarray; serum response factor	SERUM-RESPONSE FACTOR; RENAL-CELL CANCER; GENE-EXPRESSION; HEREDITARY LEIOMYOMATOSIS; GLUCOCORTICOID-RECEPTOR; TARGETED INACTIVATION; MITOCHONDRIAL DISEASE; HYPOXIA PATHWAY; KREBS CYCLE; PUR-BETA	Defects of metabolic enzymes result in a variety of manifestations not logically explained by the primary metabolic function. Dominant defects of fumarate hydratase (FH) result in predisposition to cutaneous and uterine leiomyomas, and renal cell cancer. FH is a metabolic enzyme of the tricarboxylic acid cycle, and its tumor-suppressor mechanism is not fully understood. We compared the consequences of FH deficiency and respiratory chain (RC) deficiency using global expression pattern of diploid primary fibroblasts. This approach utilized the information that RC defects do not seem to predispose to tumorigenesis, and the aim was to identify FH-specific signaling effects that might have relevance to tumor formation. These results were then compared to global expression patterns of FH-deficient and sporadic uterine leiomyoma data sets. We show here that FH-deficient fibroblasts share a common transcriptional fingerprint with FH-deficient and sporadic leiomyomas, highlighting the downregulation of serum response factor (SRF)-regulated transcripts, particularly the FOS-JUNB pathway. We confirmed the downregulation of this pathway at transcriptional and protein level. SRF has a fundamental function in the differentiation of smooth muscle progenitor cells, and its downregulation both in diploid FH-deficient primary fibroblasts and in leiomyomas suggests an early function in the mechanism of uterine leiomyoma formation in FH deficiency. Concordantly, the phosphorylated form of SRF, known to activate transcription, is undetectable in leiomyomas whereas clearly detected in several nuclei in the differentiated myometrium. A similar transcriptional SRF-pathway fingerprint in FH-deficient and sporadic leiomyomas emphasizes the potential importance of this pathway in primary events leading to leiomyomatosis.	[Raimundo, N.; Hovatta, I.; Suomalainen, A.] Univ Helsinki, Res Program Mol Neurol, FIN-00290 Helsinki, Finland; [Vanharanta, S.; Aaltonen, L. A.] Univ Helsinki, Res Program Genome Scale Biol, FIN-00290 Helsinki, Finland; [Vanharanta, S.; Aaltonen, L. A.; Hovatta, I.] Univ Helsinki, Dept Med Genet, FIN-00290 Helsinki, Finland; [Hovatta, I.] Natl Publ Hlth Inst, Dept Mol Med, Helsinki, Finland; [Hovatta, I.] Natl Publ Hlth Inst, Dept Mental Hlth & Alcohol Res, Helsinki, Finland; [Suomalainen, A.] Univ Helsinki, Cent Hosp, Dept Neurol, FIN-00290 Helsinki, Finland	University of Helsinki; University of Helsinki; University of Helsinki; Finland National Institute for Health & Welfare; Finland National Institute for Health & Welfare; University of Helsinki; Helsinki University Central Hospital	Suomalainen, A (corresponding author), Univ Helsinki, Res Program Mol Neurol, Room c523B,Haartmaninkatu 8, FIN-00290 Helsinki, Finland.	Anu.wartiovaara@helsinki.fi	Aaltonen, Lauri/A-5375-2010; Raimundo, Nuno/AAD-9498-2020; Hovatta, Iiris/D-6871-2012; Raimundo, Nuno/E-8357-2010	Aaltonen, Lauri/0000-0001-6839-4286; Raimundo, Nuno/0000-0002-5988-9129; Hovatta, Iiris/0000-0002-5990-7892; Suomalainen-Wartiovaara, Anu/0000-0003-4833-5195	Helsinki Biomedical Graduate School; Sigrid Juselius Foundation; Centre of Excellence program of Academy of Finland; University of Helsinki; EMBO Young Investigator Program	Helsinki Biomedical Graduate School; Sigrid Juselius Foundation(Sigrid Juselius Foundation); Centre of Excellence program of Academy of Finland(Academy of Finland); University of Helsinki; EMBO Young Investigator Program(European Molecular Biology Organization (EMBO))	We thank Heli Lehtonen for providing the paraffin sections and Markus Innila for skillful immunohistochemistry. The following funding sources are gratefully acknowledged: Helsinki Biomedical Graduate School (NR), Sigrid Juselius Foundation ( AS and LA), Centre of Excellence program of Academy of Finland and University of Helsinki ( AS and LA) and EMBO Young Investigator Program ( AS).; Financial support: Academy of Finland, Helsinki University, Sigrid Juselius Foundation ( for AS), Helsinki Biomedical Graduate School ( for NR).	Al Refae M, 2007, NAT CLIN PRACT ONCOL, V4, P256, DOI 10.1038/ncponc0773; Alam NA, 2003, HUM MOL GENET, V12, P1241, DOI 10.1093/hmg/ddg148; Arsenian S, 1998, EMBO J, V17, P6289, DOI 10.1093/emboj/17.21.6289; Arslan AA, 2005, HUM REPROD, V20, P852, DOI 10.1093/humrep/deh698; Balza RO, 2006, J BIOL CHEM, V281, P6498, DOI 10.1074/jbc.M509487200; Baysal BE, 2000, SCIENCE, V287, P848, DOI 10.1126/science.287.5454.848; BOURGERON T, 1994, J CLIN INVEST, V93, P2514, DOI 10.1172/JCI117261; Campione E, 2007, J INVEST DERMATOL, V127, P2271, DOI 10.1038/sj.jid.5700851; Carlini LE, 2002, J BIOL CHEM, V277, P8682, DOI 10.1074/jbc.M109754200; Carvajal-Carmona LG, 2006, J CLIN ENDOCR METAB, V91, P3071, DOI 10.1210/jc.2006-0183; CATALA F, 1995, MOL CELL BIOL, V15, P4585; Chai J, 2002, J PHYSIOL PHARMACOL, V53, P147; Chebotaev D, 2007, MOL CARCINOGEN, V46, P732, DOI 10.1002/mc.20349; Du KL, 2004, J BIOL CHEM, V279, P17578, DOI 10.1074/jbc.M400961200; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; Eng C, 2003, NAT REV CANCER, V3, P193, DOI 10.1038/nrc1013; Gottlieb E, 2005, NAT REV CANCER, V5, P857, DOI 10.1038/nrc1737; Heidenreich O, 1999, J BIOL CHEM, V274, P14434, DOI 10.1074/jbc.274.20.14434; Hoffman PJ, 2004, FERTIL STERIL, V82, P639, DOI 10.1016/j.fertnstert.2004.01.047; Irizarry RA, 2003, NUCLEIC ACIDS RES, V31, DOI 10.1093/nar/gng015; Isaacs JS, 2005, CANCER CELL, V8, P143, DOI 10.1016/j.ccr.2005.06.017; JANKNECHT R, 1992, EMBO J, V11, P1045, DOI 10.1002/j.1460-2075.1992.tb05143.x; Kelm RJ, 2003, J BIOL CHEM, V278, P38749, DOI 10.1074/jbc.M306163200; Le PP, 2005, PLOS GENET, V1, P159, DOI 10.1371/journal.pgen.0010016; Loeffen J, 2005, J INHERIT METAB DIS, V28, P799, DOI 10.1007/s10545-005-0044-7; Maradin M, 2006, J INHERIT METAB DIS, V29, P683, DOI 10.1007/s10545-006-0321-0; Marshall P, 2001, J BIOL CHEM, V276, P20719, DOI 10.1074/jbc.M102100200; MISRA RP, 1994, J BIOL CHEM, V269, P25483; Mittelstadt PR, 2003, MOL ENDOCRINOL, V17, P1534, DOI 10.1210/me.2002-0429; Parlakian A, 2004, MOL CELL BIOL, V24, P5281, DOI 10.1128/MCB.24.12.5281-5289.2004; Pipes GCT, 2006, GENE DEV, V20, P1545, DOI 10.1101/gad.1428006; Pollard P, 2005, J PATHOL, V205, P41, DOI 10.1002/path.1686; Pollard PJ, 2007, CANCER CELL, V11, P311, DOI 10.1016/j.ccr.2007.02.005; Pollard PJ, 2003, ANN MED, V35, P632, DOI 10.1080/07853890310018458; Pollard PJ, 2005, HUM MOL GENET, V14, P2231, DOI 10.1093/hmg/ddi227; Raimundo N, 2008, BBA-MOL BASIS DIS, V1782, P287, DOI 10.1016/j.bbadis.2008.01.008; Remes AM, 2004, J MOL MED, V82, P550, DOI 10.1007/s00109-004-0563-y; RIVERA VM, 1993, MOL CELL BIOL, V13, P6260, DOI 10.1128/MCB.13.10.6260; Rustin P, 1997, BBA-MOL BASIS DIS, V1361, P185, DOI 10.1016/S0925-4439(97)00035-5; Schapira AHV, 2006, LANCET, V368, P70, DOI 10.1016/S0140-6736(06)68970-8; Shozu M, 2004, CANCER RES, V64, P4677, DOI 10.1158/0008-5472.CAN-03-0560; Smeitink JA, 2006, CELL METAB, V3, P9, DOI 10.1016/j.cmet.2005.12.001; Tomlinson IPM, 2002, NAT GENET, V30, P406, DOI 10.1038/ng849; Trifunovic A, 2004, NATURE, V429, P417, DOI 10.1038/nature02517; Tyynismaa H, 2005, P NATL ACAD SCI USA, V102, P17687, DOI 10.1073/pnas.0505551102; Vanharanta S, 2006, HUM MOL GENET, V15, P97, DOI 10.1093/hmg/ddi431; Walker CL, 2005, SCIENCE, V308, P1589, DOI 10.1126/science.1112063; WANG GL, 1995, J BIOL CHEM, V270, P1230, DOI 10.1074/jbc.270.3.1230; Wei JJ, 2005, MODERN PATHOL, V18, P179, DOI 10.1038/modpathol.3800283; Weinhold B, 2000, EMBO J, V19, P5835, DOI 10.1093/emboj/19.21.5835; Ylisaukko-oja SK, 2006, EUR J HUM GENET, V14, P880, DOI 10.1038/sj.ejhg.5201630; Zhang SX, 2005, J BIOL CHEM, V280, P19115, DOI 10.1074/jbc.M413793200	52	22	22	1	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 5	2009	28	9					1261	1273		10.1038/onc.2008.472	http://dx.doi.org/10.1038/onc.2008.472			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	415AH	19151755				2022-12-28	WOS:000263906200010
J	Guigon, CJ; Zhao, L; Willingham, MC; Cheng, SY				Guigon, C. J.; Zhao, L.; Willingham, M. C.; Cheng, S-Y			PTEN deficiency accelerates tumour progression in a mouse model of thyroid cancer	ONCOGENE			English	Article						thyroid cancer; Pten; carcinogenesis; mouse model; mutations	PROTEIN-KINASE-B; COWDEN-DISEASE; GERMLINE MUTATIONS; PHOSPHOINOSITIDE 3-KINASE; TRANSCRIPTION FACTORS; SUPPRESSOR GENE; LIGAND-BINDING; BETA-RECEPTOR; HORMONE; RESISTANCE	Inactivation and silencing of PTEN have been observed in multiple cancers, including follicular thyroid carcinoma. PTEN (phosphatase and tensin homologue deleted from chromosome 10) functions as a tumour suppressor by opposing the phosphatidylinositol 3-kinase (PI3K)/protein kinase B (AKT) signalling pathway. Despite correlative data, how deregulated PTEN signalling leads to thyroid carcinogenesis is not known. Mice harbouring a dominant-negative mutant thyroid hormone receptor beta (TR beta(PV/PV) mice) spontaneously develop follicular thyroid carcinoma and distant metastases similar to human cancer. To elucidate the role of PTEN in thyroid carcinogenesis, we generated TR beta(PV/PV) mice haploinsufficient for Pten (TR beta(PV/PV)Pten(+/-) mouse). PTEN deficiency accelerated the progression of thyroid tumour and increased the occurrence of metastasis spread to the lung in TR beta(PV/PV)Pten(+/-) mice, thereby significantly reducing their survival as compared with TR beta(PV/PV)Pten(+/+) mice. AKT activation was further increased by two-fold in TR beta(PV/PV)Pten(+/-) mice thyroids, leading to increased activity of the downstream mammalian target of rapamycin (mTOR)-p70S6K signalling and decreased activity of the forkhead family member FOXO3a. Consistently, cyclin D1 expression was increased. Apoptosis was decreased as indicated by increased expression of nuclear factor-kappa B (NF-kappa B) and decreased caspase-3 activity in the thyroids of TR beta(PV/PV)Pten(+/-) mice. Our results indicate that PTEN deficiency resulted in increased cell proliferation and survival in the thyroids of TR beta(PV/PV)Pten(+/-) mice. Altogether, our study provides direct evidence to indicate that in vivo, PTEN is a critical regulator in the follicular thyroid cancer progression and invasiveness.	[Cheng, S-Y] NCI, Gene Regulat Sect, Mol Biol Lab, Ctr Canc Res, Bethesda, MD 20892 USA; [Willingham, M. C.] Wake Forest Univ, Dept Pathol, Winston Salem, NC 27109 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Wake Forest University	Cheng, SY (corresponding author), NCI, Gene Regulat Sect, Mol Biol Lab, Ctr Canc Res, 37 Convent Dr,Room 5128, Bethesda, MD 20892 USA.	chengs@mail.nih.gov	guigon, celine/L-3518-2017	guigon, celine/0000-0002-4489-4304	Center for Cancer Research; National Cancer Institute; National Institutes of Health; NATIONAL CANCER INSTITUTE [ZIABC011191, ZIABC008752] Funding Source: NIH RePORTER	Center for Cancer Research(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	;We thank Dr Hao Ying for assistance in the determination of thyroid function tests. This research was supported by the Intramural Research Program of Center for Cancer Research, National Cancer Institute, National Institutes of Health.	ABDELLATIF MM, 2008, J SURG RES IN PRESS; Blanco-Aparicio C, 2007, CARCINOGENESIS, V28, P1379, DOI 10.1093/carcin/bgm052; Di Cristofano A, 1998, NAT GENET, V19, P348, DOI 10.1038/1235; Eng C, 2002, ANN NY ACAD SCI, V968, P213, DOI 10.1111/j.1749-6632.2002.tb04337.x; Furumoto H, 2005, MOL CELL BIOL, V25, P124, DOI 10.1128/MCB.25.1.124-135.2005; Furuya F, 2006, P NATL ACAD SCI USA, V103, P1780, DOI 10.1073/pnas.0510849103; Furuya F, 2007, CARCINOGENESIS, V28, P2451, DOI 10.1093/carcin/bgm174; Greer EL, 2005, ONCOGENE, V24, P7410, DOI 10.1038/sj.onc.1209086; Guertin DA, 2007, CANCER CELL, V12, P9, DOI 10.1016/j.ccr.2007.05.008; Jiang BH, 2008, BBA-PROTEINS PROTEOM, V1784, P150, DOI 10.1016/j.bbapap.2007.09.008; Kaneshige M, 2000, P NATL ACAD SCI USA, V97, P13209, DOI 10.1073/pnas.230285997; Kato Y, 2006, ONCOGENE, V25, P2736, DOI 10.1038/sj.onc.1209299; Kim CS, 2005, ENDOCRINOLOGY, V146, P4456, DOI 10.1210/en.2005-0172; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; Liaw D, 1997, NAT GENET, V16, P64, DOI 10.1038/ng0597-64; Lu TL, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0001237; Marsh DJ, 1997, NAT GENET, V16, P333, DOI 10.1038/ng0897-333; MEIER CA, 1992, MOL ENDOCRINOL, V6, P248, DOI 10.1210/me.6.2.248; Nelen MR, 1997, HUM MOL GENET, V6, P1383, DOI 10.1093/hmg/6.8.1383; Neri LM, 2002, BBA-MOL CELL BIOL L, V1584, P73, DOI 10.1016/S1388-1981(02)00300-1; PARRILLA R, 1991, J CLIN INVEST, V88, P2123, DOI 10.1172/JCI115542; Pervin S, 2001, P NATL ACAD SCI USA, V98, P3583, DOI 10.1073/pnas.041603998; Podsypanina K, 1999, P NATL ACAD SCI USA, V96, P1563, DOI 10.1073/pnas.96.4.1563; Ramaswamy S, 2002, CANCER CELL, V2, P81, DOI 10.1016/S1535-6108(02)00086-7; Rivas M, 2003, MOL CELL ENDOCRINOL, V213, P31, DOI 10.1016/j.mce.2003.10.029; Schlumberger M, 1998, PRESSE MED, V27, P1479; Schmidt M, 2002, MOL CELL BIOL, V22, P7842, DOI 10.1128/MCB.22.22.7842-7852.2002; Shepherd PR, 1997, DIABETOLOGIA, V40, P1172, DOI 10.1007/s001250050803; Sherman SI, 1998, CANCER-AM CANCER SOC, V83, P1012; Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356; Suzuki A, 1998, CURR BIOL, V8, P1169, DOI 10.1016/S0960-9822(07)00488-5; Suzuki H, 2002, THYROID, V12, P963, DOI 10.1089/105072502320908295; Uppal S, 2007, INT J CLIN PRACT, V61, P645, DOI 10.1111/j.1742-1241.2006.00896.x; Wymann MP, 2005, CURR OPIN CELL BIOL, V17, P141, DOI 10.1016/j.ceb.2005.02.011; Yeager N, 2007, CANCER RES, V67, P959, DOI 10.1158/0008-5472.CAN-06-3524; Yen PM, 2003, TRENDS ENDOCRIN MET, V14, P327, DOI 10.1016/S1043-2760(03)00114-0; Ying H, 2003, CARCINOGENESIS, V24, P1467, DOI 10.1093/carcin/bgg111	37	73	74	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 29	2009	28	4					509	517		10.1038/onc.2008.407	http://dx.doi.org/10.1038/onc.2008.407			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	400KM	18997818	Green Accepted			2022-12-28	WOS:000262866500005
J	Wen, J; Li, R; Lu, Y; Shupnik, MA				Wen, J.; Li, R.; Lu, Y.; Shupnik, M. A.			Decreased BRCA1 confers tamoxifen resistance in breast cancer cells by altering estrogen receptor-coregulator interactions	ONCOGENE			English	Article						tamoxifen resistance; BRCA1; ER alpha; coactivators; corepressors	HORMONE-BETA-PROMOTER; RNA-POLYMERASE-II; PROGESTERONE-RECEPTOR; IN-VIVO; ANTIESTROGEN RESISTANCE; SIGNALING PATHWAYS; TISSUE-SPECIFICITY; CYCLE PROGRESSION; UBIQUITIN LIGASE; RESPONSE ELEMENT	The breast cancer susceptibility gene 1 (BRCA1) is mutated in approximately 50% of hereditary breast cancers, and its expression is decreased in 30-40% of sporadic breast cancers, suggesting a general role in breast cancer development. BRCA1 physically and functionally interacts with estrogen receptor-alpha (ER alpha) and several transcriptional regulators. We investigated the relationship between cellular BRCA1 levels and tamoxifen sensitivity. Decreasing BRCA1 expression in breast cancer cells by small interfering RNA alleviated tamoxifen-mediated growth inhibition and abolished tamoxifen suppression of several endogenous ER-targeted genes. ER-stimulated transcription and cytoplasmic signaling was increased without detectable changes in ER or ER coregulator expression. Co-immunoprecipitation studies showed that with BRCA1 knockdown, tamoxifen-bound ER alpha was inappropriately associated with coactivators, and not effectively with corepressors. Chromatin immuno-precipitation studies demonstrated that with tamoxifen, BRCA1 knockdown did not change ER alpha promoter occupancy, but resulted in increased coactivator and decreased corepressor recruitment onto the endogenous cyclin D1 promoter. Our results suggest that decreased BRCA1 levels modify ER alpha-mediated transcription and regulation of cell proliferation in part by altering ER alpha-coregulator association. In the presence of tamoxifen, decreased BRCA1 expression results in increased coactivator and decreased corepressor recruitment on ER-regulated gene promoters.	[Wen, J.; Shupnik, M. A.] Univ Virginia, Sch Med, Dept Mol Physiol & Biol Phys, Charlottesville, VA 22908 USA; [Li, R.; Lu, Y.] Univ Texas Hlth Sci Ctr San Antonio, Inst Biotechnol, Dept Mol Med, San Antonio, TX 78229 USA; [Shupnik, M. A.] Univ Virginia, Sch Med, Dept Med, Charlottesville, VA 22908 USA	University of Virginia; University of Texas System; University of Texas Health San Antonio; University of Virginia	Shupnik, MA (corresponding author), Univ Virginia, Sch Med, Dept Mol Physiol & Biol Phys, Jefferson Pk Ave,POB 800578, Charlottesville, VA 22908 USA.	mas3x@virginia.edu		Lu, Yunzhe/0000-0001-7542-6848	National Institutes of Health [DK57082, CA93506]; University of Virginia Cancer Center [P30-CA44579]; Women's Oncology Fund; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [U54HD028934] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [P30CA044579, R01CA093506] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK064604, R01DK057082] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); University of Virginia Cancer Center; Women's Oncology Fund; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	We thank Dr Sarah E Aiyar for technical advice and Dr Sarah Parsons for HER2 antibodies. The authors acknowledge support of the National Institutes of Health (DK57082 to MA Shupnik and CA93506 to R Li), the University of Virginia Cancer Center (P30-CA44579) and Women's Oncology Fund (MA Shupnik).	Basu A, 2005, FRONT BIOSCI-LANDMRK, V10, P2346, DOI 10.2741/1703; Birgisdottir V, 2006, BREAST CANCER RES, V8, DOI 10.1186/bcr1522; Bissonauth V, 2008, CANCER DETECT PREV, V32, P52, DOI 10.1016/j.cdp.2008.01.005; Chen YM, 1996, CANCER RES, V56, P3168; Clarke R, 2003, ONCOGENE, V22, P7316, DOI 10.1038/sj.onc.1206937; Clarke R, 2001, J STEROID BIOCHEM, V76, P71, DOI 10.1016/S0960-0760(00)00193-X; Curtin D, 2004, MOL ENDOCRINOL, V18, P1263, DOI 10.1210/me.2003-0221; de Mora JF, 2000, MOL CELL BIOL, V20, P5041, DOI 10.1128/MCB.20.14.5041-5047.2000; Doisneau-Sixou SF, 2003, ENDOCR-RELAT CANCER, V10, P179, DOI 10.1677/erc.0.0100179; Dowsett M, 2006, ANN ONCOL, V17, P818, DOI 10.1093/annonc/mdl016; DUBIK D, 1992, ONCOGENE, V7, P1587; Eakin CM, 2007, P NATL ACAD SCI USA, V104, P5794, DOI 10.1073/pnas.0610887104; Fan S, 1999, SCIENCE, V284, P1354, DOI 10.1126/science.284.5418.1354; Fan SJ, 2002, CANCER RES, V62, P141; Fan SJ, 2001, ONCOGENE, V20, P77, DOI 10.1038/sj.onc.1204073; Ferris HA, 2007, BIOL REPROD, V77, P1073, DOI 10.1095/biolreprod.107.064139; Fink M, 2006, STRAHLENTHER ONKOL, V182, P53; Fleming FJ, 2004, J CLIN ENDOCR METAB, V89, P375, DOI 10.1210/jc.2003-031048; Fox EM, 2008, MOL ENDOCRINOL, V22, P1781, DOI 10.1210/me.2007-0419; Girault I, 2003, CLIN CANCER RES, V9, P1259; Glover JNM, 2004, TRENDS BIOCHEM SCI, V29, P579, DOI 10.1016/j.tibs.2004.09.010; Graham JD, 1995, J BIOL CHEM, V270, P30693, DOI 10.1074/jbc.270.51.30693; Hall JM, 2001, J BIOL CHEM, V276, P36869, DOI 10.1074/jbc.R100029200; Hashizume R, 2001, J BIOL CHEM, V276, P14537, DOI 10.1074/jbc.C000881200; Horner-Glister E, 2005, J MOL ENDOCRINOL, V35, P421, DOI 10.1677/jme.1.01784; Hu YF, 2005, ONCOGENE, V24, P8343, DOI 10.1038/sj.onc.1208985; Jones LP, 2005, ONCOGENE, V24, P3554, DOI 10.1038/sj.onc.1208426; Kenny FS, 1999, CLIN CANCER RES, V5, P2069; Kilker RL, 2006, CANCER RES, V66, P11478, DOI 10.1158/0008-5472.CAN-06-1755; Krum SA, 2003, J BIOL CHEM, V278, P52012, DOI 10.1074/jbc.M308418200; Kurtev V, 2004, J BIOL CHEM, V279, P24834, DOI 10.1074/jbc.M312300200; Lin VY, 2003, J BIOL CHEM, V278, P38125, DOI 10.1074/jbc.M303882200; Liu XF, 2004, J BIOL CHEM, V279, P15050, DOI 10.1074/jbc.M311932200; Ma YX, 2007, MOL ENDOCRINOL, V21, P1905, DOI 10.1210/me.2006-0397; Ma YX, 2005, ONCOGENE, V24, P1831, DOI 10.1038/sj.onc.1208190; Magdinier F, 1998, ONCOGENE, V17, P3169, DOI 10.1038/sj.onc.1202248; Murphy L, 2004, CLIN CANCER RES, V10, P1354, DOI 10.1158/1078-0432.CCR-03-0112; Murphy LC, 2000, CANCER RES, V60, P6266; Narod SA, 2004, NAT REV CANCER, V4, P665, DOI 10.1038/nrc1431; Petz LN, 2004, J STEROID BIOCHEM, V88, P113, DOI 10.1016/j.jsbmb.2003.11.008; Razandi M, 2004, MOL CELL BIOL, V24, P5900, DOI 10.1128/MCB.24.13.5900-5913.2004; Reid G, 2003, MOL CELL, V11, P695, DOI 10.1016/S1097-2765(03)00090-X; Sabbah M, 1999, P NATL ACAD SCI USA, V96, P11217, DOI 10.1073/pnas.96.20.11217; Schreihofer DA, 2001, ENDOCRINOLOGY, V142, P3361, DOI 10.1210/en.142.8.3361; Shang YF, 2000, CELL, V103, P843, DOI 10.1016/S0092-8674(00)00188-4; Shang YF, 2002, SCIENCE, V295, P2465, DOI 10.1126/science.1068537; Shupnik MA, 2004, ONCOGENE, V23, P7979, DOI 10.1038/sj.onc.1208076; Smith CL, 2004, ENDOCR REV, V25, P45, DOI 10.1210/er.2003-0023; Srinivas G, 2004, MOL CARCINOGEN, V39, P15, DOI 10.1002/mc.10164; Starita LM, 2005, J BIOL CHEM, V280, P24498, DOI 10.1074/jbc.M414020200; Thasni KA, 2008, ANN ONCOL, V19, P696, DOI 10.1093/annonc/mdm557; Tsai HW, 2004, ENDOCRINOLOGY, V145, P2730, DOI 10.1210/en.2003-1470; Wu LJC, 1996, NAT GENET, V14, P430, DOI 10.1038/ng1296-430; Xu JW, 2005, ENDOCRINOLOGY, V146, P2031, DOI 10.1210/en.2004-0409; Yarden RI, 1999, P NATL ACAD SCI USA, V96, P4983, DOI 10.1073/pnas.96.9.4983; Zheng L, 2001, P NATL ACAD SCI USA, V98, P9587, DOI 10.1073/pnas.171174298	56	40	40	1	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 29	2009	28	4					575	586		10.1038/onc.2008.405	http://dx.doi.org/10.1038/onc.2008.405			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	400KM	18997820	Green Accepted			2022-12-28	WOS:000262866500011
J	Pursiheimo, JP; Rantanen, K; Heikkinen, PT; Johansen, T; Jaakkola, PM				Pursiheimo, J-P; Rantanen, K.; Heikkinen, P. T.; Johansen, T.; Jaakkola, P. M.			Hypoxia-activated autophagy accelerates degradation of SQSTM1/p62	ONCOGENE			English	Article						ATG8; autophagy; HIF; prolyl hydroxylase; pVHL; sequestosome 1	SIGNALING ADAPTER P62; UNFOLDED PROTEIN RESPONSE; PROLINE HYDROXYLATION; IMPORTANT MEDIATOR; BODY FORMATION; CANCER-CELLS; HIF-ALPHA; DISEASE; INHIBITION; INCLUSIONS	Sequestosome 1 (SQSTM1/p62) is a multifunctional protein involved in signal transduction, protein degradation and cell transformation. Hypoxia is a common feature of solid tumours that promotes cancer progression. Here, we report that p62 is downregulated in hypoxia in carcinoma cells and that the expression is rapidly restored in response to reoxygenation. The hypoxic p62 down-regulation did not occur at the mRNA level and was independent of the hypoxic signal mediators hypoxia-inducible factor (HIF) and von Hippel-Lindau tumour suppressor protein as well as the activity of HIF-prolyl hydroxylases and was not mediated by proteosomal destruction. Autophagy was activated in hypoxia and was required for p62 degradation. The hypoxic degradation of p62 was blocked by autophagy inhibitors as well as by the attenuation of Atg8/LC3 expression. Downregulation of p62 was required for hypoxic extracellular regulated kinase (ERK)-1/2 phosphorylation. Attenuation of p62 in normoxia activated and forced expression of p62 in hypoxia blocked the activation of ERK-1/2. The results demonstrate that hypoxic activation of autophagy induces clearance of p62 protein and implies a role for p62 in the regulation of hypoxic cancer cell survival responses.	[Pursiheimo, J-P; Rantanen, K.; Heikkinen, P. T.; Jaakkola, P. M.] Univ Turku, Turku Ctr Biotechnol, FIN-20520 Turku, Finland; [Pursiheimo, J-P; Rantanen, K.; Heikkinen, P. T.; Jaakkola, P. M.] Abo Akad Univ, Turku, Finland; [Johansen, T.] Univ Tromso, Inst Med Biol, Dept Biochem, Tromso, Norway; [Jaakkola, P. M.] Turku Univ Hosp, Dept Radiotherapy & Oncol, FIN-20520 Turku, Finland	University of Turku; Abo Akademi University; UiT The Arctic University of Tromso; University of Turku	Jaakkola, PM (corresponding author), Univ Turku, Turku Ctr Biotechnol, Tykistokatu 6B, FIN-20520 Turku, Finland.	panjaa@utu.fi	Johansen, Terje/N-2971-2015; Jaakkola, Panu M/B-4355-2012; Johansen, Terje/AAY-1753-2021	Johansen, Terje/0000-0003-1451-9578; Johansen, Terje/0000-0003-1451-9578; Jaakkola, Panu/0000-0002-2365-4985	Academy of Finland [200779, 210282, 8109024]; Emil Aaltonen Foundation; Sigrid Juselius Foundation; Norwegian Research Council (FUGE); Norwegian Cancer Society	Academy of Finland(Academy of Finland); Emil Aaltonen Foundation; Sigrid Juselius Foundation(Sigrid Juselius Foundation); Norwegian Research Council (FUGE)(Research Council of Norway); Norwegian Cancer Society(Norwegian Cancer Society)	Taina Kalevo-Mattila is acknowledged for expert technical assistance. The study was supported by The Academy of Finland (grants 200779, 210282 and 8109024), Emil Aaltonen Foundation and Sigrid Juselius Foundation to PMJ, and by grants from the Norwegian Research Council (FUGE) and Norwegian Cancer Society to TJ. PMJ is a research fellow of the Finnish Cancer Institute.	Adhami F, 2006, AM J PATHOL, V169, P566, DOI 10.2353/ajpath.2006.051066; Berra E, 2003, EMBO J, V22, P4082, DOI 10.1093/emboj/cdg392; Bjorkoy G, 2005, J CELL BIOL, V171, P603, DOI 10.1083/jcb.200507002; Bruick RK, 2001, SCIENCE, V294, P1337, DOI 10.1126/science.1066373; Duran A, 2004, DEV CELL, V6, P303, DOI 10.1016/S1534-5807(03)00403-9; Duran A, 2008, CANCER CELL, V13, P343, DOI 10.1016/j.ccr.2008.02.001; EKSTROM P, 1984, J NEUROCHEM, V43, P1342, DOI 10.1111/j.1471-4159.1984.tb05392.x; Epstein ACR, 2001, CELL, V107, P43, DOI 10.1016/S0092-8674(01)00507-4; Geetha T, 2005, MOL CELL, V20, P301, DOI 10.1016/j.molcel.2005.09.014; Ivan M, 2001, SCIENCE, V292, P464, DOI 10.1126/science.1059817; Jaakkola P, 2001, SCIENCE, V292, P468, DOI 10.1126/science.1059796; Jokilehto T, 2006, CLIN CANCER RES, V12, P1080, DOI 10.1158/1078-0432.CCR-05-2022; Kabeya Y, 2000, EMBO J, V19, P5720, DOI 10.1093/emboj/19.21.5720; Kaelin WG, 2005, ANNU REV BIOCHEM, V74, P115, DOI 10.1146/annurev.biochem.74.082803.133142; Komatsu M, 2007, CELL, V131, P1149, DOI 10.1016/j.cell.2007.10.035; Kondo Y, 2005, NAT REV CANCER, V5, P726, DOI 10.1038/nrc1692; Koumenis C, 2006, MOL CANCER RES, V4, P423, DOI 10.1158/1541-7786.MCR-06-0150; Kuusisto E, 2001, NEUROREPORT, V12, P2085, DOI 10.1097/00001756-200107200-00009; Kuusisto E, 2001, BIOCHEM BIOPH RES CO, V280, P223, DOI 10.1006/bbrc.2000.4107; Kwon DS, 2006, EUR J CELL BIOL, V85, P1189, DOI 10.1016/j.ejcb.2006.06.001; Lamark T, 2003, J BIOL CHEM, V278, P34568, DOI 10.1074/jbc.M303221200; Levine B, 2008, CELL, V132, P27, DOI 10.1016/j.cell.2007.12.018; Lim JH, 2006, MOL PHARMACOL, V70, P1856, DOI 10.1124/mol.106.028076; Liu LP, 2006, MOL CELL, V21, P521, DOI 10.1016/j.molcel.2006.01.010; Martin P, 2006, EMBO J, V25, P3524, DOI 10.1038/sj.emboj.7601250; Masson N, 2004, FEBS LETT, V570, P166, DOI 10.1016/j.febslet.2004.06.040; Minet E, 2000, FEBS LETT, V468, P53, DOI 10.1016/S0014-5793(00)01181-9; Mizushima N, 2008, NATURE, V451, P1069, DOI 10.1038/nature06639; Nakaso K, 2004, BRAIN RES, V1012, P42, DOI 10.1016/j.brainres.2004.03.029; Paludan C, 2005, SCIENCE, V307, P593, DOI 10.1126/science.1104904; Pankiv S, 2007, J BIOL CHEM, V282, P24131, DOI 10.1074/jbc.M702824200; Pugh CW, 2003, NAT MED, V9, P677, DOI 10.1038/nm0603-677; Rodriguez A, 2006, CELL METAB, V3, P211, DOI 10.1016/j.cmet.2006.01.011; Scherz-Shouval R, 2007, EMBO J, V26, P1749, DOI 10.1038/sj.emboj.7601623; Schofield CJ, 2004, NAT REV MOL CELL BIO, V5, P343, DOI 10.1038/nrm1366; SEGLEN PO, 1982, P NATL ACAD SCI-BIOL, V79, P1889, DOI 10.1073/pnas.79.6.1889; Seibenhener ML, 2004, MOL CELL BIOL, V24, P8055, DOI 10.1128/MCB.24.18.8055-8068.2004; Semenza GL, 2003, NAT REV CANCER, V3, P721, DOI 10.1038/nrc1187; Thompson HGR, 2003, ONCOGENE, V22, P2322, DOI 10.1038/sj.onc.1206325; Thuerauf DJ, 2006, CIRC RES, V99, P275, DOI 10.1161/01.RES.0000233317.70421.03; Tracy K, 2007, MOL CELL BIOL, V27, P6229, DOI 10.1128/MCB.02246-06; Wooten MW, 2006, J BIOMED BIOTECHNOL, DOI 10.1155/JBB/2006/62079; Yamamoto A, 1998, CELL STRUCT FUNCT, V23, P33, DOI 10.1247/csf.23.33; Zatloukal K, 2002, AM J PATHOL, V160, P255, DOI 10.1016/S0002-9440(10)64369-6; Zhang HF, 2008, J BIOL CHEM, V283, P10892, DOI 10.1074/jbc.M800102200	45	122	123	1	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 22	2009	28	3					334	344		10.1038/onc.2008.392	http://dx.doi.org/10.1038/onc.2008.392			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	395UZ	18931699				2022-12-28	WOS:000262550300003
J	Nihira, K; Taira, N; Miki, Y; Yoshida, K				Nihira, K.; Taira, N.; Miki, Y.; Yoshida, K.			TTK/Mps1 controls nuclear targeting of c-Abl by 14-3-3-coupled phosphorylation in response to oxidative stress	ONCOGENE			English	Article						c-Abl; TTK; oxidative stress; phosphorylation	LYN TYROSINE KINASE; DNA-DAMAGE; BCR-ABL; APOPTOTIC RESPONSE; SUBCELLULAR-LOCALIZATION; CELL-DEATH; PROTEIN; DELTA; ACTIVATION; MECHANISMS	Upon exposure to genotoxic stress, the c-Abl tyrosine kinase is released from cytoplasmic 14-3-3 proteins and then is targeted to the nucleus. Phosphorylation of Thr735 in c-Abl is critical for binding to 14-3-3; however, kinases responsible for this phosphorylation are unknown. Here, we identify CLK1, CLK4, MST1, MST2 and TTK (also known as Mps1) as novel Thr735 kinases in vitro by expression cloning strategy using phosphospeci. c antibody. We also demonstrate that ectopic expression of these kinases is capable for phosphorylation of Thr735 in cells. Importantly, upon exposure to oxidative stress, phosphorylation of Thr735 is transiently upregulated, and the status of this phosphorylation remains unchanged in cells silenced for CLK1, CLK4, MST1 or MST2. By contrast, knockdown of TTK attenuates phosphorylation of Thr735, suggesting that TTK is a physiological kinase that phosphorylates Thr735. In concert with these results, we show that, in cells silenced for TTK, c-Abl is accumulated in the nucleus even in unstressed condition and no further targeting into the nucleus occurs after oxidative stress. Moreover, nuclear entrapment of c-Abl by knocking down TTK enhances oxidative stress-induced apoptosis. These findings provide evidence that TTK phosphorylates c-Abl at Thr735 and that this phosphorylation is of importance to the cytoplasmic sequestration of c-Abl.	[Nihira, K.; Taira, N.; Miki, Y.; Yoshida, K.] Tokyo Med & Dent Univ, Med Res Inst, Dept Mol Genet, Bunkyo Ku, Tokyo 1138510, Japan	Tokyo Medical & Dental University (TMDU)	Yoshida, K (corresponding author), Tokyo Med & Dent Univ, Med Res Inst, Dept Mol Genet, Bunkyo Ku, 1-5-45 Yushima, Tokyo 1138510, Japan.	yos.mgen@mri.tmd.ac.jp		Nihira, Keishi/0000-0002-3797-9289	Ministry of Education, Science and Culture of Japan; Mochida Memorial Foundation for Medical and Pharmaceutical Research; Sumitomo Foundation; Yasuda Memorial Foundation; Astellas Foundation for Research on Metabolic Disorders; Sagawa Foundation for Promotion of Cancer Research; Osaka Cancer Research Foundation; Kato Memorial Bioscience Foundation; Uehara Memorial Foundation	Ministry of Education, Science and Culture of Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Mochida Memorial Foundation for Medical and Pharmaceutical Research; Sumitomo Foundation; Yasuda Memorial Foundation; Astellas Foundation for Research on Metabolic Disorders; Sagawa Foundation for Promotion of Cancer Research; Osaka Cancer Research Foundation; Kato Memorial Bioscience Foundation; Uehara Memorial Foundation(Uehara Memorial Foundation)	We thank Dr Xuebiao Yao for the GFP-TTK. This work was supported by grants from the Ministry of Education, Science and Culture of Japan (to KY and YM), the Mochida Memorial Foundation for Medical and Pharmaceutical Research (to KY), the Sumitomo Foundation (to KY), the Yasuda Memorial Foundation (to KY), Astellas Foundation for Research on Metabolic Disorders (to KY), the Sagawa Foundation for Promotion of Cancer Research (to KY), Osaka Cancer Research Foundation (to KY), Kato Memorial Bioscience Foundation (to KY) and Uehara Memorial Foundation (to KY).	Aitken A, 2002, BIOCHEM SOC T, V30, P351, DOI 10.1042/bst0300351; Cao C, 2003, J BIOL CHEM, V278, P29667, DOI 10.1074/jbc.M301292200; Castillo AR, 2002, J CELL BIOL, V156, P453, DOI 10.1083/jcb.200111025; de Souza PM, 2004, BIOCHEM SOC T, V32, P485, DOI 10.1042/BST0320485; Dierov J, 2004, CANCER CELL, V5, P275, DOI 10.1016/S1535-6108(04)00056-X; Druker BJ, 1996, NAT MED, V2, P561, DOI 10.1038/nm0596-561; Hagiwara M, 2005, BBA-PROTEINS PROTEOM, V1754, P324, DOI 10.1016/j.bbapap.2005.09.010; Hantschel O, 2003, CELL, V112, P845, DOI 10.1016/S0092-8674(03)00191-0; Jones MH, 1999, MOL BIOL CELL, V10, P2377, DOI 10.1091/mbc.10.7.2377; KHARBANDA S, 1995, NATURE, V376, P785, DOI 10.1038/376785a0; Kharbanda S, 1998, ONCOGENE, V17, P3309, DOI 10.1038/sj.onc.1202571; Matsuo R, 2001, J IMMUNOL METHODS, V247, P141, DOI 10.1016/S0022-1759(00)00313-6; Muslin AJ, 2000, CELL SIGNAL, V12, P703, DOI 10.1016/S0898-6568(00)00131-5; Nagar B, 2003, CELL, V112, P859, DOI 10.1016/S0092-8674(03)00194-6; Pendergast AM, 2002, ADV CANCER RES, V85, P51, DOI 10.1016/S0065-230X(02)85003-5; REUTHER GW, 1994, SCIENCE, V266, P129, DOI 10.1126/science.7939633; Straight PD, 2000, MOL BIOL CELL, V11, P3525, DOI 10.1091/mbc.11.10.3525; Stucke VM, 2002, EMBO J, V21, P1723, DOI 10.1093/emboj/21.7.1723; Sun XG, 2000, J BIOL CHEM, V275, P7470, DOI 10.1074/jbc.275.11.7470; Taagepera S, 1998, P NATL ACAD SCI USA, V95, P7457, DOI 10.1073/pnas.95.13.7457; Taira N, 2007, MOL CELL, V25, P725, DOI 10.1016/j.molcel.2007.02.007; Tsuruta F, 2004, EMBO J, V23, P1889, DOI 10.1038/sj.emboj.7600194; Vigneri P, 2001, NAT MED, V7, P228, DOI 10.1038/84683; Wang JYJ, 2000, ONCOGENE, V19, P5643, DOI 10.1038/sj.onc.1203878; WETZLER M, 1993, J CLIN INVEST, V92, P1925, DOI 10.1172/JCI116786; Yoshida K, 2006, MOL CELL BIOL, V26, P3414, DOI 10.1128/MCB.26.9.3414-3431.2006; Yoshida K, 1999, J BIOL CHEM, V274, P34663, DOI 10.1074/jbc.274.49.34663; Yoshida K, 2000, MOL CELL BIOL, V20, P5370, DOI 10.1128/MCB.20.15.5370-5380.2000; Yoshida K, 2005, CELL CYCLE, V4, P777, DOI 10.4161/cc.4.6.1746; Yoshida K, 2005, NAT CELL BIOL, V7, P278, DOI 10.1038/ncb1228; Yoshida K, 2003, EMBO J, V22, P1431, DOI 10.1093/emboj/cdg134; Yoshida K, 2002, J BIOL CHEM, V277, P48372, DOI 10.1074/jbc.M205485200; Yoshida K, 2002, MOL CELL BIOL, V22, P3292, DOI 10.1128/MCB.22.10.3292-3300.2002; Yoshida K, 2001, MOL PHARMACOL, V60, P1431, DOI 10.1124/mol.60.6.1431; Yoshida K, 2008, TRENDS MOL MED, V14, P305, DOI 10.1016/j.molmed.2008.05.003; Yoshida K, 2007, CELL SIGNAL, V19, P892, DOI 10.1016/j.cellsig.2007.01.027; Yoshikawa S, 2006, J JPN SOC FOOD SCI, V53, P281, DOI 10.3136/nskkk.53.281; Yuan ZM, 1997, P NATL ACAD SCI USA, V94, P1437, DOI 10.1073/pnas.94.4.1437; Yuan ZM, 1996, NATURE, V382, P272, DOI 10.1038/382272a0; Zhu JY, 2004, CURR TOP DEV BIOL, V59, P165, DOI 10.1016/S0070-2153(04)59007-5	40	33	34	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC	2008	27	58					7285	7295		10.1038/onc.2008.334	http://dx.doi.org/10.1038/onc.2008.334			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	382FI	18794806				2022-12-28	WOS:000261590300006
J	Zhuang, D; Mannava, S; Grachtchouk, V; Tang, WH; Patil, S; Wawrzyniak, JA; Berman, AE; Giordano, TJ; Prochownik, EV; Soengas, MS; Nikiforov, MA				Zhuang, D.; Mannava, S.; Grachtchouk, V.; Tang, W-H; Patil, S.; Wawrzyniak, J. A.; Berman, A. E.; Giordano, T. J.; Prochownik, E. V.; Soengas, M. S.; Nikiforov, M. A.			C-MYC overexpression is required for continuous suppression of oncogene-induced senescence in melanoma cells	ONCOGENE			English	Article						C-MYC; melanoma; senescence	MALIGNANT-MELANOMA; CELLULAR SENESCENCE; TUMOR-SUPPRESSOR; BRAF MUTATIONS; P53; ONCOPROTEIN; CANCER; CYCLE; NEVI; TRANSFORMATION	Malignant melanomas often harbor activating mutations in BRAF (V600E) or, less frequently, in NRAS (Q61R). Intriguingly, the same mutations have been detected at higher incidences in benign nevi, which are largely composed of senescent melanocytes. Overexpression of BRAF(V600E) or NRAS(Q61R) in human melanocytes in vitro has been shown to induce senescence, although via different mechanisms. How oncogene-induced senescence is overcome during melanoma progression remains unclear. Here, we report that in the majority of analysed BRAF(V600E)- or NRAS(Q61R)-expressing melanoma cells, C-MYC depletion induced different yet overlapping sets of senescence phenotypes that are characteristic of normal melanocytes undergoing senescence due to overexpression of BRAF(V600E) or NRAS(Q61R), respectively. These senescence phenotypes were p16(INK4A)- or p53-independent, however, several of them were suppressed by genetic or pharmacological inhibition of BRAF(V600E) or phosphoinositide 3-kinase pathways, including rapamycin-mediated inhibition of mTOR-raptor in NRAS(Q61R)-expressing melanoma cells. Reciprocally, overexpression of C-MYC in normal melanocytes suppressed BRAF(V600E)-induced senescence more efficiently than NRAS(Q61R)-induced senescence, which agrees with the generally higher rates of activating mutations in BRAF than NRAS gene in human cutaneous melanomas. Our data suggest that one of the major functions of C-MYC overexpression in melanoma progression is to continuous suppress BRAF(V600E)- or NRAS(Q61R)-dependent senescence programs.	[Zhuang, D.; Mannava, S.; Grachtchouk, V.; Wawrzyniak, J. A.; Nikiforov, M. A.] Roswell Pk Canc Inst, Dept Cell Stress Biol, Buffalo, NY 14263 USA; [Zhuang, D.; Mannava, S.; Grachtchouk, V.; Tang, W-H; Patil, S.; Soengas, M. S.; Nikiforov, M. A.] Univ Michigan, Dept Dermatol, Ann Arbor, MI 48109 USA; [Zhuang, D.; Mannava, S.; Grachtchouk, V.; Tang, W-H; Patil, S.; Giordano, T. J.; Soengas, M. S.; Nikiforov, M. A.] Univ Michigan, Ctr Comprehens Canc, Ann Arbor, MI 48109 USA; [Berman, A. E.] RAMS, Inst Biomed Chem, Moscow, Russia; [Giordano, T. J.] Univ Michigan, Dept Pathol, Ann Arbor, MI 48109 USA; [Prochownik, E. V.] Childrens Hosp Pittsburgh, Rangos Res Ctr, Hematol Oncol Sect, Pittsburgh, PA 15213 USA	Roswell Park Cancer Institute; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; Russian Academy of Medical Sciences; Institute of Biomedical Chemistry; University of Michigan System; University of Michigan; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Nikiforov, MA (corresponding author), Roswell Pk Canc Inst, Dept Cell Stress Biol, Elm & Carlton St,L3-317, Buffalo, NY 14263 USA.	mikhail.nikiforov@roswellpark.org	EBerman, Albert/F-5042-2017; Soengas, Maria S/H-6455-2015	Soengas, Maria S/0000-0003-0612-6299; Giordano, Thomas/0000-0003-0641-8873	NIH [R01 CA120244, CA107237]; University of Michigan's Cancer Center [NIH 5 P30 CA46592]; Melanoma Research Foundation Scholar; NATIONAL CANCER INSTITUTE [R01CA120244, R01CA107237, P30CA046592] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); University of Michigan's Cancer Center(University of Michigan System); Melanoma Research Foundation Scholar; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We are grateful to Michelle Vinco for assistance with the human tissue work. This work was supported by Grants NIH R01 CA120244 (MAN), CA107237 (MSS), and, in part, by the University of Michigan's Cancer Center Support Grant (NIH 5 P30 CA46592). MAN is a Melanoma Research Foundation Scholar.	Arvanitis C, 2006, SEMIN CANCER BIOL, V16, P313, DOI 10.1016/j.semcancer.2006.07.012; Bauer J, 2007, J INVEST DERMATOL, V127, P179, DOI 10.1038/sj.jid.5700490; Benanti JA, 2004, MOL CELL BIOL, V24, P2842, DOI 10.1128/MCB.24.7.2842-2852.2004; Biroccio A, 2003, J BIOL CHEM, V278, P35693, DOI 10.1074/jbc.M304597200; Boehm JS, 2005, MOL CELL BIOL, V25, P6464, DOI 10.1128/MCB.25.15.6464-6474.2005; Bringold F, 2000, EXP GERONTOL, V35, P317, DOI 10.1016/S0531-5565(00)00083-8; Chin L, 2006, GENE DEV, V20, P2149, DOI 10.1101/gad.1437206; Collado M, 2006, NAT REV CANCER, V6, P472, DOI 10.1038/nrc1884; Curtin JA, 2005, NEW ENGL J MED, V353, P2135, DOI 10.1056/NEJMoa050092; Denoyelle C, 2006, NAT CELL BIOL, V8, P1053, DOI 10.1038/ncb1471; Drayton S, 2003, CANCER CELL, V4, P301, DOI 10.1016/S1535-6108(03)00242-3; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Gil J, 2005, CANCER RES, V65, P2179, DOI 10.1158/0008-5472.CAN-03-4030; Gil J, 2006, NAT REV MOL CELL BIO, V7, P667, DOI 10.1038/nrm1987; Goding C R, 2000, Forum (Genova), V10, P176; Gollob JA, 2006, SEMIN ONCOL, V33, P392, DOI 10.1053/j.seminoncol.2006.04.002; Grandori C, 2003, GENE DEV, V17, P1569, DOI 10.1101/gad.1100303; Gray-Schopfer V, 2007, NATURE, V445, P851, DOI 10.1038/nature05661; Greulich KM, 2000, CANCER, V89, P97, DOI 10.1002/1097-0142(20000701)89:1<97::AID-CNCR14>3.0.CO;2-0; Guney I, 2006, P NATL ACAD SCI USA, V103, P3645, DOI 10.1073/pnas.0600069103; Ha L, 2007, P NATL ACAD SCI USA, V104, P10968, DOI 10.1073/pnas.0611638104; Haluska FG, 2006, CLIN CANCER RES, V12, p2301S, DOI 10.1158/1078-0432.CCR-05-2518; Haluska F, 2007, SEMIN ONCOL, V34, P546, DOI 10.1053/j.seminoncol.2007.09.011; Itahana Koji, 2007, Methods Mol Biol, V371, P21; Kastan MB, 2007, CELL, V128, P837, DOI 10.1016/j.cell.2007.02.022; Kim R, 2006, APOPTOSIS, V11, P5, DOI 10.1007/s10495-005-3088-0; Kraehn GM, 2001, BRIT J CANCER, V84, P72, DOI 10.1054/bjoc.2000.1535; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; Lutz W, 2002, BBA-REV CANCER, V1602, P61, DOI 10.1016/S0304-419X(02)00036-7; Maldonado JL, 2003, J NATL CANCER I, V95, P1878, DOI 10.1093/jnci/djg123; Meier F, 2005, FRONT BIOSCI-LANDMRK, V10, P2986, DOI 10.2741/1755; Michaloglou C, 2005, NATURE, V436, P720, DOI 10.1038/nature03890; Mooi WJ, 2006, NEW ENGL J MED, V355, P1037, DOI 10.1056/NEJMra062285; Narita M, 2003, CELL, V113, P703, DOI 10.1016/S0092-8674(03)00401-X; Nesbit CE, 1999, ONCOGENE, V18, P3004, DOI 10.1038/sj.onc.1202746; Nikiforov MA, 2002, MOL CELL BIOL, V22, P5054, DOI 10.1128/MCB.22.14.5054-5063.2002; Pollock PM, 2003, NAT GENET, V33, P19, DOI 10.1038/ng1054; Ross DA, 1998, BRIT J SURG, V85, P46; Sharma A, 2005, CANCER RES, V65, P2412, DOI 10.1158/0008-5472.CAN-04-2423; Sharpless NE, 2003, ONCOGENE, V22, P3092, DOI 10.1038/sj.onc.1206461; Soengas MS, 2001, NATURE, V409, P207, DOI 10.1038/35051606; Takaoka M, 2004, ONCOGENE, V23, P6760, DOI 10.1038/sj.onc.1207923; Tanaka H, 2000, NATURE, V404, P42, DOI 10.1038/35003506; Ventura A, 2007, NATURE, V445, P661, DOI 10.1038/nature05541; Verhaegen M, 2006, CANCER RES, V66, P11348, DOI 10.1158/0008-5472.CAN-06-1748; Vita M, 2006, SEMIN CANCER BIOL, V16, P318, DOI 10.1016/j.semcancer.2006.07.015; Wang H, 2008, ONCOGENE, V27, P1905, DOI 10.1038/sj.onc.1210823; Wu CH, 2007, P NATL ACAD SCI USA, V104, P13028, DOI 10.1073/pnas.0701953104; Xue W, 2007, NATURE, V445, P656, DOI 10.1038/nature05529; Yang Q, 2007, CELL RES, V17, P666, DOI 10.1038/cr.2007.64	50	151	158	0	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV	2008	27	52					6623	6634		10.1038/onc.2008.258	http://dx.doi.org/10.1038/onc.2008.258			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	368QY	18679422	Green Accepted			2022-12-28	WOS:000260638800001
J	Dow, LE; Elsum, IA; King, CL; Kinross, KM; Richardson, HE; Humbert, PO				Dow, L. E.; Elsum, I. A.; King, C. L.; Kinross, K. M.; Richardson, H. E.; Humbert, P. O.			Loss of human Scribble cooperates with H-Ras to promote cell invasion through deregulation of MAPK signalling	ONCOGENE			English	Article						scribble; invasion; cancer; Ras	BREAST EPITHELIAL-CELLS; LARGE TUMOR-SUPPRESSOR; PROTEASOME-MEDIATED DEGRADATION; PAPILLOMAVIRUS E6 PROTEINS; EPIDERMAL-GROWTH-FACTOR; DISCS-LARGE; TGF-BETA; MALIGNANT PROGRESSION; ONCOGENIC RAS; CYCLE ARREST	Activating mutations in genes of the Ras-mitogen-activated protein kinase (MAPK) pathway occur in approximately 30% of all human cancers; however, mutation of Ras alone is rarely sufficient to induce tumour development. Scribble is a polarity regulator recently isolated from a Drosophila screen for events that cooperate with Ras mutation to promote tumour progression and cell invasion. In mammals, Scribble regulates directed cell migration and wound healing in vivo; however, no role has been identified for mammalian Scribble in oncogenic transformation. Here we show that in human epithelial cells expressing oncogenic Ras or Raf, loss of Scribble promotes invasion of cells through extracellular matrix in an organotypic culture system. Further, we show that the mechanism by which this occurs is in the regulation of MAPK signalling by Scribble. The suppression of MAPK signalling is a highly conserved function of Scribble as it also prevents Raf-mediated defects in Drosophila wing development. Our data identify Scribble as an important mediator of MAPK signalling and provide a molecular basis for the observation that Scribble expression is decreased in many invasive human cancers.	[Dow, L. E.; Elsum, I. A.; King, C. L.; Kinross, K. M.; Humbert, P. O.] Peter MacCallum Canc Ctr, Div Res, Melbourne, Vic 8006, Australia; [Richardson, H. E.] Peter MacCallum Canc Ctr, Div Res, Cell Cycle & Dev Labs, Melbourne, Vic 8006, Australia	Peter Maccallum Cancer Center; Peter Maccallum Cancer Center	Humbert, PO (corresponding author), Peter MacCallum Canc Ctr, Div Res, Locked Bag 1,A'Beckett St, Melbourne, Vic 8006, Australia.	patrick.humbert@petermac.org	Richardson, Helena E/A-8080-2013; Humbert, Patrick O/L-4264-2016	Richardson, Helena E/0000-0003-3852-4953; Humbert, Patrick O/0000-0002-1366-6691; Elsum, Imogen/0000-0003-4525-0727; Dow, Lukas/0000-0001-7048-1418				Abdelilah-Seyfried S, 2003, DEVELOPMENT, V130, P1927, DOI 10.1242/dev.00420; AGUILARCORDOVA E, 1991, ONCOGENE, V6, P1601; Aigner K, 2007, ONCOGENE, V26, P6979, DOI 10.1038/sj.onc.1210508; Aranda V, 2006, NAT CELL BIOL, V8, P1235, DOI 10.1038/ncb1485; Audebert S, 2004, CURR BIOL, V14, P987, DOI 10.1016/j.cub.2004.05.051; Bilder D, 2000, NATURE, V403, P676, DOI 10.1038/35001108; Bilder D, 2000, SCIENCE, V289, P113, DOI 10.1126/science.289.5476.113; Brumby AM, 2003, EMBO J, V22, P5769, DOI 10.1093/emboj/cdg548; Debnath J, 2003, METHODS, V30, P256, DOI 10.1016/S1046-2023(03)00032-X; Dhillon AS, 2007, ONCOGENE, V26, P3279, DOI 10.1038/sj.onc.1210421; Dow LE, 2007, ONCOGENE, V26, P5692, DOI 10.1038/sj.onc.1210639; Dow LE, 2003, ONCOGENE, V22, P9225, DOI 10.1038/sj.onc.1207154; Dow LE, 2007, INT REV CYTOL, V262, P253, DOI 10.1016/S0074-7696(07)62006-3; Frese KK, 2006, EMBO J, V25, P1406, DOI 10.1038/sj.emboj.7601030; Gardiol D, 1999, ONCOGENE, V18, P5487, DOI 10.1038/sj.onc.1202920; Gardiol D, 2006, INT J CANCER, V119, P1285, DOI 10.1002/ijc.21982; Giunciuglio D, 1995, INT J CANCER, V63, P815, DOI 10.1002/ijc.2910630612; Goode S, 1997, GENE DEV, V11, P2532, DOI 10.1101/gad.11.19.2532; Humbert PO, 2006, TRENDS CELL BIOL, V16, P622, DOI 10.1016/j.tcb.2006.10.005; Joiakim A, 2003, DRUG METAB DISPOS, V31, P1279, DOI 10.1124/dmd.31.11.1279; Kamei Y, 2007, HUM PATHOL, V38, P1273, DOI 10.1016/j.humpath.2007.01.026; Kim ES, 2005, CYTOKINE, V29, P84, DOI 10.1016/j.cyto.2004.10.001; Kim ES, 2004, INT J ONCOL, V25, P1375; Kim MS, 2003, CANCER RES, V63, P5454; Kiyono T, 1997, P NATL ACAD SCI USA, V94, P11612, DOI 10.1073/pnas.94.21.11612; Lahuna O, 2005, EMBO J, V24, P1364, DOI 10.1038/sj.emboj.7600616; Lehmann K, 2000, GENE DEV, V14, P2610, DOI 10.1101/gad.181700; Lin HT, 2004, GYNECOL ONCOL, V93, P422, DOI 10.1016/j.ygyno.2004.01.025; Massimi P, 2004, ONCOGENE, V23, P8033, DOI 10.1038/sj.onc.1207977; McLachlan RW, 2007, J MOL MED-JMM, V85, P545, DOI 10.1007/s00109-007-0198-x; Michaloglou C, 2005, NATURE, V436, P720, DOI 10.1038/nature03890; Nakagawa S, 2000, MOL CELL BIOL, V20, P8244, DOI 10.1128/MCB.20.21.8244-8253.2000; Nakagawa S, 2004, BRIT J CANCER, V90, P194, DOI 10.1038/sj.bjc.6601465; Navarro C, 2005, ONCOGENE, V24, P4330, DOI 10.1038/sj.onc.1208632; Nguyen ML, 2003, J VIROL, V77, P6957, DOI 10.1128/JVI.77.12.6957-6964.2003; Osmani N, 2006, CURR BIOL, V16, P2395, DOI 10.1016/j.cub.2006.10.026; Overholtzer M, 2006, P NATL ACAD SCI USA, V103, P12405, DOI 10.1073/pnas.0605579103; Ozdamar B, 2005, SCIENCE, V307, P1603, DOI 10.1126/science.1105718; Pagliarini RA, 2003, SCIENCE, V302, P1227, DOI 10.1126/science.1088474; Park JI, 2003, ONCOGENE, V22, P4314, DOI 10.1038/sj.onc.1206478; Pegtel DM, 2007, CURR BIOL, V17, P1623, DOI 10.1016/j.cub.2007.08.035; Qin Y, 2005, J CELL BIOL, V171, P1061, DOI 10.1083/jcb.200506094; Reginato MJ, 2005, MOL CELL BIOL, V25, P4591, DOI 10.1128/MCB.25.11.4591-4601.2005; Sarkisian CJ, 2007, NAT CELL BIOL, V9, P493, DOI 10.1038/ncb1567; Schreiber K, 2004, ONCOGENE, V23, P3972, DOI 10.1038/sj.onc.1207507; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Seton-Rogers SE, 2004, CELL CYCLE, V3, P597, DOI 10.4161/cc.3.5.886; Seton-Rogers SE, 2004, P NATL ACAD SCI USA, V101, P1257, DOI 10.1073/pnas.0308090100; Settle M, 2003, ONCOGENE, V22, P1916, DOI 10.1038/sj.onc.1206240; Shin I, 2005, J BIOL CHEM, V280, P14675, DOI 10.1074/jbc.M411625200; Sparmann A, 2004, CANCER CELL, V6, P447, DOI 10.1016/j.ccr.2004.09.028; STANTON VP, 1989, MOL CELL BIOL, V9, P639, DOI 10.1128/MCB.9.2.639; STOREY A, 1993, ONCOGENE, V8, P919; Thomas M, 2005, ONCOGENE, V24, P6222, DOI 10.1038/sj.onc.1208757; Woodhouse E, 1998, DEV GENES EVOL, V207, P542, DOI 10.1007/s004270050145; Woods D, 1997, MOL CELL BIOL, V17, P5598, DOI 10.1128/MCB.17.9.5598; Woodworth CD, 2000, CANCER RES, V60, P4397; Yin GY, 2004, MOL CELL BIOL, V24, P875, DOI 10.1128/MCB.24.2.875-885.2004; Zhang HY, 2006, NAT CELL BIOL, V8, P227, DOI 10.1038/ncb1368	59	122	126	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 9	2008	27	46					5988	6001		10.1038/onc.2008.219	http://dx.doi.org/10.1038/onc.2008.219			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	358BO	18641685	Green Accepted			2022-12-28	WOS:000259891600002
J	Altieri, DC				Altieri, D. C.			New wirings in the survivin networks	ONCOGENE			English	Review						surviving; mitosis; IAP; cancer gene; signaling network; apoptosis	CHROMOSOMAL PASSENGER COMPLEX; CANCER STEM-CELLS; MEDIATES RADIATION-RESISTANCE; NEGATIVE BREAST-CANCER; IN-VIVO; INHIBITS APOPTOSIS; PROGENITOR CELLS; DRUG DISCOVERY; SELF-RENEWAL; TUMOR-GROWTH	A little over 10 years after its discovery in 1997, the small inhibitor of apoptosis (IAP) protein, survivin, continues to generate intense interest and keen attention from disparate segments of basic and disease-related research. Part of this interest reflects the intricate biology of this multifunctional protein that intersects fundamental networks of cellular homeostasis. Part is because of the role of survivin as a cancer gene, which touches nearly every aspect of the disease, from onset to outcome. And part is due to the potential value of survivin for novel cancer diagnostics and therapeutics, which have already reached the clinic, and with some promise. Grappling with emerging new signaling circuits in survivin biology, and their implications in cancer, will further our understanding of this nodal protein, and open fresh opportunities for translational oncology research.	Univ Massachusetts, Sch Med, Dept Canc Biol, Worcester, MA 01605 USA	University of Massachusetts System; University of Massachusetts Worcester	Altieri, DC (corresponding author), Univ Massachusetts, Sch Med, Dept Canc Biol, LRB428,364 Plantat St, Worcester, MA 01605 USA.	dario.altieri@umassmed.edu			NIH [CA78810, CA90917, HL54131]; NATIONAL CANCER INSTITUTE [R01CA090917, R01CA078810] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL054131, R37HL054131] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	I apologize to all the colleagues whose work could not be cited for reasons of space. This work was supported by NIH Grants CA78810, CA90917 and HL54131.	Adida C, 1998, AM J PATHOL, V152, P43; Al-Hajj M, 2004, CURR OPIN GENET DEV, V14, P43, DOI 10.1016/j.gde.2003.11.007; Altieri DC, 2008, NAT REV CANCER, V8, P61, DOI 10.1038/nrc2293; Altieri DC, 2006, CURR OPIN CELL BIOL, V18, P609, DOI 10.1016/j.ceb.2006.08.015; Altieri DC, 2003, NAT REV CANCER, V3, P46, DOI 10.1038/nrc968; Aoki Y, 2003, BLOOD, V101, P1535, DOI 10.1182/blood-2002-07-2130; Beverly LJ, 2005, CANCER RES, V65, P7159, DOI 10.1158/0008-5472.CAN-05-1664; Carter SL, 2006, NAT GENET, V38, P1043, DOI 10.1038/ng1861; Carvalho A, 2003, J CELL SCI, V116, P2987, DOI 10.1242/jcs.00612; Ceballos-Cancino G, 2007, ONCOGENE, V26, P7569, DOI 10.1038/sj.onc.1210560; Chen MS, 2007, J CELL SCI, V120, P468, DOI 10.1242/jcs.03348; Connell CM, 2008, J BIOL CHEM, V283, P3289, DOI 10.1074/jbc.M704461200; Dean M, 2005, NAT REV CANCER, V5, P275, DOI 10.1038/nrc1590; Delacour-Larose M, 2007, CELL CYCLE, V6, P1878, DOI 10.4161/cc.6.15.4482; Dick JE, 2003, P NATL ACAD SCI USA, V100, P3547, DOI 10.1073/pnas.0830967100; Dohi T, 2004, J BIOL CHEM, V279, P34087, DOI 10.1074/jbc.C400236200; Dohi T, 2004, J CLIN INVEST, V114, P1117, DOI 10.1172/JCI200422222; Dohi T, 2007, MOL CELL, V27, P17, DOI 10.1016/j.molcel.2007.06.004; Duhl DM, 2005, CURR OPIN DRUG DISC, V8, P431; Eckelman BP, 2006, EMBO REP, V7, P988, DOI 10.1038/sj.embor.7400795; Engelsma D, 2007, TRAFFIC, V8, P1495, DOI 10.1111/j.1600-0854.2007.00629.x; Farnie G, 2007, JNCI-J NATL CANCER I, V99, P616, DOI 10.1093/jnci/djk133; Fesik SW, 2005, NAT REV CANCER, V5, P876, DOI 10.1038/nrc1736; Fodde R, 2007, CURR OPIN CELL BIOL, V19, P150, DOI 10.1016/j.ceb.2007.02.007; Fortugno P, 2002, J CELL SCI, V115, P575; Fortugno P, 2003, P NATL ACAD SCI USA, V100, P13791, DOI 10.1073/pnas.2434345100; Fukuda S, 2006, MOL CANCER THER, V5, P1087, DOI 10.1158/1535-7163.MCT-05-0375; Fukuda S, 2002, CELL CYCLE, V1, P322, DOI 10.4161/cc.1.5.149; Ghosh JC, 2008, J BIOL CHEM, V283, P5188, DOI 10.1074/jbc.M705904200; Giet R, 2005, TRENDS CELL BIOL, V15, P241, DOI 10.1016/j.tcb.2005.03.004; Green DR, 2004, SCIENCE, V305, P626, DOI 10.1126/science.1099320; Gu LB, 2007, EXP HEMATOL, V35, P957, DOI 10.1016/j.exphem.2007.03.007; Guo Y, 2008, STEM CELLS, V26, P30, DOI 10.1634/stemcells.2007-0401; Harrington EA, 2004, NAT MED, V10, P262, DOI 10.1038/nm1003; Hetzer M, 2002, NAT CELL BIOL, V4, pE177, DOI 10.1038/ncb0702-e177; Hopfer O, 2007, EXP HEMATOL, V35, P712, DOI 10.1016/j.exphem.2007.01.054; Jeyaprakash AA, 2007, CELL, V131, P271, DOI 10.1016/j.cell.2007.07.045; Jiang YY, 2005, J NEUROSCI, V25, P6962, DOI 10.1523/JNEUROSCI.1446-05.2005; Jones G, 2000, J BIOL CHEM, V275, P22157, DOI 10.1074/jbc.M000369200; Jonkers J, 2004, CANCER CELL, V6, P535, DOI 10.1016/j.ccr.2004.12.002; Joukov V, 2006, CELL, V127, P539, DOI 10.1016/j.cell.2006.08.053; Kang BH, 2007, CELL, V131, P257, DOI 10.1016/j.cell.2007.08.028; Kang BH, 2006, J BIOL CHEM, V281, P24721, DOI 10.1074/jbc.M603175200; Keith B, 2007, CELL, V129, P465, DOI 10.1016/j.cell.2007.04.019; Kelly PN, 2007, SCIENCE, V317, P337, DOI 10.1126/science.1142596; Kim CFB, 2005, CELL, V121, P823, DOI 10.1016/j.cell.2005.03.032; Kim PJ, 2003, LANCET, V362, P205, DOI 10.1016/S0140-6736(03)13910-4; Klein UR, 2006, MOL BIOL CELL, V17, P2547, DOI 10.1091/mbc.E05-12-1133; Knauer SK, 2007, FASEB J, V21, P207, DOI 10.1096/fj.06-5741com; Knauer SK, 2006, EMBO REP, V7, P1259, DOI 10.1038/sj.embor.7400824; Koffa MD, 2006, CURR BIOL, V16, P743, DOI 10.1016/j.cub.2006.03.056; Kotwaliwale C, 2006, CELL, V127, P1105, DOI 10.1016/j.cell.2006.11.032; Krause DS, 2007, TRENDS MOL MED, V13, P470, DOI 10.1016/j.molmed.2007.09.003; Lamb J, 2007, NAT REV CANCER, V7, P54, DOI 10.1038/nrc2044; Landis MW, 2006, CANCER CELL, V9, P13, DOI 10.1016/j.ccr.2005.12.019; Lee CW, 2008, CANCER RES, V68, P5273, DOI 10.1158/0008-5472.CAN-07-6673; Lens SMA, 2006, CURR OPIN CELL BIOL, V18, P616, DOI 10.1016/j.ceb.2006.08.016; Leung CG, 2007, J EXP MED, V204, P1603, DOI 10.1084/jem.20062395; Li FZ, 2006, AM J PATHOL, V169, P1, DOI 10.2353/ajpath.2006.060121; Liu SL, 2005, BREAST CANCER RES, V7, P86, DOI 10.1186/bcr1021; Liu WH, 2007, EMBO J, V26, P1660, DOI 10.1038/sj.emboj.7601611; Liu XQ, 2006, MOL CELL BIOL, V26, P2093, DOI 10.1128/MCB.26.6.2093-2108.2006; Marconi A, 2007, STEM CELLS, V25, P149, DOI 10.1634/stemcells.2006-0165; Morgan-Lappe SE, 2007, CANCER RES, V67, P4390, DOI 10.1158/0008-5472.CAN-06-4132; Nakahara T, 2007, CANCER RES, V67, P8014, DOI 10.1158/0008-5472.CAN-07-1343; Nam S, 2005, P NATL ACAD SCI USA, V102, P5998, DOI 10.1073/pnas.0409467102; O'Connor DS, 2002, CANCER CELL, V2, P43, DOI 10.1016/S1535-6108(02)00084-3; Oh SH, 2008, CLIN CANCER RES, V14, P1581, DOI 10.1158/1078-0432.CCR-07-0952; Okada H, 2004, J EXP MED, V199, P399, DOI 10.1084/jem.20032092; Paik S, 2004, NEW ENGL J MED, V351, P2817, DOI 10.1056/NEJMoa041588; Pennartz S, 2004, MOL CELL NEUROSCI, V25, P692, DOI 10.1016/j.mcn.2003.12.011; Pohl C, 2008, CELL, V132, P832, DOI 10.1016/j.cell.2008.01.012; Quimby BB, 2003, CURR OPIN CELL BIOL, V15, P338, DOI 10.1016/S0955-0674(03)00046-2; Radtke F, 2005, SCIENCE, V307, P1904, DOI 10.1126/science.1104815; Rajalingam K, 2006, PLOS PATHOG, V2, P1013, DOI 10.1371/journal.ppat.0020114; Reedijk M, 2005, CANCER RES, V65, P8530, DOI 10.1158/0008-5472.CAN-05-1069; Ren JY, 2005, P NATL ACAD SCI USA, V102, P565, DOI 10.1073/pnas.0408744102; Reya T, 2003, NATURE, V423, P409, DOI 10.1038/nature01593; Ronchini C, 2001, MOL CELL BIOL, V21, P5925, DOI 10.1128/MCB.21.17.5925-5934.2001; Salvesen GS, 2002, NAT REV MOL CELL BIO, V3, P401, DOI 10.1038/nrm830; Sampath Janardhan, 2007, Curr Drug Discov Technol, V4, P174, DOI 10.2174/157016307782109652; Sampath SC, 2004, CELL, V118, P187, DOI 10.1016/j.cell.2004.06.026; Sandall S, 2006, CELL, V127, P1179, DOI 10.1016/j.cell.2006.09.049; Sharma SV, 2007, NAT REV CANCER, V7, P169, DOI 10.1038/nrc2088; Sharma VM, 2006, MOL CELL BIOL, V26, P8022, DOI 10.1128/MCB.01091-06; Siddiquee K, 2007, P NATL ACAD SCI USA, V104, P7391, DOI 10.1073/pnas.0609757104; Skokowa J, 2007, ANN NY ACAD SCI, V1106, P143, DOI 10.1196/annals.1392.012; Song ZY, 2003, J BIOL CHEM, V278, P23130, DOI 10.1074/jbc.M300957200; Speliotes EK, 2000, MOL CELL, V6, P211, DOI 10.1016/S1097-2765(00)00023-X; Srinivasula SM, 2008, MOL CELL, V30, P123, DOI 10.1016/j.molcel.2008.03.008; Stauber RH, 2007, CANCER RES, V67, P5999, DOI 10.1158/0008-5472.CAN-07-0494; Stylianou S, 2006, CANCER RES, V66, P1517, DOI 10.1158/0008-5472.CAN-05-3054; Sun CH, 2005, BIOCHEMISTRY-US, V44, P11, DOI 10.1021/bi0485171; Taubert H, 2007, ONCOGENE, V26, P7170, DOI 10.1038/sj.onc.1210530; TOLCHER AW, 2006, ASCO ANN M, P3014; Tulu US, 2006, CURR BIOL, V16, P536, DOI 10.1016/j.cub.2006.01.060; Uren AG, 2000, CURR BIOL, V10, P1319, DOI 10.1016/S0960-9822(00)00769-7; Vader G, 2006, EMBO REP, V7, P85, DOI 10.1038/sj.embor.7400562; Vaira V, 2007, ONCOGENE, V26, P2678, DOI 10.1038/sj.onc.1210094; van der Greef J, 2005, NAT REV DRUG DISCOV, V4, P961, DOI 10.1038/nrd1904; van Es JH, 2005, NATURE, V435, P959, DOI 10.1038/nature03659; van't Veer LJ, 2002, NATURE, V415, P530, DOI 10.1038/415530a; Verdecia MA, 2000, NAT STRUCT BIOL, V7, P602; Vong QP, 2005, SCIENCE, V310, P1499, DOI 10.1126/science.1120160; Walter D, 2006, J CELL SCI, V119, P1843, DOI 10.1242/jcs.02902; Weinstein IB, 2006, NAT CLIN PRACT ONCOL, V3, P448, DOI 10.1038/ncponc0558; Weng AP, 2004, SCIENCE, V306, P269, DOI 10.1126/science.1102160; Wheatley SP, 2007, CELL CYCLE, V6, P1220, DOI 10.4161/cc.6.10.4179; Wheatley SP, 2004, J BIOL CHEM, V279, P5655, DOI 10.1074/jbc.M311299200; Whitesell L, 2005, NAT REV CANCER, V5, P761, DOI 10.1038/nrc1716; Woodward WA, 2007, P NATL ACAD SCI USA, V104, P618, DOI 10.1073/pnas.0606599104; Xia F, 2006, CANCER RES, V66, P3392, DOI 10.1158/0008-5472.CAN-05-4537; Xia F, 2008, CANCER RES, V68, P1826, DOI 10.1158/0008-5472.CAN-07-5279; Xing Z, 2004, J EXP MED, V199, P69, DOI 10.1084/jem.20031588; Yano M, 2003, J CELL BIOL, V163, P45, DOI 10.1083/jcb.200305051; You L, 2004, CANCER RES, V64, P5385, DOI 10.1158/0008-5472.CAN-04-1227; Young JC, 2003, CELL, V112, P41, DOI 10.1016/S0092-8674(02)01250-3; Zhang T, 2001, CANCER RES, V61, P8664; Zhao J, 2000, J CELL SCI, V113, P4363	119	146	161	0	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT	2008	27	48					6276	6284		10.1038/onc.2008.303	http://dx.doi.org/10.1038/onc.2008.303			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	361YB	18931693	Green Accepted			2022-12-28	WOS:000260162800008
J	Burgess, A; Labbe, JC; Vigneron, S; Bonneaud, N; Strub, JM; Van Dorsselaer, A; Lorca, T; Castro, A				Burgess, A.; Labbe, J. -C; Vigneron, S.; Bonneaud, N.; Strub, J. M.; Van Dorsselaer, A.; Lorca, T.; Castro, A.			Chfr interacts and colocalizes with TCTP to the mitotic spindle	ONCOGENE			English	Article						checkpoint; cancer; Chfr; prophase; spindle; TCTP	CONTROLLED TUMOR PROTEIN; CHECKPOINT PROTEIN; STRESS CHECKPOINT; CELL-CYCLE; GENE; HYPERMETHYLATION; MITOSIS; DELAYS; LIGASE; GROWTH	Chfr is a checkpoint protein that plays an important function in cell cycle progression and tumor suppression, although its exact role and regulation are unclear. Previous studies have utilized overexpression of Chfr to determine the signaling pathway of this protein in vivo. In this study, we demonstrate, by using three different antibodies against Chfr, that the endogenous and highly overexpressed ectopic Chfr protein is localized and regulated differently in cells. Endogenous and lowly expressed ectopic Chfr are cytoplasmic and localize to the spindle during mitosis. Higher expression of ectopic Chfr correlates with a shift in the localization of this protein to the nucleus/PML bodies, and with a block of cell proliferation. In addition, endogenous and lowly expressed ectopic Chfr is stable throughout the cell cycle, whereas when highly expressed, ectopic Chfr is actively degraded during S-G2/M phases in an autoubiquitination and proteasome-dependent manner. A two-hybrid screen identified TCTP as a possible Chfr-interacting partner. Biochemical analysis with the endogenous proteins confirmed this interaction and identified beta-tubulin as an additional partner for Chfr, supporting the mitotic spindle localization of Chfr. The Chfr-TCTP interaction was stable throughout the cell cycle, but it could be diminished by the complete depolymerization of the microtubules, providing a possible mechanism where Chfr could be the sensor that detects microtubule disruption and then activates the prophase checkpoint.	[Burgess, A.; Labbe, J. -C; Lorca, T.; Castro, A.] Univ Montpellier 2, Ctr Rech Biochim Macromol, CNRS, UMR Labellisee Ligue Natl Canc 5237,IFR 122, Montpellier, France; [Burgess, A.; Labbe, J. -C; Vigneron, S.; Lorca, T.; Castro, A.] Univ Montpellier I, Ctr Rech Biochim Macromol, CNRS, UMR Labellisee Ligue Natl Canc 5237,IFR 122, Montpellier, France; [Bonneaud, N.] CNRS, IGH, UPR14142, Montpellier, France; [Strub, J. M.] Inst Pluridisciplinaire Hubert Curien, UMR7178, Strasbourg, France	Centre National de la Recherche Scientifique (CNRS); Universite de Montpellier; Centre National de la Recherche Scientifique (CNRS); Universite de Montpellier; Centre National de la Recherche Scientifique (CNRS); Universite de Montpellier; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute of Nuclear and Particle Physics (IN2P3)	Lorca, T (corresponding author), Univ Montpellier, Ctr Rech Biochim Macromol, CNRS, 1919 Route Mende, F-34293 Montpellier, France.	thierry.lorca@crbm.cnrs.fr; anna.castro@crbm.cnrs.fr	Burgess, Andrew/H-3339-2019; labbe, jean-claude/B-2277-2009; CASTRO, ANNA/F-4350-2010; Burgess, Andrew/C-7952-2009	Burgess, Andrew/0000-0003-4536-9226; CASTRO, ANNA/0000-0002-3655-1352; Burgess, Andrew/0000-0003-4536-9226; Lorca, Thierry/0000-0003-2007-8924; Strub, Jean-Marc/0000-0001-6224-3428	Ligue Nationale Contre le Cancer (Equipe Labellisee)	Ligue Nationale Contre le Cancer (Equipe Labellisee)(Ligue nationale contre le cancer)	We thank Julian Cau from the Montpellier RIO Imaging facility (CRBM). We also acknowledge J Casanova, JM Donnay and JC Mazur for their technical support. This work was supported by the Ligue Nationale Contre le Cancer (Equipe Labellisee). AB is a Ligue Nationale Contre le Cancer fellow.	Abrieu A, 2001, CELL, V106, P83, DOI 10.1016/S0092-8674(01)00410-X; Bothos J, 2003, ONCOGENE, V22, P7101, DOI 10.1038/sj.onc.1206831; Burgess A, 2006, J BIOL CHEM, V281, P9987, DOI 10.1074/jbc.M512714200; Chaturvedi P, 2002, CANCER RES, V62, P1797; CHEUNG H, 2003, P NATL ACAD SCI USA, V100, P7818; Corn PG, 2003, CARCINOGENESIS, V24, P47, DOI 10.1093/carcin/24.1.47; Daniels MJ, 2004, NAT STRUCT MOL BIOL, V11, P1114, DOI 10.1038/nsmb837; Erson AE, 2004, MOL CARCINOGEN, V39, P26, DOI 10.1002/mc.10161; FromontRacine M, 1997, NAT GENET, V16, P277, DOI 10.1038/ng0797-277; Gabrielli BG, 1996, J CELL SCI, V109, P1081; Gachet Y, 1999, J CELL SCI, V112, P1257; Hsu YC, 2007, NATURE, V445, P785, DOI 10.1038/nature05528; Jung J, 2004, J BIOL CHEM, V279, P49868, DOI 10.1074/jbc.M400895200; Kang DM, 2002, J CELL BIOL, V156, P249, DOI 10.1083/jcb.200108016; Liu H, 2005, MOL CELL BIOL, V25, P3117, DOI 10.1128/MCB.25.8.3117-3126.2005; Loring GL, 2008, CELL CYCLE, V7, P96, DOI 10.4161/cc.7.1.5113; Mariatos G, 2003, CANCER RES, V63, P7185; Matsusaka T, 2004, J CELL BIOL, V166, P507, DOI 10.1083/jcb.200401139; Mikhailov A, 2005, CELL CYCLE, V4, P57, DOI 10.4161/cc.4.1.1357; Mizuno K, 2002, ONCOGENE, V21, P2328, DOI 10.1038/sj.onc.1205402; MURRAY AW, 1991, SCI AM, V264, P56, DOI 10.1038/scientificamerican0391-56; Privette LM, 2007, CANCER RES, V67, P6064, DOI 10.1158/0008-5472.CAN-06-4109; Rieder CL, 2000, CURR BIOL, V10, P1067, DOI 10.1016/S0960-9822(00)00678-3; Satoh A, 2003, CANCER RES, V63, P8606; Scolnick DM, 2000, NATURE, V406, P430, DOI 10.1038/35019108; Tuynder M, 2004, P NATL ACAD SCI USA, V101, P15364, DOI 10.1073/pnas.0406776101; Tuynder M, 2002, P NATL ACAD SCI USA, V99, P14976, DOI 10.1073/pnas.222470799; Uzbekov R, 1998, EXP CELL RES, V242, P60, DOI 10.1006/excr.1998.4097; Yang Y, 2005, ONCOGENE, V24, P4778, DOI 10.1038/sj.onc.1208666; Yarm FR, 2002, MOL CELL BIOL, V22, P6209, DOI 10.1128/MCB.22.17.6209-6221.2002; Yu XC, 2005, NAT GENET, V37, P401, DOI 10.1038/ng1538	31	37	41	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 18	2008	27	42					5554	5566		10.1038/onc.2008.167	http://dx.doi.org/10.1038/onc.2008.167			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	349KX	18504434	Green Submitted			2022-12-28	WOS:000259280800002
J	Suh, HC; Leeanansaksiri, W; Ji, M; Klarmann, KD; Renn, K; Gooya, J; Smith, D; McNiece, I; Lugthart, S; Valk, PJM; Delwel, R; Keller, JR				Suh, H. C.; Leeanansaksiri, W.; Ji, M.; Klarmann, K. D.; Renn, K.; Gooya, J.; Smith, D.; McNiece, I.; Lugthart, S.; Valk, P. J. M.; Delwel, R.; Keller, J. R.			Id1 immortalizes hematopoietic progenitors in vitro and promotes a myeloproliferative disease in vivo	ONCOGENE			English	Article						Id1; myeloproliferative disease; leukemia; therapeutic target; prevention	ACUTE MYELOID-LEUKEMIA; LOOP-HELIX PROTEINS; CELL-DEVELOPMENT; TRANSGENIC MICE; STEM-CELLS; TRANSCRIPTION FACTORS; BONE-MARROW; C/EBP-ALPHA; EXPRESSION; DIFFERENTIATION	Id1 is frequently overexpressed in many cancer cells, but the functional significance of these findings is not known. To determine if Id1 could contribute to the development of hematopoietic malignancy, we reconstituted mice with hematopoietic cells overexpressing Id1. We showed for the first time that deregulated expression of Id1 leads to a myeloproliferative disease in mice, and immortalizes myeloid progenitors in vitro. In human cells, we demonstrate that Id genes are expressed in human acute myelogenous leukemia cells, and that knock down of Id1 expression inhibits leukemic cell line growth, suggesting that Id1 is required for leukemic cell proliferation. These findings established a causal relationship between Id1 overexpression and hematologic malignancy. Thus, deregulated expression of Id1 may contribute to the initiation of myeloid malignancy, and Id1 may represent a potential therapeutic target for early stage intervention in the treatment of hematopoietic malignancy.	[Suh, H. C.; Leeanansaksiri, W.; Ji, M.; Klarmann, K. D.; Renn, K.; Gooya, J.; Keller, J. R.] NCI, Basic Res Program, SAIC Frederick Inc, Frederick, MD 21702 USA; [Suh, H. C.; Leeanansaksiri, W.; Ji, M.; Klarmann, K. D.; Renn, K.; Gooya, J.; Keller, J. R.] NCI, Canc Res Ctr, Frederick, MD 21702 USA; [Smith, D.; McNiece, I.] Sidney Kimmel Comprehens Canc Ctr, Div Hematol Malignancies, Baltimore, MD USA; [Lugthart, S.; Valk, P. J. M.; Delwel, R.] Erasmus Univ, Med Ctr, Dept Hematol, Rotterdam, Netherlands	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Johns Hopkins University; Johns Hopkins Medicine; Erasmus University Rotterdam; Erasmus MC	Keller, JR (corresponding author), NCI, Basic Res Program, SAIC Frederick Inc, Bldg 560,Room 12-03, Frederick, MD 21702 USA.	kellerj@ncifcrf.gov	Valk, Peter/AAX-2823-2020; Suh, Hyung/L-5912-2019; Ji, Ming/C-2795-2011; Keller, Jonathan R./O-6677-2018	Suh, Hyung/0000-0001-6912-4157; Lugthart, Sanne/0000-0003-3007-8303	National Cancer Institute; National Institutes of Health [NO1-CO-12400]; Intramural Research Program of NIH; Center for Cancer Research; Regional Oncology Research Center [5 P30 CA06973]; NATIONAL CANCER INSTITUTE [P30CA006973, ZIABC010001] Funding Source: NIH RePORTER	National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Intramural Research Program of NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Center for Cancer Research(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Regional Oncology Research Center; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We gratefully acknowledge the technical support of Steve Stull, Kathleen Noer, Roberta Matthai and Samantha Bauchiero. We also thank Dr Nancy Colburn, Dr Sandra Ruscetti and Dr Kristbjorn Gudmundsson for their critical review of this article. This project has been funded, in part, with Federal funds from the National Cancer Institute, National Institutes of Health, under contract number NO1-CO-12400. This research was supported, in part, by the Intramural Research Program of NIH, National Cancer Institute, Center for Cancer Research. Clinical specimens were provided by the Sidney Kimmel Cancer Center at Johns Hopkins Tumor and Cell Procurement Bank, supported by the Regional Oncology Research Center Grant no. 5 P30 CA06973.	Akashi K, 2000, NATURE, V404, P193, DOI 10.1038/35004599; Akashi K, 2000, CURR OPIN IMMUNOL, V12, P144, DOI 10.1016/S0952-7915(99)00064-3; Akashi K, 2003, BLOOD, V101, P383, DOI 10.1182/blood-2002-06-1780; Alani RM, 1999, P NATL ACAD SCI USA, V96, P9637, DOI 10.1073/pnas.96.17.9637; Alani RM, 2001, P NATL ACAD SCI USA, V98, P7812, DOI 10.1073/pnas.141235398; Bain G, 1997, MOL CELL BIOL, V17, P4782, DOI 10.1128/MCB.17.8.4782; Belletti B, 2002, EXP CELL RES, V277, P107, DOI 10.1006/excr.2002.5542; Buitenhuis M, 2005, BLOOD, V105, P4272, DOI 10.1182/blood-2004-12-4883; Bullinger L, 2005, J CLIN ONCOL, V23, P6296, DOI 10.1200/JCO.2005.05.020; Castilla LH, 1999, NAT GENET, V23, P144, DOI 10.1038/13776; Cooper CL, 1997, BLOOD, V89, P3155, DOI 10.1182/blood.V89.9.3155; Fong S, 2004, TRENDS MOL MED, V10, P387, DOI 10.1016/j.molmed.2004.06.008; Grisolano JL, 1997, BLOOD, V89, P376, DOI 10.1182/blood.V89.2.376; He LZ, 1997, P NATL ACAD SCI USA, V94, P5302, DOI 10.1073/pnas.94.10.5302; Higuchi M, 2002, CANCER CELL, V1, P63, DOI 10.1016/S1535-6108(02)00016-8; Hollnagel A, 1999, J BIOL CHEM, V274, P19838, DOI 10.1074/jbc.274.28.19838; Hu M, 1997, GENE DEV, V11, P774, DOI 10.1101/gad.11.6.774; Ishiguro A, 1995, LEUKEMIA RES, V19, P989, DOI 10.1016/0145-2126(95)00084-4; JEN Y, 1992, GENE DEV, V6, P1466, DOI 10.1101/gad.6.8.1466; Kang YB, 2003, MOL CELL, V11, P915, DOI 10.1016/S1097-2765(03)00109-6; Kim D, 1999, MOL CELL BIOL, V19, P8240; Kogan SC, 2002, BLOOD, V100, P238, DOI 10.1182/blood.V100.1.238; Kondo M, 1997, CELL, V91, P661, DOI 10.1016/S0092-8674(00)80453-5; Koschmieder S, 2005, INT J HEMATOL, V81, P368, DOI 10.1532/IJH97.05051; KREIDER BL, 1992, SCIENCE, V255, P1700, DOI 10.1126/science.1372755; Kunisato A, 2004, BLOOD, V103, P3336, DOI 10.1182/blood-2003-06-1935; Lasorella A, 2000, NATURE, V407, P592, DOI 10.1038/35036504; Lasorella A, 2001, ONCOGENE, V20, P8326, DOI 10.1038/sj.onc.1205093; Leeanansaksiri W, 2005, J IMMUNOL, V174, P7014, DOI 10.4049/jimmunol.174.11.7014; Lyden D, 2001, NAT MED, V7, P1194, DOI 10.1038/nm1101-1194; Nilsson L, 2007, BLOOD, V110, P3005, DOI 10.1182/blood-2007-03-079368; Norton JD, 2000, J CELL SCI, V113, P3897; O'Neil J, 2004, CANCER CELL, V5, P587, DOI 10.1016/j.ccr.2004.05.023; Ohtani N, 2001, NATURE, V409, P1067, DOI 10.1038/35059131; Pagliuca A, 2000, CANCER RES, V60, P1376; Perk J, 2005, NAT REV CANCER, V5, P603, DOI 10.1038/nrc1673; Prabhu S, 1997, MOL CELL BIOL, V17, P5888, DOI 10.1128/MCB.17.10.5888; Quesenberry PJ, 1996, J CELL BIOCHEM, V61, P478; Rosenbauer F, 2005, BLOOD, V106, P1519, DOI 10.1182/blood-2005-02-0717; Rosmarin AG, 2005, EXP HEMATOL, V33, P131, DOI 10.1016/j.exphem.2004.08.015; Ruzinova MB, 2003, TRENDS CELL BIOL, V13, P410, DOI 10.1016/S0962-8924(03)00147-8; Sikder HA, 2003, CANCER CELL, V3, P525, DOI 10.1016/S1535-6108(03)00141-7; Suh HC, 2006, BLOOD, V107, P4308, DOI 10.1182/blood-2005-06-2216; Tenen DG, 2003, NAT REV CANCER, V3, P89, DOI 10.1038/nrc989; Valk PJM, 2004, NEW ENGL J MED, V350, P1617, DOI 10.1056/NEJMoa040465; WILSON RB, 1991, MOL CELL BIOL, V11, P6185, DOI 10.1128/MCB.11.12.6185; Wong YC, 2004, APOPTOSIS, V9, P279, DOI 10.1023/B:APPT.0000025804.25396.79; Yokota Y, 2002, J CELL PHYSIOL, V190, P21, DOI 10.1002/jcp.10042; Zhang JS, 2004, SCIENCE, V305, P1286, DOI 10.1126/science.1097937	49	42	43	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 18	2008	27	42					5612	5623		10.1038/onc.2008.175	http://dx.doi.org/10.1038/onc.2008.175			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	349KX	18542061	Green Accepted			2022-12-28	WOS:000259280800007
J	Maimets, T; Neganova, I; Armstrong, L; Lako, M				Maimets, T.; Neganova, I.; Armstrong, L.; Lako, M.			Activation of p53 by nutlin leads to rapid differentiation of human embryonic stem cells	ONCOGENE			English	Article						cell cycle; differentiation; human embryonic stem cells; p53-p21 pathway; tumour suppression	SELF-RENEWAL; TRANSCRIPTIONAL ACTIVATION; IN-VIVO; PROLIFERATION; CANCER; GENE; P21; ANTAGONISTS; QUIESCENCE; SITES	p53 is an important regulator of normal cell response to stress and frequently mutated in human tumours. Here, we studied the effects of activation of p53 and its target gene p21 in human embryonic stem cells. We show that activation of p53 with small-molecule activator nutlin leads to rapid differentiation of stem cells evidenced by changes in cell morphology and adhesion, expression of cell-specific markers for primitive endoderm and trophectoderm lineages and loss of pluripotency markers. p21 is quickly and dose-dependently activated by nutlin. It can also be activated independently from p53 by sodium butyrate, which leads to the differentiation events very similar to the ones induced by p53. During differentiation, the activating phosphorylation site of CDK2 Thr-160 becomes dephosphorylated and cyclins A and E become degraded. The target for CDK2 kinase in p53 molecule, Ser-315, also becomes dephosphorylated. We conclude that the main mechanism responsible for differentiation of human stem cells by p53 is abolition of S-phase entry and subsequent stop of cell cycle in G0/G1 phase accompanied by p21 activation.	[Maimets, T.] Univ Tartu, Inst Mol & Cell Biol, EE-51010 Tartu, Estonia; [Maimets, T.; Neganova, I.; Armstrong, L.; Lako, M.] Univ Newcastle Upon Tyne, Inst Human Genet, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England; [Neganova, I.; Armstrong, L.; Lako, M.] Univ Newcastle Upon Tyne, North East Stem Cell Inst, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England	University of Tartu; Newcastle University - UK; Newcastle University - UK	Maimets, T (corresponding author), Univ Tartu, Inst Mol & Cell Biol, Riia 23, EE-51010 Tartu, Estonia.	toivo.maimets@ut.ee	Armstrong, Lyle/B-7812-2013; Lako, Majlinda/B-6297-2013; Maimets, Toivo/E-9268-2017	Maimets, Toivo/0000-0001-6461-3365; lako, majlinda/0000-0003-1327-8573; armstrong, lyle/0000-0002-7234-9362	Estonian Science Foundation [ETF6459]; Citrina Foundation (TM); One North East Regional Developmental Agency (ML); MRC [G0301182] Funding Source: UKRI	Estonian Science Foundation; Citrina Foundation (TM); One North East Regional Developmental Agency (ML); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	We thank Ian Dimmick for help in flow cytometry and Stuart Atkinson for assistance with Quantitative real-time-PCR. This work has been supported by grants from Estonian Science Foundation (ETF6459) and Citrina Foundation (TM) and One North East Regional Developmental Agency (ML).	Cheng T, 2000, SCIENCE, V287, P1804, DOI 10.1126/science.287.5459.1804; Dontu G, 2004, BREAST CANCER RES, V6, pR605, DOI 10.1186/bcr920; Dravid G, 2005, STEM CELLS, V23, P1489, DOI 10.1634/stemcells.2005-0034; Gartel AL, 2005, CANCER RES, V65, P3980, DOI 10.1158/0008-5472.CAN-04-3995; Groszer M, 2001, SCIENCE, V294, P2186, DOI 10.1126/science.1065518; Hainaut P, 2000, ADV CANCER RES, V77, P81; Hock H, 2004, NATURE, V431, P1002, DOI 10.1038/nature02994; Hyslop L, 2005, STEM CELLS, V23, P1035, DOI 10.1634/stemcells.2005-0080; Hyslop Louise A., 2005, Expert Reviews in Molecular Medicine, V7, P1, DOI 10.1017/S1462399405009804; Joers A, 1998, ONCOGENE, V17, P2351, DOI 10.1038/sj.onc.1202146; Kippin TE, 2005, GENE DEV, V19, P756, DOI 10.1101/gad.1272305; LANE DP, 1992, NATURE, V358, P16; Lin TX, 2005, NAT CELL BIOL, V7, P165, DOI 10.1038/ncb1211; Liu M, 1996, GENE DEV, V10, P142, DOI 10.1101/gad.10.2.142; Liu M, 1996, J BIOL CHEM, V271, P31723, DOI 10.1074/jbc.271.49.31723; Meletis K, 2006, DEVELOPMENT, V133, P363, DOI 10.1242/dev.02208; Molofsky AV, 2003, NATURE, V425, P962, DOI 10.1038/nature02060; Nakano K, 1997, J BIOL CHEM, V272, P22199, DOI 10.1074/jbc.272.35.22199; Qin H, 2007, J BIOL CHEM, V282, P5842, DOI 10.1074/jbc.M610464200; Stojkovic M, 2004, STEM CELLS, V22, P790, DOI 10.1634/stemcells.22-5-790; TANAKA M, 1990, CELL, V60, P75; Tovar C, 2006, P NATL ACAD SCI USA, V103, P1888, DOI 10.1073/pnas.0507493103; Tyner SD, 2002, NATURE, V415, P45, DOI 10.1038/415045a; Vassilev LT, 2004, SCIENCE, V303, P844, DOI 10.1126/science.1092472; Vousden KH, 2002, NAT REV CANCER, V2, P594, DOI 10.1038/nrc864; Wei CL, 2006, CELL, V124, P207, DOI 10.1016/j.cell.2005.10.043; Wicha MS, 2006, CANCER RES, V66, P1883, DOI 10.1158/0008-5472.CAN-05-3153	27	99	114	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 11	2008	27	40					5277	5287		10.1038/onc.2008.166	http://dx.doi.org/10.1038/onc.2008.166			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	346UW	18521083				2022-12-28	WOS:000259096100001
J	Ueki, T; Nishidate, T; Park, JH; Lin, ML; Shimo, A; Hirata, K; Nakamura, Y; Katagiri, T				Ueki, T.; Nishidate, T.; Park, J. H.; Lin, M. L.; Shimo, A.; Hirata, K.; Nakamura, Y.; Katagiri, T.			Involvement of elevated expression of multiple cell-cycle regulator, DTL/RAMP (denticleless/RA-regulated nuclear matrix associated protein), in the growth of breast cancer cells	ONCOGENE			English	Article						cDNA microarray; molecular target; AURKB; multiple cell-cycle regulator; cytokinesis	SYNOVIAL SARCOMAS; MOLECULAR TARGETS; KINASE; GENE; IDENTIFICATION; THERAPY; COMPLEX; PHOSPHORYLATION; CARCINOGENESIS; CYTOKINESIS	To investigate the detailed molecular mechanism of mammary carcinogenesis and discover novel therapeutic targets, we previously analysed gene expression profiles of breast cancers. We here report characterization of a significant role of DTL/RAMP (denticleless/RA-regulated nuclear matrix associated protein) in mammary carcinogenesis. Semiquantitative RT-PCR and northern blot analyses confirmed upregulation of DTL/RAMP in the majority of breast cancer cases and all of breast cancer cell lines examined. Immunocytochemical and western blot analyses using anti-DTL/RAMP polyclonal antibody revealed cell-cycle-dependent localization of endogenous DTL/RAMP protein in breast cancer cells; nuclear localization was observed in cells at interphase and the protein was concentrated at the contractile ring in cytokinesis process. The expression level of DTL/RAMP protein became highest at G(1)/S phases, whereas its phosphorylation level was enhanced during mitotic phase. Treatment of breast cancer cells, T47D and HBC4, with small-interfering RNAs against DTL/RAMP effectively suppressed its expression and caused accumulation of G(2)/M cells, resulting in growth inhibition of cancer cells. We further demonstrate the in vitro phosphorylation of DTL/RAMP through an interaction with the mitotic kinase, Aurora kinase-B (AURKB). Interestingly, depletion of AURKB expression with siRNA in breast cancer cells reduced the phosphorylation of DTL/RAMP and decreased the stability of DTL/RAMP protein. These findings imply important roles of DTL/RAMP in growth of breast cancer cells and suggest that DTL/RAMP might be a promising molecular target for treatment of breast cancer.	[Ueki, T.; Nishidate, T.; Park, J. H.; Lin, M. L.; Shimo, A.; Nakamura, Y.; Katagiri, T.] Univ Tokyo, Mol Med Lab, Ctr Human Genome, Inst Med Sci,Minato Ku, Tokyo 1088639, Japan; [Ueki, T.; Hirata, K.] Sapporo Med Univ, Dept Surg, Chuo Ku, Sapporo, Hokkaido, Japan	University of Tokyo; Sapporo Medical University	Katagiri, T (corresponding author), Univ Tokyo, Mol Med Lab, Ctr Human Genome, Inst Med Sci,Minato Ku, 4-6-1 Shirokanedai, Tokyo 1088639, Japan.	tkatagi@ims.u-tokyo.ac.jp	Katagiri, Toyomasa/I-7344-2012					Adams RR, 2001, TRENDS CELL BIOL, V11, P49, DOI 10.1016/S0962-8924(00)01880-8; Bange J, 2001, NAT MED, V7, P548, DOI 10.1038/87872; Banks D, 2006, CELL CYCLE, V5, P1719, DOI 10.4161/cc.5.15.3150; Carmena M, 2003, NAT REV MOL CELL BIO, V4, P842, DOI 10.1038/nrm1245; Cheeseman LM, 2002, CELL, V111, P163, DOI 10.1016/S0092-8674(02)00973-X; Cheung WMW, 2001, J BIOL CHEM, V276, P17083, DOI 10.1074/jbc.M010802200; Dechat T, 1998, EMBO J, V17, P4887, DOI 10.1093/emboj/17.16.4887; Goto H, 2003, J BIOL CHEM, V278, P8526, DOI 10.1074/jbc.M210892200; Higa LA, 2006, NAT CELL BIOL, V8, P1277, DOI 10.1038/ncb1490; Higa LA, 2006, CELL CYCLE, V5, P1675, DOI 10.4161/cc.5.15.3149; Hirota E, 2006, INT J ONCOL, V29, P799; Lin ML, 2007, BREAST CANCER RES, V9, DOI 10.1186/bcr1650; Nagayama S, 2004, ONCOGENE, V23, P5551, DOI 10.1038/sj.onc.1207710; Nagayama S, 2005, ONCOGENE, V24, P6201, DOI 10.1038/sj.onc.1208780; Navolanic PM, 2005, INT J ONCOL, V27, P1341; Nishidate T, 2004, INT J ONCOL, V25, P797; Ohashi S, 2006, ONCOGENE, V25, P7691, DOI 10.1038/sj.onc.1209754; Park JH, 2006, CANCER RES, V66, P9186, DOI 10.1158/0008-5472.CAN-06-1601; Parkin DM, 2005, CA-CANCER J CLIN, V55, P74, DOI 10.3322/canjclin.55.2.74; Petricoin EF, 2002, NAT GENET, V32, P474, DOI 10.1038/ng1029; Sansam CL, 2006, GENE DEV, V20, P3117, DOI 10.1101/gad.1482106; Severson AF, 2000, CURR BIOL, V10, P1162, DOI 10.1016/S0960-9822(00)00715-6; Shimo A, 2007, CANCER SCI, V98, P174, DOI 10.1111/j.1349-7006.2006.00381.x; Shimokawa T, 2003, CANCER RES, V63, P6116; Terada Y, 2001, CELL STRUCT FUNCT, V26, P653, DOI 10.1247/csf.26.653; Togashi A, 2005, CANCER RES, V65, P4817, DOI 10.1158/0008-5472.CAN-05-0120	26	69	72	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP	2008	27	43					5672	5683		10.1038/onc.2008.186	http://dx.doi.org/10.1038/onc.2008.186			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	352HM	18542055				2022-12-28	WOS:000259487100003
J	Navab, R; Pedraza, C; Fallavollita, L; Wang, N; Chevet, E; Auguste, P; Jenna, S; You, Z; Bikfalvi, A; Hu, J; O'Connor, R; Erickson, A; Mort, JS; Brodt, P				Navab, R.; Pedraza, C.; Fallavollita, L.; Wang, N.; Chevet, E.; Auguste, P.; Jenna, S.; You, Z.; Bikfalvi, A.; Hu, J.; O'Connor, R.; Erickson, A.; Mort, J. S.; Brodt, P.			Loss of responsiveness to IGF-I in cells with reduced cathepsin L expression levels	ONCOGENE			English	Article						IGF; cathepsin L; apoptosis; invasion; metastasis	GROWTH-FACTOR RECEPTOR; CYSTEINE PROTEINASE; ENDOSOMAL PROTEOLYSIS; MELANOMA-CELLS; PROCATHEPSIN-L; ANTISENSE RNA; INSULIN; CANCER; CARCINOMA; METASTASIS	The lysosomal cysteine proteinase cathepsin L is involved in proteolytic processing of internalized proteins. In transformed cells, where it is frequently overexpressed, its intracellular localization and functions can be altered. Previously, we reported that treatment of highly metastatic, murine carcinoma H-59 cells with small molecule cysteine proteinase inhibitors altered the responsiveness of the type I insulin-like growth factor (IGF-I) receptor and consequently reduced cell invasion and metastasis. To assess more specifically the role of cathepsin L in IGF-I-induced signaling and tumorigenicity, we generated H-59 subclones with reduced cathepsin L expression levels. These clonal lines showed an altered responsiveness to IGF-I in vitro, as evidenced by (i) loss of IGF-I-induced receptor phosphorylation and Shc recruitment, (ii) reduced IGF-I (but not IGF-II)-induced cellular proliferation and migration, (iii) decreased anchorage-independent growth and (iv) reduced plasma membrane levels of IGF-IR. These changes resulted in increased apoptosis in vivo and an impaired ability of the cells to form liver metastases. The results demonstrate that cathepsin L expression levels regulate cell responsiveness to IGF-I and thereby identify a novel function for cathepsin L in the control of the tumorigenic/metastatic phenotype.	[Navab, R.; Pedraza, C.; Fallavollita, L.; Wang, N.; Chevet, E.; You, Z.; Mort, J. S.; Brodt, P.] McGill Univ, Dept Surg, Montreal, PQ H3A IA1, Canada; [Chevet, E.; Brodt, P.] McGill Univ, Dept Med, Montreal, PQ H3A IA1, Canada; [Chevet, E.; Auguste, P.; Jenna, S.; Brodt, P.] McGill Univ, Royal Victoria Hosp, Ctr Hlth, Organelle Signaling Lab, Montreal, PQ H3A IA1, Canada; [Chevet, E.; Auguste, P.] Univ Bordeaux 2, INSERM, Team Avenir, U889, F-33076 Bordeaux, France; [Bikfalvi, A.] Univ Bordeaux 1, INSERM, E0113, Bordeaux, France; [Auguste, P.] Univ Bordeaux 1, INSERM, U889, Bordeaux, France; [Hu, J.] Univ Toronto, Hosp Sick Children, Toronto, ON M5G 1X8, Canada; [O'Connor, R.] Univ Coll Cork, Dept Biochem, Cork, Ireland; [Erickson, A.] Univ N Carolina Chapel Hill, Dept Biochem & Biophys, N Carolina, NC USA; [Mort, J. S.] McGill Univ, Shriners Hosp, Montreal, PQ, Canada	McGill University; McGill University; McGill University; Royal Victoria Hospital; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite de Bordeaux; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite de Bordeaux; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite de Bordeaux; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University College Cork; University of North Carolina; University of North Carolina Chapel Hill; McGill University	Brodt, P (corresponding author), McGill Univ, Royal Victoria Hosp, Ctr Hlth, Organelle Signaling Lab, Room H6-25,687 Pine Ave W, Montreal, PQ H3A IA1, Canada.	pnina.brodt@muhc.mcgill.ca	chevet, eric/E-4992-2016; O'Connor, Rosemary/B-7902-2014; Navab, Roya/AGD-7380-2022	chevet, eric/0000-0001-5855-4522; O'Connor, Rosemary/0000-0002-0687-3422; Auguste, Patrick/0000-0003-1485-0295; Hu, Jim/0000-0001-9134-7103	Canadian Institute for Health Research [MT-10505]; National Cancer Institute of Canada; National Science Foundation [MCB-96141139]	Canadian Institute for Health Research(Canadian Institutes of Health Research (CIHR)); National Cancer Institute of Canada(Canadian Cancer Society (CCS)); National Science Foundation(National Science Foundation (NSF))	This work was supported initially by Grant MT-10505 from the Canadian Institute for Health Research and subsequently by a Terry Fox Frontiers Initiative Grant from the National Cancer Institute of Canada (to PB) and by Grant MCB-96141139 from the National Science Foundation (to AE). We thank Dr Edmund Ziomek (Biotechnology Research Institute, Montreal, QC, Canada) for gifts of CathC and CathS cDNA, and Drs Amir Samani and Donglei Zhang (formerly of the Division of Surgical Research, McGill University) for their help with the study.	Ahn K, 2002, TRAFFIC, V3, P147, DOI 10.1034/j.1600-0854.2002.030207.x; Authier F, 2005, FEBS LETT, V579, P4309, DOI 10.1016/j.febslet.2005.06.066; Authier F, 2002, J BIOL CHEM, V277, P9437, DOI 10.1074/jbc.M110188200; Authier F, 1999, J BIOL CHEM, V274, P33723, DOI 10.1074/jbc.274.47.33723; Baserga R, 2003, INT J CANCER, V107, P873, DOI 10.1002/ijc.11487; Benavides F, 2002, AM J PATHOL, V161, P693, DOI 10.1016/S0002-9440(10)64225-3; Boike G, 1992, Melanoma Res, V1, P333, DOI 10.1097/00008390-199201000-00004; BRODT P, 1992, BIOCHIM BIOPHYS ACTA, V1139, P77, DOI 10.1016/0925-4439(92)90085-2; BRODT P, 1986, CANCER RES, V46, P2442; Brodt P, 2001, J BIOL CHEM, V276, P33608, DOI 10.1074/jbc.M102754200; Buckley DA, 2002, J CLIN PATHOL-MOL PA, V55, P46, DOI 10.1136/mp.55.1.46; CHAMBERS AF, 1992, MOL CARCINOGEN, V5, P238, DOI 10.1002/mc.2940050311; Chow JC, 1998, J BIOL CHEM, V273, P4672, DOI 10.1074/jbc.273.8.4672; Clague MJ, 2001, J CELL SCI, V114, P3075; Collette J, 2004, INT REV CYTOL, V241, P1, DOI 10.1016/S0074-7696(04)41001-8; Denley A, 2003, HORM METAB RES, V35, P778; Desbuquois B, 2003, ENDOCRINOLOGY, V144, P5308, DOI 10.1210/en.2002-0154; DIGUGLIELMO GM, 1994, EMBO J, V13, P4269, DOI 10.1002/j.1460-2075.1994.tb06747.x; Gocheva V, 2006, GENE DEV, V20, P543, DOI 10.1101/gad.1407406; Gocheva V, 2007, CELL CYCLE, V6, P60, DOI 10.4161/cc.6.1.3669; Gordon PV, 2005, AM J PHYSIOL-GASTR L, V289, pG79, DOI 10.1152/ajpgi.00384.2004; Goulet B, 2007, MOL CANCER RES, V5, P899, DOI 10.1158/1541-7786.MCR-07-0160; Guan J, 1996, ENDOCRINOLOGY, V137, P893, DOI 10.1210/en.137.3.893; Ishidoh K, 2002, BIOL CHEM, V383, P1827, DOI 10.1515/BC.2002.206; Ishidoh K, 1998, BIOL CHEM, V379, P131; Iwata Y, 1997, ARTHRITIS RHEUM, V40, P499, DOI 10.1002/art.1780400316; Kirschke H, 2000, EUR J CANCER, V36, P787, DOI 10.1016/S0959-8049(00)00014-9; Krueger S, 2001, CANCER GENE THER, V8, P522, DOI 10.1038/sj.cgt.7700341; Levicar N, 2003, CANCER GENE THER, V10, P141, DOI 10.1038/sj.cgt.7700546; Lin FT, 1998, J BIOL CHEM, V273, P31640, DOI 10.1074/jbc.273.48.31640; Long L, 1998, CANCER RES, V58, P3243; LONG L, 1995, CANCER RES, V55, P1006; Meyer GE, 2001, ONCOGENE, V20, P7542, DOI 10.1038/sj.onc.1204927; Mohamed MM, 2006, NAT REV CANCER, V6, P764, DOI 10.1038/nrc1949; Nam T, 2002, ENDOCRINOLOGY, V143, P30, DOI 10.1210/en.143.1.30; Nam TJ, 2000, ENDOCRINOLOGY, V141, P1100, DOI 10.1210/en.141.3.1100; Navab R, 2001, J BIOL CHEM, V276, P13644, DOI 10.1074/jbc.M100019200; Navab R, 1997, CLIN EXP METASTAS, V15, P121, DOI 10.1023/A:1018496625936; Nguyen DT, 2004, MOL BIOL CELL, V15, P4248, DOI 10.1091/mbc.E03-11-0851; NIP J, 1995, J CLIN INVEST, V95, P2096, DOI 10.1172/JCI117897; Nomura T, 2005, J MED INVESTIG, V52, P1, DOI 10.2152/jmi.52.1; OU WJ, 1993, NATURE, V364, P771, DOI 10.1038/364771a0; PORTNOY DA, 1986, J BIOL CHEM, V261, P4697; Reinheckel T, 2005, J CELL SCI, V118, P3387, DOI 10.1242/jcs.02469; Reinheckel T, 2001, BIOL CHEM, V382, P735, DOI 10.1515/BC.2001.089; Rousselet N, 2004, CANCER RES, V64, P146, DOI 10.1158/0008-5472.CAN-03-1717; ROWAN AD, 1992, BIOL CHEM H-S, V373, P427, DOI 10.1515/bchm3.1992.373.2.427; Samani A A, 2001, Surg Oncol Clin N Am, V10, P289; Samani AA, 2004, CANCER RES, V64, P3380, DOI 10.1158/0008-5472.CAN-03-3780; SAMANI AA, 2001, SURG ONCOL CLIN N AM, V10, pR8; Samani AA, 2007, ENDOCR REV, V28, P20, DOI 10.1210/er.2006-0001; Sorkin A, 2002, NAT REV MOL CELL BIO, V3, P600, DOI 10.1038/nrm883; Turk B, 2000, BBA-PROTEIN STRUCT M, V1477, P98, DOI 10.1016/S0167-4838(99)00263-0; Wang N, 2006, CANCER RES, V66, P3062, DOI 10.1158/0008-5472.CAN-05-2638; WEXLER H, 1966, JNCI-J NATL CANCER I, V36, P641, DOI 10.1093/jnci/36.4.641; [杨啊晶 YANG Ajing], 2007, [中国新药杂志, Chinese Journal New Drugs], V16, P7; Yang M, 2007, NAT CELL BIOL, V9, P970, DOI 10.1038/ncb1623; Zhang DL, 2004, J BIOL CHEM, V279, P19683, DOI 10.1074/jbc.M313145200; Zhang DL, 2003, ONCOGENE, V22, P974, DOI 10.1038/sj.onc.1206197; Zwad O, 2002, FEBS LETT, V510, P211, DOI 10.1016/S0014-5793(01)03267-7	60	26	26	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 28	2008	27	37					4973	4985		10.1038/onc.2008.144	http://dx.doi.org/10.1038/onc.2008.144			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	344GL	18469859				2022-12-28	WOS:000258914800001
J	Sukhai, MA; Thomas, M; Xuan, Y; Chan, LSA; Hamadanizadeh, SA; Zhang, T; Bharadwaj, RR; Schuh, AC; Wells, RA; Kamel-Reid, S				Sukhai, M. A.; Thomas, M.; Xuan, Y.; Chan, L. S. A.; Hamadanizadeh, S. A.; Zhang, T.; Bharadwaj, R. R.; Schuh, A. C.; Wells, R. A.; Kamel-Reid, S.			Evidence of functional interaction between NuMA-RAR alpha and RXR alpha in an in vivo model of acute promyelocytic leukemia	ONCOGENE			English	Article							ACID RECEPTOR-ALPHA; RETINOIC ACID; FUSION PROTEINS; MYELOID-LEUKEMIA; DNA-BINDING; GENE; VARIANT; PLZF; NPM; DIFFERENTIATION	Acute promyelocytic leukemia (APL) is characterized by reciprocal balanced chromosomal translocations involving retinoic acid receptor-alpha (RAR alpha). RAR alpha heterodimerizes with the retinoid X receptor-alpha (RXR alpha) and transcriptionally regulates myeloid differentiation in response to ATRA (all-trans retinoic acid). Several lines of evidence suggest that APL fusion proteins interact with RXR alpha. To elucidate the role of RXR alpha in APL, we conditionally knocked out RXR alpha in the hCG-NuMA-RAR alpha APL mouse model. Phenotype analysis of NuMA-RAR alpha(+) mice demonstrated that these mice developed a myeloproliferative disease-like myeloid leukemia within 4 months of birth. While hemizygous and homozygous RXR alpha conditional knockout mice were phenotypically normal as late as 12 months of age, we observed that the leukemic phenotype in NuMA-RAR alpha(+) mice was dependent on the presence of functional RXR alpha. Bone marrow promyelocyte counts were significantly reduced in NuMA-RAR alpha(+) mice with RXRa knocked down. Significant differences in the accumulations of Gr-1(+) and Mac-1(+) cells were also seen. We further observed that genes previously identified to be cooperating events in APL were also regulated in an RXR alpha-dependent manner. We therefore propose that the APL fusion protein NuMA-RAR alpha cooperates with RXR alpha in the development of leukemia in hCG-NuMA-RAR alpha transgenic mice and suggest a novel role for RXR alpha in the pathogenesis of APL.	[Sukhai, M. A.; Thomas, M.; Xuan, Y.; Hamadanizadeh, S. A.; Zhang, T.; Bharadwaj, R. R.; Schuh, A. C.; Kamel-Reid, S.] Univ Hlth Network, Ontario Canc Inst, Princess Margaret Hosp, Div Appl Mol Oncol, Toronto, ON M5G 2M9, Canada; [Sukhai, M. A.; Thomas, M.; Chan, L. S. A.; Schuh, A. C.; Wells, R. A.; Kamel-Reid, S.] Univ Toronto, Dept Med Biophys, Toronto, ON, Canada; [Chan, L. S. A.; Wells, R. A.] Sunnybrook Hlth Sci Ctr, Sunnybrook Res Inst, Crashley Myelodysplast Syndrome Res Lab, Toronto, ON M4N 3M5, Canada; [Hamadanizadeh, S. A.; Kamel-Reid, S.] Univ Toronto, Inst Med Sci, Toronto, ON M5S 1A1, Canada; [Kamel-Reid, S.] Univ Toronto, Dept Lab Med & Pathobiol, Toronto, ON, Canada	University of Toronto; University Toronto Affiliates; University Health Network Toronto; Princess Margaret Cancer Centre; University of Toronto; University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; University of Toronto; University of Toronto	Kamel-Reid, S (corresponding author), Univ Hlth Network, Ontario Canc Inst, Princess Margaret Hosp, Div Appl Mol Oncol, Room 9-622,610 Univ Ave, Toronto, ON M5G 2M9, Canada.	Suzanne.Kamel-Reid@uhn.on.ca	Chan, Lap Shu/AAF-8737-2021	Chan, Lap Shu/0000-0003-1409-8638; Mathew, Mariam/0000-0003-2203-6939; Kamel-Reid, Suzanne/0000-0002-4386-0292				Arnould C, 1999, HUM MOL GENET, V8, P1741, DOI 10.1093/hmg/8.9.1741; BENNETT JM, 1976, BRIT J HAEMATOL, V33, P451, DOI 10.1111/j.1365-2141.1976.tb03563.x; BUGGE TH, 1992, EMBO J, V11, P1409, DOI 10.1002/j.1460-2075.1992.tb05186.x; CASTAIGNE S, 1990, BLOOD, V76, P1704; Catalano A, 2007, BLOOD, V110, P4073, DOI 10.1182/blood-2007-06-095554; Chen J, 1998, DEVELOPMENT, V125, P1943; CHEN Z, 1993, EMBO J, V12, P1161, DOI 10.1002/j.1460-2075.1993.tb05757.x; DETHE H, 1990, NATURE, V347, P558, DOI 10.1038/347558a0; Dong S, 2004, MOL CELL BIOL, V24, P4465, DOI 10.1128/MCB.24.10.4465-4475.2004; Hummel JL, 1999, ONCOGENE, V18, P633, DOI 10.1038/sj.onc.1202357; Hummel JL, 2002, CELL GROWTH DIFFER, V13, P173; Imai T, 2001, P NATL ACAD SCI USA, V98, P4581, DOI 10.1073/pnas.071056098; Kamashev D, 2004, J EXP MED, V199, P1163, DOI 10.1084/jem.20032226; Kamel-Reid S, 2003, ONCOGENE, V22, P6424, DOI 10.1038/sj.onc.1206696; KASTNER P, 1994, CELL, V78, P987, DOI 10.1016/0092-8674(94)90274-7; Kogan SC, 2002, BLOOD, V100, P238, DOI 10.1182/blood.V100.1.238; Kogan SC, 2001, J EXP MED, V193, P531, DOI 10.1084/jem.193.4.531; Li M, 2001, DEVELOPMENT, V128, P675; Li M, 2000, NATURE, V407, P633, DOI 10.1038/35036595; Licht JD, 1996, ONCOGENE, V12, P323; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Loonstra A, 2001, P NATL ACAD SCI USA, V98, P9209, DOI 10.1073/pnas.161269798; Minucci S, 2000, MOL CELL, V5, P811, DOI 10.1016/S1097-2765(00)80321-4; PEREZ A, 1993, EMBO J, V12, P3171, DOI 10.1002/j.1460-2075.1993.tb05986.x; Redner RL, 1996, BLOOD, V87, P882, DOI 10.1182/blood.V87.3.882.bloodjournal873882; Reis PP, 2002, ONCOGENE, V21, P6480, DOI 10.1038/sj.onc.1205864; RICOTE M, 2006, J LUEKOC BIOL, V4, P850; SHALABY F, 1995, NATURE, V376, P62, DOI 10.1038/376062a0; Silva MLM, 2005, ONCOL REP, V14, P663; So CW, 2000, LEUKEMIA, V14, P77, DOI 10.1038/sj.leu.2401643; Stephensen CB, 2007, IMMUNOLOGY, V121, P484, DOI 10.1111/j.1365-2567.2007.02595.x; Sukhai MA, 2004, ONCOGENE, V23, P665, DOI 10.1038/sj.onc.1207073; Taschner S, 2007, BLOOD, V109, P971, DOI 10.1182/blood-2006-04-020552.7; Truong BTH, 2003, BLOOD, V101, P1141, DOI 10.1182/blood-2002-05-1374; Wells RA, 1997, NAT GENET, V17, P109, DOI 10.1038/ng0997-109; Zeisig BB, 2007, CANCER CELL, V12, P36, DOI 10.1016/j.ccr.2007.06.006; Zhu J, 2007, CANCER CELL, V12, P23, DOI 10.1016/j.ccr.2007.06.004	37	11	12	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG	2008	27	34					4666	4677		10.1038/onc.2008.106	http://dx.doi.org/10.1038/onc.2008.106			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	334QM	18408763				2022-12-28	WOS:000258236300005
J	Fumoto, K; Lee, PC; Saya, H; Kikuchi, A				Fumoto, K.; Lee, P-C; Saya, H.; Kikuchi, A.			AIP regulates stability of Aurora-A at early mitotic phase coordinately with GSK-3 beta	ONCOGENE			English	Article						AIP; GSK-3 beta; Aurora; cell cycle; mitosis	GLYCOGEN-SYNTHASE KINASE-3; ADENOMATOUS POLYPOSIS-COLI; BETA-CATENIN; BICAUDAL-D; NEGATIVE REGULATOR; SIGNALING PATHWAY; PROTEIN-KINASE; CELL-DIVISION; SPINDLE; DYNEIN	Glycogen synthase kinase-3 (GSK-3 beta) regulates microtubule dynamics and cellular polarity through phosphorylating various microtubule associating proteins and plus-end tracking proteins. Although it was also reported that GSK-3 beta is inactivated by protein kinase B at the spindle poles, functions and targets of GSK-3 beta in the mitotic phase are unknown. Here, we identified Aurora-A-interacting protein (AIP), a negative regulator of Aurora-A, as a binding partner of GSK-3 beta. AIP was colocalized with Aurora-A and GSK-3 beta to the spindle poles in metaphase, and its depletion in cells stabilized and activated Aurora-A in early mitotic phase and caused mitotic cell arrest. Treatment of the cells with a GSK-3 beta inhibitor reduced the protein level of Aurora-A and this reduction was suppressed by AIP knockdown. AIP was phosphorylated by GSK-3 beta, and an AIP mutant in which the GSK-3 beta phosphorylation site was mutated could bind and downregulate Aurora-A more efficiently. These results suggest that GSK-3 beta modulates the early mitotic Aurora-A level through binding and phosphorylating AIP.	[Fumoto, K.; Lee, P-C; Kikuchi, A.] Hiroshima Univ, Grad Sch Biomed Sci, Dept Biochem, Minami Ku, Hiroshima 7348551, Japan; [Saya, H.] Keio Univ, Sch Med, Inst Adv Med Res, Div Gene Regulat, Tokyo, Japan	Hiroshima University; Keio University	Kikuchi, A (corresponding author), Hiroshima Univ, Grad Sch Biomed Sci, Dept Biochem, Minami Ku, 1-2-3 Kasumi, Hiroshima 7348551, Japan.	akikuchi@hiroshima-u.ac.jp	Saya, Hideyuki/J-4325-2013; Lee, Ping Chin/AGV-4612-2022	Lee, Ping Chin/0000-0002-4280-0829				Bischoff JR, 1998, EMBO J, V17, P3052, DOI 10.1093/emboj/17.11.3052; Cohen P, 2001, NAT REV MOL CELL BIO, V2, P769, DOI 10.1038/35096075; Doble BW, 2003, J CELL SCI, V116, P1175, DOI 10.1242/jcs.00384; Etienne-Manneville S, 2003, NATURE, V421, P753, DOI 10.1038/nature01423; Fumoto K, 2006, EMBO J, V25, P5670, DOI 10.1038/sj.emboj.7601459; Gruss OJ, 2002, NAT CELL BIOL, V4, P871, DOI 10.1038/ncb870; Hino S, 2003, J BIOL CHEM, V278, P14066, DOI 10.1074/jbc.M213265200; Hirota T, 2003, CELL, V114, P585, DOI 10.1016/S0092-8674(03)00642-1; Hoogenraad CC, 2001, EMBO J, V20, P4041, DOI 10.1093/emboj/20.15.4041; Hoogenraad CC, 2003, EMBO J, V22, P6004, DOI 10.1093/emboj/cdg592; Ikeda S, 1998, EMBO J, V17, P1371, DOI 10.1093/emboj/17.5.1371; Kiat LS, 2002, J BIOL CHEM, V277, P45558, DOI 10.1074/jbc.M206820200; Kimura M, 1997, J BIOL CHEM, V272, P13766, DOI 10.1074/jbc.272.21.13766; Kobayashi T, 2006, MOL CELL BIOL, V26, P898, DOI 10.1128/MCB.26.3.898-911.2006; Kufer TA, 2002, J CELL BIOL, V158, P617, DOI 10.1083/jcb.200204155; Kunitoku N, 2003, DEV CELL, V5, P853, DOI 10.1016/S1534-5807(03)00364-2; Lim SK, 2007, BIOCHEM J, V403, P119, DOI 10.1042/BJ20061272; Marumoto T, 2005, NAT REV CANCER, V5, P42, DOI 10.1038/nrc1526; Matanis T, 2002, NAT CELL BIOL, V4, P986, DOI 10.1038/ncb891; Meraldi P, 2004, CURR OPIN GENET DEV, V14, P29, DOI 10.1016/j.gde.2003.11.006; PLYTE SE, 1992, BIOCHIM BIOPHYS ACTA, V1114, P147, DOI 10.1016/0304-419X(92)90012-N; Sarkissian M, 2004, GENE DEV, V18, P48, DOI 10.1101/gad.1136004; Stenoien DL, 2003, CELL MOTIL CYTOSKEL, V55, P134, DOI 10.1002/cm.10120; SUTER B, 1989, GENE DEV, V3, P1957, DOI 10.1101/gad.3.12a.1957; Tanji C, 2002, J BIOL CHEM, V277, P36955, DOI 10.1074/jbc.M206210200; Tighe A, 2007, BMC CELL BIOL, V8, DOI 10.1186/1471-2121-8-34; Tsai MY, 2003, NAT CELL BIOL, V5, P242, DOI 10.1038/ncb936; Wakefield JG, 2003, J CELL SCI, V116, P637, DOI 10.1242/jcs.00273; Yamamoto H, 2003, EMBO J, V22, P2047, DOI 10.1093/emboj/cdg204; Yamamoto H, 1998, MOL CELL BIOL, V18, P2867, DOI 10.1128/MCB.18.5.2867; Zachariae W, 1999, GENE DEV, V13, P2039, DOI 10.1101/gad.13.16.2039; Zumbrunn J, 2001, CURR BIOL, V11, P44, DOI 10.1016/S0960-9822(01)00002-1	32	16	16	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 24	2008	27	32					4478	4487		10.1038/onc.2008.92	http://dx.doi.org/10.1038/onc.2008.92			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	329PU	18391981				2022-12-28	WOS:000257881700010
J	Arden, KC				Arden, K. C.			FOXO animal models reveal a variety of diverse roles for FOXO transcription factors	ONCOGENE			English	Review						FOXO; FKHR; daf-16; dFoxo; animal models	CAENORHABDITIS-ELEGANS; INSULIN-RECEPTOR; OXIDATIVE STRESS; LIFE-SPAN; FAT-BODY; MICE; DROSOPHILA; LONGEVITY; DAF-16; CELLS	The Foxo subfamily of FOX transcription factors plays a variety of roles in a broad assortment of diverse physiological processes including cellular differentiation, tumor suppression, metabolism, cell cycle arrest, cell death and protection from stress. Animal models have proved to be invaluable tools in furthering our understanding of the role of particular genes in complex organismal processes. Multiple animal models in diverse species, including Caenorhabditis elegans, Drosophila. melanogaster and the laboratory mouse, exist for the Foxo family of transcription factors. Foxo genes are highly conserved throughout the evolution and each of these model systems has provided valuable insight into the roles of Foxo factors. Many roles are conserved among the different model organisms. Several Foxo-related animal model systems are reviewed here along with the knowledge gleaned to date from each model system.	Univ Calif San Diego, Ludwig Inst Canc Res, Dept Med, Sch Med, La Jolla, CA 92093 USA	Ludwig Institute for Cancer Research; University of California System; University of California San Diego	Arden, KC (corresponding author), Univ Calif San Diego, Ludwig Inst Canc Res, Dept Med, Sch Med, 9500 Gilman Dr,0660, La Jolla, CA 92093 USA.	karden@ucsd.edu						Adachi M, 2007, GASTROENTEROLOGY, V132, P1434, DOI 10.1053/j.gastro.2007.01.033; Arden KC, 2006, EXP GERONTOL, V41, P709, DOI 10.1016/j.exger.2006.05.015; Castrillon DH, 2003, SCIENCE, V301, P215, DOI 10.1126/science.1086336; Furuyama T, 2004, J BIOL CHEM, V279, P34741, DOI 10.1074/jbc.M314214200; Giannakou ME, 2004, SCIENCE, V305, P361, DOI 10.1126/science.1098219; GIANNAKOU ME, 2007, DROSOPHILA AGING CEL, V6, P429; Greer EL, 2005, ONCOGENE, V24, P7410, DOI 10.1038/sj.onc.1209086; Hosaka T, 2004, P NATL ACAD SCI USA, V101, P2975, DOI 10.1073/pnas.0400093101; Hwangbo DS, 2004, NATURE, V429, P562, DOI 10.1038/nature02549; Jacobs FMJ, 2003, J BIOL CHEM, V278, P35959, DOI 10.1074/jbc.M302804200; Junger Martin A, 2003, J Biol, V2, P20, DOI 10.1186/1475-4924-2-20; Kamei Y, 2004, J BIOL CHEM, V279, P41114, DOI 10.1074/jbc.M400674200; KENYON C, 1993, NATURE, V366, P461, DOI 10.1038/366461a0; Kitamura T, 2002, J CLIN INVEST, V110, P1839, DOI 10.1172/JCI200216857; Kops GJPL, 2002, NATURE, V419, P316, DOI 10.1038/nature01036; Kramer Jamie M, 2003, BMC Dev Biol, V3, P5, DOI 10.1186/1471-213X-3-5; Lin K, 1997, SCIENCE, V278, P1319, DOI 10.1126/science.278.5341.1319; Lin L, 2004, IMMUNITY, V21, P203, DOI 10.1016/j.immuni.2004.06.016; Mukhopadhyay A, 2007, TRENDS CELL BIOL, V17, P65, DOI 10.1016/j.tcb.2006.12.004; Murakami S, 1996, GENETICS, V143, P1207; Nakae J, 2003, DEV CELL, V4, P119, DOI 10.1016/S1534-5807(02)00401-X; Nakai J, 2002, NAT GENET, V32, P245, DOI 10.1038/ng890; Ogg S, 1997, NATURE, V389, P994, DOI 10.1038/40194; Paik JH, 2007, CELL, V128, P309, DOI 10.1016/j.cell.2006.12.029; Paradis S, 1998, GENE DEV, V12, P2488, DOI 10.1101/gad.12.16.2488; Puig O, 2005, GENE DEV, V19, P2435, DOI 10.1101/gad.1340505; Puig O, 2003, GENE DEV, V17, P2006, DOI 10.1101/gad.1098703; RIDDLE DL, 1981, NATURE, V290, P268; Tothova Z, 2007, CELL, V128, P325, DOI 10.1016/j.cell.2007.01.003; Vogel G, 2007, SCIENCE, V318, P178, DOI 10.1126/science.318.5848.178	30	119	123	1	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 7	2008	27	16					2345	2350		10.1038/onc.2008.27	http://dx.doi.org/10.1038/onc.2008.27			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	285NE	18391976				2022-12-28	WOS:000254782700009
J	Woo, HH; Zhou, Y; Yi, X; David, CL; Zheng, W; Gilmore-Hebert, M; Kluger, HM; Ulukus, EC; Baker, T; Stoffer, JB; Chambers, SK				Woo, H-H; Zhou, Y.; Yi, X.; David, C. L.; Zheng, W.; Gilmore-Hebert, M.; Kluger, H. M.; Ulukus, E. C.; Baker, T.; Stoffer, J. B.; Chambers, S. K.			Regulation of non-AU-rich element containing c-fms proto-oncogene expression by HuR in breast cancer	ONCOGENE			English	Article						breast cancer; c-fms proto-oncogene; post-transcriptional regulation; HuR	MESSENGER-RNA STABILITY; STIMULATING FACTOR-1 RECEPTOR; CSF-1 RECEPTOR; BINDING PROTEIN; POSTTRANSCRIPTIONAL REGULATION; CYCLOOXYGENASE-2 EXPRESSION; MONOCYTIC DIFFERENTIATION; QUANTITATIVE-ANALYSIS; CROSS-LINKING; CARCINOMA	The role of RNA-binding proteins in cancer biology is recognized increasingly. The nucleocytoplasmic shuttling and AU-rich RNA-binding protein HuR stabilizes several cancer-related target mRNAs. The proto-oncogene c-fms, whose 3'untranslated region (3'UTR) is not AU-rich, is associated with poor prognosis in breast cancer. Using a large breast-cancer tissue array (N=670), we found nuclear HuR expression to be associated with nodal metastasis and independently with poor survival (P=0.03, RR 1.45), as well as to be co-expressed with c-fms in the breast tumors (P=0.0007). We described c-fms mRNA as a direct target of HuR in vivo, and that HuR bound specifically to a 69-nt region containing 'CUU' motifs in 3'UTR c-fms RNA. Overexpressing or silencing HuR significantly up-or down-regulated c-fms RNA expression, respectively. We also found that known glucocorticoid stimulation of c-fms RNA and protein is largely dependent on the presence of HuR. HuR, by binding to the 69-nt wild type, but not mutant, c-fms sequence can regulate reporter gene expression post-transcriptionally. We are the first to describe that HuR can regulate gene expression by binding non-AU-rich sequences in 3'UTR c-fms RNA. Collectively, our findings suggest that HuR plays a supportive role for c-fms in breast cancer progression by binding a 69-nt element in its 3'UTR, thus regulating its expression.	[Woo, H-H; Zhou, Y.; Yi, X.; David, C. L.; Zheng, W.; Baker, T.; Stoffer, J. B.; Chambers, S. K.] Univ Arizona, Arizona Canc Ctr, Tucson, AZ 85724 USA; [Gilmore-Hebert, M.] Yale Univ, Sch Med, Dept Pathol, New Haven, CT 06510 USA; [Ulukus, E. C.] Dokuz Eylul Univ, Izmir, Turkey	Arizona Center Cancer Care; University of Arizona; Yale University; Dokuz Eylul University	Chambers, SK (corresponding author), Univ Arizona, Arizona Canc Ctr, POB 245024, Tucson, AZ 85724 USA.	schambers@azcc.arizona.edu			Department of Defense [DAMD 17-02-1-0633]; Susan G Komen Breast Cancer Foundation; Breast Cancer Alliance	Department of Defense(United States Department of Defense); Susan G Komen Breast Cancer Foundation(Susan G. Komen Breast Cancer Foundation); Breast Cancer Alliance	This work was supported by Department of Defense Grant DAMD 17-02-1-0633 ( to SKC), and in part by the Susan G Komen Breast Cancer Foundation and by the Breast Cancer Alliance ( to HMK). We thank Joan A Steitz for providing the GST plasmids, and Ite A Laird-Offringa for providing purified HuR protein.	Abdelmohsen K, 2007, MOL CELL, V25, P543, DOI 10.1016/j.molcel.2007.01.011; ALLEGRA JC, 1979, CANCER RES, V39, P1447; Apponi LH, 2007, MOL CELL BIOL, V27, P6569, DOI 10.1128/MCB.00881-07; Brennan CM, 2001, CELL MOL LIFE SCI, V58, P266, DOI 10.1007/PL00000854; Camp RL, 2003, CANCER RES, V63, P1445; Camp RL, 2000, LAB INVEST, V80, P1943, DOI 10.1038/labinvest.3780204; Chambers SK, 1997, CLIN CANCER RES, V3, P999; Chambers SK, 2004, AM J OBSTET GYNECOL, V190, P974, DOI 10.1016/j.ajog.2004.01.021; CHAMBERS SK, 1993, EXP HEMATOL, V21, P1328; CHAMBERS SK, 1994, STEROIDS, V59, P514, DOI 10.1016/0039-128X(94)90069-8; Chen CYA, 2002, MOL CELL BIOL, V22, P7268, DOI 10.1128/MCB.22.20.7268-7278.2002; COUSSENS L, 1986, NATURE, V320, P277, DOI 10.1038/320277a0; De Boer P, 2006, RNA, V12, P263, DOI 10.1261/rna.2257606; de Silanes IL, 2004, P NATL ACAD SCI USA, V101, P2987, DOI 10.1073/pnas.0306453101; de Silanes IL, 2003, ONCOGENE, V22, P7146, DOI 10.1038/sj.onc.1206862; Denkert C, 2004, CLIN CANCER RES, V10, P5580, DOI 10.1158/1078-0432.CCR-04-0070; Erkinheimo TL, 2003, CANCER RES, V63, P7591; Fan XHC, 1998, EMBO J, V17, P3448, DOI 10.1093/emboj/17.12.3448; Gallouzi IE, 2001, SCIENCE, V294, P1895, DOI 10.1126/science.1064693; GOTT JM, 1991, BIOCHEMISTRY-US, V30, P6290, DOI 10.1021/bi00239a030; Heinonen M, 2005, CANCER RES, V65, P2157, DOI 10.1158/0008-5472.CAN-04-3765; Ide H, 2002, P NATL ACAD SCI USA, V99, P14404, DOI 10.1073/pnas.222537099; Kacinski BM, 2001, J SOC GYNECOL INVEST, V8, P114, DOI 10.1016/S1071-5576(01)00092-2; KACINSKI BM, 1991, ONCOGENE, V6, P941; Kluger HM, 2004, CLIN CANCER RES, V10, P173, DOI 10.1158/1078-0432.CCR-0699-3; Lal A, 2004, EMBO J, V23, P3092, DOI 10.1038/sj.emboj.7600305; Lin EY, 2001, J EXP MED, V193, P727, DOI 10.1084/jem.193.6.727; Maher MG, 1998, CLIN CANCER RES, V4, P1851; Meisner NC, 2004, CHEMBIOCHEM, V5, P1432, DOI 10.1002/cbic.200400219; Moore MJ, 2002, CELL, V108, P431, DOI 10.1016/S0092-8674(02)00645-1; Nabors LB, 2001, CANCER RES, V61, P2154; Peng SSY, 1998, EMBO J, V17, P3461, DOI 10.1093/emboj/17.12.3461; Peritz T, 2006, NAT PROTOC, V1, P577, DOI 10.1038/nprot.2006.82; SAPI E, 1995, ONCOGENE, V10, P529; Sapi E, 1996, CANCER RES, V56, P5704; STOLOW DT, 1990, MOL CELL BIOL, V10, P5937, DOI 10.1128/MCB.10.11.5937; Sureban SM, 2007, GASTROENTEROLOGY, V132, P1055, DOI 10.1053/j.gastro.2006.12.031; Toy EP, 2005, CLIN EXP METASTAS, V22, P1, DOI 10.1007/s10585-005-0718-4; Urlaub H, 2000, J BIOL CHEM, V275, P41458, DOI 10.1074/jbc.M007434200; WEBER B, 1989, MOL CELL BIOL, V9, P769, DOI 10.1128/MCB.9.2.769; Wein G, 2003, EUR J BIOCHEM, V270, P350, DOI 10.1046/j.1432-1033.2003.03396.x; Yeap BB, 2002, J BIOL CHEM, V277, P27183, DOI 10.1074/jbc.M202883200	42	29	30	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 5	2009	28	9					1176	1186		10.1038/onc.2008.469	http://dx.doi.org/10.1038/onc.2008.469			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	415AH	19151756				2022-12-28	WOS:000263906200002
J	Veuger, SJ; Hunter, JE; Durkacz, BW				Veuger, S. J.; Hunter, J. E.; Durkacz, B. W.			Ionizing radiation-induced NF-kappa B activation requires PARP-1 function to confer radioresistance	ONCOGENE			English	Article						NF-kappa B; PARP-1; ionizing radiation	ADP-RIBOSE POLYMERASE-1; APOPTOSIS PROTEIN XIAP; BREAST-CANCER CELLS; X-LINKED INHIBITOR; POLY(ADP-RIBOSE) POLYMERASE-1; TRANSCRIPTION FACTORS; THERAPEUTIC TARGET; BINDING-ACTIVITY; GENE-EXPRESSION; TUMOR-CELLS	Recent reports implicate poly(ADP-ribose) polymerase-1 (PARP-1) in the activation of nuclear factor kappaB (NF-kappa B). We investigated the role of PARP-1 in the NF-kappa B signalling cascade induced by ionizing radiation (IR). AG14361, a potent PARP-1 inhibitor, was used in two breast cancer cell lines expressing different levels of constitutively activated NF-kappa B, as well as mouse embryonic fibroblasts (MEFs) proficient or deficient for PARP-1 or NF-kappa B p65. In the breast cancer cell lines, AG14361 had no effect on IR-induced degradation of I kappa B alpha or nuclear translocation of p50 or p65. However, AG14361 inhibited IR-induced NF-kappa B-dependent transcription of a luciferase reporter gene. Similarly, in PARP-1(-/-) MEFs, IR-induced nuclear translocation of p50 and p65 was normal, but kappa B binding and transcriptional activation did not occur. AG14361 sensitized both breast cancer cell lines to IR-induced cell killing, inhibited IR-induced XIAP expression and increased caspase-3 activity. However, AG14361 failed to increase IR-induced caspase activity when p65 was knocked down by siRNA. Consistent with this, AG14361 sensitized p65(+/+) but not p65(-/-) MEFs to IR. We conclude that PARP-1 activity is essential in the upstream regulation of IR-induced NF-kappa B activation. These data indicate that potentiation of IR-induced cytotoxicity by AG14361 is mediated solely by inhibition of NF-kappa B activation.	[Veuger, S. J.; Hunter, J. E.; Durkacz, B. W.] Univ Newcastle, No Inst Canc Res, Sch Med, Newcastle Upon Tyne, Tyne & Wear, England	Newcastle University - UK	Durkacz, BW (corresponding author), Newcastle Univ, No Inst Canc Res, Sch Med, Paul OGorman Bldg, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.	b.w.durkacz@newcastle.ac.uk			Breast Cancer Campaign, UK; Cancer Research UK	Breast Cancer Campaign, UK; Cancer Research UK(Cancer Research UK)	This work was supported by the Breast Cancer Campaign, UK and Cancer Research UK.	ALTHAUS FR, 1994, MOL CELL BIOCHEM, V138, P53, DOI 10.1007/BF00928443; Andela VB, 2000, CANCER RES, V60, P6557; Barkett M, 1999, ONCOGENE, V18, P6910, DOI 10.1038/sj.onc.1203238; Basseres DS, 2006, ONCOGENE, V25, P6817, DOI 10.1038/sj.onc.1209942; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; Biswas DK, 2004, P NATL ACAD SCI USA, V101, P10137, DOI 10.1073/pnas.0403621101; Biswas DK, 2001, P NATL ACAD SCI USA, V98, P10386, DOI 10.1073/pnas.151257998; BRACH MA, 1991, J CLIN INVEST, V88, P691, DOI 10.1172/JCI115354; Calabrese CR, 2004, J NATL CANCER I, V96, P56, DOI 10.1093/jnci/djh005; Cao YX, 2003, J MAMMARY GLAND BIOL, V8, P215, DOI 10.1023/A:1025905008934; Cardoso SM, 2003, FREE RADICAL RES, V37, P967, DOI 10.1080/10715760310001595757; Carrillo A, 2004, NUCLEIC ACIDS RES, V32, P757, DOI 10.1093/nar/gkh239; Chalmers A, 2004, INT J RADIAT ONCOL, V58, P410, DOI 10.1016/j.ijrobp.2003.09.053; Chang WJ, 2001, J BIOL CHEM, V276, P47664, DOI 10.1074/jbc.M104666200; Chiarugi A, 2003, J NEUROCHEM, V85, P306, DOI 10.1046/j.1471-4159.2003.01684.x; Concin N, 2003, BREAST CANCER RES TR, V79, P37, DOI 10.1023/A:1023351717408; Criswell T, 2003, ONCOGENE, V22, P5813, DOI 10.1038/sj.onc.1206680; Dan HC, 2004, J BIOL CHEM, V279, P5405, DOI 10.1074/jbc.M312044200; Deveraux QL, 1999, EMBO J, V18, P5242, DOI 10.1093/emboj/18.19.5242; Ferreira CG, 2001, ANN ONCOL, V12, P799, DOI 10.1023/A:1011167113067; Ghosh S, 2002, CELL, V109, pS81, DOI 10.1016/S0092-8674(02)00703-1; GRUBE K, 1991, ANAL BIOCHEM, V193, P236, DOI 10.1016/0003-2697(91)90015-L; Hassa PO, 2005, J BIOL CHEM, V280, P40450, DOI 10.1074/jbc.M507553200; Hassa PO, 1999, BIOL CHEM, V380, P953, DOI 10.1515/BC.1999.118; Hassa PO, 2001, J BIOL CHEM, V276, P45588, DOI 10.1074/jbc.M106528200; Holcik M, 2001, APOPTOSIS, V6, P253, DOI 10.1023/A:1011379307472; Jung M, 2001, SEMIN RADIAT ONCOL, V11, P346, DOI 10.1053/srao.2001.26034; Kraus WL, 2003, CELL, V113, P677, DOI 10.1016/S0092-8674(03)00433-1; Martin-Oliva D, 2006, CANCER RES, V66, P5744, DOI 10.1158/0008-5472.CAN-05-3050; Nakajima H, 2004, J BIOL CHEM, V279, P42774, DOI 10.1074/jbc.M407923200; Nakshatri H, 1997, MOL CELL BIOL, V17, P3629, DOI 10.1128/MCB.17.7.3629; Oliver FJ, 1999, EMBO J, V18, P4446, DOI 10.1093/emboj/18.16.4446; Pande V, 2005, CURR MED CHEM, V12, P357, DOI 10.2174/0929867053363180; Patel NM, 2000, ONCOGENE, V19, P4159, DOI 10.1038/sj.onc.1203768; Penolazzi L, 2003, BIOCHEM PHARMACOL, V66, P1189, DOI 10.1016/S0006-2952(03)00470-2; Perkins ND, 2006, ONCOGENE, V25, P6717, DOI 10.1038/sj.onc.1209937; Pratt MAC, 2003, MOL CELL BIOL, V23, P6887, DOI 10.1128/MCB.23.19.6887-6900.2003; Raju U, 1998, INT J RADIAT BIOL, V74, P617, DOI 10.1080/095530098141195; Rayet B, 1999, ONCOGENE, V18, P6938, DOI 10.1038/sj.onc.1203221; Russo SM, 2001, INT J RADIAT ONCOL, V50, P183, DOI 10.1016/S0360-3016(01)01446-8; Scott FL, 2005, EMBO J, V24, P645, DOI 10.1038/sj.emboj.7600544; Skalitzky DJ, 2003, J MED CHEM, V46, P210, DOI 10.1021/jm0255769; Smith S, 2001, TRENDS BIOCHEM SCI, V26, P174, DOI 10.1016/S0968-0004(00)01780-1; Sovak MA, 1997, J CLIN INVEST, V100, P2952, DOI 10.1172/JCI119848; Veuger SJ, 2003, CANCER RES, V63, P6008; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; Webster GA, 1999, MOL CELL BIOL, V19, P3485; Wu JT, 2005, J SURG RES, V123, P158, DOI 10.1016/j.jss.2004.06.006; Xiao CW, 2001, ENDOCRINOLOGY, V142, P557, DOI 10.1210/en.142.2.557; Yang L, 2003, CANCER RES, V63, P6815; Zhou YM, 2005, INT J BIOCHEM CELL B, V37, P1130, DOI 10.1016/j.biocel.2004.09.006	52	99	108	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2009	28	6					832	842		10.1038/onc.2008.439	http://dx.doi.org/10.1038/onc.2008.439			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	406UI	19060926	Green Accepted			2022-12-28	WOS:000263320000006
J	Chen, RS; Song, YM; Zhou, ZY; Tong, T; Li, Y; Fu, M; Guo, XL; Dong, LJ; He, X; Qiao, HX; Zhan, QM; Li, W				Chen, R-S; Song, Y-M; Zhou, Z-Y; Tong, T.; Li, Y.; Fu, M.; Guo, X-L; Dong, L-J; He, X.; Qiao, H-X; Zhan, Q-M; Li, W.			Disruption of xCT inhibits cancer cell metastasis via the caveolin-1/beta-catenin pathway	ONCOGENE			English	Article						xCT/SLC7A11; cancer; metastasis; caveolin-1; beta-catenin; oxidative stress	BETA-CATENIN; DOWN-REGULATION; PREMATURE SENESCENCE; TYROSINE KINASES; OXIDATIVE STRESS; PLASMA-MEMBRANE; CYSTINE UPTAKE; E-CADHERIN; CAVEOLIN-1; PROTEIN	xCT, the functional subunit of the cystine/glutamate transporter xc- system, plays a critical role in the maintenance of intracellular glutathione and redox balance. Disruption of xCT significantly inhibits the growth of a variety of carcinomas, including lymphoma, glioma, prostate and breast cancer. However, the role of xCT in tumor metastasis remains largely unknown. In this study, both xCT(+/+) and xCT(-/-) melanocytes were used to evaluate the role of xCT in adhesion. xCT activity was suppressed by an inhibitor, sulfasalazine (SASP), or by xCT siRNA in an esophageal cancer cell line, KYSE150. We found that disruption of xCT enhanced homotypic cell-cell adhesion and attenuated cell-extracellular matrix adhesion. SASP significantly inhibited both cell invasion of KYSE150 in vitro and its experimental metastasis in nude mice. Caveolin-1 was upregulated and beta-catenin was recruited to the plasma membrane when xCT was deficient, which were followed by the inhibition of beta-catenin transcriptional activity. Further study revealed that the upregulation of caveolin-1 and inhibition of tumor cell invasion were mediated by reactive oxygen species-induced p38 MAPK activation. These results first establish the role of xCT in tumor metastasis and implicate a potential target for cancer therapy.	[Chen, R-S; Zhou, Z-Y; Li, Y.; Guo, X-L; He, X.; Qiao, H-X; Li, W.] Chinese Acad Sci, Inst Genet & Dev Biol, Key Lab Mol & Dev Biol, Beijing 100101, Peoples R China; [Chen, R-S; Li, Y.; Guo, X-L] Chinese Acad Sci, Grad Univ, Beijing 100101, Peoples R China; [Chen, R-S] Fujian Acad Agr Sci, Ctr Biotechnol, Fuzhou, Fujian, Peoples R China; [Song, Y-M; Tong, T.; Fu, M.; Dong, L-J; Zhan, Q-M] Peking Union Med Coll, Canc Inst Hosp, State Key Lab Mol Oncol, Beijing 100021, Peoples R China; [Song, Y-M; Tong, T.; Fu, M.; Dong, L-J; Zhan, Q-M] Chinese Acad Med Sci, Beijing 100037, Peoples R China	Chinese Academy of Sciences; Institute of Genetics & Developmental Biology, CAS; Chinese Academy of Sciences; University of Chinese Academy of Sciences, CAS; Fujian Academy of Agricultural Sciences; Chinese Academy of Medical Sciences - Peking Union Medical College; Cancer Institute & Hospital - CAMS; Peking Union Medical College; Chinese Academy of Medical Sciences - Peking Union Medical College	Li, W (corresponding author), Chinese Acad Sci, Inst Genet & Dev Biol, Key Lab Mol & Dev Biol, Datun Rd, Beijing 100101, Peoples R China.	zhanqimin@pumc.edu.cn; wli@genetics.ac.cn	Guo, Xiaoli/O-3906-2014		National Basic Research Program of China [2006CB504100, 2006CB500700, 2007CB947200]; National Natural Science Foundation of China [30525007, 30730049]	National Basic Research Program of China(National Basic Research Program of China); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	We thank Dr Richard T Swank and Dr Edward K Novak for their invaluable comments on this paper. This study was supported in part by National Basic Research Program of China (2006CB504100, 2006CB500700 and 2007CB947200), grants from National Natural Science Foundation of China (30525007 and 30730049) (to WL or XH).	Chintala S, 2005, P NATL ACAD SCI USA, V102, P10964, DOI 10.1073/pnas.0502856102; Chung WJ, 2005, J NEUROSCI, V25, P7101, DOI 10.1523/JNEUROSCI.5258-04.2005; Couet J, 1997, J BIOL CHEM, V272, P30429, DOI 10.1074/jbc.272.48.30429; Dasari A, 2006, CANCER RES, V66, P10805, DOI 10.1158/0008-5472.CAN-06-1236; Doxsee DW, 2007, PROSTATE, V67, P162, DOI 10.1002/pros.20508; Estrela JM, 2006, CRIT REV CL LAB SCI, V43, P143, DOI 10.1080/10408360500523878; Fiucci G, 2002, ONCOGENE, V21, P2365, DOI 10.1038/sj.onc.1205300; Galbiati F, 2000, J BIOL CHEM, V275, P23368, DOI 10.1074/jbc.M002020200; Gottardi CJ, 2001, CURR BIOL, V11, pR792, DOI 10.1016/S0960-9822(01)00473-0; Gout PW, 2001, LEUKEMIA, V15, P1633, DOI 10.1038/sj.leu.2402238; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; Huang Y, 2005, CANCER RES, V65, P7446, DOI 10.1158/0008-5472.CAN-04-4267; Ji J, 2007, ONCOGENE, V26, P6396, DOI 10.1038/sj.onc.1210469; Kim JY, 2001, BBA-BIOMEMBRANES, V1512, P335, DOI 10.1016/S0005-2736(01)00338-8; Lastro M, 2008, CELL SIGNAL, V20, P390, DOI 10.1016/j.cellsig.2007.10.030; Lee DF, 2007, CELL, V130, P440, DOI 10.1016/j.cell.2007.05.058; Lehrbach Dárcio Matenhauer, 2003, Arq. Gastroenterol., V40, P256, DOI 10.1590/S0004-28032003000400011; Li SW, 1996, J BIOL CHEM, V271, P29182, DOI 10.1074/jbc.271.46.29182; Liu H, 2007, ONCOGENE, V26, P5900, DOI 10.1038/sj.onc.1210400; Lu ZM, 2004, CELL CYCLE, V3, P571; Lu ZM, 2003, CANCER CELL, V4, P499, DOI 10.1016/S1535-6108(03)00304-0; Lyons SA, 2007, CANCER RES, V67, P9463, DOI 10.1158/0008-5472.CAN-07-2034; Mehlen P, 2006, NAT REV CANCER, V6, P449, DOI 10.1038/nrc1886; Morin PJ, 1999, BIOESSAYS, V21, P1021, DOI 10.1002/(SICI)1521-1878(199912)22:1<1021::AID-BIES6>3.0.CO;2-P; Narang VS, 2003, ANTICANCER RES, V23, P4571; Okamoto T, 1998, J BIOL CHEM, V273, P5419, DOI 10.1074/jbc.273.10.5419; Peifer M, 2000, SCIENCE, V287, P1606, DOI 10.1126/science.287.5458.1606; Peifer M, 1997, SCIENCE, V275, P1752, DOI 10.1126/science.275.5307.1752; Piedra J, 2003, MOL CELL BIOL, V23, P2287, DOI 10.1128/MCB.23.7.2287-2297.2003; Qiao HX, 2008, BIOCHEM BIOPH RES CO, V370, P584, DOI 10.1016/j.bbrc.2008.03.134; Roberson B, 2006, ECON THEOR, V29, P1, DOI 10.1007/s00199-005-0071-5; ROTHBERG KG, 1992, CELL, V68, P673, DOI 10.1016/0092-8674(92)90143-Z; Sahai E, 2007, NAT REV CANCER, V7, P737, DOI 10.1038/nrc2229; Sato H, 1999, J BIOL CHEM, V274, P11455, DOI 10.1074/jbc.274.17.11455; Sato H, 2000, ANTIOXID REDOX SIGN, V2, P665, DOI 10.1089/ars.2000.2.4-665; Shao SJ, 2006, J BIOL CHEM, V281, P28943, DOI 10.1074/jbc.M600235200; Shtutman M, 1999, P NATL ACAD SCI USA, V96, P5522, DOI 10.1073/pnas.96.10.5522; STETLERSTEVENSON WG, 1993, ANNU REV CELL BIOL, V9, P541, DOI 10.1146/annurev.cb.09.110193.002545; Stoner GD, 2001, CARCINOGENESIS, V22, P1737, DOI 10.1093/carcin/22.11.1737; Tominaga J, 2008, GENES CELLS, V13, P67, DOI 10.1111/j.1365-2443.2007.01149.x; Torres VA, 2007, MOL CELL BIOL, V27, P7703, DOI 10.1128/MCB.01991-06; Volonte D, 1999, FEBS LETT, V445, P431, DOI 10.1016/S0014-5793(99)00164-7; Volonte D, 2002, MOL BIOL CELL, V13, P2502, DOI 10.1091/mbc.01-11-0529; Wiechen K, 2001, AM J PATHOL, V158, P833, DOI 10.1016/S0002-9440(10)64031-X	44	113	121	0	26	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 29	2009	28	4					599	609		10.1038/onc.2008.414	http://dx.doi.org/10.1038/onc.2008.414			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	400KM	19015640				2022-12-28	WOS:000262866500013
J	Ametzazurra, A; Larrea, E; Civeira, MP; Prieto, J; Aldabe, R				Ametzazurra, A.; Larrea, E.; Civeira, M. P.; Prieto, J.; Aldabe, R.			Implication of human N-alpha-acetyltransferase 5 in cellular proliferation and carcinogenesis	ONCOGENE			English	Article						N-alpha-acetyltransferase; hNAT5/hNAT3; cellular proliferation; tumour progression	DIET-DEPENDENT CARCINOGENESIS; STRESS-INDUCED APOPTOSIS; TERMINAL ACETYLTRANSFERASES; RNA INTERFERENCE; TRANSGENIC MICE; P53; IDENTIFICATION; PROTEIN; GENES; YEAST	The N-alpha-acetyltransferase NatB, composed in Saccharomyces cerevisiae by the Nat3p and Mdm20p subunits, is an important factor for yeast growth and resistance to several stress agents. However, the expression and functional role of the mammalian counterpart has not yet been analysed. Here, we report the identification of Nat3p human homologue (hNAT5/hNAT3) and the characterization of its biological function. We found that hNAT5/hNAT3 silencing in HeLa cells results in inhibition of cell proliferation and increased sensitivity to the pro-apoptotic agent MG132. Moreover, inhibition of hNAT5/hNAT3 expression induces p53 activation and upregulation of the antiproliferative protein p21(WAF1/CIP1). The changes of the cellular transcriptome after hNAT5/hNAT3 knockdown confirmed the involvement of this protein in cell growth and survival processes. Among the genes differentially expressed, we observed upregulation of several p53-dependent antiproliferative and pro-apoptotic genes. In the c-myc transgenic mice, which is a model of inducible hepatocarcinoma, we found that hNAT5/hNAT3 was upregulated when the tumour was induced. In accordance with this observation, we noticed increased hNAT5/hNAT3 protein level in neoplastic versus non-neoplastic tissue in a high proportion of patients with hepatocellular carcinoma. Consequently, our results suggest that hNAT5/hNAT3 is required for cellular proliferation and can be implicated in tumour growth.	[Ametzazurra, A.; Larrea, E.; Prieto, J.; Aldabe, R.] Univ Navarra, CIMA, Div Gene Therapy & Hepatol, Pamplona 31008, Spain; [Civeira, M. P.; Prieto, J.] CIBER EHD, Clin Univ, Liver Unit, Pamplona, Spain	University of Navarra; CIBER - Centro de Investigacion Biomedica en Red; CIBEREHD; University of Navarra	Aldabe, R (corresponding author), Univ Navarra, CIMA, Div Gene Therapy & Hepatol, Ave Pio 12,55, Pamplona 31008, Spain.	raldabe@unav.es	Aldabe, Rafael/F-3112-2015; Larrea, Esther/L-7586-2014	Aldabe, Rafael/0000-0002-9461-020X; Larrea, Esther/0000-0002-1443-6513; Prieto, Jesus/0000-0002-1091-9593	FPU [AP2001-1567]; FIS; Instituto de Salud Carlos III; Ministerio de Sanidad y Consumo [02/3054]; Departamento de Educacion; Gobierno de Navarra (GNE-Enzima N); UTE	FPU(Spanish Government); FIS(Instituto de Salud Carlos III); Instituto de Salud Carlos III(Instituto de Salud Carlos IIIEuropean Commission); Ministerio de Sanidad y Consumo(Instituto de Salud Carlos III); Departamento de Educacion; Gobierno de Navarra (GNE-Enzima N); UTE	We thank Dr Christine Perret for the transgenic mice, Dr Carmen Berasain and Dr Maider Zabala for providing samples, Dr Francisco Borras-Cuesta and Virginia Belsue for peptides synthesis, Dr Victor Segura for bioinformatics assistance and Sandra Jusue, Maite Corres and Beatriz Carte for excellent technical assistance. AA was supported by an FPU training fellowship (AP2001-1567) and RA was supported by an FIS research contract. CIBEREHD is funded by Instituto de Salud Carlos III, and this research was partially supported by grants from Ministerio de Sanidad y Consumo (02/3054), Departamento de Educacion, Gobierno de Navarra (GNE-Enzima N) and UTE project CIMA.	Agarwal MK, 2006, P NATL ACAD SCI USA, V103, P16278, DOI 10.1073/pnas.0607210103; Arnesen T, 2006, ONCOGENE, V25, P4350, DOI 10.1038/sj.onc.1209469; Arnesen T, 2006, GENE, V371, P291, DOI 10.1016/j.gene.2005.12.008; Arnesen T, 2005, THYROID, V15, P1131, DOI 10.1089/thy.2005.15.1131; Arnesen T, 2005, BIOCHEM J, V386, P433, DOI 10.1042/BJ20041071; Bode AM, 2004, NAT REV CANCER, V4, P793, DOI 10.1038/nrc1455; BORRASCUESTA F, 1991, BIOLOGICALS, V19, P187, DOI 10.1016/1045-1056(91)90033-G; Braun K, 1998, ONCOGENE, V17, P2259, DOI 10.1038/sj.onc.1202145; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Caesar R, 2006, EUKARYOT CELL, V5, P368, DOI 10.1128/EC.5.2.368-378.2006; CARTIER N, 1994, B ACAD NAT MED PARIS, V178, P23; CARTIER N, 1992, ONCOGENE, V7, P1413; CARTIER N, 1994, B ACAD NATL MED, V178, P32; Cheung PK, 2004, CANCER RES, V64, P5929, DOI 10.1158/0008-5472.CAN-04-1216; Dutnall RN, 1998, CELL, V94, P427, DOI 10.1016/S0092-8674(00)81584-6; Fisher TS, 2005, J BIOL CHEM, V280, P17749, DOI 10.1074/jbc.M412055200; Fluge O, 2002, ONCOGENE, V21, P5056, DOI 10.1038/sj.onc.1205687; Gautschi M, 2003, MOL CELL BIOL, V23, P7403, DOI 10.1128/MCB.23.20.7403-7414.2003; Gendron RL, 2000, DEV DYNAM, V218, P300, DOI 10.1002/(SICI)1097-0177(200006)218:2<300::AID-DVDY5>3.0.CO;2-K; Hardy S, 1997, J VIROL, V71, P1842, DOI 10.1128/JVI.71.3.1842-1849.1997; Joo HY, 2007, NATURE, V449, P1068, DOI 10.1038/nature06256; Kannan K, 2001, ONCOGENE, V20, P2225, DOI 10.1038/sj.onc.1204319; Kho PS, 2004, J BIOL CHEM, V279, P21183, DOI 10.1074/jbc.M311912200; Lavin MF, 2006, CELL DEATH DIFFER, V13, P941, DOI 10.1038/sj.cdd.4401925; Lim JH, 2007, APOPTOSIS, V12, P411, DOI 10.1007/s10495-006-0576-9; Lim JH, 2006, CANCER RES, V66, P10677, DOI 10.1158/0008-5472.CAN-06-3171; Line A, 2002, BRIT J CANCER, V86, P1824, DOI 10.1038/sj.bjc.6600321; Liu G, 2005, CANCER CELL, V7, P113, DOI 10.1016/j.ccr.2005.01.019; Liu G, 2002, ONCOGENE, V21, P7195, DOI 10.1038/sj.onc.1205862; Neuwald AF, 1997, TRENDS BIOCHEM SCI, V22, P154, DOI 10.1016/S0968-0004(97)01034-7; Polevoda B, 2003, J BIOL CHEM, V278, P30686, DOI 10.1074/jbc.M304690200; Polevoda B, 2003, J MOL BIOL, V325, P595, DOI 10.1016/S0022-2836(02)01269-X; Polevoda B, 1999, EMBO J, V18, P6155, DOI 10.1093/emboj/18.21.6155; Polevoda B, 2008, J CELL BIOCHEM, V103, P492, DOI 10.1002/jcb.21418; Rellos P, 2007, J BIOL CHEM, V282, P6833, DOI 10.1074/jbc.M609721200; Reynolds A, 2004, NAT BIOTECHNOL, V22, P326, DOI 10.1038/nbt936; Sim E, 2008, DRUG METAB REV, V40, P479, DOI [10.1080/03602530802186603, 10.1080/03602530802186603 ]; SIMON HU, 1994, BIOCHEM J, V297, P389, DOI 10.1042/bj2970389; Singer JM, 2003, P NATL ACAD SCI USA, V100, P7644, DOI 10.1073/pnas.1232343100; Spurgers KB, 2006, J BIOL CHEM, V281, P25134, DOI 10.1074/jbc.M513901200; STARHEIM KK, 2008, BIOCH J; Sugiura N, 2003, J BIOL CHEM, V278, P40113, DOI 10.1074/jbc.M301218200; Sugiura N, 2001, J BIOL CHEM, V276, P14257, DOI 10.1074/jbc.M100011200; Vousden KH, 2000, CELL, V103, P691, DOI 10.1016/S0092-8674(00)00171-9; Wise-Draper TM, 2006, MOL CELL BIOL, V26, P7506, DOI 10.1128/MCB.00430-06; Xie SQ, 2001, J BIOL CHEM, V276, P43305, DOI 10.1074/jbc.M106050200; Yu J, 1999, P NATL ACAD SCI USA, V96, P14517, DOI 10.1073/pnas.96.25.14517	47	34	35	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC	2008	27	58					7296	7306		10.1038/onc.2008.332	http://dx.doi.org/10.1038/onc.2008.332			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	382FI	18794801				2022-12-28	WOS:000261590300007
J	Tsukita, S; Yamazaki, Y; Katsuno, T; Tamura, A; Tsukita, S				Tsukita, S.; Yamazaki, Y.; Katsuno, T.; Tamura, A.; Tsukita, S.			Tight junction-based epithelial microenvironment and cell proliferation	ONCOGENE			English	Review						tight junction; cell adhesion; paracellular barrier; paracellular permeability; permselectivity; epithelial cell	GALL-BLADDER EPITHELIUM; EPIDERMAL-GROWTH-FACTOR; MICE LACKING; MOLECULAR ARCHITECTURE; INTRACELLULAR CA2+; BARRIER FUNCTION; CLAUDIN; STRANDS; EXPRESSION; RECEPTOR	Belt-like tight junctions (TJs), referred to as zonula occludens, have long been regarded as a specialized differentiation of epithelial cell membranes. They are required for cell adhesion and paracellular barrier functions, and are now thought to be partly involved in fence functions and in cell polarization. Recently, the molecular bases of TJs have gradually been unveiled. TJs are constructed by TJ strands, whose basic frameworks are composed of integral membrane proteins with four transmembrane domains, designated claudins. The claudin family is supposedly composed of at least 24 members in mice and humans. Other types of integral membrane proteins with four transmembrane domains, namely occludin and tricellulin, as well as the single transmembrane proteins, JAMs (junctional adhesion molecules) and CAR (coxsackie and adenovirus receptor), are associated with TJ strands, and the high-level organization of TJ strands is likely to be established by membrane-anchored scaffolding proteins, such as ZO-1/2. Recent functional analyses of claudins in cell cultures and in mice have suggested that claudin-based TJs may have pivotal functions in the regulation of the epithelial microenvironment, which is critical for various biological functions such as control of cell proliferation. These represent the dawn of 'Barriology' (defined by Shoichiro Tsukita as the science of barriers in multicellular organisms). Taken together with recent reports regarding changes in claudin expression levels, understanding the regulation of the TJ-based microenvironment system will provide new insights into the regulation of polarization in the respect of epithelial microenvironment system and new viewpoints for developing anticancer strategies.	[Tsukita, S.; Yamazaki, Y.; Katsuno, T.; Tamura, A.; Tsukita, S.] Osaka Univ, Grad Sch Med, Grad Sch Frontier Biosci, Biol Sci Lab, Suita, Osaka 5650871, Japan	Osaka University	Tsukita, S (corresponding author), Osaka Univ, Grad Sch Med, Grad Sch Frontier Biosci, Biol Sci Lab, 2-2 Yamadaoka, Suita, Osaka 5650871, Japan.	atsukita@biosci.med.osaka-u.ac.jp						Amieva MR, 2003, SCIENCE, V300, P1430, DOI 10.1126/science.1081919; ANGELOW S, 2008, AM J PHYSL IN PRESS; Behr M, 2003, DEV CELL, V5, P611, DOI 10.1016/S1534-5807(03)00275-2; Ben-Yosef T, 2003, HUM MOL GENET, V12, P2049, DOI 10.1093/hmg/ddg210; Chao JCJ, 2003, WORLD J GASTROENTERO, V9, P2261; CLAUDE P, 1978, J MEMBRANE BIOL, V39, P219, DOI 10.1007/BF01870332; Cohen CJ, 2001, P NATL ACAD SCI USA, V98, P15191, DOI 10.1073/pnas.261452898; Colegio OR, 2003, AM J PHYSIOL-CELL PH, V284, pC1346, DOI 10.1152/ajpcell.00547.2002; D'Souza T, 2007, EXP CELL RES, V313, P3364, DOI 10.1016/j.yexcr.2007.06.026; Diamond J M, 1977, Physiologist, V20, P10; FARQUHAR MG, 1963, J CELL BIOL, V17, P375, DOI 10.1083/jcb.17.2.375; FRIZZELL RA, 1972, J GEN PHYSIOL, V59, P318, DOI 10.1085/jgp.59.3.318; Fujita K, 2000, FEBS LETT, V476, P258, DOI 10.1016/S0014-5793(00)01744-0; FURUSE M, 1993, J CELL BIOL, V123, P1777, DOI 10.1083/jcb.123.6.1777; Furuse M, 1999, J CELL BIOL, V147, P891, DOI 10.1083/jcb.147.4.891; Furuse M, 2001, J CELL BIOL, V153, P263, DOI 10.1083/jcb.153.2.263; Furuse M, 2002, J CELL BIOL, V156, P1099, DOI 10.1083/jcb.200110122; Gonzalez-Mariscal L, 2007, PROG HISTOCHEM CYTO, V42, P1, DOI 10.1016/j.proghi.2007.01.001; Gow A, 1999, CELL, V99, P649, DOI 10.1016/S0092-8674(00)81553-6; GUMBINER BM, 1993, J CELL BIOL, V123, P1631, DOI 10.1083/jcb.123.6.1631; Hamazaki Y, 2002, J BIOL CHEM, V277, P455, DOI 10.1074/jbc.M109005200; Hartsock A, 2008, BBA-BIOMEMBRANES, V1778, P660, DOI 10.1016/j.bbamem.2007.07.012; HOPFER U, 1977, AM J PHYSIOL, V233, pE445, DOI 10.1152/ajpendo.1977.233.6.E445; Hou JH, 2006, J BIOL CHEM, V281, P36117, DOI 10.1074/jbc.M608853200; Ikenouchi J, 2005, J CELL BIOL, V171, P939, DOI 10.1083/jcb.200510043; Ikenouchi J, 2003, J CELL SCI, V116, P1959, DOI 10.1242/jcs.00389; Itoh M, 2001, J CELL BIOL, V154, P491, DOI 10.1083/jcb.200103047; Itoh M, 1999, J CELL BIOL, V147, P1351, DOI 10.1083/jcb.147.6.1351; KACHAR B, 1982, NATURE, V296, P464, DOI 10.1038/296464a0; Katahira J, 1997, J CELL BIOL, V136, P1239, DOI 10.1083/jcb.136.6.1239; Katsuno T, 2008, MOL BIOL CELL, V19, P2465, DOI 10.1091/mbc.E07-12-1215; Kitajiri SI, 2004, J CELL SCI, V117, P5087, DOI 10.1242/jcs.01393; Kominsky Scott L., 2006, Expert Reviews in Molecular Medicine, V8, P1, DOI 10.1017/S1462399406000056; Konrad M, 2006, AM J HUM GENET, V79, P949, DOI 10.1086/508617; KOTTRA G, 1993, PFLUG ARCH EUR J PHY, V425, P528, DOI 10.1007/BF00374881; KOTTRA G, 1993, PFLUG ARCH EUR J PHY, V425, P535, DOI 10.1007/BF00374882; Krause G, 2008, BBA-BIOMEMBRANES, V1778, P631, DOI 10.1016/j.bbamem.2007.10.018; Lioni M, 2007, AM J PATHOL, V170, P709, DOI 10.2353/ajpath.2007.060343; Liu Y, 2000, J CELL SCI, V113, P2363; Loh YH, 2004, GENOME RES, V14, P1248, DOI 10.1101/gr.2400004; Macarthur M, 2004, AM J PHYSIOL-GASTR L, V286, pG515, DOI 10.1152/ajpgi.00475.2003; Matsuda M, 2004, J CELL SCI, V117, P1247, DOI 10.1242/jcs.00972; Mitic LL, 1998, ANNU REV PHYSIOL, V60, P121, DOI 10.1146/annurev.physiol.60.1.121; Miyamoto T, 2005, J CELL BIOL, V169, P527, DOI 10.1083/jcb.200501154; Morita K, 2002, J INVEST DERMATOL, V118, P1073, DOI 10.1046/j.1523-1747.2002.01774.x; Morita K, 1999, J CELL BIOL, V147, P185, DOI 10.1083/jcb.147.1.185; Morita K, 1999, J CELL BIOL, V145, P579, DOI 10.1083/jcb.145.3.579; Moriwaki K, 2007, DEV BIOL, V312, P509, DOI 10.1016/j.ydbio.2007.09.049; Nitta T, 2003, J CELL BIOL, V161, P653, DOI 10.1083/jcb.200302070; OKADA Y, 1977, J MEMBRANE BIOL, V31, P221, DOI 10.1007/BF01869406; Pan XY, 2007, INT J GYNECOL CANCER, V17, P233, DOI 10.1111/j.1525-1438.2006.00748.x; PINTO DS, 1982, CELL, V28, P441; POWELL DW, 1981, AM J PHYSIOL, V241, pG275, DOI 10.1152/ajpgi.1981.241.4.G275; REUSS L, 1992, TIGHT JUNCTIONS, P49; Saitou M, 2000, MOL BIOL CELL, V11, P4131, DOI 10.1091/mbc.11.12.4131; Sanchez-Pulido L, 2002, TRENDS BIOCHEM SCI, V27, P599, DOI 10.1016/S0968-0004(02)02229-6; Sasaki H, 2003, P NATL ACAD SCI USA, V100, P3971, DOI 10.1073/pnas.0630649100; Schmidt A, 2004, CELL MOL LIFE SCI, V61, P1354, DOI 10.1007/s00018-004-4010-6; Schultheis PJ, 1998, NAT GENET, V19, P282, DOI 10.1038/969; Simon DB, 1999, SCIENCE, V285, P103, DOI 10.1126/science.285.5424.103; Singh AB, 2004, J BIOL CHEM, V279, P3543, DOI 10.1074/jbc.M308682200; Song B, 2002, P NATL ACAD SCI USA, V99, P13577, DOI 10.1073/pnas.202235299; Sonoda N, 1999, J CELL BIOL, V147, P195, DOI 10.1083/jcb.147.1.195; STAEHELIN LA, 1973, J CELL SCI, V13, P763; Tamura A, 2008, GASTROENTEROLOGY, V134, P523, DOI 10.1053/j.gastro.2007.11.040; Tatum R, 2007, FEBS LETT, V581, P3887, DOI 10.1016/j.febslet.2007.07.014; Toivola DM, 2004, J CELL BIOL, V164, P911, DOI 10.1083/jcb.200308103; Tsukita S, 2001, NAT REV MOL CELL BIO, V2, P285, DOI 10.1038/35067088; Tsukita S, 2000, J CELL BIOL, V149, P13, DOI 10.1083/jcb.149.1.13; Tsukita S, 1999, TRENDS CELL BIOL, V9, P268, DOI 10.1016/S0962-8924(99)01578-0; TSUKITA S, 1989, J CELL BIOL, V108, P31, DOI 10.1083/jcb.108.1.31; TURK E, 1991, NATURE, V350, P354, DOI 10.1038/350354a0; Umeda K, 2006, CELL, V126, P741, DOI 10.1016/j.cell.2006.06.043; Van Itallie CM, 2008, J CELL SCI, V121, P298, DOI 10.1242/jcs.021485; Van Itallie CM, 2006, AM J PHYSIOL-RENAL, V291, pF1288, DOI 10.1152/ajprenal.00138.2006; Van Itallie CM, 2003, AM J PHYSIOL-RENAL, V285, pF1078, DOI 10.1152/ajprenal.00116.2003; Van Itallie CM, 2006, ANNU REV PHYSIOL, V68, P403, DOI 10.1146/annurev.physiol.68.040104.131404; VERKLEIJ AJ, 1984, BIOCHIM BIOPHYS ACTA, V779, P43, DOI 10.1016/0304-4157(84)90003-0; Vermeer PD, 2003, NATURE, V422, P322, DOI 10.1038/nature01440; Watson CJ, 2001, AM J PHYSIOL-CELL PH, V281, pC388, DOI 10.1152/ajpcell.2001.281.2.C388; Wattenhofer M, 2005, HUM MUTAT, V25, P543, DOI 10.1002/humu.20172; Wu VM, 2004, J CELL BIOL, V164, P313, DOI 10.1083/jcb.200309134; Xu JL, 2008, MOL CELL BIOL, V28, P1669, DOI 10.1128/MCB.00891-07; Yap AS, 1998, J MEMBRANE BIOL, V163, P159, DOI 10.1007/s002329900380	84	282	293	0	19	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 24	2008	27	55					6930	6938		10.1038/onc.2008.344	http://dx.doi.org/10.1038/onc.2008.344			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	375IU	19029935				2022-12-28	WOS:000261108200006
J	Shiono, M; Kobayashi, T; Takahashi, R; Sun, G; Abe, M; Zhang, D; Wang, L; Piao, X; Takagi, Y; Mineki, R; Taka, H; Tada, N; Sonobe, S; Momose, S; Ueda, M; Hino, O				Shiono, M.; Kobayashi, T.; Takahashi, R.; Sun, G.; Abe, M.; Zhang, D.; Wang, L.; Piao, X.; Takagi, Y.; Mineki, R.; Taka, H.; Tada, N.; Sonobe, S.; Momose, S.; Ueda, M.; Hino, O.			The G1556S-type tuberin variant suppresses tumor formation in tuberous sclerosis 2 mutant (Eker) rats despite its deficiency in mTOR inhibition	ONCOGENE			English	Article						tuberous sclerosis; tumor suppressor gene; Tsc2; transgenic rat; mTOR	RAPAMYCIN ANALOG CCI-779; RENAL-CARCINOMA; MOUSE MODEL; TSC2; PHOSPHORYLATION; COMPLEX; GENE; HAMARTIN; TARGET; GAP	Tuberin, a tumor-suppressor protein produced by the tuberous sclerosis gene TSC2, downregulates the Rheb-mTOR-S6K pathway (mTOR axis). Comparison of the effects of human tuberin mutations, such as G1556S, suggests that pathways other than the mTOR axis might also be involved in the pathogenesis of tuberous sclerosis. Here we test this possibility using the rat G1556S-type mutation (GSM) and a transgenic Eker (Tsc2 mutant) rat system. Cells expressing GSM-tuberin failed to downregulate the mTOR axis. GSM-tuberin had an altered localization, which underlie its reduced ability to form a complex with hamartin, and a site-specific alteration in phosphorylation status indicating diverse regulation by Akt. GSM-transgenic (GSM-Tg) rats exhibited suppression of macroscopic renal tumors following N-ethyl-N-nitrosourea treatment. Intriguingly, rats with weaker GSM-Tg expression showed microscopic cystic and pre-tumorous lesions that were restricted in size and expansion, although they had hyper-phosphorylation of ribosomal protein S6. These results highlight a novel pathway involving tuberin that regulates tumor suppression independently of the mTOR inhibitory function. Identification of such a novel pathway will provide clear implications for generation of new therapeutic targets in the treatment of these tumors.	[Hino, O.] Juntendo Univ, Sch Med, Dept Pathol & Oncol, Bunkyo Ku, Tokyo 1138421, Japan; [Mineki, R.; Taka, H.] Juntendo Univ, Sch Med, Div Prote & BioMol Sci, Tokyo 1138421, Japan; [Tada, N.] Juntendo Univ, Sch Med, Atopy Res Ctr, Tokyo 1138421, Japan; [Sonobe, S.] Juntendo Univ, Sch Med, Dept Gen Thorac Surg, Tokyo 1138421, Japan; [Momose, S.] Saitama Med Univ, Saitama Med Ctr, Dept Pathol, Saitama, Japan	Juntendo University; Juntendo University; Juntendo University; Juntendo University; Saitama Medical University	Hino, O (corresponding author), Juntendo Univ, Sch Med, Dept Pathol & Oncol, Bunkyo Ku, 2-1-1 Hongo, Tokyo 1138421, Japan.	ohino@juntendo.ac.jp	Warfield, Simon/B-3352-2009	Warfield, Simon/0000-0002-7659-3880	Ministry of Education, Culture, Sports, Science and Technology; Japan Society for the Promotion of Science; Ministry of Health, Labour and Welfare of Japan	Ministry of Education, Culture, Sports, Science and Technology(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Japan Society for the Promotion of Science(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science); Ministry of Health, Labour and Welfare of Japan(Ministry of Health, Labour and Welfare, Japan)	This research was supported by a Grant-in-aid for Cancer Research from the Ministry of Education, Culture, Sports, Science and Technology and Grants-in-Aid for Scientific Research from Japan Society for the Promotion of Science and the Ministry of Health, Labour and Welfare of Japan. We also thank Ms N Otsuji (Department of Pathology and Oncology), Mr R Tsukada, Mr F Kanai, Ms T Hidano ( Center for Biomedical Research Resources), Mr M Yoshida, Mr J Nakamoto ( Division of Ultrastructural Research), Mr Y Watanabe, Mr K Matsunami, Ms K Ochiai ( Division of Radioisotope Research), Dr T Fujimura ( Division of Proteomics and BioMolecular Science), Ms Y Kojima, Dr H Kurihara ( Division of Biomedical Imaging Research), Dr T Seki ( Department of Developmental Neurobiology), Dr T Ueno and Dr E Kominami ( Department of Biochemistry), all of Juntendo University, for their support.	Aicher LD, 2001, J BIOL CHEM, V276, P21017, DOI 10.1074/jbc.C100136200; Astrinidis A, 2005, ONCOGENE, V24, P7475, DOI 10.1038/sj.onc.1209090; Bissler JJ, 2008, NEW ENGL J MED, V358, P140, DOI 10.1056/NEJMoa063564; Dan HC, 2002, J BIOL CHEM, V277, P35364, DOI 10.1074/jbc.M205838200; Dancey JE, 2006, NAT REV DRUG DISCOV, V5, P649, DOI 10.1038/nrd2089; Davies DM, 2008, NEW ENGL J MED, V358, P200, DOI 10.1056/NEJMc072500; Easton JB, 2006, ONCOGENE, V25, P6436, DOI 10.1038/sj.onc.1209886; EKER R, 1961, NATURE, V189, P858, DOI 10.1038/189858b0; Fabian MA, 2005, NAT BIOTECHNOL, V23, P329, DOI 10.1038/nbt1068; Faivre S, 2006, NAT REV DRUG DISCOV, V5, P671, DOI 10.1038/nrd2062; Franz DN, 2006, ANN NEUROL, V59, P490, DOI 10.1002/ana.20784; Fukuda T, 1998, JPN J CANCER RES, V89, P1104, DOI 10.1111/j.1349-7006.1998.tb00503.x; Gomez M. R., 1999, TUBEROUS SCLEROSIS C; Granville CA, 2006, CLIN CANCER RES, V12, P679, DOI 10.1158/1078-0432.CCR-05-1654; Guertin DA, 2007, CANCER CELL, V12, P9, DOI 10.1016/j.ccr.2007.05.008; HINO O, 1993, P NATL ACAD SCI USA, V90, P327, DOI 10.1073/pnas.90.1.327; HINO O, 1994, BIOCHEM BIOPH RES CO, V203, P1302, DOI 10.1006/bbrc.1994.2324; HINO O, 1993, CANCER RES, V53, P5856; Inoki K, 2002, NAT CELL BIOL, V4, P648, DOI 10.1038/ncb839; Jansen AC, 2006, ANN NEUROL, V60, P528, DOI 10.1002/ana.21037; Kenerson H, 2005, PEDIATR RES, V57, P67, DOI 10.1203/01.PDR.0000147727.78571.07; Kenerson HL, 2002, CANCER RES, V62, P5645; Kobayashi T, 1997, P NATL ACAD SCI USA, V94, P3990, DOI 10.1073/pnas.94.8.3990; KOBAYASHI T, 1995, NAT GENET, V9, P70, DOI 10.1038/ng0195-70; Kobayashi T, 2003, P JPN ACAD B-PHYS, V79, P22, DOI 10.2183/pjab.79B.22; Kwiatkowski DJ, 2002, HUM MOL GENET, V11, P525, DOI 10.1093/hmg/11.5.525; Lee L, 2005, GENE CHROMOSOME CANC, V42, P213, DOI 10.1002/gcc.20118; Lee L, 2006, GENE CHROMOSOME CANC, V45, P933, DOI 10.1002/gcc.20357; Li Y, 2004, TRENDS BIOCHEM SCI, V29, P32, DOI 10.1016/j.tibs.2003.11.007; Manning BD, 2002, MOL CELL, V10, P151, DOI 10.1016/S1097-2765(02)00568-3; Manning BD, 2003, TRENDS BIOCHEM SCI, V28, P573, DOI 10.1016/j.tibs.2003.09.003; Martin DE, 2005, CURR OPIN CELL BIOL, V17, P158, DOI 10.1016/j.ceb.2005.02.008; Mayer K, 2004, J MED GENET, V41, DOI 10.1136/jmg.2003.010835; Momose S, 2002, HUM MOL GENET, V11, P2997, DOI 10.1093/hmg/11.24.2997; Nellist M, 2005, EUR J HUM GENET, V13, P59, DOI 10.1038/sj.ejhg.5201276; Nellist M, 2001, HUM MOL GENET, V10, P2889, DOI 10.1093/hmg/10.25.2889; Niida Y, 1999, HUM MUTAT, V14, P412, DOI 10.1002/(SICI)1098-1004(199911)14:5<412::AID-HUMU7>3.0.CO;2-K; O'Reilly KE, 2006, CANCER RES, V66, P1500, DOI 10.1158/0008-5472.CAN-05-2925; Shah OJ, 2004, J BIOL CHEM, V279, P20816, DOI 10.1074/jbc.M400957200; Sun GD, 2007, BIOCHEM BIOPH RES CO, V360, P181, DOI 10.1016/j.bbrc.2007.06.021; YEUNG RS, 1994, P NATL ACAD SCI USA, V91, P11413, DOI 10.1073/pnas.91.24.11413	41	6	6	0	1	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV	2008	27	52					6690	6697		10.1038/onc.2008.283	http://dx.doi.org/10.1038/onc.2008.283			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	368QY	18695678				2022-12-28	WOS:000260638800007
J	Rickman, DS; Millon, R; De Reynies, A; Thomas, E; Wasylyk, C; Muller, D; Abecassis, J; Wasylyk, B				Rickman, D. S.; Millon, R.; De Reynies, A.; Thomas, E.; Wasylyk, C.; Muller, D.; Abecassis, J.; Wasylyk, B.			Prediction of future metastasis and molecular characterization of head and neck squamous-cell carcinoma based on transcriptome and genome analysis by microarrays	ONCOGENE			English	Article						HNSCC; distant metastasis; prognosis; intrinsic groups; differentiation	LYMPH-NODE METASTASIS; HUMAN-PAPILLOMAVIRUS; BREAST-CANCER; EXPRESSION; CLASSIFICATION; IDENTIFICATION; GENES; SIGNATURE; RECEPTOR; ALCOHOL	Propensity for subsequent distant metastasis in head and neck squamous-cell carcinoma (HNSCC) was analysed using 186 primary tumours from patients initially treated by surgery that developed ( M) or did not develop (NM) metastases as the first recurrent event. Transcriptome (Affymetrix HGU133_ Plus2, QRT-PCR) and array-comparative genomic hybridization data were collected. Non-supervised hierarchical clustering based on Affymetrix data distinguished tumours differing in pathological differentiation, and identified associated functional changes. Propensity for metastasis was not associated with these subgroups. Using QRT-PCR data we identified a four-gene model (PSMD10, HSD17B12, FLOT2 and KRT17) that predicts M/NM status with 77% success in a separate 79-sample validation group of HNSCC samples. This prediction is independent of clinical criteria ( age, lymph node status, stage, differentiation and localization). The most significantlyalte red transcripts in M versus NM were significantly associated to metastasis-related functions, including adhesion, mobility and cell survival. Several genomic modi. cations were significantly associated with M/NM status ( most notably gains at 4q11-22 and Xq12-28; losses at 11q14-24 and 17q11 losses) and partly linked to transcription modi. cations. This work yields a basis for the development of prognostic molecular signatures, markers and therapeutic targets for HNSCC metastasis.	[Wasylyk, C.; Wasylyk, B.] IGBMC, CNRS, INSERM, ULP, F-67404 Illkirch Graffenstaden, France; [Rickman, D. S.; De Reynies, A.; Thomas, E.] Ligue Natl Contre Canc, Paris, France; [Millon, R.; Muller, D.; Abecassis, J.] Ctr Reg Lutte Contre Canc Paul Strauss, Strasbourg, France	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; UNICANCER; Centre Paul Strauss	Wasylyk, B (corresponding author), IGBMC, CNRS, INSERM, ULP, 1 Rue Laurent Fries,BP 10142, F-67404 Illkirch Graffenstaden, France.	boh@igbmc.u-strasbg.fr	Wasylyk, Bohdan/ABG-6778-2020; de Reyniès, Aurélien/Q-8640-2017	Wasylyk, Bohdan/0000-0002-1718-1237; de Reyniès, Aurélien/0000-0002-1328-5290; Thomas, Emilie/0000-0002-8313-7218	Ligues Nationale et Regionales; CNRS; INSERM	Ligues Nationale et Regionales; CNRS(Centre National de la Recherche Scientifique (CNRS)); INSERM(Institut National de la Sante et de la Recherche Medicale (Inserm)European Commission)	Financial support: Ligues Nationale et Regionales (Bas et Haut Rhin) contre le Cancer, CNRS, INSERM.	Applebaum KM, 2007, JNCI-J NATL CANCER I, V99, P1801, DOI 10.1093/jnci/djm233; Ashburner M, 2000, NAT GENET, V25, P25, DOI 10.1038/75556; Babuke T, 2007, EUR J CELL BIOL, V86, P525, DOI 10.1016/j.ejcb.2007.03.003; Barker N, 2006, NAT REV DRUG DISCOV, V5, P997, DOI 10.1038/nrd2154; Baudis M, 2001, BIOINFORMATICS, V17, P1228, DOI 10.1093/bioinformatics/17.12.1228; Boyault S, 2007, HEPATOLOGY, V45, P42, DOI 10.1002/hep.21467; Braakhuis BJM, 2006, J CLIN PATHOL, V59, P1254, DOI 10.1136/jcp.2005.035451; Carles A, 2006, ONCOGENE, V25, P1821, DOI 10.1038/sj.onc.1209203; Chung CH, 2004, CANCER CELL, V5, P489, DOI 10.1016/S1535-6108(04)00112-6; Cromer A, 2004, ONCOGENE, V23, P2484, DOI 10.1038/sj.onc.1207345; Dawson S, 2006, TRENDS CELL BIOL, V16, P229, DOI 10.1016/j.tcb.2006.03.001; Dupuy A, 2007, JNCI-J NATL CANCER I, V99, P147, DOI 10.1093/jnci/djk018; Esteller M, 2007, NAT REV GENET, V8, P286, DOI 10.1038/nrg2005; Foltz G, 2006, CANCER RES, V66, P6665, DOI 10.1158/0008-5472.CAN-05-4453; Forastiere A, 2001, NEW ENGL J MED, V345, P1890, DOI 10.1056/NEJMra001375; Glas AM, 2006, BMC GENOMICS, V7, DOI 10.1186/1471-2164-7-278; Gollin SM, 2001, HEAD NECK-J SCI SPEC, V23, P238, DOI 10.1002/1097-0347(200103)23:3<238::AID-HED1025>3.0.CO;2-H; Gu LH, 2007, CURR OPIN CELL BIOL, V19, P13, DOI 10.1016/j.ceb.2006.12.007; Han CY, 2005, NUCLEIC ACIDS RES, V33, P6555, DOI 10.1093/nar/gki964; Hashibe M, 2007, J NATL CANCER I, V99, P777, DOI 10.1093/jnci/djk179; Ioannidis JPA, 2007, ONCOLOGIST, V12, P301, DOI 10.1634/theoncologist.12-3-301; Irizarry RA, 2003, BIOSTATISTICS, V4, P249, DOI 10.1093/biostatistics/4.2.249; Jarvinen AK, 2006, ONCOGENE, V25, P6997, DOI 10.1038/sj.onc.1209690; Kaklamani Virginia G, 2006, Curr Treat Options Oncol, V7, P123, DOI 10.1007/s11864-006-0047-0; Le Tourneau C, 2005, HEAD NECK-J SCI SPEC, V27, P801, DOI 10.1002/hed.20254; Ludwig JA, 2005, NAT REV CANCER, V5, P845, DOI 10.1038/nrc1739; Nguyen DX, 2007, NAT REV GENET, V8, P341, DOI 10.1038/nrg2101; Ragin CCR, 2006, BRIT J CANCER, V95, P1432, DOI 10.1038/sj.bjc.6603394; Ramaswamy S, 2003, NAT GENET, V33, P49, DOI 10.1038/ng1060; Roepman P, 2005, NAT GENET, V37, P182, DOI 10.1038/ng1502; Roepman P, 2006, CANCER RES, V66, P2361, DOI 10.1158/0008-5472.CAN-05-3960; Sanderson JT, 2006, TOXICOL SCI, V94, P3, DOI 10.1093/toxsci/kfl051; Schlecht NF, 2007, J PATHOL, V213, P283, DOI 10.1002/path.2227; Simonin F, 2004, J NEUROCHEM, V89, P766, DOI 10.1111/j.1471-4159.2004.02411.x; Slebos RJC, 2006, CLIN CANCER RES, V12, P701, DOI 10.1158/1078-0432.CCR-05-2017; Sobin LH, 1997, CANCER, V80, P1803, DOI 10.1002/(SICI)1097-0142(19971101)80:9<1803::AID-CNCR16>3.0.CO;2-9; Song D, 2006, J STEROID BIOCHEM, V101, P136, DOI 10.1016/j.jsbmb.2006.06.015; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; van de Rijn M, 2002, AM J PATHOL, V161, P1991, DOI 10.1016/S0002-9440(10)64476-8; Vandesompele J, 2002, GENOME BIOL, V3, DOI 10.1186/gb-2002-3-7-research0034; Vilar M, 2006, EMBO J, V25, P1219, DOI 10.1038/sj.emboj.7601017; Zhou XF, 2006, NEOPLASIA, V8, P925, DOI 10.1593/neo.06430	42	118	122	0	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 30	2008	27	51					6607	6622		10.1038/onc.2008.251	http://dx.doi.org/10.1038/onc.2008.251			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	366RS	18679425				2022-12-28	WOS:000260501700009
J	Boya, P; Kroemer, G				Boya, P.; Kroemer, G.			Lysosomal membrane permeabilization in cell death	ONCOGENE			English	Review						lysosomal membrane permeabilization; cathepsins; programmed cell death; apoptosis; autophagy	ARYL-HYDROCARBON RECEPTOR; APOPTOSIS-INDUCING FACTOR; CATHEPSIN-B CONTRIBUTES; TRAIL-INDUCED APOPTOSIS; SALT-INDUCED APOPTOSIS; PROTEASE INHIBITOR 2A; CYTOCHROME-C RELEASE; OXIDATIVE STRESS; T-LYMPHOCYTES; HEAT-SHOCK-PROTEIN-70 FAMILY	Mitochondrial outer membrane permeabilization ( MOMP) constitutes one of the major checkpoint(s) of apoptotic and necrotic cell death. Recently, the permeabilization of yet another organelle, the lysosome, has been shown to initiate a cell death pathway, in specific circumstances. Lysosomal membrane permeabilization (LMP) causes the release of cathepsins and other hydrolases from the lysosomal lumen to the cytosol. LMP is induced by a plethora of distinct stimuli including reactive oxygen species, lysosomotropic compounds with detergent activity, as well as some endogenous cell death effectors such as Bax. LMP is a potentially lethal event because the ectopic presence of lysosomal proteases in the cytosol causes digestion of vital proteins and the activation of additional hydrolases including caspases. This latter process is usually mediated indirectly, through a cascade in which LMP causes the proteolytic activation of Bid (which is cleaved by the two lysosomal cathepsins B and D), which then induces MOMP, resulting in cytochrome c release and apoptosome-dependent caspase activation. However, massive LMP often results in cell death without caspase activation; this cell death may adopt a subapoptotic or necrotic appearance. The regulation of LMP is perturbed in cancer cells, suggesting that specific strategies for LMP induction might lead to novel therapeutic avenues.	[Boya, P.] Consejo Super Invest Cientificas, Ctr Invest Biol, Lab 3D, Dept Cellular & Mol Physiopathol, E-28040 Madrid, Spain; [Kroemer, G.] INSERM, U848, Villejuif, France; [Kroemer, G.] Inst Gustave Roussy, Villejuif, France; [Kroemer, G.] Univ Paris 11, Villejuif, France	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Investigaciones Biologicas (CIB); Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Gustave Roussy; UDICE-French Research Universities; Universite Paris Saclay	Boya, P (corresponding author), Consejo Super Invest Cientificas, Ctr Invest Biol, Lab 3D, Dept Cellular & Mol Physiopathol, Ramiro Maetzu 9, E-28040 Madrid, Spain.	pboya@cib.csic.es; kroemer@igr.fr	KROEMER, Guido/B-4263-2013; Kroemer, Guido/AAY-9859-2020; Boya, Patricia/K-2911-2014; Boya, Patricia/P-8345-2019	KROEMER, Guido/0000-0002-9334-4405; Boya, Patricia/0000-0003-3045-951X; Boya, Patricia/0000-0003-3045-951X	Ministry of Science [BFU-2006-00508]; Fundacion La Caixa [BM06-125-1]; Ligue Nationale contre le Cancer (Equipe labellisee); European Commission; Agence Nationale pour la Recherche; Institut National contre le Cancer; Canceropole Ile-de-France; Fondation pour la Recherche Medicale	Ministry of Science(Ministry of Science, ICT & Future Planning, Republic of Korea); Fundacion La Caixa(La Caixa Foundation); Ligue Nationale contre le Cancer (Equipe labellisee)(Ligue nationale contre le cancer); European Commission(European CommissionEuropean Commission Joint Research Centre); Agence Nationale pour la Recherche(French National Research Agency (ANR)); Institut National contre le Cancer; Canceropole Ile-de-France(Region Ile-de-France); Fondation pour la Recherche Medicale(Fondation pour la Recherche Medicale)	Research in our labs is supported by grants from Ministry of Science (BFU-2006-00508) and from Fundacion La Caixa (BM06-125-1) to PB and Ligue Nationale contre le Cancer (Equipe labellisee), European Commission (Active p53, ApoSys, RIGHT, TransDeath, ChemoRes, DeathTrain), Agence Nationale pour la Recherche, Institut National contre le Cancer, Canceropole Ile-de-France and Fondation pour la Recherche Medicale to GK. We thank Ana Robles and Nick Joza for editing of the paper.	Abraham MC, 2007, DEV CELL, V13, P464, DOI 10.1016/j.devcel.2007.09.008; Antunes F, 2001, BIOCHEM J, V356, P549, DOI 10.1042/0264-6021:3560549; Bidere N, 2003, J BIOL CHEM, V278, P31401, DOI 10.1074/jbc.M301911200; Biggs JR, 2001, P NATL ACAD SCI USA, V98, P3814, DOI 10.1073/pnas.071057398; Bivik C, 2007, CARCINOGENESIS, V28, P537, DOI 10.1093/carcin/bgl152; Blomgran R, 2007, J LEUKOCYTE BIOL, V81, P1213, DOI 10.1189/jlb.0506359; Boya P, 2005, MOL CELL BIOL, V25, P1025, DOI 10.1128/MCB.25.3.1025-1040.2005; Boya P, 2003, ONCOGENE, V22, P3927, DOI 10.1038/sj.onc.1206622; Boya P, 2003, J EXP MED, V197, P1323, DOI 10.1084/jem.20021952; Boya P, 2002, CELL DEATH DIFFER, V9, P465, DOI 10.1038/sj.cdd.4401006; Boya P, 2004, BBA-BIOENERGETICS, V1659, P178, DOI 10.1016/j.bbabio.2004.08.007; Boya Patricia, 2005, Birth Defects Research, V75, P281, DOI 10.1002/bdrc.20054; Broker LE, 2004, CANCER RES, V64, P27, DOI 10.1158/0008-5472.CAN-03-3060; Broker LE, 2005, CLIN CANCER RES, V11, P3155, DOI 10.1158/1078-0432.CCR-04-2223; Burke MA, 2003, DEV DYNAM, V227, P315, DOI 10.1002/dvdy.10313; Buytaert E, 2007, BBA-REV CANCER, V1776, P86, DOI 10.1016/j.bbcan.2007.07.001; Canbay A, 2003, J CLIN INVEST, V112, P152, DOI 10.1172/JCI200317740; Caruso JA, 2006, J BIOL CHEM, V281, P10954, DOI 10.1074/jbc.M508383200; Caruso JA, 2005, BIOCHEM J, V392, P325, DOI 10.1042/BJ20050313; Caruso JA, 2004, MOL PHARMACOL, V65, P1016, DOI 10.1124/mol.65.4.1016; Castino R, 2007, FREE RADICAL BIO MED, V42, P1305, DOI 10.1016/j.freeradbiomed.2006.12.030; Chen W, 2005, J BIOL CHEM, V280, P40985, DOI 10.1074/jbc.M502190200; Cheung NS, 2007, NEUROPHARMACOLOGY, V53, P505, DOI 10.1016/j.neuropharm.2007.06.014; Chipuk JE, 2004, SCIENCE, V303, P1010, DOI 10.1126/science.1092734; Cirman T, 2004, J BIOL CHEM, V279, P3578, DOI 10.1074/jbc.M308347200; CLARKE PGH, 1990, ANAT EMBRYOL, V181, P195, DOI 10.1007/bf00174615; Daugaard M, 2007, FEBS LETT, V581, P3702, DOI 10.1016/j.febsiet.2007.05.039; Daugaard M, 2007, CANCER RES, V67, P2559, DOI 10.1158/0008-5472.CAN-06-4121; De Milito A, 2007, CANCER RES, V67, P5408, DOI 10.1158/0008-5472.CAN-06-4095; DEDUVE C, 1974, BIOCHEM PHARMACOL, V23, P2495, DOI 10.1016/0006-2952(74)90174-9; Di Piazza M, 2007, J VIROL, V81, P4186, DOI 10.1128/JVI.02601-06; Doulias PT, 2003, FREE RADICAL BIO MED, V35, P719, DOI 10.1016/S0891-5849(03)00396-4; Eaton JW, 2002, FREE RADICAL BIO MED, V32, P833, DOI 10.1016/S0891-5849(02)00772-4; Emert-Sedlak L, 2005, MOL CANCER THER, V4, P733, DOI 10.1158/1535-7163.MCT-04-0301; Erdal H, 2005, P NATL ACAD SCI USA, V102, P192, DOI 10.1073/pnas.0408592102; Eskelinen Eeva-Liisa, 2006, Molecular Aspects of Medicine, V27, P495, DOI 10.1016/j.mam.2006.08.005; Fehrenbacher N, 2005, CANCER RES, V65, P2993, DOI 10.1158/0008-5472.CAN-05-0476; Fehrenbacher N, 2004, CANCER RES, V64, P5301, DOI 10.1158/0008-5472.CAN-04-1427; Felbor U, 2002, P NATL ACAD SCI USA, V99, P7883, DOI 10.1073/pnas.112632299; Feldstein AE, 2004, HEPATOLOGY, V40, P185, DOI 10.1002/hep.20283; Feldstein AE, 2006, AM J PHYSIOL-GASTR L, V290, pG1339, DOI 10.1152/ajpgi.00509.2005; Feofanov AV, 2005, BIOCHEM J, V390, P11, DOI 10.1042/BJ20041892; Ferri KF, 2001, NAT CELL BIOL, V3, pE255, DOI 10.1038/ncb1101-e255; Festjens N, 2006, BBA-BIOENERGETICS, V1757, P1371, DOI 10.1016/j.bbabio.2006.06.014; FIRESTONE RA, 1982, J MED CHEM, V25, P539, DOI 10.1021/jm00347a012; Foghsgaard L, 2001, J CELL BIOL, V153, P999, DOI 10.1083/jcb.153.5.999; Galluzzi L, 2007, CELL DEATH DIFFER, V14, P1237, DOI 10.1038/sj.cdd.4402148; Ganapathy V, 2003, AUTOIMMUN REV, V2, P290, DOI 10.1016/S1568-9972(03)00063-6; Garnett TO, 2007, APOPTOSIS, V12, P1299, DOI 10.1007/s10495-007-0058-8; Garrido C, 2006, CELL CYCLE, V5, P2592, DOI 10.4161/cc.5.22.3448; Glunde K, 2003, NEOPLASIA, V5, P533, DOI 10.1016/S1476-5586(03)80037-4; Golstein P, 2007, TRENDS BIOCHEM SCI, V32, P37, DOI 10.1016/j.tibs.2006.11.001; Gonzalez-Polo RA, 2005, J CELL SCI, V118, P3091, DOI 10.1242/jcs.02447; Groth-Pedersen L, 2007, CANCER RES, V67, P2217, DOI 10.1158/0008-5472.CAN-06-3520; Gui ZZ, 2006, BMC DEV BIOL, V6, DOI 10.1186/1471-213X-6-49; Guicciardi ME, 2007, AM J PHYSIOL-GASTR L, V292, pG1337, DOI 10.1152/ajpgi.00497.2006; Guicciardi ME, 2000, J CLIN INVEST, V106, P1127, DOI 10.1172/JCI9914; Guicciardi ME, 2004, ONCOGENE, V23, P2881, DOI 10.1038/sj.onc.1207512; Guicciardi ME, 2005, GASTROENTEROLOGY, V129, P269, DOI 10.1053/j.gastro.2005.05.022; Gyrd-Hansen M, 2004, CELL CYCLE, V3, P1484, DOI 10.4161/cc.3.12.1287; Gyrd-Hansen M, 2006, MOL CELL BIOL, V26, P7880, DOI 10.1128/MCB.00716-06; Hamilton RF, 2008, FREE RADICAL BIO MED, V44, P1246, DOI 10.1016/j.freeradbiomed.2007.12.027; Hayashi T, 1959, SUBCELLULAR PARTICLE; Heinrich M, 2004, CELL DEATH DIFFER, V11, P550, DOI 10.1038/sj.cdd.4401382; Hetz C, 2008, TRENDS CELL BIOL, V18, P38, DOI 10.1016/j.tcb.2007.10.003; Hishita T, 2001, CANCER RES, V61, P2878; Ichinose S, 2006, INT J ONCOL, V29, P349; Ishisaka R, 1999, CELL STRUCT FUNCT, V24, P465, DOI 10.1247/csf.24.465; Jones B, 1998, AM J PHYSIOL-GASTR L, V275, pG723, DOI 10.1152/ajpgi.1998.275.4.G723; Kagedal K, 2005, INT J EXP PATHOL, V86, P309, DOI 10.1111/j.0959-9673.2005.00442.x; Kagedal K, 2001, FASEB J, V15, P1592, DOI 10.1096/fj.00-0708fje; Kagedal K, 2001, BIOCHEM J, V359, P335, DOI 10.1042/0264-6021:3590335; Kaznelson DW, 2004, VIROLOGY, V320, P301, DOI 10.1016/j.virol.2003.12.018; Klionsky DJ, 2007, NAT REV MOL CELL BIO, V8, P931, DOI 10.1038/nrm2245; Koike M, 2000, J NEUROSCI, V20, P6898, DOI 10.1523/JNEUROSCI.20-18-06898.2000; Kolch W, 2005, NAT REV MOL CELL BIO, V6, P827, DOI 10.1038/nrm1743; Kralova J, 2008, ONCOGENE, V27, P3010, DOI 10.1038/sj.onc.1210960; Kroemer G, 2005, CELL DEATH DIFFER, V12, P1463, DOI 10.1038/sj.cdd.4401724; Kroemer G, 2005, NAT REV CANCER, V5, P886, DOI 10.1038/nrc1738; Kroemer G, 2007, PHYSIOL REV, V87, P99, DOI 10.1152/physrev.00013.2006; Kurz T, 2006, FEBS J, V273, P3106, DOI 10.1111/j.1742-4658.2006.05321.x; Kuwana T, 2005, MOL CELL, V17, P525, DOI 10.1016/j.molcel.2005.02.003; Laforge M, 2007, J VIROL, V81, P11426, DOI 10.1128/JVI.00597-07; Lamparska-Przybysz M, 2006, AUTOPHAGY, V2, P47, DOI 10.4161/auto.2149; Law RHP, 2006, GENOME BIOL, V7, DOI 10.1186/gb-2006-7-5-216; Lee CY, 2002, DEV BIOL, V250, P101, DOI 10.1006/dbio.2002.0784; Lee J, 2006, J IMMUNOL, V176, P4267, DOI 10.4049/jimmunol.176.7.4267; Levine B, 2008, CELL, V132, P27, DOI 10.1016/j.cell.2007.12.018; Li JH, 2005, J IMMUNOL, V175, P1858, DOI 10.4049/jimmunol.175.3.1858; Li N, 2007, CANCER RES, V67, P11176, DOI 10.1158/0008-5472.CAN-07-2333; Li W, 2004, ANN NY ACAD SCI, V1030, P427, DOI 10.1196/annals.1329.053; Li W, 2000, FEBS LETT, V470, P35, DOI 10.1016/S0014-5793(00)01286-2; Li W, 1998, FREE RADICAL RES, V29, P389, DOI 10.1080/10715769800300431; Li W, 2003, BIOCHEM J, V371, P429, DOI 10.1042/BJ20021520; Li W, 2007, CELL, V129, P1215, DOI 10.1016/j.cell.2007.03.054; LINK G, 1993, J LAB CLIN MED, V121, P127; Liu JA, 2004, ARTERIOSCL THROM VAS, V24, P1359, DOI 10.1161/01.ATV.0000134530.27208.41; Liu N, 2004, FEBS LETT, V569, P49, DOI 10.1016/j.febslet.2004.05.061; Liu N, 2003, EMBO J, V22, P5313, DOI 10.1093/emboj/cdg510; Liu N, 2004, NAT IMMUNOL, V5, P919, DOI 10.1038/ni1107; Liu ZH, 2005, MOL CANCER RES, V3, P21; Lopez-Otin C, 2007, NAT REV CANCER, V7, P800, DOI 10.1038/nrc2228; Luke CJ, 2007, CELL, V130, P1108, DOI 10.1016/j.cell.2007.07.013; Luzio JP, 2007, NAT REV MOL CELL BIO, V8, P622, DOI 10.1038/nrm2217; Madge LA, 2003, J BIOL CHEM, V278, P21295, DOI 10.1074/jbc.M212837200; Maiuri MC, 2007, NAT REV MOL CELL BIO, V8, P741, DOI 10.1038/nrm2239; MAK IT, 1985, J CLIN INVEST, V75, P58, DOI 10.1172/JCI111697; Malagoli D, 2006, TOXICOL LETT, V167, P75, DOI 10.1016/j.toxlet.2006.08.013; Mannick JB, 2001, J CELL BIOL, V154, P1111, DOI 10.1083/jcb.200104008; Marchi B, 2004, AQUAT TOXICOL, V66, P197, DOI 10.1016/j.aquatox.2003.09.003; Miao Q, 2008, J BIOL CHEM, V283, P8218, DOI 10.1074/jbc.M709789200; Michallet MC, 2004, J IMMUNOL, V172, P5405, DOI 10.4049/jimmunol.172.9.5405; Mihara M, 2003, MOL CELL, V11, P577, DOI 10.1016/S1097-2765(03)00050-9; MILLER DK, 1983, J CELL BIOL, V97, P1841, DOI 10.1083/jcb.97.6.1841; Mizushima N, 2007, GENE DEV, V21, P2861, DOI 10.1101/gad.1599207; Modjtahedi N, 2006, TRENDS CELL BIOL, V16, P264, DOI 10.1016/j.tcb.2006.03.008; Mohlig H, 2007, EXP CELL RES, V313, P2703, DOI 10.1016/j.yexcr.2007.04.020; Moor ACE, 2000, J PHOTOCH PHOTOBIO B, V57, P1, DOI 10.1016/S1011-1344(00)00065-8; Mousavi SA, 2003, BIOCHEM J, V372, P861, DOI 10.1042/BJ20021136; Nagaraj NS, 2006, J CANCER RES CLIN, V132, P171, DOI 10.1007/s00432-005-0053-9; Nylandsted J, 2004, J EXP MED, V200, P425, DOI 10.1084/jem.20040531; Nylandsted J, 2000, P NATL ACAD SCI USA, V97, P7871, DOI 10.1073/pnas.97.14.7871; Ono K, 2003, MOL CELL BIOL, V23, P665, DOI 10.1128/MCB.23.2.665-676.2003; Ostenfeld MS, 2005, CANCER RES, V65, P8975, DOI 10.1158/0008-5472.CAN-05-0269; Palermo C, 2008, TRENDS PHARMACOL SCI, V29, P22, DOI 10.1016/j.tips.2007.10.011; Paquet C, 2005, LEUKEMIA, V19, P784, DOI 10.1038/sj.leu.2403717; Paris C, 2007, APOPTOSIS, V12, P1257, DOI 10.1007/s10495-007-0052-1; Perez-Morga D, 2005, SCIENCE, V309, P469, DOI 10.1126/science.1114566; Peri P, 2007, J GEN VIROL, V88, P2101, DOI 10.1099/vir.0.82990-0; Riedl SJ, 2007, NAT REV MOL CELL BIO, V8, P405, DOI 10.1038/nrm2153; Roberg K, 1999, FREE RADICAL BIO MED, V27, P1228, DOI 10.1016/S0891-5849(99)00146-X; Roberts LR, 1997, GASTROENTEROLOGY, V113, P1714, DOI 10.1053/gast.1997.v113.pm9352877; Roberts ML, 2000, MOL CELL NEUROSCI, V16, P97, DOI 10.1006/mcne.2000.0867; Rohde M, 2005, GENE DEV, V19, P570, DOI 10.1101/gad.305405; Roussi S, 2007, APOPTOSIS, V12, P87, DOI 10.1007/s10495-006-0485-y; Sameni M, 2000, NEOPLASIA, V2, P496, DOI 10.1038/sj.neo.7900116; Sandes E, 2007, INT J MOL MED, V20, P823; Silverman GA, 2001, J BIOL CHEM, V276, P33293, DOI 10.1074/jbc.R100016200; Stahl S, 2007, BBA-PROTEINS PROTEOM, V1774, P1237, DOI 10.1016/j.bbapap.2007.07.004; Sukhova GK, 2003, J CLIN INVEST, V111, P897, DOI 10.1172/JCI200314915; Tardy C, 2006, BBA-REV CANCER, V1765, P101, DOI 10.1016/j.bbcan.2005.11.003; Taylor RC, 2008, NAT REV MOL CELL BIO, V9, P231, DOI 10.1038/nrm2312; Terman A, 2006, IUBMB LIFE, V58, P531, DOI 10.1080/15216540600904885; Thibodeau MS, 2004, TOXICOL SCI, V80, P34, DOI 10.1093/toxsci/kfh121; Trincheri NF, 2007, CARCINOGENESIS, V28, P922, DOI 10.1093/carcin/bgl223; Turk B, 2007, FEBS LETT, V581, P2761, DOI 10.1016/j.febslet.2007.05.038; Turk V, 2001, EMBO J, V20, P4629, DOI 10.1093/emboj/20.17.4629; Uchimoto T, 1999, APOPTOSIS, V4, P357, DOI 10.1023/A:1009695221038; van der Wel N, 2007, CELL, V129, P1287, DOI 10.1016/j.cell.2007.05.059; Vancompernolle K, 1998, FEBS LETT, V438, P150, DOI 10.1016/S0014-5793(98)01275-7; Vanhollebeke B, 2006, CELL MOL LIFE SCI, V63, P1937, DOI 10.1007/s00018-006-6091-x; Vasiljeva O, 2008, BIOCHIMIE, V90, P380, DOI 10.1016/j.biochi.2007.10.004; Ward DM, 2000, TRAFFIC, V1, P816; Welss T, 2003, BIOCHEMISTRY-US, V42, P7381, DOI 10.1021/bi027307q; Werneburg N, 2004, AM J PHYSIOL-GASTR L, V287, pG436, DOI 10.1152/ajpgi.00019.2004; Werneburg NW, 2007, J BIOL CHEM, V282, P28960, DOI 10.1074/jbc.M705671200; Werneburg NW, 2002, AM J PHYSIOL-GASTR L, V283, pG947, DOI 10.1152/ajpgi.00151.2002; Xue LY, 2003, ONCOGENE, V22, P9197, DOI 10.1038/sj.onc.1207019; Yacoub A, 2008, MOL CANCER THER, V7, P297, DOI 10.1158/1535-7163.MCT-07-2166; Yan CH, 2006, TOXICON, V47, P521, DOI 10.1016/j.toxicon.2006.01.010; Yap YW, 2006, J NEUROCHEM, V98, P1597, DOI 10.1111/j.1471-4159.2006.03996.x; Yeung BHY, 2006, J BIOL CHEM, V281, P11923, DOI 10.1074/jbc.M508533200; Yin L, 2005, J CELL BIOCHEM, V94, P433, DOI 10.1002/jcb.20277; Youle RJ, 2008, NAT REV MOL CELL BIO, V9, P47, DOI 10.1038/nrm2308; Yu ZQ, 2003, APMIS, V111, P643, DOI 10.1034/j.1600-0463.2003.1110607.x; Yuan XM, 2002, P NATL ACAD SCI USA, V99, P6286, DOI 10.1073/pnas.092135599; Yuan XM, 2000, FREE RADICAL BIO MED, V28, P208, DOI 10.1016/S0891-5849(99)00220-8; Zamzami N, 2000, ONCOGENE, V19, P6342, DOI 10.1038/sj.onc.1204030; Zang Y, 2001, CELL DEATH DIFFER, V8, P477, DOI 10.1038/sj.cdd.4400843; Zhao M, 2001, FEBS LETT, V509, P405, DOI 10.1016/S0014-5793(01)03185-4; Zhao M, 2001, FEBS LETT, V509, P399, DOI 10.1016/S0014-5793(01)03184-2; Zhao M, 2003, EUR J BIOCHEM, V270, P3778, DOI 10.1046/j.1432-1033.2003.03765.x; Zuzarte-Luis V, 2007, DEV DYNAM, V236, P880, DOI 10.1002/dvdy.21076; Zuzarte-Luis V, 2007, DEV BIOL, V301, P205, DOI 10.1016/j.ydbio.2006.08.008	174	993	1014	7	174	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 27	2008	27	50					6434	6451		10.1038/onc.2008.310	http://dx.doi.org/10.1038/onc.2008.310			18	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	366RR	18955971	Green Submitted			2022-12-28	WOS:000260501600004
J	Stewart, TJ; Abrams, SI				Stewart, T. J.; Abrams, S. I.			How tumours escape mass destruction	ONCOGENE			English	Review						tumour immunity; tumour escape; tumour microenvironment; immunosuppression; immunosurveillance	REGULATORY T-CELLS; MYELOID SUPPRESSOR-CELLS; FAS-MEDIATED APOPTOSIS; COLON-CARCINOMA CELLS; GROWTH-FACTOR-BETA; ANTIGEN-PROCESSING MACHINERY; IMMUNE-RESPONSES; PERIPHERAL-BLOOD; CANCER-IMMUNOTHERAPY; BREAST-CANCER	It is now well established that the immune system can control neoplastic development and growth in a process termed immunosurveillance. A link between host immunosurveillance and neoplastic progression is revealed in cases where the immune response becomes compromised due to genetic or other pathological conditions, resulting in a substantially increased incidence and rate of spontaneous tumour formation in both preclinical animal models and patients. It has also been demonstrated in tumour-bearing hosts that the tumorigenic process itself can promote a state of immunosuppression that, in turn, facilitates neoplastic progression. The ability of neoplastic populations to induce a hostile microenvironment through both cell contact-dependent and -independent immunosuppressive networks is a significant barrier to effective cellmediated immunity and immunotherapy. Thus, a competent immune system is integral for the control of neoplastic disease, and dissecting the plethora of tumour escape mechanisms that disrupt this essential host defense capability is integral for the development of effective immunotherapeutic paradigms.	[Stewart, T. J.; Abrams, S. I.] NCI, Tumor Immunol & Biol Lab, Ctr Canc Res, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Abrams, SI (corresponding author), Roswell Pk Canc Inst, Dept Immunol, Elm & Carlton St, Buffalo, NY 14263 USA.	scott.abrams@roswellpark.org	Stewart, Trina/F-5967-2012	Stewart, Trina/0000-0003-3220-9231	Intramural Research Program of the NIH; National Cancer Institute; Center for Cancer Research	Intramural Research Program of the NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Center for Cancer Research(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This research was supported (in part) by the Intramural Research Program of the NIH, National Cancer Institute, Center for Cancer Research.	Abrams SI, 2004, CURR OPIN MOL THER, V6, P71; Almand B, 2001, J IMMUNOL, V166, P678, DOI 10.4049/jimmunol.166.1.678; Andreola G, 2002, J EXP MED, V195, P1303, DOI 10.1084/jem.20011624; Blank C, 2007, CANCER IMMUNOL IMMUN, V56, P739, DOI 10.1007/s00262-006-0272-1; Bosque A, 2005, EUR J IMMUNOL, V35, P1812, DOI 10.1002/eji.200526046; Bron LP, 2004, PATHOLOGY, V36, P561, DOI 10.1080/00313020400011268; Bronte V, 2005, NAT REV IMMUNOL, V5, P641, DOI 10.1038/nri1668; Bui JD, 2007, CURR OPIN IMMUNOL, V19, P203, DOI 10.1016/j.coi.2007.02.001; Chang CC, 2007, CANCER IMMUNOL IMMUN, V56, P227, DOI 10.1007/s00262-006-0183-1; Cuenca A, 2003, CANCER RES, V63, P9007; Curiel TJ, 2004, NAT MED, V10, P942, DOI 10.1038/nm1093; Curiel TJ, 2007, J CLIN INVEST, V117, P1167, DOI 10.1172/JCI31202; Demaria S, 2005, CLIN CANCER RES, V11, P728; Dudley ME, 2002, SCIENCE, V298, P850, DOI 10.1126/science.1076514; Dudley ME, 2003, NAT REV CANCER, V3, P666, DOI 10.1038/nrc1167; Dunn GP, 2006, NAT REV IMMUNOL, V6, P836, DOI 10.1038/nri1961; Ercolini AM, 2005, J EXP MED, V201, P1591, DOI 10.1084/jem.20042167; Espana L, 2004, BREAST CANCER RES TR, V87, P33, DOI 10.1023/B:BREA.0000041579.51902.89; Ferris RL, 2006, CLIN CANCER RES, V12, P3890, DOI 10.1158/1078-0432.CCR-05-2750; Filipazzi P, 2007, J CLIN ONCOL, V25, P2546, DOI 10.1200/JCO.2006.08.5829; Flies DB, 2007, J IMMUNOTHER, V30, P251, DOI 10.1097/CJI.0b013e31802e085a; Freeman GJ, 2000, J EXP MED, V192, P1027, DOI 10.1084/jem.192.7.1027; Fricke I, 2007, CLIN CANCER RES, V13, P4840, DOI 10.1158/1078-0432.CCR-07-0409; Gallimore A, 2002, IMMUNOLOGY, V107, P5, DOI 10.1046/j.1365-2567.2002.01471.x; Giovarelli M, 1999, J IMMUNOL, V163, P4886; Gordon N, 2005, J PEDIAT HEMATOL ONC, V27, P611, DOI 10.1097/01.mph.0000188112.42576.df; Greeneltch KM, 2007, CANCER RES, V67, P10406, DOI 10.1158/0008-5472.CAN-07-1228; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Harizi H, 2001, CELL IMMUNOL, V209, P19, DOI 10.1006/cimm.2001.1785; Hirano F, 2005, CANCER RES, V65, P1089; Hoffmann TK, 2002, CLIN CANCER RES, V8, P2553; Holtschke T, 1996, CELL, V87, P307, DOI 10.1016/S0092-8674(00)81348-3; Ichihara F, 2003, CLIN CANCER RES, V9, P4404; Iwai Y, 2002, P NATL ACAD SCI USA, V99, P12293, DOI 10.1073/pnas.192461099; Jung YJ, 2004, INT J MOL MED, V13, P99; Keane MM, 1996, CANCER RES, V56, P4791; Kim R, 2004, CANCER-AM CANCER SOC, V100, P2281, DOI 10.1002/cncr.20270; Koneru M, 2005, J IMMUNOL, V174, P1830, DOI 10.4049/jimmunol.174.4.1830; Korman AJ, 2006, ADV IMMUNOL, V90, P297, DOI 10.1016/S0065-2776(06)90008-X; Kortylewski M, 2005, NAT MED, V11, P1314, DOI 10.1038/nm1325; Krambeck AE, 2006, P NATL ACAD SCI USA, V103, P10391, DOI 10.1073/pnas.0600937103; Krammer PH, 1998, ADV CANCER RES, V75, P251, DOI 10.1016/S0065-230X(08)60744-7; Kryczek I, 2006, J EXP MED, V203, P871, DOI 10.1084/jem.20050930; Kusmartsev S, 2006, CANCER IMMUNOL IMMUN, V55, P237, DOI 10.1007/s00262-005-0048-z; Kuss I, 2004, CLIN CANCER RES, V10, P3755, DOI 10.1158/1078-0432.CCR-04-0054; Latchman Y, 2001, NAT IMMUNOL, V2, P261, DOI 10.1038/85330; Leach DR, 1996, SCIENCE, V271, P1734, DOI 10.1126/science.271.5256.1734; Lee PP, 1999, NAT MED, V5, P677, DOI 10.1038/9525; Li MO, 2006, ANNU REV IMMUNOL, V24, P99, DOI 10.1146/annurev.immunol.24.021605.090737; Lin EY, 2007, CANCER RES, V67, P5064, DOI 10.1158/0008-5472.CAN-07-0912; Litzinger MT, 2007, BLOOD, V110, P3192, DOI 10.1182/blood-2007-06-094615; Liu KB, 2005, CANCER RES, V65, P4376, DOI 10.1158/0008-5472.CAN-04-4269; Liu KB, 2005, CANCER RES, V65, P1045; Liu KB, 2003, J IMMUNOL, V171, P4164, DOI 10.4049/jimmunol.171.8.4164; Liu KB, 2003, J IMMUNOL, V170, P6329, DOI 10.4049/jimmunol.170.12.6329; Liu KB, 2003, J IMMUNOL, V170, P5973, DOI 10.4049/jimmunol.170.12.5973; Liu KB, 2006, J IMMUNOL, V176, P3374, DOI 10.4049/jimmunol.176.6.3374; Liyanage UK, 2002, J IMMUNOL, V169, P2756, DOI 10.4049/jimmunol.169.5.2756; Lopez-Albaitero A, 2006, J IMMUNOL, V176, P3402, DOI 10.4049/jimmunol.176.6.3402; Mirza N, 2006, CANCER RES, V66, P9299, DOI 10.1158/0008-5472.CAN-06-1690; Nagaraj S, 2007, ADV EXP MED BIOL, V601, P213; Nishimura H, 2001, SCIENCE, V291, P319, DOI 10.1126/science.291.5502.319; Ochoa AC, 2007, CLIN CANCER RES, V13, p721S, DOI 10.1158/1078-0432.CCR-06-2197; Ochsenbein AF, 1999, P NATL ACAD SCI USA, V96, P2233, DOI 10.1073/pnas.96.5.2233; Ohigashi Y, 2005, CLIN CANCER RES, V11, P2947, DOI 10.1158/1078-0432.CCR-04-1469; Ormandy LA, 2005, CANCER RES, V65, P2457, DOI 10.1158/0008-5472.CAN-04-3232; OTTEN GR, 1991, SCIENCE, V251, P1228, DOI 10.1126/science.1900952; Overwijk WW, 2003, J EXP MED, V198, P569, DOI 10.1084/jem.20030590; Owen-Schaub L, 2000, INT J ONCOL, V17, P5; Pardoll D, 2003, ANNU REV IMMUNOL, V21, P807, DOI 10.1146/annurev.immunol.21.120601.141135; Pawelec Graham, 2002, Trends in Immunology, V23, P330, DOI 10.1016/S1471-4906(02)02255-X; Penn I, 1999, TRANSPLANT P, V31, P1260, DOI 10.1016/S0041-1345(98)01987-3; Phan GQ, 2003, P NATL ACAD SCI USA, V100, P8372, DOI 10.1073/pnas.1533209100; Pollard JW, 2004, NAT REV CANCER, V4, P71, DOI 10.1038/nrc1256; Reckamp KL, 2006, CLIN CANCER RES, V12, P3381, DOI 10.1158/1078-0432.CCR-06-0112; Rodriguez PC, 2005, J EXP MED, V202, P931, DOI 10.1084/jem.20050715; Sadun RE, 2007, CLIN CANCER RES, V13, P4016, DOI 10.1158/1078-0432.CCR-07-0016; Sakaguchi S, 2004, ANNU REV IMMUNOL, V22, P531, DOI 10.1146/annurev.immunol.21.120601.141122; Schmielau J, 2001, CANCER RES, V61, P4756; Serafini P, 2004, CANCER RES, V64, P6337, DOI 10.1158/0008-5472.CAN-04-0757; Shevach EM, 2000, ANNU REV IMMUNOL, V18, P423, DOI 10.1146/annurev.immunol.18.1.423; Sica GL, 2003, IMMUNITY, V18, P849, DOI 10.1016/S1074-7613(03)00152-3; Sinha P, 2007, CANCER RES, V67, P4507, DOI 10.1158/0008-5472.CAN-06-4174; Smyth MJ, 2006, ADV IMMUNOL, V90, P1, DOI 10.1016/S0065-2776(06)90001-7; Smyth MJ, 2000, J EXP MED, V192, P755, DOI 10.1084/jem.192.5.755; Steinman RM, 2003, ANNU REV IMMUNOL, V21, P685, DOI 10.1146/annurev.immunol.21.120601.141040; Stewart Trina J., 2007, Expert Reviews in Molecular Medicine, V9, P1, DOI 10.1017/S1462399407000233; Street SEA, 2007, CANCER RES, V67, P5454, DOI 10.1158/0008-5472.CAN-06-4084; Suzuki E, 2005, CLIN CANCER RES, V11, P6713, DOI 10.1158/1078-0432.CCR-05-0883; Takeda K, 2001, NAT MED, V7, P94, DOI 10.1038/83416; Terabe M, 2003, J EXP MED, V198, P1741, DOI 10.1084/jem.20022227; Terabe M, 2000, NAT IMMUNOL, V1, P515, DOI 10.1038/82771; Thomas DA, 2005, CANCER CELL, V8, P369, DOI 10.1016/j.ccr.2005.10.012; Thompson RH, 2006, CANCER RES, V66, P3381, DOI 10.1158/0008-5472.CAN-05-4303; Vakkila J, 2004, NAT REV IMMUNOL, V4, P641, DOI 10.1038/nri1415; van Elsas A, 1999, J EXP MED, V190, P355, DOI 10.1084/jem.190.3.355; Vogelstein B, 2004, NAT MED, V10, P789, DOI 10.1038/nm1087; von Reyher U, 1998, CANCER RES, V58, P526; Wang TH, 2004, NAT MED, V10, P48, DOI 10.1038/nm976; Whiteside TL, 2006, SEMIN CANCER BIOL, V16, P3, DOI 10.1016/j.semcancer.2005.07.008; Willimsky G, 2005, NATURE, V437, P141, DOI 10.1038/nature03954; Woo EY, 2001, CANCER RES, V61, P4766; Worth LL, 2002, ONCOL REP, V9, P823; Yang DF, 2007, CANCER RES, V67, P3301, DOI 10.1158/0008-5472.CAN-06-4068; Yang L, 2004, CANCER CELL, V6, P409, DOI 10.1016/j.ccr.2004.08.031; Yu H, 2007, NAT REV IMMUNOL, V7, P41, DOI 10.1038/nri1995; Zamanakou M, 2007, IMMUNOL LETT, V111, P69, DOI 10.1016/j.imlet.2007.06.001; Zea AH, 2005, CANCER RES, V65, P3044, DOI 10.1158/0008-5472.CAN-04-4505; Zhou G, 2006, BLOOD, V107, P628, DOI 10.1182/blood-2005-07-2737	109	150	159	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 6	2008	27	45					5894	5903		10.1038/onc.2008.268	http://dx.doi.org/10.1038/onc.2008.268			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	355QE	18836470	Bronze			2022-12-28	WOS:000259722600004
J	Huang, L; Verstrepen, L; Heyninck, K; Wullaert, A; Revets, H; De Baetselier, P; Beyaert, R				Huang, L.; Verstrepen, L.; Heyninck, K.; Wullaert, A.; Revets, H.; De Baetselier, P.; Beyaert, R.			ABINs inhibit EGF receptor-mediated NF-kappa B activation and growth of EGF receptor-overexpressing tumour cells	ONCOGENE			English	Article						ABIN; EGF receptor; NF-kappa B; proliferation; cancer	ADENOVIRAL GENE-TRANSFER; BREAST-CANCER; A20-BINDING INHIBITOR; TRANSCRIPTION FACTOR; THERAPEUTIC TARGET; BINDING-PROTEIN; CYCLIN D1; EXPRESSION; PHOSPHORYLATION; KINASE	The epidermal growth factor receptor (EGFR) is frequently overexpressed in various tumours of epidermal origin and is held responsible for tumourigenicity and tumour persistence. Increased nuclear factor (NF)-kappa B activity has been suggested to be involved in the malignant behaviour of EGFR-overexpressing cells. However, the mechanisms that regulate EGF-induced NF-kappa B activation are still largely unknown. Here we show that EGF can induce NF-kappa B-dependent gene expression independently from I kappa B alpha degradation or p100 processing in EGFR-overexpressing HEK293T cells. Moreover, EGF-induced NF-kappa B activation could be inhibited by overexpression of ABINs, which were previously identified as intracellular inhibitors of tumour necrosis factor, interleukin-1 and lipopolysaccharide-induced NF-kappa B activation. Knockdown of ABIN-1 by RNA interference boosted the NF-kappa B response upon EGF stimulation. The C-terminal ubiquitin-binding domain containing region of ABINs was crucial and sufficient for NF-kappa B inhibition. Adenoviral gene transfer of ABINs reduced constitutive NF-kappa B activity as well as the proliferation of EGFR-overexpressing A431 and DU145 human carcinoma cells. Altogether, these results demonstrate an important role for an ABIN-sensitive non-classical NF-kappa B signalling pathway in the proliferation of EGFR-overexpressing tumour cells, and indicate a potential use for ABIN gene therapy in the treatment of cancer.	[Huang, L.; Verstrepen, L.; Heyninck, K.; Wullaert, A.; Beyaert, R.] Univ Ghent VIB, Dept Mol Biomed Res, Unit Mol Signal Transduct Inflammat, B-9052 Ghent, Oost Vlaanderen, Belgium; [Huang, L.; Revets, H.; De Baetselier, P.] Vrije Univ Brussel, Cellular & Mol Immunol Lab, Brussels, Belgium; [Huang, L.; Revets, H.; De Baetselier, P.] VIB, Dept Mol & Cellular Interact, Brussels, Belgium; [Huang, L.; Verstrepen, L.; Heyninck, K.; Wullaert, A.; Beyaert, R.] Univ Ghent, Dept Mol Biol, B-9000 Ghent, Belgium	Flanders Institute for Biotechnology (VIB); Ghent University; Vrije Universiteit Brussel; Flanders Institute for Biotechnology (VIB); Ghent University	Beyaert, R (corresponding author), Univ Ghent VIB, Dept Mol Biomed Res, Unit Mol Signal Transduct Inflammat, Technol Pk 927, B-9052 Ghent, Oost Vlaanderen, Belgium.	rudi.beyaert@dmbr.ugent.be	De Baetselier, Patrick/D-3866-2014; Huang, Lieven/B-4630-2008; Wullaert, Andy/R-1924-2019; Beyaert, Rudi/B-2589-2009; Wullaert, Andy/D-2975-2018	Wullaert, Andy/0000-0001-5012-654X; Wullaert, Andy/0000-0001-5012-654X; Beyaert, Rudi/0000-0002-5704-582X	Interuniversitaire Attractiepolen [IAP6/18]; 'Fonds voor Wetenschappelijk Onderzoek-Vlaanderen' (FWO-Vlaanderen); GOA of the University of Gent; IWT-Vlaanderen; Emmanuel Vanderschueren Stichting	Interuniversitaire Attractiepolen; 'Fonds voor Wetenschappelijk Onderzoek-Vlaanderen' (FWO-Vlaanderen)(FWO); GOA of the University of Gent; IWT-Vlaanderen(Institute for the Promotion of Innovation by Science and Technology in Flanders (IWT)); Emmanuel Vanderschueren Stichting	This work was supported in part by grants from the 'Interuniversitaire Attractiepolen' (IAP6/18), the 'Fonds voor Wetenschappelijk Onderzoek-Vlaanderen' (FWO-Vlaanderen), the GOA of the University of Gent. LH is a predoctoral research fellow supported by the IWT-Vlaanderen and the Emmanuel Vanderschueren Stichting.	Adli M, 2006, J BIOL CHEM, V281, P26976, DOI 10.1074/jbc.M603133200; Anest V, 2004, J BIOL CHEM, V279, P31183, DOI 10.1074/jbc.M404380200; Anto RJ, 2003, J BIOL CHEM, V278, P25490, DOI 10.1074/jbc.M301790200; Bhat-Nakshatri P, 2002, ONCOGENE, V21, P2066, DOI 10.1038/sj.onc.1205243; Biswas DK, 2000, P NATL ACAD SCI USA, V97, P8542, DOI 10.1073/pnas.97.15.8542; Biswas DK, 2004, P NATL ACAD SCI USA, V101, P10137, DOI 10.1073/pnas.0403621101; Biswas DK, 2001, P NATL ACAD SCI USA, V98, P10386, DOI 10.1073/pnas.151257998; Buss H, 2004, J BIOL CHEM, V279, P55633, DOI 10.1074/jbc.M409825200; Carter RE, 1998, J BIOL CHEM, V273, P35000, DOI 10.1074/jbc.273.52.35000; Chen DY, 2003, ONCOGENE, V22, P4348, DOI 10.1038/sj.onc.1206532; Chinnaiyan P, 2005, CANCER RES, V65, P3328, DOI 10.1158/0008-5472.CAN-04-3547; Damiano V, 2006, CLIN CANCER RES, V12, P577, DOI 10.1158/1078-0432.CCR-05-1943; DeValck D, 1997, BIOCHEM BIOPH RES CO, V238, P590, DOI 10.1006/bbrc.1997.7343; El Bakkouri K, 2005, J BIOL CHEM, V280, P17938, DOI 10.1074/jbc.M413588200; El Sheikh SS, 2004, NEOPLASIA, V6, P846, DOI 10.1593/neo.04379; FAN Z, 1993, CANCER RES, V53, P4322; Gasparian AV, 2002, J CELL SCI, V115, P141; Grempler R, 2004, BIOCHEM J, V382, P471, DOI 10.1042/BJ20040160; Guo GZ, 2004, ONCOGENE, V23, P535, DOI 10.1038/sj.onc.1207149; Guttridge DC, 1999, MOL CELL BIOL, V19, P5785; HACKER H, 2006, SCI STKE, DOI DOI 10.1126/STKE.3572006RE13; Haussler U, 2005, AM J PHYSIOL-RENAL, V289, pF808, DOI 10.1152/ajprenal.00434.2003; Heyninck K, 2005, TRENDS BIOCHEM SCI, V30, P1, DOI 10.1016/j.tibs.2004.11.001; Heyninck K, 1999, J CELL BIOL, V145, P1471, DOI 10.1083/jcb.145.7.1471; Heyninck K, 2003, FEBS LETT, V536, P135, DOI 10.1016/S0014-5793(03)00041-3; Hinz M, 1999, MOL CELL BIOL, V19, P2690; Hoeller D, 2006, NAT CELL BIOL, V8, P163, DOI 10.1038/ncb1354; Johnston JB, 2006, CURR MED CHEM, V13, P3483, DOI 10.2174/092986706779026174; Keutgens A, 2006, BIOCHEM PHARMACOL, V72, P1069, DOI 10.1016/j.bcp.2006.06.011; Kirkwood KS, 2003, J GASTROINTEST SURG, V7, P43; KONGER RL, 1993, J CELL PHYSIOL, V156, P515, DOI 10.1002/jcp.1041560310; Le Page C, 2005, PROSTATE, V65, P306, DOI 10.1002/pros.20291; Liptay S, 2003, INT J CANCER, V105, P735, DOI 10.1002/ijc.11081; Makino K, 2004, ONCOGENE, V23, P3883, DOI 10.1038/sj.onc.1207485; Mauro C, 2006, J BIOL CHEM, V281, P18482, DOI 10.1074/jbc.M601502200; Meeran SM, 2008, FRONT BIOSCI-LANDMRK, V13, P2191, DOI 10.2741/2834; Miggin SM, 2006, J LEUKOCYTE BIOL, V80, P220, DOI 10.1189/jlb.1105672; Neumann M, 2007, FASEB J, V21, P2642, DOI 10.1096/fj.06-7615rev; Normanno N, 2006, GENE, V366, P2, DOI 10.1016/j.gene.2005.10.018; Olivier S, 2006, BIOCHEM PHARMACOL, V72, P1054, DOI 10.1016/j.bcp.2006.07.023; Pacifico F, 2006, BIOCHEM PHARMACOL, V72, P1142, DOI 10.1016/j.bcp.2006.07.032; Papoutsopoulou S, 2006, NAT IMMUNOL, V7, P606, DOI 10.1038/ni1334; Peng D, 1996, CANCER RES, V56, P3666; Reid A, 2007, EUR J CANCER, V43, P481, DOI 10.1016/j.ejca.2006.11.007; Romashkova JA, 1999, NATURE, V401, P86, DOI 10.1038/43474; Sclabas GM, 2003, J GASTROINTEST SURG, V7, P37, DOI 10.1016/S1091-255X(02)00088-4; Sethi G, 2007, ONCOGENE, V26, P7324, DOI 10.1038/sj.onc.1210544; Singh S, 2007, MOL CANCER THER, V6, P1973, DOI 10.1158/1535-7163.MCT-07-0063; Sitcheran R, 2005, EMBO J, V24, P510, DOI 10.1038/sj.emboj.7600555; STOVER DR, 1995, J BIOL CHEM, V270, P15591, DOI 10.1074/jbc.270.26.15591; Strassheim D, 2004, J IMMUNOL, V172, P5727, DOI 10.4049/jimmunol.172.9.5727; Sun L, 1998, ONCOGENE, V16, P2095, DOI 10.1038/sj.onc.1201731; Tang XM, 2006, CANCER, V107, P2637, DOI 10.1002/cncr.22315; Tian B, 2005, J BIOL CHEM, V280, P17435, DOI 10.1074/jbc.M500437200; TRAENCKNER EBM, 1995, EMBO J, V14, P2876, DOI 10.1002/j.1460-2075.1995.tb07287.x; Van Huffel S, 2001, J BIOL CHEM, V276, P30216, DOI 10.1074/jbc.M100048200; Van Laere SJ, 2007, BRIT J CANCER, V97, P659, DOI 10.1038/sj.bjc.6603906; Verstrepen L, 2008, J CELL MOL MED, V12, P316, DOI 10.1111/j.1582-4934.2007.00187.x; Wagner S, 2008, ONCOGENE, V27, P3739, DOI 10.1038/sj.onc.1211042; Weaver BK, 2007, MOL CELL BIOL, V27, P4603, DOI 10.1128/MCB.00223-07; Wullaert A, 2005, HEPATOLOGY, V42, P381, DOI 10.1002/hep.20785; Wullaert A, 2007, J BIOL CHEM, V282, P81, DOI 10.1074/jbc.M607481200; Wullaert A, 2006, TRENDS IMMUNOL, V27, P533, DOI 10.1016/j.it.2006.09.003; Yang C, 2008, BIOCHEM J, V410, P167, DOI 10.1042/BJ20070781; Zhang SL, 2002, BIOCHEM BIOPH RES CO, V297, P17, DOI 10.1016/S0006-291X(02)02086-7	65	28	32	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT	2008	27	47					6131	6140		10.1038/onc.2008.208	http://dx.doi.org/10.1038/onc.2008.208			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	360UJ	18622428				2022-12-28	WOS:000260083100006
J	Carracedo, A; Pandolfi, PP				Carracedo, A.; Pandolfi, P. P.			The PTEN-PI3K pathway: of feedbacks and cross-talks	ONCOGENE			English	Review						feedback; PTEN; PI3K; drug combination; cross-talk	INSULIN-RECEPTOR SUBSTRATE-1; TUMOR-SUPPRESSOR PTEN; ACTIVATED PROTEIN-KINASE; PROSTATE INTRAEPITHELIAL NEOPLASIA; TRANSCRIPTION FACTOR FKHR; HEMATOPOIETIC STEM-CELLS; GROWTH-FACTOR RECEPTOR; B-RAF KINASE; PHOSPHOINOSITIDE 3-KINASE; TUBEROUS SCLEROSIS	The tumor suppressor PTEN was originally identified as a negative regulator of the phosphoinositide 3-kinase (PI3K) signaling, a main regulator of cell growth, metabolism and survival. Yet this function of PTEN is extremely relevant for its tumor-suppressive ability, albeit the recent characterization of many PI3K-independent tumor-suppressive activities. PI3K-mediated PIP3 production leads to the activation of the canonical AKT-mTORC1 pathway. The implications of this signaling cascade in health and disease have been underscored by the high number of regulators within the pathway whose alterations give rise to different malignancies, including familiar syndromes, metabolic dysfunctions and cancer. Moreover, PI3K is tightly buffered at multiple levels by downstream components, which have turned this signaling pathway literally upside down. PI3K and its downstream components in turn cross-talk with a number of other pathways, thereby leading to a complex network of signals that may have dramatic consequences when perturbed. Here, we review the current status of the PTEN-PI3K signaling pathway with special emphasis on the most recent data on targets and regulation of the PTEN-PI3K axis. This provides novel provocative therapeutic implications based on the targeted modulation of PI3K-cross-talking signals.	[Carracedo, A.; Pandolfi, P. P.] Harvard Univ, Sch Med, Canc Genet Program, Beth Israel Deaconess Canc Ctr,Dept Med & Pathol, Boston, MA 02215 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School	Pandolfi, PP (corresponding author), Harvard Univ, Sch Med, Canc Genet Program, Beth Israel Deaconess Canc Ctr,Dept Med & Pathol, Boston, MA 02215 USA.	ppandolf@bidmc.harvard.edu	Carracedo, Arkaitz/F-7029-2011	Carracedo, Arkaitz/0000-0001-5957-1260	US National Cancer Institute; European Molecular Biology Organization Long-Term Fellowship Award	US National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); European Molecular Biology Organization Long-Term Fellowship Award(European Molecular Biology Organization (EMBO))	We thank all members of the Pandolfi lab who contributed to these ideas. In particular, we are grateful to L Salmena and MS Song for insightful discussions. The work of PPP was supported by the US National Cancer Institute, and AC was supported by a European Molecular Biology Organization Long-Term Fellowship Award.	Ahn Y, 2008, BIOCHEM J, V412, P331, DOI 10.1042/BJ20071403; Albuquerque C, 2002, HUM MOL GENET, V11, P1549, DOI 10.1093/hmg/11.13.1549; Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9; Almind K, 1996, J CLIN INVEST, V97, P2569, DOI 10.1172/JCI118705; Ashcroft M, 2002, ONCOGENE, V21, P1955, DOI 10.1038/sj.onc.1205276; Backer JM, 2008, BIOCHEM J, V410, P1, DOI 10.1042/BJ20071427; Bader AG, 2005, NAT REV CANCER, V5, P921, DOI 10.1038/nrc1753; Bai XC, 2007, SCIENCE, V318, P977, DOI 10.1126/science.1147379; Bandyopadhyay GK, 2005, DIABETES, V54, P2351, DOI 10.2337/diabetes.54.8.2351; Barber Domingo F, 2006, Sci STKE, V2006, ppe49, DOI 10.1126/stke.3622006pe49; Baselga J, 2008, BIOMARKERS, V13, P217, DOI [10.1080/13547500701676019, 10.1080/13547500701676019 ]; Bayascas JR, 2005, MOL CELL, V18, P143, DOI 10.1016/j.molcel.2005.03.020; Beck SE, 2007, CANCER BIOL THER, V6, P1313; Berg CE, 2002, BIOCHEM BIOPH RES CO, V293, P1021, DOI 10.1016/S0006-291X(02)00333-9; Bernardi R, 2006, NATURE, V442, P779, DOI 10.1038/nature05029; Biggs WH, 1999, P NATL ACAD SCI USA, V96, P7421, DOI 10.1073/pnas.96.13.7421; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Burgering B, 2008, ONCOGENE, V27, P2258, DOI 10.1038/onc.2008.29; Cantley LC, 2002, SCIENCE, V296, P1655, DOI 10.1126/science.296.5573.1655; Carpten JD, 2007, NATURE, V448, P439, DOI 10.1038/nature05933; CARRACEDO A, 2008, J CLIN INVE IN PRESS; CARRACEDO A, 2008, CELL, V133; Chen H, 1996, CELL, V84, P491, DOI 10.1016/S0092-8674(00)81294-5; Chen ZB, 2005, NATURE, V436, P725, DOI 10.1038/nature03918; Cloughesy TF, 2008, PLOS MED, V5, P139, DOI 10.1371/journal.pmed.0050008; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; Culjkovic B, 2008, J CELL BIOL, V181, P51, DOI 10.1083/jcb.200707018; D'Alfonso R, 2003, J CLIN ENDOCR METAB, V88, P317, DOI 10.1210/jc.2002-020807; Dan HC, 2002, J BIOL CHEM, V277, P35364, DOI 10.1074/jbc.M205838200; delPeso L, 1997, SCIENCE, V278, P687; Denley A, 2008, ONCOGENE, V27, P2561, DOI 10.1038/sj.onc.1210918; Denning G, 2007, ONCOGENE, V26, P3930, DOI 10.1038/sj.onc.1210175; Di Cristofano A, 1999, SCIENCE, V285, P2122, DOI 10.1126/science.285.5436.2122; Di Cristofano A, 1998, NAT GENET, V19, P348, DOI 10.1038/1235; Dorrello NV, 2006, SCIENCE, V314, P467, DOI 10.1126/science.1130276; Du KY, 2003, SCIENCE, V300, P1574, DOI 10.1126/science.1079817; ENDERSBY R, 2008, ONCOGENE IN PRESS; Eng C, 2003, HUM MUTAT, V22, P183, DOI 10.1002/humu.10257; Engelman JA, 2006, NAT REV GENET, V7, P606, DOI 10.1038/nrg1879; Esposito DL, 2003, J CLIN ENDOCR METAB, V88, P1468, DOI 10.1210/jc.2002-020933; Faivre S, 2006, NAT REV DRUG DISCOV, V5, P671, DOI 10.1038/nrd2062; Fivaz M, 2008, CURR BIOL, V18, P44, DOI 10.1016/j.cub.2007.11.051; Fraser MM, 2008, NEUROSCIENCE, V151, P476, DOI 10.1016/j.neuroscience.2007.10.048; Fraser MM, 2004, CANCER RES, V64, P7773, DOI 10.1158/0008-5472.CAN-04-2487; Fujita N, 2002, J BIOL CHEM, V277, P28706, DOI 10.1074/jbc.M203668200; Funamoto S, 2002, CELL, V109, P611, DOI 10.1016/S0092-8674(02)00755-9; Gao TY, 2005, MOL CELL, V18, P13, DOI 10.1016/j.molcel.2005.03.008; Garami A, 2003, MOL CELL, V11, P1457, DOI 10.1016/S1097-2765(03)00220-X; GARCIAECHEVERRI.C, 2008, ONCOGENE IN PRESS; Garlich JR, 2008, CANCER RES, V68, P206, DOI 10.1158/0008-5472.CAN-07-0669; George S, 2004, SCIENCE, V304, P1325, DOI 10.1126/science.1096706; Ghilardi N, 1996, P NATL ACAD SCI USA, V93, P6231, DOI 10.1073/pnas.93.13.6231; Greene MW, 2003, J BIOL CHEM, V278, P8199, DOI 10.1074/jbc.M209153200; Gu JG, 1998, J CELL BIOL, V143, P1375, DOI 10.1083/jcb.143.5.1375; Guan KL, 2000, J BIOL CHEM, V275, P27354; Guertin DA, 2007, CANCER CELL, V12, P9, DOI 10.1016/j.ccr.2007.05.008; Gulati P, 2008, CELL METAB, V7, P456, DOI 10.1016/j.cmet.2008.03.002; Guo SD, 1999, J BIOL CHEM, V274, P17184, DOI 10.1074/jbc.274.24.17184; Gupta S, 2007, CELL, V129, P957, DOI 10.1016/j.cell.2007.03.051; Han SW, 2008, AM J PHYSIOL-LUNG C, V294, pL1238, DOI 10.1152/ajplung.00017.2008; Harrington LS, 2004, J CELL BIOL, V166, P213, DOI 10.1083/jcb.200403069; Hartley D, 2002, J CELL BIOCHEM, V85, P304, DOI 10.1002/jcb.10135; Haruta T, 2000, MOL ENDOCRINOL, V14, P783, DOI 10.1210/me.14.6.783; Harvey R Donald, 2007, Future Oncol, V3, P639, DOI 10.2217/14796694.3.6.639; HERMAN PK, 1990, MOL CELL BIOL, V10, P6742, DOI 10.1128/MCB.10.12.6742; Hettinger K, 2007, CELL DEATH DIFFER, V14, P218, DOI 10.1038/sj.cdd.4401946; Huang JX, 2008, MOL CELL BIOL, V28, P4104, DOI 10.1128/MCB.00289-08; Im E, 2002, ONCOGENE, V21, P6356, DOI 10.1038/sj.onc.1205792; Inoki K, 2002, NAT CELL BIOL, V4, P648, DOI 10.1038/ncb839; Inoki K, 2003, GENE DEV, V17, P1829, DOI 10.1101/gad.1110003; JACOBSEN SN, 2004, J BIOL CHEM, V276, P46912; Jozwiak J, 2008, LANCET ONCOL, V9, P73, DOI 10.1016/S1470-2045(07)70411-4; Karbowniczek M, 2004, J BIOL CHEM, V279, P29930, DOI 10.1074/jbc.M402591200; Karbowniczek M, 2006, J BIOL CHEM, V281, P25447, DOI 10.1074/jbc.M605273200; Katso R, 2001, ANNU REV CELL DEV BI, V17, P615, DOI 10.1146/annurev.cellbio.17.1.615; Kawanishi M, 1997, DIABETES CARE, V20, P1043, DOI 10.2337/diacare.20.6.1043; KIM MS, 2008, BRIT J CANCER, V118, P1700; Kim S, 2004, J BIOL CHEM, V279, P4285, DOI 10.1074/jbc.M308383200; Knudson AG, 1996, J CANCER RES CLIN, V122, P135, DOI 10.1007/BF01366952; Kops GJPL, 1999, NATURE, V398, P630, DOI 10.1038/19328; Kovacina KS, 2003, J BIOL CHEM, V278, P10189, DOI 10.1074/jbc.M210837200; Kurlawalla-Martinez C, 2005, MOL CELL BIOL, V25, P2498, DOI 10.1128/MCB.25.6.2498-2510.2005; Lahlou H, 2003, J BIOL CHEM, V278, P39356, DOI 10.1074/jbc.M304524200; Lee JT, 2008, CELL CYCLE, V7, P631, DOI 10.4161/cc.7.5.5416; Li DM, 1997, CANCER RES, V57, P2124; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; Lindsay Y, 2006, J CELL SCI, V119, P5160, DOI 10.1242/jcs.000133; Liu JL, 2007, CANCER RES, V67, P11054, DOI 10.1158/0008-5472.CAN-07-1263; LoPiccolo J, 2008, DRUG RESIST UPDATE, V11, P32, DOI 10.1016/j.drup.2007.11.003; Luo J, 2005, P NATL ACAD SCI USA, V102, P10238, DOI 10.1073/pnas.0504378102; Luo J, 2005, J CELL BIOL, V170, P455, DOI 10.1083/jcb.200503088; Luo J, 2003, CANCER CELL, V4, P257, DOI 10.1016/S1535-6108(03)00248-4; Ma L, 2005, CELL, V121, P179, DOI 10.1016/j.cell.2005.02.031; Ma L, 2005, GENE DEV, V19, P1779, DOI 10.1101/gad.1314405; Ma L, 2007, CANCER RES, V67, P7106, DOI 10.1158/0008-5472.CAN-06-4798; Mabuchi S, 2002, J BIOL CHEM, V277, P33490, DOI 10.1074/jbc.M204042200; Maehama T, 1998, J BIOL CHEM, V273, P13375, DOI 10.1074/jbc.273.22.13375; Majumder PK, 2003, P NATL ACAD SCI USA, V100, P7841, DOI 10.1073/pnas.1232229100; Majumder PK, 2004, NAT MED, V10, P594, DOI 10.1038/nm1052; Malanga D, 2008, CELL CYCLE, V7, P665, DOI 10.4161/cc.7.5.5485; Manning BD, 2005, GENE DEV, V19, P1773, DOI 10.1101/gad.1314605; Manning BD, 2004, J CELL BIOL, V167, P399, DOI 10.1083/jcb.200408161; Manning BD, 2007, CELL, V129, P1261, DOI 10.1016/j.cell.2007.06.009; Mayo LD, 2001, P NATL ACAD SCI USA, V98, P11598, DOI 10.1073/pnas.181181198; Moelling K, 2002, J BIOL CHEM, V277, P31099, DOI 10.1074/jbc.M111974200; Nakae J, 1999, J BIOL CHEM, V274, P15982, DOI 10.1074/jbc.274.23.15982; Ni YG, 2007, P NATL ACAD SCI USA, V104, P20517, DOI 10.1073/pnas.0610290104; Nobukuni T, 2005, P NATL ACAD SCI USA, V102, P14238, DOI 10.1073/pnas.0506925102; O'Reilly KE, 2006, CANCER RES, V66, P1500, DOI 10.1158/0008-5472.CAN-05-2925; Ozean U, 2008, MOL CELL, V29, P541, DOI [10.1016/j.moicel.2007.12.023, 10.1016/j.molcel.2007.12.023]; Ozes ON, 2001, P NATL ACAD SCI USA, V98, P4640, DOI 10.1073/pnas.051042298; Palomero T, 2007, NAT MED, V13, P1203, DOI 10.1038/nm1636; Papakonstanti EA, 2007, EMBO J, V26, P3050, DOI 10.1038/sj.emboj.7601763; Pirola L, 2003, J BIOL CHEM, V278, P15641, DOI 10.1074/jbc.M208984200; Potter CJ, 2002, NAT CELL BIOL, V4, P658, DOI 10.1038/ncb840; Radimerski T, 2002, GENE DEV, V16, P2627, DOI 10.1101/gad.239102; Ramjaun AR, 2007, CELL CYCLE, V6, P2902, DOI 10.4161/cc.6.23.4996; Raught B, 2004, EMBO J, V23, P1761, DOI 10.1038/sj.emboj.7600193; Rena G, 1999, J BIOL CHEM, V274, P17179, DOI 10.1074/jbc.274.24.17179; Reusch HP, 2001, J BIOL CHEM, V276, P33630, DOI 10.1074/jbc.M105322200; RodriguezViciana P, 1997, CELL, V89, P457, DOI 10.1016/S0092-8674(00)80226-3; Rommel C, 1999, SCIENCE, V286, P1738, DOI 10.1126/science.286.5445.1738; Roux PP, 2007, J BIOL CHEM, V282, P14056, DOI 10.1074/jbc.M700906200; Roux PP, 2004, P NATL ACAD SCI USA, V101, P13489, DOI 10.1073/pnas.0405659101; SABATINI DM, 1994, CELL, V78, P35, DOI 10.1016/0092-8674(94)90570-3; Salmena L, 2008, CELL, V133, P403, DOI 10.1016/j.cell.2008.04.013; Sampaio C, 2008, MOL CELL BIOL, V28, P587, DOI 10.1128/MCB.01318-07; Samuels Y, 2004, SCIENCE, V304, P554, DOI 10.1126/science.1096502; Sancak Y, 2007, MOL CELL, V25, P903, DOI 10.1016/j.molcel.2007.03.003; Sano H, 2003, J BIOL CHEM, V278, P14599, DOI 10.1074/jbc.C300063200; Sarbassov DD, 2005, SCIENCE, V307, P1098, DOI 10.1126/science.1106148; Sarbassov DD, 2004, CURR BIOL, V14, P1296, DOI 10.1016/j.cub.2004.06.054; Sasaki AT, 2004, J CELL BIOL, V167, P505, DOI 10.1083/jcb.200406177; Sasaki AT, 2007, J CELL BIOL, V178, P185, DOI 10.1083/jcb.200611138; Sato S, 2004, J BIOL CHEM, V279, P33759, DOI 10.1074/jbc.M402055200; Schafer B, 2004, ONCOGENE, V23, P991, DOI 10.1038/sj.onc.1207278; Schwindinger WF, 2001, ONCOGENE, V20, P1653, DOI 10.1038/sj.onc.1204181; Shah OJ, 2004, CURR BIOL, V14, P1650, DOI 10.1016/j.cub.2004.08.026; Shahbazian D, 2006, EMBO J, V25, P2781, DOI 10.1038/sj.emboj.7601166; Stambolic V, 1998, CELL, V95, P29, DOI 10.1016/S0092-8674(00)81780-8; Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356; Stiles B, 2004, P NATL ACAD SCI USA, V101, P2082, DOI 10.1073/pnas.0308617100; Sun SY, 2005, CANCER RES, V65, P7052, DOI 10.1158/0008-5472.CAN-05-0917; Takaishi H, 1999, P NATL ACAD SCI USA, V96, P11836, DOI 10.1073/pnas.96.21.11836; Tamburini J, 2008, BLOOD, V111, P379, DOI 10.1182/blood-2007-03-080796; Tang ED, 1999, J BIOL CHEM, V274, P16741, DOI 10.1074/jbc.274.24.16741; Tee AR, 2003, CURR BIOL, V13, P1259, DOI 10.1016/S0960-9822(03)00506-2; Torres J, 2001, J BIOL CHEM, V276, P993, DOI 10.1074/jbc.M009134200; Tremblay F, 2001, J BIOL CHEM, V276, P38052; Tremblay F, 2007, P NATL ACAD SCI USA, V104, P14056, DOI 10.1073/pnas.0706517104; Trotman LC, 2006, NATURE, V441, P523, DOI 10.1038/nature04809; Trotman LC, 2007, CELL, V128, P141, DOI 10.1016/j.cell.2006.11.040; Tzatsos A, 2006, MOL CELL BIOL, V26, P63, DOI 10.1128/MCB.26.1.63-76.2006; Vander Haar E, 2007, NAT CELL BIOL, V9, P316, DOI 10.1038/ncb1547; Vasudevan KM, 2004, MOL CELL BIOL, V24, P1007, DOI 10.1128/MCB.24.3.1007-1021.2004; Vasudevan KM, 2007, CANCER RES, V67, P10343, DOI 10.1158/0008-5472.CAN-07-1827; VEZINA C, 1975, J ANTIBIOT, V28, P721, DOI 10.7164/antibiotics.28.721; Vivanco I, 2002, NAT REV CANCER, V2, P489, DOI 10.1038/nrc839; Vivanco I, 2007, CANCER CELL, V11, P555, DOI 10.1016/j.ccr.2007.04.021; Walker SM, 2004, BIOCHEM J, V379, P301, DOI 10.1042/BJ20031839; Wan X, 2007, ONCOGENE, V26, P1932, DOI 10.1038/sj.onc.1209990; Wang XJ, 2007, CELL, V128, P129, DOI 10.1016/j.cell.2006.11.039; Wang XM, 2001, EMBO J, V20, P4370, DOI 10.1093/emboj/20.16.4370; Wang YM, 2006, J INFRARED MILLIM W, V25, P50; Weinstein IB, 2008, CANCER RES, V68, P3077, DOI 10.1158/0008-5472.CAN-07-3293; Weinstein IB, 2008, CANCER RES, V68, P3086; Welch HCE, 2003, FEBS LETT, V546, P93, DOI 10.1016/S0014-5793(03)00454-X; Wells V, 2007, ONCOGENE, V26, P7709, DOI 10.1038/sj.onc.1210580; Wennstrom S, 1999, MOL CELL BIOL, V19, P4279; Wijesekara N, 2005, MOL CELL BIOL, V25, P1135, DOI 10.1128/MCB.25.3.1135-1145.2005; Wu DN, 2006, NEUROSCI LETT, V404, P98, DOI 10.1016/j.neulet.2006.05.018; Wu WD, 2003, J BIOL CHEM, V278, P28258, DOI 10.1074/jbc.M303318200; Xia DR, 2007, J BIOL CHEM, V282, P3507, DOI 10.1074/jbc.M610141200; Yart A, 2002, BBA-MOL CELL BIOL L, V1582, P107, DOI 10.1016/S1388-1981(02)00144-0; Yart A, 2001, J BIOL CHEM, V276, P8856, DOI 10.1074/jbc.M006966200; Yee WM, 1997, MOL CELL BIOL, V17, P921, DOI 10.1128/MCB.17.2.921; Yilmaz OH, 2006, NATURE, V441, P475, DOI 10.1038/nature04703; YUAN TL, 2008, ONCOGENE IN PRESS; Yuan ZQ, 2003, J BIOL CHEM, V278, P23432, DOI 10.1074/jbc.M302674200; Zhande R, 2002, MOL CELL BIOL, V22, P1016, DOI 10.1128/MCB.22.4.1016-1026.2002; Zhang BH, 2001, J BIOL CHEM, V276, P31620, DOI 10.1074/jbc.M102808200; Zhang HB, 2003, J CLIN INVEST, V112, P1223, DOI 10.1172/JCI200317222; Zhang HB, 2007, J CLIN INVEST, V117, P730, DOI 10.1172/JCI28984; Zhang HH, 2006, MOL CELL, V24, P185, DOI 10.1016/j.molcel.2006.09.019; Zhang JW, 2006, NATURE, V441, P518, DOI 10.1038/nature04747; Zhang R, 2005, ONCOGENE, V24, P3954, DOI 10.1038/sj.onc.1208548; Zhang Y, 2003, NAT CELL BIOL, V5, P578, DOI 10.1038/ncb999; ZHAO L, 2008, ONCOGENE IN PRESS; Zimmermann S, 1999, SCIENCE, V286, P1741, DOI 10.1126/science.286.5445.1741	189	653	678	1	62	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 15	2008	27	41					5527	5541		10.1038/onc.2008.247	http://dx.doi.org/10.1038/onc.2008.247			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	349KW	18794886				2022-12-28	WOS:000259280700013
J	Elcheva, I; Tarapore, RS; Bhatia, N; Spiegelman, VS				Elcheva, I.; Tarapore, R. S.; Bhatia, N.; Spiegelman, V. S.			Overexpression of mRNA-binding protein CRD-BP in malignant melanomas	ONCOGENE			English	Article						CRD-BP; beta-TrCP; mRNA stability; melanoma; Wnt/beta-catenin signaling; NF-kappa B	NF-KAPPA-B; UBIQUITIN LIGASE RECEPTOR; C-MYC; BETA-CATENIN; CODING REGION; CELLS; ACTIVATION; EXPRESSION; CANCER; HOMOLOG	Wnt/beta-catenin signaling pathway plays an important role in embryogenesis, stem cell maintenance, tumorigenesis and aging. Here, we show that RNA-binding protein, coding region determinant-binding protein (CRD-BP) (a transcriptional target of Wnt signaling pathway), is highly expressed in primary human malignant melanomas and melanoma cell lines with activated Wnt/beta-catenin signaling pathway. Upregulation of CRD-BP is associated with an elevated level of beta-TrCP1 ubiquitin ligase receptor and activation of nuclear transcriptional factors-kappa B (NF-kappa B) signaling. Knockdown of CRD-BP inhibits NF-kappa B activity, induces apoptosis, and suppresses proliferation and tumorigenic properties of melanoma cells.	[Elcheva, I.; Tarapore, R. S.; Bhatia, N.; Spiegelman, V. S.] Univ Wisconsin, Dept Dermatol, Sch Med & Publ Hlth, Madison, WI 53706 USA; [Tarapore, R. S.; Spiegelman, V. S.] Univ Wisconsin, Mol & Environm Toxicol Ctr, Sch Med & Publ Hlth, Madison, WI 53706 USA; [Spiegelman, V. S.] Univ Wisconsin, Paul P Carbone Comprehens Canc Ctr, Sch Med & Publ Hlth, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	Spiegelman, VS (corresponding author), Univ Wisconsin, Dept Dermatol, Sch Med, 445 Henry Mall,Room 301, Madison, WI 53706 USA.	spiegelman@dermatology.wisc.edu	Tarapore, Rohinton/J-8300-2012	Spiegelman, Vladimir S/0000-0003-4847-155X	NCI [CA121851]; NATIONAL CANCER INSTITUTE [R01CA121851] Funding Source: NIH RePORTER	NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Drs N Maddodi, S Devi, J Ross, P Robbins, K Kinzler and B Vogelstein for their generous gifts of reagents, S Reagan-Shaw for statistical analysis, Drs V Setaluri and S Fuchs for critical reading of the paper, and Dr K Spiegelman and Ms I Larsen for help with the paper preparation. This study was supported by NCI Grant CA121851 ( to VSS).	Basseres DS, 2006, ONCOGENE, V25, P6817, DOI 10.1038/sj.onc.1209942; Bhatia N, 2002, ONCOGENE, V21, P1501, DOI 10.1038/sj.onc.1205311; Chin L, 2006, GENE DEV, V20, P2149, DOI 10.1101/gad.1437206; Dimitriadis E, 2007, INT J CANCER, V121, P486, DOI 10.1002/ijc.22716; Doyle GA, 2000, CANCER RES, V60, P2756; Doyle GAR, 1998, NUCLEIC ACIDS RES, V26, P5036, DOI 10.1093/nar/26.22.5036; Fuchs SY, 2004, ONCOGENE, V23, P2028, DOI 10.1038/sj.onc.1207389; Giles RH, 2003, BBA-REV CANCER, V1653, P1, DOI 10.1016/S0304-419X(03)00005-2; Gilmore TD, 2006, ONCOGENE, V25, P6680, DOI 10.1038/sj.onc.1209954; Herlyn M, 2006, INT J CANCER, V118, P523, DOI 10.1002/ijc.21605; Hussein MR, 2003, J PATHOL, V199, P275, DOI 10.1002/path.1300; Ioannidis P, 2003, ANTICANCER RES, V23, P2179; Ioannidis P, 2001, INT J CANCER, V94, P480, DOI 10.1002/ijc.1512; Liu J, 2007, ONCOGENE, V26, P1954, DOI 10.1038/sj.onc.1209994; Nielsen J, 1999, MOL CELL BIOL, V19, P1262; Noubissi FK, 2006, NATURE, V441, P898, DOI 10.1038/nature04839; PROKIPCAK RD, 1994, J BIOL CHEM, V269, P9261; Rimm DL, 1999, AM J PATHOL, V154, P325, DOI 10.1016/S0002-9440(10)65278-9; Ross J, 2001, ONCOGENE, V20, P6544, DOI 10.1038/sj.onc.1204838; Rubinfeld B, 1997, SCIENCE, V275, P1790, DOI 10.1126/science.275.5307.1790; Runge S, 2000, J BIOL CHEM, V275, P29562, DOI 10.1074/jbc.M001156200; ShattuckBrandt RL, 1997, CANCER RES, V57, P3032; Smalley KSM, 2004, J INVEST DERMATOL, V123, pXVI, DOI 10.1111/j.0022-202X.2004.23430.x; Soldatenkov VA, 1999, CANCER RES, V59, P5085; Sparanese D, 2007, NUCLEIC ACIDS RES, V35, P1209, DOI 10.1093/nar/gkl1148; Spiegelman VS, 2000, MOL CELL, V5, P877, DOI 10.1016/S1097-2765(00)80327-5; Spiegelman VS, 2002, J BIOL CHEM, V277, P36624, DOI 10.1074/jbc.M204524200; Ueda Y, 2006, PIGM CELL RES, V19, P112, DOI 10.1111/j.1600-0749.2006.00304.x; Vikesaa J, 2006, EMBO J, V25, P1456, DOI 10.1038/sj.emboj.7601039; Wang H, 2008, ONCOGENE, V27, P1905, DOI 10.1038/sj.onc.1210823; Weeraratna AT, 2005, CANCER METAST REV, V24, P237, DOI 10.1007/s10555-005-1574-z; Yang JM, 2001, CANCER RES, V61, P4901	32	39	40	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 28	2008	27	37					5069	5074		10.1038/onc.2008.141	http://dx.doi.org/10.1038/onc.2008.141			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	344GL	18454174				2022-12-28	WOS:000258914800009
J	Leung, N; Turbide, C; Balachandra, B; Marcus, V; Beauchemin, N				Leung, N.; Turbide, C.; Balachandra, B.; Marcus, V.; Beauchemin, N.			Intestinal tumor progression is promoted by decreased apoptosis and dysregulated Wnt signaling in Ceacam(1-/-) mice	ONCOGENE			English	Article						CEACAM1; Wnt signaling; intestinal cancer; tumor suppressor; mouse model	FAMILIAL ADENOMATOUS POLYPOSIS; CELL-ADHESION MOLECULE; ABERRANT CRYPT FOCI; COLORECTAL-CANCER; BETA-CATENIN; BILIARY GLYCOPROTEIN; C-CAM; K-RAS; CEACAM1; APC	The carcinoembryonic antigen cell adhesion molecule 1 (CEACAM1) is downregulated in colonic and intestinal hyperplastic lesions as well as in other cancers, where it functions as a tumor suppressor. To investigate the functions of CEACAM1 in the normal intestine and in intestinal tumors, we generated a compound knockout mouse model and examined both Ceacam1(-/-) and Apc(1638N/+): Ceacam1(-/-) mice. Ceacam1(-/-) intestinal cells exhibited a significant decrease in apoptosis, with no change in proliferation or migration, however. Compound Apc(1638N/+): Ceacam1(-/-) mice demonstrated an increase in intestinal tumor multiplicity and tumor progression. Increases in intussusceptions and desmoid lesions were also observed. We have shown that CEACAM1-L associates with beta-catenin by co-immunoprecipitation and colocalization in CEACAM1-L-transfected CT26 and CT51 mouse colon carcinoma cells. Ceacam1(-/-) enterocytes displayed decreased glycogen synthase kinase 3-beta activity with corresponding nuclear localization of beta-catenin. Increased T-cell factor/Lef transcriptional activity was observed in CEACAM1-null CT51 colonic cells and in Caco2 colon cancer cells in which CEACAM1 was downregulated. A significant increased expression in c-Myc and cyclin D1 targets of the Wnt signaling pathway was also revealed in the Ceacam1(-/-) intestine. CEACAM1 therefore actively participates in Wnt signaling in intestinal cells and its downregulation in intestinal tissue contributes to malignancy by augmenting tumor multiplicity and progression.	[Beauchemin, N.] McGill Univ, McGill Canc Ctr, Lab 711, Montreal, PQ H3G 1Y6, Canada; [Leung, N.; Beauchemin, N.] McGill Univ, Dept Biochem, Montreal, PQ H3G 1Y6, Canada; [Balachandra, B.] Univ Alberta, Dept Pathol, Royal Alexandra Hosp, Edmonton, AB T6G 2E1, Canada; [Marcus, V.] McGill Univ, Ctr Hlth, Dept Pathol, Montreal, PQ H3G 1Y6, Canada; [Beauchemin, N.] McGill Univ, Dept Med, Montreal, PQ H3G 1Y6, Canada; [Beauchemin, N.] McGill Univ, Dept Oncol, Montreal, PQ H3G 1Y6, Canada	McGill University; McGill University; Royal Alexandra Hospital; University of Alberta; McGill University; McGill University; McGill University	Beauchemin, N (corresponding author), McGill Univ, McGill Canc Ctr, Lab 711, 3655 Promenade Sir William Osler, Montreal, PQ H3G 1Y6, Canada.	nicole.beauchemin@mcgill.ca						Abou-Rjaily GA, 2004, J CLIN INVEST, V114, P944, DOI 10.1172/JCI200421786; Aoki K, 2007, ONCOGENE, V26, P3511, DOI 10.1038/sj.onc.1210141; Azar T, 1997, ANN SURG, V226, P134, DOI 10.1097/00000658-199708000-00003; Beauchemin N, 1999, EXP CELL RES, V252, P243; Buckhaults P, 2001, CANCER RES, V61, P6996; de la Chapelle A, 2004, NAT REV CANCER, V4, P769, DOI 10.1038/nrc1453; Demant P, 2003, NAT REV GENET, V4, P721, DOI 10.1038/nrg1157; DVEKSLER GS, 1993, P NATL ACAD SCI USA, V90, P1716, DOI 10.1073/pnas.90.5.1716; Fodde R, 2001, NAT REV CANCER, V1, P55, DOI 10.1038/35094067; FODDE R, 1994, P NATL ACAD SCI USA, V91, P8969, DOI 10.1073/pnas.91.19.8969; Fodde R, 2001, TRENDS MOL MED, V7, P369, DOI 10.1016/S1471-4914(01)02050-0; Gray-Owen SD, 2006, NAT REV IMMUNOL, V6, P433, DOI 10.1038/nri1864; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; Hokari M, 2007, LIFE SCI, V81, P336, DOI 10.1016/j.lfs.2007.06.002; Horst AK, 2004, HANDB EXP PHARM, V165, P283, DOI 10.1007/978-3-540-68170-0_10; Horst AK, 2006, J CLIN INVEST, V116, P1596, DOI 10.1172/JCI24340; HSIEH JT, 1995, CANCER RES, V55, P190; JIN L, 2008, EXP BIOL ME IN PRESS, V233; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; Kobrossy L, 2006, J BIOL CHEM, V281, P25926, DOI 10.1074/jbc.M602555200; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; Kunath T, 1995, ONCOGENE, V11, P2375; Leung N, 2006, ONCOGENE, V25, P5527, DOI 10.1038/sj.onc.1209541; Liu W, 2007, ONCOGENE, V26, P2747, DOI 10.1038/sj.onc.1210077; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; Nagaishi T, 2006, IMMUNITY, V25, P769, DOI 10.1016/j.immuni.2006.08.026; Najjar SM, 2002, TRENDS ENDOCRIN MET, V13, P240, DOI 10.1016/S1043-2760(02)00608-2; NEUMAIER M, 1993, P NATL ACAD SCI USA, V90, P10744, DOI 10.1073/pnas.90.22.10744; Nittka S, 2004, ONCOGENE, V23, P9306, DOI 10.1038/sj.onc.1208259; Nollau P, 1997, CANCER RES, V57, P2354; Notterman DA, 2001, CANCER RES, V61, P3124; Obrink B, 1997, CURR OPIN CELL BIOL, V9, P616, DOI 10.1016/S0955-0674(97)80114-7; Patel S, 2004, BIOCHEM SOC T, V32, P803, DOI 10.1042/BST0320803; Poy MN, 2002, NAT GENET, V30, P270, DOI 10.1038/ng840; Poy MN, 2002, J BIOL CHEM, V277, P1076, DOI 10.1074/jbc.M108415200; Rowan AJ, 2000, P NATL ACAD SCI USA, V97, P3352, DOI 10.1073/pnas.97.7.3352; Sansom OJ, 2007, NATURE, V446, P676, DOI 10.1038/nature05674; Smits R, 1998, GASTROENTEROLOGY, V114, P275, DOI 10.1016/S0016-5085(98)70478-0; Takayama T, 2001, GASTROENTEROLOGY, V121, P599, DOI 10.1053/gast.2001.27203; Turbide C, 1997, CANCER RES, V57, P2781; van de Wetering M, 2002, CELL, V111, P241, DOI 10.1016/S0092-8674(02)01014-0; Velcich A, 2002, SCIENCE, V295, P1726, DOI 10.1126/science.1069094; VIVONA AA, 1993, CARCINOGENESIS, V14, P1777, DOI 10.1093/carcin/14.9.1777; Yang WC, 2005, CANCER RES, V65, P9363, DOI 10.1158/0008-5472.CAN-05-2113	45	33	33	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 21	2008	27	36					4943	4953		10.1038/onc.2008.136	http://dx.doi.org/10.1038/onc.2008.136			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	339SF	18454175				2022-12-28	WOS:000258596900008
J	Paulson, QX; Pusapati, RV; Hong, S; Weaks, RL; Conti, CJ; Johnson, DG				Paulson, Q. X.; Pusapati, R. V.; Hong, S.; Weaks, R. L.; Conti, C. J.; Johnson, D. G.			Transgenic expression of E2F3a causes DNA damage leading to ATM-dependent apoptosis	ONCOGENE			English	Article						Rb; ATM; oncogenic stress; DNA-damage response	ONCOGENE-INDUCED SENESCENCE; ATAXIA-TELANGIECTASIA; HUMAN TUMORIGENESIS; SIGNALING PATHWAY; BLADDER-CANCER; LUNG-CANCER; PROLIFERATION; OVEREXPRESSION; RETINOBLASTOMA; GENE	Many early stage human tumors display markers of a DNA-damage response (DDR), including ataxia telangiectasia mutated (ATM) kinase activation. This suggests that DNA damage accumulates during the process of carcinogenesis and that the ATM-dependent response to this damage may function to suppress cancer progression. The E2F3a transcription factor plays an important role in regulating cell proliferation and is amplified in a subset of human cancers. Similar to human premalignant lesions, we find activated ATM and other markers of the DDR in the hyperplastic epidermis of transgenic mice expressing E2F3a through a keratin 5 (K5) promoter. Primary keratinocytes from K5 E2F3a transgenic mice contain increased levels of DNA breaks compared to wild-type cells. E2F3a overexpression also induced DNA damage in primary human fibroblasts that was inhibited by blocking DNA replication. The absence of ATM impaired apoptosis induced by E2F3a and treating K5 E2F3a transgenic mice with caffeine, an inhibitor of ATM and Rad3-related (ATR), promoted skin tumor development. These findings demonstrate that the deregulated expression of E2F3a causes DNA damage under physiological conditions and indicate that the ATM-dependent response to this damage is important for the induction of apoptosis and tumor suppression.	[Paulson, Q. X.; Pusapati, R. V.; Hong, S.; Weaks, R. L.; Conti, C. J.; Johnson, D. G.] Univ Texas MD Anderson Canc Ctr, Div Sci Pk Res, Dept Carcinogenesis, Smithville, TX 78957 USA	University of Texas System; UTMD Anderson Cancer Center	Johnson, DG (corresponding author), Univ Texas MD Anderson Canc Ctr, Div Sci Pk Res, Dept Carcinogenesis, POB 389, Smithville, TX 78957 USA.	djohnson@mdanderson.org		Johnson, David/0000-0002-6223-1790	National Institutes of Health [CA098601, CA79648, U01CA105345, ES07784, CA16672]; NATIONAL CANCER INSTITUTE [R01CA079648, R01CA098601, U01CA105345, P30CA016672] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES007784] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))	We thank Mark McArthur for pathological analysis of skin lesions, Jen Smith and Pam Blau for technical assistance, Lezlee Coghlan, Dale Weiss and coworkers for animal care, Chris Brown and Joi Holcomb for graphics and Shawnda Sanders for preparation of the manuscript. This work was supported by National Institutes of Health Grants CA098601 and CA79648( to DGJ), U01CA105345, ES07784, and CA16672. RLW is supported by an American Legion Auxiliary Fellowship.	Ai LB, 2004, CANCER EPIDEM BIOMAR, V13, P150, DOI 10.1158/1055-9965.EPI-082-3; Bakkenist CJ, 2003, NATURE, V421, P499, DOI 10.1038/nature01368; Barlow C, 1996, CELL, V86, P159, DOI 10.1016/S0092-8674(00)80086-0; Bartkova J, 2005, NATURE, V434, P864, DOI 10.1038/nature03482; Bartkova J, 2006, NATURE, V444, P633, DOI 10.1038/nature05268; Davidson IF, 2006, MOL CELL, V24, P433, DOI 10.1016/j.molcel.2006.09.010; Davies H, 2005, CANCER RES, V65, P7591, DOI 10.1158/0008-5472.CAN-05-1855; Di Micco R, 2006, NATURE, V444, P638, DOI 10.1038/nature05327; DiTullio RA, 2002, NAT CELL BIOL, V4, P998, DOI 10.1038/ncb892; Feber A, 2004, ONCOGENE, V23, P1627, DOI 10.1038/sj.onc.1207274; Gorgoulis VG, 2005, NATURE, V434, P907, DOI 10.1038/nature03485; Grasemann C, 2005, ONCOGENE, V24, P6441, DOI 10.1038/sj.onc.1208792; Greenman C, 2007, NATURE, V446, P153, DOI 10.1038/nature05610; Humbert PO, 2000, GENE DEV, V14, P690; Hunt CR, 2007, CANCER RES, V67, P3010, DOI 10.1158/0008-5472.CAN-06-4328; Karaa A, 2007, INT J DERMATOL, V46, P671, DOI 10.1111/j.1365-4632.2007.03260.x; Kinzler KW, 1997, NATURE, V386, P763; Leone G, 1998, GENE DEV, V12, P2120, DOI 10.1101/gad.12.14.2120; Mallette FA, 2007, GENE DEV, V21, P43, DOI 10.1101/gad.1487307; Mandel HG, 2002, FOOD CHEM TOXICOL, V40, P1231, DOI 10.1016/S0278-6915(02)00093-5; Oeggerli M, 2004, ONCOGENE, V23, P5616, DOI 10.1038/sj.onc.1207749; Orlic M, 2006, GENE CHROMOSOME CANC, V45, P72, DOI 10.1002/gcc.20263; Paulson QX, 2006, CELL CYCLE, V5, P184, DOI 10.4161/cc.5.2.2307; Pickering MT, 2006, ONCOGENE, V25, P746, DOI 10.1038/sj.onc.1209103; Powers JT, 2004, MOL CANCER RES, V2, P203; Pusapati RV, 2006, P NATL ACAD SCI USA, V103, P1446, DOI 10.1073/pnas.0507367103; Rogakou EP, 1998, J BIOL CHEM, V273, P5858, DOI 10.1074/jbc.273.10.5858; Rogoff HA, 2004, MOL CELL BIOL, V24, P2968, DOI 10.1128/MCB.24.7.2968-2977.2004; Russell JL, 2002, MOL CELL BIOL, V22, P1360, DOI 10.1128/MCB.22.5.1360-1368.2002; Saavedra HI, 2002, CELL GROWTH DIFFER, V13, P215; Safar AM, 2005, CLIN CANCER RES, V11, P4400, DOI 10.1158/1078-0432.CCR-04-2378; Suzuki A, 2004, BIOCHEM BIOPH RES CO, V324, P986, DOI 10.1016/j.bbrc.2004.09.145; Tort F, 2006, CANCER RES, V66, P10258, DOI 10.1158/0008-5472.CAN-06-2178; Veltman JA, 2003, CANCER RES, V63, P2872; Vo QN, 2004, ONCOGENE, V23, P9432, DOI 10.1038/sj.onc.1208092; Ziebold U, 2001, GENE DEV, V15, P386, DOI 10.1101/gad.858801	36	11	12	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 21	2008	27	36					4954	4961		10.1038/onc.2008.138	http://dx.doi.org/10.1038/onc.2008.138			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	339SF	18469863	Bronze			2022-12-28	WOS:000258596900009
J	Grether-Beck, S; Salahshour-Fard, M; Timmer, A; Brenden, H; Felsner, I; Walli, R; Fullekrug, J; Krutmann, J				Grether-Beck, S.; Salahshour-Fard, M.; Timmer, A.; Brenden, H.; Felsner, I.; Walli, R.; Fuellekrug, J.; Krutmann, J.			Ceramide and raft signaling are linked with each other in UVA radiation-induced gene expression	ONCOGENE			English	Article						signaling; UVA; rafts; ceramide	LEMLI-OPITZ-SYNDROME; CONGENITAL PHOTOSENSITIVITY SYNDROME; LIPID RAFTS; ACID SPHINGOMYELINASE; BIOLOGICAL-SYSTEMS; PLASMA-MEMBRANE; INSULIN-RECEPTOR; CELL-MEMBRANES; DNA-SEQUENCE; CHOLESTEROL	Solar ultraviolet A (UVA) (320-400 nm) radiation-induced gene expression in keratinocytes is initiated at the level of the cell membrane via generation of singlet oxygen and subsequent formation of ceramide from sphingomyelin. We now report that the UVA response also involves raft signaling and that ceramide and raft signaling are linked with each other. Upon UVA irradiation, the lipid composition of rafts decreased 40% in sphingomyelin and 60% in cholesterol (Chol). Also, decrease of Chol increased the susceptibility towards UVA-induced gene expression, whereas increase of Chol completely abolished their capacity to generate signaling ceramides and to mount the subsequent UVA response. This inhibition was not associated with UVA-induced Chol oxidation and was also seen after treatment of cells with plant sterols. The UVA responsiveness depended on the ratio of Chol versus ceramide in rafts. A ratio smaller than 1 permitted initiation and transduction of the signaling response, whereas a ratio greater than 1, for example, upon sterol pretreatment, abolished this response, indicating that UVA radiation-induced ceramide signaling is controlled by the lipid composition of rafts.	[Grether-Beck, S.; Salahshour-Fard, M.; Timmer, A.; Brenden, H.; Felsner, I.; Walli, R.; Krutmann, J.] Heinrich Heine Univ Duesseldorf gGmbH, Inst Umweltmed Forsch, D-40225 Dusseldorf, Germany; [Fuellekrug, J.] Heidelberg Univ, Heidelberg, Germany	Heinrich Heine University Dusseldorf; Ruprecht Karls University Heidelberg	Grether-Beck, S (corresponding author), Heinrich Heine Univ Duesseldorf gGmbH, Inst Umweltmed Forsch, Aufm Hennekamp 50, D-40225 Dusseldorf, Germany.	grether-beck@uni-duesseldorf.de	Füllekrug, Joachim/A-6581-2008					ANDERSON RGW, 1993, P NATL ACAD SCI USA, V90, P10909, DOI 10.1073/pnas.90.23.10909; Anstey AV, 1999, J AM ACAD DERMATOL, V41, P121, DOI 10.1016/S0190-9622(99)70420-2; Anstey AV, 1999, BRIT J DERMATOL, V141, P406; Azurdia RM, 2001, BRIT J DERMATOL, V144, P143, DOI 10.1046/j.1365-2133.2001.03964.x; BACHOWSKI GJ, 1988, LIPIDS, V23, P580, DOI 10.1007/BF02535601; BATTA AK, 1995, J LIPID RES, V36, P705; Benting JH, 1999, J CELL BIOL, V146, P313, DOI 10.1083/jcb.146.2.313; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brown DA, 2000, J BIOL CHEM, V275, P17221, DOI 10.1074/jbc.R000005200; Brown DA, 1998, ANNU REV CELL DEV BI, V14, P111, DOI 10.1146/annurev.cellbio.14.1.111; Charman CR, 1998, BRIT J DERMATOL, V138, P885; DIGNAM JD, 1983, METHOD ENZYMOL, V101, P582; Emsley J, 1997, J BIOL CHEM, V272, P28512, DOI 10.1074/jbc.272.45.28512; Fitzky BU, 1998, P NATL ACAD SCI USA, V95, P8181, DOI 10.1073/pnas.95.14.8181; FOLCH J, 1957, J BIOL CHEM, V226, P497; Fukasawa M, 2000, J BIOL CHEM, V275, P34028, DOI 10.1074/jbc.M005151200; Girotti AW, 1998, J LIPID RES, V39, P1529; GIROTTI AW, 1992, J PHOTOCH PHOTOBIO B, V13, P105, DOI 10.1016/1011-1344(92)85050-5; Girotti AW, 2000, METHOD ENZYMOL, V319, P85; Gniadecki R, 2002, J INVEST DERMATOL, V118, P582, DOI 10.1046/j.1523-1747.2002.01716.x; Grether-Beck S, 2005, J INVEST DERMATOL, V125, P545, DOI 10.1111/j.0022-202X.2005.23782.x; Grether-Beck S, 2003, J BIOL CHEM, V278, P47498, DOI 10.1074/jbc.M309511200; Grether-Beck S, 2000, EMBO J, V19, P5793, DOI 10.1093/emboj/19.21.5793; GretherBeck S, 1996, P NATL ACAD SCI USA, V93, P14586, DOI 10.1073/pnas.93.25.14586; Gulbins E, 2006, AM J PHYSIOL-REG I, V290, pR11, DOI 10.1152/ajpregu.00416.2005; Gustavsson J, 1999, FASEB J, V13, P1961, DOI 10.1096/fasebj.13.14.1961; Johnston I, 2006, LANGMUIR, V22, P11284, DOI 10.1021/la061636s; Kashkar H, 2005, J BIOL CHEM, V280, P20804, DOI 10.1074/jbc.M410869200; KIM JB, 1995, MOL CELL BIOL, V15, P2582; Kolesnick RN, 2000, J CELL PHYSIOL, V184, P285; Korytowski W, 1999, PHOTOCHEM PHOTOBIOL, V70, P484; Linnik KM, 1998, J BIOL CHEM, V273, P21368, DOI 10.1074/jbc.273.33.21368; LIU PS, 1995, J BIOL CHEM, V270, P27179, DOI 10.1074/jbc.270.45.27179; MCCALLUM FS, 1985, BIOCHEM J, V232, P725, DOI 10.1042/bj2320725; MEGHA LE, 2004, J BIOL CHEM, V279, P9997; Neufeld EB, 1996, J BIOL CHEM, V271, P21604, DOI 10.1074/jbc.271.35.21604; Pike LJ, 2002, BIOCHEMISTRY-US, V41, P2075, DOI 10.1021/bi0156557; PONTE P, 1984, NUCLEIC ACIDS RES, V12, P1687, DOI 10.1093/nar/12.3.1687; Reiterer G, 2005, J NUTR, V135, P2114, DOI 10.1093/jn/135.9.2114; Ridgway ND, 1998, J BIOL CHEM, V273, P31621, DOI 10.1074/jbc.273.47.31621; Rotolo JA, 2005, J BIOL CHEM, V280, P26425, DOI 10.1074/jbc.M414569200; Schmuth M, 2004, J INVEST DERMATOL, V123, P41, DOI 10.1111/j.0022-202X.2004.22707.x; SCHNITZER JE, 1994, J CELL BIOL, V127, P1217, DOI 10.1083/jcb.127.5.1217; Schwarz T, 2005, EXP DERMATOL, V14, P788, DOI 10.1111/j.1600-0625.2005.0355g.x; Simons K, 2000, NAT REV MOL CELL BIO, V1, P31, DOI 10.1038/35036052; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; Simons K, 2002, J CLIN INVEST, V110, P597, DOI 10.1172/JCI200216390; SIMONS K, 1988, BIOCHEMISTRY-US, V27, P6197, DOI 10.1021/bi00417a001; SLOTTE JP, 1988, BIOCHEM J, V250, P653, DOI 10.1042/bj2500653; SMITH DW, 1964, J PEDIATR-US, V64, P210, DOI 10.1016/S0022-3476(64)80264-X; STADE BG, 1990, IMMUNOBIOLOGY, V182, P79, DOI 10.1016/S0171-2985(11)80585-1; STAUNTON DE, 1988, CELL, V52, P925, DOI 10.1016/0092-8674(88)90434-5; TINT GS, 1994, NEW ENGL J MED, V330, P107, DOI 10.1056/NEJM199401133300205; Tyrrell RM, 2006, PROG BIOPHYS MOL BIO, V92, P86, DOI 10.1016/j.pbiomolbio.2006.02.002; Tyrrell RM, 2004, ANTIOXID REDOX SIGN, V6, P835, DOI 10.1089/1523086041798033; Vainio S, 2002, EMBO REP, V3, P95, DOI 10.1093/embo-reports/kvf010; Valencia A, 2006, FREE RADICAL BIO MED, V40, P641, DOI 10.1016/j.freeradbiomed.2005.09.036; VANDEKERCKHOVE J, 1978, P NATL ACAD SCI USA, V75, P1106, DOI 10.1073/pnas.75.3.1106; Wolf C, 1996, J LIPID RES, V37, P1325; Xu F, 2005, P NATL ACAD SCI USA, V102, P14551, DOI 10.1073/pnas.0503590102; Yancey PG, 1996, J BIOL CHEM, V271, P16026, DOI 10.1074/jbc.271.27.16026; Yang N, 2004, J BIOL CHEM, V279, P20898, DOI 10.1074/jbc.M400625200; YANG T, 1995, J CELL BIOL, V128, P1173, DOI 10.1083/jcb.128.6.1173; Zhang YG, 2001, J BIOL CHEM, V276, P11775, DOI 10.1074/jbc.M006000200	64	20	21	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 14	2008	27	35					4768	4778		10.1038/onc.2008.116	http://dx.doi.org/10.1038/onc.2008.116			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	337OJ	18438433				2022-12-28	WOS:000258445100002
J	Stoletov, K; Klemke, R				Stoletov, K.; Klemke, R.			Catch of the day: zebrafish as a human cancer model	ONCOGENE			English	Review						zebrafish; cancer; metastasis; angiogenesis; xenotransplantant; transgenic	REGULATED TRANSGENIC ZEBRAFISH; DIFFERENT DEVELOPMENTAL-STAGES; ACUTE LYMPHOBLASTIC-LEUKEMIA; CAUSES GENOME INSTABILITY; T-CELL LEUKEMIA; DANIO-RERIO; IN-VIVO; VE-CADHERIN; EXPOSURE ROUTES; GENE-EXPRESSION	Zebrafish are making big waves in the field of cancer research. The effect has been widespread and continues to gain speed as more and more cancer researchers ride the wave of zebrafish biology. This has been largely due to the development of transgenic and xenograft models of cancer, which recapitulate many aspects of different human cancers including lymphoblastic T-cell leukemia, pancreatic cancer, melanoma and rhabdomyosarcoma. These models are already being utilized by academia and industry to search for genetic and chemical modifiers of cancer with success. The attention has been further stimulated by the amenability of zebrafish to pharmacological testing and the superior imaging properties of fish tissues that allow visualization of cancer progression and angiogenesis in live animals. This review summarizes the current zebrafish models of cancer and discusses their utility in human cancer research and future directions in the field.	[Stoletov, K.; Klemke, R.] Univ Calif San Diego, Dept Pathol, La Jolla, CA 92093 USA; [Stoletov, K.; Klemke, R.] Univ Calif San Diego, Moores Canc Ctr, La Jolla, CA 92093 USA	University of California System; University of California San Diego; University of California System; University of California San Diego	Klemke, R (corresponding author), Univ Calif San Diego, Dept Pathol, 9500 Gilman Dr,MC0612, La Jolla, CA 92093 USA.	rklemke@ucsd.edu		Stoletov, Konstantin/0000-0002-7384-2917	NCI NIH HHS [CA097022] Funding Source: Medline; NIGMS NIH HHS [GM068487] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA097022] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM068487] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ablooglu AJ, 2007, DEV DYNAM, V236, P2268, DOI 10.1002/dvdy.21229; Amatruda JF, 2002, CANCER CELL, V1, P229, DOI 10.1016/S1535-6108(02)00052-1; Amsterdam A, 2004, PLOS BIOL, V2, P690, DOI 10.1371/journal.pbio.0020139; Beckwith LG, 2000, LAB INVEST, V80, P379, DOI 10.1038/labinvest.3780042; Beis D, 2006, TRENDS CELL BIOL, V16, P105, DOI 10.1016/j.tcb.2005.12.001; Berghmans S, 2005, BIOTECHNIQUES, V39, P227, DOI 10.2144/05392RV02; Berghmans S, 2005, P NATL ACAD SCI USA, V102, P407, DOI 10.1073/pnas.0406252102; Carmeliet P, 1999, CELL, V98, P147, DOI 10.1016/S0092-8674(00)81010-7; Chen J, 2007, LEUKEMIA, V21, P462, DOI 10.1038/sj.leu.2404546; Clark EA, 2000, NATURE, V406, P532, DOI 10.1038/35020106; Faucherre A, 2008, ONCOGENE, V27, P1079, DOI 10.1038/sj.onc.1210730; Feng H, 2007, BRIT J HAEMATOL, V138, P169, DOI 10.1111/j.1365-2141.2007.06625.x; Friedl P, 2000, CELL MOL LIFE SCI, V57, P41, DOI 10.1007/s000180050498; Fukumura D, 2007, MICROVASC RES, V74, P72, DOI 10.1016/j.mvr.2007.05.003; Goessling W, 2007, J CLIN ONCOL, V25, P2473, DOI 10.1200/JCO.2006.08.9821; Goessling W, 2007, NAT METHODS, V4, P551, DOI 10.1038/NMETH1059; Hakem A, 2005, GENE DEV, V19, P1974, DOI 10.1101/gad.1310805; Haldi Maryann, 2006, Angiogenesis, V9, P139, DOI 10.1007/s10456-006-9040-2; Hall C, 2007, BMC DEV BIOL, V7, DOI 10.1186/1471-213X-7-42; Haramis APG, 2006, EMBO REP, V7, P444, DOI 10.1038/sj.embor.7400638; Her GM, 2003, FEBS LETT, V538, P125, DOI 10.1016/S0014-5793(03)00157-1; Hong WY, 2004, CANCER RES, V64, P7256, DOI 10.1158/0008-5472.CAN-04-0931; Isogai S, 2003, DEVELOPMENT, V130, P5281, DOI 10.1242/dev.00733; Jain RK, 2002, SEMIN ONCOL, V29, P3, DOI 10.1053/sonc.2002.37265; Kari G, 2007, CLIN PHARMACOL THER, V82, P70, DOI 10.1038/sj.clpt.6100223; Lam SH, 2006, NAT BIOTECHNOL, V24, P73, DOI 10.1038/nbt1169; Lam SH, 2006, CELL CYCLE, V5, P573, DOI 10.4161/cc.5.6.2550; Langenau DM, 2007, GENE DEV, V21, P1382, DOI 10.1101/gad.1545007; Langenau DM, 2005, BLOOD, V105, P3278, DOI 10.1182/blood-2004-08-3073; Langenau DM, 2005, P NATL ACAD SCI USA, V102, P6068, DOI 10.1073/pnas.0408708102; Langenau DM, 2004, P NATL ACAD SCI USA, V101, P7369, DOI 10.1073/pnas.0402248101; Langenau DM, 2003, SCIENCE, V299, P887, DOI 10.1126/science.1080280; Larson JD, 2004, DEV DYNAM, V231, P204, DOI 10.1002/dvdy.20102; Le XN, 2007, P NATL ACAD SCI USA, V104, P9410, DOI 10.1073/pnas.0611302104; Lee LMJ, 2005, DEV DYNAM, V233, P1560, DOI 10.1002/dvdy.20471; Mathias JR, 2006, J LEUKOCYTE BIOL, V80, P1281, DOI 10.1189/jlb.0506346; Mizgireuv IV, 2006, CANCER RES, V66, P3120, DOI 10.1158/0008-5472.CAN-05-3800; Mizgireuv IV, 2004, TOXICOL PATHOL, V32, P514, DOI 10.1080/01926230490496311; Mould AP, 2006, BMC CELL BIOL, V7, DOI 10.1186/1471-2121-7-24; Naumov GN, 2006, CELL CYCLE, V5, P1779, DOI 10.4161/cc.5.16.3018; Nicoli S, 2007, CANCER RES, V67, P2927, DOI 10.1158/0008-5472.CAN-06-4268; Okihiro MS, 1999, CARCINOGENESIS, V20, P933, DOI 10.1093/carcin/20.6.933; Parng C, 2002, ASSAY DRUG DEV TECHN, V1, P41, DOI 10.1089/154065802761001293; Patton EE, 2005, CURR BIOL, V15, P249, DOI 10.1016/j.cub.2005.01.031; Sabaawy HE, 2006, P NATL ACAD SCI USA, V103, P15166, DOI 10.1073/pnas.0603349103; Sahai E, 2007, NAT REV CANCER, V7, P737, DOI 10.1038/nrc2229; Shepard JL, 2007, GENE DEV, V21, P55, DOI 10.1101/gad.1470407; Shepard JL, 2005, P NATL ACAD SCI USA, V102, P13194, DOI 10.1073/pnas.0506583102; Smolowitz R, 2002, BIOL BULL, V203, P265, DOI 10.2307/1543433; Spitsbergen J, 2007, NAT METHODS, V4, P548, DOI 10.1038/nmeth0707-548; Spitsbergen JM, 2000, TOXICOL PATHOL, V28, P705, DOI 10.1177/019262330002800511; Spitsbergen JM, 2000, TOXICOL PATHOL, V28, P716, DOI 10.1177/019262330002800512; Stern HM, 2005, NAT CHEM BIOL, V1, P366, DOI 10.1038/nchembio749; Stern HM, 2003, NAT REV CANCER, V3, P533, DOI 10.1038/nrc1126; Stoletov K, 2007, P NATL ACAD SCI USA, V104, P17406, DOI 10.1073/pnas.0703446104; Sun L, 2005, MATRIX BIOL, V24, P69, DOI 10.1016/j.matbio.2004.12.002; Topczewska JM, 2006, NAT MED, V12, P925, DOI 10.1038/nm1448; Wakamatsu Y, 2001, P NATL ACAD SCI USA, V98, P10046, DOI 10.1073/pnas.181204298; Wallace KN, 2005, DEV CELL, V8, P717, DOI 10.1016/j.devcel.2005.02.015; Wallez Y, 2006, TRENDS CARDIOVAS MED, V16, P55, DOI 10.1016/j.tcm.2005.11.008; Wan HY, 2006, EXP CELL RES, V312, P1526, DOI 10.1016/j.yexcr.2006.01.016; White RM, 2008, CELL STEM CELL, V2, P183, DOI 10.1016/j.stem.2007.11.002; Wolf K, 2003, J CELL BIOL, V160, P267, DOI 10.1083/jcb.200209006; Zijlstra A, 2002, CANCER RES, V62, P7083	64	145	150	0	43	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 31	2008	27	33					4509	4520		10.1038/onc.2008.95	http://dx.doi.org/10.1038/onc.2008.95			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	332IS	18372910				2022-12-28	WOS:000258077300001
J	Tsuchida, R; Das, B; Yeger, H; Koren, G; Shibuya, M; Thorner, P; Baruchel, S; Malkin, D				Tsuchida, R.; Das, B.; Yeger, H.; Koren, G.; Shibuya, M.; Thorner, Ps; Baruchel, S.; Malkin, D.			Cisplatin treatment increases survival and expansion of a highly tumorigenic side-population fraction by upregulating VEGF/Flt1 autocrine signaling	ONCOGENE			English	Article						osteosarcoma; cisplatin; tumorigenic SP; VEGF/Flt1 autocrine	ENDOTHELIAL GROWTH-FACTOR; HUMAN OSTEOBLAST CELLS; PROSTATE-CANCER CELLS; HUMAN TUMOR-CELLS; IN-VITRO; VEGF; TRANSFORMATION; PHENOTYPE; CHEMOTHERAPY; INDUCTION	The cellular and molecular mechanisms of tumor progression following chemotherapy are largely unknown. Here, we demonstrate that cisplatin ( CDDP) treatment upregulates VEGF and Flt1 expression leading to the survival and expansion of a highly tumorigenic fraction of side-population (SP) cells in osteosarcoma (HOS), neuroblastoma (SK-N-BE2) and rhabdomyosarcoma (RH-4) cell lines. In all three lines, we show that CDDP treatment increases levels of VEGF and Flt1 expression, and induces enhanced clonogenic capacity and increased expression of the 'stemness'-associated genes Nanog, Bmi-1 and Oct-4 in the SP fraction. In HOS, these changes are associated with the transformation of a non-tumorigenic osteosarcoma SP fraction to a highly tumorigenic phenotype. Inhibition of Flt1 led to complete reduction of tumorigenicity in the HOS SP fraction, and reduction of clonogenic capacity and expression of stemness genes in the SK-N-BE(2) and RH-4 SP fractions. Treatment with U0126, a specific inhibitor of MAPK/ERK1,2 completely downregulates CDDP-induced VEGF and Flt1 expression and induction/expansion of SP fraction in all three cell lines, indicating that these effects are mediated through MAPK/ERK1,2 signaling. In conclusion, we report a novel mechanism of CDDP-induced tumor progression, whereby the activation of VEGF/Flt1 autocrine signaling leads to the survival and expansion of a highly tumorigenic SP fraction.	[Tsuchida, R.; Das, B.; Baruchel, S.; Malkin, D.] Hosp Sick Children, Dept Pediat, Div Hematol Oncol, Toronto, ON M5G 1X8, Canada; [Das, B.; Koren, G.; Baruchel, S.; Malkin, D.] Univ Toronto, Inst Med Sci, Toronto, ON M5S 1A1, Canada; [Yeger, H.; Thorner, Ps] Hosp Sick Children, Div Pathol, Toronto, ON M5G 1X8, Canada; [Yeger, H.; Thorner, Ps] Univ Toronto, Dept Lab Med & Pathobiol, Toronto, ON, Canada; [Shibuya, M.] Univ Tokyo, Inst Med Sci, Dept Genet, Div Genet, Tokyo, Japan; [Baruchel, S.; Malkin, D.] Univ Toronto, Dept Paediat, Toronto, ON M5S 1A1, Canada; [Malkin, D.] Univ Toronto, Dept Med Biophys, Toronto, ON, Canada	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University of Tokyo; University of Toronto; University of Toronto	Malkin, D (corresponding author), Hosp Sick Children, Dept Pediat, Div Hematol Oncol, 555 Univ Ave, Toronto, ON M5G 1X8, Canada.	david.malkin@sickkids.ca	Malkin, David/AAW-8715-2021; Koren, Gideon/AAG-7726-2019	Koren, Gideon/0000-0002-9234-0875				Bates RC, 2003, CURR BIOL, V13, P1721, DOI 10.1016/j.cub.2003.09.002; Behrends M, 2000, AM J PHYSIOL-HEART C, V279, pH1111, DOI 10.1152/ajpheart.2000.279.3.H1111; Bellamy WT, 2001, BLOOD, V97, P1427, DOI 10.1182/blood.V97.5.1427; Biswas S, 2007, J CLIN INVEST, V117, P1305, DOI 10.1172/JCI30740; Brozovic A, 2007, CANCER LETT, V251, P1, DOI 10.1016/j.canlet.2006.10.007; Cara S, 2001, ANN ONCOL, V12, P23, DOI 10.1023/A:1008389706725; COLE S, 2004, DRUG RESISTANCE; Cottler-Fox Michele H, 2003, Hematology Am Soc Hematol Educ Program, P419; Das B, 2005, CANCER RES, V65, P7267, DOI 10.1158/0008-5472.CAN-04-4575; Das B, 2003, EUR J CANCER, V39, P2556, DOI 10.1016/j.ejca.2003.07.002; DAS B, 2007, STEM CELLS; Dias S, 2000, J CLIN INVEST, V106, P511, DOI 10.1172/JCI8978; Ferrara N, 2003, NAT MED, V9, P669, DOI 10.1038/nm0603-669; FOLKMAN J, 1971, NEW ENGL J MED, V285, P1182; Fukumura D, 1998, CELL, V94, P715, DOI 10.1016/S0092-8674(00)81731-6; GASPARINI G, 1995, J CLIN ONCOL, V13, P765, DOI 10.1200/JCO.1995.13.3.765; Gee MFW, 2005, ONCOGENE, V24, P8025, DOI 10.1038/sj.onc.1208939; Hirschmann-Jax C, 2004, P NATL ACAD SCI USA, V101, P14228, DOI 10.1073/pnas.0400067101; Hirschmann-Jax C, 2005, CELL CYCLE, V4, P203; Ho MM, 2007, CANCER RES, V67, P4827, DOI 10.1158/0008-5472.CAN-06-3557; Kim JJ, 2005, NAT REV CANCER, V5, P516, DOI 10.1038/nrc1650; Kondo T, 2004, P NATL ACAD SCI USA, V101, P781, DOI 10.1073/pnas.0307618100; LIN XH, 1994, ENVIRON HEALTH PERSP, V102, P289, DOI 10.2307/3431804; MCALLISTER RM, 1971, CANCER-AM CANCER SOC, V27, P397, DOI 10.1002/1097-0142(197102)27:2<397::AID-CNCR2820270224>3.0.CO;2-X; Mercurio AM, 2004, SEMIN CANCER BIOL, V14, P115, DOI 10.1016/j.semcancer.2003.09.016; Miller AC, 1998, ENVIRON HEALTH PERSP, V106, P465, DOI 10.1289/ehp.98106465; Miller AC, 2001, CARCINOGENESIS, V22, P115, DOI 10.1093/carcin/22.1.115; Miura K, 2005, BIOCHEM CELL BIOL, V83, P36, DOI 10.1139/O04-106; Montanaro F, 2004, EXP CELL RES, V298, P144, DOI 10.1016/j.yexcr.2004.04.010; Patrawala L, 2005, CANCER RES, V65, P6207, DOI 10.1158/0008-5472.CAN-05-0592; Patrawala L, 2007, CANCER RES, V67, P6796, DOI 10.1158/0008-5472.CAN-07-0490; Qi L, 2003, ANTICANCER RES, V23, P3917; Ranganathan AC, 2006, CELL CYCLE, V5, P1799, DOI 10.4161/cc.5.16.3109; RICHMAN CM, 1976, BLOOD, V47, P1031; Salnikow K, 1999, CARCINOGENESIS, V20, P1819, DOI 10.1093/carcin/20.9.1819; Setoguchi T, 2004, CELL CYCLE, V3, P414; Soker S, 2001, AM J PATHOL, V159, P651, DOI 10.1016/S0002-9440(10)61736-1; Steiner HH, 2004, J NEURO-ONCOL, V66, P129, DOI 10.1023/B:NEON.0000013495.08168.8f; Strizzi L, 2001, J PATHOL, V193, P468, DOI 10.1002/path.824; Woessmann W, 2002, CANCER CHEMOTH PHARM, V50, P397, DOI 10.1007/s00280-002-0502-y	40	51	53	1	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2008	27	28					3923	3934		10.1038/onc.2008.38	http://dx.doi.org/10.1038/onc.2008.38			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	318JZ	18332870				2022-12-28	WOS:000257089000004
J	Chen, X; Guo, X; Zhang, H; Xiang, Y; Chen, J; Yin, Y; Cai, X; Wang, K; Wang, G; Ba, Y; Zhu, L; Wang, J; Yang, R; Zhang, Y; Ren, Z; Zen, K; Zhang, J; Zhang, CY				Chen, X.; Guo, X.; Zhang, H.; Xiang, Y.; Chen, J.; Yin, Y.; Cai, X.; Wang, K.; Wang, G.; Ba, Y.; Zhu, L.; Wang, J.; Yang, R.; Zhang, Y.; Ren, Z.; Zen, K.; Zhang, J.; Zhang, C-Y			Role of miR-143 targeting KRAS in colorectal tumorigenesis	ONCOGENE			English	Article						microRNA; colorectal cancer; miR-143; KRAS	MICRORNA TARGETS; EXPRESSION; CANCER; CELLS; SUPPRESSOR; TISSUES; PCR	Dysregulated expression of microRNAs ( miRNAs) is associated with a variety of diseases, including colorectal cancer. Bycomparing more than 200 miRNAs in 13 pairs of matched colorectal cancer and normal adjacent tissue samples through qRT-PCR and microarray analysis, we found a widespread disruption of miRNA expression during colorectal tumorigenesis. In particular, among a panel of presumed targets generated by in silico analysis that may interact with these aberrantly expressed miRNAs, KRAS oncogene has been further experimentally validated as the target of miR-143. First, an inverse correlation between KRAS protein and miR-143 in vivo was found. Second, KRAS expression in Lovo cells was significantly abolished by treatment with miR-143 mimic, whereas miR-143 inhibitor increased KRAS protein level. Third, luciferase reporter assay confirmed that miR-143 directly recognize the 30-untranslated region of KRAS transcripts. Four, Lovo cells treated with miR-143 inhibitor showed a stimulated cell proliferation, whereas miR-143 overexpression had an opposite effect. Finally, inhibition of KRAS expression by miR-143 inhibits constitutive phosphorylation of ERK1/2. Taken together, the present study provides the first evidences that miR-143 is significant in suppressing colorectal cancer cell growth through inhibition of KRAS translation.	[Chen, X.; Guo, X.; Zhang, H.; Xiang, Y.; Chen, J.; Yin, Y.; Cai, X.; Wang, K.; Wang, G.; Zhu, L.; Wang, J.; Yang, R.; Zhang, Y.; Ren, Z.; Zen, K.; Zhang, J.; Zhang, C-Y] Nanjing Univ, Sch Life Sci, State Key Lab Pharmaceut Biotechnol, Jiangsu Diabet Ctr, Nanjing 210093, Jiangsu, Peoples R China; [Zhang, H.] Nanjing Med Univ, Affiliated Hosp 1, Dept Gastroenterol, Nanjing, Jiangsu, Peoples R China; [Ba, Y.] Tianjin Med Univ, Canc Inst & Hosp, Tianjin, Peoples R China; [Zen, K.] Nanjing Univ, Jiangsu CDC, Joint Inst Virol, Nanjing 210093, Jiangsu, Peoples R China	Nanjing University; Nanjing Medical University; Tianjin Medical University; Nanjing University	Zhang, CY (corresponding author), Nanjing Univ, Sch Life Sci, State Key Lab Pharmaceut Biotechnol, Jiangsu Diabet Ctr, 22 Hankou Rd, Nanjing 210093, Jiangsu, Peoples R China.	kzen@nju.edu.cn; jfzhang@nju.edu.cn; cyzhang@nju.edu.cn	殷, 媛/GSE-4523-2022; CHEN, JIAO/GZA-5784-2022; zhang, jiani/GVS-2052-2022; chen, JJ/HGB-6029-2022; Yin, Yuan/AAG-1707-2020	/0000-0002-0420-4508				Akao Y, 2006, BIOL PHARM BULL, V29, P903, DOI 10.1248/bpb.29.903; Bandres E, 2006, MOL CANCER, V5, DOI 10.1186/1476-4598-5-29; Calin GA, 2004, P NATL ACAD SCI USA, V101, P2999, DOI 10.1073/pnas.0307323101; Calin GA, 2006, NAT REV CANCER, V6, P857, DOI 10.1038/nrc1997; Chen CF, 2005, NUCLEIC ACIDS RES, V33, DOI 10.1093/nar/gni178; Cummins JM, 2006, P NATL ACAD SCI USA, V103, P3687, DOI 10.1073/pnas.0511155103; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; Esau C, 2004, J BIOL CHEM, V279, P52361, DOI 10.1074/jbc.C400438200; Esquela-Kerscher A, 2006, NAT REV CANCER, V6, P259, DOI 10.1038/nrc1840; Fang JY, 2005, LANCET ONCOL, V6, P322, DOI 10.1016/S1470-2045(05)70168-6; He L, 2004, NAT REV GENET, V5, P522, DOI 10.1038/nrg1379; Jemal A, 2005, CA-CANCER J CLIN, V55, P10, DOI 10.3322/canjclin.55.1.10; John B, 2004, PLOS BIOL, V2, P1862, DOI 10.1371/journal.pbio.0020363; Johnson SM, 2005, CELL, V120, P635, DOI 10.1016/j.cell.2005.01.014; Krek A, 2005, NAT GENET, V37, P495, DOI 10.1038/ng1536; Lewis BP, 2003, CELL, V115, P787, DOI 10.1016/S0092-8674(03)01018-3; Lim LP, 2005, NATURE, V433, P769, DOI 10.1038/nature03315; Liu CG, 2004, P NATL ACAD SCI USA, V101, P9740, DOI 10.1073/pnas.0403293101; Michael MZ, 2003, MOL CANCER RES, V1, P882; Michor F, 2005, SEMIN CANCER BIOL, V15, P484, DOI 10.1016/j.semcancer.2005.06.005; Schetter AJ, 2008, JAMA-J AM MED ASSOC, V299, P425, DOI 10.1001/jama.299.4.425; Tang FC, 2006, NUCLEIC ACIDS RES, V34, DOI 10.1093/nar/gnj009; Thomson JM, 2004, NAT METHODS, V1, P47, DOI 10.1038/NMETH704; Tusher VG, 2001, P NATL ACAD SCI USA, V98, P5116, DOI 10.1073/pnas.091062498; Volinia S, 2006, P NATL ACAD SCI USA, V103, P2257, DOI 10.1073/pnas.0510565103; Welch C, 2007, ONCOGENE, V26, P5017, DOI 10.1038/sj.onc.1210293	26	458	491	3	68	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2009	28	10					1385	1392		10.1038/onc.2008.474	http://dx.doi.org/10.1038/onc.2008.474			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	417ZC	19137007				2022-12-28	WOS:000264116000011
J	Bertoli, C; Copetti, T; Lam, EWF; Demarchi, F; Schneider, C				Bertoli, C.; Copetti, T.; Lam, E. W-F; Demarchi, F.; Schneider, C.			Calpain small-1 modulates Akt/FoxO3A signaling and apoptosis through PP2A	ONCOGENE			English	Article						CAPNS-1; FoxO3A; apoptosis; PP2A; B56; Akt	PROTEIN PHOSPHATASE 2A; FORKHEAD TRANSCRIPTION FACTORS; CELL-CYCLE ARREST; TUMOR-SUPPRESSOR; KINASE-B; MAMMALIAN-CELLS; AKT; DEATH; CANCER; SURVIVAL	Here, we show that FoxO3A transcription factor is upregulated upon calpain small-1 (CAPNS1) depletion both in mouse embryonic. broblasts (MEFs) and in the human mammary carcinoma cell line MCF-7. On starvation, CAPNS1 depletion is associated with a higher rate of FoxO3A dephosphorylation and translocation to the nucleus and to a sharper increase in the levels of p27Kip1 and Bim, the products of two FoxO target genes. Notably, FoxO3A depletion in CAPNS1(-/-) MEFs reduces both the induction of Bim and apoptosis. Both okadaic acid treatment and silencing of the protein phosphatase 2A (PP2A) catalytic subunit can partially reduce starvation-induced FoxO3A activation and apoptosis in CAPNS1(-/-). broblasts. PP2A associates more tightly with Akt in CAPNS1 knockout cells, indicating that PP2A is involved in calpain-mediated FoxO regulation. Finally, we show that PP2A regulatory subunits B56 alpha and gamma are in vitro substrates of calpain, and calpain regulates B56 alpha stability in vivo, suggesting a direct role of calpain in the regulation of PP2A function. In conclusion, for the fist time we report that CAPNS1 interferes with PP2A-Akt interaction consequently affecting FoxO3A-dependent cell death. Calpain inhibition might therefore be exploited as a tool to induce apoptosis in tumors sensitive to FoxO activation.	[Bertoli, C.; Copetti, T.; Demarchi, F.; Schneider, C.] LNCIB, I-34012 Trieste, Italy; [Lam, E. W-F] Univ London Imperial Coll Sci Technol & Med, Hammersmith Hosp, Dept Oncol, Canc Res United Kingdom Labs, London, England; [Schneider, C.] Univ Udine, Dipartimento Sci & Tecnol Biomed, I-33100 Udine, Italy	Cancer Research UK; Imperial College London; Consiglio Nazionale delle Ricerche (CNR); Istituto di Tecnologie Biomediche (ITB-CNR); University of Udine	Demarchi, F (corresponding author), LNCIB, AREA Sci Pk,Padriciano 99, I-34012 Trieste, Italy.	francesca.demarchi@lncib.it; schneide@lncib.it	Lam, Eric W-F/AAW-8566-2020	Lam, Eric W-F/0000-0003-1274-3576; Demarchi, Francesca/0000-0003-1565-3162	FIRC (Fondazione italiana per la ricerca sul cancro); PRIN (Programmi di Ricerca Scientifica di Rilevante Interesse Nazionale) [2006-prot. 2006053543_003]; TRANSFOG (Translational and Functinal Onco-Genomics) EU [503438]; AIRC (Associazione italiana per la ricerca sul cancro) Grant proposal 2007 [Cod. 4752]; Progetto FAR CT cod. MIUR prog [10036]	FIRC (Fondazione italiana per la ricerca sul cancro)(Fondazione AIRC per la ricerca sul cancro); PRIN (Programmi di Ricerca Scientifica di Rilevante Interesse Nazionale)(Ministry of Education, Universities and Research (MIUR)Research Projects of National Relevance (PRIN)); TRANSFOG (Translational and Functinal Onco-Genomics) EU(European Commission); AIRC (Associazione italiana per la ricerca sul cancro) Grant proposal 2007(Fondazione AIRC per la ricerca sul cancro); Progetto FAR CT cod. MIUR prog(Ministry of Education, Universities and Research (MIUR))	We acknowledge Silvano Piazza for help in statistics. CB was a recipient of an FIRC (Fondazione italiana per la ricerca sul cancro) fellowship. This study was supported by PRIN (Programmi di Ricerca Scientifica di Rilevante Interesse Nazionale) 2006-prot. 2006053543_003, and TRANSFOG (Translational and Functinal Onco-Genomics) EU Contract 503438, AIRC (Associazione italiana per la ricerca sul cancro) Grant proposal 2007 Cod. 4752, and Progetto FAR CT cod. MIUR prog. 10036.	Altomare DA, 2005, ONCOGENE, V24, P7455, DOI 10.1038/sj.onc.1209085; Andrabi S, 2007, P NATL ACAD SCI USA, V104, P19011, DOI 10.1073/pnas.0706696104; Arthur JSC, 2000, MOL CELL BIOL, V20, P4474, DOI 10.1128/MCB.20.12.4474-4481.2000; Barreyro FJ, 2007, J BIOL CHEM, V282, P27141, DOI 10.1074/jbc.M704391200; Biggs WH, 1999, P NATL ACAD SCI USA, V96, P7421, DOI 10.1073/pnas.96.13.7421; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Carragher NO, 2004, NEOPLASIA, V6, P53, DOI 10.1016/S1476-5586(04)80053-8; Darnell GA, 2007, J BIOL CHEM, V282, P37492, DOI 10.1074/jbc.M706860200; Demarchi F, 2005, CELL DEATH DIFFER, V12, P512, DOI 10.1038/sj.cdd.4401592; Demarchi F, 2007, AUTOPHAGY, V3, P235, DOI 10.4161/auto.3661; Demarchi F, 2006, J CELL BIOL, V175, P595, DOI 10.1083/jcb.200601024; Dijkers PF, 2002, J CELL BIOL, V156, P531, DOI 10.1083/jcb.200108084; Dourdin N, 2001, J BIOL CHEM, V276, P48382, DOI 10.1074/jbc.M108893200; Essafi A, 2005, ONCOGENE, V24, P2317, DOI 10.1038/sj.onc.1208421; Gao TY, 2005, MOL CELL, V18, P13, DOI 10.1016/j.molcel.2005.03.008; Goll DE, 2003, PHYSIOL REV, V83, P731, DOI 10.1152/physrev.00029.2002; Greer EL, 2005, ONCOGENE, V24, P7410, DOI 10.1038/sj.onc.1209086; Guan N, 2006, INT J ONCOL, V29, P655; Harriman JF, 2002, CELL DEATH DIFFER, V9, P734, DOI 10.1038/sj.cdd.4401029; Janssens V, 2001, BIOCHEM J, V353, P417, DOI 10.1042/0264-6021:3530417; Kops GJPL, 1999, J MOL MED-JMM, V77, P656, DOI 10.1007/s001099900050; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; Libertini SJ, 2005, CANCER RES, V65, P10700, DOI 10.1158/0008-5472.CAN-05-1666; Manning BD, 2007, CELL, V129, P1261, DOI 10.1016/j.cell.2007.06.009; Millward TA, 1999, TRENDS BIOCHEM SCI, V24, P186, DOI 10.1016/S0968-0004(99)01375-4; Mumby M, 2007, CELL, V130, P21, DOI 10.1016/j.cell.2007.06.034; Nakamura N, 2000, MOL CELL BIOL, V20, P8969, DOI 10.1128/MCB.20.23.8969-8982.2000; Paik JH, 2007, CELL, V128, P309, DOI 10.1016/j.cell.2006.12.029; Reagan-Shaw S, 2006, CANCER RES, V66, P1062, DOI 10.1158/0008-5472.CAN-05-1018; Resjo S, 2002, CELL SIGNAL, V14, P231, DOI 10.1016/S0898-6568(01)00238-8; Rocher G, 2007, J BIOL CHEM, V282, P5468, DOI 10.1074/jbc.M609712200; Sablina AA, 2007, CELL, V129, P969, DOI 10.1016/j.cell.2007.03.047; Sandri M, 2004, CELL, V117, P399, DOI 10.1016/S0092-8674(04)00400-3; Sato S, 2000, P NATL ACAD SCI USA, V97, P10832, DOI 10.1073/pnas.170276797; Seeling JM, 1999, SCIENCE, V283, P2089, DOI 10.1126/science.283.5410.2089; Sunters A, 2003, J BIOL CHEM, V278, P49795, DOI 10.1074/jbc.M309523200; Tan Y, 2006, J BIOL CHEM, V281, P17689, DOI 10.1074/jbc.M601978200; Tang ED, 1999, J BIOL CHEM, V274, P16741, DOI 10.1074/jbc.274.24.16741; Trotman LC, 2003, PLOS BIOL, V1, P385, DOI 10.1371/journal.pbio.0000059; Trotman LC, 2006, NATURE, V441, P523, DOI 10.1038/nature04809; van der Horst A, 2007, NAT REV MOL CELL BIO, V8, P440, DOI 10.1038/nrm2190; Van Kanegan MJ, 2005, J BIOL CHEM, V280, P36029, DOI 10.1074/jbc.M506986200; Xu LJ, 2006, J BIOL CHEM, V281, P35567, DOI 10.1074/jbc.M607702200; Yan L, 2008, J BIOL CHEM, V283, P7411, DOI 10.1074/jbc.M708083200; Yin KJ, 2006, J NEUROSCI, V26, P2290, DOI 10.1523/JNEUROSCI.5103-05.2006; You H, 2006, J EXP MED, V203, P1657, DOI 10.1084/jem.20060353; Zatz M, 2005, NEW ENGL J MED, V352, P2413, DOI 10.1056/NEJMra043361; Zhang XH, 2002, J BIOL CHEM, V277, P45276, DOI 10.1074/jbc.M208063200	49	42	43	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 5	2009	28	5					721	733		10.1038/onc.2008.425	http://dx.doi.org/10.1038/onc.2008.425			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	403IN	19029949				2022-12-28	WOS:000263076400009
J	Zhang, B; Chambers, KJ; Leprince, D; Faller, DV; Wang, S				Zhang, B.; Chambers, K. J.; Leprince, D.; Faller, D. V.; Wang, S.			RETRACTED: Requirement for chromatin-remodeling complex in novel tumor suppressor HIC1-mediated transcriptional repression and growth control (Retracted article. See vol. 30, pg. 4374, 2011)	ONCOGENE			English	Article; Retracted Publication						HIC1; E2F1; Brg1; SWI/SNF; transcription; cell cycle	GENE HIC1; ANDROGEN RECEPTOR; SWI/SNF COMPLEX; PROHIBITIN; RB; E2F; EXPRESSION; CANCER; IDENTIFICATION; ACTIVATION	HIC1 is a newly discovered tumor suppressor and transcriptional repressor that is frequently silenced in human tumors. HIC1 protein expression has been linked to better outcomes in breast cancers. The molecular mechanism underlying HIC1-mediated transcriptional and growth suppression, and the relevant targets of HIC1-mediated transcriptional modulation, is currently unclear. We have identified an HIC1 DNA-binding site in E2F-responsive gene promoters and demonstrate that HIC1 targets E2F-responsive genes for transcriptional regulation and growth suppression. We and others have recently discovered that Brg1, a central component of the SWI/SNF chromatin-remodeling family, is required for the transcriptional regulation of multiple cell cycle control-related genes, including E2F-responsive promoters. We studied HIC1 interactions with, and dependence upon, Brg1 activity, and found that HIC1 can recruit Brg1 to E2F-responsive promoters and that its transcriptional repression of these genes is dependent upon Brg1. These data indicate that HIC1 is a central molecule in a novel mechanism controlling cell growth and that the disruption of this HIC1-mediated pathway may lead to abnormal cell proliferation and, ultimately, cancer.	[Zhang, B.; Chambers, K. J.; Faller, D. V.; Wang, S.] Boston Univ, Sch Med, Canc Res Ctr, Boston, MA 02118 USA; [Leprince, D.] Inst Pasteur, Inst Biol Lille, CNRS, UMR 8161, F-59019 Lille, France	Boston University; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Le Reseau International des Instituts Pasteur (RIIP); Universite de Lille - ISITE; Institut Pasteur Lille; Universite de Lille	Wang, S (corresponding author), Boston Univ, Sch Med, Canc Res Ctr, R-906,715 Albany St, Boston, MA 02118 USA.	sw184@bu.edu		Leprince, Dominique/0000-0002-1999-0775	Susan G Komen Breast Cancer Foundation Research [BCTR0403163]; National Cancer Institute [CA102940, CA101992]; Karin Grunebaum Cancer Research Foundation; DOD/CDMRP 2008 Breast Cancer Concept Award; Carter Family Foundation for Melanoma Research; BUSM Department of Medicine Pilot Project Grant Award; Aid for Cancer Research; NATIONAL CANCER INSTITUTE [R01CA101992, R03CA102940] Funding Source: NIH RePORTER	Susan G Komen Breast Cancer Foundation Research(Susan G. Komen Breast Cancer Foundation); National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Karin Grunebaum Cancer Research Foundation; DOD/CDMRP 2008 Breast Cancer Concept Award(United States Department of Defense); Carter Family Foundation for Melanoma Research; BUSM Department of Medicine Pilot Project Grant Award; Aid for Cancer Research; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Dr Srikumar P Chellappan for his continuous support. This study was partially supported by grants from Susan G Komen Breast Cancer Foundation Research Award (BCTR0403163)(SW) and the National Cancer Institute ((CA102940)(SW) and (CA101992)(DVF)) and by the Karin Grunebaum Cancer Research Foundation (DVF). SW is the recipient of DOD/CDMRP 2008 Breast Cancer Concept Award, Carter Family Foundation for Melanoma Research grant award, a BUSM Department of Medicine Pilot Project Grant Award and an Aid for Cancer Research grant award.	Aggerholm A, 2006, EUR J HAEMATOL, V76, P23, DOI 10.1111/j.1600-0609.2005.00559.x; Banine F, 2005, CANCER RES, V65, P3542, DOI 10.1158/0008-5472.CAN-04-3554; Bertrand S, 2004, BBA-GENE STRUCT EXPR, V1678, P57, DOI 10.1016/j.bbaexp.2004.01.009; Betz BL, 2002, ONCOGENE, V21, P5193, DOI 10.1038/sj.onc.1205706; Britschgi C, 2006, ONCOGENE, V25, P2030, DOI 10.1038/sj.onc.1209240; Chen WY, 2005, CELL, V123, P437, DOI 10.1016/j.cell.2005.08.011; Chen WY, 2003, NAT GENET, V33, P197, DOI 10.1038/ng1077; Chen WY, 2005, CELL CYCLE, V4, P10, DOI 10.4161/cc.4.1.1361; Chen WY, 2004, CANCER CELL, V6, P387, DOI 10.1016/j.ccr.2004.08.030; Chopin V, 2006, M S-MED SCI, V22, P54, DOI 10.1051/medsci/200622154; Dai Y, 2008, CARCINOGENESIS, V29, P1725, DOI 10.1093/carcin/bgn117; Dai Y, 2007, MOL ENDOCRINOL, V21, P1807, DOI 10.1210/me.2006-0467; Dasgupta P, 2004, MOL CELL BIOL, V24, P9527, DOI 10.1128/MCB.24.21.9527-9541.2004; Deltour S, 2002, MOL CELL BIOL, V22, P4890, DOI 10.1128/MCB.22.13.4890-4901.2002; DUNAIEF JL, 1994, CELL, V79, P119, DOI 10.1016/0092-8674(94)90405-7; Fusaro G, 2002, ONCOGENE, V21, P4539, DOI 10.1038/sj.onc.1205551; Giacinti C, 2006, ONCOGENE, V25, P5220, DOI 10.1038/sj.onc.1209615; Guerardel C, 1999, FEBS LETT, V451, P253, DOI 10.1016/S0014-5793(99)00583-9; Inayoshi Y, 2006, J BIOCHEM, V139, P177, DOI 10.1093/jb/mvj015; Lefebvre T, 2004, EUR J BIOCHEM, V271, P3843, DOI 10.1111/j.1432-1033.2004.04316.x; Melki JR, 1999, LEUKEMIA, V13, P877, DOI 10.1038/sj.leu.2401401; Nevins JR, 2001, HUM MOL GENET, V10, P699, DOI 10.1093/hmg/10.7.699; Nicoll G, 2001, BRIT J CANCER, V85, P1878, DOI 10.1054/bjoc.2001.2163; Pinte S, 2004, J BIOL CHEM, V279, P38313, DOI 10.1074/jbc.M401610200; Pinte S, 2004, ONCOGENE, V23, P4023, DOI 10.1038/sj.onc.1207504; Stankovic-Valentin N, 2006, FEBS J, V273, P2879, DOI 10.1111/j.1742-4658.2006.05301.x; Stevaux O, 2002, EMBO J, V21, P4927, DOI 10.1093/emboj/cdf501; Strobeck MW, 2001, J BIOL CHEM, V276, P9273, DOI 10.1074/jbc.M009747200; Takahashi Y, 2000, GENE DEV, V14, P804; Waha A, 2004, INT J CANCER, V110, P542, DOI 10.1002/ijc.20165; Wang S, 2002, EMBO J, V21, P3019, DOI 10.1093/emboj/cdf302; Wang S, 1999, ONCOGENE, V18, P3501, DOI 10.1038/sj.onc.1202684; Wang S, 2004, EMBO J, V23, P2293, DOI 10.1038/sj.emboj.7600231; Wang S, 2002, ONCOGENE, V21, P8388, DOI 10.1038/sj.onc.1205944; Wang S, 1999, EMBO J, V18, P1559, DOI 10.1093/emboj/18.6.1559; Wang S, 1998, MOL CELL BIOL, V18, P7487, DOI 10.1128/MCB.18.12.7487; Wong S, 2007, BIOCHEM J, V407, P451, DOI 10.1042/BJ20070151; Zhang B, 2007, ONCOGENE, V26, P7153, DOI 10.1038/sj.onc.1210509	38	20	21	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 5	2009	28	5					651	661		10.1038/onc.2008.419	http://dx.doi.org/10.1038/onc.2008.419			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	403IN	19015639	Green Accepted			2022-12-28	WOS:000263076400003
J	Kitagaki, J; Yang, Y; Saavedra, JE; Colburn, NH; Keefer, LK; Perantoni, AO				Kitagaki, J.; Yang, Y.; Saavedra, J. E.; Colburn, N. H.; Keefer, L. K.; Perantoni, A. O.			Nitric oxide prodrug JS-K inhibits ubiquitin E1 and kills tumor cells retaining wild-type p53	ONCOGENE			English	Article						JS-K; nitric oxide (NO); ubiquitin; tumor; apoptosis; p53	IN-VITRO; BETA-CATENIN; APOPTOSIS; CANCER; DESTRUCTION; TRANSLATION; GLUTATHIONE; PATHWAYS; SYSTEM; GROWTH	Nitric oxide (NO) is a major effector molecule in cancer prevention. A number of studies have shown that NO prodrug JS-K (O-2-(2,4-dinitrophenyl) 1-[(4-ethoxy-carbonyl)piperazin-1-yl]diazen-1-ium-1,2-diolate) induces apoptotic cell death in vitro and in vivo, indicating that it is a promising new therapeutic for cancer. However, the mechanism of its tumor-killing activity remains unclear. Ubiquitin plays an important role in the regulation of tumorigenesis and cell apoptosis. Our earlier report has shown that inactivation of the ubiquitin system through blocking E1(ubiquitin-activating enzyme) activity preferentially induces apoptosis in p53-expressing transformed cells. As E1 has an active cysteine residue that could potentially interact with NO, we hypothesized that JS-K could inactivate E1 activity. E1 activity was evaluated by detecting ubiquitin-E1 conjugates through immunoblotting. JS-K strikingly inhibits the ubiquitin-E1 thioester formation in cells in a dose-dependent manner with an IC50 of approximately 2 mu M, whereas a JS-K analog that cannot release NO did not affect these levels in cells. Moreover, JS-K decreases total ubiquitylated proteins and increases p53 levels, which is mainly regulated by ubiquitin and proteasomal degradation. Furthermore, JS-K preferentially induces cell apoptosis in p53-expressing transformed cells. These findings indicate that JS-K inhibits E1 activity and kills transformed cells harboring wild-type p53.	[Kitagaki, J.; Yang, Y.; Perantoni, A. O.] Natl Canc Inst Frederick, Canc & Dev Biol Lab, Ctr Canc Res, Natl Inst Hlth, Frederick, MD 21702 USA; [Saavedra, J. E.] Natl Canc Inst Frederick, Basic Res Program, SAIC Frederick, Ctr Canc Res,Natl Inst Hlth, Frederick, MD 21702 USA; [Colburn, N. H.] Natl Canc Inst Frederick, Lab Canc Prevent, Ctr Canc Res, NIH, Frederick, MD 21702 USA; [Keefer, L. K.] Natl Canc Inst Frederick, Comparat Carcinogenesis Lab, Ctr Canc Res, Natl Inst Hlth, Frederick, MD 21702 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Perantoni, AO (corresponding author), Natl Canc Inst Frederick, Canc & Dev Biol Lab, Ctr Canc Res, Natl Inst Hlth, Bldg 538,Rm 221,1050 Boyles St, Frederick, MD 21702 USA.	yangyili@ncifcrf.gov; peranton@ncifcrf.gov	Keefer, Larry K/N-3247-2014	Keefer, Larry K/0000-0001-7489-9555	NIH; National Cancer Institute; Center for Cancer Research; National Cancer Institute [NOI-CO-12400]; NATIONAL CANCER INSTITUTE [ZIABC010025, ZIABC011188] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Center for Cancer Research(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We are grateful to the NIH Fellows Editorial Board for revisions of this paper. This work was supported by the Intramural Research Program of the NIH, National Cancer Institute, Center for Cancer Research and by National Cancer Institute Contract No. NOI-CO-12400 to SAIC Inc. JK was a fellow of the Japanese Society for the Promotion of Science.	Adams J, 2004, CANCER CELL, V5, P417, DOI 10.1016/S1535-6108(04)00120-5; BANDARA LR, 1991, NATURE, V351, P494, DOI 10.1038/351494a0; CHEN JD, 1995, MOL MED, V1, P142, DOI 10.1007/BF03401562; Chen ZJJ, 2005, NAT CELL BIOL, V7, P758, DOI 10.1038/ncb0805-758; Dorrello NV, 2006, SCIENCE, V314, P467, DOI 10.1126/science.1130276; Giarre M, 1998, ANN NY ACAD SCI, V857, P43, DOI 10.1111/j.1749-6632.1998.tb10106.x; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Jaffrey SR, 2001, NAT CELL BIOL, V3, P193, DOI 10.1038/35055104; JahngenHodge J, 1997, J BIOL CHEM, V272, P28218, DOI 10.1074/jbc.272.45.28218; Jansen AP, 2005, CANCER RES, V65, P6034, DOI 10.1158/0008-5472.CAN-04-2119; Kimelman D, 2006, ONCOGENE, V25, P7482, DOI 10.1038/sj.onc.1210055; Kiziltepe T, 2007, BLOOD, V110, P709, DOI 10.1182/blood-2006-10-052845; Lipton SA, 1999, CELL DEATH DIFFER, V6, P943, DOI 10.1038/sj.cdd.4400580; Liu J, 2004, MOL CANCER THER, V3, P709; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; Ren ZG, 2003, J CELL PHYSIOL, V197, P426, DOI 10.1002/jcp.10380; Saavedra JE, 2006, J MED CHEM, V49, P1157, DOI 10.1021/jm050700k; Shami PJ, 2006, J MED CHEM, V49, P4356, DOI 10.1021/jm060022h; Shami PJ, 2003, MOL CANCER THER, V2, P409; Simeone AM, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr2095; Turchi JJ, 2006, P NATL ACAD SCI USA, V103, P4337, DOI 10.1073/pnas.0601001103; Yang YL, 2007, CANCER RES, V67, P9472, DOI 10.1158/0008-5472.CAN-07-0568; Yang YL, 2005, CANCER CELL, V7, P547, DOI 10.1016/j.ccr.2005.04.029; Yang YL, 2004, ONCOGENE, V23, P2096, DOI 10.1038/sj.onc.1207411; Ying L, 2007, CANCER RES, V67, P1407, DOI 10.1158/0008-5472.CAN-06-2149	26	47	48	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 29	2009	28	4					619	624		10.1038/onc.2008.401	http://dx.doi.org/10.1038/onc.2008.401			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	400KM	18978812	Green Accepted			2022-12-28	WOS:000262866500015
J	Suzuki, T; Tsuzuku, J; Kawakami, K; Miyasaka, T; Yamamoto, T				Suzuki, T.; Tsuzuku, J.; Kawakami, K.; Miyasaka, T.; Yamamoto, T.			Proteasome-mediated degradation of Tob is pivotal for triggering UV-induced apoptosis	ONCOGENE			English	Article						Tob; apoptosis; DNA damage; proteasome	DNA-DAMAGE; CYTOCHROME-C; CANCER-CELLS; MICE LACKING; CASPASE 9; P53; REPAIR; TRANSCRIPTION; FIBROBLASTS; ACTIVATION	Eukaryotic cells respond to genotoxic stress by inducing cell growth arrest or apoptosis. Although the p53 tumor suppressor largely contributes to the response by regulating antiproliferative or pro-apoptotic genes, some genotoxic stresses including ultraviolet (UV) light induce apoptosis even in the absence of p53. The molecular mechanisms by which cells respond to UV in the p53-independent manner remain to be established. Here, we show that UV-induced stress promotes proteasome-dependent degradation of Tob, triggering an apoptotic signal. We found that Tob with either short deletion or a tag sequence at the C terminus was resistant to UV-induced degradation. Introduction of the degradation-resistant Tob impaired UV-induced apoptosis. Reciprocally, suppression of Tob by small interfering RNA (siRNA) resulted in frequent induction of apoptosis irrespective of the presence of functional p53 even at UV doses that do not promote Tob degradation. Finally, tob-deficient (tob(-/-)) mice and primary embryonic fibroblasts (MEFs) from tob(-/-) mice exhibit increased sensitivity to UV irradiation. Thus, proteasomal clearance of Tob provides a novel p53-independent pathway for UV-induced apoptosis.	[Suzuki, T.; Tsuzuku, J.; Kawakami, K.; Miyasaka, T.; Yamamoto, T.] Univ Tokyo, Inst Med Sci, Dept Canc Biol, Div Oncol,Minato Ku, Tokyo 1088639, Japan	University of Tokyo	Yamamoto, T (corresponding author), Univ Tokyo, Inst Med Sci, Dept Canc Biol, Div Oncol,Minato Ku, 4-6-1 Shirokanedai, Tokyo 1088639, Japan.	tyamamot@ims.u-tokyo.ac.jp			Ministry of Education, Culture, Sports, Science and Technology of Japan	Ministry of Education, Culture, Sports, Science and Technology of Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT))	We thank Dr Seiji Takeuchi (University of Fukui, Japan) for technical advice about UV irradiation of animals, and Dr Robert Whittier (Institute of Medical Science, Tokyo, Japan) and Dr Marius Sudol (Weis Center for Research, Danville, PA, USA) for comments on the paper. We also thank members of our laboratory for scientific comments and valuable discussions. This study was supported by a grant for scientific research from the Ministry of Education, Culture, Sports, Science and Technology of Japan.	Bendjennat M, 2003, CELL, V114, P599, DOI 10.1016/j.cell.2003.08.001; Boiko AD, 2006, GENE DEV, V20, P236, DOI 10.1101/gad.1372606; Dornetshuber R, 2007, CHEM RES TOXICOL, V20, P465, DOI 10.1021/tx600259t; El-Mahdy MA, 2000, MUTAT RES-DNA REPAIR, V459, P135, DOI 10.1016/S0921-8777(99)00066-X; Guardavaccaro D, 2000, MOL CELL BIOL, V20, P1797, DOI 10.1128/MCB.20.5.1797-1815.2000; Hakem R, 1998, CELL, V94, P339, DOI 10.1016/S0092-8674(00)81477-4; Hiramatsu Y, 2006, CANCER RES, V66, P8477, DOI 10.1158/0008-5472.CAN-06-1603; Kondo T, 2004, J BIOL CHEM, V279, P27315, DOI 10.1074/jbc.M314023200; Kuida K, 1998, CELL, V94, P325, DOI 10.1016/S0092-8674(00)81476-2; Lackinger D, 2000, MUTAT RES-FUND MOL M, V457, P113, DOI 10.1016/S0027-5107(00)00133-0; LATONEN L, 2006, BIOCHIM BIOPHYS ACTA, V1755, P71; Lavin MF, 2006, CELL DEATH DIFFER, V13, P941, DOI 10.1038/sj.cdd.4401925; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Matsuda S, 1996, ONCOGENE, V12, P705; McKay BC, 2001, ONCOGENE, V20, P6805, DOI 10.1038/sj.onc.1204901; Naik E, 2007, J CELL BIOL, V176, P415, DOI 10.1083/jcb.200608070; Norbury CJ, 2004, ONCOGENE, V23, P2797, DOI 10.1038/sj.onc.1207532; Ratner JN, 1998, J BIOL CHEM, V273, P5184, DOI 10.1074/jbc.273.9.5184; Rouault JP, 1996, NAT GENET, V14, P482, DOI 10.1038/ng1296-482; Saldeen J, 2003, MOL CELL BIOCHEM, V243, P113, DOI 10.1023/A:1021651811345; Sasajima H, 2002, EUR J BIOCHEM, V269, P3596, DOI 10.1046/j.1432-1033.2002.03052.x; Smith ML, 2000, MOL CELL BIOL, V20, P3705, DOI 10.1128/MCB.20.10.3705-3714.2000; Suzuki T, 2002, GENE DEV, V16, P1356, DOI 10.1101/gad.962802; Tirone F, 2001, J CELL PHYSIOL, V187, P155, DOI 10.1002/jcp.1062; Tomicic MT, 2005, APOPTOSIS, V10, P1295, DOI 10.1007/s10495-005-1392-3; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Wang SY, 2006, J BIOL CHEM, V281, P34810, DOI 10.1074/jbc.M607484200; Wang XD, 2001, GENE DEV, V15, P2922; Wei MC, 2001, SCIENCE, V292, P727, DOI 10.1126/science.1059108; Woo M, 1998, GENE DEV, V12, P806, DOI 10.1101/gad.12.6.806; Yoshida H, 1998, CELL, V94, P739, DOI 10.1016/S0092-8674(00)81733-X; Yoshida Y, 2000, CELL, V103, P1085, DOI 10.1016/S0092-8674(00)00211-7; Yoshida Y, 2003, GENE DEV, V17, P1201, DOI 10.1101/gad.1088003; Zhang OH, 2003, CELL, V115, P177, DOI 10.1016/S0092-8674(03)00802-X; Zhao Y, 2008, ONCOGENE, V27, P1, DOI 10.1038/sj.onc.1210625; Zhou BBS, 2000, NATURE, V408, P433, DOI 10.1038/35044005; Zong WX, 2001, GENE DEV, V15, P1481, DOI 10.1101/gad.897601; Zou H, 1997, CELL, V90, P405, DOI 10.1016/S0092-8674(00)80501-2	38	13	13	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 22	2009	28	3					401	411		10.1038/onc.2008.387	http://dx.doi.org/10.1038/onc.2008.387			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	395UZ	18850001				2022-12-28	WOS:000262550300008
J	Pietsch, EC; Sykes, SM; McMahon, SB; Murphy, ME				Pietsch, E. C.; Sykes, S. M.; McMahon, S. B.; Murphy, M. E.			The p53 family and programmed cell death	ONCOGENE			English	Review						p53; p63; p73; apoptosis; transcription; mitochondria	DNA-BINDING DOMAIN; YES-ASSOCIATED PROTEIN; TUMOR-SUPPRESSOR P53; WILD-TYPE P53; MITOCHONDRIAL-MEMBRANE PERMEABILIZATION; APOPTOTIC TARGET GENES; PROLYL ISOMERASE PIN1; KINASE C-ABL; IN-VIVO; P53-DEPENDENT APOPTOSIS	The p53 tumor suppressor continues to hold distinction as the most frequently mutated gene in human cancer. The ability of p53 to induce programmed cell death, or apoptosis, of cells exposed to environmental or oncogenic stress constitutes a major pathway whereby p53 exerts its tumor suppressor function. In the past decade, we have discovered that p53 is not alone in its mission to destroy damaged or aberrantly proliferating cells: it has two homologs, p63 and p73, that in various cellular contexts and stresses contribute to this process. In this review, the mechanisms whereby p53, and in some cases p63 and p73, induce apoptosis are discussed. Other reviews have focused more extensively on the contribution of individual p53-regulated genes to apoptosis induction by this protein, whereas in this review, we focus more on those factors that mediate the decision between growth arrest and apoptosis by p53, p63 and p73, and on the post-translational modi. cations and protein-protein interactions that influence this decision.	[Pietsch, E. C.; Murphy, M. E.] Fox Chase Canc Ctr, Div Med Sci, Philadelphia, PA 19111 USA; [Sykes, S. M.] Brigham & Womens Hosp, Dept Med, Boston, MA 02115 USA; [McMahon, S. B.] Thomas Jefferson Med Coll, Kimmel Canc Ctr, Dept Canc Biol, Philadelphia, PA USA	Fox Chase Cancer Center; Harvard University; Brigham & Women's Hospital; Jefferson University	Murphy, ME (corresponding author), Fox Chase Canc Ctr, Div Med Sci, 333 Cottman Ave, Philadelphia, PA 19111 USA.	steven.mcmahon@mail.jci.tju.edu; Maureen.Murphy@FCCC.edu		Murphy, Maureen/0000-0001-7644-7296; McMahon, Steven/0000-0002-3405-1768	NCI NIH HHS [R01 CA102184, R01 CA080854-10, R01 CA102184-04, R01 CA080854] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA080854, R01CA102184] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abida WM, 2007, J BIOL CHEM, V282, P1797, DOI 10.1074/jbc.M609001200; Agami R, 1999, NATURE, V399, P809; Bargonetti J, 2002, CURR OPIN ONCOL, V14, P86, DOI 10.1097/00001622-200201000-00015; Barlev NA, 2001, MOL CELL, V8, P1243, DOI 10.1016/S1097-2765(01)00414-2; Basu S, 2003, MOL CELL, V11, P11, DOI 10.1016/S1097-2765(02)00776-1; Bennett M, 1998, SCIENCE, V282, P290, DOI 10.1126/science.282.5387.290; Bergamaschi D, 2004, MOL CELL BIOL, V24, P1341, DOI 10.1128/MCB.24.3.1341-1350.2004; Bergamaschi D, 2003, CANCER CELL, V3, P387, DOI 10.1016/S1535-6108(03)00079-5; Bergamaschi D, 2003, NAT GENET, V33, P162, DOI 10.1038/ng1070; Bode AM, 2004, NAT REV CANCER, V4, P793, DOI 10.1038/nrc1455; Bourdon JC, 2005, GENE DEV, V19, P2122, DOI 10.1101/gad.1339905; Budhram-Mahadeo VS, 2006, NUCLEIC ACIDS RES, V34, P6640, DOI 10.1093/nar/gkl878; CAELLES C, 1994, NATURE, V370, P220, DOI 10.1038/370220a0; Cam H, 2006, CANCER CELL, V10, P281, DOI 10.1016/j.ccr.2006.08.024; Chao C, 2006, MOL CELL BIOL, V26, P6859, DOI 10.1128/MCB.00062-06; Chen XB, 1996, GENE DEV, V10, P2438, DOI 10.1101/gad.10.19.2438; Chen XB, 2001, ONCOGENE, V20, P769, DOI 10.1038/sj.onc.1204149; Chipuk JE, 2005, SCIENCE, V309, P1732, DOI 10.1126/science.1114297; Chipuk JE, 2004, SCIENCE, V303, P1010, DOI 10.1126/science.1092734; Concin N, 2004, CANCER RES, V64, P2449, DOI 10.1158/0008-5472.CAN-03-1060; Corn PG, 1999, CANCER RES, V59, P3352; Cory S, 2002, NAT REV CANCER, V2, P647, DOI 10.1038/nrc883; Costanzo A, 2002, MOL CELL, V9, P175, DOI 10.1016/S1097-2765(02)00431-8; Das S, 2007, CELL, V130, P624, DOI 10.1016/j.cell.2007.06.013; DeYoung MP, 2007, ONCOGENE, V26, P5169, DOI 10.1038/sj.onc.1210337; DeYoung MP, 2006, CANCER RES, V66, P9362, DOI 10.1158/0008-5472.CAN-06-1619; Di Como CJ, 1999, MOL CELL BIOL, V19, P1438; Di Stefano V, 2005, ONCOGENE, V24, P5431, DOI 10.1038/sj.onc.1208717; Dietz S, 2002, FEBS LETT, V525, P93, DOI 10.1016/S0014-5793(02)03093-4; Ding HF, 2000, J BIOL CHEM, V275, P38905, DOI 10.1074/jbc.M004714200; Ding HF, 1998, J BIOL CHEM, V273, P28378, DOI 10.1074/jbc.273.43.28378; Dohn M, 2001, ONCOGENE, V20, P3193, DOI 10.1038/sj.onc.1204427; Dominguez G, 2006, J CLIN ONCOL, V24, P805, DOI 10.1200/JCO.2005.02.2350; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; Dumont P, 2003, NAT GENET, V33, P357, DOI 10.1038/ng1093; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; Erster S, 2004, MOL CELL BIOL, V24, P6728, DOI 10.1128/MCB.24.15.6728-6741.2004; Feng LJ, 2006, CELL CYCLE, V5, P2812, DOI 10.4161/cc.5.23.3526; Flores ER, 2002, NATURE, V416, P560, DOI 10.1038/416560a; Flores ER, 2005, CANCER CELL, V7, P363, DOI 10.1016/j.ccr.2005.02.019; Fridman JS, 2003, ONCOGENE, V22, P9030, DOI 10.1038/sj.onc.1207116; Gaiddon C, 2001, MOL CELL BIOL, V21, P1874, DOI 10.1128/MCB.21.5.1874-1887.2001; Gan L, 1996, P NATL ACAD SCI USA, V93, P3920, DOI 10.1073/pnas.93.9.3920; Gao CF, 1999, JPN J CANCER RES, V90, P180, DOI 10.1111/j.1349-7006.1999.tb00731.x; Gong JG, 1999, NATURE, V399, P806; Gressner O, 2005, EMBO J, V24, P2458, DOI 10.1038/sj.emboj.7600708; Grob TJ, 2001, CELL DEATH DIFFER, V8, P1213, DOI 10.1038/sj.cdd.4400962; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; Han MK, 2008, CELL STEM CELL, V2, P241, DOI 10.1016/j.stem.2008.01.002; HAUPT Y, 1995, GENE DEV, V9, P2170, DOI 10.1101/gad.9.17.2170; Haupt Ygal, 1997, Leukemia (Basingstoke), V11, P337; Helton ES, 2008, ONCOGENE, V27, P2843, DOI 10.1038/sj.onc.1210948; Hudson CD, 2005, J BIOL CHEM, V280, P11851, DOI 10.1074/jbc.M408679200; Ihrie RA, 2005, CELL, V120, P843, DOI 10.1016/j.cell.2005.01.008; Irwin M, 2000, NATURE, V407, P645, DOI 10.1038/35036614; Irwin MS, 2001, CELL GROWTH DIFFER, V12, P337; Irwin MS, 2003, CANCER CELL, V3, P403, DOI 10.1016/S1535-6108(03)00078-3; Jeffers JR, 2003, CANCER CELL, V4, P321, DOI 10.1016/S1535-6108(03)00244-7; Johnson TM, 2008, P NATL ACAD SCI USA, V105, P1215, DOI 10.1073/pnas.0706764105; Johnson TM, 2005, NAT GENET, V37, P145, DOI 10.1038/ng1498; Kaelin WG, 1999, ONCOGENE, V18, P7701, DOI 10.1038/sj.onc.1202955; Kaghad M, 1997, CELL, V90, P809, DOI 10.1016/S0092-8674(00)80540-1; Kartasheva NN, 2002, ONCOGENE, V21, P4715, DOI 10.1038/sj.onc.1205584; Katoh I, 2000, ONCOGENE, V19, P3126, DOI 10.1038/sj.onc.1203644; Kawano S, 1999, BLOOD, V94, P1113; Keyes WM, 2006, P NATL ACAD SCI USA, V103, P8435, DOI 10.1073/pnas.0602477103; KEYES WM, 2008, GENE DEV, V19, P1986; Knights CD, 2006, J CELL BIOL, V173, P533, DOI 10.1083/jcb.200512059; Koga F, 2003, CLIN CANCER RES, V9, P5501; Kuwana T, 2005, MOL CELL, V17, P525, DOI 10.1016/j.molcel.2005.02.003; Lang GA, 2004, CELL, V119, P861, DOI 10.1016/j.cell.2004.11.006; Le Cam L, 2006, CELL, V127, P775, DOI 10.1016/j.cell.2006.09.031; Letai A, 2002, CANCER CELL, V2, P183, DOI 10.1016/S1535-6108(02)00127-7; Leu JIJ, 2004, NAT CELL BIOL, V6, P443, DOI 10.1038/ncb1123; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Levy D, 2007, CELL DEATH DIFFER, V14, P743, DOI 10.1038/sj.cdd.4402063; Levy D, 2008, MOL CELL, V29, P350, DOI 10.1016/j.molcel.2007.12.022; Li MY, 2003, SCIENCE, V302, P1972, DOI 10.1126/science.1091362; Liu L, 1999, MOL CELL BIOL, V19, P1202; Luo JL, 2001, ONCOGENE, V20, P320, DOI 10.1038/sj.onc.1204080; MALKIN D, 1992, NEW ENGL J MED, V326, P1309, DOI 10.1056/NEJM199205143262002; Mantovani F, 2004, MOL CELL, V14, P625, DOI 10.1016/j.molcel.2004.05.007; Mantovani F, 2007, NAT STRUCT MOL BIOL, V14, P912, DOI 10.1038/nsmb1306; Marchenko ND, 2007, EMBO J, V26, P923, DOI 10.1038/sj.emboj.7601560; Marchenko ND, 2000, J BIOL CHEM, V275, P16202, DOI 10.1074/jbc.275.21.16202; Marin MC, 2000, NAT GENET, V25, P47, DOI 10.1038/75586; Martins CP, 2006, CELL, V127, P1323, DOI 10.1016/j.cell.2006.12.007; Melino G, 2002, NAT REV CANCER, V2, P605, DOI 10.1038/nrc861; Melino G, 2004, J BIOL CHEM, V279, P8076, DOI 10.1074/jbc.M307469200; Melino G, 2003, TRENDS BIOCHEM SCI, V28, P663, DOI 10.1016/j.tibs.2003.10.004; Michalak EM, 2008, CELL DEATH DIFFER, V15, P1019, DOI 10.1038/cdd.2008.16; Mihara M, 2003, MOL CELL, V11, P577, DOI 10.1016/S1097-2765(03)00050-9; Mills AA, 1999, NATURE, V398, P708, DOI 10.1038/19531; Muller M, 2006, DRUG RESIST UPDATE, V9, P288, DOI 10.1016/j.drup.2007.01.001; Muller M, 2005, CELL DEATH DIFFER, V12, P1564, DOI 10.1038/sj.cdd.4401774; Murray-Zmijewski F, 2006, CELL DEATH DIFFER, V13, P962, DOI 10.1038/sj.cdd.4401914; Nemajerova A, 2005, FEBS LETT, V579, P6079, DOI 10.1016/j.febslet.2005.09.074; Oda K, 2000, CELL, V102, P849, DOI 10.1016/S0092-8674(00)00073-8; Okada Y, 2002, EXP CELL RES, V276, P194, DOI 10.1006/excr.2002.5535; Olivier M, 2002, HUM MUTAT, V19, P607, DOI 10.1002/humu.10081; Olsson A, 2007, CELL DEATH DIFFER, V14, P1561, DOI 10.1038/sj.cdd.4402196; Osada M, 1998, NAT MED, V4, P839, DOI 10.1038/nm0798-839; Palacios G, 2006, ONCOGENE, V25, P6133, DOI 10.1038/sj.onc.1209641; Park BJ, 2000, CANCER RES, V60, P3370; Pediconi N, 2003, NAT CELL BIOL, V5, P552, DOI 10.1038/ncb998; Petitjean A, 2008, CARCINOGENESIS, V29, P273, DOI 10.1093/carcin/bgm258; Petros AM, 2004, FEBS LETT, V559, P171, DOI 10.1016/s0014-5793(04)00059-6; Pietsch EC, 2008, J BIOL CHEM, V283, P21294, DOI 10.1074/jbc.M710539200; Riley T, 2008, NAT REV MOL CELL BIO, V9, P402, DOI 10.1038/nrm2395; Rinaldo C, 2007, MOL CELL, V25, P739, DOI 10.1016/j.molcel.2007.02.008; Rocco JW, 2006, CANCER CELL, V9, P45, DOI 10.1016/j.ccr.2005.12.013; Sakaguchi K, 1998, GENE DEV, V12, P2831, DOI 10.1101/gad.12.18.2831; Samuels-Lev Y, 2001, MOL CELL, V8, P781, DOI 10.1016/S1097-2765(01)00367-7; Sanchez-Prieto R, 2002, ONCOGENE, V21, P974, DOI 10.1038/sj.onc.1205134; Sansome C, 2001, FEBS LETT, V488, P110, DOI 10.1016/S0014-5793(00)02368-1; Sayan AE, 2008, ONCOGENE, V27, P4363, DOI 10.1038/onc.2008.64; Sayan BS, 2007, P NATL ACAD SCI USA, V104, P10871, DOI 10.1073/pnas.0700761104; Schmale H, 1997, ONCOGENE, V15, P1363, DOI 10.1038/sj.onc.1201500; Schuler M, 2000, J BIOL CHEM, V275, P7337, DOI 10.1074/jbc.275.10.7337; Senoo M, 2004, CANCER CELL, V6, P85, DOI 10.1016/j.ccr.2004.06.005; Shaw PE, 2007, EMBO REP, V8, P40, DOI 10.1038/sj.embor.7400873; Sniezek JC, 2004, LARYNGOSCOPE, V114, P2063, DOI 10.1097/01.mlg.0000149437.35855.4b; Sot B, 2007, J BIOL CHEM, V282, P29193, DOI 10.1074/jbc.M705544200; Stiewe T, 2002, J BIOL CHEM, V277, P14177, DOI 10.1074/jbc.M200480200; Strano S, 2005, MOL CELL, V18, P447, DOI 10.1016/j.molcel.2005.04.008; Strano S, 2001, J BIOL CHEM, V276, P15164, DOI 10.1074/jbc.M010484200; Strano S, 2002, J BIOL CHEM, V277, P18817, DOI 10.1074/jbc.M201405200; Strom E, 2006, NAT CHEM BIOL, V2, P474, DOI 10.1038/nchembio809; Sykes SM, 2006, MOL CELL, V24, P841, DOI 10.1016/j.molcel.2006.11.026; Taira N, 2007, MOL CELL, V25, P725, DOI 10.1016/j.molcel.2007.02.007; Talos F, 2005, CANCER RES, V65, P9971, DOI 10.1158/0008-5472.CAN-05-1084; Tang Y, 2006, MOL CELL, V24, P827, DOI 10.1016/j.molcel.2006.11.021; Toledo F, 2006, NAT REV CANCER, V6, P909, DOI 10.1038/nrc2012; Tomita Y, 2006, J BIOL CHEM, V281, P8600, DOI 10.1074/jbc.M507611200; Trink B, 1998, NAT MED, V4, P747, DOI 10.1038/nm0798-747; Urist MJ, 2002, AM J PATHOL, V161, P1199, DOI 10.1016/S0002-9440(10)64396-9; Villunger A, 2003, SCIENCE, V302, P1036, DOI 10.1126/science.1090072; Vousden KH, 2002, NAT REV CANCER, V2, P594, DOI 10.1038/nrc864; Wager M, 2006, BRIT J CANCER, V95, P1062, DOI 10.1038/sj.bjc.6603410; WAGNER AJ, 1994, GENE DEV, V8, P2817, DOI 10.1101/gad.8.23.2817; Wang JL, 2007, J BIOL CHEM, V282, P29152, DOI 10.1074/jbc.M703408200; Weber A, 2002, INT J CANCER, V99, P22, DOI 10.1002/ijc.10296; Wei MC, 2001, SCIENCE, V292, P727, DOI 10.1126/science.1059108; Wei XL, 2005, CANCER CELL, V7, P167, DOI 10.1016/j.ccr.2005.01.008; Welchman RL, 2005, NAT REV MOL CELL BIO, V6, P599, DOI 10.1038/nrm1700; Westfall MD, 2003, MOL CELL BIOL, V23, P2264, DOI 10.1128/MCB.23.7.2264-2276.2003; Wu GJ, 2003, CANCER RES, V63, P2351; Xiang MQ, 1996, P NATL ACAD SCI USA, V93, P11950, DOI 10.1073/pnas.93.21.11950; Yan Y, 1997, J BIOL CHEM, V272, P15220, DOI 10.1074/jbc.272.24.15220; Yang A, 2000, NATURE, V404, P99, DOI 10.1038/35003607; Yang AN, 1998, MOL CELL, V2, P305, DOI 10.1016/S1097-2765(00)80275-0; Yuan ZM, 1999, NATURE, V399, P814, DOI 10.1038/21704; Zaika A, 2001, J BIOL CHEM, V276, P11310, DOI 10.1074/jbc.M005737200; Zeng XY, 2000, MOL CELL BIOL, V20, P1299, DOI 10.1128/MCB.20.4.1299-1310.2000; Zeng XY, 2001, CARCINOGENESIS, V22, P215, DOI 10.1093/carcin/22.2.215; Zheng HW, 2002, NATURE, V419, P849, DOI 10.1038/nature01116	156	225	243	1	20	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 27	2008	27	50					6507	6521		10.1038/onc.2008.315	http://dx.doi.org/10.1038/onc.2008.315			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	366RR	18955976	Green Accepted			2022-12-28	WOS:000260501600009
J	Laghi, L; Bianchi, P; Malesci, A				Laghi, L.; Bianchi, P.; Malesci, A.			Differences and evolution of the methods for the assessment of microsatellite instability	ONCOGENE			English	Review						microsatellite instability; mismatch repair defects; inherited and sporadic colorectal cancer; molecular diagnosis	NONPOLYPOSIS COLORECTAL-CANCER; ISLAND METHYLATOR PHENOTYPE; MISMATCH REPAIR DEFICIENCY; COLON-CANCER; BETHESDA GUIDELINES; SOMATIC MUTATIONS; MUTATOR PHENOTYPE; LYNCH-SYNDROME; ADJUVANT CHEMOTHERAPY; GENOMIC INSTABILITY	Microsatellite instability (MSI) originates from the systematic accumulation of uncorrected deletion/insertion in repetitive DNA tracts in cancer cells with a deficient mismatch repair system. Among colorectal cancers, the MSI signature identifies hereditary cases arising in patients with germline mutations in hMLH1, hMSH2, PMS2 and a fraction of those with hMSH6 mutations, as well as sporadic cancers with epigenetic hMLH1 promoter hypermethylation. Considering the specific pathogenesis, pathological features, natural history and response to 5-fluoro-uracil-based chemotherapy of the MSI cancers, confusion about the genetic markers for MSI recognition seems surprising. In this clinically relevant field, an agreement has not been reached concerning the use of di- or mononucleotide markers for MSI assessment. The Revised Bethesda Guidelines still recommend a panel of markers consisting of mono- and dinucleotides, despite being questioned whether it is congruous to continue to use dinucleotide markers for MSI identification. In any event, no single marker is accurate enough for MSI testing, and an awareness of their pros and cons is required for proper interpretation of results. In recent years, several papers have reported different prevalence of MSI in unrelated series, largely depending on the detection and classification method, suggesting that MSI test interpretation also requires the understanding of the phenomenon rather than simply the crude satisfaction of panel recommendations. Inaccuracies can otherwise lead to under- or overdiagnosis and inaccurate disease classification, which always have a negative impact on the clinical practice of medicine.	[Laghi, L.; Bianchi, P.; Malesci, A.] IRCCS Ist Clin Humanitas, Dept Gastroenterol, Lab Mol Gastroenterol, I-20089 Milan, Italy; [Malesci, A.] Univ Milan, Dept Internal Med, Milan, Italy	Humanitas University; IRCCS Humanitas Research Hospital; University of Milan	Laghi, L (corresponding author), IRCCS Ist Clin Humanitas, Dept Gastroenterol, Lab Mol Gastroenterol, Via Manzoni 113, I-20089 Milan, Italy.	luigi.laghi@humanitas.it	Laghi, Luigi/GZM-5831-2022; Bianchi, Paolo/E-7592-2013	Laghi, Luigi/0000-0003-4187-1059; Bianchi, Paolo/0000-0001-5786-5644				AALTONEN LA, 1993, SCIENCE, V260, P812, DOI 10.1126/science.8484121; Aaltonen LA, 1998, NEW ENGL J MED, V338, P1481, DOI 10.1056/NEJM199805213382101; Ahuja N, 1997, CANCER RES, V57, P3370; Bocker T, 1997, CANCER RES, V57, P4739; Boland CR, 2007, J CLIN ONCOL, V25, P754, DOI 10.1200/JCO.2006.09.4607; Boland CR, 2005, SEMIN CANCER BIOL, V15, P436, DOI 10.1016/j.semcancer.2005.06.001; Boland CR, 1998, CANCER RES, V58, P5248; Carethers JM, 2004, GASTROENTEROLOGY, V126, P394, DOI 10.1053/j.gastro.2003.12.023; CAWKWELL L, 1995, GASTROENTEROLOGY, V109, P465, DOI 10.1016/0016-5085(95)90334-8; de la Chapelle A, 2003, NEW ENGL J MED, V349, P209, DOI 10.1056/NEJMp038099; Dietmaier W, 1997, CANCER RES, V57, P4749; FISHEL R, 1993, CELL, V75, P1027, DOI 10.1016/0092-8674(93)90546-3; Giuffre G, 2005, J MOL DIAGN, V7, P160, DOI 10.1016/S1525-1578(10)60542-9; Goel A, 2007, GASTROENTEROLOGY, V132, P127, DOI 10.1053/j.gastro.2006.09.018; Gonzalez-Garcia I, 2000, JNCI-J NATL CANCER I, V92, P544, DOI 10.1093/jnci/92.7.544; Grady WM, 2004, CANCER METAST REV, V23, P11, DOI 10.1023/A:1025861527711; Gruber SB, 2006, GASTROENTEROLOGY, V130, P577, DOI 10.1053/j.gastro.2006.01.031; Gryfe R, 2000, NEW ENGL J MED, V342, P69, DOI 10.1056/NEJM200001133420201; HAMILTON SR, 1995, NEW ENGL J MED, V332, P839, DOI 10.1056/NEJM199503303321302; Hampel H, 2005, NEW ENGL J MED, V352, P1851, DOI 10.1056/NEJMoa043146; HEMMINKI A, 1994, NAT GENET, V8, P405, DOI 10.1038/ng1294-405; Herman JG, 1998, P NATL ACAD SCI USA, V95, P6870, DOI 10.1073/pnas.95.12.6870; Hoang JM, 1997, CANCER RES, V57, P300; Iino H, 1999, J CLIN PATHOL, V52, P5, DOI 10.1136/jcp.52.1.5; IONOV Y, 1993, NATURE, V363, P558, DOI 10.1038/363558a0; Jenkins MA, 2007, GASTROENTEROLOGY, V133, P48, DOI 10.1053/j.gastro.2007.04.044; Jiricny J, 2006, NAT REV MOL CELL BIO, V7, P335, DOI 10.1038/nrm1907; Kane MF, 1997, CANCER RES, V57, P808; Kim GP, 2007, J CLIN ONCOL, V25, P767, DOI 10.1200/JCO.2006.05.8172; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; KOI M, 1994, CANCER RES, V54, P4308; Laghi L, 2004, J NATL CANCER I, V96, P1402, DOI 10.1093/jnci/djh280; Laiho P, 2002, CANCER RES, V62, P1166; Liu B, 1996, NAT MED, V2, P169, DOI 10.1038/nm0296-169; LOTHE RA, 1993, CANCER RES, V53, P5849; Loukola A, 2001, CANCER RES, V61, P4545; MADDOX J, 1993, NATURE, V363, P667, DOI 10.1038/363667a0; Malesci A, 2007, CLIN CANCER RES, V13, P3831, DOI 10.1158/1078-0432.CCR-07-0366; Malkhosyan S, 1996, NATURE, V382, P499, DOI 10.1038/382499a0; MARKOWITZ S, 1995, SCIENCE, V268, P1336, DOI 10.1126/science.7761852; Miyaki M, 1997, NAT GENET, V17, P271, DOI 10.1038/ng1197-271; Moslein G, 1996, HUM MOL GENET, V5, P1245, DOI 10.1093/hmg/5.9.1245; Muller A, 2006, INT J COLORECTAL DIS, V21, P632, DOI 10.1007/s00384-005-0073-6; *NCBI, 2007, ONLINEMENDELIAN INH; NICOLAIDES NC, 1994, NATURE, V371, P75, DOI 10.1038/371075a0; Ohmiya N, 2001, GENE, V272, P301, DOI 10.1016/S0378-1119(01)00517-0; PAPADOPOULOS N, 1994, SCIENCE, V263, P1625, DOI 10.1126/science.8128251; PAPADOPOULOS N, 1995, SCIENCE, V268, P1915, DOI 10.1126/science.7604266; PARSONS R, 1993, CELL, V75, P1227, DOI 10.1016/0092-8674(93)90331-J; Pastrello C, 2006, EUR J HUM GENET, V14, P63, DOI 10.1038/sj.ejhg.5201517; PELTOMAKI P, 1993, SCIENCE, V260, P810, DOI 10.1126/science.8484120; Perucho M, 1999, CANCER RES, V59, P249; Pyatt R, 1999, AM J PATHOL, V155, P349, DOI 10.1016/S0002-9440(10)65131-0; Rampino N, 1997, SCIENCE, V275, P967, DOI 10.1126/science.275.5302.967; Ribic CM, 2003, NEW ENGL J MED, V349, P247, DOI 10.1056/NEJMoa022289; RodriguezBigas MA, 1997, J NATL CANCER I, V89, P1758, DOI 10.1093/jnci/89.23.1758; Roncalli M, 2000, HEPATOLOGY, V31, P846, DOI 10.1053/he.2000.5790; Samowitz WS, 2001, CANCER EPIDEM BIOMAR, V10, P917; Samowitz WS, 2005, GASTROENTEROLOGY, V129, P837, DOI 10.1053/j.gastro.2005.06.020; STRACHAN T, 1999, HUMAN MOL GENETICS, V2; Suraweera N, 2002, GASTROENTEROLOGY, V123, P1804, DOI 10.1053/gast.2002.37070; Thibodeau SN, 1998, CANCER RES, V58, P1713; THIBODEAU SN, 1993, SCIENCE, V260, P816, DOI 10.1126/science.8484122; Thibodeau SN, 1996, CANCER RES, V56, P4836; Tomlinson I, 2002, J PATHOL, V197, P6, DOI 10.1002/path.1071; Toyota M, 1999, P NATL ACAD SCI USA, V96, P8681, DOI 10.1073/pnas.96.15.8681; Truninger K, 2005, GASTROENTEROLOGY, V128, P1160, DOI 10.1053/j.gastro.2005.01.056; Umar A, 2004, J NATL CANCER I, V96, P261, DOI 10.1093/jnci/djh034; VASEN HFA, 1991, DIS COLON RECTUM, V34, P424, DOI 10.1007/BF02053699; Watanabe T, 2001, NEW ENGL J MED, V344, P1196, DOI 10.1056/NEJM200104193441603; Weinberg RA, 2006, BIOL CANC; Wu Y, 1997, GENE CHROMOSOME CANC, V18, P269, DOI 10.1002/(SICI)1098-2264(199704)18:4<269::AID-GCC4>3.0.CO;2-Z; Xicola RM, 2007, JNCI-J NATL CANCER I, V99, P244, DOI 10.1093/jnci/djk033; Yamamoto H, 1997, CANCER RES, V57, P4420; Yamashita K, 2003, CANCER CELL, V4, P121, DOI 10.1016/S1535-6108(03)00190-9; Zhou XP, 1997, ONCOGENE, V15, P1713, DOI 10.1038/sj.onc.1201337	76	79	80	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT	2008	27	49					6313	6321		10.1038/onc.2008.217	http://dx.doi.org/10.1038/onc.2008.217			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	363JK	18679418				2022-12-28	WOS:000260263400001
J	Wang, S				Wang, S.			The promise of cancer therapeutics targeting the TNF-related apoptosis-inducing ligand and TRAIL receptor pathway	ONCOGENE			English	Review						tumor necrosis factor-related apoptosis-inducing ligand; TNF receptor superfamily; DR4; KILLER/DR5; apoptosis; cancer therapy	RADIATION-INDUCED APOPTOSIS; CARCINOMA CELL-LINES; NF-KAPPA-B; DEATH-RECEPTOR; IN-VIVO; MEDIATED APOPTOSIS; TUMOR-CELL; CASPASE-9 INHIBITOR; MONOCLONAL-ANTIBODY; FUNCTIONAL-ANALYSIS	Tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) is a member of the TNF superfamily and has been shown to induce apoptosis in cancer cells but not normal cells. TRAIL triggers apoptosis through binding to its receptors DR4 and KILLER/DR5. Chemo or radiotherapy induces apoptosis through activation of p53 in response to cellular damage, whereas TRAIL induces apoptosis independent of p53. Mutations or deletions of p53 occurred in more than half of human tumors confer resistance to chemo-radiotherapy. Treatment of TRAIL-resistant tumors with agents targeting death receptors, intrinsic Bcl-2 family members, inhibitor of apoptosis proteins or PI3K/Akt pathway restores the sensitivity to TRAIL-induced apoptosis. Combination of rhTRAIL or the agonist antibody for TRAIL receptor with conventional chemotherapeutic agents results in enhanced efficacy in preventing tumor progression and metastasis. Therefore, the rational design of TRAIL-based therapy combining with other modality that either synergizes to apoptosis induction or overcomes the resistance represents a challenging strategy to achieve the systemic tumor targeting and augment the antitumor activity of cancer therapeutics.	Fudan Univ, Sch Life Sci, Inst Genet, State Key Lab Genet Engn, Shanghai 200433, Peoples R China	Fudan University	Wang, S (corresponding author), Fudan Univ, Sch Life Sci, Inst Genet, State Key Lab Genet Engn, Shanghai 200433, Peoples R China.	shulinwang@fudan.edu.cn						Adams C, 2008, CELL DEATH DIFFER, V15, P751, DOI 10.1038/sj.cdd.4402306; Ashkenazi A, 1999, J CLIN INVEST, V104, P155, DOI 10.1172/JCI6926; Ashkenazi A, 2002, NAT REV CANCER, V2, P420, DOI 10.1038/nrc821; Ashkenazi A, 2008, J CLIN INVEST, V118, P1979, DOI 10.1172/JCI34359; Blankenstein T, 2005, CURR OPIN IMMUNOL, V17, P180, DOI 10.1016/j.coi.2005.01.008; Bodmer JL, 2000, NAT CELL BIOL, V2, P241, DOI 10.1038/35008667; Burns TF, 2001, J BIOL CHEM, V276, P37879; Chawla-Sarkar M, 2004, CELL DEATH DIFFER, V11, P915, DOI 10.1038/sj.cdd.4401416; Cheng EHYA, 2001, MOL CELL, V8, P705, DOI 10.1016/S1097-2765(01)00320-3; Clohessy JG, 2006, J BIOL CHEM, V281, P5750, DOI 10.1074/jbc.M505688200; Corazza N, 2006, J CLIN INVEST, V116, P2493, DOI 10.1172/JCI27726; Cretney E, 2002, J IMMUNOL, V168, P1356, DOI 10.4049/jimmunol.168.3.1356; Degli-Esposti MA, 1997, IMMUNITY, V7, P813, DOI 10.1016/S1074-7613(00)80399-4; DegliEsposti MA, 1997, J EXP MED, V186, P1165, DOI 10.1084/jem.186.7.1165; Deng YB, 2002, GENE DEV, V16, P33, DOI 10.1101/gad.949602; Diehl GE, 2004, IMMUNITY, V21, P877, DOI 10.1016/j.immuni.2004.11.008; Emery JG, 1998, J BIOL CHEM, V273, P14363, DOI 10.1074/jbc.273.23.14363; Finnberg N, 2005, MOL CELL BIOL, V25, P2000, DOI 10.1128/MCB.25.5.2000-2013.2005; Finnberg N, 2008, J CLIN INVEST, V118, P111, DOI 10.1172/JCI29900; Fulda S, 2002, NAT MED, V8, P808, DOI 10.1038/nm735; Georgakis GV, 2006, CLIN CANCER RES, V12, P584, DOI 10.1158/1078-0432.CCR-05-1194; Gliniak B, 1999, CANCER RES, V59, P6153; Grosse-Wilde A, 2008, J CLIN INVEST, V118, P100, DOI 10.1172/JCI33061; Hall MA, 2007, CANCER CELL, V12, P4, DOI 10.1016/j.ccr.2007.06.011; Hersey P, 2001, NAT REV CANCER, V1, P142, DOI 10.1038/35101078; Hopkins-Donaldson S, 2003, CELL DEATH DIFFER, V10, P356, DOI 10.1038/sj.cdd.4401157; Hotte SJ, 2008, CLIN CANCER RES, V14, P3450, DOI 10.1158/1078-0432.CCR-07-1416; Hymowitz SG, 1999, MOL CELL, V4, P563, DOI 10.1016/S1097-2765(00)80207-5; Jin XH, 2007, J UROLOGY, V177, P1894, DOI 10.1016/j.juro.2007.01.018; Kaelin WG, 2007, METHOD ENZYMOL, V435, P371, DOI 10.1016/S0076-6879(07)35019-2; Kataoka T, 2005, CRIT REV IMMUNOL, V25, P31, DOI 10.1615/CritRevImmunol.v25.i1.30; Khanbolooki S, 2006, MOL CANCER THER, V5, P2251, DOI 10.1158/1535-7163.MCT-06-0075; Kim M, 2004, CANCER RES, V64, P4078, DOI 10.1158/0008-5472.CAN-04-0284; Kim M, 2008, CANCER RES, V68, P3440, DOI 10.1158/0008-5472.CAN-08-0014; Kim SH, 2008, CANCER RES, V68, P2062, DOI 10.1158/0008-5472.CAN-07-6278; Kim SH, 2004, J BIOL CHEM, V279, P40044, DOI 10.1074/jbc.M404541200; Kischkel FC, 2000, IMMUNITY, V12, P611, DOI 10.1016/S1074-7613(00)80212-5; Laguinge LM, 2008, CANCER RES, V68, P909, DOI 10.1158/0008-5472.CAN-06-1806; Lawrence D, 2001, NAT MED, V7, P383, DOI 10.1038/86397; LeBlanc H, 2002, NAT MED, V8, P274, DOI 10.1038/nm0302-274; Li L, 2004, SCIENCE, V305, P1471, DOI 10.1126/science.1098231; Lin Y, 2000, MOL CELL BIOL, V20, P6638, DOI 10.1128/MCB.20.18.6638-6645.2000; Liu SX, 2001, J IMMUNOL, V166, P5407, DOI 10.4049/jimmunol.166.9.5407; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; LOWE SW, 1994, SCIENCE, V266, P807, DOI 10.1126/science.7973635; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; Lub-de Hooge MN, 2005, ANN RHEUM DIS, V64, P854, DOI 10.1136/ard.2004.029058; Mace TA, 2006, IMMUNOL INVEST, V35, P279, DOI 10.1080/08820130600745463; Manning BD, 2007, CELL, V129, P1261, DOI 10.1016/j.cell.2007.06.009; Marini P, 2006, ONCOGENE, V25, P5145, DOI 10.1038/sj.onc.1209516; Marsters SA, 1997, CURR BIOL, V7, P1003, DOI 10.1016/S0960-9822(06)00422-2; Marsters SA, 1996, CURR BIOL, V6, P1669, DOI 10.1016/S0960-9822(02)70791-4; Meng XW, 2007, J BIOL CHEM, V282, P29831, DOI 10.1074/jbc.M706110200; Merino D, 2006, MOL CELL BIOL, V26, P7046, DOI 10.1128/MCB.00520-06; Mongkolsapaya J, 1999, NAT STRUCT BIOL, V6, P1048; Ozoren N, 2000, CANCER RES, V60, P6259; Ozoren N, 2002, NEOPLASIA, V4, P551, DOI 10.1038/sj.neo.7900270; Pai SI, 1998, CANCER RES, V58, P3513; Pan GH, 1997, SCIENCE, V277, P815, DOI 10.1126/science.277.5327.815; Pan GH, 1997, SCIENCE, V276, P111, DOI 10.1126/science.276.5309.111; Panner A, 2005, MOL CELL BIOL, V25, P8809, DOI 10.1128/MCB.25.20.8809-8823.2005; Pespeni MH, 2007, CANCER RES, V67, P2865, DOI 10.1158/0008-5472.CAN-06-3871; Ravi R, 2002, CURR OPIN ONCOL, V14, P490, DOI 10.1097/00001622-200209000-00004; Ray S, 2005, APOPTOSIS, V10, P1411, DOI 10.1007/s10495-005-2490-y; Ricci MS, 2007, CANCER CELL, V12, P66, DOI 10.1016/j.ccr.2007.05.006; Ricci MS, 2004, MOL CELL BIOL, V24, P8541, DOI 10.1128/MCB.24.19.8541-8555.2004; Romagnoli M, 2007, CLIN CANCER RES, V13, P6010, DOI 10.1158/1078-0432.CCR-07-0140; Rosato RR, 2007, CANCER RES, V67, P9490, DOI 10.1158/0008-5472.CAN-07-0598; Schneider P, 2003, J BIOL CHEM, V278, P5444, DOI 10.1074/jbc.M210783200; Sheridan JP, 1997, SCIENCE, V277, P818, DOI 10.1126/science.277.5327.818; Shrader M, 2007, CANCER RES, V67, P1430, DOI 10.1158/0008-5472.CAN-06-1224; Singh TR, 2005, ONCOGENE, V24, P4609, DOI 10.1038/sj.onc.1208585; Sinicrope FA, 2004, CLIN CANCER RES, V10, P8284, DOI 10.1158/1078-0432.CCR-04-1289; Smyth MJ, 2003, IMMUNITY, V18, P1, DOI 10.1016/S1074-7613(02)00502-2; Sprick MR, 2000, IMMUNITY, V12, P599, DOI 10.1016/S1074-7613(00)80211-3; Takeda K, 2001, NAT MED, V7, P94, DOI 10.1038/83416; Trauzold A, 2006, ONCOGENE, V25, P7434, DOI 10.1038/sj.onc.1209719; Vivanco I, 2002, NAT REV CANCER, V2, P489, DOI 10.1038/nrc839; Wagner KW, 2007, NAT MED, V13, P1070, DOI 10.1038/nm1627; Walczak H, 1999, NAT MED, V5, P157, DOI 10.1038/5517; Walczak H, 1997, EMBO J, V16, P5386, DOI 10.1093/emboj/16.17.5386; Wandinger KP, 2003, LANCET, V361, P2036, DOI 10.1016/S0140-6736(03)13641-0; Wang SL, 2003, P NATL ACAD SCI USA, V100, P15095, DOI 10.1073/pnas.2435285100; Wang SL, 2004, CANCER RES, V64, P6666, DOI 10.1158/0008-5472.CAN-04-1734; Wang SL, 2003, ONCOGENE, V22, P8628, DOI 10.1038/sj.onc.1207232; Wang Y, 2004, CANCER CELL, V5, P501, DOI 10.1016/S1535-6108(04)00113-8; Wei MC, 2001, SCIENCE, V292, P727, DOI 10.1126/science.1059108; Wiley SR, 1995, IMMUNITY, V3, P673, DOI 10.1016/1074-7613(95)90057-8; Wu GS, 1999, CANCER RES, V59, P2770; Wu GS, 1997, NAT GENET, V17, P141, DOI 10.1038/ng1097-141; Younes M, 2006, EUR J CANCER, V42, P542, DOI 10.1016/j.ejca.2005.11.013; Zou H, 1997, CELL, V90, P405, DOI 10.1016/S0092-8674(00)80501-2	92	168	183	1	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT	2008	27	48					6207	6215		10.1038/onc.2008.298	http://dx.doi.org/10.1038/onc.2008.298			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	361YB	18931688				2022-12-28	WOS:000260162800003
J	Moran, DM; Gawlak, G; Jayaprakash, MS; Mayar, S; Maki, CG				Moran, D. M.; Gawlak, G.; Jayaprakash, M. S.; Mayar, S.; Maki, C. G.			Geldanamycin promotes premature mitotic entry and micronucleation in irradiated p53/p21 deficient colon carcinoma cells	ONCOGENE			English	Article						HSP90; p53; micronuclei; radiation	INDUCED GENOMIC INSTABILITY; TUMOR-CELLS; CHROMOSOMAL INSTABILITY; IONIZING-RADIATION; G(2) CHECKPOINT; G1 CHECKPOINT; PHASE-I; S-PHASE; P53; INHIBITOR	P53 wild-type and p53-null or mutant cells undergo a G2-phase cell-cycle arrest in response to ionizing radiation (IR). In this study we examined the effect of heat-shock protein 90 (HSP90) inhibitor, geldanamycin (GA), on IR-induced G2 arrest in human colon adenocarcinoma cells with different p53 status. We show that GA treatment abrogates IR-induced G2-phase arrest in cells null or mutant for p53. Specifically, GA treatment pushed irradiated p53 signaling-defective cells into a premature mitosis characterized by aberrant mitotic figures, increased gamma H2AX expression and formation of micronucleated cells. Cells expressing wild-type p53 were resistant to GA-induced G2 checkpoint abrogation. Notably, GA treatment decreased levels of G2 regulatory proteins Wee1 and Chk1, and inhibitory phosphorylation of Cdc2, independent of p53 status. Further investigation identified p21 as the potential downstream effector of p53 that mediates resistance to G2 checkpoint abrogation. Clonogenic survival studies demonstrated higher sensitivity to GA alone or combination IR plus GA treatment in p53 and p21-null cells. Collectively, these data demonstrate potential mechanisms through which HSP90 inhibition can enhance the effects of ionizing radiation in p53compromised cancer cells. Combination IR plus HSP90 inhibitor therapies may be particularly useful in treating cancers that lack wild-type p53.	[Moran, D. M.; Gawlak, G.; Jayaprakash, M. S.; Mayar, S.; Maki, C. G.] Univ Chicago, Dept Radiat & Cellular Oncol, Chicago, IL 60637 USA	University of Chicago	Maki, CG (corresponding author), Univ Chicago, Dept Radiat & Cellular Oncol, 5841 S Maryland Ave,MC1105,Room G-06, Chicago, IL 60637 USA.	cmaki@rover.uchicago.edu			National Institutes of Health [RO1 CA080918]; NATIONAL CANCER INSTITUTE [R01CA080918] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by National Institutes of Health Grant RO1 CA080918.	Arlander SJH, 2003, J BIOL CHEM, V278, P52572, DOI 10.1074/jbc.M309054200; Banerji U, 2005, J CLIN ONCOL, V23, P4152, DOI 10.1200/JCO.2005.00.612; Bisht KS, 2003, CANCER RES, V63, P8984; Bull EEA, 2004, CLIN CANCER RES, V10, P8077, DOI 10.1158/1078-0432.CCR-04-1212; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; Burma S, 2001, J BIOL CHEM, V276, P42462, DOI 10.1074/jbc.C100466200; Castedo M, 2004, ONCOGENE, V23, P2825, DOI 10.1038/sj.onc.1207528; Cohen-Jonathan E, 1999, CURR OPIN CHEM BIOL, V3, P77, DOI 10.1016/S1367-5931(99)80014-3; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; Dixon H, 2002, CELL CYCLE, V1, P362, DOI 10.4161/cc.1.6.257; Dote H, 2006, CANCER RES, V66, P9211, DOI 10.1158/0008-5472.CAN-06-2181; Giono LE, 2006, J CELL PHYSIOL, V209, P13, DOI 10.1002/jcp.20689; Goes FS, 2001, EUR J BIOCHEM, V268, P2281, DOI 10.1046/j.1432-1327.2001.02105.x; Grem JL, 2005, J CLIN ONCOL, V23, P1885, DOI 10.1200/JCO.2005.12.085; Iliakis G, 2003, ONCOGENE, V22, P5834, DOI 10.1038/sj.onc.1206682; Inoue T, 2001, J BIOL CHEM, V276, P45255, DOI 10.1074/jbc.M107477200; Jackson JR, 2000, CANCER RES, V60, P566; Jascur T, 2005, MOL CELL, V17, P237, DOI 10.1016/j.molcel.2004.11.049; Kamal A, 2003, NATURE, V425, P407, DOI 10.1038/nature01913; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; Kawabe T, 2004, MOL CANCER THER, V3, P513; Limoli CL, 1997, CANCER RES, V57, P5557; MARDER BA, 1993, MOL CELL BIOL, V13, P6667, DOI 10.1128/MCB.13.11.6667; Morgan WF, 2003, RADIAT RES, V159, P567, DOI 10.1667/0033-7587(2003)159[0567:NADEOE]2.0.CO;2; Morgan WF, 2003, RADIAT RES, V159, P581, DOI 10.1667/0033-7587(2003)159[0581:NADEOE]2.0.CO;2; Noguchi M, 2006, BIOCHEM BIOPH RES CO, V351, P658, DOI 10.1016/j.bbrc.2006.10.094; NORBURY C, 1991, EMBO J, V10, P3321, DOI 10.1002/j.1460-2075.1991.tb04896.x; Pawlik TM, 2004, INT J RADIAT ONCOL, V59, P928, DOI 10.1016/j.ijrobp.2004.03.005; Rahmani M, 2003, CANCER RES, V63, P8420; RIEDER CL, 1992, J CELL SCI, V102, P387; Robles AI, 2006, CLIN CANCER RES, V12, P6547, DOI 10.1158/1078-0432.CCR-06-1178; Roninson IB, 2001, DRUG RESIST UPDATE, V4, P303, DOI 10.1054/drup.2001.0213; Russell KJ, 1996, INT J RADIAT ONCOL, V36, P1099, DOI 10.1016/S0360-3016(96)00432-4; Sarkaria JN, 1999, CANCER RES, V59, P4375; Sasaki M, 2007, J BIOL CHEM, V282, P14626, DOI 10.1074/jbc.M610514200; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; Shintani S, 2006, INT J ONCOL, V29, P1111; SUGIMOTO K, 2007, ONCOGENE; Waldman T, 1996, NATURE, V381, P713, DOI 10.1038/381713a0; Wang YL, 2004, CANCER BIOL THER, V3, P305, DOI 10.4161/cbt.3.3.697; Wang YL, 2001, CANCER RES, V61, P8211; Whitesell L, 2005, NAT REV CANCER, V5, P761, DOI 10.1038/nrc1716	42	22	22	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 18	2008	27	42					5567	5577		10.1038/onc.2008.172	http://dx.doi.org/10.1038/onc.2008.172			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	349KX	18504430	Green Accepted			2022-12-28	WOS:000259280800003
J	Demarest, RM; Ratti, F; Capobianco, AJ				Demarest, R. M.; Ratti, F.; Capobianco, A. J.			It's T-ALL about Notch	ONCOGENE			English	Review						p53; Ikaros; PTEN; Fbw7; C-myc; CSL	ACUTE LYMPHOBLASTIC-LEUKEMIA; HEMATOPOIETIC STEM-CELLS; C-MYC; TRANSCRIPTION FACTOR; IKAROS GENE; TUMOR-SUPPRESSOR; MOLECULAR PATHOGENESIS; PROTEOLYTIC ACTIVATION; LYMPHOCYTE DEVELOPMENT; INTRACELLULAR DOMAIN	T-cell acute lymphoblastic leukemia (T-ALL) is an aggressive subset of ALL with poor clinical outcome compared to B-ALL. Therefore, to improve treatment, it is imperative to delineate the molecular blueprint of this disease. This review describes the central role that the Notch pathway plays in T-ALL development. We also discuss the interactions between Notch and the tumor suppressors Ikaros and p53. Loss of Ikaros, a direct repressor of Notch target genes, and suppression of p53 mediated apoptosis are essential for development of this neoplasm. In addition to the activating mutations of Notch previously described, this review will outline combinations of mutations in pathways that contribute to Notch signaling and appear to drive T-ALL development by 'mimicking' Notch effects on cell cycle and apoptosis.	[Demarest, R. M.; Ratti, F.; Capobianco, A. J.] Wistar Inst Anat & Biol, Philadelphia, PA 19104 USA	The Wistar Institute	Capobianco, AJ (corresponding author), Wistar Inst Anat & Biol, 3601 Spruce St, Philadelphia, PA 19104 USA.	acapobianco@wistar.org	Ratti, Francesca/AAB-2116-2019	Capobianco, Anthony/0000-0002-3706-6797	NIH [R01]; Wistar Institute [T32 CA09171]; NATIONAL CANCER INSTITUTE [T32CA009171] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Wistar Institute; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank the members of the Capobianco Laboratory for their support and critical reading of the manuscript. This work was funded by NIH Grant R01 (AJ Capobianco). RM Demarest was funded by training program in Basic Cancer Research from Wistar Institute (T32 CA09171).	Aifantis I, 2008, NAT REV IMMUNOL, V8, P380, DOI 10.1038/nri2304; Amati Bruno, 1998, Frontiers in Bioscience, V3, pD250; Barata JT, 2001, BLOOD, V98, P1524, DOI 10.1182/blood.V98.5.1524; Bellavia D, 2007, CELL CYCLE, V6, P2730, DOI 10.4161/cc.6.22.4894; Bellavia D, 2007, EMBO J, V26, P1670, DOI 10.1038/sj.emboj.7601626; Beverly LJ, 2005, CANCER RES, V65, P7159, DOI 10.1158/0008-5472.CAN-05-1664; Beverly LJ, 2004, TRENDS MOL MED, V10, P591, DOI 10.1016/j.molmed.2004.10.001; Beverly LJ, 2003, CANCER CELL, V3, P551, DOI 10.1016/S1535-6108(03)00137-5; Blain SW, 1997, J BIOL CHEM, V272, P25863, DOI 10.1074/jbc.272.41.25863; Brooks CL, 2006, MOL CELL, V21, P307, DOI 10.1016/j.molcel.2006.01.020; Brou C, 2000, MOL CELL, V5, P207, DOI 10.1016/S1097-2765(00)80417-7; Dang CV, 1999, EXP CELL RES, V253, P63, DOI 10.1006/excr.1999.4686; Dohda T, 2007, EXP CELL RES, V313, P3141, DOI 10.1016/j.yexcr.2007.04.027; DOU SB, 1994, MOL CELL BIOL, V14, P3310, DOI 10.1128/MCB.14.5.3310; Dumortier A, 2006, MOL CELL BIOL, V26, P209, DOI 10.1128/MCB.26.1.209-220.2006; Eischen CM, 1999, GENE DEV, V13, P2658, DOI 10.1101/gad.13.20.2658; ELLISEN LW, 1991, CELL, V66, P649, DOI 10.1016/0092-8674(91)90111-B; Ferrando AA, 2002, CANCER CELL, V1, P75, DOI 10.1016/S1535-6108(02)00018-1; FORTINI ME, 1994, CELL, V79, P273, DOI 10.1016/0092-8674(94)90196-1; Fryer CJ, 2004, MOL CELL, V16, P509, DOI 10.1016/j.molcel.2004.10.014; Fryer CJ, 2002, GENE DEV, V16, P1397, DOI 10.1101/gad.991602; GEORGOPOULOS K, 1994, CELL, V79, P143, DOI 10.1016/0092-8674(94)90407-3; GEORGOPOULOS K, 1992, SCIENCE, V258, P808, DOI 10.1126/science.1439790; Girard L, 1996, GENE DEV, V10, P1930, DOI 10.1101/gad.10.15.1930; Goldberg JM, 2003, J CLIN ONCOL, V21, P3616, DOI 10.1200/JCO.2003.10.116; Gordon WR, 2007, NAT STRUCT MOL BIOL, V14, P295, DOI 10.1038/nsmb1227; Grabher C, 2006, NAT REV CANCER, V6, P347, DOI 10.1038/nrc1880; Guo W, 2008, NATURE, V453, P529, DOI 10.1038/nature06933; Gupta-Rossi N, 2001, J BIOL CHEM, V276, P34371, DOI 10.1074/jbc.M101343200; HAHM KM, 1994, MOL CELL BIOL, V14, P7111, DOI 10.1128/MCB.14.11.7111; HERMEKING H, 1994, SCIENCE, V265, P2091, DOI 10.1126/science.8091232; Hsieh JJD, 1996, MOL CELL BIOL, V16, P952; Jeffries S, 2002, MOL CELL BIOL, V22, P3927, DOI 10.1128/MCB.22.11.3927-3941.2002; Kathrein KL, 2008, J BIOL CHEM, V283, P10476, DOI 10.1074/jbc.M709643200; Koch U, 2007, CELL MOL LIFE SCI, V64, P2746, DOI 10.1007/s00018-007-7164-1; Levine AJ, 2006, CELL DEATH DIFFER, V13, P1027, DOI 10.1038/sj.cdd.4401910; Lopez-Nieva P, 2004, CARCINOGENESIS, V25, P1299, DOI 10.1093/carcin/bgh124; Malecki MJ, 2006, MOL CELL BIOL, V26, P4642, DOI 10.1128/MCB.01655-05; MARCU KB, 1992, ANNU REV BIOCHEM, V61, P809, DOI 10.1146/annurev.bi.61.070192.004113; Matsuoka S, 2008, GENE DEV, V22, P986, DOI 10.1101/gad.1621808; Mayo LD, 2002, J BIOL CHEM, V277, P5484, DOI 10.1074/jbc.M108302200; Meek DW, 2003, MOL CANCER RES, V1, P1017; MOLNAR A, 1994, MOL CELL BIOL, V14, P8292, DOI 10.1128/MCB.14.12.8292; Mumm JS, 2000, MOL CELL, V5, P197, DOI 10.1016/S1097-2765(00)80416-5; Mumm JS, 2000, DEV BIOL, V228, P151, DOI 10.1006/dbio.2000.9960; Murata K, 2005, MOL CELL BIOL, V25, P4262, DOI 10.1128/MCB.25.10.4262-4271.2005; Nguyen BC, 2006, GENE DEV, V20, P1028, DOI 10.1101/gad.1406006; Nicolas M, 2003, NAT GENET, V33, P416, DOI 10.1038/ng1099; O'Neil J, 2007, J EXP MED, V204, P1813, DOI 10.1084/jem.20070876; Oberg C, 2001, J BIOL CHEM, V276, P35847, DOI 10.1074/jbc.M103992200; Palomero T, 2007, NAT MED, V13, P1203, DOI 10.1038/nm1636; Pui CH, 2004, BLOOD, V104, P2690, DOI 10.1182/blood-2004-04-1616; Qi RZ, 2003, CANCER RES, V63, P8323; REBAY I, 1991, CELL, V67, P687, DOI 10.1016/0092-8674(91)90064-6; Ronchini C, 2000, ONCOGENE, V19, P3914, DOI 10.1038/sj.onc.1203719; Roy M, 2007, CURR OPIN GENET DEV, V17, P52, DOI 10.1016/j.gde.2006.12.001; Sanchez-Irizarry C, 2004, MOL CELL BIOL, V24, P9265, DOI 10.1128/MCB.24.21.9265-9273.2004; Satoh Y, 2004, J BIOL CHEM, V279, P24986, DOI 10.1074/jbc.M400407200; Schroeter EH, 1998, NATURE, V393, P382, DOI 10.1038/30756; Sharma VM, 2006, MOL CELL BIOL, V26, P8022, DOI 10.1128/MCB.01091-06; Sheaff RJ, 1997, GENE DEV, V11, P1464, DOI 10.1101/gad.11.11.1464; Sherr CJ, 2006, NAT REV CANCER, V6, P663, DOI 10.1038/nrc1954; Sherr CJ, 1998, GENE DEV, V12, P2984, DOI 10.1101/gad.12.19.2984; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Sicinska E, 2003, CANCER CELL, V4, P451, DOI 10.1016/S1535-6108(03)00301-5; Sriuranpong V, 2001, CANCER RES, V61, P3200; Stahl M, 2006, CANCER RES, V66, P7562, DOI 10.1158/0008-5472.CAN-06-0974; Struhl G, 1998, CELL, V93, P649, DOI 10.1016/S0092-8674(00)81193-9; Sun L, 1999, CLIN CANCER RES, V5, P2112; Sun L, 1996, EMBO J, V15, P5358, DOI 10.1002/j.1460-2075.1996.tb00920.x; Sun L, 1999, P NATL ACAD SCI USA, V96, P680, DOI 10.1073/pnas.96.2.680; Sun L, 1999, J CLIN ONCOL, V17, P3753, DOI 10.1200/JCO.1999.17.12.3753; Suzuki A, 1998, CURR BIOL, V8, P1169, DOI 10.1016/S0960-9822(07)00488-5; Tamura K, 1995, CURR BIOL, V5, P1416, DOI 10.1016/S0960-9822(95)00279-X; THIEL E, 1989, BLOOD, V73, P1247; Thompson BJ, 2008, J EXP MED, V205, P1395, DOI 10.1084/jem.20080277; Tsukiyama T, 2001, J IMMUNOL, V166, P304, DOI 10.4049/jimmunol.166.1.304; Uren AG, 2008, CELL, V133, P727, DOI 10.1016/j.cell.2008.03.021; Waltzer L, 1995, NUCLEIC ACIDS RES, V23, P4939, DOI 10.1093/nar/23.24.4939; Welcker M, 2008, NAT REV CANCER, V8, P83, DOI 10.1038/nrc2290; Weng AP, 2006, GENE DEV, V20, P2096, DOI 10.1101/gad.1450406; Weng AP, 2004, SCIENCE, V306, P269, DOI 10.1126/science.1102160; WINANDY S, 1995, CELL, V83, P289, DOI 10.1016/0092-8674(95)90170-1; Wu LZ, 2000, NAT GENET, V26, P484, DOI 10.1038/82644; Zhou BHP, 2001, NAT CELL BIOL, V3, P973, DOI 10.1038/ncb1101-973	85	88	92	1	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP	2008	27	38					5082	5091		10.1038/onc.2008.222	http://dx.doi.org/10.1038/onc.2008.222			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	344GM	18758476				2022-12-28	WOS:000258914900001
J	Galluzzi, L; Kepp, O; Tajeddine, N; Kroemer, G				Galluzzi, L.; Kepp, O.; Tajeddine, N.; Kroemer, G.			Disruption of the hexokinase - VDAC complex for tumor therapy	ONCOGENE			English	Editorial Material						apoptosis; mitochondria; voltage-dependent anion channel (VDAC)	PERMEABILITY TRANSITION PORE; ADENINE-NUCLEOTIDE TRANSLOCASE-2; CELL-DEATH; MITOCHONDRIA; CHEMOTHERAPY; APOPTOSIS; PHOSPHORYLATION; BINDING; KINASE; AKT	Unlike mitochondria from most normal tissues, cancer cell mitochondria demonstrate an association between the glycolytic enzyme hexokinase (HK) and the voltage-dependent anion channel (VDAC). This provides a therapeutic opportunity, as the association appears to protect tumor cells from mitochondrial outer membrane permeabilization (MOMP), an event that marks the point of no return in multiple pathways leading to cell death. In this issue of Oncogene, the plant hormone methyl jasmonate (MJ) is shown to disrupt the interaction between human HK and VDAC, causing the inhibition of glycolysis and the induction of MOMP. MJ has already been shown to have selective anticancer activity in preclinical studies, and this finding may stimulate the development of a novel class of small anticancer compounds that inhibit the HK-VDAC interaction.	[Kroemer, G.] Inst Gustave Roussy, INSERM, U848, F-94805 Villejuif, France; [Galluzzi, L.; Kepp, O.; Tajeddine, N.; Kroemer, G.] Univ Paris 11, Villejuif, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Gustave Roussy; UDICE-French Research Universities; Universite Paris Saclay	Kroemer, G (corresponding author), Inst Gustave Roussy, INSERM, U848, PR1,39 Rue Camille Desmoulins, F-94805 Villejuif, France.	kroemer@igr.fr	KROEMER, Guido/B-4263-2013; Kepp, Oliver/N-2763-2017; Galluzzi, Lorenzo/AAH-3286-2021; Kroemer, Guido/AAY-9859-2020; Kepp, Oliver/GPX-8627-2022; Galluzzi, Lorenzo/AAG-6294-2019; Galluzzi, Lorenzo/AAG-6432-2019; Galluzzi, Lorenzo/K-2709-2012	KROEMER, Guido/0000-0002-9334-4405; Kepp, Oliver/0000-0002-6081-9558; Galluzzi, Lorenzo/0000-0003-2257-8500				Adams JM, 2007, CURR OPIN IMMUNOL, V19, P488, DOI 10.1016/j.coi.2007.05.004; Alcala S, 2008, ONCOGENE, V27, P44, DOI 10.1038/sj.onc.1210600; Baines CP, 2003, CIRC RES, V92, P873, DOI 10.1161/01.RES.0000069215.36389.8D; Beutner G, 1998, BBA-BIOMEMBRANES, V1368, P7, DOI 10.1016/S0005-2736(97)00175-2; Brenner C, 2006, ONCOGENE, V25, P4744, DOI 10.1038/sj.onc.1209609; Debatin KM, 2002, ONCOGENE, V21, P8786, DOI 10.1038/sj.onc.1206039; Ferri KF, 2001, BIOESSAYS, V23, P111, DOI 10.1002/1521-1878(200102)23:2<111::AID-BIES1016>3.3.CO;2-P; Galluzzi L, 2006, ONCOGENE, V25, P4812, DOI 10.1038/sj.onc.1209598; Jang JY, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr1857; Kroemer G, 2005, NAT MED, V11, P725, DOI 10.1038/nm1263; Kroemer G, 2007, PHYSIOL REV, V87, P99, DOI 10.1152/physrev.00013.2006; Le Bras M, 2006, CANCER RES, V66, P9143, DOI 10.1158/0008-5472.CAN-05-4407; Mason KD, 2007, CELL, V128, P1173, DOI 10.1016/j.cell.2007.01.037; Miyamoto S, 2008, CELL DEATH DIFFER, V15, P521, DOI 10.1038/sj.cdd.4402285; Oltersdorf T, 2005, NATURE, V435, P677, DOI 10.1038/nature03579; Pastorino JG, 2005, CANCER RES, V65, P10545, DOI 10.1158/0008-5472.CAN-05-1925; Pedersen PL, 2007, J BIOENERG BIOMEMBR, V39, P211, DOI 10.1007/s10863-007-9094-x; Robey RB, 2006, ONCOGENE, V25, P4683, DOI 10.1038/sj.onc.1209595; Sun L, 2008, MOL CELL BIOL, V28, P1007, DOI 10.1128/MCB.00224-07; Vieira HLA, 2001, ONCOGENE, V20, P4305, DOI 10.1038/sj.onc.1204575; Zamzami N, 2000, ONCOGENE, V19, P6342, DOI 10.1038/sj.onc.1204030	21	72	76	1	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG	2008	27	34					4633	4635		10.1038/onc.2008.114	http://dx.doi.org/10.1038/onc.2008.114			3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	334QM	18469866				2022-12-28	WOS:000258236300001
J	Goldin, N; Arzoine, L; Heyfets, A; Israelson, A; Zaslavsky, Z; Bravman, T; Bronner, V; Notcovich, A; Shoshan-Barmatz, V; Flescher, E				Goldin, N.; Arzoine, L.; Heyfets, A.; Israelson, A.; Zaslavsky, Z.; Bravman, T.; Bronner, V.; Notcovich, A.; Shoshan-Barmatz, V.; Flescher, E.			Methyl jasmonate binds to and detaches mitochondria-bound hexokinase	ONCOGENE			English	Article						jasmonate; target; hexokinase; VDAC; mitochondria	DEPENDENT ANION CHANNEL; PERMEABILITY TRANSITION; ENERGY-METABOLISM; ANTICANCER AGENTS; BRAIN HEXOKINASE; CELL-DEATH; RAT-BRAIN; CANCER; APOPTOSIS; GLYCOLYSIS	Cellular bio-energetic metabolism and mitochondria are recognized as potential targets for anticancer agents, due to the numerous relevant peculiarities cancer cells exhibit. Jasmonates are anticancer agents that interact directly with mitochondria. The aim of this study was to identify mitochondrial molecular targets of jasmonates. We report that jasmonates bind to hexokinase and detach it from the mitochondria and its mitochondrial anchor-the voltage-dependent anion channel (VDAC), as judged by hexokinase immunochemical and activity determinations, surface plasmon resonance analysis and planar lipid bilayer VDAC- activity analysis. Furthermore, the susceptibility of cancer cells and mitochondria to jasmonates is dependent on the expression of hexokinase, evaluated using hexokinase-overexpressing transfect ants and its mitochondrial association. Many types of cancer cells exhibit overexpression of the key glycolytic enzyme, hexokinase, and its excessive binding to mitochondria. These characteristics are considered to play a pivotal role in cancer cell growth rate and survival. Thus, our findings provide an explanation for the selective effects of jasmonates on cancer cells. Most importantly, this is the first demonstration of a cytotoxic mechanism based on direct interaction between an anticancer agent and hexokinase. The proposed mechanism can serve to guide development of a new selective approach for cancer therapy.	[Goldin, N.; Heyfets, A.; Flescher, E.] Tel Aviv Univ, Sackler Fac Med, Dept Human Microbiol, IL-69978 Tel Aviv, Israel; [Arzoine, L.; Israelson, A.; Shoshan-Barmatz, V.] Ben Gurion Univ Negev, Dept Life Sci, IL-84105 Beer Sheva, Israel; [Zaslavsky, Z.] Tel Aviv Univ, Sackler Fac Med, Interdept Core Facil, IL-69978 Tel Aviv, Israel; [Bravman, T.; Bronner, V.; Notcovich, A.] Bio Rad Haifa, Haifa, Israel	Tel Aviv University; Sackler Faculty of Medicine; Ben Gurion University; Tel Aviv University; Sackler Faculty of Medicine	Flescher, E (corresponding author), Tel Aviv Univ, Sackler Fac Med, Dept Human Microbiol, IL-69978 Tel Aviv, Israel.	flascher@post.tau.ac.il		Israelson, Adrian/0000-0002-8289-7653				Al jamal JA, 2005, PROTEIN J, V24, P1, DOI 10.1007/s10930-004-0600-2; Azoulay-Zohar H, 2004, BIOCHEM J, V377, P347, DOI 10.1042/BJ20031465; Boozer C, 2006, CURR OPIN BIOTECH, V17, P400, DOI 10.1016/j.copbio.2006.06.012; Brawer Michael K, 2005, Rev Urol, V7 Suppl 7, pS21; BUSTAMANTE E, 1977, P NATL ACAD SCI USA, V74, P3735, DOI 10.1073/pnas.74.9.3735; Chini A, 2007, NATURE, V448, P666, DOI 10.1038/nature06006; Cuezva JM, 2002, CANCER RES, V62, P6674; Dang CV, 1999, TRENDS BIOCHEM SCI, V24, P68, DOI 10.1016/S0968-0004(98)01344-9; Debatin KM, 2002, ONCOGENE, V21, P8786, DOI 10.1038/sj.onc.1206039; Ehsani-Zonouz A, 2001, MOL CELL BIOCHEM, V223, P81, DOI 10.1023/A:1017952827675; Fingrut O, 2005, BRIT J PHARMACOL, V146, P800, DOI 10.1038/sj.bjp.0706394; Fingrut O, 2002, LEUKEMIA, V16, P608, DOI 10.1038/sj.leu.2402419; Flescher E, 2005, ANTI-CANCER DRUG, V16, P911, DOI 10.1097/01.cad.0000176501.63680.80; Flescher E, 2007, CANCER LETT, V245, P1, DOI 10.1016/j.canlet.2006.03.001; Galluzzi L, 2006, ONCOGENE, V25, P4812, DOI 10.1038/sj.onc.1209598; Gincel D, 2001, BIOCHEM J, V358, P147, DOI 10.1042/0264-6021:3580147; Goldin N, 2007, J BIOENERG BIOMEMBR, V39, P51, DOI 10.1007/s10863-006-9061-y; Green DR, 2004, SCIENCE, V305, P626, DOI 10.1126/science.1099320; Hamilton MD, 2007, NUCLEIC ACIDS RES, V35, P143, DOI 10.1093/nar/gkl1015; Hammerman PS, 2004, TRENDS BIOCHEM SCI, V29, P586, DOI 10.1016/j.tibs.2004.09.008; Heyfets A, 2007, CANCER LETT, V250, P300, DOI 10.1016/j.canlet.2006.10.013; Ishii Y, 2004, LEUKEMIA, V18, P1413, DOI 10.1038/sj.leu.2403421; Isidoro A, 2004, BIOCHEM J, V378, P17, DOI 10.1042/BJ20031541; KEISARI Y, 1992, J IMMUNOL METHODS, V146, P155, DOI 10.1016/0022-1759(92)90224-H; Kroemer G, 2006, ONCOGENE, V25, P4630, DOI 10.1038/sj.onc.1209589; Kroemer G, 2003, CURR MED CHEM, V10, P1469, DOI 10.2174/0929867033457232; Lampidis TJ, 2006, CANCER CHEMOTH PHARM, V58, P725, DOI 10.1007/s00280-006-0207-8; Lemasters JJ, 1998, BBA-BIOENERGETICS, V1366, P177, DOI 10.1016/S0005-2728(98)00112-1; Machida K, 2006, J BIOL CHEM, V281, P14314, DOI 10.1074/jbc.M513297200; Majewski N, 2004, MOL CELL, V16, P819, DOI 10.1016/j.molcel.2004.11.014; Mathupala SP, 2006, ONCOGENE, V25, P4777, DOI 10.1038/sj.onc.1209603; Miccoli L, 1998, CANCER RES, V58, P5777; NAKASHIMA RA, 1986, BIOCHEMISTRY-US, V25, P1015, DOI 10.1021/bi00353a010; OUDARD S, 1995, INT J CANCER, V62, P216, DOI 10.1002/ijc.2910620218; Pastorino JG, 2005, CANCER RES, V65, P10545, DOI 10.1158/0008-5472.CAN-05-1925; Pastorino JG, 2003, CURR MED CHEM, V10, P1535, DOI 10.2174/0929867033457269; Pedersen P L, 1978, Prog Exp Tumor Res, V22, P190; Pedersen PL, 2007, J BIOENERG BIOMEMBR, V39, P211, DOI 10.1007/s10863-007-9094-x; Pedersen PL, 2007, J BIOENERG BIOMEMBR, V39, P1, DOI 10.1007/s10863-007-9070-5; PEDERSEN PL, 2002, BIOCHIM BIOPHYS ACTA, V1355, P14; Penso J, 2003, MOL GENET METAB, V78, P74, DOI 10.1016/S1096-7192(02)00203-2; Reischer D, 2007, BRIT J PHARMACOL, V150, P738, DOI 10.1038/sj.bjp.0707146; Robey RB, 2006, ONCOGENE, V25, P4683, DOI 10.1038/sj.onc.1209595; Robey R.B., 2005, DRUG DISCOV TODAY DI, V2, P239, DOI [10.1016/j.ddmec.2005.05.021, DOI 10.1016/J.DDMEC.2005.05.021, DOI 10.1016/j.ddmec.2005.05.021]; Rotem R, 2005, CANCER RES, V65, P1984, DOI 10.1158/0008-5472.CAN-04-3091; Shoshan-Barmatz V, 2005, J MEMBRANE BIOL, V204, P57, DOI 10.1007/s00232-005-0749-4; Sun L, 2008, MOL CELL BIOL, V28, P1007, DOI 10.1128/MCB.00224-07; Varbiro G, 2001, FREE RADICAL BIO MED, V31, P548, DOI 10.1016/S0891-5849(01)00616-5; Warburg O.H., 1930, METABOLISM TUMOURS I; WILSON JE, 1989, PREP BIOCHEM, V19, P13, DOI 10.1080/10826068908544893; Wilson JE, 2003, J EXP BIOL, V206, P2049, DOI 10.1242/jeb.00241; WILSON JE, 1995, REV PHYSIOL BIOCH P, V126, P65, DOI 10.1007/BFb0049776; WILSON JE, 1968, J BIOL CHEM, V243, P3640; WILSON JE, 1989, ARCH BIOCHEM BIOPHYS, V269, P517, DOI 10.1016/0003-9861(89)90135-5; Zaid H, 2005, CELL DEATH DIFFER, V12, P751, DOI 10.1038/sj.cdd.4401599	55	151	160	1	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG	2008	27	34					4636	4643		10.1038/onc.2008.108	http://dx.doi.org/10.1038/onc.2008.108			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	334QM	18408762				2022-12-28	WOS:000258236300002
J	Chae, HD; Kim, BM; Yun, UJ; Shin, DY				Chae, H. D.; Kim, B. M.; Yun, U. J.; Shin, D. Y.			Deregulation of Cdk2 causes Bim-mediated apoptosis in p53-deficient tumors following actin damage	ONCOGENE			English	Article						actin; apoptosis; polyploidy; Bim; Cdk2	Y TRANSCRIPTION FACTOR; CDK2-DEPENDENT PHOSPHORYLATION; CELL-DEATH; P53; CHECKPOINT; EXPRESSION; INHIBITORS; ARREST; DNA; REREPLICATION	We previously reported that actin damage by treatment with an actin-depolymerizing agent including pectenotoxin-2 induces Bim-mediated apoptosis in p53-deficient human tumors. In this study, we investigated a molecular mechanism underlying Bim-mediated apoptosis of p53-deficient tumor cells following actin damage. We found that actin inhibitors increased the protein levels of p53 and p21 and thereby inactivated both Cdk2 and Cdc2 kinases. However, p53- or p21-knockout cells fail to induce p21 and hence kept both Cdk2 and Cdc2 kinases active even after treatment with actin inhibitor. The p53- or p21-knockout cells became multinucleate and polyploidy in association with induction of apoptosis. Expression of Bcl-x(L) resulted in accumulation of polyploid cells in association with inhibition of apoptosis. However, expression of a dominant negative mutant ( Cdk2dn) and treatment with chemical inhibitors for Cdk2 suppressed not only accumulation of multinucleated cells, but also induction of Bim expression and apoptosis. Therefore, these results suggest that Bim-mediated apoptosis following actin damage due to deregulation of Cdk2 and the cell cycle by the absence of functional p53.	[Chae, H. D.; Kim, B. M.; Yun, U. J.; Shin, D. Y.] Dankook Univ Coll Med, Dept Microbiol, Natl Res Lab, Cheonan 330714, South Korea; [Chae, H. D.; Kim, B. M.; Yun, U. J.; Shin, D. Y.] Seoul Natl Univ, Canc Res Inst, Seoul, South Korea	Dankook University; Seoul National University (SNU)	Shin, DY (corresponding author), Dankook Univ Coll Med, Dept Microbiol, Natl Res Lab, Anseo 29, Cheonan 330714, South Korea.	dreamer@dku.edu	Chae, Hee-Don/D-2620-2011					Amon A, 1999, CURR OPIN GENET DEV, V9, P69, DOI 10.1016/S0959-437X(99)80010-0; Andreassen PR, 2001, MOL BIOL CELL, V12, P1315, DOI 10.1091/mbc.12.5.1315; Antignani A, 2006, CURR OPIN CELL BIOL, V18, P685, DOI 10.1016/j.ceb.2006.10.004; Barreyro FJ, 2007, J BIOL CHEM, V282, P27141, DOI 10.1074/jbc.M704391200; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; Castedo M, 2006, EMBO J, V25, P2584, DOI 10.1038/sj.emboj.7601127; Chae HD, 2005, ONCOGENE, V24, P4813, DOI 10.1038/sj.onc.1208640; Chae HD, 2004, ONCOGENE, V23, P4084, DOI 10.1038/sj.onc.1207482; Di Leonardo A, 1997, CANCER RES, V57, P1013; Gilley J, 2003, J CELL BIOL, V162, P613, DOI 10.1083/jcb.200303026; GRAHAM FL, 1973, VIROLOGY, V54, P536, DOI 10.1016/0042-6822(73)90163-3; HARTWELL LH, 1989, SCIENCE, V246, P629, DOI 10.1126/science.2683079; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; Jordan MA, 1996, CANCER RES, V56, P816; JORDAN MA, 1991, CANCER RES, V51, P2212; Jung MS, 2001, ONCOGENE, V20, P5818, DOI 10.1038/sj.onc.1204748; Khan SH, 1998, CANCER RES, V58, P396; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; Lanni JS, 1998, MOL CELL BIOL, V18, P1055, DOI 10.1128/MCB.18.2.1055; Minn AJ, 1996, GENE DEV, V10, P2621, DOI 10.1101/gad.10.20.2621; Puthalakath H, 2007, CELL, V129, P1337, DOI 10.1016/j.cell.2007.04.027; Rudner AD, 1996, CURR OPIN CELL BIOL, V8, P773, DOI 10.1016/S0955-0674(96)80077-9; SEDLAK TW, 1995, P NATL ACAD SCI USA, V92, P7834, DOI 10.1073/pnas.92.17.7834; Stahl M, 2002, J IMMUNOL, V168, P5024, DOI 10.4049/jimmunol.168.10.5024; Torres K, 1998, CANCER RES, V58, P3620; Yun JH, 2003, J BIOL CHEM, V278, P36966, DOI 10.1074/jbc.M305178200	26	19	19	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 3	2008	27	29					4115	4121		10.1038/onc.2008.46	http://dx.doi.org/10.1038/onc.2008.46			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	321RV	18345036				2022-12-28	WOS:000257325100011
J	Allerstorfer, S; Sonvilla, G; Fischer, H; Spiegl-Kreinecker, S; Gauglhofer, C; Setinek, U; Czech, T; Marosi, C; Buchroithner, J; Pichler, J; Silye, R; Mohr, T; Holzmann, K; Grasl-Kraupp, B; Marian, B; Grusch, M; Fischer, J; Micksche, M; Berger, W				Allerstorfer, S.; Sonvilla, G.; Fischer, H.; Spiegl-Kreinecker, S.; Gauglhofer, C.; Setinek, U.; Czech, T.; Marosi, C.; Buchroithner, J.; Pichler, J.; Silye, R.; Mohr, T.; Holzmann, K.; Grasl-Kraupp, B.; Marian, B.; Grusch, M.; Fischer, J.; Micksche, M.; Berger, W.			FGF5 as an oncogenic factor in human glioblastoma multiforme: autocrine and paracrine activities	ONCOGENE			English	Article						FGF5; FGF receptor 1; astrocytic brain tumours; cell growth and migration; autocrine and paracrine activities	FIBROBLAST-GROWTH-FACTOR; CELL LUNG-CANCER; CENTRAL-NERVOUS-SYSTEM; IN-VITRO; HUMAN ASTROCYTOMAS; ENDOTHELIAL-CELLS; MESSENGER-RNA; FACTOR FAMILY; GLIOMA-CELLS; EXPRESSION	Fibroblast growth factor 5 (FGF5) is widely expressed in embryonic but scarcely in adult tissues. Here we report simultaneous overexpression of FGF5 and its predominant high-affinity receptor (FGFR1 IIIc) in astrocytic brain tumour specimens (N = 49) and cell cultures (N = 49). The levels of both ligand and receptor increased with enhanced malignancy in vivo and in vitro. Furthermore, secreted FGF5 protein was generally present in the supernatants of glioblastoma (GBM) cells. siRNA-mediated FGF5 down-modulation reduced moderately but significantly GBM cell proliferation while recombinant FGF5 (rFGF5) increased this parameter preferentially in cell lines with low endogenous expression levels. Apoptosis induction by prolonged serum starvation was significantly prevented by rFGF5. Moreover, tumour cell migration was distinctly stimulated by rFGF5 but attenuated by FGF5 siRNA. Blockade of FGFR1-mediated signals by pharmacological FGFR inhibitors or a dominant-negative FGFR1 IIIc protein inhibited GBM cell proliferation and/or induced apoptotic cell death. Moreover, rFGF5 and supernatants of highly FGF5-positive GBM cell lines specifically stimulated proliferation, migration and tube formation of human umbilical vein endothelial cells. In summary, we demonstrate for the first time that FGF5 contributes to the malignant progression of human astrocytic brain tumours by both autocrine and paracrine effects.	[Allerstorfer, S.; Sonvilla, G.; Fischer, H.; Gauglhofer, C.; Mohr, T.; Holzmann, K.; Grasl-Kraupp, B.; Marian, B.; Grusch, M.; Micksche, M.; Berger, W.] Med Univ Vienna, Dept Med 1, Inst Canc Res, A-1090 Vienna, Austria; [Spiegl-Kreinecker, S.; Fischer, J.] Wagner Jauregg Hosp, Dept Neurosurg, Linz, Austria; [Setinek, U.] Otto Wagner Hosp Baumgartner Hohe, Inst Pathol & Bacteriol, Vienna, Austria; [Czech, T.] Med Univ Vienna, Dept Neurosurg, A-1090 Vienna, Austria; [Marosi, C.] Med Univ Vienna, Dept Med 1, Div Clin Oncol, A-1090 Vienna, Austria; [Pichler, J.] Wagner Jauregg Hosp, Dept Internal Med, Linz, Austria; [Silye, R.] Wagner Jauregg Hosp, Inst Pathol, Linz, Austria	Medical University of Vienna; Kepler University Hospital; Medical University of Vienna; Medical University of Vienna; Kepler University Hospital; Kepler University Hospital	Berger, W (corresponding author), Med Univ Vienna, Dept Med 1, Inst Canc Res, Borschkegasse 8A, A-1090 Vienna, Austria.	walter.berger@meduniwien.ac.at	Mohr, Thomas/AAN-1180-2020; Grusch, Michael/C-1183-2008; Holzmann, Klaus/I-4437-2019	Mohr, Thomas/0000-0002-1933-847X; Grusch, Michael/0000-0001-5486-9340; Holzmann, Klaus/0000-0003-4077-3377; Berger, Walter/0000-0003-0014-1658	Austrian Science Fund FWF [P 19920] Funding Source: Medline	Austrian Science Fund FWF(Austrian Science Fund (FWF))		Antoine M, 2005, GROWTH FACTORS, V23, P87, DOI 10.1080/08977190500096004; BATES B, 1991, MOL CELL BIOL, V11, P1840, DOI 10.1128/MCB.11.4.1840; Berger W, 1999, INT J CANCER, V83, P415, DOI 10.1002/(SICI)1097-0215(19991029)83:3<415::AID-IJC19>3.0.CO;2-Y; Berger W, 2005, J CANCER RES CLIN, V131, P355, DOI 10.1007/s00432-004-0653-9; Brachner A, 2006, CANCER RES, V66, P3584, DOI 10.1158/0008-5472.CAN-05-2839; Carter TA, 2005, P NATL ACAD SCI USA, V102, P11011, DOI 10.1073/pnas.0504952102; Cavallaro U, 2001, NAT CELL BIOL, V3, P650, DOI 10.1038/35083041; Davies MA, 1998, CANCER RES, V58, P5285; ENGEBRAATEN O, 1993, INT J CANCER, V53, P209, DOI 10.1002/ijc.2910530206; Eswarakumar VP, 2005, CYTOKINE GROWTH F R, V16, P139, DOI 10.1016/j.cytogfr.2005.01.001; Galzie Z, 1997, BIOCHEM CELL BIOL, V75, P669, DOI 10.1139/bcb-75-6-669; GOMEZPINILLA F, 1993, BRAIN RES, V606, P79, DOI 10.1016/0006-8993(93)91572-A; Grose R, 2005, CYTOKINE GROWTH F R, V16, P179, DOI 10.1016/j.cytogfr.2005.01.003; Hanada K, 2001, CANCER RES, V61, P5511; HAUB O, 1991, DEVELOPMENT, V112, P397; HAUB O, 1990, P NATL ACAD SCI USA, V87, P8022, DOI 10.1073/pnas.87.20.8022; HEBERT JM, 1994, CELL, V78, P1017, DOI 10.1016/0092-8674(94)90276-3; Heffeter P, 2006, BIOCHEM PHARMACOL, V71, P426, DOI 10.1016/j.bcp.2005.11.009; HUGHES RA, 1993, NEURON, V10, P369, DOI 10.1016/0896-6273(93)90327-N; JAFFE EA, 1973, J CLIN INVEST, V52, P2745, DOI 10.1172/JCI107470; Jensen RL, 1998, SURG NEUROL, V49, P189, DOI 10.1016/S0090-3019(97)00218-8; Joy A, 1997, ONCOGENE, V14, P171, DOI 10.1038/sj.onc.1200823; Kargiotis O, 2006, J NEURO-ONCOL, V78, P281, DOI 10.1007/s11060-005-9097-6; Kornmann M, 1997, ONCOGENE, V15, P1417, DOI 10.1038/sj.onc.1201307; Kornmann M, 2001, INT J PANCREATOL, V29, P85, DOI 10.1385/IJGC:29:2:085; LINDHOLM D, 1994, EUR J NEUROSCI, V6, P244, DOI 10.1111/j.1460-9568.1994.tb00267.x; McKeehan WL, 1998, PROG NUCLEIC ACID RE, V59, P135; MORRISON RS, 1994, CANCER RES, V54, P2794; MORRISON RS, 1994, J NEURO-ONCOL, V18, P207, DOI 10.1007/BF01328955; Ornitz DM, 1996, J BIOL CHEM, V271, P15292, DOI 10.1074/jbc.271.25.15292; Ozawa K, 1998, J BIOL CHEM, V273, P29262, DOI 10.1074/jbc.273.44.29262; Panek RL, 1998, J PHARMACOL EXP THER, V286, P569; Pelton TA, 2002, J CELL SCI, V115, P329; Puputti M, 2006, MOL CANCER RES, V4, P927, DOI 10.1158/1541-7786.MCR-06-0085; Reuss B, 2003, CELL TISSUE RES, V313, P139, DOI 10.1007/s00441-003-0756-7; Reuss B, 2003, J NEUROSCI, V23, P6404; Reuss B, 2000, GLIA, V30, P231, DOI 10.1002/(SICI)1098-1136(200005)30:3<231::AID-GLIA3>3.3.CO;2-T; Rix U, 2007, BLOOD, V110, P4055, DOI 10.1182/blood-2007-07-102061; Spiegl-Kreinecker S, 2007, BRIT J CANCER, V96, P960, DOI 10.1038/sj.bjc.6603652; Stachowiak MK, 1996, MOL BRAIN RES, V38, P161, DOI 10.1016/0169-328X(96)00010-1; Steiner E, 2006, J CELL SCI, V119, P459, DOI 10.1242/jcs.02773; Sundberg JP, 1997, VET PATHOL, V34, P171, DOI 10.1177/030098589703400301; Suzuki S, 1998, J INVEST DERMATOL, V111, P963, DOI 10.1046/j.1523-1747.1998.00427.x; Suzuki S, 2000, J INVEST DERMATOL, V114, P456, DOI 10.1046/j.1523-1747.2000.00912.x; Taniguchi F, 2003, J CLIN ENDOCR METAB, V88, P773, DOI 10.1210/jc.2002-021062; Todo T, 1998, NEUROSURGERY, V43, P337, DOI 10.1097/00006123-199808000-00098; Yamada SM, 2002, NEUROL RES, V24, P244, DOI 10.1179/016164102101199864; ZHAN XI, 1988, MOL CELL BIOL, V8, P3487, DOI 10.1128/MCB.8.8.3487; Zhang LR, 1998, CANCER RES, V58, P352	49	66	70	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL	2008	27	30					4180	4190		10.1038/onc.2008.61	http://dx.doi.org/10.1038/onc.2008.61			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	324DB	18362893	Green Accepted			2022-12-28	WOS:000257496800005
J	Zhou, Q; Geahlen, RL				Zhou, Q.; Geahlen, R. L.			The protein-tyrosine kinase Syk interacts with TRAF-interacting protein TRIP in breast epithelial cells	ONCOGENE			English	Article						Syk; tyrosine kinase; breast cancer; tumor necrosis factor; TRIP; NF-kappa B	KAPPA-B ACTIVATION; TUMOR-NECROSIS-FACTOR; ANTIGEN RECEPTOR; CANCER CELLS; LOCALIZES; LYN	The nonreceptor, protein-tyrosine kinase Syk is a suppressor of breast cancer progression whose expression is inversely correlated with the invasive behavior of cancer cells. In contrast, Syk has a positive function in murine mammary tumor virus-mediated tumorigenesis. A yeast two-hybrid screen using a library from human mammary gland identified tumor necrosis factor (TNF) receptor-associated factor-interacting protein (TRIP) as an Syk-binding partner. This interaction is mediated by the C-terminal region of TRIP and is enhanced by the treatment of cells with TNF and the tyrosine phosphorylation of Syk. Syk and TRIP have opposing functions in TNF-signaling pathways. Syk enhances the activation of nuclear factor-kappa B by TNF and this is antagonized by TRIP. The overexpression of TRIP sensitizes cells to TNF-induced apoptosis, an effect that can be reversed by the coexpression of Syk.	[Zhou, Q.; Geahlen, R. L.] Purdue Univ, Dept Med Chem & Mol Pharmacol, W Lafayette, IN 47907 USA; [Zhou, Q.; Geahlen, R. L.] Purdue Univ, Purdue Canc Ctr, W Lafayette, IN 47907 USA	Purdue University System; Purdue University; Purdue University West Lafayette Campus; Purdue University System; Purdue University; Purdue University West Lafayette Campus	Geahlen, RL (corresponding author), Purdue Univ, Dept Med Chem & Mol Pharmacol, Hansen Life Sci Res Bldg,201 S Univ St, W Lafayette, IN 47907 USA.	geahlen@purdue.edu		Geahlen, Robert/0000-0001-8400-2924	NATIONAL CANCER INSTITUTE [R01CA115465] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA115465, R01 CA115465-03, CA115465] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Besse A, 2007, BIOCHEM BIOPH RES CO, V359, P660, DOI 10.1016/j.bbrc.2007.05.149; Coopman PJP, 2000, NATURE, V406, P742, DOI 10.1038/35021086; Eliopoulos AG, 2006, J BIOL CHEM, V281, P1371, DOI 10.1074/jbc.M506790200; Katz E, 2005, J EXP MED, V201, P431, DOI 10.1084/jem.20041471; Keshvara LM, 1998, J IMMUNOL, V161, P5276; Kurosaki T, 2000, CURR OPIN IMMUNOL, V12, P276, DOI 10.1016/S0952-7915(00)00087-X; Latour S, 2001, CURR OPIN IMMUNOL, V13, P299, DOI 10.1016/S0952-7915(00)00219-3; Lee SY, 1997, J EXP MED, V185, P1275, DOI 10.1084/jem.185.7.1275; Lu J, 2006, J BIOL CHEM, V281, P8806, DOI 10.1074/jbc.M507305200; Ma H, 2001, J IMMUNOL, V166, P1507, DOI 10.4049/jimmunol.166.3.1507; Moon KD, 2005, J BIOL CHEM, V280, P1543, DOI 10.1074/jbc.M407805200; Moroni M, 2004, CANCER RES, V64, P7346, DOI 10.1158/0008-5472.CAN-03-3520; Peters JD, 1996, J BIOL CHEM, V271, P4755; Regamey A, 2003, J EXP MED, V198, P1959, DOI 10.1084/jem.20031187; Salomoni P, 2006, TRENDS CELL BIOL, V16, P97, DOI 10.1016/j.tcb.2005.12.002; Takada Y, 2004, J IMMUNOL, V173, P1066, DOI 10.4049/jimmunol.173.2.1066; Toyama T, 2003, CANCER LETT, V189, P97, DOI 10.1016/S0304-3835(02)00463-9; Ulanova M, 2005, AM J PHYSIOL-LUNG C, V288, pL497, DOI 10.1152/ajplung.00246.2004; Wang L, 2005, CANCER RES, V65, P10289, DOI 10.1158/0008-5472.CAN-05-2231; Wilson J, 2002, SEMIN CANCER BIOL, V12, P113, DOI 10.1006/scbi.2001.0419; Zhou F, 2006, MOL CELL BIOL, V26, P3478, DOI 10.1128/MCB.26.9.3478-3491.2006; Zyss D, 2005, CANCER RES, V65, P10872, DOI 10.1158/0008-5472.CAN-05-1270	22	42	43	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2009	28	10					1348	1356		10.1038/onc.2008.493	http://dx.doi.org/10.1038/onc.2008.493			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	417ZC	19151749	Green Accepted			2022-12-28	WOS:000264116000007
J	Arscott, WT; LaBauve, AE; May, V; Wesley, UV				Arscott, W. T.; LaBauve, A. E.; May, V.; Wesley, U. V.			Suppression of neuroblastoma growth by dipeptidyl peptidase IV: relevance of chemokine regulation and caspase activation	ONCOGENE			English	Article						DPPIV; neuroblastoma; apoptosis; chemokine; migration and invasion	PROSTATE-CANCER CELLS; DEAMINASE COMPLEXING PROTEIN; BONE-MARROW METASTASES; ADENOSINE-DEAMINASE; TUMOR-GROWTH; MALIGNANT PHENOTYPE; SURFACE PEPTIDASES; PROGENITOR CELLS; CARCINOMA CELLS; IN-VITRO	Imbalanced protease expression and activities may contribute to the development of cancers, including neuroblastoma (NB). NB is a fatal childhood cancer of the sympathetic nervous system that frequently overexpresses mitogenic peptides, chemokines and their receptors. Dipeptidyl peptidase IV (DPPIV), a cell surface serine protease, inactivates or degrades some of these bioactive peptides and chemokines, thereby regulating cell proliferation and survival. Our studies show that DPPIV is expressed in normal neural crest-derived structures, including superior cervical and dorsal root ganglion cells, sciatic nerve, and in adrenal glands, but its expression is greatly decreased or lost in cells derived from NB, their malignant counterpart. Restoration of DPPIV expression in NB cells led to their differentiation in association with increased expression of the neural marker MAP2 and decreased expression of chemokines, including stromal-derived factor 1 (SDF1) and its receptor CXCR4. Furthermore, DPPIV promoted apoptosis, and inhibited SDF1-mediated in vitro cell migration and angiogenic potential. These changes were accompanied by caspase activation and decreased levels of phospho-Akt and MMP9 activity, which are downstream effectors of SDF1-CXCR4 signaling. Importantly, DPPIV suppressed the tumorigenic potential of NB cells in a xenotransplantation mouse model. These data support a potential role for DPPIV in inhibiting NB growth and progression.	[Arscott, W. T.; LaBauve, A. E.; Wesley, U. V.] Univ Vermont, Vermont Canc Ctr, Dept Microbiol & Mol Genet, Burlington, VT 05405 USA; [May, V.] Univ Vermont, Vermont Canc Ctr, Dept Anat & Neurobiol, Burlington, VT 05405 USA	University of Vermont; University of Vermont	Wesley, UV (corresponding author), Univ Vermont, Vermont Canc Ctr, Dept Microbiol & Mol Genet, 316A,HSRF,149 Beaumont Ave, Burlington, VT 05405 USA.	uwesley@uvm.edu		Arscott, William/0000-0003-0110-8569	National Center for Research Resources-National Institute of Health (NCRR) [COBRE 2 P20 RR016435-P4Y6]; NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR016435] Funding Source: NIH RePORTER	National Center for Research Resources-National Institute of Health (NCRR)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))	This study was supported by the Grant, Neuroscience COBRE 2 P20 RR016435-P4Y6 from the National Center for Research Resources-National Institute of Health (NCRR). We thank the Department of Microbiology and Molecular Genetics and the Vermont Cancer Center (VCC) for their support. We thank Drs Cynthia Forehand, Diane Jaworski, Rodney Parsons, Marcus Bosenberg, Rae Nishi and Cedric Wesley for helpful discussions and critical review of the paper. We thank the staff at the VCC and COBRE-Neuroscience core facilities for their technical help.	Abbott CA, 1997, ADV EXP MED BIOL, V421, P161; Airoldi I, 2006, CLIN CANCER RES, V12, P77, DOI 10.1158/1078-0432.CCR-05-1376; Airoldi I, 2008, CANCER IMMUNOL IMMUN, V57, P541, DOI 10.1007/s00262-007-0392-2; Balkwill F, 2004, NAT REV CANCER, V4, P540, DOI 10.1038/nrc1388; Barbero S, 2003, CANCER RES, V63, P1969; Bauvois B, 2004, ONCOGENE, V23, P317, DOI 10.1038/sj.onc.1207124; Belmadani A, 2005, J NEUROSCI, V25, P3995, DOI 10.1523/JNEUROSCI.4631-04.2005; Bogenrieder T, 1997, PROSTATE, V33, P225; Bonfil RD, 2007, UROL ONCOL-SEMIN ORI, V25, P407, DOI 10.1016/j.urolonc.2007.05.008; Brodeur GM, 2003, NAT REV CANCER, V3, P203, DOI 10.1038/nrc1014; Burger JA, 2006, BLOOD, V107, P1761, DOI 10.1182/blood-2005-08-3182; Carl-McGrath S, 2006, HISTOL HISTOPATHOL, V21, P1339, DOI 10.14670/HH-21.1339; Castel V, 2007, CLIN TRANSL ONCOL, V9, P478, DOI 10.1007/s12094-007-0091-7; Chinni SR, 2006, PROSTATE, V66, P32, DOI 10.1002/pros.20318; Christopherson KW, 2002, J IMMUNOL, V169, P7000, DOI 10.4049/jimmunol.169.12.7000; Dai J, 2001, CLIN CANCER RES, V7, P1370; DINJENS WNM, 1990, J PATHOL, V160, P195, DOI 10.1002/path.1711600303; Dobers J, 2000, EUR J BIOCHEM, V267, P5093, DOI 10.1046/j.1432-1327.2000.01571.x; Durinx C, 2000, EUR J BIOCHEM, V267, P5608, DOI 10.1046/j.1432-1327.2000.01634.x; Eggert A, 2000, CLIN CANCER RES, V6, P1900; Fernandis AZ, 2004, ONCOGENE, V23, P157, DOI 10.1038/sj.onc.1206910; Gabrilovac J, 2003, LIFE SCI, V73, P151, DOI 10.1016/S0024-3205(03)00257-1; Geminder H, 2001, J IMMUNOL, V167, P4747, DOI 10.4049/jimmunol.167.8.4747; Gerard C, 2001, NAT IMMUNOL, V2, P108, DOI 10.1038/84209; Ghersi G, 2002, J BIOL CHEM, V277, P29231, DOI 10.1074/jbc.M202770200; Golubkov VS, 2007, CELL CYCLE, V6, P147, DOI 10.4161/cc.6.2.3706; Guyon A, 2007, J MOL ENDOCRINOL, V38, P365, DOI 10.1677/JME-06-0013; Havre PA, 2008, FRONT BIOSCI-LANDMRK, V13, P1634, DOI 10.2741/2787; Kajiyama H, 2006, ANN NY ACAD SCI, V1086, P233, DOI 10.1196/annals.1377.007; KENNY AJ, 1989, LANCET, V2, P785; Lambeir AM, 2001, J BIOL CHEM, V276, P29839, DOI 10.1074/jbc.M103106200; Li ZJ, 2007, EXPERT OPIN THER TAR, V11, P1611, DOI 10.1517/14728222.11.12.1611; Maris JM, 2008, LANCET, V371, P1142, DOI 10.1016/S0140-6736(08)60500-0; Maris JM, 2007, LANCET, V369, P2106, DOI 10.1016/S0140-6736(07)60983-0; Matthay KK, 2008, LANCET ONCOL, V9, P195, DOI 10.1016/S1470-2045(08)70046-9; Meitar D, 1996, J CLIN ONCOL, V14, P405, DOI 10.1200/JCO.1996.14.2.405; Mentlein R, 1999, REGUL PEPTIDES, V85, P9, DOI 10.1016/S0167-0115(99)00089-0; MORRISON ME, 1993, J EXP MED, V177, P1135, DOI 10.1084/jem.177.4.1135; Nakagawara A, 2004, PROG BRAIN RES, V146, P233, DOI 10.1016/S0079-6123(03)46015-9; NAKAGAWARA A, 1994, MOL CELL BIOL, V14, P759, DOI 10.1128/MCB.14.1.759; Nanus DM, 2003, CLIN CANCER RES, V9, P6307; Nevo I, 2004, IMMUNOL LETT, V92, P163, DOI 10.1016/j.imlet.2003.10.019; Payne AS, 2002, J INVEST DERMATOL, V118, P915, DOI 10.1046/j.1523-1747.2002.01725.x; Pethiyagoda CL, 2001, CLIN EXP METASTAS, V18, P391, DOI 10.1023/A:1010930918055; PIAZZA GA, 1989, BIOCHEM J, V262, P327, DOI 10.1042/bj2620327; Proost P, 1998, FEBS LETT, V432, P73, DOI 10.1016/S0014-5793(98)00830-8; Raman D, 2007, CANCER LETT, V256, P137, DOI 10.1016/j.canlet.2007.05.013; Ren Y, 2006, ONCOGENE, V25, P3501, DOI 10.1038/sj.onc.1209395; Rundhaug JE, 2005, J CELL MOL MED, V9, P267, DOI 10.1111/j.1582-4934.2005.tb00355.x; Russell HV, 2004, J PEDIATR SURG, V39, P1506, DOI 10.1016/j.jpedsurg.2004.06.019; SAKAMOTO J, 1993, J SURG ONCOL, V52, P124, DOI 10.1002/jso.2930520214; Scala S, 2006, CLIN CANCER RES, V12, P2427, DOI 10.1158/1078-0432.CCR-05-1940; Scharpe S, 2001, Verh K Acad Geneeskd Belg, V63, P5; SCHRADER WP, 1987, J HISTOCHEM CYTOCHEM, V35, P443, DOI 10.1177/35.4.3546489; Sedo A, 1994, Sb Lek, V95, P285; Shioda T, 1998, P NATL ACAD SCI USA, V95, P6331, DOI 10.1073/pnas.95.11.6331; Singh S, 2007, CANCER METAST REV, V26, P453, DOI 10.1007/s10555-007-9068-9; Tanaka T, 2005, CANCER SCI, V96, P317, DOI 10.1111/j.1349-7006.2005.00059.x; Terauchi M, 2005, ONCOLOGY-BASEL, V69, P52, DOI 10.1159/000087476; Tran PB, 2004, J NEUROSCI RES, V76, P20, DOI 10.1002/jnr.20001; Tsuji T, 2004, INT J HEMATOL, V80, P254, DOI 10.1532/IJH97.04066; Tucker RP, 2004, INT J BIOCHEM CELL B, V36, P173, DOI 10.1016/S1357-2725(03)00243-7; Vasudevan SA, 2005, WORLD J SURG, V29, P317, DOI 10.1007/s00268-004-7820-7; Wesley UV, 2005, CANCER RES, V65, P1325, DOI 10.1158/0008-5472.CAN-04-1852; Wesley UV, 1999, J EXP MED, V190, P311, DOI 10.1084/jem.190.3.311; Wesley UV, 2004, INT J CANCER, V109, P855, DOI 10.1002/ijc.20091; Zigrino P, 2005, BIOCHIMIE, V87, P321, DOI 10.1016/j.biochi.2004.10.025	67	44	48	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 29	2009	28	4					479	491		10.1038/onc.2008.402	http://dx.doi.org/10.1038/onc.2008.402			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	400KM	18978811	Green Accepted			2022-12-28	WOS:000262866500002
J	Markey, M; Berberich, SJ				Markey, M.; Berberich, S. J.			Full-length hdmX transcripts decrease following genotoxic stress	ONCOGENE			English	Article						HdmX; p53; transcription; splicing; microRNAs	TUMOR-SUPPRESSOR P53; UBIQUITIN LIGASE ACTIVITY; EMBRYONIC LETHALITY; ONCOPROTEIN MDM2; REGULATE P53; DNA-DAMAGE; ACTIVATION; EXPRESSION; STABILITY; PROTEIN	Previous studies have suggested that the mdmX gene is constitutively transcribed, and that MdmX protein activity is instead controlled by cellular localization and DNA damage induced Mdm2-mediated ubiquitination leading to proteasomal degradation. In these studies, we report that the human mdmX (hdmX) mRNA is reproducibly decreased in various human cell lines following treatment with various DNA-damaging agents. Repression of hdmX transcripts is observed in DNA-damaged HCT116 colon cancer cells and in isogenic p53(-/-) cells, suggesting that this effect is p53-independent. Reduction in the amount of hdmX transcript occurs in both human tumor cell lines and primary human diploid fibroblasts, and results in a significant reduction of HdmX protein. Examination of hdmX promoter activity suggests that damage-induced repression of hdmX mRNA is not significantly impacted by transcription initiation. In contrast, changes in hdmX mRNA splicing appear to partly explain the reduction in full-length hdmX mRNA levels in tumor cell lines with the destabilization of full-length hdmX transcripts, potentially through microRNA miR-34a regulation, also impacting transcript levels. Taken together, this study uncovers previously unrecognized cellular mechanisms by which hdmX mRNA levels are kept low following genotoxic stress.	[Markey, M.; Berberich, S. J.] Wright State Univ, Boonshoft Sch Med, Dept Biochem & Mol Biol, Dayton, OH 45435 USA	University System of Ohio; Wright State University Dayton	Berberich, SJ (corresponding author), Wright State Univ, Boonshoft Sch Med, Dept Biochem & Mol Biol, 3640 Colonel Glenn Hwy, Dayton, OH 45435 USA.	steven.berberich@wright.edu		Markey, Michael/0000-0002-8593-2290	NIH [CA66430]; NATIONAL CANCER INSTITUTE [R01CA064430] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank members of the Berberich laboratory for their insightful discussions. This work was supported by NIH CA66430 (to SJB).	Bartel F, 2005, INT J CANCER, V117, P469, DOI 10.1002/ijc.21206; Betel D, 2008, NUCLEIC ACIDS RES, V36, pD149, DOI 10.1093/nar/gkm995; Bommer GT, 2007, CURR BIOL, V17, P1298, DOI 10.1016/j.cub.2007.06.068; Bottger V, 1999, ONCOGENE, V18, P189, DOI 10.1038/sj.onc.1202281; Chandler DS, 2006, CANCER RES, V66, P9502, DOI 10.1158/0008-5472.CAN-05-4271; Chang TC, 2007, MOL CELL, V26, P745, DOI 10.1016/j.molcel.2007.05.010; Danovi D, 2004, MOL CELL BIOL, V24, P5835, DOI 10.1128/MCB.24.13.5835-5843.2004; de Graaf P, 2003, J BIOL CHEM, V278, P38315, DOI 10.1074/jbc.M213034200; DEOCALUNA R, 1995, NATURE, V0378; Dias CS, 2006, CANCER RES, V66, P9467, DOI 10.1158/0008-5472.CAN-05-3013; Eto I, 2006, CANCER CELL INT, V6, DOI 10.1186/1475-2867-6-20; Fang SY, 2000, J BIOL CHEM, V275, P8945, DOI 10.1074/jbc.275.12.8945; Gentiletti F, 2002, ONCOGENE, V21, P867, DOI 10.1038/sj.onc.1205137; Gertz EM, 2006, BMC BIOL, V4, DOI 10.1186/1741-7007-4-41; Gilkes DM, 2006, EMBO J, V25, P5614, DOI 10.1038/sj.emboj.7601424; Gu JJ, 2002, J BIOL CHEM, V277, P19251, DOI 10.1074/jbc.C200150200; He L, 2007, NATURE, V447, P1130, DOI 10.1038/nature05939; Honda R, 1997, FEBS LETT, V420, P25, DOI 10.1016/S0014-5793(97)01480-4; Honda R, 1999, EMBO J, V18, P22, DOI 10.1093/emboj/18.1.22; Jackson MW, 1999, DNA CELL BIOL, V18, P693, DOI 10.1089/104454999314971; Jin YT, 2006, EMBO J, V25, P1207, DOI 10.1038/sj.emboj.7601010; John B, 2004, PLOS BIOL, V2, P1862, DOI 10.1371/journal.pbio.0020363; JONES SN, 1995, NATURE, V378, P206, DOI 10.1038/378206a0; Kent WJ, 2002, GENOME RES, V12, P996, DOI 10.1101/gr.229102; Li CG, 2002, MOL CELL BIOL, V22, P7562, DOI 10.1128/MCB.22.21.7562-7571.2002; Lowe SW, 2003, CURR OPIN GENET DEV, V13, P77, DOI 10.1016/S0959-437X(02)00013-8; Marine JC, 2005, BIOCHEM BIOPH RES CO, V331, P750, DOI 10.1016/j.bbrc.2005.03.151; Migliorini D, 2002, J BIOL CHEM, V277, P7318, DOI 10.1074/jbc.M108795200; MIYASHITA T, 1995, CELL, V80, P293; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; OLINER JD, 1993, NATURE, V362, P857, DOI 10.1038/362857a0; Oren M, 2003, CELL DEATH DIFFER, V10, P431, DOI 10.1038/sj.cdd.4401183; Parant J, 2001, NAT GENET, V29, P92, DOI 10.1038/ng714; Ramos YFM, 2001, CANCER RES, V61, P1839; Raver-Shapira N, 2007, MOL CELL, V26, P731, DOI 10.1016/j.molcel.2007.05.017; Rozen S, 2000, Methods Mol Biol, V132, P365; Shvarts A, 1996, EMBO J, V15, P5349, DOI 10.1002/j.1460-2075.1996.tb00919.x; Tarasov V, 2007, CELL CYCLE, V6, P1586, DOI 10.4161/cc.6.13.4436; Toledo F, 2006, NAT REV CANCER, V6, P909, DOI 10.1038/nrc2012; Vousden KH, 2002, NAT REV CANCER, V2, P594, DOI 10.1038/nrc864; Yamasaki Lili, 2003, Cancer Treat Res, V115, P209	41	24	25	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV	2008	27	52					6657	6666		10.1038/onc.2008.266	http://dx.doi.org/10.1038/onc.2008.266			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	368QY	18711402	Green Accepted			2022-12-28	WOS:000260638800004
J	Garcia-Aragoncillo, E; Carrillo, J; Lalli, E; Agra, N; Gomez-Lopez, G; Pestana, A; Alonso, J				Garcia-Aragoncillo, E.; Carrillo, J.; Lalli, E.; Agra, N.; Gomez-Lopez, G.; Pestana, A.; Alonso, J.			DAX1, a direct target of EWS/FLI1 oncoprotein, is a principal regulator of cell-cycle progression in Ewing's tumor cells	ONCOGENE			English	Article						Ewing's tumors; EWS/FLI1 oncoprotein; DAX1; NR0B1; RNA interference	ADRENAL HYPOPLASIA CONGENITA; NUCLEAR RECEPTOR DAX-1; ETS FUSION PROTEINS; FAMILY TUMORS; DNA-BINDING; GENE; SARCOMA; COREPRESSOR; EXPRESSION; PATHWAYS	The molecular hallmark of the Ewing's family of tumors is the presence of balanced chromosomal translocations, leading to the formation of chimerical transcription factors (that is, EWS/FLI1) that play a pivotal role in the pathogenesis of Ewing's tumors by deregulating gene expression. We have recently demonstrated that DAX1 (NR0B1), an orphan nuclear receptor that was not previously implicated in cancer, is induced by the EWS/FLI1 oncoprotein and is highly expressed in Ewing's tumors, suggesting that DAX1 is a biologically relevant target of EWS/FLI1-mediated oncogenesis. In this study we demonstrate that DAX1 is a direct transcriptional target of the EWS/FLI1 oncoprotein through its binding to a GGAA-rich region in the DAX1 promoter and show that DAX1 is a key player of EWS/FLI1-mediated oncogenesis. DAX1 silencing using an inducible model of RNA interference induces growth arrest in the A673 Ewing's cell line and severely impairs its capability to grow in semisolid medium and form tumors in immuno deficient mice. Gene expression pro. le analysis demonstrated that about 10% of the genes regulated by EWS/FLI1 in Ewing's cells are DAX1 targets, confirming the importance of DAX1 in Ewing's oncogenesis. Functional genomic analysis, validated by quantitative RT-PCR, showed that genes implicated in cell-cycle progression, such as CDK2, CDC6, MCM10 or SKP2 were similarly regulated by EWS/FLI1 and DAX1. These findings indicate that DAX1 is important in the pathogenesis of the Ewing's family of tumors, identify new functions for DAX1 as a cell-cycle progression regulator and open the possibility to new therapeutic approaches based on DAX1 function interference.	[Garcia-Aragoncillo, E.; Carrillo, J.; Agra, N.; Pestana, A.; Alonso, J.] UAM, CSIC, Inst Invest Biomed A Sols, Dept Biol Mol & Celular Canc,Lab Genet & Patol Mo, Madrid 28029, Spain; [Lalli, E.] Univ Nice Sophia Antipolis, CNRS, UMR6097, Inst Pharmacol Mol & Cellulaire, Valbonne, France; [Gomez-Lopez, G.] Hosp Dorrebullon, Fdn Biomed CHUVI, CHU, Vigo, Pontevedra, Spain; [Gomez-Lopez, G.] Ctr Nacl Invest Oncol, Unidad Bioinformat, Madrid, Spain	Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Cote d'Azur; Complexo Hospitalario Universitario de Vigo	Alonso, J (corresponding author), UAM, CSIC, Inst Invest Biomed A Sols, Dept Biol Mol & Celular Canc,Lab Genet & Patol Mo, C Arturo Duperier 4, Madrid 28029, Spain.	fjaviera@iib.uam.es	Lalli, Enzo/F-7052-2013; García, Jaime Carrillo/AAC-5144-2020; Gomez-Lopez, Gonzalo/D-9123-2016; Alonso, Javier/B-6012-2013	Lalli, Enzo/0000-0002-0584-5681; Gomez-Lopez, Gonzalo/0000-0002-4146-0551; Alonso, Javier/0000-0002-6287-8391; Carrillo Garcia, Jaime/0000-0002-2861-3015				Altincicek B, 2000, J BIOL CHEM, V275, P7662, DOI 10.1074/jbc.275.11.7662; Arvand A, 2001, ONCOGENE, V20, P5747, DOI 10.1038/sj.onc.1204598; Ashburner M, 2000, NAT GENET, V25, P25, DOI 10.1038/75556; BARDONI B, 1994, NAT GENET, V7, P497, DOI 10.1038/ng0894-497; Carrillo J, 2007, CLIN CANCER RES, V13, P2429, DOI 10.1158/1078-0432.CCR-06-1762; Crawford PA, 1998, MOL CELL BIOL, V18, P2949, DOI 10.1128/MCB.18.5.2949; de Alava E, 2000, J CLIN ONCOL, V18, P204, DOI 10.1200/JCO.2000.18.1.204; Ferreira BI, 2008, ONCOGENE, V27, P2084, DOI 10.1038/sj.onc.1210845; Guo WW, 1996, J CLIN ENDOCR METAB, V81, P2481, DOI 10.1210/jc.81.7.2481; Hahm KB, 1999, NAT GENET, V23, P222, DOI 10.1038/13854; Holter E, 2002, MOL ENDOCRINOL, V16, P515, DOI 10.1210/me.16.3.515; Hosack DA, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-10-r70; Ito M, 1997, MOL CELL BIOL, V17, P1476, DOI 10.1128/MCB.17.3.1476; Janknecht R, 2005, GENE, V363, P1, DOI 10.1016/j.gene.2005.08.007; Kim S, 2006, MOL CELL BIOL, V26, P2467, DOI 10.1128/MCB.26.7.2467-2478.2006; Kinsey M, 2006, MOL CANCER RES, V4, P851, DOI 10.1158/1541-7786.MCR-06-0090; Kovar H, 2005, SEMIN CANCER BIOL, V15, P189, DOI 10.1016/j.semcancer.2005.01.004; Kovar Heinrich, 1998, Current Opinion in Oncology, V10, P334, DOI 10.1097/00001622-199807000-00010; Lalli E, 2003, MOL ENDOCRINOL, V17, P1445, DOI 10.1210/me.2003-0159; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; Mendiola M, 2006, INT J CANCER, V118, P1381, DOI 10.1002/ijc.21578; Nakatani F, 2003, J BIOL CHEM, V278, P15105, DOI 10.1074/jbc.M211470200; Nishimori H, 2002, ONCOGENE, V21, P8302, DOI 10.1038/sj.onc.1206025; Prieur A, 2004, MOL CELL BIOL, V24, P7275, DOI 10.1128/MCB.24.16.7275-7283.2004; Reiner A, 2003, BIOINFORMATICS, V19, P368, DOI 10.1093/bioinformatics/btf877; Saeed AI, 2003, BIOTECHNIQUES, V34, P374, DOI 10.2144/03342mt01; Song KH, 2004, MOL ENDOCRINOL, V18, P1929, DOI 10.1210/me.2004-0043; Staege MS, 2004, CANCER RES, V64, P8213, DOI 10.1158/0008-5472.CAN-03-4059; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Suzuki T, 2002, ENDOCR RES, V28, P537, DOI 10.1081/ERC-120016835; Tamai KT, 1996, MOL ENDOCRINOL, V10, P1561, DOI 10.1210/me.10.12.1561; Tanaka K, 1997, J CLIN INVEST, V99, P239, DOI 10.1172/JCI119152; WASYLYK B, 1993, EUR J BIOCHEM, V211, P7, DOI 10.1111/j.1432-1033.1993.tb19864.x; Welford SM, 2001, J BIOL CHEM, V276, P41977, DOI 10.1074/jbc.M106757200; ZANARIA E, 1994, NATURE, V372, P635, DOI 10.1038/372635a0; Zhang H, 2000, J BIOL CHEM, V275, P39855, DOI 10.1074/jbc.C000567200	36	66	71	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 9	2008	27	46					6034	6043		10.1038/onc.2008.203	http://dx.doi.org/10.1038/onc.2008.203			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	358BO	18591936				2022-12-28	WOS:000259891600006
J	Gallimore, AM; Simon, AK				Gallimore, A. M.; Simon, A. K.			Positive and negative influences of regulatory T cells on tumour immunity	ONCOGENE			English	Review						tumour; cancer; regulatory T cells; development of regulatory T cells; Th17; Il-23	IMMUNOLOGICAL SELF-TOLERANCE; GROWTH-FACTOR-BETA; THYMIC EPITHELIAL-CELLS; TGF-BETA; CUTTING EDGE; DENDRITIC-CELLS; IN-VIVO; MEDIATED SUPPRESSION; LUNG-CANCER; OVARIAN-CARCINOMA	Clinicians and scientists have long questioned whether the immune system has a role in destroying cancerous tissue. Studies performed in animal models have, however, recently revealed that the immune system can, at least in principle, effectively control tumours. In parallel with these findings, a large body of evidence indicates that although the immune system has the capacity to control tumours, there are also regulatory mechanisms that subdue these responses. A major challenge of tumour immunotherapy, therefore, is to find ways of disabling these regulatory functions while restoring or priming any immune responses that are protective.	[Gallimore, A. M.] Cardiff Univ, Sch Med, Dept Med Biochem & Immunol, Cardiff CF14 4XN, S Glam, Wales; [Simon, A. K.] John Radcliffe Hosp, Weatherall Inst Mol Med, NIHR Biomed Res Ctr, Nuffield Dept Med, Oxford OX3 9DU, England	Cardiff University; University of Oxford	Gallimore, AM (corresponding author), Cardiff Univ, Sch Med, Dept Med Biochem & Immunol, Cardiff CF14 4XN, S Glam, Wales.	gallimoream@cardiff.ac.uk		Simon, Anna Katharina/0000-0002-4077-7995; Gallimore, Awen/0000-0001-6675-7004	Association for International Cancer Research; NIHR Biomedical Research Centre; MRC [G117/488] Funding Source: UKRI; Medical Research Council [G117/488] Funding Source: researchfish	Association for International Cancer Research; NIHR Biomedical Research Centre(National Institute for Health Research (NIHR)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)	AMG is a Medical Research Council Non-Clinical Senior research Fellow and AKS is funded by the Association for International Cancer Research and by the NIHR Biomedical Research Centre. We thank Nick Willcox and Kerstin Luhn for carefully reading the manuscript.	Antony PA, 2005, J IMMUNOL, V174, P2591, DOI 10.4049/jimmunol.174.5.2591; Apostolou I, 2002, NAT IMMUNOL, V3, P756, DOI 10.1038/ni816; Aschenbrenner K, 2007, NAT IMMUNOL, V8, P351, DOI 10.1038/ni1444; Asselin-Paturel C, 1998, INT J CANCER, V77, P7, DOI 10.1002/(SICI)1097-0215(19980703)77:1<7::AID-IJC2>3.0.CO;2-Y; Asseman C, 1999, J EXP MED, V190, P995, DOI 10.1084/jem.190.7.995; Azuma T, 2003, CANCER RES, V63, P4516; Betti M, 2006, ANN ONCOL, V17, P235; Betts G, 2007, BRIT J CANCER, V96, P1849, DOI 10.1038/sj.bjc.6603824; Betts GJ, 2006, ADV DRUG DELIVER REV, V58, P948, DOI 10.1016/j.addr.2006.05.006; Beyer M, 2006, BLOOD, V107, P3940, DOI 10.1182/blood-2005-09-3671; Bopp T, 2007, J EXP MED, V204, P1303, DOI 10.1084/jem.20062129; Brunkow ME, 2001, NAT GENET, V27, P68, DOI 10.1038/83784; Bui JD, 2006, CANCER RES, V66, P7301, DOI 10.1158/0008-5472.CAN-06-0556; Chen ML, 2005, P NATL ACAD SCI USA, V102, P419, DOI 10.1073/pnas.0408197102; Chen WJ, 2003, J EXP MED, V198, P1875, DOI 10.1084/jem.20030152; Clarke SL, 2006, PLOS ONE, V1, DOI 10.1371/journal.pone.0000129; Conrad CT, 1999, J EXP CLIN CANC RES, V18, P225; Curiel TJ, 2004, NAT MED, V10, P942, DOI 10.1038/nm1093; Curti A, 2007, BLOOD, V109, P2871, DOI 10.1182/blood-2006-07-036863; Dannull J, 2005, J CLIN INVEST, V115, P3623, DOI 10.1172/JCI25947; Darnell RB, 2003, NEW ENGL J MED, V349, P1543, DOI 10.1056/NEJMra023009; Davidson TS, 2007, J IMMUNOL, V178, P4022, DOI 10.4049/jimmunol.178.7.4022; Deaglio S, 2007, J EXP MED, V204, P1257, DOI 10.1084/jem.20062512; Derbinski J, 2001, NAT IMMUNOL, V2, P1032, DOI 10.1038/ni723; DiPaolo RJ, 2007, J IMMUNOL, V179, P4685, DOI 10.4049/jimmunol.179.7.4685; Erdman SE, 2005, CANCER RES, V65, P3998, DOI 10.1158/0008-5472.CAN-04-3104; Erdman SE, 2003, AM J PATHOL, V162, P691, DOI 10.1016/S0002-9440(10)63863-1; Fantini MC, 2007, EUR J IMMUNOL, V37, P3155, DOI 10.1002/eji.200737766; Fontenot JD, 2003, NAT IMMUNOL, V4, P330, DOI 10.1038/ni904; Ghiringhelli F, 2005, J EXP MED, V202, P919, DOI 10.1084/jem.20050463; Ghiringhelli F, 2005, J EXP MED, V202, P1075, DOI 10.1084/jem.20051511; Girardi M, 2001, SCIENCE, V294, P605, DOI 10.1126/science.1063916; Gondek DC, 2005, J IMMUNOL, V174, P1783, DOI 10.4049/jimmunol.174.4.1783; Hsieh CS, 2004, IMMUNITY, V21, P267, DOI 10.1016/j.immuni.2004.07.009; Ichihara F, 2003, CLIN CANCER RES, V9, P4404; Itoh M, 1999, J IMMUNOL, V162, P5317; Jordan MS, 2001, NAT IMMUNOL, V2, P301, DOI 10.1038/86302; Kearley J, 2005, J EXP MED, V202, P1539, DOI 10.1084/jem.20051166; Kelchtermans H, 2005, ARTHRITIS RES THER, V7, pR402, DOI 10.1186/ar1500; Kryczek I, 2000, BRIT J CANCER, V82, P621; Kryczek I, 2007, J IMMUNOL, V178, P6730, DOI 10.4049/jimmunol.178.11.6730; La Cava A, 2006, TRENDS IMMUNOL, V27, P322, DOI 10.1016/j.it.2006.05.003; Langowski JL, 2006, NATURE, V442, P461, DOI 10.1038/nature04808; Leong PP, 2006, IMMUNOL LETT, V102, P229, DOI 10.1016/j.imlet.2005.09.006; Lewkowicz P, 2006, J IMMUNOL, V177, P7155, DOI 10.4049/jimmunol.177.10.7155; Lim HW, 2005, J IMMUNOL, V175, P4180, DOI 10.4049/jimmunol.175.7.4180; Liu VC, 2007, J IMMUNOL, V178, P2883, DOI 10.4049/jimmunol.178.5.2883; Nishikawa H, 2003, P NATL ACAD SCI USA, V100, P10902, DOI 10.1073/pnas.1834479100; Numasaki M, 2003, BLOOD, V101, P2620, DOI 10.1182/blood-2002-05-1461; Nurieva R, 2007, NATURE, V448, P480, DOI 10.1038/nature05969; Pacholczyk R, 2007, IMMUNITY, V27, P493, DOI 10.1016/j.immuni.2007.07.019; Peluso I, 2007, J IMMUNOL, V178, P732, DOI 10.4049/jimmunol.178.2.732; Piccirillo CA, 2001, J IMMUNOL, V167, P1137, DOI 10.4049/jimmunol.167.3.1137; Romagnani C, 2005, EUR J IMMUNOL, V35, P2452, DOI 10.1002/eji.200526069; Roncador G, 2005, LEUKEMIA, V19, P2247, DOI 10.1038/sj.leu.2403965; Sakaguchi S, 2004, ANNU REV IMMUNOL, V22, P531, DOI 10.1146/annurev.immunol.21.120601.141122; Sharma S, 2005, CANCER RES, V65, P5211, DOI 10.1158/0008-5472.CAN-05-0141; Simon AK, 2007, EUR J IMMUNOL, V37, P758, DOI 10.1002/eji.200636593; Smyth MJ, 2006, ADV IMMUNOL, V90, P1, DOI 10.1016/S0065-2776(06)90001-7; Smyth MJ, 2006, J IMMUNOL, V176, P1582, DOI 10.4049/jimmunol.176.3.1582; Somasundaram R, 2002, CANCER RES, V62, P5267; Taams LS, 2005, HUM IMMUNOL, V66, P222, DOI 10.1016/j.humimm.2004.12.006; Tadokoro CE, 2006, J EXP MED, V203, P505, DOI 10.1084/jem.20050783; Takahashi T, 2000, J EXP MED, V192, P303, DOI 10.1084/jem.192.2.303; Tang QZ, 2006, NAT IMMUNOL, V7, P83, DOI 10.1038/ni1289; Trzonkowski P, 2004, CLIN IMMUNOL, V112, P258, DOI 10.1016/j.clim.2004.04.003; Valzasina B, 2006, CANCER RES, V66, P4488, DOI 10.1158/0008-5472.CAN-05-4217; Veldhoen M, 2006, NAT IMMUNOL, V7, P1151, DOI 10.1038/ni1391; Wang G, 2003, CANCER RES, V63, P9016; Wang HY, 2004, IMMUNITY, V20, P107, DOI 10.1016/S1074-7613(03)00359-5; Wang ZJ, 2006, J CLIN INVEST, V116, P2434, DOI 10.1172/JCI25826; Wildin RS, 2001, NAT GENET, V27, P18, DOI 10.1038/83707; Wilson NJ, 2007, NAT IMMUNOL, V8, P950, DOI 10.1038/ni1497; Yee C, 2000, J EXP MED, V192, P1637, DOI 10.1084/jem.192.11.1637; Zeng R, 2005, J EXP MED, V201, P139, DOI 10.1084/jem.20041057; Zheng SG, 2007, J IMMUNOL, V178, P2018, DOI 10.4049/jimmunol.178.4.2018; Zhou G, 2007, J IMMUNOL, V178, P2155, DOI 10.4049/jimmunol.178.4.2155; Zhou LA, 2007, NAT IMMUNOL, V8, P967, DOI 10.1038/ni1488	78	53	56	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 6	2008	27	45					5886	5893		10.1038/onc.2008.269	http://dx.doi.org/10.1038/onc.2008.269			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	355QE	18836469				2022-12-28	WOS:000259722600003
J	LaCasse, EC; Mahoney, DJ; Cheung, HH; Plenchette, S; Baird, S; Korneluk, RG				LaCasse, E. C.; Mahoney, D. J.; Cheung, H. H.; Plenchette, S.; Baird, S.; Korneluk, R. G.			IAP-targeted therapies for cancer	ONCOGENE			English	Review						XIAP; cIAP1; cIAP2; survivin; livin; birc	X-LINKED INHIBITOR; KAPPA-B ACTIVATION; UBIQUITIN-PROTEIN LIGASE; NECROSIS-FACTOR-ALPHA; MITOCHONDRIA-DERIVED ACTIVATOR; SMALL-MOLECULE ANTAGONISTS; DOMINANT-NEGATIVE ISOFORM; ANTI-APOPTOTIC PROTEINS; CELLS IN-VITRO; TNF-ALPHA	DNA damage, chromosomal abnormalities, oncogene activation, viral infection, substrate detachment and hypoxia can all trigger apoptosis in normal cells. However, cancer cells acquire mutations that allow them to survive these threats that are part and parcel of the transformation process or that may affect the growth and dissemination of the tumor. Eventually, cancer cells accumulate further mutations that make them resistant to apoptosis mediated by standard cytotoxic chemotherapy or radiotherapy. The inhibitor of apoptosis (IAP) family members, defined by the presence of a baculovirus IAP repeat (BIR) protein domain, are key regulators of cytokinesis, apoptosis and signal transduction. Specific IAPs regulate either cell division, caspase activity or survival pathways mediated through binding to their BIR domains, and/or through their ubiquitin-ligase RING domain activity. These protein-protein interactions and post-translational modi. cations are the subject of intense investigations that shed light on how these proteins contribute to oncogenesis and resistance to therapy. In the past several years, we have seen multiple approaches of IAP antagonism enter the clinic, and the rewards of such strategies are about to reap benefit. Significantly, small molecule pan-IAP antagonists that mimic an endogenous inhibitor of the IAPs, called Smac, have demonstrated an unexpected ability to sensitize cancer cells to tumor necrosis factor-alpha and to promote autocrine or paracrine production of this cytokine by the tumor cell and possibly, other cells too. This review will focus on these and other developmental therapeutics that target the IAPs in cancer.	[LaCasse, E. C.; Mahoney, D. J.; Cheung, H. H.; Plenchette, S.; Baird, S.; Korneluk, R. G.] Childrens Hosp Eastern Ontario, Apoptosis Res Ctr, Ottawa, ON K1H 8L1, Canada; [LaCasse, E. C.; Mahoney, D. J.; Cheung, H. H.; Plenchette, S.; Baird, S.; Korneluk, R. G.] Univ Ottawa, Dept Biochem Microbiol & Immunol, Ottawa, ON, Canada	University of Ottawa; Children's Hospital of Eastern Ontario; University of Ottawa	LaCasse, EC (corresponding author), Childrens Hosp Eastern Ontario, Apoptosis Res Ctr, CHEO RI2,401 Smyth Rd, Ottawa, ON K1H 8L1, Canada.	eric@arc.cheo.ca	Plenchette, Stéphanie/AAA-5155-2021	Plenchette, Stéphanie/0000-0003-4483-9206	Canadian Institutes of Health Research (CIHR); HHMI; Michael Cuccione Foundation; CIHR Institute of Cancer Research; Natural Sciences and Engineering Research Council of Canada; Optimist Club's Campaign against Childhood Cancers	Canadian Institutes of Health Research (CIHR)(Canadian Institutes of Health Research (CIHR)); HHMI(Howard Hughes Medical Institute); Michael Cuccione Foundation; CIHR Institute of Cancer Research(Canadian Institutes of Health Research (CIHR)); Natural Sciences and Engineering Research Council of Canada(Natural Sciences and Engineering Research Council of Canada (NSERC)CGIAR); Optimist Club's Campaign against Childhood Cancers	RGKis a Howard Hughes Medical Institute (HHMI) International Research Scholar and a Fellow of the Royal Society of Canada. RGK is supported by funds from the Canadian Institutes of Health Research (CIHR), and the HHMI. HHC is the recipient of a Michael Cuccione Foundation and CIHR Institute of Cancer Research postdoctoral fellowship. SP and DJM are recipients of a Natural Sciences and Engineering Research Council of Canada postdoctoral fellowships. ECL is supported by funds from the Optimist Club's Campaign against Childhood Cancers.	Adida C, 1998, AM J PATHOL, V152, P43; Adrain C, 2001, EMBO J, V20, P6627, DOI 10.1093/emboj/20.23.6627; Altieri DC, 2008, NAT REV CANCER, V8, P61, DOI 10.1038/nrc2293; Altieri DC, 2001, TRENDS MOL MED, V7, P542, DOI 10.1016/S1471-4914(01)02243-2; Amantana A, 2004, MOL CANCER THER, V3, P699; Ambrosini G, 1997, NAT MED, V3, P917, DOI 10.1038/nm0897-917; Ambrosini G, 1998, J BIOL CHEM, V273, P11177, DOI 10.1074/jbc.273.18.11177; Annunziata CM, 2007, CANCER CELL, V12, P115, DOI 10.1016/j.ccr.2007.07.004; Ansell SM, 2004, LEUKEMIA, V18, P616, DOI 10.1038/sj.leu.2403281; Arnt CR, 2002, J BIOL CHEM, V277, P44236, DOI 10.1074/jbc.M207578200; Arora V, 2007, J BIOL CHEM, V282, P26202, DOI 10.1074/jbc.M700776200; Ashhab Y, 2001, FEBS LETT, V495, P56, DOI 10.1016/S0014-5793(01)02366-3; Baens M, 2000, AM J PATHOL, V156, P1433, DOI 10.1016/S0002-9440(10)65012-2; Baens M, 2006, CANCER RES, V66, P5270, DOI 10.1158/0008-5472.CAN-05-4590; Bauvois B, 2006, MED RES REV, V26, P88, DOI 10.1002/med.20044; Bertrand MJM, 2008, MOL CELL, V30, P689, DOI 10.1016/j.molcel.2008.05.014; Bockbrader KM, 2005, ONCOGENE, V24, P7381, DOI 10.1038/sj.onc.1208888; Brennan DJ, 2008, CLIN CANCER RES, V14, P2681, DOI 10.1158/1078-0432.CCR-07-1760; Bria E, 2008, EJSO-EUR J SURG ONC, V34, P593, DOI 10.1016/j.ejso.2007.06.002; Burri L, 2005, MOL BIOL CELL, V16, P2926, DOI 10.1091/mbc.E04-12-1086; Buzzai M, 2007, CANCER RES, V67, P6745, DOI 10.1158/0008-5472.CAN-06-4447; Cao C, 2004, ONCOGENE, V23, P7047, DOI 10.1038/sj.onc.1207929; Carter BZ, 2005, BLOOD, V105, P4043, DOI 10.1182/blood-2004-08-3168; Chai JJ, 2000, NATURE, V406, P855, DOI 10.1038/35022514; Chang CC, 2004, P NATL ACAD SCI USA, V101, P13239, DOI 10.1073/pnas.0405407101; Chantalat L, 2000, MOL CELL, V6, P183, DOI 10.1016/S1097-2765(00)00019-8; Chastagner P, 2006, EMBO REP, V7, P1147, DOI 10.1038/sj.embor.7400822; Chen JY, 2006, BIOORG MED CHEM LETT, V16, P5805, DOI 10.1016/j.bmcl.2006.08.072; Chen ZH, 1999, BIOCHEM BIOPH RES CO, V264, P847, DOI 10.1006/bbrc.1999.1585; Cheung HH, 2008, MOL BIOL CELL, V19, P2729, DOI 10.1091/mbc.E08-01-0107; Cheung HH, 2006, EXP CELL RES, V312, P2347, DOI 10.1016/j.yexcr.2006.03.027; Cheung HH, 2006, CLIN CANCER RES, V12, P3238, DOI 10.1158/1078-0432.CCR-06-0817; Chu ZL, 1997, P NATL ACAD SCI USA, V94, P10057, DOI 10.1073/pnas.94.19.10057; Chung SK, 2007, GASTROENTEROLOGY, V132, P2459, DOI 10.1053/j.gastro.2007.04.024; Cillessen SAGM, 2008, BLOOD, V111, P369, DOI 10.1182/blood-2007-04-085480; Clem RJ, 2001, J BIOL CHEM, V276, P7602, DOI 10.1074/jbc.M010259200; Conte D, 2006, MOL CELL BIOL, V26, P699, DOI 10.1128/MCB.26.2.699-708.2006; Conway EM, 2000, BLOOD, V95, P1435, DOI 10.1182/blood.V95.4.1435.004k01_1435_1442; Conze DB, 2005, MOL CELL BIOL, V25, P3348, DOI 10.1128/MCB.25.8.3348-3356.2005; Coornaert B, 2008, NAT IMMUNOL, V9, P263, DOI 10.1038/ni1561; Creagh EM, 2004, J BIOL CHEM, V279, P26906, DOI 10.1074/jbc.M313859200; Crnkovic-Mertens I, 2006, J MOL MED, V84, P232, DOI 10.1007/s00109-005-0021-5; Cummings J, 2006, BRIT J CANCER, V95, P42, DOI 10.1038/sj.bjc.6603220; Dai ZY, 2003, HUM MOL GENET, V12, P791, DOI 10.1093/hmg/ddg083; Dan HC, 2004, J BIOL CHEM, V279, P5405, DOI 10.1074/jbc.M312044200; Danson S, 2007, CURR CANCER DRUG TAR, V7, P785, DOI 10.2174/156800907783220471; Davoodi J, 2004, J BIOL CHEM, V279, P40622, DOI 10.1074/jbc.M405963200; Dean EJ, 2007, CANCER TREAT REV, V33, P203, DOI 10.1016/j.ctrv.2006.11.002; Deveraux QL, 1997, NATURE, V388, P300, DOI 10.1038/40901; Deveraux QL, 1998, EMBO J, V17, P2215, DOI 10.1093/emboj/17.8.2215; Dierlamm J, 1999, BLOOD, V93, P3601, DOI 10.1182/blood.V93.11.3601; Dohi T, 2004, J BIOL CHEM, V279, P34087, DOI 10.1074/jbc.C400236200; Dohi T, 2007, MOL CELL, V27, P17, DOI 10.1016/j.molcel.2007.06.004; Du CY, 2000, CELL, V102, P33, DOI 10.1016/S0092-8674(00)00008-8; Du MQ, 2007, J CLIN EXP HEMATOP, V47, P31, DOI 10.3960/jslrt.47.31; Duckett CS, 1996, EMBO J, V15, P2685, DOI 10.1002/j.1460-2075.1996.tb00629.x; Ea CK, 2006, MOL CELL, V22, P245, DOI 10.1016/j.molcel.2006.03.026; Eckelman BP, 2006, J BIOL CHEM, V281, P3254, DOI 10.1074/jbc.M510863200; Eckelman BP, 2006, EMBO REP, V7, P988, DOI 10.1038/sj.embor.7400795; Ekert PG, 2005, CURR OPIN CELL BIOL, V17, P626, DOI 10.1016/j.ceb.2005.09.001; Engelsma D, 2007, TRAFFIC, V8, P1495, DOI 10.1111/j.1600-0854.2007.00629.x; Erl W, 1999, CIRC RES, V84, P668, DOI 10.1161/01.RES.84.6.668; Evan GI, 2001, NATURE, V411, P342, DOI 10.1038/35077213; Ferreira CG, 2001, ANN ONCOL, V12, P799, DOI 10.1023/A:1011167113067; Ferreira CG, 2001, CLIN CANCER RES, V7, P2468; Fong WG, 2000, GENOMICS, V70, P113, DOI 10.1006/geno.2000.6364; Fortugno P, 2003, P NATL ACAD SCI USA, V100, P13791, DOI 10.1073/pnas.2434345100; Fu J, 2003, J BIOL CHEM, V278, P52660, DOI 10.1074/jbc.M308036200; Fukuda S, 2006, MOL CANCER THER, V5, P1087, DOI 10.1158/1535-7163.MCT-05-0375; Fulda S, 2002, NAT MED, V8, P808, DOI 10.1038/nm735; Gaither A, 2007, CANCER RES, V67, P11493, DOI 10.1158/0008-5472.CAN-07-5173; Galderisi U, 1999, J CELL PHYSIOL, V181, P251, DOI 10.1002/(SICI)1097-4652(199911)181:2<251::AID-JCP7>3.0.CO;2-D; Galvan V, 2004, FEBS LETT, V558, P57, DOI 10.1016/S0014-5793(03)01488-1; Gleave M, 2002, CANCER METAST REV, V21, P79, DOI 10.1023/A:1020172424152; Goncalves RB, 2008, BIOCHEMISTRY-US, V47, P3832, DOI 10.1021/bi702248n; Grossman D, 2001, P NATL ACAD SCI USA, V98, P635, DOI 10.1073/pnas.230450097; Guan TJ, 2007, ACTA PHARMACOL SIN, V28, P1984, DOI 10.1111/j.1745-7254.2007.00675.x; Guo F, 2002, BLOOD, V99, P3419, DOI 10.1182/blood.V99.9.3419; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hao YY, 2004, NAT CELL BIOL, V6, P849, DOI 10.1038/ncb1159; Hauser HP, 1998, J CELL BIOL, V141, P1415, DOI 10.1083/jcb.141.6.1415; Hegde R, 2002, J BIOL CHEM, V277, P432, DOI 10.1074/jbc.M109721200; Hegde R, 2003, J BIOL CHEM, V278, P38699, DOI 10.1074/jbc.M303179200; Hess CJ, 2007, J CLIN ONCOL, V25, P1209, DOI 10.1200/JCO.2006.08.4061; Hinds MG, 1999, NAT STRUCT BIOL, V6, P648; Hochstrasser M, 2006, CELL, V124, P27, DOI 10.1016/j.cell.2005.12.025; Hong SY, 2000, J BIOL CHEM, V275, P18022, DOI 10.1074/jbc.M001202200; Hosokawa Y, 2005, APOPTOSIS, V10, P25, DOI 10.1007/s10495-005-6059-6; Hu HY, 2008, J LEUKOCYTE BIOL, V83, P393, DOI 10.1189/jlb.0507282; Hu SM, 2006, CELL CYCLE, V5, P1438, DOI 10.4161/cc.5.13.2866; Hu SM, 2006, J CLIN INVEST, V116, P174, DOI 10.1172/JCI25641; Hu YP, 2003, CLIN CANCER RES, V9, P2826; Huang RCC, 2006, SEMIN ONCOL, V33, P479, DOI 10.1053/j.seminoncol.2006.04.010; Huang YH, 2003, J BIOL CHEM, V278, P49517, DOI 10.1074/jbc.M310061200; Hunter AM, 2007, APOPTOSIS, V12, P1543, DOI 10.1007/s10495-007-0087-3; Hunter T, 2007, MOL CELL, V28, P730, DOI 10.1016/j.molcel.2007.11.019; Imoto I, 2001, CANCER RES, V61, P6629; Isakovic A, 2007, CELL MOL LIFE SCI, V64, P1290, DOI 10.1007/s00018-007-7080-4; Islam A, 2000, MED PEDIATR ONCOL, V35, P550, DOI 10.1002/1096-911X(20001201)35:6<550::AID-MPO12>3.0.CO;2-Y; Jansen B, 2002, LANCET ONCOL, V3, P672, DOI 10.1016/S1470-2045(02)00903-8; Jeyaprakash AA, 2007, CELL, V131, P271, DOI 10.1016/j.cell.2007.07.045; Jiang XY, 2001, J CELL BIOCHEM, V83, P342, DOI 10.1002/jcb.1228; Jin C, 2002, NAT REV MOL CELL BIO, V3, P453, DOI 10.1038/nrm832; Kandasamy K, 2003, CANCER RES, V63, P1712; Kanneganti TD, 2007, IMMUNITY, V27, P549, DOI 10.1016/j.immuni.2007.10.002; Kappler M, 2007, CANCER GENE THER, V14, P994, DOI 10.1038/sj.cgt.7701090; Karikari CA, 2007, MOL CANCER THER, V6, P957, DOI 10.1158/1535-7163.MCT-06-0634; Kasof GM, 2001, J BIOL CHEM, V276, P3238, DOI 10.1074/jbc.M003670200; Kaur S, 2005, J BIOL CHEM, V280, P38599, DOI 10.1074/jbc.M505671200; Keats JJ, 2007, CANCER CELL, V12, P131, DOI 10.1016/j.ccr.2007.07.003; Kipp RA, 2002, BIOCHEMISTRY-US, V41, P7344, DOI 10.1021/bi0121454; Kleinberg L, 2007, CANCER, V109, P228, DOI 10.1002/cncr.22426; Knauer SK, 2007, CELL CYCLE, V6, P1502; Kobayashi K, 1999, P NATL ACAD SCI USA, V96, P1457, DOI 10.1073/pnas.96.4.1457; Koh HJ, 2008, CURR OPIN CLIN NUTR, V11, P227, DOI 10.1097/MCO.0b013e3282fb7b76; Lacasse EC, 2005, ANN NY ACAD SCI, V1058, P215, DOI 10.1196/annals.1359.032; LaCasse EC, 1998, ONCOGENE, V17, P3247, DOI 10.1038/sj.onc.1202569; Lagace M, 2001, GENOMICS, V77, P181, DOI 10.1006/geno.2001.6635; Leaman DW, 2002, J BIOL CHEM, V277, P28504, DOI 10.1074/jbc.M204851200; Lee TH, 2004, J BIOL CHEM, V279, P33185, DOI 10.1074/jbc.M404206200; Li F, 2005, BRIT J CANCER, V92, P212, DOI 10.1038/sj.bjc.6602340; Li FZ, 1999, NAT CELL BIOL, V1, P461, DOI 10.1038/70242; Li JL, 2001, ENDOCRINOLOGY, V142, P370, DOI 10.1210/en.142.1.370; Li L, 2004, SCIENCE, V305, P1471, DOI 10.1126/science.1098231; Li XM, 2002, NATURE, V416, P345, DOI 10.1038/416345a; Lima RT, 2004, CANCER GENE THER, V11, P309, DOI 10.1038/sj.cgt.7700706; Liston P, 2003, ONCOGENE, V22, P8568, DOI 10.1038/sj.onc.1207101; Liston P, 2001, NAT CELL BIOL, V3, P128, DOI 10.1038/35055027; Liston P, 1996, NATURE, V379, P349, DOI 10.1038/379349a0; Liu SS, 2001, EUR J CANCER, V37, P1104, DOI 10.1016/S0959-8049(01)00085-5; Liu ZH, 2000, NATURE, V408, P1004, DOI 10.1038/35050006; Lu M, 2007, MOL CELL, V26, P689, DOI 10.1016/j.molcel.2007.05.006; Lucas PC, 2007, ONCOGENE, V26, P5643, DOI 10.1038/sj.onc.1210342; Madesh M, 2002, J BIOL CHEM, V277, P5651, DOI 10.1074/jbc.M108171200; Mahoney DJ, 2008, P NATL ACAD SCI USA, V105, P11778, DOI 10.1073/pnas.0711122105; Mao HL, 2007, PHARMACOL RES, V56, P483, DOI 10.1016/j.phrs.2007.09.010; Mariathasan S, 2007, NAT REV IMMUNOL, V7, P31, DOI 10.1038/nri1997; Martin Seamus J., 2001, Trends in Cell Biology, V11, P188, DOI 10.1016/S0962-8924(01)01971-7; Martins LM, 2002, J BIOL CHEM, V277, P439, DOI 10.1074/jbc.M109784200; McManus DC, 2004, ONCOGENE, V23, P8105, DOI 10.1038/sj.onc.1207967; Meli M, 2006, J MED CHEM, V49, P7721, DOI 10.1021/jm060836y; Mesri M, 2001, J CLIN INVEST, V108, P981, DOI 10.1172/JCI12983; Micali OC, 2007, BMC CANCER, V7, DOI 10.1186/1471-2407-7-52; Mizutani Y, 2007, INT J ONCOL, V30, P919; Mola G, 2007, J MOL BIOL, V366, P1055, DOI 10.1016/j.jmb.2006.11.089; Mosley JD, 2006, BIOCHEM BIOPH RES CO, V348, P1174, DOI 10.1016/j.bbrc.2006.07.176; Nachmias B, 2007, EUR J IMMUNOL, V37, P3467, DOI 10.1002/eji.200636600; Nakahara T, 2007, CANCER RES, V67, P8014, DOI 10.1158/0008-5472.CAN-07-1343; Ng CP, 2002, MOL CANCER THER, V1, P1051; Nikolovska-Coleska Z, 2004, J MED CHEM, V47, P2430, DOI 10.1021/jm030420+; Noels H, 2007, J BIOL CHEM, V282, P10180, DOI 10.1074/jbc.M611038200; Noton EA, 2006, J BIOL CHEM, V281, P1286, DOI 10.1074/jbc.M508773200; O'Connor DS, 2000, P NATL ACAD SCI USA, V97, P13103, DOI 10.1073/pnas.240390697; O'Donnell MA, 2007, CURR BIOL, V17, P418, DOI 10.1016/j.cub.2007.01.027; Obiol-Pardo C, 2008, J MOL RECOGNIT, V21, P190, DOI 10.1002/jmr.887; Olie RA, 2000, CANCER RES, V60, P2805; Oost TK, 2004, J MED CHEM, V47, P4417, DOI 10.1021/jm040037k; Pannone G, 2007, HISTOL HISTOPATHOL, V22, P1241, DOI 10.14670/HH-22.1241; Park CM, 2005, BIOORG MED CHEM LETT, V15, P771, DOI 10.1016/j.bmcl.2004.11.010; Petersen SL, 2007, CANCER CELL, V12, P445, DOI 10.1016/j.ccr.2007.08.029; PINHO MB, 2008, UROL ONCOL; Piras F, 2007, HISTOPATHOLOGY, V50, P835, DOI 10.1111/j.1365-2559.2007.02695.x; Plenchette S, 2004, BLOOD, V104, P2035, DOI 10.1182/blood-2004-01-0065; Plenchette S, 2007, CURR OPIN INVEST DR, V8, P469; Plescia J, 2005, CANCER CELL, V7, P457, DOI 10.1016/j.ccr.2005.03.035; Pohl C, 2008, CELL, V132, P832, DOI 10.1016/j.cell.2008.01.012; Qi R, 2007, CANCER GENE THER, V14, P82, DOI 10.1038/sj.cgt.7700992; Qiu XB, 2005, J BIOL CHEM, V280, P174, DOI 10.1074/jbc.M411430200; Ramp U, 2004, HUM PATHOL, V35, P1022, DOI 10.1016/j.humpath.2004.03.011; Rebeaud F, 2008, NAT IMMUNOL, V9, P272, DOI 10.1038/ni1568; Remstein ED, 2000, AM J PATHOL, V156, P1183, DOI 10.1016/S0002-9440(10)64988-7; Reu FJ, 2006, J CLIN ONCOL, V24, P3771, DOI 10.1200/JCO.2005.03.4074; Rhee I, 2002, NATURE, V416, P552, DOI 10.1038/416552a; Richter BWM, 2001, MOL CELL BIOL, V21, P4292, DOI 10.1128/MCB.21.13.4292-4301.2001; Rigaud S, 2006, NATURE, V444, P110, DOI 10.1038/nature05257; Roberts DL, 2001, J CELL BIOL, V153, P221, DOI 10.1083/jcb.153.1.221; Robertson AJ, 2006, DEV BIOL, V300, P321, DOI 10.1016/j.ydbio.2006.08.053; Rothe M, 1995, CELL, V83, P1243, DOI 10.1016/0092-8674(95)90149-3; ROY N, 1995, CELL, V80, P167, DOI 10.1016/0092-8674(95)90461-1; Ruchaud S, 2007, NAT REV MOL CELL BIO, V8, P798, DOI 10.1038/nrm2257; Sagaert X, 2006, HAEMATOLOGICA, V91, P1693; Samuel T, 2006, J BIOL CHEM, V281, P1080, DOI 10.1074/jbc.M509381200; Sanna MG, 2002, MOL CELL BIOL, V22, P1754, DOI 10.1128/MCB.22.6.1754-1766.2002; Sanna MG, 2002, J BIOL CHEM, V277, P30454, DOI 10.1074/jbc.M203312200; Sanna MG, 1998, P NATL ACAD SCI USA, V95, P6015, DOI 10.1073/pnas.95.11.6015; Santoro MM, 2007, NAT GENET, V39, P1397, DOI 10.1038/ng.2007.8; Sato S, 2008, BIOORG MED CHEM LETT, V18, P3354, DOI 10.1016/j.bmcl.2008.04.031; Schimmer AD, 2004, CANCER CELL, V5, P25, DOI 10.1016/S1535-6108(03)00332-5; Schulze-Luehrmann J, 2006, IMMUNITY, V25, P701, DOI 10.1016/j.immuni.2006.10.010; Seligson DB, 2007, CLIN CANCER RES, V13, P6056, DOI 10.1158/1078-0432.CCR-07-0960; Shankar SL, 2001, J NEUROCHEM, V79, P426, DOI 10.1046/j.1471-4159.2001.00596.x; Shim JH, 2005, GENE DEV, V19, P2668, DOI 10.1101/gad.1360605; Shin H, 2005, BIOCHEM J, V385, P1, DOI 10.1042/BJ20041107; Shin H, 2003, BIOCHEM J, V373, P965, DOI 10.1042/BJ20030583; Shu HB, 1996, P NATL ACAD SCI USA, V93, P13973, DOI 10.1073/pnas.93.24.13973; Silke J, 2005, P NATL ACAD SCI USA, V102, P16182, DOI 10.1073/pnas.0502828102; Span PN, 2006, CLIN CHEM, V52, P1693, DOI 10.1373/clinchem.2006.071613; Srinivasula SM, 2001, NATURE, V410, P112, DOI 10.1038/35065125; Stamm S, 2006, NUCLEIC ACIDS RES, V34, pD46, DOI 10.1093/nar/gkj031; Stauber RH, 2007, CANCER RES, V67, P5999, DOI 10.1158/0008-5472.CAN-07-0494; Sun CH, 1999, NATURE, V401, P818, DOI 10.1038/44617; Suzuki Y, 2001, P NATL ACAD SCI USA, V98, P8662, DOI 10.1073/pnas.161506698; Swinney DC, 2002, J BIOL CHEM, V277, P23573, DOI 10.1074/jbc.M200842200; Swisher SG, 1999, J NATL CANCER I, V91, P763, DOI 10.1093/jnci/91.9.763; Tamm I, 2000, CLIN CANCER RES, V6, P1796; Ting JPY, 2008, NAT REV IMMUNOL, V8, P372, DOI 10.1038/nri2296; Towler MC, 2007, CIRC RES, V100, P328, DOI 10.1161/01.RES.0000256090.42690.05; Tu SP, 2003, CANCER RES, V63, P7724; Uren AG, 2000, MOL CELL, V6, P961, DOI 10.1016/S1097-2765(05)00086-9; Uren AG, 1996, P NATL ACAD SCI USA, V93, P4974, DOI 10.1073/pnas.93.10.4974; Varambally S, 2005, CANCER CELL, V8, P393, DOI 10.1016/j.ccr.2005.10.001; Varfolomeev E, 2007, CELL, V131, P669, DOI 10.1016/j.cell.2007.10.030; Varfolomeev E, 2006, J BIOL CHEM, V281, P29022, DOI 10.1074/jbc.M605116200; Vaux DL, 2005, NAT REV MOL CELL BIO, V6, P287, DOI 10.1038/nrm1621; Vega F, 2001, ADV ANAT PATHOL, V8, P313, DOI 10.1097/00125480-200111000-00001; Verhagen AM, 2007, CELL DEATH DIFFER, V14, P348, DOI 10.1038/sj.cdd.4402001; Verhagen AM, 2000, CELL, V102, P43, DOI 10.1016/S0092-8674(00)00009-X; Verhagen AM, 2002, J BIOL CHEM, V277, P445, DOI 10.1074/jbc.M109891200; Vince JE, 2008, J CELL BIOL, V182, P171, DOI 10.1083/jcb.200801010; Vince JE, 2007, CELL, V131, P682, DOI 10.1016/j.cell.2007.10.037; Vucic D, 2000, CURR BIOL, V10, P1359, DOI 10.1016/S0960-9822(00)00781-8; Vucic D, 2002, J BIOL CHEM, V277, P12275, DOI 10.1074/jbc.M112045200; Vucic D, 2007, CLIN CANCER RES, V13, P5995, DOI 10.1158/1078-0432.CCR-07-0729; Wang C, 2001, NATURE, V412, P346, DOI 10.1038/35085597; Wang JD, 2006, J BIOL CHEM, V281, P2451, DOI 10.1074/jbc.M505890200; Wang JD, 2006, GASTROENTEROLOGY, V130, P747, DOI 10.1053/j.gastro.2005.12.017; Wang L, 2008, CELL, V133, P693, DOI 10.1016/j.cell.2008.03.036; Wang ZL, 2004, J BIOL CHEM, V279, P48168, DOI 10.1074/jbc.M405022200; WEGENER E, 2007, SCI STKE, pPE21; Wright ME, 2000, FEBS LETT, V481, P13, DOI 10.1016/S0014-5793(00)01962-1; Wu CJ, 2006, NAT CELL BIOL, V8, P398, DOI 10.1038/ncb1384; Wu CJ, 2005, EMBO J, V24, P1886, DOI 10.1038/sj.emboj.7600649; Wu G, 2000, NATURE, V408, P1008, DOI 10.1038/35050012; Wu MX, 2005, MODERN PATHOL, V18, P1618, DOI 10.1038/modpathol.3800478; Wu TYH, 2003, CHEM BIOL, V10, P759, DOI 10.1016/S1074-5521(03)00157-1; Xia Y, 2006, MOL CELL BIOCHEM, V286, P67, DOI 10.1007/s11010-005-9094-2; Xu L, 2007, MOL CELL, V28, P914, DOI 10.1016/j.molcel.2007.10.027; Yamamoto K, 2004, LEUKEMIA RES, V28, P1203, DOI 10.1016/j.leukres.2004.03.020; Yan Y, 2004, BRIT J CANCER, V91, P1349, DOI 10.1038/sj.bjc.6602127; Yang D, 2004, P NATL ACAD SCI USA, V101, P15100, DOI 10.1073/pnas.0406665101; Yang L, 2003, CANCER RES, V63, P6815; Yang QH, 2004, J BIOL CHEM, V279, P16963, DOI 10.1074/jbc.M401253200; Yang Y, 2000, SCIENCE, V288, P874, DOI 10.1126/science.288.5467.874; Yin W, 2006, MODERN PATHOL, V19, P1487, DOI 10.1038/modpathol.3800675; Zender L, 2006, CELL, V125, P1253, DOI 10.1016/j.cell.2006.05.030; Zhao YG, 2007, J BIOL CHEM, V282, P7777, DOI 10.1074/jbc.M609146200; Zheng D, 2008, AM J PHYSIOL-CELL PH, V294, pC126, DOI 10.1152/ajpcell.00464.2007; Zhou HL, 2005, CANCER CELL, V7, P425, DOI 10.1016/j.ccr.2005.04.012; Zou B, 2006, GASTROENTEROLOGY, V131, P1835, DOI 10.1053/j.gastro.2006.09.050	249	392	417	0	54	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT	2008	27	48					6252	6275		10.1038/onc.2008.302	http://dx.doi.org/10.1038/onc.2008.302			24	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	361YB	18931692				2022-12-28	WOS:000260162800007
J	Dotto, GP				Dotto, G. P.			Notch tumor suppressor function	ONCOGENE			English	Review						cancer stem cells; p53; p63; Rho signaling; epigenetics; keratinocytes	NF-KAPPA-B; CERVICAL-CANCER CELLS; NEGATIVE TRANSCRIPTIONAL REGULATOR; KERATINOCYTE STEM-CELLS; RBP-J-KAPPA; SIGNALING PATHWAYS; BETA-CATENIN; GROWTH ARREST; HAIR FOLLICLE; P53 HOMOLOG	Cancer development results from deregulated control of stem cell populations and alterations in their surrounding environment. Notch signaling is an important form of direct cell-cell communication involved in cell fate determination, stem cell potential and lineage commitment. The biological function of this pathway is critically context dependent. Here we review the pro-differentiation role and tumor suppressing function of this pathway, as revealed by loss-of-function in keratinocytes and skin, downstream of p53 and in cross-connection with other determinants of stem cell potential and/or tumor formation, such as p63 and Rho/CDC42 effectors. The possibility that Notch signaling elicits a duality of signals, involved in growth/differentiation control and cell survival will be discussed, in the context of novel approaches for cancer therapy.	Univ Lausanne, Inst Biochem, CH-1066 Epalinges, Switzerland; [Dotto, G. P.] Massachusetts Gen Hosp, Cutaneous Biol Res Ctr, Charlestown, MA USA	University of Lausanne; Harvard University; Massachusetts General Hospital	Dotto, GP (corresponding author), Univ Lausanne, Inst Biochem, Chemin Boveresses 155, CH-1066 Epalinges, Switzerland.	gian-paolo.dotto@unil.ch			NIH [AR39190, AR054856]; Swiss National Foundation; European Union [LSHB-CT-2005-019067]; NATIONAL CANCER INSTITUTE [R01CA073796, P01CA016038] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR039190, R01AR054856] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Swiss National Foundation(Swiss National Science Foundation (SNSF)); European Union(European Commission); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))	I thank Dr Cathrin Brisken for careful reading of the paper. This study was supported by NIH Grants AR39190, AR054856, the Swiss National Foundation, a grant from the European Union (Epistem, Sixth Framework Program, LSHB-CT-2005-019067).	Alimirah F, 2007, NEOPLASIA, V9, P427, DOI 10.1593/neo.07211; Altucci L, 2001, NAT REV CANCER, V1, P181, DOI 10.1038/35106036; Armstrong BK, 2001, J PHOTOCH PHOTOBIO B, V63, P8, DOI 10.1016/S1011-1344(01)00198-1; Artavanis-Tsakonas S, 1999, SCIENCE, V284, P770, DOI 10.1126/science.284.5415.770; Axelrod JD, 1996, SCIENCE, V271, P1826, DOI 10.1126/science.271.5257.1826; Balint K, 2005, J CLIN INVEST, V115, P3166, DOI 10.1172/JCI25001; Benitah SA, 2005, SCIENCE, V309, P933, DOI 10.1126/science.1113579; Beverly LJ, 2005, CANCER RES, V65, P7159, DOI 10.1158/0008-5472.CAN-05-1664; Blanpain C, 2006, GENE DEV, V20, P3022, DOI 10.1101/gad.1477606; Blokzijl A, 2003, J CELL BIOL, V163, P723, DOI 10.1083/jcb.200305112; Bray SJ, 2006, NAT REV MOL CELL BIO, V7, P678, DOI 10.1038/nrm2009; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Burgering BMT, 2002, TRENDS BIOCHEM SCI, V27, P352, DOI 10.1016/S0968-0004(02)02113-8; Carpten J, 2002, NAT GENET, V30, P181, DOI 10.1038/ng823; Chen YB, 2007, CANCER RES, V67, P7954, DOI 10.1158/0008-5472.CAN-07-1229; COUSO JP, 1994, CELL, V79, P259, DOI 10.1016/0092-8674(94)90195-3; D'Errico M, 2007, MUTAT RES-FUND MOL M, V614, P37, DOI 10.1016/j.mrfmmm.2006.06.009; Dajee M, 2003, NATURE, V421, P639, DOI 10.1038/nature01283; de Gruijl FR, 1999, EUR J CANCER, V35, P2003, DOI 10.1016/S0959-8049(99)00283-X; Devgan V, 2005, GENE DEV, V19, P1485, DOI 10.1101/gad.341405; Dotto GP, 2005, SCIENCE, V309, P890, DOI 10.1126/science.1117192; DOTTO GP, 1989, J CELL BIOL, V109, P3115, DOI 10.1083/jcb.109.6.3115; Estrach S, 2008, J INVEST DERMATOL, V128, P825, DOI 10.1038/sj.jid.5701113; Galceran J, 2004, GENE DEV, V18, P2718, DOI 10.1101/gad.1249504; Gat U, 1998, CELL, V95, P605, DOI 10.1016/S0092-8674(00)81631-1; Ghosh A, 2001, J BIOL CHEM, V276, P25447, DOI 10.1074/jbc.M100496200; Gius D, 2004, CANCER CELL, V6, P361, DOI 10.1016/j.ccr.2004.08.029; Gomis RR, 2006, P NATL ACAD SCI USA, V103, P12747, DOI 10.1073/pnas.0605333103; Hahn WC, 2002, NAT REV CANCER, V2, P331, DOI 10.1038/nrc795; Hofmann M, 2004, GENE DEV, V18, P2712, DOI 10.1101/gad.1248604; Iso T, 2003, J CELL PHYSIOL, V194, P237, DOI 10.1002/jcp.10208; Itoh F, 2004, EMBO J, V23, P541, DOI 10.1038/sj.emboj.7600065; Jehn BM, 1999, J IMMUNOL, V162, P635; Keyes WM, 2005, GENE DEV, V19, P1986, DOI 10.1101/gad.342305; Kim JW, 2005, P NATL ACAD SCI USA, V102, P14308, DOI 10.1073/pnas.0501600102; King KE, 2003, ONCOGENE, V22, P3635, DOI 10.1038/sj.onc.1206536; KOLEV V, 2008, NATURE CELL BIOL; Koster MI, 2004, DIFFERENTIATION, V72, P364, DOI 10.1111/j.1432-0436.2004.07208002.x; Kunnimalaiyaan M, 2006, J BIOL CHEM, V281, P39819, DOI 10.1074/jbc.M603578200; Lai EC, 2002, EMBO REP, V3, P840, DOI 10.1093/embo-reports/kvf170; Latonen L, 2005, BBA-REV CANCER, V1755, P71, DOI 10.1016/j.bbcan.2005.04.003; Laurikkala J, 2006, DEVELOPMENT, V133, P1553, DOI 10.1242/dev.02325; Laws AM, 2004, EUR J IMMUNOL, V34, P726, DOI 10.1002/eji.200324772; Lee J, 2007, DEVELOPMENT, V134, P2795, DOI 10.1242/dev.02868; Lefort K, 2007, GENE DEV, V21, P562, DOI 10.1101/gad.1484707; Li T, 2007, J BIOL CHEM, V282, P32264, DOI 10.1074/jbc.M703649200; Lin MH, 2000, DEVELOPMENT, V127, P2421; Lowell S, 2000, CURR BIOL, V10, P491, DOI 10.1016/S0960-9822(00)00451-6; Luo B, 1997, MOL CELL BIOL, V17, P6057, DOI 10.1128/MCB.17.10.6057; MacKenzie F, 2004, J BIOL CHEM, V279, P11657, DOI 10.1074/jbc.M312102200; Maillard I, 2004, BLOOD, V104, P1696, DOI 10.1182/blood-2004-02-0514; Malanchi I, 2008, NATURE, V452, P650, DOI 10.1038/nature06835; Mammucari C, 2005, DEV CELL, V8, P665, DOI 10.1016/j.devcel.2005.02.016; Mandinova A, 2008, EMBO J, V27, P1243, DOI 10.1038/emboj.2008.45; Merlo LMF, 2006, NAT REV CANCER, V6, P924, DOI 10.1038/nrc2013; Miele L, 2006, CURR CANCER DRUG TAR, V6, P313, DOI 10.2174/156800906777441771; Mills AA, 1999, NATURE, V398, P708, DOI 10.1038/19531; Missero C, 1996, GENE DEV, V10, P3065, DOI 10.1101/gad.10.23.3065; Moriyama M, 2008, DEV CELL, V14, P594, DOI 10.1016/j.devcel.2008.01.017; Mumm JS, 2000, DEV BIOL, V228, P151, DOI 10.1006/dbio.2000.9960; Mungamuri SK, 2006, CANCER RES, V66, P4715, DOI 10.1158/0008-5472.CAN-05-3830; Nair P, 2003, J VIROL, V77, P7106, DOI 10.1128/JVI.77.12.7106-7112.2003; Nguyen BC, 2006, GENE DEV, V20, P1028, DOI 10.1101/gad.1406006; Nickoloff BJ, 2002, CELL DEATH DIFFER, V9, P842, DOI 10.1038/sj.cdd.4401036; Nicolas M, 2003, NAT GENET, V33, P416, DOI 10.1038/ng1099; Niimi H, 2007, J CELL BIOL, V176, P695, DOI 10.1083/jcb.200612129; Oishi K, 2004, DEV BIOL, V276, P172, DOI 10.1016/j.ydbio.2004.08.039; Okuyama R, 2007, ONCOGENE, V26, P4478, DOI 10.1038/sj.onc.1210235; Osipo C, 2008, LAB INVEST, V88, P11, DOI 10.1038/labinvest.3700700; Oswald F, 2001, MOL CELL BIOL, V21, P7761, DOI 10.1128/MCB.21.22.7761-7774.2001; Oswald F, 1998, MOL CELL BIOL, V18, P2077, DOI 10.1128/MCB.18.4.2077; Pan YH, 2004, DEV CELL, V7, P731, DOI 10.1016/j.devcel.2004.09.014; Parsa R, 1999, J INVEST DERMATOL, V113, P1099, DOI 10.1046/j.1523-1747.1999.00780.x; Pellegrini G, 2001, P NATL ACAD SCI USA, V98, P3156, DOI 10.1073/pnas.061032098; Perera RJ, 2006, J CELL BIOCHEM, V98, P394, DOI 10.1002/jcb.20785; Petcherski AG, 2000, CURR BIOL, V10, pR471, DOI 10.1016/S0960-9822(00)00577-7; Philipp J, 1999, ONCOGENE, V18, P4689, DOI 10.1038/sj.onc.1202840; Proweller A, 2006, CANCER RES, V66, P7438, DOI 10.1158/0008-5472.CAN-06-0793; Ramdass B, 2007, GYNECOL ONCOL, V104, P352, DOI 10.1016/j.ygyno.2006.08.054; Rangarajan A, 2004, CANCER CELL, V6, P171, DOI 10.1016/j.ccr.2004.07.009; Rangarajan A, 2001, EMBO J, V20, P3427, DOI 10.1093/emboj/20.13.3427; Sade H, 2004, J BIOL CHEM, V279, P2937, DOI 10.1074/jbc.M309924200; Sahai E, 2002, NAT REV CANCER, V2, P133, DOI 10.1038/nrc725; Shin HM, 2006, EMBO J, V25, P129, DOI 10.1038/sj.emboj.7600902; Sriuranpong V, 2002, MOL CELL BIOL, V22, P3129, DOI 10.1128/MCB.22.9.3129-3139.2002; Sriuranpong V, 2001, CANCER RES, V61, P3200; Talora C, 2005, EXP CELL RES, V305, P343, DOI 10.1016/j.yexcr.2005.01.015; Talora C, 2002, GENE DEV, V16, P2252, DOI 10.1101/gad.988902; Thelu Jacques, 2002, BMC Dermatol, V2, P7, DOI 10.1186/1471-5945-2-7; Topley GI, 1999, P NATL ACAD SCI USA, V96, P9089, DOI 10.1073/pnas.96.16.9089; Truong AB, 2006, GENE DEV, V20, P3185, DOI 10.1101/gad.1463206; Vauclair S, 2007, DEV CELL, V13, P242, DOI 10.1016/j.devcel.2007.06.012; Wang L, 2007, INT J GYNECOL CANCER, V17, P1283, DOI 10.1111/j.1525-1438.2007.00927.x; Wasylyk C, 2002, MOL CELL BIOL, V22, P2687, DOI 10.1128/MCB.22.8.2687-2702.2002; Wei CL, 2006, CELL, V124, P207, DOI 10.1016/j.cell.2005.10.043; Weinberg WC, 1999, CANCER RES, V59, P2050; Weng AP, 2003, MOL CELL BIOL, V23, P655, DOI 10.1128/MCB.23.2.655-664.2003; Westfall MD, 2004, CARCINOGENESIS, V25, P857, DOI 10.1093/carcin/bgh148; Wu LZ, 2000, NAT GENET, V26, P484, DOI 10.1038/82644; Wu XW, 2006, GENE DEV, V20, P571, DOI 10.1101/gad.361406; Xia XF, 2001, P NATL ACAD SCI USA, V98, P10863, DOI 10.1073/pnas.191284198; Xu XW, 2003, AM J PATHOL, V163, P969, DOI 10.1016/S0002-9440(10)63456-6; Yamamoto N, 2003, CURR BIOL, V13, P333, DOI 10.1016/S0960-9822(03)00081-2; Yang A, 1999, NATURE, V398, P714, DOI 10.1038/19539; Yang AN, 1998, MOL CELL, V2, P305, DOI 10.1016/S1097-2765(00)80275-0; Yang XD, 2004, DEV BIOL, V269, P81, DOI 10.1016/j.ydbio.2004.01.014; Yao J, 2007, INT J GYNECOL CANCER, V17, P502, DOI 10.1111/j.1525-1438.2007.00872.x; Yugawa T, 2007, MOL CELL BIOL, V27, P3732, DOI 10.1128/MCB.02119-06; YUSPA SH, 1991, CUTANEOUS CARCINOGEN; ZAGOURAS P, 1995, P NATL ACAD SCI USA, V92, P6414, DOI 10.1073/pnas.92.14.6414; Zavadil J, 2004, EMBO J, V23, P1155, DOI 10.1038/sj.emboj.7600069; Zhang JY, 2004, GENE DEV, V18, P17, DOI 10.1101/gad.1160904; Zhang LW, 2002, J INTERF CYTOK RES, V22, P95, DOI 10.1089/107999002753452700; Zheng QJ, 2007, ONCOL REP, V17, P847; Zhu AJ, 1999, DEVELOPMENT, V126, P2285; zur Hausen H, 2000, JNCI-J NATL CANCER I, V92, P690, DOI 10.1093/jnci/92.9.690; Zweidler-McKay PA, 2005, BLOOD, V106, P3898, DOI 10.1182/blood-2005-01-0355	117	207	220	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP	2008	27	38					5115	5123		10.1038/onc.2008.225	http://dx.doi.org/10.1038/onc.2008.225			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	344GM	18758480	Green Accepted, Green Submitted			2022-12-28	WOS:000258914900005
J	Kovall, RA				Kovall, R. A.			More complicated than it looks: assembly of Notch pathway transcription complexes	ONCOGENE			English	Review						CSL; Mastermind; signal transduction; transcriptional regulation; protein-protein interactions	T-CELL LEUKEMIA; CRYSTAL-STRUCTURE; ANKYRIN DOMAIN; CAENORHABDITIS-ELEGANS; MASTERMIND; CSL; ACTIVATION; PROTEINS; RECEPTOR; ROLES	The Notch pathway is a short-range signaling mechanism between neighboring cells that results in changes in gene expression. Extracellular interactions between Notch receptors and ligands trigger proteolytic cleavage of the receptor Notch. Following cleavage, the freed intracellular domain of Notch (NotchIC) moves from the cytoplasm to the nucleus, engaging the DNA-binding transcription factor CBF-1, Su(H), Lag-1 (CSL) - the nuclear effector of the pathway. NotchIC, together with the transcriptional coactivator Mastermind, form a ternary complex with CSL that activates transcription from genes that are responsive to Notch signaling. Illuminating the molecular details that underlie formation of the transcriptionally active CSL-NotchIC-Mastermind ternary complex is key for understanding how genes are turned on in response to a Notch signal. Recently, several studies using biophysical and computational methods have scrutinized how the CSL-NotchIC-Mastermind ternary complex forms and the role individual domains play in this process. These detailed analyses have provided a wealth of molecular insights into the assembly of a Notch pathway active transcription complex but have also raised several intriguing, yet confounding questions. This review will focus on the findings of these recent biophysical studies and provide speculative models that address these unanswered questions.	Univ Cincinnati, Dept Mol Genet Biochem & Microbiol, Coll Med, Cincinnati, OH 45267 USA	University System of Ohio; University of Cincinnati	Kovall, RA (corresponding author), Univ Cincinnati, Dept Mol Genet Biochem & Microbiol, Coll Med, 231 Albert Sabin Way, Cincinnati, OH 45267 USA.	kovallra@ucmail.uc.edu	Kovall, Rhett/A-3106-2008		NIH; University of Cincinnati Barrett Cancer Center	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); University of Cincinnati Barrett Cancer Center	I thank the members of my laboratory for the stimulating discussions regarding Notch signaling, which spurred the writing of this review. In particular, I thank Jeffrey Wilson and David Friedmann for editing the manuscript and assistance with creation of the figures. I am also very grateful for the biophysical expertise and constructive criticism provided by my departmental colleagues Andrew Herr and Tom Thompson. This work was supported by grants from the NIH and the University of Cincinnati Barrett Cancer Center.	Artavanis-Tsakonas S, 1999, SCIENCE, V284, P770, DOI 10.1126/science.284.5415.770; Aster JC, 2000, MOL CELL BIOL, V20, P7505, DOI 10.1128/MCB.20.20.7505-7515.2000; Bergqvist S, 2006, J MOL BIOL, V360, P421, DOI 10.1016/j.jmb.2006.05.014; Bertagna A, 2008, BIOCHEM SOC T, V36, P157, DOI 10.1042/BST0360157; Bray S, 2001, CURR BIOL, V11, pR217, DOI 10.1016/S0960-9822(01)00109-9; Bray SJ, 2006, NAT REV MOL CELL BIO, V7, P678, DOI 10.1038/nrm2009; Chiang MY, 2006, MOL CELL BIOL, V26, P6261, DOI 10.1128/MCB.02478-05; Christensen S, 1996, DEVELOPMENT, V122, P1373; Del Bianco C, 2008, J MOL BIOL, V376, P131, DOI 10.1016/j.jmb.2007.11.061; Dyson HJ, 2005, NAT REV MOL CELL BIO, V6, P197, DOI 10.1038/nrm1589; Ehebauer MT, 2005, BIOCHEM J, V392, P13, DOI 10.1042/BJ20050515; Friedmann DR, 2008, J BIOL CHEM, V283, P14781, DOI 10.1074/jbc.M709501200; Fryer CJ, 2004, MOL CELL, V16, P509, DOI 10.1016/j.molcel.2004.10.014; Fryer CJ, 2002, GENE DEV, V16, P1397, DOI 10.1101/gad.991602; Gridley T, 2003, HUM MOL GENET, V12, pR9, DOI 10.1093/hmg/ddg052; High FA, 2008, NAT REV GENET, V9, P49, DOI 10.1038/nrg2279; Hsieh JJD, 1996, MOL CELL BIOL, V16, P952; Jacobs MD, 1998, CELL, V95, P749, DOI 10.1016/S0092-8674(00)81698-0; Jeffries S, 2002, MOL CELL BIOL, V22, P3927, DOI 10.1128/MCB.22.11.3927-3941.2002; Kimble J, 2007, ANNU REV CELL DEV BI, V23, P405, DOI 10.1146/annurev.cellbio.23.090506.123326; Koch U, 2007, CELL MOL LIFE SCI, V64, P2746, DOI 10.1007/s00018-007-7164-1; Kovall RA, 2004, EMBO J, V23, P3441, DOI 10.1038/sj.emboj.7600349; Krissinel E, 2007, J MOL BIOL, V372, P774, DOI 10.1016/j.jmb.2007.05.022; Kurooka H, 1998, NUCLEIC ACIDS RES, V26, P5448, DOI 10.1093/nar/26.23.5448; Kurooka K, 2000, J BIOL CHEM, V275, P17211, DOI 10.1074/jbc.M000909200; Lai EC, 2002, EMBO REP, V3, P840, DOI 10.1093/embo-reports/kvf170; Lubman OY, 2007, J MOL BIOL, V365, P577, DOI 10.1016/j.jmb.2006.09.071; Lubman OY, 2005, PROTEIN SCI, V14, P1274, DOI 10.1110/ps.041184105; Miele L, 2006, CURR MOL MED, V6, P905, DOI 10.2174/156652406779010830; Mosavi LK, 2004, PROTEIN SCI, V13, P1435, DOI 10.1110/ps.03554604; Mumm JS, 2000, DEV BIOL, V228, P151, DOI 10.1006/dbio.2000.9960; Nam Y, 2006, CELL, V124, P973, DOI 10.1016/j.cell.2005.12.037; Nam Y, 2003, J BIOL CHEM, V278, P21232, DOI 10.1074/jbc.M301567200; Petcherski AG, 2000, NATURE, V405, P364, DOI 10.1038/35012645; Petcherski AG, 2000, CURR BIOL, V10, pR471, DOI 10.1016/S0960-9822(00)00577-7; Roehl H, 1996, EMBO J, V15, P7002, DOI 10.1002/j.1460-2075.1996.tb01092.x; Ruas JL, 2007, CURR OPIN LIPIDOL, V18, P508, DOI 10.1097/MOL.0b013e3282efe49d; Tamura K, 1995, CURR BIOL, V5, P1416, DOI 10.1016/S0960-9822(95)00279-X; Tanigaki K, 2007, NAT IMMUNOL, V8, P451, DOI 10.1038/ni1453; Wallberg AE, 2002, MOL CELL BIOL, V22, P7812, DOI 10.1128/MCB.22.22.7812-7819.2002; Weng AP, 2004, SCIENCE, V306, P269, DOI 10.1126/science.1102160; Wilson JJ, 2006, CELL, V124, P985, DOI 10.1016/j.cell.2006.01.035; Wu LZ, 2000, NAT GENET, V26, P484, DOI 10.1038/82644; Zhou SF, 2001, MOL CELL BIOL, V21, P6222, DOI 10.1128/MCB.21.18.6222-6232.2001; Zweifel ME, 2003, PROTEIN SCI, V12, P2622, DOI 10.1110/ps.03279003	45	124	128	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP	2008	27	38					5099	5109		10.1038/onc.2008.223	http://dx.doi.org/10.1038/onc.2008.223			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	344GM	18758478	Bronze			2022-12-28	WOS:000258914900003
J	Lin, SH; Cheng, CJ; Lee, YC; Ye, X; Tsai, WW; Kim, J; Pasqualini, R; Arap, W; Navone, NM; Tu, SM; Hu, M; Yu-Lee, LY; Logothetis, CJ				Lin, S-H; Cheng, C-J; Lee, Y-C; Ye, X.; Tsai, W-W; Kim, J.; Pasqualini, R.; Arap, W.; Navone, N. M.; Tu, S-M; Hu, M.; Yu-Lee, L-Y; Logothetis, C. J.			A 45-kDa ErbB3 secreted by prostate cancer cells promotes bone formation	ONCOGENE			English	Article						prostate cancer; bone metastasis; osteoblast; p45-sErbB3	EXPRESSION; OSTEOBLASTS; CARCINOMAS; METASTASIS; MDA-BF-1; ISOFORM; PROTEIN; GROWTH; TUMORS; MICE	ErbB3 is a transmembrane growth factor receptor that has been implicated in the pathogenesis of human cancer. After finding that a truncated form of ErbB3 was present and upregulated in metastatic prostate cancer cells in lymph nodes and bone, we explored the pathophysiological functions of this unusual form of ErbB3 in the context of mouse calvaria as well as osteoblasts in vitro and the femur microenvironment in vivo. Here we demonstrate that prostate cancer cells expressed an alternatively spliced transcript that encodes a 45-kDa glycosylated protein (p45-sErbB3). The recombinant p45-sErbB3 purified from conditioned medium stimulated calvarial bone formation and induced osteoblast differentiation. Overexpression of p45-sErbB3 in the osteolytic prostate cancer cell line PC-3 converted its phenotype from bone lysing to bone forming upon injection into the femurs of immunodeficient mice. Further, we detected sErbB3 in plasma samples from patients with castration-resistant prostate cancer with bone metastasis. These observations establish that p45- sErbB3 is a structurally and functionally unique gene product of ErbB3 and suggest that p45- sErbB3 is likely one ofthe factors involved in the osteoblastic bone metastases of prostate cancer.	[Lin, S-H; Lee, Y-C; Ye, X.; Tsai, W-W] Univ Texas MD Anderson Canc Ctr, Dept Mol Pathol, Houston, TX 77030 USA; [Lin, S-H; Kim, J.; Pasqualini, R.; Arap, W.; Navone, N. M.; Tu, S-M; Logothetis, C. J.] Univ Texas MD Anderson Canc Ctr, Dept Genitourinary Med Oncol, Houston, TX 77030 USA; [Cheng, C-J] Taipei Med Univ, Dept Pathol, Taipei, Taiwan; [Hu, M.] Univ Texas MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, Houston, TX 77030 USA; [Yu-Lee, L-Y] Baylor Coll Med, Dept Med, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; Taipei Medical University; University of Texas System; UTMD Anderson Cancer Center; Baylor College of Medicine	Lin, SH (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Mol Pathol, 1515 Holcombe Blvd, Houston, TX 77030 USA.	slin@mdanderson.org			National Institutes of Health [CA111479, P50-CA90270, DK53176]; Charlotte Geyer Foundation; Prostate Cancer Foundation; NATIONAL CANCER INSTITUTE [R01CA111479, P50CA090270] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK053176] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Charlotte Geyer Foundation; Prostate Cancer Foundation; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	We thank Karen Earley, Weiping Luo, Matthew Gal. one for technical assistance, Dr Jian Kuang for critical reading of the manuscript and Christine Wogan for editing the manuscript. This work was supported by National Institutes of Health grants CA111479, P50-CA90270 and DK53176; the Charlotte Geyer Foundation and the Prostate Cancer Foundation.	ALIMANDI M, 1995, ONCOGENE, V10, P1813; Berruti A, 2000, J UROLOGY, V164, P1248, DOI 10.1016/S0022-5347(05)67149-2; BHARGAVA U, 1988, BONE, V9, P155, DOI 10.1016/8756-3282(88)90005-1; Chen NY, 2007, CANCER RES, V67, P6544, DOI 10.1158/0008-5472.CAN-07-1330; Choueiri MB, 2006, CANCER METAST REV, V25, P601, DOI 10.1007/s10555-006-9034-y; Corey E, 2002, PROSTATE, V52, P20, DOI 10.1002/pros.10091; Hellyer NJ, 2001, J BIOL CHEM, V276, P42153, DOI 10.1074/jbc.M102079200; KRAUS MH, 1989, P NATL ACAD SCI USA, V86, P9193, DOI 10.1073/pnas.86.23.9193; Liang AK, 2005, PROTEIN EXPRES PURIF, V44, P58, DOI 10.1016/j.pep.2005.03.025; LIN SH, 2008, CLIN CANC R IN PRESS; Logothetis CJ, 2005, NAT REV CANCER, V5, P21, DOI 10.1038/nrc1528; LOW SH, 1991, J BIOL CHEM, V266, P13391; Naidu R, 1998, BRIT J CANCER, V78, P1385, DOI 10.1038/bjc.1998.689; Shah RB, 2004, CANCER RES, V64, P9209, DOI 10.1158/0008-5472.CAN-04-2442; Soos G, 1996, INT J CANCER, V66, P280, DOI 10.1002/(SICI)1097-0215(19960410)66:2<280::AID-IJC24>3.0.CO;2-F; Vakar-Lopez F, 2004, J PATHOL, V203, P688, DOI 10.1002/path.1568; Wu TT, 1998, INT J CANCER, V77, P887, DOI 10.1002/(SICI)1097-0215(19980911)77:6<887::AID-IJC15>3.0.CO;2-Z; Yang J, 2001, CANCER RES, V61, P5652; Yi ES, 1997, MODERN PATHOL, V10, P142	19	21	24	1	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP	2008	27	39					5195	5203		10.1038/onc.2008.156	http://dx.doi.org/10.1038/onc.2008.156			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	344GO	18490922	Green Accepted			2022-12-28	WOS:000258915100003
J	Bae, JB; Mukhopadhyay, SS; Liu, L; Zhang, N; Tan, J; Akhter, S; Liu, X; Shen, X; Li, L; Legerski, RJ				Bae, J-B; Mukhopadhyay, S. S.; Liu, L.; Zhang, N.; Tan, J.; Akhter, S.; Liu, X.; Shen, X.; Li, L.; Legerski, R. J.			Snm1B/Apollo mediates replication fork collapse and S Phase checkpoint activation in response to DNA interstrand cross-links	ONCOGENE			English	Article						Snm1B/Apollo; interstrand cross-links; cell cycle checkpoint; ATM	DOUBLE-STRAND BREAKS; FANCONI-ANEMIA PROTEINS; NUCLEOTIDE EXCISION-REPAIR; CELL-CYCLE PROGRESSION; SACCHAROMYCES-CEREVISIAE; MITOMYCIN-C; ATAXIA-TELANGIECTASIA; V(D)J RECOMBINATION; SIGNALING PATHWAYS; DAMAGE CHECKPOINT	The removal of DNA interstrand cross-links (ICLs) has proven to be notoriously complicated due to the involvement of multiple pathways of DNA repair, which include the Fanconi anemia/BRCA pathway, homologous recombination and components of the nucleotide excision and mismatch repair pathways. Members of the SNM1 gene family have also been shown to have a role in mediating cellular resistance to ICLs, although their precise function has remained elusive. Here, we show that knockdown of Snm1B/Apollo in human cells results in hypersensitivity to mitomycin C (MMC), but not to IR. We also show that Snm1B-deficient cells exhibit a defective S phase checkpoint in response to MMC, but not to IR, and this finding may account for the specific sensitivity to the cross-linking drug. Interestingly, although previous studies have largely implicated ATR as the major kinase activated in response to ICLs, we show that it is activation of the ATM-mediated checkpoint that is defective in Snm1B-deficient cells. The requirement for Snm1B in ATM checkpoint activation specifically after ICL damage is correlated with its role in promoting double-strand break formation, and thus replication fork collapse. Consistent with this result Snm1B was found to interact directly with Mus81-Eme1, an endonuclease previously implicated in fork collapse. In addition, we also show that Snm1B interacts with the Mre11-Rad50-Nbs1 (MRN) complex and with FancD2 further substantiating its role as a checkpoint/DNA repair protein.	[Bae, J-B; Mukhopadhyay, S. S.; Liu, L.; Zhang, N.; Tan, J.; Akhter, S.; Legerski, R. J.] Univ Texas MD Anderson Canc Ctr, Dept Canc Genet, Houston, TX 77030 USA; [Liu, X.] Univ Texas MD Anderson Canc Ctr, Dept Expt Therapeut, Houston, TX 77030 USA; [Shen, X.; Li, L.] Univ Texas MD Anderson Canc Ctr, Dept Expt Radiat Oncol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Legerski, RJ (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Canc Genet, 1515 Holcombe Blvd, Houston, TX 77030 USA.	rlegersk@mdanderson.org		mukhopadhyay, sudit/0000-0001-5888-0598	NCI [CA052461, CA097175]; Cancer Center Support (Core) [CA16672]; NATIONAL CANCER INSTITUTE [P30CA016672, P01CA097175, R01CA052461] Funding Source: NIH RePORTER	NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Cancer Center Support (Core); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Tanya Paull and Steve Patrick for the gift of MRN protein, and Jeffrey Parvin for the gift of FancD2 protein. This work was supported by NCI Grants CA052461 and CA097175. DNA sequencing resources were supported by the Cancer Center Support (Core) Grant CA16672.	Ahkter S, 2005, MOL CELL BIOL, V25, P10071, DOI 10.1128/MCB.25.22.10071-10078.2005; Akhter S, 2004, MOL CELL BIOL, V24, P10448, DOI 10.1128/MCB.24.23.10448-10455.2004; Akkari YMN, 2001, MOL GENET METAB, V74, P403, DOI 10.1006/mgme.2001.3259; Andreassen PR, 2004, GENE DEV, V18, P1958, DOI 10.1101/gad.1196104; Bakkenist CJ, 2003, NATURE, V421, P499, DOI 10.1038/nature01368; Barber LJ, 2005, MOL CELL BIOL, V25, P2297, DOI 10.1128/MCB.25.6.2297-2309.2005; Bartek J, 2004, NAT REV MOL CELL BIO, V5, P792, DOI 10.1038/nrm1493; Callebaut I, 2002, NUCLEIC ACIDS RES, V30, P3592, DOI 10.1093/nar/gkf470; Chan DW, 2002, GENE DEV, V16, P2333, DOI 10.1101/gad.1015202; Chaturvedi P, 2002, CANCER RES, V62, P1797; Demuth I, 2004, ONCOGENE, V23, P8611, DOI 10.1038/sj.onc.1207895; Dominski Z, 2007, CRIT REV BIOCHEM MOL, V42, P67, DOI 10.1080/10409230701279118; Dronkert MLG, 2000, MOL CELL BIOL, V20, P4553, DOI 10.1128/MCB.20.13.4553-4561.2000; Freibaum BD, 2006, J BIOL CHEM, V281, P15033, DOI 10.1074/jbc.C600038200; Geng LY, 2007, MOL CELL BIOL, V27, P2625, DOI 10.1128/MCB.02072-06; Grossmann KF, 2001, MUTAT RES-DNA REPAIR, V487, P73, DOI 10.1016/S0921-8777(01)00106-9; HAASE E, 1989, MOL GEN GENET, V218, P64, DOI 10.1007/BF00330566; Hanada K, 2006, EMBO J, V25, P4921, DOI 10.1038/sj.emboj.7601344; HENRIQUES JAP, 1980, GENETICS, V95, P273; Ho GPH, 2006, MOL CELL BIOL, V26, P7005, DOI 10.1128/MCB.02018-05; Interthal H, 2000, MOL GEN GENET, V263, P812, DOI 10.1007/s004380000241; Ishiai M, 2004, MOL CELL BIOL, V24, P10733, DOI 10.1128/MCB.24.24.10733-10741.2004; Lambert S, 2005, BIOCHIMIE, V87, P591, DOI 10.1016/j.biochi.2004.10.020; Lenain C, 2006, CURR BIOL, V16, P1303, DOI 10.1016/j.cub.2006.05.021; Li XR, 2005, DNA REPAIR, V4, P163, DOI 10.1016/j.dnarep.2004.08.012; Li XR, 2003, DNA REPAIR, V2, P121, DOI 10.1016/S1568-7864(02)00192-1; Lukas J, 2004, DNA REPAIR, V3, P997, DOI 10.1016/j.dnarep.2004.03.006; Ma YM, 2002, CELL, V108, P781, DOI 10.1016/S0092-8674(02)00671-2; MAGANASCHWENCKE N, 1982, P NATL ACAD SCI-BIOL, V79, P1722, DOI 10.1073/pnas.79.6.1722; Matsusaka T, 2004, J CELL BIOL, V166, P507, DOI 10.1083/jcb.200401139; McPherson JP, 2004, SCIENCE, V304, P1822, DOI 10.1126/science.1094557; Mladenov E, 2007, J CELL PHYSIOL, V211, P468, DOI 10.1002/jcp.20957; Moshous D, 2001, CELL, V105, P177, DOI 10.1016/S0092-8674(01)00309-9; Moshous D, 2000, HUM MOL GENET, V9, P583, DOI 10.1093/hmg/9.4.583; Multani AS, 2000, NEOPLASIA, V2, P339, DOI 10.1038/sj.neo.7900105; Nakanishi K, 2005, P NATL ACAD SCI USA, V102, P1110, DOI 10.1073/pnas.0407796102; Nakanishi K, 2002, NAT CELL BIOL, V4, P913, DOI 10.1038/ncb879; Nojima K, 2005, CANCER RES, V65, P11704, DOI 10.1158/0008-5472.CAN-05-1214; PAINTER RB, 1980, P NATL ACAD SCI-BIOL, V77, P7315, DOI 10.1073/pnas.77.12.7315; Pannicke U, 2004, EMBO J, V23, P1987, DOI 10.1038/sj.emboj.7600206; Pichierri P, 2004, CELL CYCLE, V3, P698; Pichierri P, 2004, EMBO J, V23, P1178, DOI 10.1038/sj.emboj.7600113; Pichierri P, 2002, HUM MOL GENET, V11, P2531, DOI 10.1093/hmg/11.21.2531; Riballo E, 2004, MOL CELL, V16, P715, DOI 10.1016/j.molcel.2004.10.029; Richie CT, 2002, MOL CELL BIOL, V22, P8635, DOI 10.1128/MCB.22.24.8635-8647.2002; Rooney S, 2004, P NATL ACAD SCI USA, V101, P2410, DOI 10.1073/pnas.0308757101; Rooney S, 2002, MOL CELL, V10, P1379, DOI 10.1016/S1097-2765(02)00755-4; RUHLAND A, 1981, MUTAT RES, V91, P457, DOI 10.1016/0165-7992(81)90052-X; Sala-Trepat M, 2000, EXP CELL RES, V260, P208, DOI 10.1006/excr.2000.4994; Scolnick DM, 2000, NATURE, V406, P430, DOI 10.1038/35019108; SEYSCHAB H, 1995, BLOOD, V85, P2233, DOI 10.1182/blood.V85.8.2233.bloodjournal8582233; Shen X, 2006, J BIOL CHEM, V281, P13869, DOI 10.1074/jbc.C600071200; Sobeck A, 2006, MOL CELL BIOL, V26, P425, DOI 10.1128/MCB.26.2.425-437.2006; Stiff T, 2005, EMBO J, V24, P199, DOI 10.1038/sj.emboj.7600504; Summers MK, 2005, ONCOGENE, V24, P2589, DOI 10.1038/sj.onc.1208428; Taniguchi T, 2002, CELL, V109, P459, DOI 10.1016/S0092-8674(02)00747-X; Thompson LH, 2005, ENVIRON MOL MUTAGEN, V45, P128, DOI 10.1002/em.20109; van Overbeek M, 2006, CURR BIOL, V16, P1295, DOI 10.1016/j.cub.2006.05.022; Wang JH, 2005, DNA REPAIR, V4, P556, DOI 10.1016/j.dnarep.2005.02.001; Wang X, 2001, MOL CELL BIOL, V21, P713, DOI 10.1128/MCB.21.3.713-720.2001; WILBORN F, 1989, CURR GENET, V16, P331, DOI 10.1007/BF00340711; Xu B, 2002, MOL CELL BIOL, V22, P1049, DOI 10.1128/MCB.22.4.1049-1059.2002; Yu XC, 2005, NAT GENET, V37, P401, DOI 10.1038/ng1538; Zhang NX, 2007, DNA REPAIR, V6, P1670, DOI 10.1016/j.dnarep.2007.06.002; Zhang NX, 2005, J BIOL CHEM, V280, P40559, DOI 10.1074/jbc.M508453200; Zhang XS, 2004, MOL CELL BIOL, V24, P9207, DOI 10.1128/MCB.24.20.9207-9220.2004; Zheng HY, 2006, DNA REPAIR, V5, P566, DOI 10.1016/j.dnarep.2006.01.010; Zheng HY, 2003, MOL CELL BIOL, V23, P754, DOI 10.1128/MCB.23.2.754-761.2003	68	56	60	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 28	2008	27	37					5045	5056		10.1038/onc.2008.139	http://dx.doi.org/10.1038/onc.2008.139			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	344GL	18469862	Green Accepted			2022-12-28	WOS:000258914800007
J	Veeramani, S; Yuan, TC; Lin, FF; Lin, MF				Veeramani, S.; Yuan, T-C; Lin, F-F; Lin, M-F			Mitochondrial redox signaling by p66Shc is involved in regulating androgenic growth stimulation of human prostate cancer cells	ONCOGENE			English	Article						p66Shc; prostate cancer; DHT; reactive oxygen species	66-KDA SHC ISOFORM; BREAST-CANCER; LIFE-SPAN; P66(SHC) PROTEIN; ACID-PHOSPHATASE; EXPRESSION; PATHWAY; LINES; PROLIFERATION; APOPTOSIS	p66Shc is shown to negatively regulate the life span in mice through reactive oxygen species (ROS) production. Recent reports, however, revealed that p66Shc protein level is significantly elevated in several human cancer tissues and growth-stimulated carcinoma cells, suggesting a mitogenic and carcinogenic role for p66Shc. In this communication, we demonstrate for the first time that p66Shc mediates androgenic growth signals in androgen-sensitive human prostate cancer cells through mitochondrial ROS production. Growth stimulation of prostate cancer cells with 5 alpha-dihydrotestosterone (DHT) is accompanied by increased p66Shc level and ROS production, which is abolished by antioxidant treatments. However, antioxidant treatments do not affect the transcriptional activity of androgen receptor (AR) as observed by its inability to block DHT-induced prostate-specific antigen expression, an AR-dependent correlate of prostate cancer progression. Elevated expression of p66Shc by cDNA transfection increases the basal cell proliferation and, thus, reduces additional DHT-induced cell proliferation. Furthermore, DHT increases the translocation of p66Shc into mitochondria and its interaction with cytochrome c. Conversely, both redox-negative p66Shc mutant (W134F), which is deficient in cytochrome c interaction, and p66Shc small interfering RNA decrease DHT-induced cell proliferation. These results collectively reveal a novel role for p66Shc-ROS pathway in androgen-induced prostate cancer cell proliferation and, thus, may play a role in early prostate carcinogenesis.	[Veeramani, S.; Yuan, T-C; Lin, F-F; Lin, M-F] Univ Nebraska Med Ctr, Dept Biochem & Mol Biol, Coll Med, Omaha, NE 68198 USA; [Lin, M-F] Univ Nebraska Med Ctr, Eppley Inst Res Canc, Omaha, NE 68198 USA	University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Medical Center	Lin, MF (corresponding author), Univ Nebraska Med Ctr, Dept Biochem & Mol Biol, Coll Med, 985870 Nebraska Med Ctr, Omaha, NE 68198 USA.	mlin@unmc.edu	Veeramani, Suresh/P-7838-2019	Veeramani, Suresh/0000-0001-9217-0872	Department of Defense [W81XWH-04-1-0908, W81XWH-06-1-0070]; National Institutes of Health [R01 CA88184]; UNMC Graduate Student Fellowship; NATIONAL CANCER INSTITUTE [P30CA036727, R01CA088184] Funding Source: NIH RePORTER	Department of Defense(United States Department of Defense); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); UNMC Graduate Student Fellowship; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank the technical supports from the Flow Cytometry core facility at UNMC and Eppley Cancer Center (P30CA036727). This study was supported in part by the Department of Defense Grants (W81XWH-04-1-0908 and W81XWH-06-1-0070), National Institutes of Health (R01 CA88184) and UNMC Graduate Student Fellowship. We thank Dr Ming-Shyue Lee for the initial study of DHT effect on serine-36 phosphorylation of p66Shc. We also acknowledge Dr Larry W Oberley at University of Iowa College of Medicine (Iowa City, IA, USA) and Dr Parmender P Mehta, University of Nebraska Medical Center (Omaha, NE, USA) for the plasmids Mn-SOD and pECFP-N1, respectively.	Bourdon JC, 2007, BRIT J CANCER, V97, P277, DOI 10.1038/sj.bjc.6603886; Davol PA, 2003, CANCER RES, V63, P6772; Giorgio M, 2005, CELL, V122, P221, DOI 10.1016/j.cell.2005.05.011; Grossman SR, 2007, CLIN CANCER RES, V13, P5798, DOI 10.1158/1078-0432.CCR-07-0073; HOROSZEWICZ JS, 1983, CANCER RES, V43, P1809; Jackson JG, 2000, CLIN CANCER RES, V6, P1135; Khanday FA, 2006, J CELL BIOL, V172, P817, DOI 10.1083/jcb.200506001; Klein EA, 2001, J UROLOGY, V166, P1311, DOI 10.1016/S0022-5347(05)65759-X; Kuruma H, 2005, PROTEOMICS, V5, P1097, DOI 10.1002/pmic.200401115; Lee MS, 2004, ONCOGENE, V23, P3048, DOI 10.1038/sj.onc.1207451; Lee MS, 2004, INT J CANCER, V108, P672, DOI 10.1002/ijc.11621; Lim SD, 2005, PROSTATE, V62, P200, DOI 10.1002/pros.20137; Lin MF, 1998, J BIOL CHEM, V273, P5939, DOI 10.1074/jbc.273.10.5939; Lotti LV, 1996, MOL CELL BIOL, V16, P1946; Meng TC, 1998, J BIOL CHEM, V273, P22096, DOI 10.1074/jbc.273.34.22096; Migliaccio E, 1997, EMBO J, V16, P706, DOI 10.1093/emboj/16.4.706; Migliaccio E, 1999, NATURE, V402, P309, DOI 10.1038/46311; Navone NM, 1997, CLIN CANCER RES, V3, P2493; Nemoto S, 2006, J BIOL CHEM, V281, P10555, DOI 10.1074/jbc.M511626200; Okada S, 1997, J BIOL CHEM, V272, P28042, DOI 10.1074/jbc.272.44.28042; Orsini F, 2004, J BIOL CHEM, V279, P25689, DOI 10.1074/jbc.M401844200; Pacini S, 2004, MOL CELL BIOL, V24, P1747, DOI 10.1128/MCB.24.4.1747-1757.2004; Pandolfi S, 2005, MECH AGEING DEV, V126, P839, DOI 10.1016/j.mad.2005.03.004; Park YJ, 2005, ENDOCRINOLOGY, V146, P2473, DOI 10.1210/en.2004-1588; Pinton P, 2007, SCIENCE, V315, P659, DOI 10.1126/science.1135380; Ravichandran KS, 2001, ONCOGENE, V20, P6322, DOI 10.1038/sj.onc.1204776; Ripple MO, 1997, JNCI-J NATL CANCER I, V89, P40, DOI 10.1093/jnci/89.1.40; Stevenson LE, 1998, BREAST CANCER RES TR, V49, P119, DOI 10.1023/A:1006007227747; Trinei M, 2002, ONCOGENE, V21, P3872, DOI 10.1038/sj.onc.1205513; Veeramani S, 2005, ONCOGENE, V24, P7203, DOI 10.1038/sj.onc.1208852; Ventura A, 2004, J BIOL CHEM, V279, P2299, DOI 10.1074/jbc.M307655200; Xie YM, 1996, BIOCHEM BIOPH RES CO, V221, P140, DOI 10.1006/bbrc.1996.0559; Yang CPH, 2000, CANCER RES, V60, P5171	33	57	61	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 28	2008	27	37					5057	5068		10.1038/onc.2008.143	http://dx.doi.org/10.1038/onc.2008.143			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	344GL	18504439	Green Accepted, Green Submitted, Bronze			2022-12-28	WOS:000258914800008
J	Bitomsky, N; Wethkamp, N; Marikkannu, R; Klempnauer, KH				Bitomsky, N.; Wethkamp, N.; Marikkannu, R.; Klempnauer, K-H			siRNA-mediated knockdown of Pdcd4 expression causes upregulation of p21(Waf1/Cip1) expression	ONCOGENE			English	Article						Pdcd4; p21(Waf1/Cip1); siRNA; p53; DNA damage response	SUPPRESSOR PROTEIN PDCD4; TERMINAL MA-3 DOMAIN; NF-KAPPA-B; TRANSFORMATION SUPPRESSOR; EUKARYOTIC TRANSLATION; ANTISENSE OLIGODEOXYNUCLEOTIDE; GENE-EXPRESSION; P21 WAF1/CIP1; BREAST; P53	The transformation suppressor gene, programmed cell death gene 4 (Pdcd4), inhibits tumor-promoter-mediated transformation of mouse keratinocytes and has been implicated as a tumor suppressor gene in the development of human cancer. The Pdcd4 protein interacts with translation initiation factors eIF4A and eIF4G and binds to RNA, suggesting that it might be involved in regulating protein translation or other aspects of RNA metabolism. To study the function of Pdcd4 in more detail, we have downregulated Pdcd4 expression in HeLa cells by stable expression of shRNA. We have found that diminished Pdcd4 expression leads to increased expression of p21(Waf1/Cip1) and several other p53-regulated genes. Reporter gene studies demonstrate that Pdcd4 interferes with the activation of p53-responsive promoters genes by p53. Pdcd4 knockdown cells show decreased apoptosis and increased survival after UV irradiation. Taken together, our observations suggest a modelin which low Pdcd4 expression after DNA damage favors the survival of cells, which would be eliminated by apoptosis under normal levels of Pdcd4 expression. Our results provide the first evidence that Pdcd4 is important role in the DNA-damage response and suggest that low levels of Pdcd4 expression observed in certain tumor cells contribute to tumorigenesis by affecting the fate of DNA-damaged cells.	[Bitomsky, N.; Wethkamp, N.; Marikkannu, R.; Klempnauer, K-H] Univ Munster, Inst Biochem, D-48149 Munster, Germany	University of Munster	Klempnauer, KH (corresponding author), Univ Munster, Inst Biochem, Wilhelm Klemm Str 2, D-48149 Munster, Germany.	klempna@uni-muenster.de						Afonja O, 2004, ONCOGENE, V23, P8135, DOI 10.1038/sj.onc.1207983; Bendjennat M, 2003, CELL, V114, P599, DOI 10.1016/j.cell.2003.08.001; Biankin AV, 2001, CANCER RES, V61, P8830; Bitomsky N, 2004, ONCOGENE, V23, P7484, DOI 10.1038/sj.onc.1208064; Bode AM, 2004, NAT REV CANCER, V4, P793, DOI 10.1038/nrc1455; Bohm M, 2003, ONCOGENE, V22, P4905, DOI 10.1038/sj.onc.1206710; BURK O, 1993, EMBO J, V12, P2027, DOI 10.1002/j.1460-2075.1993.tb05852.x; Chen Y, 2003, J PATHOL, V200, P640, DOI 10.1002/path.1378; Cmarik JL, 1999, P NATL ACAD SCI USA, V96, P14037, DOI 10.1073/pnas.96.24.14037; Dorrello NV, 2006, SCIENCE, V314, P467, DOI 10.1126/science.1130276; Dupont JL, 2003, J BIOL CHEM, V278, P37256, DOI 10.1074/jbc.M302355200; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Erber R, 1997, INT J CANCER, V74, P383, DOI 10.1002/(SICI)1097-0215(19970822)74:4<383::AID-IJC4>3.0.CO;2-R; Fan YP, 2003, MOL CANCER THER, V2, P773; FORNACE AJ, 1988, P NATL ACAD SCI USA, V85, P8800, DOI 10.1073/pnas.85.23.8800; Gao F, 2007, ONCOL REP, V17, P123; Gartel AL, 2005, CANCER RES, V65, P3980, DOI 10.1158/0008-5472.CAN-04-3995; Goke A, 2002, BIOCHEM BIOPH RES CO, V297, P78, DOI 10.1016/S0006-291X(02)02129-0; Goke R, 2004, AM J PHYSIOL-CELL PH, V287, pC1541, DOI 10.1152/ajpcell.00025.2004; Gorospe M, 1997, ONCOGENE, V14, P929, DOI 10.1038/sj.onc.1200897; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; HARPER JW, 1993, CELL, V75, P805; Herold S, 2002, MOL CELL, V10, P509, DOI 10.1016/S1097-2765(02)00633-0; Hershey JWB, 2000, COLD SPRING HARBOR M, V39, P33; Hilliard A, 2006, J IMMUNOL, V177, P8095, DOI 10.4049/jimmunol.177.11.8095; Jansen AP, 2005, CANCER RES, V65, P6034, DOI 10.1158/0008-5472.CAN-04-2119; Jansen AP, 2004, MOL CANCER THER, V3, P103; JUNG JM, 1995, ONCOGENE, V11, P2021; LaBaer J, 1997, GENE DEV, V11, P847, DOI 10.1101/gad.11.7.847; Lankat-Buttgereit B, 2003, BIOL CELL, V95, P515, DOI 10.1016/j.biolcel.2003.09.003; LaRonde-LeBlanc N, 2007, MOL CELL BIOL, V27, P147, DOI 10.1128/MCB.00867-06; LINDER P, 1989, NATURE, V337, P121, DOI 10.1038/337121a0; Martoriati A, 2005, ONCOGENE, V24, P1461, DOI 10.1038/sj.onc.1208256; MOSCOVICI C, 1977, CELL, V11, P95, DOI 10.1016/0092-8674(77)90320-8; Mudduluru G, 2007, CANCER-AM CANCER SOC, V110, P1697, DOI 10.1002/cncr.22983; Ozanne BW, 2007, ONCOGENE, V26, P1, DOI 10.1038/sj.onc.1209759; Palamarchuk A, 2005, CANCER RES, V65, P11282, DOI 10.1158/0008-5472.CAN-05-3469; Prives C, 2001, CELL, V107, P815, DOI 10.1016/S0092-8674(01)00619-5; ROZEN F, 1990, MOL CELL BIOL, V10, P1134, DOI 10.1128/MCB.10.3.1134; Schlichter U, 2001, ONCOGENE, V20, P231, DOI 10.1038/sj.onc.1204071; Seoane J, 2002, NATURE, V419, P729, DOI 10.1038/nature01119; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Shibahara K, 1995, GENE, V166, P297, DOI 10.1016/0378-1119(95)00607-9; Sohn D, 2006, CANCER RES, V66, P11254, DOI 10.1158/0008-5472.CAN-06-1569; Toledo F, 2006, NAT REV CANCER, V6, P909, DOI 10.1038/nrc2012; van de Wetering M, 2003, EMBO REP, V4, P609, DOI 10.1038/sj.embor.embor865; Wang Q, 2008, ONCOGENE, V27, P1527, DOI 10.1038/sj.onc.1210793; Waters LC, 2007, ONCOGENE, V26, P4941, DOI 10.1038/sj.onc.1210305; Waters LC, 2006, J BIOMOL NMR, V36, P18, DOI 10.1007/s10858-005-5887-6; Weiss RH, 2003, CANCER CELL, V4, P425, DOI 10.1016/S1535-6108(03)00308-8; Weiss RH, 2003, CANCER LETT, V189, P39, DOI 10.1016/S0304-3835(02)00495-0; Wen YH, 2007, ONCOL REP, V18, P1387; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; Yang HS, 2003, MOL CELL BIOL, V23, P26, DOI 10.1128/MCB.23.1.26-37.2003; Yang HS, 2006, MOL CELL BIOL, V26, P1297, DOI 10.1128/MCB.26.4.1297-1306.2006; Yang HS, 2004, MOL CELL BIOL, V24, P3894, DOI 10.1128/MCB.24.9.3894-3906.2004; Yang HS, 2003, ONCOGENE, V22, P3712, DOI 10.1038/sj.onc.1206433; Yang HS, 2001, ONCOGENE, V20, P669, DOI 10.1038/sj.onc.1204137; Yang WT, 2003, CANCER, V98, P1123, DOI 10.1002/cncr.11625; Young MR, 2003, TRENDS MOL MED, V9, P36, DOI 10.1016/S1471-4914(02)00009-6; Zeng YX, 1997, NAT GENET, V15, P78, DOI 10.1038/ng0197-78; Zhang H, 2006, ONCOGENE, V25, P6101, DOI 10.1038/sj.onc.1209634	62	66	73	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 14	2008	27	35					4820	4829		10.1038/onc.2008.115	http://dx.doi.org/10.1038/onc.2008.115			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	337OJ	18427550				2022-12-28	WOS:000258445100007
J	Impens, F; Van Damme, P; Demol, H; Van Damme, J; Vandekerckhove, J; Gevaert, K				Impens, F.; Van Damme, P.; Demol, H.; Van Damme, J.; Vandekerckhove, J.; Gevaert, K.			Mechanistic insight into taxol-induced cell death	ONCOGENE			English	Article						protease substrates; caspase-like activity; taxol; cytotoxic granule	LUNG-CANCER CELLS; INDUCED APOPTOSIS; PACLITAXEL TREATMENT; PROTEOMICS; IDENTIFICATION; PROTEASE; ACTIVATION; INHIBITION; PEPTIDES; PROTEINS	We analysed the involvement of proteases during taxol-mediated cell death of human A549 non-small-cell lung carcinoma cells using a proteomics approach that specifically targets protein N termini and further detects newly formed N termini that are the result of protein processing. Our analysis revealed 27 protease-mediated cleavages, which we divided in sites C-terminal to aspartic acid (Asp) and sites C-terminal to non-Asp residues, as the result of caspase and non-caspase protease activities, respectively. Remarkably, some of the former were insensitive to potent pancaspase inhibitors, and we therefore suggest that previous inhibitor-based studies that report on the caspase-independent nature of taxol-induced cell death should be judged with care. Furthermore, many of the sites C-terminal to non-Asp residues were also uniquely observed in a model of cytotoxic granule-mediated cell death and/or found by in vitro cataloging human mu-calpain substrates using a similar proteomics technique. This thus raises the hypothesis that killing tumor cells by chemotherapy or by immune cells holds similar non-Asp-specific proteolytic components with strong indications to calpain activity.	[Gevaert, K.] Univ Ghent, Fac Med & Hlth Sci, Dept Biochem, B-9000 Ghent, Belgium; [Impens, F.; Van Damme, P.; Demol, H.; Van Damme, J.; Vandekerckhove, J.; Gevaert, K.] Univ Ghent VIB, Dept Med Prot Res, Ghent, Belgium	Ghent University; Flanders Institute for Biotechnology (VIB); Ghent University	Gevaert, K (corresponding author), Univ Ghent, Fac Med & Hlth Sci, Dept Biochem, Baertsoenkaai 3, B-9000 Ghent, Belgium.	kris.gevaert@ugent.be	Gevaert, Kris/D-6489-2017; Van Damme, Petra/C-7269-2008; Impens, Francis/C-3335-2009; Gevaert, Kris/AAE-4212-2019; Gevaert, Kris/H-3637-2013	Gevaert, Kris/0000-0002-4237-0283; Van Damme, Petra/0000-0001-9090-027X; Gevaert, Kris/0000-0002-4237-0283; Gevaert, Kris/0000-0002-4237-0283; Demol, Hans/0000-0001-7595-0148; Impens, Francis/0000-0003-2886-9616				Bidere N, 2003, J BIOL CHEM, V278, P31401, DOI 10.1074/jbc.M301911200; Blagosklonny MV, 1999, INT J CANCER, V83, P151, DOI 10.1002/(SICI)1097-0215(19991008)83:2<151::AID-IJC1>3.0.CO;2-5; Broker LE, 2004, CANCER RES, V64, P27, DOI 10.1158/0008-5472.CAN-03-3060; Broker LE, 2002, CANCER RES, V62, P4081; Day TW, 2006, BIOCHEM PHARMACOL, V71, P1551, DOI 10.1016/j.bcp.2006.02.015; de Bruin EC, 2003, CELL DEATH DIFFER, V10, P1204, DOI 10.1038/sj.cdd.4401296; DIGWEED M, 1995, MOL CELL BIOL, V15, P305, DOI 10.1128/MCB.15.1.305; Ehrlichova M, 2005, ANTICANCER RES, V25, P4215; Enoksson M, 2007, J PROTEOME RES, V6, P2850, DOI 10.1021/pr0701052; Foghsgaard L, 2001, J CELL BIOL, V153, P999, DOI 10.1083/jcb.153.5.999; Garcia-Calvo M, 1998, J BIOL CHEM, V273, P32608, DOI 10.1074/jbc.273.49.32608; Gevaert K, 2006, J PROTEOME RES, V5, P1415, DOI 10.1021/pr060026a; Gevaert K, 2003, NAT BIOTECHNOL, V21, P566, DOI 10.1038/nbt810; Ghesquiere B, 2006, J PROTEOME RES, V5, P2438, DOI 10.1021/pr060186m; Huisman C, 2002, CLIN CANCER RES, V8, P596; Janssen K, 2007, BLOOD, V110, P3662, DOI 10.1182/blood-2007-02-073213; Karmakar S, 2007, APOPTOSIS, V12, P671, DOI 10.1007/s10495-006-0024-x; Kondo H, 1997, NATURE, V388, P75, DOI 10.1038/40411; Krishan A, 1990, Methods Cell Biol, V33, P121; Leers MPG, 1999, J PATHOL, V187, P567, DOI 10.1002/(SICI)1096-9896(199904)187:5<567::AID-PATH288>3.0.CO;2-J; Leist M, 2001, NAT REV MOL CELL BIO, V2, P589, DOI 10.1038/35085008; Li R, 2005, CELL DEATH DIFFER, V12, P292, DOI 10.1038/sj.cdd.4401554; Lopez-Otin C, 2002, NAT REV MOL CELL BIO, V3, P509, DOI 10.1038/nrm858; Lu KH, 2005, CLIN CHIM ACTA, V357, P65, DOI 10.1016/j.cccn.2005.02.003; Martens L, 2005, BIOINFORMATICS, V21, P3584, DOI 10.1093/bioinformatics/bti588; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; Ofir R, 2002, CELL DEATH DIFFER, V9, P636, DOI 10.1038/sj.cdd.4401012; Ong SE, 2002, MOL CELL PROTEOMICS, V1, P376, DOI 10.1074/mcp.M200025-MCP200; Park SJ, 2004, J BIOL CHEM, V279, P51057, DOI 10.1074/jbc.M406543200; Pineiro D, 2007, EXP CELL RES, V313, P369, DOI 10.1016/j.yexcr.2006.10.020; PYTELA R, 1980, P NATL ACAD SCI-BIOL, V77, P4808, DOI 10.1073/pnas.77.8.4808; SCHIFF PB, 1980, P NATL ACAD SCI-BIOL, V77, P1561, DOI 10.1073/pnas.77.3.1561; Schotte P, 1999, FEBS LETT, V442, P117, DOI 10.1016/S0014-5793(98)01640-8; Smyth MJ, 2001, J LEUKOCYTE BIOL, V70, P18; Staes A, 2004, J PROTEOME RES, V3, P786, DOI 10.1021/pr049956p; Torres K, 1998, CANCER RES, V58, P3620; Van Damme P, 2005, NAT METHODS, V2, P771, DOI 10.1038/NMETH792; Vande Walle L, 2007, J PROTEOME RES, V6, P1006, DOI 10.1021/pr060510d; Wood DE, 1999, J BIOL CHEM, V274, P8309, DOI 10.1074/jbc.274.12.8309; Yan R, 2006, CELL MOL LIFE SCI, V63, P877, DOI 10.1007/s00018-005-5338-2; Zhao JS, 2005, INT J ONCOL, V27, P247; Zhao M, 2000, FEBS LETT, V485, P104, DOI 10.1016/S0014-5793(00)02195-5	42	36	37	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 31	2008	27	33					4580	4591		10.1038/onc.2008.96	http://dx.doi.org/10.1038/onc.2008.96			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	332IS	18408750				2022-12-28	WOS:000258077300007
J	Karam, R; Carvalho, J; Bruno, I; Graziadio, C; Senz, J; Huntsman, D; Carneiro, F; Seruca, R; Wilkinson, MF; Oliveira, C				Karam, R.; Carvalho, J.; Bruno, I.; Graziadio, C.; Senz, J.; Huntsman, D.; Carneiro, F.; Seruca, R.; Wilkinson, M. F.; Oliveira, C.			The NMD mRNA surveillance pathway downregulates aberrant E-cadherin transcripts in gastric cancer cells and in CDH1 mutation carriers	ONCOGENE			English	Article						NMD; E-cadherin; CDH1; gastric cancer; HDGC; KATO-III	NONSENSE-MEDIATED DECAY; GENE; MECHANISM; FAMILIES	Germline mutations in the gene encoding the tumour suppressor E-cadherin (CDH1) are the underlying genetic defect responsible for hereditary diffuse gastric cancer (HDGC). A remarkably high percentage (similar to 80%) of CDH1 mutations in HDGC patients and carriers generate premature termination codons (PTCs). Here, we examined whether CDH1 transcripts harbouring PTCs are downregulated by nonsense-mediated decay (NMD), an RNA surveillance pathway that degrades PTC-bearing transcripts. Using an allele-specific expression (ASE) assay to differentiate between mutated and wild-type CDH1 alleles, we found that PTC-bearing CDH1 mRNAs are strongly downregulated in normal gastric tissue from several CDH1 mutation carriers. We show that NMD is responsible for this robust downregulation, as CDH1 transcripts harbouring PTCs in the KATO-III gastric tumour cell line were upregulated in response to protein synthesis inhibitors or depletion of the NMD factors UPF1 and eIF4AIII. Analysis of HDGC patients harbouring CDH1 alleles with PTCs at a wide variety of different positions indicates an association of their predicted ability to induce NMD and an earlier age of onset of gastric cancer. This suggests that NMD may be detrimental for HDGC patients and therefore NMD is a potentially useful therapeutic target for CDH1 mutation carriers.	[Karam, R.; Bruno, I.; Wilkinson, M. F.] Univ Texas MD Anderson Canc Ctr, Dept Biochem & Mol Biol, Unit 1000, Houston, TX 77030 USA; [Karam, R.; Carvalho, J.; Carneiro, F.; Seruca, R.; Oliveira, C.] Univ Porto, Inst Mol Pathol & Immunol, Canc Genet Grp, P-4200465 Oporto, Portugal; [Karam, R.; Carneiro, F.; Seruca, R.; Oliveira, C.] Univ Porto, Fac Med, P-4100 Oporto, Portugal; [Graziadio, C.] FFFCMPA, Dept Genet, Porto Alegre, RS, Brazil; [Senz, J.; Huntsman, D.] British Columbia Canc Agcy, Hereditary Canc Program, Vancouver, BC V5Z 4E6, Canada	University of Texas System; UTMD Anderson Cancer Center; Universidade do Porto; Universidade do Porto; British Columbia Cancer Agency	Wilkinson, MF (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Biochem & Mol Biol, Unit 1000, 1515 Holcombe Blvd, Houston, TX 77030 USA.	mwilkins@mdanderson.org; carlaol@ipatimup.pt	Carneiro, Fatima/AAV-8677-2021; Carvalho, Joana/J-9476-2013; seruca, raquel/F-8187-2011; Huntsman, David/ABE-6082-2020; Oliveira, Carla/F-8188-2011; Carneiro, Fatima/J-6432-2013; Graziadio, Carla/G-5566-2015	Carneiro, Fatima/0000-0002-1964-1006; Carvalho, Joana/0000-0001-9743-438X; Oliveira, Carla/0000-0001-8340-2264; Carneiro, Fatima/0000-0002-1964-1006; Seruca, Raquel/0000-0002-8851-4166; Graziadio, Carla/0000-0001-6569-5278	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM058595] Funding Source: NIH RePORTER; NIGMS NIH HHS [5-RO1GM058595-08, R01 GM111838] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Carrel L, 2005, NATURE, V434, P400, DOI 10.1038/nature03479; CARTER MS, 1995, J BIOL CHEM, V270, P28995, DOI 10.1074/jbc.270.48.28995; Chang YF, 2007, ANNU REV BIOCHEM, V76, P51, DOI 10.1146/annurev.biochem.76.050106.093909; Dussaulx-Garin L, 2001, EUR J GASTROEN HEPAT, V13, P711, DOI 10.1097/00042737-200106000-00016; El-Bchiri J, 2005, HUM MOL GENET, V14, P2435, DOI 10.1093/hmg/ddi245; Frebourg T, 2006, J MED GENET, V43, P138, DOI 10.1136/jmg.2005.031385; Guilford P, 1998, NATURE, V392, P402, DOI 10.1038/32918; Holbrook JA, 2004, NAT GENET, V36, P801, DOI 10.1038/ng1403; Kaurah P, 2007, JAMA-J AM MED ASSOC, V297, P2360, DOI 10.1001/jama.297.21.2360; KNUDSON AG, 1971, P NATL ACAD SCI USA, V68, P820, DOI 10.1073/pnas.68.4.820; ODA T, 1994, P NATL ACAD SCI USA, V91, P1858, DOI 10.1073/pnas.91.5.1858; Oliveira C, 2006, INT J SURG PATHOL, V14, P21, DOI 10.1177/106689690601400105; Oliveira C, 2004, ONCOGENE, V23, P2236, DOI 10.1038/sj.onc.1207335; Sasaki CY, 2000, CANCER RES, V60, P7057; Suriano G, 2003, HUM MOL GENET, V12, P3007, DOI 10.1093/hmg/ddg316; Wilkinson MF, 2005, TRENDS GENET, V21, P143, DOI 10.1016/j.tig.2005.01.007	16	59	64	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2008	27	30					4255	4260		10.1038/onc.2008.62	http://dx.doi.org/10.1038/onc.2008.62			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	324DB	18427545				2022-12-28	WOS:000257496800013
J	Yang, SL; Cao, Q; Zhou, KC; Feng, YJ; Wang, YZ				Yang, S. L.; Cao, Q.; Zhou, K. C.; Feng, Y. J.; Wang, Y. Z.			Transient receptor potential channel C3 contributes to the progression of human ovarian cancer	ONCOGENE			English	Article						TRPC channels; ovarian epithelium cancer; proliferation; Ca2+/calmodulin-dependent kinase II; M phase	CAPACITATIVE CA2+ ENTRY; PROTEIN KINASE-II; CELL-PROLIFERATION; MAMMALIAN-CELLS; TRPC3 CHANNELS; CYTOSTATIC FACTOR; EPITHELIAL-CELLS; CALCIUM; EXPRESSION; ACTIVATION	Ovarian cancer (OC) is the leading cause of death from gynecological malignancy. However, the mechanism by which OC develops remains largely unknown. Increases in cytosolic free Ca2+ ([Ca2+](i)) can result in different physiological changes including cell growth, differentiation and death. The transient receptor potential (TRP) C channels are nonselective cation channels with permeability to Ca2(+). Here we report that TRPC3 channels promote human OC growth. The TRPC3 protein levels in human OC specimens were greatly increased than those in normal ovarian specimens. Downregulating TRPC3 expression in SKOV3 cells, a human OC cell line, led to reduction of proliferation, suppression in epidermal growth factor-induced Ca2+ in flux, dephosphorylation of Cdc2 and CaMKII alpha and prolonged progression through M phase of these cells. Further, decreased the expression of TRPC3 suppressed the tumor formation generated by injecting SKOV3 cells in nude mice. Together, our results suggest that increased activity of TRPC3 channels is necessary for the development of OCs. Oncogene (2009) 28, 1320-1328; doi:10.1038/onc.2008.475; published online 19 January 2009	[Yang, S. L.; Zhou, K. C.; Wang, Y. Z.] Shanghai Inst Biol Sci, Inst Neurosci, Lab Neural Signal Transduct, State Key Lab Neurosci, Shanghai 200031, Peoples R China; [Yang, S. L.; Zhou, K. C.; Wang, Y. Z.] Chinese Acad Sci, Grad Sch, Shanghai, Peoples R China; [Cao, Q.; Feng, Y. J.] Fudan Univ, Med Ctr, Obstet & Gynecol Hosp, Shanghai 200433, Peoples R China	Chinese Academy of Sciences; Shanghai Institutes for Biological Sciences, CAS; Chinese Academy of Sciences; Fudan University	Wang, YZ (corresponding author), Shanghai Inst Biol Sci, Inst Neurosci, Lab Neural Signal Transduct, State Key Lab Neurosci, 320 Yueyang Rd, Shanghai 200031, Peoples R China.	yzwang@ion.ac.cn			973 Program [2006CB806600]; National Natural Science Foundation of China [30711120566, 30621062, U0632006]	973 Program(National Basic Research Program of China); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	We thank Q Hu and HL Yao for technical support and B Shen for reading the article. This work was supported by grants from the 973 Program (2006CB806600), projects 30711120566, 30621062, U0632006 from the National Natural Science Foundation of China and project B117 from Shanghai Leading Academic Discipline Project.	Auersperg N, 1998, SEMIN ONCOL, V25, P281; Berridge MJ, 2003, NAT REV MOL CELL BIO, V4, P517, DOI 10.1038/nrm1155; Bezzerides VJ, 2004, NAT CELL BIOL, V6, P709, DOI 10.1038/ncb1150; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Clapham DE, 2001, NAT REV NEUROSCI, V2, P387, DOI 10.1038/35077544; Cook SJ, 2006, CELL CALCIUM, V39, P101, DOI 10.1016/j.ceca.2005.10.014; Cullen PJ, 2002, NAT REV MOL CELL BIO, V3, P339, DOI 10.1038/nrm808; Dietrich A, 2005, MOL CELL BIOL, V25, P6980, DOI 10.1128/MCB.25.16.6980-6989.2005; Dolmetsch RE, 1998, NATURE, V392, P933, DOI 10.1038/31960; Eder P, 2005, PFLUG ARCH EUR J PHY, V451, P99, DOI 10.1007/s00424-005-1434-2; El Boustany C, 2008, HEPATOLOGY, V47, P2068, DOI 10.1002/hep.22263; FONG YL, 1989, J BIOL CHEM, V264, P16759; Hansen DV, 2006, P NATL ACAD SCI USA, V103, P608, DOI 10.1073/pnas.0509549102; Hofmann T, 1999, NATURE, V397, P259, DOI 10.1038/16711; Hurst RS, 1998, FEBS LETT, V422, P333, DOI 10.1016/S0014-5793(98)00035-0; Hussain MM, 2003, J CLIN ONCOL, V21, P4356, DOI 10.1200/JCO.2003.04.136; Jia YC, 2007, NAT NEUROSCI, V10, P559, DOI 10.1038/nn1870; Kahl CR, 2003, ENDOCR REV, V24, P719, DOI 10.1210/er.2003-0008; KAO JPY, 1990, J CELL BIOL, V111, P183, DOI 10.1083/jcb.111.1.183; Kohn EC, 1996, CANCER RES, V56, P569; Lintschinger B, 2000, J BIOL CHEM, V275, P27799; Liu JJ, 2005, CURR BIOL, V15, P1458, DOI 10.1016/j.cub.2005.07.030; LORCA T, 1993, NATURE, V366, P270, DOI 10.1038/366270a0; Maihle N J, 2002, Cancer Treat Res, V107, P247; Minaguchi T, 2006, CANCER RES, V66, P11677, DOI 10.1158/0008-5472.CAN-06-2240; Mochida S, 2007, NATURE, V449, P336, DOI 10.1038/nature06121; Monteith GR, 2007, NAT REV CANCER, V7, P519, DOI 10.1038/nrc2171; Nicosia SV, 2003, HEMATOL ONCOL CLIN N, V17, P927, DOI 10.1016/S0889-8588(03)00056-X; Odell AF, 2005, J BIOL CHEM, V280, P37974, DOI 10.1074/jbc.M503646200; POPPER LD, 1993, CELL CALCIUM, V14, P209, DOI 10.1016/0143-4160(93)90068-H; Psyrri A, 2005, CLIN CANCER RES, V11, P8637, DOI 10.1158/1078-0432.CCR-05-1436; Rauh NR, 2005, NATURE, V437, P1048, DOI 10.1038/nature04093; Roderick HL, 2008, NAT REV CANCER, V8, P361, DOI 10.1038/nrc2374; Rosenberg P, 2004, P NATL ACAD SCI USA, V101, P9387, DOI 10.1073/pnas.0308179101; Rosker C, 2004, J BIOL CHEM, V279, P13696, DOI 10.1074/jbc.M308108200; Schultze-Mosgau A, 2000, MOL HUM REPROD, V6, P435, DOI 10.1093/molehr/6.5.435; Smyth JT, 2006, J BIOL CHEM, V281, P11712, DOI 10.1074/jbc.M510541200; Thebault S, 2006, CANCER RES, V66, P2038, DOI 10.1158/0008-5472.CAN-05-0376; Thebault S, 2005, J CELL PHYSIOL, V204, P320, DOI 10.1002/jcp.20301; TOMBES RM, 1989, J CELL BIOL, V109, P627, DOI 10.1083/jcb.109.2.627; Venkatachalam K, 2007, ANNU REV BIOCHEM, V76, P387, DOI 10.1146/annurev.biochem.75.103004.142819; Xu NH, 2003, BIOCHEM BIOPH RES CO, V306, P737, DOI 10.1016/S0006-291X(03)01061-1; Yang H, 2005, J BIOL CHEM, V280, P32230, DOI 10.1074/jbc.M504553200; Yu Y, 2004, P NATL ACAD SCI USA, V101, P13861, DOI 10.1073/pnas.0405908101; Yu Y, 2003, AM J PHYSIOL-CELL PH, V284, pC316, DOI 10.1152/ajpcell.00125.2002; Zagranichnaya TK, 2005, J BIOL CHEM, V280, P29559, DOI 10.1074/jbc.M505842200; Zhu X, 1998, J BIOL CHEM, V273, P133, DOI 10.1074/jbc.273.1.133; Zhu X, 1996, CELL, V85, P661, DOI 10.1016/S0092-8674(00)81233-7; Zitt C, 1997, J CELL BIOL, V138, P1333, DOI 10.1083/jcb.138.6.1333	49	96	101	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2009	28	10					1320	1328		10.1038/onc.2008.475	http://dx.doi.org/10.1038/onc.2008.475			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	417ZC	19151765				2022-12-28	WOS:000264116000004
J	Bach, C; Mueller, D; Buhl, S; Garcia-Cuellar, MP; Slany, RK				Bach, C.; Mueller, D.; Buhl, S.; Garcia-Cuellar, M. P.; Slany, R. K.			Alterations of the CxxC domain preclude oncogenic activation of mixed-lineage leukemia 2	ONCOGENE			English	Article						CxxC domain; MLL; MLL2; transformation	HISTONE METHYLTRANSFERASE COMPLEX; DROSOPHILA-TRITHORAX; REPRESSION DOMAIN; BINDING PROTEIN; HRX-ENL; MLL; GENE; DNA; TRANSFORMATION; MENIN	The mixed-lineage leukemia (MLL) family of histone methyltransferases has become notorious for the participation of the founding member, MLL, in fusion proteins that cause acute leukemia. Despite structural conservation, no other MLL homolog has so far been found in a similar arrangement. Here, we show that fusion proteins based on Mll2, the closest relative of MLL, are incapable of transforming hematopoietic cells. Elaborate swap experiments identified the small CxxC zinc-binding region of Mll2 and an adjacent 'post-CxxC' stretch of basic amino acids as the essential determinants for the observed difference. Gel shift experiments indicated that the combined CxxC and post-CxxC domains of MLL and Mll2 possess almost indistinguishable DNA-binding properties in vitro. Within the cellular environment, however, these motifs guided MLL and Mll2 to a largely nonoverlapping target gene repertoire, as evidenced by nuclear localization, reporter assays, and measurements of homeobox gene levels in primary cells expressing MLL and Mll2 fusion proteins. Therefore, the CxxC domain appears to be a promising target for therapies aimed at MLL fusion proteins without affecting the general function of other MLL family members.	[Bach, C.; Mueller, D.; Buhl, S.; Garcia-Cuellar, M. P.; Slany, R. K.] Univ Erlangen Nurnberg, Dept Genet, D-91058 Erlangen, Bavaria, Germany	University of Erlangen Nuremberg	Slany, RK (corresponding author), Univ Erlangen Nurnberg, Dept Genet, Staudtstr 5,Bldg A2, D-91058 Erlangen, Bavaria, Germany.	rslany@biologie.uni-erlangen.de		Bach, Christian/0000-0003-4675-7896	DFG [SL27/6-2, SFB473/D2]; Jose-Carerras-Stiftung; Curt-Bohnewald-Fond	DFG(German Research Foundation (DFG)); Jose-Carerras-Stiftung; Curt-Bohnewald-Fond	We thank Bernd Zeisig and Silvio Scheel for help in early stages of this work. Technical support of Renate Zimmermann and sharing of reagents by Francis Stewart, Boris Fehse and Carol Stocking is gratefully acknowledged. RKS was supported by DFG Grant SL27/6-2 and in part by SFB473/D2. Equipment funding came from Jose-Carerras-Stiftung and Curt-Bohnewald-Fond.	Allen MD, 2006, EMBO J, V25, P4503, DOI 10.1038/sj.emboj.7601340; Ayton PM, 2004, MOL CELL BIOL, V24, P10470, DOI 10.1128/MCB.24.23.10470-10478.2004; Birke M, 2002, NUCLEIC ACIDS RES, V30, P958, DOI 10.1093/nar/30.4.958; Caslini C, 2007, CANCER RES, V67, P7275, DOI 10.1158/0008-5472.CAN-06-2369; Chen W, 2008, CANCER CELL, V13, P432, DOI 10.1016/j.ccr.2008.03.005; Cheung N, 2007, NAT CELL BIOL, V9, P1208, DOI 10.1038/ncb1642; Demers C, 2007, MOL CELL, V27, P573, DOI 10.1016/j.molcel.2007.06.022; Dou YL, 2006, NAT STRUCT MOL BIOL, V13, P713, DOI 10.1038/nsmb1128; Dou YL, 2005, CELL, V121, P873, DOI 10.1016/j.cell.2005.04.031; FitzGerald KT, 1999, GENOMICS, V59, P187, DOI 10.1006/geno.1999.5860; Glaser S, 2006, DEVELOPMENT, V133, P1423, DOI 10.1242/dev.02302; Hughes CM, 2004, MOL CELL, V13, P587, DOI 10.1016/S1097-2765(04)00081-4; Huntsman DG, 1999, ONCOGENE, V18, P7975, DOI 10.1038/sj.onc.1203291; Krivtsov AV, 2007, NAT REV CANCER, V7, P823, DOI 10.1038/nrc2253; Lavau C, 1997, EMBO J, V16, P4226, DOI 10.1093/emboj/16.14.4226; Lee JH, 2001, J BIOL CHEM, V276, P44669, DOI 10.1074/jbc.M107179200; Mueller D, 2007, BLOOD, V110, P4445, DOI 10.1182/blood-2007-05-090514; Ruthenburg AJ, 2007, MOL CELL, V25, P15, DOI 10.1016/j.molcel.2006.12.014; Schreiner SA, 1999, LEUKEMIA, V13, P1525, DOI 10.1038/sj.leu.2401534; Slany RK, 1998, MOL CELL BIOL, V18, P122, DOI 10.1128/MCB.18.1.122; TKACHUK DC, 1992, CELL, V71, P691, DOI 10.1016/0092-8674(92)90602-9; Weber K, 2008, MOL THER, V16, P698, DOI 10.1038/mt.2008.6; Wysocka J, 2003, GENE DEV, V17, P896, DOI 10.1101/gad.252103; Xia ZB, 2003, P NATL ACAD SCI USA, V100, P8342, DOI 10.1073/pnas.1436338100; Yokoyama A, 2004, MOL CELL BIOL, V24, P5639, DOI 10.1128/MCB.24.13.5639-5649.2004; Yokoyama A, 2005, CELL, V123, P207, DOI 10.1016/j.cell.2005.09.025; YU BD, 1995, NATURE, V378, P505, DOI 10.1038/378505a0; Zeisig BB, 2004, MOL CELL BIOL, V24, P617, DOI 10.1128/MCB.24.2.617-628.2004; ZELEZNIKLE NJ, 1994, P NATL ACAD SCI USA, V91, P10610, DOI 10.1073/pnas.91.22.10610	29	62	62	0	22	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2009	28	6					815	823		10.1038/onc.2008.443	http://dx.doi.org/10.1038/onc.2008.443			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	406UI	19060922				2022-12-28	WOS:000263320000004
J	Bar, J; Feniger-Barish, R; Lukashchuk, N; Shaham, H; Moskovits, N; Goldfinger, N; Simansky, D; Perlman, M; Papa, M; Yosepovich, A; Rechavi, G; Rotter, V; Oren, M				Bar, J.; Feniger-Barish, R.; Lukashchuk, N.; Shaham, H.; Moskovits, N.; Goldfinger, N.; Simansky, D.; Perlman, M.; Papa, M.; Yosepovich, A.; Rechavi, G.; Rotter, V.; Oren, M.			Cancer cells suppress p53 in adjacent fibroblasts	ONCOGENE			English	Article						p53; stroma; tumor suppression; CAFs; genotoxic stress	STROMAL CELLS; TUMOR-SUPPRESSOR; CARCINOMA; GROWTH; TP53; MUTATIONS	The p53 tumor suppressor serves as a crucial barrier against cancer development. In tumor cells and their progenitors, p53 suppresses cancer in a cell-autonomous manner. However, p53 also possesses non-cell-autonomous activities. For example, p53 of stromal fibroblasts can modulate the spectrum of proteins secreted by these cells, rendering their microenvironment less supportive of the survival and spread of adjacent tumor cells. We now report that epithelial tumor cells can suppress p53 induction in neighboring fibroblasts, an effect reproducible by tumor cell-conditioned medium. The ability to suppress fibroblast p53 activation is acquired by epithelial cells in the course of neoplastic transformation. Specifically, stable transduction of immortalized epithelial cells by mutant H-Ras and p53-specific short inhibitory RNA endows them with the ability to quench fibroblast p53 induction. Importantly, human cancer-associated fibroblasts are more susceptible to this suppression than normal fibroblasts. These findings underscore a mechanism whereby epithelial cancer cells may overcome the non-cell-autonomous tumor suppressor function of p53 in stromal fibroblasts.	[Bar, J.] Chaim Sheba Med Ctr, Canc Res Ctr, Dept Oncol, IL-52621 Tel Hashomer, Israel; [Bar, J.; Rechavi, G.] Tel Aviv Univ, Sackler Fac Med, IL-69978 Tel Aviv, Israel; [Lukashchuk, N.] Beatson Inst Canc Res, Glasgow G61 1BD, Lanark, Scotland; [Shaham, H.; Moskovits, N.; Goldfinger, N.; Rotter, V.; Oren, M.] Weizmann Inst Sci, IL-76100 Rehovot, Israel; [Simansky, D.] Chaim Sheba Med Ctr, Dept Thorac Surg, IL-52621 Tel Hashomer, Israel; [Perlman, M.; Yosepovich, A.] Chaim Sheba Med Ctr, Inst Pathol, IL-52621 Tel Hashomer, Israel; [Papa, M.] Chaim Sheba Med Ctr, Dept Surg C, IL-52621 Tel Hashomer, Israel	Chaim Sheba Medical Center; Tel Aviv University; Sackler Faculty of Medicine; Beatson Institute; Weizmann Institute of Science; Chaim Sheba Medical Center; Chaim Sheba Medical Center; Chaim Sheba Medical Center	Bar, J (corresponding author), Ottawa Hosp Canc Ctr, Div Med Oncol, Gen Campus,501 Smyth Rd, Ottawa, ON K1H 8L6, Canada.	bar.jair@gmail.com	Bar, Jair/AAS-5743-2021	Bar, Jair/0000-0002-1224-3646; Oren, Moshe/0000-0003-4311-7172	Flight Attendant Medical Research Institute (FAMRI); National Cancer Institute [R37 CA40099]; Koschitzky family; Tel Aviv University Cancer Biology Research Center; NATIONAL CANCER INSTITUTE [R37CA040099] Funding Source: NIH RePORTER	Flight Attendant Medical Research Institute (FAMRI); National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Koschitzky family; Tel Aviv University Cancer Biology Research Center; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Dr J Schachter and Dr B Kaufman for helpful discussions. This work was supported in part by a Center of Excellence grant from the Flight Attendant Medical Research Institute (FAMRI), and by grant R37 CA40099 from the National Cancer Institute. JB was supported also by the Koschitzky family donation to the breast cancer unit of CSMC, and by a Van Bates grant from the Tel Aviv University Cancer Biology Research Center.	Bar J, 2004, ONCOGENE, V23, P2128, DOI 10.1038/sj.onc.1207325; BUCKBINDER L, 1995, NATURE, V377, P646, DOI 10.1038/377646a0; Campbell IG, 2008, NEW ENGL J MED, V358, P1634, DOI 10.1056/NEJMc086024; Dudley AC, 2008, BRIT J CANCER, V99, P118, DOI 10.1038/sj.bjc.6604465; Elenbaas B, 2001, EXP CELL RES, V264, P169, DOI 10.1006/excr.2000.5133; Hawsawi NM, 2008, CANCER RES, V68, P2717, DOI 10.1158/0008-5472.CAN-08-0192; Kalluri R, 2006, NAT REV CANCER, V6, P392, DOI 10.1038/nrc1877; Karnoub AE, 2007, NATURE, V449, P557, DOI 10.1038/nature06188; Kiaris H, 2005, CANCER RES, V65, P1627, DOI 10.1158/0008-5472.CAN-04-3791; Komarova EA, 1998, ONCOGENE, V17, P1089, DOI 10.1038/sj.onc.1202303; Kurose K, 2002, NAT GENET, V32, P355, DOI 10.1038/ng1013; Logunov DY, 2008, ONCOGENE, V27, P4521, DOI 10.1038/onc.2008.103; Milyavsky M, 2003, CANCER RES, V63, P7147; Moskovits N, 2006, CANCER RES, V66, P10671, DOI 10.1158/0008-5472.CAN-06-2323; Olumi AF, 1999, CANCER RES, V59, P5002; Patocs A, 2007, NEW ENGL J MED, V357, P2543, DOI 10.1056/NEJMoa071825; Radisky D, 2001, SEMIN CANCER BIOL, V11, P87, DOI 10.1006/scbi.2000.0360; Roukos DH, 2008, NEW ENGL J MED, V358, P1636; Tan MJ, 2000, P NATL ACAD SCI USA, V97, P109, DOI 10.1073/pnas.97.1.109; Tlsty TD, 2001, SEMIN CANCER BIOL, V11, P97, DOI 10.1006/scbi.2000.0361; Vousden KH, 2007, NAT REV MOL CELL BIO, V8, P275, DOI 10.1038/nrm2147; Wernert N, 2001, ANTICANCER RES, V21, P2259	22	51	51	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2009	28	6					933	936		10.1038/onc.2008.445	http://dx.doi.org/10.1038/onc.2008.445			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	406UI	19060923	Green Accepted			2022-12-28	WOS:000263320000015
J	Ohtani, Y; Harada, T; Funasaka, Y; Nakao, K; Takahara, C; Abdel-Daim, M; Sakai, N; Saito, N; Nishigori, C; Aiba, A				Ohtani, Y.; Harada, T.; Funasaka, Y.; Nakao, K.; Takahara, C.; Abdel-Daim, M.; Sakai, N.; Saito, N.; Nishigori, C.; Aiba, A.			Metabotropic glutamate receptor subtype-1 is essential for in vivo growth of melanoma	ONCOGENE			English	Article						mGluR1; melanoma; transgenic; tetracycline	MGLUR1 MUTANT MICE; MALIGNANT-MELANOMA; GENE-EXPRESSION; CELLS; BRAF; MUTATIONS; GLUTAMATE-RECEPTOR-1; STIMULATION; ACTIVATION; PLASTICITY	Ectopic expression of metabotropic glutamate receptor subtype 1 (mGluR1) in mouse melanocytes induces melanoma formation. Although requirement of mGluR1 for development of melanoma in the initial stage has been demonstrated, its role in melanoma growth in vivo remains unclear. In this study, we developed novel transgenic mice that conditionally express mGluR1 in melanocytes, using a tetracycline regulatory system. Pigmented lesions on the ears and tails of the transgenic mice began to appear 29 weeks after activation of the mGluR1 transgene, and the transgenic mice produced melanomas at a frequency of 100% 52 weeks after transgene activation. Subsequent inactivation of the mGluR1 transgene in melanoma-bearing mice inhibited melanoma growth with reduction of immunoreactivity to phosphorylated ERK1/2, whereas mice with persistent expression of mGluR1 developed larger melanoma burdens. mGluR1 expression is thus required not only for melanoma development but also for melanoma growth in vivo. These findings suggest that growth of melanoma can be inhibited in vivo by eliminating only one of the multiple genetic anomalies involved in tumorigenesis.	[Ohtani, Y.; Harada, T.; Takahara, C.; Aiba, A.] Kobe Univ, Div Mol Genet, Dept Physiol & Cell Biol, Grad Sch Med,Chuo Ku, Kobe, Hyogo 6500017, Japan; [Funasaka, Y.; Abdel-Daim, M.; Nishigori, C.] Kobe Univ, Div Dermatol, Dept Clin Mol Med, Grad Sch Med, Kobe, Hyogo 6500017, Japan; [Nakao, K.] RIKEN, Lab Anim Resources & Genet Engn, Ctr Dev Biol, Kobe, Hyogo, Japan; [Sakai, N.] Hiroshima Univ, Dept Mol & Pharmacol Neurosci, Grad Sch Biomed Sci, Hiroshima, Japan; [Saito, N.] Kobe Univ, Mol Pharmacol Lab, Biosignal Res Ctr, Kobe, Hyogo 6500017, Japan	Kobe University; Kobe University; RIKEN; Hiroshima University; Kobe University	Aiba, A (corresponding author), Kobe Univ, Div Mol Genet, Dept Physiol & Cell Biol, Grad Sch Med,Chuo Ku, 7-5-1 Kusunokicho, Kobe, Hyogo 6500017, Japan.	aiba@med.kobe-u.ac.jp	Sakai, Norio/AAM-5822-2021; Abdel-Daim, Mohamed M./B-2545-2013	Sakai, Norio/0000-0002-6648-8761; Abdel-Daim, Mohamed M./0000-0002-4341-2713; zhong wei, he gui/0000-0002-3066-3564	Ministry of Education, Culture, Sports, Science and Technology of Japan; Naito Foundation; Takeda Science Foundation; Uehara Memorial Foundation; Astellas Foundation for Research on Metabolic Disorders	Ministry of Education, Culture, Sports, Science and Technology of Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Naito Foundation(Naito Memorial Foundation); Takeda Science Foundation(Takeda Science Foundation (TSF)); Uehara Memorial Foundation(Uehara Memorial Foundation); Astellas Foundation for Research on Metabolic Disorders	We thank Dr S Nakanishi for rat mGluR1a cDNA, Dr Y Ishida for beta-globin insulator and the members of Aiba lab for helpful discussion. This study supported in part by Grant-in-Aid for Scientific Research on Priority Areas Molecular Brain Science, a grant for the 21st Century COE Program 'Center for Excellence for Signal Transduction Disease: Diabetes Mellitus as Model' from the Ministry of Education, Culture, Sports, Science and Technology of Japan, and grants from the Naito Foundation, the Takeda Science Foundation, the Uehara Memorial Foundation and the Astellas Foundation for Research on Metabolic Disorders.	AIBA A, 1994, CELL, V79, P365, DOI 10.1016/0092-8674(94)90204-6; AIBA A, 1994, CELL, V79, P377, DOI 10.1016/0092-8674(94)90204-6; Chen JS, 1998, MOL PHARMACOL, V54, P495, DOI 10.1124/mol.54.3.495; Chen S, 1996, J INVEST DERMATOL, V106, P1145, DOI 10.1111/1523-1747.ep12340194; Chin L, 1999, NATURE, V400, P468, DOI 10.1038/22788; CHUNG JH, 1993, CELL, V74, P505, DOI 10.1016/0092-8674(93)80052-G; Conn PJ, 1997, ANNU REV PHARMACOL, V37, P205, DOI 10.1146/annurev.pharmtox.37.1.205; CONQUET F, 1994, NATURE, V372, P237, DOI 10.1038/372237a0; Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; Handerson T, 2003, CANCER RES, V63, P5363; Huntington JT, 2004, J BIOL CHEM, V279, P33168, DOI 10.1074/jbc.M405102200; Karim F, 2001, J NEUROSCI, V21, P3771, DOI 10.1523/JNEUROSCI.21-11-03771.2001; Marin YE, 2006, CELL SIGNAL, V18, P1279, DOI 10.1016/j.cellsig.2005.10.012; Marin YE, 2005, NEUROPHARMACOLOGY, V49, P70, DOI 10.1016/j.neuropharm.2005.05.018; MASU M, 1991, NATURE, V349, P760, DOI 10.1038/349760a0; Michaloglou C, 2008, ONCOGENE, V27, P877, DOI 10.1038/sj.onc.1210704; NAKANISHI S, 1992, SCIENCE, V258, P597, DOI 10.1126/science.1329206; NAKANISHI S, 1994, NEURON, V13, P1031, DOI 10.1016/0896-6273(94)90043-4; Nambiar S, 2005, ARCH DERMATOL, V141, P165, DOI 10.1001/archderm.141.2.165; Namkoong J, 2007, CANCER RES, V67, P2298, DOI 10.1158/0008-5472.CAN-06-3665; Pollock PM, 2003, NAT GENET, V34, P108, DOI 10.1038/ng1148; Rzeski W, 2001, P NATL ACAD SCI USA, V98, P6372, DOI 10.1073/pnas.091113598; Satyamoorthy K, 2003, CANCER RES, V63, P756; Sharma A, 2005, CANCER RES, V65, P2412, DOI 10.1158/0008-5472.CAN-04-2423; Stepulak A, 2005, P NATL ACAD SCI USA, V102, P15605, DOI 10.1073/pnas.0507679102; Thandi S, 2002, J NEUROCHEM, V83, P1139, DOI 10.1046/j.1471-4159.2002.01217.x; Thomas NE, 2006, MELANOMA RES, V16, P97, DOI 10.1097/01.cmr.0000215035.38436.87; Van Dyke T, 2002, CELL, V108, P135, DOI 10.1016/S0092-8674(02)00621-9; Wong CW, 2005, J CLIN PATHOL, V58, P640, DOI 10.1136/jcp.2004.022509	30	60	64	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC	2008	27	57					7162	7170		10.1038/onc.2008.329	http://dx.doi.org/10.1038/onc.2008.329			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	379GG	18776920	Bronze			2022-12-28	WOS:000261384100003
J	Cheresh, DA; Stupack, DG				Cheresh, D. A.; Stupack, D. G.			Regulation of angiogenesis: apoptotic cues from the ECM	ONCOGENE			English	Review						apoptosis; integrin; survival; endothelial; pericyte	FOCAL ADHESION KINASE; ENDOTHELIAL PROGENITOR CELLS; INTEGRIN ALPHA(V)BETA(3)-MEDIATED ACTIVATION; TUMOR-ASSOCIATED MACROPHAGES; FACTOR-KAPPA-B; EXTRACELLULAR-MATRIX; INHIBITS ANGIOGENESIS; PROTEIN-KINASE; GLANZMANN THROMBASTHENIA; VASCULAR MORPHOGENESIS	The extracellular matrix (ECM) acts both as a physical scaffold for cells and as a repository for growth factors. Moreover, ECM structure and physical-chemical properties convey precise information to cells that profoundly influences their biology by interactions with cell surface receptors termed integrins. During angiogenesis, the perivascular ECM plays a critical role in determining the proliferative, invasive and survival responses of the local vascular cells to the angiogenic growth factors. Dynamic changes in both the ECM and the local vascular cells act in concert to regulate new blood vessel growth. The digestion of ECM components by proteolysis is critical for the invasive capacity of endothelial cells, but also creates ECM fragments, which antagonize the mechanosensory function of integrins, and can be apoptogenic. Here, we discuss the roles of integrins in modulating cellular responses to a changing ECM, in particular the regulation of survival and invasion among invasive endothelial cells.	[Cheresh, D. A.; Stupack, D. G.] UCSD Sch Med, Moores UCSD Canc Ctr, Dept Pathol, La Jolla, CA 92039 USA	University of California System; University of California San Diego	Cheresh, DA (corresponding author), UCSD Sch Med, Moores UCSD Canc Ctr, Dept Pathol, 3855 Hlth Sci Dr, La Jolla, CA 92039 USA.	dcheresh@ucsd.edu	Peng, Chunwei/F-6788-2010		NCI NIH HHS [R01 CA107263] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Acevedo LM, 2008, BLOOD, V111, P2674, DOI 10.1182/blood-2007-08-110205; Alavi A, 2003, SCIENCE, V301, P94, DOI 10.1126/science.1082015; Algvere PV, 2008, ACTA OPHTHALMOL, V86, P352, DOI 10.1111/j.1755-3768.2008.01317.x; Allavena P, 2008, CRIT REV ONCOL HEMAT, V66, P1, DOI 10.1016/j.critrevonc.2007.07.004; Andreoli CM, 2007, CURR OPIN OPHTHALMOL, V18, P502, DOI 10.1097/ICU.0b013e3282f0ca54; Aoudjit F, 2001, J CELL BIOL, V152, P633, DOI 10.1083/jcb.152.3.633; Bajou K, 1998, NAT MED, V4, P923, DOI 10.1038/nm0898-923; Banno A, 2008, BIOCHEM SOC T, V36, P229, DOI 10.1042/BST0360229; Barbero S, 2008, J BIOL CHEM, V283, P13031, DOI 10.1074/jbc.M800549200; Beekman KW, 2006, CLIN GENITOURIN CANC, V4, P299, DOI 10.3816/CGC.2006.n.012; Ben-Yosef Y, 2005, AM J PHYSIOL-CELL PH, V289, pC1321, DOI 10.1152/ajpcell.00079.2005; Bieler G, 2007, ONCOGENE, V26, P5722, DOI 10.1038/sj.onc.1210354; Blystone SD, 1999, J CELL BIOL, V145, P889, DOI 10.1083/jcb.145.4.889; Boger DL, 2001, J AM CHEM SOC, V123, P1280, DOI 10.1021/ja003579+; Boudreau N, 1997, J CELL BIOL, V139, P257, DOI 10.1083/jcb.139.1.257; Brassard DL, 1999, EXP CELL RES, V251, P33, DOI 10.1006/excr.1999.4559; Bredesen DE, 2005, CELL DEATH DIFFER, V12, P1031, DOI 10.1038/sj.cdd.4401680; Brindle NPJ, 2006, CIRC RES, V98, P1014, DOI 10.1161/01.RES.0000218275.54089.12; BROOKS PC, 1994, SCIENCE, V264, P569, DOI 10.1126/science.7512751; BROOKS PC, 1994, CELL, V79, P1157, DOI 10.1016/0092-8674(94)90007-8; Bruhl T, 2004, CIRC RES, V94, P743, DOI 10.1161/01.RES.0000120861.27064.09; Bussolino F, 2006, ENDOTHELIUM-J ENDOTH, V13, P81, DOI 10.1080/10623320600698003; Chen YH, 2006, THROMB HAEMOSTASIS, V95, P668, DOI 10.1160/TH05-11-0757; Chen Y, 2008, BLOOD, V111, P1217, DOI 10.1182/blood-2007-07-104133; Cheresh DA, 1999, J CELL BIOL, V146, P1107, DOI 10.1083/jcb.146.5.1107; COLLER BS, 1991, BLOOD, V77, P75; Courter DL, 2005, J BIOL CHEM, V280, P12145, DOI 10.1074/jbc.M412555200; CRAFT PS, 1994, ANN ONCOL, V5, P305, DOI 10.1093/oxfordjournals.annonc.a058829; Croll SD, 2004, EXP NEUROL, V187, P388, DOI 10.1016/j.expneurol.2004.02.010; Cursi S, 2006, EMBO J, V25, P1895, DOI 10.1038/sj.emboj.7601085; Dallabrida SM, 2005, CIRC RES, V96, DOI 10.1161/01.RES.0000158285.57191.60; Davis GE, 2008, CURR OPIN HEMATOL, V15, P197, DOI 10.1097/MOH.0b013e3282fcc321; Dickson PV, 2007, CLIN CANCER RES, V13, P3942, DOI 10.1158/1078-0432.CCR-07-0278; DRANSFIELD I, 1992, J CELL BIOL, V116, P1527, DOI 10.1083/jcb.116.6.1527; DUSTIN ML, 1989, NATURE, V341, P619, DOI 10.1038/341619a0; El-Sheikh A, 2005, CANCER RES, V65, P11109, DOI 10.1158/0008-5472.CAN-05-2733; Eliceiri BP, 1998, J CELL BIOL, V140, P1255, DOI 10.1083/jcb.140.5.1255; Eliceiri BP, 1999, MOL CELL, V4, P915, DOI 10.1016/S1097-2765(00)80221-X; Eliceiri BP, 2002, J CELL BIOL, V157, P149, DOI 10.1083/jcb.200109079; Erdreich-Epstein A, 2005, BLOOD, V105, P4353, DOI 10.1182/blood-2004-08-3098; Essick E, 2008, MOL CELL BIOCHEM, V314, P151, DOI 10.1007/s11010-008-9776-7; Felding-Habermann B, 1997, J CELL BIOL, V139, P1567, DOI 10.1083/jcb.139.6.1567; Ferrara N, 2003, NAT MED, V9, P669, DOI 10.1038/nm0603-669; Firth JA, 2002, J ANAT, V200, P541, DOI 10.1046/j.1469-7580.2002.00059.x; Folkman J, 2006, ANNU REV MED, V57, P1, DOI 10.1146/annurev.med.57.121304.131306; Frisch SM, 2001, CURR OPIN CELL BIOL, V13, P555, DOI 10.1016/S0955-0674(00)00251-9; Fukasawa M, 2007, CANCER BIOL THER, V6, P1173; Fukuhara S, 2008, NAT CELL BIOL, V10, P513, DOI 10.1038/ncb1714; Garmy-Susini B, 2005, BRIT J CANCER, V93, P855, DOI 10.1038/sj.bjc.6602808; Garmy-Susini B, 2005, J CLIN INVEST, V115, P1542, DOI 10.1172/JCI23445; Garton KJ, 2003, J BIOL CHEM, V278, P37459, DOI 10.1074/jbc.M305877200; Gasparini G, 1996, CLIN CANCER RES, V2, P1191; Giancotti FG, 1999, SCIENCE, V285, P1028, DOI 10.1126/science.285.5430.1028; Giannone G, 2006, TRENDS CELL BIOL, V16, P213, DOI 10.1016/j.tcb.2006.02.005; Gounis MJ, 2005, GENE THER, V12, P762, DOI 10.1038/sj.gt.3302481; Grothey A, 2008, CANCER J, V14, P170, DOI 10.1097/PPO.0b013e318178d9de; Hall H, 2004, MICROVASC RES, V68, P169, DOI 10.1016/j.mvr.2004.07.001; Hall Heike, 2004, Angiogenesis, V7, P213, DOI 10.1007/s10456-004-1328-5; Hoang MV, 2004, P NATL ACAD SCI USA, V101, P1874, DOI 10.1073/pnas.0308525100; Hodivala-Dilke KM, 1999, J CLIN INVEST, V103, P229, DOI 10.1172/JCI5487; Hood JD, 2003, J CELL BIOL, V162, P933, DOI 10.1083/jcb.200304105; Hristov M, 2007, THROMB HAEMOSTASIS, V98, P274, DOI 10.1160/TH07-03-0181; Imanishi Y, 2007, CANCER RES, V67, P4254, DOI 10.1158/0008-5472.CAN-06-4100; Ingber DE, 2002, CIRC RES, V91, P877, DOI 10.1161/01.RES.0000039537.73816.E5; Ishida S, 2003, NAT MED, V9, P781, DOI 10.1038/nm877; Jimenez B, 2000, NAT MED, V6, P41, DOI 10.1038/71517; Jin H, 2006, J CLIN INVEST, V116, P652, DOI 10.1172/JCI24751; Jin H, 2006, CANCER RES, V66, P2146, DOI 10.1158/0008-5472.CAN-05-2704; John H, 2005, BBA-PROTEINS PROTEOM, V1747, P161, DOI 10.1016/j.bbapap.2004.10.013; Kang TB, 2004, J IMMUNOL, V173, P2976, DOI 10.4049/jimmunol.173.5.2976; Kim SY, 2007, ARCH BIOCHEM BIOPHYS, V459, P40, DOI 10.1016/j.abb.2006.11.001; Kinbara K, 2003, NAT REV MOL CELL BIO, V4, P767, DOI 10.1038/nrm1229; Kiosses WB, 2002, CIRC RES, V90, P697, DOI 10.1161/01.RES.0000014227.76102.5D; Klemke RL, 1997, J CELL BIOL, V137, P481, DOI 10.1083/jcb.137.2.481; KLEMKE RL, 1994, J CELL BIOL, V127, P859, DOI 10.1083/jcb.127.3.859; Kohl K, 2007, EUR J CELL BIOL, V86, P719, DOI 10.1016/j.ejcb.2007.06.007; Larsen M, 2006, CURR OPIN CELL BIOL, V18, P463, DOI 10.1016/j.ceb.2006.08.009; Li S, 1997, J BIOL CHEM, V272, P30455, DOI 10.1074/jbc.272.48.30455; Loges S, 2007, BIOCHEM BIOPH RES CO, V357, P1016, DOI 10.1016/j.bbrc.2007.04.060; Lominadze D, 2005, AM J PHYSIOL-HEART C, V288, pH1257, DOI 10.1152/ajpheart.00856.2004; LUSCINSKAS FW, 1994, FASEB J, V8, P929, DOI 10.1096/fasebj.8.12.7522194; Lyden D, 1999, NATURE, V401, P670, DOI 10.1038/44334; Mace KA, 2005, J CELL SCI, V118, P2567, DOI 10.1242/jcs.02399; Maeshima Y, 2002, SCIENCE, V295, P140, DOI 10.1126/science.1065298; Marnmoto A, 2008, CURR OPIN HEMATOL, V15, P228, DOI 10.1097/MOH.0b013e3282fa7445; Marti Hugo H., 1999, Thrombosis and Haemostasis, V82, P44; Matter ML, 2001, J BIOL CHEM, V276, P27757, DOI 10.1074/jbc.M102014200; Mavria G, 2006, CANCER CELL, V9, P33, DOI 10.1016/j.ccr.2005.12.021; Mayo LD, 2002, TRENDS BIOCHEM SCI, V27, P462, DOI 10.1016/S0968-0004(02)02166-7; Meerovitch K, 2003, VASC PHARMACOL, V40, P77, DOI 10.1016/S1537-1891(02)00339-7; Moldovan NI, 2003, ADV EXP MED BIOL, V522, P1; Myers C, 2002, AM J PATHOL, V161, P2099, DOI 10.1016/S0002-9440(10)64488-4; Myers C, 2000, J CELL BIOL, V148, P343, DOI 10.1083/jcb.148.2.343; Nagy JA, 2006, EXP CELL RES, V312, P538, DOI 10.1016/j.yexcr.2005.10.017; OReilly MS, 1997, CELL, V88, P277, DOI 10.1016/S0092-8674(00)81848-6; Pampori N, 1999, J BIOL CHEM, V274, P21609, DOI 10.1074/jbc.274.31.21609; Parri M, 2007, J BIOL CHEM, V282, P19619, DOI 10.1074/jbc.M701319200; Pasquale EB, 2008, CELL, V133, P38, DOI 10.1016/j.cell.2008.03.011; Patel S, 2005, CANCER RES, V65, P1414, DOI 10.1158/0008-5472.CAN-04-3431; Porta C, 2007, ADV EXP MED BIOL, V604, P67, DOI 10.1007/978-0-387-69116-9_5; Potter MD, 2005, J BIOL CHEM, V280, P31906, DOI 10.1074/jbc.M505568200; Raguse JD, 2004, ORAL ONCOL, V40, P228, DOI 10.1016/j.oraloncology.2003.08.003; Reynolds LE, 2002, NAT MED, V8, P27, DOI 10.1038/nm0102-27; Rose DM, 2007, IMMUNOL REV, V218, P126, DOI 10.1111/j.1600-065X.2007.00536.x; Rose DM, 2003, J IMMUNOL, V170, P5912, DOI 10.4049/jimmunol.170.12.5912; Ruegg C, 2002, ENDOTHELIUM-J ENDOTH, V9, P151, DOI 10.1080/10623320290016591; Ruegg C, 1998, NAT MED, V4, P408, DOI 10.1038/nm0498-408; Saharinen P, 2008, NAT CELL BIOL, V10, P527, DOI 10.1038/ncb1715; Salven P, 2003, BLOOD, V101, P168, DOI 10.1182/blood-2002-03-0755; Scatena MT, 2002, TRENDS CARDIOVAS MED, V12, P83, DOI 10.1016/S1050-1738(01)00151-7; SCHLAEPFER DD, 1994, NATURE, V372, P786; Senft J, 2007, CANCER RES, V67, P11505, DOI 10.1158/0008-5472.CAN-07-5755; Sha G, 2007, HUM REPROD, V22, P3159, DOI 10.1093/humrep/dem266; Shaut CA, 2007, DEV DYNAM, V236, P951, DOI 10.1002/dvdy.21077; Shim WSN, 2007, MOL CANCER RES, V5, P655, DOI 10.1158/1541-7786.MCR-07-0072; Silletti S, 2001, P NATL ACAD SCI USA, V98, P119, DOI 10.1073/pnas.011343298; Silletti S, 2000, J CELL BIOL, V149, P1485, DOI 10.1083/jcb.149.7.1485; Storgard CM, 1999, J CLIN INVEST, V103, P47, DOI 10.1172/JCI3756; Stromblad S, 1996, J CLIN INVEST, V98, P426, DOI 10.1172/JCI118808; Stupack DG, 2006, NATURE, V439, P95, DOI 10.1038/nature04323; Stupack DG, 2005, CELL DEATH DIFFER, V12, P1021, DOI 10.1038/sj.cdd.4401658; Stupack DG, 2001, J CELL BIOL, V155, P459, DOI 10.1083/jcb.200106070; Stupack DG, 2002, J CELL SCI, V115, P3729, DOI 10.1242/jcs.00071; STUPACK DG, 1992, EXP CELL RES, V203, P443, DOI 10.1016/0014-4827(92)90019-5; STUPACK DG, 1994, CELL IMMUNOL, V155, P237, DOI 10.1006/cimm.1994.1116; Szekanecz Z, 2007, CURR OPIN RHEUMATOL, V19, P289, DOI 10.1097/BOR.0b013e32805e87ae; Todorovic V, 2005, J CELL BIOL, V171, P559, DOI 10.1083/jcb.200504015; Tsakadze NL, 2004, AM J PHYSIOL-CELL PH, V287, pC55, DOI 10.1152/ajpcell.00585.2003; Ueno M, 2007, CURR MED CHEM, V14, P1199, DOI 10.2174/092986707780597943; Uyen HD, 2002, J CELL SCI, V115, P3073; van Hinsbergh VWM, 2008, CARDIOVASC RES, V78, P203, DOI 10.1093/cvr/cvm102; van Hinsbergh VWM, 2006, ARTERIOSCL THROM VAS, V26, P716, DOI 10.1161/01.ATV.0000209518.58252.17; VANDEWIELVANKEMENADE E, 1992, J CELL BIOL, V117, P461, DOI 10.1083/jcb.117.2.461; Vieira JM, 2007, DEVELOPMENT, V134, P1833, DOI 10.1242/dev.002402; Weis S, 2004, J CELL BIOL, V167, P223, DOI 10.1083/jcb.200408130; Weis SM, 2007, BLOOD, V109, P1962, DOI 10.1182/blood-2005-10-038893; Willett CG, 2004, NAT MED, V10, P145, DOI 10.1038/nm988; Winkler F, 2004, CANCER CELL, V6, P553, DOI 10.1016/j.ccr.2004.10.011; Wu CC, 2007, P NATL ACAD SCI USA, V104, P1254, DOI 10.1073/pnas.0609806104; Wu Y, 2007, ARTERIOSCL THROM VAS, V27, P1968, DOI 10.1161/ATVBAHA.107.148759; Xu R, 2001, BIOCHEM BIOPH RES CO, V289, P264, DOI 10.1006/bbrc.2001.5970; Zhai JB, 2003, J BIOL CHEM, V278, P24865, DOI 10.1074/jbc.M302381200; Zhao HB, 2005, MOL ENDOCRINOL, V19, P771, DOI 10.1210/me.2004-0161; Zheng LX, 2006, MOL CELL BIOL, V26, P3505, DOI 10.1128/MCB.26.9.3505-3513.2006	144	100	103	2	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT	2008	27	48					6285	6298		10.1038/onc.2008.304	http://dx.doi.org/10.1038/onc.2008.304			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	361YB	18931694				2022-12-28	WOS:000260162800009
J	Araki, K; Kawauchi, K; Tanaka, N				Araki, K.; Kawauchi, K.; Tanaka, N.			IKK/NF-kappa B signaling pathway inhibits cell-cycle progression by a novel Rb-independent suppression system for E2F transcription factors	ONCOGENE			English	Article						E2F; Rb; IKK; NF-kappa B; cell cycle; HAT	TUMOR-NECROSIS-FACTOR; FAMILY-MEMBERS; GROWTH; ALPHA; PHOSPHORYLATION; ACETYLATION; ACTIVATION; DISTINCT; TRANSFORMATION; PROLIFERATION	E2Fs are key regulators of cell-cycle progression, and their transcriptional activities are regulated by histone acetyltransferases (HATs). Retinoblastoma (Rb) family proteins (pRb, p107 and p130) bind to E2Fs and inhibit their transcriptional activities by disrupting HAT binding and recruitment of histone deacetylases. In this study, we show that I kappa B kinases (IKK alpha or IKK beta) activation inhibits cell growth and E2F-dependent transcription in normal human fibroblasts. The inhibition of E2F by IKKs was not observed in cells lacking nuclear factor (NF)-kappa B/p65; however, it was observed in cells lacking three Rb family genes. p65 disrupted the physical interaction between activator E2Fs (F2F1, E2F2 and E2F3) and the HAT cofactor transactivation/transformation-domain associated protein, resulting in a reduction in E2F-responsive gene expression. Furthermore, IKK alpha and IKK beta directly phosphorylated E2F4, resulting in nuclear accumulation and enhanced DNA binding of the E2F4/p130 repressor complex. Our study describes a novel growth inhibitory system that functions by Rb-independent suppression of E2Fs by the IKK/NF-kappa B signaling pathway.	[Araki, K.; Kawauchi, K.; Tanaka, N.] Nippon Med Sch, Dept Mol Oncol, Inst Gerontol, Nakahara Ku, Kawasaki, Kanagawa 2118533, Japan	Nippon Medical School	Tanaka, N (corresponding author), Nippon Med Sch, Dept Mol Oncol, Inst Gerontol, Nakahara Ku, Kosugicho 1-396, Kawasaki, Kanagawa 2118533, Japan.	nobuta@nms.ac.jp	Kawauchi, Keiko/G-4198-2010	Tanaka, Nobuyuki/0000-0002-6373-2220	Ministry of Education, Culture, Sports, Science and Technology of Japan	Ministry of Education, Culture, Sports, Science and Technology of Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT))	We thank M Ikeda, K Ohtani, S Sugano, T Doi, MD Cole, G Leone, DV Goeddel, J Sage and T Jacks for providing the materials; K Tobiume, E Oda-Sato, Y Abe, I Uehara, W Nakajima and M Ando for the useful discussion, and Y Asano, H Hiroike and M Kawagoe for technical assistance. This work was supported by grants-in-aid from the Ministry of Education, Culture, Sports, Science and Technology of Japan.	Aggarwal BB, 2003, NAT REV IMMUNOL, V3, P745, DOI 10.1038/nri1184; AGGARWAL BB, 1995, FEBS LETT, V357, P1, DOI 10.1016/0014-5793(94)01299-G; Ait-Si-Ali S, 2000, ONCOGENE, V19, P2430, DOI 10.1038/sj.onc.1203562; Banno T, 2004, J BIOL CHEM, V279, P32633, DOI 10.1074/jbc.M400642200; Boehm JS, 2005, MOL CELL BIOL, V25, P6464, DOI 10.1128/MCB.25.15.6464-6474.2005; Brantley DM, 2001, MOL BIOL CELL, V12, P1445, DOI 10.1091/mbc.12.5.1445; DeGregori J, 2006, CURR MOL MED, V6, P739; Delhase M, 1999, SCIENCE, V284, P309, DOI 10.1126/science.284.5412.309; Ferreira R, 2001, ONCOGENE, V20, P3128, DOI 10.1038/sj.onc.1204337; Frolov MV, 2004, J CELL SCI, V117, P2173, DOI 10.1242/jcs.01227; Hahn WC, 2002, MOL CELL BIOL, V22, P2111, DOI 10.1128/MCB.22.7.2111-2123.2002; Huang WC, 2007, MOL CELL, V26, P75, DOI 10.1016/j.molcel.2007.02.019; Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621; Karin M, 2006, NATURE, V441, P431, DOI 10.1038/nature04870; Lang SE, 2001, J BIOL CHEM, V276, P32627, DOI 10.1074/jbc.M102067200; Li QT, 2002, NAT REV IMMUNOL, V2, P725, DOI 10.1038/nri910; Li QT, 2005, TRENDS IMMUNOL, V26, P318, DOI 10.1016/j.it.2005.04.003; Martinez-Balbas MA, 2000, EMBO J, V19, P662, DOI 10.1093/emboj/19.4.662; Marzio G, 2000, J BIOL CHEM, V275, P10887, DOI 10.1074/jbc.275.15.10887; McMahon SB, 1998, CELL, V94, P363, DOI 10.1016/S0092-8674(00)81479-8; Pasparakis M, 2002, NATURE, V417, P861, DOI 10.1038/nature00820; Rowland BD, 2006, CELL, V127, P871, DOI 10.1016/j.cell.2006.11.019; Seitz CS, 2000, CANCER RES, V60, P4085; Seitz CS, 1998, P NATL ACAD SCI USA, V95, P2307, DOI 10.1073/pnas.95.5.2307; Spyridopoulos I, 1998, CIRCULATION, V98, P2883, DOI 10.1161/01.CIR.98.25.2883; Takahashi Y, 2000, GENE DEV, V14, P804; Taubert S, 2004, MOL CELL BIOL, V24, P4546, DOI 10.1128/MCB.24.10.4546-4556.2004; Tergaonkar V, 2005, NAT CELL BIOL, V7, P921, DOI 10.1038/ncb1296; Trimarchi JM, 2002, NAT REV MOL CELL BIO, V3, P11, DOI 10.1038/nrm714; Trouche D, 1996, NUCLEIC ACIDS RES, V24, P4139, DOI 10.1093/nar/24.21.4139; Tu Z, 2006, J BIOL CHEM, V281, P6699, DOI 10.1074/jbc.M512439200; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784	32	29	29	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP	2008	27	43					5696	5705		10.1038/onc.2008.184	http://dx.doi.org/10.1038/onc.2008.184			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	352HM	18542057				2022-12-28	WOS:000259487100005
J	Chen, R; Alvero, AB; Silasi, DA; Kelly, MG; Fest, S; Visintin, I; Leiser, A; Schwartz, PE; Rutherford, T; Mor, G				Chen, R.; Alvero, A. B.; Silasi, D. A.; Kelly, M. G.; Fest, S.; Visintin, I.; Leiser, A.; Schwartz, P. E.; Rutherford, T.; Mor, G.			Regulation of IKK beta by miR-199a affects NF-kappa B activity in ovarian cancer cells	ONCOGENE			English	Article						inflammation; ovarian cancer; IKK beta; MyD88; chemoresistance	TOLL-LIKE RECEPTORS; KINASE-ACTIVITY; INFLAMMATION; ACTIVATION; APOPTOSIS; TUMORIGENESIS; INJURY; CHEMORESISTANCE; PROLIFERATION; STATISTICS	Cancer progression is an abnormal form of tissue repair characterized by chronic inflammation. I kappa B kinase-beta (IKK beta) required for nuclear factor-kappa B (NF-kappa B) activation plays a critical role in this process. Using EOC cells isolated from malignant ovarian cancer ascites and solid tumors, we identified IKKb as a major factor promoting a functional TLR-MyD88-NF-kappa B pathway that confers to EOC cell the capacity to constitutively secrete proinflammatory/protumor cytokines and therefore promoting tumor progression and chemoresistance. Furthermore, we describe for the first time the identification of the microRNA hsa-miR-199a as a regulator of IKK beta expression. Our study describes the property of ovarian cancer cells to enhance the inflammatory microenvironment as a result of the expression of an active IKKb pathway. Identification of these markers in patients' tumor samples may facilitate the adequate selection of treatment and open new venues for the development of effective therapy for chemoresistant ovarian cancers.	[Mor, G.] Yale Univ, Sch Med, Reprod Immunol Unit, Dept Obstet Gynecol & Reprod Sci, New Haven, CT 06520 USA; [Chen, R.] Yale Univ, Dept Mol Cellular & Dev Biol, New Haven, CT 06520 USA	Yale University; Yale University	Mor, G (corresponding author), Yale Univ, Sch Med, Reprod Immunol Unit, Dept Obstet Gynecol & Reprod Sci, 333 Cedar St,FMB 301, New Haven, CT 06520 USA.	Gil.Mor@yale.edu		Alvero, Ayesha/0000-0002-6593-3595	NATIONAL CANCER INSTITUTE [R01CA127913, R01CA118678] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA127913, R01 CA127913-02, R01 CA118678, R01 CA118678-02, R01 CA127913-01A2] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aggarwal BB, 2003, NAT REV IMMUNOL, V3, P745, DOI 10.1038/nri1184; Balkwill F, 2004, NAT REV CANCER, V4, P540, DOI 10.1038/nrc1388; Balkwill F, 2004, NATURE, V431, P405, DOI 10.1038/431405a; Barnhart BC, 2003, CELL, V114, P148, DOI 10.1016/S0092-8674(03)00561-0; Baumgartner B, 2002, LEUKEMIA, V16, P2062, DOI 10.1038/sj.leu.2402641; Chen R, 2007, AM J REPROD IMMUNOL, V57, P93, DOI 10.1111/j.1600-0897.2006.00441.x; Coussens LM, 2002, NATURE, V420, P860, DOI 10.1038/nature01322; Duan Z, 2002, CYTOKINE, V17, P234, DOI 10.1006/cyto.2001.1008; Flick MB, 2004, J SOC GYNECOL INVEST, V11, P252, DOI 10.1016/j.jsgi.2003.11.003; Fukata M, 2005, AM J PHYSIOL-GASTR L, V288, pG1055, DOI 10.1152/ajpgi.00328.2004; Greten FR, 2004, CANCER LETT, V206, P193, DOI 10.1016/j.canlet.2003.08.029; Greten FR, 2004, CELL, V118, P285, DOI 10.1016/j.cell.2004.07.013; HACKER H, 2006, SCI STKE, DOI DOI 10.1126/STKE.3572006RE13; HARROCH S, 1995, NUCLEIC ACIDS RES, V23, P3539, DOI 10.1093/nar/23.17.3539; Hu MCT, 2004, CELL, V117, P225, DOI 10.1016/S0092-8674(04)00302-2; Jemal A, 2006, CA-CANCER J CLIN, V56, P106, DOI 10.3322/canjclin.56.2.106; Jemal A, 2007, CA-CANCER J CLIN, V57, P43, DOI 10.3322/canjclin.57.1.43; Jiang DH, 2005, NAT MED, V11, P1173, DOI 10.1038/nm1315; Kamsteeg M, 2003, ONCOGENE, V22, P2611, DOI 10.1038/sj.onc.1206422; Karin M, 2002, NAT REV CANCER, V2, P301, DOI 10.1038/nrc780; Kelly MG, 2006, CANCER RES, V66, P3859, DOI 10.1158/0008-5472.CAN-05-3948; Leung CH, 2006, MOL PHARMACOL, V70, P1946, DOI 10.1124/mol.106.028480; Li L, 2004, CANCER-AM CANCER SOC, V101, P2351, DOI 10.1002/cncr.20605; Li QT, 2002, NAT REV IMMUNOL, V2, P725, DOI 10.1038/nri910; Li QT, 1999, SCIENCE, V284, P321, DOI 10.1126/science.284.5412.321; Liu BG, 2006, P NATL ACAD SCI USA, V103, P17202, DOI 10.1073/pnas.0604481103; Ludwig L, 2001, CANCER RES, V61, P4526; Luo JL, 2005, J CLIN INVEST, V115, P2625, DOI 10.1172/JCI26322; Maeda S, 2005, CELL, V121, P977, DOI 10.1016/j.cell.2005.04.014; Maeda S, 2003, IMMUNITY, V19, P725, DOI 10.1016/S1074-7613(03)00301-7; Mercurio F, 1999, MOL CELL BIOL, V19, P1526; Nakanishi C, 2005, NAT REV CANCER, V5, P297, DOI 10.1038/nrc1588; ODWYER PJ, 1994, CANCER RES, V54, P724; Pikarsky E, 2004, NATURE, V431, P461, DOI 10.1038/nature02924; Pull SL, 2005, P NATL ACAD SCI USA, V102, P99, DOI 10.1073/pnas.0405979102; Rakoff-Nahoum S, 2004, CELL, V118, P229, DOI 10.1016/j.cell.2004.07.002; Rakoff-Nahoum S, 2007, SCIENCE, V317, P124, DOI 10.1126/science.1140488; Romieu-Mourez R, 2001, CANCER RES, V61, P3810; Rothwarf D M, 1999, Sci STKE, V1999, pRE1, DOI 10.1126/stke.1999.5.re1; Schwartz Peter E, 2002, Cancer Treat Res, V107, P99; Shishodia S, 2004, BIOCHEM PHARMACOL, V68, P1071, DOI 10.1016/j.bcp.2004.04.026; Tamatani T, 2001, CANCER LETT, V171, P165, DOI 10.1016/S0304-3835(01)00611-5; Yang JM, 2001, CANCER RES, V61, P4901	43	248	269	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG	2008	27	34					4712	4723		10.1038/onc.2008.112	http://dx.doi.org/10.1038/onc.2008.112			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	334QM	18408758	Green Accepted			2022-12-28	WOS:000258236300009
J	Lu, Z; Liu, M; Stribinskis, V; Klinge, CM; Ramos, KS; Colburn, NH; Li, Y				Lu, Z.; Liu, M.; Stribinskis, V.; Klinge, C. M.; Ramos, K. S.; Colburn, N. H.; Li, Y.			MicroRNA-21 promotes cell transformation by targeting the programmed cell death 4 gene	ONCOGENE			English	Article						miR-21; PDCD4; cell transformation; microRNA; tumor suppressor	TUMOR-SUPPRESSOR GENE; INITIATION-FACTOR 4A; BREAST-CANCER; MICRO-RNA; EXPRESSION; PDCD4; TRANSLATION; SIGNATURE; BINDING; PROGRESSION	MicroRNAs (miRNAs) are small noncoding RNA molecules that negatively control expression of target genes in animals and plants. The microRNA-21 gene (mir-21) has been identified as the only miRNA commonly over-expressed in solid tumors of the lung, breast, stomach, prostate, colon, brain, head and neck, esophagus and pancreas. We initiated a screen to identify miR-21 target genes using a reporter assay and identified a potential miR-21 target in the 30-UTR of the programmed cell death 4 (PDCD4) gene. We cloned the full-length 30-UTR of human PDCD4 downstream of a reporter and found that mir-21 downregulated, whereas a modified antisense RNA to miR-21 upregulated report er activity. Moreover, deletion of the putative miR-21-binding site (miRNA regulatory element, MRE) from the 30-UTR of PDCD4, or mutations in the MRE abolished the ability of miR-21 to inhibit reporter activity, indicating that this MRE is a critical regulatory region. Western blotting showed that Pdcd4 protein levels were reduced by miR-21 in human and mouse cells, whereas quantitative real-time PCR revealed little difference at the mRNA level, suggesting translational regulation. Finally, overexpression of mir-21 in MCF-7 human breast cancer cells and mouse epidermal JB6 cells promoted soft agar colony formation by downregulating Pdcd4 protein levels. The demonstration that miR-21 promotes cell transformation supports the concept that mir-21 functions as an oncogene by a mechanism that involves translational repression of the tumor suppressor Pdcd4.	[Lu, Z.; Stribinskis, V.; Klinge, C. M.; Li, Y.] Univ Louisville, Sch Med, Ctr Genet & Mol Med, Louisville, KY 40292 USA; [Liu, M.] Chinese Acad Sci, Shanghai Inst Biol Sci, Inst Biochem & Cell Biol, State Key Lab Mol Biol, Shanghai, Peoples R China; [Colburn, N. H.] NCI, Gene Regulat Sect, Lab Canc Prevent, Ctr Canc Res, Frederick, MD 21701 USA	University of Louisville; Chinese Academy of Sciences; Shanghai Institutes for Biological Sciences, CAS; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Li, Y (corresponding author), Univ Louisville, Dept Biochem & Mol Biol, 319 Abraham Flexner Way,Rm 513-A Building, Louisville, KY 40202 USA.	yong.li@louisville.edu		liu, mo fang/0000-0003-1800-466X; Klinge, Carolyn/0000-0002-3358-4378	NATIONAL CANCER INSTITUTE [Z01BC010026, ZIABC010026, R21CA124811] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES014443] Funding Source: NIH RePORTER; NCI NIH HHS [R21-CA124811] Funding Source: Medline; NIEHS NIH HHS [P30ES014443] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ASANGANI LA, 2007, ONCOGENE        1029; Ashburner M, 2000, NAT GENET, V25, P25, DOI 10.1038/75556; Cai XZ, 2004, RNA, V10, P1957, DOI 10.1261/rna.7135204; Calin GA, 2005, NEW ENGL J MED, V353, P1793, DOI 10.1056/NEJMoa050995; Chan JA, 2005, CANCER RES, V65, P6029, DOI 10.1158/0008-5472.CAN-05-0137; Chen CF, 2005, NUCLEIC ACIDS RES, V33, DOI 10.1093/nar/gni178; Chen Y, 2003, J PATHOL, V200, P640, DOI 10.1002/path.1378; Cmarik JL, 1999, P NATL ACAD SCI USA, V96, P14037, DOI 10.1073/pnas.96.24.14037; Da C, 2004, SPECTROSC SPECT ANAL, V24, P672; Diederichs S, 2006, CANCER RES, V66, P6097, DOI 10.1158/0008-5472.CAN-06-0537; DONG Z, 2002, SCI STKE, pPL7; Frankel LB, 2008, J BIOL CHEM, V283, P1026, DOI 10.1074/jbc.M707224200; Griffiths-Jones S, 2006, NUCLEIC ACIDS RES, V34, pD140, DOI 10.1093/nar/gkj112; Hilliard A, 2006, J IMMUNOL, V177, P8095, DOI 10.4049/jimmunol.177.11.8095; Iorio MV, 2005, CANCER RES, V65, P7065, DOI 10.1158/0008-5472.CAN-05-1783; Jansen AP, 2005, CANCER RES, V65, P6034, DOI 10.1158/0008-5472.CAN-04-2119; Jansen AP, 2004, MOL CANCER THER, V3, P103; John B, 2004, PLOS BIOL, V2, P1862, DOI 10.1371/journal.pbio.0020363; Johnson SM, 2005, CELL, V120, P635, DOI 10.1016/j.cell.2005.01.014; Krek A, 2005, NAT GENET, V37, P495, DOI 10.1038/ng1536; Lawrie CH, 2007, INT J CANCER, V121, P1156, DOI 10.1002/ijc.22800; Lee S, 2006, ONCOL REP, V16, P747; Lewis BP, 2005, CELL, V120, P15, DOI 10.1016/j.cell.2004.12.035; Li L, 2007, J CELL BIOCHEM, V102, P1368, DOI 10.1002/jcb.21593; Ma Gang, 2005, Zhongguo Yi Xue Ke Xue Yuan Xue Bao, V27, P597; Meister G, 2004, RNA, V10, P544, DOI 10.1261/rna.5235104; Meng FY, 2007, GASTROENTEROLOGY, V133, P647, DOI 10.1053/j.gastro.2007.05.022; Meng FY, 2006, GASTROENTEROLOGY, V130, P2113, DOI 10.1053/j.gastro.2006.02.057; Miranda KC, 2006, CELL, V126, P1203, DOI 10.1016/j.cell.2006.07.031; Roldo C, 2006, J CLIN ONCOL, V24, P4677, DOI 10.1200/JCO.2005.05.5194; Root DE, 2006, NAT METHODS, V3, P715, DOI 10.1038/NMETH924; Si ML, 2007, ONCOGENE, V26, P2799, DOI 10.1038/sj.onc.1210083; Volinia S, 2006, P NATL ACAD SCI USA, V103, P2257, DOI 10.1073/pnas.0510565103; Wang TS, 2007, GENE CHROMOSOME CANC, V46, P336, DOI 10.1002/gcc.20415; Yang HS, 2003, MOL CELL BIOL, V23, P26, DOI 10.1128/MCB.23.1.26-37.2003; Yang HS, 2004, MOL CELL BIOL, V24, P3894, DOI 10.1128/MCB.24.9.3894-3906.2004; Yang HS, 2001, ONCOGENE, V20, P669, DOI 10.1038/sj.onc.1204137; Yu K, 2001, ENDOCR-RELAT CANCER, V8, P249, DOI 10.1677/erc.0.0080249; Zhu SM, 2007, J BIOL CHEM, V282, P14328, DOI 10.1074/jbc.M611393200	39	575	622	1	73	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 17	2008	27	31					4373	4379		10.1038/onc.2008.72	http://dx.doi.org/10.1038/onc.2008.72			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	326WY	18372920				2022-12-28	WOS:000257691100012
J	Uemura, T; Shiozaki, K; Yamaguchi, K; Miyazaki, S; Satomi, S; Kato, K; Sakuraba, H; Miyagi, T				Uemura, T.; Shiozaki, K.; Yamaguchi, K.; Miyazaki, S.; Satomi, S.; Kato, K.; Sakuraba, H.; Miyagi, T.			Contribution of sialidase NEU1 to suppression of metastasis of human colon cancer cells through desialylation of integrin beta 4	ONCOGENE			English	Article						sialidase; integrin beta 4; sialic acid; metastasis; invasion; MMP-7	MEMBRANE-ASSOCIATED SIALIDASE; TYPE-1 MATRIX-METALLOPROTEINASE; PLASMA-MEMBRANE; LYSOSOMAL SIALIDASE; APOPTOSIS SUPPRESSION; COLORECTAL-CANCER; GLYCOSYLATION; EXPRESSION; PROGRESSION; LAMININ-5	We previously found an inverse relationship between sialidase Neu1 expression and metastatic potential of murine cancer cells. To elucidate the mechanism underlying the cellular events, the human sialidase gene NEU1 was overexpressed or silenced in colon cancer HT-29 cells. When NEU1-overexpressing cells were injected transsplenically into mice, in vivo liver metastasis was significantly reduced. NEU1 suppressed cell migration, invasion and adhesion in vitro, whereas the silencing resulted in the opposite. One of the major molecular changes by NEU1 was decreased sialylation of integrin beta 4, assessed by PNA- and MAL-II-lectin blotting of immunoprecipitates with anti-integrin beta 4 antibody. The desialylation was accompanied by decreased phosphorylation of the integrin followed by attenuation of focal adhesion kinase and Erk1/2 pathway. Moreover, NEU1 caused downregulation of matrix metalloproteinase-7, overexpression of which is associated with cancer metastasis. Treatment of the cells with GalNAc-alpha-O-benzyl, an inhibitor of O-glycosylation, showed increased PNA-positive integrin beta 4 with its decreased phosphorylation, indicating that sialic acid removal from the integrin O-glycans results in the decreased phosphorylation. Biotinylation and immunofluorescence staining exhibited some NEU1 molecules to be at the cell surface accessible to the integrin. These results suggest that NEU1 is important in regulation of integrin beta 4-mediated signaling, leading to suppression of metastasis.	[Uemura, T.; Shiozaki, K.; Yamaguchi, K.; Kato, K.; Miyagi, T.] Miyagi Canc Ctr, Res Inst, Div Biochem, Natori, Miyagi 9811293, Japan; [Uemura, T.; Shiozaki, K.; Yamaguchi, K.; Kato, K.; Miyagi, T.] JST, CREST, Kawaguchi, Saitama, Japan; [Uemura, T.; Miyazaki, S.; Satomi, S.] Tohoku Univ, Grad Sch Med, Dept Adv Surg Sci & Technol, Sendai, Miyagi 980, Japan; [Sakuraba, H.] Meiji Pharmaceut Univ, Dept Analyt Biochem, Tokyo, Japan	Miyagi Cancer Center; Japan Science & Technology Agency (JST); Tohoku University; Meiji Pharmaceutical University	Miyagi, T (corresponding author), Miyagi Canc Ctr, Res Inst, Div Biochem, 47-1 Nodayama, Natori, Miyagi 9811293, Japan.	miyagi-ta173@pref.miyagi.jp		Shiozaki, Kazuhiro/0000-0002-0523-838X	Ministry of Education, Culture, Sports, Science and Technology of Japan	Ministry of Education, Culture, Sports, Science and Technology of Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT))	We appreciate the expert technical assistance of Ms Setsuko Moriya. This study was supported in part by Grants-in-Aid for Scientific Research on Priority Areas Cancer from the Ministry of Education, Culture, Sports, Science and Technology of Japan.	Dennis JW, 1999, BBA-GEN SUBJECTS, V1473, P21, DOI 10.1016/S0304-4165(99)00167-1; Duca L, 2007, J BIOL CHEM, V282, P12484, DOI 10.1074/jbc.M609505200; Fukushima Y, 1998, INT J CANCER, V76, P63, DOI 10.1002/(SICI)1097-0215(19980330)76:1<63::AID-IJC11>3.0.CO;2-H; GALJART NJ, 1988, CELL, V54, P755, DOI 10.1016/S0092-8674(88)90999-3; Giancotti FG, 1999, SCIENCE, V285, P1028, DOI 10.1126/science.285.5430.1028; Giannelli G, 2002, CLIN EXP METASTAS, V19, P217, DOI 10.1023/A:1015579204607; Hakomori S, 2002, P NATL ACAD SCI USA, V99, P10231, DOI 10.1073/pnas.172380699; Hinek A, 2006, J BIOL CHEM, V281, P3698, DOI 10.1074/jbc.M508736200; Huet G, 1998, J CELL BIOL, V141, P1311, DOI 10.1083/jcb.141.6.1311; Julenius K, 2005, GLYCOBIOLOGY, V15, P153, DOI 10.1093/glycob/cwh151; Kakugawa Y, 2002, P NATL ACAD SCI USA, V99, P10718, DOI 10.1073/pnas.152597199; Kato K, 2006, BIOCHEM J, V394, P647, DOI 10.1042/BJ20050737; Kato T, 2001, INT J CANCER, V92, P797, DOI 10.1002/ijc.1268; Koshikawa N, 2005, J BIOL CHEM, V280, P88, DOI 10.1074/jbc.M411824200; LI K, 1992, J CHROMATOGR-BIOMED, V579, P209, DOI 10.1016/0378-4347(92)80384-3; Liang F, 2006, J BIOL CHEM, V281, P27526, DOI 10.1074/jbc.M605633200; Lohi J, 2001, INT J CANCER, V94, P763, DOI 10.1002/ijc.1539; Mimori K, 2004, CLIN CANCER RES, V10, P8243, DOI 10.1158/1078-0432.CCR-04-0849; Miyagi T, 2003, GLYCOCONJUGATE J, V20, P189, DOI 10.1023/B:GLYC.0000024250.48506.bf; MIYAGI T, 1984, EUR J BIOCHEM, V141, P75, DOI 10.1111/j.1432-1033.1984.tb08159.x; MIYAGI T, 1994, FEBS LETT, V349, P255, DOI 10.1016/0014-5793(94)00682-2; Miyagi T., 2007, COMPREHENSIVE GLYCOS, V3, P297; Miyagi T, 2008, BBA-GEN SUBJECTS, V1780, P532, DOI 10.1016/j.bbagen.2007.09.016; Monti E, 2002, NEUROCHEM RES, V27, P649, DOI 10.1023/A:1020276000901; Remacle AG, 2006, J BIOL CHEM, V281, P16897, DOI 10.1074/jbc.M600295200; Remy L, 2006, CANCER RES, V66, P11228, DOI 10.1158/0008-5472.CAN-06-1187; Sawada M, 2002, INT J CANCER, V97, P180, DOI 10.1002/ijc.1598; Seales EC, 2005, CANCER RES, V65, P4645, DOI 10.1158/0008-5472.CAN-04-3117; Shiomi T, 2003, CANCER METAST REV, V22, P145, DOI 10.1023/A:1023039230052; TRAINER DL, 1998, INT J CANCER, V41, P287; Ueno S, 2006, J BIOL CHEM, V281, P7756, DOI 10.1074/jbc.M509668200; Wu YI, 2004, J BIOL CHEM, V279, P8278, DOI 10.1074/jbc.M311870200; Xia YP, 1996, J CELL BIOL, V132, P727, DOI 10.1083/jcb.132.4.727; Yamaguchi K, 2005, BIOCHEM J, V390, P85, DOI 10.1042/BJ20050017; Zeng ZS, 2002, CLIN CANCER RES, V8, P144	35	139	144	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 5	2009	28	9					1218	1229		10.1038/onc.2008.471	http://dx.doi.org/10.1038/onc.2008.471			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	415AH	19151752				2022-12-28	WOS:000263906200006
J	Lallemand, D; Manent, J; Couvelard, A; Watilliaux, A; Siena, M; Chareyre, F; Lampin, A; Niwa-Kawakita, M; Kalamarides, M; Giovannini, M				Lallemand, D.; Manent, J.; Couvelard, A.; Watilliaux, A.; Siena, M.; Chareyre, F.; Lampin, A.; Niwa-Kawakita, M.; Kalamarides, M.; Giovannini, M.			Merlin regulates transmembrane receptor accumulation and signaling at the plasma membrane in primary mouse Schwann cells and in human schwannomas	ONCOGENE			English	Article						neurofibromatosis type 2; growth factor receptors; trafficking; Schwann cells; proliferation; schwannoma	NF2 TUMOR-SUPPRESSOR; GROWTH-FACTOR; NEUROFIBROMATOSIS TYPE-2; CELLULAR SENESCENCE; TYROSINE KINASES; ERBB RECEPTORS; ACTIVATION; TUMORIGENESIS; SURVIVAL; TRANSPORT	The NF2 gene product, merlin/schwannomin, is a cytoskeleton organizer with unique growth-inhibiting activity in specific cell types. A narrow spectrum of tumors is associated with NF2 deficiency, mainly schwannomas and meningiomas, suggesting cell-specific mechanisms of growth control. We have investigated merlin function in mouse Schwann cells (SCs). We found that merlin regulates contact inhibition of proliferation by limiting the delivery of several growth factor receptors at the plasma membrane of primary SCs. Notably, upon cell-to-cell contact, merlin downregulates the membrane levels of ErbB2 and ErbB3, thus inhibiting the activity of the downstream mitogenic signaling pathways protein kinase B and mitogen-activated protein kinase. Consequently, loss of merlin activity is associated with elevated levels of ErbB receptors in primary SCs. We also observed accumulation of growth factor receptors such as ErbB2 and 3, insulin-like growth factor 1 receptor and platelet-derived growth factor receptor in peripheral nerves of Nf2-mutant mice and in human NF2 schwannomas, suggesting that this mechanism could play an important role in tumorigenesis.	[Lallemand, D.; Manent, J.; Watilliaux, A.; Siena, M.; Chareyre, F.; Lampin, A.; Niwa-Kawakita, M.; Kalamarides, M.; Giovannini, M.] INSERM, U674, Paris, France; [Lallemand, D.; Manent, J.; Watilliaux, A.; Siena, M.; Chareyre, F.; Lampin, A.; Niwa-Kawakita, M.; Kalamarides, M.; Giovannini, M.] Univ Paris 07, Inst Univ Hematol, Paris, France; [Couvelard, A.] Hop Beaujon, APHP, Serv Anat & Cytol Pathol, Clichy, France; [Kalamarides, M.] Hop Beaujon, APHP, Serv Neurochirurg, Clichy, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Ambroise-Pare - APHP; Hopital Universitaire Beaujon - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Ambroise-Pare - APHP; Hopital Universitaire Beaujon - APHP; UDICE-French Research Universities; Universite Paris Cite	Giovannini, M (corresponding author), House Ear Res Inst, Ctr Neural Tumor Res, 2100W 3rd St, Los Angeles, CA 90057 USA.	mgiovannini@hei.org	lallemand, dominique/O-7445-2017	lallemand, dominique/0000-0002-0212-7342; Anne, Couvelard/0000-0002-6316-1210; Kawakita, Michiko/0000-0002-9450-583X; Manent, Jan/0000-0001-9152-5459	US Department of Defense [W81XWH-05-10265]; Association Neurofibromatoses et Recklinghausen; Canceropole Ile-de France; Institut National du Cancer; ANR; INSERM	US Department of Defense(United States Department of Defense); Association Neurofibromatoses et Recklinghausen; Canceropole Ile-de France(Region Ile-de-France); Institut National du Cancer(Institut National du Cancer (INCA) France); ANR(French National Research Agency (ANR)); INSERM(Institut National de la Sante et de la Recherche Medicale (Inserm)European Commission)	We thank J Lippincott-Schwartz for the kind gift of the VSV-GFP construct, Z-Y Han for assistance with mouse genotyping, all members of the U674 lab for helpful discussions and support, L Goutebroze B Goud and O Hanemann for helpful suggestions, A McClatchey for many stimulating discussions, M Pla (Departement d'Experimentation Animale-Institut Universitaire d'Hematologie) and the Centre de Distribution, Typage et Archivage animal for mouse housing. DL personally thanks F Mechta-Grigoriou for helpful advice and discussions and continuous support and Odette Mariani for careful reading of the manuscript. This work was supported by Grants from the US Department of Defense (W81XWH-05-10265), Association Neurofibromatoses et Recklinghausen, Canceropole Ile-de France, Institut National du Cancer, ANR and INSERM.	Bache KG, 2004, EMBO J, V23, P2707, DOI 10.1038/sj.emboj.7600292; Bretscher A, 2002, NAT REV MOL CELL BIO, V3, P586, DOI 10.1038/nrm882; Bringold F, 2000, EXP GERONTOL, V35, P317, DOI 10.1016/S0531-5565(00)00083-8; Buzard GS, 1999, J CANCER RES CLIN, V125, P653, DOI 10.1007/s004320050330; Cheng HL, 2000, MOL CELL ENDOCRINOL, V170, P211, DOI 10.1016/S0303-7207(00)00324-5; Curto M, 2007, J CELL BIOL, V177, P893, DOI 10.1083/jcb.200703010; Deretic D, 2004, MOL BIOL CELL, V15, P359, DOI 10.1091/mbc.E03-04-0203; Fernandez-Valle C, 2002, NAT GENET, V31, P354, DOI 10.1038/ng930; Fraenzer JT, 2003, INT J ONCOL, V23, P1493; Giovannini M, 2000, GENE DEV, V14, P1617; Giovannini M, 1999, GENE DEV, V13, P978, DOI 10.1101/gad.13.8.978; Hansen MR, 2004, OTOL NEUROTOL, V25, P155, DOI 10.1097/00129492-200403000-00013; HARDY M, 1992, J NEUROSCI RES, V31, P254, DOI 10.1002/jnr.490310206; Hirokawa Y, 2004, CANCER J, V10, P20, DOI 10.1097/00130404-200401000-00006; Hirschberg K, 1998, J CELL BIOL, V143, P1485, DOI 10.1083/jcb.143.6.1485; Hyun TS, 2004, TRENDS MOL MED, V10, P194, DOI 10.1016/j.molmed.2004.02.003; Itahana K, 2004, BIOGERONTOLOGY, V5, P1, DOI 10.1023/B:BGEN.0000017682.96395.10; Jones KA, 2004, EXP CELL RES, V295, P512, DOI 10.1016/j.yexcr.2004.01.022; Jozwiak J, 2006, INT J CANCER, V118, P1, DOI 10.1002/ijc.21542; Kissil JL, 2003, MOL CELL, V12, P841, DOI 10.1016/S1097-2765(03)00382-4; Lallemand D, 2003, GENE DEV, V17, P1090, DOI 10.1101/gad.1054603; Lim JY, 2003, BIOCHEM BIOPH RES CO, V302, P238, DOI 10.1016/S0006-291X(03)00124-4; Lobsiger CS, 2000, GLIA, V30, P290, DOI 10.1002/(SICI)1098-1136(200005)30:3<290::AID-GLIA8>3.0.CO;2-6; Maitra S, 2006, CURR BIOL, V16, P702, DOI 10.1016/j.cub.2006.02.063; Manent J, 2003, J NEUROSCI METH, V123, P167, DOI 10.1016/S0165-0270(02)00349-7; Mary S, 2002, MOL BIOL CELL, V13, P285, DOI 10.1091/mbc.01-07-0337; McClatchey AI, 2005, GENE DEV, V19, P2265, DOI 10.1101/gad.1335605; Miyake K, 2001, J CELL SCI, V114, P3487; Morrison H, 2007, CANCER RES, V67, P520, DOI 10.1158/0008-5472.CAN-06-1608; MUALLEM S, 1995, J CELL BIOL, V128, P589, DOI 10.1083/jcb.128.4.589; NIKITIN AY, 1991, P NATL ACAD SCI USA, V88, P9939, DOI 10.1073/pnas.88.22.9939; Perrais M, 2007, MOL BIOL CELL, V18, P2013, DOI 10.1091/mbc.E06-04-0348; Polo S, 2004, CURR OPIN CELL BIOL, V16, P156, DOI 10.1016/j.ceb.2004.02.003; Pujuguet P, 2003, MOL BIOL CELL, V14, P2181, DOI 10.1091/mbc.E02-07-0410; Qian XL, 2004, EMBO J, V23, P1739, DOI 10.1038/sj.emboj.7600136; Rao DS, 2002, J CLIN INVEST, V110, P351, DOI 10.1172/JCI200215529; Sherman L, 1999, ONCOGENE, V18, P6692, DOI 10.1038/sj.onc.1203055; Siskova Z, 2006, MOL CELL NEUROSCI, V33, P150, DOI 10.1016/j.mcn.2006.07.001; Stanasila L, 2006, J BIOL CHEM, V281, P4354, DOI 10.1074/jbc.M511989200; Stonecypher MS, 2006, J NEUROPATH EXP NEUR, V65, P162, DOI 10.1097/01.jnen.0000199575.93794.2f; Syroid DE, 1999, J NEUROSCI, V19, P2059; Tamma G, 2005, J CELL SCI, V118, P3623, DOI 10.1242/jcs.02495	42	95	99	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2009	28	6					854	865		10.1038/onc.2008.427	http://dx.doi.org/10.1038/onc.2008.427			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	406UI	19029950	Bronze			2022-12-28	WOS:000263320000008
J	Jeong, JW; Lee, HS; Franco, HL; Broaddus, RR; Taketo, MM; Tsai, SY; Lydon, JP; DeMayo, FJ				Jeong, J-W; Lee, H. S.; Franco, H. L.; Broaddus, R. R.; Taketo, M. M.; Tsai, S. Y.; Lydon, J. P.; DeMayo, F. J.			beta-catenin mediates glandular formation and dysregulation of beta-catenin induces hyperplasia formation in the murine uterus	ONCOGENE			English	Article						beta-catenin; uterus; estrogen; hyperplasia	LEUKEMIA INHIBITORY FACTOR; FEMALE REPRODUCTIVE-TRACT; MOUSE UTERUS; ENDOMETRIAL CARCINOMAS; MICROSATELLITE INSTABILITY; TRANSCRIPTIONAL TARGET; NUCLEAR-LOCALIZATION; COLON-CARCINOMA; E-CADHERIN; CYCLIN D1	Endometrioid adenocarcinoma is the most frequent form of endometrial cancer, usually developing in pre- and perimenopausal women. beta-catenin abnormalities are common in endometrioid type endometrial carcinomas with squamous differentiation. To investigate the role of beta-catenin (Ctnnb1) in uterine development and tumorigenesis, mice were generated which expressed a dominant stabilized beta-catenin or had beta-catenin conditionally ablated in the uterus by crossing the PRCre mouse with the Ctnnb1(f(ex3)/+) mouse or Ctnnb1(f/f) mouse, respectively. Both of the beta-catenin mutant mice have fertility defects and the ability of the uterus to undergo a hormonally induced decidual reaction was lost. Expression of the dominant stabilized beta-catenin, PR(cre/+)Ctnnb1(f(ex3)/+), resulted in endometrial glandular hyperplasia, whereas ablation of b-catenin, PR(cre/+)Ctnnb1(f/f), induced squamous cell metaplasia in the murine uterus. Therefore, we have demonstrated that correct regulation of beta-catenin is important for uterine function as well as in the regulation of endometrial epithelial differentiation.	[Jeong, J-W; Franco, H. L.; Tsai, S. Y.; Lydon, J. P.; DeMayo, F. J.] Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA; [Lee, H. S.] MizMedi Hosp, Infertil & Reprod Endocrinol Ctr, Dept Obstet & Gynecol, Seoul, South Korea; [Broaddus, R. R.] Univ Texas MD Anderson Canc Ctr, Dept Pathol, Houston, TX 77030 USA; [Taketo, M. M.] Kyoto Univ, Dept Pharmacol, Grad Sch Med, Sakyo Ku, Kyoto, Japan	Baylor College of Medicine; University of Texas System; UTMD Anderson Cancer Center; Kyoto University	DeMayo, FJ (corresponding author), Baylor Coll Med, Dept Mol & Cellular Biol, 1 Baylor Plaza, Houston, TX 77030 USA.	fdemayo@bcm.edu	DeMayo, Francesco/C-6255-2019	DeMayo, Francesco/0000-0002-9480-7336	NICHD; NIH [R01HD042311, U54HD0077495, R01- CA77530, 1P50CA098258-01, R01HD057873]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [U54HD028934, R03HD077495, R01HD042311, U54HD007495, R01HD057873] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [R01CA077530, P50CA083639, P50CA098258] Funding Source: NIH RePORTER	NICHD(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Jinghua Li and Bryan Ngo for technical assistance; Janet DeMayo, MS for manuscript preparation. This study was supported by the NICHD and, the NIH R01HD042311 and NIH U54HD0077495 (to FJD), NIH R01- CA77530 and the Susan G Komen Award BCTR0503763 (to JPL), NIH 1P50CA098258-01 (to RRB), NIH R01HD057873 and pilot grant from NIH 1P50CA098258-01 (to JWJ), and the NICHD U54HD28934 (to the Universityof Virginia Center for Research in Reproduction Ligand Assayand Analysis Core).	Aberle H, 1997, EMBO J, V16, P3797, DOI 10.1093/emboj/16.13.3797; ANDERSON MC, 2002, ENDOMETRITIS METAPLA, P285; Arango NA, 2005, DEV BIOL, V288, P276, DOI 10.1016/j.ydbio.2005.09.045; Brault V, 2001, DEVELOPMENT, V128, P1253; Buchanan DL, 1999, ENDOCRINOLOGY, V140, P484, DOI 10.1210/en.140.1.484; Carta L, 2004, BIOL REPROD, V71, P444, DOI 10.1095/biolreprod.103.026534; Catasus L, 2004, HUM PATHOL, V35, P1360, DOI 10.1016/j.humpath.2004.07.019; Cunha GR, 2004, ARCH HISTOL CYTOL, V67, P417, DOI 10.1679/aohc.67.417; Daikoku T, 2004, MOL ENDOCRINOL, V18, P1238, DOI 10.1210/me.2003-0403; DELIGDISCH L, 1987, CANCER DETECT PREV, V10, P237; Deutseher E, 2007, DEV BIOL, V307, P227, DOI 10.1016/j.ydbio.2007.04.036; Di Cristofano A, 2007, ANNU REV PATHOL-MECH, V2, P57, DOI 10.1146/annurev.pathol.2.010506.091905; FINN CA, 1964, J REPROD FERTIL, V8, P331; Fukuchi T, 1998, CANCER RES, V58, P3526; Garcia-Rostan G, 1999, CANCER RES, V59, P1811; HAEGEL H, 1995, DEVELOPMENT, V121, P3529; Harada N, 1999, EMBO J, V18, P5931, DOI 10.1093/emboj/18.21.5931; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; Herington JL, 2007, J HISTOCHEM CYTOCHEM, V55, P963, DOI 10.1369/jhc.7A7199.2007; Hong KU, 2004, AM J PATHOL, V164, P577, DOI 10.1016/S0002-9440(10)63147-1; Hou XN, 2004, MOL ENDOCRINOL, V18, P3035, DOI 10.1210/me.2004-0259; Huelsken J, 2000, J CELL BIOL, V148, P567, DOI 10.1083/jcb.148.3.567; HUETHUDSON YM, 1989, ENDOCRINOLOGY, V125, P1683, DOI 10.1210/endo-125-3-1683; Ikeda T, 2000, ONCOL REP, V7, P323; Irving JA, 2005, HUM PATHOL, V36, P605, DOI 10.1016/j.humpath.2005.03.005; Jemal A, 2007, CA-CANCER J CLIN, V57, P43, DOI 10.3322/canjclin.57.1.43; Jha RK, 2006, FEBS LETT, V580, P5653, DOI 10.1016/j.febslet.2006.09.014; Kim YT, 2002, YONSEI MED J, V43, P701, DOI 10.3349/ymj.2002.43.6.701; Kobayashi K, 1999, JPN J CANCER RES, V90, P55, DOI 10.1111/j.1349-7006.1999.tb00665.x; Kong DH, 1997, NAT GENET, V17, P143, DOI 10.1038/ng1097-143; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; Koster MI, 2007, CELL CYCLE, V6, P269, DOI 10.4161/cc.6.3.3792; Lee KY, 2007, TRENDS ENDOCRIN MET, V18, P234, DOI 10.1016/j.tem.2007.06.002; Lee KY, 2007, MOL CELL BIOL, V27, P5468, DOI 10.1128/MCB.00342-07; Li QX, 2007, J BIOL CHEM, V282, P31725, DOI 10.1074/jbc.M704723200; Lim HJ, 1999, MOL ENDOCRINOL, V13, P1005, DOI 10.1210/me.13.6.1005; Lin ZH, 2006, J CANCER RES CLIN, V132, P811, DOI 10.1007/s00432-006-0130-8; Mao TL, 2001, J PATHOL, V193, P95, DOI 10.1002/1096-9896(2000)9999:9999<::AID-PATH720>3.0.CO;2-3; MARTIN L, 1973, J ENDOCRINOL, V56, P133, DOI 10.1677/joe.0.0560133; Mericskay M, 2004, DEVELOPMENT, V131, P2061, DOI 10.1242/dev.01090; Miller C, 1998, DEVELOPMENT, V125, P3201; Mirabelli-Primdahl L, 1999, CANCER RES, V59, P3346; Mohamed OA, 2005, P NATL ACAD SCI USA, V102, P8579, DOI 10.1073/pnas.0500612102; Moreno-Bueno G, 2002, ONCOGENE, V21, P7981, DOI 10.1038/sj.onc.1205924; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; Nei H, 1999, MOL CARCINOGEN, V25, P207, DOI 10.1002/(SICI)1098-2744(199907)25:3<207::AID-MC7>3.3.CO;2-W; Parr BA, 1998, NATURE, V395, P707, DOI 10.1038/27221; PENTECOST BT, 1988, MOL ENDOCRINOL, V2, P1243, DOI 10.1210/mend-2-12-1243; Risinger JI, 1998, CLIN CANCER RES, V4, P3005; Risinger JI, 1997, CANCER RES, V57, P4736; Romano RA, 2007, J INVEST DERMATOL, V127, P1175, DOI 10.1038/sj.jid.5700652; Saegusa M, 2005, LAB INVEST, V85, P768, DOI 10.1038/labinvest.3700273; Saegusa M, 2001, J PATHOL, V194, P59, DOI 10.1002/path.856; Saegusa M, 2001, BRIT J CANCER, V84, P209, DOI 10.1054/bjoc.2000.1581; Samowitz WS, 1999, CANCER RES, V59, P1442; Shtutman M, 1999, P NATL ACAD SCI USA, V96, P5522, DOI 10.1073/pnas.96.10.5522; Soyal SM, 2005, GENESIS, V41, P58, DOI 10.1002/gene.20098; Staal FJT, 1999, INT IMMUNOL, V11, P317, DOI 10.1093/intimm/11.3.317; STEWART CL, 1992, NATURE, V359, P76, DOI 10.1038/359076a0; SUNDSTROM SA, 1989, J BIOL CHEM, V264, P16941; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; Trink B, 2007, CELL CYCLE, V6, P240, DOI 10.4161/cc.6.3.3803; Vainio S, 1999, NATURE, V397, P405, DOI 10.1038/17068; Wappenschmidt B, 2004, HUM PATHOL, V35, P1260, DOI 10.1016/j.humpath.2004.06.007	64	143	151	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 8	2009	28	1					31	40		10.1038/onc.2008.363	http://dx.doi.org/10.1038/onc.2008.363			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	392HP	18806829	Green Accepted			2022-12-28	WOS:000262294100004
J	Noborio-Hatano, K; Kikuchi, J; Takatoku, M; Shimizu, R; Wada, T; Ueda, M; Nobuyoshi, M; Oh, I; Sato, K; Suzuki, T; Ozaki, K; Mori, M; Nagai, T; Muroi, K; Kano, Y; Furukawa, Y; Ozawa, K				Noborio-Hatano, K.; Kikuchi, J.; Takatoku, M.; Shimizu, R.; Wada, T.; Ueda, M.; Nobuyoshi, M.; Oh, I.; Sato, K.; Suzuki, T.; Ozaki, K.; Mori, M.; Nagai, T.; Muroi, K.; Kano, Y.; Furukawa, Y.; Ozawa, K.			Bortezomib overcomes cell adhesion-mediated drug resistance through downregulation of VLA-4 expression in multiple myeloma	ONCOGENE			English	Article						myeloma; bortezomib; drug resistance; cell adhesion; VLA-4	NF-KAPPA-B; MARROW STROMAL CELLS; BONE-MARROW; CAM-DR; BINDING-SITES; APOPTOSIS; LEUKEMIA; SUPPRESSES; ACTIVATION; MOLECULES	Multiple myeloma ( MM) is incurable, mainly because of cell adhesion-mediated drug resistance (CAM-DR). In this study, we performed functional screening using short hairpin RNA (shRNA) to de. ne the molecule(s) responsible for CAM-DR of MM. Using four bona. de myeloma cell lines (KHM-1B, KMS12-BM, RPMI8226 and U266) and primary myeloma cells, we identified CD29 (beta 1-integrin), CD44, CD49d (alpha 4-integrin, a subunit of VLA-4), CD54 ( intercellular adhesion molecule-1 (ICAM-1)), CD138 (syndecan-1) and CD184 (CXC chemokine receptor-4 (CXCR4)) as major adhesion molecules expressed on MM. shRNA-mediated knockdown of CD49d but not CD44, CD54, CD138 and CD184 significantly reversed CAM-DR of myeloma cells to bortezomib, vincristine, doxorubicin and dexamethasone. Experiments using blocking antibodies yielded almost identical results. Bortezomib was relatively resistant to CAM-DR because of its ability to specifically down-regulate CD49d expression. This property was unique to bortezomib and was not observed in other anti-myeloma drugs. Pretreatment with bortezomib was able to ameliorate CAM-DR of myeloma cells to vincristine and dexamethasone. These results suggest that VLA-4 plays a critical role in CAM-DR of MM cells. The combination of bortezomib with conventional anti-myeloma drugs may be effective in overcoming CAM-DR of MM.	[Kikuchi, J.; Shimizu, R.; Wada, T.; Furukawa, Y.] Jichi Med Univ, Ctr Mol Med, Div Stem Cell Regulat, Shimotsuke, Tochigi 3290498, Japan; [Noborio-Hatano, K.; Takatoku, M.; Ueda, M.; Nobuyoshi, M.; Oh, I.; Sato, K.; Suzuki, T.; Ozaki, K.; Mori, M.; Nagai, T.; Muroi, K.; Furukawa, Y.; Ozawa, K.] Jichi Med Univ, Dept Internal Med, Div Hematol, Shimotsuke, Tochigi 3290498, Japan	Jichi Medical University; Jichi Medical University	Furukawa, Y (corresponding author), Jichi Med Univ, Ctr Mol Med, Div Stem Cell Regulat, 3311-1 Yakushiji, Shimotsuke, Tochigi 3290498, Japan.	furuyu@jichi.ac.jp	Furukawa, Yusuke/Y-1342-2018	Furukawa, Yusuke/0000-0002-7249-6418	Ministry of Health, Welfare, and Labor of Japan; Ministry of Education, Science, Sports, and Technology of Japan; Jichi Medical School Young Investigator Award	Ministry of Health, Welfare, and Labor of Japan(Ministry of Health, Labour and Welfare, Japan); Ministry of Education, Science, Sports, and Technology of Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Jichi Medical School Young Investigator Award	This study was supported in part by grants from the Ministry of Health, Welfare, and Labor of Japan, and Grants-in-Aid for Scientific Research from the Ministry of Education, Science, Sports, and Technology of Japan. KN-H and JK are winners of the Jichi Medical School Young Investigator Award.	Annunziata CM, 2007, CANCER CELL, V12, P115, DOI 10.1016/j.ccr.2007.07.004; Chauhan D, 1996, BLOOD, V87, P1104, DOI 10.1182/blood.V87.3.1104.bloodjournal8731104; Cook G, 1997, ACTA HAEMATOL-BASEL, V97, P81; Corso A, 2005, CANCER, V104, P118, DOI 10.1002/cncr.21104; Damiano JS, 1999, BLOOD, V93, P1658, DOI 10.1182/blood.V93.5.1658; Davies AM, 2007, CLIN CANCER RES, V13, p4647S, DOI 10.1158/1078-0432.CCR-07-0334; Dolcet X, 2005, VIRCHOWS ARCH, V446, P475, DOI 10.1007/s00428-005-1264-9; Drexler Hans G, 2003, Hum Cell, V16, P101, DOI 10.1111/j.1749-0774.2003.tb00140.x; Duechler M, 2005, LEUKEMIA, V19, P260, DOI 10.1038/sj.leu.2403592; Fisher RI, 2006, J CLIN ONCOL, V24, P4867, DOI 10.1200/JCO.2006.07.9665; Hazlehurst LA, 2000, ONCOGENE, V19, P4319, DOI 10.1038/sj.onc.1203782; Hideshima T, 2001, CANCER RES, V61, P3071; Hideshima T, 2007, NAT REV CANCER, V7, P585, DOI 10.1038/nrc2189; Horton TM, 2006, CANCER CHEMOTH PHARM, V58, P13, DOI 10.1007/s00280-005-0135-z; Keats JJ, 2007, CANCER CELL, V12, P131, DOI 10.1016/j.ccr.2007.07.003; Kikuchi J, 2005, LEUKEMIA, V19, P1934, DOI 10.1038/sj.leu.2403951; Kikuchi J, 2007, STEM CELLS, V25, P2439, DOI 10.1634/stemcells.2007-0207; Kirschner KM, 2006, J BIOL CHEM, V281, P31930, DOI 10.1074/jbc.M602668200; Kyle RA, 2003, MAYO CLIN PROC, V78, P21, DOI 10.4065/78.1.21; Landowski TH, 2003, ONCOGENE, V22, P2417, DOI 10.1038/sj.onc.1206315; LIN YZ, 1995, J BIOL CHEM, V270, P14255, DOI 10.1074/jbc.270.24.14255; Matsunaga T, 2003, NAT MED, V9, P1158, DOI 10.1038/nm909; Michigami T, 2000, BLOOD, V96, P1953, DOI 10.1182/blood.V96.5.1953.h8001953_1953_1960; Mitsiades N, 2002, BLOOD, V99, P4525, DOI 10.1182/blood.V99.12.4525; Miyakoshi S, 2006, BLOOD, V107, P3492, DOI 10.1182/blood-2005-11-4541; Mori T, 2005, MOL CELL BIOL, V25, P5183, DOI 10.1128/MCB.25.12.5183-5195.2005; Mori Y, 2004, BLOOD, V104, P2149, DOI 10.1182/blood-2004-01-0236; Nefedova Y, 2003, LEUKEMIA, V17, P1175, DOI 10.1038/sj.leu.2402924; NOBORIOHATANO K, 2007, JPN J CLIN HEMATOL, V48, pA1093; Odgerel T, 2008, ONCOGENE, V27, P3102, DOI 10.1038/sj.onc.1210980; Olson DL, 2005, MOL CANCER THER, V4, P91; Pearse RN, 2001, P NATL ACAD SCI USA, V98, P11581, DOI 10.1073/pnas.201394498; Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45; Richardson PG, 2005, NEW ENGL J MED, V352, P2487, DOI 10.1056/NEJMoa043445; Richardson PG, 2003, NEW ENGL J MED, V348, P2609, DOI 10.1056/NEJMoa030288; ROSEN GD, 1994, J BIOL CHEM, V269, P15652; Schmidmaier R, 2006, INT J BIOL MARKER, V21, P218, DOI 10.1177/172460080602100404; TAKATOKU M, 2004, JPN J CLIN HEMATOL, V45, P144; Tatsumi T, 1996, JPN J CANCER RES, V87, P837, DOI 10.1111/j.1349-7006.1996.tb02108.x; Yanamandra N, 2006, CLIN CANCER RES, V12, P591, DOI 10.1158/1078-0432.CCR-05-1792; Zutter MM, 1997, BLOOD, V90, P678, DOI 10.1182/blood.V90.2.678.678_678_689	41	132	134	1	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2009	28	2					231	242		10.1038/onc.2008.385	http://dx.doi.org/10.1038/onc.2008.385			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	395CY	18850009				2022-12-28	WOS:000262501100007
J	Gray, MJ; Dallas, NA; Van Buren, G; Xia, L; Yang, AD; Somcio, RJ; Gaur, P; Mangala, LS; Vivas-Mejia, PE; Fan, F; Sanguino, AM; Gallick, GE; Lopez-Berestein, G; Sood, AK; Ellis, LM				Gray, M. J.; Dallas, N. A.; Van Buren, G.; Xia, L.; Yang, A. D.; Somcio, R. J.; Gaur, P.; Mangala, L. S.; Vivas-Mejia, P. E.; Fan, F.; Sanguino, A. M.; Gallick, G. E.; Lopez-Berestein, G.; Sood, A. K.; Ellis, L. M.			Therapeutic targeting of Id2 reduces growth of human colorectal carcinoma in the murine liver	ONCOGENE			English	Article						Id2; colorectal carcinoma; Inhibitor of DNA-binding; metastasis; siRNA	LOOP-HELIX PROTEINS; RETINOBLASTOMA PROTEIN; PANCREATIC-CANCER; CELL-CYCLE; EXPRESSION; PROLIFERATION; ANGIOGENESIS; GENE; APOPTOSIS; DIFFERENTIATION	During development inhibitor of DNA-bind-2 (Id2) regulates proliferation and differentiation. Id2 expression has been detected in cancer cells, yet its cellular function and validity as a therapeutic target remains largely unknown. Immunohistochemical analysis of colorectal cancer (CRC) specimens revealed that Id2 was undetectable in normal colonic mucosa, but occurs in 40% of primary tumors and in most CRC liver metastases (P<0.0001). Additionally, Id2 was expressed in all CRC cell lines assayed. CRC cells with reduced Id2 expression demonstrated reduced proliferation. Analysis of CRC cell cycle regulatory proteins showed that reducing Id2 levels reduces cyclin D1 levels and increased p21 levels. Reduction of Id2 expression also enhanced tumor cell apoptosis, increasing levels of the pro-apoptotic protein Bim/Bod, and cleavage of caspase-7 and poly (ADP-ribose) polymerase. In vivo studies show tumors derived from cells with decreased Id2 levels formed smaller tumors with fewer metastases compared with tumors with normal levels (P<0.05). Furthermore, intraperitoneal administration of Id2 small interfering RNA (siRNA) conjugated with the neutral liposome 1,2-dioleoyl-sn-glycero-3-phosphatidylcholine decreased tumor burden in mice compared with control treatment (P = 0.006). We conclude that Id2 is upregulated in CRC, and is important in promoting cell survival. In vivo targeting of Id2 by siRNA establishes that it is a valid therapeutic target where its expression occurs.	[Gray, M. J.; Dallas, N. A.; Van Buren, G.; Yang, A. D.; Gaur, P.; Ellis, L. M.] Univ Texas MD Anderson Canc Ctr, Dept Surg Oncol, Houston, TX 77030 USA; [Xia, L.; Somcio, R. J.; Fan, F.; Gallick, G. E.; Sood, A. K.; Ellis, L. M.] Univ Texas MD Anderson Canc Ctr, Dept Canc Biol, Houston, TX 77030 USA; [Mangala, L. S.; Sood, A. K.] Univ Texas MD Anderson Canc Ctr, Dept Gynecol Oncol, Houston, TX 77030 USA; [Vivas-Mejia, P. E.; Sanguino, A. M.; Lopez-Berestein, G.] Univ Texas MD Anderson Canc Ctr, Dept Expt Therapeut, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Gray, MJ (corresponding author), OSI Pharmaceut, Dept Canc Biol, 1 Biosci Pk Dr, Farmingdale, NY 11735 USA.	mgray@osip.com; lellis@mdanderson.org	Khaitan, Puja/AAQ-6413-2020	Khaitan, Puja/0000-0001-8654-062X	Ovarian Cancer Research Fund, Inc; Zarrow Foundation; William C Liedtke, Jr Chair in Cancer Research (LME);  [NIH-5 T32 CA09599]; NATIONAL CANCER INSTITUTE [T32CA009599] Funding Source: NIH RePORTER	Ovarian Cancer Research Fund, Inc; Zarrow Foundation; William C Liedtke, Jr Chair in Cancer Research (LME); ; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Rita Hernandez (Department of Surgical Oncology) and Christine Wogan (Department of Scientific Publications) for manuscript editing and preparation. Supported by NIH-5 T32 CA09599 (GVB, NAD, ADY and PG), Program Project Development Grant from the Ovarian Cancer Research Fund, Inc. (AKS), the Zarrow Foundation (AKS) and William C Liedtke, Jr Chair in Cancer Research (LME).	Arumugam T, 2006, J NATL CANCER I, V98, P1806, DOI 10.1093/jnci/djj498; Asirvatharn AJ, 2007, PROSTATE, V67, P1411, DOI 10.1002/pros.20633; Benezra R, 2001, ONCOGENE, V20, P8334, DOI 10.1038/sj.onc.1205160; BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; Broude EV, 2007, ONCOGENE, V26, P6954, DOI 10.1038/sj.onc.1210516; Camp ER, 2006, CLIN CANCER RES, V12, P2628, DOI 10.1158/1078-0432.CCR-05-2257; Cannarile MA, 2006, NAT IMMUNOL, V7, P1317, DOI 10.1038/ni1403; Gray MJ, 2005, CANCER RES, V65, P3664, DOI 10.1158/0008-5472.CAN-04-2229; Hsu SY, 1998, MOL ENDOCRINOL, V12, P1432, DOI 10.1210/me.12.9.1432; Hughes TA, 2005, BIOCHEM BIOPH RES CO, V329, P1267, DOI 10.1016/j.bbrc.2005.02.102; IAVARONE A, 1994, GENE DEV, V8, P1270, DOI 10.1101/gad.8.11.1270; Jen Y, 1996, DEV DYNAM, V207, P235; Kleeff J, 1998, CANCER RES, V58, P3769; Landen CN, 2005, CANCER RES, V65, P6910, DOI 10.1158/0008-5472.CAN-05-0530; Langley RR, 2003, CANCER RES, V63, P2971; Lasorella A, 2000, NATURE, V407, P592, DOI 10.1038/35036504; Lasorella A, 2005, MOL CELL BIOL, V25, P3563, DOI 10.1128/MCB.25.9.3563-3574.2005; Lasorella A, 2002, CANCER RES, V62, P301; Lasorella A, 2001, ONCOGENE, V20, P8326, DOI 10.1038/sj.onc.1205093; Lasorella A, 1996, MOL CELL BIOL, V16, P2570; Lofstedt T, 2004, J BIOL CHEM, V279, P39223, DOI 10.1074/jbc.M402904200; LUKAS J, 1995, MOL CELL BIOL, V15, P2600; O'Connor L, 1998, EMBO J, V17, P384, DOI 10.1093/emboj/17.2.384; Oliver FJ, 1998, J BIOL CHEM, V273, P33533, DOI 10.1074/jbc.273.50.33533; Pagliuca A, 2000, CANCER RES, V60, P1376; Parikh AA, 2004, AM J PATHOL, V164, P2139, DOI 10.1016/S0002-9440(10)63772-8; Prabhu S, 1997, MOL CELL BIOL, V17, P5888, DOI 10.1128/MCB.17.10.5888; Rockman SP, 2001, J BIOL CHEM, V276, P45113, DOI 10.1074/jbc.M107742200; Rothschild G, 2006, MOL CELL BIOL, V26, P4351, DOI 10.1128/MCB.01743-05; Russell RG, 2004, CANCER RES, V64, P7220, DOI 10.1158/0008-5472.CAN-04-2095; Weinberg RA, 1996, CELL, V85, P457, DOI 10.1016/S0092-8674(00)81244-1; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; Wilson JW, 2001, CANCER RES, V61, P8803; Yang AD, 2006, CLIN CANCER RES, V12, P4147, DOI 10.1158/1078-0432.CCR-06-0038; Zhang XM, 2007, CANCER SCI, V98, P308, DOI 10.1111/j.1349-7006.2007.00400.x	35	30	33	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC	2008	27	57					7192	7200		10.1038/onc.2008.356	http://dx.doi.org/10.1038/onc.2008.356			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	379GG	18806828	Green Accepted			2022-12-28	WOS:000261384100006
J	Vera, E; Canela, A; Fraga, MF; Esteller, M; Blasco, MA				Vera, E.; Canela, A.; Fraga, M. F.; Esteller, M.; Blasco, M. A.			Epigenetic regulation of telomeres in human cancer	ONCOGENE			English	Article						telomeres; subtelomeres; DNA methylation; epigenetic; telomerase; human cancer	RB FAMILY; LENGTH; RECOMBINATION; DNA; METHYLATION; CELLS; QUANTIFICATION; EXPRESSION; REPEATS	Hypomethylation of repeated elements in the genome is a common feature of human cancer, however, the direct consequences of this epigenetic defect for cancer biology are still largely unknown. Telomeres are specialized chromatin structures at the ends of eukaryotic chromosomes formed by tandem repeats of G-rich sequences and associated proteins, which have an essential role in chromosome end protection and genomic stability. Telomeric DNA repeats cannot be methylated, however, the adjacent subtelomeric DNA is heavily methylated in humans. Here, we show that the methylation status of subtelomeric DNA repeats negatively correlates with telomere length and telomere recombination in a large panel of human cancer cell lines. These findings suggest that tumor telomere length and integrity can be influenced by epigenetic factors. Finally, we show that treatment of human cancer cell lines with demethylating drugs results in hypomethylation of subtelomeric repeats and increased telomere recombination, which in turn may facilitate telomere elongation. All together, these findings suggest that tumor telomere length and integrity can be influenced by the epigenetic status of cancer cells. Oncogene (2008) 27, 6817-6833; doi: 10.1038/onc.2008.289; published online 1 September 2008	[Vera, E.; Canela, A.; Blasco, M. A.] Spanish Natl Canc Ctr CNIO, Telomeres & Telomerase Grp, Mol Oncol Program, E-28029 Madrid, Spain; [Fraga, M. F.; Esteller, M.] Spanish Natl Canc Ctr CNIO, Canc Epigenet Grp, Mol Pathol Program, E-28029 Madrid, Spain	Centro Nacional de Investigaciones Oncologicas (CNIO); Centro Nacional de Investigaciones Oncologicas (CNIO)	Blasco, MA (corresponding author), Spanish Natl Canc Ctr CNIO, Telomeres & Telomerase Grp, Mol Oncol Program, 3 Melchor Fernandez Almagro, E-28029 Madrid, Spain.	mblasco@cnio.es	Esteller, Manel/L-5956-2014; Blasco, Maria A./M-1694-2014; Fraga, Mario F/H-7824-2017	Esteller, Manel/0000-0003-4490-6093; Blasco, Maria A./0000-0002-4211-233X; Fraga, Mario F/0000-0001-8450-2603	Spanish Ministry of Education and Science (MEC); MEC [SAF2005-00277, GEN2001-4856-C1308]; Regional Government of Madrid [GR/SAL/0597/2004]; European Union [TELOSENS FIGH-CT-2002-00217, INTACT LSHC-CT-2003-506803, ZINCAGE FOOD-CT-2003-506850, RISC-RAD FI6R-CT-2003-508842, MOL CANCER MED LSHC-CT-2004-502943]; Josef Steiner Cancer Research Award 2003	Spanish Ministry of Education and Science (MEC)(Spanish Government); MEC(European Commission); Regional Government of Madrid; European Union(European Commission); Josef Steiner Cancer Research Award 2003	EV is a predoctoral fellow of the Spanish Ministry of Education and Science (MEC). MA Blasco's Laboratory is funded by the MEC (SAF2005-00277, GEN2001-4856-C1308), by the Regional Government of Madrid (GR/SAL/0597/2004), European Union (TELOSENS FIGH-CT-2002-00217, INTACT LSHC-CT-2003-506803, ZINCAGE FOOD-CT-2003-506850, RISC-RAD FI6R-CT-2003-508842, MOL CANCER MED LSHC-CT-2004-502943) and the Josef Steiner Cancer Research Award 2003.	Bailey SM, 2004, NUCLEIC ACIDS RES, V32, P3743, DOI 10.1093/nar/gkh691; Bailey SM, 2001, SCIENCE, V293, P2462, DOI 10.1126/science.1062560; Bechter OE, 2004, CANCER RES, V64, P3444, DOI 10.1158/0008-5472.CAN-04-0323; Benetti R, 2007, J CELL BIOL, V178, P925, DOI 10.1083/jcb.200703081; Benetti R, 2007, NAT GENET, V39, P243, DOI 10.1038/ng1952; Blackburn EH, 2001, CELL, V106, P661, DOI 10.1016/S0092-8674(01)00492-5; Blasco MA, 2005, NAT REV GENET, V6, P611, DOI 10.1038/nrg1656; Blasco MA, 2004, CARCINOGENESIS, V25, P1083, DOI 10.1093/carcin/bgh185; Blasco MA, 2007, NAT REV GENET, V8, P299, DOI 10.1038/nrg2047; Canela A, 2007, P NATL ACAD SCI USA, V104, P5300, DOI 10.1073/pnas.0609367104; Collins K, 2002, ONCOGENE, V21, P564, DOI 10.1038/sj.onc.1205083; de Lange T, 2005, GENE DEV, V19, P2100, DOI 10.1101/gad.1346005; Dunham MA, 2000, NAT GENET, V26, P447, DOI 10.1038/82586; Flores I, 2006, CURR OPIN CELL BIOL, V18, P254, DOI 10.1016/j.ceb.2006.03.003; Fraga MF, 2005, NAT GENET, V37, P391, DOI 10.1038/ng1531; Fraga MF, 2002, ELECTROPHORESIS, V23, P1677, DOI 10.1002/1522-2683(200206)23:11&lt;1677::AID-ELPS1677&gt;3.0.CO;2-Z; Garcia-Aranda C, 2006, CANCER-AM CANCER SOC, V106, P541, DOI 10.1002/cncr.21625; Garcia-Cao M, 2004, NAT GENET, V36, P94, DOI 10.1038/ng1278; Garcia-Cao M, 2002, NAT GENET, V32, P415, DOI 10.1038/ng1011; Gonzalo S, 2006, NAT CELL BIOL, V8, P416, DOI 10.1038/ncb1386; Gonzalo S, 2005, CELL CYCLE, V4, P752, DOI 10.4161/cc.4.6.1720; Gonzalo S, 2005, NAT CELL BIOL, V7, P420, DOI 10.1038/ncb1235; Guilleret I, 2003, EXP CELL RES, V289, P326, DOI 10.1016/S0014-4827(03)00281-7; HARLEY CB, 1990, NATURE, V345, P458, DOI 10.1038/345458a0; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; Kitagawa Y, 2000, CLIN CANCER RES, V6, P2868; Kondo T, 2000, HUM MOL GENET, V9, P597, DOI 10.1093/hmg/9.4.597; Muntoni A, 2005, HUM MOL GENET, V14, pR191, DOI 10.1093/hmg/ddi266; Samper E, 2000, EMBO REP, V1, P244, DOI 10.1093/embo-reports/kvd051; Shay JW, 2006, NAT REV DRUG DISCOV, V5, P577, DOI 10.1038/nrd2081; Steinert S, 2004, MOL CELL BIOL, V24, P4571, DOI 10.1128/MCB.24.10.4571-4580.2004	31	97	99	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 20	2008	27	54					6817	6833		10.1038/onc.2008.289	http://dx.doi.org/10.1038/onc.2008.289			17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	375IS	18762811				2022-12-28	WOS:000261108000003
J	Brellier, F; Bergoglio, V; Valin, A; Barnay, S; Chevallier-Lagente, O; Vielh, P; Spatz, A; Gorry, P; Avril, MF; Magnaldo, T				Brellier, F.; Bergoglio, V.; Valin, A.; Barnay, S.; Chevallier-Lagente, O.; Vielh, P.; Spatz, A.; Gorry, P.; Avril, M-F; Magnaldo, T.			Heterozygous mutations in the tumor suppressor gene PATCHED provoke basal cell carcinoma-like features in human organotypic skin cultures	ONCOGENE			English	Article						PATCHED; skin; keratinocyte; basal cell carcinoma; organotypic cultures; Gorlin syndrome	SONIC HEDGEHOG; CYCLE PROGRESSION; NEVUS SYNDROME; HUMAN HOMOLOG; MICE; GLI2; PTCH; KERATINOCYTES; ACTIVATION; SPECTRUM	Basal cell carcinoma of the skin is the most common type of cancer in humans. The majority of these tumors displays aberrant activation of the SONIC HEDGEHOG (SHH)/PATCHED pathway, triggered by mutations in the PATCHED tumor suppressor gene, which encodes a transmembrane receptor of SHH. In this study, we took advantage of the natural genotype (PATCHED(+/-)) of healthy keratinocytes expanded from patients with the nevoid basal cell carcinoma or Gorlin syndrome to mimic heterozygous somatic mutations thought to occur in the PATCHED gene early upon basal cell carcinoma development in the general population. PATCHED(+/-) epidermis developed on a dermal equivalent containing wild-type (WT) PATCHED(+/+). fibroblasts exhibited striking invasiveness and hyperproliferation, as well as marked differentiation impairment. Deciphering the phenotype of PATCHED(+/-) keratinocytes revealed slight increases of the transcriptional activators GLI1 and GLI2-the latter known to provoke basal cell carcinoma-like tumors when overexpressed in transgenic mice. PATCHED(+/-) keratinocytes also showed a substantial increase of the cell cycle regulator cyclin D1. These data show for the first time the physiological impact of constitutive heterozygous PATCHED mutations in primary human keratinocytes and strongly argue for a yet elusive mechanism of haploinsufficiency leading to cancer proneness.	[Bergoglio, V.; Valin, A.; Barnay, S.; Chevallier-Lagente, O.; Magnaldo, T.] Inst Gustave Roussy, FRE 2939, F-94805 Villejuif 05, France; [Brellier, F.] Friedrich Miescher Inst Biomed Res, Basel, Switzerland; [Vielh, P.; Spatz, A.] Inst Gustave Roussy, Dept Pathol, F-94805 Villejuif 05, France; [Gorry, P.] CHU Pellegrin Enfants, Serv Genet, Bordeaux, France; [Avril, M-F] Univ Paris 05, Serv Dermatol, Paris, France	UNICANCER; Gustave Roussy; Friedrich Miescher Institute for Biomedical Research; UNICANCER; Gustave Roussy; CHU Bordeaux; UDICE-French Research Universities; Universite Paris Cite	Magnaldo, T (corresponding author), Inst Gustave Roussy, FRE 2939, Rue Camille Desmoulins, F-94805 Villejuif 05, France.	marie-francoise.avril@cch.aphp.fr; magnaldo@igr.fr	SPATZ, ALAN/B-8645-2009; , GORRY/I-9725-2019; Bergoglio, Valérie VB/P-1624-2014	SPATZ, ALAN/0000-0003-3020-1420; , GORRY/0000-0002-5497-8069; Bergoglio, Valérie VB/0000-0003-2773-3178; Brellier, Florence/0000-0002-0143-472X; Barnay-Verdier, Stephanie/0000-0002-4615-3059	CNRS; ARC [9500]; Fondation de l'Avenir; SFD; AFM	CNRS(Centre National de la Recherche Scientifique (CNRS)); ARC(Australian Research Council); Fondation de l'Avenir; SFD; AFM(Association Francaise contre les Myopathies)	VB, AV, SB, have contributed equally to this work. FB and AV were recipients of PhD fellowships from the CNRS and Ligue Nationale contre le Cancer, and MESR, respectively. SB was an IGR post-doctoral fellow. We gratefully thank Dr Francoise Bernerd, Dr Howard Green, Ms Valerie Velasco, Virginie Marty, Dr Rune Toftgard, Dr Paule Opolon, and Marianne Brown-Luedi for their kind help. This work was supported by the CNRS, the ARC ( no. 9500), the Fondation de l'Avenir, the SFD and the AFM.	Adolphe C, 2006, CANCER RES, V66, P2081, DOI 10.1158/0008-5472.CAN-05-2146; Aszterbaum M, 1999, NAT MED, V5, P1285, DOI 10.1038/15242; Bernerd F, 2001, P NATL ACAD SCI USA, V98, P7817, DOI 10.1073/pnas.141221998; Bigelow RLH, 2005, J INVEST DERMATOL, V124, P457, DOI 10.1111/j.0022-202X.2004.23590.x; Boutet N, 2003, J INVEST DERMATOL, V121, P478, DOI 10.1046/j.1523-1747.2003.12423.x; BRELLIER F, 2008, BR J DERMATOL   0528; Chidambaram A, 1996, ADV CANCER RES, V70, P49, DOI 10.1016/S0065-230X(08)60871-4; Dahmane N, 1997, NATURE, V389, P876, DOI 10.1038/39918; DePinho RA, 2000, NATURE, V408, P248, DOI 10.1038/35041694; Evans T, 2000, HUM MUTAT, V16, P43, DOI 10.1002/1098-1004(200007)16:1<43::AID-HUMU8>3.3.CO;2-Z; Fan HR, 1999, J CELL BIOL, V147, P71, DOI 10.1083/jcb.147.1.71; Gailani MR, 1996, NAT GENET, V14, P78, DOI 10.1038/ng0996-78; GORLIN RJ, 1987, MEDICINE, V66, P98, DOI 10.1097/00005792-198703000-00002; Grachtchouk M, 2000, NAT GENET, V24, P216, DOI 10.1038/73417; Hahn H, 1996, J BIOL CHEM, V271, P12125, DOI 10.1074/jbc.271.21.12125; Johnson RL, 1996, SCIENCE, V272, P1668, DOI 10.1126/science.272.5268.1668; Kenney AM, 2000, MOL CELL BIOL, V20, P9055, DOI 10.1128/MCB.20.23.9055-9067.2000; Marigo V, 1996, NATURE, V384, P176, DOI 10.1038/384176a0; Mill P, 2003, GENE DEV, V17, P282, DOI 10.1101/gad.1038103; Nilsson M, 2000, P NATL ACAD SCI USA, V97, P3438, DOI 10.1073/pnas.050467397; Oro AE, 1997, SCIENCE, V276, P817, DOI 10.1126/science.276.5313.817; Pruvost-Balland C, 2006, ANN DERMATOL VENER, V133, P117, DOI 10.1016/S0151-9638(06)70861-4; Regl G, 2004, ONCOGENE, V23, P1263, DOI 10.1038/sj.onc.1207240; Reifenberger J, 2005, BRIT J DERMATOL, V152, P43, DOI 10.1111/J.1365-2133.2005.06353.X; RHEINWALD JG, 1975, CELL, V6, P331, DOI 10.1016/S0092-8674(75)80001-8; Soufir N, 2006, BRIT J CANCER, V95, P548, DOI 10.1038/sj.bjc.6603303; Stone DM, 1996, NATURE, V384, P129, DOI 10.1038/384129a0; Teh MT, 2005, CANCER RES, V65, P8597, DOI 10.1158/0008-5472.CAN-05-0842; Unden AB, 1997, CANCER RES, V57, P2336	29	9	15	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 30	2008	27	51					6601	6606		10.1038/onc.2008.260	http://dx.doi.org/10.1038/onc.2008.260			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	366RS	18679421				2022-12-28	WOS:000260501700008
J	Schickel, R; Boyerinas, B; Park, SM; Peter, ME				Schickel, R.; Boyerinas, B.; Park, S-M; Peter, M. E.			MicroRNAs: key players in the immune system, differentiation, tumorigenesis and cell death	ONCOGENE			English	Review						apoptosis; miRNA; oncomiRs; tumor progression	SCREEN IMPLICATES MIRNA-372; TUMOR-SUPPRESSOR GENE; HUMAN LUNG CANCERS; FAMILY-MEMBER BIM; MOBILITY GROUP A2; B-CELL; T-CELL; NEGATIVE SELECTION; DOWN-REGULATION; SMALL RNAS	Micro (mi)RNAs are small, highly conserved noncoding RNAs that control gene expression post-transcriptionally either via the degradation of target mRNAs or the inhibition of protein translation. Each miRNA is believed to regulate the expression of multiple mRNA targets, and many miRNAs have been linked to the initiation and progression of human cancer. miRNAs control various activities of the immune system and different stages of hematopoietic development, and their misexpression is the cause of various blood malignancies. Certain miRNAs have oncogenic activities, whereas others have the potential to act as tumor suppressors. Because they control fundamental processes such as differentiation, cell growth and cell death, the study of the role of miRNAs in human neoplasms holds great promise for novel forms of therapy. Here, we summarize the role of miRNAs and their targets in contributing to human cancers and their function as regulators of apoptotic pathways and the immune system.	[Schickel, R.; Boyerinas, B.; Park, S-M; Peter, M. E.] Univ Chicago, Ben May Dept Canc Res, Chicago, IL 60637 USA	University of Chicago	Peter, ME (corresponding author), Univ Chicago, Ben May Dept Canc Res, Chicago, IL 60637 USA.	mpeter@uchicago.edu		Peter, Marcus Ernst/0000-0003-3216-036X	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007183] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abbott AL, 2005, DEV CELL, V9, P403, DOI 10.1016/j.devcel.2005.07.009; Abe N, 2003, BRIT J CANCER, V89, P2104, DOI 10.1038/sj.bjc.6601391; Adachi M, 1996, P NATL ACAD SCI USA, V93, P2131, DOI 10.1073/pnas.93.5.2131; Akao Y, 2007, CANCER SCI, V98, P1914, DOI 10.1111/j.1349-7006.2007.00618.x; Akao Y, 2006, BIOL PHARM BULL, V29, P903, DOI 10.1248/bpb.29.903; Algeciras-Schimnich A, 2003, P NATL ACAD SCI USA, V100, P11445, DOI 10.1073/pnas.2034995100; Algeciras-Schimnich A, 2002, CURR OPIN CELL BIOL, V14, P721, DOI 10.1016/S0955-0674(02)00384-8; Asangani IA, 2008, ONCOGENE, V27, P2128, DOI 10.1038/sj.onc.1210856; Baehrecke EH, 2003, CURR BIOL, V13, pR473, DOI 10.1016/S0960-9822(03)00405-6; Barnhart BC, 2003, SEMIN IMMUNOL, V15, P185, DOI 10.1016/S1044-5323(03)00031-9; Barry M, 2000, MOL CELL BIOL, V20, P3781, DOI 10.1128/MCB.20.11.3781-3794.2000; Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5; Bernstein E, 2003, NAT GENET, V35, P215, DOI 10.1038/ng1253; Bommer GT, 2007, CURR BIOL, V17, P1298, DOI 10.1016/j.cub.2007.06.068; Bouillet P, 1999, SCIENCE, V286, P1735, DOI 10.1126/science.286.5445.1735; Bouillet P, 2002, NATURE, V415, P922, DOI 10.1038/415922a; Boyerinas B, 2008, CANCER RES, V68, P2587, DOI 10.1158/0008-5472.CAN-08-0264; Brabletz T, 1999, INT IMMUNOL, V11, P1701, DOI 10.1093/intimm/11.10.1701; Bredenkamp N, 2007, DEV GENES EVOL, V217, P227, DOI 10.1007/s00427-006-0128-x; Brennecke J, 2003, CELL, V113, P25, DOI 10.1016/S0092-8674(03)00231-9; Brueckner B, 2007, CANCER RES, V67, P1419, DOI 10.1158/0008-5472.CAN-06-4074; Calin GA, 2002, P NATL ACAD SCI USA, V99, P15524, DOI 10.1073/pnas.242606799; Calin GA, 2004, P NATL ACAD SCI USA, V101, P2999, DOI 10.1073/pnas.0307323101; Calin GA, 2005, NEW ENGL J MED, V353, P1793, DOI 10.1056/NEJMoa050995; Care A, 2007, NAT MED, V13, P613, DOI 10.1038/nm1582; Castro JE, 1996, IMMUNITY, V5, P617, DOI 10.1016/S1074-7613(00)80275-7; CHALFIE M, 1981, CELL, V24, P59, DOI 10.1016/0092-8674(81)90501-8; Chan JA, 2005, CANCER RES, V65, P6029, DOI 10.1158/0008-5472.CAN-05-0137; Chang Jinhong, 2004, RNA Biol, V1, P106, DOI 10.4161/rna.1.2.1066; Chang TC, 2008, NAT GENET, V40, P43, DOI 10.1038/ng.2007.30; Chang TC, 2007, MOL CELL, V26, P745, DOI 10.1016/j.molcel.2007.05.010; Chen CZ, 2004, SCIENCE, V303, P83, DOI 10.1126/science.1091903; Chen JF, 2006, NAT GENET, V38, P228, DOI 10.1038/ng1725; Chen Y, 2008, BLOOD, V111, P1217, DOI 10.1182/blood-2007-07-104133; Cheng AM, 2005, NUCLEIC ACIDS RES, V33, P1290, DOI 10.1093/nar/gki200; CHIAPPETTA G, 1995, ONCOGENE, V10, P1307; Ciafre SA, 2005, BIOCHEM BIOPH RES CO, V334, P1351, DOI 10.1016/j.bbrc.2005.07.030; Cimmino A, 2005, P NATL ACAD SCI USA, V102, P13944, DOI 10.1073/pnas.0506654102; Corney DC, 2007, CANCER RES, V67, P8433, DOI 10.1158/0008-5472.CAN-07-1585; Corsten MF, 2007, CANCER RES, V67, P8994, DOI 10.1158/0008-5472.CAN-07-1045; Costinean S, 2006, P NATL ACAD SCI USA, V103, P7024, DOI 10.1073/pnas.0602266103; Coultas L, 2003, SEMIN CANCER BIOL, V13, P115, DOI 10.1016/S1044-579X(02)00129-3; Cretney E, 2003, J EXP MED, V198, P491, DOI 10.1084/jem.20030634; Cui QH, 2006, MOL SYST BIOL, V2, DOI 10.1038/msb4100089; Cullen BR, 2004, MOL CELL, V16, P861, DOI 10.1016/j.molcel.2004.12.002; Dews M, 2006, NAT GENET, V38, P1060, DOI 10.1038/ng1855; Eis PS, 2005, P NATL ACAD SCI USA, V102, P3627, DOI 10.1073/pnas.0500613102; Enders A, 2003, J EXP MED, V198, P1119, DOI 10.1084/jem.20030411; Engels BM, 2006, ONCOGENE, V25, P6163, DOI 10.1038/sj.onc.1209909; ERICKSON SL, 1994, NATURE, V372, P560, DOI 10.1038/372560a0; Esau C, 2006, CELL METAB, V3, P87, DOI 10.1016/j.cmet.2006.01.005; Esau C, 2004, J BIOL CHEM, V279, P52361, DOI 10.1074/jbc.C400438200; Esquela-Kerscher A, 2006, NAT REV CANCER, V6, P259, DOI 10.1038/nrc1840; Esquela-Kerscher A, 2008, CELL CYCLE, V7, P759, DOI 10.4161/cc.7.6.5834; Fabbri M, 2007, P NATL ACAD SCI USA, V104, P15805, DOI 10.1073/pnas.0707628104; Fazi F, 2005, CELL, V123, P819, DOI 10.1016/j.cell.2005.09.023; Felli N, 2005, P NATL ACAD SCI USA, V102, P18081, DOI 10.1073/pnas.0506216102; Fontana L, 2007, NAT CELL BIOL, V9, P775, DOI 10.1038/ncb1613; Frankel LB, 2008, J BIOL CHEM, V283, P1026, DOI 10.1074/jbc.M707224200; Fukao T, 2007, CELL, V129, P617, DOI 10.1016/j.cell.2007.02.048; Galardi S, 2007, J BIOL CHEM, V282, P23716, DOI 10.1074/jbc.M701805200; Garzon R, 2006, P NATL ACAD SCI USA, V103, P5078, DOI 10.1073/pnas.0600587103; GAUWERKY CE, 1989, P NATL ACAD SCI USA, V86, P8867, DOI 10.1073/pnas.86.22.8867; Georgantas RW, 2007, P NATL ACAD SCI USA, V104, P2750, DOI 10.1073/pnas.0610983104; Giannini G, 2000, BRIT J CANCER, V83, P1503, DOI 10.1054/bjoc.2000.1494; Gillies JK, 2007, CELL CYCLE, V6, P2005, DOI 10.4161/cc.6.16.4526; Gironella M, 2007, P NATL ACAD SCI USA, V104, P16170, DOI 10.1073/pnas.0703942104; Gottardo F, 2007, UROL ONCOL-SEMIN ORI, V25, P387, DOI 10.1016/j.urolonc.2007.01.019; Gramantieri L, 2007, CANCER RES, V67, P6092, DOI 10.1158/0008-5472.CAN-06-4607; Grandori C, 2000, ANNU REV CELL DEV BI, V16, P653, DOI 10.1146/annurev.cellbio.16.1.653; Gregory PA, 2008, NAT CELL BIOL, V10, P593, DOI 10.1038/ncb1722; Grimson A, 2007, MOL CELL, V27, P91, DOI 10.1016/j.molcel.2007.06.017; Guo YQ, 2006, GENE, V384, P51, DOI 10.1016/j.gene.2006.07.011; Harris TA, 2008, P NATL ACAD SCI USA, V105, P1516, DOI 10.1073/pnas.0707493105; Hayashita Y, 2005, CANCER RES, V65, P9628, DOI 10.1158/0008-5472.CAN-05-2352; He HL, 2005, P NATL ACAD SCI USA, V102, P19075, DOI 10.1073/pnas.0509603102; He L, 2005, NATURE, V435, P828, DOI 10.1038/nature03552; He L, 2007, NATURE, V447, P1130, DOI 10.1038/nature05939; Hebert C, 2007, MOL CANCER, V6, DOI 10.1186/1476-4598-6-5; Hornstein E, 2005, NATURE, V438, P671, DOI 10.1038/nature04138; Hossain A, 2006, MOL CELL BIOL, V26, P8191, DOI 10.1128/MCB.00242-06; Hughes PD, 2008, IMMUNITY, V28, P197, DOI 10.1016/j.immuni.2007.12.017; Hutcheson J, 2008, IMMUNITY, V28, P206, DOI 10.1016/j.immuni.2007.12.015; Iorio MV, 2005, CANCER RES, V65, P7065, DOI 10.1158/0008-5472.CAN-05-1783; Janz S, 2006, DNA REPAIR, V5, P1213, DOI 10.1016/j.dnarep.2006.05.017; Joglekar MV, 2007, DEV BIOL, V311, P603, DOI 10.1016/j.ydbio.2007.09.008; Johnson CD, 2007, CANCER RES, V67, P7713, DOI 10.1158/0008-5472.CAN-07-1083; Johnson SM, 2005, CELL, V120, P635, DOI 10.1016/j.cell.2005.01.014; Johnston RJ, 2003, NATURE, V426, P845, DOI 10.1038/nature02255; Karin M, 2006, CELL, V124, P823, DOI 10.1016/j.cell.2006.02.016; Kawasaki H, 2004, NATURE, V431, P211, DOI 10.1038/nature02889; Kim VN, 2005, NAT REV MOL CELL BIO, V6, P376, DOI 10.1038/nrm1644; Kishimoto H, 1998, J EXP MED, V187, P1427, DOI 10.1084/jem.187.9.1427; Kluiver J, 2006, GENE CHROMOSOME CANC, V45, P147, DOI 10.1002/gcc.20273; Kluiver J, 2005, J PATHOL, V207, P243, DOI 10.1002/path.1825; Kumar MS, 2008, P NATL ACAD SCI USA, V105, P3903, DOI 10.1073/pnas.0712321105; Kumar MS, 2007, NAT GENET, V39, P673, DOI 10.1038/ng2003; Kutay H, 2006, J CELL BIOCHEM, V99, P671, DOI 10.1002/jcb.20982; Lagos-Quintana M, 2001, SCIENCE, V294, P853, DOI 10.1126/science.1064921; Lai EC, 2002, NAT GENET, V30, P363, DOI 10.1038/ng865; Lamhamedi-Cherradi SE, 2003, NAT IMMUNOL, V4, P255, DOI 10.1038/ni894; Landais S, 2007, CANCER RES, V67, P5699, DOI 10.1158/0008-5472.CAN-06-4478; Lawrie CH, 2007, INT J CANCER, V121, P1156, DOI 10.1002/ijc.22800; le Sage C, 2007, EMBO J, V26, P3699, DOI 10.1038/sj.emboj.7601790; Lee EJ, 2007, INT J CANCER, V120, P1046, DOI 10.1002/ijc.22394; Lee HJ, 2006, P NATL ACAD SCI USA, V103, P15669, DOI 10.1073/pnas.0605781103; Lee KH, 2006, EMBO J, V25, P1009, DOI 10.1038/sj.emboj.7601016; LEE RC, 1993, CELL, V75, P843, DOI 10.1016/0092-8674(93)90529-Y; Lee YS, 2007, GENE DEV, V21, P1025, DOI 10.1101/gad.1540407; Lehmann U, 2008, J PATHOL, V214, P17, DOI 10.1002/path.2251; Lewis BP, 2003, CELL, V115, P787, DOI 10.1016/S0092-8674(03)01018-3; Lewis BP, 2005, CELL, V120, P15, DOI 10.1016/j.cell.2004.12.035; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Li QJ, 2007, CELL, V129, P147, DOI 10.1016/j.cell.2007.03.008; Linsley PS, 2007, MOL CELL BIOL, V27, P2240, DOI 10.1128/MCB.02005-06; Liu CG, 2004, P NATL ACAD SCI USA, V101, P9740, DOI 10.1073/pnas.0403293101; Loffler D, 2007, BLOOD, V110, P1330, DOI 10.1182/blood-2007-03-081133; Lu J, 2005, NATURE, V435, P834, DOI 10.1038/nature03702; Lu L, 2007, CANCER RES, V67, P10117, DOI 10.1158/0008-5472.CAN-07-2544; Lu Y, 2007, DEV BIOL, V310, P442, DOI 10.1016/j.ydbio.2007.08.007; Lui WO, 2007, CANCER RES, V67, P6031, DOI 10.1158/0008-5472.CAN-06-0561; Lukiw WJ, 2007, J INORG BIOCHEM, V101, P1265, DOI 10.1016/j.jinorgbio.2007.06.004; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Ma L, 2007, NATURE, V449, P682, DOI 10.1038/nature06174; Marton S, 2008, LEUKEMIA, V22, P330, DOI 10.1038/sj.leu.2405022; Masaki S, 2007, BIOCHEM BIOPH RES CO, V364, P509, DOI 10.1016/j.bbrc.2007.10.077; Matsubara H, 2007, ONCOGENE, V26, P6099, DOI 10.1038/sj.onc.1210425; Mayr C, 2007, SCIENCE, V315, P1576, DOI 10.1126/science.1137999; Meng FY, 2007, GASTROENTEROLOGY, V133, P647, DOI 10.1053/j.gastro.2007.05.022; Meng FY, 2007, J BIOL CHEM, V282, P8256, DOI 10.1074/jbc.M607712200; Metzler M, 2004, GENE CHROMOSOME CANC, V39, P167, DOI 10.1002/gcc.10316; Michael MZ, 2003, MOL CANCER RES, V1, P882; Miyazawa J, 2004, CANCER RES, V64, P2024, DOI 10.1158/0008-5472.CAN-03-1855; Mott JL, 2007, ONCOGENE, V26, P6133, DOI 10.1038/sj.onc.1210436; Naguibneva I, 2006, NAT CELL BIOL, V8, P278, DOI 10.1038/ncb1373; NEWMAN MA, 2008, RNA             0119; Nielsen CB, 2007, RNA, V13, P1894, DOI 10.1261/rna.768207; O'Connell RM, 2007, P NATL ACAD SCI USA, V104, P1604, DOI 10.1073/pnas.0610731104; O'Donnell KA, 2005, NATURE, V435, P839, DOI 10.1038/nature03677; O'Rourke JR, 2007, DEV BIOL, V311, P359, DOI 10.1016/j.ydbio.2007.08.032; Ota A, 2004, CANCER RES, V64, P3087, DOI 10.1158/0008-5472.CAN-03-3773; Page DM, 1998, J IMMUNOL, V160, P120; Park SM, 2008, GENE DEV, V22, P894, DOI 10.1101/gad.1640608; Park SM, 2007, CELL CYCLE, V6, P2585, DOI 10.4161/cc.6.21.4845; Pasquinelli AE, 2000, NATURE, V408, P86, DOI 10.1038/35040556; Pekarsky Y, 2006, CANCER RES, V66, P11590, DOI 10.1158/0008-5472.CAN-06-3613; Peter ME, 2003, CELL DEATH DIFFER, V10, P26, DOI 10.1038/sj.cdd.4401186; PFEFFER K, 1993, CELL, V73, P457, DOI 10.1016/0092-8674(93)90134-C; Plaisance V, 2006, J BIOL CHEM, V281, P26932, DOI 10.1074/jbc.M601225200; Postigo AA, 1999, MOL CELL BIOL, V19, P7961; Ramkissoon SH, 2006, LEUKEMIA RES, V30, P643, DOI 10.1016/j.leukres.2005.09.001; Raver-Shapira N, 2007, MOL CELL, V26, P731, DOI 10.1016/j.molcel.2007.05.017; Reinhart BJ, 2000, NATURE, V403, P901, DOI 10.1038/35002607; Ricci MS, 2007, CANCER CELL, V12, P66, DOI 10.1016/j.ccr.2007.05.006; Rodriguez A, 2007, SCIENCE, V316, P608, DOI 10.1126/science.1139253; Roldo C, 2006, J CLIN ONCOL, V24, P4677, DOI 10.1200/JCO.2005.05.5194; Ross DT, 2000, NAT GENET, V24, P227, DOI 10.1038/73432; Salvesen GS, 2002, NAT REV MOL CELL BIO, V3, P401, DOI 10.1038/nrm830; Sampson VB, 2007, CANCER RES, V67, P9762, DOI 10.1158/0008-5472.CAN-07-2462; Sarhadi V, 2006, J PATHOL, V209, P206, DOI 10.1002/path.1960; Sathyan P, 2007, J NEUROSCI, V27, P8546, DOI 10.1523/JNEUROSCI.1269-07.2007; Scaffidi C, 1999, J BIOL CHEM, V274, P1541, DOI 10.1074/jbc.274.3.1541; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; Schmitz I, 2003, J IMMUNOL, V171, P2930, DOI 10.4049/jimmunol.171.6.2930; Schulman BRM, 2005, DEV DYNAM, V234, P1046, DOI 10.1002/dvdy.20599; Schulze-Osthoff K, 1998, EUR J BIOCHEM, V254, P439, DOI 10.1046/j.1432-1327.1998.2540439.x; Sedger LM, 2002, EUR J IMMUNOL, V32, P2246, DOI 10.1002/1521-4141(200208)32:8<2246::AID-IMMU2246>3.0.CO;2-6; Sethupathy P, 2007, AM J HUM GENET, V81, P405, DOI 10.1086/519979; Sevinsky JR, 2004, MOL CELL BIOL, V24, P4534, DOI 10.1128/MCB.24.10.4534-4545.2004; Shell S, 2007, P NATL ACAD SCI USA, V104, P11400, DOI 10.1073/pnas.0704372104; Si ML, 2007, ONCOGENE, V26, P2799, DOI 10.1038/sj.onc.1210083; SINGER GG, 1994, IMMUNITY, V1, P365, DOI 10.1016/1074-7613(94)90067-1; Strasser A, 2008, IMMUNOL CELL BIOL, V86, P57, DOI 10.1038/sj.icb.7100141; Sylvestre Y, 2007, J BIOL CHEM, V282, P2135, DOI 10.1074/jbc.M608939200; Szafranska AE, 2007, ONCOGENE, V26, P4442, DOI 10.1038/sj.onc.1210228; Taganov KD, 2006, P NATL ACAD SCI USA, V103, P12481, DOI 10.1073/pnas.0605298103; Takamizawa J, 2004, CANCER RES, V64, P3753, DOI 10.1158/0008-5472.CAN-04-0637; Tarasov V, 2007, CELL CYCLE, V6, P1586, DOI 10.4161/cc.6.13.4436; Tavazoie SF, 2008, NATURE, V451, P147, DOI 10.1038/nature06487; Tazawa H, 2007, P NATL ACAD SCI USA, V104, P15472, DOI 10.1073/pnas.0707351104; Thai TH, 2007, SCIENCE, V316, P604, DOI 10.1126/science.1141229; Tili E, 2007, J IMMUNOL, V179, P5082, DOI 10.4049/jimmunol.179.8.5082; van Rooij E, 2006, P NATL ACAD SCI USA, V103, P18255, DOI 10.1073/pnas.0608791103; Venturini L, 2007, BLOOD, V109, P4399, DOI 10.1182/blood-2006-09-045104; VERSTEEG R, 1995, EUR J CANCER, V31A, P538, DOI 10.1016/0959-8049(95)00037-J; Viswanathan SR, 2008, SCIENCE, V320, P97, DOI 10.1126/science.1154040; Volinia S, 2006, P NATL ACAD SCI USA, V103, P2257, DOI 10.1073/pnas.0510565103; Voorhoeve PM, 2007, ADV EXP MED BIOL, V604, P17, DOI 10.1007/978-0-387-69116-9_2; Voorhoeve PM, 2006, CELL, V124, P1169, DOI 10.1016/j.cell.2006.02.037; Waterhouse NJ, 2005, J BIOL CHEM, V280, P4476, DOI 10.1074/jbc.M410985200; Weant AE, 2008, IMMUNITY, V28, P218, DOI 10.1016/j.immuni.2007.12.014; Welch C, 2007, ONCOGENE, V26, P5017, DOI 10.1038/sj.onc.1210293; WIGHTMAN B, 1993, CELL, V75, P855, DOI 10.1016/0092-8674(93)90530-4; Xiao CC, 2007, CELL, V131, P146, DOI 10.1016/j.cell.2007.07.021; Xu CQ, 2007, J CELL SCI, V120, P3045, DOI 10.1242/jcs.010728; Xu PZ, 2003, CURR BIOL, V13, P790, DOI 10.1016/S0960-9822(03)00250-1; Yanaihara N, 2006, CANCER CELL, V9, P189, DOI 10.1016/j.ccr.2006.01.025; Yang BF, 2007, NAT MED, V13, P486, DOI 10.1038/nm1569; Yang J, 2004, CELL, V117, P927, DOI 10.1016/j.cell.2004.06.006; Yasui DH, 1998, J IMMUNOL, V160, P4433; Yekta S, 2004, SCIENCE, V304, P594, DOI 10.1126/science.1097434; Yu JY, 2007, SCIENCE, V318, P1917, DOI 10.1126/science.1151526; Zanette DL, 2007, BRAZ J MED BIOL RES, V40, P1435, DOI 10.1590/S0100-879X2007001100003; Zeng Y, 2006, ONCOGENE, V25, P6156, DOI 10.1038/sj.onc.1209908; Zeng Yan, 2006, V342, P49, DOI 10.1385/1-59745-123-1:49; Zhang L, 2006, P NATL ACAD SCI USA, V103, P9136, DOI 10.1073/pnas.0508889103; Zhou BY, 2007, P NATL ACAD SCI USA, V104, P7080, DOI 10.1073/pnas.0702409104; Zhu SM, 2007, J BIOL CHEM, V282, P14328, DOI 10.1074/jbc.M611393200	208	608	645	1	75	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 6	2008	27	45					5959	5974		10.1038/onc.2008.274	http://dx.doi.org/10.1038/onc.2008.274			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	355QE	18836476				2022-12-28	WOS:000259722600010
J	Bhaumik, D; Scott, GK; Schokrpur, S; Patil, CK; Campisi, J; Benz, CC				Bhaumik, D.; Scott, G. K.; Schokrpur, S.; Patil, C. K.; Campisi, J.; Benz, C. C.			Expression of microRNA-146 suppresses NF-kappa B activity with reduction of metastatic potential in breast cancer cells	ONCOGENE			English	Article						NF-kappa B; miRNA-146; metastatic breast cancer	RECEPTOR; INTERLEUKIN-1; SECRETION; ACTIVATION; SURVIVAL; INVASION; IMMUNITY; PATHWAY; PLAYERS	Cancer cells often acquire a constitutively active nuclear factor-kappa B (NF-kappa B) program to promote survival, proliferation and metastatic potential by mechanisms that remain largely unknown. Extending observations from an immunologic setting, we demonstrate that microRNA-146a and microRNA-146b (miR-146a/b) when expressed in the highly metastatic human breast cancer cell line MDA-MB-231 function to negatively regulate NF-kappa B activity. Lentiviral-mediated expression of miR-146a/b significantly downregulated interleukin (IL)-1 receptor-associated kinase and TNF receptor-associated factor 6, two key adaptor/scaffold proteins in the IL-1 and Toll-like receptor signaling pathway, known to positively regulate NF-kappa B activity. Impaired NF-kappa B activity was evident from reduced phosphorylation of the NF-kappa B inhibitor I kappa B alpha, reduced NF-kappa B DNA-binding activity and suppressed expression of the NF-kappa B target genes IL-8, IL-6 and matrix metalloproteinase-9. Functionally, miR-146a/b-expressing MDA-MB-231 cells showed markedly impaired invasion and migration capacity relative to control cells. These findings implicate miR-146a/b as a negative regulator of constitutive NF-kappa B activity in a breast cancer setting and suggest that modulating miR-146a/b levels has therapeutic potential to suppress breast cancer metastases.	[Bhaumik, D.; Scott, G. K.; Schokrpur, S.; Campisi, J.; Benz, C. C.] Buck Inst Age Res, Novato, CA 94945 USA; [Patil, C. K.; Campisi, J.] Univ Calif Berkeley, Lawrence Berkeley Lab, Berkeley, CA 94720 USA	Buck Institute for Research on Aging; United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley	Scott, GK (corresponding author), Buck Inst Age Res, 8001 Redwood Blvd, Novato, CA 94945 USA.	gscott@buckinstitute.org		Schokrpur, Shiruyeh/0000-0001-9441-9547	NIH [R01CA36773, P01-AG025901, P50-CA58207, R37-AG09909]; NATIONAL CANCER INSTITUTE [P50CA058207, R01CA036773] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P01AG025901, R37AG009909] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	This work was supported in part by NIH grants R01CA36773, P01-AG025901, P50-CA58207 and R37-AG09909 as well as Hazel P Munroe memorial funding to the Buck Institute.	Akira S, 2004, NAT REV IMMUNOL, V4, P499, DOI 10.1038/nri1391; Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5; Benoy IH, 2004, CLIN CANCER RES, V10, P7157, DOI 10.1158/1078-0432.CCR-04-0812; Bonizzi G, 2004, EMBO J, V23, P4202, DOI 10.1038/sj.emboj.7600391; Cao ZD, 1996, NATURE, V383, P443, DOI 10.1038/383443a0; Cao ZD, 1996, SCIENCE, V271, P1128, DOI 10.1126/science.271.5252.1128; Cicek M, 2005, CANCER RES, V65, P3586, DOI 10.1158/0008-5472.CAN-04-3139; Coppe JP, 2006, J BIOL CHEM, V281, P29568, DOI 10.1074/jbc.M603307200; Hayden MS, 2004, GENE DEV, V18, P2195, DOI 10.1101/gad.1228704; Hoffmann A, 2006, IMMUNOL REV, V210, P171, DOI 10.1111/j.0105-2896.2006.00375.x; Karin M, 2006, NATURE, V441, P431, DOI 10.1038/nature04870; Karres JS, 2007, CELL, V131, P136, DOI 10.1016/j.cell.2007.09.020; Lin SL, 2008, RNA, V14, P417, DOI 10.1261/rna.874808; Ma L, 2007, NATURE, V449, P682, DOI 10.1038/nature06174; Merrell MA, 2006, MOL CANCER RES, V4, P437, DOI 10.1158/1541-7786.MCR-06-0007; Monks NR, 2006, J CELL BIOCHEM, V98, P221, DOI 10.1002/jcb.20789; Scott GK, 2007, J BIOL CHEM, V282, P1479, DOI 10.1074/jbc.M609383200; Sethi G, 2008, EXP BIOL MED, V233, P21, DOI 10.3181/0707-MR-196; Singer CF, 2003, CLIN CANCER RES, V9, P4877; Sliva D, 2002, J BIOL CHEM, V277, P3150, DOI 10.1074/jbc.M109579200; Sonkoly E, 2008, SEMIN CANCER BIOL, V18, P131, DOI 10.1016/j.semcancer.2008.01.005; Taganov KD, 2007, IMMUNITY, V26, P133, DOI 10.1016/j.immuni.2007.02.005; Taganov KD, 2006, P NATL ACAD SCI USA, V103, P12481, DOI 10.1073/pnas.0605298103; Van Waes C, 2007, CLIN CANCER RES, V13, P1076, DOI 10.1158/1078-0432.CCR-06-2221; Zheng Y, 2006, J BIOL CHEM, V281, P15862, DOI 10.1074/jbc.M600660200; Zhou Y, 2005, ENDOCR-RELAT CANCER, V12, pS37, DOI 10.1677/erc.1.00977	26	487	541	0	39	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 18	2008	27	42					5643	5647		10.1038/onc.2008.171	http://dx.doi.org/10.1038/onc.2008.171			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	349KX	18504431	Green Accepted			2022-12-28	WOS:000259280800010
J	Adachi, Y; Shibai, Y; Mitsushita, J; Shang, WH; Hirose, K; Kamata, T				Adachi, Y.; Shibai, Y.; Mitsushita, J.; Shang, W. H.; Hirose, K.; Kamata, T.			Oncogenic Ras upregulates NADPH oxidase 1 gene expression through MEK-ERK-dependent phosphorylation of GATA-6	ONCOGENE			English	Article						Ras; Nox1; ROS; GATA-6; gene expression	COLON EPITHELIAL-CELLS; NADPH OXIDASE; TRANSCRIPTION FACTORS; NAD(P)H OXIDASE; REACTIVE OXYGEN; MUSCLE-CELLS; BINDING; SUPEROXIDE; PROTEIN; NOX1	Ras oncogene upregulates the expression of nicotinamide adenine dinucleotide phosphate oxidase (Nox) 1 via the Raf/MEK/ERK pathway, leading to the elevated production of reactive oxygen species that is essential for maintenance of Ras-transformation phenotypes. However, the precise transcriptional control mechanism underlying Ras-induced Nox1 expression remains to be elucidated. Here we demonstrated that via the MEK/ERK pathway, Ras signaling enhances the activity of the functional Nox1 promoter (nt -321 to -1) in colon cancer CaCo-2 cells and thereby induces the formation of the specific protein DNA complexes in the two GATA-binding site-containing regions (nt -161 to -136 and -125 to -100). Supershift assays with GATA antibodies, protein analyses and chromatin immunoprecipitation revealed that GATA-6 is a component of the specific protein - DNA complexes at the Nox1 promoter. GATA-6 was able to trans-activate the Nox1 promoter but not a promoter in which the GATA-binding sites are mutated. Moreover, GATA-6 was phosphorylated at serine residues by MEK-activated ERK, which increased GATA-6 DNA binding, correlating with suppression of the Nox1 promoter activity by an MEK inhibitor PD98059. Finally, the site-directed mutation of the consensus ERK phosphorylation site (PYS(120)P to PYA(120)P) of GATA-6 abolished its trans-activation activity, suppressing of the growth of CaCo-2 cells. On the basis of these results, we propose that oncogenic Ras signaling upregulates the transcription of Nox1 through MEK-ERK-dependent phosphorylation of GATA-6.	[Adachi, Y.; Shibai, Y.; Mitsushita, J.; Shang, W. H.; Kamata, T.] Shinshu Univ, Sch Med, Dept Mol Biol & Biochem, Nagano 3908621, Japan; [Hirose, K.] Kureha Chem Ind Co Ltd, Biomed Res Inst, Tokyo, Japan	Shinshu University	Kamata, T (corresponding author), Shinshu Univ, Sch Med, Dept Mol Biol & Biochem, 3-1-1 Asahi, Nagano 3908621, Japan.	kamatat@sch.md.shinshu-u.ac.jp	Mitsushita, Junji/D-7688-2016	Mitsushita, Junji/0000-0001-9402-4318	Ministry of Education, Culture, Sports, Science and Technology of Japan	Ministry of Education, Culture, Sports, Science and Technology of Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT))	We thank Dr J Downward, Dr E Nishida and Dr M Maeda for plasmid DNAs. This study was supported by Grant-in-Aid for Scientific Research on Priority Areas from the Ministry of Education, Culture, Sports, Science and Technology of Japan (TK).	ADACHI Y, 1994, J BIOL CHEM, V269, P2258; Akiyama Y, 2003, MOL CELL BIOL, V23, P8429, DOI 10.1128/MCB.23.23.8429-8439.2003; Arbiser JL, 2002, P NATL ACAD SCI USA, V99, P715, DOI 10.1073/pnas.022630199; Banfi B, 2001, J BIOL CHEM, V276, P37594, DOI 10.1074/jbc.M103034200; BOKOCH GM, 1994, CURR OPIN CELL BIOL, V6, P212, DOI 10.1016/0955-0674(94)90138-4; Brewer AC, 2006, FREE RADICAL BIO MED, V40, P260, DOI 10.1016/j.freeradbiomed.2005.08.022; Cheng GJ, 2001, GENE, V269, P131, DOI 10.1016/S0378-1119(01)00449-8; Chu D, 2001, J BIOL CHEM, V276, P14004, DOI 10.1074/jbc.M010262200; Debruyne PR, 2003, ONCOGENE, V22, P7199, DOI 10.1038/sj.onc.1206628; Eklund EA, 1998, J BIOL CHEM, V273, P13957, DOI 10.1074/jbc.273.22.13957; Fang RX, 2001, AM J PHYSIOL-GASTR L, V280, pG58, DOI 10.1152/ajpgi.2001.280.1.G58; Fensterer H, 2004, GENE CHROMOSOME CANC, V39, P224, DOI 10.1002/gcc.20000; Fu XY, 2006, J BIOL CHEM, V281, P20368, DOI 10.1074/jbc.M603353200; Gao XP, 1998, MOL CELL BIOL, V18, P2901, DOI 10.1128/MCB.18.5.2901; Geiszt M, 2003, J IMMUNOL, V171, P299, DOI 10.4049/jimmunol.171.1.299; Geiszt M, 2000, P NATL ACAD SCI USA, V97, P8010, DOI 10.1073/pnas.130135897; Hernandez-Hernandez A, 2006, EMBO J, V25, P3264, DOI 10.1038/sj.emboj.7601228; Kawahara T, 2004, J IMMUNOL, V172, P3051, DOI 10.4049/jimmunol.172.5.3051; Kitta K, 2003, J BIOL CHEM, V278, P4705, DOI 10.1074/jbc.M211616200; Lambeth JD, 2000, TRENDS BIOCHEM SCI, V25, P459, DOI 10.1016/S0968-0004(00)01658-3; Lambeth JD, 2004, NAT REV IMMUNOL, V4, P181, DOI 10.1038/nri1312; Lassegue B, 2001, CIRC RES, V88, P888, DOI 10.1161/hh0901.090299; Luo W, 1996, J BIOL CHEM, V271, P23445, DOI 10.1074/jbc.271.38.23445; Mahadev K, 2004, MOL CELL BIOL, V24, P1844, DOI 10.1128/MCB.24.5.1844-1854.2004; Mitsushita J, 2004, CANCER RES, V64, P3580, DOI 10.1158/0008-5472.CAN-03-3909; Molkentin JD, 2000, J BIOL CHEM, V275, P38949, DOI 10.1074/jbc.R000029200; Morimoto T, 2000, J BIOL CHEM, V275, P13721, DOI 10.1074/jbc.275.18.13721; Nelson JD, 2006, NAT PROTOC, V1, P179, DOI 10.1038/nprot.2006.27; NEWBURGER PE, 1988, P NATL ACAD SCI USA, V85, P5215, DOI 10.1073/pnas.85.14.5215; Paffenholz R, 2004, GENE DEV, V18, P486, DOI 10.1101/gad.1172504; Patient RK, 2002, CURR OPIN GENET DEV, V12, P416, DOI 10.1016/S0959-437X(02)00319-2; Suh YA, 1999, NATURE, V401, P79, DOI 10.1038/43459; Suzuki E, 1996, GENOMICS, V38, P283, DOI 10.1006/geno.1996.0630; Tenhunen O, 2004, J BIOL CHEM, V279, P24852, DOI 10.1074/jbc.M314317200; Yu YL, 2005, J BIOL CHEM, V280, P29533, DOI 10.1074/jbc.M506514200	35	92	97	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 21	2008	27	36					4921	4932		10.1038/onc.2008.133	http://dx.doi.org/10.1038/onc.2008.133			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	339SF	18454176				2022-12-28	WOS:000258596900006
J	Zhang, Y; Wang, Z; Li, X; Magnuson, NS				Zhang, Y.; Wang, Z.; Li, X.; Magnuson, N. S.			Pim kinase-dependent inhibition of c-Myc degradation	ONCOGENE			English	Article						c-Myc; phosphorylation; Pim-1/Pim-2; stabilization	TRANSGENIC MICE; TRANSCRIPTIONAL ACTIVATION; LYMPHOID TUMORS; N-MYC; PROTOONCOGENE; PHOSPHORYLATION; LYMPHOMAGENESIS; CANCER; IDENTIFICATION; GROWTH	Pim kinases are found to be highly expressed in leukemia, lymphoma, prostate and pancreatic cancer. Bitransgenic mice overexpressing either Pim-1 or Pim-2 and c-Myc succumb to pre-B-cell lymphoma at a strikingly accelerated speed. Despite that Pim-1/Pim-2 has long been recognized as a strong synergistic partner with c-Myc in tumorigenesis, the mechanism underlying the synergism is still not well understood. Overexpression of Pim-1/Pim-2 kinase dramatically stabilizes c-Myc in vivo, and the stabilization is partially mediated by phosphorylation of c-Myc by Pim kinase on a novel site, Ser329. We provide evidence that Pim-2 is more efficient in directly phosphorylating c-Myc Ser329 to stabilize c-Myc. In contrast, we find that Pim-1 is more effective in mediating a decrease in c-Myc Thr58 phosphorylation and an increase in c-Myc Ser62 phosphorylation than in phosphorylating Ser329. In either case, through stabilizing c-Myc, Pim-1/Pim-2 kinases enhance the transcriptional activity of c-Myc. Also knocking down either Pim-1 or Pim-2 dramatically decreases the endogenous levels of c-Myc and thus, its transcriptional activity. Finally, coexpression of the Pim kinases and c-Myc enhances the transforming activity of c-Myc as does the phosphomimic mutant of c-Myc on Ser329. We conclude that these findings appear to explain at least in part the mechanism underlying the synergism between the Pim kinases and c-Myc in tumorigenesis.	[Zhang, Y.; Wang, Z.; Magnuson, N. S.] Washington State Univ, Sch Mol Biosci, Pullman, WA 99163 USA; [Li, X.] Univ Idaho, Dept Microbiol Mol Biol & Biochem, Moscow, ID 83843 USA	Washington State University; Idaho; University of Idaho	Magnuson, NS (corresponding author), Washington State Univ, Sch Mol Biosci, Pullman, WA 99163 USA.	magnuson@wsu.edu	Zhang, Yandong/AAE-2231-2019	Zhang, Yandong/0000-0002-1900-7224	NATIONAL CANCER INSTITUTE [R01CA104470] Funding Source: NIH RePORTER; NCI NIH HHS [R01-CA104470] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Allen JD, 1997, ONCOGENE, V15, P1133, DOI 10.1038/sj.onc.1201288; Amati Bruno, 1998, Frontiers in Bioscience, V3, pD250; AMSON R, 1989, P NATL ACAD SCI USA, V86, P8857, DOI 10.1073/pnas.86.22.8857; BREUER M, 1991, CANCER RES, V51, P958; Bubman D, 2007, ONCOGENE, V26, P4979, DOI 10.1038/sj.onc.1210299; Chen WW, 2005, MOL CANCER RES, V3, P443, DOI 10.1158/1541-7786.MCR-05-0007; Cowling VH, 2006, SEMIN CANCER BIOL, V16, P242, DOI 10.1016/j.semcancer.2006.08.001; CUYPERS HT, 1984, CELL, V37, P141; Dang CV, 2005, CANCER CELL, V8, P177, DOI 10.1016/j.ccr.2005.08.005; DEBOTH NJ, 1989, LEUKEMIA RES, V13, P53, DOI 10.1016/0145-2126(89)90031-3; Dhanasekaran SM, 2001, NATURE, V412, P822, DOI 10.1038/35090585; Ellwood-Yen K, 2003, CANCER CELL, V4, P223, DOI 10.1016/S1535-6108(03)00197-1; FRIEDMANN M, 1992, ARCH BIOCHEM BIOPHYS, V298, P594, DOI 10.1016/0003-9861(92)90454-5; HOOVER D, 1991, J BIOL CHEM, V266, P14018; Hurlin PJ, 2006, SEMIN CANCER BIOL, V16, P265, DOI 10.1016/j.semcancer.2006.07.009; Li YY, 2006, CANCER RES, V66, P6741, DOI 10.1158/0008-5472.CAN-05-4272; Liu JY, 2007, J VIROL, V81, P10451, DOI 10.1128/JVI.00804-07; Macdonald A, 2006, BMC CELL BIOL, V7, DOI 10.1186/1471-2121-7-1; Malempati S, 2006, LEUKEMIA, V20, P1572, DOI 10.1038/sj.leu.2404317; Mikkers H, 2004, MOL CELL BIOL, V24, P6104, DOI 10.1128/MCB.24.13.6104-6115.2004; MOROY T, 1991, ONCOGENE, V6, P1941; Pelengaris S, 2002, NAT REV CANCER, V2, P764, DOI 10.1038/nrc904; Peng C, 2007, J BIOCHEM, V141, P353, DOI 10.1093/jb/mvm040; Sears R, 2000, GENE DEV, V14, P2501, DOI 10.1101/gad.836800; SELTEN G, 1985, EMBO J, V4, P1793, DOI 10.1002/j.1460-2075.1985.tb03852.x; VANDERLUGT NMT, 1995, EMBO J, V14, P2536, DOI 10.1002/j.1460-2075.1995.tb07251.x; VANLOHUIZEN M, 1989, CELL, V56, P673, DOI 10.1016/0092-8674(89)90589-8; VANLOHUIZEN M, 1991, CELL, V65, P737, DOI 10.1016/0092-8674(91)90382-9; Vita M, 2006, SEMIN CANCER BIOL, V16, P318, DOI 10.1016/j.semcancer.2006.07.015; Wanzel M, 2003, TRENDS CELL BIOL, V13, P146, DOI 10.1016/S0962-8924(03)00003-5; Yeh E, 2004, NAT CELL BIOL, V6, P308, DOI 10.1038/ncb1110; Zhang YD, 2007, MOL CANCER RES, V5, P909, DOI 10.1158/1541-7786.MCR-06-0388; Zippo A, 2007, NAT CELL BIOL, V9, P932, DOI 10.1038/ncb1618	33	165	174	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 14	2008	27	35					4809	4819		10.1038/onc.2008.123	http://dx.doi.org/10.1038/onc.2008.123			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	337OJ	18438430				2022-12-28	WOS:000258445100006
J	Olmeda, D; Montes, A; Moreno-Bueno, G; Flores, JM; Portillo, F; Cano, A				Olmeda, D.; Montes, A.; Moreno-Bueno, G.; Flores, J. M.; Portillo, F.; Cano, A.			Snai1 and Snai2 collaborate on tumor growth and metastasis properties of mouse skin carcinoma cell lines	ONCOGENE			English	Article						Snai1; Snai2; E-cadherin; EMT; invasion; metastasis	EPITHELIAL-MESENCHYMAL TRANSITIONS; TRANSCRIPTION FACTOR SNAIL; CADHERIN GENE-EXPRESSION; REPRESSES E-CADHERIN; ADHESION MOLECULE; FACTOR SLUG; PROGRESSION; SUPERFAMILY; PATHWAY; OVARIAN	Snai1 (Snail) and Snai2 (Slug), the two main members of Snail family factors, are important mediators of epithelial-mesenchymal transitions and involved in tumor progression. We recently reported that Snai1 plays a major role in tumor growth, invasion and metastasis, but the contribution of Snai2 to tumorigenesis is not yet well understood. To approach this question we have silenced Snai2 and/or Snai1 by stable RNA interference in two independent mouse skin carcinoma (HaCa4 and CarB) cell lines. We demonstrate that Snai2 knockdown has a milder effect, but collaborates with Snai1 silencing in reduction of tumor growth potential of either carcinoma cell line when injected into nude mice. Importantly, Snai1 or Snai2 silencing dramatically influences the metastatic ability of squamous carcinoma HaCa4 cells, inducing a strong reduction in liver and lung distant metastasis. However, only Snai1 knockdown has an effective action on invasiveness and fully abolishes tumor cell dissemination into the spleen. These results demonstrate that Snai1 and Snai2 collaborate on primary tumor growth and specifically contribute to site-specific metastasis of HaCa4 cells. These data also indicate that Snai1 is the major regulator of local invasion, supporting a hierarchical participation of both factors in the metastatic process.	[Olmeda, D.; Montes, A.; Moreno-Bueno, G.; Portillo, F.; Cano, A.] UAM, Inst Invest Biomed Alberto Sols, CSIC, Dept Biochem, Madrid 28029, Spain; [Flores, J. M.] Univ Complutense Madrid, Fac Vet, Dept Cirugia & Med Anim, Madrid, Spain	Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Investigaciones Biomedicas Alberto Sols (IIBM); Complutense University of Madrid	Cano, A (corresponding author), UAM, Inst Invest Biomed Alberto Sols, CSIC, Dept Biochem, C Arturo Duperier 4, Madrid 28029, Spain.	acano@iib.uam.es	Moreno-Bueno, Gema/K-9354-2016; Olmeda, David/L-4270-2017	Moreno-Bueno, Gema/0000-0002-5030-6687; Olmeda, David/0000-0001-5513-5621; Portillo Perez, Francisco/0000-0003-4922-346X				Barrallo-Gimeno A, 2005, DEVELOPMENT, V132, P3151, DOI 10.1242/dev.01907; Batlle E, 2000, NAT CELL BIOL, V2, P84, DOI 10.1038/35000034; BIRCHMEIER W, 1994, BBA-REV CANCER, V1198, P11, DOI 10.1016/0304-419X(94)90003-5; Bolos V, 2003, J CELL SCI, V116, P499, DOI 10.1242/jcs.00224; Cano A, 2000, NAT CELL BIOL, V2, P76, DOI 10.1038/35000025; Carver EA, 2001, MOL CELL BIOL, V21, P8184, DOI 10.1128/MCB.21.23.8184-8188.2001; Christofori G, 1999, TRENDS BIOCHEM SCI, V24, P73, DOI 10.1016/S0968-0004(98)01343-7; Christofori G, 2006, NATURE, V441, P444, DOI 10.1038/nature04872; Come C, 2006, CLIN CANCER RES, V12, P5395, DOI 10.1158/1078-0432.CCR-06-0478; Elloul S, 2005, CANCER-AM CANCER SOC, V103, P1631, DOI 10.1002/cncr.20946; Elloul S, 2006, VIRCHOWS ARCH, V449, P520, DOI 10.1007/s00428-006-0274-6; Fraga MF, 2004, CANCER RES, V64, P5527, DOI 10.1158/0008-5472.CAN-03-4061; Guaita S, 2002, J BIOL CHEM, V277, P39209, DOI 10.1074/jbc.M206400200; Gupta GP, 2006, CELL, V127, P679, DOI 10.1016/j.cell.2006.11.001; Hajra KM, 2002, CANCER RES, V62, P1613; Inoue A, 2002, CANCER CELL, V2, P279, DOI 10.1016/S1535-6108(02)00155-1; Jiang RL, 1998, DEV BIOL, V198, P277, DOI 10.1016/S0012-1606(98)80005-5; Jorda M, 2005, J CELL SCI, V118, P3371, DOI 10.1242/jcs.02465; Jorda M, 2007, EXP CELL RES, V313, P2389, DOI 10.1016/j.yexcr.2007.04.001; Kajita M, 2004, MOL CELL BIOL, V24, P7559, DOI 10.1128/MCB.24.17.7559-7566.2004; Llorens A, 1998, LAB INVEST, V78, P1131; Manzanares M, 2001, TRENDS GENET, V17, P178, DOI 10.1016/S0168-9525(01)02232-6; Mehlen P, 2006, NAT REV CANCER, V6, P449, DOI 10.1038/nrc1886; Moreno-Bueno G, 2003, ONCOGENE, V22, P6115, DOI 10.1038/sj.onc.1206868; NAVARRO P, 1991, J CELL BIOL, V115, P517, DOI 10.1083/jcb.115.2.517; Nieto MA, 2002, NAT REV MOL CELL BIO, V3, P155, DOI 10.1038/nrm757; Olmeda D, 2007, ONCOGENE, V26, P1862, DOI 10.1038/sj.onc.1209997; Olmeda D, 2007, CANCER RES, V67, P11721, DOI 10.1158/0008-5472.CAN-07-2318; Peinado H, 2005, EMBO J, V24, P3446, DOI 10.1038/sj.emboj.7600781; Peinado H, 2007, NAT REV CANCER, V7, P415, DOI 10.1038/nrc2131; Perez-Losada J, 2003, ONCOGENE, V22, P4205, DOI 10.1038/sj.onc.1206467; Rodrigo I, 1999, EXP CELL RES, V248, P358, DOI 10.1006/excr.1999.4438; Savagner P, 2005, J CELL PHYSIOL, V202, P858, DOI 10.1002/jcp.20188; Thiery JP, 2002, NAT REV CANCER, V2, P442, DOI 10.1038/nrc822	34	90	96	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG	2008	27	34					4690	4701		10.1038/onc.2008.118	http://dx.doi.org/10.1038/onc.2008.118			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	334QM	18408755				2022-12-28	WOS:000258236300007
J	Chen, Z; Feng, J; Saldivar, JS; Gu, D; Bockholt, A; Sommer, SS				Chen, Z.; Feng, J.; Saldivar, J-S; Gu, D.; Bockholt, A.; Sommer, S. S.			EGFR somatic doublets in lung cancer are frequent and generally arise from a pair of driver mutations uncommonly seen as singlet mutations: one-third of doublets occur at five pairs of amino acids	ONCOGENE			English	Article						EGFR; lung cancer; doublet; somatic mutation	GROWTH-FACTOR RECEPTOR; DRUG-RESISTANCE MUTATION; MULTIPLE MUTATIONS; GENE-MUTATIONS; GEFITINIB; AMPLIFICATION; SENSITIVITY; PATTERNS; MUTANTS; SUSCEPTIBILITY	Doublet mutations in cancer are not well studied. We find that allelic somatic doublet mutations are present at high frequency in the epidermal growth factor receptor (EGFR) tyrosine kinase (TK) domain in lung cancers. When doublets from the literature are added, a total of 96 doublets are available for analysis. The frequency of doublets overall is 6%, which is sevenfold greater than that observed in normal tissue in mouse. All characterized doublets are allelic, and silent mutations occur rarely. About half of all doublets contain one or two of 12 distinct missense mutations at five amino acids: E709, G719, S768, T790 and L861. The mutations at these five amino acids are seldom reported as singlets. Moreover, when the common L858 target is included, more than one-third of EGFR doublets are one of five specific missense pairs: G719/E709, G719/S768, G719/L861, L858/E709 and L858/T790. Structure suggests function: The data imply that most EGFR doublets are NOT consistent with a 'driver and passenger' mutation mechanism. EGFR doublets are highly skewed relative to singlets, consistent with functional selection of two individually suboptimal mutations that, in combination, have enhanced oncogenic potential.	[Chen, Z.; Feng, J.; Saldivar, J-S; Gu, D.; Bockholt, A.; Sommer, S. S.] City Hope Natl Med Ctr, Dept Mol Genet, Duarte, CA 91010 USA	City of Hope	Sommer, SS (corresponding author), City Hope Natl Med Ctr, Dept Mol Genet, 1500 E Duarte Rd, Duarte, CA 91010 USA.	sommerlab@coh.org			NIA NIH HHS [R01-AG19784-02] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [R01AG019784] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Arteaga CL, 2002, SEMIN ONCOL, V29, P3, DOI 10.1053/sonc.2002.35642; Bell DW, 2005, NAT GENET, V37, P1315, DOI 10.1038/ng1671; Buettner VL, 2000, MUTAT RES-FUND MOL M, V452, P219, DOI 10.1016/S0027-5107(00)00090-7; Buettner VL, 1999, ENVIRON MOL MUTAGEN, V33, P320, DOI 10.1002/(SICI)1098-2280(1999)33:4<320::AID-EM9>3.0.CO;2-S; Chen YR, 2006, ONCOGENE, V25, P1205, DOI 10.1038/sj.onc.1209159; Davies H, 2005, CANCER RES, V65, P7591, DOI 10.1158/0008-5472.CAN-05-1855; Godin-Heymann N, 2007, CANCER RES, V67, P7319, DOI 10.1158/0008-5472.CAN-06-4625; Greenman C, 2007, NATURE, V446, P153, DOI 10.1038/nature05610; Gu D, 2007, HUM MUTAT, V28, P760, DOI 10.1002/humu.20512; Hill KA, 2004, MUTAT RES-FUND MOL M, V554, P223, DOI 10.1016/j.mrfmmm.2004.05.005; Hill KA, 2003, MUTAT RES-GEN TOX EN, V534, P173, DOI 10.1016/S1383-5718(02)00277-2; Lynch TJ, 2004, NEW ENGL J MED, V350, P2129, DOI 10.1056/NEJMoa040938; Ma ESK, 2007, INT J CANCER, V120, P1828, DOI 10.1002/ijc.22506; Mulloy R, 2007, CANCER RES, V67, P2325, DOI 10.1158/0008-5472.CAN-06-4293; Paez JG, 2004, SCIENCE, V304, P1497, DOI 10.1126/science.1099314; Regales L, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000810; Shigematsu H, 2006, INT J CANCER, V118, P257, DOI 10.1002/ijc.21496; Shigematsu H, 2005, JNCI-J NATL CANCER I, V97, P339, DOI 10.1093/jnci/dji055; Shintani Satoru, 2003, Am J Clin Oncol, V26, pe150, DOI 10.1097/01.coc.0000091356.25759.69; Sjoblom T, 2006, SCIENCE, V314, P268, DOI 10.1126/science.1133427; SOMMER SS, 1980, J MOL EVOL, V15, P37, DOI 10.1007/BF01732582; SOMMER SS, 1992, BIOTECHNIQUES, V12, P82; Sordella R, 2004, SCIENCE, V305, P1163, DOI 10.1126/science.1101637; Strauss BS, 2000, MUTAT RES-FUND MOL M, V457, P93, DOI 10.1016/S0027-5107(00)00135-4; Strauss BS, 1997, CARCINOGENESIS, V18, P1445, DOI 10.1093/carcin/18.8.1445; Takano T, 2005, J CLIN ONCOL, V23, P6829, DOI 10.1200/JCO.2005.01.0793; Tam IYS, 2006, CLIN CANCER RES, V12, P1647, DOI 10.1158/1078-0432.CCR-05-1981; Vikis H, 2007, CANCER RES, V67, P4665, DOI 10.1158/0008-5472.CAN-07-0217; Yokoyama T, 2006, CANCER SCI, V97, P753, DOI 10.1111/j.1349-7006.2006.00233.x; Yun CH, 2007, CANCER CELL, V11, P217, DOI 10.1016/j.ccr.2006.12.017	30	60	67	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 17	2008	27	31					4336	4343		10.1038/onc.2008.71	http://dx.doi.org/10.1038/onc.2008.71			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	326WY	18372921				2022-12-28	WOS:000257691100008
J	De Boer, L; Oakes, V; Beamish, H; Giles, N; Stevens, F; Somodevilla-Torres, M; DeSouza, C; Gabrielli, B				De Boer, L.; Oakes, V.; Beamish, H.; Giles, N.; Stevens, F.; Somodevilla-Torres, M.; DeSouza, C.; Gabrielli, B.			Cyclin A/cdk2 coordinates centrosomal and nuclear mitotic events	ONCOGENE			English	Article						cyclin A/cdk2; G(2)/M; centrosome	XENOPUS EGG EXTRACTS; HUMAN-CELLS; CYTOPLASMIC ACCUMULATION; G2-M TRANSITION; PROTEIN-KINASE; CDK2; ACTIVATION; PHOSPHORYLATION; MITOSIS; CDC25B	Cyclin A/cdk2 has a role in progression through Sphase, and a large pool is also activated in G(2) phase. Here we report that this G(2) phase pool regulates the timing of progression into mitosis. Knock down of cyclin A by siRNA or addition of a specific cdk2 small molecule inhibitor delayed entry into mitosis by delaying cells in G(2) phase. The G(2) phase-delayed cells contained elevated levels of inactive cyclin B/cdk1. However, increased microtubule nucleation at the centrosomes was observed, and the centrosomes stained for markers of cyclin B/cdk1 activity. Both microtubule nucleation at the centrosomes and the phosphoprotein markers were lost with short-term treatment of the cdk1/2 inhibitor roscovitine but not the Mek1/2 inhibitor U0126. Cyclin A/cdk2 localized at the centrosomes in late G(2) phase after separation of the centrosomes but before the start of prophase. Thus G(2) phase cyclin A/cdk2 controls the timing of entry into mitosis by controlling the subsequent activation of cyclin B/cdk1, but also has an unexpected role in coordinating the activation of cyclin B/cdk1 at the centrosome and in the nucleus.	[De Boer, L.; Oakes, V.; Beamish, H.; Giles, N.; Stevens, F.; Somodevilla-Torres, M.; Gabrielli, B.] Univ Queensland, Princess Alexandra Hosp, Diamantina Inst Canc Immunol & Metab Med, Canc Biol Program, Brisbane, Qld 4102, Australia; [DeSouza, C.] Ohio State Univ, Dept Mol Genet, Columbus, OH 43210 USA	University of Queensland; University System of Ohio; Ohio State University	Gabrielli, B (corresponding author), Univ Queensland, Princess Alexandra Hosp, Diamantina Inst Canc Immunol & Metab Med, Canc Biol Program, Brisbane, Qld 4102, Australia.	brianG@uq.edu.au	Gabrielli, Brian G/B-3655-2011	Gabrielli, Brian G/0000-0003-3933-1651; Stevens, Frankie/0000-0002-2556-473X				Andrews PD, 2003, CURR OPIN CELL BIOL, V15, P672, DOI 10.1016/j.ceb.2003.10.013; BAILLY E, 1992, J CELL SCI, V101, P529; Berthet C, 2003, CURR BIOL, V13, P1775, DOI 10.1016/j.cub.2003.09.024; Blomberg I, 1999, MOL CELL BIOL, V19, P6183; BUENDIA B, 1992, J CELL BIOL, V116, P1431, DOI 10.1083/jcb.116.6.1431; CLARKE PR, 1992, EMBO J, V11, P1751, DOI 10.1002/j.1460-2075.1992.tb05227.x; De Souza CPC, 2000, EXP CELL RES, V257, P11, DOI 10.1006/excr.2000.4872; den Elzen N, 2001, J CELL BIOL, V153, P121, DOI 10.1083/jcb.153.1.121; Dutertre S, 2004, J CELL SCI, V117, P2523, DOI 10.1242/jcs.01108; Fung TK, 2007, MOL BIOL CELL, V18, P1861, DOI 10.1091/mbc.E06-12-1092; Furuno N, 1999, J CELL BIOL, V147, P295, DOI 10.1083/jcb.147.2.295; Gabrielli BG, 1996, J CELL SCI, V109, P1081; Goldstone S, 2001, ONCOGENE, V20, P921, DOI 10.1038/sj.onc.1204177; Gong DQ, 2007, CURR BIOL, V17, P85, DOI 10.1016/j.cub.2006.11.066; GU Y, 1992, EMBO J, V11, P3995, DOI 10.1002/j.1460-2075.1992.tb05493.x; Hu B, 2001, MOL CELL BIOL, V21, P2755, DOI 10.1128/MCB.21.8.2755-2766.2001; Jackman M, 2003, NAT CELL BIOL, V5, P143, DOI 10.1038/ncb918; KNOBLICH JA, 1993, EMBO J, V12, P65, DOI 10.1002/j.1460-2075.1993.tb05632.x; Kramer A, 2004, NAT CELL BIOL, V6, P884, DOI 10.1038/ncb1165; Krauer KG, 2004, ONCOGENE, V23, P1342, DOI 10.1038/sj.onc.1207253; Lindqvist A, 2005, J CELL BIOL, V171, P35, DOI 10.1083/jcb.200503066; Lukas C, 1999, NATURE, V401, P815, DOI 10.1038/44611; Mitra J, 2004, ONCOGENE, V23, P3361, DOI 10.1038/sj.onc.1207446; Ortega S, 2003, NAT GENET, V35, P25, DOI 10.1038/ng1232; PAGANO M, 1992, EMBO J, V11, P961, DOI 10.1002/j.1460-2075.1992.tb05135.x; PINES J, 1990, NATURE, V346, P760, DOI 10.1038/346760a0; Qiu L, 2000, MOL BIOL CELL, V11, P2069, DOI 10.1091/mbc.11.6.2069; ROSSOMANDO AJ, 1994, MOL CELL BIOL, V14, P1594, DOI 10.1128/MCB.14.3.1594; Sherr CJ, 2000, CANCER RES, V60, P3689; Stead E, 2002, ONCOGENE, V21, P8320, DOI 10.1038/sj.onc.1206015; Tetsu O, 2003, CANCER CELL, V3, P233, DOI 10.1016/S1535-6108(03)00053-9	31	103	106	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 17	2008	27	31					4261	4268		10.1038/onc.2008.74	http://dx.doi.org/10.1038/onc.2008.74			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	326WY	18372919				2022-12-28	WOS:000257691100001
J	Kalakonda, N; Fischle, W; Boccuni, P; Gurvich, N; Hoya-Arias, R; Zhao, X; Miyata, Y; MacGrogan, D; Zhang, J; Sims, JK; Rice, JC; Nimer, SD				Kalakonda, N.; Fischle, W.; Boccuni, P.; Gurvich, N.; Hoya-Arias, R.; Zhao, X.; Miyata, Y.; MacGrogan, D.; Zhang, J.; Sims, J. K.; Rice, J. C.; Nimer, S. D.			Histone H4 lysine 20 monomethylation promotes transcriptional repression by L3MBTL1	ONCOGENE			English	Article						cell cycle; chromatin; L3MBTL1; lysine monomethylation; PR-SET7	POLYCOMB GROUP PROTEIN; CELL-CYCLE; DROSOPHILA-MELANOGASTER; MITOTIC CHROMOSOMES; MAMMALIAN CHROMATIN; METHYLATION STATES; SILENT CHROMATIN; HORMONE-RECEPTOR; TUDOR DOMAIN; HP1 PROTEINS	Lethal 3 malignant brain tumor 1 (L3MBTL1), a homolog of the Drosophila polycomb tumor suppressor l(3) mbt, contains three tandem MBT repeats (3xMBT) that are critical for transcriptional repression. We recently reported that the 3xMBT repeats interact with mono- and dimethylated lysines in the amino termini of histones H4 and H1b to promote methylation-dependent chromatin compaction. Using a series of histone peptides, we now show that the recognition of mono- and dimethylated lysines in histones H3, H4 and H1.4 (but not their trimethylated or unmodified counterparts) by 3xMBT occurs in the context of a basic environment, requiring a conserved aspartic acid (D355) in the second MBT repeat. Despite the broad range of in vitro binding, the chromatin association of L3MBTL1 mirrors the progressive accumulation of H4K20 monomethylation during the cell cycle. Furthermore, transcriptional repression by L3MBTL1 is enhanced by the H4K20 monomethyltransferase PR-SET7 (to which it binds) but not SUV420H1 (an H4K20 trimethylase) or G9a (an H3K9 dimethylase) and knockdown of PR-SET7 decreases H4K20me1 levels and the chromatin association of L3MBTL1. Our studies identify the importance of H4K20 monomethylation and of PR-SET7 for L3MBTL1 function.	[Kalakonda, N.; Boccuni, P.; Gurvich, N.; Hoya-Arias, R.; Zhao, X.; Miyata, Y.; MacGrogan, D.; Zhang, J.; Nimer, S. D.] Sloan Kettering Inst, Lab Mol Aspects Hematopoiesis, New York, NY 10021 USA; [Fischle, W.] Rockefeller Univ, Lab Chromatin Biol, New York, NY 10021 USA; [Sims, J. K.; Rice, J. C.] Univ So Calif, Keck Sch Med, Dept Biochem & Mol Biol, Los Angeles, CA 90033 USA	Memorial Sloan Kettering Cancer Center; Rockefeller University; University of Southern California	Nimer, SD (corresponding author), Sloan Kettering Inst, Lab Mol Aspects Hematopoiesis, 1275 York Ave,Box 575, New York, NY 10021 USA.	nimers@mskcc.org	Rice, Judd C/B-7806-2009; MacGrogan, Donal/E-8604-2016; MacGrogan, Donal/AAR-7392-2021	MacGrogan, Donal/0000-0003-2808-8422; MacGrogan, Donal/0000-0003-2808-8422; Zhao, Xiaolan/0000-0002-8302-6905	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM075094] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM075094, R01 GM075094-01A2, R01 GM075094-02] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bannister AJ, 2001, NATURE, V410, P120, DOI 10.1038/35065138; Barski A, 2007, CELL, V129, P823, DOI 10.1016/j.cell.2007.05.009; Boccuni P, 2003, J BIOL CHEM, V278, P15412, DOI 10.1074/jbc.M300592200; Bornemann D, 1998, GENETICS, V150, P675; Botuyan MV, 2006, CELL, V127, P1361, DOI 10.1016/j.cell.2006.10.043; Dialynas GK, 2007, J CELL SCI, V120, P3415, DOI 10.1242/jcs.012914; Fang J, 2002, CURR BIOL, V12, P1086, DOI 10.1016/S0960-9822(02)00924-7; Flanagan JF, 2005, NATURE, V438, P1181, DOI 10.1038/nature04290; GATEFF E, 1993, MECH DEVELOP, V41, P15, DOI 10.1016/0925-4773(93)90052-Y; Huang Y, 2006, SCIENCE, V312, P748, DOI 10.1126/science.1125162; Huebert DJ, 2005, CURR OPIN GENET DEV, V15, P476, DOI 10.1016/j.gde.2005.08.001; Ishizuka T, 2003, MOL CELL BIOL, V23, P5122, DOI 10.1128/MCB.23.15.5122-5131.2003; Jacobs SA, 2004, METHOD ENZYMOL, V376, P131; Jacobs SA, 2002, SCIENCE, V295, P2080, DOI 10.1126/science.1069473; Jorgensen S, 2007, J CELL BIOL, V179, P1337, DOI 10.1083/jcb.200706150; Julien E, 2004, MOL CELL, V14, P713, DOI 10.1016/j.molcel.2004.06.008; Karachentsev D, 2005, GENE DEV, V19, P431, DOI 10.1101/gad.1263005; Kim J, 2006, EMBO REP, V7, P397, DOI 10.1038/sj.embor.7400625; Klymenko T, 2006, GENE DEV, V20, P1110, DOI 10.1101/gad.377406; KOFF A, 1992, SCIENCE, V257, P1689, DOI 10.1126/science.1388288; Koga H, 1999, ONCOGENE, V18, P3799, DOI 10.1038/sj.onc.1202732; Kohlmaier A, 2004, PLOS BIOL, V2, P991, DOI 10.1371/journal.pbio.0020171; Lachner M, 2002, CURR OPIN CELL BIOL, V14, P286, DOI 10.1016/S0955-0674(02)00335-6; Lachner M, 2001, NATURE, V410, P116, DOI 10.1038/35065132; Lewis PW, 2004, GENE DEV, V18, P2929, DOI 10.1101/gad.1255204; MacGrogan D, 2004, GENE CHROMOSOME CANC, V41, P203, DOI 10.1002/gcc.20087; Martens JHA, 2005, EMBO J, V24, P800, DOI 10.1038/sj.emboj.7600545; Maurer-Stroh S, 2003, TRENDS BIOCHEM SCI, V28, P69, DOI 10.1016/S0968-0004(03)00004-5; Mendez J, 2000, MOL CELL BIOL, V20, P8602, DOI 10.1128/MCB.20.22.8602-8612.2000; Mikkelsen TS, 2007, NATURE, V448, P553, DOI 10.1038/nature06008; Nishioka K, 2002, MOL CELL, V9, P1201, DOI 10.1016/S1097-2765(02)00548-8; Pesavento JJ, 2008, MOL CELL BIOL, V28, P468, DOI 10.1128/MCB.01517-07; Peters AHFM, 2003, MOL CELL, V12, P1577, DOI 10.1016/S1097-2765(03)00477-5; Pray-Grant MG, 2005, NATURE, V433, P434, DOI 10.1038/nature03242; Rice JC, 2003, MOL CELL, V12, P1591, DOI 10.1016/S1097-2765(03)00479-9; Rice JC, 2002, GENE DEV, V16, P2225, DOI 10.1101/gad.1014902; Ruthenburg AJ, 2007, MOL CELL, V25, P15, DOI 10.1016/j.molcel.2006.12.014; Schotta G, 2004, GENE DEV, V18, P1251, DOI 10.1101/gad.300704; Schotta G, 2002, EMBO J, V21, P1121, DOI 10.1093/emboj/21.5.1121; Seet BT, 2006, NAT REV MOL CELL BIO, V7, P473, DOI 10.1038/nrm1960; Sims JK, 2006, J BIOL CHEM, V281, P12760, DOI 10.1074/jbc.M513462200; Stewart MD, 2005, MOL CELL BIOL, V25, P2525, DOI 10.1128/MCB.25.7.2525-2538.2005; Talasz H, 2005, J BIOL CHEM, V280, P38814, DOI 10.1074/jbc.M505563200; Tardat M, 2007, J CELL BIOL, V179, P1413, DOI 10.1083/jcb.200706179; Trojer P, 2007, CELL, V129, P915, DOI 10.1016/j.cell.2007.03.048; Turner BM, 2007, NAT CELL BIOL, V9, P2, DOI 10.1038/ncb0107-2; Vakoc CR, 2006, MOL CELL BIOL, V26, P9185, DOI 10.1128/MCB.01529-06; Wang WK, 2003, STRUCTURE, V11, P775, DOI 10.1016/S0969-2126(03)00127-8; WISMAR J, 1995, MECH DEVELOP, V53, P141, DOI 10.1016/0925-4773(95)00431-9; Yohn CB, 2003, GENETICS, V165, P1889; Zamir I, 1997, P NATL ACAD SCI USA, V94, P14400, DOI 10.1073/pnas.94.26.14400; Zhang LW, 2003, CHROMOSOMA, V112, P77, DOI 10.1007/s00412-003-0244-6	52	117	126	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 17	2008	27	31					4293	4304		10.1038/onc.2008.67	http://dx.doi.org/10.1038/onc.2008.67			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	326WY	18408754	Green Accepted			2022-12-28	WOS:000257691100004
J	Qi, W; Shakalya, K; Stejskal, A; Goldman, A; Beeck, S; Cooke, L; Mahadevan, D				Qi, W.; Shakalya, K.; Stejskal, A.; Goldman, A.; Beeck, S.; Cooke, L.; Mahadevan, D.			NSC348884, a nucleophosmin inhibitor disrupts oligomer formation and induces apoptosis in human cancer cells	ONCOGENE			English	Article						nucleophosmin; small molecular inhibitor; NSC348884; p53; apoptosis	TUMOR-SUPPRESSOR PROTEIN; TRANSCRIPTIONAL ACTIVITY; CENTROSOME DUPLICATION; NUCLEOLAR PROTEIN-B23; DNA-DAMAGE; B23; P53; IDENTIFICATION; NUCLEAR; GROWTH	Nucleophosmin (NPM), a multifunctional nucleolar phosphoprotein is dysregulated in human malignancies leadingto anti-apoptosis and inhibition of differentiation. We evaluated the precise three-dimensional structure of NPM based on the highly conserved structure of Xenopus NO38 and its requirement to form dimers and pentamers via its N-terminal domain (residues, 1-107). We hypothesized that a small molecular inhibitor (SMI) that could disrupt the formation of dimers would inhibit aberrant NPM function(s) in cancer cells. Molecular modeling, pharmacophore design, in silico screening and interactive docking identified NSC348884 as a putative NPM SMI that disrupts a defined hydrophobic pocket required for oligomerization. NSC348884 inhibited cell proliferation at an IC50 of 1.7-4.0 mu M in distinct cancer cell lines and disrupted NPM oligomer formation by native polyacrylamide gel electrophoresis assay. Treatment of several different cancer cell types with NSC348884 upregulated p53 (increased Ser15 phosphorylation) and induced apoptosis in a dose-dependent manner that correlated with apoptotic markers: H2AX phosphorylation, poly(ADP-ribose) polymerase cleavage and Annexin V labeling. Further, NSC348884 synergized doxorubicin cytotoxicity on cancer cell viability. The data together show that NSC348884 is an SMI of NPM oligomer formation, upregulates p53, induces apoptosis and synergizes with chemotherapy. Hence, an SMI to NPM may be a useful approach to anticancer therapy.	[Qi, W.; Shakalya, K.; Stejskal, A.; Goldman, A.; Beeck, S.; Cooke, L.; Mahadevan, D.] Univ Arizona, Arizona Canc Ctr, Tucson, AZ 85724 USA	Arizona Center Cancer Care; University of Arizona	Qi, W (corresponding author), Univ Arizona, Arizona Canc Ctr, 1515 N Campbell Ave, Tucson, AZ 85724 USA.	wenqing@email.arizona.edu; dmahadevan@azcc.arizona						Ahn JY, 2005, MOL CELL, V18, P435, DOI 10.1016/j.molcel.2005.04.010; Arkin MR, 2004, NAT REV DRUG DISCOV, V3, P301, DOI 10.1038/nrd1343; Bertwistle D, 2004, MOL CELL BIOL, V24, P985, DOI 10.1128/MCB.24.3.985-996.2004; Brady SN, 2004, MOL CELL BIOL, V24, P9327, DOI 10.1128/MCB.24.21.9327-9338.2004; Chan HJ, 2005, BIOCHEM BIOPH RES CO, V333, P396, DOI 10.1016/j.bbrc.2005.04.176; CHAN WY, 1989, BIOCHEMISTRY-US, V28, P1033, DOI 10.1021/bi00429a017; CHOU YH, 1995, BIOCHEM BIOPH RES CO, V217, P313, DOI 10.1006/bbrc.1995.2779; Colombo E, 2005, MOL CELL BIOL, V25, P8874, DOI 10.1128/MCB.25.20.8874-8886.2005; Colombo E, 2002, NAT CELL BIOL, V4, P529, DOI 10.1038/ncb814; FANKHAUSER C, 1991, MOL CELL BIOL, V11, P2567, DOI 10.1128/MCB.11.5.2567; FEUERSTEIN N, 1988, J BIOL CHEM, V263, P10608; Gjerset RA, 2006, J MOL HISTOL, V37, P239, DOI 10.1007/s10735-006-9040-y; Grisendi S, 2006, NAT REV CANCER, V6, P493, DOI 10.1038/nrc1885; Herrera JE, 1996, BIOCHEMISTRY-US, V35, P2668, DOI 10.1021/bi9523320; Hingorani K, 2000, J BIOL CHEM, V275, P24451, DOI 10.1074/jbc.M003278200; Itahana K, 2003, MOL CELL, V12, P1151, DOI 10.1016/S1097-2765(03)00431-3; Kondo T, 1997, ONCOGENE, V15, P1275, DOI 10.1038/sj.onc.1201286; Korgaonkar C, 2005, MOL CELL BIOL, V25, P1258, DOI 10.1128/MCB.25.4.1258-1271.2005; Kurki S, 2004, CANCER CELL, V5, P465, DOI 10.1016/S1535-6108(04)00110-2; Lee C, 2005, CANCER RES, V65, P9834, DOI 10.1158/0008-5472.CAN-05-1759; Li J, 2005, LEUKEMIA RES, V29, P1415, DOI 10.1016/j.leukres.2005.05.005; Li J, 2004, J BIOL CHEM, V279, P41275, DOI 10.1074/jbc.C400297200; Li YP, 1996, EUR J BIOCHEM, V237, P153, DOI 10.1111/j.1432-1033.1996.0153n.x; Lim MJ, 2006, CANCER DETECT PREV, V30, P481, DOI 10.1016/j.cdp.2006.10.008; Liu Y, 2007, CANCER RES, V67, P2685, DOI 10.1158/0008-5472.CAN-06-3497; Maiguel DA, 2004, MOL CELL BIOL, V24, P3703, DOI 10.1128/MCB.24.9.3703-3711.2004; Namboodiri VMH, 2004, STRUCTURE, V12, P2149, DOI 10.1016/j.str.2004.09.017; Naoe T, 2006, CANCER SCI, V97, P963, DOI 10.1111/j.1349-7006.2006.00270.x; Nozawa Y, 1996, J PATHOL, V178, P48; Okuda M, 2002, ONCOGENE, V21, P6170, DOI 10.1038/sj.onc.1205708; Okuwaki M, 2001, FEBS LETT, V506, P272, DOI 10.1016/S0014-5793(01)02939-8; Oltersdorf T, 2005, NATURE, V435, P677, DOI 10.1038/nature03579; Oost TK, 2004, J MED CHEM, V47, P4417, DOI 10.1021/jm040037k; Oren M, 1999, J BIOL CHEM, V274, P36031, DOI 10.1074/jbc.274.51.36031; PATTERSON SD, 1995, J BIOL CHEM, V270, P9429, DOI 10.1074/jbc.270.16.9429; Qi WQ, 2003, RADIAT RES, V160, P217, DOI 10.1667/RR3038; Shields LBE, 1997, J SOC GYNECOL INVEST, V4, P298, DOI 10.1016/S1071-5576(97)00068-3; Subong ENP, 1999, PROSTATE, V39, P298; Takemura M, 1999, J BIOCHEM-TOKYO, V125, P904, DOI 10.1093/oxfordjournals.jbchem.a022367; TANAKA M, 1992, CANCER RES, V52, P3372; VALDEZ BC, 1994, J BIOL CHEM, V269, P23776; VanBelzen N, 1995, EUR J BIOCHEM, V234, P843; Vassilev LT, 2004, SCIENCE, V303, P844, DOI 10.1126/science.1092472; WANG DR, 1993, CELL MOL BIOL RES, V39, P33; Wang W, 2005, NAT CELL BIOL, V7, P823, DOI 10.1038/ncb1282; Ye KQ, 2005, CANCER BIOL THER, V4, P918, DOI 10.4161/cbt.4.9.2072; Yeh CW, 2006, MOL PHARMACOL, V70, P1443, DOI 10.1124/mol.106.024810; YUNG BY, 1990, CANCER RES, V50, P5987; Zhang YP, 2004, CELL CYCLE, V3, P259	49	83	90	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2008	27	30					4210	4220		10.1038/onc.2008.54	http://dx.doi.org/10.1038/onc.2008.54			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	324DB	18345031				2022-12-28	WOS:000257496800008
J	Wang, IC; Meliton, L; Tretiakova, M; Costa, RH; Kalinichenko, VV; Kalin, TV				Wang, I-C; Meliton, L.; Tretiakova, M.; Costa, R. H.; Kalinichenko, V. V.; Kalin, T. V.			Transgenic expression of the forkhead box M1 transcription factor induces formation of lung tumors	ONCOGENE			English	Article						winged helix DNA-binding domain; forkhead transcription factor; Foxm1; non-small cell lung cancer; lung epithelial cells; cellular proliferation	GENE-EXPRESSION; CYCLOOXYGENASE-2 EXPRESSION; HEPATOCELLULAR-CARCINOMA; FOXM1; PROGRESSION; CELLS; IDENTIFICATION; PROLIFERATION; PATHWAYS; NETWORK	The forkhead box m1 (Foxm1 or Foxm1b) protein (previously called HFH-11B, Trident, Win or MPP2) is abundantly expressed in human non-small cell lung cancers where it transcriptionally induces expression of genes essential for proliferation of tumor cells. In this study, we used Rosa26-Foxm1 transgenic mice, in which the Rosa26 promoter drives ubiquitous expression of Foxm1 transgene, to identify new signaling pathways regulated by Foxm1. Lung tumors were induced in Rosa26-Foxm1 mice using the 3-methylcholanthrene (MCA)/butylated hydroxytoluene (BHT) lung tumor initiation/promotion protocol. Tumors from MCA/BHT-treated Rosa26-Foxm1 mice displayed a significant increase in the number, size and DNA replication compared to wild-type mice. Elevated tumor formation in Rosa26-Foxm1 transgenic lungs was associated with persistent pulmonary inflammation, macrophage infiltration and increased expression of cyclooxygenase-2 (Cox-2), Cdc25C phosphatase, cyclin E2, chemokine ligands CXCL5, CXCL1 and CCL3, cathepsins and matrix metalloprotease-12. Cell culture experiments with A549 human lung adenocarcinoma cells demonstrated that depletion of Foxm1 by either short interfering RNA transfection or treatment with Foxm1-inhibiting ARF 26-44 peptide significantly reduced Cox-2 expression. In co-transfection experiments, Foxm1 protein-induced Cox-2 promoter activity and directly bound to the -2566/- 2580 bp region of human Cox-2 promoter.	[Wang, I-C; Kalinichenko, V. V.; Kalin, T. V.] Cincinnati Childrens Hosp Res Fdn, Div Pulm Biol, Cincinnati, OH 45229 USA; [Meliton, L.] Univ Chicago, Dept Med, Chicago, IL 60637 USA; [Tretiakova, M.] Univ Chicago, Dept Pathol, Chicago, IL 60637 USA; [Costa, R. H.] Univ Illinois, Dept Biochem & Mol Genet, Chicago, IL USA	Cincinnati Children's Hospital Medical Center; Cincinnati Children's Hospital Research Foundation; University of Chicago; University of Chicago; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Kalin, TV (corresponding author), Cincinnati Childrens Hosp Res Fdn, Div Pulm Biol, 3333 Burnet Ave,MLC 7009, Cincinnati, OH 45229 USA.	kal4ti@cchmc.org	Tretiakova, Maria/U-3320-2019	Wang, I-Ching/0000-0003-4398-2975	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK054687] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Acuff HB, 2006, CANCER RES, V66, P7968, DOI 10.1158/0008-5472.CAN-05-4279; Blaine SA, 2005, CARCINOGENESIS, V26, P209, DOI 10.1093/carcin/bgh302; Bratt T, 2000, BBA-PROTEIN STRUCT M, V1482, P318, DOI 10.1016/S0167-4838(00)00154-0; Chang MS, 2005, CELL SIGNAL, V17, P299, DOI 10.1016/j.cellsig.2004.07.008; Chun KS, 2004, BIOCHEM PHARMACOL, V68, P1089, DOI 10.1016/j.bcp.2004.05.031; CLARK KL, 1993, NATURE, V364, P412, DOI 10.1038/364412a0; CLEVIDENCE DE, 1993, P NATL ACAD SCI USA, V90, P3948, DOI 10.1073/pnas.90.9.3948; Costa RH, 2005, CURR OPIN GENET DEV, V15, P42, DOI 10.1016/j.gde.2004.12.007; Giaccone G, 1996, CHEST, V109, pS130, DOI 10.1378/chest.109.5_Supplement.130S; Gusarova GA, 2007, J CLIN INVEST, V117, P99, DOI 10.1172/JCI27527; Kalin TV, 2006, CANCER RES, V66, P1712, DOI 10.1158/0008-5472.CAN-05-3138; Kalinichenko VV, 2003, J BIOL CHEM, V278, P37888, DOI 10.1074/jbc.M305555200; Kalinichenko VV, 2001, DEV BIOL, V235, P489, DOI 10.1006/dbio.2001.0322; Kalinichenko VV, 2001, AM J PHYSIOL-LUNG C, V280, pL695, DOI 10.1152/ajplung.2001.280.4.L695; Kalinichenko VV, 2004, GENE DEV, V18, P830, DOI 10.1101/gad.1200704; Kim IM, 2006, CANCER RES, V66, P2153, DOI 10.1158/0008-5472.CAN-05-3003; Kim IM, 2005, J BIOL CHEM, V280, P37908, DOI 10.1074/jbc.M506531200; Kim IM, 2005, J BIOL CHEM, V280, P22278, DOI 10.1074/jbc.M500936200; Korver W, 1997, NUCLEIC ACIDS RES, V25, P1715, DOI 10.1093/nar/25.9.1715; Krupczak-Hollis K, 2004, DEV BIOL, V276, P74, DOI 10.1016/j.ydbio.2004.08.022; Kulbe H, 2004, INT J DEV BIOL, V48, P489, DOI 10.1387/ijdb.041814hk; Lee JS, 2004, HEPATOLOGY, V40, P667, DOI 10.1002/hep.20375; Ma RYM, 2005, J CELL SCI, V118, P795, DOI 10.1242/jcs.01657; Major ML, 2004, MOL CELL BIOL, V24, P2649, DOI 10.1128/MCB.24.7.2649-2661.2004; Malkinson AM, 1998, EXP LUNG RES, V24, P541, DOI 10.3109/01902149809087385; Malkinson AM, 1997, CANCER RES, V57, P2832; McCormick Frank, 1999, Trends in Cell Biology, V9, pM53, DOI 10.1016/S0962-8924(99)01668-2; Mitsuuchi Y, 2002, AM J MED GENET, V115, P183, DOI 10.1002/ajmg.10692; Nilsson I, 2000, Prog Cell Cycle Res, V4, P107; Obama K, 2005, HEPATOLOGY, V41, P1339, DOI 10.1002/hep.20718; Park HJ, 2008, ONCOGENE, V27, P1696, DOI 10.1038/sj.onc.1210814; Parkin DM, 2005, CA-CANCER J CLIN, V55, P74, DOI 10.3322/canjclin.55.2.74; Pilarsky C, 2004, NEOPLASIA, V6, P744, DOI 10.1593/neo.04277; Riedl K, 2004, DRUG RESIST UPDATE, V7, P169, DOI 10.1016/j.drup.2004.04.003; Sherr CJ, 2002, CANCER CELL, V2, P103, DOI 10.1016/S1535-6108(02)00102-2; Teh MT, 2002, CANCER RES, V62, P4773; Toloza EM, 2006, J CELL BIOCHEM, V99, P1, DOI 10.1002/jcb.20851; Tong M, 2006, CARCINOGENESIS, V27, P2170, DOI 10.1093/carcin/bgl053; van den Boom J, 2003, AM J PATHOL, V163, P1033, DOI 10.1016/S0002-9440(10)63463-3; Wang IC, 2005, MOL CELL BIOL, V25, P10875, DOI 10.1128/MCB.25.24.10875-10894.2005; Wender PA, 2000, P NATL ACAD SCI USA, V97, P13003, DOI 10.1073/pnas.97.24.13003; Wolters P J, 2000, Respir Res, V1, P170, DOI 10.1186/rr29; Wonsey DR, 2005, CANCER RES, V65, P5181, DOI 10.1158/0008-5472.CAN-04-4059; Ye HG, 1999, MOL CELL BIOL, V19, P8570; Ye HG, 1997, MOL CELL BIOL, V17, P1626, DOI 10.1128/MCB.17.3.1626; Zhao YY, 2006, J CLIN INVEST, V116, P2333, DOI 10.1172/JCI27154	46	64	70	0	1	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2008	27	30					4137	4149		10.1038/onc.2008.60	http://dx.doi.org/10.1038/onc.2008.60			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	324DB	18345025				2022-12-28	WOS:000257496800001
J	Calnan, DR; Brunet, A				Calnan, D. R.; Brunet, A.			The FoxO code	ONCOGENE			English	Review						FoxO transcription factors; post-translational modifications; high molecular weight complex; chromatin; aging; cancer	TRANSCRIPTION FACTOR FOXO1; FORKHEAD PROTEIN FOXO1; REGULATES LIFE-SPAN; OXIDATIVE-STRESS; FACTOR FKHR; PHOSPHORYLATION SITES; INSULIN-INHIBITION; MEDIATES LONGEVITY; NUCLEAR EXCLUSION; SURVIVAL SIGNALS	The FoxO family of Forkhead transcription factors plays an important role in longevity and tumor suppression by upregulating target genes involved in stress resistance, metabolism, cell cycle arrest and apoptosis. FoxO transcription factors translate a variety of environmental stimuli, including insulin, growth factors, nutrients and oxidative stress, into specific gene-expression programs. These environmental stimuli control FoxO activity primarily by regulating their subcellular localization, but also by affecting their protein levels, DNA-binding properties and transcriptional activity. The precise regulation of FoxO transcription factors is enacted by an intricate combination of post-translational modi. cations (PTMs), including phosphorylation, acetylation and ubiquitination, and binding protein partners. An intriguing possibility is that FoxO PTMs may act as a 'molecular FoxO code' read by selective protein partners to rapidly regulate gene-expression programs. The effective control of FoxO activity in response to environmental stimuli is likely to be critical to prevent aging and age-dependent diseases, including cancer, neurodegenerative diseases and diabetes.	[Calnan, D. R.; Brunet, A.] Stanford Univ, Dept Genet, Stanford, CA 94350 USA; [Calnan, D. R.; Brunet, A.] Stanford Univ, Canc Biol Program, Stanford, CA 94350 USA; [Brunet, A.] Stanford Univ, Neurosci Program, Stanford, CA 94350 USA	Stanford University; Stanford University; Stanford University	Brunet, A (corresponding author), Stanford Univ, Dept Genet, 300 Pasteur Dr, Stanford, CA 94350 USA.	anne.brunet@stanford.edu	高, 雨莉/HGU-8187-2022					Almeida M, 2007, J BIOL CHEM, V282, P27298, DOI 10.1074/jbc.M702811200; Aoki M, 2004, P NATL ACAD SCI USA, V101, P13613, DOI 10.1073/pnas.0405454101; Bakker WJ, 2004, J CELL BIOL, V164, P175, DOI 10.1083/jcb.200307056; Barthel A, 2002, ENDOCRINOLOGY, V143, P3183, DOI 10.1210/endo.143.8.8792; Biggs WH, 1999, P NATL ACAD SCI USA, V96, P7421, DOI 10.1073/pnas.96.13.7421; Bluher M, 2003, SCIENCE, V299, P572, DOI 10.1126/science.1078223; Borkhardt A, 1997, ONCOGENE, V14, P195, DOI 10.1038/sj.onc.1200814; Boura E, 2007, J BIOL CHEM, V282, P8265, DOI 10.1074/jbc.M605682200; Brownawell AM, 2001, MOL CELL BIOL, V21, P3534, DOI 10.1128/MCB.21.10.3534-3546.2001; Brunet A, 2002, J CELL BIOL, V156, P817, DOI 10.1083/jcb.200112059; Brunet A, 2001, MOL CELL BIOL, V21, P952, DOI 10.1128/MCB.21.3.952-965.2001; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Brunet A, 2004, SCIENCE, V303, P2011, DOI 10.1126/science.1094637; Cirillo LA, 2002, MOL CELL, V9, P279, DOI 10.1016/S1097-2765(02)00459-8; Daitoku H, 2004, P NATL ACAD SCI USA, V101, P10042, DOI 10.1073/pnas.0400593101; DAVIS RJ, 1994, CANCER RES, V54, P2869; Dijkers PF, 2000, CURR BIOL, V10, P1201, DOI 10.1016/S0960-9822(00)00728-4; Dixit M, 2008, CARDIOVASC RES, V77, P160, DOI 10.1093/cvr/cvm017; Dowell P, 2003, J BIOL CHEM, V278, P45485, DOI 10.1074/jbc.M309069200; Essers MAG, 2004, EMBO J, V23, P4802, DOI 10.1038/sj.emboj.7600476; Essers MAG, 2005, SCIENCE, V308, P1181, DOI 10.1126/science.1109083; Frescas D, 2005, J BIOL CHEM, V280, P20589, DOI 10.1074/jbc.M412357200; Fukuoka M, 2003, INT J MOL MED, V12, P503; Furuyama T, 2004, J BIOL CHEM, V279, P34741, DOI 10.1074/jbc.M314214200; Furuyama T, 2002, MICROSC RES TECHNIQ, V59, P331, DOI 10.1002/jemt.10213; Furuyama T, 2000, BIOCHEM J, V349, P629, DOI 10.1042/0264-6021:3490629; GALILI N, 1993, NAT GENET, V5, P230, DOI 10.1038/ng1193-230; Giannakou ME, 2004, SCIENCE, V305, P361, DOI 10.1126/science.1098219; Gomis RR, 2006, P NATL ACAD SCI USA, V103, P12747, DOI 10.1073/pnas.0605333103; Greer EL, 2007, J BIOL CHEM, V282, P30107, DOI 10.1074/jbc.M705325200; Greer EL, 2007, CURR BIOL, V17, P1646, DOI 10.1016/j.cub.2007.08.047; Guo SD, 1999, J BIOL CHEM, V274, P17184, DOI 10.1074/jbc.274.24.17184; Hatta M, 2007, J BIOL CHEM, V282, P35583, DOI 10.1074/jbc.M704735200; Henderson ST, 2001, CURR BIOL, V11, P1975, DOI 10.1016/S0960-9822(01)00594-2; Hillion J, 1997, BLOOD, V90, P3714, DOI 10.1182/blood.V90.9.3714; Holzenberger M, 2003, NATURE, V421, P182, DOI 10.1038/nature01298; Hosaka T, 2004, P NATL ACAD SCI USA, V101, P2975, DOI 10.1073/pnas.0400093101; Hribal ML, 2003, J CELL BIOL, V162, P535, DOI 10.1083/jcb.200212107; Hu MCT, 2004, CELL, V117, P225, DOI 10.1016/S0092-8674(04)00302-2; Huang H, 2005, P NATL ACAD SCI USA, V102, P1649, DOI 10.1073/pnas.0406789102; Huang HJ, 2006, SCIENCE, V314, P294, DOI 10.1126/science.1130512; Hwangbo DS, 2004, NATURE, V429, P562, DOI 10.1038/nature02549; Imae M, 2003, J MOL ENDOCRINOL, V30, P253, DOI 10.1677/jme.0.0300253; Jackson JG, 2000, ONCOGENE, V19, P4574, DOI 10.1038/sj.onc.1203825; Jacobs FMJ, 2003, J BIOL CHEM, V278, P35959, DOI 10.1074/jbc.M302804200; Jager S, 2007, P NATL ACAD SCI USA, V104, P12017, DOI 10.1073/pnas.0705070104; Kaeberlein M, 1999, GENE DEV, V13, P2570, DOI 10.1101/gad.13.19.2570; Kim MS, 2006, NAT NEUROSCI, V9, P901, DOI 10.1038/nn1731; Kitamura T, 2007, J CLIN INVEST, V117, P2477, DOI 10.1172/JCI32054; Kitamura T, 2006, NAT MED, V12, P534, DOI 10.1038/nm1392; Kitamura YI, 2005, CELL METAB, V2, P153, DOI 10.1016/j.cmet.2005.08.004; Kops GJPL, 2002, NATURE, V419, P316, DOI 10.1038/nature01036; Kops GJPL, 1999, NATURE, V398, P630, DOI 10.1038/19328; Lee SS, 2003, SCIENCE, V300, P644, DOI 10.1126/science.1083614; Lehtinen MK, 2006, CELL, V125, P987, DOI 10.1016/j.cell.2006.03.046; Li J, 2007, DEV BIOL, V301, P82, DOI 10.1016/j.ydbio.2006.10.013; Li PF, 2003, MOL CELL BIOL, V23, P104, DOI 10.1128/MCB.23.1.104-118.2003; Li XH, 2007, NATURE, V447, P1012, DOI 10.1038/nature05861; Lin K, 1997, SCIENCE, V278, P1319, DOI 10.1126/science.278.5341.1319; Liu ZP, 2005, DEV CELL, V9, P261, DOI 10.1016/j.devcel.2005.05.017; Mahmud DL, 2002, ONCOGENE, V21, P1556, DOI 10.1038/sj.onc.1205230; Mammucari C, 2007, CELL METAB, V6, P458, DOI 10.1016/j.cmet.2007.11.001; Matsumoto M, 2007, CELL METAB, V6, P208, DOI 10.1016/j.cmet.2007.08.006; Matsumoto M, 2006, J CLIN INVEST, V116, P2464, DOI 10.1172/JCI27047; Matsuzaki H, 2003, P NATL ACAD SCI USA, V100, P11285, DOI 10.1073/pnas.1934283100; Matsuzaki H, 2005, P NATL ACAD SCI USA, V102, P11278, DOI 10.1073/pnas.0502738102; Medema RH, 2000, NATURE, V404, P782, DOI 10.1038/35008115; Miyamoto K, 2007, CELL STEM CELL, V1, P101, DOI 10.1016/j.stem.2007.02.001; Motta MC, 2004, CELL, V116, P551, DOI 10.1016/S0092-8674(04)00126-6; Murphy CT, 2003, NATURE, V424, P277, DOI 10.1038/nature01789; Nakae J, 1999, J BIOL CHEM, V274, P15982, DOI 10.1074/jbc.274.23.15982; Nakae J, 2003, DEV CELL, V4, P119, DOI 10.1016/S1534-5807(02)00401-X; Nakae J, 2002, NAT GENET, V3, P3; Nasrin N, 2000, P NATL ACAD SCI USA, V97, P10412, DOI 10.1073/pnas.190326997; Nemoto S, 2004, SCIENCE, V306, P2105, DOI 10.1126/science.1101731; Nemoto S, 2002, SCIENCE, V295, P2450, DOI 10.1126/science.1069004; Nowak K, 2007, BBA-GENE STRUCT EXPR, V1769, P244, DOI 10.1016/j.bbaexp.2007.04.001; Obsil T, 2003, BIOCHEMISTRY-US, V42, P15264, DOI 10.1021/bi0352724; Obsilova V, 2005, BIOCHEMISTRY-US, V44, P11608, DOI 10.1021/bi050618r; Ogg S, 1997, NATURE, V389, P994, DOI 10.1038/40194; Oh SW, 2005, P NATL ACAD SCI USA, V102, P4494, DOI 10.1073/pnas.0500749102; Paik JH, 2007, CELL, V128, P309, DOI 10.1016/j.cell.2006.12.029; PARRY P, 1994, GENE CHROMOSOME CANC, V11, P79, DOI 10.1002/gcc.2870110203; Perrot V, 2003, J BIOL CHEM, V278, P26111, DOI 10.1074/jbc.M212750200; Plas DR, 2003, J BIOL CHEM, V278, P12361, DOI 10.1074/jbc.M213069200; Puigserver P, 2003, NATURE, V423, P550, DOI 10.1038/nature01667; Rena G, 2002, EMBO J, V21, P2263, DOI 10.1093/emboj/21.9.2263; Rena G, 2001, BIOCHEM J, V354, P605, DOI 10.1042/0264-6021:3540605; Rinner O, 2007, NAT BIOTECHNOL, V25, P345, DOI 10.1038/nbt1289; Rogina B, 2004, P NATL ACAD SCI USA, V101, P15998, DOI 10.1073/pnas.0404184101; Schilling MM, 2006, NATURE, V443, pE10, DOI 10.1038/nature05288; Schuur ER, 2001, J BIOL CHEM, V276, P33554, DOI 10.1074/jbc.M105555200; Seoane J, 2004, CELL, V117, P211, DOI 10.1016/S0092-8674(04)00298-3; Sunayama J, 2005, J CELL BIOL, V170, P295, DOI 10.1083/jcb.200409117; Teleman AA, 2005, DEV CELL, V9, P271, DOI 10.1016/j.devcel.2005.07.004; Tissenbaum HA, 2001, NATURE, V410, P227, DOI 10.1038/35065638; Tothova Z, 2007, CELL, V128, P325, DOI 10.1016/j.cell.2007.01.003; Tran H, 2002, SCIENCE, V296, P530, DOI 10.1126/science.1068712; Tsai KL, 2007, NUCLEIC ACIDS RES, V35, P6984, DOI 10.1093/nar/gkm703; Tsai WC, 2003, ENDOCRINOLOGY, V144, P5615, DOI 10.1210/en.2003-0481; van der Horst A, 2004, J BIOL CHEM, V279, P28873, DOI 10.1074/jbc.M401138200; van der Horst A, 2006, NAT CELL BIOL, V8, P1064, DOI 10.1038/ncb1469; Wang F, 2007, AGING CELL, V6, P505, DOI 10.1111/j.1474-9726.2007.00304.x; Wolff S, 2006, CELL, V124, P1039, DOI 10.1016/j.cell.2005.12.042; Xuan ZY, 2005, MECH AGEING DEV, V126, P209, DOI 10.1016/j.mad.2004.09.021; Yamamura Y, 2006, J BIOL CHEM, V281, P5267, DOI 10.1074/jbc.M512151200; Yang YH, 2005, EMBO J, V24, P1021, DOI 10.1038/sj.emboj.7600570; Yellaturu CR, 2002, J BIOL CHEM, V277, P40148, DOI 10.1074/jbc.M206376200; Zhang XH, 2002, J BIOL CHEM, V277, P45276, DOI 10.1074/jbc.M208063200; Zhao J, 2007, CELL METAB, V6, P472, DOI 10.1016/j.cmet.2007.11.004; Zhao XS, 2004, BIOCHEM J, V378, P839, DOI 10.1042/BJ20031450; Zheng WH, 2002, J NEUROCHEM, V80, P1049, DOI 10.1046/j.0022-3042.2002.00783.x	112	890	919	3	85	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 7	2008	27	16					2276	2288		10.1038/onc.2008.21	http://dx.doi.org/10.1038/onc.2008.21			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	285NE	18391970				2022-12-28	WOS:000254782700003
J	Sagara, M; Kawasaki, Y; Iemura, S; Natsume, T; Takai, Y; Akiyama, T				Sagara, M.; Kawasaki, Y.; Iemura, S-i; Natsume, T.; Takai, Y.; Akiyama, T.			Asef2 and Neurabin2 cooperatively regulate actin cytoskeletal organization and are involved in HGF-induced cell migration	ONCOGENE			English	Article						APC; Asef2; Neurabin2/Spinophilin; HGF; filopodia; migration	TUMOR-SUPPRESSOR APC; EXCHANGE FACTOR; BINDING-PROTEIN; SPINOPHILIN; DOMAIN; CDC42; IDENTIFICATION; ACTIVATION; RELEASE; CANCER	The tumor suppressor adenomatous polyposis coli (APC) is mutated in sporadic and familial colorectal tumors. APC interacts with the Rac1- and Cdc42-specific guanine-nucleotide exchange factors (GEF), Asef and Asef2, which contain an APC-binding region (ABR) in addition to Dbl homology, Pleckstrin homology (PH) and Src homology 3 (SH3) domains. APC stimulates the GEF activity of Asef and Asef2, and thereby regulates cell adhesion and migration. Here we show that Asef2, but not Asef, interacts with Neurabin2/Spinophilin, a scaffold protein that binds to Filamentous actin (F-actin). In response to hepatocyte growth factor (HGF) treatment of HeLa cells, Asef2, Neurabin2 and APC were induced to accumulate and colocalize in lamellipodia and membrane ruffles. Neurabin2 did not affect the GEF activity of Asef2. RNA interference experiments showed that Asef2, Neurabin2 and APC are involved in HGF-induced cell migration. Furthermore, knockdown of Neurabin2 resulted in the suppression of Asef2-induced filopodia formation. These results suggest that Asef2, Neurabin2 and APC cooperatively regulate actin cytoskeletal organization and are required for HGF-induced cell migration.	[Akiyama, T.] Univ Tokyo, Inst Mol & Cellular Biosci, Lab Mol & Genet Informat, Bunkyo Ku, Tokyo 1130032, Japan; [Iemura, S-i; Natsume, T.] Natl Inst Adv Ind Sci & Technol, Biomed Informat Res Ctr, Tokyo, Japan; [Takai, Y.] Kobe Univ, Grad Sch Med, Dept Biochem & Mol Biol, Div Mol & Cellular Biol, Kobe, Hyogo 657, Japan	University of Tokyo; National Institute of Advanced Industrial Science & Technology (AIST); Kobe University	Akiyama, T (corresponding author), Univ Tokyo, Inst Mol & Cellular Biosci, Lab Mol & Genet Informat, Bunkyo Ku, 1-1-1 Yayoi, Tokyo 1130032, Japan.	akiyama@iam.u-tokyo.ac.jp	Natsume, Tohru/M-7627-2018	Natsume, Tohru/0000-0002-1510-2582	Japan Society for the Promotion of Science for Young Scientists	Japan Society for the Promotion of Science for Young Scientists(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science)	This work was supported by Grants-in-Aid for Scientific Research on Priority Areas and the Organization for Pharmaceutical Safety and Research, Research Fellowships of the Japan Society for the Promotion of Science for Young Scientists, and in part by Global COE Program (Integrative Life Science Based on the Study of Biosignaling Mechanisms), MEXT, Japan.	Akiyama T, 2006, ONCOGENE, V25, P7538, DOI 10.1038/sj.onc.1210063; Allen PB, 1997, P NATL ACAD SCI USA, V94, P9956, DOI 10.1073/pnas.94.18.9956; Bellanger JM, 2000, NAT CELL BIOL, V2, P888, DOI 10.1038/35046533; Bienz M, 2000, CELL, V103, P311, DOI 10.1016/S0092-8674(00)00122-7; Birchmeier C, 2003, NAT REV MOL CELL BIO, V4, P915, DOI 10.1038/nrm1261; Boccaccio C, 2006, NAT REV CANCER, V6, P637, DOI 10.1038/nrc1912; Buchsbaum RJ, 2003, J BIOL CHEM, V278, P18833, DOI 10.1074/jbc.M207876200; Cadigan KM, 1997, GENE DEV, V11, P3286, DOI 10.1101/gad.11.24.3286; Etienne-Manneville S, 2003, NATURE, V421, P753, DOI 10.1038/nature01423; Feng J, 2000, P NATL ACAD SCI USA, V97, P9287, DOI 10.1073/pnas.97.16.9287; Ferrara N, 2005, NATURE, V438, P967, DOI 10.1038/nature04483; Fodde R, 2001, NAT REV CANCER, V1, P55, DOI 10.1038/35094067; Futter M, 2005, P NATL ACAD SCI USA, V102, P3489, DOI 10.1073/pnas.0409802102; Hamann MJ, 2007, MOL CELL BIOL, V27, P1380, DOI 10.1128/MCB.01608-06; Itoh RE, 2008, J CELL SCI, V121, P2635, DOI 10.1242/jcs.028647; Jimbo T, 2002, NAT CELL BIOL, V4, P323, DOI 10.1038/ncb779; Kawasaki Y, 2007, ONCOGENE, V26, P7620, DOI 10.1038/sj.onc.1210574; Kawasaki Y, 2003, NAT CELL BIOL, V5, P211, DOI 10.1038/ncb937; Kawasaki Y, 2000, SCIENCE, V289, P1194, DOI 10.1126/science.289.5482.1194; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; Mitin N, 2007, NAT STRUCT MOL BIOL, V14, P814, DOI 10.1038/nsmb1290; Murayama K, 2007, J BIOL CHEM, V282, P4238, DOI 10.1074/jbc.C600234200; Muroya K, 2007, BIOCHEM BIOPH RES CO, V355, P85, DOI 10.1016/j.bbrc.2007.01.131; Natsume T, 2002, ANAL CHEM, V74, P4725, DOI 10.1021/ac020018n; Polakis P, 2000, GENE DEV, V14, P1837; Ryan XZP, 2005, NEURON, V47, P85, DOI 10.1016/j.neuron.2005.05.013; Sarrouilhe D, 2006, BIOCHIMIE, V88, P1099, DOI 10.1016/j.biochi.2006.04.010; Satoh A, 1998, J BIOL CHEM, V273, P3470, DOI 10.1074/jbc.273.6.3470; Schuler H, 2008, FEBS J, V275, P59, DOI 10.1111/j.1742-4658.2007.06171.x; SU LK, 1995, CANCER RES, V55, P2972; Watanabe T, 2004, DEV CELL, V7, P871, DOI 10.1016/j.devcel.2004.10.017	31	22	25	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2009	28	10					1357	1365		10.1038/onc.2008.478	http://dx.doi.org/10.1038/onc.2008.478			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	417ZC	19151759				2022-12-28	WOS:000264116000008
J	Snijders, AM; Huey, B; Connelly, ST; Roy, R; Jordan, RCK; Schmidt, BL; Albertson, DG				Snijders, A. M.; Huey, B.; Connelly, S. T.; Roy, R.; Jordan, R. C. K.; Schmidt, B. L.; Albertson, D. G.			Stromal control of oncogenic traits expressed in response to the overexpression of GLI2, a pleiotropic oncogene	ONCOGENE			English	Article						GLI2; organotypic culture; transdifferentiation; invasion	GENE AMPLIFICATION; GENOMIC INSTABILITY; D1 OVEREXPRESSION; CARCINOMA-CELLS; TUMOR; DIFFERENTIATION; GROWTH; TISSUE; TRANSCRIPTION; INHIBITION	Hedgehog signaling is often activated in tumors, yet it remains unclear how GLI2, a transcription factor activated by this pathway, acts as an oncogene. We show that GLI2 is a pleiotropic oncogene. The overexpression induces genomic instability and blocks differentiation, likely mediated in part by enhanced expression of the stem cell gene SOX2. GLI2 also induces transforming growth factor (TGF) B1-dependent transdifferentiation of foreskin and tongue, but not gingival. broblasts into myofibroblasts, creating an environment permissive for invasion by keratinocytes, which are in various stages of differentiation having downregulated GLI2. Thus, upregulated GLI2 expression is sufficient to induce a number of the acquired characteristics of tumor cells; however, the stroma, in a tissue-specific manner, determines whether certain GLI2 oncogenic traits are expressed.	[Albertson, D. G.] Univ Calif San Francisco, Canc Res Inst, Ctr Comprehens Canc, San Francisco, CA 94143 USA; [Snijders, A. M.; Huey, B.; Roy, R.; Jordan, R. C. K.; Schmidt, B. L.; Albertson, D. G.] Univ Calif San Francisco, Helen Diller Family Comprehens Canc Ctr, San Francisco, CA 94143 USA; [Huey, B.; Albertson, D. G.] Univ Calif San Francisco, Dept Lab Med, San Francisco, CA 94143 USA; [Connelly, S. T.; Jordan, R. C. K.] Univ Calif San Francisco, Dept Orofacial Sci, San Francisco, CA 94143 USA; [Schmidt, B. L.] Univ Calif San Francisco, Dept Oral & Maxillofacial Surg, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; UCSF Medical Center; UCSF Helen Diller Family Comprehensive Cancer Center; University of California System; University of California San Francisco; UCSF Medical Center; UCSF Helen Diller Family Comprehensive Cancer Center; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Albertson, DG (corresponding author), Univ Calif San Francisco, Canc Res Inst, Ctr Comprehens Canc, 2340 Sutter St,Box 0808, San Francisco, CA 94143 USA.	albertson@cc.ucsf.edu		Schmidt, Brian/0000-0002-2409-8984	NIH [CA118323]; California Tobacco-Related Disease Research [14FT-0011]; NCI-sponsored Tumor Microenvironment Training Program; Western Oral Research Consortium (NIH) [K12 DE14609]; NATIONAL CANCER INSTITUTE [R01CA118323] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [K12DE014609] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); California Tobacco-Related Disease Research; NCI-sponsored Tumor Microenvironment Training Program; Western Oral Research Consortium (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))	We thank Drs Gillian Hall and Richard Shaw, University of Liverpool for providing oral SCC 1300C2, Dr Fritz Aberger, University of Salzburg for providing the HaCaT Tet cells, HaCaT GLI2 cells and the 6xHis-GLI2DN pcDNA4/TO vector construct and Dr Rosemary Akhurst, UCSF Helen Diller Family Comprehensive Cancer Center (HDFCCC) and Dr J Yingling (Eli Lilly and Company, Indianapolis, IN) for providing the transforming growth factor beta receptor kinase inhibitor, LY2109761. The UCSF HDFCCC Microarray, Tissue, Immunohistochemistry/Molecular Pathology and Genome Analysis Shared Resources provided assistance. This work was supported by NIH Grant CA118323. AMS was the recipient of a postdoctoral fellowship from the California Tobacco-Related Disease Research Program (14FT-0011) and a trainee of the NCI-sponsored Tumor Microenvironment Training Program: Techniques in the Establishment and Manipulation of Organotypic Model Systems. BLS is an appointee of the Western Oral Research Consortium (NIH K12 DE14609).	Albertson DG, 2003, NAT GENET, V34, P369, DOI 10.1038/ng1215; Bartkova J, 2005, NATURE, V434, P864, DOI 10.1038/nature03482; BELL E, 1981, SCIENCE, V211, P1052, DOI 10.1126/science.7008197; Ben-Porath I, 2008, NAT GENET, V40, P499, DOI 10.1038/ng.127; Bigelow RLH, 2005, J INVEST DERMATOL, V124, P457, DOI 10.1111/j.0022-202X.2004.23590.x; BOUKAMP P, 1988, J CELL BIOL, V106, P761, DOI 10.1083/jcb.106.3.761; Burnworth B, 2006, ONCOGENE, V25, P4399, DOI 10.1038/sj.onc.1209474; Cerezo A, 2003, J INVEST DERMATOL, V121, P110, DOI 10.1046/j.1523-1747.2003.12304.x; Chang HY, 2002, P NATL ACAD SCI USA, V99, P12877, DOI 10.1073/pnas.162488599; Chen YP, 2008, J BIOL CHEM, V283, P17969, DOI 10.1074/jbc.M802917200; Clement V, 2007, CURR BIOL, V17, P165, DOI 10.1016/j.cub.2006.11.033; De Wever O, 2003, J PATHOL, V200, P429, DOI 10.1002/path.1398; Delehedde M, 2001, J INVEST DERMATOL, V116, P366, DOI 10.1046/j.1523-1747.2001.01260.x; Fridlyand J, 2006, BMC CANCER, V6, DOI 10.1186/1471-2407-6-96; Gorgoulis VG, 2005, NATURE, V434, P907, DOI 10.1038/nature03485; Grachtchouk V, 2003, EMBO J, V22, P2741, DOI 10.1093/emboj/cdg271; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hooper JE, 2005, NAT REV MOL CELL BIO, V6, P306, DOI 10.1038/nrm1622; Izzo JG, 1998, ONCOGENE, V17, P2313, DOI 10.1038/sj.onc.1202153; Kalluri R, 2006, NAT REV CANCER, V6, P392, DOI 10.1038/nrc1877; Kellermann MG, 2008, ORAL ONCOL, V44, P509, DOI 10.1016/j.oraloncology.2007.07.001; Kendall J, 2007, P NATL ACAD SCI USA, V104, P16663, DOI 10.1073/pnas.0708286104; Kwei KA, 2008, ONCOGENE, V27, P3635, DOI 10.1038/sj.onc.1211012; Lacher MD, 2006, CANCER RES, V66, P1648, DOI 10.1158/0008-5472.CAN-05-2328; Lauth M, 2007, CELL CYCLE, V6, P2458, DOI 10.4161/cc.6.20.4808; Lauth M, 2007, P NATL ACAD SCI USA, V104, P8455, DOI 10.1073/pnas.0609699104; Lewis MP, 2004, BRIT J CANCER, V90, P822, DOI 10.1038/sj.bjc.6601611; Marsh D, 2008, CANCER RES, V68, P3295, DOI 10.1158/0008-5472.CAN-08-0174; MIELE M, 1989, MUTAT RES, V219, P171, DOI 10.1016/0921-8734(89)90012-X; Mueller MM, 2004, NAT REV CANCER, V4, P839, DOI 10.1038/nrc1477; Murnane JP, 2004, BIOESSAYS, V26, P1164, DOI 10.1002/bies.20125; Neill GW, 2008, CARCINOGENESIS, V29, P738, DOI 10.1093/carcin/bgn037; Nelsen CJ, 2005, J BIOL CHEM, V280, P768, DOI 10.1074/jbc.M407105200; Okubo T, 2006, GENE DEV, V20, P2654, DOI 10.1101/gad.1457106; Paulson TG, 1998, MOL CELL BIOL, V18, P3089, DOI 10.1128/MCB.18.5.3089; Que J, 2007, DEVELOPMENT, V134, P2521, DOI 10.1242/dev.003855; Regl G, 2004, ONCOGENE, V23, P1263, DOI 10.1038/sj.onc.1207240; Riobo NA, 2006, CELL CYCLE, V5, P1612, DOI 10.4161/cc.5.15.3130; Roh HJ, 2000, CANCER RES, V60, P6496; Roth JR, 2004, RES MICROBIOL, V155, P342, DOI 10.1016/j.resmic.2004.01.016; Schmidt BL, 2004, J ORAL MAXIL SURG, V62, P1055, DOI 10.1016/j.joms.2004.03.010; Schoop VM, 1999, J INVEST DERMATOL, V112, P343, DOI 10.1046/j.1523-1747.1999.00524.x; Shimizu N, 2005, EXP CELL RES, V302, P233, DOI 10.1016/j.yexcr.2004.09.001; Snijders AM, 2003, ONCOGENE, V22, P4370, DOI 10.1038/sj.onc.1206482; Snijders AM, 2005, ONCOGENE, V24, P4232, DOI 10.1038/sj.onc.1208601; Snijders AM, 2008, GENE CHROMOSOME CANC, V47, P71, DOI 10.1002/gcc.20509; Svensson S, 2003, CANCER RES, V63, P1737; Tuxhorn JA, 2001, J UROLOGY, V166, P2472, DOI 10.1016/S0022-5347(05)65620-0; Verona EV, 2007, CANCER RES, V67, P5737, DOI 10.1158/0008-5472.CAN-07-0444; Weir BA, 2007, NATURE, V450, P893, DOI 10.1038/nature06358; Zeisberg EM, 2007, CANCER RES, V67, P10123, DOI 10.1158/0008-5472.CAN-07-3127; Zhou P, 1996, CANCER RES, V56, P36	52	17	17	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 5	2009	28	5					625	637		10.1038/onc.2008.421	http://dx.doi.org/10.1038/onc.2008.421			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	403IN	19015636	Green Accepted, Green Submitted			2022-12-28	WOS:000263076400001
J	Tanuma, N; Nomura, M; Ikeda, M; Kasugai, I; Tsubaki, Y; Takagaki, K; Kawamura, T; Yamashita, Y; Sato, I; Sato, M; Katakura, R; Kikuchi, K; Shima, H				Tanuma, N.; Nomura, M.; Ikeda, M.; Kasugai, I.; Tsubaki, Y.; Takagaki, K.; Kawamura, T.; Yamashita, Y.; Sato, I.; Sato, M.; Katakura, R.; Kikuchi, K.; Shima, H.			Protein phosphatase Dusp26 associates with KIF3 motor and promotes N-cadherin-mediated cell-cell adhesion	ONCOGENE			English	Article						DUSP; cadherin; KIF3	LEFT-RIGHT ASYMMETRY; DUAL-SPECIFICITY PHOSPHATASES; TYROSINE PHOSPHATASES; KINESIN SUPERFAMILY; KINASE; COMPLEX; FAMILY	Recent studies have demonstrated essential functions for KIF3, a microtubule-directed protein motor, in subcellular transport of several cancer-relatedproteins, including the beta-catenin-cadherin(s) complex. In this study, we report identification of the protein-phosphatase Dusp26 as a novel regulator of the KIF3 motor. Here we undertake yeast two-hybridscreening and identify Kif3a, a motor subunit of the KIF3 heterotrimeric complex, as a novel Dusp26-binding protein. Co-immunoprecipitation and colocalization experiments revealed that Dusp26 associates not only with Kif3a, but also with Kap3, another subunit of the KIF3 complex. Dephosphorylation experiments in vitro and analysis using mutant forms of Dusp26 in intact cells strongly suggested that Dusp26 is recruited to the KIF3 motor mainly by interaction with Kif3a, and thereby dephosphorylates Kap3. Forced expression of Dusp26, but not its catalytically inactive mutant, promotedd istribution of beta-catenin/N-cadherin, an established KIF3 cargo, to cell-cell junction sites, resulting in increased cell-cell adhesiveness. We also showed that Dusp26 mRNA expression was downregulated in human glioblastoma samples. These results suggest previously unidentified functions of Dusp26 in intracellular transport and cell-cell adhesion. Downregulation of Dusp26 may contribute to malignant phenotypes of glioma.	[Tanuma, N.; Nomura, M.; Kasugai, I.; Shima, H.] Miyagi Canc Ctr, Res Inst, Div Canc Chemotherapy, Natori, Miyagi 9811293, Japan; [Tanuma, N.; Ikeda, M.; Tsubaki, Y.; Takagaki, K.; Kikuchi, K.] Hokkaido Univ, Inst Med Genet, Div Biochem Oncol & Immunol, Sapporo, Hokkaido, Japan; [Kawamura, T.] Univ Tokyo, RCAST, Lab Syst Biol & Med, Tokyo, Japan; [Yamashita, Y.; Katakura, R.] Miyagi Canc Ctr, Div Neurosurg, Natori, Miyagi 9811293, Japan; [Sato, I.] Miyagi Canc Ctr, Res Inst, Sect Clin Res, Natori, Miyagi 9811293, Japan; [Sato, M.] Miyagi Canc Ctr, Div Thorac Surg, Natori, Miyagi 9811293, Japan	Miyagi Cancer Center; Hokkaido University; University of Tokyo; Miyagi Cancer Center; Miyagi Cancer Center; Miyagi Cancer Center	Shima, H (corresponding author), Miyagi Canc Ctr, Res Inst, Div Canc Chemotherapy, 47-1 Nodayama, Natori, Miyagi 9811293, Japan.	shima-hi632@pref.miyagi.jp		Takagaki, Kentaro/0000-0001-8085-6201	Japan Society for the Promotion of Science of Japan	Japan Society for the Promotion of Science of Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science)	We acknowledge Dr Konomi Kamada (Hokkaido University, Japan) for kindly providing the plasmid pBTM116-HA, the L40 yeast strain and E. coli HB101, and Dr Toshio Kitamura (University of Tokyo, Japan) for the pMX-puro plasmid and PLAT-E cells. Thanks are also due to E Yoshida for secretarial assistance. This work was supported in part by Grants-in-Aid for Scientific Research (B) and Grants-in-Aid for Scientific Research (C) provided by the Japan Society for the Promotion of Science of Japan.	Alonso A, 2004, CELL, V117, P699, DOI 10.1016/j.cell.2004.05.018; Camps M, 2000, FASEB J, V14, P6, DOI 10.1096/fasebj.14.1.6; Corbit KC, 2008, NAT CELL BIOL, V10, P70, DOI 10.1038/ncb1670; Guillaud L, 2008, NAT CELL BIOL, V10, P19, DOI 10.1038/ncb1665; Haraguchi K, 2006, J BIOL CHEM, V281, P4094, DOI 10.1074/jbc.M507028200; Hirokawa N, 2000, TRAFFIC, V1, P29, DOI 10.1034/j.1600-0854.2000.010105.x; Hirokawa N, 2006, CELL, V125, P33, DOI 10.1016/j.cell.2006.03.002; Hirokawa N, 2000, NEWS PHYSIOL SCI, V15, P56; Hu YZ, 2006, MOL CELL BIOL, V26, P3282, DOI 10.1128/MCB.26.8.3282-3294.2006; Jimbo T, 2002, NAT CELL BIOL, V4, P323, DOI 10.1038/ncb779; Karcher RL, 2001, SCIENCE, V293, P1317, DOI 10.1126/science.1061086; Kinoshita E, 2006, MOL CELL PROTEOMICS, V5, P749, DOI 10.1074/mcp.T500024-MCP200; Morita S, 2000, GENE THER, V7, P1063, DOI 10.1038/sj.gt.3301206; Nishimura T, 2004, NAT CELL BIOL, V6, P328, DOI 10.1038/ncb1118; OZAWA M, 1990, P NATL ACAD SCI USA, V87, P4246, DOI 10.1073/pnas.87.11.4246; Pulido R, 2008, FEBS J, V275, P848, DOI 10.1111/j.1742-4658.2008.06250.x; Takagaki K, 2007, MOL CELL BIOCHEM, V296, P177, DOI 10.1007/s11010-006-9313-5; Takeda S, 1999, J CELL BIOL, V145, P825, DOI 10.1083/jcb.145.4.825; Teng JL, 2005, NAT CELL BIOL, V7, P474, DOI 10.1038/ncb1249; Vasudevan SA, 2005, BIOCHEM BIOPH RES CO, V330, P511, DOI 10.1016/j.bbrc.2005.03.028; Wang JY, 2006, J NEUROCHEM, V98, P89, DOI 10.1111/j.1471-4159.2006.03852.x; Yu W, 2007, ONCOGENE, V26, P1178, DOI 10.1038/sj.onc.1209899	22	40	41	2	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 5	2009	28	5					752	761		10.1038/onc.2008.431	http://dx.doi.org/10.1038/onc.2008.431			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	403IN	19043453				2022-12-28	WOS:000263076400012
J	Lee, JY; Kang, MB; Jang, SH; Qian, T; Kim, HJ; Kim, CH; Kim, Y; Kong, G				Lee, J-Y; Kang, M-B; Jang, S-H; Qian, T.; Kim, H-J; Kim, C-H; Kim, Y.; Kong, G.			Id-1 activates Akt-mediated Wnt signaling and p27(Kip1) phosphorylation through PTEN inhibition	ONCOGENE			English	Article						Id-1; PTEN; p53; breast cancer	CELL-CYCLE PROGRESSION; BETA-CATENIN; EXPRESSION; P53; TRANSCRIPTION; PATHWAY	Inhibitor of differentiation-1 (Id-1) has been accepted as a putative oncogene to promote oncogenic processes through inactivation of tumor suppressors and activation of growth promoting pathways. Here, we show that Id-1 activates the Akt pathway by inhibition of phosphatase and tensin homologue deleted on chromosome 10 (PTEN) transcription through downregulation of p53. Id-1 negatively regulated both p53 and PTEN at the transcriptional level. In promoter assay with serial deletion and chromatin immunoprecipitation assay, the binding of p53 to the PTEN promoter was reduced by Id-1, suggesting that Id-1 regulates PTEN transcription through its p53 modulation. This led to Akt phosphorylation at Ser473 and the activation of the Akt-mediated canonical Wnt signaling pathway. The glycogen synthase kinase-3 beta phosphorylation at Ser9, stabilization and nuclear localization of beta-catenin, T-cell factor (TCF)/lymphoid enhancer factor transactivation activity and cyclin D1 expression were enhanced by Id-1. On the other hand, Akt-mediated p27(Kip1) phosphorylation at Thr157 and its cytosolic localization were also increased in Id-1 overexpressing MCF7 cells. In conclusion, our results disclose Id-1 as a novel PTEN inhibitor that could activate the Akt pathway and its downstream effectors, the Wnt/TCF pathway and p27(Kip1) phosphorylation and suggest that the oncogenic function of Id-1 may be partly attributed to its PTEN inhibition in human breast carcinogenesis.	[Lee, J-Y; Kang, M-B; Jang, S-H; Qian, T.; Kim, H-J; Kong, G.] Hanyang Univ, Dept Pathol, Coll Med, Seoul 133791, South Korea; [Kim, C-H] Sungkyunkwan Univ, Dept Biol Sci, Kyonggi Do, South Korea; [Kim, Y.] Hanyang Univ, Dept Biochem, Coll Med, Seoul 133791, South Korea	Hanyang University; Sungkyunkwan University (SKKU); Hanyang University	Kong, G (corresponding author), Hanyang Univ, Dept Pathol, Coll Med, 17 Haengdang Dong, Seoul 133791, South Korea.	gkong@hanyang.ac.kr			Korean Government (MOEHRD) [KRF-2007-314-E00041]	Korean Government (MOEHRD)(Ministry of Education & Human Resources Development (MOEHRD), Republic of KoreaKorean Government)	This work was supported by a Korea Research Foundation Grant (KRF-2007-314-E00041) funded by the Korean Government (MOEHRD, Basic Research Promotion Fund).	BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; Blanco-Aparicio C, 2007, CARCINOGENESIS, V28, P1379, DOI 10.1093/carcin/bgm052; Chung TW, 2003, CANCER RES, V63, P3453; Cully M, 2006, NAT REV CANCER, V6, P184, DOI 10.1038/nrc1819; Jang KS, 2006, CANCER LETT, V244, P203, DOI 10.1016/j.canlet.2005.12.016; Kim H, 2008, BREAST CANCER RES TR, V112, P287, DOI 10.1007/s10549-007-9871-6; Kim HJ, 2007, MOL CANCER RES, V5, P321, DOI 10.1158/1541-7786.MCR-06-0218; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; Li B, 2007, CARCINOGENESIS, V28, P2313, DOI 10.1093/carcin/bgm152; Ling MT, 2006, DIFFERENTIATION, V74, P481, DOI 10.1111/j.1432-0436.2006.00083.x; Mayo LD, 2002, J BIOL CHEM, V277, P5484, DOI 10.1074/jbc.M108302200; Nelson WJ, 2004, SCIENCE, V303, P1483, DOI 10.1126/science.1094291; Shin I, 2002, NAT MED, V8, P1145, DOI 10.1038/nm759; Stambolic V, 2001, MOL CELL, V8, P317, DOI 10.1016/S1097-2765(01)00323-9; Swarbrick A, 2005, ONCOGENE, V24, P381, DOI 10.1038/sj.onc.1208188; van Noort M, 2002, J BIOL CHEM, V277, P17901, DOI 10.1074/jbc.M111635200; Vikhanskaya F, 2007, NUCLEIC ACIDS RES, V35, P2093, DOI 10.1093/nar/gkm099; Virolle T, 2001, NAT CELL BIOL, V3, P1124, DOI 10.1038/ncb1201-1124; Wang J, 2005, CANCER RES, V65, P6601, DOI 10.1158/0008-5472.CAN-04-4184; Yoo YG, 2003, J BIOL CHEM, V278, P39076, DOI 10.1074/jbc.M305101200; Yook JI, 2006, NAT CELL BIOL, V8, P1398, DOI 10.1038/ncb1508; Zhang XM, 2007, J BIOL CHEM, V282, P33284, DOI 10.1074/jbc.M705089200	22	50	58	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2009	28	6					824	831		10.1038/onc.2008.451	http://dx.doi.org/10.1038/onc.2008.451			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	406UI	19079342				2022-12-28	WOS:000263320000005
J	Pickl, M; Ries, CH				Pickl, M.; Ries, C. H.			Comparison of 3D and 2D tumor models reveals enhanced HER2 activation in 3D associated with an increased response to trastuzumab	ONCOGENE			English	Article						HER2 signaling; membrane raft; trastuzumab; 3D cell culture	HERCEPTIN-INDUCED INHIBITION; HUMAN-BREAST; LIPID RAFTS; IN-VIVO; CANCER; GROWTH; ERBB2; OVEREXPRESSION; KINASE; CELLS	Three-dimensional (3D) cell culture techniques are frequently used to model alterations in tissue architecture critically important for tumor development. Here, we report on a detailed comparison of a spheroid model of human epidermal growth factor receptor (HER2) over-expressing cancer cells with the traditional monolayer culture. In 2D culture, HER2 and HER3 form heterodimers, whereas in multicellular spheroids HER2 homodimers are formed. These homodimers localize in membrane rafts, resulting in enhanced inhibition of the proliferation of cancer cells with trastuzumab (Herceptin), a monoclonal antibody specifically targeting HER2. Within the tumor spheroids, HER2 homodimerization leads to enhanced activation of HER2 and results in a switch in signaling pathways from phosphoinositide 3-kinase (PI3K) to mitogen-activated protein kinase (MAPK). Diminished PI3K signaling is accompanied by the activation of the integrin beta 4/Rac1/PAK 2 signaling cascade. We propose that the described 3D culture system may better reflect some in vivo aspects of HER signaling and can be used to further improve the understanding of the molecular mechanisms of trastuzumab action. Furthermore, the described human multicellular tumor spheroids may allow identification of new targets for the treatment of HER2-positive breast cancer patients who currently benefit suboptimally from trastuzumab treatment.	[Pickl, M.; Ries, C. H.] Roche Diagnost GmbH, Pharmaceut Res Oncol, D-82377 Penzberg, Germany	Roche Holding	Ries, CH (corresponding author), Roche Diagnost GmbH, Pharmaceut Res Oncol, Nonnenwald 2, D-82377 Penzberg, Germany.	carola.ries@roche.com						Engelman JA, 1998, J BIOL CHEM, V273, P20448, DOI 10.1074/jbc.273.32.20448; Guo Hua, 2005, Zhonghua Bing Li Xue Za Zhi, V34, P140; Hudis CA, 2007, NEW ENGL J MED, V357, P39, DOI 10.1056/NEJMra043186; HUDZIAK RM, 1989, MOL CELL BIOL, V9, P1165, DOI 10.1128/MCB.9.3.1165; Jung JH, 2005, J BIOL CHEM, V280, P40025, DOI 10.1074/jbc.M509075200; Kwon T, 2000, J BIOL CHEM, V275, P423, DOI 10.1074/jbc.275.1.423; Lee GY, 2007, NAT METHODS, V4, P359, DOI 10.1038/NMETH1015; Longva KE, 2005, INT J CANCER, V116, P359, DOI 10.1002/ijc.21015; MILJAN EA, 2002, SCI STKE, pRE15; Mocanu MM, 2005, CANCER LETT, V227, P201, DOI 10.1016/j.canlet.2005.01.028; Nagy P, 2002, J CELL SCI, V115, P4251, DOI 10.1242/jcs.00118; Nahta R, 2006, CANCER LETT, V232, P123, DOI 10.1016/j.canlet.2005.01.041; Owens Marilyn A, 2004, Clin Breast Cancer, V5, P63, DOI 10.3816/CBC.2004.n.011; PETERSEN OW, 1992, P NATL ACAD SCI USA, V89, P9064, DOI 10.1073/pnas.89.19.9064; Pike LJ, 2006, J LIPID RES, V47, P1597, DOI 10.1194/jlr.E600002-JLR200; Razani B, 2001, BIOCHEM SOC T, V29, P494, DOI 10.1042/BST0290494; Ritter CA, 2007, CLIN CANCER RES, V13, P4909, DOI 10.1158/1078-0432.CCR-07-0701; Schoenwaelder SM, 1999, CURR OPIN CELL BIOL, V11, P274, DOI 10.1016/S0955-0674(99)80037-4; Shaw KRM, 2004, J MAMMARY GLAND BIOL, V9, P297, DOI 10.1007/s10911-004-1402-z; SHIN SI, 1975, P NATL ACAD SCI USA, V72, P4435, DOI 10.1073/pnas.72.11.4435; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; Sottocornola E, 2006, FEBS J, V273, P1821, DOI 10.1111/j.1742-4658.2006.05203.x; Sottocornola E, 2003, BBA-MOL CELL BIOL L, V1635, P55, DOI 10.1016/j.bbalip.2003.10.006; Timms JF, 2002, ONCOGENE, V21, P6573, DOI 10.1038/sj.onc.1205847; Wang SC, 2001, SEMIN ONCOL, V28, P115, DOI 10.1016/S0093-7754(01)90289-1; Weaver VM, 2002, CANCER CELL, V2, P205, DOI 10.1016/S1535-6108(02)00125-3; Wolff AC, 2007, J CLIN ONCOL, V25, P118, DOI 10.1200/JCO.2006.09.2775; Yakes FM, 2002, CANCER RES, V62, P4132; Yamada KM, 2007, CELL, V130, P601, DOI 10.1016/j.cell.2007.08.006; Yarden Y, 2001, EUR J CANCER, V37, pS3; Yaziji H, 2004, JAMA-J AM MED ASSOC, V291, P1972, DOI 10.1001/jama.291.16.1972; Zhou XY, 2004, CLIN CANCER RES, V10, P6779, DOI 10.1158/1078-0432.CCR-04-0112	32	293	296	0	22	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 22	2009	28	3					461	468		10.1038/onc.2008.394	http://dx.doi.org/10.1038/onc.2008.394			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	395UZ	18978815	Bronze			2022-12-28	WOS:000262550300013
J	Russell, MR; Jamieson, WL; Dolloff, NG; Fatatis, A				Russell, M. R.; Jamieson, W. L.; Dolloff, N. G.; Fatatis, A.			The alpha-receptor for platelet-derived growth factor as a target for antibody-mediated inhibition of skeletal metastases from prostate cancer cells	ONCOGENE			English	Article						skeletal metastasis; prostate adenocarcinoma; PDGFR alpha	PHASE-II TRIAL; IMATINIB MESYLATE; BONE-MARROW; BIOCHEMICAL RELAPSE; MOUSE MODEL; SURVIVAL; PROGRESSION; MECHANISMS; EXPRESSION; PATHWAY	Bone resorption by osteoclasts is thought to promote the proliferation of prostate cancer cells disseminated to the skeleton (Mundy, 2002). Using a mouse model of experimental metastasis, we found that although late-stage metastatic tumors were indeed surrounded by osteoclasts, these cells were spatially unrelated to the small foci of cancer cells in early-stage metastases. This is the first evidence that survival and growth of disseminated prostate cancer cells immediately after their extravasation may not depend on osteoclast involvement. Interestingly, prostate cancer cells expressing the alpha-receptor for platelet-derived growth factor (PDGFR alpha) progress during early-stages of skeletal dissemination, whereas cells expressing lower levels or lacking this receptor fail to survive after extravasation in the bone marrow. However, non-metastatic cells acquire bone-metastatic potential upon ectopic overexpression of PDGFR alpha. Finally, functional blockade of human PDGFR alpha on prostate cancer cells utilizing a novel humanized monoclonal antibody-soon to undergo phase-II clinical trials-significantly impairs the establishment of early skeletal metastases. In conclusion, our results strongly implicate PDGFR alpha in prostate cancer bone tropism through its promotion of survival and progression of early-metastatic foci, providing ground for therapeutic strategies aimed at preventing or containing the initial progression of skeletal metastases in patients affected by prostate adenocarcinoma.	[Russell, M. R.; Jamieson, W. L.; Dolloff, N. G.; Fatatis, A.] Drexel Univ, Coll Med, Dept Physiol & Pharmacol, Philadelphia, PA 19102 USA; [Fatatis, A.] Drexel Univ, Coll Med, Dept Pathol & Lab Med, Philadelphia, PA 19102 USA	Drexel University; Drexel University	Fatatis, A (corresponding author), Drexel Univ, Coll Med, Dept Physiol & Pharmacol, 245 N 15th St,New Coll Bldg MS488, Philadelphia, PA 19102 USA.	afatatis@drexelmed.edu			NIH [GM067892]; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM067892] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	The cDNA for human PDGFR alpha was a kind gift of Dr Carl-Henrik Heldin (Ludwig Institute for Cancer Research, Uppsala, Sweden). We thank Dr Olimpia Meucci (Department of Pharmacology and Physiology) for critically reading the manuscript and helpful discussion, Dr Mark Stearns (Department of Pathology and Laboratory Medicine) for helpful discussion, Dr Gregg Johannes (Department of Pathology and Laboratory Medicine) for help with the PDGFR alpha-expressing vector, Mr Michael Amatangelo for his contribution to the immuno-detection of PDGFR alpha in human tissues and Dr Nick Loizos (ImClone Systems Inc., New York, NY, USA) for kindly providing the IMC-3G3 antibody. This study was supported in part by the NIH Grant GM067892 to AF.	Andrae J, 2008, GENE DEV, V22, P1276, DOI 10.1101/gad.1653708; Bajaj GK, 2007, UROLOGY, V69, P526, DOI 10.1016/j.urology.2006.12.006; Betsholtz C, 2004, CYTOKINE GROWTH F R, V15, P215, DOI 10.1016/j.cytogfr.2004.03.005; Canon JR, 2008, CLIN EXP METASTAS, V25, P119, DOI 10.1007/s10585-007-9127-1; Carnero A, 2008, CURR CANCER DRUG TAR, V8, P187, DOI 10.2174/156800908784293659; Chambers AF, 2002, NAT REV CANCER, V2, P563, DOI 10.1038/nrc865; Dolloff NG, 2007, CANCER RES, V67, P555, DOI 10.1158/0008-5472.CAN-06-2593; Dolloff NG, 2005, ONCOGENE, V24, P6848, DOI 10.1038/sj.onc.1208815; Fidler IJ, 2003, NAT REV CANCER, V3, P453, DOI 10.1038/nrc1098; Fritz V, 2007, BONE, V40, P1032, DOI 10.1016/j.bone.2006.11.026; Gupta GP, 2007, NATURE, V446, P765, DOI 10.1038/nature05760; Heldin CH, 1999, PHYSIOL REV, V79, P1283, DOI 10.1152/physrev.1999.79.4.1283; Jamieson WL, 2008, CANCER RES, V68, P1715, DOI 10.1158/0008-5472.CAN-07-1315; Kingsley LA, 2007, MOL CANCER THER, V6, P2609, DOI 10.1158/1535-7163.MCT-07-0234; Lee YP, 2002, CANCER RES, V62, P5564; Lin AM, 2006, BJU INT, V98, P763, DOI 10.1111/j.1464-410X.2006.06396.x; Loizos N, 2005, MOL CANCER THER, V4, P369; Mathew P, 2004, J CLIN ONCOL, V22, P3323, DOI 10.1200/JCO.2004.10.116; Mathew P, 2007, CLIN CANCER RES, V13, P5816, DOI 10.1158/1078-0432.CCR-07-1269; Mundy GR, 2002, NAT REV CANCER, V2, P584, DOI 10.1038/nrc867; Nemeth JA, 1999, CANCER RES, V59, P1987; Paget S, 1989, LANCET, V8, P98, DOI [DOI 10.1016/S0140-6736(00)49915-0, 10.1016/S0140-6736(00)49915-0]; Rao K, 2005, PROSTATE, V62, P115, DOI 10.1002/pros.20130; Roodman GD, 2004, NEW ENGL J MED, V350, P1655, DOI 10.1056/NEJMra030831; ROSS RW, 2006, CANC MED, P1431; Schneider A, 2005, ENDOCRINOLOGY, V146, P1727, DOI 10.1210/en.2004-1211; Shulby SA, 2004, CANCER RES, V64, P4693, DOI 10.1158/0008-5472.CAN-03-3437; Thorarinsdottir HK, 2008, CLIN CANCER RES, V14, P3386, DOI 10.1158/1078-0432.CCR-07-1616; van der Pluijm G, 2005, CANCER RES, V65, P7682, DOI 10.1158/0008-5472.CAN-04-4188; Vantyghem SA, 2005, CLIN EXP METASTAS, V22, P351, DOI 10.1007/s10585-005-0745-1; WANG M, 1991, DIFFERENTIATION, V48, P115, DOI 10.1111/j.1432-0436.1991.tb00250.x; Wetterwald A, 2002, AM J PATHOL, V160, P1143, DOI 10.1016/S0002-9440(10)64934-6; YARDEN Y, 1986, NATURE, V323, P226, DOI 10.1038/323226a0	33	33	38	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 22	2009	28	3					412	421		10.1038/onc.2008.390	http://dx.doi.org/10.1038/onc.2008.390			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	395UZ	18850002				2022-12-28	WOS:000262550300009
J	Ivanova, IA; Nakrieko, KA; Dagnino, L				Ivanova, I. A.; Nakrieko, K-A; Dagnino, L.			Phosphorylation by p38 MAP kinase is required for E2F1 degradation and keratinocyte differentiation	ONCOGENE			English	Article						keratinocyte; E2F; differentiation; p38 mitogen-activated kinase	TRANSCRIPTION FACTORS; NUCLEAR IMPORT; SKIN; EXPRESSION; EXPORT; DYNAMICS; REPAIR	The transcription factor E2F1 plays key roles in skin homeostasis, and is essential for normal keratinocyte proliferation and epidermal regeneration after injury. We have previously established that, in differentiating keratinocytes, E2F1 activity is controlled by nuclear export and subsequent degradation. These events are triggered by differentiation-induced stimulation of protein kinase C and p38 mitogen-activated protein kinase ( MAPK). However, the mechanisms that induce E2F1 export from the nucleus and the role of p38 MAPK in this process are poorly understood. We now describe a novel regulatory pathway for E2F1, which involves phosphorylation by p38. We demonstrate that E2F1 forms complexes with active p38 through regions that exclude the N-terminus of this transcription factor, and that p38 activity is a major contributor to the phosphorylation status of E2F1 in keratinocytes. Using in vitro kinase assays, we identified Ser403 and Thr433 as the residues phosphorylated by p38. The biological significance of these observations is underscored by the inability of E2F1 mutants lacking one or both of these residues to be exported from the nucleus and degraded when keratinocytes receive differentiation stimuli, which results in impaired keratinocyte maturation.	[Ivanova, I. A.; Nakrieko, K-A; Dagnino, L.] Univ Western Ontario, Dept Physiol & Pharmacol, London, ON, Canada; [Dagnino, L.] Univ Western Ontario, Regulatory Biol & Funct Genom Res Grp, Siebens Drake Res Inst, London, ON, Canada; [Ivanova, I. A.] Univ Western Ontario, Dept Paediat, Child Hlth Res Inst, London, ON, Canada; [Ivanova, I. A.] Univ Western Ontario, Lawson Hlth Res Inst, London, ON, Canada	Western University (University of Western Ontario); Western University (University of Western Ontario); Western University (University of Western Ontario); Western University (University of Western Ontario)	Dagnino, L (corresponding author), Univ Western Ontario, Dept Physiol & Pharmacol, London, ON, Canada.	ldagnino@uwo.ca		Dagnino, Lina/0000-0003-1483-5159				Apostolova MD, 2002, J BIOL CHEM, V277, P34471, DOI 10.1074/jbc.M205827200; Balasubramanian S, 1999, INT J ONCOL, V15, P387; Berton TR, 2005, ONCOGENE, V24, P2449, DOI 10.1038/sj.onc.1208462; D'Souza SJA, 2002, J BIOL CHEM, V277, P10626, DOI 10.1074/jbc.M111956200; D'Souza SJA, 2001, J BIOL CHEM, V276, P23531, DOI 10.1074/jbc.M100780200; Dagnino L, 1997, CELL GROWTH DIFFER, V8, P553; Eckert RL, 2004, J INVEST DERMATOL, V123, P13, DOI 10.1111/j.0022-202X.2004.22723.x; FAGAN R, 1994, CELL, V78, P799, DOI 10.1016/S0092-8674(94)90522-3; Fuchs E, 2002, NAT REV GENET, V3, P199, DOI 10.1038/nrg758; Fuchs E, 1994, Princess Takamatsu Symp, V24, P290; Fuchs E, 2007, NATURE, V445, P834, DOI 10.1038/nature05659; Garcia-Alvarez G, 2007, BBA-MOL CELL RES, V1773, P375, DOI 10.1016/j.bbamcr.2006.09.015; Ivanova IA, 2007, ONCOGENE, V26, P1147, DOI 10.1038/sj.onc.1209894; Ivanova IA, 2006, ONCOGENE, V25, P430, DOI 10.1038/sj.onc.1208999; Ivanova IA, 2007, CELL CYCLE, V6, P2186, DOI 10.4161/cc.6.17.4650; McClellan KA, 2007, CELL CYCLE, V6, P2917, DOI 10.4161/cc.6.23.4997; Pierce AM, 1998, ONCOGENE, V16, P1267, DOI 10.1038/sj.onc.1201666; Rampalli S, 2007, NAT STRUCT MOL BIOL, V14, P1150, DOI 10.1038/nsmb1316; Vaezi A, 2002, DEV CELL, V3, P367, DOI 10.1016/S1534-5807(02)00259-9; Vandel L, 1999, EMBO J, V18, P4280, DOI 10.1093/emboj/18.15.4280; Vasioukhin V, 2001, CURR OPIN CELL BIOL, V13, P76, DOI 10.1016/S0955-0674(00)00177-0; Zhang XH, 2002, J BIOL CHEM, V277, P45276, DOI 10.1074/jbc.M208063200	22	24	24	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 8	2009	28	1					52	62		10.1038/onc.2008.354	http://dx.doi.org/10.1038/onc.2008.354			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	392HP	18794805				2022-12-28	WOS:000262294100006
J	Baba, T; Convery, PA; Matsumura, N; Whitaker, RS; Kondoh, E; Perry, T; Huang, Z; Bentley, RC; Mori, S; Fujii, S; Marks, JR; Berchuck, A; Murphy, SK				Baba, T.; Convery, P. A.; Matsumura, N.; Whitaker, R. S.; Kondoh, E.; Perry, T.; Huang, Z.; Bentley, R. C.; Mori, S.; Fujii, S.; Marks, J. R.; Berchuck, A.; Murphy, S. K.			Epigenetic regulation of CD133 and tumorigenicity of CD133+ovarian cancer cells	ONCOGENE			English	Article						CD133; ovarian cancer; cancer-initiating cell; DNA methylation; xenograft	STEM-CELLS; OVARIAN-CANCER; HEMATOPOIETIC STEM; INITIATING CELLS; GENE-EXPRESSION; IDENTIFICATION; GLIOBLASTOMA; CARCINOMA; TUMORS; AC133	The cancer stem cell hypothesis posits that malignant growth arises from a rare population of progenitor cells within a tumor that provide it with unlimited regenerative capacity. Such cells also possess increased resistance to chemotherapeutic agents. Resurgence of chemoresistant disease after primary therapy typifies epithelial ovarian cancer and may be attributable to residual cancer stem cells, or cancer-initiating cells, that survive initial treatment. As the cell surface marker CD133 identifies cancer-initiating cells in a number of other malignancies, we sought to determine the potential role of CD133+ cells in epithelial ovarian cancer. We detected CD133 on ovarian cancer cell lines, in primary cancers and on purified epithelial cells from ascitic fluid of ovarian cancer patients. We found CD133+ ovarian cancer cells generate both CD133+ and CD133- daughter cells, whereas CD133- cells divide symmetrically. CD133+ cells exhibit enhanced resistance to platinum-based therapy, drugs commonly used as first-line agents for the treatment of ovarian cancer. Sorted CD133+ ovarian cancer cells also form more aggressive tumor xenografts at a lower inoculum than their CD133- progeny. Epigenetic changes may be integral to the behavior of cancer progenitor cells and their progeny. In this regard, we found that CD133 transcription is controlled by both histone modi. cations and promoter methylation. Sorted CD133- ovarian cancer cells treated with DNA methyltransferase and histone deacetylase inhibitors show a synergistic increase in cell surface CD133 expression. Moreover, DNA methylation at the ovarian tissue active P2 promoter is inversely correlated with CD133 transcription. We also found that promoter methylation increases in CD133- progeny of CD133+ cells, with CD133+ cells retaining a less methylated or unmethylated state. Taken together, our results show that CD133 expression in ovarian cancer is directly regulated by epigenetic modi. cations and support the idea that CD133 demarcates an ovarian cancer-initiating cell population. The activity of these cells may be epigenetically detected and such cells might serve as pertinent chemotherapeutic targets for reducing disease recurrence.	[Baba, T.; Convery, P. A.; Matsumura, N.; Whitaker, R. S.; Kondoh, E.; Perry, T.; Huang, Z.; Berchuck, A.; Murphy, S. K.] Duke Univ, Med Ctr, Dept Obstet & Gynecol, Div Gynecol Oncol, Durham, NC 27708 USA; [Baba, T.; Matsumura, N.; Kondoh, E.; Fujii, S.] Kyoto Univ, Grad Sch Med, Dept Gynecol & Obstet, Kyoto, Japan; [Bentley, R. C.; Murphy, S. K.] Duke Univ, Dept Pathol, Durham, NC 27706 USA; [Mori, S.; Marks, J. R.; Berchuck, A.; Murphy, S. K.] Duke Inst Genome Sci & Policy, Durham, NC USA; [Marks, J. R.] Duke Univ, Dept Surg, Durham, NC USA	Duke University; Kyoto University; Duke University; Duke University; Duke University	Murphy, SK (corresponding author), Duke Univ, Med Ctr, Dept Obstet & Gynecol, Div Gynecol Oncol, 2185 F CIEMAS,Box 91012,101 Sci Dr, Durham, NC 27708 USA.	murph035@mc.duke.edu	Murphy, Susan/R-3903-2019	Murphy, Susan/0000-0001-8298-7272; BABA, Tsukasa/0000-0003-0066-3747; Matsumura, Noriomi/0000-0002-4512-7975; Kondoh, Eiji/0000-0002-8379-3143	Kislak-Fields Family Fund; Duke Comprehensive Cancer Center; Gail Parkins Memorial Ovarian Awareness Fund	Kislak-Fields Family Fund; Duke Comprehensive Cancer Center; Gail Parkins Memorial Ovarian Awareness Fund	We thank Drs John Lancaster, Jeffrey Boyd, Thomas Hamilton, Gordon Mills and Jean Hurteau for providing many of the cell lines used in these studies; Dr William E Grizzle for preparing tissue microarrays; Mike Cook for help with flow cytometry and Nancy Glover and Julie Fuller for the preparation of slides used for immunohistochemistry. This study was supported by the Kislak-Fields Family Fund, the Duke Comprehensive Cancer Center, and the Gail Parkins Memorial Ovarian Awareness Fund.	Balch C, 2007, BIOESSAYS, V29, P842, DOI 10.1002/bies.20619; Bapat SA, 2005, CANCER RES, V65, P3025, DOI 10.1158/0008-5472.CAN-04-3931; Barrett T, 2007, NUCLEIC ACIDS RES, V35, pD760, DOI 10.1093/nar/gkl887; Beier D, 2007, CANCER RES, V67, P4010, DOI 10.1158/0008-5472.CAN-06-4180; Berchuck A, 2005, CLIN CANCER RES, V11, P3686, DOI 10.1158/1078-0432.CCR-04-2398; Chang JT, 2006, BIOINFORMATICS, V22, P2926, DOI 10.1093/bioinformatics/btl483; Collins AT, 2005, CANCER RES, V65, P10946, DOI 10.1158/0008-5472.CAN-05-2018; Corbeil D, 2000, J BIOL CHEM, V275, P5512, DOI 10.1074/jbc.275.8.5512; FERRANDINA G, 2007, INT J GYNECOL CANCER, V14, P14; Frank NY, 2005, CANCER RES, V65, P4320, DOI 10.1158/0008-5472.CAN-04-3327; Gan Q, 2007, STEM CELLS, V25, P2, DOI 10.1634/stemcells.2006-0383; Huang ZQ, 2006, NUCLEIC ACIDS RES, V34, P555, DOI 10.1093/nar/gkj468; HURTEAU J, 1994, CANCER, V74, P93, DOI 10.1002/1097-0142(19940701)74:1<93::AID-CNCR2820740117>3.0.CO;2-P; JACOBS IJ, 1992, J NATL CANCER I, V84, P1793, DOI 10.1093/jnci/84.23.1793; Jones PA, 2007, CELL, V128, P683, DOI 10.1016/j.cell.2007.01.029; Lee A, 2005, NAT NEUROSCI, V8, P723, DOI 10.1038/nn1473; Lee J, 2006, CANCER CELL, V9, P391, DOI 10.1016/j.ccr.2006.03.030; Liu GT, 2006, MOL CANCER, V5, DOI 10.1186/1476-4598-5-67; Liu TX, 2007, NAT MED, V13, P78, DOI 10.1038/nm1512; Lobo NA, 2007, ANNU REV CELL DEV BI, V23, P675, DOI 10.1146/annurev.cellbio.22.010305.104154; Ma DQ, 2007, MOL PSYCHIATR, V12, P376, DOI 10.1038/sj.mp.4001927; Ma S, 2007, GASTROENTEROLOGY, V132, P2542, DOI 10.1053/j.gastro.2007.04.025; Ma Yanping, 2002, Zhonghua Nei Ke Za Zhi, V41, P798; Maitland NJ, 2008, J CLIN ONCOL, V26, P2862, DOI 10.1200/JCO.2007.15.1472; Miki J, 2007, CANCER RES, V67, P3153, DOI 10.1158/0008-5472.CAN-06-4429; Mizrak D, 2008, J PATHOL, V214, P3, DOI 10.1002/path.2283; MOK CH, 1992, CANCER RES, V52, P5119; Monzani E, 2007, EUR J CANCER, V43, P935, DOI 10.1016/j.ejca.2007.01.017; O'Brien CA, 2007, NATURE, V445, P106, DOI 10.1038/nature05372; Ohm JE, 2007, NAT GENET, V39, P237, DOI 10.1038/ng1972; Olempska M, 2007, HEPATOB PANCREAT DIS, V6, P92; Ricci-Vitiani L, 2007, NATURE, V445, P111, DOI 10.1038/nature05384; Ruau D, 2008, STEM CELLS, V31, P31; Shiras A, 2007, STEM CELLS, V25, P1478, DOI 10.1634/stemcells.2006-0585; Shmelkov SV, 2004, BLOOD, V103, P2055, DOI 10.1182/blood-2003-06-1881; Singh SK, 2004, NATURE, V432, P396, DOI 10.1038/nature03128; Szotek PP, 2006, P NATL ACAD SCI USA, V103, P11154, DOI 10.1073/pnas.0603672103; Widschwendter M, 2007, NAT GENET, V39, P157, DOI 10.1038/ng1941; Wright MH, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr1855; Yin AH, 1997, BLOOD, V90, P5002, DOI 10.1182/blood.V90.12.5002.5002_5002_5012; Yin SY, 2007, INT J CANCER, V120, P1444, DOI 10.1002/ijc.22476; Zhang S, 2008, CANCER RES, V68, P4311, DOI 10.1158/0008-5472.CAN-08-0364	42	337	365	2	40	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2009	28	2					209	218		10.1038/onc.2008.374	http://dx.doi.org/10.1038/onc.2008.374			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	395CY	18836486				2022-12-28	WOS:000262501100005
J	Wykosky, J; Palma, E; Gibo, DM; Ringler, S; Turner, CP; Debinski, W				Wykosky, J.; Palma, E.; Gibo, D. M.; Ringler, S.; Turner, C. P.; Debinski, W.			Soluble monomeric EphrinA1 is released from tumor cells and is a functional ligand for the EphA2 receptor	ONCOGENE			English	Article						ephrinA1; EphA2; glioblastoma; monomer; soluble	ENDOTHELIAL GROWTH-FACTOR; TYROSINE KINASE; IN-VITRO; PANCREATIC ADENOCARCINOMA; INDUCED ANGIOGENESIS; CRYSTAL-STRUCTURE; PROSTATE-CANCER; GLIOMA INVASION; ACTIVATION; EXPRESSION	The ephrinA1 ligand exerts antioncogenic effects in tumor cells through activation and downregulation of the EphA2 receptor and has been described as a membrane-anchored protein requiring clustering for function. However, while investigating the ephrinA1/EphA2 system in the pathobiology of glioblastoma multiforme (GBM), we uncovered that ephrinA1 is released from GBM and breast adenocarcinoma cells as a soluble, monomeric protein and is a functional form of the ligand in this state. Conditioned media containing a soluble monomer of ephrinA1 caused EphA2 internalization and downregulation, dramatic alteration of cell morphology and suppression of the Ras-MAPK pathway. Moreover, soluble monomeric ephrinA1 was functional in a physiological context, eliciting collapse of embryonic neuronal growth cones. We also found that ephrinA1 is cleaved from the plasma membrane of GBM cells, an event which involves the action of a metalloprotease. Thus, the ephrinA1 ligand can, indeed, function as a soluble monomer and may act in a paracrine manner on the EphA2 receptor without the need for juxtacrine interactions. These findings have important implications for further deciphering the function of these proteins in pathology and physiology, as well as for the design of ephrinA1-based EphA2-targeted antitumor therapeutics.	[Wykosky, J.; Palma, E.; Gibo, D. M.; Debinski, W.] Wake Forest Univ, Sch Med, Ctr Comprehens Canc, Dept Neurosurg,Brain Tumor Ctr Excellence, Winston Salem, NC 27157 USA; [Palma, E.; Debinski, W.] Wake Forest Univ, Sch Med, Ctr Comprehens Canc, Dept Radiat Oncol,Brain Tumor Ctr Excellence, Winston Salem, NC 27157 USA; [Ringler, S.; Turner, C. P.] Wake Forest Univ, Sch Med, Ctr Comprehens Canc, Dept Neurobiol & Anat,Brain Tumor Ctr Excellence, Winston Salem, NC 27157 USA; [Debinski, W.] Wake Forest Univ, Sch Med, Ctr Comprehens Canc, Dept Canc Biol,Brain Tumor Ctr Excellence, Winston Salem, NC 27157 USA	Wake Forest University; Wake Forest University; Wake Forest University; Wake Forest University	Debinski, W (corresponding author), Wake Forest Univ, Sch Med, Ctr Comprehens Canc, Dept Neurosurg,Brain Tumor Ctr Excellence, Med Ctr Blvd, Winston Salem, NC 27157 USA.	debinski@wfubmc.edu			NIH [1 F31 NSO5553301, 5 T32 CA113267-04]; NATIONAL CANCER INSTITUTE [T32CA113267] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [F31NS055533] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	This study was supported by the NIH Grant 1 F31 NSO5553301 to JW, NIH Grant 5 T32 CA113267-04 to Dr Mike Robbins (EP) and Brain Tumor Center of Excellence at Wake Forest University School of Medicine. We thank Dr Hannah Caldas and Ms Amanda Beauchamp for help with real-time PCR and Ms Carla Lema-Tome for preparing cortical neurons.	Aasheim HC, 2000, BLOOD, V95, P221, DOI 10.1182/blood.V95.1.221.001k01_221_230; BECKMANN MP, 1994, EMBO J, V13, P3757, DOI 10.1002/j.1460-2075.1994.tb06685.x; Brantley-Sieders DM, 2006, CANCER RES, V66, P10315, DOI 10.1158/0008-5472.CAN-06-1560; Carles-Kinch K, 2002, CANCER RES, V62, P2840; Chakraborti S, 2003, MOL CELL BIOCHEM, V253, P269, DOI 10.1023/A:1026028303196; Cheng N, 2002, MOL CANCER RES, V1, P2; Daniel TO, 1996, KIDNEY INT, V50, pS73; DAVIS S, 1994, SCIENCE, V266, P816, DOI 10.1126/science.7973638; DEBINSKI W, 1992, J CLIN INVEST, V90, P405, DOI 10.1172/JCI115875; DRESCHER U, 1995, CELL, V82, P359, DOI 10.1016/0092-8674(95)90425-5; Duxbury MS, 2004, BIOCHEM BIOPH RES CO, V320, P1096, DOI 10.1016/j.bbrc.2004.06.054; Duxbury MS, 2004, ONCOGENE, V23, P1448, DOI 10.1038/sj.onc.1207247; FERGUSON MAJ, 1988, ANNU REV BIOCHEM, V57, P285; Guo H, 2006, CANCER RES, V66, P7050, DOI 10.1158/0008-5472.CAN-06-0004; Hattori M, 2000, SCIENCE, V289, P1360, DOI 10.1126/science.289.5483.1360; Higashiyama S, 2005, BBA-PROTEINS PROTEOM, V1751, P110, DOI 10.1016/j.bbapap.2004.11.009; Himanen JP, 2004, NAT NEUROSCI, V7, P501, DOI 10.1038/nn1237; Himanen JP, 2001, NATURE, V414, P933, DOI 10.1038/414933a; Hoelzinger DB, 2007, J NATL CANCER I, V99, P1583, DOI 10.1093/jnci/djm187; HOLZMAN LB, 1990, MOL CELL BIOL, V10, P5830, DOI 10.1128/MCB.10.11.5830; Huovila APJ, 2005, TRENDS BIOCHEM SCI, V30, P413, DOI 10.1016/j.tibs.2005.05.006; Kinch MS, 2003, CLIN EXP METASTAS, V20, P59, DOI 10.1023/A:1022546620495; Knoll B, 2002, TRENDS NEUROSCI, V25, P145, DOI 10.1016/S0166-2236(00)02093-2; Koolpe M, 2002, J BIOL CHEM, V277, P46974, DOI 10.1074/jbc.M208495200; Kullander K, 2002, NAT REV MOL CELL BIO, V3, P475, DOI 10.1038/nrm856; Lee DC, 2003, ANN NY ACAD SCI, V995, P22, DOI 10.1111/j.1749-6632.2003.tb03207.x; Macrae M, 2005, CANCER CELL, V8, P111, DOI 10.1016/j.ccr.2005.07.005; Marquardt T, 2005, CELL, V121, P127, DOI 10.1016/j.cell.2005.01.020; McBride JL, 1998, MECH DEVELOP, V77, P201, DOI 10.1016/S0925-4773(98)00142-7; Meima L, 1997, EUR J NEUROSCI, V9, P177, DOI 10.1111/j.1460-9568.1997.tb01365.x; Miao H, 2001, NAT CELL BIOL, V3, P527, DOI 10.1038/35074604; Miao H, 2000, NAT CELL BIOL, V2, P62, DOI 10.1038/35000008; Nakamoto M, 1996, CELL, V86, P755, DOI 10.1016/S0092-8674(00)80150-6; Noblitt LW, 2004, CANCER GENE THER, V11, P757, DOI 10.1038/sj.cgt.7700761; Ogawa K, 2000, ONCOGENE, V19, P6043, DOI 10.1038/sj.onc.1204004; PANDEY A, 1995, SCIENCE, V268, P567, DOI 10.1126/science.7536959; Pasquale EB, 2005, NAT REV MOL CELL BIO, V6, P462, DOI 10.1038/nrm1662; Rashid T, 2005, NEURON, V47, P57, DOI 10.1016/j.neuron.2005.05.030; Sanderson MP, 2006, GROWTH FACTORS, V24, P121, DOI 10.1080/08977190600634373; SHAO HN, 1995, J BIOL CHEM, V270, P5636, DOI 10.1074/jbc.270.10.5636; Stein E, 1998, GENE DEV, V12, P667, DOI 10.1101/gad.12.5.667; Sweeney P, 2002, CLIN CANCER RES, V8, P2714; Thaker PH, 2004, CLIN CANCER RES, V10, P5145, DOI 10.1158/1078-0432.CCR-03-0589; Toth J, 2001, DEV CELL, V1, P83, DOI 10.1016/S1534-5807(01)00002-8; Turner CP, 2002, EXP NEUROL, V178, P21, DOI 10.1006/exnr.2002.8027; VanMeter TE, 2001, J NEURO-ONCOL, V53, P213, DOI 10.1023/A:1012280925031; Walker-Daniels J, 2002, MOL CANCER RES, V1, P79; Walker-Daniels J, 1999, PROSTATE, V41, P275, DOI 10.1002/(SICI)1097-0045(19991201)41:4<275::AID-PROS8>3.0.CO;2-T; Wang HU, 1998, CELL, V93, P741, DOI 10.1016/S0092-8674(00)81436-1; Wu QH, 2004, PATHOL ONCOL RES, V10, P26, DOI 10.1007/BF02893405; Wykosky J, 2005, MOL CANCER RES, V3, P541, DOI 10.1158/1541-7786.MCR-05-0056; Wykosky J, 2007, MOL CANCER THER, V6, P3208, DOI 10.1158/1535-7163.MCT-07-0200; Xu QL, 1997, J MOL MED-JMM, V75, P576, DOI 10.1007/s001090050142; Zelinski DP, 2001, CANCER RES, V61, P2301; Zeng GY, 2003, AM J PATHOL, V163, P2271, DOI 10.1016/S0002-9440(10)63584-5; Zhang A, 2006, ONCOL REP, V15, P831; Zucker S, 1998, INT J CANCER, V75, P780, DOI 10.1002/(SICI)1097-0215(19980302)75:5<780::AID-IJC19>3.0.CO;2-A	57	88	108	1	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC	2008	27	58					7260	7273		10.1038/onc.2008.328	http://dx.doi.org/10.1038/onc.2008.328			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	382FI	18794797	Green Accepted			2022-12-28	WOS:000261590300004
J	Taghavi, P; Verhoeven, E; Jacobs, JJL; Lambooij, JP; Stortelers, C; Tanger, E; Moolenaar, WH; van Lohuizen, M				Taghavi, P.; Verhoeven, E.; Jacobs, J. J. L.; Lambooij, J. P.; Stortelers, C.; Tanger, E.; Moolenaar, W. H.; van Lohuizen, M.			In vitro genetic screen identifies a cooperative role for LPA signaling and c-Myc in cell transformation	ONCOGENE			English	Article						LPA; transformation; screen	PROTEIN-COUPLED RECEPTOR; LYSOPHOSPHATIDIC ACID; TUMOR-SUPPRESSOR; EMBRYO FIBROBLASTS; OVARIAN-CANCER; GROWTH; RAS; KINASE; ACTIVATION; EXPRESSION	c-Myc drives uncontrolled cell proliferation in various human cancers. However, in mouse embryo fibroblasts (MEFs), c-Myc also induces apoptosis by activating the p19Arf tumor suppressor pathway. Tbx2, a transcriptional repressor of p19Arf, can collaborate with c-Myc by suppressing apoptosis. MEFs overexpressing c-Myc and Tbx2 are immortal but not transformed. We have performed an unbiased genetic screen, which identified 12 oncogenes that collaborate with c-Myc and Tbx2 to transform MEFs in vitro. One of them encodes the LPA2 receptor for the lipid growth factor lysophosphatidic acid (LPA). We find that LPA1 and LPA4, but not LPA3, can reproduce the transforming effect of LPA2. Using pharmacological inhibitors, we show that the in vitro cell transformation induced by LPA receptors is dependent on the Gi-linked ERK and PI3K signaling pathways. The transforming ability of LPA1, LPA2 and LPA4 was confirmed by tumor formation assays in vivo and correlated with prolonged ERK1/2 activation in response to LPA. Our results reveal a direct role for LPA receptor signaling in cell transformation and tumorigenesis in conjunction with c-Myc and reduced p19Arf expression. Oncogene (2008) 27, 6806-6816; doi: 10.1038/onc.2008.294;published online 1 September 2008	[Taghavi, P.; Verhoeven, E.; Jacobs, J. J. L.; Lambooij, J. P.; Tanger, E.; van Lohuizen, M.] Netherlands Canc Inst, Div Mol Genet, NL-1066 CX Amsterdam, Netherlands; [Stortelers, C.; Moolenaar, W. H.] Netherlands Canc Inst, Div Cellular Biochem, NL-1066 CX Amsterdam, Netherlands	Netherlands Cancer Institute; Netherlands Cancer Institute	van Lohuizen, M (corresponding author), Netherlands Canc Inst, Div Mol Genet, Plesmanlaan 121, NL-1066 CX Amsterdam, Netherlands.	m.v.lohuizen@nki.nl	Jacobs, Jacqueline/ABA-5652-2020	Jacobs, Jacqueline/0000-0002-7704-4795	Dutch Cancer Society [NKI 2003-2935, NKI 2003-2964]	Dutch Cancer Society(KWF Kankerbestrijding)	We thank Laurens A van Meeteren for LPA receptor plasmids and advice, Wendy Lagcher for technical assistance and Nullin Divecha and Daniel S Peeper for helpful discussions. This study was supported by grants from the Dutch Cancer Society, NKI 2003-2935 (to MvL) and NKI 2003-2964 (to WHM).	Adhikary S, 2005, NAT REV MOL CELL BIO, V6, P635, DOI 10.1038/nrm1703; BENITO M, 1993, GROWTH REGULAT, V3, P172; Boucharaba A, 2004, J CLIN INVEST, V114, P1714, DOI 10.1172/JCI200422123; BOWE MA, 1995, ANNU REV NEUROSCI, V18, P443; Datta A, 2004, J BIOL CHEM, V279, P36698, DOI 10.1074/jbc.M312305200; Ding ZY, 2006, P NATL ACAD SCI USA, V103, P15014, DOI 10.1073/pnas.0606917103; Drayton S, 2003, CANCER CELL, V4, P301, DOI 10.1016/S1535-6108(03)00242-3; Erickson JR, 2001, PROSTAG OTH LIPID M, V64, P63, DOI 10.1016/S0090-6980(01)00100-9; Fu L, 2007, CANCER-AM CANCER SOC, V110, P2672, DOI 10.1002/cncr.23110; Gil J, 2006, NAT REV MOL CELL BIO, V7, P667, DOI 10.1038/nrm1987; HEIDECKER G, 1990, MOL CELL BIOL, V10, P2503, DOI 10.1128/MCB.10.6.2503; Honda K, 1998, J CELL BIOL, V140, P1383, DOI 10.1083/jcb.140.6.1383; Honda K, 2005, GASTROENTEROLOGY, V128, P51, DOI 10.1053/j.gastro.2004.10.004; Huang MC, 2004, ONCOGENE, V23, P122, DOI 10.1038/sj.onc.1206986; Ishii I, 2000, MOL PHARMACOL, V58, P895, DOI 10.1124/mol.58.5.895; Ishii I, 2004, ANNU REV BIOCHEM, V73, P321, DOI 10.1146/annurev.biochem.73.011303.073731; Jacobs JJL, 2000, NAT GENET, V26, P291, DOI 10.1038/81583; Jacobs JJL, 1999, GENE DEV, V13, P2678, DOI 10.1101/gad.13.20.2678; Jaffe AB, 2005, ANNU REV CELL DEV BI, V21, P247, DOI 10.1146/annurev.cellbio.21.020604.150721; Jones SM, 2001, NAT CELL BIOL, V3, P165, DOI 10.1038/35055073; KhosraviFar R, 1996, MOL CELL BIOL, V16, P3923; Koh EY, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/gnf142; Kostenko EV, 2005, J BIOL CHEM, V280, P2807, DOI 10.1074/jbc.M411139200; Krimpenfort P, 2007, NATURE, V448, P943, DOI 10.1038/nature06084; LAND H, 1986, MOL CELL BIOL, V6, P1917, DOI 10.1128/MCB.6.6.1917; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; Lee CW, 2007, J BIOL CHEM, V282, P4310, DOI 10.1074/jbc.M610826200; Lee CW, 2006, J BIOL CHEM, V281, P23589, DOI 10.1074/jbc.M603670200; Lee Z, 2006, CANCER RES, V66, P2740, DOI 10.1158/0008-5472.CAN-05-2947; Lingbeek ME, 2002, J BIOL CHEM, V277, P26120, DOI 10.1074/jbc.M200403200; Mills GB, 2003, NAT REV CANCER, V3, P582, DOI 10.1038/nrc1143; Moolenaar WH, 2004, BIOESSAYS, V26, P870, DOI 10.1002/bies.20081; Noguchi K, 2003, J BIOL CHEM, V278, P25600, DOI 10.1074/jbc.M302648200; O'Regan L, 2007, CELL DIV, V2, DOI 10.1186/1747-1028-2-25; Pasternack SM, 2008, NAT GENET, V40, P329, DOI 10.1038/ng.84; Pietras K, 2003, CANCER CELL, V3, P439, DOI 10.1016/S1535-6108(03)00089-8; Prince S, 2004, CANCER RES, V64, P1669, DOI 10.1158/0008-5472.CAN-03-3286; Qi Y, 2004, NATURE, V431, P712, DOI 10.1038/nature02958; Ramjaun AR, 2007, CELL CYCLE, V6, P2902, DOI 10.4161/cc.6.23.4996; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; Seoane J, 2002, NATURE, V419, P729, DOI 10.1038/nature01119; Sherr CJ, 2006, NAT REV CANCER, V6, P663, DOI 10.1038/nrc1954; Sherr CJ, 2004, CELL, V116, P235, DOI 10.1016/S0092-8674(03)01075-4; Shields JM, 2000, TRENDS CELL BIOL, V10, P147, DOI 10.1016/S0962-8924(00)01740-2; Toyoshima M, 2007, CANCER RES, V67, P5162, DOI 10.1158/0008-5472.CAN-06-2756; van Meeteren LA, 2007, PROG LIPID RES, V46, P145, DOI 10.1016/j.plipres.2007.02.001; Ye XQ, 2005, NATURE, V435, P104, DOI 10.1038/nature03505; Zindy F, 1998, GENE DEV, V12, P2424, DOI 10.1101/gad.12.15.2424; Zuber J, 2000, NAT GENET, V24, P144, DOI 10.1038/72799	49	32	36	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 20	2008	27	54					6806	6816		10.1038/onc.2008.294	http://dx.doi.org/10.1038/onc.2008.294			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	375IS	18762810				2022-12-28	WOS:000261108000002
J	Lukasiak, S; Schiller, C; Oehlschlaeger, P; Schmidtke, G; Krause, P; Legler, DF; Autschbach, F; Schirmacher, P; Breuhahn, K; Groettrup, M				Lukasiak, S.; Schiller, C.; Oehlschlaeger, P.; Schmidtke, G.; Krause, P.; Legler, D. F.; Autschbach, F.; Schirmacher, P.; Breuhahn, K.; Groettrup, M.			Proinflammatory cytokines cause FAT10 upregulation in cancers of liver and colon	ONCOGENE			English	Article						FAT10; ubiquitin-like modifiers; hepatocellular carcinoma; colon carcinoma; interferon-gamma	UBIQUITIN-LIKE PROTEIN; HUMAN HEPATOCELLULAR-CARCINOMA; INTERFERON-GAMMA; EXPRESSION; GENE; IDENTIFICATION; DEGRADATION; APOPTOSIS	The mRNA of the ubiquitin-like modifier FAT10 has been reported to be overexpressed in 90% of hepatocellular carcinoma (HCC) and in over 80% of colon, ovary and uterus carcinomas. Elevated FAT10 expression in malignancies was attributed to transcriptional upregulation upon the loss of p53. Moreover, FAT10 induced chromosome instability in long-term in vitro culture, which led to the hypothesis that FAT10 might be involved in carcinogenesis. In this study we show that interferon (IFN)-gamma and tumor necrosis factor (TNF)-alpha synergistically upregulated FAT10 expression in liver and colon cancer cells 10- to 100-fold. Real-time RT-PCR revealed that FAT10 mRNA was significantly overexpressed in 37 of 51 (72%) of human HCC samples and in 8 of 15 (53%) of human colon carcinomas. The FAT10 cDNA sequences in HCC samples were not mutated and intact FAT10 protein was detectable. FAT10 expression in both cancer tissues correlated with expression of the IFN-gamma- and TNF-alpha-dependent proteasome subunit LMP2 strongly suggesting that proinflammatory cytokines caused the joint overexpression of FAT10 and LMP2. NIH3T3 transformation assays revealed that FAT10 had no transforming capability. Taken together, FAT10 qualifies as a marker for an interferon response in HCC and colon carcinoma but is not significantly overexpressed in cancers lacking a proinflammatory environment.	[Lukasiak, S.; Oehlschlaeger, P.; Schmidtke, G.; Groettrup, M.] Univ Constance, Div Immunol, Dept Biol, D-78457 Constance, Germany; [Schiller, C.; Autschbach, F.; Schirmacher, P.; Breuhahn, K.] Univ Heidelberg, Inst Pathol, Univ Heidelberg Hosp, D-6900 Heidelberg, Germany; [Krause, P.; Legler, D. F.; Groettrup, M.] Univ Konstanz, Biotechnol Inst Thurgau, Kreuzlingen, Switzerland	University of Konstanz; Ruprecht Karls University Heidelberg	Groettrup, M (corresponding author), Univ Constance, Div Immunol, Dept Biol, Univ Str 10, D-78457 Constance, Germany.	marcus.groettrup@uni-konstanz.de	Groettrup, Marcus/AAT-2623-2020	Legler, Daniel F./0000-0001-8610-4764; Breuhahn, Kai/0000-0002-2462-1229	Fritz Thyssen Foundation [Az 10.05.1.145, Az 10.06.2.183]	Fritz Thyssen Foundation	We thank Klaus Scherrer for the contribution of the iota antibody and Gerardo Alvarez for excellent technical assistance. Darius Moradpour is acknowledged for the contribution of HCC cell lines. This work was supported from the grants Az 10.05.1.145 and Az 10.06.2.183 of the Fritz Thyssen Foundation.	Bates EFM, 1997, EUR J IMMUNOL, V27, P2471, DOI 10.1002/eji.1830271002; Breuhahn K, 2004, CANCER RES, V64, P6058, DOI 10.1158/0008-5472.CAN-04-0292; Canaan A, 2006, MOL CELL BIOL, V26, P5180, DOI 10.1128/MCB.00966-05; Chiu YH, 2007, MOL CELL, V27, P1014, DOI 10.1016/j.molcel.2007.08.020; Fan WF, 1996, IMMUNOGENETICS, V44, P97, DOI 10.1007/s002510050095; Hipp MS, 2005, MOL CELL BIOL, V25, P3483, DOI 10.1128/MCB.25.9.3483-3491.2005; Hipp MS, 2004, J BIOL CHEM, V279, P16503, DOI 10.1074/jbc.M310114200; Kern MA, 2002, ADV CANCER RES, V86, P67, DOI 10.1016/S0065-230X(02)86003-1; Khan S, 2001, J IMMUNOL, V167, P6859, DOI 10.4049/jimmunol.167.12.6859; Lee CGL, 2003, ONCOGENE, V22, P2592, DOI 10.1038/sj.onc.1206337; Legler DF, 2006, J IMMUNOL, V176, P966, DOI 10.4049/jimmunol.176.2.966; Liu YC, 1999, P NATL ACAD SCI USA, V96, P4313, DOI 10.1073/pnas.96.8.4313; Oliva J, 2008, EXP MOL PATHOL, V84, P102, DOI 10.1016/j.yexmp.2007.12.003; Pfaffl MW, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/30.9.e36; Raasi S, 2001, J BIOL CHEM, V276, P35334, DOI 10.1074/jbc.M105139200; Raasi S, 1999, EUR J IMMUNOL, V29, P4030, DOI 10.1002/(SICI)1521-4141(199912)29:12<4030::AID-IMMU4030>3.0.CO;2-Y; Ren JW, 2006, J BIOL CHEM, V281, P11413, DOI 10.1074/jbc.M507218200; Ross MJ, 2006, J AM SOC NEPHROL, V17, P996, DOI 10.1681/ASN.2005070692; Stohwasser R, 1997, EUR J IMMUNOL, V27, P1182, DOI 10.1002/eji.1830270520; Zhang DW, 2006, ONCOGENE, V25, P2318, DOI 10.1038/sj.onc.1209220; Zhu LJ, 2005, ANAL BIOCHEM, V345, P102, DOI 10.1016/j.ab.2005.07.028	21	120	127	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 9	2008	27	46					6068	6074		10.1038/onc.2008.201	http://dx.doi.org/10.1038/onc.2008.201			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	358BO	18574467	Green Submitted			2022-12-28	WOS:000259891600009
J	Xenaki, G; Ontikatze, T; Rjaendran, R; Startford, IJ; Drive, C; Krstic-Demonacos, M; Demonacos, C				Xenaki, G.; Ontikatze, T.; Rjaendran, R.; Startford, I. J.; Drive, C.; Krstic-Demonacos, M.; Demonacos, C.			PCAF is an HIF-1 alpha cofactor that regulates p53 transcriptional activity in hypoxia	ONCOGENE			English	Article						transcription; p53; hypoxia-inducible factor; PCAF; apoptosis	HISTONE DEACETYLASE INHIBITORS; INDUCIBLE FACTOR-1 HIF-1; DNA-DAMAGE; GENE-EXPRESSION; CELLULAR-RESPONSE; INDUCED APOPTOSIS; STRUCTURAL BASIS; FACTOR 1-ALPHA; IN-VITRO; ACETYLATION	The p53 tumour suppressor is involved in several crucial cellular functions including cell-cycle arrest and apoptosis. p53 stabilization occurs under hypoxic and DNA damage conditions. However, only in the latter scenario is stabilized p53 capable of inducing the expression of its pro-apoptotic targets. Here we present evidence that under hypoxia-mimicking conditions p53 acetylation is reduced to a greater extent at K320 site targeted by P300/CBP-associated factor (PCAF) than at K382 site targeted by p300/CBP. The limited amounts of acetylated p53 at K320 are preferentially recruited to the promoter of the p21(WAF-1/CIP-1) gene, which appears to be unaffected by hypoxia, but are not recruited to the BID promoter and hence p53 is incapable of upregulating pro-apoptotic BID in hypoxic conditions. As the K320 p53 acetylation is the site predominantly affected in hypoxia, the PCAF histone acetyltransferase activity is the key regulator of the cellular fate modulated by p53 under these conditions. In addition, we provide evidence that PCAF acetylates hypoxia-inducible factor-1 alpha (HIF-1 alpha) in hypoxic conditions and that the acetylated HIF-1 alpha is recruited to a particular subset of its targets. In conclusion, PCAF regulates the balance between cell-cycle arrest and apoptosis in hypoxia by modulating the activity and protein stability of both p53 and HIF-alpha.	[Xenaki, G.; Ontikatze, T.; Rjaendran, R.; Startford, I. J.; Drive, C.; Demonacos, C.] Univ Manchester, Sch Pharm & Pharmaceut Sci, Manchester M13 9PT, Lancs, England; [Drive, C.] Univ Manchester, Paterson Inst Canc Res, Manchester M13 9PT, Lancs, England; [Krstic-Demonacos, M.] Univ Manchester, Fac Life Sci, Manchester M13 9PT, Lancs, England	University of Manchester; Paterson Institute for Cancer Research; University of Manchester; University of Manchester	Demonacos, C (corresponding author), Univ Manchester, Sch Pharm & Pharmaceut Sci, Stopford Bldg,Oxford Rd, Manchester M13 9PT, Lancs, England.	cdemonacos@manchester.ac.uk	Demonacos, Constantinos/K-1277-2019	Demonacos, Constantinos/0000-0002-4515-755X; Rajendran, Ramkumar/0000-0002-3610-8430; Dive, Caroline/0000-0002-1726-8850; stratford, ian/0000-0002-5222-4765	School of Pharmacy, University of Manchester; Cancer Research UK; MRC programme [G0500366]; Wellcome Trust [069024]; Medical Research Council [G0500366] Funding Source: researchfish; MRC [G0500366] Funding Source: UKRI	School of Pharmacy, University of Manchester; Cancer Research UK(Cancer Research UK); MRC programme(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Wellcome Trust(Wellcome TrustEuropean Commission); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	We thank W El-Deiry for providing the BID-p53-Luc reporter construct; I Talianidis for the Flag-PCAF and Flag-PCAF-DHAT constructs; T Halazonetis for the p53K320R expression vector; K Williams for the HIF-1 alpha-responsive reporters of VEGF-Luc, CA-IX-Luc, PGK-1-Luc and LDH-A-Luc; M Blaylock and the Paterson Institute for Cancer Research for assistance with FACS analysis. Our research was supported by the School of Pharmacy, University of Manchester (CD), Cancer Research UK (CDive), MRC programme grant (G0500366) to IJS and Wellcome Trust (069024) to MKD.	Achison M, 2003, ONCOGENE, V22, P3431, DOI 10.1038/sj.onc.1206434; An WG, 1998, NATURE, V392, P405, DOI 10.1038/32925; Arany Z, 1996, P NATL ACAD SCI USA, V93, P12969, DOI 10.1073/pnas.93.23.12969; Bilton R, 2006, TRENDS CELL BIOL, V16, P616, DOI 10.1016/j.tcb.2006.10.002; Blagosklonny MV, 1998, J BIOL CHEM, V273, P11995, DOI 10.1074/jbc.273.20.11995; Brahimi-Horn C, 2005, CELL SIGNAL, V17, P1, DOI 10.1016/j.cellsig.2004.04.010; Brunet A, 2004, SCIENCE, V303, P2011, DOI 10.1126/science.1094637; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; Chao C, 2006, MOL CELL BIOL, V26, P6859, DOI 10.1128/MCB.00062-06; Chen DL, 2003, J BIOL CHEM, V278, P13595, DOI 10.1074/jbc.C200694200; Cohen HY, 2004, MOL CELL, V13, P627, DOI 10.1016/S1097-2765(04)00094-2; Cory S, 2003, ONCOGENE, V22, P8590, DOI 10.1038/sj.onc.1207102; Demonacos C, 2004, NAT CELL BIOL, V6, P968, DOI 10.1038/ncb1170; Demonacos C, 2001, MOL CELL, V8, P71, DOI 10.1016/S1097-2765(01)00277-5; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Erler JT, 2004, MOL CELL BIOL, V24, P2875, DOI 10.1128/MCB.24.7.2875-2889.2004; Fei PW, 2004, CANCER CELL, V6, P597, DOI 10.1016/j.ccr.2004.10.012; Forsythe JA, 1996, MOL CELL BIOL, V16, P4604; Freedman SJ, 2003, NAT STRUCT BIOL, V10, P504, DOI 10.1038/nsb936; Freedman SJ, 2002, P NATL ACAD SCI USA, V99, P5367, DOI 10.1073/pnas.082117899; Goda N, 2003, ANTIOXID REDOX SIGN, V5, P467, DOI 10.1089/152308603768295212; Gordan JD, 2007, CANCER CELL, V11, P335, DOI 10.1016/j.ccr.2007.02.006; Greijer AE, 2004, J CLIN PATHOL, V57, P1009, DOI 10.1136/jcp.2003.015032; Hammond EM, 2006, MOL CELL BIOL, V26, P3492, DOI 10.1128/MCB.26.9.3492-3504.2006; Hammond EM, 2005, BIOCHEM BIOPH RES CO, V331, P718, DOI 10.1016/j.bbrc.2005.03.154; Hansson LO, 2002, P NATL ACAD SCI USA, V99, P10305, DOI 10.1073/pnas.122347199; Hu CJ, 2003, MOL CELL BIOL, V23, P9361, DOI 10.1128/MCB.23.24.9361-9374.2003; Jeong JW, 2002, CELL, V111, P709, DOI 10.1016/S0092-8674(02)01085-1; Jin YT, 2002, J BIOL CHEM, V277, P30838, DOI 10.1074/jbc.M204078200; Kaelin WG, 2005, ANNU REV BIOCHEM, V74, P115, DOI 10.1146/annurev.biochem.74.082803.133142; Kasper LH, 2005, EMBO J, V24, P3846, DOI 10.1038/sj.emboj.7600846; Knights CD, 2006, J CELL BIOL, V173, P533, DOI 10.1083/jcb.200512059; Koumenis C, 2001, MOL CELL BIOL, V21, P1297, DOI 10.1128/MCB.21.4.1297-1310.2001; Lando D, 2002, SCIENCE, V295, P858, DOI 10.1126/science.1068592; Liang DM, 2006, CELL CYCLE, V5, P2430, DOI 10.4161/cc.5.21.3409; Linares LK, 2007, NAT CELL BIOL, V9, P331, DOI 10.1038/ncb1545; Liu L, 1999, MOL CELL BIOL, V19, P1202; Luo JY, 2004, P NATL ACAD SCI USA, V101, P2259, DOI 10.1073/pnas.0308762101; Mahon PC, 2001, GENE DEV, V15, P2675, DOI 10.1101/gad.924501; Pan Y, 2004, ONCOGENE, V23, P4975, DOI 10.1038/sj.onc.1207657; Pescador N, 2005, BIOCHEM J, V390, P189, DOI 10.1042/BJ20042121; Poux AN, 2003, BIOCHEMISTRY-US, V42, P14366, DOI 10.1021/bi035632n; Raval RR, 2005, MOL CELL BIOL, V25, P5675, DOI 10.1128/MCB.25.13.5675-5686.2005; Ravi R, 2000, GENE DEV, V14, P34; Roy S, 2005, CELL DEATH DIFFER, V12, P482, DOI 10.1038/sj.cdd.4401581; Roy S, 2007, J BIOL CHEM, V282, P4765, DOI 10.1074/jbc.M609588200; Sakaguchi K, 1998, GENE DEV, V12, P2831, DOI 10.1101/gad.12.18.2831; Sax JK, 2002, NAT CELL BIOL, V4, P842, DOI 10.1038/ncb866; Schmid T, 2004, BIOCHEM J, V380, P289, DOI 10.1042/BJ20031299; Semenza GL, 1996, J BIOL CHEM, V271, P32529, DOI 10.1074/jbc.271.51.32529; Tyteca S, 2006, MOL CELL, V24, P807, DOI 10.1016/j.molcel.2006.12.005; Vaupel P, 2004, ONCOLOGIST, V9, P4, DOI 10.1634/theoncologist.9-90005-4; Vousden KH, 2007, NAT REV MOL CELL BIO, V8, P275, DOI 10.1038/nrm2147; Vousden KH, 2005, CELL, V120, P7, DOI 10.1016/j.cell.2004.12.027; Warnecke C, 2004, FASEB J, V18, P1462, DOI 10.1096/fj.04-1640fje; Wenger RH, 2002, FASEB J, V16, DOI 10.1096/fj.01-0944rev; Wykoff CC, 2000, CANCER RES, V60, P7075; You H, 2006, J EXP MED, V203, P1657, DOI 10.1084/jem.20060353; Zhu YH, 2002, J BIOL CHEM, V277, P22909, DOI 10.1074/jbc.M200042200	59	83	87	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 2	2008	27	44					5785	5796		10.1038/onc.2008.192	http://dx.doi.org/10.1038/onc.2008.192			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	355QC	18574470	Green Accepted			2022-12-28	WOS:000259722400003
J	Wang, X; Jiang, X				Wang, X.; Jiang, X.			Post-translational regulation of PTEN	ONCOGENE			English	Review						PTEN; tumor suppressor; protein-protein interaction; post-translational modification; ubiquitination; subpopulation	TUMOR-SUPPRESSOR PTEN; LHERMITTE-DUCLOS-DISEASE; HEMATOPOIETIC STEM-CELLS; MAJOR VAULT PROTEIN; MICE LACKING PTEN; PHOSPHATASE-ACTIVITY; NUCLEAR PTEN; NEGATIVE REGULATION; CHROMOSOME-10 PTEN; PROSTATE-CANCER	PTEN (phosphatase and tensin homolog deleted on chromosome 10) tumor suppressor regulates a variety of cellular processes including cell proliferation, growth, migration and death. This master regulator itself is also under deliberative regulation. Although the evidence for PTEN regulation and its significance in normal biology and disease is overwhelming, the mechanisms and exact functional consequences of PTEN regulation are far from clear. In this review, we discuss recent advances concerning post-translational regulation of PTEN in general, and in more detail about its regulation by ubiquitination. We also discuss some unsolved questions in the field and how they might be addressed in the future. We propose that the complex regulatory mechanisms of PTEN dictate how this tumor suppressor executes its distinct biological functions.	[Wang, X.; Jiang, X.] Mem Sloan Kettering Canc Ctr, Cell Biol Program, New York, NY 10065 USA	Memorial Sloan Kettering Cancer Center	Jiang, X (corresponding author), Mem Sloan Kettering Canc Ctr, Cell Biol Program, 1275 York Ave,Box 522, New York, NY 10065 USA.	jiangx@mskcc.org			American Cancer Society Scholar fund; Geoffrey Beene Cancer Research fund	American Cancer Society Scholar fund(American Cancer Society); Geoffrey Beene Cancer Research fund	We thank Dr Ian Ganley for critical reading and suggestions. This work was supported by an American Cancer Society Scholar fund (to XJ) and a Geoffrey Beene Cancer Research fund (to XJ).	Ali IU, 1999, JNCI-J NATL CANCER I, V91, P1922, DOI 10.1093/jnci/91.22.1922; Anan T, 1998, GENES CELLS, V3, P751, DOI 10.1046/j.1365-2443.1998.00227.x; Backman SA, 2001, NAT GENET, V29, P396, DOI 10.1038/ng782; Brognard J, 2007, MOL CELL, V25, P917, DOI 10.1016/j.molcel.2007.02.017; Brooks CL, 2006, MOL CELL, V21, P307, DOI 10.1016/j.molcel.2006.01.020; Cai ZQ, 2005, CIRC RES, V97, P1351, DOI 10.1161/01.RES.0000195656.52760.30; Chung JH, 2005, CANCER RES, V65, P4108, DOI 10.1158/0008-5472.CAN-05-0124; Crackower MA, 2002, CELL, V110, P737, DOI 10.1016/S0092-8674(02)00969-8; Di Cristofano A, 1998, NAT GENET, V19, P348, DOI 10.1038/1235; Dummler B, 2007, BIOCHEM SOC T, V35, P231, DOI 10.1042/BST0350231; Engelman JA, 2006, NAT REV GENET, V7, P606, DOI 10.1038/nrg1879; Georgescu MM, 1999, P NATL ACAD SCI USA, V96, P10182, DOI 10.1073/pnas.96.18.10182; Georgescu MM, 2000, CANCER RES, V60, P7033; Gimm O, 2000, AM J PATHOL, V156, P1693, DOI 10.1016/S0002-9440(10)65040-7; Groszer M, 2001, SCIENCE, V294, P2186, DOI 10.1126/science.1065518; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Hlobilkova A, 2000, EXP CELL RES, V256, P571, DOI 10.1006/excr.2000.4867; Iijima M, 2004, J BIOL CHEM, V279, P16606, DOI 10.1074/jbc.M312098200; Kurlawalla-Martinez C, 2005, MOL CELL BIOL, V25, P2498, DOI 10.1128/MCB.25.6.2498-2510.2005; Kwon CH, 2001, NAT GENET, V29, P404, DOI 10.1038/ng781; Kwon CH, 2006, NEURON, V50, P377, DOI 10.1016/j.neuron.2006.03.023; Kwon J, 2004, P NATL ACAD SCI USA, V101, P16419, DOI 10.1073/pnas.0407396101; Lachyankar MB, 2000, J NEUROSCI, V20, P1404; Lee JO, 1999, CELL, V99, P323, DOI 10.1016/S0092-8674(00)81663-3; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; Lindsay Y, 2006, J CELL SCI, V119, P5160, DOI 10.1242/jcs.000133; Liu XM, 2007, P NATL ACAD SCI USA, V104, P2259, DOI 10.1073/pnas.0604153104; Maccario H, 2007, BIOCHEM J, V405, P439, DOI 10.1042/BJ20061837; Maehama T, 1998, J BIOL CHEM, V273, P13375, DOI 10.1074/jbc.273.22.13375; Minaguchi T, 2006, CANCER RES, V66, P11677, DOI 10.1158/0008-5472.CAN-06-2240; Mirmohammadsadegh A, 2006, CANCER RES, V66, P6546, DOI 10.1158/0008-5472.CAN-06-0384; Mocanu MM, 2007, BRIT J PHARMACOL, V150, P833, DOI 10.1038/sj.bjp.0707155; Odriozola L, 2007, J BIOL CHEM, V282, P23306, DOI 10.1074/jbc.M611240200; Okahara F, 2004, J BIOL CHEM, V279, P45300, DOI 10.1074/jbc.C400377200; Okumura K, 2005, P NATL ACAD SCI USA, V102, P2703, DOI 10.1073/pnas.0409370102; Okumura K, 2006, J BIOL CHEM, V281, P26562, DOI 10.1074/jbc.M605391200; Oren M, 2003, CELL DEATH DIFFER, V10, P431, DOI 10.1038/sj.cdd.4401183; Oudit GY, 2008, CARDIOVASC RES, V78, P505, DOI 10.1093/cvr/cvn041; Perren A, 1999, AM J PATHOL, V155, P1253, DOI 10.1016/S0002-9440(10)65227-3; Planchon SM, 2008, J CELL SCI, V121, P249, DOI 10.1242/jcs.022459; Podsypanina K, 1999, P NATL ACAD SCI USA, V96, P1563, DOI 10.1073/pnas.96.4.1563; Raftopoulou M, 2004, SCIENCE, V303, P1179, DOI 10.1126/science.1092089; Reddy P, 2008, SCIENCE, V319, P611, DOI 10.1126/science.1152257; Rosivatz E, 2006, ACS CHEM BIOL, V1, P780, DOI 10.1021/cb600352f; Ross SH, 2007, CELL SIGNAL, V19, P1521, DOI 10.1016/j.cellsig.2007.01.026; Sasaoka T, 2006, PHARMACOL THERAPEUT, V112, P799, DOI 10.1016/j.pharmthera.2006.06.001; Shen WH, 2007, CELL, V128, P157, DOI 10.1016/j.cell.2006.11.042; Stambolic V, 1998, CELL, V95, P29, DOI 10.1016/S0092-8674(00)81780-8; Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356; Stiles BL, 2006, MOL CELL BIOL, V26, P2772, DOI 10.1128/MCB.26.7.2772-2781.2006; Subauste MC, 2005, J BIOL CHEM, V280, P5676, DOI 10.1074/jbc.M405561200; Sun LX, 2006, CANCER CELL, V9, P287, DOI 10.1016/j.ccr.2006.03.003; Takahashi Y, 2006, EMBO J, V25, P910, DOI 10.1038/sj.emboj.7600979; Tamura M, 1998, SCIENCE, V280, P1614, DOI 10.1126/science.280.5369.1614; Tolkacheva T, 2001, CANCER RES, V61, P4985; Torres J, 2001, J BIOL CHEM, V276, P993, DOI 10.1074/jbc.M009134200; Trotman LC, 2003, PLOS BIOL, V1, P385, DOI 10.1371/journal.pbio.0000059; Trotman LC, 2006, NATURE, V441, P523, DOI 10.1038/nature04809; Trotman LC, 2007, CELL, V128, P141, DOI 10.1016/j.cell.2006.11.040; Valiente M, 2005, J BIOL CHEM, V280, P28936, DOI 10.1074/jbc.M504761200; Vazquez F, 2006, P NATL ACAD SCI USA, V103, P3633, DOI 10.1073/pnas.0510570103; Vazquez F, 2000, MOL CELL BIOL, V20, P5010, DOI 10.1128/MCB.20.14.5010-5018.2000; Walker SM, 2004, BIOCHEM J, V379, P301, DOI 10.1042/BJ20031839; WANG X, 2008, BIOCH J; Wang XJ, 2007, CELL, V128, P129, DOI 10.1016/j.cell.2006.11.039; Weng LP, 2001, HUM MOL GENET, V10, P237, DOI 10.1093/hmg/10.3.237; Whang YE, 1998, P NATL ACAD SCI USA, V95, P5246, DOI 10.1073/pnas.95.9.5246; Whiteman DC, 2002, INT J CANCER, V99, P63, DOI 10.1002/ijc.10294; Wiencke JK, 2007, NEURO-ONCOLOGY, V9, P271, DOI 10.1215/15228517-2007-003; Wijesekara N, 2005, MOL CELL BIOL, V25, P1135, DOI 10.1128/MCB.25.3.1135-1145.2005; Wu WD, 2003, J BIOL CHEM, V278, P28258, DOI 10.1074/jbc.M303318200; Yilmaz OH, 2006, NATURE, V441, P475, DOI 10.1038/nature04703; Zhang JW, 2006, NATURE, V441, P518, DOI 10.1038/nature04747	73	83	86	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 15	2008	27	41					5454	5463		10.1038/onc.2008.242	http://dx.doi.org/10.1038/onc.2008.242			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	349KW	18794880				2022-12-28	WOS:000259280700007
J	Matta, H; Punj, V; Schamus, S; Mazzacurati, L; Chen, AM; Song, R; Yang, T; Chaudhary, PM				Matta, H.; Punj, V.; Schamus, S.; Mazzacurati, L.; Chen, A. M.; Song, R.; Yang, T.; Chaudhary, P. M.			A nuclear role for Kaposi's sarcoma-associated herpesvirus-encoded K13 protein in gene regulation	ONCOGENE			English	Article						K13; vFLIP; KSHV; RTA; IKK; NF-kappa B	NF-KAPPA-B; KINASE COMPLEX; ENDOTHELIAL-CELLS; INDUCED APOPTOSIS; KSHV VFLIP; IKK-GAMMA; ACTIVATION; EXPRESSION; ALPHA; PATHWAY	Kaposi's sarcoma-associated herpesvirus (KSHV)-encoded viral FLICE inhibitory protein K13 interacts with a cytosolic I kappa B kinase (IKK) complex to activate nuclear factor-kappa B (NF-kappa B). We recently reported that K13 antagonizes KSHV lytic regulator RTA ( replication and transcription activator) and blocks lytic replication, but spares RTA-induced viral interleukin-6 (vIL6). Here we report that K13 is also present in the nuclear compartment, a property not shared by its structural homologs. K13 interacts with and activates the nuclear IKK complex, and binds to the I kappa B alpha promoter. K13 mutants that are retained in the cytosol lack NF-kappa B activity. However, neither the IKKs nor NF-kappa B activation is required for nuclear localization of K13. Instead, this ability is dependent on a nuclear localization signal located in its N-terminal 40 amino acids. Finally, K13, along with p65/RelA, binds to the promoters of a number of KSHV lytic genes, including RTA, ORF57 and vGPCR, but not to the promoter of the vIL6 gene. Thus, K13 has an unexpected nuclear role in viral and cellular gene regulation and its differential binding to the promoters of lytic genes may not only contribute to the inhibition of KSHV lytic replication, but may also account for the escape of vIL6 from K13-induced transcriptional suppression.	[Matta, H.; Punj, V.; Schamus, S.; Mazzacurati, L.; Chen, A. M.; Song, R.; Chaudhary, P. M.] Univ Pittsburgh, Hillman Canc Ctr, Dept Med, Div Hematol Oncol,Canc Inst, Pittsburgh, PA 15213 USA; [Yang, T.] Univ Pittsburgh, Hillman Canc Ctr, Inst Canc, Spang Translat Res Core Facil, Pittsburgh, PA 15213 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Chaudhary, PM (corresponding author), Univ Pittsburgh, Hillman Canc Ctr, Dept Med, Div Hematol Oncol,Canc Inst, 5117 Ctr Ave,Suite 1-19A, Pittsburgh, PA 15213 USA.	chaudharypm@upmc.edu	Chaudhary, Preet/E-1970-2018	mazzacurati, lucia/0000-0002-8336-8032	ational Institutes of Health [CA85177, CA124621]; Leukemia and Lymphoma Society; Mario Lemieux Foundation; NATIONAL CANCER INSTITUTE [R01CA124621, R01CA085177] Funding Source: NIH RePORTER	ational Institutes of Health; Leukemia and Lymphoma Society(Leukemia and Lymphoma Society); Mario Lemieux Foundation; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Dr Inder Verma for providing the IKK deficient MEFs, Dr Shao-Cong Sun for NEMO-deficient Jurkat cells and Dr Mary Collins for a K13 monoclonal antibody. This work was supported by grants from the National Institutes of Health (CA85177 and CA124621), the Leukemia and Lymphoma Society and the Mario Lemieux Foundation.	An JB, 2003, ONCOGENE, V22, P3371, DOI 10.1038/sj.onc.1206407; Anest V, 2003, NATURE, V423, P659, DOI 10.1038/nature01648; BAEUERLE PA, 1988, CELL, V53, P211, DOI 10.1016/0092-8674(88)90382-0; Brown HJ, 2003, J VIROL, V77, P8532, DOI 10.1128/JVI.77.15.8532-8540.2003; Chaudhary PM, 1999, ONCOGENE, V18, P5738, DOI 10.1038/sj.onc.1202976; Chugh P, 2005, P NATL ACAD SCI USA, V102, P12885, DOI 10.1073/pnas.0408577102; Davis M, 2002, GENE DEV, V16, P439, DOI 10.1101/gad.218702; Ear T, 2005, J IMMUNOL, V175, P1834, DOI 10.4049/jimmunol.175.3.1834; Field N, 2003, J CELL SCI, V116, P3721, DOI 10.1242/jcs.00691; Ghosh S, 2002, CELL, V109, pS81, DOI 10.1016/S0092-8674(02)00703-1; Gloire G, 2006, BIOCHEM PHARMACOL, V72, P1081, DOI 10.1016/j.bcp.2006.06.017; Gorlich D, 1999, ANNU REV CELL DEV BI, V15, P607, DOI 10.1146/annurev.cellbio.15.1.607; Grossmann C, 2006, J VIROL, V80, P7179, DOI 10.1128/JVI.01603-05; Guasparri I, 2004, J EXP MED, V199, P993, DOI 10.1084/jem.20031467; Han Z, 2006, J VIROL, V80, P5251, DOI 10.1128/JVI.02570-05; Harhaj EW, 2000, ONCOGENE, V19, P1448, DOI 10.1038/sj.onc.1203445; Hayden MS, 2004, GENE DEV, V18, P2195, DOI 10.1101/gad.1228704; Hideshima T, 2002, J BIOL CHEM, V277, P16639, DOI 10.1074/jbc.M200360200; Kirshner JR, 2000, J VIROL, V74, P3586, DOI 10.1128/JVI.74.8.3586-3597.2000; Kumar A, 2001, J BIOL CHEM, V276, P2668, DOI 10.1074/jbc.M008356200; Lange A, 2007, J BIOL CHEM, V282, P5101, DOI 10.1074/jbc.R600026200; Liu L, 2002, J BIOL CHEM, V277, P13745, DOI 10.1074/jbc.M110480200; Matta H, 2007, ONCOGENE, V26, P1656, DOI 10.1038/sj.onc.1209931; Matta H, 2004, P NATL ACAD SCI USA, V101, P9399, DOI 10.1073/pnas.0308016101; Matta H, 2003, J BIOL CHEM, V278, P52406, DOI 10.1074/jbc.M307308200; Matta H, 2007, J BIOL CHEM, V282, P24858, DOI 10.1074/jbc.M700118200; Nakamura H, 2003, J VIROL, V77, P4205, DOI 10.1128/JVI.77.7.4205-4220.2003; Nekorchuk M, 2007, J VIROL, V81, P9990, DOI 10.1128/JVI.00896-07; Renard P, 2000, J BIOL CHEM, V275, P15193, DOI 10.1074/jbc.275.20.15193; Schulz TF, 2006, J PATHOL, V208, P187, DOI 10.1002/path.1904; Sun Q, 2006, ONCOGENE, V25, P2717, DOI 10.1038/sj.onc.1209298; Sun Q, 2003, BLOOD, V101, P1956, DOI 10.1182/blood-2002-07-2072; Sun QM, 2003, J BIOL CHEM, V278, P52437, DOI 10.1074/jbc.M304199200; Thome M, 1997, NATURE, V386, P517, DOI 10.1038/386517a0; Tran K, 1997, MOL CELL BIOL, V17, P5386, DOI 10.1128/MCB.17.9.5386; Verma UN, 2004, J BIOL CHEM, V279, P3509, DOI 10.1074/jbc.M309300200; Wang SZE, 2004, J VIROL, V78, P4248, DOI 10.1128/JVI.78.8.4248-4267.2004; West JT, 2003, ONCOGENE, V22, P5150, DOI 10.1038/sj.onc.1206555; Yamamoto Y, 2003, NATURE, V423, P655, DOI 10.1038/nature01576; Zhao JS, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0001067	40	14	14	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP	2008	27	39					5243	5253		10.1038/onc.2008.150	http://dx.doi.org/10.1038/onc.2008.150			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	344GO	18469854				2022-12-28	WOS:000258915100008
J	Makkonen, H; Jaaskelainen, T; Pitkanen-Arsiola, T; Rytinki, M; Waltering, KK; Matto, M; Visakorpi, T; Palvimo, JJ				Makkonen, H.; Jaaskelainen, T.; Pitkanen-Arsiola, T.; Rytinki, M.; Waltering, K. K.; Matto, M.; Visakorpi, T.; Palvimo, J. J.			Identification of ETS-like transcription factor 4 as a novel androgen receptor target in prostate cancer cells	ONCOGENE			English	Article						androgen receptor; ETS transcription factor; prostate cancer; FoxA1	ETS TRANSCRIPTION FACTOR; GENE-EXPRESSION; REGULATED ACTIVITY; OVEREXPRESSION; AMPLIFICATION; MICROARRAYS; PROTEINS; MUTATION; DOMAIN; ROLES	Transcriptional control by androgens via androgen receptor (AR) is strongly involved in prostate cancer development, but the critical target genes have remained elusive. We have characterized E twenty-six-like transcription factor 4 (ELK4) ( also known as serum response factor accessory protein 1) as a novel AR target in human prostate cancer cells. In-silico screening identified three putative AR response elements (AREs) within -10 kb from the transcription start site of ELK4. Both ARE1 at -167/-153 and ARE2 at -481/-467 bound AR in vitro and mediated androgen induction as isolated elements in transcription assays in non-prostate cells. However, merely the ARE2 that cooperates with a proximal forkhead box A1-binding site was critical for the AR-dependent activation of ELK4 promoter in prostate cancer cells. Preferential loading of holo-AR onto the ARE2 and concomitant recruitment of RNA polymerase II onto the ELK4 promoter was conformed in prostate cancer cells by chromatin immunoprecipitation. Database searches indicated that the expression of ELK4 is markedly increased in prostate cancers relative to normal prostates. Moreover, prostate cancer tissue immunostainings showed that nuclear ELK4 levels are significantly increased in androgen-refractory prostate cancers compared to untreated tumours. Reduction of the amount of ELK4 in LNCaP cells by RNAi retarded cell growth. In conclusion, ELK4 is a direct AR target in prostate cancer cells. Androgens may thus contribute to the growth of prostate cancer via influencing ELK4 levels.	[Makkonen, H.; Jaaskelainen, T.; Pitkanen-Arsiola, T.; Rytinki, M.; Palvimo, J. J.] Univ Kuopio, Inst Biomed Med Biochem, FI-70211 Kuopio, Finland; [Waltering, K. K.; Visakorpi, T.] Univ Tampere, Inst Med Technol, FIN-33101 Tampere, Finland; [Waltering, K. K.; Visakorpi, T.] Tampere Univ Hosp, Tampere, Finland; [Matto, M.] Univ Kuopio, Inst Clin Med & Clin Microbiol, FI-70211 Kuopio, Finland	University of Eastern Finland; Tampere University; Tampere University; Tampere University Hospital; University of Eastern Finland	Palvimo, JJ (corresponding author), Univ Kuopio, Inst Biomed Med Biochem, POB 1627, FI-70211 Kuopio, Finland.	Jorma.Palvimo@uku.fi		Palvimo, Jorma/0000-0003-2373-0578; Visakorpi, Tapio/0000-0002-5004-0364	Academy of Finland; Association for International Cancer Research; Finnish Cancer Foundation; Sigrid Juselius Foundation; Kuopio Naturalists' Society; Helena Vuorenmies Foundation; Karjalan Sivistysseura; Finnish Union of Experts in Science	Academy of Finland(Academy of Finland); Association for International Cancer Research; Finnish Cancer Foundation; Sigrid Juselius Foundation(Sigrid Juselius Foundation); Kuopio Naturalists' Society; Helena Vuorenmies Foundation; Karjalan Sivistysseura; Finnish Union of Experts in Science	This work was supported by grants from the Academy of Finland, Association for International Cancer Research, Finnish Cancer Foundation, Sigrid Juselius Foundation, Kuopio Naturalists' Society, Helena Vuorenmies Foundation, Karjalan Sivistysseura and Finnish Union of Experts in Science. We thank Merja Rasanen for skilful technical assistance.	Ayadi A, 2001, EMBO J, V20, P5139, DOI 10.1093/emboj/20.18.5139; Buchwalter G, 2004, GENE, V324, P1, DOI 10.1016/j.gene.2003.09.028; Cesari F, 2004, MOL CELL BIOL, V24, P294, DOI 10.1128/MCB.24.1.294-305.2004; Chen L, 2004, NEW ASTRON, V10, P39, DOI 10.1016/j.newast.2004.04.008; Cleutjens KBJM, 1997, MOL ENDOCRINOL, V11, P148, DOI 10.1210/me.11.2.148; Cleutjens KBJM, 1996, J BIOL CHEM, V271, P6379, DOI 10.1074/jbc.271.11.6379; Costello PS, 2004, NAT IMMUNOL, V5, P289, DOI 10.1038/ni1038; Culig Z, 2004, J STEROID BIOCHEM, V92, P265, DOI 10.1016/j.jsbmb.2004.10.003; Culig Z, 2002, ENDOCR-RELAT CANCER, V9, P155, DOI 10.1677/erc.0.0090155; DALTON S, 1992, CELL, V68, P597, DOI 10.1016/0092-8674(92)90194-H; Edwards S, 2005, BRIT J CANCER, V92, P376, DOI 10.1038/sj.bjc.6602261; Feldman BJ, 2001, NAT REV CANCER, V1, P34, DOI 10.1038/35094009; Gao N, 2003, MOL ENDOCRINOL, V17, P1484, DOI 10.1210/me.2003-0020; Gregory CW, 2001, CANCER RES, V61, P4315; Han GZ, 2005, P NATL ACAD SCI USA, V102, P1151, DOI 10.1073/pnas.0408925102; Heinlein CA, 2002, MOL ENDOCRINOL, V16, P2181, DOI 10.1210/me.2002-0070; Heinlein CA, 2004, ENDOCR REV, V25, P276, DOI 10.1210/er.2002-0032; Huggins C, 1941, CANCER RES, V1, P293; Jackson AL, 2006, RNA, V12, P1197, DOI 10.1261/rna.30706; KALLIO PJ, 1994, J BIOL CHEM, V269, P11514; Kang ZG, 2004, MOL ENDOCRINOL, V18, P2633, DOI 10.1210/me.2004-0245; Karvonen U, 2006, EXP CELL RES, V312, P3165, DOI 10.1016/j.yexcr.2006.06.018; Kononen J, 1998, NAT MED, V4, P844, DOI 10.1038/nm0798-844; Linja MJ, 2004, CLIN CANCER RES, V10, P1032, DOI 10.1158/1078-0432.CCR-0990-3; Linja MJ, 2001, CANCER RES, V61, P3550; Luo J, 2001, CANCER RES, V61, P4683; Magee JA, 2001, CANCER RES, V61, P5692; Maroni Paul D, 2006, N C Med J, V67, P136; Oettgen P, 2000, J BIOL CHEM, V275, P1216, DOI 10.1074/jbc.275.2.1216; PALVIMO JJ, 1993, MOL ENDOCRINOL, V7, P1399, DOI 10.1210/me.7.11.1399; RIEGMAN PHJ, 1991, MOL CELL ENDOCRINOL, V76, P181, DOI 10.1016/0303-7207(91)90272-T; Schuur ER, 1996, J BIOL CHEM, V271, P7043, DOI 10.1074/jbc.271.12.7043; Shaulian E, 2002, NAT CELL BIOL, V4, pE131, DOI 10.1038/ncb0502-e131; Shaw PE, 2003, INT J BIOCHEM CELL B, V35, P1210, DOI 10.1016/S1357-2725(03)00031-1; Stewart Alistair B., 2005, Current Medicinal Chemistry - Anti-Cancer Agents, V5, P603, DOI 10.2174/156801105774574658; TAPLIN ME, 1995, NEW ENGL J MED, V332, P1393, DOI 10.1056/NEJM199505253322101; Thompson J, 2001, MOL ENDOCRINOL, V15, P923, DOI 10.1210/me.15.6.923; Tomlins SA, 2006, CANCER RES, V66, P3396, DOI 10.1158/0008-5472.CAN-06-0168; Tomlins SA, 2005, SCIENCE, V310, P644, DOI 10.1126/science.1117679; Tomlins SA, 2007, NAT GENET, V39, P41, DOI 10.1038/ng1935; VISAKORPI T, 1995, NAT GENET, V9, P401, DOI 10.1038/ng0495-401; Wang QB, 2007, MOL CELL, V27, P380, DOI 10.1016/j.molcel.2007.05.041; Welsh JB, 2001, CANCER RES, V61, P5974; Xiao DM, 2002, REGUL PEPTIDES, V109, P141, DOI 10.1016/S0167-0115(02)00197-0; Yu YP, 2004, J CLIN ONCOL, V22, P2790, DOI 10.1200/JCO.2004.05.158; Zheng H, 2003, GENE DEV, V17, P2283, DOI 10.1101/gad.272503	46	34	45	1	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 21	2008	27	36					4865	4876		10.1038/onc.2008.125	http://dx.doi.org/10.1038/onc.2008.125			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	339SF	18469865				2022-12-28	WOS:000258596900001
J	Fanta, S; Sonnenberg, M; Skorta, I; Duyster, J; Miething, C; Aulitzky, WE; van der Kuip, H				Fanta, S.; Sonnenberg, M.; Skorta, I.; Duyster, J.; Miething, C.; Aulitzky, W. E.; van der Kuip, H.			Pharmacological inhibition of c-Abl compromises genetic stability and DNA repair in Bcr-Abl-negative cells	ONCOGENE			English	Article						imatinib mesylate; c-Abl; DNA repair; genetic stability	CHRONIC MYELOID-LEUKEMIA; TYROSINE KINASE INHIBITOR; IMATINIB MESYLATE; MUTATOR PHENOTYPE; DAMAGE; PHOSPHORYLATION; ASSOCIATION; ACTIVATION; GROWTH; STI571	Imatinib inhibits the kinase activity of Bcr-Abl and is currently the most effective drug for treatment of chronic myeloid leukemia (CML). Imatinib also blocks c-Abl, a physiological tyrosine kinase activated by a variety of stress signals including damaged DNA. We investigated the effect of pharmacological inhibition of c-Abl on the processing of irradiation-induced DNA damage in Bcr-Abl-negative cells. Cell lines and peripheral blood mononuclear cells (PBMCs) from healthy volunteers were treated with imatinib or dasatinib before gamma-irradiation. Inhibition of c-Abl caused an enhanced irradiation-induced mutation frequency and slowdown of DNA repair, whereas imatinib was ineffective in cells expressing a T315I variant of c-Abl. Mutation frequency and repair kinetics were also studied in c-Abl-/- murine embryonic fibroblasts (MEFs) retransfected with wild-type c-Abl (wt-Abl) or a kinase-defect variant of Abl (KD-Abl). Enhanced mutation frequency as well as delayed DNA repair was observed in cells expressing KD-Abl. These data indicate that pharmacological inhibition of c-Abl compromises DNA-damage response.	[Fanta, S.; Sonnenberg, M.; Skorta, I.; van der Kuip, H.] Dr Margarete Fischer Bosch Inst Clin Pharmacol, D-70376 Stuttgart, Germany; [Fanta, S.; Sonnenberg, M.; Skorta, I.; van der Kuip, H.] Univ Tubingen, Stuttgart, Germany; [Duyster, J.] Tech Univ Munich, Dept Internal Med 3, Munich, Germany; [Miething, C.] Cold Spring Harbor Lab, Ctr Canc, Cold Spring Harbor, NY 11724 USA; [Aulitzky, W. E.] Robert Bosch Krankenhaus, Dept Int Med Oncol & Hematol 2, Stuttgart, Germany	Eberhard Karls University of Tubingen; Eberhard Karls University Hospital; Eberhard Karls University of Tubingen; Technical University of Munich; University of Munich; Cold Spring Harbor Laboratory; Bosch; Robert Bosch Krankenhaus	van der Kuip, H (corresponding author), Dr Margarete Fischer Bosch Inst Clin Pharmacol, Auerbachstr 112, D-70376 Stuttgart, Germany.	heiko.van-der-kuip@ikp-stuttgart.de	Miething, Cornelius/F-9498-2014	Miething, Cornelius/0000-0003-4699-3805				Andersen MK, 2002, LEUKEMIA, V16, P1390, DOI 10.1038/sj.leu.2402634; Buchdunger E, 1996, CANCER RES, V56, P100; Canitrot Y, 1999, ONCOGENE, V18, P2676, DOI 10.1038/sj.onc.1202619; Carroll M, 1997, BLOOD, V90, P4947, DOI 10.1182/blood.V90.12.4947.4947_4947_4952; Cheng WH, 2003, MOL CELL BIOL, V23, P6385, DOI 10.1128/MCB.23.18.6385-6395.2003; Druker BJ, 1996, NAT MED, V2, P561, DOI 10.1038/nm0596-561; Druker BJ, 2006, NEW ENGL J MED, V355, P2408, DOI 10.1056/NEJMoa062867; Foray N, 2002, MOL CELL BIOL, V22, P4020, DOI 10.1128/MCB.22.12.4020-4032.2002; Goldberg Z, 2002, EMBO J, V21, P3715, DOI 10.1093/emboj/cdf384; Heinrich MC, 2000, BLOOD, V96, P925, DOI 10.1182/blood.V96.3.925.015k50_925_932; Imam SZ, 2007, NUCLEIC ACIDS RES, V35, P4941, DOI 10.1093/nar/gkm386; Kerkela R, 2006, NAT MED, V12, P908, DOI 10.1038/nm1446; Kharbanda S, 1997, NATURE, V386, P732, DOI 10.1038/386732a0; Kharbanda S, 1998, ONCOGENE, V17, P3309, DOI 10.1038/sj.onc.1202571; Michor F, 2005, NATURE, V435, P1267, DOI 10.1038/nature03669; Moehring A, 2005, CELL DEATH DIFFER, V12, P627, DOI 10.1038/sj.cdd.4401608; Picard S, 2007, BLOOD, V109, P3496, DOI 10.1182/blood-2006-07-036012; Salloukh HF, 2000, LEUKEMIA, V14, P1401, DOI 10.1038/sj.leu.2401855; Shaul Y, 2005, CELL RES, V15, P33, DOI 10.1038/sj.cr.7290261; SINGH NP, 1988, EXP CELL RES, V175, P184, DOI 10.1016/0014-4827(88)90265-0; Terre C, 2004, LEUKEMIA, V18, P1340, DOI 10.1038/sj.leu.2403399; Uemura N, 2000, BLOOD, V96, P3294; van der Kuip H, 2004, LEUKEMIA RES, V28, P405, DOI 10.1016/j.leukres.2003.08.012; Wang JYJ, 2000, ONCOGENE, V19, P5643, DOI 10.1038/sj.onc.1203878; Wei G, 2005, J BIOL CHEM, V280, P12271, DOI 10.1074/jbc.M409522200; Yuan ZM, 1999, NATURE, V399, P814, DOI 10.1038/21704; Yuan ZM, 1998, J BIOL CHEM, V273, P3799, DOI 10.1074/jbc.273.7.3799	27	18	18	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 17	2008	27	31					4380	4384		10.1038/onc.2008.68	http://dx.doi.org/10.1038/onc.2008.68			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	326WY	18362889				2022-12-28	WOS:000257691100013
J	Jeon, YJ; Kim, IK; Hong, SH; Nan, H; Kim, HJ; Lee, HJ; Masuda, ES; Meyuhas, O; Oh, BH; Jung, YK				Jeon, Y-J; Kim, I. K.; Hong, S-H; Nan, H.; Kim, H-J; Lee, H-J; Masuda, E. S.; Meyuhas, O.; Oh, B-H; Jung, Y-K			Ribosomal protein S6 is a selective mediator of TRAIL-apoptotic signaling	ONCOGENE			English	Article						TRAIL; apoptosis; ribosomal protein S6; S6 kinase 1; DR4; tumor cell	MESSENGER-RNA TRANSLATION; CELLS; PHOSPHORYLATION; RECEPTOR; FAMILY; LIGAND; IDENTIFICATION; INHIBITION; INDUCTION; PATHWAY	TRAIL (tumor necrosis factor-related apoptosis-inducing ligand) is a potent inducer of apoptosis in tumor cells and holds a promise as a therapeutic agent against cancer. To elucidate the death signaling evoked by TRAIL, we performed a functional genetic screening and rescued TRAIL-resistant Jurkat clones harboring ribosomal protein S6 (rpS6) cDNA in anti-sense frame. Reduction of rpS6 expression in Jurkat and HeLa cells attenuated apoptosis induced by TRAIL, but not those by other cell death signals, including tumor necrosis factor-a and cycloheximide, etoposide, doxorubicin, tunicamycin and staurosporine. Death receptor (DR) 4, but not DR5, was downregulated in rpS6 knockdown cells. Conversely, the sensitivity to TRAIL was increased by the ectopic expression of wild-type rpS6 and further by phospho-defective rpS6 mutant (S6-SS235,6AA), but not by phospho-mimic rpS6 mutant (S6-SS235,6DD). Also, unphosphorylatable rpS6 knock-in mouse embryo fibro-blasts (rpS6(P-/-) MEFs) were more sensitive to TRAIL than control MEFs. In addition, SKHep-1 tumor cells, which express less phospho-rpS6 and are more sensitive to TRAIL than other tumor cells, became effectively desensitized to TRAIL after rpS6 knockdown. These results suggest that rpS6, especially in its unphosphorylated form, is a selective mediator of TRAIL-induced apoptosis.	[Jeon, Y-J; Hong, S-H; Nan, H.; Kim, H-J; Lee, H-J; Jung, Y-K] Seoul Natl Univ, Sch Biol Sci, Biomax Inst, Seoul 151742, South Korea; [Kim, I. K.] Burnham Inst Med Res, La Jolla, CA USA; [Masuda, E. S.] Rigel Pharmaceut Inc, San Francisco, CA USA; [Meyuhas, O.] Hebrew Univ Jerusalem, Sch Med, Dept Biochem, IL-91010 Jerusalem, Israel; [Oh, B-H] Pohang Univ Sci & Technol, Dept Life Sci, Kyungbuk, South Korea	Seoul National University (SNU); Sanford Burnham Prebys Medical Discovery Institute; Hebrew University of Jerusalem; Pohang University of Science & Technology (POSTECH)	Jung, YK (corresponding author), Seoul Natl Univ, Sch Biol Sci, Biomax Inst, Seoul 151742, South Korea.	ykjung@snu.ac.kr	Lee, Ho-June/D-8855-2014	Lee, Ho-June/0000-0002-7019-2533; Jeon, Young-Jun/0000-0002-5998-9605; Masuda, Esteban/0000-0002-3175-2868; Jung, Yong-Keun/0000-0002-9686-3120				Ashkenazi A, 1999, J CLIN INVEST, V104, P155, DOI 10.1172/JCI6926; Beuvink I, 2005, CELL, V120, P747, DOI 10.1016/j.cell.2004.12.040; Fesik SW, 2005, NAT REV CANCER, V5, P876, DOI 10.1038/nrc1736; FRANCO R, 1990, J BIOL CHEM, V265, P4321; Harada H, 2001, P NATL ACAD SCI USA, V98, P9666, DOI 10.1073/pnas.171301998; Inoki K, 2005, NAT GENET, V37, P19, DOI 10.1038/ng1494; Jefferies HBJ, 1997, EMBO J, V16, P3693, DOI 10.1093/emboj/16.12.3693; Kim IK, 2000, BIOCHEM BIOPH RES CO, V277, P311, DOI 10.1006/bbrc.2000.3673; Kim KI, 2003, BRIT J CANCER, V88, P910, DOI 10.1038/sj.bjc.6600795; KRIEG J, 1988, J BIOL CHEM, V263, P11473; Nebbioso A, 2005, NAT MED, V11, P77, DOI 10.1038/nm1161; Pan GH, 1997, SCIENCE, V277, P815, DOI 10.1126/science.277.5327.815; Pan GH, 1997, SCIENCE, V276, P111, DOI 10.1126/science.276.5309.111; Panner A, 2005, MOL CELL BIOL, V25, P8809, DOI 10.1128/MCB.25.20.8809-8823.2005; Pende M, 2004, MOL CELL BIOL, V24, P3112, DOI 10.1128/MCB.24.8.3112-3124.2004; Pitt RM, 1996, J BIOL CHEM, V271, P12687, DOI 10.1074/jbc.271.22.12687; RAYMOND AD, 2005, CELL RES, V15, P430; Ren YG, 2004, MOL BIOL CELL, V15, P5064, DOI 10.1091/mbc.e04-03-0184; Ruvinsky I, 2005, GENE DEV, V19, P2199, DOI 10.1101/gad.351605; SHASHIREKHA S, 2005, MOL CELL BIOL, V25, P5404; Sheridan JP, 1997, SCIENCE, V277, P818, DOI 10.1126/science.277.5327.818; Stromberg T, 2004, BLOOD, V103, P3138, DOI 10.1182/blood-2003-05-1543; Wiley SR, 1995, IMMUNITY, V3, P673, DOI 10.1016/1074-7613(95)90057-8; Wu GS, 1997, NAT GENET, V17, P141, DOI 10.1038/ng1097-141	24	26	26	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 17	2008	27	31					4344	4352		10.1038/onc.2008.73	http://dx.doi.org/10.1038/onc.2008.73			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	326WY	18362888				2022-12-28	WOS:000257691100009
J	Hagos, EG; Ghaleb, AM; Dalton, WB; Bialkowska, AB; Yang, VW				Hagos, E. G.; Ghaleb, A. M.; Dalton, W. B.; Bialkowska, A. B.; Yang, V. W.			Mouse embryonic fibroblasts null for the Kruppel-like factor 4 gene are genetically unstable	ONCOGENE			English	Article						aneuploidy; centrosome amplification; cell cycle; chromosome aberrations; gamma-H2AX; KLF4	GASTRIC-CANCER DEVELOPMENT; CENTROSOME AMPLIFICATION; CYCLIN-E; CHROMOSOMAL INSTABILITY; TRANSCRIPTION FACTORS; CELL-PROLIFERATION; TUMOR-SUPPRESSOR; DNA-DAMAGE; ANEUPLOIDY; P53	Kruppel-like factor 4 (KLF4) is a zinc-finger transcription factor with tumor suppressive activity in colorectal cancer. Here, we investigated whether KLF4 is involved in maintaining genetic stability in mouse embryonic fibroblasts (MEFs) isolated from mice wild type (+/+), heterozygous (+/-), or homozygous (-/-) for the Klf4 alleles. Compared to Klf4(+/+) and Klf4(+/-) MEFs, Klf4(-/-) MEFs had both a higher level of apoptosis and rate of proliferation. Quantification of chromosome numbers showed that Klf4(-/-) MEFs were aneuploid. A higher number of Klf4(-/-) MEFs exhibited gamma-H2AX foci and had higher amounts of gamma-H2AX compared to controls. Cytogenetic analysis demonstrated the presence of numerous chromosome aberrations including dicentric chromosomes, chromatid breaks, and double minute chromosomes in Klf4(-/-) cells but in few, if any, Klf4(+/+) or Klf4(+/-) MEFs. Approximately 25% of Klf4(-/-) MEFs exhibited centrosome amplification in contrast to the less than 5% of Klf4(+/+) or Klf4(+/-) MEFs. Finally, only Klf4(-/-) MEFs were capable of anchorage-independent growth. Taken together, these findings demonstrate that MEFs null for the Klf4 alleles are genetically unstable, as evidenced by the presence of aneuploidy, chromosome aberration and centrosome amplification. The results support a crucial role for KLF4 in maintaining genetic stability and as a tumor suppressor.	[Hagos, E. G.; Ghaleb, A. M.; Dalton, W. B.; Bialkowska, A. B.; Yang, V. W.] Emory Univ, Sch Med, Dept Med, Div Digest Dis, Atlanta, GA 30322 USA; [Yang, V. W.] Emory Univ, Sch Med, Winship Canc Inst, Dept Hematol & Med Oncol, Atlanta, GA 30322 USA	Emory University; Emory University	Yang, VW (corresponding author), Emory Univ, Sch Med, Dept Med, Div Digest Dis, 201 Whitehead Res Bldg,615 Michael St, Atlanta, GA 30322 USA.	vyang@emory.edu	, ehagos/AAY-8486-2020; Dalton, William/M-7944-2017	Dalton, William/0000-0002-1314-0534	National Institutes of Health [DK52230, DK64399, CA84197]; NIH National Research Service Award [CA130308]; Emory Biochemistry, Cell and Developmental Biology (BCDB) training grant; NATIONAL CANCER INSTITUTE [R01CA084197, F32CA130308] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R24DK064399, R01DK052230] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008169] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIH National Research Service Award(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Emory Biochemistry, Cell and Developmental Biology (BCDB) training grant; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We thank Dr Klaus Kaestner and Dr Jonathan Katz for providing the Klf4<SUP>+/-</SUP> mice. This work was in part supported by grants from the National Institutes of Health ( DK52230, DK64399, and CA84197). EGH was an Emory Fellowships in Research and Science Teaching ( FIRST) fellow. AMG was the recipient of a NIH National Research Service Award ( CA130308). WBD was supported in part by an Emory Biochemistry, Cell and Developmental Biology (BCDB) training grant.	Bartkova J, 2006, NATURE, V444, P633, DOI 10.1038/nature05268; Bieker JJ, 2001, J BIOL CHEM, V276, P34355, DOI 10.1074/jbc.R100043200; Black AR, 2001, J CELL PHYSIOL, V188, P143, DOI 10.1002/jcp.1111; Chen XM, 2003, J MOL BIOL, V326, P665, DOI 10.1016/S0022-2836(02)01449-3; Chen XM, 2001, J BIOL CHEM, V276, P30423, DOI 10.1074/jbc.M101194200; Chng WJ, 2008, BLOOD, V111, P1603, DOI 10.1182/blood-2007-06-097774; D'Assoro AB, 2002, ONCOGENE, V21, P6146, DOI 10.1038/sj.onc.1205772; Dalton WB, 2007, CANCER RES, V67, P11487, DOI 10.1158/0008-5472.CAN-07-5162; Dang DT, 2000, INT J BIOCHEM CELL B, V32, P1103, DOI 10.1016/S1357-2725(00)00059-5; Dang DT, 2000, FEBS LETT, V476, P203, DOI 10.1016/S0014-5793(00)01727-0; Fukasawa K, 2005, CANCER LETT, V230, P6, DOI 10.1016/j.canlet.2004.12.028; Fukasawa K, 1996, SCIENCE, V271, P1744, DOI 10.1126/science.271.5256.1744; Fukasawa K, 1997, ONCOGENE, V15, P1295, DOI 10.1038/sj.onc.1201482; Fukasawa K, 2007, NAT REV CANCER, V7, P911, DOI 10.1038/nrc2249; Ganem NJ, 2007, CURR OPIN GENET DEV, V17, P157, DOI 10.1016/j.gde.2007.02.011; GarrettSinha LA, 1996, J BIOL CHEM, V271, P31384, DOI 10.1074/jbc.271.49.31384; Gartel AL, 2002, MOL CANCER THER, V1, P639; Ghadimi BM, 2000, GENE CHROMOSOME CANC, V27, P183, DOI 10.1002/(SICI)1098-2264(200002)27:2<183::AID-GCC10>3.0.CO;2-P; Ghaleb AM, 2007, ONCOGENE, V26, P2365, DOI 10.1038/sj.onc.1210022; Ghaleb AM, 2005, CELL RES, V15, P92, DOI 10.1038/sj.cr.7290271; Ghaleb AM, 2007, CANCER RES, V67, P7147, DOI 10.1158/0008-5472.CAN-07-1302; Ghaleb AM, 2008, CURR COLORECT CANC R, V4, P59, DOI 10.1007/s11888-008-0011-4; Hanashiro K, 2008, ONCOGENE, V27, P5288, DOI 10.1038/onc.2008.161; HARVEY M, 1993, ONCOGENE, V8, P2457; Hinchcliffe EH, 2002, ONCOGENE, V21, P6154, DOI 10.1038/sj.onc.1205826; Kaczynski J, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-2-206; Kanai M, 2006, CLIN CANCER RES, V12, P6395, DOI 10.1158/1078-0432.CCR-06-1034; Katz JP, 2005, GASTROENTEROLOGY, V128, P935, DOI 10.1053/j.gastro.2005.02.022; Katz JP, 2002, DEVELOPMENT, V129, P2619; Kawamura K, 2004, CANCER RES, V64, P4800, DOI 10.1158/0008-5472.CAN-03-3908; KIRSCHNER M, 1986, CELL, V45, P329, DOI 10.1016/0092-8674(86)90318-1; KIRSCHNER MW, 1986, NATURE, V324, P621, DOI 10.1038/324621a0; LEE JJ, 1990, ANAL BIOCHEM, V189, P1, DOI 10.1016/0003-2697(90)90036-9; LEE JM, 1994, ONCOGENE, V9, P3731; Lengauer C, 1998, NATURE, V396, P643, DOI 10.1038/25292; Lingle WL, 1999, AM J PATHOL, V155, P1941, DOI 10.1016/S0002-9440(10)65513-7; Lingle WL, 2002, P NATL ACAD SCI USA, V99, P1978, DOI 10.1073/pnas.032479999; Mayer F, 2003, ONCOGENE, V22, P3859, DOI 10.1038/sj.onc.1206469; McConnell BB, 2007, BIOESSAYS, V29, P549, DOI 10.1002/bies.20581; Rajagopalan H, 2004, NATURE, V432, P338, DOI 10.1038/nature03099; Rogakou EP, 1998, J BIOL CHEM, V273, P5858, DOI 10.1074/jbc.273.10.5858; Rowland BD, 2006, NAT REV CANCER, V6, P11, DOI 10.1038/nrc1780; Rowland BD, 2005, NAT CELL BIOL, V7, P1074, DOI 10.1038/ncb1314; Salisbury JL, 2004, J MAMMARY GLAND BIOL, V9, P275, DOI 10.1023/B:JOMG.0000048774.27697.30; Segre JA, 1999, NAT GENET, V22, P356, DOI 10.1038/11926; Shields JM, 1996, J BIOL CHEM, V271, P20009, DOI 10.1074/jbc.271.33.20009; Sotillo R, 2007, CANCER CELL, V11, P9, DOI 10.1016/j.ccr.2006.10.019; Spruck CH, 1999, NATURE, V401, P297, DOI 10.1038/45836; Takada Y, 2007, ONCOGENE, V26, P1201, DOI 10.1038/sj.onc.1209906; Tarapore P, 2002, ONCOGENE, V21, P6234, DOI 10.1038/sj.onc.1205707; Tarapore P, 2001, ONCOGENE, V20, P3173, DOI 10.1038/sj.onc.1204424; Tarapore P, 2002, CELL CYCLE, V1, P75, DOI 10.4161/cc.1.1.103; TODARO GJ, 1963, J CELL BIOL, V17, P299, DOI 10.1083/jcb.17.2.299; Tokuyama Y, 2001, J BIOL CHEM, V276, P21529, DOI 10.1074/jbc.M100014200; Weaver BAA, 2007, CANCER RES, V67, P10103, DOI 10.1158/0008-5472.CAN-07-2266; Weaver BAA, 2006, CURR OPIN CELL BIOL, V18, P658, DOI 10.1016/j.ceb.2006.10.002; Wei DY, 2005, CANCER RES, V65, P2746, DOI 10.1158/0008-5472.CAN-04-3619; Yoon HS, 2005, ONCOGENE, V24, P4017, DOI 10.1038/sj.onc.1208576; Yoon HS, 2004, J BIOL CHEM, V279, P5035, DOI 10.1074/jbc.M307631200; Yoon HS, 2003, J BIOL CHEM, V278, P2101, DOI 10.1074/jbc.M211027200; Zhang WQ, 2000, J BIOL CHEM, V275, P18391, DOI 10.1074/jbc.C000062200; Zhao WD, 2004, ONCOGENE, V23, P395, DOI 10.1038/sj.onc.1207067	62	34	35	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 5	2009	28	9					1197	1205		10.1038/onc.2008.465	http://dx.doi.org/10.1038/onc.2008.465			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	415AH	19137014	Green Accepted			2022-12-28	WOS:000263906200004
J	Lee, YG; Lee, SW; Sin, HS; Kim, EJ; Um, SJ				Lee, Y-G; Lee, S-W; Sin, H-S; Kim, E-J; Um, S-J			Kinase activity-independent suppression of p73 alpha by AMP-activated kinase alpha (AMPK alpha)	ONCOGENE			English	Article						p73 alpha; AMPK alpha; transcription; repression; cisplatin	PROTEIN-KINASE; TRANSCRIPTIONAL ACTIVITY; MAMMALIAN-CELLS; GENE-EXPRESSION; UPSTREAM KINASE; NITRIC-OXIDE; P73 FUNCTION; MEMBERS P63; SAM DOMAIN; P53	Although p73 alpha induces many of the same cellular events as p53, it is structurally distinct from p53 in that it possesses a unique COOH-terminal domain. To dissect the function of this domain, we performed yeast two-hybrid screening of a HeLa cDNA library using residues 552-636 of p73a as bait. Among the clones that showed a specific interaction with p73a was AMP-activated protein kinase alpha (AMPK alpha). Additional yeast two-hybrid assays indicated that the beta gamma-binding domain of AMPKa is critical for the interaction with p73 alpha. The interaction was further confirmed in vitro by glutathione S-transferase pull-down, and in vivo by immunoprecipitation and immunofluorescence microscopy. Transient coexpression of AMPKa resulted in downregulation of the effect of p73 alpha, but not of p53, on various p53-responsive promoters. Chromatin immunoprecipitation indicated p73 alpha-dependent recruitment of AMPKa to the p21WAF1 promoter. Treatment with 5-aminoimidazole-4-carboxamide ribonucleotide, an agonist of AMPK alpha, and expression of dominant-negative versions of AMPKa revealed that the repression of p73 alpha was independent of AMPK alpha kinase activity. In addition, cisplatin-induced growth repression was impaired when AMPK alpha was overexpressed. Upon the knock down of AMPKa by siRNA, the induction of p21WAF1 by p73 alpha was significantly increased. Taken together, these data indicate that AMPKa specifically regulates p73 alpha by a direct interaction without affecting its phosphorylation status. From these data, we speculate that AMPKa may provide a molecular clue to understand the repressive role of the C-terminus of p73 alpha in transcription and DNA damage response.	[Lee, Y-G; Lee, S-W; Um, S-J] Sejong Univ, Inst Biosci, Dept Biosci & Biotechnol, Seoul 143747, South Korea; [Sin, H-S; Um, S-J] Sejong Univ, Chebigen Inc, Seoul 143747, South Korea; [Kim, E-J] Dankook Univ, Dept Mol Biol, Gyeonggi Do, South Korea	Sejong University; Sejong University; Dankook University	Um, SJ (corresponding author), Sejong Univ, Inst Biosci, Dept Biosci & Biotechnol, 98 Kunjadong, Seoul 143747, South Korea.	nbrejk@dankook.ac.kr; umsj@sejong.ac.kr						Bentley D, 1999, CURR OPIN CELL BIOL, V11, P347, DOI 10.1016/S0955-0674(99)80048-9; Bronner M, 2004, BIOCHEM J, V384, P295, DOI 10.1042/BJ20040955; Chen H, 2003, J BIOL CHEM, V278, P45021, DOI 10.1074/jbc.M307878200; Cho YS, 2006, J BIOL CHEM, V281, P17588, DOI 10.1074/jbc.M512616200; Culmsee C, 2001, J MOL NEUROSCI, V17, P45, DOI 10.1385/JMN:17:1:45; Dai JM, 2007, J CELL PHYSIOL, V210, P161, DOI 10.1002/jcp.20831; Di Como CJ, 1999, MOL CELL BIOL, V19, P1438; Dietz S, 2002, FEBS LETT, V525, P93, DOI 10.1016/S0014-5793(02)03093-4; Hardie DG, 1998, ANNU REV BIOCHEM, V67, P821, DOI 10.1146/annurev.biochem.67.1.821; Hardie DG, 1999, BIOCHEM J, V338, P717, DOI 10.1042/0264-6021:3380717; Hawley SA, 2005, CELL METAB, V2, P9, DOI 10.1016/j.cmet.2005.05.009; Hurley RL, 2005, J BIOL CHEM, V280, P29060, DOI 10.1074/jbc.M503824200; Imamura K, 2001, BIOCHEM BIOPH RES CO, V287, P562, DOI 10.1006/bbrc.2001.5627; Jones RG, 2005, MOL CELL, V18, P283, DOI 10.1016/j.molcel.2005.03.027; Jost CA, 1997, NATURE, V389, P191, DOI 10.1038/38298; Kaghad M, 1997, CELL, V90, P809, DOI 10.1016/S0092-8674(00)80540-1; Kemp BE, 2003, BIOCHEM SOC T, V31, P162; Kemp BE, 1999, TRENDS BIOCHEM SCI, V24, P22, DOI 10.1016/S0968-0004(98)01340-1; Kim EJ, 2002, J BIOL CHEM, V277, P32020, DOI 10.1074/jbc.M200153200; Lau LMS, 2008, ONCOGENE, V27, P997, DOI 10.1038/sj.onc.1210707; Leclerc I, 2002, BIOCHEM SOC T, V30, P307, DOI 10.1042/bst0300307; Lee HK, 2007, EMBO J, V26, P3545, DOI 10.1038/sj.emboj.7601797; Lee M, 2003, J BIOL CHEM, V278, P39653, DOI 10.1074/jbc.M306104200; Leff T, 2003, BIOCHEM SOC T, V31, P224; Liu G, 2005, J BIOL CHEM, V280, P20111, DOI 10.1074/jbc.M413889200; Lizcano JM, 2004, EMBO J, V23, P833, DOI 10.1038/sj.emboj.7600110; Lo WS, 2001, SCIENCE, V293, P1142, DOI 10.1126/science.1062322; McGrath JA, 2001, HUM MOL GENET, V10, P221, DOI 10.1093/hmg/10.3.221; Osada M, 1998, NAT MED, V4, P839, DOI 10.1038/nm0798-839; Ozaki T, 1999, CANCER RES, V59, P5902; Pilon G, 2004, J BIOL CHEM, V279, P20767, DOI 10.1074/jbc.M401390200; Pozniak CD, 2000, SCIENCE, V289, P304, DOI 10.1126/science.289.5477.304; Pozniak CD, 2002, J NEUROSCI, V22, P9800; Salt I, 1998, BIOCHEM J, V334, P177, DOI 10.1042/bj3340177; Sbisa E, 2007, BMC BIOINFORMATICS, V8, DOI 10.1186/1471-2105-8-S1-S20; Shaw RJ, 2004, P NATL ACAD SCI USA, V101, P3329, DOI 10.1073/pnas.0308061100; Solaz-Fuster MC, 2006, CELL SIGNAL, V18, P1702, DOI 10.1016/j.cellsig.2006.01.021; Stein SC, 2000, BIOCHEM J, V345, P437, DOI 10.1042/0264-6021:3450437; Thanos CD, 1999, PROTEIN SCI, V8, P1708, DOI 10.1110/ps.8.8.1708; Turnley AM, 1999, J NEUROCHEM, V72, P1707, DOI 10.1046/j.1471-4159.1999.721707.x; Wang Shaowen, 2004, Novartis Found Symp, V259, P238; Weiske J, 2006, J BIOL CHEM, V281, P27356, DOI 10.1074/jbc.M513452200; Woods A, 2003, CURR BIOL, V13, P2004, DOI 10.1016/j.cub.2003.10.031; Woods A, 2005, CELL METAB, V2, P21, DOI 10.1016/j.cmet.2005.06.005; Xavier GD, 2000, P NATL ACAD SCI USA, V97, P4023, DOI 10.1073/pnas.97.8.4023; Yang A, 2000, NATURE, V404, P99, DOI 10.1038/35003607; Yang AN, 1998, MOL CELL, V2, P305, DOI 10.1016/S1097-2765(00)80275-0	47	12	13	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 19	2009	28	7					1040	1052		10.1038/onc.2008.452	http://dx.doi.org/10.1038/onc.2008.452			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	408TH	19079340				2022-12-28	WOS:000263457400010
J	Lodyga, M; De Falco, V; Bai, XH; Kapus, A; Melillo, RM; Santoro, M; Liu, M				Lodyga, M.; De Falco, V.; Bai, X-H; Kapus, A.; Melillo, R. M.; Santoro, M.; Liu, M.			XB130, a tissue-specific adaptor protein that couples the RET/PTC oncogenic kinase to PI 3-kinase pathway	ONCOGENE			English	Article						adaptor protein; protein tyrosine phosphorylation; thyroid cancer; RET/PTC; phosphatidylinositol 3-kinase; PKB/AKT	THYROID PAPILLARY CARCINOMAS; TYROSINE KINASE; PHOSPHATIDYLINOSITOL 3-KINASE; SIGNAL-TRANSDUCTION; RET PROTOONCOGENE; SH2 DOMAINS; PHOSPHOINOSITIDE 3-KINASE; MAP KINASE; CELL LINE; RAS	XB130 is a recently cloned 130kDa-adaptor protein and Src kinase substrate, structurally similar to actin-filament-associated protein. Here we show that XB130 is predominantly expressed in the thyroid. Given that XB130 is a thyroid-specific tyrosine kinase substrate, we asked whether it is targeted by RET/PTC, a genetically rearranged, constitutively active, thyroid-specific tyrosine kinase that plays a pathogenic role in papillary thyroid cancer. RET/PTC induced robust tyrosine phosphorylation of XB130, which promoted its subsequent association with the p85 alpha subunit of phosphatidylinositol 3-kinase (PI 3-kinase). We identified tyrosine 54 of XB130 as the major target of RET/PTC-mediated phosphorylation and a critical binding site for the SH2 domains of p85 alpha. Importantly, downregulation of XB130 in TPC1 papillary thyroid cancer cells, harboring the RET/PTC1 kinase, strongly reduced Akt activity without altering ERK1/2 phosphorylation, and concomitantly inhibited cell-cycle progression and survival in suspension. In conclusion, XB130 is a novel substrate of the RET/PTC kinase that links RET/PTC signaling to PI 3-kinase activation, and thereby plays an important role in sustaining proliferation and survival of thyroid tumor cells.	[Lodyga, M.; Bai, X-H; Liu, M.] Univ Hlth Network, Toronto Gen Hosp, Div Cellular & Mol Biol, Toronto, ON M5G 1L7, Canada; [De Falco, V.; Melillo, R. M.; Santoro, M.] Inst Endocrinol & Oncol Sperimentale CNR G Salvat, Dipartimento Biol & Patol Cellulare & Mol, Naples, Italy; [Kapus, A.; Liu, M.] Univ Toronto, Dept Surg, Toronto, ON, Canada	University of Toronto; University Toronto Affiliates; University Health Network Toronto; Toronto General Hospital; Consiglio Nazionale delle Ricerche (CNR); Istituto per Endocrinologia e Oncologia "Gaetano Salvatore" (IEOS-CNR); University of Toronto	Liu, M (corresponding author), Univ Hlth Network, Toronto Gen Hosp, Div Cellular & Mol Biol, TMDT 2-814,101 Coll St, Toronto, ON M5G 1L7, Canada.	masantor@unina.it; mingyao.liu@utoronto.ca	melillo, rosa marina/O-5255-2015; DE FALCO, VALENTINA/C-2061-2015	DE FALCO, VALENTINA/0000-0002-8972-7921; Liu, Mingyao/0000-0002-9188-8417; MELILLO, Rosa Marina/0000-0002-9233-5275	AstraZeneca [ZD6474]; Canadian Institutes of Health Research [MOP-13270, MOP-42546]; European Union [FP636495]; Associazione Italiana per la Ricerca sul Cancro Funding Source: Custom	AstraZeneca(AstraZeneca); Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR)); European Union(European Commission); Associazione Italiana per la Ricerca sul Cancro(Fondazione AIRC per la ricerca sul cancro)	We are grateful to Dr B Han and Dr D Winer for technical assistance. We thank AJ Ryan, AstraZeneca for the ZD6474 inhibitor. We also thank Dr S Asa and JM Hershman for human thyroid cell lines, Dr G Pelicci for GST- fusion proteins and Dr M Chiariello for the Src mutant. This work was supported by operating grants (MOP-13270, MOP-42546) from Canadian Institutes of Health Research, a grant from the Italian Association for Cancer Research, MIUR, Alleanza contro iL Cancro and the European Union Contract FP636495 (GENRISK-T).	Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; Arighi E, 2005, CYTOKINE GROWTH F R, V16, P441, DOI 10.1016/j.cytogfr.2005.05.010; BACKER JM, 1992, EMBO J, V11, P3469, DOI 10.1002/j.1460-2075.1992.tb05426.x; Besset V, 2000, J BIOL CHEM, V275, P39159, DOI 10.1074/jbc.M006908200; Carlomagno F, 2002, CANCER RES, V62, P7284; CARPENTER CL, 1993, J BIOL CHEM, V268, P9478; Castellone MD, 2003, ONCOGENE, V22, P246, DOI 10.1038/sj.onc.1206112; De Falco V, 2005, ONCOGENE, V24, P6303, DOI 10.1038/sj.onc.1208776; de Martimprey H, 2008, NUCLEIC ACIDS RES, V36, DOI 10.1093/nar/gkm1094; ESCOBEDO JA, 1991, CELL, V65, P75, DOI 10.1016/0092-8674(91)90409-R; FLYNN DC, 1993, MOL CELL BIOL, V13, P7892, DOI 10.1128/MCB.13.12.7892; Giordano TJ, 2005, ONCOGENE, V24, P6646, DOI 10.1038/sj.onc.1208822; GRIECO M, 1990, CELL, V60, P557, DOI 10.1016/0092-8674(90)90659-3; Han B, 2004, J BIOL CHEM, V279, P54793, DOI 10.1074/jbc.M406880200; HARLAN JE, 1994, NATURE, V371, P168, DOI 10.1038/371168a0; HASLAM RJ, 1993, NATURE, V363, P309, DOI 10.1038/363309b0; Hayashi H, 2000, ONCOGENE, V19, P4469, DOI 10.1038/sj.onc.1203799; Hemmings BA, 1997, SCIENCE, V277, P534, DOI 10.1126/science.277.5325.534; Iavarone C, 2006, J BIOL CHEM, V281, P10567, DOI 10.1074/jbc.M513397200; Iwashita T, 1996, ONCOGENE, V12, P481; Jung HS, 2005, MOL ENDOCRINOL, V19, P2748, DOI 10.1210/me.2005-0122; Kaplan DR, 1997, CURR OPIN CELL BIOL, V9, P213, DOI 10.1016/S0955-0674(97)80065-8; Knauf JA, 2003, ONCOGENE, V22, P4406, DOI 10.1038/sj.onc.1206602; Lodyga M, 2002, AM J PHYSIOL-LUNG C, V283, pL265, DOI 10.1152/ajplung.00492.2001; Maeda K, 2004, BIOCHEM BIOPH RES CO, V323, P345, DOI 10.1016/j.bbrc.2004.08.095; Mai KT, 2001, THYROID, V11, P859, DOI 10.1089/105072501316973118; Mariggio S, 2007, CANCER RES, V67, P11769, DOI 10.1158/0008-5472.CAN-07-1997; Marte BM, 1997, TRENDS BIOCHEM SCI, V22, P355, DOI 10.1016/S0968-0004(97)01097-9; Melillo RM, 2005, J CLIN INVEST, V115, P1068, DOI 10.1172/JCI22758; Melillo RM, 2001, ONCOGENE, V20, P209, DOI 10.1038/sj.onc.1204049; Miyagi E, 2004, MOL CARCINOGEN, V41, P98, DOI 10.1002/mc.20042; Pelicci G, 2002, MOL CELL BIOL, V22, P7351, DOI 10.1128/MCB.22.20.7351-7363.2002; PIEROTTI MA, 1992, P NATL ACAD SCI USA, V89, P1616, DOI 10.1073/pnas.89.5.1616; RORDORFNIKOLIC T, 1995, J BIOL CHEM, V270, P3662, DOI 10.1074/jbc.270.8.3662; SANTORO M, 1994, MOL CELL BIOL, V14, P663, DOI 10.1128/MCB.14.1.663; SANTORO M, 1993, CELL GROWTH DIFFER, V4, P77; SANTORO M, 1994, ONCOGENE, V9, P509; Santoro M, 1996, ONCOGENE, V12, P1821; TAKAHASHI M, 1988, ONCOGENE, V3, P571; Xu J, 2007, J BIOL CHEM, V282, P16401, DOI 10.1074/jbc.M701684200	40	51	55	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 19	2009	28	7					937	949		10.1038/onc.2008.447	http://dx.doi.org/10.1038/onc.2008.447			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	408TH	19060924				2022-12-28	WOS:000263457400001
J	Dar, AA; Belkhiri, A; El-Rifai, W				Dar, A. A.; Belkhiri, A.; El-Rifai, W.			The aurora kinase A regulates GSK-3 beta in gastric cancer cells	ONCOGENE			English	Article						AURKA; GSK-3 beta; beta-catenin; gastric cancer	BETA-CATENIN; FREQUENT OVEREXPRESSION; BARRETTS-ESOPHAGUS; OVARIAN-CANCER; CYCLIN D1; PATHWAY; CARCINOMA; TARGET; GENE; ACTIVATION	Aurora kinase A (AURKA) is located at 20q13, a region that is frequently amplified in gastric cancer. In this study, we have investigated the role of AURKA in regulating glycogen synthase kinase (GSK)-3 beta and beta-catenin/TCF complex in gastric cancer cells. Our results demonstrate a significant increase in the phosphorylation of GSK-3 beta at Ser 9 following the overexpression of AURKA in AGS cells. The immuno-precipitation with antibodies specific for AURKA and GSK-3 beta indicated that the two proteins coexist in the same protein complex. The recombinant human AURKA protein phosphorylated the GSK-3 beta protein at Ser 9 in a concentration-dependent manner, in vitro. The phosphorylation of beta-catenin (Ser33/37/Thr41) by GSK-3 beta is known to target beta-catenin towards degradation. In line with our findings, the increase in phospho-GSK-3 beta level was accompanied by a significant decrease in beta-catenin phosphorylation (Ser33/37/Thr41) and accumulation of beta-catenin protein. The knockdown of AURKA reversed the phosphorylation of GSK-3 beta and the beta-catenin protein levels. The immunofluorescence analysis demonstrated colocalization of AURKA and GSK-3 beta proteins and a significant increase in the nuclear beta-catenin levels in cells overexpressing AURKA. The beta-catenin/TCF transcription activity was measured using the pTopFlash and its mutant pFopFlash luciferase reporter vectors. Indeed, AURKA overexpression led to a significant increase in the pTopFlash reporter activity, whereas kinase dead AURKA mutant (D274A) had no effect. Consistent with these findings, we detected a significant mRNA up-regulation of several direct targets of the beta-catenin/TCF transcription complex (cyclin D1, c-MYC, c-MYC-binding protein, CLDN1, FGF18 and vascular endothelial growth factor), and a two-fold increase in the proliferation rate in AURKA overexpressing cells. We conclude that the AURKA/GSK-3 beta interaction is important in regulating beta-catenin, underscoring a novel oncogenic potential for AURKA in gastric tumorigenesis.	[El-Rifai, W.] Vanderbilt Univ, Med Ctr, Vanderbilt Ingram Canc Ctr, Nashville, TN 37232 USA; [Dar, A. A.; Belkhiri, A.; El-Rifai, W.] Vanderbilt Univ, Med Ctr, Dept Surg, Nashville, TN 37232 USA; [El-Rifai, W.] Vanderbilt Univ, Med Ctr, Dept Canc Biol, Nashville, TN 37232 USA	Vanderbilt University; Vanderbilt University; Vanderbilt University	El-Rifai, W (corresponding author), Vanderbilt Univ, Med Ctr, Vanderbilt Ingram Canc Ctr, 1255 Light Hall,2215 Garland Ave, Nashville, TN 37232 USA.	wael.el-rifai@vanderbilt.edu			National Cancer Institute [CA95103]; Vanderbilt-Ingram Cancer Center; NATIONAL CANCER INSTITUTE [R01CA131225, P50CA095103] Funding Source: NIH RePORTER	National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Vanderbilt-Ingram Cancer Center; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This study was supported by a pilot fund from the National Cancer Institute GI SPORE grant CA95103 and the Vanderbilt-Ingram Cancer Center support funds. The contents of this work are solely the responsibility of the authors and do not necessarily represent the official views of the National Cancer Institute or Vanderbilt University Medical Center.	Aberle H, 1997, EMBO J, V16, P3797, DOI 10.1093/emboj/16.13.3797; Behrens J, 1996, NATURE, V382, P638, DOI 10.1038/382638a0; Bischoff JR, 1998, EMBO J, V17, P3052, DOI 10.1093/emboj/17.11.3052; Clements WM, 2002, CANCER RES, V62, P3503; Crawford HC, 1999, ONCOGENE, V18, P2883, DOI 10.1038/sj.onc.1202627; Damalas A, 1999, EMBO J, V18, P3054, DOI 10.1093/emboj/18.11.3054; Dar AA, 2008, CANCER-AM CANCER SOC, V112, P1688, DOI 10.1002/cncr.23371; Earle CC, 1999, EUR J CANCER, V35, P1059, DOI 10.1016/S0959-8049(99)00076-3; El-Rifai W, 2002, CANCER RES, V62, P6823; El-Rifai W, 2001, GASTROENTEROLOGY, V121, P592, DOI 10.1053/gast.2001.27215; Gamallo C, 1999, AM J PATHOL, V155, P527, DOI 10.1016/S0002-9440(10)65148-6; Giet R, 2005, TRENDS CELL BIOL, V15, P241, DOI 10.1016/j.tcb.2005.03.004; Giet R, 1999, J CELL SCI, V112, P3591; Giles FJ, 2007, BLOOD, V109, P500, DOI 10.1182/blood-2006-05-025049; Giles RH, 2003, BBA-REV CANCER, V1653, P1, DOI 10.1016/S0304-419X(03)00005-2; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; Hojilla CV, 2007, J CELL SCI, V120, P1050, DOI 10.1242/jcs.003335; Hu W, 2005, ONCOL RES, V15, P49, DOI 10.3727/096504005775082101; Jemal A, 2006, CA-CANCER J CLIN, V56, P106, DOI 10.3322/canjclin.56.2.106; Kamada K, 2004, ONCOL REP, V12, P593; Katayama H, 2004, NAT GENET, V36, P55, DOI 10.1038/ng1279; Kikuchi A, 2006, EXP MOL MED, V38, P1, DOI 10.1038/emm.2006.1; Koh TJ, 2000, J CLIN INVEST, V106, P533, DOI 10.1172/JCI9476; Miller JR, 1999, ONCOGENE, V18, P7860, DOI 10.1038/sj.onc.1203245; Mitsiades CS, 2004, CURR CANCER DRUG TAR, V4, P235, DOI 10.2174/1568009043333032; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; NAKATSURU S, 1992, HUM MOL GENET, V1, P559, DOI 10.1093/hmg/1.8.559; Ogawa E, 2008, ANN SURG ONCOL, V15, P547, DOI 10.1245/s10434-007-9653-8; Orford K, 1997, J BIOL CHEM, V272, P24735, DOI 10.1074/jbc.272.40.24735; Ouchi M, 2004, J BIOL CHEM, V279, P19643, DOI 10.1074/jbc.M311780200; Pap M, 1998, J BIOL CHEM, V273, P19929, DOI 10.1074/jbc.273.32.19929; Pennica D, 1998, P NATL ACAD SCI USA, V95, P14717, DOI 10.1073/pnas.95.25.14717; Polakis P, 1999, CURR OPIN GENET DEV, V9, P15, DOI 10.1016/S0959-437X(99)80003-3; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Shtutman M, 1999, P NATL ACAD SCI USA, V96, P5522, DOI 10.1073/pnas.96.10.5522; Sourbier C, 2006, CANCER RES, V66, P5130, DOI 10.1158/0008-5472.CAN-05-1469; Sparks AB, 1998, CANCER RES, V58, P1130; Tanaka T, 1999, CANCER RES, V59, P2041; Terris B, 1999, ONCOGENE, V18, P6583, DOI 10.1038/sj.onc.1203051; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; Tong T, 2004, CLIN CANCER RES, V10, P7304, DOI 10.1158/1078-0432.CCR-04-0806; Varis A, 2001, CANCER GENET CYTOGEN, V127, P53, DOI 10.1016/S0165-4608(00)00423-4; Voeller HJ, 1998, CANCER RES, V58, P2520; Wang Chenguang, 2004, Cancer Treat Res, V119, P217; Washington K, 1998, MODERN PATHOL, V11, P805; Yamada T, 2000, CANCER RES, V60, P4761; Yang H, 2006, INT J CANCER, V119, P2304, DOI 10.1002/ijc.22154; ZHANG YJ, 1993, BIOCHEM BIOPH RES CO, V196, P1010, DOI 10.1006/bbrc.1993.2350; Zhou HY, 1998, NAT GENET, V20, P189, DOI 10.1038/2496	49	106	108	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2009	28	6					866	875		10.1038/onc.2008.434	http://dx.doi.org/10.1038/onc.2008.434			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	406UI	19060929	Green Accepted			2022-12-28	WOS:000263320000009
J	Gonzalez, ME; Li, X; Toy, K; DuPrie, M; Ventura, AC; Banerjee, M; Ljungman, M; Merajver, SD; Kleer, CG				Gonzalez, M. E.; Li, X.; Toy, K.; DuPrie, M.; Ventura, A. C.; Banerjee, M.; Ljungman, M.; Merajver, S. D.; Kleer, C. G.			Downregulation of EZH2 decreases growth of estrogen receptor-negative invasive breast carcinoma and requires BRCA1	ONCOGENE			English	Article						EZH2; polycomb group protein; breast cancer; basal-cell phenotype; BRCA1; G(2)/M	GROUP PROTEIN EZH2; DNA-DAMAGE RESPONSE; CELL-CYCLE; CDC25C PHOSPHATASE; GENE-EXPRESSION; TARGET GENES; CANCER; POLYCOMB; PHOSPHORYLATION; PROLIFERATION	Increased levels of enhancer of zeste homolog 2 (EZH2), a critical regulator of cellular memory, are associated with negative estrogen receptor (ER) expression and disease progression in breast cancer. High levels of EZH2 signal the presence of metastasis and poor outcome in breast cancer patients. To test the hypothesis that deregulation of EZH2 contributes to ER-negative breast cancer progression, EZH2 expression was inhibited in ER-negative breast cancer cells MDA-MB-231 and CAL51 using a lentivirus system. EZH2 knockdown decreased proliferation and delayed the G(2)/M cell-cycle transition, although not affecting apoptosis. In vivo, EZH2 downregulation significantly decreased breast xenograft growth and improved survival. EZH2 knockdown upregulated BRCA1 protein. Of note, BRCA1 knockdown was sufficient to rescue the effects of EZH2 downregulation on proliferation, G(2)/M arrest, and on the levels of hyperphosphorylated mitotic Cdc25C and Cyclin B1 proteins, crucial for entry into mitosis. Invasive ER-negative breast carcinomas show significant overexpression of EZH2 and downregulation of BRCA1 proteins. Taken together, we show that EZH2 is important in ER-negative breast cancer growth in vivo and in vitro, and that BRCA1 is required for the proliferative effects of EZH2. Blockade of EZH2 may provide a prime target to prevent and/or halt ER-negative breast cancer progression.	[Gonzalez, M. E.; Li, X.; Toy, K.; DuPrie, M.; Kleer, C. G.] Univ Michigan, Sch Med, Dept Pathol, Ann Arbor, MI 48109 USA; [Ventura, A. C.; Merajver, S. D.] Univ Michigan, Sch Med, Div Hematol Oncol, Dept Internal Med, Ann Arbor, MI 48109 USA; [Ventura, A. C.; Banerjee, M.; Ljungman, M.; Merajver, S. D.; Kleer, C. G.] Univ Michigan, Sch Med, Ctr Comprehens Canc, Ann Arbor, MI 48109 USA; [Banerjee, M.] Univ Michigan, Sch Med, Dept Biostat, Ann Arbor, MI 48109 USA; [Ljungman, M.] Univ Michigan, Sch Med, Dept Radiat Oncol, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Kleer, CG (corresponding author), Univ Michigan, Sch Med, Dept Pathol, 4217 Comprehens Canc Ctr,1500 E Med Ctr Dr, Ann Arbor, MI 48109 USA.	kleer@umich.edu			NIH [CA090876, CA107469, CA77612]; Avon Foundation; Burroughs Wellcome Fund; Department of Defense Breast Cancer Research Program; NATIONAL CANCER INSTITUTE [R01CA077612, K08CA090876, R01CA107469] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Avon Foundation; Burroughs Wellcome Fund(Burroughs Wellcome Fund); Department of Defense Breast Cancer Research Program(United States Department of Defense); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Dr Arul Chinnaiyan for the EZH2 plasmid, and Tracey Filzen for technical support. We thank Robin Kunkel for assistance with artwork. We thank the University of Michigan Vector Core for virus generation. This work was supported by NIH grants CA090876 (CGK), CA107469 (CGK), CA77612 (SDM), a grant from the Avon Foundation (CGK), a grant from the Burroughs Wellcome Fund (SDM) and a grant from the Department of Defense Breast Cancer Research Program(ACV).	Bachmann IM, 2006, J CLIN ONCOL, V24, P268, DOI 10.1200/JCO.2005.01.5180; Bae I, 2005, CELL CYCLE, V4, P1641, DOI 10.4161/cc.4.11.2152; Bonnet J, 2008, BIOCHEM BIOPH RES CO, V370, P483, DOI 10.1016/j.bbrc.2008.03.117; Bracken AP, 2003, EMBO J, V22, P5323, DOI 10.1093/emboj/cdg542; Bulavin DV, 2003, NAT CELL BIOL, V5, P545, DOI 10.1038/ncb994; Cao R, 2002, SCIENCE, V298, P1039, DOI 10.1126/science.1076997; Collett K, 2006, CLIN CANCER RES, V12, P1168, DOI 10.1158/1078-0432.CCR-05-1533; Cortez D, 1999, SCIENCE, V286, P1162, DOI 10.1126/science.286.5442.1162; Ding L, 2006, CANCER RES, V66, P4095, DOI 10.1158/0008-5472.CAN-05-4300; Dunphy William G., 1994, Trends in Cell Biology, V4, P202; ELLIS MJ, 2000, DIS BREAST, P749; Elstrodt F, 2006, CANCER RES, V66, P41, DOI 10.1158/0008-5472.CAN-05-2853; Fan MY, 2000, CANCER RES, V60, P6403; Foulkes WD, 2003, J NATL CANCER I, V95, P1482, DOI 10.1093/jnci/djg050; Hayes DF, 2001, J MAMMARY GLAND BIOL, V6, P375, DOI 10.1023/A:1014778713034; HOFFMANN I, 1993, EMBO J, V12, P53, DOI 10.1002/j.1460-2075.1993.tb05631.x; Jacobs JJL, 1999, NATURE, V397, P164, DOI 10.1038/16476; Jacobs JJL, 1999, GENE DEV, V13, P2678, DOI 10.1101/gad.13.20.2678; Kirmizis A, 2004, GENE DEV, V18, P1592, DOI 10.1101/gad.1200204; Kleer CG, 2003, P NATL ACAD SCI USA, V100, P11606, DOI 10.1073/pnas.1933744100; Kuzmichev A, 2002, GENE DEV, V16, P2893, DOI 10.1101/gad.1035902; Laible G, 1997, EMBO J, V16, P3219, DOI 10.1093/emboj/16.11.3219; Lakhani SR, 2005, CLIN CANCER RES, V11, P5175, DOI 10.1158/1078-0432.CCR-04-2424; MacLachlan TK, 2000, J BIOL CHEM, V275, P2777, DOI 10.1074/jbc.275.4.2777; Mullan PB, 2006, ONCOGENE, V25, P5854, DOI 10.1038/sj.onc.1209872; Narod SA, 2004, NAT REV CANCER, V4, P665, DOI 10.1038/nrc1431; Peng CY, 1997, SCIENCE, V277, P1501, DOI 10.1126/science.277.5331.1501; Ringrose L, 2004, ANNU REV GENET, V38, P413, DOI 10.1146/annurev.genet.38.072902.091907; Roshak AK, 2000, CELL SIGNAL, V12, P405, DOI 10.1016/S0898-6568(00)00080-2; Satijn DPE, 1999, BBA-GENE STRUCT EXPR, V1447, P1, DOI 10.1016/S0167-4781(99)00130-X; Shi B, 2007, MOL CELL BIOL, V27, P5105, DOI 10.1128/MCB.00162-07; Smits VAJ, 2001, BBA-GENE STRUCT EXPR, V1519, P1, DOI 10.1016/S0167-4781(01)00204-4; STRAUSFELD U, 1994, J BIOL CHEM, V269, P5989; Su I, 2005, CELL, V121, P425, DOI 10.1016/j.cell.2005.02.029; Tonini T, 2004, ONCOGENE, V23, P4930, DOI 10.1038/sj.onc.1207608; Turner N, 2004, NAT REV CANCER, V4, P814, DOI 10.1038/nrc1457; Turner NC, 2007, ONCOGENE, V26, P2126, DOI 10.1038/sj.onc.1210014; Varambally S, 2002, NATURE, V419, P624, DOI 10.1038/nature01075; Venkitaraman AR, 2002, CELL, V108, P171, DOI 10.1016/S0092-8674(02)00615-3; Wilson CA, 1999, NAT GENET, V21, P236, DOI 10.1038/6029; Xu B, 2001, MOL CELL BIOL, V21, P3445, DOI 10.1128/MCB.21.10.3445-3450.2001; Yan Y, 2005, ONCOGENE, V24, P3285, DOI 10.1038/sj.onc.1208492; Yoshikawa K, 2000, INT J CANCER, V88, P28, DOI 10.1002/1097-0215(20001001)88:1<28::AID-IJC5>3.0.CO;2-4; Yuli C, 2007, ONCOGENE, V26, P6031, DOI 10.1038/sj.onc.1210420	44	140	151	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2009	28	6					843	853		10.1038/onc.2008.433	http://dx.doi.org/10.1038/onc.2008.433			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	406UI	19079346	Green Accepted			2022-12-28	WOS:000263320000007
J	Jimeno, A; Chan, A; Cusatis, G; Zhang, X; Wheelhouse, J; Solomon, A; Chan, F; Zhao, M; Cosenza, SC; Reddy, MVR; Rudek, MA; Kulesza, P; Donehower, RC; Reddy, EP; Hidalgo, M				Jimeno, A.; Chan, A.; Cusatis, G.; Zhang, X.; Wheelhouse, J.; Solomon, A.; Chan, F.; Zhao, M.; Cosenza, S. C.; Reddy, M. V. Ramana; Rudek, M. A.; Kulesza, P.; Donehower, R. C.; Reddy, E. P.; Hidalgo, M.			Evaluation of the novel mitotic modulator ON 01910.Na in pancreatic cancer and preclinical development of an ex vivo predictive assay	ONCOGENE			English	Article						pancreatic cancer; xenograft model; biomarker; ex vivo; cyclin B1; mitotic modulator	POLO-LIKE KINASE-1; CELL-DIVISION; CYCLIN B1; CHEMOTHERAPY SENSITIVITY; RESISTANCE ASSAYS; IN-VIVO; ARREST; OVEREXPRESSION; LEADS	The pupose of this study was to evaluate the activity of ON 01910.Na, a mitotic inhibitor, in in vitro and in vivo models of pancreatic cancer and to discover biomarkers predictive of efficacy. Successive in vitro and in vivo models were used; these included cell line-derived and patient-derived tumors from our PancXenoBank, a live collection of freshly generated pancreatic cancer xeno-grafts. ON 01910.Na showed equivalent activity to gemcitabine against pancreatic cancer cell lines in vitro. The activity of the agent correlated with suppression of phospho-CDC25C and cyclin B1. These markers were optimized for a fine-needle aspirate ex vivo rapid assay. Cyclin B1 mRNA evaluation yielded the most optimal combination of accuracy and reproducibility. Next, nine patient-derived tumors from the PancXenoBank were pro. led using the assay developed in cell lines and treated with ON01910.Na for 28 days. Two cases were cataloged as potential responders and seven as resistants. There was a correlation between the ex vivo assay and sensitivity to the tested agent, as the two cases prospectively identified as sensitive met prespecified criteria for response. Of the seven tumors of predictive resistant, only one was found to be sensitive to ON 01910.Na. In addition, there was a good correlation between cyclin B1 downregulation ex vivo and changes in cyclin B1 protein post-treatment. The novel mitotic inhibitor, ON 01910.Na, showed activity in preclinical model of pancreatic cancer. A rapid assay was rationally developed that not only identified cases sensitive to ON 01910.Na, but also anticipated the pharmacodynamic events occurring after in vivo exposure.	[Jimeno, A.; Chan, A.; Cusatis, G.; Zhang, X.; Wheelhouse, J.; Solomon, A.; Chan, F.; Zhao, M.; Rudek, M. A.; Donehower, R. C.; Hidalgo, M.] Johns Hopkins Univ, Sidney Kimmel Comprehens Canc Ctr, Dept Oncol, Baltimore, MD 21231 USA; [Cosenza, S. C.; Reddy, M. V. Ramana; Reddy, E. P.] Temple Univ, Sch Med, Fels Inst Canc Res & Mol Biol, Dept Biochem, Philadelphia, PA 19122 USA; [Kulesza, P.] Univ Alabama, Dept Pathol, Wallace Tumor Inst, Birmingham, AL 35294 USA	Johns Hopkins University; Johns Hopkins Medicine; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; University of Alabama System; University of Alabama Birmingham	Hidalgo, M (corresponding author), Johns Hopkins Univ, Sidney Kimmel Comprehens Canc Ctr, Dept Oncol, 1650 Orleans St,Room 1M88, Baltimore, MD 21231 USA.	mhidalg1@jhmi.edu	Cusatis, Gianluca/G-2539-2011; HIDALGO, MANUEL/I-4995-2015; Reddy, E. Premkumar/F-6233-2011	HIDALGO, MANUEL/0000-0002-3765-3318; 	Viragh Foundation; Onconova Inc; NATIONAL CANCER INSTITUTE [R01CA116554, P30CA006973] Funding Source: NIH RePORTER	Viragh Foundation; Onconova Inc; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This study was supported in part by the Viragh Foundation and Onconova Inc.	Budirahardja Y, 2008, DEVELOPMENT, V135, P1303, DOI 10.1242/dev.019075; Dvory-Sobol H, 2006, EUR J CANCER, V42, P422, DOI 10.1016/j.ejca.2005.11.009; Gonczy P, 2008, NAT REV MOL CELL BIO, V9, P355, DOI 10.1038/nrm2388; Gumireddy K, 2005, CANCER CELL, V7, P275, DOI 10.1016/j.ccr.2005.02.009; Hassan KA, 2002, CANCER RES, V62, P6414; Hidalgo M, 2006, MOL CANCER THER, V5, P1895, DOI 10.1158/1535-7163.MCT-05-0525; Jackman M, 2003, NAT CELL BIOL, V5, P143, DOI 10.1038/ncb918; Jemal A, 2007, CA-CANCER J CLIN, V57, P43, DOI 10.3322/canjclin.57.1.43; Jimeno A, 2006, CANCER RES, V66, P2385, DOI 10.1158/0008-5472.CAN-05-2882; Jimeno A, 2005, CANCER RES, V65, P3003, DOI 10.1158/0008-5472.CAN-04-3586; JIMENO A, 2008, J CLIN ONCOL; JIMENO A, 2008 ASCO ANN M OR P; Jones S, 2008, SCIENCE, V321, P1801, DOI 10.1126/science.1164368; Korenaga D, 2002, SURGERY, V131, pS114, DOI 10.1067/msy.2002.119362; Li J, 2007, J CHROMATOGR B, V856, P198, DOI 10.1016/j.jchromb.2007.05.047; Nigg EA, 1998, CURR OPIN CELL BIOL, V10, P776, DOI 10.1016/S0955-0674(98)80121-X; Park M, 2000, CANCER RES, V60, P542; Rubio-Viqueira B, 2006, CLIN CANCER RES, V12, P4652, DOI 10.1158/1078-0432.CCR-06-0113; Samson DJ, 2004, J CLIN ONCOL, V22, P3618, DOI 10.1200/JCO.2004.04.077; Schmidt M, 2006, MOL CANCER THER, V5, P809, DOI 10.1158/1535-7163.MCT-05-0455; Schrag D, 2004, J CLIN ONCOL, V22, P3631, DOI 10.1200/JCO.2004.05.065; Slamon DJ, 2001, NEW ENGL J MED, V344, P783, DOI 10.1056/NEJM200103153441101; Smits VAJ, 2000, NAT CELL BIOL, V2, P672, DOI 10.1038/35023629; Yuan J, 2006, ONCOGENE, V25, P1753, DOI 10.1038/sj.onc.1209202	24	28	29	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 29	2009	28	4					610	618		10.1038/onc.2008.424	http://dx.doi.org/10.1038/onc.2008.424			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	400KM	19029951	Green Accepted			2022-12-28	WOS:000262866500014
J	Smith, AP; Verrecchia, A; Faga, G; Doni, M; Perna, D; Martinato, F; Guccione, E; Amati, B				Smith, A. P.; Verrecchia, A.; Faga, G.; Doni, M.; Perna, D.; Martinato, F.; Guccione, E.; Amati, B.			A positive role for Myc in TGF beta-induced Snail transcription and epithelial-to-mesenchymal transition	ONCOGENE			English	Article						TGF beta; Myc; Snail; EMT	E-CADHERIN EXPRESSION; ACTIVATOR INHIBITOR-1 GENE; EMBRYONIC STEM-CELLS; BREAST-CANCER CELLS; C-MYC; SMAD PROTEINS; TARGET GENES; IN-VIVO; REPRESSION; P15(INK4B)	Myc and transforming growth factor-beta (TGF beta) signaling are mutually antagonistic, that is Myc suppresses the activation of TGF beta-induced genes, whereas TGF beta represses c-myc transcription. Here, we report a positive role for Myc in the TGF beta response, consisting in the induction of an epithelial-to-mesenchymal transition (EMT) and the activation of the EMT-associated gene Snail. Knockdown of either Myc or the TGF beta effectors SMAD3/4 in epithelial cells eliminated Snail induction by TGF beta. Both Myc and SMAD complexes targeted the Snail promoter in vivo, DNA binding occurring in a mutually independent manner. Myc was bound prior to TGF beta treatment, and was required for rapid Snail activation upon SMAD binding induced by TGF beta. On the other hand, c-myc downregulation by TGF beta was a slower event, occurring after Snail induction. The response of Snail to another cytokine, hepatocyte growth factor (HGF), also depended on Myc and SMAD4. Thus, contrary to their antagonistic effects on Cip1 and INK4b, Myc and SMADs cooperate in signal-dependent activation of Snail in epithelial cells. Although Myc also targeted the Snail promoter in serum-stimulated fibroblasts, it was dispensable for its activation in these conditions, further illustrating that the action of Myc in transcriptional regulation is context-dependent. Our findings suggest that Myc and TGF beta signaling may cooperate in promoting EMT and metastasis in carcinomas.	[Smith, A. P.; Verrecchia, A.; Faga, G.; Doni, M.; Perna, D.; Martinato, F.; Guccione, E.; Amati, B.] IFOM IEO Campus, European Inst Oncol IEO, Dept Expt Oncol, I-20139 Milan, Italy	IFOM - FIRC Institute of Molecular Oncology; IRCCS European Institute of Oncology (IEO)	Amati, B (corresponding author), IFOM IEO Campus, European Inst Oncol IEO, Dept Expt Oncol, I-20139 Milan, Italy.	bruno.amati@ifom-ieo-campus.it	Verrecchia, Alessandro/AAQ-6454-2020; Amati, Bruno/AAM-3418-2020; Doni, Mirko/ABA-9174-2021; Faga, Giovanni/AAB-5540-2021; Doni, Mirko/AAN-6027-2020; guccione, ernesto/G-9874-2011	Verrecchia, Alessandro/0000-0002-8596-6650; Doni, Mirko/0000-0001-7099-2701; Amati, Bruno/0000-0002-2958-1799	Association for Cancer Research (AIRC); International Association for Cancer Research (AICR)	Association for Cancer Research (AIRC)(Fondazione AIRC per la ricerca sul cancro); International Association for Cancer Research (AICR)	We thank Gioacchino Natoli and Stefano Campaner for critical reading of the paper; all members of the Amati lab for discussion and feedback throughout this work; Giuseppina Giardina for help with lentiviruses; Gabriele Bucci for bioinformatic support; Peter ten Dijke, Thordur Oskarsson and Andreas Trumpp for cell lines; Pier Giuseppe Pelicci for his continuous support and enthusiasm. This work was supported by grants from the Italian Association for Cancer Research (AIRC) and the International Association for Cancer Research (AICR).	ALEXANDROW MG, 1995, P NATL ACAD SCI USA, V92, P3239, DOI 10.1073/pnas.92.8.3239; Barrallo-Gimeno A, 2005, DEVELOPMENT, V132, P3151, DOI 10.1242/dev.01907; Batlle E, 2000, NAT CELL BIOL, V2, P84, DOI 10.1038/35000034; Batsche E, 1998, MOL CELL BIOL, V18, P3647, DOI 10.1128/MCB.18.7.3647; Bolos V, 2003, J CELL SCI, V116, P499, DOI 10.1242/jcs.00224; Cano A, 2000, NAT CELL BIOL, V2, P76, DOI 10.1038/35000025; Carver EA, 2001, MOL CELL BIOL, V21, P8184, DOI 10.1128/MCB.21.23.8184-8188.2001; Chen CR, 2002, CELL, V110, P19, DOI 10.1016/S0092-8674(02)00801-2; Chen CR, 2001, P NATL ACAD SCI USA, V98, P992, DOI 10.1073/pnas.98.3.992; Chen X, 2008, CELL, V133, P1106, DOI 10.1016/j.cell.2008.04.043; Cheng ASL, 2006, MOL CELL, V21, P393, DOI 10.1016/j.molcel.2005.12.016; Claassen GF, 2000, P NATL ACAD SCI USA, V97, P9498, DOI 10.1073/pnas.150006697; Comijn J, 2001, MOL CELL, V7, P1267, DOI 10.1016/S1097-2765(01)00260-X; Dai CS, 2004, J AM SOC NEPHROL, V15, P1402, DOI 10.1097/01.ASN.0000130568.53923.FD; de Caestecker MP, 1998, GENE DEV, V12, P1587, DOI 10.1101/gad.12.11.1587; Deckers M, 2006, CANCER RES, V66, P2202, DOI 10.1158/0008-5472.CAN-05-3560; Feng XH, 2002, MOL CELL, V9, P133, DOI 10.1016/S1097-2765(01)00430-0; Fernandez PC, 2003, GENE DEV, V17, P1115, DOI 10.1101/gad.1067003; Frank SR, 2001, GENE DEV, V15, P2069, DOI 10.1101/gad.906601; Gallant P, 1996, SCIENCE, V274, P1523, DOI 10.1126/science.274.5292.1523; Grandori C, 1996, EMBO J, V15, P4344, DOI 10.1002/j.1460-2075.1996.tb00808.x; Grooteclaes ML, 2000, ONCOGENE, V19, P3823, DOI 10.1038/sj.onc.1203721; Guccione E, 2006, NAT CELL BIOL, V8, P764, DOI 10.1038/ncb1434; Hua XX, 1999, P NATL ACAD SCI USA, V96, P13130, DOI 10.1073/pnas.96.23.13130; Hua XX, 1998, GENE DEV, V12, P3084, DOI 10.1101/gad.12.19.3084; Hurlin PJ, 2006, SEMIN CANCER BIOL, V16, P265, DOI 10.1016/j.semcancer.2006.07.009; Kim JW, 2008, CELL, V132, P1049, DOI 10.1016/j.cell.2008.02.039; Kim J, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001798; Kleine-Kohlbrecher D, 2006, CURR TOP MICROBIOL, V302, P51; Leung JY, 2008, ONCOGENE, V27, P4172, DOI 10.1038/onc.2008.55; Levy L, 2005, MOL CELL BIOL, V25, P8108, DOI 10.1128/MCB.25.18.8108-8125.2005; Li ZR, 2003, P NATL ACAD SCI USA, V100, P8164, DOI 10.1073/pnas.1332764100; Mao DYL, 2003, CURR BIOL, V13, P882, DOI 10.1016/S0960-9822(03)00297-5; MIETTINEN PJ, 1994, J CELL BIOL, V127, P2021, DOI 10.1083/jcb.127.6.2021; Oft M, 2002, NAT CELL BIOL, V4, P487, DOI 10.1038/ncb807; Perez-Moreno MA, 2001, J BIOL CHEM, V276, P27424, DOI 10.1074/jbc.M100827200; Phanish MK, 2006, BIOCHEM J, V393, P601, DOI 10.1042/BJ20051106; Piek E, 1999, J CELL SCI, V112, P4557; Rubio CA, 2003, EUR J CLIN INVEST, V33, P406, DOI 10.1046/j.1365-2362.2003.01151.x; Seoane J, 2002, NATURE, V419, P729, DOI 10.1038/nature01119; Seoane J, 2001, NAT CELL BIOL, V3, P400, DOI 10.1038/35070086; Staller P, 2001, NAT CELL BIOL, V3, P392, DOI 10.1038/35070076; Thiery JP, 2003, CURR OPIN CELL BIOL, V15, P740, DOI 10.1016/j.ceb.2003.10.006; Thiery JP, 2002, NAT REV CANCER, V2, P442, DOI 10.1038/nrc822; Thiery JP, 2006, NAT REV MOL CELL BIO, V7, P131, DOI 10.1038/nrm1835; Trumpp A, 2001, NATURE, V414, P768, DOI 10.1038/414768a; Warner BJ, 1999, MOL CELL BIOL, V19, P5913; Wu SQ, 2003, ONCOGENE, V22, P351, DOI 10.1038/sj.onc.1206145; Yang JW, 2005, J AM SOC NEPHROL, V16, P68, DOI 10.1681/ASN.2003090795; Yang JW, 2003, AM J PATHOL, V163, P621, DOI 10.1016/S0002-9440(10)63689-9; Zavadil J, 2005, ONCOGENE, V24, P5764, DOI 10.1038/sj.onc.1208927; Zeller KI, 2001, J BIOL CHEM, V276, P48285, DOI 10.1074/jbc.M108506200; Zha YH, 2007, CELL BIOL INT, V31, P1089, DOI 10.1016/j.cellbi.2007.03.023	53	97	99	1	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 22	2009	28	3					422	430		10.1038/onc.2008.395	http://dx.doi.org/10.1038/onc.2008.395			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	395UZ	18978814				2022-12-28	WOS:000262550300010
J	Zhang, Y; Zhang, M; Dong, H; Yong, S; Li, X; Olashaw, N; Kruk, PA; Cheng, JQ; Bai, W; Chen, J; Nicosia, SV; Zhang, X				Zhang, Y.; Zhang, M.; Dong, H.; Yong, S.; Li, X.; Olashaw, N.; Kruk, P. A.; Cheng, J. Q.; Bai, W.; Chen, J.; Nicosia, S. V.; Zhang, X.			Deacetylation of cortactin by SIRT1 promotes cell migration	ONCOGENE			English	Article						SIRT1; cancer; migration; cortactin; deacetylation; p300	TYROSINE PHOSPHORYLATION; HISTONE DEACETYLASES; CALORIE RESTRICTION; EMS1 GENE; ACETYLATION; ACTIN; P53; OVEREXPRESSION; AMPLIFICATION; TRANSCRIPTION	Cortactin binds F-actin and promotes cell migration. We showed earlier that cortactin is acetylated. Here, we identify SIRT1 (a class III histone deacetylase) as a cortactin deacetylase and p300 as a cortactin acetylase. We show that SIRT1 deacetylates cortactin in vivo and in vitro and that the SIRT1 inhibitor EX-527 increases amounts of acetylated cortactin in ovarian cancer cells. We also show that p300 acetylates cortactin in vivo and that cells lacking or depleted of p300 express less-acetylated cortactin than do control cells. Deletion analysis mapped the SIRT1-binding domain of cortactin to its repeat region, which also binds F-actin. Mouse embryo fibroblasts (MEFs) lacking sir2 alpha (the mouse homolog of SIRT1) migrated more slowly than did wildtype cells. The expression of SIRT1 in sir2 alpha-null cells restored migratory capacity, as did expression of a deacetylation-mimetic mutant of cortactin. SIRT1 and cortactin were more abundant in breast tumor tissue than in their normal counterparts, whereas SIRT1 expression inversely correlates with the ratio of acetylation cortactin versus total cortactin. These data suggest that deacetylation of cortactin is associated with high levels of SIRT1 and tumorigenesis. Finally, breast and ovarian cancer cell lines expressing an acetylation mimetic mutant of cortactin are less motile than that of control cells, whereas cells expressing the deacetylation mimetic mutant of cortactin migrate faster than that of control cells in Transwell migration assays. In summary, our results suggest that cortactin is a novel substrate for SIRT1 and p300 and, for the first time, a possible role for SIRT1 in cell motility through deacetylation of cortactin.	[Zhang, Y.; Zhang, M.; Dong, H.; Yong, S.; Li, X.; Kruk, P. A.; Bai, W.; Nicosia, S. V.; Zhang, X.] Univ S Florida, Coll Med, Dept Pathol & Cell Biol, Tampa, FL 33612 USA; [Olashaw, N.; Kruk, P. A.; Cheng, J. Q.; Bai, W.; Chen, J.; Zhang, X.] H Lee Moffitt Canc Ctr & Res Inst, Mol Oncol Program, Tampa, FL USA; [Nicosia, S. V.] H Lee Moffitt Canc Ctr & Res Inst, Expt Therapeut Program, Tampa, FL USA	State University System of Florida; University of South Florida; H Lee Moffitt Cancer Center & Research Institute; H Lee Moffitt Cancer Center & Research Institute	Zhang, X (corresponding author), Univ S Florida, Coll Med, Dept Pathol & Cell Biol, 12901 Bruce B Downs Blvd,MDC11, Tampa, FL 33612 USA.	xzhang1@health.usf.edu	Kruk, Patricia/I-6489-2012; Bai, Wenlong/A-8977-2013	Bai, Wenlong/0000-0002-9536-0556	USE College of Medicine; H Lee Moffitt Cancer Center; USE New Researcher grant; Marsha Rivkin Center Scientific Scholar award; Bankhead-Coley Biomedical Research Program New Investigator Research Grant	USE College of Medicine; H Lee Moffitt Cancer Center; USE New Researcher grant; Marsha Rivkin Center Scientific Scholar award; Bankhead-Coley Biomedical Research Program New Investigator Research Grant	We are indebted to Dr Edward Seto for sirtuins plasmids. We thank Dr Michael W McBurney for sir2 alpha<SUP>+/+</SUP> and sir2 alpha / MEFs; Dr James A DeCaprio for p300<SUP>+/+</SUP> and p300 / MEFs; Dr Don F Cameron for microscope usage; Drs Srikumar Chellappan, Gloria Ferreira, Mike Yuan, Zheng Shen, Mei Sun and Hua Yang for helpful discussions; Ms Kathleen Merkler for critical reading of this manuscript and Dr Ulmesh Jinwal for technical assistance. We also thank the H Lee Moffitt Cancer Center Analytic Microscopy Core Facility for their technical support and H Lee Moffitt Cancer Center Tissue Procurement for breast and ovarian tissues. This work was supported partly by 'Start-up' funds from the USE College of Medicine and H Lee Moffitt Cancer Center, an USE New Researcher grant, a Marsha Rivkin Center Scientific Scholar award for ovarian cancer research and a Bankhead-Coley Biomedical Research Program New Investigator Research Grant to XZ.	Aizawa H, 2004, SCIENCE, V303, P197, DOI 10.1126/science.1089845; Bereshchenko OR, 2002, NAT GENET, V32, P606, DOI 10.1038/ng1018; Blander G, 2004, ANNU REV BIOCHEM, V73, P417, DOI 10.1146/annurev.biochem.73.011303.073651; Bouras T, 2005, J BIOL CHEM, V280, P10264, DOI 10.1074/jbc.M408748200; Bourguignon LYW, 2001, J BIOL CHEM, V276, P7327, DOI 10.1074/jbc.M006498200; Bowden ET, 1999, ONCOGENE, V18, P4440, DOI 10.1038/sj.onc.1202827; Bringuier PP, 1996, ONCOGENE, V12, P1747; Brunet A, 2004, SCIENCE, V303, P2011, DOI 10.1126/science.1094637; Bryce NS, 2005, CURR BIOL, V15, P1276, DOI 10.1016/j.cub.2005.06.043; Buday L, 2007, BBA-REV CANCER, V1775, P263, DOI 10.1016/j.bbcan.2006.12.002; Campbell DH, 1999, CANCER RES, V59, P5376; Cao H, 2005, NAT CELL BIOL, V7, P483, DOI 10.1038/ncb1246; Chen LF, 2001, SCIENCE, V293, P1653, DOI 10.1126/science.1062374; Cohen HY, 2004, MOL CELL, V13, P627, DOI 10.1016/S1097-2765(04)00094-2; Cress WD, 2000, J CELL PHYSIOL, V184, P1, DOI 10.1002/(SICI)1097-4652(200007)184:1<1::AID-JCP1>3.0.CO;2-7; Daitoku H, 2004, P NATL ACAD SCI USA, V101, P10042, DOI 10.1073/pnas.0400593101; Fulco M, 2003, MOL CELL, V12, P51, DOI 10.1016/S1097-2765(03)00226-0; Glozak MA, 2005, GENE, V363, P15, DOI 10.1016/j.gene.2005.09.010; Gregoretti IV, 2004, J MOL BIOL, V338, P17, DOI 10.1016/j.jmb.2004.02.006; Grozinger CM, 2002, CHEM BIOL, V9, P3, DOI 10.1016/S1074-5521(02)00092-3; Guarente L, 2005, MECH AGEING DEV, V126, P923, DOI 10.1016/j.mad.2005.03.013; Hallows WC, 2006, P NATL ACAD SCI USA, V103, P10230, DOI 10.1073/pnas.0604392103; Head JA, 2003, MOL BIOL CELL, V14, P3216, DOI 10.1091/mbc.e02-11-0753; Huang C, 1998, J BIOL CHEM, V273, P25770, DOI 10.1074/jbc.273.40.25770; Huffman DM, 2007, CANCER RES, V67, P6612, DOI 10.1158/0008-5472.CAN-07-0085; Ito A, 2002, EMBO J, V21, P6236, DOI 10.1093/emboj/cdf616; Iyer NG, 2004, ONCOGENE, V23, P4225, DOI 10.1038/sj.onc.1207118; Jin QH, 2007, J CELL PHYSIOL, V213, P88, DOI 10.1002/jcp.21091; KANNER SB, 1990, P NATL ACAD SCI USA, V87, P3328, DOI 10.1073/pnas.87.9.3328; Kessels MM, 2005, NAT CELL BIOL, V7, P448, DOI 10.1038/ncb0505-448; Krubasik D, 2006, BRIT J CANCER, V94, P1326, DOI 10.1038/sj.bjc.6603101; Langley E, 2002, EMBO J, V21, P2383, DOI 10.1093/emboj/21.10.2383; Leipe DD, 1997, NUCLEIC ACIDS RES, V25, P3693, DOI 10.1093/nar/25.18.3693; Li YS, 2001, CANCER RES, V61, P6906; Luo JY, 2001, CELL, V107, P137, DOI 10.1016/S0092-8674(01)00524-4; Martin KH, 2006, J CELL SCI, V119, P2851, DOI 10.1242/jcs03034; Martinez-Quiles N, 2004, MOL CELL BIOL, V24, P5269, DOI 10.1128/MCB.24.12.5269-5280.2004; Michishita E, 2005, MOL BIOL CELL, V16, P4623, DOI 10.1091/mbc.E05-01-0033; Motta MC, 2004, CELL, V116, P551, DOI 10.1016/S0092-8674(04)00126-6; Moynihan KA, 2005, CELL METAB, V2, P105, DOI 10.1016/j.cmet.2005.07.001; North BJ, 2003, MOL CELL, V11, P437, DOI 10.1016/S1097-2765(03)00038-8; Ohsawa S, 2006, FEBS LETT, V580, P5875, DOI 10.1016/j.febslet.2006.09.051; Patel AM, 1996, ONCOGENE, V12, P31; Patel AS, 1998, ONCOGENE, V16, P3227, DOI 10.1038/sj.onc.1201850; Rodgers JT, 2005, NATURE, V434, P113, DOI 10.1038/nature03354; Rodrigo JP, 2000, CLIN CANCER RES, V6, P3177; SCHUURING E, 1993, MOL CELL BIOL, V13, P2891, DOI 10.1128/MCB.13.5.2891; Solomon JM, 2006, MOL CELL BIOL, V26, P28, DOI 10.1128/MCB.26.1.28-38.2006; Stuenkel Walter, 2007, Biotechnology Journal, V2, P1360, DOI 10.1002/biot.200700087; Tanno M, 2007, J BIOL CHEM, V282, P6823, DOI 10.1074/jbc.M609554200; Timpson P, 2005, CANCER RES, V65, P3273, DOI 10.1158/0008-5472.CAN-04-2118; van der Horst A, 2004, J BIOL CHEM, V279, P28873, DOI 10.1074/jbc.M401138200; Vaquero A, 2004, MOL CELL, V16, P93, DOI 10.1016/j.molcel.2004.08.031; Weed SA, 2001, ONCOGENE, V20, P6418, DOI 10.1038/sj.onc.1204783; Weed SA, 2000, J CELL BIOL, V151, P29, DOI 10.1083/jcb.151.1.29; Wolf G, 2006, NUTR REV, V64, P89, DOI [10.1111/j.1753-4887.2006.tb00192.x, 10.1301/nr.2006.feb.89-92]; WU H, 1991, MOL CELL BIOL, V11, P5113, DOI 10.1128/MCB.11.10.5113; WU H, 1993, J CELL BIOL, V120, P1417, DOI 10.1083/jcb.120.6.1417; Yuan BZ, 2003, J MOL DIAGN, V5, P48, DOI 10.1016/S1525-1578(10)60451-5; Zhang XH, 2007, MOL CELL, V27, P197, DOI 10.1016/j.molcel.2007.05.033	60	159	162	1	22	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 22	2009	28	3					445	460		10.1038/onc.2008.388	http://dx.doi.org/10.1038/onc.2008.388			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	395UZ	18850005				2022-12-28	WOS:000262550300012
J	Smith, JR; Clarke, PA; de Billy, E; Workman, P				Smith, J. R.; Clarke, P. A.; de Billy, E.; Workman, P.			Silencing the cochaperone CDC37 destabilizes kinase clients and sensitizes cancer cells to HSP90 inhibitors	ONCOGENE			English	Article						CDC37; cochaperone; HSP90; client; 17-AAG	SHOCK-PROTEIN 90; MOLECULAR CHAPERONE; SIGNAL-TRANSDUCTION; TARGETING SUBUNIT; QUALITY-CONTROL; ATPASE ACTIVITY; BREAST-CANCER; GROWTH ARREST; IN-VITRO; COMPLEX	The cochaperone CDC37 promotes the association of HSP90 with the protein kinase subset of client proteins to maintain their stability and signalling functions. HSP90 inhibitors induce depletion of clients, which include several oncogenic kinases. We hypothesized that the targeting of CDC37 using siRNAs would compromise the maturation of these clients and increase the sensitivity of cancer cells to HSP90 inhibitors. Here, we show that silencing of CDC37 in human colon cancer cells diminished the association of kinase clients with HSP90 and reduced levels of the clients ERBB2, CRAF, CDK4 and CDK6, as well as phosphorylated AKT. CDC37 silencing promoted the proteasome-mediated degradation of kinase clients, suggesting a degradation pathway independent from HSP90 binding. Decreased cell signalling through kinase clients was also demonstrated by reduced phosphorylation of downstream substrates and colon cancer cell proliferation was subsequently reduced by the inhibition of the G1/S-phase transition. Furthermore, combining CDC37 silencing with the HSP90 inhibitor 17-AAG induced more extensive and sustained depletion of kinase clients and potentiated cell cycle arrest and apoptosis. These results support an essential role for CDC37 in concert with HSP90 in maintaining oncogenic protein kinase clients and endorse the therapeutic potential of targeting CDC37 in cancer.	[Smith, J. R.; Clarke, P. A.; de Billy, E.; Workman, P.] Inst Canc Res, Haddow Labs, Signal Transduct & Mol Pharmacol Team, Canc Res UK Ctr Canc Therapeut, Sutton SM2 5NG, Surrey, England	Cancer Research UK; University of London; Institute of Cancer Research - UK	Workman, P (corresponding author), Inst Canc Res, Haddow Labs, Signal Transduct & Mol Pharmacol Team, Canc Res UK Ctr Canc Therapeut, 15 Cotswold Rd, Sutton SM2 5NG, Surrey, England.	paul.workman@icr.ac.uk	de billy, emmanuel/AAA-6095-2020	Clarke, Paul/0000-0001-9342-1290; de Crespin de Billy, emmanuel/0000-0002-3610-7083	Cancer Research UK [CUK] [C309/A8274]; Institute of Cancer Research	Cancer Research UK [CUK](Cancer Research UK); Institute of Cancer Research	We thank our colleagues in the Signal Transduction and Molecular Pharmacology Team and Chaperone Project Team for helpful discussions. Our work is supported by Cancer Research UK [CUK] Programme Grant number C309/A8274. JRS is the recipient of a studentship from The Institute of Cancer Research. PW is a Cancer Research UK Life Fellow.	Banerji U, 2005, J CLIN ONCOL, V23, P4152, DOI 10.1200/JCO.2005.00.612; Banerji U, 2008, MOL CANCER THER, V7, P737, DOI 10.1158/1535-7163.MCT-08-0145; Basso AD, 2002, J BIOL CHEM, V277, P39858, DOI 10.1074/jbc.M206322200; Caplan AJ, 2007, TRENDS CELL BIOL, V17, P87, DOI 10.1016/j.tcb.2006.12.002; Chen SY, 1998, J BIOL CHEM, V273, P35194, DOI 10.1074/jbc.273.52.35194; Clarke PA, 2000, ONCOGENE, V19, P4125, DOI 10.1038/sj.onc.1203753; Connell P, 2001, NAT CELL BIOL, V3, P93, DOI 10.1038/35050618; Dias SD, 2005, CANCER RES, V65, P10686, DOI 10.1158/0008-5472.CAN-05-2632; Fang YF, 1998, MOL CELL BIOL, V18, P3727, DOI 10.1128/MCB.18.7.3727; Ghatak S, 2005, J BIOL CHEM, V280, P8875, DOI 10.1074/jbc.M410882200; Grammatikakis N, 1999, MOL CELL BIOL, V19, P1661; Gray PJ, 2008, NAT REV CANCER, V8, P491, DOI 10.1038/nrc2420; Gray PJ, 2007, CANCER RES, V67, P11942, DOI 10.1158/0008-5472.CAN-07-3162; Grbovic OM, 2006, P NATL ACAD SCI USA, V103, P57, DOI 10.1073/pnas.0609973103; Guo F, 2005, CANCER RES, V65, P10536, DOI 10.1158/0008-5472.CAN-05-1799; Hartson SD, 2000, BIOCHEMISTRY-US, V39, P7631, DOI 10.1021/bi000315r; Hieronymus H, 2006, CANCER CELL, V10, P321, DOI 10.1016/j.ccr.2006.09.005; Holford J, 1998, BRIT J CANCER, V77, P366, DOI 10.1038/bjc.1998.59; Holmes JL, 2008, CANCER RES, V68, P1187, DOI 10.1158/0008-5472.CAN-07-3268; Hostein I, 2001, CANCER RES, V61, P4003; Kamal A, 2003, NATURE, V425, P407, DOI 10.1038/nature01913; Lamphere L, 1997, ONCOGENE, V14, P1999, DOI 10.1038/sj.onc.1201036; Lavictoire SJ, 2003, J BIOL CHEM, V278, P5292, DOI 10.1074/jbc.M209494200; Lee P, 2002, J CELL BIOL, V159, P1051, DOI 10.1083/jcb.200210121; MacLean M, 2003, CELL STRESS CHAPERON, V8, P114, DOI 10.1379/1466-1268(2003)008<0114:CGBHAK>2.0.CO;2; Maloney A, 2002, EXPERT OPIN BIOL TH, V2, P3, DOI 10.1517/14712598.2.1.3; Mandal AK, 2007, J CELL BIOL, V176, P319, DOI 10.1083/jcb.200604106; Manning G, 2002, SCIENCE, V298, P1912, DOI 10.1126/science.1075762; McDonald E, 2006, CURR TOP MED CHEM, V6, P1091, DOI 10.2174/156802606777812004; Modi S, 2007, J CLIN ONCOL, V25, P5410, DOI 10.1200/JCO.2007.11.7960; Obermann WMJ, 1998, J CELL BIOL, V143, P901, DOI 10.1083/jcb.143.4.901; Pacey S, 2006, HANDB EXP PHARM, V172, P331; Panaretou B, 2002, MOL CELL, V10, P1307, DOI 10.1016/S1097-2765(02)00785-2; Pearl LH, 2008, BIOCHEM J, V410, P439, DOI 10.1042/BJ20071640; Pearl LH, 2006, ANNU REV BIOCHEM, V75, P271, DOI 10.1146/annurev.biochem.75.103004.142738; Pearl LH, 2005, CURR OPIN GENET DEV, V15, P55, DOI 10.1016/j.gde.2004.12.011; Powers MV, 2008, CANCER CELL, V14, P250, DOI 10.1016/j.ccr.2008.08.002; Raynaud FI, 2007, CANCER RES, V67, P5840, DOI 10.1158/0008-5472.CAN-06-4615; Roe SM, 2004, CELL, V116, P87, DOI 10.1016/S0092-8674(03)01027-4; Roe SM, 1999, J MED CHEM, V42, P260, DOI 10.1021/jm980403y; Sato S, 2000, P NATL ACAD SCI USA, V97, P10832, DOI 10.1073/pnas.170276797; Schwarze SR, 2003, CANCER RES, V63, P4614; Sharp SY, 2007, MOL CANCER THER, V6, P1198, DOI 10.1158/1535-7163.MCT-07-0149; Siligardi G, 2004, J BIOL CHEM, V279, P51989, DOI 10.1074/jbc.M410562200; Siligardi G, 2002, J BIOL CHEM, V277, P20151, DOI 10.1074/jbc.M201287200; Smith J.R., 2007, DRUG DISCOV TODAY TH, V4, P219, DOI [10.1016/j.ddstr.2008.02.005, DOI 10.1016/J.DDSTR.2008.02.005]; Stepanova L, 1996, GENE DEV, V10, P1491, DOI 10.1101/gad.10.12.1491; Stepanova L, 2000, ONCOGENE, V19, P2186, DOI 10.1038/sj.onc.1203561; Stepanova L, 1997, METHOD ENZYMOL, V283, P220; Stepanova L, 2000, MOL CELL BIOL, V20, P4462, DOI 10.1128/MCB.20.12.4462-4473.2000; Turnbull EL, 2005, FEBS J, V272, P4129, DOI 10.1111/j.1742-4658.2005.04825.x; Vaughan CK, 2006, MOL CELL, V23, P697, DOI 10.1016/j.molcel.2006.07.016; Wang HM, 2002, EMBO J, V21, P930, DOI 10.1093/emboj/21.5.930; Westerheide SD, 2004, J BIOL CHEM, V279, P56053, DOI 10.1074/jbc.M409267200; Workman P, 2004, CANCER LETT, V206, P149, DOI 10.1016/j.canlet.2003.08.032; Workman P, 2007, ANN NY ACAD SCI, V1113, P202, DOI 10.1196/annals.1391.012; Xu WP, 2003, CANCER RES, V63, P7777; Xu WP, 2002, P NATL ACAD SCI USA, V99, P12847, DOI 10.1073/pnas.202365899; Yang HJ, 2006, CANCER RES, V66, P4758, DOI 10.1158/0008-5472.CAN-05-4529; Yun BG, 2005, EXP CELL RES, V307, P212, DOI 10.1016/j.yexcr.2005.03.003; Zhang T, 2008, MOL CANCER THER, V7, P162, DOI 10.1158/1535-7163.MCT-07-0484; Zhang W, 2004, J MOL BIOL, V340, P891, DOI 10.1016/j.jmb.2004.05.007	62	96	98	1	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2009	28	2					157	169		10.1038/onc.2008.380	http://dx.doi.org/10.1038/onc.2008.380			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	395CY	18931700	Green Accepted			2022-12-28	WOS:000262501100001
J	Duan, H; Xiang, H; Ma, L; Boxer, LM				Duan, H.; Xiang, H.; Ma, L.; Boxer, L. M.			Functional long-range interactions of the IgH 3 ' enhancers with the bcl-2 promoter region in t(14;18) lymphoma cells	ONCOGENE			English	Article						t(14;18) lymphoma; bcl-2; IgH enhancer; spatial interactions	CHROMOSOME CONFORMATION; CREB PROTEINS; IN-VIVO; EXPRESSION; GENE; APOPTOSIS; CHEMORESISTANCE; LOCUS	To better understand the mechanisms underlying the role of the immunoglobulin heavy-chain gene (IgH) 3' enhancers on bcl-2 transcriptional deregulation in t(14; 18) lymphoma, we characterized the physical interactions of the IgH 3' enhancer region with the bcl-2 promoters. Using the chromosome conformation capture technique, we found that the IgH 3' enhancers physically interact with the bcl-2 promoter region over a 350 kb genomic region in t( 14; 18) lymphoma cells. No interactions of the bcl-2 promoter region with sequences distant to the IgH enhancers were observed. The physical interactions of the IgH enhancers with the bcl-2 5' region are functionally involved in the transcriptional control of bcl-2. The histone deacetylase inhibitor, trichostatin A, repressed bcl-2 transcription and decreased the IgH enhancer-bcl-2 promoter region interactions. We showed by chromatin immunoprecipitation assay and small interference RNA transfection studies that the POU2 family transcription factor Oct-2 and its cofactor Bob-1 have an important function in mediating the IgH enhancer-bcl-2 promoter region interactions. This study reveals a new aspect of the regulatory role of the IgH 3' enhancers on bcl-2 transcription in t(14; 18) lymphomas.	[Duan, H.; Xiang, H.; Ma, L.; Boxer, L. M.] Stanford Univ, Sch Med, Dept Med, Stanford, CA 94305 USA; [Duan, H.; Xiang, H.; Ma, L.; Boxer, L. M.] Vet Affairs Palo Alto Hlth Care Syst, Ctr Mol Biol Med, Palo Alto, CA USA	Stanford University; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Palo Alto Health Care System	Boxer, LM (corresponding author), Stanford Univ, Sch Med, Dept Med, CCSR 1155,269 Campus Dr, Stanford, CA 94305 USA.	lboxer@stanford.edu			National Institutes of Health [CA56764]; NATIONAL CANCER INSTITUTE [R01CA056764, R56CA056764] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This study was supported by National Institutes of Health Grant CA56764. We are grateful to Dr Job Dekker (U Mass) for advice and for providing the 3C protocol, and to Drs Tao Li, Jianqun Lin and Xinwen Qiu in Dr Andrew Hoffman's laboratory at Stanford University for expert assistance with the 3C analysis.	Dekker J, 2002, SCIENCE, V295, P1306, DOI 10.1126/science.1067799; DESOIZE B, 1994, ANTICANCER RES, V14, P2291; Duan H, 2007, ONCOGENE, V26, P2635, DOI 10.1038/sj.onc.1210061; Duan H, 2005, MOL CELL BIOL, V25, P1608, DOI 10.1128/MCB.25.5.1608-1619.2005; GRANINGER WB, 1987, J CLIN INVEST, V80, P1512, DOI 10.1172/JCI113235; Hagege H, 2007, NAT PROTOC, V2, P1722, DOI 10.1038/nprot.2007.243; Heckman CA, 2006, ONCOGENE, V25, P888, DOI 10.1038/sj.onc.1209127; Heckman CA, 2000, J BIOL CHEM, V275, P6499, DOI 10.1074/jbc.275.9.6499; Heckman CA, 2003, CANCER RES, V63, P6666; Heckman CA, 2003, ONCOGENE, V22, P7891, DOI 10.1038/sj.onc.1206639; Heckman CA, 2002, ONCOGENE, V21, P3898, DOI 10.1038/sj.onc.1205483; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; Ji L, 1996, J BIOL CHEM, V271, P22687, DOI 10.1074/jbc.271.37.22687; Ju ZL, 2007, J BIOL CHEM, V282, P35169, DOI 10.1074/jbc.M705719200; Khamlichi AA, 2000, ADV IMMUNOL, V75, P317, DOI 10.1016/S0065-2776(00)75008-5; Liu Z, 2005, MOL CELL BIOL, V25, P3220, DOI 10.1128/MCB.25.8.3220-3231.2005; MADISEN L, 1994, GENE DEV, V8, P2212, DOI 10.1101/gad.8.18.2212; MIELE A, 2006, CURRENT PROTOCOLS MO; Mills FC, 1997, J EXP MED, V186, P845, DOI 10.1084/jem.186.6.845; Palstra RJ, 2003, NAT GENET, V35, P190, DOI 10.1038/ng1244; REED JC, 1994, ANN ONCOL, V5, pS61, DOI 10.1093/annonc/5.suppl_1.S61; Schmitt CA, 2001, BLOOD CELL MOL DIS, V27, P206, DOI 10.1006/bcmd.2000.0372; SETO M, 1988, EMBO J, V7, P123, DOI 10.1002/j.1460-2075.1988.tb02791.x; Splinter E, 2004, METHOD ENZYMOL, V375, P493; Tolhuis B, 2002, MOL CELL, V10, P1453, DOI 10.1016/S1097-2765(02)00781-5; Wilson BE, 1996, MOL CELL BIOL, V16, P5546	26	29	33	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 13	2008	27	53					6720	6728		10.1038/onc.2008.286	http://dx.doi.org/10.1038/onc.2008.286			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	371XO	18695675	Green Accepted			2022-12-28	WOS:000260866200002
J	Matsushita, H; Nakajima, H; Nakamura, Y; Tsukamoto, H; Tanaka, Y; Jin, G; Yabe, M; Asai, S; Ono, R; Nosaka, T; Sugita, K; Morimoto, A; Hayashi, Y; Hotta, T; Ando, K; Miyachi, H				Matsushita, H.; Nakajima, H.; Nakamura, Y.; Tsukamoto, H.; Tanaka, Y.; Jin, G.; Yabe, M.; Asai, S.; Ono, R.; Nosaka, T.; Sugita, K.; Morimoto, A.; Hayashi, Y.; Hotta, T.; Ando, K.; Miyachi, H.			C/EBP alpha and C/EBP epsilon induce the monocytic differentiation of myelomonocytic cells with the MLL-chimeric fusion gene	ONCOGENE			English	Article						acute myeloid leukemia; mixed lineage leukemia gene; monocytic differentiation; CCAAT/enhancer binding protein-alpha; CCAAT/enhancer binding protein-epsilon	COLONY-STIMULATING FACTOR; ACUTE MYELOID-LEUKEMIA; BINDING-PROTEIN-ALPHA; TRANS-RETINOIC ACID; GRANULOCYTIC DIFFERENTIATION; DEFICIENT MICE; PU.1 GENE; EXPRESSION; PROGENITORS; MACROPHAGE	CCAAT/enhancer binding proteins (C/EBPs) have an important function in granulocytic differentiation, and are also involved in the leukemogenesis of acute myeloid leukemia (AML). Their involvement in myelomonocytic leukemia, however, is still unclear. Therefore, the expression and function of C/EBPs in myelomonocytic cells with MLL-fusion genes were investigated. Retinoic acid (RA) induced monocytic differentiation in the myelomonocytic cell lines with MLL-fusion genes, THP-1, MOLM-14 and HF-6 cells, accompanied by monocytic differentiation with the upregulation of C/EBP alpha and C/EBP epsilon. Monocytic differentiation by RA treatment was confirmed in primary AML cells using a clonogenic assay. When the activity of C/EBP alpha or C/EBP epsilon was introduced into HF-6 cells, their cellular growth was arrested through differentiation into monocytes with the concomitant marked downregulation of Myc. Cebpe mRNA was upregulated by the induction of C/EBP alpha-ER, but not vice versa, thus suggesting that C/EBP epsilon may have an important function in the differentiation process. Introduction of Myc isoforms into HF-6 cells partially antagonized the C/EBP alpha effects. These findings suggest that the ectopic expression of C/EBP epsilon, as well as C/EBP alpha, can induce the monocytic differentiation of myelomonocytic leukemic cells with MLL-fusion gene through the downregulation of Myc, thus providing insight into the development of novel therapeutic approaches.	[Matsushita, H.; Tanaka, Y.; Jin, G.; Yabe, M.; Asai, S.; Miyachi, H.] Tokai Univ, Sch Med, Dept Lab Med, Kanagawa 2591193, Japan; [Nakajima, H.] Univ Tokyo, Inst Med Sci, Ctr Excellence, Tokyo, Japan; [Nakamura, Y.; Tsukamoto, H.] Tokai Univ, Sch Med, Teaching & Res Support Ctr, Kanagawa 2591193, Japan; [Ono, R.; Nosaka, T.] Mie Univ, Grad Sch Med, Dept Microbiol, Tsu, Mie, Japan; [Sugita, K.] Univ Yamanashi, Sch Med, Dept Pediat, Yamanashi, Japan; [Morimoto, A.] Kyoto Prefectural Univ Med, Dept Pediat, Kyoto 602, Japan; [Hayashi, Y.] Gunma Childrens Med Ctr, Dept Hematol Oncol, Gunma, Japan; [Hotta, T.; Ando, K.] Tokai Univ, Sch Med, Dept Hematol, Kanagawa 2591193, Japan	Tokai University; University of Tokyo; Tokai University; Mie University; University of Yamanashi; Kyoto Prefectural University of Medicine; Gunma Children's Medical Centre; Tokai University	Matsushita, H (corresponding author), Tokai Univ, Sch Med, Dept Lab Med, 143 Shimokasuya, Kanagawa 2591193, Japan.	hmatsu@is.icc.u-tokai.ac.jp	松下, 弘道/AEX-6164-2022	松下, 弘道/0000-0002-1629-6630	Ministry of Education, Culture, Sports, Science and Technology of Japan [19591139]	Ministry of Education, Culture, Sports, Science and Technology of Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT))	We thank Dr Toshio Kitamura (Institute of Medical Science, University of Tokyo, Tokyo, Japan) for providing PLAT-E cells. This study was supported in part by Research and Study Program of Tokai University Educational System General Research Organization and a Grant-in Aid for Scientific Research (C) No. 19591139 from the Ministry of Education, Culture, Sports, Science and Technology of Japan.	Ayton PM, 2003, GENE DEV, V17, P2298, DOI 10.1101/gad.1111603; Cozzio A, 2003, GENE DEV, V17, P3029, DOI 10.1101/gad.1143403; Dahl R, 2003, NAT IMMUNOL, V4, P1029, DOI 10.1038/ni973; De Braekeleer M, 2005, ANTICANCER RES, V25, P1931; FREYTAG SO, 1992, SCIENCE, V256, P379, DOI 10.1126/science.256.5055.379; Fukuchi Y, 2006, EMBO J, V25, P3398, DOI 10.1038/sj.emboj.7601199; Gery S, 2004, BLOOD, V103, P828, DOI 10.1182/blood-2003-01-0159; Gombart AF, 2002, BLOOD, V99, P1332, DOI 10.1182/blood.V99.4.1332; Gombart AF, 2003, BLOOD, V101, P3265, DOI 10.1182/blood-2002-04-1039; HEMMI H, 1985, JPN J CANCER RES, V76, P345; Iijima K, 2004, LEUKEMIA LYMPHOMA, V45, P1017, DOI 10.1080/1042819031000163887; Johansen LM, 2001, MOL CELL BIOL, V21, P3789, DOI 10.1128/MCB.21.11.3789-3806.2001; Kawada H, 1999, EXP HEMATOL, V27, P904, DOI 10.1016/S0301-472X(99)00012-0; Kitamura T, 2003, EXP HEMATOL, V31, P1007, DOI 10.1016/j.exphem.2003.07.005; Kubota T, 2000, BLOOD, V96, P3953, DOI 10.1182/blood.V96.12.3953.h8003953_3953_3957; Kummalue T, 2003, J LEUKOCYTE BIOL, V74, P464, DOI 10.1189/jlb.1202622; Lee IH, 2002, BIOCHEM BIOPH RES CO, V294, P956, DOI 10.1016/S0006-291X(02)00581-8; Lee YJ, 2006, BLOOD, V108, P2416, DOI 10.1182/blood-2006-02-003582; Li ZY, 2005, LEUKEMIA, V19, P183, DOI 10.1038/sj.leu.2403602; Mueller BU, 2006, BLOOD, V107, P3330, DOI 10.1182/blood-2005-07-3068; Nakajima H, 2001, BLOOD, V98, P897, DOI 10.1182/blood.V98.4.897; Nakajima H, 2006, J BIOL CHEM, V281, P14494, DOI 10.1074/jbc.M600575200; Oelgeschlager M, 1996, MOL CELL BIOL, V16, P4717; Ono R, 2005, J CLIN INVEST, V115, P919, DOI 10.1172/JCI200522725; Pabst T, 2001, NAT GENET, V27, P263, DOI 10.1038/85820; Pabst T, 2001, NAT MED, V7, P444, DOI 10.1038/86515; Pan Z, 1999, J BIOL CHEM, V274, P23242, DOI 10.1074/jbc.274.33.23242; Radomska HS, 2006, J EXP MED, V203, P371, DOI 10.1084/jem.20052242; Schoch C, 2003, BLOOD, V102, P2395, DOI 10.1182/blood-2003-02-0434; Schreiner S, 2001, CANCER RES, V61, P6480; Schuster MB, 2006, BBA-REV CANCER, V1766, P88, DOI 10.1016/j.bbcan.2006.02.003; Tavor S, 2002, BLOOD, V99, P1794, DOI 10.1182/blood.V99.5.1794; Truong BTH, 2003, BLOOD, V101, P1141, DOI 10.1182/blood-2002-05-1374; Walkley CR, 2004, BLOOD, V103, P1286, DOI 10.1182/blood-2003-07-2391; Wang D, 2006, BLOOD, V108, P1223, DOI 10.1182/blood-2005-12-008763; Wang XP, 1999, BLOOD, V94, P560, DOI 10.1182/blood.V94.2.560.414k41_560_571; Williams SC, 1998, J BIOL CHEM, V273, P13493, DOI 10.1074/jbc.273.22.13493; Yamanaka R, 1997, P NATL ACAD SCI USA, V94, P13187, DOI 10.1073/pnas.94.24.13187; Zhang DE, 1996, MOL CELL BIOL, V16, P1231; Zhang P, 2004, IMMUNITY, V21, P853, DOI 10.1016/j.immuni.2004.11.006; Zheng R, 2004, BLOOD, V103, P1883, DOI 10.1182/blood-2003-06-1978	41	16	16	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 13	2008	27	53					6749	6760		10.1038/onc.2008.285	http://dx.doi.org/10.1038/onc.2008.285			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	371XO	18776924	Bronze			2022-12-28	WOS:000260866200005
J	Leikam, C; Hufnagel, A; Schartl, M; Meierjohann, S				Leikam, C.; Hufnagel, A.; Schartl, M.; Meierjohann, S.			Oncogene activation in melanocytes links reactive oxygen to multinucleated phenotype and senescence	ONCOGENE			English	Article						ROS; melanoma; senescence; oncogene; N-RAS; melanocyte	RECEPTOR TYROSINE KINASE; CELL-CYCLE ARREST; GROWTH-FACTOR; MALIGNANT-MELANOMA; RAS; EXPRESSION; PROTEIN; MUTATIONS; P53; PHOSPHORYLATION	Contrary to malignant melanoma, nevi are a benign form of melanocytic hyperproliferation. They are frequently observed as precursor lesions of melanoma, but they also feature biochemical markers of senescence. In particular, evidence for oncogene-induced melanocyte senescence as natural means to prevent tumorigenesis has been obtained in nevi with mutated B-Raf(V600E). Here, we demonstrate that strong oncogenic growth factor receptor signalling drives melanocytes into senescence, whereas weaker signals keep them in the proliferative state. Activation of oncogene-induced senescence also produces multinucleated giant cells, a long known histological feature of nevus cells. The protein levels of the senescence mediators, p53 and pRB, and their upstream activators do not correlate with senescence. However, strong oncogene signalling leads to pronounced reactive oxygen stress, and scavenging of reactive oxygen species (ROS) efficiently prevents the formation of multinucleated cells and senescence. Similarly, expression of oncogenic N-RAS results in ROS generation, DNA damage and the same multinuclear senescent phenotype. Hence, we identified oncogenic signalling-dependent ROS production as critical mediator of the melanocytic multinuclear phenotype and senescence, both of them being hallmarks of human nevus cells.	[Leikam, C.; Hufnagel, A.; Schartl, M.; Meierjohann, S.] Univ Wurzburg, Dept Physiol Chem 1, Bioctr, D-97074 Wurzburg, Germany	University of Wurzburg	Meierjohann, S (corresponding author), Univ Wurzburg, Dept Physiol Chem 1, Bioctr, D-97074 Wurzburg, Germany.	svenja.meierjohann@biozentrum.uni-wuerzburg.de		Schartl, Manfred/0000-0001-9882-5948	Deutsche Forschungsgesellschaft; German Excellence Initiative to the Graduate School of Life Sciences, University of Wurzburg	Deutsche Forschungsgesellschaft(German Research Foundation (DFG)); German Excellence Initiative to the Graduate School of Life Sciences, University of Wurzburg	We thank Dr Thorsten Stiewe for kindly providing the PAB 122 hybridoma supernatant and Professor Jurgen Hoppe for his help with the time lapse experiment. In addition, we thank Johannes Haydn for generating the melan a pWHE459 cell lines and Toni Wagner for great technical support. This work was supported by the Deutsche Forschungsgesellschaft, Transregio 17 ('RAS-dependent pathways in human cancer'). CL was supported by a grant of the German Excellence Initiative to the Graduate School of Life Sciences, University of Wurzburg.	Aguirre AJ, 2003, GENE DEV, V17, P3112, DOI 10.1101/gad.1158703; Aliouat-Denis CM, 2005, MOL CANCER RES, V3, P627, DOI 10.1158/1541-7786.MCR-05-0121; Avantaggiati ML, 1997, CELL, V89, P1175, DOI 10.1016/S0092-8674(00)80304-9; Bardeesy N, 2005, MOL CELL BIOL, V25, P4176, DOI 10.1128/MCB.25.10.4176-4188.2005; Bartkova J, 2006, NATURE, V444, P633, DOI 10.1038/nature05268; Bennett DC, 2003, ONCOGENE, V22, P3063, DOI 10.1038/sj.onc.1206446; BENNETT DC, 1989, DEVELOPMENT, V105, P379; Bischof O, 2002, EMBO J, V21, P3358, DOI 10.1093/emboj/cdf341; Blagosklonny MV, 2003, EMBO REP, V4, P358, DOI 10.1038/sj.embor.embor806; Chang DLF, 2007, ONCOGENE, V26, P4627, DOI 10.1038/sj.onc.1210254; Chao C, 2003, J BIOL CHEM, V278, P41028, DOI 10.1074/jbc.M306938200; Chen CR, 2005, CANCER RES, V65, P6017, DOI 10.1158/0008-5472.CAN-05-0677; Chin L, 2003, NAT REV CANCER, V3, P559, DOI 10.1038/nrc1145; Collado M, 2006, NAT REV CANCER, V6, P472, DOI 10.1038/nrc1884; Curtin JA, 2006, J CLIN ONCOL, V24, P4340, DOI 10.1200/JCO.2006.06.2984; Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766; Debidda M, 2006, J BIOL CHEM, V281, P38519, DOI 10.1074/jbc.M604607200; Denoyelle C, 2006, NAT CELL BIOL, V8, P1053, DOI 10.1038/ncb1471; Dumaz N, 1999, EMBO J, V18, P7002, DOI 10.1093/emboj/18.24.7002; Finkel T, 2006, ANTIOXID REDOX SIGN, V8, P1857, DOI 10.1089/ars.2006.8.1857; Geissinger E, 2002, CANCER RES, V62, P4820; Goding C R, 2000, Forum (Genova), V10, P176; Gorla GR, 2001, J CELL SCI, V114, P2943; Gray-Schopfer VC, 2006, BRIT J CANCER, V95, P496, DOI 10.1038/sj.bjc.6603283; Gray-Schopfer VC, 2005, CANCER METAST REV, V24, P165, DOI 10.1007/s10555-005-5865-1; Ha L, 2007, P NATL ACAD SCI USA, V104, P10968, DOI 10.1073/pnas.0611638104; Haluska FG, 2006, CLIN CANCER RES, V12, p2301S, DOI 10.1158/1078-0432.CCR-05-2518; Hayashi C, 2007, J CELL BIOCHEM, V101, P979, DOI 10.1002/jcb.21298; Hirose Y, 2005, CANCER RES, V65, P4861, DOI 10.1158/0008-5472.CAN-04-2633; Irani K, 1997, SCIENCE, V275, P1649, DOI 10.1126/science.275.5306.1649; Itahana K, 2002, J BIOL CHEM, V277, P18206, DOI 10.1074/jbc.M201028200; Jones CJ, 2000, MOL CELL BIOL, V20, P5690, DOI 10.1128/MCB.20.15.5690-5699.2000; KhosraviFar R, 1996, MOL CELL BIOL, V16, P3923; Kopnin PB, 2007, CANCER RES, V67, P4671, DOI 10.1158/0008-5472.CAN-06-2466; Krueger C, 2006, J GENE MED, V8, P1037, DOI 10.1002/jgm.932; Kurata S, 2000, J BIOL CHEM, V275, P23413, DOI 10.1074/jbc.C000308200; Lachat Y, 2004, ONCOGENE, V23, P6854, DOI 10.1038/sj.onc.1207872; Lambert PF, 1998, J BIOL CHEM, V273, P33048, DOI 10.1074/jbc.273.49.33048; Lee AC, 1999, J BIOL CHEM, V274, P7936, DOI 10.1074/jbc.274.12.7936; LEOPOLD JG, 1967, J PATHOL BACTERIOL, V94, P247, DOI 10.1002/path.1700940203; Li G, 2001, ONCOGENE, V20, P8125, DOI 10.1038/sj.onc.1205034; LIU X, 1993, MOL CELL BIOL, V13, P3291, DOI 10.1128/MCB.13.6.3291; Mallette FA, 2007, GENE DEV, V21, P43, DOI 10.1101/gad.1487307; Malumbres M, 2000, MOL CELL BIOL, V20, P2915, DOI 10.1128/MCB.20.8.2915-2925.2000; Meierjohann S, 2006, CANCER RES, V66, P3145, DOI 10.1158/0008-5472.CAN-05-2667; Meierjohann S, 2006, TRENDS GENET, V22, P654, DOI 10.1016/j.tig.2006.09.013; Michaloglou C, 2005, NATURE, V436, P720, DOI 10.1038/nature03890; Mirmohammadsadegh A, 2006, J INVEST DERMATOL, V126, P2272, DOI 10.1038/sj.jid.5700385; NATALI PG, 1993, BRIT J CANCER, V68, P746, DOI 10.1038/bjc.1993.422; Nuciforo PG, 2007, CARCINOGENESIS, V28, P2082, DOI 10.1093/carcin/bgm108; Passos JF, 2006, FREE RADICAL RES, V40, P1277, DOI 10.1080/10715760600917151; Pfaffl MW, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/30.9.e36; Rangel J, 2008, CANCER-AM CANCER SOC, V112, P144, DOI 10.1002/cncr.23147; Rincheval V, 2002, BIOCHEM BIOPH RES CO, V298, P282, DOI 10.1016/S0006-291X(02)02454-3; Sarkisian CJ, 2007, NAT CELL BIOL, V9, P493, DOI 10.1038/ncb1567; Satyamoorthy K, 2003, CANCER RES, V63, P756; SAVCHENKO YY, 1988, TSITOL GENET+, V22, P20; Sewing A, 1997, MOL CELL BIOL, V17, P5588, DOI 10.1128/MCB.17.9.5588; Sharpless NE, 2001, NATURE, V413, P86, DOI 10.1038/35092592; Spyridopoulos I, 2002, BASIC RES CARDIOL, V97, P117, DOI 10.1007/s003950200001; Straume O, 2000, CLIN CANCER RES, V6, P1845; Sviderskaya EV, 2002, JNCI-J NATL CANCER I, V94, P446; Takahashi A, 2006, NAT CELL BIOL, V8, P1291, DOI 10.1038/ncb1491; Vigneron A, 2005, CANCER RES, V65, P8927, DOI 10.1158/0008-5472.CAN-05-0461; Wellbrock C, 1999, EUR J BIOCHEM, V260, P275, DOI 10.1046/j.1432-1327.1999.00180.x; Wellbrock C, 1998, ONCOGENE, V16, P3047, DOI 10.1038/sj.onc.1201844; Wellbrock C, 2005, CURR BIOL, V15, P1629, DOI 10.1016/j.cub.2005.08.036; Wellbrock C, 2002, J BIOL CHEM, V277, P6443, DOI 10.1074/jbc.M110684200; WITTBRODT J, 1992, EMBO J, V11, P4239, DOI 10.1002/j.1460-2075.1992.tb05518.x; Woods D, 1997, MOL CELL BIOL, V17, P5598, DOI 10.1128/MCB.17.9.5598	70	60	60	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV	2008	27	56					7070	7082		10.1038/onc.2008.323	http://dx.doi.org/10.1038/onc.2008.323			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	376PQ	18806824				2022-12-28	WOS:000261195900002
J	Fujiwara, M; Marusawa, H; Wang, HQ; Iwai, A; Ikeuchi, K; Imai, Y; Kataoka, A; Nukina, N; Takahashi, R; Chiba, T				Fujiwara, M.; Marusawa, H.; Wang, H-Q; Iwai, A.; Ikeuchi, K.; Imai, Y.; Kataoka, A.; Nukina, N.; Takahashi, R.; Chiba, T.			Parkin as a tumor suppressor gene for hepatocellular carcinoma	ONCOGENE			English	Article						parkin; hepatocellular carcinoma; follistatin	NF-KAPPA-B; DEFICIENT MICE; ACTIVIN; DISEASE; LIVER; EXPRESSION; MECHANISMS; APOPTOSIS; UBIQUITIN; OVARIAN	The parkin was first identified as a gene implicated in autosomal recessive juvenile Parkinsonism. Deregulation of the parkin gene, however, has been observed in various human cancers, suggesting that the parkin gene may be important in tumorigenesis. To gain insight into the physiologic role of parkin, we generated parkin-/- mice lacking exon 3 of the parkin gene. We demonstrated here that parkin-/- mice had enhanced hepatocyte proliferation and developed macroscopic hepatic tumors with the characteristics of hepatocellular carcinoma. Microarray analyses revealed that parkin deficiency caused the alteration of gene expression profiles in the liver. Among them, endogenous follistatin is commonly upregulated in both nontumorous and tumorous liver tissues of parkin deficient mice. Parkin deficiency resulted in suppression of caspase activation and rendered hepatocytes resistant to apoptosis in a follistatin-dependent manner. These results suggested that parkin deficiency caused enhanced hepatocyte proliferation and resistance to apoptosis, resulting in hepatic tumor development, partially through the upregulation of endogenous follistatin. The finding that parkin deficient mice are susceptible to hepatocarcinogenesis provided the first evidence showing that parkin is indeed a tumor suppressor gene.	[Fujiwara, M.; Marusawa, H.; Iwai, A.; Ikeuchi, K.; Chiba, T.] Kyoto Univ, Grad Sch Med, Dept Gastroenterol & Hepatol, Sakyo Ku, Kyoto 6068507, Japan; [Wang, H-Q; Takahashi, R.] Kyoto Univ, Grad Sch Med, Dept Neurol, Sakyo Ku, Kyoto 6068507, Japan; [Imai, Y.; Kataoka, A.] RIKEN, Brain Sci Inst, Lab Motor Syst Neurodegenerat, Saitama, Japan; [Nukina, N.] RIKEN, Brain Sci Inst, Lab Struct Neuropathol, Saitama, Japan	Kyoto University; Kyoto University; RIKEN; RIKEN	Marusawa, H (corresponding author), Kyoto Univ, Grad Sch Med, Dept Gastroenterol & Hepatol, Sakyo Ku, 54 Kawara Cho, Kyoto 6068507, Japan.	maru@kuhp.kyoto-u.ac.jp; ryosuket@kuhp.kyoto-u.ac.jp	Nukina, Nobuyuki/GPP-6265-2022; Imai, Yuzuru/AAA-6472-2019	Imai, Yuzuru/0000-0003-2924-5231; Marusawa, Hiroyuki/0000-0002-4286-2712				Cesari R, 2003, P NATL ACAD SCI USA, V100, P5956, DOI 10.1073/pnas.0931262100; Chen YG, 2002, EXP BIOL MED, V227, P75, DOI 10.1177/153537020222700201; Dawson TM, 2003, SCIENCE, V302, P819, DOI 10.1126/science.1087753; de Groot E, 2000, MOL BIOL REP, V27, P129, DOI 10.1023/A:1007159031000; Denison SR, 2003, ONCOGENE, V22, P8370, DOI 10.1038/sj.onc.1207072; Endo Y, 2007, ONCOGENE, V26, P5587, DOI 10.1038/sj.onc.1210344; Farazi PA, 2006, NAT REV CANCER, V6, P674, DOI 10.1038/nrc1934; Farrer MJ, 2006, NAT REV GENET, V7, P306, DOI 10.1038/nrg1831; Feitelson MA, 2002, ONCOGENE, V21, P2593, DOI 10.1038/sj.onc.1205434; Germann A, 2003, INT J CANCER, V106, P187, DOI 10.1002/ijc.11215; Goldberg MS, 2003, J BIOL CHEM, V278, P43628, DOI 10.1074/jbc.M308947200; Grusch M, 2006, J HEPATOL, V45, P673, DOI 10.1016/j.jhep.2006.06.014; Hahn WC, 2002, NEW ENGL J MED, V347, P1593, DOI 10.1056/NEJMra021902; Harrison CA, 2005, TRENDS ENDOCRIN MET, V16, P73, DOI 10.1016/j.tem.2005.01.003; HULLY JR, 1994, HEPATOLOGY, V20, P854, DOI 10.1002/hep.1840200413; Itier JM, 2003, HUM MOL GENET, V12, P2277, DOI 10.1093/hmg/ddg239; Jackson PK, 2000, TRENDS CELL BIOL, V10, P429, DOI 10.1016/S0962-8924(00)01834-1; Jiang HB, 2006, J BIOL CHEM, V281, P8591, DOI 10.1074/jbc.M510926200; Kahle PJ, 2004, EMBO REP, V5, P681, DOI 10.1038/sj.embor.7400188; Kitada T, 1998, NATURE, V392, P605, DOI 10.1038/33416; Kitao Y, 2007, HUM MOL GENET, V16, P50, DOI 10.1093/hmg/ddl439; Kogure K, 2000, HEPATOLOGY, V31, P916, DOI 10.1053/he.2000.6100; Kong FM, 2000, ONCOGENE, V19, P1572, DOI 10.1038/sj.onc.1203437; Kou T, 2007, INT J CANCER, V120, P469, DOI 10.1002/ijc.22292; Laurent-Puig P, 2006, ONCOGENE, V25, P3778, DOI 10.1038/sj.onc.1209547; Lengauer C, 1998, NATURE, V396, P643, DOI 10.1038/25292; Marusawa H, 2003, EMBO J, V22, P2729, DOI 10.1093/emboj/cdg263; Matsumoto T, 2006, FEBS LETT, V580, P731, DOI 10.1016/j.febslet.2005.12.081; MILLIKIN D, 1991, CANCER RES, V51, P5449; Morett E, 1999, TRENDS BIOCHEM SCI, V24, P229, DOI 10.1016/S0968-0004(99)01381-X; MORITA R, 1991, CANCER RES, V51, P5817; NEGRINI M, 1994, CANCER RES, V54, P1331; Nikolaev AY, 2003, CELL, V112, P29, DOI 10.1016/S0092-8674(02)01255-2; Palacino JJ, 2004, J BIOL CHEM, V279, P18614, DOI 10.1074/jbc.M401135200; Patella S, 2006, AM J PHYSIOL-GASTR L, V290, pG137, DOI 10.1152/ajpgi.00080.2005; Perez FA, 2005, P NATL ACAD SCI USA, V102, P2174, DOI 10.1073/pnas.0409598102; Picchio MC, 2004, CLIN CANCER RES, V10, P2720, DOI 10.1158/1078-0432.CCR-03-0086; Rodgarkia-Dara C, 2006, MUTAT RES-REV MUTAT, V613, P123, DOI 10.1016/j.mrrev.2006.07.002; Rodriguez C, 2000, GENE CHROMOSOME CANC, V27, P76, DOI 10.1002/(SICI)1098-2264(200001)27:1<76::AID-GCC10>3.0.CO;2-E; Rossmanith W, 2002, MOL CARCINOGEN, V35, P1, DOI 10.1002/mc.10068; Saito S, 1996, CANCER RES, V56, P5586; SCHWALL RH, 1993, HEPATOLOGY, V18, P347, DOI 10.1016/0270-9139(93)90018-I; Seglen P O, 1976, Methods Cell Biol, V13, P29, DOI 10.1016/S0091-679X(08)61797-5; Shimura H, 2000, NAT GENET, V25, P302, DOI 10.1038/77060; Takabe K, 2003, HEPATOLOGY, V38, P1107, DOI 10.1053/jhep.2003.50483; Takahashi R, 2003, ANN NY ACAD SCI, V991, P101; Tanaka Y, 2006, BIOCHEM BIOPH RES CO, V341, P314, DOI 10.1016/j.bbrc.2005.12.192; Tibiletti MG, 1996, CANCER RES, V56, P4493; Toda Y, 1999, PATHOL INT, V49, P479, DOI 10.1046/j.1440-1827.1999.00875.x; TRENT JM, 1990, SCIENCE, V247, P568, DOI 10.1126/science.2300817; von Coelln R, 2004, P NATL ACAD SCI USA, V101, P10744, DOI 10.1073/pnas.0401297101; Wang F, 2004, GENE CHROMOSOME CANC, V40, P85, DOI 10.1002/gcc.20020; West AB, 2005, TRENDS NEUROSCI, V28, P348, DOI 10.1016/j.tins.2005.05.002; Willert Jennifer, 2002, BMC Dev Biol, V2, P8, DOI 10.1186/1471-213X-2-8	54	158	165	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 9	2008	27	46					6002	6011		10.1038/onc.2008.199	http://dx.doi.org/10.1038/onc.2008.199			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	358BO	18574468	Green Submitted			2022-12-28	WOS:000259891600003
J	Stutz, MA; Shattuck, DL; Laederich, MB; Carraway, KL; Sweeney, C				Stutz, M. A.; Shattuck, D. L.; Laederich, M. B.; Carraway, K. L., III; Sweeney, C.			LRIG1 negatively regulates the oncogenic EGF receptor mutant EGFRvIII	ONCOGENE			English	Article						EGFRvIII; LRIG1; negative regulator; glioblastoma	GROWTH-FACTOR RECEPTOR; KINASE INHIBITORS; DOWN-REGULATION; CELL CARCINOMA; ACTIVATION; RESISTANCE; GENE; UBIQUITYLATION; EXPRESSION; CANCER	Epidermal growth factor receptor (EGFR) mutation is frequently observed in human cancer and contributes to the growth, survival and therapeutic resistance of tumors. EGFRvIII is an oncogenic EGFR mutant resulting from the deletion of exons 2-7 and is the most common EGFR mutant observed in glioblastoma multiforme, an aggressive brain tumor. EGFRvIII is constitutively active but poorly ubiquitinated, leading to inefficient receptor trafficking to lysosomes and unattenuated oncogenic signaling. The mechanism by which EGFRvIII evades downregulation is not fully understood although recent studies suggest that its interaction with the ubiquitin ligase Cbl may be compromised. In this study, we examine the regulation of EGFRvIII by the recently identified negative regulator, LRIG1, which targets EGFR through recognition of its extracellular domain. Here, we determine whether the extracellular domain deletion in EGFRvIII renders it refractory to LRIG1 regulation. We find that EGFRvIII retains interaction with LRIG1 and is in fact more sensitive to LRIG1 action than wild-type receptor. We demonstrate that LRIG1 regulation of EGFRvIII is distinct from the only other known mechanism of EGFR regulation, Cbl-mediated degradation. Ectopic expression of LRIG1 in EGFRvIII(+) glioblastoma cells opposes EGFRvIII-driven tumor cell proliferation, survival, motility and invasion. Finally, RNAi-mediated silencing of LRIG1 alters EGFRvIII intracellular trafficking and leads to enhanced EGFRvIII expression, suggesting that loss of LRIG1 in tumors may contribute to a permissive environment for EGFRvIII overexpression, contributing to EGFRvIII oncogenesis.	[Stutz, M. A.; Shattuck, D. L.; Laederich, M. B.; Carraway, K. L., III; Sweeney, C.] Univ Calif Davis, Ctr Canc, Sacramento, CA 95817 USA	University of California System; University of California Davis	Sweeney, C (corresponding author), Univ Calif Davis, Ctr Canc, Res Bldg 3,Room 1000,4645 2nd Ave, Sacramento, CA 95817 USA.	casweeney@ucdavis.edu			NIH [CA118384, GM068994]; DOD BCRP [W81XWH-06-1-0772]; NATIONAL CANCER INSTITUTE [R01CA118384] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM068994] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); DOD BCRP(United States Department of Defense); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We thank Dr Webster Cavenee from the Ludwig Institute for Cancer Research, University of California at San Diego, La Jolla, California for the U87MG parental and EGFRvIII expressing glioblastoma cells. We thank Dr Laurel Beckett, Chief of the Division of Biostatistics at UC Davis School of Medicine, for statistical consultation. We thank Carol Oxford, Manager of the UC Davis Optical Biology Core, for her assistance in the flow cytometry experiments. This work was supported by NIH grants CA118384 (CS) and GM068994 (KLC). DLS is a recipient of a DOD BCRP predoctoral fellowship Award no. W81XWH-06-1-0772.	Anastasi S, 2005, ONCOGENE, V24, P4540, DOI 10.1038/sj.onc.1208658; Aoki T, 2007, EXPERT OPIN PHARMACO, V8, P3133, DOI 10.1517/14656566.8.18.3133; Cook PW, 1997, J CLIN INVEST, V100, P2286, DOI 10.1172/JCI119766; Davies GC, 2006, ONCOGENE, V25, P6497, DOI 10.1038/sj.onc.1209662; Ferby I, 2006, NAT MED, V12, P568, DOI 10.1038/nm1401; Goldoni S, 2007, ONCOGENE, V26, P368, DOI 10.1038/sj.onc.1209803; Grandal MV, 2007, CARCINOGENESIS, V28, P1408, DOI 10.1093/carcin/bgm058; Gur G, 2004, EMBO J, V23, P3270, DOI 10.1038/sj.emboj.7600342; Han W, 2006, CANCER BIOL THER, V5, P1361, DOI 10.4161/cbt.5.10.3226; Hedman H, 2002, ACTA ONCOL, V41, P352, DOI 10.1080/028418602760169398; Huang HJS, 1997, J BIOL CHEM, V272, P2927, DOI 10.1074/jbc.272.5.2927; Huang PH, 2007, P NATL ACAD SCI USA, V104, P12867, DOI 10.1073/pnas.0705158104; Kirisits A, 2007, INT J BIOCHEM CELL B, V39, P2173, DOI 10.1016/j.biocel.2007.07.012; Laederich MB, 2004, J BIOL CHEM, V279, P47050, DOI 10.1074/jbc.M409703200; Learn CA, 2004, CLIN CANCER RES, V10, P3216, DOI 10.1158/1078-0432.CCR-03-0521; Lindstrom AK, 2008, INT J GYNECOL CANCER, V18, P312, DOI 10.1111/j.1525-1438.2007.01021.x; Mellinghoff IK, 2005, NEW ENGL J MED, V353, P2012, DOI 10.1056/NEJMoa051918; Moscatello DK, 1998, J BIOL CHEM, V273, P200, DOI 10.1074/jbc.273.1.200; Nagane M, 1998, P NATL ACAD SCI USA, V95, P5724, DOI 10.1073/pnas.95.10.5724; Nagane M, 2001, J NEUROSURG, V95, P472, DOI 10.3171/jns.2001.95.3.0472; Nicholas MK, 2006, CLIN CANCER RES, V12, P7261, DOI 10.1158/1078-0432.CCR-06-0874; Peschard P, 2007, MOL CELL, V27, P474, DOI 10.1016/j.molcel.2007.06.023; Raizer RJ, 2005, J NEURO-ONCOL, V74, P77, DOI 10.1007/s11060-005-0603-7; Rosell R, 2006, CLIN CANCER RES, V12, P7222, DOI 10.1158/1078-0432.CCR-06-0627; Shattuck DL, 2007, MOL CELL BIOL, V27, P1934, DOI 10.1128/MCB.00757-06; Sibilia M, 2007, DIFFERENTIATION, V75, P770, DOI 10.1111/j.1432-0436.2007.00238.x; Suzuki Y, 2002, FEBS LETT, V521, P67, DOI 10.1016/S0014-5793(02)02824-7; Sweeney C, 2006, J MAMMARY GLAND BIOL, V11, P89, DOI 10.1007/s10911-006-9015-3; Tanemura A, 2005, DERMATOL SURG, V31, P423, DOI 10.1097/00042728-200504000-00008; Thomasson M, 2003, BRIT J CANCER, V89, P1285, DOI 10.1038/sj.bjc.6601208; VASSAR R, 1991, GENE DEV, V5, P714, DOI 10.1101/gad.5.5.714; Wang MY, 2006, CANCER RES, V66, P7864, DOI 10.1158/0008-5472.CAN-04-4392; Waterman H, 2002, EMBO J, V21, P303, DOI 10.1093/emboj/21.3.303; WELLS A, 1990, SCIENCE, V247, P962, DOI 10.1126/science.2305263	34	61	72	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP	2008	27	43					5741	5752		10.1038/onc.2008.185	http://dx.doi.org/10.1038/onc.2008.185			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	352HM	18542056	Green Accepted			2022-12-28	WOS:000259487100009
J	Kargiotis, O; Chetty, C; Gondi, CS; Tsung, AJ; Dinh, DH; Gujrati, M; Lakka, SS; Kyritsis, AP; Rao, JS				Kargiotis, O.; Chetty, C.; Gondi, C. S.; Tsung, A. J.; Dinh, D. H.; Gujrati, M.; Lakka, S. S.; Kyritsis, A. P.; Rao, J. S.			Adenovirus-mediated transfer of siRNA against MMP-2 mRNA results in impaired invasion and tumor-induced angiogenesis, induces apoptosis in vitro and inhibits tumor growth in vivo in glioblastoma	ONCOGENE			English	Article						MMP-2; gliomas; invasion; angiogenesis; intracranial; siRNAs	MATRIX METALLOPROTEINASES; GLIOMA-CELLS; IV COLLAGENASE; MALIGNANT GLIOMAS; METASTASIS; EXPRESSION; MIGRATION; RECEPTOR; STRATEGIES; THERAPY	Invasive tumors, including gliomas, utilize proteinases to degrade extracellular matrix components and diffuse into the adjacent tissues or migrate toward distant ones. In addition, proteinase activity is required for the formation of new blood vessels within the tumor. Levels of the proteinase matrix metalloproteinase-2 (MMP-2) are highly increased in gliomas. In this study, we examined the effect of the downregulation of MMP-2 via adenovirus-mediated siRNA in gliomas. Here, we show that siRNA delivery significantly decreased levels of MMP-2 in the glioblastoma cell lines U-87 and U-251. U-87 and U-251 cells showed impaired invasion through matrigel as well as decreased migration from tumor spheroids transfected with adenoviral vector expressing siRNA against MMP-2. Additionally, tumor-induced angiogenesis was decreased in in vitro experiments in cultured human microvascular endothelial cells (HMECs) in serum-free conditioned medium of glioblastoma cells transfected with these constructs and co-cultures of glioma cells with HMECs. We also observed decreased angiogenesis in the in vivo dorsal skin-fold chamber model. Moreover, MMP-2 inhibition induced apoptotic cell death in vitro, and suppressed tumor growth of preestablished U-251 intracranial xenografts in nude mice. Thus, specific targeting of MMP-2 may provide a novel, efficient approach for the treatment of gliomas and improve the poor outcomes of patients with these brain tumors.	[Kargiotis, O.; Chetty, C.; Gondi, C. S.; Lakka, S. S.; Rao, J. S.] Univ Illinois, Coll Med, Dept Canc Biol & Pharmacol, Peoria, IL 61605 USA; [Tsung, A. J.; Dinh, D. H.; Rao, J. S.] Univ Illinois, Coll Med, Dept Neurosurg, Peoria, IL 61605 USA; [Gujrati, M.] Univ Illinois, Coll Med, Dept Pathol, Peoria, IL 61605 USA; [Kyritsis, A. P.] Univ Ioannina, Sch Med, Dept Neurol, GR-45110 Ioannina, Greece	University of Illinois System; University of Illinois Peoria; University of Illinois System; University of Illinois Peoria; University of Illinois System; University of Illinois Peoria; University of Ioannina	Rao, JS (corresponding author), Univ Illinois, Coll Med, Dept Canc Biol & Pharmacol, 1 Illini Dr, Peoria, IL 61605 USA.	jsrao@uic.edu		Gondi, Christopher/0000-0002-3036-9920	NCI NIH HHS [R01 CA075557, R01 CA095058-04, CA 116708, R01 CA092393, R01 CA116708-02, R01 CA116708, CA 95058, CA 75557, R01 CA092393-04, R01 CA095058, R01 CA075557-09, CA 92393] Funding Source: Medline; NINDS NIH HHS [NS 47699, R01 NS057529, R01 NS047699-03, R01 NS047699, R01 NS061835, NS61835, NS57529, R01 NS057529-01, R01 NS061835-01] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA092393, R01CA116708, R01CA095058, R01CA075557] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS047699, R01NS061835, R01NS057529] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ABE T, 1994, CLIN EXP METASTAS, V12, P296, DOI 10.1007/BF01753836; Belotti D, 2003, CANCER RES, V63, P5224; BENELLI R, 1994, ONCOL RES, V6, P251; Castro MG, 2003, PHARMACOL THERAPEUT, V98, P71, DOI 10.1016/S0163-7258(03)00014-7; Chambers AF, 1997, J NATL CANCER I, V89, P1260, DOI 10.1093/jnci/89.17.1260; Chetty C, 2006, MOL CANCER THER, V5, P2289, DOI 10.1158/1535-7163.MCT-06-0169; Coussens LM, 2002, SCIENCE, V295, P2387, DOI 10.1126/science.1067100; Deryugina EI, 2002, CANCER RES, V62, P580; Deryugina EI, 1998, CANCER RES, V58, P3743; Egeblad M, 2002, NAT REV CANCER, V2, P161, DOI 10.1038/nrc745; Fang JM, 2000, P NATL ACAD SCI USA, V97, P3884, DOI 10.1073/pnas.97.8.3884; Folgueras AR, 2004, INT J DEV BIOL, V48, P411, DOI 10.1387/ijdb.041811af; FOLKMAN J, 1990, JNCI-J NATL CANCER I, V82, P4, DOI 10.1093/jnci/82.1.4; Forsyth PA, 1999, BRIT J CANCER, V79, P1828, DOI 10.1038/sj.bjc.6690291; FOWLKES JL, 1994, J BIOL CHEM, V269, P25742; Giannelli G, 1997, SCIENCE, V277, P225, DOI 10.1126/science.277.5323.225; Giese A, 1996, NEUROSURGERY, V39, P235, DOI 10.1097/00006123-199608000-00001; Goldbrunner RH, 1999, ACTA NEUROCHIR, V141, P295, DOI 10.1007/s007010050301; Gondi CS, 2004, NEURON GLIA BIOL, V1, P165, DOI 10.1017/S1740925X04000237; Gondi CS, 2004, ONCOGENE, V23, P8486, DOI 10.1038/sj.onc.1207879; Itoh T, 1998, CANCER RES, V58, P1048; Kaliski A, 2005, MOL CANCER THER, V4, P1717, DOI 10.1158/1535-7163.MCT-05-0179; Komatsu Kyoko, 2004, Brain Tumor Pathol, V21, P105, DOI 10.1007/BF02482184; Lakka SS, 2005, BRAIN PATHOL, V15, P327; Lakka SS, 2005, J BIOL CHEM, V280, P21882, DOI 10.1074/jbc.M408520200; Lakka SS, 2002, ONCOGENE, V21, P8011, DOI 10.1038/sj.onc.1205894; Lal S, 2000, J NEUROSURG, V92, P326, DOI 10.3171/jns.2000.92.2.0326; Levi E, 1996, P NATL ACAD SCI USA, V93, P7069, DOI 10.1073/pnas.93.14.7069; McCaffrey AP, 2002, NATURE, V418, P38, DOI 10.1038/418038a; MURPHY AN, 1993, J CELL PHYSIOL, V157, P351, DOI 10.1002/jcp.1041570219; NAKAOHAYASHI J, 1992, ATHEROSCLEROSIS, V92, P141, DOI 10.1016/0021-9150(92)90273-J; Park CM, 2006, CANCER RES, V66, P8511, DOI 10.1158/0008-5472.CAN-05-4340; Rao JS, 2003, NAT REV CANCER, V3, P489, DOI 10.1038/nrc1121; RAY JM, 1994, EUR RESPIR J, V7, P2062; ROSENBERG GA, 1995, J NEUROTRAUM, V12, P833, DOI 10.1089/neu.1995.12.833; Sawaya R, 1998, BIOCHEM BIOPH RES CO, V251, P632, DOI 10.1006/bbrc.1998.9466; Sawaya RE, 1996, CLIN EXP METASTAS, V14, P35, DOI 10.1007/BF00157684; Stetler-Stevenson WG, 1999, J CLIN INVEST, V103, P1237, DOI 10.1172/JCI6870; STETLERSTEVENSON WG, 1990, CANCER METAST REV, V9, P289, DOI 10.1007/BF00049520; Wang JG, 2003, IEEE T MOBILE COMPUT, V2, P65, DOI 10.1109/TMC.2003.1195152; Wild-Bode C, 2001, CANCER RES, V61, P2744; WOESSNER JF, 1991, J RHEUMATOL, V18, P99; Xia HB, 2002, NAT BIOTECHNOL, V20, P1006, DOI 10.1038/nbt739	43	99	104	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 14	2008	27	35					4830	4840		10.1038/onc.2008.122	http://dx.doi.org/10.1038/onc.2008.122			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	337OJ	18438431	Green Accepted			2022-12-28	WOS:000258445100008
J	Alm-Kristiansen, AH; Saether, T; Matre, V; Gilfillan, S; Dahle, O; Gabrielsen, OS				Alm-Kristiansen, A. H.; Saether, T.; Matre, V.; Gilfillan, S.; Dahle, O.; Gabrielsen, O. S.			FLASH acts as a co-activator of the transcription factor c-Myb and localizes to active RNA polymerase II foci	ONCOGENE			English	Article						FLASH; CASP8AP2; c-myb; PML; Cajal bodies; RNA polymerase II	PML NUCLEAR-BODIES; CAJAL BODIES; GLUCOCORTICOID-RECEPTOR; GENE-REGULATION; RAG-2 PROMOTER; FACTOR-BINDING; CELL-NUCLEUS; V-MYB; NF-M; CBP	The c-Myb oncoprotein is a DNA-binding transcription factor with a key role in early stages of hematopoiesis. To expand our knowledge of partners cooperating with c-Myb, we performed a yeast two-hybrid screening with full-length c-Myb as bait. Here, we report FLICE-associated huge protein (FLASH)/CASP8AP2 as a novel Myb-interacting protein. We show that FLASH interacts with the DNA-binding domain of c-Myb and enhances c-Myb-dependent reporter activity and expression of endogenous c-Myb target genes. Chromatin immunoprecipitation assays revealed that FLASH and c-Myb both associate with the MYC promoter region as well as with the intronic enhancer of the c-Myb target gene ADA. Furthermore, siRNA knock-down of FLASH or c-Myb both result in a reduction of MYC and ADA expression. The co-activator effect is mediated through the C-terminal part of FLASH, which binds c-Myb. The FLASH-induced enhancement is comparable with the increase seen with the c-Myb co-activator p300. We find FLASH localized in discrete nuclear speckles in several cell lines, co-localized with c-Myb in active RNA polymerase II foci. These results imply a novel molecular mechanism of regulation of c-Myb activity. We propose that c-Myb cooperates with FLASH in foci associated with active RNA polymerase II, leading to enhancement of Myb-dependent gene activation.	[Alm-Kristiansen, A. H.; Saether, T.; Matre, V.; Gilfillan, S.; Dahle, O.; Gabrielsen, O. S.] Univ Oslo, Dept Mol Biosci, N-0316 Oslo, Norway	University of Oslo	Gabrielsen, OS (corresponding author), Univ Oslo, Dept Mol Biosci, PB1041, N-0316 Oslo, Norway.	o.s.gabrielsen@imbv.uio.no		Saether, Thomas/0000-0003-4976-3810				Barcaroli D, 2006, P NATL ACAD SCI USA, V103, P14802, DOI 10.1073/pnas.0604225103; Barcaroli D, 2006, P NATL ACAD SCI USA, V103, P14808, DOI 10.1073/pnas.0604227103; Berge T, 2007, BLOOD CELL MOL DIS, V39, P278, DOI 10.1016/j.bcmd.2007.05.007; Boisvert FM, 2000, J CELL BIOL, V148, P283, DOI 10.1083/jcb.148.2.283; BURK O, 1993, EMBO J, V12, P2027, DOI 10.1002/j.1460-2075.1993.tb05852.x; Carpinelli MR, 2004, P NATL ACAD SCI USA, V101, P6553, DOI 10.1073/pnas.0401496101; Cioce M, 2005, ANNU REV CELL DEV BI, V21, P105, DOI 10.1146/annurev.cellbio.20.010403.103738; Dahle O, 2004, EXP CELL RES, V297, P118, DOI 10.1016/j.yexcr.2004.03.014; Dahle O, 2003, EUR J BIOCHEM, V270, P1338, DOI 10.1046/j.1432-1033.2003.03504.x; Dai P, 1996, GENE DEV, V10, P528, DOI 10.1101/gad.10.5.528; De Guzman RN, 2006, J MOL BIOL, V355, P1005, DOI 10.1016/j.jmb.2005.09.059; Dellaire G, 2004, BIOESSAYS, V26, P963, DOI 10.1002/bies.20089; Emambokus N, 2003, EMBO J, V22, P4478, DOI 10.1093/emboj/cdg434; ESS KC, 1995, MOL CELL BIOL, V15, P5707; Flotho C, 2006, BLOOD, V108, P1050, DOI 10.1182/blood-2006-01-0322; Fraser P, 2007, NATURE, V447, P413, DOI 10.1038/nature05916; Handwerger KE, 2006, TRENDS CELL BIOL, V16, P19, DOI 10.1016/j.tcb.2005.11.005; Imai Y, 1999, NATURE, V398, P777, DOI 10.1038/19709; Kasper LH, 2002, NATURE, V419, P738, DOI 10.1038/nature01062; Kino T, 2004, J STEROID BIOCHEM, V92, P357, DOI 10.1016/j.jsbmb.2004.09.003; Kino T, 2003, J BIOL CHEM, V278, P3023, DOI 10.1074/jbc.M209234200; Kittler R, 2004, NATURE, V432, P1036, DOI 10.1038/nature03159; Komarnitsky P, 2000, GENE DEV, V14, P2452, DOI 10.1101/gad.824700; Lipsick JS, 1999, ONCOGENE, V18, P3047, DOI 10.1038/sj.onc.1202745; Milovic-Holm K, 2007, EMBO J, V26, P391, DOI 10.1038/sj.emboj.7601504; Miranda GA, 2002, MOL IMMUNOL, V38, P1151, DOI 10.1016/S0161-5890(02)00007-X; MUCENSKI ML, 1991, CELL, V65, P677, DOI 10.1016/0092-8674(91)90099-K; NESS SA, 1993, GENE DEV, V7, P749, DOI 10.1101/gad.7.5.749; Obradovic D, 2004, MOL PHARMACOL, V65, P761, DOI 10.1124/mol.65.3.761; Oelgeschlager M, 1996, EMBO J, V15, P2771, DOI 10.1002/j.1460-2075.1996.tb00637.x; Oh IH, 1999, ONCOGENE, V18, P3017, DOI 10.1038/sj.onc.1202839; Saether T, 2007, J BIOL CHEM, V282, P13994, DOI 10.1074/jbc.M700755200; Sakamoto H, 2006, BLOOD, V108, P896, DOI 10.1182/blood-2005-09-3846; Salomoni P, 2002, CELL, V108, P165, DOI 10.1016/S0092-8674(02)00626-8; Sandberg ML, 2005, DEV CELL, V8, P153, DOI 10.1016/j.devcel.2004.12.015; Schmidt M, 2000, MOL CELL BIOL, V20, P1970, DOI 10.1128/MCB.20.6.1970-1981.2000; Sexton T, 2007, NAT STRUCT MOL BIOL, V14, P1049, DOI 10.1038/nsmb1324; SPECTOR DL, 1991, EMBO J, V10, P3467, DOI 10.1002/j.1460-2075.1991.tb04911.x; Sun J, 2005, J CELL SCI, V118, P4995, DOI 10.1242/jcs.02613; Vegiopoulos A, 2006, BLOOD, V107, P4703, DOI 10.1182/blood-2005-07-2968; Wang QF, 2000, MOL CELL BIOL, V20, P9203, DOI 10.1128/MCB.20.24.9203-9211.2000; Zimber A, 2004, CELL SIGNAL, V16, P1085, DOI 10.1016/j.cellsig.2004.03.020; Zor T, 2004, J MOL BIOL, V337, P521, DOI 10.1016/j.jmb.2004.01.038	43	40	42	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG	2008	27	34					4644	4656		10.1038/onc.2008.105	http://dx.doi.org/10.1038/onc.2008.105			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	334QM	18408764				2022-12-28	WOS:000258236300003
J	Matsui, Y; Watanabe, J; Ikegawa, M; Kamoto, T; Ogawa, O; Nishiyama, H				Matsui, Y.; Watanabe, J.; Ikegawa, M.; Kamoto, T.; Ogawa, O.; Nishiyama, H.			Cancer-specific enhancement of cisplatin-induced cytotoxicity with triptolide through an interaction of inactivated glycogen synthase kinase-3 beta with p53	ONCOGENE			English	Article						urothelial cancer; cisplatin; triptolide; p53; p21; GSK3 beta	TUMOR-NECROSIS-FACTOR; KINASE-C-ALPHA; TRIPTERYGIUM-WILFORDII; INDUCED APOPTOSIS; BLADDER-CANCER; CELL-DEATH; SUSTAINED ACTIVATION; CARCINOMA-CELLS; DNA-DAMAGE; PROLIFERATION	To improve conventional chemotherapeutic efficacy, a combination use of traditional medicines is effective but detailed mechanisms have been rarely elucidated. In the this study, we attempted to clarify how triptolide (PG490), an oxygenated diterpene derived from a Chinese herb, enhances the cisplatin (CDDP)-induced cytotoxicity in urothelial cancer cells. Our results showed that a combined CDDP/triptolide therapy induced apoptosis in urothelial cancer cell lines with wild-type p53, but not in those with mutant-type p53 or normal human urothelium. As the mechanism, triptolide suppressed CDDP-induced p53 transcriptional activity, leading to p21 attenuation, which promoted apoptosis via the activation of c-Jun N-terminal kinase (JNK) and Bax. We further demonstrated that the functional regulation of p53 by triptolide was mediated by an intranuclear association of p53 with glycogen synthase kinase-3 beta (GSK3 beta), which was inactivated by protein kinase C (PKC). This modulation of the PKC-GSK3 beta axis by triptolide was observed in a cancer-specific manner. A mouse xenograft model also showed that a combined CDDP/triptolide therapy completely suppressed tumor growth without any side effects. We expect that cancer-specific enhancement of CDDP-induced cytotoxicity with triptolide may effectively overcome the resistance to a CDDP-based conventional chemotherapy as a treatment for urothelial cancer.	[Matsui, Y.; Watanabe, J.; Kamoto, T.; Ogawa, O.; Nishiyama, H.] Kyoto Univ, Grad Sch Med, Dept Urol, Sakyo Ku, Kyoto 6608507, Japan; [Ikegawa, M.] Kyoto Prefectural Univ, Grad Sch Med Sci, Dept Genom Med Sci, Kyoto 606, Japan	Kyoto University; Kyoto Prefectural University	Ogawa, O (corresponding author), Kyoto Univ, Grad Sch Med, Dept Urol, Sakyo Ku, 54 Shogoin Kawaharacho, Kyoto 6608507, Japan.	ogawao@kuhp.kyoto-u.ac.jp	MATSUI, Yoshiyuki/I-2323-2019; Ikegawa, Masaya/AAG-5327-2020					Aaltonen V, 2006, J HISTOCHEM CYTOCHEM, V54, P795, DOI 10.1369/jhc.5A6839.2006; Asada M, 1999, EMBO J, V18, P1223, DOI 10.1093/emboj/18.5.1223; Bode AM, 2004, NAT REV CANCER, V4, P793, DOI 10.1038/nrc1455; Camacho-Carvajal MM, 2004, MOL CELL PROTEOMICS, V3, P176, DOI 10.1074/mcp.T300010-MCP200; Carter BZ, 2006, BLOOD, V108, P630, DOI 10.1182/blood-2005-09-3898; Chang WT, 2001, J BIOL CHEM, V276, P2221, DOI 10.1074/jbc.M009713200; Chen BJ, 2000, TRANSPLANTATION, V70, P1442, DOI 10.1097/00007890-200011270-00008; Cibere J, 2003, J RHEUMATOL, V30, P465; Cote RJ, 1997, NATURE, V385, P123, DOI 10.1038/385123b0; Coutts AS, 2005, BIOCHEM BIOPH RES CO, V331, P778, DOI 10.1016/j.bbrc.2005.03.150; Demidenko ZN, 2004, CANCER RES, V64, P3653, DOI 10.1158/0008-5472.CAN-04-0204; Erster S, 2004, MOL CELL BIOL, V24, P6728, DOI 10.1128/MCB.24.15.6728-6741.2004; Fidler JM, 2003, MOL CANCER THER, V2, P855; Gartel AL, 2002, MOL CANCER THER, V1, P639; Huang S, 2003, MOL CELL, V11, P1491, DOI 10.1016/S1097-2765(03)00180-1; Jiang XH, 2004, CANCER RES, V64, P5787, DOI 10.1158/0008-5472.CAN-03-1172; Jiang XH, 2001, ONCOGENE, V20, P8009, DOI 10.1038/sj.onc.1204981; Koivunen J, 2004, CANCER RES, V64, P5693, DOI 10.1158/0008-5472.CAN-03-3511; Kulikov R, 2005, MOL CELL BIOL, V25, P7170, DOI 10.1128/MCB.25.16.7170-7180.2005; KUPCHAN SM, 1972, J AM CHEM SOC, V94, P7194, DOI 10.1021/ja00775a078; Lam KS, 2003, ACCOUNTS CHEM RES, V36, P370, DOI 10.1021/ar0201299; Lee KY, 1999, J BIOL CHEM, V274, P13451, DOI 10.1074/jbc.274.19.13451; Lou YJ, 2005, LEUKEMIA RES, V29, P99, DOI 10.1016/j.leukres.2004.05.014; Mandil R, 2001, CANCER RES, V61, P4612; Mansouri A, 2003, J BIOL CHEM, V278, P19245, DOI 10.1074/jbc.M208134200; Matsui Y, 2007, CANCER RES, V67, P1212, DOI 10.1158/0008-5472.CAN-06-3283; Miyata Y, 2005, BIOCHEM BIOPH RES CO, V336, P1081, DOI 10.1016/j.bbrc.2005.08.247; Nishiyama H, 2004, EUR UROL, V45, P176, DOI 10.1016/j.eururo.2003.09.011; NIWA H, 1991, GENE, V108, P193, DOI 10.1016/0378-1119(91)90434-D; Nogawa M, 2005, CANCER LETT, V217, P243, DOI 10.1016/j.canlet.2004.07.010; Qiu DM, 1999, J BIOL CHEM, V274, P13443, DOI 10.1074/jbc.274.19.13443; SARKIS AS, 1995, J CLIN ONCOL, V13, P1384, DOI 10.1200/JCO.1995.13.6.1384; Shamon LA, 1997, CANCER LETT, V112, P113, DOI 10.1016/S0304-3835(96)04554-5; SOUTHGATE J, 1994, LAB INVEST, V71, P583; Tan J, 2005, CANCER RES, V65, P9012, DOI 10.1158/0008-5472.CAN-05-1226; Wan CK, 2006, CANCER LETT, V241, P31, DOI 10.1016/j.canlet.2005.10.001; Watanabe J, 2006, ONCOGENE, V25, P2500, DOI 10.1038/sj.onc.1209162; Watcharasit P, 2003, J BIOL CHEM, V278, P48872, DOI 10.1074/jbc.M305870200; Watcharasit P, 2002, P NATL ACAD SCI USA, V99, P7951, DOI 10.1073/pnas.122062299; Weiss RH, 2003, CANCER CELL, V4, P425, DOI 10.1016/S1535-6108(03)00308-8; Weiss RH, 2003, CANCER LETT, V189, P39, DOI 10.1016/S0304-3835(02)00495-0; Yang SM, 2003, MOL CANCER THER, V2, P65	42	29	33	1	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 31	2008	27	33					4603	4614		10.1038/onc.2008.89	http://dx.doi.org/10.1038/onc.2008.89			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	332IS	18391982				2022-12-28	WOS:000258077300009
J	Bonhomme, C; Calon, A; Martin, E; Robine, S; Neuville, A; Kedinger, M; Domon-Dell, C; Duluc, I; Freund, JN				Bonhomme, C.; Calon, A.; Martin, E.; Robine, S.; Neuville, A.; Kedinger, M.; Domon-Dell, C.; Duluc, I.; Freund, J-N			Cdx1, a dispensable homeobox gene for gut development with limited effect in intestinal cancer	ONCOGENE			English	Article						Cdx; intestine; cancer; development; mouse	DOWN-REGULATION; EXPRESSION; COLON; DIFFERENTIATION	The homeobox gene Cdx1 is involved in anteroposterior patterning in embryos and its expression selectively persists in the intestinal epithelium throughout life. In human colon cancers, Cdx1 is overexpressed in few cases and lost in the majority of adenocarcinomas. We used mouse models of gain and loss-of-function to investigate the role of Cdx1 in intestinal development and cancers. Transgenic mice overexpressing Cdx1 and knockout mice exhibited a morphologically normal intestine. Cell proliferation, specification into the four differentiated lineages and migration along the crypt-villus axis were unchanged compared to wild-type mice. Changing Cdx1 caused an inverse and dose-dependent modi. cation of the expression of the paralogous gene Cdx2, indicating that Cdx1. ne-tunes Cdx2 activity. Transgenenic and knockout mice failed to spontaneously develop tumours. Over-expressing Cdx1 was without incidence on the frequency of intestinal tumours induced chemically by azoxymethane treatment or genetically in Apc(Delta 14/+) mice. However, it augmented the severity of the tumours in Apc(Delta 14/+) mice. Inversely, the loss-of-function of Cdx1 in knockout mice was without incidence on the growth of tumours induced by azoxymethane. We conclude that Cdx1 is dispensable for intestinal development and that its overexpression could increase malignancy in early stages of tumourigenesis.	[Bonhomme, C.; Calon, A.; Martin, E.; Neuville, A.; Kedinger, M.; Domon-Dell, C.; Duluc, I.; Freund, J-N] INSERM U682, F-67200 Strasbourg, Bas Rhin, France; [Bonhomme, C.; Calon, A.; Martin, E.; Neuville, A.; Kedinger, M.; Domon-Dell, C.; Duluc, I.; Freund, J-N] Univ Louis Pasteur, Fac Med, Strasbourg, France; [Robine, S.] Inst Curie, CNRS, UMR144, F-75231 Paris, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Sorbonne Universite	Freund, JN (corresponding author), INSERM U682, 3 Ave Moliere, F-67200 Strasbourg, Bas Rhin, France.	jean-noel.freund@inserm.u-strasbg.fr	Calon, Alexandre/GPK-2061-2022; DULUC, Isabelle/AAA-7062-2022; Domon-Dell, Claire/P-2368-2017; Freund, Jean-Noel/R-4383-2016; Duluc, Isabelle/O-1972-2017	DULUC, Isabelle/0000-0001-8396-6385; Freund, Jean-Noel/0000-0002-0971-3774; Duluc, Isabelle/0000-0001-8396-6385; DOMON-DELL, Claire/0000-0002-8445-9593				Aoki K, 2003, NAT GENET, V35, P323, DOI 10.1038/ng1265; Bansal D, 2006, P NATL ACAD SCI USA, V103, P16924, DOI 10.1073/pnas.0604579103; Beck F, 1999, P NATL ACAD SCI USA, V96, P7318, DOI 10.1073/pnas.96.13.7318; Bonhomme C, 2003, GUT, V52, P1465, DOI 10.1136/gut.52.10.1465; Brabletz T, 2004, CANCER RES, V64, P6973, DOI 10.1158/0008-5472.CAN-04-1132; Domon-Dell C, 2003, ONCOGENE, V22, P7913, DOI 10.1038/sj.onc.1206756; Gross I, 2008, ONCOGENE, V27, P107, DOI 10.1038/sj.onc.1210601; Haigis K, 2006, J BIOL CHEM, V281, P638, DOI 10.1074/jbc.M509053200; Jonckheere N, 2007, J BIOL CHEM, V282, P22638, DOI 10.1074/jbc.M700905200; Lorentz O, 1997, J CELL BIOL, V139, P1553, DOI 10.1083/jcb.139.6.1553; Lynch J, 2000, J BIOL CHEM, V275, P4499, DOI 10.1074/jbc.275.6.4499; Mallo GV, 1997, INT J CANCER, V74, P35, DOI 10.1002/(SICI)1097-0215(19970220)74:1<35::AID-IJC7>3.0.CO;2-1; Mutoh H, 2004, GUT, V53, P1416, DOI 10.1136/gut.2003.032482; Pilozzi E, 2004, J PATHOL, V204, P289, DOI 10.1002/path.1641; Silberg DG, 2000, GASTROENTEROLOGY, V119, P961, DOI 10.1053/gast.2000.18142; Silberg DG, 1997, GASTROENTEROLOGY, V113, P478, DOI 10.1053/gast.1997.v113.pm9247467; Soubeyran P, 1999, GASTROENTEROLOGY, V117, P1326, DOI 10.1016/S0016-5085(99)70283-0; SUBRAMANIAN V, 1995, CELL, V83, P641, DOI 10.1016/0092-8674(95)90104-3; Vider BZ, 1997, BIOCHEM BIOPH RES CO, V232, P742, DOI 10.1006/bbrc.1997.6364	19	26	26	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 24	2008	27	32					4497	4502		10.1038/onc.2008.78	http://dx.doi.org/10.1038/onc.2008.78			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	329PU	18372917				2022-12-28	WOS:000257881700012
J	Leung, JY; Ehmann, GL; Giangrande, PH; Nevins, JR				Leung, J. Y.; Ehmann, G. L.; Giangrande, P. H.; Nevins, J. R.			A role for Myc in facilitating transcription activation by E2F1	ONCOGENE			English	Article						E2F1; Myc; promoter; transcription activation	C-MYC; DROSOPHILA-MYC; CELL-CYCLE; S-PHASE; GENE; BINDING; IDENTIFICATION; SPECIFICITY; EXPRESSION; INDUCTION	Previous work has demonstrated that E2F proteins regulate the expression of various genes encoding proteins essential for DNA replication and cell-cycle progression. E2F1 in particular is required for the initial entry to the cell cycle from a quiescent state and is required for the activation of other E2F genes. Other work has demonstrated a role for the Myc transcription factor in the activation of a large number of genes associated with cell growth, including E2F genes. We now show that Myc is required to allow the interaction of the E2F1 protein with the E2F gene promoters. As such, Myc thus provides a link between the development of a growth-competent state during the initial stage of G1 and the activation of genes essential for DNA replication at G1/S.	[Leung, J. Y.; Ehmann, G. L.; Giangrande, P. H.; Nevins, J. R.] Duke Univ, Med Ctr, Dept Mol Genet & Microbiol, Duke Inst Genome Sci & Policy, Durham, NC 27710 USA	Duke University	Nevins, JR (corresponding author), Duke Univ, Med Ctr, Dept Mol Genet & Microbiol, Duke Inst Genome Sci & Policy, Box 3382, Durham, NC 27710 USA.	j.nevins@duke.edu						Adams MR, 2000, MOL CELL BIOL, V20, P3633, DOI 10.1128/MCB.20.10.3633-3639.2000; BELLOFERNANDEZ C, 1993, P NATL ACAD SCI USA, V90, P7804, DOI 10.1073/pnas.90.16.7804; Cole MD, 1999, ONCOGENE, V18, P2916, DOI 10.1038/sj.onc.1202748; DEGREGORI J, 1995, MOL CELL BIOL, V15, P4215; Eisenman RN, 2001, GENE DEV, V15, P2023, DOI 10.1101/gad928101; Fernandez PC, 2003, GENE DEV, V17, P1115, DOI 10.1101/gad.1067003; Frank SR, 2001, GENE DEV, V15, P2069, DOI 10.1101/gad.906601; Giangrande PH, 2003, MOL CELL BIOL, V23, P3707, DOI 10.1128/MCB.23.11.3707-3720.2003; Giangrande PH, 2004, EMBO J, V23, P1336, DOI 10.1038/sj.emboj.7600134; Grandori C, 2000, ANNU REV CELL DEV BI, V16, P653, DOI 10.1146/annurev.cellbio.16.1.653; Hallstrom TC, 2003, P NATL ACAD SCI USA, V100, P10848, DOI 10.1073/pnas.1831408100; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; Johnston LA, 1999, CELL, V98, P779, DOI 10.1016/S0092-8674(00)81512-3; Kong LJ, 2007, ONCOGENE, V26, P321, DOI 10.1038/sj.onc.1209817; Leone G, 1998, GENE DEV, V12, P2120, DOI 10.1101/gad.12.14.2120; Leone G, 1997, NATURE, V387, P422, DOI 10.1038/387422a0; Leone G, 2001, MOL CELL, V8, P105, DOI 10.1016/S1097-2765(01)00275-1; Lin WC, 2001, GENE DEV, V15, P1833; Morita S, 2000, GENE THER, V7, P1063, DOI 10.1038/sj.gt.3301206; Orian A, 2003, GENE DEV, V17, P1101, DOI 10.1101/gad.1066903; Sears R, 1997, MOL CELL BIOL, V17, P5227, DOI 10.1128/MCB.17.9.5227; Takahashi Y, 2000, GENE DEV, V14, P804; Walker W, 2005, J CELL BIOL, V169, P405, DOI 10.1083/jcb.200411013; Wei CL, 2006, CELL, V124, P207, DOI 10.1016/j.cell.2005.10.043	24	68	71	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL	2008	27	30					4172	4179		10.1038/onc.2008.55	http://dx.doi.org/10.1038/onc.2008.55			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	324DB	18345030				2022-12-28	WOS:000257496800004
J	Nakamura, H; Tanimoto, K; Hiyama, K; Yunokawa, M; Kawamoto, T; Kato, Y; Yoshiga, K; Poellinger, L; Hiyama, E; Nishiyama, M				Nakamura, H.; Tanimoto, K.; Hiyama, K.; Yunokawa, M.; Kawamoto, T.; Kato, Y.; Yoshiga, K.; Poellinger, L.; Hiyama, E.; Nishiyama, M.			Human mismatch repair gene, MLH1, is transcriptionally repressed by the hypoxia-inducible transcription factors, DEC1 and DEC2	ONCOGENE			English	Article						MLH1; DEC1; DEC2; hypoxia; HIF-1	TUMOR-SUPPRESSOR PROTEIN; MAMMALIAN-CELLS; DOWN-REGULATION; CANCER-THERAPY; EXPRESSION; LOOP; MICROENVIRONMENT; DEC1/STRA13; INSTABILITY; MECHANISMS	Tumor hypoxia has been reported to cause a functional loss in DNA mismatch repair (MMR) system as a result of downregulation of MMR genes, although the precise molecular mechanisms remain unclear. In this study, we focused on the downregulation of a key MMR gene, MLH1, and demonstrated that hypoxia-inducible transcription repressors, differentiated embryo chondrocytes (DEC1 and 2), participated in its transcriptional regulation via their bindings to E-box-like motif(s) in MLH1 promoter region. In all cancer cell lines examined, hypoxia increased expression of DEC1 and 2, known as hypoxia-inducible genes, but decreased MLH1 expression in an exposure time-dependent manner at both the mRNA and protein levels. Co-transfection reporter assay revealed that DEC1 and, to greater extent, DEC2 as well as hypoxia-repressed MLH1 promoter activity. We further found that the action was remarkably inhibited by trichostatin A, and identified a possible DEC-response element in the MLH1 promoter. In vitro electrophoretic gel mobility shift and chromatin immunoprecipitation assays demonstrated that DEC1 or 2 directly bounds to the suggested element, and transient transfection assay revealed that overexpression of DEC2 repressed endogenous MLH1 expression in the cells. Hypoxia-induced DEC may impair MMR function through repression of MLH1 expression, possibly via the histone deacethylase-mediated mechanism in cancer cells.	[Nakamura, H.; Tanimoto, K.; Hiyama, K.; Yunokawa, M.; Nishiyama, M.] Hiroshima Univ, Dept Translat Canc Res, Res Inst Radiat Biol & Med, Minami Ku, Hiroshima 7348551, Japan; [Kawamoto, T.; Kato, Y.] Hiroshima Univ, Dept Dent & Med Biochem, Hiroshima 7348551, Japan; [Yoshiga, K.] Hiroshima Univ, Grad Sch Biomed Sci, Dept Mol Oral Med & Maxillofacial Surg, Hiroshima 7348551, Japan; [Poellinger, L.] Karolinska Inst, Med Noble Inst, Stockholm, Sweden; [Nakamura, H.; Hiyama, E.] Hiroshima Univ, Nat Sci Ctr Basic Res & Dev, Hiroshima 7348551, Japan; [Nishiyama, M.] Saitama Med Univ, Int Med Ctr, Saitama, Japan	Hiroshima University; Hiroshima University; Hiroshima University; Karolinska Institutet; Hiroshima University; Saitama Medical University	Tanimoto, K (corresponding author), Hiroshima Univ, Dept Translat Canc Res, Res Inst Radiat Biol & Med, Minami Ku, Kasumi 1-2-3, Hiroshima 7348551, Japan.	ktanimo@hiroshima-u.ac.jp	, 河本健/D-7938-2015; Hiyama, Eiso/A-2013-2019; Keiji, Tanimoto/U-1839-2019	, 河本健/0000-0003-3337-1775; Hiyama, Eiso/0000-0001-9179-5037; Keiji, Tanimoto/0000-0003-4912-4197				Bindra RS, 2007, CANCER LETT, V252, P93, DOI 10.1016/j.canlet.2006.12.011; Bindra RS, 2005, CANCER RES, V65, P11597, DOI 10.1158/0008-5472.CAN-05-2119; Bindra RS, 2004, MOL CELL BIOL, V24, P8504, DOI 10.1128/MCB.24.19.8504-8518.2004; BINDRA RS, 2006, ONCOGENE, V26, P1; Brown JM, 1998, CANCER RES, V58, P1408; Cairns R, 2006, MOL CANCER RES, V4, P61, DOI 10.1158/1541-7786.MCR-06-0002; Denko NC, 2003, ONCOGENE, V22, P5907, DOI 10.1038/sj.onc.1206703; Fujimoto K, 2001, BIOCHEM BIOPH RES CO, V280, P164, DOI 10.1006/bbrc.2000.4133; Harris AL, 2002, NAT REV CANCER, V2, P38, DOI 10.1038/nrc704; Hoeijmakers JHJ, 2001, NATURE, V411, P366, DOI 10.1038/35077232; Honma S, 2002, NATURE, V419, P841, DOI 10.1038/nature01123; Ivanov SV, 2007, ONCOGENE, V26, P802, DOI 10.1038/sj.onc.1209842; Ivanova AV, 2001, J BIOL CHEM, V276, P15306, DOI 10.1074/jbc.M010516200; Kawamoto T, 2004, BIOCHEM BIOPH RES CO, V313, P117, DOI 10.1016/j.bbrc.2003.11.099; Koshiji M, 2005, MOL CELL, V17, P793, DOI 10.1016/j.molcel.2005.02.015; Li YX, 2003, J BIOL CHEM, V278, P16899, DOI 10.1074/jbc.M300596200; Mihaylova VT, 2003, MOL CELL BIOL, V23, P3265, DOI 10.1128/MCB.23.9.3265-3273.2003; Miyazaki K, 2002, J BIOL CHEM, V277, P47014, DOI 10.1074/jbc.M204938200; Peltomaki P, 2001, HUM MOL GENET, V10, P735, DOI 10.1093/hmg/10.7.735; Poellinger L, 2004, CURR OPIN GENET DEV, V14, P81, DOI 10.1016/j.gde.2003.12.006; Reynolds TY, 1996, CANCER RES, V56, P5754; Sato F, 2004, EUR J BIOCHEM, V271, P4409, DOI 10.1111/j.1432-1033.2004.04379.x; Semenza GL, 2003, NAT REV CANCER, V3, P721, DOI 10.1038/nrc1187; Shen M, 1997, BIOCHEM BIOPH RES CO, V236, P294, DOI 10.1006/bbrc.1997.6960; Sun H, 2000, P NATL ACAD SCI USA, V97, P4058, DOI 10.1073/pnas.070526297; Tanimoto K, 2000, EMBO J, V19, P4298, DOI 10.1093/emboj/19.16.4298; Tanimoto K, 2003, CARCINOGENESIS, V24, P1779, DOI 10.1093/carcin/bgg132; TEICHER BA, 1994, CANCER METAST REV, V13, P139, DOI 10.1007/BF00689633; Yuan JL, 2000, CANCER RES, V60, P4372; Yun Z, 2002, DEV CELL, V2, P331, DOI 10.1016/S1534-5807(02)00131-4	30	71	73	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2008	27	30					4200	4209		10.1038/onc.2008.58	http://dx.doi.org/10.1038/onc.2008.58			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	324DB	18345027	Green Submitted			2022-12-28	WOS:000257496800007
J	Kim, DJ; Angel, JM; Sano, S; DiGiovanni, J				Kim, D. J.; Angel, J. M.; Sano, S.; DiGiovanni, J.			Constitutive activation and targeted disruption of signal transducer and activator of transcription 3 (Stat3) in mouse epidermis reveal its critical role in UVB-induced skin carcinogenesis	ONCOGENE			English	Article						Stat3; skin carcinogenesis; UVB	SQUAMOUS-CELL CARCINOMAS; NUCLEOTIDE EXCISION-REPAIR; INDUCED CUTANEOUS DAMAGE; KINASE-C-EPSILON; EPITHELIAL CARCINOGENESIS; MEDIATED ACTIVATION; TUMOR-DEVELOPMENT; PROMOTION STAGES; HAIRLESS MOUSE; DNA-DAMAGE	In this study, the potential role of Stat3 in UVB-induced skin carcinogenesis was examined using skin-specific gain and loss of function transgenic mice, that is, K5.Stat3C and K5Cre.Stat3(fl/fl) mice, respectively. The epidermis of Stat3-deficient mice was highly sensitive to UVB-induced apoptosis, whereas the epidermis of K5.Stat3C mice was more resistant to UVB-induced apoptosis. In particular, the status of Stat3 influenced the survival of ultraviolet-photoproduct cells, including those located in the hair follicles. K5.Stat3C mice exhibited significantly increased epidermal proliferation and hyperplasia in response to UVB irradiation, whereas Stat3-deficient mice showed reduced epidermal proliferation and hyperplasia. Expression of target genes regulated by Stat3, such as cyclin D1 and Bcl-x(L), was increased in epidermis of both control and UVB-irradiated K5.Stat3C mice, and downregulated in epidermis of both control and UVB-irradiated K5Cre.Stat3(fl/fl) mice. Following UVB irradiation, the formation of skin tumors in K5.Stat3C mice was accelerated and both the incidence and multiplicity of skin tumors were significantly greater than wild-type controls. In contrast, Stat3-deficient mice were resistant to UVB skin carcinogenesis. These results show that Stat3 plays an important role in the development of UVB-induced skin tumors through its effects on both survival and proliferation of keratinocytes during carcinogenesis.	[Kim, D. J.; Angel, J. M.; DiGiovanni, J.] Univ Texas MD Anderson Canc Ctr, Dept Carcinogenesis, Div Sci Pk Res, Smithville, TX USA; [Sano, S.] Osaka Univ, Grad Sch Med, Dept Dermatol, Osaka, Japan	University of Texas System; UTMD Anderson Cancer Center; Osaka University	DiGiovanni, J (corresponding author), MD Anderson, Sci Pk,1808 Pk Rd 1C,POB 389, Smithville, TX 78957 USA.	jdigiova@mdanderson.org		KIM, DAE/0000-0002-7977-9955	NCI NIH HHS [R01 CA076520, CA105345, U01 CA105345, P30 CA016672, CA76520, CA16672, R01 CA076520-02] Funding Source: Medline; NIEHS NIH HHS [P30 ES007784, P30 ES007784-12, ES07784] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA016672, R01CA076520, U01CA105345] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES007784] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Ahsan H, 2005, BIOCHEM BIOPH RES CO, V333, P241, DOI 10.1016/j.bbrc.2005.05.106; Alvarez JV, 2005, CANCER RES, V65, P5054, DOI 10.1158/0008-5472.CAN-04-4281; Aziz MH, 2007, CANCER RES, V67, P1385, DOI 10.1158/0008-5472.CAN-06-3350; Bowman T, 2000, ONCOGENE, V19, P2474, DOI 10.1038/sj.onc.1203527; Bromberg J, 2002, J CLIN INVEST, V109, P1139, DOI 10.1172/JCI200215617; Bromberg JF, 1999, CELL, V98, P295, DOI 10.1016/S0092-8674(00)81959-5; Chan KS, 2008, ONCOGENE, V27, P1087, DOI 10.1038/sj.onc.1210726; Chan KS, 2004, J CLIN INVEST, V114, P720, DOI 10.1172/JCI200421032; Chan KS, 2004, CANCER RES, V64, P2382, DOI 10.1158/0008-5472.CAN-03-3197; Cooper SJ, 2003, MOL CANCER RES, V1, P848; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; Daya-Grosjean L, 2005, MUTAT RES-FUND MOL M, V571, P43, DOI 10.1016/j.mrfmmm.2004.11.013; de Gruijl FR, 2001, J PHOTOCH PHOTOBIO B, V63, P19, DOI 10.1016/S1011-1344(01)00199-3; de Laat WL, 1999, GENE DEV, V13, P768, DOI 10.1101/gad.13.7.768; Frank David A, 2003, Cancer Treat Res, V115, P267; Friedberg EC, 2001, NAT REV CANCER, V1, P22, DOI 10.1038/35094000; Grad JM, 2000, CURR OPIN ONCOL, V12, P543, DOI 10.1097/00001622-200011000-00006; Gritsko T, 2006, CLIN CANCER RES, V12, P11, DOI 10.1158/1078-0432.CCR-04-1752; Hill LL, 1999, SCIENCE, V285, P898, DOI 10.1126/science.285.5429.898; Ichihashi M, 2003, TOXICOLOGY, V189, P21, DOI 10.1016/S0300-483X(03)00150-1; Kataoka K, 2008, CARCINOGENESIS, V29, P1108, DOI 10.1093/carcin/bgn061; Kim AL, 2002, PHOTOCHEM PHOTOBIOL, V75, P58, DOI 10.1562/0031-8655(2002)075<0058:SSAOCE>2.0.CO;2; Kim AL, 2002, BIOCHEM BIOPH RES CO, V298, P377, DOI 10.1016/S0006-291X(02)02435-X; Kim DJ, 2007, MOL CARCINOGEN, V46, P725, DOI 10.1002/mc.20342; Kraemer KH, 1997, P NATL ACAD SCI USA, V94, P11, DOI 10.1073/pnas.94.1.11; Leslie K, 2006, CANCER RES, V66, P2544, DOI 10.1158/0008-5472.CAN-05-2203; Levy DE, 2002, NAT REV MOL CELL BIO, V3, P651, DOI 10.1038/nrm909; Levy DE, 2002, J CLIN INVEST, V109, P1143, DOI 10.1172/JCI200215650; Li DL, 2001, FASEB J, V15, P2533, DOI 10.1096/fj.01-0172fje; Li L, 2002, J BIOL CHEM, V277, P17397, DOI 10.1074/jbc.M109962200; LIPPKE JA, 1981, P NATL ACAD SCI-BIOL, V78, P3388, DOI 10.1073/pnas.78.6.3388; Masuda M, 2002, CANCER RES, V62, P3351; Melnikova VO, 2005, MUTAT RES-FUND MOL M, V571, P91, DOI 10.1016/j.mrfmmm.2004.11.015; MITCHELL DL, 1989, PHOTOCHEM PHOTOBIOL, V49, P805, DOI 10.1111/j.1751-1097.1989.tb05578.x; Nijhof JGW, 2007, CARCINOGENESIS, V28, P792, DOI 10.1093/carcin/bgl213; Noonan FP, 2000, CANCER RES, V60, P3738; Pena JC, 1997, CELL GROWTH DIFFER, V8, P619; Robles AI, 1998, GENE DEV, V12, P2469, DOI 10.1101/gad.12.16.2469; Sano S, 2005, CANCER RES, V65, P5720, DOI 10.1158/0008-5472.CAN-04-4359; Sano S, 2005, NAT MED, V11, P43, DOI 10.1038/nm1162; Sano S, 1999, EMBO J, V18, P4657, DOI 10.1093/emboj/18.17.4657; Sano S, 2008, J DERMATOL SCI, V50, P1, DOI 10.1016/j.jdermsci.2007.05.016; Sarasin A, 1999, MUTAT RES-FUND MOL M, V428, P5, DOI 10.1016/S1383-5742(99)00025-3; SETLOW RB, 1966, J MOL BIOL, V17, P237, DOI 10.1016/S0022-2836(66)80105-5; Shen YH, 2001, P NATL ACAD SCI USA, V98, P1543, DOI 10.1073/pnas.041588198; Turkson J, 2000, ONCOGENE, V19, P6613, DOI 10.1038/sj.onc.1204086; Umeda J, 2003, FASEB J, V17, P610, DOI 10.1096/fj.02-0597com; Wheeler DL, 2004, CANCER RES, V64, P7756, DOI 10.1158/0008-5472.CAN-04-1881	48	60	62	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 19	2009	28	7					950	960		10.1038/onc.2008.453	http://dx.doi.org/10.1038/onc.2008.453			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	408TH	19137019	Green Accepted			2022-12-28	WOS:000263457400002
J	Hamanaka, RB; Bobrovnikova-Marjon, E; Ji, X; Liebhaber, SA; Diehl, JA				Hamanaka, R. B.; Bobrovnikova-Marjon, E.; Ji, X.; Liebhaber, S. A.; Diehl, J. A.			PERK-dependent regulation of IAP translation during ER stress	ONCOGENE			English	Article						PERK; ER stress; apoptosis; IAP	ENDOPLASMIC-RETICULUM STRESS; UNFOLDED PROTEIN RESPONSE; NF-KAPPA-B; INDUCED CELL-DEATH; MESSENGER-RNA TRANSLATION; RIBOSOME ENTRY SITE; INDUCED APOPTOSIS; MITOCHONDRIAL APOPTOSIS; MAMMALIAN-CELLS; TUMOR-GROWTH	Exposure of cells to endoplasmic reticulum (ER) stress leads to activation of phosphatidylinositol 3-kinase (PI3K)-Akt signaling pathway and transcriptional induction of the inhibitor of apoptosis family of proteins. One of the proximal effectors of the ER stress response, the PKR-like ER kinase (PERK), leads to cellular adaptation to stress by multiple mechanisms, including attenuation of protein synthesis and transcriptional induction of prosurvival genes. Although PERK activity leads to cellular adaptation to ER stress, we now demonstrate that PERK activity also inhibits the ER stress-induced apoptotic program through the induction of cellular inhibitor of apoptosis (cIAP1 and cIAP2) proteins. This induction of IAPs occurs through both transcriptional and translational responses that are PERK dependent. Reintroduction of cIAP1 or cIAP2 expression into PERK-/- murine embryonic fibroblasts during ER stress delays the early onset of ER stress-induced caspase activation and apoptosis observed in these cells. Furthermore, we demonstrate that the activation of the PI3K-Akt pathway by ER stress is dependent on PERK, suggesting additional ways in which PERK activity protects cells from ER stress-induced apoptosis.	[Hamanaka, R. B.; Bobrovnikova-Marjon, E.; Diehl, J. A.] Univ Penn, Leonard & Madlyn Abramson Family Canc Res Inst, Philadelphia, PA 19104 USA; [Hamanaka, R. B.; Bobrovnikova-Marjon, E.; Diehl, J. A.] Univ Penn, Ctr Canc, Philadelphia, PA 19104 USA; [Hamanaka, R. B.; Bobrovnikova-Marjon, E.] Univ Penn, Dept Canc Biol, Philadelphia, PA 19104 USA; [Ji, X.; Liebhaber, S. A.] Univ Penn, Dept Genet, Philadelphia, PA 19104 USA	University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania; University of Pennsylvania; University of Pennsylvania	Diehl, JA (corresponding author), Abramson Family Canc Res Inst, 454 BRB 2-3,421 Curie Blvd, Philadelphia, PA 19104 USA.	adiehl@mail.med.upenn.edu			National Institutes of Health [F32CA1238252, P01 CA104838]; Leukemia & Lymphoma Scholar award; Abramson Family Cancer Research Institute; NATIONAL CANCER INSTITUTE [P01CA104838] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Leukemia & Lymphoma Scholar award(Leukemia and Lymphoma Society); Abramson Family Cancer Research Institute; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank M Romero for technical assistance and X Yang for providing IAP expression vectors. This study was supported by a grant from the National Institutes of Health F32CA1238252 (EBM); P01 CA104838, a Leukemia & Lymphoma Scholar award and the Abramson Family Cancer Research Institute (JAD).	Bellacosa A, 2004, CANCER BIOL THER, V3, P268, DOI 10.4161/cbt.3.3.703; Bertrand MJM, 2008, MOL CELL, V30, P689, DOI 10.1016/j.molcel.2008.05.014; Bi MX, 2005, EMBO J, V24, P3470, DOI 10.1038/sj.emboj.7600777; Brewer JW, 2000, P NATL ACAD SCI USA, V97, P12625, DOI 10.1073/pnas.220247197; Cho H, 2001, J BIOL CHEM, V276, P38349, DOI 10.1074/jbc.C100462200; Clem RJ, 2001, J BIOL CHEM, V276, P7602, DOI 10.1074/jbc.M010259200; COX JS, 1993, CELL, V73, P1197, DOI 10.1016/0092-8674(93)90648-A; CROOK NE, 1993, J VIROL, V67, P2168, DOI 10.1128/JVI.67.4.2168-2174.1993; Cullinan SB, 2003, MOL CELL BIOL, V23, P7198, DOI 10.1128/MCB.23.20.7198-7209.2003; Dan HC, 2004, J BIOL CHEM, V279, P5405, DOI 10.1074/jbc.M312044200; Debatin KM, 2004, ONCOGENE, V23, P2950, DOI 10.1038/sj.onc.1207558; Deng J, 2004, MOL CELL BIOL, V24, P10161, DOI 10.1128/MCB.24.23.10161-10168.2004; Deniaud A, 2008, ONCOGENE, V27, P285, DOI 10.1038/sj.onc.1210638; Deveraux QL, 1997, NATURE, V388, P300, DOI 10.1038/40901; Di Sano F, 2006, J BIOL CHEM, V281, P2693, DOI 10.1074/jbc.M509110200; Eckelman BP, 2006, J BIOL CHEM, V281, P3254, DOI 10.1074/jbc.M510863200; Fels DR, 2006, CANCER BIOL THER, V5, P723, DOI 10.4161/cbt.5.7.2967; Fernandez J, 2002, J BIOL CHEM, V277, P19198, DOI 10.1074/jbc.M201052200; Fernandez J, 2002, J BIOL CHEM, V277, P11780, DOI 10.1074/jbc.M110778200; Harding HP, 1999, NATURE, V397, P271, DOI 10.1038/16729; Harding HP, 2000, MOL CELL, V5, P897, DOI 10.1016/S1097-2765(00)80330-5; Harding HP, 2000, MOL CELL, V6, P1099, DOI 10.1016/S1097-2765(00)00108-8; Haze K, 1999, MOL BIOL CELL, V10, P3787, DOI 10.1091/mbc.10.11.3787; Hitomi J, 2004, J CELL BIOL, V165, P347, DOI 10.1083/jcb.200310015; Hosoi T, 2007, BRAIN RES, V1152, P27, DOI 10.1016/j.brainres.2007.03.052; Hu P, 2006, MOL CELL BIOL, V26, P3071, DOI 10.1128/MCB.26.8.3071-3084.2006; Hu P, 2004, J BIOL CHEM, V279, P49420, DOI 10.1074/jbc.M407700200; Jamora C, 1996, P NATL ACAD SCI USA, V93, P7690, DOI 10.1073/pnas.93.15.7690; Ji XJ, 2003, MOL CELL BIOL, V23, P899, DOI 10.1128/MCB.23.3.899-907.2003; Jiang HY, 2003, MOL CELL BIOL, V23, P5651, DOI 10.1128/MCB.23.16.5651-5663.2003; Katayama T, 2004, J CHEM NEUROANAT, V28, P67, DOI 10.1016/j.jchemneu.2003.12.004; Kaufman RJ, 2004, TRENDS BIOCHEM SCI, V29, P152, DOI 10.1016/j.tibs.2004.01.004; Kazemi S, 2007, MOL BIOL CELL, V18, P3635, DOI 10.1091/mbc.E07-01-0053; Li JZ, 2006, J BIOL CHEM, V281, P7260, DOI 10.1074/jbc.M509868200; Liston P, 2003, ONCOGENE, V22, P8568, DOI 10.1038/sj.onc.1207101; Mathai JP, 2005, J BIOL CHEM, V280, P23829, DOI 10.1074/jbc.M500800200; Morishima N, 2004, J BIOL CHEM, V279, P50375, DOI 10.1074/jbc.M408493200; Morishima N, 2002, J BIOL CHEM, V277, P34287, DOI 10.1074/jbc.M204973200; Nakagawa T, 2000, NATURE, V403, P98, DOI 10.1038/47513; Orth R, 1997, J BIOL CHEM, V272, P8841; Petersen SL, 2007, CANCER CELL, V12, P445, DOI 10.1016/j.ccr.2007.08.029; Puthalakath H, 2007, CELL, V129, P1337, DOI 10.1016/j.cell.2007.04.027; Rao RV, 2002, J BIOL CHEM, V277, P21836, DOI 10.1074/jbc.M202726200; Reimertz C, 2003, J CELL BIOL, V162, P587, DOI 10.1083/jcb.200305149; Romero-Ramirez L, 2004, CANCER RES, V64, P5943, DOI 10.1158/0008-5472.CAN-04-1606; Roy N, 1997, EMBO J, V16, P6914, DOI 10.1093/emboj/16.23.6914; Salvesen GS, 2002, NAT REV MOL CELL BIO, V3, P401, DOI 10.1038/nrm830; Scheuner D, 2001, MOL CELL, V7, P1165, DOI 10.1016/S1097-2765(01)00265-9; Schroder M, 2005, ANNU REV BIOCHEM, V74, P739, DOI 10.1146/annurev.biochem.73.011303.074134; Scott FL, 2005, EMBO J, V24, P645, DOI 10.1038/sj.emboj.7600544; Shi YG, 1998, MOL CELL BIOL, V18, P7499, DOI 10.1128/MCB.18.12.7499; Shiozaki EN, 2003, MOL CELL, V11, P519, DOI 10.1016/S1097-2765(03)00054-6; Shiraishi H, 2006, J CELL SCI, V119, P3958, DOI 10.1242/jcs.03160; Simons M, 1999, J NEUROCHEM, V72, P292, DOI 10.1046/j.1471-4159.1999.0720292.x; Tirasophon W, 1998, GENE DEV, V12, P1812, DOI 10.1101/gad.12.12.1812; TODARO GJ, 1963, J CELL BIOL, V17, P299, DOI 10.1083/jcb.17.2.299; Varfolomeev E, 2007, CELL, V131, P669, DOI 10.1016/j.cell.2007.10.030; Vattem KM, 2004, P NATL ACAD SCI USA, V101, P11269, DOI 10.1073/pnas.0400541101; Vince JE, 2007, CELL, V131, P682, DOI 10.1016/j.cell.2007.10.037; Vucic D, 2007, CLIN CANCER RES, V13, P5995, DOI 10.1158/1078-0432.CCR-07-0729; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; Wang XZ, 1998, EMBO J, V17, P5708, DOI 10.1093/emboj/17.19.5708; Warnakulasuriyarachchi D, 2004, J BIOL CHEM, V279, P17148, DOI 10.1074/jbc.M308737200	63	70	74	4	19	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2009	28	6					910	920		10.1038/onc.2008.428	http://dx.doi.org/10.1038/onc.2008.428			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	406UI	19029953	Green Accepted			2022-12-28	WOS:000263320000013
J	Goransson, M; Andersson, MK; Forni, C; Stahlberg, A; Andersson, C; Olofsson, A; Mantovani, R; Aman, P				Goransson, M.; Andersson, M. K.; Forni, C.; Stahlberg, A.; Andersson, C.; Olofsson, A.; Mantovani, R.; Aman, P.			The myxoid liposarcoma FUS-DDIT3 fusion oncoprotein deregulates NF-kappa B target genes by interaction with NFKBIZ	ONCOGENE			English	Article						MLS/RCLS; FUS; DDIT3; NF-kappa B; NFKBIZ; sarcoma	RNA-BINDING PROTEIN; TLS-CHOP; EXPRESSION PATTERNS; GENOMIC STRUCTURE; FUS/TLS-CHOP; TRANSCRIPTION; EWS; ZETA; INTERLEUKIN-6; TRANSLOCATION	FUS (also called TLS), EWSR1 and TAF15 (also called TAF2N) are related genes involved in tumor type-specific fusion oncogenes in human malignancies. The FUS-DDIT3 fusion oncogene results from a t(12;16)(q13;p11) chromosome translocation and has a causative role in the initiation of myxoid/round cell liposarcomas (MLS/RCLS). The FUS-DDIT3 protein induces increased expression of the CAAT/enhancer-binding protein (C/EBP) and nuclear factor-kappa B (NF-kappa)-controlled gene IL8, and the N-terminal FUS part is required for this activation. Chromatin immunoprecipitation analysis showed that FUS-DDIT3 binds the IL8 promoter. Expression studies of the IL8 promoter harboring a C/EBP-NF-kappa B composite site pinpointed the importance of NF-kappa B for IL8 expression in FUS-DDIT3-expressing cells. We therefore probed for possible interaction of FUS-DDIT3 with members of the NF-kappa B family. The nuclear factor NFKBIZ colocalizes with FUS-DDIT3 in nuclear structures, and immunoprecipitation experiments showed that FUS-DDIT3 binds the C-terminal of NFKBIZ. We also report that additional NF-kappa B-controlled genes are upregulated at the mRNA level in FUS-DDIT3-expressing cell lines and they can be induced by NFKBIZ. Taken together, the results indicate that FUS-DDIT3 deregulates some NF-kappa B-controlled genes through interactions with NFKBIZ. Similar mechanisms may be a part of the transformation process in other tumor types carrying FUS, EWSR1 and TAF15 containing fusion oncogenes.	[Goransson, M.; Andersson, M. K.; Andersson, C.; Olofsson, A.; Aman, P.] Univ Gothenburg, LLCR, Dept Pathol, Sahlgrenska Acad, SE-41345 Gothenburg, Sweden; [Forni, C.; Mantovani, R.] Univ Milan, Dipartimento Sci Biomol & Biotecnol, Milan, Italy; [Stahlberg, A.] Univ Gothenburg, Sahlgrenska Acad, Ctr Brain Repair & Rehabil, Dept Clin Neurosci & Rehabil, SE-41345 Gothenburg, Sweden	University of Gothenburg; University of Milan; University of Gothenburg	Aman, P (corresponding author), Univ Gothenburg, LLCR, Dept Pathol, Sahlgrenska Acad, Gula Straket 8, SE-41345 Gothenburg, Sweden.	pierre.aman@llcr.med.gu.se		Aman, Pierre/0000-0002-1482-8875; Stahlberg, Anders/0000-0003-4243-0191	Inga-Britt and Arne Lundberg Research Foundation; Swedish Cancer Society; Assar Gabrielssons Research Foundation; Johan Jansson Foundation for Cancer Research; AIRC; Swedish Research Council	Inga-Britt and Arne Lundberg Research Foundation; Swedish Cancer Society(Swedish Cancer Society); Assar Gabrielssons Research Foundation; Johan Jansson Foundation for Cancer Research; AIRC(Fondazione AIRC per la ricerca sul cancro); Swedish Research Council	We thank Ulric Pedersen for image processing. This work was supported by grants from the Inga-Britt and Arne Lundberg Research Foundation, the Swedish Cancer Society, Assar Gabrielssons Research Foundation and the Johan Jansson Foundation for Cancer Research. RM was supported by an AIRC grant. AS is supported by a postdoctoral fellowship award from the Swedish Research Council.	AMAN P, 1992, GENE CHROMOSOME CANC, V5, P278, DOI 10.1002/gcc.2870050403; Aman P, 1996, GENOMICS, V37, P1, DOI 10.1006/geno.1996.0513; Basile A, 1997, J BIOL CHEM, V272, P8172, DOI 10.1074/jbc.272.13.8172; BIEGEL JA, 1993, GENE CHROMOSOME CANC, V7, P119, DOI 10.1002/gcc.2870070210; Bratt T, 2000, BBA-PROTEIN STRUCT M, V1482, P318, DOI 10.1016/S0167-4838(00)00154-0; Brinckerhoff CE, 2000, CLIN CANCER RES, V6, P4823; Caretti G, 2003, J BIOL CHEM, V278, P30435, DOI 10.1074/jbc.M304606200; Chen ZD, 1998, NUCLEIC ACIDS RES, V26, P1126, DOI 10.1093/nar/26.4.1126; CROZAT A, 1993, NATURE, V363, P640, DOI 10.1038/363640a0; DIFFIN F, 1994, J CLIN PATHOL, V47, P562, DOI 10.1136/jcp.47.6.562; Engstrom K, 2006, AM J PATHOL, V168, P1642, DOI 10.2353/ajpath.2006.050872; Goransson M, 2005, INT J CANCER, V115, P556, DOI 10.1002/ijc.20893; Goransson M, 2002, EXP CELL RES, V278, P125, DOI 10.1006/excr.2002.5566; Hinz M, 1999, MOL CELL BIOL, V19, P2690; Kitamura H, 2000, FEBS LETT, V485, P53, DOI 10.1016/S0014-5793(00)02185-2; Kovar H, 2005, SEMIN CANCER BIOL, V15, P189, DOI 10.1016/j.semcancer.2005.01.004; KOVAR H, 1994, KLIN PADIATR, V206, P196, DOI 10.1055/s-2008-1046605; Law Warren J., 2006, Briefings in Functional Genomics & Proteomics, V5, P8, DOI 10.1093/bfgp/ell015; LIBERMANN TA, 1990, MOL CELL BIOL, V10, P2327, DOI 10.1128/MCB.10.5.2327; LITTLEWOOD TD, 1995, NUCLEIC ACIDS RES, V23, P1686, DOI 10.1093/nar/23.10.1686; Matsuo S, 2007, BIOCHEM J, V405, P605, DOI 10.1042/BJ20061797; MATSUSAKA T, 1993, P NATL ACAD SCI USA, V90, P10193, DOI 10.1073/pnas.90.21.10193; Morohoshi F, 1998, GENE, V221, P191, DOI 10.1016/S0378-1119(98)00463-6; Motoyama M, 2005, J BIOL CHEM, V280, P7444, DOI 10.1074/jbc.M412738200; MUKAIDA N, 1990, J BIOL CHEM, V265, P21128; Nakopoulou L, 1999, HUM PATHOL, V30, P436, DOI 10.1016/S0046-8177(99)90120-X; OHNO T, 1993, CANCER RES, V53, P5859; Oikawa K, 2006, AM J SURG PATHOL, V30, P351; Olofsson A, 2004, INT J ONCOL, V25, P1349; Panagopoulos I, 1996, ONCOGENE, V12, P489; PANAGOPOULOS I, 1994, CANCER RES, V54, P6500; Perez-Losada J, 2000, ONCOGENE, V19, P6015, DOI 10.1038/sj.onc.1204018; Perez-Losada J, 2000, ONCOGENE, V19, P2413, DOI 10.1038/sj.onc.1203572; RABBITTS TH, 1993, NAT GENET, V4, P175, DOI 10.1038/ng0693-175; Riggi N, 2006, CANCER RES, V66, P7016, DOI 10.1158/0008-5472.CAN-05-3979; RON D, 1992, GENE DEV, V6, P439, DOI 10.1101/gad.6.3.439; SANCHEZGARCIA I, 1994, P NATL ACAD SCI USA, V91, P7869, DOI 10.1073/pnas.91.17.7869; Schwarzbach MHM, 2004, ONCOGENE, V23, P6798, DOI 10.1038/sj.onc.1207840; Stahlberg A, 2004, CLIN CHEM, V50, P509, DOI 10.1373/clinchem.2003.026161; Sun SC, 2003, CANCER METAST REV, V22, P405, DOI 10.1023/A:1023733231406; Thelin-Jarnum S, 1999, INT J CANCER, V83, P30, DOI 10.1002/(SICI)1097-0215(19990924)83:1<30::AID-IJC6>3.0.CO;2-4; Thelin-Jarnum S, 2002, INT J CANCER, V97, P446, DOI 10.1002/ijc.1632; Totzke G, 2006, J BIOL CHEM, V281, P12645, DOI 10.1074/jbc.M511956200; Trinh DV, 2008, J MOL BIOL, V379, P122, DOI 10.1016/j.jmb.2008.03.060; Uranishi H, 2001, J BIOL CHEM, V276, P13395, DOI 10.1074/jbc.M011176200; Vandesompele J, 2002, GENOME BIOL, V3, DOI 10.1186/gb-2002-3-7-research0034; Vincenti MP, 1998, ARTHRITIS RHEUM, V41, P1987, DOI 10.1002/1529-0131(199811)41:11<1987::AID-ART14>3.3.CO;2-#; Yamazaki S, 2001, J BIOL CHEM, V276, P27657, DOI 10.1074/jbc.M103426200; ZINSZNER H, 1994, GENE DEV, V8, P2513, DOI 10.1101/gad.8.21.2513; Zinszner H, 1997, ONCOGENE, V14, P451, DOI 10.1038/sj.onc.1200854	50	48	51	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2009	28	2					270	278		10.1038/onc.2008.378	http://dx.doi.org/10.1038/onc.2008.378			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	395CY	18850010				2022-12-28	WOS:000262501100010
J	Mourtada-Maarabouni, M; Pickard, MR; Hedge, VL; Farzaneh, F; Williams, GT				Mourtada-Maarabouni, M.; Pickard, M. R.; Hedge, V. L.; Farzaneh, F.; Williams, G. T.			GAS5, a non-protein-coding RNA, controls apoptosis and is downregulated in breast cancer	ONCOGENE			English	Article						apoptosis; snoRNA; growth arrest; oncogenesis; breast cancer; drug resistance	EXPRESSION CLONING REVEALS; HUMAN PROSTATIC-CARCINOMA; SMALL NUCLEOLAR RNAS; SNORNA HOST GENE; B-CELL LYMPHOMA; GROWTH-ARREST; FUNCTIONAL EXPRESSION; MOLECULAR REGULATION; NONCODING RNAS; IN-VITRO	Effective control of both cell survival and cell proliferation is critical to the prevention of oncogenesis and to successful cancer therapy. Using functional expression cloning, we have identified GAS5 ( growth arrest-specific transcript 5) as critical to the control of mammalian apoptosis and cell population growth. GAS5 transcripts are subject to complex post-transcriptional processing and some, but not all, GAS5 transcripts sensitize mammalian cells to apoptosis inducers. We have found that, in some cell lines, GAS5 expression induces growth arrest and apoptosis independently of other stimuli. GAS5 transcript levels were significantly reduced in breast cancer samples relative to adjacent unaffected normal breast epithelial tissues. The GAS5 gene has no significant protein-coding potential but expression encodes small nucleolar RNAs (snoRNAs) in its introns. Taken together with the recent demonstration of tumor suppressor characteristics in the related snoRNA U50, our observations suggest that such snoRNAs form a novel family of genes controlling oncogenesis and sensitivity to therapy in cancer.	[Mourtada-Maarabouni, M.; Pickard, M. R.; Hedge, V. L.; Williams, G. T.] Univ Keele, Inst Sci & Technol Med, Keele ST5 5BG, Staffs, England; [Mourtada-Maarabouni, M.; Pickard, M. R.; Hedge, V. L.; Williams, G. T.] Univ Keele, Sch Life Sci, Keele ST5 5BG, Staffs, England; [Farzaneh, F.] Kings Coll London, Dept Haematol Med, Rayne Inst, London WC2R 2LS, England	Keele University; Keele University; University of London; King's College London	Williams, GT (corresponding author), Univ Keele, Inst Sci & Technol Med, Huxley Bldg, Keele ST5 5BG, Staffs, England.	bia19@biol.keele.ac.uk; g.t.williams@keele.ac.uk	Farzaneh, Farzin/B-4902-2009; Williams, Gwyn/GQY-7555-2022	Farzaneh, Farzin/0000-0002-9275-2415; Williams, Gwyn/0000-0003-4556-9930; /0000-0001-8324-1325	Wellcome Trust; Breast Cancer Campaign; Leukemia Research Fund; BBSRC; BBSRC [BB/E005896/1] Funding Source: UKRI; Biotechnology and Biological Sciences Research Council [BB/E005896/1] Funding Source: researchfish	Wellcome Trust(Wellcome TrustEuropean Commission); Breast Cancer Campaign; Leukemia Research Fund; BBSRC(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); BBSRC(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC))	We thank Ms Ria Kishen, Dr Helen Kalirai and Professor Philip Rudland of the Liverpool Cancer Tissue Bank Research Centre for breast cancer and normal breast epithelial RNA samples, Professor Norman Maitland for PNT2C2 and P4E6 cells, and the Wellcome Trust, Breast Cancer Campaign, Leukemia Research Fund and BBSRC for financial support.	BERTHON P, 1995, INT J ONCOL, V6, P333; Bialik S, 2006, ANNU REV BIOCHEM, V75, P189, DOI 10.1146/annurev.biochem.75.103004.142615; Chinnaiyan AM, 2000, P NATL ACAD SCI USA, V97, P1754, DOI 10.1073/pnas.030545097; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; COCCIA EM, 1992, MOL CELL BIOL, V12, P3514, DOI 10.1128/MCB.12.8.3514; DANIELSEN M, 1983, MOL CELL BIOL, V3, P1310, DOI 10.1128/MCB.3.7.1310; DEISS LP, 1995, GENE DEV, V9, P15, DOI 10.1101/gad.9.1.15; Dong XY, 2008, HUM MOL GENET, V17, P1031, DOI 10.1093/hmg/ddm375; FAN SJ, 1995, CANCER RES, V55, P1649; Fleming JV, 1998, BIOCHEM J, V330, P573; Fontanier-Razzaq N, 2002, J NUTR, V132, P2137, DOI 10.1093/jn/132.8.2137; Green DR, 2002, CANCER CELL, V1, P19, DOI 10.1016/S1535-6108(02)00024-7; Hale AJ, 1996, EUR J BIOCHEM, V236, P1, DOI 10.1111/j.1432-1033.1996.00001.x; Hengartner MO, 2000, NATURE, V407, P770, DOI 10.1038/35037710; HOROSZEWICZ JS, 1983, CANCER RES, V43, P1809; Inbal B, 1997, NATURE, V390, P180, DOI 10.1038/36599; Johnstone RW, 2002, CELL, V108, P153, DOI 10.1016/S0092-8674(02)00625-6; KAIGHN ME, 1979, INVEST UROL, V17, P16; KERR JFR, 1994, CANCER-AM CANCER SOC, V73, P2013, DOI 10.1002/1097-0142(19940415)73:8<2013::AID-CNCR2820730802>3.0.CO;2-J; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; Kishore S, 2006, SCIENCE, V311, P230, DOI 10.1126/science.1118265; Kiss T, 2002, CELL, V109, P145, DOI 10.1016/S0092-8674(02)00718-3; Lacroix M, 2004, BREAST CANCER RES TR, V83, P249, DOI 10.1023/B:BREA.0000014042.54925.cc; Lam M, 1997, CELL DEATH DIFFER, V4, P283, DOI 10.1038/sj.cdd.4400249; Li F, 1997, J BIOL CHEM, V272, P30299, DOI 10.1074/jbc.272.48.30299; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; MacKeigan JP, 2000, J BIOL CHEM, V275, P38953, DOI 10.1074/jbc.C000684200; Maitland NJ, 2001, RADIAT RES, V155, P133, DOI 10.1667/0033-7587(2001)155[0133:IVMTSC]2.0.CO;2; Matera AG, 2007, NAT REV MOL CELL BIO, V8, P209, DOI 10.1038/nrm2124; Mattick JS, 2005, SCIENCE, V309, P1527, DOI 10.1126/science.1117806; Morrison LE, 2007, GENE CHROMOSOME CANC, V46, P397, DOI 10.1002/gcc.20419; Mourtacla-Maarabouni M, 2005, J LEUKOCYTE BIOL, V78, P503, DOI 10.1189/jlb.0205070; Mourtada-Maarabouni M, 2004, ONCOGENE, V23, P9419, DOI 10.1038/sj.onc.1208048; Mourtada-Maarabouni M, 2003, CELL DEATH DIFFER, V10, P1016, DOI 10.1038/sj.cdd.4401274; Mourtada-Maarabouni M, 2003, GENES CELLS, V8, P109, DOI 10.1046/j.1365-2443.2003.00619.x; Mourtada-Maarabouni M, 2002, APOPTOSIS, V7, P421, DOI 10.1023/A:1020083008017; Mourtada-Maarabouni M, 2008, J CELL SCI, V121, P939, DOI 10.1242/jcs.024646; Mourtada-Maarabouni M, 2006, EXP CELL RES, V312, P1745, DOI 10.1016/j.yexcr.2006.02.009; Muller AJ, 1998, MAMM GENOME, V9, P773, DOI 10.1007/s003359900862; Nakamura Y, 2008, CANCER GENET CYTOGEN, V182, P144, DOI 10.1016/j.cancergencyto.2008.01.013; Nupponen NN, 2001, CANCER METAST REV, V20, P155, DOI 10.1023/A:1015557308033; Raho G, 2000, GENE, V256, P13, DOI 10.1016/S0378-1119(00)00363-2; Rossini GP, 2001, TOXICON, V39, P763, DOI 10.1016/S0041-0101(00)00202-6; Sax JK, 2002, NAT CELL BIOL, V4, P842, DOI 10.1038/ncb866; SCHNEIDER C, 1988, CELL, V54, P787, DOI 10.1016/S0092-8674(88)91065-3; SMALE G, 1992, ANAL BIOCHEM, V203, P352, DOI 10.1016/0003-2697(92)90324-Z; Smedley D, 2000, GENE CHROMOSOME CANC, V28, P121, DOI 10.1002/(SICI)1098-2264(200005)28:1<121::AID-GCC14>3.0.CO;2-O; Smith CM, 1998, MOL CELL BIOL, V18, P6897, DOI 10.1128/MCB.18.12.6897; Sramkoski RM, 1999, IN VITRO CELL DEV-AN, V35, P403; Stange DE, 2006, CLIN CANCER RES, V12, P345, DOI 10.1158/1078-0432.CCR-05-1633; Sutherland LC, 2000, ONCOGENE, V19, P3774, DOI 10.1038/sj.onc.1203720; Tanaka R, 2000, GENES CELLS, V5, P277, DOI 10.1046/j.1365-2443.2000.00325.x; Thomadaki H, 2007, ANN NY ACAD SCI, V1095, P35, DOI 10.1196/annals.1397.005; Tsuji H, 2003, CARCINOGENESIS, V24, P1257, DOI 10.1093/carcin/bgg071; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; Vitali P, 2005, M S-MED SCI, V21, P1017; WARRI AM, 1993, JNCI-J NATL CANCER I, V85, P1412, DOI 10.1093/jnci/85.17.1412; Williams GT, 2004, CANCER IMMUNOL IMMUN, V53, P160, DOI 10.1007/s00262-003-0476-6; WILLIAMS GT, 1993, CELL, V74, P777, DOI 10.1016/0092-8674(93)90457-2; WILLIAMS GT, 1990, NATURE, V343, P76, DOI 10.1038/343076a0; Williams GT, 2006, GENE THER MOL BIOL, V10B, P255	61	630	678	1	54	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2009	28	2					195	208		10.1038/onc.2008.373	http://dx.doi.org/10.1038/onc.2008.373			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	395CY	18836484				2022-12-28	WOS:000262501100004
J	Vecchione, A; Fassan, M; Anesti, V; Morrione, A; Goldoni, S; Baldassarre, G; Byrne, D; D'Arca, D; Palazzo, JP; Lloyd, J; Scorrano, L; Gomella, LG; Iozzo Renato, V; Baffa, R				Vecchione, A.; Fassan, M.; Anesti, V.; Morrione, A.; Goldoni, S.; Baldassarre, G.; Byrne, D.; D'Arca, D.; Palazzo, J. P.; Lloyd, J.; Scorrano, L.; Gomella, L. G.; Iozzo Renato, V.; Baffa, R.			MITOSTATIN, a putative tumor suppressor on chromosome 12q24.1, is downregulated in human bladder and breast cancer	ONCOGENE			English	Article						bladder cancer; breast cancer; mitochondria; chromosome 12q; tumor suppressor	COMPARATIVE GENOMIC HYBRIDIZATION; HEAT-SHOCK-PROTEIN; GROWTH-FACTOR RECEPTOR; SMALL STRESS-PROTEINS; PROSTATE-CANCER; CELL CARCINOMA; ANDROGEN ABLATION; BINDING PROTEIN; IN-VIVO; HSP27	Allelic deletions on human chromosome 12q24 are frequently reported in a variety of malignant neoplasms, indicating the presence of a tumor suppressor gene(s) in this chromosomal region. However, no reasonable candidate has been identified so far. In this study, we report the cloning and functional characterization of a novel mitochondrial protein with tumor suppressor activity, henceforth designated MITOSTATIN. Human MITOSTATIN was found within a 3.2-kb transcript, which encoded a similar to 62 kDa, ubiquitously expressed protein with little homology to any known protein. We found homozygous deletions and mutations of MITOSTATIN gene in similar to 5 and similar to 11% of various cancer-derived cells and solid tumors, respectively. When transiently overexpressed, MITOSTATIN inhibited colony formation, tumor cell growth and was proapoptotic, all features shared by established tumor suppressor genes. We discovered a specific link between MITOSTATIN overexpression and downregulation of Hsp27. Conversely, MITOSTATIN knockdown cells showed an increase in cell growth and cell survival rates. Finally, MITOSTATIN expression was significantly reduced in primary bladder and breast tumors, and its reduction was associated with advanced tumor stages. Our findings support the hypothesis that MITOSTATIN has many hallmarks of a classical tumor suppressor in solid tumors and may play an important role in cancer development and progression.	[Vecchione, A.; Fassan, M.; Morrione, A.; Byrne, D.; D'Arca, D.; Gomella, L. G.; Baffa, R.] Thomas Jefferson Univ, Kimmel Canc Ctr, Dept Urol, Philadelphia, PA 19107 USA; [Anesti, V.; Scorrano, L.] Venetian Inst Mol Med, Dulbecco Telethon Inst, Padua, Italy; [Goldoni, S.; Palazzo, J. P.; Lloyd, J.; Iozzo Renato, V.] Thomas Jefferson Univ, Kimmel Canc Ctr, Dept Pathol Anat & Cell Biol, Philadelphia, PA 19107 USA; [Baldassarre, G.] CRO IRCCS, Div Expt Oncol 2, Aviano, Italy	Jefferson University; Fondazione Telethon; Dulbecco Telethon Institute (DTI); Veneto Institute Molecular Medicine; Jefferson University; IRCCS Aviano (CRO)	Baffa, R (corresponding author), Thomas Jefferson Univ, Kimmel Canc Ctr, Dept Urol, 233 S 10th St,BLSB 526, Philadelphia, PA 19107 USA.	R_Baffa@mail.jci.tju.edu	Scorrano, Luca/K-3967-2019; Fassan, Matteo/F-5152-2012; Scorrano, Luca/A-6652-2008; Baldassarre, Gustavo/K-1350-2016; D'Arca, Domenico/B-9212-2016	Scorrano, Luca/0000-0002-8515-8928; Fassan, Matteo/0000-0001-6515-5482; Scorrano, Luca/0000-0002-8515-8928; Baldassarre, Gustavo/0000-0002-9750-8825; D'Arca, Domenico/0000-0002-7240-6005; Vecchione, Andrea/0000-0002-5497-6856; Iozzo, Renato/0000-0002-5908-5112	Sidney Kimmel Foundation for Cancer Research; Benjamin Perkins Bladder Cancer Fund; Martin Greitzer Fund; Telethon Italy; AIRC Italy; National Institutes of Health [RO1 CA39481, RO1 CA47282, RO1 CA120975, RO1 DK068419]; NATIONAL CANCER INSTITUTE [R01CA120975, R01CA039481, R01CA047282] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK068419] Funding Source: NIH RePORTER	Sidney Kimmel Foundation for Cancer Research; Benjamin Perkins Bladder Cancer Fund; Martin Greitzer Fund; Telethon Italy(Fondazione Telethon); AIRC Italy(Fondazione AIRC per la ricerca sul cancro); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	We thank Florencia Bullrich for the FISH analysis, Jonathan Brody for providing CAPAN1 cells and Jason Zoeller for help with the phylogenetic tree. Dr Scorrano is a Senior Scientist of the Dulbecco-Telethon Institute. GenBank = GenBank accession number AY007230. NCBI Protein Database = NCB accession number AAG12971. This study was in part supported by the Sidney Kimmel Foundation for Cancer Research, the Benjamin Perkins Bladder Cancer Fund and the Martin Greitzer Fund (to RB), by Telethon Italy and AIRC Italy (to LS), the National Institutes of Health Grants RO1 CA39481, RO1 CA47282 and RO1 CA120975 (to RVI), RO1 DK068419 ( to AM).	Anesti V, 2006, BBA-BIOENERGETICS, V1757, P692, DOI 10.1016/j.bbabio.2006.04.013; Aubele M, 1999, CANCER GENET CYTOGEN, V110, P94, DOI 10.1016/S0165-4608(98)00205-2; Aubele MM, 2000, DIAGN MOL PATHOL, V9, P14, DOI 10.1097/00019606-200003000-00003; BOURGERON T, 1992, BIOCHEM BIOPH RES CO, V186, P16, DOI 10.1016/S0006-291X(05)80769-7; Bruey JM, 2000, ONCOGENE, V19, P4855, DOI 10.1038/sj.onc.1203850; Cereghetti GM, 2006, ONCOGENE, V25, P4717, DOI 10.1038/sj.onc.1209605; Cornford PA, 2000, CANCER RES, V60, P7099; Csordas G, 2000, J BIOL CHEM, V275, P32879, DOI 10.1074/jbc.M005609200; De Vos K, 1998, J BIOL CHEM, V273, P9673, DOI 10.1074/jbc.273.16.9673; Dimmer KS, 2008, HUM MOL GENET, V17, P201, DOI 10.1093/hmg/ddm297; EHRENFRIED JA, 1995, SURG ONCOL, V4, P197, DOI 10.1016/S0960-7404(10)80036-2; FIELD JK, 1995, BRIT J CANCER, V72, P1180, DOI 10.1038/bjc.1995.483; Frieden M, 2004, J BIOL CHEM, V279, P22704, DOI 10.1074/jbc.M312366200; Goldoni S, 2007, ONCOGENE, V26, P368, DOI 10.1038/sj.onc.1209803; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Iozzo RV, 1998, ANNU REV BIOCHEM, V67, P609, DOI 10.1146/annurev.biochem.67.1.609; Jiang F, 1998, AM J PATHOL, V153, P1467, DOI 10.1016/S0002-9440(10)65734-3; Kamada M, 2007, MOL CANCER THER, V6, P299, DOI 10.1158/1535-7163.MCT-06-0417; Kimura M, 1998, CANCER RES, V58, P2456; Knudson AG, 2000, ANNU REV GENET, V34, P1, DOI 10.1146/annurev.genet.34.1.1; Koo SH, 1999, CANCER GENET CYTOGEN, V110, P87, DOI 10.1016/S0165-4608(98)00193-9; Langdon SP, 1995, CLIN CANCER RES, V1, P1603; Lebret T, 2003, CANCER, V98, P970, DOI 10.1002/cncr.11594; LOVE S, 1994, BRIT J CANCER, V69, P743, DOI 10.1038/bjc.1994.140; Mehlen P, 1996, J BIOL CHEM, V271, P16510, DOI 10.1074/jbc.271.28.16510; Monami G, 2006, CANCER RES, V66, P7103, DOI 10.1158/0008-5472.CAN-06-0633; Moscatello DK, 1998, J CLIN INVEST, V101, P406, DOI 10.1172/JCI846; Nishizawa M, 2005, J CELL SCI, V118, P1081, DOI 10.1242/jcs.01667; Parcellier A, 2003, MOL CELL BIOL, V23, P5790, DOI 10.1128/MCB.23.16.5790-5802.2003; Peruzzi F, 1999, MOL CELL BIOL, V19, P7203, DOI 10.1128/mcb.19.10.7203; Rijken AM, 1999, GENE CHROMOSOME CANC, V26, P185, DOI 10.1002/(SICI)1098-2264(199911)26:3<185::AID-GCC1>3.0.CO;2-9; Rocchi P, 2005, CANCER RES, V65, P11083, DOI 10.1158/0008-5472.CAN-05-1840; Rocchi P, 2004, CANCER RES, V64, P6595, DOI 10.1158/0008-5472.CAN-03-3998; Santra M, 1997, J CLIN INVEST, V100, P149, DOI 10.1172/JCI119507; SANTRA M, 1995, P NATL ACAD SCI USA, V92, P7016, DOI 10.1073/pnas.92.15.7016; Sattler HP, 1999, PROSTATE, V39, P79; Schmutte C, 1997, CANCER RES, V57, P3010; Shiseki M, 1996, GENE CHROMOSOME CANC, V17, P71, DOI 10.1002/(SICI)1098-2264(199610)17:2<71::AID-GCC1>3.0.CO;2-Y; Smirnova E, 1998, J CELL BIOL, V143, P351, DOI 10.1083/jcb.143.2.351; Takashi M, 1998, UROL RES, V26, P395, DOI 10.1007/s002400050075; Tirkkonen M, 1997, CANCER RES, V57, P1222; Vecchione A, 2002, AM J PATHOL, V160, P1345, DOI 10.1016/S0002-9440(10)62561-8; Xu GX, 2002, BIOL REPROD, V67, P681, DOI 10.1095/biolreprod67.2.681	43	36	37	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2009	28	2					257	269		10.1038/onc.2008.381	http://dx.doi.org/10.1038/onc.2008.381			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	395CY	18931701	Green Submitted, Green Accepted, Green Published			2022-12-28	WOS:000262501100009
J	Luthra, R; Singh, RR; Luthra, MG; Li, YX; Hannah, C; Romans, AM; Barkoh, BA; Chen, SS; Ensor, J; Maru, DM; Broaddus, RR; Rashid, A; Albarracin, CT				Luthra, R.; Singh, R. R.; Luthra, M. G.; Li, Y. X.; Hannah, C.; Romans, A. M.; Barkoh, B. A.; Chen, S. S.; Ensor, J.; Maru, D. M.; Broaddus, R. R.; Rashid, A.; Albarracin, C. T.			MicroRNA-196a targets annexin A1: a microRNA-mediated mechanism of annexin A1 downregulation in cancers	ONCOGENE			English	Article						annexin A1; miR-196a; esophageal cancer; breast cancer; endometrial cancer	ACUTE MYELOID-LEUKEMIA; MICROARRAY ANALYSIS; PROSTATE-CANCER; MESSENGER-RNAS; EXPRESSION; CELLS; ESOPHAGEAL; APOPTOSIS; PROTEIN; CARCINOMA	Suppression of annexin A1 (ANXA1), a mediator of apoptosis and inhibitor of cell proliferation, is well documented in various cancers but the underlying mechanism remains unknown. We investigated whether decreased ANXA1 expression was mediated by microRNAs (miRNAs), which are small, non-coding RNAs that negatively regulate gene expression. Using Sanger miR-Base, we identified miR-584, miR-196a and miR-196b as potential miRNAs targeting ANXA1. Only miRNA-196a showed significant inverse correlation with ANXA1 mRNA levels in 12 cancer cell lines of esophageal, breast and endometrial origin (Pearson's correlation -0.66, P=0.019), identifying this as the candidate miRNA targeting ANXA1. Inverse correlation was also observed in 10 esophageal adenocarcinomas (Pearson's correlation -0.64, P=0.047). Analysis of paired normal/tumor tissues from additional 10 patients revealed an increase in miR-196a in the cancers (P=0.003), accompanied by a decrease in ANXA1 mRNA (P=0.004). Increasing miR-196a levels in cells by miR-196a mimics resulted in decreased ANXA1 mRNA and protein. In addition, miR-196a mimics inhibited luciferase expression in luciferase plasmid reporter that included predicted miR-196a recognition sequence from ANXA1 3'-untranslated region conforming that miR-196a directly targets ANXA1. miR-196a promoted cell proliferation, anchorage-independent growth and suppressed apoptosis, suggesting its oncogenic potential. This study demonstrated a novel mechanism of post-transcriptional regulation of ANXA1 expression and identified miR-196a as a marker of esophageal cancer.	[Luthra, R.] Univ Texas MD Anderson Canc Ctr, Div Pathol & Lab Med, Dept Hematopathol, Houston, TX 77054 USA; [Luthra, M. G.; Li, Y. X.; Maru, D. M.; Broaddus, R. R.; Rashid, A.; Albarracin, C. T.] Univ Texas MD Anderson Canc Ctr, Dept Anat Pathol, Houston, TX 77054 USA; [Chen, S. S.] Univ Texas MD Anderson Canc Ctr, Dept Lab Med, Houston, TX 77054 USA; [Ensor, J.] Univ Texas MD Anderson Canc Ctr, Dept Quantitat Sci, Houston, TX 77054 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Luthra, R (corresponding author), Univ Texas MD Anderson Canc Ctr, Div Pathol & Lab Med, Dept Hematopathol, 8515 Fannin St,NAO1-091, Houston, TX 77054 USA.	rluthra@mdanderson.org		Ensor, Joe/0000-0003-3533-4388	Goodwin Fund for Target Molecular Diagnosis; Institutional Research; NIH [1P50CA098258-01]; NATIONAL CANCER INSTITUTE [P50CA098258] Funding Source: NIH RePORTER	Goodwin Fund for Target Molecular Diagnosis; Institutional Research; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Dawn Chalaire for critical editing of the manuscript and James M Gilbert and Kim-Anh Vu for assistance with preparation of the manuscript and illustrations. We also thank Drs Raju, Izzo and Liu of MD Anderson Cancer Center for providing the cell lines used in the study. This study was supported by Goodwin Fund for Target Molecular Diagnosis and Institutional Research Grant (CT Albarracin), NIH 1P50CA098258-01, SPORE in Uterine Cancer (RR Broaddus).	Ambros V, 2007, DEVELOPMENT, V134, P1635, DOI 10.1242/dev.002006; Bagga S, 2005, CELL, V122, P553, DOI 10.1016/j.cell.2005.07.031; Bai XF, 2004, WORLD J GASTROENTERO, V10, P1466; Bloomston M, 2007, JAMA-J AM MED ASSOC, V297, P1901, DOI 10.1001/jama.297.17.1901; Debernardi S, 2007, LEUKEMIA, V21, P912, DOI 10.1038/sj.leu.2404605; Debret R, 2003, FEBS LETT, V546, P195, DOI 10.1016/S0014-5793(03)00570-2; Esquela-Kerscher A, 2006, NAT REV CANCER, V6, P259, DOI 10.1038/nrc1840; Gerke V, 2002, PHYSIOL REV, V82, P331, DOI 10.1152/physrev.00030.2001; Giraldez AJ, 2006, SCIENCE, V312, P75, DOI 10.1126/science.1122689; Hsiang CH, 2006, PROSTATE, V66, P1413, DOI 10.1002/pros.20457; Hu N, 2004, CLIN CANCER RES, V10, P6013, DOI 10.1158/1078-0432.CCR-04-0317; JOHNSON MD, 1989, HUM PATHOL, V20, P772, DOI 10.1016/0046-8177(89)90071-3; Kang JS, 2002, CLIN CANCER RES, V8, P117; Kimchi ET, 2005, CANCER RES, V65, P3146, DOI 10.1158/0008-5472.CAN-04-2490; Lim LP, 2005, NATURE, V433, P769, DOI 10.1038/nature03315; Luthra R, 2006, J CLIN ONCOL, V24, P259, DOI 10.1200/JCO.2005.03.3688; Masaki T, 1996, HEPATOLOGY, V24, P72, DOI 10.1053/jhep.1996.v24.pm0008707286; Parente L, 2004, INFLAMM RES, V53, P125, DOI 10.1007/s00011-003-1235-z; Paweletz CP, 2000, CANCER RES, V60, P6293; Rana TM, 2007, NAT REV MOL CELL BIO, V8, P23, DOI 10.1038/nrm2085; Sakamoto T, 1996, BIOCHEM BIOPH RES CO, V220, P643, DOI 10.1006/bbrc.1996.0457; Shen DJ, 2006, HUM PATHOL, V37, P1583, DOI 10.1016/j.humpath.2006.06.001; Sinha P, 1998, J BIOCHEM BIOPH METH, V37, P105, DOI 10.1016/S0165-022X(98)00020-7; Solito E, 2001, BRIT J PHARMACOL, V133, P217, DOI 10.1038/sj.bjp.0704054; Thorsteinsdottir U, 1997, MOL CELL BIOL, V17, P495, DOI 10.1128/MCB.17.1.495; Thorsteinsdottir U, 2002, BLOOD, V99, P121, DOI 10.1182/blood.V99.1.121; Vishwanatha JK, 2004, BMC CANCER, V4, DOI 10.1186/1471-2407-4-8; WALLNER BP, 1986, NATURE, V320, P77, DOI 10.1038/320077a0; Xia SH, 2002, ONCOGENE, V21, P6641, DOI 10.1038/sj.onc.1205818; Yekta S, 2004, SCIENCE, V304, P594, DOI 10.1126/science.1097434	30	217	226	0	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV	2008	27	52					6667	6678		10.1038/onc.2008.256	http://dx.doi.org/10.1038/onc.2008.256			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	368QY	18663355				2022-12-28	WOS:000260638800005
J	Tang, J; Yang, X; Liu, X				Tang, J.; Yang, X.; Liu, X.			Phosphorylation of Plk1 at Ser326 regulates its functions during mitotic progression	ONCOGENE			English	Article						Plk1; MK2; mitosis; phosphorylation	POLO-LIKE KINASES; P38 MAP KINASE; SACCHAROMYCES-CEREVISIAE; TOPOISOMERASE-II; CELL-DIVISION; ACTIVATION; CHECKPOINT; EXPRESSION; PATHWAY; CANCER	Polo-like kinase 1 (Plk1), the best characterized member of the mammalian polo-like kinase family, is well regulated throughout the cell cycle at the protein expression level. Moreover, it is known that Plk1 kinase activity is also regulated at the post-translational level through phosphorylation. However, the upstream kinases of Plk1 have not been identified. Although the involvement of the p38 MAP kinase pathway in cellular responses to stress has been well documented, the role of this pathway in normal cell cycle progression is unclear. Here, we show that phosphorylated p38 and MAP kinase-activated protein kinase 2 (MK2) are colocalized with Plk1 to the spindle poles during prophase and metaphase. Specific depletion of various members of the p38 MAP kinase pathway by the use of RNA interference revealed that the pathway is required for mitotic progression under normal growth conditions. Furthermore, MK2 directly phosphorylates Ser326 of Plk1. Ectopic expression of Plk1-S326A completely blocked cells at mitosis, likely due to the defect of bipolar spindle formation and subsequent activation of the spindle checkpoint. Only Plk1-S326E, but not the Plk1-S326A, efficiently rescued the p38 or MK2-depletion-induced mitotic defects, further solidifying the requirement of S326 phosphorylation during mitotic progression.	[Tang, J.; Yang, X.; Liu, X.] Purdue Univ, Dept Biochem, W Lafayette, IN 47907 USA; [Tang, J.; Yang, X.; Liu, X.] Purdue Univ, Ctr Canc, W Lafayette, IN 47907 USA; [Yang, X.] Sichuan Univ, Dept Chem, Chengdu 610064, Sichuan, Peoples R China	Purdue University System; Purdue University; Purdue University West Lafayette Campus; Purdue University System; Purdue University; Purdue University West Lafayette Campus; Sichuan University	Liu, X (corresponding author), Purdue Univ, Dept Biochem, 175 S Univ St, W Lafayette, IN 47907 USA.	liu8@purdue.edu			National Cancer Institute [K01 CA114401]; NATIONAL CANCER INSTITUTE [K01CA114401] Funding Source: NIH RePORTER	National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We are grateful to Dr Raymond Erikson, in whose laboratory the preliminary experiments were performed, for generously providing many cell lines and plasmids. We appreciate Eleanor Erikson, Xiaoyi Zhang and Hongchang Li for helpful discussions and critical reading of the paper. XL is a recipient of the Howard Temin Award from the National Cancer Institute (K01 CA114401).	Barr FA, 2004, NAT REV MOL CELL BIO, V5, P429, DOI 10.1038/nrm1401; Campos CBL, 2002, NEUROSCIENCE, V112, P583, DOI 10.1016/S0306-4522(02)00096-9; Cha HJ, 2007, J BIOL CHEM, V282, P22984, DOI 10.1074/jbc.M700735200; Eckerdt F, 2005, ONCOGENE, V24, P267, DOI 10.1038/sj.onc.1208273; Fan L, 2005, CELL CYCLE, V4, P1616, DOI 10.4161/cc.4.11.2125; GOLSTEYN RM, 1994, J CELL SCI, V107, P1509; Knecht R, 1999, CANCER RES, V59, P2794; Knecht R, 2000, INT J CANCER, V89, P535; Li H, 2008, J BIOL CHEM, V283, P6209, DOI 10.1074/jbc.M709007200; Lindon C, 2004, J CELL BIOL, V164, P233, DOI 10.1083/jcb.200309035; Liu XQ, 2002, P NATL ACAD SCI USA, V99, P8672, DOI 10.1073/pnas.132269599; Liu XQ, 2003, P NATL ACAD SCI USA, V100, P5789, DOI 10.1073/pnas.1031523100; Lowery DM, 2005, ONCOGENE, V24, P248, DOI 10.1038/sj.onc.1208280; Manke IA, 2005, MOL CELL, V17, P37, DOI 10.1016/j.molcel.2004.11.021; Mikhailov A, 2004, J CELL BIOL, V166, P517, DOI 10.1083/jcb.200405167; Mulvihill DP, 1999, MOL BIOL CELL, V10, P2771, DOI 10.1091/mbc.10.8.2771; Olson JM, 2004, TRENDS MOL MED, V10, P125, DOI 10.1016/j.molmed.2004.01.007; Petersen J, 2005, NATURE, V435, P507, DOI 10.1038/nature03590; Shirayama M, 1998, EMBO J, V17, P1336, DOI 10.1093/emboj/17.5.1336; Sui GC, 2002, P NATL ACAD SCI USA, V99, P5515, DOI 10.1073/pnas.082117599; Takai N, 2005, ONCOGENE, V24, P287, DOI 10.1038/sj.onc.1208272; Tang JB, 2006, P NATL ACAD SCI USA, V103, P11964, DOI 10.1073/pnas.0604987103; Tang JB, 2006, CELL CYCLE, V5, P2484, DOI 10.4161/cc.5.21.3411; Zarubin T, 2005, CELL RES, V15, P11, DOI 10.1038/sj.cr.7290257	24	40	42	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV	2008	27	52					6635	6645		10.1038/onc.2008.262	http://dx.doi.org/10.1038/onc.2008.262			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	368QY	18695677	Green Accepted			2022-12-28	WOS:000260638800002
J	Mao, JH; Wu, D; DelRosario, R; Castellanos, A; Balmain, A; Perez-Losada, J				Mao, J. H.; Wu, D.; DelRosario, R.; Castellanos, A.; Balmain, A.; Perez-Losada, J.			Atm heterozygosity does not increase tumor susceptibility to ionizing radiation alone or in a p53 heterozygous background	ONCOGENE			English	Article						Ataxia-Telangiectasia; ATM/Atm; P53; lymphoma; loss-of-heterozygosity; genetic-background	ATAXIA-TELANGIECTASIA HETEROZYGOTES; FAMILIAL BREAST-CANCER; INDUCED MAMMARY-TUMORS; DEFICIENT MICE; EARLY-ONSET; GENE; HAPLOINSUFFICIENCY; TUMORIGENESIS; MUTATIONS; RISK	Ataxia-Telangiectasia (A-T) is an autosomal recessive human disease characterized by genetic instability, radiosensitivity, immunodeficiency and cancer predisposition, because of mutation in both alleles of the ATM (ataxia-telangiectasia mutated) gene. The role of Atm heterozygosity in cancer susceptibility is controversial, in both human and mouse. Earlier studies identified deletions near the Atm gene on mouse chromosome 9 in radiation-induced lymphomas from p53 heterozygous mice. To determine whether Atm was the target of these deletions, Atm heterozygous as well as Atm/P53 double heterozygous mice were treated with ionizing radiation. There were no significant differences in tumor latency, progression and lifespan after gamma-radiation in Atm heterozygous mice compared with their wild-type control counterparts. Deletions were found on chromosome 9 near the Atm locus in radiation-induced tumors, but in 50% of the cases the deletion included the knockout allele, and the expression of Atm was maintained in the tumors indicating that loss of heterozygosity on chromosome 9 is not driven by Atm, but by an alternative tumor suppressor gene located near Atm on this chromosome. We conclude that Atm heterozygosity does not confer an increase in tumor susceptibility in this context.	[Castellanos, A.; Perez-Losada, J.] Univ Salamanca, Dept Med, Fac Med, E-37008 Salamanca, Spain; [Mao, J. H.; Wu, D.; DelRosario, R.; Balmain, A.] Univ Calif San Francisco, Helen Diller Family Comprehens Canc Ctr, San Francisco, CA 94143 USA	University of Salamanca; University of California System; University of California San Francisco; UCSF Medical Center; UCSF Helen Diller Family Comprehensive Cancer Center	Perez-Losada, J (corresponding author), Univ Salamanca, Dept Med, Fac Med, Campus Miguel Unamuno Sn, E-37008 Salamanca, Spain.	jperezlosada@usal.es	2008, Ibsal/A-1268-2012; Pérez-Losada, Jesús/A-5883-2019; Castellanos, Andres/F-3302-2016; Mao, Jian-Hua/EIZ-8595-2022; Castellanos, Antonio/J-4830-2013	Pérez-Losada, Jesús/0000-0003-2400-624X; Castellanos, Andres/0000-0003-2864-7271; Mao, Jian-Hua/0000-0001-9320-6021; Castellanos, Antonio/0000-0001-9291-0930	Spanish 'Ministerio de Educacion y Ciencia; European Community; Fondo de Investigaciones Sanitarias [PI070057]; NCI [U01 CA84244]; DOE [DE-FG02-03ER63630]; UCSF Research-Evaluation Allocation Committee (REAC); NATIONAL CANCER INSTITUTE [U01CA084244] Funding Source: NIH RePORTER	Spanish 'Ministerio de Educacion y Ciencia(Spanish Government); European Community(European Commission); Fondo de Investigaciones Sanitarias(Instituto de Salud Carlos III); NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); DOE(United States Department of Energy (DOE)); UCSF Research-Evaluation Allocation Committee (REAC); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Dr Gonzalez-Sarmiento, Dr Sanchez-Garcia and Dr Cobaleda for useful comments; and Dr Kogan for tumor pathology analysis. Dr Balmain acknowledges support from the Barbara Bass Bakar Chair of Cancer Genetics. Dr Perez-Losada is an investigator of the 'Programa Ramon y Cajal' from the Spanish 'Ministerio de Educacion y Ciencia' and the European Community, his study is partially supported by the 'Fondo de Investigaciones Sanitarias' (PI070057). Dr Castellanos is supported by the 'Fondo de Investigaciones Sanitarias' ( PI070057). These studies were also supported by NCI grant U01 CA84244 and the DOE (DE-FG02-03ER63630) to Dr Balmain, and the UCSF Research-Evaluation Allocation Committee (REAC) to Dr Mao.	Athma P, 1996, CANCER GENET CYTOGEN, V92, P130, DOI 10.1016/S0165-4608(96)00328-7; Balmain A, 2002, CELL, V108, P145, DOI 10.1016/S0092-8674(02)00622-0; Barlow C, 1996, CELL, V86, P159, DOI 10.1016/S0092-8674(00)80086-0; Barlow C, 1999, NAT GENET, V21, P359, DOI 10.1038/7684; Bishop DT, 1997, NAT GENET, V15, P226, DOI 10.1038/ng0397-226; Bowen TJ, 2005, CANCER RES, V65, P8736, DOI 10.1158/0008-5472.CAN-05-1598; BURNS PA, 1991, ENVIRON HEALTH PERSP, V93, P41, DOI 10.2307/3431166; Cai WW, 2002, NAT BIOTECHNOL, V20, P393, DOI 10.1038/nbt0402-393; Chen JD, 1998, CANCER RES, V58, P1376; CHO KR, 1992, CANCER, V70, P1727, DOI 10.1002/1097-0142(19920915)70:4+<1727::AID-CNCR2820701613>3.0.CO;2-P; Connolly L, 2006, RADIAT RES, V166, P39, DOI 10.1667/RR3578.1; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; Elson A, 1996, P NATL ACAD SCI USA, V93, P13084, DOI 10.1073/pnas.93.23.13084; FitzGerald MG, 1997, NAT GENET, V15, P307, DOI 10.1038/ng0397-307; Gatti RA, 1999, MOL GENET METAB, V68, P419, DOI 10.1006/mgme.1999.2942; Hansel DE, 2003, ANNU REV GENOM HUM G, V4, P237, DOI 10.1146/annurev.genom.4.070802.110341; Inskip HM, 1999, BRIT J CANCER, V79, P1304, DOI 10.1038/sj.bjc.6690209; JACKS T, 1994, CURR BIOL, V4, P1, DOI 10.1016/S0960-9822(00)00002-6; Karabinis ME, 2001, CARCINOGENESIS, V22, P343, DOI 10.1093/carcin/22.2.343; KEMP CJ, 1994, NAT GENET, V8, P66, DOI 10.1038/ng0994-66; Lu S, 2006, CARCINOGENESIS, V27, P848, DOI 10.1093/carcin/bgi302; Mao JH, 2004, NATURE, V432, P775, DOI 10.1038/nature03155; Matsuoka S, 2007, SCIENCE, V316, P1160, DOI 10.1126/science.1140321; Nakamura Y, 1998, NAT MED, V4, P1231, DOI 10.1038/3207; Olsen JH, 2001, JNCI-J NATL CANCER I, V93, P121, DOI 10.1093/jnci/93.2.121; Shiloh Y, 2003, NAT REV CANCER, V3, P155, DOI 10.1038/nrc1011; Spring K, 2002, NAT GENET, V32, P185, DOI 10.1038/ng958; SWIFT M, 1991, NEW ENGL J MED, V325, P1831, DOI 10.1056/NEJM199112263252602; Taylor AMR, 1996, BLOOD, V87, P423, DOI 10.1182/blood.V87.2.423.bloodjournal872423; Teraoka SN, 2001, CANCER-AM CANCER SOC, V92, P479, DOI 10.1002/1097-0142(20010801)92:3<479::AID-CNCR1346>3.0.CO;2-G; Umesako S, 2005, BREAST CANCER RES, V7, pR164, DOI 10.1186/bcr968; Vorechovsky I, 1996, CANCER RES, V56, P2726; Westphal CH, 1998, CANCER RES, V58, P5637; Westphal CH, 1997, NAT GENET, V16, P397, DOI 10.1038/ng0897-397; WOOSTER R, 1993, HUM GENET, V92, P91, DOI 10.1007/BF00216153; Worgul BV, 2002, P NATL ACAD SCI USA, V99, P9836, DOI 10.1073/pnas.162349699; Xu Y, 1996, GENE DEV, V10, P2411, DOI 10.1101/gad.10.19.2411; Yu YJ, 2001, CANCER RES, V61, P1820	38	18	18	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 30	2008	27	51					6596	6600		10.1038/onc.2008.280	http://dx.doi.org/10.1038/onc.2008.280			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	366RS	18679420				2022-12-28	WOS:000260501700007
J	Hishiya, A; Takayama, S				Hishiya, A.; Takayama, S.			Molecular chaperones as regulators of cell death	ONCOGENE			English	Review						heat-shock proteins; Hsp27; Hsp70; Hsp90; molecular chaperone; co-chaperone	HEAT-SHOCK-PROTEIN; ALPHA-B-CRYSTALLIN; ENDOPLASMIC-RETICULUM STRESS; ISCHEMIA-REPERFUSION INJURY; TRANSGENIC MOUSE MODEL; DOMINANT CONGENITAL CATARACT; TRUNCATED ANDROGEN RECEPTOR; MARINESCO-SJOGREN-SYNDROME; POSTERIOR POLAR CATARACT; FOCAL CEREBRAL-ISCHEMIA	Molecular chaperones have been reported as multifunctional antistress molecules that can regulate diverse biological processes to maintain cellular homeostasis. Molecular chaperones have critical roles for maintaining proper protein folding, protein translocation, degradation of unfolded protein, regulating signal-transduction proteins and so on. Under pathological conditions, inducible or constitutively expressed molecular chaperones protect cells from stress. Non-dividing terminally differentiated cells accumulate abnormal proteins due to chronic environmental or physiological stress; thus, proper chaperone function is critical for maintaining homeostasis of those cells, such as neuronal and muscular cells. Cancer cells also have overexpression of molecular chaperone proteins for promoting survival from stress related to growth, cell cycle, hypoxia, metastasis and genetic mutations. Here, we will focus on the function of molecular chaperone proteins for the regulation of cell death in degenerative diseases, ischemic diseases and in cancer.	[Hishiya, A.; Takayama, S.] Boston Biomed Res Inst, Cardiovasc Program, Watertown, MA 02472 USA	Boston Biomedical Research Institute	Takayama, S (corresponding author), Boston Biomed Res Inst, Cardiovasc Program, 64 Grove St, Watertown, MA 02472 USA.	takayama@bbri.org						Adachi H, 2003, J NEUROSCI, V23, P2203; Adachi H, 2007, J NEUROSCI, V27, P5115, DOI 10.1523/JNEUROSCI.1242-07.2007; Aghdassi A, 2007, CANCER RES, V67, P616, DOI 10.1158/0008-5472.CAN-06-1567; Al-Ramahi I, 2006, J BIOL CHEM, V281, P26714, DOI 10.1074/jbc.M601603200; An JJ, 2008, FEBS J, V275, P1296, DOI 10.1111/j.1742-4658.2008.06291.x; Anttonen AK, 2005, NAT GENET, V37, P1309, DOI 10.1038/ng1677; Arndt V, 2005, MOL BIOL CELL, V16, P5891, DOI 10.1091/mbc.E05-07-0660; Arrasate M, 2004, NATURE, V431, P805, DOI 10.1038/nature02998; Bailey CK, 2002, HUM MOL GENET, V11, P515, DOI 10.1093/hmg/11.5.515; Beere HM, 2000, NAT CELL BIOL, V2, P469, DOI 10.1038/35019501; Berry V, 2001, AM J HUM GENET, V69, P1141, DOI 10.1086/324158; Blagosklonny MV, 1996, P NATL ACAD SCI USA, V93, P8379, DOI 10.1073/pnas.93.16.8379; Boeri D, 2003, EUR J CLIN INVEST, V33, P500, DOI 10.1046/j.1365-2362.2003.01157.x; Bova MP, 1999, P NATL ACAD SCI USA, V96, P6137, DOI 10.1073/pnas.96.11.6137; Boyle Daniel L, 2003, BMC Ophthalmol, V3, P3, DOI 10.1186/1471-2415-3-3; Brady JP, 1997, P NATL ACAD SCI USA, V94, P884, DOI 10.1073/pnas.94.3.884; Brady JP, 2001, INVEST OPHTH VIS SCI, V42, P2924; Bruey JM, 2000, NAT CELL BIOL, V2, P645, DOI 10.1038/35023595; Bu L, 2002, NAT GENET, V31, P276, DOI 10.1038/ng921; Bucciantini M, 2002, NATURE, V416, P507, DOI 10.1038/416507a; CAIGNARD A, 1985, INT J CANCER, V36, P273, DOI 10.1002/ijc.2910360221; Carra S, 2008, J BIOL CHEM, V283, P1437, DOI 10.1074/jbc.M706304200; Caughey B, 2003, ANNU REV NEUROSCI, V26, P267, DOI 10.1146/annurev.neuro.26.010302.081142; Cecconi F, 1998, CELL, V94, P727, DOI 10.1016/S0092-8674(00)81732-8; Chai YH, 1999, J NEUROSCI, V19, P10338; Chauhan D, 2003, BLOOD, V102, P3379, DOI 10.1182/blood-2003-05-1417; Chen M, 2000, NAT MED, V6, P797, DOI 10.1038/77528; Christians E, 2000, NATURE, V407, P693, DOI 10.1038/35037669; Chun W, 2002, FEBS LETT, V515, P61, DOI 10.1016/S0014-5793(02)02436-5; Cummings CJ, 1999, NEURON, V24, P879, DOI 10.1016/S0896-6273(00)81035-1; Cummings CJ, 2001, HUM MOL GENET, V10, P1511, DOI 10.1093/hmg/10.14.1511; Dai Q, 2005, J BIOL CHEM, V280, P38673, DOI 10.1074/jbc.M507986200; Dai Q, 2003, EMBO J, V22, P5446, DOI 10.1093/emboj/cdg529; Dedmon MM, 2005, J BIOL CHEM, V280, P14733, DOI 10.1074/jbc.m413024200; DeGracia DJ, 2004, J NEUROCHEM, V91, P1, DOI 10.1111/j.1471-4159.2004.02703.x; Demand J, 2001, CURR BIOL, V11, P1569, DOI 10.1016/S0960-9822(01)00487-0; Denzel A, 2002, MOL CELL BIOL, V22, P7398, DOI 10.1128/MCB.22.21.7398-7404.2002; Der Perng M, 1999, J BIOL CHEM, V274, P33235, DOI 10.1074/jbc.274.47.33235; Dickey CA, 2006, FASEB J, V20, P753, DOI 10.1096/fj.05-5343fje; DILLMANN WH, 1986, CIRC RES, V59, P110, DOI 10.1161/01.RES.59.1.110; Dix DJ, 1996, P NATL ACAD SCI USA, V93, P3264, DOI 10.1073/pnas.93.8.3264; Dong DZ, 2008, CANCER RES, V68, P498, DOI 10.1158/0008-5472.CAN-07-2950; Efthymiou CA, 2004, BASIC RES CARDIOL, V99, P392, DOI 10.1007/s00395-004-0483-6; Eizirik DL, 2008, ENDOCR REV, V29, P42, DOI 10.1210/er.2007-0015; Ekegren T, 1999, ACTA NEUROL SCAND, V100, P317; Elliott E, 2007, J BIOL CHEM, V282, P37276, DOI 10.1074/jbc.M706379200; Evans CG, 2006, J BIOL CHEM, V281, P33182, DOI 10.1074/jbc.M606192200; Evgrafov OV, 2004, NAT GENET, V36, P602, DOI 10.1038/ng1354; Fares MA, 2002, NATURE, V417, P398, DOI 10.1038/417398a; Fernandez-Chacon R, 2004, NEURON, V42, P237, DOI 10.1016/S0896-6273(04)00190-4; Florin L, 2004, J VIROL, V78, P5546, DOI 10.1128/JVI.78.11.5546-5553.2004; Fujimoto M, 2004, EMBO J, V23, P4297, DOI 10.1038/sj.emboj.7600435; Fujimoto M, 2005, J BIOL CHEM, V280, P34908, DOI 10.1074/jbc.M506288200; Garrido C, 1999, FASEB J, V13, P2061, DOI 10.1096/fasebj.13.14.2061; Garrido C, 1998, CANCER RES, V58, P5495; Gaspary H, 1995, MOL BRAIN RES, V34, P327, DOI 10.1016/0169-328X(95)00195-X; Giffard RG, 2004, J EXP BIOL, V207, P3213, DOI 10.1242/jeb.01034; Gotz R, 2005, NAT NEUROSCI, V8, P1169, DOI 10.1038/nn1524; Grad I, 2006, MOL CELL BIOL, V26, P8976, DOI 10.1128/MCB.00734-06; Gu F, 2008, HUM MUTAT, V29, P769, DOI 10.1002/humu.20724; Gupta S, 2002, CIRCULATION, V106, P2727, DOI 10.1161/01.CIR.0000038112.64503.6E; Hansen JJ, 2002, AM J HUM GENET, V70, P1328, DOI 10.1086/339935; Hansson O, 2003, BRAIN RES, V970, P47, DOI 10.1016/S0006-8993(02)04275-0; Hartmann A, 2001, J NEUROSCI, V21, P2247, DOI 10.1523/JNEUROSCI.21-07-02247.2001; Hata R, 1999, METAB BRAIN DIS, V14, P117, DOI 10.1023/A:1020709814456; Hatakeyama S, 2004, J NEUROCHEM, V91, P299, DOI 10.1111/j.1471-4159.2004.02713.x; Havasi A, 2008, J BIOL CHEM, V283, P12305, DOI 10.1074/jbc.M801291200; Hay DG, 2004, HUM MOL GENET, V13, P1389, DOI 10.1093/hmg/ddh144; Hayashi M, 2006, NAT MED, V12, P128, DOI 10.1038/nm1327; Held T, 2006, MOL CELL BIOL, V26, P8099, DOI 10.1128/MCB.01332-06; Helmlinger D, 2004, J BIOL CHEM, V279, P55969, DOI 10.1074/jbc.M409062200; Hoehn B, 2001, J CEREBR BLOOD F MET, V21, P1303, DOI 10.1097/00004647-200111000-00006; Homma S, 2007, J NEUROSCI, V27, P7974, DOI 10.1523/JNEUROSCI.0006-07.2007; Homma S, 2006, AM J PATHOL, V169, P761, DOI 10.2353/ajpath.2006.060250; Hosaka S, 2006, CANCER SCI, V97, P623, DOI 10.1111/j.1349-7006.2006.00217.x; Howarth JL, 2007, MOL THER, V15, P1100, DOI 10.1038/sj.mt.6300163; Hu BR, 2000, J NEUROSCI, V20, P3191, DOI 10.1523/JNEUROSCI.20-09-03191.2000; Huang L, 2001, MOL CELL BIOL, V21, P8575, DOI 10.1128/MCB.21.24.8575-8591.2001; Huang L, 2007, GENESIS, V45, P487, DOI 10.1002/dvg.20319; Hunter PJ, 1999, DEVELOPMENT, V126, P1247; Hwang IK, 2007, EXP NEUROL, V208, P247, DOI 10.1016/j.expneurol.2007.08.017; Hwang JR, 2005, CELL STRESS CHAPERON, V10, P147, DOI 10.1379/CSC-90R.1; Ikawa M, 1997, NATURE, V387, P607, DOI 10.1038/42484; Irobi J, 2004, NAT GENET, V36, P597, DOI 10.1038/ng1328; Ishihara K, 2003, J BIOL CHEM, V278, P25143, DOI 10.1074/jbc.M302975200; Jaattela M, 1999, EXP CELL RES, V248, P30, DOI 10.1006/excr.1999.4455; Jamora C, 1996, P NATL ACAD SCI USA, V93, P7690, DOI 10.1073/pnas.93.15.7690; Jana NR, 2000, HUM MOL GENET, V9, P2009, DOI 10.1093/hmg/9.13.2009; Jana NR, 2005, J BIOL CHEM, V280, P11635, DOI 10.1074/jbc.M412042200; Jana NR, 2005, NEUROSCI LETT, V378, P171, DOI 10.1016/j.neulet.2004.12.031; Jones EL, 2004, INT J HYPERTHER, V20, P835, DOI 10.1080/02656730410001721807; Kalinowska M, 2005, APOPTOSIS, V10, P821, DOI 10.1007/s10495-005-0410-9; Kallio M, 2002, EMBO J, V21, P2591, DOI 10.1093/emboj/21.11.2591; Kaur J, 2000, INT J CANCER, V85, P1; Kayed R, 2003, SCIENCE, V300, P486, DOI 10.1126/science.1079469; Kelly S, 2002, ANN NEUROL, V52, P160, DOI 10.1002/ana.10264; Kieran D, 2004, NAT MED, V10, P402, DOI 10.1038/nm1021; Kim HE, 2008, MOL CELL, V30, P239, DOI 10.1016/j.molcel.2008.03.014; KINOUCHI H, 1993, BRAIN RES, V619, P334, DOI 10.1016/0006-8993(93)91630-B; Kitagawa K, 1998, STROKE, V29, P2616, DOI 10.1161/01.STR.29.12.2616; Kitamura A, 2006, NAT CELL BIOL, V8, P1163, DOI 10.1038/ncb1478; Klucken J, 2004, J BIOL CHEM, V279, P25497, DOI 10.1074/jbc.M400255200; KNOWLTON AA, 1991, J CLIN INVEST, V87, P139, DOI 10.1172/JCI114963; Kobayashi Y, 2000, J BIOL CHEM, V275, P8772, DOI 10.1074/jbc.275.12.8772; Kuboki S, 2007, AM J PHYSIOL-GASTR L, V292, pG1141, DOI 10.1152/ajpgi.00491.2006; Kumar LVS, 1999, J BIOL CHEM, V274, P24137, DOI 10.1074/jbc.274.34.24137; Ladiges WC, 2005, DIABETES, V54, P1074, DOI 10.2337/diabetes.54.4.1074; Lau S, 1997, CIRCULATION, V96, P2287; Lee S, 2005, PROTEIN SCI, V14, P593, DOI 10.1110/ps.041020705; Lee SH, 2004, STROKE, V35, P2195, DOI 10.1161/01.STR.0000136150.73891.14; Lee SH, 2001, STROKE, V32, P2905, DOI 10.1161/hs1201.099604; Li H, 2008, BBA-MOL BASIS DIS, V1782, P303, DOI 10.1016/j.bbadis.2008.01.011; Li JZ, 2006, CURR MOL MED, V6, P45, DOI 10.2174/156652406775574523; Li MW, 2000, SCIENCE, V288, P335, DOI 10.1126/science.288.5464.335; Lin KM, 2001, CIRCULATION, V103, P1787, DOI 10.1161/01.CIR.103.13.1787; Lindholm D, 2006, CELL DEATH DIFFER, V13, P385, DOI 10.1038/sj.cdd.4401778; LINNIK MD, 1995, STROKE, V26, P1670, DOI 10.1161/01.STR.26.9.1670; Litt M, 1998, HUM MOL GENET, V7, P471, DOI 10.1093/hmg/7.3.471; Liu J, 2005, J NEUROCHEM, V93, P875, DOI 10.1111/j.1471-4159.2005.03054.x; Liu MG, 2006, INVEST OPHTH VIS SCI, V47, P3461, DOI 10.1167/iovs.05-1438; Liu YZ, 2006, INVEST OPHTH VIS SCI, V47, P1069, DOI 10.1167/iovs.05-1004; Lo JF, 2004, MOL CELL BIOL, V24, P2226, DOI 10.1128/MCB.24.6.2226-2236.2004; Lu AG, 2002, J NEUROCHEM, V81, P355, DOI 10.1046/j.1471-4159.2002.00835.x; Luo SZ, 2006, MOL CELL BIOL, V26, P5688, DOI 10.1128/MCB.00779-06; Mackay DS, 2003, EUR J HUM GENET, V11, P784, DOI 10.1038/sj.ejhg.5201046; Magrane J, 2004, J NEUROSCI, V24, P1700, DOI 10.1523/JNEUROSCI.4330-03.2004; Maisnier-Patin S, 2005, NAT GENET, V37, P1376, DOI 10.1038/ng1676; Maloyan A, 2005, CIRCULATION, V112, P3451, DOI 10.1161/CIRCULATIONAHA.105.572552; MARBER MS, 1995, J CLIN INVEST, V95, P1446, DOI 10.1172/JCI117815; MARBER MS, 1994, J CLIN INVEST, V93, P1087, DOI 10.1172/JCI117059; MARTIN F, 1983, INT J CANCER, V32, P623, DOI 10.1002/ijc.2910320517; Martin LJ, 1999, J NEUROPATH EXP NEUR, V58, P459, DOI 10.1097/00005072-199905000-00005; MARTINOU JC, 1994, NEURON, V13, P1017, DOI 10.1016/0896-6273(94)90266-6; Matsui H, 2007, MOL CELL, V25, P99, DOI 10.1016/j.molcel.2006.12.007; Matsumori Y, 2005, J CEREBR BLOOD F MET, V25, P899, DOI 10.1038/sj.jcbfm.9600080; McDonough H, 2003, CELL STRESS CHAPERON, V8, P303, DOI 10.1379/1466-1268(2003)008<0303:CALBTC>2.0.CO;2; McMillan DR, 2002, MOL CELL BIOL, V22, P8005, DOI 10.1128/MCB.22.22.8005-8014.2002; MEHTA HB, 1988, CIRC RES, V63, P512, DOI 10.1161/01.RES.63.3.512; Meldrum KK, 2003, CIRC RES, V92, P293, DOI 10.1161/01.RES.0000057754.35180.99; Meldrum KK, 2001, AM J PHYSIOL-REG I, V281, pR359, DOI 10.1152/ajpregu.2001.281.1.R359; Mesaeli N, 1999, J CELL BIOL, V144, P857, DOI 10.1083/jcb.144.5.857; Miller VM, 2005, J NEUROSCI, V25, P9152, DOI 10.1523/JNEUROSCI.3001-05.2005; Min JN, 2008, MOL CELL BIOL, V28, P4018, DOI 10.1128/MCB.00296-08; Min JN, 2004, GENESIS, V40, P205, DOI 10.1002/gene.20087; Moenner M, 2007, CANCER RES, V67, P10631, DOI 10.1158/0008-5472.CAN-07-1705; Morozov V, 2006, DEVELOPMENT, V133, P813, DOI 10.1242/dev.02262; Morrison LE, 2004, AM J PHYSIOL-HEART C, V286, pH847, DOI 10.1152/ajpheart.00715.2003; Muchowski PJ, 2000, P NATL ACAD SCI USA, V97, P7841, DOI 10.1073/pnas.140202897; Muchowski PJ, 2005, NAT REV NEUROSCI, V6, P11, DOI 10.1038/nrn1587; Nagai N, 2000, J CELL BIOL, V150, P1499, DOI 10.1083/jcb.150.6.1499; Nagel F, 2008, J NEUROCHEM, V105, P853, DOI 10.1111/j.1471-4159.2007.05204.x; Nakai A, 2000, EMBO J, V19, P1545, DOI 10.1093/emboj/19.7.1545; NISHI S, 1993, BRAIN RES, V615, P281, DOI 10.1016/0006-8993(93)90039-P; Nishimoto S, 2003, NATURE, V424, P1071, DOI 10.1038/nature01895; Novoselova TV, 2005, J NEUROCHEM, V94, P597, DOI 10.1111/j.1471-4159.2005.03119.x; Nylandsted J, 2002, CANCER RES, V62, P7139; Nylandsted J, 2000, P NATL ACAD SCI USA, V97, P7871, DOI 10.1073/pnas.97.14.7871; Ona VO, 1999, NATURE, V399, P263, DOI 10.1038/20446; Ouyang YB, 2001, NEUROSCI LETT, V298, P159, DOI 10.1016/S0304-3940(00)01721-3; Papadopoulos MC, 1996, NEUROREPORT, V7, P429, DOI 10.1097/00001756-199601310-00013; Petrucelli L, 2004, HUM MOL GENET, V13, P703, DOI 10.1093/hmg/ddh083; Phillips PA, 2007, CANCER RES, V67, P9407, DOI 10.1158/0008-5472.CAN-07-1077; Pinz I, 2008, FASEB J, V22, P84, DOI 10.1096/fj.07-8130com; PLUMIER JCL, 1995, J CLIN INVEST, V95, P1854, DOI 10.1172/JCI117865; Plumier JCL, 1997, CELL STRESS CHAPERON, V2, P162, DOI 10.1379/1466-1268(1997)002<0162:TMETHI>2.3.CO;2; Pras E, 2000, INVEST OPHTH VIS SCI, V41, P3511; Radford NB, 1996, P NATL ACAD SCI USA, V93, P2339, DOI 10.1073/pnas.93.6.2339; Rajdev S, 2000, ANN NEUROL, V47, P782, DOI 10.1002/1531-8249(200006)47:6<782::AID-ANA11>3.0.CO;2-3; Ravagnan L, 2001, NAT CELL BIOL, V3, P839, DOI 10.1038/ncb0901-839; Ray PS, 2001, FASEB J, V15, P393, DOI 10.1096/fj.00-0199com; Rohn TT, 2002, NEUROBIOL DIS, V11, P341, DOI 10.1006/nbdi.2002.0549; Saleh A, 2000, NAT CELL BIOL, V2, P476, DOI 10.1038/35019510; Sanbe A, 2005, P NATL ACAD SCI USA, V102, P13592, DOI 10.1073/pnas.0503324102; Sanbe A, 2004, P NATL ACAD SCI USA, V101, P10132, DOI 10.1073/pnas.0401900101; Santhiya S, 2006, MOL VIS, V12, P768; Santos SD, 2004, NEUROSCIENCE, V126, P657, DOI 10.1016/j.neuroscience.2004.03.023; Saudou F, 1998, CELL, V95, P55, DOI 10.1016/S0092-8674(00)81782-1; Schaffar G, 2004, MOL CELL, V15, P95, DOI 10.1016/j.molcel.2004.06.029; Schmitt E, 2006, CANCER RES, V66, P4191, DOI 10.1158/0008-5472.CAN-05-3778; Selcen D, 2003, ANN NEUROL, V54, P804, DOI 10.1002/ana.10767; Senderek J, 2005, NAT GENET, V37, P1312, DOI 10.1038/ng1678; Seo JS, 1996, BIOCHEM BIOPH RES CO, V218, P582, DOI 10.1006/bbrc.1996.0103; SHARP FR, 1993, STROKE S1, V24, P72; Sharp PS, 2008, NEUROBIOL DIS, V30, P42, DOI 10.1016/j.nbd.2007.12.002; Shimura H, 2004, J BIOL CHEM, V279, P4869, DOI 10.1074/jbc.M305838200; Shimura H, 2004, J BIOL CHEM, V279, P17957, DOI 10.1074/jbc.M400351200; Shorter J, 2004, SCIENCE, V304, P1793, DOI 10.1126/science.1098007; Simon S, 2007, BIOCHEMISTRY-US, V46, P9605, DOI 10.1021/bi7003125; Singh D, 2006, MOL VIS, V12, P1372; Stankiewicz AR, 2005, J BIOL CHEM, V280, P38729, DOI 10.1074/jbc.M509497200; Steel R, 2004, J BIOL CHEM, V279, P51490, DOI 10.1074/jbc.M401314200; Sugawara T, 2002, J NEUROSCI, V22, P209, DOI 10.1523/JNEUROSCI.22-01-00209.2002; Suzuki K, 2002, CIRCULATION, V106, pI270, DOI 10.1161/01.cir.0000032880.55215.92; Suzuki K, 1999, ANN THORAC SURG, V68, P1266, DOI 10.1016/S0003-4975(99)00726-2; Suzuki T, 2007, ARCH BIOCHEM BIOPHYS, V468, P1, DOI 10.1016/j.abb.2007.09.004; Takada H, 2003, MOL CELL BIOL, V23, P4026, DOI 10.1128/MCB.23.11.4026-4033.2003; Takaki E, 2006, J BIOL CHEM, V281, P4931, DOI 10.1074/jbc.M506911200; Tam S, 2006, NAT CELL BIOL, V8, P1155, DOI 10.1038/ncb1477; Tang BS, 2005, HUM GENET, V116, P222, DOI 10.1007/s00439-004-1218-3; Tatton NA, 2000, EXP NEUROL, V166, P29, DOI 10.1006/exnr.2000.7489; Terada K, 2005, EMBO J, V24, P611, DOI 10.1038/sj.emboj.7600549; Toulmond S, 2004, BRIT J PHARMACOL, V141, P689, DOI 10.1038/sj.bjp.0705662; Trapp T, 2003, MOL CELL NEUROSCI, V23, P302, DOI 10.1016/S1044-7431(03)00013-7; Treweek TM, 2005, FEBS J, V272, P711, DOI 10.1111/j.1742-4658.2004.04507.x; Trost SU, 1998, J CLIN INVEST, V101, P855, DOI 10.1172/JCI265; Tsuchiya D, 2003, NEUROSURGERY, V53, P1179, DOI 10.1227/01.NEU.0000090341.38659.CF; Tsuchiya D, 2003, J CEREBR BLOOD F MET, V23, P718, DOI 10.1097/01.WCB.0000054756.97390.F7; Uchiyama Y, 2006, J BIOCHEM, V140, P805, DOI 10.1093/jb/mvj212; Vacher C, 2005, HUM MOL GENET, V14, P3425, DOI 10.1093/hmg/ddi372; Vicart P, 1998, NAT GENET, V20, P92, DOI 10.1038/1765; Volloch VZ, 1999, ONCOGENE, V18, P3648, DOI 10.1038/sj.onc.1202525; Voloboueva LA, 2008, J CEREBR BLOOD F MET, V28, P1009, DOI 10.1038/sj.jcbfm.9600600; Voss AK, 2000, DEVELOPMENT, V127, P1; Wacker JL, 2004, NAT STRUCT MOL BIOL, V11, P1215, DOI 10.1038/nsmb860; Wanderling S, 2007, MOL BIOL CELL, V18, P3764, DOI 10.1091/mbc.E07-03-0275; Wang GH, 2004, GENESIS, V38, P66, DOI 10.1002/gene.20005; Wang GH, 2003, GENESIS, V36, P48, DOI 10.1002/gene.10200; Wang XJ, 2003, CIRC RES, V93, P998, DOI 10.1161/01.RES.0000102401.77712.ED; Wang XJ, 2001, CIRC RES, V89, P84, DOI 10.1161/hh1301.092688; Wang YH, 1999, KIDNEY INT, V55, P2224, DOI 10.1046/j.1523-1755.1999.00476.x; Watase K, 2002, NEURON, V34, P905, DOI 10.1016/S0896-6273(02)00733-X; WEI YQ, 1995, CANCER IMMUNOL IMMUN, V40, P73, DOI 10.1007/s002620050146; Williamson CL, 2008, AM J PHYSIOL-HEART C, V294, pH249, DOI 10.1152/ajpheart.00775.2007; Wyttenbach A, 2002, HUM MOL GENET, V11, P1137, DOI 10.1093/hmg/11.9.1137; Xi JH, 2008, J BIOL CHEM, V283, P5801, DOI 10.1074/jbc.M708704200; Xiao XZ, 1999, EMBO J, V18, P5943, DOI 10.1093/emboj/18.21.5943; Xu CY, 2005, J CLIN INVEST, V115, P2656, DOI 10.1172/JCI26373; Xu DG, 1999, J NEUROSCI, V19, P5026; Xu DG, 1997, NAT MED, V3, P997, DOI 10.1038/nm0997-997; Xu LJ, 2003, NEUROL RES, V25, P697, DOI 10.1179/016164103101202183; Yenari MA, 1998, ANN NEUROL, V44, P584, DOI 10.1002/ana.410440403; Zhang LG, 2007, J BIOL CHEM, V282, P11795, DOI 10.1074/jbc.M610430200; Zhang PL, 2008, ANN CLIN LAB SCI, V38, P57; Zhao M, 2003, NEUROCHEM RES, V28, P307, DOI 10.1023/A:1022337519035; Zhou H, 2001, J BIOL CHEM, V276, P48417, DOI 10.1074/jbc.M104140200; Zourlidou A, 2007, HUM MOL GENET, V16, P1078, DOI 10.1093/hmg/ddm057	236	36	38	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 27	2008	27	50					6489	6506		10.1038/onc.2008.314	http://dx.doi.org/10.1038/onc.2008.314			18	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	366RR	18955975				2022-12-28	WOS:000260501600008
J	Hoffman, B; Liebermann, DA				Hoffman, B.; Liebermann, D. A.			Apoptotic signaling by c-MYC	ONCOGENE			English	Review						c-MYC; apoptosis; Bcl-2 family; mitochondria; death receptors; cancer	NF-KAPPA-B; CELL-CYCLE ARREST; TRANSCRIPTION FACTOR NETWORK; WILD-TYPE P53; BCL-X-L; DNA-DAMAGE; MEDIATED APOPTOSIS; GROWTH ARREST; MYELOID DIFFERENTIATION; P53-INDUCED APOPTOSIS	c-MYC has a pivotal function in growth control, differentiation and apoptosis, and its abnormal expression is associated with many tumors. Overexpression of c-MYC sensitizes cells to apoptosis by a variety of stimuli. The decision of a cell to undergo apoptosis and how this apoptotic response is regulated by c-MYC depends on the specific cell type and the physiological status of the cell. Multiple cooperating molecular pathways of cell survival and apoptosis determine whether a cell lives or dies, and understanding how c-MYC interfaces with these pathways to influence the survival of cells is important to understand normal and abnormal development, tumor initiation and progression, and response of tumors to different treatment regimens. This article will provide an overview of the function of the tumor suppressor gene product p53 in the c-MYC-mediated apoptotic response and how c-MYC amplifies the intrinsic mitochondrial pathway and triggers and/or amplifies the death receptor pathways. Finally, a model for how deregulated c-MYC prematurely triggers the normal apoptotic response associated with terminal myeloid differentiation while also blocking the differentiation program is presented.	[Hoffman, B.; Liebermann, D. A.] Temple Univ, Sch Med, Dept Biochem, Fels Inst Canc Res & Mol Biol, Philadelphia, PA 19140 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University	Hoffman, B (corresponding author), Temple Univ, Sch Med, Dept Biochem, Fels Inst Canc Res & Mol Biol, 3307 N Broad St AHB 331, Philadelphia, PA 19140 USA.	barbara.hoffman@temple.edu						ADAMS JM, 1985, NATURE, V318, P533, DOI 10.1038/318533a0; Adams JM, 1999, ONCOGENE, V18, P5268, DOI 10.1038/sj.onc.1202997; Adrain C, 2006, SCIENCE, V311, P785, DOI 10.1126/science.1124154; Amanullah A, 2002, ONCOGENE, V21, P1600, DOI 10.1038/sj.onc.1205231; Amanullah A, 2000, ONCOGENE, V19, P2967, DOI 10.1038/sj.onc.1203638; AMATI B, 1994, CURR OPIN GENET DEV, V4, P102, DOI 10.1016/0959-437X(94)90098-1; Amente S, 2006, CANCER BIOL THER, V5, P287, DOI 10.4161/cbt.5.3.2389; Amundson SA, 1998, ONCOGENE, V17, P2149, DOI 10.1038/sj.onc.1202136; Annis MG, 2005, EMBO J, V24, P2096, DOI 10.1038/sj.emboj.7600675; ASKEW DS, 1991, ONCOGENE, V6, P1915; ASKEW DS, 1993, BLOOD, V82, P2079; Baudino TA, 2001, MOL CELL BIOL, V21, P691, DOI 10.1128/MCB.21.3.691-702.2001; Bouchard C, 2007, GENE DEV, V21, P2775, DOI 10.1101/gad.453107; Brunner T, 2000, J BIOL CHEM, V275, P9767, DOI 10.1074/jbc.275.13.9767; Cao XF, 2008, J BIOL CHEM, V283, P14490, DOI 10.1074/jbc.M801107200; Cavarretta IT, 2007, ONCOGENE, V26, P2822, DOI 10.1038/sj.onc.1210097; Conzen SD, 2000, MOL CELL BIOL, V20, P6008, DOI 10.1128/MCB.20.16.6008-6018.2000; Corn PG, 2007, CANCER BIOL THER, V6, P1858, DOI 10.4161/cbt.6.12.5330; D'Angelo S, 2008, J CELL PHYSIOL, V216, P120, DOI 10.1002/jcp.21383; Dang CV, 2006, SEMIN CANCER BIOL, V16, P253, DOI 10.1016/j.semcancer.2006.07.014; Dang CV, 2005, CANCER CELL, V8, P177, DOI 10.1016/j.ccr.2005.08.005; Dansen TB, 2006, J BIOL CHEM, V281, P10890, DOI 10.1074/jbc.M513655200; Egle A, 2004, P NATL ACAD SCI USA, V101, P6164, DOI 10.1073/pnas.0401471101; Eischen CM, 1999, GENE DEV, V13, P2658, DOI 10.1101/gad.13.20.2658; Eischen CM, 2001, ONCOGENE, V20, P6983, DOI 10.1038/sj.onc.1204892; Eischen CM, 2001, MOL CELL BIOL, V21, P5063, DOI 10.1128/MCB.21.15.5063-5070.2001; Eisenman R N, 2000, Harvey Lect, V96, P1; EVAN GI, 1993, CURR OPIN GENET DEV, V3, P44, DOI 10.1016/S0959-437X(05)80339-9; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; Felsher DW, 1999, P NATL ACAD SCI USA, V96, P3940, DOI 10.1073/pnas.96.7.3940; Festjens N, 2007, CELL DEATH DIFFER, V14, P400, DOI 10.1038/sj.cdd.4402085; Francois S, 2005, J IMMUNOL, V174, P3633, DOI 10.4049/jimmunol.174.6.3633; Gartel AL, 2003, EXP CELL RES, V283, P17, DOI 10.1016/S0014-4827(02)00020-4; GUILLOUF C, 1995, BLOOD, V85, P2691, DOI 10.1182/blood.V85.10.2691.bloodjournal85102691; Hemann MT, 2005, NATURE, V436, P807, DOI 10.1038/nature03845; Henriksson M, 1996, ADV CANCER RES, V68, P109, DOI 10.1016/S0065-230X(08)60353-X; HERMEKING H, 1994, SCIENCE, V265, P2091, DOI 10.1126/science.8091232; Ho JSL, 2005, MOL CELL BIOL, V25, P7423, DOI 10.1128/MCB.25.17.7423-7431.2005; Hoffman B, 1998, ONCOGENE, V17, P3351, DOI 10.1038/sj.onc.1202592; Hoffman B, 2002, ONCOGENE, V21, P3414, DOI 10.1038/sj.onc.1205400; HSU B, 1995, ONCOGENE, V11, P175; Hueber AO, 1997, SCIENCE, V278, P1305, DOI 10.1126/science.278.5341.1305; Hurlin PJ, 2006, SEMIN CANCER BIOL, V16, P265, DOI 10.1016/j.semcancer.2006.07.009; Iaccarino I, 2003, CELL DEATH DIFFER, V10, P599, DOI 10.1038/sj.cdd.4401211; Jiang X, 2007, INT J BIOCHEM CELL B, V39, P1016, DOI 10.1016/j.biocel.2007.01.024; Juin P, 2002, MOL CELL BIOL, V22, P6158, DOI 10.1128/MCB.22.17.6158-6169.2002; Kasibhatla S, 2000, CURR BIOL, V10, P1205, DOI 10.1016/S0960-9822(00)00727-2; Kelly PN, 2007, BLOOD, V109, P4907, DOI 10.1182/blood-2006-10-051847; Klefstrom J, 1997, EMBO J, V16, P7382, DOI 10.1093/emboj/16.24.7382; Knoepfler PS, 2007, CANCER RES, V67, P5061, DOI 10.1158/0008-5472.CAN-07-0426; Kobayashi S, 2005, GASTROENTEROLOGY, V128, P2054, DOI 10.1053/j.gastro.2005.03.010; Kreuz S, 2004, J CELL BIOL, V166, P369, DOI 10.1083/jcb.200401036; Lakhani SA, 2006, SCIENCE, V311, P847, DOI 10.1126/science.1115035; Liebermann DA, 2002, LEUKEMIA, V16, P527, DOI 10.1038/sj.leu.2402477; Lindemans CA, 2006, J IMMUNOL, V176, P5529, DOI 10.4049/jimmunol.176.9.5529; Luscher B, 2001, GENE, V277, P1, DOI 10.1016/S0378-1119(01)00697-7; Lusher B, 2007, EMBO REP, V8, P1110, DOI 10.1038/sj.embor.7401121; Maclean KH, 2003, MOL CELL BIOL, V23, P7256, DOI 10.1128/MCB.23.20.7256-7270.2003; Meng FY, 2002, J BIOL CHEM, V277, P29674, DOI 10.1074/jbc.M112464200; Meyer N, 2006, SEMIN CANCER BIOL, V16, P275, DOI 10.1016/j.semcancer.2006.07.011; Meylan E, 2005, TRENDS BIOCHEM SCI, V30, P151, DOI 10.1016/j.tibs.2005.01.003; Mitchell KO, 2000, CANCER RES, V60, P6318; Nieminen AI, 2007, CELL CYCLE, V6, P2464, DOI 10.4161/cc.6.20.4917; Nieminen AI, 2007, EMBO J, V26, P1055, DOI 10.1038/sj.emboj.7601551; Nikiforov MA, 2007, P NATL ACAD SCI USA, V104, P19488, DOI 10.1073/pnas.0708380104; Nilsson JA, 2003, ONCOGENE, V22, P9007, DOI 10.1038/sj.onc.1207261; Oster SK, 2002, ADV CANCER RES, V84, P81, DOI 10.1016/S0065-230X(02)84004-0; Oster SK, 2003, ONCOGENE, V22, P1998, DOI 10.1038/sj.onc.1206228; Patel JH, 2007, J BIOL CHEM, V282, P5, DOI 10.1074/jbc.M609138200; Patel JH, 2006, J BIOL CHEM, V281, P3283, DOI 10.1074/jbc.M513038200; Pauklin S, 2005, BIOCHEM BIOPH RES CO, V334, P386, DOI 10.1016/j.bbrc.2005.06.097; Pusapati RV, 2006, P NATL ACAD SCI USA, V103, P1446, DOI 10.1073/pnas.0507367103; Ricci MS, 2007, CANCER CELL, V12, P66, DOI 10.1016/j.ccr.2007.05.006; Ricci MS, 2004, MOL CELL BIOL, V24, P8541, DOI 10.1128/MCB.24.19.8541-8555.2004; Rottmann S, 2006, CURR TOP MICROBIOL, V302, P63; Sakamuro D, 1995, ONCOGENE, V11, P2411; Sargent LM, 1996, CANCER RES, V56, P2137; Sarkar D, 2006, CANCER BIOL THER, V5, P693, DOI 10.4161/cbt.5.6.2939; Schmitt CA, 1999, GENE DEV, V13, P2670, DOI 10.1101/gad.13.20.2670; Schulze-Bergkamen H, 2004, HEPATOLOGY, V39, P645, DOI 10.1002/hep.20138; Seoane J, 2002, NATURE, V419, P729, DOI 10.1038/nature01119; SHI YF, 1992, SCIENCE, V257, P212, DOI 10.1126/science.1378649; SPENCER CA, 1991, ADV CANCER RES, V56, P1; Vafa O, 2002, MOL CELL, V9, P1031, DOI 10.1016/S1097-2765(02)00520-8; Vairapandi M, 1996, ONCOGENE, V12, P2579; Vesely DL, 2007, ONCOGENE, V26, P3041, DOI 10.1038/sj.onc.1210109; Vousden KH, 2002, CANCER CELL, V2, P351, DOI 10.1016/S1535-6108(02)00186-1; WAGNER AJ, 1994, GENE DEV, V8, P2817, DOI 10.1101/gad.8.23.2817; Wang Y, 2004, CANCER CELL, V5, P501, DOI 10.1016/S1535-6108(04)00113-8; Wu SQ, 2003, ONCOGENE, V22, P351, DOI 10.1038/sj.onc.1206145; Zindy F, 1998, GENE DEV, V12, P2424, DOI 10.1101/gad.12.15.2424	91	368	377	2	33	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 27	2008	27	50					6462	6472		10.1038/onc.2008.312	http://dx.doi.org/10.1038/onc.2008.312			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	366RR	18955973				2022-12-28	WOS:000260501600006
J	Kotadia, S; Kao, LR; Comerford, SA; Jones, RT; Hammer, RE; Megraw, TL				Kotadia, S.; Kao, L. R.; Comerford, S. A.; Jones, R. T.; Hammer, R. E.; Megraw, T. L.			PP2A-dependent disruption of centrosome replication and cytoskeleton organization in Drosophila by SV40 small tumor antigen	ONCOGENE			English	Article						SV40 ST; centriole; centrosome; PP2A; aneuploidy; cyclin E	PROTEIN PHOSPHATASE 2A; SMALL-T-ANTIGEN; HUMAN CELL-TRANSFORMATION; CYCLIN-A PROMOTER; VIRUS TYPE-1 TAX; REGULATORY SUBUNIT; CANCER PROGRESSION; E7 ONCOPROTEIN; GAMMA-TUBULIN; SIMIAN-VIRUS-40	Viruses of the DNA tumor virus family share the ability to transform vertebrate cells through the action of virus-encoded tumor antigens that interfere with normal cell physiology. They accomplish this very efficiently by inhibiting endogenous tumor suppressor proteins that control cell proliferation and apoptosis. Simian virus 40 (SV40) encodes two oncoproteins, large tumor antigen, which directly inhibits the tumor suppressors p53 and Rb, and small tumor antigen (ST), which interferes with serine/threonine protein phosphatase 2A (PP2A). We have constructed a Drosophila model for SV40 ST expression and show that ST induces supernumerary centrosomes, an activity we also demonstrate in human cells. In early Drosophila embryos, ST also caused increased microtubule stability, chromosome segregation errors, defective assembly of actin into cleavage furrows, cleavage failure, a rise in cyclin E levels and embryonic lethality. Using ST mutants and genetic interaction experiments between ST and PP2A subunit mutations, we show that all of these phenotypes are dependent on ST's interaction with PP2A. These analyses demonstrate the validity and utility of Drosophila as a model for viral oncoprotein function in vivo.	[Kotadia, S.; Kao, L. R.; Jones, R. T.; Megraw, T. L.] Univ Texas SW Med Ctr Dallas, Cecil H & Ida Green Ctr Reprod Biol Sci, Dept Pharmacol, Dallas, TX 75390 USA; [Comerford, S. A.] Univ Texas SW Med Ctr Dallas, Cecil H & Ida Green Ctr Reprod Biol Sci, Dept Mol Genet, Dallas, TX 75390 USA; [Hammer, R. E.] Univ Texas SW Med Ctr Dallas, Cecil H & Ida Green Ctr Reprod Biol Sci, Dept Biochem, Dallas, TX 75390 USA	University of Texas System; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Southwestern Medical Center Dallas	Megraw, TL (corresponding author), Univ Texas SW Med Ctr Dallas, Cecil H & Ida Green Ctr Reprod Biol Sci, Dept Pharmacol, 6001 Forest Pk Rd,Room ND11-120, Dallas, TX 75390 USA.	timothy.megraw@utsouthwestern.edu	Megraw, Tim/U-1442-2019; Megraw, Timothy/T-5186-2019	Hammer, Robert E./0000-0001-5487-7551; Megraw, Timothy/0000-0001-7455-7483; Comerford, Sarah Ann/0000-0002-7452-7759	National Institutes of Health [GM068756]; Welch Foundation [I-1610]; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM068756] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Welch Foundation(The Welch Foundation); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We thank Estelle Sontag, Hui Zou, Helena Richardson, Stefan Heidmann and Kristen Johansen for reagents and Marc Mumby for a critical reading of our paper. This work was supported by grants from the National Institutes of Health (GM068756) and the Welch Foundation (I-1610).	Ahuja D, 2005, ONCOGENE, V24, P7729, DOI 10.1038/sj.onc.1209046; Arroyo JD, 2005, ONCOGENE, V24, P7746, DOI 10.1038/sj.onc.1209038; Brinkley BR, 2001, TRENDS CELL BIOL, V11, P18, DOI 10.1016/S0962-8924(00)01872-9; Brumby AM, 2003, EMBO J, V22, P5769, DOI 10.1093/emboj/cdg548; CALLAINI G, 1990, J CELL SCI, V97, P539; Chen F, 2007, CURR BIOL, V17, P293, DOI 10.1016/j.cub.2007.01.068; Chen W, 2004, CANCER CELL, V5, P127, DOI 10.1016/S1535-6108(04)00026-1; Chen Y, 2007, NAT STRUCT MOL BIOL, V14, P527, DOI 10.1038/nsmb1254; Cho US, 2007, PLOS BIOL, V5, P1810, DOI 10.1371/journal.pbio.0050202; Cho US, 2007, NATURE, V445, P53, DOI 10.1038/nature05351; Comerford SA, 2003, ONCOGENE, V22, P2515, DOI 10.1038/sj.onc.1206259; Crawford JM, 1998, DEV BIOL, V204, P151, DOI 10.1006/dbio.1998.9061; De Luca A, 2003, CANCER RES, V63, P1430; Duensing A, 2007, ONCOGENE, V26, P6280, DOI 10.1038/sj.onc.1210456; Duensing S, 2004, ONCOGENE, V23, P8206, DOI 10.1038/sj.onc.1208012; Duensing S, 2003, J VIROL, V77, P12331, DOI 10.1128/JVI.77.22.12331-12335.2003; FROST JA, 1994, MOL CELL BIOL, V14, P6244, DOI 10.1128/MCB.14.9.6244; Fujii R, 2006, CANCER RES, V66, P9099, DOI 10.1158/0008-5472.CAN-06-1886; Fukasawa K, 2007, NAT REV CANCER, V7, P911, DOI 10.1038/nrc2249; Gaillard S, 2001, J VIROL, V75, P9799, DOI 10.1128/JVI.75.20.9799-9807.2001; Goetz F, 2001, ONCOGENE, V20, P2325, DOI 10.1038/sj.onc.1204355; Hannus M, 2002, DEVELOPMENT, V129, P3493; Hong S, 2007, J BIOL CHEM, V282, P12119, DOI 10.1074/jbc.M610392200; Horn V, 2007, MOL BIOL CELL, V18, P1233, DOI 10.1091/mbc.E06-12-1152; Janssens V, 2001, BIOCHEM J, V353, P417, DOI 10.1042/0264-6021:3530417; Kleylein-Sohn J, 2007, DEV CELL, V13, P190, DOI 10.1016/j.devcel.2007.07.002; Lavia P, 2003, ONCOGENE, V22, P6508, DOI 10.1038/sj.onc.1206861; Liao Y, 2004, CANCER RES, V64, P5938, DOI 10.1158/0008-5472.CAN-04-1533; Lingle WL, 2002, P NATL ACAD SCI USA, V99, P1978, DOI 10.1073/pnas.032479999; Mateer SC, 1998, J BIOL CHEM, V273, P35339, DOI 10.1074/jbc.273.52.35339; MAYERJAEKEL RE, 1993, CELL, V72, P621, DOI 10.1016/0092-8674(93)90080-A; Mumby M, 2007, CELL, V130, P21, DOI 10.1016/j.cell.2007.06.034; MUNGRE S, 1994, J VIROL, V68, P1675, DOI 10.1128/JVI.68.3.1675-1681.1994; Nigg EA, 2002, NAT REV CANCER, V2, P815, DOI 10.1038/nrc924; Nigg EA, 2007, TRENDS CELL BIOL, V17, P215, DOI 10.1016/j.tcb.2007.03.003; Nitta T, 2006, CANCER SCI, V97, P836, DOI 10.1111/j.1349-7006.2006.00254.x; Nunbhakdi-Craig V, 2003, J VIROL, V77, P2807, DOI 10.1128/JVI.77.5.2807-2818.2003; Pagliarini RA, 2003, SCIENCE, V302, P1227, DOI 10.1126/science.1088474; Pihan GA, 2001, CANCER RES, V61, P2212; Pim D, 2005, ONCOGENE, V24, P7830, DOI 10.1038/sj.onc.1208935; Porras A, 1996, J VIROL, V70, P6902; RAFF JW, 1989, CELL, V57, P611, DOI 10.1016/0092-8674(89)90130-X; Reed SI, 1997, CANCER SURV, V29, P7; Rothwell WF, 2000, CURR TOP DEV BIOL, V49, P409; Saenz-Robles MT, 2001, ONCOGENE, V20, P7899, DOI 10.1038/sj.onc.1204936; Schuchner S, 1999, J VIROL, V73, P9266; Schuh M, 2007, CURR BIOL, V17, P237, DOI 10.1016/j.cub.2006.11.051; Skoczylas C, 2005, VIROLOGY, V332, P596, DOI 10.1016/j.virol.2004.12.017; Skoczylas C, 2004, CELL CYCLE, V3, P606; Sluder G, 2004, CURR OPIN CELL BIOL, V16, P49, DOI 10.1016/j.ceb.2003.11.006; Snaith HA, 1996, J CELL SCI, V109, P3001; SONTAG E, 1995, J CELL BIOL, V128, P1131, DOI 10.1083/jcb.128.6.1131; SONTAG E, 1993, CELL, V75, P887, DOI 10.1016/0092-8674(93)90533-V; Sontag E, 2001, CELL SIGNAL, V13, P7, DOI 10.1016/S0898-6568(00)00123-6; Sontag JM, 2006, CELL MOL LIFE SCI, V63, P2979, DOI 10.1007/s00018-006-6300-7; Sullivan CS, 2000, MOL CELL BIOL, V20, P6233, DOI 10.1128/MCB.20.17.6233-6243.2000; Sullivan CS, 2002, MICROBIOL MOL BIOL R, V66, P179, DOI 10.1128/MMBR.66.2.179-202.2002; Tournebize R, 1997, EMBO J, V16, P5537, DOI 10.1093/emboj/16.18.5537; Tsou MFB, 2006, CURR OPIN CELL BIOL, V18, P74, DOI 10.1016/j.ceb.2005.12.008; Viquez NM, 2006, J NEUROSCI, V26, P9293, DOI 10.1523/JNEUROSCI.1740-06.2006; Watanabe G, 1996, P NATL ACAD SCI USA, V93, P12861, DOI 10.1073/pnas.93.23.12861; Wiese C, 2006, J CELL SCI, V119, P4143, DOI 10.1242/jcs.03226; Xu YH, 2006, CELL, V127, P1239, DOI 10.1016/j.cell.2006.11.033; Yang CS, 2005, MOL CELL BIOL, V25, P1298, DOI 10.1128/MCB.25.4.1298-1308.2005; YANG SI, 1991, MOL CELL BIOL, V11, P1988, DOI 10.1128/MCB.11.4.1988; Zhang J, 2007, MOL BIOL CELL, V18, P4037, DOI 10.1091/mbc.E07-05-0474	66	20	20	1	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT	2008	27	49					6334	6346		10.1038/onc.2008.254	http://dx.doi.org/10.1038/onc.2008.254			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	363JK	18663356	Green Accepted			2022-12-28	WOS:000260263400003
J	McElhinny, AS; Li, JL; Wu, L				McElhinny, A. S.; Li, J-L; Wu, L.			Mastermind-like transcriptional co-activators: emerging roles in regulating cross talk among multiple signaling pathways	ONCOGENE			English	Review						Mastermind-like co-activator; Notch; MEF2C; p53; Wnt/beta-catenin	NEUROGENIC LOCUS MASTERMIND; DROSOPHILA MASTERMIND; GENETIC CIRCUITRY; NOTCH COACTIVATOR; B-CELLS; PROTEIN; MAML1; CSL; ACTIVATOR; COMPLEX	A family of Mastermind-like (MAML) genes encodes critical transcriptional co-activators for Notch signaling, an evolutionarily conserved pathway with numerous roles in both development and human diseases. Notch receptors are cleaved upon ligand engagement and the intracellular domain of Notch shuttles to the nucleus. MAMLs form a functional DNA-binding complex with the cleaved Notch receptor and the transcription factor CSL, thereby regulating transcriptional events that are specific to the Notch pathway. Here, we review recent studies that have utilized molecular, cellular and physiological model system strategies to reveal the pivotal roles of the MAML proteins in Notch signaling. Unexpectedly, however, emerging evidence implicate MAML proteins as exciting key transcriptional co-activators in other signal transduction pathways including: muscle differentiation and myopathies (MEF2C), tumor suppressor pathway (p53) and colon carcinoma survival (beta-catenin). Thus, the MAML family appears to function in transcriptional co-activation in a multitude of cellular processes. It is hypothesized that MAML proteins mediate cross-talk among the various signaling pathways and the diverse activities of the MAML proteins converge to impact normal biological processes and human diseases, including cancers.	[Wu, L.] Univ Florida, Shands Canc Ctr, Dept Mol Genet & Microbiol, Gainesville, FL 32610 USA; [Li, J-L] Univ Florida, Interdisciplinary Ctr Biotechnol Res, Gainesville, FL 32610 USA; [McElhinny, A. S.] Ventana Med Syst Inc, Tucson, AZ USA	State University System of Florida; University of Florida; State University System of Florida; University of Florida; Roche Holding; Ventana Medical Systems, Inc.	Wu, L (corresponding author), Univ Florida, Shands Canc Ctr, Dept Mol Genet & Microbiol, 1376 Mowry Rd, Gainesville, FL 32610 USA.	lzwu@ufl.edu	Li, J L/E-6100-2018; Li, Jian-Liang/AAE-9315-2019	Li, J L/0000-0002-6487-081X; Li, Jian-Liang/0000-0002-6487-081X	NIH [R01 CA097148]; Muscular Dystrophy Association (MDA); NATIONAL CANCER INSTITUTE [R01CA097148] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Muscular Dystrophy Association (MDA)(Muscular Dystrophy Association); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported in part by NIH (R01 CA097148) and Muscular Dystrophy Association (MDA).	Alves-Guerra MC, 2007, CANCER RES, V67, P8690, DOI 10.1158/0008-5472.CAN-07-1720; Anderson LM, 2007, J CLIN INVEST, V117, P299, DOI 10.1172/JCI31288; Artavanis-Tsakonas S, 1999, SCIENCE, V284, P770, DOI 10.1126/science.284.5415.770; Aster JC, 2008, ANNU REV PATHOL-MECH, V3, P587, DOI 10.1146/annurev.pathmechdis.3.121806.154300; Bettler D, 1996, GENETICS, V143, P859; Bray SJ, 2006, NAT REV MOL CELL BIO, V7, P678, DOI 10.1038/nrm2009; Brennan K, 2002, BIOESSAYS, V24, P405, DOI 10.1002/bies.10089; FORTINI ME, 1994, CELL, V79, P273, DOI 10.1016/0092-8674(94)90196-1; Fryer CJ, 2004, MOL CELL, V16, P509, DOI 10.1016/j.molcel.2004.10.014; Fryer CJ, 2002, GENE DEV, V16, P1397, DOI 10.1101/gad.991602; Go MJ, 1998, GENETICS, V150, P211; Hall JM, 2005, MOL INTERV, V5, P343, DOI 10.1124/mi.5.6.7; Han H, 2002, INT IMMUNOL, V14, P637, DOI 10.1093/intimm/dxf030; Helms W, 1999, DEV BIOL, V215, P358, DOI 10.1006/dbio.1999.9477; High FA, 2007, J CLIN INVEST, V117, P353, DOI 10.1172/JCI30070; Hozumi K, 2004, NAT IMMUNOL, V5, P638, DOI 10.1038/ni1075; Ilagan Maria Xenia G, 2007, Cell, V128, P1246; Jeffries S, 2002, MOL CELL BIOL, V22, P3927, DOI 10.1128/MCB.22.11.3927-3941.2002; Ribeiro MSJ, 2007, BIOCHEM J, V404, P289, DOI 10.1042/BJ20061900; Kankel MW, 2007, GENETICS, V177, P2493, DOI 10.1534/genetics.107.080994; Katada T, 2003, INT J DEV BIOL, V47, P397; Katada T, 2006, MECH DEVELOP, V123, P851, DOI 10.1016/j.mod.2006.08.001; Kitagawa M, 2001, MOL CELL BIOL, V21, P4337, DOI 10.1128/MCB.21.13.4337-4346.2001; KOPAN R, 1994, DEVELOPMENT, V120, P2385; Kovall RA, 2007, CURR OPIN STRUC BIOL, V17, P117, DOI 10.1016/j.sbi.2006.11.004; Lai EC, 2002, EMBO REP, V3, P840, DOI 10.1093/embo-reports/kvf170; Lasky JL, 2005, PEDIATR RES, V57, p104R, DOI 10.1203/01.PDR.0000159632.70510.3D; Li B, 2007, CELL, V128, P707, DOI 10.1016/j.cell.2007.01.015; Lin SE, 2002, J BIOL CHEM, V277, P50612, DOI 10.1074/jbc.M209529200; LINDSELL CE, 1995, CELL, V80, P909, DOI 10.1016/0092-8674(95)90294-5; Liu ZJ, 2006, CANCER RES, V66, P4182, DOI 10.1158/0008-5472.CAN-05-3589; Luo D, 2005, SEMIN CELL DEV BIOL, V16, P612, DOI 10.1016/j.semcdb.2005.07.002; Maillard I, 2004, BLOOD, V104, P1696, DOI 10.1182/blood-2004-02-0514; Nam Y, 2006, CELL, V124, P973, DOI 10.1016/j.cell.2005.12.037; Oyama T, 2007, P NATL ACAD SCI USA, V104, P9764, DOI 10.1073/pnas.0700240104; Petcherski AG, 2000, NATURE, V405, P364, DOI 10.1038/35012645; Petcherski AG, 2000, CURR BIOL, V10, pR471, DOI 10.1016/S0960-9822(00)00577-7; Pires-daSilva A, 2003, NAT REV GENET, V4, P39, DOI 10.1038/nrg977; Proweller A, 2007, P NATL ACAD SCI USA, V104, P16275, DOI 10.1073/pnas.0707950104; Proweller A, 2006, CANCER RES, V66, P7438, DOI 10.1158/0008-5472.CAN-06-0793; Radtke F, 1999, IMMUNITY, V10, P547, DOI 10.1016/S1074-7613(00)80054-0; Roy M, 2007, CURR OPIN GENET DEV, V17, P52, DOI 10.1016/j.gde.2006.12.001; Saito T, 2003, IMMUNITY, V18, P675, DOI 10.1016/S1074-7613(03)00111-0; Segditsas S, 2006, ONCOGENE, V25, P7531, DOI 10.1038/sj.onc.1210059; Shen HX, 2006, GENE DEV, V20, P675, DOI 10.1101/gad.1383706; SMOLLER D, 1990, GENE DEV, V4, P1688, DOI 10.1101/gad.4.10.1688; Tanigakik K, 2002, NAT IMMUNOL, V3, P443, DOI 10.1038/ni793; Tu LL, 2005, J EXP MED, V202, P1037, DOI 10.1084/jem.20050923; Vousden KH, 2007, NAT REV MOL CELL BIO, V8, P275, DOI 10.1038/nrm2147; Wallberg AE, 2002, MOL CELL BIOL, V22, P7812, DOI 10.1128/MCB.22.22.7812-7819.2002; Weng AP, 2003, MOL CELL BIOL, V23, P655, DOI 10.1128/MCB.23.2.655-664.2003; Wilson JJ, 2006, CELL, V124, P985, DOI 10.1016/j.cell.2006.01.035; Wu L, 2002, MOL CELL BIOL, V22, P7688, DOI 10.1128/MCB.22.21.7688-7700.2002; Wu L, 2007, BLOOD, V110, P3618, DOI 10.1182/blood-2007-06-097030; Wu LZ, 2000, NAT GENET, V26, P484, DOI 10.1038/82644; Wu LZ, 2004, SEMIN CANCER BIOL, V14, P348, DOI 10.1016/j.semcancer.2004.04.014; Wu LZ, 2004, GENE, V328, P153, DOI 10.1016/j.gene.2003.12.007; XU T, 1990, GENE DEV, V4, P464, DOI 10.1101/gad.4.3.464; XU T, 1990, GENETICS, V126, P665; YEDVOBNICK B, 1988, GENETICS, V118, P483; Yu ST, 2007, BBA-MOL CELL BIOL L, V1771, P936, DOI 10.1016/j.bbalip.2007.01.008; Zhao YT, 2007, J BIOL CHEM, V282, P11969, DOI 10.1074/jbc.M608974200	62	111	114	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP	2008	27	38					5138	5147		10.1038/onc.2008.228	http://dx.doi.org/10.1038/onc.2008.228			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	344GM	18758483				2022-12-28	WOS:000258914900008
J	Lei, K; Townsend, DM; Tew, KD				Lei, K.; Townsend, D. M.; Tew, K. D.			Protein cysteine sulfinic acid reductase (sulfiredoxin) as a regulator of cell proliferation and drug response	ONCOGENE			English	Article						sulfiredoxin; redox; glutathione; thiols; phosphatases; regulatory kinases	TYROSINE PHOSPHATASES; S-GLUTATHIONYLATION; SIGNAL-TRANSDUCTION; REDOX REGULATION; TRANSCRIPTIONAL RESPONSE; LUNG-CANCER; ACTIVE-SITE; PEROXIREDOXIN; THIOREDOXIN; PHOSPHORYLATION	Sulfiredoxin (Srx) is one of a family of low molecular weight sulfur containing proteins linked with maintenance of cellular redox balance. One function of Srx is the reduction of cysteine sulfinic acid to sulfenic acid in proteins subject to oxidative stress. Other redox active protein families have multiple functions in regulating redox and controlling proliferation/death pathways; increased Srx has been linked with oncogenic transformation. To explore the biological functions of Srx in tumors, we established cell lines that overexpress Srx. Enhanced levels of Srx promoted cell proliferation and enhanced cell death following cisplatin. Srx overexpression triggered an alteration in expression and phosphorylation of cell cycle regulators p21, p27 and p53; stabilized the phosphatase PTEN and, importantly, interacted directly with, and enhanced the activity of, phosphatase PTP1B. In turn, this promoted Src kinase activity by dephosphorylating its inhibitory tyrosine residue (Y530). Srx expression was stimulated by cell exposure to certain growth factors. These data support a role for Srx in controlling the phosphorylation status of key regulatory kinases through effects upon phosphatase activity with an ultimate effect on pathways that influence cell proliferation.	[Lei, K.; Tew, K. D.] Med Univ S Carolina, Dept Cell & Mol Pharmacol, Charleston, SC 29425 USA; [Townsend, D. M.] Med Univ S Carolina, Dept Pharmaceut & Biomed Sci, Charleston, SC 29425 USA	Medical University of South Carolina; Medical University of South Carolina	Tew, KD (corresponding author), Med Univ S Carolina, Dept Cell & Mol Pharmacol, 173 Ashley Ave,POB 250505, Charleston, SC 29425 USA.	tewk@musc.edu			KL [T32 CA119945-02]; KDT [CA08660]; NATIONAL CANCER INSTITUTE [R01CA085660, T32CA119945] Funding Source: NIH RePORTER	KL; KDT; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Dr Carola A Neumann for providing retroviral vectors and packaging cells. This work was supported by a postdoctoral fellowship grant (T32 CA119945-02) to KL and by CA08660 to KDT. We thank the Drug Metabolism and Pharmacokinetics facility for GSH measurements.	Adler V, 1999, EMBO J, V18, P1321, DOI 10.1093/emboj/18.5.1321; Alonso A, 2004, CELL, V117, P699, DOI 10.1016/j.cell.2004.05.018; BARFORD D, 1994, SCIENCE, V263, P1397, DOI 10.1126/science.8128219; Barrett WC, 1999, BIOCHEMISTRY-US, V38, P6699, DOI 10.1021/bi990240v; Basu MK, 2005, CELL CYCLE, V4, P947, DOI 10.4161/cc.4.7.1786; Biteau B, 2003, NATURE, V425, P980, DOI 10.1038/nature02075; Bondareva AA, 2007, FREE RADICAL BIO MED, V43, P911, DOI 10.1016/j.freeradbiomed.2007.05.026; Bozonet SM, 2005, J BIOL CHEM, V280, P23319, DOI 10.1074/jbc.M502757200; Budanov AV, 2004, SCIENCE, V304, P596, DOI 10.1126/science.1095569; Chang TS, 2004, J BIOL CHEM, V279, P50994, DOI 10.1074/jbc.M409482200; Chu I, 2007, CELL, V128, P281, DOI 10.1016/j.cell.2006.11.049; CZECH MP, 1974, P NATL ACAD SCI USA, V71, P4173, DOI 10.1073/pnas.71.10.4173; Demasi APD, 2006, FEBS J, V273, P805, DOI 10.1111/j.1742-4658.2006.05116.x; Denu JM, 1998, CURR OPIN CHEM BIOL, V2, P633, DOI 10.1016/S1367-5931(98)80095-1; Diet A, 2007, J BIOL CHEM, V282, P36199, DOI 10.1074/jbc.M706420200; Dube N, 2005, BBA-PROTEINS PROTEOM, V1754, P108, DOI 10.1016/j.bbapap.2005.07.030; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Findlay VJ, 2006, CANCER RES, V66, P6800, DOI 10.1158/0008-5472.CAN-06-0484; Findlay VJ, 2005, BIOMED PHARMACOTHER, V59, P374, DOI 10.1016/j.biopha.2005.07.003; Finkel T, 2003, CURR OPIN CELL BIOL, V15, P247, DOI 10.1016/S0955-0674(03)00002-4; Fruehauf JP, 2007, CLIN CANCER RES, V13, P789, DOI 10.1158/1078-0432.CCR-06-2082; Gallogly MM, 2007, CURR OPIN PHARMACOL, V7, P381, DOI 10.1016/j.coph.2007.06.003; Gius D, 2006, ANTIOXID REDOX SIGN, V8, P1249, DOI 10.1089/ars.2006.8.1249; Glauser DA, 2007, BMC MOL BIOL, V8, DOI 10.1186/1471-2199-8-54; Grimmler M, 2007, CELL, V128, P269, DOI 10.1016/j.cell.2006.11.047; Hatahet F, 2007, FEBS J, V274, P5223, DOI 10.1111/j.1742-4658.2007.06058.x; Hirabayashi Hirohisa, 2002, Nihon Rinsho, V60 Suppl 5, P263; Holmgren A, 2005, BIOCHEM SOC T, V33, P1375, DOI 10.1042/BST0331375; HUNTER T, 1995, CELL, V80, P225, DOI 10.1016/0092-8674(95)90405-0; Jacob C, 2004, ORG BIOMOL CHEM, V2, P1953, DOI 10.1039/b406180b; Jeong W, 2006, J BIOL CHEM, V281, P14400, DOI 10.1074/jbc.M511082200; Jonsson A, 2008, J BACTERIOL, V190, P434, DOI 10.1128/JB.01058-07; Jonsson TJ, 2007, BIOCHEMISTRY-US, V46, P5709, DOI 10.1021/bi7001218; Jonsson TJ, 2005, BIOCHEMISTRY-US, V44, P8634, DOI 10.1021/bi050131i; Kaldis P, 2007, CELL, V128, P241, DOI 10.1016/j.cell.2007.01.006; Lee DY, 2006, BIOCHEMISTRY-US, V45, P15301, DOI 10.1021/bi061824h; Lee HJ, 2005, BEHAV BRAIN FUNCT, V1, DOI 10.1186/1744-9081-1-15; Lei K, 2002, MOL CELL BIOL, V22, P4929, DOI 10.1128/MCB.22.13.4929-4942.2002; Leslie NR, 2003, EMBO J, V22, P5501, DOI 10.1093/emboj/cdg513; Lillig CH, 2007, ANTIOXID REDOX SIGN, V9, P25, DOI 10.1089/ars.2007.9.25; Liu XP, 2006, CELL RES, V16, P287, DOI 10.1038/sj.cr.7310036; Martinez-Ruiz A, 2007, CARDIOVASC RES, V75, P220, DOI 10.1016/j.cardiores.2007.03.016; Nakamura H, 1997, ANNU REV IMMUNOL, V15, P351, DOI 10.1146/annurev.immunol.15.1.351; Rey P, 2007, PLANT J, V49, P505, DOI 10.1111/j.1365-313X.2006.02969.x; Rhee SG, 2007, KIDNEY INT, V72, pS3, DOI 10.1038/sj.ki.5002380; Rhee SG, 2005, CURR OPIN CELL BIOL, V17, P183, DOI 10.1016/j.ceb.2005.02.004; Roskoski R, 2005, BIOCHEM BIOPH RES CO, V331, P1, DOI 10.1016/j.bbrc.2005.03.012; Saitoh M, 1998, EMBO J, V17, P2596, DOI 10.1093/emboj/17.9.2596; Salmeen A, 2003, NATURE, V423, P769, DOI 10.1038/nature01680; Shelton MD, 2005, ANTIOXID REDOX SIGN, V7, P348, DOI 10.1089/ars.2005.7.348; Singhal S, 2005, CLIN CANCER RES, V11, P3974, DOI 10.1158/1078-0432.CCR-04-2661; SUN Y, 1995, J BIOL CHEM, V270, P19312, DOI 10.1074/jbc.270.33.19312; Tew KD, 2007, BIOCHEM PHARMACOL, V73, P1257, DOI 10.1016/j.bcp.2006.09.027; Tonks NK, 2006, NAT REV MOL CELL BIO, V7, P833, DOI 10.1038/nrm2039; Townsend DM, 2007, MOL INTERV, V7, P313, DOI 10.1124/mi.7.6.7; Townsend DM, 2006, MOL PHARMACOL, V69, P501, DOI 10.1124/mol.105.018523; TOWNSEND DM, 2008, CANC RES IN PRESS; Velu CS, 2007, BIOCHEMISTRY-US, V46, P7765, DOI 10.1021/bi700425y; Vivancos AP, 2005, P NATL ACAD SCI USA, V102, P8875, DOI 10.1073/pnas.0503251102; Wang T, 2001, J BIOL CHEM, V276, P20999, DOI 10.1074/jbc.M101355200; Woo HA, 2005, J BIOL CHEM, V280, P3125, DOI 10.1074/jbc.C400496200; Yeatman TJ, 2004, NAT REV CANCER, V4, P470, DOI 10.1038/nrc1366; Zhu CQ, 2006, J CLIN PATHOL, V59, P790, DOI 10.1136/jcp.2005.031351	63	46	50	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 21	2008	27	36					4877	4887		10.1038/onc.2008.132	http://dx.doi.org/10.1038/onc.2008.132			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	339SF	18454177	Green Accepted			2022-12-28	WOS:000258596900002
J	Bheda, A; Creek, KE; Pirisi, L				Bheda, A.; Creek, K. E.; Pirisi, L.			Loss of p53 induces epidermal growth factor receptor promoter activity in normal human keratinocytes	ONCOGENE			English	Article						p53; EGFR promoter; HPV16; human keratinocytes; YY1; Sp1	TRANSCRIPTION FACTOR YY1; CERVICAL-CANCER; GENE; IDENTIFICATION; ACTIVATION; EXPRESSION; REGULATOR; BINDING; SP1; E6	Overexpression of the epidermal growth factor receptor (EGFR) in human papillomavirus type 16-immortalized human keratinocytes (HKc) is caused by the viral oncoprotein E6, which targets p53 for degradation. We have previously observed that expression of p53 RNAi in normal HKc is associated with an increase in EGFR mRNA and protein. We now report that p53 RNAi induces EGFR promoter activityup to approximately 10-fold in normal HKc, and this effect does not require intact p53 binding sites on the EGFR promoter. Exogenous wildtype p53 inhibits the EGFR promoter at low levels, and activates it at higher concentrations. Yin Yang 1 (YY1), which negatively regulates p53, induces EGFR promoter activity, and this effect is augmented by p53 RNAi. Intact p53 binding sites on the EGFR promoter are not required for activation by YY1. In addition, Sp1 and YY1 synergistically induce the EGFR promoter in normal HKc, indicating that Sp1 may recruit YY1 as a coactivator. Wild-type p53 suppressed Sp1- and YY1-mediated induction of the EGFR promoter. We conclude that acute loss of p53 in normal HKc induces EGFR expression by a mechanism that involves YY1 and Sp1 and does not require p53 binding to the EGFR promoter.	[Pirisi, L.] Univ S Carolina, Sch Med, S Carolina Canc Ctr, Dept Pathol Microbiol & Immunol,Basic Sci Labs, Columbia, SC 29203 USA	University of South Carolina; University of South Carolina System; University of South Carolina Columbia	Pirisi, L (corresponding author), Univ S Carolina, Sch Med, S Carolina Canc Ctr, Dept Pathol Microbiol & Immunol,Basic Sci Labs, 14 Richland Med Pk,Suite 500, Columbia, SC 29203 USA.	pirisi@med.sc.edu			NATIONAL CANCER INSTITUTE [R01CA089502, P20CA096427] Funding Source: NIH RePORTER; National Institute on Minority Health and Health Disparities [P20MD001770] Funding Source: NIH RePORTER; NCI NIH HHS [P20 CA096427-03, R01 CA089502, P20CA096427, P20 CA096427, R01CA89502, R01 CA089502-05] Funding Source: Medline; NIMHD NIH HHS [P20 MD001770, P20 MD001770-030002] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); National Institute on Minority Health and Health Disparities(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Minority Health & Health Disparities (NIMHD)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIMHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Minority Health & Health Disparities (NIMHD))		Ai WD, 2000, J VIROL, V74, P5198, DOI 10.1128/JVI.74.11.5198-5205.2000; Akerman GS, 2001, CANCER RES, V61, P3837; Arteaga CL, 2002, ONCOLOGIST, V7, P31; Baldwin A, 2004, J VIROL, V78, P3953, DOI 10.1128/JVI.78.8.3953-3964.2004; DEB SP, 1994, ONCOGENE, V9, P1341; Dykxhoorn DM, 2005, ANNU REV MED, V56, P401, DOI 10.1146/annurev.med.56.082103.104606; Gordon S, 2006, ONCOGENE, V25, P1125, DOI 10.1038/sj.onc.1209080; Gronroos E, 2004, P NATL ACAD SCI USA, V101, P12165, DOI 10.1073/pnas.0402283101; HALEY J, 1987, ONCOGENE RES, V1, P375; Hu GY, 1997, JNCI-J NATL CANCER I, V89, P1271, DOI 10.1093/jnci/89.17.1271; Innocente SA, 2005, FEBS LETT, V579, P1001, DOI 10.1016/j.febslet.2004.12.073; ISHII S, 1985, P NATL ACAD SCI USA, V82, P4920, DOI 10.1073/pnas.82.15.4920; Johnson AC, 2000, MOL MED, V6, P17, DOI 10.1007/BF03401931; KAGEYAMA R, 1988, J BIOL CHEM, V263, P6329; Kawada H, 2005, J INVEST DERMATOL, V124, P1206, DOI 10.1111/j.0022-202X.2005.23748.x; Kilic G, 1999, EUR J GYNAECOL ONCOL, V20, P167; LEE JS, 1993, P NATL ACAD SCI USA, V90, P6145, DOI 10.1073/pnas.90.13.6145; LudesMeyers JH, 1996, MOL CELL BIOL, V16, P6009; Mathur SP, 2001, AM J REPROD IMMUNOL, V46, P280, DOI 10.1034/j.1600-0897.2001.d01-14.x; PIRISI L, 1988, CARCINOGENESIS, V9, P1573, DOI 10.1093/carcin/9.9.1573; PIRISI L, 1987, J VIROL, V61, P1061, DOI 10.1128/JVI.61.4.1061-1066.1987; Sheikh MS, 1997, ONCOGENE, V15, P1095, DOI 10.1038/sj.onc.1201264; Shi Y, 1997, BBA-REV CANCER, V1332, pF49, DOI 10.1016/S0304-419X(96)00044-3; Sui GC, 2004, CELL, V117, P859, DOI 10.1016/j.cell.2004.06.004; Wang X, 2006, J CELL BIOL, V172, P409, DOI 10.1083/jcb.200510002; XU J, 1993, J BIOL CHEM, V268, P16065; Yakovleva T, 2004, BIOCHEM BIOPH RES CO, V318, P615, DOI 10.1016/j.bbrc.2004.04.065; Yao YL, 2001, MOL CELL BIOL, V21, P5979, DOI 10.1128/MCB.21.17.5979-5991.2001; Yarden Y, 2001, NAT REV MOL CELL BIO, V2, P127, DOI 10.1038/35052073; Yu J, 1999, P NATL ACAD SCI USA, V96, P14517, DOI 10.1073/pnas.96.25.14517; Zhao RB, 2000, GENE DEV, V14, P981; ZYZAK LL, 1994, CELL GROWTH DIFFER, V5, P537	32	37	42	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 17	2008	27	31					4315	4323		10.1038/onc.2008.65	http://dx.doi.org/10.1038/onc.2008.65			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	326WY	18391986	Green Accepted			2022-12-28	WOS:000257691100006
J	Gehen, SC; Staversky, RJ; Bambara, RA; Keng, PC; O'Reilly, MA				Gehen, S. C.; Staversky, R. J.; Bambara, R. A.; Keng, P. C.; O'Reilly, M. A.			hSMG-1 and ATM sequentially and independently regulate the G(1) checkpoint during oxidative stress	ONCOGENE			English	Article						cell cycle; DNA damage; p53; reactive oxygen species	DAMAGE-INDUCED PHOSPHORYLATION; RNA SURVEILLANCE PROTEIN; DOUBLE-STRAND BREAKS; DNA-DAMAGE; IONIZING-RADIATION; DEPENDENT PHOSPHORYLATION; HUMAN SMG-1; KINASE; P53; UBIQUITINATION	Genotoxic stress activates the phosphatidylinositol 3-kinase-like kinases ( PIKKs) that phosphorylate proteins involved in cell cycle arrest, DNA repair and apoptosis. Previous work showed that the PIKK ataxia telangiectasia mutated ( ATM) but not ATM and Rad3 related phosphorylates p53 ( Ser15) during hyperoxia, a model of prolonged oxidative stress and DNA damage. Here, we show hSMG-1 is responsible for the rapid and early phosphorylation of p53 ( Ser15) and that ATM helps maintain phosphorylation after 24 h. Despite reduced p53 phosphorylation and abundance in cells depleted of hSMG-1 or ATM, levels of the p53 target p21 were still elevated and the G(1) checkpoint remained intact. Conditional overexpression of p21 in p53-deficient cells revealed that hyperoxia also stimulates wortmannin-sensitive degradation of p21. siRNA depletion of hSMG-1 or ATM restored p21 stability and the G(1) checkpoint during hyperoxia. These findings establish hSMG-1 as a proximal regulator of DNA damage signaling and reveal that the G1 checkpoint is tightly regulated during prolonged oxidative stress by both PIKK-dependent synthesis and proteolysis of p21.	[Staversky, R. J.; O'Reilly, M. A.] Univ Rochester, Sch Med & Dent, Dept Pediat, Rochester, NY 14642 USA; [Gehen, S. C.] Univ Rochester, Dept Environm Med, Rochester, NY 14642 USA; [Bambara, R. A.] Univ Rochester, Dept Biochem & Biophys, Rochester, NY 14642 USA; [Keng, P. C.] Univ Rochester, Dept Radiat Oncol, Rochester, NY 14642 USA	University of Rochester; University of Rochester; University of Rochester; University of Rochester	O'Reilly, MA (corresponding author), Univ Rochester, Sch Med & Dent, Dept Pediat, 601 Elmwood Ave,Box 850, Rochester, NY 14642 USA.	michael_oreilly@urmc.rochester.edu			NHLBI NIH HHS [HL-67392, R01 HL067392, R01 HL067392-06] Funding Source: Medline; NIEHS NIH HHS [T32 ES007026-21, P30 ES001247, ES-07026, P30 ES001247-349022, T32 ES007026, ES-01247, R01 ES007026] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL067392] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES007026, T32ES007026, P30ES001247] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Abraham RT, 2005, SCIENCE, V308, P510, DOI 10.1126/science.1112069; Bakkenist CJ, 2003, NATURE, V421, P499, DOI 10.1038/nature01368; Bao SD, 2001, NATURE, V411, P969, DOI 10.1038/35082110; Bartek J, 2003, CANCER CELL, V3, P421, DOI 10.1016/S1535-6108(03)00110-7; Bendjennat M, 2003, CELL, V114, P599, DOI 10.1016/j.cell.2003.08.001; Blagosklonny MV, 1996, BIOCHEM BIOPH RES CO, V227, P564, DOI 10.1006/bbrc.1996.1546; Brooks CL, 2003, CURR OPIN CELL BIOL, V15, P164, DOI 10.1016/S0955-0674(03)00003-6; Brumbaugh KM, 2004, MOL CELL, V14, P585, DOI 10.1016/j.molcel.2004.05.005; Canman CE, 1998, SCIENCE, V281, P1677, DOI 10.1126/science.281.5383.1677; Casper AM, 2002, CELL, V111, P779, DOI 10.1016/S0092-8674(02)01113-3; Chen MJ, 2001, J BIOL CHEM, V276, P16580, DOI 10.1074/jbc.M008871200; Cortez D, 2001, SCIENCE, V294, P1713, DOI 10.1126/science.1065521; Cortez D, 1999, SCIENCE, V286, P1162, DOI 10.1126/science.286.5442.1162; Coulombe P, 2004, MOL CELL BIOL, V24, P6140, DOI 10.1128/MCB.24.14.6140-6150.2004; Das KC, 2004, AM J PHYSIOL-LUNG C, V286, pL87, DOI 10.1152/ajplung.00203.2002; Denning G, 2001, J BIOL CHEM, V276, P22709, DOI 10.1074/jbc.C100144200; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Engel FB, 2003, MOL CELL BIOL, V23, P555, DOI 10.1128/MCB.23.2.555-565.2003; Gehen SC, 2007, AM J PHYSIOL-LUNG C, V292, pL716, DOI 10.1152/ajplung.00135.2006; Guo ZJ, 2000, GENE DEV, V14, P2745, DOI 10.1101/gad.842500; Helt CE, 2004, AM J PHYSIOL-LUNG C, V286, pL506, DOI 10.1152/ajplung.00243.2003; Helt CE, 2005, J BIOL CHEM, V280, P1186, DOI 10.1074/jbc.M410873200; Lee JH, 2005, SCIENCE, V308, P551, DOI 10.1126/science.1108297; Maki CG, 1997, MOL CELL BIOL, V17, P355, DOI 10.1128/MCB.17.1.355; O'Reilly MA, 2001, AM J RESP CELL MOL, V24, P703, DOI 10.1165/ajrcmb.24.6.4355; OConnor PM, 1997, CANCER SURV, V29, P151; PODUST VN, 1995, BIOCHEMISTRY-US, V34, P8869, DOI 10.1021/bi00027a039; Sheaff RJ, 2000, MOL CELL, V5, P403, DOI 10.1016/S1097-2765(00)80435-9; Smith GCM, 1999, P NATL ACAD SCI USA, V96, P11134, DOI 10.1073/pnas.96.20.11134; Stiff T, 2004, CANCER RES, V64, P2390, DOI 10.1158/0008-5472.CAN-03-3207; Suzuki K, 1999, J BIOL CHEM, V274, P25571, DOI 10.1074/jbc.274.36.25571; Tibbetts RS, 1999, GENE DEV, V13, P152, DOI 10.1101/gad.13.2.152; Touitou R, 2001, EMBO J, V20, P2367, DOI 10.1093/emboj/20.10.2367; Vitiello PF, 2006, AM J PATHOL, V168, P1838, DOI 10.2353/ajpath.2006.051162; Yamashita A, 2001, GENE DEV, V15, P2215, DOI 10.1101/gad.913001; Yoshida K, 2003, EMBO J, V22, P1431, DOI 10.1093/emboj/cdg134	36	41	41	1	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 3	2008	27	29					4065	4074		10.1038/onc.2008.48	http://dx.doi.org/10.1038/onc.2008.48			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	321RV	18332866	Green Accepted			2022-12-28	WOS:000257325100006
J	Toscano, F; El Fajoui, Z; Gay, F; Lalaoui, N; Parmentier, B; Chayvialle, JA; Scoazec, JY; Micheau, O; Abello, J; Saurin, JC				Toscano, F.; El Fajoui, Z.; Gay, F.; Lalaoui, N.; Parmentier, B.; Chayvialle, J-A; Scoazec, J-Y; Micheau, O.; Abello, J.; Saurin, J-C			p53-mediated upregulation of DcR1 impairs oxaliplatin/TRAIL-induced synergistic anti-tumour potential in colon cancer cells	ONCOGENE			English	Article						oxaliplatin; TRAIL; antagonism; p53; DcR1; colon cancer	TRAIL-INDUCED APOPTOSIS; DECOY RECEPTORS; CHEMOTHERAPEUTIC-AGENTS; COLORECTAL-CANCER; DEATH RECEPTORS; TARGETING DEATH; IN-VITRO; C-FLIP; LIGAND; P53	Oxaliplatin hasemerged as a major chemotherapeutic drug in the treatment of advanced colorectal cancer, yet like most conventional cancer therapeutics, its efficacy is often compromised due to p53 mutations. Unlike oxaliplatin, tumour necrosis factor-related apoptosis-inducing ligand (TRAIL) triggers apoptosis in a p53-independent manner, and chemotherapy is known to overcome tumour resistance to TRAIL-induced cell death in most cancer cells. Using a panel of colon cancer cell lines, we assessed the ability of oxaliplatin to sensitize to TRAIL-induced apoptosis. We demonstrate that while both drugs additively or synergistically induced apoptosis in almost all cell lines tested, p53 wild-type colon cancer cells such as HCT116, LS513 or LS174T remained resistant. Impaired TRAIL-induced cell death resulted from a strong p53 dependent, oxaliplatin-mediated, DcR1 receptor expression increase. According to our finding, downregulation of DcR1 using siRNA, in p53 wild-type colon cancer cells, restored oxaliplatin/TRAIL synergistic apoptotic activity. On the contrary, exogenous DcR1 overexpression in SW480, a p53-mutated cell line, abolished the synergy between the two drugs. Altogether we demonstrate for the first time that p53 negatively regulates oxaliplatin-mediated TRAIL-induced apoptotic activity through DcR1 upregulation. Our findings could have important implications for future therapeutic strategies, and suggest that the association oxaliplatin/TRAIL should be restricted to patients harbouring a non-functional p53 protein.	[Toscano, F.; El Fajoui, Z.; Gay, F.; Parmentier, B.; Chayvialle, J-A; Scoazec, J-Y; Abello, J.; Saurin, J-C] Fac Med Laennec, INSERM, Unite 865, Inst Fed Rech Lyon Est, F-69372 Lyon 08, France; [Toscano, F.; El Fajoui, Z.; Gay, F.; Parmentier, B.; Chayvialle, J-A; Scoazec, J-Y; Abello, J.; Saurin, J-C] Univ Lyon 1, Fac Laennec, F-69008 Lyon, France; [Lalaoui, N.; Micheau, O.] Univ Bourgogne, INSERM, U866, F-21079 Dijon, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Claude Bernard Lyon 1; Institut Agro; AgroSup Dijon; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Bourgogne	Abello, J (corresponding author), Fac Med Laennec, INSERM, Unite 865, Inst Fed Rech Lyon Est, 7 Rue G Paradin, F-69372 Lyon 08, France.	abello@lyon.inserm.fr	saurin, jean christophe/AAB-4077-2020; Lalaoui, Najoua/C-1410-2014; micheau, olivier/C-3574-2011	Lalaoui, Najoua/0000-0002-0165-3324; micheau, olivier/0000-0001-8499-7984				Ashkenazi A, 2002, NAT REV CANCER, V2, P420, DOI 10.1038/nrc821; Bouralexis S, 2003, BRIT J CANCER, V89, P206, DOI 10.1038/sj.bjc.6601021; Bouralexis S, 2005, APOPTOSIS, V10, P35, DOI 10.1007/s10495-005-6060-0; CHOU TC, 1984, ADV ENZYME REGUL, V22, P27, DOI 10.1016/0065-2571(84)90007-4; Clancy L, 2005, P NATL ACAD SCI USA, V102, P18099, DOI 10.1073/pnas.0507329102; Davidovich IA, 2004, CANCER LETT, V211, P189, DOI 10.1016/j.canlet.2004.03.026; de Almodovar CR, 2004, J BIOL CHEM, V279, P4093, DOI 10.1074/jbc.M311243200; Galligan L, 2005, MOL CANCER THER, V4, P2026, DOI 10.1158/1535-7163.MCT-05-0262; Gayet J, 2001, ONCOGENE, V20, P5025, DOI 10.1038/sj.onc.1204611; Grady WM, 2002, ANNU REV GENOM HUM G, V3, P101, DOI 10.1146/annurev.genom.3.022502.103043; Gramont Aimery de, 2005, Semin Oncol, V32, P11, DOI 10.1053/j.seminoncol.2005.06.004; He Q, 2004, ONCOGENE, V23, P2554, DOI 10.1038/sj.onc.1207351; Jang SH, 2004, INT J MOL MED, V13, P181; Jin H, 2004, CANCER RES, V64, P4900, DOI 10.1158/0008-5472.CAN-04-0408; Kelley SK, 2004, CURR OPIN PHARMACOL, V4, P333, DOI 10.1016/j.coph.2004.02.006; Kim YH, 2004, CARCINOGENESIS, V25, P1813, DOI 10.1093/carcin/bgh188; LeBlanc HN, 2003, CELL DEATH DIFFER, V10, P66, DOI 10.1038/sj.cdd.4401187; Liu XG, 2005, CANCER RES, V65, P9169, DOI 10.1158/0008-5472.CAN-05-0939; Merino D, 2007, EXPERT OPIN THER TAR, V11, P1299, DOI 10.1517/14728222.11.10.1299; Merino D, 2006, MOL CELL BIOL, V26, P7046, DOI 10.1128/MCB.00520-06; Micheau O, 2001, MOL CELL BIOL, V21, P5299, DOI 10.1128/MCB.21.16.5299-5305.2001; Micheau O, 1999, J BIOL CHEM, V274, P7987, DOI 10.1074/jbc.274.12.7987; Mita MM, 2006, ANN ONCOL, V17, P313, DOI 10.1093/annonc/mdj067; Motoki K, 2005, CLIN CANCER RES, V11, P3126, DOI 10.1158/1078-0432.CCR-04-1867; Nagane M, 2000, CANCER RES, V60, P847; Oren M, 2003, CELL DEATH DIFFER, V10, P431, DOI 10.1038/sj.cdd.4401183; Pan GH, 1997, SCIENCE, V277, P815, DOI 10.1126/science.277.5327.815; Pukac L, 2005, BRIT J CANCER, V92, P1430, DOI 10.1038/sj.bjc.6602487; Scaffidi C, 1999, J BIOL CHEM, V274, P22532, DOI 10.1074/jbc.274.32.22532; Shankar S, 2004, DRUG RESIST UPDATE, V7, P139, DOI 10.1016/j.drup.2004.03.002; Sheikh MS, 2000, LEUKEMIA, V14, P1509, DOI 10.1038/sj.leu.2401865; STEEL GG, 1979, INT J RADIAT ONCOL, V5, P85; Thorburn A, 2004, CELL SIGNAL, V16, P139, DOI 10.1016/j.cellsig.2003.08.007; Toscano F, 2007, BIOCHEM PHARMACOL, V74, P392, DOI 10.1016/j.bcp.2007.05.001; van Geelen CM, 2006, J CLIN ONCOL, V24, P4998, DOI 10.1200/JCO.2006.06.8809; Vignati S, 2002, EUR J CANCER, V38, P177, DOI 10.1016/S0959-8049(01)00345-8; Wajant H, 2005, CYTOKINE GROWTH F R, V16, P55, DOI 10.1016/j.cytogfr.2004.12.001; Yagita H, 2004, CANCER SCI, V95, P777, DOI 10.1111/j.1349-7006.2004.tb02181.x; Yamanaka T, 2000, HEPATOLOGY, V32, P482, DOI 10.1053/jhep.2000.16266	39	35	38	1	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL	2008	27	30					4161	4171		10.1038/onc.2008.52	http://dx.doi.org/10.1038/onc.2008.52			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	324DB	18345033				2022-12-28	WOS:000257496800003
J	Fu, Z; Tindall, DJ				Fu, Z.; Tindall, D. J.			FOXOs, cancer and regulation of apoptosis	ONCOGENE			English	Review						FOXO; cancer; apoptosis; Forkhead; death receptor ligand; Bcl-2 family members	FORKHEAD TRANSCRIPTION FACTOR; PROTEIN-KINASE-B; PAX3-FKHR FUSION PROTEIN; FACTOR AFX; ALVEOLAR RHABDOMYOSARCOMA; FACTOR FKHR; TUMOR SUPPRESSION; FAMILY-MEMBER; CELL-CYCLE; NEGATIVE REGULATION	Forkhead box O (FOXO) transcription factors are involved in multiple signaling pathways and play critical roles in a number of physiological and pathological processes including cancer. The importance of FOXO factors ascribes them under multiple levels of regulation including phosphorylation, acetylation/deacetylation, ubiquitination and protein-protein interactions. As FOXO factors play a pivotal role in cell fate decision, mounting evidence suggests that FOXO factors function as tumor suppressors in a variety of cancers. FOXOs are actively involved in promoting apoptosis in a mitochondria-independent and-dependent manner by inducing the expression of death receptor ligands, including Fas ligand and tumor necrosis factor-related apoptosis-inducing ligand, and Bcl-2 family members, such as Bim, bNIP3 and Bcl-X-L, respectively. An understanding of FOXO proteins and their biology will provide new opportunities for developing more effective therapeutic approaches to treat cancer.	[Fu, Z.; Tindall, D. J.] Mayo Clin, Coll Med, Dept Urol, Rochester, MN 55905 USA; [Fu, Z.; Tindall, D. J.] Mayo Clin, Coll Med, Dept Biochem & Mol Biol, Rochester, MN 55905 USA	Mayo Clinic; Mayo Clinic	Tindall, DJ (corresponding author), Mayo Clin, Coll Med, Dept Urol, Rochester, MN 55905 USA.	tindall.donald@mayo.edu	高, 雨莉/HGU-8187-2022		NCI NIH HHS [R01 CA125747, P50 CA091956-090012, P50 CA091956, R01 CA121277, CA125747, CA121277] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA121277, P50CA091956, R01CA125747] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Accili D, 2004, CELL, V117, P421, DOI 10.1016/S0092-8674(04)00452-0; Alessi DR, 1996, FEBS LETT, V399, P333, DOI 10.1016/S0014-5793(96)01370-1; Anderson MJ, 2001, P NATL ACAD SCI USA, V98, P1589, DOI 10.1073/pnas.98.4.1589; Anderson MJ, 1998, GENOMICS, V47, P187, DOI 10.1006/geno.1997.5122; Barr FG, 2001, ONCOGENE, V20, P5736, DOI 10.1038/sj.onc.1204599; Barthel A, 2005, TRENDS ENDOCRIN MET, V16, P183, DOI 10.1016/j.tem.2005.03.010; Biggs WH, 2001, MAMM GENOME, V12, P416, DOI 10.1007/s003350020002; Biggs WH, 1999, P NATL ACAD SCI USA, V96, P7421, DOI 10.1073/pnas.96.13.7421; Bois PRJ, 2003, EMBO J, V22, P1147, DOI 10.1093/emboj/cdg116; Borkhardt A, 1997, ONCOGENE, V14, P195, DOI 10.1038/sj.onc.1200814; Brownawell AM, 2001, MOL CELL BIOL, V21, P3534, DOI 10.1128/MCB.21.10.3534-3546.2001; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Brunet A, 2004, SCIENCE, V303, P2011, DOI 10.1126/science.1094637; Burgering BMT, 2002, TRENDS BIOCHEM SCI, V27, P352, DOI 10.1016/S0968-0004(02)02113-8; Cantley LC, 2002, SCIENCE, V296, P1655, DOI 10.1126/science.296.5573.1655; Castrillon DH, 2003, SCIENCE, V301, P215, DOI 10.1126/science.1086336; CLARK KL, 1993, NATURE, V364, P412, DOI 10.1038/364412a0; CORRAL J, 1993, P NATL ACAD SCI USA, V90, P8538, DOI 10.1073/pnas.90.18.8538; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; del Peso L, 1999, ONCOGENE, V18, P7328, DOI 10.1038/sj.onc.1203159; Dijkers PF, 2000, CURR BIOL, V10, P1201, DOI 10.1016/S0960-9822(00)00728-4; Dowell P, 2003, J BIOL CHEM, V278, P45485, DOI 10.1074/jbc.M309069200; Essers MAG, 2005, SCIENCE, V308, P1181, DOI 10.1126/science.1109083; Fukuoka M, 2003, INT J MOL MED, V12, P503; Furuyama T, 2004, J BIOL CHEM, V279, P34741, DOI 10.1074/jbc.M314214200; Furuyama T, 2000, BIOCHEM J, V349, P629, DOI 10.1042/0264-6021:3490629; GALILI N, 1993, NAT GENET, V5, P230, DOI 10.1038/ng1193-230; Gilley J, 2003, J CELL BIOL, V162, P613, DOI 10.1083/jcb.200303026; Greer EL, 2005, ONCOGENE, V24, P7410, DOI 10.1038/sj.onc.1209086; Hillion J, 1997, BLOOD, V90, P3714, DOI 10.1182/blood.V90.9.3714; Hosaka T, 2004, P NATL ACAD SCI USA, V101, P2975, DOI 10.1073/pnas.0400093101; Hu MCT, 2004, CELL, V117, P225, DOI 10.1016/S0092-8674(04)00302-2; Huang H, 2005, P NATL ACAD SCI USA, V102, P1649, DOI 10.1073/pnas.0406789102; Huang HJ, 2006, SCIENCE, V314, P294, DOI 10.1126/science.1130512; Jacobs FMJ, 2003, J BIOL CHEM, V278, P35959, DOI 10.1074/jbc.M302804200; Kaestner KH, 2000, GENE DEV, V14, P142; Kau TR, 2003, CANCER CELL, V4, P463, DOI 10.1016/S1535-6108(03)00303-9; Kaufmann E, 1996, MECH DEVELOP, V57, P3, DOI 10.1016/0925-4773(96)00539-4; Keller C, 2004, GENE DEV, V18, P2614, DOI 10.1101/gad.1244004; Keller C, 2004, GENE DEV, V18, P2608, DOI 10.1101/gad.1243904; Kempf BE, 1999, CELL GROWTH DIFFER, V10, P813; Kops GJPL, 1999, NATURE, V398, P630, DOI 10.1038/19328; Lagutina I, 2002, MOL CELL BIOL, V22, P7204, DOI 10.1128/MCB.22.20.7204-7216.2002; Li PF, 2003, MOL CELL BIOL, V23, P104, DOI 10.1128/MCB.23.1.104-118.2003; Lin K, 1997, SCIENCE, V278, P1319, DOI 10.1126/science.278.5341.1319; Matsuzaki H, 2003, P NATL ACAD SCI USA, V100, P11285, DOI 10.1073/pnas.1934283100; Medema RH, 2000, NATURE, V404, P782, DOI 10.1038/35008115; Modur V, 2002, J BIOL CHEM, V277, P47928, DOI 10.1074/jbc.M207509200; Motta MC, 2004, CELL, V116, P551, DOI 10.1016/S0092-8674(04)00126-6; Nakae J, 1999, J BIOL CHEM, V274, P15982, DOI 10.1074/jbc.274.23.15982; Nakamura N, 2000, MOL CELL BIOL, V20, P8969, DOI 10.1128/MCB.20.23.8969-8982.2000; Paik JH, 2007, CELL, V128, P309, DOI 10.1016/j.cell.2006.12.029; PARRY P, 1994, GENE CHROMOSOME CANC, V11, P79, DOI 10.1002/gcc.2870110203; Perrot V, 2003, J BIOL CHEM, V278, P26111, DOI 10.1074/jbc.M212750200; Puigserver P, 2003, NATURE, V423, P550, DOI 10.1038/nature01667; Ramaswamy S, 2002, CANCER CELL, V2, P81, DOI 10.1016/S1535-6108(02)00086-7; Relaix F, 2003, GENE DEV, V17, P2950, DOI 10.1101/gad.281203; Rena G, 1999, J BIOL CHEM, V274, P17179, DOI 10.1074/jbc.274.24.17179; Richards JS, 2002, MOL ENDOCRINOL, V16, P580, DOI 10.1210/me.16.3.580; Scheidler S, 1996, P NATL ACAD SCI USA, V93, P9805, DOI 10.1073/pnas.93.18.9805; Schroeder FC, 2005, J NAT PROD, V68, P574, DOI 10.1021/np049624z; Seoane J, 2004, CELL, V117, P211, DOI 10.1016/S0092-8674(04)00298-3; Stahl M, 2002, J IMMUNOL, V168, P5024, DOI 10.4049/jimmunol.168.10.5024; Sunters A, 2003, J BIOL CHEM, V278, P49795, DOI 10.1074/jbc.M309523200; Takaishi H, 1999, P NATL ACAD SCI USA, V96, P11836, DOI 10.1073/pnas.96.21.11836; Tang ED, 1999, J BIOL CHEM, V274, P16741, DOI 10.1074/jbc.274.24.16741; Tang TTL, 2002, J BIOL CHEM, V277, P14255, DOI 10.1074/jbc.M110901200; Tothova Z, 2007, CELL, V128, P325, DOI 10.1016/j.cell.2007.01.003; Tran H, 2002, SCIENCE, V296, P530, DOI 10.1126/science.1068712; van der Horst A, 2004, J BIOL CHEM, V279, P28873, DOI 10.1074/jbc.M401138200; Vivanco I, 2002, NAT REV CANCER, V2, P489, DOI 10.1038/nrc839; Vogt PK, 2005, CELL CYCLE, V4, P908, DOI 10.4161/cc.4.7.1796; Xia SJJ, 2004, ONCOGENE, V23, P6864, DOI 10.1038/sj.onc.1207850; Xia SJJ, 2002, CANCER BIOL THER, V1, P97, DOI 10.4161/cbt.51; Xuan ZY, 2005, GENOME BIOL, V6, DOI 10.1186/gb-2005-6-8-r72; Yamamura Y, 2006, J BIOL CHEM, V281, P5267, DOI 10.1074/jbc.M512151200; Yang HL, 2005, ONCOGENE, V24, P1924, DOI 10.1038/sj.onc.1208352; Zhang L, 2003, J BIOL CHEM, V278, P27, DOI 10.1074/jbc.M205424200	78	419	430	1	27	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 7	2008	27	16					2312	2319		10.1038/onc.2008.24	http://dx.doi.org/10.1038/onc.2008.24			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	285NE	18391973	Green Accepted			2022-12-28	WOS:000254782700006
J	Mourskaia, AA; Dong, Z; Ng, S; Banville, M; Zwaagstra, JC; O'Connor-McCourt, MD; Siegel, PM				Mourskaia, A. A.; Dong, Z.; Ng, S.; Banville, M.; Zwaagstra, J. C.; O'Connor-McCourt, M. D.; Siegel, P. M.			Transforming growth factor-beta 1 is the predominant isoform required for breast cancer cell outgrowth in bone	ONCOGENE			English	Article						TGF-beta isoforms; breast cancer; ligand trap; bone microenvironment	HORMONE-RELATED PROTEIN; TUMOR-SUPPRESSOR; I RECEPTOR; SKELETAL METASTASIS; BETA; EXPRESSION; SMAD; MECHANISMS; VIVO	Transforming growth factor (TGF)-beta signaling is a potent modulator of the invasive and metastatic behavior of breast cancer cells. Indeed, breast tumor responsiveness to TGF-beta is important for the development of osteolytic bone metastases. However, the specific TGF-beta isoforms that promote breast cancer outgrowth in bone is unknown. We demonstrate that expression of a TGF-beta ligand trap, which neutralizes TGF-beta 1 and TGF-beta 3, in MDA-MB-231 breast cancer cells diminished their outgrowth in bone and reduced the severity of osteolytic lesion formation when compared with controls. We further show that a reduction or loss of TGF-beta 1 expression within the bone microenvironment of TGF-beta 1+/- and TGF-beta 1-/- mice significantly reduced the incidence of breast tumor outgrowth compared with wild-type animals. Interestingly, those tumors capable of growing within the tibiae of TGF-beta 1-deficient mice had upregulated expression of all three TGF-b isoforms. Finally, breast cancer cells expressing the TGF-b ligand trap showed a pronounced reduction in their ability to form osteolytic lesions when injected into the tibiae of TGF-beta 1-/- mice. Thus, our studies show that both host- and tumor-derived TGF-beta expression plays a critical role during the establishment and outgrowth of breast cancer cells in bone.	[Mourskaia, A. A.; Dong, Z.; Zwaagstra, J. C.; Siegel, P. M.] McGill Univ, Dept Med, Montreal, PQ H3A 1A4, Canada; [Ng, S.; O'Connor-McCourt, M. D.; Siegel, P. M.] McGill Univ, Dept Anat & Cell Biol, Montreal, PQ H3A 1A4, Canada; [Banville, M.; Zwaagstra, J. C.; O'Connor-McCourt, M. D.] Natl Res Council Canada, Biotechnol Res Inst, Montreal, PQ H4P 2R2, Canada; [O'Connor-McCourt, M. D.; Siegel, P. M.] McGill Univ, Dept Biochem, Montreal, PQ H3A 1A4, Canada	McGill University; McGill University; National Research Council Canada; McGill University	Siegel, PM (corresponding author), McGill Univ, Dept Med, 740 Dr Penfield Ave,Room 2201, Montreal, PQ H3A 1A4, Canada.	peter.siegel@mcgill.ca						Bandyopadhyay A, 2006, CANCER RES, V66, P6714, DOI 10.1158/0008-5472.CAN-05-3565; Baselga J, 2008, BIOMARKERS, V13, P217, DOI [10.1080/13547500701676019, 10.1080/13547500701676019 ]; Broussau S, 2008, MOL THER, V16, P500, DOI 10.1038/sj.mt.6300383; Coleman RE, 2006, CLIN CANCER RES, V12, p6243S, DOI 10.1158/1078-0432.CCR-06-0931; De Crescenzo G, 2006, J MOL BIOL, V355, P47, DOI 10.1016/j.jmb.2005.10.022; Deckers M, 2006, CANCER RES, V66, P2202, DOI 10.1158/0008-5472.CAN-05-3560; del Re E, 2004, J BIOL CHEM, V279, P22765, DOI 10.1074/jbc.M401350200; Ehata S, 2007, CANCER SCI, V98, P127, DOI 10.1111/j.1349-7006.2006.00357.x; Engle SJ, 1999, CANCER RES, V59, P3379; Geiser AG, 1998, BONE, V23, P87, DOI 10.1016/S8756-3282(98)00078-7; Groppe J, 2008, MOL CELL, V29, P157, DOI 10.1016/j.molcel.2007.11.039; Hering S, 2001, EXP CLIN ENDOCR DIAB, V109, P107, DOI 10.1055/s-2001-14830; Hering S, 2001, EXP CLIN ENDOCR DIAB, V109, P217, DOI 10.1055/s-2001-15109; Hess KR, 2006, CANCER, V106, P1624, DOI 10.1002/cncr.21778; Janssens K, 2005, ENDOCR REV, V26, P743, DOI 10.1210/er.2004-0001; Kakonen SM, 2002, J BIOL CHEM, V277, P24571, DOI 10.1074/jbc.M202561200; Kang YB, 2005, P NATL ACAD SCI USA, V102, P13909, DOI 10.1073/pnas.0506517102; Kang YB, 2003, CANCER CELL, V3, P537, DOI 10.1016/S1535-6108(03)00132-6; Komesli S, 1998, EUR J BIOCHEM, V254, P505, DOI 10.1046/j.1432-1327.1998.2540505.x; Kozlow W, 2005, J MAMMARY GLAND BIOL, V10, P169, DOI 10.1007/s10911-005-5399-8; KULKARNI AB, 1993, P NATL ACAD SCI USA, V90, P770, DOI 10.1073/pnas.90.2.770; Liao JH, 2006, CANCER METAST REV, V25, P559, DOI 10.1007/s10555-006-9033-z; LOPEZCASILLAS F, 1993, CELL, V73, P1435, DOI 10.1016/0092-8674(93)90368-Z; MANOLAGAS SC, 1995, BONE, V17, pS63, DOI 10.1016/8756-3282(95)00180-L; Mastro AM, 2003, CLIN EXP METASTAS, V20, P275, DOI 10.1023/A:1022995403081; Minn AJ, 2005, J CLIN INVEST, V115, P44, DOI 10.1172/JCI200522320; Mourskaia AA, 2007, ANTI-CANCER AGENT ME, V7, P504, DOI 10.2174/187152007781668689; Moustakas A, 2005, J CELL SCI, V118, P3573, DOI 10.1242/jcs.02554; Mundy GR, 2002, NAT REV CANCER, V2, P584, DOI 10.1038/nrc867; Northey JJ, 2008, MOL CELL BIOL, V28, P3162, DOI 10.1128/MCB.01734-07; Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45; Rose AAN, 2006, B CANCER, V93, P931; Schmierer B, 2007, NAT REV MOL CELL BIO, V8, P970, DOI 10.1038/nrm2297; SHULL MM, 1992, NATURE, V359, P693, DOI 10.1038/359693a0; Sotiriou C, 2001, CANCER LETT, V169, P87, DOI 10.1016/S0304-3835(01)00524-9; Tang BW, 1998, NAT MED, V4, P802, DOI 10.1038/nm0798-802; WANG XF, 1991, CELL, V67, P797, DOI 10.1016/0092-8674(91)90074-9; WRANA JL, 1994, NATURE, V370, P341, DOI 10.1038/370341a0; Yin JJ, 1999, J CLIN INVEST, V103, P197, DOI 10.1172/JCI3523; Yoneda T, 2001, J BONE MINER RES, V16, P1486, DOI 10.1359/jbmr.2001.16.8.1486; Yoneda T, 2005, BIOCHEM BIOPH RES CO, V328, P679, DOI 10.1016/j.bbrc.2004.11.070	41	37	39	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 19	2009	28	7					1005	1015		10.1038/onc.2008.454	http://dx.doi.org/10.1038/onc.2008.454			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	408TH	19079339	Green Published			2022-12-28	WOS:000263457400007
J	Hoskins, EE; Morris, TA; Higginbotham, JM; Spardy, N; Cha, E; Kelly, P; Williams, DA; Wikenheiser-Brokamp, KA; Duensing, S; Wells, SI				Hoskins, E. E.; Morris, T. A.; Higginbotham, J. M.; Spardy, N.; Cha, E.; Kelly, P.; Williams, D. A.; Wikenheiser-Brokamp, K. A.; Duensing, S.; Wells, S. I.			Fanconi anemia deficiency stimulates HPV-associated hyperplastic growth in organotypic epithelial raft culture	ONCOGENE			English	Article						Fanconi anemia; human papillomavirus; keratinocyte; organotypic raft culture	GENE-EXPRESSION; DNA; PROTEIN; RADIOSENSITIVITY; IDENTIFICATION; CANCER; SUSCEPTIBILITY; PATHOGENESIS; INSTABILITY; PATHWAY	Fanconi anemia (FA) is a recessive genome instability syndrome characterized by heightened cellular sensitivity to DNA damage, aplastic anemia and cancer susceptibility. Leukemias and squamous cell carcinomas (SCCs) are the most predominant FA-associated cancers, with the latter exhibiting markedly early disease onset and aggressiveness. Although studies of hematopoietic cells derived from FA patients have provided much insight into bone marrow deficiencies and leukemogenesis, molecular transforming events in FA-deficient keratinocytes, which are the cell type of origin for SCC, are poorly understood. We describe here the growth and molecular properties of FANCA-deficient versus FANCA-corrected HPV E6/E7 immortalized keratinocytes in monolayer and organotypic epithelial raft culture. In response to DNA damage, FANCA-deficient patient-derived keratinocyte cultures displayed a G2/M phase arrest, senescence and apoptosis. Organotypic raft cultures exhibited DNA repair-associated defects with more 53BP1 foci and TdT-mediated dNTP nick end labeling-positive cells over their corrected counterparts. Interestingly, together with reduced rates of DNA damage, FA correction resulted in a marked decrease in epithelial thickness and the presence of fewer cell layers. The observed FANCA-mediated suppression of hyperplasia correlated with the detection of fewer cells transiting through the cell cycle in the absence of gross differentiation abnormalities or apoptotic differences. Importantly, the knockdown of either FANCA or FANCD2 in HPV-positive keratinocytes was sufficient for increasing epithelial hyperplasia. Our findings support a new role for FA pathways in the maintenance of differentiation-dependent cell cycle exit, with the implication that FA deficiencies may contribute to the high risk of FA patients for developing HPV-associated SCC.	[Hoskins, E. E.; Morris, T. A.; Higginbotham, J. M.; Wells, S. I.] Univ Cincinnati, Coll Med, Cincinnati Childrens Hosp Med Ctr, Dept Pediat,Div Hematol Oncol, Cincinnati, OH 45229 USA; [Spardy, N.; Cha, E.; Duensing, S.] Univ Pittsburgh, Sch Med, Dept Microbiol & Mol Genet, Pittsburgh, PA USA; [Kelly, P.] Wyeth Pharmaceut, Cambridge, MA USA; [Williams, D. A.] Harvard Univ, Childrens Hosp, Sch Med, Div Hematol Oncol, Boston, MA 02115 USA; [Wikenheiser-Brokamp, K. A.] Univ Cincinnati, Coll Med, Cincinnati Childrens Hosp Med Ctr, Dept Pediat,Div Pathol & Lab Med & Pulm Biol, Cincinnati, OH 45229 USA	Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pfizer; Harvard University; Boston Children's Hospital; Harvard Medical School; Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati	Wells, SI (corresponding author), Univ Cincinnati, Coll Med, Cincinnati Childrens Hosp Med Ctr, Dept Pediat,Div Hematol Oncol, TCHRF Room S7-206,MLC 7013,3333 Burnet Ave, Cincinnati, OH 45229 USA.	susanne.wells@cchmc.org			Public Health Service [CA102357, HL081499]; Translational Research Initiative at CCHMC; Fanconi Anemia Research Fund; NIH/NCI [R01 CA112598]; KAW-B [HL079193]; NATIONAL CANCER INSTITUTE [R01CA112598, R01CA102357] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL081499, R01HL079193] Funding Source: NIH RePORTER	Public Health Service(United States Department of Health & Human ServicesUnited States Public Health Service); Translational Research Initiative at CCHMC; Fanconi Anemia Research Fund; NIH/NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); KAW-B; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	We thank Paul Andreassen, Ruhikanta Meetei, Qishen Pang, James Mulloy, Harmut Geiger, Yi Zheng and Stella Davies for helpful discussions and critical comments on the manuscript. We thank members of the Fanconi Anemia Comprehensive Care Center (FACCC), particularly Lars Wagner, Richard Harris and Robin Mueller for human tissue samples, as well as Susan Radtke for regulatory support. We thank the patients of the FACCC for samples. We are grateful to Denis Lee and Paul Lambert for expert advice on the organotypic raft system, as well as to Maureen Hoatlin for the FANCA and to James Lessard for the monoclonal actin antibody. We thank Christopher Baum for the retroviral SF91 expression vector, and Neeraj Singh for generation of the SF91-18E6/E7 retroviral construct. We thank the flow cytometry core facility and Dan Marmer for assistance with flow sorting. Vector supernatant was provided by the CCHMC Viral Vector Core and Translational Trials Development and Support Lab. This research was supported by Public Health Service Grant CA102357, a grant from the Translational Research Initiative at CCHMC and a grant from the Fanconi Anemia Research Fund to SIW. SD and NS are supported by NIH/NCI R01 CA112598. DAW was supported by Public Health Service Grant HL081499. KAW-B was supported by HL079193.	Alter BP, 2003, CANCER-AM CANCER SOC, V97, P425, DOI 10.1002/cncr.11046; Alter BP, 2002, RADIOTHER ONCOL, V62, P345, DOI 10.1016/S0167-8140(01)00474-1; Bagby GC, 2006, SEMIN HEMATOL, V43, P147, DOI 10.1053/j.seminhematol.2006.04.005; Bremer M, 2003, STRAHLENTHER ONKOL, V179, P748, DOI 10.1007/s00066-003-1099-8; Bridge WL, 2005, NAT GENET, V37, P953, DOI 10.1038/ng1627; Chandra S, 2005, MOL THER, V12, P976, DOI 10.1016/j.ymthe.2005.04.021; de Oca RM, 2005, BLOOD, V105, P1003, DOI 10.1182/blood-2003-11-3997; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; Dorsman JC, 2007, CELL ONCOL, V29, P211; Duensing S, 2004, INT J CANCER, V109, P157, DOI 10.1002/ijc.11691; Garcia-Higuera I, 2001, MOL CELL, V7, P249, DOI 10.1016/S1097-2765(01)00173-3; Guardiola P, 2004, BLOOD, V103, P73, DOI 10.1182/blood-2003-06-2146; Hanenberg H, 2002, EXP HEMATOL, V30, P410, DOI 10.1016/S0301-472X(02)00782-8; Hoskins EE, 2008, ONCOGENE, V27, P4798, DOI 10.1038/onc.2008.121; Howlett NG, 2002, SCIENCE, V297, P606, DOI 10.1126/science.1073834; Huyen Y, 2004, NATURE, V432, P406, DOI 10.1038/nature03114; Kutler DI, 2003, J NATL CANCER I, V95, P1718, DOI 10.1093/jnci/djg091; Kutler DI, 2003, ARCH OTOLARYNGOL, V129, P106, DOI 10.1001/archotol.129.1.106; Kutler DI, 2003, BLOOD, V101, P1249, DOI 10.1182/blood-2002-07-2170; Levitus M, 2005, NAT GENET, V37, P934, DOI 10.1038/ng1625; Longworth MS, 2004, MICROBIOL MOL BIOL R, V68, P362, DOI 10.1128/MMBR.68.2.362-372.2004; Marcou Y, 2001, RADIOTHER ONCOL, V60, P75, DOI 10.1016/S0167-8140(01)00370-X; Mathew CG, 2006, ONCOGENE, V25, P5875, DOI 10.1038/sj.onc.1209878; Meetei AR, 2003, MOL CELL BIOL, V23, P3417, DOI 10.1128/MCB.23.10.3417-3426.2003; Meetei AR, 2005, NAT GENET, V37, P958, DOI 10.1038/ng1626; Meetei AR, 2003, NAT GENET, V35, P165, DOI 10.1038/ng1241; Nakahara T, 2005, J VIROL, V79, P13150, DOI 10.1128/JVI.79.20.13150-13165.2005; Niedernhofer LJ, 2005, CELL, V123, P1191, DOI 10.1016/j.cell.2005.12.009; Pagano G, 2005, EUR J HAEMATOL, V75, P93, DOI 10.1111/j.1600-0609.2005.00507.x; Rahman N, 2007, NAT GENET, V39, P165, DOI 10.1038/ng1959; Reid S, 2007, NAT GENET, V39, P162, DOI 10.1038/ng1947; Schambach A, 2000, MOL THER, V2, P435, DOI 10.1006/mthe.2000.0191; Sims AE, 2007, NAT STRUCT MOL BIOL, V14, P564, DOI 10.1038/nsmb1252; Smogorzewska A, 2007, CELL, V129, P289, DOI 10.1016/j.cell.2007.03.009; Spardy N, 2007, J VIROL, V81, P13265, DOI 10.1128/JVI.01121-07; Tamary H, 2007, PEDIATR HEMAT ONCOL, V24, P87, DOI 10.1080/08880010601123240; Taniguchi T, 2006, BLOOD, V107, P4223, DOI 10.1182/blood-2005-10-4240; Timmers C, 2001, MOL CELL, V7, P241, DOI 10.1016/S1097-2765(01)00172-1; van Zeeburg HJT, 2005, CANCER RES, V65, P1271, DOI 10.1158/0008-5472.CAN-04-3665; van Zeeburg HJT, 2004, JNCI-J NATL CANCER I, V96, P968, DOI 10.1093/jnci/djh178; Wang WD, 2007, NAT REV GENET, V8, P735, DOI 10.1038/nrg2159	41	51	53	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 5	2009	28	5					674	685		10.1038/onc.2008.416	http://dx.doi.org/10.1038/onc.2008.416			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	403IN	19015634	Green Accepted			2022-12-28	WOS:000263076400005
J	Sui, X; Shin, S; Zhang, R; Firozi, PF; Yang, L; Abbruzzese, JL; Reddy, SAG				Sui, X.; Shin, S.; Zhang, R.; Firozi, P. F.; Yang, L.; Abbruzzese, J. L.; Reddy, S. A. G.			Hdm2 is regulated by K-Ras and mediates p53-independent functions in pancreatic cancer cells	ONCOGENE			English	Article						pancreatic cancer; hdm2; K-Ras; c-Jun; cyclin D1; c-Myc	MDM2 SPLICE VARIANTS; NF-KAPPA-B; C-MYC; MESSENGER-RNA; MUTANT P53; DUCTAL ADENOCARCINOMA; INDUCED APOPTOSIS; DOWN-REGULATION; EXPRESSION; ACTIVATION	There is emerging evidence that the oncogenic potential of hdm2 (human and/or murine double minute-2 protein) stems not only from its ability to counteract tumor suppressor p53 but also from its less understood p53-independent functions. Surprisingly, little is known about the role and regulation of hdm2 in pancreatic tumors, a large proportion (50-75%) of which contain mutant p53. In this study, we determined that hdm2 was expressed in a Ras-signaling-dependent manner in various pancreatic cancer cell lines. As p53 was mutated and inactive in these cells, the expression of hdm2 was seemingly redundant. Indeed, the proliferation and survival of cell lines such as Panc-1 and Panc-28 could be inhibited by PRIMA-1 (mutant p53 activator) but not by Nutlin-3 (inhibitor of the hdm2-p53 interaction). Unexpectedly, however, the proliferation of both cell lines was strongly inhibited by hdm2-specific RNAi. Our data also revealed cyclin D1, c-Jun and c-Myc to be novel targets of hdm2 and suggested that they might mediate hdm2's role in cellular proliferation and/or survival. We conclude from our results that hdm2 is expressed in pancreatic cancer cells as a result of activated Ras signaling, and that it regulates cellular proliferation and the expression of three novel target genes by p53-independent mechanisms.	[Reddy, S. A. G.] Univ Texas MD Anderson Canc Ctr, Unit 426, Dept Gastrointestinal Med Oncol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center	Reddy, SAG (corresponding author), Univ Texas MD Anderson Canc Ctr, Unit 426, Dept Gastrointestinal Med Oncol, 1515 Holcombe Blvd, Houston, TX 77030 USA.	sa08366@odin.mdacc.tmc.edu	qiao, zhixin/I-3408-2012		Lustgarten Foundation for Pancreatic Cancer Research (SAGR); Topfer Fund for Pancreatic Cancer Research (SAGR); University Cancer Foundation at The University of Texas M. D. Anderson Cancer Center (SAGR), NCI SPORE [CA101936]; NCI [CA016672]; University of Texas M. D. Anderson Cancer Center; NATIONAL CANCER INSTITUTE [P20CA101936, P30CA016672] Funding Source: NIH RePORTER	Lustgarten Foundation for Pancreatic Cancer Research (SAGR); Topfer Fund for Pancreatic Cancer Research (SAGR); University Cancer Foundation at The University of Texas M. D. Anderson Cancer Center (SAGR), NCI SPORE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); University of Texas M. D. Anderson Cancer Center; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We are grateful to Drs Frank McCormick and Martin McMahon (University of California, San Francisco, CA, USA) for the hdm2 P2 promoter reporter constructs, Johannes Bos (Utrecht University) for the Raf1 GST-RBD plasmid and Gigi Lozano (M. D. Anderson Cancer Center, Houston, TX, USA) for the p53 and pCMV-hdm2 expression vectors. We also thank P. zer (CI-1040), Dr Bryant Darnay (pMX-BGD vector) and Dr F-X Claret (pSRa-c-Jun) for other reagents; Dr Baoan Ji for assistance with the qPCR assays and Beth L Notzon and Angelique L Geehan (M. D. Anderson Cancer Center) for editorial assistance. This work was supported by the Lustgarten Foundation for Pancreatic Cancer Research (SAGR), the Topfer Fund for Pancreatic Cancer Research (SAGR), the University Cancer Foundation at The University of Texas M. D. Anderson Cancer Center (SAGR), NCI SPORE CA101936 in Pancreatic Cancer (JLA) and NCI Grant CA016672 (DNA sequencing and media preparation facilities, The University of Texas M. D. Anderson Cancer Center).	Agrawal S, 2001, INT J ONCOL, V18, P1061; Ambrosini G, 2007, ONCOGENE, V26, P3473, DOI 10.1038/sj.onc.1210136; Asano T, 2004, ONCOGENE, V23, P8571, DOI 10.1038/sj.onc.1207902; Bai JX, 2006, J PHARMACOL EXP THER, V319, P1435, DOI 10.1124/jpet.106.110007; Bartel F, 2002, CANCER CELL, V2, P9, DOI 10.1016/S1535-6108(02)00091-0; Bond GL, 2004, CELL, V119, P591, DOI 10.1016/j.cell.2004.11.022; Brummelkamp TR, 2002, CANCER CELL, V2, P243, DOI 10.1016/S1535-6108(02)00122-8; Brunner TB, 2005, CANCER RES, V65, P8433, DOI 10.1158/0008-5472.CAN-05-0158; Bykov VJN, 2002, NAT MED, V8, P282, DOI 10.1038/nm0302-282; Carroll VA, 2008, CANCER RES, V68, P545, DOI 10.1158/0008-5472.CAN-06-4738; Chipuk JE, 2003, CANCER CELL, V4, P371, DOI 10.1016/S1535-6108(03)00272-1; Daujat S, 2001, TRENDS GENET, V17, P459, DOI 10.1016/S0168-9525(01)02369-1; Deb SP, 2003, MOL CANCER RES, V1, P1009; EBERT M, 1994, INT J ONCOL, V5, P1279; Frazier MW, 1998, MOL CELL BIOL, V18, P3735, DOI 10.1128/MCB.18.7.3735; Freedman DA, 1999, CELL MOL LIFE SCI, V55, P96, DOI 10.1007/s000180050273; Fridman JS, 2003, CANCER RES, V63, P5703; Ganguli G, 2003, MOL CANCER RES, V1, P1027; Harris LC, 2005, CURR CANCER DRUG TAR, V5, P21, DOI 10.2174/1568009053332654; Hezel AF, 2006, GENE DEV, V20, P1218, DOI 10.1101/gad.1415606; Ho JSL, 2005, MOL CELL BIOL, V25, P7423, DOI 10.1128/MCB.25.17.7423-7431.2005; Hong OY, 2000, AM J PATHOL, V157, P1623, DOI 10.1016/S0002-9440(10)64800-6; Iwakuma T, 2003, MOL CANCER RES, V1, P993; Jackson P, 2003, PROSTATE CANCER P D, V6, P174, DOI 10.1038/sj.pcan.4500634; Jones SN, 1998, P NATL ACAD SCI USA, V95, P15608, DOI 10.1073/pnas.95.26.15608; Kang JH, 2005, CELL, V123, P833, DOI 10.1016/j.cell.2005.09.011; Konnikova L, 2005, CANCER RES, V65, P6516, DOI 10.1158/0008-5472.CAN-05-0924; Lamothe B, 2007, J BIOL CHEM, V282, P4102, DOI 10.1074/jbc.M609503200; LaRusch GA, 2007, CANCER RES, V67, P450, DOI 10.1158/0008-5472.CAN-06-2710; Lee SG, 2006, P NATL ACAD SCI USA, V103, P17390, DOI 10.1073/pnas.0608386103; Levav-Cohen Y, 2005, GROWTH FACTORS, V23, P183, DOI 10.1080/08977190500196218; Lundgren K, 1997, GENE DEV, V11, P714, DOI 10.1101/gad.11.6.714; Natsume A, 2005, CANCER RES, V65, P7573, DOI 10.1158/0008-5472.CAN-05-0036; Peng YH, 2001, J BIOL CHEM, V276, P40583, DOI 10.1074/jbc.M102817200; Phelps M, 2005, J BIOL CHEM, V280, P16651, DOI 10.1074/jbc.M412334200; Phelps M, 2003, CANCER RES, V63, P2616; Phillips A, 2006, FEBS LETT, V580, P300, DOI 10.1016/j.febslet.2005.12.026; Prives C, 1999, J PATHOL, V187, P112; Ries S, 2000, CELL, V103, P321, DOI 10.1016/S0092-8674(00)00123-9; Rocha S, 2003, MOL CELL BIOL, V23, P4713, DOI 10.1128/MCB.23.13.4713-4727.2003; Ruggeri BA, 1997, CANCER, V79, P700, DOI 10.1002/(SICI)1097-0142(19970215)79:4<700::AID-CNCR7>3.0.CO;2-H; Schreiber M, 1999, GENE DEV, V13, P607, DOI 10.1101/gad.13.5.607; Shaulian E, 1997, ONCOGENE, V15, P2717, DOI 10.1038/sj.onc.1201453; Shmueli A, 2007, MOL CELL, V25, P794, DOI 10.1016/j.molcel.2007.03.006; Sigalas I, 1996, NAT MED, V2, P912, DOI 10.1038/nm0896-912; Steinman HA, 2004, J BIOL CHEM, V279, P4877, DOI 10.1074/jbc.M305966200; Sun PQ, 1998, SCIENCE, V282, P2270, DOI 10.1126/science.282.5397.2270; Van Triest M, 2001, METHOD ENZYMOL, V333, P343; Vassilev LT, 2004, SCIENCE, V303, P844, DOI 10.1126/science.1092472; Walker SR, 2007, ONCOGENE, V26, P224, DOI 10.1038/sj.onc.1209775; Weis B, 1999, ONCOGENE, V18, P2579, DOI 10.1038/sj.onc.1202602; Zhang Z, 2004, CLIN CANCER RES, V10, P1263, DOI 10.1158/1078-0432.CCR-0245-03; Zhang Z, 2005, ONCOGENE, V24, P7238, DOI 10.1038/sj.onc.1208814	53	18	18	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 5	2009	28	5					709	720		10.1038/onc.2008.423	http://dx.doi.org/10.1038/onc.2008.423			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	403IN	19029954				2022-12-28	WOS:000263076400008
J	Grosjean-Raillard, J; Tailler, M; Ades, L; Perfettini, JL; Fabre, C; Braun, T; De Botton, S; Fenaux, P; Kroemer, G				Grosjean-Raillard, J.; Tailler, M.; Ades, L.; Perfettini, J-L; Fabre, C.; Braun, T.; De Botton, S.; Fenaux, P.; Kroemer, G.			ATM mediates constitutive NF-kappa B activation in high-risk myelodysplastic syndrome and acute myeloid leukemia	ONCOGENE			English	Article						myelodysplastic syndrome; acute myeloid leukemia; ATM; NF-kappa B; IKK	INTERNAL TANDEM DUPLICATION; WORLD-HEALTH-ORGANIZATION; DNA-DAMAGE RESPONSE; THERAPEUTIC TARGET; INHIBITION; APOPTOSIS; CLASSIFICATION; MITOCHONDRIAL; SYSTEM; MUTATIONS	The anti-apoptotic transcription factor nuclear factor-kappa B (NF-kappa B) is constitutively activated in CD34(+) myeloblasts from high-risk myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) patients. Inhibition of NF-kappa B by suppressing the canonical NF-kappa B activation pathway, for instance by knockdown of the three subunits of the inhibitor of NF-kappa B (I kappa B) kinase (IKK) complex (IKK1, IKK2 and NEMO) triggers apoptosis in such cells. Here, we show that an MDS/AML model cell line exhibits a constitutive interaction, within the nucleus, of activated, S1981-phosphorylated ataxia telangiectasia mutated (ATM) with NEMO. Inhibition of ATM with two distinct pharmacological inhibitors suppressed the activating autophosphorylation of ATM, blocked the interaction of ATM and NEMO, delocalized NEMO as well as another putative NF-kappa B activator, PIDD, from the nucleus, abolished the activating phosphorylation of the catalytic proteins of the IKK complex (IKK1/2 on serines 176/180), enhanced the expression of I kappa B alpha and caused the relocalization of NF-kappa B from the nucleus to the cytoplasm, followed by apoptosis. Knockdown of ATM with small-interfering RNAs had a similar effect that could not be enhanced by knockdown of NEMO, PIDD and the p65 NF-kappa B subunit, suggesting that an ATM inhibition/depletion truly induced apoptosis through inhibition of the NF-kappa B system. Pharmacological inhibition of ATM also induced the nucleocytoplasmic relocalization of p65 in malignant myeloblasts purified from patients with high-risk MDS or AML, correlating with the induction of apoptosis. Altogether, these results support the contention that constitutively active ATM accounts for the activation of NF-kappa B in high-risk MDS and AML.	[Grosjean-Raillard, J.; Tailler, M.; Ades, L.; Perfettini, J-L; Fabre, C.; Fenaux, P.; Kroemer, G.] Inst Gustave Roussy, INSERM, U848, F-94805 Villejuif, France; [Grosjean-Raillard, J.; Tailler, M.; Ades, L.; Perfettini, J-L; Fabre, C.; Fenaux, P.; Kroemer, G.] Univ Paris 11, Villejuif, France; [Ades, L.; Braun, T.; Fenaux, P.] Univ Paris 13, AP HP, Hop Avicenne, Serv Hematol Clin, Bobigny, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Gustave Roussy; UDICE-French Research Universities; Universite Paris Saclay; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Avicenne - APHP; Universite Paris 13	Kroemer, G (corresponding author), Inst Gustave Roussy, INSERM, U848, Pavillon Rech 1,39 Rue Camille Desmoulins, F-94805 Villejuif, France.	kroemer@igr.fr	Braun, Thorsten/GRJ-8918-2022; PERFETTINI, Jean-Luc/N-4699-2017; Ades, lionel/T-6882-2019; Kroemer, Guido/AAY-9859-2020; KROEMER, Guido/B-4263-2013	PERFETTINI, Jean-Luc/0000-0002-2427-2604; KROEMER, Guido/0000-0002-9334-4405				Bakkenist CJ, 2004, TRENDS CELL BIOL, V14, P339, DOI 10.1016/j.tcb.2004.05.001; Bartkova J, 2005, CELL CYCLE, V4, P838, DOI 10.4161/cc.4.6.1742; Bartkova J, 2005, NATURE, V434, P864, DOI 10.1038/nature03482; Barzilai A, 2004, DNA REPAIR, V3, P1109, DOI 10.1016/j.dnarep.2004.03.002; Bennett JM, 2000, INT J HEMATOL, V72, P131; BENNETT JM, 1976, BRIT J HAEMATOL, V33, P451, DOI 10.1111/j.1365-2141.1976.tb03563.x; Birkenkamp KU, 2004, LEUKEMIA, V18, P103, DOI 10.1038/sj.leu.2403145; Bonizzi G, 2004, TRENDS IMMUNOL, V25, P280, DOI 10.1016/j.it.2004.03.008; Braun T, 2006, CELL DEATH DIFFER, V13, P748, DOI 10.1038/sj.cdd.4401874; Braun T, 2006, BLOOD, V107, P1156; Campbell KJ, 2004, MOL CELL, V13, P853, DOI 10.1016/S1097-2765(04)00131-5; Carvalho G, 2007, ONCOGENE, V26, P2299, DOI 10.1038/sj.onc.1210043; Castedo M, 2002, J EXP MED, V196, P1121, DOI 10.1084/jem.20021758; Castedo M, 1996, J IMMUNOL, V157, P512; Fabre C, 2007, ONCOGENE, V26, P4071, DOI 10.1038/sj.onc.1210187; Gale RE, 2008, BLOOD, V111, P2776, DOI 10.1182/blood-2007-08-109090; Ghosh S, 2002, CELL, V109, pS81, DOI 10.1016/S0092-8674(02)00703-1; Greenberg P, 1997, BLOOD, V89, P2079, DOI 10.1182/blood.V89.6.2079; Greten FR, 2004, CANCER LETT, V206, P193, DOI 10.1016/j.canlet.2003.08.029; Grosjean-Raillard J, 2008, APOPTOSIS, V13, P1148, DOI 10.1007/s10495-008-0243-4; Guzman ML, 2001, BLOOD, V98, P2301, DOI 10.1182/blood.V98.8.2301; Habraken Y, 2006, BIOCHEM PHARMACOL, V72, P1132, DOI 10.1016/j.bcp.2006.07.015; Halazonetis TD, 2008, SCIENCE, V319, P1352, DOI 10.1126/science.1140735; Hassan Z, 1999, EXP HEMATOL, V27, P1322, DOI 10.1016/S0301-472X(99)00066-1; Hickson I, 2004, CANCER RES, V64, P9152, DOI 10.1158/0008-5472.CAN-04-2727; Huang TT, 2003, CELL, V115, P565, DOI 10.1016/S0092-8674(03)00895-X; Janssens S, 2005, CELL, V123, P1079, DOI 10.1016/j.cell.2005.09.036; Karin M, 2004, NAT REV DRUG DISCOV, V3, P17, DOI 10.1038/nrd1279; Knapper S, 2007, BRIT J HAEMATOL, V138, P687, DOI 10.1111/j.1365-2141.2007.06700.x; Leone G, 2007, HAEMATOLOGICA, V92, P1389, DOI 10.3324/haematol.11034; Li NX, 2001, J BIOL CHEM, V276, P8898, DOI 10.1074/jbc.M009809200; Lin XJ, 2000, MOL PHARMACOL, V58, P1222, DOI 10.1124/mol.58.6.1222; Lin YP, 2000, NAT GENET, V26, P122, DOI 10.1038/79102; Metivier D, 1998, IMMUNOL LETT, V61, P157, DOI 10.1016/S0165-2478(98)00013-3; Mufti Ghulam, 2003, Hematology Am Soc Hematol Educ Program, P176; Rajkumar SV, 2005, J CLIN ONCOL, V23, P630, DOI 10.1200/JCO.2005.11.030; Tinel A, 2004, SCIENCE, V304, P843, DOI 10.1126/science.1095432; Vardiman JW, 2002, BLOOD, V100, P2292, DOI 10.1182/blood-2002-04-1199; Wu ZH, 2006, SCIENCE, V311, P1141, DOI 10.1126/science.1121513; Yanada M, 2005, LEUKEMIA, V19, P1345, DOI 10.1038/sj.leu.2403838; ZAMZAMI N, 2003, METH MOL B, V282, P103	41	54	59	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2009	28	8					1099	1109		10.1038/onc.2008.457	http://dx.doi.org/10.1038/onc.2008.457			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	412KE	19079347				2022-12-28	WOS:000263722900005
J	Parisi, T; Bronson, RT; Lees, JA				Parisi, T.; Bronson, R. T.; Lees, J. A.			Inhibition of pituitary tumors in Rb mutant chimeras through E2f4 loss reveals a key suppressive role for the pRB/E2F pathway in urothelium and ganglionic carcinogenesis	ONCOGENE			English	Article						E2f4; Rb; neuroendocrine tumors; urothelial cancer	CELLULAR PROLIFERATION; FAMILY PROTEINS; G(1) CONTROL; MICE; CANCER; PRB; IMMORTALIZATION; TUMORIGENESIS; CARCINOMA; GENES	The retinoblastoma protein pRB suppresses tumorigenesis largely through regulation of the E2F transcription factors. E2F4, the most abundant E2F protein, is thought to act in cooperation with pRB to restrain cell proliferation. In this study, we analyse how loss of E2f4 affects the tumorigenicity of pRB-deficient tissues. As Rb-/-; E2f4(-/-) germline mice die in utero, we generated Rb-/-; E2f4(-/-) chimeric animals to allow examination of adult tumor phenotypes. We found that loss of E2f4 had a differential effect on known Rb-associated neuroendocrine tumors. It did not affect thyroid and adrenal glands tumors but partially suppressed lung neuroendocrine hyperplasia. The most striking effect was in the pituitary where E2F4 loss delayed the development, and reduced the incidence, of Rb mutant tumors. This tumor suppression increased the longevity of the Rb-/-; E2f4(-/-) chimeric animals allowing us to identify novel tumor types. We observed ganglionic neuroendocrine neoplasms, lesions not associated earlier with mutation of either Rb or E2f4. Moreover, a subset of the Rb-/-; E2f4(-/-) chimeras developed either low- or high-grade carcinomas in the urothelium transitional epithelium supporting a key role for Rb in bladder cancer.	[Parisi, T.; Lees, J. A.] MIT, David H Koch Inst Integrat Canc Res, Dept Biol, Cambridge, MA 02139 USA; [Bronson, R. T.] Tufts Cummings Sch Vet Med, Dept Pathol, North Grafton, MA USA	Massachusetts Institute of Technology (MIT)	Lees, JA (corresponding author), MIT, David H Koch Inst Integrat Canc Res, Dept Biol, 77 Mass Ave,E17-517B, Cambridge, MA 02139 USA.	jalees@mit.edu			NIH [CA121921]; NATIONAL CANCER INSTITUTE [R01CA121921] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We are grateful to the CCR Transgenic Facility, in particular to John M Mkandawire and Peimin Qu, for technical help, and to Alicia Caron in the Histology Facility. We are also thankful to SR Frank and P White for critical reading of the paper and helpful discussion. This project was supported by NIH grants to JAL (CA121921). JAL is a Ludwig Scholar.	CLARKE AR, 1992, NATURE, V359, P328, DOI 10.1038/359328a0; Dannenberg JH, 2000, GENE DEV, V14, P3051, DOI 10.1101/gad.847700; DeGregori J, 1997, P NATL ACAD SCI USA, V94, P7245, DOI 10.1073/pnas.94.14.7245; Dinney CPN, 2004, CANCER CELL, V6, P111, DOI 10.1016/j.ccr.2004.08.002; Du W, 2006, ONCOGENE, V25, P5190, DOI 10.1038/sj.onc.1209651; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; FRIEDRICH G, 1991, GENE DEV, V5, P1513, DOI 10.1101/gad.5.9.1513; Gaubatz S, 2001, MOL CELL BIOL, V21, P1384, DOI 10.1128/MCB.21.4.1384-1392.2001; Gaubatz S, 2000, MOL CELL, V6, P729, DOI 10.1016/S1097-2765(00)00071-X; Harbour JW, 2000, GENE DEV, V14, P2393, DOI 10.1101/gad.813200; Huber K, 2006, DEV BIOL, V298, P335, DOI 10.1016/j.ydbio.2006.07.010; Humbert PO, 2000, GENE DEV, V14, P690; Humbert PO, 2000, MOL CELL, V6, P281, DOI 10.1016/S1097-2765(00)00029-0; JACKS T, 1992, NATURE, V359, P295, DOI 10.1038/359295a0; Lee EY, 2002, CANCER CELL, V2, P463, DOI 10.1016/S1535-6108(02)00207-6; Meuwissen R, 2003, CANCER CELL, V4, P181, DOI 10.1016/S1535-6108(03)00220-4; Moberg K, 1996, MOL CELL BIOL, V16, P1436; Parisi T, 2007, MOL CELL BIOL, V27, P2283, DOI 10.1128/MCB.01854-06; Rayman JB, 2002, GENE DEV, V16, P933, DOI 10.1101/gad.969202; Rempel RE, 2000, MOL CELL, V6, P293, DOI 10.1016/S1097-2765(00)00030-7; Ren B, 2002, GENE DEV, V16, P245, DOI 10.1101/gad.949802; Sage J, 2000, GENE DEV, V14, P3037, DOI 10.1101/gad.843200; Schulz WA, 2006, INT J CANCER, V119, P1513, DOI 10.1002/ijc.21852; Trimarchi JM, 2002, NAT REV MOL CELL BIO, V3, P11, DOI 10.1038/nrm714; Verona R, 1997, MOL CELL BIOL, V17, P7268, DOI 10.1128/MCB.17.12.7268; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; Wikenheiser-Brokamp KA, 2006, CELL MOL LIFE SCI, V63, P767, DOI 10.1007/s00018-005-5487-3; WILLIAMS BO, 1994, EMBO J, V13, P4251, DOI 10.1002/j.1460-2075.1994.tb06745.x; Wu LZ, 2001, NATURE, V414, P457, DOI 10.1038/35106593; Wu XR, 2005, NAT REV CANCER, V5, P713, DOI 10.1038/nrc1697; Zhang ZT, 1999, CANCER RES, V59, P3512; Ziebold U, 2003, MOL CELL BIOL, V23, P6542, DOI 10.1128/MCB.23.18.6542-6552.2003	32	13	13	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 29	2009	28	4					500	508		10.1038/onc.2008.406	http://dx.doi.org/10.1038/onc.2008.406			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	400KM	18997819	Green Accepted			2022-12-28	WOS:000262866500004
J	Neganova, I; Zhang, X; Atkinson, S; Lako, M				Neganova, I.; Zhang, X.; Atkinson, S.; Lako, M.			Expression and functional analysis of G1 to S regulatory components reveals an important role for CDK2 in cell cycle regulation in human embryonic stem cells	ONCOGENE			English	Article						human embryonic stem cell; cell cycle regulation; G1/S transition; CDK2; CYCLIN D1; CYCLIN D2	ES CELLS; DIFFERENTIATION; DERIVATION; ESTABLISHMENT; BLASTOCYSTS; INHIBITION; FEATURES; CULTURE; PHASE; LINES	One of the characteristic features of human embryonic stem cells (hESCs) is the competence for self-renewal and pluripotency. To date, little is known about cell cycle regulation in these cells and how the cell cycle machinery influences hESCs properties. A common feature of human, murine and primate ESCs is the presence of a short G1 phase, which has been viewed as a time window during which stem cells are exposed to differentiation signals. We used the hESCs differentiation model and comparisons to human embryonic carcinoma (EC) cells to study the key regulators of G1 to S transition in hESCs. Our studies show that hESCs express all G1-specific CYCLINs (D1, D2, D3 and E) and cyclin-dependent kinases (CDK) (CDK2, CDK4 and CDK6) at variable levels. In contrast to murine ESCs, most of the cell cycle regulators in hESCs show cell cycle-dependent expression, thus revealing important differences in the expression of cell cycle regulatory components between these two embryonic cell types. Knockdown of CDK2 using RNA interference resulted in hESCs arrest at G1 phase of the cell cycle and differentiation to extraembryonic lineages. This suggests an important role for CDK2 in cell cycle regulation in hESCs that are likely to bear significant impacts on the maintenance of their pluripotent phenotype.	[Neganova, I.; Zhang, X.; Atkinson, S.; Lako, M.] Newcastle Univ, NE Inst Stem Cell Res, Int Ctr Life, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England; [Neganova, I.; Zhang, X.; Atkinson, S.; Lako, M.] Newcastle Univ, Inst Human Genet, Int Ctr Life, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England	Newcastle University - UK; Newcastle University - UK	Lako, M (corresponding author), Newcastle Univ, NE Inst Stem Cell Res, Int Ctr Life, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England.	majlinda.Lako@ncl.ac.uk	Lako, Majlinda/B-6297-2013	lako, majlinda/0000-0003-1327-8573; Atkinson, Stuart P./0000-0002-8218-3730	BBSRC [BBS/B/14779]; Newcastle University; MRC [G0301182]; BBSRC [BB/E012841/1] Funding Source: UKRI; Biotechnology and Biological Sciences Research Council [BBS/B/14779, BB/E012841/1] Funding Source: researchfish; Medical Research Council [G0301182] Funding Source: researchfish	BBSRC(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); Newcastle University; MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); BBSRC(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)	We are grateful to Mr I Dimmick and Dr R Stewart for help with the. ow cytometry analysis, Dr A Hampl for useful discussions, A Khnykina for help with. gure preparation, Dr S Pryzborski for providing the EC cells, and Mr G Anyfantis and Mr D Kirk for technical assistance. This study was supported by BBSRC Grant no. BBS/B/14779, MRC Grant G0301182 and Newcastle University.	Andrews PW, 2005, BIOCHEM SOC T, V33, P1526, DOI 10.1042/BST0331526; Armstrong L, 2006, HUM MOL GENET, V15, P1894, DOI 10.1093/hmg/ddl112; Becker KA, 2006, J CELL PHYSIOL, V209, P883, DOI 10.1002/jcp.20776; Becker KA, 2007, J CELL PHYSIOL, V210, P517, DOI 10.1002/jcp.20903; BLOMEN V, 2007, CELL MOL LIFE SCI, V24, P1789; Boyer LA, 2005, CELL, V122, P947, DOI 10.1016/j.cell.2005.08.020; Brons IGM, 2007, NATURE, V448, P191, DOI 10.1038/nature05950; Calegari F, 2003, J CELL SCI, V116, P4947, DOI 10.1242/jcs.00825; Calegari F, 2005, J NEUROSCI, V25, P6533, DOI 10.1523/JNEUROSCI.0778-05.2005; Carpenter MK, 2003, CLONING STEM CELLS, V5, P79, DOI 10.1089/153623003321512193; Enver T, 2005, HUM MOL GENET, V14, P3129, DOI 10.1093/hmg/ddi345; Faast R, 2004, ONCOGENE, V23, P491, DOI 10.1038/sj.onc.1207133; Fluckiger AC, 2006, STEM CELLS, V24, P547, DOI 10.1634/stemcells.2005-0194; Ghule PN, 2007, J CELL PHYSIOL, V213, P9, DOI 10.1002/jcp.21119; Neganova I, 2008, J ANAT, V213, P30, DOI 10.1111/j.1469-7580.2008.00931.x; Pera MF, 2004, DEVELOPMENT, V131, P5515, DOI 10.1242/dev.01451; Savatier P, 2004, HDB STEM CELL ELSEVI, P53; Stead E, 2002, ONCOGENE, V21, P8320, DOI 10.1038/sj.onc.1206015; Stojkovic M, 2004, REPRODUCTION, V128, P259, DOI 10.1530/rep.1.00243; Stojkovic M, 2004, STEM CELLS, V22, P790, DOI 10.1634/stemcells.22-5-790; Tesar PJ, 2007, NATURE, V448, P196, DOI 10.1038/nature05972; Thomson JA, 1998, SCIENCE, V282, P1145, DOI 10.1126/science.282.5391.1145; WANG N, 1980, CANCER RES, V40, P796; White J, 2005, MOL BIOL CELL, V16, P2018, DOI 10.1091/mbc.e04-12-1056; Zaehres H, 2005, STEM CELLS, V23, P299, DOI 10.1634/stemcells.2004-0252	25	132	138	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 8	2009	28	1					20	30		10.1038/onc.2008.358	http://dx.doi.org/10.1038/onc.2008.358			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	392HP	18806832				2022-12-28	WOS:000262294100003
J	van Gorp, AGM; Vos, KED; Brenkman, AB; Bremer, A; van den Broek, N; Zwartkruis, F; Hershey, JW; Burgering, BMT; Calkhoven, CF; Coffer, PJ				van Gorp, A. G. M.; van der Vos, K. E.; Brenkman, A. B.; Bremer, A.; van den Broek, N.; Zwartkruis, F.; Hershey, J. W.; Burgering, B. M. T.; Calkhoven, C. F.; Coffer, P. J.			AGC kinases regulate phosphorylation and activation of eukaryotic translation initiation factor 4B	ONCOGENE			English	Article						eIF4B; mTOR; MEK; PKB; translation	MESSENGER-RNA TRANSLATION; HELICASE ACTIVITY; MTOR; CANCER; EIF4B; AKT; RECRUITMENT; DEFICIENCY; RAPAMYCIN; PEPTIDE	Eukaryotic translation initiation factor 4B (eIF4B) plays a critical role during the initiation of protein synthesis and its activity can be regulated by multiple phosphorylation events. In a search for novel protein kinase B (PKB/c-akt) substrates, we identified eIF4B as a potential target. Using an in vitro kinase assay, we found that PKB can directly phosphorylate eIF4B on serine 422 (ser422). Activation of a conditional PKB mutant, interleukin-3 (IL-3) or insulin stimulation resulted in PKB-dependent phosphorylation of this residue in vivo. This was prevented by pretreatment of cells with the phosphatidylinositol 3-kinase (PI3K) inhibitor LY294002 or pharmacological inhibition of PKB. Pretreatment of cells with rapamycin, inhibiting mTOR or U0126 to inhibit MEK, had little effect on eIF4B ser422 phosphorylation. In contrast, following amino-acid refeeding, eIF4B ser422 phosphorylation was found to be mammalian target of rapamycin (mTOR)-dependent. We further identified eIF4B ser406 as a novel mitogen-regulated phosphorylation site. Insulin-induced phosphorylation of eIF4B ser406 was dependent on both MEK and mTOR activity. Utilizing a novel translational control luciferase assay, we could further demonstrate that phosphorylation of ser406 or ser422 is essential for optimal translational activity of eIF4B. These data provide novel insights into complex multikinase regulation of eIF4B phosphorylation and reveal an important mechanism by which PKB can regulate translation, potentially critical for the transforming capacity of this AGC kinase family member.	[van Gorp, A. G. M.; van der Vos, K. E.; Coffer, P. J.] Univ Med Ctr Utrecht, Mol Immunol Lab, Dept Immunol, Utrecht, Netherlands; [Brenkman, A. B.; van den Broek, N.] Univ Med Ctr Utrecht, Dept Endocrinol & Metab Dis, Utrecht, Netherlands; [Bremer, A.; Calkhoven, C. F.] Fritz Lipmann Inst, Leibniz Inst Age Res, Jena, Germany; [Zwartkruis, F.; Burgering, B. M. T.] Univ Med Ctr Utrecht, Dept Physiol Chem, Ctr Biomed Genet, Utrecht, Netherlands; [Hershey, J. W.] Univ Calif Davis, Dept Biol Chem, Sch Med, Davis, CA 95616 USA; [Coffer, P. J.] Univ Med Ctr Utrecht, Dept Pediat Immunol, Utrecht, Netherlands	Utrecht University; Utrecht University Medical Center; Utrecht University; Utrecht University Medical Center; Leibniz Institut fur Alternsforschung - Fritz-Lipmann-Institut (FLI); Utrecht University; Utrecht University Medical Center; University of California System; University of California Davis; Utrecht University; Utrecht University Medical Center	Coffer, PJ (corresponding author), Univ Med Ctr, Mol Immunol Lab, Dept Immunol KC 020852, Lundlaan 6, NL-3584 CA Utrecht, Netherlands.	P.J.Coffer@umcutrecht.nl	Coffer, Paul/AAF-7970-2020; Coffer, Paul J/A-5769-2009	Calkhoven, Cornelis/0000-0001-6318-7210	Dutch Scientific Organization [917.36.316]	Dutch Scientific Organization(Netherlands Organization for Scientific Research (NWO))	AGM van Gorp and KE van der Vos were supported by a grant from the Dutch Scientific Organization (NWO; ZonMw 917.36.316).	BURGERING BMT, 1991, EMBO J, V10, P1103, DOI 10.1002/j.1460-2075.1991.tb08050.x; Calkhoven CF, 2000, GENE DEV, V14, P1920; Dijkers PF, 2002, J CELL BIOL, V156, P531, DOI 10.1083/jcb.200108084; DUNCAN R, 1985, J BIOL CHEM, V260, P5493; DUNCAN R, 1984, J BIOL CHEM, V259, P1882; GANI R, 1976, EXP CELL RES, V97, P249, DOI 10.1016/0014-4827(76)90614-5; Garofalo RS, 2003, J CLIN INVEST, V112, P197, DOI 10.1172/JCI200316885; Gingras AC, 1999, ANNU REV BIOCHEM, V68, P913, DOI 10.1146/annurev.biochem.68.1.913; Guertin DA, 2005, TRENDS MOL MED, V11, P353, DOI 10.1016/j.molmed.2005.06.007; Hershey JWB, 2000, COLD SPRING HARBOR M, V39, P33; Holland EC, 2004, ONCOGENE, V23, P3138, DOI 10.1038/sj.onc.1207590; Holz MK, 2005, CELL, V123, P569, DOI 10.1016/j.cell.2005.10.024; Inoki K, 2002, NAT CELL BIOL, V4, P648, DOI 10.1038/ncb839; Larsen MR, 2005, MOL CELL PROTEOMICS, V4, P873, DOI 10.1074/mcp.T500007-MCP200; LAWSON TG, 1989, BIOCHEMISTRY-US, V28, P4729, DOI 10.1021/bi00437a033; LODISH HF, 1976, ANNU REV BIOCHEM, V45, P39, DOI 10.1146/annurev.bi.45.070176.000351; Luo J, 2003, CANCER CELL, V4, P257, DOI 10.1016/S1535-6108(03)00248-4; Mamane Y, 2006, ONCOGENE, V25, P6416, DOI 10.1038/sj.onc.1209888; METHOT N, 1994, MOL CELL BIOL, V14, P2307, DOI 10.1128/MCB.14.4.2307; Methot N, 1996, MOL CELL BIOL, V16, P5328; Methot N, 1996, RNA, V2, P38; NARANDA T, 1994, J BIOL CHEM, V269, P14465; Nave BT, 1999, BIOCHEM J, V344, P427, DOI 10.1042/0264-6021:3440427; Nobukuni T, 2005, P NATL ACAD SCI USA, V102, P14238, DOI 10.1073/pnas.0506925102; Obata T, 2000, J BIOL CHEM, V275, P36108, DOI 10.1074/jbc.M005497200; Obenauer JC, 2003, NUCLEIC ACIDS RES, V31, P3635, DOI 10.1093/nar/gkg584; Pandolfi PP, 2004, ONCOGENE, V23, P3134, DOI 10.1038/sj.onc.1207618; Parker PJ, 2001, BIOCHEM SOC T, V29, P860, DOI 10.1042/0300-5127:0290860; Rajasekhar VK, 2003, MOL CELL, V12, P889, DOI 10.1016/S1097-2765(03)00395-2; Raught B, 2000, COLD SPRING HARBOR M, V39, P245; Raught B, 2004, EMBO J, V23, P1761, DOI 10.1038/sj.emboj.7600193; Richter JD, 2005, NATURE, V433, P477, DOI 10.1038/nature03205; Rogers GW, 2001, J BIOL CHEM, V276, P30914, DOI 10.1074/jbc.M100157200; ROZEN F, 1990, MOL CELL BIOL, V10, P1134, DOI 10.1128/MCB.10.3.1134; Ruggero D, 2004, NAT MED, V10, P484, DOI 10.1038/nm1042; Ruggero D, 2003, NAT REV CANCER, V3, P179, DOI 10.1038/nrc1015; Sarbassov DD, 2006, MOL CELL, V22, P159, DOI 10.1016/j.molcel.2006.03.029; Sarbassov DD, 2005, SCIENCE, V307, P1098, DOI 10.1126/science.1106148; Shahbazian D, 2006, EMBO J, V25, P2781, DOI 10.1038/sj.emboj.7601166; van Gorp AGM, 2006, CANCER RES, V66, P10760, DOI 10.1158/0008-5472.CAN-06-1111; Wiesenthal V, 2006, NUCLEIC ACIDS RES, V34, DOI 10.1093/nar/gnj029; Zhang H, 2002, J BIOL CHEM, V277, P39379, DOI 10.1074/jbc.M206399200	42	61	62	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 8	2009	28	1					95	106		10.1038/onc.2008.367	http://dx.doi.org/10.1038/onc.2008.367			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	392HP	18836482				2022-12-28	WOS:000262294100010
J	Etienne-Manneville, S				Etienne-Manneville, S.			Polarity proteins in migration and invasion	ONCOGENE			English	Review						Par proteins; epithelial mesenchymal transition (EMT); Rho GTPases; Wnt; Scribble	TUMOR-SUPPRESSOR PROTEIN; EPITHELIAL-MESENCHYMAL TRANSITION; SIGNAL-TRANSDUCTION PATHWAYS; ADENOMATOUS POLYPOSIS-COLI; CELL-SHAPE CHANGE; KINASE-C-ZETA; TIGHT JUNCTION; DISCS-LARGE; NEURONAL POLARITY; E-CADHERIN	Cancer is the result of the deregulation of cell proliferation and cell migration. In advanced tumors, cells invade the surrounding tissue and eventually form metastases. This is particularly evident in carcinomas in which epithelial cells have undergone epithelial-mesenchymal transition. Increased cell migration often correlates with a weakening of intercellular interactions. Junctions between neighboring epithelial cells are required to establish and maintain baso-apical polarity, suggesting that not only loss of cell-cell adhesion but also alteration of cell polarity is involved during invasion. Accordingly, perturbation of cell polarity is an important hallmark of advanced invasive tumors. Cell polarity is also essential for cell migration. Indeed, a front-rear polarity axis has first to be generated to allow a cell to migrate. Because cells migrate during invasion, cell polarity is not completely lost. Instead, polarity is modified. From a nonmigrating baso-apically polarized epithelial phenotype, cells acquire a polarized migrating mesenchymal phenotype. The aim of this review is to highlight the molecular relationship between the control of cell polarity and the regulation of cell motility during oncogenesis.	[Etienne-Manneville, S.] Inst Pasteur, Cell Polar & Migrat Grp, F-74724 Paris 15, France; [Etienne-Manneville, S.] CNRS, URA 2582, F-74724 Paris 15, France	Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Centre National de la Recherche Scientifique (CNRS)	Etienne-Manneville, S (corresponding author), Inst Pasteur, Cell Polar & Migrat Grp, 25 Rue Dr Roux, F-74724 Paris 15, France.	sandrine.etienne-manneville@pasteur.fr	Etienne-Manneville, Sandrine/C-5879-2015	Etienne-Manneville, Sandrine/0000-0001-6651-3675	l'Agence Nationale pour la Recherche; la Fondation de France; La Ligue contre le Cancer et l'Association pour la Recherche sur le Cancer; la Fondation Schlumberger pour l'Enseignement et la Recherche; EMBO Young Investigator Program	l'Agence Nationale pour la Recherche(French National Research Agency (ANR)); la Fondation de France(Fondation de France); La Ligue contre le Cancer et l'Association pour la Recherche sur le Cancer; la Fondation Schlumberger pour l'Enseignement et la Recherche; EMBO Young Investigator Program(European Molecular Biology Organization (EMBO))	We apologize for those authors whose work was not cited directly owing to space limitation. This work was supported by grants from the l'Agence Nationale pour la Recherche, la Fondation de France, La Ligue contre le Cancer et l'Association pour la Recherche sur le Cancer, la Fondation Schlumberger pour l'Enseignement et la Recherche, the EMBO Young Investigator Program.	Abdelilah-Seyfried S, 2003, DEVELOPMENT, V130, P1927, DOI 10.1242/dev.00420; Alessi DR, 2006, ANNU REV BIOCHEM, V75, P137, DOI 10.1146/annurev.biochem.75.103004.142702; Allen WE, 1998, J CELL BIOL, V141, P1147, DOI 10.1083/jcb.141.5.1147; Aranda V, 2008, ONCOGENE, V27, P6878, DOI 10.1038/onc.2008.340; Arquier N, 2001, DEVELOPMENT, V128, P2209; Assemat E, 2008, BBA-BIOMEMBRANES, V1778, P614, DOI 10.1016/j.bbamem.2007.08.029; Baas AF, 2004, CELL, V116, P457, DOI 10.1016/S0092-8674(04)00114-X; Barnes AP, 2007, CELL, V129, P549, DOI 10.1016/j.cell.2007.03.025; Barth AIM, 2008, SEMIN CELL DEV BIOL, V19, P245, DOI 10.1016/j.semcdb.2008.02.003; Bhowmick NA, 2001, MOL BIOL CELL, V12, P27, DOI 10.1091/mbc.12.1.27; Bilder D, 2003, NAT CELL BIOL, V5, P53, DOI 10.1038/ncb897; Bilder D, 2000, SCIENCE, V289, P113, DOI 10.1126/science.289.5476.113; Cau JL, 2005, J CELL SCI, V118, P2579, DOI 10.1242/jcs.02385; Cavallaro U, 2004, ANN NY ACAD SCI, V1014, P58, DOI 10.1196/annals.1294.006; Cavatorta AL, 2004, INT J CANCER, V111, P373, DOI 10.1002/ijc.20275; Charest PG, 2007, BIOCHEM J, V401, P377, DOI 10.1042/BJ20061432; Chen XY, 2005, NAT CELL BIOL, V7, P262, DOI 10.1038/ncb1226; Cohen EEW, 2006, CANCER RES, V66, P6296, DOI 10.1158/0008-5472.CAN-05-3139; Dhillon AS, 2007, ONCOGENE, V26, P3279, DOI 10.1038/sj.onc.1210421; DOW L, 2008, ONCOGENE; Dow LE, 2007, ONCOGENE, V26, P2272, DOI 10.1038/sj.onc.1210016; Dow LE, 2007, INT REV CYTOL, V262, P253, DOI 10.1016/S0074-7696(07)62006-3; Eder AM, 2005, P NATL ACAD SCI USA, V102, P12519, DOI 10.1073/pnas.0505641102; Etienne-Manneville S, 2005, J CELL BIOL, V170, P895, DOI 10.1083/jcb.200412172; Etienne-Manneville S, 2004, J CELL SCI, V117, P1291, DOI 10.1242/jcs.01115; Etienne-Manneville S, 2004, TRAFFIC, V5, P470, DOI 10.1111/j.1600-0854.2004.00196.x; Etienne-Manneville S, 2003, NATURE, V421, P753, DOI 10.1038/nature01423; Etienne-Manneville S, 2001, CELL, V106, P489, DOI 10.1016/S0092-8674(01)00471-8; Etienne-Manneville S, 2002, NATURE, V420, P629, DOI 10.1038/nature01148; Forcet C, 2005, HUM MOL GENET, V14, P1283, DOI 10.1093/hmg/ddi139; Friedl P, 2004, CURR OPIN CELL BIOL, V16, P14, DOI 10.1016/j.ceb.2003.11.001; Friedl P, 2003, NAT REV CANCER, V3, P362, DOI 10.1038/nrc1075; Gardiol D, 2006, INT J CANCER, V119, P1285, DOI 10.1002/ijc.21982; Goldstein B, 2007, DEV CELL, V13, P609, DOI 10.1016/j.devcel.2007.10.007; Gomes ER, 2005, CELL, V121, P451, DOI 10.1016/j.cell.2005.02.022; Goode S, 1997, GENE DEV, V11, P2532, DOI 10.1101/gad.11.19.2532; Guarino M, 2007, INT J BIOCHEM CELL B, V39, P2153, DOI 10.1016/j.biocel.2007.07.011; Helfrich I, 2007, J INVEST DERMATOL, V127, P782, DOI 10.1038/sj.jid.5700621; Hemminki A, 1999, CELL MOL LIFE SCI, V55, P735, DOI 10.1007/s000180050329; Hirohashi S, 1998, AM J PATHOL, V153, P333, DOI 10.1016/S0002-9440(10)65575-7; Huang H, 2008, CURR OPIN CELL BIOL, V20, P119, DOI 10.1016/j.ceb.2008.01.009; Humbert PO, 2008, ONCOGENE, V27, P6888, DOI 10.1038/onc.2008.341; Humbert PO, 2006, TRENDS CELL BIOL, V16, P622, DOI 10.1016/j.tcb.2006.10.005; Hurd TW, 2003, NAT CELL BIOL, V5, P137, DOI 10.1038/ncb923; Itoh M, 2001, J CELL BIOL, V154, P491, DOI 10.1083/jcb.200103047; Izumi Y, 1998, J CELL BIOL, V143, P95, DOI 10.1083/jcb.143.1.95; Jeanes A, 2008, ONCOGENE, V27, P6920, DOI 10.1038/onc.2008.343; Joberty G, 2000, NAT CELL BIOL, V2, P531, DOI 10.1038/35019573; Johansson AS, 2000, J CELL SCI, V113, P3267; Kaelin WG, 2005, COLD SH Q B, V70, P159, DOI 10.1101/sqb.2005.70.001; Katajisto P, 2007, BBA-REV CANCER, V1775, P63, DOI 10.1016/j.bbcan.2006.08.003; KEMPHUES KJ, 1988, CELL, V52, P311, DOI 10.1016/S0092-8674(88)80024-2; Kikuchi A, 2008, CANCER SCI, V99, P202, DOI 10.1111/j.1349-7006.2007.00675.x; KNUST E, 1993, DEVELOPMENT, P261; Kolsch V, 2008, J CELL SCI, V121, P551, DOI 10.1242/jcs.023333; Kopfstein L, 2006, CELL MOL LIFE SCI, V63, P449, DOI 10.1007/s00018-005-5296-8; Koster MI, 2007, ANNU REV CELL DEV BI, V23, P93, DOI 10.1146/annurev.cellbio.23.090506.123357; Kuphal S, 2006, ONCOGENE, V25, P103, DOI 10.1038/sj.onc.1209008; Kuribayashi K, 2007, J CELL BIOL, V176, P1049, DOI 10.1083/jcb.200607019; Lee MH, 2008, J CELL SCI, V121, P1141, DOI 10.1242/jcs.016634; Lemmers C, 2004, MOL BIOL CELL, V15, P1324, DOI 10.1091/mbc.E03-04-0235; Levy L, 2006, CYTOKINE GROWTH F R, V17, P41, DOI 10.1016/j.cytogfr.2005.09.009; Lin D, 2000, NAT CELL BIOL, V2, P540, DOI 10.1038/35019582; Logan CY, 2004, ANNU REV CELL DEV BI, V20, P781, DOI 10.1146/annurev.cellbio.20.010403.113126; Malliri A, 2002, NATURE, V417, P867, DOI 10.1038/nature00848; Manfruelli P, 1996, DEVELOPMENT, V122, P2283; Martin-Belmonte F, 2007, CELL, V128, P383, DOI 10.1016/j.cell.2006.11.051; Mehenni H, 2005, HUM MOL GENET, V14, P2209, DOI 10.1093/hmg/ddi225; Merlot S, 2003, J CELL SCI, V116, P3471, DOI 10.1242/jcs.00703; Mertens AEE, 2006, TRENDS CELL BIOL, V16, P308, DOI 10.1016/j.tcb.2006.04.001; Murdoch JN, 2003, HUM MOL GENET, V12, P87, DOI 10.1093/hmg/ddg014; Nakagawa S, 2004, BRIT J CANCER, V90, P194, DOI 10.1038/sj.bjc.6601465; Nishimura T, 2004, NAT CELL BIOL, V6, P328, DOI 10.1038/ncb1118; Okuda H, 2001, J BIOL CHEM, V276, P43611, DOI 10.1074/jbc.M107880200; Osmani N, 2006, CURR BIOL, V16, P2395, DOI 10.1016/j.cub.2006.10.026; Ossipova O, 2005, DEV CELL, V8, P829, DOI 10.1016/j.devcel.2005.04.011; Ossipova O, 2003, NAT CELL BIOL, V5, P889, DOI 10.1038/ncb1048; Ozdamar B, 2005, SCIENCE, V307, P1603, DOI 10.1126/science.1105718; Pagliarini RA, 2003, SCIENCE, V302, P1227, DOI 10.1126/science.1088474; Pegtel DM, 2007, CURR BIOL, V17, P1623, DOI 10.1016/j.cub.2007.08.035; Perl AK, 1998, NATURE, V392, P190, DOI 10.1038/32433; Pinheiro EM, 2004, DEVELOPMENT, V131, P5243, DOI 10.1242/dev.01412; Plant PJ, 2003, NAT CELL BIOL, V5, P301, DOI 10.1038/ncb948; Potten CS, 1997, INT J EXP PATHOL, V78, P219, DOI 10.1046/j.1365-2613.1997.280362.x; Qin Y, 2005, J CELL BIOL, V171, P1061, DOI 10.1083/jcb.200506094; Regala RP, 2005, CANCER RES, V65, P8905, DOI 10.1158/0008-5472.CAN-05-2372; Ridley AJ, 2003, SCIENCE, V302, P1704, DOI 10.1126/science.1092053; Sahai E, 2005, CURR OPIN GENET DEV, V15, P87, DOI 10.1016/j.gde.2004.12.002; Sander EE, 1998, J CELL BIOL, V143, P1385, DOI 10.1083/jcb.143.5.1385; Schermer B, 2006, J CELL BIOL, V175, P547, DOI 10.1083/jcb.200605092; Schimanski CC, 2005, ONCOGENE, V24, P3100, DOI 10.1038/sj.onc.1208520; Schlessinger K, 2007, J CELL BIOL, V178, P355, DOI 10.1083/jcb.200701083; Segditsas S, 2006, ONCOGENE, V25, P7531, DOI 10.1038/sj.onc.1210059; Shelly M, 2007, CELL, V129, P565, DOI 10.1016/j.cell.2007.04.012; Shi SH, 2003, CELL, V112, P63, DOI 10.1016/S0092-8674(02)01249-7; Shi SH, 2004, CURR BIOL, V14, P2025, DOI 10.1016/j.cub.2004.11.009; Shin K, 2007, EMBO REP, V8, P158, DOI 10.1038/sj.embor.7400890; Siegrist SE, 2007, GENE DEV, V21, P483, DOI 10.1101/gad.1511207; Stern CD, 2006, CURR OPIN GENET DEV, V16, P413, DOI 10.1016/j.gde.2006.06.005; Sun RH, 2005, CANCER RES, V65, P1433, DOI 10.1158/0008-5472.CAN-04-1163; Sun TQ, 2001, NAT CELL BIOL, V3, P628, DOI 10.1038/35083016; Tanentzapf G, 2003, NAT CELL BIOL, V5, P46, DOI 10.1038/ncb896; Tapon N, 2003, CANCER CELL, V4, P333, DOI 10.1016/S1535-6108(03)00279-4; TEPASS U, 1990, CELL, V61, P787, DOI 10.1016/0092-8674(90)90189-L; Thiery JP, 2005, DEV CELL, V8, P456, DOI 10.1016/j.devcel.2005.03.002; Thomas M, 2005, ONCOGENE, V24, P6222, DOI 10.1038/sj.onc.1208757; Thomas M, 2008, ONCOGENE, V27, P7018, DOI 10.1038/onc.2008.351; von Stein W, 2005, DEVELOPMENT, V132, P1675, DOI 10.1242/dev.01720; Wada H, 2005, DEVELOPMENT, V132, P2273, DOI 10.1242/dev.01810; Wang HR, 2003, SCIENCE, V302, P1775, DOI 10.1126/science.1090772; Wang Q, 2007, KIDNEY INT, V72, P1448, DOI 10.1038/sj.ki.5002579; Wang Q, 2004, J BIOL CHEM, V279, P30715, DOI 10.1074/jbc.M401930200; Wodarz A, 2007, NAT CELL BIOL, V9, P1016, DOI 10.1038/ncb433; Woodhouse E, 1998, DEV GENES EVOL, V207, P542, DOI 10.1007/s004270050145; Yamanaka T, 2003, CURR BIOL, V13, P734, DOI 10.1016/S0960-9822(03)00244-6; Yamanaka T, 2006, J CELL SCI, V119, P2107, DOI 10.1242/jcs.02938; Zarbalis K, 2004, PLOS BIOL, V2, P1177, DOI 10.1371/journal.pbio.0020219; Zhang L, 2006, CANCER RES, V66, P4627, DOI 10.1158/0008-5472.CAN-05-4527; Zhang SM, 2008, CANCER RES, V68, P740, DOI 10.1158/0008-5472.CAN-07-2989; Zhang X, 2007, NAT CELL BIOL, V9, P743, DOI 10.1038/ncb1603	120	212	217	1	26	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 24	2008	27	55					6970	6980		10.1038/onc.2008.347	http://dx.doi.org/10.1038/onc.2008.347			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	375IU	19029938				2022-12-28	WOS:000261108200009
J	Hatakeyama, M				Hatakeyama, M.			Linking epithelial polarity and carcinogenesis by multitasking Helicobacter pylori virulence factor CagA	ONCOGENE			English	Review						Helicobacter pylori; CagA; gastric carcinoma; epithelial polarity; PAR1/MARK	LARGE TUMOR-SUPPRESSOR; PAPILLOMAVIRUS E6 PROTEINS; BETA-CATENIN SIGNAL; KINASE-C-IOTA; HUMAN HOMOLOG; IV SECRETION; TYROSINE PHOSPHORYLATION; CELL POLARITY; IN-VIVO; PATHOGENICITY ISLAND	Loss of cell polarity and tissue architecture is a hallmark of carcinomas that arise from epithelial cells. Recent studies on Drosophila tumor suppressors have provided evidence that epithelial polarity and cell proliferation are functionally coupled, suggesting a function for polarity defects in the development of carcinomas. This notion is supported by the findings that mammalian orthologs of these Drosophila tumor suppressors are targeted by a number of viral oncoproteins. Chronic infection with Helicobacter pylori is causally associated with gastric carcinoma. H. pylori virulence factor CagA (cytotoxin-associated gene A), which is delivered into gastric epithelial cells through a bacterial type IV secretion system, has an important function in cell transformation through interacting with and deregulating SHP-2 phosphatase, a bona. de oncoprotein that is associated with human malignancies. Recent studies have further revealed that CagA specifically binds and inhibits PAR1/MARK polarity-regulating kinase, thereby causing junctional and polarity defects in epithelial cells. Thus, the bacterial oncoprotein simultaneously targets the polarity-regulating system and growth-regulatory system. These findings indicate that loss of cell polarity underlies the abnormal proliferation of epithelial cells that directs carcinogenesis.	Hokkaido Univ, Inst Med Genet, Div Mol Oncol, Inst Med Genet,Kita Ku, Sapporo, Hokkaido 0600815, Japan	Hokkaido University	Hatakeyama, M (corresponding author), Hokkaido Univ, Inst Med Genet, Div Mol Oncol, Inst Med Genet,Kita Ku, Kita 15,Nishi 7, Sapporo, Hokkaido 0600815, Japan.	mhata@igm.hokudai.ac.jp						Akopyants NS, 1998, MOL MICROBIOL, V28, P37, DOI 10.1046/j.1365-2958.1998.00770.x; Amieva MR, 2003, SCIENCE, V300, P1430, DOI 10.1126/science.1081919; Araki T, 2004, NAT MED, V10, P849, DOI 10.1038/nm1084; Asahi M, 2000, J EXP MED, V191, P593, DOI 10.1084/jem.191.4.593; Baas AF, 2004, CELL, V116, P457, DOI 10.1016/S0092-8674(04)00114-X; Backert S, 2000, CELL MICROBIOL, V2, P155, DOI 10.1046/j.1462-5822.2000.00043.x; Bagnoli F, 2005, P NATL ACAD SCI USA, V102, P16339, DOI 10.1073/pnas.0502598102; Ben-Porath I, 2005, INT J BIOCHEM CELL B, V37, P961, DOI 10.1016/j.biocel.2004.10.013; Bentires-Alj M, 2004, CANCER RES, V64, P8816, DOI 10.1158/0008-5472.CAN-04-1923; Bentires-Alj M, 2006, NAT MED, V12, P283, DOI 10.1038/nm0306-283; Betschinger J, 2004, CURR BIOL, V14, pR674, DOI 10.1016/j.cub.2004.08.017; Bilder D, 2004, GENE DEV, V18, P1909, DOI 10.1101/gad.1211604; BLASER MJ, 1995, CANCER RES, V55, P2111; Brumby AM, 2003, EMBO J, V22, P5769, DOI 10.1093/emboj/cdg548; Cavatorta AL, 2004, INT J CANCER, V111, P373, DOI 10.1002/ijc.20275; Censini S, 1996, P NATL ACAD SCI USA, V93, P14648, DOI 10.1073/pnas.93.25.14648; CORREA P, 1992, CANCER RES, V52, P6735; COVACCI A, 1993, P NATL ACAD SCI USA, V90, P5791, DOI 10.1073/pnas.90.12.5791; Drewes G, 1997, CELL, V89, P297, DOI 10.1016/S0092-8674(00)80208-1; Eder AM, 2005, P NATL ACAD SCI USA, V102, P12519, DOI 10.1073/pnas.0505641102; Franco AT, 2005, P NATL ACAD SCI USA, V102, P10646, DOI 10.1073/pnas.0504927102; Gardiol D, 1999, ONCOGENE, V18, P5487, DOI 10.1038/sj.onc.1202920; Guilford P, 1998, NATURE, V392, P402, DOI 10.1038/32918; Hatakeyama M, 2004, NAT REV CANCER, V4, P688, DOI 10.1038/nrc1433; Hatakeyama M, 2008, CURR OPIN MICROBIOL, V11, P30, DOI 10.1016/j.mib.2007.12.003; Hemminki A, 1998, NATURE, V391, P184, DOI 10.1038/34432; Higashi H, 2005, J BIOL CHEM, V280, P23130, DOI 10.1074/jbc.M503583200; Higashi H, 2004, J BIOL CHEM, V279, P17205, DOI 10.1074/jbc.M309964200; Higashi H, 2002, P NATL ACAD SCI USA, V99, P14428, DOI 10.1073/pnas.222375399; Higashi H, 2002, SCIENCE, V295, P683, DOI 10.1126/science.1067147; Humbert P, 2003, BIOESSAYS, V25, P542, DOI 10.1002/bies.10286; Hurov JB, 2004, CURR BIOL, V14, P736, DOI 10.1016/j.cub.2004.04.007; KEMPHUES KJ, 1988, CELL, V52, P311, DOI 10.1016/S0092-8674(88)80024-2; Kiyono T, 1997, P NATL ACAD SCI USA, V94, P11612, DOI 10.1073/pnas.94.21.11612; KUIPERS EJ, 1995, J NATL CANCER I, V87, P1777, DOI 10.1093/jnci/87.23.1777; Kuphal S, 2006, ONCOGENE, V25, P103, DOI 10.1038/sj.onc.1209008; Kurashima Y, 2008, INT J CANCER, V122, P823, DOI 10.1002/ijc.23190; Kwok T, 2007, NATURE, V449, P862, DOI 10.1038/nature06187; Le SS, 1997, P NATL ACAD SCI USA, V94, P6670, DOI 10.1073/pnas.94.13.6670; Lizcano JM, 2004, EMBO J, V23, P833, DOI 10.1038/sj.emboj.7600110; Macara IG, 2004, NAT REV MOL CELL BIO, V5, P220, DOI 10.1038/nrm1332; Matsumoto Y, 2007, NAT MED, V13, P470, DOI 10.1038/nm1566; Mohi MG, 2007, CURR OPIN GENET DEV, V17, P23, DOI 10.1016/j.gde.2006.12.011; Mohi MG, 2005, CANCER CELL, V7, P179, DOI 10.1016/j.ccr.2005.01.010; Muller J, 2001, MOL CELL, V8, P983, DOI 10.1016/S1097-2765(01)00383-5; Murata-Kamiya N, 2007, ONCOGENE, V26, P4617, DOI 10.1038/sj.onc.1210251; Murray NR, 2004, J CELL BIOL, V164, P797, DOI 10.1083/jcb.200311011; Naito M, 2006, GASTROENTEROLOGY, V130, P1181, DOI 10.1053/j.gastro.2005.12.038; Nakagawa S, 2000, MOL CELL BIOL, V20, P8244, DOI 10.1128/MCB.20.21.8244-8253.2000; Nakagawa S, 2004, BRIT J CANCER, V90, P194, DOI 10.1038/sj.bjc.6601465; Neel BG, 2003, TRENDS BIOCHEM SCI, V28, P284, DOI 10.1016/S0968-0004(03)00091-4; NOMURA A, 1991, NEW ENGL J MED, V325, P1132, DOI 10.1056/NEJM199110173251604; Odenbreit S, 2000, SCIENCE, V287, P1497, DOI 10.1126/science.287.5457.1497; Ohnishi N, 2008, P NATL ACAD SCI USA, V105, P1003, DOI 10.1073/pnas.0711183105; Pagliarini RA, 2003, SCIENCE, V302, P1227, DOI 10.1126/science.1088474; Panneerselvam S, 2006, STRUCTURE, V14, P173, DOI 10.1016/j.str.2005.09.022; Parkin DM, 2001, EUR J CANCER, V37, pS4, DOI 10.1016/S0959-8049(01)00267-2; Parsonnet J, 1997, GUT, V40, P297, DOI 10.1136/gut.40.3.297; PARSONNET J, 1991, NEW ENGL J MED, V325, P1127, DOI 10.1056/NEJM199110173251603; Peek RM, 2002, NAT REV CANCER, V2, P28, DOI 10.1038/nrc703; Peng CY, 1998, CELL GROWTH DIFFER, V9, P197; Poppe M, 2007, ONCOGENE, V26, P3462, DOI 10.1038/sj.onc.1210139; Prieur A, 2008, CURR OPIN CELL BIOL, V20, P150, DOI 10.1016/j.ceb.2008.01.007; Regala RP, 2005, CANCER RES, V65, P8905, DOI 10.1158/0008-5472.CAN-05-2372; Ren SM, 2006, J BIOL CHEM, V281, P32344, DOI 10.1074/jbc.M606172200; Rieder G, 2005, GASTROENTEROLOGY, V128, P1229, DOI 10.1053/j.gastro.2005.02.064; Saadat I, 2007, NATURE, V447, P330, DOI 10.1038/nature05765; Schimanski CC, 2005, ONCOGENE, V24, P3100, DOI 10.1038/sj.onc.1208520; Segal ED, 1999, P NATL ACAD SCI USA, V96, P14559, DOI 10.1073/pnas.96.25.14559; Segditsas S, 2006, ONCOGENE, V25, P7531, DOI 10.1038/sj.onc.1210059; Selbach M, 2002, J BIOL CHEM, V277, P6775, DOI 10.1074/jbc.C100754200; Stein M, 2000, P NATL ACAD SCI USA, V97, P1263, DOI 10.1073/pnas.97.3.1263; Stein M, 2002, MOL MICROBIOL, V43, P971, DOI 10.1046/j.1365-2958.2002.02781.x; Suzuki A, 2004, CURR BIOL, V14, P1425, DOI 10.1016/j.cub.2004.08.021; Suzuki A, 2006, J CELL SCI, V119, P979, DOI 10.1242/jcs.02898; Suzuki T, 1999, ONCOGENE, V18, P5967, DOI 10.1038/sj.onc.1203008; Tammer I, 2007, GASTROENTEROLOGY, V132, P1309, DOI 10.1053/j.gastro.2007.01.050; Tartaglia M, 2003, NAT GENET, V34, P148, DOI 10.1038/ng1156; TARTAGLIA M, 2001, NAT GENET, V111, P421; Tepass U, 2001, ANNU REV GENET, V35, P747, DOI 10.1146/annurev.genet.35.102401.091415; Tsutsumi R, 2006, MOL CELL BIOL, V26, P261, DOI 10.1128/MCB.26.1.261-276.2006; TUMMURU MKR, 1993, INFECT IMMUN, V61, P1799, DOI 10.1128/IAI.61.5.1799-1809.1993; Uemura N, 2001, NEW ENGL J MED, V345, P784, DOI 10.1056/NEJMoa001999; Zeaiter Z, 2008, CELL MICROBIOL, V10, P781, DOI 10.1111/j.1462-5822.2007.01084.x	84	67	73	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 24	2008	27	55					7047	7054		10.1038/onc.2008.353	http://dx.doi.org/10.1038/onc.2008.353			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	375IU	19029944				2022-12-28	WOS:000261108200015
J	De Luca, M; Brunetto, L; Asteriti, IA; Giubettini, M; Lavia, P; Guarguaglini, G				De Luca, M.; Brunetto, L.; Asteriti, I. A.; Giubettini, M.; Lavia, P.; Guarguaglini, G.			Aurora-A and ch-TOG act in a common pathway in control of spindle pole integrity	ONCOGENE			English	Article						Aurora-A; ch-TOG; MCAK; mitosis; spindle pole	D-TACC; CENTROSOME; KINASE; ORGANIZATION; ANEUPLOIDY; PROTEIN; CANCER; PHOSPHORYLATION; AMPLIFICATION; LOCALIZATION	Mitotic spindle assembly is a highly regulated process, crucial to ensure the correct segregation of duplicated chromosomes in daughter cells and to avoid aneuploidy, a common feature of tumors. Among the most important spindle regulators is Aurora-A, a mitotic centrosomal kinase frequently overexpressed in tumors. Here, we investigated the role of Aurora-A in spindle pole organization in human cells. We show that RNA interference-mediated Aurora-A inactivation causes pericentriolar material fragmentation in prometaphase, yielding the formation of spindles with supernumerary poles. This fragmentation does not necessarily involve centrioles and requires microtubules (MTs). Aurora-A-depleted prometaphases mislocalize the MT-stabilizing protein colonic hepatic tumor-overexpressed gene (ch-TOG), which abnormally accumulates at spindle poles, as well as the mitotic centromere-associated kinesin ( MCAK), the major functional antagonist of ch-TOG, which delocalizes from poles. ch-TOG is required for extrapole formation in prometaphases lacking Aurora-A, because co-depletion of Aurora-A and ch-TOG mitigates the fragmented pole phenotype. These results indicate a novel function of Aurora-A, the regulation of ch-TOG and MCAK localization, and highlight a common pathway involving the three factors in control of spindle pole integrity.	[De Luca, M.; Brunetto, L.; Asteriti, I. A.; Giubettini, M.; Lavia, P.; Guarguaglini, G.] Univ Roma La Sapienza, CNR, Inst Mol Biol & Pathol, Rome, Italy	Consiglio Nazionale delle Ricerche (CNR); Istituto di Biologia e Patologia Molecolari (IBPM-CNR); Sapienza University Rome	Guarguaglini, G (corresponding author), Univ Roma La Sapienza, CNR, IBPM, Via Apuli 4, I-00185 Rome, Italy.	giulia.guarguaglini@uniroma1.it	Lavia, Patrizia/J-5793-2019; Lavia, Patrizia/AAL-3982-2021	Lavia, Patrizia/0000-0003-3310-6701; DE LUCA, Maria/0000-0003-2329-776X; Giubettini, Maria/0000-0001-5863-1911	AIRC (Italian Association for Cancer Research)	AIRC (Italian Association for Cancer Research)(Fondazione AIRC per la ricerca sul cancro)	We thank M Ciciarello and R Mangiacasale for helpful discussions and JL Salisbury and C Walczak for reagents. This work was supported by AIRC ( Italian Association for Cancer Research) grants ( to PL).	Agnese V, 2007, ANN ONCOL, V18, P47, DOI 10.1093/annonc/mdm224; Anand S, 2003, CANCER CELL, V3, P51, DOI 10.1016/S1535-6108(02)00235-0; Andrews PD, 2005, ONCOGENE, V24, P5005, DOI 10.1038/sj.onc.1208752; Barr AR, 2007, J CELL SCI, V120, P2987, DOI 10.1242/jcs.013136; Barros TP, 2005, J CELL BIOL, V170, P1039, DOI 10.1083/jcb.200504097; Blagden SP, 2003, NAT CELL BIOL, V5, P505, DOI 10.1038/ncb0603-505; Cassimeris L, 2004, MOL BIOL CELL, V15, P1580, DOI 10.1091/mbc.E03-07-0544; Ciciarello M, 2007, CELL MOL LIFE SCI, V64, P1891, DOI 10.1007/s00018-007-6568-2; De Luca M, 2006, CELL CYCLE, V5, P296; Doxsey S, 2001, NAT REV MOL CELL BIO, V2, P688, DOI 10.1038/35089575; Fielding AB, 2008, J CELL BIOL, V180, P681, DOI 10.1083/jcb.200710074; Fukasawa K, 2005, CANCER LETT, V230, P6, DOI 10.1016/j.canlet.2004.12.028; Gadde S, 2004, CURR BIOL, V14, pR797, DOI 10.1016/j.cub.2004.09.021; Gard DL, 2004, INT REV CYTOL, V239, P179, DOI 10.1016/S0074-7696(04)39004-2; Gergely F, 2003, GENE DEV, V17, P336, DOI 10.1101/gad.245603; Giet R, 2005, TRENDS CELL BIOL, V15, P241, DOI 10.1016/j.tcb.2005.03.004; Giet R, 2002, J CELL BIOL, V156, P437, DOI 10.1083/jcb.200108135; Hoar K, 2007, MOL CELL BIOL, V27, P4513, DOI 10.1128/MCB.02364-06; Holmfeldt P, 2005, EMBO J, V24, P1256, DOI 10.1038/sj.emboj.7600601; Kinoshita K, 2005, J CELL BIOL, V170, P1047, DOI 10.1083/jcb.200503023; Koffa MD, 2006, CURR BIOL, V16, P743, DOI 10.1016/j.cub.2006.03.056; Kops GJPL, 2005, NAT REV CANCER, V5, P773, DOI 10.1038/nrc1714; Kufer TA, 2002, J CELL BIOL, V158, P617, DOI 10.1083/jcb.200204155; Lee MJ, 2001, NAT CELL BIOL, V3, P643, DOI 10.1038/35083033; LeRoy PJ, 2007, CANCER RES, V67, P5362, DOI 10.1158/0008-5472.CAN-07-0122; Luders J, 2007, NAT REV MOL CELL BIO, V8, P161, DOI 10.1038/nrm2100; Manning AL, 2007, CURR BIOL, V17, P260, DOI 10.1016/j.cub.2006.11.071; Marumoto T, 2005, NAT REV CANCER, V5, P42, DOI 10.1038/nrc1526; Marumoto T, 2003, J BIOL CHEM, V278, P51786, DOI 10.1074/jbc.M306275200; Meraldi P, 2002, EMBO J, V21, P483, DOI 10.1093/emboj/21.4.483; Nigg EA, 2006, INT J CANCER, V119, P2717, DOI 10.1002/ijc.22245; Peset I, 2005, J CELL BIOL, V170, P1057, DOI 10.1083/jcb.200504037; Sharp DJ, 2000, NATURE, V407, P41, DOI 10.1038/35024000; Weaver BAA, 2005, CANCER CELL, V8, P7, DOI 10.1016/j.ccr.2005.06.011; Weaver BAA, 2006, CURR OPIN CELL BIOL, V18, P658, DOI 10.1016/j.ceb.2006.10.002; Zhang X, 2008, MOL BIOL CELL, V19, P2752, DOI 10.1091/mbc.E08-02-0198	36	43	43	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 30	2008	27	51					6539	6549		10.1038/onc.2008.252	http://dx.doi.org/10.1038/onc.2008.252			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	366RS	18663358				2022-12-28	WOS:000260501700001
J	Sobue, S; Murakami, M; Banno, Y; Ito, H; Kimura, A; Gao, S; Furuhata, A; Takagi, A; Kojima, T; Suzuki, M; Nozawa, Y; Murate, T				Sobue, S.; Murakami, M.; Banno, Y.; Ito, H.; Kimura, A.; Gao, S.; Furuhata, A.; Takagi, A.; Kojima, T.; Suzuki, M.; Nozawa, Y.; Murate, T.			v-Src oncogene product increases sphingosine kinase 1 expression through mRNA stabilization: alteration of AU-rich element-binding proteins	ONCOGENE			English	Article						v-Src; sphingosine kinase 1; gene expression; mRNA half-life; AUF1; HuR	N-TERMINAL KINASE; GENE-EXPRESSION; C ISOFORMS; CELL-LINE; ACTIVATION; HUR; PHOSPHORYLATION; LEUKEMIA; TURNOVER; CANCER	Sphingosine kinase 1 (SPHK1) is overexpressed in solid tumors and leukemia. However, the mechanism of SPHK1 overexpression by oncogenes has not been defined. We found that v-Src-transformed NIH3T3 cells showed a high SPHK1 mRNA, SPHK1 protein and SPHK enzyme activity. siRNA of SPHK1 inhibited the growth of v-Src-NIH3T3, suggesting the involvement of SPHK1 in v-Src-induced oncogenesis. v-Src-NIH3T3 showed activations of protein kinase C-alpha, signal transducers and activators of transcription 3 and c-Jun NH2-terminal kinase. Their inhibition suppressed SPHK1 expression in v-Src-NIH3T3, whereas their overexpression increased SPHK1 mRNA in NIH3T3. Unexpectedly, the nuclear run-on assay and the promoter analysis using 50-promoter region of mouse SPHK1 did not show any significant difference between mock-and v-Src-NIH3T3. Furthermore, the half-life of SPHK1 mRNA in mock-NIH3T3 was nearly 15 min, whereas that of v-SrcNIH3T3 was much longer. Examination of two AU-rich region-binding proteins, AUF1 and HuR, that regulate mRNA decay reciprocally, showed decreased total AUF1 protein associated with increased tyrosine-phosphorylated form and increased serine-phosphorylated HuR protein in v-Src-NIH3T3. Modulation of AUF1 and HuR by their overexpression or siRNA revealed that SPHK1 mRNA in v-Src- and mock-NIH3T3 was regulated reciprocally by these factors. Our results showed, for the first time, a novel mechanism of v-Src-induced SPHK1 overexpression.	[Sobue, S.; Murakami, M.; Ito, H.; Kimura, A.; Gao, S.; Furuhata, A.; Takagi, A.; Kojima, T.; Murate, T.] Nagoya Univ, Grad Sch Hlth Sci, Dept Med Technol, Nagoya, Aichi 4668673, Japan; [Banno, Y.] Gifu Univ, Grad Sch Med, Dept Biochem, Gifu, Japan; [Suzuki, M.] Nagoya Univ, Grad Sch Med, Div Mol Carcinogenesis, Nagoya, Aichi 4668673, Japan; [Nozawa, Y.] Gifu Int Inst Biotechnol, Kakamigahara, Japan	Nagoya University; Gifu University; Nagoya University	Murate, T (corresponding author), Nagoya Univ, Sch Hlth Sci, Dept Med Technol, Higashi Ku, Daiko Minami 1-1-20, Nagoya, Aichi 4668673, Japan.	murate@met.nagoya-u.ac.jp	Kojima, Tetsuhito/I-6271-2014; Suzuki, Motoshi/I-7246-2014	Kojima, Tetsuhito/0000-0002-1905-1065; Suzuki, Motoshi/0000-0003-0682-5006				Akao Y, 2006, BIOCHEM BIOPH RES CO, V342, P1284, DOI 10.1016/j.bbrc.2006.02.070; Alvarez SE, 2007, TRENDS ENDOCRIN MET, V18, P300, DOI 10.1016/j.tem.2007.07.005; Bektas M, 2005, ONCOGENE, V24, P178, DOI 10.1038/sj.onc.1208019; BLOBEL GA, 1991, P NATL ACAD SCI USA, V88, P1162, DOI 10.1073/pnas.88.4.1162; Bonhoure E, 2006, LEUKEMIA, V20, P95, DOI 10.1038/sj.leu.2404023; BORNER C, 1992, J BIOL CHEM, V267, P12900; Bromann PA, 2005, J BIOL CHEM, V280, P10253, DOI 10.1074/jbc.M413806200; Chen CY, 2001, CELL, V107, P451, DOI 10.1016/S0092-8674(01)00578-5; Chen CY, 1998, SCIENCE, V280, P1945, DOI 10.1126/science.280.5371.1945; Cussac D, 2004, BLOOD, V103, P1464; de Silanes IL, 2004, P NATL ACAD SCI USA, V101, P2987, DOI 10.1073/pnas.0306453101; Dehm S, 2001, FEBS LETT, V487, P367, DOI 10.1016/S0014-5793(00)02354-1; Dehm SM, 2004, BIOCHEM CELL BIOL, V82, P263, DOI 10.1139/o03-077; Doller A, 2007, MOL BIOL CELL, V18, P2137, DOI 10.1091/mbc.E06-09-0850; Fawal M, 2006, BLOOD, V108, P2780, DOI 10.1182/blood-2006-04-014902; Frame MC, 2004, J CELL SCI, V117, P989, DOI 10.1242/jcs.01111; French KJ, 2003, CANCER RES, V63, P5962; FRITZ G, 1995, J BIOL CHEM, V270, P25172, DOI 10.1074/jbc.270.42.25172; Gartsbein M, 2006, J CELL SCI, V119, P470, DOI 10.1242/jcs.02744; GOOD PJ, 1995, P NATL ACAD SCI USA, V92, P4557, DOI 10.1073/pnas.92.10.4557; Greulich H, 1996, ONCOGENE, V12, P1689; Hanford DS, 1996, MOL ENDOCRINOL, V10, P1719, DOI 10.1210/me.10.12.1719; Karni R, 2002, J BIOL CHEM, V277, P42919, DOI 10.1074/jbc.M206141200; Kawamori T, 2006, FASEB J, V20, P386, DOI 10.1096/fj.05-4331fje; Kloss S, 2004, MOL PHARMACOL, V65, P1440, DOI 10.1124/mol.65.6.1440; Kuo LY, 2006, J CELL PHYSIOL, V207, P729, DOI 10.1002/jcp.20616; Lal A, 2004, EMBO J, V23, P3092, DOI 10.1038/sj.emboj.7600305; Leclerc Guy J, 2002, Cancer Cell Int, V2, P1, DOI 10.1186/1475-2867-2-1; Liu H, 2000, J BIOL CHEM, V275, P19513, DOI 10.1074/jbc.M002759200; Meyer S, 2004, CRIT REV BIOCHEM MOL, V39, P197, DOI 10.1080/10409230490513991; Murakami M, 2007, J NEUROCHEM, V102, P1585, DOI 10.1111/j.1471-4159.2007.04673.x; Nakade Y, 2003, BBA-MOL CELL BIOL L, V1635, P104, DOI 10.1016/j.bbalip.2003.11.001; Olivera A, 1999, J CELL BIOL, V147, P545, DOI 10.1083/jcb.147.3.545; Pan YX, 2005, J BIOL CHEM, V280, P34609, DOI 10.1074/jbc.M507802200; Park YJ, 2002, MOL CELL ENDOCRINOL, V194, P77, DOI 10.1016/S0303-7207(02)00185-5; Patrone G, 2000, BIOTECHNIQUES, V29, P1012, DOI 10.2144/00295st02; QURESHI SA, 1991, J BIOL CHEM, V266, P10802; Raineri I, 2004, NUCLEIC ACIDS RES, V32, P1279, DOI 10.1093/nar/gkh282; Shih SC, 1999, J BIOL CHEM, V274, P15407, DOI 10.1074/jbc.274.22.15407; Sobue S, 2006, LEUKEMIA, V20, P2042, DOI 10.1038/sj.leu.2404386; Sobue S, 2005, J NEUROCHEM, V95, P940, DOI 10.1111/j.1471-4159.2005.03399.x; STOECKLE MY, 1989, MOL CELL BIOL, V9, P4738, DOI 10.1128/MCB.9.11.4738; Stofega MR, 1997, CELL GROWTH DIFFER, V8, P113; Taha TA, 2006, J BIOCHEM MOL BIOL, V39, P113; Tezuka KI, 1996, J BIOL CHEM, V271, P22713, DOI 10.1074/jbc.271.37.22713; Turkson J, 1999, MOL CELL BIOL, V19, P7519; Vlasova IA, 2005, GENOMICS, V86, P159, DOI 10.1016/j.ygeno.2005.04.013; Wilson GM, 2003, J BIOL CHEM, V278, P33029, DOI 10.1074/jbc.M305772200; Wilusz CJ, 2001, NAT REV MOL CELL BIO, V2, P237, DOI 10.1038/35067025; Xia P, 2000, CURR BIOL, V10, P1527, DOI 10.1016/S0960-9822(00)00834-4; XIE WL, 1995, J BIOL CHEM, V270, P27622, DOI 10.1074/jbc.270.46.27622	51	26	26	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 9	2008	27	46					6023	6033		10.1038/onc.2008.198	http://dx.doi.org/10.1038/onc.2008.198			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	358BO	18574469				2022-12-28	WOS:000259891600005
J	Carbone, M; Rossi, MN; Cavaldesi, M; Notari, A; Amati, P; Maione, R				Carbone, M.; Rossi, M. N.; Cavaldesi, M.; Notari, A.; Amati, P.; Maione, R.			Poly(ADP-ribosyl)ation is implicated in the G0-G1 transition of resting cells	ONCOGENE			English	Article						c-Fos; c-Myc; G0 exit; poly(ADP-ribosyl)ation	MESSENGER-RNA LEVELS; RIBOSE POLYMERASE; GROWTH-FACTORS; TRANSCRIPTION; EXPRESSION; DIFFERENTIATION; MITOGENESIS; ACTIVATION; DOMAINS; BINDING	Poly(ADP-ribosyl)ation, catalysed by a family of poly (ADP-ribose) polymerases (PARPs), plays an important role in a large variety of physiological processes, including cell proliferation, but its role in cell cycle progression is not yet completely defined. As reported here, the examination of early times following serum stimulation of quiescent fibroblasts suggests that poly(ADP-ribosyl) ation is necessary for the transition from the G0 phase to the G1 phase. We show that PARP activity is involved in this step through the regulation of immediate-early response genes, such as c-Fos and c-Myc. This is supported by the finding that exogenous Myc expression substantially restores cell cycle reactivation in the absence of polymer synthesis. Furthermore, using RNA interference, we show that PARP-1 is the PARP family member playing the most prominent role in the upregulation of c-Fos and c-Myc during G0-G1 transition. We report that even in lectin-stimulated peripheral blood mononucleated cells, the inhibition of PARP activity interferes with the upregulation of immediate-early genes and delays the induction of proliferation, suggesting a general role for PARP-1 in linking growth factor signaling with cell cycle entry.	[Amati, P.; Maione, R.] Univ Roma La Sapienza, Dept Cellular Biotechnol & Haematol, Mol Genet Sect, Pasteur Inst Fdn Cenci Bolognetti, I-00161 Rome, Italy	Sapienza University Rome	Amati, P (corresponding author), Univ Roma La Sapienza, Dept Cellular Biotechnol & Haematol, Mol Genet Sect, Pasteur Inst Fdn Cenci Bolognetti, Viale Regina Elena 324, I-00161 Rome, Italy.	amati@bce.uniroma1.it; maione@bce.uniroma1.it	Rossi, Marianna Nicoletta/S-5083-2019	Rossi, Marianna Nicoletta/0000-0003-4485-7738	Associazione Italiana per la Ricerca sul Cancro (AIRC) [4179]; AIRC/FIRC	Associazione Italiana per la Ricerca sul Cancro (AIRC)(Fondazione AIRC per la ricerca sul cancro); AIRC/FIRC(Fondazione AIRC per la ricerca sul cancro)	We thank Dr M Crescenzi for human FB 1329 cells, Professor G Palmieri for purified PBMCs and Dr B Amati for the c-MycER-expressing cells and for helpful suggestions. We are grateful to Professor P Caiafa for useful discussions on the 'PARP world'. This work was supported by Grant no. 4179 from Associazione Italiana per la Ricerca sul Cancro (AIRC). MC was supported by a fellowship from AIRC/FIRC.	ALMENDRAL JM, 1988, MOL CELL BIOL, V8, P2140, DOI 10.1128/MCB.8.5.2140; BLANCHARD JM, 1985, NATURE, V317, P443, DOI 10.1038/317443a0; BRAVO R, 1990, CELL GROWTH DIFFER, V1, P305; Carbone M, 2006, J MOL BIOL, V363, P773, DOI 10.1016/j.jmb.2006.05.077; CESARONE CF, 1990, BIOCHIM BIOPHYS ACTA, V1087, P241, DOI 10.1016/0167-4781(90)90211-J; Cohen-Armon M, 2007, MOL CELL, V25, P297, DOI 10.1016/j.molcel.2006.12.012; D'Amours D, 1999, BIOCHEM J, V342, P249, DOI 10.1042/0264-6021:3420249; DEAN M, 1986, J BIOL CHEM, V261, P9161; EILERS M, 1991, EMBO J, V10, P133, DOI 10.1002/j.1460-2075.1991.tb07929.x; Homburg S, 2000, J CELL BIOL, V150, P293, DOI 10.1083/jcb.150.2.293; ITTEL ME, 1983, BIOCHEM BIOPH RES CO, V116, P428, DOI 10.1016/0006-291X(83)90541-7; Jagtap P, 2005, NAT REV DRUG DISCOV, V4, P421, DOI 10.1038/nrd1718; Jagtap P, 2002, CRIT CARE MED, V30, P1071, DOI 10.1097/00003246-200205000-00019; JOHNSTONE AP, 1982, NATURE, V300, P368, DOI 10.1038/300368a0; Jones SM, 2001, NAT CELL BIOL, V3, P165, DOI 10.1038/35055073; Jones SM, 2001, FEBS LETT, V490, P110, DOI 10.1016/S0014-5793(01)02113-5; Kauppinen TM, 2006, P NATL ACAD SCI USA, V103, P7136, DOI 10.1073/pnas.0508606103; Kraus WL, 2003, CELL, V113, P677, DOI 10.1016/S0092-8674(03)00433-1; LITTLEWOOD TD, 1995, NUCLEIC ACIDS RES, V23, P1686, DOI 10.1093/nar/23.10.1686; MARINI M, 1989, FEBS LETT, V253, P146, DOI 10.1016/0014-5793(89)80948-2; Marshall C, 1999, CURR OPIN CELL BIOL, V11, P732, DOI 10.1016/S0955-0674(99)00044-7; MENEGAZZI M, 1992, FEBS LETT, V297, P59, DOI 10.1016/0014-5793(92)80327-D; Olabisi OA, 2008, MOL CELL BIOL, V28, P2860, DOI 10.1128/MCB.01746-07; REED JC, 1986, P NATL ACAD SCI USA, V83, P3982, DOI 10.1073/pnas.83.11.3982; Rouleau M, 2004, J CELL SCI, V117, P815, DOI 10.1242/jcs.01080; Schreiber V, 2006, NAT REV MOL CELL BIO, V7, P517, DOI 10.1038/nrm1963; Sears RC, 2002, J BIOL CHEM, V277, P11617, DOI 10.1074/jbc.R100063200; Shieh WM, 1998, J BIOL CHEM, V273, P30069, DOI 10.1074/jbc.273.46.30069; Simbulan-Rosenthal CM, 1999, ONCOGENE, V18, P5015, DOI 10.1038/sj.onc.1202900; Simbulan-Rosenthal CM, 2003, ONCOGENE, V22, P8460, DOI 10.1038/sj.onc.1206897; SimbulanRosenthal CM, 1996, BIOCHEMISTRY-US, V35, P11622, DOI 10.1021/bi953010z; Treitinger, 1999, Braz J Infect Dis, V3, P1; Valdor R, 2008, MOL IMMUNOL, V45, P1863, DOI 10.1016/j.molimm.2007.10.044; WEIN KH, 1993, BIOCHIM BIOPHYS ACTA, V1176, P69, DOI 10.1016/0167-4889(93)90179-S	34	31	32	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT	2008	27	47					6083	6092		10.1038/onc.2008.221	http://dx.doi.org/10.1038/onc.2008.221			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	360UJ	18663363				2022-12-28	WOS:000260083100001
J	Ishikawa, Y; Onoyama, I; Nakayama, KI; Nakayama, K				Ishikawa, Y.; Onoyama, I.; Nakayama, K. I.; Nakayama, K.			Notch-dependent cell cycle arrest and apoptosis in mouse embryonic fibroblasts lacking Fbxw7	ONCOGENE			English	Article						ubiquitin ligase; Fbxw7; Notch; mouse embryonic fibroblast; tumor suppressor; p53	F-BOX PROTEIN; GLYCOGEN-SYNTHASE KINASE-3; TUMOR-SUPPRESSOR; C-MYC; UBIQUITIN LIGASE; GROWTH ARREST; MICE LACKING; ACTIVATION; TRANSCRIPTION; DEGRADATION	The F-box protein Fbxw7 mediates the ubiquitylation and consequent degradation of proteins that regulate cell cycle progression, including cyclin E, c-Myc, c-Jun and Notch. Moreover, certain human cancer cell lines harbor loss-of-function mutations in FBXW7 that result in excessive accumulation of Fbxw7 substrates, implicating Fbxw7 in tumor suppression. To elucidate the physiological function of Fbxw7, we conditionally ablated Fbxw7 in mouse embryonic fibroblasts (MEFs). Unexpectedly, loss of Fbxw7 induced cell cycle arrest and apoptosis that were accompanied by abnormal accumulation of the intracellular domain of Notch1 (NICD1). Forced expression of NICD1 in wild-type MEFs recapitulated the phenotype of the Fbxw7-deficient (Fbxw7D/D) MEFs. Conversely, deletion of Rbpj normalized the phenotype of Fbxw7(Delta/Delta) MEFs, indicating that this phenotype is dependent on the Notch1 RBP-J signaling pathway. Deletion of the p53 gene prevented cell cycle arrest but not the induction of apoptosis in Fbxw7(Delta/Delta) cells. These observations suggest that Fbxw7 does not function as an oncosuppressor in MEFs. Instead, it promotes cell cycle progression and cell survival through degradation of Notch1, with loss of Fbxw7 resulting in NICD1 accumulation, cell cycle arrest and apoptosis.	[Ishikawa, Y.; Nakayama, K.] Tohoku Univ, Grad Sch Med, Dept Dev Genet, Ctr Translat & Adv Anim Res,Aoba Ku, Sendai, Miyagi 9808575, Japan; [Ishikawa, Y.; Onoyama, I.; Nakayama, K. I.; Nakayama, K.] Japan Sci & Technol Agcy, CREST, Kawaguchi, Saitama, Japan; [Onoyama, I.; Nakayama, K. I.] Kyushu Univ, Dept Mol & Cellular Biol, Med Inst Bioregulat, Fukuoka 812, Japan	Tohoku University; Japan Science & Technology Agency (JST); Kyushu University	Nakayama, K (corresponding author), Tohoku Univ, Grad Sch Med, Dept Dev Genet, Ctr Translat & Adv Anim Res,Aoba Ku, 2-1 Seiryo Machi, Sendai, Miyagi 9808575, Japan.	nakayak2@mail.tains.tohoku.ac.jp			Ministry of Education, Culture, Sports, Science, and Technology of Japan; 21st Century Center of Excellence Program	Ministry of Education, Culture, Sports, Science, and Technology of Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); 21st Century Center of Excellence Program(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT))	We thank T Honjo for Rbpj<SUP>F/F</SUP> mice; R Tsunematsu for an NICD1 plasmid; T Kitamura for pMX-puro and Plat-E cells; Y Ono and N Kobayashi for technical assistance; N Ishida and other laboratory members for helpful discussion. This study was supported in part by a Grant-in-Aid from the Ministry of Education, Culture, Sports, Science, and Technology of Japan and by the 21st Century Center of Excellence Program.	Akhoondi S, 2007, CANCER RES, V67, P9006, DOI 10.1158/0008-5472.CAN-07-1320; Artavanis-Tsakonas S, 1999, SCIENCE, V284, P770, DOI 10.1126/science.284.5415.770; Blackwood EM, 1992, CURR OPIN GENET DEV, V2, P227, DOI 10.1016/S0959-437X(05)80278-3; Foltz DR, 2002, CURR BIOL, V12, P1006, DOI 10.1016/S0960-9822(02)00888-6; Fryer CJ, 2004, MOL CELL, V16, P509, DOI 10.1016/j.molcel.2004.10.014; Fujii Y, 2006, CANCER SCI, V97, P729, DOI 10.1111/j.1349-7006.2006.00239.x; Guentchev M, 2006, EUR J NEUROSCI, V23, P2289, DOI 10.1111/j.1460-9568.2006.04766.x; Gupta-Rossi N, 2001, J BIOL CHEM, V276, P34371, DOI 10.1074/jbc.M101343200; Han H, 2002, INT IMMUNOL, V14, P637, DOI 10.1093/intimm/dxf030; Huang QH, 2004, P NATL ACAD SCI USA, V101, P3456, DOI 10.1073/pnas.0308562100; Hubbard EJA, 1997, GENE DEV, V11, P3182, DOI 10.1101/gad.11.23.3182; Kato H, 1996, FEBS LETT, V395, P221, DOI 10.1016/0014-5793(96)01046-0; Kitagawa M, 1999, EMBO J, V18, P2401, DOI 10.1093/emboj/18.9.2401; Koepp DM, 2001, SCIENCE, V294, P173, DOI 10.1126/science.1065203; KOFF A, 1992, SCIENCE, V257, P1689, DOI 10.1126/science.1388288; Loeb KR, 2005, CANCER CELL, V8, P35, DOI 10.1016/j.ccr.2005.06.010; Lopez-Nieva P, 2004, CARCINOGENESIS, V25, P1299, DOI 10.1093/carcin/bgh124; Mao JH, 2004, NATURE, V432, P775, DOI 10.1038/nature03155; Mo JS, 2007, MOL CELL BIOL, V27, P5565, DOI 10.1128/MCB.02372-06; Moberg KH, 2001, NATURE, V413, P311, DOI 10.1038/35095068; Morita S, 2000, GENE THER, V7, P1063, DOI 10.1038/sj.gt.3301206; Nakayama K, 1996, CELL, V85, P707, DOI 10.1016/S0092-8674(00)81237-4; Nakayama KI, 2006, NAT REV CANCER, V6, P369, DOI 10.1038/nrc1881; Nateri AS, 2004, SCIENCE, V303, P1374, DOI 10.1126/science.1092880; Nicolas M, 2003, NAT GENET, V33, P416, DOI 10.1038/ng1099; O'Neil J, 2007, J EXP MED, V204, P1813, DOI 10.1084/jem.20070876; Oberg C, 2001, J BIOL CHEM, V276, P35847, DOI 10.1074/jbc.M103992200; Onoyama I, 2007, J EXP MED, V204, P2875, DOI 10.1084/jem.20062299; Radtke F, 2003, NAT REV CANCER, V3, P756, DOI 10.1038/nrc1186; Ramain P, 2001, CURR BIOL, V11, P1729, DOI 10.1016/S0960-9822(01)00562-0; Rangarajan A, 2001, EMBO J, V20, P3427, DOI 10.1093/emboj/20.13.3427; RUEL L, 1993, NATURE, V362, P557, DOI 10.1038/362557a0; Sarmento LM, 2005, J EXP MED, V202, P157, DOI 10.1084/jem.20050559; Strohmaier H, 2001, NATURE, V413, P316, DOI 10.1038/35095076; SUNDARAM M, 1993, GENETICS, V135, P765; Sundqvist A, 2005, CELL METAB, V1, P379, DOI 10.1016/j.cmet.2005.04.010; Tetzlaff MT, 2004, P NATL ACAD SCI USA, V101, P3338, DOI 10.1073/pnas.0307875101; Thompson BJ, 2007, J EXP MED, V204, P1825, DOI 10.1084/jem.20070872; Tsunematsu R, 2004, J BIOL CHEM, V279, P9417, DOI 10.1074/jbc.M312337200; Wei WY, 2005, CANCER CELL, V8, P25, DOI 10.1016/j.ccr.2005.06.005; Welcker M, 2004, P NATL ACAD SCI USA, V101, P9085, DOI 10.1073/pnas.0402770101; Welcker M, 2008, NAT REV CANCER, V8, P83, DOI 10.1038/nrc2290; Weng AP, 2006, GENE DEV, V20, P2096, DOI 10.1101/gad.1450406; Yada M, 2004, EMBO J, V23, P2116, DOI 10.1038/sj.emboj.7600217; Yang XD, 2004, DEV BIOL, V269, P81, DOI 10.1016/j.ydbio.2004.01.014; Zweidler-McKay PA, 2005, BLOOD, V106, P3898, DOI 10.1182/blood-2005-01-0355	46	44	46	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT	2008	27	47					6164	6174		10.1038/onc.2008.216	http://dx.doi.org/10.1038/onc.2008.216			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	360UJ	18641686				2022-12-28	WOS:000260083100009
J	Sripathy, SP; Chaplin, LJ; Gaikwad, NW; Rogan, EG; Montano, MM				Sripathy, S. P.; Chaplin, L. J.; Gaikwad, N. W.; Rogan, E. G.; Montano, M. M.			hPMC2 is required for recruiting an ER beta coactivator complex to mediate transcriptional upregulation of NQO1 and protection against oxidative DNA damage by tamoxifen	ONCOGENE			English	Article						PARP-1; ER beta-dependent transcription; antioxidative enzymes; tamoxifen; breast cancer	ESTROGEN-RECEPTOR-BETA; QUINONE REDUCTASE GENE; BREAST-CANCER; FUNCTIONAL IMPLICATIONS; C-FOS; ALPHA; ACTIVATION; EXPRESSION; ENZYMES; ELEMENT	In the presence of ER beta, trans-hydroxytamoxifen (TOT) protects cells against 17 beta-estradiol(E-2)-induced oxidative DNA damage (ODD) and this correlates with increased expression of the antioxidative enzyme quinone reductase (QR). Here, we investigate the molecular mechanism responsible for ER beta-mediated protection against ODD. We observe constitutive interaction between ERb and the novelprote in hPMC2. Using a combination of breast epithelial cell lines that are either positive or negative for ER alpha, we demonstrate TOT-dependent recruitment of both ERb and hPMC2 to the EpRE (electrophile response element)- regulated antioxidative enzyme QR. We further demonstrate TOT-dependent corecruitment of the coactivators Nrf2, PARP-1 (poly (ADP-ribose) polymerase 1) and topoisomerase II beta, both in the presence and absence of ER alpha. However, absence of either ER beta or hPMC2 results in nonrecruitment of PARP-1 and topoisomerase IIb, loss of antioxidative enzyme induction and attenuated protection against ODD by TOT even in the presence of Nrf2 and ERa. These findings indicate minor role for Nrf2 and ER alpha in TOT-dependent antioxidative gene regulation. However, downregulation of PARP-1 attenuates TOT-dependent antioxidative gene induction. We conclude that ER beta and hPMC2 are required for TOT-dependent recruitment of coactivators such as PARP-1 to the EpRE resulting in the induction of antioxidative enzymes and subsequent protection against ODD.	[Sripathy, S. P.; Chaplin, L. J.; Montano, M. M.] Case Western Reserve Univ, Dept Pharmacol, Cleveland, OH 44106 USA; [Gaikwad, N. W.; Rogan, E. G.] Univ Nebraska, Med Ctr, Eppley Inst Res Canc & Allied Dis, Omaha, NE USA	Case Western Reserve University; University of Nebraska System; University of Nebraska Medical Center	Montano, MM (corresponding author), Case Western Reserve Univ, Dept Pharmacol, 2901 Adelbert Rd,W305, Cleveland, OH 44106 USA.	mxm126@case.edu			NIH [CA92440, CA130066]; NATIONAL CANCER INSTITUTE [R01CA092440, R03CA130066] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by NIH Grants (CA92440 and CA130066) to MMM.	Bianco NR, 2003, MOL ENDOCRINOL, V17, P1344, DOI 10.1210/me.2002-0382; Bolton JL, 2008, CHEM RES TOXICOL, V21, P93, DOI 10.1021/tx700191p; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; CAVALIERI E, 2006, BIOCH BIOPHYS ACTA; Chang EC, 2006, ENDOCRINOLOGY, V147, P4831, DOI 10.1210/en.2006-0563; Fabian C, 2007, CANCER EPIDEM BIOMAR, V16, P2210, DOI 10.1158/1055-9965.EPI-06-1065; Gaikwad NW, 2007, FREE RADICAL BIO MED, V43, P1289, DOI 10.1016/j.freeradbiomed.2007.07.021; Gruvberger-Saal SK, 2007, CLIN CANCER RES, V13, P1987, DOI 10.1158/1078-0432.CCR-06-1823; Jordan VC, 2007, CANCER EPIDEM BIOMAR, V16, P2207, DOI 10.1158/1055-9965.EPI-07-0629; Ju BG, 2006, SCIENCE, V312, P1798, DOI 10.1126/science.1127196; Krishnakumar R, 2008, SCIENCE, V319, P819, DOI 10.1126/science.1149250; Li KM, 2004, CARCINOGENESIS, V25, P289, DOI 10.1093/carcin/bgg191; Liehr JG, 2000, ENDOCR REV, V21, P40, DOI 10.1210/er.21.1.40; Lis JT, 2006, CELL, V125, P1225, DOI 10.1016/j.cell.2006.06.016; Matthews J, 2006, MOL ENDOCRINOL, V20, P534, DOI 10.1210/me.2005-0140; Matthews Jason, 2003, Mol Interv, V3, P281, DOI 10.1124/mi.3.5.281; Menzel HJ, 2004, BRIT J CANCER, V90, P1989, DOI 10.1038/sj.bjc.6601779; Montano MM, 2007, ONCOGENE, V26, P3587, DOI 10.1038/sj.onc.1210144; Montano MM, 2000, J BIOL CHEM, V275, P34306, DOI 10.1074/jbc.M003880200; Montano MM, 2004, ONCOGENE, V23, P2442, DOI 10.1038/sj.onc.1207358; Montano MM, 1998, J BIOL CHEM, V273, P25443, DOI 10.1074/jbc.273.39.25443; Oestergaard MZ, 2006, BRIT J CANCER, V95, P525, DOI 10.1038/sj.bjc.6603272; Paech K, 1997, SCIENCE, V277, P1508, DOI 10.1126/science.277.5331.1508; Pavri R, 2005, MOL CELL, V18, P83, DOI 10.1016/j.molcel.2005.02.034; Pettersson K, 1997, MOL ENDOCRINOL, V11, P1486, DOI 10.1210/me.11.10.1486; PRESTERA T, 1995, P NATL ACAD SCI USA, V92, P8965, DOI 10.1073/pnas.92.19.8965; Ramos-Gomez M, 2001, P NATL ACAD SCI USA, V98, P3410, DOI 10.1073/pnas.051618798; Routledge EJ, 2000, J BIOL CHEM, V275, P35986, DOI 10.1074/jbc.M006777200; RUSHMORE TH, 1991, J BIOL CHEM, V266, P11632; SAKODA LC, 2007, BREAST CANC RES TREA; Shang YF, 2002, SCIENCE, V295, P2465, DOI 10.1126/science.1068537; Speirs V, 2007, J PATHOL, V211, P499, DOI 10.1002/path.2130; Strange RC, 2001, MUTAT RES-FUND MOL M, V482, P21, DOI 10.1016/S0027-5107(01)00206-8; TEW KD, 1994, CANCER RES, V54, P4313; Udler M, 2007, J CLIN ONCOL, V25, P3015, DOI 10.1200/JCO.2006.10.0099; Venugopal R, 1996, P NATL ACAD SCI USA, V93, P14960, DOI 10.1073/pnas.93.25.14960; Wong CW, 2001, BIOCHEMISTRY-US, V40, P6756, DOI 10.1021/bi010379h	37	13	13	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT	2008	27	49					6376	6384		10.1038/onc.2008.235	http://dx.doi.org/10.1038/onc.2008.235			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	363JK	18663360	Green Accepted			2022-12-28	WOS:000260263400007
J	Pandolfi, PP				Pandolfi, P. P.			P-TEN exciting years: from the cytosol to the nucleus and back to keep cancer at bay	ONCOGENE			English	Editorial Material									Harvard Univ, Sch Med, Canc Genet Program, Beth Israel Deaconess Canc Ctr,Dept Med & Pathol, Boston, MA 02215 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School	Pandolfi, PP (corresponding author), Harvard Univ, Sch Med, Canc Genet Program, Beth Israel Deaconess Canc Ctr,Dept Med & Pathol, Boston, MA 02215 USA.	ppandolf@bidmc.harvard.edu							0	7	7	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 15	2008	27	41					5386	5386		10.1038/onc.2008.279	http://dx.doi.org/10.1038/onc.2008.279			1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	349KW	18794874				2022-12-28	WOS:000259280700001
J	Britschgi, A; Trinh, E; Rizzi, M; Jenal, M; Ress, A; Tobler, A; Fey, MF; Helin, K; Tschan, MP				Britschgi, A.; Trinh, E.; Rizzi, M.; Jenal, M.; Ress, A.; Tobler, A.; Fey, M. F.; Helin, K.; Tschan, M. P.			DAPK2 is a novel E2F1/KLF6 target gene involved in their proapoptotic function	ONCOGENE			English	Article						DAPK2; E2F1; KLF6; Sp1; transcription; cell death	KRUPPEL-LIKE FACTOR-6; TRANSCRIPTION FACTORS; PROSTATE-CANCER; CPG ISLAND; APOPTOSIS; KLF6; PROMOTER; PROTEIN; FAMILY; E2F1	Death-associated protein kinase 2 (DAPK2) belongs to a family of proapoptotic Ca(2+)/calmodulin-regulated serine/threonine kinases. We recently identified DAPK2 as an enhancing factor during granulocytic differentiation. To identify transcriptional DAPK2 regulators, we cloned 2.7 kb ofthe 5'-flanking region ofthe DAPK2 gene. We found that E2F1 and Kruppel-like factor 6 (KLF6) strongly activate the DAPK2 promoter. We mapped the E2F1 and KLF6 responsive elements to a GC-rich region 50 of exon 1 containing several binding sites for KLF6 and Sp1 but not for E2F. Moreover, we showed that transcriptional activation of DAPK2 by E2F1 and KLF6 is dependent on Sp1 using Sp1/KLF6-deficient insect cells, mithramycin A treatment to block Sp1-binding or Sp1 knockdown cells. Chromatin immunoprecipitation revealed recruitment of Sp1 and to lesser extent that of E2F1 and KLF6 to the DAPK2 promoter. Activation of E2F1 in osteosarcoma cells led to an increase of endogenous DAPK2 paralleled by cell death. Inhibition of DAPK2 expression resulted in significantly reduced cell death upon E2F1 activation. Similarly, KLF6 expression in H1299 cells increased DAPK2 levels accompanied by cell death that is markedly decreased upon DAPK2 knockdown. Moreover, E2F1 and KLF6 show cooperation in activating the DAPK2 promoter. In summary, our findings establish DAPK2 as a novel Sp1-dependent target gene for E2F1 and KLF6 in cell death response.	[Britschgi, A.; Rizzi, M.; Jenal, M.; Ress, A.; Tobler, A.; Fey, M. F.; Tschan, M. P.] Univ Bern, Dept Clin Res, CH-3010 Bern, Switzerland; [Trinh, E.; Helin, K.] Univ Copenhagen, Ctr Epigenet, Biotech Res & Innovat Ctr, Copenhagen, Denmark; [Tobler, A.] Univ Hosp Bern, Inselspital, Dept Hematol, CH-3010 Bern, Switzerland; [Fey, M. F.] Univ Hosp Bern, Inselspital, Dept Med Oncol, CH-3010 Bern, Switzerland	University of Bern; University of Copenhagen; University of Bern; University Hospital of Bern; University of Bern; University Hospital of Bern	Tschan, MP (corresponding author), Univ Bern, Dept Clin Res, Murtenstr 35, CH-3010 Bern, Switzerland.	mtschan@dkf.unibe.ch	Helin, Kristian/HDM-8306-2022; Rizzi, Mattia/AHE-4168-2022; Helin, Kristian/K-2526-2019; Rizzi, Mattia/ABE-3996-2021	Helin, Kristian/0000-0003-1975-6097; Tschan, Mario P./0000-0001-5897-3647; Rizzi, Mattia/0000-0001-6987-0678	Swiss National Foundation [3100-067213]; Marlies-Schwegler Foundation; Bernese Foundation of Cancer Research; Werner and Hedy Berger-Janser Foundation of Cancer Research; Bern University Research Foundation; Danish Cancer Society	Swiss National Foundation(Swiss National Science Foundation (SNSF)); Marlies-Schwegler Foundation; Bernese Foundation of Cancer Research; Werner and Hedy Berger-Janser Foundation of Cancer Research; Bern University Research Foundation; Danish Cancer Society(Danish Cancer Society)	Expert technical assistance by D Shan and G Arvidsson is appreciated. We are grateful to Drs SL Friedmann, G Thiel and JJ Rossi for providing the KLF6, CBP/p300 and Sp1 expression plasmids as well as an U6 promoter constructs. We also thank Dr D Kojic for providing the Schneider SL2 cells. This work was supported by grants from the Swiss National Foundation 3100-067213 (to AT and MFF); the Marlies-Schwegler Foundation and the Bernese Foundation of Cancer Research (to MFF and AT); the Werner and Hedy Berger-Janser Foundation of Cancer Research (to MFF and MPT); the Bern University Research Foundation (to MPT); and the Danish Cancer Society (to KH).	ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; Bell LA, 2004, CELL DEATH DIFFER, V11, P137, DOI 10.1038/sj.cdd.4401324; Bialik S, 2006, ANNU REV BIOCHEM, V75, P189, DOI 10.1146/annurev.biochem.75.103004.142615; Bieker JJ, 2001, J BIOL CHEM, V276, P34355, DOI 10.1074/jbc.R100043200; Black AR, 2001, J CELL PHYSIOL, V188, P143, DOI 10.1002/jcp.1111; BLAKE MC, 1990, MOL CELL BIOL, V10, P6632, DOI 10.1128/MCB.10.12.6632; Botella LM, 2002, BLOOD, V100, P4001, DOI 10.1182/blood.V100.12.4001; Britschgi C, 2006, ONCOGENE, V25, P2030, DOI 10.1038/sj.onc.1209240; Chen CS, 2003, AM J PATHOL, V162, P1349, DOI 10.1016/S0002-9440(10)63930-2; Christoph F, 2006, BRIT J CANCER, V95, P1701, DOI 10.1038/sj.bjc.6603482; DeGregori J, 2006, CURR MOL MED, V6, P739; Denchi EL, 2005, EMBO REP, V6, P661, DOI 10.1038/sj.embor.7400452; Difeo A, 2006, CLIN CANCER RES, V12, P3730, DOI 10.1158/1078-0432.CCR-06-0054; Esteller M, 2001, CANCER RES, V61, P3225; Geng Y, 1996, ONCOGENE, V12, P1173; Hershko T, 2004, J BIOL CHEM, V279, P8627, DOI 10.1074/jbc.M312866200; Inbal B, 2000, MOL CELL BIOL, V20, P1044, DOI 10.1128/MCB.20.3.1044-1054.2000; Irwin M, 2000, NATURE, V407, P645, DOI 10.1038/35036614; Ito G, 2004, CANCER RES, V64, P3838, DOI 10.1158/0008-5472.CAN-04-0185; Karlseder J, 1996, MOL CELL BIOL, V16, P1659; Katzenellenbogen RA, 1999, BLOOD, V93, P4347, DOI 10.1182/blood.V93.12.4347.412k31_4347_4353; Kim Y, 1998, J BIOL CHEM, V273, P33750, DOI 10.1074/jbc.273.50.33750; KOLLMAR R, 1994, J BIOL CHEM, V269, P2252; Koutsodontis G, 2004, ONCOGENE, V23, P9190, DOI 10.1038/sj.onc.1208141; Kramps C, 2004, J BIOL CHEM, V279, P5110, DOI 10.1074/jbc.M304758200; Li D, 2005, CANCER RES, V65, P9216, DOI 10.1158/0008-5472.CAN-05-1040; Lin SY, 1996, MOL CELL BIOL, V16, P1668; Maruyama R, 2001, CANCER RES, V61, P8659; MILLER DM, 1987, AM J MED SCI, V294, P388, DOI 10.1097/00000441-198711000-00015; Moroni MC, 2001, NAT CELL BIOL, V3, P552, DOI 10.1038/35078527; Muller H, 2001, GENE DEV, V15, P267, DOI 10.1101/gad.864201; Narla G, 2003, AM J PATHOL, V162, P1047, DOI 10.1016/S0002-9440(10)63901-6; Narla G, 2001, SCIENCE, V294, P2563, DOI 10.1126/science.1066326; Parisi T, 2002, BIOCHEM BIOPH RES CO, V291, P1138, DOI 10.1006/bbrc.2002.6591; Park KK, 2003, BIOCHEM BIOPH RES CO, V306, P239, DOI 10.1016/S0006-291X(03)00941-0; Putzer BM, 2007, J CELL MOL MED, V11, P239, DOI 10.1111/j.1582-4934.2007.00030.x; Radziwill G, 2003, MOL CELL BIOL, V23, P4663, DOI 10.1128/MCB.23.13.4663-4672.2003; Reeves HL, 2004, GASTROENTEROLOGY, V126, P1090, DOI 10.1053/j.gastro.2004.01.005; Rizzi M, 2007, J LEUKOCYTE BIOL, V81, P1599, DOI 10.1189/jlb.0606400; Robertson KD, 1998, MOL CELL BIOL, V18, P6457, DOI 10.1128/MCB.18.11.6457; Shohat G, 2002, BBA-PROTEINS PROTEOM, V1600, P45, DOI 10.1016/S1570-9639(02)00443-0; Slavin DA, 2004, ONCOGENE, V23, P8196, DOI 10.1038/sj.onc.1208020; Stanelle J, 2005, CELL DEATH DIFFER, V12, P347, DOI 10.1038/sj.cdd.4401532; Suske G, 1999, GENE, V238, P291, DOI 10.1016/S0378-1119(99)00357-1; Suzuki T, 2005, ARTERIOSCL THROM VAS, V25, P1135, DOI 10.1161/01.ATV.0000165656.65359.23; Tschan MP, 2003, J BIOL CHEM, V278, P42750, DOI 10.1074/jbc.M307067200; Turner J, 1999, TRENDS BIOCHEM SCI, V24, P236, DOI 10.1016/S0968-0004(99)01406-1; Voso MT, 2004, BLOOD, V103, P698, DOI 10.1182/blood-2003-07-2249; Xie W, 2006, NUCLEIC ACIDS RES, V34, P2046, DOI 10.1093/nar/gkl150; Yin D, 2007, INT J ONCOL, V30, P65	50	29	32	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP	2008	27	43					5706	5716		10.1038/onc.2008.179	http://dx.doi.org/10.1038/onc.2008.179			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	352HM	18521079				2022-12-28	WOS:000259487100006
J	Westhoff, MA; Zhou, S; Bachem, MG; Debatin, KM; Fulda, S				Westhoff, M. A.; Zhou, S.; Bachem, M. G.; Debatin, K. M.; Fulda, S.			Identification of a novel switch in the dominant forms of cell adhesion-mediated drug resistance in glioblastoma cells	ONCOGENE			English	Article						cell adhesion-mediated drug resistance; glioblastoma; apoptosis	GAP JUNCTIONAL COMMUNICATION; DE-NOVO; TUMOR MICROENVIRONMENT; GLYCYRRHETINIC ACID; INDUCED APOPTOSIS; MULTIPLE-MYELOMA; STEM-CELLS; IN-VITRO; BRAIN; SURVIVAL	The failure of malignant cells to undergo apoptosis is a major obstacle in cancer therapy, and thus identifying the underlining molecules involved therein is imperative for improving patient survival. An important mechanism of drug resistance is cell adhesion-mediated drug resistance (CAM-DR). In this study we identify a novel switch by which glioblastoma multiforme (GBM) cells alter the mode of CAM-DR. In the absence of a microenvironmental cue provided by components of the extracellular matrix (ECM), GBM cells are able to employ an alternative, but equally effective, mode of CAM-DR by forming spheres via cell-cell interactions. Intriguingly, when inhibiting cell-cell interactions in the absence of ECM components, either by low cell density or by inhibition of gap junctions (intercellular connexin tunnels) through chemical inhibition with carbenoxyolone or coincubation with the connexin-mimicking Gap27 Cx37,43 peptide, GBM cells were sensitized to tumor necrosis factor-related apoptosis- inducing ligand- and CD95-induced apoptosis. By demonstrating that GBM cells can alternate from one form of CAM-DR (cell-substrate tethering) to another (homocellular cell-cell adhesion) and that inhibition of both forms is necessary for apoptosis sensitization, our findings not only have important implications for novel approaches to restore defective apoptosis programs, but also reveal a novel role of gap junctions in GBM.	[Westhoff, M. A.; Debatin, K. M.; Fulda, S.] Univ Childrens Hosp, Dept Hematol Oncol, D-89075 Ulm, Germany; [Zhou, S.; Bachem, M. G.] Univ Ulm, Dept Clin Chem, Ulm, Germany	Ulm University; University of Hamburg; University Medical Center Hamburg-Eppendorf; Ulm University	Fulda, S (corresponding author), Univ Childrens Hosp, Dept Hematol Oncol, Eythstr 24, D-89075 Ulm, Germany.	simone.fulda@uniklinik-ulm.de	Westhoff, Mike-Andrew/ABA-9272-2021; Debatin, Klaus-Michael/J-9704-2014; Fulda, Simone/D-5864-2011	Westhoff, Mike-Andrew/0000-0003-3256-7100; Debatin, Klaus-Michael/0000-0002-8397-1886; Fulda, Simone/0000-0002-0459-6417	Deutsche Forschungsgemeinschaft; Deutsche Krebshilfe; Ministry of Science; Research and Arts of Baden-Wurttemberg; IZKF Ulm; Wilhelm-Sander-Stiftung; Else-Kroner-Fresenius-Stiftung	Deutsche Forschungsgemeinschaft(German Research Foundation (DFG)); Deutsche Krebshilfe(Deutsche Krebshilfe); Ministry of Science(Ministry of Science, ICT & Future Planning, Republic of Korea); Research and Arts of Baden-Wurttemberg; IZKF Ulm; Wilhelm-Sander-Stiftung; Else-Kroner-Fresenius-Stiftung	We thank M Adam-Jager and S Piater for expert technical assistance. This work has been partially supported by grants from the Deutsche Forschungsgemeinschaft, the Deutsche Krebshilfe, the Ministry of Science, Research and Arts of Baden-Wurttemberg, IZKF Ulm, Wilhelm-Sander-Stiftung and Else-Kroner-Fresenius-Stiftung (to SF and KMD).	Bellail AC, 2004, INT J BIOCHEM CELL B, V36, P1046, DOI 10.1016/j.biocel.2004.01.013; Belot N, 2001, GLIA, V36, P375, DOI 10.1002/glia.1124; Bissell MJ, 2001, NAT REV CANCER, V1, P46, DOI 10.1038/35094059; Calaora V, 2001, J NEUROSCI, V21, P4740, DOI 10.1523/JNEUROSCI.21-13-04740.2001; Cheng AW, 2004, DEV BIOL, V272, P203, DOI 10.1016/j.ydbio.2004.04.031; Cordes N, 2003, STRAHLENTHER ONKOL, V179, P337, DOI 10.1007/s00066-003-1074-4; Dalton WS, 1999, DRUG RESIST UPDATE, V2, P285, DOI 10.1054/drup.1999.0097; DAVIDSON JS, 1986, BIOCHEM BIOPH RES CO, V134, P29, DOI 10.1016/0006-291X(86)90522-X; DURAND RE, 1972, EXP CELL RES, V71, P75, DOI 10.1016/0014-4827(72)90265-0; Elliott Tony, 2002, Expert Rev Anticancer Ther, V2, P449, DOI 10.1586/14737140.2.4.449; Frame MC, 2004, J CELL SCI, V117, P989, DOI 10.1242/jcs.01111; Fulda S, 1997, CANCER RES, V57, P3823; Galli R, 2004, CANCER RES, V64, P7011, DOI 10.1158/0008-5472.CAN-04-1364; GLADSON CL, 1995, J CELL SCI, V108, P947; Goldberg GS, 1996, EXP CELL RES, V222, P48, DOI 10.1006/excr.1996.0006; Green LM, 2005, RADIAT RES, V163, P172, DOI 10.1667/RR3297; Gurney JG, 2001, CURR OPIN ONCOL, V13, P160, DOI 10.1097/00001622-200105000-00005; Hazlehurst LA, 2003, CANCER RES, V63, P7900; Hazlehurst LA, 2003, ONCOGENE, V22, P7396, DOI 10.1038/sj.onc.1206943; Hazlehurst LA, 2001, CANCER METAST REV, V20, P43, DOI 10.1023/A:1013156407224; Huang RP, 1998, CANCER RES, V58, P5089; Knight MJ, 2001, ONCOGENE, V20, P5789, DOI 10.1038/sj.onc.1204810; Krysko DV, 2005, APOPTOSIS, V10, P459, DOI 10.1007/s10495-005-1875-2; LABARCA C, 1980, ANAL BIOCHEM, V102, P344, DOI 10.1016/0003-2697(80)90165-7; Levin V A, 1999, Neuro Oncol, V1, P69, DOI 10.1093/neuonc/1.1.69; Morin PJ, 2003, DRUG RESIST UPDATE, V6, P169, DOI 10.1016/S1368-7646(03)00059-1; Oliveira R, 2005, BMC CELL BIOL, V6, DOI 10.1186/1471-2121-6-7; Oloumi A, 2000, CANCER RES, V60, P5747; Sanai N, 2005, NEW ENGL J MED, V353, P811, DOI 10.1056/NEJMra043666; Schmid-Kotsas A, 1999, AM J PATHOL, V155, P1749, DOI 10.1016/S0002-9440(10)65490-9; Schmidmaier R, 2004, BLOOD, V104, P1825, DOI 10.1182/blood-2003-12-4218; Shain KH, 2001, MOL CANCER THER, V1, P69; Singh SK, 2004, NATURE, V432, P396, DOI 10.1038/nature03128; Soroceanu L, 2001, GLIA, V33, P107, DOI 10.1002/1098-1136(200102)33:2<107::AID-GLIA1010>3.0.CO;2-4; SUTHERLAND RM, 1972, BRIT J RADIOL, V45, P788, DOI 10.1259/0007-1285-45-538-788; TRAUTH BC, 1989, SCIENCE, V245, P301, DOI 10.1126/science.2787530; Uhm JH, 1999, CLIN CANCER RES, V5, P1587; Wei CJ, 2005, J BIOL CHEM, V280, P19925, DOI 10.1074/jbc.M412921200; Westhoff MA, 2004, MOL CELL BIOL, V24, P8113, DOI 10.1128/MCB.24.18.8113-8133.2004; Yuan XP, 2004, ONCOGENE, V23, P9392, DOI 10.1038/sj.onc.1208311; Zhang W, 1999, CANCER RES, V59, P1994	41	50	53	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP	2008	27	39					5169	5181		10.1038/onc.2008.148	http://dx.doi.org/10.1038/onc.2008.148			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	344GO	18469856				2022-12-28	WOS:000258915100001
J	Zhao, LJ; Subramanian, T; Chinnadurai, G				Zhao, L-J; Subramanian, T.; Chinnadurai, G.			Inhibition of transcriptional activation and cell proliferation activities of adenovirus E1A by the unique N-terminal domain of CtBP2	ONCOGENE			English	Article						E1A; CtBP; transcriptional repression; cell proliferation	NUCLEAR-LOCALIZATION; NEGATIVE MODULATION; MOLECULAR-CLONING; TRANSFORMATION; BINDING; PROTEIN; REGION; GENE; PHOSPHOPROTEIN; TUMORIGENESIS	The 243-residue E1A protein of adenovirus induces cellular proliferation, at least partly by regulating the transcription of cellular genes. This E1A function requires E1A N-terminal region and conserved regions 1 and 2 (CR1 and CR2), which interact with histone acetyl transferases, p400 chromatin-modifying complex and the Rb family proteins. A PLDLS motif at the E1A C-terminal (CR4) region, interacts with the C-terminal binding proteins (CtBP1 and CtBP2), and antagonizes some E1A functions. In this report, we discovered that the transcriptional activation function of E1A was specifically repressed by a short N-terminal domain unique to CtBP2. The CtBP2-mediated repression of E1A transcriptional activation activity is independent of histone deacetylases, which can be recruited by CtBP1/2 proteins to inhibit transcription. Fusion of the CtBP2 N-terminal 20 residues to the E1A C-terminal region rendered E1A to be inactive in transcriptional activation without interfering with E1A's ability to interact with major cofactors such as pRb, p400 and p300. Substitution of the N-terminal domain of CtBP1 for the CtBP2 domain in E1A-CtBP2 fusion partially restored the transactivation activity of E1A. In a cell-proliferation model utilizing primary baby rat kidney cells and retrovirally expressed E1A, the ability of E1A to induce cellular proliferation was strongly inhibited when the CtBP2 N-terminal region was fused to E1A. These results are consistent with a hypothesis that CtBP2 may inhibit E1A induced cell proliferation by antagonizing the transcriptional activation function controlled by the N-terminal region of E1A.	[Zhao, L-J; Subramanian, T.; Chinnadurai, G.] St Louis Univ, Sch Med, Doisy Res Ctr, Inst Mol Virol, St Louis, MO 63104 USA	Saint Louis University	Chinnadurai, G (corresponding author), St Louis Univ, Sch Med, Doisy Res Ctr, Inst Mol Virol, 1100 S Grand Blvd, St Louis, MO 63104 USA.	chinnag@slu.edu			 [CA-84941];  [CA-33616]; NATIONAL CANCER INSTITUTE [R01CA084941, R01CA033616] Funding Source: NIH RePORTER	; ; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank R Subramanian for technical assistance. This study was supported by research grants CA-84941 and CA-33616.	Bergman LM, 2006, BMC CELL BIOL, V7, DOI 10.1186/1471-2121-7-35; Berk AJ, 2005, ONCOGENE, V24, P7673, DOI 10.1038/sj.onc.1209040; BOYD JM, 1993, EMBO J, V12, P469, DOI 10.1002/j.1460-2075.1993.tb05679.x; Chinnadurai G, 2007, INT J BIOCHEM CELL B, V39, P1593, DOI 10.1016/j.biocel.2007.01.025; CHINNADURAI G, 2007, MOL BIOL INTELL UNIT, pR9; ECKNER R, 1994, GENE DEV, V8, P869, DOI 10.1101/gad.8.8.869; Fuchs M, 2001, CELL, V106, P297, DOI 10.1016/S0092-8674(01)00450-0; GRAHAM FL, 1973, VIROLOGY, V54, P536, DOI 10.1016/0042-6822(73)90163-3; Grignani F, 1998, CANCER RES, V58, P14; Hildebrand JD, 2002, MOL CELL BIOL, V22, P5296, DOI 10.1128/MCB.22.15.5296-5307.2002; Kuppuswamy M, 2008, MOL CELL BIOL, V28, P269, DOI 10.1128/MCB.01077-07; Lang SE, 2003, ONCOGENE, V22, P2836, DOI 10.1038/sj.onc.1206376; Reid JL, 1998, EMBO J, V17, P4469, DOI 10.1093/emboj/17.15.4469; Samuelson AV, 2005, J BIOL CHEM, V280, P21915, DOI 10.1074/jbc.M414564200; SCHAEPER U, 1995, P NATL ACAD SCI USA, V92, P10467, DOI 10.1073/pnas.92.23.10467; Schmitz F, 2000, NEURON, V28, P857, DOI 10.1016/S0896-6273(00)00159-8; Shi YJ, 2003, NATURE, V422, P735, DOI 10.1038/nature01550; Sollerbrant K, 1996, NUCLEIC ACIDS RES, V24, P2578, DOI 10.1093/nar/24.13.2578; SUBRAMANIAN T, 1989, ONCOGENE, V4, P415; Verger A, 2006, MOL CELL BIOL, V26, P4882, DOI 10.1128/MCB.02402-05; WANG HGH, 1993, J VIROL, V67, P476, DOI 10.1128/JVI.67.1.476-488.1993; WHYTE P, 1989, CELL, V56, P67, DOI 10.1016/0092-8674(89)90984-7; ZERLER B, 1987, MOL CELL BIOL, V7, P821, DOI 10.1128/MCB.7.2.821; Zhao LJ, 2007, ONCOGENE, V26, P7544, DOI 10.1038/sj.onc.1210569; Zhao LJ, 2006, J BIOL CHEM, V281, P36613, DOI 10.1074/jbc.M603550200; Zhao LJ, 2006, J BIOL CHEM, V281, P4183, DOI 10.1074/jbc.M509051200	26	3	3	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP	2008	27	39					5214	5222		10.1038/onc.2008.162	http://dx.doi.org/10.1038/onc.2008.162			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	344GO	18490918	Green Accepted			2022-12-28	WOS:000258915100005
J	Hernandez, JM; Floyd, DH; Weilbaecher, KN; Green, PL; Boris-Lawrie, K				Hernandez, J. M.; Floyd, D. H.; Weilbaecher, K. N.; Green, P. L.; Boris-Lawrie, K.			Multiple facets of junD gene expression are atypical among AP-1 family members	ONCOGENE			English	Review						JunD; AP-1; RNA helicase A and post-transcriptional control element; HTLV-1; cancer; heart failure	RNA HELICASE-A; LEUKEMIA-VIRUS TYPE-1; EXON JUNCTION COMPLEX; HUMAN OVARIAN-CANCER; C-JUN; MESSENGER-RNA; TRANSCRIPTIONAL ACTIVITY; DNA-BINDING; TUMOR-SUPPRESSOR; ACTIVATED TRANSCRIPTION	JunD is a versatile AP-1 transcription factor that can activate or repress a diverse collection of target genes. Precise control of junD expression and JunD protein protein interactions modulate tumor angiogenesis, cellular differentiation, proliferation and apoptosis. Molecular and clinical knowledge of two decades has revealed that precise JunD activity is elaborated by interrelated layers of constitutive transcriptional control, complex post-transcriptional regulation and a collection of post-translational modi. cations and protein-protein interactions. The stakes are high, as inappropriate JunD activity contributes to neoplastic, metabolic and viral diseases. This article deconvolutes multiple layers of control that safeguard junD gene expression and functional activity. The activity of JunD in transcriptional activation and repression is integrated into a regulatory network by which JunD exerts a pivotal role in cellular growth control. Our discussion of the JunD regulatory network integrates important open issues and posits new therapeutic targets for the neoplastic, metabolic and viral diseases associated with JunD/AP-1 expression.	[Boris-Lawrie, K.] Ohio State Univ, Dept Vet Biosci, Goss Lab, Columbus, OH 43210 USA; [Floyd, D. H.; Weilbaecher, K. N.] Washington Univ, Sch Med, Dept Med, Div Mol Oncol, St Louis, MO 63110 USA; [Green, P. L.; Boris-Lawrie, K.] Ohio State Univ, Ctr Comprehens Canc, Dept Med, Columbus, OH 43210 USA	University System of Ohio; Ohio State University; Washington University (WUSTL); James Cancer Hospital & Solove Research Institute; University System of Ohio; Ohio State University	Boris-Lawrie, K (corresponding author), Ohio State Univ, Dept Vet Biosci, Goss Lab, 1925 Coffey Rd, Columbus, OH 43210 USA.	boris-lawrie.1@osu.edu	Boris-Lawrie, Kathleen/AAB-8953-2020	Boris-Lawrie, Kathleen/0000-0001-6366-6270	NCI NIH HHS [P01 CA100730-010005, R01 CA108882, R01CA108882, P01 CA100730-01, P30CA100730, P01CA16058, P30 CA016058, P01 CA100730] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA016058, R01CA108882, P01CA100730] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abdelhaleem M, 2003, ANTICANCER RES, V23, P485; ADLER V, 1994, J BIOL CHEM, V269, P11186; Agarwal SK, 2003, P NATL ACAD SCI USA, V100, P10770, DOI 10.1073/pnas.1834524100; Akhouayri O, 2007, CALCIFIED TISSUE INT, V80, P123, DOI 10.1007/s00223-006-0102-7; ALCIVAR AA, 1991, MOL REPROD DEV, V30, P187, DOI 10.1002/mrd.1080300304; Arguni E, 2006, INT IMMUNOL, V18, P1079, DOI 10.1093/intimm/dxl041; Arnold J, 2006, BLOOD, V107, P3976, DOI 10.1182/blood-2005-11-4551; Baird SD, 2006, RNA, V12, P1755, DOI 10.1261/rna.157806; Basbous J, 2003, J BIOL CHEM, V278, P43620, DOI 10.1074/jbc.M307275200; BERGER I, 1991, ONCOGENE, V6, P561; BERGER I, 1994, DNA CELL BIOL, V13, P249, DOI 10.1089/dna.1994.13.249; Bolinger C, 2007, NUCLEIC ACIDS RES, V35, P2629, DOI 10.1093/nar/gkm124; BRADDOCK M, 1994, NUCLEIC ACIDS RES, V22, P5255, DOI 10.1093/nar/22.24.5255; Butsch M, 1999, J VIROL, V73, P4847, DOI 10.1128/JVI.73.6.4847-4855.1999; Cavanagh MH, 2006, RETROVIROLOGY, V3, DOI 10.1186/1742-4690-3-15; DEGROOT RP, 1991, EMBO J, V10, P2523, DOI 10.1002/j.1460-2075.1991.tb07792.x; Dreijerink KMA, 2006, NAT CLIN PRACT ENDOC, V2, P562, DOI 10.1038/ncpendmet0292; Eferl R, 2003, NAT REV CANCER, V3, P859, DOI 10.1038/nrc1209; Finkel T, 2006, ANTIOXID REDOX SIGN, V8, P1857, DOI 10.1089/ars.2006.8.1857; Fries F, 2007, INT J CANCER, V120, P2135, DOI 10.1002/ijc.22447; Fuchs SY, 1997, J BIOL CHEM, V272, P32163, DOI 10.1074/jbc.272.51.32163; Gallo A, 2002, ONCOGENE, V21, P6434, DOI 10.1038/sj.onc.1205822; Gerald D, 2004, CELL, V118, P781, DOI 10.1016/j.cell.2004.08.025; Gobl AE, 1999, BBA-GENE STRUCT EXPR, V1447, P51, DOI 10.1016/S0167-4781(99)00132-3; Gudikote JP, 2005, NAT STRUCT MOL BIOL, V12, P801, DOI 10.1038/nsmb980; Gunthert AR, 2002, BIOCHEM BIOPH RES CO, V294, P11, DOI 10.1016/S0006-291X(02)00427-8; HAI T, 1991, P NATL ACAD SCI USA, V88, P3720, DOI 10.1073/pnas.88.9.3720; Harper JW, 1999, NAT CELL BIOL, V1, pE5, DOI 10.1038/8952; Hartman TR, 2006, NAT STRUCT MOL BIOL, V13, P509, DOI 10.1038/nsmb1092; Hendy GN, 2005, HORM METAB RES, V37, P375, DOI 10.1055/s-2005-870152; HERSCHMAN HR, 1991, ANNU REV BIOCHEM, V60, P281, DOI 10.1146/annurev.biochem.60.1.281; Hess J, 2004, J CELL SCI, V117, P5965, DOI 10.1242/jcs.01589; Hilfiker-Kleiner D, 2005, CIRCULATION, V112, P1470, DOI 10.1161/CIRCULATIONAHA.104.518472; HIRAI SI, 1989, EMBO J, V8, P1433, DOI 10.1002/j.1460-2075.1989.tb03525.x; Hivin P, 2006, NUCLEIC ACIDS RES, V34, P2761, DOI 10.1093/nar/gkl375; Ijiri K, 2005, J BIOL CHEM, V280, P38544, DOI 10.1074/jbc.M504202200; Jochum W, 2001, ONCOGENE, V20, P2401, DOI 10.1038/sj.onc.1204389; Kallunki T, 1996, CELL, V87, P929, DOI 10.1016/S0092-8674(00)81999-6; Kameda T, 1997, CELL GROWTH DIFFER, V8, P495; Kamijo T, 1998, P NATL ACAD SCI USA, V95, P8292, DOI 10.1073/pnas.95.14.8292; Kim H, 2003, CANCER RES, V63, P6135; Kim H, 2005, EXP MOL MED, V37, P466, DOI 10.1038/emm.2005.57; Kim J, 2002, J BIOL CHEM, V277, P38037, DOI 10.1074/jbc.M207235200; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P3873, DOI 10.1093/nar/12.9.3873; Kuhlmann AS, 2007, RETROVIROLOGY, V4, DOI 10.1186/1742-4690-4-92; LAROCCA D, 1989, BIOCHEM BIOPH RES CO, V163, P1006, DOI 10.1016/0006-291X(89)92322-X; Li L, 2002, GASTROENTEROLOGY, V123, P764, DOI 10.1053/gast.2002.35386; Li M, 2007, J VIROL METHODS, V142, P159, DOI 10.1016/j.jviromet.2007.01.023; Li T, 2002, J BIOL CHEM, V277, P32668, DOI 10.1074/jbc.M203519200; LI Y, 1994, ONCOGENE, V9, P2261; Matsumoto J, 2005, ONCOGENE, V24, P1001, DOI 10.1038/sj.onc.1208297; Matsumoto K, 1998, EMBO J, V17, P2107, DOI 10.1093/emboj/17.7.2107; Matsuoka M, 2007, NAT REV CANCER, V7, P270, DOI 10.1038/nrc2111; McCabe LR, 1996, ENDOCRINOLOGY, V137, P4398, DOI 10.1210/en.137.10.4398; Mechta-Grigoriou F, 2001, ONCOGENE, V20, P2378, DOI 10.1038/sj.onc.1204381; Mehic D, 2005, J INVEST DERMATOL, V124, P212, DOI 10.1111/j.0022-202X.2004.23558.x; Meixner A, 2004, EMBO J, V23, P1325, DOI 10.1038/sj.emboj.7600133; Merrick WC., 1996, TRANSLATION CONTROL, P31; Milde-Langosch K, 2005, EUR J CANCER, V41, P2449, DOI 10.1016/j.ejca.2005.08.008; MORGAN IM, 1993, ONCOGENE, V8, P1135; Musti AM, 1996, BIOL CHEM, V377, P619, DOI 10.1515/bchm3.1996.377.10.619; Myohanen S, 2001, J BIOL CHEM, V276, P1634, DOI 10.1074/jbc.M004481200; Naito J, 2005, J BIOL CHEM, V280, P4785, DOI 10.1074/jbc.M408143200; Neyns B, 1996, ONCOGENE, V12, P1247; Nott A, 2004, GENE DEV, V18, P210, DOI 10.1101/gad.1163204; Okazaki S, 1998, BIOCHEM BIOPH RES CO, V250, P347, DOI 10.1006/bbrc.1998.9331; Persengiev SP, 2003, APOPTOSIS, V8, P225, DOI 10.1023/A:1023633704132; PFARR CM, 1994, CELL, V76, P747, DOI 10.1016/0092-8674(94)90513-4; Pollack PS, 1997, J CELL BIOCHEM, V65, P245, DOI 10.1002/(SICI)1097-4644(199705)65:2<245::AID-JCB9>3.0.CO;2-U; Pomerantz J, 1998, CELL, V92, P713, DOI 10.1016/S0092-8674(00)81400-2; Punga T, 2006, J BIOL CHEM, V281, P25278, DOI 10.1074/jbc.M604983200; Robb GB, 2007, MOL CELL, V26, P523, DOI 10.1016/j.molcel.2007.04.016; Roberts TM, 2000, J VIROL, V74, P8111, DOI 10.1128/JVI.74.17.8111-8118.2000; Roberts TM, 2003, J VIROL, V77, P11973, DOI 10.1128/JVI.77.22.11973-11984.2003; Schwenger GTF, 2002, J BIOL CHEM, V277, P47022, DOI 10.1074/jbc.M207414200; Short JD, 2002, J BIOL CHEM, V277, P32697, DOI 10.1074/jbc.M204553200; Srivastava S, 1999, J CLIN INVEST, V104, P503, DOI 10.1172/JCI7094; Takeda Y, 1999, J IMMUNOL, V163, P6269; Tange TO, 2004, CURR OPIN CELL BIOL, V16, P279, DOI 10.1016/j.ceb.2004.03.012; Thebault S, 2004, FEBS LETT, V562, P165, DOI 10.1016/S0014-5793(04)00225-X; Thepot D, 2000, DEVELOPMENT, V127, P143; TREIER M, 1994, CELL, V78, P787, DOI 10.1016/S0092-8674(94)90502-9; Troen G, 2004, J MOL DIAGN, V6, P297, DOI 10.1016/S1525-1578(10)60525-9; Tsuji Y, 2005, ONCOGENE, V24, P7567, DOI 10.1038/sj.onc.1208901; Uria JA, 1998, J BIOL CHEM, V273, P9769, DOI 10.1074/jbc.273.16.9769; Weitzman JB, 2000, MOL CELL, V6, P1109, DOI 10.1016/S1097-2765(00)00109-X; Wiegand HL, 2003, P NATL ACAD SCI USA, V100, P11327, DOI 10.1073/pnas.1934877100; Willingham AT, 2006, CELL, V125, P1215, DOI 10.1016/j.cell.2006.06.009; Xiao L, 2007, BIOCHEM J, V403, P573, DOI 10.1042/BJ20061436; Yang SH, 2004, MOL CELL, V13, P611, DOI 10.1016/S1097-2765(04)00060-7; Yazgan O, 2002, J BIOL CHEM, V277, P29710, DOI 10.1074/jbc.M204552200; Yazgan O, 2001, CANCER RES, V61, P916; Yilmaz A, 2006, CURR HIV RES, V4, P131, DOI 10.2174/157016206776055039; Zenz R, 2006, INT J BIOCHEM CELL B, V38, P1043, DOI 10.1016/j.biocel.2005.11.011; Zerbini LF, 2003, CANCER RES, V63, P2206; Zhang SS, 2004, ACTA BIOCH BIOPH SIN, V36, P177, DOI 10.1093/abbs/36.3.177; Zhang YP, 1998, CELL, V92, P725, DOI 10.1016/S0092-8674(00)81401-4; Zhou H, 2007, CELL PROLIFERAT, V40, P431, DOI 10.1111/j.1365-2184.2007.00444.x	100	75	76	2	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 14	2008	27	35					4757	4767		10.1038/onc.2008.120	http://dx.doi.org/10.1038/onc.2008.120			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	337OJ	18427548	Green Accepted			2022-12-28	WOS:000258445100001
J	Nepal, RM; Zaheen, A; Basit, W; Li, L; Berger, SA; Martin, A				Nepal, R. M.; Zaheen, A.; Basit, W.; Li, L.; Berger, S. A.; Martin, A.			AID and RAG1 do not contribute to lymphomagenesis in E mu c-myc transgenic mice	ONCOGENE			English	Article						B cells; hypermutation; activation-induced cytidine deaminase; c-myc; lymphoma; RAG	CYTIDINE DEAMINASE AID; REACTIVE B-LYMPHOCYTES; SOMATIC HYPERMUTATION; CELL LYMPHOMAS; DNA BREAKS; TRANSLOCATIONS; EXPRESSION; REGION; MOUSE; GENE	DNA breaks caused by recombination-activating gene 1 (RAG1) and activation-induced cytidine deaminase (AID) induce c-myc/immunoglobulin (Ig) heavy chain chromosomal translocations and thereby stimulate lymphomagenesis. However, constitutive expression of c-myc alone is not sufficient to induce lymphomas. Because RAG1 and AID activity occurs outside of Ig genes, we assessed whether these enzymes provide the secondary genetic lesions in El c-myc transgenic mice to promote lymphoma development. We found that the tumor incidence and tumor phenotype in E mu c-myc transgenic mice is similar in AID(+/+), AID(+/-) and AID(-/-) backgrounds in both specific pathogen-free and conventional animal facilities, indicating that AID does not contribute to lymphoma development in E mu c-myc transgenic mice. To examine the role of RAG proteins in E mu c-myc mice, we examined E mu c-myc transgenic mice that harbor the Ig-HEL heavy- and light-chain transgenes, and thus have reduced RAG expression in B cells. We found that tumor incidence was not affected by these Ig transgenes. However, we found that RAG1(-/-) E mu c-myc mice exhibited accelerated tumor development compared to controls. This data combined with our finding that E mu c-myc mice lived longer in the conventional facility than in the specific pathogen-free facility suggest an immune-mediated activity that suppresses lymphoma development.	[Nepal, R. M.; Zaheen, A.; Basit, W.; Li, L.; Berger, S. A.; Martin, A.] Univ Toronto, Dept Immunol, Toronto, ON M5S 1A8, Canada; [Berger, S. A.] Univ Hlth Network, Arthritis & Autoimmun Res Ctr, Toronto, ON, Canada	University of Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto	Martin, A (corresponding author), Univ Toronto, Dept Immunol, Med Sci Bldg 5265, Toronto, ON M5S 1A8, Canada.	alberto.martin@utoronto.ca		Martin, Alberto/0000-0002-0795-0418				ADAMS JM, 1985, NATURE, V318, P533, DOI 10.1038/318533a0; CREWS S, 1982, SCIENCE, V218, P1319, DOI 10.1126/science.7146913; Crouch EE, 2007, J EXP MED, V204, P1145, DOI 10.1084/jem.20061952; DALLAFAVERA R, 1982, P NATL ACAD SCI-BIOL, V79, P7824, DOI 10.1073/pnas.79.24.7824; Di Nola JM, 2007, ANNU REV BIOCHEM, V76, P1, DOI 10.1146/annurev.biochem.76.061705.090740; Dorsett Y, 2007, J EXP MED, V204, P2225, DOI 10.1084/jem.20070884; Egle A, 2004, P NATL ACAD SCI USA, V101, P6164, DOI 10.1073/pnas.0401471101; Eischen CM, 1999, GENE DEV, V13, P2658, DOI 10.1101/gad.13.20.2658; Fang W, 1998, IMMUNITY, V9, P35, DOI 10.1016/S1074-7613(00)80586-5; Franco S, 2006, MOL CELL, V21, P201, DOI 10.1016/j.molcel.2006.01.005; Franco S, 2006, DNA REPAIR, V5, P1030, DOI 10.1016/j.dnarep.2006.05.024; GOODNOW CC, 1988, NATURE, V334, P676, DOI 10.1038/334676a0; HARRIS AW, 1988, J EXP MED, V167, P353, DOI 10.1084/jem.167.2.353; KORSMEYER SJ, 1992, ANNU REV IMMUNOL, V10, P785, DOI 10.1146/annurev.immunol.10.1.785; Kotani A, 2007, P NATL ACAD SCI USA, V104, P1616, DOI 10.1073/pnas.0610732104; MASON DY, 1992, INT IMMUNOL, V4, P163, DOI 10.1093/intimm/4.2.163; Muramatsu M, 1999, J BIOL CHEM, V274, P18470, DOI 10.1074/jbc.274.26.18470; Muramatsu M, 2000, CELL, V102, P553, DOI 10.1016/S0092-8674(00)00078-7; Muschen M, 2000, J EXP MED, V192, P1833, DOI 10.1084/jem.192.12.1833; Pasqualucci L, 2001, NATURE, V412, P341, DOI 10.1038/35085588; Prasad VS, 1996, CYTOMETRY, V23, P131, DOI 10.1002/(SICI)1097-0320(19960201)23:2<131::AID-CYTO7>3.0.CO;2-N; Raghavan SC, 2004, NATURE, V428, P88, DOI 10.1038/nature02355; Ramiro AR, 2004, CELL, V118, P431, DOI 10.1016/j.cell.2004.08.006; Ramiro AR, 2006, NATURE, V440, P105, DOI 10.1038/nature04495; Shen HM, 1998, SCIENCE, V280, P1750, DOI 10.1126/science.280.5370.1750; Smith DP, 2005, ONCOGENE, V24, P3544, DOI 10.1038/sj.onc.1208399; VANLOHUIZEN M, 1991, CELL, V65, P737, DOI 10.1016/0092-8674(91)90382-9	27	24	24	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG	2008	27	34					4752	4756		10.1038/onc.2008.111	http://dx.doi.org/10.1038/onc.2008.111			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	334QM	18408759				2022-12-28	WOS:000258236300013
J	Yu, JS; Koujak, S; Nagase, S; Li, CM; Su, T; Wang, X; Keniry, M; Memeo, L; Rojtman, A; Mansukhani, M; Hibshoosh, H; Tycko, B; Parsons, R				Yu, J. S.; Koujak, S.; Nagase, S.; Li, C-M; Su, T.; Wang, X.; Keniry, M.; Memeo, L.; Rojtman, A.; Mansukhani, M.; Hibshoosh, H.; Tycko, B.; Parsons, R.			PCDH8, the human homolog of PAPC, is a candidate tumor suppressor of breast cancer	ONCOGENE			English	Article						PCDH8; protocadherin; breast cancer; tumor suppressor	TRANSCRIPTION FACTOR SNAIL; PARAXIAL PROTOCADHERIN; STRUCTURAL BASIS; CELL MOVEMENTS; CHROMOSOME 13Q; CADHERIN; MORPHOGENESIS; ADHESION; GENE; PROLIFERATION	Carcinoma is an altered state of tissue differentiation in which epithelial cells no longer respond to cues that keep them in their proper position. A break down in these cues has disastrous consequences not only in cancer but also in embryonic development when cells of various lineages must organize into discrete entities to form a body plan. Paraxial protocadherin (PAPC) is an adhesion protein with six cadherin repeats that organizes the formation and polarity of developing cellular structures in frog, fish and mouse embryos. Here we show that protocadherin-8 (PCDH8), the human ortholog of PAPC, is inactivated through either mutation or epigenetic silencing in a high fraction of breast carcinomas. Loss of PCDH8 expression is associated with loss of heterozygosity, partial promoter methylation, and increased proliferation. Complementation of mutant tumor cell line HCC2218 with wild-type PCDH8 inhibited its growth. Two tumor mutants, E146K and R343H, were defective for inhibition of cell growth and migration. Sur prisingly, the E146K mutant transformed the human mammary epithelial cell line MCF10A and sustained the expression of cyclin D1 and MYC without epidermal growth factor. We propose that loss of PCDH8 promotes oncogenesis in epithelial human cancers by disrupting cell-cell communication dedicated to tissue organization and repression of mitogenic signaling.	[Parsons, R.] Columbia Univ, Inst Canc Genet, Dept Pathol & Cell Biol, New York, NY 10032 USA; [Parsons, R.] Columbia Univ, Dept Med, New York, NY 10032 USA	Columbia University; Columbia University	Parsons, R (corresponding author), Columbia Univ, Inst Canc Genet, Dept Pathol & Cell Biol, 1130 St Nicholas Ave, New York, NY 10032 USA.	rep15@columbia.edu		Memeo, Lorenzo/0000-0003-4251-7203; Parsons, Ramon/0000-0002-6656-3514; Nagase, Satoru/0000-0001-5212-1128	NATIONAL CANCER INSTITUTE [R01CA082783] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA082783-05, R01 CA082783-04, R01 CA082783-07, R01 CA082783, R01 CA082783-06] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Batlle E, 2000, NAT CELL BIOL, V2, P84, DOI 10.1038/35000034; Berx G, 1998, HUM MUTAT, V12, P226, DOI 10.1002/(SICI)1098-1004(1998)12:4<226::AID-HUMU2>3.0.CO;2-D; Boggon TJ, 2002, SCIENCE, V296, P1308, DOI 10.1126/science.1071559; Cano A, 2000, NAT CELL BIOL, V2, P76, DOI 10.1038/35000025; Chou JL, 1999, BREAST CANCER RES TR, V55, P267, DOI 10.1023/A:1006217413089; Cox C, 2005, P NATL ACAD SCI USA, V102, P4542, DOI 10.1073/pnas.0408593102; Debnath J, 2003, J CELL BIOL, V163, P315, DOI 10.1083/jcb.200304159; Debnath J, 2003, METHODS, V30, P256, DOI 10.1016/S1046-2023(03)00032-X; Eiriksdottir G, 1998, EUR J CANCER, V34, P2076, DOI 10.1016/S0959-8049(98)00241-X; Guilford P, 1998, NATURE, V392, P402, DOI 10.1038/32918; Gumbiner BM, 2005, NAT REV MOL CELL BIO, V6, P622, DOI 10.1038/nrm1699; Hukriede NA, 2003, DEV CELL, V4, P83, DOI 10.1016/S1534-5807(02)00398-2; Imoto I, 2006, CANCER RES, V66, P4617, DOI 10.1158/0008-5472.CAN-05-4437; Kim SH, 1998, DEVELOPMENT, V125, P4681; Kim SH, 2000, CURR BIOL, V10, P821, DOI 10.1016/S0960-9822(00)00580-7; LISITSYN N, 1993, SCIENCE, V259, P946, DOI 10.1126/science.8438152; Medina A, 2004, EMBO J, V23, P3249, DOI 10.1038/sj.emboj.7600329; Melamed J, 1997, CLIN CANCER RES, V3, P1867; Muthuswamy SK, 2001, NAT CELL BIOL, V3, P785, DOI 10.1038/ncb0901-785; Nagar B, 1996, NATURE, V380, P360, DOI 10.1038/380360a0; Rhee J, 2003, DEV BIOL, V254, P248, DOI 10.1016/S0012-1606(02)00085-4; SHAPIRO L, 1995, NATURE, V374, P327, DOI 10.1038/374327a0; Sjoblom T, 2006, SCIENCE, V314, P268, DOI 10.1126/science.1133427; Suyama K, 2002, CANCER CELL, V2, P301, DOI 10.1016/S1535-6108(02)00150-2; Unterseher F, 2004, EMBO J, V23, P3259, DOI 10.1038/sj.emboj.7600332; WAZER DE, 1995, P NATL ACAD SCI USA, V92, P3687, DOI 10.1073/pnas.92.9.3687; Yang J, 2004, CELL, V117, P927, DOI 10.1016/j.cell.2004.06.006; Yin ZN, 1999, ONCOGENE, V18, P7576, DOI 10.1038/sj.onc.1203203; Ying J, 2006, ONCOGENE, V25, P1070, DOI 10.1038/sj.onc.1209154; Zhong Y, 1999, J CELL BIOL, V144, P351, DOI 10.1083/jcb.144.2.351	30	121	127	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG	2008	27	34					4657	4665		10.1038/onc.2008.101	http://dx.doi.org/10.1038/onc.2008.101			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	334QM	18408767	Green Accepted			2022-12-28	WOS:000258236300004
J	Tajeddine, N; Galluzzi, L; Kepp, O; Hangen, E; Morselli, E; Senovilla, L; Araujo, N; Pinna, G; Larochette, N; Zamzami, N; Modjtahedi, N; Harel-Bellan, A; Kroemer, G				Tajeddine, N.; Galluzzi, L.; Kepp, O.; Hangen, E.; Morselli, E.; Senovilla, L.; Araujo, N.; Pinna, G.; Larochette, N.; Zamzami, N.; Modjtahedi, N.; Harel-Bellan, A.; Kroemer, G.			Hierarchical involvement of Bak, VDAC1 and Bax in cisplatin-induced cell death	ONCOGENE			English	Article						apoptosis; Bcl-2 family; caspases; mitochondria; non-small cell lung cancer (NSCLC); reactive oxygen species (ROS)	DEPENDENT ANION CHANNEL; MITOCHONDRIAL-MEMBRANE PERMEABILIZATION; ADENINE-NUCLEOTIDE TRANSLOCATOR; TRANSITION PORE; CYTOCHROME-C; LUNG-CANCER; APOPTOSIS; PROTEINS; DAMAGE; BCL-2	Following the screening of a battery of distinct small-interfering RNAs that target various components of the apoptotic machinery, we found that knockdown of the voltage-dependent anion channel 1 (VDAC1) was particularly efficient in preventing cell death induced by cisplatin (CDDP) in non-small cell lung cancer cells. Both the downregulation of VDAC1 and its chemical inhibition with 4,4'-diisothiocyanatostilbene-2,2'-disulfonic acid reduced the apoptosis-associated modi. cations induced by CDDP, including mitochondrial transmembrane potential dissipation and plasma membrane permeabilization. VDAC1 inhibition strongly reduced the CDDP-induced conformational activation of Bax, yet had no discernible effect on the activation of Bak, suggesting that VDAC1 acts downstream of Bak and upstream of Bax. Accordingly, knockdown of Bak abolished the activation of Bax, whereas Bax downregulation had no effect on Bak activation. In VDAC1-depleted cells, the failure of CDDP to activate Bax could be reversed by means of the Bcl-2/Bcl-XL antagonist ABT-737, which concomitantly restored CDDP cytotoxicity. Altogether, these results delineate a novel pathway for the induction of mitochondrial membrane permeabilization (MMP) in the course of CDDP-induced cell death that involves a hierarchical contribution of Bak, VDAC1 and Bax. Moreover, our data suggest that VDAC1 may act as a facultative regulator/effector of MMP, depending on the initial cytotoxic event.	[Tajeddine, N.; Galluzzi, L.; Kepp, O.; Hangen, E.; Morselli, E.; Senovilla, L.; Zamzami, N.; Modjtahedi, N.; Kroemer, G.] Inst Gustave Roussy, INSERM, U848, F-94805 Villejuif, France; [Tajeddine, N.; Galluzzi, L.; Kepp, O.; Hangen, E.; Morselli, E.; Senovilla, L.; Araujo, N.; Pinna, G.; Zamzami, N.; Modjtahedi, N.; Harel-Bellan, A.; Kroemer, G.] Univ Paris 11, Villejuif, France; [Araujo, N.; Pinna, G.; Harel-Bellan, A.] Inst Andre Lwoff, Lab Epigenet & Canc, CNRS, FRE 2944, Villejuif, France; [Larochette, N.] Inst Biol Physicochim, Lab Biol Cellulaire & Mol Secret, CNRS, UPR1929, F-75005 Paris, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Gustave Roussy; UDICE-French Research Universities; Universite Paris Saclay; Centre National de la Recherche Scientifique (CNRS); Centre National de la Recherche Scientifique (CNRS)	Kroemer, G (corresponding author), Inst Gustave Roussy, INSERM, U848, PR1,Pavillon Rech 1,39 Rue Camille Desmoulins, F-94805 Villejuif, France.	kroemer@igr.fr	MODJTAHEDI, Nazanine/D-4377-2017; KROEMER, Guido/B-4263-2013; Galluzzi, Lorenzo/AAH-3286-2021; Kepp, Oliver/N-2763-2017; Harel-Bellan, Annick/M-9795-2015; LAROCHETTE, Nathanael/R-4298-2017; Galluzzi, Lorenzo/K-2709-2012; Galluzzi, Lorenzo/AAG-6432-2019; Kepp, Oliver/GPX-8627-2022; Kroemer, Guido/AAY-9859-2020; Senovilla, Laura/AAX-5599-2021; Galluzzi, Lorenzo/AAG-6294-2019	KROEMER, Guido/0000-0002-9334-4405; Kepp, Oliver/0000-0002-6081-9558; LAROCHETTE, Nathanael/0000-0002-7936-678X; Galluzzi, Lorenzo/0000-0003-2257-8500; Senovilla, Laura/0000-0001-6887-2436; Harel-Bellan, Annick/0000-0002-2339-153X; PINNA, Guillaume/0000-0001-7841-7250; MODJTAHEDI, NAZANINE/0000-0002-1832-0710				Baines CP, 2007, NAT CELL BIOL, V9, P550, DOI 10.1038/ncb1575; Bartz SR, 2006, MOL CELL BIOL, V26, P9377, DOI 10.1128/MCB.01229-06; Belzacq AS, 2002, BIOCHIMIE, V84, P167, DOI 10.1016/S0300-9084(02)01366-4; Berndtsson M, 2007, INT J CANCER, V120, P175, DOI 10.1002/ijc.22132; Brenner C, 2006, ONCOGENE, V25, P4744, DOI 10.1038/sj.onc.1209609; Brenner C, 2000, ONCOGENE, V19, P329, DOI 10.1038/sj.onc.1203298; Castedo M, 2003, ANN NY ACAD SCI, V1010, P19, DOI 10.1196/annals.1299.004; Chandra D, 2005, J BIOL CHEM, V280, P19051, DOI 10.1074/jbc.M501391200; Cheng EHY, 2003, SCIENCE, V301, P513, DOI 10.1126/science.1083995; Cosaert J, 2002, BRIT J CANCER, V87, P825, DOI 10.1038/sj.bjc.6600540; Criollo A, 2007, APOPTOSIS, V12, P3, DOI 10.1007/s10495-006-0328-x; Galluzzi L, 2007, NAT CELL BIOL, V9, P487, DOI 10.1038/ncb0507-487; Galluzzi L, 2007, APOPTOSIS, V12, P803, DOI 10.1007/s10495-007-0720-1; Garrido C, 2006, CELL DEATH DIFFER, V13, P1423, DOI 10.1038/sj.cdd.4401950; Griffiths GJ, 1999, J CELL BIOL, V144, P903, DOI 10.1083/jcb.144.5.903; Grimm S, 2007, APOPTOSIS, V12, P841, DOI 10.1007/s10495-007-0747-3; Kepp O, 2007, EMBO J, V26, P825, DOI 10.1038/sj.emboj.7601533; Kroemer G, 2007, PHYSIOL REV, V87, P99, DOI 10.1152/physrev.00013.2006; Lalier L, 2007, APOPTOSIS, V12, P887, DOI 10.1007/s10495-007-0749-1; Lorenzo HK, 1999, CELL DEATH DIFFER, V6, P516, DOI 10.1038/sj.cdd.4400527; Mandic A, 2003, J BIOL CHEM, V278, P9100, DOI 10.1074/jbc.M210284200; Marzo I, 1998, SCIENCE, V281, P2027, DOI 10.1126/science.281.5385.2027; Modjtahedi N, 2006, TRENDS CELL BIOL, V16, P264, DOI 10.1016/j.tcb.2006.03.008; Olaussen KA, 2006, NEW ENGL J MED, V355, P983, DOI 10.1056/NEJMoa060570; Oltersdorf T, 2005, NATURE, V435, P677, DOI 10.1038/nature03579; Perfettini JL, 2004, NAT CELL BIOL, V6, P386, DOI 10.1038/ncb0504-386; Ravagnan L, 2002, J CELL PHYSIOL, V192, P131, DOI 10.1002/jcp.10111; Reed JC, 2006, CELL DEATH DIFFER, V13, P1378, DOI 10.1038/sj.cdd.4401975; Rouge TD, 2007, CANCER RES, V67, P6253, DOI 10.1158/0008-5472.CAN-07-0538; Rudin CM, 2003, CANCER RES, V63, P312; Seve Pascal, 2005, Current Medicinal Chemistry - Anti-Cancer Agents, V5, P73, DOI 10.2174/1568011053352604; Shafir I, 1998, J BIOENERG BIOMEMBR, V30, P499, DOI 10.1023/A:1020598315287; Shimizu S, 1999, NATURE, V399, P483, DOI 10.1038/20959; Shimizu S, 2000, ONCOGENE, V19, P4309, DOI 10.1038/sj.onc.1203788; Shimizu S, 2001, J CELL BIOL, V152, P237, DOI 10.1083/jcb.152.2.237; Shimizu S, 2000, J BIOL CHEM, V275, P12321, DOI 10.1074/jbc.275.16.12321; ShoshanBarmatz V, 1996, FEBS LETT, V386, P205, DOI 10.1016/0014-5793(96)00442-5; Siddik ZH, 2003, ONCOGENE, V22, P7265, DOI 10.1038/sj.onc.1206933; Tarze A, 2007, ONCOGENE, V26, P2606, DOI 10.1038/sj.onc.1210074; THINNES FP, 1990, BIOL CHEM H-S, V371, P1047, DOI 10.1515/bchm3.1990.371.2.1047; Wang GQ, 2001, J BIOL CHEM, V276, P34307, DOI 10.1074/jbc.M103526200; Yagoda N, 2007, NATURE, V447, P864, DOI 10.1038/nature05859; ZAMZAMI N, 1995, J EXP MED, V182, P367, DOI 10.1084/jem.182.2.367; Zamzami N, 2005, BIOCHEM BIOPH RES CO, V331, P685, DOI 10.1016/j.bbrc.2005.04.013; ZAMZAMI N, 2003, METH MOL B, V282, P103; Zermati Y, 2007, MOL CELL, V28, P624, DOI 10.1016/j.molcel.2007.09.030; Zhang K, 2001, MOL PHARMACOL, V59, P837, DOI 10.1124/mol.59.4.837	47	168	176	1	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2008	27	30					4221	4232		10.1038/onc.2008.63	http://dx.doi.org/10.1038/onc.2008.63			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	324DB	18362892				2022-12-28	WOS:000257496800009
J	Vasiljeva, O; Korovin, M; Gajda, M; Brodoefel, H; Bojic, L; Kruger, A; Schurigt, U; Sevenich, L; Turk, B; Peters, C; Reinheckel, T				Vasiljeva, O.; Korovin, M.; Gajda, M.; Brodoefel, H.; Bojic, L.; Kruger, A.; Schurigt, U.; Sevenich, L.; Turk, B.; Peters, C.; Reinheckel, T.			Reduced tumour cell proliferation and delayed development of high-grade mammary carcinomas in cathepsin B-deficient mice	ONCOGENE			English	Article						apoptosis; cathepsin; differentiation; mammary cancer; mouse model; proliferation	LYSOSOMAL CYSTEINE PROTEASES; BREAST-CANCER; APOPTOSIS; PROGRESSION; METASTASIS; EXPRESSION; MEMBRANE; DEATH; ASSOCIATION; SECRETION	Expression levels of the papain-like cysteine protease cathepsin B (Ctsb) have been positively correlated with mammary tumour progression and metastasis; however, its roles in the hallmark processes of malignant growth remain poorly defined. Using Ctsb-deficient mice we investigated tumour cell differentiation, proliferation and apoptosis in the Tg(MMTV-PyMT) mouse mammary cancer model. Absence of Ctsb significantly impaired development of high-grade invasive ductal carcinomas and reduced the metastatic burden in the lungs. Mice lacking Ctsb exhibited reduced cell proliferation in mammary carcinomas and their lung metastases. Notably, intravenous injection of primarily isolated, Ctsb-expressing tumour cells into congenic Ctsb-deficient mice revealed impaired cell proliferation in the resulting experimental lung metastases, providing evidence for the involvement of Ctsb in paracrine regulation of cancer cell proliferation. No Ctsb genotype-dependent difference in tumour cell death was observed in vivo or by treatment of isolated PyMT cancer cells with tumour necrosis factor-alpha. However, cancer cells lacking Ctsb exhibited significantly higher resistance to apoptosis induction by the lysosomotropic agent Leu-Leu-OMe. Thus, our results indicate an in vivo role for Ctsb in promoting cellular anaplasia in mammary cancers and proliferation in lung metastases.	[Vasiljeva, O.; Korovin, M.; Brodoefel, H.; Schurigt, U.; Sevenich, L.; Peters, C.; Reinheckel, T.] Univ Freiburg, Inst Mol Med & Zellforsch, D-79104 Freiburg, Germany; [Vasiljeva, O.; Bojic, L.; Turk, B.] Jozef Stefan Inst, Dept Biochem & Mol & Struct Biol, Ljubljana, Slovenia; [Gajda, M.] Univ Jena, Inst Pathol, Jena, Germany; [Kruger, A.] Tech Univ Munich, Klinikum Rechts Isar, Inst Expt Onkol & Therapieforsch, Munich, Germany	University of Freiburg; Slovenian Academy of Sciences & Arts (SASA); Jozef Stefan Institute; Friedrich Schiller University of Jena; Technical University of Munich	Reinheckel, T (corresponding author), Univ Freiburg, Inst Mol Med & Zellforsch, Stefan Meier Str 17, D-79104 Freiburg, Germany.	Thomas.Reinheckel@uniklinik-freiburg.de	Korovin, Matvei/S-3137-2016; Reinheckel, Thomas/AAL-9761-2021	Korovin, Matvei/0000-0002-1278-1401; Reinheckel, Thomas/0000-0001-9866-9105; Schurigt, Uta/0000-0003-4423-5955; Turk, Boris/0000-0002-9007-5764				Blomgran R, 2007, J LEUKOCYTE BIOL, V81, P1213, DOI 10.1189/jlb.0506359; Cirman T, 2004, J BIOL CHEM, V279, P3578, DOI 10.1074/jbc.M308347200; de Visser KE, 2006, CONTRIB MICROBIOL, V13, P118, DOI 10.1159/000092969; ELSTON CW, 1991, HISTOPATHOLOGY, V19, P403, DOI 10.1111/j.1365-2559.1991.tb00229.x; Fehrenbacher N, 2004, CANCER RES, V64, P5301, DOI 10.1158/0008-5472.CAN-04-1427; Fernandez PL, 2001, INT J CANCER, V95, P51, DOI 10.1002/1097-0215(20010120)95:1<51::AID-IJC1009>3.0.CO;2-J; Frosch BA, 1999, APMIS, V107, P28, DOI 10.1111/j.1699-0463.1999.tb01523.x; Gocheva V, 2006, GENE DEV, V20, P543, DOI 10.1101/gad.1407406; Gocheva V, 2007, CELL CYCLE, V6, P60, DOI 10.4161/cc.6.1.3669; Guicciardi ME, 2000, J CLIN INVEST, V106, P1127, DOI 10.1172/JCI9914; GUY CT, 1992, MOL CELL BIOL, V12, P954, DOI 10.1128/MCB.12.3.954; Huveneers S, 2007, CANCER RES, V67, P2693, DOI 10.1158/0008-5472.CAN-06-3654; Jaattela M, 2004, ONCOGENE, V23, P2746, DOI 10.1038/sj.onc.1207513; Jedeszko C, 2004, BIOL CHEM, V385, P1017, DOI 10.1515/BC.2004.132; Lechner AM, 2006, J BIOL CHEM, V281, P39588, DOI 10.1074/jbc.M513439200; Lin EY, 2003, AM J PATHOL, V163, P2113, DOI 10.1016/S0002-9440(10)63568-7; Loffek Stefanie, 2006, J Dtsch Dermatol Ges, V4, P496, DOI 10.1111/j.1610-0387.2006.05991.x; McKerrow JH, 2000, MOL MED, V6, P450, DOI 10.1007/BF03401787; Mohamed MM, 2006, NAT REV CANCER, V6, P764, DOI 10.1038/nrc1949; Mueller MM, 2004, NAT REV CANCER, V4, P839, DOI 10.1038/nrc1477; Nagaraj NS, 2007, APOPTOSIS, V12, P125, DOI 10.1007/s10495-006-0490-1; Podgorski I, 2003, BIOCHEM SOC SYMP, V70, P263, DOI 10.1042/bss0700263; Rossi A, 2004, BIOL CHEM, V385, P363, DOI 10.1515/BC.2004.040; ROZHIN J, 1994, CANCER RES, V54, P6517; Sanchez-Beato M, 2003, BLOOD, V101, P1220, DOI 10.1182/blood-2002-07-2009; Sloan EK, 2006, BREAST CANCER RES, V8, DOI 10.1186/bcr1398; SLOANE BF, 1986, P NATL ACAD SCI USA, V83, P2483, DOI 10.1073/pnas.83.8.2483; Stoka V, 2001, J BIOL CHEM, V276, P3149, DOI 10.1074/jbc.M008944200; Stoka V, 2005, IUBMB LIFE, V57, P347, DOI 10.1080/15216540500154920; Turk B, 2000, BBA-PROTEIN STRUCT M, V1477, P98, DOI 10.1016/S0167-4838(99)00263-0; Turk B, 2007, FEBS LETT, V581, P2761, DOI 10.1016/j.febslet.2007.05.038; vanRoozendaal KEP, 1996, INT J CANCER, V65, P120, DOI 10.1002/(SICI)1097-0215(19960103)65:1<120::AID-IJC20>3.0.CO;2-J; Vasiljeva O, 2007, CURR PHARM DESIGN, V13, P387, DOI 10.2174/138161207780162962; Vasiljeva O, 2006, CANCER RES, V66, P5242, DOI 10.1158/0008-5472.CAN-05-4463; Zajc I, 2006, ANTICANCER RES, V26, P3357; Zheng X, 2004, CANCER RES, V64, P1773, DOI 10.1158/0008-5472.CAN-03-0820	36	92	93	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL	2008	27	30					4191	4199		10.1038/onc.2008.59	http://dx.doi.org/10.1038/onc.2008.59			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	324DB	18345026				2022-12-28	WOS:000257496800006
J	Deep, G; Oberlies, NH; Kroll, DJ; Agarwal, R				Deep, G.; Oberlies, N. H.; Kroll, D. J.; Agarwal, R.			Isosilybin B causes androgen receptor degradation in human prostate carcinoma cells via PI3K-Akt-Mdm2-mediated pathway	ONCOGENE			English	Article						androgen receptor; prostate specific antigen; prostate cancer; isosilybin B	CANCER CELLS; FLAVONOID ANTIOXIDANT; INDUCED APOPTOSIS; SILYBUM-MARIANUM; P53 ACTIVATION; MILK THISTLE; G(1) ARREST; IN-VIVO; SILYMARIN; GROWTH	The identification and development of novel nontoxic phytochemicals that target androgen and androgen receptor (AR) signaling remains a priority for prostate cancer (PCA) control. In the present study, we assessed the antiandrogenic efficacy of isosilybin B employing human PCA LNCaP ( mutated AR), 22Rv1 ( mutated AR) and LAPC4 ( wild-type AR) cells. Isosilybin B (10-90 mu M) treatment decreased the AR and prostate specific antigen (PSA) levels in LNCaP, 22Rv1 and LAPC4 cells, but not in non-neoplastic human prostate epithelial PWR-1E cells. Isosilybin B treatment also inhibited synthetic androgen R1881-induced nuclear localization of AR, PSA expression and cell growth, and caused G(1) arrest. In mechanistic studies identifying AR degradation, isosilybin B caused increased phosphorylation of Akt (Ser-473 and Thr-308) and Mdm2 (Ser-166), which was linked with AR degradation as pretreatment with PI3K inhibitor (LY294002)-restored AR level. Further, overexpression of kinase-dead Akt largely reversed isosilybin B mediated-AR degradation suggesting a critical role of Akt in AR degradation. Antibody pull-down results also indicated that isosilybin B treatment enhances the formation of complex between Akt, Mdm2 and AR, which promotes phosphorylation-dependent AR ubiquitination and its degradation by proteasome. Together, present findings identify a novel mechanism for isosilybin B-mediated anticancer effects in human PCA cells.	[Deep, G.; Agarwal, R.] Univ Colorado, Sch Pharm, Dept Pharmaceut Sci, Denver, CO 80262 USA; [Oberlies, N. H.; Kroll, D. J.] Ctr Organ & Med Chem, Nat Prod Lab, Res Triangle Pk, NC USA; [Agarwal, R.] Univ Colorado, Ctr Canc, Denver, CO 80262 USA	University of Colorado System; University of Colorado Denver; University of Colorado System; University of Colorado Denver	Agarwal, R (corresponding author), Univ Colorado, Sch Pharm, Dept Pharmaceut Sci, 4200 E 9th St,Box C238, Denver, CO 80262 USA.	Rajesh.Agarwal@uchsc.edu	Deep, Gagan/H-1853-2012; Oberlies, Nicholas/D-8162-2011	Oberlies, Nicholas/0000-0002-0354-8464	NATIONAL CANCER INSTITUTE [R01CA104286] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA104286] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bernard D, 2003, J CLIN INVEST, V112, P1724; Chen L, 2004, NEW ASTRON, V10, P39, DOI 10.1016/j.newast.2004.04.008; Chen LH, 2005, EMBO J, V24, P3411, DOI 10.1038/sj.emboj.7600812; Chen SY, 2006, P NATL ACAD SCI USA, V103, P15969, DOI 10.1073/pnas.0604193103; Cinar B, 2005, CANCER RES, V65, P2547, DOI 10.1158/0008-5472.CAN-04-3411; Davis-Searles PR, 2005, CANCER RES, V65, P4448, DOI 10.1158/0008-5472.CAN-04-4662; Deep G, 2006, ONCOGENE, V25, P1053, DOI 10.1038/sj.onc.1209146; Deep G, 2007, CARCINOGENESIS, V28, P1533, DOI 10.1093/carcin/bgm069; Dhanalakshmi S, 2005, J BIOL CHEM, V280, P20375, DOI 10.1074/jbc.M414640200; Gioeli D, 2006, MOL ENDOCRINOL, V20, P503, DOI 10.1210/me.2005-0351; Grossmann ME, 2001, JNCI-J NATL CANCER I, V93, P1687, DOI 10.1093/jnci/93.22.1687; Haag P, 2005, J STEROID BIOCHEM, V96, P251, DOI 10.1016/j.jsbmb.2005.04.029; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Jemal A, 2007, CA-CANCER J CLIN, V57, P43, DOI 10.3322/canjclin.57.1.43; Kim NC, 2003, ORG BIOMOL CHEM, V1, P1684, DOI 10.1039/b300099k; Klein KA, 1997, NAT MED, V3, P402, DOI 10.1038/nm0497-402; Lee DK, 2003, J CLIN ENDOCR METAB, V88, P4043, DOI 10.1210/jc.2003-030261; Lee HJ, 2003, CELL MOL LIFE SCI, V60, P1613, DOI 10.1007/s00018-003-2309-3; Liao ZM, 2005, PROSTATE, V64, P186, DOI 10.1002/pros.20224; Lin HK, 2002, EMBO J, V21, P4037, DOI 10.1093/emboj/cdf406; Lin HK, 2001, P NATL ACAD SCI USA, V98, P7200, DOI 10.1073/pnas.121173298; Mendoza N, 2002, CANCER RES, V62, P5485; Miyamoto H, 2005, MOL CARCINOGEN, V44, P1, DOI 10.1002/mc.20121; MULLER MM, 1989, NUCLEIC ACIDS RES, V17, P6420, DOI 10.1093/nar/17.15.6420; Nagabhushan M, 1996, CANCER RES, V56, P3042; Nelson WG, 2003, NEW ENGL J MED, V349, P366, DOI 10.1056/NEJMra021562; Paajarvi G, 2004, FASEB J, V18, P476, DOI 10.1096/fj.04-2745fje; Pan Y, 2003, MOL CELL BIOL, V23, P5113, DOI 10.1128/MCB.23.15.5113-5121.2003; Pliskova M, 2005, TOXICOLOGY, V215, P80, DOI 10.1016/j.tox.2005.06.020; Reddy GPV, 2006, J CELL BIOCHEM, V98, P1408, DOI 10.1002/jcb.20927; Seidlova-Wuttke D, 2003, J STEROID BIOCHEM, V86, P179, DOI 10.1016/S0960-0760(03)00270-X; Sharifi Nima, 2006, Am J Ther, V13, P166, DOI 10.1097/00045391-200603000-00013; Singh RP, 2006, MOL CARCINOGEN, V45, P436, DOI 10.1002/mc.20223; Singh RP, 2002, ANTIOXID REDOX SIGN, V4, P655, DOI 10.1089/15230860260220166; Tong QS, 2003, CHINESE MED J-PEKING, V116, P1515; Wang L, 2004, J BIOL CHEM, V279, P32444, DOI 10.1074/jbc.M313963200; Wellington K, 2001, BIODRUGS, V15, P465, DOI 10.2165/00063030-200115070-00005; Wen Y, 2000, CANCER RES, V60, P6841; Yang L, 2005, J BIOL CHEM, V280, P33558, DOI 10.1074/jbc.M504461200; Zhou BHP, 2001, NAT CELL BIOL, V3, P973, DOI 10.1038/ncb1101-973; Zi XL, 1998, CLIN CANCER RES, V4, P1055; Zi ZL, 1999, P NATL ACAD SCI USA, V96, P7490, DOI 10.1073/pnas.96.13.7490	42	47	48	1	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2008	27	28					3986	3998		10.1038/onc.2008.45	http://dx.doi.org/10.1038/onc.2008.45			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	318JZ	18332867				2022-12-28	WOS:000257089000010
J	Partridge, L; Bruning, JC				Partridge, L.; Bruening, J. C.			Forkhead transcription factors and ageing	ONCOGENE			English	Review						forkhead transcription factor; FOXO; signaling; ageing; lifespan; ageing-related disease	EXTENDS LIFE-SPAN; NEMATODE CAENORHABDITIS-ELEGANS; ACTIVATED PROTEIN-KINASE; C-ELEGANS; INSULIN-RECEPTOR; OXIDATIVE-STRESS; DIETARY RESTRICTION; CALORIE RESTRICTION; TUMOR SUPPRESSION; FACTOR FOXO1	Mutations in single genes and environmental interventions can extend healthy lifespan in laboratory model organisms. Some of the mechanisms involved show evolutionary conservation, opening the way to using simpler invertebrates to understand human ageing. Forkhead transcription factors have been found to play a key role in lifespan extension by alterations in the insulin/IGF pathway and by dietary restriction. Interventions that extend lifespan have also been found to delay or ameliorate the impact of ageing-related pathology and disease, including cancer. Understanding the mode of action of forkheads in this context will illuminate the mechanisms by which ageing acts as a risk factor for ageing-related disease, and could lead to the development of a broad-spectrum, preventative medicine for the diseases of ageing.	[Partridge, L.] Inst Healthy Aging, London WC1E 6BT, England; [Bruening, J. C.] Univ Cologne, Inst Genet, Dept Mouse Genet & Metab, D-5000 Cologne, Germany	University of London; University College London; University of Cologne	Partridge, L (corresponding author), Inst Healthy Aging, GEE,Darwin Bldg,Gower Street, London WC1E 6BT, England.	l.partridge@ucl.ac.uk	Partridge, Linda/A-5501-2010; Partridge, Linda/E-7342-2015	Partridge, Linda/0000-0001-9615-0094	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Alcedo J, 2004, NEURON, V41, P45, DOI 10.1016/S0896-6273(03)00816-X; Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9; Apfeld J, 1999, NATURE, V402, P804, DOI 10.1038/45544; Arden KC, 2007, CELL, V128, P235, DOI 10.1016/j.cell.2007.01.009; Baldauf SL, 1999, AM NAT, V154, pS178, DOI 10.1086/303292; Barnes AI, 2006, P ROY SOC B-BIOL SCI, V273, P939, DOI 10.1098/rspb.2005.3388; Berdichevsky A, 2006, CELL, V125, P1165, DOI 10.1016/j.cell.2006.04.036; Biggs WH, 1999, P NATL ACAD SCI USA, V96, P7421, DOI 10.1073/pnas.96.13.7421; Bluher M, 2003, SCIENCE, V299, P572, DOI 10.1126/science.1078223; Bonkowski MS, 2006, P NATL ACAD SCI USA, V103, P7901, DOI 10.1073/pnas.0600161103; Borkhardt A, 1997, ONCOGENE, V14, P195, DOI 10.1038/sj.onc.1200814; Broughton SJ, 2005, P NATL ACAD SCI USA, V102, P3105, DOI 10.1073/pnas.0405775102; Brunet A, 2002, J CELL BIOL, V156, P817, DOI 10.1083/jcb.200112059; Brunet A, 2001, MOL CELL BIOL, V21, P952, DOI 10.1128/MCB.21.3.952-965.2001; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Brunet A, 2004, SCIENCE, V303, P2011, DOI 10.1126/science.1094637; Burgering BMT, 2002, TRENDS BIOCHEM SCI, V27, P352, DOI 10.1016/S0968-0004(02)02113-8; Cargill SL, 2003, AGING CELL, V2, P185, DOI 10.1046/j.1474-9728.2003.00049.x; Carter ME, 2007, CURR BIOL, V17, pR113, DOI 10.1016/j.cub.2007.01.008; Casas-Tinto S, 2007, BBA-GENE STRUCT EXPR, V1769, P236, DOI 10.1016/j.bbaexp.2007.03.003; Cheung WL, 2003, CELL, V113, P507, DOI 10.1016/S0092-8674(03)00355-6; Chintapalli VR, 2007, NAT GENET, V39, P715, DOI 10.1038/ng2049; Clancy DJ, 2002, SCIENCE, V296, P319, DOI 10.1126/science.1069366; Clancy DJ, 2001, SCIENCE, V292, P104, DOI 10.1126/science.1057991; Cohen E, 2006, SCIENCE, V313, P1604, DOI 10.1126/science.1124646; DAVIS RJ, 1994, CANCER RES, V54, P2869; Dillin A, 2002, SCIENCE, V298, P830, DOI 10.1126/science.1074240; DORMAN JB, 1995, GENETICS, V141, P1399; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Essers MAG, 2004, EMBO J, V23, P4802, DOI 10.1038/sj.emboj.7600476; Frescas D, 2005, J BIOL CHEM, V280, P20589, DOI 10.1074/jbc.M412357200; FRIEDMAN DB, 1988, GENETICS, V118, P75; Friedman JR, 2006, CELL MOL LIFE SCI, V63, P2317, DOI 10.1007/s00018-006-6095-6; Fukuoka M, 2003, INT J MOL MED, V12, P503; GALILI N, 1993, NAT GENET, V5, P230, DOI 10.1038/ng1193-230; Gershman B, 2007, PHYSIOL GENOMICS, V29, P24, DOI 10.1152/physiolgenomics.00061.2006; Giannakou ME, 2007, TRENDS BIOCHEM SCI, V32, P180, DOI 10.1016/j.tibs.2007.02.007; Giannakou ME, 2004, SCIENCE, V305, P361, DOI 10.1126/science.1098219; Giannakou ME, 2004, TRENDS CELL BIOL, V14, P408, DOI 10.1016/j.tcb.2004.07.006; GIANNAKOU ME, 2007, DROSOPHILA AGING CEL, V6, P429; Greer EL, 2007, J BIOL CHEM, V282, P30107, DOI 10.1074/jbc.M705325200; Greer EL, 2007, CURR BIOL, V17, P1646, DOI 10.1016/j.cub.2007.08.047; Hamilton B, 2005, GENE DEV, V19, P1544, DOI 10.1101/gad.1308205; Hansen M, 2007, AGING CELL, V6, P95, DOI 10.1111/j.1474-9726.2006.00267.x; Hardie DG, 1998, ANNU REV BIOCHEM, V67, P821, DOI 10.1146/annurev.biochem.67.1.821; Hertweck M, 2004, DEV CELL, V6, P577, DOI 10.1016/S1534-5807(04)00095-4; Holzenberger M, 2003, NATURE, V421, P182, DOI 10.1038/nature01298; Houthoofd Koen, 2007, V35, P98; Hsin H, 1999, NATURE, V399, P362, DOI 10.1038/20694; Hsu AL, 2003, SCIENCE, V300, P1142, DOI 10.1126/science.1083701; Hu MCT, 2004, CELL, V117, P225, DOI 10.1016/S0092-8674(04)00302-2; Hwangbo DS, 2004, NATURE, V429, P562, DOI 10.1038/nature02549; Jin GS, 2004, ACTA MED OKAYAMA, V58, P197; Junger Martin A, 2003, J Biol, V2, P20, DOI 10.1186/1475-4924-2-20; Kaeberlein M, 1999, GENE DEV, V13, P2570, DOI 10.1101/gad.13.19.2570; Kaeberlein TL, 2006, AGING CELL, V5, P487, DOI 10.1111/j.1474-9726.2006.00238.x; Keller C, 2004, GENE DEV, V18, P2614, DOI 10.1101/gad.1244004; Kennedy BK, 2007, CELL MOL LIFE SCI, V64, P1323, DOI 10.1007/s00018-007-6470-y; KENYON C, 1993, NATURE, V366, P461, DOI 10.1038/366461a0; Kimura KD, 1997, SCIENCE, V277, P942, DOI 10.1126/science.277.5328.942; Kitamura T, 2006, NAT MED, V12, P534, DOI 10.1038/nm1392; Kitamura YI, 2005, CELL METAB, V2, P153, DOI 10.1016/j.cmet.2005.08.004; KLASS MR, 1983, MECH AGEING DEV, V22, P279, DOI 10.1016/0047-6374(83)90082-9; Kramer Jamie M, 2003, BMC Dev Biol, V3, P5, DOI 10.1186/1471-213X-3-5; Kuningas M, 2007, EUR J HUM GENET, V15, P294, DOI 10.1038/sj.ejhg.5201766; Kurosu H, 2005, SCIENCE, V309, P1829, DOI 10.1126/science.1112766; Lagutina I, 2002, MOL CELL BIOL, V22, P7204, DOI 10.1128/MCB.22.20.7204-7216.2002; Lee GD, 2006, AGING CELL, V5, P515, DOI 10.1111/j.1474-9726.2006.00241.x; Lee SS, 2003, SCIENCE, V300, P644, DOI 10.1126/science.1083614; Lehtinen MK, 2006, CELL, V125, P987, DOI 10.1016/j.cell.2006.03.046; Li J, 2007, DEV BIOL, V301, P82, DOI 10.1016/j.ydbio.2006.10.013; Libert S, 2007, SCIENCE, V315, P1133, DOI 10.1126/science.1136610; Libina N, 2003, CELL, V115, P489, DOI 10.1016/S0092-8674(03)00889-4; Lin K, 2001, NAT GENET, V28, P139, DOI 10.1038/88850; Lin K, 1997, SCIENCE, V278, P1319, DOI 10.1126/science.278.5341.1319; Liu YF, 2002, BIOCHEM J, V366, P633, DOI 10.1042/BJ20020095; Lunetta KL, 2007, BMC MED GENET, V8, DOI 10.1186/1471-2350-8-S1-S13; Mair W, 2003, SCIENCE, V301, P1731, DOI 10.1126/science.1086016; Marr MT, 2007, GENE DEV, V21, P175, DOI 10.1101/gad.1506407; Mazet F, 2003, GENE, V316, P79, DOI 10.1016/S0378-1119(03)00741-8; McElwee J, 2003, AGING CELL, V2, P111, DOI 10.1046/j.1474-9728.2003.00043.x; McElwee JJ, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-7-r132; Medema RH, 2000, NATURE, V404, P782, DOI 10.1038/35008115; Mikosz CA, 2001, J BIOL CHEM, V276, P16649, DOI 10.1074/jbc.M010842200; Morris JZ, 1996, NATURE, V382, P536, DOI 10.1038/382536a0; Motta MC, 2004, CELL, V116, P551, DOI 10.1016/S0092-8674(04)00126-6; Mu J, 2001, MOL CELL, V7, P1085, DOI 10.1016/S1097-2765(01)00251-9; Murphy CT, 2003, NATURE, V424, P277, DOI 10.1038/nature01789; Naimi M, 2007, ENDOCRINOLOGY, V148, P2424, DOI 10.1210/en.2006-1411; Nakae J, 2003, DEV CELL, V4, P119, DOI 10.1016/S1534-5807(02)00401-X; Nasrin N, 2000, P NATL ACAD SCI USA, V97, P10412, DOI 10.1073/pnas.190326997; Ogg S, 1997, NATURE, V389, P994, DOI 10.1038/40194; Pan KZ, 2007, AGING CELL, V6, P111, DOI 10.1111/j.1474-9726.2006.00266.x; Panowski SH, 2007, NATURE, V447, P550, DOI 10.1038/nature05837; PARRY P, 1994, GENE CHROMOSOME CANC, V11, P79, DOI 10.1002/gcc.2870110203; Partridge L, 2007, NATURE, V450, P165, DOI 10.1038/450165a; Patel NV, 2005, NEUROBIOL AGING, V26, P995, DOI 10.1016/j.neurobiolaging.2004.09.014; Peng SL, 2007, AUTOIMMUNITY, V40, P462, DOI 10.1080/08916930701464913; Perrot V, 2005, MOL ENDOCRINOL, V19, P2283, DOI 10.1210/me.2004-0292; Pinkston-Gosse J, 2007, NAT GENET, V39, P1403, DOI 10.1038/ng.2007.1; PIPER MDW, IN PRESS J INTERNAL; Puig O, 2005, GENE DEV, V19, P2435, DOI 10.1101/gad.1340505; Puig O, 2006, CELL CYCLE, V5, P503, DOI 10.4161/cc.5.5.2501; Puig O, 2003, GENE DEV, V17, P2006, DOI 10.1101/gad.1098703; Puigserver P, 2003, NATURE, V423, P550, DOI 10.1038/nature01667; Qin WP, 2006, J BIOL CHEM, V281, P21745, DOI 10.1074/jbc.M602909200; Ramaswamy S, 2002, CANCER CELL, V2, P81, DOI 10.1016/S1535-6108(02)00086-7; Rogina B, 2004, P NATL ACAD SCI USA, V101, P15998, DOI 10.1073/pnas.0404184101; Schulz TJ, 2007, CELL METAB, V6, P280, DOI 10.1016/j.cmet.2007.08.011; SELMAN C, 2007, FASEB J; Sloop KW, 2004, J CLIN INVEST, V113, P1571, DOI 10.1172/JCI200420911; Spindler SR, 2007, ANNU REV NUTR, V27, P193, DOI 10.1146/annurev.nutr.27.061406.093743; Stambolic V, 2001, MOL CELL, V8, P317, DOI 10.1016/S1097-2765(01)00323-9; Sunayama J, 2005, J CELL BIOL, V170, P295, DOI 10.1083/jcb.200409117; Syntichaki P, 2007, NATURE, V445, P922, DOI 10.1038/nature05603; Taguchi A, 2007, SCIENCE, V317, P369, DOI 10.1126/science.1142179; TANNENBAUM A, 1949, CANCER RES, V9, P724; Tissenbaum HA, 2001, NATURE, V410, P227, DOI 10.1038/35065638; Tuteja G, 2007, CELL, V130, DOI 10.1016/j.cell.2007.09.005; van der Horst A, 2007, NAT REV MOL CELL BIO, V8, P440, DOI 10.1038/nrm2190; Van Remmen H, 2003, PHYSIOL GENOMICS, V16, P29, DOI 10.1152/physiolgenomics.00122.2003; Vatamaniuk MZ, 2006, DIABETES, V55, P2730, DOI 10.2337/db05-0470; Wang F, 2007, AGING CELL, V6, P505, DOI 10.1111/j.1474-9726.2007.00304.x; Wang MC, 2005, CELL, V121, P115, DOI 10.1016/j.cell.2005.02.030; Wang MC, 2003, DEV CELL, V5, P811, DOI 10.1016/S1534-5807(03)00323-X; Wang Y, 2006, MECH AGEING DEV, V127, P741, DOI 10.1016/j.mad.2006.05.005; WEIGEL D, 1990, CELL, V63, P455, DOI 10.1016/0092-8674(90)90439-L; Wessells RJ, 2004, NAT GENET, V36, P1275, DOI 10.1038/ng1476; Wolff S, 2006, CELL, V124, P1039, DOI 10.1016/j.cell.2005.12.042; Wolfrum C, 2003, J CLIN INVEST, V112, P345, DOI 10.1172/JCI18698; Wolkow Catherine A., 2000, Science (Washington D C), V290, P147, DOI 10.1126/science.290.5489.147; Yang HL, 2005, ONCOGENE, V24, P1924, DOI 10.1038/sj.onc.1208352; You H, 2004, P NATL ACAD SCI USA, V101, P14057, DOI 10.1073/pnas.0406286101; Yu J, 2001, MOL CELL, V7, P673, DOI 10.1016/S1097-2765(01)00213-1; Zahn JM, 2007, CURR OPIN BIOTECH, V18, P355, DOI 10.1016/j.copbio.2007.07.004	135	72	74	0	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 7	2008	27	16					2351	2363		10.1038/onc.2008.28	http://dx.doi.org/10.1038/onc.2008.28			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	285NE	18391977				2022-12-28	WOS:000254782700010
J	Sun, P; Nallar, SC; Kalakonda, S; Lindner, DJ; Martin, SS; Kalvakolanu, DV				Sun, P.; Nallar, S. C.; Kalakonda, S.; Lindner, D. J.; Martin, S. S.; Kalvakolanu, D. V.			GRIM-19 inhibits v-Src-induced cell motility by interfering with cytoskeletal restructuring	ONCOGENE			English	Article						interferon; cytoskeleton; oncogenes; metastasis; growth suppression	REGULATORY GENE-PRODUCT; RETINOIC ACID; MATRIX-METALLOPROTEINASE; TYROSINE PHOSPHORYLATION; SIGNAL TRANSDUCER; STAT3 ACTIVATION; DEATH; ACTIN; CORTACTIN; PROTEIN	GRIM-19 (Gene associated with Retinoid-Interferon-induced Mortality 19) is a novel tumor suppressor regulated by interferon/retinoid combination. We have recently shown that GRIM-19 inhibits v-Src-induced oncogenic transformation and metastatic behavior of cells. Oncogenic v-Src induces cell motility by cytoskeletal remodeling, especially the formation of podosomes and. Here, we show that GRIM-19 inhibited the v-Src-induced cell motility by inhibiting cytoskeletal remodeling, that is, podosome formation. We also show that the N terminus of GRIM-19 played a major role in this process and identified critical residues in this region. More importantly, we show that tumor-associated GRIM-19 mutations disrupted its ability to inhibit v-Src-induced cell motility. These actions appear to occur independently of STAT3, a known target of GRIM-19-mediated inhibition. Lastly, tumor-associated GRIM-19 mutants significantly lost their ability to control v-Src-induced metastases in vivo, indicating the biological and pathological significance of these observations.	[Sun, P.; Nallar, S. C.; Kalakonda, S.; Martin, S. S.; Kalvakolanu, D. V.] Univ Maryland, Sch Med, Greenebaum Canc Ctr, Baltimore, MD 21201 USA; [Sun, P.; Kalvakolanu, D. V.] Univ Maryland, Grad Program Life Sci, Baltimore, MD 21201 USA; [Lindner, D. J.] Cleveland Clin, Lerner Res Inst, Taussig Canc Ctr, Cleveland, OH 44106 USA; [Lindner, D. J.] Cleveland Clin, Lerner Res Inst, Dept Canc Biol, Cleveland, OH 44106 USA; [Sun, P.; Nallar, S. C.; Kalakonda, S.; Kalvakolanu, D. V.] Univ Maryland, Sch Med, Dept Microbiol & Immunol, Baltimore, MD 21201 USA	University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore; Cleveland Clinic Foundation; Cleveland Clinic Foundation; University System of Maryland; University of Maryland Baltimore	Kalvakolanu, DV (corresponding author), Univ Maryland, Sch Med, Greenebaum Canc Ctr, 660 W Redwood St,Howard Hall Room 324, Baltimore, MD 21201 USA.	dkalvako@umaryland.edu	Lindner, Daniel/ABB-5440-2020		National Cancer Institute [CA105005]; NATIONAL CANCER INSTITUTE [R01CA105005] Funding Source: NIH RePORTER	National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	DVK thanks National Cancer Institute (CA105005) for the grant support.	Alchanati I, 2006, ONCOGENE, V25, P7138, DOI 10.1038/sj.onc.1209708; Angell JE, 2000, J BIOL CHEM, V275, P33416, DOI 10.1074/jbc.M003929200; Bromberg JF, 1998, MOL CELL BIOL, V18, P2553, DOI 10.1128/MCB.18.5.2553; Coussens LM, 2002, SCIENCE, V295, P2387, DOI 10.1126/science.1067100; ELLIS C, 1990, NATURE, V343, P377, DOI 10.1038/343377a0; Fearnley IM, 2001, J BIOL CHEM, V276, P38345, DOI 10.1074/jbc.C100444200; Frame MC, 2002, NAT REV MOL CELL BIO, V3, P233, DOI 10.1038/nrm779; Hakak Y, 2000, ONCOGENE, V19, P3164, DOI 10.1038/sj.onc.1203655; Head JA, 2003, MOL BIOL CELL, V14, P3216, DOI 10.1091/mbc.e02-11-0753; Huang C, 1997, J BIOL CHEM, V272, P13911, DOI 10.1074/jbc.272.21.13911; Itoh M, 2006, ONCOGENE, V25, P1195, DOI 10.1038/sj.onc.1209149; Jonasch E, 2001, ONCOLOGIST, V6, P34, DOI 10.1634/theoncologist.6-1-34; Kalakonda S, 2007, AM J PATHOL, V171, P1352, DOI 10.2353/ajpath.2007.070241; Kalakonda S, 2007, CANCER RES, V67, P6212, DOI 10.1158/0008-5472.CAN-07-0031; Kolla V, 1996, J BIOL CHEM, V271, P10508, DOI 10.1074/jbc.271.18.10508; Lindner DJ, 1997, CLIN CANCER RES, V3, P931; Lufei CC, 2003, EMBO J, V22, P1325, DOI 10.1093/emboj/cdg135; Ma XR, 2001, J BIOL CHEM, V276, P24843, DOI 10.1074/jbc.M100380200; Martin GS, 2001, NAT REV MOL CELL BIO, V2, P467, DOI 10.1038/35073094; Maximo V, 2005, BRIT J CANCER, V92, P1892, DOI 10.1038/sj.bjc.6602547; Mizutani K, 2002, CANCER RES, V62, P669; MONSKY WL, 1993, CANCER RES, V53, P3159; Ng DCH, 2006, J CELL BIOL, V172, P245, DOI 10.1083/jcb.200503021; Rodriguez OC, 2003, NAT CELL BIOL, V5, P599, DOI 10.1038/ncb0703-599; Scott LA, 2004, MOL CELL BIOL, V24, P1540, DOI 10.1128/MCB.24.4.1540-1559.2004; Seo T, 2002, J VIROL, V76, P8797, DOI 10.1128/JVI.76.17.8797-8807.2002; Tehrani S, 2007, P NATL ACAD SCI USA, V104, P11933, DOI 10.1073/pnas.0701077104; Tehrani S, 2006, MOL BIOL CELL, V17, P2882, DOI 10.1091/mbc.E06-03-0187; Wittmann T, 2001, J CELL SCI, V114, P3795; WU H, 1991, MOL CELL BIOL, V11, P5113, DOI 10.1128/MCB.11.10.5113; WU H, 1993, J CELL BIOL, V120, P1417, DOI 10.1083/jcb.120.6.1417; Zhang J, 2003, P NATL ACAD SCI USA, V100, P9342, DOI 10.1073/pnas.1633516100; Zhang L, 2008, CLIN CANCER RES, V14, P559, DOI 10.1158/1078-0432.CCR-07-1176	33	17	22	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2009	28	10					1339	1347		10.1038/onc.2008.480	http://dx.doi.org/10.1038/onc.2008.480			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	417ZC	19151760	Green Accepted			2022-12-28	WOS:000264116000006
J	Zagurovskaya, M; Shareef, MM; Das, A; Reeves, A; Gupta, S; Sudol, M; Bedford, MT; Prichard, J; Mohiuddin, M; Ahmed, MM				Zagurovskaya, M.; Shareef, M. M.; Das, A.; Reeves, A.; Gupta, S.; Sudol, M.; Bedford, M. T.; Prichard, J.; Mohiuddin, M.; Ahmed, M. M.			EGR-1 forms a complex with YAP-1 and upregulates Bax expression in irradiated prostate carcinoma cells	ONCOGENE			English	Article						EGR-1; YAP-1; Bax; prostate cancer; radiation	YES-ASSOCIATED PROTEIN; IONIZING-RADIATION; APOPTOSIS; TRANSCRIPTION; P53; CANCER; DOMAIN; GENE; RESISTANCE; INDUCTION	In this study, we investigated the functional role of early growth response-1 (Egr1 gene) in the regulation of radiation-induced clonogenic inhibition and apoptosis in p53 wild-type and mutant prostate cancer cells 22Rv1 and DU145, respectively. 22Rv1 cells were more sensitive to irradiation compared with DU145 cells, and the sensitivity was enhanced by overexpression of EGR-1 in both cells. Dominant-negative EGR-1 mutant (dnEGR-1) or repressor of EGR-1, NGFIA binding protein 1 (NAB1), increased radioresistance of these cells. Significant activation of caspases 3 and 9 and Bcl2-associated X (Bax) with increased poly(ADP-ribose) polymerase (PARP) cleavage and cytochrome c release was observed in radiation-exposed EGR-1 overexpressing cells. Gel shift analysis and chloramphenicol acetyl transferase (CAT) reporter assays indicate that EGR-1 transactivates the promoter of the Bax gene. Interaction of EGR-1 and Yes kinase-associated protein 1 (YAP-1) through the WW domain of YAP-1 enhances the transcriptional activity of EGR-1 on the Bax promoter as shown by chromatin immunoprecipitation and reporter assays. Irradiation of PC3 cell xenografts that were treated with adenoviral EGR-1 showed significant regression in tumor volume. These findings establish the radiation-induced pro-apoptotic action of EGR-1, in a p53-independent manner, by directly transactivating Bax, and prove that alters the B-cell CLL/lymphoma 2 (Bcl-2)/Bax ratio as one of the mechanisms resulting in significant activation of caspases, leading to cell death through the novel interaction of EGR-1 with YAP-1.	[Das, A.] Virginia Commonwealth Univ, Dept Internal Med, Richmond, VA USA; [Bedford, M. T.] Univ Texas, MD Anderson Canc Ctr, Dept Carcinogenesis, Smithville, TX USA; [Prichard, J.] Weis Ctr Res, Geisinger Clin, Dept Pathol, Danville, PA 17822 USA; [Mohiuddin, M.] Geisinger Med Clin, Geisinger Fox Chase Canc Ctr, Wilkes Barre, PA USA; [Ahmed, M. M.] Fox Chase Canc Ctr, Dept Radiat Oncol, Philadelphia, PA 19111 USA	Virginia Commonwealth University; University of Texas System; UTMD Anderson Cancer Center; Fox Chase Cancer Center; Geisinger Medical Center; Fox Chase Cancer Center	Ahmed, MM (corresponding author), Univ Miami, Sylvester Comprehens Canc Ctr, Miller Sch Med, Dept Radiat Oncol, Miami, FL 33136 USA.	amansoor@med.miami.edu	Bedford, Mark T/E-7856-2011; Das, Anindita/K-8003-2013; Ahmed, Mansoor/AAK-5988-2020	Das, Anindita/0000-0003-4422-7277; 	NIH [RO1 CA78471, DK62345]; PCRP-DOD [PC 970526, WB1XWH-04-1-0039]; Pennsylvania Department of Health [SAP4100037378]; Welch Foundation [G-1495]; NATIONAL CANCER INSTITUTE [R01CA078471] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK062345] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); PCRP-DOD; Pennsylvania Department of Health; Welch Foundation(The Welch Foundation); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	This work was supported by grants, NIH (RO1 CA78471), PCRP-DOD (PC 970526) and Charlotte Geyer foundation to MMA; post-doctoral training grant, PCRP-DOD (WB1XWH-04-1-0039) to MZ; NIH (DK62345) and Pennsylvania Department of Health Grant (SAP4100037378) to MMS and Welch Foundation Grant (G-1495) to MTB.	Abdulkadir SA, 2001, HUM PATHOL, V32, P935, DOI 10.1053/hupa.2001.27102; Abdulkadir SA, 2001, NAT MED, V7, P101, DOI 10.1038/83231; Ahmed MM, 1997, J BIOL CHEM, V272, P33056, DOI 10.1074/jbc.272.52.33056; Ahmed MM, 1996, J BIOL CHEM, V271, P29231, DOI 10.1074/jbc.271.46.29231; Antonsson B, 2001, J BIOL CHEM, V276, P11615, DOI 10.1074/jbc.M010810200; Basu S, 2003, MOL CELL, V11, P11, DOI 10.1016/S1097-2765(02)00776-1; BUTTYAN R, 1988, MOL ENDOCRINOL, V2, P650, DOI 10.1210/mend-2-7-650; Das A, 2001, J BIOL CHEM, V276, P3279, DOI 10.1074/jbc.M008454200; DATTA R, 1992, P NATL ACAD SCI USA, V89, P10149, DOI 10.1073/pnas.89.21.10149; DAY ML, 1993, CANCER RES, V53, P5597; Dong JX, 2007, CELL, V130, P1120, DOI 10.1016/j.cell.2007.07.019; Eid MA, 1998, CANCER RES, V58, P2461; Espejo Alexsandra, 2004, Methods Mol Biol, V264, P173; Kalkhoven E, 2004, BIOCHEM PHARMACOL, V68, P1145, DOI 10.1016/j.bcp.2004.03.045; KYPRIANOU N, 1994, WORLD J UROL, V12, P299; LEE JM, 1993, P NATL ACAD SCI USA, V90, P5742, DOI 10.1073/pnas.90.12.5742; Macias MJ, 2002, FEBS LETT, V513, P30, DOI 10.1016/S0014-5793(01)03290-2; Matallanas D, 2007, MOL CELL, V27, P962, DOI 10.1016/j.molcel.2007.08.008; MATHENY C, 1994, J BIOL CHEM, V269, P8176; Nair P, 1997, J BIOL CHEM, V272, P20131, DOI 10.1074/jbc.272.32.20131; Oka T, 2008, J BIOL CHEM, V283, P27534, DOI 10.1074/jbc.M804380200; Shareef MM, 2007, CANCER RES, V67, P11811, DOI 10.1158/0008-5472.CAN-07-0722; Strano S, 2007, MOL CELL, V27, P863, DOI 10.1016/j.molcel.2007.09.004; SUDOL M, 1994, ONCOGENE, V9, P2145; SUDOL M, 1995, J BIOL CHEM, V270, P14733, DOI 10.1074/jbc.270.24.14733; Svaren J, 2000, J BIOL CHEM, V275, P38524, DOI 10.1074/jbc.M005220200; Tsujimoto Y, 1998, GENES CELLS, V3, P697, DOI 10.1046/j.1365-2443.1998.00223.x; Virolle T, 2001, NAT CELL BIOL, V3, P1124, DOI 10.1038/ncb1201-1124; Zender L, 2006, CELL, V125, P1253, DOI 10.1016/j.cell.2006.05.030	29	77	80	0	24	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2009	28	8					1121	1131		10.1038/onc.2008.461	http://dx.doi.org/10.1038/onc.2008.461			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	412KE	19137013				2022-12-28	WOS:000263722900007
J	Tang, Z; Jiang, S; Du, R; Petri, ET; El-Telbany, A; Chan, PSO; Kijima, T; Dietrich, S; Matsui, K; Kobayashi, M; Sasada, S; Okamoto, N; Suzuki, H; Kawahara, K; Iwasaki, T; Nakagawa, K; Kawase, I; Christensen, JG; Hirashima, T; Halmos, B; Salgia, R; Boggon, TJ; Kern, JA; Ma, PC				Tang, Z.; Jiang, S.; Du, R.; Petri, E. T.; El-Telbany, A.; Chan, P. S. O.; Kijima, T.; Dietrich, S.; Matsui, K.; Kobayashi, M.; Sasada, S.; Okamoto, N.; Suzuki, H.; Kawahara, K.; Iwasaki, T.; Nakagawa, K.; Kawase, I.; Christensen, J. G.; Hirashima, T.; Halmos, B.; Salgia, R.; Boggon, T. J.; Kern, J. A.; Ma, P. C.			Disruption of the EGFR E884-R958 ion pair conserved in the human kinome differentially alters signaling and inhibitor sensitivity	ONCOGENE			English	Article						EGFR; MET; mutation; tyrosine kinase inhibitor; structure; kinome	GROWTH-FACTOR RECEPTOR; CELL LUNG-CANCER; C-MET; KINASE DOMAIN; THERAPEUTIC INHIBITION; SOMATIC MUTATIONS; TYROSINE KINASE; GEFITINIB; PATHWAY; COMPLEX	Targeted therapy against epidermal growth factor receptor (EGFR) represents a major therapeutic advance in lung cancer treatment. Somatic mutations of the EGFR gene, most commonly L858R (exon 21) and short in-frame exon 19 deletions, have been found to confer enhanced sensitivity toward the inhibitors gefitinib and erlotinib. We have recently identified an EGFR mutation E884K, in combination with L858R, in a patient with advanced lung cancer who progressed on erlotinib maintenance therapy, and subsequently had leptomeningeal metastases that responded to gefitinib. The somatic E884K substitution appears to be relatively infrequent and resulted in a mutant lysine residue that disrupts an ion pair with residue R958 in the EGFR kinase domain C-lobe, an interaction that is highly conserved within the human kinome as demonstrated by our sequence analysis and structure analysis. Our studies here, using COS-7 transfection model system, show that E884K works in concert with L858R in-cis, in a dominant manner, to change downstream signaling, differentially induce Mitogen-activated protein kinase (extracellular signaling-regulated kinase 1/2) signaling and associated cell proliferation and differentially alter sensitivity of EGFR phosphorylation inhibition by ERBB family inhibitors in an inhibitor-specific manner. Mutations of the conserved ion pair E884-R958 may result in conformational changes that alter kinase substrate recognition. The analogous E1271K-MET mutation conferred differential sensitivity toward preclinical MET inhibitors SU11274 (unchanged) and PHA665752 (more sensitive). Systematic bioinformatics analysis of the mutation catalog in the human kinome revealed the presence of cancer-associated mutations involving the conserved E884 homologous residue, and adjacent residues at the ion pair, in known proto-oncogenes (KIT, RET, MET and FAK) and tumor-suppressor gene (LKB1). Targeted therapy using small-molecule inhibitors should take into account potential cooperative effects of multiple kinase mutations, and their specific effects on downstream signaling and inhibitor sensitivity. Improved efficacy of targeted kinase inhibitors may be achieved by targeting the dominant activating mutations present.	[Tang, Z.; Jiang, S.; Du, R.; El-Telbany, A.; Dietrich, S.; Halmos, B.; Ma, P. C.] Case Western Reserve Univ, Sch Med, Univ Hosp Case Med Ctr, Div Hematol Oncol, Cleveland, OH 44106 USA; [Tang, Z.; Jiang, S.; Du, R.; El-Telbany, A.; Dietrich, S.; Halmos, B.; Kern, J. A.; Ma, P. C.] Case Comprehens Canc Ctr, Ireland Canc Ctr, Cleveland, OH USA; [Petri, E. T.; Boggon, T. J.] Yale Univ, Sch Med, Dept Pharmacol, New Haven, CT 06510 USA; [Chan, P. S. O.] Elpidex Biosci Inc, Los Angeles, CA USA; [Kijima, T.; Kawase, I.] Osaka Univ, Grad Sch Med, Dept Resp Med Allergy & Rheumat Dis, Osaka, Japan; [Matsui, K.; Kobayashi, M.; Sasada, S.; Okamoto, N.; Suzuki, H.; Hirashima, T.] Osaka Prefecture Med Ctr Resp & Allerg Dis, Dept Thorac Malignancy, Osaka, Japan; [Kawahara, K.] Osaka Prefectural Med Ctr Resp & Allerg Dis, Dept Pathol, Osaka, Japan; [Iwasaki, T.; Nakagawa, K.] Osaka Prefectural Med Ctr Resp & Allerg Dis, Dept Thorac Surg, Osaka, Japan; [Christensen, J. G.] Pfizer Inc, Global Res & Dev, San Diego, CA USA; [Salgia, R.] Univ Chicago, Pritzker Sch Med, Canc Res Ctr, Hematol Oncol Sect, Chicago, IL 60637 USA; [Kern, J. A.] Case Western Reserve Univ, Sch Med, Univ Hosp Case Med Ctr, Div Pulm, Cleveland, OH 44106 USA	Case Western Reserve University; Case Western Reserve University Hospital; Case Western Reserve University; Yale University; Osaka University; Osaka Prefectural Medical Center Respiratory & Allergic Diseases; Osaka Prefectural Medical Center Respiratory & Allergic Diseases; Osaka Prefectural Medical Center Respiratory & Allergic Diseases; Pfizer; University of Chicago; Case Western Reserve University; Case Western Reserve University Hospital	Ma, PC (corresponding author), Case Western Reserve Univ, Sch Med, Univ Hosp Case Med Ctr, Div Hematol Oncol, 10900 Euclid Ave,WRB 2-123, Cleveland, OH 44106 USA.	patrick.ma@case.edu	Dietrich, Sascha/J-2562-2015	Dietrich, Sascha/0000-0002-0648-1832; Kern, Jeffrey/0000-0001-9709-9622; Petri, Edward/0000-0002-3650-1523	NIH; National Cancer Institute [K08, 5K08CA102545-04, 5T32CA009085-32]; American Cancer Society (Ohio) [IRG-91-022]; Case Comprehensive Cancer Center; Ohio Cancer Research Associates; NATIONAL CANCER INSTITUTE [T32CA009085, R01CA100750, R01CA125541, K08CA102545, R01CA129501] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL058064] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); American Cancer Society (Ohio)(American Cancer Society); Case Comprehensive Cancer Center; Ohio Cancer Research Associates; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	Patrick C Ma is supported by NIH/National Cancer Institute-K08 Career Development Award (5K08CA102545-04), American Cancer Society (Ohio)-Institutional Research Grant (IRG-91-022, Case Comprehensive Cancer Center) and Ohio Cancer Research Associates (Give New Ideas A Chance) Grant Award. Titus J Boggon is an American Society of Hematology Junior Faculty Scholar. Edward T Petri is supported by an NIH/National Cancer Institute T32 training Grant (5T32CA009085-32). We thank Dr Zhenghe J Wang (Department of Genetics, Case Western Reserve University) for critically reading the manuscript and for helpful suggestions.	Bean J, 2007, P NATL ACAD SCI USA, V104, P20932, DOI 10.1073/pnas.0710370104; Bellon SF, 2008, J BIOL CHEM, V283, P2675, DOI 10.1074/jbc.M705774200; BRODSKY LI, 1992, DIMACS SERIES DISCRE, V8, P127; Chen Z, 2008, ONCOGENE, V27, P4336, DOI 10.1038/onc.2008.71; Choong NW, 2006, NAT CLIN PRACT ONCOL, V3, P50, DOI 10.1038/ncponc0400; Clamp M, 2004, BIOINFORMATICS, V20, P426, DOI 10.1093/bioinformatics/btg430; Di Renzo MF, 2000, ONCOGENE, V19, P1547, DOI 10.1038/sj.onc.1203455; Engelman JA, 2007, SCIENCE, V316, P1039, DOI 10.1126/science.1141478; Frohling S, 2007, CANCER CELL, V12, P501, DOI 10.1016/j.ccr.2007.11.005; Guo A, 2008, P NATL ACAD SCI USA, V105, P692, DOI 10.1073/pnas.0707270105; Hubbard SR, 1997, EMBO J, V16, P5572, DOI 10.1093/emboj/16.18.5572; Jackman DM, 2006, J CLIN ONCOL, V24, P4517, DOI 10.1200/JCO.2006.06.6126; Jagadeeswaran R, 2006, CANCER RES, V66, P352, DOI 10.1158/0008-5472.CAN-04-4567; Ji HB, 2007, NATURE, V448, P807, DOI 10.1038/nature06030; Jin L, 2004, J BIOL CHEM, V279, P42818, DOI 10.1074/jbc.M407096200; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kobayashi S, 2005, NEW ENGL J MED, V352, P786, DOI 10.1056/NEJMoa044238; Krause DS, 2005, NEW ENGL J MED, V353, P172, DOI 10.1056/NEJMra044389; Lo HW, 2005, CANCER CELL, V7, P575, DOI 10.1016/j.ccr.2005.05.007; Lynch TJ, 2004, NEW ENGL J MED, V350, P2129, DOI 10.1056/NEJMoa040938; Ma PC, 2007, BRIT J CANCER, V97, P368, DOI 10.1038/sj.bjc.6603884; Ma PC, 2005, CLIN CANCER RES, V11, P2312, DOI 10.1158/1078-0432.CCR-04-1708; Ma PC, 2005, CANCER RES, V65, P1479, DOI 10.1158/0008-5472.CAN-04-2650; Ma PC, 2003, CANCER RES, V63, P6272; Ma PC, 2003, CANCER METAST REV, V22, P309, DOI 10.1023/A:1023768811842; Mazzone M, 2006, FASEB J, V20, P1611, DOI 10.1096/fj.06-5947rev; Paez JG, 2004, SCIENCE, V304, P1497, DOI 10.1126/science.1099314; Peruzzi B, 2006, CLIN CANCER RES, V12, P3657, DOI 10.1158/1078-0432.CCR-06-0818; Pevarello P, 2004, J MED CHEM, V47, P3367, DOI 10.1021/jm031145u; Rikova K, 2007, CELL, V131, P1190, DOI 10.1016/j.cell.2007.11.025; Scapin G, 2003, CHEM BIOL, V10, P705, DOI 10.1016/S1074-5521(03)00159-5; Shigematsu H, 2006, INT J CANCER, V118, P257, DOI 10.1002/ijc.21496; Shinomiya N, 2004, CANCER RES, V64, P7962, DOI 10.1158/0008-5472.CAN-04-1043; Smolen GA, 2006, P NATL ACAD SCI USA, V103, P2316, DOI 10.1073/pnas.0508776103; Stamos J, 2002, J BIOL CHEM, V277, P46265, DOI 10.1074/jbc.M207135200; Tam IYS, 2006, CLIN CANCER RES, V12, P1647, DOI 10.1158/1078-0432.CCR-05-1981; Tang Z, 2008, BRIT J CANCER, V99, P911, DOI 10.1038/sj.bjc.6604559; Thomas RK, 2007, NAT GENET, V39, P347, DOI 10.1038/ng1975; Wood ER, 2004, CANCER RES, V64, P6652, DOI 10.1158/0008-5472.CAN-04-1168; Zhang XW, 2006, CELL, V125, P1137, DOI 10.1016/j.cell.2006.05.013; Zhu XT, 1999, STRUCTURE, V7, P651, DOI 10.1016/S0969-2126(99)80086-0	41	15	16	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 29	2009	28	4					518	533		10.1038/onc.2008.411	http://dx.doi.org/10.1038/onc.2008.411			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	400KM	19015641	Green Accepted, Bronze			2022-12-28	WOS:000262866500006
J	Rodriguez-Gonzalez, A; Cyrus, K; Salcius, M; Kim, K; Crews, CM; Deshaies, RJ; Sakamoto, KM				Rodriguez-Gonzalez, A.; Cyrus, K.; Salcius, M.; Kim, K.; Crews, C. M.; Deshaies, R. J.; Sakamoto, K. M.			Targeting steroid hormone receptors for ubiquitination and degradation in breast and prostate cancer	ONCOGENE			English	Article						steroid hormone receptors; ubiquitination; degradation; breast cancer; prostate cancer	HUMAN ANDROGEN RECEPTOR; ESTROGEN-RECEPTOR; COMBINATORIAL CHEMISTRY; RESPONSIVE ELEMENT; GROWTH-FACTOR; CELL-LINES; IN-VIVO; ALPHA; GENE; PROTEIN	Proteolysis targeting chimeric molecules (Protacs) target proteins for destruction by exploiting the ubiquitin-dependent proteolytic system of eukaryotic cells. We designed two Protacs that contain the peptide 'degron' from hypoxia-inducible factor-1 alpha, which binds to the Von-Hippel-Lindau (VHL) E3 ubiquitin ligase complex, linked to either dihydroxytestosterone that targets the androgen receptor (AR; Protac-A), or linked to estradiol (E2) that targets the estrogen receptor-alpha (ER alpha; Protac-B). We hypothesized that these Protacs would recruit hormone receptors to the VHL E3 ligase complex, resulting in the degradation of receptors, and decreased proliferation of hormone-dependent cell lines. Treatment of estrogen-dependent breast cancer cells with Protac-B induced the degradation of ER alpha in a proteasome-dependent manner. Protac-B inhibited the proliferation of ER alpha-dependent breast cancer cells by inducing G(1) arrest, inhibition of retinoblastoma phosphorylation and decreasing expression of cyclin D1, progesterone receptors A and B. Protac-B treatment did not affect the proliferation of estrogen-independent breast cancer cells that lacked ERa expression. Similarly, Protac-A treatment of androgen-dependent prostate cancer cells induced G(1) arrest but did not affect cells that do not express AR. Our results suggest that Protacs specifically inhibit the proliferation of hormone-dependent breast and prostate cancer cells through degradation of the ERa and AR, respectively.	[Rodriguez-Gonzalez, A.; Sakamoto, K. M.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Pediat, Gwynne Hazen Cherry Labs,Jonsson Comprehens Canc, Los Angeles, CA 90095 USA; [Rodriguez-Gonzalez, A.; Sakamoto, K. M.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Pathol & Lab Med, Gwynne Hazen Cherry Labs,Jonsson Comprehens Canc, Los Angeles, CA 90095 USA; [Rodriguez-Gonzalez, A.; Deshaies, R. J.; Sakamoto, K. M.] CALTECH, Div Biol, Pasadena, CA 91125 USA; [Cyrus, K.; Kim, K.] Univ Kentucky, Dept Pharmaceut Sci, Lexington, KY USA; [Salcius, M.; Crews, C. M.] Yale Univ, Dept Mol Cellular & Dev Biol, New Haven, CT USA; [Salcius, M.; Crews, C. M.] Yale Univ, Dept Pharmacol, New Haven, CT USA; [Salcius, M.; Crews, C. M.] Yale Univ, Dept Chem, New Haven, CT USA; [Deshaies, R. J.] CALTECH, Howard Hughes Med Inst, Pasadena, CA 91125 USA; [Sakamoto, K. M.] Univ Calif Los Angeles, Calif NanoSyst Inst, Los Angeles, CA 90095 USA	UCLA Jonsson Comprehensive Cancer Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; UCLA Jonsson Comprehensive Cancer Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; California Institute of Technology; University of Kentucky; Yale University; Yale University; Yale University; California Institute of Technology; Howard Hughes Medical Institute; University of California System; University of California Los Angeles	Sakamoto, KM (corresponding author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Pediat, Gwynne Hazen Cherry Labs,Jonsson Comprehens Canc, A2-412 MDCC CHS,10833 Le Conte Ave, Los Angeles, CA 90095 USA.	kms@ucla.edu	Deshaies, Raymond/B-8354-2014; Crews, Craig M./ABH-9346-2020	Deshaies, Raymond/0000-0002-3671-9354; Crews, Craig M./0000-0002-8456-2005; Sakamoto, Kathleen/0000-0003-0494-8838	National Institutes of Health [CA-16042, AI-28697]; Jonsson Cancer Center; UCLA AIDS Institute; David Geffen School of Medicine at UCLA; Department of Defense (USA) Prostate Cancer Research [W81XWH-06-1-0192]; Postdoctoral fellowship Ministerio de Educacion y Ciencia (Spain) MEC/Fulbright [EX 2005-0517, NIH R21 R21 CA118631];  [NIH R21 CA108545]; NATIONAL CANCER INSTITUTE [R21CA118631, P30CA016042, R21CA108545] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P30AI028697] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Jonsson Cancer Center; UCLA AIDS Institute; David Geffen School of Medicine at UCLA(University of California System); Department of Defense (USA) Prostate Cancer Research(United States Department of Defense); Postdoctoral fellowship Ministerio de Educacion y Ciencia (Spain) MEC/Fulbright(Spanish Government); ; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	We thank Tammy Phung for her kind assistance in the flow cytometry performance in the UCLA Jonsson Comprehensive Cancer Center and Center for AIDS Research FlowCore Facility that is supported by the National Institutes of Health awards CA-16042 and AI-28697, by the Jonsson Cancer Center, the UCLA AIDS Institute and the David Geffen School of Medicine at UCLA. This work was supported by NIH R21 CA108545 (KMS), Department of Defense (USA) Prostate Cancer Research Program W81XWH-06-1-0192 (AR), Postdoctoral fellowship Ministerio de Educacion y Ciencia (Spain) MEC/Fulbright EX 2005-0517 (AR) and NIH R21 R21 CA118631 (CMC). RJD is an Investigator of the Howard Hughes Medical Institute.	Alarid ET, 2003, ENDOCRINOLOGY, V144, P3469, DOI 10.1210/en.2002-0092; Bakin RE, 2003, CANCER RES, V63, P1981; Bargagna-Mohan P, 2005, BIOORG MED CHEM LETT, V15, P2724, DOI 10.1016/j.bmcl.2005.04.008; Blundell TL, 1996, NATURE, V384, P23; Borras M, 1996, J STEROID BIOCHEM, V57, P203, DOI 10.1016/0960-0760(95)00272-3; Broach JR, 1996, NATURE, V384, P14; Bubendorf L, 1999, CANCER RES, V59, P803; Butt AJ, 2005, ENDOCR-RELAT CANCER, V12, pS47, DOI 10.1677/erc.1.00993; Buzdar AU, 2003, ONCOLOGIST, V8, P335, DOI 10.1634/theoncologist.8-4-335; Clarke R, 1996, Cancer Treat Res, V87, P263; Craft N, 1999, NAT MED, V5, P280, DOI 10.1038/6495; Culig Z, 1999, BRIT J CANCER, V81, P242, DOI 10.1038/sj.bjc.6690684; CULIG Z, 1994, CANCER RES, V54, P5474; Culig ZR, 2003, J UROLOGY, V170, P1363, DOI 10.1097/01.ju.0000075099.20662.7f; DAUVOIS S, 1992, P NATL ACAD SCI USA, V89, P4037, DOI 10.1073/pnas.89.9.4037; Doisneau-Sixou SF, 2003, ENDOCR-RELAT CANCER, V10, P179, DOI 10.1677/erc.0.0100179; Duong V, 2007, CANCER RES, V67, P5513, DOI 10.1158/0008-5472.CAN-07-0967; Eder IE, 2002, CANCER GENE THER, V9, P117, DOI 10.1038/sj.cgt.7700416; Ellis MJ, 2001, J CLIN ONCOL, V19, P3808, DOI 10.1200/JCO.2001.19.18.3808; Fan MY, 2004, MOL ENDOCRINOL, V18, P2603, DOI 10.1210/me.2004-0164; Franco OE, 2003, PROSTATE, V56, P319, DOI 10.1002/pros.10258; GADDIPATI JP, 1994, CANCER RES, V54, P2861; Godoy-Tundidor S, 2002, CLIN CANCER RES, V8, P2356; Hogan JC, 1996, NATURE, V384, P17; HUGGINS C, 1967, CANCER RES, V27, P1925; Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621; Kim WY, 2004, J CLIN ONCOL, V22, P4991, DOI 10.1200/JCO.2004.05.061; Kirschberg TA, 2003, ORG LETT, V5, P3459, DOI 10.1021/ol035234c; KLEINHITPASS L, 1988, NUCLEIC ACIDS RES, V16, P647, DOI 10.1093/nar/16.2.647; Knudsen KE, 1998, J BIOL CHEM, V273, P20213, DOI 10.1074/jbc.273.32.20213; Liao XB, 2005, MOL CANCER THER, V4, P505, DOI 10.1158/1535-7163.MCT-04-0313; Linja MJ, 2001, CANCER RES, V61, P3550; Lonard DM, 2000, MOL CELL, V5, P939, DOI 10.1016/S1097-2765(00)80259-2; Moul JW, 2000, J UROLOGY, V163, P1632, DOI 10.1016/S0022-5347(05)67511-8; Parkin DM, 2005, CA-CANCER J CLIN, V55, P74, DOI 10.3322/canjclin.55.2.74; Pink JJ, 1996, CANCER RES, V56, P2321; Preisler-Mashek MT, 2002, AM J PHYSIOL-ENDOC M, V282, pE891, DOI 10.1152/ajpendo.00353.2001; Rau KM, 2005, ENDOCR-RELAT CANCER, V12, P511, DOI 10.1677/erc.1.01026; Reid G, 2003, MOL CELL, V11, P695, DOI 10.1016/S1097-2765(03)00090-X; Sakamoto KM, 2003, MOL CELL PROTEOMICS, V2, P1350, DOI 10.1074/mcp.T300009-MCP200; Sakamoto KM, 2001, P NATL ACAD SCI USA, V98, P8554, DOI 10.1073/pnas.141230798; SANTEN RJ, 1992, J CLIN ENDOCR METAB, V75, P685, DOI 10.1210/jc.75.3.685; Savarese DM, 2001, J CLIN ONCOL, V19, P2509, DOI 10.1200/JCO.2001.19.9.2509; SAVOURET JF, 1991, EMBO J, V10, P1875, DOI 10.1002/j.1460-2075.1991.tb07713.x; Schneekloth JS, 2004, J AM CHEM SOC, V126, P3748, DOI 10.1021/ja039025z; Taplin ME, 1999, CANCER RES, V59, P2511; Thiele B, 1999, J CLIN ENDOCR METAB, V84, P1751, DOI 10.1210/jc.84.5.1751; Ueda T, 2002, J BIOL CHEM, V277, P7076, DOI 10.1074/jbc.M108255200; Verdine GL, 1996, NATURE, V384, P11; Wijayaratne AL, 2001, J BIOL CHEM, V276, P35684, DOI 10.1074/jbc.M101097200; Zegarra-Moro OL, 2002, CANCER RES, V62, P1008	51	125	185	18	76	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC	2008	27	57					7201	7211		10.1038/onc.2008.320	http://dx.doi.org/10.1038/onc.2008.320			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	379GG	18794799	Green Accepted			2022-12-28	WOS:000261384100007
J	Wickenden, JA; Jin, H; Johnson, M; Gillings, AS; Newson, C; Austin, M; Chell, SD; Balmanno, K; Pritchard, CA; Cook, SJ				Wickenden, J. A.; Jin, H.; Johnson, M.; Gillings, A. S.; Newson, C.; Austin, M.; Chell, S. D.; Balmanno, K.; Pritchard, C. A.; Cook, S. J.			Colorectal cancer cells with the BRAF(V600E) mutation are addicted to the ERK1/2 pathway for growth factor-independent survival and repression of BIM	ONCOGENE			English	Article						apoptosis; BIM; BRAF; colorectal cancer; ERK1/2	B-RAF; BH3-ONLY PROTEIN; BCL-2 PROTEINS; PHOSPHORYLATION; EXPRESSION; APOPTOSIS; GENE; PROMOTES; PROLIFERATION; DEGRADATION	The RAF-mitogen-activated protein kinase kinase 1/2 extracellular signal-regulated kinase 1/2 (RAF-MEK1/2-ERK1/2) pathway is activated in many human tumours and can protect cells against growth factor deprivation; however, most such studies have relied upon overexpression of RAF or MEK constructs that are not found in tumours. Here we show that expression of the endogenous BRAF(V600E) allele in mouse embryonic fibroblasts from conditional knock-in transgenic mice activates ERK1/2, represses the BH3-only protein BIM and protects cells from growth factor withdrawal. Human colorectal cancer (CRC) cell lines harbouring BRAF(V600E) are growth factor independent for the activation of ERK1/2 and survival. However, treatment with the MEK1/2 inhibitors U0126, PD184352 or the novel clinical candidate AZD6244 (ARRY-142886) overcomes growth factor independence, causing CRC cell death. BIM is de-phosphorylated and upregulated following MEK1/2 inhibition in all CRC cell lines studied and knockdown of BIM reduces cell death, indicating that repression of BIM is a major part of the ability of BRAF(V600E) to confer growth factor-independent survival. We conclude that a single endogenous BRAF(V600E) allele is sufficient to repress BIM and prevent death arising from growth factor withdrawal, and CRC cells with BRAF(V600E) mutations are addicted to the ERK1/2 pathway for repression of BIM and growth factor-independent survival.	[Jin, H.; Pritchard, C. A.] Univ Leicester, Dept Biochem, Leicester LE1 7RH, Leics, England; [Wickenden, J. A.; Johnson, M.; Gillings, A. S.; Newson, C.; Austin, M.; Chell, S. D.; Balmanno, K.; Cook, S. J.] Babraham Inst, Mol Signalling Lab, Cambridge, England	University of Leicester; UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Babraham Institute	Pritchard, CA (corresponding author), Univ Leicester, Dept Biochem, Leicester LE1 7RH, Leics, England.	cap8@le.ac.uk; simon.cook@bbsrc.ac.uk		Balmanno, Kathryn/0000-0002-6417-3889; Chell, Simon/0000-0001-5321-9119; Pritchard, Catrin/0000-0003-1859-4487; Austin, Mark/0000-0003-4943-7265	CRUK [C1362/A6969]; Association for International Cancer Research (AICR); AstraZeneca, BBSRC [BB/E02162X/1]; Babraham Institute; BBSRC [BB/E02162X/1] Funding Source: UKRI; Biotechnology and Biological Sciences Research Council [BB/E02162X/1, BBS/E/B/0000C199, BBS/E/B/0000H151] Funding Source: researchfish	CRUK(Cancer Research UK); Association for International Cancer Research (AICR); AstraZeneca, BBSRC(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)AstraZeneca); Babraham Institute(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); BBSRC(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC))	We thank members of the SJC and CAPlabs for discussions and Richard Marais for his advice and encouragement. We particularly thank the Division of Biomedical Services at Leicester for help with breeding and Susan Giblett for isolation of MEFs. We are grateful to the Trono lab for provision of lentiviral expression systems, Paul Smith (AstraZeneca) for provision of AZD6244 and discussions and Richard Hamelin for provision of CO115 cells. Work in the CAPlab was funded by a CRUK programme grant number C1362/A6969. Work in the SJC lab was supported by the Association for International Cancer Research (AICR), AstraZeneca, BBSRC (BB/E02162X/1) and the Babraham Institute.	Boisvert-Adamo K, 2008, ONCOGENE, V27, P3301, DOI 10.1038/sj.onc.1211003; Bouillet P, 1999, SCIENCE, V286, P1735, DOI 10.1126/science.286.5445.1735; Chen L, 2005, MOL CELL, V17, P393, DOI 10.1016/j.molcel.2004.12.030; Cory S, 2003, ONCOGENE, V22, P8590, DOI 10.1038/sj.onc.1207102; Costa DB, 2007, PLOS MED, V4, P1669, DOI 10.1371/journal.pmed.0040315; Cragg MS, 2007, PLOS MED, V4, P1681, DOI 10.1371/journal.pmed.0040316; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; Davies BR, 2007, MOL CANCER THER, V6, P2209, DOI 10.1158/1535-7163.MCT-07-0231; Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766; Dijkers PF, 2000, CURR BIOL, V10, P1201, DOI 10.1016/S0960-9822(00)00728-4; Egle A, 2004, P NATL ACAD SCI USA, V101, P6164, DOI 10.1073/pnas.0401471101; Eisenmann KM, 2003, CANCER RES, V63, P8330; Ewings KE, 2007, CELL CYCLE, V6, P2236, DOI 10.4161/cc.6.18.4728; Ewings KE, 2007, EMBO J, V26, P2856, DOI 10.1038/sj.emboj.7601723; Frese KK, 2007, NAT REV CANCER, V7, P645, DOI 10.1038/nrc2192; Gilley J, 2003, J CELL BIOL, V162, P613, DOI 10.1083/jcb.200303026; Gong YX, 2007, PLOS MED, V4, P1655, DOI 10.1371/journal.pmed.0040294; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hayashi S, 2002, DEV BIOL, V244, P305, DOI 10.1006/dbio.2002.0597; Hingorani SR, 2003, CANCER CELL, V4, P437, DOI 10.1016/S1535-6108(03)00309-X; Huser M, 2001, EMBO J, V20, P1940, DOI 10.1093/emboj/20.8.1940; Jackson EL, 2001, GENE DEV, V15, P3243, DOI 10.1101/gad.943001; Karasarides M, 2004, ONCOGENE, V23, P6292, DOI 10.1038/sj.onc.1207785; Ley R, 2005, CELL DEATH DIFFER, V12, P1008, DOI 10.1038/sj.cdd.4401688; Ley R, 2003, J BIOL CHEM, V278, P18811, DOI 10.1074/jbc.M301010200; Ley R, 2004, J BIOL CHEM, V279, P8837, DOI 10.1074/jbc.M311578200; Luciano F, 2003, ONCOGENE, V22, P6785, DOI 10.1038/sj.onc.1206792; Marani M, 2004, ONCOGENE, V23, P2431, DOI 10.1038/sj.onc.1207364; Mercer K, 2005, CANCER RES, V65, P11493, DOI 10.1158/0008-5472.CAN-05-2211; Mercer KE, 2003, BBA-REV CANCER, V1653, P25, DOI 10.1016/S0304-419X(03)00016-7; Rajagopalan H, 2002, NATURE, V418, P934, DOI 10.1038/418934a; Reginato MJ, 2005, MOL CELL BIOL, V25, P4591, DOI 10.1128/MCB.25.11.4591-4601.2005; Scaduto RC, 1999, BIOPHYS J, V76, P469, DOI 10.1016/S0006-3495(99)77214-0; SHIRASAWA S, 1993, SCIENCE, V260, P85, DOI 10.1126/science.8465203; Tagawa H, 2005, ONCOGENE, V24, P1348, DOI 10.1038/sj.onc.1208300; Todd DE, 2004, ONCOGENE, V23, P3284, DOI 10.1038/sj.onc.1207467; Tuveson DA, 2004, CANCER CELL, V5, P375, DOI 10.1016/S1535-6108(04)00085-6; Vandesompele J, 2002, GENOME BIOL, V3, DOI 10.1186/gb-2002-3-7-research0034; Wallace EM, 2006, J MED CHEM, V49, P441, DOI 10.1021/jm050834y; Weinstein IB, 2002, SCIENCE, V297, P63, DOI 10.1126/science.1073096; Weston CR, 2003, ONCOGENE, V22, P1281, DOI 10.1038/sj.onc.1206261; Willis SN, 2007, SCIENCE, V315, P856, DOI 10.1126/science.1133289; Wiznerowicz M, 2003, J VIROL, V77, P8957, DOI 10.1128/JVI.77.16.8957-8951.2003; Yuen ST, 2002, CANCER RES, V62, P6451; Zantl N, 2007, ONCOGENE, V26, P7038, DOI 10.1038/sj.onc.1210510	45	55	60	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC	2008	27	57					7150	7161		10.1038/onc.2008.335	http://dx.doi.org/10.1038/onc.2008.335			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	379GG	18806830	Green Accepted			2022-12-28	WOS:000261384100002
J	Braden, WA; McClendon, AK; Knudsen, ES				Braden, W. A.; McClendon, A. K.; Knudsen, E. S.			Cyclin-dependent kinase 4/6 activity is a critical determinant of pre-replication complex assembly	ONCOGENE			English	Article						CDK; cyclin; pre-RC; tumor suppressor; cancer	DNA-REPLICATION; S-PHASE; CELL-CYCLE; PREREPLICATION COMPLEX; CHROMOSOME-REPLICATION; CHROMATIN ASSOCIATION; ORIGIN RECOGNITION; EUKARYOTIC CELLS; RE-REPLICATION; HUMAN CANCER	Cyclin-dependent kinases (CDKs) are important in regulating cell cycle transitions, particularly in coordinating DNA replication. Although the role of CDK2 activity on the replication apparatus has been extensively studied, the role of CDK4/6 in DNA replication control is less understood. Through targeted inhibition of CDK4/6 activity, we demonstrate that CDK4/6 kinase activity promotes cdc6 and cdt1 expression, and pre-replication complex (pre-RC) assembly in cycling cells. Conversely, CDK2 inhibition had no effect on the pre-RC assembly. The inhibition of pre-RC assembly is dependent on a functional retinoblastoma (RB) protein, which mediates downstream effects. As such, CDK4/6 inhibition has minimal effect on the replication apparatus in the absence of RB. The requirement of CDK4/6 was further interrogated using cells lacking D-type cyclins, in which replication complexes form normally, and correspondingly CDK4/6 inhibition had no effect on cell cycle or replication control. However, in the absence of D-type cyclins, CDK2 inhibition resulted in the attenuation of cdc6 and cdt1 levels, suggesting overlapping roles for CDK4/6 and CDK2 in regulating replication protein activity. Finally, CDK4/6 inhibition prevented the accumulation of cdc6 and cdt1 as cells progressed from mitosis through the subsequent G(1). Combined, these studies indicate that CDK4/6 activity is important in regulating the expression of these critical mediators of DNA replication.	[Knudsen, E. S.] Thomas Jefferson Univ, Dept Canc Biol, Philadelphia, PA 19107 USA; Thomas Jefferson Univ, Kimmel Canc Ctr, Philadelphia, PA 19107 USA	Jefferson University; Jefferson University	Knudsen, ES (corresponding author), Thomas Jefferson Univ, Dept Canc Biol, 233 S 10th St, Philadelphia, PA 19107 USA.	eknudsen@kimmalcancercenter.org			NIEHS [T32 ES07250-16];  [NCI CA106471]; NATIONAL CANCER INSTITUTE [R01CA106471] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [T32ES007250] Funding Source: NIH RePORTER	NIEHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); ; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))	We thank Dr Karen Knudsen and members of both Knudsen laboratories for critical review of the paper. Critical reagents were provided by Dr Piotr Sicinski and Pfizer Corp. This study was funded by a grant to ESK from the NCI CA106471. WAB and AKM are supported by NIEHS training grant T32 ES07250-16.	Aggarwal P, 2007, GENE DEV, V21, P2908, DOI 10.1101/gad.1586007; Angus SP, 2004, MOL CELL BIOL, V24, P5404, DOI 10.1128/MCB.24.12.5404-5420.2004; Bartek J, 1997, EXP CELL RES, V237, P1, DOI 10.1006/excr.1997.3776; Bartkova J, 1997, Prog Cell Cycle Res, V3, P211; Bell SP, 2002, ANNU REV BIOCHEM, V71, P333, DOI 10.1146/annurev.biochem.71.110601.135425; Blow JJ, 2002, TRENDS CELL BIOL, V12, P72, DOI 10.1016/S0962-8924(01)02203-6; Braden WA, 2006, MOL CELL BIOL, V26, P7667, DOI 10.1128/MCB.00045-06; Broceno C, 2002, P NATL ACAD SCI USA, V99, P14200, DOI 10.1073/pnas.212519499; Coverley D, 2002, NAT CELL BIOL, V4, P523, DOI 10.1038/ncb813; DAHMANN C, 1995, CURR BIOL, V5, P1257, DOI 10.1016/S0960-9822(95)00252-1; Diehl JA, 2002, CANCER BIOL THER, V1, P226, DOI 10.4161/cbt.72; Diffley JFX, 2004, CURR BIOL, V14, pR778, DOI 10.1016/j.cub.2004.09.019; Diffley JFX, 2002, J CELL SCI, V115, P869; DIFFLEY JFX, 1994, CURR OPIN CELL BIOL, V6, P368, DOI 10.1016/0955-0674(94)90028-0; Dimitrova DS, 2002, J CELL SCI, V115, P51; Dimitrova DS, 1999, J CELL BIOL, V146, P709, DOI 10.1083/jcb.146.4.709; Dutta A, 1997, ANNU REV CELL DEV BI, V13, P293, DOI 10.1146/annurev.cellbio.13.1.293; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; Ekholm-Reed S, 2004, J CELL BIOL, V165, P789, DOI 10.1083/jcb.200404092; Fry DW, 2004, MOL CANCER THER, V3, P1427; Fujita M, 1996, J BIOL CHEM, V271, P4349; Geng Y, 2007, MOL CELL, V25, P127, DOI 10.1016/j.molcel.2006.11.029; Guo Y, 2002, ONCOGENE, V21, P7545, DOI 10.1038/sj.onc.1205907; Hateboer G, 1998, MOL CELL BIOL, V18, P6679, DOI 10.1128/MCB.18.11.6679; Hua XH, 1997, J CELL BIOL, V137, P183, DOI 10.1083/jcb.137.1.183; Hwang HC, 2005, ONCOGENE, V24, P2776, DOI 10.1038/sj.onc.1208613; Knudsen KE, 2006, ONCOGENE, V25, P1620, DOI 10.1038/sj.onc.1209371; KOFF A, 1991, CELL, V66, P1217, DOI 10.1016/0092-8674(91)90044-Y; KOFF A, 1992, SCIENCE, V257, P1689, DOI 10.1126/science.1388288; Kozar K, 2004, CELL, V118, P477, DOI 10.1016/j.cell.2004.07.025; Labib K, 2000, SCIENCE, V288, P1643, DOI 10.1126/science.288.5471.1643; Labib K, 2001, MOL BIOL CELL, V12, P3658, DOI 10.1091/mbc.12.11.3658; Lei M, 1997, GENE DEV, V11, P3365, DOI 10.1101/gad.11.24.3365; Liu EB, 2004, J BIOL CHEM, V279, P17283, DOI 10.1074/jbc.C300549200; Mailand N, 2005, CELL, V122, P915, DOI 10.1016/j.cell.2005.08.013; Malumbres M, 2004, CELL, V118, P493, DOI 10.1016/j.cell.2004.08.002; Markey MP, 2002, CANCER RES, V62, P6587; Mendez J, 2000, MOL CELL BIOL, V20, P8602, DOI 10.1128/MCB.20.22.8602-8612.2000; Mimura S, 2004, NATURE, V431, P1118, DOI 10.1038/nature03024; Nguyen VQ, 2001, NATURE, V411, P1068, DOI 10.1038/35082600; Noton E, 2000, MOL CELL, V5, P85, DOI 10.1016/S1097-2765(00)80405-0; Okuno Y, 2001, EMBO J, V20, P4263, DOI 10.1093/emboj/20.15.4263; Palmero I, 1996, CANCER SURV, V27, P351; Savio M, 2006, CELL CYCLE, V5, P2153, DOI 10.4161/cc.5.18.3235; Senga T, 2006, J BIOL CHEM, V281, P6246, DOI 10.1074/jbc.M512705200; Sever-Chroneos Z, 2001, MOL CELL BIOL, V21, P4032, DOI 10.1128/MCB.21.12.4032-4045.2001; Sherr C J, 2000, Harvey Lect, V96, P73; Sherr CJ, 2002, CANCER CELL, V2, P103, DOI 10.1016/S1535-6108(02)00102-2; Sherr CJ, 2001, NAT REV MOL CELL BIO, V2, P731, DOI 10.1038/35096061; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Stillman B, 2005, FEBS LETT, V579, P877, DOI 10.1016/j.febslet.2004.12.011; Sullivan M, 2007, NAT REV MOL CELL BIO, V8, P894, DOI 10.1038/nrm2276; Tanaka S, 2002, GENE DEV, V16, P2639, DOI 10.1101/gad.1011002; Vaziri C, 2003, MOL CELL, V11, P997, DOI 10.1016/S1097-2765(03)00099-6; Woo RA, 2003, CELL CYCLE, V2, P316, DOI 10.4161/cc.2.4.468; Yan Z, 1998, P NATL ACAD SCI USA, V95, P3603, DOI 10.1073/pnas.95.7.3603; Yang K, 2006, CELL DIV, V1, DOI 10.1186/1747-1028-1-32	58	25	29	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV	2008	27	56					7083	7093		10.1038/onc.2008.319	http://dx.doi.org/10.1038/onc.2008.319			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	376PQ	18776921				2022-12-28	WOS:000261195900003
J	Muller, DW; Bosserhoff, AK				Mueller, D. W.; Bosserhoff, A-K			Integrin beta(3) expression is regulated by let-7a miRNA in malignant melanoma	ONCOGENE			English	Article						microRNA; integrins; post-transcriptional silencing; melanoma progression	GENE-EXPRESSION; MICRORNA; PROGRESSION; ALPHA(V)BETA(3); MELANOCYTES; RAS; MIA	Although integrin beta(3) is known to play an important role in melanoma progression and invasion, regulation of integrin beta(3) expression in melanoma has not been analysed in detail until today. As transcriptional regulation of integrin beta(3) was ruled out by our analysis, we concentrated on the regulation by microRNAs (miRNAs). Comparing primary melanocytes and malignant melanoma cell lines, we found that one candidate miRNA, miR-let-7a, was lost in melanoma and sequence analysis suggested an interaction with the 3'-untranslated region (3'-UTR) of integrin beta(3) mRNA. Transfection of melanoma cells with let-7a pre-miR (TM) molecules resulted in the downregulation of integrin beta(3) mRNA and protein expression. In addition, we cloned the 3'-UTR of the integrin beta(3) mRNA containing the let-7a target sequence into a reporter plasmid and revealed that let-7a negatively regulates reporter gene expression. The repressed expression of integrin beta(3) accompanies with reduced invasive potential of melanoma cells transfected with synthetic let-7a molecules observed in Boyden chamber assays. On the other hand, the induction of integrin beta(3) expression was achieved in melanocytes by transfection with let-7 a anti-miRs, resulting in invasive behavior of transfected melanocytes. In summary, we determined miRNA let-7a to be an important regulator of integrin beta(3) expression and showed that the loss of let-7a expression is involved in development and progression of malignant melanoma.	[Mueller, D. W.; Bosserhoff, A-K] Univ Regensburg, Inst Pathol, D-93053 Regensburg, Germany	University of Regensburg	Bosserhoff, AK (corresponding author), Univ Regensburg, Inst Pathol, Franz Josef Str Allee 11, D-93053 Regensburg, Germany.	anja.bosserhoff@klinik.uni-regensburg.de	Bosserhoff, Anja/GNH-4801-2022	Bosserhoff, Anja/0000-0001-8147-394X				ALBELDA SM, 1990, CANCER RES, V50, P6757; BROOKS PC, 1994, SCIENCE, V264, P569, DOI 10.1126/science.7512751; DANEN EHJ, 1995, INT J CANCER, V61, P491, DOI 10.1002/ijc.2910610411; DANEN EHJ, 1994, HISTOPATHOLOGY, V24, P249, DOI 10.1111/j.1365-2559.1994.tb00517.x; Gaur A, 2007, CANCER RES, V67, P2456, DOI 10.1158/0008-5472.CAN-06-2698; Griffiths-Jones S, 2006, NUCLEIC ACIDS RES, V34, pD140, DOI 10.1093/nar/gkj112; Haass NK, 2005, PIGM CELL RES, V18, P150, DOI 10.1111/j.1600-0749.2005.00235.x; Hwang HW, 2006, BRIT J CANCER, V94, P776, DOI 10.1038/sj.bjc.6603023; Jin Y, 1998, BLOOD, V92, P2777, DOI 10.1182/blood.V92.8.2777.420k27_2777_2790; Johnson SM, 2005, CELL, V120, P635, DOI 10.1016/j.cell.2005.01.014; Kim VN, 2005, MOL CELLS, V19, P1; Krek A, 2005, NAT GENET, V37, P495, DOI 10.1038/ng1536; Krutzfeldt J, 2005, NATURE, V438, P685, DOI 10.1038/nature04303; Lewis BP, 2003, CELL, V115, P787, DOI 10.1016/S0092-8674(03)01018-3; Li XW, 1998, INVAS METAST, V18, P1, DOI 10.1159/000024494; Park SM, 2007, CELL CYCLE, V6, P2585, DOI 10.4161/cc.6.21.4845; Porkka KP, 2007, CANCER RES, V67, P6130, DOI 10.1158/0008-5472.CAN-07-0533; Poser I, 2004, ONCOGENE, V23, P6115, DOI 10.1038/sj.onc.1207797; Rothhammer T, 2005, CANCER RES, V65, P448; Tatzel J, 2005, PIGM CELL RES, V18, P92, DOI 10.1111/j.1600-0749.2005.00212.x; Van Belle PA, 1999, HUM PATHOL, V30, P562, DOI 10.1016/S0046-8177(99)90202-2; Woods D, 2001, MOL CELL BIOL, V21, P3192, DOI 10.1128/MCB.21.9.3192-3205.2001; Zhang HH, 2007, WORLD J GASTROENTERO, V13, P2883, DOI 10.3748/wjg.v13.i20.2883	23	173	184	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV	2008	27	52					6698	6706		10.1038/onc.2008.282	http://dx.doi.org/10.1038/onc.2008.282			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	368QY	18679415				2022-12-28	WOS:000260638800008
J	Wolf, I; Levanon-Cohen, S; Bose, S; Ligumsky, H; Sredni, B; Kanety, H; Kuro-o, M; Karlan, B; Kaufman, B; Koeffler, HP; Rubinek, T				Wolf, I.; Levanon-Cohen, S.; Bose, S.; Ligumsky, H.; Sredni, B.; Kanety, H.; Kuro-o, M.; Karlan, B.; Kaufman, B.; Koeffler, H. P.; Rubinek, T.			Klotho: a tumor suppressor and a modulator of the IGF-1 and FGF pathways in human breast cancer	ONCOGENE			English	Article						breast cancer; klotho; insulin; insulin growth factor-1; tumor suppressor	GROWTH-FACTOR CONFERS; ADIPOCYTE DIFFERENTIATION; MOLECULAR-CLONING; TRPV5 CHANNEL; C/EBP-BETA; CELLS; PROTEIN; MOUSE; ACTIVATION; INHIBITION	Klotho is an anti-aging gene, which has been shown to inhibit the insulin and insulin-like growth factor 1 (IGF-1) pathways in mice hepatocytes and myocytes. As IGF-1 and insulin regulate proliferation, survival and metastasis of breast cancer, we studied klotho expression and activities in human breast cancer. Immunohistochemistry analysis of klotho expression in breast tissue arrays revealed high klotho expression in normal breast samples, but very low expression in breast cancer. In cancer samples, high klotho expression was associated with smaller tumor size and reduced KI67 staining. Forced expression of klotho reduced proliferation of MCF-7 and MDA-MB-231 breast cancer cells, whereas klotho silencing in MCF-7 cells, which normally express klotho, enhanced proliferation. Moreover, forced expression of klotho in these cells, or treatment with soluble klotho, inhibited the activation of IGF-1 and insulin pathways, and induced upregulation of the transcription factor CCAAT/enhancer-binding protein beta, a breast cancer growth inhibitor that is negatively regulated by the IGF-1-AKT axis. Co-immunoprecipitation revealed an interaction between klotho and the IGF-1 receptor. Klotho is also a known modulator of the fibroblast growth factor (FGF) pathway, a pathway that inhibits proliferation of breast cancer cells. Studies in breast cancer cells revealed increased activation of the FGF pathway by basic FGF following klotho overexpression. Klotho did not affect activation of the epidermal growth factor pathway in breast cancer cells. These data suggest klotho as a potential tumor suppressor and identify it as an inhibitor of the IGF-1 pathway and activator of the FGF pathway in human breast cancer.	[Wolf, I.; Levanon-Cohen, S.; Ligumsky, H.; Kaufman, B.; Rubinek, T.] Chaim Sheba Med Ctr, Inst Oncol, IL-52621 Ramat Gan, Israel; [Wolf, I.] Tel Aviv Univ, Sackler Fac Med, IL-69978 Tel Aviv, Israel; [Levanon-Cohen, S.; Sredni, B.] Bar Ilan Univ, Mina & Everard Goodman Fac Life Sci, Safdie Inst AIDS & Immunol Res, Ramat Gan, Israel; [Bose, S.] Univ Calif Los Angeles, Cedars Sinai Med Ctr, Sch Med, Dept Anat Pathol, Los Angeles, CA 90048 USA; [Kanety, H.] Chaim Sheba Med Ctr, Inst Endocrinol, Ramat Gan, Israel; [Kuro-o, M.] Univ Texas SW Med Ctr Dallas, Dept Pathol, Dallas, TX 75390 USA; [Karlan, B.] Womens Canc Res Inst, Dept Obstet & Gynecol, Los Angeles, CA USA; [Koeffler, H. P.] Univ Calif Los Angeles, Cedars Sinai Med Ctr, Sch Med, Div Hematol Oncol, Los Angeles, CA 90048 USA	Chaim Sheba Medical Center; Tel Aviv University; Sackler Faculty of Medicine; Bar Ilan University; Cedars Sinai Medical Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Chaim Sheba Medical Center; University of Texas System; University of Texas Southwestern Medical Center Dallas; Cedars Sinai Medical Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Wolf, I (corresponding author), Chaim Sheba Med Ctr, Inst Oncol, IL-52621 Ramat Gan, Israel.	wolf-i@inter.net.il			United States-Israel Binational Science Foundation (BSF) Jerusalem, Israel; Koschitzky Family Foundation; Israel Cancer Association; Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv Israel; The Talpiot Medical Leadership Program, Sheba Medical Center; Inger Fund; Rountree Trust; Mary Barry Foundation; Women's Cancer Research Institute; Samuel Oschin Comprehensive Cancer Institute at Cedars-Sinai Medical Center	United States-Israel Binational Science Foundation (BSF) Jerusalem, Israel(US-Israel Binational Science Foundation); Koschitzky Family Foundation; Israel Cancer Association; Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv Israel; The Talpiot Medical Leadership Program, Sheba Medical Center; Inger Fund; Rountree Trust; Mary Barry Foundation; Women's Cancer Research Institute; Samuel Oschin Comprehensive Cancer Institute at Cedars-Sinai Medical Center	This research was supported in part by grants from the United States-Israel Binational Science Foundation (BSF), Jerusalem, Israel; Koschitzky Family Foundation; the Israel Cancer Association; the Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv Israel; The Talpiot Medical Leadership Program, Sheba Medical Center; the Inger Fund, Rountree Trust and the Mary Barry Foundation and by grants from the Women's Cancer Research Institute, Samuel Oschin Comprehensive Cancer Institute at Cedars-Sinai Medical Center. HPK is a member of the Molecular Biology Institute and Jonsson Comprehensive Cancer Center at UCLA and holds the endowed Mark Goodson Chair of Oncology Research at Cedars-Sinai Medical Center/UCLA School of Medicine. IW is the Mary Barry Medical Bridges Foundation Fellow.	Arking DE, 2003, AM J HUM GENET, V72, P1154, DOI 10.1086/375035; Arking DE, 2002, P NATL ACAD SCI USA, V99, P856, DOI 10.1073/pnas.022484299; Bartucci M, 2001, CANCER RES, V61, P6747; Cha SK, 2008, P NATL ACAD SCI USA, V105, P9805, DOI 10.1073/pnas.0803223105; Chang Q, 2005, SCIENCE, V310, P490, DOI 10.1126/science.1114245; Chen CD, 2007, P NATL ACAD SCI USA, V104, P19796, DOI 10.1073/pnas.0709805104; Chihara Y, 2006, ENDOCRINOLOGY, V147, P3835, DOI 10.1210/en.2005-1529; de Oliveira RM, 2006, FEBS LETT, V580, P5753, DOI 10.1016/j.febslet.2006.09.036; den Dekker E, 2003, CELL CALCIUM, V33, P497, DOI 10.1016/S0143-4160(03)00065-4; Fenig E, 2002, ONCOL REP, V9, P875; Fenig E, 1997, CLIN CANCER RES, V3, P135; GEIER A, 1995, CANCER INVEST, V13, P480, DOI 10.3109/07357909509024911; Gery S, 2005, CLIN CANCER RES, V11, P3184, DOI 10.1158/1078-0432.CCR-04-2625; Gomis RR, 2006, CANCER CELL, V10, P203, DOI 10.1016/j.ccr.2006.07.019; Haimsohn M, 2002, ENDOCRINOLOGY, V143, P837, DOI 10.1210/en.143.3.837; Haluska P, 2006, CANCER RES, V66, P362, DOI 10.1158/0008-5472.CAN-05-1107; Hsiung R, 2002, CANCER J, V8, P303, DOI 10.1097/00130404-200207000-00006; Ikushima M, 2006, BIOCHEM BIOPH RES CO, V339, P827, DOI 10.1016/j.bbrc.2005.11.094; Imura A, 2004, FEBS LETT, V565, P143, DOI 10.1016/j.febslet.2004.03.090; Imura A, 2007, SCIENCE, V316, P1615, DOI 10.1126/science.1135901; Ito S, 2000, MECH DEVELOP, V98, P115, DOI 10.1016/S0925-4773(00)00439-1; Kato Y, 2000, BIOCHEM BIOPH RES CO, V267, P597, DOI 10.1006/bbrc.1999.2009; Kim Y, 2006, NEUROSCI LETT, V407, P189, DOI 10.1016/j.neulet.2006.08.039; Korah RM, 2000, CANCER RES, V60, P733; Kuroo M, 1997, NATURE, V390, P45, DOI 10.1038/36285; Kurosu H, 2006, J BIOL CHEM, V281, P6120, DOI 10.1074/jbc.C500457200; Kurosu H, 2005, SCIENCE, V309, P1829, DOI 10.1126/science.1112766; Lacroix M, 2004, BREAST CANCER RES TR, V83, P249, DOI 10.1023/B:BREA.0000014042.54925.cc; Li X, 2007, P NATL ACAD SCI USA, V104, P11597, DOI 10.1073/pnas.0703771104; Matsumura Y, 1998, BIOCHEM BIOPH RES CO, V242, P626, DOI 10.1006/bbrc.1997.8019; Mitsiades CS, 2004, CANCER CELL, V5, P221, DOI 10.1016/S1535-6108(04)00050-9; Ohyama Y, 1998, BIOCHEM BIOPH RES CO, V251, P920, DOI 10.1006/bbrc.1998.9576; Shiraki-Iida T, 1998, FEBS LETT, V424, P6, DOI 10.1016/S0014-5793(98)00127-6; URAKAWA I, 2006, SCIENCE, V444, P770; Utsugi T, 2000, METABOLISM, V49, P1118, DOI 10.1053/meta.2000.8606; Vandermoere F, 2005, ONCOGENE, V24, P5482, DOI 10.1038/sj.onc.1208713; Wolf I, 2007, INT J CANCER, V120, P1013, DOI 10.1002/ijc.22389; Wolf I, 2006, CANCER RES, V66, P7818, DOI 10.1158/0008-5472.CAN-05-4368; Wolf I, 2006, EUR J CANCER, V42, P1077, DOI 10.1016/j.ejca.2006.01.027; Yee D, 2006, BRIT J CANCER, V94, P465, DOI 10.1038/sj.bjc.6602963; Zarrabeitia MT, 2007, CALCIFIED TISSUE INT, V80, P10, DOI 10.1007/s00223-006-0233-x	41	216	229	0	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV	2008	27	56					7094	7105		10.1038/onc.2008.292	http://dx.doi.org/10.1038/onc.2008.292			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	376PQ	18762812				2022-12-28	WOS:000261195900004
J	Umar, S; Sarkar, S; Cowey, S; Singh, P				Umar, S.; Sarkar, S.; Cowey, S.; Singh, P.			Activation of NF-kappa B is required for mediating proliferative and antiapoptotic effects of progastrin on proximal colonic crypts of mice, in vivo	ONCOGENE			English	Article						annexin II; progastrin; NF kappa B; ERKs; Fabp-PG mice; NEMO	INTESTINAL EPITHELIAL-CELLS; TISSUE-PLASMINOGEN ACTIVATOR; ANNEXIN-II; GENE-EXPRESSION; CANCER CELLS; TRANSGENIC MICE; GROWTH; APOPTOSIS; RECEPTOR; BINDING	Mice overexpressing progastrin (PG) in intestinal mucosa (fatty acid-binding protein (Fabp)-PG mice) are at an increased risk of proximal colon carcinogenesis in response to azoxymethane. Here, we report a significant increase in the length of proximal colonic crypts in Fabp-PG mice, associated with potent antiapoptotic effects of PG, which likely contributed to the previously reported increase in colon carcinogenesis in Fabp-PG mice. Phosphorylation of kinase of I kappa B alpha (IKK alpha/beta), inhibitor of kappa B (I kappa B) a and p65NF-kappa B was significantly elevated in proximal colonic crypts of Fabp-PG versus wild-type mice, which was associated with degradation of I kappa B alpha and nuclear translocation/activation of p65. Surprisingly, distal colonic crypt cells were not as responsive to elevated levels of PG in Fabp-PG mice. Annexin II, recently described as a high-affinity receptor for PG, strongly colocalized with PG intracellularly and on basolateral membranes of proximal crypt cells, providing evidence that annexin-II binds PG in situ in colonic crypt cells. Proliferative and antiapoptotic effects of PG on proximal crypts of Fabp-PG mice were attenuated to wild-type levels, on treatment with NEMO peptide (an inhibitor of nuclear factor-kappa B (NF-kappa B) activation), demonstrating for the first time a critical role of NF-kappa B in mediating hyperproliferative affects of PG on colonic crypts of Fabp-PG mice, in vivo. Thus, downregulation of NF-kappa B may significantly reduce the increased risk of colon carcinogenesis in response to PG.	[Sarkar, S.; Cowey, S.; Singh, P.] Univ Texas Med Branch, Dept Neurosci & Cell Biol, Galveston, TX 77555 USA; [Umar, S.] Univ Texas Med Branch, Dept Internal Med, Galveston, TX USA	University of Texas System; University of Texas Medical Branch Galveston; University of Texas System; University of Texas Medical Branch Galveston	Singh, P (corresponding author), Univ Texas Med Branch, Dept Neurosci & Cell Biol, 301 Univ Blvd,Route 1043, Galveston, TX 77555 USA.	posingh@utmb.edu			NATIONAL CANCER INSTITUTE [R01CA114264, R03CA099121, R01CA097959] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA114264-04, R03 CA099121, R01 CA097959, R01 CA114264-05, CA97959, R01 CA097959-05, R03 CA099121-03, CA099121, R01 CA097959-06A2, R01 CA114264, CA114264] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ahmed S, 2005, PEPTIDES, V26, P1207, DOI 10.1016/j.peptides.2005.02.001; Aly A, 2001, INT J CANCER, V94, P307, DOI 10.1002/ijc.1483; Baldwin GS, 2001, J BIOL CHEM, V276, P7791, DOI 10.1074/jbc.M009985200; CHICONE L, 1989, BIOCHEM BIOPH RES CO, V164, P512, DOI 10.1016/0006-291X(89)91749-X; CHUNG CY, 1994, J CELL BIOL, V126, P539, DOI 10.1083/jcb.126.2.539; Cobb S, 2004, CANCER-AM CANCER SOC, V100, P1311, DOI 10.1002/cncr.20094; Dasgupta S, 2004, J IMMUNOL, V173, P1344, DOI 10.4049/jimmunol.173.2.1344; Dockray GJ, 1996, PHYSIOL REV, V76, P767, DOI 10.1152/physrev.1996.76.3.767; Ferrand A, 2005, CANCER RES, V65, P2770, DOI 10.1158/0008-5472.CAN-04-0978; Forstner J., 1994, PHYSL GASTROINTESTIN; Fric P, 2000, EUR J CANCER PREV, V9, P265, DOI 10.1097/00008469-200008000-00006; Glebov OK, 2003, CANCER EPIDEM BIOMAR, V12, P755; HAJJAR KA, 1994, J BIOL CHEM, V269, P21191; Hayden MS, 2004, GENE DEV, V18, P2195, DOI 10.1101/gad.1228704; Hong MY, 1999, CELL GROWTH DIFFER, V10, P749; Iacopetta B, 2002, INT J CANCER, V101, P403, DOI 10.1002/ijc.10635; Lifshitz S, 2001, CANCER LETT, V163, P229, DOI 10.1016/S0304-3835(00)00624-8; Liu LU, 1999, GUT, V45, P45, DOI 10.1136/gut.45.1.45; Marshman E, 2001, J PATHOL, V195, P285; May MJ, 2000, SCIENCE, V289, P1550, DOI 10.1126/science.289.5484.1550; Mills SJ, 2001, GUT, V48, P41, DOI 10.1136/gut.48.1.41; Muerkoster S, 2005, GASTROENTEROLOGY, V129, P952, DOI 10.1053/j.gastro.2005.06.059; Ortiz-Zapater E, 2007, AM J PATHOL, V170, P1573, DOI 10.2353/ajpath.2007.060850; Ottewell PD, 2005, AM J PHYSIOL-GASTR L, V288, pG541, DOI 10.1152/ajpgi.00268.2004; Ottewell PD, 2003, GASTROENTEROLOGY, V124, P1348, DOI 10.1016/S0016-5085(03)00288-9; Rengifo-Cam W, 2004, CURR PHARM DESIGN, V10, P2345, DOI 10.2174/1381612043383999; Rengifo-Cam W, 2007, CANCER RES, V67, P7266, DOI 10.1158/0008-5472.CAN-07-1206; Sarkar S, 2007, GASTROENTEROLOGY, V132, pA540; SATO M, 1992, ANAT RECORD, V233, P409, DOI 10.1002/ar.1092330308; SEVA C, 1994, SCIENCE, V265, P410, DOI 10.1126/science.8023165; Singh P, 2007, ONCOGENE, V26, P425, DOI 10.1038/sj.onc.1209798; Singh P, 2000, GASTROENTEROLOGY, V119, P162, DOI 10.1053/gast.2000.8527; Singh P, 2000, AM J PHYSIOL-GASTR L, V278, pG390, DOI 10.1152/ajpgi.2000.278.3.G390; Singh P, 2003, AM J PHYSIOL-GASTR L, V284, pG328, DOI 10.1152/ajpgi.00351.2002; Singh P, 2007, CANCER LETT, V252, P19, DOI 10.1016/j.canlet.2006.11.012; Song DH, 2003, AM J PHYSIOL-GASTR L, V285, pG217, DOI 10.1152/ajpgi.00516.2002; Umar S, 2003, CELL PROLIFERAT, V36, P361, DOI 10.1046/j.1365-2184.2003.00291.x; Umar S, 2000, AM J PHYSIOL-GASTR L, V279, pG223, DOI 10.1152/ajpgi.2000.279.1.G223; Umar S, 2007, AM J PHYSIOL-GASTR L, V292, pG599, DOI 10.1152/ajpgi.00343.2006; Wang TC, 1996, J CLIN INVEST, V98, P1918, DOI 10.1172/JCI118993; Wang Y, 2006, BRIT J PHARMACOL, V148, P814, DOI 10.1038/sj.bjp.0706784; Watanabe T, 2006, CANCER RES, V66, P9804, DOI 10.1158/0008-5472.CAN-06-1163; Wu H, 2003, AM J PHYSIOL-GASTR L, V285, pG1097, DOI 10.1152/ajpgi.00216.2003; Zizzo MG, 2006, BRIT J PHARMACOL, V148, P956, DOI 10.1038/sj.bjp.0706808	44	27	32	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 18	2008	27	42					5599	5611		10.1038/onc.2008.169	http://dx.doi.org/10.1038/onc.2008.169			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	349KX	18521082	Green Accepted			2022-12-28	WOS:000259280800006
J	Orloff, MS; Eng, C				Orloff, M. S.; Eng, C.			Genetic and phenotypic heterogeneity in the PTEN hamartoma tumour syndrome	ONCOGENE			English	Review						phenomics; personalized; PTEN; -omics; genomics	RILEY-RUVALCABA-SYNDROME; DIMENSIONALITY REDUCTION METHOD; LIPID PHOSPHATASE-ACTIVITY; CELL-CYCLE ARREST; COWDEN-SYNDROME; GERMLINE MUTATIONS; SUPPRESSOR GENE; JUVENILE POLYPOSIS; SPORADIC BREAST; SPLICE VARIANTS	Germline PTEN (Phosphatase and TENsin homologue deleted on chromosome TEN) mutations predispose to phenotypically diverse disorders that share several overlapping clinical features: Cowden syndrome, Bannayan-Riley-Ruvalcaba syndrome, Proteus syndrome and Proteus-like syndrome, collectively classified as PTEN hamartoma tumour syndrome (PHTS). The meticulous acquisition and documentation of PHTS phenotypic data at different levels and the pro. ling of the plethora of genetic changes in PTEN and other genes within the same or related pathways are important in resolving the challenge of discriminating heritable cancers from sporadic PHTS-mimicking clinical features. The characterization of PTEN and PTEN-related pathways from a multidisciplinary perspective underscores the importance of incorporating data from different -omics, which is crucial for the advancement of personalized medicine.	[Orloff, M. S.; Eng, C.] Cleveland Clin Fdn, Genom Med Inst, Cleveland, OH 44195 USA; [Eng, C.] Cleveland Clin Fdn, Lerner Res Inst, Cleveland, OH 44195 USA; [Eng, C.] Cleveland Clin Fdn, Taussig Canc Ctr, Cleveland, OH 44195 USA; [Eng, C.] Case Western Reserve Univ, Sch Med, Dept Genet, Cleveland, OH 44106 USA	Cleveland Clinic Foundation; Cleveland Clinic Foundation; Cleveland Clinic Foundation; Case Western Reserve University	Eng, C (corresponding author), Cleveland Clin, Genom Med Inst, 9500 Euclid Ave,Mailstop NE-50, Cleveland, OH 44195 USA.	engc@ccf.org		Eng, Charis/0000-0002-3693-5145	Doris Duke Distinguished Clinical Scientist Award	Doris Duke Distinguished Clinical Scientist Award(Doris Duke Charitable Foundation (DDCF))	CE is a recipient of the Doris Duke Distinguished Clinical Scientist Award, holds the Sondra J & Stephen R Hardis Chair in Cancer Genomic Medicine at the Cleveland Clinic and is an Honorary Fellow of the Cancer Research UK Human Cancer Genetics Research Group, University of Cambridge, UK.	Agrawal S, 2006, HUM MOL GENET, V15, P777, DOI 10.1093/hmg/ddi492; Arch EM, 1997, AM J MED GENET, V71, P489, DOI 10.1002/(SICI)1096-8628(19970905)71:4<489::AID-AJMG24>3.0.CO;2-B; Bartel F, 2004, MOL CANCER RES, V2, P29; Bracco L, 2003, TRENDS BIOTECHNOL, V21, P346, DOI 10.1016/S0167-7799(03)00146-X; Brinkman BMN, 2004, CLIN BIOCHEM, V37, P584, DOI 10.1016/j.clinbiochem.2004.05.015; Chanda P, 2007, AM J HUM GENET, V81, P939, DOI 10.1086/521878; Chi HB, 1999, GENOMICS, V56, P324, DOI 10.1006/geno.1998.5736; Chin K, 2006, CANCER CELL, V10, P529, DOI 10.1016/j.ccr.2006.10.009; Chung JH, 2005, CANCER RES, V65, P8096, DOI 10.1158/0008-5472.CAN-05-1888; Chung JH, 2006, HUM MOL GENET, V15, P2553, DOI 10.1093/hmg/ddl177; Chung YJ, 2007, BIOINFORMATICS, V23, P71, DOI 10.1093/bioinformatics/btl557; Dahia PM, 2000, J MED GENET, V37, P715, DOI 10.1136/jmg.37.9.715; Delnatte C, 2006, AM J HUM GENET, V78, P1066, DOI 10.1086/504301; Di Cristofano A, 1998, NAT GENET, V19, P348, DOI 10.1038/1235; Drysdale RA, 2005, NUCLEIC ACIDS RES, V33, pD390, DOI 10.1093/nar/gki046; Eng C, 2003, HUM MUTAT, V22, P183, DOI 10.1002/humu.10257; Eng C, 1998, NAT GENET, V19, P223, DOI 10.1038/897; Eng C, 2001, NAT GENET, V28, P105, DOI 10.1038/88802; Eng C, 2000, J MED GENET, V37, P828, DOI 10.1136/jmg.37.11.828; Faustino NA, 2003, GENE DEV, V17, P419, DOI 10.1101/gad.1048803; Freeman D, 2006, CANCER RES, V66, P6492, DOI 10.1158/0008-5472.CAN-05-4143; Georgescu MM, 1999, P NATL ACAD SCI USA, V96, P10182, DOI 10.1073/pnas.96.18.10182; Ginn-Pease ME, 2003, CANCER RES, V63, P282; Haiman CA, 2006, CANCER EPIDEM BIOMAR, V15, P1021, DOI 10.1158/1055-9965.EPI-05-0896; Hamilton JA, 2000, BRIT J CANCER, V82, P1671; Harris TW, 2003, NUCLEIC ACIDS RES, V31, P133, DOI 10.1093/nar/gkg053; Hettinger K, 2007, CELL DEATH DIFFER, V14, P218, DOI 10.1038/sj.cdd.4401946; Howe JR, 1998, SCIENCE, V280, P1086, DOI 10.1126/science.280.5366.1086; Howe JR, 2001, NAT GENET, V28, P184, DOI 10.1038/88919; Hsieh HF, 1999, J CLIN PATHOL-MOL PA, V52, P25, DOI 10.1136/mp.52.1.25; Kahraman A, 2005, BIOINFORMATICS, V21, P418, DOI 10.1093/bioinformatics/bti010; LEE CH, 1993, P NATL ACAD SCI USA, V90, P11713, DOI 10.1073/pnas.90.24.11713; Lee JO, 1999, CELL, V99, P323, DOI 10.1016/S0092-8674(00)81663-3; Lee SY, 2007, BIOINFORMATICS, V23, P2589, DOI 10.1093/bioinformatics/btm396; Liaw D, 1997, NAT GENET, V16, P64, DOI 10.1038/ng0597-64; Maehama T, 1998, J BIOL CHEM, V273, P13375, DOI 10.1074/jbc.273.22.13375; Maehama T, 1999, TRENDS CELL BIOL, V9, P125, DOI 10.1016/S0962-8924(99)01519-6; Marsh DJ, 1998, J MED GENET, V35, P881, DOI 10.1136/jmg.35.11.881; Marsh DJ, 1997, CANCER RES, V57, P5017; Marsh DJ, 1998, HUM MOL GENET, V7, P507, DOI 10.1093/hmg/7.3.507; Marsh DJ, 1997, NAT GENET, V16, P333, DOI 10.1038/ng0897-333; Marsh DJ, 1999, HUM MOL GENET, V8, P1461, DOI 10.1093/hmg/8.8.1461; Minaguchi T, 2006, CANCER RES, V66, P11677, DOI 10.1158/0008-5472.CAN-06-2240; Myers MP, 1997, P NATL ACAD SCI USA, V94, P9052, DOI 10.1073/pnas.94.17.9052; Myers MP, 1998, P NATL ACAD SCI USA, V95, P13513, DOI 10.1073/pnas.95.23.13513; Nelen MR, 1999, EUR J HUM GENET, V7, P267, DOI 10.1038/sj.ejhg.5200289; Nelen MR, 1996, NAT GENET, V13, P114, DOI 10.1038/ng0596-114; Okahara F, 2004, J BIOL CHEM, V279, P45300, DOI 10.1074/jbc.C400377200; Patel L, 2001, CURR BIOL, V11, P764, DOI 10.1016/S0960-9822(01)00225-1; Pezzolesi MG, 2007, HUM MOL GENET, V16, P1058, DOI 10.1093/hmg/ddm053; Pezzolesi MG, 2006, AM J HUM GENET, V79, P923, DOI 10.1086/508943; Philips AV, 2000, CELL MOL LIFE SCI, V57, P235, DOI 10.1007/PL00000687; Planchon SM, 2008, J CELL SCI, V121, P249, DOI 10.1242/jcs.022459; Podsypanina K, 1999, P NATL ACAD SCI USA, V96, P1563, DOI 10.1073/pnas.96.4.1563; Poola I, 2001, J STEROID BIOCHEM, V78, P459, DOI 10.1016/S0960-0760(01)00118-2; Ritchie MD, 2001, AM J HUM GENET, V69, P138, DOI 10.1086/321276; Sarquis MS, 2006, AM J HUM GENET, V79, P23, DOI 10.1086/504392; Shen WH, 2007, CELL, V128, P157, DOI 10.1016/j.cell.2006.11.042; Sheng XY, 2002, BIOCHEM BIOPH RES CO, V292, P422, DOI 10.1006/bbrc.2002.6662; Smith JM, 2002, J MED GENET, V39, P937, DOI 10.1136/jmg.39.12.937; Stambolic V, 1998, CELL, V95, P29, DOI 10.1016/S0092-8674(00)81780-8; Stambolic V, 2001, MOL CELL, V8, P317, DOI 10.1016/S1097-2765(01)00323-9; Stambolic V, 2000, CANCER RES, V60, P3605; Suzuki A, 1998, CURR BIOL, V8, P1169, DOI 10.1016/S0960-9822(07)00488-5; Sweet K, 2005, JAMA-J AM MED ASSOC, V294, P2465, DOI 10.1001/jama.294.19.2465; Tang YF, 2006, CANCER RES, V66, P736, DOI 10.1158/0008-5472.CAN-05-1557; Tang YF, 2006, CANCER RES, V66, P6139, DOI 10.1158/0008-5472.CAN-06-0772; Teresi RE, 2008, HUM MOL GENET, V17, P919, DOI 10.1093/hmg/ddm364; Teresi RE, 2007, AM J HUM GENET, V81, P756, DOI 10.1086/521051; Tsou HC, 1997, AM J HUM GENET, V61, P1036, DOI 10.1086/301607; Tsuchiya KD, 1998, GENE CHROMOSOME CANC, V21, P113, DOI 10.1002/(SICI)1098-2264(199802)21:2<113::AID-GCC6>3.0.CO;2-3; Vasudevan KM, 2004, MOL CELL BIOL, V24, P1007, DOI 10.1128/MCB.24.3.1007-1021.2004; Vazquez F, 2000, MOL CELL BIOL, V20, P5010, DOI 10.1128/MCB.20.14.5010-5018.2000; Virolle T, 2001, NAT CELL BIOL, V3, P1124, DOI 10.1038/ncb1201-1124; Waite KA, 2002, AM J HUM GENET, V70, P829, DOI 10.1086/340026; Waite KA, 2003, HUM MOL GENET, V12, P679, DOI 10.1093/hmg/ddg069; Wang NM, 1999, INT J MOL MED, V3, P491; Weber F, 2005, J CLIN ENDOCR METAB, V90, P6334, DOI 10.1210/jc.2005-2030; Weber Frank, 2005, Future Oncol, V1, P497; Weng LP, 2002, HUM MOL GENET, V11, P1687, DOI 10.1093/hmg/11.15.1687; Weng LP, 2001, HUM MOL GENET, V10, P237, DOI 10.1093/hmg/10.3.237; Weng LP, 2001, HUM MOL GENET, V10, P599, DOI 10.1093/hmg/10.6.599; Whelan JT, 2007, CELL CYCLE, V6, P80, DOI 10.4161/cc.6.1.3648; Yao J, 2006, CANCER RES, V66, P4065, DOI 10.1158/0008-5472.CAN-05-4083; Zbuk KM, 2007, NAT REV CANCER, V7, P35, DOI 10.1038/nrc2037; Zhang L, 2006, AM J MED GENET B, V141B, P10, DOI 10.1002/ajmg.b.30240; Zhou XP, 2000, AM J PATHOL, V157, P1123, DOI 10.1016/S0002-9440(10)64627-5; Zhou XP, 2003, AM J HUM GENET, V73, P1191, DOI 10.1086/379382; Zhou XP, 2003, AM J HUM GENET, V73, P404, DOI 10.1086/377109; Zhou XP, 2001, LANCET, V358, P210, DOI 10.1016/S0140-6736(01)05412-5	90	88	89	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 15	2008	27	41					5387	5397		10.1038/onc.2008.237	http://dx.doi.org/10.1038/onc.2008.237			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	349KW	18794875				2022-12-28	WOS:000259280700002
J	Sun, C; Dobi, A; Mohamed, A; Li, H; Thangapazham, RL; Furusato, B; Shaheduzzaman, S; Tan, SH; Vaidyanathan, G; Whitman, E; Hawksworth, DJ; Chen, Y; Nau, M; Patel, V; Vahey, M; Gutkind, JS; Sreenath, T; Petrovics, G; Sesterhenn, IA; McLeod, DG; Srivastava, S				Sun, C.; Dobi, A.; Mohamed, A.; Li, H.; Thangapazham, R. L.; Furusato, B.; Shaheduzzaman, S.; Tan, S-H; Vaidyanathan, G.; Whitman, E.; Hawksworth, D. J.; Chen, Y.; Nau, M.; Patel, V.; Vahey, M.; Gutkind, J. S.; Sreenath, T.; Petrovics, G.; Sesterhenn, I. A.; McLeod, D. G.; Srivastava, S.			TMPRSS2-ERG fusion, a common genomic alteration in prostate cancer activates C-MYC and abrogates prostate epithelial differentiation	ONCOGENE			English	Article						ERG; prostate cancer; oncogene; C-MYC; PSA; TMPRSS2-ERG	ETS TRANSCRIPTION FACTOR; ANDROGEN RECEPTOR; EXPRESSION; REARRANGEMENTS; LEUKEMIA; TARGETS; ADULTS; GENES; ERG	The high prevalence of TMPRSS2-ERG rearrangements (similar to 60%) in prostate cancer (CaP) leads to androgenic induction of the ETS-related gene (ERG) expression. However, the biological functions of ERG overexpression in CaP remain to be understood. ERG knockdown in TMPRSS2-ERG expressing CaP cells induced striking morphological changes and inhibited cell growth both in cell culture and SCID mice. Evaluation of the transcriptome and specific gene promoters in ERG siRNA-treated cells and investigation of gene expression signatures of human prostate tumors revealed ERG-mediated activation of C-MYC oncogene and the repression of prostate epithelial differentiation genes (PSA and SLC45A3/Prostein). Taken together, these data combining cell culture and animal models and human prostate tumors reveal that ERG overexpression in prostate tumor cells may contribute to the neoplastic process by activating C-MYC and by abrogating prostate epithelial differentiation as indicated by prostate epithelial specific markers.	[Sun, C.; Dobi, A.; Mohamed, A.; Li, H.; Thangapazham, R. L.; Furusato, B.; Shaheduzzaman, S.; Tan, S-H; Vaidyanathan, G.; Whitman, E.; Hawksworth, D. J.; Chen, Y.; Sreenath, T.; Petrovics, G.; McLeod, D. G.; Srivastava, S.] Uniformed Serv Univ Hlth Sci, Ctr Prostate Dis Res, Dept Surg, Rockville, MD 20852 USA; [Furusato, B.; Sesterhenn, I. A.] Armed Forces Inst Pathol, Dept Genitourinary Pathol, Washington, DC 20306 USA; [Whitman, E.; Hawksworth, D. J.; McLeod, D. G.] Walter Reed Army Med Ctr, Urol Serv, Dept Surg, Washington, DC 20307 USA; [Nau, M.; Vahey, M.] Walter Reed Army Inst Res, Div Retrovirol, Rockville, MD USA; [Patel, V.; Gutkind, J. S.] Natl Inst Dent & Craniofacial Res, Oral & Pharyngeal Canc Branch, Natl Inst Hlth, Bethesda, MD USA; [Dobi, A.; Sesterhenn, I. A.; McLeod, D. G.; Srivastava, S.] US Mil Canc Inst, Washington, DC USA	Uniformed Services University of the Health Sciences - USA; United States Department of Defense; United States Department of Defense; United States Army; Walter Reed National Military Medical Center; United States Department of Defense; United States Army; Walter Reed Army Institute of Research (WRAIR); National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR)	Srivastava, S (corresponding author), Uniformed Serv Univ Hlth Sci, Ctr Prostate Dis Res, Dept Surg, 1530 E Jefferson St, Rockville, MD 20852 USA.	ssrivastava@cpdr.org	Jackson, Benjamin L/C-4297-2012; Gutkind, J. Silvio/A-1053-2009; Gutkind, J. Silvio/J-1201-2016; Tan, Shyh-Han/I-7037-2013	Gutkind, J. Silvio/0000-0002-5150-4482; Tan, Shyh-Han/0000-0001-8250-7005; Furusato, Bungo/0000-0003-4614-9882; Petrovics, Gyorgy/0000-0003-3732-284X	US Army Medical Research and Materiel Command; NIH Grants [RO1 DK065977, RO1 CA106653]; NATIONAL CANCER INSTITUTE [R01CA106653] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [ZIADE000558] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [Z01DE000558] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK065977] Funding Source: NIH RePORTER	US Army Medical Research and Materiel Command(United States Department of DefenseUnited States ArmyU.S. Army Medical Research & Materiel Command (USAMRMC)); NIH Grants(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	Authors express sincere thanks to Ms Lakshmi Ravindranath, Ms Atekelt Y Tadese, Ms Suma Ravulapalli and Mr Christopher Cook for their superb technical support of this study. The prostate tissue specimens used in this study were obtained under an IRB-approved protocol at Walter Reed Army Medical Center. This work was funded by the CPDR through an ongoing grant from the US Army Medical Research and Materiel Command, NIH Grants RO1 DK065977 to S. S and G. P. and RO1 CA106653 to S. S. and A. D. The views expressed in this manuscript are those of the authors and do not reflect the official policy of the Department of the Army, Department of Defense or the US Government.	Baldus CD, 2006, J CLIN ONCOL, V24, P4714, DOI 10.1200/JCO.2006.06.1580; Chinnaiyan AM, 2008, NEOPLASIA, V10, P177, DOI 10.1593/neo.07822; De Marzo AM, 2007, NAT REV CANCER, V7, P256, DOI 10.1038/nrc2090; Demichelis F, 2007, J CLIN PATHOL, V60, P1185, DOI 10.1136/jcp.2007.046557; Furusato B, 2008, MODERN PATHOL, V21, P67, DOI 10.1038/modpathol.3800981; Iljin K, 2006, CANCER RES, V66, P10242, DOI 10.1158/0008-5472.CAN-06-1986; Klezovitch O, 2008, P NATL ACAD SCI USA, V105, P2105, DOI 10.1073/pnas.0711711105; Korenchuk S, 2001, IN VIVO, V15, P163; Lin BY, 1999, CANCER RES, V59, P4180; Marcucci G, 2005, CURR OPIN HEMATOL, V12, P68, DOI 10.1097/01.moh.0000149608.29685.d1; Massie CE, 2007, EMBO REP, V8, P871, DOI 10.1038/sj.embor.7401046; MEULIA T, 1992, MOL CELL BIOL, V12, P4590, DOI 10.1128/MCB.12.10.4590; Oettgen P, 2000, J BIOL CHEM, V275, P1216, DOI 10.1074/jbc.275.2.1216; Owczarek CM, 2004, GENE, V324, P65, DOI 10.1016/j.gene.2003.09.047; Petrovics G, 2005, ONCOGENE, V24, P3847, DOI 10.1038/sj.onc.1208518; Scherf M, 2005, BRIEF BIOINFORM, V6, P287, DOI 10.1093/bib/6.3.287; Seth A, 2005, EUR J CANCER, V41, P2462, DOI 10.1016/j.ejca.2005.08.013; SHAHEDUZZAMAN S, 2007, CANCER BIOL THER, V6, P1; Tomlins SA, 2005, SCIENCE, V310, P644, DOI 10.1126/science.1117679; Tomlins SA, 2007, NATURE, V448, P595, DOI 10.1038/nature06024; Turner DP, 2008, EXPERT REV ANTICANC, V8, P33, DOI 10.1586/14737140.8.1.33; Witte JS, 2007, NAT GENET, V39, P579, DOI 10.1038/ng0507-579	22	184	197	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 11	2008	27	40					5348	5353		10.1038/onc.2008.183	http://dx.doi.org/10.1038/onc.2008.183			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	346UW	18542058	Green Accepted			2022-12-28	WOS:000259096100007
J	Hasegawa, T; Enomoto, A; Kato, T; Kawai, K; Miyamoto, R; Jijiwa, M; Ichihara, M; Ishida, M; Asai, N; Murakumo, Y; Ohara, K; Niwa, Y; Goto, H; Takahashi, M				Hasegawa, T.; Enomoto, A.; Kato, T.; Kawai, K.; Miyamoto, R.; Jijiwa, M.; Ichihara, M.; Ishida, M.; Asai, N.; Murakumo, Y.; Ohara, K.; Niwa, Y.; Goto, H.; Takahashi, M.			Roles of induced expression of MAPK phosphatase-2 in tumor development in RET-MEN2A transgenic mice	ONCOGENE			English	Article						RET; MEN2A; MKP-2; cell proliferation; cell cycle	ACTIVATED PROTEIN-KINASE; CELL-CYCLE ARREST; NEOPLASIA TYPE 2B; RET PROTOONCOGENE; LACKING GDNF; HIRSCHSPRUNGS-DISEASE; TERMINAL KINASE; THYROID-CANCER; 2A MUTATION; GENE	Germline mutations in the RET tyrosine kinase gene are responsible for the development of multiple endocrine neoplasia 2A and 2B (MEN2A and MEN2B). However, knowledge of the fundamental principles that determine the mutant RET-mediated signaling remains elusive. Here, we report increased expression of mitogen-activated protein kinase phosphatase-2 (MKP-2) in carcinomas developed in transgenic mice carrying RET with the MEN2A mutation (RET-MEN2A). The expression of MKP-2 was not only induced by RET-MEN2A or RET-MEN2B mutant proteins but also by the activation of endogenous RET by its ligand, glial cell line-derived neurotrophic factor (GDNF). MKP-2 expression was also evident in the MKK-f cell line, which was established from a mammary tumor developed in a RET- MEN2A transgenic mouse. Inhibition of MKP-2 attenuated the in vitro and in vivo proliferation of MKK-f cells, which was mediated by the suppression of cyclin B1 expression. Furthermore, we found that MKP-2 is highly expressed in medullary thyroid carcinomas derived from MEN2A patients. These findings suggest that the increased expression of MKP-2 may play a crucial role in oncogenic signaling downstream of mutant RET, leading to deregulation of cell cycle.	[Hasegawa, T.; Enomoto, A.; Kato, T.; Kawai, K.; Miyamoto, R.; Jijiwa, M.; Ishida, M.; Asai, N.; Murakumo, Y.; Ohara, K.; Takahashi, M.] Nagoya Univ, Grad Sch Med, Dept Pathol, Showa Ku, Nagoya, Aichi 4668550, Japan; [Hasegawa, T.; Ohara, K.; Niwa, Y.; Goto, H.] Nagoya Univ, Grad Sch Med, Dept Gastroenterol, Nagoya, Aichi 4668550, Japan; [Enomoto, A.] Nagoya Univ, Inst Adv Res, Nagoya, Aichi 4668550, Japan; [Ichihara, M.] Chubu Univ, Dept Biomed Sci, Coll Life & Hlth Sci, Kasugai, Aichi 487, Japan; [Takahashi, M.] Nagoya Univ, Grad Sch Med, Div Mol Pathol, Ctr Neurol Dis & Cancer, Nagoya, Aichi 4668550, Japan	Nagoya University; Nagoya University; Nagoya University; Chubu University; Nagoya University	Takahashi, M (corresponding author), Nagoya Univ, Grad Sch Med, Dept Pathol, Showa Ku, 65 Tsurumai Cho, Nagoya, Aichi 4668550, Japan.	mtakaha@med.nagoya-u.ac.jp	Takahashi, Masahide/AAN-4770-2020; TAKAHASHI, Masahide/I-7244-2014; ASAI, Naoya/I-7377-2014; Enomoto, Atsushi/I-7272-2014; Kumi, Kawai/I-6275-2014	Takahashi, Masahide/0000-0002-2803-2683; Enomoto, Atsushi/0000-0002-9206-6116; Kumi, Kawai/0000-0002-7772-2605	21st Century Center of Excellence (COE) Research; Scientific Research (A); Ministry of Education, Culture, Sports, Science and Technology (MEXT) of Japan	21st Century Center of Excellence (COE) Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Scientific Research (A)(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI)); Ministry of Education, Culture, Sports, Science and Technology (MEXT) of Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT))	We thank K Hirose (Nagoya University) for providing the pNAMA shRNA expression vector, S Nakamura (Nagoya University Hospital) for providing sporadic and MEN2A MTC specimens and C Suzuki (Nagoya University) and T Urano (Shimane University) for helpful discussion. We also thank YGotoh (Tokyo University) for providing active MAPKK (pSR alpha-Delta SESE-MAPKK) and MKK6 (pcDNA3.1(+)-MKK6-EE) plasmids. This study was supported by Grants-in-Aid for The 21st Century Center of Excellence (COE) Research, Scientific Research (A) and Scientific Research on Priority Area 'Cancer' commissioned by the Ministry of Education, Culture, Sports, Science and Technology (MEXT) of Japan (to MT).	Airaksinen MS, 2002, NAT REV NEUROSCI, V3, P383, DOI 10.1038/nrn812; Asai N, 2006, PATHOL INT, V56, P164, DOI 10.1111/j.1440-1827.2006.01942.x; ASAI N, 1995, MOL CELL BIOL, V15, P1613; Cadalbert L, 2005, CELL SIGNAL, V17, P1254, DOI 10.1016/j.cellsig.2005.01.003; CARLSON KM, 1994, P NATL ACAD SCI USA, V91, P1579, DOI 10.1073/pnas.91.4.1579; Dickinson RJ, 2006, J CELL SCI, V119, P4607, DOI 10.1242/jcs.03266; DONISKELLER H, 1993, HUM MOL GENET, V2, P851, DOI 10.1093/hmg/2.7.851; EDERY P, 1994, NATURE, V367, P378, DOI 10.1038/367378a0; Eng C, 1999, J CLIN ONCOL, V17, P380, DOI 10.1200/JCO.1999.17.1.380; Enomoto A, 2005, DEV CELL, V9, P389, DOI 10.1016/j.devcel.2005.08.001; Farooq A, 2004, CELL SIGNAL, V16, P769, DOI 10.1016/j.cellsig.2003.12.008; Fukuda T, 2005, GENES CELLS, V10, P655, DOI 10.1111/j.1365-2443.2005.00866.x; Gimm O, 1997, J CLIN ENDOCR METAB, V82, P3902, DOI 10.1210/jc.82.11.3902; GUAN KL, 1995, J BIOL CHEM, V270, P7197, DOI 10.1074/jbc.270.13.7197; Hassan KA, 2002, CANCER RES, V62, P6414; HOFSTRA RMW, 1994, NATURE, V367, P375, DOI 10.1038/367375a0; Kao GD, 1997, CANCER RES, V57, P753; Kawai K, 2000, CANCER RES, V60, P5254; Kawai K, 2003, CANCER SCI, V94, P992, DOI 10.1111/j.1349-7006.2003.tb01390.x; Kodama Y, 2005, CANCER SCI, V96, P143, DOI 10.1111/j.1349-7006.2005.00023.x; Lundberg AS, 2000, CURR OPIN CELL BIOL, V12, P705, DOI 10.1016/S0955-0674(00)00155-1; MISRAPRESS A, 1995, J BIOL CHEM, V270, P14587, DOI 10.1074/jbc.270.24.14587; Moore MW, 1996, NATURE, V382, P76, DOI 10.1038/382076a0; MULLIGAN LM, 1993, NATURE, V363, P458, DOI 10.1038/363458a0; Murphy LO, 2006, TRENDS BIOCHEM SCI, V31, P268, DOI 10.1016/j.tibs.2006.03.009; NORBURY C, 1992, ANNU REV BIOCHEM, V61, P441, DOI 10.1146/annurev.bi.61.070192.002301; Owens DM, 2007, ONCOGENE, V26, P3203, DOI 10.1038/sj.onc.1210412; Park M, 2000, CANCER RES, V60, P542; Pichel JG, 1996, NATURE, V382, P73, DOI 10.1038/382073a0; Pines J, 1999, NAT CELL BIOL, V1, pE73, DOI 10.1038/11041; Porter Lisa A, 2003, Prog Cell Cycle Res, V5, P335; ROMEO G, 1994, NATURE, V367, P377, DOI 10.1038/367377a0; Rosenthal A, 1999, NEURON, V22, P201, DOI 10.1016/S0896-6273(00)81077-6; Sanchez MP, 1996, NATURE, V382, P70, DOI 10.1038/382070a0; Santana C, 2002, MUTAT RES-FUND MOL M, V508, P49, DOI 10.1016/S0027-5107(02)00172-0; SANTORO M, 1995, SCIENCE, V267, P381, DOI 10.1126/science.7824936; SCHUCHARDT A, 1994, NATURE, V367, P380, DOI 10.1038/367380a0; Sewing A, 1997, MOL CELL BIOL, V17, P5588, DOI 10.1128/MCB.17.9.5588; Shen WH, 2006, CANCER RES, V66, P6033, DOI 10.1158/0008-5472.CAN-05-3878; Shirane D, 2004, NAT GENET, V36, P190, DOI 10.1038/ng1290; Smith DP, 1997, ONCOGENE, V15, P1213, DOI 10.1038/sj.onc.1201481; Soria JC, 2000, CANCER RES, V60, P4000; Takahashi M, 2001, CYTOKINE GROWTH F R, V12, P361, DOI 10.1016/S1359-6101(01)00012-0; Takizawa CG, 2000, CURR OPIN CELL BIOL, V12, P658, DOI 10.1016/S0955-0674(00)00149-6; Taylor WR, 1999, MOL BIOL CELL, V10, P3607, DOI 10.1091/mbc.10.11.3607; Treanor JJS, 1996, NATURE, V382, P80, DOI 10.1038/382080a0; Uchida M, 2006, J CELL SCI, V119, P3067, DOI 10.1242/jcs.03043; Wang JL, 2007, J BIOL CHEM, V282, P18521, DOI 10.1074/jbc.M610538200; Watanabe T, 2002, AM J PATHOL, V161, P249, DOI 10.1016/S0002-9440(10)64176-4; Woods D, 1997, MOL CELL BIOL, V17, P5598, DOI 10.1128/MCB.17.9.5598; Yuan J, 2006, ONCOGENE, V25, P1753, DOI 10.1038/sj.onc.1209202; Yuan JP, 2004, ONCOGENE, V23, P5843, DOI 10.1038/sj.onc.1207757	52	24	24	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP	2008	27	43					5684	5695		10.1038/onc.2008.182	http://dx.doi.org/10.1038/onc.2008.182			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	352HM	18542059				2022-12-28	WOS:000259487100004
J	Maroto, B; Ye, MB; von Lohneysen, K; Schnelzer, A; Knaus, UG				Maroto, B.; Ye, M. B.; von Lohneysen, K.; Schnelzer, A.; Knaus, U. G.			P21-activated kinase is required for mitotic progression and regulates Plk1	ONCOGENE			English	Article						p21-activated kinase; Plk1; cell cycle	POLO-LIKE KINASE-1; BREAST-CANCER CELLS; SPINDLE POLES; HISTONE H3; AURORA-A; PHOSPHORYLATION; PAK1; ACTIVATION; LOCALIZATION; CYTOKINESIS	P21-activated kinases (Paks), a family of serine/threonine kinases, are effectors of the Rho GTPases Cdc42 and Rac1. Mammalian Pak1 and Pak homologs in simple eukaryotes are implicated in controlling G2/M transition and/or mitosis. Another serine/threonine kinase, polo-like kinase 1 (Plk1), is an important regulator of mitotic events, such as centrosome maturation, mitotic entry, spindle formation, sister chromatid cohesion and cytokinesis. Plk1 phosphorylation is thought to be one of the critical regulatory events leading to these Plk1-mediated functions. We show here that Pak1 is required for cell proliferation, mitotic progression and Plk1 activity in HeLa cells. Gain or loss of Pak function directly impacted phosphorylation and activity of Plk1. Phosphorylation of Plk1 on Ser 49 is important for metaphase-associated events. Inhibition of Pak activity leads to delay in G2/M progression and abnormal spindle formation, mirroring some attributes of Plk1 deregulation. Our results reveal a role for Pak in regulating Plk1 activity and mitotic progression, and connect Pak to the complex protein interaction network enabling cell division.	[Maroto, B.; Ye, M. B.; von Lohneysen, K.; Schnelzer, A.; Knaus, U. G.] Scripps Res Inst, Dept Immunol, La Jolla, CA 92037 USA	Scripps Research Institute	Knaus, UG (corresponding author), Scripps Res Inst, Dept Immunol, IMM28,10550 N Torrey Pines Rd,R203, La Jolla, CA 92037 USA.	uknaus@scripps.edu		Schnelzer, Andreas/0000-0002-5410-3561	NIH [AI35947, AI24838, AI07244-22]; University of California [8FB-0026]; German Academic Exchange; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [T32AI007244, R01AI035947, R01AI024838] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); University of California(University of California System); German Academic Exchange(Deutscher Akademischer Austausch Dienst (DAAD)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	We thank E Nishida for Plk wild-type constructs, the laboratories of G Bokoch and S Reed for sharing antibodies, J Birkenfeld for advice and K Schreiber for illustrations and administrative assistance. This work was supported by NIH (AI35947, AI24838 to UGK), by funds from the California Breast Cancer Research Program of the University of California 8FB-0026 (BM), NIH training grant T32 AI07244-22 (MY) and a German Academic Exchange (DAAD) fellowship (AS).	Balasenthil S, 2004, J BIOL CHEM, V279, P1422, DOI 10.1074/jbc.M309937200; Banerjee M, 2002, CURR BIOL, V12, P1233, DOI 10.1016/S0960-9822(02)00956-9; Barr FA, 2004, NAT REV MOL CELL BIO, V5, P429, DOI 10.1038/nrm1401; BODE AM, 2005, SCI STKE, pRE4; Bokoch GM, 2003, ANNU REV BIOCHEM, V72, P743, DOI 10.1146/annurev.biochem.72.121801.161742; De Luca M, 2006, CELL CYCLE, V5, P296; DerMardirossian C, 2004, MOL CELL, V15, P117, DOI 10.1016/j.molcel.2004.05.019; Ellinger-Ziegelbauer H, 2000, GENES CELLS, V5, P491, DOI 10.1046/j.1365-2443.2000.00337.x; Glover DM, 2005, ONCOGENE, V24, P230, DOI 10.1038/sj.onc.1208279; Hofmann C, 2004, J CELL SCI, V117, P4343, DOI 10.1242/jcs.01392; Holm C, 2006, JNCI-J NATL CANCER I, V98, P671, DOI 10.1093/jnci/djj185; Jang YJ, 2002, J BIOL CHEM, V277, P44115, DOI 10.1074/jbc.M202172200; KNAUS UG, 1995, SCIENCE, V269, P221, DOI 10.1126/science.7618083; Kumar R, 2002, J CELL PHYSIOL, V193, P133, DOI 10.1002/jcp.10167; Kumar R, 2006, NAT REV CANCER, V6, P459, DOI 10.1038/nrc1892; Lei M, 2000, CELL, V102, P387, DOI 10.1016/S0092-8674(00)00043-X; Lenart P, 2007, CURR BIOL, V17, P304, DOI 10.1016/j.cub.2006.12.046; Li F, 2002, EMBO REP, V3, P767, DOI 10.1093/embo-reports/kvf157; Lowery DM, 2005, ONCOGENE, V24, P248, DOI 10.1038/sj.onc.1208280; MANSER E, 1994, NATURE, V367, P40, DOI 10.1038/367040a0; Mira JP, 2000, P NATL ACAD SCI USA, V97, P185, DOI 10.1073/pnas.97.1.185; Nheu T, 2004, CELL CYCLE, V3, P71; Nowak SJ, 2004, TRENDS GENET, V20, P214, DOI 10.1016/j.tig.2004.02.007; Seong YS, 2002, J BIOL CHEM, V277, P32282, DOI 10.1074/jbc.M202602200; Shalom-Barak T, 2002, J BIOL CHEM, V277, P40659, DOI 10.1074/jbc.M206650200; Sumara I, 2004, CURR BIOL, V14, P1712, DOI 10.1016/j.cub.2004.09.049; Thiel DA, 2002, CURR BIOL, V12, P1227, DOI 10.1016/S0960-9822(02)00931-4; Thullberg M, 2007, ONCOGENE, V26, P1820, DOI 10.1038/sj.onc.1209983; Vadlamudi RK, 2005, MOL CELL BIOL, V25, P3726, DOI 10.1128/MCB.25.9.3726-3736.2005; van de Weerdt BCM, 2006, CELL CYCLE, V5, P853, DOI 10.4161/cc.5.8.2692; van de Weerdt BCM, 2005, MOL CELL BIOL, V25, P2031, DOI 10.1128/MCB.25.5.2031-2044.2005; van Vugt MATM, 2005, ONCOGENE, V24, P2844, DOI 10.1038/sj.onc.1208617; van Vugt MATM, 2004, J BIOL CHEM, V279, P36841, DOI 10.1074/jbc.M313681200; Xie SQ, 2005, ONCOGENE, V24, P277, DOI 10.1038/sj.onc.1208218; Xu B, 2002, MOL CELL BIOL, V22, P1049, DOI 10.1128/MCB.22.4.1049-1059.2002; Zhao ZS, 2005, MOL CELL, V20, P237, DOI 10.1016/j.molcel.2005.08.035	36	76	76	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 21	2008	27	36					4900	4908		10.1038/onc.2008.131	http://dx.doi.org/10.1038/onc.2008.131			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	339SF	18427546				2022-12-28	WOS:000258596900004
J	Arora, P; Cuevas, BD; Russo, A; Johnson, GL; Trejo, J				Arora, P.; Cuevas, B. D.; Russo, A.; Johnson, G. L.; Trejo, J.			Persistent transactivation of EGFR and ErbB2/HER2 by protease-activated receptor-1 promotes breast carcinoma cell invasion	ONCOGENE			English	Article						thrombin; GPCR; metalloprotease; MDA-MB-231; g protein	THROMBIN RECEPTOR; MONOCLONAL-ANTIBODY; CANCER; DESENSITIZATION; PROLIFERATION; CHEMOTHERAPY; MIGRATION; CLEAVAGE; REVEALS; FAMILY	Hyperactivation of ErbB signaling is implicated in metastatic breast cancer. However, the mechanisms that cause dysregulated ErbB signaling and promote breast carcinoma cell invasion remain poorly understood. One pathway leading to ErbB activation that remains unexplored in breast carcinoma cell invasion involves transactivation by G-protein-coupled receptors (GPCRs). Protease-activated receptor-1 (PAR1), a GPCR activated by extracellular proteases, is overexpressed in invasive breast cancer. PAR1 is also proposed to function in breast cancer invasion and metastasis, but how PAR1 contributes to these processes is not known. In this study, we report that proteolytic activation of PAR1 by thrombin induces persistent transactivation of EGFR and ErbB2/HER2 in invasive breast carcinoma, but not in normal mammary epithelial cells. PAR1-stimulated EGFR and ErbB2 transactivation leads to prolonged extracellular signal-regulated kinase-1 and -2 signaling and promotes breast carcinoma cell invasion. We also show that PAR1 signaling through G alpha(i/o) and metalloprotease activity is critical for ErbB transactivation and cellular invasion. Finally, we demonstrate that PAR1 expression in invasive breast carcinoma is essential for tumor growth in vivo assessed by mammary fat pad xenografts. These studies reveal a critical role for PAR1, a receptor activated by tumor-generated proteases, in hyperactivation of ErbB signaling that promotes breast carcinoma cell invasion.	[Arora, P.; Cuevas, B. D.; Russo, A.; Johnson, G. L.; Trejo, J.] Univ N Carolina, Sch Med, Lineberger Canc Res Ctr, Dept Pharmacol, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine	Trejo, J (corresponding author), Univ Calif San Diego, Sch Med, Dept Pharmacol, BSB 3018,9500 Gilman Dr, La Jolla, CA 92093 USA.	joann_trejo@med.unc.edu	, Pathology Services Core/CEZ-2246-2022	TREJO, JOANN/0000-0003-4405-6228	NHLBI NIH HHS [R01 HL073328, HL073328, R01 HL073328-06] Funding Source: Medline; NIDDK NIH HHS [R01 DK037871, DK37871] Funding Source: Medline; NIGMS NIH HHS [R37 GM030324, GM30324, R01 GM030324] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL073328] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK037871] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM030324, R01GM030324] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Arora P, 2007, J CELL SCI, V120, P921, DOI 10.1242/jcs.03409; Asakura M, 2002, NAT MED, V8, P35, DOI 10.1038/nm0102-35; Bergmann S, 2006, ONCOL REP, V15, P889; Boire A, 2005, CELL, V120, P303, DOI 10.1016/j.cell.2004.12.018; Booden MA, 2004, MOL CELL BIOL, V24, P1990, DOI 10.1128/MCB.24.5.1990-1999.2004; Borrell-Pages M, 2003, EMBO J, V22, P1114, DOI 10.1093/emboj/cdg111; Burgess AW, 2003, MOL CELL, V12, P541, DOI 10.1016/S1097-2765(03)00350-2; Cobleigh MA, 1999, J CLIN ONCOL, V17, P2639, DOI 10.1200/JCO.1999.17.9.2639; Darmoul D, 2004, MOL CANCER RES, V2, P514; Daub H, 1996, NATURE, V379, P557, DOI 10.1038/379557a0; Even-Ram S, 1998, NAT MED, V4, P909, DOI 10.1038/nm0898-909; Garrett TPJ, 2003, MOL CELL, V11, P495, DOI 10.1016/S1097-2765(03)00048-0; Gschwind A, 2003, EMBO J, V22, P2411, DOI 10.1093/emboj/cdg231; Hart S, 2005, BIOL CHEM, V386, P845, DOI 10.1515/BC.2005.099; Kelly P, 2006, P NATL ACAD SCI USA, V103, P8173, DOI 10.1073/pnas.0510254103; Kuliopulos A, 1999, BIOCHEMISTRY-US, V38, P4572, DOI 10.1021/bi9824792; Lautrette A, 2005, NAT MED, V11, P867, DOI 10.1038/nm1275; Morris DR, 2006, CANCER RES, V66, P307, DOI 10.1158/0008-5472.CAN-05-1735; Nahta R, 2007, ONCOGENE, V26, P3637, DOI 10.1038/sj.onc.1210379; Nicholson RI, 2001, EUR J CANCER, V37, pS9, DOI 10.1016/s0959-8049(01)00231-3; Noma T, 2007, J CLIN INVEST, V117, P2445, DOI 10.1172/JCI31901; Ohtsu H, 2006, AM J PHYSIOL-CELL PH, V291, pC1, DOI 10.1152/ajpcell.00620.2005; Paing MM, 2006, MOL CELL BIOL, V26, P3231, DOI 10.1128/MCB.26.8.3231-3242.2006; Paing MM, 2002, J BIOL CHEM, V277, P1292, DOI 10.1074/jbc.M109160200; Prenzel N, 1999, NATURE, V402, P884, DOI 10.1038/47260; PRICE JE, 1990, CANCER RES, V50, P717; Salah Z, 2007, MOL CANCER RES, V5, P229, DOI 10.1158/1541-7786.MCR-06-0261; Slamon DJ, 2001, NEW ENGL J MED, V344, P783, DOI 10.1056/NEJM200103153441101; VU TKH, 1991, CELL, V64, P1057, DOI 10.1016/0092-8674(91)90261-V; Wetzker R, 2003, NAT REV MOL CELL BIO, V4, P651, DOI 10.1038/nrm1173; Witton CJ, 2003, J PATHOL, V200, P290, DOI 10.1002/path.1370; Yarden Y, 2001, ONCOLOGY-BASEL, V61, P1, DOI 10.1159/000055396	32	98	101	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 24	2008	27	32					4434	4445		10.1038/onc.2008.84	http://dx.doi.org/10.1038/onc.2008.84			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	329PU	18372913	Green Published, Green Accepted			2022-12-28	WOS:000257881700006
J	Bahassi, EM; Ovesen, JL; Riesenberg, AL; Bernstein, WZ; Hasty, PE; Stambrook, PJ				Bahassi, E. M.; Ovesen, J. L.; Riesenberg, A. L.; Bernstein, W. Z.; Hasty, P. E.; Stambrook, P. J.			The checkpoint kinases Chk1 and Chk2 regulate the functional associations between hBRCA2 and Rad51 in response to DNA damage	ONCOGENE			English	Article						Rad51; DNA damage; homologous recombination; phosphorylation	CANCER SUSCEPTIBILITY GENE; HOMOLOGOUS RECOMBINATION; HUMAN BRCA2; BREAST; PROTEIN; REPAIR; HYPERSENSITIVITY; INSTABILITY; EXCHANGE; REPEATS	The cellular response to the introduction of double strand DNA breaks involves complexes of protein interactions that govern cell cycle checkpoint arrest and repair of the DNA lesions. The checkpoint kinases Chk1 and Chk2 phosphorylate the carboxy-terminal domain of hBRCA2, a protein involved in recombination-mediated DNA repair (HRR) and replication fork maintenance. Cells deficient in hBRCA2 are hypersensitive to DNA damaging agents. Phosphorylation of the residue in hBRCA2 targeted by the Chk1 and Chk2 kinases regulates its interaction with Rad51. Furthermore, the cell line lex1/lex2, which lacks the carboxy-terminal domain containing the phosphorylated residue, does not support localization of Rad51 to nuclear foci after exposure to UV or treatment with ionizing radiation (IR). The data show that either phosphorylation of Rad51 by Chk1 or phosphorylation of the carboxy-terminal domain of hBRCA2 by Chk1 or Chk2 plays a critical role in the binding of Rad51 to hBRCA2 and the subsequent recruitment of Rad51 to sites of DNA damage. While depletion of Chk1 from cells leads to loss of Rad51 localization to nuclear foci in response to replication arrest, cells lacking Chk2 also show a defect in Rad51 localization, but only in presence of double strand DNA breaks, indicating that each of these kinases may contribute somewhat differently to the formation of Rad51 nucleoprotein. laments depending on the type of DNA damage incurred by the cells.	[Bahassi, E. M.; Ovesen, J. L.; Riesenberg, A. L.; Bernstein, W. Z.; Stambrook, P. J.] Univ Cincinnati, Coll Med, Dept Cell & Canc Biol, Cincinnati, OH 45267 USA; [Hasty, P. E.] Univ Texas Hlth Sci Ctr San Antonio, Inst Biotechnol, Dept Mol Med, San Antonio, TX 78229 USA	University System of Ohio; University of Cincinnati; University of Texas System; University of Texas Health San Antonio	Stambrook, PJ (corresponding author), Univ Cincinnati, Coll Med, Dept Cell & Canc Biol, 3125 Eden Ave, Cincinnati, OH 45267 USA.	peter.stambrook@uc.edu		Hasty, Paul/0000-0003-3046-0131	NCI NIH HHS [CA 90934] Funding Source: Medline; NIEHS NIH HHS [P39-ES06096, U02 ES011038, P30-ES06096] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA090934] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [U01ES011038, P30ES006096] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Bahassi EM, 2007, MUTAT RES-FUND MOL M, V616, P201, DOI 10.1016/j.mrfmmm.2006.11.025; Baumann P, 1996, CELL, V87, P757, DOI 10.1016/S0092-8674(00)81394-X; Bork P, 1996, NAT GENET, V13, P22, DOI 10.1038/ng0596-22; Davies AA, 2001, MOL CELL, V7, P273, DOI 10.1016/S1097-2765(01)00175-7; Donoho G, 2003, GENE CHROMOSOME CANC, V36, P317, DOI 10.1002/gcc.10148; Esashi F, 2005, NATURE, V434, P598, DOI 10.1038/nature03404; Mizuta R, 1997, P NATL ACAD SCI USA, V94, P6927, DOI 10.1073/pnas.94.13.6927; Moynahan ME, 2001, MOL CELL, V7, P263, DOI 10.1016/S1097-2765(01)00174-5; Pellegrini L, 2002, NATURE, V420, P287, DOI 10.1038/nature01230; Ponder BAJ, 2000, BRIT J CANCER, V83, P1301; Sharan SK, 1997, NATURE, V386, P804, DOI 10.1038/386804a0; Shivji MKK, 2006, NUCLEIC ACIDS RES, V34, P4000, DOI 10.1093/nar/gkl505; Sorensen CS, 2005, NAT CELL BIOL, V7, P195, DOI 10.1038/ncb1212; Venkitaraman AR, 2002, CELL, V108, P171, DOI 10.1016/S0092-8674(02)00615-3; Venkitaraman AR, 2000, PHILOS T R SOC B, V355, P191, DOI 10.1098/rstb.2000.0558; Welcsh PL, 2001, HUM MOL GENET, V10, P705, DOI 10.1093/hmg/10.7.705; Wong AKC, 1997, J BIOL CHEM, V272, P31941, DOI 10.1074/jbc.272.51.31941; Xia F, 2001, P NATL ACAD SCI USA, V98, P8644, DOI 10.1073/pnas.151253498; Yu VPCC, 2000, GENE DEV, V14, P1400	19	120	130	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN	2008	27	28					3977	3985		10.1038/onc.2008.17	http://dx.doi.org/10.1038/onc.2008.17			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	318JZ	18317453				2022-12-28	WOS:000257089000009
J	Bugni, JM; Meira, LB; Samson, LD				Bugni, J. M.; Meira, L. B.; Samson, L. D.			Alkylation-induced colon tumorigenesis in mice deficient in the Mgmt and Msh6 proteins	ONCOGENE			English	Article						colorectal cancer; Mgmt; Msh6; mismatch repair; azoxymethane	INVITRO DNA-REPLICATION; MISMATCH-REPAIR; O-6-ALKYLGUANINE-DNA ALKYLTRANSFERASE; INTESTINAL TUMORIGENESIS; METHYLTRANSFERASE GENE; MUTATION FREQUENCY; KNOCKOUT MICE; APOPTOSIS; CANCER; DAMAGE	O-6-methylguanine DNA methyltransferase (MGMT) suppresses mutations and cell death that result from alkylation damage. MGMT expression is lost by epigenetic silencing in a variety of human cancers including nearly half of sporadic colorectal cancers, suggesting that this loss maybe causal. Using mice with a targeted disruption of the Mgmt gene, we tested whether Mgmt protects against azoxymethane (AOM)-induced colonic aberrant crypt foci (ACF), against AOM and dextran sulfate sodium (DSS)-induced colorectal adenomas and against spontaneous intestinal adenomas in Apc(Min) mice. We also examined the genetic interaction of the Mgmt null gene with a DNA mismatch repair null gene, namely Msh6. Both Mgmt and Msh6 independently suppress AOM-induced ACF, and combination of the two mutant alleles had a multiplicative effect. This synergism can be explained entirely by the suppression of alkylationinduced apoptosis when Msh6 is absent. In addition, following AOM_DSS treatment Mgmt protected against adenoma formation to the same degree as it protected against AOM-induced ACF formation. Finally, Mgmt de. ciency did not affect spontaneous intestinal adenoma development in Apc(Min/+) mice, suggesting that Mgmt suppresses intestinal cancer associated with exogenous alkylating agents, and that endogenous alkylation does not contribute to the rapid tumor development seen in Apc(Min/+) mice.	MIT, Biol Engn Dept, Cambridge, MA 02139 USA; MIT, Ctr Environm Hlth Sci, Cambridge, MA 02139 USA	Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT)	Samson, LD (corresponding author), MIT, Dept Environm Hlth Sci, Bldg 56-235, Cambridge, MA 02139 USA.	lsamson@mit.edu	Meira, Lisiane/AAA-4326-2020	Meira, Lisiane/0000-0003-4289-2986	NIH [ES02109, CA75576]; NCI [CA14051]; NATIONAL CANCER INSTITUTE [R01CA075576, P30CA014051] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES002109] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))	This research was supported by NIH Grants ES02109 and CA75576. We acknowledge the MIT CCR Histology facility (NCI Grant: CA14051), especially Alicia Caron. LDS is an American Cancer Society Research Professor.	Acharya S, 1996, P NATL ACAD SCI USA, V93, P13629, DOI 10.1073/pnas.93.24.13629; AQUILINA G, 1992, CANCER RES, V52, P6471; Baker SM, 1998, CANCER RES, V58, P1087; Edelmann W, 1999, CANCER RES, V59, P1301; Edelmann W, 1997, CELL, V91, P467, DOI 10.1016/S0092-8674(00)80433-X; Esteller M, 2001, CANCER RES, V61, P3225; Fang QM, 2005, BIOCHEMISTRY-US, V44, P15396, DOI 10.1021/bi051460d; Fox EJ, 2006, J MOL DIAGN, V8, P68, DOI 10.2353/jmoldx.2006.050084; Glassner BJ, 1999, MUTAGENESIS, V14, P339, DOI 10.1093/mutage/14.3.339; Haigis KM, 2002, P NATL ACAD SCI USA, V99, P8927, DOI 10.1073/pnas.132275099; HARRIS LC, 1991, NUCLEIC ACIDS RES, V19, P6163, DOI 10.1093/nar/19.22.6163; Hecht SS, 1999, MUTAT RES-FUND MOL M, V424, P127, DOI 10.1016/S0027-5107(99)00014-7; Hickman MJ, 1999, P NATL ACAD SCI USA, V96, P10764, DOI 10.1073/pnas.96.19.10764; Jiricny J, 2006, NAT REV MOL CELL BIO, V7, P335, DOI 10.1038/nrm1907; Kaina B, 2003, BIOCHEM PHARMACOL, V66, P1547, DOI 10.1016/S0006-2952(03)00510-0; Kaina B, 1997, MUTAT RES-FUND MOL M, V381, P227, DOI 10.1016/S0027-5107(97)00187-5; KARRAN P, 1992, NUCLEIC ACIDS RES, V20, P2933, DOI 10.1093/nar/20.12.2933; KAT A, 1993, P NATL ACAD SCI USA, V90, P6424, DOI 10.1073/pnas.90.14.6424; Kawate H, 1998, P NATL ACAD SCI USA, V95, P5116, DOI 10.1073/pnas.95.9.5116; Kellett M, 1992, Epithelial Cell Biol, V1, P147; Kohonen-Corish MRJ, 2002, CANCER RES, V62, P2092; Kuraguchi M, 2001, CANCER RES, V61, P7934; LARSON K, 1985, MUTAT RES, V150, P77, DOI 10.1016/0027-5107(85)90103-4; Lind GE, 2004, MOL CANCER, V3, DOI 10.1186/1476-4598-3-28; Millar CB, 2002, SCIENCE, V297, P403, DOI 10.1126/science.1073354; MYRNES B, 1984, CARCINOGENESIS, V5, P1061, DOI 10.1093/carcin/5.8.1061; Nagasaka T, 2008, INT J CANCER, V122, P2429, DOI 10.1002/ijc.23398; Reitmair AH, 1996, CANCER RES, V56, P2922; Sakumi K, 1997, CANCER RES, V57, P2415; Sandercock LE, 2004, ONCOGENE, V23, P5931, DOI 10.1038/sj.onc.1207791; Sedgwick B, 1997, CARCINOGENESIS, V18, P1561, DOI 10.1093/carcin/18.8.1561; Sieber OM, 2004, CANCER RES, V64, P8876, DOI 10.1158/0008-5472.CAN-04-2958; SNOW ET, 1984, J BIOL CHEM, V259, P8095; Sohn OS, 2001, CANCER RES, V61, P8435; Stojic L, 2004, DNA REPAIR, V3, P1091, DOI 10.1016/j.dnarep.2004.06.006; Taniguchi K, 2006, ONCOLOGY-BASEL, V71, P124, DOI 10.1159/000100522; Toft NJ, 2000, CARCINOGENESIS, V21, P593, DOI 10.1093/carcin/21.4.593; Toft NJ, 1999, P NATL ACAD SCI USA, V96, P3911, DOI 10.1073/pnas.96.7.3911; VOGELSTEIN B, 1993, TRENDS GENET, V9, P138, DOI 10.1016/0168-9525(93)90209-Z; Wali RK, 1999, CARCINOGENESIS, V20, P2355, DOI 10.1093/carcin/20.12.2355; WEI X, 1993, P NATL ACAD SCI USA, V90, P2117, DOI 10.1073/pnas.90.6.2117; Xu-Welliver M, 2002, CARCINOGENESIS, V23, P823, DOI 10.1093/carcin/23.5.823; ZAIDI NH, 1995, CARCINOGENESIS, V16, P451, DOI 10.1093/carcin/16.3.451	43	39	40	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 5	2009	28	5					734	741		10.1038/onc.2008.426	http://dx.doi.org/10.1038/onc.2008.426			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	403IN	19029948	Green Submitted, Green Accepted			2022-12-28	WOS:000263076400010
J	Wu, Y; Siadaty, MS; Berens, ME; Hampton, GM; Theodorescu, D				Wu, Y.; Siadaty, M. S.; Berens, M. E.; Hampton, G. M.; Theodorescu, D.			Overlapping gene expression profiles of cell migration and tumor invasion in human bladder cancer identify metallothionein 1E and nicotinamide N-methyltransferase as novel regulators of cell migration	ONCOGENE			English	Article						mechanism of cell movement; metastasis; gene expression; transcriptional profiling	STROMAL VERSICAN EXPRESSION; METASTASIS SUPPRESSOR GENE; BREAST-CANCER; CARCINOMA; IDENTIFICATION; MICROARRAYS; DISCOVERY; RHOGD12; PATHWAY; CD24	Cell migration is essential to cancer invasion and metastasis and is spatially and temporally integrated through transcriptionally dependent and independent mechanisms. As cell migration is studied in vitro, it is important to identify genes that both drive cell migration and are biologically relevant in promoting invasion and metastasis in patients with cancer. Here, gene expression profiling and a high-throughput cell migration system answers this question in human bladder cancer. In vitro migration rates of 40 microarray-profiled human bladder cancer cell lines were measured by radial migration assay. Genes whose expression was either directly or inversely associated with cell migration rate were identified and subsequently evaluated for their association with cancer stage in 61 patients. This analysis identified genes known to be associated with cell invasion such as versican, and novel ones, including metallothionein 1E (MT1E) and nicotinamide N-methyltransferase (NNMT), whose expression correlated positively with cancer cell migration and tumor stage. Using loss of function analysis, we show that MT1E and NNMT are necessary for cancer cell migration. These studies provide a general approach to identify the clinically relevant genes in cancer cell migration and mechanistically implicate two novel genes in this process in human bladder cancer.	[Wu, Y.; Theodorescu, D.] Univ Virginia, Hlth Sci Ctr, Dept Mol Physiol & Biol Phys, Charlottesville, VA 22908 USA; [Siadaty, M. S.] Univ Virginia, Hlth Sci Ctr, Dept Publ Hlth Sci, Charlottesville, VA 22908 USA; [Berens, M. E.] Translat Genom Res Inst, Canc & Cell Biol Div, Phoenix, AZ USA; [Hampton, G. M.] Novartis Res Fdn, Genom Inst, San Diego, CA USA	University of Virginia; University of Virginia; Translational Genomics Research Institute; Novartis	Theodorescu, D (corresponding author), Univ Virginia, Hlth Sci Ctr, Dept Mol Physiol & Biol Phys, Box 422, Charlottesville, VA 22908 USA.	dt9d@virginia.edu			NIH [CA075115]; NATIONAL CANCER INSTITUTE [R29CA075115, R01CA075115] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Dr Jay Fox and Dr Yongde Bao of the University of Virginia Array Core facility for their assistance with chip hybridization. We also thank Dr Martin A Schwartz and Dr Konstadinos Moissoglu of the Cardiovascular Research Center, University of Virginia for their assistance with time-lapse microscopy. Mr Christian Beaudry at TGen performed the high-throughput cell migration experiments. This work was supported by NIH grant CA075115 to DT.	Aigner S, 1997, BLOOD, V89, P3385, DOI 10.1182/blood.V89.9.3385; AKSOY S, 1994, J BIOL CHEM, V269, P14835; AKSOY S, 1995, GENOMICS, V29, P555, DOI 10.1006/geno.1995.9966; Altevogt P, 1988, Adv Exp Med Biol, V233, P253; Berens ME, 2004, METH MOLEC MED, V88, P219; Blaveri E, 2005, CLIN CANCER RES, V11, P4044, DOI 10.1158/1078-0432.CCR-04-2409; Calvano SE, 2005, NATURE, V437, P1032, DOI 10.1038/nature03985; Chung MJ, 2006, J AGR FOOD CHEM, V54, P3819, DOI 10.1021/jf060510y; Clark EA, 2000, NATURE, V406, P532, DOI 10.1038/35020106; de Rooij J, 2005, J CELL BIOL, V171, P153, DOI 10.1083/jcb.200506152; Dyrskjot L, 2003, NAT GENET, V33, P90, DOI 10.1038/ng1061; Faried A, 2006, EUR J CANCER, V42, P1455, DOI 10.1016/j.ejca.2006.02.012; Friederichs J, 2000, CANCER RES, V60, P6714; Friedline JA, 1998, AM J PATHOL, V152, P23; Gildea JJ, 2002, CANCER RES, V62, P6418; GORDON JN, 1993, CANCER RES, V53, P4971; Grate LR, 2005, BMC BIOINFORMATICS, V6, DOI 10.1186/1471-2105-6-97; Havaleshko DM, 2007, MOL CANCER THER, V6, P578, DOI 10.1158/1535-7163.MCT-06-0497; Jemal A, 2005, CA-CANCER J CLIN, V55, P10, DOI 10.3322/canjclin.55.1.10; Jin R, 2000, BRIT J CANCER, V83, P319, DOI 10.1054/bjoc.2000.1276; JONES RF, 1992, J CANCER RES CLIN, V118, P411, DOI 10.1007/BF01629423; Kodama J, 2007, ANN ONCOL, V18, P269, DOI 10.1093/annonc/mdl370; Kristiansen G, 2004, J MOL HISTOL, V35, P255; Lee JK, 2007, P NATL ACAD SCI USA, V104, P13086, DOI 10.1073/pnas.0610292104; Li CJ, 2007, FUNCT INTEGR GENOMIC, V7, P193, DOI 10.1007/s10142-006-0043-2; Lim BH, 2006, EXP MOL MED, V38, P455, DOI 10.1038/emm.2006.54; Liotta L, 2000, NAT REV GENET, V1, P48, DOI 10.1038/35049567; Margolis EJ, 1996, CANCER LETT, V100, P163, DOI 10.1016/0304-3835(95)04096-X; Mayburd AL, 2006, CLIN CANCER RES, V12, P1820, DOI 10.1158/1078-0432.CCR-05-2149; Modlich O, 2004, CLIN CANCER RES, V10, P3410, DOI 10.1158/1078-0432.CCR-03-0134; Mukai M, 2006, BIOCHEM BIOPH RES CO, V346, P74, DOI 10.1016/j.bbrc.2006.05.068; Nicholson BE, 2004, CANCER RES, V64, P7813, DOI 10.1158/0008-5472.CAN-04-0826; Oxford G, 2005, CANCER RES, V65, P7111, DOI 10.1158/0008-5472.CAN-04-1957; Pukkila M, 2007, J CLIN PATHOL, V60, P267, DOI 10.1136/jcp.2005.034181; Ramaswamy S, 2003, NAT GENET, V33, P49, DOI 10.1038/ng1060; Ricciardelli C, 1999, CANCER RES, V59, P2324; Roessler M, 2005, CLIN CANCER RES, V11, P6550, DOI 10.1158/1078-0432.CCR-05-0983; Sanchez-Carbayo M, 2006, J CLIN ONCOL, V24, P778, DOI 10.1200/JCO.2005.03.2375; Sanchez-Carbayo M, 2003, AM J PATHOL, V163, P505, DOI 10.1016/S0002-9440(10)63679-6; Smith SC, 2006, CANCER RES, V66, P1917, DOI 10.1158/0008-5472.CAN-05-3855; Smith SC, 2007, CLIN CANCER RES, V13, P3803, DOI 10.1158/1078-0432.CCR-06-2419; Stein JP, 2001, J CLIN ONCOL, V19, P666, DOI 10.1200/JCO.2001.19.3.666; Su AI, 2001, CANCER RES, V61, P7388; *TEAM RDC, 2003, R REF MAN; Theodorescu D, 2004, CLIN CANCER RES, V10, P3800, DOI 10.1158/1078-0432.CCR-03-0653; Thykjaer T, 2001, CANCER RES, V61, P2492; Titus B, 2005, CANCER RES, V65, P7320, DOI 10.1158/0008-5472.CAN-05-1403; van Delft JHM, 2005, MUTAT RES-FUND MOL M, V575, P17, DOI 10.1016/j.mrfmmm.2005.02.006; Witjes JA, 2006, EUR UROL, V49, P790, DOI 10.1016/j.eururo.2006.01.017; Xu JM, 2003, J CLIN ENDOCR METAB, V88, P4990, DOI 10.1210/jc.2002-021843; Yao M, 2005, J PATHOL, V205, P377, DOI 10.1002/path.1693; Zheng PS, 2004, FASEB J, V18, P754, DOI 10.1096/fj.03-0545fje	52	120	127	1	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV	2008	27	52					6679	6689		10.1038/onc.2008.264	http://dx.doi.org/10.1038/onc.2008.264			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	368QY	18724390	Green Accepted			2022-12-28	WOS:000260638800006
J	Upadhyay, G; Goessling, W; North, TE; Xavier, R; Zon, LI; Yajnik, V				Upadhyay, G.; Goessling, W.; North, T. E.; Xavier, R.; Zon, L. I.; Yajnik, V.			Molecular association between beta-catenin degradation complex and Rac guanine exchange factor DOCK4 is essential for Wnt/beta-catenin signaling	ONCOGENE			English	Article						Wnt/beta-catenin; Rac; GSK3 beta; Axin; APC; DOCK4	NUCLEOTIDE EXCHANGE; PHOSPHORYLATION; GTPASE; MECHANISM; PATHWAY; EMBRYOS; MODEL; GEF; APC; RHO	The canonical Wnt/beta-catenin pathway is a highly conserved signaling cascade that is involved in development and stem cell renewal. The deregulation of this pathway is often associated with increased cell growth and neoplasia. The small GTPase Rac has been shown to influence canonical Wnt signaling by regulating beta-catenin stability through an unknown mechanism. We report that DOCK4, a guanine nucleotide exchange factor (GEF) for Rac and a member of the CDM family of unconventional GEFs, mediates Wnt-induced Rac activation in the canonical Wnt/beta-catenin pathway. DOCK4 expression regulates cellular beta-catenin levels in response to the Wnt signal, in vitro. Biochemical studies demonstrate that DOCK4 interacts with the beta-catenin degradation complex, consisting of the proteins adenomatosis polyposis coli, Axin and glycogen synthase kinase 3 beta (GSK3 beta). This molecular interaction enhances beta-catenin stability and Axin degradation. Furthermore, we observe that DOCK4 is phosphorylated by GSK3 beta, which enhances Wnt-induced Rac activation. Using a T-cell factor reporter zebrafish we confirm that DOCK4 is required for Wnt/beta-catenin activity, in vivo. These results elucidate a novel intracellular signaling mechanism in which a Rac GEF, DOCK4 acts as a scaffold protein in the Wnt/beta-catenin pathway.	[Upadhyay, G.; Goessling, W.; Xavier, R.; Yajnik, V.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Med,Gastrointestinal Unit, Boston, MA 02114 USA; [Goessling, W.; North, T. E.; Zon, L. I.] Harvard Univ, Sch Med, Harvard Stem Cell Inst, Boston, MA 02114 USA	Harvard University; Harvard Medical School; Massachusetts General Hospital; Harvard University; Harvard Medical School	Yajnik, V (corresponding author), Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Med,Gastrointestinal Unit, 55 Fruit St,GRJ-825, Boston, MA 02114 USA.	gu6@georgetown.edu; vyajnik@partners.org	North, Trista/ABG-4789-2020; Upadhyay, Geeta/AEB-0203-2022	North, Trista/0000-0003-1249-563X; Goessling, Wolfram/0000-0001-9972-1569	NIH [DK 63933]; MGH GI unit; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K08DK063933, P30DK040561] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); MGH GI unit; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	We thank Lars von Buchholtz (NIH, MD, USA), Parool Meelu (MGH, MA, USA), Tiffany M Blake (Georgetown University, DC, USA) and Denver Matthew Lough (Georgetown University, DC, USA) for the help in the preparation of the paper. This study was supported by grant NIH DK 63933 (VY) and MGH GI unit startup funds (VY).	Aberle H, 1997, EMBO J, V16, P3797, DOI 10.1093/emboj/16.13.3797; Amit S, 2002, GENE DEV, V16, P1066, DOI 10.1101/gad.230302; Bhattacharyya R, 2007, ONCOGENE, V26, P7628, DOI 10.1038/sj.onc.1210576; Braga VMM, 2002, NAT CELL BIOL, V4, pE188, DOI 10.1038/ncb0802-e188; Brugnera E, 2002, NAT CELL BIOL, V4, P574, DOI 10.1038/ncb824; Burridge K, 2004, CELL, V116, P167, DOI 10.1016/S0092-8674(04)00003-0; Cadigan KM, 2006, J CELL SCI, V119, P395, DOI 10.1242/jcs.02826; Clevers H, 2006, CELL, V127, P469, DOI 10.1016/j.cell.2006.10.018; Cote JF, 2005, NAT CELL BIOL, V7, P797, DOI 10.1038/ncb1280; Cote JF, 2002, J CELL SCI, V115, P4901, DOI 10.1242/jcs.00219; Dorsky RI, 2002, DEV BIOL, V241, P229, DOI 10.1006/dbio.2001.0515; Esufali S, 2004, ONCOGENE, V23, P8260, DOI 10.1038/sj.onc.1208007; Gingerich JL, 2005, DEV BIOL, V286, P427, DOI 10.1016/j.ydbio.2005.07.031; Grimsley CM, 2004, J BIOL CHEM, V279, P6087, DOI 10.1074/jbc.M307087200; Ha NC, 2004, MOL CELL, V15, P511, DOI 10.1016/j.molcel.2004.08.010; Habas R, 2003, GENE DEV, V17, P295, DOI 10.1101/gad.1022203; Hagen T, 2004, BIOCHEM J, V379, P471, DOI 10.1042/BJ20031749; Harte D, 1998, J NONLINEAR SCI, V8, P581, DOI 10.1007/s003329900060; Hocevar BA, 2003, EMBO J, V22, P3084, DOI 10.1093/emboj/cdg286; Ilyas M, 1997, P NATL ACAD SCI USA, V94, P10330, DOI 10.1073/pnas.94.19.10330; Jope RS, 2004, TRENDS BIOCHEM SCI, V29, P95, DOI 10.1016/j.tibs.2003.12.004; Kang YB, 2004, CELL, V118, P277, DOI 10.1016/j.cell.2004.07.011; Katoh H, 2003, NATURE, V424, P461, DOI 10.1038/nature01817; Kimelman D, 2006, ONCOGENE, V25, P7482, DOI 10.1038/sj.onc.1210055; Link V, 2006, BMC DEV BIOL, V6, DOI 10.1186/1471-213X-6-1; Liu HJ, 2007, SCIENCE, V317, P803, DOI 10.1126/science.1143578; Liu XX, 2005, CURR BIOL, V15, P1989, DOI 10.1016/j.cub.2005.10.050; Lu MJ, 2005, CURR BIOL, V15, P371, DOI 10.1016/j.cub.2005.01.050; Luo W, 2007, EMBO J, V26, P1511, DOI 10.1038/sj.emboj.7601607; MacDonald BT, 2007, CELL, V131, DOI 10.1016/j.cell.2007.11.036; Mikels AJ, 2006, PLOS BIOL, V4, P570, DOI 10.1371/journal.pbio.0040115; Moon RT, 2002, SCIENCE, V296, P1644, DOI 10.1126/science.1071549; Schier AF, 2005, ANNU REV GENET, V39, P561, DOI 10.1146/annurev.genet.37.110801.143752; Thorpe CJ, 2005, DEVELOPMENT, V132, P1763, DOI 10.1242/dev.01733; Veeman MT, 2003, DEV CELL, V5, P367, DOI 10.1016/S1534-5807(03)00266-1; Willert K, 1999, GENE DEV, V13, P1768, DOI 10.1101/gad.13.14.1768; Wu BB, 2007, IMMUNITY, V26, P227, DOI 10.1016/j.immuni.2006.12.007; Wu XM, 2008, CELL, V133, P340, DOI 10.1016/j.cell.2008.01.052; Xing Y, 2003, GENE DEV, V17, P2753, DOI 10.1101/gad.1142603; Yajnik V, 2003, CELL, V112, P673, DOI 10.1016/S0092-8674(03)00155-7; Yan D, 2006, J MOL BIOL, V357, P755, DOI 10.1016/j.jmb.2006.01.017; Yang J, 2006, J BIOL CHEM, V281, P17751, DOI 10.1074/jbc.M600831200; Yost C, 1996, GENE DEV, V10, P1443, DOI 10.1101/gad.10.12.1443; Zeng X, 2005, NATURE, V438, P873, DOI 10.1038/nature04185	44	44	45	1	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 2	2008	27	44					5845	5855		10.1038/onc.2008.202	http://dx.doi.org/10.1038/onc.2008.202			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	355QC	18641688	Green Accepted			2022-12-28	WOS:000259722400008
J	Takagi, Y; Kobayashi, T; Shiono, M; Wang, L; Piao, X; Sun, G; Zhang, D; Abe, M; Hagiwara, Y; Takahashi, K; Hino, O				Takagi, Y.; Kobayashi, T.; Shiono, M.; Wang, L.; Piao, X.; Sun, G.; Zhang, D.; Abe, M.; Hagiwara, Y.; Takahashi, K.; Hino, O.			Interaction of folliculin (Birt-Hogg-Dube gene product) with a novel Fnip1-like (FnipL/Fnip2) protein	ONCOGENE			English	Article						BHD; S6K1; AMPK; FnipL/Fnip2; Fnip1	NIHON RAT MODEL; UNIDENTIFIED HUMAN GENES; BHD GENE; RENAL CARCINOGENESIS; COMPLETE SEQUENCES; CODING SEQUENCES; NATURAL-HISTORY; CDNA-CLONES; CANCER; MTOR	Birt-Hogg-Dube (BHD) syndrome is characterized by the development of pneumothorax, hair folliculomas and renal tumors and the responsible BHD gene is thought to be a tumor suppressor. The function of folliculin (Flcn), encoded by BHD, is totally unknown, although its interaction with Fnip1 has been reported. In this study, we identified a novel protein binding to Flcn, which is highly homologous to Fnip1, and which we named FnipL (recently reported in an independent study as Fnip2). The interaction between FnipL/Fnip2 and Flcn may be mediated mainly by the C-terminal domains of each protein as is the case for the Flcn-Fnip1 interaction. FnipL/Fnip2 and Flcn were located together in the cytoplasm in a reticular pattern, although solely expressed Flcn was found mainly in the nucleus. Cytoplasmic retention of Flcn was canceled with C-terminal truncation of FnipL/Fnip2, suggesting that FnipL/Fnip2 regulates Flcn distribution through their complex formation. By the employment of siRNA, we observed a decrease in S6K1 phosphorylation in the BHD-suppressed cell. We also observed a decrease in S6K1 phosphorylation in FNIP1- and, to a lesser extent, in FNIPL/FNIP2-suppressed cells. These results suggest that Flcn-FnipL/Fnip2 and Flcn-Fnip1 complexes positively regulate S6K1 phosphorylation and that FnipL/Fnip2 provides an important clue to elucidating the function of Flcn and the pathogenesis of BHD.	[Takagi, Y.; Kobayashi, T.; Shiono, M.; Wang, L.; Piao, X.; Sun, G.; Zhang, D.; Abe, M.; Hagiwara, Y.; Hino, O.] Juntendo Univ, Sch Med, Dept Pathol & Oncol, Bunkyo Ku, Tokyo 1138421, Japan; [Hagiwara, Y.] Immunobiol Labs Co Ltd, Div Mfg Res & Dev, Fujioka, Gunma, Japan	Juntendo University; Immuno-Biological Laboratories Co. Ltd.	Hino, O (corresponding author), Juntendo Univ, Sch Med, Dept Pathol & Oncol, Bunkyo Ku, 2-1-1 Hongo, Tokyo 1138421, Japan.	ohino@juntendo.ac.jp			Japan Society for the Promotion of Science (JSPS); Ministry of Education, Culture, Sports and Technology of Japan; Ministry of Health, Labour and Welfare of Japan	Japan Society for the Promotion of Science (JSPS)(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science); Ministry of Education, Culture, Sports and Technology of Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Ministry of Health, Labour and Welfare of Japan(Ministry of Health, Labour and Welfare, Japan)	We thank Drs Fujii H, Tsurui H, Matsuoka S, Wakiya M, Kajino K, Mr Sasahara K and Mr Takagaki T in the Department of Pathology and Oncology for helpful discussions and technical supports. We also thank Ms Ochiai K and Mr Matsunami K in the Division of Radioisotope Research for expert support. We appreciate Dr Maeda M (IBL) for production of antibodies, and Drs Okimoto K, Matsumoto I and Kouchi M (Dainippon-Sumitomo Pharma) and Dr Maeda T (Tokyo University) for helpful discussions. We also thank Kazusa DNA Research Institute for cDNA clones. This study was supported by the grants from the Japan Society for the Promotion of Science (JSPS), from the Ministry of Education, Culture, Sports and Technology of Japan, and from the Ministry of Health, Labour and Welfare of Japan.	Baba M, 2008, JNCI-J NATL CANCER I, V100, P140, DOI 10.1093/jnci/djm288; Baba M, 2006, P NATL ACAD SCI USA, V103, P15552, DOI 10.1073/pnas.0603781103; BIRT AR, 1977, ARCH DERMATOL, V113, P1674, DOI 10.1001/archderm.113.12.1674; Fukuda T, 2000, ANAL BIOCHEM, V285, P274, DOI 10.1006/abio.2000.4787; Guertin DA, 2007, CANCER CELL, V12, P9, DOI 10.1016/j.ccr.2007.05.008; Hasumi H, 2008, GENE, V415, P60, DOI 10.1016/j.gene.2008.02.022; Hino O, 2003, CANCER SCI, V94, P142, DOI 10.1111/j.1349-7006.2003.tb01410.x; KOBAYASHI T, 1995, NAT GENET, V9, P70, DOI 10.1038/ng0195-70; Kouchi M, 2006, VIRCHOWS ARCH, V448, P463, DOI 10.1007/s00428-005-0142-9; Lingaas F, 2003, HUM MOL GENET, V12, P3043, DOI 10.1093/hmg/ddg336; Nagase T, 2000, DNA RES, V7, P143, DOI 10.1093/dnares/7.2.143; Nagase T, 2001, DNA RES, V8, P319, DOI 10.1093/dnares/8.6.319; Nickerson ML, 2002, CANCER CELL, V2, P157, DOI 10.1016/S1535-6108(02)00104-6; NIWA H, 1991, GENE, V108, P193, DOI 10.1016/0378-1119(91)90434-D; Okimoto K, 2004, CURR MOL MED, V4, P887, DOI 10.2174/1566524043359737; Okimoto K, 2004, P NATL ACAD SCI USA, V101, P2023, DOI 10.1073/pnas.0308071100; Okimoto K, 2000, JPN J CANCER RES, V91, P1096, DOI 10.1111/j.1349-7006.2000.tb00890.x; Roberg KJ, 1997, GENETICS, V147, P1569; Schmidt LS, 2001, AM J HUM GENET, V69, P876, DOI 10.1086/323744; Singh SR, 2006, ONCOGENE, V25, P5933, DOI 10.1038/sj.onc.1209593; Togashi Y, 2006, ONCOGENE, V25, P2885, DOI 10.1038/sj.onc.1209317; van Slegtenhorst M, 2007, J BIOL CHEM, V282, P24583, DOI 10.1074/jbc.M700857200; Vocke CD, 2005, J NATL CANCER I, V97, P931, DOI 10.1093/jnci/dji154	23	95	99	1	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 11	2008	27	40					5339	5347		10.1038/onc.2008.261	http://dx.doi.org/10.1038/onc.2008.261			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	346UW	18663353				2022-12-28	WOS:000259096100006
J	Meador, JA; Zhao, M; Su, Y; Narayan, G; Geard, CR; Balajee, AS				Meador, J. A.; Zhao, M.; Su, Y.; Narayan, G.; Geard, C. R.; Balajee, A. S.			Histone H2AX is a critical factor for cellular protection against DNA alkylating agents	ONCOGENE			English	Article						histone H2AX; poly(ADP) ribose polymerase 1; base excision repair; alkylation DNA damage; chromosomal instability; mitogen-activated protein kinase	DOUBLE-STRAND BREAKS; IONIZING-RADIATION; CYCLE ARREST; HUMAN-CELLS; POLY(ADP-RIBOSE) POLYMERASE-1; GENOMIC INSTABILITY; COMPLEX-FORMATION; DEPENDENT MANNER; GAMMA-H2AX FOCI; MISMATCH REPAIR	Histone H2A variant H2AX is a dose-dependent suppressor of oncogenic chromosome translocations. H2AX participates in DNA double-strand break repair, but its role in other DNA repair pathways is not known. In this study, role of H2AX in cellular response to alkylation DNA damage was investigated. Cellular sensitivity to two monofunctional alkylating agents (methyl methane sulfonate and N-methyl-N'-nitro-N-nitrosoguanidine (MNNG)) was dependent on H2AX dosage, and H2AX null cells were more sensitive than heterozygous cells. In contrast to wild-type cells, H2AX-deficient cells displayed extensive apoptotic death due to a lack of cell-cycle arrest at G(2)/M phase. Lack of G(2)/M checkpoint in H2AX null cells correlated well with increased mitotic irregularities involving anaphase bridges and gross chromosomal instability. Observation of elevated poly(ADP) ribose polymerase 1 (PARP-1) cleavage suggests that MNNG-induced apoptosis occurs by PARP-1-dependent manner in H2AX-deficient cells. Consistent with this, increased activities of PARP and poly(ADP) ribose (PAR) polymer synthesis were detected in both H2AX heterozygous and null cells. Further, we demonstrate that the increased PAR synthesis and apoptotic death induced by MNNG in H2AX-deficient cells are due to impaired activation of mitogen-activated protein kinase pathway. Collectively, our novel study demonstrates that H2AX, similar to PARP-1, confers cellular protection against alkylation-induced DNA damage. Therefore, targeting either PARP-1 or histone H2AX may provide an effective way of maximizing the chemotherapeutic value of alkylating agents for cancer treatment.	[Meador, J. A.; Zhao, M.; Su, Y.; Narayan, G.; Geard, C. R.; Balajee, A. S.] Columbia Univ, Med Ctr, Dept Radiat Oncol, Coll Phys & Surg,Ctr Radiol Res, New York, NY 10032 USA	Columbia University	Balajee, AS (corresponding author), Columbia Univ, Med Ctr, Dept Radiat Oncol, Coll Phys & Surg,Ctr Radiol Res, VC 11,Room 239,168th St,630 West, New York, NY 10032 USA.	ab836@columbia.edu			US Department of Energy; Office of Sciences (BER) [DE-FG02-05ER64055]; CRG [DE-FG 02-05ER 64054]; NIH/NCI [5P01CA49062-16]; NATIONAL CANCER INSTITUTE [P01CA049062] Funding Source: NIH RePORTER	US Department of Energy(United States Department of Energy (DOE)); Office of Sciences (BER)(United States Department of Energy (DOE)); CRG; NIH/NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We acknowledge the generous gift of mouse ES cells proficient and deficient in H2AX from Dr CH Bassing and Dr FW Alt at the Department of Genetics, The CBR Institute for Biomedical Research, The Children's Hospital, Harvard Medical School, Boston, MA, USA. This study was partially supported by a research grant from US Department of Energy, Office of Sciences (BER) awarded to ASB (DE-FG02-05ER64055) and CRG (DE-FG 02-05ER 64054). ASB and CRG acknowledge the financial support received from NIH/NCI (5P01CA49062-16).	Aebi S, 1997, CLIN CANCER RES, V3, P1763; Balajee AS, 2004, EXP CELL RES, V300, P320, DOI 10.1016/j.yexcr.2004.07.022; Balajee AS, 2001, NUCLEIC ACIDS RES, V29, P1341, DOI 10.1093/nar/29.6.1341; Bassing CH, 2003, CELL, V114, P359, DOI 10.1016/S0092-8674(03)00566-X; Bassing CH, 2002, P NATL ACAD SCI USA, V99, P8173, DOI 10.1073/pnas.122228699; Beardsley DI, 2005, MOL PHARMACOL, V68, P1049, DOI 10.1124/mol.105.013888; BERANEK DT, 1990, MUTAT RES, V231, P11, DOI 10.1016/0027-5107(90)90173-2; Bouchard WJ, 2003, EXP HEMATOL, V31, P446, DOI 10.1016/S0301-472X(03)00083-3; Celeste A, 2003, NAT CELL BIOL, V5, P675, DOI 10.1038/ncb1004; Celeste A, 2002, SCIENCE, V296, P922, DOI 10.1126/science.1069398; Celeste A, 2003, CELL, V114, P371, DOI 10.1016/S0092-8674(03)00567-1; Chou YH, 2007, FOOD CHEM TOXICOL, V45, P1356, DOI 10.1016/j.fct.2007.01.012; Cohen-Armon M, 2007, MOL CELL, V25, P297, DOI 10.1016/j.molcel.2006.12.012; DADDA DF, 2003, NATURE, V426, P194, DOI DOI 10.1038/NATURE02118; Downs JA, 2000, NATURE, V408, P1001, DOI 10.1038/35050000; Ethier C, 2007, APOPTOSIS, V12, P2037, DOI 10.1007/s10495-007-0127-z; Fernandez-Capetillo O, 2004, DNA REPAIR, V3, P959, DOI 10.1016/j.dnarep.2004.03.024; Fernandez-Capetillo O, 2002, NAT CELL BIOL, V4, P993, DOI 10.1038/ncb884; Furuta T, 2003, J BIOL CHEM, V278, P20303, DOI 10.1074/jbc.M300198200; Hoeijmakers JHJ, 2001, NATURE, V411, P366, DOI 10.1038/35077232; Horton JK, 2005, J BIOL CHEM, V280, P15773, DOI 10.1074/jbc.M413841200; Hurley LH, 2002, NAT REV CANCER, V2, P188, DOI 10.1038/nrc749; Ichijima Y, 2005, BIOCHEM BIOPH RES CO, V336, P807, DOI 10.1016/j.bbrc.2005.08.164; Karran P, 2003, BIOCHIMIE, V85, P1149, DOI 10.1016/j.biochi.2003.10.007; Kauppinen TM, 2006, P NATL ACAD SCI USA, V103, P7136, DOI 10.1073/pnas.0508606103; Lomax ME, 2004, BIOCHEMISTRY-US, V43, P11017, DOI 10.1021/bi049560r; McManus KJ, 2005, MOL BIOL CELL, V16, P5013, DOI 10.1091/mbc.E05-01-0065; Mischo HE, 2005, J BIOL CHEM, V280, P9586, DOI 10.1074/jbc.M411444200; MITRA S, 1993, PROG NUCLEIC ACID RE, V44, P109, DOI 10.1016/S0079-6603(08)60218-4; Ochs K, 1999, CANCER RES, V59, P1544; Redon C, 2003, EMBO REP, V4, P678, DOI 10.1038/sj.embor.embor871; Rogakou EP, 2000, J BIOL CHEM, V275, P9390, DOI 10.1074/jbc.275.13.9390; Rogakou EP, 1999, J CELL BIOL, V146, P905, DOI 10.1083/jcb.146.5.905; Rogakou EP, 1998, J BIOL CHEM, V273, P5858, DOI 10.1074/jbc.273.10.5858; Soldani C, 2002, APOPTOSIS, V7, P321, DOI 10.1023/A:1016119328968; Stiff T, 2004, CANCER RES, V64, P2390, DOI 10.1158/0008-5472.CAN-03-3207; Takai H, 2003, CURR BIOL, V13, P1549, DOI 10.1016/S0960-9822(03)00542-6; Tibbles LA, 1999, CELL MOL LIFE SCI, V55, P1230, DOI 10.1007/s000180050369; Wang HY, 2005, J CELL PHYSIOL, V202, P492, DOI 10.1002/jcp.20141; Ward IM, 2001, J BIOL CHEM, V276, P47759, DOI 10.1074/jbc.C100569200; Xu B, 2002, MOL CELL BIOL, V22, P1049, DOI 10.1128/MCB.22.4.1049-1059.2002; Yan Y, 2007, ONCOGENE, V26, P4689, DOI 10.1038/sj.onc.1210268	42	34	35	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP	2008	27	43					5662	5671		10.1038/onc.2008.187	http://dx.doi.org/10.1038/onc.2008.187			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	352HM	18542054				2022-12-28	WOS:000259487100002
J	Osipo, C; Patel, P; Rizzo, P; Clementz, AG; Hao, L; Golde, TE; Miele, L				Osipo, C.; Patel, P.; Rizzo, P.; Clementz, A. G.; Hao, L.; Golde, T. E.; Miele, L.			ErbB-2 inhibition activates Notch-1 and sensitizes breast cancer cells to a gamma-secretase inhibitor	ONCOGENE			English	Article						ErbB-2; trastuzumab; Notch-1; GSI; breast cancer	PHASE-II TRIAL; TRASTUZUMAB RESISTANCE; TAMOXIFEN RESISTANCE; MONOCLONAL-ANTIBODY; WEEKLY VINORELBINE; 1ST-LINE THERAPY; RECEPTOR; GROWTH; HER2; CHEMOTHERAPY	ErbB-2 overexpression in breast tumors is associated with poor survival. Expression of Notch-1 and its ligand, Jagged-1, is associated with the poorest survival, including ErbB-2-positive tumors. Trastuzumab plus chemotherapy is the standard of care for ErbB-2-positive breast cancer. A proportion of tumors are initially resistant to trastuzumab and acquired resistance to trastuzumab occurs in metastatic breast cancer and is associated with poor prognosis. Thus, we investigated whether Notch-1 contributes to trastuzumab resistance. ErbB-2-positive cells have low Notch transcriptional activity compared to non-overexpressing cells. Trastuzumab or a dual epidermal growth factor receptor (EGFR)/ErbB-2 tyrosine kinase inhibitor (TKI) increased Notch activity by 2- to 6-fold in SKBr3, BT474 and MCF-7/HER2-18 cells. The increase in activity was abrogated by a Notch inhibitor, gamma-secretase inhibitor (GSI) or Notch-1 small-interfering RNA ( siRNA). Trastuzumab decreased Notch-1 (TM) precursor, increased amount and nuclear accumulation of active Notch-1(IC) and increased expression of targets, Hey1 and Deltex1 mRNAs, and Hes5, Hey1, Hes1 proteins. Importantly, trastuzumab-resistant BT474 cells treated with trastuzumab for 6 months expressed twofold higher Notch-1, twofold higher Hey1, ninefold higher Deltex1 mRNAs and threefold higher Notch-1 and Hes5 proteins, compared to trastuzumab-sensitive BT474 cells. The increase in Hey1 and Deltex1 mRNAs in resistant cells was abrogated by a Notch-1 siRNA. Cell proliferation was inhibited more effectively by trastuzumab or TKI plus a GSI than either agent alone. Decreased Notch-1 by siRNA increased efficacy of trastuzumab in BT474 sensitive cells and restored sensitivity in resistant cells. Trastuzumab plus a GSI increased apoptosis in sensitive cells by 20-30%. A GSI alone was sufficient to increase apoptosis in trastuzumab-resistant BT474 cells by 20%, which increased to 30% with trastuzumab. Notch-1 siRNA alone decreased cell growth by 30% in sensitive and more than 50% in resistant BT474 cells. Furthermore, growth of both trastuzumab sensitive and resistant cells was completely inhibited by combining trastuzumab plus Notch-1 siRNA. More importantly, Notch-1 siRNA or a GSI resensitized trastuzumab-resistant BT474 cells to trastuzumab. These results demonstrate that ErbB-2 overexpression suppresses Notch-1 activity, which can be reversed by trastuzumab or TKI. These results suggest that Notch-1 might play a novel role in resistance to trastuzumab, which could be prevented or reversed by inhibiting Notch-1.	[Osipo, C.; Rizzo, P.; Hao, L.; Miele, L.] Loyola Univ, Inst Oncol, Med Ctr, Cardinal Bernardin Canc Ctr,Dept Pathol, Maywood, IL 60153 USA; [Osipo, C.; Patel, P.; Clementz, A. G.] Loyola Univ, Cardinal Bernardin Canc Ctr, Med Ctr, Mol & Cellular Biochem Program, Maywood, IL 60153 USA; [Hao, L.; Miele, L.] Loyola Univ, Cardinal Bernardin Canc Ctr, Med Ctr, Program Mol Biol, Maywood, IL 60153 USA; [Golde, T. E.] Mayo Clin, Dept Neurosci, Jacksonville, FL 32224 USA; [Miele, L.] Loyola Univ, Dept Pharmacol & Mol Therapeut, Cardinal Bernardin Canc Ctr, Med Ctr, Maywood, IL 60153 USA	Loyola University Chicago; Loyola University Chicago; Loyola University Chicago; Mayo Clinic; Loyola University Chicago	Osipo, C (corresponding author), Loyola Univ, Inst Oncol, Med Ctr, Cardinal Bernardin Canc Ctr,Dept Pathol, 2160 S 1st Ave, Maywood, IL 60153 USA.	cosipo@lumc.edu		Miele, Lucio/0000-0002-5853-7287; rizzo, paola/0000-0001-7174-9674				Amar S, 2008, BREAST CANCER RES TR, V109, P1, DOI 10.1007/s10549-007-9636-2; Arpino G, 2005, JNCI-J NATL CANCER I, V97, P1254, DOI 10.1093/jnci/dji249; Artavanis-Tsakonas S, 1999, SCIENCE, V284, P770, DOI 10.1126/science.284.5415.770; Baonza A, 2005, DEV CELL, V8, P529, DOI 10.1016/j.devcel.2005.01.019; Baselga J, 2001, SEMIN ONCOL, V28, P4, DOI 10.1053/sonc.2001.28544; BENZ CC, 1992, BREAST CANCER RES TR, V24, P85, DOI 10.1007/BF01961241; Blaumueller CM, 1997, CELL, V90, P281, DOI 10.1016/S0092-8674(00)80336-0; Brou C, 2000, MOL CELL, V5, P207, DOI 10.1016/S1097-2765(00)80417-7; Burstein HJ, 2003, J CLIN ONCOL, V21, P2889, DOI 10.1200/JCO.2003.02.018; Burstein HJ, 2001, J CLIN ONCOL, V19, P2722, DOI 10.1200/JCO.2001.19.10.2722; Calzavara E, 2008, J CELL BIOCHEM, V103, P1405, DOI 10.1002/jcb.21527; CARTER P, 1992, P NATL ACAD SCI USA, V89, P4285, DOI 10.1073/pnas.89.10.4285; Cobleigh MA, 1999, J CLIN ONCOL, V17, P2639, DOI 10.1200/JCO.1999.17.9.2639; Dickson BC, 2007, MODERN PATHOL, V20, P685, DOI 10.1038/modpathol.3800785; Dievart A, 1999, ONCOGENE, V18, P5973, DOI 10.1038/sj.onc.1202991; Dontu G, 2004, BREAST CANCER RES, V6, pR605, DOI 10.1186/bcr920; Efstratiadis A, 2007, CELL CYCLE, V6, P418, DOI 10.4161/cc.6.4.3838; Farnie G, 2007, JNCI-J NATL CANCER I, V99, P616, DOI 10.1093/jnci/djk133; Florena AM, 2007, PATHOBIOLOGY, V74, P317, DOI 10.1159/000110024; Geyer CE, 2006, NEW ENGL J MED, V355, P2733, DOI 10.1056/NEJMoa064320; Imatani A, 2000, ONCOGENE, V19, P223, DOI 10.1038/sj.onc.1203295; Jahanzeb M, 2002, ONCOLOGIST, V7, P410, DOI 10.1634/theoncologist.7-5-410; LINDSELL CE, 1995, CELL, V80, P909, DOI 10.1016/0092-8674(95)90294-5; Logeat F, 1998, P NATL ACAD SCI USA, V95, P8108, DOI 10.1073/pnas.95.14.8108; Lu YH, 2004, INT J CANCER, V108, P334, DOI 10.1002/ijc.11445; Menendez JA, 2006, J CLIN ONCOL, V24, P3735, DOI 10.1200/JCO.2005.04.3489; Miele L, 2006, CLIN CANCER RES, V12, P1074, DOI 10.1158/1078-0432.CCR-05-2570; Miele L, 1999, J CELL PHYSIOL, V181, P393, DOI 10.1002/(SICI)1097-4652(199912)181:3<393::AID-JCP3>3.0.CO;2-6; Miele L, 2006, CURR MOL MED, V6, P905, DOI 10.2174/156652406779010830; Mumm JS, 2000, MOL CELL, V5, P197, DOI 10.1016/S1097-2765(00)80416-5; MUSS HB, 1994, NEW ENGL J MED, V330, P1260, DOI 10.1056/NEJM199405053301802; Nabholtz JM, 2001, SEMIN ONCOL, V28, P1; Nagata Y, 2004, CANCER CELL, V6, P117, DOI 10.1016/j.ccr.2004.06.022; Nahta R, 2006, CANCER LETT, V232, P123, DOI 10.1016/j.canlet.2005.01.041; Nahta R, 2005, CANCER RES, V65, P11118, DOI 10.1158/0008-5472.CAN-04-3841; O'Neill CF, 2007, AM J PATHOL, V171, P1023, DOI 10.2353/ajpath.2007.061029; Osborne CK, 2003, J NATL CANCER I, V95, P353, DOI 10.1093/jnci/95.5.353; Osipo C, 2003, J NATL CANCER I, V95, P1597, DOI 10.1093/jnci/djg079; Oswald F, 1998, MOL CELL BIOL, V18, P2077, DOI 10.1128/MCB.18.4.2077; Papaldo P, 2006, ANN ONCOL, V17, P630, DOI 10.1093/annonc/mdj110; Parks AL, 2000, DEVELOPMENT, V127, P1373; Phillips TM, 2006, JNCI-J NATL CANCER I, V98, P1777, DOI 10.1093/jnci/djj495; Politi K, 2004, SEMIN CANCER BIOL, V14, P341, DOI 10.1016/j.semcancer.2004.04.013; Price-Schiavi SA, 2002, INT J CANCER, V99, P783, DOI 10.1002/ijc.10410; Rangarajan A, 2001, VIROLOGY, V286, P23, DOI 10.1006/viro.2001.0867; Reedijk M, 2005, CANCER RES, V65, P8530, DOI 10.1158/0008-5472.CAN-05-1069; REEDIJK M, 2007, BREAST CANC RES TREA; Romond EH, 2005, NEW ENGL J MED, V353, P1673, DOI 10.1056/NEJMoa052122; Ronchini C, 2001, MOL CELL BIOL, V21, P5925, DOI 10.1128/MCB.21.17.5925-5934.2001; Schroeter EH, 1998, NATURE, V393, P382, DOI 10.1038/30756; Seidman AD, 2001, J CLIN ONCOL, V19, P2587, DOI 10.1200/JCO.2001.19.10.2587; Shou J, 2004, JNCI-J NATL CANCER I, V96, P926, DOI 10.1093/jnci/djh166; Sicinska E, 2003, CANCER CELL, V4, P451, DOI 10.1016/S1535-6108(03)00301-5; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; Slamon DJ, 2001, NEW ENGL J MED, V344, P783, DOI 10.1056/NEJM200103153441101; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; Sliwkowski MX, 1999, SEMIN ONCOL, V26, P60; Stylianou S, 2006, CANCER RES, V66, P1517, DOI 10.1158/0008-5472.CAN-05-3054; Vogel CL, 2002, J CLIN ONCOL, V20, P719, DOI 10.1200/JCO.20.3.719; Vooijs M, 2004, J BIOL CHEM, V279, P50864, DOI 10.1074/jbc.M409430200; Weber U, 2003, DEV CELL, V5, P559, DOI 10.1016/S1534-5807(03)00273-9; Weijzen S, 2002, NAT MED, V8, P979, DOI 10.1038/nm754; Weinmaster G, 1997, MOL CELL NEUROSCI, V9, P91, DOI 10.1006/mcne.1997.0612; Weng AP, 2006, GENE DEV, V20, P2096, DOI 10.1101/gad.1450406; Xia W, 2006, P NATL ACAD SCI USA, V103, P7795, DOI 10.1073/pnas.0602468103; Yarden Y, 2001, ONCOLOGY-BASEL, V61, P1, DOI 10.1159/000055396; Yokoyama Goro, 2005, Int J Clin Oncol, V10, P139	67	169	181	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 28	2008	27	37					5019	5032		10.1038/onc.2008.149	http://dx.doi.org/10.1038/onc.2008.149			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	344GL	18469855				2022-12-28	WOS:000258914800005
J	Ogiwara, H; Kohno, T; Nakanishi, H; Nagayama, K; Sato, M; Yokota, J				Ogiwara, H.; Kohno, T.; Nakanishi, H.; Nagayama, K.; Sato, M.; Yokota, J.			Unbalanced translocation, a major chromosome alteration causing loss of heterozygosity in human lung cancer	ONCOGENE			English	Article						unbalanced translocation; loss of heterozygosity; lung adenocarcinoma; tumor suppressor gene; mitotic recombination	COLORECTAL CANCERS; DNA-DAMAGE; MOLECULAR PROCESSES; 9P21 DELETIONS; ALLELIC LOSS; MECHANISMS; INSTABILITY; GENE; P53; RETINOBLASTOMA	Loss of heterozygosity (LOH) is a major genetic event causing inactivation of tumor suppressor genes in human carcinogenesis. To elucidate chromosomal mechanisms causing LOH, 201 LOHs in 10 cases of human lung cancer, which were detected bya genome-wide single nucleotide polymorphism array analysis, were investigated for responsible chromosome alterations by integrating information on breakpoints for DNA copy number changes obtained by array-comparative genome hybridization and on numerical and structural chromosomal alterations obtained by spectral karyotyping. The majority(80%) of LOHs were partial chromosome LOHs caused by structural chromosomal alterations, while the remaining (20%) were whole chromosome LOHs caused by whole chromosome deletions. Unbalanced translocation was defined as the most frequent alteration, and it accounted for 30% of all LOHs. Three other structural alterations-interstitial deletion (19%), mitotic recombination (9%) and gene conversion (6%)-also contributed to the occurrence of LOH, while terminal deletion contributed to only a small subset (1%). Since unbalanced translocation is a common chromosomal alteration in lung cancer cells, the results in the present study strongly indicate that a considerable fraction of LOHs detected in lung cancer cells are caused by unbalanced translocation.	[Ogiwara, H.; Kohno, T.; Nakanishi, H.; Nagayama, K.; Sato, M.; Yokota, J.] Natl Canc Ctr, Res Inst, Div Biol, Chuo Ku, Tokyo 1040045, Japan	National Cancer Center - Japan	Yokota, J (corresponding author), Natl Canc Ctr, Res Inst, Div Biol, Chuo Ku, 1-1,Tsukiji 5 Chome, Tokyo 1040045, Japan.	jyokota@ncc.go.jp		Ogiwara, Hideaki/0000-0003-0860-1807				Abdel-Rahman WM, 2001, P NATL ACAD SCI USA, V98, P2538, DOI 10.1073/pnas.041603298; Adams J, 2005, CANCER RES, V65, P66; Bartkova J, 2005, NATURE, V434, P864, DOI 10.1038/nature03482; Bosco G, 1998, GENETICS, V150, P1037; CAVENEE WK, 1983, NATURE, V305, P779, DOI 10.1038/305779a0; COLVY T, 2004, WHO CLASSIFICATION T, P31; Florl AR, 2003, GENE CHROMOSOME CANC, V37, P141, DOI 10.1002/gcc.10192; Gaasenbeek M, 2006, CANCER RES, V66, P3471, DOI 10.1158/0008-5472.CAN-05-3285; Girard L, 2000, CANCER RES, V60, P4894; Gorgoulis VG, 2005, NATURE, V434, P907, DOI 10.1038/nature03485; Grigorova M, 2005, CANCER GENET CYTOGEN, V162, P1, DOI 10.1016/j.cancergencyto.2005.03.007; JAMES CD, 1989, P NATL ACAD SCI USA, V86, P2858, DOI 10.1073/pnas.86.8.2858; Katsura Y, 2007, DNA REPAIR, V6, P639, DOI 10.1016/j.dnarep.2006.12.002; Kohno T, 2006, DNA REPAIR, V5, P1273, DOI 10.1016/j.dnarep.2006.05.021; LASKO D, 1991, ANNU REV GENET, V25, P281, DOI 10.1146/annurev.ge.25.120191.001433; Lieber MR, 2003, NAT REV MOL CELL BIO, V4, P712, DOI 10.1038/nrm1202; Masuda A, 2002, ONCOGENE, V21, P6884, DOI 10.1038/sj.onc.1205566; Mitelman F, 2000, MUTAT RES-REV MUTAT, V462, P247, DOI 10.1016/S1383-5742(00)00006-5; MORI N, 1989, CANCER RES, V49, P5130; NAYLOR SL, 1987, NATURE, V329, P451, DOI 10.1038/329451a0; Pennaneach V, 2006, MOL MICROBIOL, V59, P1357, DOI 10.1111/j.1365-2958.2006.05026.x; Phelps RM, 1996, J CELL BIOCHEM, P32; Robles AI, 2002, ONCOGENE, V21, P6898, DOI 10.1038/sj.onc.1205563; Roschke AV, 2003, CANCER RES, V63, P8634; SAKAMOTO H, 1986, P NATL ACAD SCI USA, V83, P3997, DOI 10.1073/pnas.83.11.3997; Sasaki S, 2003, ONCOGENE, V22, P3792, DOI 10.1038/sj.onc.1206589; Sato M, 2005, GENE CHROMOSOME CANC, V44, P405, DOI 10.1002/gcc.20253; Sato M, 2007, J THORAC ONCOL, V2, P327, DOI 10.1097/01.JTO.0000263718.69320.4c; Schmidt L, 1995, Cancer J Sci Am, V1, P191; Schrock E, 1996, SCIENCE, V273, P494, DOI 10.1126/science.273.5274.494; Sekido Y, 2003, ANNU REV MED, V54, P73, DOI 10.1146/annurev.med.54.101601.152202; Sengupta S, 2005, NAT REV MOL CELL BIO, V6, P44, DOI 10.1038/nrm1546; Shiseki M, 1996, GENE CHROMOSOME CANC, V17, P71, DOI 10.1002/(SICI)1098-2264(199610)17:2<71::AID-GCC1>3.0.CO;2-Y; Takahashi T, 1999, ONCOGENE, V18, P4295, DOI 10.1038/sj.onc.1202807; Thiagalingam S, 2001, P NATL ACAD SCI USA, V98, P2698, DOI 10.1073/pnas.051625398; Vafa O, 2002, MOL CELL, V9, P1031, DOI 10.1016/S1097-2765(02)00520-8; Virmani AK, 1998, GENE CHROMOSOME CANC, V21, P308, DOI 10.1002/(SICI)1098-2264(199804)21:4<308::AID-GCC4>3.0.CO;2-2; Weinberg RA, 2007, BIOL CANC, P209; YOKOTA J, 1987, P NATL ACAD SCI USA, V84, P9252, DOI 10.1073/pnas.84.24.9252; Yokota J, 2004, CANCER SCI, V95, P197, DOI 10.1111/j.1349-7006.2004.tb02203.x; Zhao XJ, 2004, CANCER RES, V64, P3060, DOI 10.1158/0008-5472.CAN-03-3308; Zhu CM, 2002, CELL, V109, P811, DOI 10.1016/S0092-8674(02)00770-5; ZHU X, 1992, CYTOGENET CELL GENET, V59, P248, DOI 10.1159/000133261	43	25	26	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 14	2008	27	35					4788	4797		10.1038/onc.2008.113	http://dx.doi.org/10.1038/onc.2008.113			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	337OJ	18408757				2022-12-28	WOS:000258445100004
J	Perotti, D; Gamba, B; Sardella, M; Spreafico, F; Terenziani, M; Collini, P; Pession, A; Nantron, M; Fossati-Bellani, F; Radice, P				Perotti, D.; Gamba, B.; Sardella, M.; Spreafico, F.; Terenziani, M.; Collini, P.; Pession, A.; Nantron, M.; Fossati-Bellani, F.; Radice, P.		AIEOP Wilms Tumor Study Grp	Functional inactivation of the WTX gene is not a frequent event in Wilms' tumors	ONCOGENE			English	Article						Wilms' tumor; WTX; mutation analysis; tumor suppressor; chromosome X	BETA-CATENIN; MUTATIONS; HETEROZYGOSITY; RELAXATION; CANCER; LOCUS; 16Q	For many years the precise genetic etiology of the majority of Wilms' tumors has remained unexplained. Recently, the WTX gene, mapped to chromosome Xq11.1, has been reported to be lost or mutated in approximately one-third of Wilms' tumors. Moreover, in female cases, the somatically inactivated alleles were found to invariantly derive from the active chromosome X. Consequently, WTX has been proposed as a 'one-hit' tumor suppressor gene. To provide further insights on the contribution of WTX to the development of the disease, we have examined 102 Wilms' tumors, obtained from 43 male and 57 female patients. Quantitative PCR analyses detected WTX deletions in 5 of 45 (11%) tumors from males, whereas loss of heterozygosity at WTX-linked microsatellites was observed in 9 tumors from 50 informative females (19%). However, in the latter group, using a combination of HUMARA assay and bisulfite-modified DNA sequencing, we found that the deletion affected the active chromosome X only in two cases (4%). Sequence analyses detected an inactivating somatic mutation of WTX in a single tumor, in which a strongly reduced expression of the mutant allele respect to the wildtype allele was observed, a finding not consistent with its localization on the active chromosome X. Overall, a functional somatic nullizygosity of the WTX gene was ascertained only in seven of the Wilms' tumors included in the study ( approximately 7%). Our findings indicate that previously reported estimates on the proportion of Wilms' tumors due to WTX alterations should be reconsidered.	[Spreafico, F.; Terenziani, M.; Fossati-Bellani, F.] Fdn IRCCS Ist Nazl Tumori, Dept Med Oncol, I-20133 Milan, Italy; [Collini, P.] Fdn IRCCS Ist Nazl Tumori, Dept Anat Pathol, I-20133 Milan, Italy; [Pession, A.] Policlin St Orsola Malpighi, Dept Pediat Oncol & Hematol, Bologna, Italy; [Nantron, M.] Ist Giannina Gaslini, Dept Pediat Hematol & Oncol, Genoa, Italy; [Radice, P.] IFOM Fdn Ist FIRC Oncol Mol, Milan, Italy; [Perotti, D.; Gamba, B.; Sardella, M.; Radice, P.] Fdn IRCCS Ist Nazl Tumori, Genet Susceptibil Canc Unit, Dept Expt Oncol & Labs, I-20133 Milan, Italy	Fondazione IRCCS Istituto Nazionale Tumori Milan; Fondazione IRCCS Istituto Nazionale Tumori Milan; IRCCS Azienda Ospedaliero-Universitaria di Bologna; University of Genoa; IRCCS Istituto Giannina Gaslini; IFOM - FIRC Institute of Molecular Oncology; Fondazione IRCCS Istituto Nazionale Tumori Milan	Perotti, D (corresponding author), Fdn IRCCS Ist Nazl Tumori, Genet Susceptibil Canc Unit, Dept Expt Oncol & Labs, Via Venezian 1, I-20133 Milan, Italy.	daniela.perotti@istitutotumori.mi.it	Terenziani, Monica/B-9562-2017; Pession, Andrea/O-3200-2013; Perotti, Daniela/C-2013-2017; Collini, Paola/K-7354-2016; Spreafico, Filippo/K-7813-2016; Radice, Paolo/O-3119-2013	Terenziani, Monica/0000-0002-7080-6718; Pession, Andrea/0000-0002-0379-9562; Perotti, Daniela/0000-0002-6703-2889; Collini, Paola/0000-0002-6158-210X; Spreafico, Filippo/0000-0002-5587-3509; Radice, Paolo/0000-0001-6298-4111	Associazione Italiana per la Ricerca sul Cancro Funding Source: Custom	Associazione Italiana per la Ricerca sul Cancro(Fondazione AIRC per la ricerca sul cancro)		ALLEN RC, 1992, AM J HUM GENET, V51, P1229; den Dunnen JT, 2000, HUM MUTAT, V15, P7; Fukuzawa R, 2007, J CLIN PATHOL, V60, P1013, DOI 10.1136/jcp.2006.043083; GRUNDY PE, 1994, CANCER RES, V54, P2331; Han M, 2007, GENE CHROMOSOME CANC, V46, P909, DOI 10.1002/gcc.20476; Hing S, 2001, AM J PATHOL, V158, P393, DOI 10.1016/S0002-9440(10)63982-X; Hoglund M, 2004, CANCER GENET CYTOGEN, V150, P9, DOI 10.1016/j.cancergencyto.2003.08.017; Huff V, 2007, CANCER CELL, V11, P105, DOI 10.1016/j.ccr.2007.01.011; Klamt B, 1998, GENE CHROMOSOME CANC, V22, P287, DOI 10.1002/(SICI)1098-2264(199808)22:4<287::AID-GCC4>3.0.CO;2-R; KNUDSON AG, 1972, J NATL CANCER I, V48, P313; Koesters R, 1999, CANCER RES, V59, P3880; Koesters R, 2003, J PATHOL, V199, P68, DOI 10.1002/path.1248; Li CM, 2004, AM J PATHOL, V165, P1943, DOI 10.1016/S0002-9440(10)63246-4; Little M, 1997, HUM MUTAT, V9, P209, DOI 10.1002/(SICI)1098-1004(1997)9:3<209::AID-HUMU2>3.0.CO;2-2; Little SE, 2004, J CLIN ONCOL, V22, P4140, DOI 10.1200/JCO.2004.02.136; Maiti S, 2000, CANCER RES, V60, P6288; Major MB, 2007, SCIENCE, V316, P1043, DOI 10.1126/science/1141515; MAW MA, 1992, CANCER RES, V52, P3094; Nusse R, 2007, SCIENCE, V316, P988, DOI 10.1126/science.1143337; OGAWA O, 1993, NATURE, V362, P749, DOI 10.1038/362749a0; Perotti D, 2005, J PEDIAT HEMATOL ONC, V27, P197, DOI 10.1097/01.mph.0000161270.22313.2f; Perotti D, 2004, HUM MUTAT, V24, P400, DOI 10.1002/humu.20096; Perotti D, 2005, J PEDIAT HEMATOL ONC, V27, P521, DOI 10.1097/01.mph.0000184309.22583.66; PRITCHARDJONES K, 1990, NATURE, V346, P194, DOI 10.1038/346194a0; RADICE P, 1995, GENOMICS, V27, P497, DOI 10.1006/geno.1995.1082; RAINIER S, 1993, NATURE, V362, P747, DOI 10.1038/362747a0; REEVE AE, 1989, MOL CELL BIOL, V9, P1799, DOI 10.1128/MCB.9.4.1799; Rivera MN, 2007, SCIENCE, V315, P642, DOI 10.1126/science.1137509; RUTESHOUSER EC, 2007, GENE CHROMOSOME CANC, V43, P172; Schumacher V, 1997, P NATL ACAD SCI USA, V94, P3972, DOI 10.1073/pnas.94.8.3972; Vernon EG, 2003, ONCOGENE, V22, P1371, DOI 10.1038/sj.onc.1206332	31	50	52	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 31	2008	27	33					4625	4632		10.1038/onc.2008.93	http://dx.doi.org/10.1038/onc.2008.93			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	332IS	18391980				2022-12-28	WOS:000258077300011
J	van der Weyden, L; Arends, MJ; Dovey, OM; Harrison, HL; Lefebvre, G; Conte, N; Gergely, FV; Bradley, A; Adams, DJ				van der Weyden, L.; Arends, M. J.; Dovey, O. M.; Harrison, H. L.; Lefebvre, G.; Conte, N.; Gergely, F. V.; Bradley, A.; Adams, D. J.			Loss of Rassf1a cooperates with Apc(Min) to accelerate intestinal tumourigenesis	ONCOGENE			English	Article						adenoma; adenocarcinoma; RASSF; APC; beta-catenin	TUMOR-SUPPRESSOR RASSF1A; COLORECTAL-CANCER; CODING VARIATION; MOUSE; MUTATIONS; NEOPLASIA; COMPLEX; GENOME; MICE; HYPERMETHYLATION	Promoter methylation of the RAS-association domain family 1, isoform A gene (RASSF1A) is one of the most frequent events found in human tumours. In this study we set out to test the hypothesis that loss of Rassf1a can cooperate with inactivation of the adenomatous polyposis coli (Apc) gene to accelerate intestinal tumourigenesis using the Apc-Min (Apc(Min/+)) mouse model, as mutational or deletional inactivation of APC is a frequent early event in the genesis of intestinal cancer. Further, loss of RASSF1A has also been reported to occur in premalignant adenomas of the bowel. RASSF1A has been implicated in an array of pivotal cellular processes, including regulation of the cell cycle, apoptosis, microtubule stability and most recently in the beta-catenin signalling pathway. By interbreeding isoform specific Rassf1a knockout mice with Apc(+/Min) mice, we showed that loss of Rassf1a results in a significant increase in adenomas of the small intestine and accelerated intestinal tumourigenesis leading to the earlier death of adenocarcinoma-bearing mice and decreased overall survival. Comparative genomic hybridization of adenomas from Rassf1a(-/-); Apc(+/Min) mice revealed no evidence of aneuploidy or gross chromosomal instability (no difference to adenomas from Rassf1a(+/+); Apc(+/Min) mice). Immunohistochemical analysis of adenomas revealed increased nuclear beta-catenin accumulation in adenomas from Rassf1a(-/-); Apc(+/Min) mice, compared to those from Rassf1a(+/+); Apc(+/Min) mice, but no differences in proliferation marker (Ki67) staining patterns. Collectively these data demonstrate cooperation between inactivation of Rassf1a and Apc resulting in accelerated intestinal tumourigenesis, with adenomas showing increased nuclear accumulation of beta-catenin, supporting a mechanistic link via loss of the known interaction of Rassf1 with beta-TrCP that usually mediates degradation of beta-catenin.	[van der Weyden, L.; Dovey, O. M.; Harrison, H. L.; Lefebvre, G.; Conte, N.; Bradley, A.; Adams, D. J.] Wellcome Trust Sanger Inst, Cambridge CB10 1SA, England; [Arends, M. J.] Univ Cambridge, Addenbrookes Hosp, Dept Pathol, Cambridge CB2 2QQ, England; [Gergely, F. V.] Cambridge Res Inst, Dept Oncol, Li Ka Shing Ctr, Cambridge, England	Wellcome Trust Sanger Institute; Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge; CRUK Cambridge Institute; University of Cambridge	van der Weyden, L (corresponding author), Wellcome Trust Sanger Inst, Wellcome Trust Genome Campus, Cambridge CB10 1SA, England.	lvdw@sanger.ac.uk	van der Weyden, Louise/AAV-5711-2021	van der Weyden, Louise/0000-0002-0645-1879; Harrison, Hannah/0000-0002-0054-8047; Conte, Nathalie/0000-0002-1010-3121; Adams, David/0000-0001-9490-0306; Bradley, Allan/0000-0002-2349-8839; Gergely, Fanni/0000-0002-2441-8095	Cancer Research UK [A8449] Funding Source: Medline; Wellcome Trust [079643] Funding Source: Medline	Cancer Research UK(Cancer Research UK); Wellcome Trust(Wellcome TrustEuropean Commission)		Adams DJ, 2005, NAT GENET, V37, P532, DOI 10.1038/ng1551; Alberici P, 2007, AM J PATHOL, V170, P377, DOI 10.2353/ajpath.2007.060853; Carothers AM, 2001, J BIOL CHEM, V276, P39094, DOI 10.1074/jbc.M103450200; Chung YJ, 2004, GENOME RES, V14, P188, DOI 10.1101/gr.1878804; Cunningham F, 2006, NAT GENET, V38, P853, DOI 10.1038/ng0806-853a; Estrabaud E, 2007, CANCER RES, V67, P1054, DOI 10.1158/0008-5472.CAN-06-2530; GERDES J, 1984, J IMMUNOL, V133, P1710; Graubert TA, 2007, PLOS GENET, V3, DOI 10.1371/journal.pgen.0030003; Guo C, 2007, CURR BIOL, V17, P700, DOI 10.1016/j.cub.2007.02.055; Hupe P, 2004, BIOINFORMATICS, V20, P3413, DOI 10.1093/bioinformatics/bth418; Lee S, 2004, LAB INVEST, V84, P884, DOI 10.1038/labinvest.3700108; LUONGO C, 1994, CANCER RES, V54, P5947; MOSER AR, 1990, SCIENCE, V247, P322, DOI 10.1126/science.2296722; NISHISHO I, 1991, SCIENCE, V253, P665, DOI 10.1126/science.1651563; Oliveira C, 2005, ONCOGENE, V24, P7630, DOI 10.1038/sj.onc.1208906; Reya T, 2005, NATURE, V434, P843, DOI 10.1038/nature03319; Smyth GK, 2005, STAT BIOL HEALTH, P397, DOI 10.1007/0-387-29362-0_23; Song MS, 2004, NAT CELL BIOL, V6, P129, DOI 10.1038/ncb1091; SU LK, 1992, SCIENCE, V256, P668, DOI 10.1126/science.1350108; Taketo MM, 2004, NAT GENET, V36, P320, DOI 10.1038/ng0404-320; Tommasi S, 2005, CANCER RES, V65, P92; van Amerongen R, 2006, TRENDS GENET, V22, P678, DOI 10.1016/j.tig.2006.10.001; van der Weyden L, 2005, MOL CELL BIOL, V25, P8356, DOI 10.1128/MCB.25.18.8356-8367.2005; van der Weyden L, 2007, BBA-REV CANCER, V1776, P58, DOI 10.1016/j.bbcan.2007.06.003; van Engeland M, 2002, ONCOGENE, V21, P3792, DOI 10.1038/sj.onc.1205466	25	22	22	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 24	2008	27	32					4503	4508		10.1038/onc.2008.94	http://dx.doi.org/10.1038/onc.2008.94			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	329PU	18391979	Green Accepted			2022-12-28	WOS:000257881700013
J	Liu, J; Weiss, HL; Rychahou, P; Jackson, LN; Evers, BM; Gao, T				Liu, J.; Weiss, H. L.; Rychahou, P.; Jackson, L. N.; Evers, B. M.; Gao, T.			Loss of PHLPP expression in colon cancer: role in proliferation and tumorigenesis	ONCOGENE			English	Article						PHLPP; colon cancer cells; Akt; protein kinase C; tumorigenesis	PROTEIN-KINASE-C; BREAST-CANCER; CELLS; GENE; AKT; GROWTH; CARCINOGENESIS; PHOSPHATASE; INVASION; P27	PHLPP (PH domain leucine-rich repeats protein phosphatase) represents a family of novel Ser/Thr protein phosphatases. Two highly related isoforms in this family, PHLPP1 and PHLPP2, have been identified to serve as negative regulators of Akt and protein kinase C by dephosphorylating the kinases directly. In this study, we examined the expression pattern of both PHLPP isoforms in colorectal cancer specimens and the adjacent normal mucosa using immunohistochemical staining. We found that the expression of PHLPP1 or PHLPP2 isoform was lost or decreased in 78 and 86% of tumor tissues, respectively. Stable overexpression of either PHLPP isoform in colon cancer cells decreased the rate of cell proliferation and sensitized the cells to growth inhibition induced by the phosphoinositide-3 kinase inhibitor, LY294002, whereas knockdown of either PHLPP isoform by shRNA promoted the proliferation of DLD1 cells. In addition, we demonstrated that the PHLPP-mediated growth inhibition in colon cancer cells was largely rescued by overexpression of a constitutively active Akt. Moreover, reexpression of either PHLPP isoform in HCT116 cells inhibited tumor growth in vivo. Taken together, our results strongly support a tumor suppressor role of PHLPP in colon cancer.	[Gao, T.] Univ Texas Galveston, Med Branch, Dept Pharmacol & Toxicol, Galveston, TX 77555 USA; [Liu, J.] Sichuan Univ, W China Med Sch Preclin & Forens Med, Dept Biochem & Mol Biol, Chengdu 610064, Sichuan, Peoples R China; [Liu, J.; Weiss, H. L.; Evers, B. M.; Gao, T.] Univ Texas Galveston, Med Branch, Sealy Ctr Canc Cell Biol, Galveston, TX 77555 USA; [Weiss, H. L.] Univ Texas Galveston, Med Branch, Dept Prevent Med & Community Hlth, Galveston, TX 77555 USA; [Rychahou, P.; Jackson, L. N.; Evers, B. M.] Univ Texas Galveston, Med Branch, Dept Surg, Galveston, TX 77555 USA	University of Texas System; University of Texas Medical Branch Galveston; Sichuan University; University of Texas System; University of Texas Medical Branch Galveston; University of Texas System; University of Texas Medical Branch Galveston; University of Texas System; University of Texas Medical Branch Galveston	Gao, T (corresponding author), Univ Texas Galveston, Med Branch, Dept Pharmacol & Toxicol, 301 Univ Blvd, Galveston, TX 77555 USA.	tigao@utmb.edu		Rychahou, Piotr/0000-0001-7352-9122	NIH [K01 CA10209-05]; American Cancer Society [RSG0822001TBE, R01CA104748]; NATIONAL CANCER INSTITUTE [R01CA104748, K01CA102098] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); American Cancer Society(American Cancer Society); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank UTMB. ow cytometry core for assistance with the. ow cytometry analysis, and Dr Alexandra Newton at University of California San Diego for providing the wild- type and mutant Akt and PKC bII expression constructs. This work was supported by NIH K01 CA10209-05(TG), American Cancer Society RSG0822001TBE (TG) and R01CA104748 (BME).	Brognard J, 2007, MOL CELL, V25, P917, DOI 10.1016/j.molcel.2007.02.017; Gao T, 2008, J BIOL CHEM, V283, P6300, DOI 10.1074/jbc.M707319200; Gao TY, 2005, MOL CELL, V18, P13, DOI 10.1016/j.molcel.2005.03.008; Gokmen-Polar Y, 2001, CANCER RES, V61, P1375; Hershko DD, 2006, CANCER-AM CANCER SOC, V107, P668, DOI 10.1002/cncr.22073; Kosinski C, 2007, P NATL ACAD SCI USA, V104, P15418, DOI 10.1073/pnas.0707210104; Liang JY, 2003, CELL CYCLE, V2, P339, DOI 10.4161/cc.2.4.433; Manning BD, 2005, GENE DEV, V19, P1773, DOI 10.1101/gad.1314605; Manning BD, 2007, CELL, V129, P1261, DOI 10.1016/j.cell.2007.06.009; Maroulakou IG, 2007, CANCER RES, V67, P167, DOI 10.1158/0008-5472.CAN-06-3782; Murray NR, 1999, J CELL BIOL, V145, P699, DOI 10.1083/jcb.145.4.699; Nakayama K, 2004, DEV CELL, V6, P661, DOI 10.1016/S1534-5807(04)00131-5; Newton AC, 2003, BIOCHEM J, V370, P361, DOI 10.1042/BJ20021626; Qiao M, 2007, CANCER RES, V67, P5293, DOI 10.1158/0008-5472.CAN-07-0877; REINER A, 1990, CANCER RES, V50, P7057; Rosner M, 2006, MUTAT RES-REV MUTAT, V613, P10, DOI 10.1016/j.mrrev.2006.03.001; Saaf AM, 2007, MOL BIOL CELL, V18, P4245, DOI 10.1091/mbc.E07-04-0309; Samuels Y, 2005, CANCER CELL, V7, P561, DOI 10.1016/j.ccr.2005.05.014; Samuels Y, 2004, SCIENCE, V304, P554, DOI 10.1126/science.1096502; Stewart SA, 2003, RNA, V9, P493, DOI 10.1261/rna.2192803; Yoeli-Lerner M, 2005, MOL CELL, V20, P539, DOI 10.1016/j.molcel.2005.10.033	21	126	137	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 19	2009	28	7					994	1004		10.1038/onc.2008.450	http://dx.doi.org/10.1038/onc.2008.450			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	408TH	19079341	Green Accepted			2022-12-28	WOS:000263457400006
J	Menigatti, M; Truninger, K; Gebbers, JO; Marbet, U; Marra, G; Schar, P				Menigatti, M.; Truninger, K.; Gebbers, J-O; Marbet, U.; Marra, G.; Schaer, P.			Normal colorectal mucosa exhibits sex- and segment-specific susceptibility to DNA methylation at the hMLH1 and MGMT promoters	ONCOGENE			English	Article						hMLH1; MGMT; promoter methylation; colorectal mucosa; colorectal cancer	NORMAL COLONIC-MUCOSA; CPG ISLAND METHYLATION; ABERRANT CRYPT FOCI; MICROSATELLITE INSTABILITY; GENE-EXPRESSION; O-6-METHYLGUANINE-DNA METHYLTRANSFERASE; PROXIMAL COLON; MLH1 PROMOTER; K-RAS; CANCER	Silencing of gene expression by aberrant cytosine methylation is a prominent feature of human tumors, including colorectal cancers. Epigenetic changes of this type play undisputed roles in cell transformation when they involve genes that safeguard genome stability, and they can also be detected in precancerous lesions and seemingly normal peritumoral tissues. We explored physiological conditions associated with aberrant promoter methylation involving two DNA-repair genes in normal colorectal mucosa. Samples of cecal, transverse colon, sigmoid and rectal mucosa collected from 100 healthy individuals undergoing screening colonoscopy were analysed for hMLH1 and MGMT promoter methylation with a quantitative PCR assay. Positivity in at least one colon segment was common in both sexes, with methylation involving 0.1-18.8% of the alleles (median = 0.49%). Samples from males showed no consistent patterns for either promoter, but there were striking age- and colon segment-specific differences in the female subgroup. Here, the prevalence of hMLH1 and MGMT methylation increased significantly with age, particularly in the right colon, where there was also an age- related increase in the percentage of alleles showing hMLH1 methylation. Concomitant methylation of both promoters was also significantly more common in the right colon of women. These findings paralleled immunohistochemical patterns of hMLH1 and MGMT protein loss in an independent series of 231 colorectal cancers and were consistent with current epigenetic profiles of colorectal cancer subsets. They suggest the intriguing possibility that the epigenetic signatures of cancers may have early-stage, normal-tissue counterparts that reflect potentially important aspects of the initial carcinogenetic process.	[Marra, G.] Univ Zurich, Inst Mol Canc Res, CH-8057 Zurich, Switzerland; [Menigatti, M.; Schaer, P.] Univ Basel, Dept Biomed, Basel, Switzerland; [Truninger, K.] SRO Hosp Langenthal, Langenthal, Switzerland; [Gebbers, J-O] Cantonal Hosp Lucerne, Dept Pathol, Luzern, Switzerland; [Marbet, U.] Cantonal Hosp Altdorf, Clin Internal Med, Altdorf, Switzerland	University of Zurich; University of Basel; Lucerne Cantonal Hospital	Marra, G (corresponding author), Univ Zurich, Inst Mol Canc Res, Winterthurerstr 190, CH-8057 Zurich, Switzerland.	marra@imcr.uzh.ch	Schär, Primo/G-5967-2012	Schär, Primo/0000-0003-1843-6147	Swiss National Science Foundation; Krebsliga Zentralschweiz; Krebsliga Beider Basel; Julius-Muller Stiftung, Zurich; Hanne-Liebermann Stiftung, Zurich	Swiss National Science Foundation(Swiss National Science Foundation (SNSF)European Commission); Krebsliga Zentralschweiz; Krebsliga Beider Basel; Julius-Muller Stiftung, Zurich; Hanne-Liebermann Stiftung, Zurich	We thank Josef Jiricny at the Institute of Molecular Cancer Research of the University of Zurich and our colleagues at the Department of Biomedicine of the University of Basel for helpful discussions and support throughout the project. We are also grateful to Patric Urfer and Christophe Kunz for critical reading of the manuscript, Ritva Haider for technical assistance, and Marian E Kent for editorial assistance. The study was supported by the Swiss National Science Foundation (to GM), the Krebsliga Zentralschweiz (to GM), the Krebsliga Beider Basel (to PS), Julius-Muller Stiftung, Zurich (to KT) and the Hanne-Liebermann Stiftung, Zurich (to KT).	AALTONEN LA, 1993, SCIENCE, V260, P812, DOI 10.1126/science.8484121; Ahuja N, 1998, CANCER RES, V58, P5489; Al-Ghnaniem R, 2007, AM J CLIN NUTR, V86, P1064, DOI 10.1093/ajcn/86.4.1064; Anacleto C, 2005, NEOPLASIA, V7, P331, DOI 10.1593/neo.04502; Capel E, 2007, ONCOGENE, V26, P7596, DOI 10.1038/sj.onc.1210581; Chan AOO, 2002, AM J PATHOL, V160, P1823, DOI 10.1016/S0002-9440(10)61128-5; Deng GR, 1999, CANCER RES, V59, P2029; Esteller M, 2000, CANCER RES, V60, P2368; Esteller M, 2008, NEW ENGL J MED, V358, P1148, DOI 10.1056/NEJMra072067; Fox EJ, 2006, J MOL DIAGN, V8, P68, DOI 10.2353/jmoldx.2006.050084; Gerson SL, 2004, NAT REV CANCER, V4, P296, DOI 10.1038/nrc1319; Giovannucci E, 2005, JNCI-J NATL CANCER I, V97, P1317, DOI 10.1093/jnci/dji305; Goel A, 2007, GASTROENTEROLOGY, V132, P127, DOI 10.1053/j.gastro.2006.09.018; Greenspan EJ, 2007, CARCINOGENESIS, V28, P769, DOI 10.1093/carcin/bgl209; Hiraoka S, 2006, GASTROENTEROLOGY, V131, P379, DOI 10.1053/j.gastro.2006.04.027; IONOV Y, 1993, NATURE, V363, P558, DOI 10.1038/363558a0; Issa JP, 2004, NAT REV CANCER, V4, P988, DOI 10.1038/nrc1507; Issa JPJ, 2001, CANCER RES, V61, P3573; ISSA JPJ, 1994, NAT GENET, V7, P536, DOI 10.1038/ng0894-536; Jass JR, 2002, GASTROENTEROLOGY, V123, P862, DOI 10.1053/gast.2002.35392; Kane MF, 1997, CANCER RES, V57, P808; Kawakami K, 2006, BRIT J CANCER, V94, P593, DOI 10.1038/sj.bjc.6602940; Kim SH, 2003, MOL CARCINOGEN, V37, P32, DOI 10.1002/mc.10116; Kuismanen SA, 1999, P NATL ACAD SCI USA, V96, P12661, DOI 10.1073/pnas.96.22.12661; Lindblom A, 2001, CURR OPIN ONCOL, V13, P63, DOI 10.1097/00001622-200101000-00013; Malkhosyan SR, 2000, GASTROENTEROLOGY, V119, P598, DOI 10.1053/gast.2000.16154; Menigatti M, 2001, GENE CHROMOSOME CANC, V31, P357, DOI 10.1002/gcc.1154; Menigatti M, 2007, ONCOL REP, V17, P1421; Minoo P, 2006, GUT, V55, DOI 10.1136/gut.2005.082859; Miyakura Y, 2001, GASTROENTEROLOGY, V121, P1300, DOI 10.1053/gast.2001.29616; Momparler RL, 2003, ONCOGENE, V22, P6479, DOI 10.1038/sj.onc.1206774; Nakagawa H, 2001, CANCER RES, V61, P6991; Ogino S, 2006, GUT, V55, P1000, DOI 10.1136/gut.2005.082933; Ogino S, 2007, GUT, V56, P1564, DOI 10.1136/gut.2007.119750; Percesepe A, 2001, J CLIN ONCOL, V19, P3944, DOI 10.1200/JCO.2001.19.19.3944; Reik W, 2007, NATURE, V447, P425, DOI 10.1038/nature05918; Shen LL, 2007, P NATL ACAD SCI USA, V104, P18654, DOI 10.1073/pnas.0704652104; Shen LL, 2005, JNCI-J NATL CANCER I, V97, P1330, DOI 10.1093/jnci/dji275; Slattery ML, 2001, CANCER RES, V61, P126; Soetikno RM, 2008, JAMA-J AM MED ASSOC, V299, P1027, DOI 10.1001/jama.299.9.1027; Suzuki H, 2004, NAT GENET, V36, P417, DOI 10.1038/ng1330; THIBODEAU SN, 1993, SCIENCE, V260, P816, DOI 10.1126/science.8484122; Toyota M, 1999, SEMIN CANCER BIOL, V9, P349, DOI 10.1006/scbi.1999.0135; Toyota M, 1999, P NATL ACAD SCI USA, V96, P8681, DOI 10.1073/pnas.96.15.8681; Truninger K, 2005, GASTROENTEROLOGY, V128, P1160, DOI 10.1053/j.gastro.2005.01.056; Weisenberger DJ, 2006, NAT GENET, V38, P787, DOI 10.1038/ng1834; Whitehall VLJ, 2001, CANCER RES, V61, P827; Xiong ZG, 2001, CANCER EPIDEM BIOMAR, V10, P799; Ye CZ, 2006, ONCOL REP, V16, P429	49	59	60	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2009	28	6					899	909		10.1038/onc.2008.444	http://dx.doi.org/10.1038/onc.2008.444			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	406UI	19060925				2022-12-28	WOS:000263320000012
J	Nagarajan, P; Onami, TM; Rajagopalan, S; Kania, S; Donnell, R; Venkatachalam, S				Nagarajan, P.; Onami, T. M.; Rajagopalan, S.; Kania, S.; Donnell, R.; Venkatachalam, S.			Role of chromodomain helicase DNA-binding protein 2 in DNA damage response signaling and tumorigenesis	ONCOGENE			English	Article						chromatin remodeling; lymphoma; hematopoiesis; mutant mice; tumor suppressor and DNA damage	CHROMATIN REMODELING FACTORS; HISTONE VARIANT EXCHANGE; TUMOR-SUPPRESSOR; CHD1; H2AX; H3; MUTATIONS; COMPLEX; CANCER; FAMILY	The chromodomain helicase DNA-binding proteins (CHDs) are known to affect transcription through their ability to remodel chromatin and modulate histone deacetylation. In an effort to understand the functional role of the CHD2 in mammals, we have generated a Chd2 mutant mouse model. Remarkably, the Chd2 protein appears to play a critical role in the development, hematopoiesis and tumor suppression. The Chd2 heterozygous mutant mice exhibit increased extramedullary hematopoiesis and susceptibility to lymphomas. At the cellular level, Chd2 mutants are defective in hematopoietic stem cell differentiation, accumulate higher levels of the chromatin-associated DNA damage response mediator, gamma H2AX, and exhibit an aberrant DNA damage response after X-ray irradiation. Our data suggest a direct role for the chromatin remodeling protein in DNA damage signaling and genome stability maintenance.	[Nagarajan, P.; Rajagopalan, S.; Venkatachalam, S.] Univ Tennessee, Dept Biochem & Cellular & Mol Biol, Knoxville, TN 37996 USA; [Onami, T. M.] Univ Tennessee, Dept Microbiol, Knoxville, TN 37996 USA; [Kania, S.; Donnell, R.] Univ Tennessee, Dept Pathobiol, Knoxville, TN 37996 USA	University of Tennessee System; University of Tennessee Knoxville; University of Tennessee System; University of Tennessee Knoxville; University of Tennessee System; University of Tennessee Knoxville; UT Institute of Agriculture	Venkatachalam, S (corresponding author), Univ Tennessee, Dept Biochem & Cell & Mol Biol, M407,Walters Life Sci Bldg, Knoxville, TN 37996 USA.	sundar@utk.edu	NAGARAJAN, PRABAKARAN/AAA-2881-2020; Kania, Stephen/ABF-6920-2021	NAGARAJAN, PRABAKARAN/0000-0001-6124-3274; Kania, Stephen/0000-0002-4490-7347; Donnell, Robert L./0000-0002-6778-954X	University of Tennessee; PMERF; NIH [00293621, AI05771901]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [K22AI057719] Funding Source: NIH RePORTER	University of Tennessee; PMERF; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	We are thankful to Dr Bruce McKee for critically reading the manuscript. This work was supported by the University of Tennessee startup funds, PMERF seed funds, and NIH funds (00293621) to SV and funding from NIH (AI05771901) to TMO.	Bagchi A, 2007, CELL, V128, P459, DOI 10.1016/j.cell.2006.11.052; Banath JP, 2003, CANCER RES, V63, P4347; Bernstein BE, 2002, P NATL ACAD SCI USA, V99, P8695, DOI 10.1073/pnas.082249499; Brehm A, 2000, EMBO J, V19, P4332, DOI 10.1093/emboj/19.16.4332; BRONSON RT, 1991, GROWTH DEVELOP AGING, V55, P169; Cowell IG, 1997, BBA-PROTEIN STRUCT M, V1337, P198, DOI 10.1016/S0167-4838(96)00165-3; DELMAS V, 1993, P NATL ACAD SCI USA, V90, P2414, DOI 10.1073/pnas.90.6.2414; Downs JA, 2000, NATURE, V408, P1001, DOI 10.1038/35050000; Feys T, 2007, HAEMATOL-HEMATOL J, V92, P40; Flanagan JF, 2005, NATURE, V438, P1181, DOI 10.1038/nature04290; Fukasawa M, 2006, CYTOGENET GENOME RES, V113, P138, DOI 10.1159/000090825; Gao XC, 2007, AM J HUM GENET, V80, P957, DOI 10.1086/513571; Gonzalez-Billault C, 2000, MOL CELL NEUROSCI, V16, P408, DOI 10.1006/mcne.2000.0880; Hasan S, 2002, J MOL MED, V80, P463, DOI 10.1007/s00109-002-0341-7; Heyworth C, 2002, EMBO J, V21, P3770, DOI 10.1093/emboj/cdf368; Iwasaki H, 2003, IMMUNITY, V19, P451, DOI 10.1016/S1074-7613(03)00242-5; Jeganathan K, 2007, J CELL BIOL, V179, P255, DOI 10.1083/jcb.200706015; Jin JJ, 2005, TRENDS BIOCHEM SCI, V30, P680, DOI 10.1016/j.tibs.2005.10.003; Jones DO, 2000, BIOESSAYS, V22, P124, DOI 10.1002/(SICI)1521-1878(200002)22:2&lt;124::AID-BIES4&gt;3.0.CO;2-E; Kang J, 2005, MOL CELL BIOL, V25, P661, DOI 10.1128/MCB.25.2.661-670.2005; Kina T, 2000, BRIT J HAEMATOL, V109, P280, DOI 10.1046/j.1365-2141.2000.02037.x; Kulkarni S, 2008, AM J MED GENET A, V146A, P1117, DOI 10.1002/ajmg.a.32178; Kusch T, 2004, SCIENCE, V306, P2084, DOI 10.1126/science.1103455; Lalani SR, 2006, AM J HUM GENET, V78, P303, DOI 10.1086/500273; Lukas C, 2004, EMBO J, V23, P2674, DOI 10.1038/sj.emboj.7600269; Lusser A, 2005, NAT STRUCT MOL BIOL, V12, P160, DOI 10.1038/nsmb884; Marfella CGA, 2006, J CELL PHYSIOL, V209, P162, DOI 10.1002/jcp.20718; Morrison AJ, 2004, CELL, V119, P767, DOI 10.1016/j.cell.2004.11.037; Muller C, 2001, CURR OPIN GENET DEV, V11, P167, DOI 10.1016/S0959-437X(00)00175-1; Ney PA, 2006, CURR OPIN HEMATOL, V13, P203, DOI 10.1097/01.moh.0000231415.18333.2c; Osley MA, 2007, MUTAT RES-FUND MOL M, V618, P65, DOI 10.1016/j.mrfmmm.2006.07.011; PARO R, 1991, P NATL ACAD SCI USA, V88, P263, DOI 10.1073/pnas.88.1.263; Paull TT, 2000, CURR BIOL, V10, P886, DOI 10.1016/S0960-9822(00)00610-2; Pray-Grant MG, 2005, NATURE, V433, P434, DOI 10.1038/nature03242; Qin S, 2002, MOL CELL BIOL, V22, P8353, DOI 10.1128/MCB.22.23.8353-8365.2002; Rogakou EP, 1998, J BIOL CHEM, V273, P5858, DOI 10.1074/jbc.273.10.5858; Rothkamm K, 2003, MOL CELL BIOL, V23, P5706, DOI 10.1128/MCB.23.16.5706-5715.2003; Schuster EF, 2002, MAMM GENOME, V13, P117, DOI 10.1007/s00335-001-3042-6; Simic R, 2003, EMBO J, V22, P1846, DOI 10.1093/emboj/cdg179; Sims RJ, 2005, J BIOL CHEM, V280, P41789, DOI 10.1074/jbc.C500395200; SINGH PB, 1991, NUCLEIC ACIDS RES, V19, P789, DOI 10.1093/nar/19.4.789; Socolovsky M, 2001, BLOOD, V98, P3261, DOI 10.1182/blood.V98.12.3261; Spike BT, 2004, EMBO J, V23, P4319, DOI 10.1038/sj.emboj.7600432; STOKES DG, 1995, MOL CELL BIOL, V15, P2745; Stryke D, 2003, NUCLEIC ACIDS RES, V31, P278, DOI 10.1093/nar/gkg064; Takeda Yoshihiko, 2001, Frontiers in Bioscience, V6, pd1412, DOI 10.2741/Takeda; TARGOFF IN, 1985, ARTHRITIS RHEUM, V28, P796, DOI 10.1002/art.1780280711; Thomas JO, 2001, BIOCHEM SOC T, V29, P395, DOI 10.1042/BST0290395; Tong JK, 1998, NATURE, V395, P917, DOI 10.1038/27699; Tran HG, 2000, EMBO J, V19, P2323, DOI 10.1093/emboj/19.10.2323; Tsukuda T, 2005, NATURE, V438, P379, DOI 10.1038/nature04148; van Attikum H, 2004, CELL, V119, P777, DOI 10.1016/j.cell.2004.11.033; Venkatachalam S, 1998, EMBO J, V17, P4657, DOI 10.1093/emboj/17.16.4657; Vissers LELM, 2004, NAT GENET, V36, P955, DOI 10.1038/ng1407; Voss AK, 1998, DEV DYNAM, V212, P258; Wang GG, 2007, TRENDS MOL MED, V13, P373, DOI 10.1016/j.molmed.2007.07.004; Wang GG, 2007, TRENDS MOL MED, V13, P363, DOI 10.1016/j.molmed.2007.07.003; Whiteford M L, 2000, J Med Genet, V37, pE11, DOI 10.1136/jmg.37.8.e11; WILSON GN, 1985, J MED GENET, V22, P233, DOI 10.1136/jmg.22.3.233; Woodage T, 1997, P NATL ACAD SCI USA, V94, P11472, DOI 10.1073/pnas.94.21.11472; Wu C, 1997, J BIOL CHEM, V272, P28171, DOI 10.1074/jbc.272.45.28171; Xue YT, 1998, MOL CELL, V2, P851, DOI 10.1016/S1097-2765(00)80299-3; Zhang J, 2003, BLOOD, V102, P3938, DOI 10.1182/blood-2003-05-1479; Zhang Y, 1998, CELL, V95, P279, DOI 10.1016/S0092-8674(00)81758-4	64	80	81	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2009	28	8					1053	1062		10.1038/onc.2008.440	http://dx.doi.org/10.1038/onc.2008.440			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	412KE	19137022	Green Accepted			2022-12-28	WOS:000263722900001
J	Yue, S; Chen, Y; Cheng, SY				Yue, S.; Chen, Y.; Cheng, S. Y.			Hedgehog signaling promotes the degradation of tumor suppressor Sufu through the ubiquitin-proteasome pathway	ONCOGENE			English	Article						hedgehog; Sufu; ubiquitin; lung cancer	CUBITUS INTERRUPTUS; NUCLEAR IMPORT; GLI; DROSOPHILA; COMPLEX; MEDULLOBLASTOMA; TRANSCRIPTION; TRANSDUCTION; DIVERGENCE; PARADIGMS	Sustained Sonic hedgehog (Shh) pathway activity is associated with tumorigenesis in a wide variety of tissues. Mutational inactivation of Shh receptor Patched (Ptch) and a downstream gene Suppressor of fused (Sufu), both of which are negative regulators of the pathway, increases susceptibility to cerebellum cancer in humans and mice. Sufu is a binding partner of Shh pathway transcription factor Gli. Recent data indicate that inactivation of Sufu, through either gene targeting in mice or RNAi-mediated silencing in cultured. broblasts, is sufficient to turn on Shh target gene expression. Here, we report that Sufu is degraded rapidly in certain cancer cells and we show that Shh signaling promotes ubiquitination of Sufu, which leads to its destruction in the proteasomes. We identified an ubiquitin attachment site on K257 of Sufu, and showed that Sufu-K257R mutant is more potent as a transcription repressor and cell growth inhibitor because of increased stability. These results indicate that Shh signaling regulates Sufu activity by inducing its turnover via the ubiquitin-proteasome system.	[Cheng, S. Y.] Nanjing Med Univ, Dept Dev Genet, Lab Reprod Med, Nanjing, Jiangsu, Peoples R China; [Yue, S.; Cheng, S. Y.] Nanjing Med Univ, Ctr Canc, Nanjing, Jiangsu, Peoples R China	Nanjing Medical University; Nanjing Medical University	Cheng, SY (corresponding author), Nanjing Med Univ, Dept Dev Genet, Lab Reprod Med, 140 Hanzhong Rd,Xianzhi Lou 1908, Nanjing, Jiangsu, Peoples R China.	sycheng@njmu.edu.cn			Chinese National Science Foundation [30771079]; 973 State Key Research Project [2009CB918403]	Chinese National Science Foundation(National Natural Science Foundation of China (NSFC)); 973 State Key Research Project(National Basic Research Program of China)	We thank Drs YE Zhang, A Ruiz i Altaba, R Toftgard, DJ Robbins and CM Fan for valuable reagents and suggestions. This work is supported by a Chinese National Science Foundation Grant (30771079 to SYC) and a 973 State Key Research Project Grant (2009CB918403 to SYC).	Altaba AR, 2002, NAT REV CANCER, V2, P361, DOI 10.1038/nrc796; Beachy PA, 2004, NATURE, V432, P324, DOI 10.1038/nature03100; Chen ZJJ, 2005, NAT CELL BIOL, V7, P758, DOI 10.1038/ncb0805-758; Cheng SY, 2002, P NATL ACAD SCI USA, V99, P5442, DOI 10.1073/pnas.082096999; Cooper AF, 2005, DEVELOPMENT, V132, P4407, DOI 10.1242/dev.02021; Goodrich LV, 1997, SCIENCE, V277, P1109, DOI 10.1126/science.277.5329.1109; Ho KS, 2005, DEVELOPMENT, V132, P1401, DOI 10.1242/dev.01689; Huangfu D, 2006, DEVELOPMENT, V133, P3, DOI 10.1242/dev.02169; Ingham PW, 2001, GENE DEV, V15, P3059, DOI 10.1101/gad.938601; JACOB L, 2007, SCI STKE, pCM6, DOI DOI 10.1126/STKE.4072007CM6; Kogerman P, 1999, NAT CELL BIOL, V1, P312, DOI 10.1038/13031; Kovacs JJ, 2008, SCIENCE, V320, P1777, DOI 10.1126/science.1157983; Lee Y, 2007, ONCOGENE, V26, P6442, DOI 10.1038/sj.onc.1210467; Lum L, 2003, MOL CELL, V12, P1261, DOI 10.1016/S1097-2765(03)00426-X; Merchant M, 2004, MOL CELL BIOL, V24, P8627, DOI 10.1128/MCB.24.19.8627-8641.2004; Monnier V, 1998, CURR BIOL, V8, P583, DOI 10.1016/S0960-9822(98)70227-1; Ohlmeyer JT, 1998, NATURE, V396, P749, DOI 10.1038/25533; Paces-Fessy M, 2004, BIOCHEM J, V378, P353, DOI 10.1042/BJ20030786; PREAT T, 1993, GENETICS, V135, P1047; Ruiz i Altaba A, 2007, TRENDS CELL BIOL, V17, P438, DOI 10.1016/j.tcb.2007.06.007; Sisson BE, 2006, DEV BIOL, V294, P258, DOI 10.1016/j.ydbio.2006.02.050; Stegman MA, 2000, J BIOL CHEM, V275, P21809, DOI 10.1074/jbc.C000043200; Svard J, 2006, DEV CELL, V10, P187, DOI 10.1016/j.devcel.2005.12.013; Taylor MD, 2002, NAT GENET, V31, P306, DOI 10.1038/ng916; Trotman LC, 2007, CELL, V128, P141, DOI 10.1016/j.cell.2006.11.040; Varjosalo M, 2006, DEV CELL, V10, P177, DOI 10.1016/j.devcel.2005.12.014; Wang Y, 2007, CURR OPIN CELL BIOL, V19, P159, DOI 10.1016/j.ceb.2007.02.005; Yuan Z, 2007, ONCOGENE, V26, P1046, DOI 10.1038/sj.onc.1209860	28	63	72	2	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 29	2009	28	4					492	499		10.1038/onc.2008.403	http://dx.doi.org/10.1038/onc.2008.403			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	400KM	18997815				2022-12-28	WOS:000262866500003
J	Chen, C; Zhou, Z; Liu, R; Li, Y; Azmi, PB; Seth, AK				Chen, C.; Zhou, Z.; Liu, R.; Li, Y.; Azmi, P. B.; Seth, A. K.			The WW domain containing E3 ubiquitin protein ligase 1 upregulates ErbB2 and EGFR through RING finger protein 11	ONCOGENE			English	Article						WWP1; ErbB2; EGFR; RNF11; PY motif; WW domain	GROWTH-FACTOR RECEPTOR; MEDIATES UBIQUITINATION; BREAST-CANCER; DEGRADATION; RNF11; TARGET; MONOUBIQUITINATION; LOCALIZATION; MECHANISMS; INTERACTS	The WW domain containing E3 ubiquitin protein ligase 1 (WWP1) is a homologous to the E6-associated protein C terminus-type E3 ligase frequently overexpressed in human prostate and breast cancers due to gene amplification. Previous studies suggest that WWP1 promotes cell proliferation and survival; however, the mechanism of WWP1 action is still poorly understood. Here, we showed that WWP1 upregulates and maintains erythroblastic leukemia viral oncogene homolog 2 (ErbB2) and epithelial growth factor receptor (EGFR) in multiple cell lines. WWP1 depletion dramatically attenuates the EGF-induced ERK phosphorylation. WWP1 forms a protein complex with RING finger protein 11 (RNF11), a negative regulator of ErbB2 and EGFR. The protein protein interaction is through the first and third WW domains of WWP1 and the PY motif of RNF11. Although WWP1 is able to ubiquitinate RNF11 in vitro and in vivo, WWP1 neither targets RNF11 for degradation nor changes RNF11's cellular localization. Importantly, inhibition of RNF11 can rescue WWP1 siRNA-induced ErbB2 and EGFR downregulation and growth arrest. Finally, we demonstrated that RNF11 is overexpressed in a panel of prostate and breast cancer cell lines with WWP1 expression. These findings suggest that WWP1 may promote cell proliferation and survival partially through suppressing RNF11-mediated ErbB2 and EGFR downregulation. Oncogene (2008) 27, 6845-6855; doi: 10.1038/onc.2008.288; published online 25 August 2008	[Chen, C.; Zhou, Z.; Liu, R.; Li, Y.] Albany Med Coll, Ctr Cell Biol & Canc Res, Albany, NY 12208 USA; [Azmi, P. B.; Seth, A. K.] Univ Toronto, Div Mol & Cellular Biol, Sunnybrook Res Inst, Toronto, ON, Canada; [Azmi, P. B.; Seth, A. K.] Univ Toronto, Dept Lab Med & Pathobiol, Toronto, ON, Canada	Albany Medical College; University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; University of Toronto	Chen, C (corresponding author), Albany Med Coll, Ctr Cell Biol & Canc Res, MS355,Mail Code 165,47 New Scotland Ave, Albany, NY 12208 USA.	chenc@mail.amc.edu			American Cancer Society; Department of Defense Prostate Cancer Research Program [W81XWH-07-1-0191]; Susan G Komen Breast Cancer Foundation [BCTR0503705]; Canadian Breast Cancer Research Alliance special program	American Cancer Society(American Cancer Society); Department of Defense Prostate Cancer Research Program(United States Department of Defense); Susan G Komen Breast Cancer Foundation(Susan G. Komen Breast Cancer Foundation); Canadian Breast Cancer Research Alliance special program	We thank Dr Roger Y Tsien for the mCherry vector. This work was supported in part by a grant from American Cancer Society (Chen C), a grant from the Department of Defense Prostate Cancer Research Program (W81XWH-07-1-0191, Chen C), a grant (BCTR0503705) from the Susan G Komen Breast Cancer Foundation (Chen C), and from the Canadian Breast Cancer Research Alliance special program grant on metastasis to Arun Seth.	Anderson LR, 2007, J NEUROPATH EXP NEUR, V66, P955, DOI 10.1097/nen.0b013e3181567f17; Angers A, 2004, J BIOL CHEM, V279, P11471, DOI 10.1074/jbc.M309934200; Azmi P, 2005, EUR J CANCER, V41, P2549, DOI 10.1016/j.ejca.2005.08.020; Burger A, 2006, NEOPLASIA, V8, P689, DOI 10.1593/neo.06469; Chen C, 2007, ONCOGENE, V26, P2386, DOI 10.1038/sj.onc.1210021; Chen C, 2007, INT J CANCER, V121, P2834; Chen C, 2007, CANCER METAST REV, V26, P587, DOI 10.1007/s10555-007-9091-x; Chen CS, 2005, J BIOL CHEM, V280, P41553, DOI 10.1074/jbc.M506183200; Courbard JR, 2002, J BIOL CHEM, V277, P45267, DOI 10.1074/jbc.M206460200; Flasza M, 2006, MOL MEMBR BIOL, V23, P269, DOI 10.1080/09687860600665010; Hoeller D, 2006, NAT CELL BIOL, V8, P163, DOI 10.1038/ncb1354; Jones DC, 2006, SCIENCE, V312, P1223, DOI 10.1126/science.1126313; Katz M, 2002, TRAFFIC, V3, P740, DOI 10.1034/j.1600-0854.2002.31006.x; Kitching R, 2003, BBA-MOL BASIS DIS, V1639, P104, DOI 10.1016/j.bbadis.2003.07.001; Komuro A, 2004, ONCOGENE, V23, P6914, DOI 10.1038/sj.onc.1207885; Laine A, 2007, ONCOGENE, V26, P1477, DOI 10.1038/sj.onc.1209924; Li HX, 2004, ONCOGENE, V23, P1801, DOI 10.1038/sj.onc.1207319; Magnifico A, 2003, J BIOL CHEM, V278, P43169, DOI 10.1074/jbc.M308009200; Marchese A, 2003, DEV CELL, V5, P709, DOI 10.1016/S1534-5807(03)00321-6; Martin-Serrano J, 2005, J CELL BIOL, V168, P89, DOI 10.1083/jcb.200408155; Moren A, 2005, J BIOL CHEM, V280, P22115, DOI 10.1074/jbc.M414027200; Mosser EA, 1998, BIOCHEMISTRY-US, V37, P13686, DOI 10.1021/bi981310l; Murdaca J, 2004, J BIOL CHEM, V279, P26754, DOI 10.1074/jbc.M311802200; Plant PJ, 1997, J BIOL CHEM, V272, P32329, DOI 10.1074/jbc.272.51.32329; Qiu L, 2000, J BIOL CHEM, V275, P35734, DOI 10.1074/jbc.M007300200; Rual JF, 2005, NATURE, V437, P1173, DOI 10.1038/nature04209; Seo SR, 2004, EMBO J, V23, P3780, DOI 10.1038/sj.emboj.7600398; Shaner NC, 2004, NAT BIOTECHNOL, V22, P1567, DOI 10.1038/nbt1037; Shen R, 2006, J BIOL CHEM, V281, P3569, DOI 10.1074/jbc.M506761200; Subramaniam V, 2003, BRIT J CANCER, V89, P1538, DOI 10.1038/sj.bjc.6601301; Vecchione A, 2003, MOL CELL BIOL, V23, P3363, DOI 10.1128/MCB.23.9.3363-3372.2003; Verdecia MA, 2003, MOL CELL, V11, P249, DOI 10.1016/S1097-2765(02)00774-8; Wang SZE, 2006, CANCER CELL, V10, P25, DOI 10.1016/j.ccr.2006.05.023; Woelk T, 2006, NAT CELL BIOL, V8, P1246, DOI 10.1038/ncb1484; Yarden Y, 2001, EUR J CANCER, V37, pS3; Zhang XL, 2004, BIOCHEM BIOPH RES CO, V316, P139, DOI 10.1016/j.bbrc.2004.02.033	36	39	44	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 20	2008	27	54					6845	6855		10.1038/onc.2008.288	http://dx.doi.org/10.1038/onc.2008.288			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	375IS	18724389				2022-12-28	WOS:000261108000005
J	Pene-Dumitrescu, T; Peterson, LF; Donato, NJ; Smithgall, TE				Pene-Dumitrescu, T.; Peterson, L. F.; Donato, N. J.; Smithgall, T. E.			An inhibitor-resistant mutant of Hck protects CML cells against the antiproliferative and apoptotic effects of the broad-spectrum Src family kinase inhibitor A-419259	ONCOGENE			English	Article						Bcr-Abl; CML; Hck; Stat5; pyrrolo-pyrimidine; Src-family kinase inhibitor	CHRONIC MYELOGENOUS LEUKEMIA; BCR-ABL ONCOGENE; CHRONIC MYELOID-LEUKEMIA; TYROSINE KINASE; IMATINIB MESYLATE; SH3 DOMAIN; PHOSPHATIDYLINOSITOL 3-KINASE; PHILADELPHIA-CHROMOSOME; LYMPHOBLASTIC-LEUKEMIA; HEMATOPOIETIC-CELLS	Chronic myelogenous leukemia (CML) is driven by Bcr-Abl, a constitutively active protein-tyrosine kinase that stimulates proliferation and survival of myeloid progenitors. Global inhibition of myeloid Src family kinase (SFK) activity with the broad-spectrum pyrrolo-pyrimidine inhibitor, A-419259, blocks proliferation and induces apoptosis in CML cell lines, suggesting that transformation by Bcr-Abl requires SFK activity. However, the contribution of Hck and other individual SFKs to Bcr-Abl signaling is less clear. Here, we developed an A-419259-resistant mutant of Hck by replacing the gatekeeper residue (Thr-338; c-Src numbering) in the inhibitor-binding site with a bulkier methionine residue (Hck-T338M). This substitution reduced Hck sensitivity to A-419259 by more than 30-fold without significantly affecting kinase activity in vitro. Expression of Hck-T338M protected K-562 CML cells and Bcr-Abl-transformed TF-1 myeloid cells from the apoptotic and antiproliferative effects of A-419259. These effects correlated with persistence of Hck-T338M kinase activity in the presence of the compound, and were accompanied by sustained Erk and Stat5 activation. In contrast, control cells expressing equivalent levels of wild-type Hck retained sensitivity to the inhibitor. We also show for the first time that A-419259 induces cell-cycle arrest and apoptosis in primary CD34(+) CML cells with equal potency to imatinib. These data suggest that Hck has a nonredundant function as a key downstream signaling partner for Bcr-Abl and may represent a potential drug target in CML.	[Pene-Dumitrescu, T.; Smithgall, T. E.] Univ Pittsburgh, Sch Med, Dept Mol Genet & Biochem, Pittsburgh, PA 15261 USA; [Peterson, L. F.; Donato, N. J.] Univ Michigan, Dept Internal Med, Div Hematol Oncol, Ann Arbor, MI 48109 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; University of Michigan System; University of Michigan	Smithgall, TE (corresponding author), Univ Pittsburgh, Sch Med, Dept Mol Genet & Biochem, E1240 Biomed Sci Tower, Pittsburgh, PA 15261 USA.	tsmithga@pitt.edu			National Institutes of Health [CA101828, GM077629]; NATIONAL CANCER INSTITUTE [R01CA101828] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM077629] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	This work was supported by grants from the National Institutes of Health (CA101828 and GM077629 to TES). We thank Dr David Calderwood of the Abbott Bioresearch Center for the generous gift of the Src family kinase inhibitor, A-419259 and Dr Elisabeth Buchdunger of Novartis, Inc. for providing imatinib mesylate.	Abram CL, 2000, EXP CELL RES, V254, P1, DOI 10.1006/excr.1999.4732; BEN-NERIAH Y, 1986, SCIENCE, V233, P212, DOI 10.1126/science.3460176; Bhatia R, 2003, BLOOD, V101, P4701, DOI 10.1182/blood-2002-09-2780; Bishop AC, 2000, NATURE, V407, P395, DOI 10.1038/35030148; Blencke S, 2004, CHEM BIOL, V11, P691, DOI 10.1016/j.chembiol.2004.02.029; Blencke S, 2003, J BIOL CHEM, V278, P15435, DOI 10.1074/jbc.M211158200; Boggon TJ, 2004, ONCOGENE, V23, P7918, DOI 10.1038/sj.onc.1208081; Briggs SD, 1997, J BIOL CHEM, V272, P17899, DOI 10.1074/jbc.272.29.17899; Briggs SD, 1999, J BIOL CHEM, V274, P26579, DOI 10.1074/jbc.274.37.26579; Carlesso N, 1996, J EXP MED, V183, P811, DOI 10.1084/jem.183.3.811; Cools J, 2003, NEW ENGL J MED, V348, P1201, DOI 10.1056/NEJMoa025217; Copland M, 2006, BLOOD, V107, P4532, DOI 10.1182/blood-2005-07-2947; Cortes J, 2004, BLOOD, V104, P2204, DOI 10.1182/blood-2004-04-1335; Dai Y, 2004, J BIOL CHEM, V279, P34227, DOI 10.1074/jbc.M402290200; DALEY GQ, 1990, SCIENCE, V247, P824, DOI 10.1126/science.2406902; DanhauserRiedl S, 1996, CANCER RES, V56, P3589; Das J, 2006, J MED CHEM, V49, P6819, DOI 10.1021/jm060727j; de Groot Rolf P., 2000, Molecular Cell Biology Research Communications, V3, P299, DOI 10.1006/mcbr.2000.0231; Donato NJ, 2004, CANCER RES, V64, P672, DOI 10.1158/0008-5472.CAN-03-1484; Eyers PA, 1998, CHEM BIOL, V5, P321, DOI 10.1016/S1074-5521(98)90170-3; Gesbert F, 2000, BLOOD, V96, P2269, DOI 10.1182/blood.V96.6.2269.h8002269_2269_2276; GOGA A, 1995, CELL, V82, P981, DOI 10.1016/0092-8674(95)90277-5; Gorre ME, 2001, SCIENCE, V293, P876, DOI 10.1126/science.1062538; HARRISONFINDIK D, 1995, ONCOGENE, V10, P1385; Holtz MS, 2005, LEUKEMIA, V19, P1034, DOI 10.1038/sj.leu.2403724; Hoover RR, 2001, ONCOGENE, V20, P5826, DOI 10.1038/sj.onc.1204549; Hu YG, 2004, NAT GENET, V36, P453, DOI 10.1038/ng1343; Kantarjian H, 2002, NEW ENGL J MED, V346, P645, DOI 10.1056/NEJMoa011573; Kantarjian HM, 2007, CLIN CANCER RES, V13, P1089, DOI 10.1158/1078-0432.CCR-06-2147; KELLIHER MA, 1990, P NATL ACAD SCI USA, V87, P6649, DOI 10.1073/pnas.87.17.6649; KITAMURA T, 1989, J CELL PHYSIOL, V140, P323, DOI 10.1002/jcp.1041400219; Klejman A, 2002, EMBO J, V21, P5766, DOI 10.1093/emboj/cdf562; Kobayashi S, 2005, NEW ENGL J MED, V352, P786, DOI 10.1056/NEJMoa044238; Lerner EC, 2005, J BIOL CHEM, V280, P40832, DOI 10.1074/jbc.M508782200; Lerner EC, 2002, NAT STRUCT BIOL, V9, P365, DOI 10.1038/nsb782; Lionberger JM, 2000, J BIOL CHEM, V275, P18581, DOI 10.1074/jbc.C000126200; Liu Y, 1998, BIOORGAN MED CHEM, V6, P1219, DOI 10.1016/S0968-0896(98)00099-6; Liu Y, 1999, CHEM BIOL, V6, P671, DOI 10.1016/S1074-5521(99)80118-5; LUGO TG, 1989, MOL CELL BIOL, V9, P1263, DOI 10.1128/MCB.9.3.1263; Martinelli G, 2005, LEUKEMIA, V19, P1872, DOI 10.1038/sj.leu.2403950; Mauro MJ, 2004, LEUKEMIA RES, V28, pS71, DOI 10.1016/j.leukres.2003.10.017; MCLAUGHLIN J, 1987, P NATL ACAD SCI USA, V84, P6558, DOI 10.1073/pnas.84.18.6558; Melnick JS, 2006, P NATL ACAD SCI USA, V103, P3153, DOI 10.1073/pnas.0511292103; Meyn MA, 2006, J BIOL CHEM, V281, P30907, DOI 10.1074/jbc.M605902200; Million RP, 2000, BLOOD, V96, P664; Nakajima A, 2001, LEUKEMIA, V15, P989, DOI 10.1038/sj.leu.2402137; Neshat MS, 2000, MOL CELL BIOL, V20, P1179, DOI 10.1128/MCB.20.4.1179-1186.2000; Olivieri A, 2007, ANN ONCOL, V18, P42, DOI 10.1093/annonc/mdm223; PENDERGAST AM, 1993, CELL, V75, P175, DOI 10.1016/S0092-8674(05)80094-7; Porter M, 2000, J BIOL CHEM, V275, P2721, DOI 10.1074/jbc.275.4.2721; Ptasznik A, 2004, NAT MED, V10, P1187, DOI 10.1038/nm1127; Raffel GD, 1996, J BIOL CHEM, V271, P4640; Ren RB, 2002, ONCOGENE, V21, P8629, DOI 10.1038/sj.onc.1206090; ROWLEY JD, 1973, NATURE, V243, P290, DOI 10.1038/243290a0; Sattler M, 2002, CANCER CELL, V1, P479, DOI 10.1016/S1535-6108(02)00074-0; Sattler M, 1996, ONCOGENE, V12, P839; Sawyers CL, 1999, NEW ENGL J MED, V340, P1330, DOI 10.1056/NEJM199904293401706; Schindler T, 1999, MOL CELL, V3, P639, DOI 10.1016/S1097-2765(00)80357-3; Schreiner SJ, 2002, J BIOL CHEM, V277, P45680, DOI 10.1074/jbc.M204255200; Shuai K, 1996, ONCOGENE, V13, P247; Skorski T, 1997, EMBO J, V16, P6151, DOI 10.1093/emboj/16.20.6151; Smith KM, 2003, MOL CELL, V12, P27, DOI 10.1016/S1097-2765(03)00274-0; Tamborini E, 2004, GASTROENTEROLOGY, V127, P294, DOI 10.1053/j.gastro.2004.02.021; Trible RP, 2006, J BIOL CHEM, V281, P27029, DOI 10.1074/jbc.M601128200; Warmuth M, 1997, J BIOL CHEM, V272, P33260, DOI 10.1074/jbc.272.52.33260; Wilson MB, 2002, ONCOGENE, V21, P8075, DOI 10.1038/sj.onc.1206008; Wu J, 2008, J NATL CANCER I, V100, P926, DOI 10.1093/jnci/djn188; Xu WQ, 1999, MOL CELL, V3, P629, DOI 10.1016/S1097-2765(00)80356-1; Zhang XW, 2001, MOL CELL BIOL, V21, P840, DOI 10.1128/MCB.21.3.840-853.2001; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	70	31	37	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV	2008	27	56					7055	7069		10.1038/onc.2008.330	http://dx.doi.org/10.1038/onc.2008.330			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	376PQ	18794796	Green Accepted			2022-12-28	WOS:000261195900001
J	Nausch, N; Cerwenka, A				Nausch, N.; Cerwenka, A.			NKG2D ligands in tumor immunity	ONCOGENE			English	Review						NKG2D; RAE-1; MIC-A; ULBP; NK cells; tumor immunology	NATURAL-KILLER-CELL; I-RELATED CHAIN; V-DELTA-1 T-LYMPHOCYTES; NK CELLS; CUTTING EDGE; DENDRITIC CELLS; DOWN-REGULATION; CYTOTOXIC RESPONSES; MEDIATED REJECTION; SURFACE EXPRESSION	The activating receptor NKG2D (natural-killer group 2, member D) and its ligands play an important role in the NK, gamma delta(+) and CD8(+) T-cell-mediated immune response to tumors. Ligands for NKG2D are rarely detectable on the surface of healthy cells and tissues, but are frequently expressed by tumor cell lines and in tumor tissues. It is evident that the expression levels of these ligands on target cells have to be tightly regulated to allow immune cell activation against tumors, but at the same time avoid destruction of healthy tissues. Importantly, it was recently discovered that another safeguard mechanism controlling activation via the receptor NKG2D exists. It was shown that NKG2D signaling is coupled to the IL-15 receptor pathway in a cell-specific manner suggesting that priming of NKG2D-mediated activation depends on the cellular microenvironment and the distinct cellular context. This review will provide a broad overview of our up-to-date knowledge of the NKG2D receptor and its ligands in the context of tumor immunology. Strategies to amplify NKG2D-mediated antitumor responses and counteract tumor immune escape mechanisms will be discussed.	[Nausch, N.; Cerwenka, A.] German Canc Res Ctr, Div Innate Immun, D-69120 Heidelberg, Germany	Helmholtz Association; German Cancer Research Center (DKFZ)	Cerwenka, A (corresponding author), German Canc Res Ctr, Div Innate Immun, Neuenheimer Feld 280, D-69120 Heidelberg, Germany.	a.cerwenka@dkfz.de	Nausch, Norman/M-4526-2019; Nausch, Norman/L-9276-2013	Nausch, Norman/0000-0002-9704-2148; Nausch, Norman/0000-0002-9704-2148; Cerwenka, Adelheid/0000-0001-6977-3536	Marie Curie Excellent; Deutsche Jose Carreras Leukamie Stiftung; German-Israel DKFZ/MOST; Boehringer Ingelheim Fonds	Marie Curie Excellent(European Commission); Deutsche Jose Carreras Leukamie Stiftung; German-Israel DKFZ/MOST(German-Israeli Foundation for Scientific Research and Development); Boehringer Ingelheim Fonds(Boehringer Ingelheim)	We thank Professor Lewis Lanier and Ioanna Galani for critically reading the paper. The work is supported by a Marie Curie Excellent Grant, Deutsche Jose Carreras Leukamie Stiftung, German-Israel DKFZ/MOST cooperation and Boehringer Ingelheim Fonds. We want to apologize to all authors whose work could not be cited in this review because of space limitations.	Allez M, 2007, GASTROENTEROLOGY, V132, P2346, DOI 10.1053/j.gastro.2007.03.025; Angel P, 2001, ONCOGENE, V20, P2413, DOI 10.1038/sj.onc.1204380; Armeanu S, 2005, CANCER RES, V65, P6321, DOI 10.1158/0008-5472.CAN-04-4252; Bacon L, 2004, J IMMUNOL, V173, P1078, DOI 10.4049/jimmunol.173.2.1078; Bahram S, 2005, CURR OPIN IMMUNOL, V17, P505, DOI 10.1016/j.coi.2005.07.016; BAHRAM S, 1994, P NATL ACAD SCI USA, V91, P6259, DOI 10.1073/pnas.91.14.6259; Barnett B, 2005, AM J REPROD IMMUNOL, V54, P369, DOI 10.1111/j.1600-0897.2005.00330.x; Bauer S, 1999, SCIENCE, V285, P727, DOI 10.1126/science.285.5428.727; Boissel N, 2006, J IMMUNOL, V176, P5108, DOI 10.4049/jimmunol.176.8.5108; Borchers MT, 2006, INFECT IMMUN, V74, P2578, DOI 10.1128/IAI.74.5.2578-2586.2006; Bravo MJ, 2007, TISSUE ANTIGENS, V69, P358, DOI 10.1111/j.1399-0039.2007.00823.x; Bryceson YT, 2006, BLOOD, V107, P159, DOI 10.1182/blood-2005-04-1351; Bui JD, 2006, J IMMUNOL, V176, P905, DOI 10.4049/jimmunol.176.2.905; Burgess SJ, 2006, J IMMUNOL, V176, P1490, DOI 10.4049/jimmunol.176.3.1490; Cao W, 2007, J BIOL CHEM, V282, P18922, DOI 10.1074/jbc.M702504200; Carayannopoulos LN, 2002, J IMMUNOL, V169, P4079, DOI 10.4049/jimmunol.169.8.4079; Carbone E, 2005, BLOOD, V105, P251, DOI 10.1182/blood-2004-04-1422; Carlsten M, 2007, CANCER RES, V67, P1317, DOI 10.1158/0008-5472.CAN-06-2264; Castriconi R, 2003, P NATL ACAD SCI USA, V100, P4120, DOI 10.1073/pnas.0730640100; Castriconi R, 2007, EUR J IMMUNOL, V37, P3190, DOI 10.1002/eji.200737546; Catellani S, 2007, BLOOD, V109, P2078, DOI 10.1182/blood-2006-06-028985; Cerboni C, 2007, BLOOD, V110, P606, DOI 10.1182/blood-2006-10-052720; Cerwenka A, 2000, IMMUNITY, V12, P721, DOI 10.1016/S1074-7613(00)80222-8; Cerwenka A, 2001, P NATL ACAD SCI USA, V98, P11521, DOI 10.1073/pnas.201238598; Cerwenka A, 2001, IMMUNOL REV, V181, P158, DOI 10.1034/j.1600-065X.2001.1810113.x; Chalupny NJ, 2003, BIOCHEM BIOPH RES CO, V305, P129, DOI 10.1016/S0006-291X(03)00714-9; Chan CW, 2006, NAT MED, V12, P207, DOI 10.1038/nm1352; Chang CW, 1999, J IMMUNOL, V163, P4651; Choi BK, 2007, CANCER RES, V67, P8891, DOI 10.1158/0008-5472.CAN-07-1056; Cosman D, 2001, IMMUNITY, V14, P123, DOI 10.1016/S1074-7613(01)00095-4; Coudert JD, 2005, BLOOD, V106, P1711, DOI 10.1182/blood-2005-03-0918; Dasgupta S, 2005, J IMMUNOL, V175, P5541, DOI 10.4049/jimmunol.175.8.5541; Diefenbach A, 2000, NAT IMMUNOL, V1, P119, DOI 10.1038/77793; Diefenbach A, 2003, EUR J IMMUNOL, V33, P381, DOI 10.1002/immu.200310012; Diefenbach A, 2002, NAT IMMUNOL, V3, P1142, DOI 10.1038/ni858; Diefenbach A, 2001, NATURE, V413, P165, DOI 10.1038/35093109; Diermayr S, 2008, BLOOD, V111, P1428, DOI 10.1182/blood-2007-07-101311; Doubrovina ES, 2003, J IMMUNOL, V171, P6891, DOI 10.4049/jimmunol.171.12.6891; Eagle RA, 2007, NAT REV IMMUNOL, V7, P737, DOI 10.1038/nri2144; Ehrlich LIR, 2005, J IMMUNOL, V174, P1922, DOI 10.4049/jimmunol.174.4.1922; Eisele G, 2006, BRAIN, V129, P2416, DOI 10.1093/brain/awl205; El-Sherbiny YM, 2007, CANCER RES, V67, P8444, DOI 10.1158/0008-5472.CAN-06-4230; Friese MA, 2004, CANCER RES, V64, P7596, DOI 10.1158/0008-5472.CAN-04-1627; Friese MA, 2003, CANCER RES, V63, P8996; Garrity D, 2005, P NATL ACAD SCI USA, V102, P7641, DOI 10.1073/pnas.0502439102; Gasser S, 2005, NATURE, V436, P1186, DOI 10.1038/nature03884; Germain C, 2005, CLIN CANCER RES, V11, P7516, DOI 10.1158/1078-0432.CCR-05-0872; Ghiringhelli F, 2005, J EXP MED, V202, P1075, DOI 10.1084/jem.20051511; Gilfillan S, 2002, NAT IMMUNOL, V3, P1150, DOI 10.1038/ni857; Girardi M, 2001, SCIENCE, V294, P605, DOI 10.1126/science.1063916; Glienke J, 1998, IMMUNOGENETICS, V48, P163, DOI 10.1007/s002510050420; Groh V, 2003, P NATL ACAD SCI USA, V100, P9452, DOI 10.1073/pnas.1632807100; Groh V, 1999, P NATL ACAD SCI USA, V96, P6879, DOI 10.1073/pnas.96.12.6879; Groh V, 2002, NATURE, V419, P734, DOI 10.1038/nature01112; Groh V, 1996, P NATL ACAD SCI USA, V93, P12445, DOI 10.1073/pnas.93.22.12445; Groh V, 2006, NAT IMMUNOL, V7, P755, DOI 10.1038/ni1350; Guerra N, 2008, IMMUNITY, V28, P571, DOI 10.1016/j.immuni.2008.02.016; Guilloton F, 2005, LEUKEMIA, V19, P2206, DOI 10.1038/sj.leu.2403952; Gumireddy K, 2007, P NATL ACAD SCI USA, V104, P6696, DOI 10.1073/pnas.0701145104; Hamerman JA, 2005, CURR OPIN IMMUNOL, V17, P29, DOI 10.1016/j.coi.2004.11.001; Hamerman JA, 2004, J IMMUNOL, V172, P2001, DOI 10.4049/jimmunol.172.4.2001; Ho EL, 1998, P NATL ACAD SCI USA, V95, P6320, DOI 10.1073/pnas.95.11.6320; Holdenrieder S, 2006, INT J CANCER, V118, P684, DOI 10.1002/ijc.21382; Holdenrieder S, 2006, CANCER IMMUNOL IMMUN, V55, P1584, DOI 10.1007/s00262-006-0167-1; Horng T, 2007, NAT IMMUNOL, V8, P1345, DOI 10.1038/ni1524; HOUCHINS JP, 1991, J EXP MED, V173, P1017, DOI 10.1084/jem.173.4.1017; Hue S, 2004, IMMUNITY, V21, P367, DOI 10.1016/j.immuni.2004.06.018; Jack A, 2006, SURG ONCOL, V15, P13, DOI 10.1016/j.suronc.2006.05.003; Jamieson AM, 2002, IMMUNITY, V17, P19, DOI 10.1016/S1074-7613(02)00333-3; Jinushi M, 2005, J HEPATOL, V43, P1013, DOI 10.1016/j.jhep.2005.05.026; Jinushi M, 2003, INT J CANCER, V104, P354, DOI 10.1002/ijc.10966; Jinushi M, 2003, J IMMUNOL, V170, P1249, DOI 10.4049/jimmunol.170.3.1249; Jinushi M, 2008, P NATL ACAD SCI USA, V105, P1285, DOI 10.1073/pnas.0711293105; Kaiser BK, 2007, NATURE, V447, P482, DOI 10.1038/nature05768; Kriegeskorte AK, 2005, P NATL ACAD SCI USA, V102, P11805, DOI 10.1073/pnas.0502026102; Lee JC, 2004, J IMMUNOL, V172, P7335, DOI 10.4049/jimmunol.172.12.7335; Li J, 2005, EUR J IMMUNOL, V35, P439, DOI 10.1002/eji.200425621; Liu CR, 2007, BLOOD, V109, P4336, DOI 10.1182/blood-2006-09-046201; Lucas M, 2007, IMMUNITY, V26, P503, DOI 10.1016/j.immuni.2007.03.006; Maccalli C, 2003, EUR J IMMUNOL, V33, P2033, DOI 10.1002/eji.200323909; Marten A, 2006, INT J CANCER, V119, P2359, DOI 10.1002/ijc.22186; Malarkannan S, 1998, J IMMUNOL, V161, P3501; Meresse B, 2004, IMMUNITY, V21, P357, DOI 10.1016/j.immuni.2004.06.020; Mistry AR, 2007, IMMUNOLOGY, V121, P439, DOI 10.1111/j.1365-2567.2007.02652.x; Molinero LL, 2004, J IMMUNOL, V173, P5583, DOI 10.4049/jimmunol.173.9.5583; Molinero LL, 2002, J LEUKOCYTE BIOL, V71, P791; Morgan RA, 2006, SCIENCE, V314, P126, DOI 10.1126/science.1129003; Nausch N, 2006, J IMMUNOL, V176, P7, DOI 10.4049/jimmunol.176.1.7; Nedvetzki S, 2007, BLOOD, V109, P3776, DOI 10.1182/blood-2006-10-052977; Nomura M, 1996, J BIOCHEM-TOKYO, V120, P987; Nowbakht P, 2005, BLOOD, V105, P3615, DOI 10.1182/blood-2004-07-2585; O'Callaghan CA, 2001, IMMUNITY, V15, P201, DOI 10.1016/S1074-7613(01)00187-X; Ogasawara K, 2005, J CLIN IMMUNOL, V25, P534, DOI 10.1007/s10875-005-8786-4; Ogasawara K, 2005, NAT IMMUNOL, V6, P938, DOI 10.1038/ni1236; Oppenheim DE, 2005, NAT IMMUNOL, V6, P928, DOI 10.1038/ni1239; Paloneva J, 2000, NAT GENET, V25, P357, DOI 10.1038/77153; Pappworth IY, 2007, J VIROL, V81, P474, DOI 10.1128/JVI.01777-06; Pende D, 2002, CANCER RES, V62, P6178; Pillarisetty VG, 2004, J IMMUNOL, V172, P1009, DOI 10.4049/jimmunol.172.2.1009; Poggi A, 2004, CANCER RES, V64, P9172, DOI 10.1158/0008-5472.CAN-04-2417; Rabinovich B, 2006, IMMUNOGENETICS, V58, P81, DOI 10.1007/s00251-005-0078-x; Rabinovich BA, 2003, J IMMUNOL, V170, P3572, DOI 10.4049/jimmunol.170.7.3572; Radosavljevic M, 2002, GENOMICS, V79, P114, DOI 10.1006/geno.2001.6673; Raffaghello L, 2004, NEOPLASIA, V6, P558, DOI 10.1593/neo.04316; Rausch A, 2006, EUR J IMMUNOL, V36, P1156, DOI 10.1002/eji.200535290; Roberts AI, 2001, J IMMUNOL, V167, P5527, DOI 10.4049/jimmunol.167.10.5527; Roda-Navarro P, 2007, FASEB J, V21, P1636, DOI 10.1096/fj.06-7488rev; Roda-Navarro P, 2006, P NATL ACAD SCI USA, V103, P11258, DOI 10.1073/pnas.0600721103; Rohner A, 2007, LEUKEMIA RES, V31, P1393, DOI 10.1016/j.leukres.2007.02.020; Roos WP, 2006, TRENDS MOL MED, V12, P440, DOI 10.1016/j.molmed.2006.07.007; Rosen DB, 2004, J IMMUNOL, V173, P2470, DOI 10.4049/jimmunol.173.4.2470; Routes JM, 2005, J EXP MED, V202, P1477, DOI 10.1084/jem.20050240; Salih HR, 2006, HUM IMMUNOL, V67, P188, DOI 10.1016/j.humimm.2006.02.008; Salih HR, 2003, BLOOD, V102, P1389, DOI 10.1182/blood-2003-01-0019; Salih HR, 2002, J IMMUNOL, V169, P4098, DOI 10.4049/jimmunol.169.8.4098; Schrambach S, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000518; Siren J, 2004, J GEN VIROL, V85, P2357, DOI 10.1099/vir.0.80105-0; Smyth MJ, 2004, J EXP MED, V200, P1325, DOI 10.1084/jem.20041522; Smyth MJ, 2006, J IMMUNOL, V176, P1582, DOI 10.4049/jimmunol.176.3.1582; Smyth MJ, 2005, J EXP MED, V202, P583, DOI 10.1084/jem.20050994; Song H, 2006, CELL IMMUNOL, V242, P39, DOI 10.1016/j.cellimm.2006.09.002; Song H, 2006, CELL IMMUNOL, V239, P22, DOI 10.1016/j.cellimm.2006.03.002; Steinle A, 2001, IMMUNOGENETICS, V53, P279, DOI 10.1007/s002510100325; Strong RK, 2002, MOL IMMUNOL, V38, P1029, DOI 10.1016/S0161-5890(02)00032-9; Taieb J, 2006, NAT MED, V12, P214, DOI 10.1038/nm1356; Takada A, 2008, J IMMUNOL, V180, P1678, DOI 10.4049/jimmunol.180.3.1678; Takaki R, 2005, J IMMUNOL, V175, P2167, DOI 10.4049/jimmunol.175.4.2167; Tallman MS, 2006, BEST PRACT RES CL HA, V19, P311, DOI 10.1016/j.beha.2005.11.006; Teng MWL, 2005, J BIOL CHEM, V280, P38235, DOI 10.1074/jbc.M505331200; Tieng V, 2002, P NATL ACAD SCI USA, V99, P2977, DOI 10.1073/pnas.032668099; Turkcapar N, 2007, RHEUMATOL INT, V27, P545, DOI 10.1007/s00296-006-0255-8; Venkataraman GM, 2007, J IMMUNOL, V178, P961, DOI 10.4049/jimmunol.178.2.961; Verneris MR, 2004, BLOOD, V103, P3065, DOI 10.1182/blood-2003-06-2125; Vetter CS, 2002, J INVEST DERMATOL, V118, P600, DOI 10.1046/j.1523-1747.2002.01700.x; Vilarinho S, 2007, P NATL ACAD SCI USA, V104, P18187, DOI 10.1073/pnas.0708968104; Vosshenrich CAJ, 2007, J EXP MED, V204, P2569, DOI 10.1084/jem.20071451; Waldhauer I, 2006, CANCER RES, V66, P2520, DOI 10.1158/0008-5472.CAN-05-2520; Ward J, 2007, BLOOD, V110, P1207, DOI 10.1182/blood-2006-06-028175; Watson NFS, 2006, INT J CANCER, V118, P1445, DOI 10.1002/ijc.21510; Weizman N, 2003, J BIOL CHEM, V278, P6741, DOI 10.1074/jbc.M211168200; Wiemann K, 2005, J IMMUNOL, V175, P720, DOI 10.4049/jimmunol.175.2.720; Wu J, 1999, SCIENCE, V285, P730, DOI 10.1126/science.285.5428.730; Yokoyama WM, 2002, NATURE, V419, P679, DOI 10.1038/419679a; Zhang C, 2005, INT IMMUNOPHARMACOL, V5, P1057, DOI 10.1016/j.intimp.2005.02.003; Zhang J, 2004, HAEMATOLOGICA, V89, P338; Zhang T, 2005, BLOOD, V106, P1544, DOI 10.1182/blood-2004-11-4365; Zhang T, 2007, CANCER RES, V67, P11029, DOI 10.1158/0008-5472.CAN-07-2251; Zhou H, 2006, BLOOD, V107, P3251, DOI 10.1182/blood-2005-10-4231; Zhou H, 2005, P NATL ACAD SCI USA, V102, P10846, DOI 10.1073/pnas.0502208102; Zou ZH, 1996, J BIOCHEM-TOKYO, V119, P319	150	295	314	0	30	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 6	2008	27	45					5944	5958		10.1038/onc.2008.272	http://dx.doi.org/10.1038/onc.2008.272			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	355QE	18836475				2022-12-28	WOS:000259722600009
J	Yuan, TL; Cantley, LC				Yuan, T. L.; Cantley, L. C.			PI3K pathway alterations in cancer: variations on a theme	ONCOGENE			English	Review						PI3K; PTEN; HER2; tumorigenesis	EPIDERMAL-GROWTH-FACTOR; PHOSPHOINOSITIDE 3-KINASE PATHWAY; GASTROINTESTINAL STROMAL TUMORS; FACTOR RECEPTOR; PIK3CA MUTATIONS; BREAST-CANCER; LUNG-CANCER; PHOSPHATIDYLINOSITOL-3-OH KINASE; HIGH-FREQUENCY; TRASTUZUMAB RESISTANCE	The high frequency of phosphoinositide 3-kinase (PI3K) pathway alterations in cancer has led to a surge in the development of PI3K inhibitors. Many of these targeted therapies are currently in clinical trials and show great promise for the treatment of PI3K-addicted tumors. These recent developments call for a re-evaluation of the oncogenic mechanisms behind PI3K pathway alterations. This pathway is unique in that every major node is frequently mutated or amplified in a wide variety of solid tumors. Receptor tyrosine kinases upstream of PI3K, the p110 alpha catalytic subunit of PI3K, the downstream kinase, AKT, and the negative regulator, PTEN, are all frequently altered in cancer. In this review, we will examine the oncogenic properties of these genetic alterations to understand whether they are redundant or distinct and propose treatment strategies tailored for these genetic lesions.	[Cantley, L. C.] Harvard Univ, Sch Med, Dept Syst Biol, Boston, MA 02115 USA; Beth Israel Deaconess Med Ctr, Div Signal Transduct, Boston, MA 02215 USA	Harvard University; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center	Cantley, LC (corresponding author), Harvard Univ, Sch Med, Dept Syst Biol, Boston, MA 02115 USA.	lewis_cantley@hms.harvard.edu	Cantley, Lewis C/D-1800-2014	Cantley, Lewis C/0000-0002-1298-7653	National Institutes of Health; Dana-Farber/Harvard Cancer Center SPORE [1P50CA127003-01]; NATIONAL CANCER INSTITUTE [P50CA127003] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM041890] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Dana-Farber/Harvard Cancer Center SPORE; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We thank K Courtney, M Saelzler and C Benes for insightful discussions and critical reading of the paper. This research was supported by funding to LCC from the National Institutes of Health and to TLY from a Dana-Farber/Harvard Cancer Center SPORE (1P50CA127003-01).	Abubaker J, 2008, ONCOGENE, V27, P3539, DOI 10.1038/sj.onc.1211013; Arteaga CL, 2006, CANCER CELL, V9, P421, DOI 10.1016/j.ccr.2006.05.014; Bachman KE, 2004, CANCER BIOL THER, V3, P772, DOI 10.4161/cbt.3.8.994; Barault L, 2008, INT J CANCER, V122, P2255, DOI 10.1002/ijc.23388; Barnes KR, 2008, BIOCONJUGATE CHEM, V19, P130, DOI 10.1021/bc7002204; Bauer S, 2007, ONCOGENE, V26, P7560, DOI 10.1038/sj.onc.1210558; Berns K, 2007, CANCER CELL, V12, P395, DOI 10.1016/j.ccr.2007.08.030; Bissell MJ, 2001, NAT REV CANCER, V1, P46, DOI 10.1038/35094059; Buck E, 2006, MOL CANCER THER, V5, P2676, DOI 10.1158/1535-7163.MCT-06-0166; Cantley LC, 2002, SCIENCE, V296, P1655, DOI 10.1126/science.296.5573.1655; Carpten JD, 2007, NATURE, V448, P439, DOI 10.1038/nature05933; Chen JS, 2008, MOL CANCER THER, V7, P841, DOI 10.1158/1535-7163.MCT-07-0393; Chen ZB, 2005, NATURE, V436, P725, DOI 10.1038/nature03918; Crabbe T, 2007, TRENDS BIOCHEM SCI, V32, P450, DOI 10.1016/j.tibs.2007.09.001; Downward J, 2003, NAT REV CANCER, V3, P11, DOI 10.1038/nrc969; Engelman JA, 2005, P NATL ACAD SCI USA, V102, P3788, DOI 10.1073/pnas.0409773102; Engelman JA, 2007, CLIN CANCER RES, V13, p4637S, DOI 10.1158/1078-0432.CCR-07-0653; Engelman JA, 2007, SCIENCE, V316, P1039, DOI 10.1126/science.1141478; Engelman JA, 2006, NAT REV GENET, V7, P606, DOI 10.1038/nrg1879; Fan QW, 2007, CANCER RES, V67, P7960, DOI 10.1158/0008-5472.CAN-07-2154; Fan QW, 2006, CANCER CELL, V9, P341, DOI 10.1016/j.ccr.2006.03.029; Folkman J, 2007, NAT REV DRUG DISCOV, V6, P273, DOI 10.1038/nrd2115; Fujita T, 2006, BRIT J CANCER, V94, P247, DOI 10.1038/sj.bjc.6602926; Furuyama T, 2004, J BIOL CHEM, V279, P34741, DOI 10.1074/jbc.M314214200; Garlich JR, 2008, CANCER RES, V68, P206, DOI 10.1158/0008-5472.CAN-07-0669; Graupera M, 2008, NATURE, V453, P662, DOI 10.1038/nature06892; Gupta GP, 2006, CELL, V127, P679, DOI 10.1016/j.cell.2006.11.001; Gupta S, 2007, CELL, V129, P957, DOI 10.1016/j.cell.2007.03.051; Hamada K, 2005, GENE DEV, V19, P2054, DOI 10.1101/gad.1308805; Harrington LS, 2004, J CELL BIOL, V166, P213, DOI 10.1083/jcb.200403069; Heinrich MC, 2003, SCIENCE, V299, P708, DOI 10.1126/science.1079666; Hendriks BS, 2003, CANCER RES, V63, P1130; Hirata A, 2005, CANCER RES, V65, P4253, DOI 10.1158/0008-5472.CAN-04-2748; Hirsch E, 2000, SCIENCE, V287, P1049, DOI 10.1126/science.287.5455.1049; Hofer E, 2007, THROMB HAEMOSTASIS, V97, P355, DOI 10.1160/TH06-08-0470; Hollestelle A, 2007, MOL CANCER RES, V5, P195, DOI 10.1158/1541-7786.MCR-06-0263; Howes AL, 2007, MOL CANCER THER, V6, P2505, DOI 10.1158/1535-7163.MCT-06-0698; Huang CH, 2007, SCIENCE, V318, P1744, DOI 10.1126/science.1150799; Ikeda T, 2000, ONCOL REP, V7, P567; Isakoff SJ, 2005, CANCER RES, V65, P10992, DOI 10.1158/0008-5472.CAN-05-2612; Jhawer M, 2008, CANCER RES, V68, P1953, DOI 10.1158/0008-5472.CAN-07-5659; KANG S, 2008, INT J GYNECOL CANC; Kato S, 2007, INT J CANCER, V121, P1771, DOI 10.1002/ijc.22890; Kim JS, 2007, MOL CELL BIOL, V27, P662, DOI 10.1128/MCB.00537-06; Knight ZA, 2006, CELL, V125, P733, DOI 10.1016/j.cell.2006.03.035; Kolsch V, 2008, J CELL SCI, V121, P551, DOI 10.1242/jcs.023333; Kong D, 2007, CANCER SCI, V98, P1638, DOI 10.1111/j.1349-7006.2007.00580.x; Koyasu S, 2003, NAT IMMUNOL, V4, P313, DOI 10.1038/ni0403-313; Li DN, 2007, CANCER CELL, V12, P81, DOI 10.1016/j.ccr.2007.06.005; Lim KH, 2005, CANCER CELL, V8, P381, DOI 10.1016/j.ccr.2005.10.014; Martin-Belmonte F, 2008, CURR OPIN CELL BIOL, V20, P227, DOI 10.1016/j.ceb.2008.01.001; Mellinghoff IK, 2005, NEW ENGL J MED, V353, P2012, DOI 10.1056/NEJMoa051918; Miled N, 2007, SCIENCE, V317, P239, DOI 10.1126/science.1135394; Moasser MM, 2007, ONCOGENE, V26, P6469, DOI 10.1038/sj.onc.1210477; Nagata Y, 2004, CANCER CELL, V6, P117, DOI 10.1016/j.ccr.2004.06.022; Narita Y, 2002, CANCER RES, V62, P6764; Oda K, 2005, CANCER RES, V65, P10669, DOI 10.1158/0008-5472.CAN-05-2620; Ollikainen M, 2007, INT J CANCER, V121, P915, DOI 10.1002/ijc.22768; Perez-Tenorio G, 2007, CLIN CANCER RES, V13, P3577, DOI 10.1158/1078-0432.CCR-06-1609; Ramjaun AR, 2007, CELL CYCLE, V6, P2902, DOI 10.4161/cc.6.23.4996; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; Rommel C, 2007, NAT REV IMMUNOL, V7, P191, DOI 10.1038/nri2036; Saal LH, 2005, CANCER RES, V65, P2554, DOI 10.1158/0008-5472-CAN-04-3913; Salmena L, 2008, CELL, V133, P403, DOI 10.1016/j.cell.2008.04.013; Samuels Y, 2005, CANCER CELL, V7, P561, DOI 10.1016/j.ccr.2005.05.014; Samuels Y, 2004, SCIENCE, V304, P554, DOI 10.1126/science.1096502; Sarkisian CJ, 2007, NAT CELL BIOL, V9, P493, DOI 10.1038/ncb1567; Sauter G, 1996, AM J PATHOL, V148, P1047; SOLTOFF SP, 1994, MOL CELL BIOL, V14, P3550, DOI 10.1128/MCB.14.6.3550; Stephens P, 2004, NATURE, V431, P525, DOI 10.1038/431525b; Stommel JM, 2007, SCIENCE, V318, P287, DOI 10.1126/science.1142946; Suire S, 2002, CURR BIOL, V12, P1068, DOI 10.1016/S0960-9822(02)00933-8; Sun JF, 2005, P NATL ACAD SCI USA, V102, P128, DOI 10.1073/pnas.0403198102; Tokunaga E, 2007, BREAST CANCER RES TR, V101, P249, DOI 10.1007/s10549-006-9295-8; Tornillo L, 2006, J CLIN PATHOL, V59, P557, DOI 10.1136/jcp.2005.031112; Velho S, 2005, EUR J CANCER, V41, P1649, DOI 10.1016/j.ejca.2005.04.022; Walker EH, 2000, MOL CELL, V6, P909, DOI 10.1016/S1097-2765(05)00089-4; Walker EH, 1999, NATURE, V402, P313, DOI 10.1038/46319; Wang MY, 2006, CANCER RES, V66, P7864, DOI 10.1158/0008-5472.CAN-04-4392; Wilhelm SM, 2004, CANCER RES, V64, P7099, DOI 10.1158/0008-5472.CAN-04-1443; Wymann MP, 1996, MOL CELL BIOL, V16, P1722; Yaguchi SI, 2006, JNCI-J NATL CANCER I, V98, P545, DOI 10.1093/jnci/djj133; Yuan H, 2007, CHEM BIOL, V14, P321, DOI 10.1016/j.chembiol.2007.02.007; Zhao L, 2008, P NATL ACAD SCI USA, V105, P2652, DOI 10.1073/pnas.0712169105	85	1375	1466	6	167	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 15	2008	27	41					5497	5510		10.1038/onc.2008.245	http://dx.doi.org/10.1038/onc.2008.245			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	349KW	18794884	Green Accepted			2022-12-28	WOS:000259280700011
J	Rankin, EB; Rha, J; Unger, TL; Wu, CH; Shutt, HP; Johnson, RS; Simon, MC; Keith, B; Haase, VH				Rankin, E. B.; Rha, J.; Unger, T. L.; Wu, C. H.; Shutt, H. P.; Johnson, R. S.; Simon, M. C.; Keith, B.; Haase, V. H.			Hypoxia-inducible factor-2 regulates vascular tumorigenesis in mice	ONCOGENE			English	Article						von Hippel-Lindau (VHL) tumor suppressor; hypoxia-inducible factor (HIF); hemangioma; liver angiogenesis; mouse model; Cre-loxP recombination	HIPPEL-LINDAU-DISEASE; TUMOR-SUPPRESSOR; TARGET GENES; CYCLIN D1; EXPRESSION; HEMANGIOBLASTOMAS; ERYTHROPOIETIN; IDENTIFICATION; INACTIVATION; HIF-2-ALPHA	The von Hippel-Lindau tumor suppressor pVHL regulates the stability of hypoxia-inducible factors (HIF)-1 and-2, oxygen-sensitive basic helix-loop-helix transcription factors, which mediate the hypoxic induction of angiogenic growth factors such as vascular endothelial growth factor. Loss of pVHL function results in constitutive activation of HIF-1 and HIF-2 and is associated with the development of highly vascularized tumors in multiple organs. We have used a conditional gene-targeting approach to investigate the relative contributions of HIF-1 and HIF-2 to VHL-associated vascular tumorigenesis in a mouse model of liver hemangiomas. Here we demonstrate genetically that conditional inactivation of HIF-2 alpha suppressed the development of VHL-associated liver hemangiomas and that angiogenic gene expression in hepatocytes is predominantly regulated by HIF-2 and not by HIF-1. These findings suggest that HIF-2 is the dominant HIF in the pathogenesis of VHL-associated vascular tumors and that pharmacologic targeting of HIF-2 may be an effective strategy for their treatment.	[Rankin, E. B.; Rha, J.; Unger, T. L.; Wu, C. H.; Shutt, H. P.; Haase, V. H.] Univ Penn, Sch Med, Dept Med, Philadelphia, PA 19104 USA; [Johnson, R. S.] Univ Calif San Diego, Div Biol Sci, La Jolla, CA 92093 USA; [Simon, M. C.; Keith, B.] Univ Penn, Sch Med, Abramson Family Canc Res Inst, Philadelphia, PA 19104 USA; [Simon, M. C.; Keith, B.] Univ Penn, Sch Med, Howard Hughes Med Inst, Philadelphia, PA 19104 USA	University of Pennsylvania; University of California System; University of California San Diego; University of Pennsylvania; Pennsylvania Medicine; Howard Hughes Medical Institute; University of Pennsylvania	Haase, VH (corresponding author), Univ Penn, Sch Med, Dept Med, 626 Clinical Res Bldg,415 Curie Blvd, Philadelphia, PA 19104 USA.	vhaase@mail.med.upenn.edu	Simon, Celeste/AAG-3941-2021; Haase, Volker Hans/AAJ-5061-2021; Haase, Volker Hans/A-6758-2013; Johnson, Randall/AAM-1189-2021	Haase, Volker Hans/0000-0002-7051-8994; Johnson, Randall/0000-0002-4084-6639; Rankin, Erinn/0000-0002-2045-2296; Rha, Jennifer/0000-0001-9653-4370	NIH [DK073467, CA100787]; Center for Molecular Studies in Digestive and Liver Disease [P30-DK50306]; Penn Diabetes and Endocrinology Research Center Functional Genomics Core [P30-DK19525]; American Heart Association; NATIONAL CANCER INSTITUTE [R01CA100787] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R21DK073467, P30DK050306, P30DK019525] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Center for Molecular Studies in Digestive and Liver Disease; Penn Diabetes and Endocrinology Research Center Functional Genomics Core; American Heart Association(American Heart Association); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	This work was supported by NIH grant DK073467 and CA100787 (both to VHH), the Center for Molecular Studies in Digestive and Liver Disease (P30-DK50306) and the Penn Diabetes and Endocrinology Research Center Functional Genomics Core (P30-DK19525). EBR was supported by a fellowship grant from the American Heart Association.	Biju MP, 2004, MOL CELL BIOL, V24, P9038, DOI 10.1128/MCB.24.20.9038-9047.2004; Bindra RS, 2002, CANCER RES, V62, P3014; Chavez JC, 2006, J NEUROSCI, V26, P9471, DOI 10.1523/JNEUROSCI.2838-06.2006; Fischer A, 2004, GENE DEV, V18, P901, DOI 10.1101/gad.291004; Flamme I, 1998, AM J PATHOL, V153, P25, DOI 10.1016/S0002-9440(10)65541-1; Gijtenbeek JMM, 2005, J NEURO-ONCOL, V74, P261, DOI 10.1007/s11060-004-7326-z; Gruber M, 2007, P NATL ACAD SCI USA, V104, P2301, DOI 10.1073/pnas.0608382104; Gustafsson MV, 2005, DEV CELL, V9, P617, DOI 10.1016/j.devcel.2005.09.010; Haase VH, 2001, P NATL ACAD SCI USA, V98, P1583, DOI 10.1073/pnas.98.4.1583; Holmquist-Mengelbier L, 2006, CANCER CELL, V10, P413, DOI 10.1016/j.ccr.2006.08.026; Kapitsinou PP, 2008, CELL DEATH DIFFER, V15, P650, DOI 10.1038/sj.cdd.4402313; Maher ER, 1997, MEDICINE, V76, P381, DOI 10.1097/00005792-199711000-00001; MCGRATH FP, 1992, CLIN RADIOL, V45, P37, DOI 10.1016/S0009-9260(05)81467-9; Rankin EB, 2008, CELL DEATH DIFFER, V15, P678, DOI 10.1038/cdd.2008.21; Rankin EB, 2005, MOL CELL BIOL, V25, P3163, DOI 10.1128/MCB.25.8.3163-3172.2005; Rankin EB, 2007, J CLIN INVEST, V117, P1068, DOI 10.1172/JCI30117; Raval RR, 2005, MOL CELL BIOL, V25, P5675, DOI 10.1128/MCB.25.13.5675-5686.2005; Rothhammer T, 2007, ONCOGENE, V26, P4158, DOI 10.1038/sj.onc.1210182; Vortmeyer AO, 1997, HUM PATHOL, V28, P540, DOI 10.1016/S0046-8177(97)90075-7; White P, 2005, J BIOL CHEM, V280, P3715, DOI 10.1074/jbc.M410844200; Zatyka M, 2002, CANCER RES, V62, P3803	21	118	124	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 11	2008	27	40					5354	5358		10.1038/onc.2008.160	http://dx.doi.org/10.1038/onc.2008.160			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	346UW	18490920	Green Accepted			2022-12-28	WOS:000259096100008
J	Lockwood, WW; Chari, R; Coe, BP; Girard, L; MacAulay, C; Lam, S; Gazdar, AF; Minna, JD; Lam, WL				Lockwood, W. W.; Chari, R.; Coe, B. P.; Girard, L.; MacAulay, C.; Lam, S.; Gazdar, A. F.; Minna, J. D.; Lam, W. L.			DNA amplification is a ubiquitous mechanism of oncogene activation in lung and other cancers	ONCOGENE			English	Article						gene amplification; array CGH; gene expression; integrative analysis; lung cancer; EGFR signaling	COPY NUMBER ALTERATIONS; COMPARATIVE GENOMIC HYBRIDIZATION; HIGH-RESOLUTION ANALYSIS; PATH ARRAY CGH; GENE-EXPRESSION; CELL-LINES; MICROARRAY ANALYSIS; CDNA MICROARRAYS; BREAST-CANCER; DEPENDENCY	Chromosomal translocation is the best-characterized genetic mechanism for oncogene activation. However, there are documented examples of activation by alternate mechanisms, for example gene dosage increase, though its prevalence is unclear. Here, we answered the fundamental question of the contribution of DNA amplification as a molecular mechanism driving oncogenesis. Comparing 104 cancer lines representing diverse tissue origins identified genes residing in amplification 'hotspots' and discovered an unexpected frequency of genes activated by this mechanism. The 3431 amplicons identified represent similar to 10 per hematological and similar to 36 per epithelial cancer genome. Many recurrently amplified oncogenes were previously known to be activated only by disease-specific translocations. The 135 hotspots identified contain 538 unique genes and are enriched for proliferation, apoptosis and linage-dependency genes, reflecting functions advantageous to tumor growth. Integrating gene dosage with expression data validated the downstream impact of the novel amplification events in both cell lines and clinical samples. For example, multiple downstream components of the EGFR-family-signaling pathway, including CDK5, AKT1 and SHC1, are overexpressed as a direct result of gene amplification in lung cancer. Our findings suggest that amplification is far more common a mechanism of oncogene activation than previously believed and that specific regions of the genome are hotspots of amplification.	[Lockwood, W. W.; Chari, R.; Coe, B. P.; Lam, W. L.] British Columbia Canc Res Ctr, Dept Canc Genet, Vancouver, BC V5Z 1L3, Canada; [Lockwood, W. W.; Chari, R.; Coe, B. P.; Lam, W. L.] British Columbia Canc Res Ctr, Dept Dev Biol, Vancouver, BC V5Z 1L3, Canada; [Girard, L.; Gazdar, A. F.; Minna, J. D.] Univ Texas SW Med Ctr Dallas, Hamon Ctr Therapeut Oncol Res, Dallas, TX 75390 USA; [MacAulay, C.; Lam, S.] British Columbia Canc Res Ctr, Dept Canc Imaging, Vancouver, BC V5Z 1L3, Canada	British Columbia Cancer Agency; British Columbia Cancer Agency; University of Texas System; University of Texas Southwestern Medical Center Dallas; British Columbia Cancer Agency	Lockwood, WW (corresponding author), British Columbia Canc Res Ctr, Dept Canc Genet, 675 W 10th Aveue, Vancouver, BC V5Z 1L3, Canada.	wlockwood@bccrc.ca	MacAulay, Calum/K-1795-2016; Chari, Raj/G-3285-2019; Chari, Rajagopal/B-6980-2008; Lockwood, William W/A-2879-2009; Coe, Bradley/A-2878-2009	Coe, Bradley/0000-0001-8471-4016; MacAulay, Calum/0000-0003-4440-2792	NCI NIH HHS [P50 CA070907, P50 CA070907-03S19001, P50 CA070907-09, P50 CA070907-11, P50 CA070907-110009, P50 CA070907-10] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P50CA070907] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Albertson DG, 2006, TRENDS GENET, V22, P447, DOI 10.1016/j.tig.2006.06.007; Apergis GA, 1998, J BIOL CHEM, V273, P2917, DOI 10.1074/jbc.273.5.2917; Boersma-Vreugdenhil GR, 2004, BRIT J HAEMATOL, V126, P355, DOI 10.1111/j.1365-2141.2004.05050.x; Bublil EM, 2007, CURR OPIN CELL BIOL, V19, P124, DOI 10.1016/j.ceb.2007.02.008; Buttel I, 2004, ANN NY ACAD SCI, V1028, P14, DOI 10.1196/annals.1322.002; Chari R, 2006, BMC GENOMICS, V7, DOI 10.1186/1471-2164-7-324; Chi B, 2004, BMC BIOINFORMATICS, V5, DOI 10.1186/1471-2105-5-13; Coe BP, 2006, BRIT J CANCER, V94, P1927, DOI 10.1038/sj.bjc.6603167; Coe BP, 2007, GENOMICS, V89, P647, DOI 10.1016/j.ygeno.2006.12.012; Engelman JA, 2007, SCIENCE, V316, P1039, DOI 10.1126/science.1141478; Fabbro D, 1996, EUR J CANCER, V32A, P512, DOI 10.1016/0959-8049(95)00560-9; Futreal PA, 2004, NAT REV CANCER, V4, P177, DOI 10.1038/nrc1299; Garnis C, 2006, INT J CANCER, V118, P1556, DOI 10.1002/ijc.21491; Garraway LA, 2006, NAT REV CANCER, V6, P593, DOI 10.1038/nrc1947; Greshock J, 2007, CANCER RES, V67, P3594, DOI 10.1158/0008-5472.CAN-06-3674; Heidenblad M, 2005, ONCOGENE, V24, P1794, DOI 10.1038/sj.onc.1208383; Hellman A, 2002, CANCER CELL, V1, P89, DOI 10.1016/S1535-6108(02)00017-X; Hemstrom TH, 2006, INT J CANCER, V119, P1028, DOI 10.1002/ijc.21927; Henderson LJ, 2005, BRIT J CANCER, V92, P1553, DOI 10.1038/sj.bjc.6602452; Hennessy BT, 2005, NAT REV DRUG DISCOV, V4, P988, DOI 10.1038/nrd1902; Hyman E, 2002, CANCER RES, V62, P6240; Ishkanian AS, 2004, NAT GENET, V36, P299, DOI 10.1038/ng1307; Khojasteh M, 2005, BMC BIOINFORMATICS, V6, DOI 10.1186/1471-2105-6-274; Koizumi F, 2005, INT J CANCER, V116, P36, DOI 10.1002/ijc.20985; Lockwood WW, 2007, INT J CANCER, V120, P436, DOI 10.1002/ijc.22335; Mitelman F, 2000, MUTAT RES-REV MUTAT, V462, P247, DOI 10.1016/S1383-5742(00)00006-5; Myllykangas S, 2006, ONCOGENE, V25, P7324, DOI 10.1038/sj.onc.1209717; Myllykangas S, 2006, CANCER LETT, V232, P79, DOI 10.1016/j.canlet.2005.07.045; Neve RM, 2006, CANCER CELL, V10, P515, DOI 10.1016/j.ccr.2006.10.008; Pierotti MA, 1996, GENE CHROMOSOME CANC, V16, P1; Pollack JR, 2002, P NATL ACAD SCI USA, V99, P12963, DOI 10.1073/pnas.162471999; Roccato E, 2005, CANCER RES, V65, P2572, DOI 10.1158/0008-5472.CAN-04-4294; Squire JA, 2003, GENE CHROMOSOME CANC, V38, P215, DOI 10.1002/gcc.10273; Stenhouse G, 2004, J CLIN PATHOL, V57, P383, DOI 10.1136/jcp.2003.007138; Tanaka H, 2007, CANCER RES, V67, P6007, DOI 10.1158/0008-5472.CAN-06-4774; Tonon G, 2005, P NATL ACAD SCI USA, V102, P9625, DOI 10.1073/pnas.0504126102; WAHL GM, 1984, NATURE, V307, P516, DOI 10.1038/307516a0; Wang PW, 1999, GENOMICS, V59, P275, DOI 10.1006/geno.1999.5884; Watson SK, 2004, BMC GENOMICS, V5, DOI 10.1186/1471-2164-5-6; Watson SK, 2007, HUM GENET, V120, P795, DOI 10.1007/s00439-006-0251-9; Weinstein IB, 2002, SCIENCE, V297, P63, DOI 10.1126/science.1073096; Zhou BBS, 2006, CANCER CELL, V10, P39, DOI 10.1016/j.ccr.2006.05.024	43	87	89	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 31	2008	27	33					4615	4624		10.1038/onc.2008.98	http://dx.doi.org/10.1038/onc.2008.98			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	332IS	18391978	Green Accepted			2022-12-28	WOS:000258077300010
J	Zhang, D; Shimizu, T; Araki, N; Hirota, T; Yoshie, M; Ogawa, K; Nakagata, N; Takeya, M; Saya, H				Zhang, D.; Shimizu, T.; Araki, N.; Hirota, T.; Yoshie, M.; Ogawa, K.; Nakagata, N.; Takeya, M.; Saya, H.			Aurora A overexpression induces cellular senescence in mammary gland hyperplastic tumors developed in p53-deficient mice	ONCOGENE			English	Article						Aurora A; polyploidy; apoptosis; senescence; p16; DNA damage	CENTROSOME AMPLIFICATION; DNA-DAMAGE; MAMMALIAN-CELLS; BREAST-CANCER; ONCOGENIC RAS; KINASE; P53; ACTIVATION; CHECKPOINT; ENRICHMENT	Aurora A mitotic kinase is frequently overexpressed in various human cancers and is widely considered to be an oncoprotein. However, the cellular contexts in which Aurora A induces malignancy in vivo are still unclear. We previously reported a mouse model in which overexpression of human Aurora A in the mammary gland leads to small hyperplastic changes but not malignancy because of the induction of p53-dependent apoptosis. To study the additional factors required for Aurora A-associated tumorigenesis, we generated a new Aurora A overexpression mouse model that lacks p53. We present evidence here that Aurora A overexpression in primary mouse embryonic fibroblasts (MEFs) that lack p53 overrides postmitotic checkpoint and leads to the formation of multinucleated polyploid cells. Induction of Aurora A overexpression in the mammary glands of p53-deficient mice resulted in development of precancerous lesions that were histologically similar to atypical ductal hyperplasia in human mammary tissue and showed increased cellular senescence and p16 expression. We further observed DNA damage in p53-deficient primary MEFs after Aurora A overexpression. Our results suggest that Aurora A overexpression in mammary glands is insufficient for the development of malignant tumors in p53-deficient mice because of the induction of cellular senescence. Both p53 and p16 are critical in preventing mammary gland tumorigenesis in the Aurora A overexpression mouse model.	[Zhang, D.; Shimizu, T.; Araki, N.; Saya, H.] Kumamoto Univ, Grad Sch Med Sci, Dept Tumor Genet & Biol, Kumamoto, Japan; [Hirota, T.] Japanese Fdn Canc Res, Inst Canc, Dept Expt Pathol, Tokyo 170, Japan; [Yoshie, M.; Ogawa, K.] Asahikawa Med Coll, Dept Pathol, Asahikawa, Hokkaido 078, Japan; [Nakagata, N.] Kumamoto Univ, Ctr Anim Resources & Dev, Div Reprod Engn, Kumamoto, Japan; [Takeya, M.] Kumamoto Univ, Grad Sch Med Sci, Dept Cell Pathol, Kumamoto, Japan	Kumamoto University; Japanese Foundation for Cancer Research; Asahikawa Medical College; Kumamoto University; Kumamoto University	Saya, H (corresponding author), Keio Univ, Sch Med, Inst Adv Med Res, Div Gene Regulat,Shinjuku Ku, 35 Shinano Machi, Tokyo 1608582, Japan.	hsaya@a5.keio.jp	Saya, Hideyuki/J-4325-2013	Nakagata, Naomi/0000-0002-5737-9993				Anand S, 2003, CANCER CELL, V3, P51, DOI 10.1016/S1535-6108(02)00235-0; Andreassen PR, 2001, MOL BIOL CELL, V12, P1315, DOI 10.1091/mbc.12.5.1315; Bischoff JR, 1998, EMBO J, V17, P3052, DOI 10.1093/emboj/17.11.3052; Bringold F, 2000, EXP GERONTOL, V35, P317, DOI 10.1016/S0531-5565(00)00083-8; Cahill DP, 1999, TRENDS CELL BIOL, V9, pM57, DOI 10.1016/S0962-8924(99)01661-X; Campisi J, 2001, TRENDS CELL BIOL, V11, pS27, DOI 10.1016/S0962-8924(01)02151-1; CHEN Q, 1995, P NATL ACAD SCI USA, V92, P4337, DOI 10.1073/pnas.92.10.4337; Collado M, 2005, NATURE, V436, P642, DOI 10.1038/436642a; Dimri GP, 2000, MOL CELL BIOL, V20, P273, DOI 10.1128/MCB.20.1.273-285.2000; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; Ferbeyre G, 2002, MOL CELL BIOL, V22, P3497, DOI 10.1128/MCB.22.10.3497-3508.2002; Fujiwara T, 2005, NATURE, V437, P1043, DOI 10.1038/nature04217; Fukuda T, 2005, MOL CELL BIOL, V25, P5270, DOI 10.1128/MCB.25.12.5270-5281.2005; Giet R, 2005, TRENDS CELL BIOL, V15, P241, DOI 10.1016/j.tcb.2005.03.004; Goepfert TM, 2002, CANCER RES, V62, P4115; Gritsko TM, 2003, CLIN CANCER RES, V9, P1420; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Helmbold H, 2006, ONCOGENE, V25, P5257, DOI 10.1038/sj.onc.1209613; Hirota T, 2003, CELL, V114, P585, DOI 10.1016/S0092-8674(03)00642-1; Howe HL, 2001, J NATL CANCER I, V93, P824, DOI 10.1093/jnci/93.11.824; Jeng YM, 2004, CLIN CANCER RES, V10, P2065, DOI 10.1158/1078-0432.CCR-1057-03; KALLIONIEMI A, 1994, P NATL ACAD SCI USA, V91, P2156, DOI 10.1073/pnas.91.6.2156; KANEGAE Y, 1995, NUCLEIC ACIDS RES, V23, P3816, DOI 10.1093/nar/23.19.3816; Kunitoku N, 2003, DEV CELL, V5, P853, DOI 10.1016/S1534-5807(03)00364-2; Lee AC, 1999, J BIOL CHEM, V274, P7936, DOI 10.1074/jbc.274.12.7936; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Lundberg AS, 2000, CURR OPIN CELL BIOL, V12, P705, DOI 10.1016/S0955-0674(00)00155-1; Marumoto T, 2005, NAT REV CANCER, V5, P42, DOI 10.1038/nrc1526; Marumoto T, 2003, J BIOL CHEM, V278, P51786, DOI 10.1074/jbc.M306275200; Meraldi P, 2002, EMBO J, V21, P483, DOI 10.1093/emboj/21.4.483; Narita M, 2003, CELL, V113, P703, DOI 10.1016/S0092-8674(03)00401-X; Nigg EA, 2001, NAT REV MOL CELL BIO, V2, P21, DOI 10.1038/35048096; Robles SJ, 1998, ONCOGENE, V16, P1113, DOI 10.1038/sj.onc.1201862; Sablina AA, 2005, NAT MED, V11, P1306, DOI 10.1038/nm1320; Sakakura C, 2001, BRIT J CANCER, V84, P824, DOI 10.1054/bjoc.2000.1684; Sen S, 1997, ONCOGENE, V14, P2195, DOI 10.1038/sj.onc.1201065; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Serrano M, 1996, CELL, V85, P27, DOI 10.1016/S0092-8674(00)81079-X; SYMONDS H, 1994, CELL, V78, P703, DOI 10.1016/0092-8674(94)90534-7; Tanaka T, 1999, CANCER RES, V59, P2041; te Poele RH, 2002, CANCER RES, V62, P1876; Vafa O, 2002, MOL CELL, V9, P1031, DOI 10.1016/S1097-2765(02)00520-8; Wang X, 2006, ONCOGENE, V25, P7148, DOI 10.1038/sj.onc.1209707; WU XW, 1994, P NATL ACAD SCI USA, V91, P3602, DOI 10.1073/pnas.91.9.3602; Zhang DW, 2004, ONCOGENE, V23, P8720, DOI 10.1038/sj.onc.1208153; Zhou HY, 1998, NAT GENET, V20, P189, DOI 10.1038/2496; Zhu JY, 1998, GENE DEV, V12, P2997, DOI 10.1101/gad.12.19.2997	47	38	40	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 17	2008	27	31					4305	4314		10.1038/onc.2008.76	http://dx.doi.org/10.1038/onc.2008.76			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	326WY	18372918				2022-12-28	WOS:000257691100005
J	Prendergast, GC				Prendergast, G. C.			Immune escape as a fundamental trait of cancer: focus on IDO	ONCOGENE			English	Review						immunosuppression; immunotherapy; indoleamine 2,3-dioxygenase; Bin1; IDO2	PLASMACYTOID DENDRITIC CELLS; SMALL-MOLECULE INHIBITORS; TUMOR-SUPPRESSOR BIN1; DRAINING LYMPH-NODES; REGULATORY T-CELLS; INDOLEAMINE 2,3-DIOXYGENASE; TRYPTOPHAN CATABOLISM; LUNG-CANCER; MAST-CELLS; C-MYC	Immune escape is a critical gateway to malignancy. The emergence of this fundamental trait of cancer represents the defeat of immune surveillance, a potent, multi-armed and essential mode of cancer suppression that may influence the ultimate clinical impact of an early stage tumor. Indeed, immune escape may be a central modi. er of clinical outcomes, by affecting tumor dormancy versus progression, licensing invasion and metastasis and impacting therapeutic response. Although relatively little studied until recently, immune suppression and escape in tumors are now hot areas with clinical translation of several new therapeutic agents already under way. The interconnections between signaling pathways that control immune escape and those that control proliferation, senescence, apoptosis, metabolic alterations, angiogenesis, invasion and metastasis remain virtually unexplored, offering rich new areas for investigation. Here, an overview of this area is provided with a focus on the tryptophan catabolic enzyme indoleamine 2,3-dioxygenase (IDO) and its recently discovered relative IDO2 that are implicated in suppressing T-cell immunity in normal and pathological settings including cancer. Emerging evidence suggests that during cancer progression activation of the IDO pathway might act as a preferred nodal modi. er pathway for immune escape, for example analogous to the PI3K pathway for survival or the VEGF pathway for angiogenesis. Small molecule inhibitors of IDO and IDO2 heighten chemotherapeutic efficacy in mouse models of cancer in a nontoxic fashion and an initial lead compound entered phase I clinical trials in late 2007. New modalities in this area offer promising ways to broaden the combinatorial attack on advanced cancers, where immune escape mechanisms likely provide pivotal support.	[Prendergast, G. C.] Lankenau Inst Med Res, Wynnewood, PA 19096 USA; [Prendergast, G. C.] Thomas Jefferson Univ, Dept Pathol Anat & Cell Biol, Philadelphia, PA 19107 USA; [Prendergast, G. C.] Thomas Jefferson Univ, Jefferson Med Sch, Kimmel Canc Ctr, Philadelphia, PA 19107 USA	Lankenau Medical Center; Lankenau Institute for Medical Research; Jefferson University; Jefferson University	Prendergast, GC (corresponding author), Lankenau Inst Med Res, 100 Lancaster Ave, Wynnewood, PA 19096 USA.	prendergast@limr.org			NATIONAL CANCER INSTITUTE [R01CA100123, R01CA109542, R01CA082222] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA100123, R01 CA109542, R01 CA82222] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Apetoh L, 2007, NAT MED, V13, P1050, DOI 10.1038/nm1622; Balkwill F, 2005, CANCER CELL, V7, P211, DOI 10.1016/j.ccr.2005.02.013; Ball HJ, 2007, GENE, V396, P203, DOI 10.1016/j.gene.2007.04.010; BANERJEE T, 2008, ONCOGENE IN PRESS; Bild AH, 2002, EMBO J, V21, P3255, DOI 10.1093/emboj/cdf351; Blank C, 2006, INT J CANCER, V119, P317, DOI 10.1002/ijc.21775; Bronte V, 2005, NAT REV IMMUNOL, V5, P641, DOI 10.1038/nri1668; Chang MY, 2007, CANCER RES, V67, P7605, DOI 10.1158/0008-5472.CAN-07-1100; Chang MY, 2007, CANCER RES, V67, P100, DOI 10.1158/0008-5472.CAN-06-2742; Colombo MP, 2007, NAT REV CANCER, V7, P880, DOI 10.1038/nrc2250; Coussens LM, 1999, GENE DEV, V13, P1382, DOI 10.1101/gad.13.11.1382; Curti A, 2007, BLOOD, V109, P2871, DOI 10.1182/blood-2006-07-036863; Curtis RE, 1997, NEW ENGL J MED, V336, P897, DOI 10.1056/NEJM199703273361301; DuHadaway JB, 2003, ONCOGENE, V22, P3578, DOI 10.1038/sj.onc.1206481; DuHadaway JB, 2001, CANCER RES, V61, P3151; Dunn GP, 2004, IMMUNITY, V21, P137, DOI 10.1016/j.immuni.2004.07.017; Elliott K, 1999, ONCOGENE, V18, P3564, DOI 10.1038/sj.onc.1202670; Elliott K, 2000, ONCOGENE, V19, P4669, DOI 10.1038/sj.onc.1203681; Engels EA, 2007, CANCER RES, V67, P6520, DOI 10.1158/0008-5472.CAN-07-0370; Fallarino F, 2003, NAT IMMUNOL, V4, P1206, DOI 10.1038/ni1003; Fallarino F, 2006, J IMMUNOL, V176, P6752, DOI 10.4049/jimmunol.176.11.6752; Fallarino I, 2002, CELL DEATH DIFFER, V9, P1069, DOI 10.1038/sj.cdd.4401073; Friberg M, 2002, INT J CANCER, V101, P151, DOI 10.1002/ijc.10645; Gabrilovich DI, 2007, CURR CANCER DRUG TAR, V7, P1, DOI 10.2174/156800907780006850; Galon J, 2006, SCIENCE, V313, P1960, DOI 10.1126/science.1129139; Gaspari P, 2006, J MED CHEM, V49, P684, DOI 10.1021/jm0508888; Ge K, 2000, INT J CANCER, V86, P155, DOI 10.1002/(SICI)1097-0215(20000415)86:2<155::AID-IJC2>3.0.CO;2-M; Ge K, 1999, P NATL ACAD SCI USA, V96, P9689, DOI 10.1073/pnas.96.17.9689; Ge K, 2000, INT J CANCER, V85, P376; Grohmann U, 2007, NAT MED, V13, P579, DOI 10.1038/nm1563; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hou DY, 2007, CANCER RES, V67, P792, DOI 10.1158/0008-5472.CAN-06-2925; Huber S, 2006, FRONT BIOSCI-LANDMRK, V11, P1014, DOI 10.2741/1859; Hunter KW, 2006, CANCER RES, V66, P1251, DOI 10.1158/0008-5472.CAN-05-3705; Iwai Y, 2002, P NATL ACAD SCI USA, V99, P12293, DOI 10.1073/pnas.192461099; Karni R, 2007, NAT STRUCT MOL BIOL, V14, P185, DOI 10.1038/nsmb1209; Knoepfler PS, 2006, EMBO J, V25, P2723, DOI 10.1038/sj.emboj.7601152; Koebel CM, 2007, NATURE, V450, P903, DOI 10.1038/nature06309; Lewis CE, 2006, CANCER RES, V66, P605, DOI 10.1158/0008-5472.CAN-05-4005; Lu LF, 2006, NATURE, V442, P997, DOI 10.1038/nature05010; Machiels JPH, 2001, CANCER RES, V61, P3689; MEHTA RG, 1995, CARCINOGENESIS, V16, P399, DOI 10.1093/carcin/16.2.399; Mellor AL, 2001, NAT IMMUNOL, V2, P64, DOI 10.1038/83183; Mellor AL, 2004, INT IMMUNOL, V16, P1391, DOI 10.1093/intimm/dxh140; Mellor AL, 2004, NAT REV IMMUNOL, V4, P762, DOI 10.1038/nri1457; Mellor AL, 2008, NAT REV IMMUNOL, V8, P74, DOI 10.1038/nri2233; Metz R, 2007, CANCER RES, V67, P7082, DOI 10.1158/0008-5472.CAN-07-1872; Miaczynska M, 2004, CELL, V116, P445, DOI 10.1016/S0092-8674(04)00117-5; Muller AJ, 2005, EXPERT OPIN THER TAR, V9, P831, DOI 10.1517/14728222.9.4.831; Muller AJ, 2004, CANCER BIOL THER, V3, P1236, DOI 10.4161/cbt.3.12.1232; Muller AJ, 2005, NAT MED, V11, P312, DOI 10.1038/nm1196; Muller AJ, 2007, CURR CANCER DRUG TAR, V7, P31, DOI 10.2174/156800907780006896; Muller AJ, 2006, NAT REV CANCER, V6, P613, DOI 10.1038/nrc1929; Munn DH, 2007, J CLIN INVEST, V117, P1147, DOI 10.1172/JCI31178; Munn DH, 2005, IMMUNITY, V22, P633, DOI 10.1016/j.immuni.2005.03.013; Munn DH, 1998, SCIENCE, V281, P1191, DOI 10.1126/science.281.5380.1191; Munn DH, 2004, J CLIN INVEST, V114, P280, DOI 10.1172/JCI200421583; Muto S, 2007, CANCER SCI, V98, P1549, DOI 10.1111/j.1349-7006.2007.00577.x; Obeid M, 2007, NAT MED, V13, P54, DOI 10.1038/nm1523; Popovic PJ, 2007, J NUTR, V137, p1681S, DOI 10.1093/jn/137.6.1681S; Prendergast GC, 2007, CANCER RES, V67, P3500, DOI 10.1158/0008-5472.CAN-06-4626; Ramalingam A, 2007, CELL CYCLE, V6, P1655, DOI 10.4161/cc.6.13.4413; Ramalingam A, 2007, CELL CYCLE, V6, P1914, DOI 10.4161/cc.6.15.4514; Ren G, 2006, MICROBIOL MOL BIOL R, V70, P37, DOI 10.1128/MMBR.70.1.37-120.2006; ROSE DP, 1967, LANCET, V1, P239; Routhier EL, 2003, ONCOGENE, V22, P637, DOI 10.1038/sj.onc.1206162; Roy M, 2005, NUCLEIC ACIDS RES, V33, P5026, DOI 10.1093/nar/gki792; Sakamuro D, 1996, NAT GENET, V14, P69, DOI 10.1038/ng0996-69; Schlee M, 2007, ADV CANCER RES, V97, P167, DOI 10.1016/S0065-230X(06)97007-9; Shankaran V, 2001, NATURE, V410, P1107, DOI 10.1038/35074122; Sharma MD, 2007, J CLIN INVEST, V117, P2570, DOI 10.1172/JCI31911; Soucek L, 2007, NAT MED, V13, P1211, DOI 10.1038/nm1649; Swensen SJ, 2005, RADIOLOGY, V235, P259, DOI 10.1148/radiol.2351041662; Tajiri T, 2003, CLIN CANCER RES, V9, P3345; Uyttenhove C, 2003, NAT MED, V9, P1269, DOI 10.1038/nm934; Wingender G, 2006, EUR J IMMUNOL, V36, P12, DOI 10.1002/eji.200535602; Xu Q, 2003, NUCLEIC ACIDS RES, V31, P5635, DOI 10.1093/nar/gkg786; Zou WP, 2005, NAT REV CANCER, V5, P263, DOI 10.1038/nrc1586	78	253	275	1	53	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2008	27	28					3889	3900		10.1038/onc.2008.35	http://dx.doi.org/10.1038/onc.2008.35			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	318JZ	18317452				2022-12-28	WOS:000257089000001
J	Lara, E; Mai, A; Calvanese, V; Altucci, L; Lopez-Nieva, P; Martinez-Chantar, ML; Varela-Rey, M; Rotili, D; Nebbioso, A; Ropero, S; Montoya, G; Oyarzabal, J; Velasco, S; Serrano, M; Witt, M; Villar-Garea, A; Inhof, A; Mato, JM; Esteller, M; Fraga, MF				Lara, E.; Mai, A.; Calvanese, V.; Altucci, L.; Lopez-Nieva, P.; Martinez-Chantar, M. L.; Varela-Rey, M.; Rotili, D.; Nebbioso, A.; Ropero, S.; Montoya, G.; Oyarzabal, J.; Velasco, S.; Serrano, M.; Witt, M.; Villar-Garea, A.; Inhof, A.; Mato, J. M.; Esteller, M.; Fraga, M. F.			Salermide, a Sirtuin inhibitor with a strong cancer-specific proapoptotic effect	ONCOGENE			English	Article						HDACs inhibitors; Sirtuins; cancer; apoptosis	HISTONE DEACETYLASE INHIBITORS; SMALL-MOLECULE INHIBITOR; DNA-DAMAGE; SIR2; P53; DISCOVERY; IDENTIFICATION; NICOTINAMIDE; MECHANISM; SURVIVAL	Sirtuin 1 (Sirt1) and Sirtuin 2 (Sirt2) belong to the family of NAD+(nicotinamide adenine dinucleotide-positive)dependent class III histone deacetylases and are involved in regulating lifespan. As cancer is a disease of ageing, targeting Sirtuins is emerging as a promising antitumour strategy. Here we present Salermide (N-{3-[(2-hydroxynaphthalen-1-ylmethylene)-amino]-phenyl}-2-phenyl-propionamide), a reverse amide with a strong in vitro inhibitory effect on Sirt1 and Sirt2. Salermide was well tolerated by mice at concentrations up to 100 mu M and prompted tumour-specific cell death in a wide range of human cancer cell lines. The antitumour activity of Salermide was primarily because of a massive induction of apoptosis. This was independent of global tubulin and K16H4 acetylation, which ruled out a putative Sirt2-mediated apoptotic pathway and suggested an in vivo mechanism of action through Sirt1. Consistently with this, RNA interference-mediated knockdown of Sirt1, but not Sirt2, induced apoptosis in cancer cells. Although p53 has been reported to be a target of Sirt1, genetic p53 knockdowns showed that the Sirt1-dependent proapoptotic effect of Salermide is p53-independent. We were finally able to ascribe the apoptotic effect of Salermide to the reactivation of proapoptotic genes epigenetically repressed exclusively in cancer cells by Sirt1. Taken together, our results underline Salermide's promise as an anticancer drug and provide evidence for the molecular mechanism through which Sirt1 is involved in human tumorigenesis.	[Lara, E.; Calvanese, V.; Lopez-Nieva, P.; Ropero, S.; Fraga, M. F.] CNIO, Spanish Natl Canc Res Ctr, Canc Epigenet Lab, E-28029 Madrid, Spain; [Mai, A.; Rotili, D.] Univ Roma La Sapienza, Dipartimento Studi Farmaceut, Fdn Cenci Bolognetti, Ist Pasteur, I-00185 Rome, Italy; [Altucci, L.; Nebbioso, A.] Univ Naples 2, Dipartimento Patol Gen, Naples, Italy; [Martinez-Chantar, M. L.; Varela-Rey, M.; Mato, J. M.] CIC BioGUNE, CIBERehd, Bizkaia, Spain; [Montoya, G.] CNIO, Spanish Natl Canc Res Ctr, Ctr Macromol Crystallog, E-28029 Madrid, Spain; [Oyarzabal, J.] CNIO, Spanish Natl Canc Res Ctr, Computat Chem Grp, E-28029 Madrid, Spain; [Velasco, S.; Serrano, M.] CNIO, Spanish Natl Canc Res Ctr, Tumour Suppress Grp, E-28029 Madrid, Spain; [Witt, M.] Bruker Daltonik GmbH, Bremen, Germany; [Villar-Garea, A.; Inhof, A.] Univ Munich, Histone Modificat Grp, Adolf Butenandt Inst, Munich, Germany; [Esteller, M.] ICO, PEBC, Barcelona, Spain; [Fraga, M. F.] CSIC, Ctr Nacl Biotecnol, Dept Immunol & Oncol, Madrid, Spain	Centro Nacional de Investigaciones Oncologicas (CNIO); Fondazione Cenci Bolognetti; Sapienza University Rome; Universita della Campania Vanvitelli; CIBER - Centro de Investigacion Biomedica en Red; CIBEREHD; CIC bioGUNE; Centro Nacional de Investigaciones Oncologicas (CNIO); Centro Nacional de Investigaciones Oncologicas (CNIO); Centro Nacional de Investigaciones Oncologicas (CNIO); Bruker Corporation; Bruker Daltonik GmbH; University of Munich; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro Nacional de Biotecnologia (CNB)	Fraga, MF (corresponding author), CNIO, Spanish Natl Canc Ctr, Canc Epigenet Lab, Melchor Fernandez Almagro 3, E-28029 Madrid, Spain.	mesteller@cnio.es; mffraga@cnio.es	Calvanese, Vincenzo/AAO-4311-2020; NEBBIOSO, ANGELA/GVS-1294-2022; Varela-Rey, Marta/C-5460-2019; Fraga, Mario F/H-7824-2017; Altucci, Lucia/S-8031-2019; Oyarzabal, Julen/K-7393-2017; MATO, JOSE/A-5187-2011; Chantar, Maria Luz Martinez/F-5190-2011; Rotili, Dante/J-9157-2016; Mai, Antonello/AAC-2144-2019; Nieva, Pilar López/R-9516-2019; Calvanese, Vincenzo/E-1145-2016; Serrano, Manuel/H-2634-2015; Esteller, Manel/L-5956-2014; NEBBIOSO, Angela/C-3566-2016	Calvanese, Vincenzo/0000-0002-7937-1511; Fraga, Mario F/0000-0001-8450-2603; Oyarzabal, Julen/0000-0003-1941-7255; MATO, JOSE/0000-0003-1264-3153; Chantar, Maria Luz Martinez/0000-0002-6446-9911; Nieva, Pilar López/0000-0001-6369-2444; Calvanese, Vincenzo/0000-0002-7937-1511; Serrano, Manuel/0000-0001-7177-9312; Esteller, Manel/0000-0003-4490-6093; altucci, lucia/0000-0002-7312-5387; NEBBIOSO, Angela/0000-0001-5374-3527; Villar Garea, Ana/0000-0001-8960-1635; Rotili, Dante/0000-0002-8428-8763; Varela-Rey, Marta/0000-0002-2413-8659; Mai, Antonello/0000-0001-9176-2382	European Union [LSHG-CT-2006-037415]; Spanish Ramon & Cajal Programme; Health Department of the Spanish Government [PI061267]; Health and Education and Science Departments of the Spanish Government [FIS01-04, I+D+I MCYT08-03, FU2004-02073/BMC, MEC09-05]; European Grant [TRANSFOG LSHC-CT-2004-503438, EPITRON LSHC-CT2005- 518417, APO-SYS HEALTH-F4-2007-200767]; Spanish Association Against Cancer; FIS Spanish Research Program; FPU Spanish Research Program;  [PRIN2006];  [AICR2007]	European Union(European Commission); Spanish Ramon & Cajal Programme(Spanish Government); Health Department of the Spanish Government; Health and Education and Science Departments of the Spanish Government; European Grant; Spanish Association Against Cancer; FIS Spanish Research Program; FPU Spanish Research Program(Spanish Government); ; 	This work was primarily supported by the European Union (LSHG-CT-2006-037415). MFF is funded by the Spanish Ramon & Cajal Programme and the Health Department of the Spanish Government (PI061267). Thanks are due to PRIN2006 (AM) and AICR2007 (AM) for grants. The Cancer Epigenetics group at the CNIO is supported by the Health (FIS01-04) and Education and Science (I+D+I MCYT08-03, FU2004-02073/BMC and Consolider MEC09-05) Departments of the Spanish Government, the European Grant TRANSFOG LSHC-CT-2004-503438, EPITRON LSHC-CT2005- 518417, APO-SYS HEALTH-F4-2007-200767 and the Spanish Association Against Cancer (AECC). EL is a recipient of a fellowship from the FIS Spanish Research Program. VC is a recipient of a Fellowship from the FPU Spanish Research Program.	Avalos JL, 2005, MOL CELL, V17, P855, DOI 10.1016/j.molcel.2005.02.022; Bedalov A, 2001, P NATL ACAD SCI USA, V98, P15113, DOI 10.1073/pnas.261574398; Bitterman KJ, 2002, J BIOL CHEM, V277, P45099, DOI 10.1074/jbc.M205670200; Chen WY, 2005, CELL, V123, P437, DOI 10.1016/j.cell.2005.08.011; Clark AM, 2006, J CHEM INF MODEL, V46, P1107, DOI 10.1021/ci050550m; Finnin MS, 2001, NAT STRUCT BIOL, V8, P621, DOI 10.1038/89668; Ford J, 2005, CANCER RES, V65, P10457, DOI 10.1158/0008-5472.CAN-05-1923; Fraga MF, 2007, ANN NY ACAD SCI, V1100, P60, DOI 10.1196/annals.1395.005; Fraga MF, 2007, TRENDS GENET, V23, P413, DOI 10.1016/j.tig.2007.05.008; Fraga MF, 2005, NAT GENET, V37, P391, DOI 10.1038/ng1531; Glozak MA, 2007, ONCOGENE, V26, P5420, DOI 10.1038/sj.onc.1210610; Grozinger CM, 2001, J BIOL CHEM, V276, P38837, DOI 10.1074/jbc.M106779200; Guarente L, 2005, CELL, V120, P473, DOI 10.1016/j.cell.2005.01.029; Heltweg B, 2006, CANCER RES, V66, P4368, DOI 10.1158/0008-5472.CAN-05-3617; Herranz M, 2006, BLOOD, V107, P1174, DOI 10.1182/blood-2005-05-2033; Howitz KT, 2003, NATURE, V425, P191, DOI 10.1038/nature01960; Huhtiniemi T, 2006, J COMPUT AID MOL DES, V20, P589, DOI 10.1007/s10822-006-9084-9; Jones G, 1997, J MOL BIOL, V267, P727, DOI 10.1006/jmbi.1996.0897; Kamel C, 2006, AGING CELL, V5, P81, DOI 10.1111/j.1474-9726.2006.00191.x; Lain S, 2008, CANCER CELL, V13, P454, DOI 10.1016/j.ccr.2008.03.004; Longo VD, 2006, CELL, V126, P257, DOI 10.1016/j.cell.2006.07.002; Luo JY, 2001, CELL, V107, P137, DOI 10.1016/S0092-8674(01)00524-4; Mai A, 2005, J MED CHEM, V48, P7789, DOI 10.1021/jm050100l; Mariadason JM, 2008, EPIGENETICS-US, V3, P28, DOI 10.4161/epi.3.1.5736; Marks PA, 2007, ONCOGENE, V26, P1351, DOI 10.1038/sj.onc.1210204; Marks PA, 2007, NAT BIOTECHNOL, V25, P84, DOI 10.1038/nbt1272; Min JR, 2001, CELL, V105, P269, DOI 10.1016/S0092-8674(01)00317-8; Minucci S, 2006, NAT REV CANCER, V6, P38, DOI 10.1038/nrc1779; Napper AD, 2005, J MED CHEM, V48, P8045, DOI 10.1021/jm050522v; North BJ, 2003, MOL CELL, V11, P437, DOI 10.1016/S1097-2765(03)00038-8; Olaharski AJ, 2005, PLOS GENET, V1, P689, DOI 10.1371/journal.pgen.0010077; Onufriev A, 2004, PROTEINS, V55, P383, DOI 10.1002/prot.20033; Ota H, 2006, ONCOGENE, V25, P176, DOI 10.1038/sj.onc.1209049; Parks BA, 2007, ANAL CHEM, V79, P7984, DOI 10.1021/ac070553t; Ponder JW, 2003, ADV PROTEIN CHEM, V66, P27; Pruitt K, 2006, PLOS GENET, V2, P344, DOI 10.1371/journal.pgen.0020040; RODRIGUES NR, 1990, P NATL ACAD SCI USA, V87, P7555, DOI 10.1073/pnas.87.19.7555; Ropero S, 2004, BREAST CANCER RES TR, V86, P125, DOI 10.1023/B:BREA.0000032981.20384.c6; Stuenkel Walter, 2007, Biotechnology Journal, V2, P1360, DOI 10.1002/biot.200700087; Sun YN, 2007, LUNG CANCER, V58, P21, DOI 10.1016/j.lungcan.2007.05.013; Vaquero A, 2004, MOL CELL, V16, P93, DOI 10.1016/j.molcel.2004.08.031; Vaquero A, 2006, GENE DEV, V20, P1256, DOI 10.1101/gad.1412706; Vaziri H, 2001, CELL, V107, P149, DOI 10.1016/S0092-8674(01)00527-X; Villar-Garea A, 2008, CURR PROTOC PROTEIN; Wang CG, 2006, NAT CELL BIOL, V8, P1025, DOI 10.1038/ncb1468; Xu WS, 2007, ONCOGENE, V26, P5541, DOI 10.1038/sj.onc.1210620	46	203	207	0	33	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2009	28	6					781	791		10.1038/onc.2008.436	http://dx.doi.org/10.1038/onc.2008.436			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	406UI	19060927				2022-12-28	WOS:000263320000001
J	Ehnman, M; Li, H; Fredriksson, L; Pietras, K; Eriksson, U				Ehnman, M.; Li, H.; Fredriksson, L.; Pietras, K.; Eriksson, U.			The uPA/uPAR system regulates the bioavailability of PDGF-DD: implications for tumour growth	ONCOGENE			English	Article						PDGF-D; uPA/uPAR; PDGFR beta; retention motif; proteolytic processing; tumorigenesis	UROKINASE PLASMINOGEN-ACTIVATOR; CELL-SURFACE; RECEPTOR; IDENTIFICATION; RETENTION; LIGAND; PROGRESSION; MECHANISM; ISOFORMS; SIGNAL	Members of the platelet-derived growth factor (PDGF) family are mitogens for cells of mesenchymal origin and have important functions during embryonic development, blood vessel maturation, fibrotic diseases and cancer. In contrast to the two classical PDGFs, the novel and less well-characterized members, PDGF-CC and PDGF-DD, are latent factors that need to be processed extracellularly by activating proteases, before they can mediate PDGF receptor activation. Here, we elucidate the structural requirements for urokinase plasminogen activator (uPA)-mediated activation of PDGF-DD, as well as the intricate interplay with uPA receptor (uPAR) signalling. Furthermore, we show that activated PDGF-DD, in comparison to latent, more potently transforms NIH/3T3 cells in vitro. Conversely, xenograft studies in nude mice demonstrate that cells expressing latent PDGF-DD are more tumorigenic than those expressing activated PDGF-DD. These findings imply that a fine-tuned proteolytic activation, in the local milieu, controls PDGF-DD bioavailability. Moreover, we suggest that proteolytic activation of PDGF-DD reveals a retention motif mediating interactions with pericellular components. Our proposed mechanism, where uPA not only generates active PDGF-DD, but also regulates its spatial distribution, provides novel insights into the biological function of PDGF-DD.	[Eriksson, U.] Ludwig Inst Canc Res Ltd, Karolinska Inst, Stockholm Branch, S-17177 Stockholm, Sweden	Karolinska Institutet; Ludwig Institute for Cancer Research	Eriksson, U (corresponding author), Ludwig Inst Canc Res Ltd, Karolinska Inst, Stockholm Branch, Box 240, S-17177 Stockholm, Sweden.	ulf.eriksson@licr.ki.se	Pietras, Kristian/ABE-8727-2020; Pietras, Kristian/ABG-2097-2021; Ehnman, Monika/R-3687-2016	Pietras, Kristian/0000-0001-6738-4705; Ehnman, Monika/0000-0003-0468-2531; Fredriksson, Linda/0000-0003-4952-2742	Swedish Cancer Foundation; Swedish Research Council; Novo Nordisk Foundation; Karolinska Institutet	Swedish Cancer Foundation; Swedish Research Council(Swedish Research CouncilEuropean Commission); Novo Nordisk Foundation(Novo Nordisk FoundationNovocure Limited); Karolinska Institutet(Karolinska Institutet)	We thank Carl-Henrik Heldin (Ludwig Institute for Cancer Research Ltd, Uppsala Branch) for kindly providing PAE cell lines, R33 antiserum against human PDGFRb and purified PDGF-BB protein. Soheilla Rezaian and Sara Cunha helpfully assisted with PDGF-DD protein puri. cation and tissue preparations; Erika Folestad and Christina Fieber generously provided us with human PDGF-D and VEGF-B plasmids. The Swedish Cancer Foundation, the Swedish Research Council, the Novo Nordisk Foundation and Karolinska Institutet supported this study.	Bergsten E, 2001, NAT CELL BIOL, V3, P512, DOI 10.1038/35074588; Boehm T, 1997, NATURE, V390, P404, DOI 10.1038/37126; BORK P, 1993, J MOL BIOL, V231, P539, DOI 10.1006/jmbi.1993.1305; Carmeliet P, 1999, NAT MED, V5, P495, DOI 10.1038/8379; Fredriksson L, 2005, J BIOL CHEM, V280, P26856, DOI 10.1074/jbc.M503388200; Fredriksson L, 2004, EMBO J, V23, P3793, DOI 10.1038/sj.emboj.7600397; Grunstein J, 2000, MOL CELL BIOL, V20, P7282, DOI 10.1128/MCB.20.19.7282-7291.2000; Heldin CH, 1999, PHYSIOL REV, V79, P1283, DOI 10.1152/physrev.1999.79.4.1283; HOYERHANSEN G, 1992, J BIOL CHEM, V267, P18224; Irigoyen JP, 1999, CELL MOL LIFE SCI, V56, P104, DOI 10.1007/PL00000615; Ke SH, 1997, J BIOL CHEM, V272, P16603, DOI 10.1074/jbc.272.26.16603; Kiyan J, 2005, EMBO J, V24, P1787, DOI 10.1038/sj.emboj.7600669; LAROCHELLE WJ, 1991, GENE DEV, V5, P1191, DOI 10.1101/gad.5.7.1191; LaRochelle WJ, 2002, CANCER RES, V62, P2468; LaRochelle WJ, 2001, NAT CELL BIOL, V3, P517, DOI 10.1038/35074593; Lee S, 2005, J CELL BIOL, V169, P681, DOI 10.1083/jcb.200409115; Li H, 2003, ONCOGENE, V22, P1501, DOI 10.1038/sj.onc.1206223; Li XR, 2000, NAT CELL BIOL, V2, P302, DOI 10.1038/35010579; Lindblom P, 2003, GENE DEV, V17, P1835, DOI 10.1101/gad.266803; Liu D, 2002, CANCER CELL, V1, P445, DOI 10.1016/S1535-6108(02)00072-7; Miyake H, 1999, PROSTATE, V39, P123, DOI 10.1002/(SICI)1097-0045(19990501)39:2<123::AID-PROS7>3.0.CO;2-2; Mondino A, 2004, TRENDS IMMUNOL, V25, P450, DOI 10.1016/j.it.2004.06.004; Olofsson B, 1996, J BIOL CHEM, V271, P19310, DOI 10.1074/jbc.271.32.19310; OSTMAN A, 1991, CELL REGUL, V2, P503, DOI 10.1091/mbc.2.7.503; Simon DI, 2000, J BIOL CHEM, V275, P10228, DOI 10.1074/jbc.275.14.10228; Ustach CV, 2005, MOL CELL BIOL, V25, P6279, DOI 10.1128/MCB.25.14.6279-6288.2005; Workman P, 1998, BRIT J CANCER, V77, P1; Xu L, 2005, CANCER RES, V65, P5711, DOI 10.1158/0008-5472.CAN-04-4313	28	18	20	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 29	2009	28	4					534	544		10.1038/onc.2008.410	http://dx.doi.org/10.1038/onc.2008.410			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	400KM	18997817				2022-12-28	WOS:000262866500007
J	Malecka, KA; Ho, WC; Marmorstein, R				Malecka, K. A.; Ho, W. C.; Marmorstein, R.			Crystal structure of a p53 core tetramer bound to DNA	ONCOGENE			English	Article						p53; tumor suppressor; protein/DNA complex; crystal structure	BINDING DOMAIN PEPTIDES; TUMOR-SUPPRESSOR; SEQUENCE; RECOGNITION; COMPLEX; MULTIPLE; ELEMENTS; LOOP	The tumor suppressor p53 regulates downstream genes in response to many cellular stresses and is frequently mutated in human cancers. Here, we report the use of a crosslinking strategy to trap a tetrameric p53 DNA-binding domain (p53DBD) bound to DNA and the X-ray crystal structure of the protein/DNA complex. The structure reveals that two p53DBD dimers bind to B form DNA with no relative twist and that a p53 tetramer can bind to DNA without introducing significant DNA bending. The numerous dimer-dimer interactions involve several strictly conserved residues, thus suggesting a molecular basis for p53DBD-DNA binding cooperativity. Surface residue conservation of the p53DBD tetramer bound to DNA highlights possible regions of other p53 domain or p53 cofactor interactions.	[Malecka, K. A.; Ho, W. C.; Marmorstein, R.] Wistar Inst Anat & Biol, Program Gene Express & Regulat, Philadelphia, PA 19104 USA; [Malecka, K. A.; Ho, W. C.; Marmorstein, R.] Univ Penn, Dept Chem, Philadelphia, PA 19104 USA	The Wistar Institute; University of Pennsylvania	Marmorstein, R (corresponding author), Wistar Inst Anat & Biol, Program Gene Express & Regulat, 3601 Spruce St, Philadelphia, PA 19104 USA.	marmor@wistar.org			NIGMS NIH HHS [T32 GM008275, R01 GM052880, R01 GM052880-11] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM052880, T32GM008275] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BALAGURUMOORTHY P, 1995, P NATL ACAD SCI USA, V92, P8591, DOI 10.1073/pnas.92.19.8591; Banerjee A, 2006, SCIENCE, V311, P1153, DOI 10.1126/science.1120288; Banerjee A, 2005, NATURE, V434, P612, DOI 10.1038/nature03458; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; DeLano WL, 2002, PYMOL USERS MANUAL; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158; Gasteiger E, 2003, NUCLEIC ACIDS RES, V31, P3784, DOI 10.1093/nar/gkg563; Gouet P, 1999, BIOINFORMATICS, V15, P305, DOI 10.1093/bioinformatics/15.4.305; He CA, 2002, CHEM BIOL, V9, P1297, DOI 10.1016/S1074-5521(02)00283-1; Ho WC, 2006, J BIOL CHEM, V281, P20494, DOI 10.1074/jbc.M603634200; Horn HF, 2007, ONCOGENE, V26, P1306, DOI 10.1038/sj.onc.1210263; Huang HF, 1998, SCIENCE, V282, P1669, DOI 10.1126/science.282.5394.1669; JEFFREY PD, 1995, SCIENCE, V267, P1498, DOI 10.1126/science.7878469; Kitayner M, 2006, MOL CELL, V22, P741, DOI 10.1016/j.molcel.2006.05.015; Klein C, 2001, J BIOL CHEM, V276, P37390, DOI 10.1074/jbc.M103801200; Lu XJ, 2003, NUCLEIC ACIDS RES, V31, P5108, DOI 10.1093/nar/gkg680; MACMILLAN AM, 1991, TETRAHEDRON, V47, P2603, DOI 10.1016/S0040-4020(01)81793-2; McLure KG, 1998, EMBO J, V17, P3342, DOI 10.1093/emboj/17.12.3342; MCNAMARA PT, 1990, J BIOMOL STRUCT DYN, V8, P529, DOI 10.1080/07391102.1990.10507827; Nagaich AK, 1999, P NATL ACAD SCI USA, V96, P1875, DOI 10.1073/pnas.96.5.1875; NAGAICH AK, 1994, J BIOL CHEM, V269, P7824; Nagaich AK, 1997, J BIOL CHEM, V272, P14830, DOI 10.1074/jbc.272.23.14830; Nagaich AK, 1997, J BIOL CHEM, V272, P14842, DOI 10.1074/jbc.272.23.14842; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Pan YP, 2007, J BIOL CHEM, V282, P691, DOI 10.1074/jbc.M605908200; Pan YP, 2008, J PHYS CHEM B, V112, P6716, DOI 10.1021/jp800680w; PIETENPOL JA, 1994, P NATL ACAD SCI USA, V91, P1998, DOI 10.1073/pnas.91.6.1998; Verdine GL, 2003, ANNU REV BIOCHEM, V72, P337, DOI 10.1146/annurev.biochem.72.121801.161447; Wang Y, 2007, ACTA CRYSTALLOGR D, V63, P276, DOI 10.1107/S0907444906048499; Weinberg RL, 2004, J MOL BIOL, V341, P1145, DOI 10.1016/j.jmb.2004.06.071; Zhao KH, 2001, J BIOL CHEM, V276, P12120, DOI 10.1074/jbc.M011644200; ZHURKIN VB, 1991, P NATL ACAD SCI USA, V88, P7046, DOI 10.1073/pnas.88.16.7046; Zupnick A, 2006, J BIOL CHEM, V281, P20464, DOI 10.1074/jbc.M603387200	34	65	67	1	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 22	2009	28	3					325	333		10.1038/onc.2008.400	http://dx.doi.org/10.1038/onc.2008.400			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	395UZ	18978813	Green Accepted			2022-12-28	WOS:000262550300002
J	Hawkins, ED; Russell, SM				Hawkins, E. D.; Russell, S. M.			Upsides and downsides to polarity and asymmetric cell division in leukemia	ONCOGENE			English	Review						leukemia; lymphoma; Scribble; asymmetric cell divison; polarity; self-renewal	ACUTE LYMPHOBLASTIC-LEUKEMIA; HEMATOPOIETIC STEM-CELLS; ACUTE MYELOID-LEUKEMIA; LETHAL-GIANT-LARVAE; NEUROBLAST SELF-RENEWAL; WNT-SIGNALING PATHWAY; NUCLEAR BETA-CATENIN; TUMOR-SUPPRESSOR; SPINDLE ORIENTATION; IN-VIVO	The notion that polarity regulators can act as tumor suppressors in epithelial cells is now well accepted. The function of these proteins in lymphocytes is less well explored, and their possible function as suppressors of leukemia has had little attention so far. We review the literature on lymphocyte polarity and the growing recognition that polarity proteins have an important function in lymphocyte function. We then describe molecular relationships between the polarity network and signaling pathways that have been implicated in leukemogenesis, which suggest mechanisms by which the polarity network might impact on leukemogenesis. We particularly focus on the possibility that disruption of polarity might alter asymmetric cell division ( ACD), and that this might be a leukemia-initiating event. We also explore the converse possibility that leukemic stem cells might be produced or maintained by ACD, and therefore that Dlg, Scribble and Lgl might be important regulators of this process.	[Hawkins, E. D.; Russell, S. M.] Peter MacCallum Canc Inst, Immune Signalling Lab, Div Res, Melbourne, Vic 3002, Australia; [Russell, S. M.] Swinburne Univ Technol, Ctr MicroPhoton, Fac Engn & Ind Sci, Hawthorn, Vic 3122, Australia	Peter Maccallum Cancer Center; Swinburne University of Technology	Russell, SM (corresponding author), Peter MacCallum Canc Inst, Immune Signalling Lab, Div Res, Melbourne, Vic 3002, Australia.	sarah.russell@petermac.org	Russell, Sarah M/B-9341-2009	Russell, Sarah M/0000-0001-5826-9641; Hawkins, Edwin/0000-0002-3686-8261				Affolter M, 2005, DEV CELL, V9, P19, DOI 10.1016/j.devcel.2005.06.003; Aggerholm A, 2000, EUR J HAEMATOL, V65, P109, DOI 10.1034/j.1600-0609.2000.90181.x; Albertson R, 2003, NAT CELL BIOL, V5, P166, DOI 10.1038/ncb922; Anderson AC, 2005, J IMMUNOL, V174, P890, DOI 10.4049/jimmunol.174.2.890; Aranda V, 2008, ONCOGENE, V27, P6878, DOI 10.1038/onc.2008.340; Barnard AL, 2005, BLOOD, V106, P988, DOI 10.1182/blood-2004-07-2850; Beckmann J, 2007, BLOOD, V109, P5494, DOI 10.1182/blood-2006-11-055921; Betschinger J, 2006, CELL, V124, P1241, DOI 10.1016/j.cell.2006.01.038; Betschinger J, 2004, CURR BIOL, V14, pR674, DOI 10.1016/j.cub.2004.08.017; Bhalerao S, 2005, CURR BIOL, V15, P1583, DOI 10.1016/j.cub.2005.07.061; Bilder D, 2004, GENE DEV, V18, P1909, DOI 10.1101/gad.1211604; Blot V, 2004, J CELL SCI, V117, P3983, DOI 10.1242/jcs.01266; Bonnet D, 1997, NAT MED, V3, P730, DOI 10.1038/nm0797-730; Bowman SK, 2008, DEV CELL, V14, P535, DOI 10.1016/j.devcel.2008.03.004; Bromley SK, 2000, J IMMUNOL, V165, P15, DOI 10.4049/jimmunol.165.1.15; Buzzeo MP, 2007, LEUKEMIA, V21, P1619, DOI 10.1038/sj.leu.2404768; Castor A, 2005, NAT MED, V11, P630, DOI 10.1038/nm1253; Chang JT, 2007, SCIENCE, V315, P1687, DOI 10.1126/science.1139393; Cobaleda C, 2000, BLOOD, V95, P1007, DOI 10.1182/blood.V95.3.1007.003k35_1007_1013; Coluccia AML, 2007, EMBO J, V26, P1456, DOI 10.1038/sj.emboj.7601485; Comer FI, 2007, CELL, V128, P239, DOI 10.1016/j.cell.2007.01.010; Congdon KL, 2008, CURR OPIN IMMUNOL, V20, P302, DOI 10.1016/j.coi.2008.05.003; Costello PS, 2002, NAT IMMUNOL, V3, P1082, DOI 10.1038/ni848; Cournailleau F, 2008, CURR OPIN CELL BIOL, V20, P462, DOI 10.1016/j.ceb.2008.03.007; Cully M, 2006, NAT REV CANCER, V6, P184, DOI 10.1038/nrc1819; Dahia PLM, 1999, HUM MOL GENET, V8, P185, DOI 10.1093/hmg/8.2.185; Dollar GL, 2005, NATURE, V437, P1376, DOI 10.1038/nature04116; Dustin ML, 2002, ADV EXP MED BIOL, V512, P191; Ehebauer M, 2006, SCIENCE, V314, P1414, DOI 10.1126/science.1134042; ELLISEN LW, 1991, CELL, V66, P649, DOI 10.1016/0092-8674(91)90111-B; Etienne-Manneville S, 2005, J CELL BIOL, V170, P895, DOI 10.1083/jcb.200412172; Etienne-Manneville S, 2003, NATURE, V421, P753, DOI 10.1038/nature01423; Etienne-Manneville S, 2008, ONCOGENE, V27, P6970, DOI 10.1038/onc.2008.347; Fukuda R, 2005, P NATL ACAD SCI USA, V102, P15213, DOI 10.1073/pnas.0507184102; Gerard A, 2007, J CELL BIOL, V176, P863, DOI 10.1083/jcb.200608161; Giagulli C, 2004, IMMUNITY, V20, P25, DOI 10.1016/S1074-7613(03)00350-9; Giebel B, 2006, BLOOD, V107, P2146, DOI 10.1182/blood-2005-08-3139; Gong Y, 2004, NATURE, V430, P689, DOI 10.1038/nature02796; Gonzalez C, 2007, NAT REV GENET, V8, P462, DOI 10.1038/nrg2103; Grabher C, 2006, NAT REV CANCER, V6, P347, DOI 10.1038/nrc1880; Guo W, 2008, NATURE, V453, P529, DOI 10.1038/nature06933; Guo ZY, 2007, BLOOD, V109, P5463, DOI 10.1182/blood-2006-11-059071; Hardin J, 2008, CURR OPIN GENET DEV, V18, P362, DOI 10.1016/j.gde.2008.06.006; Heit B, 2008, NAT IMMUNOL, V9, P743, DOI 10.1038/ni.1623; Hezel AF, 2008, ONCOGENE, V27, P6908, DOI 10.1038/onc.2008.342; Huber MA, 2005, CURR OPIN CELL BIOL, V17, P548, DOI 10.1016/j.ceb.2005.08.001; Humbert P, 2003, BIOESSAYS, V25, P542, DOI 10.1002/bies.10286; Humbert PO, 2008, ONCOGENE, V27, P6888, DOI 10.1038/onc.2008.341; Humbert PO, 2006, TRENDS CELL BIOL, V16, P622, DOI 10.1016/j.tcb.2006.10.005; Igakura T, 2003, SCIENCE, V299, P1713, DOI 10.1126/science.1080115; Iijima M, 2002, DEV CELL, V3, P469, DOI 10.1016/S1534-5807(02)00292-7; Ishidate T, 2000, ONCOGENE, V19, P365, DOI 10.1038/sj.onc.1203309; Ishikawa F, 2007, NAT BIOTECHNOL, V25, P1315, DOI 10.1038/nbt1350; Januschke J, 2008, ONCOGENE, V27, P6994, DOI 10.1038/onc.2008.349; Javier RT, 2008, ONCOGENE, V27, P7031, DOI 10.1038/onc.2008.352; Jones P, 1998, BLOOD, V92, P1505, DOI 10.1182/blood.V92.5.1505.417k42_1505_1511; Kallay LM, 2006, J CELL BIOCHEM, V99, P647, DOI 10.1002/jcb.20992; Kamei Y, 2007, HUM PATHOL, V38, P1273, DOI 10.1016/j.humpath.2007.01.026; KEMPHUES KJ, 1988, CELL, V52, P311, DOI 10.1016/S0092-8674(88)80024-2; Kiel MJ, 2008, NAT REV IMMUNOL, V8, P290, DOI 10.1038/nri2279; Klezovitch O, 2004, GENE DEV, V18, P559, DOI 10.1101/gad.1178004; Knoblich JA, 2008, CELL, V132, P583, DOI 10.1016/j.cell.2008.02.007; Krummel MF, 2006, NAT IMMUNOL, V7, P1143, DOI 10.1038/ni1404; Ladi E, 2006, NAT IMMUNOL, V7, P338, DOI 10.1038/ni1323; Langevin J, 2005, CURR BIOL, V15, P955, DOI 10.1016/j.cub.2005.04.054; le Viseur C, 2008, CANCER CELL, V14, P47, DOI 10.1016/j.ccr.2008.05.015; Lee CY, 2006, GENE DEV, V20, P3464, DOI 10.1101/gad.1489406; Lee CY, 2006, NATURE, V439, P594, DOI 10.1038/nature04299; Lee MH, 2008, J CELL SCI, V121, P1141, DOI 10.1242/jcs.016634; Lee OK, 2003, NAT CELL BIOL, V5, P987, DOI 10.1038/ncb1055; Li LH, 2006, CANCER RES, V66, P4553, DOI 10.1158/0008-5472.CAN-05-3986; Li Z, 2003, CELL, V114, P215, DOI 10.1016/S0092-8674(03)00559-2; Lu DS, 2004, P NATL ACAD SCI USA, V101, P3118, DOI 10.1073/pnas.0308648100; Ludford-Menting MJ, 2005, IMMUNITY, V22, P737, DOI 10.1016/j.immuni.2005.04.009; Martin-Belmonte F, 2007, CELL, V128, P383, DOI 10.1016/j.cell.2006.11.051; METCALF D, 1966, CANCER RES, V26, P483; Mikesch JH, 2007, LEUKEMIA, V21, P1638, DOI 10.1038/sj.leu.2404732; Mizumoto K, 2007, TRENDS CELL BIOL, V17, P465, DOI 10.1016/j.tcb.2007.08.004; Mizumoto K, 2007, DEV CELL, V12, P287, DOI 10.1016/j.devcel.2007.01.004; Montcouquiol M, 2003, NATURE, V423, P173, DOI 10.1038/nature01618; Moreno-Bueno G, 2008, ONCOGENE, V27, P6958, DOI 10.1038/onc.2008.346; Morrison SJ, 2008, CELL, V132, P598, DOI 10.1016/j.cell.2008.01.038; Morrison SJ, 2006, NATURE, V441, P1068, DOI 10.1038/nature04956; Mortreux F, 2003, LEUKEMIA, V17, P26, DOI 10.1038/sj.leu.2402777; Ngo NT, 2008, BRIT J HAEMATOL, V141, P771, DOI 10.1111/j.1365-2141.2008.07117.x; Nimer SD, 2008, BLOOD, V111, P4841, DOI 10.1182/blood-2007-08-078139; Nishio M, 2007, NAT CELL BIOL, V9, P36, DOI 10.1038/ncb1515; NORBERG B, 1977, LANCET, V1, P957; Ohshiro T, 2000, NATURE, V408, P593, DOI 10.1038/35046087; Okita K, 2007, NATURE, V448, P313, DOI 10.1038/nature05934; Oliaro J, 2006, P NATL ACAD SCI USA, V103, P18685, DOI 10.1073/pnas.0602458103; Orgogozo V, 2002, DEVELOPMENT, V129, P4677; Palomero T, 2007, NAT MED, V13, P1203, DOI 10.1038/nm1636; Peng CY, 2000, NATURE, V408, P596, DOI 10.1038/35046094; Petropoulos K, 2008, J EXP MED, V205, P515, DOI 10.1084/jem.20071875; Rattis FM, 2004, CURR OPIN HEMATOL, V11, P88, DOI 10.1097/01.moh.0000133649.61121.ec; Real E, 2007, J IMMUNOL, V179, P5649, DOI 10.4049/jimmunol.179.9.5649; Reya T, 2001, NATURE, V414, P105, DOI 10.1038/35102167; Roegiers F, 2005, MOL BIOL CELL, V16, P3480, DOI 10.1091/mbc.E05-03-0177; Roman-Gomez J, 2007, BLOOD, V109, P3462, DOI 10.1182/blood-2006-09-047043; Rothenberg EV, 2008, NAT REV IMMUNOL, V8, P9, DOI 10.1038/nri2232; Round JL, 2005, J EXP MED, V201, P419, DOI 10.1084/jem.20041428; Russell S, 2008, J CELL SCI, V121, P131, DOI 10.1242/jcs.021253; SAINTEMARIE G, 1965, BLOOD-J HEMATOL, V26, P765, DOI 10.1182/blood.V26.6.765.765; Sanada K, 2005, CELL, V122, P119, DOI 10.1016/j.cell.2005.05.009; Savona M, 2008, NAT REV CANCER, V8, P341, DOI 10.1038/nrc2368; Schlessinger K, 2007, J CELL BIOL, V178, P355, DOI 10.1083/jcb.200701083; SCHUMACHER HR, 1979, AM J HEMATOL, V7, P11, DOI 10.1002/ajh.2830070103; Siegrist SE, 2005, CELL, V123, P1323, DOI 10.1016/j.cell.2005.09.043; Sneddon JB, 2007, CELL STEM CELL, V1, P607, DOI 10.1016/j.stem.2007.11.009; Staal FJT, 2008, NAT REV IMMUNOL, V8, P581, DOI 10.1038/nri2360; Steelman LS, 2008, LEUKEMIA, V22, P686, DOI 10.1038/leu.2008.26; Stephenson LM, 2007, MOL CELL BIOL, V27, P7574, DOI 10.1128/MCB.00439-07; Stinchcombe JC, 2007, ANNU REV CELL DEV BI, V23, P495, DOI 10.1146/annurev.cellbio.23.090506.123521; Takano H, 2004, J EXP MED, V199, P295, DOI 10.1084/jem.20030929; Tanegashima K, 2008, EMBO J, V27, P606, DOI 10.1038/emboj.2008.9; Thiery JP, 2006, NAT REV MOL CELL BIO, V7, P131, DOI 10.1038/nrm1835; Thomas M, 2008, ONCOGENE, V27, P7018, DOI 10.1038/onc.2008.351; Toyoshima F, 2007, DEV CELL, V13, P796, DOI 10.1016/j.devcel.2007.10.014; Van Keymeulen A, 2006, J CELL BIOL, V174, P437, DOI 10.1083/jcb.200604113; Varnum-Finney B, 1998, BLOOD, V91, P4084, DOI 10.1182/blood.V91.11.4084.411k05_4084_4091; Verburgh E, 2003, J CLIN ONCOL, V21, P273, DOI 10.1200/JCO.2003.04.182; von Stein W, 2005, DEVELOPMENT, V132, P1675, DOI 10.1242/dev.01720; Wang F, 2002, NAT CELL BIOL, V4, P513, DOI 10.1038/ncb810; Wang SF, 2008, BLOOD, V111, P2878, DOI 10.1182/blood-2007-07-103119; Weerkamp F, 2006, LEUKEMIA, V20, P1197, DOI 10.1038/sj.leu.2404255; Weng AP, 2004, SCIENCE, V306, P269, DOI 10.1126/science.1102160; Wernig M, 2007, NATURE, V448, P318, DOI 10.1038/nature05944; Wikramanayake AH, 2003, NATURE, V426, P446, DOI 10.1038/nature02113; Wu H, 2007, MOL CELL, V28, P886, DOI 10.1016/j.molcel.2007.10.028; Wu MF, 2007, CELL STEM CELL, V1, P541, DOI 10.1016/j.stem.2007.08.009; Xavier R, 2004, J CELL BIOL, V166, P173, DOI 10.1083/jcb.200309044; Xie T, 2007, DEVELOPMENT, V134, P2001, DOI 10.1242/dev.002022; Xue L, 2008, P NATL ACAD SCI USA, V105, P2022, DOI 10.1073/pnas.0712059105; Yamashita YM, 2003, SCIENCE, V301, P1547, DOI 10.1126/science.1087795; Yilmaz OH, 2006, NATURE, V441, P475, DOI 10.1038/nature04703; Yin XY, 2007, J IMMUNOL, V179, P7358, DOI 10.4049/jimmunol.179.11.7358; Yoshida S, 2008, VIRUS GENES, V37, P9, DOI 10.1007/s11262-008-0234-0; Ysebaert L, 2006, LEUKEMIA, V20, P1211, DOI 10.1038/sj.leu.2404239; Zhang JW, 2006, NATURE, V441, P518, DOI 10.1038/nature04747; Zhao C, 2007, CANCER CELL, V12, P528, DOI 10.1016/j.ccr.2007.11.003; ZIGMOND SH, 1981, J CELL BIOL, V89, P585, DOI 10.1083/jcb.89.3.585	142	28	28	1	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 24	2008	27	55					7003	7017		10.1038/onc.2008.350	http://dx.doi.org/10.1038/onc.2008.350			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	375IU	19029941				2022-12-28	WOS:000261108200012
J	Pinton, P; Giorgi, C; Siviero, R; Zecchini, E; Rizzuto, R				Pinton, P.; Giorgi, C.; Siviero, R.; Zecchini, E.; Rizzuto, R.			Calcium and apoptosis: ER-mitochondria Ca2+ transfer in the control of apoptosis	ONCOGENE			English	Review						cell death; Bcl-2; endoplasmic reticulum; autophagy; mitochondria-associated membranes (MAM)	INOSITOL 1,4,5-TRISPHOSPHATE RECEPTOR; PROTEIN-KINASE-C; ENDOPLASMIC-RETICULUM CA2+; LIFE-SPAN DETERMINANT; PROSTATE-CANCER CELLS; PERMEABILITY TRANSITION; INTRACELLULAR CA2+; CYCLOPHILIN-D; CYTOCHROME-C; TRISPHOSPHATE RECEPTOR	There is a growing consensus that the various forms of cell death ( necrosis, apoptosis and autophagy) are not separated by strict boundaries, but rather share molecular effectors and signaling routes. Among the latter, a clear role is played by calcium (Ca2+), the ubiquitous second messenger involved in the control of a broad variety of physiological events. Fine tuning of intracellular Ca2+ homeostasis by anti- and proapoptotic proteins shapes the Ca2+ signal to which mitochondria and other cellular effectors are exposed, and hence the efficiency of various cell death inducers. Here, we will review: (i) the evidence linking calcium homeostasis to the regulation of apoptotic, and more recently autophagic cell death, (ii) the discussion of mitochondria as a critical, although not unique checkpoint and (iii) the molecular and functional elucidation of ER/mitochondria contacts, corresponding to the mitochondria-associated membrane (MAM) subfraction and proposed to be a specialized signaling microdomain.	[Pinton, P.; Giorgi, C.; Siviero, R.; Zecchini, E.; Rizzuto, R.] ICSI, Dept Expt & Diagnost Med, Sect Gen Pathol, I-44100 Ferrara, Italy; [Pinton, P.; Giorgi, C.; Siviero, R.; Zecchini, E.; Rizzuto, R.] Univ Ferrara, Emilia Romagna Lab Biopharmanet, I-44100 Ferrara, Italy; [Giorgi, C.] Univ Vita Salute San Raffaele, Res Unit Mol Neurosci, Ctr Excellence Cell Dev, Milan, Italy; [Giorgi, C.] Univ Vita Salute San Raffaele, IIT Network, Milan, Italy	University of Ferrara; Vita-Salute San Raffaele University; Istituto Italiano di Tecnologia - IIT; Vita-Salute San Raffaele University	Rizzuto, R (corresponding author), ICSI, Dept Expt & Diagnost Med, Sect Gen Pathol, Via Borsari 46, I-44100 Ferrara, Italy.	r.rizzuto@unife.it	Giorgi, Carlotta/K-4649-2016; Pinton, Paolo/J-8025-2012	Pinton, Paolo/0000-0001-7108-6508; Giorgi, Carlotta/0000-0002-2494-7405; Rizzuto, Rosario/0000-0001-7044-5097	Italian Association for Cancer Research (AIRC), Telethon; University of Ferrara; Italian University Ministry; Emilia Romagna Region; Italian Space Agency (ASI); NIH [1P01AG025532-01A1]; United Mitochondrial Disease Foundation (UMDF); NATIONAL INSTITUTE ON AGING [P01AG025532] Funding Source: NIH RePORTER	Italian Association for Cancer Research (AIRC), Telethon(Fondazione AIRC per la ricerca sul cancroFondazione Telethon); University of Ferrara; Italian University Ministry(Ministry of Education, Universities and Research (MIUR)); Emilia Romagna Region(Regione Emilia Romagna); Italian Space Agency (ASI)(Agenzia Spaziale Italiana (ASI)); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); United Mitochondrial Disease Foundation (UMDF); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	We are deeply indebted to past and present collaborators. This work was supported by the Italian Association for Cancer Research (AIRC), Telethon, local funds from the University of Ferrara, the Italian University Ministry, the PRRIITT program of the Emilia Romagna Region, the Italian Space Agency (ASI), NIH ( Grant no. 1P01AG025532-01A1) and the United Mitochondrial Disease Foundation (UMDF).	Alnemri ES, 1996, CELL, V87, P171, DOI 10.1016/S0092-8674(00)81334-3; Assefa Z, 2004, J BIOL CHEM, V279, P43227, DOI 10.1074/jbc.M403872200; Baehrecke EH, 2005, NAT REV MOL CELL BIO, V6, P505, DOI 10.1038/nrm1666; BAFFY G, 1993, J BIOL CHEM, V268, P6511; Baines CP, 2005, NATURE, V434, P658, DOI 10.1038/nature03434; Bano D, 2005, CELL, V120, P275, DOI 10.1016/j.cell.2004.11.049; Basso E, 2005, J BIOL CHEM, V280, P18558, DOI 10.1074/jbc.C500089200; BASTIANUTTO C, 1995, J CELL BIOL, V130, P847, DOI 10.1083/jcb.130.4.847; Bernardi P, 2006, FEBS J, V273, P2077, DOI 10.1111/j.1742-4658.2006.05213.x; Berridge MJ, 2003, NAT REV MOL CELL BIO, V4, P517, DOI 10.1038/nrm1155; Berridge MJ, 2000, NAT REV MOL CELL BIO, V1, P11, DOI 10.1038/35036035; Berridge MJ, 2002, CELL CALCIUM, V32, P235, DOI 10.1016/S0143416002001823; Biagioli M, 2008, CELL CALCIUM, V43, P184, DOI 10.1016/j.ceca.2007.05.003; Blackshaw S, 2000, FASEB J, V14, P1375, DOI 10.1096/fj.14.10.1375; Boehning D, 2003, NAT CELL BIOL, V5, P1051, DOI 10.1038/ncb1063; Brini M, 2000, EMBO J, V19, P4926, DOI 10.1093/emboj/19.18.4926; Budd SL, 1996, J NEUROCHEM, V66, P403, DOI 10.1046/j.1471-4159.1996.66010403.x; Camello P, 1996, J PHYSIOL-LONDON, V490, P585, DOI 10.1113/jphysiol.1996.sp021169; Campanella M, 2004, J BIOL CHEM, V279, P18440, DOI 10.1074/jbc.M309494200; Carafoli E, 1998, BIOCHEM BIOPH RES CO, V247, P193, DOI 10.1006/bbrc.1998.8378; Chami M, 2000, ONCOGENE, V19, P2877, DOI 10.1038/sj.onc.1203605; Chami M, 2004, J BIOL CHEM, V279, P54581, DOI 10.1074/jbc.M409663200; Chami M, 2003, J BIOL CHEM, V278, P31745, DOI 10.1074/jbc.M304202200; Chan SL, 1999, J NEUROSCI RES, V58, P167, DOI 10.1002/(SICI)1097-4547(19991001)58:1<167::AID-JNR16>3.0.CO;2-K; Clapham DE, 2007, CELL, V131, P1047, DOI 10.1016/j.cell.2007.11.028; Csordas G, 1999, EMBO J, V18, P96, DOI 10.1093/emboj/18.1.96; Danial NN, 2004, CELL, V116, P205, DOI 10.1016/S0092-8674(04)00046-7; Demaurex N, 2003, SCIENCE, V300, P65, DOI 10.1126/science.1083628; FARISS MW, 1985, SCIENCE, V227, P751, DOI 10.1126/science.3918345; Foyouzi-Youssefi R, 2000, P NATL ACAD SCI USA, V97, P5723, DOI 10.1073/pnas.97.11.5723; Garrido C, 2006, CELL DEATH DIFFER, V13, P1423, DOI 10.1038/sj.cdd.4401950; Giorgi C, 2008, CURR MOL MED, V8, P119; Giorgio M, 2005, CELL, V122, P221, DOI 10.1016/j.cell.2005.05.011; Glazner GW, 2000, J NEUROSCI, V20, P3641, DOI 10.1523/JNEUROSCI.20-10-03641.2000; Griner EM, 2007, NAT REV CANCER, V7, P281, DOI 10.1038/nrc2110; Hajnoczky G, 2003, BIOCHEM BIOPH RES CO, V304, P445, DOI 10.1016/S0006-291X(03)00616-8; HAJNOCZKY G, 1995, CELL, V82, P415, DOI 10.1016/0092-8674(95)90430-1; Hayashi T, 2007, CELL, V131, P596, DOI 10.1016/j.cell.2007.08.036; Hetts SW, 1998, JAMA-J AM MED ASSOC, V279, P300, DOI 10.1001/jama.279.4.300; Hill Michelle M, 2003, Mol Interv, V3, P19, DOI 10.1124/mi.3.1.19; Hirota J, 1999, J BIOL CHEM, V274, P34433, DOI 10.1074/jbc.274.48.34433; Hofer AM, 1998, J CELL BIOL, V140, P325, DOI 10.1083/jcb.140.2.325; Hoyer-Hansen M, 2007, MOL CELL, V25, P193, DOI 10.1016/j.molcel.2006.12.009; Jayaraman T, 1997, MOL CELL BIOL, V17, P3005, DOI 10.1128/MCB.17.6.3005; Jouaville LS, 1999, P NATL ACAD SCI USA, V96, P13807, DOI 10.1073/pnas.96.24.13807; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; Khan AA, 1996, SCIENCE, V273, P503, DOI 10.1126/science.273.5274.503; Khan MT, 2006, J BIOL CHEM, V281, P3731, DOI 10.1074/jbc.M509262200; Kobayashi S, 2002, J BIOL CHEM, V277, P33968, DOI 10.1074/jbc.M203350200; Kroemer G, 2005, CELL DEATH DIFFER, V12, P1463, DOI 10.1038/sj.cdd.4401724; Kroemer G, 2007, PHYSIOL REV, V87, P99, DOI 10.1152/physrev.00013.2006; Kruman I, 1998, J NEUROSCI RES, V51, P293, DOI 10.1002/(SICI)1097-4547(19980201)51:3<293::AID-JNR3>3.0.CO;2-B; LAM M, 1994, P NATL ACAD SCI USA, V91, P6569, DOI 10.1073/pnas.91.14.6569; Lasorsa FM, 2003, J BIOL CHEM, V278, P38686, DOI 10.1074/jbc.M304988200; Lavin MF, 1996, EXPERIENTIA, V52, P979, DOI 10.1007/BF01920107; Li C, 2007, P NATL ACAD SCI USA, V104, P12565, DOI 10.1073/pnas.0702489104; Liu YB, 2002, J NEUROCHEM, V80, P780, DOI 10.1046/j.0022-3042.2002.00744.x; Lum JJ, 2005, CELL, V120, P237, DOI 10.1016/j.cell.2004.11.046; Lynch K, 2000, ENDOCRINOLOGY, V141, P4209, DOI 10.1210/en.141.11.4209; Ma TS, 1999, CELL CALCIUM, V26, P25, DOI 10.1054/ceca.1999.0049; Mandic A, 2002, MOL CELL BIOL, V22, P3003, DOI 10.1128/MCB.22.9.3003-3013.2002; Marsh BJ, 2001, P NATL ACAD SCI USA, V98, P2399, DOI 10.1073/pnas.051631998; Mendes CCP, 2005, J BIOL CHEM, V280, P40892, DOI 10.1074/jbc.M506623200; Montero M, 2002, FASEB J, V16, P1955, DOI 10.1096/fj.02-0553fje; Nakagawa T, 2000, NATURE, V403, P98, DOI 10.1038/47513; Nakagawa T, 2005, NATURE, V434, P652, DOI 10.1038/nature03317; Nakagawa T, 2000, J CELL BIOL, V150, P887, DOI 10.1083/jcb.150.4.887; Nakamura K, 2000, J CELL BIOL, V150, P731, DOI 10.1083/jcb.150.4.731; Nicholson DW, 1999, CELL DEATH DIFFER, V6, P1028, DOI 10.1038/sj.cdd.4400598; Nicholson DW, 1997, TRENDS BIOCHEM SCI, V22, P299, DOI 10.1016/S0968-0004(97)01085-2; Nicotera P, 1998, CELL CALCIUM, V23, P173, DOI 10.1016/S0143-4160(98)90116-6; Oakes SA, 2005, P NATL ACAD SCI USA, V102, P105, DOI 10.1073/pnas.0408352102; Orrenius S, 2003, NAT REV MOL CELL BIO, V4, P552, DOI 10.1038/nrm1150; Palmer AE, 2004, P NATL ACAD SCI USA, V101, P17404, DOI 10.1073/pnas.0408030101; Parker PJ, 2004, J CELL SCI, V117, P131, DOI 10.1242/jcs.00982; Pattingre S, 2005, CELL, V122, P927, DOI 10.1016/j.cell.2005.07.002; Perry G, 1998, SCIENCE, V282, P1268; Piccini M, 1998, GENOMICS, V47, P350, DOI 10.1006/geno.1997.5104; Pinton P, 2006, CELL DEATH DIFFER, V13, P1409, DOI 10.1038/sj.cdd.4401960; Pinton P, 2001, EMBO J, V20, P2690, DOI 10.1093/emboj/20.11.2690; Pinton P, 2000, J CELL BIOL, V148, P857, DOI 10.1083/jcb.148.5.857; Pinton P, 2004, J CELL BIOL, V165, P223, DOI 10.1083/jcb.200311061; Pinton P, 1998, BIOFACTORS, V8, P243, DOI 10.1002/biof.5520080312; Pinton P, 2002, BIOCHIMIE, V84, P195, DOI 10.1016/S0300-9084(02)01373-1; Pinton P, 2001, DRUG DEVELOP RES, V52, P558, DOI 10.1002/ddr.1159; Pinton P, 2008, CELL CYCLE, V7, P304, DOI 10.4161/cc.7.3.5360; Pinton P, 2007, METHOD CELL BIOL, V80, P297, DOI 10.1016/S0091-679X(06)80015-4; Pinton P, 2007, SCIENCE, V315, P659, DOI 10.1126/science.1135380; POZZAN T, 1994, PHYSIOL REV, V74, P595, DOI 10.1152/physrev.1994.74.3.595; PRESSMAN BC, 1976, ANNU REV BIOCHEM, V45, P501, DOI 10.1146/annurev.bi.45.070176.002441; PUTNEY JW, 1990, CELL CALCIUM, V11, P611, DOI 10.1016/0143-4160(90)90016-N; Rapizzi E, 2002, J CELL BIOL, V159, P613, DOI 10.1083/jcb.200205091; Ravagnan L, 2002, J CELL PHYSIOL, V192, P131, DOI 10.1002/jcp.10111; Rimessi A, 2008, BBA-BIOENERGETICS, V1777, P808, DOI 10.1016/j.bbabio.2008.05.449; Rippo MR, 2000, FASEB J, V14, P2047, DOI 10.1096/fj.99-1028com; Rizzuto R, 2003, ONCOGENE, V22, P8619, DOI 10.1038/sj.onc.1207105; Rizzuto R, 1998, SCIENCE, V280, P1763, DOI 10.1126/science.280.5370.1763; Rizzuto R, 2006, PHYSIOL REV, V86, P369, DOI 10.1152/physrev.00004.2005; Saeki K, 2000, CELL DEATH DIFFER, V7, P1263, DOI 10.1038/sj.cdd.4400759; Schwab BL, 2002, CELL DEATH DIFFER, V9, P818, DOI 10.1038/sj.cdd.4401042; Scorrano L, 2003, SCIENCE, V300, P135, DOI 10.1126/science.1081208; SHIBASAKI F, 1995, J CELL BIOL, V131, P735, DOI 10.1083/jcb.131.3.735; Simmen T, 2005, EMBO J, V24, P717, DOI 10.1038/sj.emboj.7600559; Stone SJ, 2000, J BIOL CHEM, V275, P34534, DOI 10.1074/jbc.M002865200; Sugawara H, 1997, EMBO J, V16, P3078, DOI 10.1093/emboj/16.11.3078; Szabadkai G, 2004, MOL CELL, V16, P59, DOI 10.1016/j.molcel.2004.09.026; Szabadkai G, 2006, J CELL BIOL, V175, P901, DOI 10.1083/jcb.200608073; Szado T, 2008, P NATL ACAD SCI USA, V105, P2427, DOI 10.1073/pnas.0711324105; Szalai G, 1999, EMBO J, V18, P6349, DOI 10.1093/emboj/18.22.6349; Teranishi F, 2003, BIOCHEM BIOPH RES CO, V303, P940, DOI 10.1016/S0006-291X(03)00447-9; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; Tidball JG, 2000, INT J BIOCHEM CELL B, V32, P1, DOI 10.1016/S1357-2725(99)00095-3; Tombal B, 1999, CELL CALCIUM, V25, P19, DOI 10.1054/ceca.1998.0005; Tsujimoto Y, 2005, CELL DEATH DIFFER, V12, P1528, DOI 10.1038/sj.cdd.4401777; Turrens JF, 2003, J PHYSIOL-LONDON, V552, P335, DOI 10.1113/jphysiol.2003.049478; Twomey C, 2005, J CELL MOL MED, V9, P345, DOI 10.1111/j.1582-4934.2005.tb00360.x; VANCE JE, 1990, J BIOL CHEM, V265, P7248; Vanden Abeele F, 2002, CANCER CELL, V1, P169; Vanoverberghe K, 2004, CELL DEATH DIFFER, V11, P321, DOI 10.1038/sj.cdd.4401375; Voeltz GK, 2002, EMBO REP, V3, P944, DOI 10.1093/embo-reports/kvf202; Wang HG, 1999, SCIENCE, V284, P339, DOI 10.1126/science.284.5412.339; Wang NS, 2001, J BIOL CHEM, V276, P44117, DOI 10.1074/jbc.M101958200; White C, 2005, NAT CELL BIOL, V7, P1021, DOI 10.1038/ncb1302; Wieckowski MR, 2006, BIOCHEM BIOPH RES CO, V348, P393, DOI 10.1016/j.bbrc.2006.07.072; Xu XZS, 2001, P NATL ACAD SCI USA, V98, P10692, DOI 10.1073/pnas.191360198; Yoneda T, 2001, J BIOL CHEM, V276, P13935, DOI 10.1074/jbc.M010677200; Youle RJ, 2005, NAT REV MOL CELL BIO, V6, P657, DOI 10.1038/nrm1697; Zhang JD, 1996, P NATL ACAD SCI USA, V93, P5325, DOI 10.1073/pnas.93.11.5325	128	802	823	6	104	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 27	2008	27	50					6407	6418		10.1038/onc.2008.308	http://dx.doi.org/10.1038/onc.2008.308			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	366RR	18955969	Green Accepted			2022-12-28	WOS:000260501600002
J	Muller, A; Duque, J; Shizuru, JA; Lubbert, M				Mueller, Ams; Duque, J.; Shizuru, J. A.; Luebbert, M.			Complementing mutations in core binding factor leukemias: from mouse models to clinical applications	ONCOGENE			English	Review						core binding factor leukemias; AML1-ETO; CBF beta-MYH11; receptor tyrosine kinase; c-KIT mutation	ACUTE MYELOID-LEUKEMIA; ACUTE MYELOGENOUS LEUKEMIA; ACUTE MYELOBLASTIC-LEUKEMIA; MYOSIN HEAVY-CHAIN; INTERNAL TANDEM DUPLICATION; RECEPTOR TYROSINE KINASE; C-KIT MUTATIONS; FUSION PROTEIN; TRANSCRIPTION FACTOR; FETAL LIVER	A great proportion of acute myeloid leukemias (AMLs) display cytogenetic abnormalities including chromosomal aberrations and/or submicroscopic mutations. These abnormalities significantly influence the prognosis of the disease. Hence, a thorough genetic work-up is an essential constituent of standard diagnostic procedures. Core binding factor (CBF) leukemias denote AMLs with chromosomal aberrations disrupting one of the CBF transcription factor genes; the most common examples are translocation t(8;21) and inversion inv(16), which result in the generation of the AML1-ETO and CBF beta-MYH11 fusion proteins, respectively. However, in murine models, these alterations alone do not suffice to generate full-blown leukemia, but rather, complementary events are required. In fact, a substantial proportion of primary CBF leukemias display additional activating mutations, mostly of the receptor tyrosine kinase (RTK) c-KIT. The awareness of the impact and prognostic relevance of these 'second hits' is increasing with a wider range of mutations tested in clinical trials. Furthermore, novel agents targeting RTKs are emanating rapidly and entering therapeutic regimens. Here, we present a concise review on complementing mutations in CBF leukemias including pathophysiology, mouse models, and clinical implications.	[Mueller, Ams; Duque, J.; Luebbert, M.] Univ Med Ctr Freiburg, Dept Hematol Oncol, D-79106 Freiburg, Germany; [Mueller, Ams; Shizuru, J. A.] Stanford Univ, Med Ctr, Dept Med, Div Blood & Marrow Transplantat, Stanford, CA 94305 USA	University of Freiburg; Stanford University	Lubbert, M (corresponding author), Univ Med Ctr Freiburg, Dept Hematol Oncol, Hugstetterstr 55, D-79106 Freiburg, Germany.	michael.luebbert@uniklinik-freiburg.de	Müller, Antonia/HCI-4374-2022	Muller, Antonia Maria Susanne/0000-0003-4420-9466	Deutsche Forschungsgemeinschaft (DFG), Germany; La Caixa Stiftung-Deutscher Akademischer Austauschdienst (DAAD), Germany; German Jose-Carreras Leukemia Foundation	Deutsche Forschungsgemeinschaft (DFG), Germany(German Research Foundation (DFG)); La Caixa Stiftung-Deutscher Akademischer Austauschdienst (DAAD), Germany(Deutscher Akademischer Austausch Dienst (DAAD)); German Jose-Carreras Leukemia Foundation	We are grateful for outstanding support by the comments and remarks of both reviewers of this paper. This study was supported by the Deutsche Forschungsgemeinschaft (DFG), Germany (AM), the La Caixa Stiftung-Deutscher Akademischer Austauschdienst (DAAD), Germany (JD), and the German Jose-Carreras Leukemia Foundation (ML), respectively.	Adya N, 1998, MOL CELL BIOL, V18, P7432, DOI 10.1128/MCB.18.12.7432; Alcalay M, 2001, ONCOGENE, V20, P5680, DOI 10.1038/sj.onc.1204642; Bacher U, 2006, BLOOD, V107, P3847, DOI 10.1182/blood-2005-08-3522; Baer MR, 1997, BLOOD, V90, P1643, DOI 10.1182/blood.V90.4.1643.1643_1643_1648; Beghini A, 2000, BLOOD, V95, P726, DOI 10.1182/blood.V95.2.726; Beghini A, 2004, HAEMATOLOGICA, V89, P920; BENNETT JM, 1985, ANN INTERN MED, V103, P620, DOI 10.7326/0003-4819-103-4-620; Boissel N, 2006, LEUKEMIA, V20, P965, DOI 10.1038/sj.leu.2404188; Bowen DT, 2005, BLOOD, V106, P2113, DOI 10.1182/blood-2005-03-0867; Buchholz F, 2000, EMBO REP, V1, P133, DOI 10.1093/embo-reports/kvd027; Burel SA, 2001, MOL CELL BIOL, V21, P5577, DOI 10.1128/MCB.21.16.5577-5590.2001; Byrd JC, 2002, BLOOD, V100, P4325, DOI 10.1182/blood-2002-03-0772; Cairoli R, 2006, BLOOD, V107, P3463, DOI 10.1182/blood-2005-09-3640; Cairoli R, 2003, LEUKEMIA, V17, P471, DOI 10.1038/sj.leu.2402795; Calabi F, 2001, MOL CELL BIOL, V21, P5658, DOI 10.1128/MCB.21.16.5658-5666.2001; CAMERON S, 1994, BLOOD, V83, P2851, DOI 10.1182/blood.V83.10.2851.2851; Care RS, 2003, BRIT J HAEMATOL, V121, P775, DOI 10.1046/j.1365-2141.2003.04362.x; Castilla LH, 1999, NAT GENET, V23, P144, DOI 10.1038/13776; Castilla LH, 2004, P NATL ACAD SCI USA, V101, P4924, DOI 10.1073/pnas.0400930101; Castilla LH, 1996, CELL, V87, P687, DOI 10.1016/S0092-8674(00)81388-4; Chan EM, 2005, BLOOD, V105, P4523, DOI 10.1182/blood-2004-07-2762; Chinen Y, 2008, ONCOGENE, V27, P2249, DOI 10.1038/sj.onc.1210857; Costello R, 1997, LEUKEMIA, V11, P644, DOI 10.1038/sj.leu.2400629; de Guzman CG, 2002, MOL CELL BIOL, V22, P5506, DOI 10.1128/MCB.22.15.5506-5517.2002; Dohner K, 2006, HAEMATOLOGICA, V91, P1569; Downing JR, 1999, BRIT J HAEMATOL, V106, P296, DOI 10.1046/j.1365-2141.1999.01377.x; Elsasser A, 2003, ONCOGENE, V22, P5646, DOI 10.1038/sj.onc.1206673; ERICKSON P, 1992, BLOOD, V80, P1825; Fenske TS, 2004, P NATL ACAD SCI USA, V101, P15184, DOI 10.1073/pnas.0400751101; Gamou T, 1998, BLOOD, V91, P4028, DOI 10.1182/blood.V91.11.4028.411a45_4028_4037; Gari M, 1999, BRIT J HAEMATOL, V105, P894, DOI 10.1046/j.1365-2141.1999.01449.x; Gelmetti V, 1998, MOL CELL BIOL, V18, P7185, DOI 10.1128/MCB.18.12.7185; Goemans BF, 2005, LEUKEMIA, V19, P1536, DOI 10.1038/sj.leu.2403870; GOLUB TR, 1995, P NATL ACAD SCI USA, V92, P4917, DOI 10.1073/pnas.92.11.4917; Grimwade D, 1998, BLOOD, V92, P2322, DOI 10.1182/blood.V92.7.2322; Grisolano JL, 2003, P NATL ACAD SCI USA, V100, P9506, DOI 10.1073/pnas.1531730100; Higuchi M, 2002, CANCER CELL, V1, P63, DOI 10.1016/S1535-6108(02)00016-8; Hromas R, 2001, BLOOD, V97, P2168, DOI 10.1182/blood.V97.7.2168; Huang G, 2001, EMBO J, V20, P723, DOI 10.1093/emboj/20.4.723; Illmer T, 2007, HAEMATOL-HEMATOL J, V92, P137, DOI 10.3324/haematol.10489; Kanno Y, 1998, MOL CELL BIOL, V18, P4252, DOI 10.1128/MCB.18.7.4252; Kelly LM, 2002, ANNU REV GENOM HUM G, V3, P179, DOI 10.1146/annurev.genom.3.032802.115046; Kitabayashi I, 1998, MOL CELL BIOL, V18, P846, DOI 10.1128/MCB.18.2.846; Kogan SC, 1998, P NATL ACAD SCI USA, V95, P11863, DOI 10.1073/pnas.95.20.11863; Kohl TM, 2005, BLOOD, V105, P3319, DOI 10.1182/blood-2004-06-2068; Kottaridis PD, 2001, BLOOD, V98, P1752, DOI 10.1182/blood.V98.6.1752; Kuchenbauer F, 2006, BRIT J HAEMATOL, V134, P616, DOI 10.1111/j.1365-2141.2006.06229.x; Kuchenbauer F, 2005, BRIT J HAEMATOL, V130, P196, DOI 10.1111/j.1365-2141.2005.05595.x; Kundu M, 2005, BLOOD, V106, P3621, DOI 10.1182/blood-2005-04-1447; Kuo YH, 2006, CANCER CELL, V9, P57, DOI 10.1016/j.ccr.2005.12.014; Landrette SF, 2005, BLOOD, V105, P2900, DOI 10.1182/blood-2004-09-3630; Lasa A, 2006, HAEMATOLOGICA, V91, P1283; Lee JW, 2006, ONCOGENE, V25, P1434, DOI 10.1038/sj.onc.1209163; Li X, 2006, J CELL PHYSIOL, V208, P594, DOI 10.1002/jcp.20695; LIU P, 1993, SCIENCE, V261, P1041, DOI 10.1126/science.8351518; Look AT, 1997, SCIENCE, V278, P1059, DOI 10.1126/science.278.5340.1059; Lu Y, 2006, LEUKEMIA, V20, P987, DOI 10.1038/sj.leu.2404218; Lutterbach B, 1998, MOL CELL BIOL, V18, P7176, DOI 10.1128/MCB.18.12.7176; Marcucci G, 2005, J CLIN ONCOL, V23, P5705, DOI 10.1200/JCO.2005.15.610; MARLTON P, 1995, BLOOD, V85, P772, DOI 10.1182/blood.V85.3.772.bloodjournal853772; Merchant SH, 2004, J MOL DIAGN, V6, P271, DOI 10.1016/S1525-1578(10)60521-1; MEYERS S, 1993, MOL CELL BIOL, V13, P6336, DOI 10.1128/MCB.13.10.6336; Miyamoto T, 2000, P NATL ACAD SCI USA, V97, P7521, DOI 10.1073/pnas.97.13.7521; MIYOSHI H, 1991, P NATL ACAD SCI USA, V88, P10431, DOI 10.1073/pnas.88.23.10431; Monma F, 2006, EUR J HAEMATOL, V76, P18, DOI 10.1111/j.1600-0609.2005.00543.x; Moreno-Miralles I, 2005, J BIOL CHEM, V280, P40097, DOI 10.1074/jbc.M506855200; Mrozek K, 2004, BLOOD REV, V18, P115, DOI 10.1016/S0268-960X(03)00040-7; Mrozek K, 2001, J CLIN ONCOL, V19, P2482, DOI 10.1200/JCO.2001.19.9.2482; Nanri T, 2005, LEUKEMIA, V19, P1673, DOI 10.1038/sj.leu.2403889; Nanri T, 2005, LEUKEMIA, V19, P1361, DOI 10.1038/sj.leu.2403803; Nguyen S, 2002, BLOOD, V99, P3517, DOI 10.1182/blood.V99.10.3517; Niki M, 1997, P NATL ACAD SCI USA, V94, P5697, DOI 10.1073/pnas.94.11.5697; Nishida S, 2006, BLOOD, V107, P3303, DOI 10.1182/blood-2005-04-1656; NUCHPRAYOON I, 1994, MOL CELL BIOL, V14, P5558, DOI 10.1128/MCB.14.8.5558; NUCIFORA G, 1994, P NATL ACAD SCI USA, V91, P4004, DOI 10.1073/pnas.91.9.4004; NUCIFORA G, 1993, BLOOD, V82, P712; Okuda T, 1996, CELL, V84, P321, DOI 10.1016/S0092-8674(00)80986-1; Okuda T, 1998, BLOOD, V91, P3134, DOI 10.1182/blood.V91.9.3134.3134_3134_3143; Pabst T, 2001, NAT MED, V7, P444, DOI 10.1038/86515; Paschka P, 2006, J CLIN ONCOL, V24, P3904, DOI 10.1200/JCO.2006.06.9500; Passegue E, 2003, P NATL ACAD SCI USA, V100, P11842, DOI 10.1073/pnas.2034201100; Paulsson K, 2006, LEUKEMIA, V20, P224, DOI 10.1038/sj.leu.2404076; Peterson LF, 2004, ONCOGENE, V23, P4255, DOI 10.1038/sj.onc.1207727; Peterson LF, 2007, BLOOD, V109, P4392, DOI 10.1182/blood-2006-03-012575; Ramsey H, 2003, LEUKEMIA, V17, P1665, DOI 10.1038/sj.leu.2403048; Rhoades KL, 2000, BLOOD, V96, P2108; Rochford JJ, 2004, MOL CELL BIOL, V24, P9863, DOI 10.1128/MCB.24.22.9863-9872.2004; ROMANA SP, 1995, BLOOD, V86, P4263, DOI 10.1182/blood.V86.11.4263.bloodjournal86114263; Roskoski R, 2005, BIOCHEM BIOPH RES CO, V338, P1307, DOI 10.1016/j.bbrc.2005.09.150; Sasaki K, 1996, P NATL ACAD SCI USA, V93, P12359, DOI 10.1073/pnas.93.22.12359; Schessl C, 2005, J CLIN INVEST, V115, P2159, DOI 10.1172/JCI24225; Schittenhelm MM, 2006, CANCER RES, V66, P473, DOI 10.1158/0008-5472.CAN-05-2050; Schlenk RF, 2004, J CLIN ONCOL, V22, P3741, DOI 10.1200/JCO.2004.03.012; Schnittger S, 2007, LEUKEMIA, V21, P1843, DOI 10.1038/sj.leu.2404707; Schnittger S, 2007, LEUKEMIA, V21, P183, DOI 10.1038/sj.leu.2404465; Schnittger S, 2006, BLOOD, V107, P1791, DOI 10.1182/blood-2005-04-1466; Schnittger S, 2002, BLOOD, V100, P59, DOI 10.1182/blood.V100.1.59; Schwieger M, 2002, J EXP MED, V196, P1227, DOI 10.1084/jem.20020824; Shimada A, 2006, BLOOD, V107, P1806, DOI 10.1182/blood-2005-08-3408; Shimada H, 2000, BLOOD, V96, P655; SHURTLEFF SA, 1995, BLOOD, V85, P3695, DOI 10.1182/blood.V85.12.3695.bloodjournal85123695; Shurtleff SA, 1995, LEUKEMIA, V9, P1985; Slovak ML, 2000, BLOOD, V96, P4075, DOI 10.1182/blood.V96.13.4075; Stirewalt DL, 2001, BLOOD, V97, P3589, DOI 10.1182/blood.V97.11.3589; Sun W, 2004, BLOOD, V104, P3565, DOI 10.1182/blood-2003-12-4349; Tahirov TH, 2001, CELL, V104, P755, DOI 10.1016/S0092-8674(01)00271-9; Thiede C, 2002, BLOOD, V99, P4326, DOI 10.1182/blood.V99.12.4326; Valk PJM, 2004, HAEMATOLOGICA, V89, P106; Wang JX, 1998, P NATL ACAD SCI USA, V95, P10860, DOI 10.1073/pnas.95.18.10860; Wang Q, 1996, CELL, V87, P697, DOI 10.1016/S0092-8674(00)81389-6; Wang Q, 1996, P NATL ACAD SCI USA, V93, P3444, DOI 10.1073/pnas.93.8.3444; Wang YY, 2005, P NATL ACAD SCI USA, V102, P1104, DOI 10.1073/pnas.0408831102; Wiemels JL, 2002, BLOOD, V99, P3801, DOI 10.1182/blood.V99.10.3801; Yan M, 2004, P NATL ACAD SCI USA, V101, P17468, DOI 10.1073/pnas.0406142101; Yan M, 2006, NAT MED, V12, P945, DOI 10.1038/nm1443; Yang YD, 2002, CANCER RES, V62, P2232; Yergeau DA, 1997, NAT GENET, V15, P303, DOI 10.1038/ng0397-303; Yuan YZ, 2001, P NATL ACAD SCI USA, V98, P10398, DOI 10.1073/pnas.171321298; Zhang DE, 1996, MOL CELL BIOL, V16, P1231	119	43	47	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 2	2008	27	44					5759	5773		10.1038/onc.2008.196	http://dx.doi.org/10.1038/onc.2008.196			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	355QC	18604246				2022-12-28	WOS:000259722400001
J	Korkaya, H; Paulson, A; Iovino, F; Wicha, MS				Korkaya, H.; Paulson, A.; Iovino, F.; Wicha, M. S.			HER2 regulates the mammary stem/progenitor cell population driving tumorigenesis and invasion	ONCOGENE			English	Article						breast cancer; cancer stem cells; HER2; PI3-K/Akt pathway; ALDH	BREAST-CANCER CELLS; STEM-CELLS; TRASTUZUMAB RESISTANCE; SELF-RENEWAL; IN-VITRO; GENE; AMPLIFICATION; HERCEPTIN; CARCINOMA; PATHWAY	The cancer stem cell hypothesis proposes that cancers arise in stem/progenitor cells through disregulation of self-renewal pathways generating tumors, which are driven by a component of 'tumor-initiating cells' retaining stem cell properties. The HER2 gene is amplified in 20-30% of human breast cancers and has been implicated in mammary tumorigenesis as well as in mediating aggressive tumor growth and metastasis. We demonstrate that HER2 overexpression drives mammary carcinogenesis, tumor growth and invasion through its effects on normal and malignant mammary stem cells. HER2 overexpression in normal mammary epithelial cells (NMEC) increases the proportion of stem/progenitor cells as demonstrated by in vitro mammosphere assays and the expression of stem cell marker aldehyde dehydrogenase (ALDH) as well as by generation of hyperplastic lesions in humanized fat pads of NOD (nucleotide-binding oligomerization domain)/SCID (severe combined immunodeficient) mice. Overexpression of HER2 in a series of breast carcinoma cell lines increases the ALDH-expressing 'cancer stem cell' population which displays increased expression of stem cell regulatory genes, increased invasion in vitro and increased tumorigenesis in NOD/SCID mice. The effects of HER2 overexpression on breast cancer stem cells are blocked by trastuzumab in sensitive, but not resistant, cell lines, an effect mediated by the PI3-kinase/Akt pathway. These studies provide support for the cancer stem cell hypothesis by suggesting that the effects of HER2 amplification on carcinogenesis, tumorigenesis and invasion may be due to its effects on normal and malignant mammary stem/progenitor cells. Furthermore, the clinical efficacy of trastuzumab may relate to its ability to target the cancer stem cell population in HER2-amplified tumors.	[Korkaya, H.; Paulson, A.; Iovino, F.; Wicha, M. S.] Univ Michigan, Dept Internal Med, Ctr Comprehens Canc, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan	Korkaya, H (corresponding author), Univ Michigan, Dept Internal Med, Ctr Comprehens Canc, 1500 E Med Ctr Dr,7110 CCGC, Ann Arbor, MI 48109 USA.	hkorkaya@med.umich.edu	Korkaya, Hasan/C-2201-2009; Iovino, Flora/K-8834-2016; Wicha, Max/AAE-7268-2019; Korkaya, Hasan/GRY-1016-2022; Korkaya, Hasan/ABD-6282-2020	Iovino, Flora/0000-0002-6374-5582; Korkaya, Hasan/0000-0002-0719-5862; Paulson, Amanda/0000-0003-3118-4618	NIH [CA129765, CA101860]; University of Michigan Cancer Center NIH [5 P 30 CA46592]; Taubman Institute; NATIONAL CANCER INSTITUTE [R01CA101860, R01CA129765, P30CA046592] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); University of Michigan Cancer Center NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Taubman Institute; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We would like to thank Dr Thomas Giordano and the University of Michigan Cancer Center Flow Cytometry core for their assistance, Dr Bruce Boman, Dr Emmanuelle Charafe-Jauffret, Dr Gabriela Dontu, Dr Suling Liu and Dr Christophe Ginestier for their advice and critical review of this manuscript. The HER2 construct is a generous gift from Dr Ignatoski. This work was supported by NIH Grants CA129765 and CA101860 and in part by the University of Michigan Cancer Center NIH support Grant 5 P 30 CA46592 and by the Taubman Institute.	Al-Hajj M, 2003, P NATL ACAD SCI USA, V100, P3983, DOI 10.1073/pnas.0530291100; ALLRED DC, 1994, BREAST CANCER RES TR, V32, P13, DOI 10.1007/BF00666202; Berns K, 2007, CANCER CELL, V12, P395, DOI 10.1016/j.ccr.2007.08.030; Beuzeboc P, 1999, B CANCER, V86, P544; Burstein HJ, 2001, J CLIN ONCOL, V19, P2722, DOI 10.1200/JCO.2001.19.10.2722; Dontu G, 2004, BREAST CANCER RES, V6, pR605, DOI 10.1186/bcr920; Dontu G, 2003, GENE DEV, V17, P1253, DOI 10.1101/gad.1061803; Finn RS, 2007, BREAST CANCER RES TR, V105, P319, DOI 10.1007/s10549-006-9463-x; Ginestier C, 2007, CELL STEM CELL, V1, P555, DOI 10.1016/j.stem.2007.08.014; Knuefermann C, 2003, ONCOGENE, V22, P3205, DOI 10.1038/sj.onc.1206394; Korkaya H, 2007, BIODRUGS, V21, P299, DOI 10.2165/00063030-200721050-00002; Kucab JE, 2005, BREAST CANCER RES, V7, pR796, DOI 10.1186/bcr1294; Li XX, 2008, JNCI-J NATL CANCER I, V100, P672, DOI 10.1093/jnci/djn123; Liu SL, 2006, CANCER RES, V66, P6063, DOI 10.1158/0008-5472.CAN-06-0054; Ma S, 2008, ONCOGENE, V27, P1749, DOI 10.1038/sj.onc.1210811; Miller KD, 2004, ONCOLOGIST, V9, P16, DOI 10.1634/theoncologist.9-suppl_3-16; Nagata Y, 2004, CANCER CELL, V6, P117, DOI 10.1016/j.ccr.2004.06.022; PAIK S, 1990, J CLIN ONCOL, V8, P103, DOI 10.1200/JCO.1990.8.1.103; Park K, 2006, HISTOPATHOLOGY, V48, P702, DOI 10.1111/j.1365-2559.2006.02403.x; Phillips TM, 2006, JNCI-J NATL CANCER I, V98, P1777, DOI 10.1093/jnci/djj495; Saal LH, 2007, P NATL ACAD SCI USA, V104, P7564, DOI 10.1073/pnas.0702507104; Seidman AD, 2001, J CLIN ONCOL, V19, P2587, DOI 10.1200/JCO.2001.19.10.2587; Sheridan C, 2006, BREAST CANCER RES, V8, DOI 10.1186/bcr1610; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; Stingl J, 1998, DIFFERENTIATION, V63, P201, DOI 10.1111/j.1432-0436.1998.00201.x; Tanner M, 2004, MOL CANCER THER, V3, P1585; Tokuzawa Y, 2003, MOL CELL BIOL, V23, P2699, DOI 10.1128/MCB.23.8.2699-2708.2003; Welham MJ, 2007, BIOCHEM SOC T, V35, P225, DOI 10.1042/BST0350225; Wicha MS, 2006, CANCER RES, V66, P1883, DOI 10.1158/0008-5472.CAN-05-3153; Xu RL, 2002, MODERN PATHOL, V15, P116, DOI 10.1038/modpathol.3880503	31	425	456	0	27	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT	2008	27	47					6120	6130		10.1038/onc.2008.207	http://dx.doi.org/10.1038/onc.2008.207			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	360UJ	18591932	Green Submitted, Green Accepted, Bronze, Green Published			2022-12-28	WOS:000260083100005
J	Bleeker, FE; Felicioni, L; Buttitta, F; Lamba, S; Cardone, L; Rodolfo, M; Scarpa, A; Leenstra, S; Frattini, M; Barbareschi, M; Del Grammastro, M; Sciarrotta, MG; Zanon, C; Marchetti, A; Bardelli, A				Bleeker, F. E.; Felicioni, L.; Buttitta, F.; Lamba, S.; Cardone, L.; Rodolfo, M.; Scarpa, A.; Leenstra, S.; Frattini, M.; Barbareschi, M.; Del Grammastro, M.; Sciarrotta, M. G.; Zanon, C.; Marchetti, A.; Bardelli, A.			AKT1(E17K) in human solid tumours	ONCOGENE			English	Article						AKT1; PIK3CA; mutation; cancer	PIK3CA MUTATIONS; HUMAN BREAST; GENE; PTEN	The serine- threonine kinase AKT1 is a central player in the oncogenic pathway controlled by PI3K. Recently, a somatic mutation in AKT1 (E17K) has been detected in breast, colorectal, lung and ovarian cancers. The E17K change results in constitutive AKT1 activation and induces leukaemia in mice. We determined the occurrence of the E17K variant in a panel of 764 tumour samples. These included breast, lung, ovarian, colorectal and pancreatic carcinomas as well as melanomas and glioblastomas. Despite the fact that these tumours are known to bear alterations in genes involved in the PI3K signalling pathway, AKT1(E17K) was detected only in breast (16/273), colorectal (1/88) and lung(1/155) cancers. Within the neoplasms of breast origin, the AKT1(E17K) variant was mutually exclusive with respect to the PIK3CA(E454K) (or H1047R) alleles and was present only in ductal and lobular histotypes. Our results, showing that AKT1 mutations seem to occur in a tissue-specific fashion have basic and clinical implications. First, the activity of mutated AKT1 in oncogenic PI3K signalling could be strictly dependent on the cell and tissue milieu. Second, therapeutic efforts aimed at selective targeting the AKT1(E17K) variant could be effective mainly in specific cancer types.	[Bleeker, F. E.; Lamba, S.; Cardone, L.; Zanon, C.; Bardelli, A.] Univ Turin, Sch Med, Mol Genet Lab, Oncogenom Ctr,Inst Canc Res & Treatment, Candiolo, Italy; [Bleeker, F. E.] Locat Acad Med Ctr, Neurosurg Ctr Amsterdam, Amsterdam, Netherlands; [Felicioni, L.; Buttitta, F.; Del Grammastro, M.; Sciarrotta, M. G.; Marchetti, A.] Univ Fdn, Ctr Excellence Aging, Clin Res Ctr, Chieti, Italy; [Rodolfo, M.; Frattini, M.] Ist Nazl Tumori, Dept Expt Oncol, I-20133 Milan, Italy; [Scarpa, A.] Univ Verona, Dept Pathol, Sect Anat Pathol, I-37100 Verona, Italy; [Leenstra, S.] St Elizabeth Hosp, Dept Neurosurg, Tilburg, Netherlands; [Frattini, M.] Osped San Giovanni Bellinzona, Oncol Inst So Switzerland, Bellinzona, Switzerland; [Barbareschi, M.] Santa Chiara Hosp, Unit Surg Pathol, Trento, Italy; [Bardelli, A.] FIRC Inst Mol Oncol, Milan, Italy	Consiglio Nazionale delle Ricerche (CNR); Istituto di Genetica Molecolare (IGM-CNR); IRCCS Fondazione del Piemonte per l'Oncologia; University of Turin; Fondazione IRCCS Istituto Nazionale Tumori Milan; University of Verona; Elisabeth-TweeSteden Ziekenhuis (ETZ); Institute of Oncology Research (IOR); Regional Hospital of Bellinzona & Valleys, San Giovanni; Santa Chiara Hospital; IFOM - FIRC Institute of Molecular Oncology	Bardelli, A (corresponding author), Univ Turin, Sch Med, Mol Genet Lab, Oncogenom Ctr,Inst Canc Res & Treatment, Str Prov 142 Km 3-95, I-10060 Turin, Italy.	a.bardelli@unito.it	scarpa, aldo/K-6832-2016; Barbareschi, Mattia/AAF-2043-2020; rodolfo, monica/H-2671-2012; BARDELLI, Alberto/J-9721-2018	scarpa, aldo/0000-0003-1678-739X; rodolfo, monica/0000-0002-9196-0298; Lamba, Simona Elena/0000-0003-3207-1594; Cardone, Luca/0000-0001-8184-2856; Zanon, Carlo/0000-0003-2539-7238; BARDELLI, Alberto/0000-0003-1647-5070	Italian Association for Cancer Research; Italian Ministry of Health; Regione Piemonte; Italian Ministry of University and Research and Association for International Cancer Research (AICR- UK, A Bardelli); EU FP6 [037297]; Netherlands Genomic Initiative Fellowship	Italian Association for Cancer Research(Fondazione AIRC per la ricerca sul cancro); Italian Ministry of Health(Ministry of Health, Italy); Regione Piemonte(Regione Piemonte); Italian Ministry of University and Research and Association for International Cancer Research (AICR- UK, A Bardelli); EU FP6(European Commission); Netherlands Genomic Initiative Fellowship	We thank Dr T Hulsebos and Professor Dr Troost for making glioblastoma tumour samples available. We thank Dr S Pilotti and Dr M Pierotti for providing the colorectal cancer samples. This work was supported by grants from Italian Association for Cancer Research (AIRC, A Bardelli), Italian Ministry of Health, Regione Piemonte (A Bardelli), Italian Ministry of University and Research and Association for International Cancer Research (AICR- UK, A Bardelli), EU FP6 contract 037297 (A Bardelli) and MolDiagPaca (AS). FB is supported by a Netherlands Genomic Initiative Fellowship.	Balakrishnan A, 2007, CANCER RES, V67, P3545, DOI 10.1158/0008-5472.CAN-07-0065; Barbareschi M, 2007, CLIN CANCER RES, V13, P6064, DOI 10.1158/1078-0432.CCR-07-0266; Benvenuti S, 2008, HUM MUTAT, V29, P284, DOI 10.1002/humu.20648; Brugge J, 2007, CANCER CELL, V12, P104, DOI 10.1016/j.ccr.2007.07.014; Carpten JD, 2007, NATURE, V448, P439, DOI 10.1038/nature05933; Frattini M, 2005, CANCER RES, V65, P11227, DOI 10.1158/0008-5472.CAN-05-2780; Guldberg P, 1997, CANCER RES, V57, P3660; Karakas B, 2006, BRIT J CANCER, V94, P455, DOI 10.1038/sj.bjc.6602970; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; Malanga D, 2008, CELL CYCLE, V7, P665, DOI 10.4161/cc.7.5.5485; Saal LH, 2005, CANCER RES, V65, P2554, DOI 10.1158/0008-5472-CAN-04-3913; Samuels Y, 2004, SCIENCE, V304, P554, DOI 10.1126/science.1096502; Schonleben F, 2006, CLIN CANCER RES, V12, P3851, DOI 10.1158/1078-0432.CCR-06-0292; Wood LD, 2007, SCIENCE, V318, P1108, DOI 10.1126/science.1145720	14	155	156	1	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 18	2008	27	42					5648	5650		10.1038/onc.2008.170	http://dx.doi.org/10.1038/onc.2008.170			3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	349KX	18504432				2022-12-28	WOS:000259280800011
J	Knobbe, CB; Lapin, V; Suzuki, A; Mak, TW				Knobbe, C. B.; Lapin, V.; Suzuki, A.; Mak, T. W.			The roles of PTEN in development, physiology and tumorigenesis in mouse models: a tissue-by-tissue survey	ONCOGENE			English	Review						PTEN; mouse; conditional gene-targeting; KO	TUMOR-SUPPRESSOR GENE; PTEN/PI3K PATHWAY GOVERNS; HEMATOPOIETIC STEM-CELLS; MICE LACKING PTEN; CRE RECOMBINASE; NEGATIVE REGULATION; CONDITIONAL LOSS; DEFICIENT MICE; LUNG-CANCER; SOMA SIZE	In 1997, PTEN (phosphatase and tensin homologue deleted on chromosome 10, 10q23.3) was identified as an important tumor suppressor gene that is inactivated in a wide variety of human cancers. Ever since, PTEN's function has been extensively studied, and huge progress has been made in understanding PTEN's role in normal physiology and disease. In this review, we will systematically summarize the important data that have been gained from gene inactivation studies in mice and will put these data into physiological context using a tissue-by-tissue approach. We will cover mice exhibiting complete and constitutive inactivation of Pten as well as a large number of strains in which Pten has been conditionally deleted in specific tissues. We hope to highlight not only the tumor suppressive function of Pten but also its roles in embryogenesis and in the maintenance of the normal physiological functions of many organ systems.	[Knobbe, C. B.; Lapin, V.; Mak, T. W.] Univ Toronto, Campbell Family Inst Breast Canc Res, Toronto, ON, Canada; [Lapin, V.; Mak, T. W.] Univ Toronto, Dept Med Biophys, Toronto, ON, Canada; [Suzuki, A.] Kyushu Univ, Med Inst Bioregulat, Div Embryon & Genet Engn, Fukuoka 812, Japan	University of Toronto; University of Toronto; Kyushu University	Mak, TW (corresponding author), Princess Margaret Hosp, Univ Hlth Network, 7th Floor,Room 706,620 Univ Ave, Toronto, ON M5G 2C1, Canada.	tmak@uhnres.utoronto.ca	Knobbe-Thomsen, Christiane/J-4963-2014; Knobbe-Thomsen, Christiane B/D-3116-2019; Suzuki, Akira/GYD-6697-2022	Suzuki, Akira/0000-0002-5950-8808; Knobbe-Thomsen, Christiane/0000-0003-1231-0076	Alexander-von-Humboldt Foundation; Canadian Institutes of Health Research	Alexander-von-Humboldt Foundation(Alexander von Humboldt Foundation); Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR))	We thank Mary Saunders for editing. CBK is supported by the Alexander-von-Humboldt Foundation. VL is supported by a Doctoral Research Award from the Canadian Institutes of Health Research.	Abel ED, 2001, NATURE, V409, P729, DOI 10.1038/35055575; Anzelon AN, 2003, NAT IMMUNOL, V4, P287, DOI 10.1038/ni892; Aveyard JS, 1999, BRIT J CANCER, V80, P904, DOI 10.1038/sj.bjc.6690439; Backman SA, 2001, NAT GENET, V29, P396, DOI 10.1038/ng782; Backman SA, 2004, P NATL ACAD SCI USA, V101, P1725, DOI 10.1073/pnas.0308217100; Backman SA, 2002, CURR OPIN NEUROBIOL, V12, P516, DOI 10.1016/S0959-4388(02)00354-9; Butler MG, 2005, J MED GENET, V42, P318, DOI 10.1136/jmg.2004.024646; Chalhoub N, 2006, BRAIN RES, V1100, P32, DOI 10.1016/j.brainres.2006.05.013; Crackower MA, 2002, CELL, V110, P737, DOI 10.1016/S0092-8674(02)00969-8; DeMarzo AM, 2003, LANCET, V361, P955, DOI 10.1016/S0140-6736(03)12779-1; Deocampo N D, 2003, Minerva Endocrinol, V28, P145; Di Cristofano A, 1999, SCIENCE, V285, P2122, DOI 10.1126/science.285.5436.2122; Di Cristofano A, 1998, NAT GENET, V19, P348, DOI 10.1038/1235; Ford-Hutchinson AF, 2007, J BONE MINER RES, V22, P1245, DOI 10.1359/JBMR.070420; Fraser MM, 2004, CANCER RES, V64, P7773, DOI 10.1158/0008-5472.CAN-04-2487; Groszer M, 2006, P NATL ACAD SCI USA, V103, P111, DOI 10.1073/pnas.0509939103; Groszer M, 2001, SCIENCE, V294, P2186, DOI 10.1126/science.1065518; Gu GQ, 2002, DEVELOPMENT, V129, P2447; Hagenbeek TJ, 2008, LEUKEMIA, V22, P608, DOI 10.1038/sj.leu.2405056; Hagenbeek TJ, 2004, J EXP MED, V200, P883, DOI 10.1084/jem.20040495; Hamada K, 2005, GENE DEV, V19, P2054, DOI 10.1101/gad.1308805; He XC, 2007, NAT GENET, V39, P189, DOI 10.1038/ng1928; Herman GE, 2007, GENET MED, V9, P268, DOI 10.1097/GIM.0b013e31804d683b; Hernando E, 2007, NAT MED, V13, P748, DOI 10.1038/nm1560; Horie Y, 2004, J CLIN INVEST, V113, P1774, DOI 10.1172/JCI200420513; Inoue-Narita T, 2008, CANCER RES, V68, P5760, DOI 10.1158/0008-5472.CAN-08-0889; Kimura T, 2003, DEVELOPMENT, V130, P1691, DOI 10.1242/dev.00392; Kishimoto H, 2007, BLOOD, V109, P3316, DOI 10.1182/blood-2006-07-038059; Knobbe CB, 2002, NEURO-ONCOLOGY, V4, P196; Kola B, 2006, TRENDS ENDOCRIN MET, V17, P205, DOI 10.1016/j.tem.2006.05.006; Kurlawalla-Martinez C, 2005, MOL CELL BIOL, V25, P2498, DOI 10.1128/MCB.25.6.2498-2510.2005; Kuroda S, 2008, EUR J IMMUNOL, V38, P1331, DOI 10.1002/eji.200737302; Kwon CH, 2001, NAT GENET, V29, P404, DOI 10.1038/ng781; Kwon CH, 2003, P NATL ACAD SCI USA, V100, P12923, DOI 10.1073/pnas.2132711100; Kwon CH, 2006, NEURON, V50, P377, DOI 10.1016/j.neuron.2006.03.023; Li G, 2002, DEVELOPMENT, V129, P4159; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; Li Y, 2001, BMC Mol Biol, V2, P2, DOI 10.1186/1471-2199-2-2; Liu JH, 2000, MOL CARCINOGEN, V29, P143, DOI 10.1002/1098-2744(200011)29:3<143::AID-MC3>3.0.CO;2-A; Liu XM, 2007, P NATL ACAD SCI USA, V104, P2259, DOI 10.1073/pnas.0604153104; Lomeli H, 2000, GENESIS, V26, P116, DOI 10.1002/(SICI)1526-968X(200002)26:2<116::AID-GENE4>3.0.CO;2-X; Lu TL, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0001237; Ma XQ, 2005, CANCER RES, V65, P5730, DOI 10.1158/0008-5472.CAN-04-4519; Maddison LA, 2000, GENESIS, V26, P154, DOI 10.1002/(SICI)1526-968X(200002)26:2<154::AID-GENE18>3.0.CO;2-2; Maehama T, 1998, J BIOL CHEM, V273, P13375, DOI 10.1074/jbc.273.22.13375; Marandola P, 2004, ANN NY ACAD SCI, V1028, P294, DOI 10.1196/annals.1322.034; Marino S, 2002, DEVELOPMENT, V129, P3513; Marsit CJ, 2005, HUM PATHOL, V36, P768, DOI 10.1016/j.humpath.2005.05.006; Nguyen KTT, 2006, MOL CELL BIOL, V26, P4511, DOI 10.1128/MCB.00238-06; Nishio M, 2007, NAT CELL BIOL, V9, P36, DOI 10.1038/ncb1515; Ogawa S, 2007, BRAIN RES, V1168, P112, DOI 10.1016/j.brainres.2007.06.074; Oudit GY, 2008, CARDIOVASC RES, V78, P505, DOI 10.1093/cvr/cvn041; Ovchinnikov DA, 2000, GENESIS, V26, P145, DOI 10.1002/(SICI)1526-968X(200002)26:2<145::AID-GENE14>3.0.CO;2-C; Pasqualucci L, 2008, NAT GENET, V40, P108, DOI 10.1038/ng.2007.35; Plum L, 2006, J CLIN INVEST, V116, P1886, DOI 10.1172/JCI27123; Podsypanina K, 1999, P NATL ACAD SCI USA, V96, P1563, DOI 10.1073/pnas.96.4.1563; Postic C, 2000, GENESIS, V26, P149, DOI 10.1002/(SICI)1526-968X(200002)26:2<149::AID-GENE16>3.0.CO;2-V; Postic C, 2001, RECENT PROG HORM RES, V56, P195, DOI 10.1210/rp.56.1.195; Ratnacaram CK, 2008, P NATL ACAD SCI USA, V105, P2521, DOI 10.1073/pnas.0712021105; Reddy P, 2008, SCIENCE, V319, P611, DOI 10.1126/science.1152257; Saal LH, 2008, NAT GENET, V40, P102, DOI 10.1038/ng.2007.39; Saam JR, 1999, J BIOL CHEM, V274, P38071, DOI 10.1074/jbc.274.53.38071; Shao J, 2007, CARCINOGENESIS, V28, P2476, DOI 10.1093/carcin/bgm186; Sorlie T, 2001, P NATL ACAD SCI USA, V98, P10869, DOI 10.1073/pnas.191367098; Stambolic V, 1998, CELL, V95, P29, DOI 10.1016/S0092-8674(00)81780-8; Stambolic V, 2000, CANCER RES, V60, P3605; Stanger BZ, 2005, CANCER CELL, V8, P185, DOI 10.1016/j.ccr.2005.07.015; Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356; Stiles B, 2004, P NATL ACAD SCI USA, V101, P2082, DOI 10.1073/pnas.0308617100; Stiles BL, 2006, MOL CELL BIOL, V26, P2772, DOI 10.1128/MCB.26.7.2772-2781.2006; Subramanian KK, 2007, BLOOD, V109, P4028, DOI 10.1182/blood-2006-10-055319; Suzuki A, 2007, BIOCHEM SOC T, V35, P172, DOI 10.1042/BST0350172; Suzuki A, 2004, BIOCHEM SOC T, V32, P362, DOI 10.1042/BST0320362; Suzuki A, 2003, J EXP MED, V197, P657, DOI 10.1084/jem.20021101; Suzuki A, 2003, CANCER RES, V63, P674; Suzuki A, 2001, IMMUNITY, V14, P523, DOI 10.1016/S1074-7613(01)00134-0; Suzuki A, 1998, CURR BIOL, V8, P1169, DOI 10.1016/S0960-9822(07)00488-5; Tang JM, 2006, LUNG CANCER, V51, P181, DOI 10.1016/j.lungcan.2005.10.003; Taniyama K, 2001, J PATHOL, V194, P341, DOI 10.1002/path.908; Teng Y, 2006, CANCER RES, V66, P6972, DOI 10.1158/0008-5472.CAN-06-0507; Trotman LC, 2003, PLOS BIOL, V1, P385, DOI 10.1371/journal.pbio.0000059; Tsuruta H, 2006, CANCER RES, V66, P8389, DOI 10.1158/0008-5472.CAN-05-4627; van Nederveen FH, 2006, J PATHOL, V209, P274, DOI 10.1002/path.1968; Wagner KU, 2001, TRANSGENIC RES, V10, P545, DOI 10.1023/A:1013063514007; Walker GJ, 2002, J INVEST DERMATOL, V119, P783, DOI 10.1046/j.1523-1747.2002.00217.x; Wang DS, 2000, INT J CANCER, V88, P620, DOI 10.1002/1097-0215(20001115)88:4<620::AID-IJC16>3.0.CO;2-Z; Wang SY, 2003, CANCER CELL, V4, P209, DOI 10.1016/S1535-6108(03)00215-0; Wei QX, 2006, CANCER RES, V66, P7429, DOI 10.1158/0008-5472.CAN-06-0712; WIESTLER OD, 2000, WHO CLASSIFICATION T; Wijesekara N, 2005, MOL CELL BIOL, V25, P1135, DOI 10.1128/MCB.25.3.1135-1145.2005; Wu XT, 2001, MECH DEVELOP, V101, P61, DOI 10.1016/S0925-4773(00)00551-7; Xue L, 2008, P NATL ACAD SCI USA, V105, P2022, DOI 10.1073/pnas.0712059105; Yanagi S, 2007, J CLIN INVEST, V117, P2929, DOI 10.1172/JCI31854; Yang LL, 2005, CANCER RES, V65, P8671, DOI 10.1158/0008-5472.CAN-05-0800; Yeager N, 2007, CANCER RES, V67, P959, DOI 10.1158/0008-5472.CAN-06-3524; Yilmaz OH, 2006, NATURE, V441, P475, DOI 10.1038/nature04703; Yoo LI, 2006, CANCER RES, V66, P1929, DOI 10.1158/0008-5472.CAN-05-1986; You MJ, 2002, P NATL ACAD SCI USA, V99, P1455, DOI 10.1073/pnas.022632099; Yue Q, 2005, DEVELOPMENT, V132, P3281, DOI 10.1242/dev.01891; Zhang JW, 2006, NATURE, V441, P518, DOI 10.1038/nature04747; Zhang M, 2002, J BIOL CHEM, V277, P44005, DOI 10.1074/jbc.M208265200; Zhu D, 2006, P NATL ACAD SCI USA, V103, P14836, DOI 10.1073/pnas.0605722103	102	95	99	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 15	2008	27	41					5398	5415		10.1038/onc.2008.238	http://dx.doi.org/10.1038/onc.2008.238			18	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	349KW	18794876				2022-12-28	WOS:000259280700003
J	Bessard, A; Fremin, C; Ezan, F; Fautrel, A; Gailhouste, L; Baffet, G				Bessard, A.; Fremin, C.; Ezan, F.; Fautrel, A.; Gailhouste, L.; Baffet, G.			RNAi-mediated ERK2 knockdown inhibits growth of tumor cells in vitro and in vivo	ONCOGENE			English	Article						MEK/ERK pathway; MEK inhibitor; U0126; RNAi; tumor growth; in vivo	HUMAN HEPATOCELLULAR-CARCINOMA; SMALL INTERFERING RNAS; MAP KINASE PATHWAY; S-PHASE ENTRY; PROTEIN-KINASES; MEK INHIBITOR; HUMAN LIVER; SUPPRESSES GROWTH; MAMMALIAN-CELLS; EXPRESSION	The MAPK MEK/ERK pathway is often upregulated in cancer cells and represents an attractive target for development of anticancer drugs. Only few data concerning the specific functions of ERK1 and 2 are reported in the literature. In this report, we investigated the specific role of ERK1 and 2 in liver tumor growth both in vitro and in vivo. DNA synthesis and cells in S phase analysed by flow cytometry, correlated with strong inhibition of Cdk1 and cyclin E levels, are strongly reduced after exposure to MEK inhibitor, U0126. We obtained a significant reduction of colony formation in soft agar assays and a reduction in the size of tumor xenografts in nude mice treated with U0126. Then, we could specifically abolished ERK1 or 2 expression by small-interfering RNA (siRNA) and demonstrated that ERK2 knockdown but not ERK1 interferes with the process of replication. Moreover, we found that colony formation and tumor growth in vivo were significantly inhibited by targeting ERK2 using stable chemically modified siRNA. Taken together, our results emphasize the importance of the MEK/ERK pathway in liver cancer cell growth in vitro and in vivo and argue for a crucial role of ERK2 in this regulation.	[Bessard, A.; Fremin, C.; Ezan, F.; Gailhouste, L.; Baffet, G.] Univ Rennes 1, Hop Pontchaillou, IFR 140, INSERM U522, F-35033 Rennes, France; [Fautrel, A.] Univ Rennes 1, CHU Rennes, IFR140, F-35033 Rennes, France	CHU Rennes; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Rennes; CHU Rennes; Universite de Rennes	Baffet, G (corresponding author), Univ Rennes 1, Rue H Guillou, F-35033 Rennes, France.	georges.baffet@rennes.inserm.fr	Baffet, Georges/M-1583-2016; Bessard, Anne/K-2396-2015; Fautrel, Alain/AAL-7391-2020; Baffet, Georges/I-2574-2015	FAUTREL, Alain/0000-0002-3449-0779	Institut National de la Sante et de la Recherche Medicale; Association pour la Recherche sur le Cancer (ARC)	Institut National de la Sante et de la Recherche Medicale(Institut National de la Sante et de la Recherche Medicale (Inserm)); Association pour la Recherche sur le Cancer (ARC)(Fondation ARC pour la Recherche sur le Cancer)	We thank Dr P Loyer for flow cytometry advices, Sigma-Aldrich and Dr Heike Lehrmann for giving us the LNA ERK2 oligonucleotides, and C Ribault for technical assistance. This research was supported by the Institut National de la Sante et de la Recherche Medicale and the Association pour la Recherche sur le Cancer (ARC). A Bessard and C Fremin are a recipient of fellowship from the Region Bretagne/INSERM and the Ministere de l'Education Nationale et de la Technologie, respectively, and the ARC.	Aharinejad S, 2004, CANCER RES, V64, P5378, DOI 10.1158/0008-5472.CAN-04-0961; ALBRECHT JH, 1995, BIOCHEM BIOPH RES CO, V209, P648, DOI 10.1006/bbrc.1995.1548; ALBRECHT JH, 1993, AM J PHYSIOL, V265, pG857, DOI 10.1152/ajpgi.1993.265.5.G857; ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; Andrieux LO, 2007, CANCER RES, V67, P2114, DOI 10.1158/0008-5472.CAN-06-3821; Arslan MA, 2006, CURR CANCER DRUG TAR, V6, P623, DOI 10.2174/156800906778742479; Behlke MA, 2006, MOL THER, V13, P644, DOI 10.1016/j.ymthe.2006.01.001; Bessard A, 2007, J CELL PHYSIOL, V212, P526, DOI 10.1002/jcp.21049; Braasch DA, 2003, BIOCHEMISTRY-US, V42, P7967, DOI 10.1021/bi0343774; BRONDELLO JM, 1995, ONCOGENE, V10, P1895; Dahlgren C, 2006, BIOCHEM BIOPH RES CO, V341, P1211, DOI 10.1016/j.bbrc.2006.01.085; Davies SP, 2000, BIOCHEM J, V351, P95, DOI 10.1042/0264-6021:3510095; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7689; Duesbery NS, 2001, P NATL ACAD SCI USA, V98, P4089, DOI 10.1073/pnas.061031898; Elbashir SM, 2002, METHODS, V26, P199, DOI 10.1016/S1046-2023(02)00023-3; Elmen J, 2005, NUCLEIC ACIDS RES, V33, P439, DOI 10.1093/nar/gki193; Fischer AM, 2005, IMMUNITY, V23, P431, DOI 10.1016/j.immuni.2005.08.013; Fremin C, 2007, HEPATOLOGY, V45, P1035, DOI 10.1002/hep.21551; Gysin S, 2005, CANCER RES, V65, P4870, DOI 10.1158/0008-5472.CAN-04-2848; Haass NK, 2008, CLIN CANCER RES, V14, P230, DOI 10.1158/1078-0432.CCR-07-1440; Hilger RA, 2002, ONKOLOGIE, V25, P511, DOI 10.1159/000068621; Huynh H, 2003, BMC GASTROENTEROL, V3, DOI 10.1186/1471-230X-3-19; Ito Y, 1998, HEPATOLOGY, V27, P951, DOI 10.1002/hep.510270409; Klein PJ, 2006, NEOPLASIA, V8, P1, DOI 10.1593/neo.05373; Lefloch R, 2008, MOL CELL BIOL, V28, P511, DOI 10.1128/MCB.00800-07; Leung RKM, 2005, PHARMACOL THERAPEUT, V107, P222, DOI 10.1016/j.pharmthera.2005.03.004; Liu L, 2006, CANCER RES, V66, P11851, DOI 10.1158/0008-5472.CAN-06-1377; Liu X, 2004, ONCOGENE, V23, P763, DOI 10.1038/sj.onc.1207188; LoRusso PM, 2005, J CLIN ONCOL, V23, P5281, DOI 10.1200/JCO.2005.14.415; Loyer P, 1996, J BIOL CHEM, V271, P11484, DOI 10.1074/jbc.271.19.11484; Mook OR, 2007, MOL CANCER THER, V6, P833, DOI 10.1158/1535-7163.MCT-06-0195; MORELCHANY E, 1978, EUR J CANCER, V14, P1341, DOI 10.1016/0014-2964(78)90116-0; Normanno N, 2006, J CELL PHYSIOL, V207, P420, DOI 10.1002/jcp.20588; Pages G, 1999, SCIENCE, V286, P1374, DOI 10.1126/science.286.5443.1374; PAGES G, 1993, P NATL ACAD SCI USA, V90, P8319, DOI 10.1073/pnas.90.18.8319; Rescan C, 2001, MOL BIOL CELL, V12, P725, DOI 10.1091/mbc.12.3.725; REUBER MD, 1961, J NATL CANCER I, V26, P891; Saba-El-Leil MK, 2003, EMBO REP, V4, P964, DOI 10.1038/sj.embor.embor939; Sanjo H, 2007, MOL CELL BIOL, V27, P1236, DOI 10.1128/MCB.01530-06; Schmidt CM, 1997, BIOCHEM BIOPH RES CO, V236, P54, DOI 10.1006/bbrc.1997.6840; Sebolt-Leopold JS, 1999, NAT MED, V5, P810, DOI 10.1038/10533; Sebolt-Leopold JS, 2004, NAT REV CANCER, V4, P937, DOI 10.1038/nrc1503; Sebolt-Leopold JS, 2006, NATURE, V441, P457, DOI 10.1038/nature04874; Stennicke HR, 1997, J BIOL CHEM, V272, P25719, DOI 10.1074/jbc.272.41.25719; Takei Y, 2004, CANCER RES, V64, P3365, DOI 10.1158/0008-5472.CAN-03-2682; Talarmin H, 1999, MOL CELL BIOL, V19, P6003; Vantaggiato Chiara, 2006, J Biol, V5, P14, DOI 10.1186/jbiol38; Wabnitz PA, 2004, PHARM RES, V21, P1670, DOI 10.1023/B:PHAM.0000041464.27579.d0; Wang D, 2007, BBA-MOL CELL RES, V1773, P1248, DOI 10.1016/j.bbamcr.2006.11.009; Yeh TC, 2007, CLIN CANCER RES, V13, P1576, DOI 10.1158/1078-0432.CCR-06-1150	50	65	71	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 11	2008	27	40					5315	5325		10.1038/onc.2008.163	http://dx.doi.org/10.1038/onc.2008.163			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	346UW	18521085				2022-12-28	WOS:000259096100004
J	Yde, CW; Olsen, BB; Meek, D; Watanabe, N; Guerra, B				Yde, C. W.; Olsen, B. B.; Meek, D.; Watanabe, N.; Guerra, B.			The regulatory beta-subunit of protein kinase CK2 regulates cell-cycle progression at the onset of mitosis	ONCOGENE			English	Article						CK2 beta; Wee1; PLK1; CDC25A; cell cycle	NEGATIVE REGULATION; CDC25A PHOSPHATASE; SOMATIC WEE1; INDUCED S; PHOSPHORYLATION; CHECKPOINT; INACTIVATION; DEGRADATION; CHK1; LOCALIZATION	Cell-cycle transition from the G(2) phase into mitosis is regulated by the cyclin-dependent protein kinase 1 (CDK1) in complex with cyclin B. CDK1 activity is controlled by both inhibitory phosphorylation, catalysed by the Myt1 and Wee1 kinases, and activating dephosphorylation, mediated by the CDC25 dual-specificity phosphatase family members. In somatic cells, Wee1 is downregulated by phosphorylation and ubiquitin-mediated degradation to ensure rapid activation of CDK1 at the beginning of M phase. Here, we show that downregulation of the regulatory beta-subunit of protein kinase CK2 by RNA interference results in delayed cell-cycle progression at the onset of mitosis. Knockdown of CK2 beta causes stabilization of Wee1 and increased phosphorylation of CDK1 at the inhibitory Tyr15. PLK1-Wee1 association is an essential event in the degradation of Wee1 in unperturbed cell cycle. We have found that CK2 beta participates in PLK1-Wee1 complex formation whereas its cellular depletion leads to disruption of PLK1-Wee1 interaction and reduced Wee1 phosphorylation at Ser53 and 121. The data reported here reinforce the notion that CK2 beta has functions that are independent of its role as the CK2 regulatory subunit, identifying it as a new component of signaling pathways that regulate cell-cycle progression at the entry of mitosis.	[Yde, C. W.; Olsen, B. B.; Guerra, B.] Univ So Denmark, Dept Biochem & Mol Biol, DK-5230 Odense, Denmark; [Meek, D.] Univ Dundee, Biomed Res Ctr, Ninewells Hosp, Dundee, Scotland; [Meek, D.] Univ Dundee, Sch Med, Dundee, Scotland; [Watanabe, N.] RIKEN, Antibiot Lab, Discovery Res Inst, Wako, Saitama, Japan	University of Southern Denmark; University of Dundee; University of Dundee; RIKEN	Guerra, B (corresponding author), Univ So Denmark, Dept Biochem & Mol Biol, Campusvej 55, DK-5230 Odense, Denmark.	bag@bmb.sdu.dk	Olsen, Birgitte B/U-2382-2017; Watanabe, Nobumoto/N-6959-2015	Olsen, Birgitte B/0000-0002-6130-0387; Watanabe, Nobumoto/0000-0002-2130-1334; Guerra, Barbara/0000-0003-1136-2413	Novo Nordisk Foundation [5373]; Danish Medical Research Council [271-07-0464]	Novo Nordisk Foundation(Novo Nordisk FoundationNovocure Limited); Danish Medical Research Council(Danish Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC))	We thank T Holm for technical assistance. This study was supported by the Novo Nordisk Foundation, grant no. 5373 and the Danish Medical Research Council, grant no. 271-07-0464 to BG.	Bibby AC, 2005, INT J BIOL SCI, V1, P67; Boutros R, 2006, CURR OPIN CELL BIOL, V18, P185, DOI 10.1016/j.ceb.2006.02.003; Busino L, 2004, ONCOGENE, V23, P2050, DOI 10.1038/sj.onc.1207394; COLEMAN TR, 1993, CELL, V72, P919, DOI 10.1016/0092-8674(93)90580-J; Faust M, 2000, CELL TISSUE RES, V301, P329, DOI 10.1007/s004410000256; Glover CVC, 1998, PROG NUCLEIC ACID RE, V59, P95; Guerra B, 1999, FEBS LETT, V462, P353, DOI 10.1016/S0014-5793(99)01553-7; Guerra B, 2003, ONCOGENE, V22, P4933, DOI 10.1038/sj.onc.1206721; Karisson-Rosenthal C, 2006, TRENDS CELL BIOL, V16, P285, DOI 10.1016/j.tcb.2006.04.002; Katayama K, 2005, MOL CELL BIOL, V25, P5725, DOI 10.1128/MCB.25.13.5725-5737.2005; Kohn EA, 2003, CANCER RES, V63, P31; Kreutzer J, 2007, INT J ONCOL, V31, P1251; Kurki S, 2004, CANCER CELL, V5, P465, DOI 10.1016/S1535-6108(04)00110-2; Litchfield DW, 2003, BIOCHEM J, V369, P1, DOI 10.1042/BJ20021469; LUSCHER B, 1994, EUR J BIOCHEM, V220, P521, DOI 10.1111/j.1432-1033.1994.tb18651.x; Mailand N, 2000, SCIENCE, V288, P1425, DOI 10.1126/science.288.5470.1425; Molinari M, 2000, EMBO REP, V1, P71, DOI 10.1093/embo-reports/kvd018; PARKER LL, 1993, NATURE, V363, P736, DOI 10.1038/363736a0; Perry JA, 2007, CELL DIV, V2, DOI 10.1186/1747-1028-2-12; Pines J, 1999, NAT CELL BIOL, V1, pE73, DOI 10.1038/11041; Seeber S, 2005, APOPTOSIS, V10, P875, DOI 10.1007/s10495-005-0380-y; Sia RAL, 1998, EMBO J, V17, P6678, DOI 10.1093/emboj/17.22.6678; Sorensen CS, 2003, CANCER CELL, V3, P247, DOI 10.1016/S1535-6108(03)00048-5; STALTER G, 1994, BIOCHEM BIOPH RES CO, V202, P141, DOI 10.1006/bbrc.1994.1904; TANG ZH, 1993, EMBO J, V12, P3427, DOI 10.1002/j.1460-2075.1993.tb06017.x; Timofeeva OA, 2006, ONCOGENE, V25, P7555, DOI 10.1038/sj.onc.1209742; Toczyski DP, 1997, CELL, V90, P1097, DOI 10.1016/S0092-8674(00)80375-X; van Vugt MATM, 2004, MOL CELL, V15, P799, DOI 10.1016/j.molcel.2004.07.015; Watanabe N, 2004, P NATL ACAD SCI USA, V101, P4419, DOI 10.1073/pnas.0307700101; Watanabe N, 2005, P NATL ACAD SCI USA, V102, P11663, DOI 10.1073/pnas.0500410102; WU L, 1993, NATURE, V363, P738, DOI 10.1038/363738a0; Xiao Z, 2003, J BIOL CHEM, V278, P21767, DOI 10.1074/jbc.M300229200; Yamane K, 2005, CANCER RES, V65, P4362, DOI 10.1158/0008-5472.CAN-04-3941; Zhao H, 2002, P NATL ACAD SCI USA, V99, P14795, DOI 10.1073/pnas.182557299	34	43	48	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 28	2008	27	37					4986	4997		10.1038/onc.2008.146	http://dx.doi.org/10.1038/onc.2008.146			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	344GL	18469858				2022-12-28	WOS:000258914800002
J	LaFiura, KM; Edwards, H; Taub, JW; Matherly, LH; Fontana, JA; Mohamed, AN; Ravindranath, Y; Ge, Y				LaFiura, K. M.; Edwards, H.; Taub, J. W.; Matherly, L. H.; Fontana, J. A.; Mohamed, A. N.; Ravindranath, Y.; Ge, Y.			Identification and characterization of novel AML1-ETO fusion transcripts in pediatric t(8;21) acute myeloid leukemia: a report from the Children's Oncology Group	ONCOGENE			English	Article						t(8;21); AML1-ETO; acute myeloid leukemia; fusion transcripts	ACUTE MYELOBLASTIC-LEUKEMIA; HIGH-DOSE CYTARABINE; DOWN-SYNDROME; AML1/ETO; EXPRESSION; REMISSION; GENE; AML; INTENSIFICATION; PROMOTER	t(8;21)(q22;q22) results in the AML1-ETO (A1E) fusion gene and is a common cytogenetic abnormality in acute myeloid leukemia (AML). Although insertions at the breakpoint region of the A1E fusion transcripts have been reported, additional structural alterations are largely uncharacterized. By RT-PCR amplifications and DNA sequencing, numerous in-frame and out-of-frame AML1b-ETO and AML1c-ETO transcripts were identified in 13 pediatric t(8; 21) AMLs, likely resulting from alternate splicing, internal deletions and/or breakpoint region insertions involving both the AML1 (RUNX1) and ETO regions. The in-frame A1E fusion transcript forms represented minor forms. These structure alterations were found in AML1c-ETO but not AML1b-ETO transcripts in two adult t(8;21) AMLs. Although no analogous alterations were detected in native AML1b transcripts, identical alterations in native ETO transcripts were identified. When transfected into HeLa cells, only AML1b, and not the in-frame A1E forms, transactivated the GM-CSF promoter. In co-transfection experiments, the effects of A1E proteins on GM-CSF transactivation by AML1b ranged from repressive to activating. Our results demonstrate a remarkable and unprecedented heterogeneity in A1E fusion transcripts in t(8;21) myeloblasts and suggest that synthesis of alternate A1E transcript and protein forms can significantly impact the regulation of AML1 responsive genes.	[LaFiura, K. M.; Edwards, H.; Taub, J. W.; Matherly, L. H.; Fontana, J. A.; Ravindranath, Y.; Ge, Y.] Wayne State Univ, Sch Med, Barbara Ann Karmanos Canc Inst, Dev Therapeut Program, Detroit, MI 48201 USA; [Taub, J. W.; Ravindranath, Y.] Childrens Hosp Michigan, Div Pediat Hematol Oncol, Detroit, MI 48201 USA; [Taub, J. W.; Ravindranath, Y.] Wayne State Univ, Sch Med, Dept Pediat, Detroit, MI 48201 USA; [Matherly, L. H.; Ge, Y.] Wayne State Univ, Sch Med, Dept Pharmacol, Detroit, MI 48201 USA; [Fontana, J. A.] John D Dingell Vet Affairs Med Ctr, Dept Med, Detroit, MI USA; [Mohamed, A. N.] Wayne State Univ, Sch Med, Barbara Ann Karmanos Canc Inst, Div Hematol Oncol, Detroit, MI 48201 USA	Barbara Ann Karmanos Cancer Institute; Wayne State University; Children's Hospital of Michigan; Wayne State University; Wayne State University; Barbara Ann Karmanos Cancer Institute; Wayne State University	Ge, Y (corresponding author), Wayne State Univ, Sch Med, Barbara Ann Karmanos Canc Inst, Dev Therapeut Program, 110 E Warren Ave, Detroit, MI 48201 USA.	gey@karmanos.org		Ge, Yubin/0000-0002-8748-716X; Fontana, Joseph/0000-0003-3829-3358	Karmanos Cancer Institute, Leukemia Research Life, the Children's Research Center of Michigan, the Children's Leukemia Foundation of Michigan, the National Cancer Institute [CA92308, CA76641]; Pediatric Oncology Group [CA30969]; Children's Oncology Group [CA98543]; NATIONAL CANCER INSTITUTE [P30CA022453, U10CA098543, R01CA076641, U10CA030969, R01CA092308] Funding Source: NIH RePORTER	Karmanos Cancer Institute, Leukemia Research Life, the Children's Research Center of Michigan, the Children's Leukemia Foundation of Michigan, the National Cancer Institute; Pediatric Oncology Group; Children's Oncology Group; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Dr Robert J Arceci and the Children's Oncology Group AML Biology Subcommittee for authorizing and providing the clinical specimens that made this study possible. This work was supported by grants from the Karmanos Cancer Institute, Leukemia Research Life, the Children's Research Center of Michigan, the Children's Leukemia Foundation of Michigan, the National Cancer Institute (CA92308 and CA76641), the Leukemia and Lymphoma Society, BPCT Golf Charity, the Sehn Family Foundation and the Dale Meyer Memorial Endowment for Leukemia Research. JW Taub is a Scholar in Clinical Research of the Leukemia and Lymphoma Society. This work was also supported by the Pediatric Oncology Group Grant CA30969 and the Children's Oncology Group Grant CA98543.	Becton D, 2006, BLOOD, V107, P1315, DOI 10.1182/blood-2004-08-3218; Bloomfield CD, 1998, CANCER RES, V58, P4173; Byrd JC, 1999, J CLIN ONCOL, V17, P3767, DOI 10.1200/JCO.1999.17.12.3767; Chang M, 2000, LEUKEMIA, V14, P1201, DOI 10.1038/sj.leu.2401832; Entz-Werle N, 2005, LEUKEMIA, V19, P2072, DOI 10.1038/sj.leu.2403932; ERICKSON P, 1992, BLOOD, V80, P1825; Erickson PF, 1996, BLOOD, V88, P1813; Frank R, 1995, ONCOGENE, V11, P2667; Ge YB, 2005, JNCI-J NATL CANCER I, V97, P226, DOI 10.1093/jnci/dji026; Grimwade D, 1998, BLOOD, V92, P2322, DOI 10.1182/blood.V92.7.2322; Kardos G, 2005, LEUKEMIA, V19, P2063, DOI 10.1038/sj.leu.2403873; Klampfer L, 1996, P NATL ACAD SCI USA, V93, P14059, DOI 10.1073/pnas.93.24.14059; Leroy H, 2005, LEUKEMIA, V19, P367, DOI 10.1038/sj.leu.2403627; Lu Y, 2006, LEUKEMIA, V20, P987, DOI 10.1038/sj.leu.2404218; Lutterbach B, 2000, GENE, V245, P223, DOI 10.1016/S0378-1119(00)00014-7; Lutterbach B, 1998, MOL CELL BIOL, V18, P3604, DOI 10.1128/MCB.18.6.3604; Marcucci G, 2000, CANCER INVEST, V18, P768, DOI 10.3109/07357900009012209; Michaud J, 2003, CANCER INVEST, V21, P105, DOI 10.1081/CNV-120018821; MIYOSHI H, 1995, NUCLEIC ACIDS RES, V23, P2762, DOI 10.1093/nar/23.14.2762; NUCIFORA G, 1993, BLOOD, V81, P883; Perel Y, 2005, LEUKEMIA, V19, P2082, DOI 10.1038/sj.leu.2403867; Peterson LF, 2004, ONCOGENE, V23, P4255, DOI 10.1038/sj.onc.1207727; Raimondi SC, 1999, BLOOD, V94, P3707; Rubnitz JE, 2002, LEUKEMIA, V16, P2072, DOI 10.1038/sj.leu.2402633; Saunders MJ, 1996, LEUKEMIA, V10, P1139; Schlenk RF, 2004, J CLIN ONCOL, V22, P3741, DOI 10.1200/JCO.2004.03.012; Schnittger S, 2003, BLOOD, V102, P2746, DOI 10.1182/blood-2003-03-0880; Smith FO, 2005, LEUKEMIA, V19, P2054, DOI 10.1038/sj.leu.2403925; Strout MP, 1999, ANN HEMATOL, V78, P251, DOI 10.1007/s002770050511; TANAKA T, 1995, EMBO J, V14, P341, DOI 10.1002/j.1460-2075.1995.tb07008.x; Wolford JK, 1998, GENE, V212, P103, DOI 10.1016/S0378-1119(98)00141-3; Yan M, 2004, P NATL ACAD SCI USA, V101, P17468, DOI 10.1073/pnas.0406142101; Yan M, 2006, NAT MED, V12, P945, DOI 10.1038/nm1443; Yoo SJ, 2005, HAEMATOLOGICA, V90, P1493	34	14	15	1	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 21	2008	27	36					4933	4942		10.1038/onc.2008.134	http://dx.doi.org/10.1038/onc.2008.134			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	339SF	18469864	Green Accepted			2022-12-28	WOS:000258596900007
J	Sureban, SM; Ramalingam, S; Natarajan, G; May, R; Subramaniam, D; Bishnupuri, KS; Morrison, AR; Dieckgraefe, BK; Brackett, DJ; Postier, RG; Houchen, CW; Anant, S				Sureban, S. M.; Ramalingam, S.; Natarajan, G.; May, R.; Subramaniam, D.; Bishnupuri, K. S.; Morrison, A. R.; Dieckgraefe, B. K.; Brackett, D. J.; Postier, R. G.; Houchen, C. W.; Anant, S.			Translation regulatory factor RBM3 is a proto-oncogene that prevents mitotic catastrophe	ONCOGENE			English	Article						cyclooxygenase-2; RNA stability; transformation; mitosis; cell cycle	RNA-BINDING-PROTEIN; CYCLOOXYGENASE-2 GENE-EXPRESSION; COLON-CANCER CELLS; AU-RICH ELEMENTS; MESSENGER-RNA; PROSTAGLANDIN E-2; 3'-UNTRANSLATED REGION; OVARIAN-CARCINOMA; STABILITY FACTOR; CYCLE ARREST	RNA-binding proteins play a key role in post-transcriptional regulation of mRNA stability and translation. We have identified that RBM3, a translation regulatory protein, is significantly upregulated in human tumors, including a stage-dependent increase in colorectal tumors. Forced RBM3 overexpression in NIH3T3 mouse fibroblasts and SW480 human colon epithelial cells increases cell proliferation and development of compact multicellular spheroids in soft agar suggesting the ability to induce anchorage-independent growth. In contrast, down-regulating RBM3 in HCT116 colon cancer cells with specific siRNA decreases cell growth in culture, which was partially overcome when treated with prostaglandin E(2), a product of cyclooxygenase (COX)-2 enzyme activity. Knockdown also resulted in the growth arrest of tumor xenografts. We have also identified that RBM3 knockdown increases caspase-mediated apoptosis coupled with nuclear cyclin B1, and phosphorylated Cdc25c, Chk1 and Chk2 kinases, implying that under conditions of RBM3 downregulation, cells undergo mitotic catastrophe. RBM3 enhances COX-2, IL-8 and VEGF mRNA stability and translation. Conversely, RBM3 knockdown results in loss in the translation of these transcripts. These data demonstrate that the RNA stabilizing and translation regulatory protein RBM3 is a novel proto-oncogene that induces transformation when overexpressed and is essential for cells to progress through mitosis.	[Sureban, S. M.; Ramalingam, S.; Natarajan, G.; May, R.; Subramaniam, D.; Houchen, C. W.; Anant, S.] Univ Oklahoma, Hlth Sci Ctr, Dept Med, Oklahoma City, OK 73126 USA; [Bishnupuri, K. S.; Morrison, A. R.; Dieckgraefe, B. K.] Washington Univ, Sch Med, Dept Med, St Louis, MO 63110 USA; [Brackett, D. J.; Postier, R. G.] Univ Oklahoma, Hlth Sci Ctr, Dept Surg, Oklahoma City, OK 73126 USA; [Brackett, D. J.; Postier, R. G.; Houchen, C. W.; Anant, S.] OU Canc Inst, Oklahoma City, OK USA; [Anant, S.] Univ Oklahoma, Hlth Sci Ctr, Dept Cell Biol, Oklahoma City, OK 73126 USA	University of Oklahoma System; University of Oklahoma Health Sciences Center; Washington University (WUSTL); University of Oklahoma System; University of Oklahoma Health Sciences Center; University of Oklahoma System; University of Oklahoma Health Sciences Center; University of Oklahoma System; University of Oklahoma Health Sciences Center	Anant, S (corresponding author), Univ Oklahoma, Hlth Sci Ctr, Dept Med, 970 Stanton L Young Blvd,WP1360, Oklahoma City, OK 73126 USA.	shrikant-anant@ouhsc.edu	Anant, Shrikant/AAF-8020-2020; Ramalingam, Satish/H-1577-2018; Sureban, Sripathi/Q-8232-2019	Ramalingam, Satish/0000-0002-3076-279X; Sureban, Sripathi/0000-0001-5476-9593	NATIONAL CANCER INSTITUTE [R01CA135559, R01CA109269] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK062265] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA109269-01A1, R01 CA109269, R01 CA135559, CA-109269] Funding Source: Medline; NIDDK NIH HHS [R01 DK062265-06, R01 DK062265, DK-62265] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDREIS PG, 1981, EXP CELL RES, V134, P265, DOI 10.1016/0014-4827(81)90425-0; Blaxall BC, 2000, MOL CARCINOGEN, V28, P76; Bulavin DV, 2002, CURR OPIN GENET DEV, V12, P92, DOI 10.1016/S0959-437X(01)00270-2; Canman CE, 2001, CURR BIOL, V11, pR121, DOI 10.1016/S0960-9822(01)00057-4; Carpenter B, 2006, BRIT J CANCER, V95, P921, DOI 10.1038/sj.bjc.6603349; CHEN CYA, 1995, MOL CELL BIOL, V15, P5777; CHEN CYA, 1995, TRENDS BIOCHEM SCI, V20, P465, DOI 10.1016/S0968-0004(00)89102-1; Chen YQ, 1999, ONCOGENE, V18, P2747, DOI 10.1038/sj.onc.1202629; Cok SJ, 2001, J BIOL CHEM, V276, P23179, DOI 10.1074/jbc.M008461200; Danno S, 1997, BIOCHEM BIOPH RES CO, V236, P804, DOI 10.1006/bbrc.1997.7059; de Silanes IL, 2003, ONCOGENE, V22, P7146, DOI 10.1038/sj.onc.1206862; Denkert C, 2004, CLIN CANCER RES, V10, P5580, DOI 10.1158/1078-0432.CCR-04-0070; Denkert C, 2006, MODERN PATHOL, V19, P1261, DOI 10.1038/modpathol.3800645; DERRY JMJ, 1995, HUM MOL GENET, V4, P2307, DOI 10.1093/hmg/4.12.2307; Deschenes-Furry J, 2005, J BIOL CHEM, V280, P25361, DOI 10.1074/jbc.M410929200; Dixon DA, 2000, J BIOL CHEM, V275, P11750, DOI 10.1074/jbc.275.16.11750; Dixon DA, 2001, J CLIN INVEST, V108, P1657, DOI 10.1172/JCI200112973; Doree M, 2002, J CELL SCI, V115, P2461; Dresios J, 2005, P NATL ACAD SCI USA, V102, P1865, DOI 10.1073/pnas.0409764102; Dubois RN, 1998, FASEB J, V12, P1063, DOI 10.1096/fasebj.12.12.1063; EBERHART CE, 1994, GASTROENTEROLOGY, V107, P1183, DOI 10.1016/0016-5085(94)90246-1; Erkinheimo TL, 2005, GYNECOL ONCOL, V99, P14, DOI 10.1016/j.ygyno.2005.04.047; Erkinheimo TL, 2003, CANCER RES, V63, P7591; Fan XHC, 1998, P NATL ACAD SCI USA, V95, P15293, DOI 10.1073/pnas.95.26.15293; Fan XHC, 1998, EMBO J, V17, P3448, DOI 10.1093/emboj/17.12.3448; Hacker S, 2004, J BIOL CHEM, V279, P5049, DOI 10.1074/jbc.C300522200; Heinonen M, 2005, CANCER RES, V65, P2157, DOI 10.1158/0008-5472.CAN-04-3765; Krysan K, 2005, CANCER RES, V65, P6275, DOI 10.1158/0008-5472.CAN-05-0216; LANDEGREN U, 1984, J IMMUNOL METHODS, V67, P379, DOI 10.1016/0022-1759(84)90477-0; Landen CN, 2005, CANCER RES, V65, P6910, DOI 10.1158/0008-5472.CAN-05-0530; Maller JL, 1991, CURR OPIN CELL BIOL, V3, P269; MILLAR JBA, 1992, CELL, V68, P407, DOI 10.1016/0092-8674(92)90177-E; Mukhopadhyay D, 2003, MOL CELL, V11, P113, DOI 10.1016/S1097-2765(03)00012-1; Mukhopadhyay D, 2003, ANN NY ACAD SCI, V1010, P504, DOI 10.1196/annals.1299.093; Munkarah AR, 2002, J SOC GYNECOL INVEST, V9, P168, DOI 10.1016/S1071-5576(02)00141-7; Myer VE, 1997, EMBO J, V16, P2130, DOI 10.1093/emboj/16.8.2130; Nabors LB, 2001, CANCER RES, V61, P2154; Ning SC, 1999, RADIAT RES, V151, P659, DOI 10.2307/3580204; Ohi R, 1999, CURR OPIN CELL BIOL, V11, P267, DOI 10.1016/S0955-0674(99)80036-2; Peng SSY, 1998, EMBO J, V17, P3461, DOI 10.1093/emboj/17.12.3461; PinolRoma S, 1997, SEMIN CELL DEV BIOL, V8, P57, DOI 10.1006/scdb.1996.0122; Ristimaki A, 1996, BIOCHEM J, V318, P325, DOI 10.1042/bj3180325; Shao JY, 2003, CANCER RES, V63, P5218; Sheng HM, 1998, CANCER RES, V58, P362; Sheng HM, 2001, J BIOL CHEM, V276, P18075, DOI 10.1074/jbc.M009689200; Shyu AB, 2000, CELL, V102, P135, DOI 10.1016/S0092-8674(00)00018-0; Smart F, 2007, J NEUROCHEM, V101, P1367, DOI 10.1111/j.1471-4159.2007.04521.x; Stark George R, 2004, Methods Mol Biol, V280, P51; Sureban SM, 2007, GASTROENTEROLOGY, V132, P1055, DOI 10.1053/j.gastro.2006.12.031; Sutherland LC, 2005, J CELL BIOCHEM, V94, P5, DOI 10.1002/jcb.20204; Taylor WR, 2001, ONCOGENE, V20, P1803, DOI 10.1038/sj.onc.1204252; Wahl AF, 1996, NAT MED, V2, P72, DOI 10.1038/nm0196-72; Walworth NC, 2001, CURR OPIN GENET DEV, V11, P78, DOI 10.1016/S0959-437X(00)00160-X; Wang DZ, 2005, GASTROENTEROLOGY, V128, P1445, DOI 10.1053/j.gastro.2004.09.080; Wu Gaosong, 2005, J Huazhong Univ Sci Technolog Med Sci, V25, P42; Yamashita H, 2003, ANTICANCER RES, V23, P4671	56	98	110	1	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 31	2008	27	33					4544	4556		10.1038/onc.2008.97	http://dx.doi.org/10.1038/onc.2008.97			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	332IS	18427544	Green Accepted			2022-12-28	WOS:000258077300004
J	Mashima, T; Sato, S; Sugimoto, Y; Tsuruo, T; Seimiya, H				Mashima, T.; Sato, S.; Sugimoto, Y.; Tsuruo, T.; Seimiya, H.			Promotion of glioma cell survival by acyl-CoA synthetase 5 under extracellular acidosis conditions	ONCOGENE			English	Article						low pH; acyl-CoA synthetase; lipid metabolism; microenvironment; midkine	HUMAN HEPATOCELLULAR-CARCINOMA; PROLIFERATOR-ACTIVATED RECEPTOR; HUMAN-MELANOMA CELLS; GENE-EXPRESSION; THERAPEUTIC TARGET; DRUG-RESISTANCE; GROWTH-FACTOR; SOLID TUMORS; MIDKINE; CANCER	Extracellular acidosis (low pH) is a tumor microenvironmental stressor that has a critical function in the malignant progression and met astatic dissemination of tumors. To survive under stress conditions, tumor cells must evolve resistance to stress-induced toxicity. Acyl-CoA synthetase 5 (ACSL5) is a member of the ACS family, which converts fatty acid to acyl-CoA. ACSL5 is frequently overexpressed in malignant glioma, whereas its functional significance is still unknown. Using retrovirus-mediated stable gene transfer ( gain of function) and small interfering RNA-mediated gene silencing ( loss of function), we show here that ACSL5 selectively promotes human glioma cell survival under extracellular acidosis. ACSL5 enhanced cell survival through its ACS catalytic activity. To clarify the genome-wide changes in cell signaling pathways by ACSL5, we performed cDNA microarray analysis and identified an ACSL5-dependent gene expression signature. The analysis revealed that ACSL5 was critical to the expression of tumor-related factors including midkine (MDK), a heparin-binding growth factor frequently overexpressed in cancer. Knockdown of MDK expression significantly attenuated ACSL5-mediated survival under acidic state. These results indicate that ACSL5 is a critical factor for survival of glioma cells under acidic tumor microenvironment, thus providing novel molecular basis for cancer therapy.	[Seimiya, H.] Japanese Fdn Canc Res, Div Mol Biotherapy, Ctr Canc Chemotherapy, Koto Ku, Tokyo 1358550, Japan; [Sato, S.] Japanese Fdn Canc Res, Div Expt Chemotherapy, Ctr Canc Chemotherapy, Tokyo 1358550, Japan; [Sugimoto, Y.] Keio Univ, Dept Chemotherapy, Fac Pharm, Tokyo, Japan; [Sugimoto, Y.] Japanese Fdn Canc Res, Div Gene Therapy, Ctr Canc Chemotherapy, Tokyo 1358550, Japan	Japanese Foundation for Cancer Research; Japanese Foundation for Cancer Research; Keio University; Japanese Foundation for Cancer Research	Seimiya, H (corresponding author), Japanese Fdn Canc Res, Div Mol Biotherapy, Ctr Canc Chemotherapy, Koto Ku, 3-10-6 Ariake, Tokyo 1358550, Japan.	hseimiya@jfcr.or.jp		Seimiya, Hiroyuki/0000-0003-3314-9736				BOGAZZI F, 1994, J BIOL CHEM, V269, P11683; Brusselmans K, 2005, CANCER RES, V65, P6719, DOI 10.1158/0008-5472.CAN-05-0571; Cao Y, 2000, P NATL ACAD SCI USA, V97, P11280, DOI 10.1073/pnas.200367597; Cao Y, 2001, CANCER RES, V61, P8429; Caviglia JM, 2004, J BIOL CHEM, V279, P11163, DOI 10.1074/jbc.M311392200; Coe NR, 1999, J BIOL CHEM, V274, P36300, DOI 10.1074/jbc.274.51.36300; Coleman RA, 2002, J NUTR, V132, P2123, DOI 10.1093/jn/132.8.2123; Gassler N, 2005, J PATHOL, V207, P295, DOI 10.1002/path.1831; Graeber TG, 1996, NATURE, V379, P88, DOI 10.1038/379088a0; Harris AL, 2002, NAT REV CANCER, V2, P38, DOI 10.1038/nrc704; Hatzivassiliou G, 2005, CANCER CELL, V8, P311, DOI 10.1016/j.ccr.2005.09.008; Ikematsu S, 2000, BRIT J CANCER, V83, P701, DOI 10.1054/bjoc.2000.1339; Jia HL, 2007, CLIN CANCER RES, V13, P1133, DOI 10.1158/1078-0432.CCR-06-1025; Kadomatsu K, 1997, BRIT J CANCER, V75, P354, DOI 10.1038/bjc.1997.58; KADOMATSU K, 2004, CANC LETT, V204, P1391; Kitanaka C, 1999, CELL DEATH DIFFER, V6, P508, DOI 10.1038/sj.cdd.4400526; Knudsen KE, 2000, MOL CELL BIOL, V20, P7751, DOI 10.1128/MCB.20.20.7751-7763.2000; Kuhajda FP, 2006, CANCER RES, V66, P5977, DOI 10.1158/0008-5472.CAN-05-4673; Lewin TM, 2001, J BIOL CHEM, V276, P24674, DOI 10.1074/jbc.M102036200; Liang YC, 2005, WORLD J GASTROENTERO, V11, P2557, DOI 10.3748/wjg.v11.i17.2557; Maeda S, 2007, BRIT J CANCER, V97, P405, DOI 10.1038/sj.bjc.6603879; Mashek DG, 2006, J BIOL CHEM, V281, P945, DOI 10.1074/jbc.M507646200; Mashima T, 2005, DRUG RESIST UPDATE, V8, P339, DOI 10.1016/j.drup.2005.11.001; Mashima T, 2005, JNCI-J NATL CANCER I, V97, P765, DOI 10.1093/jnci/dji133; Menendez JA, 2007, NAT REV CANCER, V7, P763, DOI 10.1038/nrc2222; Mirkin BL, 2005, ONCOGENE, V24, P4965, DOI 10.1038/sj.onc.1208671; Mishima K, 1997, NEUROSCI LETT, V233, P29, DOI 10.1016/S0304-3940(97)00619-8; Mishima K, 2001, CANCER RES, V61, P5349; NAKAGAWARA A, 1995, CANCER RES, V55, P1792; OBrien T, 1996, CANCER RES, V56, P2515; Ohtsubo T, 1997, CANCER RES, V57, P3910; Reichert M, 2002, CANCER, V95, P1113, DOI 10.1002/cncr.10767; Rofstad EK, 2006, CANCER RES, V66, P6699, DOI 10.1158/0008-5472.CAN-06-0983; Schoonjans K, 1996, J LIPID RES, V37, P907; Seimiya H, 1999, BIOCHEM BIOPH RES CO, V260, P365, DOI 10.1006/bbrc.1999.0910; Soengas MS, 1999, SCIENCE, V284, P156, DOI 10.1126/science.284.5411.156; Sung YK, 2003, CANCER SCI, V94, P421, DOI 10.1111/j.1349-7006.2003.tb01458.x; Sung YK, 2007, EXP MOL MED, V39, P477, DOI 10.1038/emm.2007.52; Takei Y, 2001, CANCER RES, V61, P8486; TANNOCK IF, 1989, CANCER RES, V49, P4373; Tao QG, 2007, JNCI-J NATL CANCER I, V99, P1668, DOI 10.1093/jnci/djm208; Tomida A, 1999, ANTI-CANCER DRUG DES, V14, P169; Tong Y, 2007, J NEUROCHEM, V100, P1097, DOI 10.1111/j.1471-4159.2006.04276.x; UEHARA K, 1992, J BIOCHEM-TOKYO, V111, P563, DOI 10.1093/oxfordjournals.jbchem.a123797; van den Beucken T, 2006, CANCER BIOL THER, V5, P749, DOI 10.4161/cbt.5.7.2972; VAUPEL P, 1989, CANCER RES, V49, P6449; Xie SH, 1997, CANCER RES, V57, P2295; Yamashita Y, 2000, ONCOGENE, V19, P5919, DOI 10.1038/sj.onc.1203981; Ye C, 1999, BRIT J CANCER, V79, P179, DOI 10.1038/sj.bjc.6690030; Yeh CS, 2006, CANCER LETT, V233, P297, DOI 10.1016/j.canlet.2005.03.050	50	52	57	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 8	2009	28	1					9	19		10.1038/onc.2008.355	http://dx.doi.org/10.1038/onc.2008.355			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	392HP	18806831				2022-12-28	WOS:000262294100002
J	Chan, YW; Chen, Y; Poon, RYC				Chan, Y. W.; Chen, Y.; Poon, R. Y. C.			Generation of an indestructible cyclin B1 by caspase-6-dependent cleavage during mitotic catastrophe	ONCOGENE			English	Article						apoptosis; cell cycle; checkpoint; cyclin; DNA damage; mitotic catastrophe	CELL-CYCLE; DNA-DAMAGE; CHECKPOINT PATHWAY; DEPENDENT KINASES; APOPTOSIS; DEATH; CHK1; PHOSPHORYLATION; ACTIVATION; DISTINCT	Overriding the G(2) DNA damage checkpoint permits precocious entry into mitosis that ultimately leads to mitotic catastrophe. Mitotic catastrophe is manifested by an unscheduled activation of CDK1, caspase activation and apoptotic cell death. We found that although cyclin B1 was required for mitotic catastrophe, it was cleaved into a similar to 35kDa protein by a caspase-dependent mechanism during the process. Cyclin B1 cleavage occurred after Asp123 in the motif ILVD123 down arrow, and mutation of this motif attenuated the cleavage. Cleavage was abolished by a pan-caspase inhibitor as well as by specific inhibitors for the effector caspase-6 and the initiator caspase-8. Cleavage created a truncated cyclin B1 lacking part of the NH2-terminal regulatory domain that included the destruction box sequence. Although cleavage of cyclin B1 itself was not absolutely required for mitotic catastrophe, expression of the truncated product enhanced cell death. In support of this, ectopic expression of this truncated cyclin B1 was not only sufficient to induce mitotic block and apoptosis but also enhanced mitotic catastrophe induced by ionizing radiation and caffeine. These data underscore a possible linkage between mitotic and apoptotic functions by caspase-dependent processing of mitotic activators.	[Chan, Y. W.; Chen, Y.; Poon, R. Y. C.] Hong Kong Univ Sci & Technol, Dept Biochem, Hong Kong, Hong Kong, Peoples R China	Hong Kong University of Science & Technology	Poon, RYC (corresponding author), Hong Kong Univ Sci & Technol, Dept Biochem, Hong Kong, Hong Kong, Peoples R China.	rycpoon@ust.hk	Chan, Gary/P-7347-2019	Chan, Gary/0000-0002-6196-7675; Poon, Randy/0000-0001-5571-6231	Hong Kong Research Grants Council [66207, HKUST6439/06M]	Hong Kong Research Grants Council(Hong Kong Research Grants Council)	Many thanks are due to members of the Poon Lab for constructive criticism on the manuscript. We thank Julian Gannon, Tim Hunt and Katsumi Yamashita for generous gifts of reagents. We also thank Talha Arooz and Wai Yi Siu for technical assistance and Jeremy PK Chow for the original observation of cyclin B1 cleavage. This work was supported in part by the Hong Kong Research Grants Council Grants 66207 and HKUST6439/06M to RYCP.	Arooz T, 2000, BIOCHEMISTRY-US, V39, P9494, DOI 10.1021/bi0009643; Baek KH, 2005, ONCOL RES, V15, P161, DOI 10.3727/096504005776367906; Blasina A, 1999, CURR BIOL, V9, P1135, DOI 10.1016/S0960-9822(99)80486-2; Blasina A, 1999, CURR BIOL, V9, P1, DOI 10.1016/S0960-9822(99)80041-4; Castedo M, 2002, CELL DEATH DIFFER, V9, P1287, DOI 10.1038/sj.cdd.4401130; Castedo M, 2004, ONCOGENE, V23, P4362, DOI 10.1038/sj.onc.1207572; Castedo M, 2004, ONCOGENE, V23, P2825, DOI 10.1038/sj.onc.1207528; Chan TA, 1999, NATURE, V401, P616, DOI 10.1038/44188; Chan YW, 2008, J BIOL CHEM, V283, P15716, DOI 10.1074/jbc.M800629200; Chan YW, 2008, CELL CYCLE, V7, P1449, DOI 10.4161/cc.7.10.5880; Chow JPH, 2003, MOL BIOL CELL, V14, P3989, DOI 10.1091/mbc.E03-03-0168; Chow JPH, 2003, J BIOL CHEM, V278, P40815, DOI 10.1074/jbc.M306683200; Falck J, 2001, NATURE, V410, P842, DOI 10.1038/35071124; Fung TK, 2005, CELL CYCLE, V4, P1411, DOI 10.4161/cc.4.10.2046; Fung TK, 2002, J BIOL CHEM, V277, P35140, DOI 10.1074/jbc.M205503200; Fung TK, 2007, MOL BIOL CELL, V18, P1861, DOI 10.1091/mbc.E06-12-1092; Furnari B, 1999, MOL BIOL CELL, V10, P833, DOI 10.1091/mbc.10.4.833; Giles N, 2003, J BIOL CHEM, V278, P28580, DOI 10.1074/jbc.M304027200; Graham RK, 2006, CELL, V125, P1179, DOI 10.1016/j.cell.2006.04.026; Hall-Jackson CA, 1999, ONCOGENE, V18, P6707, DOI 10.1038/sj.onc.1203077; Ho CC, 2006, CANCER RES, V66, P2233, DOI 10.1158/0008-5472.CAN-05-1790; Ho CC, 2005, EXP CELL RES, V304, P1, DOI 10.1016/j.yexcr.2004.10.016; Kastan MB, 2004, NATURE, V432, P316, DOI 10.1038/nature03097; Kim M, 2005, MOL CELL BIOL, V25, P9232, DOI 10.1128/MCB.25.21.9232-9248.2005; Konishi Y, 2002, MOL CELL, V9, P1005, DOI 10.1016/S1097-2765(02)00524-5; Kramer A, 2004, NAT CELL BIOL, V6, P884, DOI 10.1038/ncb1165; Lee J, 2001, MOL BIOL CELL, V12, P551, DOI 10.1091/mbc.12.3.551; Li KKW, 2002, LIVER, V22, P259, DOI 10.1046/j.0106-9543.2002.01629.x; Mailand N, 2000, SCIENCE, V288, P1425, DOI 10.1126/science.288.5470.1425; Mansilla S, 2006, CELL CYCLE, V5, P53, DOI 10.4161/cc.5.1.2267; Niida H, 2005, J BIOL CHEM, V280, P39246, DOI 10.1074/jbc.M505009200; Orth K, 1996, J BIOL CHEM, V271, P16443, DOI 10.1074/jbc.271.28.16443; Peng CY, 1997, SCIENCE, V277, P1501, DOI 10.1126/science.277.5331.1501; POON RYC, 1995, MOL BIOL CELL, V6, P1197, DOI 10.1091/mbc.6.9.1197; POON RYC, 1995, SCIENCE, V270, P90, DOI 10.1126/science.270.5233.90; Rothblum-Oviatt CJ, 2001, CELL GROWTH DIFFER, V12, P581; Ruchaud S, 2002, EMBO J, V21, P1967, DOI 10.1093/emboj/21.8.1967; Sanchez Y, 1997, SCIENCE, V277, P1497, DOI 10.1126/science.277.5331.1497; Schmitt E, 2006, J CELL SCI, V119, P4269, DOI 10.1242/jcs.03200; Siu WY, 2004, MOL CANCER THER, V3, P621; Siu WY, 1999, EXP CELL RES, V250, P131, DOI 10.1006/excr.1999.4551; Slee EA, 2001, J BIOL CHEM, V276, P7320, DOI 10.1074/jbc.M008363200; Stack JH, 1997, DEVELOPMENT, V124, P3185; Takahashi A, 1996, P NATL ACAD SCI USA, V93, P8395, DOI 10.1073/pnas.93.16.8395; Vogel C, 2007, CANCER RES, V67, P339, DOI 10.1158/0008-5472.CAN-06-2548; Yam CH, 1999, CANCER RES, V59, P5075; Yam CH, 1999, MOL CELL BIOL, V19, P635; Yam CH, 2000, J BIOL CHEM, V275, P3158, DOI 10.1074/jbc.275.5.3158; Yanagida M, 2005, PHILOS T R SOC B, V360, P609, DOI 10.1098/rstb.2004.1615; Yang J, 1998, GENE DEV, V12, P2131, DOI 10.1101/gad.12.14.2131; Yim H, 2003, MOL BIOL CELL, V14, P4250, DOI 10.1091/mbc.E03-01-0029; Yim H, 2006, J CELL BIOL, V174, P77, DOI 10.1083/jcb.200509141	52	16	17	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2009	28	2					170	183		10.1038/onc.2008.369	http://dx.doi.org/10.1038/onc.2008.369			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	395CY	18820706				2022-12-28	WOS:000262501100002
J	Hagelstrom, RT; Askin, KF; Williams, AJ; Ramaiah, L; Desaintes, C; Goodwin, EH; Ullrich, RL; Bailey, SM				Hagelstrom, R. T.; Askin, K. F.; Williams, A. J.; Ramaiah, L.; Desaintes, C.; Goodwin, E. H.; Ullrich, R. L.; Bailey, S. M.			DNA-PKcs and ATM influence generation of ionizing radiation-induced bystander signals	ONCOGENE			English	Article						DNA-PKcs; ATM; ionizing radiation; bystander effect	DEPENDENT PROTEIN-KINASE; SISTER-CHROMATID EXCHANGES; STRAND BREAK REPAIR; CATALYTIC SUBUNIT; INTERCELLULAR COMMUNICATION; V(D)J RECOMBINATION; ALPHA-PARTICLES; LOW FLUENCES; CELLS; DEFICIENCY	The phenomenon by which irradiated cells influence non-irradiated neighboring cells, referred to as the bystander effect (BSE), is not well understood in terms of the underlying pathways involved. We sought to enlighten connections between DNA damage repair and the BSE. Utilizing sister chromatid exchange (SCE) frequencies as a marker of the BSE, we performed cell transfer strategies that enabled us to distinguish between generation versus reception of a bystander signal. We find that DNA-dependent Protein Kinase catalytic subunit (DNA-PKcs) and Ataxia Telangectasia Mutated (ATM) are necessary for the generation of such a bystander signal in normal human cells following gamma (gamma)-ray exposure, but are not required for its reception. Importantly, we also show that directly irradiated human cells do not respond to receipt of a bystander signal, helping to explain why the BSE is a low-dose phenomenon. These studies provide the first evidence for a role of the DNA damage response proteins DNA-PKcs and ATM specifically in the generation of a bystander signal and intercellular signaling.	[Hagelstrom, R. T.; Askin, K. F.; Williams, A. J.; Ramaiah, L.; Ullrich, R. L.; Bailey, S. M.] Colorado State Univ, Dept Environm & Radiol Hlth Sci, Ft Collins, CO 80523 USA; [Desaintes, C.] CEN SCK, Radiobiol Lab, B-2400 Mol, Belgium; [Goodwin, E. H.] KromaTiD Inc, Ft Collins, CO USA	Colorado State University; Belgian Nuclear Research Centre (SCK-CEN)	Bailey, SM (corresponding author), Colorado State Univ, Dept Environm & Radiol Hlth Sci, Campus Delivery 1618, Ft Collins, CO 80523 USA.	sbailey@colostate.edu	Ramaiah, Lila/GPX-6746-2022		NIH/NCI [CA-09236-30, CA-043322-20]; US Department of Energy (DOE) [DE-FG02-01ER63239]; National Aeronautics and Space Administration (NASA) [NNJ04HD83G]; NATIONAL CANCER INSTITUTE [R01CA043322] Funding Source: NIH RePORTER	NIH/NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); US Department of Energy (DOE)(United States Department of Energy (DOE)); National Aeronautics and Space Administration (NASA)(National Aeronautics & Space Administration (NASA)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Dakim Gaines for technical assistance. Support for this research is gratefully acknowledged from the NIH/NCI, Grants CA-09236-30 (RLU) and CA-043322-20 (RLU and SMB), the US Department of Energy (DOE), Grant DE-FG02-01ER63239 (RLU and SMB), and from the National Aeronautics and Space Administration (NASA), Grant NNJ04HD83G (SMB).	ARDITO G, 1980, Bollettino Societa Italiana Biologia Sperimentale, V56, P719; Azzam EI, 1998, RADIAT RES, V150, P497, DOI 10.2307/3579865; Azzam EI, 2001, P NATL ACAD SCI USA, V98, P473, DOI 10.1073/pnas.011417098; Bailey SM, 1999, P NATL ACAD SCI USA, V96, P14899, DOI 10.1073/pnas.96.26.14899; Bailey SM, 2004, DNA REPAIR, V3, P225, DOI 10.1016/j.dnarep.2003.10.013; Bailey SM, 2001, SCIENCE, V293, P2462, DOI 10.1126/science.1062560; Banaz-Yasar F, 2008, J CELL BIOCHEM, V103, P149, DOI 10.1002/jcb.21395; Barzilai A, 2002, DNA REPAIR, V1, P3, DOI 10.1016/S1568-7864(01)00007-6; Blunt T, 1996, P NATL ACAD SCI USA, V93, P10285, DOI 10.1073/pnas.93.19.10285; Collis SJ, 2005, ONCOGENE, V24, P949, DOI 10.1038/sj.onc.1208332; Denchi EL, 2007, NATURE, V448, P1068, DOI 10.1038/nature06065; Deshpande A, 1996, RADIAT RES, V145, P260, DOI 10.2307/3578980; Dudley DD, 2005, ADV IMMUNOL, V86, P43, DOI 10.1016/S0065-2776(04)86002-4; Fritz G, 2006, MOL BIOL CELL, V17, P851, DOI 10.1091/mbc.E05-07-0606; Grifalconi M, 2007, MUTAT RES-FUND MOL M, V625, P102, DOI 10.1016/j.mrfmmm.2007.06.004; Hu BR, 2006, CARCINOGENESIS, V27, P245, DOI 10.1093/carcin/bgi224; Iyer R, 2002, RADIAT RES, V157, P3, DOI 10.1667/0033-7587(2002)157[0003:APIIIT]2.0.CO;2; JACKSON SP, 1995, TRENDS BIOCHEM SCI, V20, P412, DOI 10.1016/S0968-0004(00)89090-8; Kanasugi Y, 2007, INT J RADIAT BIOL, V83, P73, DOI 10.1080/09553000601121116; Kashino G, 2007, J RADIAT RES, V48, P327, DOI 10.1269/jrr.07008; Lavin MF, 2007, CELL CYCLE, V6, P931, DOI 10.4161/cc.6.8.4180; Lehnert BE, 1997, CANCER RES, V57, P2164; Lieber MR, 1999, GENES CELLS, V4, P77, DOI 10.1046/j.1365-2443.1999.00245.x; Meek K, 2004, IMMUNOL REV, V200, P132, DOI 10.1111/j.0105-2896.2004.00162.x; Morgan WF, 2003, ONCOGENE, V22, P7094, DOI 10.1038/sj.onc.1206992; Mothersill C, 2004, RADIAT RES, V161, P256, DOI 10.1667/RR3136; Mothersill C, 1998, RADIAT RES, V149, P256, DOI 10.2307/3579958; Nagasawa H, 2005, RADIAT RES, V164, P141, DOI 10.1667/RR3420; Nagasawa H, 2003, INT J RADIAT BIOL, V79, P35, DOI 10.1080/0955300021000019230; Nagasawa H, 2002, MUTAT RES-FUND MOL M, V508, P121, DOI 10.1016/S0027-5107(02)00193-8; NAGASAWA H, 1992, CANCER RES, V52, P6394; O'Neill-Mehlenbacher A, 2007, INT J RADIAT BIOL, V83, P593, DOI 10.1080/09553000701481782; Okayasu R, 2000, CANCER RES, V60, P4342; Pandita TK, 2002, ONCOGENE, V21, P611, DOI 10.1038/sj.onc.1205060; Panta GR, 2004, MOL CELL BIOL, V24, P1823, DOI 10.1128/MCB.24.5.1823-1835.2004; Seymour CB, 2000, RADIAT RES, V153, P508, DOI 10.1667/0033-7587(2000)153[0508:RCOBAT]2.0.CO;2; Shao CL, 2006, RADIAT RES, V166, P479, DOI 10.1667/RR3600.1; Weil MM, 1997, GENETICS, V146, P1061; Weinstock DM, 2006, MOL CELL BIOL, V26, P131, DOI 10.1128/MCB.26.1.131-139.2006; WOLFF S, 1975, EXP CELL RES, V93, P23, DOI 10.1016/0014-4827(75)90418-8; Wu LJ, 1999, P NATL ACAD SCI USA, V96, P4959, DOI 10.1073/pnas.96.9.4959; Xu WM, 2000, NAT CELL BIOL, V2, P339, DOI 10.1038/35014028; Yang HY, 2007, RADIAT RES, V168, P292, DOI 10.1667/RR0864.1; Yu YJ, 2001, CANCER RES, V61, P1820; Zhang Y, 2007, CANCER LETT, V250, P63, DOI 10.1016/j.canlet.2006.09.021	45	26	29	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 13	2008	27	53					6761	6769		10.1038/onc.2008.276	http://dx.doi.org/10.1038/onc.2008.276			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	371XO	18679419				2022-12-28	WOS:000260866200006
J	Zalzali, H; Naudin, C; Bastide, P; Quittau-Prevostel, C; Yaghi, C; Poulat, F; Jay, P; Blache, P				Zalzali, H.; Naudin, C.; Bastide, P.; Quittau-Prevostel, C.; Yaghi, C.; Poulat, F.; Jay, P.; Blache, P.			CEACAM1, a SOX9 direct transcriptional target identified in the colon epithelium	ONCOGENE			English	Article						CEACAM1; colon epithelium; SOX9	CARCINOEMBRYONIC ANTIGEN; GENE; EXPRESSION; ENHANCER; PROTEIN; CELLS; MODEL	A deletion of the transcription factor SOX9 gene in the mice intestine affects the morphology of the colon epithelium and leads to hyperplasia. Nevertheless, direct transcriptional targets of SOX9 in this tissue are still unknown. A microarray analysis identified the tumor suppressor carcinoembryonic antigen-related cell adhesion molecule 1 (CEACAM1) as a possible SOX9 target gene and we demonstrate here that SOX9 upregulates CEACAM1 in human colonic cells. Moreover, CEACAM1 expression is reduced in colon of SOX9-deficient mouse, suggesting an important function for SOX9 in the transcriptional activation of the CEACAM1 gene. We further identified SOX9-binding sequences in the human and rat CEACAM1 promoters, and an electrophoretic mobility shift together with a chromatin immunoprecipitation provided an additional evidence of the SOX9 binding to the human promoter. In addition, we established that histone acyl-transferase p300 behaves as an SOX9 coactivator of the rat and human CEACAM1 promoters. These results highlight CEACAM1 as the first direct target of SOX9 identified in the colon epithelium.	[Blache, P.] Univ Montpellier, CNRS, UMR 5203, Inst Genome Fonct, F-34094 Montpellier 5, France; [Zalzali, H.; Naudin, C.; Bastide, P.; Quittau-Prevostel, C.; Jay, P.; Blache, P.] INSERM, U661, Montpellier, France; [Zalzali, H.; Naudin, C.; Bastide, P.; Quittau-Prevostel, C.; Jay, P.; Blache, P.] Univ Montpellier 1, Montpellier, France; [Yaghi, C.] Univ St Joseph Achrafieh, Serv Gastroenterol, CHU Hotel Dieu France, Beirut, Lebanon; [Poulat, F.] Inst Genet Humaine, CNRS, UPR 1142, Montpellier, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Montpellier; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier; Universite de Montpellier; Centre National de la Recherche Scientifique (CNRS); Universite de Montpellier	Blache, P (corresponding author), Univ Montpellier, CNRS, UMR 5203, Inst Genome Fonct, 141 Rue Cardonille, F-34094 Montpellier 5, France.	philippe.blache@igf.cnrs.fr	Jay, Philippe/ABD-9223-2020; POULAT, FRANCIS/AAV-2170-2020; Prevostel, Corinne/AAO-1433-2020; Jay, Philippe/I-7116-2016	Jay, Philippe/0000-0003-0156-5700; POULAT, FRANCIS/0000-0003-2070-1296; Jay, Philippe/0000-0003-0156-5700; Yaghi, Cesar/0000-0003-4130-2606; PREVOSTEL, Corinne/0000-0002-7553-087X	Agence Nationale pour la Recherche; Association pour la Recherche contre le Cancer [3570, 3636]; Ligue Nationale contre le Cancer (Equipe Labellisee); Fondation pour la Recherche Medicale; Groupement des Entreprises Francaises dans la Lutte contre le Cancer; National Council for Scientific Research Lebanon	Agence Nationale pour la Recherche(French National Research Agency (ANR)); Association pour la Recherche contre le Cancer(Fondation ARC pour la Recherche sur le Cancer); Ligue Nationale contre le Cancer (Equipe Labellisee)(Ligue nationale contre le cancer); Fondation pour la Recherche Medicale(Fondation pour la Recherche Medicale); Groupement des Entreprises Francaises dans la Lutte contre le Cancer; National Council for Scientific Research Lebanon	This work was supported by Agence Nationale pour la Recherche, Association pour la Recherche contre le Cancer (nos. 3570 and 3636), Ligue Nationale contre le Cancer (Equipe Labellisee), Fondation pour la Recherche Medicale, Groupement des Entreprises Francaises dans la Lutte contre le Cancer and the National Council for Scientific Research Lebanon. We thank Dr Horst and Dr Beauchemin for the anti-CEACAM1 antibodies, Dr Najjar and Dr Beauchemin for the luciferase reporter.	Bastide P, 2007, J CELL BIOL, V178, P635, DOI 10.1083/jcb.200704152; Blache P, 2004, J CELL BIOL, V166, P37, DOI 10.1083/jcb.200311021; Chen CJ, 1996, J BIOL CHEM, V271, P28181, DOI 10.1074/jbc.271.45.28181; Darido C, 2008, CANCER RES, V68, P4258, DOI 10.1158/0008-5472.CAN-07-5805; HAUCK W, 1994, EUR J BIOCHEM, V223, P529, DOI 10.1111/j.1432-1033.1994.tb19022.x; Hemmila E, 2004, J VIROL, V78, P10156, DOI 10.1128/JVI.78.18.10156-10165.2004; Jay P, 2005, CANCER RES, V65, P2193, DOI 10.1158/0008-5472.CAN-04-1484; Jenkins E, 2005, MATRIX BIOL, V24, P177, DOI 10.1016/j.matbio.2005.02.004; Kuespert K, 2006, CURR OPIN CELL BIOL, V18, P565, DOI 10.1016/j.ceb.2006.08.008; Leung N, 2006, ONCOGENE, V25, P5527, DOI 10.1038/sj.onc.1209541; Lu BJ, 2006, BMC CANCER, V6, DOI 10.1186/1471-2407-6-40; Mertin S, 1999, NUCLEIC ACIDS RES, V27, P1359, DOI 10.1093/nar/27.5.1359; Najjar SM, 1996, J BIOL CHEM, V271, P8809, DOI 10.1074/jbc.271.15.8809; Nittka S, 2004, ONCOGENE, V23, P9306, DOI 10.1038/sj.onc.1208259; Notarnicola C, 2006, GENE EXPR PATTERNS, V6, P695, DOI 10.1016/j.modgep.2006.01.001; Tsuda M, 2003, J BIOL CHEM, V278, P27224, DOI 10.1074/jbc.M303471200; WAGENER C, 1983, J IMMUNOL, V130, P2308; Zhou G, 1998, J BIOL CHEM, V273, P14989, DOI 10.1074/jbc.273.24.14989	18	36	36	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV	2008	27	56					7131	7138		10.1038/onc.2008.331	http://dx.doi.org/10.1038/onc.2008.331			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	376PQ	18794798				2022-12-28	WOS:000261195900007
J	Mumm, JB; Oft, M				Mumm, J. B.; Oft, M.			Cytokine-based transformation of immune surveillance into tumor-promoting inflammation	ONCOGENE			English	Review						IL-23; IL-12; Th17; inflammation; tumor immune surveillance	GROWTH-FACTOR-BETA; NECROSIS-FACTOR-ALPHA; COLLAGEN-INDUCED ARTHRITIS; CD8(+) T-CELLS; TGF-BETA; AUTOIMMUNE INFLAMMATION; CANCER PROGRESSION; ANTICANCER THERAPY; COLORECTAL-CANCER; LYMPHOCYTES-T	During the last decade, it has become clear that the mammalian immune system is able to recognize and partially suppress nascent tumors. Human T cells specific to oncogenes and onco-fetal antigens are present in human cancer patients and their tumors. At the same time, molecular links between tumor-associated inflammation and tumor progression have been uncovered, providing an explanation for the long recognized epidemiological link between inflammation and cancer. The synopsis of these findings suggests a new interpretation of tumor immunity. It appears that antigen recognition or antigen-specific T-cell expansion at large is not as profoundly impaired in tumor patients as the correct polarization, the survival and the effector function of tumor-infiltrating T cells. This review will focus on pro-inflammatory cytokines likely to contribute to the deregulation of tumor-specific immunity and its consequences.	[Mumm, J. B.; Oft, M.] Schering Plough Biopharma, Dept Oncol, Palo Alto, CA 94303 USA	Merck & Company	Oft, M (corresponding author), Schering Plough Biopharma, Dept Oncol, 901 Calif Ave, Palo Alto, CA 94303 USA.	martin.oft@spcorp.com						Aggarwal BB, 2006, ANN NY ACAD SCI, V1091, P151, DOI 10.1196/annals.1378.063; Alonzi T, 1998, J EXP MED, V187, P461, DOI 10.1084/jem.187.4.461; Ancrile B, 2007, GENE DEV, V21, P1714, DOI 10.1101/gad.1549407; Atkins MB, 1997, CLIN CANCER RES, V3, P409; Atreya R, 2000, NAT MED, V6, P583, DOI 10.1038/75068; BAFFET G, 1991, MOL BIOL MED, V8, P141; Balkwill F, 2005, CANCER CELL, V7, P211, DOI 10.1016/j.ccr.2005.02.013; Becker C, 2004, IMMUNITY, V21, P491, DOI 10.1016/j.immuni.2004.07.020; Betti M, 2006, ANN ONCOL, V17, P235; Betz UAK, 1998, INT IMMUNOL, V10, P1175, DOI 10.1093/intimm/10.8.1175; Bierie B, 2006, NAT REV CANCER, V6, P506, DOI 10.1038/nrc1926; Blankenstein T, 2005, CURR OPIN IMMUNOL, V17, P180, DOI 10.1016/j.coi.2005.01.008; Borkowski TA, 1996, J EXP MED, V184, P2417, DOI 10.1084/jem.184.6.2417; Bowman EP, 2006, CURR OPIN INFECT DIS, V19, P245, DOI 10.1097/01.qco.0000224818.42729.67; BRANDES ME, 1991, J IMMUNOL, V147, P1600; Cebon Jonathan, 2003, Cancer Immun, V3, P7; Chan JR, 2006, J EXP MED, V203, P2577, DOI 10.1084/jem.20060244; Chen WJ, 2001, J EXP MED, V194, P439, DOI 10.1084/jem.194.4.439; Coussens LM, 2002, NATURE, V420, P860, DOI 10.1038/nature01322; Cua DJ, 2003, NATURE, V421, P744, DOI 10.1038/nature01355; Curiel TJ, 2004, NAT MED, V10, P942, DOI 10.1038/nm1093; Derynck R, 2001, NAT GENET, V29, P117, DOI 10.1038/ng1001-117; Dudley ME, 2002, SCIENCE, V298, P850, DOI 10.1126/science.1076514; Feldmann M, 2001, ANNU REV IMMUNOL, V19, P163, DOI 10.1146/annurev.immunol.19.1.163; Folkman J, 2007, NAT REV DRUG DISCOV, V6, P273, DOI 10.1038/nrd2115; Galon J, 2006, SCIENCE, V313, P1960, DOI 10.1126/science.1129139; Happel KI, 2003, J IMMUNOL, V170, P4432, DOI 10.4049/jimmunol.170.9.4432; Harrison ML, 2007, J CLIN ONCOL, V25, P4542, DOI 10.1200/JCO.2007.11.2136; Jager E, 2003, INT J CANCER, V106, P817, DOI 10.1002/ijc.11292; Kaplan DH, 1998, P NATL ACAD SCI USA, V95, P7556, DOI 10.1073/pnas.95.13.7556; Kastelein RA, 2007, ANNU REV IMMUNOL, V25, P221, DOI 10.1146/annurev.immunol.22.012703.104758; KEHRL JH, 1986, J EXP MED, V163, P1037, DOI 10.1084/jem.163.5.1037; KNUTH A, 1984, P NATL ACAD SCI-BIOL, V81, P3511, DOI 10.1073/pnas.81.11.3511; Kolls JK, 2004, IMMUNITY, V21, P467, DOI 10.1016/j.immuni.2004.08.018; Kryczek I, 2007, J IMMUNOL, V178, P6730, DOI 10.4049/jimmunol.178.11.6730; Landi S, 2003, CANCER RES, V63, P3560; Langowski JL, 2007, TRENDS IMMUNOL, V28, P207, DOI 10.1016/j.it.2007.03.006; Langowski JL, 2006, NATURE, V442, P461, DOI 10.1038/nature04808; Langrish CL, 2005, J EXP MED, V201, P233, DOI 10.1084/jem.20041257; Letterio JJ, 2005, ONCOGENE, V24, P5701, DOI 10.1038/sj.onc.1208922; Li MO, 2006, ANNU REV IMMUNOL, V24, P99, DOI 10.1146/annurev.immunol.24.021605.090737; Lin WW, 2007, J CLIN INVEST, V117, P1175, DOI 10.1172/JCI31537; Liu SJ, 2007, J LEUKOCYTE BIOL, V82, P354, DOI 10.1189/jlb.0207111; Lo CH, 2003, J IMMUNOL, V171, P600, DOI 10.4049/jimmunol.171.2.600; Maeda S, 2005, CELL, V121, P977, DOI 10.1016/j.cell.2005.04.014; Mangan PR, 2006, NATURE, V441, P231, DOI 10.1038/nature04754; McGeachy MJ, 2007, NAT IMMUNOL, V8, P1390, DOI 10.1038/ni1539; Mocellin S, 2005, CYTOKINE GROWTH F R, V16, P35, DOI 10.1016/j.cytogfr.2004.11.001; Moore RJ, 1999, NAT MED, V5, P828, DOI 10.1038/10552; Naito Y, 1998, CANCER RES, V58, P3491; Nakae S, 2003, J IMMUNOL, V171, P6173, DOI 10.4049/jimmunol.171.11.6173; Novelli F, 2004, CYTOKINE GROWTH F R, V15, P367, DOI 10.1016/j.cytogfr.2004.03.009; Numasaki M, 2003, BLOOD, V101, P2620, DOI 10.1182/blood-2002-05-1461; Oft M, 2002, NAT CELL BIOL, V4, P487, DOI 10.1038/ncb807; Parham C, 2002, J IMMUNOL, V168, P5699, DOI 10.4049/jimmunol.168.11.5699; Rao VSR, 2006, ONCOL REP, V15, P179; ROBERTS AB, 1986, P NATL ACAD SCI USA, V83, P4167, DOI 10.1073/pnas.83.12.4167; Rohekar S, 2008, ARTHRITIS RHEUM-US, V58, P82, DOI 10.1002/art.23185; Rose-John S, 2006, J LEUKOCYTE BIOL, V80, P227, DOI 10.1189/jlb.1105674; Rosenberg SA, 2005, J IMMUNOL, V175, P6169, DOI 10.4049/jimmunol.175.9.6169; Scott KA, 2003, MOL CANCER THER, V2, P445; Sepulveda H, 1999, J IMMUNOL, V163, P1133; Smith PC, 2001, CYTOKINE GROWTH F R, V12, P33, DOI 10.1016/S1359-6101(00)00021-6; Strobl H, 1996, J IMMUNOL, V157, P1499; Szlosarek P, 2006, EUR J CANCER, V42, P745, DOI 10.1016/j.ejca.2006.01.012; Szlosarek PW, 2003, LANCET ONCOL, V4, P565, DOI 10.1016/S1470-2045(03)01196-3; Trinchieri G, 2003, NAT REV IMMUNOL, V3, P133, DOI 10.1038/nri1001; Trinchieri G, 2003, IMMUNITY, V19, P641, DOI 10.1016/S1074-7613(03)00296-6; Uhlig HH, 2006, IMMUNITY, V25, P309, DOI 10.1016/j.immuni.2006.05.017; van der Bruggen P, 2002, IMMUNOL REV, V188, P51, DOI 10.1034/j.1600-065X.2002.18806.x; VANDERBRUGGEN P, 1991, SCIENCE, V254, P1643, DOI 10.1126/science.1840703; WAHL SM, 1987, P NATL ACAD SCI USA, V84, P5788, DOI 10.1073/pnas.84.16.5788; Williams RO, 2000, J IMMUNOL, V165, P7240, DOI 10.4049/jimmunol.165.12.7240; Wilson NJ, 2007, NAT IMMUNOL, V8, P950, DOI 10.1038/ni1497; WONG GHW, 1984, NATURE, V310, P688, DOI 10.1038/310688a0; Wrzesinski SH, 2007, CLIN CANCER RES, V13, P5262, DOI 10.1158/1078-0432.CCR-07-1157; Yang L, 2008, CANCER CELL, V13, P23, DOI 10.1016/j.ccr.2007.12.004; ZHANG XH, 1995, J EXP MED, V182, P699, DOI 10.1084/jem.182.3.699	78	90	96	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 6	2008	27	45					5913	5919		10.1038/onc.2008.275	http://dx.doi.org/10.1038/onc.2008.275			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	355QE	18836472				2022-12-28	WOS:000259722600006
J	Wotton, S; Terry, A; Kilbey, A; Jenkins, A; Herzyk, P; Cameron, E; Neil, JC				Wotton, S.; Terry, A.; Kilbey, A.; Jenkins, A.; Herzyk, P.; Cameron, E.; Neil, J. C.			Gene array analysis reveals a common Runx transcriptional programme controlling cell adhesion and survival	ONCOGENE			English	Article						Runx; adhesion; survival; microarray; transcription	DEPENDENT ACTIVATION; FUSION PROTEIN; REPRESSION; LEUKEMIA; CBFA1; DISRUPTION; RESISTANCE; EXPRESSION; MOLECULES; MECHANISM	The Runx genes are important in development and cancer, where they can act either as oncogenes or tumour suppressors. We compared the effects of ectopic Runx expression in established fibroblasts, where all three genes produce an indistinguishable phenotype entailing epithelioid morphology and increased cell survival under stress conditions. Gene array analysis revealed a strongly overlapping transcriptional signature, with no examples of opposing regulation of the same target gene. A common set of 50 highly regulated genes was identified after further filtering on regulation by inducible RUNX1-ER. This set revealed a strong bias toward genes with annotated roles in cancer and development, and a preponderance of targets encoding extracellular or surface proteins, reflecting the marked effects of Runx on cell adhesion. Furthermore, in silico prediction of resistance to glucocorticoid growth inhibition was confirmed in fibroblasts and lymphoid cells expressing ectopic Runx. The effects of fibroblast expression of common RUNX1 fusion oncoproteins (RUNX1-ETO, TEL-RUNX1 and CBFB-MYH11) were also tested. Although two direct Runx activation target genes were repressed (Ncam1 and Rgc32), the fusion proteins appeared to disrupt the regulation of downregulated targets (Cebpd, Id2 and Rgs2) rather than impose constitutive repression. These results elucidate the oncogenic potential of the Runx family and reveal novel targets for therapeutic inhibition.	[Wotton, S.; Terry, A.; Kilbey, A.; Jenkins, A.; Cameron, E.; Neil, J. C.] Univ Glasgow, Inst Comparat Med, Mol Oncol Lab, Fac Vet Med, Glasgow G61 1QH, Lanark, Scotland; [Herzyk, P.] Univ Glasgow, Inst Biomed & Life Sci, Sir Henry Wellcome Funct Genom Facil, Glasgow G61 1QH, Lanark, Scotland	University of Glasgow; University of Glasgow	Wotton, S (corresponding author), Univ Glasgow, Inst Comparat Med, Mol Oncol Lab, Fac Vet Med, Bearsden Rd, Glasgow G61 1QH, Lanark, Scotland.	S.Wotton@vet.gla.ac.uk; j.c.neil@vet.gla.ac.uk			Cancer Research, UK; Leukaemia Research Fund of Great Britain	Cancer Research, UK(Cancer Research UK); Leukaemia Research Fund of Great Britain	We thank Scott Hiebert (Vanderbilt Cancer Centre, TN, USA) for RUNX1/ETO and CBFB-MYH11 plasmids, Alan Friedman (Johns Hopkins University, MD, USA) for the AML-ER plasmid and Olivier Bernard (INSERM, Paris, France) for the TEL/RUNX1 construct. We are grateful to Torsten Schaller for the murine Runx3 cDNA and to Monica Stewart and Karen Blyth for helpful comments. This work was supported by a programme grant from Cancer Research, UK, and the Leukaemia Research Fund of Great Britain.	Amann JM, 2001, MOL CELL BIOL, V21, P6470, DOI 10.1128/MCB.21.19.6470-6483.2001; Bae SC, 2006, GENE, V366, P58, DOI 10.1016/j.gene.2005.10.017; Baran Y, 2007, J BIOL CHEM, V282, P10922, DOI 10.1074/jbc.M610157200; Bianchini R, 2006, J PHARMACOL EXP THER, V319, P887, DOI 10.1124/jpet.106.108480; Bleicher RJ, 2002, BBA-MOL CELL BIOL L, V1585, P172, DOI 10.1016/S1388-1981(02)00338-4; Blyth K, 2006, CANCER RES, V66, P2195, DOI 10.1158/0008-5472.CAN-05-3558; BLYTH K, 1995, ONCOGENE, V10, P1717; Blyth K, 2001, ONCOGENE, V20, P295, DOI 10.1038/sj.onc.1204090; Blyth K, 2005, NAT REV CANCER, V5, P376, DOI 10.1038/nrc1607; Breitling R, 2004, FEBS LETT, V573, P83, DOI 10.1016/j.febslet.2004.07.055; Breitling Rainer, 2005, Journal of Bioinformatics and Computational Biology, V3, P1171, DOI 10.1142/S0219720005001442; Chaffer CL, 2007, CELLS TISSUES ORGANS, V185, P7, DOI 10.1159/000101298; Ducy P, 1999, GENE DEV, V13, P1025, DOI 10.1101/gad.13.8.1025; Durst KL, 2003, MOL CELL BIOL, V23, P607, DOI 10.1128/MCB.23.2.607-619.2003; Edgar R, 2002, NUCLEIC ACIDS RES, V30, P207, DOI 10.1093/nar/30.1.207; Fenrick R, 1999, MOL CELL BIOL, V19, P6566; Fukushima-Nakase Y, 2005, BLOOD, V105, P4298, DOI 10.1182/blood-2004-08-3372; Huang XM, 1999, NAT STRUCT BIOL, V6, P624; Inoue K, 2002, NAT NEUROSCI, V5, P946, DOI 10.1038/nn925; Irizarry RA, 2003, BIOSTATISTICS, V4, P249, DOI 10.1093/biostatistics/4.2.249; Ito Y, 2004, ONCOGENE, V23, P4198, DOI 10.1038/sj.onc.1207755; Javed A, 2000, J CELL SCI, V113, P2221; Jeffery IB, 2006, BMC BIOINFORMATICS, V7, DOI 10.1186/1471-2105-7-359; Jiang HM, 2005, MOL CELL BIOL, V25, P10675, DOI 10.1128/MCB.25.24.10675-10683.2005; Kilbey A, 2007, CANCER RES, V67, P11263, DOI 10.1158/0008-5472.CAN-07-3016; Le Stunff H, 2002, J CELL BIOL, V158, P1039, DOI 10.1083/jcb.200203123; Levanon D, 2002, EMBO J, V21, P3454, DOI 10.1093/emboj/cdf370; Linggi B, 2002, NAT MED, V8, P743, DOI 10.1038/nm726; Lou JR, 2000, ONCOGENE, V19, P2695, DOI 10.1038/sj.onc.1203588; Lutterbach B, 2000, J BIOL CHEM, V275, P651, DOI 10.1074/jbc.275.1.651; MANN R, 1983, CELL, V33, P153, DOI 10.1016/0092-8674(83)90344-6; Miething C, 2007, P NATL ACAD SCI USA, V104, P4594, DOI 10.1073/pnas.0604716104; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; Osato M, 1999, BLOOD, V93, P1817, DOI 10.1182/blood.V93.6.1817.406k36_1817_1824; Otto F, 2003, J CELL BIOCHEM, V89, P9, DOI 10.1002/jcb.10491; Otto F, 1997, CELL, V89, P765, DOI 10.1016/S0092-8674(00)80259-7; Song WJ, 1999, NAT GENET, V23, P166, DOI 10.1038/13793; Speck NA, 2002, NAT REV CANCER, V2, P502, DOI 10.1038/nrc840; Stewart M, 2002, J VIROL, V76, P4364, DOI 10.1128/JVI.76.9.4364-4369.2002; Stewart M, 1997, P NATL ACAD SCI USA, V94, P8646, DOI 10.1073/pnas.94.16.8646; Swantek D, 2004, DEVELOPMENT, V131, P2281, DOI 10.1242/dev.01109; Terry A, 2004, GENE, V336, P115, DOI 10.1016/j.gene.2004.04.015; Vaillant F, 2002, J IMMUNOL, V169, P2866, DOI 10.4049/jimmunol.169.6.2866; Vaillant F, 1999, ONCOGENE, V18, P7124, DOI 10.1038/sj.onc.1203202; Wang Q, 1996, P NATL ACAD SCI USA, V93, P3444, DOI 10.1073/pnas.93.8.3444; Wotton S, 2002, CANCER RES, V62, P7181; Wotton SF, 2004, ONCOGENE, V23, P5476, DOI 10.1038/sj.onc.1207729	47	50	50	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 2	2008	27	44					5856	5866		10.1038/onc.2008.195	http://dx.doi.org/10.1038/onc.2008.195			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	355QC	18560354	Green Accepted			2022-12-28	WOS:000259722400009
J	Li, J; Yuan, J				Li, J.; Yuan, J.			Caspases in apoptosis and beyond	ONCOGENE			English	Review						caspase; apoptosis; programmed cell death	PROGRAMMED CELL-DEATH; AUTOIMMUNE LYMPHOPROLIFERATIVE SYNDROME; INTERLEUKIN-1-BETA CONVERTING-ENZYME; INDUCED-PROXIMITY MODEL; CYTOCHROME-C RELEASE; KAPPA-B ACTIVATION; CAENORHABDITIS-ELEGANS; INFLAMMATORY CASPASES; IL-1-BETA-CONVERTING ENZYME; P53-INDUCED PROTEIN	The demonstration of protein sequence and functional homology of the Caenorhabditis elegans programmed cell death gene product, CED-3, with human caspase-1 in 1993 triggered an explosion of research activities toward the understanding of molecular mechanisms of apoptosis. During the past 15 years, a plethora of knowledge has been obtained on the mammalian caspases, the homologs of CED-3, with regard to their distinct physiological functions, their substrates, different activation mechanisms, the signal transduction pathways that lead to their activation as well as their involvement in the pathogenesis of diseases. Such knowledge is beginning to be translated into new therapies for the treatment of human diseases.	[Li, J.; Yuan, J.] Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA	Harvard University; Harvard Medical School	Yuan, J (corresponding author), Harvard Univ, Sch Med, Dept Cell Biol, 240 Longwood Ave, Boston, MA 02115 USA.	jyuan@hms.harvard.edu			NIA [R37 AG12859]	NIA(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	We thank Yuan Lab members for helpful comments. This work was supported, in part, by a Merit Award from NIA (R37 AG12859). We apologize to colleagues whose work could no be cited due to space constraints.	Acehan D, 2002, MOL CELL, V9, P423, DOI 10.1016/S1097-2765(02)00442-2; Allan LA, 2003, NAT CELL BIOL, V5, P647, DOI 10.1038/ncb1005; Allan LA, 2007, MOL CELL, V26, P301, DOI 10.1016/j.molcel.2007.03.019; Beisner DR, 2005, J IMMUNOL, V175, P3469, DOI 10.4049/jimmunol.175.6.3469; Bergeron L, 1998, GENE DEV, V12, P1304, DOI 10.1101/gad.12.9.1304; Berube C, 2005, P NATL ACAD SCI USA, V102, P14314, DOI 10.1073/pnas.0506475102; Boatright KM, 2003, MOL CELL, V11, P529, DOI 10.1016/S1097-2765(03)00051-0; Brady SC, 2005, MOL CELL BIOL, V25, P10543, DOI 10.1128/MCB.25.23.10543-10555.2005; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; CERRETTI DP, 1992, SCIENCE, V256, P97, DOI 10.1126/science.1373520; Chai JJ, 2001, CELL, V107, P399, DOI 10.1016/S0092-8674(01)00544-X; Chipuk JE, 2008, TRENDS CELL BIOL, V18, P157, DOI 10.1016/j.tcb.2008.01.007; Chun HJ, 2002, NATURE, V419, P395, DOI 10.1038/nature01063; Cuenin S, 2008, ONCOGENE, V27, P387, DOI 10.1038/sj.onc.1210635; Dahm R, 1999, OPHTHALMIC RES, V31, P163, DOI 10.1159/000055530; Degterev A, 2003, ONCOGENE, V22, P8543, DOI 10.1038/sj.onc.1207107; Denecker G, 2008, J CELL BIOL, V180, P451, DOI 10.1083/jcb.200709098; Denecker G, 2007, NAT CELL BIOL, V9, P666, DOI 10.1038/ncb1597; Eckhart L, 2000, BIOCHEM BIOPH RES CO, V277, P655, DOI 10.1006/bbrc.2000.3698; ELLIS HM, 1986, CELL, V44, P817, DOI 10.1016/0092-8674(86)90004-8; Fernando P, 2002, P NATL ACAD SCI USA, V99, P11025, DOI 10.1073/pnas.162172899; Fernando P, 2007, FASEB J, V21, P8, DOI 10.1096/fj.06-5912hyp; Fritz JH, 2006, NAT IMMUNOL, V7, P1250, DOI 10.1038/ni1412; Fuentes-Prior P, 2004, BIOCHEM J, V384, P201, DOI 10.1042/BJ20041142; Fujita J, 2008, CELL STEM CELL, V2, P595, DOI 10.1016/j.stem.2008.04.001; Ghayur T, 1997, NATURE, V386, P619, DOI 10.1038/386619a0; Gottlob K, 2001, GENE DEV, V15, P1406, DOI 10.1101/gad.889901; Gross A, 1999, GENE DEV, V13, P1899, DOI 10.1101/gad.13.15.1899; Guo Y, 2002, J BIOL CHEM, V277, P13430, DOI 10.1074/jbc.M108029200; Hakem R, 1998, CELL, V94, P339, DOI 10.1016/S0092-8674(00)81477-4; Hammerman PS, 2004, TRENDS BIOCHEM SCI, V29, P586, DOI 10.1016/j.tibs.2004.09.008; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hawkins PN, 2003, NEW ENGL J MED, V348, P2583, DOI 10.1056/NEJM200306193482523; Helfer B, 2006, CANCER RES, V66, P4273, DOI 10.1158/0008-5472.CAN-05-4183; HENGARTNER MO, 1994, CELL, V76, P665, DOI 10.1016/0092-8674(94)90506-1; HENGARTNER MO, 1992, NATURE, V356, P494, DOI 10.1038/356494a0; Hoffman HM, 2004, LANCET, V364, P1779, DOI 10.1016/S0140-6736(04)17401-1; Hotchkiss RS, 2006, NAT REV IMMUNOL, V6, P813, DOI 10.1038/nri1943; Hotchkiss RS, 2000, NAT IMMUNOL, V1, P496, DOI 10.1038/82741; Hotchkiss RS, 1999, P NATL ACAD SCI USA, V96, P14541, DOI 10.1073/pnas.96.25.14541; HOWLEY B, 2008, J CELL MOL MED, DOI DOI 10.1111/J.1582-4934.2008.002929X; Janssens S, 2005, CELL, V123, P1079, DOI 10.1016/j.cell.2005.09.036; Janzen V, 2008, CELL STEM CELL, V2, P584, DOI 10.1016/j.stem.2008.03.012; Juo P, 1998, CURR BIOL, V8, P1001, DOI 10.1016/S0960-9822(07)00420-4; Kang SJ, 2000, J CELL BIOL, V149, P613, DOI 10.1083/jcb.149.3.613; Kang TB, 2004, J IMMUNOL, V173, P2976, DOI 10.4049/jimmunol.173.5.2976; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; Kuida K, 1998, CELL, V94, P325, DOI 10.1016/S0092-8674(00)81476-2; Kuida K, 1996, NATURE, V384, P368, DOI 10.1038/384368a0; KUIDA K, 1995, SCIENCE, V267, P2000, DOI 10.1126/science.7535475; Lakhani SA, 2006, SCIENCE, V311, P847, DOI 10.1126/science.1115035; Lassus P, 2002, SCIENCE, V297, P1352, DOI 10.1126/science.1074721; Lavrik I, 2005, J CELL SCI, V118, P265, DOI 10.1242/jcs.01610; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Li JY, 2007, NAT CELL BIOL, V9, P276, DOI 10.1038/ncb1541; LI P, 1995, CELL, V80, P401, DOI 10.1016/0092-8674(95)90490-5; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Lin XY, 2000, J BIOL CHEM, V275, P39920, DOI 10.1074/jbc.M007255200; Lin YP, 2000, NAT GENET, V26, P122, DOI 10.1038/79102; Lippens S, 2000, CELL DEATH DIFFER, V7, P1218, DOI 10.1038/sj.cdd.4400785; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Luthi AU, 2007, CELL DEATH DIFFER, V14, P641, DOI 10.1038/sj.cdd.4402103; LYNCH DH, 1994, IMMUNITY, V1, P131, DOI 10.1016/1074-7613(94)90106-6; Mariathasan S, 2004, NATURE, V430, P213, DOI 10.1038/nature02664; Mariathasan S, 2006, NATURE, V440, P228, DOI 10.1038/nature04515; Martinon F, 2007, CELL DEATH DIFFER, V14, P10, DOI 10.1038/sj.cdd.4402038; Martinon F, 2005, TRENDS IMMUNOL, V26, P447, DOI 10.1016/j.it.2005.06.004; Martinon F, 2002, MOL CELL, V10, P417, DOI 10.1016/S1097-2765(02)00599-3; Martinon F, 2004, CELL, V117, P561, DOI 10.1016/j.cell.2004.05.004; Meng XW, 2006, CURR OPIN CELL BIOL, V18, P668, DOI 10.1016/j.ceb.2006.10.008; Micheau O, 2003, CELL, V114, P181, DOI 10.1016/S0092-8674(03)00521-X; Miura M, 2004, J CLIN INVEST, V114, P1704, DOI 10.1172/JCI200420427; MIURA M, 1993, CELL, V75, P653, DOI 10.1016/0092-8674(93)90486-A; Nahle Z, 2002, NAT CELL BIOL, V4, P859, DOI 10.1038/ncb868; Nakagawa T, 2000, NATURE, V403, P98, DOI 10.1038/47513; Nutt LK, 2005, CELL, V123, P89, DOI 10.1016/j.cell.2005.07.032; Poyet JL, 2001, J BIOL CHEM, V276, P28309, DOI 10.1074/jbc.C100250200; Qin HX, 1999, NATURE, V399, P549, DOI 10.1038/21124; Rathmell JC, 2003, MOL CELL BIOL, V23, P7315, DOI 10.1128/MCB.23.20.7315-7328.2003; Riedl SJ, 2004, NAT REV MOL CELL BIO, V5, P897, DOI 10.1038/nrm1496; Riedl SJ, 2001, P NATL ACAD SCI USA, V98, P14790, DOI 10.1073/pnas.221580098; Robertson JD, 2002, J BIOL CHEM, V277, P29803, DOI 10.1074/jbc.M204185200; Saleh M, 2006, NATURE, V440, P1064, DOI 10.1038/nature04656; Salmena L, 2003, GENE DEV, V17, P883, DOI 10.1101/gad.1063703; Salvesen GS, 1999, P NATL ACAD SCI USA, V96, P10964, DOI 10.1073/pnas.96.20.10964; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; Schweizer A, 2003, J BIOL CHEM, V278, P42441, DOI 10.1074/jbc.M304895200; Shcherbina A, 1999, BLOOD, V93, P4222, DOI 10.1182/blood.V93.12.4222.412k34_4222_4231; Shi YG, 2002, MOL CELL, V9, P459, DOI 10.1016/S1097-2765(02)00482-3; Shi YG, 2004, CELL, V117, P855, DOI 10.1016/j.cell.2004.06.007; Slee EA, 1999, J CELL BIOL, V144, P281, DOI 10.1083/jcb.144.2.281; Stennicke HR, 2000, BIOCHEM J, V350, P563, DOI 10.1042/0264-6021:3500563; Straus SE, 1999, ANN INTERN MED, V130, P591, DOI 10.7326/0003-4819-130-7-199904060-00020; Su H, 2005, SCIENCE, V307, P1465, DOI 10.1126/science.1104765; SULSTON JE, 1977, DEV BIOL, V56, P110, DOI 10.1016/0012-1606(77)90158-0; SULSTON JE, 1983, DEV BIOL, V100, P64, DOI 10.1016/0012-1606(83)90201-4; THORNBERRY NA, 1992, NATURE, V356, P768, DOI 10.1038/356768a0; Thornberry NA, 1997, J BIOL CHEM, V272, P17907, DOI 10.1074/jbc.272.29.17907; Tinel A, 2004, SCIENCE, V304, P843, DOI 10.1126/science.1095432; Tinsley KW, 2000, SHOCK, V13, P1, DOI 10.1097/00024382-200013010-00001; Troy CM, 2000, J NEUROSCI, V20, P1386; Varfolomeev EE, 1998, IMMUNITY, V9, P267, DOI 10.1016/S1074-7613(00)80609-3; Vila M, 2003, NAT REV NEUROSCI, V4, P365, DOI 10.1038/nrn1100; Vinzing M, 2008, J IMMUNOL, V180, P6808, DOI 10.4049/jimmunol.180.10.6808; Wang J, 1999, CELL, V98, P47, DOI 10.1016/S0092-8674(00)80605-4; WANG LY, 1996, J POLYM RES, V3, P1; Wang SY, 1998, CELL, V92, P501, DOI 10.1016/S0092-8674(00)80943-5; WATANABEFUKUNAG.R, 1992, NATURE, V356, P317; Wesche-Soldato DE, 2005, BLOOD, V106, P2295, DOI 10.1182/blood-2004-10-4086; Wyllie A H, 1980, Int Rev Cytol, V68, P251; Yi CH, 2007, J CELL BIOL, V179, P619, DOI 10.1083/jcb.200708090; Yu XC, 2005, STRUCTURE, V13, P1725, DOI 10.1016/j.str.2005.09.006; YUAN JY, 1992, DEVELOPMENT, V116, P309; YUAN JY, 1993, CELL, V75, P641, DOI 10.1016/0092-8674(93)90485-9; Zamboni DS, 2006, NAT IMMUNOL, V7, P318, DOI 10.1038/ni1305; Zeni F, 1997, CRIT CARE MED, V25, P1095, DOI 10.1097/00003246-199707000-00001; Zermati Y, 2001, J EXP MED, V193, P247, DOI 10.1084/jem.193.2.247; Zou H, 1997, CELL, V90, P405, DOI 10.1016/S0092-8674(00)80501-2	119	736	765	1	49	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT	2008	27	48					6194	6206		10.1038/onc.2008.297	http://dx.doi.org/10.1038/onc.2008.297			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	361YB	18931687				2022-12-28	WOS:000260162800002
J	Liu, L; Chen, L; Chung, J; Huang, S				Liu, L.; Chen, L.; Chung, J.; Huang, S.			Rapamycin inhibits F-actin reorganization and phosphorylation of focal adhesion proteins	ONCOGENE			English	Article						rapamycin; mammalian target of rapamycin; F-actin; lamellipodia; focal adhesion kinase	RICTOR-MTOR COMPLEX; GROWTH-FACTOR; MAMMALIAN TARGET; TYROSINE PHOSPHORYLATION; CELL-GROWTH; SIGNALING PATHWAY; BINDING PARTNER; MUSCLE-CELLS; AMINO-ACID; KINASE	An early event of cell migration is characterized as the rapid reorganization of the actin cytoskeleton. Recently, we have demonstrated that rapamycin inhibits tumor cell motility. To understand the underlying mechanism, this study was set to determine whether rapamycin inhibition of cell motility is related to its prevention of F-actin reorganization. We found that rapamycin prevented type I insulin-like growth factor (IGF-I)-stimulated F-actin reorganization in human rhabdomyosarcoma (Rh30), Ewing sarcoma (Rh1), glioblastoma (U-373) and prostate carcinoma (PC-3) cells, and concurrently inhibited phosphorylation of focal adhesion proteins, including focal adhesion kinase (FAK), paxillin and p130(Cas) in the cells. The effect of rapamycin was blocked by expression of a rapamycin-resistant mutant of mTOR (mTORrr), but not a kinase-dead mTORrr. Downregulation of raptor mimicked the effect of rapamycin. Cells infected with a recombinant adenovirus expressing constitutively active and rapamycin-resistant mutant of p70 S6 kinase 1 (S6K1) conferred to resistance to rapamycin. Further, IGF-I failed to stimulate F-actin reorganization and phosphorylation of the focal adhesion proteins in the S6K1-downregulated cells. Expression of constitutively hypophosphorylated eukaryotic initiation factor 4E (eIF4E)-binding protein 1 (4E-BP1-5A) inhibited IGF-I-stimulated F-actin reorganization, but did not alter the cellular protein or phosphorylation levels of the focal adhesion proteins. The results suggest that rapamycin inhibits IGF-I-induced F-actin reorganization and phosphorylation of the focal adhesion proteins by disruption of mTOR-raptor complex. Both S6K1 and 4E-BP1 pathways, mediated by the mTOR-raptor complex, are involved in the regulation of IGF-I-stimulated F-actin reorganization, but only the former controls IGF-I-stimulated phosphorylation of the focal adhesion proteins.	[Liu, L.; Chen, L.; Chung, J.; Huang, S.] Louisiana State Univ, Hlth Sci Ctr, Dept Biochem & Mol Biol, Shreveport, LA 71130 USA; [Chung, J.; Huang, S.] Louisiana State Univ, Hlth Sci Ctr, Feist Weiller Canc Ctr, Shreveport, LA 71130 USA	Louisiana State University System; Louisiana State University Health Sciences Center at Shreveport; Louisiana State University System; Louisiana State University Health Sciences Center at Shreveport	Huang, S (corresponding author), Louisiana State Univ, Hlth Sci Ctr, Dept Biochem & Mol Biol, 1501 Kings Highway, Shreveport, LA 71130 USA.	shuan1@lsuhsc.edu	Huang, Shile/I-1632-2019	Huang, Shile/0000-0002-3239-1072	NIH [R01 CA115414]; Louisiana Board of Regents [LEQSF(2006-09)-RD-A-18]; Feist-Weiller Cancer Center Award; Louisiana State University Health Sciences Center, Shreveport, LA, USA; NATIONAL CANCER INSTITUTE [R01CA115414] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Louisiana Board of Regents; Feist-Weiller Cancer Center Award; Louisiana State University Health Sciences Center, Shreveport, LA, USA; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Drs Robert T Abraham, Peter J Houghton, John C Lawrence, John Blenis and David M Sabatini for providing cell lines or constructs. This study was supported in part by NIH Grant R01 CA115414 ( SH), Louisiana Board of Regents (LEQSF(2006-09)-RD-A-18) (SH), and the Feist-Weiller Cancer Center Award (SH), Louisiana State University Health Sciences Center, Shreveport, LA, USA.	Berven LA, 2004, EXP CELL RES, V296, P183, DOI 10.1016/j.yexer.2003.12.032; Boffa DJ, 2004, CLIN CANCER RES, V10, P293, DOI 10.1158/1078-0432.CCR-0629-3; Casamassima A, 1998, J BIOL CHEM, V273, P26149, DOI 10.1074/jbc.273.40.26149; Erbay E, 2001, J BIOL CHEM, V276, P36079, DOI 10.1074/jbc.C100406200; Fonseca BD, 2007, J BIOL CHEM, V282, P24514, DOI 10.1074/jbc.M704406200; Frias MA, 2006, CURR BIOL, V16, P1865, DOI 10.1016/j.cub.2006.08.001; Gan BY, 2006, J BIOL CHEM, V281, P37321, DOI 10.1074/jbc.M605241200; Govindarajan G, 2000, CIRC RES, V87, P710, DOI 10.1161/01.RES.87.8.710; Guba M, 2002, NAT MED, V8, P128, DOI 10.1038/nm0202-128; Guertin DA, 2007, CANCER CELL, V12, P9, DOI 10.1016/j.ccr.2007.05.008; Guvakova MA, 1999, EXP CELL RES, V251, P244, DOI 10.1006/excr.1999.4566; Hara K, 2002, CELL, V110, P177, DOI 10.1016/S0092-8674(02)00833-4; Hosoi H, 1999, CANCER RES, V59, P886; Huang S, 2003, MOL CELL, V11, P1491, DOI 10.1016/S1097-2765(03)00180-1; Jacinto E, 2004, NAT CELL BIOL, V6, P1122, DOI 10.1038/ncb1183; Jacinto E, 2006, CELL, V127, P125, DOI 10.1016/j.cell.2006.08.033; KADOWAKI T, 1986, J BIOL CHEM, V261, P6141; Kanellopoulou C, 2005, GENE DEV, V19, P489, DOI 10.1101/gad.1248505; Kim DH, 2003, MOL CELL, V11, P895, DOI 10.1016/S1097-2765(03)00114-X; Kim DH, 2002, CELL, V110, P163, DOI 10.1016/S0092-8674(02)00808-5; Konstantopoulos N, 1996, BIOCHEM J, V314, P387, DOI 10.1042/bj3140387; Leopoldt D, 2001, J CELL PHYSIOL, V188, P106, DOI 10.1002/jcp.1102; LeRoith D, 2003, CANCER LETT, V195, P127, DOI 10.1016/S0304-3835(03)00159-9; Leventhal PS, 1997, J BIOL CHEM, V272, P5214, DOI 10.1074/jbc.272.8.5214; Liu L, 2006, ONCOGENE, V25, P7029, DOI 10.1038/sj.onc.1209691; Loewith R, 2002, MOL CELL, V10, P457, DOI 10.1016/S1097-2765(02)00636-6; Luan FL, 2003, KIDNEY INT, V63, P917, DOI 10.1046/j.1523-1755.2003.00805.x; Malik RK, 1996, J BIOL CHEM, V271, P29785, DOI 10.1074/jbc.271.47.29785; Mothe-Satney I, 2000, MOL CELL BIOL, V20, P3558, DOI 10.1128/MCB.20.10.3558-3567.2000; Nave BT, 1999, BIOCHEM J, V344, P427, DOI 10.1042/0264-6021:3440427; O'Reilly KE, 2006, CANCER RES, V66, P1500, DOI 10.1158/0008-5472.CAN-05-2925; Pearce LR, 2007, BIOCHEM J, V405, P513, DOI 10.1042/BJ20070540; Ridley AJ, 2003, SCIENCE, V302, P1704, DOI 10.1126/science.1092053; Sancak Y, 2007, MOL CELL, V25, P903, DOI 10.1016/j.molcel.2007.03.003; Sarbassov DD, 2005, SCIENCE, V307, P1098, DOI 10.1126/science.1106148; Sarbassov DD, 2004, CURR BIOL, V14, P1296, DOI 10.1016/j.cub.2004.06.054; Schalm SS, 2005, J BIOL CHEM, V280, P11101, DOI 10.1074/jbc.M413995200; Sekulic A, 2000, CANCER RES, V60, P3504; Shu LL, 2002, J BIOL CHEM, V277, P16726, DOI 10.1074/jbc.M112285200; SMITH MA, 2006, PEDIAT BLOOD CANC, V50, P703; Tremblay F, 2001, J BIOL CHEM, V276, P38052; Tzatsos A, 2006, MOL CELL BIOL, V26, P63, DOI 10.1128/MCB.26.1.63-76.2006; Vander Haar E, 2007, NAT CELL BIOL, V9, P316, DOI 10.1038/ncb1547; Wan X, 2007, ONCOGENE, V26, P1932, DOI 10.1038/sj.onc.1209990; Wan XL, 2005, CANCER RES, V65, P2406, DOI 10.1158/0008-5472.CAN-04-3135; Wullschleger S, 2006, CELL, V124, P471, DOI 10.1016/j.cell.2006.01.016; Yang Q, 2006, GENE DEV, V20, P2820, DOI 10.1101/gad.1461206	47	130	135	2	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 28	2008	27	37					4998	5010		10.1038/onc.2008.137	http://dx.doi.org/10.1038/onc.2008.137			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	344GL	18504440	Green Accepted			2022-12-28	WOS:000258914800003
J	Momota, H; Shih, AH; Edgar, M; Holland, E				Momota, H.; Shih, A. H.; Edgar, M. A.; Holland, E. C.			C-Myc and beta-catenin cooperate with loss of p53 to generate multiple members of the primitive neuroectodermal tumor family in mice	ONCOGENE			English	Article						c-Myc; beta-catenin; p53; primitive neuroectodermal tumor; mouse model	CHOROID-PLEXUS TUMORS; LARGE CELL/ANAPLASTIC MEDULLOBLASTOMAS; PEDIATRIC-ONCOLOGY-GROUP; NEURAL PROGENITORS; SONIC HEDGEHOG; ANAPLASTIC MEDULLOBLASTOMA; SOMATIC MUTATIONS; IN-VIVO; EXPRESSION; CELLS	Primitive neuroectodermal tumors ( PNETs) are a family of primary malignant brain tumors that include medulloblastomas. Although genetic models of a subset of medulloblastomas are documented over the past decade, the molecular basis of other subclasses of PNET remains unclear. As elevated c-Myc expression, activation of Wnt/beta-catenin signaling and dysfunction of p53 are seen in human PNETs, we investigated what role these abnormalities have in the formation of PNETs. Incorporating these abnormalities, we generated supratentorial PNET (sPNET) in mice using somatic cell gene transfer. We show that sPNETs arise from GFAP-expressing cells by forced c-Myc expression combined with p53 inactivation. beta-catenin activation promotes tumor progression and induces divergent differentiation. These c-Myc+beta-catenin-induced PNETs are histologically similar to large cell/anaplastic medulloblastomas and can occur in both cerebrum and cerebellum. Furthermore, we have obtained one PNET with marked epithelial differentiation having histological resemblance to choroid plexus carcinoma in this series. Our results in mice suggest that sPNET with varied differentiation and large cell/anaplastic medulloblastomas may be two tumor groups with similar genetic foundations. These data provide insights into the biology and classification of human PNETs and suggest that multiple tumor types or variants can be generated from a fixed set of genetic abnormalities.	[Momota, H.; Shih, A. H.; Holland, E. C.] Mem Sloan Kettering Canc Ctr, Dept Canc Biol & Genet, New York, NY 10021 USA; [Edgar, M. A.] Mem Sloan Kettering Canc Ctr, Dept Pathol, New York, NY 10021 USA; [Holland, E. C.] Mem Sloan Kettering Canc Ctr, Dept Surg Neusurg & Neurol, New York, NY 10021 USA	Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center	Holland, E (corresponding author), Mem Sloan Kettering Canc Ctr, Dept Canc Biol & Genet, 1275 York Ave, New York, NY 10021 USA.	hollande@mskcc.org			NATIONAL CANCER INSTITUTE [R01CA099489, R01CA100688] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA099489, R01 CA100688] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADESINA AM, 1994, CANCER RES, V54, P5649; ANWER UE, 1989, ARCH PATHOL LAB MED, V113, P84; Brown HG, 2000, J NEUROPATH EXP NEUR, V59, P857, DOI 10.1093/jnen/59.10.857; Carlotti CG, 2002, ACTA NEUROPATHOL, V103, P1; Dai C, 2001, GENE DEV, V15, P1913, DOI 10.1101/gad.903001; Eberhart CG, 2005, BMC CANCER, V5, DOI 10.1186/1471-2407-5-19; Eberhart CG, 2002, CANCER-AM CANCER SOC, V94, P552, DOI 10.1002/cncr.10189; Frank AJ, 2004, MOL BRAIN RES, V121, P137, DOI 10.1016/j.molbrainres.2003.11.016; Fults D, 2002, NEOPLASIA, V4, P32, DOI 10.1038/sj.neo.7900200; Gessl M, 2003, BRAIN PATHOL, V13, P409; Goodrich LV, 1997, SCIENCE, V277, P1109, DOI 10.1126/science.277.5329.1109; Green DR, 2002, CANCER CELL, V1, P19, DOI 10.1016/S1535-6108(02)00024-7; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; Hill TP, 2005, DEV CELL, V8, P727, DOI 10.1016/j.devcel.2005.02.013; Ho YS, 1996, CANCER LETT, V104, P103, DOI 10.1016/0304-3835(96)04238-3; Holland EC, 2000, NAT GENET, V25, P55, DOI 10.1038/75596; Holland EC, 1998, GENE DEV, V12, P3675, DOI 10.1101/gad.12.23.3675; JACKS T, 1994, CURR BIOL, V4, P1, DOI 10.1016/S0960-9822(00)00002-6; JANZER RC, 1985, CLIN NEUROPATHOL, V4, P93; Jay V, 1996, ARCH PATHOL LAB MED, V120, P1061; Koch A, 2001, INT J CANCER, V93, P445, DOI 10.1002/ijc.1342; Kratz JE, 2002, BMC CANCER, V2, DOI 10.1186/1471-2407-2-33; Kraus JA, 2002, NEUROPATH APPL NEURO, V28, P325, DOI 10.1046/j.1365-2990.2002.00413.x; Leonard JR, 2001, J NEUROSURG, V95, P82, DOI 10.3171/jns.2001.95.1.0082; Louis DN, 2007, ACTA NEUROPATHOL, V114, P97, DOI 10.1007/s00401-007-0243-4; Marino S, 2000, GENE DEV, V14, P994; McCall TD, 2007, CANCER RES, V67, P5179, DOI 10.1158/0008-5472.CAN-06-4177; OHGAKI H, 1993, MOL CARCINOGEN, V8, P74, DOI 10.1002/mc.2940080203; Pauklin S, 2005, BIOCHEM BIOPH RES CO, V334, P386, DOI 10.1016/j.bbrc.2005.06.097; Pillai A, 2004, J NEUROSURG, V100, P1076, DOI 10.3171/jns.2004.100.6.1076; Rao G, 2003, NEOPLASIA, V5, P198, DOI 10.1016/S1476-5586(03)80052-0; Reifenberger J, 1998, J NEUROPATH EXP NEUR, V57, P179; Rostomily RC, 1997, CANCER RES, V57, P3526; Russo C, 1999, CANCER, V86, P331, DOI 10.1002/(SICI)1097-0142(19990715)86:2<331::AID-CNCR18>3.0.CO;2-#; SAYLORS RL, 1991, CANCER RES, V51, P4721; Sevenet N, 1999, HUM MOL GENET, V8, P2359, DOI 10.1093/hmg/8.13.2359; Shakhova O, 2006, CANCER RES, V66, P5190, DOI 10.1158/0008-5472.CAN-05-3545; Su XH, 2006, MOL CELL BIOL, V26, P1666, DOI 10.1128/MCB.26.5.1666-1678.2006; van de Wetering M, 2002, CELL, V111, P241, DOI 10.1016/S0092-8674(02)01014-0; Vital A, 1998, J NEUROPATH EXP NEUR, V57, P1061, DOI 10.1097/00005072-199811000-00009; Weiner HL, 2002, CANCER RES, V62, P6385; Wetmore C, 2001, CANCER RES, V61, P513; YUASA H, 1993, NEUROSURGERY, V32, P131, DOI 10.1227/00006123-199301000-00021	43	38	39	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 24	2008	27	32					4392	4401		10.1038/onc.2008.81	http://dx.doi.org/10.1038/onc.2008.81			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	329PU	18372915				2022-12-28	WOS:000257881700002
J	Pendas-Franco, N; Garcia, JM; Pena, C; Valle, N; Palmer, HG; Heinaniemi, M; Carlberg, C; Jimenez, B; Bonilla, F; Munoz, A; Gonzalez-Sancho, JM				Pendas-Franco, N.; Garcia, J. M.; Pena, C.; Valle, N.; Palmer, H. G.; Heinaeniemi, M.; Carlberg, C.; Jimenez, B.; Bonilla, F.; Munoz, A.; Gonzalez-Sancho, J. M.			DICKKOPF-4 is induced by TCF/beta-catenin and upregulated in human colon cancer, promotes tumour cell invasion and angiogenesis and is repressed by 1 alpha, 25-dihydroxyvitamin D-3	ONCOGENE			English	Article						DICKKOPF-4; vitamin D; colon cancer; Wnt; beta-catenin	WNT SIGNALING PATHWAY; COLORECTAL-CANCER; EPIGENETIC INACTIVATION; GENE FAMILY; VITAMIN-D; DIFFERENTIATION; PROTEIN; TARGET	Aberrant activation of the Wnt/beta-catenin signaling pathway is a hallmark of colon cancer. We show that the Wnt antagonist DICKKOPF-4 (DKK-4) gene is repressed by 1 alpha, 25-dihydroxyvitamin D-3 (1,25(OH)(2)D-3) in human colon cancer cells. This effect correlated with the inhibition of the DKK-4 promoter. Chromatin immunoprecipitation assays revealed that 1,25(OH)(2)D-3 induces early and transient binding of the vitamin D receptor (VDR) and the SMRT corepressor to the region adjacent to the transcription start site of DKK-4. Additionally, we demonstrate that the DKK-4 gene is a new downstream target of TCF/beta-catenin. Remarkably, expression of DKK-4 messenger RNA (mRNA) was not detected in a series of 29 human normal (N) colon biopsies but expression was upregulated in all the matched tumour (T) tissues. An inverse correlation existed between the expression of DKK-4 and VDR RNA in the Ts. Ectopic DKK-4 expression increased the migration and invasion properties of colon cancer cells and conditioned media (CM) from DKK-4-expressing cells enhanced the capacity to migrate and form capillary-like tubules of human primary microvascular endothelial cells. In conclusion, DKK-4 is upregulated in colon cancer and is associated with the acquisition of malignant properties by neoplastic cells. DKK-4 downregulation is a novel effect of 1,25(OH)(2)D-3 that may contribute to its anticancer action.	[Pendas-Franco, N.; Valle, N.; Jimenez, B.; Munoz, A.; Gonzalez-Sancho, J. M.] Univ Autonoma Madrid, Inst Invest Biomed Alberto Sols, Dept Canc Biol, Consejo Super Invest Cient, E-28029 Madrid, Spain; [Garcia, J. M.; Pena, C.; Bonilla, F.] Hosp Univ Puerta Hierro, Madrid, Spain; [Palmer, H. G.] Cambridge Res Inst, Cambridge, England; [Heinaeniemi, M.; Carlberg, C.] Univ Luxembourg, Life Sci Res Unit, Luxembourg, Luxembourg; [Jimenez, B.; Gonzalez-Sancho, J. M.] Univ Autonoma Madrid, Fac Med, Dept Bioquim, E-28029 Madrid, Spain	Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Investigaciones Biomedicas Alberto Sols (IIBM); Hospital Puerta de Hierro-Majadahonda; CRUK Cambridge Institute; University of Cambridge; University of Luxembourg; Autonomous University of Madrid	Munoz, A (corresponding author), Univ Autonoma Madrid, Inst Invest Biomed Alberto Sols, Dept Canc Biol, Consejo Super Invest Cient, Arturo Duperier 4, E-28029 Madrid, Spain.	amunoz@iib.uam.es	Palmer, Héctor G./AAG-8332-2019; Cuenca, Benilde Jimenez/K-9959-2014; Munoz, Alberto/O-6393-2014; Heinäniemi, Merja/C-5051-2014; Gonzalez-Sancho, Jose/AAA-6010-2019; Valle, Noelia/AAA-2975-2019; Carlberg, Carsten/C-9075-2011; Heinaniemi, Merja/AAS-4530-2020; Seoane, Joan/AAG-9173-2019	Munoz, Alberto/0000-0003-3890-4251; Heinäniemi, Merja/0000-0001-6190-3439; Gonzalez-Sancho, Jose/0000-0001-5875-1964; Valle, Noelia/0000-0002-3377-5035; Carlberg, Carsten/0000-0003-2633-0684; Heinaniemi, Merja/0000-0001-6190-3439; Seoane, Joan/0000-0002-6541-5974; Jimenez Cuenca, Benilde/0000-0002-1806-6636; Palmer, Hector/0000-0002-9823-5638				Abu-Jawdeh G, 1999, LAB INVEST, V79, P439; Aguilera O, 2006, ONCOGENE, V25, P4116, DOI 10.1038/sj.onc.1209439; Aguilera O, 2007, CARCINOGENESIS, V28, P1877, DOI 10.1093/carcin/bgm094; Ballestar E, 2003, EMBO J, V22, P6335, DOI 10.1093/emboj/cdg604; Bazzi H, 2007, DEV BIOL, V305, P498, DOI 10.1016/j.ydbio.2007.02.035; Caneparo L, 2007, GENE DEV, V21, P465, DOI 10.1101/gad.406007; Dufourcq P, 2002, CIRCULATION, V106, P3097, DOI 10.1161/01.CIR.0000039342.85015.5C; Gonzalex-Sancho JM, 2005, ONCOGENE, V24, P1098, DOI 10.1038/sj.onc.1208303; Kawano Y, 2003, J CELL SCI, V116, P2627, DOI 10.1242/jcs.00623; Kimura-Yoshida C, 2005, DEV CELL, V9, P639, DOI 10.1016/j.devcel.2005.09.011; Krupnik VE, 1999, GENE, V238, P301, DOI 10.1016/S0378-1119(99)00365-0; Logan CY, 2004, ANNU REV CELL DEV BI, V20, P781, DOI 10.1146/annurev.cellbio.20.010403.113126; Mao BY, 2003, GENE, V302, P179, DOI 10.1016/S0378-1119(02)01106-X; Niehrs C, 2006, ONCOGENE, V25, P7469, DOI 10.1038/sj.onc.1210054; Ordonez-Moran P, 2005, FRONT BIOSCI-LANDMRK, V10, P2723, DOI 10.2741/1731; Palmer HG, 2001, J CELL BIOL, V154, P369, DOI 10.1083/jcb.200102028; Pendas-Franco N, 2007, DIFFERENTIATION, V75, P193, DOI 10.1111/j.1432-0436.2006.00131.x; Polakis P, 2007, CURR OPIN GENET DEV, V17, P45, DOI 10.1016/j.gde.2006.12.007; Roth W, 2000, ONCOGENE, V19, P4210, DOI 10.1038/sj.onc.1203783; Segditsas S, 2006, ONCOGENE, V25, P7531, DOI 10.1038/sj.onc.1210059; Sick S, 2006, SCIENCE, V314, P1447, DOI 10.1126/science.1130088; Vaisanen S, 2005, J MOL BIOL, V350, P65, DOI 10.1016/j.jmb.2005.04.057; Vandesompele J, 2002, GENOME BIOL, V3, DOI 10.1186/gb-2002-3-7-research0034; Wang TT, 2005, MOL ENDOCRINOL, V19, P2685, DOI 10.1210/me.2005-0106; Xi Y, 2008, ONCOL REP, V19, P257	25	129	133	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 24	2008	27	32					4467	4477		10.1038/onc.2008.88	http://dx.doi.org/10.1038/onc.2008.88			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	329PU	18408752				2022-12-28	WOS:000257881700009
J	Wang, X; Di, K; Zhang, X; Han, HY; Wong, YC; Leung, SCL; Ling, MT				Wang, X.; Di, K.; Zhang, X.; Han, H. Y.; Wong, Y. C.; Leung, S. C. L.; Ling, M-T			Id-1 promotes chromosomal instability through modification of APC/C activity during mitosis in response to microtubule disruption	ONCOGENE			English	Article						Id-1; mitosis; aneuploidy; Cdc20; Cdh1	LOOP-HELIX PROTEIN; SPINDLE ASSEMBLY CHECKPOINT; PROSTATE-CANCER; P16(INK4A) EXPRESSION; CELLULAR SENESCENCE; SIGNALING PATHWAY; OVEREXPRESSION; ACTIVATION; ID1; DIFFERENTIATION	Id-1 (Inhibitor of DNA binding/differential-1) plays a positive role in tumorigenesis through regulation of multiple signaling pathways. Recently, it is suggested that upregulation of Id-1 in cancer cells promotes chromosomal instability. However, the underlying molecular mechanism is not known. In this study, we report a novel function of Id-1 in regulation of mitosis through physical interaction with Cdc20 (cell division cycle protein 20) and Cdh1 (Cdc20 homolog 1). During early mitosis, Id-1 interacts with Cdc20 and RASSF1A (Ras association domain family 1A), leading to enhanced APC(Cdc20) activity, which in turn promotes cyclin B1/securin degradation and premature mitosis. During late mitosis, Id-1 binds to Cdh1 and disrupts the interaction between Cdh1 and APC, resulting in suppression of APC Cdh1 activity. On the other hand, overexpression of Cdh1 leads to Id-1 protein degradation, suggesting that Id-1 may also act as a substrate of APC(Cdh1). The negative effect of Id-1 on APC(Cdh1) results in suppression of APC(Cdh1)-induced Aurora A and Cdc20 degradation, leading to failure in cytokinesis. As a result, overexpression of Id-1 in human prostate epithelial cells leads to polyploidy in response to microtubule disruption, and this effect is abolished when Id-1 expression is suppressed using antisense technology. These results demonstrate a novel function of Id-1 in promoting chromosomal instability through modi. cation of APC/C activity during mitosis and provide a novel molecular mechanism accounted for the function of Id-1 as an oncogene.	[Wang, X.; Di, K.; Zhang, X.; Han, H. Y.; Wong, Y. C.; Leung, S. C. L.; Ling, M-T] Univ Hong Kong, Fac Med, Dept Anat, Canc Biol Grp, Hong Kong, Hong Kong, Peoples R China	University of Hong Kong	Wang, X (corresponding author), Univ Hong Kong, Fac Med, Dept Anat, Canc Biol Grp, 1-F Bldg,21 Sassoon Road, Hong Kong, Hong Kong, Peoples R China.	xhwang@hkucc.hku.hk; patling@hkucc.hku.hk						Alani RM, 1999, P NATL ACAD SCI USA, V96, P9637, DOI 10.1073/pnas.96.17.9637; Alani RM, 2001, P NATL ACAD SCI USA, V98, P7812, DOI 10.1073/pnas.141235398; Anand S, 2003, CANCER CELL, V3, P51, DOI 10.1016/S1535-6108(02)00235-0; BARONE MV, 1994, P NATL ACAD SCI USA, V91, P4985, DOI 10.1073/pnas.91.11.4985; Bright RK, 1997, CANCER RES, V57, P995; Crane R, 2004, J CELL SCI, V117, P5975, DOI 10.1242/jcs.01418; Di K, 2006, BIOL CELL, V98, P523, DOI 10.1042/BC20060026; Fong S, 2003, P NATL ACAD SCI USA, V100, P13543, DOI 10.1073/pnas.2230238100; Forootan SS, 2007, HUM PATHOL, V38, P1321, DOI 10.1016/j.humpath.2007.02.011; HARA E, 1994, J BIOL CHEM, V269, P2139; Hasskarl J, 2004, ONCOGENE, V23, P1930, DOI 10.1038/sj.onc.1207310; Lasorella A, 2006, NATURE, V442, P471, DOI 10.1038/nature04895; Li Y, 1997, P NATL ACAD SCI USA, V94, P12431, DOI 10.1073/pnas.94.23.12431; Lin ML, 2001, STEM CELLS, V19, P205, DOI 10.1634/stemcells.19-3-205; Ling MT, 2006, DIFFERENTIATION, V74, P481, DOI 10.1111/j.1432-0436.2006.00083.x; Ling MT, 2003, ONCOGENE, V22, P4498, DOI 10.1038/sj.onc.1206693; Ling MT, 2002, ONCOGENE, V21, P8498, DOI 10.1038/sj.onc.1206007; Meraldi P, 2002, EMBO J, V21, P483, DOI 10.1093/emboj/21.4.483; Mondal G, 2007, CARCINOGENESIS, V28, P81, DOI 10.1093/carcin/bgl100; Nakayama KI, 2006, NAT REV CANCER, V6, P369, DOI 10.1038/nrc1881; Nickoloff BJ, 2000, J BIOL CHEM, V275, P27501; Ohtani N, 2001, NATURE, V409, P1067, DOI 10.1038/35059131; Ouyang XS, 2002, J UROLOGY, V167, P2598, DOI 10.1016/S0022-5347(05)65044-6; Perk J, 2005, NAT REV CANCER, V5, P603, DOI 10.1038/nrc1673; Peters JM, 2006, NAT REV MOL CELL BIO, V7, P644, DOI 10.1038/nrm1988; Prabhu S, 1997, MOL CELL BIOL, V17, P5888, DOI 10.1128/MCB.17.10.5888; Schindl M, 2003, CLIN CANCER RES, V9, P779; Schoppmann SF, 2003, INT J CANCER, V104, P677, DOI 10.1002/ijc.11009; Song MS, 2004, NAT CELL BIOL, V6, P129, DOI 10.1038/ncb1091; Tang J, 2002, LAB INVEST, V82, P1073, DOI 10.1097/01.LAB.0000022223.65962.3A; Tang ZY, 2004, MOL CELL, V16, P387, DOI 10.1016/j.molcel.2004.09.031; To-Ho KW, 2008, ONCOGENE, V27, P347, DOI 10.1038/sj.onc.1210633; Wong YC, 2004, APOPTOSIS, V9, P279, DOI 10.1023/B:APPT.0000025804.25396.79; Yuen HF, 2006, MODERN PATHOL, V19, P931, DOI 10.1038/modpathol.3800602; Zhang XM, 2007, CANCER SCI, V98, P308, DOI 10.1111/j.1349-7006.2007.00400.x; Zhang XM, 2006, INT J CANCER, V118, P2072, DOI 10.1002/ijc.21592; Zheng WJ, 2004, J BIOL CHEM, V279, P31524, DOI 10.1074/jbc.M400365200	37	20	20	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 24	2008	27	32					4456	4466		10.1038/onc.2008.87	http://dx.doi.org/10.1038/onc.2008.87			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	329PU	18372912				2022-12-28	WOS:000257881700008
J	De Santis, G; Miotti, S; Mazzi, M; Canevari, S; Tomassetti, A				De Santis, G.; Miotti, S.; Mazzi, M.; Canevari, S.; Tomassetti, A.			E-cadherin directly contributes to PI3K/AKT activation by engaging the PI3K-p85 regulatory subunit to adherens junctions of ovarian carcinoma cells	ONCOGENE			English	Article						E-cadherin; PI3K; cell/cell adhesion; ovarian carcinoma	BETA-CATENIN; PHOSPHOINOSITIDE 3-KINASE; PIK3CA GENE; PHOSPHATIDYLINOSITOL 3-KINASE; SURFACE EPITHELIUM; PROTEIN-KINASE; ALPHA-CATENIN; ADHESION; CANCER; EXPRESSION	E-cadherin (cadh), a member of a family of integral membrane glycoproteins that represent the major component of adherens junctions (AJs), mediates cell-cell adhesion through the calcium-dependent homophilic interaction of its extracellular domain. Metastatic human carcinomas frequently lose E-cadh expression, whereas epithelial ovarian cancer (EOCs) maintain properties characteristic of Mullerian epithelium during tumor progression, including E-cadh expression. Here, we examined the potential role of cell-cell contacts in EOCs through E-cadh homophilic interactions in PI3K/AKT activation whose altered signaling has been implicated in EOC pathogenesis. We show that E-cadh is predominantly expressed at cell-cell contacts and its functionality is necessary and sufficient for the activation of the PI3K/AKT pathway. E-cadh knockdown and phosphoinositide-3-kinase (PI3K) inhibition complement each other in impairing cell-cycle progression and proliferation of ovarian carcinoma cells. E-cadh is stably bound to the PI3K complex, and the de novo formation of E-cadh/beta-catenin complexes following calcium deprivation and subsequent calcium restoration recruits the PI3K p85 subunit to the site of the cell-cell contacts. The finding that E-cadh-mediated AJ formation contributes to PI3K/AKT activation in EOC cells by a mechanism that appears to be restricted to these cells provides the underpinning for therapeutic strategies that exploit PI3K inhibition to halt EOCs.	[De Santis, G.; Miotti, S.; Mazzi, M.; Canevari, S.; Tomassetti, A.] Fdn IRCCS Ist Nazl Tumori, Dept Expt Oncol, Unit Mol Therapies, I-20133 Milan, Italy	Fondazione IRCCS Istituto Nazionale Tumori Milan	Tomassetti, A (corresponding author), Fdn IRCCS Ist Nazl Tumori, Dept Expt Oncol, Unit Mol Therapies, Via Venezian 1, I-20133 Milan, Italy.	antonella.tomassetti@istitutotumori.mi.it	Tomassetti, Antonella/G-7906-2015	Tomassetti, Antonella/0000-0001-6772-9937	Associazione Italiana Ricerca Cancro (AIRC); Cariplo Foundation [2003-1740]	Associazione Italiana Ricerca Cancro (AIRC)(Fondazione AIRC per la ricerca sul cancro); Cariplo Foundation(Fondazione Cariplo)	We thank Gloria Bosco for her secretarial assistance. This work was supported by grants to SC from Associazione Italiana Ricerca Cancro (AIRC) and the Cariplo Foundation (grant number 2003-1740).	Ahmed N, 2007, J CELL PHYSIOL, V213, P581, DOI 10.1002/jcp.21240; Amzel LM, 2008, NAT REV CANCER, V8, P665, DOI 10.1038/nrc2443; Anderson CB, 2002, P NATL ACAD SCI USA, V99, P8683, DOI 10.1073/pnas.122235399; Andl CD, 2005, CANCER BIOL THER, V4, P28, DOI 10.4161/cbt.4.1.1431; Aunoble B, 2000, INT J ONCOL, V16, P567; Brugge J, 2007, CANCER CELL, V12, P104, DOI 10.1016/j.ccr.2007.07.014; Calautti E, 2005, J BIOL CHEM, V280, P32856, DOI 10.1074/jbc.M506119200; Campbell IG, 2004, CANCER RES, V64, P7678, DOI 10.1158/0008-5472.CAN-04-2933; Carneiro F, 2008, J CLIN PATHOL, V61, P25, DOI 10.1136/jcp.2006.043679; Castellano G, 2006, CANCER RES, V66, P10709, DOI 10.1158/0008-5472.CAN-06-1327; Conacci-Sorrell M, 2003, J CELL BIOL, V163, P847, DOI 10.1083/jcb.200308162; Davies BR, 1998, HISTOPATHOLOGY, V32, P69; Herzig M, 2007, ONCOGENE, V26, P2290, DOI 10.1038/sj.onc.1210029; Himanen JP, 2007, CURR OPIN CELL BIOL, V19, P534, DOI 10.1016/j.ceb.2007.08.004; Kovacs EM, 2002, J BIOL CHEM, V277, P6708, DOI 10.1074/jbc.M109640200; Levine DA, 2005, CLIN CANCER RES, V11, P2875, DOI 10.1158/1078-0432.CCR-04-2142; Marques FR, 2004, GYNECOL ONCOL, V94, P16, DOI 10.1016/j.ygyno.2004.03.037; McLachlan RW, 2007, MOL BIOL CELL, V18, P3214, DOI 10.1091/mbc.E06-12-1154; McLachlan RW, 2007, J MOL MED-JMM, V85, P545, DOI 10.1007/s00109-007-0198-x; Miotti S, 2005, AM J PATHOL, V167, P1411, DOI 10.1016/S0002-9440(10)61228-X; Niessen CM, 2008, BBA-BIOMEMBRANES, V1778, P562, DOI 10.1016/j.bbamem.2007.12.015; Pang JH, 2005, J BIOL CHEM, V280, P3043, DOI 10.1074/jbc.M412148200; Pece S, 1999, J BIOL CHEM, V274, P19347, DOI 10.1074/jbc.274.27.19347; Qian XL, 2004, EMBO J, V23, P1739, DOI 10.1038/sj.emboj.7600136; Reddy P, 2005, MOL ENDOCRINOL, V19, P2564, DOI 10.1210/me.2004-0342; Samuels Y, 2005, CANCER CELL, V7, P561, DOI 10.1016/j.ccr.2005.05.014; Samuels Y, 2004, SCIENCE, V304, P554, DOI 10.1126/science.1096502; Sanna E, 2007, EXP CELL RES, V313, P1307, DOI 10.1016/j.yexcr.2007.02.005; Seidel B, 2004, ONCOGENE, V23, P5532, DOI 10.1038/sj.onc.1207718; Sundfeldt K, 2003, MOL CELL ENDOCRINOL, V202, P89, DOI 10.1016/S0303-7207(03)00068-6; Tomassetti A, 2008, NEOPLASIA, V10, P1481, DOI 10.1593/neo.81004; van Hengel J, 2007, BBA-MOL CELL RES, V1773, P78, DOI 10.1016/j.bbamcr.2006.08.033; van Roy F, 2008, CELL MOL LIFE SCI, V65, P3756, DOI 10.1007/s00018-008-8281-1; VIRNEKAS B, 1994, NUCLEIC ACIDS RES, V22, P5600, DOI 10.1093/nar/22.25.5600; Vivanco I, 2002, NAT REV CANCER, V2, P489, DOI 10.1038/nrc839; Vogt PK, 2007, TRENDS BIOCHEM SCI, V32, P342, DOI 10.1016/j.tibs.2007.05.005; Wang Y, 2005, HUM MUTAT, V25, DOI 10.1002/humu.9316; Woenckhaus J, 2007, VIRCHOWS ARCH, V450, P387, DOI 10.1007/s00428-006-0358-3; Wong AST, 2003, J CELL BIOL, V161, P1191, DOI 10.1083/jcb.200212033; Woodfield RJ, 2001, BIOCHEM J, V360, P335, DOI 10.1042/0264-6021:3600335; Xie ZJ, 2007, J BIOL CHEM, V282, P8695, DOI 10.1074/jbc.M609135200; Yap AS, 2007, CURR OPIN CELL BIOL, V19, P508, DOI 10.1016/j.ceb.2007.09.008; Zhang L, 2007, CLIN CANCER RES, V13, P5314, DOI 10.1158/1078-0432.CCR-06-2660	43	73	75	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 5	2009	28	9					1206	1217		10.1038/onc.2008.470	http://dx.doi.org/10.1038/onc.2008.470			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	415AH	19151754				2022-12-28	WOS:000263906200005
J	Yan, J; Yang, Y; Zhang, H; King, C; Kan, HM; Cai, Y; Yuan, CX; Bloom, GS; Hua, X				Yan, J.; Yang, Y.; Zhang, H.; King, C.; Kan, H-M; Cai, Y.; Yuan, C-X; Bloom, G. S.; Hua, X.			Menin interacts with IQGAP1 to enhance intercellular adhesion of beta-cells	ONCOGENE			English	Article						menin; IQGAP1; intercellular adhesion; migration	MULTIPLE ENDOCRINE NEOPLASIA; E-CADHERIN; GENE; CDC42; PROTEIN; RAC1; SUPPRESSOR; EXPRESSION; MIGRATION; BINDING	Multiple endocrine neoplasia type 1 (MEN1) is a dominantly inherited tumor syndrome that results from the mutation of the MEN1 gene that encodes protein menin. Stable overexpression of MEN1 has been shown to partially suppress the Ras-mediated morphological changes of fibroblast cells. Little is known about the molecular mechanisms by which menin decreases the oncogenic effects on cell morphology and other phenotypes. Here we showed that ectopic expression of menin in pretumor beta-cells increases islet cell adhesion and reduces cell migration. Our further studies revealed that menin interacts with the scaffold protein, IQ motif containing GTPase activating protein 1 (IQGAP1), reduces GTP-Rac1 interaction with IQGAP1 but increases epithelial cadherin (E-cadherin)/beta-catenin interaction with IQGAP1. Consistent with an essential role for menin in regulating beta-cell adhesion in vivo, accumulations of beta-catenin and E-cadherin are reduced at cell junctions in the islets from Men1-excised mice. Together, these results de. ne a novel menin-IQGAP1 pathway that controls cell migration and cell-cell adhesion in endocrine cells.	[Yan, J.; Yang, Y.; Zhang, H.; King, C.; Hua, X.] Univ Penn, Sch Med, Abramson Family Canc Res Inst, Dept Canc Biol, Philadelphia, PA 19104 USA; [Zhang, H.] Sun Yat Sen Univ, Zhongshan Ophthalm Ctr, Guangzhou 510275, Guangdong, Peoples R China; [Kan, H-M; Cai, Y.; Bloom, G. S.] Univ Virginia, Dept Biol, Charlottesville, VA USA; [Yuan, C-X] Univ Penn, Sch Med, Dept Prote Facil, Philadelphia, PA 19104 USA; [Bloom, G. S.] Univ Virginia, Dept Cell Biol, Charlottesville, VA USA	University of Pennsylvania; Pennsylvania Medicine; Sun Yat Sen University; University of Virginia; University of Pennsylvania; University of Virginia	Hua, X (corresponding author), Univ Penn, Sch Med, Abramson Family Canc Res Inst, Dept Canc Biol, 421 Curie Blvd, Philadelphia, PA 19104 USA.	huax@mail.med.upenn.edu	Zhang, Hui/F-9253-2011	Yan, Jizhou/0000-0001-7482-7842	NIH [R01-CA-100912, R01-CA-113962, R01-NS051746]; American Diabetes Association [7-07-RA-60]; NATIONAL CANCER INSTITUTE [R01CA113962, R01CA100912] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS051746] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); American Diabetes Association(American Diabetes Association); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	The parent clonal beta HC9 insulin-secreting cells (Radvanyi et al., 1993) were obtained from the cell repository of the Diabetes Research Center at the University of Pennsylvania, with permission of Dr FM Matschinsky. We thank Dr Faming Zhang for his gifts of purified MBP-tagged menin and nontagged menin, Dr Martin A Schwartz for mutant human Rac1 vectors and Dr Ruth Kroschewski for the IQGAP1 C-terminal constructs (C1-C4). All confocal images and quantitative analyses of fluorescent intensity were conducted at the Biomedical Imaging Core Facility at the University of Pennsylvania. We thank Peter Blessington, Alicia Nelson, Hai Shen, Mercy Gohil and Elena Blagoi for their technical assistance. A special thanks to Dr Claudia Andl and Dr Margaret Chou for their stimulating discussions. This work was supported in part from NIH grants (R01-CA-100912 and R01-CA-113962 to XH, and R01-NS051746 to GSB), and a grant from the American Diabetes Association (7-07-RA-60 to XH).	Andl CD, 2006, CANCER RES, V66, P9878, DOI 10.1158/0008-5472.CAN-05-4157; Bai F, 2007, MOL CELL BIOL, V27, P1495, DOI 10.1128/MCB.01764-06; Bashour AM, 1997, J CELL BIOL, V137, P1555, DOI 10.1083/jcb.137.7.1555; Bensenor LB, 2007, J CELL SCI, V120, P658, DOI 10.1242/jcs.03376; Bertolino P, 2003, CANCER RES, V63, P4836; Brandt DT, 2007, J CELL BIOL, V178, P193, DOI 10.1083/jcb.200612071; Chandrasekharappa SC, 1997, SCIENCE, V276, P404, DOI 10.1126/science.276.5311.404; Chen YX, 2006, P NATL ACAD SCI USA, V103, P1018, DOI 10.1073/pnas.0510347103; Crabtree JS, 2003, MOL CELL BIOL, V23, P6075, DOI 10.1128/MCB.23.17.6075-6085.2003; Crabtree JS, 2001, P NATL ACAD SCI USA, V98, P1118, DOI 10.1073/pnas.98.3.1118; DONNADIEU E, 1992, J IMMUNOL, V148, P2643; Fukata M, 2002, CELL, V109, P873, DOI 10.1016/S0092-8674(02)00800-0; Fukata M, 1999, J BIOL CHEM, V274, P26044, DOI 10.1074/jbc.274.37.26044; Fukata M, 2001, MOL CELL BIOL, V21, P2165, DOI 10.1128/MCB.21.6.2165-2183.2001; Grohmanova K, 2004, J BIOL CHEM, V279, P48495, DOI 10.1074/jbc.M408113200; Guru SC, 1999, MAMM GENOME, V10, P592, DOI 10.1007/s003359901051; Guru SC, 1998, P NATL ACAD SCI USA, V95, P1630, DOI 10.1073/pnas.95.4.1630; Hart MJ, 1996, EMBO J, V15, P2997, DOI 10.1002/j.1460-2075.1996.tb00663.x; Huang SC, 1999, LAB INVEST, V79, P301; Hughes CM, 2004, MOL CELL, V13, P587, DOI 10.1016/S1097-2765(04)00081-4; Jiang K, 2004, MOL CELL BIOL, V24, P5565, DOI 10.1128/MCB.24.12.5565-5576.2004; Kim YS, 1999, ONCOGENE, V18, P5936, DOI 10.1038/sj.onc.1203005; Kissil JL, 2007, CANCER RES, V67, P8089, DOI 10.1158/0008-5472.CAN-07-2300; Kuroda S, 1998, SCIENCE, V281, P832, DOI 10.1126/science.281.5378.832; La P, 2004, ENDOCRINOLOGY, V145, P3443, DOI 10.1210/en.2004-0124; Lakhani VT, 2007, ANNU REV MED, V58, P253, DOI 10.1146/annurev.med.58.100305.115303; Lambert M, 2002, J CELL BIOL, V157, P469, DOI 10.1083/jcb.200107104; Le Clainche C, 2007, J BIOL CHEM, V282, P426, DOI 10.1074/jbc.M607711200; Li SH, 2000, MOL CELL BIOL, V20, P697, DOI 10.1128/MCB.20.2.697-701.2000; Lopez-Egido JR, 2002, EXP CELL RES, V278, P175, DOI 10.1006/excr.2002.5575; Mataraza JM, 2007, CELL SIGNAL, V19, P1857, DOI 10.1016/j.cellsig.2007.04.011; Mataraza JM, 2003, J BIOL CHEM, V278, P41237, DOI 10.1074/jbc.M304838200; Mateer SC, 2002, J BIOL CHEM, V277, P12324, DOI 10.1074/jbc.M109535200; Milne TA, 2005, P NATL ACAD SCI USA, V102, P749, DOI 10.1073/pnas.0408836102; Milne TA, 2002, MOL CELL, V10, P1107, DOI 10.1016/S1097-2765(02)00741-4; Noritake J, 2005, J CELL SCI, V118, P2085, DOI 10.1242/jcs.02379; Price LS, 2004, J BIOL CHEM, V279, P35127, DOI 10.1074/jbc.M404917200; RADVANYI F, 1993, MOL CELL BIOL, V13, P4223, DOI 10.1128/MCB.13.7.4223; Ridley AJ, 2001, TRENDS CELL BIOL, V11, P471, DOI 10.1016/S0962-8924(01)02153-5; Rittmeyer EN, 2008, J CELL SCI, V121, P391, DOI 10.1242/jcs.016881; Schnepp RW, 2006, CANCER RES, V66, P5707, DOI 10.1158/0008-5472.CAN-05-4518; Shaner NC, 2004, NAT BIOTECHNOL, V22, P1567, DOI 10.1038/nbt1037; Taylor SJ, 1996, CURR BIOL, V6, P1621, DOI 10.1016/S0960-9822(02)70785-9; Watanabe T, 2004, DEV CELL, V7, P871, DOI 10.1016/j.devcel.2004.10.017; Watanabe T, 2005, NOVART FDN SYMP, V269, P223; Watanabe T, 2005, NOVART FDN SYMP, V269, P101; Watanabe Takashi, 2005, Novartis Found Symp, V269, P92; Yan JZ, 2006, PLOS ONE, V1, DOI 10.1371/journal.pone.0000047; Yan JZ, 2006, MOL CELL BIOL, V26, P155, DOI 10.1128/MCB.26.1.155-168.2006; Yokoyama A, 2005, CELL, V123, P207, DOI 10.1016/j.cell.2005.09.025	50	40	46	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 19	2009	28	7					973	982		10.1038/onc.2008.435	http://dx.doi.org/10.1038/onc.2008.435			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	408TH	19079338	Green Accepted			2022-12-28	WOS:000263457400004
J	Lee, SH; Kim, J; Kim, WH; Lee, YM				Lee, S. H.; Kim, J.; Kim, W-H; Lee, Y. M.			Hypoxic silencing of tumor suppressor RUNX3 by histone modification in gastric cancer cells	ONCOGENE			English	Article						hypoxia; RUNX3; histone methylation; histone deacetylation; G9a; HDAC1	HELICOBACTER-PYLORI; DNA METHYLATION; GENE-EXPRESSION; E-CADHERIN; GROWTH; HYPERMETHYLATION; DEACETYLASE; REPRESSION; METHYLTRANSFERASE; UBIQUITINATION	RUNX3 is a tumor suppressor that is silenced in cancer following hypermethylation of its promoter. The effects of hypoxia in tumor suppressor gene (TSG) transcription are largely unknown. Here, we investigated hypoxia-induced silencing mechanisms of RUNX3. The expression of RUNX3 was downregulated in response to hypoxia in human gastric cancer cells at the transcriptional level. This downregulation was abolished following treatment with the histone deacetylase ( HDAC) inhibitor trichostatin A (TSA) and cytosine methylation inhibitor 5-aza-2-deoxycytidine (5-Aza), suggesting that an epigenetic regulatory mechanism may be involved in RUNX3 silencing by hypoxia. DNA methylation PCR and bisulfite-sequencing data revealed that hypoxia did not affect the methylation of RUNX3 promoter. A chromatin immunoprecipitation (ChIP) assay revealed increased histone H3-lysine 9 dimethylation and decreased H3 acetylation in the RUNX3 promoter following hypoxia. Hypoxia resulted in the upregulation of G9a histone methyltransferase (HMT) and HDAC1; additionally, overexpression of G9a and HDAC1 attenuated RUNX3 expression. The overexpression of G9a and HDAC1, but not their mutants, inhibited the nuclear localization and expression of RUNX3. Diminished mRNA expression and nuclear localization of RUNX3 during hypoxia was abolished by siRNA-mediated knockdown of G9a and HDAC1. This study suggests that hypoxia silences RUNX3 by epigenetic histone regulation during the progression of gastric cancer.	[Lee, S. H.; Lee, Y. M.] Kyungpook Natl Univ, Sch Life Sci & Biotechnol, Dept Nat Sci, Taegu 702701, South Korea; [Kim, J.; Kim, W-H] Seoul Natl Univ, Coll Med, Dept Pathol, Seoul 151, South Korea; [Kim, J.; Kim, W-H] Seoul Natl Univ, Coll Med, Canc Res Inst, Seoul, South Korea	Kyungpook National University; Seoul National University (SNU); Seoul National University (SNU)	Lee, YM (corresponding author), Kyungpook Natl Univ, Sch Life Sci & Biotechnol, Dept Nat Sci, Taegu 702701, South Korea.	lym@knu.ac.kr	Kim, Wooho/G-3703-2011		National R&D Program for Cancer Control, Ministry of Health and Welfare [0520120-1]; Korea Science and Engineering Foundation (KOSEF) [MOST; R01-2006-000-11046-0]	National R&D Program for Cancer Control, Ministry of Health and Welfare(Ministry of Health & Welfare (MOHW), Republic of Korea); Korea Science and Engineering Foundation (KOSEF)(Korea Science and Engineering Foundation)	Expression vectors of full-length HDAC1 and HDAC1 mutants were kindly provided by Dr Kyu-Won Kim (Seoul National University), GFP-tagged human G9a expression vector, pEGFP-hG9a, and its SET domain deletion mutant, pEGFP-hG9a (Delta SET) were by Martin Walsh (Mount Sinai School of Medicine, New York, NY, USA) and myc-tagged RUNX3 plasmids in pCS4 was by Dr Suk-Chul Bae (Chungbuk National University, Korea). This work was supported by National R&D Program for Cancer Control, Ministry of Health and Welfare (0520120-1) and the Korea Science and Engineering Foundation (KOSEF) grant funded by the Korea government (MOST; R01-2006-000-11046-0).	Anderson C, 2006, MOL DIAGN THER, V10, P345, DOI 10.1007/BF03256211; Bachman KE, 2003, CANCER CELL, V3, P89, DOI 10.1016/S1535-6108(02)00234-9; Bae SC, 2006, GENE, V366, P58, DOI 10.1016/j.gene.2005.10.017; Baylin SB, 2000, TRENDS GENET, V16, P168, DOI 10.1016/S0168-9525(99)01971-X; Box AH, 2004, CARCINOGENESIS, V25, P2325, DOI 10.1093/carcin/bgh274; Bunn HF, 1996, PHYSIOL REV, V76, P839, DOI 10.1152/physrev.1996.76.3.839; Chan AOO, 2003, AM J PATHOL, V163, P370, DOI 10.1016/S0002-9440(10)63663-2; Chen HB, 2006, CANCER RES, V66, P9009, DOI 10.1158/0008-5472.CAN-06-0101; Durst KL, 2004, ONCOGENE, V23, P4220, DOI 10.1038/sj.onc.1207122; Ekstrom AM, 2001, GASTROENTEROLOGY, V121, P784, DOI 10.1053/gast.2001.27999; Esteban MA, 2006, CANCER RES, V66, P3567, DOI 10.1158/0008-5472.CAN-05-2670; Fahrner JA, 2002, CANCER RES, V62, P7213; Gibbons RJ, 2005, HUM MOL GENET, V14, pR85, DOI 10.1093/hmg/ddi106; Harris AL, 2002, NAT REV CANCER, V2, P38, DOI 10.1038/nrc704; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; Huang CH, 2007, BIOCHEM PHARMACOL, V73, P990, DOI 10.1016/j.bcp.2006.12.013; Ito K, 2005, CANCER RES, V65, P7743, DOI 10.1158/0008-5472.CAN-05-0743; Ivanov SV, 2007, ONCOGENE, V26, P802, DOI 10.1038/sj.onc.1209842; Jin YH, 2004, J BIOL CHEM, V279, P29409, DOI 10.1074/jbc.M313120200; Johnson EN, 2003, J BIOL CHEM, V278, P1686, DOI 10.1074/jbc.M210250200; Johnstone RW, 2002, NAT REV DRUG DISCOV, V1, P287, DOI 10.1038/nrd772; Jones PA, 2007, CELL, V128, P683, DOI 10.1016/j.cell.2007.01.029; Jones PL, 1998, NAT GENET, V19, P187, DOI 10.1038/561; Kim JH, 2001, COMPOS INTERFACE, V7, P443, DOI 10.1163/156855400750262932; Krishnamachary B, 2006, CANCER RES, V66, P2725, DOI 10.1158/0008-5472.CAN-05-3719; Li QL, 2002, CELL, V109, P113, DOI 10.1016/S0092-8674(02)00690-6; Li QL, 2004, BIOCHEM BIOPH RES CO, V314, P223, DOI 10.1016/j.bbrc.2003.12.079; Liu YL, 1998, NUCLEIC ACIDS RES, V26, P1038, DOI 10.1093/nar/26.4.1038; Meng AX, 2005, RADIOTHER ONCOL, V76, P168, DOI 10.1016/j.radonc.2005.06.025; Mihaylova VT, 2003, MOL CELL BIOL, V23, P3265, DOI 10.1128/MCB.23.9.3265-3273.2003; Momparler RL, 2003, ONCOGENE, V22, P6479, DOI 10.1038/sj.onc.1206774; Nan XS, 1997, CELL, V88, P471, DOI 10.1016/S0092-8674(00)81887-5; Nan XS, 1998, NATURE, V393, P386, DOI 10.1038/30764; Nguyen CT, 2002, CANCER RES, V62, P6456; Nielsen SJ, 2001, NATURE, V412, P561, DOI 10.1038/35087620; Okano M, 1999, CELL, V99, P247, DOI 10.1016/S0092-8674(00)81656-6; Robertson KD, 2000, NAT GENET, V25, P338, DOI 10.1038/77124; Robertson KD, 1999, NUCLEIC ACIDS RES, V27, P2291, DOI 10.1093/nar/27.11.2291; Semenza GL, 2003, ANNU REV MED, V54, P17, DOI 10.1146/annurev.med.54.101601.152418; Shaw J, 2006, CIRC RES, V99, P1347, DOI 10.1161/01.RES.0000251744.06138.50; Takebayashi S, 2001, BIOCHEM BIOPH RES CO, V288, P921, DOI 10.1006/bbrc.2001.5863; Tamaru H, 2003, MOL CELL BIOL, V23, P2379, DOI 10.1128/MCB.23.7.2379-2394.2003; Uemura N, 2001, NEW ENGL J MED, V345, P784, DOI 10.1056/NEJMoa001999; Ushijima T, 2004, CANCER CELL, V5, P121, DOI 10.1016/S1535-6108(04)00033-9; Wade PA, 1999, NAT GENET, V23, P62, DOI 10.1038/12664; Wei DY, 2005, CANCER RES, V65, P4809, DOI 10.1158/0008-5472.CAN-04-3741; Yoder JA, 1997, J MOL BIOL, V270, P385, DOI 10.1006/jmbi.1997.1125	47	114	122	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2009	28	2					184	194		10.1038/onc.2008.377	http://dx.doi.org/10.1038/onc.2008.377			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	395CY	18850007				2022-12-28	WOS:000262501100003
J	Guo, X; Waddell, DS; Wang, W; Wang, Z; Liberati, NT; Yong, S; Liu, X; Wang, XF				Guo, X.; Waddell, D. S.; Wang, W.; Wang, Z.; Liberati, N. T.; Yong, S.; Liu, X.; Wang, X-F			Ligand-dependent ubiquitination of Smad3 is regulated by casein kinase 1 gamma 2, an inhibitor of TGF-beta signaling	ONCOGENE			English	Article						Smad3; TGF-beta; CKI gamma 2; ubiquitination; phosphorylation	GROWTH-FACTOR-BETA; TRANSCRIPTION FACTORS; CELL-MEMBRANE; MH1 DOMAIN; I FAMILY; DEGRADATION; ACTIVATION; WNT; MECHANISM; PROTEINS	Transforming growth factor-beta (TGF-beta) elicits a variety of cellular activities primarily through a signaling cascade mediated by two key transcription factors, Smad2 and Smad3. Numerous regulatory mechanisms exist to control the activity of Smad3, thereby modulating the strength and specificity of TGF-beta responses. In search for potential regulators of Smad3 through a yeast two-hybrid screen, we identified casein kinase 1 gamma 2 (CKI gamma 2) as a novel Smad3-interacting protein. In mammalian cells, CKI gamma 2 selectively and constitutively binds Smad3 but not Smad1, -2 or -4. Functionally, CKI gamma 2 inhibits Smad3-mediated TGF-beta responses including induction of target genes and cell growth arrest, and this inhibition is dependent on CKI gamma 2 kinase activity. Mechanistically, CKI gamma 2 does not affect the basal levels of Smad proteins or activity of the receptors. Rather, CKI gamma 2 preferentially promotes the ubiquitination and degradation of activated Smad3 through direct phosphorylation of its MH2 domain at Ser418. Importantly, mutation of Ser418 to alanine or aspartic acid causes an increase or decrease of Smad3 activity, respectively, in the presence of TGF-beta. CKI gamma 2 is the first kinase known to mark activated Smad3 for destruction. Given its negative function in TGF-beta signaling and its reported overexpression in human cancers, CKI gamma 2 may act as an oncoprotein during tumorigenesis.	[Guo, X.; Waddell, D. S.; Liberati, N. T.; Yong, S.; Wang, X-F] Duke Univ, Med Ctr, Dept Pharmacol & Canc Biol, Durham, NC 27710 USA; [Wang, W.; Liu, X.] Univ Colorado, Dept Chem & Biochem, Boulder, CO 80309 USA; [Wang, Z.] Duke Univ, Med Ctr, Dept Neurobiol, Durham, NC 27710 USA	Duke University; University of Colorado System; University of Colorado Boulder; Duke University	Wang, XF (corresponding author), Duke Univ, Med Ctr, Dept Pharmacol & Canc Biol, C218 LSRC Bldg,La Salle St Extens, Durham, NC 27710 USA.	wang0011@mc.duke.edu	Waddell, David/J-7435-2015; Waddell, David/AAG-3774-2020	Waddell, David/0000-0001-6749-4461; Waddell, David/0000-0001-6749-4461; LIU, XUEDONG/0000-0001-7209-4964	NIH [DK064113, GM083000, GM083172]; Department of Defense Breast Cancer [DAMD17-00-1-0299]; National Science Foundation; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK064113] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM083172, R01GM083000] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Department of Defense Breast Cancer(United States Department of Defense); National Science Foundation(National Science Foundation (NSF)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We thank Drs Jun Kusuda, Joan Massague, Xin-Hua Feng, Rik Derynck, Jun-Lin Guan, James Woodgett and Anita Roberts for valuable reagents. We appreciate the Wang laboratory members for insightful scienti. c discussions and excellent technical support. We thank Natalie Ahn, Kathryn Resing and Will Old for MS facility and support. This work was supported by NIH grants DK064113 and GM083000 to X-F W, and an NIH Grant GM083172 to XL. DSW was supported by Department of Defense Breast Cancer Predoctoral Fellowship DAMD17-00-1-0299. NTL was supported by a National Science Foundation Predoctoral Fellowship.	Bierie B, 2006, NAT REV CANCER, V6, P506, DOI 10.1038/nrc1926; Davidson G, 2005, NATURE, V438, P867, DOI 10.1038/nature04170; Dennler S, 1999, ONCOGENE, V18, P1643, DOI 10.1038/sj.onc.1202729; Dunn NR, 2005, GENE DEV, V19, P152, DOI 10.1101/gad.1243205; Fukuchi M, 2001, MOL BIOL CELL, V12, P1431, DOI 10.1091/mbc.12.5.1431; Gross SD, 1998, CELL SIGNAL, V10, P699, DOI 10.1016/S0898-6568(98)00042-4; Guo X, 2008, GENE DEV, V22, P106, DOI 10.1101/gad.1590908; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; Heldin CH, 1999, NAT CELL BIOL, V1, pE195, DOI 10.1038/70223; Imoto S, 2005, FEBS LETT, V579, P2853, DOI 10.1016/j.febslet.2005.04.023; Inman GJ, 2002, MOL CELL, V10, P283, DOI 10.1016/S1097-2765(02)00585-3; Izzi L, 2006, NEOPLASIA, V8, P677, DOI 10.1593/neo.06472; Jayaraman L, 2000, J BIOL CHEM, V275, P40710, DOI 10.1074/jbc.M005799200; Kitabayashi AN, 1997, GENOMICS, V46, P133, DOI 10.1006/geno.1997.4991; Knippschild U, 2005, CELL SIGNAL, V17, P675, DOI 10.1016/j.cellsig.2004.12.011; Komuro A, 2004, ONCOGENE, V23, P6914, DOI 10.1038/sj.onc.1207885; Kretschmer A, 2003, ONCOGENE, V22, P6748, DOI 10.1038/sj.onc.1206791; Liberati NT, 2001, J BIOL CHEM, V276, P22595, DOI 10.1074/jbc.M010778200; Liberati NT, 1999, P NATL ACAD SCI USA, V96, P4844, DOI 10.1073/pnas.96.9.4844; Lin X, 2000, J BIOL CHEM, V275, P36818, DOI 10.1074/jbc.C000580200; Lin X, 2006, CELL, V125, P915, DOI 10.1016/j.cell.2006.03.044; Liu CM, 2002, CELL, V108, P837, DOI 10.1016/S0092-8674(02)00685-2; Lo RS, 1999, NAT CELL BIOL, V1, P472, DOI 10.1038/70258; Long JY, 2004, P NATL ACAD SCI USA, V101, P99, DOI 10.1073/pnas.0307598100; Massague J, 2000, NAT REV MOL CELL BIO, V1, P169, DOI 10.1038/35043051; Massague J, 2005, GENE DEV, V19, P2783, DOI 10.1101/gad.1350705; Massague J, 2000, CELL, V103, P295, DOI 10.1016/S0092-8674(00)00121-5; Peters JM, 1999, NATURE, V401, P345, DOI 10.1038/43830; Piek E, 2001, J BIOL CHEM, V276, P19945, DOI 10.1074/jbc.M102382200; Poncelet AC, 2007, J BIOL CHEM, V282, P15534, DOI 10.1074/jbc.M701991200; Price MA, 2002, CELL, V108, P823, DOI 10.1016/S0092-8674(02)00664-5; Price MA, 2006, GENE DEV, V20, P399, DOI 10.1101/gad.1394306; Reguly T, 2003, TRENDS CELL BIOL, V13, P216, DOI 10.1016/S0962-8924(03)00075-8; Roberts AB, 2006, CYTOKINE GROWTH F R, V17, P19, DOI 10.1016/j.cytogfr.2005.09.008; Schilling SH, 2006, CELL, V125, P838, DOI 10.1016/j.cell.2006.05.015; Schmierer B, 2005, MOL CELL BIOL, V25, P9845, DOI 10.1128/MCB.25.22.9845-9858.2005; Shi YG, 1998, CELL, V94, P585, DOI 10.1016/S0092-8674(00)81600-1; Shi YG, 2003, CELL, V113, P685, DOI 10.1016/S0092-8674(03)00432-X; Vielhaber E, 2001, IUBMB LIFE, V51, P73, DOI 10.1080/15216540152122049; Waddell DS, 2004, J BIOL CHEM, V279, P29236, DOI 10.1074/jbc.M400880200; Wang WS, 2005, NEPHROLOGY, V10, P48, DOI 10.1111/j.1440-1797.2005.00334.x; Weinstein M, 2000, CYTOKINE GROWTH F R, V11, P49, DOI 10.1016/S1359-6101(99)00028-3; Xu L, 2002, MOL CELL, V10, P271, DOI 10.1016/S1097-2765(02)00586-5; Yagi K, 1999, J BIOL CHEM, V274, P703, DOI 10.1074/jbc.274.2.703; Zeng X, 2005, NATURE, V438, P873, DOI 10.1038/nature04185; ZHAI LM, 1995, J BIOL CHEM, V270, P12717, DOI 10.1074/jbc.270.21.12717	46	25	28	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC	2008	27	58					7235	7247		10.1038/onc.2008.337	http://dx.doi.org/10.1038/onc.2008.337			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	382FI	18794808	Green Accepted			2022-12-28	WOS:000261590300002
J	Tanos, B; Rodriguez-Boulan, E				Tanos, B.; Rodriguez-Boulan, E.			The epithelial polarity program: machineries involved and their hijacking by cancer	ONCOGENE			English	Review						epithelial polarity; vesicular trafficking; polarity proteins; polarity lipids; epithelial mesenchymal transition; epithelial tumors	DARBY CANINE KIDNEY; GROWTH-FACTOR RECEPTOR; PROTEIN-KINASE-C; BASOLATERAL PLASMA-MEMBRANE; INFLUENZA-VIRUS HEMAGGLUTININ; TUMOR-SUPPRESSOR PROTEIN; CLATHRIN ADAPTER COMPLEXES; GPI-ANCHORED PROTEINS; TRANS-GOLGI NETWORK; MDCK CELLS	The Epithelial Polarity Program (EPP) adapts and integrates three ancient cellular machineries to construct an epithelial cell. The polarized trafficking machinery adapts the cytoskeleton and ancestral secretory and endocytic machineries to the task of sorting and delivering different plasma membrane (PM) proteins to apical and basolateral surface domains. The domain-identity machinery builds a tight junctional fence (TJ) between apical and basolateral PM domains and adapts ancient polarity proteins and polarity lipids on the cytoplasmic side of the PM, which have evolved to perform a diversity of polarity tasks across cells and species, to provide 'identity' to each epithelial PM domain. The 3D organization machinery utilizes adhesion molecules as positional sensors of other epithelial cells and the basement membrane and small GTPases as integrators of positional information with the activities of the domain-identity and polarized trafficking machineries. Cancer is a disease mainly of epithelial cells (90% of human cancers are carcinomas that derive from epithelial cells) that hijacks the EPP machineries, resulting in loss of epithelial polarity, which often correlates in extent with the aggressiveness of the tumor. Here, we review how the EPP integrates its three machineries and the strategies used by cancer to hijack them.	[Tanos, B.; Rodriguez-Boulan, E.] Weill Cornell Med Coll, Dept Ophthalmol, Margaret Dyson Vis Res Inst, New York, NY 10065 USA; [Rodriguez-Boulan, E.] Weill Cornell Med Coll, Dept Cell & Dev Biol, New York, NY 10065 USA	Cornell University; Cornell University	Rodriguez-Boulan, E (corresponding author), Weill Cornell Med Coll, Dept Ophthalmol, Margaret Dyson Vis Res Inst, 1300 York Ave, New York, NY 10065 USA.	boulan@med.cornell.edu		Tanos, Barbara/0000-0002-7045-9496	NIH [GM 34107, EY08538]; Dyson Foundation; Research to Prevent Blindness Foundation; NATIONAL EYE INSTITUTE [R01EY008538] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM034107] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Dyson Foundation; Research to Prevent Blindness Foundation(Research to Prevent Blindness (RPB)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We thank Aparna Lakkaraju for her artistic support and Marcelino Cereijido for useful comments on the manuscript. This study was supported by NIH Grants GM 34107 and EY08538 to ERB, by the Dyson Foundation and by the Research to Prevent Blindness Foundation.	Al-Nedawi K, 2008, NAT CELL BIOL, V10, P619, DOI 10.1038/ncb1725; Anders M, 2003, P NATL ACAD SCI USA, V100, P1943, DOI 10.1073/pnas.0337599100; Ang AL, 2004, J CELL BIOL, V167, P531, DOI 10.1083/jcb.200408165; APODACA G, 1994, J CELL BIOL, V125, P67, DOI 10.1083/jcb.125.1.67; Aranda V, 2008, ONCOGENE, V27, P6878, DOI 10.1038/onc.2008.340; Aranda V, 2006, NAT CELL BIOL, V8, P1235, DOI 10.1038/ncb1485; AROETI B, 1994, EMBO J, V13, P2297, DOI 10.1002/j.1460-2075.1994.tb06513.x; Baas AF, 2004, TRENDS CELL BIOL, V14, P312, DOI 10.1016/j.tcb.2004.04.001; Baas AF, 2004, CELL, V116, P457, DOI 10.1016/S0092-8674(04)00114-X; BACALLAO R, 1989, J CELL BIOL, V109, P2817, DOI 10.1083/jcb.109.6.2817; Balkovetz DF, 2006, AM J PHYSIOL-RENAL, V290, pF572, DOI 10.1152/ajprenal.00135.2005; Bao J, 2003, P NATL ACAD SCI USA, V100, P2438, DOI 10.1073/pnas.0437945100; Barrios-Rodiles M, 2005, SCIENCE, V307, P1621, DOI 10.1126/science.1105776; Benjamin JM, 2008, SEMIN CANCER BIOL, V18, P53, DOI 10.1016/j.semcancer.2007.08.003; Bilder D, 2004, GENE DEV, V18, P1909, DOI 10.1101/gad.1211604; Bodemann BO, 2008, NAT REV CANCER, V8, P133, DOI 10.1038/nrc2296; Bonazzi M, 2005, NAT CELL BIOL, V7, P570, DOI 10.1038/ncb1260; Bonifacino JS, 2004, NAT REV MOL CELL BIO, V5, P23, DOI 10.1038/nrm1279; Bonifacino JS, 2003, ANNU REV BIOCHEM, V72, P395, DOI 10.1146/annurev.biochem.72.121801.161800; Borg JP, 2000, NAT CELL BIOL, V2, P407, DOI 10.1038/35017038; BOULAN ER, 1980, CELL, V20, P45, DOI 10.1016/0092-8674(80)90233-0; Breitfeld PP, 1989, CURR OPIN CELL BIOL, V1, P617, DOI 10.1016/0955-0674(89)90024-0; Bretscher A, 1999, CURR OPIN CELL BIOL, V11, P109, DOI 10.1016/S0955-0674(99)80013-1; BREWER CB, 1991, J CELL BIOL, V114, P413, DOI 10.1083/jcb.114.3.413; BROWN DA, 1989, SCIENCE, V245, P1499, DOI 10.1126/science.2571189; BROWN DA, 1992, CELL, V68, P533, DOI 10.1016/0092-8674(92)90189-J; Brown PS, 2000, TRAFFIC, V1, P124, DOI 10.1034/j.1600-0854.2000.010205.x; Cancino J, 2007, MOL BIOL CELL, V18, P4872, DOI 10.1091/mbc.E07-06-0563; Cao C, 2006, BIOCHEM J, V400, P225, DOI 10.1042/BJ20060816; Cereijido M, 2004, PHYSIOL REV, V84, P1229, DOI 10.1152/physrev.00001.2004; CEREIJIDO M, 1978, J CELL BIOL, V77, P853, DOI 10.1083/jcb.77.3.853; Cereijido M, 2008, BBA-BIOMEMBRANES, V1778, P770, DOI 10.1016/j.bbamem.2007.09.001; Ceresa BP, 2006, HISTOL HISTOPATHOL, V21, P987, DOI 10.14670/HH-21.987; Chen JQ, 2006, BREAST CANCER RES TR, V96, P1, DOI 10.1007/s10549-005-9053-3; Chen XY, 2005, NAT CELL BIOL, V7, P262, DOI 10.1038/ncb1226; Cohen D, 2004, J CELL BIOL, V164, P717, DOI 10.1083/jcb.200308104; Cohen D, 2001, TRAFFIC, V2, P556, DOI 10.1034/j.1600-0854.2001.20805.x; Comer FI, 2007, CELL, V128, P239, DOI 10.1016/j.cell.2007.01.010; Condeelis J, 2005, ANNU REV CELL DEV BI, V21, P695, DOI 10.1146/annurev.cellbio.21.122303.120306; Dardousis K, 2007, MOL THER, V15, P94, DOI 10.1038/sj.mt.6300003; Deborde S, 2008, NATURE, V452, P719, DOI 10.1038/nature06828; Delacour D, 2006, CURR BIOL, V16, P408, DOI 10.1016/j.cub.2005.12.046; Delacour D, 2007, TRAFFIC, V8, P379, DOI 10.1111/j.1600-0854.2007.00539.x; Deora AA, 2004, MOL BIOL CELL, V15, P4148, DOI 10.1091/mbc.E04-01-0058; Di Paolo G, 2006, NATURE, V443, P651, DOI 10.1038/nature05185; DIAKONOVA M, 1995, J CELL SCI, V108, P2499; Dikic I, 2007, EUR J CELL BIOL, V86, P505, DOI 10.1016/j.ejcb.2007.04.005; Dow LE, 2007, INT REV CYTOL, V262, P253, DOI 10.1016/S0074-7696(07)62006-3; Drees F, 2005, CELL, V123, P903, DOI 10.1016/j.cell.2005.09.021; Eder AM, 2005, P NATL ACAD SCI USA, V102, P12519, DOI 10.1073/pnas.0505641102; Ellis MA, 2006, AM J PHYSIOL-RENAL, V291, pF707, DOI 10.1152/ajprenal.00161.2006; Etienne-Manneville S, 2003, CURR OPIN CELL BIOL, V15, P67, DOI 10.1016/S0955-0674(02)00005-4; Etienne-Manneville S, 2008, ONCOGENE, V27, P6970, DOI 10.1038/onc.2008.347; Feng W, 2008, J BIOL CHEM, V283, P23440, DOI 10.1074/jbc.M802482200; FIEDLER K, 1995, CELL, V81, P309, DOI 10.1016/0092-8674(95)90380-1; Fields IC, 2007, J CELL BIOL, V177, P477, DOI 10.1083/jcb.200610047; Folsch H, 1999, CELL, V99, P189, DOI 10.1016/S0092-8674(00)81650-5; Folsch H, 2003, J CELL BIOL, V163, P351, DOI 10.1083/jcb.200309020; Folsch H, 2001, J CELL BIOL, V152, P595, DOI 10.1083/jcb.152.3.595; Frankel P, 2005, EMBO J, V24, P54, DOI 10.1038/sj.emboj.7600497; FRIEDERICH E, 1989, CELL, V59, P461, DOI 10.1016/0092-8674(89)90030-5; Fujita Y, 2002, NAT CELL BIOL, V4, P222, DOI 10.1038/ncb758; Fullekrug J, 2004, ANN NY ACAD SCI, V1014, P164, DOI 10.1196/annals.1294.017; FUTTER CE, 1995, J BIOL CHEM, V270, P10999, DOI 10.1074/jbc.270.18.10999; Galli T, 1998, MOL BIOL CELL, V9, P1437, DOI 10.1091/mbc.9.6.1437; Gan YB, 2002, NAT CELL BIOL, V4, P605, DOI 10.1038/ncb827; Gao L, 2002, CURR BIOL, V12, P221, DOI 10.1016/S0960-9822(01)00663-7; Gassama-Diagne A, 2006, NAT CELL BIOL, V8, P963, DOI 10.1038/ncb1461; Gibson MC, 2003, CURR OPIN CELL BIOL, V15, P747, DOI 10.1016/j.ceb.2003.10.008; GILBERT T, 1991, J CELL SCI, V100, P451; GILBERT T, 1991, J CELL BIOL, V113, P275, DOI 10.1083/jcb.113.2.275; Goldstein B, 2007, DEV CELL, V13, P609, DOI 10.1016/j.devcel.2007.10.007; GOTTLIEB TA, 1993, J CELL BIOL, V120, P695, DOI 10.1083/jcb.120.3.695; Gravotta D, 2007, P NATL ACAD SCI USA, V104, P1564, DOI 10.1073/pnas.0610700104; Grindstaff KK, 1998, CELL, V93, P731, DOI 10.1016/S0092-8674(00)81435-X; Halbleib JM, 2006, GENE DEV, V20, P3199, DOI 10.1101/gad.1486806; HAMMERTON RW, 1991, SCIENCE, V254, P847, DOI 10.1126/science.1658934; HANNAN LA, 1993, J CELL BIOL, V120, P353, DOI 10.1083/jcb.120.2.353; Hansel DE, 2004, CLIN CANCER RES, V10, P6152, DOI 10.1158/1078-0432.CCR-04-0285; Hara-Chikuma M, 2008, J MOL MED-JMM, V86, P221, DOI 10.1007/s00109-007-0272-4; Hara-Chikuma M, 2008, MOL CELL BIOL, V28, P326, DOI 10.1128/MCB.01482-07; He C, 2002, J BIOL CHEM, V277, P38284, DOI 10.1074/jbc.M104646200; Hezel AF, 2008, ONCOGENE, V27, P6908, DOI 10.1038/onc.2008.342; Hirokawa N, 1998, SCIENCE, V279, P519, DOI 10.1126/science.279.5350.519; Huang F, 2007, P NATL ACAD SCI USA, V104, P16904, DOI 10.1073/pnas.0707416104; HUBER LA, 1993, J CELL BIOL, V123, P35, DOI 10.1083/jcb.123.1.35; Humbert PO, 2008, ONCOGENE, V27, P6888, DOI 10.1038/onc.2008.341; HUNZIKER W, 1994, EMBO J, V13, P2963, DOI 10.1002/j.1460-2075.1994.tb06594.x; Hurd TW, 2003, NAT CELL BIOL, V5, P137, DOI 10.1038/ncb923; Igaki T, 2006, CURR BIOL, V16, P1139, DOI 10.1016/j.cub.2006.04.042; Jacob R, 2004, J BIOL CHEM, V279, P3680, DOI 10.1074/jbc.C300503200; Jacob R, 2001, CURR BIOL, V11, P1444, DOI 10.1016/S0960-9822(01)00446-8; Janvier K, 2003, J CELL BIOL, V163, P1281, DOI 10.1083/jcb.200307157; Jaulin F, 2007, DEV CELL, V13, P511, DOI 10.1016/j.devcel.2007.08.001; Jeanes A, 2008, ONCOGENE, V27, P6920, DOI 10.1038/onc.2008.343; Ji C, 2008, CANCER CHEMOTH PHARM, V62, P857, DOI 10.1007/s00280-007-0674-6; Joberty G, 2000, NAT CELL BIOL, V2, P531, DOI 10.1038/35019573; Kang YB, 2004, CELL, V118, P277, DOI 10.1016/j.cell.2004.07.011; Keller P, 1997, J CELL SCI, V110, P3001; King LS, 2004, NAT REV MOL CELL BIO, V5, P687, DOI 10.1038/nrm1469; Kirchhausen T, 2000, NAT REV MOL CELL BIO, V1, P187, DOI 10.1038/35043117; Kolsch V, 2008, J CELL SCI, V121, P551, DOI 10.1242/jcs.023333; Kotelevets L, 2004, FASEB J, V18, P115, DOI 10.1096/fj.04-1942fje; Kreitzer G, 2000, NAT CELL BIOL, V2, P125, DOI 10.1038/35000081; Kreitzer G, 2003, NAT CELL BIOL, V5, P126, DOI 10.1038/ncb917; Kroschewski R, 1999, NAT CELL BIOL, V1, P8, DOI 10.1038/8977; Kundu A, 1996, J VIROL, V70, P6508, DOI 10.1128/JVI.70.9.6508-6515.1996; Lafont F, 1999, P NATL ACAD SCI USA, V96, P3734, DOI 10.1073/pnas.96.7.3734; LANGDON WY, 1989, P NATL ACAD SCI USA, V86, P1168, DOI 10.1073/pnas.86.4.1168; Langevin J, 2005, DEV CELL, V9, P365, DOI 10.1016/j.devcel.2005.07.013; Latorre IJ, 2005, J CELL SCI, V118, P4283, DOI 10.1242/jcs.02560; LEBIVIC A, 1991, J CELL BIOL, V115, P607, DOI 10.1083/jcb.115.3.607; Lee JH, 2007, NATURE, V447, P1017, DOI 10.1038/nature05828; LEGALL AH, 1994, FASEB J, V8, pA17; Lehman K, 1999, J CELL BIOL, V146, P125, DOI 10.1083/jcb.146.1.125; LEITINGER B, 1995, P NATL ACAD SCI USA, V92, P10109, DOI 10.1073/pnas.92.22.10109; Lemmers C, 2002, J BIOL CHEM, V277, P25408, DOI 10.1074/jbc.M202196200; Lin D, 2000, NAT CELL BIOL, V2, P540, DOI 10.1038/35019582; Lin SS, 1998, J CELL BIOL, V142, P51, DOI 10.1083/jcb.142.1.51; LISANTI MP, 1989, J CELL BIOL, V109, P2145, DOI 10.1083/jcb.109.5.2145; LISANTI MP, 1988, P NATL ACAD SCI USA, V85, P9557, DOI 10.1073/pnas.85.24.9557; Lo HW, 2007, CANCER RES, V67, P9066, DOI 10.1158/0008-5472.CAN-07-0575; Low SH, 1998, J CELL BIOL, V141, P1503, DOI 10.1083/jcb.141.7.1503; Low SH, 1996, MOL BIOL CELL, V7, P2007, DOI 10.1091/mbc.7.12.2007; Lu H, 2005, NAT CELL BIOL, V7, P1232, DOI 10.1038/ncb1324; Lu ZM, 2000, MOL CELL BIOL, V20, P462, DOI 10.1128/MCB.20.2.462-467.2000; Lynch DK, 2003, J BIOL CHEM, V278, P21805, DOI 10.1074/jbc.M211407200; Martin-Belmonte F, 2008, CURR OPIN CELL BIOL, V20, P227, DOI 10.1016/j.ceb.2008.01.001; Martin-Belmonte F, 2007, CELL CYCLE, V6, P1957, DOI 10.4161/cc.6.16.4583; Martin-Belmonte F, 2007, CELL, V128, P383, DOI 10.1016/j.cell.2006.11.051; Massimi P, 2008, ONCOGENE, V27, P1800, DOI 10.1038/sj.onc.1210810; Matter K, 2003, NAT REV MOL CELL BIO, V4, P225, DOI 10.1038/nrm1055; MATTER K, 1992, CELL, V71, P741, DOI 10.1016/0092-8674(92)90551-M; Merlot S, 2003, J CELL SCI, V116, P3471, DOI 10.1242/jcs.00703; Miaczynska M, 2004, CURR OPIN CELL BIOL, V16, P400, DOI 10.1016/j.ceb.2004.06.005; MIETTINEN PJ, 1994, J CELL BIOL, V127, P2021, DOI 10.1083/jcb.127.6.2021; Mirouse V, 2007, J CELL BIOL, V177, P387, DOI 10.1083/jcb.200702053; Miyoshi J, 2005, ADV DRUG DELIVER REV, V57, P815, DOI 10.1016/j.addr.2005.01.008; Moreno-Bueno G, 2008, ONCOGENE, V27, P6958, DOI 10.1038/onc.2008.346; Moskalenko S, 2003, J BIOL CHEM, V278, P51743, DOI 10.1074/jbc.M308702200; Mostov K, 2003, NAT CELL BIOL, V5, P287, DOI 10.1038/ncb0403-287; Murray NR, 2004, J CELL BIOL, V164, P797, DOI 10.1083/jcb.200311011; Musch A, 2004, TRAFFIC, V5, P1, DOI 10.1046/j.1600-0854.2003.00149.x; Musch A, 2002, MOL BIOL CELL, V13, P158, DOI 10.1091/mbc.01-10-0496; Musch A, 2001, EMBO J, V20, P2171, DOI 10.1093/emboj/20.9.2171; Naim HY, 1999, J BIOL CHEM, V274, P17961, DOI 10.1074/jbc.274.25.17961; Nejsum LN, 2007, J CELL BIOL, V178, P323, DOI 10.1083/jcb.200705094; Nelson WJ, 2003, NATURE, V422, P766, DOI 10.1038/nature01602; Nishimura T, 2007, DEV CELL, V13, P15, DOI 10.1016/j.devcel.2007.05.003; Noda Y, 2001, J CELL BIOL, V155, P77, DOI 10.1083/jcb.200108042; O'Brien LE, 2001, NAT CELL BIOL, V3, P831, DOI 10.1038/ncb0901-831; Odorizzi G, 1997, J CELL BIOL, V137, P1255, DOI 10.1083/jcb.137.6.1255; Ohno H, 1999, FEBS LETT, V449, P215, DOI 10.1016/S0014-5793(99)00432-9; OHNO H, 1995, SCIENCE, V269, P1872, DOI 10.1126/science.7569928; Okuda H, 2001, J BIOL CHEM, V276, P43611, DOI 10.1074/jbc.M107880200; Orth JD, 2006, CANCER RES, V66, P3603, DOI 10.1158/0008-5472.CAN-05-2916; Orzech E, 2000, J BIOL CHEM, V275, P15207, DOI 10.1074/jbc.275.20.15207; Owen DJ, 2004, ANNU REV CELL DEV BI, V20, P153, DOI 10.1146/annurev.cellbio.20.010403.104543; Ozdamar B, 2005, SCIENCE, V307, P1603, DOI 10.1126/science.1105718; Oztan A, 2007, MOL BIOL CELL, V18, P3978, DOI 10.1091/mbc.E07-02-0097; Pagliarini RA, 2003, SCIENCE, V302, P1227, DOI 10.1126/science.1088474; Palacios F, 2005, MOL CELL BIOL, V25, P389, DOI 10.1128/MCB.25.1.389-402.2005; Paladino S, 2004, J CELL BIOL, V167, P699, DOI 10.1083/jcb.200407094; Peinado H, 2007, NAT REV CANCER, V7, P415, DOI 10.1038/nrc2131; Perret E, 2005, CURR OPIN CELL BIOL, V17, P423, DOI 10.1016/j.ceb.2005.06.008; POTENZA M, 1992, YEAST, V8, P549, DOI 10.1002/yea.320080706; POWELL SK, 1991, NATURE, V353, P76, DOI 10.1038/353076a0; Qin Y, 2005, J CELL BIOL, V171, P1061, DOI 10.1083/jcb.200506094; Raftopoulou M, 2004, SCIENCE, V303, P1179, DOI 10.1126/science.1092089; Rai T, 2006, AM J PHYSIOL-CELL PH, V290, pC298, DOI 10.1152/ajpcell.00356.2005; Rajasekaran AK, 1996, J CELL BIOL, V132, P451, DOI 10.1083/jcb.132.3.451; Regala RP, 2005, CANCER RES, V65, P8905, DOI 10.1158/0008-5472.CAN-05-2372; Regala RP, 2005, J BIOL CHEM, V280, P31109, DOI 10.1074/jbc.M505402200; REMY L, 1990, BIOL CELL, V69, P129, DOI 10.1016/0248-4900(90)90339-5; Rittmeyer EN, 2008, J CELL SCI, V121, P391, DOI 10.1242/jcs.016881; Rodriguez-Boulan E, 2005, NAT REV MOL CELL BIO, V6, P233, DOI 10.1038/nrm1593; RODRIGUEZBOULAN E, 1992, ANNU REV CELL BIOL, V8, P395, DOI 10.1146/annurev.cb.08.110192.002143; RODRIGUEZBOULAN E, 1978, P NATL ACAD SCI USA, V75, P5071, DOI 10.1073/pnas.75.10.5071; Roh MH, 2003, J CELL SCI, V116, P2895, DOI 10.1242/jcs.00500; Rojas R, 2001, MOL BIOL CELL, V12, P2257, DOI 10.1091/mbc.12.8.2257; ROTHMAN JE, 1994, NATURE, V372, P55, DOI 10.1038/372055a0; Roush DL, 1998, J BIOL CHEM, V273, P26862, DOI 10.1074/jbc.273.41.26862; Sakurai-Yageta M, 2008, J CELL BIOL, V181, P985, DOI 10.1083/jcb.200709076; Salazar G, 2002, MOL BIOL CELL, V13, P1677, DOI 10.1091/mbc.01-08-0403; SALVAREZZA SB, MOL BIOL CE IN PRESS; Scheiffele P, 1997, EMBO J, V16, P5501, DOI 10.1093/emboj/16.18.5501; Schermer B, 2006, J CELL BIOL, V175, P547, DOI 10.1083/jcb.200605092; Schock F, 2002, ANNU REV CELL DEV BI, V18, P463, DOI 10.1146/annurev.cellbio.18.022602.131838; Segall JE, 1996, CLIN EXP METASTAS, V14, P61, DOI 10.1007/BF00157687; Sheff DR, 2002, MOL BIOL CELL, V13, P262, DOI 10.1091/mbc.01-07-0320; Shen Y, 2008, J BIOL CHEM, V283, P5127, DOI 10.1074/jbc.M703300200; Shin K, 2006, ANNU REV CELL DEV BI, V22, P207, DOI 10.1146/annurev.cellbio.22.010305.104219; Shipitsin M, 2004, MOL CELL BIOL, V24, P5746, DOI 10.1128/MCB.24.13.5746-5756.2004; Shoshani L, 2005, MOL BIOL CELL, V16, P1071, DOI 10.1091/mbc.E04-03-0267; Simmen T, 2002, NAT CELL BIOL, V4, P154, DOI 10.1038/ncb745; SIMONS K, 1990, CELL, V62, P207, DOI 10.1016/0092-8674(90)90357-K; Sorkin A, 2000, CURR BIOL, V10, P1395, DOI 10.1016/S0960-9822(00)00785-5; Sorkin A, 2001, BIOCHEM SOC T, V29, P480, DOI 10.1042/BST0290480; Sorkin A, 2000, J CELL SCI, V113, P4375; Spiczka KS, 2008, J CELL SCI, V121, P2880, DOI 10.1242/jcs.031641; Stein MP, 2003, ADV DRUG DELIVER REV, V55, P1421, DOI 10.1016/j.addr.2003.07.009; Stephens L, 2008, CURR BIOL, V18, pR485, DOI 10.1016/j.cub.2008.04.048; Storrs CH, 2007, J VIROL, V81, P4080, DOI 10.1128/JVI.02545-06; Tai AW, 1999, CELL, V97, P877, DOI 10.1016/S0092-8674(00)80800-4; Tanos B, 2006, J BIOL CHEM, V281, P32714, DOI 10.1074/jbc.M603126200; TerBush DR, 1996, EMBO J, V15, P6483, DOI 10.1002/j.1460-2075.1996.tb01039.x; TERBUSH DR, 1995, J CELL BIOL, V130, P299, DOI 10.1083/jcb.130.2.299; Thiery JP, 2002, NAT REV CANCER, V2, P442, DOI 10.1038/nrc822; Thomas M, 2008, ONCOGENE, V27, P7018, DOI 10.1038/onc.2008.351; Tsukita S, 2008, ONCOGENE, V27, P6930, DOI 10.1038/onc.2008.344; Turley EA, 2008, NAT CLIN PRACT ONCOL, V5, P280, DOI 10.1038/ncponc1089; van Ijzendoorn SCD, 2003, INT REV CYTOL, V232, P59, DOI 10.1016/S0074-7696(03)32002-9; VAN MEER G, 1987, J CELL BIOL, V105, P1623, DOI 10.1083/jcb.105.4.1623; VANZEIJL MJAH, 1990, CELL REGUL, V1, P921, DOI 10.1091/mbc.1.12.921; VEGASALAS DE, 1987, J CELL BIOL, V104, P1249, DOI 10.1083/jcb.104.5.1249; Verkman AS, 2008, J MOL MED, V86, P523, DOI 10.1007/s00109-008-0303-9; Vermeer PD, 2003, NATURE, V422, P322, DOI 10.1038/nature01440; Vieira AV, 1996, SCIENCE, V274, P2086, DOI 10.1126/science.274.5295.2086; Wang F, 2006, ACTA PHARMACOL SIN, V27, P395, DOI 10.1111/j.1745-7254.2006.00318.x; Wang F, 1998, P NATL ACAD SCI USA, V95, P14821, DOI 10.1073/pnas.95.25.14821; Wang HR, 2006, METHOD ENZYMOL, V406, P437, DOI 10.1016/S0076-6879(06)06032-0; Wang JX, 2002, INT J MOL SCI, V3, P4, DOI 10.3390/i3010004; Weaver VM, 1997, J CELL BIOL, V137, P231, DOI 10.1083/jcb.137.1.231; Wellner RB, 2005, TISSUE ENG, V11, P1449, DOI 10.1089/ten.2005.11.1449; Wodarz A, 2007, NAT CELL BIOL, V9, P1016, DOI 10.1038/ncb433; Wu WJ, 2003, CELL, V114, P715, DOI 10.1016/S0092-8674(03)00688-3; Wu XY, 2000, P NATL ACAD SCI USA, V97, P4233, DOI 10.1073/pnas.97.8.4233; Wu Y, 2000, J BIOL CHEM, V275, P21477, DOI 10.1074/jbc.M909741199; Yamada S, 2005, CELL, V123, P889, DOI 10.1016/j.cell.2005.09.020; Yarden Y, 2001, ONCOLOGY-BASEL, V61, P1, DOI 10.1159/000055396; Yarden Y, 2001, EUR J CANCER, V37, pS3; Yarden Y, 2007, CELL, V131, DOI 10.1016/j.cell.2007.11.013; Yeaman C, 1997, J CELL BIOL, V139, P929, DOI 10.1083/jcb.139.4.929; Yeaman C, 2004, J CELL SCI, V117, P559, DOI 10.1242/jcs.00893; Yeaman C, 2004, NAT CELL BIOL, V6, P106, DOI 10.1038/ncb1090; Yip SC, 2007, J CELL SCI, V120, P3138, DOI 10.1242/jcs.005298; Zhang XY, 2005, J CELL BIOL, V170, P273, DOI 10.1083/jcb.200502055; Zhang XY, 2001, J BIOL CHEM, V276, P46745, DOI 10.1074/jbc.M107464200; Zhao M, 1999, MOL BIOL CELL, V10, P1259, DOI 10.1091/mbc.10.4.1259	239	127	131	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 24	2008	27	55					6939	6957		10.1038/onc.2008.345	http://dx.doi.org/10.1038/onc.2008.345			19	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	375IU	19029936				2022-12-28	WOS:000261108200007
J	Salah, Z; Haupt, S; Maoz, M; Baraz, L; Rotter, V; Peretz, T; Haupt, Y; Bar-Shavit, R				Salah, Z.; Haupt, S.; Maoz, M.; Baraz, L.; Rotter, V.; Peretz, T.; Haupt, Y.; Bar-Shavit, R.			p53 controls hPar1 function and expression	ONCOGENE			English	Article						PAR1; p53; protease; promoter activity; transcription factor	PROTEASE-ACTIVATED RECEPTOR-1; WILD-TYPE P53; HUMAN ENDOTHELIAL-CELLS; GAIN-OF-FUNCTION; MUTANT P53; THROMBIN RECEPTOR; TUMOR-SUPPRESSOR; PROSTATE-CANCER; TRANSCRIPTIONAL REGULATION; MUTATION ANALYSIS	Human protease-activated receptor 1(hPar1) is a bonafide receptor of the hemostatic protease thrombin, and has a central function in tumor progression. Inactivation of the tumor suppressor gene p53 is one of the most common genomic alterations occurring in cancer. Here, we address the interrelations between p53 and hPar1 in cancer. We demonstrate an inverse correlation between hPar1 gene expression and wild-type (wt) p53 levels, and a direct correlation with levels of the mutant (mt) p53. Bioinformatic search revealed the presence of at least two p53 motifs in the hPar1 promoter. Indeed, temperature-sensitive (ts) p53 forms reduced hPar1 promoter activity on wt p53 expression. Ectopic introduction of the p53R175H mutant into cells lacking p53 caused a moderate two-fold induction of hPar1 promoter activity. Chromatin immunoprecipitation (ChIP) analyses confirmed a physical association between the p53 protein and hPar1 chromatin fragments. In parallel, PAR1 function is attenuated by p53, as shown by inhibition of pFAK levels and a Matrigel invasion assay. Ectopic reinforcement of hPar1 rescued the inhibition conferred by p53, confirming that p53 directly affects hPar1 expression and function. Altogether, we provide evidence for a direct binding between p53 and hPar1 chromatin, and assign hPar1 as a target of p53. Oncogene (2008) 27, 6866-6874; doi: 10.1038/onc.2008.324; published online 29 September 2008	[Salah, Z.; Maoz, M.; Baraz, L.; Peretz, T.; Bar-Shavit, R.] Hadassah Univ, Med Ctr, Dept Oncol, Jerusalem, Israel; [Haupt, S.; Haupt, Y.] Hebrew Univ Jerusalem, Hadassah Med Sch, Dept Immunol, Lautenberg Ctr, IL-91010 Jerusalem, Israel; [Rotter, V.] Weizmann Inst Sci, Dept Mol Cell Biol, Rehovot, Israel	Hebrew University of Jerusalem; Hadassah University Medical Center; Hebrew University of Jerusalem; Weizmann Institute of Science	Bar-Shavit, R (corresponding author), Hadassah Hebrew Univ Hosp, Dept Oncol, POB 12000, IL-91120 Jerusalem, Israel.	rachel.bar-shavit@ekmd.huji.ac.il		Haupt, Ygal/0000-0001-5925-0096	Israel Science Foundation by the Israel Academy of Science and Humanities; The Israel Cancer Association; MECC (Middle East Cancer Consortium)	Israel Science Foundation by the Israel Academy of Science and Humanities(Israel Science Foundation); The Israel Cancer Association; MECC (Middle East Cancer Consortium)	Grant support: Israel Science Foundation by the Israel Academy of Science and Humanities, The Israel Cancer Association and MECC (Middle East Cancer Consortium) Small Grant Program (R Bar-Shavit).	Ahn J, 1999, ONCOGENE, V18, P5954, DOI 10.1038/sj.onc.1202986; ALBINI A, 1987, CANCER RES, V47, P3239; Aylon Y, 2007, CELL, V130, P597, DOI 10.1016/j.cell.2007.08.005; Blagosklonny MV, 2000, FASEB J, V14, P1901, DOI 10.1096/fj.99-1078rev; Booden MA, 2004, MOL CELL BIOL, V24, P1990, DOI 10.1128/MCB.24.5.1990-1999.2004; Cadwell C, 2001, GENE, V277, P15, DOI 10.1016/S0378-1119(01)00696-5; Caunt M, 2006, CANCER RES, V66, P4125, DOI 10.1158/0008-5472.CAN-05-2570; Chay CH, 2002, UROLOGY, V60, P760, DOI 10.1016/S0090-4295(02)01969-6; Chen XB, 1996, GENE DEV, V10, P2438, DOI 10.1101/gad.10.19.2438; Darmoul D, 2003, AM J PATHOL, V162, P1503, DOI 10.1016/S0002-9440(10)64283-6; Dearth LR, 2007, CARCINOGENESIS, V28, P289, DOI 10.1093/carcin/bgl132; Di Agostino S, 2006, CANCER CELL, V10, P191, DOI 10.1016/j.ccr.2006.08.013; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; Even-Ram S, 1998, NAT MED, V4, P909, DOI 10.1038/nm0898-909; Even-Ram SC, 2001, J BIOL CHEM, V276, P10952, DOI 10.1074/jbc.M007027200; Farmer G, 1996, MOL CELL BIOL, V16, P4295; Hamroun D, 2006, HUM MUTAT, V27, P14, DOI 10.1002/humu.20269; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Ho J, 2003, CELL DEATH DIFFER, V10, P404, DOI 10.1038/sj.cdd.4401191; ISAACS WB, 1991, CANCER RES, V51, P4716; Joerger AC, 2007, ONCOGENE, V26, P2226, DOI 10.1038/sj.onc.1210291; Kastan MB, 2007, CELL, V128, P837, DOI 10.1016/j.cell.2007.02.022; Kato S, 2003, P NATL ACAD SCI USA, V100, P8424, DOI 10.1073/pnas.1431692100; Laptenko O, 2006, CELL DEATH DIFFER, V13, P951, DOI 10.1038/sj.cdd.4401916; Levine AJ, 2006, CELL DEATH DIFFER, V13, P1027, DOI 10.1038/sj.cdd.4401910; Li FZ, 1996, J BIOL CHEM, V271, P26320, DOI 10.1074/jbc.271.42.26320; Martins CP, 2006, CELL, V127, P1323, DOI 10.1016/j.cell.2006.12.007; Mayo LD, 2001, P NATL ACAD SCI USA, V98, P11598, DOI 10.1073/pnas.181181198; Menendez D, 2006, P NATL ACAD SCI USA, V103, P1406, DOI 10.1073/pnas.0508103103; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; MILNER J, 1991, MOL CELL BIOL, V11, P12, DOI 10.1128/MCB.11.1.12; Nystedt S, 1996, J BIOL CHEM, V271, P14910, DOI 10.1074/jbc.271.25.14910; Olivier M, 2002, HUM MUTAT, V19, P607, DOI 10.1002/humu.10081; Ossovskaya VS, 1996, P NATL ACAD SCI USA, V93, P10309, DOI 10.1073/pnas.93.19.10309; Prowald A, 2007, PROSTATE, V67, P1751, DOI 10.1002/pros.20660; Resnick MA, 2003, P NATL ACAD SCI USA, V100, P9934, DOI 10.1073/pnas.1633803100; Riewald M, 2005, J BIOL CHEM, V280, P19808, DOI 10.1074/jbc.M500747200; Salah Z, 2005, FASEB J, V19, P62, DOI 10.1096/fj.04-2386com; Salah Z, 2007, CANCER RES, V67, P9835, DOI 10.1158/0008-5472.CAN-07-1886; Salah Z, 2007, MOL CANCER RES, V5, P229, DOI 10.1158/1541-7786.MCR-06-0261; Schmidt VA, 1996, J BIOL CHEM, V271, P9307, DOI 10.1074/jbc.271.16.9307; Sharpless NE, 2007, NATURE, V445, P606, DOI 10.1038/nature05567; Sigal A, 2000, CANCER RES, V60, P6788; Soussi T, 2007, ONCOGENE, V26, P2145, DOI 10.1038/sj.onc.1210280; Strano S, 2007, ONCOGENE, V26, P2212, DOI 10.1038/sj.onc.1210296; Tellez C, 2003, J BIOL CHEM, V278, P46632, DOI 10.1074/jbc.M309159200; Vousden KH, 2007, NAT REV MOL CELL BIO, V8, P275, DOI 10.1038/nrm2147; Vousden KH, 2002, NAT REV CANCER, V2, P594, DOI 10.1038/nrc864; Weinberg RL, 2005, J MOL BIOL, V348, P589, DOI 10.1016/j.jmb.2005.03.014; Weisz L, 2004, CANCER RES, V64, P8318, DOI 10.1158/0008-5472.CAN-04-1145; Willis A, 2004, ONCOGENE, V23, P2330, DOI 10.1038/sj.onc.1207396; Wu SQ, 2002, BLOOD, V100, P4454, DOI 10.1182/blood-2002-02-0415; Yin YJ, 2003, FASEB J, V17, P163, DOI 10.1096/fj.02-0316com	53	17	17	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 20	2008	27	54					6866	6874		10.1038/onc.2008.324	http://dx.doi.org/10.1038/onc.2008.324			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	375IS	18820708				2022-12-28	WOS:000261108000007
J	Bettayeb, K; Oumata, N; Echalier, A; Ferandin, Y; Endicott, JA; Galons, H; Meijer, L				Bettayeb, K.; Oumata, N.; Echalier, A.; Ferandin, Y.; Endicott, J. A.; Galons, H.; Meijer, L.			CR8, a potent and selective, roscovitine-derived inhibitor of cyclin-dependent kinases	ONCOGENE			English	Article						cyclin-dependent kinase; kinase inhibitor; roscovitine; CR8; CDK9; cyclin	R-ROSCOVITINE; PROTEIN-KINASES; CELL-CYCLE; IN-VITRO; TARGETS; CYC202; CDC2; PHARMACOKINETICS; PHOSPHORYLATION; OLOMOUCINE	Among the ten pharmacological inhibitors of cyclin-dependent kinases (CDKs) currently in clinical trials, the purine roscovitine (CYC202, Seliciclib) is undergoing phase 2 trials against non-small-cell lung and nasopharyngeal cancers. An extensive medicinal chemistry study, designed to generate more potent analogues of roscovitine, led to the identification of an optimal substitution at the N6 position (compound CR8). An extensive selectivity study (108 kinases) highlights the exquisite selectivity of CR8 for CDK1/2/3/5/7/9. CR8 was 2- to 4-fold more potent than (R)-roscovitine at inhibiting these kinases. Cocrystal structures of (R)-CR8 and (R)-roscovitine with pCDK2/cyclin A showed that both inhibitors adopt essentially identical positions. The cellular effects of CR8 and (R)-roscovitine were investigated in human neuroblastoma SH-SY5Y cells. CR8 inhibited the phosphorylation of CDK1 and 9 substrates, with a 25-50 times higher potency compared to (R)-roscovitine. CR8 was consistently more potent than (R)-roscovitine at inducing apoptotic cell death parameters: 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium reduction ( 40-fold), lactate dehydrogenase release (35-fold), caspases activation (68-fold) and poly-(ADP-ribose) polymerase cleavage (50-fold). This improved cell death-inducing activity of CR8 over (R)-roscovitine was observed in 25 different cell lines. Altogether these results show that second-generation analogues of (R)-roscovitine can be designed with improved antitumor potential.	[Oumata, N.; Galons, H.] Univ Paris 05, INSERM, U648, Lab Chim Organ 2, F-75270 Paris 06, France; [Bettayeb, K.; Ferandin, Y.; Meijer, L.] CNRS, Cell Cycle Grp, Biol Stn, Bretagne, France; [Echalier, A.; Endicott, J. A.] Univ Oxford, Dept Biochem, Lab Mol Biophys, Oxford OX1 3QU, England	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Centre National de la Recherche Scientifique (CNRS); University of Oxford	Galons, H (corresponding author), Univ Paris 05, INSERM, U648, Lab Chim Organ 2, 4 Ave Observ, F-75270 Paris 06, France.	herve.galons@univ-paris5.fr; meijer@sb-roscoff.fr		, laurent/0000-0003-3511-4916; Endicott, Jane/0000-0003-4868-0116	EEC [FP6-2002]; 'Canceropole Grand-Ouest'; 'Institut National du Cancer' (INCa 'Cancer Detection d'innovations 20060); 'Association France-Alzheimer Finistere'; 'Ligue Nationale contre le Cancer (Comite du Finistere)'; 'Ministere de la Recherche'; Association pour la Recherche sur le Cancer; Institut National du Cancer	EEC; 'Canceropole Grand-Ouest'; 'Institut National du Cancer' (INCa 'Cancer Detection d'innovations 20060)(Institut National du Cancer (INCA) France); 'Association France-Alzheimer Finistere'; 'Ligue Nationale contre le Cancer (Comite du Finistere)'; 'Ministere de la Recherche'(Ministry of Science and Innovation, Spain (MICINN)Ministry of Research, France); Association pour la Recherche sur le Cancer(Fondation ARC pour la Recherche sur le CancerAustralian Research Council); Institut National du Cancer(Institut National du Cancer (INCA) France)	We are grateful to J Boix, C Guillouzo and J Mester for cell lines, G Ponzio for the human foreskin primary. broblasts, Dr Michael Kubbutat (ProQinase, Freiburg, Germany) and Sir Philip Cohen (Dundee, UK) for the selectivity panel assays and to the beamline scientists at the ESRF (ID14-EH-2 and ID14-EH-1) for providing excellent facilities for crystal data collection. This research was supported by grants from the EEC (FP6-2002-Life Sciences and Health, PRO-KINASE Research Project) (LM, JE), the 'Canceropole Grand-Ouest' grant (LM), the 'Institut National du Cancer' (INCa 'Cancer Detection d'innovations 20060) (LM), the 'Association France-Alzheimer Finistere' (LM) and the 'Ligue Nationale contre le Cancer (Comite du Finistere)' (LM). KB was supported by a fellowship from the 'Ministere de la Recherche' and from the 'Association pour la Recherche sur le Cancer'. NO benefited from a PhD fellowship from the 'Institut National du Cancer'. The structures of pCDK2/cyclin A/(R)-roscovitine, and pCDK2/cyclin A/(R)-CR8 have been deposited in the PDB with accession number codes 3DDQ and 3DDP, respectively.	Bach S, 2005, J BIOL CHEM, V280, P31208, DOI 10.1074/jbc.M500806200; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Bain J, 2003, BIOCHEM J, V371, P199, DOI 10.1042/BJ20021535; Bain J, 2007, BIOCHEM J, V408, P297, DOI 10.1042/BJ20070797; Becker F, 2004, CHEM BIOL, V11, P211, DOI 10.1016/j.chembiol.2004.02.001; Behrend L, 2000, ONCOGENE, V19, P5303, DOI 10.1038/sj.onc.1203939; Benson C, 2007, BRIT J CANCER, V96, P29, DOI 10.1038/sj.bjc.6603509; Brown NR, 1999, NAT CELL BIOL, V1, P438, DOI 10.1038/15674; Cai DP, 2006, CANCER RES, V66, P9270, DOI 10.1158/0008-5472.CAN-06-1758; Chang YT, 1999, CHEM BIOL, V6, P361, DOI 10.1016/S1074-5521(99)80048-9; de la Motte S, 2004, INT J CLIN PHARM TH, V42, P232; Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158; Fabian MA, 2005, NAT BIOTECHNOL, V23, P329, DOI 10.1038/nbt1068; Fischer PM, 2005, EXPERT OPIN INV DRUG, V14, P457, DOI 10.1517/13543784.14.4.457; Goga A, 2007, NAT MED, V13, P820, DOI 10.1038/nm1606; Gray NS, 1998, SCIENCE, V281, P533, DOI 10.1126/science.281.5376.533; Guzi Timothy, 2004, Curr Opin Investig Drugs, V5, P1311; Haesslein Jean-Luc, 2002, Current Topics in Medicinal Chemistry, V2, P1037, DOI 10.2174/1568026023393291; Hallaert DYH, 2007, CELL DEATH DIFFER, V14, P1958, DOI 10.1038/sj.cdd.4402211; Havlicek L, 1997, J MED CHEM, V40, P408, DOI 10.1021/jm960666x; Kapasi AJ, 2008, J VIROL, V82, P394, DOI 10.1128/JVI.01681-07; Knippschild U, 2005, ONKOLOGIE, V28, P508, DOI 10.1159/000087137; Knockaert M, 2002, TRENDS PHARMACOL SCI, V23, P417, DOI 10.1016/S0165-6147(02)02071-0; Kostich M, 2002, GENOME BIOL, V3; Kwon YG, 1997, P NATL ACAD SCI USA, V94, P2168, DOI 10.1073/pnas.94.6.2168; LANGSTON JW, 1983, SCIENCE, V219, P979, DOI 10.1126/science.6823561; Legraverend M, 2000, J MED CHEM, V43, P1282, DOI 10.1021/jm9911130; Malumbres M, 2005, TRENDS BIOCHEM SCI, V30, P630, DOI 10.1016/j.tibs.2005.09.005; Malumbres M, 2008, TRENDS PHARMACOL SCI, V29, P16, DOI 10.1016/j.tips.2007.10.012; Manning G, 2002, SCIENCE, V298, P1912, DOI 10.1126/science.1075762; McClue SJ, 2002, INT J CANCER, V102, P463, DOI 10.1002/ijc.10738; McClue SJ, 2008, DRUG METAB DISPOS, V36, P561, DOI 10.1124/dmd.107.019232; Meijer L, 1997, EUR J BIOCHEM, V243, P527, DOI 10.1111/j.1432-1033.1997.t01-2-00527.x; Meijer L, 2003, ACCOUNTS CHEM RES, V36, P417, DOI 10.1021/ar0201198; Meijer L, 2006, MONOGRAPHS ENZYME IN, V2, P187; Misra RN, 2006, DRUG FUTURE, V31, P43, DOI 10.1358/dof.2006.031.01.953584; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Niedner RH, 2006, PROTEINS, V63, P78, DOI 10.1002/prot.20825; Nutley BP, 2005, MOL CANCER THER, V4, P125; OUMATA N, 2008, J MED CHEM IN PRESS; Payton M, 2006, CANCER RES, V66, P4299, DOI 10.1158/0008-5472.CAN-05-2507; Raynaud FI, 2005, CLIN CANCER RES, V11, P4875, DOI 10.1158/1078-0432.CCR-04-2264; Reinhardt J, 2007, PROTEIN EXPRES PURIF, V54, P101, DOI 10.1016/j.pep.2007.02.020; Ribas J, 2006, ONCOGENE, V25, P6304, DOI 10.1038/sj.onc.1209648; Ribas J, 2004, EXP CELL RES, V295, P9, DOI 10.1016/j.yexcr.2003.12.019; Ribas J, 2006, EXP CELL RES, V312, P2394, DOI 10.1016/j.yexcr.2006.04.021; Shapiro GI, 2006, J CLIN ONCOL, V24, P1770, DOI 10.1200/JCO.2005.03.7689; SMITH PJ, 2006, CDK INHIBITORS CYCLI, V2; Tang L, 2005, J BIOL CHEM, V280, P31220, DOI 10.1074/jbc.M500805200; Vandromme L, 2006, BIOORG MED CHEM LETT, V16, P3144, DOI 10.1016/j.bmcl.2006.03.060; Vita M, 2005, EUR J PHARM SCI, V25, P91, DOI 10.1016/j.ejps.2005.02.001	51	141	144	1	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 2	2008	27	44					5797	5807		10.1038/onc.2008.191	http://dx.doi.org/10.1038/onc.2008.191			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	355QC	18574471				2022-12-28	WOS:000259722400004
J	Impera, L; Albano, F; Lo Cunsolo, C; Funes, S; Iuzzolino, P; Laveder, F; Panagopoulos, I; Rocchi, M; Storlazzi, CT				Impera, L.; Albano, F.; Lo Cunsolo, C.; Funes, S.; Iuzzolino, P.; Laveder, F.; Panagopoulos, I.; Rocchi, M.; Storlazzi, C. T.			A novel fusion 5 ' AFF3/3 ' BCL2 originated from a t(2;18)(q11.2;q21.33) translocation in follicular lymphoma	ONCOGENE			English	Article						AFF3; BCL2; fusion gene; follicular lymphoma; translocation	ACUTE LYMPHOBLASTIC-LEUKEMIA; GENE; BREAKPOINTS; BCL2; LAF4; MLL	Follicular lymphoma is the second most frequent type of non-Hodgkin's lymphoma in adults. The basic molecular defect consists of the t(14;18)(q32;q21) translocation, juxtaposing the B-cell lymphoma protein 2 gene BCL2 to the immunoglobulin heavy chain locus IGH@, and leading to the antiapoptotic BCL2 protein overproduction. Variations in the t(14;18) are rare and can be classified into two categories: (i) simple variants, involving chromosomes 18 and 2, or 22, in which the fusion partner of BCL2 is the light-chain IGK@ or IGL@; (ii) complex variant translocations occurring among chromosomes 14, 18 and other chromosomes. We report a follicular lymphoma case showing BCL2 overexpression, detected by immunohistochemistry and real-time quantitative PCR, consequently to the formation of a novel fusion gene between the 5' of the lymphoid nuclear transcriptional activator gene AFF3 at 2q11.2, and the 3' of BCL2. This case shows evidence, for the first time, of BCL2 overexpression consequently to the fusion of BCL2 to a non-IG partner locus.	[Impera, L.; Rocchi, M.; Storlazzi, C. T.] Univ Bari, Dept Genet & Microbiol, I-70126 Bari, Italy; [Albano, F.] Univ Bari, Sect Hematol, Dept Pathol, I-70126 Bari, Italy; [Lo Cunsolo, C.; Funes, S.; Iuzzolino, P.] Osped San Martino Genova, Dipartimento Med Lab, Belluno, Italy; [Laveder, F.] Osped San Martino Genova, Dipartimento Discipline Med, Belluno, Italy; [Panagopoulos, I.] Univ Lund Hosp, Dept Clin Genet, S-22185 Lund, Sweden	Universita degli Studi di Bari Aldo Moro; Universita degli Studi di Bari Aldo Moro; ULSS 1 Dolomiti; Ospedale di Belluno; University of Genoa; IRCCS AOU San Martino IST; ULSS 1 Dolomiti; Ospedale di Belluno; University of Genoa; IRCCS AOU San Martino IST; Lund University; Skane University Hospital	Storlazzi, CT (corresponding author), Univ Bari, Dept Genet & Microbiol, Via Amendola 165-A, I-70126 Bari, Italy.	c.storlazzi@biologia.uniba.it	Albano, Francesco/J-2352-2016	Albano, Francesco/0000-0001-7926-6052; Rocchi, Mariano/0000-0002-9451-5616; Storlazzi, Clelia Tiziana/0000-0002-1696-0028; Panagopoulos, Ioannis/0000-0003-2159-5341	AIRC (Associazione Italiana per la Ricerca sul Cancro); MiUR (Ministero dell'Istruzione, dell'Universita e della Ricerca)	AIRC (Associazione Italiana per la Ricerca sul Cancro)(Fondazione AIRC per la ricerca sul cancro); MiUR (Ministero dell'Istruzione, dell'Universita e della Ricerca)(Ministry of Education, Universities and Research (MIUR))	We thank Dr Maria Corsignano Guastadisegni for her contribution to the study, and Professor Roscoe Stanyon for language revision of an earlier version. This study has been supported by the AIRC (Associazione Italiana per la Ricerca sul Cancro), and the MiUR (Ministero dell'Istruzione, dell'Universita e della Ricerca).	Bentley G, 2005, CANCER GENET CYTOGEN, V157, P12, DOI 10.1016/j.cancergencyto.2004.05.012; Chinen Y, 2008, ONCOGENE, V27, P2249, DOI 10.1038/sj.onc.1210857; de Jong D, 2005, J CLIN ONCOL, V23, P6358, DOI 10.1200/JCO.2005.26.856; Hiwatari M, 2003, ONCOGENE, V22, P2851, DOI 10.1038/sj.onc.1206389; Mahmoodi M, 2004, CANCER GENET CYTOGEN, V154, P160, DOI 10.1016/j.cancergencyto.2004.02.008; Storlazzi CT, 2007, LEUKEMIA, V21, P2221, DOI 10.1038/sj.leu.2404784; Weinberg OK, 2007, J MOL DIAGN, V9, P530, DOI 10.2353/jmoldx.2007.070038; Yonetani N, 2001, JPN J CANCER RES, V92, P933, DOI 10.1111/j.1349-7006.2001.tb01183.x	8	6	6	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT	2008	27	47					6187	6190		10.1038/onc.2008.214	http://dx.doi.org/10.1038/onc.2008.214			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	360UJ	18622426	Green Submitted			2022-12-28	WOS:000260083100011
J	Liao, YL; Sun, YM; Chau, GY; Chau, YP; Lai, TC; Wang, JL; Horng, JT; Hsiao, M; Tsou, AP				Liao, Y-L; Sun, Y-M; Chau, G-Y; Chau, Y-P; Lai, T-C; Wang, J-L; Horng, J-T; Hsiao, M.; Tsou, A-P			Identification of SOX4 target genes using phylogenetic footprinting-based prediction from expression microarrays suggests that overexpression of SOX4 potentiates metastasis in hepatocellular carcinoma	ONCOGENE			English	Article						SOX4; HCC metastasis; synexpression; target prediction	BREAST-CANCER METASTASIS; TRANSCRIPTIONAL REGULATION; MOUSE GENOME; CELLS; MICE; GUIDANCE; FAMILY; SYNEXPRESSION; NEOPLASMS; PROTEINS	A comprehensive microarray analysis of hepatocellular carcinoma (HCC) revealed distinct synexpression patterns during intrahepatic metastasis. Recent evidence has demonstrated that synexpression group member genes are likely to be regulated by master control gene(s). Here we investigate the functions and gene regulation of the transcription factor SOX4 in intrahepatic metastatic HCC. SOX4 is important in tumor metastasis as RNAi knockdown reduces tumor cell migration, invasion, in vivo tumorigenesis and metastasis. A multifaceted approach integrating gene pro. ling, binding site computation and empirical veri. cation by chromatin immunoprecipitation and gene ablation refined the consensus SOX4 binding motif and identified 32 binding loci in 31 genes with high confidence. RNAi knockdown of two SOX4 target genes, neuropilin 1 and semaphorin 3C, drastically reduced cell migration activity in HCC cell lines suggesting that SOX4 exerts some of its action via regulation of these two downstream targets. The discovery of 31 previously unidentified targets expands our knowledge of how SOX4 modulates HCC progression and implies a range of novel SOX4 functions. This integrated approach sets a paradigm whereby a subset of member genes from a synexpression group can be regulated by one master control gene and this is exemplified by SOX4 and advanced HCC.	[Liao, Y-L; Tsou, A-P] Natl Yang Ming Univ, Dept Biotechnol & Lab Sci Med, Taipei 112, Taiwan; [Sun, Y-M; Horng, J-T] Natl Cent Univ, Inst Comp Sci & Informat Engn, Chungli 32054, Taiwan; [Chau, G-Y] Taipei Vet Gen Hosp, Dept Surg, Taipei, Taiwan; [Chau, Y-P] Natl Yang Ming Univ, Inst Anat & Cell Biol, Taipei 112, Taiwan; [Lai, T-C; Wang, J-L; Hsiao, M.] Acad Sinica, Genom Res Ctr, Taipei 115, Taiwan	National Yang Ming Chiao Tung University; National Central University; Taipei Veterans General Hospital; National Yang Ming Chiao Tung University; Academia Sinica - Taiwan	Tsou, AP (corresponding author), Natl Yang Ming Univ, Dept Biotechnol & Lab Sci Med, Taipei 112, Taiwan.	horng@db.csie.ncu.edu.tw; mhsiao@gate.sinica.edu.tw; aptsou@ym.edu.tw	Lai, Tsung-Ching/AAQ-9967-2021; Hsiao, Michael/U-6238-2019	Hsiao, Michael/0000-0001-8529-9213	National Research Program for Genomic Medicine (NRPGM); National Science Council; National Research Program for Genomic Medicine [NSC 94-3112-B-001-003, NSC 94-3112-B-001-018-Y]; National Science Council [NSC 95-2752-B-010-002-PAE]; Ministry of Education	National Research Program for Genomic Medicine (NRPGM)(Ministry of Science and Technology, Taiwan); National Science Council(Ministry of Science and Technology, Taiwan); National Research Program for Genomic Medicine(Ministry of Science and Technology, Taiwan); National Science Council(Ministry of Science and Technology, Taiwan); Ministry of Education	We acknowledge the technical supports provided by the Microarray & Gene Expression Analysis Core Facility of the VGH National Yang-Ming University Genome Research Center (VYMGC). The Gene Expression Analysis Core Facility is supported by National Research Program for Genomic Medicine (NRPGM), National Science Council. RNAi reagents were obtained from the National RNAi Core Facility located at the Institute of Molecular Biology/Genomic Research Center, Academia Sinica (supported by the National Research Program for Genomic Medicine Grants of NSC (NSC 94-3112-B-001-003 and NSC 94-3112-B-001-018-Y). We thank Dr Hua-Chien Chen for providing the PCR primers for the RT-qPCR assays. This work was supported in part by grant (NSC 95-2752-B-010-002-PAE) from National Science Council (Program for Promoting Academic Excellence of Universities Phase II) and a grant from the Ministry of Education, Aim for the Top University Plan to APT and YPC.	Aaboe M, 2006, CANCER RES, V66, P3434, DOI 10.1158/0008-5472.CAN-05-3456; ATTIA MAM, 1966, CANCER RES, V26, P1787; Bielenberg DR, 2006, EXP CELL RES, V312, P584, DOI 10.1016/j.yexcr.2005.11.024; Bowles J, 2000, DEV BIOL, V227, P239, DOI 10.1006/dbio.2000.9883; Chau GY, 2007, HISTOPATHOLOGY, V51, P204, DOI 10.1111/j.1365-2559.2007.02738.x; Chen X, 2002, MOL BIOL CELL, V13, P1929, DOI 10.1091/mbc.02-02-0023; Cheung M, 2000, MOL BRAIN RES, V79, P180, DOI 10.1016/S0169-328X(00)00109-1; El-Serag HB, 2007, GASTROENTEROLOGY, V132, P2557, DOI 10.1053/j.gastro.2007.04.061; Fickett JW, 2000, CURR OPIN BIOTECH, V11, P19, DOI 10.1016/S0958-1669(99)00049-X; Geijsen N, 2001, SCIENCE, V293, P1136, DOI 10.1126/science.1059157; Gonthier B, 2007, CEREB CORTEX, V17, P1712, DOI 10.1093/cercor/bhl082; Grizzi F, 2007, J TRANSL MED, V5, DOI 10.1186/1479-5876-5-3; Guan KL, 2003, NAT REV NEUROSCI, V4, P941, DOI 10.1038/nrn1254; Hardison RC, 1997, GENOME RES, V7, P959, DOI 10.1101/gr.7.10.959; He ZG, 1997, CELL, V90, P739, DOI 10.1016/S0092-8674(00)80534-6; Herman JG, 2007, INT J ONCOL, V30, P1231; Hong TM, 2007, CLIN CANCER RES, V13, P4759, DOI 10.1158/1078-0432.CCR-07-0001; Hunt SMN, 1999, BIOL REPROD, V61, P476, DOI 10.1095/biolreprod61.2.476; Hur EH, 2004, BIOCHEM BIOPH RES CO, V325, P59, DOI 10.1016/j.bbrc.2004.09.215; Kamachi Y, 2000, TRENDS GENET, V16, P182, DOI 10.1016/S0168-9525(99)01955-1; Kang YB, 2003, CANCER CELL, V3, P537, DOI 10.1016/S1535-6108(03)00132-6; Karaulanov E, 2004, EMBO J, V23, P844, DOI 10.1038/sj.emboj.7600101; Kim Y, 2005, TOXICOL PATHOL, V33, P175, DOI 10.1080/01926230590522130; Lee YC, 2003, J BIOL CHEM, V278, P39615, DOI 10.1074/jbc.M304095200; Liu PB, 2006, CANCER RES, V66, P4011, DOI 10.1158/0008-5472.CAN-05-3055; Lu YS, 2007, HEPATOLOGY, V46, P1119, DOI 10.1002/hep.21804; Maes T, 2002, GENOMICS, V80, P21, DOI 10.1006/geno.2002.6799; McCracken S, 1997, ONCOGENE, V15, P2929, DOI 10.1038/sj.onc.1201474; Mertin S, 1999, NUCLEIC ACIDS RES, V27, P1359, DOI 10.1093/nar/27.5.1359; Minn AJ, 2005, NATURE, V436, P518, DOI 10.1038/nature03799; Nelson JD, 2006, NUCLEIC ACIDS RES, V34, DOI 10.1093/nar/gnj004; Niehrs C, 1999, NATURE, V402, P483, DOI 10.1038/990025; Paget S., 1889, LANCET, V1, P571, DOI DOI 10.1016/S0140-6736(00)49915-0; Pramoonjago P, 2006, ONCOGENE, V25, P5626, DOI 10.1038/sj.onc.1209566; Remenyi A, 2004, NAT STRUCT MOL BIOL, V11, P812, DOI 10.1038/nsmb820; Schilham MW, 1996, NATURE, V380, P711, DOI 10.1038/380711a0; SHOUVAL D, 1988, VIRCHOWS ARCH A, V412, P595, DOI 10.1007/BF00844296; Tang ZY, 2004, J CANCER RES CLIN, V130, P187, DOI 10.1007/s00432-003-0511-1; Tavazoie SF, 2008, NATURE, V451, P147, DOI 10.1038/nature06487; VANDEWETERING M, 1993, EMBO J, V12, P3847, DOI 10.1002/j.1460-2075.1993.tb06063.x; Wasserman WW, 2000, NAT GENET, V26, P225, DOI 10.1038/79965; Wilson M, 2002, CURR OPIN GENET DEV, V12, P441, DOI 10.1016/S0959-437X(02)00323-4; WOTTON D, 1995, J BIOL CHEM, V270, P7515, DOI 10.1074/jbc.270.13.7515; Ya J, 1998, CIRC RES, V83, P986, DOI 10.1161/01.RES.83.10.986; Ye QH, 2003, NAT MED, V9, P416, DOI 10.1038/nm843	45	162	171	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 18	2008	27	42					5578	5589		10.1038/onc.2008.168	http://dx.doi.org/10.1038/onc.2008.168			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	349KX	18504433				2022-12-28	WOS:000259280800004
J	Fornari, F; Gramantieri, L; Ferracin, M; Veronese, A; Sabbioni, S; Calin, GA; Grazi, GL; Giovannini, C; Croce, CM; Bolondi, L; Negrini, M				Fornari, F.; Gramantieri, L.; Ferracin, M.; Veronese, A.; Sabbioni, S.; Calin, G. A.; Grazi, G. L.; Giovannini, C.; Croce, C. M.; Bolondi, L.; Negrini, M.			MiR-221 controls CDKN1C/p57 and CDKN1B/p27 expression in human hepatocellular carcinoma	ONCOGENE			English	Article						microRNA; cyclin-dependent kinase inhibitors; HCC	P27(KIP1); MICRORNAS; P57(KIP2); DIFFERENTIATION; PROTEIN; CANCER; PROLIFERATION; APOPTOSIS; LIVER	The identification of target mRNAs is a key step for assessing the role of aberrantly expressed microRNAs in human cancer. MiR-221 is upregulated in human hepatocellular carcinoma (HCC) as well as in other malignancies. One proven target of miR-221 is CDKN1B/p27, whose downregulation affects HCC prognosis. Here, we proved that the cyclin-dependent kinase inhibitor (CDKI) CDKN1C/p57 is also a direct target of miR-221. Indeed, downregulation of both CDKN1B/p27 and CDKN1C/p57 occurs in response to miR-221 transfection into HCC-derived cells and a significant upregulation of both CDKN1B/p27 and CDKN1C/p57 occurs in response to antimiR-221 transfection. A direct interaction of miR-221 with a target site on the 30 UTR of CDKN1C/p57 mRNA was also demonstrated. By controlling these two CDKIs, upregulation of miR-221 can promote growth of HCC cells by increasing the number of cells in S-phase. To assess the relevance of these studies in primary tumors, matched HCC and cirrhosis samples were assayed for miR-221, for CDKN1B/p27 and CDKN1C/p57 expression. MiR-221 was upregulated in 71% of HCCs, whereas CDKN1B/p27 and CDKN1C/p57 proteins were down-regulated in 77% of cases. A significant inverse correlation between miR-221 and both CDKN1B/p27 and CDKN1C/p57 was found in HCCs. In conclusion, we suggest that miR-221 has an oncogenic function in hepatocarcinogenesis by targeting CDKN1B/p27 and CDKN1C/p57, hence promoting proliferation by controlling cell-cycle inhibitors. These findings establish a basis toward the development of therapeutic strategies aimed at blocking miR-221 in HCC.	[Fornari, F.; Gramantieri, L.; Giovannini, C.; Bolondi, L.] Univ Bologna, Dipartimento Med Interna & Gastroenterol, Policlin S Orsola, I-40138 Bologna, Italy; [Fornari, F.; Gramantieri, L.; Giovannini, C.; Bolondi, L.] Univ Bologna, Ctr Ric Biomed Appl, Policlin S Orsola, I-40138 Bologna, Italy; [Ferracin, M.; Veronese, A.; Sabbioni, S.; Croce, C. M.; Negrini, M.] Univ Ferrara, Dipartimento Med Sperimentale & Diagnost, I-44100 Ferrara, Italy; [Ferracin, M.; Veronese, A.; Sabbioni, S.; Croce, C. M.; Negrini, M.] Univ Ferrara, Ctr Interdipartimentale Ric Cancro, I-44100 Ferrara, Italy; [Calin, G. A.] Univ Texas MD Anderson Canc Ctr, Dept Expt Therapeut, Houston, TX 77030 USA; [Grazi, G. L.] Univ Bologna, Dipartimento Chirurg & Trapianti, Policlin S Orsola, Bologna, Italy; [Croce, C. M.] Ohio State Univ, Ctr Comprehens Canc, Columbus, OH 43210 USA	IRCCS Azienda Ospedaliero-Universitaria di Bologna; University of Bologna; IRCCS Azienda Ospedaliero-Universitaria di Bologna; University of Bologna; University of Ferrara; University of Ferrara; University of Texas System; UTMD Anderson Cancer Center; IRCCS Azienda Ospedaliero-Universitaria di Bologna; University of Bologna; James Cancer Hospital & Solove Research Institute; University System of Ohio; Ohio State University	Gramantieri, L (corresponding author), Univ Bologna, Dipartimento Med Interna & Gastroenterol, Policlin S Orsola, Via Massarenti 9, I-40138 Bologna, Italy.	laura.gramantieri@aosp.bo.it; ngm@unife.it	Ferracin, Manuela/K-2097-2016; Young, Richard A/F-6495-2012; Calin, George/E-9390-2011; Negrini, Massimo/J-2377-2016; Grazi, Gian Luca/J-7215-2018; Gramantieri, Laura/J-3862-2019; Fornari, Francesca/K-6748-2016; Gramantieri, Laura/K-8603-2016; Veronese, Angelo/I-4292-2019; Giovannini, Catia/K-7853-2016	Ferracin, Manuela/0000-0002-1595-6887; Young, Richard A/0000-0001-8855-8647; Negrini, Massimo/0000-0002-0007-1920; Grazi, Gian Luca/0000-0002-3279-0313; Gramantieri, Laura/0000-0002-5187-9559; Giovannini, Catia/0000-0003-1904-1577; Veronese, Angelo/0000-0002-1451-1392; Calin, George/0000-0001-6704-5615; Fornari, Francesca/0000-0002-4302-4411	Associazione Italiana per la Ricerca sul Cancro (AIRC); Italian Ministero dell' Universita e della Ricerca Scientifica; Italian Ministero della Salute; Fondazione CARISBO; National Cancer Institute; Kimmel Foundation Scholar; Fondazione Italiana per la Ricerca sul Cancro (FIRC)	Associazione Italiana per la Ricerca sul Cancro (AIRC)(Fondazione AIRC per la ricerca sul cancro); Italian Ministero dell' Universita e della Ricerca Scientifica(Ministry of Education, Universities and Research (MIUR)); Italian Ministero della Salute(Ministry of Health, Italy); Fondazione CARISBO(Fondazione Carisbo); National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Kimmel Foundation Scholar; Fondazione Italiana per la Ricerca sul Cancro (FIRC)(Fondazione AIRC per la ricerca sul cancro)	This work was supported by Associazione Italiana per la Ricerca sul Cancro (AIRC regional grant), by grants from Italian Ministero dell' Universita e della Ricerca Scientifica and from Italian Ministero della Salute to MN; by Associazione Italiana per la Ricerca sul Cancro (AIRC regional grant) and Fondazione CARISBO to LB and by Program Project Grants from the National Cancer Institute to CMC and by a Kimmel Foundation Scholar award to GAC. FF is a recipient of a fellowship from Associazione Italiana per la Ricerca sul Cancro (AIRC) and MF is a recipient of a fellowship from Fondazione Italiana per la Ricerca sul Cancro (FIRC).	Abou-Alfa GK, 2006, J CLIN ONCOL, V24, P4293, DOI 10.1200/JCO.2005.01.3441; Bolondi L, 2003, J HEPATOL, V39, P1076, DOI 10.1016/S0168-8278(03)00349-0; Bosch FX, 2004, GASTROENTEROLOGY, V127, pS5, DOI 10.1053/j.gastro.2004.09.011; Bruix J, 2005, HEPATOLOGY, V42, P1208, DOI 10.1002/hep.20933; Calin GA, 2006, NAT REV CANCER, V6, P857, DOI 10.1038/nrc1997; Ciafre SA, 2005, BIOCHEM BIOPH RES CO, V334, P1351, DOI 10.1016/j.bbrc.2005.07.030; Cimmino A, 2005, P NATL ACAD SCI USA, V102, P13944, DOI 10.1073/pnas.0506654102; Diaz-Meyer N, 2003, J MED GENET, V40, P797, DOI 10.1136/jmg.40.11.797; EDMONDSON HA, 1954, CANCER-AM CANCER SOC, V7, P462, DOI 10.1002/1097-0142(195405)7:3<462::AID-CNCR2820070308>3.0.CO;2-E; Felli N, 2005, P NATL ACAD SCI USA, V102, P18081, DOI 10.1073/pnas.0506216102; Galardi S, 2007, J BIOL CHEM, V282, P23716, DOI 10.1074/jbc.M701805200; Gillies JK, 2007, CELL CYCLE, V6, P2005, DOI 10.4161/cc.6.16.4526; Gottardo F, 2007, UROL ONCOL-SEMIN ORI, V25, P387, DOI 10.1016/j.urolonc.2007.01.019; Gramantieri L, 2007, CANCER RES, V67, P6092, DOI 10.1158/0008-5472.CAN-06-4607; He HL, 2005, P NATL ACAD SCI USA, V102, P19075, DOI 10.1073/pnas.0509603102; Hui AM, 1998, CANCER LETT, V132, P67, DOI 10.1016/S0304-3835(98)00164-5; Ito Y, 2001, ONCOLOGY-BASEL, V61, P221, DOI 10.1159/000055378; Johnson SM, 2005, CELL, V120, P635, DOI 10.1016/j.cell.2005.01.014; Krutzfeldt J, 2005, NATURE, V438, P685, DOI 10.1038/nature04303; le Sage C, 2007, EMBO J, V26, P3699, DOI 10.1038/sj.emboj.7601790; Lee EJ, 2007, INT J CANCER, V120, P1046, DOI 10.1002/ijc.22394; Lee MH, 2001, CELL MOL LIFE SCI, V58, P1907, DOI 10.1007/PL00000826; Lei PP, 2005, WORLD J GASTROENTERO, V11, P4587, DOI 10.3748/wjg.v11.i29.4587; Lencioni R, 2005, SEMIN LIVER DIS, V25, P162, DOI 10.1055/s-2005-871196; LLOVET JM, 2007, ASCO M CHIC; Nakai S, 2002, INT J ONCOL, V20, P769; Nan KJ, 2005, WORLD J GASTROENTERO, V11, P1237, DOI 10.3748/wjg.v11.i8.1237; Nan KJ, 2004, WORLD J GASTROENTERO, V10, P1425; Negrini M, 2007, J CELL SCI, V120, P1833, DOI 10.1242/jcs.03450; O'Donnell KA, 2005, NATURE, V435, P839, DOI 10.1038/nature03677; Sangiovanni A, 2004, GASTROENTEROLOGY, V126, P1005, DOI 10.1053/j.gastro.2003.12.049; Schwienbacher C, 2000, P NATL ACAD SCI USA, V97, P5445, DOI 10.1073/pnas.090087497; Soejima H, 2004, ONCOGENE, V23, P4380, DOI 10.1038/sj.onc.1207576; Tannapfel A, 2000, INT J CANCER, V89, P350, DOI 10.1002/1097-0215(20000720)89:4<350::AID-IJC6>3.0.CO;2-3; Visone R, 2007, ENDOCR-RELAT CANCER, V14, P791, DOI 10.1677/ERC-07-0129; Yan Y, 1997, GENE DEV, V11, P973, DOI 10.1101/gad.11.8.973; Zhang PM, 1997, NATURE, V387, P151, DOI 10.1038/387151a0	37	499	548	0	27	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP	2008	27	43					5651	5661		10.1038/onc.2008.178	http://dx.doi.org/10.1038/onc.2008.178			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	352HM	18521080				2022-12-28	WOS:000259487100001
J	Aghi, M; Visted, T; DePinho, RA; Chiocca, EA				Aghi, M.; Visted, T.; DePinho, R. A.; Chiocca, E. A.			Oncolytic herpes virus with defective ICP6 specifically replicates in quiescent cells with homozygous genetic mutations in p16	ONCOGENE			English	Article						oncolytic virus; gene therapy; glioma; brain tumor; mechanism of replication; tumor-suppressor gene	RIBONUCLEOTIDE REDUCTASE; GLIOBLASTOMA-MULTIFORME; HUMAN GLIOMAS; THERAPY; CANCER; PATHWAY; DELETION; KINASE; MUTANT; PERMISSIVENESS	Oncolytic herpes simplex viruses (HSVs), in clinical trials for the treatment of malignant gliomas, are assumed to be selective for tumor cells because their replication is strongly attenuated in quiescent cells, but not in cycling cells. Oncolytic selectivity is thought to occur because mutations in viral ICP6 (encoding a viral ribonucleotide reductase function) and/or gamma 34.5 function are respectively complemented by mammalian ribonucleotide reductase and GADD34, whose genes are expressed in cycling cells. However, it is estimated that only 5-15% of malignant glioma cells are in mitosis at any one time. Therefore, effective replication of HSV oncolytic viruses might be limited to a subpopulation of tumor cells, since at any one time the majority of tumor cells would not be cycling. However, we report that an HSV with defective ICP6 function replicates in quiescent cultured murine embryonic fibroblasts obtained from mice with homozygous p16 deletions. Furthermore, intracranial inoculation of this virus into the brains of p16-/- mice provides evidence of viral replication that does not occur when the virus is injected into the brains of wild-type mice. These approaches provide in vitro and in vivo evidence that ICP6-negative HSVs are 'molecularly targeted,' because they replicate in quiescent tumor cells carrying specific oncogene deletions, independent of cell cycle status.	[Chiocca, E. A.] Ohio State Univ, Dept Neurosurg, Med Ctr, Dardinger Lab Neurooncol & Neurosci, Columbus, OH 43210 USA; [Chiocca, E. A.] Ohio State Univ, James Comprehens Canc Ctr, Med Ctr, Columbus, OH 43210 USA; [Aghi, M.; Visted, T.] Massachusetts Gen Hosp, Dept Neurosurg, Boston, MA 02114 USA; [DePinho, R. A.] Harvard Univ, Sch Med,Belfer Inst Innovat Canc Sci, Dana Farber Canc Inst,Ctr Appl Canc sci, Dept Med Oncol & Med Genet, Boston, MA 02115 USA	University System of Ohio; Ohio State University; James Cancer Hospital & Solove Research Institute; University System of Ohio; Ohio State University; Harvard University; Massachusetts General Hospital; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School	Chiocca, EA (corresponding author), Ohio State Univ, Dept Neurosurg, Med Ctr, Dardinger Lab Neurooncol & Neurosci, Wiseman Hall,400 W 10th Ave, Columbus, OH 43210 USA.	EA.Chiocca@osumc.edu		DePinho, Ronald/0000-0002-5625-577X	NATIONAL CANCER INSTITUTE [P01CA069246, P01CA095616, R01CA084628, R01CA085139] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS041571] Funding Source: NIH RePORTER; NCI NIH HHS [U01 CA084628, R01 CA85139, R01 CA085139, P01 CA69246, R01 CA084628, P01 CA069246, P01 CA095616] Funding Source: Medline; NINDS NIH HHS [R01 NS41571, R01 NS041571] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Aghi M, 2005, ONCOGENE, V24, P7802, DOI 10.1038/sj.onc.1209037; Burns KL, 1998, J NEUROPATH EXP NEUR, V57, P122, DOI 10.1097/00005072-199802000-00003; Costello JF, 1996, CANCER RES, V56, P2405; ELLEDGE SJ, 1992, TRENDS BIOCHEM SCI, V17, P119, DOI 10.1016/0968-0004(92)90249-9; Farassati F, 2001, NAT CELL BIOL, V3, P745, DOI 10.1038/35087061; Finney D.J., 1971, PROBIT ANAL; Fu XP, 2006, MOL THER, V13, P882, DOI 10.1016/j.ymthe.2006.02.007; GOLDSTEIN DJ, 1988, VIROLOGY, V166, P41, DOI 10.1016/0042-6822(88)90144-4; GrayBablin J, 1997, CANCER RES, V57, P604; HOSHINO T, 1989, J NEUROSURG, V71, P335, DOI 10.3171/jns.1989.71.3.0335; Ikeda K, 1999, NAT MED, V5, P881, DOI 10.1038/11320; Jiang H, 2005, NEOPLASIA, V7, P48, DOI 10.1593/neo.04391; Kamiryo T, 2002, J NEUROSURG, V96, P815, DOI 10.3171/jns.2002.96.5.0815; Kirn D, 2001, NAT MED, V7, P781, DOI 10.1038/89901; Komata T, 2000, GENE THER, V7, P2071, DOI 10.1038/sj.gt.3301327; McCart JA, 2001, CANCER RES, V61, P8751; Nakamura M, 1998, Brain Tumor Pathol, V15, P83, DOI 10.1007/BF02478888; Nakamura T, 2005, NAT BIOTECHNOL, V23, P209, DOI 10.1038/nbt1060; Norman KL, 2004, P NATL ACAD SCI USA, V101, P11099, DOI 10.1073/pnas.0404310101; O'Shea CC, 2005, CANCER CELL, V8, P61, DOI 10.1016/j.ccr.2005.06.009; Ohgaki H, 2007, AM J PATHOL, V170, P1445, DOI 10.2353/ajpath.2007.070011; Ono Y, 1996, J NEUROPATH EXP NEUR, V55, P1026, DOI 10.1097/00005072-199655100-00002; Sharpless NE, 2001, NATURE, V413, P86, DOI 10.1038/35092592; Smith KD, 2006, J VIROL, V80, P1110, DOI 10.1128/JVI.80.3.1110-1120.2006; Stojdl DF, 2000, NAT MED, V6, P821, DOI 10.1038/77558; Ueki K, 1996, CANCER RES, V56, P150; Wang CC, 2006, CANCER RES, V66, P6756, DOI 10.1158/0008-5472.CAN-06-0185; Watanabe T, 2001, ACTA NEUROPATHOL, V101, P185; Wein LM, 2003, CANCER RES, V63, P1317; Wurdinger T, 2005, GENE THER, V12, P1394, DOI 10.1038/sj.gt.3302535; Yoon SS, 1999, J GASTROINTEST SURG, V3, P34, DOI 10.1016/S1091-255X(99)80005-5	31	63	70	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL	2008	27	30					4249	4254		10.1038/onc.2008.53	http://dx.doi.org/10.1038/onc.2008.53			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	324DB	18345032	Green Published, Bronze, Green Submitted			2022-12-28	WOS:000257496800012
J	Pickering, MT; Stadler, BM; Kowalik, TF				Pickering, M. T.; Stadler, B. M.; Kowalik, T. F.			miR-17 and miR-20a temper an E2F1-induced G1 checkpoint to regulate cell cycle progression	ONCOGENE			English	Article						checkpoint; DNA damage; E2F1; miRNA	DOUBLE-STRAND BREAKS; E2F1 TRANSCRIPTION FACTOR; GEL-ELECTROPHORESIS; DNA; APOPTOSIS; PHOSPHORYLATION; EXPRESSION; MICRORNAS; ONCOGENE; CANCERS	The stringent regulation of cell cycle progression helps to maintain genetic stability in cells. MicroRNAs (miRNAs) are critical regulators of gene expression in diverse cellular pathways, including developmental patterning, hematopoietic differentiation and antiviral defense. Here, we show that two c-Myc-regulated miRNAs, miR-17 and miR-20a, govern the transition through G1 in normal diploid human cells. Inhibition of these miRNAs leads to a G1 checkpoint due to an accumulation of DNA double-strand breaks, resulting from premature temporal accumulation of the E2F1 transcription factor. Surprisingly, gross changes in E2F1 levels were not required to initiate the DNA damage response and checkpoint, as these responses could occur with a less than twofold change in E2F1 protein levels. Instead, our findings indicate that the precise timing of E2F1 expression dictates S-phase entry and that accurate timing of E2F1 accumulation requires converging signals from the Rb/E2F pathway and the c-Myc-regulated miR-17 and miR-20a miRNAs to circumvent a G1 checkpoint arising from the untimely accumulation of E2F1. These data provide a mechanistic view of miRNA-based regulation of E2F1 in the context of the emerging model that miRNAs coordinate the timing of cell cycle progression.	[Pickering, M. T.; Stadler, B. M.; Kowalik, T. F.] Univ Massachusetts, Dept Mol Genet & Microbiol, Sch Med, Worcester, MA 01605 USA	University of Massachusetts System; University of Massachusetts Worcester	Kowalik, TF (corresponding author), Univ Massachusetts, Dept Mol Genet & Microbiol, Sch Med, 55 Lake Ave N, Worcester, MA 01605 USA.	timothy.kowalik@umassmed.edu		Pickering, Mary/0000-0002-0515-7248	Dimes Foundation [6-FY06-344]; NIH [AI0766189, 5 P30 DK32520]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI076189] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK032520] Funding Source: NIH RePORTER	Dimes Foundation; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	This study was supported in parts by research grants from the March of Dimes Foundation (6-FY06-344) and the NIH (AI0766189 and 5 P30 DK32520). The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH.	Bartkova J, 2005, NATURE, V434, P864, DOI 10.1038/nature03482; Calin GA, 2006, NAT REV CANCER, V6, P857, DOI 10.1038/nrc1997; DEGREGORI J, 1995, MOL CELL BIOL, V15, P4215; Dimova DK, 2005, ONCOGENE, V24, P2810, DOI 10.1038/sj.onc.1208612; Dimri GP, 2000, MOL CELL BIOL, V20, P273, DOI 10.1128/MCB.20.1.273-285.2000; Frame FM, 2006, ONCOGENE, V25, P3258, DOI 10.1038/sj.onc.1209352; Halazonetis TD, 2008, SCIENCE, V319, P1352, DOI 10.1126/science.1140735; He L, 2005, NATURE, V435, P828, DOI 10.1038/nature03552; Hong SL, 2008, CELL CYCLE, V7, P391, DOI 10.4161/cc.7.3.5286; Hutvagner G, 2004, PLOS BIOL, V2, P465, DOI 10.1371/journal.pbio.0020098; Ivanovska I, 2008, MOL CELL BIOL, V28, P2167, DOI 10.1128/MCB.01977-07; Lomazzi M, 2002, NAT GENET, V31, P190, DOI 10.1038/ng891; Matsubara H, 2007, ONCOGENE, V26, P6099, DOI 10.1038/sj.onc.1210425; Mendell JT, 2008, CELL, V133, P217, DOI 10.1016/j.cell.2008.04.001; O'Donnell KA, 2005, NATURE, V435, P839, DOI 10.1038/nature03677; OLIVE PL, 1991, CANCER RES, V51, P4671; OLIVE PL, 1992, EXP CELL RES, V198, P259, DOI 10.1016/0014-4827(92)90378-L; PERSSON H, 1985, MOL CELL BIOL, V5, P2903, DOI 10.1128/MCB.5.11.2903; Pickering MT, 2006, ONCOGENE, V25, P746, DOI 10.1038/sj.onc.1209103; Powers JT, 2004, MOL CANCER RES, V2, P203; RABBITTS PH, 1985, EMBO J, V4, P2009, DOI 10.1002/j.1460-2075.1985.tb03885.x; Rogakou EP, 1999, J CELL BIOL, V146, P905, DOI 10.1083/jcb.146.5.905; Rogakou EP, 1998, J BIOL CHEM, V273, P5858, DOI 10.1074/jbc.273.10.5858; Rogoff HA, 2004, MOL CELL BIOL, V24, P2968, DOI 10.1128/MCB.24.7.2968-2977.2004; Schultz LB, 2000, J CELL BIOL, V151, P1381, DOI 10.1083/jcb.151.7.1381; Sylvestre Y, 2007, J BIOL CHEM, V282, P2135, DOI 10.1074/jbc.M608939200; Woods K, 2007, J BIOL CHEM, V282, P2130, DOI 10.1074/jbc.C600252200; Wu LZ, 2001, NATURE, V414, P457, DOI 10.1038/35106593; Yao G, 2008, NAT CELL BIOL, V10, P476, DOI 10.1038/ncb1711	29	132	139	1	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 8	2009	28	1					140	145		10.1038/onc.2008.372	http://dx.doi.org/10.1038/onc.2008.372			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	392HP	18836483	Green Accepted			2022-12-28	WOS:000262294100014
J	Zhu, ZH; Yu, YP; Shi, YK; Nelson, JB; Luo, JH				Zhu, Z-H; Yu, Y. P.; Shi, Y-K; Nelson, J. B.; Luo, J-H			CSR1 induces cell death through inactivation of CPSF3	ONCOGENE			English	Article						CSR1; CPSF3; cell death; RNA polyadenylation	POLYADENYLATION FACTOR CPSF-73; PROSTATE-CANCER; METASTASIS; HETEROZYGOSITY; STATISTICS; 8P21-23; MARKERS	CSR1 (cellular stress response 1), a newly characterized tumor-suppressor gene, undergoes hypermethylation in over 30% of prostate cancers. Re-expression of CSR1 inhibits cell growth and induces cell death, but the mechanism by which CSR1 suppresses tumor growth is not clear. In this study, we screened a prostate cDNA library using a yeast two-hybrid system and found that the cleavage and polyadenylation-specific factor 3 (CPSF3), an essential component for converting heteronuclear RNA to mRNA, binds with high affinity to the CSR1 C terminus. Further analyses determined that the binding motifs for CPSF3 are located between amino acids 440 and 543. The interaction between CSR1 and CPSF3 induced CPSF3 translocation from the nucleus to the cytoplasm, resulting in inhibition of polyadenylation both in vitro and in vivo. Downregulation of CPSF3 using small interfering RNA induced cell death in a manner similar to CSR1 expression. A CSR1 mutant unable to bind to CPSF3 did not alter CPSF3 subcellular distribution, did not inhibit its polyadenylation activity and did not induce cell death. In summary, CSR1 appears to induce cell death through a novel mechanism by hijacking a critical RNA processing enzyme.	[Zhu, Z-H; Yu, Y. P.; Shi, Y-K; Luo, J-H] Univ Pittsburgh, Sch Med, Dept Pathol, Pittsburgh, PA 15260 USA; [Nelson, J. B.] Univ Pittsburgh, Sch Med, Dept Urol, Pittsburgh, PA USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Luo, JH (corresponding author), Univ Pittsburgh, Sch Med, Dept Pathol, Pittsburgh, PA 15260 USA.	luoj@msx.upmc.edu			National Cancer Institute [RO1 CA098249]; NATIONAL CANCER INSTITUTE [R01CA098249] Funding Source: NIH RePORTER; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR000005] Funding Source: NIH RePORTER	National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS))	This study was supported by grants from the National Cancer Institute to JHL (RO1 CA098249), the development fund from the Department of Urology, University of Pittsburgh and the John Rangos Foundation for Enhancement of Research in Pathology.	Coon SW, 2004, INT J CANCER, V111, P206, DOI 10.1002/ijc.20254; Dominski Z, 2005, CELL, V123, P37, DOI 10.1016/j.cell.2005.08.002; Dominski Z, 2005, MOL CELL BIOL, V25, P1489, DOI 10.1128/MCB.25.4.1489-1500.2005; Gallucci M, 2006, CANCER LETT, V237, P76, DOI 10.1016/j.canlet.2005.05.033; Han HJ, 1998, HUM MOL GENET, V7, P1039, DOI 10.1093/hmg/7.6.1039; Isaacs JT, 1997, AM J PATHOL, V150, P1511; Jemal A, 2005, CA-CANCER J CLIN, V55, P10, DOI 10.3322/canjclin.55.1.10; Jemal A, 2008, CA-CANCER J CLIN, V58, P71, DOI 10.3322/CA.2007.0010; Jemal A, 2007, CA-CANCER J CLIN, V57, P43, DOI 10.3322/canjclin.57.1.43; Kurimoto F, 2001, INT J MOL MED, V8, P89; Luo JH, 2002, MOL CARCINOGEN, V33, P25, DOI 10.1002/mc.10018; OHATA H, 1993, GENE CHROMOSOME CANC, V7, P85, DOI 10.1002/gcc.2870070204; Ryan K, 2004, RNA, V10, P565, DOI 10.1261/rna.5214404; WIJSMAN JH, 1993, J HISTOCHEM CYTOCHEM, V41, P7, DOI 10.1177/41.1.7678025; Wistuba II, 1999, CANCER RES, V59, P1973; Yu GY, 2006, AM J PATHOL, V168, P597, DOI 10.2353/ajpath.2006.050620; Yu YP, 2006, CANCER RES, V66, P7414, DOI 10.1158/0008-5472.CAN-06-0227; Yu YP, 2004, J CLIN ONCOL, V22, P2790, DOI 10.1200/JCO.2004.05.158	18	34	40	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 8	2009	28	1					41	51		10.1038/onc.2008.359	http://dx.doi.org/10.1038/onc.2008.359			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	392HP	18806823	Green Accepted			2022-12-28	WOS:000262294100005
J	McKenzie, S; Sakamoto, S; Kyprianou, N				McKenzie, S.; Sakamoto, S.; Kyprianou, N.			Maspin modulates prostate cancer cell apoptotic and angiogenic response to hypoxia via targeting AKT	ONCOGENE			English	Article						hypoxia; maspin; prostate cancer; apoptosis; tumor suppression; angiogenesis	INDUCIBLE FACTOR-I; TUMOR-SUPPRESSOR; UP-REGULATION; HUMAN BREAST; EXPRESSION; ADHESION; VEGF; CONTRIBUTES; PROGRESSION; METASTASIS	Hypoxia has been previously linked to the development of both benign prostatic hyperplasia and prostate cancer. This study investigated the effect of maspin, an extracellular matrix (ECM) tumor suppressor, on the apoptotic response of prostate cancer cells to hypoxia. Gene expression pro. ling of human benign and malignant prostate epithelial cells after exposure to hypoxia or normoxia revealed dramatic changes in ECM regulators. Maspin was found to be overexpressed in response to hypoxia in prostate cancer cells, but not in benign prostate cells. To dissect the contribution of maspin to tumor cell responses within a hypoxic microenvironment, we used maspin-overexpressing DU-145 human prostate cancer cells. Exposure to hypoxic conditions (1% O-2) led to a significant increase in apoptosis in the DU-145 maspin cells, compared to DU-145 neo-transfectants without a significant effect on cell migration. This enhanced sensitivity to hypoxia-induced apoptosis leads to a significant suppression of tumor growth and tumor vascularity in vivo by targeting Akt and focal adhesion kinase activation. Our findings implicate maspin in prostate cancer cell response to hypoxia via recruitment of intracellular signaling partners. This study may have significance in the identification of maspin-driven therapeutic targeting in advanced metastatic prostate cancer.	[McKenzie, S.; Sakamoto, S.; Kyprianou, N.] Univ Kentucky, Div Urol, Dept Surg, Lucille P Markey Canc Ctr,Coll Med, Lexington, KY 40536 USA; [McKenzie, S.; Sakamoto, S.; Kyprianou, N.] Univ Kentucky, Dept Mol & Cellular Biochem, Coll Med, Lucille P Markey Canc Ctr, Lexington, KY 40536 USA; [McKenzie, S.; Sakamoto, S.; Kyprianou, N.] Univ Kentucky, Dept Pathol, Coll Med, Lucille P Markey Canc Ctr, Lexington, KY 40536 USA	University of Kentucky; University of Kentucky; University of Kentucky	Kyprianou, N (corresponding author), Univ Kentucky, Div Urol, Dept Surg, Lucille P Markey Canc Ctr,Coll Med, MS 283,800 Rose St, Lexington, KY 40536 USA.	nkypr2@uky.edu			National Institutes of Health, NIH [CA107575-01]; NATIONAL CANCER INSTITUTE [R01CA107575] Funding Source: NIH RePORTER	National Institutes of Health, NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by a grant from the National Institutes of Health, NIH CA107575-01 (NK). We thank Menglei Zhu for expert assistance with the preparation of the figures and Lorie Howard for help with the paper submission.	Abraham S, 2003, J UROLOGY, V169, P1157, DOI 10.1097/01.ju.0000040245.70349.37; Amir S, 2005, CANCER BIOL THER, V4, P400; Blacque OE, 2002, J BIOL CHEM, V277, P10783, DOI 10.1074/jbc.M110992200; Cher ML, 2003, P NATL ACAD SCI USA, V100, P7847, DOI 10.1073/pnas.1331360100; Corley KM, 2005, J CELL BIOCHEM, V96, P971, DOI 10.1002/jcb.20559; Debes JD, 2004, NEW ENGL J MED, V351, P1488, DOI 10.1056/NEJMp048178; Denk AE, 2007, PIGM CELL RES, V20, P112, DOI 10.1111/j.1600-0749.2007.00363.x; Domann FE, 2000, INT J CANCER, V85, P805, DOI 10.1002/(SICI)1097-0215(20000315)85:6<805::AID-IJC12>3.0.CO;2-5; Ferrara N, 2003, NAT MED, V9, P669, DOI 10.1038/nm0603-669; Fu XYS, 2005, PROSTATE, V63, P215, DOI 10.1002/pros.20190; Gao N, 2004, MOL CELL BIOCHEM, V255, P33, DOI 10.1023/B:MCBI.0000007259.65742.16; Garrison JB, 2007, CANCER RES, V67, P11344, DOI 10.1158/0008-5472.CAN-07-1662; Jemal A, 2006, CA-CANCER J CLIN, V56, P106, DOI 10.3322/canjclin.56.2.106; Jiang N, 2002, ONCOGENE, V21, P4089, DOI 10.1038/sj.onc.1205507; Kimbro KS, 2006, ENDOCR-RELAT CANCER, V13, P739, DOI 10.1677/erc.1.00728; Kyprianou N, 2000, HISTOL HISTOPATHOL, V15, P1211, DOI 10.14670/HH-15.1211; Lee BL, 2008, CARCINOGENESIS, V29, P44, DOI 10.1093/carcin/bgm232; Lee SM, 2006, CANCER LETT, V242, P231, DOI 10.1016/j.canlet.2005.11.001; Liu JY, 2004, CANCER RES, V64, P1703, DOI 10.1158/0008-5472.CAN-03-2568; McKenzie S, 2006, J CELL BIOCHEM, V97, P18, DOI 10.1002/jcb.20634; Ngamkitidechakul C, 2003, J BIOL CHEM, V278, P31796, DOI 10.1074/jbc.M302408200; Rennebeck G, 2005, CANCER RES, V65, P11230, DOI 10.1158/0008-5472.CAN-05-2763; Rofstad EK, 2005, CANCER RES, V65, P2387, DOI 10.1158/0008-5472.CAN-04-3039; Schaefer JS, 2003, CURR MOL MED, V3, P653, DOI 10.2174/1566524033479519; Semenza GL, 2002, TRENDS MOL MED, V8, pS62, DOI 10.1016/S1471-4914(02)02317-1; Semenza GL, 2003, NAT REV CANCER, V3, P721, DOI 10.1038/nrc1187; Sheng S, 1996, P NATL ACAD SCI USA, V93, P11669, DOI 10.1073/pnas.93.21.11669; Shi YH, 2005, J PATHOL, V205, P530, DOI 10.1002/path.1734; Tahmatzopoulos A, 2005, ONCOGENE, V24, P5375, DOI 10.1038/sj.onc.1208684; Welsh SJ, 2003, CURR CANCER DRUG TAR, V3, P391, DOI 10.2174/1568009033481732; Zhang M, 2000, NAT MED, V6, P196, DOI 10.1038/72303; ZOU ZQ, 1994, SCIENCE, V263, P526, DOI 10.1126/science.8290962	32	26	29	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC	2008	27	57					7171	7179		10.1038/onc.2008.321	http://dx.doi.org/10.1038/onc.2008.321			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	379GG	18931702	Green Accepted			2022-12-28	WOS:000261384100004
J	Wang, Y; Mikhailova, M; Bose, S; Pan, CX; White, RD; Ghosh, PM				Wang, Y.; Mikhailova, M.; Bose, S.; Pan, C-X; White, Rw deVere; Ghosh, P. M.			Regulation of androgen receptor transcriptional activity by rapamycin in prostate cancer cell proliferation and survival	ONCOGENE			English	Article						androgen independence; Akt; apoptosis; mTOR; raptor; rictor	SIGNAL-TRANSDUCTION PATHWAYS; MAMMALIAN TARGET; MTOR; KINASE; PHOSPHORYLATION; PROTEIN; GROWTH; RICTOR; CYTOSKELETON; PROGRESSION	The mTOR (mammalian target of rapamycin) inhibit or rapamycin caused growth arrest in both androgen-dependent and androgen-independent prostate cancer cells; however, long-term treatment induced resistance to the drug. The aim of this study was to investigate methods that can overcome this resistance. Here, we show that rapamycin treatment stimulated androgen receptor (AR) transcriptional activity, whereas suppression of AR activity with the antiandrogen bicalutamide sensitized androgen-dependent, as well as AR-sensitive androgen-independent prostate cancer cells, to growth inhibition by rapamycin. Further, the combination of rapamycin and bicalutamide, but not the individual drugs, induced significant levels of apoptosis in prostate cancer cells. The net effect of rapamycin is determined by its individual effects on the mTOR complexes mTORC1 (mTOR/raptor/G beta L) and mTORC2 (mTOR/rictor/sin1/G beta L). Inhibition of both mTORC1 and mTORC2 by rapamycin-induced apoptosis, whereas rapamycin-stimulation of AR transcriptional activity resulted from the inhibition of mTORC1, but not mTORC2. The effect of rapamycin on AR transcriptional activity was mediated by the phosphorylation of the serine/threonine kinase Akt, which also partially mediated apoptosis induced by rapamycin and bicalutamide. These results indicate the presence of two parallel cell-survival pathways in prostate cancer cells: a strong Akt-independent, but rapamycin-sensitive pathway downstream of mTORC1, and an AR-dependent pathway downstream of mTORC2 and Akt, that is stimulated by mTORC1 inhibition. Thus, the combination of rapamycin and bicalutamide induce apoptosis in prostate cancer cells by simultaneously inhibiting both pathways and hence would be of therapeutic value in prostate cancer treatment.	[Wang, Y.; Bose, S.; Pan, C-X; White, Rw deVere; Ghosh, P. M.] VA No Calf Hlth Care Syst, Res Serv, Mather, CA 95655 USA; [Wang, Y.; Pan, C-X; Ghosh, P. M.] Univ Calif Davis, Sch Med, Sacramento, CA 95817 USA; [Mikhailova, M.] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA	University of California System; University of California Davis; University of Texas System; University of Texas Health San Antonio	Ghosh, PM (corresponding author), VA No Calf Hlth Care Syst, Res Serv, 10535 Hosp Way, Mather, CA 95655 USA.	paramita.ghosh@ucdmc.ucdavis.edu	WANG, YU/E-4655-2013		Department of Veterans Affairs; National Cancer Institute [CA109057]; NATIONAL CANCER INSTITUTE [R21CA109057, R01CA133209] Funding Source: NIH RePORTER	Department of Veterans Affairs(US Department of Veterans Affairs); National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Dr Hsing-Jien Kung for critical reading of the manuscript, Dr Barry Furr, AstraZeneca, Cheshire, UK, for the gift of bicalutamide (Casodex), Dr Bandana Chatterjee, University of Texas Health Science Center at San Antonio (UTHSCSA) for hPSA-luc construct; Dr LuZhe Sun, UTHSCSA, for beta-gal construct and LNAI cell line. We are grateful to Sherra Johnson and Naveen K Krishnegowda for technical assistance in some of the experiments described. This study was supported by a Merit award from the Department of Veterans Affairs and award CA109057 from the National Cancer Institute.	Agus DB, 1999, J NATL CANCER I, V91, P1869, DOI 10.1093/jnci/91.21.1869; Boehmer A, 2005, ANTICANCER RES, V25, P4481; BROWN EJ, 1994, NATURE, V369, P756, DOI 10.1038/369756a0; Cao C, 2006, CANCER RES, V66, P10040, DOI 10.1158/0008-5472.CAN-06-0802; Cinar B, 2005, CANCER RES, V65, P2547, DOI 10.1158/0008-5472.CAN-04-3411; Edwards J, 2005, BJU INT, V95, P1320, DOI 10.1111/j.1464-410X.2005.05526.x; Gao N, 2003, BIOCHEM BIOPH RES CO, V310, P1124, DOI 10.1016/j.bbrc.2003.09.132; Ghosh PM, 1999, ONCOGENE, V18, P4120, DOI 10.1038/sj.onc.1202792; Ghosh PM, 2005, ENDOCR-RELAT CANCER, V12, P119, DOI 10.1677/erc.1.00835; Ghosh PM, 2002, CANCER RES, V62, P2630; Ghosh PM, 2001, AM J PHYSIOL-RENAL, V280, pF972, DOI 10.1152/ajprenal.2001.280.6.F972; Gingras AC, 2001, GENE DEV, V15, P807, DOI 10.1101/gad.887201; Hartig PC, 2002, TOXICOL SCI, V66, P82, DOI 10.1093/toxsci/66.1.82; Hresko RC, 2005, J BIOL CHEM, V280, P40406, DOI 10.1074/jbc.M508361200; Jacinto E, 2004, NAT CELL BIOL, V6, P1122, DOI 10.1038/ncb1183; Kremer CL, 2006, PROSTATE, V66, P1203, DOI 10.1002/pros.20410; Lee CH, 2007, ANNU REV PHARMACOL, V47, P443, DOI 10.1146/annurev.pharmtox.47.120505.105359; Lin HK, 2003, J BIOL CHEM, V278, P50902, DOI 10.1074/jbc.M300676200; Lu S, 1999, MOL ENDOCRINOL, V13, P376, DOI 10.1210/me.13.3.376; Persad S, 2001, J BIOL CHEM, V276, P27462, DOI 10.1074/jbc.M102940200; Petrylak D, 2005, BJU INT, V96, P41, DOI 10.1111/j.1464-410X.2005.05946.x; SABATINI DM, 1994, CELL, V78, P35, DOI 10.1016/0092-8674(94)90570-3; Sarbassov DD, 2005, CURR OPIN CELL BIOL, V17, P596, DOI 10.1016/j.ceb.2005.09.009; Sarbassov DD, 2006, MOL CELL, V22, P159, DOI 10.1016/j.molcel.2006.03.029; Sarbassov DD, 2005, SCIENCE, V307, P1098, DOI 10.1126/science.1106148; Sarbassov DD, 2004, CURR BIOL, V14, P1296, DOI 10.1016/j.cub.2004.06.054; Sharef S, 2006, J CLIN ONCOL, V24, P14584; Shi YJ, 2005, MOL CANCER THER, V4, P1533, DOI 10.1158/1535-7163.MCT-05-0068; Tzatsos A, 2006, MOL CELL BIOL, V26, P63, DOI 10.1128/MCB.26.1.63-76.2006; Wu LC, 2005, CANCER RES, V65, P2825, DOI 10.1158/0008-5472.CAN-04-3137	30	78	81	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV	2008	27	56					7106	7117		10.1038/onc.2008.318	http://dx.doi.org/10.1038/onc.2008.318			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	376PQ	18776922	Green Accepted			2022-12-28	WOS:000261195900005
J	Franke, TF				Franke, T. F.			PI3K/Akt: getting it right matters	ONCOGENE			English	Review						Akt/PKB; PI3K/PTEN; PDK2; mTORC; Akt-interacting proteins; human disease	PROTEIN-KINASE-B; PLECKSTRIN HOMOLOGY DOMAIN; PROMOTES CELL-SURVIVAL; GLYCOGEN-SYNTHASE KINASE-3; N-TERMINAL KINASE; FORKHEAD TRANSCRIPTION FACTOR; ISOFORM-SPECIFIC REGULATION; SIGNAL-REGULATING KINASE-1; SUPPRESSES TUMOR-GROWTH; SERINE-THREONINE KINASE	The Akt serine/threonine kinase (also called protein kinase B) has emerged as a critical signaling molecule within eukaryotic cells. Significant progress has been made in clarifying its regulation by upstream kinases and identifying downstream mechanisms that mediate its effects in cells and contribute to signaling specificity. Here, we provide an overview of present advances in the field regarding the function of Akt in physiological and pathological cell function within a more generalized framework of Akt signal transduction. An emphasis is placed on the involvement of Akt in human diseases ranging from cancer to metabolic dysfunction and mental disease.	[Franke, T. F.] NYU, Sch Med, Dept Psychiat, New York, NY 10016 USA; [Franke, T. F.] NYU, Sch Med, Dept Pharmacol, New York, NY 10016 USA	New York University; New York University	Franke, TF (corresponding author), NYU, Sch Med, Dept Psychiat, 550 1 Ave,Milhauser Labs TCH-550, New York, NY 10016 USA.	thomas.franke@nyumc.org			National Science Foundation [IOS-0757780]; National Institutes of Health [RO1MH079439]; G Harold & Leila Y Mathers Foundation; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH079439] Funding Source: NIH RePORTER	National Science Foundation(National Science Foundation (NSF)); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); G Harold & Leila Y Mathers Foundation; NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))	Work on the Akt signaling cascade in Dr Franke's laboratory is supported by the National Science Foundation (NSF award IOS-0757780), the National Institutes of Health (grant RO1MH079439), Susan G Komen for the Cure and the G Harold & Leila Y Mathers Foundation. Ithank Alexander Broad and Andrew Sideris for assistance with the Akt signaling schematics, and Terry McIntosh for diligent production of this manuscript.	Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9; Alessi DR, 1996, FEBS LETT, V399, P333, DOI 10.1016/S0014-5793(96)01370-1; Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; Anai M, 2005, J BIOL CHEM, V280, P18525, DOI 10.1074/jbc.M500586200; Aoki M, 1998, P NATL ACAD SCI USA, V95, P14950, DOI 10.1073/pnas.95.25.14950; Arboleda MJ, 2003, CANCER RES, V63, P196; Arnold SE, 2005, PROG BRAIN RES, V147, P319, DOI 10.1016/S0079-6123(04)47023-X; Ashcroft M, 2002, ONCOGENE, V21, P1955, DOI 10.1038/sj.onc.1205276; AUGER KR, 1989, CELL, V57, P167, DOI 10.1016/0092-8674(89)90182-7; Bachman KE, 2004, CANCER BIOL THER, V3, P772, DOI 10.4161/cbt.3.8.994; Bae SS, 2003, J BIOL CHEM, V278, P49530, DOI 10.1074/jbc.M306782200; Balendran A, 1999, CURR BIOL, V9, P393, DOI 10.1016/S0960-9822(99)80186-9; Barthel A, 1999, J BIOL CHEM, V274, P20281, DOI 10.1074/jbc.274.29.20281; Barthwal MK, 2003, J BIOL CHEM, V278, P3897, DOI 10.1074/jbc.M211598200; Basso AD, 2002, J BIOL CHEM, V277, P39858, DOI 10.1074/jbc.M206322200; Beaulieu JM, 2007, TRENDS PHARMACOL SCI, V28, P166, DOI 10.1016/j.tips.2007.02.006; Beaulieu JM, 2004, P NATL ACAD SCI USA, V101, P5099, DOI 10.1073/pnas.0307921101; Beaulieu JM, 2005, CELL, V122, P261, DOI 10.1016/j.cell.2005.05.012; BELLACOSA A, 1993, ONCOGENE, V8, P745; BELLACOSA A, 1991, SCIENCE, V254, P274, DOI 10.1126/science.1833819; Berra E, 1998, J BIOL CHEM, V273, P10792, DOI 10.1074/jbc.273.17.10792; Berwick DC, 2004, J CELL SCI, V117, P5985, DOI 10.1242/jcs.01517; Berwick DC, 2002, J BIOL CHEM, V277, P33895, DOI 10.1074/jbc.M204681200; Biondi RM, 2000, EMBO J, V19, P979, DOI 10.1093/emboj/19.5.979; Bleeker FE, 2008, ONCOGENE, V27, P5648, DOI 10.1038/onc.2008.170; Bozulic L, 2008, MOL CELL, V30, P203, DOI 10.1016/j.molcel.2008.02.024; Brazil DP, 2002, CELL, V111, P293, DOI 10.1016/S0092-8674(02)01083-8; Brazil DP, 2001, TRENDS BIOCHEM SCI, V26, P657, DOI 10.1016/S0968-0004(01)01958-2; Brognard J, 2007, MOL CELL, V25, P917, DOI 10.1016/j.molcel.2007.02.017; Brugge J, 2007, CANCER CELL, V12, P104, DOI 10.1016/j.ccr.2007.07.014; Brunet A, 2001, MOL CELL BIOL, V21, P952, DOI 10.1128/MCB.21.3.952-965.2001; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; Butler MG, 2005, J MED GENET, V42, P318, DOI 10.1136/jmg.2004.024646; Calleja V, 2007, PLOS BIOL, V5, P780, DOI 10.1371/journal.pbio.0050095; Campbell IG, 2004, CANCER RES, V64, P7678, DOI 10.1158/0008-5472.CAN-04-2933; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; Carnero A, 2008, CURR CANCER DRUG TAR, V8, P187, DOI 10.2174/156800908784293659; Carpten JD, 2007, NATURE, V448, P439, DOI 10.1038/nature05933; CARTER AN, 1994, BIOCHEM J, V301, P415, DOI 10.1042/bj3010415; Cerezo A, 1998, MOL BIOL CELL, V9, P3107, DOI 10.1091/mbc.9.11.3107; Chan TO, 1999, ANNU REV BIOCHEM, V68, P965, DOI 10.1146/annurev.biochem.68.1.965; Cheadle JP, 2000, HUM GENET, V107, P97, DOI 10.1007/s004390000348; Chen HK, 2003, CELL, V113, P457, DOI 10.1016/S0092-8674(03)00349-0; Chen WS, 2001, GENE DEV, V15, P2203, DOI 10.1101/gad.913901; Cheng JQ, 1996, P NATL ACAD SCI USA, V93, P3636, DOI 10.1073/pnas.93.8.3636; Cho H, 2001, J BIOL CHEM, V276, P38349, DOI 10.1074/jbc.C100462200; Cho H, 2001, SCIENCE, V292, P1728, DOI 10.1126/science.292.5522.1728; COFFER PJ, 1991, EUR J BIOCHEM, V201, P475, DOI 10.1111/j.1432-1033.1991.tb16305.x; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; Dan HC, 2004, J BIOL CHEM, V279, P5405, DOI 10.1074/jbc.M312044200; Danial NN, 2003, NATURE, V424, P952, DOI 10.1038/nature01825; Datta SR, 2000, MOL CELL, V6, P41, DOI 10.1016/S1097-2765(00)00006-X; Deprez J, 1997, J BIOL CHEM, V272, P17269, DOI 10.1074/jbc.272.28.17269; Dong B, 2007, J BIOL CHEM, V282, P25131, DOI 10.1074/jbc.M702123200; Dong LQ, 2005, AM J PHYSIOL-ENDOC M, V289, pE187, DOI 10.1152/ajpendo.00011.2005; Downward J, 2003, NATURE, V424, P896, DOI 10.1038/424896a; Dragoi AM, 2005, EMBO J, V24, P779, DOI 10.1038/sj.emboj.7600539; Du KY, 2005, ONCOGENE, V24, P7401, DOI 10.1038/sj.onc.1209099; Du KY, 2003, SCIENCE, V300, P1574, DOI 10.1126/science.1079817; Dudek H, 1997, SCIENCE, V275, P661, DOI 10.1126/science.275.5300.661; Dummler B, 2006, MOL CELL BIOL, V26, P8042, DOI 10.1128/MCB.00722-06; Easton JB, 2006, CANCER CELL, V9, P153, DOI 10.1016/j.ccr.2006.02.027; Easton RM, 2005, MOL CELL BIOL, V25, P1869, DOI 10.1128/MCB.25.5.1869-1878.2005; Emamian ES, 2004, NAT GENET, V36, P131, DOI 10.1038/ng1296; Engelman JA, 2006, NAT REV GENET, V7, P606, DOI 10.1038/nrg1879; Feng JH, 2004, J BIOL CHEM, V279, P41189, DOI 10.1074/jbc.M406731200; Figueroa C, 2003, J BIOL CHEM, V278, P47922, DOI 10.1074/jbc.M307357200; FRANKE TF, 1994, ONCOGENE, V9, P141; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; Franke TF, 2003, ONCOGENE, V22, P8983, DOI 10.1038/sj.onc.1207115; Franke TF, 1997, NATURE, V390, P116, DOI 10.1038/36442; Franke TF, 1997, SCIENCE, V275, P665, DOI 10.1126/science.275.5300.665; Franke TF, 2008, SCI SIGNAL, V1, DOI 10.1126/scisignal.124pe29; Franke TF, 2007, AM J PHYSIOL-CELL PH, V293, pC1768, DOI 10.1152/ajpcell.00451.2007; Freeman DJ, 2003, CANCER CELL, V3, P117, DOI 10.1016/S1535-6108(03)00021-7; Frias MA, 2006, CURR BIOL, V16, P1865, DOI 10.1016/j.cub.2006.08.001; Fritzius T, 2008, EMBO J, V27, P1399, DOI 10.1038/emboj.2008.67; Fujita E, 1999, BIOCHEM BIOPH RES CO, V264, P550, DOI 10.1006/bbrc.1999.1387; Gajewski TF, 1996, CELL, V87, P589, DOI 10.1016/S0092-8674(00)81377-X; Gao HD, 2007, MOL CELL BIOCHEM, V305, P35, DOI 10.1007/s11010-007-9525-3; Gao TY, 2005, MOL CELL, V18, P13, DOI 10.1016/j.molcel.2005.03.008; Garcia BG, 2005, MOL PHARMACOL, V68, P102, DOI 10.1124/mol.104.009092; George S, 2004, SCIENCE, V304, P1325, DOI 10.1126/science.1096706; Gottlob K, 2001, GENE DEV, V15, P1406, DOI 10.1101/gad.889901; Greenman C, 2007, NATURE, V446, P153, DOI 10.1038/nature05610; Guertin DA, 2007, CANCER CELL, V12, P9, DOI 10.1016/j.ccr.2007.05.008; Guertin DA, 2006, DEV CELL, V11, P859, DOI 10.1016/j.devcel.2006.10.007; Hao YS, 2008, MOL CELL BIOL, V28, P2851, DOI 10.1128/MCB.01917-07; Harrington LS, 2005, TRENDS BIOCHEM SCI, V30, P35, DOI 10.1016/j.tibs.2004.11.003; Hashimoto M, 2004, J BIOL CHEM, V279, P23622, DOI 10.1074/jbc.M313784200; Hawkins PT, 2006, BIOCHEM SOC T, V34, P647, DOI 10.1042/BST0340647; HILES ID, 1992, CELL, V70, P419, DOI 10.1016/0092-8674(92)90166-A; Hill MM, 1999, MOL CELL BIOL, V19, P7771; Hill MM, 2002, CURR BIOL, V12, P1251, DOI 10.1016/S0960-9822(02)00973-9; Hodgkinson CP, 2002, BIOCHEMISTRY-US, V41, P10351, DOI 10.1021/bi026065r; Holland EC, 2000, NAT GENET, V25, P55, DOI 10.1038/75596; Hsiung SC, 2008, J NEUROSCI RES, V86, P2326, DOI 10.1002/jnr.21676; Humbert S, 2002, DEV CELL, V2, P831, DOI 10.1016/S1534-5807(02)00188-0; Hutchinson J, 2001, MOL CELL BIOL, V21, P2203, DOI 10.1128/MCB.21.6.2203-2212.2001; Hutchinson JN, 2004, CANCER RES, V64, P3171, DOI 10.1158/0008-5472.CAN-03-3465; Ingley E, 2000, FEBS LETT, V478, P253, DOI 10.1016/S0014-5793(00)01866-4; Inoki K, 2002, NAT CELL BIOL, V4, P648, DOI 10.1038/ncb839; Jahn T, 2002, MOL CELL BIOL, V22, P979, DOI 10.1128/MCB.22.4.979-991.2002; Jia YH, 2007, IMMUNITY, V27, P453, DOI 10.1016/j.immuni.2007.07.016; Jiang TY, 2003, J BIOL CHEM, V278, P15789, DOI 10.1074/jbc.M212525200; Jiang ZY, 2003, P NATL ACAD SCI USA, V100, P7569, DOI 10.1073/pnas.1332633100; JONES PF, 1991, CELL REGUL, V2, P1001, DOI 10.1091/mbc.2.12.1001; JONES PF, 1991, P NATL ACAD SCI USA, V88, P4171, DOI 10.1073/pnas.88.10.4171; Jones RG, 2000, J EXP MED, V191, P1721, DOI 10.1084/jem.191.10.1721; Juhasz G, 2008, J CELL BIOL, V181, P655, DOI 10.1083/jcb.200712051; Kennedy SG, 1999, MOL CELL BIOL, V19, P5800; Kihara A, 2001, J CELL BIOL, V152, P519, DOI 10.1083/jcb.152.3.519; Kim AH, 2003, J BIOL CHEM, V278, P29830, DOI 10.1074/jbc.M305349200; Kim AH, 2001, MOL CELL BIOL, V21, P893, DOI 10.1128/MCB.21.3.893-901.2001; Kim AH, 2002, NEURON, V35, P697, DOI 10.1016/S0896-6273(02)00821-8; Kim MS, 2008, BRIT J CANCER, V98, P1533, DOI 10.1038/sj.bjc.6604212; Kim YB, 2000, ENDOCRINOLOGY, V141, P2328, DOI 10.1210/en.141.7.2328; Kohn AD, 1996, J BIOL CHEM, V271, P31372, DOI 10.1074/jbc.271.49.31372; KOHN AD, 1995, EMBO J, V4288, P4295; KONISHI H, 1994, BIOCHEM BIOPH RES CO, V205, P817, DOI 10.1006/bbrc.1994.2738; Kwon CH, 2006, NEURON, V50, P377, DOI 10.1016/j.neuron.2006.03.023; Kwon T, 2000, J BIOL CHEM, V275, P423, DOI 10.1074/jbc.275.1.423; Lai WS, 2006, P NATL ACAD SCI USA, V103, P16906, DOI 10.1073/pnas.0604994103; LAM K, 1994, J BIOL CHEM, V269, P20648; LI TJ, 1995, IMMUNITY, V2, P451, DOI 10.1016/1074-7613(95)90026-8; Li Y, 2002, J BIOL CHEM, V277, P11352, DOI 10.1074/jbc.M109062200; Liang J, 2002, NAT MED, V8, P1153, DOI 10.1038/nm761; Lin CH, 2001, NEURON, V31, P841, DOI 10.1016/S0896-6273(01)00433-0; Liu D, 2000, CURR BIOL, V10, P1233, DOI 10.1016/S0960-9822(00)00733-8; LopezIlasaca M, 1997, SCIENCE, V275, P394, DOI 10.1126/science.275.5298.394; LoPiccolo J, 2008, DRUG RESIST UPDATE, V11, P32, DOI 10.1016/j.drup.2007.11.003; Lu DM, 2006, J BIOL CHEM, V281, P22799, DOI 10.1074/jbc.M603390200; Lynch DK, 1999, ONCOGENE, V18, P8024, DOI 10.1038/sj.onc.1203258; Lyons TR, 2007, J BIOL CHEM, V282, P21987, DOI 10.1074/jbc.M704321200; Mabuchi S, 2004, ENDOCRINOLOGY, V145, P49, DOI 10.1210/en.2003-0792; Maehama T, 1998, J BIOL CHEM, V273, P13375, DOI 10.1074/jbc.273.22.13375; Maehama T, 2007, BIOL PHARM BULL, V30, P1624, DOI 10.1248/bpb.30.1624; Maira SM, 2001, SCIENCE, V294, P374, DOI 10.1126/science.1062030; Majumder PK, 2003, P NATL ACAD SCI USA, V100, P7841, DOI 10.1073/pnas.1232229100; Malanga D, 2008, CELL CYCLE, V7, P665, DOI 10.4161/cc.7.5.5485; Malstrom S, 2001, P NATL ACAD SCI USA, V98, P14967, DOI 10.1073/pnas.231467698; Mamane Y, 2006, ONCOGENE, V25, P6416, DOI 10.1038/sj.onc.1209888; Manning BD, 2004, J CELL BIOL, V167, P399, DOI 10.1083/jcb.200408161; Manning BD, 2007, CELL, V129, P1261, DOI 10.1016/j.cell.2007.06.009; Mayo LD, 2001, P NATL ACAD SCI USA, V98, P11598, DOI 10.1073/pnas.181181198; McDonald PC, 2008, CANCER RES, V68, P1618, DOI 10.1158/0008-5472.CAN-07-5869; Meili R, 1999, EMBO J, V18, P2092, DOI 10.1093/emboj/18.8.2092; Mitsuuchi Y, 1999, ONCOGENE, V18, P4891, DOI 10.1038/sj.onc.1203080; Nakatani K, 1999, BIOCHEM BIOPH RES CO, V257, P906, DOI 10.1006/bbrc.1999.0559; Nakatani K, 1999, J BIOL CHEM, V274, P21528, DOI 10.1074/jbc.274.31.21528; Nawa M, 2008, CELL SIGNAL, V20, P493, DOI 10.1016/j.cellsig.2007.11.004; Nobukuni T, 2007, CURR OPIN CELL BIOL, V19, P135, DOI 10.1016/j.ceb.2007.02.019; Noguchi M, 2007, FASEB J, V21, P2273, DOI 10.1096/fj.06-7684com; Noshita N, 2002, NEUROBIOL DIS, V9, P294, DOI 10.1006/nbdi.2002.0482; Obata T, 2000, J BIOL CHEM, V275, P36108, DOI 10.1074/jbc.M005497200; Ogawara Y, 2002, J BIOL CHEM, V277, P21843, DOI 10.1074/jbc.M109745200; Ogg S, 1998, MOL CELL, V2, P887, DOI 10.1016/S1097-2765(00)80303-2; Okubo Y, 1998, J BIOL CHEM, V273, P25961, DOI 10.1074/jbc.273.40.25961; Orsulic S, 2002, CANCER CELL, V1, P53, DOI 10.1016/S1535-6108(01)00002-2; Pap M, 1998, J BIOL CHEM, V273, P19929, DOI 10.1074/jbc.273.32.19929; Paradis S, 1999, GENE DEV, V13, P1438, DOI 10.1101/gad.13.11.1438; Paradis S, 1998, GENE DEV, V12, P2488, DOI 10.1101/gad.12.16.2488; Paramio JM, 2001, MOL CELL BIOL, V21, P7449, DOI 10.1128/MCB.21.21.7449-7459.2001; Park HS, 2002, J BIOL CHEM, V277, P2573, DOI 10.1074/jbc.M110299200; Peng XD, 2003, GENE DEV, V17, P1352, DOI 10.1101/gad.1089403; Persad S, 2000, P NATL ACAD SCI USA, V97, P3207, DOI 10.1073/pnas.060579697; Pierce SB, 2001, GENE DEV, V15, P672, DOI 10.1101/gad.867301; Plas DR, 2001, J BIOL CHEM, V276, P12041, DOI 10.1074/jbc.M010551200; Plas DR, 2002, NAT IMMUNOL, V3, P515, DOI 10.1038/ni0602-515; Raymond JR, 2001, PHARMACOL THERAPEUT, V92, P179, DOI 10.1016/S0163-7258(01)00169-3; Reiling JH, 2006, ONCOGENE, V25, P6373, DOI 10.1038/sj.onc.1209889; Rickle A, 2004, NEUROREPORT, V15, P955, DOI 10.1097/00001756-200404290-00005; Rossig L, 2002, J BIOL CHEM, V277, P9684, DOI 10.1074/jbc.M106157200; Rossig L, 2001, MOL CELL BIOL, V21, P5644, DOI 10.1128/MCB.21.16.5644-5657.2001; Russo SJ, 2007, NAT NEUROSCI, V10, P93, DOI 10.1038/nn1812; Ryder J, 2004, CELL SIGNAL, V16, P187, DOI 10.1016/j.cellsig.2003.07.004; Salinas M, 2001, MOL CELL NEUROSCI, V17, P67, DOI 10.1006/mcne.2000.0921; Salmena L, 2008, CELL, V133, P403, DOI 10.1016/j.cell.2008.04.013; Samuels Y, 2004, SCIENCE, V304, P554, DOI 10.1126/science.1096502; Sancak Y, 2007, MOL CELL, V25, P903, DOI 10.1016/j.molcel.2007.03.003; Sano H, 2003, J BIOL CHEM, V278, P14599, DOI 10.1074/jbc.C300063200; Sarbassov DD, 2006, MOL CELL, V22, P159, DOI 10.1016/j.molcel.2006.03.029; Sarbassov DD, 2005, SCIENCE, V307, P1098, DOI 10.1126/science.1106148; Scanga SE, 2000, ONCOGENE, V19, P3971, DOI 10.1038/sj.onc.1203739; Scheid MP, 2001, NAT REV MOL CELL BIO, V2, P760, DOI 10.1038/35096067; Schenck A, 2008, CELL, V133, P486, DOI 10.1016/j.cell.2008.02.044; SCHU PV, 1993, SCIENCE, V260, P88, DOI 10.1126/science.8385367; Shaw RJ, 2006, NATURE, V441, P424, DOI 10.1038/nature04869; Shin I, 2002, NAT MED, V8, P1145, DOI 10.1038/nm759; Shioi T, 2000, EMBO J, V19, P2537, DOI 10.1093/emboj/19.11.2537; Shioi T, 2002, MOL CELL BIOL, V22, P2799, DOI 10.1128/MCB.22.8.2799-2809.2002; Sjoblom T, 2006, SCIENCE, V314, P268, DOI 10.1126/science.1133427; STAAL SP, 1977, P NATL ACAD SCI USA, V74, P3065, DOI 10.1073/pnas.74.7.3065; Stambolic V, 2001, MOL CELL, V8, P317, DOI 10.1016/S1097-2765(01)00323-9; Staveley BE, 1998, CURR BIOL, V8, P599, DOI 10.1016/S0960-9822(98)70231-3; Stephens L, 1998, SCIENCE, V279, P710, DOI 10.1126/science.279.5351.710; Stephens LR, 1997, CELL, V89, P105, DOI 10.1016/S0092-8674(00)80187-7; STEPHENS LR, 1991, NATURE, V351, P33, DOI 10.1038/351033a0; Sun LG, 2004, J CELL SCI, V117, P3021, DOI 10.1242/jcs.01142; Szanto I, 2000, P NATL ACAD SCI USA, V97, P2355, DOI 10.1073/pnas.050580497; Tan HY, 2008, J CLIN INVEST, V118, P2200, DOI [10.1172/JCI3472S, 10.1172/JCI34725]; Tee AR, 2003, CURR BIOL, V13, P1259, DOI 10.1016/S0960-9822(03)00506-2; Tee AR, 2002, P NATL ACAD SCI USA, V99, P13571, DOI 10.1073/pnas.202476899; Toker A, 2000, CELL, V103, P185, DOI 10.1016/S0092-8674(00)00110-0; Toker A, 2000, J BIOL CHEM, V275, P8271, DOI 10.1074/jbc.275.12.8271; Tokuda E, 2007, CANCER RES, V67, P9666, DOI 10.1158/0008-5472.CAN-07-1050; Tschopp O, 2005, DEVELOPMENT, V132, P2943, DOI 10.1242/dev.01864; Vandromme M, 2001, J BIOL CHEM, V276, P8173, DOI 10.1074/jbc.M005587200; Verdu J, 1999, NAT CELL BIOL, V1, P500, DOI 10.1038/70293; Virbasius JV, 1996, J BIOL CHEM, V271, P13304, DOI 10.1074/jbc.271.23.13304; Wang LF, 2007, J BIOL CHEM, V282, P20036, DOI 10.1074/jbc.M702376200; White DE, 2001, ONCOGENE, V20, P7064, DOI 10.1038/sj.onc.1204910; Wiznitzer M, 2004, J CHILD NEUROL, V19, P675, DOI 10.1177/08830738040190090701; Wurmser AE, 2002, J CELL BIOL, V158, P761, DOI 10.1083/jcb.200112050; Xu ZH, 2001, MOL CELL BIOL, V21, P4713, DOI 10.1128/MCB.21.14.4713-4724.2001; Yamada E, 2005, J CELL BIOL, V168, P921, DOI 10.1083/jcb.200408182; Yang J, 2002, NAT STRUCT BIOL, V9, P940, DOI 10.1038/nsb870; Yang J, 2002, MOL CELL, V9, P1227, DOI 10.1016/S1097-2765(02)00550-6; Yano S, 1998, NATURE, V396, P584, DOI 10.1038/25147; Yuan ZQ, 2005, J BIOL CHEM, V280, P21483, DOI 10.1074/jbc.M500097200; Yuan ZQ, 2003, J BIOL CHEM, V278, P23432, DOI 10.1074/jbc.M302674200; Yue YZ, 2004, J BIOL CHEM, V279, P12883, DOI 10.1074/jbc.M312308200; Yun SJ, 2008, BIOCHEM BIOPH RES CO, V371, P138, DOI 10.1016/j.bbrc.2008.04.029; Zeng ZH, 2007, BLOOD, V109, P3509, DOI 10.1182/blood-2006-06-030833; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3; Zhao AZ, 2000, J BIOL CHEM, V275, P11348, DOI 10.1074/jbc.275.15.11348; Zhao JJ, 2003, CANCER CELL, V3, P483, DOI 10.1016/S1535-6108(03)00088-6; Zhou BHP, 2001, NAT CELL BIOL, V3, P245, DOI 10.1038/35060032; Zhou HL, 2000, J CELL BIOL, V151, P483, DOI 10.1083/jcb.151.3.483	230	539	576	5	68	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 27	2008	27	50					6473	6488		10.1038/onc.2008.313	http://dx.doi.org/10.1038/onc.2008.313			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	366RR	18955974				2022-12-28	WOS:000260501600007
J	Tait, SWG; Green, DR				Tait, S. W. G.; Green, D. R.			Caspase-independent cell death: leaving the set without the final cut	ONCOGENE			English	Review						caspases; mitochondria; caspase-independent cell death; mitochondrial outer membrane permeabilization; cancer	APOPTOSIS-INDUCING FACTOR; STRESS-INDUCED APOPTOSIS; TUMOR-NECROSIS-FACTOR; CYTOCHROME-C RELEASE; DIFFERENTIAL REQUIREMENT; SYMPATHETIC NEURONS; CONFERS RESISTANCE; APAF-1 EXPRESSION; DROSOPHILA CELLS; SERINE-PROTEASE	Apoptosis is dependent upon caspase activation leading to substrate cleavage and, ultimately, cell death. Although required for the apoptotic phenotype, it has become apparent that cells frequently die even when caspase function is blocked. This process, termed caspase-independent cell death (CICD), occurs in response to most intrinsic apoptotic cues, provided that mitochondrial outer membrane permeabilization has occurred. Death receptor ligation can also trigger a form of CICD termed necroptosis. In this review, we will examine the molecular mechanisms governing CICD, highlight recent findings demonstrating recovery from conditions of CICD and discuss potential pathophysiological functions of these processes.	[Tait, S. W. G.; Green, D. R.] St Jude Childrens Res Hosp, Dept Immunol, Memphis, TN 38105 USA	St Jude Children's Research Hospital	Green, DR (corresponding author), St Jude Childrens Res Hosp, Dept Immunol, 332 N Lauderdale, Memphis, TN 38105 USA.	Douglas.Green@stjude.org	Green, Douglas R/N-8083-2018	Green, Douglas R/0000-0002-7332-1417; Tait, Stephen/0000-0001-7697-132X	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI047891] Funding Source: NIH RePORTER; NIAID NIH HHS [R01 AI047891-10, R01 AI047891] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Abraham MC, 2007, DEV CELL, V12, P73, DOI 10.1016/j.devcel.2006.11.012; Arnoult D, 2003, EMBO J, V22, P4385, DOI 10.1093/emboj/cdg423; Arnoult D, 2007, TRENDS CELL BIOL, V17, P6, DOI 10.1016/j.tcb.2006.11.001; Bahi N, 2006, J BIOL CHEM, V281, P22943, DOI 10.1074/jbc.M601025200; Balsam LB, 2005, J SURG RES, V124, P194, DOI 10.1016/j.jss.2004.09.017; Berry DL, 2007, CELL, V131, P1137, DOI 10.1016/j.cell.2007.10.048; Braun JS, 2007, EXP NEUROL, V206, P183, DOI 10.1016/j.expneurol.2007.03.032; Brown D, 2006, P NATL ACAD SCI USA, V103, P9918, DOI 10.1073/pnas.0603950103; Cauwels A, 2003, NAT IMMUNOL, V4, P387, DOI 10.1038/ni914; Cecconi F, 1998, CELL, V94, P727, DOI 10.1016/S0092-8674(00)81732-8; Chan PH, 2004, NEUROCHEM RES, V29, P1943, DOI 10.1007/s11064-004-6869-x; Chautan M, 1999, CURR BIOL, V9, P967, DOI 10.1016/S0960-9822(99)80425-4; Chauvier D, 2007, CELL DEATH DIFFER, V14, P387, DOI 10.1038/sj.cdd.4402044; Chen HC, 2003, J CELL BIOL, V160, P189, DOI 10.1083/jcb.200211046; Cheung ECC, 2006, EMBO J, V25, P4061, DOI 10.1038/sj.emboj.7601276; Chipuk JE, 2005, NAT REV MOL CELL BIO, V6, P268, DOI [10.1038/nrm1573, 10.1038/nrm2239]; Chipuk JE, 2008, TRENDS CELL BIOL, V18, P157, DOI 10.1016/j.tcb.2008.01.007; Colell A, 2007, CELL, V129, P983, DOI 10.1016/j.cell.2007.03.045; DeBerardinis RJ, 2008, CURR OPIN GENET DEV, V18, P54, DOI 10.1016/j.gde.2008.02.003; Degenhardt K, 2006, CANCER CELL, V10, P51, DOI 10.1016/j.ccr.2006.06.001; Degterev A, 2005, NAT CHEM BIOL, V1, P112, DOI 10.1038/nchembio711; Degterev A, 2008, NAT CHEM BIOL, V4, P313, DOI 10.1038/nchembio.83; Deming PB, 2004, MOL CELL BIOL, V24, P10289, DOI 10.1128/MCB.24.23.10289-10299.2004; Denmeade SR, 1999, PROSTATE, V39, P269; Deshmukh M, 2002, J NEUROSCI, V22, P8018; Deshmukh M, 1998, NEURON, V21, P695, DOI 10.1016/S0896-6273(00)80587-5; Du CY, 2000, CELL, V102, P33, DOI 10.1016/S0092-8674(00)00008-8; Ekert PG, 2004, J CELL BIOL, V165, P835, DOI 10.1083/jcb.200312031; ELLIS HM, 1986, CELL, V44, P817, DOI 10.1016/0092-8674(86)90004-8; Fraser AG, 1997, EMBO J, V16, P6192, DOI 10.1093/emboj/16.20.6192; Fujimoto A, 2004, CANCER RES, V64, P2245, DOI 10.1158/0008-5472.CAN-03-2932; GASSER SM, 1982, J BIOL CHEM, V257, P3034; Goldstein JC, 2000, ANN NY ACAD SCI, V926, P132; Green DR, 2002, CANCER CELL, V1, P19, DOI 10.1016/S1535-6108(02)00024-7; Gustafsson AB, 2008, CARDIOVASC RES, V77, P334, DOI 10.1093/cvr/cvm005; Hakem R, 1998, CELL, V94, P339, DOI 10.1016/S0092-8674(00)81477-4; Hao ZY, 2005, CELL, V121, P579, DOI 10.1016/j.cell.2005.03.016; Haraguchi M, 2000, J EXP MED, V191, P1709, DOI 10.1084/jem.191.10.1709; Hirsch T, 1997, ONCOGENE, V15, P1573, DOI 10.1038/sj.onc.1201324; Hoffarth S, 2008, CELL DEATH DIFFER, V15, P161, DOI 10.1038/sj.cdd.4402256; Holler N, 2000, NAT IMMUNOL, V1, P489, DOI 10.1038/82732; Horvitz HR, 2003, BIOSCIENCE REP, V23, P239, DOI 10.1023/B:BIRE.0000019187.19019.e6; Jaattela M, 2003, NAT IMMUNOL, V4, P416, DOI 10.1038/ni0503-416; Jia L, 2001, BLOOD, V98, P414, DOI 10.1182/blood.V98.2.414; Johnson CE, 2007, P NATL ACAD SCI USA, V104, P20820, DOI 10.1073/pnas.0709101105; Jones JM, 2003, NATURE, V425, P721, DOI 10.1038/nature02052; Joza N, 2001, NATURE, V410, P549, DOI 10.1038/35069004; Kawahara A, 1998, J CELL BIOL, V143, P1353, DOI 10.1083/jcb.143.5.1353; Kelliher MA, 1998, IMMUNITY, V8, P297, DOI 10.1016/S1074-7613(00)80535-X; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; Klein JA, 2002, NATURE, V419, P367, DOI 10.1038/nature01034; Kuida K, 1998, CELL, V94, P325, DOI 10.1016/S0092-8674(00)81476-2; Lavrik I, 2005, J CELL SCI, V118, P265, DOI 10.1242/jcs.01610; Leo C, 2007, CLIN CANCER RES, V13, P1149, DOI 10.1158/1078-0432.CCR-06-2371; Levine B, 2008, CELL, V132, P27, DOI 10.1016/j.cell.2007.12.018; Li K, 2000, CELL, V101, P389, DOI 10.1016/S0092-8674(00)80849-1; Li LY, 2001, NATURE, V412, P95, DOI 10.1038/35083620; Lindsten T, 2000, MOL CELL, V6, P1389, DOI 10.1016/S1097-2765(00)00136-2; Lorenzo HK, 1999, CELL DEATH DIFFER, V6, P516, DOI 10.1038/sj.cdd.4400527; Lu M, 2007, MOL CELL, V26, P689, DOI 10.1016/j.molcel.2007.05.006; Martinou I, 1999, J CELL BIOL, V144, P883, DOI 10.1083/jcb.144.5.883; Misaghi S, 2006, CELL DEATH DIFFER, V13, P163, DOI 10.1038/sj.cdd.4401716; Munoz-Pinedo C, 2006, P NATL ACAD SCI USA, V103, P11573, DOI 10.1073/pnas.0603007103; Muro I, 2006, DEVELOPMENT, V133, P3305, DOI 10.1242/dev.02495; Ohta T, 1997, J BIOL CHEM, V272, P23111, DOI 10.1074/jbc.272.37.23111; Okuno S, 1998, J BIOL CHEM, V273, P34272, DOI 10.1074/jbc.273.51.34272; Potts PR, 2003, J CELL BIOL, V163, P789, DOI 10.1083/jcb.200307130; Pyo JO, 2005, J BIOL CHEM, V280, P20722, DOI 10.1074/jbc.M413934200; Revillion F, 2000, EUR J CANCER, V36, P1038, DOI 10.1016/S0959-8049(00)00051-4; Ricci JE, 2004, CELL, V117, P773, DOI 10.1016/j.cell.2004.05.008; Rozman-Pungercar J, 2003, CELL DEATH DIFFER, V10, P881, DOI 10.1038/sj.cdd.4401247; Sanchis D, 2003, CELL DEATH DIFFER, V10, P977, DOI 10.1038/sj.cdd.4401267; Sarin A, 1997, IMMUNITY, V6, P209, DOI 10.1016/S1074-7613(00)80427-6; Sasaki H, 2000, CANCER RES, V60, P5659; Schafer ZT, 2006, DEV CELL, V10, P549, DOI 10.1016/j.devcel.2006.04.008; Schmitt CA, 2002, CANCER CELL, V1, P289, DOI 10.1016/S1535-6108(02)00047-8; Scott CL, 2004, J CELL BIOL, V164, P89, DOI 10.1083/jcb.200310041; Soengas MS, 1999, SCIENCE, V284, P156, DOI 10.1126/science.284.5411.156; Soengas MS, 2001, NATURE, V409, P207, DOI 10.1038/35051606; Stefanis L, 2005, NEUROSCIENTIST, V11, P50, DOI 10.1177/1073858404271087; Susin SA, 1999, NATURE, V397, P441, DOI 10.1038/17135; Suzuki Y, 2001, MOL CELL, V8, P613, DOI 10.1016/S1097-2765(01)00341-0; Tamm I, 2004, HEMATOL J, V5, P489, DOI 10.1038/sj.thj.6200549; Taylor RC, 2008, NAT REV MOL CELL BIO, V9, P231, DOI 10.1038/nrm2312; Temkin V, 2006, MOL CELL BIOL, V26, P2215, DOI 10.1128/MCB.26.6.2215-2225.2006; Vahsen N, 2004, EMBO J, V23, P4679, DOI 10.1038/sj.emboj.7600461; Vande Walle L, 2008, CELL DEATH DIFFER, V15, P453, DOI 10.1038/sj.cdd.4402291; Varkey J, 1999, J CELL BIOL, V144, P701, DOI 10.1083/jcb.144.4.701; Vercammen D, 1998, J EXP MED, V187, P1477, DOI 10.1084/jem.187.9.1477; Verhagen AM, 2000, CELL, V102, P43, DOI 10.1016/S0092-8674(00)00009-X; Waterhouse NJ, 1998, CELL DEATH DIFFER, V5, P1051, DOI 10.1038/sj.cdd.4400425; Wilkinson JC, 2004, MOL CELL BIOL, V24, P7003, DOI 10.1128/MCB.24.16.7003-7014.2004; Wolf BB, 2001, J BIOL CHEM, V276, P34244, DOI 10.1074/jbc.M011778200; Xiang JL, 1996, P NATL ACAD SCI USA, V93, P14559, DOI 10.1073/pnas.93.25.14559; Yamaguchi K, 1999, EMBO J, V18, P179, DOI 10.1093/emboj/18.1.179; Yoshida H, 1998, CELL, V94, P739, DOI 10.1016/S0092-8674(00)81733-X; Yu L, 2004, SCIENCE, V304, P1500, DOI 10.1126/science.1096645; Yu L, 2008, AUTOPHAGY, V4, P567, DOI 10.4161/auto.5902; Zermati Y, 2007, MOL CELL, V28, P624, DOI 10.1016/j.molcel.2007.09.030; Zimmermann KC, 2002, J CELL BIOL, V156, P1077, DOI 10.1083/jcb.20112068; Zlobec I, 2007, EUR J CANCER, V43, P1101, DOI 10.1016/j.ejca.2007.01.029	101	258	267	0	29	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 27	2008	27	50					6452	6461		10.1038/onc.2008.311	http://dx.doi.org/10.1038/onc.2008.311			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	366RR	18955972	Green Accepted			2022-12-28	WOS:000260501600005
J	Blair, GE; Cook, GP				Blair, G. E.; Cook, G. P.			Cancer and the immune system: an overview - Introduction	ONCOGENE			English	Editorial Material									[Blair, G. E.] Univ Leeds, Fac Biol Sci, Inst Mol & Cellular Biol, Leeds LS2 9JT, W Yorkshire, England; [Cook, G. P.] Univ Leeds, Leeds Inst Mol Med, Leeds LS2 9JT, W Yorkshire, England	University of Leeds; University of Leeds	Blair, GE (corresponding author), Univ Leeds, Fac Biol Sci, Inst Mol & Cellular Biol, Garstang Bldg,Room 8-52D, Leeds LS2 9JT, W Yorkshire, England.	g.e.blair@leeds.ac.uk	Blair, George Eric/A-5906-2008	Blair, George Eric/0000-0003-0440-1795; Cook, Graham/0000-0003-0223-3652				Bonavida B, 2007, ONCOGENE, V26, P3592, DOI 10.1038/sj.onc.1210369; Dunn GP, 2002, NAT IMMUNOL, V3, P991, DOI 10.1038/ni1102-991; Kaufmann SHE, 2008, NAT IMMUNOL, V9, P705, DOI 10.1038/ni0708-705; O'Neill LAJ, 2008, ONCOGENE, V27, P158, DOI 10.1038/sj.onc.1210903; TENG MWL, 2008, J LEUKOCYTE BIOL, V84, P1	5	15	16	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 6	2008	27	45					5868	5868		10.1038/onc.2008.277	http://dx.doi.org/10.1038/onc.2008.277			1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	355QE	18836467				2022-12-28	WOS:000259722600001
J	Hasselblatt, P; Gresh, L; Kudo, H; Guinea-Viniegra, J; Wagner, EF				Hasselblatt, P.; Gresh, L.; Kudo, H.; Guinea-Viniegra, J.; Wagner, E. F.			The role of the transcription factor AP-1 in colitis-associated and beta-catenin-dependent intestinal tumorigenesis in mice	ONCOGENE			English	Article						colitis-associated cancer; c-Jun; c-Fos; APC; azoxymethane; colorectal carcinoma	DEXTRAN SODIUM-SULFATE; C-JUN; CYCLIN D1; COLON CARCINOGENESIS; COLORECTAL-CANCER; MOUSE INTESTINE; APC LOSS; EXPRESSION; GENE; PROLIFERATION	Chronic inflammation is an important cancer risk factor but the molecular pathways linking inflammation and cancer are incompletely understood. The transcription factor c-Jun/AP-1 (activator protein 1) is involved in inflammatory responses and tumorigenesis and has been proposed as an essential mediator of oncogenic beta-catenin signaling in the intestine. Here, we examined the functions of c-Jun in two distinct mouse models of conditional and intestine-specific activation of beta-catenin. c-Jun is strongly expressed in the small intestine of mutant mice. However, beta-catenin-dependent cell proliferation is surprisingly not affected in mice lacking c-jun in intestinal epithelium, suggesting that c-Jun is not an essential immediate target of beta-catenin signaling in the small intestine. To examine the functions of Jun and Fos proteins during inflammation and cancer in the colon, colitis-associated tumors were induced chemically in the respective knockout mice. Tumors were characterized by activated beta-catenin and strongly expressed c-Jun and JunB. However, tumorigenesis was not affected by inactivation of c-Jun in either intestinal epithelium or myeloid cells. Moreover, tumorigenesis was not altered in mice lacking junB, junD, c-fos, fra-1 or fra-2, suggesting that inhibition of c-Jun or other single AP-1 proteins is not a determining factor in colitis-associated cancer in mice.	[Hasselblatt, P.; Gresh, L.; Kudo, H.; Guinea-Viniegra, J.; Wagner, E. F.] Res Inst Mol Pathol, A-1030 Vienna, Austria	Vienna Biocenter (VBC); Research Institute of Molecular Pathology (IMP)	Wagner, EF (corresponding author), Spanish Natl Canc Ctr CNIO, Canc Cell Biol Program, Melchor Fernandez Almagro 3, E-28029 Madrid, Spain.	ewagner@cnio.es	Hasselblatt, Peter/AAF-3681-2021	Gresh, Lionel/0000-0002-2333-1748; Wagner, Erwin F/0000-0001-7872-0196; Kudo, Hiromi/0000-0003-4313-7165	Austrian Industrial Research Promotion Fund; WWTF; German Research Foundation; EMBO; Boehringer Ingelheim	Austrian Industrial Research Promotion Fund; WWTF; German Research Foundation(German Research Foundation (DFG)); EMBO(European Molecular Biology Organization (EMBO)); Boehringer Ingelheim(Boehringer Ingelheim)	We are very grateful to Drs L Bakiri, A Behrens, R Eferl and O Sansom for critical reading of the manuscript and helpful discussions, Drs S Robine, C Hartmann, M Taketo and O Sansom for providing mutant mice and V Komnenovic and M Grivej for technical assistance with immunohistochemistry. The IMP is funded by Boehringer Ingelheim and this work was also supported by the Austrian Industrial Research Promotion Fund and by a WWTF grant from the city of Vienna. PH and LG were funded by postdoctoral fellowships of the German Research Foundation and EMBO, respectively.	Andreu P, 2005, DEVELOPMENT, V132, P1443, DOI 10.1242/dev.01700; Bantel H, 2002, FASEB J, V16, P1832, DOI 10.1096/fj.02-0223fje; Becker C, 2004, IMMUNITY, V21, P491, DOI 10.1016/j.immuni.2004.07.020; Behrens A, 2002, EMBO J, V21, P1782, DOI 10.1093/emboj/21.7.1782; Clarke AR, 2006, ONCOGENE, V25, P7512, DOI 10.1038/sj.onc.1210065; Clausen BE, 1999, TRANSGENIC RES, V8, P265, DOI 10.1023/A:1008942828960; Clevers H, 2006, CELL, V127, P469, DOI 10.1016/j.cell.2006.10.018; Eferl R, 2003, NAT REV CANCER, V3, P859, DOI 10.1038/nrc1209; Eferl R, 2004, EMBO J, V23, P2789, DOI 10.1038/sj.emboj.7600282; Eferl R, 2007, GENESIS, V45, P447, DOI 10.1002/dvg.20311; El Marjou F, 2004, GENESIS, V39, P186, DOI 10.1002/gene.20042; Fleischmann A, 2003, J NEUROSCI, V23, P9116; Greten FR, 2004, CELL, V118, P285, DOI 10.1016/j.cell.2004.07.013; Harada N, 1999, EMBO J, V18, P5931, DOI 10.1093/emboj/18.21.5931; Hasselblatt P, 2007, P NATL ACAD SCI USA, V104, P17105, DOI 10.1073/pnas.0706272104; Hulit J, 2004, MOL CELL BIOL, V24, P7598, DOI 10.1128/MCB.24.17.7598-7611.2004; Janne PA, 2000, NEW ENGL J MED, V342, P1960, DOI 10.1056/NEJM200006293422606; Kenner L, 2004, J CELL BIOL, V164, P613, DOI 10.1083/jcb.200308155; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; Mann B, 1999, P NATL ACAD SCI USA, V96, P1603, DOI 10.1073/pnas.96.4.1603; Meixner A, 2004, EMBO J, V23, P1325, DOI 10.1038/sj.emboj.7600133; Nateri AS, 2005, NATURE, V437, P281, DOI 10.1038/nature03914; Radtke F, 2005, SCIENCE, V307, P1904, DOI 10.1126/science.1104815; Sabapathy K, 2001, J EXP MED, V193, P317, DOI 10.1084/jem.193.3.317; Sansom OJ, 2005, J BIOL CHEM, V280, P28463, DOI 10.1074/jbc.M500191200; Sansom OJ, 2004, GENE DEV, V18, P1385, DOI 10.1101/gad.287404; Sansom OJ, 2007, NATURE, V446, P676, DOI 10.1038/nature05674; Shaulian E, 2002, NAT CELL BIOL, V4, pE131, DOI 10.1038/ncb0502-e131; Shibata H, 1997, SCIENCE, V278, P120, DOI 10.1126/science.278.5335.120; Suzuki R, 2004, CANCER SCI, V95, P721, DOI 10.1111/j.1349-7006.2004.tb03252.x; Takahashi M, 2004, CANCER SCI, V95, P475, DOI 10.1111/j.1349-7006.2004.tb03235.x; Taketo MM, 2006, ONCOGENE, V25, P7522, DOI 10.1038/sj.onc.1210058; Tanaka T, 2003, CANCER SCI, V94, P965, DOI 10.1111/j.1349-7006.2003.tb01386.x; Thepot D, 2000, DEVELOPMENT, V127, P143; Tong C, 2007, AM J PATHOL, V171, P297, DOI 10.2353/ajpath.2007.061036; Wagner EF, 2005, IMMUNOL REV, V208, P126, DOI 10.1111/j.0105-2896.2005.00332.x; Wang HL, 2000, CARCINOGENESIS, V21, P1313, DOI 10.1093/carcin/21.7.1313; Wang HLL, 2002, INT J CANCER, V101, P301, DOI 10.1002/ijc.10630	38	26	27	1	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT	2008	27	47					6102	6109		10.1038/onc.2008.211	http://dx.doi.org/10.1038/onc.2008.211			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	360UJ	18679426				2022-12-28	WOS:000260083100003
J	Yin, Y; Shen, WH				Yin, Y.; Shen, W. H.			PTEN: a new guardian of the genome	ONCOGENE			English	Review						PTEN; p53; tumor suppressor; genome guardian; genomic instability; chromosome instability	TUMOR-SUPPRESSOR PTEN; CELL-CYCLE CONTROL; WILD-TYPE P53; HETEROZYGOUS GERMLINE MUTATION; LIPID PHOSPHATASE-ACTIVITY; MAJOR VAULT PROTEIN; COWDEN-DISEASE; BREAST-CANCER; NUCLEAR PTEN; GROWTH SUPPRESSION	The phosphatase and tensin homolog deleted on chromosome 10 (PTEN) tumor suppressor is a phosphatase that antagonizes the phosphoinositol-3-kinase/AKT signaling pathway and suppresses cell survival as well as cell proliferation. PTEN is the second most frequently mutated gene in human cancer after p53. Germline mutations of PTEN have been found in cancer susceptibility syndromes, such as Cowden syndrome, in which over 80% of patients have mutations of PTEN. Homozygous deletion of Pten causes embryonic lethality, suggesting that PTEN is essential for embryonic development. Mice heterozygous for Pten develop spontaneous tumors in a variety of organs comparable with the spectrum of its mutations in human cancer. The mechanisms of PTEN functions in tumor suppression are currently under intense investigation. Recent studies demonstrate that PTEN plays an essential role in the maintenance of chromosomal stability and that loss of PTEN leads to massive alterations of chromosomes. The tumor suppressor p53 is known as a guardian of the genome that mediates the cellular response to environmental stress, leading to cell cycle arrest or cell death. Through completely different mechanisms, PTEN also protects the genome from instability. Thus, we propose that PTEN is a new guardian of the genome. In this review, we will discuss new discoveries on the role of PTEN in tumor suppression and explore mechanisms by which PTEN maintains genomic stability.	[Yin, Y.; Shen, W. H.] Columbia Univ, Dept Radiat Oncol, Coll Phys & Surg, New York, NY 10032 USA	Columbia University	Yin, Y (corresponding author), Columbia Univ, Dept Radiat Oncol, Coll Phys & Surg, VC11-213,630 W 168th St, New York, NY 10032 USA.	yy151@columbia.edu		SHEN, WEN/0000-0002-5830-6518	National Institutes of Health [R01 CA102447]; NATIONAL CANCER INSTITUTE [R01CA102447] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We are grateful to Drs C Walsh and HB Lieberman for their critical comments on the manuscript. This work was supported by a grant from the National Institutes of Health (R01 CA102447 to YY).	Abounader R, 2004, ONCOGENE, V23, P9173, DOI 10.1038/sj.onc.1208146; Agrawal S, 2005, HUM MOL GENET, V14, P2459, DOI 10.1093/hmg/ddi246; Backman SA, 2001, NAT GENET, V29, P396, DOI 10.1038/ng782; Backman SA, 2004, P NATL ACAD SCI USA, V101, P1725, DOI 10.1073/pnas.0308217100; Bai F, 2006, MOL CELL BIOL, V26, P4564, DOI 10.1128/MCB.00266-06; Baker SJ, 2007, CELL, V128, P25, DOI 10.1016/j.cell.2006.12.023; Bilbao C, 2006, INT J CANCER, V119, P563, DOI 10.1002/ijc.21862; BISCHOFF FZ, 1991, ONCOGENE, V6, P183; Borresen-Dale AL, 2003, HUM MUTAT, V21, P292, DOI 10.1002/humu.10174; Cantley LC, 1999, P NATL ACAD SCI USA, V96, P4240, DOI 10.1073/pnas.96.8.4240; Chang CJ, 2008, MOL CELL BIOL, V28, P3281, DOI 10.1128/MCB.00310-08; Chang CJ, 2004, J BIOL CHEM, V279, P29841, DOI 10.1074/jbc.M401488200; Chen ZB, 2005, NATURE, V436, P725, DOI 10.1038/nature03918; Chung JH, 2005, CANCER RES, V65, P4108, DOI 10.1158/0008-5472.CAN-05-0124; Cully M, 2006, NAT REV CANCER, V6, P184, DOI 10.1038/nrc1819; Das S, 2003, P NATL ACAD SCI USA, V100, P7491, DOI 10.1073/pnas.0932835100; Di Cristofano A, 1998, NAT GENET, V19, P348, DOI 10.1038/1235; Di Cristofano A, 2000, CELL, V100, P387, DOI 10.1016/S0092-8674(00)80674-1; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; Emerling BM, 2008, P NATL ACAD SCI USA, V105, P2622, DOI 10.1073/pnas.0706790105; Eng C, 2003, HUM MUTAT, V22, P183, DOI 10.1002/humu.10257; Eng C, 1998, NAT GENET, V19, P223, DOI 10.1038/897; Fanning AS, 1999, CURR OPIN CELL BIOL, V11, P432, DOI 10.1016/S0955-0674(99)80062-3; Flores-Delgado G, 2007, J PROTEOME RES, V6, P1165, DOI 10.1021/pr060504h; Freeman DJ, 2003, CANCER CELL, V3, P117, DOI 10.1016/S1535-6108(03)00021-7; FRIEND SH, 1986, NATURE, V323, P643, DOI 10.1038/323643a0; Fujisawa H, 2000, LAB INVEST, V80, P65, DOI 10.1038/labinvest.3780009; Georgescu MM, 1999, P NATL ACAD SCI USA, V96, P10182, DOI 10.1073/pnas.96.18.10182; Georgescu MM, 2000, CANCER RES, V60, P7033; Gildea JJ, 2004, ONCOGENE, V23, P6788, DOI 10.1038/sj.onc.1207599; Gimm O, 2000, AM J PATHOL, V156, P1693, DOI 10.1016/S0002-9440(10)65040-7; Ginn-Pease ME, 2003, CANCER RES, V63, P282; Gu JG, 1998, J CELL BIOL, V143, P1375, DOI 10.1083/jcb.143.5.1375; GUAN KL, 1994, GENE DEV, V8, P2939, DOI 10.1101/gad.8.24.2939; Hong TM, 2000, AM J RESP CELL MOL, V23, P355, DOI 10.1165/ajrcmb.23.3.4002; Iida S, 2000, ANTICANCER RES, V20, P1901; Iida S, 1998, INT J MOL MED, V1, P565; Kanaseki T, 2002, PATHOBIOLOGY, V70, P34, DOI 10.1159/000066001; Kang-Park S, 2003, FEBS LETT, V545, P203, DOI 10.1016/S0014-5793(03)00535-0; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; Kato H, 2000, CLIN CANCER RES, V6, P3937; Kimura T, 2003, DEVELOPMENT, V130, P1691, DOI 10.1242/dev.00392; Koul A, 2002, CANCER, V94, P2369, DOI 10.1002/cncr.10498; Koul D, 2007, MOL CELL BIOCHEM, V300, P77, DOI 10.1007/s11010-006-9371-8; Kurose K, 2002, NAT GENET, V32, P355, DOI 10.1038/ng1013; Lachyankar MB, 2000, J NEUROSCI, V20, P1404; LANE DP, 1992, NATURE, V358, P16; Langerod A, 2007, BREAST CANCER RES, V9, DOI 10.1186/bcr1675; Lee JO, 1999, CELL, V99, P323, DOI 10.1016/S0092-8674(00)81663-3; Leslie NR, 2007, CURR BIOL, V17, P115, DOI 10.1016/j.cub.2006.12.026; Leslie NR, 2004, BIOCHEM J, V382, P1, DOI 10.1042/BJ20040825; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Levine Arnold J., 2004, Cell, VS116, pS67, DOI 10.1016/S0092-8674(04)00036-4; Li DM, 1997, CANCER RES, V57, P2124; Li DM, 1998, P NATL ACAD SCI USA, V95, P15406, DOI 10.1073/pnas.95.26.15406; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; Li J, 1998, CANCER RES, V58, P5667; Liaw D, 1997, NAT GENET, V16, P64, DOI 10.1038/ng0597-64; Liliental J, 2000, CURR BIOL, V10, P401, DOI 10.1016/S0960-9822(00)00417-6; Liu FH, 2005, J CELL BIOCHEM, V96, P221, DOI 10.1002/jcb.20525; Liu JL, 2005, MOL CELL BIOL, V25, P6211, DOI 10.1128/MCB.25.14.6211-6224.2005; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; Maehama T, 1998, J BIOL CHEM, V273, P13375, DOI 10.1074/jbc.273.22.13375; Mahimainathan L, 2004, J BIOL CHEM, V279, P15258, DOI 10.1074/jbc.M314328200; Maier D, 1999, CANCER RES, V59, P5479; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; Matsushima-Nishiu M, 2001, CANCER RES, V61, P3741; Mayo LD, 2002, TRENDS BIOCHEM SCI, V27, P462, DOI 10.1016/S0968-0004(02)02166-7; Mayo MW, 2002, J BIOL CHEM, V277, P11116, DOI 10.1074/jbc.M108670200; McGarrity TJ, 2003, AM J GASTROENTEROL, V98, P1429, DOI 10.1016/S0002-9270(03)00276-4; MEDEMA RH, 1995, P NATL ACAD SCI USA, V92, P6289, DOI 10.1073/pnas.92.14.6289; Minaguchi T, 2006, CANCER RES, V66, P11677, DOI 10.1158/0008-5472.CAN-06-2240; Moon SK, 2004, ARCH BIOCHEM BIOPHYS, V421, P267, DOI 10.1016/j.abb.2003.11.007; Myers MP, 1997, P NATL ACAD SCI USA, V94, P9052, DOI 10.1073/pnas.94.17.9052; Myers MP, 1998, P NATL ACAD SCI USA, V95, P13513, DOI 10.1073/pnas.95.23.13513; Nan B, 2003, J MOL ENDOCRINOL, V31, P169, DOI 10.1677/jme.0.0310169; Okumura K, 2005, CELL CYCLE, V4, P540, DOI 10.4161/cc.4.4.1614; Paramio JM, 1999, ONCOGENE, V18, P7462, DOI 10.1038/sj.onc.1203151; Park MJ, 2002, CANCER RES, V62, P6318; Parsons R, 2004, SEMIN CELL DEV BIOL, V15, P171, DOI 10.1016/j.semcdb.2003.12.021; Perren A, 2000, AM J PATHOL, V157, P1097, DOI 10.1016/S0002-9440(10)64624-X; Podsypanina K, 1999, P NATL ACAD SCI USA, V96, P1563, DOI 10.1073/pnas.96.4.1563; Puc J, 2005, CANCER CELL, V7, P193, DOI 10.1016/j.ccr.2005.01.009; Puc J, 2005, CELL CYCLE, V4, P927, DOI 10.4161/cc.4.7.1795; QUELLE DE, 1995, ONCOGENE, V11, P635; Raftopoulou M, 2004, SCIENCE, V303, P1179, DOI 10.1126/science.1092089; Ramaswamy S, 1999, P NATL ACAD SCI USA, V96, P2110, DOI 10.1073/pnas.96.5.2110; Saal LH, 2008, NAT GENET, V40, P102, DOI 10.1038/ng.2007.39; Sano T, 1999, CANCER RES, V59, P1820; Sansal I, 2004, J CLIN ONCOL, V22, P2954, DOI 10.1200/jco.2004.02.141; Shen WH, 2007, CELL, V128, P157, DOI 10.1016/j.cell.2006.11.042; Shin KH, 2002, INT J ONCOL, V21, P997; Shmueli A, 2005, CELL, V121, P963, DOI 10.1016/j.cell.2005.06.018; Shmueli A, 2004, MOL CELL, V13, P4, DOI 10.1016/S1097-2765(03)00529-X; Simpson L, 2001, EXP CELL RES, V264, P29, DOI 10.1006/excr.2000.5130; Stambolic V, 1998, CELL, V95, P29, DOI 10.1016/S0092-8674(00)81780-8; Stambolic V, 2000, CANCER RES, V60, P3605; Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356; STRONG LC, 1992, AM J EPIDEMIOL, V135, P190, DOI 10.1093/oxfordjournals.aje.a116271; Sulis ML, 2003, TRENDS CELL BIOL, V13, P478, DOI 10.1016/S0962-8924(03)00175-2; Sun H, 1999, P NATL ACAD SCI USA, V96, P6199, DOI 10.1073/pnas.96.11.6199; Suzuki A, 1998, CURR BIOL, V8, P1169, DOI 10.1016/S0960-9822(07)00488-5; Tamura M, 1998, SCIENCE, V280, P1614, DOI 10.1126/science.280.5369.1614; Tang YF, 2006, CANCER RES, V66, P736, DOI 10.1158/0008-5472.CAN-05-1557; TLSTY TD, 1994, COLD SPRING HARB SYM, V59, P265, DOI 10.1101/SQB.1994.059.01.031; Trotman LC, 2006, NATURE, V441, P523, DOI 10.1038/nature04809; Trotman LC, 2007, CELL, V128, P141, DOI 10.1016/j.cell.2006.11.040; Vivanco I, 2007, CANCER CELL, V11, P555, DOI 10.1016/j.ccr.2007.04.021; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Waite KA, 2002, AM J HUM GENET, V70, P829, DOI 10.1086/340026; Wang SI, 1997, CANCER RES, V57, P4183; Wang XJ, 2007, CELL, V128, P129, DOI 10.1016/j.cell.2006.11.039; WEINBERG RA, 1992, CANCER SURV, V12, P43; Weng LP, 2002, HUM MOL GENET, V11, P1687, DOI 10.1093/hmg/11.15.1687; Weng LP, 2001, HUM MOL GENET, V10, P237, DOI 10.1093/hmg/10.3.237; Weng LP, 2001, HUM MOL GENET, V10, P605, DOI 10.1093/hmg/10.6.605; Whiteman DC, 2002, INT J CANCER, V99, P63, DOI 10.1002/ijc.10294; Woiwode A, 2008, MOL CELL BIOL, V28, P4204, DOI 10.1128/MCB.01912-07; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; YIN YX, 1992, CELL, V70, P937, DOI 10.1016/0092-8674(92)90244-7; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0	122	267	274	0	26	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 15	2008	27	41					5443	5453		10.1038/onc.2008.241	http://dx.doi.org/10.1038/onc.2008.241			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	349KW	18794879				2022-12-28	WOS:000259280700006
J	Hanashiro, K; Kanai, M; Geng, Y; Sicinski, P; Fukasawa, K				Hanashiro, K.; Kanai, M.; Geng, Y.; Sicinski, P.; Fukasawa, K.			Roles of cyclins A and E in induction of centrosome amplification in p53-compromised cells	ONCOGENE			English	Article						centrosome; cyclin A; cyclin E; CDK2; p53; centrosome amplification	CHROMOSOME INSTABILITY; E OVEREXPRESSION; DNA-SYNTHESIS; P53 MUTATION; CANCER; DUPLICATION; HYPERAMPLIFICATION; ACTIVATION; EXPRESSION; EXPOSURE	Abnormal amplification of centrosomes, which occurs frequently in cancers, leads to high frequencies of mitotic defect and chromosome segregation error, profoundly affecting the rate of tumor progression. Centrosome amplification results primarily from overduplication of centrosomes, and p53 is involved in the regulation of centrosome duplication partly through controlling the activity of cyclin-dependent kinase (CDK) 2-cyclin E, a kinase complex critical for the initiation of centrosome duplication. Thus, loss or mutational inactivation of p53 leads to an increased frequency of centrosome amplification. Moreover, the status of cyclin E greatly influences the frequency of centrosome amplification in cells lacking functional p53. Here, we dissected the roles of CDK2-associating cyclins, namely cyclins E and A, in centrosome amplification in the p53-negative cells. We found that loss of cyclin E was readily compensated by cyclin A for triggering the initiation of centrosome duplication, and thus the centrosome duplication kinetics was not significantly altered in cyclin E-deficient cells. It has been shown that cells lacking functional p53, when arrested in either early S-phase or late G(2) phase, continue to reduplicate centrosomes, resulting in centrosome amplification. In cells arrested in early S phase, cyclin E, but not cyclin A, is important in centrosome amplification, whereas in the absence of cyclin E, cyclin A is important for centrosome amplification. In late G(2)-arrested cells, cyclin A is important in centrosome amplification irrespective of the cyclin E status. These findings advance our understandings of the mechanisms underlying the numeral abnormality of centrosomes and consequential genomic instability associated with loss of p53 function and aberrant expression of cyclins E and A in cancer cells.	[Hanashiro, K.; Kanai, M.; Fukasawa, K.] H Lee Moffitt Canc Ctr & Res Inst, Mol Oncol Program, Tampa, FL 33612 USA; [Geng, Y.; Sicinski, P.] Dana Farber Canc Inst, Dept Canc Biol, Boston, MA 02115 USA; [Geng, Y.; Sicinski, P.] Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA	H Lee Moffitt Cancer Center & Research Institute; Harvard University; Dana-Farber Cancer Institute; Harvard University; Harvard Medical School	Fukasawa, K (corresponding author), H Lee Moffitt Canc Ctr & Res Inst, Mol Oncol Program, 12902 Magnolia Dr,SRB-2, Tampa, FL 33612 USA.	kenji.fukasawa@mof.tt.org	Kanai, Motomu/J-6807-2016	Kanai, Motomu/0000-0003-1977-7648	National Institutes of Health, USA [CA90522, CA108950]; NATIONAL CANCER INSTITUTE [R01CA108950, R01CA090522] Funding Source: NIH RePORTER	National Institutes of Health, USA(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank C French, A Wilson and M Crowe for technical assistance, and Drs Z Andrysik and S Schwemberger for FACS analysis. This research is supported by the grants from National Institutes of Health, USA (CA90522 to KF and CA108950 to PS).	BALCZON R, 1995, J CELL BIOL, V130, P105, DOI 10.1083/jcb.130.1.105; Bennett RA, 2004, ONCOGENE, V23, P6823, DOI 10.1038/sj.onc.1207561; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Carroll PE, 1999, ONCOGENE, V18, P1935, DOI 10.1038/sj.onc.1202515; Coverley D, 2002, NAT CELL BIOL, V4, P523, DOI 10.1038/ncb813; DEGREGORI J, 1995, MOL CELL BIOL, V15, P4215; Desdouets C, 1995, Prog Cell Cycle Res, V1, P115; Dodson H, 2004, EMBO J, V23, P3864, DOI 10.1038/sj.emboj.7600393; Fukasawa K, 2005, CANCER LETT, V230, P6, DOI 10.1016/j.canlet.2004.12.028; Fukasawa K, 1996, SCIENCE, V271, P1744, DOI 10.1126/science.271.5256.1744; Fukasawa K, 2007, NAT REV CANCER, V7, P911, DOI 10.1038/nrc2249; Geng Y, 2003, CELL, V114, P431, DOI 10.1016/S0092-8674(03)00645-7; Hinchcliffe EH, 1999, SCIENCE, V283, P851, DOI 10.1126/science.283.5403.851; HOFFMAN BD, 1991, CYTOMETRY, V12, P26, DOI 10.1002/cyto.990120105; Horn HF, 2007, ONCOGENE, V26, P1306, DOI 10.1038/sj.onc.1210263; JOSHI HC, 1994, CURR OPIN CELL BIOL, V6, P55, DOI 10.1016/0955-0674(94)90116-3; Kastan MB, 2004, NATURE, V432, P316, DOI 10.1038/nature03097; Kawamura K, 2006, CANCER SCI, V97, P252, DOI 10.1111/j.1349-7006.2006.00168.x; Kawamura K, 2004, CANCER RES, V64, P4800, DOI 10.1158/0008-5472.CAN-03-3908; Lacey KR, 1999, P NATL ACAD SCI USA, V96, P2817, DOI 10.1073/pnas.96.6.2817; Mussman JG, 2000, ONCOGENE, V19, P1635, DOI 10.1038/sj.onc.1203460; Ossovskaya VS, 1996, P NATL ACAD SCI USA, V93, P10309, DOI 10.1073/pnas.93.19.10309; Pihan GA, 1998, CANCER RES, V58, P3974; Sweeney C, 1996, DEVELOPMENT, V122, P53; Tarapore P, 2001, ONCOGENE, V20, P3173, DOI 10.1038/sj.onc.1204424; Taylor WR, 2001, ONCOGENE, V20, P1803, DOI 10.1038/sj.onc.1204252; Tokuyama Y, 2001, J BIOL CHEM, V276, P21529, DOI 10.1074/jbc.M100014200; Wang XJ, 1998, MOL CARCINOGEN, V23, P185, DOI 10.1002/(SICI)1098-2744(199811)23:3<185::AID-MC7>3.0.CO;2-5; Wong C, 2003, NAT CELL BIOL, V5, P539, DOI 10.1038/ncb993	29	32	33	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 11	2008	27	40					5288	5302		10.1038/onc.2008.161	http://dx.doi.org/10.1038/onc.2008.161			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	346UW	18490919	Green Accepted			2022-12-28	WOS:000259096100002
J	Petrie, K; Guidez, F; Zhu, J; Howell, L; Owen, G; Chew, YP; Parks, S; Waxman, S; Licht, J; Mittnacht, S; Zelent, A				Petrie, K.; Guidez, F.; Zhu, J.; Howell, L.; Owen, G.; Chew, Y. P.; Parks, S.; Waxman, S.; Licht, J.; Mittnacht, S.; Zelent, A.			Retinoblastoma protein and the leukemia-associated PLZF transcription factor interact to repress target gene promoters	ONCOGENE			English	Article						PLZF; Rb; E2F1	ACUTE PROMYELOCYTIC LEUKEMIA; ZINC-FINGER PROTEIN; PML-RAR-ALPHA; HISTONE DEACETYLASE; PROGENITOR CELLS; FUSION PROTEINS; SELF-RENEWAL; E2F FUNCTION; DNA-BINDING; STEM-CELLS	Translocations of the retinoic acid receptor-alpha (RAR alpha) locus with the promyelocytic leukemia zinc-finger (PLZF) or PML genes lead to expression of oncogenic PLZF RAR alpha or PML-RAR alpha fusion proteins, respectively. These fusion oncoproteins constitutively repress RAR alpha target genes, in large part through aberrant recruitment of multiprotein co-repressor complexes. PML and PML RAR alpha have previously been shown to associate with the retinoblastoma (Rb) tumour suppressor protein in its hypophosphorylated state. Here, we demonstrate that PLZF also interacts with Rb in vitro and in vivo. The interaction between PLZF and Rb is mediated through the Rb pocket and the region of PLZF that lies between its transcriptional repression (poxvirus and zinc-finger, POZ) and DNA-binding (zinc-finger) domains. In addition, Rb can simultaneously interact with PLZF and the E2F1 S phase-inducing transcription factor, suggesting that these proteins can exist in the same multiprotein complex. In contrast to the interaction of Rb with PML or E2F1, the PLZF-Rb interaction is not dependent on hypophosphorylation of Rb. These data are supported by chromatin immunoprecipitation analysis, which indicates that PLZF associates with the promoter region of CDC6, a known E2F/Rb target gene. Co-expression of PLZF and Rb results in enhancement of transcriptional repression of PLZF and E2F/Rb target genes, indicating functional co-operation between the two proteins. Both PLZF and Rb have been shown to function in stem cells and taken together these data suggest that interactions between PLZF and Rb could be important in stem cell biology.	[Petrie, K.; Howell, L.; Zelent, A.] Inst Canc Res, Sect Haemato Oncol, Sutton SM2 5NG, Surrey, England; [Guidez, F.; Parks, S.] Kings Coll London, Dept Med & Mol Genet, London WC2R 2LS, England; [Zhu, J.] Shanghai Med Univ 2, Ruijin Hosp, Shanghai Inst Hematol, Shanghai, Peoples R China; [Owen, G.] Catholic Univ Chile, Fac Biol Sci, Dept Physiol, Santiago, Chile; [Chew, Y. P.; Mittnacht, S.] Inst Canc Res, Canc Res UK Ctr Cell & Mol Biol, London, England; [Waxman, S.] Mt Sinai Sch Med, Div Hematol & Med Oncol, New York, NY 10029 USA; [Licht, J.] Northwestern Univ, Feinberg Sch Med, Div Hematol Oncol, Chicago, IL 60611 USA	University of London; Institute of Cancer Research - UK; University of London; King's College London; Shanghai Jiao Tong University; Pontificia Universidad Catolica de Chile; Cancer Research UK; Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK; Icahn School of Medicine at Mount Sinai; Northwestern University; Feinberg School of Medicine	Zelent, A (corresponding author), Inst Canc Res, Sect Haemato Oncol, 15 Cotswold Rd, Sutton SM2 5NG, Surrey, England.	arthur.zelent@icr.ac.uk	Zelent, Arthur/B-3532-2009; Petrie, Kevin/I-7115-2015; Guidez, Fabien/P-4220-2019; Licht, Jonathan/L-4239-2019; Owen, Gareth Ivor/A-5100-2013; Licht, Jonathan/AAL-9184-2020; Guidez, Fabien/B-3750-2009	Petrie, Kevin/0000-0002-9805-9152; Guidez, Fabien/0000-0003-1380-4473; Licht, Jonathan/0000-0002-3942-1369; Zelent, Arthur/0000-0002-7968-9888	Leukaemia Research Fund of Great Britain; Samuel Waxman Cancer Research Foundation; Kay Kendall Leukaemia Fund; Cancer Research UK; National Institute of Health [CA59936]; NATIONAL CANCER INSTITUTE [R01CA059936] Funding Source: NIH RePORTER	Leukaemia Research Fund of Great Britain; Samuel Waxman Cancer Research Foundation; Kay Kendall Leukaemia Fund; Cancer Research UK(Cancer Research UK); National Institute of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We acknowledge support from the Leukaemia Research Fund of Great Britain (AZ and FG), the Samuel Waxman Cancer Research Foundation, the Kay Kendall Leukaemia Fund (KP), Cancer Research UK (SM) and the National Institute of Health (CA59936, AZ, JL and SW). We also thank Drs Angela Barrett and Manuel Boix-Chornet for critical reading of the article.	Alcalay M, 1998, MOL CELL BIOL, V18, P1084, DOI 10.1128/MCB.18.2.1084; Barna M, 2002, DEV CELL, V3, P499, DOI 10.1016/S1534-5807(02)00289-7; Barna M, 2000, NAT GENET, V25, P166, DOI 10.1038/76014; Bergh G, 1999, BLOOD, V94, P1971; Buaas FW, 2004, NAT GENET, V36, P647, DOI 10.1038/ng1366; CHEN Z, 1994, P NATL ACAD SCI USA, V91, P1178, DOI 10.1073/pnas.91.3.1178; Chew YP, 1998, ONCOGENE, V17, P2177, DOI 10.1038/sj.onc.1202443; Costoya JA, 2004, NAT GENET, V36, P653, DOI 10.1038/ng1367; CROOK T, 1991, ONCOGENE, V6, P873; Dai MS, 2002, J BIOL CHEM, V277, P26327, DOI 10.1074/jbc.M201834200; Dong S, 1996, P NATL ACAD SCI USA, V93, P3624, DOI 10.1073/pnas.93.8.3624; Felsani A, 2006, ONCOGENE, V25, P5277, DOI 10.1038/sj.onc.1209621; Galderisi U, 2006, ONCOGENE, V25, P5250, DOI 10.1038/sj.onc.1209736; Giacinti C, 2006, ONCOGENE, V25, P5220, DOI 10.1038/sj.onc.1209615; Giangrande PH, 2004, EMBO J, V23, P1336, DOI 10.1038/sj.emboj.7600134; Grignani F, 1998, NATURE, V391, P815, DOI 10.1038/35901; Guidez F, 2005, MOL CELL BIOL, V25, P5552, DOI 10.1128/MCB.25.13.5552-5566.2005; Guidez F, 1998, BLOOD, V91, P2634, DOI 10.1182/blood.V91.8.2634.2634_2634_2642; He LZ, 1998, NAT GENET, V18, P126, DOI 10.1038/ng0298-126; Hong SH, 1997, P NATL ACAD SCI USA, V94, P9028, DOI 10.1073/pnas.94.17.9028; Hsieh JK, 1997, GENE DEV, V11, P1840, DOI 10.1101/gad.11.14.1840; Ivins S, 2003, ONCOGENE, V22, P3685, DOI 10.1038/sj.onc.1206328; Kelly KF, 2006, TRENDS CELL BIOL, V16, P578, DOI 10.1016/j.tcb.2006.09.003; Khan MM, 2001, J BIOL CHEM, V276, P43491, DOI 10.1074/jbc.C100532200; Koken MHM, 1997, P NATL ACAD SCI USA, V94, P10255, DOI 10.1073/pnas.94.19.10255; Korenjak M, 2004, CELL, V119, P181, DOI 10.1016/j.cell.2004.09.034; Labbaye C, 1999, ONCOGENE, V18, P3529, DOI 10.1038/sj.onc.1202682; Licht JD, 1996, ONCOGENE, V12, P323; Lin RJ, 1998, NATURE, V391, P811, DOI 10.1038/35895; Macaluso M, 2006, ONCOGENE, V25, P5263, DOI 10.1038/sj.onc.1209680; McConnell MJ, 2003, MOL CELL BIOL, V23, P9375, DOI 10.1128/MCB.23.24.9375-9388.2003; Morris EJ, 2001, ADV CANCER RES, V82, P1, DOI 10.1016/S0065-230X(01)82001-7; MUDRYJ M, 1990, EMBO J, V9, P2179, DOI 10.1002/j.1460-2075.1990.tb07387.x; Petrie K, 2003, J BIOL CHEM, V278, P16059, DOI 10.1074/jbc.M212935200; Piazza F, 2004, MOL CELL BIOL, V24, P10456, DOI 10.1128/MCB.24.23.10456-10469.2004; REID A, 1995, BLOOD, V86, P4544, DOI 10.1182/blood.V86.12.4544.bloodjournal86124544; Schlisio S, 2002, EMBO J, V21, P5775, DOI 10.1093/emboj/cdf577; Shaknovich R, 1998, MOL CELL BIOL, V18, P5533, DOI 10.1128/MCB.18.9.5533; Sivertsen EA, 2006, BRIT J HAEMATOL, V135, P117, DOI 10.1111/j.1365-2141.2006.06252.x; Walkley CR, 2006, P NATL ACAD SCI USA, V103, P9057, DOI 10.1073/pnas.0603389103; Warrell RP, 1997, INT J CANCER, V70, P496, DOI 10.1002/(SICI)1097-0215(19970207)70:4<496::AID-IJC25>3.3.CO;2-P; Yan Z, 1998, P NATL ACAD SCI USA, V95, P3603, DOI 10.1073/pnas.95.7.3603; YAVUZER U, 1995, ONCOGENE, V10, P123; Yeyati PL, 1999, ONCOGENE, V18, P925, DOI 10.1038/sj.onc.1202375; Yoshimoto T, 2006, EXP CELL RES, V312, P2040, DOI 10.1016/j.yexcr.2006.03.001; Zarkowska T, 1997, J BIOL CHEM, V272, P12738, DOI 10.1074/jbc.272.19.12738; Zelent A, 2001, ONCOGENE, V20, P7186, DOI 10.1038/sj.onc.1204766	47	8	8	1	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP	2008	27	39					5260	5266		10.1038/onc.2008.159	http://dx.doi.org/10.1038/onc.2008.159			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	344GO	18504436				2022-12-28	WOS:000258915100010
J	Komori, K; Takagi, Y; Sanada, M; Lim, TH; Nakatsu, Y; Tsuzuki, T; Sekiguchi, M; Hidaka, M				Komori, K.; Takagi, Y.; Sanada, M.; Lim, T-H; Nakatsu, Y.; Tsuzuki, T.; Sekiguchi, M.; Hidaka, M.			A novel protein, MAPO1, that functions in apoptosis triggered by O-6-methylguanine mispair in DNA	ONCOGENE			English	Article						apoptosis; gene-trap mutagenesis; Mapo1; MGMT; O-6-methylguanine	EMBRYONIC STEM-CELLS; ALKYLATION-INDUCED APOPTOSIS; MISMATCH REPAIR; O-6-ALKYLGUANINE-DNA ALKYLTRANSFERASE; ANTINEOPLASTIC DRUGS; ESCHERICHIA-COLI; INDUCE APOPTOSIS; KNOCKOUT MICE; MUTL-ALPHA; ATR KINASE	O-6-Methylguanine produced in DNA induces mutation due to its ambiguous base-pairing properties during DNA replication. To suppress such an outcome, organisms possess a mechanism to eliminate cells carrying O-6-methylguanine by inducing apoptosis that requires the function of mismatch repair proteins. To identify other factors involved in this apoptotic process, we performed retrovirus-mediated gene-trap mutagenesis and isolated a mutant that acquired resistance to a simple alkylating agent, N-methyl-N-nitrosourea (MNU). However, it was still sensitive to methyl methanesulfonate, 1-(4-amino-2methyl- 5-pyrimidinyl) methyl-3-(2-chloroethyl)-3-nitrosourea, etoposide and ultraviolet irradiation. Moreover, the mutant exhibited an increased mutant frequency after exposure to MNU. The gene responsible was identified and designated Mapo1 (O-6-methylguanine- induced apoptosis 1). When the expression of the gene was inhibited by small interfering RNA, MNU-induced apoptosis was significantly suppressed. In the Mapo1-defective mutant cells treated with MNU, the mitochondrial membrane depolarization and caspase-3 activation were severely suppressed, although phosphorylation of p53, CHK1 and histone H2AX was observed. The orthologs of the Mapo1 gene are present in various organisms from nematode to humans. Both mouse and human MAPO1 proteins expressed in cells localize in the cytoplasm. We therefore propose that MAPO1 may play a role in the signaltransduction pathway of apoptosis induced by O-6-methyl-guanine-mispaired lesions.	[Hidaka, M.] Fukuoka Dent Coll, Dept Physiol Sci & Mol Biol, Sawara Ku, Fukuoka 8140193, Japan; [Komori, K.; Sekiguchi, M.; Hidaka, M.] Biomol Engn Res Inst, Dept Mol Biol, Suita, Osaka, Japan; [Takagi, Y.; Sekiguchi, M.] Fukuoka Dent Coll, Frontier Res Ctr, Fukuoka 8140193, Japan; [Lim, T-H; Nakatsu, Y.; Tsuzuki, T.; Hidaka, M.] Kyushu Univ, Fac Med Sci, Dept Med Biophys & Radiat Biol, Fukuoka 812, Japan	Fukuoka Dental College (FDC); Fukuoka Dental College (FDC); Kyushu University	Hidaka, M (corresponding author), Fukuoka Dent Coll, Dept Physiol Sci & Mol Biol, Sawara Ku, 2-15-1 Tamura, Fukuoka 8140193, Japan.	hidaka@college.fdcnet.ac.jp		Nakatsu, Yoshimichi/0000-0001-7408-7071	Kazusa DNA Research Institute [hKIAA1450cDNA]; Ministry of Education, Culture, Sports, Science and Technology of Japan	Kazusa DNA Research Institute; Ministry of Education, Culture, Sports, Science and Technology of Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT))	We thank the Kazusa DNA Research Institute for providing hKIAA1450cDNA. This study was supported by grants (including a Frontier Research Grant) from the Ministry of Education, Culture, Sports, Science and Technology of Japan.	BERANEK DT, 1990, MUTAT RES, V231, P11, DOI 10.1016/0027-5107(90)90173-2; BRANCH P, 1993, NATURE, V362, P652, DOI 10.1038/362652a0; Caporali S, 2004, MOL PHARMACOL, V66, P478; Cejka P, 2003, EMBO J, V22, P2245, DOI 10.1093/emboj/cdg216; Christmann M, 2000, J BIOL CHEM, V275, P36256, DOI 10.1074/jbc.M005377200; COSSARIZZA A, 1994, EXP CELL RES, V214, P323, DOI 10.1006/excr.1994.1264; COULONDRE C, 1977, J MOL BIOL, V117, P577, DOI 10.1016/0022-2836(77)90059-6; Fishel R, 1998, GENE DEV, V12, P2096, DOI 10.1101/gad.12.14.2096; Glaab WE, 1998, MUTAT RES-FUND MOL M, V398, P197, DOI 10.1016/S0027-5107(98)00004-9; Glassner BJ, 1999, MUTAGENESIS, V14, P339, DOI 10.1093/mutage/14.3.339; Guo G, 2004, NATURE, V429, P891, DOI 10.1038/nature02653; Haracska L, 2000, MOL CELL BIOL, V20, P8001, DOI 10.1128/MCB.20.21.8001-8007.2000; Hickman MJ, 2004, MOL CELL, V14, P105, DOI 10.1016/S1097-2765(04)00162-5; Hickman MJ, 1999, P NATL ACAD SCI USA, V96, P10764, DOI 10.1073/pnas.96.19.10764; Hidaka M, 2005, NUCLEIC ACIDS RES, V33, P5703, DOI 10.1093/nar/gki878; Ishida Y, 1999, NUCLEIC ACIDS RES, V27, DOI 10.1093/nar/27.24.e35; ITO T, 1994, MUTAT RES, V314, P273, DOI 10.1016/0921-8777(94)90071-X; KAINA B, 1991, CARCINOGENESIS, V12, P1857; Kaina B, 2007, DNA REPAIR, V6, P1079, DOI 10.1016/j.dnarep.2007.03.008; Karran P, 2001, CARCINOGENESIS, V22, P1931, DOI 10.1093/carcin/22.12.1931; KAT A, 1993, P NATL ACAD SCI USA, V90, P6424, DOI 10.1073/pnas.90.14.6424; Kawate H, 2000, CARCINOGENESIS, V21, P301, DOI 10.1093/carcin/21.2.301; Kawate H, 1998, P NATL ACAD SCI USA, V95, P5116, DOI 10.1073/pnas.95.9.5116; LI GM, 1995, P NATL ACAD SCI USA, V92, P1950, DOI 10.1073/pnas.92.6.1950; LOECHLER EL, 1984, P NATL ACAD SCI-BIOL, V81, P6271, DOI 10.1073/pnas.81.20.6271; Margison GP, 2002, BIOESSAYS, V24, P255, DOI 10.1002/bies.10063; Meikrantz W, 1998, CARCINOGENESIS, V19, P369, DOI 10.1093/carcin/19.2.369; Ochs K, 2000, CANCER RES, V60, P5815; Pegg AE, 2000, MUTAT RES-REV MUTAT, V462, P83, DOI 10.1016/S1383-5742(00)00017-X; Peng M, 2007, EMBO J, V26, P3238, DOI 10.1038/sj.emboj.7601754; Pepponi R, 2003, J PHARMACOL EXP THER, V304, P661, DOI 10.1124/jpet.102.043950; Sakumi K, 1997, CANCER RES, V57, P2415; Sanada M, 2007, CARCINOGENESIS, V28, P2657, DOI 10.1093/carcin/bgm188; SINGER B, 1989, P NATL ACAD SCI USA, V86, P8271, DOI 10.1073/pnas.86.21.8271; Stojic L, 2004, GENE DEV, V18, P1331, DOI 10.1101/gad.294404; Takagi Y, 2003, DNA REPAIR, V2, P1135, DOI 10.1016/S1568-7864(03)00134-4; Takagi Y, 2008, BIOCHEM PHARMACOL, V76, P303, DOI 10.1016/j.bcp.2008.05.008; Tominaga Y, 1997, CARCINOGENESIS, V18, P889, DOI 10.1093/carcin/18.5.889; Tsuzuki T, 1996, CARCINOGENESIS, V17, P1215, DOI 10.1093/carcin/17.6.1215; Wiles MV, 2000, NAT GENET, V24, P13, DOI 10.1038/71622; Yoshioka K, 2006, MOL CELL, V22, P501, DOI 10.1016/j.molcel.2006.04.023	41	8	10	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB	2009	28	8					1142	1150		10.1038/onc.2008.462	http://dx.doi.org/10.1038/onc.2008.462			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	412KE	19137017				2022-12-28	WOS:000263722900009
J	Wang, T; Chen, YH; Hong, H; Zeng, Y; Zhang, J; Lu, JP; Jeansonne, B; Lu, Q				Wang, T.; Chen, Y-H; Hong, H.; Zeng, Y.; Zhang, J.; Lu, J-P; Jeansonne, B.; Lu, Q.			Increased nucleotide polymorphic changes in the 5 '-untranslated region of delta-catenin (CTNND2) gene in prostate cancer	ONCOGENE			English	Article						single-strand conformation polymorphism; single nucleotide polymorphism; 5 '-UTR mutation; methylation; gene amplification	CARCINOMA-CELL-LINE; DU-CHAT SYNDROME; E-CADHERIN; EXPRESSION; PROTEIN; JUNCTION; PAX6; PCR; OVEREXPRESSION; IDENTIFICATION	Cancer pathogenesis involves multiple genetic and epigenetic alterations, which result in oncogenic changes in gene expression. delta-Catenin (CTNND2) is overexpressed in cancer, although the mechanisms of its upregulation are highly variable. Here we report that in prostate cancer, the methylation of CpG islands in the delta-catenin promoter was not a primary regulatory event. There was also no delta-catenin gene amplification. However, using the single-strand conformation polymorphism analysis, we observed the increased nucleotide changes in the 5'-untranslated region of delta-catenin gene in human prostate cancer. At least one such change (-9 G>A) is a true somatic point mutation associated with a high Gleason's score, poorly differentiated prostatic adenocarcinoma. Laser capture microdissection coupled with PCR analyses detected the mutation only in cancerous but not in the adjacent benign prostatic tissues. Using chimeric genes encoding the luciferase reporter, we found that this mutation, but not a random mutation or a mutation that disrupts an upstream open reading frame, resulted in a remarkably higher expression and enzyme activity. This mutation did not affect transcriptional efficiency, suggesting that it promotes delta-catenin translation. This is the first report of delta-catenin gene mutation in cancer and supports the notion that multiple mechanisms contribute to its increased expression in carcinogenesis.	[Wang, T.; Chen, Y-H; Zeng, Y.; Zhang, J.; Lu, J-P; Jeansonne, B.; Lu, Q.] E Carolina Univ, Brody Sch Med, Dept Anat & Cell Biol, Greenville, NC 27834 USA; [Hong, H.] E Carolina Univ, Brody Sch Med, Dept Pathol & Lab Med, Greenville, NC 27834 USA; [Lu, Q.] E Carolina Univ, Brody Sch Med, Leo Jenkins Canc Ctr, Greenville, NC 27834 USA; [Wang, T.] Capital Med Univ, Dept Oncol, Beijing, Peoples R China	University of North Carolina; East Carolina University; University of North Carolina; East Carolina University; University of North Carolina; East Carolina University; Capital Medical University	Lu, Q (corresponding author), E Carolina Univ, Brody Sch Med, Dept Anat & Cell Biol, 7N84 Brody Sci Bldg,600 Moye Blvd, Greenville, NC 27834 USA.	luq@ecu.edu	Lu, Jianping/AFL-6811-2022	Lu, Jianping/0000-0001-9601-0040	NIH; NCI [CA111891]; Department of Defense [PC040569]; NATIONAL CANCER INSTITUTE [R01CA111891] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Department of Defense(United States Department of Defense); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Melissa Clark and GW Lanford for excellent technical assistance, and Lu laboratory members for many helpful discussions. This study was supported in part by NIH/NCI (CA111891) and the Department of Defense (PC040569) grants (QL).	Burger MJ, 2002, INT J CANCER, V100, P228, DOI 10.1002/ijc.10468; Cervera M, 2005, AM J MED GENET A, V136A, P381, DOI 10.1002/ajmg.a.30791; Duparc RH, 2006, DEV BIOL, V300, P647, DOI 10.1016/j.ydbio.2006.07.045; Fatima S, 2006, INT J MOL MED, V17, P159; Griffin E, 2001, NAT MED, V7, P840, DOI 10.1038/89969; Ho C, 2000, J COMP NEUROL, V420, P261; HOROSZEWICZ JS, 1983, CANCER RES, V43, P1809; Huang FY, 2006, GYNECOL ONCOL, V103, P219, DOI 10.1016/j.ygyno.2006.02.028; KAIGHN ME, 1979, INVEST UROL, V17, P16; Kim K, 2008, BIOCHEM BIOPH RES CO, V369, P414, DOI 10.1016/j.bbrc.2008.02.069; Kindich R, 2005, CLIN CHEM, V51, P649, DOI 10.1373/clinchem.2004.045013; Lang D, 2008, MOL CARCINOGEN, V47, P148, DOI 10.1002/mc.20375; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Lu Q, 2005, HUM PATHOL, V36, P1037, DOI 10.1016/j.humpath.2005.07.012; Lu Q, 1999, J CELL BIOL, V144, P519, DOI 10.1083/jcb.144.3.519; Marinescu RC, 1999, AM J MED GENET, V86, P66, DOI 10.1002/(SICI)1096-8628(19990903)86:1<66::AID-AJMG13>3.0.CO;2-N; Mayes DA, 2006, CANCER RES, V66, P9809, DOI 10.1158/0008-5472.CAN-05-3877; Medina M, 2000, GENOMICS, V63, P157, DOI 10.1006/geno.1999.6090; Murthy SK, 2005, ARCH PATHOL LAB MED, V129, P39; Nakayama S, 2001, INT J CANCER, V93, P667, DOI 10.1002/ijc.1386; Paffenholz R, 1997, DIFFERENTIATION, V61, P293, DOI 10.1046/j.1432-0436.1997.6150293.x; Paffenholz R, 1999, EXP CELL RES, V250, P452, DOI 10.1006/excr.1999.4534; PRETLOW TG, 1993, J NATL CANCER I, V85, P394, DOI 10.1093/jnci/85.5.394; Ren B, 2006, ONCOGENE, V25, P1090, DOI 10.1038/sj.onc.1209134; Signori E, 2001, ONCOGENE, V20, P4596, DOI 10.1038/sj.onc.1204620; Sramkoski RM, 1999, IN VITRO CELL DEV-AN, V35, P403; STONE KR, 1978, INT J CANCER, V21, P274, DOI 10.1002/ijc.2910210305; Tanahashi H, 1999, NEUROREPORT, V10, P563, DOI 10.1097/00001756-199902250-00022; UMBAS R, 1994, CANCER RES, V54, P3929; WEIJERMAN PC, 1994, CANCER RES, V54, P5579; Zhang HT, 2004, CLIN CANCER RES, V10, P2359, DOI 10.1158/1078-0432.CCR-0959-3; Zheng M, 2004, AM J PATHOL, V165, P63, DOI 10.1016/S0002-9440(10)63275-0; Zhou JH, 1997, NEUROREPORT, V8, P2085, DOI 10.1097/00001756-199705260-00054	33	32	35	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 29	2009	28	4					555	564		10.1038/onc.2008.399	http://dx.doi.org/10.1038/onc.2008.399			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	400KM	18978817	Green Submitted, Green Accepted			2022-12-28	WOS:000262866500009
J	Wilson, TR; McEwan, M; McLaughlin, K; Le Clorennec, C; Allen, WL; Fennell, DA; Johnston, PG; Longley, DB				Wilson, T. R.; McEwan, M.; McLaughlin, K.; Le Clorennec, C.; Allen, W. L.; Fennell, D. A.; Johnston, P. G.; Longley, D. B.			Combined inhibition of FLIP and XIAP induces Bax-independent apoptosis in type II colorectal cancer cells	ONCOGENE			English	Article						FLIP; Bax; XIAP; colorectal cancer; caspase 3	X-LINKED INHIBITOR; RECEPTOR-INDUCED APOPTOSIS; C-FLIP; CASPASE-9 INHIBITOR; PROGNOSTIC MARKER; DEATH RECEPTORS; EXPRESSION; TRAIL; TUMOR; PROTEIN	Death receptors can directly(type I cells) or indirectly induce apoptosis by activating mitochondrial-regulated apoptosis (type II cells). The level of caspase 8 activation is thought to determine whether a cell is type I or II, with type II cells less efficient at activating this caspase following death receptor activation. FLICE-inhibitory protein (FLIP) blocks death receptor-mediated apoptosis by inhibiting caspase 8 activation; therefore, we assessed whether silencing FLIP could convert type II cells into type I. FLIP silencing-induced caspase 8 activation in Bax wild-type and null HCT116 colorectal cancer cells; however, complete caspase 3 processing and apoptosis were only observed in Bax wild-type cells. Bax-null cells were also more resistant to chemotherapy and tumor necrosis factor-related apoptosis inducing ligand and, unlike the Bax wild-type cells, were not sensitized to these agents by FLIP silencing. Further analyses indicated that release of second mitochondrial activator of caspases from mitochondria and subsequent inhibition of X-linked inhibitor of apoptosis protein ( XIAP) was required to induce full caspase 3 processing and apoptosis following FLIP silencing. These results indicate that silencing FLIP does not necessarily by pass the requirement for mitochondrial involvement in type II cells. Furthermore, targeting FLIP and XIAP may represent a therapeutic strategy for the treatment of colorectal tumors with defects in mitochondrial-regulated apoptosis.	[Wilson, T. R.; McEwan, M.; McLaughlin, K.; Le Clorennec, C.; Allen, W. L.; Fennell, D. A.; Johnston, P. G.; Longley, D. B.] Queens Univ Belfast, Drug Resistance Lab, Ctr Canc Res & Cell Biol, Belfast BT9 7BL, Antrim, North Ireland	Queens University Belfast	Longley, DB (corresponding author), Queens Univ Belfast, Drug Resistance Lab, Ctr Canc Res & Cell Biol, 97 Lisburn Rd, Belfast BT9 7BL, Antrim, North Ireland.	d.longley@qub.ac.uk	McEwan, Miranda V/A-6900-2012; Wilson, Timothy R/F-8210-2012	McLaughlin, Kirsty/0000-0002-3584-4911	Cancer Research UK, the Medical Research Council; Ulster Cancer Foundation; Medical Research Council [G0400302] Funding Source: researchfish; MRC [G0400302] Funding Source: UKRI	Cancer Research UK, the Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)Cancer Research UK); Ulster Cancer Foundation; Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	This study was supported by: Cancer Research UK, the Medical Research Council and the Ulster Cancer Foundation.	Adams JM, 2007, ONCOGENE, V26, P1324, DOI 10.1038/sj.onc.1210220; Arango D, 2004, BRIT J CANCER, V91, P1931, DOI 10.1038/sj.bjc.6602215; Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Berger AB, 2006, CELL RES, V16, P961, DOI 10.1038/sj.cr.7310112; Bratton SB, 2003, CELL DEATH DIFFER, V10, P4, DOI 10.1038/sj.cdd.4401176; Broaddus VC, 2005, J BIOL CHEM, V280, P12486, DOI 10.1074/jbc.M408190200; Chai JJ, 2000, NATURE, V406, P855, DOI 10.1038/35022514; Cummins JM, 2004, CANCER RES, V64, P3006, DOI 10.1158/0008-5472.CAN-04-0046; Dean EJ, 2007, EXPERT OPIN THER TAR, V11, P1459, DOI 10.1517/14728222.11.11.1459; Deng YB, 2002, GENE DEV, V16, P33, DOI 10.1101/gad.949602; Deveraux QL, 1999, GENE DEV, V13, P239, DOI 10.1101/gad.13.3.239; Du CY, 2000, CELL, V102, P33, DOI 10.1016/S0092-8674(00)00008-8; Ekert PG, 2001, CELL DEATH DIFFER, V8, P662, DOI 10.1038/sj.cdd.4400895; Ferreira CG, 2001, CLIN CANCER RES, V7, P2468; Galligan L, 2005, MOL CANCER THER, V4, P2026, DOI 10.1158/1535-7163.MCT-05-0262; Guo F, 2002, BLOOD, V99, P3419, DOI 10.1182/blood.V99.9.3419; Han J, 2004, LEUKEMIA, V18, P1671, DOI 10.1038/sj.leu.2403496; Hu YP, 2003, CLIN CANCER RES, V9, P2826; Hyer ML, 2005, CANCER RES, V65, P4799, DOI 10.1158/0008-5472.CAN-04-3319; Jansson A, 2002, J CLIN ONCOL, V20, P811, DOI 10.1200/JCO.20.3.811; Jonsson G, 2003, ANTICANCER RES, V23, P1213; Kang SY, 2007, CLIN CANCER RES, V13, P4146, DOI 10.1158/1078-0432.CCR-06-3063; Kim SH, 2004, J BIOL CHEM, V279, P40044, DOI 10.1074/jbc.M404541200; KISCHKEL FC, 1995, EMBO J, V14, P5579, DOI 10.1002/j.1460-2075.1995.tb00245.x; Krajewska M, 2003, CLIN CANCER RES, V9, P4914; Kroemer G, 2000, NAT MED, V6, P513, DOI 10.1038/74994; LaCasse EC, 2006, CLIN CANCER RES, V12, P5231, DOI 10.1158/1078-0432.CCR-06-0608; LeBlanc H, 2002, NAT MED, V8, P274, DOI 10.1038/nm0302-274; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Li M, 2007, CHINESE MED J-PEKING, V120, P469, DOI 10.1097/00029330-200703020-00007; Longley DB, 2006, ONCOGENE, V25, P838, DOI 10.1038/sj.onc.1209122; Mathas S, 2004, J EXP MED, V199, P1041, DOI 10.1084/jem.20031080; Mizutani Y, 2007, INT J ONCOL, V30, P919; Ozoren N, 2000, CANCER RES, V60, P6259; Ozoren N, 2002, NEOPLASIA, V4, P551, DOI 10.1038/sj.neo.7900270; Ryu BK, 2001, J PATHOL, V194, P15, DOI 10.1002/path.835; Scaffidi C, 1999, J BIOL CHEM, V274, P1541, DOI 10.1074/jbc.274.3.1541; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; Schimmer AD, 2003, CANCER RES, V63, P1242; Slee EA, 1999, J CELL BIOL, V144, P281, DOI 10.1083/jcb.144.2.281; Sun XM, 2002, J BIOL CHEM, V277, P11345, DOI 10.1074/jbc.M109893200; Tamm I, 2004, HEMATOL J, V5, P489, DOI 10.1038/sj.thj.6200549; Theodorakis P, 2002, CANCER RES, V62, P3373; Valnet-Rabier MB, 2005, BRIT J HAEMATOL, V128, P767, DOI 10.1111/j.1365-2141.2005.05378.x; Verdine GL, 2007, CLIN CANCER RES, V13, P7264, DOI 10.1158/1078-0432.CCR-07-2184; von Haefen C, 2004, ONCOGENE, V23, P8320, DOI 10.1038/sj.onc.1207971; Wang SL, 2003, P NATL ACAD SCI USA, V100, P15095, DOI 10.1073/pnas.2435285100; Wang XD, 2001, GENE DEV, V15, P2922; Werner AB, 2002, J BIOL CHEM, V277, P40760, DOI 10.1074/jbc.M204351200; Wilson TR, 2007, CANCER RES, V67, P5754, DOI 10.1158/0008-5472.CAN-06-3585; Yeh WC, 2000, IMMUNITY, V12, P633, DOI 10.1016/S1074-7613(00)80214-9; Zhang L, 2000, SCIENCE, V290, P989, DOI 10.1126/science.290.5493.989; Zhou XD, 2004, CLIN SCI, V106, P397, DOI 10.1042/CS20030238; Zou H, 1999, J BIOL CHEM, V274, P11549, DOI 10.1074/jbc.274.17.11549	54	37	37	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 8	2009	28	1					63	72		10.1038/onc.2008.366	http://dx.doi.org/10.1038/onc.2008.366			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	392HP	18820704				2022-12-28	WOS:000262294100007
J	Raafat, A; Lawson, S; Bargo, S; Klauzinska, M; Strizzi, L; Goldhar, AS; Buono, K; Salomon, D; Vonderhaar, BK; Callahan, R				Raafat, A.; Lawson, S.; Bargo, S.; Klauzinska, M.; Strizzi, L.; Goldhar, A. S.; Buono, K.; Salomon, D.; Vonderhaar, B. K.; Callahan, R.			Rbpj conditional knockout reveals distinct functions of Notch4/Int3 in mammary gland development and tumorigenesis	ONCOGENE			English	Article						RBP-J; Int3; tumorigenesis	TRUNCATED INT3 GENE; NEOPLASTIC TRANSFORMATION; CELL-DIFFERENTIATION; NOTCH; ACTIVATION; TUMOR; EXPRESSION; SUPPRESSOR; EPITHELIUM; MICE	Transgenic mice expressing the Notch 4 intracellular domain (ICD) (Int3) in the mammary gland have two phenotypes: arrest of mammary alveolar/lobular development and mammary tumorigenesis. Notch4 signaling is mediated primarily through the interaction of Int3 with the transcription repressor/activator Rbpj. We have conditionally ablated the Rbpj gene in the mammary glands of mice expressing whey acidic protein (Wap)-Int3. Interestingly, Rbpj knockout mice (Wap-Cre(+)/Rbpj(-/-)/Wap-Int3) have normal mammary gland development, suggesting that the effect of endogenous Notch signaling on mammary gland development is complete by day 15 of pregnancy. RBP-J heterozygous (Wap-Cre(+)/Rbpj(-/-)/Wap-Int3) and Rbpj control (Rbpj(flox/flox)/Wap-Int3) mice are phenotypically the same as Wap-Int3 mice with respect to mammary gland development and tumorigenesis. In addition, the Wap-Cre(+)/Rbpj(-/-)/Wap-Int3- knockout mice also developed mammary tumors at a frequency similar to Rbpj heterozygous and Wap-Int3 control mice but with a slightly longer latency. Thus, the effect on mammary gland development is dependent on the interaction of the Notch ICD with the transcription repressor/activator Rbpj, and Notch-induced mammary tumor development is independent of this interaction.	[Raafat, A.; Lawson, S.; Bargo, S.; Klauzinska, M.; Strizzi, L.; Goldhar, A. S.; Salomon, D.; Vonderhaar, B. K.; Callahan, R.] NCI, Mammary Biol & Tumorigenesis Lab, NIH, Bethesda, MD 20892 USA; [Buono, K.] NIDDKD, Lab Genet & Physiol, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Callahan, R (corresponding author), NCI, Mammary Biol & Tumorigenesis Lab, NIH, 37 Convent Dr,Bldg 37,Room 1118A, Bethesda, MD 20892 USA.	rc54d@nih.gov			NIH; National Cancer Institute; Center for Cancer Research; NATIONAL CANCER INSTITUTE [ZIABC008226, ZIABC005148] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Center for Cancer Research(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	The Rbpj<SUP>flox/flox</SUP> mice were kindly provided by Dr Tasuku Honjo, Department of Medical Chemistry, Graduate School of Medicine, Kyoto University, Kyoto, Japan, and the WAP-Cre mice were kindly provided by Dr Lothar Hennighausen, Laboratory of Genetics and Physiology, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD, USA. This research was supported by the Intramural Research Program of the NIH, National Cancer Institute, Center for Cancer Research.	Bashyam MD, 2002, CANCER, V94, P1821, DOI 10.1002/cncr.10362; Bray S, 2001, CURR BIOL, V11, pR217, DOI 10.1016/S0960-9822(01)00109-9; Buono KD, 2006, DEV BIOL, V293, P565, DOI 10.1016/j.ydbio.2006.02.043; Callahan R, 2004, J MAMMARY GLAND BIOL, V9, P145, DOI 10.1023/B:JOMG.0000037159.63644.81; Dumont E, 2000, ONCOGENE, V19, P556, DOI 10.1038/sj.onc.1203352; Furriols M, 2001, CURR BIOL, V11, P60, DOI 10.1016/S0960-9822(00)00044-0; Furriols M, 2000, DEV BIOL, V227, P520, DOI 10.1006/dbio.2000.9923; GALLAHAN D, 1987, J VIROL, V61, P66, DOI 10.1128/JVI.61.1.66-74.1987; Gallahan D, 1997, ONCOGENE, V14, P1883, DOI 10.1038/sj.onc.1201035; Gallahan D, 1996, CANCER RES, V56, P1775; Han H, 2002, INT IMMUNOL, V14, P637, DOI 10.1093/intimm/dxf030; Hu CY, 2006, AM J PATHOL, V168, P973, DOI 10.2353/ajpath.2006.050416; Imatani A, 2000, ONCOGENE, V19, P223, DOI 10.1038/sj.onc.1203295; Jeffries S, 2000, MOL CELL BIOL, V20, P3928, DOI 10.1128/MCB.20.11.3928-3941.2000; JHAPPAN C, 1992, GENE DEV, V6, P345, DOI 10.1101/gad.6.3.345; Kato H, 1996, FEBS LETT, V395, P221, DOI 10.1016/0014-5793(96)01046-0; KORDON EC, 1995, J VIROL, V69, P8066, DOI 10.1128/JVI.69.12.8066-8069.1995; Leong KG, 2007, J EXP MED, V204, P2935, DOI 10.1084/jem.20071082; Levy OA, 2002, DEV NEUROSCI-BASEL, V24, P79, DOI 10.1159/000064948; Luo D, 2005, SEMIN CELL DEV BIOL, V16, P612, DOI 10.1016/j.semcdb.2005.07.002; MacKenzie F, 2004, J BIOL CHEM, V279, P11657, DOI 10.1074/jbc.M312102200; Oakes SR, 2006, BREAST CANCER RES, V8, DOI 10.1186/bcr1411; Raafat A, 2007, ONCOGENE, V26, P662, DOI 10.1038/sj.onc.1209823; Raafat A, 2004, ONCOGENE, V23, P9401, DOI 10.1038/sj.onc.1208187; ROBBINS J, 1992, J VIROL, V66, P2594, DOI 10.1128/JVI.66.4.2594-2599.1992; Shawber C, 1996, DEVELOPMENT, V122, P3765; Shin HM, 2006, EMBO J, V25, P129, DOI 10.1038/sj.emboj.7600902; SMITH GH, 1995, CELL GROWTH DIFFER, V6, P563; Stylianou S, 2006, CANCER RES, V66, P1517, DOI 10.1158/0008-5472.CAN-05-3054; Wagner KU, 1997, NUCLEIC ACIDS RES, V25, P4323, DOI 10.1093/nar/25.21.4323; Yoder BJ, 2007, BREAST J, V13, P172, DOI 10.1111/j.1524-4741.2007.00393.x; Zheng X, 2008, P NATL ACAD SCI USA, V105, P3368, DOI 10.1073/pnas.0711591105	32	46	46	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2009	28	2					219	230		10.1038/onc.2008.379	http://dx.doi.org/10.1038/onc.2008.379			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	395CY	18836481	Green Accepted			2022-12-28	WOS:000262501100006
J	Lopez, JI; Mouw, JK; Weaver, VM				Lopez, J. I.; Mouw, J. K.; Weaver, V. M.			Biomechanical regulation of cell orientation and fate	ONCOGENE			English	Review						tension; integrins; migration; extracellular matrix; epithelial cell; force	SMOOTH-MUSCLE-CELLS; MAMMARY-GLAND DEVELOPMENT; VITRO MECHANICAL COMPRESSION; TRACTION FORCE MICROSCOPY; BREAST EPITHELIAL-CELLS; EXTRACELLULAR-MATRIX; BASEMENT-MEMBRANE; LYSYL OXIDASE; IN-VITRO; BRANCHING MORPHOGENESIS	Biomechanical regulation of tumor phenotypes have been noted for several decades, yet the function of mechanics in the co-evolution of the tumor epithelium and altered cancer extracellular matrix has not been appreciated until fairly recently. In this review, we examine the dynamic interaction between the developing epithelia and the extracellular matrix, and discuss how similar interactions are exploited by the genetically modified epithelium during tumor progression. We emphasize the process of mechanoreciprocity, which is a phenomenon observed during epithelial transformation, in which tension generated within the extracellular microenvironment induce and cooperate with opposing reactive forces within transformed epithelium to drive tumor progression and metastasis. We highlight the importance of matrix remodeling, and present a new, emerging paradigm that underscores the importance of tissue morphology as a key regulator of epithelial cell invasion and metastasis.	[Lopez, J. I.; Mouw, J. K.; Weaver, V. M.] Univ Calif San Francisco, Dept Surg, San Francisco, CA 94143 USA; [Lopez, J. I.; Mouw, J. K.; Weaver, V. M.] Univ Calif San Francisco, Ctr Bioengn & Tissue Regenerat, San Francisco, CA 94143 USA; [Weaver, V. M.] Univ Calif San Francisco, Inst Regenerat Med, San Francisco, CA 94143 USA; [Weaver, V. M.] Univ Calif San Francisco, Dept Bioengn & Therapeut Sci, San Francisco, CA 94143 USA; [Weaver, V. M.] Univ Calif San Francisco, Dept Anat, San Francisco, CA 94143 USA; [Weaver, V. M.] Univ Penn, Dept Bioengn, Philadelphia, PA 19104 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of Pennsylvania	Weaver, VM (corresponding author), Univ Calif San Francisco, Dept Surg, 513 Parnassus Ave,Med Sci S1364, San Francisco, CA 94143 USA.	Valerie.Weaver@ucsfmedctr.org		Weaver, Valerie marie/0000-0003-4786-6752; Mouw, Janna K/0000-0002-9846-8466	NIH [7R01CA078731-07]; DOD Breast Cancer Research Era of Hope [W81XWH-05-1-330 (BC044791), BC06262]; CIRM [RS1-00449]; DOE [A107165]; NIH NCI Training [5T32CA108462-04]; NATIONAL CANCER INSTITUTE [R01CA078731, T32CA108462] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); DOD Breast Cancer Research Era of Hope(United States Department of Defense); CIRM(California Institute for Regenerative Medicine); DOE(United States Department of Energy (DOE)); NIH NCI Training(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We apologize to the authors whose work is not cited because of space limitations. This work was supported by NIH Grant 7R01CA078731-07, DOD Breast Cancer Research Era of Hope Grant W81XWH-05-1-330 (BC044791), CIRM Grant RS1-00449 and DOE Grant A107165 to VMW, NIH NCI Training Grant 5T32CA108462-04 to JL and DOD Breast Cancer Research Era of Hope Grant BC06262 to JM.	Adam RM, 2003, J UROLOGY, V169, P2388, DOI 10.1097/01.ju.0000063980.99368.35; Akiri G, 2003, CANCER RES, V63, P1657; Alowami S, 2003, BREAST CANCER RES, V5, pR129, DOI 10.1186/bcr622; AUNINS JG, 1990, BIOTECHNOL PROGR, V6, P54, DOI 10.1021/bp00001a009; Avvisato CL, 2007, J CELL SCI, V120, P2672, DOI 10.1242/jcs.03476; BARCELLOSHOFF MH, 1989, DEVELOPMENT, V105, P223; Beningo KA, 2002, TRENDS CELL BIOL, V12, P79, DOI 10.1016/S0962-8924(01)02205-X; Bissell MJ, 2002, DIFFERENTIATION, V70, P537, DOI 10.1046/j.1432-0436.2002.700907.x; Bissell MJ, 1999, CANCER RES, V59, p1757S; BISSELL MJ, 1982, J THEOR BIOL, V99, P31, DOI 10.1016/0022-5193(82)90388-5; Brancaccio M, 2006, CARDIOVASC RES, V70, P422, DOI 10.1016/j.cardiores.2005.12.015; BUTCHER DT, 2008, NAT REV CAN IN PRESS; Cardoso WV, 2006, DEVELOPMENT, V133, P1611, DOI 10.1242/dev.02310; CHAMBARD M, 1984, BIOL CELL, V51, P315, DOI 10.1111/j.1768-322X.1984.tb00310.x; Chen CS, 1997, SCIENCE, V276, P1425, DOI 10.1126/science.276.5317.1425; Chiquet M, 2007, APPL PHYSIOL NUTR ME, V32, P967, DOI 10.1139/H07-053; Choquet D, 1997, CELL, V88, P39, DOI 10.1016/S0092-8674(00)81856-5; Chrenek MA, 2001, BREAST CANCER RES, V3, P224, DOI 10.1186/bcr300; Clark EA, 1998, J CELL BIOL, V142, P573, DOI 10.1083/jcb.142.2.573; Condeelis J, 2003, NAT REV CANCER, V3, P921, DOI 10.1038/nrc1231; Coussens LM, 2002, NATURE, V420, P860, DOI 10.1038/nature01322; Cox EA, 2001, MOL BIOL CELL, V12, P265, DOI 10.1091/mbc.12.2.265; DAVIES PF, 1995, PHYSIOL REV, V75, P519, DOI 10.1152/physrev.1995.75.3.519; Debnath J, 2003, METHODS, V30, P256, DOI 10.1016/S1046-2023(03)00032-X; Decitre M, 1998, LAB INVEST, V78, P143; del Pozo MA, 2004, SCIENCE, V303, P839, DOI 10.1126/science.1092571; Demou ZN, 2005, CANCER RES, V65, P5674, DOI 10.1158/0008-5472.CAN-04-1682; Egeblad M, 2002, NAT REV CANCER, V2, P161, DOI 10.1038/nrc745; EMERMAN JT, 1977, IN VITRO CELL DEV B, V13, P316, DOI 10.1007/BF02616178; Erler JT, 2006, CANCER RES, V66, P10238, DOI 10.1158/0008-5472.CAN-06-3197; Eshchenko TY, 2007, BIOCHEMISTRY-MOSCOW+, V72, P1016, DOI 10.1134/S0006297907090143; Farge E, 2003, CURR BIOL, V13, P1365, DOI 10.1016/S0960-9822(03)00576-1; Friedrichs J, 2007, J MOL BIOL, V372, P594, DOI 10.1016/j.jmb.2007.06.078; Fukuda S, 2003, P NATL ACAD SCI USA, V100, P13152, DOI 10.1073/pnas.2336130100; Gan Y, 2007, REV SCI INSTRUM, V78, DOI 10.1063/1.2754076; Garcia R, 2007, NAT MATER, V6, P405, DOI 10.1038/nmat1925; Ghosh K, 2007, BIOMATERIALS, V28, P671, DOI 10.1016/j.biomaterials.2006.09.038; Giannelli G, 1997, SCIENCE, V277, P225, DOI 10.1126/science.277.5323.225; Grodzinsky AJ, 2000, ANNU REV BIOMED ENG, V2, P691, DOI 10.1146/annurev.bioeng.2.1.691; Gudjonsson T, 2002, J CELL SCI, V115, P39; Gupta V, 2006, CARDIOVASC RES, V72, P375, DOI 10.1016/j.cardiores.2006.08.017; Hamill OP, 2001, PHYSIOL REV, V81, P685, DOI 10.1152/physrev.2001.81.2.685; Hebner C, 2008, ANNU REV PATHOL-MECH, V3, P313, DOI 10.1146/annurev.pathmechdis.3.121806.151526; Heinemeier KM, 2007, J PHYSIOL-LONDON, V582, P1303, DOI 10.1113/jphysiol.2007.127639; Helmlinger G, 1997, NAT BIOTECHNOL, V15, P778, DOI 10.1038/nbt0897-778; Hochmuth RM, 2000, J BIOMECH, V33, P15, DOI 10.1016/S0021-9290(99)00175-X; Huang HD, 2004, AM J PHYSIOL-CELL PH, V287, pC1, DOI 10.1152/ajpcell.00559.2003; Ichimiya H, 2007, ORAL SURG ORAL MED O, V103, P334, DOI 10.1016/j.tripleo.2006.05.026; INGBER DE, 1986, ENDOCRINOLOGY, V119, P1768, DOI 10.1210/endo-119-4-1768; Ingman WV, 2006, DEV DYNAM, V235, P3222, DOI 10.1002/dvdy.20972; Kass L, 2007, INT J BIOCHEM CELL B, V39, P1987, DOI 10.1016/j.biocel.2007.06.025; Katsumi A, 2005, J BIOL CHEM, V280, P16546, DOI 10.1074/jbc.C400455200; Katsumi A, 2004, J BIOL CHEM, V279, P12001, DOI 10.1074/jbc.R300038200; Keller R, 2003, DIFFERENTIATION, V71, P171, DOI 10.1046/j.1432-0436.2003.710301.x; Kenny PA, 2007, MOL ONCOL, V1, P84, DOI 10.1016/j.molonc.2007.02.004; Kirschmann DA, 2002, CANCER RES, V62, P4478; Kleinman HK, 2003, CURR OPIN BIOTECH, V14, P526, DOI 10.1016/j.copbio.2003.08.002; Larsen M, 2006, CURR OPIN CELL BIOL, V18, P463, DOI 10.1016/j.ceb.2006.08.009; LEIVO I, 1983, MED BIOL, V61, P1; Leivonen SK, 2007, INT J CANCER, V121, P2119, DOI 10.1002/ijc.23113; Lelievre S, 1996, RECENT PROG HORM RES, V51, P417; Lo CM, 2000, BIOPHYS J, V79, P144, DOI 10.1016/S0006-3495(00)76279-5; LOKESHWAR VB, 2008, J BIOL CHEM; Lopez-Otin C, 2007, NAT REV CANCER, V7, P800, DOI 10.1038/nrc2228; Mogilner A, 2003, BIOPHYS J, V84, P1591, DOI 10.1016/S0006-3495(03)74969-8; Moore KA, 2005, DEV DYNAM, V232, P268, DOI 10.1002/dvdy.20237; Munevar S, 2001, BIOPHYS J, V80, P1744, DOI 10.1016/S0006-3495(01)76145-0; Muroi Y, 2007, J DENT RES, V86, P786, DOI 10.1177/154405910708600819; Muschler J, 2002, CANCER RES, V62, P7102; Nelson CM, 2006, ANNU REV CELL DEV BI, V22, P287, DOI 10.1146/annurev.cellbio.22.010305.104315; Nguyen HT, 2000, AM J PHYSIOL-CELL PH, V279, pC1155, DOI 10.1152/ajpcell.2000.279.4.C1155; Numaguchi Yasushi, 2003, Angiogenesis, V6, P55, DOI 10.1023/A:1025821517679; O'Brien LE, 2001, NAT CELL BIOL, V3, P831, DOI 10.1038/ncb0901-831; Padera TP, 2004, NATURE, V427, P695, DOI 10.1038/427695a; Page-McCaw A, 2007, NAT REV MOL CELL BIO, V8, P221, DOI 10.1038/nrm2125; PANJABI MM, 1979, ACTA ORTHOP SCAND, V50, P653, DOI 10.3109/17453677908991288; Paszek MJ, 2004, J MAMMARY GLAND BIOL, V9, P325, DOI 10.1007/s10911-004-1404-x; Paszek MJ, 2005, CANCER CELL, V8, P241, DOI 10.1016/j.ccr.2005.08.010; Payne SL, 2007, J CELL BIOCHEM, V101, P1338, DOI 10.1002/jcb.21371; Pedersen JA, 2005, ANN BIOMED ENG, V33, P1469, DOI 10.1007/s10439-005-8159-4; Pelham RJ, 1997, P NATL ACAD SCI USA, V94, P13661, DOI 10.1073/pnas.94.25.13661; PETERSEN OW, 1993, P NATL ACAD SCI USA, V90, P2556; PETERSEN OW, 1992, P NATL ACAD SCI USA, V89, P9064, DOI 10.1073/pnas.89.19.9064; Polte TR, 2004, AM J PHYSIOL-CELL PH, V286, pC518, DOI 10.1152/ajpcell.00280.2003; Pommerenke H, 1996, EUR J CELL BIOL, V70, P157; Quinn TP, 2002, AM J PHYSIOL-LUNG C, V282, pL897, DOI 10.1152/ajplung.00044.2001; Reichelt J, 2007, EUR J CELL BIOL, V86, P807, DOI 10.1016/j.ejcb.2007.06.004; Reno F, 2005, WOUND REPAIR REGEN, V13, P255, DOI 10.1111/j.1067-1927.2005.130307.x; Reno F, 2002, ARCH DERMATOL, V138, P475, DOI 10.1001/archderm.138.4.475; Robinson GW, 2007, NAT REV GENET, V8, P963, DOI 10.1038/nrg2227; RODRIGUEZBOULAN E, 1983, J CELL BIOL, V96, P866, DOI 10.1083/jcb.96.3.866; Rutkowski JM, 2007, TRENDS CELL BIOL, V17, P44, DOI 10.1016/j.tcb.2006.11.007; Sabass B, 2008, BIOPHYS J, V94, P207, DOI 10.1529/biophysj.107.113670; Samani A, 2007, PHYS MED BIOL, V52, P1565, DOI 10.1088/0031-9155/52/6/002; Schmedlen KH, 2002, BIOMATERIALS, V23, P4325, DOI 10.1016/S0142-9612(02)00177-1; SCHWARTZ MA, 2008, CURR OPIN CELL BIOL; Silver Frederick H, 2003, Crit Rev Biomed Eng, V31, P255, DOI 10.1615/CritRevBiomedEng.v31.i4.10; Simian M, 2001, DEVELOPMENT, V128, P3117; Stern R, 2008, SEMIN CANCER BIOL, V18, P275, DOI 10.1016/j.semcancer.2008.03.017; Sternlicht MD, 2006, DIFFERENTIATION, V74, P365, DOI 10.1111/j.1432-0436.2006.00105.x; Strongin AY, 2006, CANCER METAST REV, V25, P87, DOI 10.1007/s10555-006-7892-y; Tamada M, 2004, DEV CELL, V7, P709, DOI 10.1016/j.devcel.2004.08.021; Triplett Jason W., 2007, Molecular & Cellular Biomechanics, V4, P13; Unger Meredith, 2003, Methods Mol Biol, V223, P315; Vanderploeg EJ, 2004, J BIOMECH, V37, P1941, DOI 10.1016/j.jbiomech.2004.02.048; Vincent TL, 2007, OSTEOARTHR CARTILAGE, V15, P752, DOI 10.1016/j.joca.2007.01.021; Volokh KY, 2006, ACTA BIOMATER, V2, P493, DOI 10.1016/j.actbio.2006.04.002; Wall ME, 2007, J BIOMECH, V40, P173, DOI 10.1016/j.jbiomech.2005.10.032; WANG AZ, 1990, J CELL SCI, V95, P137; WANG AZ, 1990, J CELL SCI, V95, P153; Wang HB, 2001, P NATL ACAD SCI USA, V98, P11295, DOI 10.1073/pnas.201201198; Wang JHC, 2006, BIOMECH MODEL MECHAN, V5, P1, DOI 10.1007/s10237-005-0012-z; Watson CJ, 2006, BREAST CANCER RES, V8, DOI 10.1186/bcr1401; WEAVER VM, 1995, SEMIN CANCER BIOL, V6, P175, DOI 10.1006/scbi.1995.0021; Weaver VM, 1997, J CELL BIOL, V137, P231, DOI 10.1083/jcb.137.1.231; Wells RG, 2008, SCI SIGNAL, V1, DOI 10.1126/stke.110pe13; Willis BC, 2007, AM J PHYSIOL-LUNG C, V293, pL525, DOI 10.1152/ajplung.00163.2007; Wipff PJ, 2007, J CELL BIOL, V179, P1311, DOI 10.1083/jcb.200704042; Wiseman BS, 2002, SCIENCE, V296, P1046, DOI 10.1126/science.1067431; Wong JY, 2003, LANGMUIR, V19, P1908, DOI 10.1021/la026403p; Wyckoff JB, 2006, CURR BIOL, V16, P1515, DOI 10.1016/j.cub.2006.05.065; Yeung T, 2005, CELL MOTIL CYTOSKEL, V60, P24, DOI 10.1002/cm.20041	122	103	104	1	26	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 24	2008	27	55					6981	6993		10.1038/onc.2008.348	http://dx.doi.org/10.1038/onc.2008.348			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	375IU	19029939	Green Accepted			2022-12-28	WOS:000261108200010
J	Thomas, M; Narayan, N; Pim, D; Tomaic, V; Massimi, P; Nagasaka, K; Kranjec, C; Gammoh, N; Banks, L				Thomas, M.; Narayan, N.; Pim, D.; Tomaic, V.; Massimi, P.; Nagasaka, K.; Kranjec, C.; Gammoh, N.; Banks, L.			Human papillomaviruses, cervical cancer and cell polarity	ONCOGENE			English	Review						HPV; E6; PDZ; cell polarity	LARGE TUMOR-SUPPRESSOR; PDZ DOMAIN PROTEIN; HUMAN DISCS LARGE; ANCHORAGE-INDEPENDENT GROWTH; HEMATOPOIETIC STEM-CELLS; LIPID PHOSPHATASE PTEN; TYPE-16 E6 PROTEIN; BINDING MOTIF; HPV E6; HUMAN HOMOLOG	Human papillomaviruses (HPVs) are the causative agents of a number of human cancers, of which cervical cancer is the most important. This occurs following persistent infection with a limited number of viral subtypes and is characterized by continued expression of the viral E6 and E7 oncoproteins. A unique characteristic of the cancer-causing HPV types is the presence of a PDZ recognition motif on the carboxy terminus of the E6 oncoprotein. Through this motif, E6 directs the proteasome-mediated degradation of cellular proteins involved in the regulation of cell polarity and in cell proliferation control. The se include components of the Scrib and Par polarity complexes, as well as a number of other PDZ domain-containing substrates. Thus, PVs are now providing novel insights into the functioning of many of these cellular proteins, and into which of these functions, in particular, are relevant for maintaining normal cellular homeostasis. In this review, we discuss the biological consequences of papillomaviral targeting of these cell polarity regulators, both with respect to the viral life cycle and, most importantly, to the development of HPV-induced malignancy.	[Thomas, M.; Narayan, N.; Pim, D.; Tomaic, V.; Massimi, P.; Nagasaka, K.; Kranjec, C.; Gammoh, N.; Banks, L.] Int Ctr Genet Engn & Biotechnol, I-34012 Trieste, Italy	International Center for Genetic Engineering & Biotechnology (ICGEB)	Banks, L (corresponding author), Int Ctr Genet Engn & Biotechnol, Padriciano 99, I-34012 Trieste, Italy.	banks@icgeb.org	Nagasaka, Kazunori/AAM-4311-2020	Nagasaka, Kazunori/0000-0002-0696-5175; Kranjec, Christian/0000-0001-9713-7406	ICGEB Fellowship Programme; Associazione Italiana per la Ricerca sul Cancro; Association for International Cancer Research; YKK Scholarship Foundation; Kanzawa Medical Research Foundation	ICGEB Fellowship Programme; Associazione Italiana per la Ricerca sul Cancro(Fondazione AIRC per la ricerca sul cancro); Association for International Cancer Research; YKK Scholarship Foundation; Kanzawa Medical Research Foundation(Kanzawa Medical Research Foundation)	We gratefully acknowledge research support provided by the ICGEB Fellowship Programme, the Associazione Italiana per la Ricerca sul Cancro and the Association for International Cancer Research. K Nagasaka is supported by the YKK Scholarship Foundation and the Kanzawa Medical Research Foundation.	Adey NB, 2000, CANCER RES, V60, P35; Alvarez-Salas LM, 1998, P NATL ACAD SCI USA, V95, P1189, DOI 10.1073/pnas.95.3.1189; ANDROPHY EJ, 1987, EMBO J, V6, P989, DOI 10.1002/j.1460-2075.1987.tb04849.x; Aranda V, 2008, ONCOGENE, V27, P6878, DOI 10.1038/onc.2008.340; ARBEIT JM, 1994, J VIROL, V68, P4358, DOI 10.1128/JVI.68.7.4358-4368.1994; BANKS L, 1987, J GEN VIROL, V68, P1351, DOI 10.1099/0022-1317-68-5-1351; BARBOSA MS, 1989, ONCOGENE, V4, P1529; Becamel C, 2001, J BIOL CHEM, V276, P12974, DOI 10.1074/jbc.M008089200; Bilder D, 2004, GENE DEV, V18, P1909, DOI 10.1101/gad.1211604; Bilder D, 2003, NAT CELL BIOL, V5, P53, DOI 10.1038/ncb897; Bilder D, 2000, NATURE, V403, P676, DOI 10.1038/35001108; Blobe GC, 2001, J BIOL CHEM, V276, P39608, DOI 10.1074/jbc.M106831200; Bohl J, 2007, J BIOL CHEM, V282, P9392, DOI 10.1074/jbc.M610002200; Brake T, 2005, P NATL ACAD SCI USA, V102, P2490, DOI 10.1073/pnas.0409883102; Butz K, 2000, P NATL ACAD SCI USA, V97, P6693, DOI 10.1073/pnas.110538897; Butz K, 2003, ONCOGENE, V22, P5938, DOI 10.1038/sj.onc.1206894; Cavatorta AL, 2004, INT J CANCER, V111, P373, DOI 10.1002/ijc.20275; CAVATORTA AL, 2008, GENE; Chetkovich DM, 2002, J NEUROSCI, V22, P5791; Comer FI, 2007, CELL, V128, P239, DOI 10.1016/j.cell.2007.01.010; Coyne CB, 2004, J BIOL CHEM, V279, P48079, DOI 10.1074/jbc.M409061200; de Villiers EM, 2004, VIROLOGY, V324, P17, DOI 10.1016/j.virol.2004.03.033; Dobrosotskaya I, 1997, J BIOL CHEM, V272, P31589, DOI 10.1074/jbc.272.50.31589; Dobrosotskaya IY, 2001, BIOCHEM BIOPH RES CO, V283, P969, DOI 10.1006/bbrc.2001.4880; Dobrosotskaya IY, 2000, BIOCHEM BIOPH RES CO, V270, P903, DOI 10.1006/bbrc.2000.2471; Doorbar J, 2006, CLIN SCI, V110, P525, DOI 10.1042/CS20050369; DOW L, 2008, ONCOGENE; Eckert RL, 2002, J INVEST DERM SYMP P, V7, P36, DOI 10.1046/j.1523-1747.2002.19634.x; Efimova T, 2003, J BIOL CHEM, V278, P34277, DOI 10.1074/jbc.M302759200; Etienne-Manneville S, 2008, ONCOGENE, V27, P6970, DOI 10.1038/onc.2008.347; Favre-Bonvin A, 2005, J VIROL, V79, P4229, DOI 10.1128/JVI.79.7.4229-4237.2005; Feng W, 2008, J BIOL CHEM, V283, P23440, DOI 10.1074/jbc.M802482200; Filippova M, 2007, J VIROL, V81, P4116, DOI 10.1128/JVI.01924-06; Firestein BL, 2001, MOL BIOL CELL, V12, P3465, DOI 10.1091/mbc.12.11.3465; Fuja TJ, 2004, CANCER RES, V64, P942, DOI 10.1158/0008-5472.CAN-03-2100; Garcia-Mata R, 2007, MOL CELL BIOL, V27, P8683, DOI 10.1128/MCB.00157-07; Gardiol D, 1999, ONCOGENE, V18, P5487, DOI 10.1038/sj.onc.1202920; Gardiol D, 2002, J GEN VIROL, V83, P283, DOI 10.1099/0022-1317-83-2-283; Gardiol D, 2006, INT J CANCER, V119, P1285, DOI 10.1002/ijc.21982; Glaunsinger BA, 2000, ONCOGENE, V19, P5270, DOI 10.1038/sj.onc.1203906; Hamazaki Y, 2002, J BIOL CHEM, V277, P455, DOI 10.1074/jbc.M109005200; Hampson L, 2004, INT J ONCOL, V25, P1249; Hanada T, 1997, J BIOL CHEM, V272, P26899, DOI 10.1074/jbc.272.43.26899; Handa K, 2007, J VIROL, V81, P1379, DOI 10.1128/JVI.01712-06; HAWLEYNELSON P, 1989, EMBO J, V8, P3905, DOI 10.1002/j.1460-2075.1989.tb08570.x; Herber R, 1996, J VIROL, V70, P1873, DOI 10.1128/JVI.70.3.1873-1881.1996; Higuchi M, 2007, J VIROL, V81, P11900, DOI 10.1128/JVI.00532-07; Humbert PO, 2008, ONCOGENE, V27, P6888, DOI 10.1038/onc.2008.341; Humbert PO, 2006, TRENDS CELL BIOL, V16, P622, DOI 10.1016/j.tcb.2006.10.005; Ide N, 1999, ONCOGENE, V18, P7810, DOI 10.1038/sj.onc.1203153; Ivanova IA, 2006, ONCOGENE, V25, P430, DOI 10.1038/sj.onc.1208999; James MA, 2006, J VIROL, V80, P5301, DOI 10.1128/JVI.01942-05; Januschke J, 2008, ONCOGENE, V27, P6994, DOI 10.1038/onc.2008.349; Javier RT, 2008, ONCOGENE, V27, P7031, DOI 10.1038/onc.2008.352; Jeansonne B, 2003, CELL MOL BIOL, V49, P13; Jeong KW, 2007, ONCOGENE, V26, P487, DOI 10.1038/sj.onc.1209837; Jing M, 2007, J VIROL, V81, P2231, DOI 10.1128/JVI.01979-06; Kimber WA, 2002, BIOCHEM J, V361, P525, DOI 10.1042/0264-6021:3610525; Kiyono T, 1997, P NATL ACAD SCI USA, V94, P11612, DOI 10.1073/pnas.94.21.11612; Koh YH, 1999, CELL, V98, P353, DOI 10.1016/S0092-8674(00)81964-9; Kotelevets L, 2004, FASEB J, V18, P115, DOI 10.1096/fj.04-1942fje; Kuhne C, 2000, ONCOGENE, V19, P5884, DOI 10.1038/sj.onc.1203988; Lanaspa MA, 2007, P NATL ACAD SCI USA, V104, P13672, DOI 10.1073/pnas.0702752104; Latorre IJ, 2005, J CELL SCI, V118, P4283, DOI 10.1242/jcs.02560; Le SS, 1997, P NATL ACAD SCI USA, V94, P6670, DOI 10.1073/pnas.94.13.6670; Lee CH, 2004, J VIROL, V78, P12366, DOI 10.1128/JVI.78.22.12366-12377.2004; Lee SS, 2000, J VIROL, V74, P9680, DOI 10.1128/JVI.74.20.9680-9693.2000; Legouis R, 2003, EMBO REP, V4, P1096, DOI 10.1038/sj.embor.7400006; Mantovani F, 2001, J CELL SCI, V114, P4285; Margolis B, 2005, J CELL SCI, V118, P5157, DOI 10.1242/jcs.02597; Martin-Belmonte F, 2007, CELL, V128, P383, DOI 10.1016/j.cell.2006.11.051; Massimi P, 2006, ONCOGENE, V25, P4276, DOI 10.1038/sj.onc.1209457; Massimi P, 2004, ONCOGENE, V23, P8033, DOI 10.1038/sj.onc.1207977; MASSIMI P, 2008, EXP CELL R IN PRESS; McLaughlin M, 2002, J BIOL CHEM, V277, P6406, DOI 10.1074/jbc.M108724200; Moreno-Bueno G, 2008, ONCOGENE, V27, P6958, DOI 10.1038/onc.2008.346; Nakagawa S, 2000, MOL CELL BIOL, V20, P8244, DOI 10.1128/MCB.20.21.8244-8253.2000; Nakagawa S, 2004, BRIT J CANCER, V90, P194, DOI 10.1038/sj.bjc.6601465; NARAYAN N, 2008, J CELL SCI IN PRESS; Navarro C, 2005, ONCOGENE, V24, P4330, DOI 10.1038/sj.onc.1208632; Nguyen ML, 2003, J VIROL, V77, P6957, DOI 10.1128/JVI.77.12.6957-6964.2003; Ohashi M, 2004, VIROLOGY, V320, P52, DOI 10.1016/j.virol.2003.11.014; OSTROW RS, 1991, VIROLOGY, V181, P424; Pim D, 2000, ONCOGENE, V19, P719, DOI 10.1038/sj.onc.1203374; Pim D, 1999, ONCOGENE, V18, P7403, DOI 10.1038/sj.onc.1203134; Pim D, 1997, ONCOGENE, V15, P257, DOI 10.1038/sj.onc.1201202; Plant PJ, 2003, NAT CELL BIOL, V5, P301, DOI 10.1038/ncb948; Reynaud C, 2000, J BIOL CHEM, V275, P33962, DOI 10.1074/jbc.M000465200; Riley RR, 2003, CANCER RES, V63, P4862; Roberts S, 2007, EXP CELL RES, V313, P2521, DOI 10.1016/j.yexcr.2007.05.017; Sabio G, 2005, EMBO J, V24, P1134, DOI 10.1038/sj.emboj.7600578; Schimanski CC, 2005, ONCOGENE, V24, P3100, DOI 10.1038/sj.onc.1208520; Shai A, 2008, CANCER RES, V68, P2622, DOI 10.1158/0008-5472.CAN-07-5266; Shai A, 2007, CANCER RES, V67, P1626, DOI 10.1158/0008-5472.CAN-06-3344; Shen WH, 2007, CELL, V128, P157, DOI 10.1016/j.cell.2006.11.042; SMOTKIN D, 1986, P NATL ACAD SCI USA, V83, P4680, DOI 10.1073/pnas.83.13.4680; Song S, 2000, VIROLOGY, V267, P141, DOI 10.1006/viro.1999.0106; Song SY, 1999, J VIROL, V73, P5887, DOI 10.1128/JVI.73.7.5887-5893.1999; Songyang Z, 1997, SCIENCE, V275, P73, DOI 10.1126/science.275.5296.73; Sonoda T, 2006, BIOCHEM BIOPH RES CO, V350, P748, DOI 10.1016/j.bbrc.2006.09.109; Spanos WC, 2008, J VIROL, V82, P2493, DOI 10.1128/JVI.02188-07; Spanos WC, 2008, HEAD NECK-J SCI SPEC, V30, P139, DOI 10.1002/hed.20673; STEELE C, 1992, CANCER RES, V52, P4706; Storrs CH, 2007, J VIROL, V81, P4080, DOI 10.1128/JVI.02545-06; Tamguney T, 2007, J CELL SCI, V120, P4071, DOI 10.1242/jcs.015230; Tanentzapf G, 2003, NAT CELL BIOL, V5, P46, DOI 10.1038/ncb896; Thomas M, 2001, ONCOGENE, V20, P5431, DOI 10.1038/sj.onc.1204719; Thomas M, 2005, ONCOGENE, V24, P6222, DOI 10.1038/sj.onc.1208757; Thomas M, 2002, ONCOGENE, V21, P5088, DOI 10.1038/sj.onc.1205668; Thomas M, 1999, ONCOGENE, V18, P7690, DOI 10.1038/sj.onc.1202953; Thomas M, 2008, VIROLOGY, V376, P371, DOI 10.1016/j.virol.2008.03.021; Topffer S, 2007, J GEN VIROL, V88, P2956, DOI 10.1099/vir.0.83123-0; TOMAIC V, 2008, ONCOGENE IN PRESS; Trotman LC, 2007, CELL, V128, P141, DOI 10.1016/j.cell.2006.11.040; Ullmer C, 1998, FEBS LETT, V424, P63, DOI 10.1016/S0014-5793(98)00141-0; Vazquez F, 2006, P NATL ACAD SCI USA, V103, P3633, DOI 10.1073/pnas.0510570103; von Stein W, 2005, DEVELOPMENT, V132, P1675, DOI 10.1242/dev.01720; VONKNEBEL M, 1992, INT J CANCER, V51, P831, DOI 10.1002/ijc.2910510527; Wang SY, 2006, P NATL ACAD SCI USA, V103, P1480, DOI 10.1073/pnas.0510652103; Wang XJ, 2007, CELL, V128, P129, DOI 10.1016/j.cell.2006.11.039; Watson RA, 2003, J CELL SCI, V116, P4925, DOI 10.1242/jcs.00809; Watson RA, 2002, CARCINOGENESIS, V23, P1791, DOI 10.1093/carcin/23.11.1791; Weiss RS, 1997, J VIROL, V71, P7873, DOI 10.1128/JVI.71.10.7873-7880.1997; Wood CE, 2007, J VIROL, V81, P6339, DOI 10.1128/JVI.00233-07; Wu H, 2007, MOL CELL, V28, P886, DOI 10.1016/j.molcel.2007.10.028; Wu XY, 2000, P NATL ACAD SCI USA, V97, P4233, DOI 10.1073/pnas.97.8.4233; Wu Y, 2000, J BIOL CHEM, V275, P21477, DOI 10.1074/jbc.M909741199; Yamanaka T, 2003, CURR BIOL, V13, P734, DOI 10.1016/S0960-9822(03)00244-6; Yamanaka T, 2006, J CELL SCI, V119, P2107, DOI 10.1242/jcs.02938; Yilmaz OH, 2006, NATURE, V441, P475, DOI 10.1038/nature04703; Yoshinouchi M, 2003, MOL THER, V8, P762, DOI 10.1016/j.ymthe.2003.08.004; Zhang HC, 2007, CELL SIGNAL, V19, P261, DOI 10.1016/j.cellsig.2006.06.008; Zhang JW, 2006, NATURE, V441, P518, DOI 10.1038/nature04747; Zhang Y, 2007, J VIROL, V81, P3618, DOI 10.1128/JVI.02044-06; zur Hausen H, 2002, NAT REV CANCER, V2, P342, DOI 10.1038/nrc798; zur Hausen H, 1999, SEMIN CANCER BIOL, V9, P405, DOI 10.1006/scbi.1999.0144	136	134	139	0	20	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 24	2008	27	55					7018	7030		10.1038/onc.2008.351	http://dx.doi.org/10.1038/onc.2008.351			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	375IU	19029942				2022-12-28	WOS:000261108200013
J	Taniguchi, E; Nishijo, K; McCleish, AT; Michalek, JE; Grayson, MH; Infante, AJ; Abboud, HE; Legallo, RD; Qualman, SJ; Rubin, BP; Keller, C				Taniguchi, E.; Nishijo, K.; McCleish, A. T.; Michalek, J. E.; Grayson, M. H.; Infante, A. J.; Abboud, H. E.; Legallo, R. D.; Qualman, S. J.; Rubin, B. P.; Keller, C.			PDGFR-A is a therapeutic target in alveolar rhabdomyosarcoma	ONCOGENE			English	Article						PDGFR-A; therapeutic target; alveolar rhabdomyosarcoma	GROWTH-FACTOR; IN-VIVO; ALPHA; KINASE; ACTIVATION; EXPRESSION; IMATINIB; RECEPTOR; DISEASE; CELLS	Alveolar rhabdomyosarcoma is an aggressive skeletal muscle cancer of childhood. Our initial studies of rhabdomyosarcoma gene expression for patients enrolled in a national clinical trial suggested that platelet-derived growth factor receptor A (PDGFR-A) may be a mediator of disease progression and metastasis. Using our conditional mouse tumor models that authentically recapitulate the primary mutations and metastatic progression of alveolar rhabdomyosarcomas in humans, we found by immunoblotting and immunokinase assays that PDGFR-A and its downstream effectors, mitogen-activated protein kinase and Akt, were highly activated in both primary and metastatic tumors. Inhibition of PDGFR-A by RNA interference, small molecule inhibitor or neutralizing antibody had a dramatic effect on tumor cell growth both in vitro and in vivo, although resistance evolved in one-third of tumors. These results establish proof-of-principal for PDGFR-A as a therapeutic target in alveolar rhabdomyosarcoma.	[Taniguchi, E.; Nishijo, K.; McCleish, A. T.; Keller, C.] Univ Texas Hlth Sci Ctr San Antonio, Dept Cellular & Struct Biol, Greehey Childrens Canc Res Inst, San Antonio, TX 78229 USA; [Michalek, J. E.; Grayson, M. H.; Infante, A. J.; Keller, C.] Univ Texas Hlth Sci Ctr San Antonio, Dept Pediat, San Antonio, TX 78229 USA; [Michalek, J. E.] Univ Texas Hlth Sci Ctr San Antonio, Dept Epidemiol & Biostat, San Antonio, TX 78229 USA; [Abboud, H. E.] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, San Antonio, TX 78229 USA; [Legallo, R. D.] Univ Virginia Hlth Syst, Dept Pathol, Charlottesville, VA USA; [Qualman, S. J.] Ohio State Univ, Dept Pediat, Columbus Childrens Res Inst, Ctr Childhood Canc, Columbus, OH 43210 USA; [Rubin, B. P.] Cleveland Clin, Taussig Canc Ctr, Dept Anat Pathol, Cleveland, OH 44106 USA; [Rubin, B. P.] Cleveland Clin, Lerner Res Inst, Cleveland, OH 44106 USA	University of Texas System; University of Texas Health San Antonio; University of Texas System; University of Texas Health San Antonio; University of Texas System; University of Texas Health San Antonio; University of Texas System; University of Texas Health San Antonio; University of Virginia; University System of Ohio; Ohio State University; Nationwide Childrens Hospital; Research Institute at Nationwide Children's Hospital; Cleveland Clinic Foundation; Cleveland Clinic Foundation	Keller, C (corresponding author), Univ Texas Hlth Sci Ctr San Antonio, Dept Cellular & Struct Biol, Greehey Childrens Canc Res Inst, 8403 Floyd Curl Dr,MC7784, San Antonio, TX 78229 USA.	kellerc2@uthscsa.edu		Keller, Charles/0000-0003-2505-7487	NIH [RO1CA 133229]; University Research Council (UTHSCSA); Sarcoma Foundation of America; Amschwand Sarcoma Cancer Foundation; National Cancer Institute Center; San Antonio Cancer Center [P30 CA54174]; NATIONAL CANCER INSTITUTE [R01CA133229, P30CA054174] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); University Research Council (UTHSCSA); Sarcoma Foundation of America; Amschwand Sarcoma Cancer Foundation; National Cancer Institute Center(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); San Antonio Cancer Center; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Dr Frederic G Barr ( The University of Pennsylvania School of Medicine) for providing Pax3: Fkhr cDNA and Pax7: Fkhr cDNA, and Dr Guillermina Lozano ( University of Texas M. D. Anderson Cancer Center) for providing p53 cDNA. This work was funded in part by grants from NIH RO1CA 133229, the University Research Council (UTHSCSA), the Sarcoma Foundation of America, and the Amschwand Sarcoma Cancer Foundation. Animal care costs for this study were in part defrayed by a National Cancer Institute Center grant to the San Antonio Cancer Center ( Grant number P30 CA54174), of which CK is a member. We thank Dr Sharon B Murphy for critical reading of this article, and Gary Chisholm for statistical support.	Armistead PM, 2007, CANCER, V110, P2293, DOI 10.1002/cncr.23038; Arndt CAS, 1999, NEW ENGL J MED, V341, P342, DOI 10.1056/NEJM199907293410507; Blandford MC, 2006, PEDIATR BLOOD CANCER, V46, P329, DOI 10.1002/pbc.20466; Capdeville R, 2002, NAT REV DRUG DISCOV, V1, P493, DOI 10.1038/nrd839; Choudhury GG, 2000, KIDNEY INT, V57, P908, DOI 10.1046/j.1523-1755.2000.00907.x; Cools J, 2003, NEW ENGL J MED, V348, P1201, DOI 10.1056/NEJMoa025217; Crist WM, 2001, J CLIN ONCOL, V19, P3091, DOI 10.1200/JCO.2001.19.12.3091; DEVARE SG, 1983, P NATL ACAD SCI-BIOL, V80, P731, DOI 10.1073/pnas.80.3.731; Engelman JA, 2007, SCIENCE, V316, P1039, DOI 10.1126/science.1141478; Epstein JA, 1998, MOL CELL BIOL, V18, P4118, DOI 10.1128/MCB.18.7.4118; Heinrich MC, 2003, J CLIN ONCOL, V21, P4342, DOI 10.1200/JCO.2003.04.190; Heldin CH, 1999, PHYSIOL REV, V79, P1283, DOI 10.1152/physrev.1999.79.4.1283; Keller C, 2004, GENE DEV, V18, P2614, DOI 10.1101/gad.1244004; Keller C, 2004, GENE DEV, V18, P2608, DOI 10.1101/gad.1243904; MacDonald TJ, 2001, NAT GENET, V29, P143, DOI 10.1038/ng731; Matei D, 2006, ONCOGENE, V25, P2060, DOI 10.1038/sj.onc.1209232; Mehrotra M, 2004, J CELL BIOCHEM, V93, P741, DOI 10.1002/jcb.20138; Meijerink J, 2001, J MOL DIAGN, V3, P55, DOI 10.1016/S1525-1578(10)60652-6; Pani L, 2002, GENE DEV, V16, P676, DOI 10.1101/gad.969302; Ricono JM, 2002, AM J PHYSIOL-RENAL, V282, pF211, DOI 10.1152/ajprenal.0323.2000; Schneider L, 2005, CURR BIOL, V15, P1861, DOI 10.1016/j.cub.2005.09.012; Stover EH, 2005, BLOOD, V106, P3206, DOI 10.1182/blood-2005-05-1932; Stover EH, 2006, P NATL ACAD SCI USA, V103, P8078, DOI 10.1073/pnas.0601192103; Takahashi Y, 2004, MODERN PATHOL, V17, P660, DOI 10.1038/modpathol.3800101; Underwood TJ, 2007, FEBS LETT, V581, P5831, DOI 10.1016/j.febslet.2007.11.056	25	69	74	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 30	2008	27	51					6550	6560		10.1038/onc.2008.255	http://dx.doi.org/10.1038/onc.2008.255			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	366RS	18679424	Green Accepted			2022-12-28	WOS:000260501700002
J	Chang, YM; Bai, L; Liu, S; Yang, JC; Kung, HJ; Evans, CP				Chang, Y-M; Bai, L.; Liu, S.; Yang, J. C.; Kung, H-J; Evans, C. P.			Src family kinase oncogenic potential and pathways in prostate cancer as revealed by AZD0530	ONCOGENE			English	Article						Src; FAK; prostate cancer; AZD0530; proliferation; migration	FOCAL ADHESION KINASE; NONRECEPTOR TYROSINE KINASES; ANDROGEN-INDEPENDENT GROWTH; BETA-CATENIN; C-MYC; BREAST-CANCER; CYCLIN D1; NEUROENDOCRINE DIFFERENTIATION; SIGNAL-TRANSDUCTION; CARCINOMA-CELLS	Prostate cancer is the most frequently diagnosed cancer in American men. We have previously demonstrated that Src mediates androgen-independent proliferation in prostate cancer. We sought to investigate the Src-mediated oncogenic pathways and tumor biology using AZD0530, a novel Src family kinase/Abl dual-kinase inhibitor that is entering phase II clinical trials. We show that while both Src and Abl are expressed in all prostate cancer cell lines, Src but not Abl is activated in the prostate. Furthermore, Src activation is inhibited by AZD0530 in a rapid and dose-dependent manner. We show that Src mediates cell proliferation in DU145 and PC3 cells at the G1 phase of cell cycle. Src inhibition resulted in decreased binding of beta-catenin to the promoters of G1 phase cell cycle regulators cyclin D1 and c-Myc. C-Myc may also be regulated at the protein level by extracellular signal-regulated kinase 1/2 and GSK3 beta. Cell motility factors focal adhesion kinase, p130CAS and paxillin activation in DU145 and PC3 cells were also inhibited. Administration of AZD0530 in mice reduced orthotopic DU145 xenograft growth by 45%. We have further delineated the Src-mediated oncogenic growth and migration pathways in prostate cancer and established mechanistic rationale for Src inhibition as novel therapy in the treatment of prostate cancer.	[Evans, C. P.] Univ Calif Davis, Med Ctr, Dept Urol, Sacramento, CA 95817 USA; [Liu, S.; Kung, H-J] Univ Calif Davis, Dept Biol Chem & Mol Med, Sacramento, CA 95817 USA; [Kung, H-J; Evans, C. P.] Univ Calif Davis, Ctr Canc, Sacramento, CA 95817 USA	University of California System; University of California Davis; University of California System; University of California Davis; University of California System; University of California Davis	Evans, CP (corresponding author), Univ Calif Davis, Med Ctr, Dept Urol, 4860 Y St Suite 3500, Sacramento, CA 95817 USA.	kung@ucdavis.edu; cpevans@ucdavis.edu	Kung, Hsing-Jien/C-7651-2013		National Institutes of Health [KO8 DK60748-01, RO1 DK52659]; Department of Defense [PC040161]; NATIONAL CANCER INSTITUTE [R01CA114575] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK078243, K08DK060748, R01DK052659] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Department of Defense(United States Department of Defense); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	This study was supported by National Institutes of Health Grant KO8 DK60748-01 (CPE), RO1 DK52659 (H-JK) and Department of Defense Grant PC040161 (CPE). The contents of this report are solely the responsibility of the authors and do not necessarily represent the official views of the National Institutes of Health or the Department of Defense.	ALBANESE C, 1995, J BIOL CHEM, V270, P23589, DOI 10.1074/jbc.270.40.23589; BANG YJ, 1994, P NATL ACAD SCI USA, V91, P5330, DOI 10.1073/pnas.91.12.5330; BARONE MV, 1995, NATURE, V378, P509, DOI 10.1038/378509a0; Biscardi JS, 2000, BREAST CANCER RES, V2, P203, DOI 10.1186/bcr55; BJELFMAN C, 1990, MOL CELL BIOL, V10, P361, DOI 10.1128/MCB.10.1.361; Bowman T, 2001, P NATL ACAD SCI USA, V98, P7319, DOI 10.1073/pnas.131568898; Bromann PA, 2004, ONCOGENE, V23, P7957, DOI 10.1038/sj.onc.1208079; Chang YM, 2007, NEOPLASIA, V9, P90, DOI 10.1593/neo.06694; Chen GP, 2004, CANCER-AM CANCER SOC, V101, P1345, DOI 10.1002/cncr.20518; Cheng JQ, 2005, ONCOGENE, V24, P7482, DOI 10.1038/sj.onc.1209088; Cronauer MV, 2005, INT J ONCOL, V26, P1033; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; Daaka Y, 2002, BBA-MOL CELL BIOL L, V1582, P265, DOI 10.1016/S1388-1981(02)00180-4; de la Taille A, 2003, CLIN CANCER RES, V9, P1801; Desai SJ, 2006, CANCER RES, V66, P10449, DOI 10.1158/0008-5472.CAN-06-2582; Devi GR, 2002, PROSTATE, V53, P200, DOI 10.1002/pros.10151; Diehl JA, 1998, GENE DEV, V12, P3499, DOI 10.1101/gad.12.22.3499; Dominguez-Sola D, 2004, NAT CELL BIOL, V6, P288, DOI 10.1038/ncb0404-288; Dong JT, 2006, J CELL BIOCHEM, V97, P433, DOI 10.1002/jcb.20696; EVANS CP, 1991, INT J CANCER, V49, P109, DOI 10.1002/ijc.2910490120; Farkas A, 2005, J NEUROSCI RES, V80, P855, DOI 10.1002/jnr.20521; Furstoss O, 2002, EMBO J, V21, P514, DOI 10.1093/emboj/21.4.514; Gao LF, 2005, CLIN CANCER RES, V11, P6333, DOI 10.1158/1078-0432.CCR-05-0148; Golas JM, 2003, CANCER RES, V63, P375; Gray MJ, 2005, ONCOGENE, V24, P3110, DOI 10.1038/sj.onc.1208513; Guo ZY, 2006, CANCER CELL, V10, P309, DOI 10.1016/j.ccr.2006.08.021; Hakak Y, 1999, CURR BIOL, V9, P1039, DOI 10.1016/S0960-9822(99)80453-9; Hauck CR, 2002, EMBO J, V21, P6289, DOI 10.1093/emboj/cdf631; Hennequin LF, 2006, J MED CHEM, V49, P6465, DOI 10.1021/jm060434q; Hiscox S, 2006, BREAST CANCER RES TR, V97, P263, DOI 10.1007/s10549-005-9120-9; Jemal A, 2008, CA-CANCER J CLIN, V58, P71, DOI 10.3322/CA.2007.0010; Karni R, 2005, MOL CELL BIOL, V25, P5031, DOI 10.1128/MCB.25.12.5031-5039.2005; Kim D, 2007, ONCOGENE, V26, P4571, DOI 10.1038/sj.onc.1210230; Kotha A, 2006, MOL CANCER THER, V5, P621, DOI 10.1158/1535-7163.MCT-05-0268; Lee D, 2006, CLIN LUNG CANCER, V7, P381, DOI 10.3816/CLC.2006.n.020; Lee LF, 2004, ONCOGENE, V23, P2197, DOI 10.1038/sj.onc.1207344; Lee LF, 2001, MOL CELL BIOL, V21, P8385, DOI 10.1128/MCB.21.24.8385-8397.2001; Li GP, 2003, CELL BIOCHEM BIOPHYS, V39, P45, DOI 10.1385/CBB:39:1:45; Lombardo LJ, 2004, J MED CHEM, V47, P6658, DOI 10.1021/jm049486a; Morin PJ, 1999, BIOESSAYS, V21, P1021, DOI 10.1002/(SICI)1521-1878(199912)22:1<1021::AID-BIES6>3.0.CO;2-P; Nam S, 2005, CANCER RES, V65, P9185, DOI 10.1158/0008-5472.CAN-05-1731; Nam S, 2005, P NATL ACAD SCI USA, V102, P5998, DOI 10.1073/pnas.0409467102; Park SI, 2008, CANCER RES, V68, P3323, DOI 10.1158/0008-5472.CAN-07-2997; Parsons JT, 2003, J CELL SCI, V116, P1409, DOI 10.1242/jcs.00373; Planas-Silva MD, 2006, BIOCHEM BIOPH RES CO, V341, P73, DOI 10.1016/j.bbrc.2005.12.164; Prathapam T, 2006, P NATL ACAD SCI USA, V103, P2695, DOI 10.1073/pnas.0511186103; Qiu Y, 1998, P NATL ACAD SCI USA, V95, P3644, DOI 10.1073/pnas.95.7.3644; QUELLE DE, 1993, GENE DEV, V7, P1559, DOI 10.1101/gad.7.8.1559; Roura S, 1999, J BIOL CHEM, V274, P36734, DOI 10.1074/jbc.274.51.36734; Rovin JD, 2002, PROSTATE, V53, P124, DOI 10.1002/pros.10114; Schaller MD, 2001, BBA-MOL CELL RES, V1540, P1, DOI 10.1016/S0167-4889(01)00123-9; Sears RC, 2004, CELL CYCLE, V3, P1133, DOI 10.4161/cc.3.9.1145; Slack JK, 2001, ONCOGENE, V20, P1152, DOI 10.1038/sj.onc.1204208; Steiner MS, 1998, HUM GENE THER, V9, P747, DOI 10.1089/hum.1998.9.5-747; STEPHENSON RA, 1992, J NATL CANCER I, V84, P951, DOI 10.1093/jnci/84.12.951; Taj MM, 2001, PROSTATE, V47, P194, DOI 10.1002/pros.1063; Tsai YT, 2000, MOL CELL BIOL, V20, P2043, DOI 10.1128/MCB.20.6.2043-2054.2000; Unni E, 2004, CANCER RES, V64, P7156, DOI 10.1158/0008-5472.CAN-04-1121; Verras M, 2006, CANCER LETT, V237, P22, DOI 10.1016/j.canlet.2005.06.004; Vinall RL, 2006, ONCOGENE, V25, P2082, DOI 10.1038/sj.onc.1209246; Watanabe G, 1996, P NATL ACAD SCI USA, V93, P12861, DOI 10.1073/pnas.93.23.12861; Yeatman TJ, 2004, NAT REV CANCER, V4, P470, DOI 10.1038/nrc1366; Yuan ZL, 2005, SCIENCE, V307, P269, DOI 10.1126/science.1105166; Zhu S, 2007, CANCER RES, V67, P10129, DOI 10.1158/0008-5472.CAN-06-4338	64	128	132	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT	2008	27	49					6365	6375		10.1038/onc.2008.250	http://dx.doi.org/10.1038/onc.2008.250			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	363JK	18679417	Green Accepted			2022-12-28	WOS:000260263400006
J	Gentile, A; D'Alessandro, L; Lazzari, L; Martinoglio, B; Bertotti, A; Mira, A; Lanzetti, L; Comoglio, PM; Medico, E				Gentile, A.; D'Alessandro, L.; Lazzari, L.; Martinoglio, B.; Bertotti, A.; Mira, A.; Lanzetti, L.; Comoglio, P. M.; Medico, E.			Met-driven invasive growth involves transcriptional regulation of Arhgap12	ONCOGENE			English	Article						HGF; Rac1; scatter; GTPase activating protein; Rho family; gene trapping	GTPASE-ACTIVATING PROTEINS; CELL-CELL ADHESION; HEPATOCYTE GROWTH; SCATTER-FACTOR; TYROSINE KINASE; RHO GTPASES; PHOSPHATIDYLINOSITOL 3-KINASE; EPITHELIAL-CELLS; FACTOR-RECEPTOR; IN-VITRO	Invasive growth is a complex biological program triggered by hepatocyte growth factor (HGF) through its tyrosine kinase receptor encoded by the Met proto-oncogene. The program involves-besides proliferation-cell dissociation, motility and invasiveness, controlled by intracellular signals impinging on PI3K and on the small G-proteins of the Rac/Rho family. The mechanism(s) unbalancing Rac/Rho activation are still not completely clarified. Here, we describe a functional link between HGF and Arhgap12, a gene encoding a previously uncharacterized protein of the RhoGAP family. We identified Arhgap12 as a transcriptional target of HGF, through a novel gene trapping strategy. We found that Arhgap12 mRNA and protein are robustly suppressed by HGF treatment, but not by serum. Arhgap12 displayed GTPase activating protein (GAP) activity towards Rac1 and, upon overexpression, impaired cell scattering, invasion and adhesion to fibronectin in response to HGF. Consistently, Arhgap12 silencing by RNA interference selectively increased the scatter and adhesion responses. These data show that HGF-driven invasive growth involves transcriptional regulation of a Rac1-specific GAP.	[Gentile, A.; D'Alessandro, L.; Lazzari, L.; Martinoglio, B.; Mira, A.; Medico, E.] Univ Turin, Sch Med, Lab Funct Genom, Oncogenom Ctr,Inst Canc Res & Treatment, I-10060 Turin, Italy; [Bertotti, A.; Comoglio, P. M.] Univ Turin, Sch Med, Div Mol Oncol, Inst Canc Res & Treatment, I-10060 Turin, Italy; [Lanzetti, L.] Univ Turin, Sch Med, Div Mol Angiogenesis, Inst Canc Res & Treatment, I-10060 Turin, Italy	University of Turin; University of Turin; University of Turin	Medico, E (corresponding author), Univ Turin, Sch Med, Lab Funct Genom, Oncogenom Ctr,Inst Canc Res & Treatment, Str Prov 142 Km 3,95, I-10060 Turin, Italy.	enzo.medico@ircc.it	Medico, Enzo/AAC-3185-2021; gentile, alessandra/L-4299-2013; Lazzari, Luca/AAH-6475-2020	Medico, Enzo/0000-0002-3917-2438; gentile, alessandra/0000-0002-3367-8833; MARTINOGLIO, BARBARA/0000-0002-2342-2500; Lazzari, Luca/0000-0001-6841-4240; Mira, Alessia/0000-0002-8456-8159; Comoglio, Paolo/0000-0002-7056-5328; Bertotti, Andrea/0000-0001-8196-7608; LANZETTI, Letizia/0000-0001-7541-5524	AIRC; EC; FIRB; MIUR; Ricerca Finalizzata; Regione Piemonte and San Paolo to EM and PMC	AIRC(Fondazione AIRC per la ricerca sul cancro); EC(European CommissionEuropean Commission Joint Research Centre); FIRB(Ministry of Education, Universities and Research (MIUR)Fund for Investment in Basic Research (FIRB)); MIUR(Ministry of Education, Universities and Research (MIUR)); Ricerca Finalizzata(Ministry of Health, ItalyMinistry of Health Italy - Ricerca Finalizzata (MOH-RF)); Regione Piemonte and San Paolo to EM and PMC	We thank Antonella Cignetto and Michela Bruno for secretarial assistance; Daniela Cantarella, Raffaella Albano, Laura Palmas and Solange Tienga for technical assistance and Giorgio Scita, Livio Trusolino and Lucia Biondi for helpful discussion and feedback. A particular thank to Luigi Naldini and Michele De Palma for early feedback on the design of viral traps. AG and AB are recipients of a fellowship from FIRC. This work was supported by grants from AIRC, EC (TRANSFOG EC Integrated project contract no. 503438), FIRB, MIUR, Ricerca Finalizzata, Regione Piemonte and San Paolo to EM and PMC.	Bar-Sagi D, 2000, CELL, V103, P227, DOI 10.1016/S0092-8674(00)00115-X; Bertotti A, 2003, TRENDS BIOCHEM SCI, V28, P527, DOI 10.1016/j.tibs.2003.09.001; Birchmeier C, 2003, NAT REV MOL CELL BIO, V4, P915, DOI 10.1038/nrm1261; Boccaccio C, 1998, NATURE, V391, P285, DOI 10.1038/34657; Bosse T, 2007, MOL CELL BIOL, V27, P6615, DOI 10.1128/MCB.00367-07; Braga VMM, 1997, J CELL BIOL, V137, P1421, DOI 10.1083/jcb.137.6.1421; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; CICCHETTI P, 1995, EMBO J, V14, P3127, DOI 10.1002/j.1460-2075.1995.tb07315.x; Comoglio PM, 2002, J CLIN INVEST, V109, P857, DOI 10.1172/JCI200215392; Dull T, 1998, J VIROL, V72, P8463, DOI 10.1128/JVI.72.11.8463-8471.1998; Finkielstein CV, 2006, J BIOL CHEM, V281, P27317, DOI 10.1074/jbc.M605560200; Follenzi A, 2000, NAT GENET, V25, P217, DOI 10.1038/76095; Furge KA, 2000, ONCOGENE, V19, P5582, DOI 10.1038/sj.onc.1203859; Furukawa Y, 2001, BIOCHEM BIOPH RES CO, V284, P643, DOI 10.1006/bbrc.2001.5022; Grisendi S, 2001, J BIOL CHEM, V276, P46632, DOI 10.1074/jbc.M104323200; Gual P, 2000, ONCOGENE, V19, P1509, DOI 10.1038/sj.onc.1203514; Guo FK, 2006, J BIOL CHEM, V281, P18652, DOI 10.1074/jbc.M603508200; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Hordijk PL, 1997, SCIENCE, V278, P1464, DOI 10.1126/science.278.5342.1464; Itoh RE, 2002, MOL CELL BIOL, V22, P6582, DOI 10.1128/MCB.22.18.6582-6591.2002; Iyer VR, 1999, SCIENCE, V283, P83, DOI 10.1126/science.283.5398.83; Keely PJ, 1997, NATURE, V390, P632, DOI 10.1038/37656; Kurokawa K, 2004, MOL BIOL CELL, V15, P1003, DOI 10.1091/mbc.E03-08-0609; Ma PC, 2003, CANCER METAST REV, V22, P309, DOI 10.1023/A:1023768811842; Matsuda M, 2008, EXP CELL RES, V314, P939, DOI 10.1016/j.yexcr.2007.11.009; Medico E, 2001, CANCER RES, V61, P5861; Medico E, 1996, MOL BIOL CELL, V7, P495, DOI 10.1091/mbc.7.4.495; Moon SY, 2003, TRENDS CELL BIOL, V13, P13, DOI 10.1016/S0962-8924(02)00004-1; NALDINI L, 1995, J BIOL CHEM, V270, P603, DOI 10.1074/jbc.270.2.603; Pankov R, 2005, J CELL BIOL, V170, P793, DOI 10.1083/jcb.200503152; PARKER PJ, 1995, CURR BIOL, V5, P577, DOI 10.1016/S0960-9822(95)00113-8; Peck J, 2002, FEBS LETT, V528, P27, DOI 10.1016/S0014-5793(02)03331-8; Ponzetto C, 1996, J BIOL CHEM, V271, P14119, DOI 10.1074/jbc.271.24.14119; PONZETTO C, 1994, CELL, V77, P261, DOI 10.1016/0092-8674(94)90318-2; RIDLEY AJ, 1995, MOL CELL BIOL, V15, P1110; RIDLEY AJ, 1993, EMBO J, V12, P5151, DOI 10.1002/j.1460-2075.1993.tb06210.x; ROSEN EM, 1990, J CELL SCI, V96, P639; Royal I, 2000, MOL BIOL CELL, V11, P1709, DOI 10.1091/mbc.11.5.1709; ROYAL I, 1995, J BIOL CHEM, V270, P27780, DOI 10.1074/jbc.270.46.27780; Sander EE, 1999, J CELL BIOL, V147, P1009, DOI 10.1083/jcb.147.5.1009; Sander EE, 1998, J CELL BIOL, V143, P1385, DOI 10.1083/jcb.143.5.1385; Seoh ML, 2003, FEBS LETT, V539, P131, DOI 10.1016/S0014-5793(03)00213-8; Takenawa T, 2001, J CELL SCI, V114, P1801; Trusolino L, 2002, NAT REV CANCER, V2, P289, DOI 10.1038/nrc779; Trusolino L, 2001, CELL, V107, P643, DOI 10.1016/S0092-8674(01)00567-0; Wheeler AP, 2006, J CELL SCI, V119, P2749, DOI 10.1242/jcs.03024; Zandy NL, 2007, P NATL ACAD SCI USA, V104, P17686, DOI 10.1073/pnas.0703077104; Zeng QH, 2002, J BIOL CHEM, V277, P25203, DOI 10.1074/jbc.M201598200; Zhang Z, 2002, INT J BIOCHEM CELL B, V34, P325, DOI 10.1016/S1357-2725(01)00134-0	49	26	26	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 18	2008	27	42					5590	5598		10.1038/onc.2008.173	http://dx.doi.org/10.1038/onc.2008.173			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	349KX	18504429	Green Submitted			2022-12-28	WOS:000259280800005
J	Keniry, M; Parsons, R				Keniry, M.; Parsons, R.			The role of PTEN signaling perturbations in cancer and in targeted therapy	ONCOGENE			English	Review						PTEN; PI3K; AKT; targeted chemotherapy	TUMOR-SUPPRESSOR GENE; PROTEIN-KINASE B; PLECKSTRIN HOMOLOGY DOMAIN; TUBEROUS SCLEROSIS; PHOSPHATIDYLINOSITOL 3-KINASE; ALVEOLAR RHABDOMYOSARCOMA; PHOSPHOINOSITIDE 3-KINASE; TRASTUZUMAB RESISTANCE; NUCLEAR-LOCALIZATION; PHOSPHATASE-ACTIVITY	The PTEN tumor suppressor was discovered by its homozygous deletion and other mutations in cancer. Since then, PTEN has been shown to be a non-redundant, evolutionarily conserved phosphatase whose function affects diverse cellular progresses such as cell cycle progression, cell proliferation, chemotaxis, apoptosis, aging, muscle contractility, DNA damage response, angiogenesis and cell polarity. In accordance with its ability to influence multiple crucial cellular processes, PTEN has a major role in the pathogenesis of numerous diseases such as diabetes, autism and almost every cancer examined. This review will discuss the diverse ways in which PTEN signaling is modified in cancer, and how these changes correlate with and might possibly affect the action of targeted chemotherapy.	[Keniry, M.; Parsons, R.] Columbia Univ, Dept Pathol, Inst Canc Genet, New York, NY 10032 USA; [Keniry, M.; Parsons, R.] Columbia Univ, Herbert Irving Comprehens Canc Ctr, New York, NY 10032 USA; [Parsons, R.] Columbia Univ, Med Ctr, Dept Med, New York, NY 10032 USA	Columbia University; Columbia University; Columbia University	Parsons, R (corresponding author), Columbia Univ, Med Ctr, Dept Pathol & Med, 630 W 168th St, New York, NY 10032 USA.	rep15@columbia.edu		Parsons, Ramon/0000-0002-6656-3514	DOD [PC050068]; Avon Foundation; Octoberwoman Foundation; NCI [CA097403, CA082783]; NATIONAL CANCER INSTITUTE [R01CA082783, P01CA097403] Funding Source: NIH RePORTER	DOD(United States Department of Defense); Avon Foundation; Octoberwoman Foundation; NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank the members of the Parsons Laboratory for the critical reading of this paper. MK received support from the DOD (PC050068). RP received support from the Avon Foundation, the Octoberwoman Foundation, and the NCI (Grants CA097403 and CA082783).	Accili D, 2004, CELL, V117, P421, DOI 10.1016/S0092-8674(04)00452-0; Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9; Alessi DR, 1996, FEBS LETT, V399, P333, DOI 10.1016/S0014-5793(96)01370-1; Ali IU, 1999, JNCI-J NATL CANCER I, V91, P1922, DOI 10.1093/jnci/91.22.1922; AUGER KR, 1989, CELL, V57, P167, DOI 10.1016/0092-8674(89)90182-7; Baker SJ, 2007, CELL, V128, P25, DOI 10.1016/j.cell.2006.12.023; Barr FG, 2001, ONCOGENE, V20, P5736, DOI 10.1038/sj.onc.1204599; Bayascas JR, 2005, CURR BIOL, V15, P1839, DOI 10.1016/j.cub.2005.08.066; BELLACOSA A, 1995, INT J CANCER, V64, P280, DOI 10.1002/ijc.2910640412; Berns K, 2007, CANCER CELL, V12, P395, DOI 10.1016/j.ccr.2007.08.030; Bose S, 1998, ONCOGENE, V17, P123, DOI 10.1038/sj.onc.1201940; Cairns P, 1998, ONCOGENE, V16, P3215, DOI 10.1038/sj.onc.1201855; Cairns P, 1997, CANCER RES, V57, P4997; Campbell IG, 2004, CANCER RES, V64, P7678, DOI 10.1158/0008-5472.CAN-04-2933; Carpten JD, 2007, NATURE, V448, P439, DOI 10.1038/nature05933; Chang CJ, 2008, MOL CELL BIOL, V28, P3281, DOI 10.1128/MCB.00310-08; Chen ML, 2006, GENE DEV, V20, P1569, DOI 10.1101/gad.1395006; Chiariello E, 1998, ONCOGENE, V16, P541, DOI 10.1038/sj.onc.1201689; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; Currie RA, 1999, BIOCHEM J, V337, P575, DOI 10.1042/0264-6021:3370575; Dahia PLM, 1997, CANCER RES, V57, P4710; Das S, 2003, P NATL ACAD SCI USA, V100, P7491, DOI 10.1073/pnas.0932835100; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; Deleris P, 2006, J CELL BIOCHEM, V98, P469, DOI 10.1002/jcb.20695; Di Cristofano A, 1998, NAT GENET, V19, P348, DOI 10.1038/1235; Di Cristofano A, 2001, NAT GENET, V27, P222, DOI 10.1038/84879; Dourdin N, 2008, CANCER RES, V68, P2122, DOI 10.1158/0008-5472.CAN-07-5727; Duerr EM, 1998, ONCOGENE, V16, P2259, DOI 10.1038/sj.onc.1201756; Fang XJ, 1999, ONCOGENE, V18, P6635, DOI 10.1038/sj.onc.1203076; Feilotter HE, 1998, ONCOGENE, V16, P1743, DOI 10.1038/sj.onc.1200205; Fingar DC, 2002, GENE DEV, V16, P1472, DOI 10.1101/gad.995802; Frattini M, 2007, BRIT J CANCER, V97, P1139, DOI 10.1038/sj.bjc.6604009; Frech M, 1997, J BIOL CHEM, V272, P8474, DOI 10.1074/jbc.272.13.8474; Freeman DJ, 2003, CANCER CELL, V3, P117, DOI 10.1016/S1535-6108(03)00021-7; Fukuyama M, 2006, CURR BIOL, V16, P773, DOI 10.1016/j.cub.2006.02.073; Furnari FB, 1997, P NATL ACAD SCI USA, V94, P12479, DOI 10.1073/pnas.94.23.12479; Furnari FB, 1998, CANCER RES, V58, P5002; Georgescu MM, 1999, P NATL ACAD SCI USA, V96, P10182, DOI 10.1073/pnas.96.18.10182; Georgescu MM, 2000, CANCER RES, V60, P7033; Gil A, 2006, MOL BIOL CELL, V17, P4002, DOI 10.1091/mbc.E06-05-0380; Goberdhan DCI, 1999, GENE DEV, V13, P3244, DOI 10.1101/gad.13.24.3244; Goswami A, 2005, MOL CELL, V20, P33, DOI 10.1016/j.molcel.2005.08.016; Gupta S, 2007, CELL, V129, P957, DOI 10.1016/j.cell.2007.03.051; Hwangbo DS, 2004, NATURE, V429, P562, DOI 10.1038/nature02549; Iijima M, 2002, CELL, V109, P599, DOI 10.1016/S0092-8674(02)00745-6; Iijima M, 2002, DEV CELL, V3, P469, DOI 10.1016/S1534-5807(02)00292-7; Janetopoulos C, 2005, DEV CELL, V8, P467, DOI 10.1016/j.devcel.2005.02.010; Jhawer M, 2008, CANCER RES, V68, P1953, DOI 10.1158/0008-5472.CAN-07-5659; Keller C, 2004, GENE DEV, V18, P2608, DOI 10.1101/gad.1243904; Kim MJ, 2002, P NATL ACAD SCI USA, V99, P2884, DOI 10.1073/pnas.042688999; Kim RH, 2005, CANCER CELL, V7, P263, DOI 10.1016/j.ccr.2005.02.010; Kitamura YI, 2005, CELL METAB, V2, P153, DOI 10.1016/j.cmet.2005.08.004; Klarlund JK, 1997, SCIENCE, V275, P1927, DOI 10.1126/science.275.5308.1927; Klinghoffer RA, 1996, MOL CELL BIOL, V16, P5905; Kokubo Y, 2005, BRIT J CANCER, V92, P1711, DOI 10.1038/sj.bjc.6602559; Laffargue M, 1999, J BIOL CHEM, V274, P32835, DOI 10.1074/jbc.274.46.32835; Lagutina I, 2002, MOL CELL BIOL, V22, P7204, DOI 10.1128/MCB.22.20.7204-7216.2002; Lee SR, 2002, J BIOL CHEM, V277, P20336, DOI 10.1074/jbc.M111899200; Leslie NR, 2003, EMBO J, V22, P5501, DOI 10.1093/emboj/cdg513; Li AG, 2006, MOL CELL, V23, P575, DOI 10.1016/j.molcel.2006.06.028; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; Li J, 1998, CANCER RES, V58, P5667; Liang J, 2002, NAT MED, V8, P1153, DOI 10.1038/nm761; Liaw D, 1997, NAT GENET, V16, P64, DOI 10.1038/ng0597-64; Lievre A, 2006, CANCER RES, V66, P3992, DOI 10.1158/0008-5472.CAN-06-0191; Lin WM, 1998, CLIN CANCER RES, V4, P2577; Lindsay Y, 2006, J CELL SCI, V119, P5160, DOI 10.1242/jcs.000133; Liu FH, 2005, J CELL BIOCHEM, V96, P221, DOI 10.1002/jcb.20525; Liu JL, 2005, MOL CELL BIOL, V25, P6211, DOI 10.1128/MCB.25.14.6211-6224.2005; Long X, 2005, CURR BIOL, V15, P702, DOI 10.1016/j.cub.2005.02.053; Ma L, 2005, CELL, V121, P179, DOI 10.1016/j.cell.2005.02.031; Ma L, 2005, GENE DEV, V19, P1779, DOI 10.1101/gad.1314405; Maehama T, 1998, J BIOL CHEM, V273, P13375, DOI 10.1074/jbc.273.22.13375; Manning BD, 2002, MOL CELL, V10, P151, DOI 10.1016/S1097-2765(02)00568-3; Manning BD, 2007, CELL, V129, P1261, DOI 10.1016/j.cell.2007.06.009; Marsh DJ, 1997, NAT GENET, V16, P333, DOI 10.1038/ng0897-333; Moasser MM, 2007, ONCOGENE, V26, P6469, DOI 10.1038/sj.onc.1210477; Myers MP, 1998, P NATL ACAD SCI USA, V95, P13513, DOI 10.1073/pnas.95.23.13513; Nagata Y, 2004, CANCER CELL, V6, P117, DOI 10.1016/j.ccr.2004.06.022; Nakamura N, 2000, MOL CELL BIOL, V20, P8969, DOI 10.1128/MCB.20.23.8969-8982.2000; Ogg S, 1998, MOL CELL, V2, P887, DOI 10.1016/S1097-2765(00)80303-2; Okumura K, 2006, J BIOL CHEM, V281, P26562, DOI 10.1074/jbc.M605391200; Palomero T, 2007, NAT MED, V13, P1203, DOI 10.1038/nm1636; Pao W, 2005, PLOS MED, V2, P57, DOI 10.1371/journal.pmed.0020017; Parsons DW, 2005, NATURE, V436, P792, DOI 10.1038/436792a; Podsypanina K, 1999, P NATL ACAD SCI USA, V96, P1563, DOI 10.1073/pnas.96.4.1563; Potter CJ, 2002, NAT CELL BIOL, V4, P658, DOI 10.1038/ncb840; Puc J, 2005, CANCER CELL, V7, P193, DOI 10.1016/j.ccr.2005.01.009; Puc J, 2005, CELL CYCLE, V4, P927, DOI 10.4161/cc.4.7.1795; RAITANO AB, 1995, P NATL ACAD SCI USA, V92, P11746, DOI 10.1073/pnas.92.25.11746; Ramaswamy S, 1999, P NATL ACAD SCI USA, V96, P2110, DOI 10.1073/pnas.96.5.2110; Rasheed BKA, 1997, CANCER RES, V57, P4187; Rubin MA, 2000, HUM PATHOL, V31, P504, DOI 10.1053/hp.2000.6713; Saal LH, 2008, NAT GENET, V40, P102, DOI 10.1038/ng.2007.39; Saal LH, 2007, P NATL ACAD SCI USA, V104, P7564, DOI 10.1073/pnas.0702507104; Saal LH, 2005, CANCER RES, V65, P2554, DOI 10.1158/0008-5472-CAN-04-3913; Samuels Y, 2005, CANCER CELL, V7, P561, DOI 10.1016/j.ccr.2005.05.014; Samuels Y, 2004, SCIENCE, V304, P554, DOI 10.1126/science.1096502; Sarbassov DD, 2005, SCIENCE, V307, P1098, DOI 10.1126/science.1106148; Sasaki AT, 2007, J CELL BIOL, V178, P185, DOI 10.1083/jcb.200611138; SERUNIAN LA, 1990, J VIROL, V64, P4718, DOI 10.1128/JVI.64.10.4718-4725.1990; Shao XY, 1998, INT J CANCER, V77, P684, DOI 10.1002/(SICI)1097-0215(19980831)77:5<684::AID-IJC4>3.3.CO;2-8; She QB, 2005, CANCER CELL, V8, P287, DOI 10.1016/j.ccr.2005.09.006; Shen WH, 2007, CELL, V128, P157, DOI 10.1016/j.cell.2006.11.042; SKOLNIK EY, 1991, CELL, V65, P83, DOI 10.1016/0092-8674(91)90410-Z; Sorensen PHB, 2002, J CLIN ONCOL, V20, P2672, DOI 10.1200/JCO.2002.03.137; Stambolic V, 1998, CELL, V95, P29, DOI 10.1016/S0092-8674(00)81780-8; Stambolic V, 2001, MOL CELL, V8, P317, DOI 10.1016/S1097-2765(01)00323-9; Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356; Stokoe D, 1997, SCIENCE, V277, P567, DOI 10.1126/science.277.5325.567; Tanaka K, 1999, J BIOL CHEM, V274, P3919, DOI 10.1074/jbc.274.7.3919; Tashiro H, 1997, CANCER RES, V57, P3935; Tee AR, 2003, CURR BIOL, V13, P1259, DOI 10.1016/S0960-9822(03)00506-2; Tee AR, 2002, P NATL ACAD SCI USA, V99, P13571, DOI 10.1073/pnas.202476899; Teng DHF, 1997, CANCER RES, V57, P5221; Tolkacheva T, 2001, CANCER RES, V61, P4985; Torres J, 2003, J BIOL CHEM, V278, P30652, DOI 10.1074/jbc.M212610200; Trotman LC, 2006, NATURE, V441, P523, DOI 10.1038/nature04809; Trotman LC, 2007, CELL, V128, P141, DOI 10.1016/j.cell.2006.11.040; Vasudevan KM, 2007, CANCER RES, V67, P10343, DOI 10.1158/0008-5472.CAN-07-1827; Vazquez F, 2000, MOL CELL BIOL, V20, P5010, DOI 10.1128/MCB.20.14.5010-5018.2000; Vazquez F, 2001, J BIOL CHEM, V276, P48627, DOI 10.1074/jbc.C100556200; Vermeij J, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-3; Vivanco I, 2007, CANCER CELL, V11, P555, DOI 10.1016/j.ccr.2007.04.021; WALLASCH C, 1995, EMBO J, V14, P4267, DOI 10.1002/j.1460-2075.1995.tb00101.x; Wang SI, 1998, CLIN CANCER RES, V4, P811; Wang SI, 1997, CANCER RES, V57, P4183; Wang XJ, 2007, CELL, V128, P129, DOI 10.1016/j.cell.2006.11.039; Wiencke JK, 2007, NEURO-ONCOLOGY, V9, P271, DOI 10.1215/15228517-2007-003; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Yang H, 2008, CANCER RES, V68, P425, DOI 10.1158/0008-5472.CAN-07-2488; Yao DG, 2008, J CELL SCI, V121, P1758, DOI 10.1242/jcs.021147; You MJ, 2002, P NATL ACAD SCI USA, V99, P1455, DOI 10.1073/pnas.022632099; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3; Zhang HB, 2003, J CLIN INVEST, V112, P1223, DOI 10.1172/JCI200317222; Zhang Y, 2003, NAT CELL BIOL, V5, P578, DOI 10.1038/ncb999; Zhao L, 2008, P NATL ACAD SCI USA, V105, P2652, DOI 10.1073/pnas.0712169105; Zhou XP, 2000, HUM MOL GENET, V9, P765, DOI 10.1093/hmg/9.5.765; Zhou XP, 2002, AM J PATHOL, V161, P439, DOI 10.1016/S0002-9440(10)64200-9; Zhou XP, 2001, LANCET, V358, P210, DOI 10.1016/S0140-6736(01)05412-5	140	279	296	0	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 15	2008	27	41					5477	5485		10.1038/onc.2008.248	http://dx.doi.org/10.1038/onc.2008.248			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	349KW	18794882				2022-12-28	WOS:000259280700009
J	Leslie, NR; Batty, IH; Maccario, H; Davidson, L; Downes, CP				Leslie, N. R.; Batty, I. H.; Maccario, H.; Davidson, L.; Downes, C. P.			Understanding PTEN regulation: PIP2, polarity and protein stability	ONCOGENE			English	Review						phosphatase; phosphoinositide; cell polarity; Akt; SHIP	TUMOR-SUPPRESSOR PTEN; PHOSPHATIDYLINOSITOL 3,4,5-TRISPHOSPHATE ACCUMULATION; PHOSPHOLIPASE C-GAMMA; TENSIN-HOMOLOG; NEURONAL POLARITY; REDOX REGULATION; CELL POLARITY; LEADING-EDGE; PHOSPHATASE-ACTIVITY; LIPID PHOSPHATASES	The PTEN tumour suppressor is a lipid and protein phosphatase that inhibits phosphoinositide 3-kinase (PI3K)-dependent signalling by dephosphorylating phosphatidylinositol 3,4,5-trisphosphate (PtdInsP(3)). Here, we discuss the concept of PTEN as an 'interfacial enzyme', which exists in a high activity state when bound transiently at membrane surfaces containing its substrate and other acidic lipids, such as PtdIns(4,5)P-2 and phosphatidylserine (PtdSer). This mechanism ensures that PTEN functions in a spatially restricted manner, and may explain its involvement in forming the gradients of PtdInsP(3), which are necessary for generating and/or sustaining cell polarity during motility, in developing neurons and in epithelial tissues. Coordinating PTEN activity with alternative mechanisms of PtdInsP(3) metabolism, by the tightly regulated SHIP 5-phoshatases, synthesizing the independent second messenger PtdIns(3,4)P-2, may also be important for cellular polarization in some cell types. Superimposed on this interfacial mechanism are additional post-translational regulatory processes, which generally act to reduce PTEN activity. Oxidation of the active site cysteine residue by reactive oxygen species and phosphorylation of serine/threonine residues at sites in the C-terminus of the protein inhibit PTEN. These phosphorylation sites also appear to play a role in regulating both stability and localization of PTEN, as does ubiquitination of PTEN. Because genetic studies in mice show that the level of expression of PTEN in an organism profoundly influences tumour susceptibility, factors that regulate PTEN, localization, activity and turnover should be important in understanding its biological functions as a tumour suppressor.	[Leslie, N. R.; Batty, I. H.; Maccario, H.; Davidson, L.; Downes, C. P.] Univ Dundee, Div Mol Physiol, Coll Life Sci, James Black Ctr, Dundee DD1 5EH, Scotland	University of Dundee	Leslie, NR (corresponding author), Univ Dundee, Div Mol Physiol, Coll Life Sci, James Black Ctr, Dow St, Dundee DD1 5EH, Scotland.	n.r.leslie@dundee.ac.uk; c.p.downes@dundee.ac.uk	Leslie, Nicholas/D-2699-2009	LESLIE, Nicholas/0000-0001-5131-0541	Medical Research Council; Association for International Cancer Research; consortium of pharmaceutical companies comprising Astra Zeneca; Boehringer Ingelheim; GlaxoSmithKline; Merck and Co; Merck KGaA; Pfizer; Medical Research Council [G9403619] Funding Source: researchfish; MRC [G9403619] Funding Source: UKRI	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Association for International Cancer Research; consortium of pharmaceutical companies comprising Astra Zeneca(AstraZeneca); Boehringer Ingelheim(Boehringer Ingelheim); GlaxoSmithKline(GlaxoSmithKline); Merck and Co(Merck & Company); Merck KGaA; Pfizer(Pfizer); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	Research in the Inositol Lipid Signalling laboratory is funded by the Medical Research Council, the Association for International Cancer Research and a consortium of pharmaceutical companies comprising Astra Zeneca, Boehringer Ingelheim, GlaxoSmithKline, Merck and Co., Merck KGaA and Pfizer.	Adler CE, 2006, NAT NEUROSCI, V9, P511, DOI 10.1038/nn1666; Ahn Y, 2008, BIOCHEM J, V412, P331, DOI 10.1042/BJ20071403; Al-Khouri AM, 2005, J BIOL CHEM, V280, P35195, DOI 10.1074/jbc.M503045200; Aoki K, 2005, MOL BIOL CELL, V16, P2207, DOI 10.1091/mbc.e04-10-0904; Arevalo MA, 2006, MOL BIOL CELL, V17, P3369, DOI 10.1091/mbc.E05-12-1144; Arimura N, 2007, NAT REV NEUROSCI, V8, P194, DOI 10.1038/nrn2056; Backers K, 2003, ADV ENZYME REGUL, V43, P15, DOI 10.1016/S0065-2571(02)00043-2; Bae YS, 1998, J BIOL CHEM, V273, P4465, DOI 10.1074/jbc.273.8.4465; Baker SJ, 2007, CELL, V128, P25, DOI 10.1016/j.cell.2006.12.023; Batty IH, 1996, BIOCHEM J, V317, P347, DOI 10.1042/bj3170347; BATTY IH, 2001, BIOCHEM J, V379, P641; BATTY IH, 2002, BIOCHEM J, V407, P255; Blero D, 2001, BIOCHEM BIOPH RES CO, V282, P839, DOI 10.1006/bbrc.2001.4639; Cai ZQ, 2005, CIRC RES, V97, P1351, DOI 10.1161/01.RES.0000195656.52760.30; Campbell RB, 2003, J BIOL CHEM, V278, P33617, DOI 10.1074/jbc.C300296200; Chadborn NH, 2006, J CELL SCI, V119, P951, DOI 10.1242/jcs.02801; Charest PG, 2006, CURR OPIN GENET DEV, V16, P339, DOI 10.1016/j.gde.2006.06.016; Choi YC, 2004, FUND CLIN PHARMACOL, V18, P547, DOI 10.1111/j.1472-8206.2004.00284.x; Costello PS, 2002, NAT IMMUNOL, V3, P1082, DOI 10.1038/ni848; Covey TM, 2007, ONCOGENE, V26, P5784, DOI 10.1038/sj.onc.1210391; Das S, 2003, P NATL ACAD SCI USA, V100, P7491, DOI 10.1073/pnas.0932835100; Dey N, 2008, CANCER RES, V68, P1862, DOI 10.1158/0008-5472.CAN-07-1182; Dowler S, 2000, BIOCHEM J, V351, P19, DOI 10.1042/0264-6021:3510019; Dowler S, 1999, BIOCHEM J, V342, P7, DOI 10.1042/0264-6021:3420007; Downes CP, 2007, BIOCHEM SOC T, V35, P188, DOI 10.1042/BST0350188; Downes CP, 2007, BIOCHEM SOC SYMP, V74, P69, DOI 10.1042/BSS2007c07; Dyson JM, 2005, INT J BIOCHEM CELL B, V37, P2260, DOI 10.1016/j.biocel.2005.05.003; Falasca M, 1998, EMBO J, V17, P414, DOI 10.1093/emboj/17.2.414; Franca-Koh J, 2007, NAT CELL BIOL, V9, P15, DOI 10.1038/ncb0107-15; Funamoto S, 2002, CELL, V109, P611, DOI 10.1016/S0092-8674(02)00755-9; Gil A, 2006, MOL BIOL CELL, V17, P4002, DOI 10.1091/mbc.E06-05-0380; Gimm O, 2000, AM J PATHOL, V156, P1693, DOI 10.1016/S0002-9440(10)65040-7; Giuriato S, 1997, J BIOL CHEM, V272, P26857, DOI 10.1074/jbc.272.43.26857; Giuriato S, 2002, BIOCHEM BIOPH RES CO, V296, P106, DOI 10.1016/S0006-291X(02)00787-8; Guo A, 2008, P NATL ACAD SCI USA, V105, P692, DOI 10.1073/pnas.0707270105; Harriague J, 2002, NAT IMMUNOL, V3, P1090, DOI 10.1038/ni847; Harris SJ, 2008, J BIOL CHEM, V283, P2465, DOI 10.1074/jbc.R700044200; Helgason CD, 1998, GENE DEV, V12, P1610, DOI 10.1101/gad.12.11.1610; Heo WD, 2006, SCIENCE, V314, P1458, DOI 10.1126/science.1134389; Hoshino Y, 2007, J CELL BIOCHEM, V100, P515, DOI 10.1002/jcb.21085; Hui STY, 2008, P NATL ACAD SCI USA, V105, P3921, DOI 10.1073/pnas.0800293105; Iglesias PA, 2008, CURR OPIN CELL BIOL, V20, P35, DOI 10.1016/j.ceb.2007.11.011; Iijima M, 2004, J BIOL CHEM, V279, P16606, DOI 10.1074/jbc.M312098200; Iijima M, 2002, CELL, V109, P599, DOI 10.1016/S0092-8674(02)00745-6; Iijima M, 2002, DEV CELL, V3, P469, DOI 10.1016/S1534-5807(02)00292-7; Ijuin T, 2000, J BIOL CHEM, V275, P10870, DOI 10.1074/jbc.275.15.10870; Insall R, 2007, CURR OPIN MICROBIOL, V10, P578, DOI 10.1016/j.mib.2007.10.004; Janetopoulos C, 2006, J CELL BIOL, V174, P485, DOI 10.1083/jcb.200603156; Jiang H, 2005, CELL, V120, P123, DOI 10.1016/j.cell.2004.12.033; Keizer-Gunnink I, 2007, J CELL BIOL, V177, P579, DOI 10.1083/jcb.200611046; Kim KY, 2004, EUR J PHARMACOL, V497, P267, DOI 10.1016/j.ejphar.2004.06.058; Kortholt A, 2007, MOL BIOL CELL, V18, P4772, DOI 10.1091/mbc.E07-05-0407; Kotelevets L, 2004, FASEB J, V18, P115, DOI 10.1096/fj.04-1942fje; Koul D, 2002, ONCOGENE, V21, P2357, DOI 10.1038/sj/onc/1205296; Krause M, 2004, DEV CELL, V7, P571, DOI 10.1016/j.devcel.2004.07.024; Krugmann S, 2006, METHOD ENZYMOL, V406, P91, DOI 10.1016/S0076-6879(06)06008-3; Krugmann S, 2004, CURR BIOL, V14, P1380, DOI 10.1016/j.cub.2004.07.058; Krystal G, 1999, INT J BIOCHEM CELL B, V31, P1007, DOI 10.1016/S1357-2725(99)00072-2; Kwon J, 2004, P NATL ACAD SCI USA, V101, P16419, DOI 10.1073/pnas.0407396101; Lacalle RA, 2004, J CELL SCI, V117, P6207, DOI 10.1242/jcs.01545; Lazar DF, 2006, NAT REV DRUG DISCOV, V5, P333, DOI 10.1038/nrd2007; Lee JO, 1999, CELL, V99, P323, DOI 10.1016/S0092-8674(00)81663-3; Lee SR, 2002, J BIOL CHEM, V277, P20336, DOI 10.1074/jbc.M111899200; Leslie NR, 2007, CURR BIOL, V17, P115, DOI 10.1016/j.cub.2006.12.026; Leslie NR, 2006, ANTIOXID REDOX SIGN, V8, P1765, DOI 10.1089/ars.2006.8.1765; Leslie NR, 2004, BIOCHEM J, V382, P1, DOI 10.1042/BJ20040825; Leslie NR, 2003, EMBO J, V22, P5501, DOI 10.1093/emboj/cdg513; Leslie NR, 2001, BIOCHEM J, V357, P427, DOI 10.1042/0264-6021:3570427; Li DM, 1997, CANCER RES, V57, P2124; Li Z, 2005, NAT CELL BIOL, V7, P399, DOI 10.1038/ncb1236; Li Z, 2003, CELL, V114, P215, DOI 10.1016/S0092-8674(03)00559-2; Liliental J, 2000, CURR BIOL, V10, P401, DOI 10.1016/S0960-9822(00)00417-6; Lindsay Y, 2006, J CELL SCI, V119, P5160, DOI 10.1242/jcs.000133; Liu FH, 2005, J CELL BIOCHEM, V96, P221, DOI 10.1002/jcb.20525; Liu H, 2004, J CELL BIOL, V164, P603, DOI 10.1083/jcb.200306090; Lu YL, 2003, J BIOL CHEM, V278, P40057, DOI 10.1074/jbc.M303621200; Maccario H, 2007, BIOCHEM J, V405, P439, DOI 10.1042/BJ20061837; Majerus PW, 1999, J BIOL CHEM, V274, P10669, DOI 10.1074/jbc.274.16.10669; Manning BD, 2007, CELL, V129, P1261, DOI 10.1016/j.cell.2007.06.009; Martin-Belmonte F, 2007, CELL, V128, P383, DOI 10.1016/j.cell.2006.11.051; McConnachie G, 2003, BIOCHEM J, V371, P947, DOI 10.1042/BJ20021848; Meili R, 1999, EMBO J, V18, P2092, DOI 10.1093/emboj/18.8.2092; Miller SJ, 2002, FEBS LETT, V528, P145, DOI 10.1016/S0014-5793(02)03274-X; Mochizuki Y, 1999, J BIOL CHEM, V274, P36790, DOI 10.1074/jbc.274.51.36790; Ning K, 2006, EMBO J, V25, P2377, DOI 10.1038/sj.emboj.7601118; Nishio M, 2007, NAT CELL BIOL, V9, P36, DOI 10.1038/ncb1515; NORRIS FA, 1995, J BIOL CHEM, V270, P16128, DOI 10.1074/jbc.270.27.16128; Norris FA, 1997, J BIOL CHEM, V272, P23859, DOI 10.1074/jbc.272.38.23859; Nystuen A, 2001, NEURON, V32, P203, DOI 10.1016/S0896-6273(01)00468-8; Odriozola L, 2007, J BIOL CHEM, V282, P23306, DOI 10.1074/jbc.M611240200; Okahara F, 2004, J BIOL CHEM, V279, P45300, DOI 10.1074/jbc.C400377200; Okamura A, 2006, LIFE SCI, V78, P1624, DOI 10.1016/j.lfs.2005.07.041; Okumura K, 2005, P NATL ACAD SCI USA, V102, P2703, DOI 10.1073/pnas.0409370102; Okumura K, 2006, J BIOL CHEM, V281, P26562, DOI 10.1074/jbc.M605391200; Ong CJ, 2007, BLOOD, V110, P1942, DOI 10.1182/blood-2007-03-079699; Pallares J, 2005, MODERN PATHOL, V18, P719, DOI 10.1038/modpathol.3800347; Papakonstanti EA, 2007, EMBO J, V26, P3050, DOI 10.1038/sj.emboj.7601763; Parente CA, 1998, CELL, V95, P81, DOI 10.1016/S0092-8674(00)81784-5; Perren A, 2000, AM J PATHOL, V157, P1097, DOI 10.1016/S0002-9440(10)64624-X; Perren A, 1999, AM J PATHOL, V155, P1253, DOI 10.1016/S0002-9440(10)65227-3; Pinal N, 2006, CURR BIOL, V16, P140, DOI 10.1016/j.cub.2005.11.068; Rafiq K, 2006, J BIOL CHEM, V281, P19781, DOI 10.1074/jbc.M513040200; Raftopoulou M, 2004, SCIENCE, V303, P1179, DOI 10.1126/science.1092089; Redfern RE, 2008, BIOCHEMISTRY-US, V47, P2162, DOI 10.1021/bi702114w; Rhee SG, 2005, CURR OPIN CELL BIOL, V17, P183, DOI 10.1016/j.ceb.2005.02.004; Rikova K, 2007, CELL, V131, P1190, DOI 10.1016/j.cell.2007.11.025; Rohrschneider LR, 2000, GENE DEV, V14, P505; Sanchez T, 2005, P NATL ACAD SCI USA, V102, P4312, DOI 10.1073/pnas.0409784102; Seo JH, 2005, MOL BIOL CELL, V16, P348, DOI 10.1091/mbc.E04-05-0369; Servant G, 2000, SCIENCE, V287, P1037, DOI 10.1126/science.287.5455.1037; Shi SH, 2003, CELL, V112, P63, DOI 10.1016/S0092-8674(02)01249-7; Shin HW, 2005, J CELL BIOL, V170, P607, DOI 10.1083/jcb.200505128; Simonsen A, 2001, CURR OPIN CELL BIOL, V13, P485, DOI 10.1016/S0955-0674(00)00240-4; Sleeman MW, 2005, NAT MED, V11, P199, DOI 10.1038/nm1178; Song P, 2007, CIRCULATION, V116, P1585, DOI 10.1161/CIRCULATIONAHA.107.716498; Subauste MC, 2005, J BIOL CHEM, V280, P5676, DOI 10.1074/jbc.M405561200; Suzuki A, 2003, J EXP MED, V197, P657, DOI 10.1084/jem.20021101; Suzuki A, 2008, CANCER SCI, V99, P209, DOI 10.1111/j.1349-7006.2007.00670.x; Takahashi Y, 2006, EMBO J, V25, P910, DOI 10.1038/sj.emboj.7600979; Taylor V, 2000, MOL CELL BIOL, V20, P6860, DOI 10.1128/MCB.20.18.6860-6871.2000; Thomas CC, 2002, CURR BIOL, V12, P1256, DOI 10.1016/S0960-9822(02)00972-7; Tolkacheva T, 2001, CANCER RES, V61, P4985; Torres J, 2003, J BIOL CHEM, V278, P30652, DOI 10.1074/jbc.M212610200; Torres J, 2001, J BIOL CHEM, V276, P993, DOI 10.1074/jbc.M009134200; Trotman LC, 2007, CELL, V128, P141, DOI 10.1016/j.cell.2006.11.040; Valiente M, 2005, J BIOL CHEM, V280, P28936, DOI 10.1074/jbc.M504761200; Van der Kaay J, 1999, J BIOL CHEM, V274, P35963, DOI 10.1074/jbc.274.50.35963; Van Keymeulen A, 2006, J CELL BIOL, V174, P437, DOI 10.1083/jcb.200604113; Vazquez F, 2006, P NATL ACAD SCI USA, V103, P3633, DOI 10.1073/pnas.0510570103; Vazquez F, 2000, MOL CELL BIOL, V20, P5010, DOI 10.1128/MCB.20.14.5010-5018.2000; Vazquez F, 2001, J BIOL CHEM, V276, P48627, DOI 10.1074/jbc.C100556200; von Stein W, 2005, DEVELOPMENT, V132, P1675, DOI 10.1242/dev.01720; Vyas P, 2000, P NATL ACAD SCI USA, V97, P13696, DOI 10.1073/pnas.250476397; Walker SM, 2004, BIOCHEM J, V379, P301, DOI 10.1042/BJ20031839; Wang XJ, 2007, CELL, V128, P129, DOI 10.1016/j.cell.2006.11.039; Weiner OD, 2002, CURR OPIN CELL BIOL, V14, P196, DOI 10.1016/S0955-0674(02)00310-1; Wodarz A, 2007, NAT CELL BIOL, V9, P1016, DOI 10.1038/ncb433; Wu H, 2007, MOL CELL, V28, P886, DOI 10.1016/j.molcel.2007.10.028; Wu WD, 2003, J BIOL CHEM, V278, P28258, DOI 10.1074/jbc.M303318200; Wu XY, 2000, P NATL ACAD SCI USA, V97, P4233, DOI 10.1073/pnas.97.8.4233; Xu JS, 2003, CELL, V114, P201, DOI 10.1016/S0092-8674(03)00555-5; Yeung T, 2008, SCIENCE, V319, P210, DOI 10.1126/science.1152066; Yeung T, 2007, IMMUNOL REV, V219, P17, DOI 10.1111/j.1600-065X.2007.00546.x; Yeung T, 2006, SCIENCE, V313, P347, DOI 10.1126/science.1129551; Yu CX, 2005, MOL PHARMACOL, V68, P847, DOI 10.1124/mol.104.010504	145	170	175	0	19	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 15	2008	27	41					5464	5476		10.1038/onc.2008.243	http://dx.doi.org/10.1038/onc.2008.243			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	349KW	18794881				2022-12-28	WOS:000259280700008
J	Chekenya, M; Krakstad, C; Svendsen, A; Netland, IA; Staalesen, V; Tysnes, BB; Selheim, F; Wang, J; Sakariassen, PO; Sandal, T; Lonning, PE; Flatmark, T; Enger, PO; Bjerkvig, R; Sioud, M; Stallcup, WB				Chekenya, M.; Krakstad, C.; Svendsen, A.; Netland, I. A.; Staalesen, V.; Tysnes, B. B.; Selheim, F.; Wang, J.; Sakariassen, P. O.; Sandal, T.; Lonning, P. E.; Flatmark, T.; Enger, P. O.; Bjerkvig, R.; Sioud, M.; Stallcup, W. B.			The progenitor cell marker NG2/MPG promotes chemoresistance by activation of integrin-dependent PI3K/Akt signaling	ONCOGENE			English	Article						apoptosis; chemoresistance; integrin; NG2/MPG	CHONDROITIN SULFATE PROTEOGLYCAN; ACUTE MYELOID-LEUKEMIA; PDGF ALPHA-RECEPTOR; NG2 PROTEOGLYCAN; MONOCLONAL-ANTIBODY; GROWTH-FACTOR; HUMAN HOMOLOG; BRAIN-TUMORS; EXPRESSION; PHOSPHORYLATION	Chemoresistance represents a major problem in the treatment of many malignancies. Overcoming this obstacle will require improved understanding of the mechanisms responsible for this phenomenon. The progenitor cell marker NG2/melanoma proteoglycan (MPG) is aberrantly expressed by various tumors, but its role in cell death signaling and its potential as a therapeutic target are largely unexplored. We have assessed cytotoxic drug-induced cell death in glioblastoma spheroids from 15 patients, as well as in five cancer cell lines that differ with respect to NG2/MPG expression. The tumors were treated with doxorubicin, etoposide, carboplatin, temodal, cisplatin and tumor necrosis factor (TNF)alpha. High NG2/MPG expression correlated with multidrug resistance mediated by increased activation of alpha 3 beta 1 integrin/PI3K signaling and their downstream targets, promoting cell survival. NG2/MPG knockdown with shRNAs incorporated into lentiviral vectors attenuated beta 1 integrin signaling revealing potent antitumor effects and further sensitized neoplastic cells to cytotoxic treatment in vitro and in vivo. Thus, as a novel regulator of the antiapoptotic response, NG2/MPG may represent an effective therapeutic target in several cancer subtypes.	[Chekenya, M.; Svendsen, A.; Netland, I. A.; Tysnes, B. B.; Wang, J.; Sakariassen, P. O.; Enger, P. O.; Bjerkvig, R.] Univ Bergen, Dept Biomed, Norlux Neuro Oncol Grp, N-5009 Bergen, Norway; [Staalesen, V.] Univ Bergen, Dept Mol Biol, N-5009 Bergen, Norway; [Lonning, P. E.] Haukeland Hosp, Dept Oncol, N-5021 Bergen, Norway; [Flatmark, T.] Univ Bergen, Dept Biomed, Sect Biochem & Mol Biol, N-5009 Bergen, Norway; [Enger, P. O.] Haukeland Hosp, Dept Neurosurg, N-5021 Bergen, Norway; [Bjerkvig, R.] CRP Sante, Norlux Neuro Oncol Grp, Luxembourg, Luxembourg; [Sioud, M.] Norwegian Radium Hosp, Dept Immunol, Mol Med Grp, Oslo, Norway; [Stallcup, W. B.] Tumor Microenvironm Program, Canc Res Ctr, Burnham Med Res Inst, La Jolla, CA USA	University of Bergen; University of Bergen; University of Bergen; Haukeland University Hospital; University of Bergen; University of Bergen; Haukeland University Hospital; Luxembourg Institute of Health; University of Oslo; Sanford Burnham Prebys Medical Discovery Institute	Chekenya, M (corresponding author), Univ Bergen, Dept Biomed, Norlux Neuro Oncol Grp, Jonas Lies Vei 91, N-5009 Bergen, Norway.	martha.chekenya@biomed.uib.no	Krakstad, Camilla/AAB-5138-2020	Krakstad, Camilla/0000-0002-0174-8139; Lonning, Per Eystein/0000-0002-8890-6303; Chekenya, PhD, Dr Philos, Dr. Martha/0000-0001-7241-3451	The Norwegian Cancer Society; The Bergen Translational Research Group; Familien Blix Fond; University of Bergen; National Institutes of Health [RO1 CA95287]; Sixth EU Framework Programme; Helse-Vest; NATIONAL CANCER INSTITUTE [R01CA095287] Funding Source: NIH RePORTER	The Norwegian Cancer Society(Norwegian Cancer SocietyEuropean Commission); The Bergen Translational Research Group; Familien Blix Fond; University of Bergen; National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Sixth EU Framework Programme(European Commission); Helse-Vest; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This study was supported by research grants from The Norwegian Cancer Society, The Bergen Translational Research Group, Familien Blix Fond, The University of Bergen, and a RO1 CA95287 grant from the National Institutes of Health. This study was also supported by the Sixth EU Framework Programme and Helse-Vest. We thank Narve Brekka, Tove Johansen, Christine Eriksen, Erna Finsas and Nina Lied Larsen for their technical assistance. We thank Jesus Planaguma for assistance with image analysis.	ARROYO AG, 1992, J CELL BIOL, V117, P659, DOI 10.1083/jcb.117.3.659; BEG AA, 1996, SCIENCE, V274, P784; Behm FG, 1996, BLOOD, V87, P1134, DOI 10.1182/blood.V87.3.1134.bloodjournal8731134; Belachew S, 2003, J CELL BIOL, V161, P169, DOI 10.1083/jcb.200210110; Burg MA, 1997, EXP CELL RES, V235, P254, DOI 10.1006/excr.1997.3674; Burg MA, 1998, J CELL PHYSIOL, V177, P299, DOI 10.1002/(SICI)1097-4652(199811)177:2<299::AID-JCP12>3.3.CO;2-0; Campoli MR, 2004, CRIT REV IMMUNOL, V24, P267, DOI 10.1615/CritRevImmunol.v24.i4.40; Cantrell DA, 2001, J CELL SCI, V114, P1439; Chekenya M, 2002, NEUROPATH APPL NEURO, V28, P367, DOI 10.1046/j.1365-2990.2002.00412.x; Chekenya M, 2002, FASEB J, V16, P586, DOI 10.1096/fj.01-0632fje; Damiano JS, 1999, BLOOD, V93, P1658, DOI 10.1182/blood.V93.5.1658; Downward J, 2004, SEMIN CELL DEV BIOL, V15, P177, DOI 10.1016/j.semcdb.2004.01.002; Eisenmann KM, 1999, NAT CELL BIOL, V1, P507, DOI 10.1038/70302; Fang XX, 1999, MOL BIOL CELL, V10, P3373, DOI 10.1091/mbc.10.10.3373; Frisch SM, 1997, CURR OPIN CELL BIOL, V9, P701, DOI 10.1016/S0955-0674(97)80124-X; Fukushi J, 2004, MOL BIOL CELL, V15, P3580, DOI 10.1091/mbc.E04-03-0236; Goretzki L, 1999, J BIOL CHEM, V274, P16831, DOI 10.1074/jbc.274.24.16831; Goretzki L, 2000, J BIOL CHEM, V275, P28625, DOI 10.1074/jbc.M002290200; Grako KA, 1999, J CELL SCI, V112, P905; GRAKO KA, 1995, EXP CELL RES, V221, P231, DOI 10.1006/excr.1995.1371; HEMLER ME, 1984, J IMMUNOL, V132, P3011; Hilden JM, 1997, BLOOD, V89, P3801, DOI 10.1182/blood.V89.10.3801.3801_3801_3805; Joo NE, 2008, CELL DEATH DIFFER, V15, P899, DOI 10.1038/cdd.2008.22; Kumar CC, 1998, ONCOGENE, V17, P1365, DOI 10.1038/sj.onc.1202172; LENTER M, 1993, P NATL ACAD SCI USA, V90, P9051, DOI 10.1073/pnas.90.19.9051; Li Y, 2003, BRIT J OPHTHALMOL, V87, P629, DOI 10.1136/bjo.87.5.629; Luque A, 1996, J BIOL CHEM, V271, P11067, DOI 10.1074/jbc.271.19.11067; Makagiansar IT, 2007, J CELL BIOL, V178, P155, DOI 10.1083/jcb.200612084; Makagiansar IT, 2004, J BIOL CHEM, V279, P55262, DOI 10.1074/jbc.M411045200; Mauvieux L, 1999, BRIT J HAEMATOL, V107, P674; Miura M, 2006, STEM CELLS, V24, P1095, DOI 10.1634/stemcells.2005-0403; Nishiyama A, 1996, J NEUROSCI RES, V43, P315, DOI 10.1002/(SICI)1097-4547(19960201)43:3<315::AID-JNR6>3.3.CO;2-3; Nishiyama A, 1996, J NEUROSCI RES, V43, P299, DOI 10.1002/(SICI)1097-4547(19960201)43:3<299::AID-JNR5>3.0.CO;2-E; Pluschke G, 1996, P NATL ACAD SCI USA, V93, P9710, DOI 10.1073/pnas.93.18.9710; Sandal T, 2002, J BIOL CHEM, V277, P20783, DOI 10.1074/jbc.M112248200; SCHRAPPE M, 1991, CANCER RES, V51, P4986; Shoshan Y, 1999, P NATL ACAD SCI USA, V96, P10361, DOI 10.1073/pnas.96.18.10361; Smith FO, 1996, BLOOD, V87, P1123, DOI 10.1182/blood.V87.3.1123.bloodjournal8731123; Stallcup WB, 2002, J NEUROCYTOL, V31, P423, DOI 10.1023/A:1025731428581; Stallcup WB, 2001, J CELL SCI, V114, P2315; Tan C, 2004, CANCER CELL, V5, P79, DOI 10.1016/S1535-6108(03)00281-2; TYSNES OB, 1985, THROMB RES, V40, P329, DOI 10.1016/0049-3848(85)90268-3; Vivanco I, 2002, NAT REV CANCER, V2, P489, DOI 10.1038/nrc839; Wewer UM, 1997, AM J PATHOL, V151, P1191; Yang JB, 2004, J CELL BIOL, V165, P881, DOI 10.1083/jcb.200403174	45	115	120	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP	2008	27	39					5182	5194		10.1038/onc.2008.157	http://dx.doi.org/10.1038/onc.2008.157			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	344GO	18469852	Green Accepted			2022-12-28	WOS:000258915100002
J	Kouzmenko, AP; Takeyama, K; Kawasaki, Y; Akiyama, T; Kato, S				Kouzmenko, A. P.; Takeyama, K.; Kawasaki, Y.; Akiyama, T.; Kato, S.			Truncation mutations abolish chromatin-associated activities of adenomatous polyposis coli	ONCOGENE			English	Article						adenomatous polyposis coli; chromatin; nuclear protein complexes; DNA repair	DOUBLE-STRAND BREAKS; BETA-CATENIN DEGRADATION; COLORECTAL TUMOR-CELLS; GENETIC INSTABILITY; APC MUTATIONS; SUBCELLULAR-LOCALIZATION; CHROMOSOMAL INSTABILITY; NUCLEAR RECEPTOR; UBIQUITIN LIGASE; DIOXIN RECEPTOR	The adenomatous polyposis coli (APC) is a tumor suppressor whose loss of function leads to colon cancer. APC shuttles between the nucleus and cytoplasm, however its role in the nucleus remains elusive. We have found that nuclear APC specifically associates with transcriptionally active chromatin through structural elements located downstream to the region of frequent truncation mutations found in colorectal tumors. We show that a recombinant APC fragment comprising such elements associates in vivo with euchromatin and preferentially binds in vitro to acetylated histone H3. Induction of DNA double-strand breaks (DSB) stimulates accumulation of APC at the damaged DNA chromatin marked by histone H2AX and S139-phosphorylated histone H2AX. A nuclear complex containing the DNA-dependent protein kinase catalytic subunit (DNAPKcs) and APC associates with chromatin in response to DNA DSB. APC knockdown with siRNA decreased the rate of DNA DSB-induced S139 histone H2AX phosphorylation in cells expressing endogenous full-length APC, but not in colon cancer cells with its truncation mutants, whereas ectopic APC expression stimulated the H2AX phosphorylation regardless of the type of endogenous APC. Our data suggest that APC involves in the DSB DNA repair and that truncation mutations impair chromatin-associated functions of APC.	[Kouzmenko, A. P.; Takeyama, K.; Kawasaki, Y.; Akiyama, T.; Kato, S.] Univ Tokyo, Inst Mol & Cellular Biosci, Dept Nucl Signaling, Bunkyo Ku, Tokyo 1130032, Japan; [Kouzmenko, A. P.; Kato, S.] Japan Sci & Technol Agcy, ERATO, Kawaguchi, Saitama, Japan	University of Tokyo; Japan Science & Technology Agency (JST)	Kato, S (corresponding author), Univ Tokyo, Inst Mol & Cellular Biosci, Dept Nucl Signaling, Bunkyo Ku, Yayoi 1-1-1, Tokyo 1130032, Japan.	alexk@iam.u-tokyo.ac.jp; uskato@mail.ecc.u-tokyo.ac.jp			Program for Promotion of Basic Research Activities for Innovative Biosciences (PROBRAIN); Ministry of Education, Culture, Sports, Science and Technology; Exploratory Research for Advanced Technology (ERATO); Japan Science and Technology Agency (JST)	Program for Promotion of Basic Research Activities for Innovative Biosciences (PROBRAIN); Ministry of Education, Culture, Sports, Science and Technology(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Exploratory Research for Advanced Technology (ERATO)(Japan Science & Technology Agency (JST)); Japan Science and Technology Agency (JST)(Japan Science & Technology Agency (JST))	We thank Professor AW Burgess (Ludwig Institute for Cancer Research, Melbourne Branch) for critical reading of the paper and members of the Department of Nuclear Signaling for constructive discussions, advice and support. This study was funded in part by the Program for Promotion of Basic Research Activities for Innovative Biosciences (PROBRAIN) and priority areas from the Ministry of Education, Culture, Sports, Science and Technology (to SK), and by the Kato Nuclear Complex Project grant from the Exploratory Research for Advanced Technology (ERATO), Japan Science and Technology Agency (JST).	Akiyama T, 2006, ONCOGENE, V25, P7538, DOI 10.1038/sj.onc.1210063; Bassing CH, 2003, CELL, V114, P359, DOI 10.1016/S0092-8674(03)00566-X; Bienz M, 2002, NAT REV MOL CELL BIO, V3, P328, DOI 10.1038/nrm806; Brocardo M, 2005, EMBO REP, V6, P184, DOI 10.1038/sj.embor.7400329; Burma S, 2004, DNA REPAIR, V3, P909, DOI 10.1016/j.dnarep.2004.03.021; Celeste A, 2003, CELL, V114, P371, DOI 10.1016/S0092-8674(03)00567-1; Deka J, 1999, ONCOGENE, V18, P5654, DOI 10.1038/sj.onc.1202944; Dempke W, 2000, ANTI-CANCER DRUG, V11, P225, DOI 10.1097/00001813-200004000-00001; Fagman H, 2003, ONCOGENE, V22, P6013, DOI 10.1038/sj.onc.1206731; Faux MC, 2004, J CELL SCI, V117, P427, DOI 10.1242/jcs.00862; Fernandez-Capetillo O, 2004, DNA REPAIR, V3, P959, DOI 10.1016/j.dnarep.2004.03.024; Fodde R, 2001, NAT REV CANCER, V1, P55, DOI 10.1038/35094067; Fujita N, 2003, CELL, V113, P207, DOI 10.1016/S0092-8674(03)00234-4; Furuta T, 2003, J BIOL CHEM, V278, P20303, DOI 10.1074/jbc.M300198200; Gaasenbeek M, 2006, CANCER RES, V66, P3471, DOI 10.1158/0008-5472.CAN-05-3285; Gounari F, 2005, NAT IMMUNOL, V6, P800, DOI 10.1038/ni1228; Green RA, 2003, J CELL BIOL, V163, P949, DOI 10.1083/jcb.200307070; Groisman R, 2003, CELL, V113, P357, DOI 10.1016/S0092-8674(03)00316-7; Henderson BR, 2000, NAT CELL BIOL, V2, P653, DOI 10.1038/35023605; Henderson BR, 2002, EMBO REP, V3, P834, DOI 10.1093/embo-reports/kvf181; Hermsen M, 2002, GASTROENTEROLOGY, V123, P1109, DOI 10.1053/gast.2002.36051; Homfray TFR, 1998, HUM MUTAT, V11, P114, DOI 10.1002/(SICI)1098-1004(1998)11:2<114::AID-HUMU3>3.0.CO;2-J; Ishiguro K, 2006, GUT, V55, P695, DOI 10.1136/gut.2005.079459; Jimbo T, 2002, NAT CELL BIOL, V4, P323, DOI 10.1038/ncb779; JOSLYN G, 1993, P NATL ACAD SCI USA, V90, P11109, DOI 10.1073/pnas.90.23.11109; Ju BG, 2006, SCIENCE, V312, P1798, DOI 10.1126/science.1127196; Kawasaki Y, 2007, ONCOGENE, V26, P7620, DOI 10.1038/sj.onc.1210574; Kawasaki Y, 2003, NAT CELL BIOL, V5, P211, DOI 10.1038/ncb937; Kawasaki Y, 2000, SCIENCE, V289, P1194, DOI 10.1126/science.289.5482.1194; Khanna KK, 2001, NAT GENET, V27, P247, DOI 10.1038/85798; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; Kitagawa H, 2003, CELL, V113, P905, DOI 10.1016/S0092-8674(03)00436-7; Kouzmenko AP, 2004, J BIOL CHEM, V279, P40255, DOI 10.1074/jbc.C400331200; KOUZMENKO AP, 2008, GENES CELLS IN PRESS; Lee KK, 2007, NAT REV MOL CELL BIO, V8, P284, DOI 10.1038/nrm2145; Li ZY, 2005, CANCER RES, V65, P5195, DOI 10.1158/0008-5472.CAN-04-4609; Liu J, 2001, MOL CELL, V7, P927, DOI 10.1016/S1097-2765(01)00241-6; Memezawa A, 2007, ONCOGENE, V26, P5038, DOI 10.1038/sj.onc.1210320; Mogensen MM, 2002, J CELL BIOL, V157, P1041, DOI 10.1083/jcb.200203001; Morrison AJ, 2005, CELL CYCLE, V4, P568; Murr R, 2007, ONCOGENE, V26, P5358, DOI 10.1038/sj.onc.1210605; Nathke I, 2006, NAT REV CANCER, V6, P967, DOI 10.1038/nrc2010; Nathke IS, 2004, ANNU REV CELL DEV BI, V20, P337, DOI 10.1146/annurev.cellbio.20.012103.094541; Neufeld KL, 2000, EMBO REP, V1, P519; Ohtake F, 2003, NATURE, V423, P545, DOI 10.1038/nature01606; Ohtake F, 2007, NATURE, V446, P562, DOI 10.1038/nature05683; Osley MA, 2006, TRENDS GENET, V22, P671, DOI 10.1016/j.tig.2006.09.007; Park JH, 2006, EMBO J, V25, P3986, DOI 10.1038/sj.emboj.7601291; Pommier Y, 2006, NAT REV CANCER, V6, P789, DOI 10.1038/nrc1977; POWELL SM, 1992, NATURE, V359, P235, DOI 10.1038/359235a0; Rosin-Arbesfeld R, 2000, NATURE, V406, P1009, DOI 10.1038/35023016; Schneikert J, 2007, HUM MOL GENET, V16, P199, DOI 10.1093/hmg/ddl464; Shibata H, 1997, SCIENCE, V278, P120, DOI 10.1126/science.278.5335.120; Shih IM, 2001, CANCER RES, V61, P818; Sierra J, 2006, GENE DEV, V20, P586, DOI 10.1101/gad.1385806; Squatrito M, 2006, TRENDS CELL BIOL, V16, P433, DOI 10.1016/j.tcb.2006.07.007; Steffensen IL, 2005, MUTAT RES-GEN TOX EN, V587, P73, DOI 10.1016/j.mrgentox.2005.07.004; Steffensen IL, 2006, MUTAT RES-GEN TOX EN, V611, P71, DOI 10.1016/j.mrgentox.2006.07.004; Strom A, 2007, DEVELOPMENT, V134, P2719, DOI 10.1242/dev.02875; Tighe A, 2004, J CELL SCI, V117, P6339, DOI 10.1242/jcs.01556; van Attikum H, 2005, NAT REV MOL CELL BIO, V6, P757, DOI 10.1038/nrm1737; Wysocka J, 2006, NATURE, V442, P86, DOI 10.1038/nature04815; Xiao JH, 2003, J BIOL CHEM, V278, P29954, DOI 10.1074/jbc.M304761200; Yanagisawa J, 2002, MOL CELL, V9, P553, DOI 10.1016/S1097-2765(02)00478-1; Zhang F, 2001, MOL CELL BIOL, V21, P8143, DOI 10.1128/MCB.21.23.8143-8156.2001	65	22	22	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 21	2008	27	36					4888	4899		10.1038/onc.2008.127	http://dx.doi.org/10.1038/onc.2008.127			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	339SF	18454178				2022-12-28	WOS:000258596900003
J	Nam, CH; Lobato, MN; Appert, A; Drynan, LF; Tanaka, T; Rabbitts, TH				Nam, C-H; Lobato, M. N.; Appert, A.; Drynan, L. F.; Tanaka, T.; Rabbitts, T. H.			An antibody inhibitor of the LMO2-protein complex blocks its normal and tumorigenic functions	ONCOGENE			English	Article						antibody; leukaemia; LMO2; scFv; gene therapy; X-SCID	T-CELL PROLIFERATION; TRANSGENIC MICE; CHROMOSOMAL TRANSLOCATION; INTRACELLULAR ANTIBODIES; PROTEIN RBTN2; HIGH-AFFINITY; DOMAIN; GENE; LMO2; EXPRESSION	The LIM-domain protein LMO2 is a T-cell oncogenic protein first recognized by gene activation through chromosomal translocations, but it is also responsible for leukaemias arising as secondary, adverse effects in an X-SCID gene therapy trial. There are no specific reagents currently available to analyse the LMO2 multiprotein complex or to combat LMO2-dependent leukaemias. Accordingly, we have isolated an anti-LMO2 single chain Fv antibody fragment to determine if intracellular interference with LMO2-protein complexes can avert LMO2-dependent functions in normal and cancer settings. The anti-LMO2 single chain Fv, obtained using Intracellular Antibody Capture (IAC) technology, is specifc for LMO2 among the LIM-only protein family and binds LMO2 through the third and fourth LIM fingers. Using vector-mediated expression of anti-LMO2 scFv, we show inhibition of Lmo2-dependent erythropoiesis but not endothelial development. We also demonstrate inhibition of Lmo2-dependent leukaemia in a mouse T-cell tumour-igenesis transplantation assay with retroviral-mediated expression of anti-LMO2 scFv. Our studies establish that interference with the LMO2 multiprotein complex inhibits both normal and tumourigenic roles. The antibody fragment is a tool for dissecting LMO2 function in haematopoiesis and leukaemia and is a lead for development of therapeutics against LMO2-dependent T-ALL.	[Tanaka, T.; Rabbitts, T. H.] St James Univ Hosp, Leeds Inst Mol Med, Sect Expt Therapeut, Leeds LS9 7TF, W Yorkshire, England; [Nam, C-H; Lobato, M. N.; Appert, A.; Drynan, L. F.; Rabbitts, T. H.] MRC, Mol Biol Lab, Cambridge CB2 2QH, England	Saint James's University Hospital; University of Leeds; MRC Laboratory Molecular Biology	Rabbitts, TH (corresponding author), St James Univ Hosp, Leeds Inst Mol Med, Sect Expt Therapeut, Wellcome Trust Brenner Bldg, Leeds LS9 7TF, W Yorkshire, England.	thr@leeds.ac.uk	Drynan, Lesley/V-2984-2019; Rabbitts, Terence/D-6262-2016	Rabbitts, Terence/0000-0002-4982-2609	Medical Research Council; MRC [G0600914] Funding Source: UKRI; Medical Research Council [G0600914, MC_U105178807] Funding Source: researchfish	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)	This work was supported by the Medical Research Council. CHN was supported by a fellowship from the Lady Tata Memorial Trust. We would like to thank Dr T Kitamura ( University of Tokyo) for PlatE packaging cells and Dr D Baltimore ( California Institute of Technology) for pMIG vector.	ALDERTON G, 2007, NATURE REV CANC, V7, P570; Bai SH, 2006, CRIT REV THER DRUG, V23, P437, DOI 10.1615/CritRevTherDrugCarrierSyst.v23.i6.10; FIZZOTTI M, 1994, LEUKEMIA, V8, P1124; Forster A, 2005, COLD SH Q B, V70, P275, DOI 10.1101/sqb.2005.70.008; Grutz G, 1998, ONCOGENE, V17, P2799, DOI 10.1038/sj.onc.1202502; Hacein-Bey-Abina S, 2003, SCIENCE, V302, P415, DOI 10.1126/science.1088547; Holt L J, 2000, Nucleic Acids Res, V28, pE72, DOI 10.1093/nar/28.15.e72; KARLSSON O, 1990, NATURE, V344, P879, DOI 10.1038/344879a0; Kenny DA, 1998, P NATL ACAD SCI USA, V95, P11257, DOI 10.1073/pnas.95.19.11257; LARSON RC, 1995, ONCOGENE, V11, P853; Larson RC, 1996, EMBO J, V15, P1021, DOI 10.1002/j.1460-2075.1996.tb00439.x; LARSON RC, 1994, ONCOGENE, V9, P3675; Nam CH, 2006, MOL THER, V13, P15, DOI 10.1016/j.ymthe.2005.09.010; NEALE GAM, 1995, BLOOD, V86, P3060; Peer D, 2007, NAT NANOTECHNOL, V2, P751, DOI 10.1038/nnano.2007.387; Racevskis J, 1999, BBA-GENE STRUCT EXPR, V1445, P148, DOI 10.1016/S0167-4781(99)00037-8; Sheets MD, 1998, P NATL ACAD SCI USA, V95, P6157, DOI 10.1073/pnas.95.11.6157; SPANOPOULOU E, 1994, GENE DEV, V8, P1030, DOI 10.1101/gad.8.9.1030; Tanaka T, 2003, J MOL BIOL, V331, P1109, DOI 10.1016/S0022-2836(03)00836-2; Tanaka T, 2003, EMBO J, V22, P1025, DOI 10.1093/emboj/cdg106; Tanaka T, 2007, EMBO J, V26, P3250, DOI 10.1038/sj.emboj.7601744; Tse E, 2002, J MOL BIOL, V317, P85, DOI 10.1006/jmbi.2002.5403; Van Parijs L, 1999, IMMUNITY, V11, P281, DOI 10.1016/S1074-7613(00)80103-X; Wadman IA, 1997, EMBO J, V16, P3145, DOI 10.1093/emboj/16.11.3145; WARREN AJ, 1994, CELL, V78, P45, DOI 10.1016/0092-8674(94)90571-1; Yamada Y, 1998, P NATL ACAD SCI USA, V95, P3890, DOI 10.1073/pnas.95.7.3890	26	39	41	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 21	2008	27	36					4962	4968		10.1038/onc.2008.130	http://dx.doi.org/10.1038/onc.2008.130			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	339SF	18438427				2022-12-28	WOS:000258596900010
J	Frederick, LA; Matthews, JA; Jamieson, L; Justilien, V; Thompson, EA; Radisky, DC; Fields, AP				Frederick, L. A.; Matthews, J. A.; Jamieson, L.; Justilien, V.; Thompson, E. A.; Radisky, D. C.; Fields, A. P.			Matrix metalloproteinase-10 is a critical effector of protein kinase C iota-Par6 alpha-mediated lung cancer	ONCOGENE			English	Article						non-small cell lung cancer; Rac1; PB1 domain; cellular invasion; anchorage-independent growth	SQUAMOUS-CELL CARCINOMA; C-IOTA; TRANSFORMED GROWTH; EXPRESSION; INVASION; TARGET; CDC42; LINKS; HEAD; NECK	Protein kinase C iota (PKC iota) drives transformed growth of non-small cell lung cancer (NSCLC) cells through the Rho family GTPase Rac1. We show here that PKC iota activates Rac1 in NSCLC cells by formation of a PKC iota-Par6 alpha complex that drives anchorage-independent growth and invasion through activation of matrix metalloproteinase-10 (MMP-10) expression. RNAi-mediated knockdown of PKC iota, Par6 alpha or Rac1 expression inhibits NSCLC transformation and MMP-10 expression in vitro. Expression of wild-type Par6 alpha in Par6 alpha-deficient cells restores transformation and MMP-10 expression, whereas expression of Par6 alpha mutants that either cannot bind PKC iota (Par6 alpha-K19A) or couple to Rac1 (Par6 alpha-Delta CRIB) do not. Knockdown of MMP-10 expression blocks anchorage-independent growth and invasion of NSCLC cells and addition of catalytically active MMP-10 to PKC iota- or Par6 alpha-deficient cells restores anchorage-independent growth and invasion. Dominant-negative PKC iota inhibits tumorigenicity and MMP-10 expression in subcutaneous NSCLC tumors. MMP-10 and PKC iota are coordinately overexpressed in primary NSCLC tumors, and tumor MMP-10 expression predicts poor survival in NSCLC patients. Our data define a PKC iota-Par6 alpha-Rac1 signaling axis that drives anchorage-independent growth and invasion of NSCLC cells through induction of MMP-10 expression.	[Frederick, L. A.; Matthews, J. A.; Jamieson, L.; Justilien, V.; Thompson, E. A.; Radisky, D. C.; Fields, A. P.] Mayo Clin, Coll Med, Dept Canc Biol, Jacksonville, FL 32224 USA	Mayo Clinic	Fields, AP (corresponding author), Mayo Clin, Coll Med, Dept Canc Biol, Griffin Canc Res Bldg,Rm 212,4500 San Pablo Rd, Jacksonville, FL 32224 USA.	fields.alan@mayo.edu	Radisky, Derek/B-6569-2018	Radisky, Derek/0000-0002-1962-8784	NCI NIH HHS [R01 CA081436-11, R01 CA081436, CA081436] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA081436] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bodey B, 2001, IN VIVO, V15, P175; Cho NH, 2004, ONCOGENE, V23, P845, DOI 10.1038/sj.onc.1207140; Delebecq TJ, 2000, CLIN CANCER RES, V6, P1086; Egeblad M, 2002, NAT REV CANCER, V2, P161, DOI 10.1038/nrc745; Erdogan E, 2006, J BIOL CHEM, V281, P28450, DOI 10.1074/jbc.M606054200; Fields AP, 2007, PHARMACOL RES, V55, P487, DOI 10.1016/j.phrs.2007.04.015; Garber ME, 2001, P NATL ACAD SCI USA, V98, P13784, DOI 10.1073/pnas.241500798; Gill JH, 2004, NEOPLASIA, V6, P777, DOI 10.1593/neo.04283; Imoto I, 2001, BIOCHEM BIOPH RES CO, V286, P559, DOI 10.1006/bbrc.2001.5428; Impola U, 2004, J PATHOL, V202, P14, DOI 10.1002/path.1479; Joberty G, 2000, NAT CELL BIOL, V2, P531, DOI 10.1038/35019573; Kleinman HK, 2005, SEMIN CANCER BIOL, V15, P378, DOI 10.1016/j.semcancer.2005.05.004; Kren L, 2006, Cesk Patol, V42, P16; Mathew R, 2002, CANCER DETECT PREV, V26, P222, DOI 10.1016/S0361-090X(02)00035-1; MULLER D, 1991, INT J CANCER, V48, P550, DOI 10.1002/ijc.2910480412; Noda Y, 2001, GENES CELLS, V6, P107, DOI 10.1046/j.1365-2443.2001.00404.x; O-charoenrat P, 2001, ARCH OTOLARYNGOL, V127, P813; Osada H, 2002, ONCOGENE, V21, P7421, DOI 10.1038/sj.onc.1205802; Pimkhaokham A, 2000, JPN J CANCER RES, V91, P1126, DOI 10.1111/j.1349-7006.2000.tb00895.x; Qiu RG, 2000, CURR BIOL, V10, P697, DOI 10.1016/S0960-9822(00)00535-2; Regala RP, 2005, CANCER RES, V65, P8905, DOI 10.1158/0008-5472.CAN-05-2372; Regala RP, 2005, J BIOL CHEM, V280, P31109, DOI 10.1074/jbc.M505402200; Snaddon J, 2001, BRIT J CANCER, V84, P1630, DOI 10.1054/bjoc.2001.1848; Stallings-Mann M, 2006, CANCER RES, V66, P1767, DOI 10.1158/0008-5472.CAN-05-3405; Van Themsche C, 2004, J IMMUNOL, V173, P3605, DOI 10.4049/jimmunol.173.6.3605; Zhang J, 2004, J BIOL CHEM, V279, P22118, DOI 10.1074/jbc.M400774200	26	71	79	1	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 14	2008	27	35					4841	4853		10.1038/onc.2008.119	http://dx.doi.org/10.1038/onc.2008.119			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	337OJ	18427549	Green Accepted			2022-12-28	WOS:000258445100009
J	Sobczak, I; Galabova-Kovacs, G; Sadzak, I; Kren, A; Christofori, G; Baccarini, M				Sobczak, I.; Galabova-Kovacs, G.; Sadzak, I.; Kren, A.; Christofori, G.; Baccarini, M.			B-Raf is required for ERK activation and tumor progression in a mouse model of pancreatic beta-cell carcinogenesis	ONCOGENE			English	Article						Raf kinases; ERK pathway; angiogenesis; tumor progression	MULTISTAGE CARCINOGENESIS; ANGIOGENIC SWITCH; REGULATED KINASE; GROWTH; MICE; GENE; EXPRESSION; PATHWAY; CANCER; P53	Activation of the Raf/MEK/ERK pathway, often by gain-of-function mutations of RAS or RAF, is observed in many human cancers. The extracellular signal-regulated kinase (ERK) pathway is required for the proliferation of cancer cell lines harboring activating BRAF or, to a lesser extent, activating RAS mutations. It is still unclear, however, whether the pathway is required in vivo for tumor development, particularly in tumors in which B-Raf is not mutationally activated. During embryonic development, B-Raf is essential for angiogenesis in the placenta. To address the question of whether B-Raf contributed to tumor angiogenesis in vivo we conditionally ablated B-Raf in a model of pancreatic islet carcinoma driven by the functional inactivation of tumor suppressors (RIP1Tag2), which critically depends on angiogenesis for growth. We find that B-Raf is dispensable for the proliferation of tumor cells in culture, but necessary for ERK activation and for the expression of angiogenic factors by tumor cells in vivo and in vitro. In vivo, these defects result in the formation of hollow tumors with decreased vessel density and strongly reduced proliferation. The progression from adenoma to carcinoma is also significantly impaired. Thus, endogenous B-Raf contributes to the development of RIP1Tag2 tumors by supporting the stromal response and tumor progression.	[Sobczak, I.; Galabova-Kovacs, G.; Sadzak, I.; Baccarini, M.] Univ Vienna, Dept Microbiol & Immunol, Max F Perutz Labs, A-1030 Vienna, Austria; [Kren, A.; Christofori, G.] Univ Basel, Ctr Biomed, Inst Biochem & Genet, Dept Clin Biol Sci, Basel, Switzerland	Medical University of Vienna; University of Vienna; Vienna Biocenter (VBC); Max F. Perutz Laboratories (MFPL); University of Basel	Baccarini, M (corresponding author), Univ Vienna, Dept Microbiol & Immunol, Max F Perutz Labs, Dr Bohr Gasse 9, A-1030 Vienna, Austria.	manuela.baccarini@univie.ac.at	Baccarini, Manuela/B-6481-2014	Baccarini, Manuela/0000-0002-3033-391X				Abdulkadir SA, 2001, NAT MED, V7, P101, DOI 10.1038/83231; Ahlgren U, 1998, GENE DEV, V12, P1763, DOI 10.1101/gad.12.12.1763; Baron V, 2006, CANCER GENE THER, V13, P115, DOI 10.1038/sj.cgt.7700896; Bergers G, 2000, NAT CELL BIOL, V2, P737, DOI 10.1038/35036374; Bergers G, 1999, SCIENCE, V284, P808, DOI 10.1126/science.284.5415.808; Bild AH, 2006, NATURE, V439, P353, DOI 10.1038/nature04296; Casanovas O, 2005, CANCER CELL, V8, P299, DOI 10.1016/j.ccr.2005.09.005; Cavallaro U, 2001, BBA-REV CANCER, V1552, P39, DOI 10.1016/S0304-419X(01)00038-5; Chen AP, 2006, J NEUROSCI RES, V83, P28, DOI 10.1002/jnr.20703; Compagni A, 2000, CANCER RES, V60, P7163; De Benedetti A, 2004, ONCOGENE, V23, P3189, DOI 10.1038/sj.onc.1207545; Downward J, 2006, NATURE, V439, P274, DOI 10.1038/439274a; Dumaz N, 2006, CANCER RES, V66, P9483, DOI 10.1158/0008-5472.CAN-05-4227; EFRAT S, 1988, P NATL ACAD SCI USA, V85, P9037, DOI 10.1073/pnas.85.23.9037; Eid MA, 1998, CANCER RES, V58, P2461; Emuss V, 2005, CANCER RES, V65, P9719, DOI 10.1158/0008-5472.CAN-05-1683; Galabova-Kovacs G, 2006, P NATL ACAD SCI USA, V103, P1325, DOI 10.1073/pnas.0507399103; Galabova-Kovacs G, 2006, CELL CYCLE, V5, P1514, DOI 10.4161/cc.5.14.2981; Garnett MJ, 2004, CANCER CELL, V6, P313, DOI 10.1016/j.ccr.2004.09.022; Gavert N, 2005, J CELL BIOL, V168, P633, DOI 10.1083/jcb.200408051; Gomez E, 2002, J BIOL CHEM, V277, P48146, DOI 10.1074/jbc.M209165200; HANAHAN D, 1985, NATURE, V315, P115, DOI 10.1038/315115a0; Hashizume H, 2000, AM J PATHOL, V156, P1363, DOI 10.1016/S0002-9440(10)65006-7; Herbert TP, 2002, J BIOL CHEM, V277, P11591, DOI 10.1074/jbc.M110367200; Herzig M, 1999, BIOL CHEM, V380, P203, DOI 10.1515/BC.1999.028; Inoue M, 2002, CANCER CELL, V1, P193, DOI 10.1016/S1535-6108(02)00031-4; Krones-Herzig A, 2005, CANCER RES, V65, P5133, DOI 10.1158/0008-5472.CAN-04-3742; Krones-Herzig A, 2003, P NATL ACAD SCI USA, V100, P3233, DOI 10.1073/pnas.2628034100; Lee CG, 2004, J EXP MED, V200, P377, DOI 10.1084/jem.20040104; Lim KH, 2005, CANCER CELL, V8, P381, DOI 10.1016/j.ccr.2005.10.014; Mikula M, 2001, EMBO J, V20, P1952, DOI 10.1093/emboj/20.8.1952; Morrison TB, 1998, BIOTECHNIQUES, V24, P954; Nozawa H, 2006, P NATL ACAD SCI USA, V103, P12493, DOI 10.1073/pnas.0601807103; Pannu J, 2007, J BIOL CHEM, V282, P10405, DOI 10.1074/jbc.M611742200; Perl AK, 1999, NAT MED, V5, P286, DOI 10.1038/6502; Rolli-Derkinderen M, 2003, J BIOL CHEM, V278, P18859, DOI 10.1074/jbc.M211696200; Roux PP, 2004, P NATL ACAD SCI USA, V101, P13489, DOI 10.1073/pnas.0405659101; Solit DB, 2006, NATURE, V439, P358, DOI 10.1038/nature04304; Sugimoto H, 2006, CANCER BIOL THER, V5, P1640, DOI 10.4161/cbt.5.12.3354; Ueda T, 2004, MOL CELL BIOL, V24, P6539, DOI 10.1128/MCB.24.15.6539-6549.2004; Wang XM, 2007, METHOD ENZYMOL, V431, P113, DOI 10.1016/S0076-6879(07)31007-0; Waskiewicz AJ, 1997, EMBO J, V16, P1909, DOI 10.1093/emboj/16.8.1909; Wellbrock C, 2004, NAT REV MOL CELL BIO, V5, P875, DOI 10.1038/nrm1498; Xian XJ, 2006, J CLIN INVEST, V116, P642, DOI 10.1172/JCI25705	44	16	17	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 14	2008	27	35					4779	4787		10.1038/onc.2008.128	http://dx.doi.org/10.1038/onc.2008.128			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	337OJ	18490924				2022-12-28	WOS:000258445100003
J	Unger, K; Malisch, E; Thomas, G; Braselmann, H; Walch, A; Jackl, G; Lewis, P; Lengfelder, E; Bogdanova, T; Wienberg, J; Zitzelsberger, H				Unger, K.; Malisch, E.; Thomas, G.; Braselmann, H.; Walch, A.; Jackl, G.; Lewis, P.; Lengfelder, E.; Bogdanova, T.; Wienberg, J.; Zitzelsberger, H.			Array CGH demonstrates characteristic aberration signatures in human papillary thyroid carcinomas governed by RET/PTC	ONCOGENE			English	Article						papillary thyroid carcinoma; array CGH; RET/PTC; candidate genes; tumour development; aberration signature	COMPARATIVE GENOMIC HYBRIDIZATION; TUMOR-SUPPRESSOR GENE; SQUAMOUS-CELL CARCINOMA; HIGH PREVALENCE; PROSTATE-CANCER; DOWN-REGULATION; BREAST-CANCER; EXPRESSION; RET; REARRANGEMENTS	The aim of this study is to investigate additional genetic alterations in papillary thyroid carcinomas (PTCs) with known RET/PTC rearrangements. We applied array-based comparative genomic hybridization (array CGH) to 33 PTC (20 PTC from adults, 13 post-Chernobyl PTC from children) with known RET/PTC status. Principal component analysis and hierarchical cluster analysis identified cases with similar aberration patterns. Significant deviations between tumour-groups were obtained by statistical testing (Fisher's exact test in combination with Benjamini-Hochberg FDR-controlling procedure). FISH analysis on FFPE sections was applied to validate the array CGH data. Deletions were found more frequently in RET/PTC-positive and RET/PTC-negative tumours than amplifications. Specific aberration signatures were identified that discriminated between RET/PTC-positive and RET/PTC-negative cases (aberrations on chromosomes 1p, 3q, 4p, 7p, 9p/q, 10q, 12q, 13q and 21q). In addition, childhood and adult RET/PTC-positive cases differ significantly for a deletion on the distal part of chromosome 1p. There are additional alterations in RET/PTC-positive tumours, which may act as modifiers of RET activation. In contrast, alterations in RET/PTC-negative tumours indicate alternative routes of tumour development. The data presented serve as a starting point for further studies on gene expression and function of genes identified in this study.	[Unger, K.; Malisch, E.; Braselmann, H.; Jackl, G.; Zitzelsberger, H.] Deutsch Forschungszentrum Gesundheit & Umwelt Gmb, Inst Mol Strahlenbiol, Helmholtz Zentrum Munchen, D-85764 Neuherberg, Germany; [Unger, K.; Thomas, G.] Hammersmith Hosp, Dept Histopathol, London W12 0HS, England; [Walch, A.] Deutsch Forschungszentrum Gesundheit & Umwelt Gmb, Helmholtz Zentrum Munchen, Inst Pathol, D-85764 Neuherberg, Germany; [Lewis, P.] Swansea Univ, Swansea Med Sch, Swansea, W Glam, Wales; [Lengfelder, E.] Univ Munich, Inst Strahlenbiol, Munich, Germany; [Bogdanova, T.] Ukraine Acad Med Sci, Inst Endocrinol & Metab, Kiev, Ukraine; [Wienberg, J.] Univ Munich, Dept Biol 2, Munich, Germany	Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; Imperial College London; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; Swansea University; University of Munich; National Academy of Medical Sciences of Ukraine; V. P. Komissarenko Institute of Endocrinology & Metabolism of the National Academy of Medical Science of Ukraine; University of Munich	Zitzelsberger, H (corresponding author), Helmholtz Zentrum Munchen, Inst Mol Radiobiol, Ingolstadter Landstr 1, D-85764 Neuherberg, Germany.	zitzelsberger@helmholtz-muenchen.de	Walch, Axel/B-4554-2012; Unger, Kristian/F-3730-2018	Walch, Axel/0000-0001-5578-4023; Unger, Kristian/0000-0002-0374-2320; Bogdanova, Tetiana/0000-0001-5119-0236				Adolphe C, 2006, CANCER RES, V66, P2081, DOI 10.1158/0008-5472.CAN-05-2146; Azuma K, 2005, ONCOGENE, V24, P4754, DOI 10.1038/sj.onc.1208654; Camacho-Vanegas O, 2007, INT J CANCER, V121, P1390, DOI 10.1002/ijc.22809; Chang M, 2005, EMBO J, V24, P2024, DOI 10.1038/sj.emboj.7600684; Cheung CC, 2000, J CLIN ENDOCR METAB, V85, P878, DOI 10.1210/jc.85.2.878; Chunduru S, 2002, J NEURO-ONCOL, V60, P201, DOI 10.1023/A:1021130620178; Ciampi R, 2007, ENDOCRINOLOGY, V148, P936, DOI 10.1210/en.2006-0921; COLLINS CM, 1996, P INT SOC MAGN RES M, V1, P253; Corson TW, 2007, GENE CHROMOSOME CANC, V46, P617, DOI 10.1002/gcc.20457; De Falco V, 2005, ONCOGENE, V24, P6303, DOI 10.1038/sj.onc.1208776; De Lellis R.A., 2004, WHO CLASSIFICATION T, V3rd; Demichelis F, 2007, ONCOGENE, V26, P4596, DOI 10.1038/sj.onc.1210237; Dickinson RE, 2004, BRIT J CANCER, V91, P2071, DOI 10.1038/sj.bjc.6602222; Djeu JY, 2002, CLIN CANCER RES, V8, P636; Dong M, 2007, J CLIN INVEST, V117, P206, DOI 10.1172/JCI29293; Doyon Y, 2006, MOL CELL, V21, P51, DOI 10.1016/j.molcel.2005.12.007; Duquette ML, 2007, CANCER RES, V67, P2586, DOI 10.1158/0008-5472.CAN-06-2419; Elisei R, 2001, J CLIN ENDOCR METAB, V86, P3211, DOI 10.1210/jc.86.7.3211; Engers R, 2006, BRIT J CANCER, V95, P1081, DOI 10.1038/sj.bjc.6603385; Fiegler H, 2003, GENE CHROMOSOME CANC, V36, P361, DOI 10.1002/gcc.10155; Finn SP, 2004, VIRCHOWS ARCH, V445, P396, DOI 10.1007/s00428-004-1070-9; GRIECO M, 1990, CELL, V60, P557, DOI 10.1016/0092-8674(90)90659-3; Hammarsund M, 2004, FEBS LETT, V556, P75, DOI 10.1016/S0014-5793(03)01371-1; Hou P, 2007, CLIN CANCER RES, V13, P1161, DOI 10.1158/1078-0432.CCR-06-1125; Hou W, 2005, CLIN CANCER RES, V11, P5595, DOI 10.1158/1078-0432.CCR-05-0384; Hu SY, 2006, INT J CANCER, V119, P2322, DOI 10.1002/ijc.22110; Huang H, 2007, J CANCER RES CLIN, V133, P761, DOI 10.1007/s00432-007-0221-1; Hupe P, 2004, BIOINFORMATICS, V20, P3413, DOI 10.1093/bioinformatics/bth418; ISHIZAKA Y, 1991, ONCOGENE, V6, P1667; JHIANG SM, 1994, J LAB CLIN MED, V123, P331; Jimenez-Velasco A, 2005, LEUKEMIA, V19, P2347, DOI 10.1038/sj.leu.2403974; Kadota M, 2003, ONCOL REP, V10, P35; Kitamura Y, 1999, J CLIN ENDOCR METAB, V84, P4043, DOI 10.1210/jc.84.11.4043; Klugbauer S, 1995, ONCOGENE, V11, P2459; Konishi T, 2006, ONCOGENE, V25, P3160, DOI 10.1038/sj.onc.1209342; La Rosa P, 2006, BIOINFORMATICS, V22, P2066, DOI 10.1093/bioinformatics/btl359; Li L, 2007, J CELL BIOCHEM, V102, P1368, DOI 10.1002/jcb.21593; Louhelainen JP, 2006, ONCOGENE, V25, P2409, DOI 10.1038/sj.onc.1209228; NAGATA S, 1994, ADV IMMUNOL, V57, P129, DOI 10.1016/S0065-2776(08)60672-0; Neuvial P, 2006, BMC BIOINFORMATICS, V7, DOI 10.1186/1471-2105-7-264; Nielsen SJ, 2001, NATURE, V412, P561, DOI 10.1038/35087620; O'Donnell KA, 2006, MOL CELL BIOL, V26, P2373, DOI 10.1128/MCB.26.6.2373-2386.2006; Okawa ER, 2008, ONCOGENE, V27, P803, DOI 10.1038/sj.onc.1210675; PIEROTTI MA, 1992, P NATL ACAD SCI USA, V89, P1616, DOI 10.1073/pnas.89.5.1616; Powell N, 2005, J PATHOL, V205, P558, DOI 10.1002/path.1736; Puxeddu E, 2005, ENDOCR-RELAT CANCER, V12, P319, DOI 10.1677/erc.1.00947; Rabes HM, 2000, CLIN CANCER RES, V6, P1093; Repana K, 2006, ANTICANCER RES, V26, P4949; Rhoden KJ, 2006, J CLIN ENDOCR METAB, V91, P2414, DOI 10.1210/jc.2006-0240; Rhoden KJ, 2004, LAB INVEST, V84, P1557, DOI 10.1038/labinvest.3700198; Richter H, 2004, THYROID, V14, P1061, DOI 10.1089/thy.2004.14.1061; Riedl SJ, 2007, NAT REV MOL CELL BIO, V8, P405, DOI 10.1038/nrm2153; Rouveirol C, 2006, BIOINFORMATICS, V22, P849, DOI 10.1093/bioinformatics/btl004; Santoro M, 2004, CELL MOL LIFE SCI, V61, P2954, DOI 10.1007/s00018-004-4276-8; Shan ZH, 2004, ONCOGENE, V23, P6612, DOI 10.1038/sj.onc.1207857; Singh B, 2000, SURGERY, V128, P888, DOI 10.1067/msy.2000.110847; Smida J, 1999, INT J CANCER, V80, P32, DOI 10.1002/(SICI)1097-0215(19990105)80:1<32::AID-IJC7>3.3.CO;2-C; Takakura S, 2001, INT J ONCOL, V18, P817; Tan XQ, 1998, TRENDS CELL BIOL, V8, P116, DOI 10.1016/S0962-8924(97)01208-7; Thomas GA, 1999, J CLIN ENDOCR METAB, V84, P4232, DOI 10.1210/jc.84.11.4232; Torosyan Y, 2006, CANCER RES, V66, P9609, DOI 10.1158/0008-5472.CAN-06-1574; Unger K, 2006, BRIT J CANCER, V94, P1472, DOI 10.1038/sj.bjc.6603109; Unger K, 2004, J CLIN ENDOCR METAB, V89, P4272, DOI 10.1210/jc.2003-031870; van Beers EH, 2006, BRIT J CANCER, V94, P333, DOI 10.1038/sj.bjc.6602889; Wang YG, 2007, J CLIN ENDOCR METAB, V92, P2387, DOI 10.1210/jc.2006-2019; Worthylake DK, 2000, NATURE, V408, P682, DOI 10.1038/35047014; Wreesmann VB, 2007, ORL-J OTO-RHIN-LARYN, V69, P218, DOI 10.1159/000101542; Yang LC, 2005, ONCOGENE, V24, P697, DOI 10.1038/sj.onc.1208179; Yoo NJ, 2007, APMIS, V115, P354, DOI 10.1111/j.1600-0463.2007.apm_632.x; Zhang Q, 2005, J HISTOCHEM CYTOCHEM, V53, P1371, DOI 10.1369/jhc.4A6508.2005	70	33	42	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 31	2008	27	33					4592	4602		10.1038/onc.2008.99	http://dx.doi.org/10.1038/onc.2008.99			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	332IS	18408749				2022-12-28	WOS:000258077300008
J	Shankar, E; Sivaprasad, U; Basu, A				Shankar, E.; Sivaprasad, U.; Basu, A.			Protein kinase C epsilon confers resistance of MCF-7 cells to TRAIL by Akt-dependent activation of Hdm2 and downregulation of p53	ONCOGENE			English	Article						Akt; Bid; p53; PKC epsilon; TRAIL	BREAST-CANCER CELLS; CASPASE ACTIVATION; INDUCED APOPTOSIS; DEATH RECEPTORS; MDM2; PHOSPHORYLATION; UBIQUITINATION; PROMOTES; GENE; DEGRADATION	Protein kinase C epsilon (PKC epsilon) acts as an antiapoptotic protein and inhibits tumor necrosis factor-alpha (TNF)-related apoptosis-inducing ligand (TRAIL)-induced apoptosis in MCF-7 breast cancer cells. Members of the TNF receptor superfamily trigger apoptosis independent of the tumor suppressor protein p53, which primarily affects DNA damage-induced apoptosis. We have previously shown that PKCe acts upstream of Akt to inhibit receptor-initiated cell death. Since Akt can regulate p53, we have examined the involvement of p53 in PKC epsilon-mediated TRAIL resistance. Overexpression of PKCe in MCF-7 cells (MCF-7/PKC epsilon) caused a decrease in p53 and an increase in human homolog of murine double minute 2 (Hdm2) and phospho-Hdm2. Depletion of p53 by siRNA attenuated, whereas depletion of Hdm2 enhanced TRAIL-mediated apoptosis. Knockdown of Akt decreased Hdm2 phosphorylation, increased p53 level and potentiated TRAIL-induced cell death. Depletion of PKCe from MCF-7 cells caused an increase in p53, whereas knockdown of p53 caused a decrease in Bid mRNA. Depletion of Akt from MCF-7/PKCe cells resulted in an increase in p53 and Bid. These results suggest that PKCe mediates TRAIL resistance by Akt-mediated phosphorylation of Hdm2 resulting in suppression of p53 expression and down-regulation of Bid in MCF-7 breast cancer cells.	[Shankar, E.; Sivaprasad, U.; Basu, A.] Univ N Texas, Hlth Sci Ctr, Dept Mol Biol & Immunol, Ft Worth, TX 76107 USA; [Shankar, E.; Basu, A.] Univ N Texas, Hlth Sci Ctr, Inst Canc Res, Ft Worth, TX 76107 USA	University of North Texas System; University of North Texas Health Science Center; University of North Texas System; University of North Texas Health Science Center	Basu, A (corresponding author), Univ N Texas, Hlth Sci Ctr, Dept Mol Biol & Immunol, 3500 Camp Bowie Blvd, Ft Worth, TX 76107 USA.	abasu@hsc.unt.edu	Shankar, Eswar/E-5139-2015	Shankar, Eswar/0000-0001-8968-838X; Basu, Alakananda/0000-0002-1656-0788	NATIONAL CANCER INSTITUTE [R01CA071727] Funding Source: NIH RePORTER; NCI NIH HHS [CA71727] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Basu A, 2002, J BIOL CHEM, V277, P41850, DOI 10.1074/jbc.M205997200; Basu A, 1999, BIOCHEMISTRY-US, V38, P4245, DOI 10.1021/bi982854q; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; CHEN JD, 1993, MOL CELL BIOL, V13, P4107, DOI 10.1128/MCB.13.7.4107; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; Ehrhardt H, 2008, ONCOGENE, V27, P783, DOI 10.1038/sj.onc.1210666; Eskes R, 2000, MOL CELL BIOL, V20, P929, DOI 10.1128/MCB.20.3.929-935.2000; Feng JH, 2004, J BIOL CHEM, V279, P35510, DOI 10.1074/jbc.M404936200; Gross A, 1999, J BIOL CHEM, V274, P1156, DOI 10.1074/jbc.274.2.1156; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Kelley SK, 2004, CURR OPIN PHARMACOL, V4, P333, DOI 10.1016/j.coph.2004.02.006; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Li S, 2007, MOL CANCER THER, V6, P1031, DOI 10.1158/1535-7163.MCT-06-0643; LIU X, 2004, CANCER RES, V83, P5078; Lu DM, 2004, INT J ONCOL, V25, P671; Lu DM, 2006, J BIOL CHEM, V281, P22799, DOI 10.1074/jbc.M603390200; Mayo LD, 2001, P NATL ACAD SCI USA, V98, P11598, DOI 10.1073/pnas.181181198; MIYASHITA T, 1995, CELL, V80, P293; Nakano K, 2001, MOL CELL, V7, P683, DOI 10.1016/S1097-2765(01)00214-3; O'Toole A, 2001, BIOCHEM J, V359, P119, DOI 10.1042/0264-6021:3590119; Oda E, 2000, SCIENCE, V288, P1053, DOI 10.1126/science.288.5468.1053; Ogawara Y, 2002, J BIOL CHEM, V277, P21843, DOI 10.1074/jbc.M109745200; Oren M, 1999, J BIOL CHEM, V274, P36031, DOI 10.1074/jbc.274.51.36031; OWENSCHAUB LB, 1995, MOL CELL BIOL, V15, P3032; Rozan LM, 2007, CELL DEATH DIFFER, V14, P3, DOI 10.1038/sj.cdd.4402058; Rudner J, 2005, ONCOGENE, V24, P130, DOI 10.1038/sj.onc.1208191; Sax JK, 2002, NAT CELL BIOL, V4, P842, DOI 10.1038/ncb866; Schuler M, 2000, J BIOL CHEM, V275, P7337, DOI 10.1074/jbc.275.10.7337; Sivaprasad U, 2007, CELL DEATH DIFFER, V14, P851, DOI 10.1038/sj.cdd.4402077; Toledo F, 2006, NAT REV CANCER, V6, P909, DOI 10.1038/nrc2012; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Vousden KH, 2006, J CELL SCI, V119, P5015, DOI 10.1242/jcs.03293; Vousden KH, 2002, NAT REV CANCER, V2, P594, DOI 10.1038/nrc864; Wang SL, 2003, ONCOGENE, V22, P8628, DOI 10.1038/sj.onc.1207232; Weber HO, 2005, ONCOGENE, V24, P1965, DOI 10.1038/sj.onc.1208389; Wu GS, 1997, NAT GENET, V17, P141, DOI 10.1038/ng1097-141; Yu J, 2001, MOL CELL, V7, P673, DOI 10.1016/S1097-2765(01)00213-1; ZAUBERMAN A, 1993, EMBO J, V12, P2799, DOI 10.1002/j.1460-2075.1993.tb05941.x; Zhou BHP, 2001, NAT CELL BIOL, V3, P973, DOI 10.1038/ncb1101-973	40	39	40	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN	2008	27	28					3957	3966		10.1038/onc.2008.39	http://dx.doi.org/10.1038/onc.2008.39			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	318JZ	18317451				2022-12-28	WOS:000257089000007
J	Gross, DN; van den Heuvel, APJ; Birnbaum, MJ				Gross, D. N.; van den Heuvel, A. P. J.; Birnbaum, M. J.			The role of FoxO in the regulation of metabolism	ONCOGENE			English	Review						FoxO; liver; adipocyte; beta cell; skeletal muscle; metabolism	FORKHEAD TRANSCRIPTION FACTOR; HUMAN SKELETAL-MUSCLE; PANCREATIC BETA-CELLS; PROTEIN-KINASE-B; INSULIN-RECEPTOR GENE; TERMINAL ADIPOCYTE DIFFERENTIATION; ELEMENT-BINDING PROTEIN-1C; NUCLEAR FACTOR 3-BETA; FATTY-ACID SYNTHASE; LIVER-X-RECEPTORS	Forkhead proteins, and FoxO1 in particular, play a significant role in regulating whole body energy metabolism. Glucose homeostasis is achieved by adjusting endogenous glucose production as well as glucose uptake by peripheral tissues in response to insulin. In the fasted state, the liver is primarily responsible for maintaining glucose levels, with FoxO1 playing a key role in promoting the expression of gluconeogenic enzymes. Following feeding, pancreatic beta cells secrete insulin, which promotes the uptake of glucose by peripheral tissues including skeletal muscle and adipose tissue, and can in part suppress gluconeogenic enzyme expression in the liver. In addition to directly regulating metabolism, FoxO1 also plays a role in the formation of both adipose tissue and skeletal muscle, two major organs that are critical for maintaining energy homeostasis. The importance of FoxO1 in energy homeostasis is particularly striking under conditions of metabolic dysfunction or insulin resistance. In obese or diabetic states, FoxO1-dependent gene expression promotes some of the deleterious characteristics associated with these conditions, including hyperglycemia and glucose intolerance. In addition, the increase in pancreatic beta cell mass that normally occurs in response to a rise in insulin demand is blunted by nuclear FoxO1 expression. However, under these same pathophysiological conditions, FoxO1 expression may help drive the expression of genes involved in combating oxidative stress, thereby preserving cellular function. FoxO1 may also be involved in promoting the switch from carbohydrate to fatty acid as the major energy source during starvation.	[Gross, D. N.; van den Heuvel, A. P. J.; Birnbaum, M. J.] Univ Penn, Sch Med, Inst Diabet Obes & Metab, Cox Inst, Philadelphia, PA 19104 USA; [Gross, D. N.; van den Heuvel, A. P. J.; Birnbaum, M. J.] Univ Penn, Howard Hughes Med Inst, Philadelphia, PA 19104 USA	University of Pennsylvania; Howard Hughes Medical Institute; University of Pennsylvania	Birnbaum, MJ (corresponding author), Univ Penn, Sch Med, Inst Diabet Obes & Metab, Cox Inst, 415 Curie Blvd,CRB Rm 322, Philadelphia, PA 19104 USA.	birnbaum@mail.med.upenn.edu	van den Heuvel, Antonius PJ/J-8145-2012	Birnbaum, Morris/0000-0001-9972-8680	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK056886] Funding Source: NIH RePORTER; Howard Hughes Medical Institute Funding Source: Medline; NIDDK NIH HHS [R01 DK056886] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); Howard Hughes Medical Institute(Howard Hughes Medical Institute); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ACCILI D, 1991, P NATL ACAD SCI USA, V88, P4708, DOI 10.1073/pnas.88.11.4708; Accili D, 2004, CELL, V117, P421, DOI 10.1016/S0092-8674(04)00452-0; Accili D, 1996, NAT GENET, V12, P106, DOI 10.1038/ng0196-106; Ahima RS, 2000, TRENDS ENDOCRIN MET, V11, P327, DOI 10.1016/S1043-2760(00)00301-5; Alberti KGMM, 2006, DIABETIC MED, V23, P469, DOI 10.1111/j.1464-5491.2006.01858.x; Allen DL, 2007, AM J PHYSIOL-CELL PH, V292, pC188, DOI 10.1152/ajpcell.00542.2005; Altomonte J, 2003, AM J PHYSIOL-ENDOC M, V285, pE718, DOI 10.1152/ajpendo.00156.2003; Altomonte J, 2004, J CLIN INVEST, V114, P1493, DOI 10.1172/JCI200419992; ARAKI E, 1994, NATURE, V372, P186, DOI 10.1038/372186a0; Armoni M, 2006, J BIOL CHEM, V281, P19881, DOI 10.1074/jbc.M600320200; Bai L, 2008, MOL CELL BIOCHEM, V307, P129, DOI 10.1007/s11010-007-9592-5; Barthel A, 2001, BIOCHEM BIOPH RES CO, V285, P897, DOI 10.1006/bbrc.2001.5261; Bastie CC, 2005, J BIOL CHEM, V280, P14222, DOI 10.1074/jbc.M413625200; Baudry A, 2006, J CELL SCI, V119, P889, DOI 10.1242/jcs.02792; Ben-Shushan E, 2001, J BIOL CHEM, V276, P17533, DOI 10.1074/jbc.M009088200; Beqaj S, 2002, J CELL BIOL, V156, P893, DOI 10.1083/jcb.200107049; Biggs WH, 1999, P NATL ACAD SCI USA, V96, P7421, DOI 10.1073/pnas.96.13.7421; Bodine SC, 2001, SCIENCE, V294, P1704, DOI 10.1126/science.1065874; Bois PRJ, 2003, EMBO J, V22, P1147, DOI 10.1093/emboj/cdg116; Bouwens L, 2005, PHYSIOL REV, V85, P1255, DOI 10.1152/physrev.00025.2004; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Bruning JC, 1997, CELL, V88, P561, DOI 10.1016/S0092-8674(00)81896-6; Burgering BMT, 2002, TRENDS BIOCHEM SCI, V27, P352, DOI 10.1016/S0968-0004(02)02113-8; Buteau J, 1999, DIABETOLOGIA, V42, P856, DOI 10.1007/s001250051238; Buteau J, 2006, DIABETES, V55, P1190, DOI 10.2337/db05-0825; Chen PL, 1996, GENE DEV, V10, P2794, DOI 10.1101/gad.10.21.2794; Coburn CT, 2000, J BIOL CHEM, V275, P32523, DOI 10.1074/jbc.M003826200; Conejo R, 2002, ONCOGENE, V21, P3739, DOI 10.1038/sj.onc.1205469; Coolican SA, 1997, J BIOL CHEM, V272, P6653, DOI 10.1074/jbc.272.10.6653; Cuenda A, 1999, J BIOL CHEM, V274, P4341, DOI 10.1074/jbc.274.7.4341; Daitoku H, 2003, DIABETES, V52, P642, DOI 10.2337/diabetes.52.3.642; de Lange P, 2007, FASEB J, V21, P3431, DOI 10.1096/fj.07-8527rev; Dong XC, 2006, J CLIN INVEST, V116, P101, DOI 10.1172/JCI25735; Dowell P, 2003, J BIOL CHEM, V278, P45485, DOI 10.1074/jbc.M309069200; Du KY, 2003, SCIENCE, V300, P1574, DOI 10.1126/science.1079817; Duivenvoorden I, 2005, DIABETES, V54, P664, DOI 10.2337/diabetes.54.3.664; Eberle D, 2004, BIOCHIMIE, V86, P839, DOI 10.1016/j.biochi.2004.09.018; Erbay E, 2001, J BIOL CHEM, V276, P36079, DOI 10.1074/jbc.C100406200; Essers MAG, 2004, EMBO J, V23, P4802, DOI 10.1038/sj.emboj.7600476; Fajas L, 2002, DEV CELL, V3, P39, DOI 10.1016/S1534-5807(02)00190-9; Farmer SR, 2005, INT J OBESITY, V29, pS13, DOI 10.1038/sj.ijo.0802907; Foretz M, 1999, P NATL ACAD SCI USA, V96, P12737, DOI 10.1073/pnas.96.22.12737; Freemark M, 2002, ENDOCRINOLOGY, V143, P1378, DOI 10.1210/en.143.4.1378; Frescas D, 2005, J BIOL CHEM, V280, P20589, DOI 10.1074/jbc.M412357200; Furukawa S, 2004, J CLIN INVEST, V114, P1752, DOI [10.1172/JCI21625, 10.1172/JCI20042162S]; Furukawa-Hibi Y, 2005, ANTIOXID REDOX SIGN, V7, P752, DOI 10.1089/ars.2005.7.752; Furuyama T, 2003, BIOCHEM J, V375, P365, DOI 10.1042/BJ20030022; GALILI N, 1993, NAT GENET, V5, P230, DOI 10.1038/ng1193-230; Gan LX, 2005, BIOCHEM BIOPH RES CO, V337, P1092, DOI 10.1016/j.bbrc.2005.09.169; Garcia-Ocana A, 2000, J BIOL CHEM, V275, P1226, DOI 10.1074/jbc.275.2.1226; Glass DJ, 2003, NAT CELL BIOL, V5, P87, DOI 10.1038/ncb0203-87; Glauser DA, 2007, J ENDOCRINOL, V193, P195, DOI 10.1677/JOE-06-0191; Gleason CE, 2007, P NATL ACAD SCI USA, V104, P8681, DOI 10.1073/pnas.0702844104; Goldberg IJ, 1996, J LIPID RES, V37, P693; Gomes MD, 2001, P NATL ACAD SCI USA, V98, P14440, DOI 10.1073/pnas.251541198; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; GRANKVIST K, 1981, BIOCHEM J, V199, P393, DOI 10.1042/bj1990393; Greer EL, 2005, ONCOGENE, V24, P7410, DOI 10.1038/sj.onc.1209086; Greiwe JS, 2000, J APPL PHYSIOL, V89, P176, DOI 10.1152/jappl.2000.89.1.176; Grill V, 2001, DIABETES, V50, pS122, DOI 10.2337/diabetes.50.2007.S122; Hajri T, 2002, ANNU REV NUTR, V22, P383, DOI 10.1146/annurev.nutr.22.020402.130846; Hajri T, 2002, J CLIN INVEST, V109, P1381, DOI [10.1172/JCI200214596, 10.1172/JCI0214596]; Hall RK, 2000, J BIOL CHEM, V275, P30169, DOI 10.1074/jbc.M004898200; Hansmannel F, 2006, BIOCHEM J, V399, P275, DOI 10.1042/BJ20060811; Herzig S, 2001, NATURE, V413, P179, DOI 10.1038/35093131; Hirota K, 2003, J BIOL CHEM, V278, P13056, DOI 10.1074/jbc.C200553200; Holz George G, 2005, Sci STKE, V2005, ppe2; Hribal ML, 2003, J CELL BIOL, V162, P535, DOI 10.1083/jcb.200212107; Huang BL, 2002, DIABETES, V51, P276, DOI 10.2337/diabetes.51.2.276; Huang H, 2007, EXP CLIN ENDOCR DIAB, V115, P417, DOI 10.1055/s-2007-981660; Imae M, 2003, J MOL ENDOCRINOL, V30, P253, DOI 10.1677/jme.0.0300253; ITO Y, 1990, SCIENCE, V249, P790, DOI 10.1126/science.2167514; Jackerott M, 2006, DIABETES, V55, P2705, DOI 10.2337/db06-0244; Jagoe RT, 2001, CURR OPIN CLIN NUTR, V4, P183, DOI 10.1097/00075197-200105000-00003; Jiang BH, 1999, P NATL ACAD SCI USA, V96, P2077, DOI 10.1073/pnas.96.5.2077; Jiang BH, 1998, P NATL ACAD SCI USA, V95, P14179, DOI 10.1073/pnas.95.24.14179; Jing EX, 2007, CELL METAB, V6, P105, DOI 10.1016/j.cmet.2007.07.003; Joseph SB, 2002, J BIOL CHEM, V277, P11019, DOI 10.1074/jbc.M111041200; Joshi RL, 1996, EMBO J, V15, P1542, DOI 10.1002/j.1460-2075.1996.tb00498.x; Kaeberlein M, 1999, GENE DEV, V13, P2570, DOI 10.1101/gad.13.19.2570; Kaliman P, 1998, MOL ENDOCRINOL, V12, P66, DOI 10.1210/mend.12.1.0047; Kamei Y, 2004, J BIOL CHEM, V279, P41114, DOI 10.1074/jbc.M400674200; Kamei Y, 2003, FEBS LETT, V536, P232, DOI 10.1016/S0014-5793(03)00062-0; Kaneto H, 2002, J BIOL CHEM, V277, P30010, DOI 10.1074/jbc.M202066200; Kaneto H, 2007, CURR MED CHEM, V14, P1745; KATZ J, 1984, J CLIN INVEST, V74, P1901, DOI 10.1172/JCI111610; Kawamori D, 2006, J BIOL CHEM, V281, P1091, DOI 10.1074/jbc.M508510200; Kawamori D, 2003, DIABETES, V52, P2896, DOI 10.2337/diabetes.52.12.2896; Kido Y, 2000, J CLIN INVEST, V105, P199, DOI 10.1172/JCI7917; Kim SJ, 2005, J BIOL CHEM, V280, P22297, DOI 10.1074/jbc.M500540200; Kim SY, 2004, J BIOL CHEM, V279, P30823, DOI 10.1074/jbc.M313223200; Kitamura T, 2002, J CLIN INVEST, V110, P1839, DOI 10.1172/JCI200216857; Kitamura T, 2007, ENDOCR J, V54, P507, DOI 10.1507/endocrj.KR-109; Kitamura T, 2007, J CLIN INVEST, V117, P2477, DOI 10.1172/JCI32054; Kitamura YI, 2005, CELL METAB, V2, P153, DOI 10.1016/j.cmet.2005.08.004; Kubota N, 2000, DIABETES, V49, P1880, DOI 10.2337/diabetes.49.11.1880; Kulkarni RN, 2002, NAT GENET, V31, P111, DOI 10.1038/ng872; Kulkarni RN, 1999, CELL, V96, P329, DOI 10.1016/S0092-8674(00)80546-2; Kuriyama H, 2002, DIABETES, V51, P2915, DOI 10.2337/diabetes.51.10.2915; Kushner JA, 2002, J CLIN INVEST, V109, P1193, DOI 10.1172/JCI200214439; Kushner JA, 2005, J BIOL CHEM, V280, P39388, DOI 10.1074/jbc.M504155200; Kwon HS, 2004, DIABETES, V53, P899, DOI 10.2337/diabetes.53.4.899; LADU MJ, 1991, AM J PHYSIOL, V260, pR953, DOI 10.1152/ajpregu.1991.260.5.R953; Lantz KA, 2005, CLIN SCI, V108, P195, DOI 10.1042/CS20040309; Large V, 2004, DIABETES METAB, V30, P294, DOI 10.1016/S1262-3636(07)70121-0; Lecker SH, 2004, FASEB J, V18, P39, DOI 10.1096/fj.03-0610com; Lee CH, 2006, P NATL ACAD SCI USA, V103, P3444, DOI 10.1073/pnas.0511253103; Lee CS, 2002, DIABETES, V51, P2546, DOI 10.2337/diabetes.51.8.2546; Lee SW, 2004, J AM SOC NEPHROL, V15, P1537, DOI 10.1097/01.ASN.0000127211.86206.E1; Lefebvre P, 2006, J CLIN INVEST, V116, P571, DOI 10.1172/JCI27989; Leger B, 2006, FASEB J, V20, P583, DOI 10.1096/fj.05-5249fje; Leger B, 2006, J PHYSIOL-LONDON, V576, P923, DOI 10.1113/jphysiol.2006.116715; Li XH, 2007, NATURE, V447, P1012, DOI 10.1038/nature05861; Lindberg K, 2005, J MOL ENDOCRINOL, V35, P231, DOI 10.1677/jme.1.01840; Luquet S, 2003, FASEB J, V17, P2299, DOI 10.1096/fj.03-0269fje; Mandrup S, 1997, J BIOL CHEM, V272, P5367, DOI 10.1074/jbc.272.9.5367; Matsumoto M, 2007, CELL METAB, V6, P208, DOI 10.1016/j.cmet.2007.08.006; Matsumoto M, 2006, J CLIN INVEST, V116, P2464, DOI 10.1172/JCI27047; McKinsey TA, 2002, CURR OPIN CELL BIOL, V14, P763, DOI 10.1016/S0955-0674(02)00389-7; McPherron AC, 1997, NATURE, V387, P83, DOI 10.1038/387083a0; Meriane M, 2000, MOL BIOL CELL, V11, P2513, DOI 10.1091/mbc.11.8.2513; Miki H, 2001, MOL CELL BIOL, V21, P2521, DOI 10.1128/MCB.21.7.2521-2532.2001; Morrison RF, 2000, J NUTR, V130, p3116S, DOI 10.1093/jn/130.12.3116S; Morrison RF, 1999, J BIOL CHEM, V274, P17088, DOI 10.1074/jbc.274.24.17088; Mounier C, 2006, ENDOCRINOLOGY, V147, P2383, DOI 10.1210/en.2005-0902; Murtaugh LC, 2007, DEVELOPMENT, V134, P427, DOI 10.1242/dev.02770; Naimi M, 2007, ENDOCRINOLOGY, V148, P2424, DOI 10.1210/en.2006-1411; Nakae J, 2003, DEV CELL, V4, P119, DOI 10.1016/S1534-5807(02)00401-X; Nakae J, 2006, J CLIN INVEST, V116, P2473, DOI 10.1172/JCI25518; Nakai J, 2002, NAT GENET, V32, P245, DOI 10.1038/ng890; NEWGARD CB, 1995, ANNU REV BIOCHEM, V64, P689, DOI 10.1146/annurev.biochem.64.1.689; Nishiyama T, 2004, J BIOL CHEM, V279, P47311, DOI 10.1074/jbc.M403546200; Okada T, 2007, P NATL ACAD SCI USA, V104, P8977, DOI 10.1073/pnas.0608703104; Park S, 2006, J BIOL CHEM, V281, P1159, DOI 10.1074/jbc.M508307200; Peters SJ, 2001, AM J PHYSIOL-ENDOC M, V281, pE1151, DOI 10.1152/ajpendo.2001.281.6.E1151; Picard F, 2004, NATURE, V429, P771, DOI 10.1038/nature02583; Pilegaard H, 2003, DIABETES, V52, P657, DOI 10.2337/diabetes.52.3.657; Pilegaard H, 2000, AM J PHYSIOL-ENDOC M, V279, pE806; Poitout V, 2002, ENDOCRINOLOGY, V143, P339, DOI 10.1210/en.143.2.339; Postic C, 2004, DIABETES METAB, V30, P398, DOI 10.1016/S1262-3636(07)70133-7; Prado CL, 2004, P NATL ACAD SCI USA, V101, P2924, DOI 10.1073/pnas.0308604100; Puigserver P, 2003, NATURE, V423, P550, DOI 10.1038/nature01667; Qu S, 2007, AM J PHYSIOL-ENDOC M, V292, pE421, DOI 10.1152/ajpendo.00157.2006; Qu S, 2006, ENDOCRINOLOGY, V147, P5641, DOI 10.1210/en.2006-0541; RANDLE PJ, 1986, BIOCHEM SOC T, V14, P799, DOI 10.1042/bst0140799; RAURAMAA R, 1980, HORM METAB RES, V12, P591, DOI 10.1055/s-2007-999207; Reisz-Porszasz S, 2003, AM J PHYSIOL-ENDOC M, V285, pE876, DOI 10.1152/ajpendo.00107.2003; Rhee J, 2003, P NATL ACAD SCI USA, V100, P4012, DOI 10.1073/pnas.0730870100; Ritzel RA, 2004, J CLIN ENDOCR METAB, V89, P795, DOI 10.1210/jc.2003-031120; Robertson RP, 2004, DIABETES, V53, pS119, DOI 10.2337/diabetes.53.2007.S119; Rodgers JT, 2005, NATURE, V434, P113, DOI 10.1038/nature03354; Rosen ED, 2000, GENE DEV, V14, P1293; Rosen ED, 1999, MOL CELL, V4, P611, DOI 10.1016/S1097-2765(00)80211-7; Rosen ED, 2000, ANNU REV CELL DEV BI, V16, P145, DOI 10.1146/annurev.cellbio.16.1.145; Rosen ED, 2006, NAT REV MOL CELL BIO, V7, P885, DOI 10.1038/nrm2066; Roth U, 2004, J BIOL CHEM, V279, P2623, DOI 10.1074/jbc.M308391200; Sacheck JM, 2007, FASEB J, V21, P140, DOI 10.1096/fj.06-6604com; Samuel VT, 2006, DIABETES, V55, P2042, DOI 10.2337/db05-0705; Sandri M, 2004, CELL, V117, P399, DOI 10.1016/S0092-8674(04)00400-3; Schilling MM, 2006, NATURE, V443, pE10, DOI 10.1038/nature05288; Sekine K, 2007, EMBO J, V26, P3607, DOI 10.1038/sj.emboj.7601784; Southgate RJ, 2005, FASEB J, V19, P2072, DOI 10.1096/fj.05-3993fje; Southgate RJ, 2007, J BIOL CHEM, V282, P21176, DOI 10.1074/jbc.M702039200; Spriet LL, 2004, J APPL PHYSIOL, V96, P2082, DOI 10.1152/japplphysiol.01318.2003; Stitt TN, 2004, MOL CELL, V14, P395, DOI 10.1016/S1097-2765(04)00211-4; Stoffers DA, 2000, DIABETES, V49, P741, DOI 10.2337/diabetes.49.5.741; Straub SG, 2002, DIABETES-METAB RES, V18, P451, DOI 10.1002/dmrr.329; Subauste AR, 2007, AM J PHYSIOL-ENDOC M, V293, pE159, DOI 10.1152/ajpendo.00629.2006; TAMEMOTO H, 1994, NATURE, V372, P182, DOI 10.1038/372182a0; Tang ED, 1999, J BIOL CHEM, V274, P16741, DOI 10.1074/jbc.274.24.16741; Tang QQ, 2003, P NATL ACAD SCI USA, V100, P44, DOI 10.1073/pnas.0137044100; Tiedge M, 1998, DIABETES, V47, P1578, DOI 10.2337/diabetes.47.10.1578; Tissenbaum HA, 2001, NATURE, V410, P227, DOI 10.1038/35065638; Tobin KAR, 2002, J BIOL CHEM, V277, P10691, DOI 10.1074/jbc.M109771200; Tseng YH, 2004, MOL CELL BIOL, V24, P1918, DOI 10.1128/MCB.24.5.1918-1929.2004; Tsintzas K, 2006, J PHYSIOL-LONDON, V575, P291, DOI 10.1113/jphysiol.2006.109892; Tsuchida A, 2004, J BIOL CHEM, V279, P30817, DOI 10.1074/jbc.M402367200; Tureckova J, 2001, J BIOL CHEM, V276, P39264, DOI 10.1074/jbc.M104991200; WANG ND, 1995, SCIENCE, V269, P1108, DOI 10.1126/science.7652557; Wang XL, 1999, ENDOCRINOLOGY, V140, P4904, DOI 10.1210/en.140.10.4904; Wang YX, 2003, CELL, V113, P159, DOI 10.1016/S0092-8674(03)00269-1; Wilson EM, 2007, J BIOL CHEM, V282, P5106, DOI 10.1074/jbc.C600315200; Withers DJ, 1998, NATURE, V391, P900, DOI 10.1038/36116; Wu KL, 1997, MOL CELL BIOL, V17, P6002, DOI 10.1128/MCB.17.10.6002; Wu PF, 1998, BIOCHEM J, V329, P197, DOI 10.1042/bj3290197; Wu ZD, 1996, MOL CELL BIOL, V16, P4128; Xu JF, 2004, J BIOL CHEM, V279, P35914, DOI 10.1074/jbc.M402297200; Yamauchi T, 1996, MOL CELL BIOL, V16, P3074; YEH WC, 1995, GENE DEV, V9, P168, DOI 10.1101/gad.9.2.168; Yoon JC, 2001, NATURE, V413, P131, DOI 10.1038/35093050; Yoshikawa H, 2004, AM J PHYSIOL-ENDOC M, V287, pE1202, DOI 10.1152/ajpendo.00255.2004; Zhang WW, 2006, J BIOL CHEM, V281, P10105, DOI 10.1074/jbc.M600272200	192	397	413	1	50	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 7	2008	27	16					2320	2336		10.1038/onc.2008.25	http://dx.doi.org/10.1038/onc.2008.25			17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	285NE	18391974				2022-12-28	WOS:000254782700007
J	Cole, MD; Cowling, VH				Cole, M. D.; Cowling, V. H.			Specific regulation of mRNA cap methylation by the c-Myc and E2F1 transcription factors	ONCOGENE			English	Article						E2F1; gene expression; mRNA cap methylation; Myc; translation	CONDITIONAL MUTANTS; POLYMERASE-II; GENES; EXPRESSION; TRANSLATION; BINDING; IDENTIFICATION; ONCOPROTEINS; RECRUITMENT; ACTIVATION	Methylation of the mRNA 50 guanosine cap is essential for efficient gene expression. The 50 methyl cap binds to eIF4E, which is the first step in the recruitment of mRNA to the 40S ribosomal subunit. To investigate whether mRNA cap methylation is regulated in a gene-specific manner, we established a method to detect the relative level of cap methylation on specific mRNAs. We found that two transcription factors, c-Myc and E2F1, induce cap methylation of their transcriptional target genes, and therefore, c-Myc and E2F1 upregulate gene expression by simultaneously inducing transcription and promoting translation. c-Myc-induced cap methylation is greater than transcriptional induction for the majority of its target genes, indicating that this is a major mechanism by which Myc regulates gene expression.	[Cowling, V. H.] Univ Dundee, Coll Life Sci, Div Cell Biol & Immunol, Dundee DD1 5EH, Scotland; [Cole, M. D.] Dartmouth Med Sch, Dept Pharmacol, Lebanon, NH USA; [Cole, M. D.] Dartmouth Med Sch, Dept Genet, Lebanon, NH USA	University of Dundee; Dartmouth College; Dartmouth College	Cowling, VH (corresponding author), Univ Dundee, Coll Life Sci, Div Cell Biol & Immunol, Dow St,MSI WTB Complex, Dundee DD1 5EH, Scotland.	v.h.cowling@dundee.ac.uk		Cowling, Victoria/0000-0001-7638-4870	NIH; MRC; MRC [G0700240] Funding Source: UKRI; Medical Research Council [G0700240] Funding Source: researchfish; NATIONAL CANCER INSTITUTE [R01CA055248, P30CA023108] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Klara Acs for much helpful advice. We thank Kristian Helin for the E2F1-ER construct. This study was funded by NIH grants to MDC and an MRC grant to VHC.	Bentley DL, 2005, CURR OPIN CELL BIOL, V17, P251, DOI 10.1016/j.ceb.2005.04.006; Blais A, 2007, CURR OPIN CELL BIOL, V19, P658, DOI 10.1016/j.ceb.2007.10.003; Boon K, 2001, EMBO J, V20, P1383, DOI 10.1093/emboj/20.6.1383; Bush A, 1998, GENE DEV, V12, P3797, DOI 10.1101/gad.12.24.3797; Cowling VH, 2007, MOL CELL BIOL, V27, P2059, DOI 10.1128/MCB.01828-06; Cowling VH, 2006, SEMIN CANCER BIOL, V16, P242, DOI 10.1016/j.semcancer.2006.08.001; Cowling VH, 2006, MOL CELL BIOL, V26, P4226, DOI 10.1128/MCB.01959-05; Dang CV, 2006, SEMIN CANCER BIOL, V16, P253, DOI 10.1016/j.semcancer.2006.07.014; Gingras AC, 1999, ANNU REV BIOCHEM, V68, P913, DOI 10.1146/annurev.biochem.68.1.913; Gomez-Roman N, 2006, BIOCHEM SOC SYMP, V73, P141, DOI 10.1042/bss0730141; Gu MG, 2005, CURR OPIN STRUC BIOL, V15, P99, DOI 10.1016/j.sbi.2005.01.009; Guo QM, 2000, CANCER RES, V60, P5922; Iaquinta PJ, 2007, CURR OPIN CELL BIOL, V19, P649, DOI 10.1016/j.ceb.2007.10.006; Jacobson A, 1996, ANNU REV BIOCHEM, V65, P693, DOI 10.1146/annurev.bi.65.070196.003401; Kim S, 2000, P NATL ACAD SCI USA, V97, P11198, DOI 10.1073/pnas.200372597; McCracken S, 1997, GENE DEV, V11, P3306, DOI 10.1101/gad.11.24.3306; Moteki S, 2002, MOL CELL, V10, P599, DOI 10.1016/S1097-2765(02)00660-3; Muller H, 2001, GENE DEV, V15, P267, DOI 10.1101/gad.864201; Nikiforov MA, 2002, MOL CELL BIOL, V22, P5054, DOI 10.1128/MCB.22.14.5054-5063.2002; Schmidt EV, 2004, ONCOGENE, V23, P3217, DOI 10.1038/sj.onc.1207548; Schuhmacher M, 2001, NUCLEIC ACIDS RES, V29, P397, DOI 10.1093/nar/29.2.397; Schwer B, 1998, NUCLEIC ACIDS RES, V26, P2050, DOI 10.1093/nar/26.9.2050; Schwer B, 2000, GENETICS, V155, P1561; Shatkin AJ, 2000, NAT STRUCT BIOL, V7, P838, DOI 10.1038/79583; SHATKIN AJ, 1976, CELL, V9, P645, DOI 10.1016/0092-8674(76)90128-8; Shuman S, 2002, NAT REV MOL CELL BIO, V3, P619, DOI 10.1038/nrm880; Sims RJ, 2004, CURR OPIN CELL BIOL, V16, P263, DOI 10.1016/j.ceb.2004.04.004; von der Haar T, 2004, NAT STRUCT MOL BIOL, V11, P503, DOI 10.1038/nsmb779; Zeller KI, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-10-r69	29	56	57	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 5	2009	28	9					1169	1175		10.1038/onc.2008.463	http://dx.doi.org/10.1038/onc.2008.463			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	415AH	19137018	Green Accepted			2022-12-28	WOS:000263906200001
J	Fleming, YM; Ferguson, GJ; Spender, LC; Larsson, J; Karlsson, S; Ozanne, BW; Grosse, R; Inman, GJ				Fleming, Y. M.; Ferguson, G. J.; Spender, L. C.; Larsson, J.; Karlsson, S.; Ozanne, B. W.; Grosse, R.; Inman, G. J.			TGF-beta-mediated activation of RhoA signalling is required for efficient (V12)HaRas and (V600E)BRAF transformation	ONCOGENE			English	Article						TGF-beta; RhoA; Ras; Raf; transformation	GROWTH-FACTOR-BETA; TRANSCRIPTION FACTORS; TUMOR-SUPPRESSOR; GTPASES; PATHWAYS; CANCER; RAS; REORGANIZATION; PROLIFERATION; KINASE	Transforming growth factor beta-1 (TGF-beta) acts as both a tumour suppressor and a tumour promoter in a context-dependent manner. The tumour-promoting activities of TGF-beta are likely to result from a combination of Smad and non-Smad signalling pathways but remain poorly understood. Here we show that TGF-beta-mediated activation of RhoA is dependent on the kinase activity of ALK5 and that continuous ALK5 activity maintains basal RhoA-ROCK signalling, cell morphology and actin dynamics in serum-starved rodent fibroblasts independently of Smad2, Smad3 and Smad4. In immortalized human diploid. broblasts, we show that oncogenic rewiring by transduction of (V12)HaRas instigates regulation of RhoA-ROCK signalling through an autocrine TGF-beta 1-ALK5 pathway. Furthermore, we show that ALK5-mediated activation of RhoA is required for efficient (V12)HaRas, V-Raf and (V600E)BRAF transformation and (V12)HaRas-mediated anchorage-independent growth. These findings identify a new pro-oncogenic activity of TGF-beta and indicate that tumours harbouring (V12)HaRas and (V600E)BRAF mutations may be susceptible to TGF-beta signalling inhibitors.	[Fleming, Y. M.; Ferguson, G. J.; Spender, L. C.; Inman, G. J.] Beatson Inst Canc Res, Growth Factor Signalling Lab, Glasgow G61 1BD, Lanark, Scotland; [Larsson, J.; Karlsson, S.] Univ Lund Hosp, Inst Lab Med, Lund, Sweden; [Larsson, J.; Karlsson, S.] Univ Lund Hosp, Lund Strateg Res Ctr Stem Cell Biol & Cell Therap, Lund, Sweden; [Ozanne, B. W.] Beatson Inst Canc Res, Invas & Metastasis Lab, Glasgow G61 1BD, Lanark, Scotland; [Grosse, R.] Univ Heidelberg, Inst Pharmacol, D-6900 Heidelberg, Germany	Beatson Institute; Lund University; Skane University Hospital; Lund University; Skane University Hospital; Beatson Institute; Ruprecht Karls University Heidelberg	Inman, GJ (corresponding author), Beatson Inst Canc Res, Growth Factor Signalling Lab, Garscube Estate,Switchback Rd, Glasgow G61 1BD, Lanark, Scotland.	g.inman@beatson.gla.ac.uk		Inman, Gareth/0000-0002-6264-4253; Grosse, Robert/0000-0002-3380-5273	Association for International Cancer Research; Cancer Research UK	Association for International Cancer Research; Cancer Research UK(Cancer Research UK)	We thank P ten-Dijke, R Treisman, C Hill, T Crook, X-F Wang, R Derynck, A Hall and M Olson for valuable reagents. We thank J Wyke and M Olson for critically reading the paper and for discussions during the course of this work. This work was supported by an Association for International Cancer Research fellowship to GJI (GJI, YMF, GJF and LCS) and Cancer Research UK (YMF, GJI, GJF, LCS, and BWO).	Bhowmick NA, 2003, P NATL ACAD SCI USA, V100, P15548, DOI 10.1073/pnas.2536483100; Bhowmick NA, 2001, MOL BIOL CELL, V12, P27, DOI 10.1091/mbc.12.1.27; Bruna A, 2007, CANCER CELL, V11, P147, DOI 10.1016/j.ccr.2006.11.023; Chen D, 2004, GROWTH FACTORS, V22, P233, DOI 10.1080/08977190412331279890; Chen SY, 2006, J BIOL CHEM, V281, P1765, DOI 10.1074/jbc.M507771200; CROOK T, 1994, CELL, V79, P817, DOI 10.1016/0092-8674(94)90071-X; Derynck R, 2003, NATURE, V425, P577, DOI 10.1038/nature02006; Edlund S, 2002, MOL BIOL CELL, V13, P902, DOI 10.1091/mbc.01-08-0398; Goulimari P, 2005, J BIOL CHEM, V280, P42242, DOI 10.1074/jbc.M508690200; Inman GJ, 2002, MOL PHARMACOL, V62, P65, DOI 10.1124/mol.62.1.65; Jaffe AB, 2005, ANNU REV CELL DEV BI, V21, P247, DOI 10.1146/annurev.cellbio.21.020604.150721; Kang YB, 2005, P NATL ACAD SCI USA, V102, P13909, DOI 10.1073/pnas.0506517102; Larsson J, 2001, EMBO J, V20, P1663, DOI 10.1093/emboj/20.7.1663; Massague J, 2005, GENE DEV, V19, P2783, DOI 10.1101/gad.1350705; Moustakas A, 2005, J CELL SCI, V118, P3573, DOI 10.1242/jcs.02554; Olson MF, 1998, NATURE, V394, P295, DOI 10.1038/28425; Ozanne BW, 2006, CURR OPIN GENET DEV, V16, P65, DOI 10.1016/j.gde.2005.12.012; Pardali K, 2007, BBA-REV CANCER, V1775, P21, DOI 10.1016/j.bbcan.2006.06.004; QIU RG, 1995, P NATL ACAD SCI USA, V92, P11781, DOI 10.1073/pnas.92.25.11781; Roberts AB, 2003, P NATL ACAD SCI USA, V100, P8621, DOI 10.1073/pnas.1633291100; Sahai E, 1998, EMBO J, V17, P1350, DOI 10.1093/emboj/17.5.1350; Sahai E, 2001, EMBO J, V20, P755, DOI 10.1093/emboj/20.4.755; Sahai E, 2002, NAT REV CANCER, V2, P133, DOI 10.1038/nrc725; Sahai E, 1999, CURR BIOL, V9, P136, DOI 10.1016/S0960-9822(99)80067-0; Shen X, 2001, J BIOL CHEM, V276, P15362, DOI 10.1074/jbc.M009534200; Shi YG, 2003, CELL, V113, P685, DOI 10.1016/S0092-8674(03)00432-X; Uehata M, 1997, NATURE, V389, P990, DOI 10.1038/40187; Vardouli L, 2005, J BIOL CHEM, V280, P11448, DOI 10.1074/jbc.M402651200; Wakefield LM, 2002, CURR OPIN GENET DEV, V12, P22, DOI 10.1016/S0959-437X(01)00259-3; ZHENG Y, 1995, J BIOL CHEM, V270, P9031, DOI 10.1074/jbc.270.16.9031	30	35	35	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 19	2009	28	7					983	993		10.1038/onc.2008.449	http://dx.doi.org/10.1038/onc.2008.449			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	408TH	19079344				2022-12-28	WOS:000263457400005
J	Samadi, N; Gaetano, C; Goping, IS; Brindley, DN				Samadi, N.; Gaetano, C.; Goping, I. S.; Brindley, D. N.			Autotaxin protects MCF-7 breast cancer and MDA-MB-435 melanoma cells against Taxol-induced apoptosis	ONCOGENE			English	Article						ceramides; chemotherapy; chemoresistance; lysophosphatidate; lysophosphatidylcholine; phosphatidylinositol 3-kinase	LYSOPHOSPHATIDIC ACID RECEPTOR; RETRACTED ARTICLE. SEE; COUPLED RECEPTOR; PREVENTS APOPTOSIS; SURVIVAL FACTOR; OVARIAN; TUMOR; GROWTH; ACTIVATION; PACLITAXEL	Autotaxin (ATX) promotes cancer cell survival, growth, migration, invasion and metastasis. ATX converts extracellular lysophosphatidylcholine (LPC) into lysophosphatidate (LPA). As these lipids have been reported to affect cell signaling through their own G-protein-coupled receptors, ATX could modify the balance of this signaling. Also, ATX affects cell adhesion independently of its catalytic activity. We investigated the interactions of ATX, LPC and LPA on the apoptotic effects of Taxol, which is commonly used in breast cancer treatment. LPC had no significant effect on Taxol-induced apoptosis in MCF-7 breast cancer cells, which do not secrete significant ATX. Addition of incubation medium from MDA-MB-435 melanoma cells, which secrete ATX, or recombinat ATX enabled LPC to inhibit Taxol-induced apoptosis of MCF-7 cells. Inhibiting ATX activity blocked this protection against apoptosis. We conclude that LPC has no significant effect in protecting MCF-7 cells against Taxol treatment unless it is converted to LPA by ATX. LPA strongly antagonized Taxol-induced apoptosis through stimulating phosphatidylinositol 3-kinase and inhibiting ceramide formation. LPA also partially reversed the Taxol-induced arrest in the G2/M phase of the cell cycle. Our results support the hypothesis that therapeutic inhibition of ATX activity could improve the efficacy of Taxol as a chemotherapeutic agent for cancer treatment.	[Gaetano, C.; Goping, I. S.; Brindley, D. N.] Univ Alberta, Dept Biochem, Signal Transduct Res Grp, Edmonton, AB T6G 2S2, Canada; [Samadi, N.] Univ Alberta, Dept Lab Med & Pathol, Edmonton, AB T6G 2S2, Canada	University of Alberta; University of Alberta	Brindley, DN (corresponding author), Univ Alberta, Dept Biochem, Signal Transduct Res Grp, Edmonton, AB T6G 2S2, Canada.	david.brindley@ualberta.ca	Gaetano, Carlo/P-9997-2019	Gaetano, Carlo/0000-0002-5238-1832; samadi, nasser/0000-0001-7960-6432				Aoki J, 2002, J BIOL CHEM, V277, P48737, DOI 10.1074/jbc.M206812200; Asakuma J, 2003, CANCER RES, V63, P1365; Baudhuin LM, 2002, MOL PHARMACOL, V62, P660, DOI 10.1124/mol.62.3.660; Bergstralh DT, 2006, CANCER TREAT REV, V32, P166, DOI 10.1016/j.ctrv.2006.01.004; Brindley DN, 2004, J CELL BIOCHEM, V92, P900, DOI 10.1002/jcb.20126; BRINDLEY DN, 1993, J NUTR BIOCHEM, V4, P442, DOI 10.1016/0955-2863(93)90061-Z; Chappell J, 2001, J BIOL CHEM, V276, P38023; Charles AG, 2001, CANCER CHEMOTH PHARM, V47, P444, DOI 10.1007/s002800000265; Chen M, 2007, AM J PHYSIOL-CELL PH, V292, pC1927, DOI 10.1152/ajpcell.00400.2006; Clair T, 2003, CANCER RES, V63, P5446; Contos JJA, 2000, P NATL ACAD SCI USA, V97, P13384, DOI 10.1073/pnas.97.24.13384; Croset M, 2000, BIOCHEM J, V345, P61, DOI 10.1042/0264-6021:3450061; Cui P, 2007, BIOORG MED CHEM LETT, V17, P1634, DOI 10.1016/j.bmcl.2006.12.114; Demidenko ZN, 2008, ONCOGENE, V27, P4402, DOI 10.1038/onc.2008.82; Dennis J, 2005, J NEUROSCI RES, V82, P737, DOI 10.1002/jnr.20686; Dufour G, 2004, J BIOL CHEM, V279, P44113, DOI 10.1074/jbc.M405323200; Fang XJ, 2000, BIOCHEM J, V352, P135, DOI 10.1042/0264-6021:3520135; Fang XJ, 2002, BBA-MOL CELL BIOL L, V1582, P257, DOI 10.1016/S1388-1981(02)00179-8; Ferry G, 2008, J PHARMACOL EXP THER, V327, P809, DOI 10.1124/jpet.108.141911; Fox MA, 2004, MOL CELL NEUROSCI, V27, P140, DOI 10.1016/j.mcn.2004.06.002; Frankel A, 1996, CLIN CANCER RES, V2, P1307; Furui T, 1999, CLIN CANCER RES, V5, P4308; Gauthier R, 2001, AM J PHYSIOL-CELL PH, V280, pC1540, DOI 10.1152/ajpcell.2001.280.6.C1540; Goetzl EJ, 1999, CANCER RES, V59, P5370; Goetzl EJ, 1999, J IMMUNOL, V162, P2049; Hama K, 2004, J BIOL CHEM, V279, P17634, DOI 10.1074/jbc.M313927200; Harnois C, 2004, J CELL PHYSIOL, V198, P209, DOI 10.1002/jcp.10399; Hu XJ, 2005, J BIOL CHEM, V280, P9498, DOI 10.1074/jbc.M410455200; Inoue CN, 2001, CLIN SCI, V101, P11, DOI 10.1042/CS20000293; Jasinska R, 1999, BIOCHEM J, V340, P677, DOI 10.1042/0264-6021:3400677; Jemal A, 2006, CA-CANCER J CLIN, V56, P106, DOI 10.3322/canjclin.56.2.106; Kabarowski JHS, 2001, SCIENCE, V293, P702, DOI 10.1126/science.1061781; Kim K, 2005, FASEB J, V19, P819, DOI 10.1096/fj.04-2988fje; Koh JS, 1998, J CLIN INVEST, V102, P716, DOI 10.1172/JCI1002; Krajewski S, 1999, ENDOCR-RELAT CANCER, V6, P29, DOI 10.1677/erc.0.0060029; Lee CW, 2006, J BIOL CHEM, V281, P23589, DOI 10.1074/jbc.M603670200; Levine JS, 1997, AM J PHYSIOL-RENAL, V273, pF575, DOI 10.1152/ajprenal.1997.273.4.F575; Lin P, 2003, J BIOL CHEM, V278, P14379, DOI 10.1074/jbc.M209101200; Marchetti P, 2002, CRIT REV ONCOL HEMAT, V44, pS3; Martin A, 1997, ONCOGENE, V14, P1571, DOI 10.1038/sj.onc.1200987; McGrogan BT, 2008, BBA-REV CANCER, V1785, P96, DOI 10.1016/j.bbcan.2007.10.004; Melet A, 2008, ADV EXP MED BIOL, V615, P47, DOI 10.1007/978-1-4020-6554-5_4; Mills GB, 2003, NAT REV CANCER, V3, P582, DOI 10.1038/nrc1143; Moolenaar WH, 2004, BIOESSAYS, V26, P870, DOI 10.1002/bies.20081; Murph MM, 2007, MOL CANCER RES, V5, P1201, DOI 10.1158/1541-7786.MCR-06-0338; Nam SW, 2000, ONCOGENE, V19, P241, DOI 10.1038/sj.onc.1203263; Nam SW, 2001, CANCER RES, V61, P6938; Pasternack SM, 2008, NAT GENET, V40, P329, DOI 10.1038/ng.84; Pilquil C, 2006, J BIOL CHEM, V281, P38418, DOI 10.1074/jbc.M601670200; Radeff-Huang J, 2004, J CELL BIOCHEM, V92, P949, DOI 10.1002/jcb.20094; Radu CG, 2004, P NATL ACAD SCI USA, V101, P245, DOI 10.1073/pnas.2536801100; Ramjaun AR, 2007, ONCOGENE, V26, P970, DOI 10.1038/sj.onc.1209852; Rikitake Y, 2002, ARTERIOSCL THROM VAS, V22, P2049, DOI 10.1161/01.ATV.0000040598.18570.54; Rusovici R, 2007, BBA-GEN SUBJECTS, V1770, P1194, DOI 10.1016/j.bbagen.2007.04.008; Sakashita F, 2008, CANCER CHEMOTH PHARM, V62, P379, DOI 10.1007/s00280-007-0614-5; Saunders DE, 1997, INT J CANCER, V70, P214, DOI 10.1002/(SICI)1097-0215(19970117)70:2<214::AID-IJC13>3.0.CO;2-I; Sietsma H, 2002, NEUROCHEM RES, V27, P665, DOI 10.1023/A:1020228117739; Snyder JP, 2001, P NATL ACAD SCI USA, V98, P5312, DOI 10.1073/pnas.051309398; So J, 2005, GYNECOL ONCOL, V97, P870, DOI 10.1016/j.ygyno.2005.03.004; Spankuch B, 2007, ONCOGENE, V26, P5793, DOI 10.1038/sj.onc.1210355; STRACKE ML, 1992, J BIOL CHEM, V267, P2524; Sun BL, 2003, INT J MOL MED, V12, P633; Swanton C, 2007, CANCER CELL, V11, P498, DOI 10.1016/j.ccr.2007.04.011; Tigyi G, 2003, PROG LIPID RES, V42, P498, DOI 10.1016/S0163-7827(03)00035-3; Tomura H, 2005, CELL SIGNAL, V17, P1466, DOI 10.1016/j.cellsig.2005.06.002; Umezu-Goto M, 2002, J CELL BIOL, V158, P227, DOI 10.1083/jcb.200204026; Weiner JA, 1999, P NATL ACAD SCI USA, V96, P5233, DOI 10.1073/pnas.96.9.5233; Xu Y, 1998, JAMA-J AM MED ASSOC, V280, P719, DOI 10.1001/jama.280.8.719; Yang SY, 2002, CLIN EXP METASTAS, V19, P603, DOI 10.1023/A:1020950420196; Ye XQ, 2002, BBA-MOL CELL BIOL L, V1585, P108, DOI 10.1016/S1388-1981(02)00330-X; Yue JM, 2004, CELL SIGNAL, V16, P385, DOI 10.1016/j.cellsig.2003.08.012; Zhu K, 2001, J BIOL CHEM, V276, P41325, DOI 10.1074/jbc.M008057200	72	73	79	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 19	2009	28	7					1028	1039		10.1038/onc.2008.442	http://dx.doi.org/10.1038/onc.2008.442			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	408TH	19079345				2022-12-28	WOS:000263457400009
J	Schiewer, MJ; Morey, LM; Burd, CJ; Liu, Y; Merry, DE; Ho, SM; Knudsen, KE				Schiewer, M. J.; Morey, L. M.; Burd, C. J.; Liu, Y.; Merry, D. E.; Ho, S-M; Knudsen, K. E.			Cyclin D1 repressor domain mediates proliferation and survival in prostate cancer	ONCOGENE			English	Article						androgen receptor; testosterone; prostatic adenocarcinoma; cell cycle	ANDROGEN-RECEPTOR REGULATION; D-DEPENDENT KINASE; INDEPENDENT MECHANISM; CELL-PROLIFERATION; ESTROGEN-RECEPTOR; GENE-EXPRESSION; CARCINOMA-CELLS; CO-REPRESSOR; DNA-BINDING; ACTIVATION	Regulation of the androgen receptor (AR) is critical to prostate cancer (PCa) development; therefore, AR is the first line therapeutic target for disseminated tumors. Cell cycle-dependent accumulation of cyclin D1 negatively modulates the transcriptional regulation of AR through discrete, CDK4-independent mechanisms. The transcriptional corepressor function of cyclin D1 resides within a defined motif termed repressor domain (RD), and it was hypothesized that this motif could be utilized as a platform to develop new strategies for blocking AR function. Here, we demonstrate that expression of the RD peptide is sufficient to disrupt AR transcriptional activation of multiple, prostate-specific AR target genes. Importantly, these actions are sufficient to specifically inhibit S-phase progression in AR-positive PCa cells, but not in AR-negative cells or tested AR-positive cells of other lineages. As expected, impaired cell cycle progression resulted in a suppression of cell doubling. Additionally, cell death was observed in AR-positive cells that maintain androgen dependence and in a subset of castrate-resistant PCa cells, dependent on Akt activation status. Lastly, the ability of RD to cooperate with existing hormone therapies was examined, which revealed that RD enhanced the cellular response to an AR antagonist. Together, these data demonstrate that RD is sufficient to disrupt AR-dependent transcriptional and proliferative responses in PCa, and can enhance efficacy of AR antagonists, thus establishing the impetus for development of RD-based mimetics.	[Merry, D. E.; Knudsen, K. E.] Thomas Jefferson Univ, Kimmel Canc Ctr, Philadelphia, PA 19107 USA; [Schiewer, M. J.; Knudsen, K. E.] Thomas Jefferson Univ, Dept Canc Biol, Philadelphia, PA 19107 USA; [Morey, L. M.; Ho, S-M] Univ Cincinnati, Coll Med, Dept Environm Hlth, Cincinnati, OH 45267 USA; [Burd, C. J.] NIEHS, Mol Carcinogenesis Lab, Res Triangle Pk, NC 27709 USA; [Liu, Y.; Merry, D. E.] Thomas Jefferson Univ, Dept Biochem & Mol Biol, Philadelphia, PA 19107 USA; [Ho, S-M] Univ Cincinnati, Coll Med, Cter Environm Genet, Cincinnati, OH USA; [Ho, S-M] Univ Cincinnati, Coll Med, UC Barrett Canc Ctr, Cincinnati, OH USA; [Knudsen, K. E.] Thomas Jefferson Univ, Dept Urol, Philadelphia, PA 19107 USA	Jefferson University; Jefferson University; University System of Ohio; University of Cincinnati; National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); Jefferson University; University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati; Jefferson University	Knudsen, KE (corresponding author), Thomas Jefferson Univ, Kimmel Canc Ctr, Bluemle Life Sci Bldg,233 S 10th St,Room 1008A, Philadelphia, PA 19107 USA.	karen.knudsen@kimmelcancercenter.org		Schiewer, Matthew/0000-0002-2325-4228; Burd, Craig/0000-0002-6899-6751; Knudsen, Karen/0000-0002-1301-890X	NIH [CA099996, CA116777, CA015776, CA062269, CA112532];  [T32-CA117846]; NATIONAL CANCER INSTITUTE [T32CA117846, R01CA112532, R01CA099996, R01CA015776, R01CA116777, R01CA062269] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES006096] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); ; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))	We thank the K Knudsen lab for critical input, especially SM Godoy Tundidor; S Schwemberger, S Fox and M Faradaugh for technical assistance, and the E Knudsen laboratory for commentary. This work was supported by NIH grants CA099996 and CA116777 (to KEK); CA015776, CA062269, CA112532 (to SMH). LMM was supported by training grant T32-CA117846.	Agus DB, 1999, J NATL CANCER I, V91, P1869, DOI 10.1093/jnci/91.21.1869; Balk SP, 2008, NUCL RECEPT SIGNAL, V6; Bienvenu F, 2001, J BIOL CHEM, V276, P16840, DOI 10.1074/jbc.M100795200; BIRRELL SN, 1995, J STEROID BIOCHEM, V52, P459, DOI 10.1016/0960-0760(95)00005-K; Burd CJ, 2005, MOL ENDOCRINOL, V19, P607, DOI 10.1210/me.2004-0266; Burnstein KL, 2005, J CELL BIOCHEM, V95, P657, DOI 10.1002/jcb.20460; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; Cheng H, 2006, CANCER RES, V66, P10613, DOI 10.1158/0008-5472.CAN-06-0028; Cheng MG, 1998, P NATL ACAD SCI USA, V95, P1091, DOI 10.1073/pnas.95.3.1091; Chmelar R, 2007, INT J CANCER, V120, P719, DOI 10.1002/ijc.22365; Coqueret O, 2002, GENE, V299, P35, DOI 10.1016/S0378-1119(02)01055-7; Davies MA, 1999, CANCER RES, V59, P2551; ESQUENET M, 1995, MOL CELL ENDOCRINOL, V109, P105, DOI 10.1016/0303-7207(95)03490-X; Ewen ME, 2004, TRENDS MOL MED, V10, P158, DOI 10.1016/j.molmed.2004.02.005; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; Feldman BJ, 2001, NAT REV CANCER, V1, P34, DOI 10.1038/35094009; Franke TF, 1997, CELL, V88, P435, DOI 10.1016/S0092-8674(00)81883-8; Fu MF, 2004, ENDOCRINOLOGY, V145, P5439, DOI 10.1210/en.2004-0959; Fu MF, 2005, J BIOL CHEM, V280, P16934, DOI 10.1074/jbc.M500403200; Ganter B, 1998, EMBO J, V17, P255, DOI 10.1093/emboj/17.1.255; Ghosh PM, 2005, ENDOCR-RELAT CANCER, V12, P119, DOI 10.1677/erc.1.00835; Gottschalk AR, 2005, INT J RADIAT ONCOL, V61, P1183, DOI 10.1016/j.ijrobp.2004.12.024; Gregory CW, 2001, CANCER RES, V61, P2892; Hadaschik BA, 2007, UROL ONCOL-SEMIN ORI, V25, P413, DOI 10.1016/j.urolonc.2007.05.010; Hess-Wilson JK, 2006, CANCER RES, V66, P11998, DOI 10.1158/0008-5472.CAN-06-2249; Hu B, 2007, CANCER RES, V67, P8810, DOI 10.1158/0008-5472.CAN-07-1140; Inoue K, 1998, MOL CELL BIOL, V18, P1590, DOI 10.1128/MCB.18.3.1590; James MK, 2008, MOL CELL BIOL, V28, P498, DOI 10.1128/MCB.02171-06; Jemal A, 2007, CA-CANCER J CLIN, V57, P43, DOI 10.3322/canjclin.57.1.43; KAIGHN ME, 1979, INVEST UROL, V17, P16; Kato A, 1998, BIOCHEM BIOPH RES CO, V245, P70, DOI 10.1006/bbrc.1998.8377; Knudsen KE, 2006, CELL DIV, V1, DOI 10.1186/1747-1028-1-15; Knudsen KE, 1999, CANCER RES, V59, P2297; Knudsen KE, 1998, J BIOL CHEM, V273, P20213, DOI 10.1074/jbc.273.32.20213; Li JW, 2006, MOL ENDOCRINOL, V20, P776, DOI 10.1210/me.2005-0298; Li JW, 2002, GENE DEV, V16, P687, DOI 10.1101/gad.962502; Lilja H, 2008, NAT REV CANCER, V8, P268, DOI 10.1038/nrc2351; Lin HM, 2002, J BIOL CHEM, V277, P28733, DOI 10.1074/jbc.M203380200; Locke JA, 2008, CANCER RES, V68, P6407, DOI 10.1158/0008-5472.CAN-07-5997; MATSUSHIME H, 1992, CELL, V71, P323, DOI 10.1016/0092-8674(92)90360-O; MAUCHER A, 1993, J CANCER RES CLIN, V119, P669, DOI 10.1007/BF01215986; McMenamin ME, 1999, CANCER RES, V59, P4291; Mehra R, 2007, CANCER RES, V67, P7991, DOI 10.1158/0008-5472.CAN-07-2043; Mehra R, 2007, MODERN PATHOL, V20, P538, DOI 10.1038/modpathol.3800769; Minamiguchi K, 2004, MOL CELL ENDOCRINOL, V214, P175, DOI 10.1016/j.mce.2003.10.060; Montgomery RB, 2008, CANCER RES, V68, P4447, DOI 10.1158/0008-5472.CAN-08-0249; Mullany LK, 2008, CELL CYCLE, V7, P2215, DOI 10.4161/cc.7.14.6274; Neuman E, 1997, MOL CELL BIOL, V17, P5338, DOI 10.1128/MCB.17.9.5338; Olshavsky NA, 2008, ONCOGENE, V27, P3111, DOI 10.1038/sj.onc.1210981; Parry D, 1999, MOL CELL BIOL, V19, P1775; Perner S, 2007, AM J SURG PATHOL, V31, P882, DOI 10.1097/01.pas.0000213424.38503.aa; Petre CE, 2002, J BIOL CHEM, V277, P2207, DOI 10.1074/jbc.M106399200; Petre-Draviam CE, 2005, ONCOGENE, V24, P431, DOI 10.1038/sj.onc.1208200; Petre-Draviam CE, 2003, CANCER RES, V63, P4903; Petrylak DP, 2005, UROLOGY, V65, P3, DOI 10.1016/j.urology.2005.03.053; Pienta KJ, 2006, CLIN CANCER RES, V12, P1665, DOI 10.1158/1078-0432.CCR-06-0067; Quayle SN, 2007, P NATL ACAD SCI USA, V104, P1331, DOI 10.1073/pnas.0606718104; Quayle SN, 2007, BMC GENOMICS, V8, DOI 10.1186/1471-2164-8-32; QUELLE DE, 1993, GENE DEV, V7, P1559, DOI 10.1101/gad.7.8.1559; Reutens AT, 2001, MOL ENDOCRINOL, V15, P797, DOI 10.1210/me.15.5.797; RUNDLETT SE, 1990, MOL ENDOCRINOL, V4, P708, DOI 10.1210/mend-4-5-708; Salesi N, 2005, J EXP CLIN CANC RES, V24, P175; Shand RL, 2006, CURR OPIN UROL, V16, P123, DOI 10.1097/01.mou.0000193384.39351.64; Sharifi N, 2005, JAMA-J AM MED ASSOC, V294, P238, DOI 10.1001/jama.294.2.238; Sharifi N, 2002, J MOL MED, V80, P219, DOI 10.1007/s00109-001-0305-3; Shen MM, 2007, CANCER RES, V67, P6535, DOI 10.1158/0008-5472.CAN-07-1271; SKAPEK SX, 1995, SCIENCE, V267, P1022, DOI 10.1126/science.7863328; Stanbrough M, 2006, CANCER RES, V66, P2815, DOI 10.1158/0008-5472.CAN-05-4000; Subbarayan V, 2005, NEOPLASIA, V7, P280, DOI 10.1593/neo.04457; Tomlins SA, 2007, NATURE, V448, P595, DOI 10.1038/nature06024; Walcott JL, 2002, J BIOL CHEM, V277, P50855, DOI 10.1074/jbc.M209466200; Wang CG, 2003, MOL CELL BIOL, V23, P6159, DOI 10.1128/MCB.23.17.6159-6173.2003; Wang CG, 2006, P NATL ACAD SCI USA, V103, P11567, DOI 10.1073/pnas.0603363103; Wilson S, 2005, BIOCHEM J, V388, P967, DOI 10.1042/BJ20041066; WONG CI, 1993, J BIOL CHEM, V268, P19004; Xu YY, 2006, CANCER RES, V66, P7783, DOI 10.1158/0008-5472.CAN-05-4472; Zhu P, 2006, CELL, V124, P615, DOI 10.1016/j.cell.2005.12.032; Zwijsen RML, 1998, GENE DEV, V12, P3488, DOI 10.1101/gad.12.22.3488	78	19	19	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 19	2009	28	7					1016	1027		10.1038/onc.2008.446	http://dx.doi.org/10.1038/onc.2008.446			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	408TH	19079343	Green Accepted			2022-12-28	WOS:000263457400008
J	Li, NF; Kocher, HM; Salako, MA; Obermueller, E; Sandle, J; Balkwill, F				Li, N. F.; Kocher, H. M.; Salako, M. A.; Obermueller, E.; Sandle, J.; Balkwill, F.			A novel function of colony-stimulating factor 1 receptor in hTERT immortalization of human epithelial cells	ONCOGENE			English	Article						colony-stimulating factor 1 receptor; hTERT; immortalization; human epithelial cells	CSF-1 M-CSF; TELOMERASE; EXPRESSION; GROWTH; CYTOKINE; MARKER; P53	The receptor for macrophage colony-stimulating factor 1 receptor (CSF1R) is a product of the proto-oncogene c-fms and a member of the class III transmembrane tyrosine kinase receptor family. Earlier, we described increased mRNA expression of CSF1R in human telomerase reverse transcriptase (hTERT) immortalized human ovarian surface epithelial (IOSE) cell lines derived from a single donor. Here, we further describe that CSF1R is upregulated at both the mRNA and protein level in hTERT immortalized human normal OSE cells from two different donors and in hTERT immortalized human pancreatic ductal epithelial cells. CSF1R was not upregulated in hTERT immortalized epithelial clones that subsequently underwent senescence or in immortalized fibroblasts. Upon stimulation by the CSF1R ligand CSF1, the immortalized epithelial cell lines showed rapid internalization of CSF1R with concomitant down-modulation and colocalization of phosphorylated NF kappa Bp65 with hTERT protein, hTERT translocation into the nucleus and the binding of c-Myc to the hTERT promoter region. Reducing the expression of CSF1R using short hairpin interfering RNA abolished these effects and also decreased cell survival and the number of population doublings under suboptimal culture conditions. The telomerase inhibitor GRN163L confirmed a role for telomerase in the cleavage of the intracellular domain of CSF1R. On the basis of these findings, we suggest that CSF1R may be a critical factor facilitating hTERT immortalization of epithelial cells.	[Li, N. F.; Salako, M. A.; Obermueller, E.; Balkwill, F.] Barts & London Queen Marys Sch Med & Dent, Inst Canc, Ctr Canc & Inflammat, London EC1M 6BQ, England; [Li, N. F.; Kocher, H. M.; Salako, M. A.; Obermueller, E.; Sandle, J.; Balkwill, F.] Barts & London Queen Marys Sch Med & Dent, Canc Res UK Clin Ctr, London EC1M 6BQ, England; [Kocher, H. M.; Sandle, J.] Barts & London Queen Marys Sch Med & Dent, Inst Canc, Tumor Biol Ctr, London EC1M 6BQ, England	University of London; Queen Mary University London; Cancer Research UK; University of London; Queen Mary University London; University of London; Queen Mary University London	Balkwill, F (corresponding author), Barts & London Queen Marys Sch Med & Dent, Inst Canc, Ctr Canc & Inflammat, Charter House Sq, London EC1M 6BQ, England.	frances.balkwill@cancer.org.uk		LI, Ningfeng/0000-0001-5908-9976; Kocher, Hemant M/0000-0001-6771-1905; Balkwill, Frances/0000-0002-5587-9759	Medical Research Council [G0501974] Funding Source: Medline; MRC [G0501974] Funding Source: UKRI	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Akiyama M, 2003, CANCER RES, V63, P18; Hahn WC, 2002, MOL CELLS, V13, P351; Herbert BS, 2005, ONCOGENE, V24, P5262, DOI 10.1038/sj.onc.1208760; Jiang XR, 1999, NAT GENET, V21, P111, DOI 10.1038/5056; KACINSKI BM, 1989, INT J RADIAT ONCOL, V17, P159, DOI 10.1016/0360-3016(89)90383-0; KACINSKI BM, 1990, INT J RADIAT ONCOL, V19, P619, DOI 10.1016/0360-3016(90)90488-6; KACINSKI BM, 1988, INT J RADIAT ONCOL, V15, P823, DOI 10.1016/0360-3016(88)90113-7; Li NF, 2007, CELL PROLIFERAT, V40, P780, DOI 10.1111/j.1365-2184.2007.00462.x; Li NFF, 2004, LAB INVEST, V84, P923, DOI 10.1038/labinvest.3700093; Morales CP, 1999, NAT GENET, V21, P115, DOI 10.1038/5063; Rohrschneider LR, 1997, MOL REPROD DEV, V46, P96; SCHOLL SM, 1994, JNCI-J NATL CANCER I, V86, P120, DOI 10.1093/jnci/86.2.120; SHERR CJ, 1988, J CELL BIOCHEM, V38, P179, DOI 10.1002/jcb.240380305; STANLEY ER, 1983, J CELL BIOCHEM, V21, P151, DOI 10.1002/jcb.240210206; TANG RP, 1992, J CELL BIOCHEM, V50, P350, DOI 10.1002/jcb.240500403; Urban S, 2002, CURR OPIN GENET DEV, V12, P512, DOI 10.1016/S0959-437X(02)00334-9; WHITAKER NJ, 1995, ONCOGENE, V11, P971; Yang G, 2007, ONCOGENE, V26, P1492, DOI 10.1038/sj.onc.1209905	18	28	31	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 5	2009	28	5					773	780		10.1038/onc.2008.412	http://dx.doi.org/10.1038/onc.2008.412			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	403IN	18997822				2022-12-28	WOS:000263076400014
J	Miyake, I; Ohira, M; Nakagawara, A; Sakai, R				Miyake, I.; Ohira, M.; Nakagawara, A.; Sakai, R.			Distinct role of ShcC docking protein in the differentiation of neuroblastoma	ONCOGENE			English	Article						Shc family; ERK; neuroblastoma; differentiation; RNAi	PHOSPHOTYROSINE-BINDING DOMAINS; ANAPLASTIC LYMPHOMA KINASE; GROWTH-FACTOR RECEPTOR; SRC HOMOLOGY 2; ADAPTER PROTEIN; PLASMA-MEMBRANE; P190 RHOGAP; N-SHC; ACTIVATION; EXPRESSION	The biological and clinical heterogeneityof neuroblastoma is closely associated with signaling pathways that control cellular characteristics such as proliferation, survival and differentiation. The Shc family of docking proteins is important in these pathways by mediating cellular signaling. In this study, we analysed the expression levels of ShcA and ShcC proteins in 46 neuroblastoma samples and showed that a significantly high er level of ShcC protein is observed in neuroblastomas with poor prognostic factors such as advanced stage and MYCN amplification (P < 0.005), whereas the expression level of ShcA showed no signi. cant association with these factors. Using TNB1 cells that express a high level of ShcC protein, it was demonstrated that knockdown of ShcC by RNAi caused elevation in the phosphorylation of ShcA, which resulted in sustained extracellular signal-regulated kinase activation and neurite outgrowth. The neurites induced by ShcC knockdown expressed several markers of neuronal differentiation suggesting that the expression of ShcC potentially has a function in inhibiting the differentiation of neuroblastoma cells. In addition, marked suppression of in vivo tumorigenicity of TNB1 cells in nude mice was observed by stable knockdown of ShcC protein. These findings indicate that ShcC is a therapeutic target that might induce differentiation in the aggressive type of neuroblastomas.	[Sakai, R.] Natl Canc Ctr, Res Inst, Div Growth Factor, Chuo Ku, Tokyo 1040045, Japan; [Ohira, M.; Nakagawara, A.] Chiba Canc Ctr, Res Inst, Div Biochem, Chiba 2608717, Japan	National Cancer Center - Japan; Chiba Cancer Center	Sakai, R (corresponding author), Natl Canc Ctr, Res Inst, Div Growth Factor, Chuo Ku, Tokyo 1040045, Japan.	rsakai@ncc.go.jp		Sakai, Ryuichi/0000-0001-6833-1103	Ministry of Health, Labor and Welfare of Japan for the third-term Comprehensive 10-year Strategy for Cancer Control; Grants-in-Aid for Scientific Research [21390317] Funding Source: KAKEN	Ministry of Health, Labor and Welfare of Japan for the third-term Comprehensive 10-year Strategy for Cancer Control(Ministry of Health, Labour and Welfare, Japan); Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	This work was supported by a Grant-in-Aid from the Ministry of Health, Labor and Welfare of Japan for the third-term Comprehensive 10-year Strategy for Cancer Control.	Berwanger B, 2002, CANCER CELL, V2, P377, DOI 10.1016/S1535-6108(02)00179-4; BRODEUR GM, 1992, AM J PEDIAT HEMATOL, V14, P111; Brouns MR, 2000, DEVELOPMENT, V127, P4891; Brouns MR, 2001, NAT CELL BIOL, V3, P361, DOI 10.1038/35070042; Dhillon AS, 2003, MOL CELL BIOL, V23, P1983, DOI 10.1128/MCB.23.6.1983-1993.2003; GIUDICI AM, 1992, EUR J CELL BIOL, V58, P383; Hecht M, 2004, CANCER RES, V64, P6109, DOI 10.1158/0008-5472.CAN-04-1014; Hecker TP, 2002, CANCER RES, V62, P2699; Hinsby AM, 2004, J NEUROCHEM, V91, P694, DOI 10.1111/j.1471-4159.2004.02772.x; IWAMOTO T, 1993, BRIT J CANCER, V67, P504, DOI 10.1038/bjc.1993.94; LEEVERS SJ, 1994, NATURE, V369, P411, DOI 10.1038/369411a0; Liu HY, 2002, J BIOL CHEM, V277, P26046, DOI 10.1074/jbc.M111659200; Magrassi L, 2005, ONCOGENE, V24, P5198, DOI 10.1038/sj.onc.1208708; Marshall GM, 1997, CANCER RES, V57, P5399; Miyake I, 2005, ONCOGENE, V24, P3206, DOI 10.1038/sj.onc.1208523; Miyake I, 2002, ONCOGENE, V21, P5823, DOI 10.1038/sj.onc.1205735; Moro L, 1998, EMBO J, V17, P6622, DOI 10.1093/emboj/17.22.6622; Nakagawara A, 1997, EUR J CANCER, V33, P2050, DOI 10.1016/S0959-8049(97)00280-3; NAKAGAWARA A, 1993, NEW ENGL J MED, V328, P847, DOI 10.1056/NEJM199303253281205; Nakamura T, 1996, ONCOGENE, V13, P1111; Nakamura T, 1998, J BIOL CHEM, V273, P6960, DOI 10.1074/jbc.273.12.6960; Nakamura T, 2002, ONCOGENE, V21, P22, DOI 10.1038/sj.onc.1205019; O'Bryan JP, 1998, J BIOL CHEM, V273, P20431, DOI 10.1074/jbc.273.32.20431; OBryan JP, 1996, P NATL ACAD SCI USA, V93, P2729, DOI 10.1073/pnas.93.7.2729; Ohira M, 2003, ONCOGENE, V22, P5525, DOI 10.1038/sj.onc.1206853; Opel D, 2007, CANCER RES, V67, P735, DOI 10.1158/0008-5472.CAN-06-2201; Osajima-Hakomori Y, 2005, AM J PATHOL, V167, P213, DOI 10.1016/S0002-9440(10)62966-5; Pelicci G, 1996, ONCOGENE, V13, P633; QIU MS, 1992, NEURON, V9, P705, DOI 10.1016/0896-6273(92)90033-A; Ravichandran KS, 2001, ONCOGENE, V20, P6322, DOI 10.1038/sj.onc.1204776; Sakai R, 2000, NEURON, V28, P819, DOI 10.1016/S0896-6273(00)00156-2; Schwab M, 2003, LANCET ONCOL, V4, P472, DOI 10.1016/S1470-2045(03)01166-5; STOKOE D, 1994, SCIENCE, V264, P1463, DOI 10.1126/science.7811320; Terui E, 2005, CLIN CANCER RES, V11, P3280, DOI 10.1158/1078-0432.CCR-04-1681; Wary KK, 1998, CELL, V94, P625, DOI 10.1016/S0092-8674(00)81604-9; Wary KK, 1996, CELL, V87, P733, DOI 10.1016/S0092-8674(00)81392-6; Wellbrock C, 2002, J BIOL CHEM, V277, P6443, DOI 10.1074/jbc.M110684200; Yaka R, 1998, J CELL BIOCHEM, V70, P425, DOI 10.1002/(SICI)1097-4644(19980901)70:3<425::AID-JCB15>3.0.CO;2-J; Yamada M, 2002, BRAIN RES, V955, P183, DOI 10.1016/S0006-8993(02)03432-7	39	15	16	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 5	2009	28	5					662	673		10.1038/onc.2008.413	http://dx.doi.org/10.1038/onc.2008.413			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	403IN	18997821				2022-12-28	WOS:000263076400004
J	Guo, C; Gasparian, AV; Zhuang, Z; Bosykh, DA; Komar, AA; Gudkov, AV; Gurova, KV				Guo, C.; Gasparian, A. V.; Zhuang, Z.; Bosykh, D. A.; Komar, A. A.; Gudkov, A. V.; Gurova, K. V.			9-Aminoacridine-based anticancer drugs target the PI3K/AKT/mTOR, NF-kappa B and p53 pathways	ONCOGENE			English	Article						proteomics; quinacrine; cell death; PI3 kinase-gamma; PTEN	MESSENGER-RNAS; INFLAMMATION; PI3K-GAMMA; TRANSLATION; INHIBITION; ACTIVATION; MECHANISM; RAPAMYCIN; CELLS; MDM2	Acquisition of a transformed phenotype involves deregulation of several signal transduction pathways contributing to unconstrained cell growth. Understanding the interplay of different cancer-related signaling pathways is important for development of efficacious multitargeted anticancer drugs. The small molecule 9-aminoacridine (9AA) and its derivative, the antimalaria drug quinacrine, have selective toxicity for tumor cells and can simultaneously suppress nuclear factor-kappa B (NF-kappa B) and activate p53 signaling. To investigate the mechanism underlying these drug activities, we used a combination of two-dimensional protein separation by gel electrophoresis and mass spectrometry to identify proteins whose expression is altered in tumor cells by 9AA treatment. We found that 9AA treatment results in selective downregulation of a specific catalytic subunit of the phosphoinositide 3-kinase (PI3K) family, p110 gamma. Further exploration of this observation demonstrated that the mechanism of action of 9AA involves inhibition of the prosurvival AKT/ mammalian target of rapamycin (mTOR) pathway that lies downstream of PI3K. p110 gamma translation appears to be regulated by mTOR and feeds back to further modulate mTOR and AKT, there by impacting the p53 and NF-kappa B pathways as well. These results reveal functional interplay among the PI3K/AKT/mTOR, p53 and NF-kappa B pathways that are frequently deregulated in cancer and suggest that their simultaneous targeting by a single small molecule such as 9AA could result in efficacious and selective killing of transformed cells.	[Gudkov, A. V.; Gurova, K. V.] Roswell Pk Canc Inst, Dept Cell Stress Biol, Buffalo, NY 14263 USA; [Guo, C.] Case Western Reserve Univ, Dept Biochem, Cleveland, OH 44106 USA; [Guo, C.] Lerner Res Inst, Dept Mol Genet, Cleveland, OH USA; [Gasparian, A. V.; Bosykh, D. A.; Gudkov, A. V.; Gurova, K. V.] Cleveland Biolabs Inc, Buffalo, NY USA; [Zhuang, Z.] Natl Inst Hlth, Bethesda, MD USA; [Komar, A. A.] Cleveland State Univ, Dept Biol, Ctr Gene Regulat Hlth & Dis, Cleveland, OH 44115 USA	Roswell Park Cancer Institute; Case Western Reserve University; Cleveland Clinic Foundation; National Institutes of Health (NIH) - USA; University System of Ohio; Cleveland State University	Gudkov, AV (corresponding author), Roswell Pk Canc Inst, Dept Cell Stress Biol, BLSC L3-301,Elm & Carlton St, Buffalo, NY 14263 USA.	andrei.gudkov@roswellpark.org; katerina.gurova@roswellpark.org		Komar, Anton/0000-0003-4188-0633; Gudkov, Andrei/0000-0003-2548-0154				Bensaad K, 2005, NAT MED, V11, P1278, DOI 10.1038/nm1205-1278; Budanov AV, 2008, CELL, V134, P451, DOI 10.1016/j.cell.2008.06.028; Camps M, 2005, NAT MED, V11, P936, DOI 10.1038/nm1284; Feng ZH, 2005, P NATL ACAD SCI USA, V102, P8204, DOI 10.1073/pnas.0502857102; Furuta M, 2004, ONCOGENE, V23, P6806, DOI 10.1038/sj.onc.1207770; Gingras AC, 2003, CURR TOP MICROBIOL, V279, P169; Gudkov AV, 2005, PROTEIN REV, V2, P225, DOI 10.1007/0-387-30127-5_10; Gurova KV, 2005, P NATL ACAD SCI USA, V102, P17448, DOI 10.1073/pnas.0508888102; Huang SL, 2003, CANCER BIOL THER, V2, P222, DOI 10.4161/cbt.2.3.360; Jeong SJ, 2005, ONCOGENE, V24, P6719, DOI 10.1038/sj.onc.1208825; Jung KJ, 2008, J VIROL, V82, P8537, DOI 10.1128/JVI.00690-08; Kang S, 2006, P NATL ACAD SCI USA, V103, P1289, DOI 10.1073/pnas.0510772103; Karin M, 2005, NAT REV IMMUNOL, V5, P749, DOI 10.1038/nri1703; Komar AA, 2005, J BIOL CHEM, V280, P23425, DOI 10.1074/jbc.R400041200; Kucharczak J, 2003, ONCOGENE, V22, P8961, DOI 10.1038/sj.onc.1207230; Levine AJ, 2006, GENE DEV, V20, P267, DOI 10.1101/gad.1363206; Mayo LD, 2002, J BIOL CHEM, V277, P5484, DOI 10.1074/jbc.M108302200; Mayo LD, 2001, P NATL ACAD SCI USA, V98, P11598, DOI 10.1073/pnas.181181198; Okamoto H, 2007, CANCER BIOL THER, V6, P391, DOI 10.4161/cbt.6.3.3731; Ozes ON, 1999, NATURE, V401, P82; Rommel C, 2007, NAT REV IMMUNOL, V7, P191, DOI 10.1038/nri2036; Sarbassov DD, 2005, SCIENCE, V307, P1098, DOI 10.1126/science.1106148; Shi YJ, 2005, J BIOL CHEM, V280, P10964, DOI 10.1074/jbc.M407874200; Sizemore N, 2002, J BIOL CHEM, V277, P3863, DOI 10.1074/jbc.M110572200; STEPHENS L, 1994, CELL, V77, P83, DOI 10.1016/0092-8674(94)90237-2; STONE KL, 1993, PRACTICAL GUIDE PROT; TERADA N, 1994, P NATL ACAD SCI USA, V91, P11477, DOI 10.1073/pnas.91.24.11477; Yamboliev IA, 2000, AM J PHYSIOL-CELL PH, V279, pC352, DOI 10.1152/ajpcell.2000.279.2.C352	29	98	102	2	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2009	28	8					1151	1161		10.1038/onc.2008.460	http://dx.doi.org/10.1038/onc.2008.460			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	412KE	19137016				2022-12-28	WOS:000263722900010
J	White-Gilbertson, S; Mullen, T; Senkal, C; Lu, P; Ogretmen, B; Obeid, L; Voelkel-Johnson, C				White-Gilbertson, S.; Mullen, T.; Senkal, C.; Lu, P.; Ogretmen, B.; Obeid, L.; Voelkel-Johnson, C.			Ceramide synthase 6 modulates TRAIL sensitivity and nuclear translocation of active caspase-3 in colon cancer cells	ONCOGENE			English	Article						TRAIL; ceramide; apoptosis; ceramide synthase; longevity assurance homologue	LONGEVITY ASSURANCE GENE-1; INDUCED APOPTOSIS; FAMILY-MEMBERS; HUMAN HEAD; RESISTANCE; DEATH; METASTASIS; ACTIVATION; GROWTH; IDENTIFICATION	We have previously shown that the death receptor ligand TRAIL (tumor necrosis factor-related apoptosis-inducing ligand) induces an increase of intracellular C-16-ceramide in sensitive SW480 but not in resistant SW620 cells. Resistance in SW620 cells was overcome by exogenous ceramide, leading us to propose that defective ceramide signaling contributes to TRAIL resistance. In this study we found that the increase in C16-ceramide in SW480 cells was inhibited by fumonisin B1, an inhibitor of ceramide synthases (CerS). Protein analysis revealed that TRAIL-resistant SW620 cells expressed lower levels of ceramide synthase 6 (CerS6, also known as longevity assurance homologue 6), which prompted us to investigate the effect of CerS6 modulation on TRAIL phenotype. RNAi against CerS6 resulted in a specific and significant decrease of the C-16-ceramide species, which was sufficient to inhibit TRAIL-induced apoptosis. In cells with decreased levels of CerS6, caspase-3 was activated but failed to translocate into the nucleus. CerS6 localized primarily to the perinuclear region, suggesting this enzyme may be important in regulation of nuclear permeability. Moderate elevation in CerS6 expression was sufficient to reverse TRAIL resistance in SW620 cells. These results suggest that modulation of CerS6 expression may constitute a new therapeutic strategy to alter apoptotic susceptibility.	[White-Gilbertson, S.; Lu, P.; Voelkel-Johnson, C.] Med Univ S Carolina, Dept Microbiol & Immunol, Charleston, SC 29403 USA; [Mullen, T.; Obeid, L.] Med Univ S Carolina, Dept Med, Charleston, SC 29403 USA; [Senkal, C.; Ogretmen, B.] Med Univ S Carolina, Dept Biochem & Mol Biol, Charleston, SC 29403 USA; [Obeid, L.] Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC USA	Medical University of South Carolina; Medical University of South Carolina; Medical University of South Carolina; US Department of Veterans Affairs; Veterans Health Administration (VHA); Ralph H Johnson VA Medical Center	Voelkel-Johnson, C (corresponding author), Med Univ S Carolina, Dept Microbiol & Immunol, POB 250504,173 Ashley Ave, Charleston, SC 29403 USA.	johnsocv@musc.edu		obeid, lina/0000-0002-0734-0847	NCI NIH HHS [R01 CA088932-07, CA-097132, R01 CA088932, CA-088932, P01 CA097132-060004, P01CA097132, P01 CA097132] Funding Source: Medline; NCRR NIH HHS [P20 RR017698, P20 RR017698-02, P20 RR017698-01, P20 RR017698-03, C06 RR018823, 1P20-RR17698] Funding Source: Medline; NIA NIH HHS [R01 AG016583, AG016583] Funding Source: Medline; NIDCR NIH HHS [DE016572, R01 DE016572, R01 DE016572-04] Funding Source: Medline; NIEHS NIH HHS [1T32ES012878, T32 ES012878] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA088932, P01CA097132] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [C06RR018823, P20RR017698] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [R01DE016572] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [T32ES012878] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG016583] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Ashkenazi A, 2008, J CLIN INVEST, V118, P1979, DOI 10.1172/JCI34359; BARUA S, 2008, MOL PHARM IN PRESS, DOI DOI 10.1021/MP80057J; Basnakian AG, 2005, AM J PHYSIOL-RENAL, V288, pF308, DOI 10.1152/ajprenal.00204.2004; Beckman M, 2004, APOPTOSIS, V9, P363, DOI 10.1023/B:APPT.0000025813.75258.b5; Birbes H, 2005, BIOCHEM J, V386, P445, DOI 10.1042/BJ20041627; BOSE R, 1995, CELL, V82, P405, DOI 10.1016/0092-8674(95)90429-8; Charles AG, 2001, CANCER CHEMOTH PHARM, V47, P444, DOI 10.1007/s002800000265; Cremesti A, 2001, J BIOL CHEM, V276, P23954, DOI 10.1074/jbc.M101866200; de Jong S, 2001, CANCER METAST REV, V20, P51, DOI 10.1023/A:1013112624971; Dohi T, 2004, J BIOL CHEM, V279, P34087, DOI 10.1074/jbc.C400236200; Eto M, 2003, PROSTATE, V57, P66, DOI 10.1002/pros.10275; Faleiro L, 2000, J CELL BIOL, V151, P951, DOI 10.1083/jcb.151.5.951; Ferrando-May E, 2001, CELL DEATH DIFFER, V8, P495, DOI 10.1038/sj.cdd.4400837; Garzotto M, 1999, CANCER RES, V59, P5194; Gulbins E, 2003, ONCOGENE, V22, P7070, DOI 10.1038/sj.onc.1207146; Huerta S, 2007, J SURG RES, V142, P184, DOI 10.1016/j.jss.2006.12.551; Jaattela M, 1998, EMBO J, V17, P6124, DOI 10.1093/emboj/17.21.6124; Kamada S, 2005, MOL CELL BIOL, V25, P9469, DOI 10.1128/MCB.25.21.9469-9477.2005; Kamada S, 2005, J BIOL CHEM, V280, P857, DOI 10.1074/jbc.C400538200; Karahatay S, 2007, CANCER LETT, V256, P101, DOI 10.1016/j.canlet.2007.06.003; Kelley SK, 2001, J PHARMACOL EXP THER, V299, P31; Kitatani K, 2006, J BIOL CHEM, V281, P36793, DOI 10.1074/jbc.M608137200; Koschny R, 2007, J MOL MED, V85, P923, DOI 10.1007/s00109-007-0194-1; Koybasi S, 2004, J BIOL CHEM, V279, P44311, DOI 10.1074/jbc.M406920200; Kroesen BJ, 2003, J BIOL CHEM, V278, P14723, DOI 10.1074/jbc.M210756200; MacFarlane M, 2003, TOXICOL LETT, V139, P89, DOI 10.1016/S0378-4274(02)00422-8; Mizutani Y, 2005, BIOCHEM J, V390, P263, DOI 10.1042/BJ20050291; Moulin M, 2007, APOPTOSIS, V12, P1703, DOI 10.1007/s10495-007-0096-2; Ndozangue-Touriguine O, 2008, ONCOGENE, V27, P6012, DOI 10.1038/onc.2008.197; Ogretmen B, 2004, NAT REV CANCER, V4, P604, DOI 10.1038/nrc1411; Ogretmen B, 2002, J BIOL CHEM, V277, P12960, DOI 10.1074/jbc.M110699200; Peter Marcus E, 2004, Biochem J, V382, pe1; Pewzner-Jung Y, 2006, J BIOL CHEM, V281, P25001, DOI 10.1074/jbc.R600010200; Provenzani A, 2006, CARCINOGENESIS, V27, P1323, DOI 10.1093/carcin/bgi377; Riebeling C, 2003, J BIOL CHEM, V278, P43452, DOI 10.1074/jbc.M307104200; Selzner M, 2001, CANCER RES, V61, P1233; Senkal CE, 2007, MOL CANCER THER, V6, P712, DOI 10.1158/1535-7163.MCT-06-0558; Sharpe JC, 2004, BBA-MOL CELL RES, V1644, P107, DOI 10.1016/j.bbamcr.2003.10.016; Siskind LJ, 2000, J BIOL CHEM, V275, P38640, DOI 10.1074/jbc.C000587200; Stiban J, 2008, J LIPID RES, V49, P625, DOI 10.1194/jlr.M700480-JLR200; Thomas RL, 1999, J BIOL CHEM, V274, P30580, DOI 10.1074/jbc.274.43.30580; Tran EJ, 2006, CELL, V125, P1041, DOI 10.1016/j.cell.2006.05.027; Ueda N, 2001, J AM SOC NEPHROL, V12, P2384, DOI 10.1681/ASN.V12112384; Venkataraman K, 2002, J BIOL CHEM, V277, P35642, DOI 10.1074/jbc.M205211200; Voelkel-Johnson C, 2005, MOL CANCER THER, V4, P1320, DOI 10.1158/1535-7163.MCT-05-0086; Widlak P, 2005, J CELL BIOCHEM, V94, P1078, DOI 10.1002/jcb.20409; Wiley SR, 1995, IMMUNITY, V3, P673, DOI 10.1016/1074-7613(95)90057-8; Wilson MR, 1998, CELL DEATH DIFFER, V5, P646, DOI 10.1038/sj.cdd.4400394; Xu ZW, 2005, J LIPID RES, V46, P1229, DOI 10.1194/jlr.M500001-JLR200; Yasuhara N, 1997, GENES CELLS, V2, P55, DOI 10.1046/j.1365-2443.1997.1010302.x	50	106	109	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2009	28	8					1132	1141		10.1038/onc.2008.468	http://dx.doi.org/10.1038/onc.2008.468			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	412KE	19137010	Green Accepted			2022-12-28	WOS:000263722900008
J	Takai, A; Toyoshima, T; Uemura, M; Kitawaki, Y; Marusawa, H; Hiai, H; Yamada, S; Okazaki, IM; Honjo, T; Chiba, T; Kinoshita, K				Takai, A.; Toyoshima, T.; Uemura, M.; Kitawaki, Y.; Marusawa, H.; Hiai, H.; Yamada, S.; Okazaki, I. M.; Honjo, T.; Chiba, T.; Kinoshita, K.			A novel mouse model of hepatocarcinogenesis triggered by AID causing deleterious p53 mutations	ONCOGENE			English	Article						hepatic cancer; stem cell marker; activation-induced cytidine deaminase; Cre recombinase; somatic mutation; animal model	INDUCED CYTIDINE DEAMINASE; HEPATOCELLULAR-CARCINOMA; CONSTITUTIVE EXPRESSION; STEM-CELLS; HBX GENE; CANCER; VIRUS; STEATOHEPATITIS; PROLIFERATION; GENERATION	Activation-induced cytidine deaminase (AID), the only enzyme that is known to be able to induce mutations in the human genome, is required for somatic hypermutation and class-switch recombination in B lymphocytes. Recently, we showed that AID is implicated in the pathogenesis of human cancers including hepatitis C virus (HCV)-induced human hepatocellular carcinoma (HCC). In this study, we established a new AID transgenic mouse model (TNAP-AID) in which AID is expressed in cells producing tissue-nonspeci. c alkaline phosphatase (TNAP), which is a marker of primordial germ cells and immature stem cells, including ES cells. High expression of TNAP was found in the liver of the embryos and adults of TNAP-AID mice. HCC developed in 27% of these mice at the age of approximately 90 weeks. The HCC that developed in TNAP-AID mice expressed alpha-fetoprotein and had deleterious mutations in the tumour suppressor gene Trp53, some of which corresponded to those found in human cancer. In conclusion, TNAP-AID is a mouse model that spontaneously develops HCC, sharing genetic and phenotypic features with human HCC, which develops in the inflamed liver as a result of the accumulation of genetic changes.	[Toyoshima, T.; Uemura, M.; Hiai, H.; Kinoshita, K.] Shiga Med Ctr Res Inst, Shiga 5248524, Japan; [Takai, A.; Marusawa, H.; Chiba, T.] Kyoto Univ, Grad Sch Med, Dept Gastroenterol & Hepatol, Kyoto, Japan; [Kitawaki, Y.; Okazaki, I. M.; Honjo, T.] Kyoto Univ, Grad Sch Med, Dept Immunol & Genom Med, Kyoto, Japan; [Yamada, S.] Immunobiol Labs Co Ltd, Mikasa Lab, Mikasa, Japan	Kyoto University; Kyoto University; Immuno-Biological Laboratories Co. Ltd.	Kinoshita, K (corresponding author), Shiga Med Ctr Res Inst, 5-4-1930, Shiga 5248524, Japan.	kkinoshi.shigamed@mac.com	Honjo, Tasuku/N-4470-2016	Marusawa, Hiroyuki/0000-0002-4286-2712; Okazaki, Il-mi/0000-0001-8644-0100	Grant-in-Aid for Scientific Research [17013042, 18390122]; Takeda Science Foundation	Grant-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI)); Takeda Science Foundation(Takeda Science Foundation (TSF))	We thank Dr Andras Nagy for his generous gift of TNAP-Cre mice, Dr Takashi Shinohara for suggesting the choice of the Cre mouse strain, Dr Yoshinobu Toda for the preparation of tissue sections and Dr Masayuki Tsuji for technical help with the immunohistochemical analyses. We also thank Dr Sidonia Fagarasan for critical reading of the manuscript and discussions. This study was supported by Grant-in-Aid for Scientific Research (17013042 and 18390122) and the Takeda Science Foundation.	Endo Y, 2007, ONCOGENE, V26, P5587, DOI 10.1038/sj.onc.1210344; Factor VM, 1997, CANCER RES, V57, P2089; Fan CY, 1998, J BIOL CHEM, V273, P15639, DOI 10.1074/jbc.273.25.15639; Honjo T, 2002, ANNU REV IMMUNOL, V20, P165, DOI 10.1146/annurev.immunol.20.090501.112049; Horie Y, 2004, J CLIN INVEST, V113, P1774, DOI 10.1172/JCI200420513; Katzenellenbogen M, 2006, CANCER RES, V66, P4001, DOI 10.1158/0008-5472.CAN-05-2937; KIM CM, 1991, NATURE, V351, P317, DOI 10.1038/351317a0; Kinoshita K, 2006, INT J HEMATOL, V83, P201, DOI 10.1532/IJH97.06011; KOIKE K, 1994, HEPATOLOGY, V19, P810, DOI 10.1002/hep.1840190403; Koike K, 2002, J GASTROEN HEPATOL, V17, P394, DOI 10.1046/j.1440-1746.2002.02763.x; Komori J, 2008, HEPATOLOGY, V47, P888, DOI 10.1002/hep.22125; Kotani A, 2005, P NATL ACAD SCI USA, V102, P4506, DOI 10.1073/pnas.0500830102; Kou T, 2007, INT J CANCER, V120, P469, DOI 10.1002/ijc.22292; Kues WA, 2005, BIOL REPROD, V72, P1020, DOI 10.1095/biolreprod.104.031229; Lomeli H, 2000, GENESIS, V26, P116, DOI 10.1002/(SICI)1526-968X(200002)26:2<116::AID-GENE4>3.0.CO;2-X; Ma W, 2006, ONCOGENE, V25, P4207, DOI 10.1038/sj.onc.1209450; Maeda S, 2005, CELL, V121, P977, DOI 10.1016/j.cell.2005.04.014; Marusawa H, 2008, INT J BIOCHEM CELL B, V40, P1399, DOI 10.1016/j.biocel.2008.01.018; Matsumoto Y, 2007, NAT MED, V13, P470, DOI 10.1038/nm1566; Morgan HD, 2004, J BIOL CHEM, V279, P52353, DOI 10.1074/jbc.M407695200; MURAKAMI H, 1993, CANCER RES, V53, P1719; Muto T, 2006, P NATL ACAD SCI USA, V103, P2752, DOI 10.1073/pnas.0510970103; Nakau M, 2002, CANCER RES, V62, P4549; Okazaki I, 2003, J EXP MED, V197, P1173, DOI 10.1084/jem.20030275; Petitjean A, 2007, HUM MUTAT, V28, P622, DOI 10.1002/humu.20495; Riehle KJ, 2008, J EXP MED, V205, P91, DOI 10.1084/jem.20070820; Sakurai T, 2006, P NATL ACAD SCI USA, V103, P10544, DOI 10.1073/pnas.0603499103; SANDGREN EP, 1989, ONCOGENE, V4, P715; Schreck S, 2006, J PATHOL, V210, P26, DOI 10.1002/path.2014; Sell S, 2001, HEPATOLOGY, V33, P738, DOI 10.1053/jhep.2001.21900; Thorgeirsson SS, 2002, NAT GENET, V31, P339, DOI 10.1038/ng0802-339; Tsuji M, 2008, IMMUNITY, V29, P261, DOI 10.1016/j.immuni.2008.05.014; URVEN LE, 1993, BIOL REPROD, V48, P564, DOI 10.1095/biolreprod48.3.564; Vogelstein B, 2004, NAT MED, V10, P789, DOI 10.1038/nm1087; Wang L, 2005, BIOL REPROD, V73, P149, DOI 10.1095/biolreprod.104.037150; Yoshikawa K, 2002, SCIENCE, V296, P2033, DOI 10.1126/science.1071556; Zuker M, 2003, NUCLEIC ACIDS RES, V31, P3406, DOI 10.1093/nar/gkg595	37	56	56	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 29	2009	28	4					469	478		10.1038/onc.2008.415	http://dx.doi.org/10.1038/onc.2008.415			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	400KM	18997814	Green Submitted			2022-12-28	WOS:000262866500001
J	Clark, ES; Brown, B; Whigham, AS; Kochaishvili, A; Yarbrough, WG; Weaver, AM				Clark, E. S.; Brown, B.; Whigham, A. S.; Kochaishvili, A.; Yarbrough, W. G.; Weaver, A. M.			Aggressiveness of HNSCC tumors depends on expression levels of cortactin, a gene in the 11q13 amplicon	ONCOGENE			English	Article						cortactin; secretion; tumor progression; HNSCC; head and neck cancer	SQUAMOUS-CELL CARCINOMA; GROWTH-FACTOR-RECEPTOR; CLATHRIN-COATED PITS; BREAST-CANCER; EPITHELIAL-CELLS; POOR-PROGNOSIS; FACTOR-ALPHA; CYCLIN D1; HEPATOCELLULAR-CARCINOMA; ACTIN POLYMERIZATION	11q13 amplification is a late-stage event in several cancers that is often associated with poor prognosis. Among 11q13-amplified genes, the actin assembly protein cortactin/CTTN is considered a likely candidate for direct involvement in tumor progression because of its cell motility-enhancing functions. We modulated cortactin expression in head and neck squamous cell carcinoma (HNSCC) cell lines. Cortactin expression levels directly correlated with tumor size, vascularization and cell proliferation in an orthotopic HNSCC in vivo model. In contrast, under normal in vitro culture conditions, cortactin expression levels had no effect on cell proliferation. However, cell lines in which cortactin expression was reduced by knockdown (KD) grew poorly in vitro under harsh conditions of growth factor deprivation, anchorage independence and space constraint. In contrast, overexpression of cortactin enhanced in vitro growth under the same harsh conditions. Surprisingly, defects in growth factor-independent proliferation of cortactin-KD cells were rescued by coculture with cortactin-expressing cells. As the cocultured cells are separated by permeable filters, cortactin-expressing cells must secrete growth-supporting autocrine factors to rescue the cortactin-KD cells. Overall, cortactin expression modulates multiple cellular traits that may allow survival in a tumor environment, suggesting that the frequent overexpression of cortactin in tumors is not an epiphenomenon but rather promotes tumor aggressiveness.	[Weaver, A. M.] Vanderbilt Univ, Sch Med, Dept Canc Biol, Nashville, TN 37232 USA; [Brown, B.; Whigham, A. S.; Kochaishvili, A.; Yarbrough, W. G.] Vanderbilt Univ, Dept Otolaryngol, Nashville, TN 37232 USA; [Weaver, A. M.] Vanderbilt Univ, Dept Pathol, Nashville, TN 37232 USA	Vanderbilt University; Vanderbilt University; Vanderbilt University	Weaver, AM (corresponding author), Vanderbilt Univ, Sch Med, Dept Canc Biol, 23rd Ave S Pierce,448 PRB, Nashville, TN 37232 USA.	alissa.weaver@vanderbilt.edu	Clark, Emily/GVR-7159-2022; Yarbrough, Wendell G/A-1969-2011; Whigham, Amy/AAT-7183-2020	Whigham, Amy/0000-0001-7648-1988	Robert J Kleberg Jr and Helen C Kleberg Foundation;  [1R21DE018244]; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R21DE018244] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM075126] Funding Source: NIH RePORTER	Robert J Kleberg Jr and Helen C Kleberg Foundation; ; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We thank Julie Maier, Izu Iwueke and the IHC core for technical support; and Drs Ambra Pozzi and Vito Quaranta for advice. This work was supported by 1R21DE018244 to AMW. WGY, BB, ASW, and AK are partially supported through a grant from the Robert J Kleberg Jr and Helen C Kleberg Foundation. An endowment supporting the Barry Baker Laboratory for Head and Neck Oncology as well as the Robert J Kleberg Jr and Helen C Kleberg Foundation and an Ingram Professorship to WGY also provided support for this project.	AKERVALL JA, 1995, CANCER, V76, P853, DOI 10.1002/1097-0142(19950901)76:5<853::AID-CNCR2820760520>3.0.CO;2-6; BATES SE, 1990, ENDOCRINOLOGY, V126, P596, DOI 10.1210/endo-126-1-596; Bryce NS, 2005, CURR BIOL, V15, P1276, DOI 10.1016/j.cub.2005.06.043; Cao H, 2005, NAT CELL BIOL, V7, P483, DOI 10.1038/ncb1246; Cao H, 2003, MOL CELL BIOL, V23, P2162, DOI 10.1128/MCB.23.6.2162-2170.2003; Chuma M, 2004, J HEPATOL, V41, P629, DOI 10.1016/j.jhep.2004.06.018; Clark ES, 2008, EUR J CELL BIOL, V87, P581, DOI 10.1016/j.ejcb.2008.01.008; Clark ES, 2007, CANCER RES, V67, P4227, DOI 10.1158/0008-5472.CAN-06-3928; Debnath J, 2005, NAT REV CANCER, V5, P675, DOI 10.1038/nrc1695; Debnath J, 2003, METHODS, V30, P256, DOI 10.1016/S1046-2023(03)00032-X; ETHIER SP, 1991, CELL GROWTH DIFFER, V2, P593; Ethier SP, 1996, MOL CARCINOGEN, V15, P134; Freier K, 2006, GENE CHROMOSOME CANC, V45, P118, DOI 10.1002/gcc.20270; Gabrilove JL, 2001, ONCOLOGIST, V6, P4; Gibcus JH, 2008, BRIT J CANCER, V98, P950, DOI 10.1038/sj.bjc.6604246; Gibcus JH, 2007, CLIN CANCER RES, V13, P6257, DOI 10.1158/1078-0432.CCR-07-1247; Greer RO, 2007, ORAL ONCOL, V43, P735, DOI 10.1016/j.oraloncology.2006.09.007; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hiratsuka S, 2006, NAT CELL BIOL, V8, P1369, DOI 10.1038/ncb1507; Hofman P, 2008, BRIT J CANCER, V98, P956, DOI 10.1038/sj.bjc.6604245; Hui R, 1998, ONCOGENE, V17, P1053, DOI 10.1038/sj.onc.1202023; Karnoub AE, 2007, NATURE, V449, P557, DOI 10.1038/nature06188; Katsube T, 2004, ARCH BIOCHEM BIOPHYS, V427, P79, DOI 10.1016/j.abb.2004.04.015; Li YS, 2001, CANCER RES, V61, P6906; Luo ML, 2006, CANCER RES, V66, P11690, DOI 10.1158/0008-5472.CAN-06-1484; MARKOWITZ SD, 1990, J CLIN INVEST, V86, P356, DOI 10.1172/JCI114709; MEREDITH SD, 1995, ARCH OTOLARYNGOL, V121, P790; Merrifield CJ, 2005, CELL, V121, P593, DOI 10.1016/j.cell.2005.03.015; Myllykangas S, 2007, SEMIN CANCER BIOL, V17, P42, DOI 10.1016/j.semcancer.2006.10.005; Ohoka Y, 1998, GENES CELLS, V3, P603, DOI 10.1046/j.1365-2443.1998.00216.x; Ormandy CJ, 2003, BREAST CANCER RES TR, V78, P323, DOI 10.1023/A:1023033708204; Ostman A, 2004, CYTOKINE GROWTH F R, V15, P275, DOI 10.1016/j.cytogfr.2004.03.002; RANGAN SRS, 1972, CANCER, V29, P117, DOI 10.1002/1097-0142(197201)29:1<117::AID-CNCR2820290119>3.0.CO;2-R; Rodrigo JP, 2000, CLIN CANCER RES, V6, P3177; SCHUURING E, 1995, GENE, V159, P83, DOI 10.1016/0378-1119(94)00562-7; SCHUURING E, 1992, ONCOGENE, V7, P355; Shores CG, 1998, LARYNGOSCOPE, V108, P1358, DOI 10.1097/00005537-199809000-00019; SOMERS KD, 1990, ONCOGENE, V5, P915; Takes RP, 1997, ARCH OTOLARYNGOL, V123, P412; Tsao MS, 1996, EXP CELL RES, V223, P268, DOI 10.1006/excr.1996.0081; Uruno T, 2001, NAT CELL BIOL, V3, P259, DOI 10.1038/35060051; van Rossum AGSH, 2006, BMC CANCER, V6, DOI 10.1186/1471-2407-6-58; Weaver AM, 2008, CANCER LETT, V265, P157, DOI 10.1016/j.canlet.2008.02.066; Weaver AM, 2001, CURR BIOL, V11, P370, DOI 10.1016/S0960-9822(01)00098-7; WEICHSELBAUM RR, 1986, P NATL ACAD SCI USA, V83, P2684, DOI 10.1073/pnas.83.8.2684; WILLIAMS ME, 1993, ARCH OTOLARYNGOL, V119, P1238; WU H, 1991, MOL CELL BIOL, V11, P5113, DOI 10.1128/MCB.11.10.5113; WU H, 1993, J CELL BIOL, V120, P1417, DOI 10.1083/jcb.120.6.1417; Yuan BZ, 2003, J MOL DIAGN, V5, P48, DOI 10.1016/S1525-1578(10)60451-5; Zhu JW, 2005, J CELL SCI, V118, P807, DOI 10.1242/jcs.01668	50	68	68	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 22	2009	28	3					431	444		10.1038/onc.2008.389	http://dx.doi.org/10.1038/onc.2008.389			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	395UZ	18931703	Green Accepted			2022-12-28	WOS:000262550300011
J	Li, S; Szymborski, A; Miron, MJ; Marcellus, R; Binda, O; Lavoie, JN; Branton, PE				Li, S.; Szymborski, A.; Miron, M-J; Marcellus, R.; Binda, O.; Lavoie, J. N.; Branton, P. E.			The adenovirus E4orf4 protein induces growth arrest and mitotic catastrophe in H1299 human lung carcinoma cells	ONCOGENE			English	Article						adenovirus; E4orf4; cell death; growth arrest; mitotic catastrophe; apoptosis	CYCLIN-E OVEREXPRESSION; P53-INDEPENDENT APOPTOSIS; SACCHAROMYCES-CEREVISIAE; MITOCHONDRIAL CONTROL; TRANSFORMED-CELLS; PHOSPHATASE 2A; DEATH; PROLIFERATION; CANCER; INHIBITION	The human adenovirus E4orf4 protein, when expressed alone, induces p53-independent death in a wide range of cancer cells. Earlier studies by our groups suggested that although in some cases cell death can be associated with some hallmarks of apoptosis, it is not always affected by caspase inhibitors. Thus it is unlikely that E4orf4-induced cell death occurs uniquely through apoptosis. In the present studies using H1299 human lung carcinoma cells as a model system we found that death is induced in the absence of activation of any of the caspases tested, accumulation of reactive oxygen species, or release of cytochrome c from mitochondria. E4orf4 caused a substantial change in cell morphology, including vigorous membrane blebbing, multiple nuclei in many cells and increased cell volume. Most of these characteristics are not typical of apoptosis, but they are of necrosis. FACS analysis and western blotting for cell cycle markers showed that E4orf4-expressing cells became arrested in G(2)/M and also accumulated high levels of cyclin E. The presence of significant numbers of tetraploid and polyploid cells and some cells with micronuclei suggested that E4orf4 appears to induce death in these cells through a process resulting from mitotic catastrophe.	[Li, S.; Szymborski, A.; Miron, M-J; Binda, O.; Branton, P. E.] McGill Univ, Dept Biochem, Montreal, PQ H3G 1Y6, Canada; [Lavoie, J. N.] Univ Laval, Ctr Rech Cancerol, Hotel Dieu Quebec, Quebec City, PQ, Canada; [Marcellus, R.] Gemin X Biotechnol Inc, Montreal, PQ, Canada; [Branton, P. E.] McGill Univ, Dept Oncol, Montreal, PQ H3G 1Y6, Canada; [Branton, P. E.] McGill Univ, McGill Canc Ctr, Montreal, PQ H3G 1Y6, Canada	McGill University; Laval University; McGill University; McGill University	Branton, PE (corresponding author), McGill Univ, Dept Biochem, McIntyre Med Sci Bldg,Room 701,365 Promenade Sir, Montreal, PQ H3G 1Y6, Canada.	philip.branton@mcgill.ca	Binda, Olivier/A-5941-2009	Binda, Olivier/0000-0002-1539-0828; Lavoie, Josee N/0000-0001-6912-1132	Canadian Cancer Society through the National Cancer Institute of Canada; Canadian Institutes of Health Research; Gemin X Biotechnologics Inc	Canadian Cancer Society through the National Cancer Institute of Canada; Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR)); Gemin X Biotechnologics Inc	We thank Dennis Takayesu for technical support and Denis Paquette, Helen Chan and Mark Watson from Gemin X Biotechnologies Inc. for making some of the DNA constructs and for help in some experimental protocols. We also thank Eric Massicotte and Nathalie Tessier of Institut des reserches cliniques de Montreal and Ken McDonald at McGill Life Sciences Complex for performing flow cytometry analyses, and Jacynthe Lalibete from the Department of Pharmacology and Therapeutics at McGill University for confocal microscopy study. Gordon Shore provided anti-caspase and anti-actin antibodies. This work was supported by grants from the Canadian Cancer Society through the National Cancer Institute of Canada (PEB, JNL), the Canadian Institutes of Health Research (PEB, JNL), and from Gemin X Biotechnologics Inc (PEB).	BACCHETTI S, 1993, INT J ONCOL, V3, P781; Bartek J, 2007, CURR OPIN CELL BIOL, V19, P238, DOI 10.1016/j.ceb.2007.02.009; Blagosklonny MV, 2007, CELL CYCLE, V6, P70, DOI 10.4161/cc.6.1.3682; Blagosklonny MV, 2002, CELL CYCLE, V1, P103, DOI 10.4161/cc.1.2.108; Castedo M, 2004, ONCOGENE, V23, P2825, DOI 10.1038/sj.onc.1207528; COSSARIZZA A, 1993, BIOCHEM BIOPH RES CO, V197, P40, DOI 10.1006/bbrc.1993.2438; Debnath J, 2005, AUTOPHAGY, V1, P66, DOI 10.4161/auto.1.2.1738; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; Elmore S, 2007, TOXICOL PATHOL, V35, P495, DOI 10.1080/01926230701320337; Fadok VA, 1998, CELL DEATH DIFFER, V5, P551, DOI 10.1038/sj.cdd.4400404; Fleury C, 2002, BIOCHIMIE, V84, P131, DOI 10.1016/S0300-9084(02)01369-X; Jaattela M, 2002, ANN MED, V34, P480, DOI 10.1080/078538902321012423; Keck JM, 2007, J CELL BIOL, V178, P371, DOI 10.1083/jcb.200703202; Kelekar A, 2005, ANN NY ACAD SCI, V1066, P259, DOI 10.1196/annals.1363.015; Keyomarsi K, 1997, Prog Cell Cycle Res, V3, P171; Kornitzer D, 2001, J CELL BIOL, V154, P331, DOI 10.1083/jcb.200104104; Koutsami MK, 2006, J PATHOL, V209, P512, DOI 10.1002/path.2005; Kroemer G, 2003, BIOCHEM BIOPH RES CO, V304, P433, DOI 10.1016/S0006-291X(03)00614-4; Kroemer G, 2000, NAT MED, V6, P513, DOI 10.1038/74994; Lavoie JN, 1998, J CELL BIOL, V140, P637, DOI 10.1083/jcb.140.3.637; Lavoie JN, 2000, J CELL BIOL, V150, P1037, DOI 10.1083/jcb.150.5.1037; Leist M, 2001, NAT REV MOL CELL BIO, V2, P589, DOI 10.1038/35085008; Li PF, 1999, EMBO J, V18, P6027, DOI 10.1093/emboj/18.21.6027; Livne A, 2001, J VIROL, V75, P789, DOI 10.1128/JVI.75.2.789-798.2001; Lockshin RA, 2001, NAT REV MOL CELL BIO, V2, P545, DOI 10.1038/35080097; Mansilla S, 2006, CELL CYCLE, V5, P53, DOI 10.4161/cc.5.1.2267; Marcellus RC, 1998, J VIROL, V72, P7144, DOI 10.1128/JVI.72.9.7144-7153.1998; Marcellus RC, 2000, J VIROL, V74, P7869, DOI 10.1128/JVI.74.17.7869-7877.2000; Mazumder S, 2004, CURR CANCER DRUG TAR, V4, P65, DOI 10.2174/1568009043481669; Robert A, 2002, J CELL BIOL, V158, P519, DOI 10.1083/jcb.200201106; Roopchand DE, 2001, ONCOGENE, V20, P5279, DOI 10.1038/sj.onc.1204693; Shtrichman R, 1999, P NATL ACAD SCI USA, V96, P10080, DOI 10.1073/pnas.96.18.10080; Shtrichman R, 1998, J VIROL, V72, P2975, DOI 10.1128/JVI.72.4.2975-2982.1998; Strasser A, 2000, ANNU REV BIOCHEM, V69, P217, DOI 10.1146/annurev.biochem.69.1.217; Tsujimoto Y, 2005, CELL DEATH DIFFER, V12, P1528, DOI 10.1038/sj.cdd.4401777; VOJTA PJ, 1995, BBA-REV CANCER, V1242, P29, DOI 10.1016/0304-419X(95)00002-W; Wang XD, 2001, GENE DEV, V15, P2922	37	38	39	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 22	2009	28	3					390	400		10.1038/onc.2008.393	http://dx.doi.org/10.1038/onc.2008.393			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	395UZ	18955965				2022-12-28	WOS:000262550300007
J	Seng, S; Avraham, HK; Birrane, G; Jiang, S; Li, H; Katz, G; Bass, CE; Zagozdzon, R; Avraham, S				Seng, S.; Avraham, H. K.; Birrane, G.; Jiang, S.; Li, H.; Katz, G.; Bass, C. E.; Zagozdzon, R.; Avraham, S.			NRP/B mutations impair Nrf2-dependent NQO1 induction in human primary brain tumors	ONCOGENE			English	Article						NRP/B mutation; Nrf2; NQO1; primary brain tumors	NUCLEAR-MATRIX PROTEINS; ANTIOXIDANT RESPONSIVE ELEMENTS; DT-DIAPHORASE; CANCER CELLS; GENE; NRF2; EXPRESSION; ENC-1; OXIDOREDUCTASE-1; DIFFERENTIATION	Brain tumors are associated with genetic alterations of oncogenes and tumor suppressor genes. Accumulation of reactive oxygen species (ROS) in cells leads to oxidative stress-induced damage, resulting in tumorigenesis. Here, we showed that the nuclear matrix protein nuclear restricted protein in brain (NRP/B) was colocalized and interacted with NF-E2-related factor 2 (Nrf2). During oxidative stress response, NRP/B expression and its interaction with Nrf2 were upregulated in SH-SY5Y cells. Association of NRP/B with Nrf2 was crucial for NAD(P)H:quinone oxidoreductase 1 (NQO1) expression. NRP/B was localized predominantly in the nucleus of normal brain cells, whereas in primary brain tumors NRP/B was almost exclusively contained in the cytoplasm. In addition, unlike wild-type NRP/B, the expression of NRP/B mutants isolated from primary brain tumors was found in the cytoplasm, and these mutants failed to induce Nrf2-dependent NQO1 transcription. Thus, NRP/B mutations and their altered localization resulted in changes in NRP/B function and deregulation of Nrf2-dependent NQO1 activation in brain tumors. This study provides insights into the mechanism by which the NRP/B modulates Nrf2-dependent NQO1 induction in cellular protection against ROS in brain tumors.	[Seng, S.; Avraham, H. K.; Birrane, G.; Jiang, S.; Li, H.; Katz, G.; Bass, C. E.; Zagozdzon, R.; Avraham, S.] Harvard Univ, Sch Med, Harvard Inst Med, Beth Israel Deaconess Med Ctr,Div Expt Med, Boston, MA 02115 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School	Avraham, S (corresponding author), Harvard Univ, Sch Med, Harvard Inst Med, Beth Israel Deaconess Med Ctr,Div Expt Med, 4 Blackfan Circle, Boston, MA 02115 USA.	savraham@bidmc.harvard.edu	Zagozdzon, Radoslaw/AAC-4298-2019; Zagozdzon, Radoslaw/K-2141-2012	Zagozdzon, Radoslaw/0000-0002-7957-2372; Birrane, Gabriel/0000-0002-1759-5499; Katz, Gabrielle/0000-0002-9233-5654; Avraham, Hava/0000-0002-7545-3640; Bass, Caroline/0000-0002-5856-6387	NIH [HL80699, CA096805]; Department of Defense Cancer Concept Award; NATIONAL CANCER INSTITUTE [R01CA096805] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL080699] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Department of Defense Cancer Concept Award(United States Department of Defense); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	We thank Janet Delahanty and Makara Men for editing the paper. This study was supported by NIH grants HL80699 (SA), CA096805 (HKA) and the Department of Defense Cancer Concept Award (SA).	Alberti I, 2000, J CELL BIOCHEM, V79, P471, DOI 10.1002/1097-4644(20001201)79:3<471::AID-JCB120>3.3.CO;2-F; Andreassi MG, 2003, MUTAT RES-REV MUTAT, V543, P67, DOI 10.1016/S1383-5742(02)00089-3; Asher G, 2002, P NATL ACAD SCI USA, V99, P3099, DOI 10.1073/pnas.052706799; Asher G, 2001, P NATL ACAD SCI USA, V98, P1188, DOI 10.1073/pnas.021558898; BARDWELL VJ, 1994, GENE DEV, V8, P1664, DOI 10.1101/gad.8.14.1664; Begleiter A, 1997, ONCOL RES, V9, P371; Berezney R, 1995, INT REV CYTOL, V162A, P1; Bode J, 2000, J CELL BIOCHEM, P3; Dalton TD, 1999, ANNU REV PHARMACOL, V39, P67, DOI 10.1146/annurev.pharmtox.39.1.67; FEY EG, 1984, P NATL ACAD SCI-BIOL, V81, P4409, DOI 10.1073/pnas.81.14.4409; Fujita M, 2001, CANCER RES, V61, P7722; Furukawa M, 2005, MOL CELL BIOL, V25, P162, DOI 10.1128/MCB.25.1.162-171.2005; Getzenberg RH, 1996, CANCER RES, V56, P1690; Hammarsund M, 2004, HUM MOL GENET, V13, P2925, DOI 10.1093/hmg/ddh315; He D, 1995, INT REV CYTOL, V162B, P1; Hernandez MC, 1998, EXP CELL RES, V242, P470, DOI 10.1006/excr.1998.4109; Hernandez MC, 1997, J NEUROSCI, V17, P3038; Itoh K, 1999, GENE DEV, V13, P76, DOI 10.1101/gad.13.1.76; Kim TA, 2000, GENE, V255, P105, DOI 10.1016/S0378-1119(00)00297-3; Kim TA, 1998, J CELL BIOL, V141, P553, DOI 10.1083/jcb.141.3.553; Konety BR, 1999, J CELL BIOCHEM, P183; Lee JM, 2004, J BIOCHEM MOL BIOL, V37, P139; Liang XQ, 2004, ONCOGENE, V23, P5890, DOI 10.1038/sj.onc.1207776; Loidl P, 1995, INT REV CYTOL, V162B, P377; Long DJ, 2002, CANCER RES, V62, P3030; Louis DN, 2002, CANCER CELL, V1, P125, DOI 10.1016/S1535-6108(02)00040-5; Maher EA, 2001, GENE DEV, V15, P1311, DOI 10.1101/gad.891601; Nguyen T, 2003, J BIOL CHEM, V278, P4536, DOI 10.1074/jbc.M207293200; Nioi P, 2004, MUTAT RES-FUND MOL M, V555, P149, DOI 10.1016/j.mrfmmm.2004.05.023; RILEY RJ, 1992, BIOCHEM PHARMACOL, V43, P1657, DOI 10.1016/0006-2952(92)90694-E; Saunders WS, 2000, P NATL ACAD SCI USA, V97, P303, DOI 10.1073/pnas.97.1.303; Seng S, 2007, CANCER RES, V67, P8596, DOI 10.1158/0008-5472.CAN-06-3785; Venugopal R, 1996, P NATL ACAD SCI USA, V93, P14960, DOI 10.1073/pnas.93.25.14960; Wakabayashi N, 2004, P NATL ACAD SCI USA, V101, P2040, DOI 10.1073/pnas.0307301101; Wasserman WW, 1997, P NATL ACAD SCI USA, V94, P5361, DOI 10.1073/pnas.94.10.5361; Wechsler-Reya R, 2001, ANNU REV NEUROSCI, V24, P385, DOI 10.1146/annurev.neuro.24.1.385; Zipper LM, 2002, J BIOL CHEM, V277, P36544, DOI 10.1074/jbc.M206530200	37	16	17	1	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 22	2009	28	3					378	389		10.1038/onc.2008.396	http://dx.doi.org/10.1038/onc.2008.396			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	395UZ	18981988				2022-12-28	WOS:000262550300006
J	de Muga, SV; Timpson, P; Cubells, L; Evans, R; Hayes, TE; Rentero, C; Hegemann, A; Reverter, M; Leschner, J; Pol, A; Tebar, F; Daly, RJ; Enrich, C; Grewal, T				Vila de Muga, S.; Timpson, P.; Cubells, L.; Evans, R.; Hayes, T. E.; Rentero, C.; Hegemann, A.; Reverter, M.; Leschner, J.; Pol, A.; Tebar, F.; Daly, R. J.; Enrich, C.; Grewal, T.			Annexin A6 inhibits Ras signalling in breast cancer cells	ONCOGENE			English	Article						Annexin A6; p120GAP; Ras; EGF receptor; breast cancer	GTPASE-ACTIVATING PROTEIN; GROWTH-FACTOR RECEPTOR; COMPARATIVE GENOMIC HYBRIDIZATION; CARCINOMA-CELLS; H-RAS; INTERACTION NETWORK; MEMBRANE-BINDING; RAF-1 ACTIVATION; PLASMA-MEMBRANE; GENETIC SCREEN	Overexpression of epidermal growth factor receptor (EGFR) is associated with enhanced activation of wild-type (hyperactive) Ras in breast cancer. Little is known about the regulation of Ras inactivation and GTPase-activating proteins (GAPs), such as p120GAP, in cells with hyperactive Ras. Recently, we showed that in EGFR-over-expressing A431 cells, which lack endogenous Annexin A6 (AnxA6), ectopic expression of AnxA6 stimulates membrane recruitment of p120GAP to modulate Ras signalling. We now demonstrate that, AnxA6 is downregulated in a number of EGFR-overexpressing and estrogen receptor (ER)-negative breast cancer cells. In these cells, AnxA6 overexpression promotes Ca2+ - and EGF-inducible membrane targeting of p120GAP. In ER-negative MDA-MB-436 cells, overexpression of p120GAP, but not CAPRI or a p120GAP mutant lacking the AnxA6-binding domain inhibits Ras/MAPK activity. AnxA6 knockdown in MDA-MB-436 increases Ras activity and cell proliferation in anchorage-independent growth assays. Furthermore, AnxA6 co-immunoprecipitates with H-Ras in a Ca2+ - and EGF-inducible manner and fluorescence resonance energy transfer (FRET) microscopy confirmed that AnxA6 is in close proximity of active (G12V), but not inactive (S17N) H-Ras. Thus, association of AnxA6 with H-Ras-containing protein complexes may contribute to regulate p120GAP/Ras assembly in EGFR-overexpressing and ER-negative breast cancer cells.	[Evans, R.; Hayes, T. E.; Hegemann, A.; Leschner, J.; Grewal, T.] Univ Sydney, Fac Pharm A15, Sydney, NSW 2006, Australia; [Vila de Muga, S.; Cubells, L.; Rentero, C.; Reverter, M.; Tebar, F.; Enrich, C.] Univ Barcelona, Fac Med, Dept Cellular Biol, Barcelona 7, Spain; [Timpson, P.; Daly, R. J.] Garvan Inst Med Res, Sydney, NSW, Australia; [Pol, A.; Enrich, C.] Univ Barcelona, Fac Med, IDIBAPS, Barcelona 7, Spain	University of Sydney; University of Barcelona; Garvan Institute of Medical Research; University of Barcelona; Hospital Clinic de Barcelona; IDIBAPS	Grewal, T (corresponding author), Univ Sydney, Fac Pharm A15, Sydney, NSW 2006, Australia.	enrich@ub.edu; tgrewal@pharm.usyd.edu.au	Pol, Albert/M-1865-2014; Timpson, Paul/A-9429-2016; Daly, Roger J/C-8179-2009; timpson, paul/E-1618-2011; Rentero Alfonso, Carles/L-4430-2017; Tebar, Francesc/H-1498-2015	Pol, Albert/0000-0002-1750-1085; Rentero Alfonso, Carles/0000-0003-4684-0278; Tebar, Francesc/0000-0002-9522-9726; Enrich, Carlos/0000-0003-0382-2993; Timpson, Paul/0000-0002-5514-7080; Grewal, Thomas/0000-0002-7937-8887; Daly, Roger/0000-0002-5739-8027	Ministerio de Educacion y Ciencia, Spain [BFU2006-01151, V-2006-RET2008-0, PR-2006-0142]; National Health and Medical Research Council of Australia [510293, 510294]; National Heart Foundation of Australia [G06S2559]	Ministerio de Educacion y Ciencia, Spain(Spanish Government); National Health and Medical Research Council of Australia(National Health and Medical Research Council (NHMRC) of Australia); National Heart Foundation of Australia(National Heart Foundation of Australia)	We thank Dr Maria Calvo (SCT-UB) for her excellent assistance in confocal microscopy. This study was supported by grants to CE (BFU2006-01151, V-2006-RET2008-0 and fellowship PR-2006-0142 from Ministerio de Educacion y Ciencia, Spain) and TG (510293 and 510294 from the National Health and Medical Research Council of Australia and G06S2559 from the National Heart Foundation of Australia). SV is thankful to Ministerio de Educacion y Ciencia, Spain, (FPI mobility Program) for a short-term fellowship at the laboratory of TG (Sydney, Australia).	Agazie YM, 2003, MOL CELL BIOL, V23, P7875, DOI 10.1128/MCB.23.21.7875-7886.2003; Bernards A, 2005, GROWTH FACTORS, V23, P143, DOI 10.1080/08977190500130480; Blagoev B, 2003, NAT BIOTECHNOL, V21, P315, DOI 10.1038/nbt790; Boon LM, 2005, CURR OPIN GENET DEV, V15, P265, DOI 10.1016/j.gde.2005.03.004; Chetcuti A, 2001, CANCER RES, V61, P6331; Chow A, 1999, FEBS LETT, V460, P166, DOI 10.1016/S0014-5793(99)01336-8; Cook SJ, 2006, CELL CALCIUM, V39, P101, DOI 10.1016/j.ceca.2005.10.014; COOPER JA, 1993, MOL CELL BIOL, V13, P1737, DOI 10.1128/MCB.13.3.1737; Cubells L, 2008, J BIOL CHEM, V283, P10174, DOI 10.1074/jbc.M706618200; Cubells L, 2007, TRAFFIC, V8, P1568, DOI 10.1111/j.1600-0854.2007.00640.x; Cullen PJ, 2006, CURR OPIN CELL BIOL, V18, P157, DOI 10.1016/j.ceb.2006.02.012; Cullen PJ, 2002, NAT REV MOL CELL BIO, V3, P339, DOI 10.1038/nrm808; Daly RJ, 2002, ONCOGENE, V21, P5175, DOI 10.1038/sj.onc.1205522; DAVIES AA, 1989, HUM GENET, V82, P234, DOI 10.1007/BF00291161; Davis AJ, 1996, J BIOL CHEM, V271, P24333, DOI 10.1074/jbc.271.40.24333; de Diego I, 2002, J BIOL CHEM, V277, P32187, DOI 10.1074/jbc.M205499200; deFazio A, 2000, INT J CANCER, V87, P487, DOI 10.1002/1097-0215(20000815)87:4<487::AID-IJC5>3.0.CO;2-J; Downward J, 2003, NAT REV CANCER, V3, P11, DOI 10.1038/nrc969; EDWARDS HC, 1995, MOL CELL BIOCHEM, V149, P293, DOI 10.1007/BF01076591; Fleet A, 1999, BIOCHEM BIOPH RES CO, V260, P540, DOI 10.1006/bbrc.1999.0915; Fridman M, 2000, J BIOL CHEM, V275, P30363, DOI 10.1074/jbc.M003193200; GAWLER DJ, 1995, ONCOGENE, V10, P817; GIDEON P, 1992, MOL CELL BIOL, V12, P2050, DOI 10.1128/MCB.12.5.2050; Grewal T, 2000, J BIOL CHEM, V275, P33806, DOI 10.1074/jbc.M002662200; Grewal T, 2005, ONCOGENE, V24, P5809, DOI 10.1038/sj.onc.1208743; Grewal T, 2006, CURR SIGNAL TRANSD T, V1, P147, DOI 10.2174/157436206777012066; Grewal T, 2006, BIOESSAYS, V28, P1211, DOI 10.1002/bies.20503; HUANG DCS, 1993, MOL CELL BIOL, V13, P2420, DOI 10.1128/MCB.13.4.2420; Jaumot M, 2001, ONCOGENE, V20, P3949, DOI 10.1038/sj.onc.1204526; Jin HC, 2007, P NATL ACAD SCI USA, V104, P12353, DOI 10.1073/pnas.0700153104; Johannsdottir HK, 2006, INT J CANCER, V119, P1052, DOI 10.1002/ijc.21934; Jones RB, 2006, NATURE, V439, P168, DOI 10.1038/nature04177; Karpova TS, 2003, J MICROSC-OXFORD, V209, P56, DOI 10.1046/j.1365-2818.2003.01100.x; Kolch W, 2005, NAT REV MOL CELL BIO, V6, P827, DOI 10.1038/nrm1743; Kolfschoten IGM, 2005, CELL, V121, P849, DOI 10.1016/j.cell.2005.04.017; KRAUS MH, 1984, P NATL ACAD SCI-BIOL, V81, P5384, DOI 10.1073/pnas.81.17.5384; Kupzig S, 2006, J BIOL CHEM, V281, P9891, DOI 10.1074/jbc.M512802200; Leighton X, 2004, CANCER LETT, V210, P239, DOI 10.1016/j.canlet.2004.01.018; Lockyer PJ, 2001, CURR BIOL, V11, P981, DOI 10.1016/S0960-9822(01)00261-5; Loo LWM, 2004, CANCER RES, V64, P8541, DOI 10.1158/0008-5472.CAN-04-1992; Malaney S, 2001, J MAMMARY GLAND BIOL, V6, P101, DOI 10.1023/A:1009572700317; Moreto J, 2008, CELL SIGNAL, V20, P1092, DOI 10.1016/j.cellsig.2008.01.022; MOSS SE, 1990, FEBS LETT, V261, P299, DOI 10.1016/0014-5793(90)80576-5; Murakoshi H, 2004, P NATL ACAD SCI USA, V101, P7317, DOI 10.1073/pnas.0401354101; NORI M, 1991, MOL CELL BIOL, V11, P2812, DOI 10.1128/MCB.11.5.2812; Pena V, 2008, EMBO REP, V9, P350, DOI 10.1038/embor.2008.20; Pierga JY, 2007, BRIT J CANCER, V96, P341, DOI 10.1038/sj.bjc.6603483; Plowman SJ, 2005, BBA-MOL CELL RES, V1746, P274, DOI 10.1016/j.bbamcr.2005.06.004; Pons M, 2001, FEBS LETT, V501, P69, DOI 10.1016/S0014-5793(01)02635-7; Pons M, 2001, EXP CELL RES, V269, P13, DOI 10.1006/excr.2001.5268; Rentero C, 2006, CELL SIGNAL, V18, P1006, DOI 10.1016/j.cellsig.2005.08.008; Rual JF, 2005, NATURE, V437, P1173, DOI 10.1038/nature04209; Sacks DB, 2006, BIOCHEM SOC T, V34, P833, DOI 10.1042/BST0340833; SMYTHE E, 1994, J CELL BIOL, V124, P301, DOI 10.1083/jcb.124.3.301; Strzelecka-Kiliszek A, 2008, J CELL BIOCHEM, V104, P418, DOI 10.1002/jcb.21632; Tebar F, 2002, MOL BIOL CELL, V13, P2057, DOI 10.1091/mbc.01-12-0571; THEOBALD J, 1994, BBA-MOL CELL RES, V1223, P383, DOI 10.1016/0167-4889(94)90099-X; THEOBALD J, 1995, BRIT J CANCER, V71, P786, DOI 10.1038/bjc.1995.152; Timpson P, 2007, CANCER RES, V67, P9304, DOI 10.1158/0008-5472.CAN-07-0798; vanderGeer P, 1997, MOL CELL BIOL, V17, P1840, DOI 10.1128/MCB.17.4.1840; Vishwanatha JK, 2004, BMC CANCER, V4, DOI 10.1186/1471-2407-4-8; Walker SA, 2004, EMBO J, V23, P1749, DOI 10.1038/sj.emboj.7600197; Walker SA, 2003, FEBS LETT, V546, P6, DOI 10.1016/S0014-5793(03)00412-5; Wang Z, 2002, J BIOL CHEM, V277, P24022, DOI 10.1074/jbc.M201949200; Wang ZX, 1996, CELL GROWTH DIFFER, V7, P123; Westbrook TF, 2005, CELL, V121, P837, DOI 10.1016/j.cell.2005.03.033	67	55	56	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 22	2009	28	3					363	377		10.1038/onc.2008.386	http://dx.doi.org/10.1038/onc.2008.386			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	395UZ	18850003				2022-12-28	WOS:000262550300005
J	Aranda, V; Nolan, ME; Muthuswamy, SK				Aranda, V.; Nolan, M. E.; Muthuswamy, S. K.			Par complex in cancer: a regulator of normal cell polarity joins the dark side	ONCOGENE			English	Review						polarity; cancer; ErbB2; Par6; aPKC	PROTEIN-KINASE-C; VON-HIPPEL-LINDAU; TUMOR-SUPPRESSOR PROTEIN; EPITHELIAL TIGHT JUNCTION; HUMAN-BREAST-CANCER; MESENCHYMAL TRANSITION; APICAL LOCALIZATION; DOWN-REGULATION; CDC42 CONTROLS; ACTS UPSTREAM	In the past 20 years, the discovery and characterization of the molecular machinery that controls cellular polarization have enabled us to achieve a better understanding of many biological processes. Spatial asymmetry or establishment of cell polarity during embryogenesis, epithelial morphogenesis, neuronal differentiation, and migration of fibroblasts and T cells are thought to rely on a small number of evolutionarily conserved proteins and pathways. Correct polarization is crucial for normal cell physiology and tissue homeostasis, and is lost in cancer. Thus, cell polarity signaling is likely to have an important function in tumor progression. Recent findings have identified a regulator of cell polarity, the Par complex, as an important signaling node in tumorigenesis. In normal cell types, the Par complex is part of the molecular machinery that regulates cell polarity and maintains normal cell homeostasis. As such, the polarity regulators are proposed to have a tumor suppressor function, consistent with the loss of polarity genes associated with hyperproliferation in Drosophila melanogaster. However, recent studies showing that some members of this complex also display pro-oncogenic activities suggest a more complex regulation of the polarity machinery during cellular transformation. Here, we examine the existing data about the different functions of the Par complex. We discuss how spatial restriction, binding partners and substrate specificity determine the signaling properties of Par complex proteins. A better understanding of these processes will very likely shed some light on how the Par complex can switch from a normal polarity regulation function to promotion of transformation downstream of oncogenes.	[Aranda, V.; Nolan, M. E.; Muthuswamy, S. K.] Cold Spring Harbor Lab, Cold Spring Harbor, NY 11724 USA	Cold Spring Harbor Laboratory	Muthuswamy, SK (corresponding author), Cold Spring Harbor Lab, 1 Bungtown Rd, Cold Spring Harbor, NY 11724 USA.	muthuswa@cshl.edu	Muthuswamy, Senthil K/AGY-2834-2022	Muthuswamy, Senthil K/0000-0001-6564-9634	NCI NIH HHS [R01 CA098830-05A2, R56 CA098830, R01 CA098830] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R56CA098830, R01CA098830] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Anderson DC, 2008, SCIENCE, V320, P1771, DOI 10.1126/science.1156063; Aranda V, 2006, NAT CELL BIOL, V8, P1235, DOI 10.1038/ncb1485; Assemat E, 2008, BBA-BIOMEMBRANES, V1778, P614, DOI 10.1016/j.bbamem.2007.08.029; Betschinger J, 2005, CURR BIOL, V15, P276, DOI 10.1016/j.cub.2005.01.012; Betschinger J, 2003, NATURE, V422, P326, DOI 10.1038/nature01486; Bialucha CU, 2007, J CELL BIOL, V178, P575, DOI 10.1083/jcb.200612022; Bilder D, 2003, CURR BIOL, V13, pR661, DOI 10.1016/S0960-9822(03)00599-2; Bilder D, 2004, GENE DEV, V18, P1909, DOI 10.1101/gad.1211604; Bilder D, 2003, NAT CELL BIOL, V5, P53, DOI 10.1038/ncb897; Bose R, 2006, CURR OPIN CELL BIOL, V18, P206, DOI 10.1016/j.ceb.2006.02.005; Cai Y, 2005, ONCOGENE, V24, P4293, DOI 10.1038/sj.onc.1208593; Calzada MJ, 2006, CANCER RES, V66, P1553, DOI 10.1158/0008-5472.CAN-05-3236; Cau JL, 2005, J CELL SCI, V118, P2579, DOI 10.1242/jcs.02385; Chabu C, 2008, DEVELOPMENT, V135, P2739, DOI 10.1242/dev.024059; Chen XY, 2006, J CELL BIOL, V172, P671, DOI 10.1083/jcb.200510061; Chen XY, 2005, NAT CELL BIOL, V7, P262, DOI 10.1038/ncb1226; Cohen EEW, 2006, CANCER RES, V66, P6296, DOI 10.1158/0008-5472.CAN-05-3139; Debnath J, 2003, METHODS, V30, P256, DOI 10.1016/S1046-2023(03)00032-X; Donson AM, 2000, J NEURO-ONCOL, V47, P109, DOI 10.1023/A:1006406208376; Dow LE, 2007, INT REV CYTOL, V262, P253, DOI 10.1016/S0074-7696(07)62006-3; Ebnet K, 2001, EMBO J, V20, P3738, DOI 10.1093/emboj/20.14.3738; Ebnet K, 2003, J CELL SCI, V116, P3879, DOI 10.1242/jcs.00704; Ebnet K, 2008, FRONT BIOSCI-LANDMRK, V13, P6520, DOI 10.2741/3172; Eder AM, 2005, P NATL ACAD SCI USA, V102, P12519, DOI 10.1073/pnas.0505641102; Etienne-Manneville S, 2005, J CELL BIOL, V170, P895, DOI 10.1083/jcb.200412172; Etienne-Manneville S, 2003, CURR OPIN CELL BIOL, V15, P67, DOI 10.1016/S0955-0674(02)00005-4; Etienne-Manneville S, 2004, J CELL SCI, V117, P1291, DOI 10.1242/jcs.01115; Etienne-Manneville S, 2003, NATURE, V421, P753, DOI 10.1038/nature01423; Etienne-Manneville S, 2008, ONCOGENE, V27, P6970, DOI 10.1038/onc.2008.347; Etienne-Manneville S, 2001, CELL, V106, P489, DOI 10.1016/S0092-8674(01)00471-8; Etienne-Manneville S, 2002, NATURE, V420, P629, DOI 10.1038/nature01148; Farooqui R, 2006, EXP CELL RES, V312, P1514, DOI 10.1016/j.yexcr.2006.01.018; Feng W, 2008, J BIOL CHEM, V283, P23440, DOI 10.1074/jbc.M802482200; Fields AP, 2007, BIOCHEM SOC T, V35, P996, DOI 10.1042/BST0350996; Fields Alan P, 2003, Methods Mol Biol, V233, P539; Fields AP, 2007, PHARMACOL RES, V55, P487, DOI 10.1016/j.phrs.2007.04.015; Fleming TP, 2000, SEMIN CELL DEV BIOL, V11, P291, DOI 10.1006/scdb.2000.0179; Gao L, 2004, J BIOL CHEM, V279, P41557, DOI 10.1074/jbc.M403723200; Garrard SM, 2003, EMBO J, V22, P1125, DOI 10.1093/emboj/cdg110; Gerard A, 2007, J CELL BIOL, V176, P863, DOI 10.1083/jcb.200608161; Goldstein B, 2007, DEV CELL, V13, P609, DOI 10.1016/j.devcel.2007.10.007; Gomes ER, 2005, CELL, V121, P451, DOI 10.1016/j.cell.2005.02.022; Grifoni D, 2007, ONCOGENE, V26, P5960, DOI 10.1038/sj.onc.1210389; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hebner C, 2008, ANNU REV PATHOL-MECH, V3, P313, DOI 10.1146/annurev.pathmechdis.3.121806.151526; Hirose T, 2002, J CELL SCI, V115, P2485; Horne-Badovinac S, 2008, PLOS GENET, V4, DOI 10.1371/journal.pgen.0040008; Hoshino M, 2005, J BIOL CHEM, V280, P22868, DOI 10.1074/jbc.M411592200; Huber MA, 2005, CURR OPIN CELL BIOL, V17, P548, DOI 10.1016/j.ceb.2005.08.001; Hugo H, 2007, J CELL PHYSIOL, V213, P374, DOI 10.1002/jcp.21223; Hurd TW, 2003, NAT CELL BIOL, V5, P137, DOI 10.1038/ncb923; Hurov JB, 2004, CURR BIOL, V14, P736, DOI 10.1016/j.cub.2004.04.007; Hurov J, 2007, CELL CYCLE, V6, P1966, DOI 10.4161/cc.6.16.4576; Hutterer A, 2004, DEV CELL, V6, P845, DOI 10.1016/j.devcel.2004.05.003; Izumi Y, 1998, J CELL BIOL, V143, P95, DOI 10.1083/jcb.143.1.95; Ji QZ, 2008, BIOCHEM CELL BIOL, V86, P227, DOI [10.1139/O08-035, 10.1139/o08-035]; Jin YT, 2008, ONCOL RES, V17, P59, DOI 10.3727/096504008784523630; Joberty G, 2000, NAT CELL BIOL, V2, P531, DOI 10.1038/35019573; Johnson DI, 1999, MICROBIOL MOL BIOL R, V63, P54, DOI 10.1128/MMBR.63.1.54-105.1999; Kay AJ, 2001, CURR BIOL, V11, P474, DOI 10.1016/S0960-9822(01)00141-5; Kemphues K, 2000, CELL, V101, P345, DOI 10.1016/S0092-8674(00)80844-2; KEMPHUES KJ, 1988, CELL, V52, P311, DOI 10.1016/S0092-8674(88)80024-2; Kim M, 2007, J CELL SCI, V120, P2309, DOI 10.1242/jcs.007443; Kojima Y, 2008, HUM PATHOL, V39, P824, DOI 10.1016/j.humpath.2007.11.001; Kuehn EW, 2007, CANCER RES, V67, P4537, DOI 10.1158/0008-5472.CAN-07-0391; Kuphal S, 2006, ONCOGENE, V25, P103, DOI 10.1038/sj.onc.1209008; Kurban G, 2006, CANCER RES, V66, P1313, DOI 10.1158/0008-5472.CAN-05-2560; Kuribayashi K, 2007, J CELL BIOL, V176, P1049, DOI 10.1083/jcb.200607019; Lee CY, 2006, NATURE, V439, P594, DOI 10.1038/nature04299; Lee MH, 2008, J CELL SCI, V121, P1141, DOI 10.1242/jcs.016634; Lemmers C, 2004, MOL BIOL CELL, V15, P1324, DOI 10.1091/mbc.E03-04-0235; Li ZH, 2008, J CELL BIOL, V180, P31, DOI 10.1083/jcb.200707007; Lin D, 2000, NAT CELL BIOL, V2, P540, DOI 10.1038/35019582; Ludford-Menting MJ, 2005, IMMUNITY, V22, P737, DOI 10.1016/j.immuni.2005.04.009; Macara IG, 2004, NAT REV MOL CELL BIO, V5, P220, DOI 10.1038/nrm1332; Martin-Belmonte F, 2008, CURR OPIN CELL BIOL, V20, P227, DOI 10.1016/j.ceb.2008.01.001; Martin-Belmonte F, 2007, CELL CYCLE, V6, P1957, DOI 10.4161/cc.6.16.4583; Martin-Belmonte F, 2007, CELL, V128, P383, DOI 10.1016/j.cell.2006.11.051; Mertens AEE, 2005, J CELL BIOL, V170, P1029, DOI 10.1083/jcb.200502129; Moeschel K, 2004, J BIOL CHEM, V279, P25157, DOI 10.1074/jbc.M402477200; Moreno-Bueno G, 2008, ONCOGENE, V27, P6958, DOI 10.1038/onc.2008.346; Morrison SJ, 2006, NATURE, V441, P1068, DOI 10.1038/nature04956; Moscat J, 2000, EMBO REP, V1, P399, DOI 10.1093/embo-reports/kvd098; Moscat J, 2006, CELL DEATH DIFFER, V13, P702, DOI 10.1038/sj.cdd.4401823; Munro EM, 2006, CURR OPIN CELL BIOL, V18, P86, DOI 10.1016/j.ceb.2005.12.007; Murray NR, 2004, J CELL BIOL, V164, P797, DOI 10.1083/jcb.200311011; Muthuswamy SK, 2001, NAT CELL BIOL, V3, P785, DOI 10.1038/ncb0901-785; Nagai-Tamai Y, 2002, GENES CELLS, V7, P1161, DOI 10.1046/j.1365-2443.2002.00590.x; Nakayama M, 2008, DEV CELL, V14, P205, DOI 10.1016/j.devcel.2007.11.021; Nance J, 2003, DEVELOPMENT, V130, P5339, DOI 10.1242/dev.00735; Nishimura T, 2005, NAT CELL BIOL, V7, P270, DOI 10.1038/ncb1227; Noda Y, 2001, GENES CELLS, V6, P107, DOI 10.1046/j.1365-2443.2001.00404.x; NOLAN ME, 2008, CANCER RES, V68, P1; Okuda H, 1999, BIOCHEM BIOPH RES CO, V263, P491, DOI 10.1006/bbrc.1999.1347; Okuda H, 2001, J BIOL CHEM, V276, P43611, DOI 10.1074/jbc.M107880200; Ozdamar B, 2005, SCIENCE, V307, P1603, DOI 10.1126/science.1105718; Pegtel DM, 2007, CURR BIOL, V17, P1623, DOI 10.1016/j.cub.2007.08.035; PETERSEN OW, 1992, P NATL ACAD SCI USA, V89, P9064, DOI 10.1073/pnas.89.19.9064; Peterson FC, 2004, MOL CELL, V13, P665, DOI 10.1016/S1097-2765(04)00086-3; Plant PJ, 2003, NAT CELL BIOL, V5, P301, DOI 10.1038/ncb948; Qiu RG, 2000, CURR BIOL, V10, P697, DOI 10.1016/S0960-9822(00)00535-2; Regala RP, 2008, CANCER RES, V68, P5888, DOI 10.1158/0008-5472.CAN-08-0438; Regala RP, 2005, CANCER RES, V65, P8905, DOI 10.1158/0008-5472.CAN-05-2372; Rolls MM, 2003, J CELL BIOL, V163, P1089, DOI 10.1083/jcb.200306079; Schimanski CC, 2005, ONCOGENE, V24, P3100, DOI 10.1038/sj.onc.1208520; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; SLAMON DJ, 1987, NEW ENGL J MED, V317, P955, DOI 10.1056/NEJM198710083171509; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; Sotillos S, 2004, J CELL BIOL, V166, P549, DOI 10.1083/jcb.200311031; Stallings-Mann M, 2006, CANCER RES, V66, P1767, DOI 10.1158/0008-5472.CAN-05-3405; Sun RH, 2005, CANCER RES, V65, P1433, DOI 10.1158/0008-5472.CAN-04-1163; Suzuki A, 2004, CURR BIOL, V14, P1425, DOI 10.1016/j.cub.2004.08.021; Suzuki A, 2006, J CELL SCI, V119, P979, DOI 10.1242/jcs.02898; Tepass U, 2001, ANNU REV GENET, V35, P747, DOI 10.1146/annurev.genet.35.102401.091415; Tong XK, 2000, J BIOL CHEM, V275, P29894, DOI 10.1074/jbc.M004096200; Townsend TA, 2008, J BIOL CHEM, V283, P13834, DOI 10.1074/jbc.M710607200; Tsukita S, 2008, ONCOGENE, V27, P6930, DOI 10.1038/onc.2008.344; Tsuruga T, 2007, ONCOL RES, V16, P431, DOI 10.3727/000000007783980855; Underwood JM, 2006, J CELL PHYSIOL, V208, P141, DOI 10.1002/jcp.20639; Wang HR, 2006, METHOD ENZYMOL, V406, P437, DOI 10.1016/S0076-6879(06)06032-0; Wang HR, 2003, SCIENCE, V302, P1775, DOI 10.1126/science.1090772; Wang JB, 2005, J BIOL CHEM, V280, P22883, DOI 10.1074/jbc.M414375200; Wang Q, 2004, J BIOL CHEM, V279, P30715, DOI 10.1074/jbc.M401930200; Wang XY, 2008, BBA-MOL BASIS DIS, V1782, P51, DOI 10.1016/j.bbadis.2007.11.002; Weaver VM, 1996, BIOCHEM CELL BIOL, V74, P833, DOI 10.1139/o96-089; Weyrich P, 2007, MOL CELL ENDOCRINOL, V268, P30, DOI 10.1016/j.mce.2007.01.011; Weyrich P, 2004, MOL ENDOCRINOL, V18, P1287, DOI 10.1210/me.2003-0253; Wodarz A, 2007, NAT CELL BIOL, V9, P1016, DOI 10.1038/ncb433; Wu H, 2007, MOL CELL, V28, P886, DOI 10.1016/j.molcel.2007.10.028; Xiang B, 2006, METHOD ENZYMOL, V406, P692, DOI 10.1016/S0076-6879(06)06054-X; Yamanaka T, 2001, GENES CELLS, V6, P721, DOI 10.1046/j.1365-2443.2001.00453.x; Yamanaka T, 2008, FRONT BIOSCI-LANDMRK, V13, P6693, DOI 10.2741/3182; Yarden Y, 2001, ONCOLOGY-BASEL, V61, P1, DOI 10.1159/000055396; Yarden Y, 2001, NAT REV MOL CELL BIO, V2, P127, DOI 10.1038/35052073; Yi P, 2008, MOL CELL, V29, P465, DOI 10.1016/j.molcel.2007.12.030; Zhang HY, 2008, DEV CELL, V14, P216, DOI 10.1016/j.devcel.2007.11.020; Zhang HY, 2006, NAT CELL BIOL, V8, P227, DOI 10.1038/ncb1368; Zhang L, 2006, CANCER RES, V66, P4627, DOI 10.1158/0008-5472.CAN-05-4527	138	73	77	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 24	2008	27	55					6878	6887		10.1038/onc.2008.340	http://dx.doi.org/10.1038/onc.2008.340			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	375IU	19029931	Green Accepted			2022-12-28	WOS:000261108200002
J	Shen, J; Vakifahmetoglu, H; Stridh, H; Zhivotovsky, B; Wiman, KG				Shen, J.; Vakifahmetoglu, H.; Stridh, H.; Zhivotovsky, B.; Wiman, K. G.			PRIMA-1(MET) induces mitochondrial apoptosis through activation of caspase-2	ONCOGENE			English	Article						apoptosis; cancer therapy; caspase-2; mutant p53; PRIMA-1(MET)	CYTOCHROME-C RELEASE; MUTANT P53; BREAST-CANCER; CELLS; GENE; RESTORATION; DEATH; PUMA; TRANSCRIPTION; INDUCTION	p53 mutations occur frequently in human tumors. The low-molecular-weight compound PRIMA-1(MET) reactivates mutant p53, induces apoptosis in human tumor cells and inhibits tumor xenograft growth in vivo. Here, we show that PRIMA-1(MET) induces mutant p53-dependent mito-chondria-mediated apoptosis through activation of caspase-2 with subsequent cytochrome c release and further activation of downstream caspase-9 and caspase-3. Inhibition of caspase-2 by a selective inhibitor and/or siRNA prevents cytochrome c release on PRIMA-1(MET) treatment and causes a significant reduction in PRIMA-1(MET)-induced cell death. Our findings highlight a chain of cellular events triggered by PRIMA-1(MET) that lead to apoptotic cell death. This should facilitate further development and optimization of eficient PRIMA-1(MET)-based anticancer drugs.	[Wiman, K. G.] Karolinska Univ Hosp, CCK, Karolinska Inst, Dept Oncol Pathol, SE-17176 Stockholm, Sweden; [Vakifahmetoglu, H.; Zhivotovsky, B.] Karolinska Inst, Inst Environm Med, Div Toxicol, S-10401 Stockholm, Sweden	Karolinska Institutet; Karolinska University Hospital; Karolinska Institutet	Wiman, KG (corresponding author), Karolinska Univ Hosp, CCK, Karolinska Inst, Dept Oncol Pathol, R8-04, SE-17176 Stockholm, Sweden.	klas.wiman@ki.se	Wiman, Klas/AAB-8399-2021; Zhivotovsky, Boris/A-4346-2014	Wiman, Klas/0000-0002-7113-524X; Zhivotovsky, Boris/0000-0002-2238-3482	Swedish and Stockholm Cancer Societies; Swedish Research Council; EU 6th and 7th Framework Programs; Karolinska Institutet	Swedish and Stockholm Cancer Societies; Swedish Research Council(Swedish Research CouncilEuropean Commission); EU 6th and 7th Framework Programs(European Commission); Karolinska Institutet(Karolinska Institutet)	This study was supported by grants from the Swedish and Stockholm Cancer Societies, the Swedish Research Council, the EU 6th and 7th Framework Programs, and Karolinska Institutet. This publication reflects the author's views and not necessarily those of the EC partners. The information in this document is provided as is and no guarantee or warranty is given that the information is fit for any particular purpose. The user thereof uses the information at its sole risk and liability. The Community is not liable for any use that may be made of the information contained herein.	ALSHABANAH OA, 1995, CHEMOTHERAPY, V41, P368, DOI 10.1159/000239369; Bergeron L, 1998, GENE DEV, V12, P1304, DOI 10.1101/gad.12.9.1304; BERGH J, 1995, NAT MED, V1, P1029, DOI 10.1038/nm1095-1029; Bykov VJN, 2005, J BIOL CHEM, V280, P30384, DOI 10.1074/jbc.M501664200; Bykov VJN, 2005, ONCOGENE, V24, P3484, DOI 10.1038/sj.onc.1208419; Bykov VJN, 2003, EUR J CANCER, V39, P1828, DOI 10.1016/S0959-8049(03)00454-4; Bykov VJN, 2002, NAT MED, V8, P282, DOI 10.1038/nm0302-282; Chipuk JE, 2005, SCIENCE, V309, P1732, DOI 10.1126/science.1114297; Chipuk JE, 2003, CANCER CELL, V4, P371, DOI 10.1016/S1535-6108(03)00272-1; Ding HF, 2000, J BIOL CHEM, V275, P38905, DOI 10.1074/jbc.M004714200; Fulda S, 2006, ONCOGENE, V25, P4798, DOI 10.1038/sj.onc.1209608; Gross A, 1999, J BIOL CHEM, V274, P1156, DOI 10.1074/jbc.274.2.1156; Guimaraes DP, 2002, BIOCHIMIE, V84, P83, DOI 10.1016/S0300-9084(01)01356-6; Guo Y, 2002, J BIOL CHEM, V277, P13430, DOI 10.1074/jbc.M108029200; Lassus P, 2002, SCIENCE, V297, P1352, DOI 10.1126/science.1074721; Lin YP, 2000, NAT GENET, V26, P122, DOI 10.1038/79102; Nakano K, 2001, MOL CELL, V7, P683, DOI 10.1016/S1097-2765(01)00214-3; Olivier M, 2006, CLIN CANCER RES, V12, P1157, DOI 10.1158/1078-0432.CCR-05-1029; Read SH, 2002, J CELL BIOL, V159, P739, DOI 10.1083/jcb.200209004; Robertson JD, 2002, J BIOL CHEM, V277, P29803, DOI 10.1074/jbc.M204185200; Schuler M, 2000, J BIOL CHEM, V275, P7337, DOI 10.1074/jbc.275.10.7337; Tinel A, 2004, SCIENCE, V304, P843, DOI 10.1126/science.1095432; Tyagi A, 2006, CARCINOGENESIS, V27, P2269, DOI 10.1093/carcin/bgl098; Vakifahmetoglu H, 2006, ONCOGENE, V25, P5683, DOI 10.1038/sj.onc.1209569; Ventura A, 2007, NATURE, V445, P661, DOI 10.1038/nature05541; Xue W, 2007, NATURE, V445, P656, DOI 10.1038/nature05529; Yin XM, 2006, GENE, V369, P7, DOI 10.1016/j.gene.2005.10.038; Yu J, 2001, MOL CELL, V7, P673, DOI 10.1016/S1097-2765(01)00213-1	28	49	49	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 30	2008	27	51					6571	6580		10.1038/onc.2008.249	http://dx.doi.org/10.1038/onc.2008.249			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	366RS	18663359				2022-12-28	WOS:000260501700004
J	Hossain, MS; Ozaki, T; Wang, H; Nakagawa, A; Takenobu, H; Ohira, M; Kamijo, T; Nakagawara, A				Hossain, M. S.; Ozaki, T.; Wang, H.; Nakagawa, A.; Takenobu, H.; Ohira, M.; Kamijo, T.; Nakagawara, A.			N-MYC promotes cell proliferation through a direct transactivation of neuronal leucine-rich repeat protein-1(NLRR1) gene in neuroblastoma	ONCOGENE			English	Article						c-myc; neuroblastoma; N-MYC; NLRR1; proliferation; transactivation	MOUSE NERVOUS-SYSTEM; DNA-BINDING; EXPRESSION; PROTEIN; ONCOGENE; ZIPPER; AMPLIFICATION; ASSOCIATION; PROGRESSION; ACTIVATION	Neuronal leucine-rich repeat protein-1(NLRR1) gene encodes a type I transmembrane protein with unknown function. We have previously described that NLRR1 gene is highly expressed in unfavorable neuroblastomas as compared with favorable tumors and its higher expression levels correlate significantly with poor clinical outcome. In this study, we have found that NLRR1 gene is one of direct target genes for N-MYC and its gene product contributes to N-MYC-dependent growth promotion in neuroblastoma. Expression levels of NLRR1 were significantly associated with those of N-MYC in various neuroblastoma cell lines as well as primary neuroblastoma tissues. Indeed, enforced expression of N-MYC resulted in a remarkable induction of the endogenous NLRR1. Consistent with these results, we have identified two functional E-boxes within the promoter region and intron 1 of NLRR1 gene. Intriguingly, c-myc also transactivated NLRR1 gene. Enforced expression of NLRR1 promoted cell proliferation and rendered cells resistant to serum deprivation. In support with these observations, small-interfering RNA-mediated knock-down of the endogenous NLRR1-reduced growth rate and sensitized cells to serum starvation. Collectively, our present findings provide a novel insight into understanding molecular mechanisms behind aggressive neuroblastoma with N-MYC amplification.	[Hossain, M. S.; Ozaki, T.; Wang, H.; Takenobu, H.; Ohira, M.; Kamijo, T.; Nakagawara, A.] Chiba Canc Ctr, Res Inst, Div Biochem, Chuoh Ku, Chiba 2608717, Japan; [Hossain, M. S.; Ozaki, T.; Nakagawara, A.] Chiba Univ, Grad Sch Med, Dept Mol Biol & Oncol, Chiba, Japan; [Wang, H.] China Med Univ, ShengJing Hosp, Dept Pediat, Shenyang, Peoples R China; [Nakagawa, A.] Natl Ctr Child Hlth & Dev, Dept Pathol, Tokyo, Japan	Chiba Cancer Center; Chiba University; China Medical University; National Center for Child Health & Development - Japan	Nakagawara, A (corresponding author), Chiba Canc Ctr, Res Inst, Div Biochem, Chuoh Ku, 666-2 Nitona, Chiba 2608717, Japan.	akiranak@chiba-cc.jp			Ministry of Health, Labour and Welfare; Ministry of Education, Culture, Sports, Science and Technology, Japan; Uehara Memorial Foundation; Hisamitsu Pharmaceutical Co	Ministry of Health, Labour and Welfare(Ministry of Health, Labour and Welfare, Japan); Ministry of Education, Culture, Sports, Science and Technology, Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Uehara Memorial Foundation(Uehara Memorial Foundation); Hisamitsu Pharmaceutical Co	We are grateful to Dr M Schwab for providing the expression plasmid for N-MYC. We thank Ms Y Nakamura for technical assistance. This work was supported in part by a Grant-in-Aid from the Ministry of Health, Labour and Welfare for Third Term Comprehensive Control Research for Cancer, a Grant-in-Aid for Scientific Research on Priority Areas from the Ministry of Education, Culture, Sports, Science and Technology, Japan, a Grant-in-Aid for Scientific Research from Japan Society for the Promotion of Science, Uehara Memorial Foundation and Hisamitsu Pharmaceutical Co.	ALEX R, 1992, NUCLEIC ACIDS RES, V20, P2257, DOI 10.1093/nar/20.9.2257; Bando T, 2005, MOL CELL BIOL, V25, P4166, DOI 10.1128/MCB.25.10.4166-4175.2005; BERNARDS R, 1986, CELL, V47, P667, DOI 10.1016/0092-8674(86)90509-X; Blackwood EM, 1992, CURR OPIN GENET DEV, V2, P227, DOI 10.1016/S0959-437X(05)80278-3; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; Boon K, 2001, EMBO J, V20, P1383, DOI 10.1093/emboj/20.6.1383; BRODEUR GM, 1992, AM J PEDIAT HEMATOL, V14, P111; Degterev A, 2003, ONCOGENE, V22, P8543, DOI 10.1038/sj.onc.1207107; Fukamachi K, 2002, J BIOL CHEM, V277, P43549, DOI 10.1074/jbc.C200502200; Hamano S, 2004, INT J ONCOL, V24, P1457; KOHL NE, 1983, CELL, V35, P359, DOI 10.1016/0092-8674(83)90169-1; KOUZARIDES T, 1988, NATURE, V336, P646, DOI 10.1038/336646a0; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; Lasorella A, 2000, NATURE, V407, P592, DOI 10.1038/35036504; Lutz W, 1996, ONCOGENE, V13, P803; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; NEGRONI A, 1991, CELL GROWTH DIFFER, V2, P511; SCHWAB M, 1983, NATURE, V305, P245, DOI 10.1038/305245a0; SEEGER RC, 1985, NEW ENGL J MED, V313, P1111, DOI 10.1056/NEJM198510313131802; Slack A, 2005, P NATL ACAD SCI USA, V102, P731, DOI 10.1073/pnas.0405495102; Taguchi A, 1996, MOL BRAIN RES, V35, P31, DOI 10.1016/0169-328X(95)00178-U; Taniguchi H, 1996, MOL BRAIN RES, V36, P45, DOI 10.1016/0169-328X(95)00243-L; TORRES R, 1992, Current Opinion in Cell Biology, V4, P468, DOI 10.1016/0955-0674(92)90013-3; Truscott M, 2007, J BIOL CHEM, V282, P30216, DOI 10.1074/jbc.M702328200; Wang J, 1998, GENE DEV, V12, P1769, DOI 10.1101/gad.12.12.1769; Weiss WA, 1997, EMBO J, V16, P2985, DOI 10.1093/emboj/16.11.2985	26	31	34	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 9	2008	27	46					6075	6082		10.1038/onc.2008.200	http://dx.doi.org/10.1038/onc.2008.200			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	358BO	18591937				2022-12-28	WOS:000259891600010
J	Brondello, JM; Pillaire, MJ; Rodriguez, C; Gourraud, PA; Selves, J; Cazaux, C; Piette, J				Brondello, J-M; Pillaire, M. J.; Rodriguez, C.; Gourraud, P-A; Selves, J.; Cazaux, C.; Piette, J.			Novel evidences for a tumor suppressor role of Rev3, the catalytic subunit of Pol zeta	ONCOGENE			English	Article						Rev3; DNA damage; Chk2; colon carcinoma	DNA-DAMAGE CHECKPOINTS; STRAND-BREAK REPAIR; HOMOLOGOUS RECOMBINATION; SACCHAROMYCES-CEREVISIAE; POSTREPLICATION REPAIR; ANTICANCER BARRIER; POLYMERASE-KAPPA; MAMMALIAN-CELLS; CANCER; TUMORIGENESIS	Cell cycle checkpoints and DNA repair act in concert to ensure DNA integrity during perturbation of normal replication or in response to genotoxic agents. Deficiencies in these protective mechanisms can lead to cellular transformation and ultimately tumorigenesis. Here we focused on Rev3, the catalytic subunit of the low-fidelity DNA repair polymerase zeta. Rev3 is believed to play a role in double-strand break (DSB)-induced DNA repair by homologous recombination. In line with this hypothesis, we show the accumulation of chromatin-bound Rev3 protein in late S-G2 of untreated cells and in response to clastogenic DNA damage as well as an gamma-H2AX accumulation in Rev3-depleted cells. Moreover, serine 995 of Rev3 is in vitro phosphorylated by the DSB-inducible checkpoint kinase, Chk2. Our data also disclose a significant reduction of rev3 gene expression in 74 colon carcinomas when compared to the normal adjacent tissues. This reduced expression is independent of the carcinoma stages, suggesting that the downregulation of rev3 might have occurred early during tumorigenesis.	[Brondello, J-M] Hop St Eloi, INSERM, U844, F-34091 Montpellier 05, France; [Brondello, J-M; Rodriguez, C.; Piette, J.] Univ Montpellier 1, INSERM, U868, Ctr Reg Cancerol Montpellier,CRCM Val Aurelle Lam, Montpellier 5, France; [Pillaire, M. J.; Cazaux, C.] CNRS, IPBS, UMR 5089, Toulouse, France; [Gourraud, P-A] Univ Toulouse 3, CHU Toulouse, Serv Hosp Epidemiol,Unite Rech Clin, INSERM U558,Fac Med,Dept Epidemiol & Sante Publ, F-31062 Toulouse, France; [Selves, J.] Univ Toulouse 3, INSERM, Ctr Physiopathol Toulouse Purpan, U563, F-31062 Toulouse, France; [Selves, J.] Univ Toulouse 3, Dept Anatomopathol, F-31062 Toulouse, France; [Piette, J.] CNRS, UMR5535, Inst Genet Mol Montpellier, Montpellier, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier; CHU de Montpellier; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier; UNICANCER; Institut Regional du Cancer Montpellier / Val d'Aurelle (ICM); Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Toulouse; Universite Toulouse III - Paul Sabatier; CHU de Toulouse; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Montpellier	Brondello, JM (corresponding author), Hop St Eloi, INSERM, U844, Batiment INM BP74103,80 Rue A Fiche, F-34091 Montpellier 05, France.	jean-marc.brondello@inserm.fr	Gourraud, Pierre-Antoine FD/O-3024-2015; Brondello, Jean-Marc/U-8232-2017; Piette, Jacques/F-7109-2011; Pillaire, Marie-Jeanne/P-1579-2014	Brondello, Jean-Marc/0000-0001-5991-3945; Pillaire, Marie-Jeanne/0000-0001-6866-7416; Gourraud, Pierre-Antoine/0000-0003-1131-9554	Canceropole Grand Sud Ouest; Association pour la Recherche sur le Cancer	Canceropole Grand Sud Ouest; Association pour la Recherche sur le Cancer(Fondation ARC pour la Recherche sur le CancerAustralian Research Council)	We gratefully thank Professor CW Lawrence for providing Rev3 cDNA and Dr C Jorgensen for gift of human mesenchymal stem cells. We also greatly thank R Guimbaud and K Gordien (Inserm/CHU Purpan, Toulouse) for collection and annotation of the tumors, as well as JM Maoret from the plateforme de Genomique et Biologie Moleculaire', IFR31 Toulouse for his technical help on the 7900HT fast real-time PCR systems. This work was supported by the Canceropole Grand Sud Ouest grant 2003-2006 and the Association pour la Recherche sur le Cancer.	Barbour L, 2006, GENETICS, V174, P1789, DOI 10.1534/genetics.106.056283; Bartek J, 2007, CELL CYCLE, V6, P2344, DOI 10.4161/cc.6.19.4754; Bartkova J, 2005, NATURE, V434, P864, DOI 10.1038/nature03482; Bartkova J, 2006, NATURE, V444, P633, DOI 10.1038/nature05268; Bavoux C, 2005, CANCER RES, V65, P325; Bindra RS, 2007, CANCER METAST REV, V26, P249, DOI 10.1007/s10555-007-9061-3; Blais V, 2004, MOL BIOL CELL, V15, P552, DOI 10.1091/mbc.E03-08-0580; Boddy MN, 2000, MOL CELL BIOL, V20, P8758, DOI 10.1128/MCB.20.23.8758-8766.2000; Brondello JM, 2007, BIOCHEM BIOPH RES CO, V354, P1028, DOI 10.1016/j.bbrc.2007.01.091; Burma S, 2001, J BIOL CHEM, V276, P42462, DOI 10.1074/jbc.C100466200; Canitrot Y, 2004, NUCLEIC ACIDS RES, V32, P5104, DOI 10.1093/nar/gkh848; Chomczynski P, 2006, NAT PROTOC, V1, P581, DOI 10.1038/nprot.2006.83; Gorgoulis VG, 2005, NATURE, V434, P907, DOI 10.1038/nature03485; Guo CX, 2003, EMBO J, V22, P6621, DOI 10.1093/emboj/cdg626; Hochegger H, 2004, BIOESSAYS, V26, P151, DOI 10.1002/bies.10403; Ishikawa K, 2006, DNA CELL BIOL, V25, P406, DOI 10.1089/dna.2006.25.406; Johnson RE, 1998, GENE DEV, V12, P3137, DOI 10.1101/gad.12.19.3137; Kai M, 2003, GENE DEV, V17, P64, DOI 10.1101/gad.1043203; Laiho M, 2003, ANN MED, V35, P391, DOI 10.1080/07853890310014605; Lapointe J, 2004, P NATL ACAD SCI USA, V101, P811, DOI 10.1073/pnas.0304146101; Lawrence CW, 1996, CANCER SURV, V28, P21; Lemee F, 2007, ONCOGENE, V26, P3387, DOI 10.1038/sj.onc.1210116; Liang F, 1998, P NATL ACAD SCI USA, V95, P5172, DOI 10.1073/pnas.95.9.5172; Lisby M, 2004, CELL, V118, P699, DOI 10.1016/j.cell.2004.08.015; Lisby M, 2004, CURR OPIN CELL BIOL, V16, P328, DOI 10.1016/j.ceb.2004.03.011; Lisby M, 2003, CELL CYCLE, V2, P479, DOI 10.4161/cc.2.5.483; Liu VF, 1999, MOL CELL BIOL, V19, P1126; McIlwraith MJ, 2005, MOL CELL, V20, P783, DOI 10.1016/j.molcel.2005.10.001; Melo J, 2002, CURR OPIN CELL BIOL, V14, P237, DOI 10.1016/S0955-0674(02)00312-5; Nelson JR, 1996, SCIENCE, V272, P1646, DOI 10.1126/science.272.5268.1646; O'Neill T, 2002, J BIOL CHEM, V277, P16102, DOI 10.1074/jbc.M111705200; Rattray AJ, 2003, ANNU REV GENET, V37, P31, DOI 10.1146/annurev.genet.37.042203.132748; Rattray AJ, 2005, MOL CELL, V20, P658, DOI 10.1016/j.molcel.2005.11.018; Sabbioneda S, 2005, J BIOL CHEM, V280, P38657, DOI 10.1074/jbc.M507638200; Sartori AA, 2007, NATURE, V450, P509, DOI 10.1038/nature06337; Slupphaug G, 2003, MUTAT RES-FUND MOL M, V531, P231, DOI 10.1016/j.mrfmmm.2003.06.002; Sonoda E, 2003, EMBO J, V22, P3188, DOI 10.1093/emboj/cdg308; Sorensen CS, 2005, NAT CELL BIOL, V7, P195, DOI 10.1038/ncb1212; STRATHERN JN, 1995, GENETICS, V140, P965; Tan YJ, 2007, MOL CELL BIOL, V27, P1007, DOI 10.1128/MCB.01068-06; TODOROV IT, 1995, J CELL BIOL, V129, P1433, DOI 10.1083/jcb.129.6.1433; Van Sloun PPH, 2002, MOL CELL BIOL, V22, P2159, DOI 10.1128/MCB.22.7.2159-2169.2002; Yamamoto Ken-ichi, 2006, Subcell Biochem, V40, P327; Zhang JR, 2004, MOL CELL BIOL, V24, P708, DOI 10.1128/MCB.24.2.708-718.2004; Zhu F, 2003, WORLD J GASTROENTERO, V9, P1165, DOI 10.3748/wjg.v9.i6.1165	45	36	38	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT	2008	27	47					6093	6101		10.1038/onc.2008.212	http://dx.doi.org/10.1038/onc.2008.212			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	360UJ	18622427				2022-12-28	WOS:000260083100002
J	Dhanasekaran, DN; Reddy, EP				Dhanasekaran, D. N.; Reddy, E. P.			JNK signaling in apoptosis	ONCOGENE			English	Review						JNK; apoptosis; cell death; MAP3K; MKK4; MKK7	N-TERMINAL KINASE; ACTIVATED PROTEIN-KINASES; STRESS-INDUCED APOPTOSIS; C-JUN; CELL-DEATH; CYTOCHROME-C; MAP KINASES; MITOCHONDRIAL APOPTOSIS; PERSISTENT ACTIVATION; DEPENDENT APOPTOSIS	Jun N-terminal kinases or JNKs play a critical role in death receptor-initiated extrinsic as well as mitochondrial intrinsic apoptotic pathways. JNKs activate apoptotic signaling by the upregulation of pro-apoptotic genes through the transactivation of specific transcription factors or by directly modulating the activities of mitochondrial pro-and antiapoptotic proteins through distinct phosphorylation events. This review analyses our present understanding of the role of JNK in apoptotic signaling and the various mechanisms by which JNK promotes apoptosis.	[Dhanasekaran, D. N.; Reddy, E. P.] Temple Univ, Sch Med, Fels Inst Canc Res & Mol Biol, Philadelphia, PA 19140 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University	Dhanasekaran, DN (corresponding author), Temple Univ, Sch Med, Fels Inst Canc Res & Mol Biol, 3307 N Broad St, Philadelphia, PA 19140 USA.	danny001@temple.edu	Reddy, E. Premkumar/F-6233-2011		National Institutes of Health [CA123233, CA109820]; NATIONAL CANCER INSTITUTE [R01CA109820, R01CA123233] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG022022] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	Studies presented in the authors' laboratories were supported by the National Institutes of Health grants CA123233 (to DND) and CA109820 (to EPR).	Aoki H, 2002, J BIOL CHEM, V277, P10244, DOI 10.1074/jbc.M112355200; Barone MC, 2008, J NEUROCHEM, V106, P734, DOI 10.1111/j.1471-4159.2008.05427.x; Behrens A, 1999, NAT GENET, V21, P326, DOI 10.1038/6854; Bjorkblom B, 2008, J BIOL CHEM, V283, P19704, DOI 10.1074/jbc.M707744200; Bossy-Wetzel E, 1999, J BIOL CHEM, V274, P17484, DOI 10.1074/jbc.274.25.17484; CANO E, 1995, TRENDS BIOCHEM SCI, V20, P117, DOI 10.1016/S0968-0004(00)88978-1; CANO E, 1994, MOL CELL BIOL, V14, P7352, DOI 10.1128/MCB.14.11.7352; Chang LF, 2001, NATURE, V410, P37, DOI 10.1038/35065000; Chauhan D, 2003, J BIOL CHEM, V278, P17593, DOI 10.1074/jbc.C300076200; Chen YR, 2000, INT J ONCOL, V16, P651; Chen YR, 1996, J BIOL CHEM, V271, P631, DOI 10.1074/jbc.271.2.631; Chen ZH, 1999, ONCOGENE, V18, P173, DOI 10.1038/sj.onc.1202276; Chinnaiyan Arul M., 1999, Neoplasia (New York), V1, P5; DAI TN, 1995, ONCOGENE, V10, P849; DAVIS RJ, 1994, TRENDS BIOCHEM SCI, V19, P470, DOI 10.1016/0968-0004(94)90132-5; Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1; Deng YB, 2003, CELL, V115, P61, DOI 10.1016/S0092-8674(03)00757-8; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; Dhanasekaran DN, 2007, ONCOGENE, V26, P3185, DOI 10.1038/sj.onc.1210411; Dhanasekaran DN, 2007, ONCOGENE, V26, P3097, DOI 10.1038/sj.onc.1210395; Dhanasekaran N, 1998, ONCOGENE, V17, P1447, DOI 10.1038/sj.onc.1202251; Donovan N, 2002, J BIOL CHEM, V277, P40944, DOI 10.1074/jbc.M206113200; Elmore S, 2007, TOXICOL PATHOL, V35, P495, DOI 10.1080/01926230701320337; Fan MY, 2001, DRUG RESIST UPDATE, V4, P253, DOI 10.1054/drup.2001.0214; Fanger GR, 1997, CURR OPIN GENET DEV, V7, P67, DOI 10.1016/S0959-437X(97)80111-6; Ferrandi C, 2004, BRIT J PHARMACOL, V142, P953, DOI 10.1038/sj.bjp.0705873; Fuchs SY, 1998, P NATL ACAD SCI USA, V95, P10541, DOI 10.1073/pnas.95.18.10541; Fujino G, 2007, MOL CELL BIOL, V27, P8152, DOI 10.1128/MCB.00227-07; Gross A, 1999, GENE DEV, V13, P1899, DOI 10.1101/gad.13.15.1899; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; Hill MM, 2004, EMBO J, V23, P2134, DOI 10.1038/sj.emboj.7600210; Johnson GL, 2007, BBA-MOL CELL RES, V1773, P1341, DOI 10.1016/j.bbamcr.2006.12.009; Jones EV, 2007, BIOCHEM J, V405, P617, DOI 10.1042/BJ20061778; Kharbanda S, 2000, J BIOL CHEM, V275, P322, DOI 10.1074/jbc.275.1.322; Kolomeichuk SN, 2008, FEBS J, V275, P1889, DOI 10.1111/j.1742-4658.2008.06349.x; Kuwana T, 2002, CELL, V111, P331, DOI 10.1016/S0092-8674(02)01036-X; Lei K, 2002, MOL CELL BIOL, V22, P4929, DOI 10.1128/MCB.22.13.4929-4942.2002; Lei K, 2003, P NATL ACAD SCI USA, V100, P2432, DOI 10.1073/pnas.0438011100; Letai A, 2002, CANCER CELL, V2, P183, DOI 10.1016/S1535-6108(02)00127-7; Lin AN, 2002, AGING CELL, V1, P112, DOI 10.1046/j.1474-9728.2002.00014.x; Liu H, 2000, MOL CELL BIOL, V20, P2198, DOI 10.1128/MCB.20.6.2198-2208.2000; Liu J, 2005, CELL RES, V15, P36, DOI 10.1038/sj.cr.7290262; Liu TC, 2000, BIOCHEM BIOPH RES CO, V274, P811, DOI 10.1006/bbrc.2000.3236; Madesh M, 2002, J BIOL CHEM, V277, P5651, DOI 10.1074/jbc.M108171200; Marani M, 2002, MOL CELL BIOL, V22, P3577, DOI 10.1128/MCB.22.11.3577-3589.2002; Matsuzawa A, 2001, J BIOCHEM-TOKYO, V130, P1; Mei Y, 2008, NEUROSCIENCE, V151, P771, DOI 10.1016/j.neuroscience.2007.10.057; Nagata Y, 2007, MACROMOLECULES, V40, P6, DOI 10.1021/ma062007s; Oleinik NV, 2007, ONCOGENE, V26, P7222, DOI 10.1038/sj.onc.1210526; PRASAD MVVSV, 1995, J BIOL CHEM, V270, P18655, DOI 10.1074/jbc.270.31.18655; Puthalakath H, 2002, CELL DEATH DIFFER, V9, P505, DOI 10.1038/sj.cdd.4400998; Puthalakath H, 1999, MOL CELL, V3, P287, DOI 10.1016/S1097-2765(00)80456-6; Raman M, 2007, ONCOGENE, V26, P3100, DOI 10.1038/sj.onc.1210392; ROBITAILLE K, 2008, CELL DEATH DIFFER; Sanchez-Perez I, 1998, ONCOGENE, V16, P533, DOI 10.1038/sj.onc.1201578; Schroeter H, 2003, BIOCHEM J, V372, P359, DOI 10.1042/BJ20030201; SLUSS HK, 1994, MOL CELL BIOL, V14, P8376, DOI 10.1128/MCB.14.12.8376; Srivastava RK, 1999, P NATL ACAD SCI USA, V96, P3775, DOI 10.1073/pnas.96.7.3775; Sunayama J, 2005, J CELL BIOL, V170, P295, DOI 10.1083/jcb.200409117; Tobiume K, 2001, EMBO REP, V2, P222, DOI 10.1093/embo-reports/kve046; Tournier C, 2000, SCIENCE, V288, P870, DOI 10.1126/science.288.5467.870; Tsuruta F, 2004, EMBO J, V23, P1889, DOI 10.1038/sj.emboj.7600194; Turjanski AG, 2007, ONCOGENE, V26, P3240, DOI 10.1038/sj.onc.1210415; Uehara T, 2005, J HEPATOL, V42, P850, DOI 10.1016/j.jhep.2005.01.030; Verheij M, 1996, NATURE, V380, P75, DOI 10.1038/380075a0; Wang XT, 2007, CELL SIGNAL, V19, P1844, DOI 10.1016/j.cellsig.2007.04.005; WESTWICK JK, 1994, J BIOL CHEM, V269, P26396; Widmann C, 1998, MOL CELL BIOL, V18, P2416, DOI 10.1128/MCB.18.4.2416; Wilson DJ, 1996, EUR J IMMUNOL, V26, P989, DOI 10.1002/eji.1830260505; Xu ZH, 2001, MOL CELL BIOL, V21, P4713, DOI 10.1128/MCB.21.14.4713-4724.2001; Yamamoto K, 1999, MOL CELL BIOL, V19, P8469; Yang DD, 1997, NATURE, V389, P865, DOI 10.1038/39899; Zanke BW, 1996, CURR BIOL, V6, P606, DOI 10.1016/S0960-9822(02)00547-X	73	1059	1108	8	113	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT	2008	27	48					6245	6251		10.1038/onc.2008.301	http://dx.doi.org/10.1038/onc.2008.301			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	361YB	18931691	Green Accepted			2022-12-28	WOS:000260162800006
J	Ou, WB; Zhu, MJ; Demetri, GD; Fletcher, CDM; Fletcher, JA				Ou, W-b; Zhu, M-j; Demetri, G. D.; Fletcher, C. D. M.; Fletcher, J. A.			Protein kinase C-theta regulates KIT expression and proliferation in gastrointestinal stromal tumors	ONCOGENE			English	Article						PRKCQ; KIT; shRNA; gastrointestinal neoplasm; sarcoma; imatinib	RECEPTOR TYROSINE KINASES; KAPPA-B ACTIVATION; RETINOID-X-RECEPTOR; T-CELL-ACTIVATION; PKC-THETA; INTESTINAL EPITHELIUM; ANTICANCER THERAPY; IMATINIB MESYLATE; MOLECULAR-CLONING; GENE-EXPRESSION	Oncogenic KIT or PDGFRA receptor tyrosine kinase mutations are compelling therapeutic targets in gastrointestinal stromal tumors (GISTs), and the KIT/PDGFRA kinase inhibitor, imatinib, is standard of care for patients with metastatic GIST. However, most of these patients eventually develop clinical resistance to imatinib and other KIT/PDGFRA kinase inhibitors and there is an urgent need to identify novel therapeutic strategies. We reported previously that protein kinase C-theta (PKC theta) is activated in GIST, irrespective of KIT or PDGFRA mutational status, and is expressed at levels unprecedented in other mesenchymal tumors, therefore serving as a diagnostic marker of GIST. Herein, we characterize biological functions of PKC theta in imatinib-sensitive and imatinib-resistant GISTs, showing that lentivirus-mediated PKC theta knockdown is accompanied by inhibition of KIT expression in three KIT+/PKC theta+ GIST cell lines, but not in a comparator KIT+/PKCh theta-Ewing's sarcoma cell line. PKC theta knockdown in the KIT+ GISTs was associated with inhibition of the phosphatidylinositol-3-kinase/AKT signaling pathway, upregulation of the cyclin-dependent kinase inhibitors p21 and p27, antiproliferative effects due to G(1) arrest and induction of apoptosis, comparable to the effects seen after direct knockdown of KIT expression by KIT short-hairpin RNA. These novel findings highlight that PKC theta warrants clinical evaluation as a potential therapeutic target in GISTs, including those cases containing mutations that confer resistance to KIT/PDGFRA kinase inhibitors.	[Ou, W-b; Zhu, M-j; Fletcher, C. D. M.; Fletcher, J. A.] Harvard Univ, Sch Med, Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA; [Demetri, G. D.] Dana Farber Harvard Canc Ctr, Ludwig Ctr, Boston, MA USA; [Demetri, G. D.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Dana-Farber Cancer Institute; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School	Ou, WB (corresponding author), Harvard Univ, Sch Med, Brigham & Womens Hosp, Dept Pathol, 75 Francis St, Boston, MA 02115 USA.	wou@rics.bwh.harvard.edu; jfletcher@partners.org	Ou, Wen-Bin/J-1142-2019	, Wenbin/0000-0002-6311-9442	GI SPORE [1P50CA127003-01]; Life Raft Group; Cesarini Team for the Pan-Massachusetts Challenge; Virginia and Daniel K Ludwig Trust for Cancer Research; Ronald O Perelman Fund; Stutman GIST Cancer Research Fund; Rubenstein Foundation; NATIONAL CANCER INSTITUTE [P50CA127003] Funding Source: NIH RePORTER	GI SPORE; Life Raft Group; Cesarini Team for the Pan-Massachusetts Challenge; Virginia and Daniel K Ludwig Trust for Cancer Research; Ronald O Perelman Fund; Stutman GIST Cancer Research Fund; Rubenstein Foundation; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by grants from an anonymous donor, GI SPORE 1P50CA127003-01, the Life Raft Group, Cesarini Team for the Pan-Massachusetts Challenge, the Virginia and Daniel K Ludwig Trust for Cancer Research, the Ronald O Perelman Fund for Cancer Research, the Stutman GIST Cancer Research Fund, the Rubenstein Foundation and Leslie's Links. We thank Sarah E Bulmer and William Hahn for providing shRNA constructs.	Allander SV, 2001, CANCER RES, V61, P8624; Altman A, 2003, IMMUNOL REV, V192, P53, DOI 10.1034/j.1600-065X.2003.00027.x; Ashton AW, 1999, J BIOL CHEM, V274, P20805, DOI 10.1074/jbc.274.30.20805; BAIER G, 1993, J BIOL CHEM, V268, P4997; Banan A, 2005, J PHARMACOL EXP THER, V313, P962, DOI 10.1124/jpet.104.083428; Banan A, 2004, AM J PHYSIOL-CELL PH, V287, pC218, DOI 10.1152/ajpcell.00575.2003; Bauer B, 2001, J BIOL CHEM, V276, P31627, DOI 10.1074/jbc.M103098200; Bauer S, 2007, ONCOGENE, V26, P7560, DOI 10.1038/sj.onc.1210558; Bi K, 2001, NAT IMMUNOL, V2, P556, DOI 10.1038/88765; Blay JY, 2005, ANN ONCOL, V16, P566, DOI 10.1093/annonc/mdi127; Blay P, 2004, CLIN CANCER RES, V10, P4089, DOI 10.1158/1078-0432.CCR-04-0630; BLUMEJENSEN P, 1995, J BIOL CHEM, V270, P14192, DOI 10.1074/jbc.270.23.14192; BLUMEJENSEN P, 1993, EMBO J, V12, P4199, DOI 10.1002/j.1460-2075.1993.tb06104.x; BLUMEJENSEN P, 1994, J BIOL CHEM, V269, P21793; Cerda SR, 2006, ONCOGENE, V25, P3123, DOI 10.1038/sj.onc.1209360; CHANG JD, 1993, J BIOL CHEM, V268, P14208; Corless CL, 2005, J CLIN ONCOL, V23, P5357, DOI 10.1200/JCO.2005.14.068; Corless CL, 2004, J CLIN ONCOL, V22, P3813, DOI 10.1200/JCO.2004.05.140; Debiec-Rychter M, 2005, GASTROENTEROLOGY, V128, P270, DOI 10.1053/j.gastro.2004.11.020; Deeds L, 2003, J BIOL CHEM, V278, P39782, DOI 10.1074/jbc.M306854200; Demetri GD, 2002, NEW ENGL J MED, V347, P472, DOI 10.1056/NEJMoa020461; Drevs J, 2003, CURR DRUG TARGETS, V4, P113, DOI 10.2174/1389450033346885; Duensing A, 2004, ONCOGENE, V23, P3999, DOI 10.1038/sj.onc.1207525; Duensing A, 2004, CANCER RES, V64, P5127, DOI 10.1158/0008-5472.CAN-04-0559; Fletcher CDM, 2002, HUM PATHOL, V33, P459, DOI 10.1053/hupa.2002.123545; Frey MR, 1997, J BIOL CHEM, V272, P9424; Gschwind A, 2004, NAT REV CANCER, V4, P361, DOI 10.1038/nrc1360; Heinrich MC, 2003, SCIENCE, V299, P708, DOI 10.1126/science.1079666; Heinrich MC, 2006, J CLIN ONCOL, V24, P4764, DOI 10.1200/JCO.2006.06.2265; Hirota S, 1998, SCIENCE, V279, P577, DOI 10.1126/science.279.5350.577; Ishaq M, 2002, J IMMUNOL, V169, P732, DOI 10.4049/jimmunol.169.2.732; Janeway KA, 2007, CANCER RES, V67, P9084, DOI 10.1158/0008-5472.CAN-07-1938; Jiang XH, 2002, ONCOGENE, V21, P6113, DOI 10.1038/sj.onc.1205778; Lee KY, 2005, SCIENCE, V308, P114, DOI 10.1126/science.1107107; Liu YH, 2000, J BIOL CHEM, V275, P3603, DOI 10.1074/jbc.275.5.3603; Lux ML, 2000, AM J PATHOL, V156, P791, DOI 10.1016/S0002-9440(10)64946-2; Medeiros F, 2004, AM J SURG PATHOL, V28, P889, DOI 10.1097/00000478-200407000-00007; Medinger M, 2005, CURR PHARM DESIGN, V11, P1139, DOI 10.2174/1381612053507611; Motegi A, 2005, PATHOL INT, V55, P106, DOI 10.1111/j.1440-1827.2005.01806.x; Nielsen TO, 2002, LANCET, V359, P1301, DOI 10.1016/S0140-6736(02)08270-3; Paez JG, 2004, SCIENCE, V304, P1497, DOI 10.1126/science.1099314; Rastinejad F, 2001, CURR OPIN STRUC BIOL, V11, P33, DOI 10.1016/S0959-440X(00)00165-2; Rossi F, 2006, P NATL ACAD SCI USA, V103, P12843, DOI 10.1073/pnas.0511076103; Rubin BP, 2001, CANCER RES, V61, P8118; Sordella R, 2004, SCIENCE, V305, P1163, DOI 10.1126/science.1101637; Southwell BR, 2003, NEUROGASTROENT MOTIL, V15, P139, DOI 10.1046/j.1365-2982.2003.00394.x; Sun ZM, 2000, NATURE, V404, P402, DOI 10.1038/35006090; Tarn C, 2006, CANCER RES, V66, P5477, DOI 10.1158/0008-5472.CAN-05-3906; Teixeira C, 2003, BLOOD, V102, P1414, DOI 10.1182/blood-2002-11-3621; Tuveson DA, 2001, ONCOGENE, V20, P5054, DOI 10.1038/sj.onc.1204704; Villalba M, 1999, J IMMUNOL, V163, P5813; Villalba M, 2002, J CELL BIOL, V157, P253, DOI 10.1083/jcb.200201097; Wang DH, 2004, MOL CELL BIOL, V24, P164, DOI 10.1128/MCB.24.1.164-171.2003; Zhu MJ, 2007, ONCOGENE, V26, P6386, DOI 10.1038/sj.onc.1210464	54	61	63	1	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 18	2008	27	42					5624	5634		10.1038/onc.2008.177	http://dx.doi.org/10.1038/onc.2008.177			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	349KX	18521081	Green Accepted			2022-12-28	WOS:000259280800008
J	D'Souza, B; Miyamoto, A; Weinmaster, G				D'Souza, B.; Miyamoto, A.; Weinmaster, G.			The many facets of Notch ligands	ONCOGENE			English	Review						Notch ligands; Notch signaling; endocytosis; proteolysis; actin cytoskeleton	ABNORMAL VERTEBRAL SEGMENTATION; HUMAN HEMATOPOIETIC STEM; AXIAL SKELETAL DEFECTS; UBIQUITIN LIGASE; LUNATIC FRINGE; GROWTH-FACTOR; DELTA-ENDOCYTOSIS; SIGNALING PATHWAY; MIND BOMB; INTRACELLULAR DOMAIN	The Notch signaling pathway regulates a diverse array of cell types and cellular processes and is tightly regulated by ligand binding. Both canonical and noncanonical Notch ligands have been identified that may account for some of the pleiotropic nature associated with Notch signaling. This review focuses on the molecular mechanisms by which Notch ligands function as signaling agonists and antagonists, and discusses different modes of activating ligands as well as findings that support intrinsic ligand signaling activity independent of Notch. Post-translational modi. cation, proteolytic processing, endocytosis and membrane trafficking, as well as interactions with the actin cytoskeleton may contribute to the recently appreciated multifunctionality of Notch ligands. The regulation of Notch ligand expression by other signaling pathways provides a mechanism to coordinate Notch signaling with multiple cellular and developmental cues. The association of Notch ligands with inherited human disorders and cancer highlights the importance of understanding the molecular nature and activities intrinsic to Notch ligands.	[D'Souza, B.; Miyamoto, A.; Weinmaster, G.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Biol Chem, Los Angeles, CA 90095 USA; [Weinmaster, G.] Univ Calif Los Angeles, Inst Mol Biol, Los Angeles, CA 90095 USA; [Weinmaster, G.] Univ Calif Los Angeles, Jonsson Comprehens Canc Ctr, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; UCLA Jonsson Comprehensive Cancer Center; University of California System; University of California Los Angeles	Weinmaster, G (corresponding author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Biol Chem, 615 Charles Young Dr S,Box 951737,BSRB-390A, Los Angeles, CA 90095 USA.	gweinmaster@mednet.ucla.edu			NIH; AICR; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R37NS031885] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); AICR; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	We thank Esra Cagavi for helpful comments and the NIH and AICR for support to GW and BD, respectively.	Acar M, 2008, CELL, V132, P247, DOI 10.1016/j.cell.2007.12.016; Aho S, 2004, J CELL BIOCHEM, V92, P1271, DOI 10.1002/jcb.20125; Akai J, 2005, GENE DEV, V19, P2877, DOI 10.1101/gad.357705; Albig AR, 2008, MICROVASC RES, V76, P7, DOI 10.1016/j.mvr.2008.01.001; Amsen D, 2004, CELL, V117, P515, DOI 10.1016/S0092-8674(04)00451-9; Aoto J, 2007, BRAIN RES, V1184, P72, DOI 10.1016/j.brainres.2006.11.033; Artavanis-Tsakonas S, 1999, SCIENCE, V284, P770, DOI 10.1126/science.284.5415.770; Ascano JM, 2003, J BIOL CHEM, V278, P8771, DOI 10.1074/jbc.M211427200; Bachmann E, 1996, J REPROD FERTIL, V107, P279; BAKER NE, 1990, SCIENCE, V250, P1370, DOI 10.1126/science.2175046; Baladron V, 2005, EXP CELL RES, V303, P343, DOI 10.1016/j.yexcr.2004.10.001; Bardin AJ, 2006, DEV CELL, V10, P245, DOI 10.1016/j.devcel.2005.12.017; Barrantes ID, 1999, CURR BIOL, V9, P470, DOI 10.1016/S0960-9822(99)80212-7; Barriere H, 2006, TRAFFIC, V7, P282, DOI 10.1111/j.1600-0854.2006.00384.x; Barsi JC, 2005, MECH DEVELOP, V122, P1106, DOI 10.1016/j.mod.2005.06.005; Bland CE, 2003, J BIOL CHEM, V278, P13607, DOI 10.1074/jbc.C300016200; Bray SJ, 2008, BMC DEV BIOL, V8, DOI 10.1186/1471-213X-8-11; Bray SJ, 2006, NAT REV MOL CELL BIO, V7, P678, DOI 10.1038/nrm2009; Brone B, 2005, AM J PHYSIOL-CELL PH, V288, pC20, DOI 10.1152/ajpcell.00368.2004; Bruckner K, 2000, NATURE, V406, P411, DOI 10.1038/35019075; Bulman MP, 2000, NAT GENET, V24, P438, DOI 10.1038/74307; Campos AH, 2002, CIRC RES, V91, P999, DOI 10.1161/01.RES.0000044944.99984.25; Carmena A, 2002, DEV BIOL, V244, P226, DOI 10.1006/dbio.2002.0606; Chen N, 2004, DEV CELL, V6, P183, DOI 10.1016/S1534-5807(04)00021-8; Chen WB, 2004, DEV BIOL, V267, P361, DOI 10.1016/j.ydbio.2003.11.010; Cheng P, 2008, IMMUNOL RES, V41, P1, DOI 10.1007/s12026-007-8011-z; Chitnis A, 2006, DEV DYNAM, V235, P886, DOI 10.1002/dvdy.20683; CHITNIS A, 1995, NATURE, V375, P761, DOI 10.1038/375761a0; Chou YH, 2002, DEV CELL, V3, P839, DOI 10.1016/S1534-5807(02)00362-3; Cui XY, 2004, J BIOL CHEM, V279, P25858, DOI 10.1074/jbc.M313505200; Dahlqvist C, 2003, DEVELOPMENT, V130, P6089, DOI 10.1242/dev.00834; Dallas MH, 2005, J EXP MED, V201, P1361, DOI 10.1084/jem.20042450; de Joussineau C, 2003, NATURE, V426, P555, DOI 10.1038/nature02157; Deblandre GA, 2001, DEV CELL, V1, P795, DOI 10.1016/S1534-5807(01)00091-0; deCelis JF, 1997, DEVELOPMENT, V124, P3241; Delaney C, 2005, BLOOD, V106, P2693, DOI 10.1182/blood-2005-03-1131; delaPompa J, 1997, DEVELOPMENT, V124, P1139; Delwig A, 2006, EXP CELL RES, V312, P1345, DOI 10.1016/j.yexcr.2005.12.037; Dequeant ML, 2006, SCIENCE, V314, P1595, DOI 10.1126/science.1133141; Doherty D, 1996, GENE DEV, V10, P421, DOI 10.1101/gad.10.4.421; Dorsky RI, 1997, NATURE, V385, P67, DOI 10.1038/385067a0; Dravis C, 2004, DEV BIOL, V271, P272, DOI 10.1016/j.ydbio.2004.03.027; Dunwoodie SL, 2002, DEVELOPMENT, V129, P1795; Dunwoodie SL, 1997, DEVELOPMENT, V124, P3065; Dyczynska E, 2007, J BIOL CHEM, V282, P436, DOI 10.1074/jbc.M605451200; Eiraku M, 2005, NAT NEUROSCI, V8, P873, DOI 10.1038/nn1492; Eiraku M, 2002, J BIOL CHEM, V277, P25400, DOI 10.1074/jbc.M110793200; Emery G, 2005, CELL, V122, P763, DOI 10.1016/j.cell.2005.08.017; Estrach S, 2007, J CELL SCI, V120, P2944, DOI 10.1242/jcs.016253; Estrach S, 2006, DEVELOPMENT, V133, P4427, DOI 10.1242/dev.02644; Eun SH, 2007, GENETICS, V175, P1163, DOI 10.1534/genetics.106.067959; Faux CH, 2001, J NEUROSCI, V21, P5587, DOI 10.1523/JNEUROSCI.21-15-05587.2001; FEHON RG, 1990, CELL, V61, P523, DOI 10.1016/0092-8674(90)90534-L; Fitzgerald K, 1995, DEVELOPMENT, V121, P4275; Fiuza UM, 2007, J ENDOCRINOL, V194, P459, DOI 10.1677/JOE-07-0242; Franklin JL, 1999, CURR BIOL, V9, P1448, DOI 10.1016/S0960-9822(00)80114-1; Geffers I, 2007, J CELL BIOL, V178, P465, DOI 10.1083/jcb.200702009; GIBSON MA, 1991, J BIOL CHEM, V266, P7596; Gibson MA, 1996, J BIOL CHEM, V271, P1096, DOI 10.1074/jbc.271.2.1096; Glittenberg M, 2006, EMBO J, V25, P4697, DOI 10.1038/sj.emboj.7601337; Gordon WR, 2007, NAT STRUCT MOL BIOL, V14, P295, DOI 10.1038/nsmb1227; Gridley T, 1997, MOL CELL NEUROSCI, V9, P103, DOI 10.1006/mcne.1997.0610; Gridley T, 2003, HUM MOL GENET, V12, pR9, DOI 10.1093/hmg/ddg052; Gupta R, 2007, SCIENCE, V316, P590, DOI 10.1126/science.1136031; Hagedorn EJ, 2006, J CELL BIOL, V173, P443, DOI 10.1083/jcb.200602054; Haltiwanger RS, 2004, ANNU REV BIOCHEM, V73, P491, DOI 10.1146/annurev.biochem.73.011303.074043; Harris BZ, 2001, J CELL SCI, V114, P3219; Hatakeyama J, 2004, DEVELOPMENT, V131, P5539, DOI 10.1242/dev.01436; Hawryluk MJ, 2006, TRAFFIC, V7, P262, DOI 10.1111/j.1600-0854.2006.00383.x; Heath E, 2008, BMC DEV BIOL, V8, DOI 10.1186/1471-213X-8-18; Hellstrom M, 2007, NATURE, V445, P776, DOI 10.1038/nature05571; Henrique D, 1997, CURR BIOL, V7, P661, DOI 10.1016/S0960-9822(06)00293-4; Hicks C, 2000, NAT CELL BIOL, V2, P515, DOI 10.1038/35019553; Hicks C, 2002, J NEUROSCI RES, V68, P655, DOI 10.1002/jnr.10263; Hiratochi M, 2007, NUCLEIC ACIDS RES, V35, P912, DOI 10.1093/nar/gkl1128; Hofmann M, 2004, GENE DEV, V18, P2712, DOI 10.1101/gad.1248604; Holland SJ, 1996, NATURE, V383, P722, DOI 10.1038/383722a0; Horvath CAJ, 2007, INT J BIOCHEM CELL B, V39, P1765, DOI 10.1016/j.biocel.2006.12.004; Hsiung F, 2005, NATURE, V437, P560, DOI 10.1038/nature03951; Hsueh YP, 2000, NATURE, V404, P298, DOI 10.1038/35005118; Hu QD, 2003, CELL, V115, P163, DOI 10.1016/S0092-8674(03)00810-9; Hukriede NA, 1997, DEVELOPMENT, V124, P3427; Hurlbut GD, 2007, CURR OPIN CELL BIOL, V19, P166, DOI 10.1016/j.ceb.2007.02.012; Ikeuchi T, 2003, J BIOL CHEM, V278, P7751, DOI 10.1074/jbc.C200711200; Irvine KD, 2008, CELL, V132, P177, DOI 10.1016/j.cell.2008.01.005; Itoh F, 2004, EMBO J, V23, P541, DOI 10.1038/sj.emboj.7600065; Itoh M, 2003, DEV CELL, V4, P67, DOI 10.1016/S1534-5807(02)00409-4; Itoh T, 2005, DEV CELL, V9, P791, DOI 10.1016/j.devcel.2005.11.005; Jacobsen TL, 1998, DEVELOPMENT, V125, P4531; Jafar-Nejad H, 2005, DEV CELL, V9, P351, DOI 10.1016/j.devcel.2005.06.010; Jelen F, 2003, ACTA BIOCHIM POL, V50, P985; Karanu FN, 2000, J EXP MED, V192, P1365, DOI 10.1084/jem.192.9.1365; Klein T, 1997, DEV BIOL, V189, P123, DOI 10.1006/dbio.1997.8564; Klein T, 1998, DEVELOPMENT, V125, P2951; Klueg KM, 1999, J CELL SCI, V112, P3289; Klueg KM, 1998, MOL BIOL CELL, V9, P1709, DOI 10.1091/mbc.9.7.1709; Kluppel M, 2005, BIOESSAYS, V27, P115, DOI 10.1002/bies.20187; Koch U, 2001, IMMUNITY, V15, P225, DOI 10.1016/S1074-7613(01)00189-3; Koch U, 2007, CELL MOL LIFE SCI, V64, P2746, DOI 10.1007/s00018-007-7164-1; Kolev V, 2005, FEBS LETT, V579, P5798, DOI 10.1016/j.febslet.2005.09.042; Koo BK, 2005, DEVELOPMENT, V132, P3459, DOI 10.1242/dev.01922; Koo BK, 2005, J BIOL CHEM, V280, P22335, DOI 10.1074/jbc.M501631200; Koo BK, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0001221; Koutelou E, 2008, J BIOL CHEM, V283, P3846, DOI 10.1074/jbc.M706974200; Krivtsov AV, 2007, J CELL BIOCHEM, V101, P767, DOI 10.1002/jcb.21232; Kusumi K, 2004, GENESIS, V39, P115, DOI 10.1002/gene.20034; Kusumi K, 1998, NAT GENET, V19, P274, DOI 10.1038/961; LABORDA J, 1993, J BIOL CHEM, V268, P3817; Ladi E, 2005, J CELL BIOL, V170, P983, DOI 10.1083/jcb.200503113; Lai EC, 2001, DEV CELL, V1, P783, DOI 10.1016/S1534-5807(01)00092-2; Lai EC, 2005, DEVELOPMENT, V132, P2319, DOI 10.1242/dev.01825; Lai EC, 2001, P NATL ACAD SCI USA, V98, P5637, DOI 10.1073/pnas.101135498; Lai EC, 2001, DEV BIOL, V231, P217, DOI 10.1006/dbio.2000.0124; Langevin J, 2005, DEV CELL, V9, P365, DOI 10.1016/j.devcel.2005.07.013; LaVoie MJ, 2003, J BIOL CHEM, V278, P34427, DOI 10.1074/jbc.M302659200; Le Borgne R, 2006, CURR OPIN CELL BIOL, V18, P213, DOI 10.1016/j.ceb.2006.02.011; Le Borgne R, 2005, PLOS BIOL, V3, P688, DOI 10.1371/journal.pbio.0030096; Le Borgne R, 2003, DEV CELL, V5, P139, DOI 10.1016/S1534-5807(03)00187-4; Le Borgne R, 2003, CURR BIOL, V13, pR273, DOI 10.1016/S0960-9822(03)00199-4; Leask A, 2006, J CELL SCI, V119, P4803, DOI 10.1242/jcs.03270; Lee JH, 2005, J ENDOCRINOL, V187, P283, DOI 10.1677/joe.1.06305; LEHMANN R, 1983, ROUX ARCH DEV BIOL, V192, P62, DOI 10.1007/BF00848482; Lei L, 2003, DEVELOPMENT, V130, P6411, DOI 10.1242/dev.00883; Leong KG, 2006, BLOOD, V107, P2223, DOI 10.1182/blood-2005-08-3329; Li JL, 2007, CANCER RES, V67, P11244, DOI 10.1158/0008-5472.CAN-07-0969; Lieber T, 2002, GENE DEV, V16, P209, DOI 10.1101/gad.942302; Limbourg A, 2007, CIRC RES, V100, P363, DOI 10.1161/01.RES.0000258174.77370.2c; Liotta F, 2008, STEM CELLS, V26, P279, DOI 10.1634/stemcells.2007-0454; Liu ZJ, 2003, MOL CELL BIOL, V23, P14, DOI 10.1128/MCB.23.1.14-25.2003; Lobov IB, 2007, P NATL ACAD SCI USA, V104, P3219, DOI 10.1073/pnas.0611206104; Loomes KM, 2007, DEV DYNAM, V236, P2943, DOI 10.1002/dvdy.21296; Lowell S, 2000, CURR BIOL, V10, P491, DOI 10.1016/S0960-9822(00)00451-6; Lowell S, 2001, MECH DEVELOP, V107, P133, DOI 10.1016/S0925-4773(01)00459-2; Lu L, 2008, STEM CELLS, V26, P580, DOI 10.1634/stemcells.2007-0106; McGlinn E, 2005, MECH DEVELOP, V122, P1218, DOI 10.1016/j.mod.2005.06.012; Micchelli CA, 1997, DEVELOPMENT, V124, P1485; Minamizato T, 2007, BIOCHEM BIOPH RES CO, V354, P567, DOI 10.1016/j.bbrc.2007.01.029; Mishra-Gorur K, 2002, J CELL BIOL, V159, P313, DOI 10.1083/jcb.200203117; Miyamoto A, 2006, J BIOL CHEM, V281, P10089, DOI 10.1074/jbc.M600298200; Mizuhara E, 2005, J BIOL CHEM, V280, P26499, DOI 10.1074/jbc.M500375200; MLODZIK M, 1990, GENE DEV, V4, P1848, DOI 10.1101/gad.4.11.1848; Mok LP, 2005, BMC DEV BIOL, V5, DOI 10.1186/1471-213X-5-6; Morel V, 2003, DEV GENES EVOL, V213, P65, DOI 10.1007/s00427-003-0296-x; Morrison SJ, 2000, CELL, V101, P499, DOI 10.1016/S0092-8674(00)80860-0; Mukherjee A, 2005, NAT CELL BIOL, V7, P1191, DOI 10.1038/ncb1327; Muraguchi T, 2007, NAT NEUROSCI, V10, P838, DOI 10.1038/nn1922; Nakata A, 2004, GENES CELLS, V9, P1125, DOI 10.1111/j.1365-2443.2004.00795.x; Nanda N, 2005, J BIOL CHEM, V280, P24680, DOI 10.1074/jbc.M413411200; Nehring LC, 2005, J BIOL CHEM, V280, P20349, DOI 10.1074/jbc.M500273200; Nichols JT, 2007, TRAFFIC, V8, P959, DOI 10.1111/j.1600-0854.2007.00592.x; Nichols JT, 2007, J CELL BIOL, V176, P445, DOI 10.1083/jcb.200609014; Noguera-Troise I, 2006, NATURE, V444, P1032, DOI 10.1038/nature05355; Nueda ML, 2007, J MOL BIOL, V367, P1281, DOI 10.1016/j.jmb.2006.10.043; Okajima T, 2003, J BIOL CHEM, V278, P42340, DOI 10.1074/jbc.M308687200; OKAJIMA T, 2008, J BIOCH         0213; Okajima T, 2008, BMC BIOL, V6, DOI 10.1186/1741-7007-6-1; Osborne BA, 2007, NAT REV IMMUNOL, V7, P64, DOI 10.1038/nri1998; Overstreet E, 2004, DEVELOPMENT, V131, P5355, DOI 10.1242/dev.01434; PANIN VM, 2002, J BIOL CHEM, V29, P29; Parks AL, 2000, DEVELOPMENT, V127, P1373; Parks AL, 1997, MECH DEVELOP, V63, P61, DOI 10.1016/S0925-4773(97)00675-8; Parks AL, 2006, GENETICS, V174, P1947, DOI 10.1534/genetics.106.061630; Patel NS, 2005, CANCER RES, V65, P8690, DOI 10.1158/0008-5472.CAN-05-1208; Pavlopoulos E, 2001, DEV CELL, V1, P807, DOI 10.1016/S1534-5807(01)00093-4; Pfister S, 2003, J MOL BIOL, V333, P229, DOI 10.1016/j.jmb.2003.08.043; Piccoli DA, 2001, SEMIN LIVER DIS, V21, P525, DOI 10.1055/s-2001-19036; Pintar A, 2007, BIOL DIRECT, V2, DOI 10.1186/1745-6150-2-19; Pitsouli C, 2005, DEVELOPMENT, V132, P4041, DOI 10.1242/dev.01979; Powell PA, 2001, NATURE, V409, P626, DOI 10.1038/35054566; Qi HL, 1999, SCIENCE, V283, P91, DOI 10.1126/science.283.5398.91; Quilliam LA, 1999, J BIOL CHEM, V274, P23850, DOI 10.1074/jbc.274.34.23850; Rampal R, 2007, CURR MOL MED, V7, P427, DOI 10.2174/156652407780831593; Raymond Tracy, 2007, Proc Am Thorac Soc, V4, P635, DOI 10.1513/pats.200706-067TH; Renaud O, 2001, DEV BIOL, V240, P361, DOI 10.1006/dbio.2001.0482; Roca C, 2007, GENE DEV, V21, P2511, DOI 10.1101/gad.1589207; Ross DA, 2004, MOL CELL BIOL, V24, P3505, DOI 10.1128/MCB.24.8.3505-3513.2004; Roux A, 2006, NATURE, V441, P528, DOI 10.1038/nature04718; Ruan YL, 2001, P NATL ACAD SCI USA, V98, P9907, DOI 10.1073/pnas.171321098; Sainson RCA, 2008, ANGIOGENESIS, V11, P41, DOI 10.1007/s10456-008-9098-0; Sakamoto K, 2002, J BIOL CHEM, V277, P29399, DOI 10.1074/jbc.M203727200; Sakamoto K, 2002, DEV BIOL, V241, P313, DOI 10.1006/dbio.2001.0517; Sapir A, 2005, DEVELOPMENT, V132, P123, DOI 10.1242/dev.01546; Seals DF, 2003, GENE DEV, V17, P7, DOI 10.1101/gad.1039703; Seo S, 2006, DEV BIOL, V294, P458, DOI 10.1016/j.ydbio.2006.03.035; Seugnet L, 1997, DEV BIOL, V192, P585, DOI 10.1006/dbio.1997.8723; Shimizu K, 2001, J BIOL CHEM, V276, P25753, DOI 10.1074/jbc.M103473200; Shimizu K, 1999, J BIOL CHEM, V274, P32961, DOI 10.1074/jbc.274.46.32961; Shimizu K, 2002, EMBO J, V21, P294, DOI 10.1093/emboj/21.3.294; Shoji H, 2000, J BIOL CHEM, V275, P5485, DOI 10.1074/jbc.275.8.5485; Six E, 2003, P NATL ACAD SCI USA, V100, P7638, DOI 10.1073/pnas.1230693100; Six EM, 2004, J BIOL CHEM, V279, P55818, DOI 10.1074/jbc.M408022200; Skwarek LC, 2007, DEV CELL, V13, P783, DOI 10.1016/j.devcel.2007.10.020; Small D, 2001, J BIOL CHEM, V276, P32022, DOI 10.1074/jbc.M100933200; SMAS CM, 1993, CELL, V73, P725, DOI 10.1016/0092-8674(93)90252-L; Song R, 2006, J BIOL CHEM, V281, P36391, DOI 10.1074/jbc.M606601200; Stahl M, 2008, J BIOL CHEM, V283, P13638, DOI 10.1074/jbc.M802027200; Stanley P, 2007, CURR OPIN STRUC BIOL, V17, P530, DOI 10.1016/j.sbi.2007.09.007; Staub O, 2006, PHYSIOL REV, V86, P669, DOI 10.1152/physrev.00020.2005; Suchting S, 2007, P NATL ACAD SCI USA, V104, P3225, DOI 10.1073/pnas.0611177104; Sun X, 1996, DEVELOPMENT, V122, P2465; Sun X, 1997, DEVELOPMENT, V124, P3439; Takahashi Y, 2003, DEVELOPMENT, V130, P4259, DOI 10.1242/dev.00629; Takeuchi T, 2005, AM J PATHOL, V166, P1817, DOI 10.1016/S0002-9440(10)62491-1; Thibout H, 2003, J CLIN ENDOCR METAB, V88, P327, DOI 10.1210/jc.2002-020304; Thurston G, 2007, NAT REV CANCER, V7, P327, DOI 10.1038/nrc2130; Traub LM, 2007, J CELL SCI, V120, P543, DOI 10.1242/jcs.03385; Trifonova R, 2004, J BIOL CHEM, V279, P13285, DOI 10.1074/jbc.C300564200; Tsuda L, 2002, CELL, V110, P625, DOI 10.1016/S0092-8674(02)00875-9; Turnpenny PD, 2003, J MED GENET, V40, P333, DOI 10.1136/jmg.40.5.333; Turnpenny PD, 2007, DEV DYNAM, V236, P1456, DOI 10.1002/dvdy.21182; Varnum-Finney B, 2000, J CELL SCI, V113, P4313; Vas V, 2004, J LEUKOCYTE BIOL, V75, P714, DOI 10.1189/jlb.1003462; Visan I, 2006, IMMUNOL REV, V209, P76, DOI 10.1111/j.0105-2896.2006.00360.x; Visan I, 2006, NAT IMMUNOL, V7, P634, DOI 10.1038/ni1345; Vitt UA, 2001, MOL ENDOCRINOL, V15, P681, DOI 10.1210/me.15.5.681; Vollrath B, 2001, MOL CELL BIOL, V21, P7481, DOI 10.1128/MCB.21.21.7481-7494.2001; Wang WD, 2005, DEVELOPMENT, V132, P2883, DOI 10.1242/dev.01860; Wang WD, 2004, DEVELOPMENT, V131, P5367, DOI 10.1242/dev.01413; Wang YH, 2006, J NUTR, V136, P2953, DOI 10.1093/jn/136.12.2953; Wang YH, 2006, MOL CELL BIOL, V26, P5421, DOI 10.1128/MCB.02437-05; Weinmaster G, 1997, MOL CELL NEUROSCI, V9, P91, DOI 10.1006/mcne.1997.0612; Wesley CS, 1999, MOL CELL BIOL, V19, P5743; Williams CK, 2006, BLOOD, V107, P931, DOI 10.1182/blood-2005-03-1000; Wright GJ, 2004, DEVELOPMENT, V131, P5659, DOI 10.1242/dev.01417; Wu SY, 2005, NAT STRUCT MOL BIOL, V12, P879, DOI 10.1038/nsmb987; Xu AG, 2007, J BIOL CHEM, V282, P35153, DOI 10.1074/jbc.M707040200; Yan MH, 2007, CLIN CANCER RES, V13, P7243, DOI 10.1158/1078-0432.CCR-07-1393; Yang LT, 2005, MOL BIOL CELL, V16, P927, DOI 10.1091/mbc.e04-07-0614; Yeh E, 2001, CURR BIOL, V11, P1675, DOI 10.1016/S0960-9822(01)00527-9; Yeh E, 2000, EMBO J, V19, P4827, DOI 10.1093/emboj/19.17.4827; Zavadil J, 2004, EMBO J, V23, P1155, DOI 10.1038/sj.emboj.7600069; Zhang CJ, 2007, J MOL BIOL, V366, P1115, DOI 10.1016/j.jmb.2006.11.096; Zhang CJ, 2007, DEV BIOL, V305, P14, DOI 10.1016/j.ydbio.2007.01.034; Zhang N, 2002, GENESIS, V33, P21, DOI 10.1002/gene.10081; Zolkiewska A, 2008, CELL MOL LIFE SCI, V65, P2056, DOI 10.1007/s00018-008-7586-4	235	335	349	0	37	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP	2008	27	38					5148	5167		10.1038/onc.2008.229	http://dx.doi.org/10.1038/onc.2008.229			20	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	344GM	18758484	Green Accepted			2022-12-28	WOS:000258914900009
J	Caffarel, MM; Moreno-Bueno, G; Cerutti, C; Palacios, J; Guzman, M; Mechta-Grigoriou, F; Sanchez, C				Caffarel, M. M.; Moreno-Bueno, G.; Cerutti, C.; Palacios, J.; Guzman, M.; Mechta-Grigoriou, F.; Sanchez, C.			JunD is involved in the antiproliferative effect of Delta(9)-tetrahydrocannabinol on human breast cancer cells	ONCOGENE			English	Article						cannabinoids; breast cancer; JunD; AP-1; p27; testin	NEUROPROTECTIVE ANTIOXIDANTS; INDUCED APOPTOSIS; TUMOR-CELLS; PROTEIN; TRANSFORMATION; CANNABINOIDS; CANNABIDIOL; STRESS; AP-1; PROLIFERATION	It has been recently shown that cannabinoids, the active components of marijuana and their derivatives, inhibit cell cycle progression of human breast cancer cells. Here we studied the mechanism of Delta(9)-tetrahydrocannabinol (THC) antiproliferative action in these cells, and show that it involves the modulation of JunD, a member of the AP-1 transcription factor family. THC activates JunD both by upregulating gene expression and by translocating the protein to the nuclear compartment, and these events are accompanied by a decrease in cell proliferation. Of interest, neither JunD activation nor proliferation inhibition was observed in human non-tumour mammary epithelial cells exposed to THC. We confirmed the importance of JunD in THC action by RNA interference and genetic ablation. Thus, in both JunD-silenced human breast cancer cells and JunD knockout mice-derived immortalized. broblasts, the antiproliferative effect exerted by THC was significantly diminished. Gene array and siRNA experiments support that the cyclin-dependent kinase inhibitor p27 and the tumour suppressor gene testin are candidate JunD targets in cannabinoid action. In addition, our data suggest that the stress-regulated protein p8 participates in THC antiproliferative action in a JunD-independent manner. In summary, this is the first report showing not only that cannabinoids regulate JunD but, more generally, that JunD activation reduces the proliferation of cancer cells, which points to a new target to inhibit breast cancer progression.	[Caffarel, M. M.; Cerutti, C.; Palacios, J.; Sanchez, C.] Univ Complutense, Sch Biol, Dept Biochem & Mol Biol 1, E-28040 Madrid, Spain; [Moreno-Bueno, G.] Univ Autonoma Madrid, Dept Biochem, Inst Invest Biomed Alberto Sols, Madrid, Spain; [Palacios, J.] Hosp Univ Virgen Rocio, Dept Pathol, Seville, Spain; [Mechta-Grigoriou, F.] Inst Curie, INSERM, U830, Paris, France	Complutense University of Madrid; Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Investigaciones Biomedicas Alberto Sols (IIBM); Virgen del Rocio University Hospital; UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite Paris Cite	Sanchez, C (corresponding author), Univ Complutense, Sch Biol, Dept Biochem & Mol Biol 1, C Jose Antonio Novais 2, E-28040 Madrid, Spain.	cristina.sanchez@quim.ucm.es	Moreno-Bueno, Gema/K-9354-2016; Palacios, Jose/AAV-3765-2020; Cerutti, Camilla/ABC-4159-2021; Cerutti, Camilla/U-8890-2019; Sanchez, Cristina/H-4980-2017; MECHTA-GRIGORIOU, Fatima/C-5253-2017; Sanchez, Cristina/AFQ-4745-2022	Moreno-Bueno, Gema/0000-0002-5030-6687; Cerutti, Camilla/0000-0001-9426-686X; Sanchez, Cristina/0000-0002-1428-3078; MECHTA-GRIGORIOU, Fatima/0000-0002-3751-6989; Guzman, Manuel/0000-0001-7475-118X; Caffarel, Maria/0000-0002-7442-6827	Fondo de Investigaciones Sanitarias; Fundacion Mutua Madrilena; Spanish Ministry of Education and Science; ISCIII-RETIC; Comunidad de Madrid; Inserm Avenir; Institut Curie; Fondation de France	Fondo de Investigaciones Sanitarias(Instituto de Salud Carlos III); Fundacion Mutua Madrilena(Instituto de Salud Carlos III); Spanish Ministry of Education and Science(Spanish Government); ISCIII-RETIC(Instituto de Salud Carlos III); Comunidad de Madrid(Comunidad de Madrid); Inserm Avenir(Institut National de la Sante et de la Recherche Medicale (Inserm)); Institut Curie; Fondation de France(Fondation de France)	We are indebted to the personnel of the Genomics Unit ( Complutense University) for expert advice on RT-qPCR experiments, and to the members of our laboratories for technical support and critical discussions on this work, especially to M Salazar. C Sanchez and G Moreno-Bueno are researchers of the 'Ramon y Cajal Program' of the Spanish Ministry of Education and Science. MM Caffarel is the recipient of a fellowship from the Spanish Ministry of Education and Science. This work was supported by grants from Fondo de Investigaciones Sanitarias (C Sanchez and J Palacios), Fundacion Mutua Madrilena (C Sanchez), Spanish Ministry of Education and Science (J Palacios and M Guzman), ISCIII-RETIC (J Palacios), Comunidad de Madrid (M Guzman) and Inserm Avenir, Institut Curie and Fondation de France (F Mechta-Grigoriou).	Bakiri L, 2002, MOL CELL BIOL, V22, P4952, DOI 10.1128/MCB.22.13.4952-4964.2002; Berdyshev EV, 2001, BIOCHEM J, V360, P67, DOI 10.1042/0264-6021:3600067; Blazquez C, 2006, FASEB J, V20, P2633, DOI 10.1096/fj.06-6638fje; Caffarel MM, 2006, CANCER RES, V66, P6615, DOI 10.1158/0008-5472.CAN-05-4566; Carracedo A, 2006, CANCER CELL, V9, P301, DOI 10.1016/j.ccr.2006.03.005; Carracedo A, 2006, CANCER RES, V66, P6748, DOI 10.1158/0008-5472.CAN-06-0169; De Petrocellis L, 1998, P NATL ACAD SCI USA, V95, P8375, DOI 10.1073/pnas.95.14.8375; Drusco A, 2005, P NATL ACAD SCI USA, V102, P10947, DOI 10.1073/pnas.0504934102; Eferl R, 2003, NAT REV CANCER, V3, P859, DOI 10.1038/nrc1209; Gerald D, 2004, CELL, V118, P781, DOI 10.1016/j.cell.2004.08.025; Giuliano M, 2006, INT J MOL MED, V17, P811; Guzman M, 2006, BRIT J CANCER, V95, P197, DOI 10.1038/sj.bjc.6603236; Guzman M, 2003, NAT REV CANCER, V3, P745, DOI 10.1038/nrc1188; Hampson AJ, 1998, P NATL ACAD SCI USA, V95, P8268, DOI 10.1073/pnas.95.14.8268; Hampson AJ, 2000, ANN NY ACAD SCI, V899, P274, DOI 10.1111/j.1749-6632.2000.tb06193.x; Iuvone T, 2004, J NEUROCHEM, V89, P134, DOI 10.1111/j.1471-4159.2003.02327.x; Lallemand D, 1997, ONCOGENE, V14, P819, DOI 10.1038/sj.onc.1200901; Ligresti A, 2006, J PHARMACOL EXP THER, V318, P1375, DOI 10.1124/jpet.106.105247; Maccarrone M, 2003, J BIOL CHEM, V278, P33896, DOI 10.1074/jbc.M303994200; Malumbres M, 2001, NAT REV CANCER, V1, P222, DOI 10.1038/35106065; Mechta F, 1997, ONCOGENE, V14, P837, DOI 10.1038/sj.onc.1200900; Mechta-Grigoriou F, 2001, ONCOGENE, V20, P2378, DOI 10.1038/sj.onc.1204381; PFARR CM, 1994, CELL, V76, P747, DOI 10.1016/0092-8674(94)90513-4; Salazar M, 2006, J BIOL CHEM, V281, P14841, DOI 10.1074/jbc.M513737200; Sarnataro D, 2006, MOL PHARMACOL, V70, P1298, DOI 10.1124/mol.106.025601; Stickeler E, 1999, ONCOGENE, V18, P3574, DOI 10.1038/sj.onc.1202671; VANDAM H, 1993, EMBO J, V12, P479, DOI 10.1002/j.1460-2075.1993.tb05680.x; Weitzman JB, 2000, MOL CELL, V6, P1109, DOI 10.1016/S1097-2765(00)00109-X; Zhao Q, 2005, J BIOL CHEM, V280, P26735, DOI 10.1074/jbc.M412828200	29	55	58	0	21	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 28	2008	27	37					5033	5044		10.1038/onc.2008.145	http://dx.doi.org/10.1038/onc.2008.145			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	344GL	18454173				2022-12-28	WOS:000258914800006
J	Stemmer, V; de Craene, B; Berx, G; Behrens, J				Stemmer, V.; de Craene, B.; Berx, G.; Behrens, J.			Snail promotes Wnt target gene expression and interacts with beta-catenin	ONCOGENE			English	Article						beta-catenin; colorectal cancer; epithelial-mesenchymal transition; snail; Wnt	EPITHELIAL-MESENCHYMAL TRANSITION; TRANSCRIPTION FACTOR SNAIL; TUMOR PROGRESSION; SIGNALING PATHWAY; MODULATION; TUMORIGENESIS; CANCER; CELLS	The transcription factor snail represses epithelial gene expression and thereby promotes epithelial-mesenchymal transitions (EMT) and tumor invasion. The Wnt/beta-catenin pathway is also involved in EMT and was shown to activate snail. Here, we demonstrate that snail increases Wnt reporter gene activity induced by beta-catenin, LRP6 or dishevelled, and also promotes transcription activated by GAL4-beta-catenin fusion proteins. Snail mutants lacking the transcriptional repressor domain also stimulate beta-catenin-dependent transcription indicating that downregulation of snail target genes is not required for this activity. Snail interacts with beta-catenin in immunoprecipitation experiments at its N-terminus, which is required for activation by snail. In colorectal cancer cell lines, overexpression of snail leads to increased expression of Wnt target genes, whereas downregulation of endogenous snail by siRNA reduces target gene expression. Our data indicate a positive feedback stimulation of the Wnt pathway by activation of snail.	[Stemmer, V.; Behrens, J.] Univ Erlangen Nurnberg, Nikolaus Fiebiger Ctr Mol Med, D-91054 Erlangen, Germany; [de Craene, B.; Berx, G.] Univ Ghent VIB, Dept Mol Biomed Res Mol & Cellular Oncol, Ghent, Zwijnaarde, Belgium	University of Erlangen Nuremberg; Flanders Institute for Biotechnology (VIB); Ghent University	Behrens, J (corresponding author), Univ Erlangen Nurnberg, Nikolaus Fiebiger Ctr Mol Med, Glueckstr 6, D-91054 Erlangen, Germany.	jbehrens@molmed.uni-erlangen.de	De Craene, Bram/B-9373-2009	Berx, Geert/0000-0001-5770-2458				Bachelder RE, 2005, J CELL BIOL, V168, P29, DOI 10.1083/jcb.200409067; Barrallo-Gimeno A, 2005, DEVELOPMENT, V132, P3151, DOI 10.1242/dev.01907; Batlle E, 2000, NAT CELL BIOL, V2, P84, DOI 10.1038/35000034; Behrens J, 2005, BIOCHEM SOC T, V33, P672, DOI 10.1042/BST0330672; Brabletz T, 2001, P NATL ACAD SCI USA, V98, P10356, DOI 10.1073/pnas.171610498; Brembeck FH, 2004, GENE DEV, V18, P2225, DOI 10.1101/gad.317604; Cano A, 2000, NAT CELL BIOL, V2, P76, DOI 10.1038/35000025; Dale JK, 2006, DEV CELL, V10, P355, DOI 10.1016/j.devcel.2006.02.011; De Craene B, 2005, CANCER RES, V65, P6237, DOI 10.1158/0008-5472.CAN-04-3545; Hsu SC, 1998, MOL CELL BIOL, V18, P4807, DOI 10.1128/MCB.18.8.4807; Huber MA, 2005, CURR OPIN CELL BIOL, V17, P548, DOI 10.1016/j.ceb.2005.08.001; Jho EH, 2002, MOL CELL BIOL, V22, P1172, DOI 10.1128/MCB.22.4.1172-1183.2002; Krieghoff E, 2006, J CELL SCI, V119, P1453, DOI 10.1242/jcs.02864; Lustig B, 2002, MOL CELL BIOL, V22, P1184, DOI 10.1128/MCB.22.4.1184-1193.2002; Peinado H, 2004, MOL CELL BIOL, V24, P306, DOI 10.1128/MCB.24.1.306-319.2004; Roy HK, 2004, MOL CANCER THER, V3, P1159; Yook JI, 2006, NAT CELL BIOL, V8, P1398, DOI 10.1038/ncb1508; Zhou BHP, 2004, NAT CELL BIOL, V6, P931, DOI 10.1038/ncb1173	18	186	198	0	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 28	2008	27	37					5075	5080		10.1038/onc.2008.140	http://dx.doi.org/10.1038/onc.2008.140			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	344GL	18469861				2022-12-28	WOS:000258914800010
J	Polager, S; Ofir, M; Ginsberg, D				Polager, S.; Ofir, M.; Ginsberg, D.			E2F1 regulates autophagy and the transcription of autophagy genes	ONCOGENE			English	Article						E2F; autophagy; LC3; ATG1; DRAM	PROGRAMMED CELL-DEATH; APOPTOSIS; TARGET; PATHWAYS; ROLES; YEAST; DRAM; P53	The retinoblastoma pathway is often inactivated in human tumors resulting in deregulated E2F activity that can induce both proliferation and cell death. Although the role of E2F in apoptosis is well characterized, little is known regarding its putative participation in other cell death pathways. We show here that activation of E2F1 upregulates the expression off our autophagy genes microtubule-associated protein-1 light chain-3 (LC3), autophagy-related gene-1 (ATG1), ATG5 and damage-regulated autophagy modulator (DRAM). E2F1-mediated induction of LC3, ATG1 and DRAM is direct and indeed, endogenous E2F1 can be found bound to regions encompassing the promoters of these genes. Regulation of ATG5 by E2F1 is indirect. Importantly, we demonstrate that E2F1 activation enhances autophagy and conversely, reducing endogenous E2F1 expression inhibits DNA damage-induced autophagy. These studies identify E2F1 as a transcriptional regulator of autophagy, and for the first time establish a role for E2F1 in DNA damage-induced autophagy.	[Polager, S.; Ofir, M.; Ginsberg, D.] Bar Ilan Univ, Mina & Everard Goodman Fac Life Sci, IL-52900 Ramat Gan, Israel	Bar Ilan University	Ginsberg, D (corresponding author), Bar Ilan Univ, Mina & Everard Goodman Fac Life Sci, IL-52900 Ramat Gan, Israel.	ginsbed@mail.biu.ac.il		ginsberg, doron/0000-0002-1257-4920				Baehrecke EH, 2005, NAT REV MOL CELL BIO, V6, P505, DOI 10.1038/nrm1666; Crighton D, 2007, CELL DEATH DIFFER, V14, P1071, DOI 10.1038/sj.cdd.4402108; Crighton D, 2006, CELL, V126, P121, DOI 10.1016/j.cell.2006.05.034; DeGregori J, 2006, CURR MOL MED, V6, P739; Dimova DK, 2005, ONCOGENE, V24, P2810, DOI 10.1038/sj.onc.1208612; Edinger AL, 2004, CURR OPIN CELL BIOL, V16, P663, DOI 10.1016/j.ceb.2004.09.011; Feng ZH, 2005, P NATL ACAD SCI USA, V102, P8204, DOI 10.1073/pnas.0502857102; Fortin A, 2004, J BIOL CHEM, V279, P28706, DOI 10.1074/jbc.M400376200; Ginsberg D, 2002, FEBS LETT, V529, P122, DOI 10.1016/S0014-5793(02)03270-2; Gozuacik D, 2007, CURR TOP DEV BIOL, V78, P217, DOI 10.1016/S0070-2153(06)78006-1; Hershko T, 2004, J BIOL CHEM, V279, P8627, DOI 10.1074/jbc.M312866200; Kabeya Y, 2000, EMBO J, V19, P5720, DOI 10.1093/emboj/19.21.5720; Kirisako T, 1999, J CELL BIOL, V147, P435, DOI 10.1083/jcb.147.2.435; Klionsky DJ, 2000, SCIENCE, V290, P1717, DOI 10.1126/science.290.5497.1717; Reef S, 2006, MOL CELL, V22, P463, DOI 10.1016/j.molcel.2006.04.014; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Shimizu S, 2004, NAT CELL BIOL, V6, P1221, DOI 10.1038/ncb1192; Stevens C, 2004, DNA REPAIR, V3, P1071, DOI 10.1016/j.dnarep.2004.03.034; Tracy K, 2007, MOL CELL BIOL, V27, P6229, DOI 10.1128/MCB.02246-06; Tsuneoka M, 2003, CELL STRUCT FUNCT, V28, P195; Vigo E, 1999, MOL CELL BIOL, V19, P6379; Weinmann AS, 2001, MOL CELL BIOL, V21, P6820, DOI 10.1128/MCB.21.20.6820-6832.2001; WU XW, 1994, P NATL ACAD SCI USA, V91, P3602, DOI 10.1073/pnas.91.9.3602	23	194	200	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 14	2008	27	35					4860	4864		10.1038/onc.2008.117	http://dx.doi.org/10.1038/onc.2008.117			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	337OJ	18408756				2022-12-28	WOS:000258445100011
J	Hirabayashi, S; Nakagawa, K; Sumita, K; Hidaka, S; Kawai, T; Ikeda, M; Kawata, A; Ohno, K; Hata, Y				Hirabayashi, S.; Nakagawa, K.; Sumita, K.; Hidaka, S.; Kawai, T.; Ikeda, M.; Kawata, A.; Ohno, K.; Hata, Y.			Threonine 74 of MOB1 is a putative key phosphorylation site by MST2 to form the scaffold to activate nuclear Dbf2-related kinase 1	ONCOGENE			English	Article						NDR kinase; Hippo pathway; mammalian sterile 20-like kinase 2; Mps one binder 1	CELL-CYCLE EXIT; TUMOR-SUPPRESSOR; PROMOTES APOPTOSIS; PROTEIN-KINASE; NDR KINASES; HIPPO; DROSOPHILA; PROLIFERATION; SALVADOR; GROWTH	Mammalian nuclear Dbf2-related (NDR) kinases (LATS1 and 2, NDR1 and 2) play a role in cell proliferation, apoptosis and morphological changes. These kinases are regulated by mammalian sterile 20-like kinases (MSTs) and Mps one binder (MOB) 1. Okadaic acid (OA), which activates MST2, facilitates the complex formation of MOB1, MST2 and NDR1 in HEK293FT cells. The in vitro biochemical study demonstrates the phosphorylation of MOB1 by MST2. The phosphorylated MOB1 alone is capable to partially activate NDR1 in vitro, but MST2 is also required for the full activation. The knockdown of MOB1 or MST2 abolishes the OA-induced NDR1 activation in HEK293FT cells. Among MOB1 mutants, in which each serine or threonine residue is replaced with alanine, MOB1 T74A and T181A mutants fail to activate NDR1. Thr74, but not Thr181, is phosphorylated by MST2 in vitro, although MOB1 is also phosphorylated by MST2 at other site(s). The interaction of MOB1 T74A with NDR1 is barely enhanced by OA treatment. These findings indicate that the phosphorylation of MOB1 at Thr74 by MST2 is essential to make a complex of MOB1, MST2 and NDR1, and to fully activate NDR1.	[Hirabayashi, S.; Nakagawa, K.; Sumita, K.; Hidaka, S.; Kawai, T.; Ikeda, M.; Kawata, A.; Hata, Y.] Tokyo Med & Dent Univ, Grad Sch Med, Dept Med Biochem, Bunkyo Ku, Tokyo 1138519, Japan; [Sumita, K.; Ohno, K.] Tokyo Med & Dent Univ, Grad Sch Med, Dept Neurosurg, Tokyo 1138519, Japan	Tokyo Medical & Dental University (TMDU); Tokyo Medical & Dental University (TMDU)	Hata, Y (corresponding author), Tokyo Med & Dent Univ, Grad Sch Med, Dept Med Biochem, Bunkyo Ku, 1-5-45 Yushima, Tokyo 1138519, Japan.	yuhammch@tmd.ac.jp	Sumita, Kazutaka/AAI-1553-2019					Bichsel SJ, 2004, J BIOL CHEM, V279, P35228, DOI 10.1074/jbc.M404542200; Bothos J, 2005, CANCER RES, V65, P6568, DOI 10.1158/0008-5472.CAN-05-0862; Chan EH, 2005, ONCOGENE, V24, P2076, DOI 10.1038/sj.onc.1208445; Creasy CL, 1995, GENE, V167, P303, DOI 10.1016/0378-1119(95)00653-2; Edgar BA, 2006, CELL, V124, P267, DOI 10.1016/j.cell.2006.01.005; Hariharan IK, 2006, CURR BIOL, V16, pR1037, DOI 10.1016/j.cub.2006.11.012; Harvey KF, 2003, CELL, V114, P457, DOI 10.1016/S0092-8674(03)00557-9; He Y, 2005, MOL BIOL CELL, V16, P4139, DOI 10.1091/mbc.e05-01-0018; Hergovich A, 2005, MOL CELL BIOL, V25, P8259, DOI 10.1128/MCB.25.18.8259-8272.2005; Hergovich A, 2006, NAT REV MOL CELL BIO, V7, P253, DOI 10.1038/nrm1891; Hergovich A, 2006, BIOCHEM BIOPH RES CO, V345, P50, DOI 10.1016/j.bbrc.2006.03.244; Ikeda M, 2007, EXP CELL RES, V313, P1484, DOI 10.1016/j.yexcr.2007.02.013; Jia JH, 2003, GENE DEV, V17, P2514, DOI 10.1101/gad.1134003; Lai ZC, 2005, CELL, V120, P675, DOI 10.1016/j.cell.2004.12.036; Lee KK, 2002, J BIOL CHEM, V277, P12351, DOI 10.1074/jbc.M108138200; Luca FC, 1998, MOL BIOL CELL, V9, P29, DOI 10.1091/mbc.9.1.29; Pantalacci S, 2003, NAT CELL BIOL, V5, P921, DOI 10.1038/ncb1051; Stavridi ES, 2003, STRUCTURE, V11, P1163, DOI 10.1016/S0969-2126(03)00182-5; Stegert MR, 2005, MOL CELL BIOL, V25, P11019, DOI 10.1128/MCB.25.24.11019-11029.2005; Tapon N, 2002, CELL, V110, P467, DOI 10.1016/S0092-8674(02)00824-3; Udan RS, 2003, NAT CELL BIOL, V5, P914, DOI 10.1038/ncb1050; Valverde P, 2000, BIOCHEM BIOPH RES CO, V276, P990, DOI 10.1006/bbrc.2000.3582; Wei X, 2007, EMBO J, V26, P1772, DOI 10.1038/sj.emboj.7601630; Wu S, 2003, CELL, V114, P445, DOI 10.1016/S0092-8674(03)00549-X	24	46	51	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 17	2008	27	31					4281	4292		10.1038/onc.2008.66	http://dx.doi.org/10.1038/onc.2008.66			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	326WY	18362890				2022-12-28	WOS:000257691100003
J	Wischermann, K; Popp, S; Moshir, S; Scharfetter-Kochanek, K; Wlaschek, M; de Gruijl, F; Hartschuh, W; Greinert, R; Volkmer, B; Faust, A; Rapp, A; Schmezer, P; Boukamp, P				Wischermann, K.; Popp, S.; Moshir, S.; Scharfetter-Kochanek, K.; Wlaschek, M.; de Gruijl, F.; Hartschuh, W.; Greinert, R.; Volkmer, B.; Faust, A.; Rapp, A.; Schmezer, P.; Boukamp, P.			UVA radiation causes DNA strand breaks, chromosomal aberrations and tumorigenic transformation in HaCaT skin keratinocytes	ONCOGENE			English	Article						DNA double strand breaks; tumor formation; chromosomal aberrations; telomere length; radiation regimes	OXIDATIVE STRESS; IN-VITRO; H2AX PHOSPHORYLATION; COMET ASSAY; HUMAN-CELLS; DAMAGE; PROGRESSION; REPAIR; TUMOR; OVEREXPRESSION	The role of UVA-radiation-the major fraction in sunlight-in human skin carcinogenesis is still elusive. We here report that different UVA exposure regime (4 x 5 J/cm(2) per week or 1 x 20 J/cm(2) per week) caused tumorigenic conversion (tumors in nude mice) of the HaCaT skin keratinocytes. While tumorigenicity was not associated with general telomere shortening, we found new chromosomal changes characteristic for each recultivated tumor. Since this suggested a nontelomere-dependent relationship between UVA irradiation and chromosomal aberrations, we investigated for alternate mechanisms of UVA-dependent genomic instability. Using the alkaline and neutral comet assay as well as gamma-H2AX foci formation on irradiated HaCaT cells (20-60 J/cm(2)), we show a dosedependent and long lasting induction of DNA single and double (ds) strand breaks. Extending this to normal human skin keratinocytes, we demonstrate a comparable damage response and, additionally, a significant induction and maintenance of micronuclei (MN) with more acentric fragments (indicative of ds breaks) than entire chromosomes particularly 5 days post irradiation. Thus, physiologically relevant UVA doses cause long-lasting DNA strand breaks, a prerequisite for chromosomal aberration that most likely contribute to tumorigenic conversion of the HaCaT cells. Since normal keratinocytes responded similarly, UVA may likewise contribute to the complex karyotype characteristic for human skin carcinomas.	[Wischermann, K.; Popp, S.; Moshir, S.; Boukamp, P.] German Canc Res Ctr, Div Genet Skin Carcinogenesis, D-69120 Heidelberg, Germany; [Scharfetter-Kochanek, K.; Wlaschek, M.] Univ Ulm, Dept Dermatol & Allerg Dis, Ulm, Germany; [de Gruijl, F.] Leiden Univ, Med Ctr, Dept Dermatol, Leiden, Netherlands; [Hartschuh, W.] Heidelberg Univ, Dept Dermatol, D-6900 Heidelberg, Germany; [Greinert, R.; Volkmer, B.; Faust, A.] Dermatol Ctr, Mol Cell Biol Div, Buxtehude, Germany; [Rapp, A.] Univ Oxford, Sir William Dunn Sch Pathol, Oxford OX1 3RE, England; [Schmezer, P.] German Canc Res Ctr, Div Toxicol & Canc Risk Factors, D-69120 Heidelberg, Germany	Helmholtz Association; German Cancer Research Center (DKFZ); Ulm University; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Ruprecht Karls University Heidelberg; University of Oxford; Helmholtz Association; German Cancer Research Center (DKFZ)	Boukamp, P (corresponding author), German Canc Res Ctr, Div Genet Skin Carcinogenesis, Neuenheimer Feld 280,Postfach 101949, D-69120 Heidelberg, Germany.	P.Boukamp@DKFZ-Heidelberg.de	Rapp, Alexander/F-5327-2012	Rapp, Alexander/0000-0001-9108-3929				ARMITAGE P, 1955, BIOMETRICS, V11, P375, DOI 10.2307/3001775; Armstrong BK, 2001, J PHOTOCH PHOTOBIO B, V63, P8, DOI 10.1016/S1011-1344(01)00198-1; Bleuel K, 1999, P NATL ACAD SCI USA, V96, P2065, DOI 10.1073/pnas.96.5.2065; Boukamp P, 1997, GENE CHROMOSOME CANC, V19, P201, DOI 10.1002/(SICI)1098-2264(199708)19:4<201::AID-GCC1>3.0.CO;2-0; BOUKAMP P, 1990, CANCER RES, V50, P2840; BOUKAMP P, 1995, ONCOGENE, V11, P961; BOUKAMP P, 1988, J CELL BIOL, V106, P761, DOI 10.1083/jcb.106.3.761; BOUKAMP P, 1990, DIFFERENTIATION, V44, P150, DOI 10.1111/j.1432-0436.1990.tb00548.x; Boukamp P, 1999, ONCOGENE, V18, P5638, DOI 10.1038/sj.onc.1202934; Boukamp Petra, 2005, J Dtsch Dermatol Ges, V3, P493, DOI 10.1111/j.1610-0387.2005.05037.x; Burnworth B, 2006, ONCOGENE, V25, P4399, DOI 10.1038/sj.onc.1209474; Cadet J, 2005, MUTAT RES-FUND MOL M, V571, P3, DOI 10.1016/j.mrfmmm.2004.09.012; COCHRAN WG, 1954, BIOMETRICS, V10, P417, DOI 10.2307/3001616; COHEN J, 1960, EDUC PSYCHOL MEAS, V20, P37, DOI 10.1177/001316446002000104; de Gruijl FR, 2002, SKIN PHARMACOL APPL, V15, P316, DOI 10.1159/000064535; Emri G, 2000, J INVEST DERMATOL, V115, P435, DOI 10.1046/j.1523-1747.2000.00057.x; *FED OFF RAD PROT, 2006, CONT SOL UV MON GERM; Fenech M, 2000, MUTAT RES-FUND MOL M, V455, P81, DOI 10.1016/S0027-5107(00)00065-8; Fenech M, 2002, TOXICOLOGY, V181, P411, DOI 10.1016/S0300-483X(02)00480-8; Figueroa R, 2000, CANCER RES, V60, P2770; Folkman J, 1991, Princess Takamatsu Symp, V22, P339; Garinis GA, 2005, EMBO J, V24, P3952, DOI 10.1038/sj.emboj.7600849; He YY, 2006, ONCOGENE, V25, P3680, DOI 10.1038/sj.onc.1209384; Ikehata H, 2004, MUTAT RES-FUND MOL M, V556, P11, DOI 10.1016/j.mrfmmm.2004.06.038; Ikehata H, 2003, MUTAGENESIS, V18, P511, DOI 10.1093/mutage/geg030; Ikehata H, 2007, PHOTOCHEM PHOTOBIOL, V83, P196, DOI 10.1562/2006-02-28-IR-822; Kielbassa C, 1997, CARCINOGENESIS, V18, P811, DOI 10.1093/carcin/18.4.811; Krude T, 1999, EXP CELL RES, V247, P148, DOI 10.1006/excr.1998.4342; LEHMAN TA, 1993, CARCINOGENESIS, V14, P833, DOI 10.1093/carcin/14.5.833; Limoli CL, 2002, P NATL ACAD SCI USA, V99, P233, DOI 10.1073/pnas.231611798; Marti TM, 2006, P NATL ACAD SCI USA, V103, P9891, DOI 10.1073/pnas.0603779103; Murnane JP, 2004, BIOESSAYS, V26, P1164, DOI 10.1002/bies.20125; MUTZHAS MF, 1981, J INVEST DERMATOL, V76, P42, DOI 10.1111/1523-1747.ep12524813; Obermueller E, 2004, CANCER RES, V64, P7801, DOI 10.1158/0008-5472.CAN-03-3301; Oikawa S, 1999, FEBS LETT, V453, P365, DOI 10.1016/S0014-5793(99)00748-6; Olive PL, 1999, INT J RADIAT BIOL, V75, P395, DOI 10.1080/095530099140311; OLIVE PL, 1993, RADIAT RES, V136, P130, DOI 10.2307/3578650; Parangi S, 1996, P NATL ACAD SCI USA, V93, P2002, DOI 10.1073/pnas.93.5.2002; Phillipson RP, 2002, FREE RADICAL BIO MED, V32, P474, DOI 10.1016/S0891-5849(01)00829-2; Popp S, 2002, INT J CANCER, V99, P352, DOI 10.1002/ijc.10321; Popp S, 2000, J INVEST DERMATOL, V115, P1095, DOI 10.1046/j.1523-1747.2000.00173.x; Rapp A, 2000, J PHOTOCH PHOTOBIO B, V56, P109, DOI 10.1016/S1011-1344(00)00052-X; Rapp A, 2004, J CELL SCI, V117, P4935, DOI 10.1242/jcs.01355; Rogakou EP, 1998, J BIOL CHEM, V273, P5858, DOI 10.1074/jbc.273.10.5858; Rothkamm K, 2003, P NATL ACAD SCI USA, V100, P5057, DOI 10.1073/pnas.0830918100; Sedelnikova OA, 2002, RADIAT RES, V158, P486, DOI 10.1667/0033-7587(2002)158[0486:QDOIID]2.0.CO;2; Skobe M, 1998, P NATL ACAD SCI USA, V95, P1050, DOI 10.1073/pnas.95.3.1050; Tefferi A, 2005, MAYO CLIN PROC, V80, P390, DOI 10.4065/80.3.390; Thompson LH, 2004, MOL B INT U, P107; Von Zglinicki T, 2000, FREE RADICAL BIO MED, V28, P64, DOI 10.1016/S0891-5849(99)00207-5; Wischermann K, 2007, MUTAT RES-GEN TOX EN, V630, P122, DOI 10.1016/j.mrgentox.2007.02.009; Wondrak GT, 2006, PHOTOCH PHOTOBIO SCI, V5, P215, DOI 10.1039/b504573h	52	65	69	0	4	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 17	2008	27	31					4269	4280		10.1038/onc.2008.70	http://dx.doi.org/10.1038/onc.2008.70			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	326WY	18372922				2022-12-28	WOS:000257691100002
J	Beverly, LJ; Varmus, HE				Beverly, L. J.; Varmus, H. E.			MYC-induced myeloid leukemogenesis is accelerated by all six members of the antiapoptotic BCL family	ONCOGENE			English	Article						BCL2; BCLxl; BCLw; MCL1; BFL1; BCLb	CELL LUNG-CANCER; BH3 MIMETIC ABT-737; C-MYC; DRUG-RESISTANCE; LEUKEMIA; APOPTOSIS; PROTEINS; SURVIVAL; DEATH; GENE	Signals that control the. ne balance between cell death and cell survival are altered during tumorigenesis. Understanding the mechanisms by which this balance is perturbed, leading to excessive cell survival, is important for designing effective therapies. Proteins belonging to the B-cell lymphoma (BCL) family are known to regulate death responses to apoptotic signals, especially those originating within cells. A subset of BCL family members capable of inhibiting cell death is known to contribute to tumorigenesis; however, it is not known whether all six antiapoptotic BCL family members play a causal role in tumor development. Using a mouse model of MYC-driven leukemia, we showed that, in addition to the well characterized BCL2 and BCLxl (BCL2L1), the other four family members-BCLw (BCL2L2), BCLb (BCL2L10), BFL1 (BCL2A1) and MCL1-also cooperate with MYC to accelerate leukemogenesis. In addition, high levels of each family member are found in either solid human tumors or cell lines derived from human leukemias or lymphomas.	[Beverly, L. J.; Varmus, H. E.] Mem Sloan Kettering Canc Ctr, Dept Canc Genet & Biol, New York, NY 10065 USA	Memorial Sloan Kettering Cancer Center	Beverly, LJ (corresponding author), Mem Sloan Kettering Canc Ctr, Dept Canc Genet & Biol, 1275 York Ave,Box 62, New York, NY 10065 USA.	BeverlyL@mskcc.org			NIH [P01 2PO1CA094060-06A1]; NATIONAL CANCER INSTITUTE [P01CA094060] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank members of the Varmus laboratory, especially G Sanchez, A Giannakou and MA Melnick, for expert handling of the mouse colony, including genotyping, and for performing immunohistochemistry on embedded tissue sections. Funding for this project was provided, in part, by NIH P01 2PO1CA094060-06A1 to HEV.	Chen L, 2005, MOL CELL, V17, P393, DOI 10.1016/j.molcel.2004.12.030; Chen S, 2007, CANCER RES, V67, P782, DOI 10.1158/0008-5472.CAN-06-3964; Cory S, 2003, ONCOGENE, V22, P8590, DOI 10.1038/sj.onc.1207102; Cosulich SC, 1997, CURR BIOL, V7, P913, DOI 10.1016/S0960-9822(06)00410-6; Hemann MT, 2005, NATURE, V436, P807, DOI 10.1038/nature03845; Holinger EP, 1999, J BIOL CHEM, V274, P13298, DOI 10.1074/jbc.274.19.13298; Horvitz HR, 1999, CANCER RES, V59, p1701S; Kawasaki T, 2007, CANCER SCI, V98, P1070, DOI 10.1111/j.1349-7006.2007.00491.x; Kohl TM, 2007, LEUKEMIA, V21, P1763, DOI 10.1038/sj.leu.2404776; Konopleva M, 2006, CANCER CELL, V10, P375, DOI 10.1016/j.ccr.2006.10.006; Lanave C, 2004, GENE, V333, P71, DOI 10.1016/j.gene.2004.02.017; Larkin MA, 2007, BIOINFORMATICS, V23, P2947, DOI 10.1093/bioinformatics/btm404; Letai A, 2004, CANCER CELL, V6, P241, DOI 10.1016/j.ccr.2004.07.011; Luo H, 2005, BLOOD, V106, P2452, DOI 10.1182/blood-2005-02-0734; Mandal M, 2005, J EXP MED, V201, P603, DOI 10.1084/jem.20041924; Reed JC, 2006, NAT CLIN PRACT ONCOL, V3, P388, DOI 10.1038/ncponc0538; Riedl SJ, 2007, NAT REV MOL CELL BIO, V8, P405, DOI 10.1038/nrm2153; Schultz J, 1998, P NATL ACAD SCI USA, V95, P5857, DOI 10.1073/pnas.95.11.5857; Shoemaker AR, 2008, CLIN CANCER RES, V14, P3268, DOI 10.1158/1078-0432.CCR-07-4622; Swanson PJ, 2004, J IMMUNOL, V172, P6684, DOI 10.4049/jimmunol.172.11.6684; Valdez BC, 2008, LEUKEMIA RES, V32, P1684, DOI 10.1016/j.leukres.2008.01.016; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; Wesarg E, 2007, INT J CANCER, V121, P2387, DOI 10.1002/ijc.22977; Yasui K, 2004, CANCER RES, V64, P1403, DOI 10.1158/0008-5472.CAN-3263-2; Youle RJ, 2008, NAT REV MOL CELL BIO, V9, P47, DOI 10.1038/nrm2308; Zhai D, 2006, CELL DEATH DIFFER, V13, P1419, DOI 10.1038/sj.cdd.4401937	26	86	89	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 5	2009	28	9					1274	1279		10.1038/onc.2008.466	http://dx.doi.org/10.1038/onc.2008.466			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	415AH	19137012	Green Accepted			2022-12-28	WOS:000263906200011
J	Shimwell, NJ; Martin, A; Bruton, RK; Blackford, AN; Sedgwick, GG; Gallimore, PH; Turnell, AS; Grand, RJA				Shimwell, N. J.; Martin, A.; Bruton, R. K.; Blackford, A. N.; Sedgwick, G. G.; Gallimore, P. H.; Turnell, A. S.; Grand, R. J. A.			Adenovirus 5 E1A is responsible for increased expression of insulin receptor substrate 4 in established adenovirus 5-transformed cell lines and interacts with IRS components activating the PI3 kinase/Akt signalling pathway	ONCOGENE			English	Article						Ad5E1A; IRS-1; IRS-2; IRS-4; Akt	GROWTH-FACTOR-I; LARGE T-ANTIGEN; GENE-EXPRESSION; BINDING PROTEIN; DNA-REPAIR; TRANSCRIPTIONAL ADAPTER; SIMIAN ADENOVIRUSES; GLUCOSE-HOMEOSTASIS; SEQUENCE-ANALYSIS; MEDIATOR COMPLEX	Using mass spectrometric analysis insulin receptor substrate 4 (IRS-4) has been identified as a novel adenovirus 5 early region 1A (Ad5E1A)-binding protein. IRS-4 interacts with both the transcriptional activation domain (conserved region 3) and the N-terminal region of Ad5E1A13S. Prolonged expression of Ad5E1A13S is required for the observed dramatic increase in the levels of IRS-4 mRNA and protein in Ad5E1-transformed human cell lines. Once expressed, as well as binding to E1A and the insulin receptor, IRS-4 remains tyrosine phosphorylated and constitutively associates with the regulatory p85 subunit of phosphoinositide 3 kinase, resulting in the phosphorylation of Akt (causing activation) and GSK-3 beta (causing inhibition). Reducing IRS-4 expression using small interfering RNA (siRNA) in established Ad5E1A-expressing cell lines decreases the activation of Akt and cellular proliferation. During Ad5 infection, IRS-4 is not expressed. However, Ad5E1A associates with IRS-1, increasing Akt and GSK-3 beta phosphorylation and tyrosine phosphorylation of IRS-1 itself. We conclude that the association and altered regulation of IRS proteins by Ad5E1A contribute to the adenovirus-transformed phenotype and modulates viral infection in an Akt-dependent manner.	[Grand, R. J. A.] Univ Birmingham, Inst Canc Studies, Sch Canc Sci, Canc Res UK, Birmingham B15 2TT, W Midlands, England	Cancer Research UK; University of Birmingham	Grand, RJA (corresponding author), Univ Birmingham, Inst Canc Studies, Sch Canc Sci, Canc Res UK, Birmingham B15 2TT, W Midlands, England.	R.J.A.Grand@bham.ac.uk	Blackford, Andrew N/H-6575-2019	Blackford, Andrew N/0000-0003-1979-021X	Cancer Research UK	Cancer Research UK(Cancer Research UK)	We are most grateful to Dr Joe Mymryk (University of Western Ontario) for the gift of various AdE1A constructs, Professor Thomas Dobner (University of Hamburg) for a gift of the Ad5-transformed rat cell lines, Professor Derek Leroith (Mount Sinai School of Medicine) for IRS-4 cDNA and Cancer Research UK for their financial support.	ARAKI E, 1995, MOL ENDOCRINOL, V9, P1367, DOI 10.1210/me.9.10.1367; ARAKI E, 1994, NATURE, V372, P186, DOI 10.1038/372186a0; ARANY Z, 1995, NATURE, V374, P81, DOI 10.1038/374081a0; Avvakumov N, 2004, VIROLOGY, V329, P477, DOI 10.1016/j.virol.2004.08.007; Avvakumov N, 2002, J VIROL, V76, P7968, DOI 10.1128/JVI.76.16.7968-7975.2002; Barral PM, 2005, FEBS LETT, V579, P2752, DOI 10.1016/j.febslet.2005.03.095; Bartholomeusz C, 2006, ONCOGENE, V25, P79, DOI 10.1038/sj.onc.1209014; BAYLEY ST, 1994, INT J ONCOL, V5, P425; Berk AJ, 2005, ONCOGENE, V24, P7673, DOI 10.1038/sj.onc.1209040; BOYD JM, 1993, EMBO J, V12, P469, DOI 10.1002/j.1460-2075.1993.tb05679.x; Boyer TG, 1999, NATURE, V399, P276, DOI 10.1038/20466; Bruton RK, 2007, ONCOGENE, V26, P7467, DOI 10.1038/sj.onc.1210551; Cai DS, 2003, J BIOL CHEM, V278, P25323, DOI 10.1074/jbc.M212430200; Cuevas EP, 2007, J HEPATOL, V46, P1089, DOI 10.1016/j.jhep.2007.01.031; DeAngelis T, 2006, ONCOGENE, V25, P32, DOI 10.1038/sj.onc.1209013; Dearth RK, 2007, CELL CYCLE, V6, P705, DOI 10.4161/cc.6.6.4035; Dillon RL, 2007, ONCOGENE, V26, P1338, DOI 10.1038/sj.onc.1210202; DYSON N, 1992, J VIROL, V66, P6893, DOI 10.1128/JVI.66.12.6893-6902.1992; ECKNER R, 1994, GENE DEV, V8, P869, DOI 10.1101/gad.8.8.869; Endter C, 2004, CURR TOP MICROBIOL, V273, P163; Fantin VR, 1998, J BIOL CHEM, V273, P10726, DOI 10.1074/jbc.273.17.10726; Fantin VR, 2000, AM J PHYSIOL-ENDOC M, V278, pE127, DOI 10.1152/ajpendo.2000.278.1.E127; Fantin VR, 1999, BIOCHEM BIOPH RES CO, V260, P718, DOI 10.1006/bbrc.1999.0967; FEI ZL, 1995, MOL CELL BIOL, V15, P4232; Flaherty DM, 2004, AM J PHYSIOL-LUNG C, V287, pL393, DOI 10.1152/ajplung.00359.2003; Frisch SM, 2002, NAT REV MOL CELL BIO, V3, P441, DOI 10.1038/nrm827; Gallimore PH, 2001, ONCOGENE, V20, P7824, DOI 10.1038/sj.onc.1204913; GEISBERG JV, 1995, MOL CELL BIOL, V15, P6283; GEISBERG JV, 1994, P NATL ACAD SCI USA, V91, P2488, DOI 10.1073/pnas.91.7.2488; Giovannone B, 2000, DIABETES-METAB RES, V16, P434, DOI 10.1002/1520-7560(2000)9999:9999<::AID-DMRR159>3.0.CO;2-8; Honma M, 2006, GENES CELLS, V11, P143, DOI 10.1111/j.1365-2443.2006.00926.x; KELEKAR A, 1987, MOL CELL BIOL, V7, P3899, DOI 10.1128/MCB.7.11.3899; KIM HS, 1995, MOL ENDOCRINOL, V9, P178, DOI 10.1210/me.9.2.178; Lavan BE, 1997, J BIOL CHEM, V272, P21403, DOI 10.1074/jbc.272.34.21403; LEE WS, 1991, CELL, V67, P365, DOI 10.1016/0092-8674(91)90188-5; LIU F, 1994, NATURE, V368, P520, DOI 10.1038/368520a0; LIU F, 1990, CELL, V61, P1217, DOI 10.1016/0092-8674(90)90686-9; Liu SCH, 1999, J BIOL CHEM, V274, P18093, DOI 10.1074/jbc.274.25.18093; Manning BD, 2007, CELL, V129, P1261, DOI 10.1016/j.cell.2007.06.009; Qiu HQ, 2005, ONCOGENE, V24, P5656, DOI 10.1038/sj.onc.1208721; Qu BH, 1999, J BIOL CHEM, V274, P31179, DOI 10.1074/jbc.274.44.31179; Rasti M, 2005, J VIROL, V79, P5594, DOI 10.1128/JVI.79.9.5594-5605.2005; Rasti M, 2006, EMBO J, V25, P2710, DOI 10.1038/sj.emboj.7601169; Reiss K, 2006, J CELL PHYSIOL, V206, P295, DOI 10.1002/jcp.20455; STEIN RW, 1987, MOL CELL BIOL, V7, P1164, DOI 10.1128/MCB.7.3.1164; TAMEMOTO H, 1994, NATURE, V372, P182, DOI 10.1038/372182a0; Taniguchi CM, 2006, NAT REV MOL CELL BIO, V7, P85, DOI 10.1038/nrm1837; TIMMERS HTM, 1988, J BIOL CHEM, V263, P1329; Trojanek J, 2006, J CELL PHYSIOL, V206, P35, DOI 10.1002/jcp.20425; Trojanek J, 2003, MOL CELL BIOL, V23, P7510, DOI 10.1128/MCB.23.21.7510-7524.2003; Tseng YH, 2004, MOL CELL BIOL, V24, P1918, DOI 10.1128/MCB.24.5.1918-1929.2004; Tsuruzoe K, 2001, MOL CELL BIOL, V21, P26, DOI 10.1128/MCB.21.1.26-38.2001; Virkamaki A, 1999, J CLIN INVEST, V103, P931, DOI 10.1172/JCI6609; Wang G, 2002, J VIROL, V76, P9186, DOI 10.1128/JVI.76.18.9186-9193.2002; Ward DG, 2006, BRIT J CANCER, V94, P1898, DOI 10.1038/sj.bjc.6603188; White MF, 1998, MOL CELL BIOCHEM, V182, P3, DOI 10.1023/A:1006806722619; White MF, 2006, CAN J PHYSIOL PHARM, V84, P725, DOI 10.1139/Y06-008; WHYTE P, 1989, CELL, V56, P67, DOI 10.1016/0092-8674(89)90984-7; Withers DJ, 1998, NATURE, V391, P900, DOI 10.1038/36116; Zhou-Li Fei, 1995, Molecular and Cellular Biology, V15, P4232	60	17	17	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 5	2009	28	5					686	697		10.1038/onc.2008.417	http://dx.doi.org/10.1038/onc.2008.417			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	403IN	19029952				2022-12-28	WOS:000263076400006
J	Scaltriti, M; Verma, C; Guzman, M; Jimenez, J; Parra, JL; Pedersen, K; Smith, DJ; Landolfi, S; Cajal, SRY; Arribas, J; Baselga, J				Scaltriti, M.; Verma, C.; Guzman, M.; Jimenez, J.; Parra, J. L.; Pedersen, K.; Smith, D. J.; Landolfi, S.; Ramon y Cajal, S.; Arribas, J.; Baselga, J.			Lapatinib, a HER2 tyrosine kinase inhibitor, induces stabilization and accumulation of HER2 and potentiates trastuzumab-dependent cell cytotoxicity	ONCOGENE			English	Article						ErbB receptor; trastuzumab; tyrosine kinase inhibitor; antibody-dependent cell cytotoxicity (ADCC); breast cancer	FACTOR RECEPTOR EGFR; METASTATIC BREAST-CANCER; MONOCLONAL-ANTIBODY; ADJUVANT CHEMOTHERAPY; DOWN-REGULATION; PHASE-II; GROWTH; ERBB2; HERCEPTIN; EXPRESSION	Lapatinib is a human epidermal growth factor receptor 2 (HER2) tyrosine kinase inhibitor (TKI) that has clinical activity in HER2-amplified breast cancer. In vitro studies have shown that lapatinib enhances the effects of the monoclonal antibody trastuzumab suggesting partially non-overlapping mechanisms of action. To dissect these mechanisms, we have studied the effects of lapatinib and trastuzumab on receptor expression and receptor signaling and have identified a new potential mechanism for the enhanced antitumor activity of the combination. Lapatinib, given alone or in combination with trastuzumab to HER2-overexpressing breast cancer cells SKBR3 and MCF7-HER2, inhibited HER2 phosphorylation, prevented receptor ubiquitination and resulted in a marked accumulation of inactive receptors at the cell surface. By contrast, trastuzumab alone caused enhanced HER2 phosphorylation, ubiquitination and degradation of the receptor. By immunoprecipitation and computational protein modeling techniques we have shown that the lapatinib-induced HER2 accumulation at the cell surface also results in the stabilization of inactive HER2 homo- (HER2/HER2) and hetero- (HER2/EGFR and HER2/HER3) dimers. Lapatinib-induced accumulation of HER2 and trastuzumab-mediated downregulation of HER2 was also observed in vivo, where the combination of the two agents triggered complete tumor remissions in all cases after 10 days of treatment. Accumulation of HER2 at the cell surface by lapatinib enhanced immune-mediated trastuzumab-dependent cytotoxicity. We propose that this is a novel mechanism of action of the combination that may be clinically relevant and exploitable in the therapy of patients with HER2-positive tumors.	[Scaltriti, M.; Guzman, M.; Parra, J. L.; Pedersen, K.; Arribas, J.; Baselga, J.] Vall Hebron Univ Hosp, Dept Med Oncol, Vall Hebron Res Inst, Barcelona 08035, Spain; [Verma, C.; Smith, D. J.] Bioinformat Inst, Biomol Modeling & Design Grp, Singapore, Singapore; [Jimenez, J.; Landolfi, S.; Ramon y Cajal, S.] Vall Hebron Univ Hosp, Dept Pathol, Barcelona 08035, Spain; [Baselga, J.] Univ Autonoma Barcelona, E-08193 Barcelona, Spain	Autonomous University of Barcelona; Hospital Universitari Vall d'Hebron; Vall d'Hebron Institut de Recerca (VHIR); Agency for Science Technology & Research (A*STAR); A*STAR - Bioinformatics Institute (BII); Hospital Universitari Vall d'Hebron; Autonomous University of Barcelona	Baselga, J (corresponding author), Vall Hebron Univ Hosp, Dept Med Oncol, Vall Hebron Res Inst, Paseo Vall Hebron 119-129, Barcelona 08035, Spain.	jbaselga@vhebron.net	Ramon y Cajal, Santiago/H-4955-2016; 高, 雨莉/HGU-8187-2022; Arribas, Joaquin/M-4482-2014	Ramon y Cajal, Santiago/0000-0002-3867-1390; Arribas, Joaquin/0000-0002-0504-0664; Jimenez, Jose/0000-0002-2576-1776; Landolfi, Stefania/0000-0002-1059-635X	Breast Cancer Research Foundation; NATIONAL CANCER INSTITUTE [P30CA008748] Funding Source: NIH RePORTER	Breast Cancer Research Foundation; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported in full by a grant of the Breast Cancer Research Foundation.	Anido J, 2003, CLIN CANCER RES, V9, P1274; Arteaga CL, 1997, J BIOL CHEM, V272, P23247, DOI 10.1074/jbc.272.37.23247; Austin CD, 2004, MOL BIOL CELL, V15, P5268, DOI 10.1091/mbc.E04-07-0591; Baselga J, 1996, J CLIN ONCOL, V14, P737, DOI 10.1200/JCO.1996.14.3.737; Baselga J, 1998, CANCER RES, V58, P2825; Baselga J., 2006, J CLIN ONCOL, V24, P3006; Baselga J, 2006, SCIENCE, V312, P1175, DOI 10.1126/science.1125951; Bleeker WK, 2004, J IMMUNOL, V173, P4699, DOI 10.4049/jimmunol.173.7.4699; BROOKS BR, 1983, J COMPUT CHEM, V4, P187, DOI 10.1002/jcc.540040211; Chu I, 2005, CANCER RES, V65, P18; Citri A, 2006, NAT REV MOL CELL BIO, V7, P505, DOI 10.1038/nrm1962; Clynes RA, 2000, NAT MED, V6, P443, DOI 10.1038/74704; Cuello M, 2001, CANCER RES, V61, P4892; Diermeier S, 2005, EXP CELL RES, V304, P604, DOI 10.1016/j.yexcr.2004.12.008; Gan HK, 2007, J BIOL CHEM, V282, P2840, DOI 10.1074/jbc.M605136200; Gennari R, 2004, CLIN CANCER RES, V10, P5650, DOI 10.1158/1078-0432.CCR-04-0225; Geyer CE, 2006, NEW ENGL J MED, V355, P2733, DOI 10.1056/NEJMoa064320; Henson ES, 2006, CLIN CANCER RES, V12, P845, DOI 10.1158/1078-0432.CCR-05-0754; Hommelgaard AM, 2004, MOL BIOL CELL, V15, P1557, DOI 10.1091/mbc.E03-08-0596; Huang SM, 2004, CANCER RES, V64, P5355, DOI 10.1158/0008-5472.CAN-04-0562; Izumi Y, 2002, NATURE, V416, P279, DOI 10.1038/416279b; Johns TG, 2003, P NATL ACAD SCI USA, V100, P15871, DOI 10.1073/pnas.2036503100; Kim JY, 2003, J NEUROSCI, V23, P5561; Klapper LN, 2000, CANCER RES, V60, P3384; Konecny GE, 2006, CANCER RES, V66, P1630, DOI 10.1158/0008-5472.CAN-05-1182; Li X, 2007, CANCER RES, V67, P8716, DOI 10.1158/0008-5472.CAN-06-3731; Lichtner RB, 2001, CANCER RES, V61, P5790; Longva KE, 2005, INT J CANCER, V116, P359, DOI 10.1002/ijc.21015; Lu Y, 2007, CANCER RES, V67, P8240, DOI 10.1158/0008-5472.CAN-07-0589; Marmor MD, 2004, ONCOGENE, V23, P2057, DOI 10.1038/sj.onc.1207390; Marty M, 2005, J CLIN ONCOL, V23, P4265, DOI 10.1200/JCO.2005.04.173; Matar P, 2004, CLIN CANCER RES, V10, P6487, DOI 10.1158/1078-0432.CCR-04-0870; Milella M, 2004, CLIN CANCER RES, V10, P7747, DOI 10.1158/1078-0432.CCR-04-0908; Mimura K, 2005, CLIN CANCER RES, V11, P4898, DOI 10.1158/1078-0432.CCR-04-2476; Musolino A, 2008, J CLIN ONCOL, V26, P1789, DOI 10.1200/JCO.2007.14.8957; OSHAUGHNESSY J, 2008, J CLIN ONCOL S, V26; Ozcelik C, 2002, P NATL ACAD SCI USA, V99, P8880, DOI 10.1073/pnas.122249299; Perera RM, 2005, CLIN CANCER RES, V11, P6390, DOI 10.1158/1078-0432.CCR-04-2653; Piccart-Gebhart MJ, 2005, NEW ENGL J MED, V353, P1659, DOI 10.1056/NEJMoa052306; Romond EH, 2005, NEW ENGL J MED, V353, P1673, DOI 10.1056/NEJMoa052122; Rusnak DW, 2001, MOL CANCER THER, V1, P85; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; Scaltriti M, 2007, J NATL CANCER I, V99, P628, DOI 10.1093/jnci/djk134; Sergina NV, 2007, NATURE, V445, P437, DOI 10.1038/nature05474; Serra V, 2008, CANCER RES, V68, P8022, DOI 10.1158/0008-5472.CAN-08-1385; SLAMON D, 2005, 28 ANN SAN ANT BREAS; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; Slamon DJ, 2001, NEW ENGL J MED, V344, P783, DOI 10.1056/NEJM200103153441101; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; Sliwkowski MX, 1999, SEMIN ONCOL, V26, P60; Tang Y, 2007, J IMMUNOL, V179, P2815, DOI 10.4049/jimmunol.179.5.2815; Tseng PH, 2006, MOL PHARMACOL, V70, P1534, DOI 10.1124/mol.106.023911; Tzahar E, 1996, MOL CELL BIOL, V16, P5276; Valabrega G, 2005, ONCOGENE, V24, P3002, DOI 10.1038/sj.onc.1208478; Wang ZX, 1999, MOL BIOL CELL, V10, P1621, DOI 10.1091/mbc.10.5.1621; Wolpoe ME, 2003, J IMMUNOL, V171, P2161, DOI 10.4049/jimmunol.171.4.2161; Wood ER, 2004, CANCER RES, V64, P6652, DOI 10.1158/0008-5472.CAN-04-1168; Xia WL, 2005, ONCOGENE, V24, P6213, DOI 10.1038/sj.onc.1208774; Yarden Y, 2001, NAT REV MOL CELL BIO, V2, P127, DOI 10.1038/35052073; Yuste L, 2005, CANCER RES, V65, P6801, DOI 10.1158/0008-5472.CAN-04-4023; Zhang XW, 2006, CELL, V125, P1137, DOI 10.1016/j.cell.2006.05.013; ZHENG JH, 1993, ACTA CRYSTALLOGR D, V49, P362, DOI 10.1107/S0907444993000423	62	305	314	2	24	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2009	28	6					803	814		10.1038/onc.2008.432	http://dx.doi.org/10.1038/onc.2008.432			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	406UI	19060928				2022-12-28	WOS:000263320000003
J	Thayaparasingham, B; Kunz, A; Peters, N; Kulms, D				Thayaparasingham, B.; Kunz, A.; Peters, N.; Kulms, D.			Sensitization of melanoma cells to TRAIL by UVB-induced and NF-kappa B-mediated downregulation of xIAP	ONCOGENE			English	Article						apoptosis; TRAIL; UVB; xIAP; NF-kappa B	X-LINKED INHIBITOR; INDUCED APOPTOSIS; MALIGNANT-MELANOMA; FLIP EXPRESSION; LIGAND; ACTIVATION; RESISTANCE; CASPASE-8; PROTEINS; MEMBER	Effective treatment of malignant melanoma with the tumor-selective death ligand tumor necrosis-related apoptosis-inducing ligand (TRAIL) is curtailed by the fact that many melanoma cell lines are a priori resistant against TRAIL-induced apoptosis. By investigating 18 melanoma cell lines, we show that TRAIL susceptibility is completely independent of the tumor progression stage but can be positively stimulated by co-exposure to a sublethal ultraviolet B light (UVB) dose, providing an excellent tool to study the mechanism underlying TRAIL resistance. TRAIL resistance could be linked to the ratio of x-linked inhibitor of apoptosis proteins (xIAP) and caspase-3 levels within the cell. UVB-induced sensitization coincides with enhanced xIAP degradation, allowing full caspase-3 processing and activation. It is also accompanied by concomitant I kappa B alpha degradation, resulting in nuclear factor-kappa B (NF-kappa B)-dependent transcriptional repression of xIAP. Loss of xIAP in turn was reduced upon overexpression of an I kappa B alpha super-repressor, thus NF-kappa B activation seems to be responsible for differential regulation of xIAP and consequently determines TRAIL susceptibility. As xIAP-mediated blockade of apoptosis seems to be the dominant cause of TRAIL resistance of all melanoma cell lines investigated here, our data suggest that direct chemical xIAP inhibition or combination treatment with DNA-damaging agents may offer new therapeutic strategies to generally sensitize melanoma toward TRAIL-induced apoptosis.	[Thayaparasingham, B.; Kunz, A.; Peters, N.; Kulms, D.] Univ Stuttgart, Inst Cell Biol & Immunol, D-70569 Stuttgart, Germany	University of Stuttgart	Kulms, D (corresponding author), Univ Stuttgart, Inst Cell Biol & Immunol, Allmandring 31, D-70569 Stuttgart, Germany.	Dagmar.Kulms@izi.uni-stuttgart.de	Kulms, Dagmar/H-1653-2014		Deutsche Krebshilfe [106699]	Deutsche Krebshilfe(Deutsche Krebshilfe)	We thank Amgen/Genentech (Seattle, USA) for providing TRAIL antibodies. We are grateful to F Meier (Department of Dermato-Oncology, University of Tubingen) for providing melanoma cell lines and melanocytes, H Walczak (Tumour Immunology Unit, Imperial College London) for supplying iz-TRAIL and to H Kashkar (Institute for Medical Microbiology, University of Cologne) for the xIAP-pEGFPC3 construct. This study was funded by Deutsche Krebshilfe 106699.	Amiri KI, 2005, CANCER METAST REV, V24, P301, DOI 10.1007/s10555-005-1579-7; Bouralexis S, 2003, BRIT J CANCER, V89, P206, DOI 10.1038/sj.bjc.6601021; Bullani RR, 2001, J INVEST DERMATOL, V117, P360, DOI 10.1046/j.0022-202x.2001.01418.x; Campbell KJ, 2004, MOL CELL, V13, P853, DOI 10.1016/S1097-2765(04)00131-5; Chawla-Sarkar M, 2004, CELL DEATH DIFFER, V11, P915, DOI 10.1038/sj.cdd.4401416; Cheung HH, 2008, MOL BIOL CELL, V19, P2729, DOI 10.1091/mbc.E08-01-0107; CLARK WH, 1991, CANCER METAST REV, V10, P83, DOI 10.1007/BF00049406; Degli-Esposti MA, 1997, IMMUNITY, V7, P813, DOI 10.1016/S1074-7613(00)80399-4; DegliEsposti MA, 1997, J EXP MED, V186, P1165, DOI 10.1084/jem.186.7.1165; Delhase M, 1999, SCIENCE, V284, P309, DOI 10.1126/science.284.5412.309; Dohi T, 2004, J BIOL CHEM, V279, P34087, DOI 10.1074/jbc.C400236200; Eckelman BP, 2006, EMBO REP, V7, P988, DOI 10.1038/sj.embor.7400795; Ehrhardt H, 2003, ONCOGENE, V22, P3842, DOI 10.1038/sj.onc.1206520; ELDER DE, 1993, SEMIN DIAGN PATHOL, V10, P18; Falschlehner C, 2007, INT J BIOCHEM CELL B, V39, P1462, DOI 10.1016/j.biocel.2007.02.007; Flaherty KT, 2006, CLIN CANCER RES, V12, p2366S, DOI 10.1158/1078-0432.CCR-05-2505; Franco AV, 2001, J IMMUNOL, V166, P5337, DOI 10.4049/jimmunol.166.9.5337; Ganten TM, 2006, CLIN CANCER RES, V12, P2640, DOI 10.1158/1078-0432.CCR-05-2635; Geserick P, 2008, ONCOGENE, V27, P3211, DOI 10.1038/sj.onc.1210985; Griffith TS, 1998, J IMMUNOL, V161, P2833; Jeremias I, 1998, EUR CYTOKINE NETW, V9, P687; Kashkar H, 2003, J EXP MED, V198, P341, DOI 10.1084/jem.20021279; Kashkar H, 2007, BLOOD, V109, P3982, DOI 10.1182/blood-2006-10-053959; Koschny R, 2007, J MOL MED, V85, P923, DOI 10.1007/s00109-007-0194-1; Kothny-Wilkes G, 1998, J BIOL CHEM, V273, P29247, DOI 10.1074/jbc.273.44.29247; Kurbanov BM, 2005, J INVEST DERMATOL, V125, P1010, DOI 10.1111/j.0022-202X.2005.23900.x; Larribere L, 2004, CELL DEATH DIFFER, V11, P1084, DOI 10.1038/sj.cdd.4401475; Lasithiotakis KG, 2006, CANCER-AM CANCER SOC, V107, P1331, DOI 10.1002/cncr.22126; Li QT, 2002, NAT REV IMMUNOL, V2, P725, DOI 10.1038/nri910; Meier F, 2005, FRONT BIOSCI-LANDMRK, V10, P2986, DOI 10.2741/1755; Meier F., 1998, FRONT BIOSCI J VIS L, V3, P1005, DOI [10.2741/a341, DOI 10.2741/A341]; Merino D, 2007, EXPERT OPIN THER TAR, V11, P1299, DOI 10.1517/14728222.11.10.1299; Merino D, 2006, MOL CELL BIOL, V26, P7046, DOI 10.1128/MCB.00520-06; Micheau O, 2002, J BIOL CHEM, V277, P45162, DOI 10.1074/jbc.M206882200; Micheau O, 2004, LEUKEMIA, V18, P1578, DOI 10.1038/sj.leu.2403497; Micheau O, 2001, MOL CELL BIOL, V21, P5299, DOI 10.1128/MCB.21.16.5299-5305.2001; Panner A, 2005, MOL CELL BIOL, V25, P8809, DOI 10.1128/MCB.25.20.8809-8823.2005; Pitt RM, 1996, J BIOL CHEM, V271, P12687, DOI 10.1074/jbc.271.22.12687; Poppelmann B, 2005, J BIOL CHEM, V280, P15635, DOI 10.1074/jbc.M413006200; Ricci MS, 2004, MOL CELL BIOL, V24, P8541, DOI 10.1128/MCB.24.19.8541-8555.2004; Riccioni R, 2005, HAEMATOLOGICA, V90, P612; Shi RX, 2005, CANCER RES, V65, P7815, DOI 10.1158/0008-5472.CAN-04-3875; Sohn D, 2006, MOL CELL BIOL, V26, P1967, DOI 10.1128/MCB.26.5.1967-1978.2006; Sprick MR, 2000, IMMUNITY, V12, P599, DOI 10.1016/S1074-7613(00)80211-3; Strozyk E, 2006, ONCOGENE, V25, P6239, DOI 10.1038/sj.onc.1209655; Ueda Y, 2006, PIGM CELL RES, V19, P112, DOI 10.1111/j.1600-0749.2006.00304.x; Wajant H, 2001, ONCOGENE, V20, P4101, DOI 10.1038/sj.onc.1204558; Walczak H, 1999, NAT MED, V5, P157, DOI 10.1038/5517; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; Wang YF, 2002, ENDOCRINOLOGY, V143, P2732, DOI 10.1210/en.143.7.2732; Wiley SR, 1995, IMMUNITY, V3, P673, DOI 10.1016/1074-7613(95)90057-8; Xiao C, 2005, EXP CELL RES, V304, P244, DOI 10.1016/j.yexcr.2004.11.002; Zeise E, 2004, J INVEST DERMATOL, V123, P746, DOI 10.1111/j.0022-202X.2004.23420.x; Zhang XD, 2006, CLIN CANCER RES, V12, P1355, DOI 10.1158/1078-0432.CCR-05-2084	54	25	25	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 22	2009	28	3					345	362		10.1038/onc.2008.397	http://dx.doi.org/10.1038/onc.2008.397			18	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	395UZ	18978816				2022-12-28	WOS:000262550300004
J	Cao, Q; Yu, J; Dhanasekaran, SM; Kim, JH; Mani, RS; Tomlins, SA; Mehra, R; Laxman, B; Cao, X; Yu, J; Kleer, CG; Varambally, S; Chinnaiyan, AM				Cao, Q.; Yu, J.; Dhanasekaran, S. M.; Kim, J. H.; Mani, R-S; Tomlins, S. A.; Mehra, R.; Laxman, B.; Cao, X.; Yu, J.; Kleer, C. G.; Varambally, S.; Chinnaiyan, A. M.			Repression of E-cadherin by the polycomb group protein EZH2 in cancer	ONCOGENE			English	Article						polycomb group protein; histone; EZH2; E-cadherin; epigenetics	CELL-CELL-ADHESION; HUMAN BREAST-CANCER; H3 LYSINE-27 METHYLATION; EMBRYONIC STEM-CELLS; PROSTATE-CANCER; DOWN-REGULATION; TARGET GENES; DEVELOPMENTAL REGULATORS; CATENIN EXPRESSION; EPITHELIAL-CELLS	Enhancer of zeste homolog 2 (EZH2) is a critical component of the polycomb-repressive complex 2 (PRC2), which is involved in gene silencing and histone H3 lysine 27 methylation. EZH2 has a master regulatory function in controlling such processes as stem cell differentiation, cell proliferation, early embryogenesis and X chromosome inactivation. Although benign epithelial cells express very low levels of EZH2, increased levels of EZH2 have been observed in aggressive solid tumors such as those of the prostate, breast and bladder. The mechanism by which EZH2 mediates tumor aggressiveness is unclear. Here, we demonstrate that EZH2 mediates transcriptional silencing of the tumor suppressor gene E-cadherin by trimethylation of H3 lysine 27. Histone deacetylase inhibitors can prevent EZH2-mediated repression of E-cadherin and attenuate cell invasion, suggesting a possible mechanism that may be useful for the development of therapeutic treatments. Taken together, these observations provide a novel mechanism of E-cadherin regulation and establish a functional link between dysregulation of EZH2 and repression of E-cadherin during cancer progression.	[Cao, Q.; Yu, J.; Dhanasekaran, S. M.; Kim, J. H.; Mani, R-S; Tomlins, S. A.; Mehra, R.; Laxman, B.; Yu, J.; Kleer, C. G.; Varambally, S.; Chinnaiyan, A. M.] Univ Michigan, Sch Med, Dept Pathol, Ann Arbor, MI 48109 USA; [Cao, Q.; Yu, J.; Dhanasekaran, S. M.; Kim, J. H.; Mani, R-S; Tomlins, S. A.; Mehra, R.; Laxman, B.; Cao, X.; Yu, J.; Varambally, S.; Chinnaiyan, A. M.] Univ Michigan, Sch Med, Michigan Ctr Translat Pathol, Ann Arbor, MI 48109 USA; [Mehra, R.; Kleer, C. G.; Varambally, S.; Chinnaiyan, A. M.] Univ Michigan, Sch Med, Ctr Comprehens Canc, Ann Arbor, MI 48109 USA; [Cao, X.; Chinnaiyan, A. M.] Univ Michigan, Sch Med, Howard Hughes Med Inst, Ann Arbor, MI 48109 USA; [Chinnaiyan, A. M.] Univ Michigan, Sch Med, Dept Urol, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; Howard Hughes Medical Institute; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Chinnaiyan, AM (corresponding author), Univ Michigan, Sch Med, Dept Pathol, 1400 E Med Ctr Dr,5316 CCGC, Ann Arbor, MI 48109 USA.	arul@umich.edu	Cao, Qi/A-5517-2010	Cao, Qi/0000-0002-5140-3681; Tomlins, Scott/0000-0001-8661-9821; Dhanasekaran, saravana mohan/0000-0002-0489-2224; Mani, Ram/0000-0003-3552-7905; Varambally, Sooryanarayana/0000-0002-2277-1127	National Institutes of Health [R01 CA97063, U01 CA111275, P50 CA69568]; Department of Defense [PC040517, PC051081, PC060266, R01CA107469]; NATIONAL CANCER INSTITUTE [R01CA097063, R01CA107469, P50CA069568, U01CA111275, K99CA129565] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Department of Defense(United States Department of Defense); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Professor Eric Fearon for providing the E-cadherin promoter-reporter constructs. We thank Jill Granger for critically reading the paper and for her thoughtful suggestions. We thank R Kunkel for help in figure preparation and the staff of the Microscopy and Image Analyses laboratory at the University of Michigan for their assistance in the microscopic analyses employed in this study. We thank the University of Michigan Vector Core for virus generation. AMC is supported by a Burroughs Welcome Foundation Award in Clinical Translational Research. SAT is supported by the Medical Scientist Training Program and a Rackham Pre-doctoral Award. This research was supported in part by National Institutes of Health Grant R01 CA97063 (to AMC); U01 CA111275 (to AMC); P50 CA69568 (to AMC); Department of Defense Grants PC040517 (to RM), PC051081 (to AMC and SV), PC060266 (to JY) and R01CA107469 (to CGK).	Bachmann IM, 2006, J CLIN ONCOL, V24, P268, DOI 10.1200/JCO.2005.01.5180; Batlle E, 2000, NAT CELL BIOL, V2, P84, DOI 10.1038/35000034; Beke L, 2007, ONCOGENE, V26, P4590, DOI 10.1038/sj.onc.1210248; Boyer LA, 2006, NATURE, V441, P349, DOI 10.1038/nature04733; Bracken AP, 2006, GENE DEV, V20, P1123, DOI 10.1101/gad.381706; Breuer RHJ, 2004, NEOPLASIA, V6, P736, DOI 10.1593/neo.04160; Bryant RJ, 2007, PROSTATE, V67, P547, DOI 10.1002/pros.20550; Cao R, 2002, SCIENCE, V298, P1039, DOI 10.1126/science.1076997; Chen H, 2005, J BIOL CHEM, V280, P22437, DOI 10.1074/jbc.M501379200; DAMSKY CH, 1983, CELL, V34, P455, DOI 10.1016/0092-8674(83)90379-3; Day ML, 1999, J BIOL CHEM, V274, P9656, DOI 10.1074/jbc.274.14.9656; DORUDI S, 1995, BRIT J CANCER, V71, P614, DOI 10.1038/bjc.1995.119; FRIXEN UH, 1993, CANCER RES, V53, P3618; FRIXEN UH, 1991, J CELL BIOL, V113, P173, DOI 10.1083/jcb.113.1.173; Fujii S, 2008, CANCER SCI, V99, P738, DOI 10.1111/j.1349-7006.2008.00743.x; Fujita Y, 2002, NAT CELL BIOL, V4, P222, DOI 10.1038/ncb758; Hajra KM, 2002, CANCER RES, V62, P1613; Hajra KM, 1999, ONCOGENE, V18, P7274, DOI 10.1038/sj.onc.1203336; Halbleib JM, 2006, GENE DEV, V20, P3199, DOI 10.1101/gad.1486806; HAYBITTLE JL, 1982, BRIT J CANCER, V45, P361, DOI 10.1038/bjc.1982.62; Hirohashi S, 2003, CANCER SCI, V94, P575, DOI 10.1111/j.1349-7006.2003.tb01485.x; Jacobs JJL, 2002, BBA-REV CANCER, V1602, P151, DOI 10.1016/S0304-419X(02)00052-5; Jacobs JJL, 1999, SEMIN CELL DEV BIOL, V10, P227, DOI 10.1006/scdb.1999.0304; Kirmizis A, 2004, GENE DEV, V18, P1592, DOI 10.1101/gad.1200204; Kleer CG, 2003, P NATL ACAD SCI USA, V100, P11606, DOI 10.1073/pnas.1933744100; Kondo Y, 2008, NAT GENET, V40, P741, DOI 10.1038/ng.159; Koyanagi M, 2005, J BIOL CHEM, V280, P31470, DOI 10.1074/jbc.M504766200; Lee TI, 2006, CELL, V125, P301, DOI 10.1016/j.cell.2006.02.043; MAYER B, 1993, CANCER RES, V53, P1690; MOLL R, 1993, AM J PATHOL, V143, P1731; Ohm JE, 2007, NAT GENET, V39, P237, DOI 10.1038/ng1972; OKA H, 1993, CANCER RES, V53, P1696; Palacios F, 2005, MOL CELL BIOL, V25, P389, DOI 10.1128/MCB.25.1.389-402.2005; PALACIOS J, 1995, VIRCHOWS ARCH, V427, P259; Peinado H, 2004, MOL CELL BIOL, V24, P306, DOI 10.1128/MCB.24.1.306-319.2004; PIERCEALL WE, 1995, ONCOGENE, V11, P1319; Plath K, 2003, SCIENCE, V300, P131, DOI 10.1126/science.1084274; RASBRIDGE SA, 1993, J PATHOL, V169, P245, DOI 10.1002/path.1711690211; Rhodes DR, 2003, J NATL CANCER I, V95, P661, DOI 10.1093/jnci/95.9.661; ROSEN PP, 1990, SURG CLIN N AM, V70, P937; Saito T, 2004, ONCOGENE, V23, P8629, DOI 10.1038/sj.onc.1207960; Satijn DPE, 1999, BBA-GENE STRUCT EXPR, V1447, P1, DOI 10.1016/S0167-4781(99)00130-X; Schlesinger Y, 2007, NAT GENET, V39, P232, DOI 10.1038/ng1950; Sparmann A, 2006, NAT REV CANCER, V6, P846, DOI 10.1038/nrc1991; Sudo T, 2005, BRIT J CANCER, V92, P1754, DOI 10.1038/sj.bjc.6602531; Taghavi P, 2006, NATURE, V439, P794, DOI 10.1038/439794a; Takeno S, 2004, AM J CLIN PATHOL, V122, P78, DOI 10.1309/WJL90JPEM17RBUHT; Tan J, 2007, GENE DEV, V21, P1050, DOI 10.1101/gad.1524107; Tolhuis B, 2006, NAT GENET, V38, P694, DOI 10.1038/ng1792; UMBAS R, 1994, CANCER RES, V54, P3929; Umbas R, 1997, INT J CANCER, V74, P374, DOI 10.1002/(SICI)1097-0215(19970822)74:4<374::AID-IJC2>3.0.CO;2-S; van der Vlag J, 1999, NAT GENET, V23, P474, DOI 10.1038/70602; Vandesompele J, 2002, GENOME BIOL, V3, DOI 10.1186/gb-2002-3-7-research0034; Varambally S, 2002, NATURE, V419, P624, DOI 10.1038/nature01075; Vire E, 2006, NATURE, V439, P871, DOI 10.1038/nature04431; Weikert S, 2005, INT J MOL MED, V16, P349; Widschwendter M, 2007, NAT GENET, V39, P157, DOI 10.1038/ng1941; Wijnhoven BPL, 2000, BRIT J SURG, V87, P992, DOI 10.1046/j.1365-2168.2000.01513.x; Wu ZY, 2005, WORLD J GASTROENTERO, V11, P3139, DOI 10.3748/wjg.v11.i20.3139; Yu J, 2007, CANCER CELL, V12, P419, DOI 10.1016/j.ccr.2007.10.016; Yu J, 2007, CANCER RES, V67, P10657, DOI 10.1158/0008-5472.CAN-07-2498	61	429	453	1	19	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC	2008	27	58					7274	7284		10.1038/onc.2008.333	http://dx.doi.org/10.1038/onc.2008.333			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	382FI	18806826	Green Accepted			2022-12-28	WOS:000261590300005
J	Koyama, N; Zhang, J; Huqun; Miyazawa, H; Tanaka, T; Su, X; Hagiwara, K				Koyama, N.; Zhang, J.; Huqun; Miyazawa, H.; Tanaka, T.; Su, X.; Hagiwara, K.			Identification of IGFBP-6 as an effector of the tumor suppressor activity of SEMA3B	ONCOGENE			English	Article						semaphorin 3B; insulin-like growth factor-binding protein-6; beta-catenin; microarray; tumor suppression	INSULIN-LIKE-GROWTH; FACTOR BINDING PROTEIN-6; CHEMOREPELLENT SEMAPHORIN-III; CANCER CELLS; MEDIATED APOPTOSIS; BREAST-CANCER; RECEPTOR; LUNG; GENES; DIFFERENTIATION	SEMA3B, a member of class 3 semaphorins, is a tumor suppressor. Competition with vascular endothelial growth factor ( VEGF)(165) explains a portion of the activity, whereas the VEGF-independent mechanism was not elucidated. We employed a microarray and screened for the genes whose expression was increased by SEMA3B in NCI-H1299 cells. Insulin-like growth factor-binding protein-6 (IGFBP-6), a tumor suppressor, showed greatest difference in the expression level. Introduction of IGFBP-6 cDNA reduced colony formation both on the dish surface and in soft agar. Insulin-like growth factor II, which antagonizes IGFBP-6, partly abrogated the effect. Inhibition of IGFBP-6 by small interfering RNA diminished the sub-G0/G1 population that was induced by SEMA3B and abrogated the growth suppressive effect of SEMA3B. We concluded that IGFBP-6 is the effector of tumor suppressor activity of SEMA3B in NCI-H1299 cells. It has been reported that beta-catenin suppresses the expression of IGFBP-6. Introduction of beta-catenin into the cells partly abrogated the growth suppressive effect of SEMA3B. Our result indicates that semaphorin signaling and beta-catenin signaling converge on IGFBP-6 and antithetically affect their functions.	[Koyama, N.; Zhang, J.; Huqun; Miyazawa, H.; Tanaka, T.; Hagiwara, K.] Saitama Med Univ, Dept Resp Med, Moroyama, Saitama 3500495, Japan; [Zhang, J.; Su, X.] Inner Mongolia Med Coll, Clin Res Ctr, Hohhot, Inner Mongolia, Peoples R China	Saitama Medical University; Inner Mongolia Medical University	Koyama, N (corresponding author), Saitama Med Univ, Dept Resp Med, 38 Morohongo, Moroyama, Saitama 3500495, Japan.	nkoyama@saitama-med.ac.jp			Japan Society for the Promotion of Science [18390242, 16590738]; Comprehensive Research on Aging and Health from the Ministry of Health, Labor and Welfare, Japan	Japan Society for the Promotion of Science(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science); Comprehensive Research on Aging and Health from the Ministry of Health, Labor and Welfare, Japan(Ministry of Health, Labour and Welfare, Japan)	We thank Ms Akemi Yokote for technical assistance. This study was supported in part by the following grants-in-aid: 1) for scientific research ( nos. 18390242 and 16590738) from the Japan Society for the Promotion of Science and 2) for Comprehensive Research on Aging and Health from the Ministry of Health, Labor and Welfare, Japan.	Bach LA, 1999, HORM METAB RES, V31, P226, DOI 10.1055/s-2007-978723; BACH LA, 1995, ENDOCRINOLOGY, V136, P5061, DOI 10.1210/en.136.11.5061; BACH LA, 1994, ENDOCRINOLOGY, V135, P2168, DOI 10.1210/en.135.5.2168; Barz T, 2006, CANCER RES, V66, P11975, DOI 10.1158/0008-5472.CAN-06-1529; Behar O, 1996, NATURE, V383, P525, DOI 10.1038/383525a0; Castro-Rivera E, 2004, P NATL ACAD SCI USA, V101, P11432, DOI 10.1073/pnas.0403969101; Chow LSN, 2006, ONCOGENE, V25, P310, DOI 10.1038/sj.onc.1209001; Christensen CRL, 1998, CANCER RES, V58, P1238; Clevers H, 2006, CELL, V127, P469, DOI 10.1016/j.cell.2006.10.018; Denys H, 2004, ONCOGENE, V23, P654, DOI 10.1038/sj.onc.1207160; Feng XL, 2006, MOL CELL BIOL, V26, P9244, DOI 10.1128/MCB.01538-06; Firth SM, 2002, ENDOCR REV, V23, P824, DOI 10.1210/er.2001-0033; Gallicchio MA, 2001, INT J CANCER, V94, P645, DOI 10.1002/ijc.1519; Grellier P, 1998, CANCER RES, V58, P1670; Gu CH, 2005, SCIENCE, V307, P265, DOI 10.1126/science.1105416; Guttmann-Raviv N, 2006, CANCER LETT, V231, P1, DOI 10.1016/j.canlet.2004.12.047; Hall KT, 1996, P NATL ACAD SCI USA, V93, P11780, DOI 10.1073/pnas.93.21.11780; He ZG, 1997, CELL, V90, P739, DOI 10.1016/S0092-8674(00)80534-6; Kannan K, 2001, ONCOGENE, V20, P3449, DOI 10.1038/sj.onc.1204446; KATO M, 1995, J BIOL CHEM, V270, P12373, DOI 10.1074/jbc.270.21.12373; Koike H, 2005, BRIT J CANCER, V92, P1538, DOI 10.1038/sj.bjc.6602520; KOLODKIN AL, 1993, CELL, V75, P1389, DOI 10.1016/0092-8674(93)90625-Z; Leng SL, 2001, MOL CELL ENDOCRINOL, V174, P121, DOI 10.1016/S0303-7207(00)00444-5; Mac Gabhann F, 2006, PLOS COMPUT BIOL, V2, P1649, DOI 10.1371/journal.pcbi.0020180; MARTIN JL, 1990, J BIOL CHEM, V265, P4124; Miao HQ, 1999, J CELL BIOL, V146, P233, DOI 10.1083/jcb.146.1.233; Nasarre P, 2005, NEOPLASIA, V7, P180, DOI 10.1593/neo.04481; Nelson WJ, 2004, SCIENCE, V303, P1483, DOI 10.1126/science.1094291; Ochi K, 2002, NEOPLASIA, V4, P82, DOI 10.1038/sj.neo.7900211; Pasterkamp RJ, 1998, J NEUROSCI, V18, P9962; Scholl FA, 2000, BRIT J CANCER, V82, P1239; Sekido Y, 1996, P NATL ACAD SCI USA, V93, P4120, DOI 10.1073/pnas.93.9.4120; Soker S, 1998, CELL, V92, P735, DOI 10.1016/S0092-8674(00)81402-6; Soker S, 1996, J BIOL CHEM, V271, P5761, DOI 10.1074/jbc.271.10.5761; Sueoka N, 2000, ONCOGENE, V19, P4432, DOI 10.1038/sj.onc.1203813; Tomizawa Y, 2001, P NATL ACAD SCI USA, V98, P13954, DOI 10.1073/pnas.231490898; Tran TS, 2007, ANNU REV CELL DEV BI, V23, P263, DOI 10.1146/annurev.cellbio.22.010605.093554; Usami N, 2003, ONCOGENE, V22, P7922, DOI 10.1038/sj.onc.1206533; Yao RS, 2002, ONCOGENE, V21, P5814, DOI 10.1038/sj.onc.1205422; Yu J, 2001, MOL CELL, V7, P673, DOI 10.1016/S1097-2765(01)00213-1	40	19	19	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 30	2008	27	51					6581	6589		10.1038/onc.2008.263	http://dx.doi.org/10.1038/onc.2008.263			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	366RS	18985860				2022-12-28	WOS:000260501700005
J	Ewald, B; Sampath, D; Plunkett, W				Ewald, B.; Sampath, D.; Plunkett, W.			Nucleoside analogs: molecular mechanisms signaling cell death	ONCOGENE			English	Review						stalled replication forks; DNA damage; DNA repair; sensors; checkpoints; DNA methylation	CHRONIC LYMPHOCYTIC-LEUKEMIA; S-PHASE CHECKPOINT; NIJMEGEN BREAKAGE SYNDROME; FLUDARABINE PLUS CYCLOPHOSPHAMIDE; NUCLEOTIDE EXCISION-REPAIR; STALLED REPLICATION FORKS; EARLY EMBRYONIC LETHALITY; HUMAN DNA-POLYMERASES; DOUBLE-STRAND BREAKS; HISTONE DEACETYLASE INHIBITORS	Nucleoside analogs are structurally similar antimetabolites that have a broad range of action and are clinically active in both solid tumors and hematological malignancies. Many of these agents are incorporated into DNA by polymerases during normal DNA synthesis, an action that blocks further extension of the nascent strand and causes stalling of replication forks. The molecular mechanisms that sense stalled replication forks activate cell cycle checkpoints and DNA repair processes, which may contribute to drug resistance. When replication forks are not stabilized by these molecules or when subsequent DNA repair processes are overwhelmed, apoptosis is initiated either by these same DNA damage sensors or by alternative mechanisms. Recently, strategies aimed at targeting DNA damage checkpoints or DNA repair processes have demonstrated effectiveness in sensitizing cells to nucleoside analogs, thus offering a means to elude drug resistance. In addition to their DNA synthesis-directed actions many nucleoside analogs trigger apoptosis by unique mechanisms, such as causing epigenetic modi. cations or by direct activation of the apoptosome. A review of the cellular and molecular responses to clinically relevant agents provides an understanding of the mechanisms that cause apoptosis and may provide rationale for the development of novel therapeutic strategies.	[Plunkett, W.] Univ Texas MD Anderson Canc Ctr, Dept Expt Therapeut, Unit 71, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center	Plunkett, W (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Expt Therapeut, Unit 71, 1515 Holcombe Blvd, Houston, TX 77030 USA.	wplunket@mdanderson.org	Sampath, Deepa/J-3298-2016; Sampath, Deepa/T-5069-2019	Sampath, Deepa/0000-0002-4366-8436	National Cancer Institute [CA28596, CA32839, CA81534, CA100632]; NIH; NATIONAL CANCER INSTITUTE [R21CA100623, R01CA028596, R01CA032839, P20CA081534, P01CA081534] Funding Source: NIH RePORTER	National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Lisa S Chen for her assistance with chemical structures. Portions of the work described from the authors' laboratories were supported by Grants CA28596, CA32839, CA81534, and CA100632 from the National Cancer Institute, NIH.	Achanta G, 2001, CANCER RES, V61, P8723; AGARWAL RP, 1982, PHARMACOL THERAPEUT, V17, P399, DOI 10.1016/0163-7258(82)90023-7; Ahluwalia A, 2001, GYNECOL ONCOL, V82, P261, DOI 10.1006/gyno.2001.6291; Azuma A, 2001, MOL PHARMACOL, V59, P725, DOI 10.1124/mol.59.4.725; BAKER CH, 1991, J MED CHEM, V34, P1879, DOI 10.1021/jm00110a019; Bakkenist CJ, 2003, NATURE, V421, P499, DOI 10.1038/nature01368; Balakrishnan K, 2006, BLOOD, V108, P2392, DOI 10.1182/blood-2006-03-007468; Bantia S, 2003, INT IMMUNOPHARMACOL, V3, P879, DOI 10.1016/S1567-5769(03)00076-6; Bartek J, 2003, CANCER CELL, V3, P421, DOI 10.1016/S1535-6108(03)00110-7; Belinsky SA, 1998, P NATL ACAD SCI USA, V95, P11891, DOI 10.1073/pnas.95.20.11891; Bellosillo B, 2002, BLOOD, V100, P1810, DOI 10.1182/blood-2001-12-0327; BIANCHI V, 1992, EXP CELL RES, V199, P120, DOI 10.1016/0014-4827(92)90469-O; Brown EJ, 2000, GENE DEV, V14, P397; Brueckner B, 2007, CANCER J, V13, P17, DOI 10.1097/PPO.0b013e31803c7245; Bueno MJ, 2008, CANCER CELL, V13, P496, DOI 10.1016/j.ccr.2008.04.018; Burma S, 2004, DNA REPAIR, V3, P909, DOI 10.1016/j.dnarep.2004.03.021; Buschfort C, 1997, CANCER RES, V57, P651; Busino L, 2004, ONCOGENE, V23, P2050, DOI 10.1038/sj.onc.1207394; Calin GA, 2006, NAT REV CANCER, V6, P857, DOI 10.1038/nrc1997; Carney JP, 1998, CELL, V93, P477, DOI 10.1016/S0092-8674(00)81175-7; CARSON DA, 1986, EXP CELL RES, V164, P273, DOI 10.1016/0014-4827(86)90028-5; CARSON DA, 1992, P NATL ACAD SCI USA, V89, P2970, DOI 10.1073/pnas.89.7.2970; CARSON DA, 1983, BLOOD, V62, P737; CARSON DA, 1990, SEMIN HEMATOL, V27, P260; Catovsky D, 2007, LANCET, V370, P230, DOI 10.1016/S0140-6736(07)61125-8; Chaney SG, 1996, JNCI-J NATL CANCER I, V88, P1346, DOI 10.1093/jnci/88.19.1346; CHANG CN, 1992, J BIOL CHEM, V267, P13938; Chen R, 2005, BLOOD, V106, P2513, DOI 10.1182/blood-2005-04-1678; Chen YH, 2004, DNA REPAIR, V3, P1025, DOI 10.1016/j.dnarep.2004.03.003; Cheng JC, 2003, J NATL CANCER I, V95, P399, DOI 10.1093/jnci/95.5.399; Chou KM, 2000, J BIOL CHEM, V275, P31009, DOI 10.1074/jbc.M004082200; Christiano C, 2003, J BIOL CHEM, V278, P30057, DOI 10.1074/jbc.M301136200; Cliby WA, 2002, J BIOL CHEM, V277, P1599, DOI 10.1074/jbc.M106287200; Cortez D, 2001, SCIENCE, V294, P1713, DOI 10.1126/science.1065521; Costanzo V, 2001, MOL CELL, V8, P137, DOI 10.1016/S1097-2765(01)00294-5; Crews KR, 2002, J CLIN ONCOL, V20, P4217, DOI 10.1200/JCO.2002.10.006; D'Amours D, 2002, NAT REV MOL CELL BIO, V3, P317, DOI 10.1038/nrm805; de Klein A, 2000, CURR BIOL, V10, P479, DOI 10.1016/S0960-9822(00)00447-4; de Laat WL, 1999, GENE DEV, V13, P768, DOI 10.1101/gad.13.7.768; de Toledo SM, 2000, ONCOGENE, V19, P6185, DOI 10.1038/sj.onc.1204020; Delacroix S, 2007, GENE DEV, V21, P1472, DOI 10.1101/gad.1547007; Dewson G, 2003, ONCOGENE, V22, P2643, DOI 10.1038/sj.onc.1206326; Doench JG, 2004, GENE DEV, V18, P504, DOI 10.1101/gad.1184404; Eastman A, 2002, MOL CANCER THER, V1, P1067; Eichhorst BF, 2006, BLOOD, V107, P885, DOI 10.1182/blood-2005-06-2395; EWALD B, 2008, CANC RES IN PRESS; Ewald B, 2007, MOL CANCER THER, V6, P1239, DOI 10.1158/1535-7163.MCT-06-0633; Flinn IW, 2007, J CLIN ONCOL, V25, P793, DOI 10.1200/JCO.2006.08.0762; Gandhi V, 2007, SEMIN ONCOL, V34, pS8, DOI 10.1053/j.seminoncol.2007.11.003; GELEZIUNAS R, 1991, J NATL CANCER I, V83, P557, DOI 10.1093/jnci/83.8.557; Genini D, 2000, BLOOD, V96, P3537; Genini D, 2000, J BIOL CHEM, V275, P29, DOI 10.1074/jbc.275.1.29; Goodman GR, 2003, J CLIN ONCOL, V21, P891, DOI 10.1200/JCO.2003.05.093; Gottifredi V, 2001, P NATL ACAD SCI USA, V98, P1036, DOI 10.1073/pnas.021282898; Gourdeau H, 2001, CANCER RES, V61, P7217; Gourdeau H, 2001, CANCER CHEMOTH PHARM, V47, P236, DOI 10.1007/s002800000223; Grant S, 1998, ADV CANCER RES, V72, P197; Griffith DA, 1996, BBA-REV BIOMEMBRANES, V1286, P153, DOI 10.1016/S0304-4157(96)00008-1; Grove KL, 1996, CANCER RES, V56, P4187; GROVE KL, 1995, CANCER RES, V55, P3008; Han L, 2007, CANCER BIOL THER, V6, P1284; Heffernan TP, 2002, MOL CELL BIOL, V22, P8552, DOI 10.1128/MCB.22.24.8552-8561.2002; HEINEMANN V, 1992, CANCER RES, V52, P533; HEINEMANN V, 1990, MOL PHARMACOL, V38, P567; HEINEMANN V, 1988, CANCER RES, V48, P4024; Helleday T, 2008, NAT REV CANCER, V8, P193, DOI 10.1038/nrc2342; HENTOSH P, 1990, J BIOL CHEM, V265, P4033; Herman JG, 1996, CANCER RES, V56, P722; Herman JG, 1997, CANCER RES, V57, P837; HERTEL LW, 1990, CANCER RES, V50, P4417; Hickson I, 2004, CANCER RES, V64, P9152, DOI 10.1158/0008-5472.CAN-04-2727; Hotte SJ, 2006, ANN ONCOL, V17, P334, DOI 10.1093/annonc/mdj076; Hsi LC, 2005, MOL CANCER THER, V4, P1740, DOI 10.1158/1535-7163.MCT-05-0218; Huang P, 2000, LEUKEMIA, V14, P1405, DOI 10.1038/sj.leu.2401845; HUANG P, 1991, CANCER RES, V51, P6110; HUANG P, 1990, J BIOL CHEM, V265, P16617; HUANG P, 1991, MOL PHARMACOL, V39, P449; Jazayeri A, 2006, NAT CELL BIOL, V8, P37, DOI 10.1038/ncb1337; Jeong SY, 2003, J BIOL CHEM, V278, P46782, DOI 10.1074/jbc.M304551200; Jiemjit A, 2008, ONCOGENE, V27, P3615, DOI 10.1038/sj.onc.1211018; Johnson S A, 2001, Expert Opin Pharmacother, V2, P929, DOI 10.1517/14656566.2.6.929; Jones PA, 2007, CELL, V128, P683, DOI 10.1016/j.cell.2007.01.029; Jones PL, 1999, SEMIN CANCER BIOL, V9, P339, DOI 10.1006/scbi.1999.0134; Kamiya K, 1996, J BIOL CHEM, V271, P19428, DOI 10.1074/jbc.271.32.19428; Kanda T, 2005, ONCOL REP, V14, P975; KANTARJIAN H, 2007, ASH ANN M, V110, P884; Kantarjian H, 2007, BLOOD, V109, P52, DOI 10.1182/blood-2006-05-021162; Karnitz LM, 2005, MOL PHARMACOL, V68, P1636, DOI 10.1124/mol.105.012716; Kawabe T, 2004, MOL CANCER THER, V3, P513; Kicska GA, 2001, P NATL ACAD SCI USA, V98, P4593, DOI 10.1073/pnas.071050798; Kitada S, 1998, BLOOD, V91, P3379, DOI 10.1182/blood.V91.9.3379; Kohn EA, 2002, J BIOL CHEM, V277, P26553, DOI 10.1074/jbc.M202040200; Konopleva M, 2000, BLOOD, V95, P3929; Kortmansky J, 2005, J CLIN ONCOL, V23, P1875, DOI 10.1200/JCO.2005.03.116; Kozlov SV, 2006, EMBO J, V25, P3504, DOI 10.1038/sj.emboj.7601231; KRENITSKY TA, 1967, MOL PHARMACOL, V3, P526; Krishnan P, 2003, J BIOL CHEM, V278, P36726, DOI 10.1074/jbc.M307052200; Krishnan P, 2002, J BIOL CHEM, V277, P5453, DOI 10.1074/jbc.M109025200; KUFE DW, 1984, MOL PHARMACOL, V25, P322; KUFE DW, 1980, J BIOL CHEM, V255, P8997; KUKHANOVA M, 1995, J BIOL CHEM, V270, P23055, DOI 10.1074/jbc.270.39.23055; Kumagai A, 2006, CELL, V124, P943, DOI 10.1016/j.cell.2005.12.041; Kurz EU, 2004, DNA REPAIR, V3, P889, DOI 10.1016/j.dnarep.2004.03.029; Lara PN, 2005, CLIN CANCER RES, V11, P4444, DOI 10.1158/1078-0432.CCR-04-2602; Lee J, 2007, J BIOL CHEM, V282, P28036, DOI 10.1074/jbc.M704635200; Leoni LM, 1998, P NATL ACAD SCI USA, V95, P9567, DOI 10.1073/pnas.95.16.9567; LI LH, 1970, CANCER RES, V30, P2760; Liu XJ, 2008, MOL CANCER THER, V7, P133, DOI 10.1158/1535-7163.MCT-07-0416; Liu XJ, 2005, CANCER RES, V65, P6874, DOI 10.1158/0008-5472.CAN-05-0288; Liu ZF, 2006, RAPID COMMUN MASS SP, V20, P1117, DOI 10.1002/rcm.2423; Lopes M, 2001, NATURE, V412, P557, DOI 10.1038/35087613; Luo GB, 1999, P NATL ACAD SCI USA, V96, P7376, DOI 10.1073/pnas.96.13.7376; Mailand N, 2005, CELL, V122, P915, DOI 10.1016/j.cell.2005.08.013; MATSUDA A, 1991, J MED CHEM, V34, P2917, DOI 10.1021/jm00113a034; Matsuoka S, 2007, SCIENCE, V316, P1160, DOI 10.1126/science.1140321; Matsuura S, 1998, NAT GENET, V19, P179, DOI 10.1038/549; Matthews DJ, 2007, CELL CYCLE, V6, P104, DOI 10.4161/cc.6.1.3699; McDermott KM, 2006, PLOS BIOL, V4, P350, DOI 10.1371/journal.pbio.0040051; Mertens D, 2006, P NATL ACAD SCI USA, V103, P7741, DOI 10.1073/pnas.0600494103; Mirzoeva OK, 2001, MOL CELL BIOL, V21, P281, DOI 10.1128/MCB.21.1.281-288.2001; Mirzoeva OK, 2003, MOL CANCER RES, V1, P207; MIYASHITA T, 1993, BLOOD, V81, P151; MONTGOMERY JA, 1992, J MED CHEM, V35, P397, DOI 10.1021/jm00080a029; Moreno-Herrero F, 2005, NATURE, V437, P440, DOI 10.1038/nature03927; Morita S, 2006, ONCOLOGY-BASEL, V71, P437, DOI 10.1159/000107110; Moufarij MA, 2006, BLOOD, V108, P4187, DOI 10.1182/blood-2006-05-023259; Myers JS, 2006, J BIOL CHEM, V281, P9346, DOI 10.1074/jbc.M513265200; Nakatsuka S, 2003, CANCER SCI, V94, P87, DOI 10.1111/j.1349-7006.2003.tb01357.x; O'Driscoll M, 2003, NAT GENET, V33, P497, DOI 10.1038/ng1129; OHNO Y, 1988, CANCER RES, V48, P1494; Oki Y, 2006, REV RECENT CLIN TRIA, V1, P169, DOI 10.2174/157488706776876490; Olson E, 2007, MOL CELL BIOL, V27, P6053, DOI 10.1128/MCB.00532-07; Palii SS, 2008, MOL CELL BIOL, V28, P752, DOI 10.1128/MCB.01799-07; PARKER WB, 1991, CANCER RES, V51, P2386; PARKER WB, 1988, MOL PHARMACOL, V34, P485; Paull TT, 1998, MOL CELL, V1, P969, DOI 10.1016/S1097-2765(00)80097-0; Paulsen RD, 2007, DNA REPAIR, V6, P953, DOI 10.1016/j.dnarep.2007.02.015; Perez RP, 2006, CLIN CANCER RES, V12, P7079, DOI 10.1158/1078-0432.CCR-06-0197; Pines J, 1999, NAT CELL BIOL, V1, pE73, DOI 10.1038/11041; Plunkett W, 1996, SEMIN ONCOL, V23, P3; Plunkett W, 2001, Cancer Chemother Biol Response Modif, V19, P21; PLUNKETT W, 1995, SEMIN ONCOL, V22, P3; PLUNKETT W, 1982, CANCER RES, V42, P2092; Pogribny IP, 2002, CANCER LETT, V176, P169, DOI 10.1016/S0304-3835(01)00748-0; Raj K, 2007, LEUKEMIA, V21, P1937, DOI 10.1038/sj.leu.2404796; Rao VA, 2003, CLIN CANCER RES, V9, P3204; Rice JC, 2001, CURR OPIN CELL BIOL, V13, P263, DOI 10.1016/S0955-0674(00)00208-8; Richon VM, 2002, CLIN CANCER RES, V8, P662; Riedl SJ, 2007, NAT REV MOL CELL BIO, V8, P405, DOI 10.1038/nrm2153; ROBERTSON LE, 1993, BLOOD, V81, P143; Robinson HMR, 2006, ONCOGENE, V25, P5359, DOI 10.1038/sj.onc.1209532; Robison JG, 2005, J BIOL CHEM, V280, P12927, DOI 10.1074/jbc.M414391200; Robison JG, 2004, J BIOL CHEM, V279, P34802, DOI 10.1074/jbc.M404750200; ROSS DD, 1990, CANCER RES, V50, P2658; Saito Y, 2006, CANCER CELL, V9, P435, DOI 10.1016/j.ccr.2006.04.020; Sampath D, 2006, BLOOD, V107, P2517, DOI 10.1182/blood-2005-08-3351; Sampath D, 2002, MOL PHARMACOL, V62, P680, DOI 10.1124/mol.62.3.680; Sandoval A, 1996, CLIN CANCER RES, V2, P1731; SCHINAZI RF, 1992, ANTIMICROB AGENTS CH, V36, P672, DOI 10.1128/AAC.36.3.672; Schmelz K, 2005, INT J CANCER, V114, P683, DOI 10.1002/ijc.20797; SETO S, 1985, J CLIN INVEST, V75, P377, DOI 10.1172/JCI111710; SETO S, 1986, J IMMUNOL, V136, P2839; Shao RG, 1997, CANCER RES, V57, P4029; Shen LL, 2003, BLOOD, V101, P4131, DOI 10.1182/blood-2002-08-2466; Shi Z, 2001, CANCER RES, V61, P1065; Shieh SY, 2000, GENE DEV, V14, P289; Shiloh Y, 2003, NAT REV CANCER, V3, P155, DOI 10.1038/nrc1011; Shiloh Y, 2006, TRENDS BIOCHEM SCI, V31, P402, DOI 10.1016/j.tibs.2006.05.004; SNYDER RD, 1984, CHEM-BIOL INTERACT, V50, P1, DOI 10.1016/0009-2797(84)90127-3; Stewart GS, 1999, CELL, V99, P577, DOI 10.1016/S0092-8674(00)81547-0; Stracker TH, 2004, DNA REPAIR, V3, P845, DOI 10.1016/j.dnarep.2004.03.014; Stresemann C, 2008, INT J CANCER, V123, P8, DOI 10.1002/ijc.23607; Sugiyama K, 2000, INT J CANCER, V85, P703, DOI 10.1002/(SICI)1097-0215(20000301)85:5<703::AID-IJC17>3.0.CO;2-7; Sun YL, 2007, MOL CELL BIOL, V27, P8502, DOI 10.1128/MCB.01382-07; Takai D, 2002, P NATL ACAD SCI USA, V99, P3740, DOI 10.1073/pnas.052410099; Tang XM, 2004, MOL CANCER RES, V2, P685; Tibbetts RS, 1999, GENE DEV, V13, P152, DOI 10.1101/gad.13.2.152; Tili Esmerina, 2007, Future Oncol, V3, P521, DOI 10.2217/14796694.3.5.521; TOWNSEND AJ, 1987, MOL PHARMACOL, V32, P330; Toyooka S, 2003, CLIN CANCER RES, V9, P3034; Trenz K, 2006, EMBO J, V25, P1764, DOI 10.1038/sj.emboj.7601045; Trujillo KM, 1998, J BIOL CHEM, V273, P21447, DOI 10.1074/jbc.273.34.21447; Tse AN, 2007, CLIN CANCER RES, V13, P1955, DOI 10.1158/1078-0432.CCR-06-2793; TSENG WC, 1982, MOL PHARMACOL, V21, P474; Tsimberidou AM, 2008, J CLIN ONCOL, V26, P196, DOI 10.1200/JCO.2007.11.8513; van den Bosch M, 2003, EMBO REP, V4, P844, DOI 10.1038/sj.embor.embor925; van der Donk WA, 1998, BIOCHEMISTRY-US, V37, P6419, DOI 10.1021/bi9729357; Varon R, 1998, CELL, V93, P467, DOI 10.1016/S0092-8674(00)81174-5; VESELY J, 1977, VOP ONKOL+, V23, P65; Villunger A, 2003, SCIENCE, V302, P1036, DOI 10.1126/science.1090072; Walton TJ, 2008, PROSTATE, V68, P210, DOI 10.1002/pros.20673; Wang JL, 2002, CELL CYCLE, V1, P267, DOI 10.4161/cc.1.4.137; Wang J, 2007, P NATL ACAD SCI USA, V104, P14324, DOI 10.1073/pnas.0706803104; Wang JH, 2008, CHEM MATER, V20, P20, DOI 10.1021/cm702375e; Wang Y, 2000, GENE DEV, V14, P927; Wang YQ, 2008, CANCER RES, V68, P3881, DOI 10.1158/0008-5472.CAN-07-6885; Welch S, 2007, GYNECOL ONCOL, V106, P305, DOI 10.1016/j.ygyno.2007.02.018; Wen Q, 2008, MOL BIOL CELL, V19, P1693, DOI 10.1091/mbc.E07-09-0975; Xiao YH, 1997, NUCLEIC ACIDS RES, V25, P2985, DOI 10.1093/nar/25.15.2985; Xiao Z, 2005, ONCOGENE, V24, P1403, DOI 10.1038/sj.onc.1208309; XIE CX, 1995, CANCER RES, V55, P2847; Xie KC, 1996, CANCER RES, V56, P3030; Yamaguchi-Iwai Y, 1999, EMBO J, V18, P6619, DOI 10.1093/emboj/18.23.6619; Yamauchi T, 2001, CLIN CANCER RES, V7, P3580; Yan PS, 2001, CANCER RES, V61, P8375; YANG SW, 1992, J BIOL CHEM, V267, P2345; Zhang L, 2008, P NATL ACAD SCI USA, V105, P7004, DOI 10.1073/pnas.0801615105; Zhang YW, 2006, CELL CYCLE, V5, P125, DOI 10.4161/cc.5.2.2308; Zhao H, 2001, MOL CELL BIOL, V21, P4129, DOI 10.1128/MCB.21.13.4129-4139.2001; Zhao M, 2004, J CHROMATOGR B, V813, P81, DOI 10.1016/j.jchromb.2004.09.012; Zhou BBS, 2004, NAT REV CANCER, V4, P216, DOI 10.1038/nrc1296; Zhu J, 2001, CURR BIOL, V11, P105, DOI 10.1016/S0960-9822(01)00019-7; Zhu WG, 2001, CANCER RES, V61, P1327; Zou L, 2003, SCIENCE, V300, P1542, DOI 10.1126/science.1083430	214	157	164	0	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 27	2008	27	50					6522	6537		10.1038/onc.2008.316	http://dx.doi.org/10.1038/onc.2008.316			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	366RR	18955977				2022-12-28	WOS:000260501600010
J	Leng, X; Lin, H; Ding, T; Wang, Y; Wu, Y; Klumpp, S; Sun, T; Zhou, Y; Monaco, P; Belmont, J; Aderem, A; Akira, S; Strong, R; Arlinghaus, R				Leng, X.; Lin, H.; Ding, T.; Wang, Y.; Wu, Y.; Klumpp, S.; Sun, T.; Zhou, Y.; Monaco, P.; Belmont, J.; Aderem, A.; Akira, S.; Strong, R.; Arlinghaus, R.			Lipocalin 2 is required for BCR-ABL-induced tumorigenesis	ONCOGENE			English	Article						lipocalin 2; CML; tumorigenesis; BCR-ABL; apoptosis	GELATINASE-ASSOCIATED LIPOCALIN; CHRONIC MYELOGENOUS LEUKEMIA; NGAL; MICE; INDUCTION; CANCER; INFECTION; APOPTOSIS; COMPLEX; GROWTH	Our previous studies indicate that reduction of lipocalin 2 (mouse 24p3) expression by either anti-sense or siRNA approaches strongly reduces the overgrowth of BCR-ABL + mouse myeloid 32D in marrow and spleen of NOD/SCID mice. In this study, we used the mouse bone marrow transplant model to further explore the role of 24p3 in BCR-ABL-induced leukemia. Consistent with our previous findings, when using non-irradiated mice as recipient, donor marrow cells expressing BCR-ABL but lacking 24p3 did not cause leukemia or any disease after 75 days, whereas all mice receiving wild type BCR-ABL donor cells died with CML-like disease. An agar clone of the BCR-ABL + human CML cell line K562 (C5) that secretes relatively high levels of lipocalin 2 (human NGAL) induced suppression of hematopoiesis in spleen and marrow of mice, leading to early death in contrast to parental K562 or K562 clone (C6) expressing low amounts of NGAL. Compared with K562 cells, overexpressing NGAL in K562 led to a higher apoptosis rate and an atrophy phenotype in the spleen of the inoculated mice. Plasma from both leukemic mice and CML patients showed elevated lipocalin 2 levels compared with healthy individuals. Moreover, we found that a primary stable cell line from wild-type mouse marrow cells expressing BCR-ABL caused solid tumors in nude mice whereas a similar BCR-ABL + cell line from 24p3 null mice did not. These findings demonstrate that lipocalin 2 has at least two functions related to tumorigenesis, one involving apoptosis induction of normal hematopoietic cells and the other being tissue invasion by leukemia cells.	[Leng, X.; Lin, H.; Ding, T.; Wang, Y.; Sun, T.; Zhou, Y.; Arlinghaus, R.] Univ Texas MD Anderson Canc Ctr, Dept Mol Pathol, Houston, TX 77030 USA; [Wu, Y.] Univ Texas MD Anderson Canc Ctr, Dept Pathol, Houston, TX 77030 USA; [Klumpp, S.] Univ Texas MD Anderson Canc Ctr, Dept Vet Med, Houston, TX 77030 USA; [Monaco, P.; Belmont, J.] Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA; [Aderem, A.] Inst Syst Biol, Seattle, WA USA; [Akira, S.] Osaka Univ, Dept Host Def, Microbial Dis Res Inst, Osaka, Japan; [Akira, S.] Japan Sci & Technol Corp, Exploratory Res Adv Technol ERAYO, Osaka, Japan; [Strong, R.] Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; Baylor College of Medicine; Institute for Systems Biology (ISB); Osaka University; Japan Science & Technology Agency (JST); Fred Hutchinson Cancer Center	Arlinghaus, R (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Mol Pathol, 7435 Fannin St,Unit 951, Houston, TX 77030 USA.	rarlingh@mdanderson.org	Belmont, John W/AAI-2494-2019; Akira, Shizuo/C-3134-2009; Belmont, John/AAH-6084-2021	Belmont, John W/0000-0001-7409-3578; 	NIH [PO1 CA49639]; NATIONAL CANCER INSTITUTE [P01CA049639] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We also want to thank Dr Bastinaella Perazzona for critically reading the paper. This research was supported in part by a grant from NIH (PO1 CA49639).	BEN-NERIAH Y, 1986, SCIENCE, V233, P212, DOI 10.1126/science.3460176; Berger T, 2006, P NATL ACAD SCI USA, V103, P1834, DOI 10.1073/pnas.0510847103; DALEY GQ, 1990, SCIENCE, V247, P824, DOI 10.1126/science.2406902; Devireddy LR, 2005, CELL, V123, P1293, DOI 10.1016/j.cell.2005.10.027; Devireddy LR, 2001, SCIENCE, V293, P829, DOI 10.1126/science.1061075; Egeblad M, 2002, NAT REV CANCER, V2, P161, DOI 10.1038/nrc745; Fernandez CA, 2005, CLIN CANCER RES, V11, P5390, DOI 10.1158/1078-0432.CCR-04-2391; Flo TH, 2004, NATURE, V432, P917, DOI 10.1038/nature03104; Flower DR, 1996, BIOCHEM J, V318, P1; Furutani M, 1998, CANCER LETT, V122, P209, DOI 10.1016/S0304-3835(97)00391-1; Goetz DH, 2002, MOL CELL, V10, P1033, DOI 10.1016/S1097-2765(02)00708-6; GROFFEN J, 1984, CELL, V36, P93, DOI 10.1016/0092-8674(84)90077-1; Guo JQ, 2002, LEUKEMIA, V16, P2447, DOI 10.1038/sj.leu.2402730; KJELDSEN L, 1993, J BIOL CHEM, V268, P10425; Li SG, 1999, J EXP MED, V189, P1399, DOI 10.1084/jem.189.9.1399; Lim R, 2007, INT J CANCER, V120, P2426, DOI 10.1002/ijc.22352; Lin F, 2001, ONCOGENE, V20, P1873, DOI 10.1038/sj.onc.1204409; Lin H, 2005, ONCOGENE, V24, P3246, DOI 10.1038/sj.onc.1208500; Miharada K, 2005, FASEB J, V19, P1881, DOI 10.1096/fj.05-3809fje; Miharada K, 2008, J CELL PHYSIOL, V215, P526, DOI 10.1002/jcp.21334; Nieborowska-Skorska M, 2006, CANCER RES, V66, P4108, DOI 10.1158/0008-5472.CAN-05-1584; Pear WS, 1998, BLOOD, V92, P3780, DOI 10.1182/blood.V92.10.3780.422k15_3780_3792; Rudd PM, 1999, BIOCHEMISTRY-US, V38, P13937, DOI 10.1021/bi991162e; Yan L, 2001, J BIOL CHEM, V276, P37258, DOI 10.1074/jbc.M106089200; Yang J, 2002, MOL CELL, V10, P1045, DOI 10.1016/S1097-2765(02)00710-4; Zhang HH, 2007, J CLIN PATHOL, V60, P555, DOI 10.1136/jcp.2006.039297	26	75	76	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT	2008	27	47					6110	6119		10.1038/onc.2008.209	http://dx.doi.org/10.1038/onc.2008.209			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	360UJ	18663364	Green Accepted			2022-12-28	WOS:000260083100004
J	Tong, Y; Ben-Shlomo, A; Zhou, C; Wawrowsky, K; Melmed, S				Tong, Y.; Ben-Shlomo, A.; Zhou, C.; Wawrowsky, K.; Melmed, S.			Pituitary tumor transforming gene 1 regulates Aurora kinase A activity	ONCOGENE			English	Article						PTTG1; Aurora kinase A; drug response	HUMAN-CELLS; DNA-DAMAGE; TRANSCRIPTIONAL ACTIVATION; OVARIAN-CANCER; HUMAN SECURIN; HISTONE H3; A KINASE; PTTG; CHECKPOINT; EXPRESSION	Pituitary tumor transforming gene 1 (PTTG1), a transforming gene highly expressed in several cancers, is a mammalian securin protein regulating both G1/S and G2/M phases. Using protein array screening, we showed PTTG1 interacting with Aurora kinase A (Aurora-A), and confirmed the interaction using co-immunoprecipitation, His-tagged pull-down assays and intracellular immunofluorescence colocalization. PTTG1 transfection into HCT116 cells prevented Aurora-A T288 autophosphorylation, inhibited phosphorylation of the histone H3 Aurora-A substrate and resulted in abnormally condensed chromatin. PTTG1-null cell proliferation was more sensitive to Aurora-A knock down and to Aurora kinase Inhibitor III treatment. The results indicate that PTTG1 and Aurora-A interact to regulate cellular responses to anti-neoplastic drugs. PTTG1 knockdown is therefore a potential approach to improve the efficacy of tumor Aurora kinase inhibitors.	[Tong, Y.; Ben-Shlomo, A.; Zhou, C.; Wawrowsky, K.; Melmed, S.] Univ Calif Los Angeles, Cedars Sinai Med Ctr, Dept Med, David Geffen Sch Med,Cedars Sinai Res Inst, Los Angeles, CA 90048 USA	Cedars Sinai Medical Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Melmed, S (corresponding author), Univ Calif Los Angeles, Cedars Sinai Med Ctr, Dept Med, David Geffen Sch Med,Cedars Sinai Res Inst, 8700 Beverly Blvd,Acad Affairs,Room 2015, Los Angeles, CA 90048 USA.	melmed@csmc.edu	Zhou, Cuiqi/B-1568-2010; Ben-Shlomo, Anat/AAH-6009-2021		NIH [CA 75979, T32 DK007770]; The Doris Factor Molecular Endocrinology Laboratory; NATIONAL CANCER INSTITUTE [R01CA075979] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007770] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); The Doris Factor Molecular Endocrinology Laboratory; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	PTTG1 WT and KO HCT116 cells were kindly provided by Dr Bert Vogelstein, Johns Hopkins University. PTTG1-GFP and PTTG1-PCDNA3.1 plasmids were kindly provided by Dr Run Yu. Supported by NIH Grant CA 75979 (SM), T32 DK007770, and The Doris Factor Molecular Endocrinology Laboratory.	Akino K, 2005, J SURG RES, V129, P142, DOI 10.1016/j.jss.2005.04.019; Bernal JA, 2008, CELL DEATH DIFFER, V15, P202, DOI 10.1038/sj.cdd.4402254; Bernal JA, 2002, NAT GENET, V32, P306, DOI 10.1038/ng997; Bernal JA, 2007, J BIOCHEM, V141, P737, DOI 10.1093/jb/mvm076; Boelaert K, 2003, FASEB J, V17, P1631, DOI 10.1096/fj.02-0948com; Cheeseman LM, 2002, CELL, V111, P163, DOI 10.1016/S0092-8674(02)00973-X; Chen SS, 2002, EMBO J, V21, P4491, DOI 10.1093/emboj/cdf409; Chien WW, 2000, J BIOL CHEM, V275, P19422, DOI 10.1074/jbc.M910105199; Crosio C, 2002, MOL CELL BIOL, V22, P874, DOI 10.1128/MCB.22.3.874-885.2002; Donangelo I, 2006, ENDOCRINOLOGY, V147, P4781, DOI 10.1210/en.2006-0544; El-Naggar SM, 2007, INT J ONCOL, V31, P137; Eyers PA, 2003, CURR BIOL, V13, P691, DOI 10.1016/S0960-9822(03)00166-0; Gadea BB, 2005, MOL BIOL CELL, V16, P1305, DOI 10.1091/mbc.E04-10-0891; Gil-Bernabe AM, 2006, MOL CELL BIOL, V26, P4017, DOI 10.1128/MCB.01904-05; Heaney AP, 1999, NAT MED, V5, P1317, DOI 10.1038/15275; Heaney AP, 2000, LANCET, V355, P716, DOI 10.1016/S0140-6736(99)10238-1; Hirota T, 2003, CELL, V114, P585, DOI 10.1016/S0092-8674(03)00642-1; Horn V, 2007, MOL BIOL CELL, V18, P1233, DOI 10.1091/mbc.E06-12-1152; Hornig NCD, 2002, CURR BIOL, V12, P973, DOI 10.1016/S0960-9822(02)00847-3; Hutterer A, 2006, DEV CELL, V11, P147, DOI 10.1016/j.devcel.2006.06.002; Ikezoe T, 2007, MOL CANCER THER, V6, P1851, DOI 10.1158/1535-7163.MCT-07-0067; Kakar SS, 2006, INT J ONCOL, V29, P387; Kim D, 2006, CLIN OTOLARYNGOL, V31, P246; Kim DS, 2007, CARCINOGENESIS, V28, P749, DOI 10.1093/carcin/bgl202; Krystyniak A, 2006, ONCOGENE, V25, P338, DOI 10.1038/sj.onc.1209056; Lai YQ, 2007, J BIOCHEM MOL BIOL, V40, P966; Li JJ, 2006, PHARMACOL THERAPEUT, V111, P974, DOI 10.1016/j.pharmthera.2006.02.006; Li M, 2007, MOL CELL BIOL, V27, P3481, DOI 10.1128/MCB.02088-06; Lindon C, 2004, J CELL BIOL, V164, P233, DOI 10.1083/jcb.200309035; Marumoto T, 2002, GENES CELLS, V7, P1173, DOI 10.1046/j.1365-2443.2002.00592.x; McCabe CJ, 2003, CLIN ENDOCRINOL, V58, P141, DOI 10.1046/j.1365-2265.2003.01598.x; Mountzios G, 2008, CANCER TREAT REV, V34, P175, DOI 10.1016/j.ctrv.2007.09.005; Ohashi S, 2006, ONCOGENE, V25, P7691, DOI 10.1038/sj.onc.1209754; Pascreau Gaetan, 2003, Prog Cell Cycle Res, V5, P369; Pei L, 1999, J BIOL CHEM, V274, P3151, DOI 10.1074/jbc.274.5.3151; Pei L, 1997, MOL ENDOCRINOL, V11, P433, DOI 10.1210/me.11.4.433; Pei L, 2001, J BIOL CHEM, V276, P8484, DOI 10.1074/jbc.M009654200; Pei L, 2000, J BIOL CHEM, V275, P31191, DOI 10.1074/jbc.M002451200; Pereira G, 2003, SCIENCE, V302, P2120, DOI 10.1126/science.1091936; Prigent C, 2003, J CELL SCI, V116, P3677, DOI 10.1242/jcs.00735; Saez C, 1999, ONCOGENE, V18, P5473, DOI 10.1038/sj.onc.1202914; Sheleg SV, 2007, J VIROL, V81, P7894, DOI 10.1128/JVI.00555-07; Solbach C, 2004, BREAST, V13, P80, DOI 10.1016/j.breast.2003.09.008; Sun CB, 2007, BIOCHEM BIOPH RES CO, V352, P220, DOI 10.1016/j.bbrc.2006.11.004; Tarabykin V, 2000, MECH DEVELOP, V92, P301, DOI 10.1016/S0925-4773(00)00243-4; Tong Y, 2007, ONCOGENE, V26, P5596, DOI 10.1038/sj.onc.1210339; Vlotides G, 2007, ENDOCR REV, V28, P165, DOI 10.1210/er.2006-0042; Vogel C, 2005, J BIOL CHEM, V280, P4025, DOI 10.1074/jbc.C400545200; Vogel C, 2007, CANCER RES, V67, P339, DOI 10.1158/0008-5472.CAN-06-2548; Waizenegger IC, 2002, CURR BIOL, V12, P1368, DOI 10.1016/S0960-9822(02)01073-4; Walter AO, 2000, ONCOGENE, V19, P4906, DOI 10.1038/sj.onc.1203847; Wang H, 2001, GENE DEV, V15, P1361, DOI 10.1101/gad.893201; Wang ZY, 2000, J BIOL CHEM, V275, P7459, DOI 10.1074/jbc.275.11.7459; Wang ZY, 2003, P NATL ACAD SCI USA, V100, P3428, DOI 10.1073/pnas.0638052100; Wang ZY, 2001, MOL ENDOCRINOL, V15, P1870, DOI 10.1210/me.15.11.1870; XUE Y, 2008, MOL CELL PROTEOMICS; Yang H, 2006, INT J CANCER, V119, P2304, DOI 10.1002/ijc.22154; Yu R, 2003, ENDOCRINOLOGY, V144, P4991, DOI 10.1210/en.2003-0305; ZHANG D, 2008, ONCOGENE; Zhang DW, 2004, ONCOGENE, V23, P8720, DOI 10.1038/sj.onc.1208153; Zhang Y, 2007, BIOCHEM BIOPH RES CO, V357, P347, DOI 10.1016/j.bbrc.2007.03.129; Zhou HY, 1998, NAT GENET, V20, P189, DOI 10.1038/2496; Zou H, 1999, SCIENCE, V285, P418, DOI 10.1126/science.285.5426.418	63	21	23	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT	2008	27	49					6385	6395		10.1038/onc.2008.234	http://dx.doi.org/10.1038/onc.2008.234			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	363JK	18663361				2022-12-28	WOS:000260263400008
J	Yu, JW; Shi, Y				Yu, J. W.; Shi, Y.			FLIP and the death effector domain family	ONCOGENE			English	Review						apoptosis; extrinsic cell death; caspase-8; DED; FLIP; NF-kappa B	NF-KAPPA-B; APOPTOSIS-INDUCING LIGAND; T-CELL PROLIFERATION; REGULATES FAS/TNFR1-INDUCED APOPTOSIS; RECEPTOR-INDUCED APOPTOSIS; SIGNALING COMPLEX DISC; FAS-MEDIATED APOPTOSIS; C-FLIPL; CRYSTAL-STRUCTURE; CASPASE-8 ACTIVATION	Death effector domains (DEDs) are protein interaction modules found in a number of proteins known to regulate apoptosis from death receptors. The core DED family members that orchestrate programmed cell death from death receptors include the adaptor protein FADD, the initiator caspases procaspases-8 and -10 and the regulatory protein c-FLIP. Through homotypic DED interactions, these proteins assemble into the death-inducing signaling complex (DISC) to regulate initiator caspase activation and launch the apoptotic proteolytic cascade. A considerable body of evidence, however, is revealing that the same core group of DED-containing proteins also paradoxically promotes survival and proliferation in lymphocytes and possibly other cell types. This review delves into recent findings regarding these two opposing functional aspects of the core DED proteins. We discuss the current effort expanding our structural and biochemical view of how DED proteins assemble into the DISC to fully activate initiator caspases and execute cell death, and finally we examine details linking the same proteins to proliferation and describe how this outcome might be achieved through restricted activation of initiator caspases.	[Yu, J. W.; Shi, Y.] Princeton Univ, Dept Mol Biol, Lewis Thomas Lab, Princeton, NJ 08544 USA	Princeton University	Yu, JW (corresponding author), Princeton Univ, Dept Mol Biol, Lewis Thomas Lab, Princeton, NJ 08544 USA.	jwyu@princeton.edu; ygshi@princeton.edu			National Institutes of Health [2 R01 CA90269]; Damon Runyon Cancer Research Foundation [DRG-1905-06]; NATIONAL CANCER INSTITUTE [R01CA090269] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Damon Runyon Cancer Research Foundation; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	Work from Yigong Shi's laboratory in this area of research was supported by a grant from the National Institutes of Health (2 R01 CA90269). Jong W Yu is a Damon Runyon Fellow supported by the Damon Runyon Cancer Research Foundation (DRG-1905-06).	Abe K, 2000, ANN NY ACAD SCI, V926, P52; Alappat EC, 2005, MOL CELL, V19, P321, DOI 10.1016/j.molcel.2005.06.024; Alcivar A, 2003, ONCOGENE, V22, P291, DOI 10.1038/sj.onc.1206099; ALDERSON MR, 1993, J EXP MED, V178, P2231, DOI 10.1084/jem.178.6.2231; Algeciras-Schimnich A, 2002, MOL CELL BIOL, V22, P207, DOI 10.1128/MCB.22.1.207-220.2002; Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Bagneris C, 2008, MOL CELL, V30, P620, DOI 10.1016/j.molcel.2008.04.029; Bang S, 2000, J BIOL CHEM, V275, P36217, DOI 10.1074/jbc.M006620200; Bao Q, 2007, CELL DEATH DIFFER, V14, P56, DOI 10.1038/sj.cdd.4402028; Beisner DR, 2005, J IMMUNOL, V175, P3469, DOI 10.4049/jimmunol.175.6.3469; Berglund H, 2000, J MOL BIOL, V302, P171, DOI 10.1006/jmbi.2000.4011; Bidere N, 2006, CURR BIOL, V16, P1666, DOI 10.1016/j.cub.2006.06.062; Boatright KM, 2004, BIOCHEM J, V382, P651, DOI 10.1042/BJ20040809; Boatright KM, 2003, MOL CELL, V11, P529, DOI 10.1016/S1097-2765(03)00051-0; Boissonnas A, 2002, EUR J IMMUNOL, V32, P3007, DOI 10.1002/1521-4141(2002010)32:10<3007::AID-IMMU3007>3.0.CO;2-9; Carrington PE, 2006, MOL CELL, V22, P599, DOI 10.1016/j.molcel.2006.04.018; Chan FKM, 2000, SCIENCE, V288, P2351, DOI 10.1126/science.288.5475.2351; Chang DW, 2002, EMBO J, V21, P3704, DOI 10.1093/emboj/cdf356; Chang DW, 2003, EMBO J, V22, P4132, DOI 10.1093/emboj/cdg414; Chang LF, 2006, CELL, V124, P601, DOI 10.1016/j.cell.2006.01.021; Chau H, 2005, J EXP MED, V202, P405, DOI 10.1084/jem.20050118; Chaudhary PM, 1999, ONCOGENE, V18, P5738, DOI 10.1038/sj.onc.1202976; Chun HJ, 2002, NATURE, V419, P395, DOI 10.1038/nature01063; Condorelli G, 1999, ONCOGENE, V18, P4409, DOI 10.1038/sj.onc.1202831; Curtin JF, 2003, CELL SIGNAL, V15, P983, DOI 10.1016/S0898-6568(03)00093-7; Danial NN, 2004, CELL, V116, P205, DOI 10.1016/S0092-8674(04)00046-7; Desbarats J, 2000, NAT MED, V6, P920, DOI 10.1038/78688; Desbarats J, 2003, NAT CELL BIOL, V5, P118, DOI 10.1038/ncb916; Dohrman A, 2005, J IMMUNOL, V174, P5270, DOI 10.4049/jimmunol.174.9.5270; Donepudi M, 2003, MOL CELL, V11, P543, DOI 10.1016/S1097-2765(03)00059-5; Eberstadt M, 1998, NATURE, V392, P941, DOI 10.1038/31972; Field N, 2003, J CELL SCI, V116, P3721, DOI 10.1242/jcs.00691; Golks A, 2005, J BIOL CHEM, V280, P14507, DOI 10.1074/jbc.M414425200; Golks A, 2006, J EXP MED, V203, P1295, DOI 10.1084/jem.20051556; Goltsev YV, 1997, J BIOL CHEM, V272, P19641, DOI 10.1074/jbc.272.32.19641; Green DR, 2002, CANCER CELL, V1, P19, DOI 10.1016/S1535-6108(02)00024-7; Guasparri I, 2006, EMBO REP, V7, P114, DOI 10.1038/sj.embor.7400580; Han DKM, 1997, P NATL ACAD SCI USA, V94, P11333, DOI 10.1073/pnas.94.21.11333; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hill JM, 2004, J BIOL CHEM, V279, P1474, DOI 10.1074/jbc.M304996200; Holler N, 2003, MOL CELL BIOL, V23, P1428, DOI 10.1128/MCB.23.4.1428-1440.2003; Hu SM, 1997, J BIOL CHEM, V272, P17255, DOI 10.1074/jbc.272.28.17255; Huang BH, 1996, NATURE, V384, P638, DOI 10.1038/384638a0; Inohara N, 1997, P NATL ACAD SCI USA, V94, P10717, DOI 10.1073/pnas.94.20.10717; Irmler M, 1997, NATURE, V388, P190, DOI 10.1038/40657; Jeong EJ, 1999, J BIOL CHEM, V274, P16337, DOI 10.1074/jbc.274.23.16337; Kataoka T, 2004, MOL CELL BIOL, V24, P2627, DOI 10.1128/MCB.24.7.2627-2636.2004; Kataoka T, 2000, CURR BIOL, V10, P640, DOI 10.1016/S0960-9822(00)00512-1; Kaufmann M, 2002, FEBS LETT, V527, P250, DOI 10.1016/S0014-5793(02)03146-0; Kennedy NJ, 1999, J EXP MED, V190, P1891, DOI 10.1084/jem.190.12.1891; KISCHKEL FC, 1995, EMBO J, V14, P5579, DOI 10.1002/j.1460-2075.1995.tb00245.x; Krammer PH, 2000, NATURE, V407, P789, DOI 10.1038/35037728; Krueger A, 2001, MOL CELL BIOL, V21, P8247, DOI 10.1128/MCB.21.24.8247-8254.2001; Lee HJ, 2007, NAT CELL BIOL, V9, P1303, DOI 10.1038/ncb1650; Lens SMA, 2002, MOL CELL BIOL, V22, P5419, DOI 10.1128/MCB.22.15.5419-5433.2002; Li FY, 2006, J BIOL CHEM, V281, P2960, DOI 10.1074/jbc.M511074200; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Liu L, 2002, J BIOL CHEM, V277, P13745, DOI 10.1074/jbc.M110480200; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Maedler K, 2002, P NATL ACAD SCI USA, V99, P8236, DOI 10.1073/pnas.122686299; Medema JP, 1997, EMBO J, V16, P2794, DOI 10.1093/emboj/16.10.2794; Micheau O, 2002, J BIOL CHEM, V277, P45162, DOI 10.1074/jbc.M206882200; Misra RS, 2007, J BIOL CHEM, V282, P19365, DOI 10.1074/jbc.M610610200; Mitsiades CS, 2006, CLIN CANCER RES, V12, P3705, DOI 10.1158/1078-0432.CCR-05-2493; Muppidi JR, 2006, CELL DEATH DIFFER, V13, P1641, DOI 10.1038/sj.cdd.4401855; Muppidi JR, 2004, NAT IMMUNOL, V5, P182, DOI 10.1038/ni1024; Naito M, 2004, MOL CELL BIOL, V24, P8418, DOI 10.1128/MCB.24.19.8418-8427.2004; Nakagiri S, 2005, MOL CELL BIOL, V25, P9249, DOI 10.1128/MCB.25.21.9249-9258.2005; Nakajima A, 2006, EMBO J, V25, P5549, DOI 10.1038/sj.emboj.7601423; Ozoren N, 2003, SEMIN CANCER BIOL, V13, P135, DOI 10.1016/S1044-579X(02)00131-1; Peter ME, 2007, CELL, V129, P447, DOI 10.1016/j.cell.2007.04.031; Pyo JO, 2005, J BIOL CHEM, V280, P20722, DOI 10.1074/jbc.M413934200; Qi W, 2007, EMBO J, V26, P65, DOI 10.1038/sj.emboj.7601483; Rasper DM, 1998, CELL DEATH DIFFER, V5, P271, DOI 10.1038/sj.cdd.4400370; Rathmell JC, 2002, CELL, V109, pS97, DOI 10.1016/S0092-8674(02)00704-3; Rawlings DJ, 2006, NAT REV IMMUNOL, V6, P799, DOI 10.1038/nri1944; Reed J. C., 2004, SCI STKE, V2004, pre9, DOI DOI 10.1126/STKE.2392004RE9; Renganathan H, 2005, BIOCHEM J, V390, P729, DOI 10.1042/BJ20050378; Riedl SJ, 2004, NAT REV MOL CELL BIO, V5, P897, DOI 10.1038/nrm1496; Salmena L, 2003, GENE DEV, V17, P883, DOI 10.1101/gad.1063703; Sandu C, 2006, CELL DEATH DIFFER, V13, P2052, DOI 10.1038/sj.cdd.4401966; Scaffidi C, 1999, J BIOL CHEM, V274, P1541, DOI 10.1074/jbc.274.3.1541; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; Shu HB, 1997, IMMUNITY, V6, P751, DOI 10.1016/S1074-7613(00)80450-1; Siegel RM, 2000, SCIENCE, V288, P2354, DOI 10.1126/science.288.5475.2354; Siegel RM, 2004, J CELL BIOL, V167, P735, DOI 10.1083/jcb.200406101; Siegel RM, 1998, J CELL BIOL, V141, P1243, DOI 10.1083/jcb.141.5.1243; Srinivasula SM, 1997, J BIOL CHEM, V272, P18542, DOI 10.1074/jbc.272.30.18542; Stilo R, 2003, BIOCHEM BIOPH RES CO, V303, P1034, DOI 10.1016/S0006-291X(03)00487-X; Stupack DG, 2006, NATURE, V439, P95, DOI 10.1038/nature04323; Stupack DG, 2001, J CELL BIOL, V155, P459, DOI 10.1083/jcb.200106070; Su H, 2005, SCIENCE, V307, P1465, DOI 10.1126/science.1104765; Thomas LR, 2004, J BIOL CHEM, V279, P32780, DOI 10.1074/jbc.M401680200; Thomas LR, 2002, J BIOL CHEM, V277, P34343, DOI 10.1074/jbc.M204169200; Thorburn J, 2005, MOL BIOL CELL, V16, P1189, DOI 10.1091/mbc.E04-10-0906; Vaux DL, 2000, CURR OPIN IMMUNOL, V12, P719, DOI 10.1016/S0952-7915(00)00168-0; Vilimanovich U, 2008, CELL MOL LIFE SCI, V65, P814, DOI 10.1007/s00018-008-7513-8; Wajant H, 2003, ESSAYS BIOCHEM, V39, P53, DOI 10.1042/bse0390053; Walczak H, 1999, NAT MED, V5, P157, DOI 10.1038/5517; Wang SL, 2003, ONCOGENE, V22, P8628, DOI 10.1038/sj.onc.1207232; Yang JK, 2005, MOL CELL, V20, P939, DOI 10.1016/j.molcel.2005.10.023; Yao Z, 2007, EMBO J, V26, P1068, DOI 10.1038/sj.emboj.7601571; Yu L, 2004, SCIENCE, V304, P1500, DOI 10.1126/science.1096645; Yuan JY, 2000, NATURE, V407, P802, DOI 10.1038/35037739; Zhang JK, 1998, NATURE, V392, P296, DOI 10.1038/32681; Zhang N, 2005, J EXP MED, V202, P395, DOI 10.1084/jem.20050117	106	99	103	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT	2008	27	48					6216	6227		10.1038/onc.2008.299	http://dx.doi.org/10.1038/onc.2008.299			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	361YB	18931689				2022-12-28	WOS:000260162800004
J	Shiota, M; Izumi, H; Onitsuka, T; Miyamoto, N; Kashiwagi, E; Kidani, A; Hirano, G; Takahashi, M; Naito, S; Kohno, K				Shiota, M.; Izumi, H.; Onitsuka, T.; Miyamoto, N.; Kashiwagi, E.; Kidani, A.; Hirano, G.; Takahashi, M.; Naito, S.; Kohno, K.			Twist and p53 reciprocally regulate target genes via direct interaction	ONCOGENE			English	Article						YB-1; Twist; p53; GST-fusion protein array; membrane pull-down assay	SAETHRE-CHOTZEN SYNDROME; BOX-BINDING-PROTEIN; BHLH PROTEIN; CANCER-CELLS; DRUG-RESISTANCE; NEURAL-TUBE; EXPRESSION; DNA; MORPHOGENESIS; CISPLATIN	Twist is basic helix-loop-helix transcription factor that binds to E-boxes in gene promoters. Twist possesses an oncogenic function by interfering with the tumor suppressor function of p53. Using a membrane pull-down assay, we found that Twist directly interacts with p53 and that this interaction underlies the inhibitory effects on p53 target gene expression. Twist interacted with the DNA-binding domain of p53 and suppressed the DNA-binding activity of p53. Transcriptional activation of the p21 promoter by p53 was significantly repressed by the expression of Twist. On the other hand, p53 interacted with the N-terminal domain of Twist and repressed Twist-dependent YB-1 promoter activity. Importantly, we found that p53-dependent growth suppression was canceled by the expression of either Twist or YB-1. Thus, our data suggest that Twist inhibits p53 function via a direct interaction with p53.	[Shiota, M.; Izumi, H.; Onitsuka, T.; Miyamoto, N.; Kashiwagi, E.; Kidani, A.; Hirano, G.; Takahashi, M.; Kohno, K.] Univ Occupat & Environm Hlth, Sch Med, Dept Mol Biol, Yahatanishi Ku, Kitakyushu, Fukuoka 8078555, Japan; [Shiota, M.; Kashiwagi, E.; Naito, S.] Kyushu Univ, Grad Sch Med Sci, Dept Urol, Fukuoka 812, Japan	University of Occupational & Environmental Health - Japan; Kyushu University	Kohno, K (corresponding author), Univ Occupat & Environm Hlth, Sch Med, Dept Mol Biol, Yahatanishi Ku, 1-1 Iseigaoka, Kitakyushu, Fukuoka 8078555, Japan.	k-kohno@med.uoeh-u.ac.jp	Shiota, Masaki/Q-9387-2019	Shiota, Masaki/0000-0002-3306-4858	Ministry of Education, Culture, Sports, Science, and Technology of Japan (Mext) [13218132, 17590257]; Kobayashi Institute for Innovative Cancer Chemotherapy; grant-in-aid for Cancer Research from the Fukuoka Cancer Society, Japan	Ministry of Education, Culture, Sports, Science, and Technology of Japan (Mext)(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Kobayashi Institute for Innovative Cancer Chemotherapy; grant-in-aid for Cancer Research from the Fukuoka Cancer Society, Japan	This work was supported in part by the Ministry of Education, Culture, Sports, Science, and Technology of Japan (Mext), Kakenhi (13218132 and 17590257), the Kobayashi Institute for Innovative Cancer Chemotherapy and a grant-in-aid for Cancer Research from the Fukuoka Cancer Society, Japan. We thank Satoko Takazaki and Yukiko Yoshiura for their technical assistance.	Alexander NR, 2006, CANCER RES, V66, P3365, DOI 10.1158/0008-5472.CAN-05-3401; Castanon I, 2001, DEVELOPMENT, V128, P3145; CHEN ZF, 1995, GENE DEV, V9, P686, DOI 10.1101/gad.9.6.686; ELDEIRY WS, 1994, CANCER RES, V54, P1169; ElGhouzzi V, 1997, NAT GENET, V15, P42; Funato N, 2001, MOL CELL BIOL, V21, P7416, DOI 10.1128/MCB.21.21.7416-7428.2001; Hamamori Y, 1997, MOL CELL BIOL, V17, P6563, DOI 10.1128/MCB.17.11.6563; Hamamori Y, 1999, CELL, V96, P405, DOI 10.1016/S0092-8674(00)80553-X; Howard TD, 1997, NAT GENET, V15, P36, DOI 10.1038/ng0197-36; Igarashi T, 2007, ONCOGENE, V26, P4749, DOI 10.1038/sj.onc.1210289; Imamura T, 2001, J BIOL CHEM, V276, P7534, DOI 10.1074/jbc.M008143200; Izumi H, 2003, BIOCHEM J, V373, P713, DOI 10.1042/BJ20021902; Izumi H, 2001, NUCLEIC ACIDS RES, V29, P1200, DOI 10.1093/nar/29.5.1200; Jayaraman L, 1998, GENE DEV, V12, P462, DOI 10.1101/gad.12.4.462; Kaghad M, 1997, CELL, V90, P809, DOI 10.1016/S0092-8674(00)80540-1; Kohno K, 2005, EUR J CANCER, V41, P2577, DOI 10.1016/j.ejca.2005.08.007; Lee YM, 1997, J BIOL CHEM, V272, P17531, DOI 10.1074/jbc.272.28.17531; Liu L, 1999, MOL CELL BIOL, V19, P1202; Maestro R, 1999, GENE DEV, V13, P2207, DOI 10.1101/gad.13.17.2207; Ohga T, 1996, CANCER RES, V56, P4224; Okamoto T, 2000, ONCOGENE, V19, P6194, DOI 10.1038/sj.onc.1204029; QUERTERMOUS EE, 1994, P NATL ACAD SCI USA, V91, P7066, DOI 10.1073/pnas.91.15.7066; Shiota M, 2008, CANCER RES, V68, P98, DOI 10.1158/0008-5472.CAN-07-2981; Soo K, 2002, DEV BIOL, V247, P251, DOI 10.1006/dbio.2002.0699; Stasinopoulos IA, 2005, J BIOL CHEM, V280, P2294, DOI 10.1074/jbc.M411018200; THISSE B, 1988, EMBO J, V7, P2175, DOI 10.1002/j.1460-2075.1988.tb03056.x; Torigoe Takayuki, 2005, Current Medicinal Chemistry - Anti-Cancer Agents, V5, P15, DOI 10.2174/1568011053352587; Uramoto H, 2003, BIOCHEM J, V371, P301, DOI 10.1042/BJ20021646; Uramoto H, 2002, J BIOL CHEM, V277, P31694, DOI 10.1074/jbc.M200266200; Valsesia-Wittmann S, 2004, CANCER CELL, V6, P625, DOI 10.1016/j.ccr.2004.09.033; Wakasugi T, 2007, ONCOGENE, V26, P5194, DOI 10.1038/sj.onc.1210326; Wang XH, 2004, ONCOGENE, V23, P474, DOI 10.1038/sj.onc.1207128; Yang J, 2004, CELL, V117, P927, DOI 10.1016/j.cell.2004.06.006	33	92	95	3	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 18	2008	27	42					5543	5553		10.1038/onc.2008.176	http://dx.doi.org/10.1038/onc.2008.176			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	349KX	18504427				2022-12-28	WOS:000259280800001
J	Sanchez, A; Setien, F; Martinez, N; Oliva, JL; Herranz, M; Fraga, MF; Alaminos, M; Esteller, M; Rojas, JM				Sanchez, A.; Setien, F.; Martinez, N.; Oliva, J. L.; Herranz, M.; Fraga, M-F; Alaminos, M.; Esteller, M.; Rojas, J. M.			Epigenetic inactivation of the ERK inhibitor Spry2 in B-cell diffuse lymphomas	ONCOGENE			English	Article						hSpry2; epigenetic; lymphomas; B cells; suppressor gene	SPROUTY PROTEINS; PROSTATE-CANCER; DNA METHYLATION; CPG ISLANDS; SUPPRESSOR	Spry2 has been characterized as a negative regulator of the extracellular-regulated kinase (ERK) pathway. In this study we analysed whether epigenetic alterations of hSpry2 promoter occur in human lymphoid/hematopoietic malignancies. Our results revealed that hSpry2 promoter was hypermethylated in the HT cell line derived from a B-cell diffuse lymphoma, which correlated with decreased hSpry2 expression. We detected deregulation of the ERK pathway in these cells, but not in other blood cell lines expressing hSpry2. In addition, the ectopic overexpression of hSpry2 in HT cells drastically reduced the activation of ERK upon phorbol 12-myristate-13-acetate stimulation. Nude mice inoculated with HT mock cells developed tumors seven times larger than those from HT-hSpry2-transfected cells. We found hypermethylation of hSpry2 promoter in 37% ( 26 cases out of 71) of primary tumors from patients with B-cell diffuse lymphoma but none in normal B lymphocytes from 37 healthy individuals. Finally, we detected that hSpry2 promoter hypermethylation was associated with a significant decrease in the 5-year survival rate. These data suggest that hSpry2 could be important in lymphoid malignancies.	[Sanchez, A.; Martinez, N.; Oliva, J. L.; Rojas, J. M.] Inst Salud Carlos III, Ctr Nacl Microbiol, Unidad Biologi Celular, Madrid 28220, Spain; [Setien, F.; Herranz, M.; Fraga, M-F; Alaminos, M.; Esteller, M.] Spanish Natl Canc Ctr, Canc Epigenet Lab, Mol Pathol Programme, Madrid, Spain	Instituto de Salud Carlos III; Centro Nacional de Microbiologa (CNM); Centro Nacional de Investigaciones Oncologicas (CNIO)	Rojas, JM (corresponding author), Inst Salud Carlos III, Ctr Nacl Microbiol, Unidad Biologi Celular, Carretera Majadahonda Pozuelo,Km 2, Madrid 28220, Spain.	jmrojas@isciii.es	Rojas, José M/D-3718-2018; Fraga, Mario F/H-7824-2017; ALAMINOS, MIGUEL/N-9960-2016; Esteller, Manel/L-5956-2014; Rojas, José M./AAA-3354-2021; Herranz, Michel/L-2561-2016	Rojas, José M/0000-0002-5383-3482; Fraga, Mario F/0000-0001-8450-2603; ALAMINOS, MIGUEL/0000-0003-4876-2672; Esteller, Manel/0000-0003-4490-6093; Rojas, José M./0000-0002-7547-2825; 	Ministerio de Educacion y Ciencia, Spain [SAF2006-04247]; Fundacion Mutua Madrilena Automovilista [FMMA-2005]; Fundacio la Caixa [BM04/179-02]; Comunidad de Madrid, Spain [GR/SAL/0291/2004]; Instituto de Salud Carlos III; Spanish Association Against Cancer (AECC) [FIS01-04)]	Ministerio de Educacion y Ciencia, Spain(Spanish Government); Fundacion Mutua Madrilena Automovilista; Fundacio la Caixa(La Caixa FoundationEuropean Commission); Comunidad de Madrid, Spain(Comunidad de Madrid); Instituto de Salud Carlos III(Instituto de Salud Carlos IIIEuropean Commission); Spanish Association Against Cancer (AECC)	We thank Dr A Torano and Dr M Dominguez for the comments and help to recruit the healthy volunteers. AS was recipient of a fellowship from the Instituto de Salud Carlos III. This work was supported by grants SAF2006-04247 from the Ministerio de Educacion y Ciencia, Spain; FMMA-2005 from the Fundacion Mutua Madrilena Automovilista; BM04/179-02 from the Fundacio la Caixa'; GR/SAL/0291/2004 from the Comunidad de Madrid, Spain and RETICS from the Instituto de Salud Carlos III (Red Tematica de Investigacion Cooperativa en Cancer) to JMR; and the Health (FIS, FIS01-04) and Science (I+D+I) departments of the Spanish Government to ME and the Spanish Association Against Cancer (AECC) to JMR and ME.	Bundschu K, 2007, BIOESSAYS, V29, P897, DOI 10.1002/bies.20632; Cabrita MA, 2008, ANGIOGENESIS, V11, P53, DOI 10.1007/s10456-008-9089-1; Ebinu JO, 1998, SCIENCE, V280, P1082, DOI 10.1126/science.280.5366.1082; Egger G, 2004, NATURE, V429, P457, DOI 10.1038/nature02625; Esteller M, 2002, J NATL CANCER I, V94, P26; Fraga MF, 2004, CANCER RES, V64, P5527, DOI 10.1158/0008-5472.CAN-03-4061; GARDINERGARDEN M, 1987, J MOL BIOL, V196, P261, DOI 10.1016/0022-2836(87)90689-9; Lo TL, 2006, CANCER LETT, V242, P141, DOI 10.1016/j.canlet.2005.12.032; Lopez-Serra L, 2006, CANCER RES, V66, P8342, DOI 10.1158/0008-5472.CAN-06-1932; Martinez N, 2007, CELL SIGNAL, V19, P2277, DOI 10.1016/j.cellsig.2007.07.008; Mason JM, 2006, TRENDS CELL BIOL, V16, P45, DOI 10.1016/j.tcb.2005.11.004; McKie AB, 2005, ONCOGENE, V24, P2166, DOI 10.1038/sj.onc.1208371; Platanias LC, 2003, BLOOD, V101, P4667, DOI 10.1182/blood-2002-12-3647; Wang JH, 2006, PROSTATE, V66, P613, DOI 10.1002/pros.20353	14	21	22	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 21	2008	27	36					4969	4972		10.1038/onc.2008.129	http://dx.doi.org/10.1038/onc.2008.129			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	339SF	18427547				2022-12-28	WOS:000258596900011
J	Burgering, B				Burgering, Bmth			A brief introduction to FOXOlogy	ONCOGENE			English	Editorial Material						transcription; insulin; aging; cell cycle; cell death; evolution	PROTEIN-KINASE-B; INSULIN-RECEPTOR SUBSTRATE; EXTENDS LIFE-SPAN; FORK HEAD DOMAIN; AGE-1 PI3 KINASE; CAENORHABDITIS-ELEGANS; TRANSCRIPTION FACTORS; AKT PROTOONCOGENE; ACTIVATION; LONGEVITY	Members of the Forkhead box O (FOXO) class of transcription factors are key players in the regulation of cell-fate decisions, such as cell death, cell proliferation and cell metabolism. Furthermore, in model organisms, it has by now been demonstrated that FOXO function affects the life span of these organisms. Multiple signal transduction pathways regulate FOXO function, but most importantly, they are negatively regulated by protein kinase B (PKB/AKT)-mediated phosphorylation and constitute, therefore, an important downstream component of insulin signalling. This review issue provides a timely overview of our understanding of FOXO function and how signalling affects FOXO function. Taken together, the reviewed studies on FOXO function and regulation provide compelling evidence that FOXOs act at the crossroad between aging and age-related diseases including diabetes and cancer. With this perspective, further studies on FOXO function and regulation may shed light on how age impacts on the onset and progression of disease.	Univ Med Ctr Utretch, Phys Chem Lab, NL-3584 CG Utrecht, Netherlands	Utrecht University; Utrecht University Medical Center	Burgering, B (corresponding author), Univ Med Ctr Utretch, Phys Chem Lab, Universiteitweg 100, NL-3584 CG Utrecht, Netherlands.	burgering@umcutrecht.nl						Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9; Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; Andjelkovic M, 1997, J BIOL CHEM, V272, P31515, DOI 10.1074/jbc.272.50.31515; Brownawell AM, 2001, MOL CELL BIOL, V21, P3534, DOI 10.1128/MCB.21.10.3534-3546.2001; Brunet A, 2001, MOL CELL BIOL, V21, P952, DOI 10.1128/MCB.21.3.952-965.2001; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Brunet A, 2004, SCIENCE, V303, P2011, DOI 10.1126/science.1094637; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; Carlsson P, 2002, DEV BIOL, V250, P1, DOI 10.1006/dbio.2002.0780; CASSADA RC, 1975, DEV BIOL, V46, P326, DOI 10.1016/0012-1606(75)90109-8; CHUNG JK, 1994, NATURE, V370, P71, DOI 10.1038/370071a0; Clancy DJ, 2001, SCIENCE, V292, P104, DOI 10.1126/science.1057991; DAVIS RJ, 1994, CANCER RES, V54, P2869; DORMAN JB, 1995, GENETICS, V141, P1399; DOWNWARD J, 1994, FEBS LETT, V338, P113, DOI 10.1016/0014-5793(94)80346-3; Essers MAG, 2004, EMBO J, V23, P4802, DOI 10.1038/sj.emboj.7600476; Essers MAG, 2005, SCIENCE, V308, P1181, DOI 10.1126/science.1109083; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; Franke TF, 1997, SCIENCE, V275, P665, DOI 10.1126/science.275.5300.665; Furuyama T, 2000, BIOCHEM J, V349, P629, DOI 10.1042/0264-6021:3490629; GALILI N, 1993, NAT GENET, V5, P230, DOI 10.1038/ng1193-230; HAFEN E, 1993, PHILOS T R SOC B, V340, P273, DOI 10.1098/rstb.1993.0068; HARLAN JE, 1994, NATURE, V371, P168, DOI 10.1038/371168a0; Jacobs FMJ, 2003, J BIOL CHEM, V278, P35959, DOI 10.1074/jbc.M302804200; Kaestner KH, 2000, GENE DEV, V14, P142; KENYON C, 1993, NATURE, V366, P461, DOI 10.1038/366461a0; Kimura KD, 1997, SCIENCE, V277, P942, DOI 10.1126/science.277.5328.942; Kops GJPL, 1999, NATURE, V398, P630, DOI 10.1038/19328; MAYER BJ, 1993, CELL, V73, P629, DOI 10.1016/0092-8674(93)90244-K; MING XF, 1994, NATURE, V371, P426, DOI 10.1038/371426a0; Mora A, 2004, SEMIN CELL DEV BIOL, V15, P161, DOI 10.1016/j.semcdb.2003.12.022; Morris JZ, 1996, NATURE, V382, P536, DOI 10.1038/382536a0; Motta MC, 2004, CELL, V116, P551, DOI 10.1016/S0092-8674(04)00126-6; MUSACCHIO A, 1993, TRENDS BIOCHEM SCI, V18, P343, DOI 10.1016/0968-0004(93)90071-T; Nakae J, 1999, J BIOL CHEM, V274, P15982, DOI 10.1074/jbc.274.23.15982; Ogg S, 1997, NATURE, V389, P994, DOI 10.1038/40194; Ogg S, 1998, MOL CELL, V2, P887, DOI 10.1016/S1097-2765(00)80303-2; Oh SW, 2005, P NATL ACAD SCI USA, V102, P4494, DOI 10.1073/pnas.0500749102; Paradis S, 1999, GENE DEV, V13, P1438, DOI 10.1101/gad.13.11.1438; Paradis S, 1998, GENE DEV, V12, P2488, DOI 10.1101/gad.12.16.2488; Plas DR, 2002, TRENDS ENDOCRIN MET, V13, P74; Rena G, 1999, J BIOL CHEM, V274, P17179, DOI 10.1074/jbc.274.24.17179; RIDDLE DL, 1981, NATURE, V290, P668, DOI 10.1038/290668a0; Stephens L, 1998, SCIENCE, V279, P710, DOI 10.1126/science.279.5351.710; Stokoe D, 1997, SCIENCE, V277, P567, DOI 10.1126/science.277.5325.567; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; Teleman AA, 2005, DEV CELL, V9, P271, DOI 10.1016/j.devcel.2005.07.004; Tissenbaum HA, 2001, NATURE, V410, P227, DOI 10.1038/35065638; van der Horst A, 2004, J BIOL CHEM, V279, P28873, DOI 10.1074/jbc.M401138200; Wang MC, 2005, CELL, V121, P115, DOI 10.1016/j.cell.2005.02.030; WEIGEL D, 1990, CELL, V63, P455, DOI 10.1016/0092-8674(90)90439-L; WHITE MF, 1985, NATURE, V318, P183, DOI 10.1038/318183a0; Wolff S, 2006, CELL, V124, P1039, DOI 10.1016/j.cell.2005.12.042; Wolkow CA, 2002, J BIOL CHEM, V277, P49591, DOI 10.1074/jbc.M207866200; Yang ZY, 2002, J BIOL CHEM, V277, P8068, DOI 10.1074/jbc.M106091200	55	156	158	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 7	2008	27	16					2258	2262		10.1038/onc.2008.29	http://dx.doi.org/10.1038/onc.2008.29			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	285NE	18391968				2022-12-28	WOS:000254782700001
